<SEC-DOCUMENT>0000950123-23-008455.txt : 20240105
<SEC-HEADER>0000950123-23-008455.hdr.sgml : 20240105
<ACCEPTANCE-DATETIME>20230907152644
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000950123-23-008455
CONFORMED SUBMISSION TYPE:	DRS/A
PUBLIC DOCUMENT COUNT:		59
FILED AS OF DATE:		20230907
<PUBLIC-REL-DATE>20240105
DATE AS OF CHANGE:		20230907

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Metagenomi Technologies, LLC
		CENTRAL INDEX KEY:			0001785279
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				832735153
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRS/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-06800
		FILM NUMBER:		231242067

	BUSINESS ADDRESS:	
		STREET 1:		1545 PARK AVENUE
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608
		BUSINESS PHONE:		(510) 871-4880

	MAIL ADDRESS:	
		STREET 1:		5959 HORTON STREET
		STREET 2:		FLOOR 7
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS/A
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>DRS/A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>As confidentially submitted to the Securities and Exchange Commission on
September&nbsp;7, 2023 as Amendment No. 1 to the draft registration statement submitted on August 3, 2023. This Amendment No. 1 has not been publicly filed with the Securities and Exchange Commission and all information herein remains confidential.
</B></P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="right"><B>Registration No.&nbsp;333&#150;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">S-1</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>THE
SECURITIES ACT OF 1933 </I></B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Metagenomi Technologies, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:6pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2836</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">83-2735153</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>(Primary Standard Industrial</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>Classification Code Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Metagenomi Technologies, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>1545 Park Avenue </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Emeryville, California 94608 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(510) <FONT STYLE="white-space:nowrap">871-4880</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>(Address, including zip code, and telephone number, including area code, of registrant&#146;s principal executive offices) </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Brian C. Thomas, Ph.D. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Chief Executive Officer </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Metagenomi Technologies, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>1545 Park Avenue </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Emeryville, California 94608 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(510) <FONT STYLE="white-space:nowrap">871-4880</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including area code, of agent for service) </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Copies to: </I></B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Mitchell S. Bloom</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Edwin M. O&#146;Connor</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Justin S. Platt</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Goodwin
Procter LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>100 Northern Avenue</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Boston, Massachusetts 02210</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">(617)&nbsp;570-1000</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Richard D. Truesdell, Jr.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Yasin Keshvargar</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Davis
Polk&nbsp;&amp; Wardwell LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>450 Lexington Avenue</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>New York, New York 10017</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(212) <FONT STYLE="white-space:nowrap">450-4000</FONT></B></P></TD></TR>
</TABLE>  <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman"><B>Approximate date of commencement of proposed sale to the public</B>: As soon as practicable after the effective date of this registration statement. </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933,
as amended, check the following box.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b)
under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman">If this Form is a post-effective
amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <FONT STYLE="white-space:nowrap">non-accelerated</FONT>
filer, a smaller reporting company or an emerging growth company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting company&#148; and &#147;emerging growth company&#148; in Rule <FONT
STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934. </P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">Large&nbsp;Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-accelerated</FONT> filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging growth company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman"><B>The registrant hereby amends
this registration statement on such date or dates as may be necessary to delay its effective date until the registrant files a further amendment which specifically states that this registration statement shall thereafter become effective in
accordance with Section&nbsp;8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&nbsp;8(a), may determine.
</B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>EXPLANATORY NOTE </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Metagenomi Technologies, LLC, the registrant whose name appears on the cover of this registration statement, is a Delaware limited liability company. Prior to the
effectiveness of this registration statement, Metagenomi Technologies, LLC will complete a series of transactions pursuant to which Metagenomi Technologies, LLC will merge with and into its wholly-owned subsidiary, Metagenomi, Inc., a Delaware
corporation, with Metagenomi, Inc. continuing as the surviving corporation. We refer to this reorganization throughout the prospectus included in this registration statement as the &#147;Reorganization.&#148; Except as disclosed in the prospectus,
the consolidated financial statements and summary consolidated financial data and other financial information included in this registration statement are those of Metagenomi Technologies, LLC and its subsidiaries and do not give effect to the
Reorganization. Shares of the common stock of Metagenomi, Inc. are being offered by the prospectus included in this registration statement. </P>  <P STYLE="font-size:8pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><FONT COLOR="#8b3f4e"><B>The information in this preliminary prospectus is not complete and may be changed. We may not
sell these securities until the Securities and Exchange Commission declares our registration statement effective. This preliminary prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any
jurisdiction where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial"><FONT COLOR="#8b3f4e"><B>Subject to completion, dated &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023 </B></FONT></P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:11pt; font-family:arial"><B>PRELIMINARY PROSPECTUS </B></P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares </I></B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g425213g00s01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><B><I>Common Stock </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This is an initial
public offering of shares of common stock of Metagenomi, Inc. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are offering
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock. We expect that the initial public offering price will be between
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Prior to this offering, there has been no public market for our common stock. We have applied to list our common stock on the Nasdaq Global Select Market under the
symbol &#147;MGX.&#148; We believe that upon the completion of this offering, we will meet the standards for listing on the Nasdaq Global Select Market, and the closing of this offering is contingent upon such listing. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are an &#147;emerging growth company&#148; under the federal securities laws and, as such, we have elected to comply with certain reduced public company reporting
requirements for this prospectus and for future filings. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Per&nbsp;share</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Initial public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">$</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">$</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Underwriting discounts and commissions(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">$</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">$</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Proceeds, before expenses, to Metagenomi, Inc.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See &#147;Underwriting&#148; beginning on page 257 of this prospectus for additional information regarding underwriting compensation. </TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have granted the underwriters an option for a period of 30 days to purchase an additional
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock from us at the initial public offering price, less underwriting discounts and commissions. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Investing in our common stock involves a high degree of risk. Before buying any shares, you should read carefully the discussion of the material risks of investing in
our common stock under the heading &#147;<A HREF="#toc425213_4">Risk Factors</A>&#148; starting on page 18 of this prospectus. </B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Neither the Securities
and Exchange Commission nor any state securities commission has approved or disapproved of these securities, or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The underwriters expect to deliver the shares against payment in New York, New York on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:13pt" ALIGN="center">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="29%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:13pt">
<TD VALIGN="top"><B>J.P.&nbsp;Morgan</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>Jefferies</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>TD&nbsp;Cowen</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Wells&nbsp;Fargo&nbsp;Securities</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>BMO&nbsp;Capital&nbsp;Markets</B></TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:14pt; font-family:arial" ALIGN="center"><B>Chardan </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:11pt; font-family:arial"><B>Prospectus
dated&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc"></A>Table of contents </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc425213_1">Prospectus Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc425213_2">The Offering</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc425213_3">Summary Consolidated Financial Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc425213_4">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc425213_5">Special Note Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc425213_6">Reorganization</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc425213_7">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc425213_8">Dividend Policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc425213_9">Capitalization</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc425213_10">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc425213_11">Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc425213_12">Business</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">129</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc425213_13">Management</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">217</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc425213_14">Executive Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">227</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc425213_15">Director Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">237</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc425213_16">Certain Relationships and Related Person Transactions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">239</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc425213_17">Principal Stockholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">243</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc425213_18">Description of Capital Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">245</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc425213_19">Shares Eligible for Future Sale</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">251</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc425213_20">Material U.S. Federal Income Tax Considerations for <FONT STYLE="white-space:nowrap">Non-U.S.
</FONT> Holders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">253</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc425213_21">Underwriting</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">257</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc425213_22">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">271</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc425213_23">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">271</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc425213_23a">Changes in Independent Registered Public Accounting Firm </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">271</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc425213_24">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">272</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc425213_25">Index to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have not, and the underwriters have not, authorized anyone to provide any information or to make any representation other than
those contained in this prospectus, any amendment or supplement to this prospectus or any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for, and can provide
no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the shares of common stock offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so.
The information contained in this prospectus, any amendment or supplement to this prospectus or any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of shares of our common stock. Our
business, financial condition, results of operations and prospects may have changed since that date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For investors outside the United States: We have not, and the underwriters have not, done anything that would permit
this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform
themselves about, and observe any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside the United States. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Market data and certain other statistical information used throughout this prospectus are based on independent industry publications, governmental publications, reports
by market research firms, or other independent sources that we believe to be reliable sources. Industry publications and third-party research, surveys, and studies generally indicate that their information has been obtained from sources believed to
be reliable, although they do not guarantee the accuracy or completeness of such information. We are responsible for all of the disclosure contained in this prospectus, and we believe that these sources are reliable; however, we have not
independently verified the information contained in such publications. While we are not aware of any misstatements regarding any third-party information presented in this prospectus, their estimates, in particular, as they relate to projections,
involve numerous assumptions, are subject to risks and uncertainties, and are subject to change based on various factors, including those discussed under the section entitled &#147;Risk&nbsp;Factors&#148; and elsewhere in this prospectus. Some data
are also based on our good faith estimates. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We intend to apply for various trademarks that we use in connection with the operation of our business. This prospectus
may also contain trademarks, service marks and trade names of third parties, which are the property of their respective owners. Our use or display of third parties&#146; trademarks, service marks, trade names or products in this prospectus is not
intended to, and does not imply a relationship with, or endorsement or sponsorship by us. Solely for convenience, the trademarks, service marks and trade names referred to in this prospectus may appear without the TM or SM symbols, but the omission
of such references is not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable owner of these trademarks, service marks and trade names. </P>
<P STYLE="font-size:16pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc425213_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>This summary highlights information contained in greater detail elsewhere in this prospectus and does not contain all of the information that you should consider in
making your investment decision. Before investing in our common stock, you should carefully read this entire prospectus, including our consolidated financial statements and the related notes thereto included elsewhere in this prospectus. You should
also consider, among other things, the information set forth under the sections entitled &#147;Risk Factors,&#148; &#147;Special Note Regarding Forward-Looking Statements,&#148; and &#147;Management&#146;s Discussion and Analysis of Financial
Condition and Results of Operations,&#148; in each case included elsewhere in this prospectus. </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Prior to the completion of this offering, we will complete a
series of transactions pursuant to which Metagenomi Technologies, LLC will merge with and into its wholly-owned subsidiary, Metagenomi, Inc., a Delaware corporation, with Metagenomi, Inc. continuing as the surviving corporation. See
&#147;Reorganization.&#148; Except where the context otherwise requires or where otherwise indicated, the terms &#147;Metagenomi,&#148; &#147;we,&#148; &#147;us,&#148; &#147;our,&#148; &#147;our company,&#148; &#147;the company,&#148; and &#147;our
business&#148; refer, prior to the Reorganization discussed below, to Metagenomi Technologies, LLC and, after the Reorganization, to Metagenomi, Inc. </I></P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Overview </B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are a precision genetic medicines company committed to
developing curative therapeutics for patients using our proprietary, comprehensive metagenomics-derived genome editing toolbox. Genetic diseases are caused by a diverse set of mutations that have been largely inaccessible by genome engineering
approaches to date. Genetic mutations are seen in a variety of forms, including deletions, insertions, single-base-pair changes and sequence repeats, and are found throughout the genome and across a variety of different cell types, tissues, and
organ systems. Additionally, many diseases lack a genetic origin but have the potential to be effectively and permanently addressed through genome editing. We are harnessing the power of metagenomics, the study of genetic material recovered from the
natural environment, to unlock four billion years of microbial evolution to discover and develop a suite of novel editing tools capable of correcting any type of genetic mutation found anywhere in the genome. Our comprehensive genome editing toolbox
includes programmable nucleases, base editors, and RNA and <FONT STYLE="white-space:nowrap">DNA-mediated</FONT> integration systems (including prime editing systems and clustered regularly interspaced short palindromic repeat
(&#147;CRISPR&#148;)-associated transposases (&#147;CASTs&#148;)). We believe our diverse and modular toolbox positions us to access the entire genome and select the optimal tool to unlock the full potential of genome editing for patients. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The company was founded by pioneers in the field of metagenomics, a powerful science that allows us to tap into the diversity of microbial life on this planet. The
metagenomics process starts by collecting samples from microbe-rich ecosystems ranging from simple home gardens to extreme locations such as hydrothermal vents below the ocean. We then extract the DNA from these environmental samples and deeply
sequence them to fully reconstruct the genomes of the resident microbes. Each sample may include thousands of distinct genomes from previously unknown organisms revealing novel cellular machinery that we utilize as building blocks for our editing
systems. Using high-throughput screening, artificial intelligence (&#147;AI&#148;), and proprietary algorithms, we rapidly mine through billions of novel proteins from our genome-resolved metagenomics database to create genome editing tools. To
date, we have analyzed over 380 trillion of base pairs, predicted over 6&nbsp;billion proteins, including over 150&nbsp;million CRISPR-associated (&#147;Cas&#148;) proteins and over 1.4&nbsp;million CRISPRs, which we estimate has resulted in the
identification of over 20,000 novel genome editing systems. We&nbsp;have assembled extensive libraries of millions of nucleases, deaminases, reverse transcriptases (&#147;RTs&#148;) and over one thousand CASTs. Our platform enables us to rapidly and
effectively find, screen, and select tools with </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
the highest targetability, specificity, and efficiency in order to develop them into genetic medicines. The iterative nature of our process, underpinned by AI, allows us to continuously push the
boundaries of innovation. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Our proprietary toolbox of editing systems<U></U> </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have developed an expansive and modular toolbox of next-generation genome editing systems that will allow us to interact with the human genome in a site-specific
manner, where each tool can be matched to specific disease targets. Figure 1 summarizes our diverse and versatile toolbox of different editing capabilities with the potential to address the full spectrum of genetic diseases.<B> </B> </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:arial"><B>Figure 1.</B> Our Toolbox. </P> <P STYLE="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g425213g12u12.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our programmable nucleases are the backbone of our broad set of genome editing tools. These novel nucleases including type II
and type V Cas nucleases, of which some are ultra-small systems that we call SMall Arginine-Rich sysTems (&#147;SMART&#148;) nucleases, have unique targeting abilities and can be programmed by guide RNAs (&#147;gRNA&#148;) to target and cut at
specific locations in any genome sequence. Targeted genomic breaks trigger DNA repair pathways that can be used for genome editing, for example, to integrate a gene at a target site <FONT STYLE="white-space:nowrap">(knock-in)</FONT> or for gene
inactivation (knock-down). </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our toolbox contains thousands of CRISPR nucleases with diverse abilities to target different parts of the genome, allowing us to select
the ideal nuclease for targeting any given gene in a site-specific manner and potentially overcome a major limitation of first-generation CRISPR/Cas9 systems. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We
also modify our nucleases to either nick the genome (i.e., a nickase that cuts one strand of the DNA) or to simply bind to target sites (i.e., a nuclease dead variant). These capabilities (searching, cutting, nicking, and binding) can be leveraged
as a chassis by adding on additional effector enzymes to create base editors for single nucleotide changes, RNA-mediated integration systems for large integrations (&#147;Little RIGS&#148;) for prime editing with small RNA-templated genomic
replacements/corrections, and RNA-mediated integration systems </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
for large integrations (&#147;Big RIGS&#148;) for large RNA-templated gene integrations. Using modular engineering, we match nickases with deaminases and RTs for base editing and RNA-mediated
integration systems (&#147;RIGS&#148;), respectively. Furthermore, nucleases can be engineered by swapping the search modules of the enzyme to expand the targetability of the chassis, which is critical for site-specific genomic modifications. Given
the measured targeting density of our toolbox, we believe that essentially any codon in the human genome could be addressed with our gene editing systems. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our
highly active nucleases have gone through extensive preclinical evaluation for both <I>in vivo</I> and <I>ex vivo</I> applications, with demonstration of broad potency of these systems across human primary cells, mouse, and nonhuman primate
(&#147;NHP&#148;) models. Our base editors, RIGS, and CAST systems have demonstrated activity across various cell-based models. In addition to evaluating system activity, we have undertaken detailed characterization of guide-specific on- and
off-target effects. We routinely identify guides that have no or minimal verifiable off-target editing, thus overcoming another limitation of first-generation CRISPR/Cas9 systems. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition to overcoming the activity, targetability, and specificity limitations of first-generation systems, our nuclease toolbox was designed to have broad
compatibility with viral and nonviral delivery technologies. This compatibility is accomplished by having a variety of nuclease and gRNA structures, which range in terms of their size and biochemistry. For example, small guides for some type V Cas
systems streamline manufacturing for delivery by lipid nanoparticle (&#147;LNP&#148;) approaches, and SMART nickases can be used to construct base editors that are small enough to fit within the packaging limitations of adeno-associated viruses
(&#147;AAV&#148;). SpCas9, which is currently used in most base editing applications, is roughly three times the size of some of our smallest SMART nickases and cannot be efficiently packaged into a single AAV. Combined, we believe these features
will facilitate delivery of our genome editing tools to previously inaccessible tissue types and organ systems. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">While nucleases, base editors, and prime editors can
precisely address a wide variety of genomic modifications required to treat disease, the fact that many diseases are caused by a multitude of mutations across a gene means that a diverse set of editing tools are required to fully address these
patient populations. The integration of a complete and functional gene through targeted genome editing may provide a way in which every patient with a given disease could potentially be treated by a single genetic medicine. Big RIGS and CASTs are
novel genome editing systems that are under development to achieve what has been a major challenge for the genome editing field&#151;large, targeted genomic integrations. Initial preclinical readouts conducted in mammalian cells indicate that these
systems could potentially have a major impact on how diseases caused by <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">loss-of-function</FONT></FONT> mutations, the most common cause of genetic diseases, can be addressed through
genome editing. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Therapeutic translation roadmap and initial programs<U></U> </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are taking a stepwise approach deploying our genome editing toolbox to develop potentially curative therapies for patients. Our lead programs are selected to both
address important diseases and to establish new standards in targetability, precision, efficiency, and scope of editing capabilities. Figure 2 summarizes the portfolio of programs that we and our partners are advancing, as we aim to match the
optimal genome editing tools for each indication. Each of these indications were chosen based on our conviction in the underlying biology, existence of validating preclinical and clinical data, availability of pharmacodynamic and translational tools
to assess early proof-of-concept, relevant value supporting outcome measures, and ongoing clinical unmet need. While we do not currently have any approved products and all of our product candidates are preclinical, our lead programs capture an
ever-growing set of translational learnings and insights that will inform and accelerate future programs. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:arial"><B>Figure 2:</B> <I></I>Therapeutic Translation<I></I>. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g425213g42c52.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Hemophilia A&#151;novel, durable, knock-in approach for expression of Factor VIII </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Hemophilia A is the most common X-linked inherited bleeding disorder and is caused by mutations in the Factor VIII (&#147;FVIII&#148;) gene leading to loss of functional
FVIII protein that impacts the body&#146;s ability to form normal clots in response to injury. FVIII is normally produced in the liver within sinusoidal endothelial cells and is then secreted into the bloodstream where it acts as a cofactor for the
catalytic activation of Factor X in the clotting pathway. The lack of functional FVIII disrupts the normal clotting cascade and predisposes patients to increased risk of bleeding, either spontaneously or in response to injury or surgery. Repeated
bleeding episodes in joints or soft tissues can lead to progressive joint damage, inflammation, pain, and mobility impairment. Intracranial bleeding is of greatest concern as this can be rapidly fatal or lead to major morbidity. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Rather than provide the FVIII gene in an episomal location, which risks dilution from cell division or cell death as well as episomal transcriptional silencing, our
approach is to insert a FVIII DNA cassette into a "safe harbor location," within an intron of the albumin gene that is not expected to have deleterious effects. FVIII expression is then driven by the strong native albumin promoter. This approach has
previously been demonstrated in preclinical studies to lead to therapeutically relevant expression of a different clotting factor (Factor IX) with negligible impact to systemic circulating albumin levels. Our FVIII knock-in approach is designed to
provide stable expression and clinically relevant circulating levels of FVIII, even at low integration rates because of the strength of the albumin promoter. We have demonstrated the feasibility of the FVIII gene knock-in approach in mice with
several mouse specific guides and different FVIII DNA donor cassettes, with integration of the FVIII gene leading to FVIII mRNA expression and therapeutically relevant levels of FVIII protein in the blood. We are finalizing donor DNA cassette
optimization and performing our next set of NHP studies to demonstrate and quantify FVIII integration and FVIII protein expression. In parallel, we are manufacturing mRNA, guide RNA, AAV and LNP to support future investigational new drug
(&#147;IND&#148;)-enabling studies. We expect to select a final development candidate in the first half of 2024 and initiate <FONT STYLE="white-space:nowrap">IND-enabling</FONT> Good Laboratory Practices studies thereafter. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Primary Hyperoxaluria, Type 1 (&#147;PH1&#148;)&#151;a durable knockdown of HAO1 for substrate reduction therapy
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">PH1 is a rare autosomal recessive metabolic disease arising from loss of function mutations in the alanine-glyoxylate aminotransferase (&#147;AGXT&#148;)
gene that encodes alanine glyoxylate aminotransferase. This enzyme is found in peroxisomes of the liver where it catalyzes the conversion of glyoxylate to glycine and pyruvate. Lack of functional AGXT leads to an accumulation of glyoxylate
substrate, which is then converted to oxalate and excreted in the kidney. The excess urinary oxalate forms an insoluble complex with urinary calcium that leads to the production of calcium oxalate crystal precipitates. This pathologic process
results in the formation of repeated calcium oxalate urolithiasis and nephrolithiasis, which in turn leads to obstructive uropathy, inflammation, fibrosis, tubular toxicity, and progressive loss of kidney function. PH1 is a serious disease that
causes kidney failure. More than 70% of individuals with PH1 mutations will develop end-stage renal disease, with a median age in young adulthood. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The goal of our
genome editing approach is to durably knock down HAO1 resulting in stable and permanent reduction of oxalate levels to effect a lifelong benefit. We have performed nuclease and guide screening to select an optimal nuclease and gRNA combination.
Along with our partner ModernaTX, Inc. (&#147;Moderna&#148;), we have achieved preclinical proof-of-concept in an AGXT knock-out mouse which is an accepted disease model of PH1. We are in the final stages of confirming the candidate to take into NHP
studies and are scheduled to begin NHP studies in 2023 to support final development candidate selection thereafter. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Transthyretin Amyloidosis&#151;a
single treatment to knockdown TTR gene expression </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Transthyretin amyloidosis is a disease of misfolded and aggregated transthyretin (&#147;TTR&#148;) protein
that can deposit in tissues causing organ dysfunction, primarily in the heart and/or peripheral nerves. The TTR protein is normally produced in the liver and circulates in a homotetramer (four copies of the same TTR protein bound together) where it
serves as a carrier protein for vitamin A and thyroxine. Certain mutations have been identified that can cause TTR homotetramers to fall apart, misfold, and aggregate into insoluble fibrils that deposit in cardiac tissue and peripheral nerves.
However, more commonly, the normal aging process is associated with an increased propensity for TTR misfolding and aggregation in the heart without any known genetic sequence variation. These distinctions lead to TTR amyloidosis being characterized
as either hereditary transthyretin amyloidosis (&#147;ATTRv&#148;) caused by mutations in TTR, or wild-type ATTR amyloidosis (&#147;ATTRwt&#148;). It is estimated that globally there are approximately 50,000 patients with ATTRv and between 300,000
and 500,000 patients with ATTRwt. Among the larger ATTRwt patient population, the most common presentation is a rapidly progressive, restrictive, and hypertrophic cardiomyopathy due to progressive deposition of insoluble TTR fibrils, which result in
thickening of the myocardium and stiffening of the ventricles. These pathologic processes lead to impaired diastolic function and progressive cardiomyopathy that typically leads to progressive heart failure and often death within three to five years
from disease onset. Although cardiac manifestations are more common and severe, patients with neurologic manifestations also experience significant morbidity, loss of functionality, and impaired quality of life. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Using our novel nucleases, we aim to provide efficient TTR knockdown and halt further deposition of amyloid fibrils. Previous experience suggests a clinical correlation
between the degree of TTR knockdown and potential for benefit in familial forms of the disease, which are expected to translate similarly to wild type forms. The high degree of <I>in vivo</I> editing efficiency and specificity of our nuclease
platform suggest the potential for a single treatment to knockdown TTR gene expression and remove the requirement for life-long therapy. Along with our partner Ionis Pharmaceuticals, Inc. (&#147;Ionis&#148;), we are currently in advanced stages of
nuclease and guide selection and expect to move into NHP studies in 2024. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Further areas of therapeutic activity and interest </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In parallel with our translation efforts in our lead programs using our novel programmable nucleases to <FONT STYLE="white-space:nowrap">knock-in</FONT> or knock-down
gene expression in liver-associated targets, we are developing more complex editing systems for liver associated targets as well as moving beyond the liver. Given that our genome editing toolbox contains small editing systems designed to be amenable
to viral vector delivery, and given the progress established in targeting the central nervous system and muscle with established AAV capsids, our first extrahepatic indications will be neurodegenerative and neuromuscular diseases. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Building on our experience delivering our nucleases to the liver via LNP systems, we are extending that experience delivering novel RIGS to the liver to potentially
correct ATP7B mutations in Wilson&#146;s disease and PiZ mutations in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">alpha-1-antitrypsin</FONT></FONT> deficiency (&#147;A1AT deficiency&#148;). We are also exploring addressing A1AT
deficiency via a base editor approach given the predominant mutation involves a single base pair. Both of these liver diseases have well-defined biology, readily available translational biomarkers for early proof-of-concept, established development
pathways based on prior drug approvals, and important unmet medical needs. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Building on our experience with our novel type II and type V programmable nucleases, we
are extending that experience by working to deliver these nucleases via AAV to the central nervous system to potentially knock-down genetic targets important for both spontaneous and familial amyotrophic lateral sclerosis (SOD1, ATXN2) and
Charcot-Marie-Tooth Type 1a (PMP22). In addition, we are working to address a series of mutations common in Duchenne Muscular Dystrophy with our programmable nucleases through exon skipping approaches. In diseases outside of the liver, we intend to
initially leverage known biology and clinical validation achieved with <FONT STYLE="white-space:nowrap">RNA-targeted</FONT> approaches like antisense and small interfering RNA (&#147;siRNA&#148;) to advance more potent and definitive <FONT
STYLE="white-space:nowrap">one-time</FONT> genome editing treatments. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Building on our experience with both <FONT STYLE="white-space:nowrap">knock-in</FONT> gene
expression and smaller gene corrections with RIGS, we are progressing our larger <FONT STYLE="white-space:nowrap">RNA-</FONT> and <FONT STYLE="white-space:nowrap">DNA-mediated</FONT> integration systems to potentially provide a single curative
approach to cystic fibrosis. As opposed to currently-available therapies limited to subsets of patients with individual mutations, we intend to deliver a full copy of a functional cystic fibrosis transmembrane conductance regulator
(&#147;CFTR&#148;) gene. This approach can similarly be pursued across many other diseases characterized by loss of function mutations. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><U>Our Team </U></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have assembled a world-class team that is driven by a passion to create potentially curative genetic medicines through the discovery of novel genome editing
technologies by harnessing the power of metagenomics. Key members of our executive and leadership team include: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Brian C. Thomas, Ph.D., Chief Executive Officer and Founder,</B> prior to
<FONT STYLE="white-space:nowrap">co-founding</FONT> the company, Dr. Thomas spent more than 20 years in academic research at UC Berkeley helping to pioneer the field of metagenomics. Dr. Thomas has been cited over 16,000 times and listed as an
inventor in 28 patent families. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Jian Irish, Ph.D., President and Chief Operating Officer</B>, has held biopharma executive leadership roles for nearly
20 years at Kite Pharma / Gilead, Sanofi, and Amgen in drug development and global operations, and has helped launch several breakthrough medicines. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Sarah Noonberg, M.D., Ph.D., Chief Medical Officer</B>, has spent more than 20 years in translational and clinical
development leadership roles with a track record of advancing therapeutic programs from discovery to commercialization, including at Medivation and BioMarin. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Alan Brooks, Ph.D., SVP of Preclinical</B>, has worked on genetic medicines providing scientific leadership in
translational research for more than 25 years, including at Casebia Therapeutics and Bayer Healthcare. Dr.&nbsp;Brooks&#146; research has led to 20 publications and numerous patent filings. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Simon Harnest, Chief Investment Officer and SVP of Strategy</B>, has held leadership roles in corporate finance and
strategy in the life sciences sector, having raised over $1 billion in public and private capital, including leading Cellectis&#146; U.S. IPO and subsequent <FONT STYLE="white-space:nowrap">spin-out</FONT> and IPO of Calyxt. </P></TD></TR></TABLE>
 <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Christopher T. Brown, Ph.D., VP of Discovery,</B> is a former scientist at the Jill F. Banfield laboratory at UC
Berkeley and an expert in using metagenomics to discover novel microbial systems for use in genome editing. Dr. Brown&#146;s research has resulted in over 35 publications and over 20 patent family filings. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Simren Delaney, Ph.D., LLM, VP of Legal,</B> is specialized in Intellectual Property and Patent law, having previously
worked at Wilson Sonsini Goodrich&nbsp;&amp; Rosati, and plays an instrumental role in driving the development of the company&#146;s growing IP portfolio. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Michael Conway, MBA, CPA, VP of Finance</B>, has spent nearly 20 years in finance leadership positions at life science
and technology companies, including Adamas Pharmaceuticals, InterMune, and Intel. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our company is supported by our board of directors, Scientific
Advisory Board, and a leading syndicate of investors, with more than 30 funds supporting our Series B and Series B-1 preferred unit financings. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><U>Our Strategy
</U></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our goal is to harness the power of our proprietary metagenomics platform to create curative genetic medicines for patients.&nbsp;Key components of our
strategy to achieve this goal include: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Leverage our leadership position in metagenomics to continually advance and expand innovative genome editing tools.
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Develop and deliver products that make precise modifications to the human genome to cure disease. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Build a fully integrated genome editing company. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Expand therapeutic impact to patients through continued investment in business development and enabling partnerships,
including with our existing partners Moderna, Ionis, and <FONT STYLE="white-space:nowrap">Affini-T</FONT> Therapeutics, Inc. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Maintain our entrepreneurial outlook, scientifically rigorous approach, and culture of tireless commitment to patients.
</P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Risks Associated with Our Business </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We have incurred significant losses since inception. We expect to incur losses for the foreseeable future and may never
achieve or maintain profitability. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We have never generated revenue from product sales and may never become profitable. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We will need substantial additional funding in addition to the net proceeds we receive from this offering. If we are unable
to raise additional capital when needed on acceptable terms, or at all, we may be forced to delay, reduce, or terminate certain research and product development programs, future commercialization efforts or other operations. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We are very early in our development efforts, and we have not yet initiated IND-enabling studies or clinical development of
any product candidate. As a result, we expect it will be many years before we commercialize any product candidate, if ever. If we are unable to advance our current or future product candidates into and through clinical trials, obtain regulatory
approval and ultimately commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We are subject to additional development challenges and risks due to the novel nature of our genome editing technology.
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Clinical drug development involves a lengthy and expensive process, with an uncertain outcome. Because genome editing is
novel and the regulatory landscape that will govern our potential product candidates is uncertain and may change, we cannot predict the time and cost of obtaining regulatory approval, if we receive it at all, for our potential product candidates.
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">The genome editing field is relatively new and is evolving rapidly. We are focusing our research and development efforts on
genome editing using programmable nucleases, base editing, and RNA and <FONT STYLE="white-space:nowrap">DNA-mediated</FONT> integration systems (including prime editors and Cas transposes), but other genome editing technologies may be discovered
that provide significant advantages over such technologies, which could materially harm our business. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">If any of the product candidates we may develop or the delivery modes we rely on cause undesirable side effects, it could
delay or prevent their regulatory approval, limit the commercial potential or result in significant negative consequences following any potential regulatory approval. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Positive results from early preclinical studies of any product candidates we may develop are not necessarily predictive of
the results of later preclinical studies and any future clinical trials of such product candidates. If we cannot replicate the positive results from our earlier preclinical studies of any product candidates we may develop in our later preclinical
studies and future clinical trials, we may be unable to successfully develop, obtain regulatory approval for and commercialize such product candidates. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We may find it difficult to enroll patients in our future clinical trials given the limited number of patients who have the
diseases any product candidates we identify or develop are intended to target. If we experience delays or difficulties in the enrollment of patients in clinical trials, our clinical development activities and our receipt of necessary regulatory
approvals could be delayed or prevented. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Genetic therapies are novel, and any product candidates we develop may be complex and difficult to manufacture. We could
experience delays in satisfying regulatory authorities or production problems that result in delays in our development programs, limit the supply of the product candidates we may develop or otherwise harm our business. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We face significant competition in an environment of rapid technological change, and there is a possibility that our
competitors may achieve regulatory approval before us or develop therapies that are safer or more advanced or effective than ours, which may harm our financial condition and our ability to successfully market or commercialize any product candidates
we may develop. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">While we intend to seek designations for our potential product candidates with the U.S. Food and Drug Administration (the
&#147;FDA&#148;) and comparable foreign regulatory authorities that are intended to confer benefits such as a faster development process or an accelerated regulatory pathway, there can be no assurance that we will successfully obtain such
designations. In addition, even if one or more of our potential product candidates are granted such designations, we may not be able to realize the intended benefits of such designations. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Because we are developing product candidates in the field of genetic medicines in which there is little clinical
experience, there is increased risk that the FDA, the European Medicines Agency or other regulatory authorities may not consider the endpoints of our clinical trials to provide clinically meaningful results and that these results may be difficult to
analyze. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">If preclinical studies or clinical trials of any product candidates we may identify and develop fail to demonstrate safety
and efficacy to the satisfaction of regulatory authorities or do not otherwise produce positive results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of
such product candidates. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Even if we complete the necessary clinical trials, we cannot predict when, or if, we will obtain regulatory approval to
commercialize a product candidate we may develop in the United States or any other jurisdiction, and any such approval may be for a more narrow indication than we seek. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">If conflicts arise between us and our collaborators or strategic partners, these parties may act in a manner adverse to us
and could limit our ability to implement our strategies. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We have entered into collaborations, and may enter into additional collaborations, with third parties for the research,
development, manufacture and commercialization of programs or product candidates. If these collaborations are not successful, our business could be adversely affected. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Our collaborators and strategic partners may control aspects of our clinical trials, which could result in delays and other
obstacles in the commercialization of our proposed products and materially harm our results of operations. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Our future success depends on our ability to retain our Chief Executive Officer and other key executives and to attract,
retain, and motivate qualified personnel. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Our commercial success depends on our ability to obtain, maintain, enforce, and otherwise protect our intellectual property
and proprietary technology, and if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors or other third parties could develop and commercialize products and product candidates similar to ours and our
ability to successfully develop and commercialize our genome editing systems may be adversely affected. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Intellectual property rights do not necessarily address all potential threats to our business. </P></TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Corporate Information </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We commenced our current operations and converted to a
Delaware limited liability company in September 2018. We were originally founded as Metagenomi.co, a Delaware corporation, in September 2016. Prior to the completion of this offering, we intend to engage in a series of transactions, which we refer
to collectively as the Reorganization. As a result of the Reorganization, Metagenomi Technologies, LLC will merge with and into its wholly-owned subsidiary, Metagenomi, Inc., a Delaware corporation, with Metagenomi, Inc. continuing as the surviving
corporation. In connection with the Reorganization, (i)&nbsp;all of the outstanding common unitholders of Metagenomi Technologies, LLC will receive shares of common stock of Metagenomi, Inc., (ii) all of the outstanding preferred unitholders of
Metagenomi Technologies, LLC will receive shares of preferred stock of Metagenomi, Inc. and (iii)&nbsp;all of the outstanding holders of profits interest units in Metagenomi Technologies, LLC will receive shares of common stock and restricted common
stock in Metagenomi, Inc. as determined by the applicable provisions of the Metagenomi Technologies, LLC operating agreement in effect immediately prior to </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
the Reorganization. Immediately prior to the completion of this offering, all outstanding shares of preferred stock of Metagenomi, Inc. will be converted into shares of common stock. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Metagenomi, Inc. will become the registrant for purposes of this offering, and our consolidated financial statements will be reported from Metagenomi, Inc. See
&#147;Reorganization&#148; and &#147;Description of Capital Stock&#148; for additional information, including a description of the terms of our capital stock following the Reorganization and the terms of our amended and restated certificate of
incorporation and amended and restated bylaws that will be in effect upon the completion of this offering. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our principal executive offices are located at 1545 Park
Avenue Emeryville, California 94608, and our telephone number is (510) <FONT STYLE="white-space:nowrap">871-4880.</FONT> </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our website address is
https://www.metagenomi.co. The information contained in or accessible from our website is not incorporated into this prospectus, and you should not consider it part of this prospectus. We have included our website address in this prospectus solely
as an inactive textual reference. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Implications of Being an Emerging Growth Company </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We qualify as an &#147;emerging growth company&#148; as defined in the Jumpstart Our Business Startups Act of 2012, as amended (the &#147;JOBS Act&#148;). As an emerging
growth company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies. These provisions include: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">being permitted to present only two years of audited financial statements, in addition to any required unaudited interim
financial statements, with correspondingly reduced &#147;Management&#146;s discussion and analysis of financial condition and results of operations&#148; disclosure in this prospectus; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reduced disclosure about our executive compensation arrangements; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">not being required to hold advisory votes on executive compensation or to obtain stockholder approval of any golden
parachute arrangements not previously approved; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">an exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting
pursuant to the Sarbanes-Oxley Act of 2002; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">an exemption from compliance with the requirements of the Public Company Accounting Oversight Board regarding the
communication of critical audit matters in the auditor&#146;s report on the financial statements. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may take advantage of these exemptions for up
to five years or such earlier time that we are no longer an emerging growth company. We would cease to be an emerging growth company on the date that is the earliest of (i)&nbsp;the last day of the fiscal year in which we have total annual gross
revenues of $1.235&nbsp;billion or more; (ii)&nbsp;the last day of our fiscal year following the fifth anniversary of the date of the completion of this offering; (iii)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in
nonconvertible debt during the previous three years; or (iv)&nbsp;the date on which we are deemed to be a large accelerated filer under the rules of the Securities and Exchange Commission (the &#147;SEC&#148;). We may choose to take advantage of
some but not all of these exemptions. We have taken advantage of reduced reporting requirements in this prospectus. Accordingly, the information contained herein may be different from the information you receive from other public companies in which
you hold stock. Additionally, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this exemption and,
therefore, while we are an emerging growth company we will not be subject to new or revised accounting standards at the same time that they become applicable to other public companies that are not emerging growth companies. As a result of this
election, our financial statements may not be comparable to those of other public companies that comply with new or revised accounting pronouncements as of public company effective dates. We may choose to early adopt any new or revised accounting
standards whenever such early adoption is permitted for private companies. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc425213_2"></A>THE OFFERING </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="28%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial"><B></B>Shares of common stock offered by us<B> </B></P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="28%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial"><B></B>Shares of our common stock to be outstanding after this offering<B> </B></P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares (or &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares if the underwriters exercise their
option to purchase additional shares in full). </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="28%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial"><B></B>Underwriters&#146; option to purchase additional shares<B> </B></P></TD>
<TD>We have granted the underwriters a <FONT STYLE="white-space:nowrap">30-day</FONT> option to purchase up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares of our common stock at
the initial public offering price, less underwriting discounts and commissions on the same terms as set forth in this prospectus. </TD></TR></TABLE> <P STYLE="font-size:11pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="28%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial"><B></B>Use of proceeds<B> </B></P></TD>
<TD>We estimate that the net proceeds to us from the sale&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in this offering will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or $
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million if the underwriters exercise their option to purchase additional shares in full, assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share,
the estimated midpoint of the price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. We intend to use the net proceeds of this
offering, together with our existing cash and cash equivalents and available-for-sale marketable securities, to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and for general
corporate purposes. See &#147;Use of Proceeds.&#148; </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="28%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial"><B></B>Proposed Nasdaq Global Select Market symbol<B> </B></P></TD>
<TD>We have applied to list our common stock on the Nasdaq Global Select Market under the symbol &#147;MGX.&#148; The closing of this offering is contingent upon such listing. </TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="28%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial"><B></B>Risk factors<B> </B></P></TD>
<TD>Investment in our common stock involves substantial risks. You should read this prospectus carefully, including the section entitled &#147;Risk Factors&#148; and the consolidated financial statements and the related notes to those statements
included in this prospectus, before investing in our common stock. </TD></TR></TABLE>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The number of shares of our common stock outstanding after this offering
assumes the Reorganization takes place immediately prior to the completion of this offering and is based on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock (including
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of unvested restricted common stock) issued in exchange for common units and profits interests outstanding as of June 30, 2023, and after giving
effect to the conversion of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our redeemable convertible preferred stock, issued in connection with the Reorganization in exchange for
redeemable convertible preferred units outstanding as of June 30, 2023, into an equivalent number of shares of our common stock immediately prior to the completion of this offering: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The number of shares of common stock to be outstanding after this offering excludes: </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock
reserved for future issuance under our 2023 Stock Option and Incentive Plan, which will become effective on the date immediately prior to execution of the underwriting agreement related to this offering; and </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock
reserved for future issuance under our 2023 Employee Stock Purchase Plan, which will become effective immediately prior to execution of the underwriting agreement related to this offering. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Except as otherwise noted, all information in this prospectus: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">assumes no vesting of the restricted common stock described above; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">assumes no exercise of the underwriters&#146; option to purchase up to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional shares of common stock in this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">assumes the filing of our amended and restated certificate of incorporation and the effectiveness of our amended and
restated bylaws, which will occur upon the closing of this offering. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc425213_3"></A>SUMMARY CONSOLIDATED FINANCIAL DATA </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following tables present the summary consolidated financial data for Metagenomi Technologies, LLC and its consolidated subsidiary. You should read the following
summary consolidated financial data together with our consolidated financial statements and the related notes appearing elsewhere in this prospectus and the &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations&#148; section of this prospectus. We have derived the consolidated statements of operations for the years ended December&nbsp;31, 2022 and 2021 from our audited consolidated financial statements appearing elsewhere in this prospectus. The
consolidated statements of operations for the six months ended June 30, 2023 and 2022 and the consolidated balance sheet data as of June&nbsp;30, 2023 have been derived from our unaudited condensed consolidated financial statements appearing
elsewhere in this prospectus, which have been prepared on the same basis as the audited consolidated financial statements. In the opinion of management, the unaudited data reflect all adjustments, consisting only of normal recurring adjustments,
necessary for a fair statement of the financial information in those statements. Our historical results are not necessarily indicative of the results that may be expected in any future period. The summary consolidated financial data included in this
section are not intended to replace the consolidated financial statements and the related notes included elsewhere in this prospectus. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Six&nbsp;Months&nbsp;Ended</B><br><B>June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="right"><B>(in thousands, except share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Consolidated Statements of Operations Data:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;6,692</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;19,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,701</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,834</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,084</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,895</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,947</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(44,640</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,997</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,901</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(302</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(98</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(98</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Change in fair value of long-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total other income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,505</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,616</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss before provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,442</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(41,024</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,493</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,046</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,569</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,092</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,095</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(21,442</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(43,593</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,585</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(29,141</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss per unit attributable to common unitholders, basic and diluted(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.77</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7.34</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.13</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4.90</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Weighted-average common units outstanding, basic and diluted(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,691,431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,938,654</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,929,662</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,947,500</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Pro forma net loss per share attributable to common stockholders, basic and diluted (unaudited)(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Pro forma weighted-average common stock outstanding, basic and diluted (unaudited)(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:2pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See Note 16 to our audited consolidated financial statements and Note 14 to our unaudited condensed consolidated financial statements included elsewhere in this prospectus for details on the calculation of basic and
diluted net loss per unit attributable to common unitholders. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See &#147;Unaudited Pro Forma Net Loss Per Share Attributable to Common Stockholders&#148; subsection below for details on our unaudited pro forma calculations. </TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Unaudited Pro Forma Net Loss Per Share Attributable to Common Stockholders </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The unaudited pro forma basic and diluted net loss per share attributable to common stockholders for the year ended December&nbsp;31, 2022 and for the six months ended
June 30, 2023 has been computed to give effect to (i) the Reorganization, (ii) the conversion of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our redeemable convertible preferred stock outstanding as of December&nbsp;31, 2022 and June 30, 2023, respectively, into an equivalent number
of shares of our common stock as if such conversion occurred on January&nbsp;1, 2022 and (iii) the filing and effectiveness of our amended and restated certificate of incorporation that will be in effect immediately prior to the completion of this
offering. The unaudited pro forma net loss attributable to common stockholders gives effect to the adjustments described below. The unaudited pro forma net loss per share attributable to common stockholders,
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
basic and diluted, does not include the effect of the shares of our common stock expected to be sold in this offering. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table sets forth the computation of the unaudited pro forma basic and diluted net loss per share assuming the offering is completed on January 1, 2022:
</P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;Ended</B><br><B>December&nbsp;31,&nbsp;2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Six&nbsp;Months&nbsp;Ended<BR>June 30,&nbsp;2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>(unaudited)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>(unaudited)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right"><B>(in&nbsp;thousands,&nbsp;except&nbsp;share&nbsp;and&nbsp;per&nbsp;share&nbsp;data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(43,593</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(29,141</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Weighted-average common units outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,938,654</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,947,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Pro forma adjustment to reflect the issuance of common stock in exchange for common units in connection with
the Reorganization(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Pro forma adjustment to reflect the issuance of common stock in exchange for vested profits interests in
connection with the Reorganization(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Pro forma adjustment to reflect the conversion of redeemable convertible preferred stock issued in
connection with the conversion of the redeemable convertible preferred units from the Reorganization into common stock(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Pro forma weighted-average common shares outstanding, basic and diluted (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Pro forma net loss per share attributable to common stockholders, basic and diluted (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Reflects the exchange of (i) 5,947,500 common units for&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock and
(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vested profits interests for &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common
stock in connection with the Reorganization, as if such exchange had occurred on January 1, 2022. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Reflects the conversion of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our redeemable convertible preferred stock, issued in connection with the
Reorganization in exchange for redeemable convertible preferred units, into an equivalent number of shares of our common stock, as if such conversion had occurred on January&nbsp;1, 2022. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="12" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As of June 30, 2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Pro&nbsp;Forma(1)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Pro&nbsp;Forma<BR>As&nbsp;Adjusted(2)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Condensed Consolidated Balance Sheet Data:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">51,648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Available-for-sale marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">266,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Working capital(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">259,907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">408,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">160,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Redeemable convertible preferred units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">350,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(105,830</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total members&#146;/shareholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000" ALIGN="right">(102,539</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The consolidated pro forma balance sheet data gives effect to (i) the Reorganization, (ii) the conversion of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our redeemable convertible preferred stock, issued
in connection with the Reorganization in exchange for redeemable convertible preferred units outstanding as of June 30, 2023, into an equivalent number of shares of our common stock immediately prior to the closing of this offering, and (iii) the
filing and effectiveness of our amended and restated certificate of incorporation upon the closing of this offering. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The pro forma as adjusted consolidated balance sheet data gives effect to the pro forma adjustments set forth in footnote (1) above and our issuance and sale of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of
our common stock offered in this offering at an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the estimated midpoint of the price range set forth on the cover page of this prospectus,
after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. The pro forma as adjusted information set forth in the table above is illustrative only and will be adjusted based on the actual initial
public offering price and other terms of this offering as determined at pricing. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We define working capital as current assets less current liabilities. See our consolidated financial statements included elsewhere in this prospectus for further details regarding our current assets and current
liabilities. </TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Each $1.00 increase or decrease in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per
share, which is the estimated midpoint of the price range set forth on the cover page of this prospectus, would increase or decrease, as applicable, the pro forma as adjusted amount of each of our cash and cash equivalents, working capital, total
assets, and total members&#146;/shareholders&#146; equity (deficit) by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the
same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase or decrease of 1,000,000 shares in the number of shares offered by us as set forth on the cover page of
this prospectus, would increase or decrease, as applicable, the pro forma as adjusted amount of each of cash and cash equivalents, working capital, total assets, and total members&#146;/shareholders&#146; equity (deficit) by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming no change in the assumed initial public offering price per share and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by
us. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc425213_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below together with all of the other
information contained in this prospectus, including our consolidated financial statements and related notes appearing at the end of this prospectus, before deciding to invest in our common stock. If any of the events or developments described below
were to occur, our business, prospects, operating results and financial condition could suffer materially, the trading price of our common stock could decline and you could lose all or part of your investment. The risks and uncertainties described
below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect our business. </I></P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Risks Related to Financial Position and Need for Capital </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We have
incurred significant losses since inception. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability. </I></B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Since
inception, we have incurred significant operating losses. Our net loss was $21.4&nbsp;million and $43.6&nbsp;million for the years ended December&nbsp;31, 2021 and 2022, and $18.6 million and $29.1 million for the six months ended June 30, 2022 and
2023, respectively. As of June 30, 2023, we had an accumulated deficit of $105.8&nbsp;million. We have financed our operations primarily through issuing redeemable convertible preferred units and convertible promissory notes and entering into
collaboration agreements. Substantially all of our losses have resulted from expenses incurred in connection with our research and development and from general and administrative costs associated with our operations. We expect to continue to incur
significant expenses and increasing operating losses for the foreseeable future. The net losses we incur may fluctuate significantly from quarter to quarter. We anticipate that our expenses will increase substantially if and as we: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">advance our&nbsp;current research activities and further develop our platform; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">continue preclinical development and initiate clinical trials for any product candidates we may identify;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">seek regulatory approval for any product candidates for which we successfully complete clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">establish our manufacturing capabilities, including internal manufacturing facilities and contracting with other vendors;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">ultimately, commercialize our future product candidates requiring significant marketing, sales, and distribution
infrastructure expenses; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">hire additional research and development, clinical, commercial, general and administration personnel;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">develop, maintain, expand, protect, and enforce our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> product candidates, intellectual property and technologies;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">confirm, maintain or obtain freedom to operate for any of our owned or licensed technologies and product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">establish and maintain collaborations; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">add operational, financial and management information systems and personnel; or </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">incur additional legal, audit, accounting, compliance, insurance, investor relations and other expenses to operate as a
public company that we did not incur as a private company. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As a result, we will need substantial additional funding to support our continuing operations and pursue our growth
strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through the sale of equity, debt financings, or other capital sources, which may include collaborations with other
companies or other strategic transactions. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such agreements as and
when needed, we may have to significantly delay, reduce or eliminate the development and commercialization of our platform or delay our pursuit of potential <FONT STYLE="white-space:nowrap">in-licenses</FONT> or acquisitions. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have not initiated clinical development of any potential product candidate and expect that it will be many years, if ever, before we have a product candidate ready
for commercialization. To become and remain profitable, we must develop and, either directly or through collaborators, eventually commercialize a therapy or therapies with market potential. This will require us to be successful in a range of
challenging activities, including identifying product candidates, completing preclinical studies and clinical trials of product candidates, obtaining regulatory approval for these product candidates, manufacturing, marketing and selling those
therapies for which we may obtain regulatory approval and satisfying any post-marketing requirements. We may never succeed in these activities and, even if we do, may never generate revenues that are significant or large enough to achieve
profitability. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Because of the numerous risks and uncertainties associated with developing our technology and any potential product candidates, we are unable to
predict the extent of any future losses or when we will become profitable, if at all. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable
would decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company could also cause you to lose
all or part of your investment. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We have never generated revenue from product sales and may never become profitable. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our ability to generate revenue from product sales and achieve profitability depends on our ability, alone or with collaborative partners, to successfully complete the
development of, and obtain the regulatory approvals necessary to commercialize, product candidates we may identify for development. We may not generate revenues from product sales for many years, if ever. Our ability to generate future revenues from
product sales depends heavily on our or our collaborators&#146; ability to successfully: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">identify product candidates and successfully complete research development of any product candidates we may identify;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">seek and obtain regulatory approvals for any product candidates for which we successfully complete clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">launch and commercialize any product candidates for which we may obtain regulatory approval by establishing a sales force,
marketing and distribution infrastructure, or alternatively, collaborating with a commercialization partner; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">qualify for adequate coverage and reimbursement by government and third-party payors for any product candidates for which
we may obtain regulatory approval; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">establish and maintain supply and manufacturing relationships with third parties that can provide adequate, in both amount
and quality, products and services to support clinical development and the market demand for any product candidates for which we obtain regulatory approval; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">develop, maintain and enhance a sustainable, scalable, reproducible and transferable manufacturing process for the product
candidates we may develop; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">address competing technological and market developments; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">negotiate favorable terms in any collaboration, licensing or other arrangements into which we may enter and performing our
obligations in such collaborations; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">receive market acceptance by physicians, patients, healthcare payors, and others in the medical community;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">maintain, protect, enforce, defend and expand our portfolio of intellectual property and other proprietary rights,
including patents, trade secrets and <FONT STYLE="white-space:nowrap">know-how;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">defend against third-party intellectual property claims of infringement, misappropriation or other violation; and
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">attract, hire and retain qualified personnel. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our expenses could increase beyond expectations if we are required by the U.S. Food and Drug Administration (the &#147;FDA&#148;) or other regulatory authorities to
perform preclinical studies or clinical trials in addition to those that we currently anticipate. Even if one or more of the product candidates we may develop are approved for commercial sale, we anticipate incurring significant costs associated
with commercializing any approved product candidate. Additionally, such products may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives. Even if we are able to generate revenues
from the sale of any approved product candidates, we may not become profitable and may need to obtain additional funding to continue operations. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We will need
substantial additional funding in addition to the net proceeds we receive from this offering. If we are unable to raise additional capital when needed on acceptable terms, or at all, we may be forced to delay, reduce, or terminate certain of our
research and product development programs, future commercialization efforts or other operations. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Developing gene editing products, including conducting
preclinical studies and clinical trials, is a very time-consuming, expensive and uncertain process that takes years to complete. Our operations have consumed substantial amounts of cash since inception, and we expect our expenses to increase in
connection with our ongoing activities, particularly as we identify, continue the research and development of, initiate and conduct clinical trials of, and seek regulatory approval for, any product candidates we may identify. In addition, if we
obtain regulatory approval for any product candidates we may identify, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing, and distribution to the extent that such sales, marketing,
manufacturing, and distribution are not the responsibility of a collaborator. Other unanticipated costs may also arise. Furthermore, upon the closing of this offering, we expect to incur additional costs associated with operating as a public
company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on acceptable terms, we would be forced to delay, reduce, or eliminate our
research and product development programs, future commercialization efforts or other operations. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of June 30, 2023, our cash, cash equivalents and
available-for-sale marketable securities were $318.4 million. We expect that the net proceeds from this offering, together with our existing cash, cash equivalents, and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities, will enable us to fund our operating expenses and capital expenditure requirements
into&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. However, our operating plan may change as a result of factors currently unknown to us, and we may need to seek funding sooner than planned. Our
future capital requirements will depend on many factors, including: </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the timing and progress of research and development, preclinical&nbsp;and clinical development activities;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the number, scope and duration of clinical trials required for regulatory approval of our future product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs, timing, and outcome of regulatory review of any of our future product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs of manufacturing clinical and commercial supplies of our future product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and
distribution, for any of our future product candidates for which we receive regulatory approval; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs of preparing, filing and prosecuting our patent applications, maintaining and enforcing our patents and other
intellectual property rights and defending intellectual property-related claims; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to maintain existing, and establish new, strategic collaborations, licensing or other arrangements, and the
financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to establish and maintain collaboration and license agreements on favorable terms, if at all;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the extent to which we acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> other product candidates and
technologies; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any product liability or other lawsuits related to our future product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our implementation of various computerized informational systems and efforts to enhance operational systems;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">expenses incurred to attract, hire and retain skilled personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs of operating as a public company; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to establish a commercially viable pricing structure and obtain approval for coverage and adequate
reimbursement from third-party and government payers; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the extent to which we acquire or invest in businesses, products, and technologies; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the effect of competing technological and market developments; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, as well as other factors, including economic
uncertainty and geopolitical tensions, which may exacerbate the magnitude of the factors discussed above. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Identifying potential product candidates
and conducting preclinical testing and clinical trials is a time-consuming, expensive, and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain regulatory approval and achieve
product sales. In addition, our future product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if
at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all. In addition, we may seek additional capital
due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent that we raise additional capital through the sale of equity or convertible debt
securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available, may involve agreements that
include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, declaring dividends, and possibly other restrictions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any additional fundraising efforts may divert our management from their <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities, which may adversely affect our ability to develop and commercialize our product candidates. We have no committed sources of additional capital and, if we are unable to raise additional
capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of our future product candidates or other research and development initiatives. Without
sufficient funding, our license agreements and any future collaboration agreements may also be terminated if we are unable to meet the payment or other obligations under such agreements. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce, or terminate our product
development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. Additionally, if we raise funds through additional collaborations, strategic
alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or product candidates we develop, or we may have to grant licenses on terms that may
not be favorable to us and/or that may reduce the value of our common stock. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our short operating history may make it difficult for you to evaluate the success
of our business to date and to assess our future viability. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are an early-stage company. We commenced our operations in September 2018. Our operations to
date have been limited to organizing and staffing our company, business planning, raising capital, and research and development activities such as acquiring and developing our platform and technology and identifying and beginning to advance
preclinical testing of potential product candidates. All of our programs are still in the research or lead optimization stage of development and their risk of failure is high. We have not yet demonstrated an ability to initiate or successfully
complete any clinical trials, including large-scale, pivotal clinical trials, obtain regulatory approvals, manufacture a commercial-scale therapy, arrange for a third party to do so on our behalf or conduct sales and marketing activities necessary
for successful commercialization. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our limited operating history, particularly in light of the rapidly evolving genome editing field, may make it difficult to
evaluate our technology and industry and predict our future performance. Our short history as an operating company makes any assessment of our future success or viability subject to significant uncertainty. We will encounter risks and difficulties
frequently experienced by very early stage companies in rapidly evolving fields. If we do not address these risks successfully, our business will suffer. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In
addition, as a new business that is rapidly growing, we may encounter other unforeseen expenses, difficulties, complications, and delays in our product development. We will need to transition from a company with a research focus to a company capable
of conducting clinical trials and ultimately supporting commercial activities if any of our future product candidates are approved. We may not be successful in such a transition. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our future ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Since our inception, we have incurred losses and we may never achieve profitability. As of December&nbsp;31, 2022, we had U.S. federal net operating loss carryforwards
of $0.02&nbsp;million (which are not subject to expiration) and state net operating loss carryforwards of $8.3&nbsp;million (which begin to expire in various amounts in 2037), and $2.8 million of research credit carryforwards for state income tax
purposes (which do not expire and can be carried forward indefinitely). To the extent that we continue to generate taxable losses, under current law, our unused U.S. federal net operating losses (&#147;NOLs&#148;) may be carried forward to offset a
portion of future taxable income, if any. Additionally, we continue to generate business tax credits, including research and development tax credits, which generally may be carried forward to offset a portion of future taxable income, if any,
subject </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
to expiration of such credit carryforwards. Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;), if a corporation undergoes an &#147;ownership
change,&#148; generally defined as one or more shareholders or groups of shareholders who own at least 5&nbsp;percent of the corporation&#146;s equity increasing their equity ownership in the aggregate by more than 50 percentage points (by value)
over a three-year period, the corporation&#146;s ability to use its <FONT STYLE="white-space:nowrap">pre-change</FONT> NOLs and other <FONT STYLE="white-space:nowrap">pre-change</FONT> tax attributes (such as research and development tax credits) to
offset its post-change income or taxes may be limited. Similar rules may apply under state tax laws. Our prior equity offerings and other changes in our stock ownership have resulted in such ownership changes in the past. In addition, we may
experience ownership changes in the future as a result of this offering or subsequent shifts in our stock ownership, some of which are outside of our control. As a result, if we earn net taxable income, our ability to use our <FONT
STYLE="white-space:nowrap">pre-change</FONT> NOLs or other <FONT STYLE="white-space:nowrap">pre-change</FONT> tax attributes to offset U.S. federal taxable income may be subject to limitations, which could potentially result in increased future tax
liability to us. Additional limitations on our ability to utilize our NOLs to offset future taxable income may arise as a result of our corporate structure whereby NOLs generated by our subsidiary may not be available to offset taxable income earned
by our subsidiary. There is a risk that due to changes under the tax law, regulatory changes or other unforeseen reasons, our existing NOLs or business tax credits could expire or otherwise be unavailable to offset future income tax liabilities. At
the state level, there may also be periods during which the use of NOLs or business tax credits is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. For these reasons, we may not be able to realize a
tax benefit from the use of our NOLs or tax credits, even if we attain profitability. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Changes in tax laws or in their implementation or interpretation may
adversely affect our business and financial condition. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The rules dealing with U.S. federal, state and local income taxation are constantly under review by
persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect our business and our financial condition.
In recent years, many such changes have been made and changes are likely to continue to occur in the future. We cannot predict whether, when, in what form or with what effective dates, tax laws, regulations and rulings may be enacted, promulgated or
decided or whether they could increase our tax liability or require changes in the manner in which we operate in order to minimize increases in our tax liability. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Risks Related to Business, Technology, and Industry </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We are very early
in our development efforts, and we have not yet initiated <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies or clinical development of any product candidate. As a result, we expect it will be many years before we commercialize any product
candidate, if ever. If we are unable to advance our future product candidates into and through clinical trials, obtain regulatory approval and ultimately commercialize our product candidates or experience significant delays in doing so, our business
will be materially harmed. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are very early in our development efforts and have focused our research and development efforts to date on research efforts
including preclinical studies. Currently, all of our programs are still in the research or lead optimization stage of development. Our ability to generate product revenues, which we do not expect will occur for many years, if ever, will depend
heavily on the successful development, regulatory approval and eventual commercialization of our future product candidates, which may never occur. We have not yet generated revenue from product sales, and we may never be able to develop or
commercialize a marketable product. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Commencing clinical trials in the United States is subject to acceptance by the FDA of an investigational new drug
(&#147;IND&#148;) application and finalizing the trial design based on discussions with the FDA. In the event that the FDA requires us to complete additional preclinical studies or we are required to satisfy other FDA requests prior
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
to commencing clinical trials, the start of our first clinical trials may be delayed or we may be unsuccessful obtaining clearance to proceed into clinical development. Even after we receive and
incorporate guidance from the FDA, the FDA could disagree that we have satisfied their requirements to commence any clinical trial or change their position on the acceptability of our trial design or the clinical endpoints selected, which may
require us to complete additional preclinical studies or clinical trials, delay the enrollment of our clinical trials, abandon our clinical development plans or meet stricter approval conditions than we currently expect. There are equivalent
processes and risks applicable to clinical trial applications in other countries, including countries in the European Union. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, clinical trials conducted
in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country. We may conduct one or more of our clinical trials with one or more
trial sites that are located outside the United States. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of these data is subject to conditions imposed by the FDA, and there can be no assurance
that the FDA will accept data from trials conducted outside of the United States. If the FDA does not accept the data from any trial that we conduct outside the United States, it would likely result in the need for additional trials, which would be
costly and time-consuming and could delay or permanently halt our development of the applicable product candidates. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Commercialization of any product candidates we
may develop will require preclinical and clinical development; regulatory approval in multiple jurisdictions; manufacturing supply, capacity and expertise; a commercial organization; and significant marketing efforts. The success of product
candidates we may identify and develop will depend on many factors, including the following: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">timely and successful completion of preclinical studies, including toxicology studies, biodistribution studies and
minimally efficacious dose studies in animals, where applicable; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">effective INDs or comparable foreign applications that allow commencement of our planned clinical trials or future clinical
trials for any product candidates we may develop; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">successful enrollment and completion of clinical trials, including under the FDA&#146;s current Good Clinical Practices
(&#147;GCPs&#148;), current Good Laboratory Practices (&#147;GLPs&#148;), and any additional regulatory requirements from foreign regulatory authorities; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">positive results from our future clinical trials that support a finding of safety and effectiveness and an acceptable
risk-benefit profile in the intended populations; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">receipt of regulatory approvals from applicable regulatory authorities; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">establishment of arrangements through our own facilities or with third-party manufacturers for clinical supply and, where
applicable, commercial manufacturing capabilities; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">establishment, maintenance, defense and enforcement of patent, trademark, trade secret and other intellectual property
protection or regulatory exclusivity for any product candidates we may develop; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">commercial launch of any product candidates we may develop, if approved, whether alone or in collaboration with others;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">acceptance of the benefits and use of our product candidates we may develop, including method of administration, if and
when approved, by patients, the medical community and third-party payors; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">effective competition with other therapies; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">maintenance of a continued acceptable safety, tolerability and efficacy profile of any product candidates we may develop
following approval; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">establishment and maintenance of healthcare coverage and adequate reimbursement by payors. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we do not succeed in one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize
any product candidates we may develop, which would materially harm our business. If we are unable to advance our product candidates to clinical development, obtain regulatory approval and ultimately commercialize our product candidates, or
experience significant delays in doing so, our business will be materially harmed. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We are subject to additional development challenges and risks due to the
novel nature of our genome editing technology. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Because our <I>in vivo</I> technology potentially involves genome editing across multiple cell and tissue
types, we are subject to many of the challenges and risks that other genome editing therapeutics and gene therapies face, including: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">regulatory guidance regarding the requirements governing gene and genome editing therapy product candidates have changed
and may continue to change in the future; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">to date, only a limited number of products that involve <I>in vivo</I> gene transfer have been approved globally;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">improper modulation of a gene sequence, including unintended editing events or insertion of a sequence into certain
locations in a patient&#146;s chromosome, could lead to cancer, other aberrantly functioning cells or other diseases, including death; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">corrective expression of a missing protein in patients&#146; cells could result in the protein being recognized as foreign,
and lead to a sustained immunological reaction against the expressed protein or expressing cells, which could be severe or life-threatening; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">regulatory agencies may require extended <FONT STYLE="white-space:nowrap">follow-up</FONT> observation periods of patients
who receive treatment using genome editing product candidates including, for example, the FDA&#146;s recommended <FONT STYLE="white-space:nowrap">15-year</FONT> <FONT STYLE="white-space:nowrap">follow-up</FONT> observation period for these patients,
and we will need to adopt such observation periods for product candidates we develop if required by the relevant regulatory agency, which could vary by country or region. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Furthermore, our technology has potential application for <I>ex vivo</I> immune cell editing strategies. Because <I>ex vivo</I> application of our technology potentially
involves editing human cells and then delivering modified cells to patients, we may be subject to many of the challenges and risks that engineered cell therapies face. For example, clinical trials using engineered cell-based gene therapies may
require unique products to be created for each patient and such individualistic manufacturing may be both inefficient and cost-prohibitive. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Clinical drug
development involves a lengthy and expensive process, with an uncertain outcome. Because genome editing is novel and the regulatory landscape that will govern our potential product candidates is uncertain and may change, we cannot predict the time
and cost of obtaining regulatory approval, if we receive it at all, for our potential product candidates. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The time required to obtain approval for any of
our potential product candidates from the FDA, the European Medicines Agency (&#147;EMA&#148;) or other comparable foreign regulatory authorities is unpredictable but typically takes many years following the commencement of clinical trials and
depends upon numerous factors, including the substantial discretion of regulatory authorities. For more information on the regulatory approval process, see &#147;Business&#151;Government Regulation.&#148; Clinical trials may fail to demonstrate that
our product candidates are safe for humans and effective for indicated uses. Even if initial clinical trials in any of any product candidates we may develop are successful, such product candidates may fail to show the desired safety and efficacy in
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
later stages of clinical development despite having successfully advanced through preclinical studies and initial clinical trials. There is a high failure rate for drugs and biologics proceeding
through clinical trials. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in later stage clinical trials even after achieving promising results in earlier stage clinical trials. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Because genome editing is novel, the regulatory requirements that will govern any novel genome editing product candidates we develop may continue to evolve. Within the
broader genetic therapy field, a limited number of gene therapy products have received marketing authorization from the FDA and the EMA to date. Even with respect to more established products that fit into the categories of gene therapies or cell
therapies, the regulatory landscape is still developing. Regulatory requirements governing gene therapy products and cell therapy products have changed frequently and may continue to change in the future. For example, in January 2020, the FDA issued
several new guidance documents on gene therapy products, and in March 2022, the FDA published a draft guidance document providing recommendations for human genome editing gene therapy products. Moreover, there is substantial, and sometimes
uncoordinated, overlap in those responsible for regulation of existing gene therapy products and cell therapy products. For example, in the United States, the FDA has established the Office of Therapeutic Products (&#147;OTP&#148;) within its Center
for Biologics Evaluation and Research (&#147;CBER&#148;) to consolidate the review of gene therapy and related products, and the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER on its review. Gene therapy clinical trials may
also be subject to review and oversight by an institutional biosafety committee (&#147;IBC&#148;), a local institutional committee that reviews and oversees certain basic and clinical research conducted at the institution participating in the
clinical trial. Although the FDA decides whether individual gene therapy protocols may proceed, the review process and determinations of other reviewing bodies, such as an IBC or institutional review board (&#147;IRB&#148;), can impede or delay the
initiation of a clinical trial, even if the FDA has reviewed the trial and approved its initiation. For example, more recently, some genome editing companies have seen significant delays in receiving FDA authorization to allow the initiation of
their clinical trials, and has suspended ongoing trials, due to the FDA&#146;s placement of clinical holds on their INDs. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The same applies in the European Union.
The EMA&#146;s Committee for Advanced Therapies (&#147;CAT&#148;) is responsible for assessing the quality, safety and efficacy of advanced-therapy medicinal products (i.e. gene therapy, somatic-cell therapy or tissue-engineered medicines). The role
of the CAT is to prepare a draft opinion on an application for marketing authorization for a gene therapy medicinal candidate that is submitted to the Committee for Medicinal Products for Human Use (&#147;CHMP&#148;) before CHMP adopts its opinion
which is submitted to the European Commission for the final decision on whether to grant a marketing authorization or not. In the European Union, the EMA publishes guidelines for the development and evaluation of gene therapy medicinal products to
assist in preparing marketing authorization applications, however these are continually under review. The EMA may issue new guidelines concerning the development and marketing authorization for gene therapy medicinal products and require that we
comply with these new guidelines. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Adverse developments in post-marketing experience or in clinical trials conducted by others of gene therapy products, cell therapy
products or products developed through the application of genome editing technology may cause the FDA, the EMA and other regulatory bodies to revise the requirements for development or approval of our potential product candidates or limit the use of
products utilizing genome editing technologies, either of which could materially harm our business. In addition, the clinical trial requirements of the FDA, the EMA and other regulatory authorities and the criteria these regulators use to determine
the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of the potential products. The regulatory approval process for novel product candidates can be more expensive
and take longer than for other, better known or more extensively studied pharmaceutical or other product candidates. Regulatory agencies administering existing or future regulations or legislation may not allow production and marketing of products
utilizing genome editing technology in a timely manner or under </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
technically or commercially feasible conditions. In addition, regulatory action or private litigation could result in expenses, delays or other impediments to our research programs or the
commercialization of resulting products. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The regulatory review committees and advisory groups described above and any new guidelines they promulgate may lengthen
the regulatory review process, require us to perform additional studies or trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of these treatment
candidates or lead to significant post-approval limitations or restrictions. As we advance our research programs and develop future product candidates, we will be required to consult with these regulatory and advisory groups and to comply with
applicable guidelines. If we fail to do so, we may be required to delay or discontinue development of any product candidates we identify and develop. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>The
genome editing field is relatively new and is evolving rapidly. We are focusing our research and development efforts on genome editing using programmable nucleases, base editing, and RNA and <FONT STYLE="white-space:nowrap">DNA-mediated</FONT>
integration systems (including prime editors and CRISPR-associated (&#147;Cas&#148;) transposes), but other genome editing technologies may be discovered that provide significant advantages over such technologies, which could materially harm our
business. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To date, we have focused our efforts on genome editing technologies using programmable nucleases, base editing, and RNA and <FONT
STYLE="white-space:nowrap">DNA-mediated</FONT> integration systems (including prime editors and Cas transposes backed by our metagenomics database. Other companies have previously undertaken research and development of genome editing technologies
using zinc finger nucleases, engineered meganucleases and transcription activator-like effector nucleases, but to date none have obtained regulatory approval for a product candidate. There can be no certainty that genome editing technology will lead
to the development of genetic medicines or that other genome editing technologies will not be considered better or more attractive for the development of medicines. A number of alternative approaches are being developed by others. Our investments
may not be consistent with the expectations of our stockholders and may not produce the benefits that we expect, in which case our growth, business, financial condition, and results of operations could be adversely affected. See &#147;Risk
Factors&#151;Risks Related to Business, Technology and Industry&#151;We face significant competition in an environment of rapid technological change, and there is a possibility that our competitors may achieve regulatory approval before us or
develop therapies that are safer or more advanced or effective than ours, which may harm our financial condition and our ability to successfully market or commercialize any product candidates we may develop.&#148; Similarly, another new genome
editing technology that has not been discovered yet may be more attractive than programmable nucleases, base editing, and RNA and <FONT STYLE="white-space:nowrap">DNA-mediated</FONT> integration systems. Moreover, if we decide to develop genome
editing technologies other than those involving such technologies, we cannot be certain we will be able to obtain rights to such technologies. Any of these factors could reduce or eliminate our commercial opportunity, and could have a material
adverse effect on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If any of the product candidates we may develop or the delivery
modes we rely on cause undesirable side effects, it could delay or prevent their development or potential regulatory approval, limit the commercial potential or result in significant negative consequences following any potential regulatory approval.
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To date, we have not evaluated any product candidates in human clinical trials. It is impossible to predict when or if any product candidates we may develop
will ultimately prove safe in humans. In the genomic medicine field, there have been several significant adverse events from gene therapy treatments in the past, including reported cases of leukemia and death. Product candidates we may develop may
be associated with undesirable side effects, unexpected characteristics or other serious adverse events, including <FONT STYLE="white-space:nowrap">off-target</FONT> cuts of DNA, or the introduction of cuts in DNA at locations other than the target
sequence. These <FONT STYLE="white-space:nowrap">off-target</FONT> cuts could lead to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
disruption of a gene or a genetic regulatory sequence at an unintended site in the DNA, or, in those instances where we also provide a segment of DNA to serve as a repair template, it is possible
that following <FONT STYLE="white-space:nowrap">off-target</FONT> cut events, DNA from such repair template could be integrated into the genome at an unintended site, potentially disrupting another important gene or genomic element. There is also
the potential risk of delayed adverse events following exposure to genome editing therapy due to persistent biologic activity of the genetic material or other components of products used to carry the genetic material. Possible adverse side effects
that could occur with treatment with genome editing products include an immunologic reaction after administration which could substantially limit the effectiveness of the treatment If any of our genome editing technologies demonstrate a similar
effect, we may decide or be required to halt or delay preclinical development or clinical development of any product candidates we may develop. In addition to serious adverse events or side effects caused by any product candidate we may develop, the
administration process or related procedures also can cause undesirable side effects. If any such events occur, our preclinical studies or clinical trials could be delayed, suspended or terminated. There can be no assurance that our genome editing
technologies will not cause severe or undesirable side effects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If in the future we are unable to demonstrate that such adverse events were caused by factors other
than our product candidate, the FDA, the EMA or other comparable foreign regulatory authorities could order us to cease further clinical studies of, or deny approval of, any product candidates we develop for any or all targeted indications. Even if
we are able to demonstrate that all future serious adverse events are not product-related, such occurrences could affect patient recruitment or the ability of enrolled patients to complete the trial. Moreover, if we elect, or are required, to delay,
suspend or terminate any clinical trial of any product candidate we may develop, the commercial prospects of such product candidates may be harmed and our ability to generate product revenues from any of these product candidates may be delayed or
eliminated. Any of these occurrences may harm our ability to identify and develop product candidates, and may harm our business, financial condition, result of operations and prospects significantly. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Viral vectors, including the adeno-associated virus (&#147;AAV&#148;), which are relatively new approaches used for disease treatment, also have known side effects, and
for which additional risks could develop in the future. In past clinical trials that were conducted by others with <FONT STYLE="white-space:nowrap">non-AAV</FONT> vectors, significant side effects were caused by gene therapy treatments, including
reported cases of myelodysplasia, leukemia and death. Other potential side effects could include an immunologic reaction and insertional oncogenesis, which is the process whereby the insertion of a functional gene near a gene that is important in
cell growth or division results in uncontrolled cell division, which could potentially enhance the risk of cancer. If the vectors we use demonstrate a similar side effect, or other adverse events, we may be required to halt or delay further clinical
development of any potential product candidates. Such delayed adverse events may also occur in other viral vectors, including AAV vectors. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition to side
effects and adverse events caused by our product candidates, the conditioning, administration process or related procedures which may be used to condition a patient for gene therapy treatment also can cause adverse side effects and adverse events. A
gene therapy patient is generally administered cytotoxic drugs to remove stem cells from the bone marrow to create sufficient space in the bone marrow for the modified stem cells to engraft and produce new cells. This procedure compromises the
patient&#146;s immune system, and conditioning regimens have been associated with adverse events in clinical trial participants. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Additionally, if we successfully
develop a product candidate and it receives regulatory approval, the FDA could require us to adopt a Risk Evaluation and Mitigation Strategy (&#147;REMS&#148;) to ensure that the benefits of treatment with such product candidate outweighs the risks
for each potential patient, which may include, among other things, a medication guide outlining the risks of the product for distribution to patients, a communication plan </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
to healthcare practitioners, extensive patient monitoring, or distribution systems and processes that are highly controlled, restrictive, and more costly than what is typical for the industry.
Furthermore, if we or others later identify undesirable side effects caused by any product candidate that we may develop that receives regulatory approval, several potentially significant negative consequences could result, including: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">regulatory authorities may revoke licenses or suspend, vary or withdraw approvals of such product candidate;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">regulatory authorities may require additional warnings on the label; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we may be required to change the way a product candidate is administered or conduct additional clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we could be sued and held liable for harm caused to patients; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our reputation may suffer. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any of these events could prevent us from achieving or maintaining market acceptance of our genome editing technology and any product candidates we may identify and
develop and could have a material adverse effect on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Positive results from early
preclinical studies of any product candidates we may develop may not necessarily be predictive of the results of later preclinical studies and any future clinical trials of such product candidates. If we cannot replicate the positive results from
our earlier preclinical studies of any product candidates we may develop in our later preclinical studies and future clinical trials, we may be unable to successfully develop, obtain regulatory approval for and commercialize such product candidates.
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any positive results from our preclinical studies of any product candidates we may develop may not necessarily be predictive of the results from later
preclinical studies and clinical trials of such product candidates. Similarly, even if we are able to complete our planned preclinical studies or any future clinical trials of any product candidates we may develop according to our current
development timeline, the positive results from such preclinical studies and clinical trials of our product candidates may not be replicated in subsequent preclinical studies or clinical trial results. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials after achieving positive results in
early-stage development and we cannot be certain that we will not face similar setbacks. These setbacks have been caused by, among other things, preclinical findings made while clinical trials were underway or safety or efficacy observations made in
preclinical studies and clinical trials, including previously unreported adverse events. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses and many companies that believed their product candidates
performed satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain regulatory approval. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may also consider additional delivery
modes, which may carry additional known and unknown risks. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may also consider additional delivery modes, which may carry additional known and unknown
risks. For example, we intend to use lipid nanoparticles (&#147;LNPs&#148;) to deliver our nucleases. While LNPs have been used to deliver smaller molecules, such as small interfering RNA (&#147;siRNA&#148;), they have not been clinically proven to
deliver large RNA molecules. Furthermore, as with many <FONT STYLE="white-space:nowrap">AAV-mediated</FONT> gene therapy approaches, certain patients&#146; immune systems might prohibit the successful delivery, thereby potentially limiting treatment
outcomes of these patients. Even if initial clinical trials in any of our potential product candidates we may develop are successful, these product candidates we may develop may fail to show the desired safety and efficacy in later stages of
clinical development despite having successfully advanced through preclinical studies and initial clinical trials. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may find it difficult to enroll patients in our future clinical trials given the limited number of patients
who have the diseases any product candidates we identify or develop are intended to target. If we experience delays or difficulties in the enrollment of patients in clinical trials, our clinical development activities and our receipt of necessary
regulatory approvals could be delayed or prevented. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As we progress our programs, we may not be able to initiate or continue clinical trials for any product
candidates we identify or develop if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA, the EMA or other comparable regulatory authorities outside the United States, or
as needed to provide appropriate statistical power for a given trial. Enrollment may be particularly challenging for some of the rare genetically defined diseases we are targeting in some of our discovery programs. In addition, if patients are
unwilling to participate in our genome editing trials because of negative publicity from adverse events related to the biotechnology, gene therapy or genome editing fields, competitive clinical trials for similar patient populations, clinical trials
in competing product candidates or for other reasons, the timeline for recruiting patients, conducting studies and obtaining regulatory approval of our potential product candidates may be delayed. Moreover, some of our competitors may have ongoing
clinical trials for product candidates that would treat the same indications as our potential product candidates, and patients who would otherwise be eligible for our future clinical trials may instead enroll in clinical trials of our
competitors&#146; product candidates. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Patient enrollment is also affected by other factors, some of which may include: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">severity of the disease under investigation; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">size of the patient population and process for identifying patients, including proximity and availability of clinical trial
sites for prospective patients with conditions that have small patient pools; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">design of the trial protocol, including efforts to facilitate timely enrollment in clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">availability and efficacy of approved medications for the disease under investigation; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">availability of genetic testing for potential patients and ability to monitor patients adequately during and after
treatment; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">ability to obtain and maintain patient informed consent; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">risk that enrolled patients will drop out before completion of the trial; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">eligibility and exclusion criteria for the trial in question; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">perceived risks and benefits of the product candidate under trial and genome editing as a therapeutic approach; and
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">patient referral practices of physicians. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, our ability to successfully initiate, enroll and complete a clinical trial in any foreign country is subject to numerous risks unique to conducting business
in foreign countries, some of which may include: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">difficulty in establishing or managing relationships with clinical research organizations (&#147;CROs&#148;) and
physicians; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">different standards for the conduct of clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">different <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> for patients
with a particular disease; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">difficulty in locating qualified local consultants, physicians and partners; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">potential burden of complying with a variety of foreign laws, medical standards and regulatory requirements, including the
regulation of pharmaceutical and biotechnology products and treatment and of genome editing technologies. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Enrollment delays in our future clinical trials may result in increased development costs for our potential product
candidates, which would cause the value of our company to decline and limit our ability to obtain additional financing. If we or our collaborators have difficulty enrolling a sufficient number of patients to conduct our future clinical trials as
planned, we may need to delay, limit or terminate ongoing or planned clinical trials or entire clinical programs, any of which would have an adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Genetic therapies are novel, and any product candidates we develop may be complex and difficult to manufacture. We could experience delays in satisfying regulatory
authorities or production problems that result in delays in our development programs, limit the supply of the product candidates we may develop or otherwise harm our business. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any product candidates we may develop will likely require processing steps that are more complex than those required for most chemical pharmaceuticals. Moreover, unlike
chemical pharmaceuticals, the physical and chemical properties of a biologic such as the product candidates we intend to develop generally cannot be fully characterized. As a result, assays of the finished product candidate may not be sufficient to
ensure that the product candidate will perform in the intended manner. Problems with the manufacturing process, even minor deviations from the normal process, could result in product defects or manufacturing failures that result in lot failures,
product recalls, product liability claims, insufficient inventory or potentially delay progression of our potential IND filings. If we successfully develop product candidates, we may encounter problems achieving adequate quantities and quality of
clinical-grade materials that meet the FDA, the EMA or other comparable applicable foreign standards or specifications with consistent and acceptable production yields and costs. For example, the current approach of manufacturing AAV vectors may
fall short of supplying required number of doses needed for advanced stages of preclinical studies or clinical trials, and the FDA may ask us to demonstrate that we have the appropriate manufacturing processes in place to support the higher-dose
group in our preclinical studies or clinical trials. In addition, any product candidates we may develop will require complicated delivery methods, each of which will introduce additional complexities in the manufacturing process. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, the FDA, the EMA and other regulatory authorities may require us to submit samples of any lot of any approved product together with the protocols showing
the results of applicable tests at any time. Under some circumstances, the FDA, the EMA or other regulatory authorities may require that we not distribute a lot until the agency authorizes its release. Slight deviations in the manufacturing process,
including those affecting quality attributes and stability, may result in unacceptable changes in the product that could result in lot failures or product recalls. Lot failures or product recalls could cause us to delay clinical trials or product
launches, which could be costly to us and otherwise harm our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Given the nature of biologics
manufacturing there is a risk of contamination during manufacturing. Any contamination could materially harm our ability to produce product candidates on schedule and could harm our results of operations and cause reputational damage. Some of the
raw materials that we anticipate will be required in our manufacturing process are derived from biologic sources. Such raw materials are difficult to procure and may be subject to contamination or recall. A material shortage, contamination, recall
or restriction on the use of biologically derived substances in the manufacture of any product candidates we may develop could adversely impact or disrupt the commercial manufacturing or the production of clinical material, which could materially
harm our development timelines and our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any problems in our manufacturing process or the
facilities with which we contract could make us a less attractive collaborator for potential partners, including larger pharmaceutical companies and academic </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
research institutions, which could limit our access to additional attractive development programs. Problems in third-party manufacturing process or facilities also could restrict our ability to
ensure sufficient clinical material for any clinical trials we may be conducting or are planning to conduct and meet market demand for any product candidates we develop and commercialize. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We face significant competition in an environment of rapid technological change, and there is a possibility that our competitors may achieve regulatory approval
before us or develop therapies that are safer or more advanced or effective than ours, which may harm our financial condition and our ability to successfully market or commercialize any product candidates we may develop. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The development and commercialization of new drug products is highly competitive. Moreover, the genome editing field is characterized by rapidly changing technologies,
significant competition and a strong emphasis on intellectual property. We will face competition with respect to any product candidates that we may seek to develop or commercialize in the future from major pharmaceutical companies, specialty
pharmaceutical companies and biotechnology companies worldwide. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent or other
intellectual property protection and establish collaborative arrangements for research, development, manufacturing and commercialization. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There are a number of
large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of products for the treatment of the disease indications for which we have research programs. Some of these competitive products
and therapies are based on scientific approaches that are the same as or similar to our approach, while others are based on entirely different approaches. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Amongst
publicly traded peers, there are several companies utilizing CRISPR/Cas technology, including Caribou Biosciences, Inc., Editas Medicine, Inc., CRISPR Therapeutics AG, Intellia Therapeutics, Inc. and Graphite Bio, Inc. Several additional companies
such as Sangamo Therapeutics, Inc., Precision BioSciences, Inc., bluebird bio, Inc., and Cellectis Inc. utilize alternative nuclease-based genome editing technologies, including zinc finger nucleases (&#147;ZFNs&#148;), engineered meganucleases and
transcription-activator like effector nucleases (&#147;TALENs&#148;). Beam Therapeutics utilizes base editing technology. Prime Medicine utilizes prime editing technology. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, other private companies such as Tessera Therapeutics, Inc. and Tome Biosciences, Inc. have announced their work in recombinase DNA and RNA gene writers,
although little is known publicly about their science or portfolio. Other companies have announced intentions to enter the genome editing field, such as Moderna, Inc. and Pfizer Inc. Most recently, new epigenetic editing companies have emerged, such
as Chroma Medicine, Inc. and Tune Therapeutics, Inc. In addition, we face competition from companies utilizing gene therapy, oligonucleotides and cell therapy therapeutic approaches. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Several private companies such as Arbor Biotechnologies, Inc., Scribe Therapeutics Inc., and Mammoth Biosciences, Inc. are actively searching for novel genome editing
components and have reported the discovery of new <FONT STYLE="white-space:nowrap">DNA-cutting</FONT> enzymes. Other companies are active in LNP delivery technologies and advancing those into therapeutics using genetic therapies, including Recode
Therapeutics, Inc., Verve Therapeutics, Inc., Generation Bio Co. and Beam Therapeutics, among others. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any product candidates that we successfully develop and
commercialize will compete with existing therapies and new therapies that may become available in the future that are approved to treat the same diseases for which we may obtain approval for any product candidates we may develop. This may include
other types of therapies, such as small molecule, antibody and/or protein therapies. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Many of our current or potential competitors, either alone or with their
collaboration partners, may have significantly greater financial resources and expertise in research and development, manufacturing, conducting preclinical studies and clinical trials, obtaining regulatory approvals and marketing approved products
than we do. Mergers and acquisitions in the pharmaceutical, biotechnology and gene therapy industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting
and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Our commercial
opportunity could be reduced or eliminated if our competitors develop and commercialize product candidates that are safer, more effective, have fewer or less severe side effects, are more convenient, or are less expensive than any product candidates
that we may develop or that would render any product candidates that we may develop obsolete or <FONT STYLE="white-space:nowrap">non-competitive.</FONT> Our competitors also may obtain FDA or other regulatory approval for their product candidates
more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. Additionally, technologies developed by our competitors may render our potential
product candidates uneconomical or obsolete, and we may not be successful in marketing any product candidates we may develop against competitors. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, as a
result of the expiration or successful challenge of our patent or other intellectual property rights, we could face risks relating to our ability to successfully prevent or delay launch of competitors&#146; products. The availability of our
competitors&#146; products could limit the demand and the price we are able to charge for any product candidates that we may develop and commercialize. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Adverse public perception of genome editing and cellular therapy products may negatively impact demand for, or regulatory approval of, any product candidates we
may develop. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The product candidates we may develop will involve editing the human genome. The clinical and commercial success of any product candidates we
may develop will depend in part on public acceptance of the use of genome editing therapies for the prevention or treatment of human diseases. Public attitudes may be influenced by claims that genome editing is unsafe, unethical, or immoral, and,
consequently, our products may not gain the acceptance of the public or the medical community. Negative public reaction to gene therapy in general could result in greater government regulation and stricter labeling requirements of genome editing
products, including any of our product candidates, and could cause a decrease in the demand for any products we may develop. Adverse public attitudes may adversely impact our ability to enroll clinical trials. Additionally, ethical, social and legal
concerns about genome editing and gene therapy could result in additional regulations restricting or prohibiting any product candidates we may develop. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>The
commercial success of any of the product candidates we may develop will depend upon the degree of market acceptance by physicians, patients, third-party payors and others in the medical community. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Even if we obtain the requisite approvals from the FDA in the United States, the EMA in the European Union and other regulatory authorities internationally, the
commercial success of any product candidates we may develop will depend, in part, on the acceptance of physicians, patients and health care payors of genome editing and gene therapy products in general, and our product candidates in particular, as
medically necessary, cost-effective and safe. Any product that we commercialize may not gain acceptance by physicians, patients, health care payors and others in the medical community who may opt for existing treatments with which they are already
familiar and for which greater clinical data may be available. The degree of market acceptance of genome editing and gene therapy products and, in particular, any product candidates we may develop, if approved for commercial sale, will depend on
several factors, including: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the efficacy, durability and safety of such product candidates as demonstrated in any future clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the potential and perceived advantages of such product candidates over alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the cost of treatment relative to alternative treatments; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the clinical indications for which the product candidate is approved by the FDA, the EMA or other regulatory authorities;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">patient awareness of, and willingness to seek, genotyping; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the willingness of physicians to prescribe new therapies; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the willingness of the target patient population to try new therapies; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the prevalence and severity of any side effects; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">product labeling or product insert requirements of the FDA, the EMA or other regulatory authorities, including any
limitations or warnings contained in a product&#146;s approved labeling; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">relative convenience and ease of administration; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the strength of marketing and distribution support; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the timing of market introduction of competitive products; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">publicity concerning our products or competing products and treatments; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">sufficient third-party payor coverage and reimbursement. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Even if a potential product displays a favorable efficacy and safety profile in preclinical studies and future clinical trials, market acceptance of the product will not
be fully known until after it is launched. If any product candidates we may develop do not achieve an adequate level of acceptance following regulatory approval, if ever, we may not generate significant product revenue and may not become profitable.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that
may be more profitable or for which there is a greater likelihood of success. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have limited financial and managerial resources. As a result, we may forego
or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to timely capitalize on viable commercial products
or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial
potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us
to retain sole development and commercialization rights to such product candidate. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If, in the future, we are unable to establish sales and marketing
capabilities or enter into agreements with third parties to sell and market products based on our technologies, we may not be successful in commercializing our future product candidates if and when any such product candidates are approved and we may
not be able to generate any revenue. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We do not currently have a sales or marketing infrastructure and, as a company, have no experience in the sale,
marketing or distribution of therapeutic products. To achieve commercial success for any potential approved product candidate for which we retain sales and marketing responsibilities, we must build our sales, marketing, managerial and other <FONT
STYLE="white-space:nowrap">non-technical</FONT> capabilities or make arrangements with third parties to perform these services. In the future, we may choose to build a focused sales and marketing infrastructure to sell, or participate in sales
activities with our collaborators for, some of our product candidates if and when they are approved. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There are risks involved with both establishing our own sales and marketing capabilities and entering into
arrangements with third parties to perform these services. For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a
sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly and our investment would be lost if we cannot
retain or reposition our sales and marketing personnel. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Factors that may inhibit our efforts to commercialize our product candidates on our own include: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our inability to recruit, train and retain adequate numbers of effective sales and marketing personnel;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any
future product that we may develop; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the lack of complementary treatments to be offered by sales personnel, which may put us at a competitive disadvantage
relative to companies with more extensive product lines; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">unforeseen costs and expenses associated with creating an independent sales and marketing organization.
</P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we enter into arrangements with third parties to perform sales, marketing and distribution services, our product revenue or the profitability
to us from these revenue streams is likely to be lower than if we were to market and sell any product candidates that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell and market our
product candidates or may be unable to do so on terms that are favorable to us. We likely will have little control over such third parties and any of them may fail to devote the necessary resources and attention to sell and market our product
candidates effectively. If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we may not be successful in commercializing our product candidates. Further, our business,
results of operations, financial condition and prospects will be materially adversely affected. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Due to the novel nature of our technology and the potential
for any product candidates we may develop to offer therapeutic benefit in a single administration or limited number of administrations, we face uncertainty related to pricing and reimbursement for such product candidates. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our initial target patient populations are relatively small, as a result of which the pricing and reimbursement of any product candidates we may develop, if approved,
must be adequate to support the necessary commercial infrastructure. If we are unable to obtain adequate levels of reimbursement, our ability to successfully market and sell any such product candidates will be adversely affected. The manner and
level at which reimbursement is provided for services related to any product candidates we may develop (e.g., for administration of our product candidate to patients) is also important. Inadequate reimbursement for such services may lead to
physician and payor resistance and adversely affect our ability to market or sell our product candidates. In addition, we may need to develop new reimbursement models in order to realize adequate value. Payors may not be able or willing to adopt
such new models, and patients may be unable to afford that portion of the cost that such models may require them to bear. If we determine such new models are necessary but we are unsuccessful in developing them, or if such models are not adopted by
payors, our business, financial condition, results of operations, and prospects could be adversely affected. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We expect the cost of a single administration of a
genome editing therapy, such as those we are seeking to develop, to be substantial, when and if they achieve regulatory approval. We expect that coverage and reimbursement by government and private payors will be essential for most patients to be
able to afford these treatments. Accordingly, sales of any such product candidates will depend substantially, both domestically and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
abroad, on the extent to which the costs of any of our product candidates will be paid by government authorities, private health plans, and other third-party payors. Payors may not be willing to
pay high prices for a single administration. Coverage and reimbursement by a third-party payor may depend upon several factors, including the third-party payor&#146;s determination that use of a product is: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a covered benefit under its health plan; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">safe, effective, and medically necessary; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">appropriate for the specific patient; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">cost-effective; and </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">neither experimental nor investigational. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Obtaining coverage and reimbursement for a product from third-party payors is a time-consuming and costly process that could require us to provide to the payor
supporting scientific, clinical, and cost-effectiveness data. There is significant uncertainty related to third-party coverage and reimbursement of newly approved products. We may not be able to provide data sufficient to gain acceptance with
respect to coverage and reimbursement. If coverage and reimbursement are not available, or are available only at limited levels, we may not be able to successfully commercialize any of our product candidates. Even if coverage is provided, the
approved reimbursement amount may not be adequate to realize a sufficient return on our investment. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the United States, no uniform policy exists for coverage and
reimbursement for products among third-party payors. Therefore, decisions regarding the extent of coverage and amount of reimbursement to be provided can differ significantly from payor to payor. The process for determining whether a payor will
provide coverage for a product may be separate from the process for setting the reimbursement rate a payor will pay for the product. One third-party payor&#146;s decision to cover a particular product or service does not ensure that other payors
will also provide coverage for the medical product or service. Third-party payors may limit coverage to specific products on an approved list or formulary, which may not include all <FONT STYLE="white-space:nowrap">FDA-approved</FONT> products for a
particular indication. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Further, third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical
products and services, in addition to their safety and efficacy. In order to secure coverage and reimbursement for any product that might be approved for sale, we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the
medical necessity and cost-effectiveness of any product candidates we may develop, in addition to the costs required to obtain FDA or comparable regulatory approvals. Additionally, we may also need to provide discounts to purchasers, private health
plans or government healthcare programs. Despite our best efforts, any product candidates we may develop may not be considered medically necessary or cost-effective. If third-party payors do not consider a product to be cost-effective compared to
other available therapies, they may not cover an approved product as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to sell our products at a profit. A decision by a third-party payor not to cover
a product could reduce physician utilization once the product is approved and have a material adverse effect on sales, our operations and financial condition. Finally, in some foreign countries, the proposed pricing for a product candidate must be
approved before it may be lawfully marketed. The requirements governing product pricing vary widely from country to country. For example, in the EU, pricing and reimbursement of pharmaceutical products are regulated at a national level under the
individual EU Member States&#146; social security systems. Some foreign countries provide options to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and can control the prices of
medicinal products for human use. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost effectiveness of a particular product candidate to currently available
therapies. A country may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance
that any country that has price </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
controls or reimbursement limitations for products will allow favorable reimbursement and pricing arrangements for any of our product candidates. Even if approved for reimbursement, historically,
product candidates launched in some foreign countries, such as some countries in the EU, do not follow price structures of the United States and prices generally tend to be significantly lower. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If we are not able to establish collaborations on a timely basis, on commercially reasonable terms, or at all, we may have to alter, reduce or delay our
development and commercialization plans, or increase our expenditures to fund development or commercialization activities at our own expense. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For some of
the product candidates we may develop, we may decide to collaborate with other pharmaceutical and biotechnology companies for the development and potential commercialization of those product candidates. We face significant competition in seeking
appropriate collaborations and collaborations are complex and time-consuming to negotiate and document. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#146;s
resources and expertise, the terms and conditions of the proposed collaboration, and the proposed collaborator&#146;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval
by the FDA, the EMA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of
competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge, and industry and market conditions generally. The
collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may also be restricted under existing collaboration agreements from entering into future collaboration agreements on certain terms with potential collaborators. In
addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators, which further increases competition we face in seeking
potential collaborations. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have
to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any
sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may
need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to develop product candidates or bring them to market and generate product revenue. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our results of operations could be adversely affected by general conditions in the global economy, geopolitical tensions and in the global financial markets. A severe or
prolonged economic downturn or additional global financial and political crises could result in a variety of risks to our business, including weakened demand for any product candidates we develop or our ability to raise additional capital when
needed on acceptable terms, if at all. A weak or declining economy could also strain our suppliers or other third parties and create import and export issues, possibly resulting in supply disruption. Any of the foregoing could harm our business and
we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We face risks related to health epidemics, pandemics and other widespread outbreaks of contagious disease,
including the COVID-19 pandemic, which could significantly disrupt our operations, impact our financial results or otherwise adversely impact our business. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Significant outbreaks of contagious diseases and other adverse public health developments could have a material impact on our business operations and operating results.
For example, the spread of COVID-19 has affected segments of the global economy and our operations. As a result of the COVID-19 pandemic or similar public health crises that may arise, we may experience disruptions that could adversely impact our
operations, research and development, and as we continue developing, any preclinical studies, clinical trials and manufacturing activities we may conduct, some of which may include: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">delays or disruptions in research programs, preclinical studies, clinical trials or IND-enabling studies that we or our
collaborators may conduct; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">interruption or delays in the operations of the FDA, the EMA and comparable foreign regulatory agencies;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">interruption of, or delays in receiving and distributing, supplies of drug substance and drug product from our contract
manufacturing organizations (&#147;CMOs&#148;), to preclinical or clinical research sites or delays or disruptions in any preclinical studies or clinical trials performed by CROs; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">limitations imposed on our business operations by local, state or federal authorities to address a pandemic or similar
public health crises; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">business disruptions caused by potential workplace, laboratory and office closures and an increased reliance on employees
working from home, disruptions to or delays in ongoing laboratory experiments and operations, staffing shortages, travel limitations, and cybersecurity and data accessibility or security issues. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, the trading prices for biopharmaceutical companies have been highly volatile as a result of the COVID-19 pandemic and we may face similar volatility in our
stock price after we complete this public offering. We cannot predict the scope and severity of any economic recovery after the COVID-19 pandemic abates, including following any additional &#147;waves&#148; or other intensifying of the pandemic. If
we or any of the third parties with whom we engage were to experience additional shutdowns or other business disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially and negatively
affected, which could have a material adverse impact on our business, financial condition, our results of operations and prospects. Furthermore, the COVID-19 pandemic could exacerbate the other risks described in this section. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our operations are vulnerable to interruption by disasters, terrorist activity, pandemics and other events beyond our control, which could harm our business.
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our facilities are located in California. We have not undertaken a systematic analysis of the potential consequences to our business and financial results
from a major flood, power loss, terrorist activity, pandemics or other regional or global disasters and generally do not have a recovery plan for such events. In addition, we do not carry sufficient insurance to compensate us for actual losses from
interruption of our business that may occur, and any losses or damages incurred by us could harm our business. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and
expenses. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may use artificial intelligence in our business, and challenges with properly managing its use, as well as uncertainty regarding the legal
landscape surrounding the use of AI could result in reputational harm, competitive harm, and legal liability, and adversely affect our results of operations. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We incorporate artificial intelligence (&#147;AI&#148;) solutions into our platform, and these applications may become important in our operations over time. There are
significant risks involved in utilizing AI and no assurance can be provided that the usage of such AI will enhance our business or assist our business in being more efficient or profitable. Known risks of AI currently include inaccuracy, bias,
toxicity, intellectual property infringement or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
misappropriation, data privacy and cybersecurity and data provenance. In addition, AI may have errors or inadequacies that are not easily detectable. AI may also be subject to data herding and
interconnectedness (i.e., multiple market participants utilizing the same data), which may adversely impact our business. If the data used to train AI or the content, analyses, or recommendations that AI applications assist in producing are or are
alleged to be deficient, inaccurate, incomplete, overbroad or biased, our business, financial condition, and results of operations may be adversely affected. The legal landscape and subsequent legal protection for the use of AI remains uncertain,
and development of the law in this area could impact our ability to enforce our proprietary rights or protect against infringing uses. If we do not have sufficient rights to use the data on which AI relies or to the outputs produced by AI
applications, we may incur liability through the violation of certain laws, third-party privacy or other rights or contracts to which we are a party. Our use of AI applications may also, in the future, result in cybersecurity incidents that
implicate the personal data of customers or patients. Any such cybersecurity incidents related to our use of AI applications could adversely affect our reputation and results of operations. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Risks Related to Regulatory, Legal, and Clinical Trials </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>While we
intend to seek designations for our potential product candidates with the FDA and comparable foreign regulatory authorities that are intended to confer benefits such as a faster development process or an accelerated regulatory pathway, there can be
no assurance that we will successfully obtain such designations. In addition, even if one or more of our potential product candidates are granted such designations, we may not be able to realize the intended benefits of such designations.
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The FDA and comparable foreign regulatory authorities offer certain designations for product candidates that are designed to encourage the research and
development of product candidates that are intended to address conditions with significant unmet medical need. These designations may confer benefits such as additional interaction with regulatory authorities, a potentially accelerated regulatory
pathway and priority review. However, there can be no assurance that we will successfully obtain such designations for any potential product candidates. In addition, while such designations could expedite the development or approval process, they
generally do not change the standards for approval. Even if we obtain such designations for one or more of our potential product candidates, there can be no assurance that we will realize their intended benefits. For example, we may seek fast track
designation for some of our potential product candidates. If a therapy is intended for the treatment of a serious or life threatening condition and the therapy nonclinical or clinical data demonstrates the potential to address unmet medical needs
for this condition, the therapy sponsor may apply for fast track designation. The FDA has broad discretion whether or not to grant this designation, so even if we believe a particular product candidate is eligible for this designation, there can be
no assurance that the FDA would decide to grant it. Even if we do receive fast track designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures, and receiving a fast track designation
does not provide assurance of ultimate FDA approval. In addition, the FDA may withdraw fast track designation if it believes that the designation is no longer supported by data from our clinical development program. Additionally, we may seek a
breakthrough therapy designation for some of our potential product candidates. A breakthrough therapy is defined as a therapy that is intended, alone or in combination with one or more other therapies, to treat a serious or life-threatening disease
or condition, and preliminary clinical evidence indicates that the therapy may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in
clinical development. For therapies that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while
minimizing the number of patients placed in ineffective control regimens. Therapies designated as breakthrough therapies by the FDA may also be eligible for accelerated approval. Designation as a breakthrough therapy is within the discretion of the
FDA. Accordingly, even if we believe one of our potential product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
instead determine not to make such designation. In any event, the receipt of a breakthrough therapy designation for a product candidate may not result in a faster development process, review or
approval compared to therapies considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our potential product candidates qualify as breakthrough therapies, the
FDA may later decide that such product candidates no longer meet the conditions for qualification. In addition, we may seek a regenerative medicine advanced therapy (&#147;RMAT&#148;) designation for some of our potential product candidates. An RMAT
is defined as cell therapies, therapeutic tissue engineering products, human cell and tissue products and combination products using any such therapies or products. Gene therapies, including genetically modified cells that lead to a durable
modification of cells or tissues may meet the definition of a regenerative medicine therapy. The RMAT program is intended to facilitate efficient development and expedite review of RMATs, which are intended to treat, modify, reverse or cure a
serious or life-threatening disease or condition. A new drug application or a biologics license application (&#147;BLA&#148;) for an RMAT may be eligible for priority review or accelerated approval through (1)&nbsp;surrogate or intermediate
endpoints reasonably likely to predict long-term clinical benefit or (2)&nbsp;reliance upon data obtained from a meaningful number of sites. Benefits of such designation also include early interactions with the FDA to discuss any potential surrogate
or intermediate endpoint to be used to support accelerated approval. A regenerative medicine therapy that is granted accelerated approval and is subject to post-approval requirements may fulfill such requirements through the submission of clinical
evidence, clinical trials, patient registries or other sources of real world evidence, such as electronic health records; the collection of larger confirmatory data sets; or post-approval monitoring of all patients treated with such therapy prior to
its approval. RMAT designation is within the discretion of the FDA. Accordingly, even if we believe one of our potential product candidates meets the criteria for designation as a regenerative medicine advanced therapy, the FDA may disagree and
instead determine not to make such designation. In any event, the receipt of RMAT designation for a product candidate may not result in a faster development process, review or approval compared to drugs considered for approval under conventional FDA
procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our potential product candidates qualify as for RMAT designation, the FDA may later decide that the biological products no longer meet the conditions
for qualification. We may also seek rare pediatric disease designation for some of our potential product candidates. The FDA defines &#147;rare pediatric disease&#148; as a (i)&nbsp;serious or life-threatening disease in which the serious or
life-threatening manifestations primarily affect individuals aged from birth to 18 years, including age groups often called neonates, infants, children, and adolescents; and (ii)&nbsp;a rare disease or condition within the meaning of the Orphan Drug
Act. Designation of a product candidate as a product for a rare pediatric disease does not guarantee that a marketing application for such product candidate will meet the eligibility criteria for a rare pediatric disease priority review voucher
(&#147;PRV&#148;) at the time the application is approved. Under the U.S. Federal Food, Drug, and Cosmetic Act (&#147;FDCA&#148;), we will need to request a rare pediatric disease PRV in our original marketing application for any potential product
candidates for which we have received rare pediatric disease designation. The FDA may determine that a marketing application for any such product candidates, if approved, does not meet the eligibility criteria for a PRV. Under the current statutory
sunset provisions, after September&nbsp;30, 2024, the FDA may only award a PRV for an approved rare pediatric disease product application if the sponsor has rare pediatric disease designation for the drug or biologic that is the subject of such
application, and that designation was granted by September&nbsp;30, 2024. After September&nbsp;30, 2026, the FDA may not award any rare pediatric disease PRVs. However, it is possible the authority for FDA to award rare pediatric disease PRV will be
further extended by Congress. As such, if we do not obtain approval of a marketing application for any of our potential product candidates on or before September&nbsp;30, 2026, and if the PRV program is not extended by Congressional action, we may
not receive a PRV. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the future, we may also seek approval of product candidates under the FDA&#146;s accelerated approval pathway. A product may be eligible for
accelerated approval if it is designed to treat a serious or life-threatening disease or condition and generally provides a meaningful advantage over available therapies upon a determination that the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
product candidate has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit or on a clinical endpoint that can be measured
earlier than irreversible morbidity or mortality (&#147;IMM&#148;) that is reasonably likely to predict an effect on IMM or other clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically
meaningful in the context of a given disease, such as IMM. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign or other measure that is thought to predict
clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably likely to predict an
effect on irreversible morbidity or mortality or other clinical benefit. The accelerated approval pathway may be used in cases in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage, but is a clinically
important improvement from a patient and public health perspective. If granted, accelerated approval is usually contingent on the sponsor&#146;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verity and
describe the drug&#146;s clinical benefit. Under the Food and Drug Omnibus Reform Act of 2022 (&#147;FDORA&#148;), the FDA is permitted to require, as appropriate, that a post-approval confirmatory study or studies be underway prior to approval or
within a specified time period after the date of approval for a product granted accelerated approval. FDORA also requires sponsors to send updates to the FDA every 180 days on the status of such studies, including progress toward enrollment targets,
and the FDA must promptly post this information publicly. FDORA also gives the FDA increased authority to withdraw approval of a drug or biologic granted accelerated approval on an expedited basis if the sponsor fails to conduct such studies in a
timely manner, send the necessary updates to the FDA, or if such post-approval studies fail to verify the drug&#146;s predicted clinical benefit. Under FDORA, the FDA is empowered to take action, such as issuing fines, against companies that fail to
conduct with due diligence any post-approval confirmatory study or submit timely reports to the agency on their progress. There can be no assurance that the FDA would allow any of the product candidates we may develop to proceed on an accelerated
approval pathway, and even if the FDA did allow such pathway, there can be no assurance that such submission or application will be accepted or that any expedited development, review or approval will be granted on a timely basis, or at all.
Moreover, even if we received accelerated approval, any post-approval studies required to confirm and verify clinical benefit may not show such benefit, which could lead to withdrawal of any approvals we have obtained. Receiving accelerated approval
does not assure that the product&#146;s accelerated approval will eventually be converted to a traditional approval. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If the FDA determines that a product candidate
offers a treatment for a serious condition and, if approved, the product would provide a significant improvement in safety or effectiveness, the FDA may designate the product candidate for priority review. A priority review designation means that
the goal for the FDA to review an application is six months, rather than the standard review period of ten months. We may request priority review for the product candidates that we may develop. The FDA has broad discretion with respect to whether or
not to grant priority review status to a product candidate, so even if we believe a particular product candidate is eligible for such designation or status, the FDA may decide not to grant it. Moreover, a priority review designation does not
necessarily result in an expedited regulatory review or approval process or necessarily confer any advantage with respect to approval compared to conventional FDA procedures. Receiving priority review from the FDA does not guarantee approval within
the <FONT STYLE="white-space:nowrap">six-month</FONT> review cycle or at all. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, in the European Union, we may seek to participate in the PRIority
Medicines (&#147;PRIME&#148;) scheme for our potential product candidates. The PRIME scheme is intended to encourage development of products in areas of unmet medical need and provides accelerated assessment of products representing substantial
innovation, where the marketing authorization application will be made through the centralized procedure in the European Union. Products from small- and <FONT STYLE="white-space:nowrap">medium-sized</FONT> enterprises may qualify for earlier entry
into the PRIME scheme than larger companies on the basis of compelling <FONT STYLE="white-space:nowrap">non-clinical</FONT> data and tolerability data from initial clinical trials. Eligible products must target conditions for which there is an unmet
medical need (no treatment option exists in the European Union or, they can offer a major therapeutic advantage over existing treatments). Many benefits accrue to sponsors of product candidates with PRIME designation, including but not
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and accelerated marketing authorization
application assessment once a dossier has been submitted. There is no guarantee, however, that our potential product candidates would be deemed eligible for the PRIME scheme and even if we do participate in the PRIME scheme, where during the course
of development a product no longer meets the eligibility criteria, support under the PRIME scheme may be withdrawn. PRIME eligibility does not change the standards for product approval, and there is no assurance that any such designation or
eligibility will result in expedited review or approval. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Healthcare and other reform legislation may increase the difficulty and cost for us and any
collaborators we may have to obtain regulatory approval of and commercialize any product candidates we may develop and affect the prices we, or they, may obtain. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the United States and some foreign jurisdictions, there have been and continue to be ongoing efforts to implement legislative and regulatory changes regarding the
healthcare system. Such changes could prevent or delay regulatory approval of any product candidates that we may develop, restrict or regulate post-approval activities and affect our ability to profitably sell any product candidates for which we
obtain regulatory approval. Although we cannot predict what healthcare or other reform efforts will be successful, such efforts may result in more rigorous coverage criteria, in additional downward pressure on the price that we, or our future
collaborators, may receive for any approved products or in other consequences that may adversely affect our ability to achieve or maintain profitability. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Within the
United States, the federal government and individual states have aggressively pursued healthcare reform, as evidenced by the passing of the Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively,
the &#147;ACA&#148;), and the ongoing efforts to modify or repeal that legislation. The ACA significantly changed the way healthcare is financed by both governmental and private insurers and contains a number of provisions that affect coverage and
reimbursement of drug products and/or that could potentially reduce the demand for pharmaceutical products such as increasing drug rebates under state Medicaid programs for brand name prescription drugs and extending those rebates to Medicaid
managed care and assessing a fee on manufacturers and importers of brand name prescription drugs reimbursed under certain government programs, including Medicare and Medicaid. Other aspects of healthcare reform, such as expanded government
enforcement authority and heightened standards that could increase compliance-related costs, could also affect our business. Modifications have been implemented under the former Trump administration and additional modifications or repeal may occur.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There have also been executive, judicial, and congressional challenges to certain aspects of the ACA. It is unclear how other healthcare reform measures of the
Biden administration or other efforts, if any, to challenge, repeal or replace the ACA will impact our business. There is no assurance that federal or state healthcare reform will not adversely affect our future business and financial results, and
we cannot predict how future federal or state legislative, judicial or administrative changes relating to healthcare reform will affect our business. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition,
other legislative changes have been proposed and adopted in the United States since the ACA was enacted. For example, the American Rescue Plan Act of 2021 eliminates the statutory Medicaid drug rebate cap, currently set at 100&nbsp;percent of a
drug&#146;s average manufacturer price, for single source and innovator multiple source drugs, beginning January&nbsp;1, 2024. The U.S. Budget Control Act of 2011 and subsequent legislation, among other things, included aggregate reductions of
Medicare payments to providers of 2% per fiscal year, which remain in effect through 2032. The American Taxpayer Relief Act of 2012 further reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment
centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Additionally, there has
been increasing legislative and enforcement interest in the United States with respect to drug pricing practices, which has resulted in several U.S. Congressional inquiries and federal and state legislation designed to, among other things, bring
more transparency to drug pricing, reduce the cost of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
prescription drugs, and review the relationship between pricing and manufacturer patient programs. The Inflation Reduction Act of 2022 (the &#147;IRA&#148;), for example, includes several
provisions that may impact our business to varying degrees, including provisions that reduce the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> spending cap for Medicare Part D beneficiaries to $2,000
starting in 2025, eliminating the prescription drug coverage gap; impose new manufacturer financial liability on certain drugs under Medicare Part D, allow the U.S. government to negotiate Medicare Part B and Part D price caps for certain high-cost
drugs and biologics without generic or biosimilar competition; require companies to pay rebates to Medicare for certain drug prices that increase faster than inflation; and delay until January&nbsp;1, 2032 the implementation of an HHS rebate rule
that would have limited the fees that pharmacy benefit managers can charge. Further, under the IRA, orphan drugs are exempted from the Medicare drug price negotiation program, but only if they have one orphan designation and for which the only
approved indication is for that disease or condition. If a product receives multiple orphan designations or has multiple approved indications, it may not qualify for the orphan drug exemption. The effects of the IRA on our business and the
healthcare industry in general is not yet known. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, President Biden has issued multiple executive orders that have sought to reduce prescription drug
costs. In February 2023, HHS issued a proposal in response to an October 2022 Biden executive order that proposes a Medicare drug pricing model that will test whether targeted Medicare payment adjustments will sufficiently incentivize manufacturers
to complete confirmatory trials for drugs approved through the FDA&#146;s accelerated approval pathway. Although a number of these and other proposed measures may require authorization through additional legislation to become effective, and the
Biden administration may reverse or otherwise change these measures, both the Biden administration and Congress have indicated that they will continue to seek new legislative measures to control drug costs. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We cannot predict the initiatives that may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations and other
payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the demand for our product candidates, if we obtain regulatory approval; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to set a price that we believe is fair for our approved products; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to generate revenue and achieve or maintain profitability; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the level of taxes that we are required to pay; and </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the availability of capital. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect
our future profitability. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed
to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain drug access and marketing cost disclosure and transparency measures, and designed to encourage
importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, financial condition, results of operations and prospects. In addition,
regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could
reduce the ultimate demand for our drugs or put pressure on our drug pricing, which could negatively affect our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Because we are developing product candidates in the field of genetic medicines in which there is little clinical experience, there is increased risk that the FDA,
the EMA or other regulatory authorities may not consider the endpoints of our clinical trials to provide clinically meaningful results and that these results may be difficult to analyze. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In order to proceed into clinical development of any product candidates we identify, we will need to submit INDs or clinical trial applications to regulatory authorities
and obtain regulatory clearance to commence clinical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
development. Because the product candidates we identify are based on novel gene-editing technology, we may be unsuccessful in obtaining clearance from regulatory authorities to proceed into
clinical development. In order to commence clinical development, we will need to identify success criteria and endpoints such that the FDA, the EMA or other regulatory authorities will be able to determine the clinical efficacy and safety profile of
any product candidates we may develop. As we are initially seeking to identify and develop product candidates to treat diseases in which there is little clinical experience using new technologies, and while we may have opportunities to discuss our
clinical development plans with regulatory authorities prior to commencing clinical development, there is heightened risk that the FDA, the EMA or other regulatory authorities may not consider the clinical trial endpoints that we propose to provide
clinically meaningful results (reflecting a tangible benefit to patients). In addition, the resulting clinical data and results may be difficult to analyze. Even if the FDA does find our success criteria to be sufficiently validated and clinically
meaningful, we may not achieve the <FONT STYLE="white-space:nowrap">pre-specified</FONT> endpoints to a degree of statistical significance. This may be a particularly significant risk for many of the genetically defined diseases for which we plan to
develop product candidates because many of these diseases such as PH1 have small patient populations, and designing and executing a rigorous clinical trial with appropriate statistical power is more difficult than with diseases that have larger
patient populations. Furthermore, even if we do achieve the <FONT STYLE="white-space:nowrap">pre-specified</FONT> criteria, we may produce results that are unpredictable or inconsistent with the results of the
<FONT STYLE="white-space:nowrap">non-primary</FONT> endpoints or other relevant data. The FDA also weighs the benefits of a product against its risks, and the FDA may view the efficacy results in the context of safety as not being supportive of
regulatory approval. Other regulatory authorities in the European Union and other countries may make similar comments with respect to these endpoints and data. Any product candidates we may develop will be based on a novel technology that makes it
difficult to predict the time and cost of development and of subsequently obtaining regulatory approval. No genome editing therapeutic product has been approved in the United States or in Europe. Within the broader genome product field, only a
limited number of gene therapy products, such as uniQure N.V.&#146;s Glybera and Abecma from Bristol Myers Squibb and bluebird bio, have received marketing authorization or regulatory approval from the European Commission or the FDA. Some of these
products have taken years to register and have had to deal with significant issues in their post-marketing experience. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If preclinical studies or clinical
trials of any product candidates we may identify and develop fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or do not otherwise produce positive results, we may incur additional costs or experience delays in
completing, or ultimately be unable to complete, the development and commercialization of such product candidates. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Before obtaining regulatory approval from
regulatory authorities for the sale of any product candidates we may identify and develop, we must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy in humans. Clinical testing is
expensive, difficult to design and implement, can take many years to complete, and is uncertain as to outcome. A failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical testing and early clinical trials
may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Moreover,
preclinical and clinical data are often susceptible to varying interpretations and analyses. Many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to
obtain regulatory approval of their product candidates. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We and our collaborators, if any, may experience numerous unforeseen events during, or as a result of,
clinical trials that could delay or prevent our ability to receive regulatory approval or commercialize any product candidates we may identify and develop, including: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">delays in reaching a consensus with regulators on trial design; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">regulators, IRBs, or independent ethics committees may not authorize us or our investigators to commence a clinical trial
or conduct a clinical trial at a prospective trial site; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">delays in reaching or failing to reach agreement on acceptable clinical trial contracts or clinical trial protocols with
prospective CROs and clinical trial sites; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">clinical trials of any product candidates we may develop may produce negative or inconclusive results, and we may decide,
or regulators may require us, to conduct additional clinical trials or abandon product development or research programs; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">difficulty in designing well-controlled clinical trials due to ethical considerations which may render it inappropriate to
conduct a trial with a control arm that can be effectively compared to a treatment arm; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">difficulty in designing clinical trials and selecting endpoints for diseases that have not been well-studied and for which
the natural history and course of the disease is poorly understood; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the number of patients required for clinical trials of any product candidates we may develop may be larger than we
anticipate; enrollment of suitable participants in these clinical trials, which may be particularly challenging for some of the rare genetically defined diseases we are targeting in our most advanced programs, may be delayed or slower than we
anticipate; or patients may drop out of these clinical trials at a higher rate than we anticipate; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in
a timely manner, or at all; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">regulators, IRBs, or independent ethics committees may require that we or our investigators suspend or terminate clinical
research or clinical trials of any product candidates we may develop for various reasons, including noncompliance with regulatory requirements, a finding of undesirable side effects or other unexpected characteristics, or that the participants are
being exposed to unacceptable health risks or after an inspection of our clinical trial operations or trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the cost of clinical trials of any product candidates we may develop may be greater than we anticipate;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the supply or quality of any product candidates we may develop or other materials necessary to conduct preclinical studies
or clinical trials of any product candidates we may develop may be insufficient or inadequate, including as a result of delays in the testing, validation, manufacturing, and delivery of any product candidates we may develop to the preclinical study
sites or clinical sites by us or by third parties with whom we have contracted to perform certain of those functions; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">delays in having patients complete participation in a trial or return for post-treatment
<FONT STYLE="white-space:nowrap">follow-up;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">clinical trial sites dropping out of a trial; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">selection of clinical endpoints that require prolonged periods of clinical observation or analysis of the resulting data;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">occurrence of serious adverse events associated with any product candidates we may develop that are viewed to outweigh
their potential benefits; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">occurrence of serious adverse events in trials of the same class of agents conducted by other sponsors; and
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols.
</P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we or our collaborators are required to conduct additional clinical trials or other testing of any product candidates we may develop beyond
those that we currently contemplate, if we or our collaborators are unable to successfully complete clinical trials or other testing of any product candidates we may develop, or if the results of these trials or tests are not positive or are only
modestly positive or if there are safety concerns, we or our collaborators may: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">be delayed in obtaining regulatory approval for any such product candidates we may develop or not obtain regulatory
approval at all; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">obtain approval for indications or patient populations that are not as broad as intended or desired; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings, including
boxed warnings; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">be subject to changes in the way the product is administered; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">be required to perform additional clinical trials to support approval or be subject to additional post-marketing testing
requirements; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">have regulatory authorities withdraw, or suspend, their approval of the product or impose restrictions on its distribution
in the form of a REMS, or through modification to an existing REMS; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">be sued; or </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">experience damage to our reputation. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Product development costs will also increase if we or our collaborators experience delays in clinical trials or other testing or in obtaining regulatory approvals. We do
not know whether any clinical trials will begin as planned, will need to be restructured, or will be completed on schedule, or at all. Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to
commercialize any product candidates we may develop, could allow our competitors to bring products to market before we do, and could impair our ability to successfully commercialize any product candidates we may develop, any of which may harm our
business, financial condition, results of operations, and prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Failure to access or a significant delay in accessing animal research models may
materially adversely affect our ability to advance our preclinical programs and successfully develop any product candidates we may identify, which could result in significant harm to our business. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Consistent with various rules, regulations and current good manufacturing practices (&#147;cGMP&#148;), our ability to advance our preclinical programs and successfully
develop any product candidates we may identify requires access to animal research models sufficient to assess safety and in some cases to establish the rationale for therapeutic use. Failure to access or a significant delay in accessing animal
research models that meet our needs or that fulfil regulatory requirements may materially adversely affect our ability to advance our preclinical programs and successfully develop any product candidates we may identify and this could result in
significant harm to our business. During the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, researchers and CROs (including those engaged by us) experienced significant limitations in their access to animal research models, specifically
including a sharp reduction in the availability of <FONT STYLE="white-space:nowrap">non-human</FONT> primates (&#147;NHPs&#148;) originating from breeding farms in Southeast Asia and limited access to the generation of genetically-modified rodent
models used in efficacy evaluations. Prior to the pandemic, China was the leading exporter of NHPs employed in basic and applied research; however, early in 2020, China ceased exportation of cynomolgus monkeys, the species most commonly involved in
pharmaceutical product development. This change in the world supply of a critical research model has resulted in increased demand from breeding farms principally located in Cambodia, Vietnam, and Mauritius Island, with a resultant marked increase in
unit pricing. Consequently, this has further exacerbated an already constrained NHP supply for research purposes. If we are unable to obtain NHPs in sufficient quantities and in a timely manner to meet the needs of our preclinical research programs,
if the price of NHPs that are available increases significantly, or if our suppliers are unable to ship the NHPs in their possession that are reserved for us, our ability to advance our preclinical programs and successfully develop any preclinical
candidates we may identify may be materially adversely affected or significantly delayed. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Even if we complete the necessary clinical trials, we cannot predict
when, or if, we will obtain regulatory approval to commercialize a product candidate we may develop in the United States or any other jurisdiction, and any such approval may be for a more narrow indication than we seek. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We cannot commercialize a product candidate until the appropriate regulatory authorities have reviewed and approved the product candidate. Even if our product candidates
meet their safety and efficacy endpoints in clinical trials, the regulatory authorities may not complete their review processes in a timely manner, or we may not be able to obtain regulatory approval. Additional delays may result if an FDA advisory
committee or other regulatory authority recommends <FONT STYLE="white-space:nowrap">non-approval</FONT> or restrictions on approval. In addition, we may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
experience delays or rejections based upon additional government regulation from future legislation or administrative action, or changes in regulatory authority policy during the period of
product development, clinical trials, and the review process. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Regulatory authorities also may approve a product candidate for more limited indications than
requested or they may impose significant limitations in the form of narrow indications, warnings or a REMS. These regulatory authorities may require labeling that includes precautions or contraindications with respect to conditions of use, or may
grant approval subject to the performance of costly post-marketing clinical trials. In addition, regulatory authorities may not approve the labeling claims that are necessary or desirable for the successful commercialization of our product
candidates. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates and materially adversely affect our business, financial condition, results of operations, and prospects. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Regulatory approval by the FDA in the United States, if obtained, does not ensure approval by regulatory authorities in other countries or jurisdictions. In addition,
clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country. Approval processes vary among countries
and can involve additional product candidate testing and validation and additional administrative review periods. Seeking regulatory approval outside the United States could result in difficulties and costs for us and require additional preclinical
studies or clinical trials which could be costly and time-consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our product candidates in those countries. The foreign regulatory
approval process involves all of the risks associated with FDA approval. We do not have any product candidates approved for sale in any jurisdiction, including international markets, and we do not have experience in obtaining regulatory approval in
international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and
our ability to realize the full market potential of our product candidates will be unrealized. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Even if we, or any of our collaborators or strategic partners,
obtain regulatory approvals for any product candidates we may develop, the terms of approvals and ongoing regulation of such product candidates could require the substantial expenditure of resources and may limit how we, or they, manufacture and
market such product candidates, which could materially impair our ability to generate revenue. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any product candidate for which we obtain regulatory
approval, along with the manufacturing processes, post-approval clinical data, labeling, advertising and promotional activities for such product, will be subject to continual requirements of and review by the FDA, the EMA and other regulatory
authorities. These requirements include submissions of safety and other post-marketing information and reports, facility registration and drug listing requirements, cGMP relating to quality control, quality assurance and corresponding maintenance of
records and documents, applicable product tracking and tracing requirements and requirements regarding the distribution of samples to physicians and recordkeeping. In addition, our manufacturing and testing facilities will be required to undergo <FONT
STYLE="white-space:nowrap">pre-license</FONT> inspections and <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspections. Even if regulatory approval of a product candidate is granted, the approval may be subject to limitations on the
indicated uses for which the products may be marketed or to the conditions of approval, or contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the products. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Accordingly, assuming we, or any collaborators we may have, receive regulatory approval for one or more product candidates we develop, we, and such collaborators, and
our and their contract manufacturers will continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production, product surveillance and quality control. If we and such collaborators are not able to
comply with post-approval regulatory requirements, we and such collaborators could have the regulatory approvals for our products withdrawn by regulatory authorities and our, or such collaborators&#146;, ability to market any future
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
products could be limited, which could adversely affect our ability to achieve or sustain profitability. Furthermore, the cost of compliance with post-approval regulations may have a negative
effect on our business, operating results, financial condition and prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may not be able to obtain orphan drug designation or exclusivity for our
potential product candidates, and even if we do, that designation may not provide an expedited development or regulatory review or approval process and any orphan drug exclusivity we may receive for approved products may not prevent the FDA or the
EMA from approving other competing products. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Under the Orphan Drug Act, the FDA may designate a product candidate as an orphan drug if it is a drug or
biologic intended to treat a rare disease or condition. A similar regulatory scheme governs approval of orphan product candidates by the EMA in the European Union. Generally, if a product with an orphan drug designation subsequently receives the
first regulatory approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA or the EMA (as applicable) from approving another marketing application for another
similar product candidate for the same orphan therapeutic indication for that time period. The applicable period is seven years in the United States and ten years in the European Union. The exclusivity period in the European Union can be reduced to
six years if at the end of the fifth year it is determined that a product no longer meets the criteria for orphan designation, including if the product is sufficiently profitable so that market exclusivity is no longer justified. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In order for the FDA to grant orphan drug exclusivity to one of our potential product candidates, the agency must find that the product candidate is indicated for the
treatment of a condition or disease that affects fewer than 200,000 individuals in the United States or that affects 200,000 or more individuals in the United States and for which there is no reasonable expectation that the cost of developing and
making the product candidate available for the disease or condition will be recovered from sales of the product in the United States. The FDA may conclude that the condition or disease for which we seek orphan drug exclusivity does not meet this
standard. Even if we obtain orphan drug exclusivity for a product candidate, that exclusivity may not effectively protect the product candidate from competition because different product candidates can be approved for the same condition. In
addition, even after an orphan drug is approved, the FDA can subsequently approve the same product candidate for the same condition if the FDA concludes that the later product candidate is clinically superior in that it is shown to be safer, more
effective or makes a major contribution to patient care compared with the product that has orphan exclusivity. Orphan drug exclusivity may also be lost if the FDA or EMA determines that the request for designation was materially defective or if the
manufacturer is unable to assure sufficient quantity of the product to meet the needs of the patients with the rare disease or condition. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We are subject to
U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international
markets. We can face criminal liability and other serious consequences for violations, which can harm our business. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are subject to export control and
import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department&#146;s Office of Foreign Assets Control, the
U.S. Foreign Corrupt Practices Act of 1977, as amended (the &#147;FCPA&#148;), the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money
laundering laws in the countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and other collaborators from authorizing, promising, offering, or
providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We may engage third parties to sell our products outside the United States, to conduct clinical trials, and/or to obtain
necessary permits, licenses, patent registrations, and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors, and other collaborators, even if we do not explicitly authorize
or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax
reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If we or any contract manufacturers and suppliers we engage
fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We and any contract manufacturers and suppliers we engage are subject to numerous federal, state, and local environmental, health, and safety laws, regulations, and
permitting requirements, including those governing laboratory procedures; the generation, handling, use, storage, treatment, and disposal of hazardous and regulated materials and wastes; the emission and discharge of hazardous materials into the
ground, air, and water; and employee health and safety. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste. We generally contract with third
parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for
any resulting damages, and any liability could exceed our resources. Under certain environmental laws, we could be held responsible for costs relating to any contamination at our current or past facilities and at third-party facilities. We also
could incur significant costs associated with civil or criminal fines and penalties. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Compliance with applicable environmental laws and regulations may be expensive,
and current or future environmental laws and regulations may impair our research and product development efforts. In addition, we cannot entirely eliminate the risk of accidental injury or contamination from these materials or wastes. Although we
maintain workers&#146; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential
liabilities. We carry pollution insurance to protect against possible biological or hazardous waste accidents. However, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding
our resources, and our clinical trials or regulatory approvals could be suspended, which could have a material adverse effect on our business, financial condition, results of operations, and prospects. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, we may incur substantial costs in order to comply with current or future environmental, health, and safety laws, regulations, and permitting requirements.
These current or future laws, regulations, and permitting requirements may impair our research, development, or production efforts. Failure to comply with these laws, regulations, and permitting requirements also may result in substantial fines,
penalties, or other sanctions or business disruption, which could have a material adverse effect on our business, financial condition, results of operations, and prospects. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any third-party contract manufacturers and suppliers we engage will also be subject to these and other environmental, health, and safety laws and regulations.
Liabilities they incur pursuant to these laws and regulations could result in significant costs or an interruption in operations, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including <FONT
STYLE="white-space:nowrap">non-compliance</FONT> with regulatory standards and requirements and insider trading. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are exposed to the risk of fraud or
other misconduct by our employees, consultants and commercial partners, and, if we commence clinical trials, our principal investigators. Misconduct by these parties could </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
include intentional failures to comply with FDA regulations or the regulations applicable in the European Union and other jurisdictions, provide accurate information to the FDA, the EMA and other
regulatory authorities, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and
business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations restrict or prohibit a wide range
of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct also could involve the improper use of information obtained in the course of clinical trials or
interactions with the FDA, the EMA or other regulatory authorities, which could result in regulatory sanctions and cause serious harm to our reputation. We are also exposed to risks in connection with any insider trading violations by employees or
others affiliated with us. Upon the effectiveness of this registration statement, we will adopt a code of conduct and an insider trading policy applicable to all of our employees, but it is not always possible to identify and deter employee
misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a
failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, financial
condition, results of operations and prospects, including the imposition of significant fines or other sanctions. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Product liability lawsuits against us could
cause us to incur substantial liabilities and could limit commercialization of any product candidates that we may develop. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We will face an inherent risk of
product liability exposure related to the testing of any product candidates we may develop in human clinical trials and will face an even greater risk if we commercially sell such product candidates. If we cannot successfully defend ourselves
against claims that our product candidates caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">decreased demand for any product candidates that we may develop; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">injury to our reputation and significant negative media attention; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">withdrawal of clinical trial participants; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">significant costs to defend the related litigation; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">substantial monetary awards to trial participants or patients; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">loss of revenue; and </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the inability to commercialize any product candidates that we may develop. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We anticipate that we will need to increase our insurance coverage when we begin clinical trials and if we successfully commercialize any product candidate. Insurance
coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our internal computer and information technology systems, or those of our third-party vendors, collaborators, contractors, consultants or other third parties, may
fail, become unavailable, or suffer security incidents or data breaches, loss or leakage of data and other disruptions, which could result in a material disruption of our product development programs, compromise confidential, sensitive or personal
information related to our business or prevent us from accessing critical information, potentially exposing us to liability or otherwise adversely affecting our business. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our internal computer and information technology systems and those of our current and any future third-party vendors, collaborators, contractors, consultants or other
third parties, are vulnerable to damage or interruption </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
from, among other things, computer viruses, computer hackers, phishing attacks, ransomware, malware, social engineering, service interruptions, system malfunction, malicious code, employee theft,
fraud, misconduct or misuse, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">denial-of-service</FONT></FONT> attacks, sophisticated nation-state and nation-state-supported actors, unauthorized access, natural disasters, terrorism,
war and telecommunication and electrical failures. While we seek to protect our information technology systems from system failure, accident and security breach, we have in the past and may in the future experience phishing and other security
incidents which could result in a disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other proprietary, personal or confidential information or other disruptions. For example, the loss
of clinical trial data from future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Controls employed by our information technology department and other third parties could prove inadequate, and our ability to monitor such third parties&#146; data
security practices is limited. Due to applicable laws, rules, regulations and standards or contractual obligations, we may be held responsible for any information security failure or cybersecurity attack attributed to our third-party vendors as they
relate to the information we share with them. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we were to experience a cybersecurity breach or other security incident relating to our information systems or
data, the costs, time and effort associated with the investigation, remediation and potential notification of the breach to counterparties, regulators and data subjects could be material. We may incur significant costs in an effort to detect and
prevent security incidents, and we may face increased costs and requirements to expend substantial resources in the event of an actual or perceived security incident. In addition, techniques used to sabotage or to obtain unauthorized access to
networks in which data is stored or through which data is transmitted change frequently, become more complex over time and generally are not recognized until launched against a target. The risk of a security breach or disruption, particularly
through cyberattacks including supply chain attacks such as SolarWinds or cyber intrusion, including by computer hackers, foreign governments, and cyber terrorists, has generally increased as the number, intensity, and sophistication of attempted
attacks and intrusions from around the world have increased. As a result, we and our third-party vendors may be unable to anticipate these techniques or implement adequate preventative measures quickly enough to prevent either an electronic
intrusion into our systems or services or a compromise of critical information. We cannot guarantee that we will be able to detect or prevent any such incidents, and, our remediation efforts may not be successful or timely. Our efforts to improve
security and protect data from compromise may also identify previously undiscovered instances of data breaches or other cybersecurity incidents. If we do not allocate and effectively manage the resources necessary to build and sustain the proper
technology and cybersecurity infrastructure, we could suffer significant business disruption, including transaction errors, supply chain or manufacturing interruptions, processing inefficiencies, data loss or the loss of or damage to intellectual
property or other proprietary, personal or confidential information. Additionally, we do not currently maintain cybersecurity insurance, and any insurance we may maintain in the future against the risk of this type of loss in the future may not be
sufficient to cover actual losses, or may not apply to the circumstances relating to any particular loss. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To the extent that any disruption or security breach were
to result in a loss of, or damage to, our or our third-party vendors&#146;, collaborators&#146;, contractors&#146;, consultants&#146; or other third parties&#146; data, including personal data, or applications or inappropriate disclosure, loss,
destruction or alteration of, or access to, confidential, personal or proprietary information, we could incur significant liability including litigation exposure, substantial penalties and fines, we could become the subject of regulatory action,
inquiry or investigation, our competitive position could be harmed, we could incur significant reputational damage and the further development and commercialization of any product candidates we may develop could be delayed. Any of the above could
have a material adverse effect on our business, financial condition, results of operations or prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Laws and regulations governing any international operations we may have in the future may preclude us from
developing, manufacturing and selling certain product candidates we may identify outside of the United States and require us to develop and implement costly compliance programs. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are subject to numerous laws and regulations in each jurisdiction outside the United States in which we operate. The creation, implementation and maintenance of
international business practices compliance programs is costly and such programs are difficult to enforce, particularly where reliance on third parties is required. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The FCPA, prohibits any U.S. individual or business from paying, offering, authorizing payment or offering of anything of value, directly or indirectly, to any foreign
official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are
listed in the United States to comply with certain accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise
and maintain an adequate system of internal accounting controls for international operations. The anti-bribery provisions of the FCPA are enforced primarily by the Department of Justice. The SEC is involved with enforcement of the books and records
provisions of the FCPA. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Similarly, the U.K. Bribery Act 2010 has extra-territorial effect for companies and individuals having a connection with the United Kingdom.
The U.K. Bribery Act prohibits inducements both to public officials and private individuals and organizations. Compliance with the FCPA and the U.K. Bribery Act is expensive and difficult, particularly in countries in which corruption is a
recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials.
Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. Our expansion outside of the United States has required, and
will continue to require, us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing or selling certain drugs and drug candidates outside of the United States, which could limit our
growth potential and increase our development costs. The failure to comply with laws governing international business practices may result in substantial penalties, including suspension or debarment from government contracting. Violation of the FCPA
can result in significant civil and criminal penalties. Indictment alone under the FCPA can lead to suspension of the right to do business with the U.S. government until the pending claims are resolved. Conviction of a violation of the FCPA can
result in long-term disqualification as a government contractor. The termination of a government contract or relationship as a result of our failure to satisfy any of our obligations under laws governing international business practices would have a
negative impact on our operations and harm our reputation and ability to procure government contracts. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#146;s accounting provisions. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We are subject to stringent and often unsettled laws, rules, regulations, policies, standards and contractual obligations related to data privacy and security and
changes in such laws, rules, regulations, policies, standards and contractual obligations could adversely affect our business. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are subject to data
privacy and protection laws, rules, regulations, policies, standards and contractual obligations that apply to the collection, transmission, storage, use, disclosure, transfer, maintenance and other </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
processing of sensitive, personal and personally-identifying information, which, among other things, impose certain requirements relating to the privacy, security, transmission and other
processing of personal information, including comprehensive regulatory systems in the United States and European Union. The legislative and regulatory landscape for privacy and data protection continues to evolve in jurisdictions worldwide, and
there has been an increasing focus on privacy and data protection issues with the potential to affect our business. However, our data privacy program is in its early stages and we have not yet assessed the applicability of and our compliance with
data privacy-related laws, rules and regulations. As a result, we cannot guarantee that we are and have been in compliance with all applicable data privacy and protection laws, rules regulations, policies and standards, and we may need to expend
significant resources to implement privacy compliance measures. Additionally, we rely on certain third-party vendors to process certain confidential, sensitive or personal information on our behalf. Failure by us or our third-party vendors to comply
with any of these laws, rules, regulations, contractual obligations or standards could result in notification obligations, enforcement actions, regulatory investigations or inquiries, significant fines, imprisonment of company officials and public
censure, litigation and claims for damages by affected individuals, customers or business partners, damage to our reputation and loss of goodwill, any of which could have a material adverse effect on our business, financial condition, results of
operations or prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There are numerous U.S. federal and state laws, rules and regulations related to the privacy and security of personal information. In
particular, regulations promulgated pursuant to the Health Insurance Portability and Accountability Act of 1996 (&#147;HIPAA&#148;), establish privacy and security standards that limit the use and disclosure of individually identifiable health
information, or protected health information, and require the implementation of administrative, physical and technological safeguards to protect the privacy of protected health information and ensure the confidentiality, integrity and availability
of electronic protected health information. The Genetic Information Nondiscrimination Act of 2008 (&#147;GINA&#148;), which clarified that genetic information is protected under HIPAA and restricts the use and disclosure of genetic information. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Additionally, laws in all 50 states require businesses to provide notice to customers whose personally identifiable information has been disclosed as a result of a data
breach. These laws are not consistent, and compliance in the event of a widespread data breach is difficult and may be costly. Moreover, states have been frequently amending existing laws, requiring attention to changing regulatory requirements. We
also may be contractually required to notify patients or other counterparties of a security breach. Although we may have contractual protections with our service providers, any actual or perceived security breach could harm our reputation and brand,
expose us to potential liability or require us to expend significant resources on data security and in responding to any such actual or perceived breach. Any contractual protections we may have from our service providers may not be sufficient to
adequately protect us from any such liabilities and losses, and we may be unable to enforce any such contractual protections. In addition to government regulation, privacy advocates and industry groups have and may in the future propose
self-regulatory standards from time to time. These and other industry standards may legally or contractually apply to us, or we may elect to comply with such standards. Determining whether personal information has been handled in compliance with
applicable privacy standards and our contractual obligations can be complex and may be subject to changing interpretation. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we are unable to properly protect the
privacy and security of personal information, we could be alleged or actually found to have breached our contracts. Furthermore, if we fail to comply with applicable privacy laws, including applicable HIPAA privacy and security standards, we could
face significant administrative, civil and criminal penalties. HHS has the discretion to impose penalties without attempting to resolve violations through informal means, and such enforcement activity can result in financial liability and
reputational harm, and responses to such enforcement activity can consume significant internal resources. In addition, state attorneys general are authorized to bring civil actions seeking either injunctions or damages in response to violations that
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
threaten the privacy or security of the personal information of state residents. We cannot be sure how these laws, rules and regulations will be interpreted, enforced or applied to our
operations. In addition to the risks associated with enforcement activities and potential contractual liabilities, our ongoing efforts to comply with evolving laws, rules and regulations at the international, federal and state level may be costly
and require ongoing modifications to our policies, procedures and systems. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We make public statements about our use, collection, disclosure and other processing of
personal information through our privacy policies and information provided on our website. Although we endeavor to comply with our public statements and documentation, we may at times fail to do so or be alleged to have failed to do so. The
publication of our privacy policies and other statements that provide promises and assurances about data privacy and security can subject us to potential government or legal action if they are found to be deceptive, unfair or misrepresentative of
our actual practices. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Data privacy remains an evolving landscape at both the domestic and international level, with new laws, rules and regulations coming into
effect and continued legal challenges. For example, California enacted the California Consumer Privacy Act of 2018 (&#147;CCPA&#148;), which went into effect on January&nbsp;1, 2020 and, among other things, requires companies that process
information on California residents to make new disclosures to consumers about their data collection, use and sharing practices, allow consumers to opt out of certain data sharing with third parties and provide a new cause of action for data
breaches. Additionally, California voters approved the California Privacy Rights Act (&#147;CPRA&#148;), which went into effect on January&nbsp;1, 2023. The CPRA significantly modifies the CCPA, including by introducing additional obligations such
as data minimization and storage limitations and granting additional rights to California residents such as correction of personal information and additional <FONT STYLE="white-space:nowrap">opt-out</FONT> rights. The CPRA also creates a new state
agency that will be vested with authority to implement and enforce the CCPA and the CPRA. The enactment of the CCPA is prompting a wave of similar legislative developments in other states and at the federal level, reflecting a trend toward more
stringent privacy legislation in the United States. For example, at least four such state laws (in Virginia, Colorado, Connecticut and Utah) have taken effect, or are scheduled to take effect in 2023. Certain state laws may be more stringent or
broader in scope, or offer greater individual rights, with respect to confidential, sensitive and personal information than federal, international or other state laws, and such laws may differ from each other, which may complicate compliance
efforts. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our efforts to comply with the evolving data protection laws, rules and regulations may be unsuccessful. It is possible that these laws, rules and
regulations may be interpreted and applied in a manner that is inconsistent with our practices and our efforts to comply with the evolving data protection rules may be unsuccessful. The laws are not consistent, and compliance in the event of a
widespread data breach is costly and time-consuming. States are also frequently amending existing laws, requiring attention to frequently changing regulatory requirements. We must devote significant resources to understanding and complying with this
changing landscape. Failure by us or our third-party vendors to comply with laws, rules and regulations regarding data privacy and protection would expose us to risk of enforcement actions taken by data protection authorities and carries with it the
potential for significant penalties if we are found to be <FONT STYLE="white-space:nowrap">non-compliant.</FONT> Similarly, failure to comply with federal and state laws, rules and regulations in the United States regarding privacy and security of
personal information could expose us to penalties under such laws, rules and regulations. Any such failure by us or our third-party vendors to comply with data protection and privacy laws, rules and regulations could result in significant
government-imposed fines or orders requiring that we change our practices, claims for damages or other liabilities, regulatory investigations and enforcement action, litigation and significant costs for remediation, any of which could adversely
affect our business. Even if we are not determined to have violated these laws, rules or regulations, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could
harm our business, financial condition, results of operations or prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Risks Related to Third Party Relationships </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If conflicts arise between us and our collaborators or strategic partners, these parties may act in a manner adverse to us and could limit our ability to implement
our strategies. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If conflicts arise between our collaborators and corporate or strategic partners and us, the other party may act in a manner adverse to us
and could limit our ability to implement our strategies. Some of our collaborators and strategic partners are conducting multiple product development efforts within each area that is the subject of the collaboration with us. Our collaborators or
strategic partners, however, may develop, either alone or with others, products in related fields that are competitive with the product candidates we may develop that are the subject of these collaborations with us. Competing products, either
developed by the collaborators or strategic partners or to which the collaborators or strategic partners have rights, may result in the withdrawal of partner support for any product candidates we may develop. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Additionally, some of our collaborators or strategic partners could also become our competitors in the future. Our collaborators or strategic partners could develop
competing products, preclude us from entering into collaborations with their competitors, fail to obtain timely regulatory approvals, prevent us from obtaining timely regulatory approvals, terminate their agreements with us prematurely or fail to
devote sufficient resources to the collaboration efforts, including development, delivery, manufacturing and commercialization of products. Any of these developments could harm our company and product development efforts. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We have entered into collaborations, and may enter into additional collaborations, with third parties for the research, development, manufacture and
commercialization of programs or product candidates. If these collaborations are not successful, our business could be adversely affected. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As part of our
strategy, we have entered into collaborations and intend to seek to enter into additional collaborations with third parties for one or more of our programs or product candidates we may develop. For example, in October 2021, we entered into a
Strategic Collaboration and License Agreement with ModernaTX, Inc. (&#147;Moderna&#148;), focused on advancing new genome editing system for <I>in vivo</I> human therapeutic applications, in June 2022, we entered into a Development, Option and
License Agreement with <FONT STYLE="white-space:nowrap">Affini-T</FONT> Therapeutics, Inc. <FONT STYLE="white-space:nowrap">(&#147;Affini-T&#148;)</FONT> to develop and commercialize gene edited T-cell receptor
<FONT STYLE="white-space:nowrap">(&#147;TCR&#148;)-based</FONT> therapeutic products exclusively in the field of treatment, prevention or diagnosis of any human cancer using products with any engineered primary TCR alpha/beta T cells and
non-exclusively in the field of treatment, prevention or diagnosis of any human cancer using products with certain other engineered immune cells worldwide, and in November 2022, we entered into a Collaboration and License Agreement with Ionis
Pharmaceuticals, Inc. (&#147;Ionis&#148;) to research, develop and commercialize investigational medicines using genome editing technologies. Our likely collaborators for any other collaboration arrangements include large and <FONT
STYLE="white-space:nowrap">mid-size</FONT> pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies. We have under these agreements, and we may have under any other arrangements that we may enter into with
any third parties, limited control over the amount and timing of resources that collaborators dedicate to the development or commercialization of our product candidates. Our ability to generate revenue from these arrangements may depend on our
collaborators&#146; abilities to successfully perform the functions assigned to them in these arrangements. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Collaborations that we enter into may not be successful,
and any success will depend heavily on the efforts and activities of such collaborators. Collaborations pose a number of risks, including the following: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">collaborators have significant discretion in determining the amount and timing of efforts and resources that they will
apply to these collaborations; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">collaborators may not perform their obligations as expected; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">collaborators may not pursue development of our product candidates or may elect not to continue or renew development
programs based on results of clinical trials or other studies, changes in the collaborators&#146; strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">collaborators may not pursue commercialization of any product candidates that achieve regulatory approval or may elect not
to continue or renew commercialization programs based on results of clinical trials or other studies, changes in the collaborators&#146; strategic focus or available funding, or external factors, such as an acquisition, that may divert resources or
create competing priorities; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">collaborators may delay preclinical studies and clinical trials, provide insufficient funding for a preclinical study or
clinical trial program, stop a preclinical study or clinical trial or abandon a product candidate, repeat or conduct new preclinical studies or clinical trials or require a new formulation of a product candidate for preclinical or clinical testing;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we may not have access to, or may be restricted from disclosing, certain information regarding product candidates being
developed or commercialized under a collaboration and, consequently, may have limited ability to inform our stockholders about the status of such product candidates on a discretionary basis; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with
our product candidates and products if the collaborators believe that the competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own
product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a collaborator may fail to comply with applicable regulatory requirements regarding the development, manufacture,
distribution or marketing of a product candidate or product; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory
approval may not commit sufficient resources to the marketing and distribution of such product or products; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">disagreements with collaborators, including disagreements over intellectual property or proprietary rights, contract
interpretation or the preferred course of development, might cause delays or terminations of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates,
or might result in litigation or arbitration, any of which would be time-consuming and expensive; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">collaborators may not properly obtain, maintain, enforce, defend or protect our intellectual property or proprietary rights
or may use our proprietary information in such a way as to potentially lead to disputes or legal proceedings that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">disputes may arise with respect to the ownership of intellectual property or other rights developed pursuant to our
collaborations; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">collaborators may infringe, misappropriate or otherwise violate the intellectual property or proprietary rights of third
parties, which may expose us to litigation and potential liability; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">collaborations may be terminated for the convenience of the collaborator, and, if terminated, we could be required to raise
additional capital to pursue further development or commercialization of the applicable product candidates. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Collaboration agreements may not lead
to development or commercialization of product candidates in the most efficient manner, or at all. If any current or future collaborations do not result in the successful development and commercialization of products or if one of our collaborators
terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. If we do not receive the funding we expect under these agreements, our development of our product candidates
could be delayed and we may need additional resources to develop our product candidates. All of the risks relating to product development, regulatory approval and commercialization described in this prospectus also apply to the activities of our
collaborators. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Collaboration agreements may require us to incur <FONT STYLE="white-space:nowrap">non-recurring</FONT> and other charges, increase our near- and
long-term expenditures, issue securities that dilute our existing stockholders, or disrupt our management and business. For more information, see the section titled &#147;Business&#151;Our License and Collaboration Agreements.&#148; </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We could face significant competition in seeking appropriate collaborators, and the negotiation process is time-consuming and complex. Our ability to reach a definitive
collaboration agreement will depend, among other things, upon our assessment of the collaborator&#146;s resources and expertise, the terms and conditions of the proposed collaboration, and the proposed collaborator&#146;s evaluation of several
factors. If we license rights to any product candidates we or our collaborators may develop, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company
culture. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may also be restricted under existing collaboration agreements from entering into future collaboration agreements on certain terms with potential
collaborators. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators, which further increases competition we
face in seeking potential collaborations. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Additionally, subject to its contractual obligations to us, if a collaborator of ours is involved in a business
combination, the collaborator might deemphasize or terminate the development or commercialization of any product candidate licensed to it by us. If one of our collaborators terminates its agreement with us, we may find it more difficult to attract
new collaborators and our perception in the business and financial communities could be adversely affected. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our collaborators and strategic partners may
control aspects of our clinical trials, which could result in delays and other obstacles in the commercialization of our proposed products and materially harm our results of operations. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For some programs, we will depend on third party collaborators and strategic partners to design and conduct our clinical trials. As a result, we may not be able to
conduct these programs in the manner or on the time schedule we currently contemplate, which may negatively impact our business operations. In addition, if any of these collaborators or strategic partners withdraw support for our programs or
proposed products or otherwise impair their development, our business could be negatively affected. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In October 2021, we entered into a Strategic Collaboration and
License Agreement with Moderna focused on advancing new genome editing system for <I>in vivo</I> human therapeutic applications, in June 2022, we entered into a Development, Option and License Agreement with
<FONT STYLE="white-space:nowrap">Affini-T</FONT> to develop and commercialize gene edited <FONT STYLE="white-space:nowrap">TCR-based</FONT> therapeutic products exclusively in the field of treatment, prevention or diagnosis of any human cancer using
products with any engineered primary TCR alpha/beta T cells and non-exclusively in the field of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
treatment, prevention or diagnosis of any human cancer using products with certain other engineered immune cells worldwide, and in November 2022, we entered into a Collaboration and License
Agreement with Ionis to research, develop and commercialize investigational medicines for up to eight potential genetic targets using genome editing technologies. Our lack of control over the clinical development in our agreements with Moderna, <FONT
STYLE="white-space:nowrap">Affini-T</FONT> and Ionis could cause delays or other difficulties in the development and commercialization of product candidates, which may prevent completion of intended IND applications in a timely fashion, if at all.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, the termination of these agreements would prevent us from receiving any milestone, royalty payments and other benefits under that agreement, which
would have a materially adverse effect on our results of operations. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our collaborators or strategic partners may decide to adopt alternative technologies or
may be unable to develop commercially viable products with our technology, which would negatively impact our revenues and our strategy to develop these products. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our collaborators or strategic partners may adopt alternative technologies, which could decrease the marketability of our genome editing technology. Additionally,
because our current or future collaborators or strategic partners are likely to be working on more than one development project, they could choose to shift their resources to projects other than those they are working on with us. If they do so, this
would delay our ability to test our technology and would delay or terminate the development of potential products based on our genome editing technology. Further, our collaborators and strategic partners may elect not to develop products arising out
of our collaborative and strategic partnering arrangements or to devote sufficient resources to the development, manufacturing, marketing or sale of these products. The failure to develop and commercialize a product candidate pursuant to our
agreements with our current or future collaborators would prevent us from receiving future milestone and royalty payments which would negatively impact our revenues. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We expect to rely on third parties to conduct our clinical trials and some aspects of our research, as well as some aspects of our delivery methods, and those
third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research or testing. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We expect to rely
on third parties, such as CROs, clinical data management organizations, medical institutions, preclinical laboratories and clinical investigators, to conduct some aspects of our research. For example, we may rely on a third party to supply LNPs or
AAVs, or to conduct our preclinical animal experiments. Any of these third parties may terminate their engagements with us at any time under certain criteria. If we need to enter into alternative arrangements, it may delay our product development
activities. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our reliance on these third parties for clinical research and other development activities will reduce our control over these activities but will not
relieve us of our responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA, the EMA and
other regulatory authorities require us and the study sites and investigators we work with to comply with standards, commonly referred to as GLPs and GCPs for conducting, recording and reporting the results of preclinical studies and clinical trials
to assure, amongst other things, that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. In the United States, we also are required to register certain clinical
trials and post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Although we intend to design the preclinical studies and clinical trials for our potential product candidates, CROs will conduct some or all of the preclinical studies
and clinical trials. As a result, many important aspects of our development programs, including their conduct and timing, will be outside of our direct control. Our reliance on third </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
parties to conduct preclinical studies and future clinical trials will also result in less direct control over the management of data developed through preclinical studies and clinical trials
than would be the case if we were relying entirely upon our own staff. Communicating with outside parties can also be challenging, potentially leading to mistakes as well as difficulties in coordinating activities. Among other reasons that may delay
or impact the development of our potential product candidates, outside parties may: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">have staffing difficulties; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">fail to comply with contractual obligations; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">experience regulatory compliance issues; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">undergo changes in priorities or become financially distressed; or </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">form relationships with other entities, some of which may be our competitors. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">These factors may materially adversely affect the willingness or ability of third parties to conduct our preclinical studies and clinical trials and may subject us to
unexpected cost increases that are beyond our control. If the CROs and other third parties do not perform such preclinical studies and future clinical trials in a satisfactory manner, breach their obligations to us or fail to comply with regulatory
requirements, the development, regulatory approval and commercialization of our potential product candidates may be delayed, we may not be able to obtain regulatory approval and commercialize our potential product candidates or our development
programs may be materially and irreversibly harmed. If we are unable to rely on preclinical and clinical data collected by our CROs and other third parties, we could be required to repeat, extend the duration of or increase the size of any
preclinical studies or clinical trials we conduct and this could significantly delay commercialization and require greater expenditures. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may also expect to rely
on other third parties to store and distribute drug supplies for our future clinical trials. Any performance failure on the part of our distributors could delay clinical development or regulatory approval of any product candidates we may develop or
commercialization of our therapies, producing additional losses and depriving us of potential product revenue. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Manufacturing biologic products is complex and
subject to product loss for a variety of reasons. We contract with third parties for the manufacture of certain materials for our development programs and expect to continue to do so for clinical trials and commercialization. This reliance on third
parties increases the risk that we will not have sufficient quantities of our future product candidates or products or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization
efforts. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We operate and are expanding our cGMP manufacturing facility which is currently capable of manufacturing clinical grade nucleases and mRNA to
supply both wholly-owned and collaboration programs. We also partner with CMOs for guide RNA (&#147;gRNA&#148;) and DNA template development and supply. We also rely, and expect to continue to rely, on third parties for gRNA and DNA template
development and supply, as well as for preclinical and clinical testing and commercial manufacture if any of our product candidates receive regulatory approval. We also expect to rely on these third parties for certain logistics, including
packaging, labeling, storage, and distribution. This reliance on third parties increases the risk that we will not have sufficient quantities of our materials or future product candidates or products or such quantities at an acceptable cost or
quality, which could delay, prevent or impair our development or commercialization efforts. We may be unable to establish any agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with
third-party manufacturers, reliance on third-party manufacturers entails additional risks, including: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reliance on the third party for regulatory compliance and quality assurance; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the possible breach of the manufacturing agreement by the third party; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the possible misappropriation of our proprietary information, including our trade secrets and know-how; and
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us.
</P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We or our third-party manufacturers may encounter shortages in the raw materials or active pharmaceutical ingredients necessary to produce our
future product candidates in the quantities needed for our preclinical studies or clinical trials or, if our future product candidates are approved, in sufficient quantities for commercialization or to meet an increase in demand, as a result of
capacity constraints or delays or disruptions in the market for the raw materials or active pharmaceutical ingredients, including shortages caused by the purchase of such raw materials or active pharmaceutical ingredient by our competitors or
others. The failure of us or our third-party manufacturers to obtain the raw materials or active pharmaceutical ingredients necessary to manufacture sufficient quantities of our future product candidates may have a material adverse effect on our
business. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Components of a finished therapeutic product approved for commercial sale or used in late-stage clinical trials must be manufactured in accordance with
cGMP. We, along with our third-party manufacturers, are subject to inspection and approval by regulatory authorities before we can commence the manufacture and sale of any of our future product candidates, and thereafter subject to ongoing
inspection from time to time. We or our third-party manufacturers may not be able to comply with cGMP or similar regulatory requirements outside of the United States. Our failure, or the failure of our third-party manufacturers, to comply with
applicable regulations could result in regulatory actions, such as the issuance of FDA Form 483 notices of observations, warning letters or sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays,
suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our products. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Manufacturing biologic products, such as the product candidates we intend to develop, is complex, especially in large quantities. Biologic products must be made
consistently and in compliance with a clearly defined manufacturing process. Accordingly, it is essential to be able to validate and control the manufacturing process to assure that it is reproducible. Any product candidates and products that we may
develop may compete with other product candidates and products for access to manufacturing facilities. As a result, we may not obtain access to these facilities on a priority basis or at all. There are a limited number of manufacturers that operate
under cGMP and that might be capable of manufacturing for us. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any performance failure on the part of our existing or future manufacturers could delay clinical
development or regulatory approval. We do not currently have arrangements in place for redundant supply or a source for bulk drug substance nor do we have any agreements with third-party manufacturers for long-term commercial supply. If any of our
contract manufacturers cannot perform as agreed, we may be required to replace such manufacturers. Although we believe that there are several potential alternative manufacturers who could manufacture materials or future product candidates or
products we may develop, we may incur added costs and delays in identifying and qualifying any such replacement or be unable to reach agreement with an alternative manufacturer. If we are required to change third party-manufacturers for any reason,
we will be required to verify that the new third party-manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations. We will also need to verify, such as through a manufacturing
comparability study, that any new manufacturing process will produce our materials or future product candidates or products according to the specifications previously submitted to the FDA or another regulatory authority. The delays associated with
the verification of a new third party-manufacturer could negatively affect our ability to develop product candidates or commercialize our products in a timely manner or within budget. Furthermore, a third party-manufacturer may possess technology
related to the manufacture of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
our materials or future product candidates or products that such third party-manufacturer owns independently. This would increase our reliance on such third party-manufacturer or require us to
obtain a license from such third party-manufacturer in order to have another third party-manufacturer manufacture our materials or future product candidates or products, which may not be available on commercially reasonable terms, or at all. In
addition, changes in manufacturers often involve changes in manufacturing procedures and processes, which could require that we conduct bridging studies between our prior clinical supply used in our clinical trials and that of any new manufacturer.
We may be unsuccessful in demonstrating the comparability of clinical supplies which could require the conduct of additional clinical trials. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our current and
anticipated future dependence upon others for the manufacture of materials and any future product candidates or products we may develop may adversely affect our future profit margins and our ability to commercialize any products that receive
regulatory approval on a timely and competitive basis. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our relationships with healthcare providers, physicians, and third-party payors will be subject to applicable
anti-kickback, fraud and abuse, anti-bribery and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, and diminished profits and future earnings. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our relationships with healthcare providers, physicians, and third-party payors will be subject to applicable anti-kickback, fraud and abuse, anti-bribery and
other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, and diminished profits and future earnings. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Healthcare providers, including physicians, and third-party payors play a primary role in the recommendation and prescription of any product candidates that we may
develop for which we obtain regulatory approval and marketing approval. Our current and future arrangements with third-party payors, healthcare providers and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and
regulations that may constrain the business or financial arrangements and relationships through which we market, sell, and distribute our products for which we obtain regulatory approval. Restrictions under applicable federal and state healthcare
laws and regulations, including certain laws and regulations applicable only if we have marketed products, include the following: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the civil FCA, prohibits knowingly presenting or causing the presentation of a false, fictitious or fraudulent claim for
payment to the U.S. government. Actions under the FCA may be brought by the Attorney General or as a qui tam action by a private individual in the name of the government. Violations of the FCA can result in very significant monetary penalties, for
each false claim and treble the amount of the government&#146;s damages. Manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#147;cause&#148; the submission of false
or fraudulent claims; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the federal Anti-Kickback Statute prohibits, among other things, persons from soliciting, receiving or providing
remuneration, directly or indirectly, to induce either the referral of an individual, for an item or service or the purchasing or ordering of a good or service, for which payment may be made under federal healthcare programs such as Medicare and
Medicaid. The federal Anti-Kickback Statute has been interpreted to apply to arrangements between manufacturers on one hand and prescribers, purchasers, and formulary managers on the other. A person or entity does not need to have actual knowledge
of the statute or specific intent to violate it in order to have committed a violation. A violation of the federal Anti-Kickback Statute can also form the basis for FCA liability; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">HIPAA, which, in addition to privacy protections applicable to healthcare providers and other entities, prohibits executing
a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent
to violate it in order to have committed a violation; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (&#147;HITECH&#148;),
and its implementing regulations, including the final omnibus rule published on January&nbsp;25, 2013, imposes, among other things, certain requirements relating to the privacy, security and transmission of individually identifiable health
information. Among other things, HITECH makes HIPAA&#146;s privacy and security standards directly applicable to &#147;business associates,&#148; defined as independent contractors or agents of covered entities that create, receive, maintain,
transmit, or obtain, protected health information in connection with providing a service for or on behalf of a covered entity, and their covered subcontractors. HITECH also increased the civil and criminal penalties that may be imposed against
covered entities, business associates and possibly other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#146;s fees and
costs associated with pursuing federal civil actions; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the FDCA, which among other things, strictly regulates drug marketing, prohibits manufacturers from marketing such products
for <FONT STYLE="white-space:nowrap">off-label</FONT> use and regulates the distribution of samples; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">federal laws that require pharmaceutical manufacturers to report certain calculated product prices to the government or
provide certain discounts or rebates to government authorities or private entities, often as a condition of reimbursement under government healthcare programs; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">federal transparency laws, including the federal Physician Payment Sunshine Act created under the Patient Protection and
Affordable Care Act as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the ACA), and its implementing regulations, which requires manufacturers of certain drugs, devices, medical supplies, and biologics, among
others, to track and disclose payments under Medicare, Medicaid or the Children&#146;s Health Insurance Program (with certain exceptions) and other transfers of value they make to U.S. physicians (defined to include doctors, dentists, optometrists,
podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Effective January&nbsp;1, 2022, these reporting obligations will extend to include transfers
of value made to certain <FONT STYLE="white-space:nowrap">non-physician</FONT> providers such as physician assistants and nurse practitioners. This information is subsequently made publicly available in a searchable format on a Centers for
Medicare&nbsp;&amp; Medicaid Services (&#147;CMS&#148;) website. Failure to disclose required information may result in civil monetary penalties for all payments, transfers of value or ownership or investment interests that are not timely,
accurately and completely reported in an annual submission. Certain states also mandate implementation of compliance programs, impose restrictions on drug manufacturer marketing practices and/or require the tracking and reporting of gifts,
compensation and other remuneration to physicians and/or other healthcare providers; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">analogous state and foreign laws and regulations, such as state anti-kickback, anti-bribery and false claims laws, which
may apply to healthcare items or services that are reimbursed by <FONT STYLE="white-space:nowrap">non-governmental</FONT> third-party payors, including private insurers. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Some state laws also require pharmaceutical companies to comply with specific compliance standards, restrict financial interactions between pharmaceutical companies and
healthcare providers or require pharmaceutical companies to report information related to payments to healthcare providers or marketing expenditures. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Efforts to
ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Given the breadth of the laws and regulations, limited guidance for certain laws and regulations and
evolving government interpretations of the laws and regulations, governmental authorities may possibly conclude that our business practices may not comply with healthcare laws and regulations. If our operations are found to be in violation of any of
the laws described above or any other government regulations that apply to us, we may be subject to significant penalties, including civil and </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">criminal penalties,
damages, fines, exclusion from participation in government healthcare programs, such as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
Medicare and Medicaid, individual imprisonment, and the curtailment or restructuring of our operations, any of which could adversely affect our business, financial condition, results of
operations, and prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase,
supply, order, or use of medicinal products is prohibited in the European Union. The provision of benefits or advantages to also induce or reward improper performance generally is governed by the national anti-bribery laws of European Union Member
States, and the Bribery Act 2010 in the United Kingdom. Infringement of these laws could result in substantial fines and imprisonment. EU Directive 2001/83/EC, which is the EU Directive governing medicinal products for human use, further provides
that, where medicinal products are being promoted to persons qualified to prescribe or supply them, no gifts, pecuniary advantages or benefits in kind may be supplied, offered or promised to such persons unless they are inexpensive and relevant to
the practice of medicine or pharmacy. This provision has been transposed into the Human Medicines Regulations 2012 and so remains applicable in the United Kingdom despite its departure from the EU. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Payments made to physicians in certain European Union Member States must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior
notification and approval by the physician&#146;s employer, his or her competent professional organization, and/or the regulatory authorities of the individual European Union Member States. These requirements are provided in the national laws,
industry codes, or professional codes of conduct applicable in the European Union Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Risks Related to Personnel, Operations, and Growth </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our future success
depends on our ability to retain our Chief Executive Officer and other key executives and to attract, retain, and motivate qualified personnel. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are
highly dependent on Brian C. Thomas, our Chief Executive Officer as well as the other principal members of our management and scientific teams. Dr.&nbsp;Thomas and such other principal members are engaged &#147;at will,&#148; meaning we or they may
terminate the relationship at any time. We do not maintain &#147;key person&#148; insurance for any of our executives or other employees. The loss of the services of any of these persons could impede the achievement of our research, development and
commercialization objectives. For us to successfully compete and grow, we must recruit, retain, and develop talent who can provide the necessary expertise across a broad spectrum of disciplines. In addition, we must develop, maintain and, as
necessary, implement appropriate succession plans to ensure we have the necessary human capital capable of maintaining continuity in our business. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Recruiting and
retaining qualified scientific, clinical, manufacturing and sales and marketing personnel will also be critical to our success. In addition, our company-building efforts and establishment of a company culture will also be important to developing an
innovative company in a high-evolving area. We may not be able to succeed in these efforts to build Metagenomi as an attractive and exciting place to build a career or to attract and retain these types of personnel on acceptable terms given the
competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on
consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors, including our scientific
<FONT STYLE="white-space:nowrap">co-founders,</FONT> may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. We may also encounter
problems hiring and retaining the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
experienced scientific, quality control and manufacturing personnel needed to manage our manufacturing process, which could result in delays in our production or difficulties in maintaining
compliance with applicable regulatory requirements. The inability to recruit, or loss of services of, certain executives, key employees, consultants or advisors, may impede the progress of our research, development and commercialization objectives
and have a material adverse effect on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We expect to expand our research, development,
delivery, manufacturing, commercialization, regulatory, and future sales and marketing capabilities over time, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may fail to manage our growth effectively. As of June&nbsp;30, 2023, we had more than 200 full-time employees, of which 69 have M.D. or Ph.D. degrees. Within our
workforce, 176 employees are engaged in research and development and 35 are engaged in business development, finance, legal, and general management and administration. In connection with the growth and advancement of our pipeline and becoming a
public company, we expect to increase the number of our employees and the scope of our operations, particularly in the areas of research and clinical development, regulatory affairs and, if any of our future product candidates receive regulatory
approval, sales and marketing. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities, and continue to recruit and train additional qualified
personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expected expansion of our operations or recruit and
train additional qualified personnel. Moreover, the expected physical expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the
execution of our business plans or disrupt our operations. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As a growing biotechnology company, we are actively developing our platform technology and pursuing
development of future product candidates in many therapeutic areas and across a wide range of diseases. Successfully developing product candidates for and fully understanding the regulatory and manufacturing pathways to all of these therapeutic
areas and disease states requires a significant depth of talent, resources and corporate processes in order to allow simultaneous execution across multiple areas. We will need to transition from a company with a research focus to a company capable
of conducting clinical trials and ultimately supporting commercial activities if any of our product candidates are approved. We may not be successful in such a transition. Due to our limited resources, we may not be able to effectively manage this
simultaneous execution and the expansion of our operations or recruit and train additional qualified personnel. This may result in weaknesses in our infrastructure, give rise to operational mistakes, legal or regulatory compliance failures, loss of
business opportunities, loss of employees and reduced productivity among remaining employees. The physical expansion of our operations may lead to significant costs and may divert financial resources from other projects, such as the development of
our potential product candidates. If our management is unable to effectively manage our expected development and expansion, our expenses may increase more than expected, our ability to generate or increase our revenue could be reduced and we may not
be able to implement our business strategy. Our future financial performance and our ability to compete effectively and commercialize any product candidates we may develop will depend in part on our ability to effectively manage the future
development and expansion of our company, and may prevent us from achieving or maintaining profitability. We cannot assure you that we will be able to compete effectively in the future against existing or new competitors, and our failure to do so
could harm our business, financial condition, and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could
hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved, or commercialized in a timely manner or at all, which could negatively impact our
business. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels,
statutory, regulatory, and policy changes, the FDA&#146;s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#146;s ability to perform routine functions. Average review
times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and
unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for biologics or modifications to approved biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our
business. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Risks Related to Our Intellectual Property </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our
commercial success depends on our ability to obtain, maintain, enforce, and otherwise protect our intellectual property and proprietary technology, and if the scope of the intellectual property protection obtained is not sufficiently broad, our
competitors or other third parties could develop and commercialize products and product candidates similar to ours and our ability to successfully develop and commercialize our genome editing systems may be adversely affected. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our commercial success depends, in large part, on our ability to obtain and maintain intellectual property rights protection through patents, trademarks, and trade
secrets in the United States and other countries with respect to our proprietary genome editing systems. If we do not adequately protect our intellectual property rights, competitors or other third parties may be able to erode, negate or preempt any
competitive advantage we may have, which could harm our business and ability to achieve profitability. To protect our proprietary position, we have filed patent applications and may file other patent applications in the United States or abroad
related to our genome editing systems that are important to our business; we may also license or purchase patents or patent applications filed by others. The patent application process is expensive, time-consuming and complex. We may not be able to
file, prosecute, maintain, enforce or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may not be able to
obtain patents on certain inventions if those inventions are publicly disclosed prior to our filing a patent application covering them. We enter into nondisclosure and confidentiality agreements with parties who have access to confidential
information, including confidential information regarding inventions not yet disclosed in patent applications. We cannot guarantee that any of these parties will not breach these confidentiality agreements and publicly disclose any of our inventions
before a patent application is filed covering such inventions. If such confidential information is publicly disclosed, we may not be able to successfully patent it and consequently, we may not be able to prevent third parties from using such
inventions. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If the scope of the patent protection we obtain is not sufficiently broad, we may not be able to prevent others from developing and commercializing
technology and products similar or identical to ours. The degree of patent protection we require to successfully compete in the marketplace may be unavailable or severely limited in some cases and may not adequately protect our rights or permit us
to gain or keep any competitive advantage. We cannot provide any assurances that any of our patents have, or that any of our pending owned patent applications that mature into issued patents will include claims with a scope sufficient to protect our
proprietary genome editing systems or otherwise provide any competitive advantage. Other parties have developed or may develop technologies that may be related or competitive with our approach, and may have
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
filed or may file patent applications and may have been issued or may be issued patents with claims that overlap or conflict with our patent portfolio, either by claiming the same compounds,
formulations or methods or by claiming subject matter that could dominate our patent position. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Furthermore, patents have a
limited lifespan. In the United States, the natural expiration of a patent is generally twenty years after it is filed. Various extensions may be available; however, the life of a patent, and the protection it affords, is limited. Given the amount
of time required for the development, testing and regulatory review of new genome editing systems, patents protecting such genome editing systems might expire before or shortly after such genome editing systems are commercialized. As a result, our
patent portfolio may not provide us with adequate and continuing patent protection sufficient to exclude others from commercializing products similar or identical to ours. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Even if they are unchallenged, our owned patents and pending patent applications, if issued, may not provide us with any meaningful protection or prevent competitors
from designing around our patent claims to circumvent our patent portfolio by developing similar or alternative genome editing systems in a <FONT STYLE="white-space:nowrap">non-infringing</FONT> manner. For example, a third party may develop a
genome editing system that provides benefits similar to our genome editing systems but falls outside the scope of our patent protection or license rights. If the patent protection provided by the patent and patent applications we hold or pursue with
respect to our genome editing systems is not sufficiently broad to impede such competition, our ability to successfully commercialize our product genome editing systems could be negatively affected, which would harm our business. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We, or any future partners, collaborators, or licensees, may fail to identify patentable aspects of inventions made in the course of development and commercialization
activities before it is too late to obtain patent protection on them. Therefore, we may miss potential opportunities to strengthen our patent position. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">It is
possible that defects of form in the preparation or filing of our patent portfolio may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, claim scope, or requests for patent term adjustments. If we
or our partners, collaborators, or licensees whether current or future, fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If our partners, collaborators, or
licensees are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. If there are material defects in the form, preparation, prosecution, or
enforcement of our patent portfolio, such patents may be invalid and/or unenforceable, and such applications may never result in valid, enforceable patents. Periodic maintenance fees, renewal fees, annuity fees and various other government fees on
patents and/or applications will be due to be paid to the U.S. Patent and Trademark Office (&#147;USPTO&#148;) and various government patent agencies outside of the United States over the lifetime of our owned or licensed patents and patent
applications. We rely on our outside counsel or our licensing partners to pay these fees due to U.S. and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> patent agencies. The USPTO and various <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
government patent agencies require compliance with several procedural, documentary, fee payment and other similar provisions during the patent application process. Any of these outcomes could impair our ability to prevent competition from third
parties, which may have an adverse impact on our business. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The patent position of biotechnology and pharmaceutical companies carries uncertainty. In addition, the
determination of patent rights with respect to genome editing technologies commonly involves complex legal and factual questions, which are dependent upon the current legal and intellectual property context, extant legal precedent and
interpretations of the law by individuals. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are characterized by uncertainty. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pending patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such
applications. Assuming the other requirements for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
patentability are met, currently, the first to file a patent application is generally entitled to the patent. However, prior to March&nbsp;16, 2013, in the United States, the first to invent was
entitled to the patent. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are not published until 18 months after filing, or in some
cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in our patent portfolio, or that we were the first to file for patent protection of such inventions. If third parties have filed prior patent
applications on inventions claimed in our patent portfolio that were filed on or before March&nbsp;15, 2013, an interference proceeding in the United States can be initiated by such third parties to determine who was the first to invent any of the
subject matter covered by our patent portfolio. If third parties have filed such prior applications after March&nbsp;15, 2013, a derivation proceeding in the United States can be initiated by such third parties to determine whether our invention was
derived from theirs. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Moreover, because the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, our patents may be
challenged in the courts or patent offices in the United States and abroad. There is no assurance that all the potentially relevant prior art relating to our patent portfolio has been found. Publications of discoveries in the scientific literature
often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing or, in some cases, not at all. Therefore, we cannot know with certainty whether we
were the first to make the inventions claimed in our patent portfolio, or that we were the first to file for patent protection of such inventions. If such prior art exists, it may be used to invalidate a patent, or may prevent a patent from issuing
from a pending patent application. For example, such patent filings may be subject to a third-party submission of prior art to the USPTO, or to other patent offices around the world. Alternately or additionally, we may become involved in post-grant
review procedures, oppositions, derivation proceedings, ex parte reexaminations, inter partes review, supplemental examinations, or interference proceedings or challenges before the USPTO or in district court in the United States, or similar
proceedings in various foreign jurisdictions, including both national and regional, challenging patents or patent applications in which we have rights, including patents on which we rely to protect our business. An adverse determination in any such
challenges may result in loss of the patent or claims in the patent portfolio being narrowed, invalidated or held unenforceable, in whole or in part, or in denial of the patent application or loss or reduction in the scope of one or more claims of
the patent portfolio, any of which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pending and future patent applications may not result in patents being issued that protect our business, in whole or in part, or which effectively prevent others from
commercializing competitive products. Competitors may also be able to design around our patents. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or
narrow the scope of our patent protection. In addition, the laws of foreign countries may not protect our rights to the same extent or in the same manner as the laws of the United States. For example, patent laws in various jurisdictions, including
jurisdiction covering significant commercial markets, such as the European Patent Office, China, and Japan, restrict the patentability of methods of treatment of the human body more than United States law does. If these developments were to occur,
they could have a material adverse effect on our ability to generate revenue. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The patent application process is subject to numerous risks and uncertainties, and
there can be no assurance that we or any of our future development partners will be successful in protecting our genome editing systems by obtaining and defending patents. These risks and uncertainties include the following: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee
payment and other provisions during the patent process. There are situations in which noncompliance, whether intentional or not, can result in abandonment or lapse of a patent or patent
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">
application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have
been the case; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">patent applications may not result in any patents being issued; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Company-owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents that have been issued or may be issued in the
future may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our competitors, many of whom have substantially greater resources and many of whom have made significant investments in
competing technologies, may seek or may have already obtained patents that will limit, interfere with or eliminate our ability to make, use, and sell our genome editing systems; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent
protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts,
allowing foreign competitors a better opportunity to create, develop and market competing products; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">countries other than the U.S. may, under certain circumstances, force us to grant a license under our patents to a
competitor, thus allowing the competitor to compete with us in that jurisdiction or forcing us to lower the price of our drug in that jurisdiction. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Issued patents that we have or may obtain or license may not provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide
us with any competitive advantage. Our competitors may be able to circumvent our patents by developing similar or alternative technologies or products in a <FONT STYLE="white-space:nowrap">non-infringing</FONT> manner. Our competitors may also seek
approval to market their own products similar to or otherwise competitive with our products. In these circumstances, we may need to defend or assert our patents, or both, including by filing lawsuits alleging patent infringement. In any of these
types of proceedings, a court or other agency with jurisdiction may find our patents invalid or unenforceable, or that our competitors do not infringe our patents. Thus, even if we have valid and enforceable patents, these patents still may not
provide protection against competing products or processes sufficient to achieve our business objectives. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We maintain certain information as company trade secrets.
This information may relate to inventions that are not patentable or not optimally protected with patents. We use commercially acceptable practices to protect this information, including, for example, limiting access to the information and requiring
passwords for our computers. Additionally, we execute confidentiality agreements with any third parties to whom we may provide access to the information and with our employees, consultants, scientific advisors, collaborators, vendors, contractors,
and advisors. We cannot provide any assurances that all such agreements have been duly executed, and third parties may still obtain this information or may come upon this or similar information independently. It is possible that technology relevant
to our business will be independently developed by a person who is not a party to such a confidentiality or invention assignment agreement. If any of our trade secrets were to be independently developed by a competitor or other third party, we would
have no right to prevent such competitor or third party, or those to whom they communicate such independently developed information, from using that information to compete with us. We may not be able to prevent the unauthorized disclosure or use of
our technical knowledge or trade secrets by contract manufacturers, consultants, collaborators, vendors, advisors, former employees and current employees. Monitoring unauthorized uses and disclosures is difficult and we do not know whether the steps
we have taken to protect our proprietary technologies will be effective. Furthermore, if the parties to our confidentiality agreements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
breach or violate the terms of these agreements, we may not have adequate remedies for any such breach or violation, and we could lose our trade secrets as a consequence of such breaches or
violations. Our trade secrets could otherwise become known or be independently discovered by our competitors. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third
parties for misappropriating our trade secrets. If any of these events occurs or if we otherwise lose protection for our trade secrets, our business, financial condition, results of operation and prospects may be materially and adversely harmed.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>It is difficult and costly to protect our intellectual property and our proprietary technologies, and we may not be able to ensure their protection.
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our commercial success will depend in part on obtaining and maintaining patent protection and trade secret protection for our proprietary genome editing
systems, as well as on successfully defending these patents against potential third-party challenges. Our ability to protect our genome editing systems from unauthorized making, using, selling, offering to sell or importing by third parties is
dependent on the extent to which we have rights under valid and enforceable patents that cover these activities. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The patent positions of pharmaceutical,
biotechnology and other life sciences companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved and have in recent years been the subject of much litigation. Changes in
either the patent laws or in interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property. Over the past decade, U.S. federal courts have increasingly invalidated pharmaceutical and
biotechnology patents during litigation often based on changing interpretations of patent law. Further, the determination that a patent application or patent claim meets all the requirements for patentability is a subjective determination based on
the application of law and jurisprudence. The ultimate determination by the USPTO or by a court or other trier of fact in the United States, or corresponding foreign national patent offices or courts, on whether a claim meets all requirements of
patentability cannot be assured. Although we have conducted searches for third-party publications, patents and other information that may affect the patentability of claims in our patent portfolio, we cannot be certain that all relevant information
has been identified. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in our own patent portfolio. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We cannot provide assurances
that any of our patent applications will be found to be patentable, including over our own prior art publications or patent literature, or will issue as patents. Neither can we make assurances as to the scope of any claims that may issue from our
pending and future patent applications nor to the outcome of any proceedings by any potential third parties that could challenge the patentability, validity or enforceability of our patent portfolio in the United States or foreign jurisdictions. Any
such challenge, if successful, could limit patent protection for our genome editing systems and/or materially harm our business. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition to challenges during
litigation, third parties can challenge the validity of our patents in the United States using post-grant review and inter partes review proceedings, which some third parties have been using to cause the cancellation of selected or all claims of
issued patents of competitors. For a patent filed March&nbsp;16, 2013 or later, a petition for post-grant review can be filed by a third party in a nine-month window from issuance of the patent. A petition for inter partes review can be filed
immediately following the issuance of a patent if the patent has an effective filing date prior to March&nbsp;16, 2013. A petition for inter partes review can be filed after the nine-month period for filing a post-grant review petition has expired
for a patent with an effective filing date of March&nbsp;16, 2013 or later. Post-grant review proceedings can be brought on any ground of invalidity, whereas inter partes review proceedings can only raise an invalidity challenge based on published
prior art and patents. These adversarial actions at the USPTO review patent claims without the presumption of validity afforded to U.S. patents in lawsuits in U.S. federal courts and use a lower burden of proof than used in litigation in U.S.
federal courts. Therefore, it is generally </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
considered easier for a competitor or third party to have a U.S. patent invalidated in a USPTO post-grant review or inter partes review proceeding than invalidated in a litigation in a U.S.
federal court. If any of our patents are challenged by a third party in such a USPTO proceeding, there is no guarantee that we will be successful in defending the patent, which may result in a loss of the challenged patent right to us. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or
permit us to gain or keep our competitive advantage. For example: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we may not be able to generate sufficient data to support full patent applications that protect the entire breadth of
developments in one or more of our programs; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">it is possible that one or more of our pending patent applications will not become an issued patent or, if issued, that the
patent(s) claims will have sufficient scope to protect our technology, provide us with commercially viable patent protection or provide us with any competitive advantages; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">if our pending applications issue as patents, they may be challenged by third parties as invalid or unenforceable under
United States or foreign laws; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we may not successfully commercialize our genome editing systems, if approved, before our relevant patents expire;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we may not be the first to make the inventions covered by our patent portfolio; or </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we may not develop additional proprietary technologies or genome editing systems that are separately patentable.
</P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, to the extent that we are unable to obtain and maintain patent protection for our genome editing systems, or in the event that such
patent protection expires, it may no longer be cost-effective to extend our portfolio by pursuing additional development of any of our genome editing systems for <FONT STYLE="white-space:nowrap">follow-on</FONT> indications. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Patent terms may be inadequate to protect our competitive position on our products for an adequate amount of time. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its
earliest U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT> filing date. The patent term of a U.S. patent may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the United States Patent and
Trademark Office in granting a patent, or may be shortened if a patent is terminally disclaimed over an earlier-filed patent. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Various extensions may be available,
but the life of a patent, and the protection it affords, is limited. Given the amount of time required for the development, testing and regulatory review of new genome editing systems, patents protecting such genome editing systems might expire
before or shortly after such genome editing systems are commercialized. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the United States, the Drug Price Competition and Patent Term Restoration Act of 1984
permits a Patent Term Extension (&#147;PTE&#148;) of up to five years beyond the normal expiration of the patent to compensate patent owners for loss of enforceable patent term due to the lengthy regulatory approval process. A PTE grant cannot
extend the remaining term of a patent beyond a total of 14 years from the date of the product approval. Further, PTE may only be applied once per product, and only with respect to an approved indication&#151;in other words, only one patent (for
example, covering the product itself, an approved use of said product, or a method of manufacturing said product) can be extended by PTE. We anticipate applying for PTE in the United States. Similar extensions may be available in other countries
where we are prosecuting patents and we likewise anticipate applying for such extensions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The granting of such patent term extensions is not guaranteed and is subject to numerous requirements. We might not be
granted an extension because of, for example, failure to apply within applicable periods, failure to apply prior to the expiration of relevant patents or otherwise failure to satisfy any of the numerous applicable requirements. In addition, to the
extent we wish to pursue patent term extension based on a patent that we <FONT STYLE="white-space:nowrap">in-license</FONT> from a third party, we would need the cooperation of that third party. Moreover, the applicable authorities, including the
FDA and the USPTO in the United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more
limited extensions than we request. If this occurs, our competitors may be able to obtain approval of competing products following our patent expiration by referencing our clinical and preclinical data and launch their product earlier than might
otherwise be the case. If this were to occur, it could have a material adverse effect on our ability to generate revenue. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Changes in the interpretation of
patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The United States Congress is responsible for passing laws establishing patentability standards. As with any laws, implementation is left to federal agencies and the
federal courts based on their interpretations of the laws. Interpretation of patent standards can vary significantly within the USPTO, and across the various federal courts, including the U.S. Supreme Court. Recently, the Supreme Court has ruled on
several patent cases, generally limiting the types of inventions that can be patented. Further, there are open questions regarding interpretation of patentability standards that the Supreme Court has yet to decisively address. Absent clear guidance
from the Supreme Court, the USPTO has become increasingly conservative in its interpretation of patent laws and standards. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition to increasing uncertainty
with regard to our ability to obtain patents in the future, the legal landscape in the U.S. has created uncertainty with respect to the value of patents. Depending on any actions by Congress, and future decisions by the lower federal courts and the
U.S. Supreme Court, along with interpretations by the USPTO, the laws and regulations governing patents could change in unpredictable ways and could weaken our ability to obtain new patents or to enforce our existing patents and patents that we
might obtain in the future. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The U.S. Supreme Court has ruled on several patent cases in recent years; these cases often narrow the scope of patent protection
available to inventions in the biotechnology and pharmaceutical spaces. For example, in <I>Association for Molecular Pathology v. Myriad Genetics, Inc.</I> (&#147;<I>Myriad</I>&#148;), the Supreme Court ruled that a &#147;naturally occurring DNA
segment is a product of nature and not patent eligible merely because it has been isolated,&#148; and invalidated Myriad Genetics&#146; claims on the isolated BRCA1 and BRCA2 genes. Certain claims of our patent portfolio relate to genome editing
systems. While we believe that our proprietary genome editing systems involve significant human intervention, components of the system, such as the isolated nucleases with no modifications, are derived from naturally-occurring products. To the
extent that such claims are deemed to be directed to natural products, or to lack an inventive concept above and beyond an isolated natural product, a court may decide the claims are directed to patent-ineligible subject matter and are invalid. The
application of <I>Myriad</I> to biotechnology inventions has continued to develop and may continue to change over time. Subsequent rulings in cases or guidance or procedures issued by the USPTO relating to patent eligibility may have a negative
impact on our business. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In <I>Amgen Inc. v. Sanofi</I> (&#147;<I>Amgen</I>&#148;), the U.S. Supreme Court held that certain of Amgen&#146;s patent claims defined a
class of antibodies by their function of binding to a particular antigen. The U.S. Supreme Court further wrote that because the patent claims defined the claimed class of antibodies only by their function of binding to a particular antigen, a
skilled artisan would have to use significant trial and error to identify and make all of the molecules in that class. The U.S. Supreme Court ultimately held that Amgen failed to properly enable its patent
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
claims. Certain claims of our patent portfolio relate to broad classes of gene editors. To the extent that a court finds that the skilled artisan would need significant trial and error to
identify all the gene editors in that class, the court may find the claims invalid under <I>Amgen</I>. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the relevant <FONT STYLE="white-space:nowrap">law-making</FONT>
bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Further, a new court system recently became operational in the European Union. The Unified Patent Court (&#147;UPC&#148;) began accepting patent cases on June&nbsp;1,
2023. The UPC is a common patent court with jurisdiction over patent infringement and revocation proceedings effective for multiple member states of the European Union. The broad geographic reach of the UPC could enable third parties to seek
revocation of any of our European patents in a single proceeding at the UPC rather than through multiple proceedings in each of the individual European Union member states in which the European patent is validated. Under the UPC, a successful
revocation proceeding for a European Patent under the UPC would result in loss of patent protection in those European Union countries. Accordingly, a single proceeding under the UPC could result in the partial or complete loss of patent protection
in numerous European Union countries. Such a loss of patent protection could have a material adverse impact on our business and our ability to commercialize our technology and product candidates and, resultantly, on our business, financial
condition, prospects and results of operations. Moreover, the controlling laws and regulations of the UPC will develop over time and we cannot predict what the outcomes of cases tried before the UPC will be. The case law of the UPC may adversely
affect our ability to enforce or defend the validity of our European patents. Patent owners have the option to <FONT STYLE="white-space:nowrap">opt-out</FONT> their European Patents from the jurisdiction of the UPC, defaulting to <FONT
STYLE="white-space:nowrap">pre-UPC</FONT> enforcement mechanisms. We have decided to opt out certain European patents and patent applications from the UPC. However, if certain formalities and requirements are not met, our European patents and patent
applications could be subject to the jurisdiction of the UPC. We cannot be certain that our European patents and patent applications will avoid falling under the jurisdiction of the UPC, if we decide to opt out of the UPC. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may not be able to seek or obtain patent protection throughout the world or enforce such patent protection once obtained. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Filing, prosecuting, enforcing, and defending patents protecting our genome editing systems in all countries throughout the world would be prohibitively expensive, and
our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. The requirements for patentability may differ in certain countries, particularly in developing countries; thus, even
in countries where we do pursue patent protection, there can be no assurance that any patents will issue with claims that cover our products. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Moreover, our ability
to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in foreign intellectual property laws. Additionally, laws of some countries outside of the United States and Europe do not afford intellectual
property protection to the same extent as the laws of the United States and Europe. Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. This could make it
difficult for us to stop the infringement of our patents or the misappropriation of our other intellectual property rights. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third
parties. Consequently, we may not be able to prevent third parties from practicing our inventions in certain countries outside the United States and Europe or from selling or importing products made from our inventions in and into the United States
or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop and market their own products and, further, may export otherwise infringing products to territories where we have
patent protection, if our ability to enforce our patents to stop infringing activities is inadequate. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent
them from competing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Proceedings to enforce our patent rights, whether successful or not, could result in substantial costs and divert our
efforts and resources from other aspects of our business. Further, such proceedings could put our patents at risk of being invalidated, held unenforceable or interpreted narrowly; put our pending patent applications at risk of not issuing; and
provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Furthermore, while we intend to protect our intellectual
property rights in major markets for our products, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our products, if approved. Accordingly, our efforts to protect our
intellectual property rights in such countries may be inadequate. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>In order to protect our competitive position around our future product candidates, we may
become involved in lawsuits to enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful and which may result in our patents being found invalid or unenforceable. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Competitors may seek to commercialize competitive products to our genome editing systems. In order to protect our competitive position, we may become involved in
lawsuits asserting infringement of our patents, or misappropriation or other violations of other of our intellectual property rights. Litigation is expensive and time consuming and would likely divert the time and attention of our management and
scientific personnel. There can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded. Even if we ultimately prevail in such
claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we file a patent infringement lawsuit against a perceived infringer, such a lawsuit could provoke the defendant to counterclaim that we infringe their patents and/or
that our patents are invalid and/or unenforceable. In patent litigation in the United States, it is commonplace for a defendant to counterclaim alleging invalidity and/or unenforceability. In any patent litigation there is a risk that a court will
decide that the asserted patents are invalid or unenforceable, in whole or in part, and that we do not have the right to stop the defendant from using the invention at issue. With respect to a counterclaim of invalidity, we cannot be certain that
there is no invalidating prior art of which we and the patent examiner were unaware during prosecution. There is also a risk that, even if the validity of such patents is upheld, the court will construe the patent claims narrowly or decide that we
do not have the right to stop the other party from using the invention at issue on the grounds that our patent claims do not cover the invention. If any of our patents are found invalid or unenforceable, or construed narrowly, our ability to stop
the other party from launching a competitive product would be materially impaired. Further, such adverse outcomes could limit our ability to assert those patents against future competitors. Loss of patent protection would have a material adverse
impact on our business. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Even if we establish infringement of any of our patents by a competitive product, a court may decide not to grant an injunction against
further infringing activity, thus allowing the competitive product to continue to be marketed by the competitor. It is difficult to obtain an injunction in U.S. litigation and a court could decide that the competitor should instead pay us a
&#147;reasonable royalty&#148; as determined by the court, and/or other monetary damages. A reasonable royalty or other monetary damages may or may not be an adequate remedy. Loss of exclusivity and/or competition from a related product would have a
material adverse impact on our business. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Litigation often involves significant amounts of public disclosures. Such disclosures could have a materially adverse
impact on our competitive position or our stock prices. During any litigation we would be required to produce voluminous records related to our patents and our research and development activities in a process called discovery. The discovery process
may result in the disclosure of some of our confidential information. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these
results to be negative, it could adversely affect the price of our common shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Litigation is inherently expensive, and the outcome is often uncertain. Any litigation likely would substantially
increase our operating losses and reduce our resources available for development activities. Further, we may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able
to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. As a result, we may conclude that even if a competitor is infringing any of our patents, the
risk-adjusted cost of bringing and enforcing such a claim or action may be too high or not in the best interest of our company or our stockholders. In such cases, we may decide that the more prudent course of action is to simply monitor the
situation or initiate or seek some other <FONT STYLE="white-space:nowrap">non-litigious</FONT> action or solution. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If in the future, we <FONT
STYLE="white-space:nowrap">in-license</FONT> any patent rights, we may not have the right to file a lawsuit for infringement and may have to rely on a licensor to enforce these rights for us. If we are not able to directly assert our licensed patent
rights against infringers or if a licensor does not vigorously prosecute any infringement claims on our behalf, we may have difficulty competing in certain markets where such potential infringers conduct their business, and our commercialization
efforts may suffer as a result. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Concurrently with an infringement litigation, third parties may also be able to challenge the validity of our patents before
administrative bodies in the United States or abroad. Such mechanisms include <FONT STYLE="white-space:nowrap">re-examination,</FONT> post grant review and equivalent proceedings in foreign jurisdictions, e.g., opposition proceedings. Such
proceedings could result in revocation or amendment of our patents in such a way that they no longer cover our products, potentially negatively impacting any concurrent litigation. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If we are sued for infringing intellectual property rights of third parties, such litigation could be costly and time consuming and could prevent or delay us from
developing or commercializing our genome editing systems. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our commercial success depends, in part, on our ability to develop, manufacture, market and sell
our genome editing systems without infringing, misappropriating or otherwise violating the intellectual property and other proprietary rights of third parties. However, our research, development and commercialization activities may be subject to
claims that we infringe, misappropriate or otherwise violate patents or other intellectual property rights owned or controlled by third parties. Third parties may have U.S. and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> issued patents and
pending patent applications relating to compounds, methods of manufacturing compounds and/or methods of use for the treatment of the disease indications for which we are developing our genome editing systems. If any third-party patents or patent
applications are found to cover our genome editing systems, or their methods of use or manufacture, we may not be free to manufacture or market such genome editing systems as planned without obtaining a license, which may not be available on
commercially reasonable terms, or at all. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There is a substantial amount of intellectual property litigation in the biotechnology and pharmaceutical industries, and
we may become party to, or threatened with, litigation or other adversarial proceedings regarding intellectual property rights with respect to our genome editing systems, including patent infringement lawsuits in the U.S. or abroad. There may be
third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the composition, use or manufacture of our genome editing systems. Third parties may assert infringement
claims against us based on existing patents that they own or <FONT STYLE="white-space:nowrap">in-license</FONT> or patents that may grant to them (or which they may <FONT STYLE="white-space:nowrap">in-license)</FONT> in the future, regardless of the
merit of such patents or infringement claims. If our defenses to such assertions of infringement were unsuccessful, we could be liable for a court-determined reasonable royalty on our existing sales and further damages to the patent owner (or
licensee), such as lost profits. Such royalties and damages could be significant. If we are found to have willfully infringed the claims of a third party&#146;s patent, the third party could be awarded treble damages and attorney&#146;s fees.
Further, unless we obtain a license to such patent, we may be precluded from commercializing the infringing genome editing system. Any of the aforementioned could have a material adverse effect on our business, financial condition, results of
operations and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">While we perform periodic searches for relevant patents and patent applications with respect to our genome editing
systems, including Cas proteins and therapeutic applications, we cannot guarantee the completeness or thoroughness of any of our patent searches or analyses including, but not limited to, the identification of relevant patents, the scope of patent
claims or the expiration of relevant patents, nor can we be certain that we have identified each and every patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of any of our genome
editing systems in any jurisdiction. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that any of our genome editing systems may be accused of
infringing. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. Accordingly, third parties may assert infringement claims against us based on intellectual property rights
that exist now or arise in the future. The outcome of intellectual property litigation is subject to uncertainties that cannot be adequately quantified in advance. The pharmaceutical and biotechnology industries have produced a significant number of
patents, and it may not always be clear to industry participants, including us, which patents cover various types of products or methods of use or manufacture. The scope of protection afforded by a patent is subject to interpretation by the courts,
and the interpretation is not always uniform. If we were sued for patent infringement, we would need to demonstrate that the relevant product or methods of using the product either do not infringe the patent claims of the relevant patent or that the
patent claims are invalid or unenforceable, and we may not be able to do this. Proving invalidity is difficult. For example, in the United States, proving invalidity requires a showing of clear and convincing evidence to overcome the presumption of
validity enjoyed by issued patents. Even if we are successful in these proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel could be diverted in pursuing these proceedings, which could
significantly harm our business and operating results. In addition, parties making claims against us may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources, and we
may not have sufficient resources to bring these actions to a successful conclusion. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Numerous third-party U.S. and foreign issued patents and pending patent
applications exist in the fields in which we are developing genome editing systems. Our genome editing systems make use of CRISPR-based technology, which is a field that is highly active for patent filings and complex litigation. As of June 2019, it
was reported that approximately 2072 patent families worldwide related to CRISPR genome editing inventions and their uses. That number has continued to increase. The extensive patent filings related to CRISPR make it difficult for us to assess the
full extent of relevant patents and pending applications that may cover our genome editing systems and their use or manufacture. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture
or methods for treatment related to the use or manufacture of our genome editing systems. We are aware of multiple patents and patent applications directed to CRISPR technologies, Cas molecules, and their uses in genome editing. For example, we are
aware of patent portfolios related to CRISPR/Cas genome editing systems that are owned or <FONT STYLE="white-space:nowrap">co-owned</FONT> by Sigma Aldrich, Stanford University and Agilent Technologies, the Broad Institute and/or Harvard University
and/or the Massachusetts Institute of Technology (&#147;MIT&#148;), and Targetgene Biotechnologies. We are also aware of patent portfolios related to base editing systems that are owned or <FONT STYLE="white-space:nowrap">co-owned</FONT> by Beam
Therapeutics, the Broad Institute and/or Harvard University and/or MIT, the University of California, Duke University, Kobe University, the Max Planck Institute, Wageningen University, and Bioray Laboratories. We are also aware of patent portfolios
related to CRISPR associated transposase/retro-transposase (&#147;CAST&#148;) systems that are owned or <FONT STYLE="white-space:nowrap">co-owned</FONT> by the Broad Institute, Arbor Biotechnologies, and the University of Rochester. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Intellectual property litigation is common in the biotechnology space and multiple parties have engaged in litigation to protect and enforce their CRISPR/Cas related
patent estates. For example, patents and patent applications directed to catalytically-active Cas9 systems have been the subject of extensive adversarial patent </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">office proceedings. These proceedings include U.S. Patent and Trademark Office Patent Trial and Appeal Board </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
(&#147;PTAB&#148;) proceedings involving the Broad Institute and the University of California regarding the priority of inventions with respect to certain U.S. patents and patent applications
each owns directed to catalytically-active Cas9. Our genome editing technologies do not use catalytically-active Cas9 and we are not aware of any third-party patents or patent applications that we believe cover our
<FONT STYLE="white-space:nowrap">Cas-related</FONT> genome editing system and proprietary technology. However, we may not have identified all relevant third-party patents and patent applications. Therefore, there can be no assurance that third
parties will not assert patents against us in the future or that our patents and patent applications will not be challenged. Any litigation brought against us or our patents or patent applications, even if meritless, could have a material adverse
effect on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we are found to infringe, misappropriate or otherwise violate a third
party&#146;s intellectual property rights, we could be forced, including by court order, to cease developing, manufacturing or commercializing the infringing product. Alternatively, we may be required to obtain a license from such third party in
order to use the infringing technology and continue developing, manufacturing or marketing the infringing product. If we were required to obtain a license to continue to manufacture or market the affected product, we may be required to pay
substantial royalties or grant cross-licenses to our patents. Even if we were able to obtain a license, it could be nonexclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us. We cannot assure
you that any such license will be available on acceptable terms, if at all. Ultimately, we could be prevented from commercializing a product, or be forced to cease some aspect of our business operations as a result of claims of patent infringement
or violation of other intellectual property rights, Further, the outcome of intellectual property litigation is subject to uncertainties that cannot be adequately quantified in advance, including the demeanor and credibility of witnesses and the
identity of any adverse party. This is especially true in intellectual property cases that may turn on the testimony of experts as to technical facts upon which experts may reasonably disagree. Furthermore, we may not be able to obtain any required
license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors access to the same technologies licensed to us;
alternatively or additionally it could include terms that impede or destroy our ability to compete successfully in the commercial marketplace. In addition, we could be found liable for significant monetary damages, including treble damages and
attorneys&#146; fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing a product or force us to cease some of our business operations, which could harm our business. Claims that we
have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business. Furthermore, because of the substantial amount of discovery required in connection with intellectual property
litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have
material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operations, financial condition and prospects. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Others may challenge inventorship or claim an ownership interest in our intellectual property which could expose it to litigation and have a significant adverse
effect on its prospects. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Determinations of inventorship can be subjective. While we undertake to accurately identify correct inventorship of inventions made
on our behalf by our employees, consultants and contractors, an employee, consultant or contractor may disagree with our determination of inventorship and assert a claim of inventorship. Any disagreement over inventorship could result in our being
forced to defend our determination of inventorship in a legal action which could result in substantial costs and be a distraction to our senior management and scientific personnel. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">While we typically require employees, consultants and contractors who may develop intellectual property on our behalf to execute agreements assigning such intellectual
property to us, we may be unsuccessful in obtaining </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
execution of assignment agreements with each party who in fact develops intellectual property that we regard as our own. Moreover, even when we obtain agreements assigning intellectual property
to us, the assignment of intellectual property rights may not be self-executing or the assignment agreements may be breached. In either case, we may be forced to bring claims against third parties, or defend claims that they may bring against us, to
determine the ownership of what we regard as our intellectual property. Furthermore, individuals executing agreements with us may have preexisting or competing obligations to a third party, such as an academic institution, and thus an agreement with
us may be ineffective in perfecting ownership of inventions developed by that individual. If we are unsuccessful in obtaining assignment agreements from an employee, consultant or contractor who develops intellectual property on our behalf, the
employee, consultant or contractor may later claim ownership of the invention. Any disagreement over ownership of intellectual property could result in our losing ownership, or exclusive ownership, of the contested intellectual property, paying
monetary damages and/or being enjoined from clinical testing, manufacturing and marketing of the affected product candidate(s). Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs
and be a distraction to our senior management and scientific personnel. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may be subject to claims by third parties asserting that our employees or we have
misappropriated their intellectual property or claiming ownership of what we regard as our own intellectual property. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Many of our current and former
employees and our licensors&#146; current and former employees, including our senior management, were previously employed at universities or at other biotechnology or pharmaceutical companies, including some which may be competitors or potential
competitors. Although we take commercially reasonable steps to ensure that our employees do not use the proprietary information, <FONT STYLE="white-space:nowrap">know-how</FONT> or trade secrets of others in their work for us, including
incorporating such intellectual property into our genome editing systems, we may be subject to claims that we or these employees have misappropriated the intellectual property of a third party. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we or any of our employees are accused of misappropriating the proprietary information, <FONT STYLE="white-space:nowrap">know-how</FONT> or trade secrets of a third
party, we may be forced to defend such claims in litigation. If we are found to have misappropriated the intellectual property rights of a third party, we may be forced to pay monetary damages, sustain reputational damage, lose key personnel, or
lose valuable intellectual property rights. Further, it may become necessary for us to obtain a license from such third party to commercialize any of our genome editing systems. Such a license may not be available on commercially reasonable terms or
at all. Any of the aforementioned could materially affect the commercialization of any of our genome editing systems. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to
management. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We consider proprietary trade secrets or confidential <FONT STYLE="white-space:nowrap">know-how</FONT> and unpatented <FONT STYLE="white-space:nowrap">know-how</FONT> to
be important to our business. We may rely on trade secrets or confidential <FONT STYLE="white-space:nowrap">know-how</FONT> to protect our technology, especially where patent protection is believed by us to be of limited value. We expect to rely on
third parties for future manufacturing of our genome editing systems, and any future genome editing systems. We also expect to collaborate with third parties on the development of our genome editing systems and any future genome editing systems. As
a result of the aforementioned collaborations, we must, at times, share trade secrets with our collaborators. We also conduct joint research and development programs that may require us to share trade secrets under the terms of our research and
development partnerships or similar agreements. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Trade secrets or confidential <FONT STYLE="white-space:nowrap">know-how</FONT> can be difficult to maintain as
confidential. To protect this type of information against disclosure or appropriation by competitors, our policy is to require our employees, consultants, contractors </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
and advisors to enter into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with us prior to beginning research or
disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. However, current or former employees, consultants, contractors and
advisers may unintentionally or willfully disclose our confidential information to competitors, and confidentiality agreements may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. The need to share
trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements.
Given that our proprietary position is based, in part, on our <FONT STYLE="white-space:nowrap">know-how</FONT> and trade secrets, a competitor&#146;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive
position and may have an adverse effect on our business and results of operations. Enforcing a claim that a third party obtained illegally and is using trade secrets or confidential <FONT STYLE="white-space:nowrap">know-how</FONT> is expensive, time
consuming and unpredictable. The enforceability of confidentiality agreements may vary from jurisdiction to jurisdiction. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, these agreements typically
restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our trade secrets, although our agreements may contain certain limited publication rights. Despite our efforts to
protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties, independent development or publication of information by any of our third-party collaborators. A competitor&#146;s
discovery of our trade secrets would impair our competitive position and have an adverse impact on our business. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may need to acquire or license additional
intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A third party may
hold intellectual property, including patent rights that are important or necessary to the development of our genome editing systems. It may be necessary for us to use the patented or proprietary technology of one or more third parties to
commercialize our current and future product candidates. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The licensing and acquisition of third-party intellectual property rights is a competitive area, and a
number of more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash
resources and greater clinical development. If we are unable to acquire such intellectual property outright, or obtain licenses to such intellectual property from such third parties when needed or on commercially reasonable terms, our ability to
commercialize our genome editing systems, if approved, would likely be delayed or we may have to abandon development of that product genome editing systems or program and our business and financial condition could suffer. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we <FONT STYLE="white-space:nowrap">in-license</FONT> additional genome editing systems in the future, we might become dependent on proprietary rights from third
parties with respect to those genome editing systems. Any termination of such licenses could result in the loss of significant rights and would cause material adverse harm to our ability to develop and commercialize any genome editing systems
subject to such licenses. Even if we are able to <FONT STYLE="white-space:nowrap">in-license</FONT> any such necessary intellectual property, it could be on nonexclusive terms, including with respect to the use, field or territory of the licensed
intellectual property, thereby giving our competitors and other third parties access to the same intellectual property licensed to us. <FONT STYLE="white-space:nowrap">In-licensing</FONT> IP rights could require us to make substantial licensing and
royalty payments. Patents licensed to us could be put at risk of being invalidated or interpreted narrowly in litigation filed by or against our licensors or another licensee or in administrative proceedings. If any
<FONT STYLE="white-space:nowrap">in-licensed</FONT> patents are invalidated or held unenforceable, we may not be able to prevent competitors or other third parties from developing and commercializing competitive products. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may not have the right to control the prosecution, maintenance, enforcement or defense of patents and patent applications that we license from third parties. In such
cases, we would be reliant on the licensor to take </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
any necessary actions. We cannot be certain that such licensor would act with our best interests in mind, or in compliance with applicable laws and regulations, or that their actions would result
in valid and enforceable patents. For example, it is possible that a licensor&#146;s actions in enforcing and/or defending a patent licensed by use may be less vigorous than had we conducted them ourselves. Any of the foregoing could have a material
adverse effect on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Disputes may also arise between us and our licensors regarding
intellectual property subject to a license agreement, including: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the scope of rights granted under the license agreement and other interpretation-related issues; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our financial or other obligations under the license agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">whether and the extent to which our technology and processes infringe intellectual property of the licensor that is not
subject to the licensing agreement; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our right to sublicense patent and other rights to third parties under collaborative development relationships;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our diligence obligations with respect to the use of licensed technology in relation to our development and
commercialization of our genome editing systems and what activities satisfy those diligence obligations; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from the joint creation or use
of intellectual property by our licensors and us and our partners; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the priority of invention of patented technology. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be
unable to successfully develop and commercialize the affected genome editing systems. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The risks described elsewhere pertaining to our intellectual property rights
also apply to the intellectual property rights that we may own or <FONT STYLE="white-space:nowrap">in-license</FONT> now or in the future, and any failure by us or our licensors to obtain, maintain, defend and enforce these rights could have an
adverse effect on our business. In some cases we may not have control over the prosecution, maintenance or enforcement of the patents that we license, and may not have sufficient ability to provide input into the patent prosecution, maintenance and
defense process with respect to such patents, and potential future licensors may fail to take the steps that we believe are necessary or desirable in order to obtain, maintain, defend and enforce the licensed patents. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our trademarks of interest and our business
may be adversely affected. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on
other marks. We rely on both registration and common law protection for our trademarks. As a means to enforce our trademark rights and prevent infringement, we may be required to file trademark claims against third parties or initiate trademark
opposition proceedings. This can be expensive and time-consuming, particularly for a company of our size. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name
recognition by potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In
addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be
adversely affected. During trademark registration proceedings, we may receive rejections. Although we would be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in
comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our
trademarks, and our trademarks may not survive such proceedings. Moreover, any name we propose to use for our products in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a
trademark. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA objects to any of our proposed product names, we may be required to expend significant
additional resources in an effort to identify a usable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. If we are unable to establish name recognition
based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Intellectual property rights do
not necessarily address all potential threats to our business. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The degree of future protection afforded by our intellectual property rights is uncertain
because intellectual property rights have limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">others may be able to make products that are competitive to our genome editing systems or any of our future genome editing
systems but that are not covered by the claims of our patent portfolio; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">others may independently develop similar or alternative technologies or otherwise circumvent any of our technologies
without infringing our patent portfolio; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we or any of our collaborators might not have been the first to invent the inventions covered by our patent portfolio;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we or any of our collaborators might not have been the first to file patent applications covering certain of the patents or
patent applications that we or they own or have obtained a license, or will own or will have obtained a license; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">it is possible that our pending patent applications or those that we may file in the future will not lead to issued
patents; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">others may have access to the same intellectual property rights licensed to us on a
<FONT STYLE="white-space:nowrap">non-exclusive</FONT> basis in the future; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">issued patents that we own may not provide us with any competitive advantage, or may be held invalid or unenforceable,
including as a result of legal challenges by our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our competitors might conduct research and development activities in countries where we do not have patent rights, or in
countries where research and development safe harbor laws exist, and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">ownership of our patent portfolio may be challenged by third parties; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the patents of third parties or pending or future applications of third parties, if issued, may have an adverse effect on
our business; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">patent enforcement is expensive and time-consuming and difficult to predict; thus, we may not be able to enforce any of our
patents against a competitor; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we may choose not to file a patent application for certain inventions, instead choosing to rely on trade secret protection,
and a third party may subsequently file a patent covering such intellectual property. </P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Risks Related to the Offering, our Common Stock, and
Operating as a Public Company </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>You will incur immediate and substantial dilution as a result of this offering. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If you purchase common stock in this offering, you will incur immediate and substantial dilution of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share,
representing the difference between the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the estimated midpoint of the price range set forth on the cover page of this prospectus, and our pro forma
as adjusted net tangible book value per share as of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2023 after giving effect to this offering. To the extent the underwriters exercise their option to
purchase additional shares or our restricted common stock issued in the Reorganization vests, you will incur further dilution. For a further description of the dilution you will experience immediately after this offering, see &#147;Dilution.&#148;
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>The market price of our common stock may be volatile, which could result in substantial losses for investors purchasing shares in this offering. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The initial public offering price for our common stock was determined through negotiations with the underwriters. This initial public offering price may vary from the
market price of our common stock after the offering. As a result, you may not be able to sell your common stock at or above the initial public offering price. The market price for our common stock may be influenced by those factors discussed in this
&#147;Risk Factors&#148; section and many others, some of which may include: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the success of existing or new competitive product candidates or technologies; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the timing and results of preclinical studies and clinical trials for any product candidates we may develop;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">failure or discontinuation of any of our development and research programs; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">results of any preclinical studies, clinical trials or regulatory approvals of product candidates of our competitors, or
announcements about new research programs or product candidates of our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">developments or changing views regarding the use of genetic therapies, including those that involve genome editing;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">commencement or termination of collaborations for our product development and research programs; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">regulatory or legal developments in the United States and other countries; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">developments or disputes concerning patent applications, issued patents or other intellectual property or proprietary
rights; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the recruitment or departure of key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the level of expenses related to any of our research programs, clinical development programs or product candidates that we
may develop; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the results of our efforts to develop product candidates; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities
analysts, if any, that cover our stock; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">announcement or expectation of additional financing efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">sales of our common stock by us, our insiders or other stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">expiration of market <FONT STYLE="white-space:nowrap">stand-off</FONT> or <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreements; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">variations in our financial results or those of companies that are perceived to be similar to us; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">changes in the structure of healthcare payment systems; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">market conditions in the pharmaceutical and biotechnology sectors; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">general economic, industry and market conditions, including <FONT STYLE="white-space:nowrap">COVID-19,</FONT> the conflict
between Russia and Ukraine, rising interest rates and inflation; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the other factors described in this &#147;Risk Factors&#148; section. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In recent years, the stock market in general and the market for pharmaceutical and biotechnology companies in particular, has experienced extreme price and volume
fluctuations that have often been unrelated or disproportionate to changes in the operating performance of the companies whose stock is experiencing those price and volume fluctuations. In particular, in relation to uncertainty around inflation and
the U.S. Federal Reserve&#146;s measures to slow inflation, the stock market has been exceptionally volatile. Market and industry factors may seriously affect the market price of our common stock, regardless of our actual operating performance.
These fluctuations may be even more pronounced in the trading market for our stock shortly following this offering. Following periods of such volatility in the market price of a company&#146;s securities, securities class action litigation has often
been brought against that company. Because of the potential volatility of our stock price, we may become the target of securities litigation in the future. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Securities litigation could result in substantial costs and divert management&#146;s attention and resources from our business. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We have wide discretion in the use of the net proceeds from this offering and may not use them effectively. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We cannot specify with certainty the particular uses of the net proceeds we will receive from this offering. Our management will have wide discretion in the application
of the net proceeds, including for any of the purposes described in &#147;Use of Proceeds.&#148; Accordingly, you will have to rely upon the judgment of our management with respect to the use of the proceeds, with only limited information concerning
management&#146;s specific intentions. Our management may spend a portion or all of the net proceeds from this offering in ways that our stockholders may not desire or that may not yield a favorable return. The failure by our management to apply
these funds effectively could harm our business, financial condition, results of operations and prospects. Pending their use, we may invest the net proceeds from this offering in a manner that does not produce income or that loses value. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We will incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance
initiatives and corporate governance practices. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As a public company, and particularly after we are no longer an &#147;emerging growth company,&#148; we will
incur significant legal, accounting and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act of 2002 (&#147;SOX&#148;), the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of the
Nasdaq Global Select Market and other applicable securities rules and regulations impose </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. We expect that we will need to
hire additional accounting, finance and other personnel in connection with our becoming, and our efforts to comply with the requirements of being, a public company. Our management and other personnel will need to devote a substantial amount of time
towards maintaining compliance with these requirements. These requirements will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, we expect that the rules and regulations
applicable to us as a public company may make it more difficult and more expensive for us to obtain director and officer liability insurance, which could make it more difficult for us to attract and retain qualified members of our board of
directors. We are currently evaluating these rules and regulations and cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. These rules and regulations are often subject to varying interpretations, in
many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance
matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pursuant to SOX Section&nbsp;404, we will be required to furnish
a report by our management on our internal control over financial reporting beginning with our second filing of an Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> with the SEC after we become a public company. However, while we
remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with SOX Section&nbsp;404
within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources,
potentially engage outside consultants, adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls
are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or
at all, that our internal control over financial reporting is effective as required by SOX Section&nbsp;404. This could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial
statements. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We do not know whether a market will develop for our common stock or what the market price of our common stock will be, and, as a result, it may
be difficult for you to sell your shares of our common stock. </I></B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Before this offering, there was no public trading market for our common stock. Although we
have applied to list our common stock on the Nasdaq Global Select Market, an active trading market for our shares may never develop or be sustained following this offering. If a market for our common stock does not develop or is not sustained, it
may be difficult for you to sell your shares of common stock at an attractive price or at all. We cannot predict the prices at which our common stock will trade. It is possible that in one or more future periods our results of operations may be
below the expectations of public market analysts and investors, and, as a result of these and other factors, the price of our common stock may fall. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If
securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The trading market for our common stock will rely in part on the research and reports that industry or financial analysts publish about us or our business. We do not
currently have and may never obtain research coverage by industry or financial analysts. If no or few analysts commence coverage of us, the trading price of our stock would likely decrease. Even if we do obtain analyst coverage, if one or more of
the analysts covering our business downgrade their evaluations of our stock, the price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could
cause our stock price to decline. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Future sales of our common stock in the public market could cause our stock price to fall. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our stock price could decline as a result of sales of a large number of shares of our common stock after this offering or the perception that these sales could occur.
These sales, or the possibility that these sales may occur, also might make it more difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon completion of this offering,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock will be
outstanding (or&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock will be outstanding assuming exercise in full of the underwriters&#146; option to purchase additional shares),
based on our shares outstanding as of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023. All shares of common stock expected to be sold in this offering will be freely tradable without restriction
or further registration under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), unless held by our &#147;affiliates,&#148; as that term is defined in Rule 144 under the Securities Act. The resale of the
remaining&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, or approximately&nbsp;&nbsp;&nbsp;&nbsp;% of our outstanding shares after this offering, is currently prohibited or otherwise restricted as a
result of securities law provisions, market standoff agreements entered into by our stockholders with us or <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements entered into by our stockholders with the underwriters. However, subject to
applicable securities law restrictions and excluding shares of restricted common stock that will remain unvested, these shares will be able to be sold in the public market beginning 180 days after the date of this prospectus. Shares of unvested
restricted common stock that were issued and outstanding as of the date of this prospectus will become available for sale immediately upon the vesting of such shares, as applicable, and the expiration of any applicable market <FONT
STYLE="white-space:nowrap">stand-off</FONT> or <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements. Shares issued upon the exercise of stock options pursuant to future awards that may be granted under our equity incentive plans or pursuant to
future awards granted under those plans will become available for sale in the public market to the extent permitted by the provisions of applicable vesting schedules, any applicable market <FONT STYLE="white-space:nowrap">stand-off</FONT> and <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements and Rule 144 and Rule 701 under the Securities Act. For more information see the section entitled &#147;Shares Eligible for Future Sale&#148; included elsewhere in this prospectus. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon completion of this offering, the holders of approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares, or
approximately&nbsp;&nbsp;&nbsp;&nbsp;%, of our common stock, will have rights, subject to some conditions, to require us to file registration statements covering the sale of their shares or to include their shares in registration statements that we
may file for ourselves or other stockholders. We also intend to register the offer and sale of all shares of common stock that we may issue under our equity compensation plans. Once we register the offer and sale of shares for the holders of
registration rights and shares to be issued under our equity incentive plans, they can be freely sold in the public market upon issuance, subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described in the section entitled
&#147;Underwriting&#148; included elsewhere in this prospectus. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, in the future, we may issue additional shares of common stock or other equity or debt
securities convertible into common stock in connection with a financing, acquisition, litigation settlement, employee arrangements or otherwise. Any such issuance could result in substantial dilution to our existing stockholders and could cause our
stock price to decline. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We are an &#147;emerging growth company&#148; and the reduced disclosure requirements applicable to emerging growth companies may make
our common stock less attractive to investors. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are an &#147;emerging growth company,&#148; as defined in the Jumpstart Our Business Startups Act of 2012
(the &#147;JOBS Act&#148;), and may remain an emerging growth company for up to five years. For so long as we remain an emerging growth company, we are permitted and plan to rely on exemptions from certain disclosure requirements that are applicable
to other public companies that are not emerging growth companies. These exemptions include not being required to comply with the auditor attestation requirements of SOX Section&nbsp;404, not being required to comply with any requirement for a
supplement to the auditor&#146;s report providing additional information about the audit and the financial statements, reduced disclosure obligations regarding executive compensation and exemptions from the requirements of holding a nonbinding
advisory vote on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
executive compensation and stockholder approval of any golden parachute payments not previously approved. As a result, the information we provide stockholders will be different than the
information that is available with respect to other public companies. In this prospectus, we have not included all of the executive compensation related information that would be required if we were not an emerging growth company. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting
standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this exemption, and, therefore, while we
are an emerging growth company we will not be subject to the new or revised accounting standards at the same time that they become applicable to other public companies that are not emerging growth companies. As a result of this election, our
financial statements may not be comparable to those of other public companies that comply with new or revised accounting pronouncements as of public company effective dates. We may choose to early adopt any new or revised accounting standards
whenever such early adoption is permitted for private companies. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We cannot predict whether investors will find our common stock less attractive if we rely on these
exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Insiders will continue to have substantial influence over us after this offering, which could limit your ability to affect the outcome of key transactions,
including a change of control. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">After this offering, our directors and executive officers and their affiliates will beneficially own shares representing
approximately&nbsp;&nbsp;&nbsp;&nbsp;% percent of our outstanding common stock. As a result, these stockholders, if they act together, will be able to influence our management and affairs and all matters requiring stockholder approval. For example,
these stockholders may be able to control elections of directors, amendments of our organizational documents or approval of any merger, sale of assets or other major corporate transaction. This concentration of ownership may have the effect of
delaying or preventing a change in control of our company and might affect the market price of our common stock. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We do not expect to pay any dividends for the
foreseeable future. Investors in this offering may never obtain a return on their investment. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">You should not rely on an investment in our common stock to
provide dividend income. We do not anticipate that we will pay any dividends to holders of our common stock in the foreseeable future. Instead, we plan to retain any earnings to maintain and expand our existing operations. In addition, any future
credit facility may contain terms prohibiting or limiting the amount of dividends that may be declared or paid on our common stock. Accordingly, investors must rely on sales of their common stock after price appreciation, which may never occur, as
the only way to realize any return on their investment. As a result, investors seeking cash dividends should not purchase our common stock. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If we fail to
establish and maintain proper and effective internal control over financial reporting, our operating results and our ability to operate our business could be harmed. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Ensuring that we have adequate internal financial and accounting controls and procedures in place so that we can produce accurate financial statements on a timely basis
is a costly and time-consuming effort that needs to be <FONT STYLE="white-space:nowrap">re-evaluated</FONT> frequently. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements in accordance with generally accepted accounting principles. In connection with this offering, we intend to </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">begin the process of documenting, reviewing and improving our internal controls and procedures for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
compliance with SOX Section&nbsp;404, which will require annual management assessment of the effectiveness of our internal control over financial reporting starting with our second filing of an
Annual Report on Form 10-K. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Implementing any appropriate changes to our internal controls may distract our officers and employees, entail substantial costs to
modify our existing processes and take significant time to complete. These changes may not, however, be effective in maintaining the adequacy of our internal controls, and any failure to maintain that adequacy or consequent inability to produce
accurate financial statements on a timely basis could increase our operating costs and harm our business. In addition, investors&#146; perceptions that our internal controls are inadequate or that we are unable to produce accurate financial
statements on a timely basis cause investors to lose confidence in the accuracy and completeness of our financial reports and could cause the market price of our common stock to decline significantly. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon the closing of this offering, we will become subject to the periodic reporting requirements of the Exchange Act. We designed our disclosure controls and procedures
to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules
and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control
system are met. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">These inherent limitations include the facts that judgments in decision-making can be faulty and that breakdowns can occur because of simple error
or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system,
misstatements due to error or fraud may occur and not be detected. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our amended and restated bylaws that will become effective upon the effectiveness of our
registration statement designate specific courts as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit stockholders&#146; ability to obtain a favorable judicial forum for disputes with us.
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pursuant to our amended and restated bylaws that will become effective upon the effectiveness of our registration statement, unless we consent in writing to
the selection of an alternative forum, the Court of Chancery of the State of Delaware is the sole and exclusive forum for any state law claims for (i)&nbsp;any derivative action or proceeding brought on our behalf; (ii)&nbsp;any action asserting a
claim of or based on a breach of a fiduciary duty owed by any director, officer or other employee of ours to us or our stockholders; (iii)&nbsp;any action asserting a claim pursuant to any provision of the DGCL, our amended and restated certificate
of incorporation or our amended and restated bylaws or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware; or (iv)&nbsp;any action asserting a claim governed by the internal affairs doctrine (the
&#147;Delaware Forum Provision&#148;). The Delaware Forum Provision will not apply to any causes of action arising under the Securities Act or the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;). Our amended and restated
bylaws further provide that unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall be the sole and exclusive forum for resolving any complaint asserting a cause of action arising
under the Securities Act, the Exchange Act, the respective rules and regulations promulgated thereunder or the Federal Forum Provision. In addition, our amended and restated bylaws provide that any person or entity purchasing or otherwise acquiring
any interest in shares of our capital stock is deemed to have notice of and consented to the Delaware Forum Provision and the Federal Forum Provision; provided, however, that stockholders cannot and will not be deemed to have waived our compliance
with the federal securities laws and the rules and regulations thereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We recognize that the Delaware Forum Provision and the Federal Forum Provision in our amended and restated bylaws may
impose additional litigation costs on stockholders in pursuing any such claims, particularly if the stockholders do not reside in or near the State of Delaware. Additionally, the forum selection clauses in our amended and restated bylaws may limit
our stockholders&#146; ability to bring a claim in a judicial forum that they find favorable for disputes with us or our directors, officers or employees, which may discourage the filing of lawsuits against us and our directors, officers and
employees, even though an action, if successful, might benefit our stockholders. In addition, while the Delaware Supreme Court ruled in March 2020 that federal forum selection provisions purporting to require claims under the Securities Act be
brought in federal court are &#147;facially valid&#148; under Delaware law, there is uncertainty as to whether other courts will enforce our Federal Forum Provision. If the Federal Forum Provision is found to be unenforceable, we may incur
additional costs associated with resolving such matters. The Federal Forum Provision may also impose additional litigation costs on stockholders who assert that the provision is not enforceable or invalid. The Court of Chancery of the State of
Delaware and the federal district courts of the United States may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the
action, and such judgments may be more or less favorable to us than our stockholders. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Provisions in our amended and restated certificate of incorporation and
amended and restated bylaws that will become effective upon the effectiveness of our registration statement and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be
beneficial to our stockholders, and may prevent attempts by our stockholders to replace or remove our current management. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our amended and restated
certificate of incorporation and amended and restated bylaws that will become effective upon the effectiveness of our registration statement and Delaware law contain provisions that may have the effect of discouraging, delaying or preventing a
change in control of us or changes in our management that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. Our amended and restated certificate of incorporation, which will
become effective immediately prior to the closing of this offering, and amended and restated bylaws, which will become effective upon the effectiveness of the registration statement of which this prospectus is a part, include provisions that: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">authorize &#147;blank check&#148; preferred stock, which could be issued by our board of directors without stockholder
approval and may contain voting, liquidation, dividend and other rights superior to our common stock; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">create a classified board of directors whose members serve staggered three-year terms; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">specify that special meetings of our stockholders can be called only by our board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">prohibit stockholder action by written consent; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of our stockholders,
including proposed nominations of persons for election to our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though
less than a quorum; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">provide that our directors may be removed only for cause; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">specify that no stockholder is permitted to cumulate votes at any election of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">expressly authorized our board of directors to make, alter, amend or repeal our amended and restated bylaws; and
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">require supermajority votes of the holders of our common stock to amend specified provisions of our amended and restated
certificate of incorporation and amended and restated bylaws. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">These provisions, alone or together, could delay or prevent hostile takeovers and
changes in control or changes in our management. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, because we are incorporated in the State of Delaware, we are governed by the provisions of Section&nbsp;203 of the DGCL, which prohibits a person who owns
in excess of 15&nbsp;percent of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15&nbsp;percent of our outstanding voting stock,
unless the merger or combination is approved in a prescribed manner. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any provision of our amended and restated certificate of incorporation, amended and restated
bylaws or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock and could also affect the price that some investors
are willing to pay for our common stock. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Adverse developments affecting the financial services industry could adversely affect our current and projected
business operations and our financial condition and results of operations. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Adverse developments that affect financial institutions, such as events involving
liquidity that are rumored or actual, have in the past and may in the future lead to bank failures and market-wide liquidity problems. For example, on March&nbsp;10, 2023, Silicon Valley Bank (&#147;SVB&#148;) was closed by the California Department
of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation (&#147;FDIC&#148;) as receiver. Similarly, on March&nbsp;12, 2023, Signature Bank was also swept into receivership. The U.S. Department of Treasury,
the Federal Reserve Board (the &#147;Federal Reserve&#148;), and the FDIC released a statement that indicated that all depositors of SVB would have access to all of their funds, including funds held in uninsured deposit accounts, after only one
business day of closure. The U.S. Department of Treasury, FDIC and Federal Reserve have announced a program to provide up to $25&nbsp;billion of loans to financial institutions secured by certain of such government securities held by financial
institutions to mitigate the risk of potential losses on the sale of such instruments, widespread demands for customer withdrawals or other liquidity needs of financial institutions for immediately liquidity may exceed the capacity of such program.
There is no guarantee, however, that the U.S. Department of Treasury, FDIC and Federal Reserve will provide access to uninsured funds in the future in the event of the closure of other banks or financial institutions, or that they would do so in a
timely fashion. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">At this time, we hold substantially all of our cash on deposit at SVB (which has been assumed by First Citizens) and we have not experienced any
adverse impact to our current and projected business operations, financial condition or results of operations as a result of the closure of SVB or any other banks. We plan to diversify our cash deposit holdings between multiple financial
institutions. However, uncertainty remains over liquidity concerns in the broader financial services industry, and our business, our business partners, or industry as a whole may be adversely impacted in ways that we cannot predict at this time. If,
for example, other banks and financial institutions enter receivership or become insolvent in the future in response to financial conditions affecting the banking system and financial markets, our ability to access our existing cash, cash
equivalents and available-for-sale marketable securities may be threatened. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Although we expect to assess our banking relationships as we believe necessary or
appropriate, our access to cash in amounts adequate to finance or capitalize our current and projected future business operations could be significantly impaired by factors that affect the financial institutions with which we have banking
relationships, and in turn, us. These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under various types of financial, credit or liquidity agreements or arrangements,
disruptions or instability in the financial services industry or financial markets, or concerns or negative expectations about the prospects for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
companies in the financial services industry. These factors could also include factors involving financial markets or the financial services industry generally. The results of events or concerns
that involve one or more of these factors could include a variety of material and adverse impacts on our current and projected business operations and our financial condition and results of operations. These could include, but may not be limited to,
delayed access to deposits or other financial assets or the uninsured loss of deposits or other financial assets; or termination of cash management arrangements and/or delays in accessing or actual loss of funds subject to cash management
arrangements. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, widespread investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing
terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for us to acquire financing on acceptable terms or at
all. Any decline in available funding or access to our cash and liquidity resources could, among other risks, adversely impact our ability to meet our operating expenses, financial obligations or fulfill our other obligations, result in breaches of
our financial and/or contractual obligations or result in violations of federal or state wage and hour laws. Any of these impacts, or any other impacts resulting from the factors described above or other related or similar factors not described
above, could have material adverse impacts on our liquidity and our current and/or projected business operations and financial condition and results of operations. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, one or more of our critical vendors, third party manufacturers, or other business partners could be adversely affected by any of the liquidity or other
risks that are described above, which in turn, could have a material adverse effect on our current and/or projected business operations and results of operations and financial condition. Any business partner bankruptcy or insolvency, or any breach
or default by a business partner, or the loss of any significant supplier relationships, could result in material adverse impacts on our current and/or projected business operations and financial condition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc425213_5"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This prospectus, including the sections entitled &#147;Prospectus Summary,&#148; &#147;Risk Factors,&#148; &#147;Management&#146;s Discussion and Analysis of Financial
Condition and Results of Operations,&#148; and &#147;Business,&#148; contains express or implied forward-looking statements that are based on our management&#146;s belief and assumptions and on information currently available to our management.
Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties
and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements in
this prospectus include, but are not limited to, statements about: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the initiation, timing, progress and results of our research and development programs, preclinical studies and future
clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to demonstrate, and the timing of, preclinical
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> <I>in vivo</I> and <I>ex vivo </I>for multiple programs; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to advance any product candidates that we may identify and successfully complete any clinical studies,
including the manufacture of any such product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to quickly leverage programs within our initial target indications and to progress additional programs to
further develop our pipeline; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the timing of our IND applications submissions; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the implementation of our strategic plans for our business, programs and technology; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the scope of protection we are able to establish and maintain for intellectual property rights covering our genome editing
technology and platform; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">developments related to our competitors and our industry; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to leverage the clinical, regulatory, and manufacturing advancements made by genome editing programs to
accelerate our clinical trials and approval of product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to identify and enter into future license agreements and collaborations; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">developments related to our genome editing technology and platform; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">regulatory developments in the United States and foreign countries; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to attract and retain key scientific and management personnel; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our use of proceeds from this offering, estimates of our expenses, capital requirements, and needs for additional
financing. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In some cases, you can identify forward-looking statements by terminology such as &#147;may,&#148; &#147;should,&#148;
&#147;expects,&#148; &#147;intends,&#148; &#147;plans,&#148; &#147;anticipates,&#148; &#147;believes,&#148; &#147;estimates,&#148; &#147;predicts,&#148; &#147;potential,&#148; &#147;continue&#148; or the negative of these terms or other comparable
terminology. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, which are, in some cases, beyond our control and
which could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the section entitled &#147;Risk Factors&#148; and elsewhere in this
prospectus. If one or more of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking
statements. No forward-looking statement is a guarantee of future performance. You should read this prospectus and the documents that we reference in this prospectus and have filed with the SEC as exhibits to the registration statement, of which
this prospectus forms a part, completely and with the understanding that our actual future results may be materially different from any future results expressed or implied by these forward-looking statements. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The forward-looking statements in this prospectus represent our views as of the date of this prospectus. We anticipate that subsequent events and developments will cause
our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should therefore not rely on these
forward-looking statements as representing our views as of any date subsequent to the date of this prospectus. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This prospectus also contains estimates, projections
and other information concerning our industry, our business and the markets for our product candidates. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties
and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. Unless otherwise expressly stated, we obtained this industry, business, market, and other data from our own internal
estimates and research as well as from reports, research surveys, studies, and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources. While we are not
aware of any misstatements regarding any third-party information presented in this prospectus, their estimates, in particular, as they relate to projections, involve numerous assumptions, are subject to risks and uncertainties and are subject to
change based on various factors, including those discussed under the section entitled &#147;Risk Factors&#148; and elsewhere in this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc425213_6"></A>REORGANIZATION </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We intend to engage in a series of transactions pursuant to which Metagenomi Technologies, LLC, the sole stockholder and holding company parent of Metagenomi, Inc., will
merge with and into Metagenomi, Inc., and Metagenomi, Inc. will continue to exist as the surviving corporation. Throughout this prospectus, we refer to these transactions and the related transactions enumerated below collectively as the
&#147;Reorganization.&#148; To consummate the Reorganization, we will file a certificate of merger and amended and restated certificate of incorporation with the Secretary of State of the State of Delaware. In connection with the Reorganization:
</P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">holders of Metagenomi Technologies, LLC&#146;s outstanding Series <FONT STYLE="white-space:nowrap">A-1</FONT> redeemable
convertible preferred units (&#147;Series&nbsp;A-1 preferred units&#148;) will receive&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;share of <FONT STYLE="white-space:nowrap">Series&nbsp;A-1</FONT>
redeemable convertible preferred stock (&#147;Series&nbsp;A-1 preferred stock&#148;) of Metagenomi, Inc. for each Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred unit held immediately prior to the Reorganization, with an aggregate
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our Series <FONT STYLE="white-space:nowrap">A-1</FONT> redeemable convertible preferred stock issued in the Reorganization;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">holders of Metagenomi Technologies, LLC&#146;s outstanding Series <FONT STYLE="white-space:nowrap">A-2</FONT> redeemable
convertible preferred units (&#147;Series&nbsp;A-2 preferred units&#148;) will receive&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;share of Series <FONT STYLE="white-space:nowrap">A-2</FONT>
redeemable convertible preferred stock <FONT STYLE="white-space:nowrap">(&#147;Series&nbsp;A-2</FONT> preferred stock&#148;) of Metagenomi, Inc.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;for each
Series <FONT STYLE="white-space:nowrap">A-2</FONT> preferred unit held immediately prior to the Reorganization, with an aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our Series <FONT
STYLE="white-space:nowrap">A-2</FONT> redeemable convertible preferred stock issued in the Reorganization; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">holders of Metagenomi Technologies, LLC&#146;s outstanding Series <FONT STYLE="white-space:nowrap">A-3</FONT> redeemable
convertible preferred units (&#147;Series&nbsp;A-3 preferred units&#148;) will receive&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;share of Series <FONT STYLE="white-space:nowrap">A-3</FONT>
redeemable convertible preferred stock <FONT STYLE="white-space:nowrap">(&#147;Series&nbsp;A-3</FONT> preferred stock&#148;) of Metagenomi, Inc.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;for each
Series <FONT STYLE="white-space:nowrap">A-3</FONT> preferred unit held immediately prior to the Reorganization, with an aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our Series <FONT
STYLE="white-space:nowrap">A-3</FONT> redeemable convertible preferred stock issued in the Reorganization; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">holders of Metagenomi Technologies, LLC&#146;s outstanding Series <FONT STYLE="white-space:nowrap">A-4</FONT> redeemable
convertible preferred units (&#147;Series&nbsp;A-4 preferred units&#148;) will receive&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;share of Series <FONT STYLE="white-space:nowrap">A-4</FONT>
redeemable convertible preferred stock <FONT STYLE="white-space:nowrap">(&#147;Series&nbsp;A-4</FONT> preferred stock&#148;) of Metagenomi, Inc.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;for each
Series <FONT STYLE="white-space:nowrap">A-4</FONT> preferred unit held immediately prior to the Reorganization, with an aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our <FONT
STYLE="white-space:nowrap">Series&nbsp;A-4</FONT> redeemable convertible preferred stock issued in the Reorganization; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">holders of Metagenomi Technologies, LLC&#146;s outstanding Series <FONT STYLE="white-space:nowrap">A-5</FONT> redeemable
convertible preferred units (&#147;Series&nbsp;A-5 preferred units&#148;) will receive&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;share of Series <FONT STYLE="white-space:nowrap">A-5</FONT>
redeemable convertible preferred stock <FONT STYLE="white-space:nowrap">(&#147;Series&nbsp;A-5</FONT> preferred stock&#148;) of Metagenomi, Inc. for each Series <FONT STYLE="white-space:nowrap">A-5</FONT> preferred unit held immediately prior to the
Reorganization, with an aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our Series <FONT STYLE="white-space:nowrap">A-5</FONT> redeemable convertible preferred stock issued in the
Reorganization; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">holders of Metagenomi Technologies, LLC&#146;s outstanding Series B redeemable convertible preferred units
(&#147;Series&nbsp;B preferred units&#148;) will receive&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;share of Series B redeemable convertible preferred stock (&#147;Series&nbsp;B preferred
stock&#148;) of Metagenomi, Inc.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;for each Series B preferred unit held immediately prior to the Reorganization, with an aggregate
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our Series B redeemable convertible preferred stock issued in the Reorganization; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">holders of Metagenomi Technologies, LLC&#146;s outstanding Series <FONT STYLE="white-space:nowrap">B-1</FONT> redeemable
convertible preferred units (&#147;Series&nbsp;B-1 preferred units&#148;) will receive&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;share of Series <FONT STYLE="white-space:nowrap">B-1</FONT>
redeemable convertible preferred stock (&#147;Series&nbsp;B-1 preferred stock&#148;) of Metagenomi, Inc.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;for each Series
<FONT STYLE="white-space:nowrap">B-1</FONT> preferred unit held immediately prior to the Reorganization, with an aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our Series <FONT
STYLE="white-space:nowrap">B-1</FONT> redeemable convertible preferred stock issued in the Reorganization; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">holders of Metagenomi Technologies, LLC&#146;s outstanding common units will
receive&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock of Metagenomi, Inc. for each common unit held immediately prior to the Reorganization, with an aggregate
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock (which includes
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of unvested restricted common stock) issued in the Reorganization; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">holders of Metagenomi Technologies, LLC&#146;s outstanding profits interests will
receive&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock of Metagenomi, Inc. for each profits interest held immediately prior to the Reorganization, with an aggregate
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock issued (which
includes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of unvested restricted common stock) in the Reorganization. Vesting terms of outstanding profits interests will
not change. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Metagenomi, Inc.&#146;s Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred stock, Series
<FONT STYLE="white-space:nowrap">A-2</FONT> preferred stock, Series <FONT STYLE="white-space:nowrap">A-3</FONT> preferred stock, Series <FONT STYLE="white-space:nowrap">A-4</FONT> preferred stock, Series <FONT STYLE="white-space:nowrap">A-5</FONT>
preferred stock, and Series B preferred stock and Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred stock will be designated as preferred stock under Metagenomi, Inc.&#146;s amended and restated certificate of incorporation. All
outstanding shares of our redeemable convertible preferred stock will be convertible into shares of common stock on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;basis.</FONT></FONT> </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In connection with the Reorganization, by operation of law, Metagenomi, Inc. will acquire all assets of Metagenomi Technologies, LLC, and assume all of its liabilities
and obligations. The purpose of the Reorganization is to reorganize our corporate structure so that Metagenomi, Inc. will continue as a corporation and the existing investors of Metagenomi Technologies, LLC will own Metagenomi, Inc. capital stock
rather than members&#146; equity interests in Metagenomi Technologies, LLC. The Reorganization generally is intended to be non-taxable for U.S. income tax purposes. Except as context otherwise requires, all information included in this prospectus is
presented giving effect to the Reorganization. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc425213_7"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We estimate that the net proceeds to us from the sale of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our
common stock in this offering will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million if the underwriters exercise in full their option to purchase
additional shares, assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the estimated midpoint of the price range set forth on the cover page of this prospectus, and after deducting estimated
underwriting discounts and commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A $1.00 increase (decrease) in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the estimated midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the net proceeds to us from this offering by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and
estimated offering expenses payable by us. An increase (decrease) of 1,000,000 shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase (decrease) net proceeds to us from this offering by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming no change in the assumed initial public offering price per share, the estimated midpoint of the price range set forth on the cover page of this prospectus, and after deducting
estimated underwriting discounts and commissions and estimated offering expenses payable by us. We do not expect that a change in the offering price or the number of shares by these amounts would have a material effect on our intended uses of the
net proceeds from this offering, although it may impact the amount of time prior to which we may need to seek additional capital. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of June 30, 2023, we had
cash, cash equivalents and available-for-sale marketable securities of $318.4&nbsp;million. We currently intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, as follows: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;;
and </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the remainder for general corporate purposes. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Based on our current plans, we believe our existing cash and cash equivalents and available-for-sale marketable securities, together with the net proceeds from this
offering, will be sufficient to fund our operations and capital expenditure requirements into&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">All of our programs are currently in preclinical stage of development. The expected use of the net proceeds from this offering represents our intentions based upon our
current plans and business conditions, which could change in the future as our plans and business conditions evolve. As of the date of this prospectus, we cannot predict with certainty all of the particular uses for the net proceeds to be received
upon the closing of this offering or the amounts that we will actually spend on the uses set forth above. The amounts and timing of our actual expenditures may vary significantly depending on numerous factors, including the progress of our research
and development, the status of and results from <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies or clinical trials we may commence in the future, as well as any collaborations that we may enter into with third parties for our product
candidates or strategic opportunities that become available to us, and any unforeseen cash needs. As a result, our management will retain broad discretion over the allocation of the net proceeds from this offering. We expect the net proceeds from
this offering, together with our existing cash and cash equivalents, and available-for-sale marketable securities, will not be sufficient for us to advance any of our programs through regulatory approval, and we will need to raise additional capital
to complete the development and potential commercialization of any of our programs. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pending our use of proceeds from this offering, we intend to invest the net
proceeds in a variety of capital preservation instruments, including short-term, investment-grade, interest-bearing financial instruments and U.S. government securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc425213_8"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have never declared or paid any cash dividends on our members&#146; capital. We currently intend to retain any future earnings to fund the development and expansion
of our business, and therefore we do not anticipate paying cash dividends on our common stock in the foreseeable future. Any future determination to pay dividends will be at the discretion of our board of directors and will depend on our results of
operations, financial condition, capital requirements and other factors deemed relevant by our board of directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><A NAME="toc425213_9"></A>CAPITALIZATION </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table sets forth our cash, cash equivalents, available-for-sale marketable securities and our capitalization as of June 30, 2023: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">on an actual basis; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">on a pro forma basis to give effect to (i)&nbsp;the Reorganization, (ii)&nbsp;the conversion of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our redeemable convertible preferred stock, issued in connection with the Reorganization in exchange for redeemable convertible preferred
units outstanding as of June 30, 2023, in connection with the Reorganization, into an equivalent number of shares of our common stock, immediately prior to the completion of this offering and (iii)&nbsp;the filing and effectiveness of our amended
and restated certificate of incorporation immediately prior to the completion of this offering, in each case as if such events had occurred on June 30, 2023; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">on a pro forma as adjusted basis to give further effect to our issuance and sale of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock in this offering at an assumed initial public offering price of $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share,
which is the estimated midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The pro forma as adjusted information below is illustrative only, and our capitalization following the completion of this offering will be adjusted based on the actual
initial public offering price and other terms of this offering determined at pricing. You should read the information in this table together with our consolidated financial statements and the related notes included elsewhere in this prospectus and
&#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; section of this prospectus. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="12" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As of June&nbsp;30, 2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Pro&nbsp;forma</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Pro forma<BR>as&nbsp;adjusted</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in&nbsp;thousands,&nbsp;except&nbsp;share&nbsp;and&nbsp;per&nbsp;share&nbsp;data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$ 51,648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Available-for-sale</FONT></FONT>
marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">266,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total cash, cash equivalents and available-for-sale marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 318,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Redeemable convertible preferred units; no par value; 41,813,375&nbsp;units authorized,
41,813,375&nbsp;units issued and outstanding, actual; no units authorized issued and outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">350,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Redeemable Convertible preferred stock; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;par value; no
shares authorized, issued and outstanding, actual; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized and no shares issued and outstanding, pro forma; and no shares authorized, issued and outstanding, pro forma
as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Members&#146;/Stockholders&#146; equity (deficit):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Profits interests, no par value; 14,604,165 units authorized, 9,370,804 units issued and outstanding,
actual; no units authorized, issued and outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Common units, no par value; 66,000,000&nbsp;units authorized, 5,947,500&nbsp;units issued and outstanding,
actual; no units authorized, issued and outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Preferred stock, $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;par value; no shares authorized, issued or
outstanding, actual and pro forma; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized and no shares issued or outstanding, pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Common stock, $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;par value; no shares authorized, issued and
outstanding, actual; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares issued and outstanding, pro forma;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares issued and outstanding, pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accumulated other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(429</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(105,830</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total members&#146;/stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(102,539</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">248,219</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Each $1.00 increase (decrease) in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the estimated midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted amount of each of cash and cash
equivalents, total stockholders&#146; equity (deficit) and total capitalization by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus,
remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Each increase (decrease) of 1,000,000 shares in the number of shares offered by us, as set forth on the cover page
of this prospectus, would increase (decrease) the pro forma as adjusted amount of each of cash and cash equivalents, total stockholders&#146; equity (deficit) and total capitalization by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million,
assuming no change in the assumed initial public offering price per share and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">You should read the information in this table together with our consolidated financial statements and the related notes included elsewhere in this prospectus and
&#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; section of this prospectus. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The number of shares of our
common stock outstanding after this offering assumes the Reorganization takes place immediately prior to the completion of this offering and is based on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock (including &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of unvested
restricted common stock) issued in exchange for common units and profits interests outstanding as of June 30, 2023, and after giving effect to the conversion of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our redeemable convertible preferred stock, issued in connection with the Reorganization in exchange for redeemable convertible preferred units
outstanding as of June 30, 2023, into an equivalent number of shares of our common stock immediately prior to the completion of this offering. </P>   <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The number
of shares of common stock to be outstanding after this offering excludes: </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock
reserved for future issuance under our 2023 Stock Option and Incentive Plan (the &#147;2023 Plan&#148;), which will become effective on the date immediately prior to execution of the underwriting agreement related to this offering; and
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock
reserved for future issuance under our 2023 Employee Stock Purchase Plan (the &#147;ESPP&#148;), which will become effective on the date immediately prior to the execution of the underwriting agreement related to this offering.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc425213_10"></A>DILUTION </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If you invest in our common stock in this offering, your ownership interest will be diluted immediately to the extent of the difference between the initial public
offering price per share of our common stock and the pro forma as adjusted net tangible book value per share of our common stock immediately after this offering. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our historical net tangible book value (deficit) as of June 30, 2023 was $(104.2) million, or $(17.52) per our common unit. Our historical net tangible book value
(deficit) is the amount of our total tangible assets less our total liabilities and the carrying values of our redeemable convertible preferred units, which is not included within members&#146; deficit. Our historical net tangible book value
(deficit) per unit represents historical net tangible book value (deficit) divided by 5,947,500 of our common units outstanding as of June 30, 2023. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our pro forma
net tangible book value as of June 30, 2023 was $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share of our common stock. Pro forma net tangible book value represents the amount of our
total tangible assets less our total liabilities, after giving effect to (i) the Reorganization, (ii) the conversion of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our redeemable
convertible preferred stock, issued in connection with the Reorganization in exchange for redeemable convertible preferred units into an equivalent number of shares of our common stock immediately prior to the completion of this offering, and (iii)
the filing and effectiveness of our amended and restated certificate of incorporation immediately prior to the completion of this offering. Pro forma net tangible book value per share represents pro forma net tangible book value divided by the total
number of shares outstanding as of June 30, 2023, after giving effect to the pro forma adjustments described above. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">After giving further effect to our issuance and
sale of&nbsp;shares of our common stock in this offering at an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the estimated midpoint of the price range set forth on the cover page of this
prospectus, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma as adjusted net tangible book value as of June 30, 2023 would have been
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. This amount represents an immediate increase in pro forma as adjusted net tangible book value of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share to our existing stockholders and immediate dilution in pro forma as adjusted net tangible book value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share to new investors
purchasing common stock in this offering. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Dilution per share to new investors is determined by subtracting pro forma as adjusted net tangible book value per
share after this offering from the initial public offering price per share paid by new investors. The following table illustrates this dilution on a per share basis (without giving effect to any exercise by the underwriters of their option to
purchase additional shares): </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom"><B>Assumed initial public offering price per share</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><B>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Historical net tangible book value (deficit) per common unit as of June 30, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17.52</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Increase per share attributable to the pro forma adjustments described above</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Pro forma net tangible book value per share as of June 30, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Increase in pro forma as adjusted net tangible book value per share attributable to new investors
participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Pro forma as adjusted net tangible book value per share immediately after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Dilution per share to new investors participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The dilution information discussed above is illustrative only and will change based on the actual initial public offering price and
other terms of this offering determined at pricing.&nbsp;Each $1.00 increase (decrease) in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the estimated midpoint of the price range
set forth on the cover page of this prospectus, would increase (decrease) our pro forma as adjusted net tangible book value per share after this offering by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and dilution per share to new investors purchasing common stock in this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming
that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Each increase of
1,000,000 shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase our pro forma as adjusted net tangible book value per share after this offering by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and decrease dilution per share to new investors purchasing common stock in this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming no change in the assumed initial public
offering price per share and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Each decrease of 1,000,000 shares in the number of shares offered by us, as set forth on the cover page of
this prospectus, would decrease our pro forma as adjusted net tangible book value per share after this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and increase dilution per share to new investors purchasing common stock in this
offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming no change in the assumed initial public offering price and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If the underwriters exercise their option to purchase additional shares in full, our pro forma as adjusted net tangible book value per share after this offering would be
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, representing an immediate increase in pro forma as adjusted net tangible book value per share of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to existing stockholders and immediate dilution in
pro forma as adjusted net tangible book value per share of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to new investors purchasing common stock in this offering, based on the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes on the pro forma as adjusted basis described above, the total number of shares of common stock purchased from us on an as converted to
common stock basis, the total consideration paid or to be paid, and the average price per share paid or to be paid by existing members/stockholders and by new investors in this offering at an assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the estimated midpoint of the estimated price range set forth on the cover of this prospectus, before deducting estimated underwriting discounts and commissions and estimated
offering expenses payable by us. As the table shows, new investors purchasing common stock in this offering will pay an average price per share substantially higher than our existing members/ stockholders paid. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Units/Shares&nbsp;Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total&nbsp;Consideration</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000;border-bottom:1.00px solid #000000"><B>Average&nbsp;Price<BR>Per&nbsp;Unit/Share</B></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Existing members/stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">47,760,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$351,637,285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$7.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Investors participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="17" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="17" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="17" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The table above assumes no exercise of the underwriters&#146; option to purchase additional shares in this offering. If the
underwriters&#146; option to purchase additional shares is exercised in full, the number of shares of our common stock held by existing stockholders would be reduced to &nbsp;&nbsp;&nbsp;&nbsp; percent of the total number of shares of our common
stock outstanding after this offering, and the number of shares of common stock held by new investors purchasing common stock in this offering would be increased to &nbsp;&nbsp;&nbsp;&nbsp; percent of the total number of shares of our common stock
outstanding after this offering. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The discussion and tables above assume the Reorganization takes immediately place prior to the completion of this offering and
are based on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock (including&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
of unvested restricted common stock) issued in exchange for common units and profits interests outstanding as of June 30, 2023, and after giving effect to the conversion of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our redeemable convertible preferred stock, issued in connection with the Reorganization, in exchange for redeemable convertible preferred
units outstanding as of June 30, 2023, into an equivalent number of shares of our common stock immediately prior to the completion of this offering. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The number of
shares of common stock to be outstanding after this offering excludes: </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock
reserved for future issuance under the 2023 Plan; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock
reserved for future issuance under the ESPP. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To the extent that new stock options are issued, or we issue additional shares of common stock in the
future, there will be further dilution to new investors. In addition, we may choose to raise additional capital because of market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future
operating plans. If we raise additional capital through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc425213_11"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>You should read the following discussion and analysis of our financial condition and results of operations together with our audited consolidated
financial statements and unaudited condensed consolidated financial statements and the related notes appearing elsewhere in this prospectus. This discussion and other parts of this prospectus contain forward-looking statements that involve risks and
uncertainties, such as statements regarding our plans, objectives, expectations, intentions and projections. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute
to such differences include, but are not limited to, those discussed in the &#147;Risk Factors&#148; section of this prospectus. Our historical results are not necessarily indicative of the results that may be expected for any period in the future.
</I></P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Overview </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are a precision genetic medicines company committed to
developing curative therapeutics for patients using our proprietary, comprehensive metagenomics-derived genome editing toolbox. Genetic diseases are caused by a diverse set of mutations that have been largely inaccessible by genome engineering
approaches to date. Genetic mutations are seen in a variety of forms, including deletions, insertions, single-base-pair changes and sequence repeats, and are found throughout the genome and across a variety of different cell types, tissues, and
organ systems. Additionally, many diseases lack a genetic origin but have the potential to be effectively and permanently addressed through genome editing. We are harnessing the power of metagenomics, the study of genetic material recovered from the
natural environment, to unlock four billion years of microbial evolution to discover and develop a suite of novel editing tools capable of correcting any type of genetic mutation found anywhere in the genome. Our comprehensive genome editing toolbox
includes programmable nucleases, base editors, and RNA and <FONT STYLE="white-space:nowrap">DNA-mediated</FONT> integration systems (including prime editing systems and clustered regularly interspaced short palindromic repeat
(&#147;CRISPR&#148;)-associated transposases (&#147;CASTs&#148;)). We believe our diverse and modular toolbox positions us to access the entire genome and select the optimal tool to unlock the full potential of genome editing for patients. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Since our inception, we have devoted substantially all of our resources to organizing and staffing our company, business planning, raising capital, research and
development activities, building our intellectual property portfolio and providing general and administrative support for these operations. We have historically financed our operations primarily through issuing redeemable convertible preferred units
and convertible promissory notes and entering into collaboration agreements, which generate collaboration revenue. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have incurred significant operating losses
since inception and we expect to continue to incur substantial losses for the foreseeable future. Our net losses were $21.4&nbsp;million and $43.6&nbsp;million for the years ended December&nbsp;31, 2021 and 2022, respectively. Our net losses were
$18.6&nbsp;million and $29.1&nbsp;million for the six months ended June&nbsp;30, 2022 and 2023, respectively. As of June&nbsp;30, 2023, we had an accumulated deficit of $105.8&nbsp;million. We anticipate that our expenses and operating losses will
increase substantially for the foreseeable future as we: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">advance our&nbsp;current research activities and further develop our platform; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">develop, maintain, expand, and protect our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">continue preclinical development and initiate clinical trials for any product candidates we may identify;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">seek regulatory approval for any product candidates for which we successfully complete clinical trials;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">establish our manufacturing capabilities, including internal manufacturing facilities and contracting with other vendors;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">ultimately, commercialize any future product candidates for which we receive regulatory approval, requiring significant
marketing, sales, and distribution infrastructure expenses; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">hire additional research and development, clinical, commercial, general and administrative personnel;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> product candidates, intellectual property and technologies;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">establish and maintain collaborations; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">add operational, financial and management information systems and personnel; or </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">incur additional legal, audit, accounting, compliance, insurance, investor relations and other expenses to operate as a
public company that we did not incur as a private company. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We will not generate revenue from product sales unless and until we successfully
initiate and complete clinical development and obtain regulatory approval for one or more product candidates. If we obtain regulatory approval for any product candidate and do not enter into a commercialization partnership, we expect to incur
significant expenses related to developing our commercialization capability to support product sales, manufacturing, marketing, and distribution. As a result, we will need substantial additional funding to support our continuing operations and
pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of equity offerings, debt financings, collaborations, strategic alliances, and
marketing, distribution or licensing arrangements with third parties. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into
such agreements as and when needed, we may have to significantly delay, reduce or eliminate the development and commercialization of our platform or delay our pursuit of potential <FONT STYLE="white-space:nowrap">in-licenses</FONT> or acquisitions.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of June&nbsp;30, 2023, we had cash, cash equivalents and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT>
marketable securities of $318.4&nbsp;million. We believe that the anticipated net proceeds from this offering, together with our existing cash, cash equivalents and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities will be sufficient to fund our operating expenses and capital expenditure requirements through
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. See &#147;Liquidity and
Capital Resources&#148; and &#147;Risk Factors&#151;Risks Related To Our Financial Position and Need for Additional Capital.&#148; </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Macroeconomic Trends </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Unfavorable conditions in the economy in the United States and abroad may negatively affect the growth of our business and our results of operations. For example,
macroeconomic events, including, rising inflation, tensions in U.S.-China relations, the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, the U.S. Federal Reserve raising interest rates, recent and potential future disruptions in access to
bank deposits and lending commitments due to bank failures and the Russia-Ukraine war, have led to economic uncertainty and volatility globally. The effect of macroeconomic conditions may not be fully reflected in our results of operations until
future periods. To date, the macroeconomic trends discussed above have not had a material adverse impact on our business, financial condition or results of operations. If, however, economic uncertainty increases or the global economy worsens, our
business, financial condition and results of operations may be harmed. For further discussion of the potential impacts of macroeconomic events on our business, financial condition, and operating results, refer to the section titled &#147;Risk
Factors&#148; included elsewhere in this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Collaboration and License Agreements </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Moderna Strategic Collaboration and License Agreement </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On
October&nbsp;29, 2021, the effective date, we entered into a Strategic Collaboration and License Agreement (the &#147;Moderna Agreement&#148;) with Moderna. We will collaborate with Moderna on the research and development of <I>in vivo</I> genome
editing therapies directed at certain targets and the commercialization of such genome editing therapies. The collaboration provides Moderna with exclusive access to our technology platform during the research period in (1)&nbsp;the field of <I>in
vivo </I>gene editing technology for a therapeutic, ameliorative or prophylactic application by way of <FONT STYLE="white-space:nowrap">knock-out</FONT> through InDel formation or base editing or insertion of an exogenous DNA template (such field,
&#147;DT Field&#148;) and (2)&nbsp;the field of <I>in vivo</I> gene editing technology for a therapeutic, ameliorative or prophylactic application outside the use of (a)&nbsp;DNA donor templates and (b)&nbsp;no exogenous template at all but
including (c)&nbsp;correction by base editing (such field, &#147;RT Field&#148;). We formed a joint steering committee, a joint research subcommittee and a joint patent subcommittee to oversee the collaboration activities. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Under the terms of the Moderna Agreement, we and Moderna will collaborate on one or more programs in the RT Field (the &#147;Moderna RT program&#148;) and two programs
in the DT Field (the &#147;Moderna DT program&#148; and the &#147;DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> program&#148;). </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">With respect to the Moderna RT
and Moderna DT programs, we will collaborate on the research and development of product candidates under the approved research plans. The initial research term of the Moderna RT program is four years, which may be extended by Moderna for an
additional three years upon written notice and a payment of extension fees. The initial research term of the Moderna DT program is four years. We granted to Moderna an option to obtain an exclusive license to develop, manufacture and commercialize
up to ten Moderna RT program candidates and up to two Moderna DT program candidates at any time during the research term and prior to filing of an IND application with the FDA or any similar application filed with a regulatory authority in a country
other than the United States (&#147;U.S.&#148;), subject to Moderna&#146;s payment of an option exercise fee of $10.0&nbsp;million per target. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">With respect to the
DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> program, we will work together with Moderna on the <FONT STYLE="white-space:nowrap">co-development</FONT> and commercialization of products and share costs and profits equally. We maintain
commercialization rights in the U.S. (subject to Moderna&#146;s right to appoint up to 50% of the U.S. sales force for the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> program), while Moderna maintains these rights in countries other than the
U.S. The initial research term for the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> program is four years, and each party has a right to <FONT STYLE="white-space:nowrap">opt-out</FONT> of the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT>
program at any time, at which point the other party has the right to solely continue the development and commercialization activities. If there is no development candidate nomination by the end of the initial research term, the DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> program will expire, unless we have mutually agreed to continue the program. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">During the year ended December&nbsp;31, 2021,
we received a <FONT STYLE="white-space:nowrap">non-refundable</FONT> upfront payment of $40.0&nbsp;million and a $5.0&nbsp;million payment for the first year of research costs. Concurrent with the Moderna Collaboration Agreement, Moderna also
provided $30.0&nbsp;million in cash in the form of a convertible promissory note (see Note 9 in our audited consolidated financial statements included elsewhere in this prospectus) pursuant to a convertible promissory note agreement dated
October&nbsp;29, 2021 (the &#147;Moderna Convertible Promissory Note Agreement&#148;). The convertible promissory note was converted into shares of Series B redeemable convertible preferred units in January 2022. Moderna will reimburse us up to
$5.0&nbsp;million in annual research and development costs related to the Moderna DT and Moderna RT programs, or up to the agreed amount of expenses per the budget. As of June&nbsp;30, 2023, we have received a total of $49.6&nbsp;million under the
Moderna Collaboration Agreement, not including cost-sharing payments under the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> program. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For the Moderna RT and Moderna DT programs, we are eligible to receive (i)&nbsp;technology milestone fees related
to the achievement of certain preclinical research objectives of up to $75.0&nbsp;million, (ii)&nbsp;development and regulatory milestones of up to $100.0&nbsp;million per target, (iii)&nbsp;sales milestones of up to $200.0&nbsp;million per target,
and (iv)&nbsp;royalties ranging from a <FONT STYLE="white-space:nowrap">mid-single</FONT> digit to a <FONT STYLE="white-space:nowrap">low-teens</FONT> percentage of annual net sales of a licensed product. Any profits and losses from co-development
and commercialization of the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> program are shared equally between us and Moderna. With respect to the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> program for which the <FONT
STYLE="white-space:nowrap">opt-out</FONT> party has exercised its <FONT STYLE="white-space:nowrap">opt-out</FONT> right, the continuing party will pay to the <FONT STYLE="white-space:nowrap">opt-out</FONT> party, certain development, regulatory and
sales milestone payments that will not exceed an aggregate $239.0&nbsp;million per DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> target, and <FONT STYLE="white-space:nowrap">opt-out</FONT> royalties ranging from a high-single digit to a <FONT
STYLE="white-space:nowrap">low-teens</FONT> percentage of annual net sales of a licensed product. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The term of the Moderna Agreement will continue on a licensed <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-licensed</FONT></FONT> product and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, until the expiration of the
applicable royalty term. The royalty term commences on the first commercial sale of a licensed product and terminates on the latest of: (a)&nbsp;the expiration or abandonment of the last valid claim of a patent within the licensed Moderna DT or RT
technology; (b)&nbsp;10 years after the first commercial sale of a licensed product; and (c)&nbsp;expiration of the regulatory exclusivity. Upon the expiration of the term of a licensed product in the Moderna DT or Moderna RT program, the licenses
granted to Moderna will survive and become perpetual, fully paid and royalty-free. Each party may terminate the Moderna Agreement on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">program-by-program</FONT></FONT> basis upon
written notice to the other party for an uncured material breach or insolvency. We may terminate the Moderna Agreement upon written notice to Moderna for a patent challenge. Additionally, Moderna may terminate the agreement at its convenience with
respect to Moderna DT or Moderna RT programs for any reason upon at least: (a)&nbsp;60 days&#146; prior written notice if a first commercial sale has not occurred for the products in such program, or (b)&nbsp;180 days&#146; prior written notice if a
first commercial sale of a product in such program has occurred. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We concluded that the Moderna DT and Moderna RT programs are in the scope of ASC 606. We determined
that the licenses granted to Moderna, and its participation in the joint steering committee are not capable of being distinct from the preclinical research and development services and therefore concluded that there are two performance obligations:
(1)&nbsp;the Moderna RT program and (2)&nbsp;the Moderna DT program. We also concluded that the option to obtain an exclusive license and options to extend Moderna RT program term do not include significant incremental discounts, and as such, the
options do not provide material rights. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We concluded the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> program research activities are within the scope of ASC
808, as we and Moderna are both active participants in the research, development and commercialization activities, are exposed to significant risks and rewards that are dependent on the success of the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT>
program activities and share costs and profits equally. We determined that the guidance in ASC 730, <I>Research and Development</I>, was appropriate to apply to the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> program research activities by
analogy, based on the nature of the cost sharing provisions of the agreement. We concluded that DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> program is one unit of accounting, as the <FONT STYLE="white-space:nowrap">co-exclusive</FONT> license
is not distinct from the research and development and the participation in joint steering committee activities. We recognize payments to or from Moderna related to the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> program cost sharing research
activities as an increase to or reduction of research and development expenses, respectively. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We concluded that the Moderna Collaboration Agreement and the Moderna
Convertible Promissory Note Agreement should be combined and treated as a single arrangement for accounting purposes as the agreements were entered into contemporaneously and in contemplation of one another. We estimated the contract consideration
to be $90.0&nbsp;million, which consisted of: 1) the <FONT STYLE="white-space:nowrap">non-refundable</FONT> upfront collaboration payment of $40.0&nbsp;million received in 2021, 2) $30.0&nbsp;million in cash received in 2021 in exchange for the
convertible promissory note and 3) the estimated cost reimbursements for Moderna DT and Moderna RT programs of $20.0&nbsp;million. We constrained future milestones, as we assessed that it is probable that the inclusion of such variable consideration
could result in a significant reversal of cumulative revenue in future </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
periods. During the year ended December&nbsp;31, 2021, we recorded $30.0&nbsp;million of the contract consideration for the convertible promissory note based on the fair value (see Note 9 in our
audited consolidated financial statements included elsewhere in this prospectus) and allocated the transaction price of $60.0&nbsp;million to each of the following programs on a relative standalone selling price basis: 1) $49.5&nbsp;million to the
Moderna RT program, 2) $5.5&nbsp;million to the Moderna DT program, and 3) $5.0&nbsp;million to the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> program. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The
variable consideration is reevaluated at each reporting period and as changes in circumstances occur. We recognize revenue for each of the Moderna DT and Moderna RT programs as collaboration revenue based on the measure of progress using an
estimated cost-based input method each reporting period. We also amortize the allocation consideration for the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> program of $5.0&nbsp;million as a credit to research and development expenses during the
discovery and lead optimization phases for the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> program. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We recognized collaboration revenue of $0.2&nbsp;million
and $14.5&nbsp;million in the consolidated statements of operations and comprehensive loss for the years ended December&nbsp;31, 2021 and 2022, respectively. We recognized collaboration revenue of $6.7&nbsp;million and $8.9&nbsp;million in the
condensed consolidated statements of operations and comprehensive loss for the six months ended June&nbsp;30, 2022 and 2023, respectively. As of December&nbsp;31, 2022 and June&nbsp;30, 2023, deferred revenue related to the Moderna Agreement was
$30.2&nbsp;million and $21.0&nbsp;million, respectively. Collaboration revenue recognized during the six months ended June&nbsp;30, 2022 and 2023 included $6.7&nbsp;million and $8.9&nbsp;million that was included in deferred revenue as of
December&nbsp;31, 2021 and 2022, respectively. The value of the transaction price allocated to the remaining unsatisfied portion of the performance obligations was approximately $33.1&nbsp;million as of June&nbsp;30, 2023, which we expect to
recognize as revenue over the next two-to-three years. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We recognized $0.2&nbsp;million and $0.3&nbsp;million in credits to research and development expenses related
to cost sharing allocation and amortization of the collaboration advance, respectively, within research and development expenses in the consolidated statement of operations and comprehensive loss during the year ended December&nbsp;31, 2021. We
recognized $0.9&nbsp;million and $3.5&nbsp;million in credits to research and development expenses related to cost sharing allocation and amortization of the collaboration advance, respectively, during the year ended December&nbsp;31, 2022. We
recognized less than $0.1&nbsp;million and $1.7&nbsp;million in credits to research and development expenses related to cost sharing allocation and amortization of the collaboration advance, respectively, within research and development expenses in
the condensed consolidated statement of operations and comprehensive loss during the six months ended June&nbsp;30, 2022. We recognized $0.4&nbsp;million and $0.4&nbsp;million in credits to research and development expenses related to cost sharing
allocation and amortization of the collaboration advance during the six months ended June&nbsp;30, 2023, respectively. As of December&nbsp;31, 2022, the collaboration advance balance was $1.1&nbsp;million, partially offset by the cost-sharing
receivable balance of $0.4&nbsp;million, which was presented as a collaboration advance on our condensed consolidated balance sheet. As of June&nbsp;30, 2023, the collaboration advance balance was $0.8&nbsp;million, partially offset by the
cost-sharing receivable balance of $0.4&nbsp;million, which was presented as a collaboration advance on our condensed consolidated balance sheet. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For additional
information regarding the Moderna Agreement, please see the section titled &#147;Business&#151;Our License and Collaboration Agreements.&#148; </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I><FONT
STYLE="white-space:nowrap">Affini-T</FONT> Development, Option and License Agreement </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On June&nbsp;14, 2022, the effective date, we entered into a
Development, Option and License Agreement (the <FONT STYLE="white-space:nowrap">&#147;Affini-T</FONT> Agreement&#148;) with <FONT STYLE="white-space:nowrap">Affini-T.</FONT> Pursuant to the <FONT STYLE="white-space:nowrap">Affini-T</FONT> Agreement,
we and <FONT STYLE="white-space:nowrap">Affini-T</FONT> have agreed to identify, develop or optimize certain reagents using our proprietary technology for <FONT STYLE="white-space:nowrap">Affini-T</FONT> to use such reagents to develop and
commercialize gene edited <FONT STYLE="white-space:nowrap">TCR-based</FONT> therapeutic products exclusively in the field of treatment, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
prevention or diagnosis of any human cancer using products with any engineered primary TCR alpha/beta T cells and <FONT STYLE="white-space:nowrap">non-exclusively</FONT> in the field of
treatment, prevention or diagnosis of any human cancer using products with certain other engineered immune cells worldwide. A joint steering committee was established by both parties to assign alliance managers and project leaders to oversee the
collaboration activities. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pursuant to the <FONT STYLE="white-space:nowrap">Affini-T</FONT> Agreement, we granted <FONT STYLE="white-space:nowrap">Affini-T</FONT>
options to receive, on a <FONT STYLE="white-space:nowrap">pre-specified</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">target-by-pre-specified</FONT></FONT></FONT> target basis, for up to
six <FONT STYLE="white-space:nowrap">pre-specified</FONT> targets, either (i)&nbsp;an exclusive, royalty-bearing, sublicensable worldwide license under all of our applicable intellectual property to research, develop, manufacture, use, commercialize
and otherwise exploit any <FONT STYLE="white-space:nowrap">TCR-based</FONT> therapy, preventative treatment, or diagnostic for humans that is directed to such <FONT STYLE="white-space:nowrap">pre-specified</FONT> target, contains or comprises
Primary TCR alpha/beta T Cells and is derived from <I>ex vivo application of our reagent (the &#147;Exclusive Option&#148;) or (ii)&nbsp;a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> royalty-bearing, sublicensable worldwide license under
all our applicable intellectual property to research, develop, manufacture, use commercialize and otherwise exploit any <FONT STYLE="white-space:nowrap">TCR-based</FONT> therapy, preventative treatment, or diagnostic for humans that is directed to
such <FONT STYLE="white-space:nowrap">pre-specified</FONT> target, contains or comprises TCR natural killer (&#147;NK&#148;) cells derived from iPSC immune cells or TCR T cells derived from donor-derived or iPSC immune cells. <FONT
STYLE="white-space:nowrap">Affini-T</FONT> can exercise its options for either an exclusive license or a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license, or both, for each <FONT STYLE="white-space:nowrap">pre-specified</FONT> target by
providing written notice prior to the earlier of (x)&nbsp;the end of the <FONT STYLE="white-space:nowrap">Affini-T</FONT> Agreement term or (y) 90 days following the filing of an IND for a licensed product directed to a <FONT
STYLE="white-space:nowrap">pre-specified</FONT> target, subject to the payment of certain fees per each option exercised. After the option exercise, <FONT STYLE="white-space:nowrap">Affini-T</FONT> has agreed to use commercially reasonable efforts
to conduct all development and commercialization activities for a licensed product, and development and commercialization of all licensed products will be at <FONT STYLE="white-space:nowrap">Affini-T&#146;s</FONT> sole cost and expense. </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In connection with the <FONT STYLE="white-space:nowrap">Affini-T</FONT> Agreement, we received upfront equity consideration of 719,920 shares of <FONT
STYLE="white-space:nowrap">Affini-T&#146;s</FONT> common stock with an estimated fair value of $1.3&nbsp;million in June 2022. The fair value of <FONT STYLE="white-space:nowrap">Affini-T&#146;s</FONT> shares of common stock was estimated by our
management, considering the most recent third-party valuation. <FONT STYLE="white-space:nowrap">Affini-T</FONT> has also agreed to reimburse us for expenses incurred while performing research activities under the research plans. As of June&nbsp;30,
2023, we received a total of $1.9&nbsp;million related to reimbursable expenses and recognized $2.3&nbsp;million in accounts receivable. Additionally, we are eligible to receive (i) 933,650 shares of
<FONT STYLE="white-space:nowrap">Affini-T&#146;s</FONT> common stock upon the achievement of a regulatory milestone, which is the earlier of a submission of a drug master file to the FDA or an acceptance of an IND filing for a licensed product by
the FDA, (ii)&nbsp;up to $18.8&nbsp;million in future developmental milestone payments depending on the completion of or the number of patients dosed in, the relevant human clinical trial, or the initiation of a pivotal trial, and $40.6&nbsp;million
in future regulatory approval milestone payments, which include regulatory approvals in the U.S. and other markets for licensed products directed to a <FONT STYLE="white-space:nowrap">pre-specified</FONT> target if options for both exclusive and <FONT
STYLE="white-space:nowrap">non-exclusive</FONT> licenses are exercised with respect to such target, (iii)&nbsp;up to $250.0&nbsp;million in sales-based milestones for aggregate sales of all licensed products directed to a given <FONT
STYLE="white-space:nowrap">pre-specified</FONT> target and (iv)&nbsp;royalties ranging from a <FONT STYLE="white-space:nowrap">low-single</FONT> digit to high-single digit percentage of worldwide annual net sales of licensed products. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The initial term of the <FONT STYLE="white-space:nowrap">Affini-T</FONT> Agreement is five years from the effective date. If
<FONT STYLE="white-space:nowrap">Affini-T</FONT> exercises an Exclusive Option with respect to any <FONT STYLE="white-space:nowrap">pre-specified</FONT> target during the initial term, the initial term will be extended by an additional five years.
Following the expiration of the extended term, if any, the agreement will continue on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">target-by-target</FONT></FONT> basis and expire with respect to such target upon the expiration
of the royalty term for all licensed products directed to such target. The <FONT STYLE="white-space:nowrap">Affini-T</FONT> Agreement may be terminated during the term by either party for an uncured material breach by, or bankruptcy of, the other
party. Additionally, <FONT STYLE="white-space:nowrap">Affini-T</FONT> may terminate the <FONT STYLE="white-space:nowrap">Affini-T</FONT> Agreement for convenience, in its entirety, on a research <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">plan-by-research</FONT></FONT> plan basis, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">target-by-target</FONT></FONT> basis or on a licensed <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">product-by-licensed</FONT></FONT> product basis, by providing prior written notice. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We concluded that the
<FONT STYLE="white-space:nowrap">Affini-T</FONT> Agreement is in the scope of ASC 606 and that there is one performance obligation to perform research activities under the <FONT STYLE="white-space:nowrap">Affini-T</FONT> Agreement. Exclusive and <FONT
STYLE="white-space:nowrap">non-exclusive</FONT> licenses are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
optional contingent purchases that do not include significant incremental discounts, and therefore do not provide a material right. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">At the effective date, the transaction price consisted of the upfront equity consideration with an estimated fair value of $1.3&nbsp;million and estimated research
reimbursement costs. Research reimbursement costs represent variable consideration, and our management estimates what portion to include in total consideration at the end of each reporting period. Other payments under the <FONT
STYLE="white-space:nowrap">Affini-T</FONT> Agreement, including additional equity consideration and development and regulatory milestones, also represent variable consideration, and are constrained to the extent that the inclusion of such variable
consideration could result in a significant reversal of cumulative revenue in future periods. As of December&nbsp;31, 2022 and June&nbsp;30, 2023, additional equity consideration and future development and regulatory milestone payments were excluded
from the estimated total transaction price as they were considered constrained. The transaction price is reevaluated in each reporting period and as changes in circumstances occur. We recognize revenue each reporting period based on the measure of
progress using an estimated cost-based input method. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We recognized $2.6&nbsp;million in collaboration revenue in the consolidated statements of operations and
comprehensive loss during the year ended December&nbsp;31, 2022. We recognized $2.6&nbsp;million in collaboration revenue in the condensed consolidated statements of operations and comprehensive loss during the six months ended June&nbsp;30, 2023.
As of December&nbsp;31, 2022, we recorded $1.3&nbsp;million in contract assets on the consolidated balance sheet, related to services performed but not invoiced. There was no contract asset related to services performed as of June&nbsp;30, 2023. As
of December&nbsp;31, 2022 and June&nbsp;30, 2023, deferred revenue related to the <FONT STYLE="white-space:nowrap">Affini-T</FONT> Agreement was zero and $0.4&nbsp;million, respectively. In June 2023, the joint steering committee approved the budget
for estimated research reimbursement costs for the <FONT STYLE="white-space:nowrap">Affini-T</FONT> Agreement, which resulted in a $2.4&nbsp;million reduction to variable consideration. The value of the transaction price allocated to the remaining
unsatisfied portion of the performance obligation was approximately $3.0&nbsp;million as of June&nbsp;30, 2023, which we expect to recognize as revenue over the next
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">four-to-five</FONT></FONT> years. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For additional information regarding the <FONT
STYLE="white-space:nowrap">Affini-T</FONT> Agreement, please see the section titled &#147;Business&#151;Our License and Collaboration Agreements.&#148; </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Ionis
Collaboration and License Agreement </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On November&nbsp;10, 2022, the effective date, we entered into a Collaboration and License Agreement (the &#147;Ionis
Agreement&#148;) with Ionis to collaborate on drug discovery and exploratory research activities to advance new medicines using gene editing strategies, with the goal of discovering novel medicines. Pursuant to the terms of the Ionis Agreement, we
granted Ionis and its affiliates a worldwide exclusive, royalty-bearing license, with the right to grant sublicenses, to use all licensed systems and licensed products in the field of <I>in vivo</I> gene editing for all therapeutic, prophylactic,
palliative, and analgesic uses in humans. In connection with the Ionis Agreement, we also have the right to exercise an exclusive option to <FONT STYLE="white-space:nowrap">co-develop</FONT> and
<FONT STYLE="white-space:nowrap">co-commercialize</FONT> certain products under a drug discovery program. A joint steering committee was established by both parties to coordinate, oversee, and monitor the research and drug discovery activities under
the Ionis Agreement. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We will collaborate to discover therapeutic products under a drug discovery program and develop a drug discovery plan for each target, selected
by Ionis. The target selection is divided into two waves: up to four targets in Wave 1 and up to four targets in Wave 2. For each drug discovery program, once the parties identify a development candidate that is suitable for further development,
Ionis will be responsible for the development and commercialization of products resulting from such program. Per the terms of the Ionis Agreement, at any time prior to the designation of a development candidate for a drug discovery program and for
any reason, Ionis may replace the collaboration target, provided such target has not previously been substituted out. Ionis may substitute (i)&nbsp;up to two Wave 1 targets and (ii)&nbsp;up to two Wave 2 targets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The drug discovery activities for a program commence on the selection of a target and expire upon the earlier of
(a)&nbsp;completion of all drug discovery activities for such program, (b)&nbsp;the fifth anniversary of the effective date and (c)&nbsp;selection of a development candidate for such drug discovery program. If one or more Wave 2 targets become
collaboration targets as a result of the parties achieving enabled delivery and less than two years are remaining in the drug discovery term, then the term will be extended to the earlier of (i)&nbsp;the time that we complete all of our activities
under the applicable drug discovery plan and (ii)&nbsp;the seventh anniversary of the effective date, subject to our consent. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We will also conduct an exploratory
research program, and will jointly optimize guide RNA (&#147;gRNA&#148;) and select delivery technologies and other activities. The exploratory research activities commence on the effective date and expire upon the earlier of (a)&nbsp;completion of
all exploratory research activities established in the exploratory research plan, and (b)&nbsp;the fifth anniversary of the effective date. We have the exclusive option to <FONT STYLE="white-space:nowrap">co-develop</FONT> and <FONT
STYLE="white-space:nowrap">co-commercialize</FONT> the licensed products under a drug discovery program (the <FONT STYLE="white-space:nowrap">&#147;Co-Co</FONT> Option&#148;) with Ionis. The <FONT STYLE="white-space:nowrap">Co-Co</FONT> Option may
be exercised for (a)&nbsp;the initial Wave 1 target (&#147;Target 1&#148;), (b)&nbsp;no more than one of the other three discovery programs for the Wave 1 targets, and (c)&nbsp;no more than two drug discovery programs for the Wave 2 targets that
become collaboration targets. If we exercise the <FONT STYLE="white-space:nowrap">Co-Co</FONT> Option for a particular drug discovery program, that drug discovery program will automatically be deemed a
<FONT STYLE="white-space:nowrap">&#147;Co-Co</FONT> Program&#148;, all corresponding licensed products be deemed <FONT STYLE="white-space:nowrap">&#147;Co-Co</FONT> Products,&#148; we will be obligated to pay Ionis an option exercise fee, and we and
Ionis will enter into a separate <FONT STYLE="white-space:nowrap">co-development</FONT> and <FONT STYLE="white-space:nowrap">co-commercialization</FONT> agreement. The <FONT STYLE="white-space:nowrap">Co-Co</FONT> Option exercise fee will equal 50%
of Ionis&#146; internal costs and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs incurred in the conduct of the drug discovery activities prior to the exercise of the <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Option and be reduced by 50% of our corresponding costs incurred. Future development and commercialization costs will be shared equally. We may elect to reduce our cost-share percentage anywhere between 50%
and 25% on a <FONT STYLE="white-space:nowrap">go-forward</FONT> basis, provided we will continue to bear 50% of the costs of any clinical trials ongoing at the time of the election through the completion of the clinical trials. We will manufacture
all licensed systems and certain components of the applicable licensed products that are needed by Ionis for use in its development activities and all of our manufactured components needed by Ionis for use in its commercialization activities. We
will provide the manufactured components at a price that represents the cost of goods plus 15%. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pursuant to the terms of the Ionis Agreement, we have also been
granted an option to obtain a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> royalty-bearing license, with the right to grant sublicenses, for certain Ionis&#146; background technology to use in up to eight therapeutic products discovered by
us in the field of <I>in vivo</I> gene editing and directed to a Collaboration Target (each such product, a &#147;Metagenomi Product&#148; and each such option an &#147;Ionis IP Option&#148;), but subject to encumbrance checks with respect to
particular targets. A Collaboration Target is a target that is selected by Ionis, and, with respect to us, is not the subject of discussions with a third party, is not the subject of a contractual grant of rights to a third party nor the subject of
an internal research and development program. If we exercise our Ionis IP Option, we will pay to Ionis up to several million dollars per Metagenomi Product upon achievement of certain clinical and regulatory milestones. We are also obligated to pay
Ionis royalties in an amount equal to a low single-digit royalty on the net sales of the applicable Metagenomi Product on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In November 2022, we received an $80.0&nbsp;million upfront
payment from Ionis for the Wave 1 drug discovery research collaboration and selected Target 1. Ionis selected its second target (&#147;Target 2&#148;) in Wave 1 in December 2022, and we expect Ionis will select two final additional Wave 1 targets
(&#147;Target 3&#148; and &#147;Target 4&#148;) within the 12 months from the effective date, as permitted under the arrangement. Ionis has an option to select up to four Wave 2 targets at any time during the drug discovery term, if (a)&nbsp;an IND
for any licensed product directed to a Wave 1 target is filed with the applicable regulatory authority or (b)&nbsp;the parties achieve enabled delivery for a <FONT STYLE="white-space:nowrap">non-liver</FONT> target under the exploratory research
activities, by providing written notice and by paying a Wave 2 target selection fee of $15.0&nbsp;million or $30.0&nbsp;million, depending on and per the selected target. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Ionis is obligated to reimburse us for all internal costs and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs incurred in the performance of the exploratory research activities, up to an aggregate of $10.0&nbsp;million, which is payable in quarterly installments of $0.5&nbsp;million during the
exploratory research term. As of June&nbsp;30, 2023, we received a total of $1.0&nbsp;million related to the reimbursable expenses. We are also eligible to receive (a)&nbsp;up to $29.0&nbsp;million in future development milestone payments for each
licensed product; (b)&nbsp;up to $60.0&nbsp;million in future regulatory milestone payments for each licensed product; (c)&nbsp;up to $250.0&nbsp;million in sales-based milestones for each licensed product; and (d)&nbsp;royalties on annual net sales
of licensed products from a <FONT STYLE="white-space:nowrap">mid-single-digit</FONT> to <FONT STYLE="white-space:nowrap">low-teens</FONT> percentage, subject to customary reductions. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The term of the Ionis Agreement will continue (i)&nbsp;with respect to the drug discovery programs, until the expiration of all applicable royalty terms for a licensed
product, (ii)&nbsp;with respect to the <FONT STYLE="white-space:nowrap">Co-Co</FONT> Programs, until the parties cease all exploitation for the <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products that are the subject to such <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Program, and (iii)&nbsp;with respect to the Metagenomi Products, until the expiration of the royalty term for a Metagenomi Product. The royalty term ends on the latest of the following two dates: (i)&nbsp;the
expiration of (A)&nbsp;the last claim of any issued and unexpired patent, or (B)&nbsp;a claim within a patent application that has not been pending for more than seven years from the earliest date to which the claim or applicable patent application
is entitled to claim priority and which claim has not been revoked, cancelled, withdrawn, held invalid, or abandoned, or (ii)&nbsp;12 years following the first commercial sale of a licensed product. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Ionis Agreement may be terminated during the term by either party for an uncured material breach or bankruptcy by the other party. Additionally, Ionis may terminate
the Ionis Agreement for convenience and without penalty, in its entirety or on a licensed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-licensed</FONT></FONT> product basis, by providing 90 days&#146; written notice.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We concluded that the Ionis Agreement is in the scope of ASC 606 at the effective date and until we exercise our <FONT STYLE="white-space:nowrap">Co-Co</FONT>
Option for any drug discovery program, which was determined to not be probable at the effective date and as of December&nbsp;31, 2022 and June&nbsp;30, 2023. We also concluded that exclusive licenses and participation in a joint steering committee
are not distinct from discovery research services and should thus be combined into one performance obligation (the &#147;discovery program&#148;). We also concluded that exploratory research services are a separate and distinct performance
obligation (the &#147;exploratory program&#148;). As the Ionis options for Wave 2 targets are optional purchases and do not have significant incremental discounts, as such, the options do not provide material rights. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We allocated the total estimated transaction price of $90.0&nbsp;million, which consisted of an $80.0&nbsp;million upfront payment received in November 2022 and a
$10.0&nbsp;million reimbursement for research costs, into two performance obligations, and was determined based on their estimated standalone selling prices. We concluded that future development and commercial supply agreements are at market terms,
as the terms were consistent with industry standards as of the effective date. We constrain future milestone payments under the arrangement to the extent that the inclusion of such variable consideration could result in a significant reversal of
cumulative revenue in future periods. We constrained all development and regulatory milestone payments at the effective date and as of December&nbsp;31, 2022 and June&nbsp;30, 2023. We are recognizing revenue of $80.0&nbsp;million related to the
discovery program and of $10.0&nbsp;million related to exploratory program over the research terms using an estimated cost-based input method as a measure of progress for each obligation. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We recognized $0.1&nbsp;million in collaboration revenue in the consolidated statements of operations and comprehensive loss during the year ended December&nbsp;31,
2022. We recognized $8.5&nbsp;million in collaboration revenue in the condensed consolidated statements of operations and comprehensive loss during the six months ended June&nbsp;30, 2023, which was included in deferred revenue as of
December&nbsp;31, 2022. As of December&nbsp;31, 2022 and June&nbsp;30, 2023, deferred revenue related to the Ionis Agreement was $79.9&nbsp;million and $72.5&nbsp;million, respectively. The value of the transaction price allocated to the remaining
performance obligations was </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
approximately $81.4&nbsp;million as of June&nbsp;30, 2023, which we expect to recognize as revenue over the next
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">four-to-five</FONT></FONT> years. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For additional information regarding the lonis Agreement, please
see the section titled &#147;Business&#151;Our License and Collaboration Agreements.&#148; </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Amendment to the LLC Agreement </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our LLC Agreement was amended on July&nbsp;31, 2023 to provide for <FONT STYLE="white-space:nowrap">&#147;catch-up&#148;</FONT> distributions for profits interests once
the applicable <FONT STYLE="white-space:nowrap">catch-up</FONT> threshold amount for such profits interests was met (the &#147;Amendment to the LLC Agreement&#148;). </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The LLC Agreement provides each profits interest with a distribution threshold amount, which is determined on the date of issuance and represents the amount that would
be distributed if, immediately after issuance, we sold all of our assets at fair market value and distributed the net proceeds in liquidation. A profits interest does not participate in our distributions until an amount equal to its distribution
threshold amount has been distributed to our other members with units that either have a lower threshold amount or no threshold amount. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Once the applicable
distribution threshold amount has been met for a particular profits interest, such profits interest will participate in our distributions on a pro rata basis until the <FONT STYLE="white-space:nowrap">catch-up</FONT> threshold amount has been met.
Once the <FONT STYLE="white-space:nowrap">catch-up</FONT> threshold amount has been met, subsequent <FONT STYLE="white-space:nowrap">&#147;catch-up&#148;</FONT> distributions will be made solely to holders of profits interests until such holders
have received an amount equal to the amount such holders would have received had the distribution threshold not existed. Once the profits interest holders have received distributions in an amount equal to what they would have received had the
distribution threshold not existed, all subsequent distributions are made on a pro rata basis with common unitholders. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The
<FONT STYLE="white-space:nowrap">catch-up</FONT> threshold amount of $11.84 per unit reflected the estimated fair value of the our common unit as of July&nbsp;31, 2023, as determined by our board of managers, with input from management, and
considering our most recently available third-party valuation of common units. The amendment to the LLC Agreement resulted in a change to the fair value of the profits interests and will be accounted for as a modification of the profits
interests&#146; awards. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Reorganization </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We currently operate as a
Delaware limited liability company under the name Metagenomi Technologies, LLC. Prior to the completion of this offering, we intend to complete a series of transactions pursuant to which Metagenomi Technologies, LLC will merge with and into its
wholly-owned subsidiary, Metagenomi, Inc., a Delaware corporation, with Metagenomi, Inc. continuing as the surviving corporation. In connection with the Reorganization (i)&nbsp;all of the outstanding common unitholders of Metagenomi Technologies,
LLC will receive shares of common stock of Metagenomi, Inc., (ii) all of the outstanding redeemable convertible preferred unitholders of Metagenomi Technologies, LLC will receive shares of redeemable convertible preferred stock of Metagenomi, Inc.
and (iii)&nbsp;all of the outstanding holders of profits interests in Metagenomi Technologies, LLC will receive shares of common stock or restricted common stock in Metagenomi, Inc. For more information on the Reorganization, see the section titled
&#147;Reorganization&#148; included elsewhere in this prospectus. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Components of Results of Operations </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Collaboration Revenue </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have not generated any revenue from product
sales and do not expect to generate any revenue from the sale of products for the foreseeable future. Our ability to generate product revenues will depend on the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
successful development and eventual commercialization of any product candidates that we identify. If we fail to complete the development of any future product candidates in a timely manner or to
obtain regulatory approval for such product candidates, our ability to generate future revenue and our results of operations and financial position would be materially adversely affected. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To date, all of our revenue consists of collaboration revenue, earned from collaboration agreements with Moderna, Ionis and
<FONT STYLE="white-space:nowrap">Affini-T.</FONT> These agreements may include the following types of promised goods or services: (i)&nbsp;grants of licenses, (ii)&nbsp;performance of research and development services and (iii)&nbsp;participation on
joint research and/or development committees. They also may include options to obtain licenses to our intellectual property or to extend the term of the research activities. Our revenues under such collaboration agreements were $0.2&nbsp;million and
$17.2&nbsp;million for the years ended December&nbsp;31, 2021 and 2022, respectively. Our revenues under collaboration agreements were $6.7&nbsp;million and $20.0&nbsp;million for the six months ended June&nbsp;30, 2022 and 2023, respectively. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For additional information about our revenue recognition policy related to our collaboration agreements, refer to Note 2 in our audited consolidated financial statements
included elsewhere in this prospectus. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Operating Expenses </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our
operating expenses consist of (i)&nbsp;research and development expenses and (ii)&nbsp;general and administrative expenses. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Research and Development </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The largest component of our total operating expenses since our inception has been research and development activities. Research and development expenses consist
primarily of compensation and benefits for research and development employees, including unit-based&nbsp;compensation; the costs of acquiring research and development supplies and services; manufacturing process development costs; the research and
development expenses that we share with our collaboration partners for <FONT STYLE="white-space:nowrap">co-development</FONT> programs; other outside services and consulting costs; and allocated facilities, information technology and overhead
expenses. Research and development costs are expensed as&nbsp;incurred. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have not reported program costs since our inception because we have not historically
tracked or recorded our research and development expenses on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">a&nbsp;program-by-program&nbsp;basis.</FONT></FONT> We use our personnel and infrastructure resources across the breadth
of our research and development activities, which are directed toward developing our platform. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We expect our research and development expenses to increase
substantially for the foreseeable future as we continue to invest in research and development activities related to developing our platform, including investments in manufacturing, as we advance our programs and conduct clinical trials. The process
of conducting the necessary clinical research to obtain regulatory approval is costly and time-consuming, and the successful development of our platform is highly uncertain. As a result, we are unable to determine the duration and completion costs
of our research and development projects, the costs of related clinical development costs or when and to what extent we will generate revenue from the commercialization of our platform. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>General and Administrative </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">General and administrative expenses consist
primarily of personnel costs, including unit-based compensation expense and other expenses for outside professional services, including legal fees relating to intellectual </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
property and corporate matters; professional fees for accounting, auditing, consulting and tax services; insurance costs; administrative travel expenses; website development costs; marketing and
public relations costs; and facilities, information technology and other allocated overhead costs. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We anticipate that our general and administrative expenses will
increase in the future as we increase our headcount to support development of our platform and our continued research activities. We also anticipate that we will incur increased accounting, audit, legal, regulatory, compliance and director and
officer insurance costs as well as investor and public relations expenses associated with being a public company. We also expect our intellectual property expenses to increase as we expand our intellectual property portfolio. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Total Other Income, Net </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Total other income, net includes interest
income from our investments in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities, grant income, change in fair value of our investments in the
<FONT STYLE="white-space:nowrap">Affini-T</FONT> convertible note, preferred stock and common stock shares related to our investment in Affini-T, interest expense on the Moderna convertible note issued in November 2021, which was converted into
redeemable convertible preferred units in January 2022. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Provision for Income Taxes </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Metagenomi Technologies, LLC is taxed under the provisions of Subchapter K &#151; Partners and Partnerships of the Internal Revenue Code. Under those provisions,
Metagenomi Technologies, LLC does not pay federal or state corporate income taxes on its taxable income. Instead, each member includes net operating income or loss for Metagenomi on its individual return. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The wholly owned subsidiary of Metagenomi Technologies, LLC, Metagenomi Inc., is a corporation for tax purposes and is subject to income taxes. We recognized income tax
expense for the year ended December&nbsp;31, 2022 and for the six months ended June&nbsp;30, 2022 and 2023 for domestic federal and state income taxes. After giving effect to this offering, Metagenomi, Inc. will continue as the surviving
corporation. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of December&nbsp;31, 2022, we had net operating loss carryforwards of $0.02&nbsp;million and $8.3&nbsp;million for federal and state income tax
purposes, respectively, available to reduce future taxable income, if any. The federal net operating loss carryforwards do not expire. State net operating loss carryforwards begin expiring in 2037. As of December&nbsp;31, 2022, we had state research
and development credit carryforwards of $2.8&nbsp;million, which do not expire. As of December&nbsp;31, 2022, we had no federal research and development credit carryforwards. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A valuation allowance is provided for deferred tax assets where the recoverability of the assets is uncertain. The determination to provide a valuation allowance is
dependent upon the assessment of whether it is more likely than not that sufficient future taxable income will be generated to utilize the deferred tax assets. Based on the weight of the available evidence, which includes our consolidated
entities&#146; historical operating losses and forecast of future losses, we have provided a full valuation allowance against the deferred tax assets resulting from the tax loss and credits carried forward. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Utilization of the net operating loss and credit carryforwards may be subject to a substantial annual limitation due to an ownership change limitation as provided by
section 382 of the Internal Revenue Code, as amended, and similar state provisions. The annual limitation may result in the expiration of net operating losses and credits before utilization. In the event that we have a change of ownership,
utilization of the net operating loss and tax credit carryforwards may be restricted. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Results of Operations </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Comparison of the Six Months Ended June&nbsp;30, 2022 and 2023 </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The
following table summarizes our results of operations for the six months ended June&nbsp;30, 2022 and 2023 (in thousands): </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Six Months ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>$</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,692</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,302</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,834</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,084</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,895</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,997</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,901</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,904</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(98</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,559</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Change in fair value of long-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,776</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(82</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss before provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,493</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,046</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,553</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,092</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,095</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,003</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,585</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(29,141</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,556</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Collaboration Revenue </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our
revenue consists of collaboration revenue recognized under our agreements with Moderna, <FONT STYLE="white-space:nowrap">Affini-T</FONT> and Ionis. We recognize revenue as the performance obligations are satisfied. Collaboration revenue increased by
$13.3&nbsp;million, from $6.7&nbsp;million for the six months ended June&nbsp;30, 2022 to $20.0&nbsp;million for the six months ended June&nbsp;30, 2023. The increase in collaboration revenue for the six months ended June&nbsp;30, 2023, was
primarily driven by an increase in revenue of $11.1&nbsp;million related to <FONT STYLE="white-space:nowrap">Affini-T</FONT> and Ionis agreements, which we entered in June 2022 and November 2022, respectively. We did not recognize revenue under
these agreements during the six months ended June&nbsp;30, 2022. Collaboration revenue related to the Moderna Agreement increased by $2.2&nbsp;million for the six months ended June&nbsp;30, 2023 compared to the six months ended June&nbsp;30, 2022,
as we performed more services and our collaboration activities progressed. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The collaboration revenue for the six months ended June&nbsp;30, 2022 and 2023 included
the following (in thousands): </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Six Months ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>$</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Moderna</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,692</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><FONT STYLE="white-space:nowrap">Affini-T</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Ionis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,692</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,302</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes our research and development expenses for the periods indicated (in thousands): </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Six Months ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>$</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Personnel-related costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,865</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,091</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Laboratory materials and supplies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Facilities and overhead costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,780</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,048</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other research and development expenses and consulting costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,364</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">42,811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Research and development expenses increased by $26.0&nbsp;million, from $16.9&nbsp;million for the six months ended
June&nbsp;30, 2022 to $42.8&nbsp;million for the six months ended June&nbsp;30, 2023. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Personnel-related costs, including employee payroll and related expenses,
increased by $8.1&nbsp;million, including a $0.3&nbsp;million increase in unit-based compensation expense, as a result of increased headcount in our research and development organization. Laboratory materials and supplies increased by
$4.2&nbsp;million due to significant expansion of our research and development operations. Facilities and allocated overhead costs, including rent and facilities, depreciation and amortization, repairs and maintenance and information
technology-related expenses allocated to research and development increased by $7.3&nbsp;million, including a $3.8&nbsp;million increase in rent and facilities expenses as we entered into a new lease agreement in November 2022 that commenced in
January 2023, and a $1.3&nbsp;million increase in depreciation and amortization expense as we continue investing in our manufacturing facility. Other research and development and consulting costs increased by $6.4&nbsp;million mainly due to external
research and development costs of $4.4&nbsp;million and consulting services of $1.1&nbsp;million to support our research and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> development activities. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Other research and development and consulting costs include expenses related to the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> program under the Moderna Agreement.
Each quarter, a <FONT STYLE="white-space:nowrap">true-up</FONT> is performed to calculate how much is owed by us or Moderna to equally split the costs incurred during the quarter towards the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> program.
When Moderna owes a payment to us, we account for this as a reduction of research and development expense. When we owe a payment to Moderna, we account for this as an addition to research and development expense. For the six months ended
June&nbsp;30, 2022 and 2023, the total cost <FONT STYLE="white-space:nowrap">true-ups</FONT> reduced our research and development expenses by less than $0.1&nbsp;million and $0.4&nbsp;million, respectively. Additionally, we amortized
$1.7&nbsp;million and $0.4&nbsp;million of the upfront $5.0&nbsp;million payment received from Moderna allocated to the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> program to offset our share of the DT
<FONT STYLE="white-space:nowrap">Co-Co</FONT> development costs for the six months ended June&nbsp;30, 2022 and 2023, respectively. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>General and
Administrative Expenses </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">General and administrative expenses increased by $5.3&nbsp;million, from $7.8&nbsp;million for the six months ended June&nbsp;30,
2022 to $13.1&nbsp;million for the six months ended June&nbsp;30, 2023, as we continued expanding our operations to support our business strategy and the development of therapeutic programs utilizing our metagenomics platform. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Employee payroll and related expenses increased by $2.2&nbsp;million, including a $0.2&nbsp;million increase in unit-based compensation expense, as a result of increase
in headcount of our executives and administrative personnel. Expenses related to professional consulting services increased by $3.1&nbsp;million due to increased spending on consulting and outside services to support our growing operations. Other
general and administrative expenses, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
including insurance, information technology, office supplies, subscriptions and licenses and other miscellaneous expenses, increased by less than $0.1&nbsp;million. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Total Other Income, Net </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Total other income, net, increased by
$10.4&nbsp;million, from $0.5&nbsp;million for the six months ended June&nbsp;30, 2022 to $10.9&nbsp;million for the six months ended June&nbsp;30, 2023. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Interest
income, which includes interest income and amortization of premiums and discounts on our investments in <FONT STYLE="white-space:nowrap">available-for</FONT> sale marketable securities, increased by $7.6&nbsp;million from $0.4&nbsp;million for the
six months ended June&nbsp;30, 2022 to $8.0&nbsp;million for the six months ended June&nbsp;30, 2023, due to increased investment activity and higher interest rates during the six months ended June&nbsp;30, 2023. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The change in fair value of long-term investments increased by $2.8&nbsp;million, from $0.1&nbsp;million for the six months ended June&nbsp;30, 2022 to $2.9&nbsp;million
for the six months ended June&nbsp;30, 2023, as our investment in <FONT STYLE="white-space:nowrap">Affini-T</FONT> was <FONT STYLE="white-space:nowrap">re-measured</FONT> at fair value. For more details on our investment in <FONT
STYLE="white-space:nowrap">Affini-T,</FONT> refer to Note 5 in our unaudited condensed consolidated financial statements included elsewhere in this prospectus. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Provision for Income Taxes </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We recognized an income tax provision as a
result of our taxable income related to upfront payments received under the Moderna and Ionis agreements and the change in the net capitalization of our research and development expenses under the newly enacted Internal Revenue Code Section&nbsp;174
(&#147;Section&nbsp;174&#148;), which became effective on January&nbsp;1, 2022. Section&nbsp;174 changed the tax treatment of research and experimentation (R&amp;E) expenditures, which requires the capitalization of R&amp;E expenditures over a
period of five years for R&amp;E paid or incurred in the United States and 15 years for R&amp;E paid or incurred outside of the United States. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For the six months
ended June 30, 2022 and 2023, we recorded a provision for income taxes of $1.1 million and $4.1 million by applying the estimated annual effective tax rate to the year-to-date measure of ordinary income, respectively. The increase in the income tax
provision during the six months ended June 30, 2023 is primarily due to the higher forecasted research and development spend, which results in corresponding increases to Section 174 capitalization and taxable income for the year. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Comparison of the Years Ended December&nbsp;31, 2021 and 2022 </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes our results of operations for the years ended December&nbsp;31, 2021 and 2022 (in thousands): </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Years ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>$</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,661</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,701</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,989</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,947</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(44,640</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,693</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(302</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(98</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Change in fair value of long-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,666</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,505</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,616</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss before provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,442</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(41,024</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,582</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,569</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,569</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(21,442</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(43,593</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(22,151</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Collaboration Revenue </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our
revenue consists of collaboration revenue recognized under our agreements with Moderna, <FONT STYLE="white-space:nowrap">Affini-T</FONT> and Ionis. We recognize revenue as the performance obligations are satisfied. Collaboration revenue increased by
$17.0&nbsp;million, from $0.2&nbsp;million for the year ended December&nbsp;31, 2021 to $17.2&nbsp;million for the year ended December&nbsp;31, 2022. The increase in collaboration revenue for the year ended December&nbsp;31, 2022, was primarily
driven by a $14.3&nbsp;million increase in revenue related to the Moderna Agreement as our research and collaboration activities progressed and a $2.7&nbsp;million increase related to the <FONT STYLE="white-space:nowrap">Affini-T</FONT> and Ionis
agreements, which we entered into in June and November 2022, respectively. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The collaboration revenue for the years ended December&nbsp;31, 2021 and 2022 included
the following: </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Years ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>$</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Moderna</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><FONT STYLE="white-space:nowrap">Affini-T</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Ionis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes our research and development expenses for the periods indicated (in thousands): </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Years ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>$</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Personnel-related costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,436</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Laboratory materials and supplies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,004</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Facilities and overhead costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other research and development expenses and consulting costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,977</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,661</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Research and development expenses increased by $28.7&nbsp;million, from $14.5&nbsp;million for the year ended December&nbsp;31,
2021 to $43.1&nbsp;million for the year ended December&nbsp;31, 2022. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Personnel-related costs, including employee payroll and related expenses, increased by
$15.5&nbsp;million, including a $0.7&nbsp;million increase in unit-based compensation expense, as a result of increased headcount in our research and development organization. Laboratory materials and supplies increased by $7.0&nbsp;million due to
significant expansion of our research and development operations. Facilities and allocated overhead, including rent, repairs and maintenance costs, common facilities and information technology related expenses allocated to research and development
increased by $4.2&nbsp;million as a result of the expansion of our business operations. Other research and development and consulting costs increased by $2.0&nbsp;million due to increases in external consulting services to support our research and <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> development activities. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Other research and development and consulting costs include expenses related to the DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> program under our collaboration agreement with Moderna. Each quarter, a <FONT STYLE="white-space:nowrap">true-up</FONT> is performed to calculate how much is owed by us or Moderna to equally split the costs
incurred during the quarter towards the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> program. When Moderna owes a payment to us, we account for this as a reduction of research and development expense. When we owe a payment to Moderna, we account
for this as an addition to research and development expense. For the years ended December&nbsp;31, 2021 and 2022, the total cost <FONT STYLE="white-space:nowrap">true-ups</FONT> reduced our research and development expenses by $0.2&nbsp;million and
$0.9&nbsp;million, respectively. Additionally, for the year ended December&nbsp;31, 2021, $5.0&nbsp;million of the upfront payment received under the Moderna Agreement in November 2021 was allocated to the DT
<FONT STYLE="white-space:nowrap">Co-Co</FONT> program, which was presented as a collaboration advance on our consolidated balance sheet. For&nbsp;the years ended December&nbsp;31, 2021 and 2022, $0.3&nbsp;million and $3.5&nbsp;million of this
upfront payment was amortized, respectively, to offset our share of the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> development costs. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>General and
Administrative Expenses </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">General and administrative expenses increased by $9.0&nbsp;million, from $9.7&nbsp;million for the year ended December&nbsp;31, 2021
to $18.7&nbsp;million for the year ended December&nbsp;31, 2022. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Employee payroll and related expenses increased by $3.3&nbsp;million, including a $0.7&nbsp;million
increase in unit-based compensation expense, as a result of increase in headcount of our executives and administrative personnel. Expenses related to professional consulting services increased by $4.1&nbsp;million due to increased spending on
consulting and outside services to support our growing operations. Other general and administrative expenses, including insurance, information technology, office supplies, subscriptions and licenses, and other miscellaneous expenses, increased by
$1.6&nbsp;million as we continued expanding our operations to support our business strategy and the development of therapeutic programs utilizing our metagenomics platform. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Total Other Income, Net </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Total other income, net, increased by $1.1&nbsp;million, from $2.5&nbsp;million net income for the year ended December&nbsp;31, 2021 to $3.6&nbsp;million for the year
ended December&nbsp;31, 2022. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Interest income, which includes interest income and amortization of premiums and discounts on our investment in <FONT
STYLE="white-space:nowrap">available-for</FONT> sale marketable securities, increased by $3.4&nbsp;million from $0.04&nbsp;million for the year ended December&nbsp;31, 2021 to $3.4&nbsp;million for the year ended December&nbsp;31, 2022, due to
increased investment activity and higher interest rates during the year ended December&nbsp;31, 2022. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The change in fair value of long-term investments decreased by
$2.7&nbsp;million, from $2.8&nbsp;million for the year ended December&nbsp;31, 2021 to $0.1&nbsp;million for the year ended December&nbsp;31, 2022, as our investment in the <FONT STYLE="white-space:nowrap">Affini-T</FONT> convertible promissory note
was <FONT STYLE="white-space:nowrap">re-measured</FONT> at fair value and converted to preferred stock shares of <FONT STYLE="white-space:nowrap">Affini-T</FONT> in March 2022. For more details on our investment in the
<FONT STYLE="white-space:nowrap">Affini-T</FONT> convertible promissory note, refer to Note 5 in our audited consolidated financial statements included elsewhere in this prospectus. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Provision for Income Taxes </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We recognized an income tax provision of
$2.6&nbsp;million for the year ended December&nbsp;31, 2022 as a result of our taxable income related to an upfront payment received under the Moderna Agreement and the change in the net capitalization of our research and development expenses under
the newly enacted Internal Revenue Code Section&nbsp;174 (&#147;Section&nbsp;174&#148;), which became effective on January&nbsp;1, 2022. Section&nbsp;174 changed the tax treatment of research and experimentation (R&amp;E) expenditures, which
requires the capitalization of R&amp;E expenditures over a period of five years for R&amp;E paid or incurred in the United States and 15 years for R&amp;E paid or incurred outside of the United States. We did not recognize income taxes for the year
ended December&nbsp;31, 2021. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Sources of Liquidity </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Since our inception, we have incurred significant
operating losses. We have historically funded our operations primarily through sales of our redeemable convertible preferred units and convertible promissory notes, which generated approximately $351.6&nbsp;million in aggregate gross proceeds.
Additionally, through June&nbsp;30, 2023, we received approximately $120.0&nbsp;million upfront cash payments from collaboration and licensing agreements. As of June&nbsp;30, 2023, we had $318.4&nbsp;million in cash, cash equivalents and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Future Funding Requirements </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance the development of our platform. In addition, upon
the completion of this offering, we expect to incur additional costs associated with operating as a public company. The timing and amount of our operating expenditures will depend largely on: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the timing and progress of research and development, preclinical&nbsp;and clinical development activities;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the number, scope and duration of clinical trials required for regulatory approval of our future product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs, timing, and outcome of regulatory review of any of our future product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs of manufacturing clinical and commercial supplies of our future product candidates; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">118 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and
distribution, for any of our future product candidates for which we receive regulatory approval; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the cost of filing and prosecuting our patent applications, and maintaining and enforcing our patents and other
intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to maintain existing, and establish new, strategic collaborations, licensing or other arrangements, and the
financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any product liability or other lawsuits related to our future product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our implementation of various computerized informational systems and efforts to enhance operational systems;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">expenses incurred to attract, hire and retain skilled personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs of operating as a public company; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to establish a commercially viable pricing structure and obtain approval for coverage and adequate
reimbursement from third-party and government payers; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the extent to which we acquire or invest in businesses, products, and technologies. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the effect of competing technological and market developments; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, as well as other factors, including inflation,
economic uncertainty and geopolitical tensions, which may exacerbate the magnitude of the factors discussed above. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of June&nbsp;30, 2023, we
had $318.4&nbsp;million in cash, cash equivalents and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities. We believe that our existing cash, cash equivalents and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities will be sufficient to fund our current operating plan for at least the next 12 months. Based on our current operating plan, we
estimate that our existing cash, cash equivalents and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities, together with the estimated net proceeds from this offering, will be
sufficient to fund our projected operating expenses and capital expenditure requirements into &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We have based this estimate on assumptions that may prove
to be wrong, and we could exhaust our available capital resources sooner than we expect. We expect that we will require additional funding to: continue our current research development activities; develop, maintain, expand and protect our
intellectual property portfolio; further develop our platform; and hire additional research, clinical and scientific personnel. If we receive regulatory approval for any of our product candidates, we expect to incur significant commercialization
expenses related to product manufacturing, sales, marketing and distribution, depending on where we choose to commercialize our products. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Until such time, if ever,
as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances, and marketing, distribution or licensing arrangements with third
parties. To the extent that we raise additional capital through the sale of equity or convertible debt securities, ownership interest for existing investors may be materially diluted, and the terms of such securities could include liquidation or
other preferences that adversely affect existing investors&#146; rights as a stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include restrictive covenants that limit our ability to take specified
actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to
relinquish valuable rights to our technologies, future revenue streams, research programs or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we
may be required to delay, reduce or eliminate our product development or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Cash Flows </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes our sources and uses of
cash for the periods presented (in thousands): </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Years ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Six Months ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net cash provided by (used in) operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,724</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,067</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(47,087</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(74,316</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(122,200</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(67,128</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(90,787</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">239,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net (decrease) increase in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,137</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">147,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">54,109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(133,618</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Cash Flows from Operating Activities </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Net cash used in operating activities for the six months ended June&nbsp;30, 2022 was $23.1&nbsp;million. This is primarily due to our net loss for the period of
$18.6&nbsp;million, decreased by net <FONT STYLE="white-space:nowrap">non-cash</FONT> charges of $2.5&nbsp;million and increased by a net reduction of $7.0&nbsp;million in our net operating assets and liabilities. The net <FONT
STYLE="white-space:nowrap">non-cash</FONT> charges primarily consisted of $0.9&nbsp;million in unit-based compensation expense, a $0.6&nbsp;million <FONT STYLE="white-space:nowrap">non-cash</FONT> lease expense and $0.5&nbsp;million in depreciation
and amortization expense. The net change in our operating assets and liabilities primarily consisted of a $8.1&nbsp;million decrease in deferred revenue and collaboration advances as we recognized collaboration revenue under the Moderna agreement, a
$0.8&nbsp;million increase in prepaid expenses and other current assets, partially offset by a $0.7&nbsp;million increase in income tax payable, a $0.5&nbsp;million increase in accounts payable due to the timing of payments to our vendors, a
$0.5&nbsp;million increase in accrued expenses and other current liabilities. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Net cash used in operating activities for the six months ended June&nbsp;30, 2023 was
$47.1&nbsp;million. This was primarily due to our net loss of $29.1&nbsp;million, increased by net <FONT STYLE="white-space:nowrap">non-cash</FONT> income of $2.8&nbsp;million and increased by a net reduction of $15.1&nbsp;million in our net
operating assets and liabilities. The net <FONT STYLE="white-space:nowrap">non-cash</FONT> charges consisted of a $4.5&nbsp;million credit related to amortization of the discounts on
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities, $2.9&nbsp;million for the change in fair value of our investments in <FONT STYLE="white-space:nowrap">Affini-T</FONT> and
$0.5&nbsp;million in amortization of <FONT STYLE="white-space:nowrap">non-cash</FONT> collaboration revenue related to the <FONT STYLE="white-space:nowrap">Affini-T</FONT> Agreement, all partially offset by $2.0&nbsp;million <FONT
STYLE="white-space:nowrap">non-cash</FONT> lease expense, $1.9&nbsp;million in depreciation and amortization expense and $1.2&nbsp;million in unit-based compensation expense. The net change in our operating assets and liabilities primarily consisted
of a $16.2&nbsp;million decrease in deferred revenue and collaboration advances as we recognized revenue under our collaboration agreements, and a $2.3&nbsp;million increase in accounts receivable related to the
<FONT STYLE="white-space:nowrap">Affini-T</FONT> Agreement, a $0.7&nbsp;million decrease in operating lease liabilities due to recurring payments under the existing lease agreements, all partially offset by a $1.3&nbsp;million decrease in contract
assets related to the <FONT STYLE="white-space:nowrap">Affini-T</FONT> Agreement, a&nbsp;$1.2&nbsp;million increase in income tax payable due to additional tax expense and the timing of tax payments, a $0.9&nbsp;million increase in accounts payable
due to the timing of payments to our vendors and a $0.7&nbsp;million increase in other <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Net cash
provided by operating activities for the year ended December&nbsp;31, 2021 was $24.3&nbsp;million. This is primarily due to our net loss for the period of $21.4&nbsp;million adjusted by net <FONT STYLE="white-space:nowrap">non-cash</FONT> charges of
$0.6&nbsp;million </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
and a net change of $46.3&nbsp;million in our net operating assets and liabilities. The <FONT STYLE="white-space:nowrap">non-cash</FONT> charges primarily consisted of $2.8&nbsp;million for the
change in fair value of our investment in the <FONT STYLE="white-space:nowrap">Affini-T</FONT> convertible note and $0.9&nbsp;million for <FONT STYLE="white-space:nowrap">non-cash</FONT> lease expense. The changes in our net operating assets and
liabilities primarily consisted of a $44.2&nbsp;million increase in deferred revenue primarily due to the receipt of an upfront payment under the Moderna Agreement, a $1.9&nbsp;million increase in accrued expenses and other current liabilities and a
$0.7&nbsp;million increase in accounts payable, partially offset by a $0.5&nbsp;million increase in prepaid expenses and other current assets. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Net cash provided by
operating activities for the year ended December&nbsp;31, 2022 was $29.7&nbsp;million. This was primarily due to our net loss of $43.6&nbsp;million, adjusted by net <FONT STYLE="white-space:nowrap">non-cash</FONT> charges of $3.8&nbsp;million and a
net change of $69.5&nbsp;million in our net operating assets and liabilities. The <FONT STYLE="white-space:nowrap">non-cash</FONT> charges primarily consisted of $2.0&nbsp;million of unit-based compensation expense, $1.7&nbsp;million of depreciation
expense and $1.3&nbsp;million for <FONT STYLE="white-space:nowrap">non-cash</FONT> lease expense, reduced by $1.1&nbsp;million for the amortization of the discount on our investment in
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities. The changes in our net operating assets and liabilities primarily consisted of a $65.7&nbsp;million increase in deferred
revenue primarily due to the receipt of an upfront payment under the Ionis Agreement, a $4.5&nbsp;million increase in accrued expenses and other current liabilities, a $1.5&nbsp;million increase in income tax payable and a $1.0&nbsp;million increase
in other <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities, partially offset by an increase of $2.5&nbsp;million in prepaid expenses and other current assets and an increase of $1.3&nbsp;million in contract assets. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Cash Flows from Investing Activities </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Net cash used in investing activities
for the six months ended June&nbsp;30, 2022 was $67.1&nbsp;million, which consisted of $88.5&nbsp;million of purchases of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities and
$7.2&nbsp;million of purchases of property and equipment, both partially offset by $28.5&nbsp;million in proceeds from maturities and sales of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT>
marketable securities. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Net cash used in investing activities for the six months ended June&nbsp;30, 2023 was $90.8&nbsp;million, which consisted of
$169.0&nbsp;million of purchases of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities and $5.8&nbsp;million of purchases of property and equipment, both partially offset by
$84.0&nbsp;million in proceeds from maturities and sales of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Net cash used in investing activities for the year ended December&nbsp;31, 2021 was $74.3&nbsp;million, which consisted of $69.3&nbsp;million of purchases of <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities, $2.9&nbsp;million of purchases of property and equipment and $2.2&nbsp;million investment in preferred stock of ViTToria
Biotherapeutics, Inc. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Net cash used in investing activities for the year ended December&nbsp;31, 2022 was $122.2&nbsp;million, which consisted of
$214.9&nbsp;million of purchases of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities, $14.0&nbsp;million of purchases of property and equipment, partially offset by
$106.6&nbsp;million in proceeds from maturities and sales of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Cash Flows from Financing Activities </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Net cash provided by financing
activities for the six months ended June&nbsp;30, 2022 was $144.3&nbsp;million, which consisted of net cash proceeds received from the issuance of Series B redeemable convertible preferred units. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Net cash provided by financing activities for the six months ended June&nbsp;30, 2023 was $4.3&nbsp;million, which primarily consisted of net cash proceeds from the
issuance of Series <FONT STYLE="white-space:nowrap">B-1</FONT> redeemable convertible preferred units. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">121 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Net cash provided by financing activities for the year ended December&nbsp;31, 2021 was $39.9&nbsp;million, which
consisted of $30.0&nbsp;million net cash proceeds received from the issuance of a convertible note and $9.9&nbsp;million net cash proceeds from our issuance of Series <FONT STYLE="white-space:nowrap">A-5</FONT> preferred units. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Net cash provided by financing activities for the year ended December&nbsp;31, 2022 was $239.6&nbsp;million, which consisted of net cash proceeds from our issuance of
Series B and Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred units. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Contractual Obligations and Commitments </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Leases </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of December&nbsp;31, 2022, our future remaining operating lease
payments were $3.3&nbsp;million within the next twelve months and $23.9&nbsp;million for the remainder of the leases&#146; terms, with respect to leases already commenced as of such date. In addition, we entered into a lease in November 2022 with a
lease commencement date in January 2023, for which we are obligated to make lease payments of $2.9&nbsp;million in the next twelve months and $46.2&nbsp;million through March 2031. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of June&nbsp;30, 2023, we leased our office and laboratory space under three lease agreements with a weighted-average remaining lease term of 7.6 years. Remaining
lease obligations under our <FONT STYLE="white-space:nowrap">non-cancellable</FONT> leases were $73.9&nbsp;million as of June&nbsp;30, 2023, including $3.2&nbsp;million payable through December&nbsp;31, 2023 and $70.7&nbsp;million for the reminder
of the leases&#146; terms. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Refer to Note 10 in our audited consolidated financial statements and Note 8 in our unaudited condensed consolidated financial statements
included elsewhere in this prospectus for more information on our lease obligations. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Recently Issued Accounting Pronouncements </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A description of recently issued accounting pronouncements that may potentially impact our financial position, results of operations or cash flows is disclosed in Note 2
to our consolidated financial statements included elsewhere in this prospectus. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Critical Accounting Policies and Significant Judgments and Estimates </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our management&#146;s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in
accordance with generally accepted accounting principles (&#147;GAAP&#148;). The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of
contingent assets and liabilities at the date of the financial statements, as well as the reported expenses incurred during the reporting periods. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On an ongoing
basis, we evaluate our estimates and judgments, including but not limited to those related to revenue recognition under our collaboration agreements, accrued research and development costs, the fair value of common units and unit-based compensation
expense, the valuation of deferred tax assets, and uncertain income tax positions. These estimates and assumptions are monitored and analyzed by us for changes in facts and circumstances, and material changes in these estimates and assumptions could
occur in the future. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of
assets and liabilities that are not readily apparent from other sources. Changes in estimates are reflected in reported results for the period in which they become known. Actual results may differ from these estimates under different assumptions or
conditions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">122 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">While our significant accounting policies are described in more detail in Note&nbsp;2 to our audited consolidated
financial statements and unaudited condensed consolidated financial statements included elsewhere in this prospectus, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of
our financial statements. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Collaboration Arrangements and Revenue Recognition </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We apply judgment to determine whether a collaboration agreement is within the scope of revenue recognition, Accounting Standard Codification Topic 606, <I>Revenue from
Contract with Customers</I>, or other accounting guidance at the effective date and throughout the term of the agreement. We perform the following five steps in determining the appropriate amount of revenue to be recognized as we fulfill our
obligations under each of these agreements: 1) identification of the promised goods and services in the contract; 2) determination of whether the promised goods or services are performance obligations including whether they are distinct in the
context of the contract; 3) measurement of the transaction price, including any constraint on variable consideration; 4) allocation of the transaction price to the performance obligations; and 5) recognition of revenue when, or as, we satisfy each
performance obligation. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Promises in collaboration agreements may include (i)&nbsp;grants of licenses, (ii)&nbsp;performance of research and development services,
and (iii)&nbsp;participation on joint research and/or development committees. They also may include options to obtain licenses to our intellectual property or to extend the term of the research activities. We assess whether each promise is a
distinct performance obligation and should be accounted for separately or should be combined with other promises into one performance obligation. Judgment is required to determine whether the license to intellectual property is distinct from the
research and development services or participation on steering committees. The event-based milestone payments, royalties and cost reimbursements represent variable consideration. We evaluate the probability that the event-based milestones will be
achieved and estimates the amount to be included in the transaction price using the most likely amount method. We include cost reimbursement in the transaction price using the expected value method. Unlike other contingency payments, sales-based
milestones and royalties are not included in the transaction price based on estimates at the inception of the contract, but rather, are included when sales or usage occur. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To estimate the transaction price, we include upfront payment and variable consideration, such as research and development milestones, reimbursement for our services,
that is subject to a constraint. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur and when the
uncertainty associated with the variable consideration is subsequently resolved. These estimates are <FONT STYLE="white-space:nowrap">re-assessed</FONT> each reporting period as required. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">After we estimate the transaction price, we allocate it to the identified performance obligations based on the standalone selling price (&#147;SSP&#148;) of each
distinct performance obligation. Judgment is required to determine the SSP. In instances where the SSP is not directly observable, such as when a license or service is not sold separately, the SSP is determined using information that may include
market conditions and other observable inputs. When licenses are combined with other promises, we utilize our judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied
over time or at a point in time. If we conclude over time, we recognize revenue based on the measure of progress using an estimated cost-based input method each reporting period. In applying the cost-based input method, we measure actual costs
incurred relative to budgeted costs to fulfill our performance obligation.&nbsp;These budgeted costs consist of our employee full-time equivalent hours plus allowable external (third-party) costs incurred. Management applies considerable judgment in
estimating expected costs as such costs are key inputs when applying the cost-based input method. We recognize revenue based on actual costs incurred as a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">123 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
percentage of total budgeted costs as we complete a performance obligation applied to the transaction price. A significant change in the estimate of expected costs for the remainder of a contract
term could have a material impact on revenue recognized, including the possible reversal of previously recognized revenue, at each reporting period, as well as a related impact on contract assets and liabilities. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Accrued Research and Development Expenses </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Research and development
expenses are recognized as services are performed and as costs occur. Research and development expense accruals are estimated based on the level of services performed, progress of the work orders, including the phase or completion of events, and
contracted costs. We make significant judgments and estimates in determining the accrual balance at each reporting period. If the actual timing of the performance of services or the level of effort varies from the original estimates, we will adjust
the accrual accordingly. To date, there have been no material differences between estimates of such expenses and the amounts actually incurred. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Nonrefundable
advance payments for goods or services to be received in the future for use in research and development activities are capitalized and recorded in prepaid expenses and other current assets, and then expensed as the related goods are delivered or the
services are performed. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Unit-Based Compensation Expense </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Unit-based compensation expense related to the profits interests granted to employees, consultants and our board of managers members is measured at the grant date based
on the fair value of the profits interests. Compensation expense for those awards is recognized over the requisite service period, which is generally the vesting period. We use the straight-line method to record the expense of awards with
service-based vesting conditions. We account for forfeitures as they occur. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We use the Black-Scholes option-pricing model to determine the fair value of profits
interests. The following summarizes the inputs used: </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Common Unit Fair Value</I>&nbsp;&#151; See the subsection titled &#147;&#151;Determination of Fair Value of
Common Units&#148; below. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Expected Volatility</I><I></I>&nbsp;&#151;&nbsp;Expected volatility is estimated by studying the volatility of the prices of shares of
common stock of comparable public companies for similar terms. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Expected Term</I><I></I>&nbsp;&#151;&nbsp;Expected term represents the period that our profits
interests are expected to be outstanding and expected exit/liquidation term. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Risk-Free Interest Rate</I><I></I>&nbsp;&#151;&nbsp;The risk-free interest rate is
based on the U.S.&nbsp;Treasury <FONT STYLE="white-space:nowrap">zero-coupon</FONT> bonds issued in effect at the time of grant for periods corresponding with the expected term of the option. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Expected Dividend</I><I></I>&nbsp;&#151;&nbsp;The Black-Scholes valuation model calls for a single expected dividend yield as an input. To date, we have not declared
or paid any dividends. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We recorded unit-based compensation expense of $0.4&nbsp;million and $2.0&nbsp;million for the&nbsp;years ended December&nbsp;31, 2021 and
2022, respectively. We recorded unit-based compensation expense of $0.9&nbsp;million and $1.2&nbsp;million for the&nbsp;six months ended June&nbsp;30, 2022 and 2023, respectively. As of June&nbsp;30, 2023, there was $16.8&nbsp;million of total
unrecognized unit-based compensation expense, which we expect to recognize over a remaining weighted-average period of 3.3 years. We expect to continue to grant these awards in the future, and to the extent that we do, our unit-based compensation
expense recognized in future periods will likely increase. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">124 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The intrinsic value of all outstanding profits interests as of June&nbsp;30, 2023 was
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million based on the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the estimated midpoint of the price range set forth on the cover
page of this prospectus, of which approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million related to vested profits interests and approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million related to unvested profits
interests. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Profits Units Grants </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes
by grant date the number of profits interests granted from January 1, 2022, the per unit participating threshold amount and the estimated fair value of the common unit on each grant date: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Grant date</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Number&nbsp;of&nbsp;profits<BR>interests granted</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Threshold<BR>amount&nbsp;per&nbsp;unit</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Estimated&nbsp;fair<BR>value per<BR>common unit</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">April 25, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">941,755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">May 26, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,224,466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">July 12, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">October 28, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">519,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">March 24, 2023*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">462,460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">June 25, 2023*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">283,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">June 26, 2023*</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">1,247,193</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">7.40</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">10.26</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">*</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The fair value per common unit for grants during the 2023 fiscal year was interpolated between the valuation reports&#146; dates in connection with a retrospective fair value assessment for accounting purposes.
</TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Determination of Fair Value of Common Units </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As
there has been no public market for our common units to date, the estimated fair value of our common units has been determined by our board of managers as of the date of each award grant with input from management, considering our most recently
available third-party valuations of common unit, and our board of managers&#146; assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through
the date of the grant. These third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants&#146; Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity
Securities Issued as Compensation (&#145;the Practice Aid&#148;). </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For valuations performed prior to December&nbsp;20, 2022, in accordance with the Practice Aid, we
determined the option-pricing method (&#147;OPM&#148;) was the most appropriate method for determining the fair value of our common unit based on our stage of development and other relevant factors, which used a market approach to estimate our
enterprise value. Within the OPM framework, the backsolve method for inferring the total equity value implied by a recent financing transaction involves the construction of an allocation model that takes into account our capital structure and the
rights, preferences and privileges of each class of unit then assumes reasonable inputs for the other OPM variables (expected time to liquidity, volatility and risk-free rate). The total equity value is then iterated in the model until the model
output value for the equity class sold in a recent financing round equals the price paid in that round. The OPM is generally utilized when specific future liquidity events are difficult to forecast (i.e., the enterprise has many choices and options
available), and the enterprise&#146;s value depends on how well it follows an uncharted path through the various possible opportunities and challenges. In determining the estimated fair value of the common stock, our board of managers also
considered the fact that the stockholders could not freely trade the common stock in the public markets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">125 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
Accordingly, we applied discounts to reflect the lack of marketability of its common stock based on the weighted-average expected time to liquidity. The estimated fair value of the common stock
at each grant date reflected <FONT STYLE="white-space:nowrap">a&nbsp;non-marketability&nbsp;discount</FONT> partially based on the anticipated likelihood and timing of a future liquidity event. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For valuations performed after December&nbsp;20, 2022, in accordance with the Practice Aid, we determined the hybrid method was the most appropriate method for
determining the fair value of our common unit based on our stage of development and other relevant factors. The hybrid method is a probability-weighted expected return method (&#147;PWERM&#148;), where the equity value in one or more scenarios is
calculated using an OPM. The PWERM is a scenario-based methodology that estimates the fair value of common unit based upon an analysis of future values for the company, assuming various outcomes. The common unit value is based on the
probability-weighted present value of expected future investment returns considering each of the possible outcomes available as well as the rights of each class of members&#146; units. The future value of the common unit under each outcome is
discounted back to the valuation date at an appropriate risk-adjusted discount rate and probability weighted to arrive at an indication of value for the common unit. A discount for lack of marketability of the common unit is then applied to arrive
at an indication of value for the common unit. In addition to considering the results of independent third-party valuations, our board of managers considered various objective and subjective factors to determine the thresholds for the profits
interests as of each grant date, including: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the prices at which we sold shares of redeemable convertible preferred units and the superior rights and preferences of the
redeemable convertible preferred units relative to our common units at the time of each grant; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the progress of our research and development programs; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">milestones achieved by us; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the state of the industry and the economy; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our stage of development and commercialization and our business strategy; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">external market conditions affecting the biopharmaceutical industry and trends within the biopharmaceutical industry;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our financial position, including cash on hand, and our historical and forecasted performance and operating results;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the lack of an active public market for our common stock and our preferred stock; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the likelihood of achieving a liquidity event, such as an initial public offering (&#147;IPO&#148;), or our sale in light
of prevailing market conditions; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the analysis of IPOs and the market performance of similar companies in the biopharmaceutical industry.
</P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The assumptions underlying these valuations are highly complex and subjective and represent management&#146;s best estimates, which involved
inherent uncertainties and the application of management&#146;s judgment. As a result, if we had used significantly different assumptions or estimates, the fair value of our common unit and our unit-based compensation expense could be materially
different. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Once a public trading market for our common stock has been established in connection with the completion of this offering, it will no longer be necessary
for our board of managers to estimate the fair value of our common unit in connection with our accounting for granted profits interests and other such awards we may grant, as the fair value of our common unit or stock will be determined based on the
quoted market price of our common unit or stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">126 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Income Taxes </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We
are taxed under the provisions of Subchapter K - Partners and Partnerships of the Internal Revenue Code. Under those provisions, we do not pay federal or state corporate income taxes on our taxable income. Instead, each member includes net operating
income or loss for us on its individual tax return. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Metagenomi, Inc., our wholly-owned subsidiary, accounts for income taxes using the asset and liability method.
We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in our audited consolidated financial statements and unaudited condensed consolidated financial statements or tax returns.
Deferred tax assets and liabilities are determined based on the difference between the accounting and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. A valuation
allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets will not be realized. We assess the need for a valuation allowance against our deferred tax assets based on all
available evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies, results of recent operations, and our historical earnings experience by taxing jurisdiction. Significant
judgment is required in making this assessment. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Tax benefits related to uncertain tax positions are recognized when it is more likely than not that a tax position
will be sustained during an audit. Uncertain tax positions are recorded based upon certain recognition and measurement criteria. Significant judgment is required in making this assessment, and, therefore, we
<FONT STYLE="white-space:nowrap">re-evaluate</FONT> uncertain tax positions and consider various factors, including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, and changes
in facts or circumstances related to a tax position. We adjust the amount of the liability to reflect any subsequent changes in the relevant facts and circumstances surrounding the uncertain tax positions. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">During the periods presented we did not have, nor do we currently have, any <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements as defined in the
rules and regulations of the SEC. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Quantitative and Qualitative Disclosures About Market Risks </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Interest Rate Risk </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The primary objectives of our investment activities
are to ensure liquidity and to preserve capital. We are exposed to market risks related to changes in interest rates of our cash equivalents and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT>
marketable securities. However, due to the nature of these cash equivalents and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities, we do not believe that a hypothetical 10%
increase or decrease in interest rates during any of the periods presented would have had a material effect on our audited consolidated financial statements and unaudited condensed consolidated financial statements included elsewhere in this
prospectus. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Effects of Inflation </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Inflation generally affects us
by increasing our cost of labor and research and development costs. We do not believe that inflation had a material effect on our business, results of operations, or financial condition, or on our audited consolidated financial statements and
unaudited condensed consolidated financial statements included elsewhere in this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">127 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Emerging Growth Company Status </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We qualify as an &#147;emerging growth company,&#148; as defined in the JOBS Act. As an emerging growth company, we may take advantage of specified reduced disclosure
and other requirements that are otherwise applicable generally to public companies. These provisions include: (i)&nbsp;being permitted to present only two years of audited financial statements, in addition to any required unaudited interim financial
statements, with correspondingly reduced &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; disclosure in this prospectus; (ii)&nbsp;reduced disclosure about our executive compensation
arrangements; (iii)&nbsp;not being required to hold advisory votes on executive compensation or to obtain stockholder approval of any golden parachute arrangements not previously approved; (iv)&nbsp;an exemption from the auditor attestation
requirement in the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act of 2002; and (v)&nbsp;an exemption from compliance with the requirements of the Public Company Accounting Oversight Board regarding the
communication of critical audit matters in the auditor&#146;s report on the financial statements. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may take advantage of these exemptions for up to five years or
such earlier time that we are no longer an emerging growth company. We would cease to be an emerging growth company on the date that is the earliest of (i)&nbsp;the last day of the fiscal year in which we have total annual gross revenues of
$1.235&nbsp;billion or more; (ii)&nbsp;the last day of our fiscal year following the fifth anniversary of the date of the completion of this offering; (iii)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in nonconvertible debt
during the previous three years; or (iv)&nbsp;the date on which we are deemed to be a large accelerated filer under the rules of the SEC. We may choose to take advantage of some but not all of these exemptions. We have taken advantage of reduced
reporting requirements in this prospectus. Accordingly, the information contained herein may be different from the information you receive from other public companies in which you hold stock. Additionally, the JOBS Act provides that an emerging
growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would
otherwise apply to private companies. We have elected to avail ourselves of this exemption and, therefore, while we are an emerging growth company we will not be subject to new or revised accounting standards at the same time that they become
applicable to other public companies that are not emerging growth companies. As a result of this election, our audited consolidated financial statements and unaudited condensed consolidated financial statements may not be comparable to those of
other public companies that comply with new or revised accounting pronouncements as of public company effective dates. We may choose to early adopt any new or revised accounting standards whenever such early adoption is permitted for private
companies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">128 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc425213_12"></A>BUSINESS </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><U>Overview </U></B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are a precision genetic medicines company committed to
developing curative therapeutics for patients using our proprietary, comprehensive metagenomics-derived genome editing toolbox. Genetic diseases are caused by a diverse set of mutations that have been largely inaccessible by genome engineering
approaches to date. Genetic mutations are seen in a variety of forms, including deletions, insertions, single-base-pair changes and sequence repeats, and are found throughout the genome and across a variety of different cell types, tissues, and
organ systems. Additionally, many diseases lack a genetic origin but have the potential to be effectively and permanently addressed through genome editing. We are harnessing the power of metagenomics, the study of genetic material recovered from the
natural environment, to unlock four billion years of microbial evolution to discover and develop a suite of novel editing tools capable of correcting any type of genetic mutation found anywhere in the genome. Our comprehensive genome editing toolbox
includes programmable nucleases, base editors, and RNA and <FONT STYLE="white-space:nowrap">DNA-mediated</FONT> integration systems (including prime editing systems and clustered regularly interspaced short palindromic repeat
(&#147;CRISPR&#148;)-associated transposases (&#147;CASTs&#148;)). We believe our diverse and modular toolbox positions us to access the entire genome and select the optimal tool to unlock the full potential of genome editing for patients. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The company was founded by pioneers in the field of metagenomics, a powerful science that allows us to tap into the diversity of microbial life on this planet. The
metagenomics process starts by collecting samples from microbe-rich ecosystems ranging from simple home gardens to extreme locations such as hydrothermal vents below the ocean. We then extract the DNA from these environmental samples and deeply
sequence them to fully reconstruct the genomes of the resident microbes. Each sample may include thousands of distinct genomes from previously unknown organisms revealing novel cellular machinery that we utilize as building blocks for our editing
systems. Using high-throughput screening, artificial intelligence (&#147;AI&#148;), and proprietary algorithms, we rapidly mine through billions of novel proteins from our genome-resolved metagenomics database to create genome editing tools. To
date, we have analyzed over 380 trillion base pairs of DNA sequencing data, predicted over 6&nbsp;billion proteins, including over 150&nbsp;million CRISPR-associated (&#147;Cas&#148;) proteins, and identified over 1.4&nbsp;million CRISPRs, which we
estimate has resulted in the identification of over 20,000 novel genome editing systems. We have assembled extensive libraries of millions of nucleases, deaminases, reverse transcriptases (&#147;RTs&#148;) and over one thousand CASTs. Our platform
enables us to rapidly and effectively find, screen, and select tools with the highest targetability, specificity, and efficiency in order to develop them into genetic medicines. The iterative nature of our process, underpinned by AI, allows us to
continuously push the boundaries of innovation. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Our proprietary toolbox of editing systems </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have developed an expansive and modular toolbox of next-generation genome editing systems that will allow us to interact with the human genome in a site-specific
manner, where each tool can be matched to specific disease targets. Figure 1 summarizes our diverse and versatile toolbox of different editing capabilities with the potential to address the full spectrum of genetic diseases.<B> </B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">129 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Figure 1</B>. Our Toolbox. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g425213g12u12.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our programmable nucleases are the backbone of our broad set of genome editing tools. These novel nucleases including type II and
type V Cas nucleases, of which some are ultra-small systems that we call SMall Arginine-Rich sysTems (&#147;SMART&#148;) nucleases, have unique targeting abilities and can be programmed by guide RNAs (&#147;gRNAs&#148;) to target and cut at specific
locations in any genome sequence. Targeted genomic breaks trigger DNA repair pathways that can be used for genome editing, for example, to integrate a gene at a target site <FONT STYLE="white-space:nowrap">(knock-in)</FONT> or for gene inactivation
(knock-down). </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our toolbox contains thousands of CRISPR nucleases with diverse abilities to target different parts of the genome, allowing us to potentially select
the ideal nuclease for targeting any given gene in a site-specific manner and overcome a major limitation of first-generation CRISPR/Cas9 systems. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We also modify
our nucleases to either nick the genome (i.e., a nickase that cuts one strand of the DNA) or to simply bind to target sites (i.e., a nuclease dead variant). These capabilities (searching, cutting, nicking, and binding) can be leveraged as a chassis
by adding on additional effector enzymes to create base editors for single nucleotide changes, RNA-mediated integration systems for large integrations (&#147;Little RIGS&#148;) (prime editing with small RNA-templated genomic
replacements/corrections), and RNA-mediated integration systems for large integrations (&#147;Big RIGS&#148;) for large RNA-templated gene integrations. Using modular engineering, we match nickases with deaminases and RTs for base editing and
RNA-mediated integration systems (&#147;RIGS&#148;), respectively. Furthermore, nucleases can be engineered by swapping the search modules of the enzyme to expand the targetability of the chassis, which is critical for site-specific genomic
modifications. Given the measured targeting density of our toolbox, we believe that essentially any codon in the human genome could be addressed with our gene editing systems. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our highly active nucleases have gone through extensive preclinical evaluation for both <I>in vivo</I> and <I>ex vivo</I> applications, with demonstration of broad
potency of these systems across human primary cells, mouse, and nonhuman primate (&#147;NHP&#148;) models. Our base editors, RIGS, and CAST systems have demonstrated activity across various cell-based models. In addition to evaluating system
activity, we have undertaken detailed characterization of guide-specific on- and off-target effects. We routinely identify guides that have no or minimal verifiable <FONT STYLE="white-space:nowrap">off-target</FONT> editing, thus overcoming another
limitation of first-generation CRISPR/Cas9 systems. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">130 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition to overcoming the activity, targetability, and specificity limitations of first-generation systems, our
nuclease toolbox was designed to have broad compatibility with viral and nonviral delivery technologies. This compatibility is accomplished by having a variety of nuclease and gRNA structures, which range in terms of their size and biochemistry. For
example, small guides for some type V Cas systems streamline manufacturing for delivery by lipid nanoparticle (&#147;LNP&#148;) approaches, and SMART nickases can be used to construct base editors that are small enough to fit within the packaging
limitations of adeno-associated viruses (&#147;AAV&#148;). SpCas9, which is currently used in most base editing applications, is roughly three times the size of some of the smallest SMART nickases and cannot be efficiently packaged into a single
AAV. Combined, we believe these features will facilitate delivery of our genome editing tools to previously inaccessible tissue types and organ systems. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">While
nucleases, base editors, and prime editors can precisely address a wide variety of genomic modifications required to treat disease, the fact that many diseases are caused by a multitude of mutations across a gene means that a diverse set of editing
tools are required to fully address these patient populations. The integration of a complete and functional gene through targeted genome editing may provide a way in which every patient with a given disease could potentially be treated by a single
genetic medicine. Big RIGS and CASTs are novel genome editing systems that are under development to achieve what has been a major challenge for the genome editing field &#151; large, targeted genomic integrations. Initial preclinical readouts
conducted in mammalian cells indicate that these systems could potentially have a major impact on how diseases caused by <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">loss-of-function</FONT></FONT> mutations, the most common
cause of genetic diseases, can be addressed through genome editing. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Therapeutic translation roadmap and initial programs </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are taking a stepwise approach deploying our genome editing toolbox to develop potentially curative therapies for patients. Our lead programs are selected to both
address important diseases and to establish new standards in targetability, precision, efficiency, and scope of editing capabilities. Figure 2 summarizes the portfolio of programs that we and our partners are advancing, as we aim to match the
optimal genome editing tools for each indication. Each of these indications were chosen based on our conviction in the underlying biology, existence of validating preclinical and clinical data, availability of pharmacodynamic and translational tools
to assess early proof-of-concept, relevant value supporting outcome measures, and ongoing clinical unmet need. While we do not currently have any approved products and all of our product candidates are preclinical, our lead programs capture an
ever-growing set of translational learnings and insights that will inform and accelerate future programs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">131 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:arial"><B>Figure 2</B>. Therapeutic Translation. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g425213g42c52.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Hemophilia A&#151;novel, durable , knock-in approach for expression of Factor VIII </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Hemophilia A is the most common X-linked inherited bleeding disorder and is caused by mutations in the Factor&nbsp;VIII (&#147;FVIII&#148;) gene leading to loss of
functional FVIII protein that impacts the body&#146;s ability to form normal clots in response to injury. FVIII is normally produced in the liver within sinusoidal endothelial cells and is then secreted into the bloodstream where it acts as a
cofactor for the catalytic activation of Factor X in the clotting pathway. The lack of functional FVIII disrupts the normal clotting cascade and predisposes patients to increased risk of bleeding, either spontaneously or in response to injury or
surgery. Repeated bleeding episodes in joints or soft tissues can lead to progressive joint damage, inflammation, pain, and mobility impairment. Intracranial bleeding is of greatest concern as this can be rapidly fatal or lead to major morbidity.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The standard of care for patients with severe hemophilia A, involves lifelong repeated intravenous (&#147;IV&#148;) infusions of recombinant FVIII preparations
prophylactically and in response to bleeding events. The major limitation of this approach is fluctuating FVIII activity levels, with trough values that can still result in breakthrough microscopic and macroscopic bleeding events, particularly
within sensitive and previously damaged joints. Additionally, frequent FVIII infusions are inconvenient, which can be associated with suboptimal compliance, and in some patients result in inhibitor formation (antibodies against FVIII) that
compromise efficacy. More recently, emicizumab, a bispecific antibody, has been approved for hemophilia A in the United States. Valoctocogene roxaparvovec, the first hemophilia A gene therapy, was conditionally approved for use in Europe in August
2022 and was approved in the United States in June 2023. This genetic medicine delivers a FVIII gene construct to the liver using an AAV vector; however, longitudinal clinical data has demonstrated that FVIII levels drop over time. Importantly, AAV
gene therapy is also not a feasible treatment approach for infants or children due to the high degree of liver growth during pre-adulthood that would dilute out the episomal FVIII levels during progressive rounds of liver cell division. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Rather than provide the FVIII gene in an episomal location, which risks dilution from cell division or cell death as well as episomal transcriptional silencing, our
approach is to insert a FVIII DNA cassette into a "safe harbor location," within an intron of the albumin gene that is not expected to have deleterious effects. FVIII expression is then driven off the strength of the native albumin promoter. This
approach has previously been demonstrated in preclinical studies to lead to therapeutically relevant expression of a different clotting factor (Factor IX) with negligible impact to systemic circulating albumin levels. Our FVIII knock-in approach is
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">132 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
designed to provide stable expression and clinically relevant circulating levels of FVIII, even at low integration rates because of the strength of the albumin promoter. We have demonstrated the
feasibility of the FVIII gene knock-in approach in mice with several mouse specific guides and different FVIII DNA donor cassettes, with integration of the FVIII gene leading to FVIII mRNA expression and therapeutically relevant levels of FVIII
protein in the blood. We are finalizing donor DNA cassette optimization and performing our next set of NHP studies to demonstrate and quantify FVIII integration and protein expression. In parallel, we are manufacturing mRNA, gRNA, AAV and LNP to
support future IND enabling studies. We expect to select a final development candidate in the first half of 2024 and initiate <FONT STYLE="white-space:nowrap">IND-enabling</FONT> GLP studies thereafter. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Primary Hyperoxaluria, Type 1 (&#147;PH1&#148;)&#151;a durable knockdown of HAO1 for substrate reduction therapy </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">PH1 is a rare autosomal recessive metabolic disease arising from loss of function mutations in the alanine-glyoxylate aminotransferase (&#147;AGXT&#148;) gene that
encodes alanine glyoxylate aminotransferase. This enzyme is found in peroxisomes of the liver where it catalyzes the conversion of glyoxylate to glycine and pyruvate. Lack of functional AGXT leads to an accumulation of glyoxylate substrate, which is
then converted to oxalate and excreted in the kidney. The excess urinary oxalate forms an insoluble complex with urinary calcium that leads to the production of calcium oxalate crystal precipitates. This pathologic process results in the formation
of repeated calcium oxalate urolithiasis and nephrolithiasis, which in turn leads to obstructive uropathy, inflammation, fibrosis, tubular toxicity, and progressive loss of kidney function. PH1 is a serious disease that causes kidney failure. More
than 70% of individuals with PH1 mutations will develop end-stage renal disease, with a median age in young adulthood. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Until recently, the standard of care for
treating PH1 was primarily supportive in nature, with hydration and diuretics used to reduce urinary oxalate concentration, pyridoxine (vitamin B6) to enhance residual function of alanine glyoxylate aminotransferase catalytic activity, and
hemodialysis once renal function progressed to end stage. More recently, the standard of care has been updated to include treatment with lumasiran, a small interfering RNA (&#147;siRNA&#148;) therapeutic approved in adults and children with PH1 that
acts to reduce the levels of urinary oxalate. Using a therapeutic approach known as substrate reduction therapy, lumasiran targets mRNA from a separate gene, HAO1, that encodes glycolate oxidase (&#147;GO&#148;). Lumasiran has been generally well
tolerated in clinical studies of adults and children with PH1 but as a siRNA therapy, it requires repeat subcutaneous administration indefinitely in order to maintain its effect. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The goal of our genome editing approach is to durably knock down HAO1 resulting in stable and permanent reduction of oxalate levels to effect a lifelong benefit. We have
performed nuclease and guide screening to select an optimal nuclease and gRNA combination. Along with our partner ModernaTX, Inc. (&#147;Moderna&#148;) we have achieved preclinical proof-of-concept in an AGXT knock-out mouse which is an accepted
disease model of PH1. We are in the final stages of confirming the candidate to take into NHP studies and are scheduled to begin NHP studies in 2023 to support final development candidate selection thereafter. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Transthyretin Amyloidosis&#151;a single treatment to knockdown TTR gene expression </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Transthyretin amyloidosis is a disease of misfolded and aggregated transthyretin (&#147;TTR&#148;) protein that can deposit in tissues causing organ dysfunction,
primarily in the heart and/or peripheral nerves. The TTR protein is normally produced in the liver and circulates in a homotetramer (four copies of the same TTR protein bound together) where it serves as a carrier protein for vitamin A and
thyroxine. Certain mutations have been identified that can cause TTR homotetramers to fall apart, misfold, and aggregate into insoluble fibrils that deposit in cardiac tissue and peripheral nerves. However, more commonly, the normal aging process is
associated with an increased propensity for TTR misfolding and aggregation in the heart without any known genetic sequence variation. These distinctions lead to TTR amyloidosis being characterized as either hereditary
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">133 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
transthyretin amyloidosis (&#147;ATTRv&#148;) caused by mutations in TTR, or wild-type ATTR amyloidosis (&#147;ATTRwt&#148;). It is estimated that globally there are approximately 50,000 patients
with ATTRv and between 300,000 and 500,000 patients with ATTRwt. Among the larger ATTRwt patient population, the most common presentation is a rapidly progressive, restrictive, and hypertrophic cardiomyopathy due to progressive deposition of
insoluble TTR fibrils, which result in thickening of the myocardium and stiffening of the ventricles. These pathologic processes lead to impaired diastolic function and progressive cardiomyopathy that typically leads to progressive heart failure and
often death within three to five years from disease onset. Although cardiac manifestations are more common and severe, patients with neurologic manifestations also experience significant morbidity, loss of functionality, and impaired quality of
life. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To date, treatment options for patients with TTR amyloidosis, including those with either cardiomyopathy or polyneuropathy manifestations, consist of
efforts to stabilize the TTR tetramer with a small molecule (tafamadis), or knock down TTR levels through antisense oligonucleotides (i.e., inotersen and eplontersen which is currently under regulatory review in the U.S.) or siRNA strategies (i.e.,
patisiran and vutrisiran). Although these approaches have improved clinical outcomes for patients with TTR amyloidosis, the disease is still associated with significant morbidity and mortality and requires lifelong therapy to maintain therapeutic
benefit. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Using our novel nucleases, we aim to provide efficient TTR knockdown and halt further deposition of amyloid fibrils. Previous experience suggests a
clinical correlation between the degree of TTR knockdown and potential for benefit in familial forms of the disease, which are expected to translate similarly to wild type forms. The high degree of <I>in vivo</I> editing efficiency and specificity
of our nuclease platform suggest the potential for a single treatment to knockdown TTR gene expression and remove the requirement for life-long therapy. Along with our partner Ionis Pharmaceuticals, Inc. (&#147;Ionis&#148;), we are currently in
advanced stages of nuclease and guide selection and expect to move into NHP studies in 2024. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Further areas of therapeutic activity and interest
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In parallel with our translation efforts in our lead programs using our novel programmable nucleases to <FONT STYLE="white-space:nowrap">knock-in</FONT> or
knock-down gene expression in liver-associated targets, we are developing more complex editing systems for liver associated targets as well as moving beyond the liver. Given that our genome editing toolbox contains small editing systems designed to
be amenable to viral vector delivery, and given the progress established in targeting the central nervous system and muscle with established AAV capsids, our first extrahepatic indications will be neurodegenerative and neuromuscular diseases. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Building on our experience delivering our nucleases to the liver via LNP systems, we are extending that experience delivering novel RIGS to the liver to potentially
correct ATP7B mutations in Wilson&#146;s disease and PiZ mutations in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">alpha-1-antitrypsin</FONT></FONT> deficiency (&#147;A1AT deficiency&#148;). We are also exploring addressing A1AT
deficiency via a base editor approach given the predominant mutation involves a single base pair. Both of these liver diseases have well-defined biology, readily available translational biomarkers for early proof-of-concept, established development
pathways based on prior drug approvals, and important unmet medical needs. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Building on our experience with our novel type II and type V programmable nucleases, we
are extending that experience by working to deliver these nucleases via AAV to the central nervous system to potentially knock down genetic targets important for both spontaneous and familial amyotrophic lateral sclerosis (SOD1, ATXN2) and
Charcot-Marie-Tooth Type 1a (PMP22). In addition, we are working to address a&nbsp;series of mutations common in Duchenne Muscular Dystrophy with our programmable nucleases through exon skipping approaches. In diseases outside of the liver, we
intend to initially leverage known biology and clinical validation achieved with <FONT STYLE="white-space:nowrap">RNA-targeted</FONT> approaches like antisense and siRNA to advance more potent and definitive
<FONT STYLE="white-space:nowrap">one-time</FONT> genome editing treatments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">134 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Building on our experience with both <FONT STYLE="white-space:nowrap">knock-in</FONT> gene expression and smaller gene
corrections with RIGS, we are progressing our larger <FONT STYLE="white-space:nowrap">RNA-</FONT> and <FONT STYLE="white-space:nowrap">DNA-mediated</FONT> integration systems to potentially provide a single curative approach to cystic fibrosis. As
opposed to currently-available therapies limited to subsets of patients with individual mutations, we intend to deliver a full copy of a functional cystic fibrosis transmembrane conductance regulator (&#147;CFTR&#148;) gene. This approach can
similarly be pursued across many other diseases characterized by loss of function mutations. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><U>Our Team </U></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have assembled a world-class team that is driven by a passion to create potentially curative genetic medicines through the discovery of novel genome editing
technologies by harnessing the power of metagenomics. Key members of our executive and leadership team include: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Brian C. Thomas, Ph.D., Chief Executive Officer and Founder</B>, prior to co-founding the company, Dr. Thomas spent more
than 20&nbsp;years in academic research at UC Berkeley helping to pioneer the field of metagenomics. Dr.&nbsp;Thomas has been cited over 16,000 times and listed as an inventor in 28 patent families. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Jian Irish, Ph.D., President and Chief Operating Officer</B>, has held biopharma executive leadership roles for nearly
20 years at Kite Pharma / Gilead, Sanofi, and Amgen in drug development and global operations, and has helped launch several breakthrough medicines. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Sarah Noonberg, M.D., Ph.D., Chief Medical Officer</B>, has spent more than 20 years in translational and clinical
development leadership roles with a track record of advancing therapeutic programs from discovery to commercialization, including at Medivation and BioMarin. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Alan Brooks, Ph.D., SVP of Preclinical</B>, has worked on genetic medicines providing scientific leadership in
translational research for more than 25 years, including at Casebia Therapeutics and Bayer Healthcare. Dr.&nbsp;Brooks&#146; research has led to 20 publications and numerous patent filings. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Simon Harnest, Chief Investment Officer and SVP of Strategy</B>, has held leadership roles in corporate finance and
strategy in the life sciences sector, having raised over $1 billion in public and private capital, including leading Cellectis&#146; U.S. IPO and subsequent <FONT STYLE="white-space:nowrap">spin-out</FONT> and IPO of Calyxt. </P></TD></TR></TABLE>
 <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Christopher T. Brown, Ph.D., VP of Discovery,</B> is a former scientist at the Jillian F. Banfield laboratory at UC
Berkeley and an expert in using metagenomics to discover novel microbial systems for use in genome editing. Dr. Brown&#146;s research has resulted in over 35 publications and over 20 patent family filings. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Simren Delaney, Ph.D., LLM, VP of Legal,</B> is specialized in Intellectual Property and Patent law, having previously
worked at Wilson Sonsini Goodrich&nbsp;&amp; Rosati, and plays an instrumental role in driving the development of the company&#146;s growing IP portfolio. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Michael Conway, MBA, CPA, VP of Finance,</B> has spent nearly 20 years in finance leadership positions at life science
and technology companies, including Adamas Pharmaceuticals, InterMune, and Intel. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our company is supported by our board of directors, Scientific
Advisory Board, and a leading syndicate of investors, with more than 30&nbsp;funds supporting our Series B preferred unit and Series B-1 preferred unit financings (collectively, the &#147;Series B preferred unit financing&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">135 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><U>Our Strategy </U></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our
goal is to harness the power of our proprietary metagenomics platform to create curative genetic medicines for patients. Key components of our strategy to achieve this goal include: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Leverage our leadership position in metagenomics to continually advance and expand innovative genome editing tools.
</B>We expect to build on the diversity and versatility of our toolbox through continuous interrogation of novel microbial genomic information, identification of highly active natural enzymes, design and optimization of genome editing systems, and
continuous integration of learnings to accelerate development. In connection with these discoveries, we will continue to strenuously file and protect our intellectual property. Coupled with our trade secret protection around our discovery platform,
our broad intellectual property estate creates a significant barrier to entry. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Develop and deliver products that make precise modifications to the human genome to cure disease.</B> We focus on
disease areas with well understood disease biology, readily available translational biomarkers for early proof-of-concept, clear development pathways, and important unmet medical need. We are taking a stepwise approach deploying our genome editing
toolbox to develop potentially curative therapies for patients. Along with our development efforts using our novel programmable nucleases to knock-in or <FONT STYLE="white-space:nowrap">knock-down</FONT> gene expression in liver-associated targets,
we are leveraging our toolbox to deliver more complex editing systems to targets in and outside the liver. Our approach allows us to systematically incorporate knowledge and insights from our initial development programs, thereby accelerating
therapeutic translation across our genome editing technologies. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Build a fully integrated genome editing company. </B>Our team includes experts in discovery, preclinical and clinical
development, encompassing all major functions necessary to take a molecule from target identification through registrational clinical trials. To rapidly translate editing technologies into genetic medicines, we strategically invest in automation,
characterization, and manufacturing capabilities. This applies not only to process development and manufacturing for clinical trial materials, but also high throughput automated screening and genome sequencing, and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">state-of-the-art</FONT></FONT></FONT> characterization assays. We believe our ability to develop and characterize complex human genome editing components is essential to pursue a successful
regulatory pathway for genetic medicine development. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Expand therapeutic impact to patients through continued investment in business development and enabling partnerships.
</B>We carefully consider opportunities for business development such as collaborations and partnerships with industry leaders that have unique strengths and we may pursue additional partnership opportunities which complement our technologies, with
the objective of accelerating our programs and pushing forward our therapeutic translation efforts. Our existing partnerships with Moderna, Ionis, and Affini-T Therapeutics, Inc. (&#147;Affini-T&#148;) demonstrate our thoughtful approach to
collaborating with industry pioneers to accelerate and optimize the development of our genetic therapeutic candidates. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Maintain our entrepreneurial outlook, scientifically rigorous approach, and culture of tireless commitment to patients.
</B>We are a team of experienced drug discoverers, developers, and company builders who are united by our mission and passion to unlock the full potential of genome editing for patients with high unmet needs. We are dedicated to attracting and
retaining top talent and partnerships at the intersection of academia and industry. We are unwavering in our commitment to deliver cutting-edge technology and unlock the long-awaited, transformative potential of genome editing.
</P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Introduction to Genome Editing and Limitations with Current Approaches </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Genome editing is a new treatment modality that has the potential to revolutionize healthcare by creating permanent, <FONT STYLE="white-space:nowrap">one-time</FONT>
treatments that address disease at the genomic level. Genome editing involves the alteration of genetic material of a living organism by inserting, replacing, converting, or deleting nucleotides </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">136 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
within the DNA. Several approaches and technologies are being studied and developed in order to perform these edits, including: </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:arial"><B><I>Nuclease-based genome editing:</I></B> Several genome editing methods rely on a class of enzymes called nucleases to create double-stranded breaks
in DNA at a targeted location to cause gene inactivation, gene insertion, or alter gene splicing. Examples of nucleases include CRISPR associated nucleases, zinc finger nucleases (&#147;ZFNs&#148;), engineered meganucleases, and
transcription-activator like effector nucleases (&#147;TALENs&#148;). The discovery and characterization of a particular nuclease, Cas protein&nbsp;9 from <I>Streptococcus pyogenes</I> (&#147;SpCas9&#148;), has been leveraged to develop a number of
different therapeutic approaches. Importantly, additional novel and distinct Cas nucleases exist in nature and have the potential to be developed into tools for genome editing. When introduced at target sites in a genome sequence, genomic breaks
trigger DNA repair pathways that can be used for genome editing. If a&nbsp;DNA template is provided, the DNA repair machinery may incorporate the sequence at the site of the genomic break, resulting in a site-specific
<FONT STYLE="white-space:nowrap">knock-in.</FONT> If not, the cut will lead to the disruption of a gene sequence and subsequent knock-down of the encoded protein. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:arial"><B><I>Base editing:</I></B> Base editing is a genome editing approach that relies on using deaminases to chemically convert specific nucleotides in a
genome. Deaminases are enzymes that catalyze chemical reactions to remove an amino group. Multiple programmable nuclease platforms, such as CRISPR nucleases, have been harnessed for base editing by using the programmable nature of these enzymes to
direct deaminases to specific genomic target sites. In these cases, the nuclease activity is deactivated, thus creating a&nbsp;nicking or nuclease-dead version that does not disrupt the ability of the enzyme to be programmed to target specific
genomic sites for editing. There are two primary types of base editors: adenine base editors (&#147;ABEs&#148;) and cytosine base editors (&#147;CBEs&#148;). ABEs convert adenine-thymine base pairs to guanine-cytosine base pairs. CBEs target
cytosine-guanine and convert them to thymine-adenine. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:arial"><B><I><FONT STYLE="white-space:nowrap">RNA-mediated</FONT> integration, including prime
editing: </I></B><FONT STYLE="white-space:nowrap">RNA-mediated</FONT> integration systems (&#147;RIGS&#148;) are genome editing systems that make programmable genomic modifications that are encoded in RNA templates.<B><I> </I></B>Because the
modifications are encoded in RNA, these systems have the ability to repair diverse mutations, including insertions, deletions, and all types of point mutations. These systems rely on RTs to convert messages encoded as RNA into DNA. CRISPR systems
are used to direct RTs to genomic target sites. Some systems use a nickase to create a target-specific site that primes the activity of the RT and results in the corrected genomic sequence encoded in the RNA to be incorporated into the genome. Prime
editing can be accomplished with RIGS, as can large, targeted genomic integrations. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:arial"><B><I><FONT STYLE="white-space:nowrap">DNA-mediated</FONT>
integration, including CAST: </I></B>CASTs are a class of genome editing systems that provide directed and programmable genomic integration of large DNA templates. CASTs are naturally occurring systems that have been engineered to accomplish large
integrations for genome editing in various cell types and for therapeutic applications. The systems consist of a catalytically dead Cas effector that can be programmed by gRNAs to target a transposase to integrate large DNA cargos into specific
genomic target sites. DNA-templated integrations can be accomplished with other transposase and recombinase systems; however, these systems typically require extensive protein engineering in order to alter their targetability, or need to be used in
concert with other genome editing tools such as prime editing systems in order to incorporate targeting motifs into specific genomic sites. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There have been
significant advancements in genome editing since the seminal research that led to the discovery of CRISPR SpCas9 and its application in humans. However, there remain key limitations that must be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">137 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
addressed to unlock the full potential of genome editing. We believe the key limitations facing current genome editing platforms are: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><I>1)</I></TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I></I><B><I>First-generation technology lacks the ability and flexibility for accomplishing complex genome editing. </I></B>The majority of genome editing platforms are limited to a single genome editing approach, such
as gene insertions/deletions, single nucleotide changes, or small gene corrections. As a result, they are faced with inherent limitations including the diversity of edits in which they can employ and, as a result, an inability to address a range of
diseases. In addition, they lack the flexibility to tailor their genome editing system to a broad range of genomic targets of interest. </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><I>2)</I></TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I></I><B><I>Lack specificity and control over resulting edits. </I></B>Current genome editing platforms have a narrow armamentarium of genome editing systems and therefore limited access to systems capable of high
activity and specificity at desired target sites. This lack of control and specificity is often measured by <FONT STYLE="white-space:nowrap">&#147;off-target&#148;</FONT> edits which can pose a risk for undesirable side effects or unexpected safety
findings. </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Size of current genome editing technologies limits </I></B><B>in vivo</B><B><I> delivery methods and target organs.</I></B> First-generation SpCas9 systems are about 1,300 amino acids (&#147;aa&#148;) in length
and as such are not feasible to package into many delivery vectors such as AAV. As such, their delivery is largely limited to LNP systems, which precludes delivery to many tissues outside of the liver. </TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><I>4)</I></TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I></I><B><I>Inability to access certain sequences in the genome.</I></B> SpCas9 is only able to target DNA sequences which contain a flanking sequence of &#147;NGG&#148;, restricting the range in genetic targets it can
be programmed to locate, and subsequently limiting the ability to address certain underlying mutations that drive disease. </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><I>5)</I><I></I></TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I></I><B><I>Substantial engineering requirements. </I></B>Limited access to highly active natural nucleases and effectors drives the need for substantial modifications to make a system operate at
therapeutically-relevant levels, resulting in long lead times from discovery to candidate nomination. </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><I>6)</I></TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I></I><B><I>Narrow terms of license agreement from academic institutions. </I></B>The majority of genome editing platforms have been formed as a result of a licensing agreement for specific genome editing systems or
technology from academic institutions and are therefore limited to the confines of that technology arrangement. Alternatively, genome editing tools developed by us are built from highly novel components derived from our metagenomics database, and
thus are not subject to these constraints. </TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In order to address these broad challenges with current genome editing approaches, we have leveraged our
deep expertise with metagenomics to develop a proprietary discovery platform that is designed to continuously identify novel editing systems and optimize our expansive editing toolbox. Starting at the microbial level, our multifaceted platform
enables discovery beyond nucleases, translating highly active natural enzymes into powerful genome editing systems optimized for efficiency and specificity. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><U>Our Metagenomics Platform </U></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We believe genome editing tools with
capabilities that go beyond the current technology landscape will be required in order to treat the vast majority of genetic diseases. Our goal is to unlock the full potential of genome editing by developing tools with new capabilities using novel
cellular machinery discovered from the natural environment. Our company was founded by Brian C. Thomas and Jillian F. Banfield, pioneers in the field of metagenomics. They recognized the power that naturally evolved microbial systems could have in
revolutionizing access to enhanced genome editing technologies to create potentially highly efficacious and curative genetic medicines. Our metagenomics discovery platform is foundational to our business and therapeutic pipeline. This platform
enables us to rapidly and effectively find and engineer highly active natural enzymes sourced from nature into genome editing tools that are highly specific, efficient, and have enhanced targetability. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">138 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">CRISPR systems, having been studied for decades, are known to be ubiquitous in the microbial world. However, it was
not until the recent discovery and characterization of CRISPR-SpCas9 that it became possible to use these systems as tools for genome editing. SpCas9 is only a single representative of the CRISPR systems that exist in nature, leaving open the
potential to identify and develop new genome editing tools through continued and systematic discovery efforts. The vast majority of microbes, including bacteria, archaea, viruses, fungi, and single-celled eukaryotes, are extremely difficult, and
potentially impossible, to study using traditional laboratory methods. We aim to address the limitations of traditional laboratory methods through a process whereby microbes are recovered from the natural environment and studied based on their
genetic blueprint-their genome sequences. This approach has supported the ability to characterize the extent of CRISPR biology on the planet, and to expand beyond CRISPR to identify a vast collection of novel enzymes and other cellular machinery.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Samples from diverse climates and geographies have been used to build a metagenomic database that is continuously analyzed via high-throughput screening that
utilizes AI and proprietary algorithms to direct our discovery efforts. This continuous genome mining process generates expansive libraries of novel systems, including nucleases, deaminases, RTs, and CAST systems (together, &#147;effector
enzymes&#148;), that make up the foundational building blocks necessary to assemble a modular, novel genome editing toolbox that can be harnessed to make precise changes to the human genome to address a variety of important diseases with curative
intent. We have simultaneously developed a modular approach to engineering that involves interchanging key components in a high-speed process to translate the discovery of novel nucleases and other effector enzymes into optimized genome editing
systems with substantially reduced translation time compared with previously described systems. We estimate that our metagenomics platform and modular engineering process has resulted in the discovery of over 20,000 novel genome editing systems, to
which we are seeking coverage through our pending patent portfolio. These systems span hundreds of novel nuclease families and fuel a growing genome editing toolbox. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><U>Mining Our Natural Environment to Create an Expansive Genomics Database</U> </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We
aim to harness the power of the metagenome by using our continuous genome mining process to assemble a&nbsp;broad, diverse library of novel genome editing nucleases and other effector enzymes. This is accomplished by studying all the DNA from
microbial communities at the same time. Our mining process begins with proprietary sampling in which our scientists collect samples from diverse climates and geographies to build a database that spans broad biodiversity including, but not limited to
our local natural environments and extreme environments such as from high-altitudes, high-temperatures, and hydrothermal vents below the ocean. Samples collected in a&nbsp;natural environment may contain billions of cells representing tens of
thousands of distinct species. Every sample collected from a&nbsp;natural environment is subjected to deep DNA sequencing and bioinformatics analysis to identify and functionally analyze recovered microbial genomes for the discovery of genetic
elements of interest. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Through our metagenomics process, DNA is extracted from these environmental samples and sequenced in order to reconstruct the genomes of the
resident microbes. The process of DNA extraction and sequencing results in the fragmentation of each individual microbial genome into small sections which are blended into a&nbsp;backdrop of all other sequences present. Due to the clonal replication
of the organisms in microbial communities, multiple copies of nearly-identical genome sequences are recovered, and the overlap between these sequences provides the information needed to reconstruct the original genomes. This complex process is only
the beginning. Once reconstructed, it is necessary to predict the function of each section of the newly reconstructed genomes. Our platform has facilitated the discovery of vast sequences and functional components that, to our knowledge, have never
been published before. These novel components have resulted from the unique selective pressures that microbes face from different environments and that drive immense genomic diversification. The evolutionary process of natural selection provides
highly optimized enzymes that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">139 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
require little protein engineering. The novelty of the genomes recovered from metagenomics requires the de novo prediction of genes, proteins, <FONT STYLE="white-space:nowrap">non-coding</FONT>
RNAs, and other essential features. This is due to previously studied &#145;reference&#146; sequences not providing enough information to sufficiently guide this process. Considering that these evolutionary processes have been at work for billions
of years, there is considerable genetic diversity to mine for the development of highly-optimized genome editing tools. Our industry-leading database of novel microbial genetic sequences provides the basis for our discovery process. To date, our
continuous genome mining process has analyzed over 380 trillion base pairs of DNA sequence, an amount of data roughly equivalent to what would be required to sequence hundreds of thousands of human genomes, and resulted in the prediction of over 6
billion proteins and over 1.4&nbsp;million CRISPR loci &#150; including over 150&nbsp;million Cas proteins. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:arial"><U>Leveraging AI
and High-Throughput Screening to Identify Novel Editing Systems</U> </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To interrogate our metagenomics database, our platform combines AI, including machine learning,
and proprietary algorithms run on expansive cloud computing infrastructure to screen for novel CRISPR nucleases and other effector enzymes at high speed. The screening process consists of high-throughput sequencing that allows us to quickly analyze
large amounts of genomic data and subsequently synthesize the identified components, building blocks, into functioning CRISPR nucleases and other effector enzymes that can be interrogated biochemically and in mammalian cells. Once extensively
characterized, novel nucleases and other effector enzymes are categorized into our ever-expanding library. Through the metagenomics-driven discovery process we have characterized one of the largest known libraries of novel nucleases, which we
estimate includes 20,000 novel genome editing systems from hundreds of nuclease families. We have also assembled a robust library of other effector enzymes to design and engineer the next generation of genome editing systems that are fit for
essentially any therapeutic purpose. Our effector enzyme library includes over three million deaminases, over five&nbsp;million RTs, and thousands of CAST systems, as shown in Figure 3 below. The continuous interrogation of an ever-expanding
database of programmable nucleases and other enzyme effectors accelerates the pace of learning and insights to feedback into proprietary machine learning algorithms and further separates us from peer companies. As we continue to build upon our
metagenomic library, we expect to make additional discoveries of novel genome editing technology and expand our toolbox.</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Figure 3</B>. Our Effector Enzyme
Library. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g425213g61f03.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">140 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">From this library, we select our lead nucleases and other effector enzymes through a funnel of stringent performance
and safety criteria that involves testing in a series of cell-free, cell-based, and <I>in vivo</I> experiments. Ultimately, we prioritize editing systems that exhibit high editing efficiency and precision, and have a compact size that will optimize
their delivery. Because most systems added to our genome editing toolbox have different genomic targeting specifications, we believe that our expanding toolbox could enable us to target every base pair in the human genome. This process, highlighted
in Figure 4, helps us to identify highly active natural enzymes that require minimal engineering and optimization to translate into potentially curative genetic medicine. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Figure 4</B>. Overview of High-Throughput Screening Process. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g425213g62f04.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:arial"><U>Modular Engineering Translates Metagenomic Discoveries into Genetic Medicines</U> </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">By selecting highly active nucleases from our library, our process requires minimal optimization to develop genome editing systems. We utilize a modular engineering
approach to match lead nuclease candidates with an optimal gRNA and targeting domain in order to optimize targeting, specificity, and editing efficiency. Furthermore, additional effector enzymes can be included to modify the function of the system,
for example by adding a deaminase to a nickase variant for base editing. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This process leverages our vast library of editing systems to perform targeting domain
swaps between enzymes, substituting domains from less-active enzymes into the backbone of highly-active nucleases in order to modify their targeting ability. These chimeric enzymes provide us with unique access to high efficiency editing at gene
loci. The modular engineering process is accelerated using <I>in silico</I> screening algorithms to predict the optimal chimera. This predicative, high-speed engineering process allows us to continually iterate across each component of the genome
editing system to quickly develop an engineered system that is optimized for various therapeutic applications. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Modular engineering can be used to adjust the
targeting of high-performing systems by leveraging the diverse targeting capabilities of diverse Metagenomi nucleases. Given the measured targeting density of our toolbox, we believe that essentially any codon and ultimately every base pair in the
human genome could be addressed with our gene editing systems. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our metagenomics platform and modular engineering process has supported the discovery and development
of our broad genome editing toolbox at a rapid pace since our company&#146;s founding in 2018. Genome editing remains in the early stages of development and our platform allows us to continuously learn, iterate, and optimize our genome editing
toolbox in pursuit of curative genome editing medicines. The increasing insights </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">141 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
from our modular engineering and target domain swapping are captured and further interrogated and organized by our proprietary AI platform to accelerate the pace of future development and further
separate us from our peers. As the genetic medicine field continues to rapidly evolve, our platform positions us to be at the forefront of unlocking the full potential of genome editing through the continuous discovery of new editing systems and the
development of the next wave of genetic medicines. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">142 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><U>Our Solution: Proprietary Toolbox Derived from Our Metagenomic Approach </U></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Our Platform of Genome Editing Technologies </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Gene Edit</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="center"><B>Metagenomi&nbsp;(&#147;MG&#148;)&nbsp;Tools</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Key Attributes</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px dashed #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-BOTTOM:1px dashed #000000"><B>Type II Nucleases</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px dashed #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px dashed #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">&#149;&#8194;&#8202;Extensive targetability (Alexander et al 2023,
Lamothe et al 2023)</P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">&#149;&#8194;&#8202;Can be converted
to nickases for base editing and RIGS</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="middle"><B>Knock-down/<BR>Gene activation Knock-in /<BR>Gene&nbsp;insertion&nbsp;Exon&nbsp;skipping&nbsp;/ <BR>Gene modification</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px dashed #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-BOTTOM:1px dashed #000000"><B>Type V Nucleases</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px dashed #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px dashed #000000"> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">&#149;&#8194;&#8202;Systems with small gRNAs (Goltsman et al 2020)</P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">&#149;&#8194;&#8202;Includes ultra-small systems that expand
delivery approaches (e.g.,&nbsp;AAV)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-BOTTOM:1px solid #000000"><B>SMART Nucleases</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">&#149;&#8194;&#8202;Ultra&#150;small systems expand delivery approaches (e.g.,&nbsp;AAV) (Goltsman et al 2022)</P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">&#149;&#8194;&#8202;Can be converted to nickases for base
editing and RIGS</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="middle" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Nucleotide changes<BR></B>(i.e. base editing)<B></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-BOTTOM:1px solid #000000"><B>ABE and CBE</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">&#149;&#8194;&#8202;Engineered from MG nickase and MG deaminase</P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">&#149;&#8194;&#8202;CBE also include MG uracil glycosylase
inhibitor (&#147;UGI&#148;)</P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">&#149;&#8194;&#8202;Base
editors engineered from type II have extensive genomic targetability</P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">&#149;&#8194;&#8202;SMART base editors are smallest nickase-based systems characterized to date</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="middle" STYLE="BORDER-BOTTOM:1px solid #000000"><B></B><B>Small replacements /<BR>corrections (1-100 base<BR>pair replacement,<BR>insertion, or deletion)<BR>(i.e.&nbsp;prime editing)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Little RIGS</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">&#149;&#8194;&#8202;Engineered from MG nickase and MG RT</P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">&#149;&#8194;&#8202;Ultra-small RTs are highly active and accurate for prime editing</P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">&#149;&#8194;&#8202;Enabled by extensive targetability and
deliverability of MG nickases</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="middle" ROWSPAN="2" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Large insertions<BR></B>(&gt;100&nbsp;base pair<BR>integrations)<B></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px dashed #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-BOTTOM:1px dashed #000000"><B>RNA-templated: Big RIGS</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px dashed #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px dashed #000000"> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">&#149;&#8194;&#8202;Engineered from MG nickase and MG RT</P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">&#149;&#8194;&#8202;MG RT are accurate, and can convert &gt;4,000 bp RNA templates into DNA</P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">&#149;&#8194;&#8202;Programmable integration of large
transgenes delivered as RNA</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-BOTTOM:1px solid #000000"><B>DNA-templated: CAST and other systems</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">&#149;&#8194;&#8202;CASTs are naturally occurring programmable transposase systems</P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">&#149;&#8194;&#8202;Ability to site-specifically integrate
large transgenes delivered as DNA, possibly including templates much larger than 4,000 bp</P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">&#149;&#8194;&#8202;Potential to addresses any genetic disease driven by loss of function</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">143 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">All components of our toolbox have been discovered and derived from our proprietary metagenomics library. We have
assembled a full suite of differentiated tools that, together, can potentially effectuate any desired gene modification &#150; gene <FONT STYLE="white-space:nowrap">knock-down,</FONT> gene <FONT STYLE="white-space:nowrap">knock-in</FONT> and
replacements. We believe there is no other single platform enabling the breadth and differentiation of genome editing technologies as our toolbox. All elements of our toolbox are wholly owned, and we have constructed a broad patent estate that
protects our intellectual property, and it will continue to expand as we discover, interrogate, and optimize our novel editing systems. As we continue to expand our metagenomic library, we expect to make additional discoveries of novel genome
editing technology. The core technologies in our toolbox to date are outlined in the above table. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Key Attributes of Our Proprietary Toolbox </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Key advantages of our platform and technologies are: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Potential to create a full spectrum of genetic medicines </I></B><B>&#150; </B>Our broad suite of genome editing technologies include: programmable nucleases, base editors, RIGS and CASTs, that, together, can
potentially effectuate any desired modification to the genome &#150; gene <FONT STYLE="white-space:nowrap">knock-down,</FONT> gene <FONT STYLE="white-space:nowrap">knock-in,</FONT> and replacements. This allows us to address a diverse set of
mutations by matching the right tool to a specific target, with limited unintended effects such as <FONT STYLE="white-space:nowrap">off-target</FONT> editing. As such, we intend to prosecute a genetic medicine therapeutic development strategy across
a broad array of diseases and target organs including liver, central nervous system, muscle, kidney, and lung. </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Potential next generation genome editing systems </I></B>&#150; Our scientific underpinnings based in metagenomics provides a continuous engine for discovering and developing potential next generation genome
editing systems. For example, RIGS and CAST. As we continue to build upon our metagenomic library we expect to expand our toolbox as we make more discoveries. We have constructed a broad patent estate that protects our intellectual property, and it
will continue to expand as we discover, interrogate, and optimize our novel editing systems. </TD></TR></TABLE>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><I>3)</I></TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I></I><B><I>Ultra-small nuclease platform to expand </I></B><B>in vivo</B> <B><I>delivery of multiple genome editing systems </I></B>&#150; Compact systems create potential advantages for delivery, manufacturing, and
dosing. For example, at 429 aa in length the SMART nuclease is a fraction of the size of the industry-standard SpCas9 system, which is 1,300 aa and exceeds the delivery capacity of standard AAV vectors. The ability to package our systems into a
single AAV will enable more efficient targeting of organs and diseases beyond what is currently possible with LNP delivery. </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">4)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Designed to edit any target in the human genome</I></B><I> </I>&#150; Our metagenomics library contains hundreds of nucleases with diverse targeting abilities that allow us to address a diverse set of mutations
that cause disease, including those found at sites that often cannot be targeted by first-generation nucleases. This allows us to select the ideal nuclease for any target site of interest. Given the measured targeting density of our toolbox, we
believe that essentially any codon in the human genome could be addressed with our gene editing systems. </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">5)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Shortened optimization period &#150;</I></B> We benefit from a diverse set of highly-active nucleases and effectors which have required little <FONT STYLE="white-space:nowrap">-if</FONT> <FONT
STYLE="white-space:nowrap">any-</FONT> protein engineering to optimize. These highly active natural enzymes allow us to quickly identify systems for therapeutic development. As a result of not having to heavily engineer systems to be active in human
genome editing applications, we are able to move quickly from discovery to candidate nomination for particular genetic disease applications. </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">6)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B><I>Ability to target large gene integrations into the genome using our RIGS and CAST systems &#150;</I></B> Our novel
RIGS and CAST systems allow for programmable, large gene insertions, an outcome which has been a major challenge for the genome editing field. RIGS are a proprietary genome editing system engineered from nickases and RTs, while CAST are systems that
exist in nature but have required engineering to allow </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">144 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">
for mammalian genome editing. We believe we are the first to demonstrate targeted genomic integration in human cells using compact CAST systems. While CAST have the theoretical capability to
integrate very large DNA templates into the genome, RIGS are also being developed in order to achieve targeted, large genomic integrations when all components need to be delivered as RNA, for example when using standard LNP delivery technology.
</P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Specific Components of Our Toolbox </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I><U>Programmable Nucleases </U></I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:arial">Overview </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Figure 5</B>. Schematic Showing
Programmable Nucleases and Their Use for Genome Editing. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g425213g63f05.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are building a toolbox that includes programmable nucleases that are selected to target any site in the human genome with high
precision. Most therapeutic genome editing applications to date use CRISPR/SpCas9 as the programmable nuclease. However, this system has several limitations that prevent its broad use across the thousands of genetic diseases that impact patients.
Most importantly, SpCas9 is limited by where it can be targeted in the human genome and in some cases has a lack of specificity that leads to frequent <FONT STYLE="white-space:nowrap">off-target</FONT> editing. In addition, the size of the SpCas9
enzyme complicates options for delivery using industry-standard methods. We have explored diverse programmable nucleases found in nature in order to identify novel systems that overcome all of these limitations (Figure&nbsp;5). </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The discovery of new CRISPR enzymes with unique functionality and structure may offer the potential to further disrupt genome editing technologies, improving speed,
specificity, functionality, and ease of use. CRISPR systems are commonly organized into two classes, six types and expanding number of subtypes based on shared functional characteristics and evolutionary similarity. We focus our attention on CRISPR
type II and type V systems, owing to the simplicity of these programmable nucleases. Type II and type V nucleases are <FONT STYLE="white-space:nowrap">RNA-guided</FONT> enzymes that can be programmed to target specific sequences of DNA, and
sometimes RNA. Unlike type II nucleases, type V nucleases are more likely to generate staggered versus <FONT STYLE="white-space:nowrap">blunt-end</FONT> cuts in double stranded DNA. Nucleases from both of these systems are extensively used in
biotechnology, despite limitations that prevent their more widespread use in therapeutic applications. Our type II and type V CRISPR systems are distinct from previously studied CRISPR enzymes (including protein sequence, size, and biochemistry),
while maintaining the core functionality of being programmable nucleases. Our lead systems have undergone extensive study across multiple mammalian cell types and animal models, demonstrating their utility as genome editing tools in both <I>in
vivo</I> and <I>ex vivo</I> applications. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Throughout our search for novel programmable nucleases, we have identified several new types of ultra-small nucleases that
range in size from approximately 450 aa to 1,000 aa, compared with typical type II and type V nucleases which are typically between 1,000 aa and 1,500 aa in length (for comparison, the most studied SpCas9 enzyme is 1,368 aa). Our newly-discovered,
ultra-small nucleases include new types that we collectively refer to as SMART, as well as those that come from novel type V sub-groups. Given their small size, these new systems have the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">145 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
potential to be delivered to additional therapeutic target sites that expand beyond what is possible with first-generation systems. In adapting these novel systems into potential precision
genetic medicines, our programmable nucleases are designed to have the capability to target essentially any therapeutically relevant genomic site with a high level of specificity (i.e. with limited <FONT STYLE="white-space:nowrap">off-target</FONT>
editing), while expanding compatibility with available delivery technologies. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><U>Our Approach </U></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To date, we have identified thousands of novel CRISPR type II, type V and SMART nucleases, including ultra-small systems, expanding the collection of known programmable
nucleases by mining our proprietary metagenomics database. Using high-throughput <I>in vitro</I> testing, we have validated the activity of hundreds of novel nucleases. This has led to the identification of highly-active natural nucleases while also
enabling us to catalog the unique targeting capabilities of each system. We select for natural, <FONT STYLE="white-space:nowrap">un-engineered</FONT> systems with high activity and specificity. Our best-characterized nucleases have demonstrated
activity levels meeting and often greatly exceeding SpCas9 while exhibiting low levels of <FONT STYLE="white-space:nowrap">off-target</FONT> editing in mammalian cells. Given the measured targeting density of our toolbox, we believe that essentially
any codon in the human genome could be addressed with our gene editing systems. The targeting density (frequency of targetable sites in the human genome) of the toolbox greatly increases the likelihood of identifying a highly active and specific
nuclease and gRNA combination for any therapeutically relevant genomic target. We can use these programmable nucleases for genome editing, and also as a chassis for developing base editors and RIGS. The diverse biochemistry of these novel systems,
including their size and DNA cutting profiles, makes it possible to link editing systems to the particular genomic target, edit type, and delivery technology we believe are required to develop genetic medicines. Additional discovery and
characterization of programmable nucleases will further expand the targeting density of our toolbox, improving the overall activity and specificity of lead systems identified for therapeutic development. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Our best-characterized type II and type V nucleases are suitable for a wide variety of genome editing applications </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Nucleases with the activity and specificity required for potential therapeutic genome editing applications are identified through a series of high-throughput screening
and characterization steps. Novel protein and gRNAs are first predicted bioinformatically and then validated in both cell-free and mammalian cell screens. These steps validate the activity of a system and provide an accurate measure of targeting and
specificity profiles. This approach has been applied to both type II and type V CRISPR nucleases in order to establish an expanding collection of well-characterized systems. In addition to discovery of novel nucleases with distinct targeting
capabilities, a modular protein engineering approach is also used in order to create chimeric systems. The chimera approach leverages the high activity of <FONT STYLE="white-space:nowrap">top-performing</FONT> systems but changes where they can edit
by incorporating distinct targeting domains from related systems. Through continuous discovery and refinement, this collection of systems will expand, with the potential to target essentially every site in the human genome, while also creating a
chassis to support the accelerated development of base editing, prime editing, and targeted integration systems. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">146 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Given the measured targeting density of our toolbox, we believe that essentially any codon in the human genome
could be addressed with our gene editing systems. </I></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>Figure 6</B>. Our Expanding Nuclease Toolbox is Designed to Enable Extensive Targeting throughout the Human Genome.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"><B>Figure 6a</B>. Our nucleases have shown high editing efficiency in mammalian cells.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Figure 6b</B>. Given the measured targeting density of our toolbox, we believe that essentially any codon in the human genome could be addressed
with our gene editing systems.</P> <P STYLE="font-size:8pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:7.5pt">
<TD VALIGN="bottom"> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:59pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt; margin-right:0.60em" ALIGN="center">


<IMG SRC="g425213g69e65.jpg" ALT="LOGO">
</P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:7.5pt; font-family:arial">*&#8195;&#8194;Editing efficiency was determined based on the frequency of InDels detected by next generation sequencing
(&#147;NGS&#148;) at genomic sites targeted by each nuclease.</P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-2.00em; font-size:7.5pt; font-family:arial">*&#8195;&#8194;Graph depicts editing efficiency for the top five guides for each of six nucleases.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g425213g64f07.jpg" ALT="LOGO">
</P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:7.5pt; font-family:arial">*&#8195;&#8194;Graph depicts cumulative targetability.</P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:7.5pt; font-family:arial">*&#8195;&#8194;Targeting density (targetability) is the average distance between nuclease target sites in the human genome.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
</TABLE>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our nucleases are capable of highly efficient genome editing in mammalian cells. Systems are tested across a collection of gRNAs
designed based on the unique requirements and targeting preferences determined for each system. If a nuclease is routinely capable of editing at near-saturating levels, sometimes up to 99% editing efficiency, the system will go through further
characterization and therapeutic development. Figure 6a shows the high editing efficiency of six systems observed in mammalian cells, indicating that they have the potential for broad use in therapeutic development given an ability to rapidly
identify high performing guides that require minimal optimization. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Given that each nuclease has distinct genomic targeting capabilities, we are able to determine
which sites in the human genome can be addressed by each system. Figure 6b shows how the targeting density of our toolbox increases with each new system. Given the measured targeting density of our toolbox, we believe that essentially any codon in
the human genome could be addressed with our gene editing systems. This collection of systems includes both natural enzymes as well as chimeric forms that have been engineered to alter the targetability of the nuclease. For reference, SpCas9 is able
to target roughly every ten base pairs in the human genome. The targeting density of the toolbox increases the likelihood of identifying a highly-potent guide for any desired genome edit. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">147 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Our nuclease toolbox is on track to target anywhere in the human genome </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Figure 7</B>. Our Nucleases are Compact with Diverse Targeting Sequence Motifs, Selected to Enable Broad Genome Editing Applications. </P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g425213g00k01.jpg" ALT="LOGO">
 </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Graph depicts a selection of our nucleases, including their size in aa on the horizontal axis and their corresponding targeting motifs shown as sequence logos (PAM and TAM sequences), compared to SpCas9.
</TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Multiple parameters are considered when screening and promoting nucleases for further development, including the size of the system, activity across
various assays and cell types, and targeting. For CRISPR systems, nuclease targeting is limited by a PAM sequence, or protospacer adjacent motif. The PAM is a short DNA sequence motif that must be present next to a target sequence in order for the
nuclease to cut at the target site. Other systems have similar requirements that go by different names. For example, some SMART nucleases recognize functionally orthologous sequences called target-adjacent motifs (&#147;TAMs&#148;). Figure 7 shows
the diversity of protein sizes and targeting motifs recognized by our nucleases. The vast diversity of the protein size and targeting motif requirements of our nucleases continues to fuel toolbox development and will enable the identification of
additional systems that could make it possible to target nearly every base pair in the human genome. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Our nucleases are highly active across many human cell types
which may indicate broad potential utility for human therapeutic applications </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Beyond initial nuclease benchmarking conducted in immortalized mammalian cell
lines, we have conducted extensive surveys to show that these systems can be used in a variety of primary cells important for preclinical studies (i.e., T cells, natural killer (&#147;NK&#148;) cells, B cells, hematopoietic stem cells
(&#147;HSCs&#148;) and induced pluripotent stem cells (&#147;iPSCs&#148;)), as illustrated by Figure 8 below. The versatility of these exemplary systems indicates their potential use in broad therapeutic applications. These benchmarks against SpCas9
also indicate that our systems may have potency advantages in which fewer genome editing reagents will need to be delivered in order to achieve high levels of genome editing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">148 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Figure 8</B>. Our Nucleases Show High Editing Efficiency in Human T Cells, NK Cells, B Cells, HSCs, and iPSCs. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g425213g17k03.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Two example nucleases are shown, type II <FONT STYLE="white-space:nowrap">MG3-6</FONT> and type V <FONT STYLE="white-space:nowrap">MG29-1.</FONT> </TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Editing efficiency was determined based on the frequency of InDels detected by NGS at genomic sites targeted by each nuclease. </TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Our nucleases exhibit high specificity when benchmarked in multiple mammalian cell types </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our therapeutic development of genome editing systems require that they exhibit high activity and specificity across multiple cell-based models. We employ a broad set of
specificity and off-target assessment methodologies, including <I>in silico</I>, biochemical, and cell-based approaches. Figure 9 shows peer-reviewed and published <FONT STYLE="white-space:nowrap">off-target</FONT> assessments conducted using an
unbiased, industry standard, cell-based, oligonucleotide capture method. In Figure 9a we show that two of our nucleases are more specific than SpCas9 when compared across multiple guides, and in Figure 9b we show that we can identify guides with no
to minimal detectable <FONT STYLE="white-space:nowrap">off-targets</FONT> with two lead nucleases tested in both immortalized and primary human cells. This trend has continued, and we are able to identify guides that have minimal or no detectable
off-target activity for therapeutic targets. It is expected that the higher specificity of these systems will translate into better safety profiles across various therapeutic genome editing applications. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">149 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Figure 9</B>. Our Nucleases are Highly Specific. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Figure 9a</B>. Our nucleases are highly specific in multiple mammalian cell types. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g425213g01a17.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Figure 9b</B>. Our best-characterized nucleases have guides that showed no to minimal detectable
<FONT STYLE="white-space:nowrap">off-target</FONT> edits when assayed in immortalized and primary human cells. </P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center"><B>


<IMG SRC="g425213g01b17.jpg" ALT="LOGO">
 </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Figure 9a: <FONT STYLE="white-space:nowrap">Off-target</FONT> analysis showed that our type II <FONT STYLE="white-space:nowrap">MG3-6</FONT> and <FONT STYLE="white-space:nowrap">MG3-8</FONT> nucleases have high
specificity in multiple mammalian cell types as measured by the number of <FONT STYLE="white-space:nowrap">off-target</FONT> sites and the fraction of <FONT STYLE="white-space:nowrap">on-target</FONT> reads. The target sites are the same between the
three nucleases, including SpCas9. <FONT STYLE="white-space:nowrap">Off-target</FONT> experiments were conducted at N &#061; 2, and reads for both replicates were summed for analysis. Double strand break (&#147;DSB&#148;) discovery via capture of a
double-stranded oligonucleotide in primary T cells using the same <FONT STYLE="white-space:nowrap">MG3-6</FONT> and <FONT STYLE="white-space:nowrap">MG29-1</FONT> guides from (A; averaged across three biological replicates). Source: Alexander et al
2023 CRISPR Journal </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Figure 9b: DSB discovery via capture of a double-stranded oligonucleotide in HEK293T cells with SpCas9 (on target read in gray), guides <FONT STYLE="white-space:nowrap">MG3-6</FONT> TRAC B2, TRAC D2, TRAC 6, and GR 3
(on target in blue), and <FONT STYLE="white-space:nowrap">MG29-1</FONT> guides TRAC 9, TRAC 19, TRAC 35, and GR 13 (on target in yellow) across three biological replicates. Source: Lamothe et al 2023 CRISPR Journal </TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Our nucleases enable highly efficient and specific </I>in vivo<I> genome editing in preclinical evaluations </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Type II MG3-6/8 is our chimeric nuclease that has been extensively characterized <I>in vitro</I> and <I>in vivo</I>. This system is engineered from the <FONT
STYLE="white-space:nowrap">MG3-6</FONT> chassis, which was discovered from the genome of a commensal, <FONT STYLE="white-space:nowrap">non-pathogenic</FONT> representative of the human microbiome that showed high editing efficiencies when tested
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">150 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
across multiple mammalian cell types (see Figures 6, 8 and 9 above). The engineering involved changing the PAM interacting domain of the chassis, which enables the enzyme to be targeted to new
sites in the human genome. Figure 10 shows that this system is suitable for <I>in vivo</I> applications, based on saturating levels of editing achieved in a mouse study with a single administration of nuclease mRNA and guide encapsulated in a LNP
with tropism to the liver. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Figure 10</B>. In Vivo Editing in Mice with MG3-6/8 Nuclease. </P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom">Editing efficiency was determined based on the<BR>frequency of InDels detected by next generation<BR>sequencing (&#147;NGS&#148;) at genomic sites targeted by each<BR>nuclease.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">


<IMG SRC="g425213g01a99.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Delivery by mRNA and LNP, dosing at 1 mg/kg. </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Mean of 79% genome editing efficiency as measured by the frequency of InDels detected by NGS at the targeted genomic site. </TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, one of our most highly characterized type V nucleases, <FONT STYLE="white-space:nowrap">MG29-1,</FONT> demonstrated high activity and specificity during
multiple preclinical studies spanning from <I>in vitro</I> to NHP. Originating from a bacterial genome found in a deep sea hydrothermal vent, <FONT STYLE="white-space:nowrap">MG29-1</FONT> has a smaller protein (1,280 aa) and gRNA (~70 nt) compared
with <FONT STYLE="white-space:nowrap">MG3-6</FONT> (1,135 aa and ~110 nt) and SpCas9 (1,368 aa and ~100 nt). <FONT STYLE="white-space:nowrap">MG29-1</FONT> has demonstrated up to 97% editing in primary mouse hepatocytes in culture (Figure 11a),
superior liver editing to an exemplary SpCas9 guide targeting an overlapping genomic site when delivered to mice using a LNP that delivers primarily to the hepatocytes in the liver (Figure 11b), and on average 50% editing in the whole liver of NHP
when delivered in a LNP that delivers primarily to the hepatocytes in the liver (Figure 11c, guide 2). Because hepatocytes make up about 70% of the cells in the liver, the 50% editing in the whole liver achieved in NHP translates to editing of about
70% of the hepatocytes which are the therapeutically relevant target cell. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">151 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Figure 11</B>. Our Type V <FONT STYLE="white-space:nowrap">MG29-1</FONT> Nuclease is a Highly Active Natural Enzyme
for <I>In Vivo</I> Genome Editing. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:12pt ;"><B>Figure 11a</B>. <FONT STYLE="white-space:nowrap">MG29-1</FONT> achieved saturating levels of editing in primary mouse hepatocytes.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="padding-bottom:12pt ;"><B>Figure 11b</B>. <FONT STYLE="white-space:nowrap">MG29-1</FONT> has higher <I></I>potency than SpCas9 when editing mouse liver cell genomes <I>in vivo.</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="padding-bottom:12pt ;"><B>Figure 11c</B>. MG29-1 demonstrates successful editing in NHPs.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g425213g18a19.jpg" ALT="LOGO">
</P> <P STYLE="font-size:8pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="center">


<IMG SRC="g425213g18b20.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g425213g18c21.jpg" ALT="LOGO">
</P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="font-size:8pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:7.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:7.5pt; font-family:arial">*&#8195;&#8194;50% whole liver editing &#061; 70% hepatocytes editing.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:7.5pt; font-family:arial"><FONT
STYLE="white-space:nowrap">*&#8195;&#8194;MG29-1</FONT> and SpCas9 were delivered by LNP with <FONT STYLE="white-space:nowrap">co-formulated</FONT> mRNA and gRNA.</P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:7.5pt; font-family:arial">*&#8195;&#8194;gRNAs for both <FONT STYLE="white-space:nowrap">MG29-1</FONT> and SpCas9 have overlapping target sites.</P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:7.5pt; font-family:arial">*&#8195;&#8194;mRNAs for both nucleases use the same
overall design and were codon optimized with the same algorithm.</P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:7.5pt; font-family:arial">*&#8195;&#8194;The SpCas9 gRNA incorporated extensive optimizations published in the literature.</P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:7.5pt; font-family:arial">*&#8195;&#8194;InDels were analyzed by NGS four days after
IV infusion.</P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-2.00em; font-size:7.5pt; font-family:arial">*&#8195;&#8194;L, M, H, refer to low,
medium and high doses.</P></TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We use multiple unbiased, industry standard methods to identify putative <FONT STYLE="white-space:nowrap">off-target</FONT> edits, which
are then investigated using sensitive targeted sequencing. To date no detectable off target editing has been observed for the <FONT STYLE="white-space:nowrap">MG29-1</FONT> lead guide for one of our therapeutic programs at therapeutically relevant
doses. Preliminary off-target assessment of MG29-1 lead guide for a second program has not identified detectable off-target sites to date which is consistent with MG29-1 being a highly efficient, specific and programmable nuclease suitable for broad
<I>in vivo</I> genome editing applications. Beyond <FONT STYLE="white-space:nowrap">MG29-1,</FONT> the multitude of nucleases in our toolbox enables us to screen an extensive guide library for any genomic locus of interest. For exemplary lead guides
that have been examined for off-target editing we observe minimal or no detectable <FONT STYLE="white-space:nowrap">off-target</FONT> editing. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Our ultra-small
nucleases are efficient genome editors that unlock additional delivery modalities </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Delivery of genome editing payloads is often restricted by the size
limitations of the delivery vehicle. Therefore, we leverage our metagenomics database to find new nucleases that are significantly smaller than current systems. After searching through billions of predicted proteins from bioinformatically
reconstructed microbial genomes, we uncovered several distinct types of ultra-small nucleases. Our lead ultra-small nucleases are significantly smaller than CRISPR SpCas9, enabling new and improved <I>in vivo</I> delivery methods and new
possibilities for building base editing systems and prime editors that can be packaged in <FONT STYLE="white-space:nowrap">size-constrained</FONT> delivery vehicles. Typical CRISPR Cas9 systems are about 1,300 aa in length whereas some of these new
systems are just over 450&nbsp;aa. Compact systems create potential advantages for delivery, manufacturing, and dosing. Furthermore, they can be delivered to organs and tissues currently only accessible by AAV, given that the nucleases are
well-within the packaging limitations of these delivery vectors. The smaller size of these nucleases compared to previous systems potentially unlock target indications beyond applications in the liver. Because of their novel biochemistry and
divergence from typical type II, we refer to some of these ultra-small nucleases as SMART. In addition, we identified several novel families of ultra-small type V nucleases. Unlike compact type V, and all other previously studied type V, SMART have
a dual catalytic domain structure that enables engineering of nickase variants that can be used for base and prime editing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">152 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Figure 12 shows that genome editing efficiencies achieved for SMART and compact type V nucleases are comparable to
other lead systems. These results show that our ultra-small nucleases are highly efficient genome editing systems that have the potential for extensive therapeutic applications, including for those in which delivery is a limiting factor. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="5"><B>Figure 12</B>. Our Ultra-Small Nucleases are Designed to be Highly Efficient Genome Editing Systems that Are Well-Within the Packaging Limits of AAV Vectors.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"><B>Figure 12a</B>. Schematic representation of how our ultra-small nucleases are a fraction of the size of a typical CRISPR SpCas9 nuclease.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Figure 12b</B>. SMART nuclease showed high editing efficiency in mammalian cells, prior to optimization.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Figure 12c</B>. Compact type V nuclease showed high editing efficiency in mammalian cells, prior to optimization.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g425213g29a65.jpg" ALT="LOGO">
</P> <P STYLE="font-size:8pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center"><SUP STYLE="font-size:75%; vertical-align:top">


<IMG SRC="g425213g29b87.jpg" ALT="LOGO">
</SUP></P> <P STYLE="font-size:8pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g425213g29c87.jpg" ALT="LOGO">
</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:7.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> *&#8195;&#8194;InDels are measured by NGS.<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:7.5pt">*&#8195;&#8194;Each bar represents
a distinct guide.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> *&#8195;&#8194;InDels are measured by NGS.<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:7.5pt">*&#8195;&#8194;Each bar represents
a distinct guide.</P></TD></TR>
</TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Base Editors </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Overview </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Figure 13</B>. Schematic Showing the Two Primary Types of Base Editors under Development. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g425213g29e65.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We leverage our toolbox of programmable nucleases to develop a highly targetable and flexible base editing platform compatible
with various delivery technologies. Base editing modifies individual bases in the genome without making double-stranded breaks in the DNA. This approach uses a chemical reaction designed to create precise, predictable, and efficient genetic outcomes
at the targeted sequence. These precise changes to individual base pairs in the genome can be used to correct or change genomic sequence in order to address disease. Notably, the most common class of genetic mutations are errors of a single base,
known as point mutations. These point mutations, many of which could be addressed with a base editor, represent approximately 58% of all the known genetic errors associated with disease. Furthermore, base editors can be used to precisely knock-down
genes by introducing premature stop codons or interrupting gene splice sites. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">153 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There are two types of base editors: ABEs and CBEs. ABEs convert adenine-thymine base pairs to guanine-cytosine base
pairs. CBEs target cytosine-guanine and convert them to thymine-adenine. We are developing both ABEs and CBEs, which have been validated across multiple mammalian cell types and <I>in vivo</I>, to enable broad use of the base editing approach for
addressing disease (Figure 13). </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Base editors are composed of a targeting enzyme, typically a programmable nuclease that has been engineered to localize to a
specific site in the genome but not cause a dsDNA break, and a deaminase, which is responsible for the chemical conversion of targeted genomic bases. Base editors can be engineered using modified nickase programmable nucleases that have been
engineered to nick rather than cut genomic targets (i.e. a nickase variant). The nickase recognizes and binds to specific DNA sequences, determined by a gRNA, enabling deaminases that are fused to the nickase to modify the targeted bases. Typically,
the modified bases are found on the single-stranded DNA that is exposed at a target site when the gRNA is bound to one of the strands of DNA. The efficiency of cytosine base editors can be improved by the addition of another enzyme called a UGI. The
UGI protects edited bases against DNA repair machinery that would otherwise remove them and revert the edited sequence back to its original form. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Base editing
results in one or more mismatched bases in the dsDNA, which are resolved by DNA repair mechanisms in the cell. Nickases are typically used such that the DNA strand opposite to the modified bases is nicked, thus biasing DNA repair pathways to favor
the modified strand over the original sequence. The result is a precise change in one or more targeted bases without creating double-stranded breaks or requiring a donor template. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B></B><I>Our Approach</I><B> </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are leveraging our toolbox of programmable
nucleases and our metagenomics discovery platform to develop next generation base editing tools. Our programmable nucleases provide the ability to efficiently and precisely target locations in the genome required in order to potentially create a
wide-variety of genetic medicines. In addition, the availability of ultra-small SMART effectors enables us to develop base editors that could be delivered to various target tissues and organs. While established base editing systems using SpCas9
require splitting the system into two AAV vectors for delivery, those developed from SMART are designed to be within the packaging limitations of a single AAV. We have discovered and engineered what we believe to be two of the smallest base editors
developed to date, one SMART ABE that is 623 aa in length and another SMART ABE that is 969 aa. These systems provide substantial opportunities for vector optimization compared with SpCas9 ABEs that are 1,588 aa. Furthermore, the flexibility of the
modular, chimeric nuclease platform, enables rapid optimization of base editors capable of editing at a multitude of target sites, since engineering and optimization applied to one base editor can rapidly be applied to other systems with the
capability of targeting to new genomic sites. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Given that base editors require deaminases, and a UGI in the case of cytosine base editors, substantial enzyme
discovery beyond programmable nucleases has been required in order to develop highly efficient base editors that have the potential to overcome the limitations of the current technology. We have mined over three million deaminases in order to
identify enzymes with the capability to function as part of base editing systems. In many cases these novel deaminases have required minimal protein engineering to achieve therapeutically-relevant editing efficiencies in multiple studies. The
ability of our metagenomics discovery platform to identify novel enzymes with high activity makes it possible to rapidly develop differentiated technology that surpasses first-generation systems. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">154 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B></B><I>Our base editors are highly active in mammalian cells across various genomic targets</I><B> </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>Figure 14</B> ABE and CBE Developed from Type II <FONT STYLE="white-space:nowrap">MG3-6</FONT> System Have Been Shown to be Highly Active in Mammalian Cells.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"><B>Figure 14a</B>. ABE screening identified guides capable of achieving saturating levels of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">A-to-G</FONT></FONT> genome editing in mammalian cells.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Figure 14b</B>. CBE screening identified highly active deaminases for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">C-to-T</FONT></FONT> editing, compared to published control.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="center">


<IMG SRC="g425213g86y35.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="center">


<IMG SRC="g425213g62c06.jpg" ALT="LOGO">
</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:7.5pt; font-family:arial">*&#8195;&#8194;Optimized ABE construct tested in Hepa <FONT STYLE="white-space:nowrap">1-6</FONT> cells
with mRNA delivery.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:7.5pt; font-family:arial">*&#8195;&#8194;Unoptimized CBE construct tested in HEK293T cells with plasmid delivery.</P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-2.00em; font-size:7.5pt; font-family:arial">*&#8195;&#8194;CBE control uses hyperactive CDA
A0A2K5RDN7.</P></TD></TR>
</TABLE>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our base editors are highly active and progressing towards <I>in vivo</I> therapeutic applications. Both of our ABE and CBE systems
have been tested in mammalian cells in order to determine editing efficiency, where a large collection of guides spanning various genomic loci were tested for each system. Figure 14 shows that an optimized ABE construct delivered by mRNA achieved up
to 96% editing efficiency, while a CBE tested without construct optimization using a less-efficient plasmid delivery approach achieved up to 58% editing efficiency. Notably, our CBE outperformed an industry-standard control CBE by several fold in
this benchmarking experiment. Additional optimization of these already competitive CBE systems is expected to rapidly improve editing efficiencies to create systems for <I>in vivo</I> therapeutic applications, while the ABE systems have already
progressed into <I>in vivo</I> studies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">155 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Our base editing platform has broad in vivo therapeutic potential </I></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>Figure 15</B>. Lead ABE System Developed from Type II <FONT STYLE="white-space:nowrap">MG3-6</FONT> System Demonstrated High Activity in Primary Cells and in an <I>in vivo</I> Mouse Model.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial"><B>Figure 15a</B>. Our lead ABE system efficiently edited primary mouse hepatocytes at example target sites.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Figure 15b</B>. Our lead ABE system demonstrated activity <I>in vivo</I> when delivered to mouse livers by mRNA and LNP.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g425213g25i26.jpg" ALT="LOGO">
</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="center">


<IMG SRC="g425213g20j89.jpg" ALT="LOGO">
</P></TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In order to demonstrate the utility of the <FONT STYLE="white-space:nowrap">MG3-6</FONT> ABE platform for <I>in vivo</I> base editing, a
lead construct design was tested both in primary cells and in mice. Multiple guides were tested in each study, designed to target different genomic loci. Figure 15 shows the results of these evaluations of the ABE platform, where up to 60% editing
efficiency was demonstrated in primary hepatocytes and 35% efficiency was achieved across all liver cells in an initial <I>in vivo</I> study using mRNA and LNP delivery. Given that approximately 70% of liver cells are hepatocytes, and therefore
targetable by the LNP platform, this editing experiment suggests that approximately 50% of all targetable cells were successfully edited. We believe this level of editing, which is comparable to other initial <I>in vivo</I> base editing studies,
supports the potential to rapidly progress towards therapeutic applications. Given that both the ABE and CBE data shown in Figures 14 and 15 are based on a chimeric <FONT STYLE="white-space:nowrap">MG3-6</FONT> nickase, we anticipate that the broad
targetability of this system will enable rapid development of multiple potential new therapeutic applications of base editing technology. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">156 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Our SMART have been engineered to create ultra-small base editors, expanding the potential deliverability of base
editing technology </I></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="5"><B>Figure 16</B>. SMART Can be Engineered into Ultra-Small Base Editors with Naturally High Editing Efficiency and AAV Compatibility.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"><B>Figure 16a</B>. Ultra-small SMART base editors are a fraction of the size of a typical Cas9 system, enabling AAV delivery.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Figure 16b</B>. SMART ABE exhibited a similar editing profile <I>in vitro </I>compared to SpCas9.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Figure 16c</B>. SMART ABE were active in mammalian cells.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="center">


<IMG SRC="g425213g50a51.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="center">


<IMG SRC="g425213g50a52.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="center">


<IMG SRC="g425213g50a53.jpg" ALT="LOGO">
</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:7.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">*&#8195;&#8194;SMART <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ABE-MG34-1</FONT></FONT> base editing at four<BR>genomic targets loci in <I>E. coli.</I> vs.<BR> reference SpCas9
system.<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:7.5pt">*&#8195;&#8194;Heatmap values represent the mean of<BR>two independent
experiments.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">*&#8195;&#8194;SMART ABE achieved up to 22% base<BR> editing efficiency in human cells.<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:7.5pt">*&#8195;&#8194;Base editing efficiency shown at three<BR>genomic targets tested in human<BR>HEK293T cells.</P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:7.5pt">*&#8195;&#8194;Heatmap values represent the mean of<BR>three independent
experiments.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:7.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> *&#8195;&#8194;The target sequence for each locus is shown above the heatmap.<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:7.5pt">*&#8195;&#8194;Heatmaps represent the percentage of NGS reads supporting an edit at each position.</P></TD></TR>
</TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">Source:</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Goltsman et al 2022 Nature Communications </TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Figure 16 illustrates how our ultra-small SMART nucleases provide an
opportunity to develop compact base editors with the potential to improve delivery using existing AAV technology. Our engineered, but unoptimized SMART ABE systems were observed to edit target loci at levels comparable to reference SpCas9 systems,
and with up to 22% editing efficiency in mammalian cells. Achieving this level of efficiency with an unoptimized system, comparable to initial base editing readouts achieved with SpCas9, indicates that additional engineering has the potential to
rapidly and significantly improve editing efficiencies. The SMART ABE highlighted in Figure&nbsp;16 is one of the smallest nickase-based systems with activity in mammalian cells (969 aa), and at 623 aa another SMART ABE under development is even
smaller. Together, these systems provide us with unique opportunities to optimize base editors using the naturally compact, precise, and programmable SMART platform. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">157 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><FONT STYLE="white-space:nowrap">RNA-Mediated</FONT> Integration Systems: RIGS for prime editing and large genomic
integrations </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I></I></B><I>Overview</I><B><I> </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Figure 17</B>.
Schematic Showing Application of RIGS for Small Replacements and Large Integrations. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g425213g27i06.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Programmable nucleases, which use dsDNA breaks to trigger DNA repair machinery to enact specific genomic changes, and base
editors, which use chemical modifications to convert specific base pairs in the human genome, cannot address all mutations that cause disease. RIGS are being developed in order to encode any type of genomic modification in an RNA template, and thus
create any type of genome modification necessary to address a disease (Figure 17). RIGS involve using RTs to convert genomic corrections encoded in RNA into DNA, and are engineered with programmable nucleases or nickases to incorporate newly
synthesized DNA messages into the genome at specified target sites. Importantly, any genomic modification can be encoded in the RNA template. Furthermore, the potential for having an <FONT STYLE="white-space:nowrap">all-RNA</FONT> format for the
system, including delivery of the protein components as mRNA, could simplify delivery for some applications. For example, the <FONT STYLE="white-space:nowrap">all-RNA</FONT> format could enable use of LNPs for delivery of systems to the liver for
large, targeted genomic integrations. The enzymatic nature of the genome integration, combined with the ability to deliver the entire system as RNA is of particular importance when considering large integrations, since the delivery of DNA templates
at concentrations required for integration mediated by DNA repair machinery can be toxic. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">One implementation of RIGS is to use our programmable nickases and RTs for
prime editing. Prime editing can repair diverse mutations, including all types of point mutations, deletion mutations, insertion and duplication mutations and insertion-deletion mutations. As with other genome editing approaches, prime editing
systems, and RIGS more broadly, create permanent modifications at natural genomic locations, resulting in durable edits that are passed on through cell divisions and that are expressed under natural mechanisms specific to the gene or target of
interest. One key aspect of prime editing is the modification of a CRISPR gRNA to create a pegRNA (&#147;prime editing gRNA&#148;). In this design, the typical backbone and targeting components of the gRNA are maintained; however, additional
sequence is added to the guide in order to code for a desired genomic correction and to prime a RT to begin synthesizing new DNA sequence. During prime editing a portion of the pegRNA containing the genomic modification is copied into DNA at a
specific site in the genome sequence. Once </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">158 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
the RT has incorporated the new DNA sequence into the target site, DNA repair machinery will finalize the genome edit by removing the corresponding section of the original sequence, synthesizing
any required complementary DNA, and ligating the ends of the nicked DNA strands. We have discovered a collection of novel RTs that can be combined with our nickases to perform prime editing in mammalian cells at levels and with accuracy that
surpasses industry-standard systems. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Current prime editing and RNA-templated editing approaches are limited by the size of the RNA template that can be incorporated
into a genomic site. This limitation is based on multiple aspects of the system design, including 1) the need to encode gRNA and RT template sequences in a single pegRNA, and 2) the processivity and fidelity of the RT. The first constraint can be
addressed by creating new system designs in which the gRNA and repair template are encoded in separate RNA molecules, where additional engineering ensures that the templates and RT are able to <FONT STYLE="white-space:nowrap">co-localize</FONT> to
the nucleus, and more specifically, to targeted sites in the genome. Regarding the second point, processivity and fidelity are biochemical characteristics that relate to the ability of an RT to traverse through large and structurally complex RNA
templates (processivity) and to do so without introducing errors (fidelity). We have identified and developed novel RTs that we believe surpass the processivity and fidelity requirements for therapeutic delivery of transgenes as RNA templates, for
example in order to treat diseases by introducing a complete and correct copy of a gene in order to overcome a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">loss-of-function</FONT></FONT> mutation. Furthermore, we are engineering
these RTs with programmable nucleases and nickases to achieve large, targeted genomic integrations. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Our Approach </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Similar to base editing, development of RIGS leverages our expansive platform of programmable nucleases that can be converted into nickases, including ultra-small SMART,
as well as a metagenomics discovery approach that enables the rapid identification of novel RTs that have the specific characteristics necessary for different genome editing applications. The targetability of our toolbox of programmable nucleases
will enable essentially any target sites of interest to be addressed, and compatibility with ultra-small SMART effectors could expand the deliverability of RIGS to therapeutically relevant tissues and organs. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Little RIGS describes systems used for prime editing (e.g., for small genomic replacements such
as transversions, transitions, insertions, and deletions), while Big RIGS describes systems capable of making large targeted genomic integrations. The mechanisms driving these systems differ from one another, but both are based on using a reverse
transcriptase to incorporate genomic corrections encoded in RNA into target sites in the genome identified by a programmable nickase or nuclease. We identified five million RT candidates from novel families in order to find systems for Little and
Big RIGS development. RTs found in nature are highly diverse, but typically do not have all the characteristics suited towards being useful in a therapeutic context. Based on measured enzyme characteristics such as fidelity and processivity, RTs are
nominated and combined with our programmable nucleases/nickases for either Little and/or Big RIGS engineering. Our Little RIGS are benchmarked against industry-standard prime editing systems in order to rapidly identify <FONT
STYLE="white-space:nowrap">top-performing</FONT> systems. Currently, we believe no genome editing system has been described that is comparable to Big RIGS. Our Big and Little RIGS are undergoing indication-specific optimization. We believe that this
combination of discovery and system optimization will enable the rapid development of best genome editing systems that, together, can enact any type of genomic edit. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">159 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Our RIGS have shown complex prime editing in mammalian cells </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Figure 18</B>. Our RTs Outperformed Benchmarks for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">G-to-T</FONT></FONT> Prime Editing in Mammalian
Cells.<I> </I>Graph Depicts a Broad Range of RTs that Exhibited Higher Natural Activity than Unengineered Prime Editing RT. </P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g425213g55v25.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Unengineered prime editing control RT is from Moloney murine leukemia virus (&#147;MMLV&#148;). </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">RTs were cloned into a plasmid backbone that was <FONT STYLE="white-space:nowrap">co-transfected</FONT> with chemically synthesized pegRNAs designed to edit the genome of human HEK293T cells. </TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Genomic DNA was isolated 72 hours post transfection and target loci were amplified for NGS to evaluate editing outcomes. </TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our RTs are benchmarked against natural and engineered variants of an RT widely used for prime editing in order to identify highly active natural enzymes for further
optimization along with our programmable nickases. Figure 18 shows that our natural RTs are more active than a control RT when used for prime editing. In addition, our minimally engineered RTs demonstrated up to 6 times higher activity than the
unengineered control RT for a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">G-to-T</FONT></FONT> change. This indicates that we can potentially optimize gene editing activity quicker than comparable prime editing RTs.
Figure&nbsp;19 shows that a minimally engineered Metagenomi RT has editing efficiencies equivalent to or better than engineered, industry-standard prime editing RT. Notably, this has been achieved with an ultra-small RT that is only 251 aa in
length, compared with the 671 aa of the standard prime editing RT. For therapeutic applications, complex corrections must be precise, and the precision of RIGS depends on the unique characteristics of the reverse transcriptase used. Figure&nbsp;19
also shows that one of our RTs has demonstrated significantly higher editing accuracy compared to the engineered, industry-standard control. In order to measure optimal activity for new systems, multiple primer binding sequence (PBS) lengths must be
tested. In some case, Metagenomi RT are more active across a broader range and with smaller PBS lengths compared with the control, providing more flexibility around pegRNA design. We believe our RIGS are distinguished from typical systems used for
prime editing by the high efficiency and accuracy of the RTs, as well as the broad targetability of our programmable nickases. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">160 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Figure 19</B>.<I> </I>Our Ultra-Small RTs are Efficient and Accurate Systems for Conducting Complex Genomic Corrections in Mammalian Cells.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">


<IMG SRC="g425213g41s00.jpg" ALT="LOGO">
</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:7.5pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="font-size:8pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:7.5pt; font-family:arial">*&#8195;&#8194;The
engineered prime editing benchmark RT is the MMLV variant used in PE2 prime editing systems.</P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:7.5pt; font-family:arial">*&#8195;&#8194;RT were tested with an unoptimized plasmid delivery system that enables high-throughput benchmarking of novel RT
to identify leads.</P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:7.5pt; font-family:arial">*&#8195;&#8194;Plasmids encoding RT
and Cas were <FONT STYLE="white-space:nowrap">co-transfected</FONT> with chemically synthesized pegRNAs designed to edit the genome of human HEK293T cells.</P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-2.00em; font-size:7.5pt; font-family:arial">*&#8195;&#8194;Genomic DNA was isolated 72 hours post transfection and target loci were amplified for NGS to evaluate editing
outcomes.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD COLSPAN="3" VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Our novel RTs are selected to enable the development of Big RIGS for RNA-templated, large, targeted therapeutic transgene integration
</I></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Figure 20</B>. Our RTs Have Been Observed to be Active, Processive, and High-Fidelity.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"><B>Figure 20a</B>. Our RTs were more processive than RT typically used for prime editing, enabling transcriptions of large gene templates in mammalian cells.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Figure 20b</B>. Our RTs were more accurate than industry-standard RT.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="center">


<IMG SRC="g425213g00a13.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="center">


<IMG SRC="g425213g00a14.jpg" ALT="LOGO">
</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:7.5pt; font-family:arial">*&#8195;&#8194;Prime editing benchmark RT is MMLV.</P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:7.5pt; font-family:arial">*&#8195;&#8194;Processivity was measured by qPCR
quantification of cDNA produced in mammalian cells from 4 kb templates.</P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-2.00em; font-size:7.5pt; font-family:arial">*&#8195;&#8194;Typically, less than 1% of 4 kb templates are fully transcribed by MMLV.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:7.5pt; font-family:arial">*&#8195;&#8194;Template modifications are <FONT STYLE="white-space:nowrap">N1-methylpseudouridine.</FONT></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-2.00em; font-size:7.5pt; font-family:arial">*&#8195;&#8194;Fidelity was measured by NGS.</P></TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our RTs were screened based on their activity and processivity in mammalian cells in order to identify highly active systems capable of
reverse transcribing RNA templates over 4,000 base pairs in length (&gt;4 kbp). We chose the 4 kb benchmark as many potential therapeutic targets could be addressed with a genomic integration of this size (current prime editing systems are limited
to RNA-templated integration around 100 bp). In Figure 20, our best-characterized RTs were compared with industry standard systems in order to benchmark their </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">161 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
activity, processivity, and fidelity. When tested in mammalian cells, our RTs were routinely able to fully transcribe a 4 kbp template into DNA. In Figure 20a, we show that our RTs demonstrated
orders of magnitude more processivity than control RT when tested on these large templates, which we believe is a strong indication of being able to convert therapeutically relevant templates delivered as RNA into DNA for genomic integration.
Importantly, Figure 20b also shows that on average our RTs transcribed over 4 kbp without introducing errors. Furthermore, template modifications <FONT STYLE="white-space:nowrap">(N1-methylpseudouridine),</FONT> which could enable delivery of RNA
templates less likely to trigger an immune response, improved fidelity. We are engineering our RTs along with our programmable nucleases and nickases for targeted genomic integration of a donor template delivered as RNA. Initial readouts show that
when combined with a CRISPR effector and targeting gRNA, Metagenomi RT are able to incorporate newly synthesized DNA from an RNA template into a target site. In principle, these systems, which represent a major step forward in the genome editing
space, could be delivered entirely as RNA and could enable large, targeted exogenous gene integrations. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><FONT STYLE="white-space:nowrap">DNA-Mediated</FONT>
Integration Systems: CAST and other approaches to achieving large genomic integrations </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Overview </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Figure 21</B>. Schematic Showing Application of CAST for Large, Targeted Genomic Integrations. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g425213g96b78.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Genome editing approaches based on nucleases, base editing, and prime editing are capable of precisely modifying the genome to address
disease. However, for therapeutic approaches that necessitate expression of an exogenous gene or complete gene correction, large integration approaches are needed. Many individual diseases are associated with a wide variety of genetic mutations and
thus may require an entire healthy gene to counteract each of the many different underlying causes. For example, there are over 1,800 mutations in the CFTR gene associated with cystic fibrosis. While in theory most of these mutations could be
addressed using distinct and mutation-specific base or prime editing systems, this would require the optimization and translation of a large number of genome editing therapies. Alternatively, integration of a complete and correct copy of the CFTR
gene could potentially cure patients with varying mutations in a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-and-done</FONT></FONT> treatment. Directed DNA integration has largely been considered the ultimate goal of
corrective genome editing, where enzymatic systems with this capability could provide safe and sustained therapeutic protein expression. By developing <FONT STYLE="white-space:nowrap">DNA-mediated</FONT> integration systems and RIGS, we are at the
forefront of creating a new class of genome editing therapeutics. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Many efforts over the past decades have sought to achieve direct DNA integration in order to
develop treatments that work across diverse tissues, cell types, and genetic variants. Established transposase and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">162 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
lentiviral systems are efficient at inserting large DNA cargos into the human genome but result in <FONT STYLE="white-space:nowrap">non-specific</FONT> and sometimes hyperactive integrations that
have led to severe adverse events during clinical trials. Furthermore, recombinases have gained attention recently as a possible solution, given that they are able to incorporate large (&gt;10 kbp) genomic cargos in a
<FONT STYLE="white-space:nowrap">non-random,</FONT> site-specific manner in mammalian cells. However, these systems typically require additional genome editing tools, such as prime editing systems, in order to first install recognition sites into
the genome. These recognition sites are required by the recombinase and thus control where the enzyme can incorporate new genomic material. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">CASTs are a new
technology that is exciting because of their programmable, site-specific, and enzymatic integration capabilities. While these systems have been challenging to translate for mammalian cell and human therapeutic applications, we have had recent
breakthrough success by demonstrating that the most compact type of CAST, based on catalytically dead nucleases, are capable of programmable and targeted DNA integration into the genome of human cells. Our CASTs are being developed in order to
enable large (&gt;10 kbp), targeted genomic integrations for therapeutic applications. This technology has the potential to address a large collection of complex genetic diseases driven by a loss of function mutation, such as cystic fibrosis. </P>
 <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Our Approach </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are pursuing multiple approaches to achieve targeted,
large genomic integrations, including both RNA and DNA templated systems. Unlike RNA-templated systems that undergo a copying mechanism in order to integrate into the genome, DNA templated systems orchestrate the direct mobilization of the template
into the genome. This direct integration avoids copying mechanisms that may be inhibited by certain template features, and thus allows for the incorporation of much larger templates compared with <FONT STYLE="white-space:nowrap">RNA-mediated</FONT>
systems. Given that RNA-templated systems may have delivery advantages for some applications, we are developing both technologies to have the broadest potential to address diseases through targeted integration of large transgenes. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The development of our novel CAST systems was made possible by the discovery and engineering of active natural variants from our metagenomic library. CASTs are being
developed to achieve accurate and efficient integration of large DNA cargos at a target locus, without depending on dsDNA breaks. CASTs are unique in that they combine the programmability of a CRISPR effector with the enzymatic integration
capability of a transposase. We hypothesized that activity in human cells could be accomplished by combining novel system discovery with systematic development designed to tune the systems to the mammalian nuclear environment. We conducted a
detailed survey of newly-discovered CAST systems and demonstrated the ability of novel systems for programmable integration of a transgene <I>in vitro</I> and in <I>E. coli</I>. The high efficiency of our systems enabled us to demonstrate directed
transposase activity into single copy, safe harbor loci in the genome of human cells, as shown in Figure&nbsp;21. Our results will enable the rapid development and optimization of CASTs to address unmet therapeutic and biotechnological needs. We
believe we are the first to achieve this milestone using the most compact variety of CASTs. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are also developing systems based on recombinases and other
mobile elements that can be used in combination with programmable nucleases, including catalytically dead variants, as well as with Little RIGS in order to affect large, targeted genomic integrations under circumstances where CASTs are not the ideal
genome editing technology. Beyond therapeutic use, novel systems with these capabilities could enable synthetic biology, antibody discovery, functional genomics, animal model development, and various other unmet needs in the biotechnology space.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">163 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Our novel and engineered CASTs are capable of integrating large DNA cargo at a safe-harbor locus in the human
genome </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have shown preclinical <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-capability</FONT></FONT> for our CASTs by
demonstrating targeted integration of a large DNA template in the genome of mammalian cells. Translation from bacteria to human cell editing required protein engineering to mitigate the complex coordination between multiple protein and nucleotide
components. Figure 22 shows <FONT STYLE="white-space:nowrap">PCR-based</FONT> confirmation achieved by detecting the junction between the donor DNA template and the target sequence in the genome of HEK293T cells. Targeted integration was achieved by
delivering the CAST system as an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">all-in-one</FONT></FONT> plasmid, while the DNA donor is delivered on a second plasmid. We believe the ability to target payloads to a single copy,
safe-harbor locus now allows for further therapeutic-driven optimization and development. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Figure 22.</B> Our CASTs Demonstrated Targeted Integration of a DNA
Template at a Safe-harbor Locus in the Genome of Mammalian Cells. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g425213g85l79.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">PCR of junction between template and target confirms integration at target loci in HEK293T cells. </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Successful transposition is indicated by a band of the correct size in the gel in treated samples, but not in the null target (control) sample. </TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Sequencing of PCR products from the junction between the template and target confirmed integration. </TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Future Novel
Editing System Discoveries </I></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our scientific underpinnings based in metagenomics provides a continuous engine for discovering and developing potentially next
generation genome editing systems. As we continue to build upon our metagenomic library, we expect to make additional discoveries of novel technology, and expand our toolbox to further unlock the field of genome editing. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><U>Our Pipeline </U></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are taking a stepwise approach deploying our genome
editing toolbox to develop potentially curative therapies for patients. Our lead programs are selected to both address important diseases and to establish new standards in targetability, precision, efficiency, and scope of editing capabilities.
Figure 23 summarizes the portfolio of programs that we and our partners are advancing, as we aim to match the optimal genome editing tools for each indication. Each of these indications were chosen based on our conviction in the underlying biology,
existence of validating preclinical and clinical data, availability of pharmacodynamic and translational tools to assess early proof-of-concept, relevant value-supporting outcome measures, and ongoing clinical unmet need. Our lead programs capture
an ever-growing set of translational learnings and insights that will inform and accelerate future programs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">164 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Figure 23.</B> Therapeutic Translation. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g425213g42c52.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><U>Hemophilia A&#151;novel, durable, knock-in approach for expression of Factor VIII </U></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>The Disease </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Hemophilia A is the most common
<FONT STYLE="white-space:nowrap">X-linked</FONT> inherited bleeding disorder and is caused by mutations in the FVIII gene leading to loss of functional FVIII protein that impacts the body&#146;s ability to form normal clots in response to injury.
FVIII is normally produced in the liver within sinusoidal endothelial cells and is then secreted into the bloodstream where it acts as a cofactor for the catalytic activation of Factor X in the clotting pathway. The lack of functional FVIII disrupts
the normal clotting cascade and predisposes patients to increased risk of bleeding, either spontaneously or in response to injury or surgery. Repeated bleeding episodes in joints or soft tissues can lead to progressive joint damage, inflammation,
pain, and mobility impairment. Intracranial bleeding is of greatest concern as this can be rapidly fatal or lead to major morbidity. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The severity of hemophilia A is
directly correlated to the amount of residual FVIII activity. Severe hemophilia is defined as less than 1% of normal FVIII activity, moderate hemophilia defined as <FONT STYLE="white-space:nowrap">1-5%</FONT> of normal FVIII activity and mild
hemophilia defined as 5 to 40% of normal FVIII activity. There are estimated to be nearly 30,000 patients with hemophilia A in the United States and more than 500,000 patients with hemophilia A globally. Of these, approximately 60% have severe
disease and are at the greatest risk of spontaneous life-threatening bleeding events. In these patients, diagnosis typically occurs in infancy due to exaggerated bleeding in response to minor injury or routine medical procedures. As the inheritance
of hemophilia A is <FONT STYLE="white-space:nowrap">X-linked,</FONT> the vast majority of patients are male. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Limitations of Current Approaches </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The standard of care for patients with severe hemophilia A involves life-long repeated IV infusions of recombinant FVIII preparations prophylactically and in response to
bleeding events. The major limitation of this approach is fluctuating FVIII activity levels, with trough values that can still result in breakthrough microscopic and macroscopic bleeding events, particularly within sensitive and previously damaged
joints. Additionally, frequent FVIII infusions are inconvenient, which can be associated with suboptimal compliance, and in some patients result </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">165 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
in inhibitor formation (antibodies against FVIII) that compromise efficacy. More recently, emicizumab, a bispecific antibody, has been approved for hemophilia A in the United States that acts as
functional FVIII mimetic in binding Factors IXa and X to support catalytic activation. This antibody approach has the benefit of a longer half-life than typical recombinant FVIII protein infusions that allows for less frequent administration but has
the drawback of not being a true FVIII protein replacement therapy and breakthrough bleeding has been reported. Both the bispecific antibody and FVIII protein replacement approaches have a high economic burden (estimated lifetime cost of $15 to
18&nbsp;million per patient). </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Valoctocogene roxaparvovec, the first hemophilia A gene therapy, was conditionally approved for use in Europe in August 2022 and was
approved in the United States in June 2023. This genetic medicine delivers a FVIII gene construct to the liver using an AAV vector. Once transduction of liver cells occurs, the FVIII gene resides in an episomal state (meaning not integrated in the
genome) where it is transcribed from an artificial engineered exogenous promoter to produce FVIII mRNA which is translated into FVIII protein. This gene therapy approach has the potential benefit of constant production of FVIII protein by the liver;
however, longitudinal clinical data has demonstrated that FVIII levels drop over time. To date, repeat dosing of a gene therapy has not been possible due to the production of high titers of neutralizing antibodies to the AAV vector. Importantly, AAV
gene therapy is also not a feasible treatment approach for infants or children due to the high degree of liver growth during pre-adulthood that would dilute out the episomal FVIII gene during progressive rounds of liver cell division. Thus, there
continues to be a significant unmet need in hemophilia A for a curative therapy that can provide life-long protection from bleeding events in adults and children. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Our Approach and Results </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Experience with early hemophilia A gene therapy
approaches suggest that morbidity and mortality from the disease can be markedly reduced by achieving only moderate amounts of stable FVIII expression. For instance, achieving stable FVIII activity above <FONT STYLE="white-space:nowrap">5-10%</FONT>
of normal activity level has the potential to convert a patient with severe hemophilia at risk of catastrophic bleeding into a patient only at risk for bleeding in the setting of major trauma or surgery. Achieving stable levels of FVIII above 15%
activity level could provide complete joint protection and may allow patients to have a functional cure from their disease. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Rather than provide the FVIII gene in an
episomal location, which risks dilution from cell division or cell death as well as episomal transcriptional silencing, our approach is to insert a FVIII DNA cassette into a &#147;safe harbor location,&#148; within an intron of the albumin gene that
is not expected to have deleterious effects. FVIII expression is then driven by the strong native albumin promoter. This approach has previously been demonstrated in preclinical studies to lead to therapeutically relevant expression of a different
clotting factor (Factor IX) with negligible impact to systemic circulating albumin levels. Our FVIII knock-in approach is designed to provide stable expression and clinically relevant circulating levels of FVIII, even at low integration rates
because of the strength of the albumin promoter. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our approach is fundamentally different from the AAV gene therapy approaches. AAV gene therapy approaches use a
viral vector to deliver a replacement FVIII gene driven off a <FONT STYLE="white-space:nowrap">non-natural</FONT> promoter that exists in an episomal state (not integrated in the genome). This AAV FVIII gene therapy approach has been associated with
the loss of FVIII expression over time in patients, a phenomenon hypothesized to be due to a combination of loss of the DNA encoding the FVIII gene (due to liver cell replication) and silencing of the episomal FVIII expression. Because our approach
is designed to permanently integrate the FVIII gene into the genome of the patient, the FVIII gene should not be lost from the liver when the liver cells divide (because it is integrated in the genome and therefore transferred to the daughter cells
during cell division), which may allow for a therapeutic option for children with hemophilia. Silencing of expression may be less likely to occur with our approach because we are using an endogenous albumin promoter rather than a synthetically
designed promoter in a <FONT STYLE="white-space:nowrap">non-natural</FONT> episomal state. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As shown in Figure 24, our hemophilia A genome editing program has two
components: a LNP component that is designed to deliver mRNA along with a gRNA to the liver to produce a highly efficient and specific nuclease to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">166 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
create a precise cut at the albumin safe harbor gene locus; and an AAV vector that is designed to deliver the donor template FVIII DNA that becomes inserted into the nuclease cut site by the
naturally occurring DNA repair process called <FONT STYLE="white-space:nowrap">non-homologous</FONT> end joining. The DNA template encodes a FVIII protein, and the sequence has been optimized to improve expression. In preclinical mouse models we
have demonstrated that this FVIII <FONT STYLE="white-space:nowrap">knock-in</FONT> approach leads to stable integration and clinically relevant circulating levels of FVIII. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Figure 24</B>. Therapeutic Approach to Hemophilia A Genome Editing. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g425213g19a10.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have performed guide RNA screening in human and mouse cells to identify both candidate clinical guides and mouse surrogate guides.
In the case of the human guide screen, a total of 77 guides for three of our nucleases were screened against albumin intron 1 in liver cell lines, and two guides (called guide 1 and guide 2) were selected as potential leads. Primary human
hepatocytes (&#147;PHH&#148;) isolated from the livers of deceased individuals are the most appropriate preclinical model to evaluate human liver genome editing. Guide 1 and guide 2 displayed dose dependent editing in PHH with guide 2 exhibiting the
highest potency (Figure 25). Genome editing nucleases can edit at sites other than the intended target site, an activity that is dependent on the specific nuclease and guide. Editing at <FONT STYLE="white-space:nowrap">non-target</FONT> sites
(called <FONT STYLE="white-space:nowrap">off-target</FONT> editing) is undesirable due to the potential to cause damage to the host cell DNA (commonly called &#147;genotoxicity&#148;). We have analyzed
<FONT STYLE="white-space:nowrap">off-target</FONT> editing of guides 1 and 2 in PHH using an industry standard in-cell method that identifies potential off-target sites. Guide 2, the most potent guide that is being advanced to our next NHP study
exhibited low off-target editing when evaluated by this in-cell oligo integration method with only two potential <FONT STYLE="white-space:nowrap">off-target</FONT> sites detected at low frequencies of 0.07% of on target editing. Guide 1, that is
less potent and remains as a backup, displayed a less favorable off-target profile when assayed by the oligo integration method with 1 potential off-target site detected at 5% of the on-target editing frequency. Both guides are being further
evaluated using a combination of in silico prediction and biochemical assays to nominate potential off-target sites that will be tested in PHH to determine if any of these potential off-target sites are bona fide off-target sites. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">167 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Figure 25</B>. Editing at the Human Albumin Locus by Lead Nuclease and Guides in Primary Human Hepatocytes. Each
Set of Four Bars is a Dose Response (from High Dose to Low Dose Going from Left to Right) Performed at Three Different Molar Ratios of mRNA to gRNA. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g425213g11m20.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">*</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Each set of four bars is a dose response (from high dose to low dose going from left to right) performed at three different molar ratios of mRNA to guide RNA </TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have demonstrated the feasibility of the FVIII gene <FONT STYLE="white-space:nowrap">knock-in</FONT> approach in mice with several mouse specific guides and different
FVIII DNA donor cassettes as shown in Figure 26, with integration of the FVIII gene leading to FVIII mRNA expression and therapeutically relevant levels of FVIII protein in the blood. In these experiments, we quantified integration of the FVIII gene
in the correct (forward) orientation at the target site in the albumin locus at frequencies between 1% to 2%. In the same mice, we measured FVIII protein in the blood at levels of <FONT STYLE="white-space:nowrap">5-10%</FONT> of normal, levels that
would be sufficient to prevent the majority of bleeding events in hemophilia patients. Efforts to further optimize the DNA donor cassette to potentially achieve even higher levels of FVIII protein per integrated copy are ongoing. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Figure 26</B>. Integration and Expression of FVIII in Rodents after Genome Editing. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g425213g11m21.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">168 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The editing efficiency of the two lead gRNA sequences (guide 1 and guide 2) were evaluated in non-human primates
(&#147;NHPs&#148;). Guide 1 is a perfect match to the target sequence in the NHP genome while guide 2 required a single nucleotide change in the spacer to match perfectly to the target sequence in NHPs. The same nuclease mRNA sequence was used with
both guides and the guide and mRNA were <FONT STYLE="white-space:nowrap">co-delivered</FONT> with the same LNP formulation by IV infusion of three cynomolgus macaques per group at a dose of 1.25 mg RNA per kg body weight. The editing efficiency in
five different regions of the liver (representing the different liver lobes) were measured by determining the InDels at the target site using next generation sequencing in each of the three animals per treatment group as shown in Figure 27. Editing
levels were similar across the five liver regions (represented by the five dots in each bar) demonstrating that editing was homogenous across the entire liver. Guide 2 resulted in a mean editing efficiency of 50% amongst the three animals. This
represents editing in approximately 70% of hepatocytes because hepatocytes make up about 70% of the cells in the liver and the LNP delivers primarily to hepatocytes. Based on our mouse studies, we expect that this level of editing may be sufficient
to achieve the required level of donor template DNA integration. Because InDel formation in the albumin safe harbor locus occurs within the <FONT STYLE="white-space:nowrap">non-coding</FONT> intron these high levels of editing do not result in
measurable changes in circulating albumin levels in edited mice. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Figure 27</B>. Efficient Editing in NHPs at the Safe Harbor Locus for the Hemophilia A Program.
</P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g425213g01m21.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">*</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Each bar is an animal and each datapoint represents a different lobe of the liver. </TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Next Steps </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are finalizing donor DNA cassette optimization and performing our next set of NHP studies to demonstrate and quantify FVIII integration and FVIII protein expression.
In parallel, we are manufacturing mRNA, gRNA, AAV and LNP to support future IND-enabling studies. We expect to select a final development candidate in the first half of 2024 and initiate IND-enabling GLP studies thereafter. The progress we have made
on this program not only validates the efficiency and specificity of our novel nucleases in rodent and NHP models, but also supports our ongoing efforts with other large gene integration approaches. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Primary Hyperoxaluria, Type 1&#151;a durable knockdown of HAO1 for substrate reduction therapy </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>The Disease </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">PH1 is a rare autosomal recessive metabolic disease arising from
loss of function mutations in the AGXT gene that encodes alanine glyoxylate aminotransferase. This enzyme is found in peroxisomes of the liver where it catalyzes the conversion of glyoxylate to glycine and pyruvate. Lack of functional AGXT leads to
an accumulation of glyoxylate substrate, which is then converted to oxalate and excreted in the kidney. The excess </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">169 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
urinary oxalate forms an insoluble complex with urinary calcium that leads to the production of calcium oxalate crystal precipitates. This pathologic process results in the formation of repeated
calcium oxalate urolithiasis and nephrolithiasis, which in turn leads to obstructive uropathy, inflammation, fibrosis, tubular toxicity, and progressive loss of kidney function. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">PH1 is a serious disease that causes kidney failure. More than 70% of individuals with PH1 mutations will develop end-stage renal disease, with a median age in young
adulthood. Patients with PH1 continue to experience morbidity and mortality even after the development of <FONT STYLE="white-space:nowrap">end-stage</FONT> renal disease due to progressive systemic calcium oxalate precipitation in various organs
(systemic oxalosis). Despite renal replacement therapy or kidney transplantation, patients with PH1 have an overall shorter lifespan than patients with other causes of renal failure, highlighting the progressive and severe nature of this metabolic
disease. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">PH1 is the most common of the primary hyperoxalurias but is a rare disease with an estimated prevalence of approximately one to three in 1,000,000
individuals. While epidemiologic data on PH1 is limited, these estimates suggest there are approximately 1,000 to 3,000 patients in both the United States and Europe, and possibly up to 20,000 patients globally. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Limitations of Current Approaches </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Until recently, the standard of care for
treating PH1 was primarily supportive in nature, with hydration and diuretics used to reduce urinary oxalate concentration, pyridoxine (vitamin B6) to enhance residual function of alanine glyoxylate aminotransferase catalytic activity, and
hemodialysis once renal function progressed to end stage. Liver transplantation has also been explored as a means of providing patients with a normal copy of AGXT and has been used alone in early-stage patients or as a combined liver-kidney
transplant in more advanced patients. Transplantation approaches have limitations due to donor availability, morbidity associated with the surgical procedure, and lifelong immunosuppression required to inhibit graft rejection. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">More recently, the standard of care has been updated to include treatment with lumasiran, a siRNA therapeutic approved in adults and children with PH1 that acts to
reduce the levels of urinary oxalate. Using a therapeutic approach known as substrate reduction therapy, lumasiran targets mRNA from a separate gene, HAO1, that encodes GO. By inhibiting GO, levels of glyoxylate are reduced, which results in reduced
downstream levels of oxalate. As a result, lower urinary oxalate results in decreased urinary calcium oxalate stone formation. It is anticipated that inhibition of renal oxalate accumulation and stone formation can slow or prevent continued loss of
renal function. Lumasiran has been generally well tolerated in clinical studies of adults and children with PH1 but it requires repeat subcutaneous administration indefinitely in order to maintain its effect. In addition, injection site reactions
are common among patients taking lumasiran and the degree of urinary oxalate reduction has been observed to not reach normal levels in many patients. Thus, there is a potential to improve clinical outcomes for PH1 patients with a <FONT
STYLE="white-space:nowrap">one-time</FONT> administration of a therapy that inhibits urinary oxalate accumulation, prevents calcium oxalate stone formation, and protects renal function. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Our Approach and Results </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The goal of our genome editing approach is to
durably knock down HAO1 resulting in stable and permanent reduction of oxalate levels to effect a lifelong benefit. We plan to deliver mRNA for one of our lead nucleases and a guide encapsulated within a single LNP as shown in Figure 28 below. We
expect the mRNA and HAO1 gRNA will be released in hepatocytes (the cell type in the liver that expresses the HAO1 gene) where the mRNA will be expressed into the nuclease that forms a complex with the guide and create a double stranded break in the
HAO1 gene and inhibits gene expression. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">170 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Figure 28</B>. Genome Editing Strategy for Targeting HAO1. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g425213g47c44.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The safety of this durable knock-down of HAO1 is supported by human genetic observations of an individual lacking a functional copy of
the HAO1 gene with no evidence of a pathologic phenotype. The safety of this approach is also supported by up to three years of clinical data using a siRNA approach to silence this gene. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have performed nuclease and guide screening to select an optimal nuclease and gRNA combination. The double strand break created by the selected nuclease has been
observed to be efficiently and rapidly repaired by the cell via a process that introduces small InDels to the sequence at the target site. When these InDels alter the reading frame of the gene (so called &#147;out of frame&#148; InDels) this results
in degradation of the HAO1 mRNA. Because different nucleases and guides generate distinct InDel profiles, we included analysis of the InDel profile as a selection criterion during our nuclease /gRNA screen. In addition to the InDel profile, we also
screened for the efficiency of HAO1 mRNA reduction and impact on the HAO1 mRNA sequences using whole transcriptome RNA sequencing (&#147;RNAseq&#148;). This screening process resulted in selection of a lead guide that targets an identical sequence
in humans and mice which enables the evaluation of the lead human guide in mouse models. The potency of this lead nuclease and guide was tested in PHH <I>in vitro</I> as shown in Figure&nbsp;29, demonstrating dose-dependent editing when delivered by
a LNP with tropism to the liver. Preliminary evaluation of <FONT STYLE="white-space:nowrap">off-target</FONT> editing in primary human hepatocytes using industry standard approaches has shown minimal off-target events. No editing was observed at
selected potential off-target sites in PHH that were edited at a dose of nuclease and guide that resulted in maximal on-target editing. Three <FONT STYLE="white-space:nowrap">off-target</FONT> edits were observed but only at doses more than <FONT
STYLE="white-space:nowrap">20-fold</FONT> higher than the dose that resulted in maximal <FONT STYLE="white-space:nowrap">on-target</FONT> editing. In addition, these three off-target sites were edited at low frequency (less than 1% of <FONT
STYLE="white-space:nowrap">on-target</FONT> editing) and were located in <FONT STYLE="white-space:nowrap">non-coding</FONT> regions of the genome that we believe pose minimal concern. Additional off-target evaluation is planned prior to development
candidate nomination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">171 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Figure 29</B>. Editing Dose Response in Primary Human Hepatocytes with the Lead Nuclease mRNA and Guide Targeting
HAO1 Delivered in a LNP. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g425213g01m24.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In normal mice we have demonstrated dose dependent saturating levels of hepatocyte genome editing of HAO1 and up to 90% reduction of
target GO protein, providing strong preclinical proof-of-concept as shown in Figure&nbsp;30. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Figure 30</B>. Dose Dependent Editing, mRNA Knockdown and Protein
Knockdown of HAO1 in Normal Mice after a Single Administration of the Lead Nuclease mRNA and Lead Guide Encapsulated in a LNP with Tropism to the Liver. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt; margin-left:11%" ALIGN="center">


<IMG SRC="g425213g26g26.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Additionally, along with our partner Moderna, we have achieved
preclinical proof-of-concept in an AGXT knock-out mouse which is an accepted disease model of PH1 (Figure 31). AGXT knock-out mice have elevated oxalate in the urine (measured with a mass spec assay) of about 500 mg per gram of creatinine compared
to about 190 mg per gram of creatinine in mice of the same strain (BL/6) with a wild type AGXT genotype. Cohorts of male and female mice were given a single administration of the lead nuclease mRNA and gRNA encapsulated in a LNP with tropism to the
liver. Dose dependent editing at the target site in HAO1 in the liver was measured at the end of this study (when the mice were sacrificed). As a control a Cas9 mRNA and a potent Cas9 guide targeting HAO1 from a published source were also packaged
in the LNP with tropism to the liver and tested at a single dose. The editing of HAO1 had the expected effect of dose dependently reducing urinary oxalate, with the highest dose achieving oxalate levels compared to that of wild type mice. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">172 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Figure 31.</B> Preclinical Proof of Concept in PH1 Disease Model (AGXT -/- mice). </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="55%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"><B>Figure 31a. </B>Dose dependent editing of the HAO1 gene in AGXT -/- mice.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>Figure 31b. </B>Dose-dependent reduction in urinary oxalate reaching normalization at highest dose.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" ALIGN="center">


<IMG SRC="g425213g57a59.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g425213g57a60.jpg" ALT="LOGO">
</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top">Source: Moderna</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Source: Moderna</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The durability of this approach was demonstrated by continued knockdown of GO protein even after partial hepatectomy (removal of about
two thirds of the liver) and rapid liver <FONT STYLE="white-space:nowrap">re-growth</FONT> (Figure 32). In this study wild type mice were given a single injection of either buffer or a liver tropic LNP encapsulating the MG nuclease mRNA and the lead
gRNA targeting HAO1. Eight days after dosing a liver hepatectomy was performed in which about two thirds of the liver was removed. This stimulates the majority of the remaining liver cells to enter cell division and results in rapid re-growth of the
liver that restores the normal liver size within 7 to 10 days. Eight days after partial hepatectomy the levels of GO protein (the product of the HAO1 gene) in the liver were reduced by more than 90%, the same as the level of knockdown in edited mice
that did not undergo hepatectomy. This result demonstrates that the knock down of HAO1 expression was not compromised by extensive liver growth and that the fitness of edited hepatocytes was not impacted by editing. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Figure 32.</B> Knockdown of the Protein Encoded by HAO1 after HAO1 Gene Editing was Maintained Following Partial Hepatectomy. Control Mice were Injected with Buffer
as a Control. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g425213g58b60.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; margin-left:2%; text-indent:-1%; font-size:8pt; font-family:arial">Source: Moderna </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">173 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Next Steps </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are in the
final stages of confirming the candidate to take into NHP studies and are scheduled to begin NHP studies in 2023 to support final development candidate selection thereafter. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This program is partnered with Moderna for both development and commercialization. The partnership enables us to leverage Moderna&#146;s deep expertise in mRNA and LNP
technology to ensure efficient delivery of our nuclease to hepatocytes. In turn, we provide the novel programmable nuclease and guide chemistry to support precise targeting of the HAO1 gene. In addition to further validating our therapeutic
platform, to the best of our knowledge this program represents the first time a type V nuclease is being developed for a therapeutic <I>in</I> <I>vivo</I> genome editing approach. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:arial"><U>Transthyretin Amyloidosis&#151;a single treatment to knockdown TTR gene expression</U> </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>The Disease </I></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Transthyretin amyloidosis is a disease of misfolded and
aggregated TTR protein that can deposit in tissues causing organ dysfunction, primarily in the heart and/or peripheral nerves. The TTR protein is normally produced in the liver and circulates in a homotetramer (four copies of the same TTR protein
bound together) where it serves as a carrier protein for vitamin A and thyroxine. Certain mutations have been identified that can cause TTR homotetramers to fall apart, misfold, and aggregate into insoluble fibrils that deposit in cardiac tissue and
peripheral nerves. However, more commonly, the normal aging process is associated with an increased propensity for TTR misfolding and aggregation in the heart without any known genetic sequence variation. These distinctions lead to TTR amyloidosis
being characterized as either ATTRv caused by mutations in TTR, or ATTRwt. It is estimated that globally there are approximately 50,000 patients with ATTRv and between 300,000 and 500,000 patients with ATTRwt. Among the larger ATTRwt patient
population, the most common presentation is a rapidly progressive, restrictive, and hypertrophic cardiomyopathy due to progressive deposition of insoluble TTR fibrils, which result in thickening of the myocardium and stiffening of the ventricles.
These pathologic processes lead to impaired diastolic function and progressive cardiomyopathy that typically leads to progressive heart failure and often death within three to five years from disease onset. Although cardiac manifestations are more
common and severe, patients with neurologic manifestations also experience significant morbidity, loss of functionality, and impaired quality of life. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Limitations of Current Approaches </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To date, treatment options for patients
with TTR amyloidosis, including those with either cardiomyopathy or polyneuropathy manifestations, consist of efforts to stabilize the TTR tetramer with a small molecule (tafamadis) or knock down TTR levels through antisense oligonucleotides (i.e.,
inotersen and eplontersen which is currently under regulatory review in the U.S.) or siRNA strategies (i.e., patisiran and vutrisiran). </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Tafamadis was studied in
a randomized trial of patients with either ATTRv and ATTRwt cardiomyopathy and demonstrated reductions in <FONT STYLE="white-space:nowrap">all-cause</FONT> mortality and cardiovascular-related hospitalizations and reduced the decline in quality of
life and functional capacity over 30 months compared to placebo. Tafamadis is currently approved to treat patients with ATTR cardiomyopathy in the U.S. and patients with ATTRv and ATTR cardiomyopathy in the EU and in other parts of the world.
Inotersen has demonstrated benefit in patients with ATTRv and polyneuropathy and is approved in the U.S., EU, and in other parts of the world. Eplontersen has demonstrated benefit in patients with ATTRv and polyneuropathy and is currently under
regulatory review in the U.S. Eplontersen is also being studied in a Phase 3 trial for patients with ATTR cardiomyopathy. Patisiran is approved for the treatment of polyneuropathy of ATTRv in adults in the U.S., EU, and other parts of the world.
Patisiran is currently under regulatory review for the treatment of patients with ATTR cardiomyopathy based on a randomized study demonstrating improvement in the <FONT STYLE="white-space:nowrap">6-Minute</FONT> Walk Test and quality of life over 12
months </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">174 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
compared to placebo. Vutrisiran has demonstrated benefit in patients with ATTRv and polyneuropathy and is approved for use in ATTRv in the U.S., EU, and other parts of the world. Although these
approaches have improved clinical outcomes for patients with TTR amyloidosis, the disease is still associated with significant morbidity and mortality and requires lifelong therapy to maintain therapeutic benefit. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Our Approach/Next Steps </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">More recently, early-stage third-party studies have
demonstrated the feasibility of knocking down TTR (wild type or mutated versions) using a CRISPR based genome editing approach in a small number of patients. Clinical validation of this TTR knockdown approach is provided by antisense and siRNA
clinical experience and further suggests the potential longer-term safety and tolerability of this approach. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Using our novel nucleases, we aim to provide
efficient TTR knockdown and halt further deposition of amyloid fibrils. Previous experience suggests a clinical correlation between the degree of TTR knockdown and potential for benefit in familial forms of the disease, which are expected to
translate similarly to wild type forms. The high degree of <I>in vivo</I> editing efficiency and specificity of our nuclease platform suggest the potential for a single treatment to knockdown TTR gene expression and remove the requirement for
life-long therapy. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Along with our partner Ionis, we are currently in advanced stages of nuclease and guide selection and expect to move into NHP studies in
2024. We believe one of the strengths of our technology platform is applying our multiple nucleases that have distinct <FONT STYLE="white-space:nowrap">non-overlapping</FONT> PAMs to create a larger number of guides for a given target. Starting with
a larger number of guides should increase the chance of finding highly active and specific guides/nuclease combinations. Leveraging multiple nucleases with a diversity of PAMs enabled a high targeting density for the TTR gene as illustrated in
Figure 33a. By comparison significantly fewer <FONT STYLE="white-space:nowrap">(3.8-fold</FONT> fewer) guides are available when using SpCas9 (Figure 33b). We have screened more than 500 guides against the human TTR gene using six of our nucleases.
With one additional nuclease in progress we will ultimately have screened 535 guides. Our high throughput screening platform has enabled us to screen approximately 500 guides in a four-month time span. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Figure 33a</B>. High density of gRNA targeting the coding and regulatory regions of the TTR gene enabled by our platform of nucleases with diverse PAMs. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g425213g28a10.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">175 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Figure 33b</B>. Density of SpCas9 gRNA targeting the coding and regulatory regions of the TTR gene. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g425213g28a20.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are in the process of selecting lead guides and nucleases for evaluation in mouse models that carry the human TTR gene. Promising
early leads have shown potent TTR mRNA knockdown in primary human hepatocytes. We plan to deliver our programmable nuclease and its associated gRNA to the liver using LNP technology, which has been shown to be highly selective for hepatocytes. This
program not only provides a novel nuclease approach to knocking down TTR levels, but also leverages our partner&#146;s long-standing clinical development expertise in the TTR amyloidosis field to accelerate our efforts. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><U>Cardiovascular Disease &#150; a gene editing solution to eliminate angiotensinogen </U>gene expression </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>The Disease </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Cardiovascular disease is the leading cause of death worldwide
and implicated in the deaths of approximately 17.9&nbsp;million individuals each year. Although cardiovascular diseases are not genetically defined diseases, there are well validated gene targets and signaling pathways that address potent sources of
vasoconstriction allowing for the creation of an important genetic medicine for these common diseases.&nbsp;Among the most important of these signaling pathways that have demonstrated marked clinical benefit in both hypertension and heart failure is
the renin-angiotensin-aldosterone system (RAS) pathway, that has been successfully targeted by a number of important medications including renin inhibitors, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, and aldosterone
antagonists.&nbsp;Beyond its effect on blood pressure control, inhibitors of the RAS pathway have been shown to provide meaningful clinical benefit in ischemic heart disease and chronic heart failure as well as in diabetic nephropathy, and other
forms of chronic renal insufficiency. However, continuous <FONT STYLE="white-space:nowrap">24-hour</FONT> inhibition of the RAS pathway with oral agents is not always successful, especially if compliance is suboptimal. Importantly, despite use of
RAS inhibitors, diurnal variability in blood pressure and nocturnal blood pressure elevations can still occur. Recent early stage clinical studies using antisense and siRNA approaches to durably suppress the RAS pathway by targeting liver derived
angiotensinogen provides important clinical validation of this approach as a means of safely reducing blood pressure without incurring hypotension, hypokalemia, or acute renal injury. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Limitations of Current Therapy </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Although there are numerous approved classes
of drugs that have demonstrated clinical benefit in patients with cardiovascular disease and refractory hypertension patients, many patients do not reach their blood pressure goals or continue to have cardiovascular disease progression. In addition
to contributions from underlying </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">176 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
stiffened arteries and/or increased sympathetic tone, patients may have suboptimal adherence in taking a large number of daily oral pills. Importantly, current treatments often do not fully
provide reliable and consistent <FONT STYLE="white-space:nowrap">24-hour</FONT> control of blood pressure which can leave patients exposed to diurnal variation and early morning blood pressure surges associated with cardiovascular events. Adverse
effects of polypharmacy approaches and complicated food effects or drug-drug interactions can further negatively affect compliance and lead to poor outcomes. Therefore, despite the availability of oral medications, there remains a significant unmet
need for a well-tolerated, durable approach to blood pressure control and cardiovascular protection with a clinically validated target.</P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Our Approach/Next Steps
</I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our goal is to knockdown the expression of angiotensinogen in the liver using one of our programmable nucleases to generate a durable reduction in blood
pressure from a single treatment. Angiotensinogen, encoded by the gene AGT, is at the top of the RAS pathway and the precursor to highly vasoconstrictive peptides angiotensin I and II and is thus an attractive and novel target for reduction of blood
pressure. Inhibiting angiotensinogen protein production from the liver has the advantage of minimizing inhibition of the RAS pathway in the kidney which will provide a better safety profile by keeping the small amount of kidney production of AGT
intact and thus avoiding renal dysfunction that is common with current medications and ensuring adequate vasoactive homeostasis in stress situations. A second potential advantage of targeting AGT is that it may limit escape mechanisms that restore
angiotensin II levels or angiotensin II signaling. Clinical proof of concept for reduction of AGT protein levels comes from ongoing clinical trials of antisense
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(IONIS-AGT-L</FONT></FONT><SUB STYLE="font-size:75%; vertical-align:bottom">Rx</SUB>) and siRNA <FONT STYLE="white-space:nowrap">(ALN-AGT)</FONT> drug candidates that have shown
reduced mRNA levels of AGT in the liver and consequently reduced levels of AGT protein in the blood. We plan to deliver a programmable nuclease and its associated guide RNA to the liver using LNP technology. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Along with our partner Ionis Pharmaceuticals we are currently in advanced stages of nuclease and guide screening and expect to move into NHP studies in late 2024 or
early 2025. We believe one of the strengths of our technology platform is being able to access a larger proportion of the human genome by applying our multiple nucleases that have distinct <FONT STYLE="white-space:nowrap">non-overlapping</FONT>
PAMs.&nbsp;We have the potential to screen up to 1,490 guides using six MG nucleases against the AGT gene. To date we have screened 441 guides against the coding region of AGT and are planning to screen an additional 420 guides against regulatory
regions.&nbsp;Leveraging the multiple MG nucleases with a diversity of PAMs enables a high targeting density as illustrated for the seven MG nucleases that are being screened against AGT (Figure 34a). By comparison significantly fewer guides <FONT
STYLE="white-space:nowrap">(2.5-fold</FONT> fewer) are available when using spCas9 (Figure 34b). Multiple guides with potent editing of the AGT gene in human cells were identified in our initial guide screen against the coding sequence. We are in
the process of completing the guide screen and selecting lead guides/nucleases for evaluation in mouse models that carry the human AGT gene. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">177 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Figure 34a</B>: High density of guide RNA targeting coding and regulatory regions of the AGT gene enabled by
our platform of nucleases with diverse PAMs </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g425213g01a01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Figure 34b</B>: Density of spCas9 guide RNA targeting the coding and regulatory regions the AGT gene</P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g425213g01b01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We believe that this program is expected to be one of the first <FONT STYLE="white-space:nowrap">co-development</FONT> efforts to
develop a gene editing therapy for more common, <FONT STYLE="white-space:nowrap">non-genetically</FONT> defined cardiovascular indications. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><U>A1AT Deficiency
</U></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>The Disease </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A1AT deficiency is an autosomal recessive disease
arising from loss of the normal A1AT protein encoded by the gene SERPINA1. Clinical manifestations of A1AT deficiency are primarily in the lung due to the toxic loss of normal function of A1AT, and occasionally in the liver due to the toxic effects
of accumulation of abnormal A1AT. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">AIAT is a highly abundant plasma protein that acts as an inhibitor of the potent proteolytic enzyme neutrophil elastase.
Neutrophil elastase is involved in the host response to infection, but when unchecked can degrade connective tissue. In the lung, clinical manifestations of A1AT deficiency include emphysema and bronchiectasis
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">178 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
from destruction of normal alveolar connective tissue. In patients with liver disease, the primary pathophysiology is liver inflammation and cirrhosis due to buildup of abnormal A1AT protein.
Liver disease is more often found in children with A1AT deficiency, and lung disease is more often found in adults with A1AT. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A1AT deficiency is a clinically
underrecognized disease, especially those with pulmonary manifestations as it is often mistaken for other forms of chronic obstructive pulmonary disease. Recent estimates from genetic screening suggest that 80,000 to 100,000 individuals in the
United States have severe deficiencies of A1AT and approximately 40,000 to 60,000 have clinically manifest emphysema caused by A1AT deficiency. As not all individuals with A1AT deficiency present similarly, it is believed that environmental factors
such as exposure to smoke, allergens, chemicals, and other environmental factors likely impact the severity and clinical manifestations. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Limitations of Current
Therapy </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Patients with A1AT deficiency are often treated with protein augmentation therapy. The goal of augmentation therapy is to increase circulating levels of
A1AT sufficiently to balance the adverse effects of unchecked neutrophil elastase and slow the progression of emphysema. Augmentation therapy consists of an IV infusion of purified pooled donor plasma enriched for A1AT protein levels given weekly.
While studies have demonstrated the ability to achieve higher circulating levels of A1AT with augmentation therapy, longer term impacts on protecting lung function are limited. This approach is also costly and not available for many patients.
Infusions have also been associated with adverse events including <FONT STYLE="white-space:nowrap">flu-like</FONT> reactions, fever, and rarely anaphylaxis. In severe cases of lung or liver disease, organ transplantation may be required to preserve
life but are associated with post-transplant risks and long-term immunosuppression requirements. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Our Approach/Next Steps </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The most frequent mutation responsible for A1AT deficiency is the PiZ mutation that changes the normal amino acid at position 342, which is glutamic acid, to lysine
(E342K). Patients that are homozygous for the PiZ allele (called ZZ allele) make up more than 90% of the patients globally. We propose to correct this mutation back to normal using either an adenine base editor or Little RIGS. Because individuals
that are heterozygous for the PiZ mutation (so called ZM allele) have minimal pathology, it is expected that editing of 50% of the alleles would be therapeutic. The most common DNA sequence change that creates the E342K mutation is a G to A change
at the first position of the codon; GAG (normal) to <U>A</U>AG (PiZ). Converting the PiZ sequence (<U>A</U>AG) to the normal sequence (GAG) requires changing the underlined A to G which can be achieved using an adenine base editor. For this approach
to be successful, a potent gRNA needs to be identified that targets the editing window to the ABE at the precise location of the codon for amino acid 342. There are five additional A bases within 5 bp on either side of the target A base in the 342
codon which could be subject to bystander edits (defined as edits at non-target bases within the site targeted by the guide), several of which would change additional aa with unpredictable impacts on the structure and function of the protein. Given
the complexity of this edit, we will evaluate multiple genome editing systems, including base editors and RIGS, in order to advance the most effective genome editing approach. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><U>Wilson&#146;s Disease </U></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>The Disease </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Wilson&#146;s disease is an autosomal recessive disease of copper metabolism resulting from impaired function of the intracellular copper transporter encoded by the gene
ATP7B. Mutations in ATP7B lead to impaired biliary excretion of copper, leading to copper accumulation in multiple organs including liver, brain, and eye. Given the large size of the gene and allelic heterogeneity, the disease has been difficult to
target with any genetic </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">179 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
medicine to date. While impaired copper excretion begins at birth, the effect is typically not observed clinically until later in childhood or early adulthood and the majority of patients are
diagnosed between ages five and 35. The most common manifestation is chronic active hepatitis that can progress to liver cirrhosis; however, a variety of neurologic and psychiatric manifestations may also be present and undiagnosed. Such symptoms
may include dysarthria, gait impairment, dystonia, depression, irritability, and personality changes. Diagnosis is typically suggested by abnormalities in blood ceruloplasmin and/or <FONT STYLE="white-space:nowrap">24-hour</FONT> urine copper as
well as the presence of Kayser-Fleisher rings on ocular examination. Additional diagnostic certainty can come from liver biopsy and ATP7B sequencing. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Wilson&#146;s
disease has an estimated global prevalence of one patient per 10,000 to 30,000 individuals although recent genotyping studies suggest that the actual genetic prevalence may be substantially higher. This estimate suggests that there are more than
30,000 patients with Wilson&#146;s disease in the United States alone. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Limitations of Current Therapy </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Wilson&#146;s disease is a serious disease that is fatal if left untreated, typically from cirrhosis and liver failure. Once diagnosed, the standard of care for
Wilson&#146;s disease involves chronic treatments to try and remove copper from the body using copper chelators and efforts to minimize copper absorption from the gastrointestinal tract. Treatment must be lifelong to prevent copper reaccumulation
and side effects from chelator therapy (e.g. hypersensitivity reactions, fever, changes to blood counts) are common and can lead to treatment discontinuation. If treatment is discontinued, patients are at risk for hepatic decompensation or the
development of new neurologic symptoms. In patients with delayed diagnosis or rapidly progressive disease, liver transplant may be required with associated post-transplant risks and need for immunosuppression. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There are no genetic medicines approved for Wilson&#146;s disease. A genetic medicine has the potential to eliminate the need for life-long therapy and copper monitoring
as well as reduce the risk for adverse events. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Our Approach/Next Steps </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Wilson&#146;s disease is inherited in a recessive manner meaning that heterozygotes (people having one mutant allele and one wild type allele) are not affected. This
means that correction of only one of the two mutant alleles should be sufficient to confer a normal phenotype on the hepatocyte, the cell type in the liver in which the ATP7B gene performs its function. Patients with Wilson&#146;s disease have a
diverse spectrum of different mutation types (point mutations, deletions, splice site mutations) that are located throughout the ATP7B gene although different ethnic groups bear different predominant mutations. Common mutations in specific
population groups include H1069Q (30-70% of Wilson&#146;s disease patients in Germany, 30-70% in US Caucasians), M645R (approximately 30% of Wilson&#146;s disease patients in Spain), R778L (40% of Wilson&#146;s disease patients in Korea,
approximately 30% in China). </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are working to treat Wilson&#146;s disease using a Big RIGS insertion, potentially the first known instance of a targeted large
gene insertion with this approach. We believe this represents the ideal approach for genome editing for Wilson&#146;s disease because we expect that it could enable the majority of patients to be treated with the same therapy irrespective of their
specific mutation(s) in ATP7B. The ATP7B gene spans 76,000 bp of DNA in the human genome, and the protein coding sequence of ATP7B is 4,398 bp in length which encodes a protein of 1,465 aa. The majority of the pathogenic mutations identified in
ATP7B are located in the <FONT STYLE="white-space:nowrap">C-terminal</FONT> half of the protein between amino acid positions 645 and 1373 which are encoded in exons 6 to 21 (Figure&nbsp;35). This region includes the three most frequent mutations
(H1069Q, R778L, M645R, I1148T) as well as many other less common mutations. We are evaluating a genome editing approach in which a donor template that encodes exons 6 to 21 of the ATP7B gene (2460 bp) is inserted in to the ATP7B locus at intron 6
(downstream of exon 5) such that exons </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">180 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
1 through 5 of the endogenous gene are functionally fused to the inserted wild type exons 6 to 21. We believe this will generate a wild type ATP7B protein driven from the endogenous ATP7B
promoter thereby preserving the normal levels of ATP7B and normal regulation of expression. This approach should be applicable to all Wilson&#146;s disease patients except for those with mutations in exons 1 to 5 which represent only a small
fraction of the patient population. This approach leverages an all RNA based editing system such that the editing components could theoretically be delivered in a single LNP that is taken up by the hepatocytes of the liver. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Figure 35</B>. Genome Editing Strategy for Wilson&#146;s Disease. </P>  <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g425213g27n27.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><U>Familial Amyotrophic Lateral Sclerosis (&#147;ALS&#148;) </U></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>The Disease </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">ALS is a rapidly progressive neurodegenerative disorder of upper
and lower motor neurons leading to weakness, disability, and death. The prevalence of ALS is approximately four to six patients per 100,000 individuals and it is estimated that over 5,000 patients are diagnosed each year in the United States. While
the majority of ALS cases have no known family history, it is estimated that approximately 10% of cases are due to inherited causes. Of these, among the more prominent causes is from a mutation in the gene superoxide dismutase 1 (&#147;SOD1&#148;).
SOD1 ALS (occasionally referred to as ALS1), is an autosomal dominant condition associated with toxic gain of function of SOD1 leading to protein misfolding and intraneuronal cytotoxicity. While the mechanism of action of SOD1 pathophysiology is
poorly understood, it is unique in that histopathologically it does not contain typical cytoplasmic inclusions of the nuclear binding protein <FONT STYLE="white-space:nowrap">TDP-43</FONT> seen in other spontaneous and familial forms of ALS. The
median age of diagnosis of SOD1 ALS is <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mid-to-late</FONT></FONT> 40s, and similar to other forms of ALS, progressive weakness and loss of voluntary function is rapid with a median
survival after diagnosis of approximately three years. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Limitations of Current Therapy </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Despite significant investment in research over recent decades, the standard of care for treating all forms of ALS is suboptimal and there remains no cure. There are
currently three drugs approved in the United States to treat all forms of ALS (riluzole, sodium phenylbutyrate and taurursodiol, edaravone), and one recent accelerated drug approval for SOD1 ALS (tofersen). To date, only modest benefit in slowing
disease progression or improving survival has been observed, and all of these medications require repeat administration or dosing and are associated with adverse effects. In a Phase 3 clinical trial, tofersen, which is an antisense olignonucleotide
targeting SOD1 delivered directly to the cerebrospinal fluid and that requires repeated lumbar puncture monthly, did not result in a statistically significant change on clinical measures after 28 weeks of treatment, but did show a nominally
statistically significant benefit on a biomarker, neurofilament light chain, and longer term administration was associated with slowing of disease. Clinically significant adverse reactions with tofersen include myositis and/or radiculitis,
papilledema and elevated intracranial pressure, and aseptic meningitis, and additionally adverse reactions can occur from repeated lumbar puncture procedures. Thus, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">181 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
despite this precision medicine approach, there remains significant unmet need for effective therapies that can halt disease progression and improve overall survival from SOD1 ALS. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Our Approach/Next Steps </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our approach is to build upon the data generated by
tofersen and use one of our programmable nucleases to durably knock down SOD1 levels with a single administration, thus capturing durable benefit with a clinically validated disease target without requiring the patient burden of repeat intrathecal
administrations of an oligonucleotide. We plan to deliver the nuclease and associated guide using an AAV vector with sufficient tropism for lower motor neurons. We are currently initiating guide screening efforts to potently and selectively knock
down SOD1 levels and determining the appropriate nuclease/guide system for AAV packaging. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><U>Spontaneous ALS </U></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>The Disease and Limitations of Current Therapy </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As noted above, ALS is a
relentless and ultimately fatal disease of motor neurons with no known cure. Approximately 90% of ALS does not have a known family history or clear genetic cause. While the underlying cause of ALS in most cases is unknown, a common histopathologic
finding involves misfolded cytoplasmic protein aggregates that include <FONT STYLE="white-space:nowrap">TDP-43.</FONT> As <FONT STYLE="white-space:nowrap">TDP-43</FONT> is a highly conserved nuclear RNA and DNA binding protein involved in RNA
processing, the clinical manifestations of ALS may arise both from the toxic cytoplasmic <FONT STYLE="white-space:nowrap">TDP-43</FONT> aggregates as well as RNA processing abnormalities from the loss of normal nuclear functions of <FONT
STYLE="white-space:nowrap">TDP-43.</FONT> The initial symptom of ALS is a gradual onset of muscle weakness that is typically painless. These symptoms are often followed by muscle twitching, loss of coordination, falls, and fatigue that impair
functionality. As the disease progresses, loss of ambulation, spasticity, and diaphragmatic weakness progresses with the most common cause of death being respiratory failure. Despite the approval of several classes of oral compounds for spontaneous
ALS, effects on preserving clinical functionality and survival are modest. There remains significant unmet need for safe and effective therapies that can halt disease progression and improve overall survival from spontaneous ALS. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Our Approach/Next Steps </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><FONT STYLE="white-space:nowrap">TDP-43</FONT>
intracytoplasmic inclusions and proteinopathy are hallmarks of the vast majority of ALS histopathology; however, targeting <FONT STYLE="white-space:nowrap">TDP-43</FONT> directly has not been feasible due to its critical role in RNA processing and
other cellular functions. We intend to develop an ALS therapy that targets the ATXN2 gene, which we believe is an attractive target based on strong third-party preclinical data targeting the gene ATXN2, which encodes the protein Ataxin 2, and has
been shown to be a powerful genetic modifier of <FONT STYLE="white-space:nowrap">TDP-43</FONT> in yeast and flies, and importantly, knockdown of Ataxin 2, either by antisense oligonucleotides or by genetic manipulation has improved survival and
motor function in a mouse model of ALS. A Phase 1/2 clinical trial of an investigational antisense oligonucleotide targeting Ataxin 2 in adults with ALS that is administered intrathecally is in progress, which will provide further information about
the safety and efficacy of this approach. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our plan is to deliver a nuclease and associated guide using an AAV vector with sufficient tropism for lower motor
neurons. We are currently initiating guide screening efforts to potently and selectively knock down Ataxin 2 levels and determining the appropriate nuclease/guide system for AAV packaging. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><U>Charcot-Marie-Tooth Type 1a (&#147;CMT1a&#148;) </U></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>The Disease </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">CMT1a is part of a larger classification of hereditary peripheral motor and sensory neuropathies caused by pathogenic mutations in proteins associated with myelin
formation and axonal signal propagation. CMT1a is an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">182 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
autosomal dominant disease arising from a gene duplication of PMP22 (peripheral myelin <FONT STYLE="white-space:nowrap">protein-22)</FONT> and overexpression of PMP22 protein. PMP22 is tightly
regulated and expressed in Schwann cells that control the production of myelin sheaths around axons. Patients with CMT1a have altered myelination that impairs nerve conduction and neuromuscular function. Patients typically present in the first or
second decade of life with lower extremity weakness, atrophy, falls, and sensory deficits. The disease is slowly progressive and impairs mobility, and can also involve changes to distal upper extremities and limb deformities. Although life
expectancy is typically preserved, CMT1a leads to significant disability and impaired quality of life. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Although exact prevalence estimates vary, CMT is believed to
affect one patient per 2,500 individuals, with approximately 126,000 patients in the United States alone. Of those approximately half are believed to have CMT1a, the most common form of the disease. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Limitations of Current Therapy </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The treatment of CMT1a and other forms of CMT
are largely supportive and there are no approved treatments. Existing standard of care involves physical therapy, stretching, orthotics, and occasional foot surgery to improve deformities that impair ambulation. Patients should be screened for
conditions that can exacerbate neuropathies such as vitamin deficiencies or diabetes in an attempt to mitigate against more rapid progression. There are investigational efforts for RNA targeted therapeutics to reduce PMP22 overexpression with strong
preclinical data to support the approach, but clinical studies are very early and therapies would need to be given lifelong. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Our Approach/Next Steps </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our approach to CMT1A is a permanent reduction of PMP22 protein levels to the normal range by knockdown of PMP22 expression using our nuclease platform. There is
preclinical proof-of-concept for this approach in a mouse model of CMT1A using AAV9 to express a siRNA against PMP22. We intend to use our novel nucleases to introduce InDels in the promoter region of PMP22 that lead to a reproducible reduction of
PMP22 expression to the normal range. We anticipate that this editing approach will be delivered via an AAV with the goal of achieving uniformly high levels of genome editing while minimizing the risk of toxicity resulting from reducing PMP22 levels
to below normal at a cellular level. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We believe the diversity of our nuclease platforms including type V systems such as
<FONT STYLE="white-space:nowrap">MG29-1</FONT> that create larger deletions and are more likely to inactivate promoters by eliminating transcription factor binding sites, lends itself to identification of nuclease guide combinations that are
efficient and result in partial reduction in the expression of the PMP22 gene. We plan to perform a guide screen targeting the promoter region first in HEK293 cells (a cell line that expresses PMP22 mRNA) and active guides with promising InDel
profiles and editing potency will be further evaluated for PMP22 mRNA knockdown. Lead systems will be vectorized into AAV9 viruses and evaluated in the CMT1a mouse model. Once reduction of PMP22 expression is confirmed, the therapeutic benefit can
be evaluated via various endpoints including tissue morphology, nerve conduction velocity, circulating biomarkers and behavioral tests to support candidate selection. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><U>Duchenne Muscular Dystrophy (&#147;DMD&#148;) </U></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>The Disease </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">DMD is an <FONT STYLE="white-space:nowrap">X-linked</FONT> recessive myopathic disease involving loss of function mutations of dystrophin, a large protein critical for
the stabilization and protection of muscle fibers encoded by the DMD gene. In the setting of absent or abnormal dystrophin, muscle fibers are prone to injury, degeneration, fibrosis, and ultimately fatty infiltration and replacement. DMD typically
presents in early childhood with initial symptoms of muscle </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">183 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
weakness and progresses rapidly to loss of ambulation as well as respiratory muscle fatigue and cardiomyopathy. In general, large proximal muscles are affected earlier than smaller distal
muscles, and lower extremity muscles are affected earlier than upper extremity muscles. Patients are often wheelchair bound before teen years and often die in their late teens and early twenties from cardiopulmonary complications. Prior to
clinically overt findings, patients typically have marked elevations in the muscle enzyme creatine kinase that can serve as the earliest indicator of muscle inflammation and degeneration. DMD is estimated to occur in one of every 3,500 live births,
and as an x linked recessive disease is observed almost entirely in males. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">DMD is the largest gene identified in humans to date spanning approximately 2.3 Mbp, and
the severity of clinical manifestations of the muscular dystrophy is in part related to the location and type of dystrophin mutation and resulting residual amount of dystrophin present. Accordingly, <FONT STYLE="white-space:nowrap">in-frame</FONT>
mutations with residual dystrophin of <FONT STYLE="white-space:nowrap">5-50%</FONT> are associated with a less severe clinical course than early truncating mutations with residual dystrophin levels of 0-5%. These findings have led to drug
development efforts to restore out of frame mutations into <FONT STYLE="white-space:nowrap">in-frame</FONT> mutations that result in an abnormal but partially effective dystrophin protein. Additionally, it has been observed that <FONT
STYLE="white-space:nowrap">in-frame</FONT> deletions of large portions of the central part of the dystrophin protein coding region are well tolerated, which has provided the basis for gene transfer approaches of a &#147;microdystrophin&#148;
protein. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Limitations of Current Approaches </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Despite significant efforts
to develop precision medicines for DMD, results to date have not led to meaningful improvements in the standard of care for patients. The mainstay of treatment for DMD is glucocorticoids to address muscle inflammation and improve proximal muscle
strength and respiratory function. However, the benefits of glucocorticoids have to be weighed against their long-term risks that include excessive weight gain, impact on growth, cataract formation, bone loss/fracture risk, and behavioral changes.
More recently several genetic therapies that induce exon skipping have been approved in the United States to address specific mutations (e.g., exon 45 (casimersen), exon 51 (etiplirsen), exon 53 (golodirsen)) or induce readthrough of stop mutations
(ataluren). These therapies have shown modest improvement in muscle dystrophin levels but their overall impact on clinical outcomes has not been established. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Our
Approach/Next Steps </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">DMD patients often have deletions of entire exons (frequently in the hotspot region of exons <FONT STYLE="white-space:nowrap">45-55)</FONT>
which results in the flanking exons being spliced out of frame at the mRNA level. Approved therapies have aimed to correct these mutations by restoring the open reading frame through &#147;exon skipping&#148;, thus avoiding degradation of the mRNA
and/or premature protein termination. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our proposed genome editing approach is to more effectively facilitate exon skipping by making permanent changes at the DNA
level using genome editing that inactivate the splice acceptor (5&#146; exon splice junction sequence) of the exon that follows the deleted exon such that after transcription the RNA splicing machinery &#147;skips&#148; over that exon, splices to
the following exon, and restores the proper reading frame. The resulting proteins will lack the domains encoded by the mutated and skipped exons but these are known to function nearly as well as normal dystrophin. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For example, one common mutation is deletion of exon 44, which results in exon 43 being aberrantly spliced to exon 45 and an out of frame mRNA (designated as
&#147;STOP&#148; in Figure 36) which is then degraded or translated into a truncated protein. As shown in the Figure 36 below, skipping of exon 45 results in splicing from exon 43 to 46 and restores protein expression. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">184 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Figure 36</B>. Example of Exon Skipping Approach for Dystrophin Exon 45 that Results in Splicing of Exon 43 to
46 Thereby Restoring the Correct Translational Reading Frame and Thus Dystrophin Function. </P>  <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g425213g37a01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We believe a similar strategy can be employed for deletions of exons 50, 51, and 53, creating a franchise of development programs for
DMD. We are in the process of initiating a guide screen using our toolbox of DSB nucleases and base editors that are small enough to package in a single AAV vector to inactivate the splice acceptors of the various exons within this hotspot region.
The splice acceptor sequence is short (composed of a poly-pyrimidine tract of about 10 to 15 bases followed a short distance away by the three base consensus sequence
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">C/T-A-G)</FONT></FONT> which limits the number of guides that can be designed to inactivate the splice acceptor when using a single nuclease. We are leveraging our collection of small
nucleases that have a variety of different PAMs to enable more guides to be designed against each splice acceptor. Hits from this guide screen will be assayed in cardiac and/or skeletal muscle cells <I>in vitro</I>. The nuclease/guide combinations
that show potent activity in muscle cells will then be evaluated in human cells in which the DMD gene contains the relevant pathogenic mutations to evaluate exon skipping activity. <I>In vivo</I> evaluation of leads will be performed in mouse models
of DMD. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Because DMD affects skeletal and cardiac muscles throughout the body of DMD patients, effective therapy will require delivery to a large proportion of these
muscles with the diaphragm and heart muscle being of particular importance. To date the only delivery system that is able to deliver to these tissues is AAV, with AAV serotype 9 showing the most promising delivery profile. Because a maximum of up to
5 kb of DNA can be packaged inside the AAV virus it is not possible to deliver SpCas9 and a guide or current SpCas9 derived base editors and a guide in a single AAV. While these larger systems can be split between two AAVs, this reduces potency due
to the dose limiting toxicity of AAV and the need to administer two viruses (effectively doubling the dose). A dual AAV approach also increases manufacturing complexity and costs. We are leveraging our collection of smaller editing systems that can
be packaged in a single AAV (currently three nucleases). </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The potential therapeutic benefit of editing the DMD gene in mouse models will be assayed at the mRNA and
protein level, and by functional endpoints such as maximum force output. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><U>Cystic fibrosis </U></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Cystic fibrosis is an autosomal recessive lung disease caused by mutations in the CFTR gene. Mutations impact electrolyte transport in cells that produce mucus, sweat,
and digestive fluids causing these secretions to be thicker and more viscous than normal. As a result, these secretions become sticky and can clog passageways and ducts, particularly in the lung and pancreas. Over time, these thick mucus secretions
in the lung cause </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">185 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
chronic lung infections, inflammation, fibrosis and ultimately destructive bronchoalveolar lung disease resulting in progressive pulmonary failure. The pancreas is similarly affected and blockage
of ducts in the pancreas lead to loss of exocrine function and pancreatic insufficiency. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The overall incidence of cystic fibrosis is estimated at one patient in
3,000 to 6,000 live births in the US and Europe, but rates depend strongly on geographic location and ethnicity with higher rates in Caucasians of northern European descent and much lower rates in Asians. It is estimated that there are approximately
30,000 individuals living with cystic fibrosis in the US and 70,000 individuals worldwide. Over the past few decades, improvements in antibiotic treatments, supportive measures, multidisciplinary care centers, and newer targeted medications have
increased the overall life expectancy from late childhood to the fourth decade. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Limitations in Current Approaches </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">One of the challenges in developing precision medicines for cystic fibrosis is the large nature of the gene and the varied mutations along the gene that result in loss
of protein expression, loss of function, misfolding and mislocalization within the cell. Accordingly, therapeutic efforts have required individualized approaches tailored to certain mutations to improve CFTR function. Although such medications have
improved rates of lung function decline, not all patients have mutations amenable to CFTR targeted therapies. Further, none of these therapies offer a true cure to the underlying gene mutation, and patients continue to experience morbidity and
mortality from cystic fibrosis disease progression. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Our Approach/Next Steps </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our goal for a genome editing based treatment for cystic fibrosis is <FONT STYLE="white-space:nowrap">two-fold:</FONT> (1)&nbsp;a permanent curative therapy from a
single treatment, and (2)&nbsp;a therapy that is applicable to the majority of cystic fibrosis patients. We believe this could be achieved by integrating a functional version of the CFTR gene into the genome of the lung basal stem cells
(alternatively called bronchioalveolar stem cells). The basal stem cells are believed to give rise to the lung epithelial cells that are the site of CFTR expression that is defective in cystic fibrosis patients. Stem cells are a specialized
population of cells that are maintained for a person&#146;s lifetime and are the source for renewal of differentiated cells. Editing the stem cells should ensure that the introduced functional CFTR gene is not lost over time due to the shedding of
differentiated epithelial cells. By integrating a functional CFTR gene rather than correcting individual cystic fibrosis causing mutations, a single therapy could treat the majority of cystic fibrosis patients. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We intend to explore two of our genome editing modalities in cystic fibrosis. The Big RIGS technology and CAST systems both have the potential to integrate large pieces
of DNA (in this case encoding a CFTR gene) into a specific site in the genome. For the Big RIGS approach, the CFTR gene would be delivered as an RNA that is reverse transcribed into DNA to provide the DNA template for integration. In the case of
CAST, the CFTR gene would be delivered as double stranded DNA that is recognized by the CAST system and integrated at the desired site by the transposase. Delivery to the basal stem cells of the lungs can theoretically be achieved by IV dosing. We
may also evaluate a <FONT STYLE="white-space:nowrap">non-viral</FONT> delivery system for lung delivery. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We believe the Big RIGS system has the advantage that it
can be delivered using only RNA for which <FONT STYLE="white-space:nowrap">non-viral</FONT> RNA delivery technologies such as LNP are well established. In contrast, delivery of DNA (that would be required for CAST) by
<FONT STYLE="white-space:nowrap">non-viral</FONT> delivery vectors is not well established with the main barrier being transit of the DNA into the nucleus. However, in a preliminary study we have recently demonstrated delivery of a 4.6 kb double
stranded DNA to the nuclei of cells in the liver of mice by IV administered LNP. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">186 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Cell Therapy Applications Using Our Platform </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Identifying and optimizing novel nucleases from our metagenomics platform has involved a series of stringent efficiency, activity, and specificity testing in a variety
of immune cell types which yields a comprehensive dataset that demonstrates our genome editing capabilities for cell therapy applications. Many cell therapies require multiple simultaneous genome edits to enhance efficacy, safety, and/or durability
of these products. In the allogeneic cell therapy setting, additional gene edits are required to decrease the immunogenicity of the cell therapies to prevent rejection by the host immune system. Our toolbox provides an important advantage compared
to the current cell therapy landscape as we are able to use either single or multiple genome editing enzymes to implement multiple gene edits (&#147;multiplex editing&#148;) with high efficiency and specificity. These gene edits could be either
knock outs or knock ins. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are currently working on various discovery stage projects in-house and with collaborators to evaluate the efficacy and specificity of
our enzymes for the engineering CAR-T and TCR-T cell product candidates. Figure 37 shows an example of highly efficient multiplex editing demonstrated with two of our lead nucleases, where multiplex editing in T cells resulted in high editing
efficiency for double knock-out of alpha and beta T-cell receptor (&#147;TCR&#148;). In the context of our collaboration with <FONT STYLE="white-space:nowrap">Affini-T,</FONT> knock-out of both TCR chains enabled
<FONT STYLE="white-space:nowrap">TCR-based</FONT> T cell therapy by preventing endogenous and exogenous TCR mispairing. TCR mispairing can reduce the expression of therapeutic TCRs and may also result in the creation of unintentional chimeric TCRs
with undesirable activities. Thus, we believe knock-out of both the endogenous alpha and beta chains in alpha beta T&nbsp;cells is critical for creating safe and effective T&nbsp;cell therapies engineered with exogenous TCRs. We believe the
successful multiplexing of our nucleases for TCR T cell development suggests that these systems will have the potential to be utilized for editing across additional <I>ex vivo</I> cell therapy applications. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Figure 37</B>. Exemplary Type II <FONT STYLE="white-space:nowrap">MG3-6</FONT> and Type V <FONT STYLE="white-space:nowrap">MG29-1</FONT> Nucleases Exhibited Highly
Efficient Multiplexed Genome Editing in Primary Human <FONT STYLE="white-space:nowrap">T-Cells.</FONT> </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g425213g72w54.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">T cell genome editing, applicable to our partnership with <FONT STYLE="white-space:nowrap">Affini-T.</FONT> Individually formulated RNPs were delivered to T cells and genome editing assayed by DNA sequencing of TRAC-,
TRBC1-, and TRBC2-specific amplicons. For TRBC, the average of the editing in TRBC1 and TRBC2 is reported. </TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our initial lead nucleases can be used to
efficiently engineer primary human T&nbsp;cells, demonstrating utility for cell therapy applications. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our programmable nucleases have achieved key requirements
for T cell engineering, including genome editing dsDNA-break induced <FONT STYLE="white-space:nowrap">knock-in</FONT> of a chimeric antigen receptor (CAR, Figure 38). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">187 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Figure 38</B>. Example of Two Lead Nucleases, Type II <FONT STYLE="white-space:nowrap">MG3-6</FONT> and Type V <FONT STYLE="white-space:nowrap">MG29-1,</FONT> Capable of Engineering Primary Human T Cells.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"><B>Figure 38a.</B> <FONT STYLE="white-space:nowrap">MG3-6</FONT> and <FONT STYLE="white-space:nowrap">MG29-1</FONT> enabled efficient CAR <FONT STYLE="white-space:nowrap">knock-in</FONT> in human T cells.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>Figure 38b.</B> Engineered T cells exhibited <FONT STYLE="white-space:nowrap">CAR-specific</FONT> cytotoxicity.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g425213g41a02.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g425213g41a01.jpg" ALT="LOGO">
</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:7.5pt; font-family:arial">*&#8195;&#8194;Nucleases were delivered as RNP and CAR donor template by AAV.</P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:7.5pt; font-family:arial">*&#8195;&#8194;Nucleases were programmed to target the
TRAC locus.</P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-2.00em; font-size:7.5pt; font-family:arial">*&#8195;&#8194;CAR integration into T
cells from 10 T cell donors with <FONT STYLE="white-space:nowrap">MG3-6</FONT> and <FONT STYLE="white-space:nowrap">MG29-1</FONT> and either 5E4 or 1E5 MOI.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:7.5pt; font-family:arial">*&#8195;&#8194;Dose-dependent, <FONT STYLE="white-space:nowrap">CAR-</FONT> and antigen-specific cytotoxic
activity of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">MG3-6-</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">MG29-1-based</FONT></FONT> <FONT STYLE="white-space:nowrap">CAR-T</FONT> cells
when exposed to cells expressing the CAR target antigen BCMA. Data from the <FONT STYLE="white-space:nowrap">MG3-6</FONT> anti-BCMA CAR are given in blue, from the <FONT STYLE="white-space:nowrap">MG29-1</FONT> anti-BCMA CAR are given in yellow, and
an <FONT STYLE="white-space:nowrap">anti-TNP</FONT> CAR integrated with <FONT STYLE="white-space:nowrap">MG3-6</FONT> or <FONT STYLE="white-space:nowrap">MG29-1</FONT> in gray; cytotoxic response to parental line is shown in the bottom
panel.</P></TD></TR>
</TABLE>   <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our <FONT STYLE="white-space:nowrap">MG29-1</FONT> nuclease is a highly active and specific nuclease being used for <I>ex
vivo</I> T cell engineering in collaboration with Affini-T Therapeutics. <FONT STYLE="white-space:nowrap">Affini-T</FONT> Therapeutics is developing a cell therapy based on engineering the TCR of T cells to recognize mutant KRAS for the treatment of
patients with solid tumors. Figure 39 shows that <FONT STYLE="white-space:nowrap">Affini-T</FONT> scientists were able to demonstrate that our exemplary type V <FONT STYLE="white-space:nowrap">MG29-1</FONT> nuclease can be used to knock-out both
alpha and beta TCRs in primary T cells, without any verifiable <FONT STYLE="white-space:nowrap">off-targets.</FONT> Furthermore, <FONT STYLE="white-space:nowrap">Affini-T</FONT> scientists showed that the double knock-out improved expression of a
transgenic TCR, and that <FONT STYLE="white-space:nowrap">MG29-1</FONT> can be used to engineer functional TCR T&nbsp;cells by <FONT STYLE="white-space:nowrap">knock-in</FONT> of a transgene into the TRAC locus (data not shown). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">188 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"><B>Figure 39a</B>. <FONT STYLE="white-space:nowrap">MG29-1</FONT> tested in primary human CD4/CD8 T cells showed specificity in two loci.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>Figure 39b</B>. Oligonucleotide capture in primary T cells identified putative <FONT STYLE="white-space:nowrap">MG29-1</FONT> <FONT STYLE="white-space:nowrap">off-targets.</FONT> More sensitive methods did not verify such
results.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g425213g42a01.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g425213g42a02.jpg" ALT="LOGO">
</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:7.5pt; font-family:arial">*&#8195;&#8194;InDel formation was evaluated for 590 computationally predicted off-targets across TRAC and
TRBC, allowing for up to six mismatches.</P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:7.5pt; font-family:arial">*&#8195;&#8194;Off-targets had <FONT STYLE="white-space:nowrap">100-fold</FONT> fewer barcodes compared with
target sites.</P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:7.5pt; font-family:arial">*&#8195;&#8194;Off-target sites could
not be validated with amplicon-based NGS sequencing.</P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-2.00em; font-size:7.5pt; font-family:arial">*&#8195;&#8194;The presence of &gt;9 mismatches in the off-target sites may indicate that they are not likely to be true
positives.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Data generated by <FONT STYLE="white-space:nowrap">Affini-T</FONT> Therapeutics.</TD></TR>
</TABLE>   <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We plan to use our gene editing enzymes to engineer different T cell subsets with either chimeric antigen receptors (CARs) or
engineered TCRs targeting antigens expressed in various tumor indications, including hematological and solid tumor malignancies. We are currently investigating different tumor targets and tumor indications to select future T cell therapy product
candidates. In addition, we plan to use CAR-T cells in auto-immune diseases driven by the production of autoantibodies, including conditions such as systemic lupus erythematosus, rheumatoid arthritis, myasthenia gravis, autoimmune hemolytic anemia,
immune-mediated thrombotic thrombocytopenic purpura, and possibly others. We will use T cells engineered with chimeric antigen receptors against B cell markers to deplete the B cell compartment and eliminate the production of autoantibodies. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">189 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><U>Our License and Collaboration Agreements </U></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Moderna Strategic Collaboration and License Agreement </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On October 29,
2021, the effective date, we entered into a Strategic Collaboration and License Agreement (the &#147;Moderna Agreement&#148;) with Moderna. We will collaborate with Moderna on the research and development of <I>in vivo</I> genome editing therapies
directed at certain targets and the commercialization of such genome editing therapies. The collaboration provides Moderna with exclusive access to our technology platform during the research period in (1) the field of <I>in vivo</I> gene editing
technology for a therapeutic, ameliorative or prophylactic application by way of knock-out through InDel formation or base editing or insertion of an exogenous DNA template (such field, &#147;DT Field&#148;) and (2) the field of <I>in vivo</I> gene
editing technology for a therapeutic, ameliorative or prophylactic application outside the use of (a) DNA donor templates and (b) no exogenous template at all but including (c) correction by base editing (such field, &#147;RT Field&#148;). We formed
a joint steering committee, a joint research subcommittee and a joint patent subcommittee to oversee the collaboration activities. Each of us and Moderna must use commercially reasonable efforts to perform and complete our respective activities
under research plans and commercialization plans approved by the joint steering committee. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Under the terms of the Moderna Agreement, we and Moderna will collaborate
on one or more programs in the RT Field (the &#147;Moderna RT program&#148;) and two programs in the DT Field (the &#147;Moderna DT program&#148; and the &#147;DT Co-Co program&#148;). We and Moderna have each granted the other party a non-exclusive
license in such party&#146;s (i) background technology, including intellectual property rights controlled by each party related to each respective program, and (ii) the know-how and patents that come into control of each party relating to the
program and during the respective program term, in each case to carry out activities in the applicable research programs. We shall own certain intellectual property that relates to our technology platform (&#147;Metagenomi Program Technology&#148;).
Moderna shall own certain intellectual property that relates to Moderna&#146;s technology platform (&#147;Moderna Program Technology&#148;). Any intellectual property discovered, invented, conceived or created during an applicable research term that
is not Metagenomi Program Technology or Moderna Program Technology shall be jointly owned by us and Moderna. Further, we granted Moderna a perpetual, irrevocable, royalty-free, nonexclusive license under Metagenomi Program Technology to the extent
pertaining to the exploitation of donor templates or guides to which Moderna has any inventive contribution. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">With respect to the Moderna RT and Moderna DT programs,
we will collaborate on the research and development of product candidates under the approved research plans. The initial research term of the Moderna RT program is four years, which may be extended by Moderna for an additional three years upon
written notice and a payment of extension fees. The initial research term of the Moderna DT program is four years. We granted to Moderna an option to obtain an exclusive license to develop, manufacture and commercialize up to ten Moderna RT program
candidates and up to two Moderna DT program candidates at any time during the research term and prior to filing of an investigational new drug (&#147;IND&#148;) application with the Food and Drug Administration (&#147;FDA&#148;) or any similar
application filed with a regulatory authority in a country other than the United States (&#147;U.S.&#148;), subject to Moderna&#146;s payment of an option exercise fee of $10.0 million per target. If we or any of our affiliates wish to grant any
third party rights in certain targets in the DT Program prior to the earlier of the (a) second anniversary of the agreement or (b) 90 days after achievement of certain readiness standards, we shall provide Moderna with written notice thereof and
Moderna shall have a right of first negotiation to negotiate an agreement on the terms of a collaboration and license agreement for such targets. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">With respect to
the DT Co-Co program, we will work together with Moderna on the co-development and commercialization of products and share costs and profits equally. We granted Moderna a co-exclusive (with us and our affiliates) license under our patents and
know-how related to PH1, the DT Co-Co target, to exploit all applications </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">190 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
of such target in the DT Co-Co program. We maintain commercialization rights in the U.S. (subject to Moderna&#146;s right to appoint up to 50% of the U.S. sales force for the DT Co-Co program),
while Moderna maintains these rights in countries other than the U.S. The initial research term for the DT Co-Co program is four years, and each party has a right to opt-out of the DT Co-Co program at any time, at which point the other party has the
right to solely continue the development and commercialization activities, provided that the party which has opted-out shall have a right of first offer in the event that the other party wishes to grant a license or sublicense to a third party with
respect to the DT Co-Co program. If there is no development candidate nomination by the end of the initial research term, the DT Co-Co program will expire, unless we have mutually agreed to continue the program. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">During the year ended December 31, 2021, we received a non-refundable upfront payment of $40.0&nbsp;million and a $5.0 million payment for the first year of research
costs. Concurrent with the Moderna Collaboration Agreement, Moderna also provided $30.0 million in cash in the form of a convertible promissory note (see Note&nbsp;9 in our audited consolidated financial statements included elsewhere in this
prospectus) pursuant to a convertible promissory note agreement dated October 29, 2021 (the &#147;Moderna Convertible Promissory Note Agreement&#148;). The convertible promissory note was converted into shares of Series B redeemable convertible
preferred units in January 2022. Moderna will reimburse us up to $5.0 million in annual research and development costs related to the Moderna DT and Moderna RT programs, or up to the agreed amount of expenses per the budget. As of June&nbsp;30,
2023, we have received a total of $49.6&nbsp;million under the Moderna Collaboration Agreement, not including cost-sharing payments under the DT Co-Co program. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For
the Moderna RT and Moderna DT programs, we are eligible to receive (i) technology milestone fees related to the achievement of certain preclinical research objectives of up to $75.0 million, (ii) development and regulatory milestones of up to $100.0
million per target, (iii) sales milestones of up to $200.0 million per target, and (iv) royalties ranging from a mid-single digit to a low-teens percentage of annual net sales of a licensed product. Any profits and losses from the co-development and
commercialization of the DT Co-Co program are shared equally between us and Moderna. With respect to the DT Co-Co program for which the opt-out party has exercised its opt-out right, the continuing party will pay to the opt-out party, certain
development, regulatory and sales milestone payments that will not exceed an aggregate $239.0 million per DT Co-Co target, and opt-out royalties ranging from a high-single digit to a low-teens percentage of annual net sales of a licensed product.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The term of the Moderna Agreement will continue on a licensed product-by-licensed product and country-by-country basis, until the expiration of the applicable
royalty term. The royalty term commences on the first commercial sale of a licensed product and terminates on the latest of: (a) the expiration or abandonment of the last valid claim of a patent within the licensed Moderna DT or RT technology; (b)
10 years after the first commercial sale of a licensed product; and (c) expiration of the regulatory exclusivity. Upon the expiration of the term of a licensed product in the Moderna DT or Moderna RT program, the licenses granted to Moderna will
survive and become perpetual, fully paid and royalty-free. Each party may terminate the Moderna Agreement on a program-by-program basis upon written notice to the other party for an uncured material breach or insolvency. In lieu of termination for
our material breach, Moderna may, upon written notice, continue the agreement with respect to the relevant collaboration target at Moderna&#146;s amounts payable reduced by 50%, or in the case of a DT Co-Co-Target, Moderna may propose, subject to
arbitration, to adjust the profit and loss share for DT Co-Co Products to provide Moderna with an additional share of the net profits (not to exceed 75% of the total net profits). We may terminate the Moderna Agreement upon written notice to Moderna
for a patent challenge. Additionally, Moderna may terminate the agreement at its convenience with respect to Moderna DT or Moderna RT programs for any reason upon at least: (a) 60 days&#146; prior written notice if a first commercial sale has not
occurred for the products in such program, or (b) 180 days&#146; prior written notice if a first commercial sale of a product in such program has occurred. Upon termination, all licenses granted under the agreement with respect to the applicable
products under the agreement shall terminate, subject to an orderly wind-down period, provided that any permitted sublicense granted to a third party shall survive (provided such third party did not cause the termination through uncured material
breach). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">191 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Affini-T Development, Option and License Agreement </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On June 14, 2022, the effective date, we entered into a Development, Option and License Agreement (the &#147;Affini-T Agreement&#148;) with Affini-T. Pursuant to the
Affini-T Agreement, we and Affini-T have agreed to identify, develop or optimize certain reagents using our proprietary technology for Affini-T to use such reagents to develop and commercialize gene edited TCR-based therapeutic products exclusively
in the field of treatment, prevention or diagnosis of any human cancer using products with any engineered primary TCR alpha/beta T cells and <FONT STYLE="white-space:nowrap">non-exclusively</FONT> in the field of treatment, prevention or diagnosis
of any human cancer using products with certain other engineered immune cells worldwide. A joint steering committee was established by both parties to assign alliance managers and project leaders to oversee the collaboration activities. We must use
commercially reasonable efforts to perform and complete our obligations under research plans approved by the joint steering committee. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pursuant to the Affini-T
Agreement, we granted Affini-T options to receive, on a pre-specified target-by-pre-specified target basis, for up to six pre-specified targets, either (i) an exclusive, royalty-bearing, sublicensable worldwide license under all of our applicable
intellectual property to research, develop, manufacture, use, commercialize and otherwise exploit any TCR-based therapy, preventative treatment, or diagnostic for humans that is directed to such pre-specified target, contains or comprises Primary
TCR alpha/beta T Cells and is derived from <I>ex vivo </I>application of our reagent (the &#147;Exclusive Option&#148;) or (ii) a non-exclusive, royalty-bearing, sublicensable worldwide license under all our applicable intellectual property to
research, develop, manufacture, use commercialize and otherwise exploit any TCR-based therapy, preventative treatment, or diagnostic for humans that is directed to such pre-specified target, contains or comprises TCR NK cells derived from iPSC
immune cells or TCR T cells derived from donor-derived or iPSC immune cells. Affini-T can exercise its options for either an exclusive license or a non-exclusive license, or both, for each pre-specified target by providing written notice prior to
the earlier of (x) the end of the Affini-T Agreement term or (y) 90&nbsp;days following the filing of an IND for a licensed product directed to a pre-specified target, subject to the payment of certain fees per each option exercised. After the
option exercise, Affini-T has agreed to use commercially reasonable efforts to conduct all development and commercialization activities for a licensed product, and development and commercialization of all licensed products will be at Affini-T&#146;s
sole cost and expense. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On a target-by-target basis, (1) until the earlier of Affini-T&#146;s (a) exercise of an Exclusive Option, (b) written notice not to
exercise an Exclusive Option or (c) expiration of an applicable Exclusive Option or (2) upon exercise of an Exclusive Option, we and our affiliates shall not exploit, or work with any third party to exploit, any <I>ex vivo</I> gene edited products
directed to the applicable target covered by such Exclusive Option. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In connection with the Affini-T Agreement, we received upfront equity consideration of
719,920 shares of Affini-T&#146;s common stock with an estimated fair value of $1.3&nbsp;million in June 2022. The fair value of Affini-T&#146;s shares of common stock was estimated by our management, considering the most recent third-party
valuation. Affini-T has also agreed to reimburse us for expenses incurred while performing research activities under the research plans. As of June&nbsp;30, 2023, we received a total of $1.9&nbsp;million related to reimbursable expenses and
recognized $2.3&nbsp;million in accounts receivable. Additionally, we are eligible to receive (i) 933,650 shares of Affini-T&#146;s common stock upon the achievement of a regulatory milestone, which is the earlier of a submission of a drug master
file to the FDA or an acceptance of an IND filing for a licensed product by the FDA, (ii) up to $18.8 million in future developmental milestone payments depending on the completion of or the number of patients dosed in, the relevant human clinical
trial, or the initiation of a pivotal trial, and $40.6 million in future regulatory approval milestone payments, which include regulatory approvals in the U.S. and other markets for licensed products directed to a pre-specified target if options for
both exclusive and non-exclusive licenses are exercised with respect to such target, (iii) up to $250.0 million in sales-based milestones for aggregate sales of all licensed products directed to a given pre-specified target and (iv) royalties
ranging from a low-single digit to high-single digit percentage of worldwide annual net sales of licensed products.</P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The initial term of the Affini-T Agreement
is five years from the effective date. If Affini-T exercises an Exclusive Option with respect to any pre-specified target during the initial term, the initial term will be extended by an additional five years. Following the expiration of the
extended term, if any, the agreement will continue on a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">192 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
target-by-target basis and expire with respect to such target upon the expiration of the royalty term for all licensed products directed to such target. The Affini-T Agreement may be terminated
during the term by either party for an uncured material breach by, or bankruptcy of, the other party. Additionally, Affini-T may terminate the Affini-T Agreement for convenience, in its entirety, on a research plan-by-research plan basis, on a
target-by-target basis or on a licensed product-by-licensed product basis, by providing prior written notice. Upon a material breach and with written notice to us, in lieu of termination, Affini-T shall have the right to continue the agreement at
payments payable at a certain percentage reduction. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Ionis Collaboration and License Agreement </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On November 10, 2022, the effective date, we entered into a Collaboration and License Agreement (the &#147;Ionis Agreement&#148;) with Ionis to collaborate on drug
discovery and exploratory research activities to advance new medicines using gene editing strategies, with the goal of discovering novel medicines. Pursuant to the terms of the Ionis Agreement, we granted Ionis and its affiliates a worldwide
exclusive, royalty-bearing license, with the right to grant sublicenses, to use all licensed systems and licensed products in the field of <I>in vivo</I> gene editing for all therapeutic, prophylactic, palliative, and analgesic uses in humans. In
connection with the Ionis Agreement, we also have the right to exercise an exclusive option to co-develop and co-commercialize certain products under a drug discovery program. A joint steering committee was established by both parties to coordinate,
oversee, and monitor the research and drug discovery activities under the Ionis Agreement. Each party must use commercially reasonable efforts to perform and complete its respective activities under the applicable program plans approved by the joint
steering committee. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We will collaborate to discover therapeutic products under a drug discovery program and develop a drug discovery plan for each target, selected
by Ionis. The target selection is divided into two waves: up to four targets in Wave 1 and up to four targets in Wave 2. For each drug discovery program, once the parties identify a development candidate that is suitable for further development,
Ionis will be responsible for the development and commercialization of products resulting from such program. Per the terms of the Ionis Agreement, at any time prior to the designation of a development candidate for a drug discovery program and for
any reason, Ionis may replace the collaboration target, provided such target has not previously been substituted out. Ionis may substitute (i) up to two Wave 1 targets and (ii) up to two Wave 2 targets. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The drug discovery activities for a program commence on the selection of a target and expire upon the earlier of (a)&nbsp;completion of all drug discovery activities for
such program, (b) the fifth anniversary of the effective date and (c)&nbsp;selection of a development candidate for such drug discovery program. If one or more Wave 2 targets become collaboration targets as a result of the parties achieving enabled
delivery and less than two years are remaining in the drug discovery term, then the term will be extended to the earlier of (i) the time that we complete all of our activities under the applicable drug discovery plan and (ii) the seventh anniversary
of the effective date, subject to our consent. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We will also conduct an exploratory research program, and will jointly optimize gRNA and select delivery technologies
and other activities. The exploratory research activities commence on the effective date and expire upon the earlier of (a) completion of all exploratory research activities established in the exploratory research plan, and (b) the fifth anniversary
of the effective date. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have the exclusive option to co-develop and co-commercialize the licensed products under a drug discovery program (the &#147;Co-Co
Option&#148;) with Ionis. The Co-Co Option may be exercised for (a) the initial Wave 1 target (&#147;Target 1&#148;), (b) no more than one of the other three discovery programs for the Wave 1 targets, and (c)&nbsp;no more than two drug discovery
programs for the Wave 2 targets that become collaboration targets. If we exercise the Co-Co Option for a particular drug discovery program, that drug discovery program will automatically be deemed a &#147;Co-Co Program&#148;, all corresponding
licensed products be deemed &#147;Co-Co Products,&#148; we will be obligated to pay Ionis an option exercise fee, and we and Ionis will enter into a separate co-development and co&shy;commercialization agreement. The Co-Co Option exercise fee will
equal 50% of Ionis&#146; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">193 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
internal costs and out-of-pocket costs incurred in the conduct of the drug discovery activities prior to the exercise of the Co-Co Option and be reduced by 50% of our corresponding costs
incurred. Future development and commercialization costs will be shared equally. We may elect to reduce our cost-share percentage anywhere between 50% and 25% on a go-forward basis, provided we will continue to bear 50% of the costs of any clinical
trials ongoing at the time of the election through the completion of the clinical trials. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We will manufacture all licensed systems and certain components of the
applicable licensed products that are needed by Ionis for use in its development activities and all of our manufactured components needed by Ionis for use in its commercialization activities. We will provide the manufactured components at a price
that represents the cost of goods plus 15%. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pursuant to the terms of the Ionis Agreement, we have also been granted an option to obtain a non-exclusive,
royalty-bearing license, with the right to grant sublicenses, for certain Ionis&#146; background technology to use in up to eight therapeutic products discovered by us in the field of <I>in vivo</I> gene editing and directed to a Collaboration
Target (each such product, a &#147;Metagenomi Product&#148; and each such option an &#147;Ionis IP Option&#148;), but subject to encumbrance checks with respect to particular targets. A Collaboration Target is a target that is selected by Ionis,
and, with respect to us, is not the subject of discussions with a third party, is not the subject of a contractual grant of rights to a third party nor the subject of an internal research and development program. If we exercise our Ionis IP Option,
we will pay to Ionis up to several million dollars per Metagenomi Product upon achievement of certain clinical and regulatory milestones. We are also obligated to pay Ionis royalties in an amount equal to a low single-digit royalty on the net sales
of the applicable Metagenomi Product on <FONT STYLE="white-space:nowrap">product-by-product</FONT> and country-by-country basis. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In November 2022, we received an
$80.0 million upfront payment from Ionis for the Wave 1 drug discovery research collaboration and selected Target 1. Ionis selected its second target (&#147;Target 2&#148;) in Wave 1 in December 2022, and we expect Ionis will select two final
additional Wave 1 targets (&#147;Target 3&#148; and &#147;Target 4&#148;) within the 12 months from the effective date, as permitted under the arrangement. Ionis has an option to select up to four Wave 2 targets at any time during the drug discovery
term, if (a) an IND for any licensed product directed to a Wave 1 target is filed with the applicable regulatory authority or (b) the parties achieve enabled delivery for a non-liver target under the exploratory research activities, by providing
written notice and by paying a Wave&nbsp;2 target selection fee of $15.0 million or $30.0 million, depending on and per the selected target. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Ionis is obligated to
reimburse us for all internal costs and out-of-pocket costs incurred in the performance of the exploratory research activities, up to an aggregate of $10.0 million, which is payable in quarterly installments of $0.5&nbsp;million during the
exploratory research term. As of June&nbsp;30, 2023, we received a total of $1.0&nbsp;million related to the reimbursable expenses. We are also eligible to receive (a) up to $29.0&nbsp;million in future development milestone payments for each
licensed product; (b) up to $60.0&nbsp;million in future regulatory milestone payments for each licensed product; (c)&nbsp;up to $250.0 million in sales-based milestones for each licensed product; and (d) royalties on annual net sales of licensed
products from a mid-single-digit to low-teens percentage, subject to customary reductions.</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The term of the Ionis Agreement will continue (i) with respect to the drug
discovery programs, until the expiration of all applicable royalty terms for a licensed product, (ii) with respect to the Co-Co Programs, until the parties cease all exploitation for the Co-Co Products that are the subject to such Co-Co Program, and
(iii)&nbsp;with respect to the Metagenomi Products, until the expiration of the royalty term for a Metagenomi Product. The royalty term ends on the latest of the following two dates: (i) the expiration of (A) the last claim of any issued and
unexpired patent, or (B) a claim within a patent application that has not been pending for more than seven years from the earliest date to which the claim or applicable patent application is entitled to claim priority and which claim has not been
revoked, cancelled, withdrawn, held invalid, or abandoned, or (ii) 12&nbsp;years following the first commercial sale of a licensed product. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Ionis Agreement
may be terminated during the term by either party for an uncured material breach or bankruptcy by the other party. Additionally, Ionis may terminate the Ionis Agreement for convenience and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">194 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
without penalty, in its entirety or on a licensed product-by-licensed product basis, by providing 90 days&#146; written notice. Upon termination, Ionis will transfer to us ownership of all
regulatory approvals, and all licenses granted under the agreement with respect to the applicable products under the agreement shall terminate, subject to an orderly wind-down period and a right for Ionis to sell or otherwise dispose of applicable
products on hand at the time of such termination. Upon our written request within 30 days following termination, Ionis will grant us an exclusive, royalty-bearing (as agreed by the parties at such time), right and license, with the right to grant
sublicenses through multiple tiers, to patent rights and know-how controlled by Ionis and used in the development, commercialization, or exploitation of terminated products, solely for the exploitation of such terminated products in the terminated
countries. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><U>Competition </U></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The pharmaceutical and biotechnology
industries, including the gene therapy and genome editing fields, are characterized by rapidly advancing technologies, intense competition, and a reliance on strong intellectual property. We believe our metagenomics powered discovery platform along
with our expertise in genome editing, drug discovery, clinical development, manufacturing and our ever-increasing IP portfolio, provide us with several key competitive advantages over our peers. Despite our competitive advantages, we face
competition from several companies. There are numerous publicly traded companies utilizing CRISPR/Cas nuclease technology, including Caribou Biosciences, Inc., Editas Medicine, Inc., CRISPR Therapeutics AG, Intellia Therapeutics, Inc., and Graphite
Bio, Inc., among others. Beam Therapeutics Inc. and Verve Therapeutics, Inc. utilize base editing technology and Prime Medicine utilizes prime editing technology. Several other companies such as Sangamo Therapeutics, Inc., Precision BioSciences,
Inc., Cellectis S.A., and bluebird bio, Inc. utilize first-generation nuclease-based genome editing technologies, including ZFNs, engineered meganucleases and TALENs. We also face competition from companies utilizing gene therapy, oligonucleotides,
and <FONT STYLE="white-space:nowrap">CAR-T</FONT> therapeutic approaches. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There are several other private companies such as Arbor Biotech, Chroma Medicine, Inc.,
Mammoth Biosciences, Scribe Therapeutics, Tessera Therapeutics, Tome Biosciences, and Tune Therapeutics, Inc. that have announced they are working on genome- and epigenome-editing therapies. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future that
are approved to treat the same diseases for which we may obtain approval for our product candidates. This may include other genome editing companies using antiquated or next generation genome editing approaches or other types of therapies, such as
small molecule, antibody, and/or protein therapies. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, many of our current or potential competitors, either alone or with their collaboration partners,
have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials and approved products than we do today. Mergers and acquisitions in the pharmaceutical,
biotechnology and gene therapy industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through
collaborative arrangements with large and established companies. We also compete with these companies in recruiting, hiring, and retaining qualified scientific and management talent, establishing clinical trial sites and patient registration for
clinical trials, obtaining manufacturing slots at contract manufacturing organizations. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, particularly if
they represent cures, have fewer or less severe side effects, are more convenient, or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we
may obtain approval for ours, which could result in our competitors establishing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">195 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
a strong market position before we are able to enter the market. The key competitive factors affecting the success of all of our programs are likely to be their efficacy, safety, convenience, and
availability of reimbursement. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><U>Manufacturing </U></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our genome editing
technology is composed of multiple genome editing components including the nuclease, mRNA, gRNA, and in some instances may include a donor DNA or RNA template for insertions. We have extensively characterized each of these components and have made
significant investment in scalable manufacturing and process automation to meet stringent current good manufacturing practices (&#147;cGMP&#148;). Our <FONT STYLE="white-space:nowrap">in-house</FONT> cGMP facility is capable of manufacturing
clinical grade nucleases and mRNA to supply both wholly-owned and collaboration programs. We partner with contact manufacturing organizations (&#147;CMOs&#148;) for gRNA and DNA template development and supply and continue to invest in both viral
and <FONT STYLE="white-space:nowrap">non-viral</FONT> delivery technologies internally and with partners. We believe our ability to develop, characterize, and manufacture complex human genome editing components is essential to maintaining a
competitive edge while pursuing a successful regulatory pathway for genetic medicine. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><U>Intellectual Property </U></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our success depends in large part upon our ability to obtain and maintain our technology and intellectual property. To protect our intellectual property rights, we
primarily rely on patents and trade secret laws, confidentiality procedures, and employee disclosure and invention assignment agreements. Our intellectual property is critical to our business and we strive to protect it through a variety of
approaches, including by obtaining and maintaining patent protection in various countries for our genome editing technology and other inventions that are important to our business. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years from its earliest U.S.
<FONT STYLE="white-space:nowrap">non-provisional</FONT> filing date. The time required for development, testing, and regulatory review of our genome editing systems limits the commercially useful lifespan of our patents. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The patent positions of companies like ours are generally uncertain and involve complex legal and factual questions. No consistent policy regarding the scope of
patentable claims in the field of genome editing has emerged, for example, in the United States and in Europe. Changes in the patent laws and rules, either by legislation, judicial decisions, or regulatory interpretation may diminish our ability to
protect our inventions and enforce our intellectual property rights. These changes could affect the scope and value of our intellectual property. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Filing,
prosecuting, enforcing, and defending patents protecting our genome editing systems in all countries throughout the world would be prohibitively expensive. We cannot seek patent protection for our genome editing systems throughout the world.
Furthermore, the intellectual property rights we obtain in some countries outside the United States can be less extensive than those obtained in the United States. The requirements for patentability may differ in certain countries, particularly in
developing countries; thus, even in countries where we do pursue patent protection, there can be no assurance that any patents will issue with claims that cover our products. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our ability to stop third parties from infringing any of our patented inventions, either directly or indirectly, will depend in part on our success in obtaining,
defending, and enforcing patent claims that cover our genome editing systems. We cannot be sure that any patents will be granted with respect to any of our pending patent applications or with respect to any patent applications filed by us in the
future. We cannot be sure that any of our existing patents or any patents that may be granted to us in the future will be found by a court to be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">196 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
enforceable. Protecting our competitive position around our genome editing systems may involve lawsuits to enforce our patents or other intellectual property, which is expensive and time
consuming, and may ultimately be unsuccessful. Furthermore, our issued patents and those that may issue in the future may be challenged, narrowed, circumvented, or invalidated, which could limit our ability to stop competitors from marketing related
genome editing systems or limit the length of the term of patent protection that we may have for our genome editing systems and future gene therapies. We cannot be sure that any of our existing patents or any patents that may be granted to us in the
future will be useful in protecting our commercialized genome editing systems. The rights granted under any issued patents may not provide us with complete protection or competitive advantages against competitors with similar but not identical
technology or technologies that achieve similar outcomes but with different approaches. For these reasons, we may have competition for our genome editing systems. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our issued patents and those that may issue in the future do not guarantee us the right to practice our genome editing systems. Third parties may have issued patents or
be granted patents in the future that could block our ability to commercialize our genome editing systems. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We and third parties rely on trade secrets to protect
certain aspects of our genome editing systems. If we are unable to protect the confidentiality of our trade secrets, our competitive position could be harmed. Furthermore, reliance on trade secrets does not prevent third parties from independently
inventing those aspects of our genome editing systems. While we take commercially reasonable steps to ensure that our employees do not use the trade secrets of third parties, third parties may file claims asserting that we or our employees have
misappropriated their trade secret. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For this and other risks related to our technology, inventions, improvements, platforms, and genome editing technology, please
see the section entitled &#147;Risk Factors&#151;Risks Related to Our Intellectual Property.&#148; </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Patent Portfolio </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of June&nbsp;30, 2023, we own two issued U.S. patents, 13 pending U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent applications, 46 pending U.S.
provisional patent applications, 75 pending foreign patent applications, including in Australia, Canada, China, Europe, Great Britain, Hong Kong, India, Japan, Korea, Mexico and Brazil, and 25 Patent Cooperation Treaty (&#147;PCT&#148;) patent
applications. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The patent portfolios for our genome editing systems as of June&nbsp;30, 2023 are summarized below. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our type II CRISPR systems are protected by two issued U.S. patents with composition of matter claims covering genome editing systems using Type II nucleases, three
pending U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent applications with composition of matter claims covering genome editing systems using Type II nucleases and methods of using them, and two pending U.S. provisional patent
applications with composition of matter claims covering genome editing systems using Type II nucleases and methods of using them. Our type II CRISPR systems are also protected by two issued foreign patents with composition of matter claims covering
genome editing systems using Type II nucleases, including in Great Britain and Mexico, 24 pending foreign patent applications with composition of matter claims covering genome editing systems using Type II nucleases and methods of using them,
including in Australia, Canada, China, Europe, Great Britain, Hong Kong, India, Japan, Korea, Mexico, and Brazil, and two PCT patent applications with composition of matter claims covering genome editing systems using Type II nucleases and methods
of using them. The aforementioned issued US patents will expire on February&nbsp;14, 2040, and the issued foreign patents will expire on February&nbsp;14, 2040. If issued, the aforementioned patent applications are expected to expire between
February&nbsp;14, 2040 and May&nbsp;6, 2041. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">197 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our type V CRISPR systems are protected by two pending U.S.
<FONT STYLE="white-space:nowrap">non-provisional</FONT> patent applications with composition of matter claims covering genome editing systems using Type V nucleases and three pending U.S. provisional patent applications with composition of matter
claims covering genome editing systems using Type V nucleases and methods of using them. Our type V CRISPR systems are also protected by one issued foreign patent with composition of matter claims covering genome editing systems using Type V
nucleases, including in Great Britain, 10 pending foreign patent applications with composition of matter claims covering genome editing systems using Type V nucleases and methods of using them, including in Australia, Canada, China, Europe, Great
Britain, Hong&nbsp;Kong, India, Japan, South Korea, and Mexico, and one PCT patent application with composition of matter claims covering genome editing systems using Type V nucleases and methods of using them. If issued, the aforementioned patent
applications are expected to expire between March&nbsp;6, 2041 and July&nbsp;29, 2043. The aforementioned issued foreign patents will expire on March&nbsp;6, 2041. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our base editor systems are protected by three pending U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent applications with composition of matter claims
covering genome editing systems using nucleases and base editors and methods of using them, and one pending U.S. provisional patent application with composition of matter claims covering genome editing systems using nucleases and base editors and
methods of using them. Our base editor systems are also protected by 12 pending foreign patent applications with composition of matter claims covering genome editing systems using nucleases and base editors and methods of using them, including in
Australia, Canada, China, Europe, Great Britain, Hong&nbsp;Kong, India, Japan, Korea, Mexico, and Brazil, and one PCT patent applications with composition of matter claims covering genome editing systems using nucleases and base editors and methods
of using them. If issued, the aforementioned patent applications are expected to expire on September&nbsp;10, 2041. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our CAST systems are protected by two pending
U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent applications with composition of matter claims covering genome editing systems using nucleases in combination with either recombinases or transposases and methods of using them, and
one pending U.S. provisional patent application with composition of matter claims covering genome editing systems using nucleases in combination with either recombinases or transposases and methods of using them. Our CAST systems are also protected
by 17 pending foreign patent applications with composition of matter claims covering genome editing systems using nucleases in combination with either recombinases or transposases and methods of using them, including in Australia, Brazil, Canada,
China, Europe, Great Britain, India, Japan, South Korea, and Mexico, and two PCT patent applications with composition of matter claims covering genome editing systems using nucleases in combination with either recombinases or transposases and
methods of using them. If issued, the aforementioned patent applications are expired to expire between August&nbsp;23, 2041 and March&nbsp;23, 2043. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our Cas chimera
systems are protected by one pending U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application with composition of matter claims covering genome editing systems using chimeric nucleases and methods of using them. Our Cas
chimera systems are also protected by two pending foreign patent applications, including in Great Britain and Hong Kong with composition of matter claims covering genome editing systems using chimeric nucleases, one PCT patent application with
composition of matter claims covering genome editing systems using chimeric nucleases and two PCT patent applications with composition of matter claims covering genome editing systems using chimeric nucleases and methods of using them. If issued,
the aforementioned patent applications are expected to expire on January&nbsp;21, 2042. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our SMART nuclease systems are protected by one pending U.S. <FONT
STYLE="white-space:nowrap">non-provisional</FONT> patent application with composition of matter claims covering genome editing systems using small nucleases, and one pending U.S. provisional patent application with composition of matter covering
genome editing systems using small nucleases and methods of using them. Our SMART nuclease systems are also protected by 10 pending foreign </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">patent applications with
composition of matter covering genome editing systems using small nucleases and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">198 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
methods of using them, including in Australia, Canada, China, Europe, Great Britain, Hong Kong, India, Japan, Korea, and Mexico, and two PCT patent applications with composition of matter claims
covering genome editing systems using small nucleases and methods of using them. If issued, the aforementioned patent applications are expected to expire on March&nbsp;31, 2040. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We cannot predict whether the patent applications we pursue or may license in the future will issue as patents in any particular jurisdiction or whether the claims of
any issued patents will provide any protection from competitors. Even if our pending patent applications are granted as issued patents, those patents, as well as any patents we may license in the future from third parties now or in the future, may
be challenged, circumvented or invalidated by third parties. Consequently, we may not obtain or maintain adequate patent protection for any of our programs and genome editing systems. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which we file, the patent
term is 20 years from the earliest date of filing of a <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application. In the United States, the patent term of a patent may be extended by patent term adjustment, which compensates the
patent owner for patent office delays. Additionally, in the United States, patents that cover an <FONT STYLE="white-space:nowrap">FDA-approved</FONT> drug or biologic may also be eligible for patent term extension, which permits patent term
restoration as compensation for the patent term lost during FDA regulatory review process. The Hatch-Waxman Act permits a patent term extension of up to five years beyond the expiration of the patent. The length of the patent term extension is
related to the length of time the drug or biologic is under regulatory review. Patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent applicable to an approved
drug or biologic may be extended and only those claims covering the approved drug or biologic, a method for using it, or a method for manufacturing it may be extended. Similar provisions are available in European Member States and other foreign
jurisdictions to extend the term of a patent that covers an approved drug or biologic. In the future, if our investigational gene therapies receive FDA approval, we expect to apply for patent term extensions where applicable on patents covering
those products. We plan to seek patent term extensions to any of our issued patents in any jurisdiction where these are available, however there is no guarantee that the applicable authorities, including the U.S. Patent and Trademark Office
(&#147;USPTO&#148;) in the United States, will agree with our assessment of whether these extensions should be granted, and if granted, the length of these extensions. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our intellectual property is critical to our business and we strive to protect it through a variety of approaches, including by obtaining and maintaining patent
protection in various countries for our genome editing technology and other inventions that are important to our business. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Trademarks </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of June&nbsp;30, 2023, we own the trademark registrations for Metagenomi in the United States. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Trade Secrets and Proprietary Information </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition to our reliance on
patent protection for our inventions, investigational gene therapies and research programs, we also rely on trade secrets, <FONT STYLE="white-space:nowrap">know-how,</FONT> confidentiality agreements and continuing technological innovation to
develop and maintain our competitive position. Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees, advisors and consultants, these agreements may be breached and we
may not have adequate remedies for any breach. In addition, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology. As a
result, we may not be able to meaningfully protect our trade secrets. It is our policy to require our employees, consultants, outside </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">199 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements
provide that all confidential information concerning our business or financial affairs developed or made known to the individual or entity during the course of the party&#146;s relationship with us is to be kept confidential and not disclosed to
third parties except in specific circumstances. In the case of employees, the agreements provide that all inventions conceived of by the individual during the course of employment, and which relate to or are reasonably capable or being used in our
current or planned business or research and development are our exclusive property. In addition, we take other appropriate precautions, such as physical and technological security measures, to guard against misappropriation of our technology by
third parties. However, such agreements and policies may be breached and we may not have adequate remedies for such breaches. For more information regarding the risks related to our intellectual property, see &#147;Risk Factors&#151;Risks Related to
Our Intellectual Property.&#148; </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><U>Government Regulation </U></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the
United States, biological products, including gene therapy products, are subject to regulation under the Federal Food, Drug, and Cosmetic Act (&#147;FD&amp;C Act&#148;), and the Public Health Service Act (&#147;PHS Act&#148;), and other federal,
state, local and foreign statutes and regulations. Both the FD&amp;C Act and the PHS Act and their corresponding regulations govern, among other things, the research, development, clinical trial, testing, manufacturing, safety, efficacy, labeling,
packaging, storage, record keeping, distribution, reporting, advertising, and other promotional practices involving biological products. Each clinical trial protocol for a gene therapy product must be reviewed by the FDA. FDA approval must be
obtained before the marketing of biological products. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time
and financial resources and we may not be able to obtain the required regulatory approvals. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>U.S. Biological Product Development Process </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The process required by the FDA before a biological product candidate may be marketed in the United States generally involves the following: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">completion of nonclinical laboratory tests and animal studies according to good laboratory practices (&#147;GLPs&#148;),
unless justified and applicable requirements for the humane use of laboratory animals or other applicable regulations; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">submission to the FDA of an application for an IND, which must become effective before human clinical trials may begin;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">approval of the protocol and related documentation by an independent institutional review board (&#147;IRB&#148;), or
ethics committee at each clinical trial site before each study may be initiated; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">performance of adequate and well-controlled human clinical trials according to the FDA&#146;s regulations commonly referred
to as good clinical practices (&#147;GCPs&#148;), and any additional requirements for the protection of human research subjects and their health information, to establish the safety and efficacy of the proposed biological product for its intended
use; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">submission to the FDA of a biologics license application (&#147;BLA&#148;), for regulatory approval that includes
sufficient evidence of establishing the safety, purity and potency of the proposed biological product for its intended indication, including from results of nonclinical testing and clinical trials; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">200 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the biological product is
produced to assess compliance with cGMP, to assure that the facilities, methods and controls are adequate to preserve the biological product&#146;s identity, strength, quality and purity and, if applicable, the FDA&#146;s current good tissue
practices (&#147;CGTPs&#148;), for the use of human cellular and tissue products; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">potential FDA audit of the nonclinical study and clinical trial sites that generated the data in support of the BLA in
accordance with any applicable expedited programs or designations; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">review of the product candidate by an FDA advisory committee, where appropriate or if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">payment of user fees for FDA review of the BLA (unless a fee waiver applies); and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">FDA review and approval, or licensure, of the BLA. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Before testing any biological product candidate, including a gene therapy product, in humans, the product candidate enters the preclinical testing stage. Preclinical
tests, also referred to as nonclinical studies, include laboratory evaluations of product biological characteristics, chemistry, toxicity, and formulation, as well as animal studies to assess the potential safety and activity of the product
candidate. The conduct of the preclinical tests must comply with federal regulations and requirements including GLPs. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">An IND is an exemption from the FD&amp;C Act
that allows an investigational product candidate to be shipped in interstate commerce for use in a clinical trial and a request for FDA authorization to administer such investigational product candidate to humans. Such authorization must be secured
prior to interstate shipment and administration of any product candidate that is not the subject of an approved BLA. In support of a request for an IND, applicants must submit a protocol for each clinical trial and any subsequent protocol amendments
must be submitted to the FDA as part of the IND. In addition, the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical trials, among other
things, must be submitted to the FDA as part of an IND. The FDA requires a <FONT STYLE="white-space:nowrap">30-day</FONT> waiting period after the filing of each IND before clinical trials may begin. This waiting period is designed to allow the FDA
to review the IND to determine whether human research subjects will be exposed to unreasonable health risks. At any time during this <FONT STYLE="white-space:nowrap">30-day</FONT> period the FDA may raise concerns or questions about the conduct of
the trials as outlined in the IND and impose a clinical hold or partial clinical hold. In this case, the IND sponsor and the FDA must resolve any outstanding concerns before clinical trials can begin. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Following commencement of a clinical trial, the FDA may also place a clinical hold or partial clinical hold on that trial. A clinical hold is an order issued by the FDA
to the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation. A partial clinical hold is a delay or suspension of only part of the clinical work requested under the IND. No more than 30 days after imposition of a
clinical hold or partial clinical hold, the FDA will provide the sponsor a written explanation of the basis for the hold. Following issuance of a clinical hold or partial clinical hold, an investigation may only resume after the FDA has notified the
sponsor that the investigation may proceed. There also are requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries. Information about certain clinical trials, including clinical trial
results, must be submitted within specific timeframes for publication on the www.clinicaltrials.gov website. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A sponsor may choose, but is not required, to conduct a
foreign clinical trial under an IND. When a foreign clinical trial is conducted under an IND, all FDA IND requirements must be met unless waived. When a foreign clinical trial is not conducted under an IND, the sponsor must ensure that the study
complies with certain regulatory requirements of the FDA in order to use the study as support for an IND or application for regulatory approval or licensing. In particular, such studies must be conducted in accordance with GCP, including review and
approval by an independent ethics committee (&#147;IEC&#148;), and informed consent from subjects. The FDA must be able to validate the data through an onsite inspection, if deemed necessary by the FDA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">201 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">An IRB representing each institution participating in the clinical trial must review and approve the plan for any
clinical trial before it commences at that institution, and the IRB must conduct continuing review and reapprove the study at least annually. The IRB must review and approve, among other things, the study protocol and informed consent information to
be provided to study subjects. An IRB must operate in compliance with FDA regulations. An IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in
accordance with the IRB&#146;s requirements or if the product candidate has been associated with unexpected serious harm to patients. Some trials are overseen by an independent group of qualified experts organized by the trial sponsor, known as a
data safety monitoring board or committee (&#147;DSMB&#148;). This group provides authorization as to whether or not a trial may move forward at designated check points based on access that only the group maintains to available data from the study.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition to the submission of an IND to the FDA before initiation of a clinical trial in the United States, certain human clinical trials involving recombinant
or synthetic nucleic acid molecules may be subject to oversight of institutional biosafety committees (&#147;IBCs&#148;), as set forth in the National Institutes of Health (&#147;NIH&#148;), Guidelines for Research Involving Recombinant or Synthetic
Nucleic Acid Molecules (&#147;NIH Guidelines&#148;). Under the NIH Guidelines, recombinant and synthetic nucleic acids are defined as: (i)&nbsp;molecules that are constructed by joining nucleic acid molecules that can replicate in a living cell
(i.e., recombinant nucleic acids); (ii) nucleic acid molecules that are chemically or by other means synthesized or amplified, including those that are chemically or otherwise modified but can base pair with naturally occurring nucleic acid
molecules (i.e., synthetic nucleic acids); or (iii)&nbsp;molecules that result from the replication of those described in (i)&nbsp;or (ii). Specifically, under the NIH Guidelines, supervision of human gene transfer trials includes evaluation and
assessment by an IBC, a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to
public health or the environment, and such review may result in some delay before initiation of a clinical trial. While the NIH Guidelines are not mandatory unless the research in question is being conducted at or sponsored by institutions receiving
NIH funding for recombinant or synthetic nucleic acid molecule research, many companies and other institutions not otherwise subject to the NIH Guidelines voluntarily follow them. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Clinical trials typically are conducted in three sequential phases that may overlap or be combined: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Phase 1. The biological product candidate is initially introduced into healthy human subjects and tested for safety. In the
case of some biological product candidates for severe or life-threatening diseases, especially when the product candidate may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in
patients. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Phase 2. The biological product candidate is evaluated in a limited patient population to identify possible adverse effects
and safety risks, to preliminarily evaluate the efficacy of the product candidate for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Phase 3. Clinical trials are undertaken to further evaluate dosage, clinical efficacy, potency and safety in an expanded
patient population at geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the product candidate and provide an adequate basis for approval and product labeling.
</P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Post-approval clinical trials, sometimes referred to as Phase&nbsp;4 clinical trials, may be conducted after initial regulatory approval. These
clinical trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety <FONT STYLE="white-space:nowrap">follow-up.</FONT> The FDA generally recommends that
sponsors&nbsp;of human gene therapy product candidates and genome editing product candidates observe subjects for potential gene therapy-related delayed adverse events for up to a <FONT STYLE="white-space:nowrap">15-year</FONT> period, including
five years of annual examinations followed by ten years of annual queries, either by telephone or by questionnaire, of study subjects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">202 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">During all phases of clinical development, the FDA requires extensive monitoring and auditing of all clinical
activities, clinical data, and clinical trial investigators. Annual progress reports detailing the results of the clinical trials must be submitted to the FDA. Written IND safety reports must be promptly submitted to the FDA and the investigators
for serious and unexpected suspected adverse events, any findings from other studies, tests in laboratory animals or<I>&nbsp;in vitro</I>&nbsp;testing that suggest a significant risk for human subjects, or any clinically important increase in the
rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for reporting.
The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor&#146;s initial receipt of the information. The FDA or the sponsor, acting on its own or based on
a recommendation from the sponsor&#146;s data safety monitoring board may suspend a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Similarly, an IRB can
suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#146;s requirements or if the biological product candidate has been associated with unexpected serious harm
to patients. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Concurrent with clinical trials, companies usually complete additional animal studies and also must develop additional information about the physical
characteristics of the biological product candidate as well as finalize a process for manufacturing the product candidate in commercial quantities in accordance with cGMP. To help reduce the risk of the introduction of adventitious agents with use
of biological product candidates, the PHS Act emphasizes the importance of manufacturing control for product candidates whose attributes cannot be precisely defined. The manufacturing process must be capable of consistently producing quality batches
of the product candidate and, among other things, the sponsor must develop methods for testing the identity, strength, quality, potency, and purity of the final biological product. Additionally, appropriate packaging must be selected and tested and
stability studies must be conducted to demonstrate that the biological product candidate does not undergo unacceptable deterioration over its shelf life. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>U.S.
Review and Approval Processes </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">After the completion of clinical trials of a biological product candidate, FDA approval of a BLA must be obtained before
commercial marketing of the biological product. The BLA must include results of product development, laboratory and animal studies, human studies, information on the manufacture and composition of the product, proposed labeling and other relevant
information. The testing and approval processes require substantial time and effort and there can be no assurance that the FDA will accept the BLA for filing and, even if filed, that any approval will be granted on a timely basis, if at all. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Within 60 days following submission of the application, the FDA reviews a BLA to determine if it is substantially complete before the FDA accepts it for filing. The FDA
may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. The resubmitted application
also is subject to review before the FDA accepts it for filing. In most cases, the submission of a BLA is subject to a substantial application user fee, although the fee may be waived under certain circumstances. Under the performance goals and
policies implemented by the FDA under the Prescription Drug User Fee Act (&#147;PDUFA&#148;), for original BLAs, the FDA targets ten months from the filing date in which to complete its initial review of a standard application and respond to the
applicant, and six months from the filing date for an application with priority review. The FDA does not always meet its PDUFA goal dates, and the review process is often significantly extended by FDA requests for additional information or
clarification. This review typically takes 12 months from the date the BLA is submitted to the FDA because the FDA has approximately two months to make a &#145;&#145;filing&#146;&#146; decision. The review process and the PDUFA goal date may be
extended by three months if the FDA requests or the BLA sponsor otherwise provides additional information or clarification regarding information already provided in the submission within the last three months before the PDUFA goal date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">203 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Once the submission is accepted for filing, the FDA begins an <FONT STYLE="white-space:nowrap">in-depth</FONT>
substantive review of the BLA. The FDA reviews the BLA to determine, among other things, whether the proposed product is safe, pure, and potent for its intended use, and whether the product is being manufactured in accordance with cGMP to ensure the
continued safety, purity, and potency of such product. The FDA may refer applications for novel biological products or biological products that present difficult or novel questions of safety or efficacy to an advisory committee, typically a panel
that includes clinicians and other experts, for review, evaluation, and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it
considers such recommendations carefully when making decisions. During the biological product approval process, the FDA also will determine whether a Risk Evaluation and Mitigation Strategy (&#147;REMS&#148;), is necessary to assure the safe use of
the biological product. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS; the FDA will not approve the BLA without a REMS, if required. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Before approving a BLA, the FDA typically will inspect the facilities at which the product is manufactured. The FDA will not approve the product unless it determines
that the manufacturing processes and facilities are in compliance with cGMP and adequate to assure consistent production of the product within required specifications. For a gene therapy product, the FDA also will not approve the product if the
manufacturer is not in compliance with the CGTPs. These are FDA regulations that govern the methods used in, and the facilities and controls used for, the manufacture of human cells, tissues, and cellular and tissue-based products
(&#147;HCT/Ps&#148;), which are human cells or tissue intended for implantation, transplant, infusion, or transfer into a human recipient. The primary intent of the CGTP requirements is to ensure that cell and tissue-based products are manufactured
in a manner designed to prevent the introduction, transmission and spread of communicable disease. FDA regulations also require tissue establishments to register and list their HCT/Ps with the FDA and, when applicable, to evaluate donors through
appropriate screening and testing. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure that the clinical trials were conducted in compliance with IND study requirements and GCP requirements. To
assure cGMP, CGTP and GCP compliance, an applicant must incur significant expenditure of time, money, and effort in the areas of training, record keeping, production and quality control. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Under the Pediatric Research Equity Act (&#147;PREA&#148;), a BLA or supplement to a BLA for a novel product (e.g., new active ingredient, new indication, etc.) must
contain data to assess the safety and effectiveness of the biological product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is
safe and effective. The FDA may grant deferrals for submission of data or full or partial waivers. Unless otherwise required by regulation, PREA does not apply to any biological product for an indication for which orphan designation has been
granted. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the biological product will be manufactured, the FDA may issue an
approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the
application is complete, and the application will not be approved in its present form. A Complete Response Letter will usually describe all of the deficiencies that the FDA has identified in the BLA, except that where the FDA determines that the
data supporting the application are inadequate to support approval, the FDA may issue the Complete Response Letter without first conducting required inspections, testing submitted product lots and/or reviewing proposed labeling. In issuing the
Complete Response Letter, the FDA may recommend actions that the applicant might take to place the BLA in condition for approval, including requests for additional information or clarification, which may include the potential requirement for
additional preclinical studies or clinical trials or additional manufacturing activities. If a Complete Response Letter is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw
the application or request an opportunity for a hearing. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">204 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to
monitor safety or efficacy of a product. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If a product receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or
the indications for use may otherwise be limited, including to subpopulations of patients, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings precautions or interactions be
included in the product labeling. The FDA may impose restrictions and conditions on product distribution, prescribing or dispensing in the form of a REMS, or otherwise limit the scope of any approval. In addition, the FDA may require post-marketing
clinical trials, sometimes referred to as Phase&nbsp;4 clinical trials, designed to further assess a biological product&#146;s safety and effectiveness, and testing and surveillance programs to monitor the safety of approved products that have been
commercialized. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Orphan Drug Designation </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Under the Orphan Drug Act, the
FDA may grant orphan designation to a drug or biological product candidate intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than
200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making a drug or biological product candidate available in the United States for this type of disease or condition will be
recovered from sales of the product. Orphan product designation must be requested before submitting a BLA. After the FDA grants orphan product designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by
the FDA. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If a product candidate that has orphan drug designation subsequently receives the first FDA approval for the disease or condition for which it has such
designation, the product is entitled to orphan drug exclusive approval (or exclusivity), which means that the FDA may not approve any other applications, including a full BLA, to market the same product for the same indication for seven years,
except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity by means of greater effectiveness, greater safety or providing a major contribution to patient care or if the holder of the orphan
drug exclusivity cannot assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the product was designated. Orphan drug exclusivity does not prevent the FDA from
approving a different drug or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the
BLA application fee. A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan drug designation. In addition, exclusive marketing rights in the
United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or
condition. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Expedited Development and Review Programs </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The FDA has
various programs, including fast track designation, breakthrough therapy designation, priority review and accelerated approval, that are intended to expedite or simplify the process for the development and FDA review of drugs and biologics that are
intended for the treatment of serious or life-threatening diseases or conditions. These programs do not change the standards for approval but may help expedite the development or approval process. To be eligible for fast track designation, new drugs
and biological products must be intended to treat a serious or life-threatening condition and demonstrate the potential to address unmet medical needs for the condition. Fast track designation applies to the combination of the product and the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">205 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
specific indication for which it is being studied. The sponsor of a new drug or biologic may request the FDA to designate the drug or biologic as a fast track product at any time during the
clinical development of the product. One benefit of fast track designation, for example, is that the FDA may consider for review sections of the marketing application for a product that has received fast track designation on a rolling basis before
the complete application is submitted. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Under the FDA&#146;s breakthrough therapy program, products intended to treat a serious or life-threatening disease or
condition may be eligible for the benefits of the fast track program when preliminary clinical evidence demonstrates that such product may have substantial improvement on one or more clinically significant endpoints over existing therapies.
Additionally, the FDA will seek to ensure the sponsor of a breakthrough therapy product receives timely advice and interactive communications to help the sponsor design and conduct a development program as efficiently as possible. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any product is eligible for priority review if it has the potential to provide safe and effective therapy where no satisfactory alternative therapy exists or a
significant improvement in the treatment, diagnosis or prevention of a disease compared to marketed products. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug or biological product designated for
priority review in an effort to facilitate the review. Under priority review, the FDA&#146;s goal is to review an application in six months once it is filed, compared to ten months for a standard review. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Additionally, a product may be eligible for accelerated approval. Drug or biological products studied for their safety and effectiveness in treating serious or
life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may receive accelerated approval, which means that they may be approved on the basis of adequate and well-controlled clinical trials establishing
that the product has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on the basis of an effect on an intermediate clinical endpoint other than survival or irreversible morbidity. As a condition of
approval, the FDA may require that a sponsor of a drug or biological product receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials with due diligence, and, under the Food and Drug Omnibus Reform Act of
2022 (&#147;FDORA&#148;), the FDA is now permitted to require, as appropriate, that such trials be underway prior to approval or within a specific time period after the date of approval for a product granted accelerated approval. Under FDORA, the
FDA has increased authority for expedited procedures to withdraw approval of a product or indication approved under accelerated approval if, for example, the confirmatory trial fails to verify the predicted clinical benefit of the product. In
addition, for products being considered for accelerated approval, the FDA generally requires, unless otherwise informed by the agency, that all advertising and promotional materials intended for dissemination or publication be submitted to the
agency for review, which could adversely affect the timing of the commercial launch of the product. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>RMAT Designation </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As part of the 21<SUP STYLE="font-size:75%; vertical-align:top">st</SUP> Century Cures Act, Congress amended the FD&amp;C Act to facilitate an efficient development
program for and expedite review of regenerative medicine advanced therapies (&#147;RMAT&#148;), which include cell and gene therapies, therapeutic tissue engineering products, human cell and tissue products and combination products using any such
therapies or products. RMAT do not include those HCT/Ps regulated solely under section&nbsp;361 of the PHS Act and 21&nbsp;CFR Part&nbsp;1271. This program is intended to facilitate efficient development and expedite review of regenerative medicine
therapies, which are intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition and qualify for RMAT designation. A drug sponsor may request that FDA designate a drug as a RMAT concurrently with or at any time
after submission of an IND. FDA has 60 calendar days to determine whether the drug meets the criteria, including whether there is preliminary clinical evidence indicating that the drug has the potential to address unmet medical needs for a serious
or life-threatening disease </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">206 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
or condition. A BLA for a regenerative medicine therapy that has received RMAT designation may be eligible for priority review or accelerated approval through use of surrogate or intermediate
endpoints reasonably likely to predict long-term clinical benefit, or reliance upon data obtained from a meaningful number of sites.&nbsp;Benefits of RMAT designation also include early interactions with FDA to discuss any potential surrogate or
intermediate endpoint to be used to support accelerated approval.&nbsp;A regenerative medicine therapy with RMAT designation that is granted accelerated approval and is subject to post-approval requirements may fulfill such requirements through the
submission of clinical evidence from clinical trials, patient registries, or other sources of real world evidence, such as electronic health records; the collection of larger confirmatory data sets; or post-approval monitoring of all patients
treated with such therapy prior to its approval. Like some of the FDA&#146;s other expedited development programs, RMAT designation does not change the standards for approval but may help expedite the development or approval process. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Rare Pediatric Disease Designation and Priority Review Vouchers </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Under the or
FD&amp;C Act, as amended, the FDA incentivizes the development of product candidates that meet the definition of a &#147;rare pediatric disease,&#148; defined to mean a serious or life-threatening disease in which the serious of life-threatening
manifestations primarily affect individuals aged from birth to 18 years and the disease affects fewer than 200,000 individuals in the United States or affects 200,000 or more in the United States and for which there is no reasonable expectation that
the cost of developing and making in the United States a drug or biologic for such disease or condition will be received from sales in the United States of such drug or biologic. The sponsor of a product candidate for a rare pediatric disease may be
eligible for a voucher that can be used to obtain a priority review for a subsequent marketing application after the date of approval of the rare pediatric disease drug product. A sponsor may request rare pediatric disease designation from the FDA
prior to the submission of its BLA. A rare pediatric disease designation does not guarantee that a sponsor will receive a priority review voucher (&#147;PRV&#148;) upon approval of its BLA. Moreover, a sponsor who chooses not to submit a rare
pediatric disease designation request may nonetheless receive a PRV upon approval of their marketing application if they request such a voucher in their original marketing application and meet all of the eligibility criteria. If a PRV is received,
it may be sold or transferred an unlimited number of times. Congress has extended the PRV program until September&nbsp;30, 2024, with the potential for PRVs to be granted until September&nbsp;30, 2026. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Post-Approval Requirements </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Maintaining substantial compliance with
applicable federal, state and local statutes and regulations requires the expenditure of substantial time and financial resources. Products manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by
the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. If there are any modifications to
the product, including changes in indications, labeling or manufacturing processes or facilities, the applicant may be required to submit and obtain FDA approval of a new BLA or BLA supplement, which may require the development of additional data or
preclinical studies and clinical trials. Such regulatory reviews can result in denial or modification of the planned changes, or requirements to conduct additional tests or evaluations that can substantially delay or increase the cost of the planned
changes. The FDA may also impose a number of post-approval requirements as a condition of approval of a BLA. For example, the FDA may require post-marketing testing, including Phase 4 clinical trials, and surveillance to further assess and monitor
the product&#146;s safety and effectiveness after commercialization. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Manufacturers of biological products are required to comply with applicable requirements in the
cGMP, including quality control and quality assurance and maintenance of records and documentation. Other post-approval requirements applicable to biological products include reporting of cGMP deviations that may affect
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">207 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
the identity, potency, purity and overall safety of a distributed product, record-keeping requirements, reporting of adverse effects, reporting updated safety and efficacy information, and
complying with&nbsp;electronic record and signature requirements. After a BLA is approved, the product also may be subject to official lot release. As part of the manufacturing process, the manufacturer is required to perform certain tests on each
lot of the product before it is released for distribution. If the product is subject to official release by the FDA, the manufacturer submits samples of each lot of product to the FDA together with a release protocol showing a summary of the history
of manufacture of the lot and the results of all of the manufacturer&#146;s tests performed on the lot. The FDA also may perform certain confirmatory tests on lots of some products, such as viral vaccines, before releasing the lots for distribution
by the manufacturer. In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, potency, and effectiveness of biological products. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We also must comply with the FDA&#146;s advertising and promotion requirements, such as those related to
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> advertising, the prohibition on promoting products for uses or in patient populations that are not described in the product&#146;s approved labeling
(known as <FONT STYLE="white-space:nowrap">&#147;off-label</FONT> use&#148;), industry-sponsored scientific and educational activities, and promotional activities involving the internet. Discovery of previously unknown problems or the failure to
comply with the applicable regulatory requirements may result in restrictions on the marketing of a product or withdrawal of the product from the market as well as possible civil or criminal sanctions. Failure to comply with the applicable U.S.
requirements at any time during the product development process, approval process or after approval, may subject an applicant or manufacturer to administrative or judicial civil or criminal sanctions and adverse publicity. FDA sanctions could
include refusal to approve pending applications, withdrawal of an approval, clinical holds, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of
government contracts, mandated corrective advertising or communications with doctors or other stakeholders, debarment, restitution, disgorgement of profits, or civil or criminal penalties. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Biological product manufacturers and other entities involved in the manufacture and distribution of approved biological products, and those supplying products,
ingredients, and components of them, are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other
laws. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. Discovery of problems with a product after approval may result in restrictions on a product,
manufacturer, or holder of an approved BLA, including withdrawal of the product from the market. In addition, changes to the manufacturing process or facility generally require prior FDA approval before being implemented and other types of changes
to the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA review and approval. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>U.S. Patent Term
Restoration and Marketing Exclusivity </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Depending upon the timing, duration, and specifics of the FDA approval of the use of our product candidates, some U.S.
patents that may issue from our pending patent applications may be eligible for limited patent term extension under the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for
patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#146;s approval date. The patent term
restoration period is generally <FONT STYLE="white-space:nowrap">one-half</FONT> the time between the effective date of an IND and the submission date of a BLA plus the time between the submission date of a BLA and the approval of that application,
except that the review period is reduced by any time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved biological product is eligible for the extension and the application for the extension must
be submitted prior to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">208 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
the expiration of the patent. In addition, only those claims covering the approved product, a method for using it, or a method for manufacturing it may be extended, and a patent can only be
extended once and only for a single product. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we may apply for restoration of patent term for one of the
patents that may issue from our pending patent applications, if and as applicable, to add patent life beyond its current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the
relevant BLA. However, there can be no assurance that our pending patent applications will issue or that we will benefit from any patent term extension or favorable adjustments to the terms of any patents we may own or
<FONT STYLE="white-space:nowrap">in-license</FONT> in the future. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A biological product can obtain pediatric market exclusivity in the United States. Pediatric
exclusivity, if granted, adds six months to existing exclusivity periods and may be granted based on the voluntary completion of a pediatric study in accordance with an <FONT STYLE="white-space:nowrap">FDA-issued</FONT> &#147;Written Request&#148;
for such a study. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Biologics Price Competition and Innovation Act of 2009 created an abbreviated approval pathway for biological products shown to be similar to,
or interchangeable with, an <FONT STYLE="white-space:nowrap">FDA-licensed</FONT> reference biological product. This amendment to the PHS Act attempts to minimize duplicative testing. Biosimilarity, which requires that there be no clinically
meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, can be shown through analytical studies, animal studies and a clinical trial or trials. Interchangeability requires that a
product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product and, for products&nbsp;administered multiple times, the biologic and the reference
biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A reference biological product is granted four- and <FONT STYLE="white-space:nowrap">12-year</FONT> exclusivity periods from the time of first licensure of the product.
FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four years after the date of first licensure of the reference product, and FDA will not approve an application for a
biosimilar or interchangeable product based on the reference biological product until twelve years after the date of first licensure of the reference product. &#147;First licensure&#148; typically means the initial date the particular product at
issue was licensed in the United States. Date of first licensure does not include the date of licensure of (and a new period of exclusivity is not available for) a biological product if the licensure is for a supplement for the biological product or
for a subsequent application by the same sponsor or manufacturer of the biological product (or licensor, predecessor in interest, or other related entity) for a change (not including a modification to the structure of the biological product) that
results in a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device or strength, or for a modification to the structure of the biological product that does not result in a change in safety, purity, or
potency. Therefore, one must determine whether a new product includes a modification to the structure of a previously licensed product that results in a change in safety, purity, or potency to assess whether the licensure of the new product is a
first licensure that triggers its own period of exclusivity. Whether a subsequent application, if approved, warrants exclusivity as the &#147;first licensure&#148; of a biological product is determined on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis with data submitted by the sponsor. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Regulation Outside of the United States </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition to regulations in the United States, we are subject to a variety of regulations in other jurisdictions governing clinical studies, commercial sales, and
distribution of our products. Most countries outside of the United States require that clinical trial applications be submitted to and approved by the local regulatory authority for each clinical study. In the European Union, for example, an
application must be submitted to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">209 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
national competent authority and an independent ethics committee in each country in which we intend to conduct clinical trials, much like the FDA and IRB, respectively. Under the new Clinical
Trials Regulation (EU) No 536/2014, which replaced the Clinical Trials Directive 2001/20/EC on January&nbsp;31, 2022, a single application is now made through the Clinical Trials Information System (&#147;CTIS&#148;) for clinical trial authorization
in up to 30 EU/EEA countries at the same time and with a single set of documentation. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The assessment of applications for clinical trials is divided into two parts
(Part I contains scientific and medicinal product documentation and Part II contains the national and patient-level documentation). Part I is assessed by a coordinated review by the competent authorities of all European Union Member States in which
an application for authorization of a clinical trial has been submitted (Member States concerned) of a draft report prepared by a Reference Member State. Part II is assessed separately by each Member State concerned. The role of the relevant ethics
committees in the assessment procedure will continue to be governed by the national law of the Member State concerned, however overall related timelines are defined by the Clinical Trials Regulation. The new Clinical Trials Regulation also provides
for simplified reporting procedures for clinical trial sponsors. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, whether or not we obtain FDA approval for a product, we must obtain approval of a
product by the comparable regulatory authorities of countries outside the United States before we can commence marketing of the product in those countries. The approval process and requirements vary from country to country, so the number and type of
nonclinical, clinical, and manufacturing studies needed may differ, and the time may be longer or shorter than that required for FDA approval. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To obtain regulatory
approval of our medicinal products under the European Union regulatory system, we are required to submit a marketing authorization application (&#147;MAA&#148;), to be assessed in the centralized procedure. The centralized procedure allows
applicants to obtain a marketing authorization (&#147;MA&#148;) that is valid throughout the European Union, and the additional Member States of the European Economic Area (Iceland, Liechtenstein and Norway) (&#147;EEA&#148;). It is compulsory for
medicinal products manufactured using biotechnological processes, orphan medicinal products, advanced therapy medicinal products (gene-therapy, somatic cell-therapy or tissue-engineered medicines) and human products containing a new active substance
which is not authorized in the European Union and which is intended for the treatment of HIV, AIDS, cancer, neurodegenerative disorders, auto-immune and other immune dysfunctions, viral diseases or diabetes. The centralized procedure is optional for
any other products containing new active substances not authorized in the European Union or for products which constitute a significant therapeutic, scientific, or technical innovation or for which a centralized authorization is in the interests of
patients at European Union level. When a company wishes to place on the market a medicinal product that is eligible for the centralized procedure, it sends an application directly to the European Medicines Agency (&#147;EMA&#148;), to be assessed by
the Committee for Medicinal Products for Human Use (&#147;CHMP&#148;). The CHMP is responsible for conducting the assessment of whether a medicine meets the required quality, safety, and efficacy requirements, and whether the product has a positive
risk/benefit profile. The procedure results in a European Commission decision, which is valid in all European Union Member States. The centralized procedure is as follows: full copies of the MAA are sent to a rapporteur and a <FONT
STYLE="white-space:nowrap">co-rapporteur</FONT> designated by the competent EMA scientific committee. They coordinate the EMA&#146;s scientific assessment of the medicinal product and prepare draft reports. Once the draft reports are prepared (other
experts might be called upon for this purpose), they are sent to the CHMP, whose comments or objections are communicated to the applicant. The rapporteur is therefore the privileged interlocutor of the applicant and continues to play this role, even
after the MA has been granted. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The rapporteur and <FONT STYLE="white-space:nowrap">co-rapporteur</FONT> then assess the applicant&#146;s replies, submit them for
discussion to the CHMP, and taking into account the conclusions of this debate, prepare a final assessment report. Once the evaluation is completed, the CHMP gives a favorable or unfavorable opinion as to whether to grant the authorization. When the
opinion is favorable, it shall include the draft summary of product characteristics (&#147;SmPC&#148;), the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">210 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
package leaflet, and the texts proposed for the various packaging materials. The time limit for the evaluation procedure is 210 days (excluding clock stops, when additional written or oral
information is to be provided by the applicant in response to questions asked by the CHMP). The EMA then has fifteen days to forward its opinion to the European Commission, which will make a binding decision on the grant of an MA within 67 days of
the receipt of the CHMP opinion. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There are two other procedures in the European Union for the grant of an MA in multiple European Union Member States. The
decentralized procedure provides for approval by one or more other, or Concerned Member States, of an assessment of an application performed by one Member State, known as the Reference Member State. Under this procedure, an applicant submits an
application, or dossier, and related materials including a draft SmPC, and draft labeling and package leaflet, to the Reference Member State and Concerned Member States. The Reference Member State prepares a draft assessment and drafts of the
related materials within 120 days after receipt of a valid application. Within 90 days of receiving the Reference Member State&#146;s assessment report, each Concerned Member State must decide whether to approve the assessment report and related
materials. If a Member State cannot approve the assessment report and related materials on the grounds of potential serious risk to the public health, the disputed points may eventually be referred to the European Commission, whose decision is
binding on all Member States. Where a product has already been authorized for marketing in a European Union Member State, this national MA can be recognized in other Member States through the mutual recognition procedure. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The criteria for designating an &#147;orphan medicinal product&#148; in the European Union are similar in principle to those in the United States. Under Article 3 of
Regulation (EC) 141/2000, a medicinal product may be designated as an orphan medicinal product if it is intended for the diagnosis, prevention, or treatment of a life-threatening or chronically debilitating condition that affects no more than five
in 10,000 persons in the European Union when the application is made. In addition, orphan designation can be granted if the product is intended for a life threatening, seriously debilitating, or serious and chronic condition in the European Union
and, without incentives, it is unlikely that sales of the product in the European Union would be sufficient to justify the necessary investment in its development. Orphan designation is only available if there is no other satisfactory method
approved in the European Union of diagnosing, preventing, or treating the applicable orphan condition, or if such a method exists, the proposed orphan medicinal product will be of significant benefit to patients affected by such condition, as
defined in Regulation (EC) 847/2000. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Orphan designation provides opportunities for fee reductions, protocol assistance, and access to the centralized procedure. Fee
reductions are limited to the first year after an MA, except for small and medium enterprises. In addition, if a product which has an orphan designation subsequently receives a centralized MA for the indication for which it has such designation, the
product is entitled to orphan market exclusivity, which means the EMA may not approve any other application to market a similar medicinal product for the same indication for a period of ten years. A &#147;similar medicinal product&#148; is defined
as a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication. The exclusivity period may be reduced to six years if, at
the end of the fifth year, it is shown that the designation criteria are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity. Additionally, an MA may be granted to a
similar medicinal product for the same indication at any time if: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the second applicant can establish that its product, although similar to the authorized product, is safer, more effective
or otherwise clinically superior; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the MA holder of the authorized product consents to a second orphan medicinal product application; or
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the MA holder of the authorized product cannot supply enough orphan medicinal product. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">211 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A pediatric investigation plan (&#147;PIP&#148;), in the European Union is aimed at ensuring that the necessary data
are obtained to support the authorization of a medicine for children, through studies in children. All applications for Mas for new medicines have to include the results of studies as described in an agreed PIP, unless the medicine is exempt because
of a deferral or waiver. This requirement also applies when an MA holder wants to add a new indication, pharmaceutical form, or route of administration for a medicine that is already authorized and covered by intellectual property rights. Several
rewards and incentives for the development of pediatric medicines for children are available in the European Union. Medicines authorized across the European Union with the results of studies from a PIP included in the product information are
eligible for an extension of their supplementary protection certificate (&#147;SPC&#148;) by six months (provided an application for such extension is made at the same time as filing the SPC application for the product, or at any point up to two
years before the SPC expires). This is the case even when the studies&#146; results are negative. For orphan medicinal products, the incentive is an additional two years of market exclusivity. Scientific advice and protocol assistance at the EMA are
free of charge for questions relating to the development of pediatric medicines. Medicines developed specifically for children that are already authorized but are not protected by a patent or supplementary protection certificate are eligible for a <FONT
STYLE="white-space:nowrap">pediatric-use</FONT> MA (&#147;PUMA&#148;). If a PUMA is granted, the product will benefit from ten&nbsp;years of market protection as an incentive. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In March 2016, the EMA launched an initiative, the PRIority Medicines (&#147;PRIME&#148;) scheme, to facilitate development of product candidates in indications, often
rare, for which few or no therapies currently exist. The PRIME scheme is intended to encourage development of products in areas of unmet medical need and provides accelerated assessment of products representing substantial innovation reviewed under
the centralized procedure. Products from small- and <FONT STYLE="white-space:nowrap">medium-sized</FONT> enterprises may qualify for earlier entry into the PRIME scheme than larger companies on the basis of compelling
<FONT STYLE="white-space:nowrap">non-clinical</FONT> data and tolerability data from initial clinical trials. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory
dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and potentially accelerated MAA assessment once a dossier has been submitted. Importantly, once a candidate medicine has been selected for
the PRIME scheme, a dedicated contact and rapporteur from the CHMP or from the Committee for Advanced Therapies (&#147;CAT&#148;) are appointed early in the PRIME scheme facilitating increased understanding of the product at EMA&#146;s committee
level. An initial meeting with the CHMP/CAT rapporteur initiates these relationships and includes a team of multidisciplinary experts at the EMA to provide guidance on the overall development and regulatory strategies. PRIME eligibility does not
change the standards for product approval, and there is no assurance that any such designation or eligibility will result in expedited review or approval. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The
aforementioned European Union rules are generally applicable in the EEA. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The United Kingdom left the European Union on January&nbsp;31, 2020, and the United Kingdom
and the European Union have concluded a trade and cooperation agreement (&#147;TCA&#148;) which was provisionally applicable since January&nbsp;1, 2021 and has been formally applicable since May&nbsp;1, 2021. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The TCA includes specific provisions concerning pharmaceuticals, which include the mutual recognition of GMP, inspections of manufacturing facilities for medicinal
products and GMP documents issued, but does not provide for wholesale mutual recognition of United Kingdom and European Union pharmaceutical regulations. At present, Great Britain has implemented European Union legislation on the marketing,
promotion and sale of medicinal products through the Human Medicines Regulations 2012 (as amended). Except in respect of the new European Union Clinical Trials Regulation, the regulatory regime in Great Britain therefore largely aligns with current
European Union medicines regulations, however it is possible that these regimes will diverge more significantly in future now that Great Britain&#146;s regulatory system is independent from the European Union and the TCA does not provide for mutual
recognition of United Kingdom and European Union pharmaceutical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">212 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
legislation. However, notwithstanding that there is no wholesale recognition of European Union pharmaceutical legislation under the TCA, under a new framework mentioned below which will be put in
place by the Medicines and Healthcare products Regulatory Agency (&#147;MHRA&#148;), the United Kingdom&#146;s medicines regulator, from January&nbsp;1, 2024, the MHRA has stated that it will take into account decisions on the approval of Mas from
the EMA (and certain other regulators) when considering an application for a Great Britain MA. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On February&nbsp;27, 2023, the United Kingdom government and the
European Commission announced a political agreement in principle to replace the Northern Ireland Protocol with a new set of arrangements, known as the &#147;Windsor Framework&#148;. This new framework fundamentally changes the existing system under
the Northern Ireland Protocol, including with respect to the regulation of medicinal products in the United Kingdom. In particular, the MHRA will be responsible for approving all medicinal products destined for the United Kingdom market (i.e., Great
Britain and Northern Ireland), and the EMA will no longer have any role in approving medicinal products destined for Northern Ireland. A single United Kingdom-wide MA will be granted by the MHRA for all medicinal products to be sold in the United
Kingdom, enabling products to be sold in a single pack and under a single authorization throughout the United Kingdom. The Windsor Framework was approved by the European Union-United Kingdom Joint Committee on March&nbsp;24, 2023, so the United
Kingdom government and the European Union will enact legislative measures to bring it into law. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The MHRA has introduced changes to national licensing procedures,
including procedures to prioritize access to new medicines that will benefit patients, an accelerated assessment procedure and new routes of evaluation for novel products and biotechnological products. All existing European Union Mas for centrally
authorized products were automatically converted (grandfathered) into United Kingdom Mas free of charge on January&nbsp;1, 2021. For a period of three years from January&nbsp;1, 2021, the MHRA may&nbsp;rely on a decision taken by the European
Commission on the approval of a new MA in the centralized procedure, in order to more quickly grant a new Great Britain MA. A separate application will, however, still be required. On January&nbsp;24, 2023, the MHRA announced that a new
international recognition framework will be put in place from January&nbsp;1, 2024, which will have regard to decisions on the approval of Mas made by the EMA and certain other regulators when determining an application for a new Great Britain MA.
There is now no <FONT STYLE="white-space:nowrap">pre-MA</FONT> orphan designation in Great Britain. Instead, the MHRA reviews applications for orphan designation in parallel to the corresponding MAA. The criteria are essentially the same, but have
been tailored for the Great Britain market, i.e., the prevalence of the condition in Great Britain (rather than the European Union) must not be more than five in 10,000. Should an orphan designation be granted, the period of market exclusivity will
be set from the date of first approval of the product in Great Britain. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Other Healthcare Laws and Compliance Requirements </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Other Healthcare Laws </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Biotechnology companies are subject to additional
healthcare laws in the jurisdictions in which they conduct their business that may constrain the financial arrangements and relationships through which we research, as well as, in the future sell, market and distribute any products for which we
obtain regulatory approval. Such laws include, without limitation, state and federal patient data privacy and security laws, federal and state anti-kickback laws, physician-self referral laws, false claims and transparency laws and regulations with
respect to drug pricing and payments and other transfers of value made to physicians and other health care providers, and similar healthcare laws and regulations in the EU and other jurisdictions. Violations of any of such laws or any other
governmental regulations that apply may result in significant penalties, including, without limitation, administrative, civil and criminal penalties, damages, fines, disgorgement, the curtailment or restructuring of operations, integrity oversight
and reporting obligations to resolve allegations of noncompliance, and exclusion from participation in federal and state healthcare programs and imprisonment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">213 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Coverage and Reimbursement </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Sales of any product depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state, and foreign government
healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement for such product by third-party payors. Decisions regarding the extent of coverage and amount of reimbursement to be provided are made on
a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">plan-by-plan</FONT></FONT> basis. These third-party payors are increasingly reducing coverage and reimbursement for medical products, drugs and services. For products administered
under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the
treatment or procedure in which the product is used may not be available, which may impact physician utilization. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The U.S. government, state legislatures and
foreign governments have also continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic (or biosimilar) products. Adoption of price controls
and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product. Decreases in third-party reimbursement for any product or a decision by a
third-party payor not to cover a product could reduce physician usage and patient demand for the product and also have a material adverse effect on sales. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Healthcare Reform </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the United States, in March 2010, the Patient Protection
and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, each as amended, collectively known as the ACA, was enacted, which substantially changed the way healthcare is financed by both governmental and private
insurers, and significantly affected the pharmaceutical industry. The ACA contained a number of provisions, including those governing enrollment in federal healthcare programs, reimbursement adjustments and changes to fraud and abuse laws. Since its
enactment, there have been judicial and Congressional challenges to certain aspects of the ACA. Other legislative changes have been proposed and adopted since the ACA was enacted, including aggregate reductions of Medicare payments to providers of
2% per fiscal year. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Additionally, President Biden has issued multiple executive orders that have sought to reduce prescription drug costs. There has also been
increasing legislative and enforcement interest in the United States with respect to drug pricing practices. Specifically, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products,
which has resulted in several U.S. Congressional inquiries and proposed and enacted federal and state legislation. The Inflation Reduction Act of 2022 (&#147;IRA&#148;), includes several provisions that impact the pharmaceutical industry, including
provisions that reduce the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> spending cap for Medicare Part D beneficiaries to $2,000 starting in 2025; impose new manufacturer financial liability on
certain drugs under Medicare Part D, allow the U.S. government to negotiate Medicare Part B and Part D price caps for certain high-cost drugs and biologics without generic or biosimilar competition; require companies to pay rebates to Medicare for
drug prices that increase faster than inflation; and delay until January&nbsp;1, 2032 the implementation of the HHS rebate rule that would have limited the fees that pharmacy benefit managers can charge. Further, under the IRA, orphan drugs are
exempted from the Medicare drug price negotiation program, but only if they have one orphan designation and for which the only approved indication is for that disease or condition. If a product receives multiple orphan designations or has multiple
approved indications, it may not qualify for the orphan drug exemption. The effects of the IRA on our business and the healthcare industry in general is not yet known. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could impact the amounts that federal and state
governments and other third-party payors will pay for healthcare products and services. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">214 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Data Privacy&nbsp;&amp; Security </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Numerous state, federal and foreign laws govern the collection, dissemination, use, access to, confidentiality and security of personal information, including
health-related information. As our operations and business grow, we may become subject to or affected by U.S. federal and state laws and regulations, including the Health Information Portability and Accountability Act of 1996, and its implementing
regulations, as amended (&#147;HIPAA&#148;), that govern the collection, use, disclosure, and protection of health-related and other personal information. In California the California Consumer Protection Act (&#147;CCPA&#148;), which went into
effect on January&nbsp;1, 2020 and was amended effective January&nbsp;1, 2023, establishes a new privacy framework for covered businesses by creating an expanded definition of personal information, establishing new data privacy rights for consumers
in the State of California, imposing special rules on the collection of consumer data from minors, and creating a new and potentially severe statutory damages framework for violations of the CCPA and for businesses that fail to implement reasonable
security procedures and practices to prevent data breaches. While clinical trial data and information governed by HIPAA are currently exempt from the current version of the CCPA, other personal information may be applicable and possible changes to
the CCPA may broaden its scope. Other states, including Virginia (effective January&nbsp;1, 2023), Colorado (effective July&nbsp;1, 2023), Connecticut (effective July&nbsp;1, 2023), and Utah (effective December&nbsp;31, 2023) have passed privacy
legislation and more states may do so in the future, including Iowa, where the Iowa state legislature passed a comprehensive privacy legislation on March&nbsp;15, 2023. State and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> laws, including for
example the EU General Data Protection Regulation, also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating
compliance efforts. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. Privacy and security laws, regulations, and other obligations are constantly
evolving, may conflict with each other to complicate compliance efforts, and can result in investigations, proceedings, or actions that lead to significant civil and/or criminal penalties and restrictions on data processing. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><U>Employees and Human Capital Resources </U></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of June&nbsp;30, 2023, we
had more than 200 full-time employees, of which 69 have M.D. or Ph.D. degrees. Within our workforce, 176 employees are engaged in research and development and 35 are engaged in business development, finance, legal, and general management and
administration. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and new employees, advisors
and consultants. The principal purposes of our equity incentive plans are to attract, retain and reward personnel through the granting of equity-based compensation awards in order to increase shareholder value and the success of our company by
motivating such individuals to perform to the best of their abilities and achieve our objectives. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><U>Facilities </U></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our corporate headquarters is located in Emeryville, California, where we lease and occupy approximately 23,851 square feet of laboratory and office space at 1545 Park
Avenue, Emeryville, California 94608. The current term of our lease expires in February 2031. The company also leases approximately 23,155 square feet of office space at 1485 Park Avenue, Emeryville, California 94608 and subleases approximately
75,662 square feet of combined office, research and laboratory space at 5959 Horton Street, Emeryville, California 94608. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">215 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We believe that our facilities are adequate for our current needs and for the foreseeable future. To meet the future
needs of our business, we may lease additional or alternate space. We believe that suitable additional or substitute space at commercially reasonable terms will be available as needed to accommodate any future expansion of our operations. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><U>Legal proceedings </U></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">From time to time, we may become involved in legal
proceedings arising from the ordinary course of business. We record a liability for such matters when it is probable that future losses will be incurred and that such losses can be reasonably estimated. Significant judgment by us is required to
determine both probability and the estimated amount. Our management is currently not aware of any legal matters that could have a material adverse effect on our financial position, results of operations or cash flows. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">216 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc425213_13"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table sets forth information about our executive officers and directors as of the date of this prospectus. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="66%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Name</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Position(s)</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"><I>Executive Officers</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Brian C. Thomas, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Jian Irish, Ph.D., MBA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">President and Chief Operating Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Sarah Noonberg, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Medical Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Simon Harnest, M.Sc</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Investment Officer and Senior Vice President of Strategy</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Alan Brooks, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Senior Vice President of Preclinical</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Christopher T. Brown, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Vice President of Discovery</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Simren Delaney, Ph.D., LLM</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Vice President of Legal</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Michael Conway, MBA, CPA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Vice President of Finance</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Juergen Eckhardt, M.D., MBA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Sebasti&aacute;n Bernales, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Risa Stack, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Willard Dere, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Santhosh Palani, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="7" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following is a biographical summary of the experience of our executive officers and directors. There are no family relationships
among any of our executive officers or directors. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Executive Officers </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Brian C. Thomas, Ph.D.</I></B>, is our founder and has served as our Chief Executive Officer since September 2016. Since December 2022, Dr.&nbsp;Thomas has served
as Chairman of the Board of Directors of Haya Therapeutics, Inc. Previously, from 2001 to 2017, Dr.&nbsp;Thomas served as a program manager at University of California, Berkeley. From 1999 to 2001, Dr.&nbsp;Thomas served as a lead bioinformatics
scientist at EOS Biotechnology (now PDL, Inc.). Dr.&nbsp;Thomas received his B.Sc. in cellular biology and his Ph.D. in biochemistry from University of Kansas and completed his post-doctoral research in computational biology at University of
California, Berkeley. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our board of directors believes that Dr.&nbsp;Thomas is qualified to serve as a director because of his considerable academic and research
expertise, as well as his expansive knowledge about our Company as our founder and Chief Executive Officer. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Jian Irish, Ph.D., MBA</I></B>, has served as our
President since November 2021 and our Chief Operating Officer since January 2021. Prior to joining us, Dr.&nbsp;Irish held positions as Senior Vice President, Global Head of Manufacturing and Senior Vice President of Supply Chain at Kite Pharma (now
a subsidiary of Gilead) from September 2016 to December 2020. Dr. Irish served as Interim Chief Operating Officer of Affini-T Therapeutics from January 2021 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">217 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
to January 2022. Dr. Irish also served as Interim Chief Technology Officer and a board member for Fosun Kite, a joint venture between Kite Pharma and Fosun Pharma, from October 2018 to April
2020. From December 2014 to August 2016, Dr. Irish held positions as Vice President of Biologics Supply, Outsourcing, Partnerships, and External Manufacturing and Vice President of Product Development at Sanofi. From January 2000 to September 2014,
Dr. Irish held various leadership positions at Amgen in operations, including Executive Director of JAPAC Supply, Executive Director of Contract Manufacturing, Officer for Kirin-Amgen JV, and Global Operations Team Leader. Dr.&nbsp;Irish currently
serves as an advisor to Ori Biotech, ORCA Biosystems, and ViTToria Biotherapeutics. Dr.&nbsp;Irish received a B.S. in chemical engineering from East China University of Science and Technology, an M.S. and Ph.D. in pharmaceutical sciences from Chiba
University, and an MBA from University of California, Los Angeles, Anderson School of Management. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Sarah Noonberg, M.D., Ph.D.</I></B>, has served as our Chief
Medical Officer since January 2023. Prior to joining us, Dr.&nbsp;Noonberg served as the Chief Medical Officer at Maze Therapeutics, Nohla Therapeutics and Prothena Corporation plc (Nasdaq: PRTA) from July 2020 to September 2022, May 2018 to May
2019 and May 2017 to May 2018, respectively. Dr.&nbsp;Noonberg served as Group Vice President and Head of Global Clinical Development at BioMarin Pharmaceuticals Inc. (Nasdaq: BMRN) from August 2015 to March 2017. From May 2007 to August 2015, she
held several positions at Medivation, Inc., a biopharmaceutical company, culminating in the position of Senior Vice President of Early Development. Dr.&nbsp;Noonberg currently serves on the board of directors of Neoleukin Therapeutics (Nasdaq: NLTX)
and Marinus Pharmaceuticals (Nasdaq: MRNS). She has also previously served on the board of directors of Protagonist Therapeutics, Inc. (Nasdaq: PTGX) from December 2017 to May 2023. Dr.&nbsp;Noonberg received her B.S. in engineering at Dartmouth
College, her Ph.D. in bioengineering from the University of California, Berkeley and her M.D. from the University of California, San Francisco. Dr.&nbsp;Noonberg is a board-certified internist and completed her residency at Johns Hopkins Hospital.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Simon Harnest, M.Sc</I></B>, has served as our Chief Investment Officer and Senior Vice President of Strategy since July 2021. Prior to joining us,
Mr.&nbsp;Harnest held various positions, most recently as Chief Investment Officer and Senior Vice President of Strategy and Finance, at Cellectis Inc. from April 2014 to July 2021. Mr. Harnest also served as Vice President, Corporate Strategy and
Finance at Calyxt from March 2016 to December 2019. Mr.&nbsp;Harnest received his B.Sc in economics from University of Westminster, Westminster Business School and his M.Sc in social studies from London School of Economics, London. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Alan Brooks, Ph.D.</I></B>, has served as our Senior Vice President of Preclinical since January 2023 and previously served as our Director of Preclinical and Vice
President of Preclinical from November 2019 to January 2023. Prior to joining us, Dr. Brooks served as a principal scientist at Casebia Therapeutics from August 2017 to August 2019. From October 2007 to August 2017, Dr. Brooks held various positions
at Bayer AG, including scientist, senior scientist and principal scientist. Dr. Brooks received his B.Sc in biological sciences from University of Leicester, UK and his Ph.D. in molecular and developmental biology from University of Warwick, UK. He
completed his postdoctoral fellowship at the Gladstone Institute/University of California, San Francisco. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Christopher T. Brown, Ph.D., </I></B>has served as
our Vice President of Discovery since January 2023 and previously served as our Senior Bioinformatics Scientist, Director of Discovery and Senior Director of Discovery from September 2018 to December 2022. Prior to joining us, Dr.&nbsp;Brown
conducted post-doctoral research at the University of California, Berkeley from January 2017 to August 2018. He received his B.Sc in microbiology from the University of Florida and his Ph.D. in plant&nbsp;and microbial biology from the University of
California, Berkeley. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Simren Delaney, Ph.D., LLM</I></B>, has served as our Vice President of Legal since February 2020 and previously served as our Chief of
Staff from January 2022 to December 2022. Prior to joining us, Dr.&nbsp;Delaney was an associate at Wilson Sonsini Goodrich&nbsp;&amp; Rosati from October 2016 to February 2020. Dr.&nbsp;Delaney received her B.Sc in science, LL.B. and Ph.D. in
organic chemistry from Deakin University, and her LL.M. from University of California, College of the Law, San Francisco. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">218 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Michael Conway, MBA, CPA, </I></B>has served as our Vice President of Finance since March 2022. Prior to joining
us, Mr.&nbsp;Conway served as Senior Director of Financial Planning and Analysis and Vice President of Finance at Adamas Pharmaceuticals, Inc. from March 2016 to December 2021, where he was responsible for leading the accounting and financial
planning and analysis functions. Mr. Conway received his BBA in management information systems from University of Notre Dame, his MBA from University of Michigan, Ross School of Business, and is a certified public accountant in the state of
California. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Juergen Eckhardt, M.D., MBA</I></B>, has served as our Chairman of the Board of Directors since September 2020. Dr.&nbsp;Eckhardt has served as Head of Leaps at
Bayer AG since February 2019 and previously served as Head of Venture Investments from September 2016 to February 2019. He currently serves on the boards of Dewpoint Therapeutics, Khloris Biosciences, Oerth Bio, and a few other private biotechnology
companies and foundations. Previously, Dr.&nbsp;Eckhardt served as a management consultant and Associate Partner at McKinsey&nbsp;&amp; Co. and a member of McKinsey&#146;s Healthcare Leadership Team from 1994 to 2002. Dr.&nbsp;Eckhardt received his
M.D. from the University of Basel and his MBA from INSEAD in Fontainebleau, France. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our board of directors believes that Dr.&nbsp;Eckhardt is qualified to serve as
a director because of his extensive experience in strategy, finance, leadership and drug development. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Sebasti&aacute;n Bernales, Ph.D.</I></B>, has served on
our board of directors since December 2020 and previously served as a Director of Metagenomi, Inc. from September 2016 to April 2020. Dr.&nbsp;Bernales has been a General Partner at Humboldt Fund since February 2020 and has been a Venture Partner at
DROIA Ventures since August 2020. He has served as the Chief Executive Officer of Praxis Biotech LLC since July 2016 and a member of Sake Holdings LLC since May 2020. Dr. Bernales is also the founder of Merken Biotech. Dr. Bernales is a member of
the boards of directors of PhageLab, Botanical Solutions, Momentum, Vedra, Alesta, and a few other private biotechnology companies and foundations. Dr. Bernales currently serves as an advisor to NotCo, Levita Magnetics, and Leyden Labs. From 2007 to
2016, Dr.&nbsp;Bernales worked at Medivation Inc., culminating in the position of Vice President of Discovery Biology. He received his B.S. from Catholic University in Chile and his Ph.D. in cell biology at the University of California in San
Francisco. He completed his postdoctoral training at the University of California in San Francisco. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our board of directors believes that Dr.&nbsp;Bernales is
qualified to serve as a director because of his significant experience in biotechnology industry. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Risa Stack, Ph.D.</I></B>, has served on our board of
directors since April 2022. Dr. Stack has been a Partner at The Production Board since May 2022. Previously, Dr. Stack was a Venture Partner at RA Capital from September 2020 to March 2022. Dr.&nbsp;Stack was a founder and served as Chairperson of
Menlo Microsystems from December 2016 to September 2018, and served as a General Manager at General Electric from January 2013 to September 2018. Dr.&nbsp;Stack was a Partner at Kleiner Perkins from June 2003 to December 2012. Before joining Kleiner
Perkins, Dr. Stack was a Principal at JP Morgan Partners from September 1996 to May 2003. Dr. Stack currently serves on the Board of Directors of COPD Foundation. Dr.&nbsp;Stack received her B.S. in genetics and development from the University of
Illinois and her Ph.D. in immunology from the University of Chicago. Dr.&nbsp;Stack was a member of the second class of Kauffman Fellows. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our board of directors
believes that Dr.&nbsp;Stack is qualified to serve as a director because of her extensive investment experience, knowledge of financial markets and expertise in personalized medicine, therapeutics and platform technology companies. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Willard Dere, M.D.</I></B>, has served on our board of directors since August 2021. Dr.&nbsp;Dere currently serves as Chief Advisor and Chief Medical Officer at
Angitia since July 2022, and on the board of directors of BioMarin, Seres </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">219 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
and Mersana. He also serves on the Scientific Advisory Boards of Surrozen, AliveGen and Heranova Lifesciences Dr. Dere served as a Professor of Internal Medicine from November 2014 to July 2022
at the University of Utah School of Medicine, and is currently Professor Emeritus, a position he has held since July 2022. Dr. Dere also served as Associate Vice President for Research, Co-Director of The Center for Genomic Medicine and Co-Director
of the Utah Clinical and Translational Science Institute at the University of Utah Health Sciences Center during this time period. Before joining the University of Utah, Dr. Dere held various positions at Amgen, Inc., including Senior Vice President
of Global Development and Corporate, then International Chief Medical Officer, from July 2003 to October 2014. From 1989 to 2003, Dr. Dere held multiple positions in clinical research, and regulatory affairs and safety at Eli Lilly and Company. He
was also an assistant professor from 1989 to 1999 and a clinical associate professor from 1999 to 2009 at the Indiana University School of Medicine. Dr. Dere received his B.A. in history, zoology and M.D. from the University of California, Davis; he
completed his postdoctoral training at the University of Utah in internal medicine, and at the University of California, San Francisco in endocrinology and metabolism. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our board of directors believes that Dr.&nbsp;Dere is qualified to serve as a director because of extensive experience in drug development, and as a board of directors
member on several public companies. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Santhosh Palani, Ph.D.</I></B>, has served on our board of directors since January 2022. Dr.&nbsp;Palani is currently an
investment partner at PFM Health Sciences since June 2020. He was a Principal at New Enterprise Associates from May 2018 to May 2020. From 2016 to 2018, Dr.&nbsp;Palani was a Vice President at Cowen and Company. He previously served as an Associate
Director in Oncology Clinical Development at Pfizer from 2013 to 2016 and as a Scientist in Oncology Preclinical Development at Takeda Pharmaceuticals from 2012 to 2013. Dr. Palani currently serves on the Board of Directors of Turnstone Biologics.
Dr.&nbsp;Palani received his B.S. and M.S. in chemical engineering from the University of Madras and Texas A&amp;M University, respectively. Dr.&nbsp;Palani received his Ph.D. in Bioengineering from the University of Pennsylvania and completed his
postdoctoral work in biochemistry and molecular biophysics at Columbia University. Dr.&nbsp;Palani is a CFA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Charterholder. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our board of directors believes that Dr.&nbsp;Palani is qualified to serve as a director because of his strong financial background and significant industry experience
in the fields of internal medicine and endocrinology. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Board Composition </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our board of managers currently consists of 6 members, each of whom is a member pursuant to the board composition provisions of our current certificate of incorporation
and agreements with our stockholders, which agreements are described in the section of this prospectus entitled &#147;Certain Relationships and Related Person Transactions.&#148; These board composition provisions will terminate upon the closing of
this offering. Upon the termination of these provisions, there will be no further contractual obligations regarding the election of our directors. Our nomination and corporate governance committee and our board of directors may therefore consider a
broad range of factors relating to the qualifications and background of nominees. Our nomination and corporate governance committee&#146;s and our board of directors&#146; priority in selecting board members is identification of persons who will
further the interests of our stockholders through their established record of professional accomplishment, the ability to contribute positively to the collaborative culture among board members, knowledge of our business, understanding of the
competitive landscape, professional and personal experiences and expertise relevant to our growth strategy. Our directors hold office until their successors have been elected and qualified or until their earlier resignation or removal. Our amended
and restated certificate of incorporation and amended and restated bylaws that will become effective upon the closing of this offering also provide that our directors may be removed only for cause by the affirmative vote of the holders of at least <FONT
STYLE="white-space:nowrap">two-thirds</FONT> of the votes that all our stockholders would be entitled to cast in an annual election of directors, and that any vacancy on our board of directors, including a vacancy resulting from an enlargement of
our board of directors, may be filled only by vote of a majority of our directors then in office. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">220 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Staggered Board </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In
accordance with the terms of our amended and restated certificate of incorporation and our amended and restated bylaws that will become effective upon the closing of this offering, our board of directors will be divided into three staggered classes
of directors and each director will be assigned to one of the three classes. At each annual meeting of the stockholders, one class of directors will be elected for a three-year term to succeed the directors of the same class whose terms are then
expiring. The terms of the directors will expire upon the election and qualification of successor directors at the annual meeting of stockholders to be held during the years 2024 for Class&nbsp;I directors, 2025 for Class&nbsp;II directors and 2026
for Class&nbsp;III directors. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Our Class&nbsp;I directors will
be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Our Class&nbsp;II directors will
be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;; and </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Our Class&nbsp;III directors will
be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our amended and restated certificate of
incorporation and amended and restated bylaws that will become effective upon the closing of this offering will provide that the number of our directors shall be fixed from time to time by a resolution of the majority of our board of directors. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The division of our board of directors into three classes with staggered three-year terms may delay or prevent stockholder efforts to effect a change of our management
or a change in control. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Director Independence </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have applied to list
our common stock on the Nasdaq Global Select Market. Under the Nasdaq listing rules, independent directors must comprise a majority of a listed company&#146;s board of directors within twelve months from the date of listing. In addition, the Nasdaq
listing rules require that, subject to specified exceptions, each member of a listed company&#146;s audit, compensation and nominating and governance committees be independent within twelve months from the date of listing. Audit committee members
must also satisfy additional independence criteria, including those set forth in Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> under the Securities Exchange Act of 1934 (the &#147;Exchange Act&#148;), and compensation committee members must
also satisfy the independence criteria set forth in Rule <FONT STYLE="white-space:nowrap">10C-1</FONT> under the Exchange Act. Under Nasdaq listing rules, a director will only qualify as an &#147;independent director&#148; if, in the opinion of that
company&#146;s board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. In order to be considered independent for purposes of Rule
<FONT STYLE="white-space:nowrap">10A-3</FONT> under the Exchange Act, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors, or any other board
committee: (i)&nbsp;accept, directly or indirectly, any consulting, advisory, or other compensatory fee from the listed company or any of its subsidiaries, other than compensation for board service; or (ii)&nbsp;be an affiliated person of the listed
company or any of its subsidiaries. In order to be considered independent for purposes of Rule <FONT STYLE="white-space:nowrap">10C-1,</FONT> the board of directors must consider, for each member of a compensation committee of a listed company, all
factors specifically relevant to determining whether a director has a relationship to such company which is material to that director&#146;s ability to be independent from management in connection with the duties of a compensation committee member,
including, but not limited to: the source of compensation of the director, including any consulting advisory or other compensatory fee paid by such company to the director, and whether the director is affiliated with the company or any of its
subsidiaries or affiliates. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; 2023, our board of directors undertook a review of the
composition of our board of directors and its committees and the independence of each director. Based upon information requested from and provided by each director concerning his background, employment and affiliations, including family
relationships, our board of directors has determined that all members of our board of directors, except&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, are independent
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">221 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
directors, including for purposes of Nasdaq and the SEC rules. In making that determination, our board of directors considered the relationships that each director has with us and all other facts
and circumstances the board of directors deemed relevant in determining independence, including the potential deemed beneficial ownership of our capital stock by each director, including <FONT STYLE="white-space:nowrap">non-employee</FONT> directors
that are affiliated with certain of our major stockholders. Upon the completion of this offering, we expect that the composition and functioning of our board of directors and each of our committees will comply with all applicable requirements of
Nasdaq and the rules and regulations of the SEC. There are no family relationships among any of our executive officers and directors. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We intend to adopt a policy,
subject to and effective upon the effectiveness of the registration statement of which this prospectus forms a part, that outlines a process for our securityholders to send communications to the board of directors. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Board Committees </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our board of directors will establish an audit committee, a
compensation committee and a nomination and corporate governance committee, each of which will operate pursuant to a charter to be adopted by our board of directors and will be effective upon the effectiveness of the registration statement of which
this prospectus forms a part. We believe that the composition and functioning of all of our committees will comply with the applicable requirements of Nasdaq, the Sarbanes-Oxley Act of 2002 and SEC rules and regulations that will be applicable to
us. We intend to comply with future requirements to the extent they become applicable to us. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Following the consummation of this offering, the full text of our audit
committee charter, compensation committee charter and nomination and corporate governance committee charter will be posted on the investor relations portion of our website at https://www.metagenomi.co. We do not incorporate the information contained
on, or accessible through, our corporate website into this prospectus, and you should not consider it a part of this prospectus. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Audit Committee </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon the effectiveness of the registration statement of which this prospectus forms a part, our audit committee will consist of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and will be chaired by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. The functions of the audit
committee will include: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">appointing, approving the compensation of, and assessing the independence of our independent registered public accounting
firm; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><FONT STYLE="white-space:nowrap">pre-approving</FONT> auditing and permissible
<FONT STYLE="white-space:nowrap">non-audit</FONT> services, and the terms of such services, to be provided by our independent registered public accounting firm; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reviewing the overall audit plan with our independent registered public accounting firm and members of management
responsible for preparing our financial statements; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reviewing and discussing with management and our independent registered public accounting firm our annual and quarterly
financial statements and related disclosures as well as critical accounting policies and practices used by us; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">coordinating the oversight and reviewing the adequacy of our internal control over financial reporting;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">establishing policies and procedures for the receipt and retention of accounting-related complaints and concerns;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">222 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">recommending based upon the audit committee&#146;s review and discussions with management and our independent registered
public accounting firm whether our audited financial statements shall be included in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">monitoring the integrity of our financial statements and our compliance with legal and regulatory requirements as they
relate to our financial statements and accounting matters; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">preparing the audit committee report required by SEC rules to be included in our annual proxy statement;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reviewing all related person transactions for potential conflict of interest situations and approving all such
transactions; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reviewing quarterly earnings releases. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">All members of our audit committee will meet the requirements for financial literacy under the applicable rules and regulations of the SEC and the Nasdaq listing rules.
Our board of directors has determined that &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; qualifies as an &#147;audit committee financial expert&#148; within the meaning of applicable SEC
regulations. In making this determination, our board of directors considered the nature and scope of experience that &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; has previously had with public
reporting companies, including service as &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. Our board of directors has determined that all of the directors that will become members of our audit
committee upon the effectiveness of the registration statement of which this prospectus forms a part satisfy the relevant independence requirements for service on the audit committee set forth in the rules of the SEC and the Nasdaq listing rules.
Both our independent registered public accounting firm and management will periodically meet privately with our audit committee. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Compensation Committee </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon the effectiveness of the registration statement of which this prospectus forms a part, our compensation committee will consist of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and will be chaired by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. The functions of the
compensation committee will include: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">annually reviewing and recommending to the board of directors the corporate goals and objectives relevant to the
compensation of our Chief Executive Officer; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">evaluating the performance of our Chief Executive Officer in light of such corporate goals and objectives and based on such
evaluation (i)&nbsp;reviewing and determining the cash compensation of our Chief Executive Officer and (ii)&nbsp;reviewing and approving grants and awards to our Chief Executive Officer under equity-based plans; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reviewing and approving the compensation of our other executive officers; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reviewing and establishing our overall management compensation, philosophy and policy; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">overseeing and administering our compensation and similar plans; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">evaluating and assessing potential and current compensation advisors in accordance with the independence standards
identified in the applicable Nasdaq listing rules; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reviewing and approving our policies and procedures for the grant of equity-based awards; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reviewing and recommending to the board of directors the compensation of our directors; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">preparing our compensation committee report if and when required by SEC rules; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reviewing and discussing annually with management our &#147;Compensation Discussion and Analysis,&#148; if and when
required, to be included in our annual proxy statement; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">223 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reviewing and approving the retention or termination of any consulting firm or outside advisor to assist in the evaluation
of compensation matters. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Each member of our compensation committee will be a <FONT STYLE="white-space:nowrap">non-employee</FONT> director, as
defined in Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act, and an outside director, as defined pursuant to Section&nbsp;162(m) of the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;). </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Nominating and Corporate Governance Committee </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon the effectiveness of the
registration statement of which this prospectus forms a part, our nominating and corporate governance committee will consist of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and will be chaired by
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. The functions of the nominating and corporate governance committee will include: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">developing and recommending to the board of directors criteria for board and committee membership; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">establishing procedures for identifying and evaluating board of director candidates, including nominees recommended by
stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reviewing the composition of the board of directors to ensure that it is composed of members containing the appropriate
skills and expertise to advise us; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">identifying individuals qualified to become members of the board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">recommending to the board of directors the persons to be nominated for election as directors and to each of the
board&#146;s committees; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">developing and recommending to the board of directors a code of business conduct and ethics and a set of corporate
governance guidelines; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">overseeing the evaluation of our board of directors and management. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our board of directors may from time to time establish other committees. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Compensation Committee Interlocks and Insider Participation </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">None of the
members of our compensation committee is, or has at any time during the prior three years been, one of our officers or employees. None of our executive officers currently serve, or have in the past fiscal year served, as a member of the board of
directors or compensation committee of any entity that has one or more of its executive officers serving as a member of our board of directors or our compensation committee. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Code of Business Conduct and Ethics </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our board of directors intends to adopt,
subject to and effective upon the effectiveness of the registration statement of which this prospectus forms a part, a Code of Business Conduct and Ethics in connection with this offering. The Code of Business Conduct and Ethics will apply to all of
our employees, officers (including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions), agents and representatives, including directors and consultants.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We intend to disclose future amendments to certain provisions of our Code of Business Conduct and Ethics and our Code of Ethics on our website identified below.
Upon the completion of this offering, the full text of our Code of Business Conduct and Ethics and our Code of Ethics will be posted on our website at https://www. Metagenomi.co. The inclusion of our website address in this prospectus does not
include or incorporate by reference the information on our website into this prospectus, and you should not consider that information a part of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">224 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Limitations on Liability and Indemnification Agreements </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As permitted by Delaware law, provisions in our amended and restated certificate of incorporation and amended and restated bylaws, both of which will become effective
upon the closing of this offering, limit or eliminate the personal liability of directors for a breach of their fiduciary duty of care as a director. The duty of care generally requires that, when acting on behalf of the corporation, a director
exercise an informed business judgment based on all material information reasonably available to him or her. Consequently, a director will not be personally liable to us or our stockholders for monetary damages or breach of fiduciary duty as a
director, except for liability for: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any breach of the director&#146;s duty of loyalty to us or our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any act related to unlawful stock repurchases, redemptions or other distributions or payments of dividends; or
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any transaction from which the director derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">These limitations of liability do not limit or eliminate our rights or any stockholder&#146;s rights to seek <FONT STYLE="white-space:nowrap">non-monetary</FONT> relief,
such as injunctive relief or rescission. These provisions will not alter a director&#146;s liability under other laws, such as the federal securities laws or other state or federal laws. Our amended and restated certificate of incorporation that
will become effective upon the closing of this offering also authorizes us to indemnify our officers, directors and other agents to the fullest extent permitted under Delaware law. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As permitted by Delaware law, our amended and restated bylaws to be effective upon the consummation of this offering will provide that: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we will indemnify our directors, officers, employees and other agents to the fullest extent permitted by law;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we must advance expenses to our directors and officers, and may advance expenses to our employees and other agents, in
connection with a legal proceeding to the fullest extent permitted by law; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the rights provided in our amended and restated bylaws are not exclusive. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If Delaware law is amended to authorize corporate action further eliminating or limiting the personal liability of a director or officer, then the liability of our
directors or officers will be so eliminated or limited to the fullest extent permitted by Delaware law, as so amended. Our amended and restated bylaws will also permit us to secure insurance on behalf of any officer, director, employee or other
agent for any liability arising out of his or her actions in connection with their services to us, regardless of whether our amended and restated bylaws permit such indemnification. We have obtained such insurance. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition to the indemnification that will be provided for in our amended and restated certificate of incorporation and amended and restated bylaws, we plan to enter
into separate indemnification agreements with each of our directors and executive officers, which may be broader than the specific indemnification provisions contained in the Delaware General Corporation Law. These indemnification agreements may
require us, among other things, to indemnify our directors and executive officers for some expenses, including attorneys&#146; fees, expenses, judgments, fines and settlement amounts incurred by a director or executive officer in any action or
proceeding arising out of his service as one of our directors or executive officers or any other company or enterprise to which the person provides services at our request. We believe that these provisions and agreements are necessary to attract and
retain qualified individuals to serve as directors and executive officers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">225 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This description of the indemnification provisions of our amended and restated certificate of incorporation, our
amended and restated bylaws and our indemnification agreements is qualified in its entirety by reference to these documents, each of which is attached as an exhibit to the registration statement of which this prospectus forms a part. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Insofar as indemnification for liabilities arising under the Securities Act, may be permitted to our directors, officers and controlling persons pursuant to the
foregoing provisions, or otherwise, we have been advised that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act, and is, therefore, unenforceable. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There is no pending litigation or proceeding naming any of our directors or officers as to which indemnification is being sought, nor are we aware of any pending or
threatened litigation that may result in claims for indemnification by any director or officer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">226 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc425213_14"></A>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following discussion contains forward looking statements that are based on our current plans, considerations, expectations and determinations regarding our future
compensation programs. The actual amount and form of compensation and the compensation policies and practices that we adopt in the future may differ materially from currently planned programs as summarized in this discussion. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As an emerging growth company, we have opted to comply with the executive compensation disclosure rules applicable to &#147;smaller reporting companies,&#148; as such
term is defined in the rules promulgated under the Securities Act. The compensation provided to our named executive officers for the fiscal year ended December&nbsp;31, 2022 is detailed in the 2022 Summary Compensation Table and accompanying
footnotes and narrative that follow. Our named executive officers for the fiscal year ended December&nbsp;31, 2022 are: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Brian C. Thomas, Ph.D., our Chief Executive Officer; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Jian Irish, Ph.D., MBA, our President and Chief Operating Officer; and </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Simon Harnest, MSc, our Chief Investment Officer. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To date, the compensation of our named executive officers has consisted of a combination of base salary, cash bonuses and equity awards in the form of profits interests,
as described below. Our named executive officers, like all of our full-time employees, are eligible to participate in our health and welfare benefit plans. As we transition from a private company to a publicly traded company, we intend to evaluate
our compensation values and philosophy and compensation plans and arrangements as circumstances require. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>2022 Summary Compensation Table </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table shows the total compensation earned by, or paid to, our named executive officers for services rendered to us in all capacities during the fiscal year
ended December&nbsp;31, 2022. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Name&nbsp;and&nbsp;Principal</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:arial"><B>Position</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="right"><B>Salary</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:arial" ALIGN="right"><B>($)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="right"><B>Bonus(1)</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:arial" ALIGN="right"><B>($)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="right"><B>Stock</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="right"><B>Awards(2)</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:arial" ALIGN="right"><B>($)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="right"><B><FONT STYLE="white-space:nowrap">Non-Equity</FONT><BR>Incentive Plan<BR>Compensation(3)</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:arial" ALIGN="right"><B>($)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="right"><B>All
Other<BR>Compensation(4)</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:arial" ALIGN="right"><B>($)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="right"><B>Total</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:arial" ALIGN="right"><B>($)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Brian C. Thomas, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; font-size:10pt; font-family:arial"><I>Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,223,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">318,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,156,629</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Jian Irish, Ph.D., MBA</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial"><I>President and Chief Operating Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">450,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">313,084</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">260,354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,084,428</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Simon Harnest, MSc</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial"><I>Chief Investment Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">340,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">113,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">153,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">606,561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:8pt">
<TD COLSPAN="28" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The amounts reported in this column reflect one time special bonuses paid to Mr. Thomas and Ms. Irish for performance during fiscal year ended December 31, 2022. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The amounts reported in this column represent the aggregate grant date fair value of profits interests granted to the named executive officers during 2022, as calculated in accordance with Financial Accounting Standards
Board (&#147;FASB&#148;), Accounting Standards Codification (&#147;ASC&#148;), Topic 718. Such grant date value does not take into account any estimated forfeitures related to service-based vesting conditions. The assumptions used in the grant date
fair value of the awards in this column are described in Note 13 &#150; Profits Interests Plan to our consolidated financial statements included elsewhere in this prospectus. These awards are described in more detail under &#147;Narrative Disclosure
to Summary Compensation Table &#150; Equity-Based Compensation&#148; below. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The amounts reported represent annual bonuses under our annual cash bonus program based on achievement of company performance and individual performance during the year ended December&nbsp;31, 2022. For more information
on these bonuses, see description of the annual performance bonuses under the section titled &#147;Narrative Disclosure to Summary Compensation Table &#150; Annual Cash Bonuses&#148; below. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(4)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The amounts reported reflect an employer matching contribution on the employee&#146;s behalf under our 401(k) plan. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">227 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Narrative Disclosure to Summary Compensation Table </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>2022 Base Salaries </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our named executive officers each receive a base
salary to compensate them for services rendered to our Company. The base salary payable to each named executive officer is intended to provide a fixed component of compensation reflecting the executive&#146;s skill set, experience, role and
responsibilities. Base salaries may be adjusted from time to time to realign salaries with market levels after taking into account individual responsibilities, performance and experience. Mr.&nbsp;Harnest&#146;s base salary was adjusted effective as
of March&nbsp;31, 2022 from $335,000 to $341,600. The base salaries for Dr.&nbsp;Thomas and Dr.&nbsp;Irish were not adjusted during the calendar year 2022. As of December&nbsp;31, 2022, the base salaries for Dr.&nbsp;Thomas, Dr.&nbsp;Irish and
Mr.&nbsp;Harnest were $500,000, $450,000 and $341,600, respectively. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>2022 Cash Bonuses </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For the fiscal year ended December&nbsp;31, 2022, each of the named executive officers was eligible to earn an annual cash bonus determined by our board of directors in
its sole discretion, based on achievement of certain individual and corporate performance goals, relating primarily to research and development goals, clinical milestones, business development and organizational goals. The target annual bonus for
each of our named executive officers for the fiscal year ended December&nbsp;31, 2022 was equal to the percentage of the executive&#146;s respective annual base salary specified below: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Name</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Target&nbsp;Bonus<BR>Percentage</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Brian C. Thomas</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Jian Irish</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Simon Harnest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="4" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">With respect to the fiscal year ended December&nbsp;31, 2022, our compensation committee approved a payout of cash bonuses in an amount
of 127% of target for Mr. Thomas, 129% for Ms. Irish and 128% for Mr. Harnest. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Equity-Based Compensation </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Although we do not yet have a formal policy with respect to the grant of equity incentive awards to our executive officers, we believe that equity grants provide our
executives with a strong link to our long-term performance, create an ownership culture and help to align the interests of our executives and our unitholders. We have granted our named executive officers profits interests under our 2019 Equity
Incentive Plan (the &#147;2019 Plan&#148;). These profits interests are subject to time-based vesting conditions and are intended to be treated as &#147;profits interests&#148; for U.S. federal income tax purposes. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In connection with the Reorganization, profits interests will be exchanged for shares of common stock and restricted common stock of Metagenomi, Inc. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For additional information regarding outstanding equity awards held by our named executive officers as of December&nbsp;31, 2022, see the &#147;<I>Outstanding Equity
Awards at 2022 Fiscal Year End</I>&#148; table below. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Perquisites/Personal Benefits </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Perquisites or other personal benefits are not a significant component of our executive compensation program. Accordingly, we do not provide significant perquisites or
other personal benefits to our executive officers, including our named executive officers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">228 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>401(k) Plan </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We
maintain a retirement savings plan (&#147;401(k) plan&#148;) that is intended to qualify for favorable tax treatment under Section&nbsp;401(a) of the Code, and contains a cash or deferred feature that is intended to meet the requirements of
Section&nbsp;401(k) of the Code. U.S. employees are generally eligible to participate in the 401(k) plan, subject to certain criteria. Participants may make <FONT STYLE="white-space:nowrap">pre-tax</FONT> and certain
<FONT STYLE="white-space:nowrap">after-tax</FONT> (Roth) salary deferral contributions to the plan from their eligible earnings up to the statutorily prescribed annual limit under the Code. Participants who are 50 years of age or older may
contribute additional amounts based on the statutory limits for <FONT STYLE="white-space:nowrap">catch-up</FONT> contributions. Participant contributions are held in trust as required by law. We provide employer matching contributions of 100% on the
first 5% of participant&#146;s compensation contributed to our 401(k) plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">229 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Outstanding Equity Awards at 2022 Fiscal Year End </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table lists all outstanding equity awards held by our named executive officers as of December&nbsp;31, 2022. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="16" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Stock Awards(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Name</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Grant&nbsp;Date</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Vesting<BR>Commencement<BR>Date</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Number&nbsp;of&nbsp;Shares<BR>or Units of Stock<BR>That Have Not<BR>Vested (#)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="right"><B>Market&nbsp;Value&nbsp;of<BR>Shares&nbsp;or&nbsp;Units&nbsp;of<BR>Stock That Have</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:arial" ALIGN="right"><B>Not&nbsp;Vested&nbsp;($)(2)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Equity&nbsp;Incentive<BR>Plan awards:<BR>Number of<BR>Unearned&nbsp;Shares,<BR>Units&nbsp;or&nbsp;Other<BR>Rights&nbsp;That&nbsp;Have<BR>Not&nbsp;Vested
(#)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Equity&nbsp;Incentive<BR>Plan awards:<BR>Market Value of<BR>Unearned&nbsp;Shares,<BR>Units&nbsp;or&nbsp;Other<BR>Rights&nbsp;That&nbsp;Have<BR>Not&nbsp;Vested
($)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Brian C. Thomas, Ph.D.(3)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">11/2/21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">11/1/21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">92,223</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial"><I>Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/26/22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/21/22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">649,139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Jian Irish, Ph.D., MBA(4)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/26/21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/5/21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial"><I>President and Chief </I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/2/21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/1/21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">322,776</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial"><I>Operating Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/26/22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/21/22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Simon Harnest, MSc</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8/30/21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/6/21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial"><I>Chief Investment Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/26/22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/21/22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="24" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">All awards in this table consist of profits interests granted under the 2019 Plan that are intended to qualify as &#147;profits interests&#148; for U.S. tax purposes. They do not require the payment of an exercise price
and will only obtain value as value of the underlying security rises above its grant date value, which is referred to as the &#147;Threshold Amount.&#148; The profits interests vest as follows: 25% vest on the one year anniversary of the vesting
commencement date; and then the remaining 75% of the total profits interests vest in substantially equal amounts on each monthly anniversary of the vesting commencement date thereafter, until fully vested on the fourth anniversary of the vesting
commencement date, based upon the participant&#146;s continued service on each applicable vesting date. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents the fair market value of profits interests that were unvested as of December&nbsp;31, 2022. The fair market value assumes an initial public offering prior of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the estimated midpoint of the price range set forth on the cover page of this prospectus. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Awards held by Dr.&nbsp;Thomas are subject to certain acceleration provisions, as summarized below under &#147;Employment Arrangements in Place Prior to the Offering for Named Executive Officers.&#148;
</TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(4)</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Awards held by Dr.&nbsp;Irish are subject to certain acceleration provisions, as summarized below under &#147;Employment Arrangements in Place Prior to the Offering for Named Executive Officers.&#148; </TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">230 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Executive Compensation Arrangements </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have entered into offer letters and/or employment agreements with each of our named executive officers. Each offer letter or employment agreement provides for <FONT
STYLE="white-space:nowrap">&#147;at-will&#148;</FONT> employment and the compensation and benefits described below. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Employment Arrangements in Place Prior to
The Offering for Named Executive Officers </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Brian C. Thomas </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On
March&nbsp;20, 2023, the Company executed an executive employment agreement with Dr.&nbsp;Thomas (the &#147;Thomas Employment Agreement&#148;), for the position of Chief Executive Officer. The Thomas Employment Agreement provides for
Dr.&nbsp;Thomas&#146;s <FONT STYLE="white-space:nowrap">at-will</FONT> employment. Dr.&nbsp;Thomas&#146;s current base salary is $520,000 and he is eligible to receive an annual bonus with an annual target amount of 50% of his annual base salary.
Dr.&nbsp;Thomas is eligible to participate in the employee benefit plans available to our employees, subject to the terms of such plans. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon termination of
Dr.&nbsp;Thomas&#146;s employment by us without Cause or his resignation for Good Reason outside of the Change in Control Period, as such terms are defined in the Thomas Employment Agreement, subject to (i)&nbsp;Dr.&nbsp;Thomas resigning from all
positions, (ii)&nbsp;signing a general release of claims in favor of the Company and (iii)&nbsp;not breaching any of the post-employment covenants and contractual obligations to the Company, Dr.&nbsp;Thomas shall be entitled to (A)&nbsp;a lump sum
payment equal to nine (9)&nbsp;months of his then current base salary and <FONT STYLE="white-space:nowrap">pro-rated</FONT> target bonus, based on the number of days he was employed in such year, divided by 365, payable within sixty (60)&nbsp;days
following his termination, and (B)&nbsp;if Dr.&nbsp;Thomas was participating in the Company&#146;s group health plan immediately prior to the termination date, a monthly cash payment for nine (9)&nbsp;months in an amount equal to
Dr.&nbsp;Thomas&#146;s and his eligible dependents monthly COBRA premium. In addition, and subject to the same conditions, upon a termination by us without Cause or his resignation for Good Reason during the Change in Control Period, he shall be
entitled to (A)&nbsp;a lump sum payment equal to twelve (12)&nbsp;months of his then current base salary and <FONT STYLE="white-space:nowrap">pro-rated</FONT> target bonus, based on the number of days he was employed in such year, divided by 365,
payable within sixty (60)&nbsp;days following his termination, (B)&nbsp;if Dr.&nbsp;Thomas was participating in the Company&#146;s group health plan immediately prior to the termination date, a monthly cash payment for twelve (12)&nbsp;months in an
amount equal to Dr.&nbsp;Thomas&#146;s and his eligible dependents monthly COBRA premium, and (C)&nbsp;full acceleration of his then outstanding and unvested equity awards. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Jian Irish </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On January&nbsp;19, 2021, the Company executed an offer letter
with Dr.&nbsp;Irish (the &#147;Irish Offer Letter&#148;), for the position of Chief Operations Officer. The Irish Offer Letter provides for Dr.&nbsp;Irish&#146;s <FONT STYLE="white-space:nowrap">at-will</FONT> employment. Dr.&nbsp;Irish was promoted
to President and Chief Operating Officer effective November&nbsp;1, 2021. Dr.&nbsp;Irish&#146;s current base salary is $468,000 and she is eligible to receive an annual bonus with an annual target amount of 45% of her annual salary. Dr.&nbsp;Irish
is eligible to participate in the employee benefit plans available to our employees, subject to the terms of such plans. The Irish Offer Letter provides for Dr.&nbsp;Irish&#146;s eligibility to receive a grant of profits interests under the 2019
Plan, which will be subject to full acceleration upon the occurrence of a Change of Control (as defined in the Irish Offer Letter). </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon a termination of
Dr.&nbsp;Irish&#146;s agreement by us without Cause, or her resignation for Good Reason, as such terms are defined in the Irish Offer Letter, she will be eligible to receive six (6)&nbsp;months of base salary,
<FONT STYLE="white-space:nowrap">pro-rated</FONT> annual bonus, and six (6)&nbsp;months vesting acceleration. </P> <P STYLE="font-size:8pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">231 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Dr.&nbsp;Irish entered into an Employee Invention Assignment and Confidentiality Agreement that contains various
restrictive covenants, including <FONT STYLE="white-space:nowrap">non-solicitation</FONT> provisions that apply during her employment and for a period of twelve months thereafter. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Simon Harnest </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On June&nbsp;10, 2021, the Company executed an offer letter
with Mr.&nbsp;Harnest (the &#147;Harnest Offer Letter&#148;), for the position of Chief Investment Officer and Senior Vice President of Strategy. The Harnest Offer Letter provides for Mr.&nbsp;Harnest&#146;s
<FONT STYLE="white-space:nowrap">at-will</FONT> employment. Mr.&nbsp;Harnest&#146;s current base salary is $365,512 and he is eligible to receive an annual bonus with an annual target amount of 35% of his base salary. Mr.&nbsp;Harnest is eligible to
participate in the employee benefit plans available to our employees, subject to the terms of such plans. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Mr.&nbsp;Harnest entered into an Employee Invention
Assignment and Confidentiality Agreement that contains various restrictive covenants, including <FONT STYLE="white-space:nowrap">non-solicitation</FONT> provisions that apply during his employment and for a period of twelve months thereafter. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Employee Benefit and Equity Compensation Plans </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>2019 Equity Incentive
Plan </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The 2019 Plan was initially approved by the board of managers of the Company in March 2019. The 2019 Plan provided for the grant of profits interests,
restricted common units, options to purchase common units and restricted equity units to selected employees, officers, directors and consultants of the Company. The total number of common units available for grant and issuance under the 2019 Plan is
14,604,165 common units. Common units that are (i)&nbsp;cancelled, forfeited, settled in cash, used to pay withholding obligations or that expire by their terms at any time and (ii)&nbsp;that are reacquired by the Company pursuant to a right of
first refusal or repurchase by the Company, will again become available for issuance under the 2019 Plan. Our board of managers administers the 2019 Plan and has the authority to take any action necessary or advisable for the administration of the
2019 Plan. Our board has the right and discretion to grant awards under the 2019 Plan to participants. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Common units designated as profits interests by the board of
managers are intended to meet the definition of a &#147;profits interests&#148; set forth in IRS Revenue Procedures <FONT STYLE="white-space:nowrap">93-27</FONT> and <FONT STYLE="white-space:nowrap">2001-43.</FONT> Accordingly, such profits
interests do not give the holder a share of the proceeds if the Company&#146;s assets were sold at fair market value and the proceeds of such disposition were distributed in a complete liquidation of the Company immediately after the date of grant,
but give the holder a right to share in the appreciation in the value of a common unit from the date of receipt to the future, as determined by the applicable provisions of the Company&#146;s operating agreement in effect immediately prior to the
Reorganization. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon a liquidation event, as defined in the 2019 Plan, the board of managers may in its sole discretion, cancel all outstanding and unexercised
awards, including profits interests and other unvested awards, in each case, without consideration, as of the date of such liquidation event. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The 2019 Plan will
terminate automatically ten (10)&nbsp;years after the later of (i)&nbsp;the date when the board adopted the 2019 Plan and (ii)&nbsp;the date when the board approved the most recent increase in the number of common units reserved under the 2019 Plan,
which was also subsequently approved by the members of the company. The board of managers may amend, suspend or terminate the 2019 Plan at any time and for any reason; provided, that any amendment that would materially adversely impact an award
shall only be effective with respect to such award if the holder thereof so consents prior to the date of the amendment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">232 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023,&nbsp;&nbsp;&nbsp;&nbsp;profits
interests have been issued under the 2019 Plan. See &#147;Reorganization.&#148; </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>2023 Stock Option and Incentive Plan </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our 2023 Plan was adopted by our board of directors on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023, approved by our stockholders
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;2023 and will become effective upon the date immediately preceding the date on which the registration statement of which this prospectus is part is declared effective
by the SEC. The 2023 Plan will replace the 2019 Plan as our board of directors has determined not to make additional awards under the 2019 Plan following the closing of our initial public offering. The 2023 Plan allows us to make equity-based and
cash-based incentive awards to our officers, employees, directors and consultants. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have initially
reserved&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock for the issuance of awards under the 2023 Plan (the &#147;Initial Limit&#148;). The 2023 Plan provides that the number
of shares reserved and available for issuance under the 2023 Plan will automatically increase on January&nbsp;1, 2024 and each January&nbsp;1 thereafter,
by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; percent of the outstanding number of shares of our common stock on the immediately preceding December&nbsp;31 or such lesser number of shares as
determined by our compensation committee (the &#147;Annual Increase&#148;). The number of shares reserved under the 2023 Plan is subject to adjustment in the event of a stock split, stock dividend or other change in our capitalization. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares we issue under the 2023 Plan will be authorized but unissued shares or shares that we reacquire. The shares of common stock underlying any awards under the
2023 Plan and the 2019 Plan that are forfeited, cancelled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, reacquired by us prior to vesting, satisfied without the issuance of stock, expire or are
otherwise terminated (other than by exercise) will be added back to the shares of common stock available for issuance under the 2023 Plan. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The maximum number of
shares of common stock that may be issued in the form of incentive stock options shall not exceed the Initial Limit, cumulatively increased on January&nbsp;1, 2024 and on each January&nbsp;1 thereafter by the lesser of the Annual Increase for such
year or&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The grant date fair value of all
awards made under our 2023 Plan and all other cash compensation paid by us to any <FONT STYLE="white-space:nowrap">non-employee</FONT> director in any calendar year for services as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director
shall not exceed $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;; provided, however, that such amount shall be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for the calendar year in which the applicable
<FONT STYLE="white-space:nowrap">non-employee</FONT> director is initially elected or appointed to the board of directors. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The 2023 Plan will be administered by our
compensation committee. Our compensation committee has the full power to select, from among the individuals eligible for awards, the individuals to whom awards will be granted and the number of shares subject to such awards, to make any combination
of awards to participants, to accelerate at any time the exercisability or vesting of any award and to determine the specific terms and conditions of each award, subject to the provisions of the 2023 Plan. Persons eligible to participate in the 2023
Plan will be those full or part-time officers, employees, <FONT STYLE="white-space:nowrap">non-employee</FONT> directors and consultants as selected from time to time by our compensation committee in its discretion. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The 2023 Plan permits the granting of both options to purchase common stock intended to qualify as incentive stock options under Section&nbsp;422 of the Code and options
that do not so qualify. The option exercise price of each option will be determined by our compensation committee but generally may not be less than 100&nbsp;percent of the fair market value of our common stock on the date of grant unless the option
(i)&nbsp;is granted pursuant to a transaction described in, and in a manner consistent with Section&nbsp;424(a) of the Code, (ii)&nbsp;is granted to an individual who is not subject to U.S. income tax or (iii)&nbsp;complies with Section&nbsp;409A of
the Code. The term of each </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">233 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
option will be fixed by our compensation committee and may not exceed 10 years from the date of grant. Our compensation committee will determine at what time or times each option may be
exercised. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our compensation committee may award stock appreciation rights under the 2023 Plan subject to such conditions and restrictions as it may determine. Stock
appreciation rights entitle the recipient to shares of common stock, or cash, equal to the value of the appreciation in our stock price over the exercise price. The exercise price of each stock appreciation right will be determined by our
compensation committee but generally may not be less than 100&nbsp;percent of the fair market value of our common stock on the date of grant unless the stock appreciation right (i)&nbsp;is granted pursuant to a transaction described in, and in a
manner consistent with Section&nbsp;424(a) of the Code, (ii)&nbsp;is granted to an individual who is not subject to U.S. income tax or (iii)&nbsp;complies with Section&nbsp;409A of the Code. The term of each stock appreciation right will be fixed by
our compensation committee and may not exceed 10 years from the date of grant. Our compensation committee will determine at what time or times each stock appreciation right may be exercised. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our compensation committee may award restricted shares of common stock and restricted stock units to participants subject to such conditions and restrictions as it may
determine. These conditions and restrictions may include the achievement of certain performance goals and/or continued employment with us through a specified vesting period. Our compensation committee may also grant shares of common stock that are
free from any restrictions under the 2023 Plan. Unrestricted stock may be granted to participants in recognition of past services or for other valid consideration and may be issued in lieu of cash compensation due to such participant. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our compensation committee may grant dividend equivalent rights to participants that entitle the recipient to receive credits for dividends that would be paid if the
recipient had held a specified number of shares of common stock. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our compensation committee may grant cash bonuses under the 2023 Plan to participants, subject to
the achievement of certain performance goals. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The 2023 Plan provides that upon the effectiveness of a &#147;sale event,&#148; as defined in the 2023 Plan, an
acquirer or successor entity may assume, continue or substitute outstanding awards under the 2023 Plan. To the extent that awards granted under the 2023 Plan are not assumed or continued or substituted by the successor entity, upon the effective
time of the sale event, such awards shall terminate. In the event of such termination, (i)&nbsp;individuals holding options and stock appreciation rights will be permitted to exercise such options and stock appreciation rights (to the extent
exercisable) within a specified period of time prior to the sale event or (ii)&nbsp;we may make or provide for a payment, in cash or in kind, to participants holding vested and exercisable options and stock appreciation rights equal&nbsp;(A) the
difference between the per share cash consideration payable to stockholders in the sale event and the per share exercise price of the options or stock appreciation rights, multiplied by (B)&nbsp;the number of shares subject to such outstanding
vested and exercisable options and stock appreciation rights (to the extent exercisable at prices not in excess of the per share cash consideration), and we may make or provide for a payment, in cash or in kind, to participants holding other vested
awards equal to the per share cash consideration multiplied by the number of vested shares underlying such awards. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our board of directors may amend or discontinue
the 2023 Plan and our compensation committee may amend or cancel outstanding awards for purposes of satisfying changes in law or any other lawful purpose, but no such action may adversely affect rights under an award without the holder&#146;s
consent. Certain amendments to the 2023 Plan require the approval of our stockholders. The administrator of the 2023 Plan is specifically authorized to exercise its discretion to reduce the exercise price of outstanding stock options and stock
appreciation rights or effect the repricing of such awards through cancellation and <FONT STYLE="white-space:nowrap">re-grants</FONT> without stockholder consent. No awards may be granted under the 2023 Plan after the date that is 10 years from the
effective date of the 2023 Plan. No awards under the 2023 Plan have been made prior to the date of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">234 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>2023 Employee Stock Purchase Plan </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our ESPP was adopted by our board of directors on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023, approved by our stockholders
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023 and will become effective on the date immediately preceding the date on which the registration statement of which this prospectus forms a part
is declared effective by the SEC. The ESPP is intended to qualify as an &#147;employee stock purchase plan&#148; within the meaning of Section&nbsp;423 of the Code. The ESPP initially reserves and authorizes the issuance of up to a total
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock to participating employees. The ESPP provides that the number of shares reserved and available for issuance will
automatically increase on January&nbsp;1, 2024 and each January&nbsp;1 thereafter through January&nbsp;1, 2033, by the least of (i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common
stock, (ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;percent of the outstanding number of shares of common stock on the immediately preceding December&nbsp;31, or (iii)&nbsp;such lesser number of
shares of common stock as determined by the administrator of the ESPP. The number of shares reserved under the ESPP is subject to adjustment in the event of a stock split, stock dividend or other change in our capitalization. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">All employees who are customarily employed by us or one of our designated subsidiaries for more
than&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;hours per week and who we have employed for at
least&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;days are eligible to participate in the ESPP. However, any employee who owns&nbsp;5&nbsp;percent or more of the total combined voting power or value
of all classes of our stock will not be eligible to purchase shares of common stock under the ESPP. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may make one or more offerings each year to our employees to
purchase shares under the ESPP. Offerings will usually begin on
each&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and will continue for <FONT
STYLE="white-space:nowrap">six-month</FONT> periods, referred to as offering periods. Each eligible employee may elect to participate in any offering by submitting an enrollment form at least&nbsp;15&nbsp;business days before the applicable offering
date </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Each employee who is a participant in the ESPP may purchase shares of our common stock by authorizing payroll deductions of up to 15&nbsp;percent of his or her
eligible compensation during an offering period. Unless the participating employee has previously withdrawn from the offering, his or her accumulated payroll deductions will be used to purchase shares of our common stock on the last business day of
the offering period at a price equal to&nbsp;85&nbsp;percent of the fair market value of the shares of our common stock on the first business day or the last business day of the offering period, whichever is lower, provided that no more than a
number of shares of common stock determined by dividing $25,000 by the fair market value of our common stock on the offering date of the offering (or a lesser number as established by the plan administrator in advance of the offering period) may be
purchased by any one employee during each offering period. Under applicable tax rules, an employee may purchase no more than $25,000 worth of shares of our common stock, valued at the start of the purchase period, under the ESPP in any calendar
year. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The accumulated payroll deductions of any employee who is not a participant on the last day of an offering period will be refunded. An employee&#146;s rights
under the ESPP terminate upon voluntary withdrawal from the plan or when the employee ceases employment with us for any reason. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The ESPP may be terminated or
amended by our board of directors at any time. An amendment that increases the number of shares of our common stock authorized under the ESPP and certain other amendments require the approval of our stockholders. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Senior Executive Cash Incentive Bonus Plan </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023 our board of directors adopted the Senior Executive Cash Incentive Bonus Plan (the
&#147;Bonus Plan&#148;). The Bonus Plan provides for annual cash bonus payments based upon the attainment of Company and individual performance targets established by our compensation committee. The payment targets will be related to financial and
operational measures or objectives with respect to our Company (the &#147;Corporate Performance Goals&#148;), as well as individual performance objectives. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">235 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our compensation committee may select Corporate Performance Goals from among the following: cash flow (including, but
not limited to, operating cash flow and free cash flow); revenue; corporate revenue; earnings before interest, taxes, depreciation, and amortization; net income (loss) (either before or after interest, taxes, depreciation, and/or amortization);
changes in the market price of our common stock; economic value-added; acquisitions or strategic transactions, including collaborations, joint ventures, or promotion arrangements; operating income (loss); return on capital assets, equity, or
investment; stockholder returns; sales; net sales; return on sales; gross or net profit levels; productivity; expense efficiency; margins; operating efficiency; customer satisfaction; working capital; earnings (loss) per share of our common stock;
bookings, new bookings, or renewals; sales or market shares; number of customers, number of new customers, or customer references; operating income and/or net annual recurring revenue; or any other performance goal as selected by the compensation
committee, any of which may be measured in absolute terms, as compared to any incremental increase, in terms of growth, as compared to results of a peer group, against the market as a whole, compared to applicable market indices, and/or measured on
a <FONT STYLE="white-space:nowrap">pre-tax</FONT> or <FONT STYLE="white-space:nowrap">post-tax</FONT> basis. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Each executive officer who is selected to participate
in the Bonus Plan will have a target bonus opportunity set for each performance period. The bonus formulas will be adopted in each performance period by the compensation committee and communicated to each executive. The Corporate Performance Goals
will be measured at the end of each performance period after our financial reports have been published or such other appropriate time as the compensation committee determines. If the Corporate Performance Goals and individual performance objectives
are met, payments will be made as soon as practicable following the end of each performance period, but no later than 74 days after the end of the fiscal year in which such performance period ends. Subject to the rights contained in any agreement
between the executive officer and us, an executive officer must be employed by us on the bonus payment date to be eligible to receive a bonus payment. The Bonus Plan also permits the compensation committee to approve additional bonuses to executive
officers in its sole discretion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">236 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc425213_15"></A>DIRECTOR COMPENSATION </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>2022 Director Compensation Table </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table presents the total
compensation paid by the Company to <FONT STYLE="white-space:nowrap">non-employee</FONT> members of our board of managers during the fiscal year ended December&nbsp;31, 2022. Other than as set forth in the table and described more fully below, we
did not pay any compensation, make any equity awards or <FONT STYLE="white-space:nowrap">non-equity</FONT> awards to, or pay any other compensation to any of the members of our board of managers in 2022 for their services as members of the board of
managers. Dr.&nbsp;Thomas, our Chief Executive Officer, does not receive any compensation from the Company for his service on our board of managers. See the section titled &#147;Executive Compensation&#148; for more information on the compensation
paid to or earned by Dr.&nbsp;Thomas as an employee for year ended December&nbsp;31, 2022. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Name</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Fees&nbsp;Earned<BR>or Paid in<BR>Cash ($)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Total&nbsp;($)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Sebasti&aacute;n Bernales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Willard H. Dere(1)(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Juergen Eckhardt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Santosh Palani</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Risa Stack(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="8" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Dere and Dr.&nbsp;Stack each held 94,856 profits interests granted under the 2019 Plan as of December&nbsp;31, 2022. None of our other <FONT STYLE="white-space:nowrap">non-employee</FONT> directors held any
equity awards as of December&nbsp;31, 2022. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We entered into an Independent Manager Offer Letter with Dr.&nbsp;Dere, pursuant to which he is eligible to receive cash compensation of $30,000 for each calendar year for his services to our board of managers.
</TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Policy </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In connection with this offering, we intend to adopt a new <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation policy that will become effective
as of the completion of this offering and will be designed to enable us to attract and retain, on a long term basis, highly qualified <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Under the policy, <FONT STYLE="white-space:nowrap">our&nbsp;non-employee&nbsp;directors</FONT> will be eligible to receive cash retainers (which will be payable
quarterly in arrears and prorated for partial years of service) and equity awards as set forth below: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Annual Retainer for Board Membership</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">for general availability and participation in meetings and conference calls of our Board of
Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Additional Annual Retainer for Committee Membership</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Audit Committee Chairperson: </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Audit Committee member (other than Chairperson): </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Compensation Committee Chairperson: </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Compensation Committee member (other than Chairperson): </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Nominating and Corporate Governance Committee Chairperson: </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Nominating and Corporate Governance Committee member (other than Chairperson): </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Science&nbsp;&amp; Technology Committee Chairperson: </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Science&nbsp;&amp; Technology Committee member (other than Chairperson): </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Additional Retainer
for</B><B></B><B><FONT STYLE="white-space:nowrap">&nbsp;Non-Executive</FONT></B><B></B><B>&nbsp;Chairperson of the Board</B>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, our policy will provide that, upon initial election or appointment to our board of directors, each <FONT
STYLE="white-space:nowrap">new&nbsp;non-employee&nbsp;director</FONT> will be granted <FONT STYLE="white-space:nowrap">a&nbsp;one-time&nbsp;grant</FONT> of <FONT STYLE="white-space:nowrap">a&nbsp;non-statutory&nbsp;stock</FONT> option to purchase
shares </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">237 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
of our common stock equivalent to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in value on the date of such director&#146;s election or appointment to the board of directors (the
&#147;Director Initial Grant&#148;). The Director Initial Grant will vest&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, subject to the <FONT STYLE="white-space:nowrap">non-employee</FONT>
director&#146;s continued services to the us. On the date of each annual meeting of stockholders of our company following the completion of this offering, each non-employee director who will continue as a
<FONT STYLE="white-space:nowrap">non-employee</FONT> director following such meeting will be granted an annual award of a <FONT STYLE="white-space:nowrap">non-statutory</FONT> stock option to purchase shares of common stock equivalent to
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in value (the &#147;Director Annual Grant&#148;). The Director Annual Grant will vest in full on the earlier of the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the grant date or
on the date of our next annual meeting of stockholders, subject to the <FONT STYLE="white-space:nowrap">non-employee</FONT> director&#146;s continued services to us. Such awards are subject to full acceleration vesting upon the sale of our company.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The aggregate amount of compensation, including both equity compensation and cash compensation, paid to
<FONT STYLE="white-space:nowrap">any&nbsp;non-employee&nbsp;director</FONT> for service as <FONT STYLE="white-space:nowrap">a&nbsp;non-employee&nbsp;director</FONT> in a calendar year period will not exceed
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in the first calendar year such individual becomes <FONT STYLE="white-space:nowrap">a&nbsp;non-employee&nbsp;director</FONT> and
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in any other calendar year. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We will reimburse all <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">reasonable&nbsp;out-of-pocket&nbsp;expenses</FONT></FONT> incurred by directors for their attendance at meetings of our board of directors or any committee thereof. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Employee directors will receive no additional compensation for their service as a director. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">238 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc425213_16"></A>CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following is a description of transactions or series of transactions since January&nbsp;1, 2020, to which we were or will be a party, in which: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the amount involved in the transaction exceeds, or will exceed, $120,000; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">in which any of our executive officers, directors or holder of five percent or more of any class of our capital stock,
including their immediate family members or affiliated entities, had or will have a direct or indirect material interest. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Compensation
arrangements for our named executive officers and our directors are described elsewhere in this prospectus under &#147;Executive Compensation&#148; and &#147;Director Compensation.&#148; </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Series&nbsp;A-4 and Series&nbsp;A-5 Preferred Unit Financings </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">From 2020 to
2021, we sold an aggregate of 9,861,297 Series A-4 and Series A-5 preferred units in multiple closings, consisting of (i) 8,280,360 Series <FONT STYLE="white-space:nowrap">A-4</FONT> preferred units sold at a purchase price of $4.84875 per unit for
an aggregate amount of $40.1&nbsp;million and (ii) 1,580,937 Series <FONT STYLE="white-space:nowrap">A-5</FONT> preferred units sold at a purchase price of $6.32536 per unit for an aggregate amount of $10.0&nbsp;million, for total aggregate proceeds
of $50.1&nbsp;million. The following table summarizes purchases of our Series A-4 and Series A-5 preferred units as described above by related persons: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Stockholder</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Numbers&nbsp;of&nbsp;Series&nbsp;A-4/Series&nbsp;A-5</FONT></FONT></B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>preferred units</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Total purchase<BR>price</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Bayer HealthCare LLC(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,062,387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,999,998.97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Humboldt Fund I, LP(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,062,387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,999,998.97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Entities affiliated with RA Capital(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,580,937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,999,995.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Sake Holdings LLC(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">929,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,504,813.62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Entities affiliated with Sozo Ventures(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">710,907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,447,010.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="8" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Juergen Eckhardt, a manager on our board of managers, is an affiliate of Bayer Consumer Care AG, which is an affiliate of Bayer HealthCare LLC. Bayer HealthCare LLC holds more than 5 percent of our voting securities.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Sebasti&aacute;n Bernales, a manager on our board of managers, is an affiliate of Humboldt Fund. Humboldt Fund I, LP is an affiliated fund of Humboldt Fund. Humboldt Fund I, LP holds more than 5 percent of our voting
securities. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents 1,343,796 Series A-5 preferred units purchased by RA Capital Healthcare Fund, L.P. and 237,141 Series A-5 preferred units purchased by RA Capital Nexus Fund II, L.P. Entities affiliated with RA Capital
collectively hold more than 5 percent of our voting securities. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(4)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Sebasti&aacute;n Bernales, a manager on our board of managers, is an affiliate of Sake Holdings LLC. Sake Holdings LLC holds more than 5 percent of our voting securities. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(5)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents 319,908 Series A-4 preferred units purchased by Sozo Ventures &#150; Truebridge Fund II, L.P. and 390,999 Series A-4 preferred units purchased by Sozo Ventures II-S, L.P. Entities affiliated with Sozo
Ventures collectively hold more than 5 percent of our voting securities. </TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Series B Preferred Unit Financing </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In 2022 and 2023, we sold an aggregate of 22,162,743 Series B and Series B-1 preferred units in multiple closings, consisting of (i) 15,054,263 Series&nbsp;B preferred
units, which includes (a) 12,446,876 Series B preferred units sold at a purchase price of $11.64951 per unit and (b) 2,607,387 Series B preferred units which converted pursuant to a promissory note with a principal amount of $30.0&nbsp;million and
accrued interest of $0.4 million </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">239 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
between the Company and ModernaTx, Inc., for an aggregate amount of $175.4&nbsp;million and (ii) 7,108,480 Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred units sold at a purchase
price of $14.06770 per unit for an aggregate amount of $100.0&nbsp;million, for total aggregate proceeds of $275.4&nbsp;million. The following table summarizes purchases of our Series B and Series B-1 preferred units by related persons: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Stockholder</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B><FONT STYLE="white-space:nowrap">Numbers&nbsp;of&nbsp;Series&nbsp;B/Series&nbsp;B-1</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>preferred&nbsp;units</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Total purchase<BR>price</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">ModernaTX, Inc.(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,982,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35,655,978.39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Bayer HealthCare LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,920,757</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,529,689.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Humboldt Fund I, LP(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,250,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,825,929.39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Entities affiliated with RA Capital(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000,575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,000,002.54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Entities affiliated with Sozo Ventures(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">816,063</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,442,237.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="8" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents 2,607,387 Series B preferred units and 375,413 Series B-1 preferred units. ModernaTX, Inc. holds more than 5 percent of our voting securities. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents 1,030,086 Series B preferred units and 890,671 Series B-1 preferred units. Juergen Eckhardt, a manager on our board of managers, is an affiliate of Bayer Consumer Care AG, which is an affiliate of Bayer
HealthCare LLC. Bayer HealthCare LLC holds more than 5 percent of our voting securities. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents 1,143,905 Series B preferred units and 106,627 Series B-1 preferred units. Sebasti&aacute;n Bernales, a manager on our board of managers, is an affiliate of Humboldt Fund. Humboldt Fund I, LP is an affiliated
fund of Humboldt Fund. Humboldt Fund I, LP holds more than 5 percent of our voting securities. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(4)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents 600,883 Series B preferred units and 99,519 Series B-1 preferred unit purchased by RA Capital Healthcare Fund, L.P., and 257,522 Series B preferred units and 42,651 Series B-1 preferred units purchased by RA
Capital Nexus Fund II, L.P. Entities affiliated with RA Capital collectively hold more than 5 percent of our voting securities. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(5)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents 429,202 Series B preferred units and 386,861 Series B-1 preferred units purchased by Sozo Ventures lll, L.P. Entities affiliated with Sozo Ventures collectively hold more than 5 percent of our voting
securities. </TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Agreements with Unitholders </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In connection with
our Series&nbsp;A-1, Series&nbsp;A-2, Series&nbsp;A-3, Series&nbsp;A-4, and Series&nbsp;A-5 preferred unit financings and our Series&nbsp;B preferred unit financing, we entered into investors&#146; rights, voting and right of first refusal and <FONT
STYLE="white-space:nowrap">co-sale</FONT> agreements containing registration rights, information rights, voting rights and rights of first refusal, among other things, with certain holders of our preferred units and certain holders of our common
units. These unitholder agreements will terminate upon the closing of this offering, except for the registration rights granted under our investors&#146; rights agreement, as more fully described in &#147;Description of Capital
Stock&#151;Registration Rights.&#148; </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In connection with our Series <FONT STYLE="white-space:nowrap">A-4</FONT> preferred unit financing, we entered into a side
letter agreement (the &#147;Humboldt Side Letter&#148;), with Humboldt Fund I, LP (&#147;Humboldt&#148;). Pursuant to the Humboldt Side Letter, we represented and warranted to Humboldt regarding certain U.S. tax status and CFIUS matters. We agreed
that Humboldt would not be deemed a competitor for any purpose under the financing agreements. We further agreed to use commercially reasonable efforts to comply with all record-keeping, reporting and other reasonable request necessary to comply
with any applicable U.S. tax law or to allow Humboldt and its Partners to comply with the applicable provisions of U.S. tax law with respect to the direct or indirect ownership of the Company. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In connection with our Series <FONT STYLE="white-space:nowrap">A-5</FONT> preferred unit financing, we entered into a side letter agreement (the &#147;RA Capital Side
Letter&#148;), with RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund II, L.P. (collectively, &#147;RA Capital&#148;). Pursuant to the RA Capital Side Letter, RA Capital is entitled to purchase a portion of the preferred units in the event
that the Company sells preferred units in a single transaction or series of related transactions </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">240 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">following the date of the RA Capital Side Letter, primarily for capital raising purposes, with gross proceeds to the
Company in excess of $10,000,000. In addition, the Series <FONT STYLE="white-space:nowrap">A-5</FONT> preferred units held by RA Capital shall not be automatically converted into common units without the prior written approval of RA Capital, but
shall remain subject to conversion immediately upon the closing of this offering. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We entered into a research and development master service agreement (the
&#147;Bayer R&amp;D Agreement&#148;), with Bayer Healthcare LLC (&#147;Bayer&#148;), in November 2019. Bayer was performing research and development services under the Bayer R&amp;D Agreement in accordance with the statement of works agreed by the
parties. Services under the Bayer R&amp;D Agreement were completed as of December&nbsp;31, 2020, and we accrued $0.2&nbsp;million in accrued expenses and other current liabilities as of December&nbsp;31, 2020. We paid $0.2&nbsp;million to Bayer in
February and March 2021 in connection with the Bayer R&amp;D Agreement. </P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Convertible
Promissory Note with <FONT STYLE="white-space:nowrap">Affini-T</FONT> </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In December 2020, we entered into a convertible promissory note agreement and a side
letter with <FONT STYLE="white-space:nowrap">Affini-T</FONT> Therapeutics, Inc. <FONT STYLE="white-space:nowrap">(&#147;Affini-T&#148;),</FONT> a private biotechnology company. We paid cash of $1.5&nbsp;million as a principal amount of the
promissory note with 6% annual interest and maturity in December 2021. The promissory note was convertible in <FONT STYLE="white-space:nowrap">Affini-T&#146;s</FONT> next qualifying round of financing at a conversion price equal to the lesser of
(i)&nbsp;85% of the price per share paid by other investors (or 80% if the qualified financing occurs after June&nbsp;24, 2021) or (ii)&nbsp;the price per share obtained by dividing $30.0&nbsp;million by the number of shares of common stock of <FONT
STYLE="white-space:nowrap">Affini-T</FONT> outstanding immediately prior to the qualified financing. In accordance with the side letter, we were engaged to perform the certain services for <FONT STYLE="white-space:nowrap">Affini-T.</FONT> As a
consideration for services, we received 1,867,300 shares of <FONT STYLE="white-space:nowrap">Affini-T</FONT> common stock, of which 10% of such shares were vested at the issuance date and 90% of such shares were subject to forfeiture if no genome
editing licensing agreement was finalized between us and <FONT STYLE="white-space:nowrap">Affini-T</FONT> by October&nbsp;31, 2021. Effective November&nbsp;1, 2021, 1,653,570 common stock shares issued to us were forfeited and cancelled as the
license agreement was not signed between the parties. When we entered into the convertible promissory note, our chief business officer at the time also served as chief executive officer of <FONT STYLE="white-space:nowrap">Affini-T.</FONT> Our chief
business officer departed the company in November 2021 and <FONT STYLE="white-space:nowrap">Affini-T</FONT> was no longer a related party of the company as of December&nbsp;31, 2021. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In March 2022, <FONT STYLE="white-space:nowrap">Affini-T</FONT> closed a qualified round of financing, and the convertible promissory note and accrued interest were
converted into 527,035 shares of Series A convertible preferred stock of <FONT STYLE="white-space:nowrap">Affini-T.</FONT> </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Equity Grants to Executive Officers
</B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have historically granted profits interests to our named executive officers as more fully described in the section entitled &#147;Executive
Compensation&#148;. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Indemnification Agreements </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In connection with this
offering, we intend to enter into new agreements to indemnify our directors and executive officers. These agreements will, among other things, require us to indemnify these individuals for certain expenses (including attorneys&#146; fees),
judgments, fines and settlement amounts reasonably incurred by such person in any action or proceeding, including any action by or in our right, on account of any services undertaken by such person on behalf of our company or that person&#146;s
status as a member of our board of directors to the maximum extent allowed under Delaware law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">241 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Policies for Approval of Related Party Transactions </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our board of directors reviews and approves transactions with directors, officers, and holders of five percent or more of our voting securities and their affiliates,
each a related party. Prior to this offering, the material facts as to the related party&#146;s relationship or interest in the transaction were disclosed to our board of directors prior to their consideration of such transaction, and the
transaction was not considered approved by our board of directors unless a majority of the directors who are not interested in the transaction approved the transaction. Further, when stockholders are entitled to vote on a transaction with a related
party, the material facts of the related party&#146;s relationship or interest in the transaction were disclosed to the stockholders, who must approve the transaction in good faith. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In connection with this offering, we expect to adopt a written related party transactions policy that will provide that such transactions must be approved by our audit
committee. This policy will become effective on the date on which the registration statement of which this prospectus forms a part is declared effective by the SEC. Pursuant to this policy, the audit committee has the primary responsibility for
reviewing and approving or disapproving &#147;related party transactions,&#148; which are transactions between us and related persons in which the aggregate amount involved exceeds or may be expected to exceed $120,000 and in which a related person
has or will have a direct or indirect material interest. For purposes of this policy, a related person will be defined as a director, executive officer, nominee for director, or greater than 5&nbsp;percent beneficial owner of our common stock, in
each case since the beginning of the most recently completed year, and their immediate family members. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">242 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc425213_17"></A>PRINCIPAL STOCKHOLDERS </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table sets forth, as of June&nbsp;30, 2023, information regarding the beneficial ownership of our common stock by: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">each person, or group of affiliated persons, who is known by us to be the beneficial owner of five percent or more of our
outstanding common stock (on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to common stock basis); </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">each of our directors; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">each of our named executive officers; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">all of our current directors and executive officers as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The information in the following table is calculated based on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of
common stock deemed to be outstanding before this offering and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock outstanding after this offering, assuming no exercise by the
underwriters of their option to purchase additional shares of common stock. The number of shares outstanding is based on the number of shares of common stock outstanding (including
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of unvested restricted common stock) as of June&nbsp;30, 2023 as adjusted to give effect to: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the conversion of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares
of our redeemable convertible preferred stock outstanding as of June&nbsp;30, 2023 into an equivalent number of shares of our common stock, which will occur immediately prior to the completion of this offering; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the sale of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common
stock in this offering (assuming no exercise of the underwriters&#146; option to purchase additional shares). </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Each individual or entity shown on
the table has furnished information with respect to beneficial ownership. Except as otherwise indicated below, the address of each officer, director and five percent stockholder listed below is c/o Metagenomi Technologies, LLC, 1545 Park Avenue,
Emeryville, California 94608. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">243 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have determined beneficial ownership in accordance with the rules of the SEC, and the information is not
necessarily indicative of beneficial ownership for any other purpose. These rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those securities as well
as any shares of common stock that the person has the right to acquire within 60&nbsp;days of June&nbsp;30, 2023 through the exercise of stock options or other rights. These shares are deemed to be outstanding and beneficially owned by the person
holding those options for the purpose of computing the percentage ownership of that person, but they are not treated as outstanding for the purpose of computing the percentage ownership of any other person. Unless otherwise indicated, the persons or
entities identified in this table have sole voting and investment power with respect to all shares shown as beneficially owned by them. </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000;border-bottom:1.00px solid #000000"><B>Shares of<BR>common&nbsp;stock<BR>beneficially<BR>owned</B></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Percentage&nbsp;of&nbsp;shares<BR>beneficially&nbsp;owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Before&nbsp;offering</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>After&nbsp;offering</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>5% or Greater Stockholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Bayer HealthCare LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Humboldt Fund I, LP (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">ModernaTX, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Sake Holdings LLC (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Entities affiliated with Sozo Ventures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Entities affiliated with RA Capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Directors, Named Executive Officers and Other Executive Officers</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Brian C. Thomas, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Juergen Eckhardt, M.D., MBA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Sebasti&aacute;n Bernales, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Risa Stack, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Willard Dere, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Santhosh Palani, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Jian Irish, Ph.D., MBA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Simon Harnest, MSc</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">All executive officers and directors as a group (13
persons)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Less than one percent. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of redeemable convertible preferred stock held by Humboldt Fund I, LP. Humboldt Fund I, LP is solely managed by Humboldt
Capital, LLC, which is in turn managed by Sebastian Bernales, Francisco Dopazo and Benjamin Quiroga. As a result, each such individual may be deemed to share voting and dispositive power with respect to the shares held by Humboldt Fund I, LP. Each
of Mr.&nbsp;Bernales, Dopazo and Quiroga expressly disclaims beneficial ownership of the shares held by Humboldt Fund I, LP, except to the extent of his pecuniary interest in such shares. The address for Humboldt Fund I, LP is 477&nbsp;Madison Ave.,
6th&nbsp;Floor, New York, NY&nbsp;10022. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of redeemable convertible preferred stock held by Sake Holdings LLC. Sake Holdings LLC is managed by its board of directors
which consists of Sebastian Bernales and Eduardo Ergas. As a result, each such individual may be deemed to share voting and dispositive power with respect to the shares held by Sake Holdings LLC. Each of Mr.&nbsp;Bernales and Mr.&nbsp;Ergas
expressly disclaims beneficial ownership of the shares held by Sake Holdings LLC, except to the extent of his pecuniary interest in such shares. The address for Sake Holdings LLC is 1700 Owens Street, Suite&nbsp;515, San Francisco, CA&nbsp;94158.
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">244 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc425213_18"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following descriptions are summaries of the material terms of our amended and restated certificate of incorporation and amended and restated bylaws, which will be
effective immediately upon the closing of this offering. The descriptions of the common stock and preferred stock give effect to changes to our capital structure, including the Reorganization, that will occur immediately prior to the closing of this
offering. We refer in this section to our amended and restated certificate of incorporation as our certificate of incorporation, and we refer to our amended and restated bylaws as our bylaws. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>General </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon completion of this offering, our authorized capital stock will
consist of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock, par value $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share,
and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of preferred stock, par value $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, all of which shares of preferred stock will be
undesignated. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of June 30, 2023,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock
were outstanding and held of record by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;stockholders, after giving effect to the Reorganization. This amount assumes the conversion of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our redeemable convertible preferred stock outstanding as of June 30, 2023 into an equivalent number of shares of our common stock, which will
occur immediately prior to the closing of this offering. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Common Stock </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of the common stockholders. The holders of our common
stock do not have any cumulative voting rights. Holders of our common stock are entitled to receive ratably any dividends declared by our board of directors out of funds legally available for that purpose, subject to any preferential dividend rights
of any outstanding preferred stock. Our common stock has no preemptive rights, conversion rights or other subscription rights or redemption or sinking fund provisions. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to share ratably in all assets remaining after payment of all
debts and other liabilities and any liquidation preference of any outstanding preferred stock. The shares to be issued by us in this offering will be, when issued and paid for, validly issued, fully paid and
<FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Preferred Stock </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Immediately prior to the completion of this offering, all outstanding shares of our preferred stock will be converted into shares of our common stock. Upon the closing
of this offering, our board of directors will have the authority, without further action by our stockholders, to issue up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of preferred stock in
one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences,
sinking fund terms and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of common stock. The issuance of our preferred stock could adversely affect the voting power of holders
of common stock and the likelihood that such holders will receive dividend payments and payments upon our liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change in control of our
company or other corporate action. Immediately after consummation of this offering, no shares of preferred stock will be outstanding, and we have no present plan to issue any shares of preferred stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">245 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Options </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We expect to
reserve&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock for future issuance under the 2023 Plan. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Registration Rights </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon the completion of this offering, the holders
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock, including those issuable upon the conversion of preferred stock upon closing of this offering, will be entitled to rights
with respect to the registration of these securities under the Securities Act. These rights are provided under the terms of an amended and restated investors&#146; rights agreement between us, certain holders of our common stock and holders of our
preferred stock. The amended and restated investors&#146; rights agreement includes demand registration rights, short-form registration rights and piggyback registration rights. All fees, costs, and expenses of underwritten registrations under this
agreement will be borne by us and all selling expenses, including underwriting discounts and selling commissions, will be borne by the holders of the shares being registered. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Demand Registration Rights </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Beginning 180 days after the effective
date of this registration statement, the holders of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock, including those issuable upon the conversion of shares of our preferred
units upon closing of this offering, are entitled to demand registration rights. Under the terms of the amended and restated investors&#146; rights agreement, we will be required, upon the written request of holders of at least a majority of the
securities eligible for registration then outstanding to file a registration statement with respect to at least a majority of the securities eligible for registration then outstanding, we will be required to file a registration statement within 60
days of such request covering all securities eligible for registration that our securityholders request to be included in such registration. We are required to effect only one registration pursuant to this provision of the amended and restated
investors&#146; rights agreement in any twelve-month period. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Short-Form Registration Rights </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pursuant to the amended and restated investors&#146; rights agreement, if we are eligible to file a registration statement on Form
<FONT STYLE="white-space:nowrap">S-3,</FONT> upon the written request of securityholders holding at least twenty percent of the securities eligible for registration then outstanding we will be required to file a Form
<FONT STYLE="white-space:nowrap">S-3</FONT> registration restatement with respect to outstanding securities of such securityholders having an aggregate price to the public of at least $5&nbsp;million. We are required to effect only two registrations
in any twelve-month period pursuant to this provision of the amended and restated investors&#146; rights agreement. The right to have such shares registered on Form <FONT STYLE="white-space:nowrap">S-3</FONT> is further subject to other specified
conditions and limitations. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Piggyback Registration Rights </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pursuant to the amended and restated investors&#146; rights agreement, if we register any of our securities either for our own account or for the account of other
security holders, the holders of our common stock, including those issuable upon the conversion of our preferred units, are entitled to include their shares in the registration. Subject to certain exceptions contained in the amended and restated
investors&#146; rights agreement, we and the underwriters may limit the number of shares included in the underwritten offering to the number of shares which we and the underwriters determine in our sole discretion will not jeopardize the success of
the offering. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Indemnification </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our amended and restated
investors&#146; rights agreement contains customary cross-indemnification provisions, under which we are obligated to indemnify holders of registrable securities in the event of material misstatements
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">246 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
or omissions in the registration statement attributable to us, and they are obligated to indemnify us for material misstatements or omissions attributable to them. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Expiration of Registration Rights </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The demand registration rights, and
short form registration rights granted under the amended and restated investors&#146; rights agreement will terminate on the earliest to occur of (a)&nbsp;the closing of certain liquidation events, (b)&nbsp;the fifth anniversary of the completion of
this offering or (c)&nbsp;at such time after this offering when the holders&#146; shares may be sold without restriction pursuant to Rule 144 under the Securities Act within a three month period. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Expenses </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Ordinarily, other than underwriting discounts and
commissions, we are generally required to pay all expenses incurred by us related to any registration effected pursuant to the exercise of these registration rights. These expenses may include all registration and filing fees, printing expenses,
fees and disbursements of our counsel, reasonable fees, and disbursements of a counsel for the selling security holders and <FONT STYLE="white-space:nowrap">blue-sky</FONT> fees and expenses. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Anti-Takeover Effects of Delaware Law and Certain Provisions of Our Certificate of Incorporation and Bylaws to be in Effect Upon the Completion of this Offering
</B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Some provisions of Delaware law include, and our certificate of incorporation and bylaws to be in effect upon the completion of this offering will include a
number of provisions that may have the effect of delaying, deferring or preventing another party from acquiring control of us and encouraging persons considering unsolicited tender offers or other unilateral takeover proposals to negotiate with our
board of directors rather than pursue <FONT STYLE="white-space:nowrap">non-negotiated</FONT> takeover attempts. These provisions include the items described below. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Board Composition and Filling Vacancies </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our certificate of
incorporation will provide for the division of our board of directors into three classes serving staggered three-year terms, with one class being elected each year. Our certificate of incorporation also will provide that directors may be removed
only for cause and then only by the affirmative vote of the holders of <FONT STYLE="white-space:nowrap">two-thirds</FONT> or more of the shares then entitled to vote at an election of directors. Furthermore, any vacancy on our board of directors,
however occurring, including a vacancy resulting from an increase in the size of our board, may only be filled by the affirmative vote of a majority of our directors then in office even if less than a quorum. The classification of directors,
together with the limitations on removal of directors and treatment of vacancies, has the effect of making it more difficult for stockholders to change the composition of our board of directors. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>No Written Consent of Stockholders </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our certificate of incorporation
will provide that all stockholder actions are required to be taken by a vote of the stockholders at an annual or special meeting, and that stockholders may not take any action by written consent in lieu of a meeting. This limit may lengthen the
amount of time required to take stockholder actions and would prevent the amendment of our bylaws or removal of directors by our stockholders without holding a meeting of stockholders. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Meetings of Stockholders </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our certificate of incorporation and bylaws
will provide that only a majority of the members of our board of directors then in office may call special meetings of stockholders and only those matters set forth in the notice </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">247 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
of the special meeting may be considered or acted upon at a special meeting of stockholders. Our bylaws will limit the business that may be conducted at an annual meeting of stockholders to those
matters properly brought before the meeting. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Advance Notice Requirements </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our bylaws will establish advance notice procedures with regard to stockholder proposals relating to the nomination of candidates for election as directors or new
business to be brought before meetings of our stockholders. These procedures will provide that notice of stockholder proposals must be timely given in writing to our corporate secretary prior to the meeting at which the action is to be taken.
Generally, to be timely, notice must be received at our principal executive offices not less than 90 days nor more than 120 days prior to the first anniversary date of the annual meeting for the preceding year. Our bylaws will specify the
requirements as to form and content of all stockholders&#146; notices. These requirements may preclude stockholders from bringing matters before the stockholders at an annual or special meeting. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Amendment to Certificate of Incorporation and Bylaws </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any amendment of
our certificate of incorporation must first be approved by a majority of our board of directors, and if required by law or our certificate of incorporation, must thereafter be approved by a majority of the outstanding shares entitled to vote on the
amendment and a majority of the outstanding shares of each class entitled to vote thereon as a class, except that the amendment of the provisions relating to stockholder action, board composition, limitation of liability and the amendment of our
bylaws and certificate of incorporation must be approved by not less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding shares entitled to vote on the amendment, and not less than
<FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding shares of each class entitled to vote thereon as a class. Our bylaws may be amended by the affirmative vote of a majority of the directors then in office, subject to any
limitations set forth in the bylaws; and may also be amended by the affirmative vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding shares entitled to vote on the amendment, or, if our board of directors recommends
that the stockholders approve the amendment, by the affirmative vote of the majority of the outstanding shares entitled to vote on the amendment, in each case voting together as a single class. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Undesignated Preferred Stock </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our certificate of incorporation will
provide for&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;authorized shares of preferred stock. The existence of authorized but unissued shares of preferred stock may enable our board of directors to
discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. For example, if in the due exercise of its fiduciary obligations, our board of directors were to determine that a takeover proposal is not
in the best interests of our stockholders, our board of directors could cause shares of preferred stock to be issued without stockholder approval in one or more private offerings or other transactions that might dilute the voting or other rights of
the proposed acquirer or insurgent stockholder or stockholder group. In this regard, our certificate of incorporation will grant our board of directors broad power to establish the rights and preferences of authorized and unissued shares of
preferred stock. The issuance of shares of preferred stock could decrease the amount of earnings and assets available for distribution to holders of shares of common stock. The issuance may also adversely affect the rights and powers, including
voting rights, of these holders and may have the effect of delaying, deterring or preventing a change in control of us. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Delaware Anti-Takeover Statute
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon completion of this offering, we will be subject to the provisions of Section&nbsp;203 of the Delaware General Corporation Law. In general,
Section&nbsp;203 prohibits a publicly held Delaware corporation from engaging in a </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">&#147;business combination&#148; with an &#147;interested stockholder&#148; for a
three-year period following the time that this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">248 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
stockholder becomes an interested stockholder, unless the business combination is approved in a prescribed manner. Under Section&nbsp;203, a business combination between a corporation and an
interested stockholder is prohibited unless it satisfies one of the following conditions: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">before the stockholder became interested, our board of directors approved either the business combination or the
transaction which resulted in the stockholder becoming an interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested
stockholder owned at least 85&nbsp;percent of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and
also officers, and employee stock plans, in some instances, but not the outstanding voting stock owned by the interested stockholder; or </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">at or after the time the stockholder became interested, the business combination was approved by our board of directors and
authorized at an annual or special meeting of the stockholders by the affirmative vote of at <FONT STYLE="white-space:nowrap">least&nbsp;two-thirds&nbsp;of</FONT> the outstanding voting stock which is not owned by the interested stockholder.
</P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Section&nbsp;203 defines a business combination to include: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any merger or consolidation involving the corporation and the interested stockholder; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any sale, transfer, lease, pledge, exchange, mortgage or other disposition involving the interested stockholder of
10&nbsp;percent or more of the assets of the corporation; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the
corporation to the interested stockholder; or </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial
benefits provided by or through the corporation. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In general, Section&nbsp;203 defines an interested stockholder as any entity or person
beneficially owning 15&nbsp;percent or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Choice of Forum </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our bylaws will provide that, unless we consent in writing
to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for any state law claims for (1)&nbsp;any derivative action or proceeding brought on our behalf, (2)&nbsp;any action
asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, and employees to us or our stockholders, (3)&nbsp;any action asserting a claim arising pursuant to the Delaware General Corporation Law, our certificate of
incorporation or our bylaws (including the interpretation, validity or enforceability thereof), or (4)&nbsp;any action asserting a claim that is governed by the internal affairs doctrine; provided, however, that the this provision shall not apply to
any causes of action arising under the Securities Act or Exchange Act. In addition, our bylaws will provide that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall be the
sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. Any person or entity purchasing or otherwise acquiring any interest in our securities shall be deemed to have notice of and consented
to these forum provisions. These forum provisions may impose additional costs on stockholders, may limit our stockholders&#146; ability to bring a claim in a forum they find favorable, and the designated courts may reach different judgments or
results than other courts.&nbsp;In addition, there is uncertainty as to whether the federal forum provision for Securities Act claims will be enforced, which may impose additional costs on us and our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">249 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Stock Exchange Listing </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have applied to list our common stock on the Nasdaq Global Select Market under the proposed trading symbol &#147;MGX.&#148; The closing of this offering is contingent
upon such listing. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Transfer Agent and Registrar </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Transfer Agent
and Registrar for our common stock will be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">250 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc425213_19"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Prior to this offering, there has been no public market for our shares. Future sales of our common stock in the public market, or the availability of such shares for
sale in the public market, could adversely affect market prices prevailing from time to time. As described below, only a limited number of shares will be available for sale shortly after this offering due to contractual and legal restrictions on
resale. Nevertheless, sales of shares of our common stock in the public market after such restrictions lapse, or the perception that those sales may occur, could adversely affect the prevailing market price at such time and our ability to raise
equity capital in the future. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Based on the number of shares outstanding as of June 30, 2023, upon the completion of this offering and after giving effect to the
Reorganization,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock will be outstanding, assuming the issuance
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares offered by us in this offering, no exercise of the underwriters&#146; option to purchase additional shares and no exercise of outstanding
options. Of the outstanding shares, all of the shares sold in this offering will be freely tradable, except that any shares held by our affiliates, as that term is defined in Rule&nbsp;144 under the Securities Act, may only be sold in compliance
with the limitations described below, and&nbsp;restricted shares of common stock are subject to time-based vesting terms. All remaining shares of common stock held by existing stockholders immediately prior to the completion of this offering will be
&#147;restricted securities&#148; as such term is defined in Rule 144 under the Securities Act. These restricted securities were issued and sold by us in private transactions and are eligible for public sale only if registered under the Securities
Act or if they qualify for an exemption from registration under the Securities Act, including the exemptions provided by Rule 144 or Rule 701, summarized below. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Rule&nbsp;144 </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In general, a person who has beneficially owned restricted
stock for at least six months would be entitled to sell their securities provided that (i)&nbsp;such person is not deemed to have been one of our affiliates at the time of, or at any time during the 90 days preceding, a sale and (ii)&nbsp;we are
subject to the periodic reporting requirements of the Exchange Act for at least 90 days before the sale. Persons who have beneficially owned restricted shares for at least six months but who are our affiliates at the time of, or any time during the
90 days preceding, a sale, would be subject to additional restrictions, by which such person would be entitled to sell within any three-month period only a number of securities that does not exceed the greater of either of the following: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">1&nbsp;percent of the number of shares then outstanding, which will equal
approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares immediately after this offering, assuming no exercise of the underwriters&#146; option to purchase additional shares, based on the
number of shares outstanding as of June 30, 2023; or </P></TD></TR></TABLE>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the average weekly trading volume of our common stock on the Nasdaq Global Select Market during the four calendar weeks
preceding the filing of a notice on Form&nbsp;144 with respect to the sale; </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">provided, in each case, that we are subject to the periodic reporting
requirements of the Exchange Act for at least 90&nbsp;days before the sale. Such sales both by affiliates and by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> must also comply with the manner of sale, current public information and notice
provisions of Rule&nbsp;144. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Rule&nbsp;701 </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Rule&nbsp;701 under the
Securities Act, as in effect on the date of this prospectus, permits resales of shares in reliance upon Rule&nbsp;144 but without compliance with certain restrictions of Rule&nbsp;144, including the holding period requirement. Most of our employees,
executive officers or directors who purchased shares under a written compensatory plan or contract may be entitled to rely on the resale provisions of Rule&nbsp;701, but all holders of Rule&nbsp;701 shares are required to wait until 90 days after
the date of this prospectus before selling their shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">251 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">However, substantially all Rule&nbsp;701 shares are subject to <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreements as described below and under &#147;Underwriting&#148; included elsewhere in this prospectus and will become eligible for sale upon the expiration of the restrictions set forth in those agreements. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We, all of our
directors and officers, and substantially all of our stockholders have agreed not to sell or otherwise transfer or dispose of any of our securities for a period of 180 days from the date of this prospectus, subject to certain exceptions. The
representatives of the underwriters may, in their sole discretion, permit early release of shares subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements. See the section entitled &#147;Underwriting,&#148; included elsewhere in
this prospectus for more information. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Registration Rights </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon
completion of this offering, certain holders of our securities will be entitled to various rights with respect to registration of their shares under the Securities Act.&nbsp;Registration of these shares under the Securities Act would result in these
shares becoming fully tradable without restriction under the Securities Act immediately upon the effectiveness of the registration.&nbsp;See the section entitled &#147;Description of Capital Stock&#151;Registration Rights&#148; included elsewhere in
this prospectus for more information. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Equity Incentive Plans </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We intend
to file one or more registration statements on <FONT STYLE="white-space:nowrap">Form&nbsp;S-8</FONT> under the Securities Act to register our shares issued or reserved for issuance under our equity incentive plans. The first such registration
statement is expected to be filed soon after the date of this prospectus and will automatically become effective upon filing with the SEC. Accordingly, shares registered under such registration statement will be available for sale in the open
market, unless such shares are subject to vesting restrictions with us or the <FONT STYLE="white-space:nowrap">lock-up</FONT> restrictions described above. As of the date of this prospectus, we estimate that such registration statement on <FONT
STYLE="white-space:nowrap">Form&nbsp;S-8</FONT> will cover approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">252 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc425213_20"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS FOR
<FONT STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following discussion is a summary of certain material U.S. federal income tax considerations
applicable to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders (as defined below) with respect to their ownership and disposition of shares of our common stock issued pursuant to this offering, referred to below as &#147;our common
stock&#148;. For purposes of this discussion, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder means a beneficial owner of our common stock that is for U.S. federal income tax purposes: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a <FONT STYLE="white-space:nowrap">non-resident</FONT> alien individual; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a foreign corporation or other foreign organization taxable as a corporation; or </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a foreign trust or estate the income of which is not subject to U.S. federal income tax on a net income basis.
</P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This discussion does not address the tax treatment of partnerships or other entities that are pass-through entities for U.S. federal income tax
purposes or persons that hold their common stock through partnerships or other pass-through entities. A partner in a partnership or other pass-through entity that will hold our common stock should consult his, her or its tax advisor regarding the
tax consequences of acquiring, holding and disposing of our common stock through a partnership or other pass-through entity, as applicable. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This discussion is based
on current provisions of the U.S. Internal Revenue Code of 1986, as amended, which we refer to as the Code, existing and proposed U.S. Treasury Regulations promulgated thereunder, current administrative rulings and judicial decisions, all as in
effect as of the date of this prospectus and, all of which are subject to change or to differing interpretation, possibly with retroactive effect. Any such change or differing interpretation could alter the tax consequences to <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holders described in this prospectus. There can be no assurance that the Internal Revenue Service, which we refer to as the IRS, will not challenge one or more of the tax consequences described herein. We
assume in this discussion that a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder holds shares of our common stock as a capital asset within the meaning of Section&nbsp;1221 of the Code, generally property held for investment. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This discussion does not address all aspects of U.S. federal income taxation that may be relevant to a particular <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder
in light of that <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s individual circumstances nor does it address any aspects of U.S. state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> taxes, the alternative minimum tax, the
Medicare contribution tax on net investment income, the rules regarding qualified small business stock within the meaning of Section&nbsp;1202 of the Code, or any other aspect of any U.S. federal tax other than income taxes. This discussion also
does not consider any specific facts or circumstances that may apply to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder and does not address the special tax rules applicable to particular <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holders, such as: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">insurance companies; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> or governmental organizations; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">financial institutions; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">brokers or dealers in securities; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">&#147;regulated investment companies&#148; and &#147;real estate investment trusts&#148;; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">pension plans; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">&#147;controlled foreign corporations,&#148; &#147;passive foreign investment companies,&#148; and corporations that
accumulate earnings to avoid U.S. federal income tax; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">&#147;qualified foreign pension funds,&#148; or entities wholly owned by a &#147;qualified foreign pension fund&#148;;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">253 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">partnerships or other entities or arrangements treated as partnerships for U.S. federal income tax purposes (and partners
and investors therein); </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">persons deemed to sell our common stock under the constructive sale provisions of the Code; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">persons who have elected to mark securities to market for U.S. federal income tax purposes; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">persons that hold our common stock as part of a straddle, conversion transaction, synthetic security, or other integrated
investment; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">U.S. expatriates. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This discussion is for general information only and is not tax advice. Accordingly, all prospective <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders of our
common stock should consult their tax advisors with respect to the U.S. federal, state, local and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax consequences of the purchase, ownership and disposition of our common stock. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Distributions on Our Common Stock </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have never declared or paid any cash
distributions on our members&#146; capital, and we do not anticipate paying cash distributions on our common stock for the foreseeable future. Distributions, if any, on our common stock will generally constitute dividends for U.S. federal income tax
purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. If a distribution exceeds our current and accumulated earnings and profits, the excess will be treated as a <FONT
STYLE="white-space:nowrap">tax-free</FONT> return of the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s investment, up to such holder&#146;s tax basis in the common stock. Any remaining excess will be treated as capital gain, subject
to the tax treatment described below in &#147;Gain on Sale or Other Taxable Disposition of Our Common Stock.&#148; Any such distributions will also be subject to the discussions below under the sections entitled &#147;Backup Withholding and
Information Reporting&#148; and &#147;Withholding and Information Reporting Requirements&#151;FATCA.&#148; </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Subject to the discussion in the following two paragraphs
in this section, dividends paid to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will be subject to withholding of U.S. federal income tax at a 30&nbsp;percent rate or a reduced rate specified by an applicable income tax treaty
between the United States and such holder&#146;s country of residence. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Dividends that are treated as effectively connected with a trade or business conducted by a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder within the United States and, if an applicable income tax treaty so provides, that are attributable to a permanent establishment or a fixed base maintained by the
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder within the United States, are generally exempt from the 30&nbsp;percent withholding tax if the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder satisfies applicable certification
requirements. However, such U.S. effectively connected income, net of specified deductions and credits, is taxed at the same graduated U.S. federal income tax rates applicable to United States persons (as defined in the Code). Any U.S. effectively
connected income received by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that is a corporation may also, under certain circumstances, be subject to an additional &#147;branch profits tax&#148; at a 30&nbsp;percent rate or a reduced
rate specified by an applicable income tax treaty between the United States and such holder&#146;s country of residence. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder of our common stock who claims the benefit of an applicable income tax treaty between the United States and such holder&#146;s country of residence generally will be required to provide a
properly executed IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (or other applicable or successor form) to the applicable withholding agent and
satisfy applicable certification and other requirements. Any documentation provided to an applicable withholding agent may need to be updated in certain circumstances. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders are urged to consult
their tax advisors regarding their entitlement to benefits under a relevant income tax treaty. A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that is eligible for a reduced rate of U.S. withholding tax under an income tax treaty may
obtain a refund or credit of any excess amounts withheld by timely filing an appropriate claim with the IRS. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">254 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Gain on Sale or Other Taxable Disposition of Our Common Stock </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Subject to the discussions below under &#147;Backup Withholding and Information Reporting&#148; and &#147;Withholding and Information Reporting
Requirements&#151;FATCA,&#148; a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will not be subject to any U.S. federal income or withholding tax on any gain realized upon such holder&#146;s sale or other taxable disposition of
shares of our common stock unless: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the gain is effectively connected with the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s conduct of a U.S.
trade or business and, if an applicable income tax treaty so provides, is attributable to a permanent establishment or a fixed base maintained by such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder in the United States, in which case the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will be taxed on a net income basis at the graduated U.S. federal income tax rates applicable to United States persons (as defined in the Code) and, if the
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is a foreign corporation, the branch profits tax described above in &#147;Distributions on Our Common Stock&#148; also may apply; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is a nonresident alien individual who is present in the United
States for a period or periods aggregating 183 days or more in the taxable year of the disposition and certain other conditions are met, in which case the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will be subject to a 30&nbsp;percent
tax (or such lower rate as may be specified by an applicable income tax treaty between the United States and such holder&#146;s country of residence) on the net gain derived from the disposition, which may be offset by certain U.S. source capital
losses of the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder, if any (even though the individual is not considered a resident of the United States), provided that the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder has timely filed
U.S. federal income tax returns with respect to such losses; or </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we are, or have been, at any time during the five-year period preceding such sale or other taxable disposition (or the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s holding period, if shorter) a &#147;U.S. real property holding corporation,&#148; as described below, unless our common stock is regularly traded on an established securities market and the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder holds no more than 5&nbsp;percent of our outstanding common stock, directly or indirectly, actually or constructively, during the shorter of the <FONT STYLE="white-space:nowrap">5-year</FONT> period
ending on the date of the disposition or the period that the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder held our common stock. Generally, a corporation is a U.S. real property holding corporation if the fair market value of its U.S.
real property interests, as defined in the Code and applicable Treasury regulations, equals or exceeds 50&nbsp;percent of the sum of the fair market value of its worldwide real property interests plus its other assets used or held for use in a trade
or business. Although there can be no assurance, we do not believe that we are, or have been, a U.S. real property holding corporation, or that we are likely to become one in the future. No assurance can be provided that our common stock will be
regularly traded on an established securities market for purposes of the rules described above. </P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Backup Withholding and Information Reporting
</B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We (or the applicable paying agent) must report annually to the IRS and to each <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder the gross amount of the
distributions on our common stock paid to such holder and the tax withheld, if any, with respect to such distributions. A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder may have to comply with specific certification procedures to establish
that the holder is not a United States person (as defined in the Code) in order to avoid backup withholding at the applicable rate with respect to dividends on our common stock. Dividends paid to <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holders subject to withholding of U.S. federal income tax, as described above in &#147;Distributions on Our Common Stock,&#148; generally will be exempt from U.S. backup withholding. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Information reporting and backup withholding will generally apply to the proceeds of a disposition of our common stock by a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder effected by or through the U.S. office of any broker, U.S. or foreign, unless the holder certifies its status as a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder and satisfies certain
other requirements, or otherwise establishes an exemption. Generally, information reporting and backup withholding will not apply to a payment of disposition proceeds to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder where the transaction
is effected outside the United States through </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">255 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a broker. However, for information reporting purposes, dispositions effected through a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a broker with substantial U.S. ownership or operations generally will be treated in a manner similar to dispositions effected through a U.S. office of a broker. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax advisors regarding the application of the information reporting and backup withholding
rules to them. Copies of information returns may be made available to the tax authorities of the country in which the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder resides or is incorporated under the provisions of a specific treaty or
agreement. Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules from a payment to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder can be refunded or credited against the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s U.S. federal income tax liability, if any, provided that an appropriate claim is filed with the IRS in a timely manner. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Withholding and Information Reporting Requirements&#151;FATCA </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Provisions of
the Code commonly referred to as the Foreign Account Tax Compliance Act (FATCA) generally impose a U.S. federal withholding tax at a rate of 30&nbsp;percent on payments of dividends on, or, subject to the discussion of certain proposed U.S. Treasury
regulations below, gross proceeds from the sale or other disposition of, our common stock paid to a foreign entity unless (i)&nbsp;if the foreign entity is a &#147;foreign financial institution,&#148; such foreign entity undertakes certain due
diligence, reporting, withholding, and certification obligations, (ii)&nbsp;if the foreign entity is not a &#147;foreign financial institution,&#148; such foreign entity identifies certain of its U.S. investors, if any, or (iii)&nbsp;the foreign
entity is otherwise exempt under FATCA. However, the U.S. Treasury released proposed regulations which, if finalized in their present form, would eliminate the federal withholding tax of 30&nbsp;percent applicable to the gross proceeds of a sale or
other disposition of our common stock. In the preamble to such proposed regulations, the U.S. Treasury stated that taxpayers (including withholding agents) may generally rely on the proposed regulations until final regulations are issued. Under
certain circumstances, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder may be eligible for refunds or credits of this withholding tax. An intergovernmental agreement between the United&nbsp;States and an applicable foreign country may
modify the requirements described in this paragraph. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax advisors regarding the possible implications of this legislation on their investment in our common stock and the
entities through which they hold our common stock, including, without limitation, the process and deadlines for meeting the applicable requirements to prevent the imposition of the 30&nbsp;percent withholding tax under FATCA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">256 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc425213_21"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are offering the shares of common stock described in this prospectus through a number of underwriters. J.P. Morgan Securities LLC, Jefferies LLC, Cowen and Company,
LLC, Wells Fargo Securities, LLC, and BMO Capital Markets Corp. are acting as joint book-running managers of the offering and as representatives of the underwriters. We have entered into an underwriting agreement with the underwriters. Subject to
the terms and conditions of the underwriting agreement, we have agreed to sell to the underwriters, and each underwriter has severally agreed to purchase, at the public offering price less the underwriting discounts and commissions set forth on the
cover page of this prospectus, the number of shares of common stock listed next to its name in the following table: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom"><B>Name</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Number&nbsp;of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>shares&nbsp;of</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>common&nbsp;stock</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="4" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">J.P. Morgan Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Jefferies LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cowen and Company, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Wells Fargo Securities, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">BMO Capital Markets Corp.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Chardan Capital Markets, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The underwriters are committed to purchase all the shares of common stock offered by us if they purchase any shares of common stock. The
underwriting agreement also provides that if an underwriter defaults, the purchase commitments of <FONT STYLE="white-space:nowrap">non-defaulting</FONT> underwriters may also be increased, or the offering may be terminated. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The underwriters propose to offer the shares of common stock directly to the public at the initial public offering price set forth on the cover page of this prospectus
and to certain dealers at that price less a concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. Any such dealers may resell shares of common stock to certain other brokers or dealers at a discount of up to
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share from the initial public offering price. After the initial offering of the shares of common stock to the public, if all of the shares of common stock are not sold at the initial public
offering price, the underwriters may change the offering price and the other selling terms. Sales of any shares of common stock made outside of the United States may be made by affiliates of the underwriters. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The underwriters have an option to buy up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
additional shares of common stock from us to cover sales of shares of common stock by the underwriters which exceed the number of shares of common stock specified in the table above. The underwriters have 30&nbsp;days from the date of this
prospectus to exercise this option to purchase additional shares of common stock. If any shares of common stock are purchased with this option to purchase additional shares of common stock, the underwriters will purchase shares of common stock in
approximately the same proportion as shown in the table above. If any additional shares of common stock are purchased, the underwriters will offer the additional shares of common stock on the same terms as those on which the shares of common stock
are being offered. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">257 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The underwriting fee is equal to the public offering price per share of common stock less the amount paid by the
underwriters to us per share of common stock. The underwriting fee is $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. The following table shows the per share and total underwriting discounts and commissions to be paid to the
underwriters assuming both no exercise and full exercise of the underwriters&#146; option to purchase additional shares of common stock. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Without</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>option&nbsp;to</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>purchase</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>additional</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>shares&nbsp;of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>common&nbsp;stock</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>exercise</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>With&nbsp;full</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>option to</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>purchase</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>additional</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>shares of<BR>common&nbsp;stock</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>exercise</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Per Common Share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We estimate that the total expenses of this offering, including registration, filing, and listing fees, printing fees and legal and
accounting expenses, but excluding the underwriting discounts and commissions, will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million. We have agreed to reimburse the underwriters for expenses relating to clearance of this
offering with the Financial Industry Regulatory Authority, Inc. of up to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A prospectus in electronic format may be
made available on the web sites maintained by one or more underwriters, or selling group members, if any, participating in the offering. The underwriters may agree to allocate a number of shares of common stock to underwriters and selling group
members for sale to their online brokerage account holders. Internet distributions will be allocated by the representatives to underwriters and selling group members that may make Internet distributions on the same basis as other allocations. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have agreed that we will not (i)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant
any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, or submit to, or file with, the SEC a registration statement under the Securities Act relating to, any of our shares of common stock or
securities convertible into or exercisable or exchangeable for any of our shares of common stock, or publicly disclose the intention to make any offer, sale, pledge, loan, disposition or filing, or (ii)&nbsp;enter into any swap or other arrangement
that transfers all or a portion of the economic consequences associated with the ownership of any shares of common stock or any such other securities (regardless of whether any of these transactions are to be settled by the delivery of shares of
common stock or such other securities, in cash or otherwise), in each case without the prior written consent of the representatives for a period of 180&nbsp;days after the date of this prospectus, other than the shares of our common stock to be sold
in this offering. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our directors and executive officers, and substantially all of our stockholders (such persons, the
<FONT STYLE="white-space:nowrap">&#147;lock-up</FONT> parties&#148;) have entered into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters prior to the commencement of this offering pursuant to which each <FONT
STYLE="white-space:nowrap">lock-up</FONT> party, with limited exceptions, for a period of 180 days after the date of this prospectus (such period, the &#147;restricted period&#148;), may not (and may not cause any of their direct or indirect
affiliates to), without the prior written consent of the representatives, (1)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to
purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of our common stock or any securities convertible into or exercisable or exchangeable for our common stock (including without limitation, common stock or such
other securities which may be deemed to be beneficially owned by such <FONT STYLE="white-space:nowrap">lock-up</FONT> parties in accordance with the rules and regulations of the SEC and securities which may be issued upon exercise of a stock option
or warrant (collectively with the common stock, the <FONT STYLE="white-space:nowrap">&#147;lock-up</FONT> securities&#148;), (2) enter into any hedging, swap or other agreement or transaction that transfers, in whole or in part, any of the economic
consequences of ownership of the <FONT STYLE="white-space:nowrap">lock-up</FONT> securities, whether any such transaction described in clause (1)&nbsp;or (2) above is to be settled by delivery of <FONT STYLE="white-space:nowrap">lock-up</FONT>
securities, in cash or otherwise, (3)&nbsp;make any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">258 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
demand for, or exercise any right with respect to, the registration of any <FONT STYLE="white-space:nowrap">lock-up</FONT> securities, or (4)&nbsp;publicly disclose the intention to do any of the
foregoing. Such persons or entities have further acknowledged that these undertakings preclude them from engaging in any hedging or other transactions or arrangements (including, without limitation, any short sale or the purchase or sale of, or
entry into, any put or call option, or combination thereof, forward, swap or any other derivative transaction or instrument, however described or defined) designed or intended, or which could reasonably be expected to lead to or result in, a sale or
disposition or transfer (by any person or entity, whether or not a signatory to such agreement) of any economic consequences of ownership, in whole or in part, directly or indirectly, of any <FONT STYLE="white-space:nowrap">lock-up</FONT>
securities, whether any such transaction or arrangement (or instrument provided for thereunder) would be settled by delivery of <FONT STYLE="white-space:nowrap">lock-up</FONT> securities, in cash or otherwise. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The restrictions described in the immediately preceding paragraph and contained In the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements between the
underwriters and the <FONT STYLE="white-space:nowrap">lock-up</FONT> parties do not apply, subject in certain cases to various conditions, to certain transactions, including (a)&nbsp;transfers or disposals of
<FONT STYLE="white-space:nowrap">lock-up</FONT> securities: (i)&nbsp;as bona fide gifts, or for bona fide estate planning purposes, (ii)&nbsp;by will or intestacy or any other testamentary document, (iii)&nbsp;to any trust for the direct or indirect
benefit of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party or any immediate family member, (iv)&nbsp;to a corporation, partnership, limited liability company, investment fund or other entity (A)&nbsp;of which the <FONT
STYLE="white-space:nowrap">lock-up</FONT> party and/or its immediate family members are the legal and beneficial owner of all of the outstanding equity securities or similar interests, or (B)&nbsp;controlled by, or under common control with, the
undersigned or the immediate family of the undersigned (v)&nbsp;to a nominee or custodian of a person or entity to whom a disposition or transfer would be permissible under clauses (i)&nbsp;through (iv), (vi) in the case of a corporation,
partnership, limited liability company, trust or other business entity, (A)&nbsp;to another corporation, partnership, limited liability company, trust or other business entity that is an affiliate of the
<FONT STYLE="white-space:nowrap">lock-up</FONT> party, or to any investment fund or other entity controlling, controlled by, managing or managed by or under common control with the <FONT STYLE="white-space:nowrap">lock-up</FONT> party or its
affiliates or (B)&nbsp;as part of a distribution to limited members, members or stockholders of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party; (vii)&nbsp;by operation of law, (viii)&nbsp;to us from an employee upon death, disability or
termination of employment of such employee, (ix)&nbsp;as part of a sale of <FONT STYLE="white-space:nowrap">lock-up</FONT> securities acquired in open market transactions after the completion of this offering, (x)&nbsp;to us in connection with the
vesting, settlement or exercise of restricted stock units, options, warrants or other rights to purchase shares of our common stock (including &#147;net&#148; or &#147;cashless&#148; exercise), including for the payment of exercise price and tax and
remittance payments, or (xi)&nbsp;pursuant to a bona fide third-party tender offer, merger, consolidation or other similar transaction approved by our board of directors and made to all shareholders involving a change in control, provided that if
such transaction is not completed, all such <FONT STYLE="white-space:nowrap">lock-up</FONT> securities would remain subject to the restrictions in the immediately preceding paragraph; provided that (A)&nbsp;in the case of any transfer or
distribution pursuant to clause (a)(i), (ii), (iii), (iv), (v), (vi) and (vii), such transfer shall not involve a disposition for value and each donee, devisee, transferee or distributee shall execute and deliver to the representatives a <FONT
STYLE="white-space:nowrap">lock-up</FONT> letter in the form of the <FONT STYLE="white-space:nowrap">lock-up</FONT> letter, (B)&nbsp;in the case of any transfer or distribution pursuant to clause (a), (iii), (iv), (v), (vi), (ix) and (x)&nbsp;no
filing by any party (donor, donee, devisee, transferor, transferee, distributer or distributee) under the Exchange Act, or other public announcement shall be required or shall be made voluntarily in connection with such transfer or distribution
(other than a filing on a Form 5 or a filing required pursuant to Section&nbsp;13 of the Exchange Act and the rules and regulations promulgated thereunder made after the expiration of the restricted period referred to above) and (C)&nbsp;in the case
of any transfer or distribution pursuant to clause (a)(i), (ii), (vii) and (viii)&nbsp;it shall be a condition to such transfer that no public filing, report or announcement shall be voluntarily made and if any filing under Section&nbsp;16(a) of the
Exchange Act, or other public filing, report or announcement reporting a reduction in beneficial ownership of shares of common stock in connection with such transfer or distribution shall be legally required during the restricted period, such
filing, report or announcement shall clearly indicate in the footnotes thereto the nature and conditions of such transfer; (b)&nbsp;exercise of the options, settlement of RSUs or other equity awards, or the exercise of warrants granted pursuant to
plans described in in this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">259 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
prospectus, provided that any <FONT STYLE="white-space:nowrap">lock-up</FONT> securities received upon such exercise, vesting or settlement would be subject to restrictions similar to those in
the immediately preceding paragraph; (c)&nbsp;the conversion of outstanding preferred stock, warrants to acquire preferred stock, or convertible securities into shares of our common stock or warrants to acquire shares of our common stock, provided
that any common stock or warrant received upon such conversion would be subject to restrictions similar to those in the immediately preceding paragraph; and (d)&nbsp;the establishment by <FONT STYLE="white-space:nowrap">lock-up</FONT> parties of
trading plans under Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act, provided that such plan does not provide for the transfer of <FONT STYLE="white-space:nowrap">lock-up</FONT> securities during the restricted period.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The representatives, in their sole discretion, may release the securities subject to any of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the
underwriters described above, in whole or in part at any time. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have agreed to indemnify the underwriters against certain liabilities, including liabilities under
the Securities Act. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have applied to have our common stock approved for listing/quotation on the Nasdaq Global Select Market under the symbol &#147;MGX.&#148;
The closing of this offering is contingent upon such listing. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In connection with this offering, the underwriters may engage in stabilizing transactions, which
involves making bids for, purchasing and selling shares of common stock in the open market for the purpose of preventing or retarding a decline in the market price of the common stock while this offering is in progress. These stabilizing
transactions may include making short sales of common stock, which involves the sale by the underwriters of a greater number of shares of common stock than they are required to purchase in this offering, and purchasing shares of common stock on the
open market to cover positions created by short sales. Short sales may be &#147;covered&#148; shorts, which are short positions in an amount not greater than the underwriters&#146; option to purchase additional shares of common stock referred to
above, or may be &#147;naked&#148; shorts, which are short positions in excess of that amount. The underwriters may close out any covered short position either by exercising their option to purchase additional shares, in whole or in part, or by
purchasing shares of common stock in the open market. In making this determination, the underwriters will consider, among other things, the price of shares of common stock available for purchase in the open market compared to the price at which the
underwriters may purchase shares of common stock through the option to purchase additional shares of common stock. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price
of the common stock in the open market that could adversely affect investors who purchase in this offering. To the extent that the underwriters create a naked short position, they will purchase shares of common stock in the open market to cover the
position. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The underwriters have advised us that, pursuant to Regulation&nbsp;M of the Securities Act, they may also engage in other activities that stabilize,
maintain or otherwise affect the price of the common stock, including the imposition of penalty bids. This means that if the representatives of the underwriters purchase common stock in the open market in stabilizing transactions or to cover short
sales, the representatives can require the underwriters that sold those shares of common stock as part of this offering to repay the underwriting discount received by them. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">These activities may have the effect of raising or maintaining the market price of the common stock or preventing or retarding a decline in the market price of the
common stock, and, as a result, the price of the common stock may be higher than the price that otherwise might exist in the open market. If the underwriters commence these activities, they may discontinue them at any time. The underwriters may
carry out these transactions on the open market, in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">260 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Prior to this offering, there has been no public market for our common stock. The initial public offering price will
be determined by negotiations between us and the representatives of the underwriters. In determining the initial public offering price, we and the representatives of the underwriters expect to consider a number of factors including: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the information set forth in this prospectus and otherwise available to the representatives; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our prospects and the history and prospects for the industry in which we compete; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">an assessment of our management; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our prospects for future earnings; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the general condition of the securities markets at the time of this offering; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the recent market prices of, and demand for, publicly traded common stock of generally comparable companies; and
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">other factors deemed relevant by the underwriters and us. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Neither we nor the underwriters can assure investors that an active trading market will develop for our shares of common stock, or that the shares of common stock will
trade in the public market at or above the initial public offering price. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Other than in the United States, no action has been taken by us or the underwriters that
would permit a public offering of the securities offered by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be offered or sold, directly or indirectly, nor may this
prospectus or any other offering material or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable
rules and regulations of that jurisdiction. Persons into whose possession this prospectus comes are advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus. This prospectus
does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an offer or a solicitation is unlawful. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Certain of the underwriters and their affiliates have provided in the past to us and our affiliates and may provide from time to time in the future certain commercial
banking, financial advisory, investment banking and other services for us and such affiliates in the ordinary course of their business, for which they have received and may continue to receive customary fees and commissions. In addition, from time
to time, certain of the underwriters and their affiliates may effect transactions for their own account or the account of customers, and hold on behalf of themselves or their customers, long or short positions in our debt or equity securities or
loans, and may do so in the future. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to Prospective Investors in the European Economic Area </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In relation to each Member State of the European Economic Area (each a &#147;Relevant State&#148;), no shares of our common stock have been offered or will be offered
pursuant to the offering to the public in that Relevant State prior to the publication of a prospectus in relation to the shares of our common stock which has been approved by the competent authority in that Relevant State or, where appropriate,
approved in another Relevant State and notified to the competent authority in that Relevant State, all in accordance with the Prospectus Regulation), except that offers of shares of common stock may be made to the public in that Relevant State at
any time under the following exemptions under the Prospectus Regulation: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">a)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to any legal entity which is a qualified investor as defined under the Prospectus Regulation; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">261 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">b)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to fewer than 150 natural or legal persons (other than qualified investors as defined under the Prospectus Regulation), subject to obtaining the prior consent of the underwriters for any such offer; or
</TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">c)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in any other circumstances falling within Article 1(4) of the Prospectus Regulation, </TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">provided that no such offer of
shares of common stock shall require the Issuer or any underwriter to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Each person in a Relevant State who initially acquires any shares of common stock or to whom any offer is made will be deemed to have represented, acknowledged and
agreed to and with the Company and the underwriters that it is a qualified investor within the meaning of the Prospectus Regulation. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the case of any shares of
common stock being offered to a financial intermediary as that term is used in Article 5(1) of the Prospectus Regulation, each such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares of common stock
acquired by it in the offer have not been acquired on a <FONT STYLE="white-space:nowrap">non-discretionary</FONT> basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which may give rise
to an offer to the public other than their offer or resale in a Relevant State to qualified investors, in circumstances in which the prior consent of the underwriters has been obtained to each such proposed offer or resale. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company, the underwriters and their affiliates will rely upon the truth and accuracy of the foregoing representations, acknowledgements and agreements. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For the purposes of this provision, the expression an &#147;offer to the public&#148; in relation to any shares of common stock in any Relevant State means the
communication in any form and by any means of sufficient information on the terms of the offer and any shares of common stock to be offered so as to enable an investor to decide to purchase or subscribe for any shares of common stock, and the
expression &#147;Prospectus Regulation&#148; means Regulation (EU) 2017/1129. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to Prospective Investors in the United Kingdom </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In relation to the United Kingdom (the &#147;UK&#148;), no shares of our common stock have been offered or will be offered pursuant to the offering to the public in the
UK prior to the publication of a prospectus in relation to the shares of common stock which has been approved by the Financial Conduct Authority in the UK in accordance with the UK Prospectus Regulation and the FSMA, except that offers of shares of
common stock may be made to the public in the UK at any time under the following exemptions under the UK Prospectus Regulation and the FSMA: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(a)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to any legal entity which is a qualified investor as defined under the UK Prospectus Regulation; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(b)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to fewer than 150 natural or legal persons (other than qualified investors as defined under the UK Prospectus Regulation), subject to obtaining the prior consent of the underwriters for any such offer; or
</TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(c)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">at any time in other circumstances falling within section 86 of the FSMA, </TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">provided that no such offer of shares of
common stock shall require the Issuer or any underwriter to publish a prospectus pursuant to Section&nbsp;85 of the FSMA or Article 3 of the UK Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the UK Prospectus Regulation.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Each person in the UK who initially acquires any shares of common stock or to whom any offer is made will be deemed to have represented, acknowledged and agreed to
and with the Company and the underwriters that it is a qualified investor within the meaning of the UK Prospectus Regulation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">262 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the case of any shares of common stock being offered to a financial intermediary as that term is used in Article
5(1) of the UK Prospectus Regulation, each such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares of common stock acquired by it in the offer have not been acquired on a
<FONT STYLE="white-space:nowrap">non-discretionary</FONT> basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer to the public other than their offer or
resale in the UK to qualified investors, in circumstances in which the prior consent of the underwriters has been obtained to each such proposed offer or resale. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company, the underwriters and their affiliates will rely upon the truth and accuracy of the foregoing representations, acknowledgements and agreements. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For the purposes of this provision, the expression an &#147;offer to the public&#148; in relation to any shares of our common stock in the UK means the communication in
any form and by any means of sufficient information on the terms of the offer and any shares of our common stock to be offered so as to enable an investor to decide to purchase or subscribe for any shares of our common stock, the expression &#147;UK
Prospectus Regulation&#148; means Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018, and the expression &#147;FSMA&#148; means the Financial Services and Markets Act 2000. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This document is for distribution only to persons who (i)&nbsp;have professional experience in matters relating to investments and who qualify as investment
professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the &#147;Financial Promotion Order&#148;), (ii) are persons falling within Article 49(2)(a) to (d)
(&#147;high net worth companies, unincorporated associations etc.&#148;) of the Financial Promotion Order, (iii)&nbsp;are outside the United Kingdom, or (iv)&nbsp;are persons to whom an invitation or inducement to engage in investment activity
(within the meaning of Section&nbsp;21 of the FSMA) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as &#147;relevant
persons&#148;). This document is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this document relates is available only to relevant
persons and will be engaged in only with relevant persons. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to Prospective Investors in Canada </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares of common stock may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National
Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> Prospectus Exemptions or subsection&nbsp;73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National
<FONT STYLE="white-space:nowrap">Instrument&nbsp;31-103</FONT> Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the shares of common stock must be made in accordance with an exemption from, or in a transaction
not subject to, the prospectus requirements of applicable securities laws. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Securities legislation in certain provinces or territories of Canada may provide a
purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed
by the securities legislation of the purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or
consult with a legal advisor. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pursuant to section 3A.3 of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> Underwriting Conflicts (&#147;NI <FONT
STYLE="white-space:nowrap">33-105&#148;),</FONT> the underwriters are not required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in connection with this
offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">263 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to Prospective Investors in Switzerland </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares of common stock may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange (&#147;SIX&#148;), or on any other stock exchange
or regulated trading facility in Switzerland. This document does not constitute a prospectus within the meaning of, and has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss
Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other
offering or marketing material relating to the shares of common stock, or the offering may be publicly distributed or otherwise made publicly available in Switzerland. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Neither this document nor any other offering or marketing material relating to the offering, the Company, the shares of common stock have been or will be filed with or
approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of shares of common stock will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA (&#147;FINMA&#148;), and the
offer of shares of common stock has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes (&#147;CISA&#148;). The investor protection afforded to acquirers of interests in collective investment schemes
under the CISA does not extend to acquirers of shares of common stock. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to Prospective Investors in Hong Kong </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares of common stock have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a)&nbsp;to
&#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (&#147;SFO&#148;), of Hong Kong and any rules made thereunder; or (b)&nbsp;in other circumstances which do not result in the
document being a &#147;prospectus&#148; as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap.&nbsp;32) of Hong Kong) (&#147;CO&#148;), or which do not constitute an offer to the public within the meaning of the CO. No
advertisement, invitation or document relating to the shares of common stock has been or may be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the
contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to shares of common stock which are or are intended to be disposed of only
to persons outside Hong Kong or only to &#147;professional investors&#148; as defined in the SFO and any rules made thereunder. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to Prospective Investors
in Singapore </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Each joint book-running manager has acknowledged that this prospectus has not been registered as a prospectus with the Monetary Authority of
Singapore. Accordingly, each joint book-running manager has represented and agreed that it has not offered or sold any shares of common stock or caused the shares of common stock to be made the subject of an invitation for subscription or purchase
and will not offer or sell any shares of common stock or cause the shares of common stock to be made the subject of an invitation for subscription or purchase, and has not circulated or distributed, nor will it circulate or distribute, this
prospectus or any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the shares of common stock, whether directly or indirectly, to any person in Singapore other than: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(a)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to an institutional investor (as defined in Section&nbsp;4A of the Securities and Futures Act (Chapter 289) of Singapore, as modified or amended from time to time (the &#147;SFA&#148;)) pursuant to Section&nbsp;274 of
the SFA; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(b)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to a relevant person (as defined in Section&nbsp;275(2) of the SFA) pursuant to Section&nbsp;275(1) of the SFA, or any person pursuant to Section&nbsp;275(1A) of the SFA, and in accordance with the conditions specified
in Section&nbsp;275 of the SFA; or </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">264 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(c)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. </TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Where the
shares of common stock are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(a)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals,
each of whom is an accredited investor; or </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(b)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor, securities or securities-based
derivatives contracts (each term as defined in Section&nbsp;2(1) of the SFA) of that corporation or the beneficiaries&#146; rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or
that trust has acquired the shares of common stock pursuant to an offer made under Section&nbsp;275 of the SFA except: </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to an institutional investor or to a relevant person, or to any person arising from an offer referred to in Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA; </TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">where no consideration is or will be given for the transfer; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">where the transfer is by operation of law; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">as specified in Section&nbsp;276(7) of the SFA; or </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">as specified in Regulation 37A of the Securities and Futures (Offers of Investments) (Securities and Securities-based Derivatives Contracts) Regulations 2018. </TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Singapore SFA Product Classification&#151;In connection with Section&nbsp;309B of the SFA and the CMP Regulations 2018, unless otherwise specified before an offer of
shares of common stock, we have determined, and hereby notify all relevant persons (as defined in Section&nbsp;309A(1) of the SFA), that the shares of common stock are &#145;&#145;prescribed capital markets products&#146;&#146; (as defined in the
CMP Regulations 2018) and Excluded Investment Products (as defined in MAS Notice SFA <FONT STYLE="white-space:nowrap">04-N12:</FONT> Notice on the Sale of Investment Products and MAS Notice <FONT STYLE="white-space:nowrap">FAA-N16:</FONT> Notice on
Recommendations on Investment Products). </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to Prospective Investors in Japan </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares of common stock have not been and will not be registered pursuant to Article 4, Paragraph 1 of the Financial Instruments and Exchange Act. Accordingly, none
of the shares of common stock nor any interest therein may be offered or sold, directly or indirectly, in Japan or to, or for the benefit of, any &#147;resident&#148; of Japan (which term as used herein means any person resident in Japan, including
any corporation or other entity organized under the laws of Japan), or to others for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Japan or to or for the benefit of a resident of Japan, except pursuant to
an exemption from the registration requirements of, and otherwise in compliance with, the Financial Instruments and Exchange Act and any other applicable laws, regulations and ministerial guidelines of Japan in effect at the relevant time. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to Prospective Investors in the United Arab Emirates </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares of
common stock have not been, and are not being, publicly offered, sold, promoted or advertised in the United Arab Emirates (including the Dubai International Financial Centre) other than in compliance with the laws of the United Arab Emirates (and
the Dubai International Financial Centre) governing the issue, offering and sale of securities. Further, this prospectus does not constitute a public offer of securities in the United Arab </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">265 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
Emirates (including the Dubai International Financial Centre) and is not intended to be a public offer. This prospectus has not been approved by or filed with the Central Bank of the United Arab
Emirates, the Securities and Commodities Authority or the Dubai Financial Services Authority. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to Prospective Investors in Israel </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the State of Israel this prospectus shall not be regarded as an offer to the public to purchase shares of common stock under the Israeli Securities Law,
5728&#151;1968, which requires a prospectus to be published and authorized by the Israel Securities Authority, if it complies with certain provisions of Section&nbsp;15 of the Israeli Securities Law, 5728&#150;1968, including, inter alia, if:
(i)&nbsp;the offer is made, distributed or directed to not more than 35 investors, subject to certain conditions (the &#147;Addressed Investors&#148;); or (ii)&nbsp;the offer is made, distributed or directed to certain qualified investors defined in
the First Addendum of the Israeli Securities Law, 5728&#151;1968, subject to certain conditions (the &#147;Qualified Investors&#148;).&nbsp;The Qualified Investors shall not be taken into account in the count of the Addressed Investors and may be
offered to purchase securities in addition to the 35 Addressed Investors.&nbsp;We have not and will not take any action that would require it to publish a prospectus in accordance with and subject to the Israeli Securities Law,
5728&#151;1968.&nbsp;We have not and will not distribute this prospectus or make, distribute or direct an offer to subscribe for our shares of common stock to any person within the State of Israel, other than to Qualified Investors and up to 35
Addressed Investors. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Qualified Investors may have to submit written evidence that they meet the definitions set out in of the First Addendum to the Israeli
Securities Law, 5728&#151;1968.&nbsp;In particular, we may request, as a condition to be offered shares of common stock, that Qualified Investors will each represent, warrant and certify to us and/or to anyone acting on our behalf: (i)&nbsp;that it
is an investor falling within one of the categories listed in the First Addendum to the Israeli Securities Law, 5728&#151;1968; (ii)&nbsp;which of the categories listed in the First Addendum to the Israeli Securities Law, 5728&#151;1968 regarding
Qualified Investors is applicable to it; (iii)&nbsp;that it will abide by all provisions set forth in the Israeli Securities Law, 5728&#151;1968 and the regulations promulgated thereunder in connection with the offer to be issued shares of common
stock; (iv)&nbsp;that the shares of common stock that it will be issued are, subject to exemptions available under the Israeli Securities Law, 5728&#151;1968: (a) for its own account; (b)&nbsp;for investment purposes only; and (c)&nbsp;not issued
with a view to resale within the State of Israel, other than in accordance with the provisions of the Israeli Securities Law, 5728&#151;1968; and (v)&nbsp;that it is willing to provide further evidence of its Qualified Investor
status.&nbsp;Addressed Investors may have to submit written evidence in respect of their identity and may have to sign and submit a declaration containing, inter alia, the Addressed Investor&#146;s name, address and passport number or Israeli
identification number. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to Prospective Investors in Australia </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This prospectus: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(a)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">does not constitute a disclosure document or a prospectus under Chapter 6D.2 of the Corporations Act 2001 (Cth) (the &#147;Corporations Act&#148;); </TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(b)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">has not been, and will not be, lodged with the Australian Securities and Investments Commission (&#147;ASIC&#148;), as a disclosure document for the purposes of the Corporations Act and does not purport to include the
information required of a disclosure document for the purposes of the Corporations Act; and </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(c)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">may only be provided in Australia to select investors who are able to demonstrate that they fall within one or more of the categories of investors, available under section 708 of the Corporations Act (&#147;Exempt
Investors&#148;). </TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares of common stock may not be directly or indirectly offered for subscription or purchased or sold, and no invitations to
subscribe for or buy the shares of common stock may be issued, and no draft or definitive offering </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">266 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
memorandum, advertisement or other offering material relating to any shares of common stock may be distributed in Australia, except where disclosure to investors is not required under Chapter 6D
of the Corporations Act or is otherwise in compliance with all applicable Australian laws and regulations. By submitting an application for the shares of common stock, you represent and warrant to us that you are an Exempt Investor. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As any offer of shares of common stock under this document will be made without disclosure in Australia under Chapter 6D.2 of the Corporations Act, the offer of those
securities for resale in Australia within 12 months may, under section 707 of the Corporations Act, require disclosure to investors under Chapter&nbsp;6D.2 if none of the exemptions in section 708 applies to that resale. By applying for the shares
of common stock you undertake to us that you will not, for a period of 12 months from the date of issue of the shares of common stock, offer, transfer, assign or otherwise alienate those shares of common stock to investors in Australia except in
circumstances where disclosure to investors is not required under Chapter 6D.2 of the Corporations Act or where a compliant disclosure document is prepared and lodged with ASIC. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to Prospective Investors in China </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This prospectus will not be
circulated or distributed in the PRC and the shares of common stock will not be offered or sold, and will not be offered or sold to any person for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale directly or indirectly to any residents
of the PRC except pursuant to any applicable laws and regulations of the PRC. Neither this prospectus nor any advertisement or other offering material may be distributed or published in the PRC, except under circumstances that will result in
compliance with applicable laws and regulations. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to Prospective Investors in Korea </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares of common stock have not been and will not be registered under the Financial Investments Services and Capital Markets Act of Korea and the decrees and
regulations thereunder (&#147;FSCMA&#148;), and the shares of common stock have been and will be offered in Korea as a private placement under the FSCMA. None of the shares of common stock may be offered, sold or delivered directly or indirectly, or
offered or sold to any person for re-offering or resale, directly or indirectly, in Korea or to any resident of Korea except pursuant to the applicable laws and regulations of Korea, including the FSCMA and the Foreign Exchange Transaction Law of
Korea and the decrees and regulations thereunder (&#147;FETL&#148;). Furthermore, the purchaser of the shares of common stock shall comply with all applicable regulatory requirements (including but not limited to requirements under the FETL) in
connection with the purchase of the shares of common stock. By the purchase of the shares of common stock, the relevant holder thereof will be deemed to represent and warrant that if it is in Korea or is a resident of Korea, it purchased the shares
of common stock pursuant to the applicable laws and regulations of Korea. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to Prospective Investors in Saudi Arabia </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This document may not be distributed in the Kingdom of Saudi Arabia except to such persons as are permitted under the Offers of Securities Regulations as issued by the
board of the Saudi Arabian Capital Market Authority (&#147;CMA&#148;), pursuant to resolution number <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2-11-2004</FONT></FONT> dated 4&nbsp;October 2004 as amended by resolution number <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-28-2008,</FONT></FONT> as amended (the &#147;CMA Regulations&#148;). The CMA does not make any representation as to the accuracy or completeness of this document and expressly disclaims
any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this document. Prospective purchasers of the shares of common stock offered hereby should conduct their own due diligence on the accuracy of the
information relating to the securities. If you do not understand the contents of this document, you should consult an authorized financial adviser. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">267 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to Prospective Investors in the Dubai International Financial Centre (&#147;DIFC&#148;) </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This document relates to an Exempt Offer in accordance with the Markets Rules 2012 of the Dubai Financial Services Authority (&#147;DFSA&#148;). This document is
intended for distribution only to persons of a type specified in the Markets Rules 2012 of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no responsibility for reviewing or verifying any documents in
connection with Exempt Offers. The DFSA has not approved this prospectus supplement nor taken steps to verify the information set forth herein and has no responsibility for this document. The shares of common stock to which this document relates may
be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the shares of common stock offered should conduct their own due diligence on the securities. If you do not understand the contents of this document, you should
consult an authorized financial advisor. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In relation to its use in the DIFC, this document is strictly private and confidential and is being distributed to a
limited number of investors and must not be provided to any person other than the original recipient, and may not be reproduced or used for any other purpose. The interests in the securities may not be offered or sold directly or indirectly to the
public in the DIFC. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to Prospective Investors in Bermuda </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Shares
of common stock may be offered or sold in Bermuda only in compliance with the provisions of the Investment Business Act of 2003 of Bermuda which regulates the sale of securities in Bermuda. Additionally,
<FONT STYLE="white-space:nowrap">non-Bermudian</FONT> persons (including companies) may not carry on or engage in any trade or business in Bermuda unless such persons are permitted to do so under applicable Bermuda legislation. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to prospective investors in the British Virgin Islands </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares of
common stock are not being and may not be offered to the public or to any person in the British Virgin Islands for purchase or subscription by or on behalf of us. The shares of common stock may be offered to companies incorporated under the BVI
Business Companies Act, 2004 (British Virgin Islands) (BVI Companies), but only where the offer will be made to, and received by, the relevant BVI Company entirely outside of the British Virgin Islands. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to prospective investors in Taiwan </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares of common stock have
not been and will not be registered with the Financial Supervisory Commission of Taiwan pursuant to relevant securities laws and regulations and may not be sold, issued or offered within Taiwan through a public offering or in circumstances which
constitutes an offer within the meaning of the Securities and Exchange Act of Taiwan that requires a registration or approval of the Financial Supervisory Commission of Taiwan. No person or entity in Taiwan has been authorized to offer, sell, give
advice regarding or otherwise intermediate the offering and sale of the shares of common stock in Taiwan. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to prospective investors in South Africa
</B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Due to restrictions under the securities laws of South Africa, no &#147;offer to the public&#148; (as such term is defined in the South African Companies Act,
No.&nbsp;71 of 2008 (as amended or <FONT STYLE="white-space:nowrap">re-enacted)</FONT> (the South African Companies Act), is being made in connection with the issue of the shares of common stock in South Africa. Accordingly, this document does not,
nor is it intended to, constitute a &#147;registered prospectus&#148; (as that term is defined in the South African Companies Act) prepared and registered under the South African Companies Act and has not been approved by, and/or filed with, the
South African Companies and Intellectual Property Commission or any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">268 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
other regulatory authority in South Africa. The shares of common stock are not offered, and the offer shall not be transferred, sold, renounced or delivered, in South Africa or to a person with
an address in South Africa, unless one or other of the following exemptions stipulated in section 96 (1) applies: </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:arial">Section&nbsp;96
(1) (a) the offer, transfer, sale, renunciation or delivery is to: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(i)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons whose ordinary business, or part of whose ordinary business, is to deal in securities, as principal or agent; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the South African Public Investment Corporation; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons or entities regulated by the Reserve Bank of South Africa; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">authorized financial service providers under South African law; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(v)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">financial institutions recognized as such under South African law; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a wholly-owned subsidiary of any person or entity contemplated in (iii), (iv) or (v), acting as agent in the capacity of an authorized portfolio manager for a pension fund, or as manager for a collective investment
scheme (in each case duly registered as such under South African law); or </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any combination of the person in (i)&nbsp;to (vi); or </TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Section&nbsp;96 (1) (b) the total contemplated acquisition cost of
the shares of common stock, for any single addressee acting as principal is equal to or greater than ZAR1,000,000 or such higher amount as may be promulgated by notice in the Government Gazette of South Africa pursuant to section 96(2)(a) of the
South African Companies Act. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Information made available in this prospectus should not be considered as &#147;advice&#148; as defined in the South African Financial
Advisory and Intermediary Services Act, 2002. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to prospective investors in Malaysia </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">No prospectus or other offering material or document in connection with the offer and sale of the shares of common stock has been or will be registered with the
Securities Commission of Malaysia (&#147;Commission&#148;), for the Commission&#146;s approval pursuant to the Capital Markets and Services Act 2007. Accordingly, this prospectus and any other document or material in connection with the offer or
sale, or invitation for subscription or purchase, of the shares of common stock may not be circulated or distributed, nor may the shares of common stock be offered or sold, or be made the subject of an invitation for subscription or purchase,
whether directly or indirectly, to persons in Malaysia other than (i)&nbsp;a closed end fund approved by the Commission; (ii)&nbsp;a holder of a Capital Markets Services License; (iii)&nbsp;a person who acquires the shares of common stock, as
principal, if the offer is on terms that the shares of common stock may only be acquired at a consideration of not less than RM250,000 (or its equivalent in foreign currencies) for each transaction; (iv)&nbsp;an individual whose total net personal
assets or total net joint assets with his or her spouse exceeds RM3&nbsp;million (or its equivalent in foreign currencies), excluding the value of the primary residence of the individual; (v)&nbsp;an individual who has a gross annual income
exceeding RM300,000 (or its equivalent in foreign currencies) per annum in the preceding twelve months; (vi)&nbsp;an individual who, jointly with his or her spouse, has a gross annual income of RM400,000 (or its equivalent in foreign currencies),
per annum in the preceding twelve months; (vii)&nbsp;a corporation with total net assets exceeding RM10&nbsp;million (or its equivalent in a foreign currencies) based on the last audited accounts; (viii)&nbsp;a partnership with total net assets
exceeding RM10&nbsp;million (or its equivalent in foreign currencies); (ix) a bank licensee or insurance licensee as defined in the Labuan Financial Services and Securities Act 2010; (x) an Islamic bank licensee or takaful licensee as defined in the
Labuan Financial Services and Securities Act 2010; and (xi)&nbsp;any other person as may be specified by the Commission; provided that, in the each of the preceding categories (i)&nbsp;to (xi), the distribution of the shares of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">269 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
common stock is made by a holder of a Capital Markets Services License who carries on the business of dealing in securities. The distribution in Malaysia of this prospectus is subject to
Malaysian laws. This prospectus does not constitute and may not be used for the purpose of public offering or an issue, offer for subscription or purchase, invitation to subscribe for or purchase any securities requiring the registration of a
prospectus with the Commission under the Capital Markets and Services Act 2007. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to prospective investors in Qatar </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares of common stock described in this prospectus have not been, and will not be, offered, sold or delivered, at any time, directly or indirectly in the State of
Qatar in a manner that would constitute a public offering. This prospectus has not been, and will not be, registered with or approved by the Qatar Financial Markets Authority or Qatar Central Bank and may not be publicly distributed. This prospectus
is intended for the original recipient only and must not be provided to any other person. It is not for general circulation in the State of Qatar and may not be reproduced or used for any other purpose. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">270 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc425213_22"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The validity of the shares of common stock offered by this prospectus will be passed upon for us by Goodwin Procter LLP, Boston, Massachusetts. Certain legal matters
relating to this offering will be passed upon for the underwriters by Davis Polk&nbsp;&amp; Wardwell LLP, New York, New York. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc425213_23"></A>EXPERTS
</B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The financial statements as of December 31, 2022 and 2021 and for the years then ended included in this Prospectus have been so included in reliance on the
report of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In connection with their engagement, PricewaterhouseCoopers LLP (&#147;PwC&#148;) notified us that a business relationship existed between a PwC member firm and a
beneficial owner that has significant influence (&#147;BOSI&#148;) over the Company, whereby the BOSI participated in an online platform operated and maintained by the PwC member firm and had access to dedicated space at the PwC member firm&#146;s
physical location in which the BOSI and other business partners and innovators participated on such platform and/or within the physical location to exchange experiences and ideas, search for technologies, pose challenges to others to provide
proposed solutions, make direct contacts and to meet virtually or in person. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The existence of this business relationship identified is inconsistent with SEC and
PCAOB auditor independence rules provided in Rule 2-01 of Regulation S-X. The matter was resolved on June 7, 2023, upon the termination of the business relationship between the BOSI and the PwC member firm. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">PwC provided an overview of the facts and circumstances surrounding the business relationship to our audit committee and management, including that the entity involved
was a BOSI and not an affiliate of the Company, and other relevant facts. The PwC audit engagement team members did not participate in the PwC member firm&#146;s activities and engagements with the BOSI or any entity that is part of the PwC member
firm&#146;s business relationship with the BOSI, and the business relationship was not quantitatively or qualitatively material to the PwC member firm or the BOSI. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Considering the facts presented, our audit committee and PwC have concluded that the business relationship would not impair PwC&#146;s application of objective and
impartial judgment on any matters encompassed within the audit engagement performed by PwC for our consolidated financial statements as of and for the fiscal years ended December 31, 2022 and 2021, and the review for the interim periods for the six
months ended June 30, 2023 and 2022, and that a reasonable investor with knowledge of all relevant facts and circumstances would conclude that PwC is capable of remaining objective and impartial with respect to the audit and reviews of the
Company&#146;s consolidated financial statements. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc425213_23a"></A>CHANGES IN INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On September 24, 2021, KPMG, LLP (&#147;KPMG&#148;) was engaged as the independent registered public accounting firm&nbsp;to audit our consolidated financial statements
for the fiscal year ended December 31, 2020 in accordance with auditing standards generally accepted in the United States. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">During the two fiscal years ended
December&nbsp;31, 2020 and 2019 and the subsequent interim period through September&nbsp;24, 2021 we did not consult with KPMG on (i) matters that involved the application of accounting principles to a specified transaction either completed or
proposed, or the type of audit opinion that might be rendered on our consolidated financial statements, and neither a written report nor oral advice was provided to us that KPMG concluded was an important factor considered by us in reaching a
decision as to any accounting, auditing or financial reporting issue, or (ii) any matter that was either the subject of a &#147;disagreement&#148; or a &#147;reportable event&#148; (as defined in Item 304(a)(1)(iv) and Item 304(a)(1)(v) of
Regulation&nbsp;S-K and the related instructions, respectively). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">271 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On April&nbsp;28, 2022, our audit committee dismissed KPMG as our independent registered public accounting firm.</P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">KPMG has never issued an audit report on our consolidated financial statements. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">During the two fiscal years ended December 31, 2021 and 2020, and the subsequent period through April 28, 2022, (1) there were no disagreements (as that term is used in
Item&nbsp;304(a)(1)(iv) of Regulation S-K and the related instructions) between us and KPMG on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to
the satisfaction of KPMG, would have caused KPMG to make reference thereto in a report on our financial statements for the year ended December 31, 2020 if a report were to be issued, and (2) there were no &#147;reportable events&#148; as such term
is defined in Item 304(a)(1)(v) of Regulation S-K.</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have provided KPMG with a copy of the disclosures set forth under the heading &#147;Changes in Independent
Registered Public Accounting Firm&#148; and have requested that KPMG furnish a letter addressed to the SEC stating whether or not KPMG agrees with such statements. A copy of the letter is filed as&nbsp;Exhibit 16.1&nbsp;to the registration statement
of which this prospectus forms a part.</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On April 28, 2022, PwC was approved as the independent registered public accounting firm for the fiscal year ended December
31, 2021.</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">During the two most recent fiscal years ended December 31, 2021 and the subsequent interim period through April 28, 2022 we did not consult with PwC on (i)
matters that involved the application of accounting principles to a specified transaction either completed or proposed, or the type of audit opinion that might be rendered on our consolidated financial statements, and neither a written report nor
oral advice was provided to us that PwC concluded was an important factor considered by us in reaching a decision as to any accounting, auditing or financial reporting issue, or (ii) any matter that was either the subject of a
&#147;disagreement&#148; or a &#147;reportable event&#148; (as defined in Item 304(a)(1)(iv) and Item 304(a)(1)(v) of Regulation S-K and the related instructions, respectively). </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc425213_24"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have filed
with the SEC a registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> (File Number <FONT STYLE="white-space:nowrap">333-</FONT>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) under the Securities Act with respect to the common stock we are offering by this prospectus. This prospectus, which constitutes part of the
registration statement, does not contain all of the information included in the registration statement. For further information pertaining to us and our common stock, you should refer to the registration statement and to its exhibits. Whenever we
make reference in this prospectus to any of our contracts, agreements or other documents, the references are not necessarily complete, and you should refer to the exhibits attached to the registration statement for copies of the actual contract,
agreement or other document. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon the completion of the offering, we will be subject to the informational requirements of the Exchange Act and will file annual,
quarterly and current reports, proxy statements and other information with the SEC. You can read our SEC filings, including the registration statement, at the SEC&#146;s website at www.sec.gov. We also maintain a website at https://www.metagenomi.co
and upon completion of the offering, you may access, free of charge, our annual reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> quarterly reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> current reports on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> and any amendments to those reports, as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC. The information contained in, or that can be accessed through,
our website is not part of, and is not incorporated into, this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">272 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="index"></A><A NAME="toc425213_25"></A>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Index to Consolidated Financial Statements as of December 2021 and 2022 and for the years ended December&nbsp;31, 2021 and 2022: </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="96%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#fin425213_1">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#fin425213_2">Consolidated Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#fin425213_3">Consolidated Statements of Operations and Comprehensive Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#fin425213_4">Consolidated Statements of Redeemable Convertible Preferred Units and Members&#146; Deficit
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#fin425213_5">Consolidated Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#fin425213_6">Notes to the Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Index to Unaudited Condensed Consolidated Financial Statements as of June 30, 2023 and for the six months ended June 30, 2022
and 2023: </B></P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#fin425213_7">Condensed Consolidated Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#fin425213_8">Condensed Consolidated Statements of Operations and Comprehensive Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#fin425213_9">Condensed Consolidated Statements of Redeemable Convertible Preferred Units and Members&#146;
 Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#fin425213_10">Condensed Consolidated Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#fin425213_11">Notes to the Unaudited Condensed Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="fin425213_1"></A>Report of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To the Board of Managers and Members of Metagenomi Technologies, LLC </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Opinion on
the Financial Statements </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have audited the accompanying consolidated balance sheets of Metagenomi Technologies, LLC and its subsidiary (the
&#147;Company&#148;) as of December&nbsp;31, 2022 and 2021, and the related consolidated statements of operations and comprehensive loss, of redeemable convertible preferred units and members&#146; deficit, and of cash flows for the years then
ended, including the related notes (collectively referred to as the &#147;consolidated financial statements&#148;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company
as of December&nbsp;31, 2022 and 2021, and the results of its operations and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Basis for Opinion </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">These consolidated financial statements are the
responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting
Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the
PCAOB. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB and in accordance with auditing standards
generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error
or fraud. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or
fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the
accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">/s/ PricewaterhouseCoopers LLP </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">San Jose, California </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">August&nbsp;3, 2023 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have served as the Company&#146;s auditor since 2022. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="fin425213_2"></A>Consolidated Balance Sheets </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>(in thousands, except units) </B></P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 39,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;184,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Available-for-sale</FONT></FONT>
marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">177,690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Contract assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">762</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108,916</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">366,899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Long-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating lease <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT>
assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">141,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 414,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Liabilities, redeemable convertible preferred units and members&#146; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1,354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 2,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Income tax payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Current portion of operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Collaboration advance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,559</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,041</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Convertible promissory note and accrued interest, net of discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><FONT STYLE="white-space:nowrap">Non-current</FONT> portion of operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,965</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Collaboration advance, <FONT STYLE="white-space:nowrap">non-current</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Deferred revenue, <FONT STYLE="white-space:nowrap">non-current</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98,041</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">142,811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Commitments and contingencies (Note 10)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Redeemable convertible preferred units: 19,650,632 and 41,813,375 units authorized as of December&nbsp;31,
2021 and 2022, respectively; 19,650,632 and 41,478,621 units issued and outstanding as of December&nbsp;31, 2021 and 2022, respectively. Liquidation preference $76,669 and $347,335 as of December&nbsp;31, 2021 and 2022, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">346,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Members&#146; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Common units: 32,000,000 and 66,000,000 units authorized as of December&nbsp;31, 2021 and 2022,
respectively; 5,947,500 units issued and outstanding as of December&nbsp;31, 2021 and 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Profits interests: 6,020,644 and 14,604,165 units authorized as of December&nbsp;31, 2021 and 2022,
respectively; 5,783,758 and 7,516,073 units issued and outstanding as of December&nbsp;31, 2021 and 2022, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">547</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accumulated other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(274</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33,096</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(76,689</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total members&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,544</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(74,428</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total liabilities, redeemable convertible preferred units and members&#146;
deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">141,992</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right"> 414,486</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="fin425213_3"></A>Consolidated Statements of Operations and Comprehensive Loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>(in thousands, except units and per unit data) </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Years ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 17,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,701</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,947</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(44,640</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(302</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(98</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Change in fair value of long-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total other income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,505</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,616</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss before provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,442</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(41,024</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,569</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> (21,442</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> (43,593</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other comprehensive loss:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Unrealized loss on
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(253</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> (21,463</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> (43,846</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss per unit attributable to common unitholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> (3.77</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> (7.34</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Weighted average common units outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">5,691,431</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">5,938,654</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:200pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="fin425213_4"></A>Consolidated Statements of Redeemable Convertible Preferred Units and Members&#146;
Deficit </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>(in thousands, except units) </B></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Redeemable<BR>Convertible Preferred<BR>Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Common Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Profits Interests</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000;border-bottom:1.00px solid #000000"><B>Accumulated<BR>Other<BR>Comprehensive</B><br><B>Loss</B></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000;border-bottom:1.00px solid #000000"><B>Accumulated</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000;border-bottom:1.00px solid #000000"><B>Total<BR>Members&#146;</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Units</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Units</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Units</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial"><B>BALANCE&#151;January 1, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,069,695</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">66,547</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,947,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,302,239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,654</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,456</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Issuance of Series A-5 redeemable convertible preferred units, net of issuance costs of $52</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,580,937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,948</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Issuance of profits interests</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,550,854</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Cancellation and forfeiture of profits interests</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(69,335</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Unit-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,442</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,442</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="25" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial"><B>BALANCE&#151;December 31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,650,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">76,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,947,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,783,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">547</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(21</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(33,096</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(32,544</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="25" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Issuance of Series B redeemable convertible preferred units for cash, net of</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">issuance costs of $697</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,446,876</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Issuance of Series B redeemable convertible preferred units upon conversion of convertible note and accrued
interest</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,607,387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Issuance of Series B-1 redeemable convertible preferred units, net of issuance costs of $361</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,773,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Issuance of profits interests</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,763,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Cancellation and forfeiture of profits interests</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,031,041</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Unit-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(253</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(253</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43,593</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43,593</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="25" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial"><B>BALANCE&#151;December 31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">41,478,621</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">346,103</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">5,947,500</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">7,516,073</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2,509</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(274</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(76,689</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(74,428</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="25" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="25" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="fin425213_5"></A>Consolidated Statements of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>(in thousands) </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Years&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Cash flows from operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(21,442</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(43,593</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Adjustments to reconcile net loss to net cash provided by operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Unit-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Loss on fixed assets <FONT STYLE="white-space:nowrap">write-off</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><FONT STYLE="white-space:nowrap">Non-cash</FONT> lease expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Amortization of premiums and discounts on
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,129</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Amortization of <FONT STYLE="white-space:nowrap">non-cash</FONT> collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(314</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><FONT STYLE="white-space:nowrap">Non-cash</FONT> interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">302</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Change in fair value of long-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,760</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(94</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(502</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,465</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Contract assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,274</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(173</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">695</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">721</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Income tax payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Deferred revenue and collaboration advance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;44,228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;65,661</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,854</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(88</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(81</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net cash provided by operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,724</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Cash flows from investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,903</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,977</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Purchases of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(69,258</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(214,850</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Purchases of long-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,155</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Maturities and sales of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106,627</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(74,316</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(122,200</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Cash flows from financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Proceeds from issuance of redeemable convertible preferred units, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,948</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">239,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Proceeds from issuance of convertible promissory note, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">239,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net change in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,137</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">147,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cash, cash equivalents and restricted cash at the beginning of the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cash, cash equivalents and restricted cash at the end of the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 43,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 190,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Reconciliation of cash, cash equivalents and restricted cash</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 39,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 184,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cash, cash equivalents and restricted cash at the end of the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right"> 43,396</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right"> 190,514</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Consolidated Statements of Cash Flows</B>&nbsp;(Continued)<B> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>(in thousands) </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Years ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Supplemental cash flow information</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Issuance of Series B redeemable convertible preferred units upon conversion of convertible promissory note
and accrued interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;30,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Common shares of <FONT STYLE="white-space:nowrap">Affini-T</FONT> received for collaboration
revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1,295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating lease <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT>
assets obtained in exchange for new lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;18,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><FONT STYLE="white-space:nowrap">Non-cash</FONT> expense related to a lease modification</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 2,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Deferred finance issuance costs included in other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Unpaid finance issuance costs included in accounts payable and accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Purchases of property and equipment included in
accounts payable and accrued expenses</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #000000" ALIGN="right"> 725</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #000000" ALIGN="right"> 1,247</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:400pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="fin425213_6"></A>Notes to the consolidated financial statements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>1. Description of business, organization and liquidity </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Organization
and business </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Metagenomi Technologies, LLC (&#147;Metagenomi&#148;), together with its wholly owned subsidiary Metagenomi, Inc. (&#147;Metagenomi Inc.&#148;)
(together, the &#147;Company&#148;) is a gene editing biotechnology company developing &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; therapeutics by leveraging a toolbox of next-generation gene
editing systems to accurately edit DNA. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Formation and group reorganizations </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Metagenomi.co was incorporated in September 2016 in the State of Delaware and is headquartered in Emeryville, California. In September 2018, Metagenomi.co formed a
subsidiary, Metagenomi Technologies, LLC, as its sole member. In November 2018, the two companies completed a reorganization where Metagenomi Technologies, LLC became the parent of Metagemoni.co. The reorganization was a transaction of entities
under common control and did not change the group. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In December 2018, Metagenomi formed another wholly owned subsidiary, Metagenomi IP Technologies, LLC. Metagenomi
IP Technologies, LLC did not have any operations except for the initial transfer of IP from Metagenomi.co and an ongoing license of its technology to Metagenomi.co. Key activities of Metagenomi were raising capital to support operations of
Metagenomi.co. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In April 2020, Metagenomi.co changed its name to Metagenomi, Inc. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In December 2021, the group completed another <FONT STYLE="white-space:nowrap">tax-free</FONT> reorganization, whereby Metagenomi IP Technologies, LLC merged with and
into Metagenomi, Inc. As of December&nbsp;31, 2022, the group consisted of two entities: Metagenomi Technologies, LLC and its subsidiary, Metagenomi Inc. Both 2018 and 2021 reorganizations were accounted as transactions under common control at
historical carrying values. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Liquidity and going concern </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The
Company has incurred significant losses from operations since its inception. During the years ended December&nbsp;31, 2021 and 2022, the Company incurred net losses of $21.4&nbsp;million and $43.6&nbsp;million, respectively. As of December&nbsp;31,
2022, the Company had an accumulated deficit of $76.7&nbsp;million. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company has historically financed its operations primarily through issuance of redeemable
convertible preferred units, convertible promissory notes and its collaboration agreements with Moderna, Affini-T and Ionis (see Note 7). The Company expects to continue to incur substantial losses, and its ability to achieve and sustain
profitability will depend on the successful development, approval, and commercialization of any product candidates it may develop, and on the achievement of sufficient revenue to support its cost structure. The Company may never achieve
profitability and, unless and until it does, it will need to continue to raise additional capital. Management expects that existing cash and cash equivalents and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities of $362.1&nbsp;million as of December&nbsp;31, 2022, will be sufficient to fund its current operating plan for at least the next
12 months from the date of issuance of these consolidated financial statements. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>2. Summary of significant accounting policies </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Basis of presentation </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">These consolidated financial statements have
been prepared in accordance with accounting principles generally accepted in the United States of America (&#147;U.S. GAAP&#148;). The accompanying consolidated financial statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
include the accounts of Metagenomi and Metagenomi Inc., a wholly owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#147;ASC&#148;) and
Accounting Standards Updates (&#147;ASU&#148;) of the Financial Accounting Standards Board (&#147;FASB&#148;). </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Use of estimates </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and
liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. On an ongoing basis, the Company evaluates estimates and assumptions,
including but not limited to those related to revenue recognition under its collaboration agreements, the fair value of its common and redeemable convertible preferred units, the fair value of derivative liabilities, unit-based compensation expense,
accruals for research and development expenses, the fair value of long-term investments and convertible promissory notes in private companies, the valuation of deferred tax assets, and uncertain income tax positions. Management bases its estimates
on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily
apparent from other sources. Actual results may differ materially from those estimates. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Segment and geographical information </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company operates and manages its business as one reportable and operating segment, which is the business of developing next generation gene-editing technologies and
therapies. The chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. All of the Company&#146;s long-lived
assets are located in the United States. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Risks and uncertainties </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company is subject to certain risks and uncertainties, including, but not limited to, changes in any of the following areas that the Company believes could have a
material adverse effect on the future financial position or results of operations: the Company&#146;s ability to advance the development of its next generation gene-editing platform, timing and ability to advance any product candidates it may
develop into and through <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical development; costs and timelines associated with the manufacturing of clinical supplies of any product candidates the Company may develop; regulatory
approval, market acceptance of, and reimbursement for any product candidates the Company may develop; performance of third-party vendors; competition from pharmaceutical or other gene-editing companies with greater financial resources or expertise;
protection of intellectual property; litigation or claims against the Company based on intellectual property or other factors; and its ability to attract and retain employees necessary to support its growth. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company&#146;s business and operations may be affected by worldwide economic conditions, which may continue to be impacted by global macroeconomic challenges such as
the effects of the ongoing geopolitical conflicts in Ukraine, tensions in U.S.-China relations, the COVID-19 pandemic, uncertainty in the markets, including disruptions in the banking industry, and inflationary trends. Fiscal year 2022 was marked by
significant market uncertainty, increasing inflationary pressures. These market dynamics may continue into 2023 and these and similar adverse market conditions may negatively impact the Company&#146;s operations and financial position. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Cash and cash equivalents </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Cash equivalents are defined as short-term, highly liquid investments with original maturities of 90 days or less at the date of purchase. As of December&nbsp;31, 2021
and 2022, the Company&#146;s cash and cash equivalents consisted of deposit accounts and investments in money market funds. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Marketable securities
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Investments with original maturities of greater than 90 days are classified as
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities on the consolidated balance sheets and consist primarily of U.S. Treasury, corporate debt obligations, commercial paper,
government agency obligations and asset-backed securities. As&nbsp;the Company&#146;s entire investment portfolio is considered available for use in current operations, the Company classifies all investments as <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">available-for-sale</FONT></FONT> and as current assets, even though the stated maturity may be more than one year from the current consolidated balance sheets date. <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Available-for-sale</FONT></FONT> securities are carried at fair value, with unrealized gains and losses reported in accumulated other comprehensive loss, which is a separate component of members&#146; deficit in the
consolidated balance sheets. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The amortized cost of securities is adjusted for amortization of premiums and accretion of discounts to maturity, which are both
recorded to interest income in the consolidated statements of operations and comprehensive loss. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Changes in the fair value of <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">available-for-sale</FONT></FONT> securities are reflected within unrealized loss on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities, net in the
consolidated statements of operations and comprehensive loss. Realized gains and losses on the sale of securities are determined by specific identification of each security&#146;s cost basis. The Company regularly reviews its investment portfolio to
determine if any security is impaired, which would require it to record an allowance for credit losses or an impairment charge in the period any such determination is made. In making this judgment, the Company evaluates, among other things, the
extent to which the fair value of a security is less than its amortized cost, its intent to sell or whether it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis, the financial
condition of the issuer and any changes thereto, and, as necessary, the portion of a decline in fair value that is credit-related. This assessment could change in the future due to new developments or changes in assumptions related to any particular
security. Realized gains and losses, allowances for credit losses and impairments on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> securities, if any, are recorded to interest expense, net in the
consolidated statements of operations and comprehensive loss.</P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Long-term investments </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company determines at the inception of each arrangement whether an investment or other interest is considered a variable interest entity (&#147;VIE&#148;). If the
investment or other interest is determined to be a VIE, the Company evaluates whether it is considered the primary beneficiary. The primary beneficiary of a VIE is the party that meets both of the following criteria: (i)&nbsp;has the power to direct
the activities that most significantly impact the VIE&#146;s economic performance; and (ii)&nbsp;has the obligation to absorb losses or the right to receive benefits from the VIE. For investments in VIEs in which the Company is considered the
primary beneficiary, the assets, liabilities and results of operations of the VIE are included in the Company&#146;s consolidated financial statements. As of December&nbsp;31, 2021 and 2022, there were&nbsp;no&nbsp;VIEs for which the Company was the
primary beneficiary. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If the Company concludes that it exercises significant influence over an investees&#146; operations, it may account for its investment either
using the equity method of accounting or fair value method. The election to account for an investment at fair value is irrevocable unless an event occurs creating a new election date. If the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
Company does not have a significant influence, it accounts for its investment at fair value and may elect to account for an equity security without a readily determinable fair value using the
measurement alternative method. The measurement alternative method allows the Company to measure the equity investment at its cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for
the identical or a similar investment of the same issuer. Changes in fair value and impairment losses are recognized as other income (expenses) in the consolidated statements of operations and comprehensive loss. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Restricted cash </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Restricted cash of $4.1&nbsp;million and
$6.1&nbsp;million as of December&nbsp;31, 2021 and 2022, respectively, represents security deposits in the form of a letter of credit issued in connection with the Company&#146;s leases (see Note 10). </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Concentration of credit risk </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Cash and cash equivalents, marketable
securities and investments in convertible promissory notes are financial instruments that potentially subject the Company to concentrations of credit risk. As of December&nbsp;31, 2021 and 2022, cash consists of cash deposited with one financial
institution, Silicon Valley Bank (&#147;SVB&#148;), and account balances exceed federally insured limits. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On March&nbsp;10, 2023, SVB was closed by the California
Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation (&#147;FDIC&#148;) as receiver. On March&nbsp;12, 2023 the FDIC transferred all deposits, both insured and uninsured, and substantially all
assets from the former SVB to a newly created, full-service FDIC-operated &#147;bridge bank&#148;, Silicon Valley Bridge Bank, N.A. (&#147;SVBB&#148;) and the FDIC, Treasury Department, and Federal Reserve announced that all deposits will be fully
protected, whether or not they had been insured by the FDIC. On March&nbsp;27, 2023, First-Citizens Bank&nbsp;&amp; Trust Company assumed all of SVBB&#146;s customer deposits and certain other liabilities and acquired substantially all of
SVBB&#146;s loans and certain other assets from the FDIC. As of the date of the issuance of these consolidated financial statements, the Company has full access to and control over all its cash, cash equivalents and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company also has investments in money market funds, U.S. Treasuries,
corporate debt obligations, commercial paper, government agency obligations and asset-backed securities, which can be subject to certain credit risks. The Company mitigates the risks by investing in high-grade instruments, limiting its exposure to
any one issuer and monitoring the ongoing creditworthiness of the financial institutions and issuers. The Company has not experienced any losses on its financial instruments. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Concentration of collaboration revenue and contract assets </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The
following table summarizes the percentages of collaboration revenues and of contract assets from each of the Company&#146;s customers that individually accounted for 10% or more of its collaboration revenues: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Collaboration&nbsp;revenue</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Contract&nbsp;assets</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Customer A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Customer B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company reviews its contract assets for impairment. No&nbsp;contract asset impairment was recorded as of
December&nbsp;31, 2022. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Fair value measurements </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Fair value is
defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The carrying amounts of cash equivalents, prepaid expenses and other current
assets, accounts payable, accrued expenses and other liabilities, approximate fair value due to their short-term maturities. Financial instruments, such as money market funds, marketable securities and certain equity and long-term investments are
measured at fair value at each reporting date (see Note 3). </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Deferred finance issuance costs </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Deferred finance issuance&nbsp;costs, consisting of legal fees relating <FONT STYLE="white-space:nowrap">to&nbsp;in-process&nbsp;equity</FONT> financings or offerings
are capitalized. The&nbsp;deferred finance issuance&nbsp;costs will be offset against&nbsp;offering&nbsp;proceeds upon the completion of the&nbsp;financing or the offering. In the event the&nbsp;financing or the offering&nbsp;is terminated or
delayed,&nbsp;deferred finance issuance&nbsp;costs will be expensed immediately as a charge to general and administrative expenses in the consolidated statements of operations and comprehensive loss. As of December&nbsp;31, 2021, the Company
capitalized and recorded $0.1&nbsp;million in issuance costs related to its Series B preferred unit financing in other assets in the consolidated balance sheets, which closed in January 2022. There were no deferred finance issuance costs as of
December&nbsp;31, 2022. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Property and equipment, net </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Property and
equipment are recorded at cost, less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally three to five years, and leasehold improvements are
amortized over the shorter of the lease term or the estimated useful life of the asset. Repairs and maintenance expenditures, which are not considered improvements and do not extend the useful life of property and equipment, are expensed as
incurred. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation and amortization are removed from the consolidated balance sheets and the resulting gain or loss is reflected in the consolidated statements of
operations and comprehensive loss in the period realized. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Leases </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company determines whether an arrangement is or contains a lease at the inception of the arrangement and whether such a lease should be classified as a financing
lease or operating lease at the commencement date of the lease. Leases with a term greater than one year are recognized on the consolidated balance sheets as operating
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset (&#147;ROU asset&#148;) and operating lease liabilities. We elected not to recognize the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and lease liabilities for leases with lease terms of one year or less (short-term leases). Lease liabilities and their corresponding ROU assets are recorded based on the present value of
lease payments over the lease term. The Company considers the lease term to be the noncancelable period that it has the right to use the underlying asset, together with any periods where it is reasonably certain it will exercise an option to extend
(or not terminate) the lease. As the interest rate implicit in the Company&#146;s lease contracts is not readily determinable, the Company utilizes its incremental borrowing rate (&#147;IBR&#148;) based on the information available at the
commencement date to determine the present value of lease payments. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Rent expense for operating leases is recognized on a straight-line basis over the lease term.
The Company has elected to not separate lease and <FONT STYLE="white-space:nowrap">non-lease</FONT> components for its real estate leases and instead accounts for each </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
separate lease component and the <FONT STYLE="white-space:nowrap">non-lease</FONT> components associated with that lease component as a single lease component. Variable lease payments are
recognized as incurred. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of December&nbsp;31, 2021 and 2022, the Company had no finance leases. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Impairment of long-lived assets </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company reviews long-lived assets
for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparing the carrying amount to the future undiscounted net cash flows which the assets
are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows generated by the
assets. There have been no such impairments of long-lived assets in the years ended December&nbsp;31, 2021 and 2022. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Redeemable convertible preferred units
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company records redeemable convertible preferred units at their respective fair values on the dates of issuance, net of issuance costs. The redeemable
convertible preferred units are recorded outside of permanent equity because while it is not mandatory, redemption is contingent upon the occurrence of certain events considered not solely within the Company&#146;s control. The Company has not
adjusted the carrying values of the redeemable convertible preferred units to the liquidation preferences of such units because it is uncertain whether or when a deemed liquidation event would occur that would obligate the Company to pay the
liquidation preferences to holders of redeemable convertible preferred units. Subsequent adjustments to the carrying values to the liquidation preferences will be made only when it becomes probable that such a deemed liquidation event will occur.
</P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Collaboration arrangements and revenue recognition </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">At the
inception of an agreement, the Company evaluates if an agreement is a collaborative arrangement within the scope of ASC 808, <I>Collaborative Arrangements</I> (&#147;ASC 808&#148;). For collaborative arrangements that fall within the scope of ASC
808, the Company first determines which elements of the collaboration are deemed to be a performance obligation with a customer within the scope of ASC Topic 606, <I>Revenue from Contracts with Customers</I> (&#147;ASC 606&#148;). For elements of
collaboration arrangements that are accounted for pursuant to ASC 808 and are not subject to the guidance in ASC 606, the Company applies the revenue recognition model under ASC 606 or other guidance, as deemed appropriate. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company <FONT STYLE="white-space:nowrap">re-evaluates</FONT> whether the license agreement continues to be a collaborative arrangement, or whether the license
agreement becomes a collaborative arrangement, whenever there is a change in either the roles of the participants in the arrangement or the participants&#146; exposure to significant risks and rewards dependent on the ultimate commercial success of
the endeavor. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Under ASC 606, the Company recognizes revenue when the Company&#146;s customer obtains control of promised goods or services, in an amount that
reflects the consideration which the Company expects to receive in exchange for those goods and services. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: (i)&nbsp;identify
the contract(s) with a customer; (ii)&nbsp;identify the performance obligations in the contract; (iii)&nbsp;determine the transaction price, including the constraint on variable consideration; (iv)&nbsp;allocate the transaction price to the
performance obligations in the contract; and (v)&nbsp;recognize revenue when or as the Company satisfies a performance obligation. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company&#146;s revenue is
primarily derived through its license, research, development and option agreements. These agreements may include the following types of promised goods or services: (i)&nbsp;grants of licenses, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
(ii)&nbsp;performance of research and development services, and (iii)&nbsp;participation on joint research and/or development committees. They also may include options to obtain licenses to the
Company&#146;s intellectual property or to extend the term of the research activities. Payments to the Company under these arrangements typically include one or more of the following: <FONT STYLE="white-space:nowrap">non-refundable</FONT> upfront
payments; reimbursement for research services; research, development or regulatory milestone payments; profit-sharing arrangements; and royalty and commercial sales milestone payments. The event-based milestone payments, royalties and cost
reimbursements represent variable consideration. The Company evaluates the probability that the event-based milestones will be achieved and estimates the amount to be included in the transaction price using the most likely amount method. The Company
includes cost reimbursement in the transaction price using the expected value method. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A performance obligation is a promise in a contract to transfer a distinct
good or service to the customer and is the unit of account in ASC 606. The Company allocates the total transaction price, including variable consideration that is not constrained, to each performance obligation based on the estimated standalone
selling price and recognizes revenue when, or as, the performance obligation is satisfied. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of
cumulative revenue recognized will not occur. At the end of each reporting period, the Company <FONT STYLE="white-space:nowrap">re-evaluates</FONT> the estimated variable consideration included in the transaction price and any related constraint,
and if necessary, adjusts its estimate of the overall transaction price. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company&#146;s collaboration and license agreements include contingent payments related
to sales-based milestones and royalties. Sales-based milestones and royalties are typically payable when annual sales of a covered product reach specified levels and sales occur. When intellectual property license is determined to be a predominant
promise in the arrangement, sales-based milestones and royalties are recognized at the later of when the associated performance obligation has been satisfied or when the sales occur. Unlike other contingency payments, such as regulatory milestones,
sales-based milestones and royalties are not included in the transaction price based on estimates at the inception of the contract, but rather, are included when the sales or usage occur. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In cases when upfront payment contains a material right for the optional services the Company may provide in the future, the material right is treated as a separate
performance obligation. The value allocated to such material right is deferred and recognized as revenue when the performance obligation is satisfied, and the optional services are provided, or when the right expires. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Contract assets and contract liabilities </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A contract asset is a right
to consideration in exchange for goods or services that the Company has transferred to a customer when that right is conditional and is not just subject to the passage of time. A receivable is recorded on the consolidated balance sheets when the
Company has unconditional rights to consideration. As of December&nbsp;31, 2022, the contract asset balance of $1.3&nbsp;million related to revenue recognized and unbilled under the Affini-T Agreement (Note 7). </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A contract liability is an obligation to transfer goods or services for which the Company has received consideration, or for which an amount of consideration is due from
the customer. Contract liabilities consist of deferred revenue and relate to amounts invoiced to, or advance consideration received from, licensees that precede the Company&#146;s satisfaction of the associated performance obligations. The
Company&#146;s deferred revenue primarily results from upfront payments received relating to the performance obligations that are satisfied over time under the Company&#146;s revenue arrangements (Note 7). </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company&#146;s contract balances are reported in a net contract asset or liability position on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">contract-by-contract</FONT></FONT> basis at the end of each reporting period. Changes in the contract assets and the contract </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
liabilities balances during the period are the result of the issuance of invoices, receipts of <FONT STYLE="white-space:nowrap">non-refundable</FONT> upfront payments and recognition of deferred
revenues. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Research and development expenses </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Research and
development costs are expensed as incurred. Research and development costs include salaries, unit-based compensation, and benefits for employees performing research and development activities, an allocation of facility and overhead expenses,
expenses incurred under agreements with consultants, third-party organizations and vendors that conduct research and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> activities, regulatory support activities, manufacturing process development
activities and provide supplies. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Research and development expenses accruals are estimated based on the level of services performed, progress of the work orders,
including the phase or completion of events, and contracted costs. The estimated costs of research and development services provided, but not yet invoiced, are included in accrued expenses and other current liabilities in the consolidated balance
sheets. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accrual accordingly. To date, there have been no material differences between estimates of such
expenses and the amounts actually incurred. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Nonrefundable advance payments for goods or services to be received in the future for use in research and development
activities are capitalized and recorded in prepaid expenses and other current assets, and then expensed as the related goods are delivered or the services are performed. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Patent costs </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">All patent-related costs incurred in connection with
filing and prosecuting patent applications are expensed as incurred due to the uncertainty of the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses in the consolidated statements of operations and
comprehensive loss. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Unit-based compensation expense </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The
Company&#146;s unit-based equity awards include issuance of profits interests that are granted to employees and consultants under the 2019 Equity Incentive Plan. Profits interests usually vest over four years and are a separate class of equity with
defined rights within the LLC Agreement. A profits interest is an interest in the increase in the value of the Company over the threshold amount, as determined at the time of grant on a per unit basis. The holder, therefore, has the right to
participate in distributions of profits only in excess of the threshold amount. The threshold amount is based on the valuation of the common units on or around the grant date. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company accounts for profits interests granted in accordance with ASC 718, <I>Compensation-Stock Compensation</I> (ASC 718). In accordance with ASC 718, compensation
expense is measured at the estimated fair value of the profits interest using the Black-Scholes option-pricing model and is included as compensation expense over the vesting period during which an employee or a consultant provides service in
exchange for the award. Unit-based compensation expense is recognized over the awards&#146; vesting period on a straight-line basis and recorded as either research and development or general and administrative expenses in the consolidated statements
of operations and comprehensive loss based on the function to which the related services are provided. Forfeitures are accounted for as they occur. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Income
taxes </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Metagenomi is taxed under the provisions of Sub chapter K- Partners and Partnerships of the Internal Revenue Code. Under those provisions, Metagenomi
does not pay federal or state corporate income taxes on its taxable income. Instead, each member includes net operating income or loss for Metagenomi on its individual return. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Metagenomi Inc. uses the liability method to account for income taxes. Under this method, deferred tax assets and
liabilities are determined based on differences between the financial statement carrying amounts of existing assets and liabilities and their tax bases. Deferred tax assets and liabilities are measured using enacted tax rates applied to taxable
income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Metagenomi Inc. assesses the likelihood of deferred tax assets being realized. It provides a valuation allowance when it is more likely than not that some portion or all
of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which the temporary differences representing net future deductible amounts
become deductible. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Tax benefits related to uncertain tax positions are recognized when it is more likely than not that a tax position will be sustained during an
audit. Tax positions that meet the <FONT STYLE="white-space:nowrap">more-likely-than-not</FONT> threshold are measured at the largest amount of tax benefit that is greater than 50% likely of being realized upon settlement with the taxing authority.
Interest and penalties related to unrecognized tax benefits are included within the provision for income tax. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Net loss per unit </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company calculates basic and diluted net loss per unit in conformity with the <FONT STYLE="white-space:nowrap">two-class</FONT> method required for participating
securities. Under the <FONT STYLE="white-space:nowrap">two-class</FONT> method, basic net loss per unit is computed by dividing the net loss by the weighted average number of common units outstanding during the period, without consideration of
potentially dilutive securities. Diluted net loss per unit is computed by dividing the net loss by the sum of the weighted average number of common units outstanding during the period plus the dilutive effects of potentially dilutive securities
outstanding during the period. Potentially dilutive securities include incentive units, unvested restricted common units and redeemable convertible preferred units. The dilutive effect of incentive units and unvested restricted common units is
computed using the treasury stock method and the dilutive effect of redeemable convertible preferred units is calculated using the <FONT STYLE="white-space:nowrap">if-converted</FONT> method. For all periods presented, diluted net loss per unit is
the same as basic net loss per unit since the effect of including potential dilutive securities is anti-dilutive and incentive units&#146; participation thresholds were not met. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Comprehensive loss </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Comprehensive income (loss) is defined as a change
in equity of a business enterprise during a period resulting from transactions from <FONT STYLE="white-space:nowrap">non-owner</FONT> sources. The Company&#146;s other comprehensive income (loss) is comprised solely of unrealized gains (losses) on <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities. The Company has not recorded any reclassifications from other comprehensive income (loss) to net loss during the periods presented.
</P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Recently issued accounting pronouncements </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company noted no
recently issued accounting pronouncements that will impact its consolidated financial statements and were not adopted by the Company. No new accounting pronouncements were adopted during the year ended December&nbsp;31, 2022. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>3. Fair value measurements </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Assets and liabilities recorded at fair value on a
recurring basis in the consolidated balance sheets, are categorized based upon the level of judgment associated with inputs used to measure their fair values. The accounting guidance for fair value provides a framework for measuring fair value and
requires certain </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
disclosures about how fair value is determined. The accounting guidance establishes a three-level valuation hierarchy that prioritizes the inputs to valuation techniques used to measure fair
value based upon whether such inputs are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions made by the reporting entity. The three-level
hierarchy for the inputs to valuation techniques is briefly summarized as follows: </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:arial"><I>Level</I><I></I><I>&nbsp;1 </I>&#151; Inputs are unadjusted,
quoted prices in active markets for identical assets or liabilities at the measurement date; </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:arial"><I>Level</I><I></I><I>&nbsp;2 </I>&#151; Inputs are
observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be
corroborated by observable market data for substantially the full term of the related assets or liabilities; and </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:arial"><I>Level</I><I></I><I>&nbsp;3
</I><B>&#151; </B>Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. An
assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. Changes in the ability to observe valuation inputs may
result in a reclassification of levels of certain securities within the fair value hierarchy. The Company recognizes transfers into and out of levels within the fair value hierarchy in the period in which the actual event or change in circumstances
that caused the transfer occurs. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company&#146;s financial instruments measured at fair value on a recurring basis consist of Level&nbsp;1, Level&nbsp;2, and
Level&nbsp;3 financial instruments. Usually, marketable securities are considered Level&nbsp;2 when their fair values are determined using inputs that are observable in the market or can be derived principally from or corroborated by observable
market data such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level&nbsp;2 financial instruments are valued using comparisons to like-kind financial
instruments and models that use readily observable market data as their basis. U.S. Government bonds, corporate debt obligations, commercial paper, government agency obligations and asset-backed securities are valued primarily using market prices of
comparable securities, bid/ask quotes, interest rate yields and prepayment spreads and are included in Level&nbsp;2. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Financial assets and liabilities are considered
Level&nbsp;3 when their fair values are determined using pricing models, discounted cash flow methodologies, or similar techniques, and at least one significant model assumption or input is unobservable. The Company&#146;s investments in a
convertible promissory note, preferred stock shares and restricted common stock of Affini-T Therapeutics Inc. (&#147;Affini-T&#148;) (see Note 5) are Level&nbsp;3 financial assets. </P>
<P STYLE="font-size:8pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes the estimated fair value of the financial instruments that were measured at fair value
on a recurring basis by level within the fair value hierarchy as of December&nbsp;31, 2021 (in thousands): </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="16" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Money market funds (included in cash and cash equivalents)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 34,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">34,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">U.S. Treasury bills</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,989</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,989</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Government agency obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Corporate debt obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Commercial paper</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Asset-backed securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,052</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,052</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Long-term investments (Note 5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total fair value of assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">108,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">37,929</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">65,869</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>    <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, restricted cash of $4.1&nbsp;million as of December&nbsp;31, 2021, collateralized by the Company&#146;s cash
equivalents, are financial assets measured at fair value and is a Level&nbsp;1 financial instruments under the fair value hierarchy. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes
the estimated fair value of the financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy as of December&nbsp;31, 2022 (in thousands): </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="16" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Money market funds (included in cash and cash equivalents)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">182,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">182,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">U.S. Treasury bills</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,821</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,821</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">U.S. Government bonds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Government agency obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Corporate debt obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Commercial paper</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Asset-backed securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,403</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,403</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Long-term investments (Note 5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total fair value of assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">365,782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">197,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">162,869</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>    <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, restricted cash of $6.1&nbsp;million as of December&nbsp;31, 2022, collateralized by the Company&#146;s cash
equivalents, are financial assets measured at fair value and is a Level&nbsp;1 financial instruments under the fair value hierarchy. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In December 2020, the Company
entered into a convertible promissory note agreement and a side letter with Affini-T (see Note 5), and recorded an aggregate $1.5&nbsp;million investment in Affini-T within long-term investments on the consolidated balance sheet related to
(i)&nbsp;the Affini-T Convertible Promissory Note and (ii)&nbsp;shares of Affini-T&#146;s common stock. The Company concluded it exercised significant influence over Affini-T, and the Company elected the fair value method to account for the
investment in Affini-T. The fair value of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
common stock shares was estimated by the Company&#146;s management, considering the most recent third-party valuation, which was based on an option-pricing model and Affini-T&#146;s most recent
round of financing. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">During the year ended December&nbsp;31, 2021, the Company recognized an aggregate $2.8&nbsp;million change in fair value of its investment in
Affini-T within the change in fair value of long-term investments in the consolidated statement of operations and comprehensive loss consisting of a $2.5&nbsp;million change in fair value of the Affini-T Convertible Promissory Note and a
$0.3&nbsp;million change in fair value of the shares of Affini-T common stock. As of December&nbsp;31, 2021, the aggregate fair value of the Company&#146;s investment in Affini-T was $4.3&nbsp;million, of which $4.0&nbsp;million related to the
Affini-T Convertible Promissory Note and $0.3&nbsp;million related to the shares of Affini-T common stock. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In March 2022, the Company&#146;s investment in the
Affini-T Convertible Promissory Note was converted into shares of convertible preferred stock, resulting in no convertible note outstanding as of December&nbsp;31, 2022 (see Note 5). The fair value of the convertible preferred stock shares was based
on cash paid per share by third party investors. During the year ended December&nbsp;31, 2022, the Company recognized a change in fair value of the Affini-T Convertible Promissory Note of $0.1&nbsp;million within the change in fair value of
long-term investments in the consolidated statement of operations and comprehensive loss. There was no change in the fair value of the shares of Affini-T common stock during the year ended December&nbsp;31, 2022. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of December&nbsp;31, 2021, the fair value of the Affini-T Convertible Promissory Note was estimated using the fair value of preferred stock using Affini-T&#146;s
recent valuation and future payments discounted at a rate of 6%. As of the date of the conversion, the fair value was estimated as $4.1&nbsp;million, which was the fair value of the convertible preferred stock issued upon the conversion and as of
December&nbsp;31, 2022. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There were no transfers between Level&nbsp;1 and Level&nbsp;2 categories in the years ended December&nbsp;31, 2021 and 2022. As of
December&nbsp;31, 2021 and 2022, the Company&#146;s investments in Affini-T were accounted as Level&nbsp;3 investments and recorded at fair value. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>4. <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Available-for-sale</FONT></FONT> marketable securities </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes the amortized
cost, unrealized gains (losses) and estimated fair value of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities as of December&nbsp;31, 2021 (in thousands): </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amortized<BR>cost</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Unrealized<BR>gains</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Unrealized<BR>losses</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Estimated<BR>fair value</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 34,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 34,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">U.S. Treasury obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,989</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,989</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Government agency obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Corporate debt obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Commercial paper</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Asset-backed securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,052</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103,819</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103,798</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Less: amounts classified as cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34,940</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34,940</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT>
marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 68,879</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(21</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 68,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes the amortized cost, unrealized gains (losses) and estimated fair value of the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities as of December&nbsp;31, 2022 (in thousands): </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amortized<BR>cost</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Unrealized<BR>gains</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Unrealized<BR>losses</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Estimated<BR>fair value</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 182,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 182,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">U.S. Treasury bills</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,821</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">U.S. Government bonds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(69</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Government agency obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Corporate debt obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,041</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(151</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Commercial paper</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Asset-backed securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(105</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,403</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">360,406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(329</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">360,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Less: amounts classified as cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(182,441</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(182,441</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT>
marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 177,965</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(329</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 177,690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of December&nbsp;31, 2021 and 2022, no significant facts or circumstances were present to indicate a deterioration in the
creditworthiness of the issuers of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> securities, and the Company has no requirement or intention to sell these securities before maturity or
recovery of their amortized cost basis. The Company considered the current and expected future economic and market conditions and determined that its investments were not significantly impacted. For all securities with a fair value less than its
amortized cost basis, the Company determined the decline in fair value below amortized cost basis to be immaterial and <FONT STYLE="white-space:nowrap">non-credit</FONT> related, and therefore no allowance for losses has been recorded.&nbsp;During
the years ended&nbsp;December 31, 2021 and 2022, the Company did not recognize any impairment losses on its investments. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company&#146;s policy is to exclude the
applicable accrued interest from both the fair value and the amortized cost basis of its <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> securities for purposes of identifying and measuring an
impairment. The Company presents accrued interest receivable related to the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> securities in prepaid expenses and other current assets, separate from
available-for-sale marketable securities in the consolidated balance sheets. As of December&nbsp;31, 2021 and 2022, accrued interest receivable was $0.2&nbsp;million and $0.3&nbsp;million, respectively. The Company&#146;s accounting policy is to not
measure an allowance for credit losses for accrued interest receivables and to <FONT STYLE="white-space:nowrap">write-off</FONT> any uncollectible accrued interest receivable as a reversal of interest income in a timely manner, which it considers to
be in the period in which the Company determines the accrued interest will not be collected. The Company has&nbsp;not written off any accrued interest receivables for the years ended December&nbsp;31, 2021 and 2022. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The amortized cost and fair value of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities by
contractual maturity were as follows as of December&nbsp;31, 2021 (in thousands): </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amortized<BR>cost</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Estimated<BR>fair&nbsp;value</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Maturing within one year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">67,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">67,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Maturing in one to five years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT>
marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">68,879</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">68,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The amortized cost and fair value of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities by contractual maturity were as follows as of December&nbsp;31, 2022 (in thousands): </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amortized<BR>cost</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Estimated<BR>fair&nbsp;value</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Maturing within one year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">163,259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">163,030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Maturing in one to five years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,660</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT>
marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">177,965</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">177,690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>5. Long-term investments </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Affini-T investment </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In December 2020, the Company entered into a
convertible promissory note agreement and a side letter with Affini-T, a private biotechnology company. The Company participated with other investors in Affini-T&#146;s convertible notes financing and paid cash of $1.5&nbsp;million as a principal
amount of a convertible promissory note with 6% annual interest and maturity in December 2021. The Affini-T Convertible Promissory Note was convertible in Affini-T&#146;s next qualifying round of financing at a conversion price equal to the lesser
of (i) 85% of the price per share paid by other investors (or 80% if the qualified financing occurs after June&nbsp;24, 2021) or (ii)&nbsp;the price per share obtained by dividing $30.0&nbsp;million by the number of shares of common stock of
Affini-T outstanding immediately prior to the qualified financing. In accordance with the side letter, the Company was engaged to perform the testing of its gene editing system to <FONT STYLE="white-space:nowrap">knock-in</FONT> <FONT
STYLE="white-space:nowrap">T-cell</FONT> receptor (&#147;TCR&#148;) targets in primary <FONT STYLE="white-space:nowrap">T-cells</FONT> as selected by Affini-T. As consideration for services, the Company received 1,867,300 shares of restricted common
stock of Affini-T, of which 10% of the shares vested on the issuance date and 90% shares were subject to forfeiture if no gene editing licensing agreement was finalized between the Company and Affini-T by October&nbsp;31, 2021. Effective
November&nbsp;1, 2021, 1,653,570 shares of restricted common stock issued to the Company were forfeited and cancelled as a license agreement was not signed between the parties. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In March 2022, Affini-T closed a qualifying round of financing, and the Affini-T Convertible Promissory Note and accrued interest were converted into 527,035 Series A
convertible preferred stock shares of Affini-T. The Company accounted for its investments in the Affini-T Convertible Promissory Note and convertible preferred stock at fair value (see Note 3). </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company performed a VIE analysis and concluded that it was not a primary beneficiary of Affini-T. The Company concluded that it exercised significant influence over
Affini-T until November 2021, when shares of restricted common stock were forfeited and the Company&#146;s former chief business officer, who was also the founder and chief executive officer of Affini-T, resigned. The Company accounted for its
investment in 213,730 shares of Affini-T common stock at fair value of $0.3&nbsp;million for each of the periods ending December&nbsp;31, 2021 and 2022 (see Note 3). </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In June 2022, the Company entered into a Development, Option and License Agreement with Affini-T to perform research and development activities (see Note 7). The Company
received an upfront equity consideration of 719,920 shares of Affini-T&#146;s common stock with an estimated fair value of $1.3&nbsp;million in June 2022. The fair value of common shares was estimated by the Company&#146;s management, considering
the most recent third-party valuation. No impairment loss was recognized on the Company&#146;s investment in Affini-T as of December&nbsp;31, 2021 and 2022. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>ViTToria investment </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company purchased 603,262 Series <FONT
STYLE="white-space:nowrap">Seed-2</FONT> convertible preferred stock shares of ViTToria Biotherapeutics, Inc. (&#147;Vittoria&#148;), a private biotechnology company, for a total of $2.2&nbsp;million cash in July and December 2021.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
During the years ended December&nbsp;31, 2021 and 2022, the Company did not have a board seat and owned less than 20% of outstanding voting shares of Vittoria. The investment in Vittoria does not
provide the Company the ability to control or have significant influence over Vittoria&#146;s operations. The Company accounted for the investment in Vittoria&#146;s Series <FONT STYLE="white-space:nowrap">Seed-2</FONT> convertible preferred stock
using the measurement alternative method. The fair value of the investment was estimated by management using per share price of $3.57, which was the price paid for convertible preferred stock shares by other investors. As of December&nbsp;31, 2021
and 2022, the carrying value of Vittoria&#146;s investment was $2.2&nbsp;million and no impairment was recognized. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>6. Consolidated balance sheets components
</B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Property and equipment, net consists of the following (in thousands): </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Useful&nbsp;life</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR><BR></TD>
<TD VALIGN="bottom" ALIGN="right">lesser&nbsp;of<BR>useful&nbsp;life&nbsp;or<BR>the&nbsp;lease&nbsp;term</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Computers and related equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Construction in progress</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">887</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,415</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Less: Accumulated depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(553</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,248</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The depreciation and amortization expense was $0.4&nbsp;million and $1.7&nbsp;million for the years ended December&nbsp;31, 2021 and
2022, respectively. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Prepaid expenses and other current assets consist of the following (in thousands): </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Payroll tax credit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Interest receivable on
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Prepaid research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Grant income receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">762</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Other assets consist of the following (in thousands): </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating lease deposit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Prepaid property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Long-term prepaid services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Deferred finance issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Accrued expenses and other current liabilities consist of the following (in thousands): </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accrued personnel related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,819</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accrued legal and professional services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">414</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accrued purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accrued research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>7. Significant agreements </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Moderna
strategic collaboration and license agreement </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Terms of the agreement </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On October&nbsp;29, 2021, the effective date, the Company entered into a Strategic Collaboration and License Agreement (the &#147;Moderna Agreement&#148;) with
ModernaTX, Inc. (&#147;Moderna&#148;). The parties will collaborate on the research and development of <I>in vivo</I> genome editing therapies directed at certain targets and the commercialization of such genome editing therapies. The collaboration
provides Moderna with exclusive access to the Company&#146;s technology platform during the research period in (1)&nbsp;the field of <I>in vivo</I> gene editing technology for a therapeutic, ameliorative or prophylactic application by way of
knock-out through InDel formation or base editing or insertion of an exogenous DNA template (such field, &#147;DT Field&#148;) and (2)&nbsp;the field of <I>in vivo</I> gene editing technology for a therapeutic, ameliorative or prophylactic
application outside the use of (a) DNA donor templates and (b) no exogenous template at all but including (c) correction by base editing (such field, &#147;RT Field&#148;). The parties formed a joint steering committee, a joint research subcommittee
and a joint patent subcommittee to oversee the collaboration activities. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Under the terms of the Moderna Agreement, the parties will collaborate on one or more
programs in the RT Field (the &#147;Moderna RT program&#148;) and two programs in the DT Field (the &#147;Moderna DT program&#148; and the &#147;DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> program&#148;). </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">With respect to the Moderna RT and Moderna DT programs, the parties will collaborate on the research and development of product candidates under the approved research
plans. The initial research term of the Moderna RT program is four years, which may be extended by Moderna for an additional three years upon written notice and a payment of extension fees. The initial research term of the Moderna DT program is four
years. The Company granted to Moderna an option to obtain an exclusive license to develop, manufacture and commercialize up to ten Moderna RT program candidates and up to two Moderna DT program candidates at any time during the research term and
prior to filing of an investigational new drug (&#147;IND&#148;) application with the Food Drug and Administration (&#147;FDA&#148;) or any similar application filed with a regulatory authority in a country other than the United States
(&#147;U.S.&#148;), subject to Moderna&#146;s payment of an option exercise fee of $10.0 million per target. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">With respect to the DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> program, the parties will work together on the <FONT STYLE="white-space:nowrap">co-development</FONT> and commercialization of products and share costs and profits equally. The Company maintains
commercialization rights in the U.S. (subject to Moderna&#146;s right to appoint up to 50% of the U.S. sales force for the DT Co-Co program), while Moderna maintains these rights in countries other than the U.S. The initial research term for the DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> program is four years, and each party has a right to <FONT STYLE="white-space:nowrap">opt-out</FONT> of the DT Co-Co program at any time, at which point the other party has the right to solely continue the
development and commercialization activities. If there is no development candidate nomination by the end of the initial research term, the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> program will expire, unless the parties have mutually agreed
to continue the program. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">During the year ended December 31, 2021, the Company received a <FONT STYLE="white-space:nowrap">non-refundable</FONT>
upfront payment of $40.0&nbsp;million and a $5.0&nbsp;million payment for the first year of research costs. Concurrent with the Moderna Collaboration Agreement, Moderna also provided $30.0&nbsp;million in cash in the form of a convertible promissory
note (see Note 9) pursuant to a convertible promissory note agreement dated October&nbsp;29, 2021 (the &#147;Moderna Convertible Promissory Note Agreement&#148;). Moderna will reimburse the Company up to $5.0&nbsp;million in annual research and
development costs related to the Moderna DT and Moderna RT programs, or up to the agreed amount of expenses per the budget. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For the Moderna RT and Moderna DT
programs, the Company is eligible to receive (i)&nbsp;technology milestone fees related to the achievement of certain preclinical research objectives of up to $75.0&nbsp;million, (ii)&nbsp;development and regulatory milestones of up to $100.0
million per target, (iii) sales milestones of up to $200.0&nbsp;million per target, and (iv)&nbsp;royalties ranging from a <FONT STYLE="white-space:nowrap">mid-single</FONT> digit to a low-teens percentage of annual net sales of a licensed product.
Any profits and losses from the co-development and commercialization of the DT Co-Co program are shared equally between the Company and Moderna. With respect to the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> program for which the <FONT
STYLE="white-space:nowrap">opt-out</FONT> party has exercised its <FONT STYLE="white-space:nowrap">opt-out</FONT> right, the continuing party will pay to the <FONT STYLE="white-space:nowrap">opt-out</FONT> party, certain development, regulatory and
sales milestone payments that will not exceed an aggregate $239.0&nbsp;million per DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> target, and <FONT STYLE="white-space:nowrap">opt-out</FONT> royalties ranging from a high-single digit to a <FONT
STYLE="white-space:nowrap">low-teens</FONT> percentage of annual net sales of a licensed product. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The term of the Moderna Agreement will continue on a licensed
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-licensed</FONT></FONT> product and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, until the expiration of the
applicable royalty term. The royalty term commences on the first commercial sale of a licensed product and terminates on the latest of: (a)&nbsp;the expiration or abandonment of the last valid claim of a patent within the licensed Moderna DT or RT
technology; (b) 10 years after the first commercial sale of a licensed product; and (c)&nbsp;expiration of the regulatory exclusivity. Upon the expiration of the term of a licensed product in the Moderna DT or Moderna RT program, the licenses
granted to Moderna will survive and become perpetual, fully paid and royalty-free. Each party may terminate the Moderna Agreement on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">program-by-program</FONT></FONT> basis upon
written notice to the other party for an uncured material breach or insolvency. The Company may terminate the Moderna Agreement upon written notice to Moderna for a patent challenge. Additionally, Moderna may terminate the agreement at its
convenience with respect to Moderna DT or Moderna RT programs for any reason upon at least: (a) 60 days&#146; prior written notice if a first commercial sale has not occurred for the products in such program, or (b) 180 days&#146; prior written
notice if a first commercial sale of a product in such program has occurred. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Accounting analysis and revenue recognition </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company concluded that the Moderna DT and Moderna RT programs are in the scope of ASC 606. The Company determined that the licenses granted to Moderna, and its
participation in the joint steering committee are not capable of being distinct from the preclinical research and development services and therefore concluded that there are two performance obligations: (1)&nbsp;the Moderna RT program and
(2)&nbsp;the Moderna DT program. The Company also concluded that the option to obtain an exclusive license and options to extend Moderna RT program term do not include significant incremental discounts, and as such, the options do not provide
material rights. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company concluded the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> program research activities are within the scope of ASC 808, as the
Company and Moderna are both active participants in the research, development and commercialization activities, are exposed to significant risks and rewards that are dependent on the success of the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT>
program activities and share costs and profits equally. The Company determined that the guidance in ASC 730, <I>Research and Development</I>, was appropriate to apply to the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> program research
activities by analogy, based on the nature of the cost sharing provisions of the agreement. The Company concluded that DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
program is one unit of accounting, as the co- exclusive license is not distinct from the research and development and the participation in joint steering committee activities. The Company
recognizes payments to or from Moderna related to the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> program cost sharing research activities as an increase to or reduction of research and development expenses, respectively. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company concluded that the Moderna Collaboration Agreement and the Moderna Convertible Promissory Note Agreement should be combined and treated as a single
arrangement for accounting purposes as the agreements were entered into contemporaneously and in contemplation of one another. The Company estimated the contract consideration to be $90.0&nbsp;million, which consisted of: 1) the <FONT
STYLE="white-space:nowrap">non-refundable</FONT> upfront collaboration payment of $40.0&nbsp;million received in 2021, 2) $30.0&nbsp;million in cash received in 2021 in exchange for the convertible promissory note and 3) the estimated cost
reimbursements for Moderna DT and Moderna RT programs of $20.0&nbsp;million. The Company constrained future milestones, as it assessed that it is probable that the inclusion of such variable consideration could result in a significant reversal of
cumulative revenue in future periods. During the year ended December 31, 2021, the Company recorded $30.0&nbsp;million of the contract consideration for the convertible promissory note based on the fair value (see Note 9) and allocated the
transaction price of $60.0&nbsp;million to each of the following programs on a relative standalone selling price basis: 1) $49.5&nbsp;million to the Moderna RT program, 2) $5.5&nbsp;million to the Moderna DT program, and 3) $5.0&nbsp;million to the
DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> program. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The variable consideration is reevaluated at each reporting period and as changes in circumstances occur.
The Company recognizes revenue for each of the Moderna DT and Moderna RT programs as collaboration revenue based on the measure of progress using an estimated cost-based input method each reporting period. The Company also amortizes the allocation
consideration for the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> program of $5.0&nbsp;million as a credit to research and development expenses during the discovery and lead optimization phases for the DT Co-Co program. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company recognized collaboration revenue of $0.2&nbsp;million and $14.5&nbsp;million in the consolidated statements of operations and comprehensive loss for the
years ended December&nbsp;31, 2021 and 2022, respectively. As of December&nbsp;31, 2021 and 2022, deferred revenue related to Moderna was $39.7&nbsp;million and $30.2&nbsp;million, respectively. Collaboration revenue recognized during the year ended
December&nbsp;31, 2022 included $14.5&nbsp;million that was included in deferred revenue as of December&nbsp;31, 2021. The value of the transaction price allocated to the remaining unsatisfied portion of the performance obligations was approximately
$41.9&nbsp;million as of December&nbsp;31, 2022, which the Company expects to recognize as revenue over the next <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">three-to-four</FONT></FONT> years. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company recognized $0.2&nbsp;million and $0.3&nbsp;million in credits to research and development expenses related to cost sharing allocation and amortization of the
collaboration advance, respectively, within research and development expenses in the consolidated statement of operations and comprehensive loss during the year ended December&nbsp;31, 2021. The Company recognized $0.9&nbsp;million and
$3.5&nbsp;million in credits to research and development expenses related to cost sharing allocation and amortization of the collaboration advance, respectively, during the year ended December&nbsp;31, 2022. As of December&nbsp;31, 2021, the
collaboration advance balance was $4.7&nbsp;million, partially offset by the cost-sharing receivable balance of $0.2&nbsp;million, which was presented as a collaboration advance on the Company&#146;s consolidated balance sheet. As of
December&nbsp;31, 2022, the collaboration advance balance was $1.1&nbsp;million, partially offset by the cost-sharing receivable balance of $0.4&nbsp;million, which was presented as a collaboration advance on the Company&#146;s consolidated balance
sheet. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Affini-T development, option and license agreement </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Terms of the agreement </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On June&nbsp;14, 2022, the effective date, the Company
entered into a Development, Option and License Agreement (the &#147;Affini-T Agreement&#148;) with Affini-T. Pursuant to the Affini-T Agreement, the parties have agreed to identify, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
develop or optimize certain reagents using the Company&#146;s proprietary technology for Affini-T to use such reagents to develop and commercialize gene edited
<FONT STYLE="white-space:nowrap">T-cell</FONT> receptor (&#147;TCR&#148;)-based therapeutic products exclusively in the field of treatment, prevention or diagnosis of any human cancer using products with any engineered primary TCR alpha/beta T cells
and non-exclusively in the field of treatment, prevention or diagnosis of any human cancer using products with certain other engineered immune cells worldwide. A joint steering committee was established by both parties to assign alliance managers
and project leaders to oversee the collaboration activities. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pursuant to the Affini-T Agreement, the Company granted Affini-T options to receive, on a
pre-specified target-by-pre-specified target basis, for up to six pre-specified targets, either (i) an exclusive, royalty-bearing, sublicensable worldwide license under all of the Company&#146;s applicable intellectual property to research, develop,
manufacture, use, commercialize and otherwise exploit any TCR-based therapy, preventative treatment, or diagnostic for humans that is directed to such pre-specified target, contains or comprises Primary TCR alpha/beta T Cells and is derived from
<I>ex vivo </I>application of a Company reagent (the &#147;Exclusive Option&#148;) or (ii) a non-exclusive, royalty-bearing, sublicensable worldwide license under all of the Company&#146;s applicable intellectual property to research, develop,
manufacture, use commercialize and otherwise exploit any TCR-based therapy, preventative treatment, or diagnostic for humans that is directed to such pre-specified target, contains or comprises TCR natural killer (&#147;NK&#148;) cells derived from
iPSC immune cells or TCR T cells derived from donor-derived or iPSC immune cells. Affini-T can exercise its options for either an exclusive license or a non-exclusive license, or both, for each pre-specified target by providing written notice prior
to the earlier of (x) the end of the Affini-T Agreement term or (y) 90 days following the filing of an IND for a licensed product directed to a pre-specified target, subject to the payment of certain fees per each option exercised. After the option
exercise, Affini-T has agreed to use commercially reasonable efforts to conduct all development and commercialization activities for a licensed product, and development and commercialization of all licensed products will be at Affini-T&#146;s sole
cost and expense. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In connection with the Affini-T Agreement, the Company received upfront equity consideration of 719,920 shares of Affini-T&#146;s common stock
with an estimated fair value of $1.3&nbsp;million in June 2022. The fair value of Affini-T&#146;s shares of common stock was estimated by the Company&#146;s management, considering the most recent third-party valuation. Affini-T has also agreed to
reimburse the Company for expenses incurred while performing research activities under the research plans. Additionally, the Company is eligible to receive (i) 933,650 shares of Affini-T&#146;s common stock upon the achievement of a regulatory
milestone, which is the earlier of a submission of a drug master file to the FDA or an acceptance of an IND filing for a licensed product by the FDA, (ii)&nbsp;up to $18.8&nbsp;million in future developmental milestone payments depending on the
completion of or the number of patients dosed in, the relevant human clinical trial, or the initiation of a pivotal trial, and $40.6&nbsp;million in future regulatory approval milestone payments, which include regulatory approvals in the U.S. and
other markets for licensed products directed to a pre-specified target if options for both exclusive and <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licenses are exercised with respect to such target, (iii)&nbsp;up to $250.0&nbsp;million
in sales-based milestones for aggregate sales of all licensed products directed to a given pre-specified target and (iv)&nbsp;royalties ranging from a <FONT STYLE="white-space:nowrap">low-single</FONT> digit to high-single digit percentage of
worldwide annual net sales of licensed products.</P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The initial term of the Affini-T Agreement is five years from the effective date. If Affini-T exercises an
Exclusive Option with respect to any pre-specified target during the initial term, the initial term will be extended by an additional five years. Following the expiration of the extended term, if any, the agreement will continue on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">target-by-target</FONT></FONT> basis and expire with respect to such target upon the expiration of the royalty term for all licensed products directed to such target. The Affini-T Agreement
may be terminated during the term by either party for an uncured material breach by, or bankruptcy of, the other party. Additionally, Affini-T may terminate the Affini-T Agreement for convenience, in its entirety, on a research plan-by-research plan
basis, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">target-by-target</FONT></FONT> basis or on a licensed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-licensed</FONT></FONT> product basis, by
providing prior written notice. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Accounting analysis and revenue recognition </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company concluded that the Affini-T Agreement is in the scope of ASC 606 and that there is one performance obligation to perform research activities under the
Affini-T Agreement. Exclusive and <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licenses are optional contingent purchases that do not include significant incremental discounts, and therefore do not provide a material right. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">At the effective date, the transaction price consisted of the upfront equity consideration with an estimated fair value of $1.3&nbsp;million and estimated research
reimbursement costs. Research reimbursement costs represent variable consideration, and the Company&#146;s management estimates what portion to include in total consideration at the end of each reporting period. Other payments under the Affini-T
Agreement, including additional equity consideration and development and regulatory milestones, also represent variable consideration, and are constrained to the extent that the inclusion of such variable consideration could result in a significant
reversal of cumulative revenue in future periods. As of December&nbsp;31, 2022, additional equity consideration and future development and regulatory milestone payments were excluded from the estimated total transaction price as they were considered
constrained. The transaction price is reevaluated in each reporting period and as changes in circumstances occur. The Company recognizes revenue each reporting period based on the measure of progress using an estimated cost-based input method. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company recognized $2.6&nbsp;million in collaboration revenue in the consolidated statements of operations and comprehensive loss during the year ended
December&nbsp;31, 2022. As of December&nbsp;31, 2022, the Company recorded $1.3&nbsp;million in contract assets on the consolidated balance sheet, related to services performed but not invoiced. There was no deferred revenue related to the Affini-T
Agreement as of December&nbsp;31, 2022. The value of the transaction price allocated to the remaining unsatisfied portion of the performance obligation was approximately $8.0&nbsp;million as of December&nbsp;31, 2022, which the Company expects to
recognize as revenue over the next <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">five-to-six</FONT></FONT> years. In June 2023, the joint steering committee approved the budget for estimated research reimbursement costs for the
Affini-T Agreement, which resulted in a $2.4 million reduction to variable consideration. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Ionis collaboration and license agreement </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Terms of the agreement </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On November&nbsp;10, 2022, the effective date, the
Company entered into a Collaboration and License Agreement (the &#147;Ionis Agreement&#148;) with Ionis Pharmaceuticals, Inc. (&#147;Ionis&#148;) to collaborate on drug discovery and exploratory research activities to advance new medicines using
gene editing strategies, with the goal of discovering novel medicines. Pursuant to the terms of the Ionis Agreement, the Company granted Ionis and its affiliates a worldwide exclusive, royalty-bearing license, with the right to grant sublicenses, to
use all licensed systems and licensed products in the field of <I>in vivo</I> gene editing for all therapeutic, prophylactic, palliative, and analgesic uses in humans. In connection with the Ionis Agreement, the Company also has the right to
exercise an exclusive option to <FONT STYLE="white-space:nowrap">co-develop</FONT> and <FONT STYLE="white-space:nowrap">co-commercialize</FONT> certain products under a drug discovery program. A joint steering committee was established by both
parties to coordinate, oversee, and monitor the research and drug discovery activities under the Ionis Agreement. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The parties will collaborate to discover
therapeutic products under a drug discovery program and develop a drug discovery plan for each target, selected by Ionis. The target selection is divided into two waves: up to four targets in Wave 1 and up to four targets in Wave 2. For each drug
discovery program, once the parties identify a development candidate that is suitable for further development, Ionis will be responsible for the development and commercialization of products resulting from such program. Per the terms of the Ionis
Agreement, at any time prior to the designation of a development candidate for a drug discovery program and for any reason, Ionis may replace the collaboration target, provided such target has not previously been substituted out. Ionis may
substitute (i)&nbsp;up to two Wave 1 targets and (ii)&nbsp;up to two Wave 2 targets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The drug discovery activities for a program commence on the selection of a target and expire upon the earlier of
(a)&nbsp;completion of all drug discovery activities for such program, (b)&nbsp;the fifth anniversary of the effective date and (c)&nbsp;selection of a development candidate for such drug discovery program. If one or more Wave 2 targets become
collaboration targets as a result of the parties achieving enabled delivery and less than two years are remaining in the drug discovery term, then the term will be extended to the earlier of (i)&nbsp;the time that the Company completes all of its
activities under the applicable drug discovery plan and (ii)&nbsp;the seventh anniversary of the effective date, subject to the Company&#146;s consent. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The parties
will also conduct an exploratory research program, and will jointly optimize gRNA and select delivery technologies and other activities. The exploratory research activities commence on the effective date and expire upon the earlier of
(a)&nbsp;completion of all exploratory research activities established in the exploratory research plan, and (b)&nbsp;the fifth anniversary of the effective date. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company has the exclusive option to <FONT STYLE="white-space:nowrap">co-develop</FONT> and <FONT STYLE="white-space:nowrap">co-commercialize</FONT> the licensed
products under a drug discovery program (the <FONT STYLE="white-space:nowrap">&#147;Co-Co</FONT> Option&#148;) with Ionis. The <FONT STYLE="white-space:nowrap">Co-Co</FONT> Option may be exercised for (a)&nbsp;the initial Wave 1 target (&#147;Target
1&#148;), (b) no more than one of the other three discovery programs for the Wave 1 targets, and (c)&nbsp;no more than two drug discovery programs for the Wave 2 targets that become collaboration targets. If the Company exercises the <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Option for a particular drug discovery program, that drug discovery program will automatically be deemed a <FONT STYLE="white-space:nowrap">&#147;Co-Co</FONT> Program&#148;, all corresponding licensed products
be deemed <FONT STYLE="white-space:nowrap">&#147;Co-Co</FONT> Products,&#148; the Company will be obligated to pay Ionis an option exercise fee, and the parties will enter into a separate <FONT STYLE="white-space:nowrap">co-development</FONT> and
co-commercialization agreement. The <FONT STYLE="white-space:nowrap">Co-Co</FONT> Option exercise fee will equal 50% of Ionis&#146; internal costs and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT>
costs incurred in the conduct of the drug discovery activities prior to the exercise of the <FONT STYLE="white-space:nowrap">Co-Co</FONT> Option and be reduced by 50% of the Company&#146;s corresponding costs incurred. Future development and
commercialization costs will be shared equally. The Company may elect to reduce its cost-share percentage anywhere between 50% and 25% on a <FONT STYLE="white-space:nowrap">go-forward</FONT> basis, provided the Company will continue to bear 50% of
the costs of any clinical trials ongoing at the time of the election through the completion of the clinical trials. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company will manufacture all licensed
systems and certain components of the applicable licensed products that are needed by Ionis for use in its development activities and all of the Company&#146;s manufactured components needed by Ionis for use in its commercialization activities. The
Company will provide the manufactured components at a price that represents the cost of goods plus 15%. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pursuant to the terms of the Ionis Agreement, the Company
has also been granted an option to obtain a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> royalty-bearing license, with the right to grant sublicenses, for certain Ionis&#146; background technology to use in up to eight therapeutic products
discovered by the Company in the field of <I>in vivo</I> gene editing and directed to a Collaboration Target (each such product, a &#147;Metagenomi Product&#148; and each such option an &#147;Ionis IP Option&#148;), but subject to encumbrance checks
with respect to particular targets. A Collaboration Target is a target that is selected by Ionis, and, with respect to the Company is not the subject of discussions with a third party, is not the subject of a contractual grant of rights to a third
party nor the subject of a Company bona fide research and development program. If the Company exercises its Ionis IP Option, the Company will pay to Ionis up to several million dollars per Metagenomi Product upon achievement of certain clinical and
regulatory milestones. The Company is also obligated to pay Ionis royalties in an amount equal to a low single-digit royalty on the net sales of the applicable Metagenomi Product on
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In November 2022, the Company received an $80.0&nbsp;million upfront payment from Ionis for the Wave 1 drug discovery research collaboration and selected Target 1. Ionis
selected its second target (&#147;Target 2&#148;) in Wave 1 in December 2022, and will select two final additional Wave 1 targets (&#147;Target 3&#148; and &#147;Target 4&#148;) within the 12 months from the effective date, as permitted under the
arrangement. Ionis has an option to select up to four </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
Wave 2 targets at any time during the drug discovery term, if (a)&nbsp;an IND for any licensed product directed to a Wave 1 target is filed with the applicable regulatory authority or
(b)&nbsp;the parties achieve enabled delivery for a <FONT STYLE="white-space:nowrap">non-liver</FONT> target under the exploratory research activities, by providing written notice and by paying a Wave 2 target selection fee of $15.0&nbsp;million or
$30.0&nbsp;million, depending on and per the selected target. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Ionis is obligated to reimburse the Company for all internal costs and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs incurred in the performance of the exploratory research activities, up to an aggregate of $10.0&nbsp;million, which is payable in quarterly installments of
$0.5&nbsp;million during the exploratory research term. The Company is also eligible to receive (a)&nbsp;up to $29.0&nbsp;million in future development milestone payments for each licensed product; (b)&nbsp;up to $60.0&nbsp;million in future
regulatory milestone payments for each licensed product; (c)&nbsp;up to $250.0&nbsp;million in sales-based milestones for each licensed product; and (d)&nbsp;royalties on annual net sales of licensed products from a
<FONT STYLE="white-space:nowrap">mid-single-digit</FONT> to <FONT STYLE="white-space:nowrap">low-teens</FONT> percentage, subject to customary reductions.</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The term
of the Ionis Agreement will continue (i)&nbsp;with respect to the drug discovery programs, until the expiration of all applicable royalty terms for a licensed product, (ii)&nbsp;with respect to the <FONT STYLE="white-space:nowrap">Co-Co</FONT>
Programs, until the parties cease all exploitation for the <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products that are the subject to such <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program, and (iii)&nbsp;with respect to the Metagenomi
Products, until the expiration of the royalty term for a Metagenomi Product. The royalty term ends on the latest of the following two dates: (i)&nbsp;the expiration of (A)&nbsp;the last claim of any issued and unexpired patent, or (B)&nbsp;a claim
within a patent application that has not been pending for more than seven years from the earliest date to which the claim or applicable patent application is entitled to claim priority and which claim has not been revoked, cancelled, withdrawn, held
invalid, or abandoned, or (ii) 12 years following the first commercial sale of a licensed product. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Ionis Agreement may be terminated during the term by
either party for an uncured material breach or bankruptcy by the other party. Additionally, Ionis may terminate the Ionis Agreement for convenience and without penalty, in its entirety or on a licensed <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">product-by-licensed</FONT></FONT> product basis, by providing 90 days&#146; written notice. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Accounting analysis and revenue
recognition </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company concluded that the Ionis Agreement is in the scope of ASC 606 at the effective date and until the Company exercises its <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Option for any drug discovery program, which was determined to not be probable at the effective date and as of December&nbsp;31, 2022. The Company also concluded that exclusive licenses and participation in a
joint steering committee are not distinct from discovery research services and should thus be combined into one performance obligation (the &#147;discovery program&#148;). The Company also concluded that exploratory research services are a separate
and distinct performance obligation (the &#147;exploratory program&#148;). As the Ionis options for Wave 2 targets are optional purchases and do not have significant incremental discounts, as such, the options do not provide material rights. </P>
 <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company allocated the total estimated transaction price of $90.0&nbsp;million, which consisted of an $80.0&nbsp;million upfront payment received in November 2022
and a $10.0&nbsp;million reimbursement for research costs, into two performance obligations, and was determined based on their estimated standalone selling prices. The Company concluded that future development and commercial supply agreements are at
market terms, as the terms were consistent with industry standards as of the effective date. The Company constrains future milestone payments under the arrangement to the extent that the inclusion of such variable consideration could result in a
significant reversal of cumulative revenue in future periods. The Company constrained all development and regulatory milestone payments at the effective date and as of December&nbsp;31, 2022. The Company is recognizing revenue of $80.0&nbsp;million
related to the discovery program and of $10.0&nbsp;million related to exploratory program over the research terms using an estimated cost-based input method as a measure of progress for each obligation. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company recognized $0.1&nbsp;million in collaboration revenue in the consolidated statements of operations and comprehensive loss during the year ended
December&nbsp;31, 2022. As of December&nbsp;31, 2022, deferred revenue </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
related to the Ionis Agreement was $79.9&nbsp;million. The value of the transaction price allocated to the remaining performance obligations was approximately $89.9&nbsp;million as of
December&nbsp;31, 2022, which the Company expects to recognize as revenue over the next <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">five-to-six</FONT></FONT> years. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>8. Cystic fibrosis foundation grant income </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In April 2021, the Company
received an award of $0.6&nbsp;million to finance a development program (the &#147;CFF Grant Letter&#148;), to discover and use novel gene-editing systems to correct cystic fibrosis transmembrane conductance regulator mutations, from Cystic Fibrosis
Foundation (&#147;CFF&#148;), a <FONT STYLE="white-space:nowrap">non-profit</FONT> organization. In accordance with CFF Grant Letter, the Company received $0.4&nbsp;million upon initiation of the development program in June 2021 and expects to
receive $0.2&nbsp;million upon the program completion in 2023 fiscal year. The award was provided to the Company without a provision for financial return to CFF. However, in the event that CFF provides additional funding to the Company, pursuant to
a separate agreement between CFF and the Company (a &#147;Future Funding Agreement&#148;), CFF may receive royalty rights, an equity interest, a debt instrument or other consideration of economic value that is based on the amount of funding CFF has
provided to the Company, the award amount actually paid to the Company under the current award will be treated as an advance towards, and included in, the award amount, investment amount, principal amount or other similar term representing the
amount of funding provided by CFF to the Company under the Future Funding Agreement. The Company does not expect to receive any future funding from CFF and concluded that funds received are <FONT STYLE="white-space:nowrap">non-refundable.</FONT> The
Company recognized $0.2&nbsp;million and $0.3&nbsp;million related to the progress of a development program during the years ended December&nbsp;31, 2021 and 2022, respectively, as other income (expense), net, in the consolidated statements of
operations and comprehensive loss, as this grant is not considered an ongoing major and central operation of the Company&#146;s business. The Company recognized $0.2&nbsp;million and zero of deferred grant income in accrued expenses and other
current liabilities in the consolidated balance sheet as of December&nbsp;31, 2021 and December&nbsp;31, 2022, respectively. The Company recognized $0.1&nbsp;million of grant income receivable in prepaid expenses and other current assets in the
consolidated balance sheets as of December&nbsp;31, 2022. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>9. Convertible promissory note </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In October 2021, together with the Moderna Agreement, the Company issued a convertible promissory note for $30.0&nbsp;million to Moderna with 6.0% annual interest
payable upon the note maturity in April 2023. The Company cannot prepay the convertible promissory note without Moderna&#146;s consent. The outstanding principal amount and any unpaid accrued interest is automatically convertible into redeemable
convertible preferred units sold in a private financing with total gross cash proceeds of not less than $50.0&nbsp;million (the &#147;Qualified Financing&#148;) at a conversion price equal to the purchase price per unit that depends on the timing of
the qualified financing: i) 100% of the lowest price paid per unit by investors in the qualified financing, if the qualified financing occurs within three months from the note issuance date; ii) 95% of the lowest price paid per unit by investors in
the qualified financing, if the qualified financing occurs between three and six months from the note issuance date; iii) 90% of the lowest price paid per unit by investors in the qualified financing, if the qualified financing occurs between six
and twelve months from the note issuance date; iv) 85% of the lowest price paid per unit by investors in the qualified financing, if the qualified financing occurs after twelve months from the note issuance date. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Moderna also had an option to convert the note on similar terms in the event of a <FONT STYLE="white-space:nowrap">non-qualified</FONT> financing using the conversion
price upon a qualified financing. Upon maturity, the outstanding principal and accrued interest is either due and payable in full or converted in the Series <FONT STYLE="white-space:nowrap">A-5</FONT> redeemable convertible preferred units (or the
most senior redeemable convertible preferred units of the Company then outstanding) at a conversion price equal to the original issue price of the Series <FONT STYLE="white-space:nowrap">A-5</FONT> redeemable convertible preferred units (or the most
senior units of the Company then outstanding). Principal and accrued interest of the note were payable in cash in an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
event of default. In a deemed liquidation event the outstanding principal and accrued and unpaid interest is either due and payable in full, plus 50% on the outstanding principal amount of the
note or were convertible into the common units of the Company at a conversion price equal to the original issue price of the Series <FONT STYLE="white-space:nowrap">A-5</FONT> redeemable convertible preferred units (or the most senior units of the
Company then outstanding). In the event that the Company closes its initial public offering of its common units or common stock or other equity securities with total gross proceeds of not less than $50.0&nbsp;million (&#147;Qualified IPO&#148;), the
principal and unpaid accrued interest then outstanding is convertible automatically into the same type of the Company&#146;s securities issued upon IPO at 90% of the lowest purchase price paid per equity securities in the Qualified IPO. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The convertible promissory note is carried at amortized cost, which management estimates approximates its fair value. On the issuance date of the convertible promissory
note, the Company concluded that certain embedded unit-settled conversion put features, qualified IPO features and deemed liquidation put features were derivatives that required bifurcation. The Company estimated the fair value of embedded
derivatives was minimal due to the low probability of settlement events for these features. The Company recognized $34,000 of issuance costs as a debt discount related to legal fees, which was amortized to interest expense over the term of the note
using effective interest method. The Company recognized $0.3&nbsp;million and $0.1&nbsp;million of accrued interest expense in the consolidated statements of operations and comprehensive loss for the years ended December&nbsp;31, 2021 and 2022,
respectively. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The convertible promissory note and all accrued interest were converted, upon the Qualified Financing, into 2,607,387 Series B redeemable convertible
preferred units without any discount in January 2022 (see Note 11) and no gain or loss was recognized on the conversion. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>10. Commitments and contingencies
</B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Operating leases </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In November 2019, the Company entered
into a <FONT STYLE="white-space:nowrap">5-year</FONT> operating lease for laboratory and office space in Emeryville, California. In conjunction with signing the lease, the Company secured a letter of credit in favor of the lessor in the amount of
$0.2&nbsp;million. The lease agreement includes a renewal provision allowing the Company to extend this lease for an additional 5 years at the prevailing rental rate, which the Company was not reasonably certain to exercise. In addition to base
rent, the Company was obligated to pay variable costs related to its share of operating expenses and taxes as well as parking fees for unreserved parking spaces in a shared lot. In March 2021, this lease was modified to shorten the lease term to
terminate in April 2021. Lease payments made related to this lease in 2021 totaled $0.1&nbsp;million. In May 2021, the letter of credit related to this lease was canceled. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In January 2021, the Company entered into a <FONT STYLE="white-space:nowrap">ten-year</FONT> operating lease for laboratory and office space in Emeryville, California.
The lease commencement date was in February 2021. In conjunction with signing this lease, the Company secured a letter of credit for $3.3&nbsp;million, which is recorded as noncurrent restricted cash in the consolidated balance sheets. The lease
agreement includes a renewal provision allowing the Company to extend this lease for an additional five years, which the Company is not reasonably certain to exercise. In addition to base rent, the Company pays variable costs related to operating
expenses and taxes, which are recognized as incurred. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In September 2021, the Company entered into a <FONT STYLE="white-space:nowrap">9.25-year</FONT> operating
lease for office space in Emeryville, California, with a lease commencement date in November 2021. In conjunction with signing the lease, the Company secured a letter of credit for $0.8&nbsp;million, which is recorded as noncurrent restricted cash
in the consolidated balance sheets. In addition to base rent, the Company will pay variable costs related to operating expenses and taxes, which are recognized as incurred. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In November 2022, the Company entered into an <FONT STYLE="white-space:nowrap">8.25-year</FONT> sublease for office,
research and laboratory space in Emeryville, California, with a lease commencement date in January 2023. In conjunction with signing the lease, the Company secured a letter of credit for $2.0&nbsp;million, which is recorded as restricted cash in the
consolidated balance sheet as of December&nbsp;31, 2022. Payments for base rent required under this lease are expected to total approximately $49.3&nbsp;million over the term, of which $2.9&nbsp;million is payable within the 12 months. In addition
to base rent, the Company will pay variable costs related to its share of operating expenses and taxes. As this lease has not yet commenced as of December&nbsp;31, 2022, no <FONT STYLE="white-space:nowrap">right-of</FONT> use asset or lease
liability is recorded. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Operating lease cost for the years ended December&nbsp;31, 2021 and 2022, totaled $2.2&nbsp;million and $3.5&nbsp;million, respectively,
including $0.5&nbsp;million and $0.4&nbsp;million of variable lease cost, respectively. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Supplemental information related to the Company&#146;s operating leases is
as follows (in thousands): </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Years ended<BR>December&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cash paid for amounts included in the measurement of lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1,453</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 2,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Weighted average remaining lease term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Weighted-average discount rate</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">10.1%</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">10.1%</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes a maturity analysis of the Company&#146;s operating lease liabilities showing the aggregate lease payments
as of December&nbsp;31, 2022 (in thousands): </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:2.00pt solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">2023</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000" ALIGN="right"> 3,279</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">2027</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total future lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Less imputed interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,633</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total lease liability balance(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Less: current operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,515</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><FONT STYLE="white-space:nowrap">Non-current</FONT> operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Total lease liability as of December&nbsp;31, 2022 excludes lease payments of $49.3&nbsp;million for a lease signed but not yet commenced. </TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Legal contingencies </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">From time to time, the Company may become
involved in legal proceedings arising from the ordinary course of business. The Company records a liability for such matters when it is probable that future losses will be incurred and that such losses can be reasonably estimated. Significant
judgment by the Company is required to determine both probability and the estimated amount. Management is currently not aware of any legal matters that could have a material adverse effect on the Company&#146;s financial position, results of
operations or cash flows. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Guarantees and indemnifications </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the
normal course of business, the Company enters into agreements that contain a variety of representations and provide for general indemnification. Its exposure under these agreements is unknown because it involves claims that may be made against the
Company in the future. To the extent permitted under Delaware law, the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
Company has agreed to indemnify its directors and officers for certain events or occurrences while the director or officer is, or was serving, at a request in such capacity. To date, the Company
has not paid any claims or been required to defend any action related to its indemnification obligations. As of December&nbsp;31, 2021 and 2022, the Company did not have any material indemnification claims that were probable or reasonably possible
and consequently has not recorded related liabilities. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>11. Redeemable convertible preferred units </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On March&nbsp;15, 2021, the Company closed the Series <FONT STYLE="white-space:nowrap">A-5</FONT> financing and issued 1,580,937 shares of the Series <FONT
STYLE="white-space:nowrap">A-5</FONT> redeemable convertible preferred units for gross cash proceeds of $10.0&nbsp;million. The Company incurred $0.1&nbsp;million in issuance costs. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On January&nbsp;21, 2022, the Company closed the Series B financing and issued 12,446,876 shares of the Series B redeemable convertible preferred units for gross cash
proceeds of $145.0&nbsp;million. The Company incurred $0.7&nbsp;million in issuance costs. Concurrently with the closing of the Series B financing, the outstanding Moderna convertible promissory note and accrued interest of $30.4&nbsp;million was
converted into 2,607,387 Series B Preferred Units, at a conversion price equal to the price per unit paid by the Series B investors. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On December&nbsp;20, 2022, the
Company entered into Series <FONT STYLE="white-space:nowrap">B-1</FONT> redeemable convertible preferred unit purchase agreement to sell up to 7,108,480 Series B redeemable convertible preferred units at the purchase price of $14.06770. In December
2022, the Company sold and issued 6,773,726 shares of the Series <FONT STYLE="white-space:nowrap">B-1</FONT> redeemable convertible preferred units for gross cash proceeds of $95.3&nbsp;million in the initial closing. The Company incurred
$0.4&nbsp;million issuance costs. Additional shares may be sold within 90 days of the initial closing. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of December&nbsp;31, 2022, the Company operated under the
Amended and Restated Limited Liability Company Agreement dated December&nbsp;20, 2022 (the &#147;LLC Agreement&#148;). The LLC Agreement provides for eight classes of units: common units, Series <FONT STYLE="white-space:nowrap">A-1</FONT> redeemable
convertible preferred units (Series <FONT STYLE="white-space:nowrap">A-1),</FONT> Series <FONT STYLE="white-space:nowrap">A-2</FONT> redeemable convertible preferred units (Series <FONT STYLE="white-space:nowrap">A-2),</FONT> Series <FONT
STYLE="white-space:nowrap">A-3</FONT> redeemable convertible preferred units (Series <FONT STYLE="white-space:nowrap">A-3),</FONT> Series <FONT STYLE="white-space:nowrap">A-4</FONT> redeemable convertible preferred units (Series <FONT
STYLE="white-space:nowrap">A-4),</FONT> Series <FONT STYLE="white-space:nowrap">A-5</FONT> redeemable convertible preferred units (Series <FONT STYLE="white-space:nowrap">A-5),</FONT> Series B redeemable convertible preferred units (Series B) and
Series <FONT STYLE="white-space:nowrap">B-1</FONT> redeemable convertible preferred units (Series <FONT STYLE="white-space:nowrap">B-1).</FONT> </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The redeemable
convertible preferred units as of December&nbsp;31, 2021, consisted of the following (in thousands, except unit data): </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Units<BR>authorized</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Units issued<BR>and<BR>outstanding</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Aggregate<BR>liquidation<BR>preference</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Net<BR>carrying<BR>value</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series <FONT STYLE="white-space:nowrap">A-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,501,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,501,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series <FONT STYLE="white-space:nowrap">A-2</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">774,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">774,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series <FONT STYLE="white-space:nowrap">A-3</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,513,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,513,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series <FONT STYLE="white-space:nowrap">A-4</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,280,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,280,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series <FONT STYLE="white-space:nowrap">A-5</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,580,937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,580,937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,948</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,650,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,650,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">76,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">76,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The redeemable convertible preferred units as of December&nbsp;31, 2022, consisted of the following (in thousands,
except unit data): </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Units<BR>authorized</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Units issued<BR>and<BR>outstanding</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Aggregate<BR>liquidation<BR>preference</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Net<BR>carrying<BR>value</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series <FONT STYLE="white-space:nowrap">A-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,501,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,501,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 24,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 24,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series <FONT STYLE="white-space:nowrap">A-2</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">774,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">774,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series <FONT STYLE="white-space:nowrap">A-3</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,513,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,513,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series <FONT STYLE="white-space:nowrap">A-4</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,280,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,280,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series <FONT STYLE="white-space:nowrap">A-5</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,580,937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,580,937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,948</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,054,263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,054,263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">175,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">174,678</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series <FONT STYLE="white-space:nowrap">B-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,108,480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,773,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95,291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,813,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,478,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">347,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">346,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The holders of the redeemable convertible preferred units have various rights and preference as follows: </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Voting rights </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Each redeemable convertible preferred unit is entitled
to one vote for each common unit into which such redeemable convertible preferred unit is then convertible. The redeemable convertible preferred unitholders and the common unitholders vote together on all matters as a single class, except as
otherwise provided by law or the provisions of the LLC Agreement. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Board of Managers consists of up to seven individuals. As long as at least 618,716 Series <FONT
STYLE="white-space:nowrap">A-1</FONT> redeemable convertible preferred units, Series <FONT STYLE="white-space:nowrap">A-2</FONT> redeemable convertible preferred units and/or Series <FONT STYLE="white-space:nowrap">A-3</FONT> redeemable convertible
preferred units remain outstanding, the members holding a majority of the outstanding Series <FONT STYLE="white-space:nowrap">A-1</FONT> redeemable convertible preferred units, Series <FONT STYLE="white-space:nowrap">A-2</FONT> redeemable
convertible preferred units and Series <FONT STYLE="white-space:nowrap">A-3</FONT> redeemable convertible preferred units, voting together as a single class on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis, are entitled to elect one
manager. As long as at least 1,654,555 Series <FONT STYLE="white-space:nowrap">A-4</FONT> redeemable convertible preferred units remain outstanding, the members holding a majority of the Series <FONT STYLE="white-space:nowrap">A-4</FONT> redeemable
convertible preferred units, voting as a single class, are entitled to elect one manager. As long as at least 316,187 Series <FONT STYLE="white-space:nowrap">A-5</FONT> redeemable convertible preferred units remain outstanding, the members holding a
majority of the Series <FONT STYLE="white-space:nowrap">A-5</FONT> redeemable convertible preferred units, voting as a single class, are entitled to elect one manager. As long as at least 3,010,852 Series B redeemable convertible preferred units
remain outstanding, the members holding a majority of the Series B redeemable convertible preferred units, voting as a single class, are entitled to elect one manager. The members holding a majority of the common units, voting as a single class are
entitled to elect one manager. The members holding a majority of the units then outstanding, voting together as a single class on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to common units basis are entitled to elect any remaining
managers. As of December&nbsp;31, 2021 and 2022, respectively, the Company&#146;s Board of Managers consisted of five and six individuals, respectively. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Conversion </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Each redeemable convertible preferred unit is convertible
into common units at the option of a holder at the then applicable conversion price, which is equal the original purchase price, subject to adjustments for recapitalization and others. The original purchase price is equal to $3.2325 per Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Preferred Unit, $0.6456 per Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Unit, $1.1713 per Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Unit, $4.84875 per Series <FONT
STYLE="white-space:nowrap">A-4</FONT> Preferred Unit, $6.32536 per Series <FONT STYLE="white-space:nowrap">A-5</FONT> Preferred Unit, $11.64951 per Series B Preferred Unit, and $14.06770 per Series <FONT STYLE="white-space:nowrap">B-1</FONT>
Preferred Unit. As of December&nbsp;31, 2021 and 2022, the redeemable convertible preferred units were convertible into common units at a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> conversion ratio.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Each redeemable convertible preferred unit is automatically convertible into common units (or shares of common stock,
if the Company is converted into a corporation), based on the then-effective applicable conversion rate (A)&nbsp;at any time upon the affirmative vote or written consent of (i)&nbsp;the members holding a majority of the redeemable convertible
preferred units then outstanding, (ii)&nbsp;the members holding a majority of the Series B redeemable convertible preferred units then outstanding, and (iii)&nbsp;the members holding a majority of the Series
<FONT STYLE="white-space:nowrap">B-1</FONT> redeemable convertible preferred units then outstanding, or (B)&nbsp;immediately upon the closing of a firmly underwritten public offering pursuant to an effective registration statement under the
Securities Act of 1933, as amended, covering the offer and sale of common units (or other common securities) with the gross cash proceeds to the Company, before underwriting discounts, commissions and offering expenses, are at least
$100.0&nbsp;million, or (C)&nbsp;the closing of a merger, acquisition or other business combination involving the Company and a publicly traded special purpose acquisition company (&#147;SPAC&#148;) or its subsidiary or affiliate in which the
surviving public company has available immediately cash of at least $100.0&nbsp;million in the aggregate greater than the cash on the Company&#146;s consolidated balance sheets as of immediately prior to such merger, acquisition or other business
combination (including proceeds of a private investment in public equity transaction that is substantially contemporaneous with or conditioned on such merger, acquisition or other business combination, and any redemptions from the SPAC&#146;s trust
account). </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Anti-dilution and other protective provisions </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The
holders of the redeemable convertible preferred units have proportional anti-dilution protection right for unit splits, unit dividends and similar recapitalizations, subject to certain exclusions, anti-dilution price protection for additional sales
of securities by the Company for consideration per unit less than the applicable conversion price per unit of any series of the redeemable convertible preferred units, on a broad-based weighted average basis. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The holders of the redeemable convertible preferred units have certain protective rights. The Company shall not, either directly or by amendment, merger, consolidation
or otherwise, without the prior written approval of members holding a majority of the redeemable convertible preferred units then outstanding to alter or change the rights, preferences or privileges of the redeemable convertible preferred units;
consummate a liquidation or a deemed liquidation event; change the Company&#146;s LLC Agreement; authorize or create any new class or series of units or other equity security; increase or decrease the authorized number of the common units or the
redeemable convertible preferred units or any series; redeem, acquire or repurchase any, or make any distribution on, any common units or redeemable convertible preferred units; change the compensation or equity awards granted to executive officers
of the Company, unless such transaction is approved by the Board of Managers; increase or decrease the authorized number of managers constituting the Board of Managers and amend other rights or enter into certain transactions. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Liquidation preference </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the event of a liquidation, a deemed
liquidation event (including a consolidation, merger or reorganization or a sale, lease, transfer, exclusive irrevocable license or other disposition of all or substantially all of the assets of the Company), dissolution or <FONT
STYLE="white-space:nowrap">winding-up</FONT> of the Company, the funds are distributed first to the members holding the redeemable convertible preferred units in proportion to and to the extent of their unreturned original purchase price per
redeemable convertible preferred unit, until each member holding the redeemable convertible preferred units has received cumulative distributions in an amount equal to the unreturned original purchase price for each of such member&#146;s redeemable
convertible preferred unit. Second, to the members holding common units and the redeemable convertible preferred units pro rata based on the number of units held by each such holder, assuming for this purpose that all the redeemable convertible
preferred units have been converted into common units as of the date of such operating distribution or distribution of net proceeds </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
or assets available for distribution, whether in cash or in other property. Third, the amounts that would otherwise be distributed to any redeemable convertible preferred unit holder pursuant to
the liquidation preference on <FONT STYLE="white-space:nowrap">as-converted</FONT> to common units basis will be reduced by an amount equal to the remaining preferred participation threshold amount for such redeemable convertible preferred unit. The
preferred participation threshold amount for a redeemable convertible preferred unit is equal to the original purchase price, reduced by distributions paid. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Distributions preference </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Distributions, when determined by the Board
of Managers, are payable to the members holding the redeemable convertible preferred units, pro rata in proportion to the liquidation preference amounts in respect of the redeemable convertible preferred units held by such members; thereafter, to
the members in proportion to the number of shares held by such members, on as converted basis. No distributions were declared or made from inception and during the years ended December&nbsp;31, 2021 and 2022. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Redemption </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The redeemable convertible preferred units are not
redeemable except in the event of certain effected deemed liquidation events, that are not in the Company&#146;s control. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>12. Common units </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of December&nbsp;31, 2021 and 2022, the Company was authorized to issue 32,000,000 and 66,000,000 common units, respectively. Each common unit is entitled to cast one
vote. The holders of common units are also entitled to receive distributions whenever funds are legally available and when declared by the Company&#146;s Board of Managers, subject to prior rights of the holders of the redeemable convertible
preferred units. No distributions have been declared from inception to date. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of December&nbsp;31, 2021 and 2022, the Company reserved common units for future
issuance as follows: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Outstanding redeemable convertible preferred units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,650,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,478,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Outstanding profits interests</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,783,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,516,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Units available for grants under 2019 Equity Incentive Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">236,886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,088,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total common units reserved for future issuance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,671,276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,082,786</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Founders and investors common units </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In June&nbsp;2017, Metagenomi Inc. issued 4,687,500 shares of its common stock at a purchase price of $0.0001 per share to its founders and investors for services, which
was an estimated fair value determined by the Board of Managers at the issuance date. Pursuant to the terms of the stock purchase agreements, 25% of the shares vested on the first anniversary of the vesting start date and monthly over the next
36&nbsp;months. Vesting of shares is accelerated upon a change of control event (including an acquisition of the Company by another entity by means of any transaction or series of related transactions, or a sale of all or substantially all of the
assets of the Company). The Company has a right to repurchase unvested shares upon termination of services provided by the founders to the Company at the price lower of i) the purchase price or ii) the fair value at the date of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
repurchase. In November 2018, in connection with the reorganization, common stock issued by Metagenomi Inc. was exchanged for common units of Metagenomi with the same terms. The estimated fair
value of common unit at the modification date was determined to be $0.02 per unit, based on the Company&#146;s recent common unit valuation, and the modification expense was immaterial. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In March 2019, the Company issued 1,260,000 common units to an investor for services with a purchase price of $0.02 per unit, which was based on the recent
Company&#146;s common stock valuation. As long as the investor continues to provide services, 25% of the shares vested immediately and the remainder vested monthly over the next 36&nbsp;months. Vesting of shares is accelerated upon a change of
control event. The Company has a right to repurchase unvested shares upon termination of services provided by the founders to the Company at the price lower of i) the purchase price or ii) the fair value at the date of repurchase. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company accounts for issued common units as unit-based&nbsp;compensation to founders and investors as service providers and recognizes unit-based&nbsp;compensation
expense of $0.1&nbsp;million over the vesting period. The Company had 494,689 and 78,750 common units vested during the years ended December&nbsp;31, 2021 and December&nbsp;31, 2022, respectively, each having fair value of less than
$0.1&nbsp;million. 78,750 and zero common units were unvested as of December&nbsp;31, 2021 and 2022, respectively. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table provides a summary of common
units with vesting conditions activity during the year ended December&nbsp;31, 2022: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Number&nbsp;of<BR>common<BR>units<BR>unvested</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Weighted-<BR>average<BR>grant&nbsp;date<BR>fair value</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Unvested as of January&nbsp;1, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Common Units vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(78,750</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Unvested as of December&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>13. Profits interests plan </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company
grants profits interests under the 2019 Equity Incentive Plan, adopted on March&nbsp;13, 2019 (the &#147;2019 Plan&#148;). The Company may grant profits interests with a threshold amount, which may be zero, established by the Board of Managers on
the date of issuance. Accordingly, such profits interests do not give a holder a share of the proceeds if the Company&#146;s assets were sold at fair market value and the proceeds of such disposition were distributed in complete liquidation of the
Company immediately after the date of grant but give a holder a right to share in the appreciation in the value of a common unit from the date of receipt to the future, as specifically provided in the LLC Agreement. The 2019 Plan allows for grants
of profits interests to the Company&#146;s officers, employees, directors and consultants. Profits interests generally vest monthly over four years, with or without <FONT STYLE="white-space:nowrap">one-</FONT> year cliff vesting in the first year.
In the event of a profits interest holder&#146;s termination, the unvested portion of such profits interest is automatically forfeited and cancelled without any additional consideration. Additionally, the Company has the right to repurchase the
vested portion of such profits interest at its fair market value, which is based on the fair market value of a common unit (as determined by the Board of Managers), less the applicable profits interest threshold amount, at any time during the <FONT
STYLE="white-space:nowrap">12-month</FONT> period after termination of a profits interest holder&#146;s service to the Company. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The number of common units reserved
for issuance under the 2019 Plan was 6,020,644 and 14,604,165 at December&nbsp;31, 2021, and 2022, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The table below presents a summary of activities and a reconciliation of common units authorized and remaining for
grant under the 2019 Plan during the year ended December&nbsp;31, 2022: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Units<BR>available for<BR>grants</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Profits<BR>interests</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Weighted-<BR>average</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>threshold<BR>amount</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Aggregate<BR>intrinsic value<BR>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Outstanding as of January&nbsp;1, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">236,886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,783,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1,372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Authorized</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,583,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Profits interests granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,763,356</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,763,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Forfeited and expired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,031,041</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,031,041</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Outstanding as of December&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,088,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,516,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">34,398</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Vested and expected to vest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,088,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,516,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">34,398</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The aggregate intrinsic value is calculated as the positive difference between the threshold amount of the profits interests and the fair
value of the Company&#146;s common unit as of December&nbsp;31, 2021 and 2022. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">During the years ended December&nbsp;31, 2021 and 2022, the Company granted 3,550,854
and 2,763,356 profits interests with a weighted average grant date fair value of $1.03 and $1.90, respectively. The total fair value of the profits interests vested during the years ended December&nbsp;31, 2021 and 2022 was $0.2&nbsp;million and
$1.1&nbsp;million, respectively. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Unit-based compensation expense </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company estimated the fair value of profits interests on the grant date using the Black-Scholes option-pricing model based on the following assumptions for the years
ended December&nbsp;31, 2021 and 2022: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Years ended December&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79.62%&nbsp;&#151;&nbsp;91.19%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79.57%&nbsp;&#151;&nbsp;82.60%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.66&nbsp;&#151;&nbsp;6.63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.51&nbsp;&#151;&nbsp;4.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.18%&nbsp;&#151; 0.94%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.65%&nbsp;&#151; 4.33%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Threshold range</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">0.34&nbsp;&#151;&nbsp;$0.51</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">3.20</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Expected volatility</I></B>&#151;The Company is a private company and lacks company-specific historical and implied volatility
information. Therefore, the Company estimates its expected unit&#146;s volatility based on the historical volatility of a publicly traded set of peer companies and expect to continue to do so until the Company has adequate historical data regarding
the volatility of the Company&#146;s traded unit or stock price. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Expected term</I></B>&#151;The expected term of profits interests has been determined based
on the expected time to liquidity and expected vesting term. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Risk-free interest rate</I></B>&#151;The risk-free interest rate is determined by reference to
the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Dividends</I></B>&#151;Expected dividend yield is zero because the Company does not pay cash dividends on common units and does not expect to pay any cash
dividends in the foreseeable future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The grant date fair value of common units utilized in the Black-Scholes model is determined by the Company&#146;s
Board of Managers with the assistance of management. The grant date fair value of common units is determined using valuation methodologies which utilizes certain assumptions including probability weighting of expected exit events, volatility, time
to liquidation, a risk-free interest rate and an assumption for a discount for lack of marketability. In determining the fair value of the common units, the methodologies used to estimate the enterprise value were performed using methodologies,
approaches, and assumptions consistent with the American Institute of Certified Public Accountants Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table presents the classification of unit -based compensation expense for the years ended December&nbsp;31, 2021 and 2022 (in thousands): </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Years ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total unit-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The above unit-based compensation expense related to the following unit-based awards for the years ended December&nbsp;31, 2021 and 2022
(in thousands): </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Years ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Profits Interests</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">365</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Common Units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total unit-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There was $3.3 million and $5.7&nbsp;million in unrecognized unit-based compensation expense related to the profits interests as of
December&nbsp;31, 2021 and 2022, respectively, that was expected to be recognized over a weighted-average period of 3.81 and 3.03 years, respectively. There was less than $0.1&nbsp;million unrecognized unit-based compensation expense related to the
common units with vesting conditions as of December&nbsp;31, 2021, that was expected to be recognized over a weighted-average period of 0.2 years. As of December&nbsp;31, 2022, there was no unrecognized expense related to the common units with
vesting conditions.<B> </B> </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>14. Related party transactions </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The
Company&#146;s former chief business officer was a founder, and a chief executive officer of Affini-T. Affini-T was a related party when the Company exercised significant influence until November 2021. In November 2021, certain common stock shares
were forfeited, and the chief business officer resigned from the Company. As of December&nbsp;31, 2021, Affini-T is no longer a related party of the Company (see Note 5). </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Bayer Healthcare LLC (&#147;Bayer&#148;) is a significant investor in the Company and has a Board seat. The Company and Bayer entered into a research and development
master service agreement in November 2019. Bayer was performing research and development services under the agreement in accordance with the statement of works agreed by the parties. Services under this agreement were completed as of
December&nbsp;31, 2020, and the Company accrued $0.2&nbsp;million in accrued expenses and other current liabilities as of December&nbsp;31, 2020. The Company paid $0.2&nbsp;million to Bayer in February and March 2021 and there were no other services
provided by Bayer to the Company during the years ended December&nbsp;31, 2021 and December&nbsp;31, 2022. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In connection with Series B and Series <FONT STYLE="white-space:nowrap">B-1</FONT> financings, the Company reimbursed
certain investors for finance issuance costs that they incurred totaling $0.4&nbsp;million. As of December&nbsp;31, 2022, $0.1&nbsp;million of Series <FONT STYLE="white-space:nowrap">B-1</FONT> financing costs reimbursable to investors is recorded
in accrued expenses and other current liabilities in the consolidated balance sheets. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>15. Income taxes </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Metagenomi is treated as a partnership for tax purposes, and thus, is not subject to income taxes. It is the responsibility of the LLC members to report their
proportionate share of any taxable income or loss generated by Metagenomi to the appropriate taxing authorities and pay the associated taxes, if any. With respect to the Company&#146;s subsidiary, Metagenomi Inc. is a corporation for tax purposes
and is subject to income taxes which have been included in the consolidated financial statements. <FONT STYLE="white-space:nowrap">All&nbsp;pre-tax&nbsp;losses</FONT> have been incurred in the United States. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">During the year ended December&nbsp;31, 2022, income tax expense consisted of the following (in thousands): </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:2.00pt solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Current:</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Federal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">State</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total current tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Deferred:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Federal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">State</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total deferred tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company recognized an income tax provision of $2.6&nbsp;million for the year ended December&nbsp;31, 2022 as a result of their
taxable income related to an upfront payment received under the Moderna Agreement and capitalization of their research and development expenses under the newly enacted Internal Revenue Code Section&nbsp;174 (&#147;Section&nbsp;174&#148;), which
became effective on January&nbsp;1, 2022. Section&nbsp;174 changed the tax treatment of research and experimentation (R&amp;E) expenditures, which requires the capitalization of R&amp;E expenditures over a period of five years for R&amp;E paid or
incurred in the United States and 15&nbsp;years for R&amp;E paid or incurred outside of the United States. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">During the year ended December&nbsp;31, 2021, the Company
had no income tax expense, and all losses were from the U.S. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The effective tax rate of the Company&#146;s provision for income taxes differs from the federal
statutory rate of 21%&nbsp;for the years ended December&nbsp;31, 2021 and 2022, is as follows: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Years&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2021</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Statutory rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Nontaxable LLC losses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15.99</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.13</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">State tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Permanent and other adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.12</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1.31</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Change in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6.49</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(41.02</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Research credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6.26</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Significant components of the deferred tax assets for federal and state income taxes as of December&nbsp;31, 2021 and
2022, are as follows (in thousands): </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Years ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Deferred Tax Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net operating loss carry forwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,601</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Research credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,568</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Reserves and accruals</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Capitalized research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,901</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,677</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Deferred Tax Liabilities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(607</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,583</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT> asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,051</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,685</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total gross deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,658</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,268</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Less: Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,019</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,846</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A valuation allowance is required to be established when it is more likely than not that all or a portion of a deferred tax asset will
not be realized. Realization of deferred tax assets is dependent upon future earnings, the timing and amount of which are uncertain. Metagenomi Inc. believes that, based on a number of factors such as the history of operating losses, it is more
likely than not that the deferred tax assets will not be fully realized, such that a full valuation allowance has been recorded. The valuation allowance increased by $1.4&nbsp;million and $16.8&nbsp;million for the years ended December&nbsp;31, 2021
and 2022, respectively, primarily due to the increase in deferred revenue and capitalization of research and development expenses under newly enacted Section 174. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of December&nbsp;31, 2022, Metagenomi Inc. had $0.02&nbsp;million and $8.3&nbsp;million of net operating loss carryforwards for federal and state income tax purposes,
respectively. Federal net operating loss carryforwards do not expire. State net operating loss carryforwards begin expiring in 2037. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of December&nbsp;31, 2022,
Metagenomi Inc. had $0 and $2.8&nbsp;million of research credit carryforwards for federal and state income tax purposes, respectively. State research credit carryforwards do not expire and can be carried forward indefinitely. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Utilization of some of the federal and state net operating losses and credit carryforwards may be subject to annual limitations due to the change in ownership provisions
of the Internal Revenue Code of 1986 (&#147;Internal Revenue Code&#148;) and similar state provisions. The annual limitation may result in the expiration of net operating losses and credits before utilization. As of December&nbsp;31, 2022, the
Company has completed an IRC Section&nbsp;382 analysis from inception through the year ended December&nbsp;31, 2022. The Company experienced two ownership changes in August 2019 and January 2022. Net operating losses generated prior to
December&nbsp;31, 2017, of $0.3 million are permanently limited for federal tax purposes. Net federal operating losses generated after December&nbsp;31, 2017 are not limited as they can be carried forward indefinitely, subject to an 80% income
limitation. Net operating losses of $0.1&nbsp;million are permanently limited for California tax purposes. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Metagenomi Inc. uses the &#147;more likely than not&#148;
criterion for recognizing the income tax benefit of uncertain income tax positions and establishing measurement criteria for income tax benefits. Although it is reasonably </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
possible that certain unrecognized tax benefits may increase or decrease within the next twelve months due to tax examination changes, settlement activities, expirations of statute of
limitations, or the impact on recognition and measurement considerations related to the results of published tax cases or other similar activities, Metagenomi Inc. does not anticipate significant changes to unrecognized tax benefits over the next 12
months. During the years ended December&nbsp;31, 2021 and 2022, no interest or penalties were recognized relating to unrecognized tax benefits. In the event Metagenomi Inc. should need to recognize interest and penalties related to unrecognized
income tax liabilities, this amount will be recorded as an accrued liability and an increase to income tax expense. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The changes in the balance of gross unrecognized
tax benefits, which excludes interest and penalties, for the years ended December&nbsp;31, 2021 and 2022, are as follows (in thousands): </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Years ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Beginning balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Gross increases&#151;tax position in current period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Gross increases&#151;tax position in prior periods</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Reductions for tax positions of prior years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Ending balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Metagenomi Inc. files tax returns in the U.S. and California. Metagenomi Inc. is not currently under examination in any of these
jurisdictions and all its tax years remain effectively open to examination due to net operating losses from inception. Metagenomi Inc. recognized $1.0&nbsp;million of uncertain tax positions as other
<FONT STYLE="white-space:nowrap">non-current</FONT> liabilities and $0.8&nbsp;million was netted against deferred tax assets. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In accordance with the Tax Cuts and
Jobs Act of 2017, research and experimental (R&amp;E) expenses under Internal Revenue Code Section&nbsp;174 are required to be capitalized beginning in 2022. R&amp;E expenses are required to be amortized over a period of 5 years for domestic
expenses and 15 years for foreign expenses. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On August&nbsp;16, 2022, President Biden signed into law the Inflation Reduction Act of 2022, which includes an
Alternative Minimum Tax based on the Adjusted Financial Statement Income of Applicable Corporations. Based on an initial evaluation, the Company does not believe the Inflation Reduction Act will have a material impact on the income tax provision and
cash taxes. The Company will continue to monitor the changes in tax laws and regulations to evaluate their potential impact on the business. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>16. Net loss per
unit </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Basic and diluted net loss per unit attributable to common unitholders is calculated as follows (in thousands except share and per share amounts): </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Years ended December&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss attributable to common members</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(21,442</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(43,593</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Weighted average common units outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,947,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,947,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Less: Weighted-average unvested common units subject to repurchase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(256,069</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,846</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Weighted average units used to computing basic and diluted net loss per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,691,431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,938,654</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss per unit attributable to common unitholders&#151;basic and diluted:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.77</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7.34</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following outstanding potentially dilutive securities have been excluded from the calculation of diluted net loss
per unit, as their effect is anti-dilutive: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Years ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Redeemable convertible preferred units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,650,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,478,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Profits interests</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,783,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,516,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Unvested common units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,513,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,994,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>17. Employee retirement plan </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company has
a defined contribution plan under Section&nbsp;401(k) of the Internal Revenue Code (the &#147;401(k) Plan&#148;), covering its employees. Employees may contribute a percentage of their annual compensation to this plan, subject to the maximum
allowable amount set by the Internal Revenue Service. The 401(k) Plan provides that the Company matches each participant&#146;s contribution at 100% up to the first 5% of the employee&#146;s eligible compensation. The Company&#146;s contributions to
the 401(k) Plan were $0.2&nbsp;million and $0.6&nbsp;million for the years ended December&nbsp;31, 2021 and 2022, respectively. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>18. Subsequent events
</B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company has reviewed and evaluated subsequent events through August&nbsp;3, 2023, the date that the consolidated financial statements were available to
be issued. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In January 2023, the Company sold an additional 334,754 Series <FONT STYLE="white-space:nowrap">B-1</FONT> redeemable convertible preferred units in
accordance with the Series <FONT STYLE="white-space:nowrap">B-1</FONT> purchase agreement and received gross cash proceeds of $4.7&nbsp;million. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In March and June
2023, the Company granted 450,860 and 1,530,523 profits interests to officers, employees and consultants with a threshold amount of $5.75 and $7.40, respectively. These profits interests vest over a period of two to four years. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>19. Subsequent events (unaudited) </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company has reviewed and evaluated
subsequent events through September&nbsp;7, 2023, the date that the consolidated financial statements were available to be reissued. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Profits Interests Grants
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In September 2023, the Company granted 274,830 profits interests awards to officers, employees and consultants with a threshold amount of $11.84. In July
and September 2023, the Company canceled and re-issued 781,312 profits interests awards with thresholds of $7.40 and $11.84. Issued profits interests vest over a period of two to four years. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Amendment to the LLC Agreement </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company&#146;s LLC Agreement was
amended on July 31, 2023 to provide for &#147;catch-up&#148; distributions for profits interests once the applicable catch-up threshold amount for such profits interests was met (the &#147;Amendment to the LLC Agreement&#148;). </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The LLC Agreement provides each profits interest with a distribution threshold amount, which is determined on the date of issuance and represents the amount that would
be distributed if, immediately after issuance, the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
Company sold all of its assets at fair market value and distributed the net proceeds in liquidation. A profits interest does not participate in Company distributions until an amount equal to its
distribution threshold amount has been distributed to other members of the Company with units that either have a lower threshold amount or no threshold amount. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Once
the applicable distribution threshold amount has been met for a particular profits interest, such profits interest will participate in Company distributions on a pro rata basis until the catchup threshold amount has been met. Once the catch-up
threshold amount has been met, subsequent &#147;catch-up&#148; distributions will be made solely to holders of profits interests until such holders have received an amount equal to the amount such holders would have received had the distribution
threshold not existed. Once the profits interest holders have received distributions in an amount equal to what they would have received had the distribution threshold not existed, all subsequent distributions are made on a pro rata basis with
common unitholders. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The catch-up threshold amount of $11.84 per unit reflected the estimated fair value of the </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Company&#146;s common unit as of July 31, 2023, as determined by the Company&#146;s board of managers, with input from management, and considering the Company&#146;s
most recently available third-party valuations of common units. The amendment to the LLC Agreement resulted in a change to the fair value of the profits interests and will be accounted for as a modification of the profits interests&#146; awards.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="fin425213_7"></A>Condensed Consolidated Balance Sheets </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>(in thousands, except units) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>(unaudited) </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right"><B>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">184,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">51,648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Available-for-sale</FONT></FONT>
marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">177,690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">266,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Contract assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">366,899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">324,238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,834</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Long-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,676</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating lease <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT>
assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">414,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">408,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Liabilities, redeemable convertible preferred units and members&#146; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Income tax payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Current portion of operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Collaboration advance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><FONT STYLE="white-space:nowrap">Non-current</FONT> portion of operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Deferred revenue, <FONT STYLE="white-space:nowrap">non-current</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">142,811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">160,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Commitments and contingencies (Note 8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Redeemable convertible preferred units: 41,813,375 units authorized as of December&nbsp;31, 2022 and
June&nbsp;30, 2023; 41,478,621 and 41,813,375 units issued and outstanding as of December&nbsp;31, 2022 and June&nbsp;30, 2023, respectively. Liquidation preference $347,335 and $352,044 as of December&nbsp;31, 2022 and June&nbsp;30, 2023,
respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">346,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">350,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Members&#146; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Common units: 66,000,000 units authorized as of December&nbsp;31, 2022 and June&nbsp;30, 2023; 5,947,500
units issued and outstanding as of December&nbsp;31, 2022 and June&nbsp;30, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Profits interests: 14,604,165 units authorized as of December&nbsp;31, 2022 and June&nbsp;30, 2023;
7,516,073 and 9,370,804 units issued and outstanding as of December&nbsp;31, 2022 and June&nbsp;30, 2023, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accumulated other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(274</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(429</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(76,689</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(105,830</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total members&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(74,428</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(102,539</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total liabilities, redeemable convertible preferred units and members&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">414,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">408,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial"><I>The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="fin425213_8"></A>Condensed Consolidated Statements of Operations and Comprehensive Loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>(in thousands, except units and per unit data) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>(unaudited) </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Six months ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,692</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,834</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,084</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,895</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,997</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,901</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(98</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Change in fair value of long-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss before provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,493</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,046</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,092</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,095</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,585)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(29,141)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other comprehensive loss:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Unrealized loss on
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(170</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(155</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,755)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(29,296)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss per unit attributable to common unitholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.13)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4.90)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Weighted average common units outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">5,929,662</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">5,947,500</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:200pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial"><I>The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="fin425213_9"></A>Condensed Consolidated Statements of Redeemable Convertible Preferred Units and
Members&#146; Deficit </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>(in thousands, except units) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>(unaudited)
</B></P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Redeemable<BR>Convertible Preferred<BR>Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Common Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Profits Interests</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Accumulated<BR>Other<BR>Comprehensive<BR>Loss</B></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="right"><B>Accumulated</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:arial" ALIGN="right"><B>Deficit</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="right"><B>Total<BR>Members&#146;</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:arial" ALIGN="right"><B>Deficit</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Units</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Units</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Units</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">BALANCE&#151;January 1, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,650,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">76,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,947,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,783,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">547</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(21</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(33,096)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(32,544)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Issuance of Series B redeemable convertible preferred units for cash, net of issuance costs of $697</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,446,876</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Issuance of Series B redeemable convertible preferred units upon conversion of convertible note and accrued
interest</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,607,387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Issuance of profits interests</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,166,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Cancellation and forfeiture of profits interests</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(543,469</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Unit-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(170</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(170</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,585</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,585</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="25" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">BALANCE&#151;June 30, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,704,895</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">251,173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,947,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,406,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,443</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(191</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(51,681)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(50,403)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="25" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">BALANCE&#151;January 1, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,478,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">346,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,947,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,516,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(274</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(76,689</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(74,428</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Issuance of Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Units, net of issuance costs of
$54</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">334,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Issuance of profits interests</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,992,983</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Cancellation and forfeiture of profits interests</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(138,252</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Unit-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(155</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(155</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29,141</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29,141</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="25" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">BALANCE&#151;June 30, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">41,813,375</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">350,758</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">5,947,500</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">9,370,804</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3,694</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(429</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(105,830)</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(102,539)</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="25" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="25" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial"><I>The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="fin425213_10"></A>Condensed Consolidated Statements of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>(in thousands) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>(unaudited) </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Six months ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Cash flows from operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,585</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(29,141</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Adjustments to reconcile net loss to net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Unit-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Loss on fixed assets <FONT STYLE="white-space:nowrap">write-off</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><FONT STYLE="white-space:nowrap">Non-cash</FONT> lease expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">644</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,042</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Amortization of premiums and discounts on
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,536</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Amortization of <FONT STYLE="white-space:nowrap">non-cash</FONT> collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(507</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><FONT STYLE="white-space:nowrap">Non-cash</FONT> interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Change in fair value of long-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(94</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,870</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,328</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Contract assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(780</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">882</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Income tax payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Deferred revenue and collaboration advance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,144</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,161</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(184</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(717</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,067</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(47,087</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Cash flows from investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,189</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,818</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Purchases of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(88,469</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(168,977</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Maturities and sales of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,008</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(67,128</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(90,787</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Cash flows from financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Payments of initial public offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Proceeds from issuance of redeemable convertible preferred units, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net change in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(133,618</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cash, cash equivalents and restricted cash at the beginning of the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">190,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cash, cash equivalents and restricted cash at the end of the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">97,505</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">56,896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Reconciliation of cash, cash equivalents and restricted cash</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">93,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">51,648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cash, cash equivalents and restricted cash at the end of the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">97,505</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">56,896</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial"><I>The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Condensed Consolidated Statements of Cash Flows&nbsp;(Continued) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>(in thousands) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>(unaudited) </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Six months ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Supplemental cash flow information</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Issuance of Series B redeemable convertible preferred units upon conversion of convertible promissory note
and accrued interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Common shares of <FONT STYLE="white-space:nowrap">Affini-T</FONT> received for collaboration
revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating lease <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT>
assets obtained in exchange for new lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,608</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Purchases of property and equipment included in accounts payable and accrued expenses and other current
liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,593</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Deferred finance issuance costs included in
accounts payable and accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #000000">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #000000" ALIGN="right">1,621</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:400pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial"><I>The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="fin425213_11"></A>Notes to the Unaudited Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>1. Description of business, organization and liquidity </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Organization
and business </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Metagenomi Technologies, LLC (&#147;Metagenomi&#148;), together with its wholly owned subsidiary Metagenomi, Inc. (&#147;Metagenomi Inc.&#148;)
(together, the &#147;Company&#148;) is a gene editing biotechnology company developing therapeutics by leveraging a toolbox of next-generation gene editing systems to accurately edit DNA. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Liquidity and going concern </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company has incurred significant
losses from operations since its inception. During the six months ended June&nbsp;30, 2022 and 2023, the Company incurred net losses of $18.6&nbsp;million and $29.1&nbsp;million, respectively. As of June&nbsp;30, 2023, the Company had an accumulated
deficit of $105.8&nbsp;million. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company has historically financed its operations primarily through issuance of redeemable convertible preferred units,
convertible promissory notes and its collaboration agreements with Moderna, <FONT STYLE="white-space:nowrap">Affini-T</FONT> and Ionis (see Note 7). The Company expects to continue to incur substantial losses, and its ability to achieve and sustain
profitability will depend on the successful development, approval, and commercialization of any product candidates it may develop, and on the achievement of sufficient revenue to support its cost structure. The Company may never achieve
profitability and, unless and until it does, it will need to continue to raise additional capital. Management expects that existing cash, cash equivalents and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities of $318.4&nbsp;million as of June&nbsp;30, 2023, will be sufficient to fund its current operating plan for at least the next 12
months from the date of issuance of these condensed consolidated financial statements. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>2. Summary of significant accounting policies </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Basis of presentation </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">These condensed consolidated financial
statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#147;U.S. GAAP&#148;) and pursuant to the rules and regulations of the Securities and Exchanges Commission (&#147;SEC&#148;)
regarding interim financial reporting. The accompanying condensed consolidated financial statements include the accounts of Metagenomi and Metagenomi Inc., a wholly owned subsidiary. All intercompany balances and transactions have been eliminated in
consolidation. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The interim condensed consolidated balance sheet as of June&nbsp;30, 2023, and the condensed consolidated statements of operations, and cash flows
for the six months ended June&nbsp;30, 2022 and 2023 are unaudited. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and reflect, in the opinion of
management, all adjustments of a normal and recurring nature that are necessary for the fair statement of the Company&#146;s financial position as of June&nbsp;30, 2023 and its results of operations and cash flows for the six months ended
June&nbsp;30, 2022 and 2023. The financial data and the other financial information disclosed in these notes to the condensed consolidated financial statements related to the <FONT STYLE="white-space:nowrap">six-month</FONT> periods are also
unaudited. The results of operations for the six months ended June&nbsp;30, 2023 are not necessarily indicative of the results to be expected for the year ending December&nbsp;31, 2023, or for any other future annual or interim period. The condensed
consolidated balance sheet as of December&nbsp;31, 2022, included herein was derived from the audited consolidated financial statements as of that date. Certain information and footnote disclosures normally included in financial statements prepared
in accordance with U.S. GAAP have been condensed or omitted from these interim condensed consolidated financial statements. These unaudited condensed financial statements should be read in conjunction with the Company&#146;s audited consolidated
financial statements included elsewhere in this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Notes to the Unaudited Condensed Consolidated Financial Statements </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the
Accounting Standards Codification (&#147;ASC&#148;) and Accounting Standards Updates (&#147;ASU&#148;) of the Financial Accounting Standards Board (&#147;FASB&#148;). </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Use of estimates </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The preparation of financial statements in
conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported
amounts of expenses during the reporting period. On an ongoing basis, the Company evaluates estimates and assumptions, including but not limited to those related to revenue recognition under its collaboration agreements, the fair value of its common
and redeemable convertible preferred units, the fair value of derivative liabilities, unit-based compensation expense, accruals for research and development expenses, the fair value of long-term investments, the valuation of deferred tax assets and
uncertain income tax positions. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the
carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from those estimates. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Risks
and uncertainties </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company is subject to certain risks and uncertainties, including, but not limited to, changes in any of the following areas that the
Company believes could have a material adverse effect on the future financial position or results of operations: the Company&#146;s ability to advance the development of its next generation gene-editing platform, timing and ability to advance any
product candidates it may develop into and through pre-clinical and clinical development; costs and timelines associated with the manufacturing of clinical supplies of any product candidates the Company may develop; regulatory approval, market
acceptance of, and reimbursement for any product candidates the Company may develop; performance of third-party vendors; competition from pharmaceutical or other gene-editing companies with greater financial resources or expertise; protection of
intellectual property; litigation or claims against the Company based on intellectual property or other factors; and its ability to attract and retain employees necessary to support its growth. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company&#146;s business and operations may be affected by worldwide economic conditions, which may continue to be impacted by global macroeconomic challenges such as
the effects of the ongoing geopolitical conflicts in Ukraine, tensions in U.S.-China relations, the COVID-19 pandemic, uncertainty in the markets, including disruptions in the banking industry, and inflationary trends. Fiscal year 2022 was marked by
significant market uncertainty, increasing inflationary pressures. These market dynamics may continue into 2023 and these and similar adverse market conditions may negatively impact the Company&#146;s operations and financial position. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Concentration of credit risk </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Cash and cash equivalents, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities and preferred and common stock shares related to our investment in <FONT STYLE="white-space:nowrap">Affini-T</FONT> (Note 5) are
financial instruments that potentially subject the Company to concentrations of credit risk. As of December&nbsp;31, 2022 and June&nbsp;30, 2023, cash consists of cash deposited with two financial institutions and account balances exceed federally
insured limits. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Notes to the Unaudited Condensed Consolidated Financial Statements </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On March&nbsp;10, 2023, SVB was closed by the California Department of Financial Protection and Innovation, which
appointed the Federal Deposit Insurance Corporation (&#147;FDIC&#148;) as receiver. On March&nbsp;12, 2023 the FDIC transferred all deposits, both insured and uninsured, and substantially all assets from the former SVB to a newly created,
full-service FDIC-operated &#147;bridge bank&#148;, Silicon Valley Bridge Bank, N.A. (&#147;SVBB&#148;) and the FDIC, Treasury Department, and Federal Reserve announced that all deposits will be fully protected, whether or not they had been insured
by the FDIC. On March&nbsp;27, 2023, First-Citizens Bank&nbsp;&amp; Trust Company assumed all of SVBB&#146;s customer deposits and certain other liabilities and acquired substantially all of SVBB&#146;s loans and certain other assets from the FDIC.
As of June&nbsp;30, 2023, the Company&#146;s held cash and cash equivalents of $47.9&nbsp;million at SVB. As of the date of the issuance of these condensed consolidated financial statements, the Company has full access to and control over all its
cash, cash equivalents and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company
also has investments in money market funds, U.S. Treasuries, corporate debt obligations, commercial paper, government agency obligations and asset-backed securities, which can be subject to certain credit risks. The Company mitigates the risks by
investing in high-grade instruments, limiting its exposure to any one issuer and monitoring the ongoing creditworthiness of the financial institutions and issuers. The Company has not experienced any losses on its financial instruments. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Concentration of collaboration revenue, accounts receivable and contract assets </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes the percentages of collaboration revenues, accounts receivable and contract assets from each of the Company&#146;s customers that
individually accounted for 10% or more of its collaboration revenues, accounts receivable and contract assets: </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Collaboration revenue</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Six&nbsp;months&nbsp;ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Customer A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Customer B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Customer C</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Contract assets</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>December&nbsp;31,<BR>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>June&nbsp;30,<BR>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Customer C</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>100%</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>0%</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Accounts receivable </B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>December&nbsp;31,<BR>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>June&nbsp;30,<BR>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Customer C</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>0%</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>100%</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company reviews its accounts receivable and contract assets for impairment and credit loss allowance. No&nbsp;impairment or
credit loss allowance was recorded as of December&nbsp;31, 2022 and June&nbsp;30, 2023. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Notes to the Unaudited Condensed Consolidated Financial Statements </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Deferred finance issuance costs </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Deferred finance issuance&nbsp;costs, consisting of legal fees relating <FONT STYLE="white-space:nowrap">to&nbsp;in-process&nbsp;equity</FONT> financings and initial
public offering are capitalized. The&nbsp;deferred finance issuance&nbsp;costs will be offset against&nbsp;offering&nbsp;proceeds upon the completion of the&nbsp;financing or the offering. In the event the&nbsp;financing or the offering&nbsp;is
terminated or delayed,&nbsp;deferred finance issuance&nbsp;costs will be expensed immediately as a charge to general and administrative expenses in the condensed consolidated statements of operations and comprehensive loss. The Company had no
deferred finance issuance costs capitalized and $1.7&nbsp;million of deferred finance issuance costs as of December&nbsp;31, 2022 and June&nbsp;30, 2023, respectively, included in other assets in the condensed consolidated balance sheets. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Recently issued accounting pronouncements </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company noted no
recently issued accounting pronouncements that will impact its condensed consolidated financial statements and were not adopted by the Company. No new accounting pronouncements were adopted during the six months ended June&nbsp;30, 2023. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>3. Fair value measurements </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Assets and liabilities recorded at fair value on a
recurring basis in the condensed consolidated balance sheets, are categorized based upon the level of judgment associated with inputs used to measure their fair values. The accounting guidance for fair value provides a framework for measuring fair
value and requires certain disclosures about how fair value is determined. The accounting guidance establishes a three-level valuation hierarchy that prioritizes the inputs to valuation techniques used to measure fair value based upon whether such
inputs are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions made by the reporting entity. The three-level hierarchy for the inputs to valuation
techniques is briefly summarized as follows: </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:arial"><I>Level</I><I></I><I>&nbsp;1 </I>&#151; Inputs are unadjusted, quoted prices in active markets for
identical assets or liabilities at the measurement date; </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:arial"><I>Level</I><I></I><I>&nbsp;2 </I>&#151; Inputs are observable, unadjusted quoted prices in
active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for
substantially the full term of the related assets or liabilities; and </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:arial"><I>Level</I><I></I><I>&nbsp;3 </I><B>&#151; </B>Unobservable inputs that are
significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Assets and liabilities measured at
fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. An assessment of the significance of a particular input to the fair value measurement in its entirety requires
management to make judgments and consider factors specific to the asset or liability. Changes in the ability to observe valuation inputs may result in a reclassification of levels of certain securities within the fair value hierarchy. The Company
recognizes transfers into and out of levels within the fair value hierarchy in the period in which the actual event or change in circumstances that caused the transfer occurs. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company&#146;s financial instruments measured at fair value on a recurring basis consist of Level&nbsp;1, Level&nbsp;2, and Level&nbsp;3 financial instruments.
Usually, marketable securities are considered Level&nbsp;2 when their fair values are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Notes to the Unaudited Condensed Consolidated Financial Statements </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data such as pricing for similar securities, recently executed
transactions, cash flow models with yield curves, and benchmark securities. In addition, Level&nbsp;2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their
basis. U.S. Government bonds, corporate debt obligations, commercial paper, government agency obligations and asset-backed securities are valued primarily using market prices of comparable securities, bid/ask quotes, interest rate yields and
prepayment spreads and are included in Level&nbsp;2. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Financial assets and liabilities are considered Level&nbsp;3 when their fair values are determined using
pricing models, discounted cash flow methodologies, or similar techniques, and at least one significant model assumption or input is unobservable. The Company&#146;s investments in preferred stock and common stock shares of <FONT
STYLE="white-space:nowrap">Affini-T</FONT> Therapeutics Inc. <FONT STYLE="white-space:nowrap">(&#147;Affini-T&#148;)</FONT> (see Note 5) are Level&nbsp;3 financial assets. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes the estimated fair value of the financial instruments that were measured at fair value on a recurring basis by level within the fair value
hierarchy as of December&nbsp;31, 2022 (in thousands): </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="16" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Money market funds (included in cash and cash equivalents)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">182,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">182,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">U.S. Treasury bills(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,821</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,821</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">U.S. Government bonds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Government agency obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Corporate debt obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Commercial paper</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Asset-backed securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,403</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,403</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Long-term investments (Note 5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total fair value of assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">365,782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">182,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">177690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Certain prior period amounts have been reclassified to conform to the current period presentation. </TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table
summarizes the estimated fair value of the financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy as of June&nbsp;30, 2023 (in thousands): </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="16" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>June&nbsp;30, 2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Money market funds (included in cash and cash equivalents)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">46,801</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">46,801</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">U.S. Treasury bills</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">U.S. Government bonds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Government agency obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Corporate debt obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Commercial paper</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Asset-backed securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Foreign debt securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Long-term investments (Note 5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total fair value of assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">322,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">46,801</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">266,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Notes to the Unaudited Condensed Consolidated Financial Statements </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, restricted cash of $6.1&nbsp;million and $5.2&nbsp;million as of December&nbsp;31, 2022 and
June&nbsp;30, 2023, respectively, collateralized by the Company&#146;s cash equivalents, are financial assets measured at fair value and are Level&nbsp;1 financial instruments under the fair value hierarchy. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company&#146;s investments in shares of <FONT STYLE="white-space:nowrap">Affini-T</FONT> common stock and preferred stock are accounted at fair value and are
Level&nbsp;3 investments. The fair value is estimated based on information available to management including recent financing transactions, capitalization and rights and preferences of outstanding securities and is based on option-pricing model. The
estimated fair value of the Company&#146;s investment in <FONT STYLE="white-space:nowrap">Affini-T</FONT> was $5.7&nbsp;million and $8.5&nbsp;million as of December&nbsp;31, 2022 and June 30, 2023, respectively. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table sets forth a summary of the changes in the fair value of the Company&#146;s Level&nbsp;3 financial assets (in thousands): </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Fair value as of January&nbsp;1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Change in fair value included in other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Fair value of investment received as collaboration consideration (Note 7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Fair value as of June&nbsp;30</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There were no transfers within the fair value hierarchy during the six months ended June&nbsp;30, 2022 and 2023. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>4. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Available-for-sale</FONT></FONT> marketable securities </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes the amortized cost, unrealized gains (losses) and estimated fair value of the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities as of December&nbsp;31, 2022 (in thousands): </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amortized<BR>cost</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Unrealized<BR>gains</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Unrealized<BR>losses</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Estimated<BR>fair value</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">182,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">182,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">U.S. Treasury bills</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,821</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">U.S. Government bonds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(69</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Government agency obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Corporate debt obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,041</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(151</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Commercial paper</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Asset-backed securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(105</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,403</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">360,406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(329</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">360,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Less: amounts classified as cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(182,441</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(182,441</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT>
marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">177,965</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(329</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">177,690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Notes to the Unaudited Condensed Consolidated Financial Statements </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes the amortized cost, unrealized gains (losses) and estimated fair value of the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities as of June&nbsp;30, 2023 (in thousands): </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amortized<BR>cost</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Unrealized<BR>gains</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Unrealized<BR>losses</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Estimated<BR>fair value</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">46,801</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">46,801</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">U.S. Treasury bills</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">U.S. Government bonds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Government agency obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(165</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Corporate debt obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(151</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Commercial paper</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Asset-backed securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Foreign debt securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">314,022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(440</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">313,593</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Less: amounts classified as cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(46,801</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(46,801</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT>
marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">267,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(440</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">266,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of December&nbsp;31, 2022 and June&nbsp;30, 2023, no significant facts or circumstances were present to indicate a
deterioration in the creditworthiness of the issuers of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> securities, and the Company has no requirement or intention to sell these securities
before maturity or recovery of their amortized cost basis. The Company considered the current and expected future economic and market conditions and determined that its investments were not significantly impacted. For all securities with a fair
value less than its amortized cost basis, the Company determined the decline in fair value below amortized cost basis to be immaterial and <FONT STYLE="white-space:nowrap">non-credit</FONT> related, and therefore no allowance for losses has been
recorded.&nbsp;During the six months ended June&nbsp;30, 2022 and 2023, the Company did not recognize any impairment losses on its investments. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company&#146;s
policy is to exclude the applicable accrued interest from both the fair value and the amortized cost basis of its <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> securities for purposes of
identifying and measuring an impairment. The Company presents accrued interest receivable related to the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> securities in prepaid expenses and other
current assets, separate from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities in the condensed consolidated balance sheets. As of December&nbsp;31, 2022 and June&nbsp;30, 2023,
accrued interest receivable was $0.3&nbsp;million and $0.7&nbsp;million, respectively. The Company&#146;s accounting policy is to not measure an allowance for credit losses for accrued interest receivable and to
<FONT STYLE="white-space:nowrap">write-off</FONT> any uncollectible accrued interest receivable as a reversal of interest income in a timely manner, which it considers to be in the period in which the Company determines the accrued interest will not
be collected. The Company has&nbsp;not written off any accrued interest receivable for the six months ended June&nbsp;30, 2022 and 2023. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The amortized cost and fair
value of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities by contractual maturity were as follows as of December&nbsp;31, 2022 (in thousands): </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amortized<BR>cost</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Estimated<BR>fair&nbsp;value</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Maturing within one year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">163,259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">163,030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Maturing in one to five years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,660</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT>
marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">177,965</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">177,690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Notes to the Unaudited Condensed Consolidated Financial Statements </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The amortized cost and fair value of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities by contractual maturity were as follows as of June&nbsp;30, 2023 (in thousands): </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amortized<BR>cost</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Estimated<BR>fair&nbsp;value</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Maturing within one year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">258,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">257,813</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Maturing in one to five years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,076</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT>
marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">267,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">266,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>5. Long-term investments </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I><FONT
STYLE="white-space:nowrap">Affini-T</FONT> investment </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of December&nbsp;31, 2022 and June&nbsp;30, 2023, the Company had investments in shares of
preferred stock and common stock of <FONT STYLE="white-space:nowrap">Affini-T.</FONT> The Company performed a VIE analysis and concluded that it was not a primary beneficiary of <FONT STYLE="white-space:nowrap">Affini-T</FONT> as of
December&nbsp;31, 2022 and June&nbsp;30, 2023. The Company is using the fair value method to account for its investments in <FONT STYLE="white-space:nowrap">Affini-T</FONT> with changes in fair value recorded to the condensed consolidated statements
of operations and other comprehensive loss (see Note 3). </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of December&nbsp;31, 2022, the fair value of common stock shares was estimated by management,
considering the most recent third-party valuation, and the fair value of preferred stock shares was estimated based on recent sales of similar preferred stock to another investor for cash. As of June&nbsp;30, 2023, the fair values of common stock
and preferred stock shares were estimated by management using an option-pricing valuation model and recent financing transactions at <FONT STYLE="white-space:nowrap">Affini-T.</FONT> The Company recognized changes in fair value of $0.1&nbsp;million
and of $2.9&nbsp;million for the six months ended June&nbsp;30, 2022 and 2023, respectively. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">No impairment loss was recognized on the Company&#146;s investment in <FONT
STYLE="white-space:nowrap">Affini-T</FONT> as of December&nbsp;31, 2022 or June&nbsp;30, 2023. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>ViTToria investment </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of December&nbsp;31, 2022 and June&nbsp;30, 2023, the Company had investment in shares of preferred stock of ViTToria Biotherapeutics, Inc. (&#147;Vittoria&#148;), a
private biotechnology company. The Company accounts for its investment in Vittoria using the measurement alternative method. As of December&nbsp;31, 2022 and June&nbsp;30, 2023, the carrying value of Vittoria&#146;s investment was $2.2&nbsp;million
and no impairment was recognized. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Notes to the Unaudited Condensed Consolidated Financial Statements </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>6. Condensed consolidated balance sheets components </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Property and equipment, net consists of the following (in thousands): </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>June&nbsp;30,</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Useful&nbsp;life</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR><BR></TD>
<TD VALIGN="bottom" ALIGN="right">lesser&nbsp;of<BR>useful&nbsp;life&nbsp;or<BR>the&nbsp;lease&nbsp;term</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,786</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">3-5</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Computers and related equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">3-5</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Construction in progress</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Less: Accumulated depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,248</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,100</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,834</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Depreciation and amortization expense was $0.5&nbsp;million and $1.9&nbsp;million for the six months ended June&nbsp;30, 2022
and 2023, respectively. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Prepaid expenses and other current assets consist of the following (in thousands): </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Payroll tax credit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Interest receivable on
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">668</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Prepaid research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Grant income receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Other assets consist of the following (in thousands): </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating lease deposit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Long-term prepaid services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Deferred finance issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,660</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Notes to the Unaudited Condensed Consolidated Financial Statements </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Accrued expenses and other current liabilities consist of the following (in thousands): </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accrued personnel related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,819</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,881</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accrued legal and professional services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accrued purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accrued research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>7. Significant agreements </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Moderna strategic collaboration and license agreement </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Terms of the
agreement </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On October&nbsp;29, 2021, the effective date, the Company entered into a Strategic Collaboration and License Agreement (the &#147;Moderna
Agreement&#148;) with ModernaTX, Inc. (&#147;Moderna&#148;). The parties will collaborate on the research and development of <FONT STYLE="white-space:nowrap">in-vivo</FONT> genome editing therapies directed at certain targets and the
commercialization of such genome editing therapies. The collaboration provides Moderna with exclusive access to the Company&#146;s technology platform during the research period in (1)&nbsp;the field of in vivo gene editing technology for a
therapeutic, ameliorative or prophylactic application by way of <FONT STYLE="white-space:nowrap">knock-out</FONT> through InDel formation or base editing or insertion of an exogenous DNA template (such field, &#147;DT Field&#148;) and (2)&nbsp;the
field of in vivo gene editing technology for a therapeutic, ameliorative or prophylactic application outside the use of (a)&nbsp;DNA donor templates and (b)&nbsp;no exogenous template at all but including (c)&nbsp;correction by base editing (such
field, &#147;RT Field&#148;). The parties formed a joint steering committee, a joint research subcommittee and a joint patent subcommittee to oversee the collaboration activities. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Under the terms of the Moderna Agreement, the parties will collaborate on one or more programs in the RT Field (the &#147;Moderna RT program&#148;) and two programs in
the DT Field (the &#147;Moderna DT program&#148; and the &#147;DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> program&#148;). </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">With respect to the Moderna RT and
Moderna DT programs, the parties will collaborate on the research and development of product candidates under the approved research plans. The initial research term of the Moderna RT program is four years, which may be extended by Moderna for an
additional three years upon written notice and a payment of extension fees. The initial research term of the Moderna DT program is four years. The Company granted to Moderna an option to obtain an exclusive license to develop, manufacture and
commercialize up to ten Moderna RT program candidates and up to two Moderna DT program candidates at any time during the research term and prior to filing of an investigational new drug (&#147;IND&#148;) application with the Food and Drug
Administration (&#147;FDA&#148;) or any similar application filed with a regulatory authority in a country other than the United States (&#147;U.S.&#148;), subject to Moderna&#146;s payment of an option exercise fee of $10.0&nbsp;million per target.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">With respect to the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> program, the parties will work together on the
<FONT STYLE="white-space:nowrap">co-development</FONT> and commercialization of products and share costs and profits equally. The Company maintains commercialization rights in the U.S. (subject to Moderna&#146;s right to appoint up to 50% of the
U.S. sales force for the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Notes to the Unaudited Condensed Consolidated Financial Statements </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
program), while Moderna maintains these rights in countries other than the U.S. The initial research term for the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> program is four years, and each
party has a right to <FONT STYLE="white-space:nowrap">opt-out</FONT> of the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> program at any time, at which point the other party has the right to solely continue the development and commercialization
activities. If there is no development candidate nomination by the end of the initial research term, the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> program will expire, unless the parties have mutually agreed to continue the program. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">During the year ended December&nbsp;31, 2021, the Company received a <FONT STYLE="white-space:nowrap">non-refundable</FONT> upfront payment of $40.0&nbsp;million and a
$5.0&nbsp;million payment for the first year of research costs. Concurrent with the Moderna Collaboration Agreement, Moderna also provided $30.0&nbsp;million in cash in the form of a convertible promissory note pursuant to a convertible promissory
note agreement dated October&nbsp;29, 2021 (the &#147;Moderna Convertible Promissory Note Agreement&#148;). The convertible promissory note was converted into shares of Series B redeemable convertible preferred units in January 2022 (see Note 9).
Moderna will reimburse the Company up to $5.0&nbsp;million in annual research and development costs related to the Moderna DT and Moderna RT programs, or up to the agreed amount of expenses per the budget. As of June&nbsp;30, 2023, the Company has
received a total of $49.6&nbsp;million under the Moderna Agreement, not including cost-sharing payments under the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> program. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For the Moderna RT and Moderna DT programs, the Company is eligible to receive (i)&nbsp;technology milestone fees related to the achievement of certain preclinical
research objectives, of up to $75.0&nbsp;million, (ii)&nbsp;development and regulatory milestones of up to $100.0&nbsp;million per target, (iii)&nbsp;sales milestones of up to $200.0&nbsp;million per target and (iv)&nbsp;royalties ranging from a <FONT
STYLE="white-space:nowrap">mid-single</FONT> digit to a <FONT STYLE="white-space:nowrap">low-teens</FONT> percentage of annual net sales of a licensed product. Any profits and losses from the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> program
are shared equally between the Company and Moderna. With respect to the co-development and commercialization of the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> program for which the <FONT STYLE="white-space:nowrap">opt-out</FONT> party has
exercised its <FONT STYLE="white-space:nowrap">opt-out</FONT> right, the continuing party will pay to the <FONT STYLE="white-space:nowrap">opt-out</FONT> party, certain development, regulatory and sales milestone payments that will not exceed an
aggregate $239.0&nbsp;million per DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> target, and <FONT STYLE="white-space:nowrap">opt-out</FONT> royalties ranging from a high-single digit to a <FONT STYLE="white-space:nowrap">low-teens</FONT>
percentage of annual net sales of a licensed product. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The term of the Moderna Agreement will continue on a licensed <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">product-by-licensed</FONT></FONT> product and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, until the expiration of the applicable royalty term. The royalty term
commences on the first commercial sale of a licensed product and terminates on the latest of: (a)&nbsp;the expiration or abandonment of the last valid claim of a patent within the licensed Moderna DT or RT technology; (b) 10 years after the first
commercial sale of a licensed product; and (c)&nbsp;expiration of the regulatory exclusivity. Upon the expiration of the term of a licensed product in the Moderna DT or Moderna RT program, the licenses granted to Moderna will survive and become
perpetual, fully paid and royalty-free. Each party may terminate the Moderna Agreement on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">program-by-program</FONT></FONT> basis upon written notice to the other party for an
uncured material breach or insolvency. The Company may terminate the Moderna Agreement upon written notice to Moderna for a patent challenge. Additionally, Moderna may terminate the agreement at its convenience with respect to Moderna DT or Moderna
RT programs for any reason upon at least: (a) 60 days&#146; prior written notice if a first commercial sale has not occurred for the products in such program, or (b) 180 days&#146; prior written notice if a first commercial sale of a product in such
program has occurred. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Accounting analysis and revenue recognition </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The
Company concluded that the Moderna DT and Moderna RT programs are in the scope of ASC 606. The Company determined that the licenses granted to Moderna, and its participation in the joint steering committee are not capable of being distinct from the
preclinical research and development services and therefore concluded that there are two performance obligations: (1)&nbsp;the Moderna RT program and (2)&nbsp;the Moderna DT </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Notes to the Unaudited Condensed Consolidated Financial Statements </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
program. The Company also concluded that the option to obtain an exclusive license and options to extend Moderna RT program term do not include significant incremental discounts, and as such, the
options do not provide material rights. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company concluded the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> program research activities are within the scope
of ASC 808, as the Company and Moderna are both active participants in the research, development and commercialization activities, are exposed to significant risks and rewards that are dependent on the success of the DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> program activities and share costs and profits equally. The Company determined that the guidance in ASC 730, <I>Research and Development</I>, was appropriate to apply to the DT
<FONT STYLE="white-space:nowrap">Co-Co</FONT> program research activities by analogy, based on the nature of the cost sharing provisions of the agreement. The Company concluded that DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> program is one
unit of accounting, as the <FONT STYLE="white-space:nowrap">co-exclusive</FONT> license is not distinct from the research and development and the participation in joint steering committee activities. The Company recognizes payments to or from
Moderna related to the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> program cost sharing research activities as an increase to or reduction of research and development expenses, respectively. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company concluded that the Moderna Collaboration Agreement and the Moderna Convertible Promissory Note Agreement should be combined and treated as a single
arrangement for accounting purposes as the agreements were entered into contemporaneously and in contemplation of one another. The Company estimated the contract consideration to be $90.0&nbsp;million, which consisted of: 1) the <FONT
STYLE="white-space:nowrap">non-refundable</FONT> upfront collaboration payment of $40.0&nbsp;million received in 2021, 2) $30.0&nbsp;million in cash received in 2021 in exchange for the convertible promissory note and 3) the estimated cost
reimbursements for Moderna DT and Moderna RT programs of $20.0&nbsp;million. The Company constrained future milestones, as it assessed that it is probable that the inclusion of such variable consideration could result in a significant reversal of
cumulative revenue in future periods. During the year ended December&nbsp;31, 2021, the Company recorded $30.0&nbsp;million of the contract consideration for the convertible promissory note based on the fair value and allocated the transaction price
of $60.0&nbsp;million to each of the following programs on a relative standalone selling price basis: 1) $49.5&nbsp;million to the Moderna RT program, 2) $5.5&nbsp;million to the Moderna DT program, and 3) $5.0&nbsp;million to the DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> program. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The variable consideration is reevaluated at each reporting period and as changes in circumstances occur. The
Company recognizes revenue for each of the Moderna DT and Moderna RT programs as collaboration revenue based on the measure of progress using an estimated cost-based input method each reporting period. The Company also amortizes the allocation
consideration for the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> program of $5.0&nbsp;million as a credit to research and development expenses during the discovery and lead optimization phases for the DT
<FONT STYLE="white-space:nowrap">Co-Co</FONT> program. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company recognized collaboration revenue of $6.7&nbsp;million and $8.9&nbsp;million in the condensed
consolidated statements of operations and comprehensive loss for the six months ended June&nbsp;30, 2022 and 2023, respectively. As of December&nbsp;31, 2022 and June&nbsp;30, 2023, deferred revenue related to the Moderna Agreement was
$30.2&nbsp;million and $21.0&nbsp;million, respectively. Collaboration revenue recognized during the six months ended June&nbsp;30, 2022 and 2023 included $6.7 million and $8.9&nbsp;million that was included in deferred revenue as of
December&nbsp;31, 2021 and 2022, respectively. The value of the transaction price allocated to the remaining unsatisfied portion of the performance obligations was approximately $33.1&nbsp;million as of June&nbsp;30, 2023, which the Company expects
to recognize as revenue over the next two-to-three years. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company recognized less than $0.1&nbsp;million and $1.7&nbsp;million in credits to research and
development expenses related to cost sharing allocation and amortization of the collaboration advance, respectively, within research and development expenses in the condensed consolidated statement of operations and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Notes to the Unaudited Condensed Consolidated Financial Statements </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
comprehensive loss during the six months ended June&nbsp;30, 2022. The Company recognized $0.4&nbsp;million and $0.4&nbsp;million in credits to research and development expenses related to cost
sharing allocation and amortization of the collaboration advance during the six months ended June&nbsp;30, 2023, respectively. As of December&nbsp;31, 2022, the collaboration advance balance was $1.1&nbsp;million, partially offset by the
cost-sharing receivable balance of $0.4&nbsp;million, which was presented as a collaboration advance on the Company&#146;s condensed consolidated balance sheet. As of June&nbsp;30, 2023, the collaboration advance balance was $0.8&nbsp;million,
partially offset by the cost-sharing receivable balance of $0.4&nbsp;million, which was presented as a collaboration advance on the Company&#146;s condensed consolidated balance sheet. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I><FONT STYLE="white-space:nowrap">Affini-T</FONT> development, option and license agreement </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Terms of the agreement </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On June&nbsp;14, 2022, the effective date, the Company
entered into a Development, Option and License Agreement (the <FONT STYLE="white-space:nowrap">&#147;Affini-T</FONT> Agreement&#148;) with <FONT STYLE="white-space:nowrap">Affini-T.</FONT> Pursuant to the
<FONT STYLE="white-space:nowrap">Affini-T</FONT> Agreement, the parties have agreed to identify, develop or optimize certain reagents using the Company&#146;s proprietary technology for <FONT STYLE="white-space:nowrap">Affini-T</FONT> to use such
reagents to develop and commercialize gene edited <FONT STYLE="white-space:nowrap">T-cell</FONT> receptor (&#147;TCR&#148;)-based therapeutic products exclusively in the field of treatment, prevention or diagnosis of any human cancer using products
with any engineered primary TCR alpha/beta T cells and <FONT STYLE="white-space:nowrap">non-exclusively</FONT> in the field of treatment, prevention or diagnosis of any human cancer using products with certain other engineered immune cells
worldwide. A joint steering committee was established by both parties to assign alliance managers and project leaders to oversee the collaboration activities. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pursuant to the <FONT STYLE="white-space:nowrap">Affini-T</FONT> Agreement, the Company granted <FONT STYLE="white-space:nowrap">Affini-T</FONT> options to receive, on a
<FONT STYLE="white-space:nowrap">pre-specified</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">target-by-pre-specified</FONT></FONT></FONT> target basis, for up to six <FONT
STYLE="white-space:nowrap">pre-specified</FONT> targets, either (i)&nbsp;an exclusive, royalty-bearing, sublicensable worldwide license under all of the Company&#146;s applicable intellectual property to research, develop, manufacture, use,
commercialize and otherwise exploit any <FONT STYLE="white-space:nowrap">TCR-based</FONT> therapy, preventative treatment, or diagnostic for humans that is directed to such <FONT STYLE="white-space:nowrap">pre-specified</FONT> target, contains or
comprises Primary TCR alpha/beta T Cells and is derived from ex vivo application of a Company reagent (the &#147;Exclusive Option&#148;) or (ii)&nbsp;a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> royalty-bearing, sublicensable worldwide
license under all of the Company&#146;s applicable intellectual property to research, develop, manufacture, use commercialize and otherwise exploit any <FONT STYLE="white-space:nowrap">TCR-based</FONT> therapy, preventative treatment, or diagnostic
for humans that is directed to such <FONT STYLE="white-space:nowrap">pre-specified</FONT> target, contains or comprises TCR natural killer (&#147;NK&#148;) cells derived from iPSC immune cells or TCR T cells derived from donor-derived or iPSC immune
cells. <FONT STYLE="white-space:nowrap">Affini-T</FONT> can exercise its options for either an exclusive license or a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license, or both, for each
<FONT STYLE="white-space:nowrap">pre-specified</FONT> target by providing written notice prior to the earlier of (x)&nbsp;the end of the <FONT STYLE="white-space:nowrap">Affini-T</FONT> Agreement term or (y) 90 days following the filing of an IND
for a licensed product directed to a <FONT STYLE="white-space:nowrap">pre-specified</FONT> target, subject to the payment of certain fees per each option exercised. After the option exercise, <FONT STYLE="white-space:nowrap">Affini-T</FONT> has
agreed to use commercially reasonable efforts to conduct all development and commercialization activities for a licensed product, and development and commercialization of all licensed products will be at
<FONT STYLE="white-space:nowrap">Affini-T&#146;s</FONT> sole cost and expense. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In connection with the <FONT STYLE="white-space:nowrap">Affini-T</FONT> Agreement,
the Company received upfront equity consideration of 719,920 shares of <FONT STYLE="white-space:nowrap">Affini-T&#146;s</FONT> common stock with an estimated fair value of $1.3&nbsp;million in June 2022. The fair value of <FONT
STYLE="white-space:nowrap">Affini-T&#146;s</FONT> shares of common stock was estimated by management, considering the most recent third-party valuation. <FONT STYLE="white-space:nowrap">Affini-T</FONT> has also agreed to reimburse the Company for
expenses incurred while performing research activities under the research plans. As of June&nbsp;30, 2023, the Company received a total of $1.9&nbsp;million from Affini-T related to reimbursable expenses and recognized $2.3&nbsp;million in accounts
receivable. Additionally, the Company is eligible to receive (i) 933,650 shares of <FONT STYLE="white-space:nowrap">Affini-T&#146;s</FONT> common stock upon the achievement of a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Notes to the Unaudited Condensed Consolidated Financial Statements </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
regulatory milestone, which is the earlier of a submission of a drug master file to the FDA or an acceptance of an IND filing for a licensed product by the FDA, (ii)&nbsp;up to $18.8&nbsp;million
in future developmental milestone payments depending on the completion of or the number of patients dosed in, the relevant human clinical trial, or the initiation of a pivotal trial, and $40.6&nbsp;million in future regulatory approval milestone
payments, which include regulatory approvals in the U.S. and other markets for licensed products directed to a <FONT STYLE="white-space:nowrap">pre-specified</FONT> target if options for both exclusive and
<FONT STYLE="white-space:nowrap">non-exclusive</FONT> licenses are exercised with respect to such target, (iii)&nbsp;up to $250.0&nbsp;million in sales-based milestones for aggregate sales of all licensed products directed to a given <FONT
STYLE="white-space:nowrap">pre-specified</FONT> target and (iv)&nbsp;royalties ranging from a <FONT STYLE="white-space:nowrap">low-single</FONT> digit to high-single digit percentage of worldwide annual net sales of licensed products.</P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The initial term of the <FONT STYLE="white-space:nowrap">Affini-T</FONT> Agreement is five years from the effective date. If
<FONT STYLE="white-space:nowrap">Affini-T</FONT> exercises an Exclusive Option with respect to any <FONT STYLE="white-space:nowrap">pre-specified</FONT> target during the initial term, the initial term will be extended by an additional five years.
Following the expiration of the extended term, if any, the agreement will continue on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">target-by-target</FONT></FONT> basis and expire with respect to such target upon the expiration
of the royalty term for all licensed products directed to such target. The <FONT STYLE="white-space:nowrap">Affini-T</FONT> Agreement may be terminated during the term by either party for an uncured material breach by, or bankruptcy of, the other
party. Additionally, <FONT STYLE="white-space:nowrap">Affini-T</FONT> may terminate the <FONT STYLE="white-space:nowrap">Affini-T</FONT> Agreement for convenience, in its entirety, on a research <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">plan-by-research</FONT></FONT> plan basis, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">target-by-target</FONT></FONT> basis or on a licensed <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">product-by-licensed</FONT></FONT> product basis, by providing prior written notice. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Accounting analysis and revenue recognition
</I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company concluded that the <FONT STYLE="white-space:nowrap">Affini-T</FONT> Agreement is in the scope of ASC 606 and that there is one performance
obligation to perform research activities under the <FONT STYLE="white-space:nowrap">Affini-T</FONT> Agreement. Exclusive and <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licenses are optional contingent purchases that do not include
significant incremental discounts, and therefore do not provide a material right. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">At the effective date, the transaction price consisted of the upfront equity
consideration with an estimated fair value of $1.3&nbsp;million and estimated research reimbursement costs. Research reimbursement costs represent variable consideration, and the Company&#146;s management estimates what portion to include in total
consideration at the end of each reporting period. Other payments under the <FONT STYLE="white-space:nowrap">Affini-T</FONT> Agreement, including additional equity consideration and development and regulatory milestones, also represent variable
consideration, and are constrained to the extent that the inclusion of such variable consideration could result in a significant reversal of cumulative revenue in future periods. As of December&nbsp;31, 2022 and June&nbsp;30, 2023, additional equity
consideration and future development and regulatory milestone payments were excluded from the estimated total transaction price as they were considered constrained. The transaction price is reevaluated in each reporting period and as changes in
circumstances occur. The Company recognizes revenue each reporting period based on the measure of progress using an estimated cost-based input method. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company
recognized zero and $2.6&nbsp;million in collaboration revenue in the condensed consolidated statements of operations and comprehensive loss during the six months ended June&nbsp;30, 2022 and 2023, respectively. As of December&nbsp;31, 2022, the
Company recorded $1.3&nbsp;million in contract assets on the condensed consolidated balance sheet, related to services performed but not invoiced. There was no contract asset related to services performed as of June&nbsp;30, 2023. As of
December&nbsp;31, 2022 and June&nbsp;30, 2023, deferred revenue related to the <FONT STYLE="white-space:nowrap">Affini-T</FONT> Agreement was zero and $0.4&nbsp;million, respectively. In June 2023, the joint steering committee approved the budget
for estimated research reimbursement costs for the <FONT STYLE="white-space:nowrap">Affini-T</FONT> Agreement, which resulted in a $2.4&nbsp;million reduction to variable consideration. The value of the transaction price allocated to the remaining
unsatisfied portion of the performance obligation was approximately $3.0&nbsp;million as of June&nbsp;30, 2023, which the Company expects to recognize as revenue over the next
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">four-to-five</FONT></FONT> years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Notes to the Unaudited Condensed Consolidated Financial Statements </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Ionis collaboration and license agreement </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Terms of the agreement </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On November&nbsp;10, 2022, the effective date, the
Company entered into a Collaboration and License Agreement (the &#147;Ionis Agreement&#148;) with Ionis Pharmaceuticals, Inc. (&#147;Ionis&#148;) to collaborate on drug discovery and exploratory research activities to advance new medicines using
gene editing strategies, with the goal of discovering novel medicines. Pursuant to the terms of the Ionis Agreement, the Company granted Ionis and its affiliates a worldwide exclusive, royalty-bearing license, with the right to grant sublicenses, to
use all licensed systems and licensed products in the field of in vivo gene editing for all therapeutic, prophylactic, palliative, and analgesic uses in humans. In connection with the Ionis Agreement, the Company also has the right to exercise an
exclusive option to <FONT STYLE="white-space:nowrap">co-develop</FONT> and <FONT STYLE="white-space:nowrap">co-commercialize</FONT> certain products under a drug discovery program. A joint steering committee was established by both parties to
coordinate, oversee and monitor the research and drug discovery activities under the Ionis Agreement. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The parties will collaborate to discover therapeutic products
under a drug discovery program and develop a drug discovery plan for each target, selected by Ionis. The target selection is divided into two waves: up to four targets in Wave 1 and up to four targets in Wave 2. For each drug discovery program, once
the parties identify a development candidate that is suitable for further development, Ionis will be responsible for the development and commercialization of products resulting from such program. Per the terms of the Ionis Agreement, at any time
prior to the designation of a development candidate for a drug discovery program and for any reason, Ionis may replace the collaboration target, provided such target has not previously been substituted out. Ionis may substitute (i)&nbsp;up to two
Wave 1 targets and (ii)&nbsp;up to two Wave 2 targets. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The drug discovery activities for a program commence on the selection of a target and expire upon the earlier
of (a)&nbsp;completion of all drug discovery activities for such program, (b)&nbsp;the fifth anniversary of the effective date and (c)&nbsp;selection of a development candidate for such drug discovery program. If one or more Wave 2 targets become
collaboration targets as a result of the parties achieving enabled delivery and less than two years are remaining in the drug discovery term, then the term will be extended to the earlier of (i)&nbsp;the time that the Company completes all of its
activities under the applicable drug discovery plan and (ii)&nbsp;the seventh anniversary of the effective date, subject to the Company&#146;s consent. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The parties
will also conduct an exploratory research program, and will jointly optimize gRNA and select delivery technologies and other activities. The exploratory research activities commence on the effective date and expire upon the earlier of
(a)&nbsp;completion of all exploratory research activities established in the exploratory research plan, and (b)&nbsp;the fifth anniversary of the effective date. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company has the exclusive option to <FONT STYLE="white-space:nowrap">co-develop</FONT> and <FONT STYLE="white-space:nowrap">co-commercialize</FONT> the licensed
products under a drug discovery program (the <FONT STYLE="white-space:nowrap">&#147;Co-Co</FONT> Option&#148;) with Ionis. The <FONT STYLE="white-space:nowrap">Co-Co</FONT> Option may be exercised for (a)&nbsp;the initial Wave 1 target (&#147;Target
1&#148;), (b) no more than one of the other three discovery programs for the Wave 1 targets, and (c)&nbsp;no more than two drug discovery programs for the Wave 2 targets that become collaboration targets. If the Company exercises the <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Option for a particular drug discovery program, that drug discovery program will automatically be deemed a <FONT STYLE="white-space:nowrap">&#147;Co-Co</FONT> Program&#148;, all corresponding licensed products
be deemed <FONT STYLE="white-space:nowrap">&#147;Co-Co</FONT> Products,&#148; the Company will be obligated to pay Ionis an option exercise fee, and the parties will enter into a separate <FONT STYLE="white-space:nowrap">co-development</FONT> and
co-commercialization agreement. The <FONT STYLE="white-space:nowrap">Co-Co</FONT> Option exercise fee will equal 50% of Ionis&#146; internal costs and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT>
costs incurred in the conduct of the drug discovery activities prior to the exercise of the <FONT STYLE="white-space:nowrap">Co-Co</FONT> Option and be reduced by 50% of the Company&#146;s corresponding costs incurred. Future development and
commercialization costs will be shared equally. The Company may elect to reduce its cost-share percentage anywhere between 50% and 25% on a <FONT STYLE="white-space:nowrap">go-forward</FONT> basis, provided the Company will continue
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Notes to the Unaudited Condensed Consolidated Financial Statements </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
to bear 50% of the costs of any clinical trials ongoing at the time of the election through the completion of the clinical trials. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company will manufacture all licensed systems and certain components of the applicable licensed products that are needed by Ionis for use in its development
activities and all of the Company&#146;s manufactured components needed by Ionis for use in its commercialization activities. The Company will provide the manufactured components at a price that represents the cost of goods plus 15%. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pursuant to the terms of the Ionis Agreement, the Company has also been granted an option to obtain a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT>
royalty-bearing license, with the right to grant sublicenses, for certain Ionis&#146; background technology to use in up to eight therapeutic products discovered by the Company in the field of in vivo gene editing and directed to a Collaboration
Target (each such product, a &#147;Metagenomi Product&#148; and each such option an &#147;Ionis IP Option&#148;), but subject to encumbrance checks with respect to particular targets. A Collaboration Target is a target that is selected by Ionis,
and, with respect to the Company is not the subject of discussions with a third party, is not the subject of a contractual grant of rights to a third party nor the subject to an internal research and development program. If the Company exercises its
Ionis IP Option, the Company will pay to Ionis up to several million dollars per Metagenomi Product upon achievement of certain clinical and regulatory milestones. The Company is also obligated to pay Ionis royalties in an amount equal to a low
single-digit royalty on the net sales of the applicable Metagenomi Product on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In November 2022, the Company received an
$80.0&nbsp;million upfront payment from Ionis for the Wave 1 drug discovery research collaboration and selected Target 1. Ionis selected its second target (&#147;Target 2&#148;) in Wave 1 in December 2022, and the Company expects Ionis will select
two final additional Wave 1 targets (&#147;Target 3&#148; and &#147;Target 4&#148;) within the 12 months from the effective date, as permitted under the arrangement. Ionis has an option to select up to four Wave 2 targets at any time during the drug
discovery term, if (a)&nbsp;an IND for any licensed product directed to a Wave 1 target is filed with the applicable regulatory authority or (b)&nbsp;the parties achieve enabled delivery for a <FONT STYLE="white-space:nowrap">non-liver</FONT> target
under the exploratory research activities, by providing written notice and by paying a Wave 2 target selection fee of $15.0&nbsp;million or $30.0&nbsp;million, depending on and per the selected target. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Ionis is obligated to reimburse the Company for all internal costs and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT>
costs incurred in the performance of the exploratory research activities, up to an aggregate of $10.0&nbsp;million, which is payable in quarterly installments of $0.5&nbsp;million during the exploratory research term. As of June&nbsp;30, 2023, the
Company received a total of $1.0&nbsp;million related to the reimbursable expenses. The Company is also eligible to receive (a)&nbsp;up to $29.0&nbsp;million in future development milestone payments for each licensed product; (b)&nbsp;up to
$60.0&nbsp;million in future regulatory milestone payments for each licensed product; (c)&nbsp;up to $250.0&nbsp;million in sales-based milestones for each licensed product; and (d)&nbsp;royalties on annual net sales of licensed products from a <FONT
STYLE="white-space:nowrap">mid-single-digit</FONT> to <FONT STYLE="white-space:nowrap">low-teens</FONT> percentage, subject to customary reductions.</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The term of the
Ionis Agreement will continue (i)&nbsp;with respect to the drug discovery programs, until the expiration of all applicable royalty terms for a licensed product, (ii)&nbsp;with respect to the <FONT STYLE="white-space:nowrap">Co-Co</FONT> Programs,
until the parties cease all exploitation for the <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products that are the subject to such <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program, and (iii)&nbsp;with respect to the Metagenomi Products, until
the expiration of the royalty term for a Metagenomi Product. The royalty term ends on the latest of the following two dates: (i)&nbsp;the expiration of (A)&nbsp;the last claim of any issued and unexpired patent, or (B)&nbsp;a claim within a patent
application that has not been pending for more than seven years from the earliest date to which the claim or applicable patent application is entitled to claim priority and which claim has not been revoked, cancelled, withdrawn, held invalid, or
abandoned, or (ii) 12 years following the first commercial sale of a licensed product. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Notes to the Unaudited Condensed Consolidated Financial Statements </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Ionis Agreement may be terminated during the term by either party for an uncured material breach or bankruptcy
by the other party. Additionally, Ionis may terminate the Ionis Agreement for convenience and without penalty, in its entirety or on a licensed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-licensed</FONT></FONT>
product basis, by providing 90 days&#146; written notice. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Accounting analysis and revenue recognition </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company concluded that the Ionis Agreement is in scope of ASC 606 at the effective date and until the Company exercises its
<FONT STYLE="white-space:nowrap">Co-Co</FONT> Option for any drug discovery program, which was determined to not be probable at the effective date and as of December&nbsp;31, 2022 and June&nbsp;30, 2023. The Company also concluded that exclusive
licenses and participation in a joint steering committee are not distinct from discovery research services and should thus be combined into one performance obligation (the &#147;discovery program&#148;). The Company also concluded that exploratory
research services are a separate and distinct performance obligation (the &#147;exploratory program&#148;). As the Ionis options for Wave 2 targets are optional purchases and do not have significant incremental discounts, as such, the options do not
provide material rights. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company allocated the total estimated transaction price of $90.0&nbsp;million, which consisted of an $80.0&nbsp;million upfront payment
received in November 2022 and a $10.0&nbsp;million reimbursement for research costs, into two performance obligations, and was determined based on their estimated standalone selling prices. The Company concluded that future development and
commercial supply agreements are at market terms, as the terms were consistent with industry standards as of the effective date. The Company constrains future milestone payments under the arrangement to the extent that the inclusion of such variable
consideration could result in a significant reversal of cumulative revenue in future periods. The Company constrained all development and regulatory milestone payments at the effective date and as of December&nbsp;31, 2022 and June&nbsp;30, 2023.
The Company is recognizing revenue of $80.0&nbsp;million related to the discovery program and of $10.0&nbsp;million related to exploratory program over the research terms using an estimated cost-based input method as a measure of progress for each
obligation. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company recognized $8.5&nbsp;million in collaboration revenue in the condensed consolidated statements of operations and comprehensive loss during
the six months ended June&nbsp;30, 2023, which was included in deferred revenue as of December&nbsp;31, 2022. As of December&nbsp;31, 2022 and June&nbsp;30, 2023, deferred revenue related to the Ionis Agreement was $79.9&nbsp;million and
$72.5&nbsp;million, respectively. The value of the transaction price allocated to the remaining performance obligations was approximately $81.4&nbsp;million as of June&nbsp;30, 2023, which the Company expects to recognize as revenue over the next <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">four-to-five</FONT></FONT> years. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>8. Commitments and contingencies </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Operating leases </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In January 2021, the Company entered into a <FONT
STYLE="white-space:nowrap">ten-year</FONT> operating lease for laboratory and office space in Emeryville, California. The lease commencement date was in February 2021. In conjunction with signing this lease, the Company secured a letter of credit
for $3.3&nbsp;million, which is recorded as noncurrent restricted cash in the condensed consolidated balance sheets. As of December&nbsp;31, 2022 and June&nbsp;30, 2023, the balance of this letter of credit was $3.3&nbsp;million and
$2.5&nbsp;million, respectively. The lease agreement includes a renewal provision allowing the Company to extend this lease for an additional five years, which the Company is not reasonably certain to exercise. In addition to base rent, the Company
pays variable costs related to its share of operating expenses and taxes, which are recognized as incurred. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Notes to the Unaudited Condensed Consolidated Financial Statements </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In September 2021, the Company entered into a <FONT STYLE="white-space:nowrap">9.25-year</FONT> operating lease for
office space in Emeryville, California, with a lease commencement date in November 2021. In conjunction with signing the lease, the Company secured a letter of credit for $0.8&nbsp;million, which is recorded as noncurrent restricted cash in the
condensed consolidated balance sheets as of December&nbsp;31, 2022 and June&nbsp;30, 2023. In addition to base rent, the Company pays variable costs related to its share of operating expenses and taxes, which are recognized as incurred. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In November 2022, the Company entered into an <FONT STYLE="white-space:nowrap">8.25-year</FONT> sublease for office, research and laboratory space in Emeryville,
California, with a lease commencement date in January 2023. In conjunction with signing the lease, the Company secured a letter of credit for $2.0&nbsp;million, which is recorded as noncurrent restricted cash in the condensed consolidated balance
sheet as of December&nbsp;31, 2022 and June&nbsp;30, 2023. Monthly base rent under the lease is approximately $0.5&nbsp;million and is subject to annual escalation. During the initial 18&nbsp;months from the lease commencement date, 50% of the
monthly base rent is abated. In addition to base rent, the Company pays variable costs related to its share of operating expenses and taxes, which are recognized as incurred. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Operating lease costs for the six months ended June&nbsp;30, 2022 and 2023 totaled $1.7&nbsp;million and $6.1&nbsp;million, respectively, including $0.1&nbsp;million and
$1.4&nbsp;million of variable lease cost, respectively. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Supplemental information related to the Company&#146;s operating leases is as follows (in thousands): </P>
 <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Six months ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cash paid for amounts included in the measurement of lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1,109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 3,406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Weighted average remaining lease term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Weighted-average discount rate</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">10.1%</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">10.4%</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes a maturity analysis of the Company&#146;s operating lease liabilities showing the aggregate lease
payments as of June&nbsp;30, 2023 (in thousands): </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:2.00pt solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">2023 (remaining)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000" ALIGN="right">3,217</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,673</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">2027</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total future lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,873</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Less imputed interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,411</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total lease liability balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Less: current operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,843</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><FONT STYLE="white-space:nowrap">Non-current</FONT> operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">46,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Legal contingencies </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">From
time to time, the Company may become involved in legal proceedings arising from the ordinary course of business. The Company records a liability for such matters when it is probable that future losses will be
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Notes to the Unaudited Condensed Consolidated Financial Statements </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
incurred and that such losses can be reasonably estimated. Significant judgment by the Company is required to determine both probability and the estimated amount. Management is currently not
aware of any legal matters that could have a material adverse effect on the Company&#146;s financial position, results of operations or cash flows. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Guarantees and indemnifications </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the normal course of business, the
Company enters into agreements that contain a variety of representations and provide for general indemnification. Its exposure under these agreements is unknown because it involves claims that may be made against the Company in the future. To the
extent permitted under Delaware law, the Company has agreed to indemnify its directors and officers for certain events or occurrences while the director or officer is, or was serving, at a request in such capacity. To date, the Company has not paid
any claims or been required to defend any action related to its indemnification obligations. As of December&nbsp;31, 2022 and June&nbsp;30, 2023, the Company did not have any material indemnification claims that were probable or reasonably possible
and consequently has not recorded related liabilities. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>9. Redeemable convertible preferred units </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On January&nbsp;21, 2022, the Company closed the Series B financing and issued 12,446,876 shares of the Series B redeemable convertible preferred units for gross cash
proceeds of $145.0&nbsp;million. The Company incurred $0.7&nbsp;million in issuance costs. Concurrently with the closing of the Series B financing, the outstanding Moderna convertible promissory note and accrued interest of $30.4&nbsp;million was
converted into 2,607,387 Series B Preferred Units, at a conversion price equal to the price per unit paid by the Series B investors. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On December&nbsp;20, 2022, the
Company entered into Series <FONT STYLE="white-space:nowrap">B-1</FONT> redeemable convertible preferred unit purchase agreement to sell up to 7,108,480 Series B redeemable convertible preferred units at the purchase price of $14.06770. In December
2022, the Company sold and issued 6,773,726 shares of the Series <FONT STYLE="white-space:nowrap">B-1</FONT> redeemable convertible preferred units for gross cash proceeds of $95.3&nbsp;million in the initial closing. The Company incurred
$0.4&nbsp;million issuance costs. Additional shares may be sold within 90 days of the initial closing. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In January 2023, the Company sold an additional 334,754
Series <FONT STYLE="white-space:nowrap">B-1</FONT> redeemable convertible preferred units in accordance with the Series <FONT STYLE="white-space:nowrap">B-1</FONT> purchase agreement and received gross cash proceeds of $4.7&nbsp;million. The Company
incurred $0.1&nbsp;million in issuance costs. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of December&nbsp;31, 2022 and June&nbsp;30, 2023, the Company operated under the Amended and Restated Limited
Liability Company Agreement dated December&nbsp;20, 2022 (the &#147;LLC Agreement&#148;). The LLC Agreement provides for eight classes of units: common units, Series <FONT STYLE="white-space:nowrap">A-1</FONT> redeemable convertible preferred units
(Series <FONT STYLE="white-space:nowrap">A-1),</FONT> Series <FONT STYLE="white-space:nowrap">A-2</FONT> redeemable convertible preferred units (Series <FONT STYLE="white-space:nowrap">A-2),</FONT> Series <FONT STYLE="white-space:nowrap">A-3</FONT>
redeemable convertible preferred units (Series <FONT STYLE="white-space:nowrap">A-3),</FONT> Series <FONT STYLE="white-space:nowrap">A-4</FONT> redeemable convertible preferred units (Series <FONT STYLE="white-space:nowrap">A-4),</FONT> Series <FONT
STYLE="white-space:nowrap">A-5</FONT> redeemable convertible preferred units (Series <FONT STYLE="white-space:nowrap">A-5),</FONT> Series B redeemable convertible preferred units (Series B) and Series <FONT STYLE="white-space:nowrap">B-1</FONT>
redeemable convertible preferred units (Series <FONT STYLE="white-space:nowrap">B-1).</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Notes to the Unaudited Condensed Consolidated Financial Statements </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The redeemable convertible preferred units as of December&nbsp;31, 2022, consisted of the following (in thousands,
except unit data): </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Units<BR>authorized</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Units Issued<BR>and<BR>outstanding</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Aggregate<BR>liquidation<BR>preference</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Net<BR>carrying<BR>value</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series <FONT STYLE="white-space:nowrap">A-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,501,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,501,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 24,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 24,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series <FONT STYLE="white-space:nowrap">A-2</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">774,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">774,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series <FONT STYLE="white-space:nowrap">A-3</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,513,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,513,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series <FONT STYLE="white-space:nowrap">A-4</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,280,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,280,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series <FONT STYLE="white-space:nowrap">A-5</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,580,937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,580,937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,948</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,054,263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,054,263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">175,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">174,678</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series <FONT STYLE="white-space:nowrap">B-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,108,480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,773,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95,291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,813,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,478,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">347,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">346,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The redeemable convertible preferred units as of June&nbsp;30, 2023, consisted of the following (in thousands, except unit
data): </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Units<BR>authorized</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Units issued<BR>and<BR>outstanding</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Aggregate<BR>liquidation<BR>preference</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Net<BR>carrying<BR>value</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series <FONT STYLE="white-space:nowrap">A-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,501,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,501,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 24,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 24,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series <FONT STYLE="white-space:nowrap">A-2</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">774,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">774,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series <FONT STYLE="white-space:nowrap">A-3</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,513,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,513,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series <FONT STYLE="white-space:nowrap">A-4</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,280,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,280,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series <FONT STYLE="white-space:nowrap">A-5</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,580,937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,580,937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,948</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,054,263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,054,263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">175,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">174,678</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series <FONT STYLE="white-space:nowrap">B-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,108,480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,108,480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,813,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,813,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">352,044</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">350,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The holders of the redeemable convertible preferred units have various rights and preference as follows: </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Voting rights </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Each redeemable convertible preferred unit is entitled
to one vote for each common unit into which such redeemable convertible preferred unit is then convertible. The redeemable convertible preferred unitholders and the common unitholders vote together on all matters as a single class, except as
otherwise provided by law or the provisions of the LLC Agreement. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Board of Managers consists of up to seven individuals. As long as at least 618,716 Series <FONT
STYLE="white-space:nowrap">A-1</FONT> redeemable convertible preferred units, Series <FONT STYLE="white-space:nowrap">A-2</FONT> redeemable convertible preferred units and/or Series <FONT STYLE="white-space:nowrap">A-3</FONT> redeemable convertible
preferred units remain outstanding, the members holding a majority of the outstanding Series <FONT STYLE="white-space:nowrap">A-1</FONT> redeemable convertible preferred units, Series <FONT STYLE="white-space:nowrap">A-2</FONT> redeemable
convertible preferred units and Series <FONT STYLE="white-space:nowrap">A-3</FONT> redeemable convertible preferred units, voting together as a single class on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis, are entitled to elect one
manager. As long as at least 1,654,555 Series <FONT STYLE="white-space:nowrap">A-4</FONT> redeemable convertible preferred units remain outstanding, the members holding a majority of the Series <FONT STYLE="white-space:nowrap">A-4</FONT> redeemable
convertible preferred units, voting as a single class, are entitled to elect one manager. As long as at least 316,187 Series <FONT STYLE="white-space:nowrap">A-5</FONT> redeemable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Notes to the Unaudited Condensed Consolidated Financial Statements </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
convertible preferred units remain outstanding, the members holding a majority of the Series <FONT STYLE="white-space:nowrap">A-5</FONT> redeemable convertible preferred units, voting as a single
class, are entitled to elect one manager. As long as at least 3,010,852 Series B redeemable convertible preferred units remain outstanding, the members holding a majority of the Series B redeemable convertible preferred units, voting as a single
class, are entitled to elect one manager. The members holding a majority of the common units, voting as a single class are entitled to elect one manager. The members holding a majority of the units then outstanding, voting together as a single class
on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to common units basis are entitled to elect any remaining managers. As of each December&nbsp;31, 2022 and June&nbsp;30, 2023 the Company&#146;s Board of Managers consisted of six
individuals. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Conversion </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Each redeemable convertible preferred
unit is convertible into common units at the option of a holder at the then applicable conversion price, which is equal the original purchase price, subject to adjustments for recapitalization and others. The original purchase price is equal to
$3.2325 per Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Unit, $0.6456 per Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Unit, $1.1713 per Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Unit, $4.84875 per
Series <FONT STYLE="white-space:nowrap">A-4</FONT> Preferred Unit, $6.32536 per Series <FONT STYLE="white-space:nowrap">A-5</FONT> Preferred Unit, $11.64951 per Series B Preferred Unit, and $14.06770 per Series
<FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Unit. As of December&nbsp;31, 2022 and June&nbsp;30, 2023, the redeemable convertible preferred units were convertible into common units at a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">one-for-one</FONT></FONT> conversion ratio. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Each redeemable convertible preferred unit is automatically convertible into common units (or
shares of common stock, if the Company is converted into a corporation), based on the then-effective applicable conversion rate (A)&nbsp;at any time upon the affirmative vote or written consent of (i)&nbsp;the members holding a majority of the
redeemable convertible preferred units then outstanding, (ii)&nbsp;the members holding a majority of the Series B redeemable convertible preferred units then outstanding, and (iii)&nbsp;the members holding a majority of the Series <FONT
STYLE="white-space:nowrap">B-1</FONT> redeemable convertible preferred units then outstanding, or (B)&nbsp;immediately upon the closing of a firmly underwritten public offering pursuant to an effective registration statement under the Securities Act
of 1933, as amended, covering the offer and sale of common units (or other common securities) with the gross cash proceeds to the Company, before underwriting discounts, commissions and offering expenses, are at least $100.0&nbsp;million, or
(C)&nbsp;the closing of a merger, acquisition or other business combination involving the Company and a publicly traded special purpose acquisition company (&#147;SPAC&#148;) or its subsidiary or affiliate in which the surviving public company has
available immediately cash of at least $100.0&nbsp;million in the aggregate greater than the cash on the Company&#146;s condensed consolidated balance sheets as of immediately prior to such merger, acquisition or other business combination
(including proceeds of a private investment in public equity transaction that is substantially contemporaneous with or conditioned on such merger, acquisition or other business combination, and any redemptions from the SPAC&#146;s trust account).
</P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Anti-dilution and other protective provisions </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The holders of the
redeemable convertible preferred units have proportional anti-dilution protection right for unit splits, unit dividends and similar recapitalizations, subject to certain exclusions, anti-dilution price protection for additional sales of securities
by the Company for consideration per unit less than the applicable conversion price per unit of any series of the redeemable convertible preferred units, on a broad-based weighted average basis. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The holders of the redeemable convertible preferred units have certain protective rights. The Company shall not, either directly or by amendment, merger, consolidation
or otherwise, without the prior written approval of members holding a majority of the redeemable convertible preferred units then outstanding to alter or change </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Notes to the Unaudited Condensed Consolidated Financial Statements </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
the rights, preferences or privileges of the redeemable convertible preferred units; consummate a liquidation or a deemed liquidation event; change the Company&#146;s LLC Agreement; authorize or
create any new class or series of units or other equity security; increase or decrease the authorized number of the common units or the redeemable convertible preferred units or any series; redeem, acquire or repurchase any, or make any distribution
on, any common units or redeemable convertible preferred units; change the compensation or equity awards granted to executive officers of the Company, unless such transaction is approved by the Board of Managers; increase or decrease the authorized
number of managers constituting the Board of Managers and amend other rights or enter into certain transactions. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Liquidation preference </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the event of a liquidation, a deemed liquidation event (including a consolidation, merger or reorganization or a sale, lease, transfer, exclusive irrevocable license
or other disposition of all or substantially all of the assets of the Company), dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company, the funds are distributed first to the members holding the redeemable convertible
preferred units in proportion to and to the extent of their unreturned original purchase price per redeemable convertible preferred unit, until each member holding the redeemable convertible preferred units has received cumulative distributions in
an amount equal to the unreturned original purchase price for each of such member&#146;s redeemable convertible preferred unit. Second, to the members holding common units and the redeemable convertible preferred units pro rata based on the number
of units held by each such holder, assuming for this purpose that all the redeemable convertible preferred units have been converted into common units as of the date of such operating distribution or distribution of net proceeds or assets available
for distribution, whether in cash or in other property. Third, the amounts that would otherwise be distributed to any redeemable convertible preferred unit holder pursuant to the liquidation preference on
<FONT STYLE="white-space:nowrap">as-converted</FONT> to common units basis will be reduced by an amount equal to the remaining preferred participation threshold amount for such redeemable convertible preferred unit. The preferred participation
threshold amount for a redeemable convertible preferred unit is equal to the original purchase price, reduced by distributions paid. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Distributions preference
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Distributions, when determined by the Board of Managers, are payable to the members holding the redeemable convertible preferred units, pro rata in
proportion to the liquidation preference amounts in respect of the redeemable convertible preferred units held by such members; thereafter, to the members in proportion to the number of shares held by such members, on as converted basis. No
distributions were declared or made from inception and during the six months ended June&nbsp;30, 2022 and 2023. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Redemption </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The redeemable convertible preferred units are not redeemable except in the event of certain effected deemed liquidation events, that are not in the Company&#146;s
control. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>10. Common units </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of December&nbsp;31, 2022 and
June&nbsp;30, 2023, the Company was authorized to issue 66,000,000 common units. Each common unit is entitled to cast one vote. The holders of common units are also entitled to receive distributions whenever funds are legally available and when
declared by the Company&#146;s Board of Managers, subject to prior rights of the holders of the redeemable convertible preferred units. No distributions have been declared from inception to date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Notes to the Unaudited Condensed Consolidated Financial Statements </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of December&nbsp;31, 2022 and June&nbsp;30, 2023, the Company reserved common units for future issuance as
follows: </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Outstanding redeemable convertible preferred units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,478,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,813,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Outstanding profits interests</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,516,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,370,804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Units available for grants under 2019 Equity Incentive Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,088,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,233,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total common units reserved for future issuance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,082,786</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,417,540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Founders and investors common units </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In June&nbsp;2017, Metagenomi Inc. issued 4,687,500 shares of its common stock at a purchase price of $0.0001 per share to its founders and investors for services, which
was an estimated fair value determined by the Board of Managers at the issuance date. Pursuant to the terms of the stock purchase agreements, 25% of the shares vested on the first anniversary of the vesting start date and monthly over the next
36&nbsp;months. Vesting of shares is accelerated upon a change of control event (including an acquisition of the Company by another entity by means of any transaction or series of related transactions, or a sale of all or substantially all of the
assets of the Company). The Company has a right to repurchase unvested shares upon termination of services provided by the founders to the Company at the price lower of i) the purchase price or ii) the fair value at the date of repurchase. In
November 2018, in connection with the reorganization, common stock issued by Metagenomi Inc. was exchanged for common units of Metagenomi with the same terms. The estimated fair value of common unit at the modification date was determined to be
$0.02 per unit, based on the Company&#146;s recent common unit valuation, and the modification expense was immaterial. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In March 2019, the Company issued 1,260,000
common units to an investor for services with a purchase price of $0.02 per unit, which was based on the recent Company&#146;s common stock valuation. As long as the investor continues to provide services, 25% of the shares vested immediately and
the remainder vested monthly over the next 36&nbsp;months. Vesting of shares is accelerated upon a change of control event. The Company has a right to repurchase unvested shares upon termination of services provided by the founders to the Company at
the price lower of i) the purchase price or ii) the fair value at the date of repurchase. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company accounts for issued common units as
unit-based&nbsp;compensation to founders and investors as service providers and recognizes unit-based&nbsp;compensation expense of $0.1&nbsp;million over the vesting period. The Company had 78,750 common units vested during the six months ended
June&nbsp;30, 2022, having a fair value of less than $0.1&nbsp;million. There were no common units unvested as of December&nbsp;31, 2022 and June&nbsp;30, 2023. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>11. Profits interests plan </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company grants profits interests under the
2019 Equity Incentive Plan, adopted on March&nbsp;13, 2019 (the &#147;2019 Plan&#148;). The Company may grant profits interests with a threshold amount, which may be zero, established by the Board of Managers on the date of issuance. Accordingly,
such profits interests do not give a holder a share of the proceeds if the Company&#146;s assets were sold at fair market value and the proceeds of such disposition were distributed in complete liquidation of the Company immediately after the date
of grant but give a holder a right to share in the appreciation in the value of a common unit from the date of receipt to the future, as specifically provided in the LLC Agreement. The 2019 Plan allows for grants of profits interests to the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Notes to the Unaudited Condensed Consolidated Financial Statements </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
Company&#146;s officers, employees, directors and consultants. Profits interests generally vest monthly over four years, with or without <FONT STYLE="white-space:nowrap">one-</FONT> year cliff
vesting in the first year. In the event of a profits interest holder&#146;s termination, the unvested portion of such profits interest is automatically forfeited and cancelled without any additional consideration. Additionally, the Company has the
right to repurchase the vested portion of such profits interest at its fair market value, which is based on the fair market value of a common unit (as determined by the Board of Managers), less the applicable profits interest threshold amount, at
any time during the <FONT STYLE="white-space:nowrap">12-month</FONT> period after termination of a profits interest holder&#146;s service to the Company. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The number
of common units reserved for issuance under the 2019 Plan was 14,604,165 as of June&nbsp;30, 2023. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The table below presents a summary of activities and a
reconciliation of common units authorized and remaining for grant under the 2019 Plan during the six months ended June&nbsp;30, 2023: </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Units<BR>available&nbsp;for<BR>grants</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Profits<BR>interests</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Weighted-<BR>average</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>threshold<BR>amount</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Aggregate<BR>intrinsic&nbsp;value<BR>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Outstanding as of January&nbsp;1, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,088,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,516,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Profits interests granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,992,983</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,992,983</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Forfeited and expired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">138,252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(138,252</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Outstanding as of June&nbsp;30, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,233,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,370,804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75,663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Vested and expected to vest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,233,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,370,804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75,663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The aggregate intrinsic value is calculated as the positive difference between the threshold amount of the profits interests and
the fair value of the Company&#146;s common unit as of June&nbsp;30, 2023. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">During the six months ended June&nbsp;30, 2022 and 2023, the Company granted 2,166,221
and 1,992,983 profits interests with a weighted average grant date fair value of $1.89 and $6.32, respectively. The total fair value of the profits interests vested during the six months ended June&nbsp;30, 2022 and 2023 was $0.2&nbsp;million and
$1.7&nbsp;million, respectively. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Unit-based compensation expense </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company estimated the fair value of profits interests on the grant date using the Black-Scholes option-pricing model based on the following assumptions for the six
months ended June&nbsp;30, 2022 and 2023: </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Six months ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79.57%&nbsp;&#151;82.26%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78.57%&nbsp;&#151;&nbsp;86.33%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.52&nbsp;&#151;&nbsp;4.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.00&nbsp;&#151;&nbsp;4.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.65%&nbsp;&#151;&nbsp;2.82%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.50%&nbsp;&#151;&nbsp;4.47%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Threshold range</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">3.2</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">5.75&nbsp;&#151;&nbsp;7.40</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Expected volatility</I></B>&#151;The Company is a private company and lacks company-specific historical and implied
volatility information. Therefore, the Company estimates its expected unit&#146;s volatility based on the historical volatility of a publicly traded set of peer companies and expect to continue to do so until the Company has adequate historical data
regarding the volatility of the Company&#146;s traded unit or stock price. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Notes to the Unaudited Condensed Consolidated Financial Statements </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Expected term</I></B>&#151;The expected term of profits interests has been determined based on the expected
time to liquidity and expected vesting term. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Risk-free interest rate</I></B>&#151;The risk-free interest rate is determined by reference to the U.S. Treasury
yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Dividends</I></B>&#151;Expected dividend yield is zero because the Company does not pay cash dividends on common units and does not expect to pay any cash
dividends in the foreseeable future. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The grant date fair value of common units utilized in the Black-Scholes model is determined by the Company&#146;s Board of
Managers with the assistance of management. The grant date fair value of common units is determined using valuation methodologies which utilizes certain assumptions including probability weighting of expected exit events, volatility, time to
liquidation, a risk-free interest rate and an assumption for a discount for lack of marketability. In determining the fair value of the common units, the methodologies used to estimate the enterprise value were performed using methodologies,
approaches, and assumptions consistent with the American Institute of Certified Public Accountants Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table presents the classification of unit -based compensation expense for the six months ended June&nbsp;30, 2022 and 2023 (in thousands): </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Six&nbsp;months&nbsp;ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total unit-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The above unit-based compensation expense related to the following unit-based awards for the six months ended June&nbsp;30, 2022
and 2023 (in thousands): </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Six&nbsp;months&nbsp;ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Profits Interests</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Common Units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total unit-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There was $6.5&nbsp;million and $16.8&nbsp;million in unrecognized unit-based compensation expense related to the profits
interests as of June&nbsp;30, 2022 and 2023, respectively, that is expected to be recognized over a weighted-average period of 3.4 and 3.3 years, respectively. There was no unrecognized unit-based compensation expense related to the common units as
of December&nbsp;31, 2022 and June&nbsp;30, 2023, as all common units were fully vested.<B> </B> </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>12. Related party transactions </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In connection with Series B financing, the Company reimbursed certain investors for finance issuance costs that they incurred totaling $0.3&nbsp;million during the six
months ended June&nbsp;30, 2022. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Notes to the Unaudited Condensed Consolidated Financial Statements </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In connection with Series <FONT STYLE="white-space:nowrap">B-1</FONT> financing, the Company reimbursed certain
investors for finance issuance costs that they incurred totaling $0.1&nbsp;million during the year ended December&nbsp;31, 2022. As of December&nbsp;31, 2022, $0.1&nbsp;million of Series <FONT STYLE="white-space:nowrap">B-1</FONT> financing costs
reimbursable to investors is recorded in accrued expenses and other current liabilities in the condensed consolidated balance sheets. The reimbursable Series <FONT STYLE="white-space:nowrap">B-1</FONT> financing costs were fully paid during the six
months ended June&nbsp;30, 2023. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>13. Income taxes </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Metagenomi is treated
as a partnership for tax purposes, and thus, is not subject to income taxes. It is the responsibility of the LLC members to report their proportionate share of any taxable income or loss generated by Metagenomi to the appropriate taxing authorities
and pay the associated taxes, if any. With respect to the Company&#146;s subsidiary, Metagenomi Inc. is a corporation for tax purposes and is subject to income taxes which have been included in the condensed consolidated financial statements. All <FONT
STYLE="white-space:nowrap">pre-tax</FONT> losses have been incurred in the United States. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company provides for income taxes in interim periods based on the
estimated annual effective tax rate for the year, adjusting for discrete items in the quarter in which they arise. The income tax provision for the six months ended June&nbsp;20, 2022 and 2023 was related to the timing differences of the recognition
of upfront payments received under the Company&#146;s collaboration agreements for tax and financial reporting purposes and capitalization of its research and development expenses under the newly enacted Internal Revenue Code Section&nbsp;174
(&#147;Section&nbsp;174&#148;), which became effective on January&nbsp;1, 2022. The effective tax rate differs from the U.S. statutory rate primarily due to the full valuation allowances on the Company&#146;s net deferred tax assets as it is more
likely than not that all of the deferred tax assets will not be realized. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For the six months ended June&nbsp;30, 2022 and 2023, the Company recorded a provision for
income taxes of $1.1&nbsp;million and $4.1&nbsp;million by applying its estimated annual effective tax rate to its <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-date</FONT></FONT> measure of ordinary income, respectively.
The increase in the provision for income taxes during the six months ended June&nbsp;30, 2023 is primarily due to the higher forecasted research and development spend, which results in corresponding increases to Section&nbsp;174 capitalization and
taxable income for the year. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>14. Net loss per unit </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Basic and diluted
net loss per unit attributable to common unitholders is calculated as follows (in thousands except share and per share amounts): </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Six months ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss attributable to common members</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,585</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(29,141</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Weighted-average common units outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,947,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,947,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Less: Weighted-average unvested common units subject to repurchase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,838</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Weighted-average units used to compute basic and diluted net loss per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,929,662</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,947,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss per unit attributable to common unitholders&#151;basic and diluted:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.13</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4.90</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Notes to the Unaudited Condensed Consolidated Financial Statements </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following outstanding potentially dilutive securities have been excluded from the calculation of diluted net
loss per unit, as their effect is anti-dilutive: </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Six months ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Redeemable convertible preferred units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,704,895</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,813,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Profits interests</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,406,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,370,804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Unvested common units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,111,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,184,179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; BORDER-BOTTOM:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>15. Subsequent events </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company
has reviewed and evaluated subsequent events through September&nbsp;7, 2023, the date that the condensed consolidated financial statements were available to be issued. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Profits Interests Grants </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In September 2023, the Company granted
274,830 profits interests awards to officers, employees and consultants with a threshold amount of $11.84. In July and September 2023, the Company canceled and re-issued 781,312 profits interests awards with thresholds of $7.40 and $11.84. Issued
profits interests vest over a period of two to four years. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Amendment to the LLC Agreement </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company&#146;s LLC Agreement was amended on July&nbsp;31, 2023 to provide for <FONT STYLE="white-space:nowrap">&#147;catch-up&#148;</FONT> distributions for profits
interests once the applicable <FONT STYLE="white-space:nowrap">catch-up</FONT> threshold amount for such profits interests was met (the &#147;Amendment to the LLC Agreement&#148;). </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The LLC Agreement provides each profits interest with a distribution threshold amount, which is determined on the date of issuance and represents the amount that would
be distributed if, immediately after issuance, the Company sold all of its assets at fair market value and distributed the net proceeds in liquidation. A profits interest does not participate in Company distributions until an amount equal to its
distribution threshold amount has been distributed to other members of the Company with units that either have a lower threshold amount or no threshold amount. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Once
the applicable distribution threshold amount has been met for a particular profits interest, such profits interest will participate in Company distributions on a pro rata basis until the <FONT STYLE="white-space:nowrap">catch-up</FONT> threshold
amount has been met. Once the <FONT STYLE="white-space:nowrap">catch-up</FONT> threshold amount has been met, subsequent <FONT STYLE="white-space:nowrap">&#147;catch-up&#148;</FONT> distributions will be made solely to holders of profits interests
until such holders have received an amount equal to the amount such holders would have received had the distribution threshold not existed. Once the profits interest holders have received distributions in an amount equal to what they would have
received had the distribution threshold not existed, all subsequent distributions are made on a pro rata basis with common unitholders. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The <FONT
STYLE="white-space:nowrap">catch-up</FONT> threshold amount of $11.84 per unit reflected the estimated fair value of the Company&#146;s common unit as of July&nbsp;31, 2023, as determined by the Company&#146;s board of managers, with input from
management, and considering the Company&#146;s most recently available third-party valuations of common units. The amendment to the LLC Agreement resulted in a change to the fair value of the profits interests and will be accounted for as a
modification of the profits interests&#146; awards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:48pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:18pt; font-family:arial" ALIGN="center"><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares </I></B></P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:96pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center"><B>


<IMG SRC="g425213g00s01.jpg" ALT="LOGO">
 </B></P> <P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:18pt; font-family:arial" ALIGN="center"><B><I>Common Stock </I></B></P>
<P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:24pt; font-family:arial" ALIGN="center"><B>Prospectus </B></P> <P STYLE="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:13pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:13pt">
<TD VALIGN="top"><B>J.P.&nbsp;Morgan</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Jefferies</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>TD&nbsp;Cowen</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Wells&nbsp;Fargo&nbsp;Securities</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>BMO&nbsp;Capital&nbsp;Markets</B></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:13pt; font-family:arial" ALIGN="center"><B>Chardan </B></P>
<P STYLE="margin-top:48pt; margin-bottom:0pt; font-size:10pt; font-family:arial">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023 </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Through and including &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023 (the 25th day after the date of this prospectus), all dealers
that effect transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to the dealers&#146; obligation to deliver a prospectus when acting as underwriters and with
respect to their unsold allotments or subscriptions. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Part II </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Information Not
Required in Prospectus </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Item&nbsp;13. Other Expenses of Issuance and Distribution </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table sets forth the costs and expenses, other than underwriting discounts and commissions, to be paid by us in connection with the sale of the shares of
common stock being registered hereby. All amounts shown are estimates except for the SEC registration fee, the FINRA filing fee and the Nasdaq Global Market initial listing fee. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:1pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Nasdaq listing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Printing and engraving expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Transfer agent and registrar fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Miscellaneous</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="4" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">To be provided by amendment. </TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Item&nbsp;14. Indemnification of Directors and Officers </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Section&nbsp;145 of the Delaware General Corporation Law (the &#147;DGCL&#148;) authorizes a corporation to indemnify its directors and officers against liabilities
arising out of actions, suits and proceedings to which they are made or threatened to be made a party by reason of the fact that they have served or are currently serving as a director or officer to a corporation. The indemnity may cover expenses
(including attorneys&#146; fees) judgments, fines and amounts paid in settlement actually and reasonably incurred by the director or officer in connection with any such action, suit or proceeding. Section&nbsp;145 permits corporations to pay
expenses (including attorneys&#146; fees) incurred by directors and officers in advance of the final disposition of such action, suit or proceeding. In addition, Section&nbsp;145 provides that a corporation has the power to purchase and maintain
insurance on behalf of its directors and officers against any liability asserted against them and incurred by them in their capacity as a director or officer, or arising out of their status as such, whether or not the corporation would have the
power to indemnify the director or officer against such liability under Section&nbsp;145. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have adopted provisions in our amended and restated certificate of
incorporation and amended and restated bylaws to be in effect upon the effectiveness of this registration statement that limit or eliminate the personal liability of our directors to the fullest extent permitted by the DGCL, as it now exists or may
in the future be amended. Consequently, a director will not be personally liable to us or our stockholders for monetary damages or breach of fiduciary duty as a director, except for liability for: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any breach of the director&#146;s duty of loyalty to us or our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any unlawful payments related to dividends or unlawful stock purchases, redemptions or other distributions; or
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any transaction from which the director derived an improper personal benefit. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">These limitations of liability do not alter director liability under the federal securities laws and do not affect the
availability of equitable remedies such as an injunction or rescission. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, our amended and restated bylaws to be in effect upon the effectiveness of this
registration statement provide that: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we will indemnify our directors, officers and, in the discretion of our board of directors, certain employees to the
fullest extent permitted by the DGCL, as it now exists or may in the future be amended; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we will advance reasonable expenses, including attorneys&#146; fees, to our directors and, in the discretion of our board
of directors, to our officers and certain employees, in connection with legal proceedings relating to their service for or on behalf of us, subject to limited exceptions. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We intend to enter into indemnification agreements with each of our directors and executive officers. These agreements provide that we will indemnify each of our
directors, certain of our executive officers and, at times, their affiliates to the fullest extent permitted by Delaware law. We will advance expenses, including attorneys&#146; fees (but excluding judgments, fines and settlement amounts), to each
indemnified director or executive officer in connection with any proceeding in which indemnification is available and we will indemnify our directors and officers for any action or proceeding arising out of that person&#146;s services as a director
or officer brought on behalf of us or in furtherance of our rights. Additionally, certain of our directors or officers may have certain rights to indemnification, advancement of expenses or insurance provided by their affiliates or other third
parties, which indemnification relates to and might apply to the same proceedings arising out of such director&#146;s or officer&#146;s services as a director referenced herein. Nonetheless, we have agreed in the indemnification agreements that our
obligations to those same directors or officers are primary and any obligation of such affiliates or other third parties to advance expenses or to provide indemnification for the expenses or liabilities incurred by those directors are secondary.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We also maintain general liability insurance which covers certain liabilities of our directors and officers arising out of claims based on acts or omissions in
their capacities as directors or officers, including liabilities under the Securities Act. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The underwriting agreement filed as Exhibit 1.1 to this registration
statement provides for indemnification of us and our directors and officers by the underwriters against certain liabilities under the Securities Act and the Exchange Act. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Item&nbsp;15. Recent Sales of Unregistered Securities </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the three years
preceding the filing of this registration statement, we have issued the following securities that were not registered under the Securities Act: </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>(a) Preferred
Units </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">From 2020 to 2021, we sold an aggregate of 9,861,297 Series A preferred units in multiple closings, consisting of (i) 8,280,360 Series <FONT
STYLE="white-space:nowrap">A-4</FONT> preferred units sold at a purchase price of $4.84875 per unit for an aggregate amount of $40.1&nbsp;million and (ii) 1,580,937 Series <FONT STYLE="white-space:nowrap">A-5</FONT> preferred units sold at a
purchase price of $6.32536 per unit for an aggregate amount of $10.0&nbsp;million, for total aggregate proceeds of $50.1&nbsp;million. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In 2022 and 2023, we sold an
aggregate of 22,162,743 Series B preferred units in multiple closings, consisting of (i) 15,054,263 Series B preferred units, which includes (a) 12,446,876 Series B preferred units sold at a purchase price of $11.64951 per unit and (b) 2,607,387
Series B preferred units which converted pursuant to a promissory note with a principal amount of $30.0&nbsp;million and accrued interest of $0.4&nbsp;million between the Company and ModernaTx, Inc., for an aggregate amount of $175.4&nbsp;million
and (ii) 7,108,480 Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred units sold at a purchase price of $14.06770 per unit for an aggregate amount of $100.0&nbsp;million, for total aggregate proceeds of $275.4&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">No underwriters were involved in the foregoing sales of securities. The sales of securities described above were
deemed to be exempt from registration pursuant to Section&nbsp;4(a)(2) of the Securities Act, including Regulation D and Rule 506 promulgated thereunder, as transactions by an issuer not involving a public offering. All of the purchasers in these
transactions represented to us in connection with their purchase that they were acquiring the securities for investment and not distribution, that they could bear the risks of the investment and could hold the securities for an indefinite period of
time. Such purchasers received written disclosures that the securities had not been registered under the Securities Act and that any resale must be made pursuant to a registration or an available exemption from such registration. All of the
foregoing securities are deemed restricted securities for the purposes of the Securities Act. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>(b) Profits Interests </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Since January&nbsp;1, 2020, we have granted an aggregate of 9,903,897 profits interests, with profits interests threshold amounts ranging from $0.08 to $11.84 per unit,
to employees, directors and consultants pursuant to the 2019 Plan. No common units have been issued pursuant to the 2019 Plan. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The issuances of the securities
under the 2019 Plan described above were deemed to be exempt from registration pursuant to Section&nbsp;4(a)(2) of the Securities Act or Rule 701 promulgated under the Securities Act as transactions pursuant to compensatory benefit plans. The
profits interests are deemed to be restricted securities for purposes of the Securities Act. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The issuance of securities described above to employees and consultants
outside of the 2019 Plan were deemed exempt from registration pursuant to Section&nbsp;4(a)(2) of the Securities Act as transactions by an issuer not involving a public offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Item&nbsp;16. Exhibits and Financial Statement Schedules </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Exhibits. </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit<BR>number</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:arial" ALIGN="center"><B>Exhibit table</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;1.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Form of Underwriting Agreement</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;3.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Amended and Restated Limited Liability Company Agreement of the Registrant, as currently in
effect</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;3.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Form of Amended and Restated Certificate of Incorporation of the Registrant (to be effective upon the
closing of this offering)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;3.3*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Form of Amended and Restated <FONT STYLE="white-space:nowrap">By-laws</FONT> (to be effective upon the
closing of this offering)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;4.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Amended and Restated Investors&#146; Rights Agreement among the Registrant and certain of its
stockholders, dated December&nbsp;20, 2022</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;4.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Form of Common Stock Certificate</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;5.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Opinion of Goodwin Procter LLP</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;10.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">2019 Equity Incentive Plan, as amended, and forms of award agreements thereunder</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;10.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">2023 Stock Option and Incentive Plan and forms of award agreements thereunder</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;10.3*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">2023 Employee Stock Purchase Plan</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;10.4*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Form of Officer Indemnification Agreement</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;10.5*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Form of Director Indemnification Agreement</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;10.6&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Strategic Collaboration and License Agreement by and between the Registrant and ModernaTX, Inc., dated
October&nbsp;29, 2021</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;10.7&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Collaboration and License Agreement by and between the Registrant and Ionis Pharmaceuticals, Inc., dated
November&nbsp;10, 2022</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;10.8&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Development, Option and License Agreement by and between the Registrant and Affini-T Therapeutics, Inc.,
dated June 14, 2022</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;10.9*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Lease Agreement between EPL Halleck Investors LLC and Metagenomi, Inc., dated January&nbsp;22,
2021</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;10.10*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Sublease Agreement between Zymergen Inc. and Metagenomi, Inc., dated November&nbsp;11, 2022</P></TD></TR>

<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;10.11*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Lease Agreement between Park Avenue Building LLC and Metagenomi, Inc., dated
September&nbsp;29,&nbsp;2021</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;10.12*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Employment Agreement between the Registrant and Brian C. Thomas, to be in effect upon the closing of this
offering</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;10.13*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Employment Agreement between the Registrant and Jian Irish, to be in effect upon the closing of this
offering</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;10.14*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Employment Agreement between the Registrant and Simon Harnest, to be in effect upon the closing of this
offering</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;16.1**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Letter from KPMG LLP to the Securities and Exchange Commission dated August&nbsp;3, 2023</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;21.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Subsidiaries of the Registrant</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;23.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;23.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Consent of Goodwin Procter LLP (included in Exhibit 5.1)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;24.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Power of Attorney (included on signature page to this registration statement)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">107*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Filing Fees Exhibit</P></TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">To be filed by amendment. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">**</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Previously filed. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Portions of this exhibit (indicated by asterisks) will be omitted in accordance with the rules of the SEC because the Registrant has determined that information is not material and would be competitively harmful if
publicly disclosed. </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Financial Statement Schedules. </TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">None. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Item&nbsp;17. Undertakings </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The undersigned Registrant hereby undertakes to
provide to the underwriters at the closing specified in the Underwriting Agreement certificates in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to
the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for
indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted
by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate
jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The undersigned Registrant hereby undertakes that: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of
prospectus filed by the Registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective. </TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities
offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">II-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Signatures </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pursuant to the
requirements of the Securities Act, Metagenomi Technologies, LLC has duly caused this registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of
Emeryville, California, on the&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;day of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Metagenomi Technologies, LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:arial">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Brian C. Thomas, Ph.D.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial">Chief Executive Officer</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Signatures and Power of Attorney </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">KNOW
ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Brian C. Thomas and Michael Conway, and each of them, either of whom may act without the joinder of the other, as his true and lawful <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents with full power of substitution and <FONT STYLE="white-space:nowrap">re-substitution,</FONT> for him or her and in his or her name, place and
stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to sign any registration statement for the same offering covered by the registration statement that is to be
effective upon filing pursuant to Rule&nbsp;462(b) promulgated under the Securities Act, and all post-effective amendments thereto, and to file the same, with all exhibits thereto and all documents in connection therewith, with the SEC, granting
unto said <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in
and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and
agents or any of them, or his or her or their substitute or substitutes, may lawfully do or cause to be done or by virtue hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">II-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pursuant to the requirements of the Securities Act, this registration statement has been signed by the following
persons in the capacities indicated on the&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;day of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="45%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:arial" ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:arial" ALIGN="center"><B>Title</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:arial">&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Chief Executive Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">Brian C. Thomas, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">(Principal Executive Officer)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:arial">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Vice President of Finance</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">Michael Conway, MBA, CPA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">(Principal Financial Officer and Principal Accounting Officer)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:arial">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">Juergen Eckhardt, M.D., MBA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:arial">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">Sebasti&aacute;n Bernales, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:arial">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">Risa Stack, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:arial">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">Willard Dere, M.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:arial">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">Santhosh Palani, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">II-7 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>2
<FILENAME>filename2.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.6</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.6 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>CONFIDENTIAL </B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STRATEGIC
COLLABORATION AND LICENSE AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Between </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MODERNATX, INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>and
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>METAGENOMI, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>October&nbsp;29, 2021 </B></P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 1 DEFINITIONS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 2 GOVERNANCE AND JOINT STEERING COMMITTEE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>ALLIANCE MANAGER</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>WORKING GROUPS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>JOINT STEERING COMMITTEE</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>SPECIFIC RESPONSIBILITIES OF THE JSC</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>MEETINGS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>JOINT RESEARCH COMMITTEE</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>JOINT DEVELOPMENT COMMITTEE</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>JOINT COMMERCIALIZATION COMMITTEE</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>JOINT PATENT COMMITTEE</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>DECISIONS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>AUTHORITY</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>DISCONTINUATION OF JSC</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 3 RT RESEARCH ACTIVITIES AND OPTION</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>GOALS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>RT TECHNOLOGY RESEARCH PLAN</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>RT PRECLINICAL RESEARCH PLAN</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>OBLIGATIONS DURING THE RT RESEARCH TERM</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>RT RESEARCH TERM COSTS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>SUBCONTRACTORS FOR THE RT PLANS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>RECORDS AND REPORTS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>RT RESEARCH TERM EXTENSION</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>RT OPTION</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>METAGENOMI BEC PROGRAMS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 4 MODERNA DT RESEARCH ACTIVITIES AND OPTION</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>RESERVED DT TARGET DISCONTINUANCE</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>RIGHT OF FIRST NEGOTIATION</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>DT TARGET EVALUATION PLAN</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>DT MODERNA RESEARCH PLAN</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>OBLIGATIONS DURING THE DT MODERNA RESEARCH TERM</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>DT MODERNA RESEARCH TERM COSTS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(continued) </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>SUBCONTRACTORS FOR THE DT PLANS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>RECORDS AND REPORTS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>DT OPTION</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 5 LICENSES; EXCLUSIVITY; MANUFACTURE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>RT RESEARCH TERM LICENSE</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>RT PRECLINICAL RESEARCH TECHNOLOGY TRANSFER</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>DT MODERNA RESEARCH TERM LICENSE</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>DT MODERNA RESEARCH TERM TECHNOLOGY TRANSFER</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>DT <FONT STYLE="white-space:nowrap">CO-CO</FONT> PROGRAM LICENSE</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>DT <FONT STYLE="white-space:nowrap">CO-CO</FONT> RESEARCH TECHNOLOGY TRANSFER</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>SUBLICENSING</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>RESPONSIBILITY FOR SUBLICENSEES</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>SUBCONTRACTING FOR DT <FONT STYLE="white-space:nowrap">CO-CO</FONT> PLANS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>THIRD PARTY <FONT STYLE="white-space:nowrap">IN-LICENSES</FONT> IN THE DT <FONT STYLE="white-space:nowrap">CO-CO</FONT> PROGRAM</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>THIRD PARTY <FONT STYLE="white-space:nowrap">IN-LICENSES</FONT> IN RT PROGRAMS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>THIRD PARTY <FONT STYLE="white-space:nowrap">IN-LICENSES</FONT> IN DT PROGRAMS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>LICENSE TO MODERNA UPON EXERCISE OF THE RT OPTION</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.14</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>RT TECHNOLOGY TRANSFER</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.15</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>LICENSE TO MODERNA UPON EXERCISE OF THE DT OPTION</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.16</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>DT TECHNOLOGY TRANSFER</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.17</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>METAGENOMI LICENSED COLLABORATION TECHNOLOGY UPDATE</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.18</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>COLLABORATION MATERIALS TRANSFER</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.19</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>NO OTHER RIGHTS AND RETAINED RIGHTS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.20</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>RT EXCLUSIVITY</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.21</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>DT EXCLUSIVITY</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.22</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>DT <FONT STYLE="white-space:nowrap">CO-CO</FONT> TARGET EXCLUSIVITY</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.23</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>MANUFACTURE</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.24</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>GOVERNMENT APPROVALS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.25</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>PAYMENTS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 6 COLLABORATION ACTIVITIES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>LEAD PARTY</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-ii- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(continued) </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>DT <FONT STYLE="white-space:nowrap">CO-CO</FONT> PLANS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>DT <FONT STYLE="white-space:nowrap">CO-CO</FONT> PRODUCT RESEARCH ACTIVITIES</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>DT <FONT STYLE="white-space:nowrap">CO-CO</FONT> PRODUCT DEVELOPMENT ACTIVITIES</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>REGULATORY AFFAIRS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>MEDICAL AFFAIRS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>COMMERCIALIZATION</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B><FONT STYLE="white-space:nowrap">OPT-OUT</FONT> RIGHT</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>PRESERVATION OF PROGRAM ASSETS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>SAFETY CONCERN</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 7 FEES, ROYALTIES, &amp; PAYMENTS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>UPFRONT PAYMENT</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>CONVERTIBLE NOTE</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>RESEARCH FUNDING</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B><FONT STYLE="white-space:nowrap">CO-CO</FONT> PRODUCTS PROFIT AND LOSS SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>APPORTIONMENT OF COSTS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>ACCOUNTING; AUDIT</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>DISPUTED PAYMENTS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>MILESTONE PAYMENTS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>ROYALTIES ON PRODUCTS DIRECTED AGAINST AN RT TARGET</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>ROYALTIES ON PRODUCTS DIRECTED AGAINST A DT MODERNA TARGET</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B><FONT STYLE="white-space:nowrap">OPT-OUT</FONT> MILESTONES AND ROYALTIES</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>PAYMENT; REPORTS; ROYALTY MINIMUM</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>METHOD OF PAYMENT; FOREIGN EXCHANGE</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.14</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>RECORDS AND AUDITS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.15</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>DEFAULT INTEREST</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.16</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>TAXES</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 8 INTELLECTUAL PROPERTY</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>OWNERSHIP OF INTELLECTUAL PROPERTY</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>PATENT PROSECUTION AND MAINTENANCE</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>INFRINGEMENT BY THIRD PARTIES</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-iii- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(continued) </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>DEFENSE AND SETTLEMENT OF THIRD PARTY CLAIMS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>PATENT EXTENSION</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>UNIFIED PATENT COURT</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>COMMON INTEREST</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>TRADEMARKS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 9 REPRESENTATIONS, WARRANTIES AND COVENANTS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>MUTUAL REPRESENTATIONS AND WARRANTIES</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>METAGENOMI REPRESENTATIONS AND WARRANTIES</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>MODERNA REPRESENTATIONS AND WARRANTIES</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>COVENANTS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>COMPLIANCE</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>DISCLAIMER</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 10 INDEMNIFICATION</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>INDEMNITY</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>LOSSES IN THE TERRITORY</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>INSURANCE</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 11 CONFIDENTIALITY</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>CONFIDENTIAL INFORMATION</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>PUBLICITY</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>PUBLICATION</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 12 TERM&nbsp;&amp; TERMINATION</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>TERM</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>TERMINATION FOR MATERIAL BREACH OR INSOLVENCY OR PATENT CHALLENGE</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>MODERNA OPTION TO CONTINUE IN LIEU OF TERMINATION</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>TERMINATION FOR CONVENIENCE BY MODERNA</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>TERMINATION FOR CONVENIENCE BY PRIMARY PARTY</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>EFFECTS OF TERMINATION</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>SURVIVAL</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>BANKRUPTCY CODE</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 13 GOVERNING LAW; DISPUTE RESOLUTION</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-iv- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(continued) </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>GOVERNING LAWS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>DISPUTES</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>ARBITRATION</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>BASEBALL ARBITRATION</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>EQUITABLE RELIEF; REMEDY FOR BREACH OF EXCLUSIVITY</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>EXCLUDED CLAIMS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 14 MISCELLANEOUS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>ENTIRE AGREEMENT; AMENDMENT</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>LIMITATION OF LIABILITY</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>INDEPENDENT CONTRACTORS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>NOTICE</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>SEVERABILITY</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B><FONT STYLE="white-space:nowrap">NON-USE</FONT> OF NAMES</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>ASSIGNMENT</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>ACQUISITION OF EXISTING COMPETING PROGRAMS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>METAGENOMI CHANGE OF CONTROL</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>ACQUIRER ENGAGED IN COMPETING PROGRAM</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>FIREWALLED PROGRAMS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>FIREWALL AUDITS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>WAIVERS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.14</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>FORCE MAJEURE</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.15</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>INTERPRETATION</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.16</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>EXPENSES</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.17</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>FURTHER ASSURANCES</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.18</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>NO THIRD PARTY BENEFICIARY RIGHTS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.19</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>CONSTRUCTION</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.20</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>CUMULATIVE REMEDIES</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.21</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>EXTENSION TO AFFILIATES</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.22</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>OTHER ACTIVITIES</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.23</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>COUNTERPARTS; ELECTRONIC SIGNATURES</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-v- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Listing of Schedules </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Schedule A: DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Target </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Schedule B: Manufacturing Cost </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Schedule C: Certain Technology
Milestones </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Schedule D: Reserved DT Targets </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Schedule E:
Approved Subcontractors </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Schedule F: Existing <FONT STYLE="white-space:nowrap">Co-Co</FONT> <FONT STYLE="white-space:nowrap">In-Licenses</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Schedule G: Existing RT <FONT STYLE="white-space:nowrap">In-Licenses</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Schedule H: Existing DT <FONT STYLE="white-space:nowrap">In-Licenses</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Schedule I: Material Transfer Record </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Schedule J: <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Products Profit and Loss Share </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Schedule K: Existing Patents </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Schedule L: RT Technology Research Plan </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Schedule M:
Partnership Tax Matters </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Schedule N: Joint Press Release </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Schedule O: DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Research Plan </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STRATEGIC COLLABORATION AND LICENSE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This <B>STRATEGIC COLLABORATION AND LICENSE AGREEMENT </B>(this &#147;<B>Agreement</B>&#148;) is entered into as of October&nbsp;29, 2021 (the
&#147;<B>Effective Date</B>&#148;) by and between <B>METAGENOMI, INC.</B>, a company incorporated under the laws of Delaware having an address at 1545 Park Ave, Emeryville, CA 94608 (&#147;<B>Metagenomi</B>&#148;), and <B>MODERNATX, INC.</B>, a
corporation organized and existing under the laws of Delaware, with its principal business office located at 200 Technology Square, Cambridge, MA 02139 (&#147;<B>Moderna</B>&#148;). Moderna and Metagenomi are each hereafter referred to individually
as a &#147;<B>Party</B>&#148; and together as the &#147;<B>Parties</B>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL></B><SMALL></SMALL>, Metagenomi is
a biotechnology company focused on using metagenomics and machine learning to discover novel genome editing systems; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL></B><SMALL></SMALL>, Moderna is a pharmaceutical company engaged in the research, development, manufacturing,
marketing and distribution of mRNA-based therapeutic products; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL></B><SMALL></SMALL>, Moderna and Metagenomi
desire to establish a collaboration to discover novel genome editing technologies for use as <I>in vivo</I> genome editing therapies; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL></B><SMALL></SMALL>, Metagenomi and Moderna desire to collaborate in the research and development of <I>in vivo</I>
genome editing therapies directed at certain targets as well as the commercialization of such genome editing therapies all as set forth in the Program Plans (as defined below); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL></B><SMALL></SMALL>, Moderna will provide an equity investment in Metagenomi in the form of a convertible note
pursuant to the Convertible Note Instruments dated October&nbsp;29, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>N<SMALL>OW</SMALL>,
T<SMALL>HEREFORE</SMALL></B><SMALL></SMALL>, in consideration of the mutual covenants contained herein, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Parties hereby agree as follows:
</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Article 1 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEFINITIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Capitalized
terms used in this Agreement and the Schedules hereto shall have the following meanings (or as defined elsewhere in this Agreement): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.1
&#147;<B>Affiliate</B>&#148; means, with respect to a Person (including a Party), any entity that, at the relevant time (whether as of the Effective Date or thereafter), directly or indirectly through one or more intermediaries, controls, is
controlled by, or is under common control with such Person, for so long as such control exists. As used in this Section&nbsp;1.1, &#147;control&#148; means: (a)&nbsp;to possess, directly or indirectly, the power to direct or cause the direction of
the management or policies of an entity, whether through ownership of voting securities or by contract relating to voting rights or corporate governance; or (b)&nbsp;direct or indirect ownership of more than fifty percent (50%) (or such lesser
percentage that is the maximum allowed to be owned by a foreign entity in a particular jurisdiction) of the voting share capital or other equity interest in such entity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.2 &#147;<B>Allowable Overruns</B>&#148; means, for a particular DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Candidate or DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product, as applicable, any amount that is less than [***] (or such other percentage as may be approved by the JSC) above the most recent budgeted
costs and expenses for a Calendar Year on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-date</FONT></FONT> basis set forth in any applicable Research Budget, Development Budget, Medical Affairs Budget, or
Commercialization Budget, as applicable, for such Calendar Year; provided that such amount is not attributable to (a) the breach of this Agreement or (b) the gross negligence or willful misconduct of either Party or any of its Affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.3 &#147;<B>Applicable Laws</B>&#148; means the applicable provisions of any and all federal, national, supranational, regional, state and
local laws, treaties, statutes, rules, regulations, guidelines or requirements, administrative codes, guidance, ordinances, judgments, decrees, directives, injunctions, orders, or permits of or from any court, arbitrator, Regulatory Authority,
Governmental Authority, data protection authority, taxing authority, national securities exchange or exchange listing organization having jurisdiction over or related to the relevant subject item that may be in effect from time to time during the
Term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.4 &#147;<B>Approved Labeling</B>&#148; means, with respect to a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product:
(a)&nbsp;the Regulatory Authority-approved full prescribing information for such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product; and (b)&nbsp;the Regulatory Authority-approved labels and other written, printed, or graphic materials on any
container, wrapper, or any package insert that is used with or for such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.5
&#147;<B>Background Technology</B>&#148; means, with respect to a Party, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-</FONT></FONT> Program basis, any and all materials, Patents,
<FONT STYLE="white-space:nowrap">Know-How</FONT> and other intellectual property rights Controlled by such Party or any of its Affiliates as of the Effective Date or that comes into the Control of such Party or any of its Affiliates during the Term
(other than Program Technology), in each case related to or otherwise pertaining to such Program, and in the case of Moderna, to the extent Moderna makes any of the foregoing available to Metagenomi pursuant to this Agreement. Background Technology
shall not include any materials, Patents, <FONT STYLE="white-space:nowrap">Know-How</FONT> or other intellectual property rights Controlled by a New Affiliate of a Party and not also Controlled by such Party or any of its Affiliates, provided that
such New Affiliate is not utilizing the Metagenomi Licensed Collaboration Technology or the Moderna Licensed Collaboration Technology with respect to the activity that would otherwise be restricted under Sections 5.20 (RT Exclusivity), 5.21 (DT
Exclusivity), or 5.22 (DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Target Exclusivity), as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.6 &#147;<B>Base
Editing</B>&#148; means [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.7 &#147;<B>Base Editing Correction Readiness</B>&#148; means the criteria for Base Editing correction as
specified in part 2 of the Base Editing Readiness Milestones in <B>Schedule C </B>(Certain Technology Milestones). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.8 &#147;<B>Base
Editing Knockout Readiness</B>&#148; means the criteria for Base Editing knockout as specified in part 1 of the Base Editing Readiness Milestones in <B>Schedule C </B>(Certain Technology Milestones). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.9 &#147;<B>Base Editing Readiness Milestone</B>&#148; means [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.10 &#147;<B>BEC</B>&#148; means [***]. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.11 &#147;<B>Biosimilar Application</B>&#148; means an application submitted to the FDA
under subsection (k)&nbsp;of Section&nbsp;351 of the PHSA, or any analogous application submitted to a Regulatory Authority in the U.S. or in another country in the world. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.12 &#147;<B>Biosimilar Product</B>&#148; means, with respect to a Product, and on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Product-by-Product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, any product (including a &#147;generic product,&#148; &#147;biogeneric,&#148; <FONT
STYLE="white-space:nowrap">&#147;follow-on</FONT> biologic,&#148; <FONT STYLE="white-space:nowrap">&#147;follow-on</FONT> biological product,&#148; <FONT STYLE="white-space:nowrap">&#147;follow-on</FONT> protein product,&#148; &#147;similar
biological medicinal product,&#148; or &#147;biosimilar product&#148;) approved by way of an abbreviated regulatory mechanism by the relevant Regulatory Authority in a country in reference to such Product, that in each case: (a)&nbsp;is sold in the
same country (or is commercially available in the same country via import from another country) as such Product by any Third Party that is not a Sublicensee of the applicable Party or any of its Affiliates and that did not purchase such product in a
chain of distribution that included any of the applicable Party or any of its Affiliates or its Sublicensees; and (b)&nbsp;meets the equivalency determination by the applicable Regulatory Authority in such country (including a determination that the
product is &#147;comparable,&#148; &#147;interchangeable,&#148; &#147;bioequivalent,&#148; &#147;biosimilar&#148; or other term of similar meaning, with respect to the Product), in each case, as is necessary to permit substitution of such product
for the Product under Applicable Law in such country, including, with respect to the U.S., to an Abbreviated New Drug Applications under Section&nbsp;505(j) of the FD&amp;C Act (21 USC 355(j)) or is approved as a &#147;Biosimilar Biologic
Product&#148; under Title VII, Subtitle A Biologics Price Competition and Innovation Act of 2009, Section&nbsp;42 U.S.C. 262, Section&nbsp;351 of the PHSA, or, outside the U.S., in accordance with European Directive 2001/83/EC on the Community Code
for medicinal products (Article 10(4) and Section&nbsp;4, Part II of Annex I) and European Regulation EEC/2309/93 establishing the Community procedures for the authorization and evaluation of medicinal products, each as amended, and together with
all associated guidance, and any counterparts thereof or equivalent process inside or outside of the U.S. or EU to the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.13
&#147;<B>Business Day</B>&#148; means any day other than Saturday, Sunday, or any day that banks are authorized or required to be closed in the state of New York or the Commonwealth of Massachusetts or the state of California. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.14 &#147;<B>Calendar Quarter</B>&#148; means each respective period of three (3)&nbsp;consecutive months ending on March&nbsp;31,
June&nbsp;30, September&nbsp;30 and December&nbsp;31 of any Calendar Year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.15 &#147;<B>Calendar Year</B>&#148; means each respective
period of twelve (12)&nbsp;consecutive months commencing on January&nbsp;1 and ending on December 31. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.16 &#147;<B>Candidate</B>&#148;
means a BEC Candidate, an RT Candidate, a DT Moderna Candidate or a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Candidate, as the case may be. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.17 &#147;<B>Change of Control</B>&#148; means, with respect to either Party: (i)&nbsp;the acquisition by a Third Party, in one transaction
or a series of related transactions, of direct or indirect beneficial ownership of more than fifty percent (50%) of the outstanding voting equity securities of such Party (excluding, for clarity, an acquisition by a Third Party where the
stockholders of such acquired Party immediately prior to such transaction hold a majority of the voting shares of outstanding capital stock of the surviving entity immediately following such transaction); (ii) a merger or consolidation involving
such Party, as a result of which a Third Party acquires direct or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
indirect beneficial ownership of more than fifty percent (50%) of the voting power of the surviving entity immediately after such merger, reorganization or consolidation; or (iii)&nbsp;a sale of
all or substantially all of the assets of such Party in one transaction or a series of related transactions to a Third Party. The acquiring or combining Third Party in any of (i), (ii) or (iii), and any of such Third Party&#146;s Affiliates (whether
in existence as of or any time following the applicable transaction, but other than the acquired Party and its Affiliates as in existence prior to the applicable transaction or other Affiliates such Party or its Affiliates controls (directly or
indirectly) after the applicable transaction) are referred to collectively herein as the &#147;<B>Acquirer</B>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, with
respect to Metagenomi, the term &#147;Change of Control&#148; shall not include (i)&nbsp;any sale of shares of capital stock of Metagenomi or any of its Affiliates, in a single transaction or series of related transactions, in which Metagenomi or
its applicable Affiliate issues new securities for cash or the cancellation or conversion of indebtedness or a combination thereof, or (ii)&nbsp;any merger or consolidation of Metagenomi or any of its Affiliates (including a special purpose
acquisition company (SPAC)), in each case ((i) and (ii)) where such transaction(s) are conducted primarily for <I>bona fide</I> equity financing purposes or for becoming a publicly listed company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.18 &#147;<B>Clinical Trial&#148; </B>means a Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial, or any
post-Regulatory Approval human clinical trial, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.19 &#147;<B>CMC</B>&#148; means Chemistry and Manufacturing Controls,
which includes (a)&nbsp;Manufacturing process development records for products, (b)&nbsp;all chemistry, Manufacturing and control procedures necessary for Manufacture of products, and (c)&nbsp;sourcing and testing of all raw materials and components
used in the Manufacture of products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.20 &#147;<B>CMC Activities</B>&#148; means [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.21 &#147;<B>CMC Matters</B>&#148; means [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.22 &#147;<B><FONT STYLE="white-space:nowrap">Co-Co</FONT> <FONT STYLE="white-space:nowrap">In-License</FONT></B>&#148; means <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Moderna <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements or <FONT STYLE="white-space:nowrap">Co-Co</FONT> Metagenomi <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements, as applicable.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.23 &#147;<B>Collaboration Materials</B>&#148; means any tangible <FONT STYLE="white-space:nowrap">(non-document)</FONT> materials
Controlled by a Party or any of its Affiliates that are delivered to the other Party under this Agreement, including to conduct Research as set forth in an applicable Program Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.24 &#147;<B>Collaboration Target</B>&#148; means an RT Target, a DT Moderna Target or the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT>
Target, as the case may be. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.25 &#147;<B>Commercial Overhead Charge</B>&#148; means[***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.26 &#147;<B>Commercialization</B>&#148; means any and all activities directed to the offering for sale and sale of a Product, including:
(a)&nbsp;activities directed to storing, marketing, promoting, detailing, distributing, importing, exporting, selling and offering to sell (including receiving, accepting, and filling orders); (b) handling all returns; (c)&nbsp;controlling
invoicing, order processing, and collection of accounts receivable for the sales; (d)&nbsp;booking and recording sales in its books of account; (e)&nbsp;distributing and managing inventory; (f)&nbsp;interacting with Regulatory Authorities regarding
any of the foregoing; and (g)&nbsp;seeking Pricing and Reimbursement Approvals (as applicable). When used as a verb, &#147;to <B>Commercialize</B>&#148; and &#147;<B>Commercializing</B>&#148; means to engage in Commercialization and
&#147;<B>Commercialized</B>&#148; has a corresponding meaning. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.27 &#147;<B>Commercialization Budget</B>&#148; means, the budget for activities under the
applicable Commercialization Plan for each DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.28 &#147;<B>Commercialization
Costs</B>&#148; means [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding any provision to the contrary set forth in this Agreement no Milestone Payment shall be considered a
Commercialization Cost, and no expense included as a Commercialization Cost shall be included as an Eligible Development Cost, Eligible Medical Affairs Cost, Cost of Sales, or Other Operating Expense. Commercialization Costs specifically exclude any
costs or expenses of a Party or its Affiliates to the extent caused by such Party or its Affiliate&#146;s breach of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.29
&#147;<B>Commercially Reasonable Efforts</B>&#148; means [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.30 &#147;<B>Control</B>&#148; or &#147;<B>Controlled</B>&#148; means,
with respect to any materials, <FONT STYLE="white-space:nowrap">Know-How,</FONT> Patents, or other intellectual property rights, that a Party or any of its Affiliates has the legal authority or right (whether by ownership, license, or otherwise) to
grant to the other Party a license, covenant not to sue, sublicense, access, or right to use (as applicable) under such materials, <FONT STYLE="white-space:nowrap">Know-How,</FONT> Patents, or other intellectual property rights, on the terms and
conditions set forth herein, in each case without violating any obligations of the granting Party owed to a Third Party, breaching the terms of any agreement with a Third Party or subjecting the granting Party to any fee or charge in addition to the
fees or charges the Parties have agreed to pay pursuant to this Agreement. Notwithstanding the foregoing, any New Affiliate of a Party shall not be considered an Affiliate of such Party for the purposes of this definition, provided that such New
Affiliate is not utilizing the Metagenomi Licensed Collaboration Technology or the Moderna Licensed Collaboration Technology with respect to the activity that would otherwise be restricted under Sections 5.20 (RT Exclusivity), 5.21 (DT Exclusivity),
or 5.22 (DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Target Exclusivity), as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.31 &#147;<B>Cost of Sales</B>&#148;
means, with respect to a given Calendar Quarter, the aggregate Manufacturing Costs (calculated in accordance with U.S. GAAP) for all DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products sold in the Territory during such Calendar Quarter. Cost
of Sales also includes royalties payable to Third Parties, if any, cost of shipping to customers, and applicable warehousing and insurance costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.32 &#147;<B>Cover</B>&#148; means, with respect to a claim of a Patent and a given Collaboration Target or Product or a given item of <FONT
STYLE="white-space:nowrap">Know-How,</FONT> that such claim would be infringed, absent a license, by the making, use, importation, exportation, offering for sale, sale, or other Exploitation of such Collaboration Target or Product or such item of <FONT
STYLE="white-space:nowrap">Know-How</FONT> (considering claims of patent applications to be issued as then pending). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.33 &#147;<B>Data
Package</B>&#148; means, on a Collaboration <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Target-by-Collaboration</FONT></FONT> Target basis, the package of data (e.g., results, data (including raw data and summaries thereof),
conclusions and findings) to be generated pursuant to the Program Plan for such Collaboration Target, including for purposes of demonstrating achievement of indicated success criteria. For clarity, the specific contents of each Data Package shall be
determined by the JSC and set forth in the applicable Program Plan and ownership of the contents shall be determined in accordance with Section&nbsp;8.1.2 (Ownership of Intellectual Property). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.34 &#147;<B>DC Nomination</B>&#148; means the nomination of a DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Candidate by the JSC to advance to <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies, including, without limitation, any GLP Toxicology Studies. A DT <FONT STYLE="white-space:nowrap">Co-Co</FONT>
Candidate that has been so nominated shall become a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.35
&#147;<B>Development</B>&#148; means all internal and external research, development, and regulatory activities regarding pharmaceutical or biologic products, including (a)&nbsp;research, <FONT STYLE="white-space:nowrap">non-</FONT> clinical
testing, toxicology, route of synthesis, <FONT STYLE="white-space:nowrap">non-clinical</FONT> activities, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies, and Clinical Trials (including any Phase IV Required Clinical Trial, but
expressly excluding Phase IV Optional Clinical Trials), and (b)&nbsp;preparation, submission, review, and development of data or information for the purpose of submission to a Regulatory Authority to obtain authorization to conduct Clinical Trials
and to obtain, support, or maintain Regulatory Approval of a Product, but excluding activities directed to Manufacturing or Commercialization. Development shall include development and regulatory activities for additional forms, formulations, or
Indications for a Product after receipt of Regulatory Approval of such Product, including Clinical Trials initiated following receipt of Regulatory Approval or any Clinical Trial to be conducted after receipt of Regulatory Approval that was mandated
by the applicable Regulatory Authority as a condition of such Regulatory Approval with respect to an approved formulation or Indication (such as post-marketing studies and observational studies, if required by any Regulatory Authority in any country
in the Territory to support or maintain Regulatory Approval for a Product in such country). &#147;<B>Develop</B>,&#148; &#147;<B>Developing</B>,&#148; and &#147;<B>Developed</B>&#148; shall be construed accordingly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.36 &#147;<B>Development Budget</B>&#148; means, the budget for activities under the applicable Development Plan for each DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.37 &#147;<B>Development Costs</B>&#148; means [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.38 &#147;<B>Directed Against</B>&#148; means [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.39 &#147;<B>Distribution Matters</B>&#148; means all issues and decisions regarding the distribution of DT
<FONT STYLE="white-space:nowrap">Co-Co</FONT> Products, including decisions as to whether and with which wholesalers and distributors to contract, and the terms of contracts with such wholesalers and distributors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.40 &#147;<B>Divestiture</B>&#148; means the sale or transfer of rights to the Competing Program by Metagenomi (or its Affiliate) to a Third
Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.41 &#147;<B>DMF</B>&#148; means any drug master file filed with the FDA, and any equivalent filing in other countries or
regulatory jurisdictions, or any other mechanism for achieving the purposes of a drug master file in any jurisdiction where there is no equivalent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.42 &#147;<B>Dollar</B>&#148; means a U.S. dollar, and &#147;<B>$</B>&#148; is to be interpreted accordingly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.43 &#147;<B>Donor Template</B>&#148; means [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.44 <B>&#147;DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Candidate&#148; </B>means [***]. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.45 <B>&#147;DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product</B>&#148; means a DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Candidate nominated through DC Nomination for further Development in the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.46 &#147;<B>DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Research Costs</B>&#148; means [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.47 &#147;<B>DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Target</B>&#148; means the target identified in <B>Schedule A </B>(DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Target). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.48 &#147;<B>DT Field</B>&#148; means <I>in vivo</I> Gene Editing for a therapeutic,
ameliorative or prophylactic application by way [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.49 &#147;<B>DT <FONT STYLE="white-space:nowrap">In-Licenses</FONT></B>&#148;
means DT Moderna <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements or DT Metagenomi <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.50 &#147;<B>DT Moderna Research Term</B>&#148; means the period that commences on the Effective Date and continuing until four
(4)&nbsp;years after the Effective Date, unless earlier terminated pursuant to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.51 &#147;<B>DT Option Fee&#148;
</B>means ten million Dollars ($10,000,000) for each DT Moderna Research Program with respect to which Moderna has exercised a DT Option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.52 &#147;<B>DT Program <FONT STYLE="white-space:nowrap">Know-How</FONT></B>&#148; means, with respect to a Party, on a DT <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-</FONT></FONT> DT Program basis, all materials and <FONT STYLE="white-space:nowrap">Know-How</FONT> that comes into the Control of such Party or any of its Affiliates during the
Term for such DT Moderna Research Program that relates or otherwise pertains to such DT Program, including that (a)&nbsp;relates or otherwise pertains to the DT Moderna Target of such DT Program, (b)&nbsp;is otherwise necessary or useful in
Researching, Developing, Manufacturing, Commercializing or otherwise Exploiting Licensed Products Directed Against such DT Moderna Target in the DT Field in the Territory or (c) [***] (a), (b) and (c)&nbsp;to the extent Moderna makes any of the
foregoing available to Metagenomi pursuant to this Agreement. For clarity, &#147;DT Program <FONT STYLE="white-space:nowrap">Know-How&#148;</FONT> includes all of such Party&#146;s rights in its solely-owned Program Technology constituting materials
and <FONT STYLE="white-space:nowrap">Know-How</FONT> that satisfy the foregoing, and any jointly-owned <FONT STYLE="white-space:nowrap">Know-How</FONT> within the Program Technology that satisfies the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.53 &#147;<B>DT Program Patents</B>&#148; means all Patents that Cover any of the DT Program
<FONT STYLE="white-space:nowrap">Know-How.</FONT> For clarity, DT Program Patents include any Joint Patents that satisfy the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.54 &#147;<B>DT Program Technology</B>&#148; means the DT Program <FONT STYLE="white-space:nowrap">Know-How</FONT> and the DT Program
Patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.55 &#147;<B>DT Targets</B>&#148; means the DT Moderna Targets and the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Target.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.56 &#147;<B>Eligible <FONT STYLE="white-space:nowrap">Co-Co</FONT> Research Cost</B>&#148; means [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.57 &#147;<B>Eligible Development Costs</B>&#148; means [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.58 &#147;<B>Eligible Medical Affairs Costs</B>&#148; means [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.59 &#147;<B>EMA</B>&#148; means the European Medicines Agency or any successor agency thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.60 &#147;<B>E.U.</B>&#148; means the European Union. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.61 &#147;<B><FONT STYLE="white-space:nowrap">Ex-U.S.</FONT></B>&#148; means all countries in the Territory other than the U.S. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.62 &#147;<B>Executive Officers</B>&#148; means [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.63 &#147;<B>Exploit</B>&#148; means to make, use, offer to sell, sell, import, export, practice, research, develop, manufacture,
commercialize or otherwise exploit (including Research, Develop, Manufacture, perform Medical Affairs activities and Commercialize Products), and have others do the same. &#147;<B>Exploitation</B>&#148; and &#147;<B>Exploiting</B>&#148; shall be
construed accordingly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.64 &#147;<B>External Costs</B>&#148; mean [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.65 &#147;<B>FD&amp;C Act</B>&#148; means the United States Federal Food, Drug and Cosmetic Act, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.66 &#147;<B>FDA</B>&#148; means the United States Food and Drug Administration or any successor agency thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.67 &#147;<B>Field</B>&#148; means all uses, including any and all uses for the diagnosis, prevention, amelioration, and treatment of any
disease or medical condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.68 &#147;<B>Firewall Period</B>&#148; means, with respect to a Competing Program of an Acquirer of a
Party, the period commencing on the applicable Firewall Event and ending on the earlier of: (a)&nbsp;Divestiture of the Competing Program by such Acquirer; and (b)&nbsp;the expiration of such Party&#146;s exclusivity obligations under this Agreement
(in respect of the relevant Competing Program). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.69 &#147;<B>Firewalls</B>&#148; means effective walls and screens established between a
Party, on the one hand, and on the other hand, an Acquirer of such Party which has a Competing Program, to ensure that no <FONT STYLE="white-space:nowrap">non-public</FONT> information, materials (such as lab notebooks, document management systems
or other documented or memorialized <FONT STYLE="white-space:nowrap">Know-How)</FONT> or <FONT STYLE="white-space:nowrap">non-personnel</FONT> resources directly relating to any RT Targets, DT Targets, Candidates, Products, or the Program, or any <FONT
STYLE="white-space:nowrap">non-public</FONT> information, materials or <FONT STYLE="white-space:nowrap">non-personnel</FONT> resources relating to Patents provided, or made accessible, to such Party by the other Party are accessible by personnel of
the Acquirer working on the Competing Program during the Firewall Period. For purposes of this definition, &#147;Firewalls&#148; shall include, during the Firewall Period, as necessary to satisfy this definition: (a)&nbsp;walls and screens (whether
technical or physical) between (i)&nbsp;on the one hand, personnel of such Party performing Research or Development activities under, or otherwise working on or involved with, the Program or having access to any of the other Party&#146;s Licensed
Collaboration Technology, <FONT STYLE="white-space:nowrap">non-public</FONT> materials (such as lab notebooks, document management systems or other forms in which such <FONT STYLE="white-space:nowrap">Know-How</FONT> may be memorialized) or <FONT
STYLE="white-space:nowrap">non-personnel</FONT> resources, in each case, directly relating to the Program (all of the foregoing, collectively, &#147;<B>Collaboration Personnel</B>&#148;) and (ii)&nbsp;on the other hand, personnel of an Acquirer
working on the Competing Program, or having access to any nonpublic materials (such as lab notebooks, document management systems or other forms in which such <FONT STYLE="white-space:nowrap">Know-How</FONT> may be memorialized) or <FONT
STYLE="white-space:nowrap">non-personnel</FONT> resources, in each case, directly relating to the Competing Program (all of the foregoing, collectively, &#147;<B>Competing Program Personnel</B>&#148;); and (b)&nbsp;processes ensuring that
(i)&nbsp;Collaboration Personnel do not perform any Research or Development activities under the Competing Program or have access to any <FONT STYLE="white-space:nowrap">non-public</FONT> materials </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(such as lab notebooks, document management systems or other forms in which such <FONT STYLE="white-space:nowrap">Know-How</FONT> may be memorialized) or
<FONT STYLE="white-space:nowrap">non-personnel</FONT> resources, in each case, directly relating to the Competing Program and (ii)&nbsp;Competing Program Personnel do not perform Research or Development activities or any other work under the Program
or have access to any of the other Party&#146;s Licensed Collaboration Technology, <FONT STYLE="white-space:nowrap">non-public</FONT> materials (such as lab notebooks, document management systems or other forms in which such <FONT
STYLE="white-space:nowrap">Know-How</FONT> may be memorialized) or <FONT STYLE="white-space:nowrap">non-personnel</FONT> resources, in each case, directly relating to the Program. Notwithstanding the foregoing, &#147;<B>Firewalls</B>&#148; shall not
(i)&nbsp;require activities specific to the Program to be performed in a separate facility than activities that are specific to the Competing Program, provided that the activities specific to the Program are performed in a different location within
such facility than the activities specific to the Competing Program, (ii)&nbsp;restrict Collaboration Personnel from working together with Competing Program Personnel on Exploitation of any compound or product that is neither the subject of the
Program nor the subject of the Competing Program, or (iii)&nbsp;restrict executive officers or members of the board of directors of such Party or its Affiliates, including the Acquirer, from accessing or receiving disclosure of information solely as
necessary to enable executive officers and the board of directors to comply with (x)&nbsp;their fiduciary obligations to such Party or its Affiliates or (y)&nbsp;Applicable Laws; provided that such executive officers or members of the board of
directors are prohibited from using any information pertaining to the Program or any other activities covered under this Agreement to inform or make decisions regarding or relating to any Competing Programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.70 &#147;<B>First Commercial Sale</B>&#148; means the first sale of a Product by a Party or its Affiliates or their Sublicensees to a Third
Party (excluding any Sublicensee) for end use or consumption of such Product in a given country after Regulatory Approval and any Pricing and Reimbursement Approvals required to market and sell the Product has been granted with respect to such
Product in such country in which such Product is sold. Furthermore, for purposes of clarity, the term &#147;First Commercial Sale&#148; as used in this Agreement shall not include: (a)&nbsp;sales for purposes of testing any Product, or of any
Product samples; (b)&nbsp;any distribution or other sale solely for <FONT STYLE="white-space:nowrap">so-</FONT> called treatment investigational new drug sales, named patient sales, compassionate or emergency use sales or <FONT
STYLE="white-space:nowrap">pre-license</FONT> sales, in each case provided that such Product is distributed without charge or sold at or below cost; (c)&nbsp;any sale of a Product by a Party to its Affiliate (or their Sublicensees), unless there is
a subsequent resale of the Product by such Affiliate or Sublicensee; nor (d)&nbsp;other similar <FONT STYLE="white-space:nowrap">non-commercial</FONT> sales. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.71 &#147;<B>FTE</B>&#148; means a qualified full time person, or more than one person working the equivalent of a full-time person
performing activities under a Program Plan, where &#147;full time&#148; is based upon a total of [***] working hours per Calendar Year. For clarity, no individual person can ever constitute more than a single FTE. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.72 &#147;<B>FTE Rate</B>&#148; means [***] per FTE per Calendar Year, which shall be prorated for the period beginning on the Effective Date
and ending on December&nbsp;31, 2021, and which rate is subject to annual adjustment in each Calendar Year during the Term as agreed by the JSC based on the percentage increase or decrease in the Consumer Price Index for All Urban Consumers <FONT
STYLE="white-space:nowrap">(CPI-U)</FONT> published by the U.S. Bureau of Labor Statistics as of December&nbsp;31 of each Calendar Year, over the level of such Consumer Price Index as of December&nbsp;31 of the prior Calendar Year, with the first
such increase to be effective on January&nbsp;1, 2022. Notwithstanding the foregoing, for any Calendar Year during the Term that is less than a full year, the above referenced rate shall be proportionately reduced to reflect such portion of such
full Calendar Year. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.73 &#147;<B>Gene Editing</B>&#148; or &#147;<B>Gene-Editing</B>&#148; means [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.74 &#147;<B>GLP Tox Commitment Date</B>&#148; means [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.75 &#147;<B>GLP Toxicology Study</B>&#148; means, with respect to a Candidate or a Product, an <I>in vivo</I> toxicology study that is
conducted in compliance with then-current Good Laboratory Practices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.76 &#147;<B>Good Clinical Practices</B>&#148; or
&#147;<B>GCP</B>&#148; means the then-current good clinical practice standards, practices, and procedures promulgated or endorsed by the applicable Regulatory Authority as set forth in the guidelines imposed by such Regulatory Authority or
Applicable Law, as each may be updated from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">time-to-time,</FONT></FONT> to the extent such standards are not less stringent than applicable U.S. standards or ICH Guidelines, including
ICH E6. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.77 &#147;<B>Good Laboratory Practices</B>&#148; or &#147;<B>GLPs</B>&#148; means all applicable Good Laboratory Practice
standards, including, as applicable: (a)&nbsp;as set forth in the then-current good laboratory practice standards promulgated or endorsed by the FDA as defined in 21 C.F.R. Part 58; and (b)&nbsp;the equivalent Applicable Laws in any relevant
country, each as may be amended and applicable from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.78 &#147;<B>Good Manufacturing Practices</B>&#148; or
&#147;<B>GMP</B>&#148; means the then-current good manufacturing practice standards, practices, and procedures promulgated or endorsed by the applicable Regulatory Authority as set forth in the guidelines imposed by such Regulatory Authority or
Applicable Law, as each may be updated from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">time-to-time,</FONT></FONT> to the extent such standards are not less stringent than applicable U.S. standards as provided in, but not
limited to, 21 C.F.R. Parts 210 and 211, or ICH Guidelines, including ICH Q7. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.79 &#147;<B>Good Research Practices</B>&#148; or
&#147;<B>GRP</B>&#148; means research practices consistent with the Research Quality Association (RQA), 2014 Quality in Research Guidelines for Working in <FONT STYLE="white-space:nowrap">Non-Regulated</FONT> Research, as may be amended and
applicable from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.80 &#147;<B>Government Official</B>&#148; means: (i)&nbsp;any officer, employee (including physicians,
hospital administrators, or other healthcare professionals), agent, representative, department, agency, de facto official, representative, corporate entity, instrumentality or subdivision of any government, military or international organization,
including any ministry or department of health or any state-owned or affiliated company or hospital; (ii)&nbsp;any candidate for political office, any political party or any official of a political party, in each case for the purpose of obtaining or
retaining business for or with, or directing business to, any Person, including either Party; or (iii)&nbsp;any Person acting in an official capacity on behalf of any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.81 &#147;<B>Governmental Authority</B>&#148; means any national, international, federal, state, provincial or local government, or political
subdivision thereof, or any multinational organization or any authority, agency or commission entitled to exercise any administrative, executive, judicial, legislative, police, regulatory or taxing authority or power, and any court or tribunal (or
any department, bureau or division thereof, or any governmental arbitrator or arbitral body). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.82 &#147;<B>Guide</B>&#148; means [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.83 &#147;<B>IND</B>&#148; means an investigational new drug application filed with the FDA or any similar application filed with a
Regulatory Authority in a country other than the U.S. required to commence Clinical Trials of a pharmaceutical product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.84 &#147;<B>IND
Filing</B>&#148; means, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Program</FONT></FONT> basis, the filing of an IND for a Product in such Program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.85 &#147;<B>Indication</B>&#148; means a disease (a)&nbsp;for which a Product is indicated for treatment and (b)&nbsp;that is described in
the Product label as required by the Regulatory Approval granted by the applicable Regulatory Authority. An Indication is only distinct from another Indication if (a)&nbsp;the diseases associated with such Indications are listed in two different
blocks of the <FONT STYLE="white-space:nowrap">ICD-10</FONT> and (b)&nbsp;Regulatory Approvals are based, in whole or in part, on separate clinical studies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.86 &#147;<B>Initial DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Research Term</B>&#148; means the period that commences on the
Effective Date and continuing until [***] after the Effective Date, unless earlier terminated pursuant to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.87
&#147;<B>Initiation</B>&#148; means, with respect to a Clinical Trial, the first dosing in the first human subject in such Clinical Trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.88 &#147;<B>Internal Compliance Codes</B>&#148; means a Party&#146;s internal policies and procedures intended to ensure that a Party
complies with Applicable Laws, Party-Specific Regulations, and such Party&#146;s internal ethical, medical and similar standards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.89
&#147;<B>Internal Costs</B>&#148; means [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.90 &#147;<B>Joint Patents</B>&#148; means any Patents that Cover any Joint IP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.91 &#147;<B><FONT STYLE="white-space:nowrap">Know-How</FONT></B>&#148; means any proprietary scientific or technical information,
inventions, discoveries, results and data of any type whatsoever, in any tangible or intangible form, including inventions, discoveries, databases, safety information, practices, methods, instructions, techniques, processes, drawings, documentation,
specifications, formulations, formulae, knowledge, knowhow, trade secrets, materials, skill, experience, test data and other information and technology applicable to formulations, compositions or products or to their manufacture, development,
registration, use, marketing or sale or to methods of assaying or testing them, including pharmacological, pharmaceutical, medicinal chemistry, biological, chemical, biochemical, toxicological and clinical test data, physical and analytical, safety,
quality control data, manufacturing, and stability data, materials, studies and procedures, and manufacturing process and development information, results and data. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.92 &#147;<B>Licensed Collaboration Technology</B>&#148; means the Metagenomi Licensed Collaboration Technology or the Moderna Licensed
Collaboration Technology, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.93 &#147;<B>Licensed DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Technology</B>&#148;
means the Metagenomi Licensed DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Technology or the Moderna Licensed DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Technology, as applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.94 &#147;<B>Licensed DT Product</B>&#148; means [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.95 &#147;<B>Licensed Product</B>&#148; means a Licensed DT Product or a Licensed RT Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.96 &#147;<B>Licensed RT Product</B>&#148; means [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.97 &#147;<B>Licensing Income</B>&#148; means all amounts (including upfront payments, license fees, and milestone payments) received by a
Party or any of its Affiliates from any licensee or sublicensee in consideration for the grant by such Party or any of its Affiliates of a license or sublicense of any of the rights granted under this Agreement with respect to a DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Product in the Territory in accordance with Section&nbsp;5.7.1 (Rights to Grant Licenses and Sublicenses in the Territory). Notwithstanding the foregoing, Licensing Income shall exclude any such payment
received by a Party or any of its Affiliates from any such sublicensee in return for, as payment or consideration for, or otherwise in respect of: (a)&nbsp;equity or debt of a Party or its Affiliate purchased by such sublicensee at or below the fair
market value of such equity or debt as of the date of the purchase, (b)&nbsp;reimbursement of such Party or its Affiliates&#146; actual Manufacturing Costs of DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products with no markup,
(c)&nbsp;reimbursement with no markup for the performance of services by such Party or its Affiliate under any such sublicense, (d)&nbsp;reimbursement of such Party&#146;s or its Affiliate&#146;s External Costs and other expenses, including patent
expenses, (e)&nbsp;the sale of a Party or its Affiliate in whole or in part to a Third Party, or (f)&nbsp;a bona-fide loan, provided that any loan amounts that are forgiven shall be included in Licensing Income to the extent not otherwise captured
in the foregoing clauses (a) &#150; (e). Licensing Income in the form of <FONT STYLE="white-space:nowrap">non-cash</FONT> consideration shall be valued at fair market value at the time of receipt by the relevant Party. In addition, (i)&nbsp;to the
extent that a payment not explicitly tied to the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product is made under a sublicense agreement that grants rights to both the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product and one or more
other products (<I>e.g.</I>, an upfront payment), then a <I>pro rata</I> portion of such payment shall be determined by agreement of the Parties reached in good faith based on an equitable method of determining the same that takes into account the
relative fair market value of the sublicense, which shall be considered Licensing Income which such <I>pro rata</I> portion shall be calculated based on the number of products with respect to which rights are granted under such a sublicense
agreement and (ii)&nbsp;to the extent that a payment is made under a sublicense that grants rights to the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product in the Territory, then a <I>pro rata</I> portion of such payment shall be considered
Licensing Income, which <I>pro rata</I> portion shall be allocated based on the value of the rights granted in the Territory, in each case ((i) and (ii)), only if such amounts have not also been shared by the Parties as Eligible Development Costs,
Eligible Medical Affairs Costs, Commercialization Costs, or Other Operating Expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.98 &#147;<B>LNP</B>&#148; means [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.99 &#147;<B>Mammalian Cell Milestone</B>&#148; means [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.100 &#147;<B>Manufacture</B>&#148; means, with respect to a Product, those manufacturing-related activities that support the Development
(including the seeking and obtaining of Regulatory Approvals) and Commercialization of such Product, including manufacturing process development and <FONT STYLE="white-space:nowrap">scale-up,</FONT> validation, qualification and audit of clinical
and commercial manufacturing facilities, bulk production and fill/finish work, related quality assurance technical support activities and CMC Activities, and including the synthesis, manufacturing, processing, formulating, packaging, labeling,
holding, quality control testing and release of such Product. &#147;Manufacturing&#148; and &#147;Manufactured&#148; have a correlative meaning. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.101 &#147;<B>Manufacturing Cost</B>&#148; has the meaning set forth in <B>Schedule B
</B>(Manufacturing Cost). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.102 &#147;<B>Material Communications</B>&#148; means written, telephonic, or
<FONT STYLE="white-space:nowrap">in-person</FONT> communications from or with any Regulatory Authority (including any meeting minutes from any meetings with any Regulatory Authority) concerning any of the following: key product quality attributes
(<I>e</I>.<I>g</I>., purity), safety findings affecting the platform (<I>e</I>.<I>g</I>., Serious Adverse Events, emerging safety signals), clinical or <FONT STYLE="white-space:nowrap">non-clinical</FONT> findings affecting patient safety, lack of
efficacy, receipt or denial of Regulatory Approval, the design of Clinical Trials, or the need for additional <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies or <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies
(<I>e</I>.<I>g</I>., additional toxicology or carcinogenicity studies). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.103 &#147;<B>Materials</B>&#148; means any tangible chemical or
biological material, including any compounds, DNA and RNA, mRNA Constructs, polypeptides, clones, cells, plasmids, lipids, vectors, receptors, any other nucleic acids and Polynucleotides, proteins, peptides and any expression product, progeny,
derivative or other improvement thereto, along with any tangible chemical or biological material embodying any <FONT STYLE="white-space:nowrap">Know-How.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.104 &#147;<B>Medical Affairs</B>&#148; means activities conducted by, on behalf of, or in consultation with a Party&#146;s medical
scientific affairs departments, including medical affairs, field medical (medical scientific liaisons and payor liaisons), medical information and health economics outcomes research, development and execution of strategic and tactical medical
product plans, generation of clinical and health economic outcomes data via post hoc analyses, Phase IV Optional Clinical Trials and real world evidence studies; development of economic models, production of value dossiers, key opinion leader
strategy development and communications, generation and execution of responses to medical information requests, publication of scientific findings, presentations at medical scientific congresses and virtual medical engagements; medical education,
symposia, congresses, advisory boards (to the extent related to Medical Affairs or clinical guidance), conducting health economics and outcomes research, conducting medical science liaison activities, activities performed in connection with patient
registries, and other medical programs and communications, including continuing education grants, and research grants (including conducting investigator-initiated studies), to the extent related to medical scientific affairs and not to other
activities that involve the promotion, marketing, sale, or other Commercialization of the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.105 &#147;<B>Medical Affairs Budget</B>&#148; means, the budget for activities under the applicable Medical Affairs Plan for each DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.106 &#147;<B>Medical Affairs Costs</B>&#148; means [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.107 &#147;<B>Metagenomi Housemarks</B>&#148; means (a)&nbsp;the corporate logo of Metagenomi, (b)&nbsp;the trademark &#147;Metagenomi&#148;,
(c) any other Trademark, trade name, or service mark (whether registered or unregistered) containing the word &#147;Metagenomi&#148;, (d) any other corporate logo or Trademark of Metagenomi used by Metagenomi to identify Metagenomi or any of its
Affiliates, and (e)&nbsp;all intellectual property rights and goodwill associated with any and all of the foregoing in clauses (a)&nbsp;through (e). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.108 &#147;<B>Metagenomi Licensed Collaboration Technology</B>&#148; means the Metagenomi
Licensed DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Technology, Licensed RT Technology and Licensed DT Moderna Technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.109
&#147;<B>Metagenomi Licensed DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> <FONT STYLE="white-space:nowrap">Know-How</FONT></B>&#148; means all materials and <FONT STYLE="white-space:nowrap">Know-How</FONT> that Metagenomi or any of its
Affiliates Control as of the Effective Date or during the Term that (a)&nbsp;relates or otherwise pertains to the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Target or (b)&nbsp;is otherwise necessary or useful in Researching, Developing,
Manufacturing, Commercializing or otherwise Exploiting DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products Directed Against such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Target in the DT Field in the Territory, in each case of
(a)&nbsp;and (b), to the extent Metagenomi makes available or is required to make available to Moderna pursuant to this Agreement. For clarity, &#147;Metagenomi Licensed DT <FONT STYLE="white-space:nowrap">Co-Co</FONT>
<FONT STYLE="white-space:nowrap">Know-How&#148;</FONT> includes all of Metagenomi&#146;s rights in the Metagenomi Program Technology constituting materials and <FONT STYLE="white-space:nowrap">Know-How</FONT> that satisfy the foregoing and
Metagenomi&#146;s interest in any jointly-owned materials or <FONT STYLE="white-space:nowrap">Know-How</FONT> within the Program Technology that satisfies the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.110 &#147;<B>Metagenomi Licensed DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Patent</B>&#148; means any Patent that Metagenomi or any
of its Affiliates Control as of the Effective Date or during the Term that (a)&nbsp;Covers any of the Metagenomi Licensed DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> <FONT STYLE="white-space:nowrap">Know-How,</FONT> (b)&nbsp;Covers or claims
the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Target or (c)&nbsp;would otherwise Cover any of the Research, Development, Manufacture, Commercialization or other Exploitation of one or more DT <FONT STYLE="white-space:nowrap">Co-Co</FONT>
Products Directed Against such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Target in the DT Field in the Territory, in each case of (a), (b) and (c), to the extent Metagenomi makes available or is required to make available to Moderna pursuant
to this Agreement. For clarity, &#147;Metagenomi Licensed DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Patent&#148; includes all of Metagenomi&#146;s rights in the Metagenomi Program Technology constituting Patents that satisfy the foregoing,
and Metagenomi&#146;s interest in any Joint Patent that satisfies the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.111 &#147;<B>Metagenomi Licensed DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Technology</B>&#148; means, individually or collectively, the Metagenomi Licensed DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Patents and Metagenomi Licensed DT
<FONT STYLE="white-space:nowrap">Co-Co</FONT> <FONT STYLE="white-space:nowrap">Know-How.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.112 &#147;<B>Moderna
Housemarks</B>&#148; means (a)&nbsp;the corporate logo of Moderna, (b)&nbsp;the trademark &#147;Moderna&#148;, (c) any other Trademark, trade name, or service mark (whether registered or unregistered) containing the word &#147;Moderna&#148;, (d) any
other corporate logo or Trademark of Moderna used by Moderna to identify Moderna or any of its Affiliates, and (e)&nbsp;all intellectual property rights and goodwill associated with any and all of the foregoing in clauses (a)&nbsp;through (e). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.113 &#147;<B>Moderna Licensed Collaboration Technology</B>&#148; means Moderna&#146;s Background Technology, RT Program Technology, and DT
Program Technology, and the Moderna Licensed DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Technology. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.114 &#147;<B>Moderna Licensed DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> <FONT
STYLE="white-space:nowrap">Know-How</FONT></B>&#148; means all materials and <FONT STYLE="white-space:nowrap">Know-How</FONT> that Moderna or any of its Affiliates Control as of the Effective Date or during the Term that (a)&nbsp;relates or
otherwise pertains to the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Target or (b)&nbsp;is otherwise necessary or useful in Researching, Developing, Manufacturing, Commercializing or otherwise Exploiting DT
<FONT STYLE="white-space:nowrap">Co-Co</FONT> Products Directed Against such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Target in the DT Field in the Territory, in each case of (a)&nbsp;and (b), to the extent Moderna makes available to
Metagenomi pursuant to this Agreement. For clarity, &#147;Moderna Licensed DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> <FONT STYLE="white-space:nowrap">Know-How&#148;</FONT> includes all of Moderna&#146;s rights in the Moderna Program
Technology constituting materials and <FONT STYLE="white-space:nowrap">Know-How</FONT> that satisfy the foregoing, and Moderna&#146;s interest in any jointly-owned materials or <FONT STYLE="white-space:nowrap">Know-How</FONT> within the Program
Technology that satisfies the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.115 &#147;<B>Moderna Licensed DT <FONT STYLE="white-space:nowrap">Co-Co</FONT>
Patent</B>&#148; means any Patent that Moderna or any of its Affiliates Control as of the Effective Date or during the Term that (a)&nbsp;Covers any of the Moderna Licensed DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> <FONT
STYLE="white-space:nowrap">Know-How,</FONT> (b)&nbsp;Covers or claims the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Target or (c)&nbsp;would otherwise Cover any of the Research, Development, Manufacture, Commercialization or other
Exploitation of one or more DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products Directed Against such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Target in the DT Field in the Territory, in each case of (a), (b) and (c), to the extent
Moderna makes available to Metagenomi pursuant to this Agreement. For clarity, &#147;Moderna Licensed DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Patent&#148; includes all of Moderna&#146;s rights in the Moderna Program Technology constituting
Patents that satisfy the foregoing and Moderna&#146;s interest in any Joint Patent that satisfies the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.116 &#147;<B>Moderna
Licensed DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Technology</B>&#148; means, individually or collectively, the Moderna Licensed DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Patents and Moderna Licensed DT
<FONT STYLE="white-space:nowrap">Co-Co</FONT> <FONT STYLE="white-space:nowrap">Know-How.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.117 &#147;<B>mRNA Construct</B>&#148;
means [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.118 &#147;<B><FONT STYLE="white-space:nowrap">mRNA-LNP</FONT> Technology</B>&#148; means [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.119 &#147;<B>Mutual Confidentiality Agreement</B>&#148; means that certain Mutual Confidentiality Agreement entered into between the Parties
as of March&nbsp;1, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.120 &#147;<B>NDA</B>&#148; means (a)&nbsp;any New Drug Application (as defined in the FD&amp;C Act), any
Biologics License Application (&#147;<B>BLA</B>&#148;) (as defined in the PHSA) and applicable regulations promulgated thereunder by the FDA filed with the FDA to gain approval to market a pharmaceutical product in the U.S., (b) a marketing
authorization application (&#147;<B>MAA</B>&#148;) filed with (i)&nbsp;the EMA under the centralized EMA filing procedure to gain approval to market a biopharmaceutical in the E.U., or (ii)&nbsp;a Regulatory Authority in any E.U. country if the
centralized EMA filing procedure is not used to gain approval to market a biopharmaceutical in the E.U., or (c)&nbsp;any other equivalent or related Regulatory Filing filed in support of approval to market a biopharmaceutical in any country outside
of the U.S. or E.U., and, in each case ((a) through (c)), including any amendments thereto, and supplemental applications, but excluding applications for Reimbursement Approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.121 &#147;<B>Net Sales</B>&#148; means, with respect to any Product, the gross amounts invoiced by a Party (including any Affiliate of such
Party) or any Sublicensee thereof (each, a &#147;<B>Selling Party</B>&#148;) to Third Party customers for sales of such Product in the Territory, less the following deductions actually incurred, allowed, paid, accrued or specifically allocated in
its financial statements for such Product, all in accordance with U.S. GAAP, consistently applied, for: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Such amounts shall be determined from the books and records of such Party or its Sublicensee
maintained in accordance with U.S. GAAP or, in the case of Sublicensees, such similar accounting principles, consistently applied. Net Sales shall not be imputed to transfers of Products for use in clinical trials,
<FONT STYLE="white-space:nowrap">non-clinical</FONT> development activities or other development activities with respect to Products, as applicable, by or on behalf of the Parties, for bona fide charitable purposes or for compassionate use, patient
program or for Product samples, if no monetary consideration exceeding the cost of goods for such Product is received for such transfers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that the Product is sold as part of a Combination Product (where &#147;<B>Combination Product</B>&#148; means [***], the Net
Sales of such Product, for the purposes of determining royalty payments, shall be determined by multiplying the Net Sales of the Combination Product by the fraction, A / (A+B), where A is the weighted average sale price of the Product when sold
separately for the same dosage as contained in the Combination Product in finished form, and B is the weighted average sale price of the Other Product(s) sold separately in finished form. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that the weighted average sale price of the Product can be determined but the weighted average sale price of the Other Product(s)
cannot be determined, Net Sales for purposes of determining royalty payments shall be calculated by multiplying the Net Sales of the Combination Product by the fraction A / C where A is the weighted average sale price of the Product when sold
separately in finished form and C is the weighted average sale price of the Combination Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that the weighted average
sale price of the Other Product(s) can be determined but the weighted average sale price of the Product cannot be determined, Net Sales for purposes of determining royalty payments shall be calculated by multiplying the Net Sales of the Combination
Product by the following formula: one (1)&nbsp;minus (B / C) where B is the weighted average sale price of the Other Product(s) when sold separately in finished form and C is the weighted average sale price of the Combination Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that the weighted average sale price of both the Product and the Other Product(s) in the Combination Product cannot be
determined, the Parties shall enter into good faith negotiations to determine the appropriate value to be allocated to the Product and the Other Product(s). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The weighted average sale price for a Product, Other Product, or Combination Product shall be calculated once each Calendar Year and such
price shall be used during all applicable royalty reporting periods for the entire following Calendar Year. When determining the weighted average sale price of a Product, Other Product or Combination Product, the weighted average sale price shall be
calculated by dividing the sales dollars (translated into U.S. dollars) by the units of active ingredient sold during the twelve (12)&nbsp;months (or the number of months sold in a partial Calendar Year) of the preceding Calendar Year for the
respective Product, Other Product or Combination Product. In the initial Calendar Year, a forecasted weighted average sale price shall be used for the Product, Other Products or Combination Product. Any over or under payment in the initial year due
to a difference between forecasted and actual weighted average sale prices shall be paid or credited in the first royalty payment of the following Calendar Year. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Adjuvants and excipients shall not be deemed to be &#147;active compound(s) or
ingredients&#148; except where such adjuvant or excipient is recognized by the FDA as an active ingredient in accordance with 21 C.F.R. &#167; 210.3(b)(7). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.122 &#147;<B>New Affiliate</B>&#148; means a Third Party that becomes an Affiliate of a Party after the Effective Date through or after a
Change of Control of such Party, other than (i)&nbsp;such Party, (ii) any Affiliates of such Party immediately before the consummation of such Change of Control, or (iii)&nbsp;any other Affiliates such Party or its
<FONT STYLE="white-space:nowrap">pre-consummation</FONT> Affiliates controls (directly or indirectly) after such Change of Control (including any direct or indirect subsidiaries of such Party or any such
<FONT STYLE="white-space:nowrap">pre-consummation</FONT> Affiliates). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.123 &#147;<B>NHP Milestone</B>&#148; means [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.124 &#147;<B><FONT STYLE="white-space:nowrap">Non-Orphan</FONT> Indication</B>&#148; mean an Indication other than an Orphan Indication.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.125 &#147;<B>Nonclinical Studies</B>&#148; means all <FONT STYLE="white-space:nowrap">non-human</FONT> animal studies, including
preclinical studies and toxicology studies, of Products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.126 &#147;<B>Operating Profits or Losses</B>&#148; means the profits or losses
for a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product in the Territory calculated in accordance with Section&nbsp;7.4 <FONT STYLE="white-space:nowrap">(Co-Co</FONT> Products Profit and Loss Share). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.127 &#147;<B>Orphan Indication</B>&#148; means an Indication for use of a drug to treat a rare disease or condition where the number of
people affected by the disease or condition in the U.S. is less than two hundred thousand (200,000) persons or where the Indication for use otherwise meets the criteria for orphan drug designation under section 526(a) of the FD&amp;C Act and 21
C.F.R. 316.21. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.128 &#147;<B>Other Operating Expenses</B>&#148; means [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No expense included as an Other Operating Expense shall also be included as a deduction under Net Sales, Commercialization Cost, Eligible Development Cost,
Cost of Sales, or Eligible Medical Affairs Cost. Other Operating Expenses specifically exclude any costs or expenses of a Party or its Affiliates to the extent caused by such Party or its Affiliate&#146;s breach of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.129 &#147;<B>Overspend</B>&#148; means, for a particular DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product, any amount that exceeds
Allowable Overruns for a Calendar Year on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-date</FONT></FONT> basis set forth in any Research Budget, Development Budget, Medical Affairs Budget, or Commercialization Budget,
as applicable, for such Calendar Year; provided that such amount is not attributable to (a)&nbsp;the breach of this Agreement or (b)&nbsp;the gross negligence or willful misconduct of either Party or any of its Affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.130 &#147;<B>Packaging and Labeling</B>&#148; means primary, secondary, or tertiary packaging and labeling of a DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Product (in its commercial packaging presentation) for sale or use in the Territory, consistent with respect to the Commercialization Plan, including the Approved Labeling and insertion of materials such as
patient inserts, patient medication guides, and professional inserts and any other written, printed, or graphic materials accompanying such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product and any brand security or anti-counterfeiting
measures included in the packaging elements for such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product considered to be part of the finished packaged DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product, and all testing and release
thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.131 &#147;<B>Patents</B>&#148; means: (a)&nbsp;pending patent applications, issued
patents, utility models and designs; (b)&nbsp;reissues, substitutions, confirmations, registrations, validations, <FONT STYLE="white-space:nowrap">re-examinations,</FONT> additions, continuations, continued prosecution applications, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part,</FONT></FONT> or divisions of or to any of the foregoing; and (c)&nbsp;extensions, renewals or restorations of any of the foregoing by existing or future extension,
renewal or restoration mechanisms, including supplementary protection certificates or the equivalent thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.132
&#147;<B>Person</B>&#148; means any corporation, limited or general partnership, limited liability company, joint venture, trust, unincorporated association, governmental body, authority, bureau or agency, any other entity or body, or an individual.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.133 &#147;<B>Pharmacovigilance Costs</B>&#148; means [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.134 &#147;<B>Phase I Clinical Trial</B>&#148; means a clinical trial of a Product generally consistent with 21 C.F.R. &#167; 312.21(a) (or
the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> equivalent thereof). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.135 &#147;<B>Phase I Readout</B>&#148; means the
substantially final biostatistical analysis of primary and secondary clinical outcomes or endpoints, as applicable, for a Phase I Clinical Trial prior to the publication of the final clinical study report for such Phase I Clinical Trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.136 &#147;<B>Phase II Clinical Trial</B>&#148; means a clinical trial of a Product generally consistent with 21 C.F.R. &#167; 312.21(b) (or
the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> equivalent thereof). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.137 &#147;<B>Phase III Clinical Trial</B>&#148; means a
clinical trial of a Product generally consistent with 21 C.F.R. &#167; 312.21(c) (or the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> equivalent thereof). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.138 &#147;<B>Phase IV Optional Clinical Trial</B>&#148; means any post-approval clinical study for a pharmaceutical or biologic product in a
country with respect to any Indication for which Regulatory Approval has been received in a particular country, and that is principally intended to support the Commercialization of a product, including (a)&nbsp;investigator-initiated clinical
studies initiated after Regulatory Approval of a product, (b)&nbsp;post-marketing surveillance studies of a product, and (c)&nbsp;any health and economic outcomes research and other reviews/analyses/studies relating to value and access issues, in
each case, that is not a Phase IV Required Clinical Trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.139 &#147;<B>Phase IV Required Clinical Trial</B>&#148; means any
post-approval clinical study initiated following receipt of Regulatory Approval for a pharmaceutical or biologic product in a country in an Indication or to be conducted after receipt of Regulatory Approval of a product in an Indication, in each
case, that was required by the applicable Regulatory Authority in any country in the Territory as a condition of receiving or maintaining a Regulatory Approval for such product with respect to such Indication in such country (such as post-marketing
approval studies and observational studies, if required by any Regulatory Authority in any country in the Territory to support or maintain Regulatory Approval for such product in such Indication in such country). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.140 &#147;<B>PHSA</B>&#148; means the United States Public Health Service Act, as amended. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.141 &#147;<B>Pivotal Trial</B>&#148; means any (a)&nbsp;Clinical Trial in humans that
meets the requirements of 21 C.F.R. &#167; 312.21(c), as amended (or its successor regulation), or, with respect to any other country or jurisdiction, the equivalent of such a clinical trial in such other country or jurisdiction, or (b)&nbsp;other
Clinical Trial of a pharmaceutical or biologic product, the results of which, together with prior data and information concerning such product, are intended to be or otherwise are sufficient, without any additional Clinical Trial, to meet the
evidentiary standard for demonstrating the safety, efficacy, and of such active substance of such product established by a Regulatory Authority in any particular jurisdiction and is intended to support, or otherwise supports, the submission of an
MAA in such jurisdiction (including any bridging study). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.142 &#147;<B>Polynucleotide</B>&#148;, [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.143 &#147;<B>Pricing and Reimbursement Approval</B>&#148; means an approval, agreement, determination, or other decision by the applicable
Governmental Authority that establishes prices charged to <FONT STYLE="white-space:nowrap">end-users</FONT> for biopharmaceutical products that a pharmaceutical or biologic product shall be reimbursed by the Governmental Authorities or Regulatory
Authorities in the Territory or any other approvals related to pricing, reimbursement, or access to a pharmaceutical or biologic product (including all activities related to tenders and contracts). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.144 &#147;<B>Pricing Matters</B>&#148; means [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.145 &#147;<B>Product</B>&#148; means Licensed Product or DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product, as the case may be. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.146 &#147;<B>Product Marks</B>&#148; means any Trademark (whether registered or unregistered) for use on, with, or to refer to a DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Product or used with patient support or other information or services or Product Materials associated with a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product in the Territory during the Term, including
related internet domain names. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.147 &#147;<B>Product Materials</B>&#148; means any and all promotional materials, training materials,
medical education materials, Packaging and Labeling, and all other literature or other information related to a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product for use in the Territory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.148 &#147;<B>Program</B>&#148; means the RT Technology Research Program, the RT Preclinical Research Programs, the DT Target Evaluation
Program, the DT Moderna Research Programs and the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program, as the case may be. For clarity, references to a Program (and the underlying definitions) hereunder refer to such Program both during the
Research Term and thereafter for the Term (including the applicable Collaboration Target and related Products). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.149 &#147;<B>Program
Patents</B>&#148; means all Patents that Cover any of the Program Technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.150 &#147;<B>Program Plan</B>&#148; means the RT
Technology Research Plan, the RT Preclinical Research Plan, the DT Target Evaluation Plan, the DT Moderna Research Plan or a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Plan, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.151 &#147;<B>Prosecute and Maintain</B>&#148; or &#147;<B>Prosecution and Maintenance</B>&#148; with respect to a particular Patent, means
all activities associated with the preparation, filing, prosecution and maintenance of such Patent, together with the conduct of interferences, derivation proceedings, <I>inter partes</I> review and post-grant review, the defense of oppositions and
other similar proceedings with respect to that Patent, but not including any activities associated with claims, including as a counterclaim or declaratory judgment action, of unpatentability, invalidity or unenforceability of such Patent that are
brought by a Third Party, in connection with an Infringement under Section&nbsp;8.3 (Infringement by Third Parties) or otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.152 &#147;<B>Region</B>&#148; means (A)&nbsp;with respect to Moderna, <FONT
STYLE="white-space:nowrap">Ex-U.S.,</FONT> and (B)&nbsp;with respect to Metagenomi, U.S. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.153 &#147;<B>Regulatory Approval</B>&#148;
means, collectively, any and all approvals (including supplements, amendments, <FONT STYLE="white-space:nowrap">pre-</FONT> and post-approvals, Pricing and Reimbursement Approvals), licenses, registrations, permits, notifications, and authorizations
(including marketing and labeling authorizations) or waivers of any Regulatory Authority that are necessary for the testing, research, development, registration, manufacture (including formulation), use, storage, import, export, transport,
promotion, marketing, distribution, offer for sale, sale or other commercialization of a pharmaceutical product (including any Product) in any country or jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.154 &#147;<B>Regulatory Authority</B>&#148; means any Governmental Authority that has responsibility in its applicable jurisdiction over the
testing, research, development, registration, manufacture (including formulation), use, storage, import, export, transport, promotion, marketing, distribution, offer for sale, sale or other commercialization of pharmaceutical products (including any
Product) in a given jurisdiction. For countries where governmental approval is required for pricing or reimbursement for a pharmaceutical product (including any Product) to be reimbursed by national health insurance (or its local equivalent),
Regulatory Authority includes any Governmental Authority whose review or approval of pricing or reimbursement of such product is required. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.155 &#147;<B>Regulatory Costs</B>&#148; means Internal Costs and External Costs incurred by either Party (or their Affiliates), as
applicable, in connection with the preparation or maintenance of Regulatory Documentation with respect to the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products, including any meetings with Regulatory Authorities in connection therewith and
any filing, user, maintenance and other fees paid to Regulatory Authorities, preparation of Regulatory Filings for, and the obtaining and maintenance of Regulatory Approvals including compliance with Regulatory Approvals and requirements of such
Regulatory Authorities, adverse event recordation and reporting and regulatory affairs activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.156 &#147;<B>Regulatory
Documentation</B>&#148; means all: (a)&nbsp;applications (including all INDs and applications for Regulatory Approval), registrations, licenses, authorizations and approvals (including Regulatory Approvals); (b) correspondence and reports submitted
to or received from Regulatory Authorities (including minutes and official contact reports relating to any communications with any Regulatory Authority) and all supporting documents with respect thereto, including all adverse event files and
complaint files; (c)&nbsp;supplements or changes to any of the foregoing following Regulatory Approval; and (d)&nbsp;clinical and other data, including Clinical Trial data, contained or relied upon in any of the foregoing; in each case ((a), (b),
(c) and (d)) relating to a Collaboration Target and Products Directed Against a Collaboration Target. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.157 &#147;<B>Regulatory
Exclusivity</B>&#148; means, with respect to each Product in any country in the Territory, a period of exclusivity (other than Patents exclusivity) granted or afforded by Applicable Laws or by a Regulatory Authority in such country that prevents the
approval or marketing of any Biosimilar Product of such Licensed Product in such country, including reference product exclusivity under Section&nbsp;351(k)(7)(C) of the PHSA and pediatric exclusivity under Section&nbsp;351(m) of the same and any
foreign equivalents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.158 &#147;<B>Regulatory Filings</B>&#148; means all applications, filings, and dossiers,
and other documents, data, results, and materials submitted to a Regulatory Authority in support of Development or Commercialization of a pharmaceutical or biologic product for an Indication, including for the purpose of obtaining Regulatory
Approval from that Regulatory Authority. Regulatory Filings include all INDs, NDAs, BLAs and other applications for Regulatory Approval and their equivalents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.159 &#147;<B>Regulatory Responsible Party</B>&#148; means, with respect to a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product, on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis in the Territory, (i)&nbsp;the Lead Party prior to any <FONT STYLE="white-space:nowrap">Opt-Out</FONT> and the
<FONT STYLE="white-space:nowrap">Opt-Out</FONT> Date or (ii)&nbsp;the Primary Party after the <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.160 &#147;<B>Reimbursement Approval</B>&#148; means an approval, agreement, determination, or other decision by the applicable Governmental
Authority that establishes prices charged to <FONT STYLE="white-space:nowrap">end-users</FONT> for biopharmaceutical products that a pharmaceutical or biologic product shall be reimbursed by the Governmental Authorities or Regulatory Authorities in
the Territory or any other approvals related to pricing, reimbursement, or access to a pharmaceutical or biologic product (including all activities related to tenders and contracts). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.161 &#147;<B>Research</B>&#148; means, with respect to a Collaboration Target, any research and <FONT STYLE="white-space:nowrap">pre-</FONT>
clinical activities through delivery of a Data Package for such Collaboration Target, as set forth in the applicable Program Plan for such Collaboration Target. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.162 &#147;<B>Research Budget</B>&#148; means RT Research Budget, DT Moderna Research Budget, or DT
<FONT STYLE="white-space:nowrap">Co-Co</FONT> Research Budget, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.163 &#147;<B>Research Costs&#148; </B>means [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.164 &#147;<B>Research Term</B>&#148; means (i)&nbsp;with respect to the RT Programs, the RT Research Term, (ii)&nbsp;with respect to the DT
Programs, the DT Moderna Research Term, or (iii)&nbsp;with respect to the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program, the Term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.165 &#147;<B>Reserved DT Targets</B>&#148; means any of the nine (9)&nbsp;targets identified in <B>Schedule</B><B></B><B>&nbsp;D
</B>(Reserved DT Targets). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.166 &#147;<B>Results</B>&#148; means all data (including raw data that has not undergone any processing,
either manually or through automated computer software, processed, distilled, analyzed or summarized data, and all representations of part or all of the data), results, findings, analyses and observations that are created or in any way generated by
a Party or Third Parties acting on a Party&#146;s behalf pursuant to this Agreement in the applicable Program. Results do not include Patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.167 &#147;<B>Rodent Milestone</B>&#148; means [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.168 &#147;<B>RT Field</B>&#148; means <I>in vivo</I> Gene Editing for a therapeutic, ameliorative or prophylactic application [***]. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.169 &#147;<B>RT <FONT STYLE="white-space:nowrap">In-Licenses</FONT></B>&#148; means RT
Moderna <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements or RT Metagenomi <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.170 &#147;<B>RT Option Fee</B>&#148; means ten million Dollars ($10,000,000) for each RT Preclinical Research Program with respect to which
Moderna has exercised an RT Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.171 &#147;<B>RT Program <FONT STYLE="white-space:nowrap">Know-How</FONT></B>&#148; means, with
respect to a Party, on an RT <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-</FONT></FONT> RT Program basis, all materials and <FONT STYLE="white-space:nowrap">Know-How</FONT> that comes into the Control of such Party
or any of its Affiliates during the Term that relates or otherwise pertains to such RT Program, including that (a)&nbsp;relates or otherwise pertains to the RT Target of such RT Program, (b)&nbsp;is otherwise necessary or useful in Researching,
Developing, Manufacturing, Commercializing or otherwise Exploiting Licensed Products Directed Against such RT Target in the RT Field in the Territory, or (c)&nbsp;relates to novel delivery technology relevant to the RT Field, and in the case of
Moderna, for each of (a), (b) and (c)&nbsp;to the extent Moderna makes any of the foregoing available to Metagenomi pursuant to this Agreement. For clarity, &#147;RT Program <FONT STYLE="white-space:nowrap">Know-How&#148;</FONT> includes all of such
Party&#146;s rights in its solely-owned Program Technology constituting materials and <FONT STYLE="white-space:nowrap">Know-How</FONT> that satisfy the foregoing, and any jointly-owned materials or <FONT STYLE="white-space:nowrap">Know-How</FONT>
within the Program Technology that satisfies the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.172 &#147;<B>RT Program Patents</B>&#148; means all Patents that Cover any
of the RT Program <FONT STYLE="white-space:nowrap">Know-How.</FONT> For clarity, RT Program Patents include any Joint Patents that satisfy the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.173 &#147;<B>RT Program Technology</B>&#148; means the RT Program <FONT STYLE="white-space:nowrap">Know-How</FONT> and the RT Program
Patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.174 &#147;<B>RT Research Term</B>&#148; means the period that commences on the Effective Date and continuing until [***] after
the Effective Date (the &#147;<B>Initial RT Research Term</B>&#148;), as may be extended by Moderna pursuant to Section&nbsp;3.8 (RT Research Term Extension), unless earlier terminated pursuant to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.175 &#147;<B>RT Research Term Extension Fee</B>&#148; means, with respect to (i)&nbsp;extension of the Initial RT Research Term by [***];
(ii) extension of the Initial RT Research Term by [***]; and (iii)&nbsp;extension of the Initial RT Research Term by [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.176
&#147;<B>RT Target</B>&#148; means [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.177 &#147;<B>RT Technology Milestones</B>&#148; means, collectively, the Mammalian Cell
Milestones, the Rodent Milestones and the NHP Milestones. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.178 &#147;<B>Safety Concern</B>&#148; means, with respect to any Product,
(a)&nbsp;any safety concern required to be reported under 21 C.F.R. &#167; 312.32 if an IND with respect to such product was open at the time of the observation (or that would be so reportable if an IND was not open at such time), or (b)&nbsp;a
toxicity or drug safety issue or a Serious Adverse Event reasonably related to or observed in connection with Development or Commercialization activities with respect to a Product, as determined by either Party, in accordance with its standard
operating procedures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.179 &#147;<B>Sales Force</B>&#148; means the full set of sales representatives, field managers, district
managers, regional managers, national sales managers, regional trainers, medical science trainers and the training department and other personnel assigned by the Parties for each DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.180 &#147;<B>Serious Adverse Event</B>&#148; means an adverse drug experience or
circumstance that results in any of the following outcomes (a)&nbsp;death, (b) life threatening condition, (c)&nbsp;inpatient hospitalization or a prolongation of existing hospitalization, (d)&nbsp;persistent or significant disability or incapacity
or substantial disruption of the ability to conduct normal life functions, (e)&nbsp;or a congenital anomaly/birth defect, (f)&nbsp;significant intervention required to prevent permanent impairment or damage, or (g)&nbsp;a medical event that may not
result in death, be life threatening, or require hospitalization but, based on appropriate medical judgment, that may jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the outcomes described in
clauses (a)&nbsp;through (f). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.181 &#147;<B>Sublicensee</B>&#148; means a Third Party that is granted a license or sublicense to
research, develop, make, have made, use, keep, import, export, offer for sale, sell, or otherwise exploit one or more Products in the Field in the Territory (including any option to any of the foregoing), beyond the mere right to purchase such
Products from a Party and its Affiliates, and excludes each Party&#146;s Affiliates or Third Party subcontractors that act solely for such Party or its Affiliates in the supply chain or that perform discrete services (as opposed to being granted
broad rights or responsibilities) on behalf of such Party or its Affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.182 &#147;<B>Territory</B>&#148; means worldwide. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.183 &#147;<B>Third Party</B>&#148; means a Person other than (a)&nbsp;Moderna or its Affiliates and (b)&nbsp;Metagenomi or its Affiliates.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.184 &#147;<B>Third Party Payment</B>&#148; means all milestone, royalty, and other payments (including required reimbursement for costs
incurred in connection with enforcement or other actions and required sharing of certain recoveries) paid by a Party to any Third Party pursuant to a <FONT STYLE="white-space:nowrap">Co-Co</FONT> <FONT STYLE="white-space:nowrap">In-License.</FONT>
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.185 &#147;<B>Trademark</B>&#148; means any trademark, trade name, service mark, service name, product name, brand, domain name, trade
dress, logo, slogan, or other indicia of origin or ownership, and (a)&nbsp;all registrations, applications for registrations, and other intellectual property rights associated with any of the foregoing, and (b)&nbsp;the goodwill associated with each
of the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.186 &#147;<B>U.S.</B>&#148; means the United States of America and its territories and possessions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.187 &#147;<B>U.S. GAAP</B>&#148; means generally accepted accounting principles as practiced in the U.S., as generally and consistently
applied throughout each Party&#146;s organization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.188 &#147;<B>Valid Claim</B>&#148; means a claim of any pending Patent application
or any issued, unexpired U.S. or granted foreign Patent that has not been dedicated to the public, disclaimed, abandoned or held invalid or unenforceable by a court or other body of competent jurisdiction from which no further appeal can be taken,
and that has not been explicitly disclaimed, or admitted in writing to be invalid or unenforceable or of a scope not Covering a particular product or service through reissue, disclaimer or otherwise, provided <I>that</I> if a particular claim has
not issued within seven (7)&nbsp;years of its initial priority date, it shall not be considered a Valid Claim for purposes of this Agreement unless and until such claim is included in an issued or granted Patent, notwithstanding the foregoing
definition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.189 <B>Additional Definitions</B>. These additional definitions have the meaning set forth
in the following Sections: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Term</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Section</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquirer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>1.17</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Preamble</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alliance Manager</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Annual Research Funding Amount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.3.1</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Antitrust Filings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.24.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Antitrust Laws</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.24.1</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed Commercialization Activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.7.4</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed Development Activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.4.6</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed Medical Affairs Activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.6.4</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BEC Candidates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.10.1</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Breaching Party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>12.2.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change of Control Notice</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>14.9.1</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Claim</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10.1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Clinical Supply Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.23</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Co-Co</FONT> Metagenomi
<FONT STYLE="white-space:nowrap">In-License</FONT> Agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.10.3(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Co-Co</FONT> Moderna
<FONT STYLE="white-space:nowrap">In-License</FONT> Agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.10.2</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Code</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>12.8</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration Personnel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>1.69</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Combination Product</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>1.121</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Combination Product Development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.4.8</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Combination Product Development Proposal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.4.8</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commercial Supply Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.23</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commercialization Activities Cure Period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.7.4</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commercialization Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.2.1</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Competing Program</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>14.8</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Competing Program Personnel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>1.69</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Confidential Information</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>11.1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible Note Instruments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.2</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cure Period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>12.2.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Designated Party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>8.3.6(a)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Development Activities Cure Period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.4.6</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Development Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.2.1</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disclosing Party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>11.1.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Discontinued Target</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.1</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Discontinued Target ROFN Exercise Notice</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.2.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Discontinued Target ROFN Exercise Period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.2.2</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Discontinued Target ROFN Negotiation Period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.2.2</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Term</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Section</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Discontinued Target ROFN Notice</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.2.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dispute</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>13.2</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DOJ</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.24.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Plans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.2</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.2.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DT Exclusivity Period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.21</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DT License</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.15</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DT Metagenomi <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.12.2</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DT Moderna Candidate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.4</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DT Moderna Excess Costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.6</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DT Moderna <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.12.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DT Moderna Records</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.8.1</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DT Moderna Research Budgets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.6</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DT Moderna Research Licensed Technology</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.3</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DT Moderna Research Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.4</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DT Moderna Research Program</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.4</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DT Moderna Research Program</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.4</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DT Moderna Results</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.8.2</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DT Moderna Royalty Term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.10.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DT Moderna Target</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.4</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DT Moderna Target Development and Regulatory Milestone Event</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.8.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DT Moderna Target Sales Milestone Events</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.8.1</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DT Option</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.9</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DT Option Exercise Date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.9</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DT Option Period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.9</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DT Plans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.4</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DT Programs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.4</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DT Reduction Date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.1</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DT Target Evaluation Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effective Date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Preamble</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Excluded Claim</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>13.6</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing Patents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>9.2.5(a)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Firewall Event</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>14.11</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FTC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.24.2</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">HSR Act</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.24.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">HSR Clearance Date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.24.2</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">HSR Filing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.24.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ICC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>13.2</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ICC Arbitration Rules</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>13.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Indemnitee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10.1.3</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Indemnitor</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10.1.3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Infringement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>8.3.1</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial RT Research Term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>1.174</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">JCC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.3</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Term</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Section</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">JDC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joint IP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>8.1.2(d)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">JPC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">JRC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.3</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">JSC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">JSC <FONT STYLE="white-space:nowrap">Co-Chair</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.3</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Know-How</FONT> Transfer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>14.9.2(a)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lead Party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.1</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">License Effective Date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.24.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Licensed DT Moderna Technology</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.15</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Licensed RT Technology</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.13</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Losses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10.1.1</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MAA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>1.120</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Material Transfer Record</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.18</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Medical Affairs Activities Cure Period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.6.4</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Medical Affairs Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.2.1</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Medical Affairs Working Group</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.7.2(e)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Metagenomi</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Preamble</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Metagenomi Development Cost Share Notice</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.4.4(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Metagenomi Indemnitee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10.1.2</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Metagenomi Program Assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.9</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Metagenomi Program Technology</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>8.1.2(b)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Milestone Payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.8.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Moderna</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Preamble</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Moderna Development Cost Share Notice</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.4.4(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Moderna Indemnitee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10.1.1</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Moderna Program Assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.9</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Moderna Program Technology</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>8.1.2(c)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New Collaboration Development Activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.4.7(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New Development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.4.7(a)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New Development Activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.4.7(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New Development Proposal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.4.7(a)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-Breaching</FONT> Party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>12.2.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notices and Consents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>9.2.11</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Opt-In</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>12.5</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Opt-In</FONT> Date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>12.5</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Opt-In</FONT> Party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>12.5.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Opt-In</FONT> Right</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>12.5</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Opt-In</FONT> Transition Activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>12.5.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Opt-In</FONT> Transition Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>12.5.2</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Opt-Out</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.8.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Opt-Out</FONT> Date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.8.1</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Opt-Out</FONT> DT <FONT STYLE="white-space:nowrap">Co-Co</FONT>
Milestone Payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.11.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Opt-Out</FONT> DT <FONT STYLE="white-space:nowrap">Co-Co</FONT>
Product Development and Regulatory Milestone Events</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.11.1</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Term</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Section</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Opt-Out</FONT> DT <FONT STYLE="white-space:nowrap">Co-Co</FONT>
Product Sales Milestone Events</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.11.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Opt-Out</FONT> DT <FONT STYLE="white-space:nowrap">Co-Co</FONT>
Program</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.8.1</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Opt-Out</FONT> Party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.8.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Opt-Out</FONT> Right</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.8.1</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Opt-Out</FONT> Royalty Term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.11.2(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Opt-Out</FONT> Transition Activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.8.2(b)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Opt-Out</FONT> Transition Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.8.2(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Opt-Out</FONT> Trigger</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.8.1</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other Product(s)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>1.121</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Preamble</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Party-Specific Regulations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>9.5.3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.16.3</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pharmacovigilance Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.5.7</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Primary Party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.8.1</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Profit and Loss Share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.4</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Program Technology</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>8.1.2(a)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proposed Combination Product</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.4.8</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Publishing Notice</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>11.3.2</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Publishing Party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>11.3.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Receiving Party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>11.1.2</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Regulatory Working Group</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.7.2(d)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research Continuance Scenario</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>14.9.2(b)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research Transfer Scenario</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>14.9.2(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reversion Product</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>12.6.2</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ROFN Exercise Notice</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.2.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ROFN Exercise Period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.2.1</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ROFN Negotiation Period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.2.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ROFN Notice</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.2.1</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ROFO</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.8.3(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ROFO License Terms</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.8.3(b)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ROFO Notice</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.8.3(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ROFO Period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.8.3(b)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RT Candidate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RT Excess Costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.5</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RT Exclusivity Period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.20</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RT License</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.13</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RT Metagenomi <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.11.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RT Moderna <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.11.2</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RT Option</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.9</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RT Option Exercise Date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.9</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RT Option Period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.9</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RT Plans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.3</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RT Preclinical Research Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RT Preclinical Research Program</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.1</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Term</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Section</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RT Programs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RT Records</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.7.1</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RT Research Budgets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.5</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RT Research Licensed Technology</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.1</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RT Research Term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>1.174</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RT Results</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.7.2</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RT Royalty Term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.9.4</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RT Target Development and Regulatory Milestone Events</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.8.1</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RT Target Sales Milestone Events</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.8.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RT Technology Research Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.2</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RT Technology Research Program</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling Party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>1.121</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shared Infringement Defense Costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>8.4.3(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shared Patent Defense Costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>8.4.3(a)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shared Patent Enforcement Costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>8.3.7</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shared Patent Term Extension Costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>8.5</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>12.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Termination Notice Period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>12.6.3</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third Party Claim</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>8.4</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third Party Patent Challenge</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>8.4</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trademark Costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.7.10(d)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transition Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>12.6.4</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">UC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>9.2.4</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Upfront Payment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.1</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working Group</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.2</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Article 2 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GOVERNANCE AND JOINT STEERING COMMITTEE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1 <B>Alliance Manager</B>. Within thirty (30)&nbsp;days following the Effective Date, each Party shall appoint an individual to act as the
Alliance Manager for such Party (each, an &#147;<B>Alliance Manager</B>&#148;). Each Alliance Manager shall thereafter be permitted to attend meetings of the JSC or any of its subcommittees as a nonvoting observer. The Alliance Managers shall be the
primary point of contact for the Parties regarding the collaboration activities contemplated under this Agreement and shall help facilitate all such activities hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2 <B>Working Groups</B>. The Parties shall establish one or more working groups (each, a &#147;<B>Working Group</B>&#148;) to oversee the
activities of the Program Plans. In addition, from time to time, the Parties may establish a Working Group to oversee particular additional projects or activities. Each Working Group shall undertake the activities delegated to it by the JSC. During
the process of establishing each Working Group, such Working Group and the JSC shall agree regarding which matters such Working Group shall resolve on its own and which matters such Working Group shall advise the JSC regarding (and with respect to
which such advice-specific matters the JSC shall resolve). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.3 <B>Joint Steering Committee</B>. Within thirty (30)&nbsp;days after the Effective Date,
the Parties shall establish a cross-functional, joint steering committee (the &#147;<B>JSC</B>&#148;) composed of up to three (3)&nbsp;senior representatives from each Party that shall oversee and manage the collaboration between the Parties with
respect to each Program during the applicable Term. The JSC may, from time to time, establish subcommittees as it deems necessary to further the purposes of this Agreement; provided that the JSC shall in any event establish (i)&nbsp;a joint research
subcommittee (&#147;<B>JRC</B>&#148;) in accordance with Section&nbsp;2.6 (Joint Research Committee), (ii) a joint development subcommittee (&#147;<B>JDC</B>&#148;) in accordance with Section&nbsp;2.7 (Joint Development Committee), (iii) a joint
commercialization subcommittee (&#147;<B>JCC</B>&#148;) in accordance with Section&nbsp;2.8 (Joint Commercialization Committee), and (iv)&nbsp;a joint patent subcommittee (&#147;<B>JPC</B>&#148;) in accordance with Section&nbsp;2.9 (Joint Patent
Committee). Each Party shall appoint its respective representatives to the JSC from time to time, and may change its representatives, in its sole discretion, effective upon notice to the other Party designating such change. The representatives from
each Party shall have appropriate technical credentials, experience and knowledge pertaining to and ongoing familiarity with the Research and the applicable Programs. One (1)&nbsp;of the Moderna representatives and one (1)&nbsp;of the Metagenomi
representatives on the JSC shall be designated the JSC <FONT STYLE="white-space:nowrap">Co-Chairs</FONT> (each, a &#147;<B>JSC <FONT STYLE="white-space:nowrap">Co-Chair</FONT></B>&#148;). The JSC <FONT STYLE="white-space:nowrap">Co-Chairs</FONT>
shall be responsible for calling meetings of the JSC, circulating agendas and performing administrative tasks required to assure efficient operation of the JSC but shall not have any extra or additional vote. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.4 <B>Specific Responsibilities of the JSC</B>. The JSC shall: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.4.1 discuss, and approve each Research Budget and applicable Program Plan (including the specific contents of each Data Package) and, for
the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program, the criteria for DC Nomination, and review, discuss, and approve any amendments that may be necessary or desired to each Research Budget and applicable Program Plan; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.4.2 address issues arising in the performance of the applicable Program Plans; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.4.3 determine whether a Program Plan has been completed; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.4.4 establish subcommittees, direct and oversee any operating subcommittee on all significant issues, and resolve disputed matters that may
arise at the subcommittees; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.4.5 review, discuss, and determine whether to approve the Commercial Overhead Charge, as described in
Section&nbsp;1.25 (&#147;<B>Commercial Overhead Charge</B>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.4.6 review, discuss, and determine whether to approve as Allowable
Overruns any amounts that are more than [***] above the most recent <FONT STYLE="white-space:nowrap">JSC-approved</FONT> budgeted costs and expenses for a Calendar Year on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-date</FONT></FONT> basis set forth in any Research Budget, Development Budget, Medical Affairs Budget, or Commercialization Budget, as applicable, for such Calendar Year, as
described in Section&nbsp;1.2 (&#147;<B>Allowable Overruns</B>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.4.7 review, discuss, and determine whether to approve any
changes in the FTE Rate, as described in Section&nbsp;1.72 (&#147;<B>FTE Rate</B>&#148;); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.4.8 review, discuss, and determine whether to approve each update to each applicable
Program Plan, including any significant financial review, in each case, proposed by the Parties or a JSC subcommittee; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.4.9 review,
discuss, and determine whether to approve any Overspend for a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product, as described in Sections 6.3.2 (Eligible <FONT STYLE="white-space:nowrap">Co-Co</FONT> Research Cost), 6.4.4(a) (Eligible
Development Costs), 6.6.3 (Medical Affairs Costs) and 6.7.3 (Commercialization Costs and Expenses); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.4.10 review, discuss, and determine
whether to approve any proposal to add a Proposed Combination Product to the Development Plan for a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product, as described in Section&nbsp;6.4.8 (Combination Products); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.4.11 review, discuss, and determine whether to approve Pricing and Reimbursement Approvals for the DT
<FONT STYLE="white-space:nowrap">Co-Co</FONT> Products in accordance with Section&nbsp;6.7.5 (Pricing Matters; Pricing and Reimbursement Approvals; Information Sharing; Pricing Strategy); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.4.12 perform such other functions as appropriate, and direct each subcommittee to perform such other functions as appropriate, to further
the purposes of this Agreement, in each case as agreed in writing by the Parties; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.4.13 resolve all matters that are in dispute as
escalated to the JSC by a subcommittee that cannot be resolved by such subcommittee; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.4.14 perform any and all tasks and
responsibilities that are expressly attributed to the JSC under this Agreement or as otherwise agreed by the Parties in writing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.5
<B>Meetings</B>. The JSC and each of its subcommittees shall each meet at least once per Calendar Quarter during the Research Term, and more often as may be necessary. The JSC and each of its subcommittees may conduct such meetings by telephone,
videoconference, internet meeting or in person, as determined by their members for each meeting. Each Party may call special meetings of the JSC or any of its subcommittees with at least ten (10)&nbsp;Business Days&#146; prior written notice, or a
shorter time period in exigent circumstances, to resolve particular matters requested by such Party that are within the purview of the JSC or the subcommittee, as applicable. Each Party may invite a reasonable number of participants, in addition to
its representatives, to attend JSC and subcommittee meetings in a nonvoting capacity; provided that if either Party intends to have any Third Party (including any consultant) attend such a meeting, such Party shall provide prior written notice to
the other Party. Such Party shall ensure that such Third Party is bound by confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> obligations consistent with the terms of this Agreement. Each Party is responsible for its own expenses
incurred in connection with participating in and attending all such meetings. Each Party&#146;s Alliance Manager or his/her designee shall keep minutes of each JSC and subcommittee meeting that records in writing all decisions made, action items
assigned or completed and other appropriate matters. Each Party&#146;s Alliance Manager shall help consolidate and then send meeting minutes to all members of the JSC or the subcommittee, as applicable, promptly after a meeting for review. Each
member shall have ten (10)&nbsp;Business Days from receipt in which to comment on and to approve the minutes (such approval not to be unreasonably withheld, conditioned or delayed). If a member, within such time period, does not notify either
Party&#146;s Alliance Manager that s/he does not approve of the minutes, the minutes shall be deemed to have been approved by such member. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.6 <B>Joint Research Committee</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.6.1 The JSC shall establish the JRC, consisting of an equal number of subject matter experts from each of Moderna and Metagenomi, within
five (5)&nbsp;days after the establishment of the JSC (or such longer period of time as mutually agreed by the Parties), each Party shall designate in writing three such representatives for the JRC. The JRC may elect to vary the number of
representatives from time to time. Either Party may replace its representatives with similarly qualified individuals at any time upon prior written notice to the other Party (including via email notification). If agreed by the JRC on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis (such agreement not to be unreasonably withheld, conditioned, or delayed), the JRC may invite other personnel of either Party from relevant support
functions to participate in the discussions and meetings of the JRC, provided that such participants shall have no voting authority at the JRC and that any <FONT STYLE="white-space:nowrap">non-employee</FONT> participants are bound by written
obligations of <FONT STYLE="white-space:nowrap">non-use</FONT> and confidentiality and obligations to assign intellectual property that are at least as restrictive or protective of the Parties and their respective intellectual property and
Confidential Information as those set forth in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.6.2 <B>Specific responsibilities of the JRC</B>. The JRC shall have the
following responsibilities: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) discuss, prepare and submit to the JSC for approval each Research Budget and Program Plan (including the
specific contents of each Data Package) and, for the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program, the criteria for DC Nomination, and all annual and interim amendments to each Research Budget and Program Plan; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) determine whether a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Candidate has met the approved criteria for DC Nomination; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) monitor and report the progress of the Research activities and ensuring open and frequent exchange between the Parties; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) identify and resolve any scientific or technical conflicts between the Parties; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) review, modify and oversee the implementation of each Program Plan including coordination of Research activities between the Parties;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) coordinate with the JPC all patent activities as they relate to the results of the Research activities in keeping with the overall
patent strategy delineated by the JPC; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) take such action that is contemplated for the JRC to take under this Agreement; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) perform such other functions as directed by the JSC in accordance with Section&nbsp;2.4.12 (Specific Responsibilities of the JSC). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.7 <B>Joint Development Committee</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.7.1 <B>General</B>. Within thirty (30)&nbsp;days after DC Nomination, or earlier as determined by the JSC, the Parties shall establish the
JDC to coordinate the Development activities (including the related regulatory activities) of the Parties related to the Development of DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Candidate in accordance with the Development Plan. Each Party
shall initially appoint three (3)&nbsp;representatives to the JDC, with each representative having knowledge and expertise in the development of compounds and products similar to the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Candidates and
the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products and having sufficient seniority within the applicable Party to make decisions arising within the scope of the JDC&#146;s responsibilities. The JDC may change its size from time to time;
provided, that the JDC shall consist at all times of an equal number of representatives of each Party. Each Party may replace any of its JDC representatives with a qualified employee of such Party at any time upon written notice to the other Party.
The JDC may invite <FONT STYLE="white-space:nowrap">non-members</FONT> to participate in the discussions and meetings of the JDC; provided, that such participants shall have no voting authority at the JDC and shall be bound by the confidentiality
obligations no less stringent than those provided in this Agreement. The JDC shall have two <FONT STYLE="white-space:nowrap">(2)&nbsp;co-chairpersons,</FONT> one from each Party. The role of the
<FONT STYLE="white-space:nowrap">co-chairpersons</FONT> shall be to convene and preside at meetings of such JDC. The Alliance Managers shall work with the <FONT STYLE="white-space:nowrap">co-chairpersons</FONT> to prepare and circulate agendas and
to ensure the preparation of minutes. The <FONT STYLE="white-space:nowrap">co-chairpersons</FONT> shall have no additional powers or rights beyond those held by the other JDC representatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.7.2 <B>Specific Responsibilities of the JDC</B>. The JDC shall have the following responsibilities: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) discuss, prepare and submit to the JSC for approval of the Development Plan and Development Budget and all annual and interim amendments
to the Development Plan and Development Budget. For clarity, (i)&nbsp;Metagenomi will be responsible for preparing any regional Development Plans and regional Development Budget in the U.S. and (ii)&nbsp;Moderna will be responsible for preparing any
regional Development Plans and regional Development Budget in all countries in the Territory other than the U.S. Such regional Development Plans are to be part of the Development Plan and Development Budget and thereby subject to comments and
proposed changes by the other Party and approval by the JSC as part of the global Development Plan; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) oversee the conduct of the
Development Plan; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) create, implement and review the overall strategy for Development and the design of all Clinical Trials, and
Nonclinical Studies conducted under the Development Plan; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) oversee the conduct of a Working Group created by the JSC related to
regulatory activities in the Territory (&#147;<B>Regulatory Working Group</B>&#148;) in accordance with Section&nbsp;6.5 (Regulatory Affairs), which shall consist of equal representatives from each Party; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) oversee the conduct of a Working Group created by the JSC related to Medical Affairs activities in the Territory (&#147;<B>Medical
Affairs Working Group</B>&#148;) in accordance with Section&nbsp;6.6 (Medical Affairs), which shall consist of equal representatives from each Party;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) decide whether and when to initiate or discontinue any Clinical Trial and any
Nonclinical Study under the Development Plan, and initiate or discontinue any Clinical Trial and any Nonclinical Study; provided, that nothing is intended to limit a Party&#146;s ability to comply with Applicable Laws or manage subject safety; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) allocate budgeted resources and determine priorities for each Clinical Trial and Nonclinical Study under the Development Plan, and
oversee the conduct of all Clinical Trials and Nonclinical Studies under the Development Plan; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) discuss and coordinate roles and
responsibilities between the Parties for Development activities in the Territory; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) facilitate the flow of information between the
Parties with respect to the Development of a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product, including any Manufacturing updates related to clinical supply; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(j) review the overall strategy regarding Regulatory Approval of a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product in the Territory;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(k) discuss, review and oversee the conduct of any Clinical Trials in the Territory that may be included in a Development Plan; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(l) review and approve terms (other than those set forth in Sections 3.6 (Subcontractors for the RT Plans) and 4.7 (Subcontractors for the DT
Plans)) between a Party and a Third Party subcontractor with respect to any Development work to be conducted by such subcontractor; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(m) perform such other functions as directed by the JSC in accordance with Section&nbsp;2.4.12 (Specific Responsibilities of the JSC). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.8 <B>Joint Commercialization Committee</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.8.1 <B>Formation</B>. No later than twelve (12)&nbsp;months prior to the anticipated first NDA or BLA filing, as applicable, for the first
DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product in the Territory, the Parties shall establish the JCC to oversee and manage the Commercialization with respect to such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.8.2 <B>Composition</B>. Each Party shall initially appoint three (3)&nbsp;representatives to the JCC, with each representative having
knowledge and expertise working with products similar to the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products, and having sufficient seniority within the applicable Party to make decisions arising within the scope of the JCC&#146;s
responsibilities. The JCC may change its size from time to time by mutual consent of its members; provided, that the JCC shall consist at all times of an equal number of representatives of each of Metagenomi and Moderna. Each Party may replace any
of its JCC representatives with a qualified employee of such Party at any time upon written notice to the other Party. The JCC may invite <FONT STYLE="white-space:nowrap">non-members</FONT> to participate in the discussions and meetings of the JCC;
provided that such participants shall have no voting authority at the JCC and shall be bound by the confidentiality obligations no less stringent than those provided in this Agreement. The JCC shall have two
<FONT STYLE="white-space:nowrap">(2)&nbsp;co-chairpersons,</FONT> one from each Party. The role of the chairpersons shall be to convene and preside at meetings of the JCC and to ensure the preparation of minutes, but the chairpersons shall have no
additional powers or rights beyond those held by the other JCC representatives. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.8.3 <B>Specific Responsibilities of the JCC</B>. The JCC shall have the following
responsibilities: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) discuss, prepare and submit to the JSC for approval of the Commercialization Plan (including Commercialization
Budget) and all annual and interim amendments to such Commercialization Plan (including Commercialization Budget). For clarity, (i)&nbsp;Metagenomi will be responsible for preparing any regional Commercialization Plan and regional Commercialization
Budget in the U.S. and (ii)&nbsp;Moderna will be responsible for any regional Commercialization Plan and regional Commercialization Budget in all countries in the Territory other than the U.S. Such regional Commercialization Plans are to be part of
the Commercialization Plan and Commercialization Budget and thereby subject to comments and proposed changes by the other Party and approval by the JSC as part of the global Commercialization Plan; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) monitor and discuss Commercialization of DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products in the Territory, including
Distribution Matters; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) discuss, review and approve changes to the Parties&#146; Commercialization responsibilities, including <FONT
STYLE="white-space:nowrap">re-allocating</FONT> and potentially shifting (based on mutual agreement of both Parties and not subject to escalation) responsibilities between the Parties in relation to each Party&#146;s capabilities in a given aspect
of Commercialization; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) establish policies and procedures and a joint promotional review Working Group, for review and approval of any
promotional materials for any DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product in the Territory, including with respect to the resolution of any disagreement between the Parties at the joint promotional review working; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) discuss, review and approve the use of Product Marks in any packages and labels for a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT>
Product; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) discuss, review and approve Pricing Matters in the Territory in accordance with the Commercialization Plan; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) review and approve terms (other than those set forth in Sections 3.6 (Subcontractors for the RT Plans) and 4.7 (Subcontractors for the DT
Plans)) between a Party and a Third Party subcontractor with respect to any Commercialization work to be conducted by such subcontractor; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) perform such other functions as directed by the JSC in accordance with Section&nbsp;2.4.12 (Specific Responsibilities of the JSC). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.9 <B>Joint Patent Committee</B>. The JSC shall establish the JPC, consisting of one
(1)&nbsp;subject matter expert from each Party or such other number as the JSC may agree upon (with an equal number of experts from each of Moderna and Metagenomi), within five (5)&nbsp;days after the establishment of the JSC. The JPC shall be
responsible for evaluating technology arising during the applicable Research Term under this Agreement, including (a)&nbsp;making initial determination of inventorship, (b)&nbsp;determining whether such technology is Metagenomi Program Technology or
Moderna Program Technology (including whether certain technologies can be separately categorized and separately patentable and subject to separate assignment and license obligations hereunder), and (c)&nbsp;coordination of the Parties with respect
to managing the preparation, filing, prosecution, maintenance, enforcement and defense of Joint IP (and determining whether any such Joint IP should be maintained as trade secret in lieu of patenting), including in accordance with the provisions set
forth in Article 8 (Intellectual Property); provided that disputes at the JPC with respect to Patent strategy with respect to Article 8 (Intellectual Property) shall be resolved in accordance with Article 8 (Intellectual Property) and shall not be
escalated to the JSC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.10 <B>Decisions</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.10.1 <B>Decision-making Generally</B>. The JSC, subcommittees, including the JRC, JDC, JCC and JPC, and Working Groups shall endeavor to
make decisions by consensus, with the representatives of each Party having, collectively, one (1)&nbsp;vote on behalf of that Party (which vote shall, with respect to the JSC, be exercised by the respective JSC
<FONT STYLE="white-space:nowrap">Co-Chairs).</FONT> Unless expressly provided for herein, JSC decisions shall not be subject to a <FONT STYLE="white-space:nowrap">tie-breaking</FONT> vote. Deadlocks in the case of subcommittees and Working Groups
(except, for clarity, deadlocks at the JPC with respect to Patent strategy under Article 8 (Intellectual Property), which shall be resolved in accordance with Article 8 (Intellectual Property)) shall be referred to the JSC for final disposition. If
the JSC cannot reach consensus or a dispute arises that cannot be resolved within the JSC, either Party may refer such dispute to the Executive Officers for discussion and attempted resolution in good faith. If consensus cannot be reached with
respect to a decision within thirty (30)&nbsp;days after attempted resolution by the Executive Officers, then, subject to Section&nbsp;2.10.2 (Decision-making for DT CoCo Plans): (a) Moderna has the deciding vote with respect to [***]; provided that
Moderna shall not resolve any such matter under the foregoing clause (a)&nbsp;in a manner that would [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.10.2 <B>Decision-making for
DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Plans</B>. All matters within the purview of the JSC with respect to the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Plans shall be decided by consensus, with no
<FONT STYLE="white-space:nowrap">tie-breaking</FONT> vote, and any failure to reach consensus shall be resolved in accordance with Section&nbsp;13.4 (Baseball Arbitration) with the goal of advancing the DT
<FONT STYLE="white-space:nowrap">Co-Co</FONT> Program in an expedited fashion, provided that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Moderna shall have the deciding vote
on [***]; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Metagenomi shall have the deciding vote on all matters related to the application of Metagenomi Licensed DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Technology to Metagenomi&#146;s activities under the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Plans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.10.3 <B>Disputes for Achievement of Milestones</B>. If the JSC is unable to reach consensus on whether [***] Milestone or [***] Milestone
has been achieved, and if Moderna exercises its decision-making right pursuant to [***] then at the request of Metagenomi such dispute shall be resolved in accordance with Section&nbsp;13.4 (Baseball Arbitration) provided that Metagenomi shall only
have the right to request arbitration one (1)&nbsp;time for achievement of each [***] Milestone. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.11 <B>Authority</B>. The JSC, the JSC <FONT STYLE="white-space:nowrap">Co-Chairs</FONT>
and each subcommittee have only the powers assigned expressly to them in this Article 2 (Governance and Joint Steering Committee) and elsewhere in this Agreement, and does not have any power to amend, modify or waive compliance with this Agreement.
Each Party retains the rights, powers and discretion granted to it under this Agreement and neither Party may delegate or vest such rights, powers or discretion in the JSC or subcommittee unless expressly provided for in this Agreement or the
Parties expressly so agree in writing. The JSC shall not have the power to amend, waive or modify any term of this Agreement, and no decision of the JSC shall be in contravention of any terms and conditions of this Agreement. It is understood and
agreed that issues to be formally decided by the JSC are limited to those specific issues that are expressly provided in this Agreement to be decided by the JSC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.12 <B>Discontinuation of JSC</B>. The JSC will continue, on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Program</FONT></FONT> basis, until the expiration or termination of the Research Term for such Program. Upon disbanding of the JSC with respect to a Program, any
subcommittees and Working Groups with respect to such Program shall be promptly disbanded with immediate effect (unless the Parties otherwise mutually agree). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Article 3 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RT RESEARCH
ACTIVITIES AND OPTION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1 <B>Goals</B>. The objectives for the RT Research Term are for the Parties: (i)&nbsp;to discover and advance
Gene Editing technology within the RT Field to meet the RT Technology Milestones (the &#147;<B>RT Technology Research Program</B>&#148;); and (ii)&nbsp;to discover and advance Licensed Product candidates within the RT Field (each, a &#147;<B>RT
Candidate</B>&#148;) Directed Against specific RT Targets identified in the RT Preclinical Research Plans in order to permit Moderna to evaluate whether to exercise the RT Option with respect to any such RT Target (with respect to each specific RT
Target, an &#147;<B>RT Preclinical Research Program</B>&#148;; together with the RT Technology Research Program, the &#147;<B>RT Programs</B>&#148;). Notwithstanding anything to the contrary herein, the Parties may also perform Research under the RT
Technology Research Program involving specific targets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.2 <B>RT Technology Research Plan</B>. During the RT Research Term, the Research
activities in the RT Technology Research Program shall follow a research plan and budget detailing principal objectives and the activities to be undertaken by both Parties, which includes: (a)&nbsp;the responsibilities of the Parties, and (b)&nbsp;a
timeline showing the key activities and timeframes in which such activities are expected to be completed (the &#147;<B>RT Technology Research Plan</B>&#148;). The initial RT Technology Research Plan appended in <B>Schedule L </B>(RT Technology
Research Plan) shall be presented by the Parties to the JSC for approval within thirty (30)&nbsp;days after the Effective Date. Moderna shall have the right to modify or amend the RT Technology Research Plan, provided that any modifications or
amendments to the RT Technology Research Plan shall be subject to review by the JRC and approval by the JSC. The RT Technology Research Plan shall provide for achieving the [***] milestone. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.3 <B>RT Preclinical Research Plan</B>. At any time during the RT Research Term, Moderna
may initiate one or more RT Preclinical Research Programs by written notice to Metagenomi. Upon receiving such a written notice, the Parties shall jointly propose a research and development plan and budget detailing principal objectives and the
activities to be undertaken by both Parties in the RT Preclinical Research Program(s), which includes: (a)&nbsp;the responsibilities of the Parties, and (b)&nbsp;a timeline showing the key activities and timeframes in which such activities are
expected to be completed (each, an &#147;<B>RT Preclinical Research Plan</B>&#148;; together with the RT Technology Research Plan, the &#147;<B>RT Plans</B>&#148;). The initial RT Preclinical Research Plan shall be reviewed by the JRC and approved
by the JSC. Moderna shall have the right to modify or amend the RT Preclinical Research Plan, provided that any modifications or amendments to the RT Preclinical Research Plan shall be subject to review by the JRC and approval by the JSC. Moderna
shall use Commercially Reasonable Efforts to identify potential programs in the RT Field and to establish RT Plans for such programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.4
<B>Obligations During the RT Research Term</B>. Each Party shall use Commercially Reasonable Efforts to perform and complete (itself or through its Affiliates or by permitted subcontracting) its obligations under the RT Plans. Neither Party shall be
required to perform any work which is not contemplated by any RT Plan, unless such additional work is reflected in a mutually agreed amendment to the applicable RT Plan. Without limiting the generality of the foregoing, on an RT Preclinical Research
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-RT</FONT></FONT> Preclinical Research Program basis, each Party shall use Commercially Reasonable Efforts to perform and complete its activities under the applicable RT
Preclinical Research Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.5 <B>RT Research Term Costs</B>. Metagenomi&#146;s Research Costs incurred under the RT Technology Research
Plan and any RT Preclinical Research Plan shall, on an annual basis, first be credited against the Annual Research Funding Amounts. Upon fully consuming the Annual Research Funding Amount for any given year by Metagenomi&#146;s Research Costs
(which, for the avoidance of doubt, include Research Costs incurred under the DT Plans), Moderna shall pay Metagenomi for Metagenomi&#146;s Research Costs incurred under the RT Plans which are not covered by the Annual Research Funding Amount (the
&#147;<B>RT Excess Costs</B>&#148;) so long as the aggregate Research Costs incurred by Metagenomi in the RT Programs do not exceed the aggregate budgets therefor set forth in the RT Plans (the &#147;<B>RT Research Budgets</B>&#148;), provided
<I>that</I> Moderna&#146;s obligation to compensate Metagenomi for RT Excess Costs shall be subject to Metagenomi&#146;s obligation to provide reports describing all of Metagenomi&#146;s Research Costs incurred under the RT Technology Research Plan
and any RT Preclinical Research Plan, including any RT Excess Costs. Within [***] after the end of each Calendar Quarter, Metagenomi shall send such a report to Moderna describing all of Metagenomi&#146;s Research Costs incurred under the RT
Technology Research Plan and any RT Preclinical Research Plan, including any RT Excess Costs, for such Calendar Quarter. Moderna may reasonably request additional supporting documentation for Metagenomi&#146;s Research Costs described in such
reports and Metagenomi shall provide such documentation (e.g. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> cost breakdowns and general allocation of FTEs). No later than [***] after receipt of any
such invoice from Metagenomi, Moderna shall make payment of undisputed amounts for the RT Excess Costs for such Calendar Quarter. Reimbursement of any RT Excess Costs in excess of the RT Research Budgets shall be subject to approval by the JSC.
Metagenomi shall use the Annual Research Funding Amounts it receives from Moderna under this Agreement solely to carry out its activities in the RT Technology Research Program, the RT Preclinical Research Programs, the DT Target Evaluation Program,
and the DT Moderna Research Programs in accordance with the applicable Program Plans therefor and the terms and conditions of this Agreement and for no other purposes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.6 <B>Subcontractors for the RT Plans</B>. Subject to the remainder of this
Section&nbsp;3.6 (Subcontractors for the RT Plans), each Party may engage subcontractors to perform its obligations under the applicable RT Plan. In all cases, such Party shall ensure that (a)&nbsp;it remains responsible for the work allocated to
such subcontractors to the same extent it would if it had done such work itself, (b)&nbsp;the subcontractor undertakes in writing obligations of confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> regarding Confidential Information
that are at least as protective as those undertaken by such Party with respect to Confidential Information pursuant to Article 11 (Confidentiality), and (c)&nbsp;the subcontractor undertakes in writing to assign or exclusively license back (with the
right to sublicense through multiple tiers) all intellectual property with respect to all Results and all other intellectual property arising out of such subcontracted activities, in each case in the course of performing any such work under the
applicable RT Plan to such Party such that such Party shall Control such intellectual property. Without limiting the generality of the foregoing, each Party may subcontract any of its obligations under the applicable RT Plan to a university or
academic institution on reasonable and customary terms, provided that, (a)&nbsp;such Party shall use reasonable efforts to ensure that such subcontracting relationship is consistent with, and such university or academic institution abides by, the
terms and obligations set forth in this Section&nbsp;3.6 (Subcontractors for the RT Plans) (or such revisions to such terms or obligations as the Parties may mutually agree) and (b)&nbsp;neither the U.S. government nor any agency thereof has funded
or will fund any part of such subcontracting relationship. The engagement of any subcontractor in compliance with this Section&nbsp;3.6 (Subcontractors for the RT Plans) shall not relieve either Party of its obligations under the applicable RT Plan
or this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.7 <B>Records and Reports</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.7.1 <B>Records</B>. Metagenomi and Moderna shall maintain, or cause to be maintained, during the RT Research Term and for a reasonable
period of time thereafter that is consistent with industry standards, complete and accurate written (or electronic) records of its activities under each RT Plan in sufficient detail and in a good scientific manner appropriate for scientific, patent
and regulatory purposes, which records shall reasonably reflect all work performed by or on behalf of such Party under the applicable RT Plan (the &#147;<B>RT Records</B>&#148;). Moderna may request a copy of any RT Records of Metagenomi. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.7.2 <B>Reports</B>. Metagenomi and Moderna shall report on a Calendar Quarter basis to the other Party through the JRC its Results in
conducting activities under the RT Plans (the &#147;<B>RT Results</B>&#148;). In addition, for each RT Program, each Party shall provide the JRC with, on a Calendar Quarter basis during the RT Research Term, all RT Results generated by or on behalf
of such Party in performance of its activities under the applicable RT Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.7.3 <B>Ownership; Confidentiality</B>. Each Party shall
own all rights, title and interest (including all intellectual property rights) in and to the RT Results and the RT Records generated by or for it in accordance with Section&nbsp;8.1.2 (Ownership of Intellectual Property). The RT Results and RT
Records constitute Confidential Information and shall in each case be subject to the rights and obligations of the Parties under this Agreement, including Article 11 (Confidentiality) and the licenses granted hereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.8 <B>RT Research Term Extension</B>. Notwithstanding anything to the contrary, Moderna
may, in its sole discretion, extend the RT Research Term by one (1)&nbsp;year for up to three (3) separate times each upon (i)&nbsp;written notice to Metagenomi provided at least [***] prior to the expiration of the existing RT Research Term and
(ii)&nbsp;payment of the applicable RT Research Term Extension Fee. If Moderna desires that Metagenomi conduct additional Research activities within the RT Field after the expiration of the RT Research Term and Metagenomi agrees to conduct such
additional activities, the Parties shall negotiate in good faith the terms and conditions of Metagenomi&#146;s conduct of such additional activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.9 <B>RT Option</B>. On an RT Preclinical Research
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-RT</FONT></FONT> Preclinical Research Program basis, Metagenomi hereby grants to Moderna the right, but not the obligation, to exercise an exclusive option, exercisable at
any time during the Term but [***] (the &#147;<B>RT Option Period</B>&#148;), to obtain the licenses set forth in Section&nbsp;5.13 (License to Moderna Upon Exercise of the RT Option) with respect to such RT Preclinical Research Program (the
&#147;<B>RT Option</B>&#148;). Moderna may exercise the RT Option up to ten (10)&nbsp;times, each with respect to an RT Target under an RT Preclinical Research Program at its own choosing in its sole discretion. No later than thirty (30)&nbsp;days
after the beginning of the RT Option Period for each RT Preclinical Research Program, Metagenomi shall (a)&nbsp;provide to Moderna the Data Package for such RT Preclinical Research Program, and (b)&nbsp;afford reasonable access during normal
business hours to Metagenomi&#146;s personnel by Moderna and its representatives as Moderna may reasonably request to assist Moderna in deciding whether to exercise the RT Option. Moderna may exercise the RT Option with respect to an RT Preclinical
Research Program by delivering an RT Option exercise notice in respect of such RT Option to Metagenomi at any time during the Term prior to the expiration of the applicable RT Option Period for such RT Preclinical Research Program (the date of such
delivery, the &#147;<B>RT Option Exercise Date</B>&#148;). The RT Option exercise notice shall include the RT Target that is the subject of such RT Option, to be designated as follows: (i)&nbsp;an election of a set of up to [***] genes that are
reasonably known or hypothesized in the scientific arts (A) [***]. Within [***] after the RT Option Exercise Date, Moderna shall pay the RT Option Fee for such RT Preclinical Research Program to Metagenomi. For clarity, on an RT Preclinical Research
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-RT</FONT></FONT> Preclinical Research Program basis, after Moderna exercises its RT Option with respect to such RT Preclinical Research Program, Moderna shall be solely
responsible and have sole authority for all Development (including IND Filing), Manufacturing and Commercialization of all Licensed RT Products for such RT Preclinical Research Program, and Moderna shall use Commercially Reasonable Efforts to
Develop and Commercialize one or more Licensed RT Products for each such RT Preclinical Research Program. For the avoidance of doubt, Moderna may exercise the RT Option with respect to such RT Preclinical Research Program during the RT Option
Period, regardless of whether the applicable RT Preclinical Research Plan has been put in place and whether activities under the applicable RT Preclinical Research Plan have been completed or carried out at all. If Moderna does not exercise the RT
Option during the RT Option Period, then Metagenomi shall have no further obligation to Moderna with respect to such RT Preclinical Research Program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.10 <B>Metagenomi BEC Programs</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.10.1 Starting [***] after the Effective Date and during the Initial RT Research Term, Metagenomi may from time to time propose to the JSC in
writing an RT Target for use in the RT Field, if such RT Target is not already included in an ongoing RT Preclinical Research Program, for which Metagenomi wishes to initiate a research program to discover and advance candidates Directed Against
such RT Target in the RT Field through BEC (each such research </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
program, a, &#147;<B>Metagenomi BEC Program</B>&#148; and such candidates, the &#147;<B>BEC Candidates</B>&#148;) along with written justification of why such RT Target is amenable to a BEC
approach in the RT Field, in sufficient detail for the JSC to assess the feasibility and prospect of applying BEC in the RT Field on such RT Target. If, within [***] days after the JSC&#146;s receipt of the written proposal and justification,
Moderna (a)&nbsp;has not provided written notice to Metagenomi to initiate an RT Preclinical Research Program for such RT Target in the RT Field or (b)&nbsp;has provided Metagenomi with written notice that it does not have an intent to do so,
Metagenomi may initiate such Metagenomi BEC Program at its own cost and expense, provided that Metagenomi may not initiate more than [***] Metagenomi BEC Programs during each Calendar Year during the Initial Research Term. Metagenomi will
periodically (through the JSC) thereafter provide information about the status and activities of such Metagenomi BEC Program promptly upon (and in any event within [***] after) Moderna&#146;s reasonable request, in sufficient detail to allow Moderna
to assess the status and to review the activities of such Metagenomi BEC Program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.10.2 Subject to the remainder of this
Section&nbsp;3.10.2 (Metagenomi BEC Programs), Metagenomi may engage subcontractors to perform its activities in the Metagenomi BEC Programs. In all cases, Metagenomi shall ensure that (a)&nbsp;it remains responsible for the work allocated to such
subcontractors to the same extent it would if it had done such work itself, (b)&nbsp;the subcontractor undertakes in writing obligations of confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> regarding Confidential Information that
are at least as protective as those undertaken by Metagenomi with respect to Confidential Information pursuant to Article 11 (Confidentiality), and (c)&nbsp;the subcontractor undertakes in writing to assign or exclusively license back (with the
right to sublicense through multiple tiers) all intellectual property with respect to all data (including raw data that has not undergone any processing, either manually or through automated computer software, processed, distilled, analyzed or
summarized data, and all representations of part or all of the data), results, findings, analyses and observations, and all other intellectual property arising out of such subcontracted activities, in each case in the course of performing any such
work in the applicable Metagenomi BEC Programs such that Metagenomi shall Control such intellectual property. Except as expressly set forth in this Section&nbsp;3.10, (Metagenomi BEC Programs) Metagenomi and its Affiliates shall not, itself or with
or through any Third Party, nor authorize, (sub)license (including granting any option, covenant not to sue, or other like right thereto) or otherwise enable any Third Party to, directly or indirectly, design, identify, research, manufacture,
develop, commercialize or otherwise exploit any candidate or product in connection with the application of BEC in the RT Field during the Initial RT Research Term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.10.3 Moderna may at any time during the Initial RT Research Program initiate an RT Preclinical Research Program for an RT Target which is
also the subject of a Metagenomi BEC Program by written notice to Metagenomi, and within [***] days after receiving such written notice, (a)&nbsp;Metagenomi will cooperate with Moderna to transfer the activities of such Metagenomi BEC Program to
such RT Preclinical Research Program, (b)&nbsp;the Parties shall jointly propose an RT Preclinical Research Plan for such RT Preclinical Research Program, taking into account the activities that have been conducted in such Metagenomi BEC Program,
and (c)&nbsp;Moderna shall pay to Metagenomi an amount equal to Metagenomi&#146;s costs incurred to date in such Metagenomi BEC Program that is transferred to Moderna upon the earlier of (i)&nbsp;the Base Editing system generated under such
Metagenomi BEC Program achieving during the Initial RT Research Term the Base Editing Correction Readiness milestone for the RT Target of such Metagenomi BEC Program or (ii)&nbsp;Moderna exercises the RT Option with respect to such RT Preclinical
Research Program; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
provided that such payment under this clause (c)&nbsp;by Moderna may also be made by crediting any unused amounts from the Annual Research Funding Amount and shall not exceed [***]. From and
after the end of the thirty <FONT STYLE="white-space:nowrap">(30)-day</FONT> period, the Parties&#146; rights and obligations with respect to RT Preclinical Research Programs under this Agreement (including, without limitation, those under Sections
3.4 (Obligations During the RT Research Term) through 3.9 (RT Option) and the applicable licenses granted under Article 5 (Licenses; Exclusivity; Manufacture)) shall apply to such RT Preclinical Research Program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.10.4 During the Initial RT Research Term, Metagenomi will notify Moderna in writing no later than [***] days prior to the anticipated GLP
Tox Commitment Date of any Metagenomi BEC Program of the upcoming GLP Tox Commitment Date, together with a full data package for the Metagenomi BEC Program, with sufficient data (e.g., results, data (including raw data and summaries thereof),
conclusions and findings), consistent with industry standard, for purposes of demonstrating achievement of indicated success criteria for GLP Toxicology Study, for Moderna to review. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) If within [***] of receiving such notice and data package, Moderna has not provided written notice to Metagenomi of Moderna&#146;s
intention to initiate an RT Preclinical Research Program for the RT Target that is also the subject of such Metagenomi BEC Program, (i)&nbsp;Metagenomi is free to pursue such Metagenomi BEC Program without any further obligation to Moderna under
this Agreement and the applicable RT Target in such Metagenomi BEC Program with respect to BEC, and (ii)&nbsp;the RT Target in such Metagenomi BEC Program shall remain available to Moderna for purposes of initiating an RT Preclinical Research
Program, provided, however, such RT Preclinical Research Program directed to such RT Target shall not include BEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) If within [***]
of receiving such notice and data package, Moderna provides a written notice to Metagenomi of Moderna&#146;s intention to initiate an RT Preclinical Research Program for the RT Target that is also the subject of such Metagenomi BEC Program,
(i)&nbsp;Metagenomi will cooperate with Moderna to transfer the activities of such Metagenomi BEC Program to the newly established RT Preclinical Research Program, (ii)&nbsp;the Parties shall jointly propose an RT Preclinical Research Plan for such
RT Preclinical Research Program, taking into account the activities that have been conducted in such Metagenomi BEC Program, and (iii)&nbsp;Moderna shall pay to Metagenomi an amount equal to Metagenomi&#146;s costs incurred to date in such
Metagenomi BEC Program that is transferred to Moderna upon the earlier of (A)&nbsp;the Base Editing system generated under such Metagenomi BEC Program during the Initial RT Research Term achieving the [***] milestone for the RT Target of such
Metagenomi BEC Program or (B)&nbsp;Moderna exercises the RT Option with respect to such RT Preclinical Research Program; provided that such payment under this clause (iii)&nbsp;by Moderna may also be made by crediting any unused amounts from the
Annual Research Funding Amount and shall not exceed [***]. From and after the end of the [***] period, the Parties&#146; rights and obligations with respect to RT Preclinical Research Programs under this Agreement (including, without limitation,
those under Sections 3.4 (Obligations During the RT Research Term) through 3.9 (RT Option) and the applicable licenses granted under Article 5 (Licenses; Exclusivity; Manufacture)) shall apply to such RT Preclinical Research Program. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.10.5 For clarity, Moderna is not obligated to provide any funding to Metagenomi or its
Affiliates in connection with the Metagenomi BEC Programs, and Metagenomi and its Affiliates shall not use any Annual Research Funding Amounts (or any portion thereof) or any other funding provided by Moderna under this Agreement in connection with
the Metagenomi BEC Programs. Moderna and its Affiliates are not obligated to grant, and do not and shall not grant, Metagenomi or its Affiliates any license under any intellectual property, or otherwise provide to Metagenomi or its Affiliates any
technology (including, without limitation, any <FONT STYLE="white-space:nowrap">mRNA-LNP</FONT> Technology), in each case in connection with the Metagenomi BEC Programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.10.6 For clarity, after the end of the Initial RT Research Term, Metagenomi is free to pursue BEC in the RT Field without any further
obligation to Moderna with respect to BEC in the RT Field under this Agreement except in relation to any RT Options exercised before the expiration of the applicable RT Option Period. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Article 4 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MODERNA DT
RESEARCH ACTIVITIES AND OPTION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.1 <B>Reserved DT Target Discontinuance</B>. Within [***] after the earlier of (i) [***] after
achieving Base Editing Knockout Readiness or (ii)&nbsp;the [***] anniversary of the Effective Date, but in no event earlier than the [***] of the Effective Date (the &#147;<B>DT Reduction Date</B>&#148;), in the event the number of Reserved DT
Targets remaining as of the DT Reduction Date is greater than [***], Moderna shall reduce the number of Reserved DT Targets remaining to [***] by selecting, at its own choosing, the appropriate number of targets from among the remaining [***] for
exclusion from the [***]. Notwithstanding the foregoing, within [***], in the event the number of Reserved DT Targets remaining as of the [***] of the Effective Date is greater than [***] Moderna shall reduce the number of Reserved DT Targets
remaining to [***] by selecting, at its own choosing, the appropriate number of targets from among the remaining Reserved DT [***] for exclusion from the Reserved DT Targets. Within [***] after the [***] of the Effective Date, in the event the
number of Reserved DT Targets remaining as of the [***] of the Effective Date is greater than [***], Moderna shall reduce the number of Reserved DT Targets remaining to [***] by selecting, at its own choosing, the appropriate number of targets from
among the remaining Reserved DT Targets for exclusion from the Reserved DT Targets. Any Reserved DT Target selected by Moderna for exclusion from the Reserved DT Targets pursuant to this Section&nbsp;4.1 (Reserved DT Target Discontinuance) shall,
from and after such selection, be referred to as a &#147;<B>Discontinued Target</B>&#148; and cease to be a Reserved DT Target. In the event such Reserved DT Target is the subject of an ongoing DT Moderna Research Program at the time Moderna selects
it for exclusion, the DT Moderna Research Program is deemed to have been terminated by Moderna pursuant to Section&nbsp;12.4 (Termination for Convenience by Moderna), and such Reserved DT Target shall cease to be a DT Moderna Target, in each case as
of the date of such selection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.2 <B>Right of First Negotiation</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.2.1 If, (a)&nbsp;at any time prior to the earlier of (i) [***] after achieving Base Editing Knockout Readiness or (ii)&nbsp;the [***] of the
Effective Date, Metagenomi or any of its Affiliates wishes to grant any Third Party any rights related to the target [***] within the DT Field in the Territory, (b)&nbsp;at any time prior to the earlier of (i) [***] after achieving Base Editing
Knockout Readiness or (ii)&nbsp;the [***] of the Effective Date, Metagenomi or any of its Affiliates wishes to grant any Third Party any rights related to the target [***] within the DT Field in the Territory, or (c)&nbsp;at any time prior to the
[***] of the Effective Date, Metagenomi or any of its Affiliates wishes </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to grant any Third Party any rights related to [***] (each time period in (a), (b) or (c), a &#147;<B>ROFN Period</B>&#148;), Metagenomi shall provide Moderna with written notice thereof, which
notice shall identify the rights Metagenomi or its applicable Affiliate wishes to grant, and the applicable countries or regions of the Territory to which the applicable grant of rights would apply, together with such information and data in
Metagenomi&#146;s or its applicable Affiliate&#146;s Control that would be reasonably useful for Moderna to determine wither to exercise its right under this Section&nbsp;4.2.1 (Right of First Negotiation) (the &#147;<B>ROFN Notice</B>&#148;).
Moderna shall have a right of first negotiation on the terms and conditions set forth in this Section&nbsp;4.2.1 (Right of First Negotiation). In the event Moderna wishes to exercise its right of first negotiation with respect to such target [***],
as applicable, identified in the ROFN Notice, it shall do so in writing (the &#147;<B>ROFN Exercise Notice</B>&#148;) no later than [***] after Moderna&#146;s receipt of the applicable ROFN Notice (the &#147;<B>ROFN Exercise Period</B>&#148;). Upon
Metagenomi&#146;s receipt of the applicable ROFN Exercise Notice, Metagenomi and Moderna shall negotiate in good faith to attempt to reach agreement on the terms of a collaboration and license agreement for the target [***] as applicable, in the
applicable countries or regions of the Territory similar to the terms related to DT Moderna Research Programs in this Agreement as if the target [***] as applicable, were a DT Moderna Target. If (A)&nbsp;the Parties do not enter into such
collaboration and license agreement within [***] of Metagenomi&#146;s receipt of the applicable ROFN Exercise Notice (the &#147;<B>ROFN Negotiation Period</B>&#148;), (B) Moderna fails to respond during the applicable ROFN Exercise Period, or
(C)&nbsp;Moderna notifies Metagenomi that it elects not to exercise such negotiation right, Metagenomi or its applicable Affiliate shall be free to seek to enter into an agreement granting rights to the target [***] as applicable, in the countries
or regions in the Territory with the Third Party, each as identified in the applicable ROFN Notice; provided that in the event Metagenomi or its applicable Affiliate does not enter into such an agreement within [***] days from (x)&nbsp;in the case
of clause (A), expiration of the applicable ROFN Negotiation Period, or (y)&nbsp;in the case of clauses (B)&nbsp;and (C), expiration of the applicable ROFN Exercise Period (or earlier delivery of notice by Moderna to Metagenomi that it elects not to
exercise such negotiation right), Metagenomi shall thereafter be obligated to, prior to entering into any such agreement, resubmit the ROFN Notice and enter into good faith negotiations with Moderna regarding such rights as specified above in this
Section&nbsp;4.2.1 (Right of First Negotiation) at Moderna&#146;s request, so long as the applicable ROFN Period has not expired. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.2.2
If, at any time within [***] after a Discontinued Target becomes a Discontinued Target (the &#147;<B>Discontinued Target ROFN Period</B>&#148;), Metagenomi or any of its Affiliates wishes to grant any Third Party any rights related to such
Discontinued Target within the DT Field in the Territory, Metagenomi shall provide Moderna with written notice thereof, which notice shall identify the rights Metagenomi or its applicable Affiliate wishes to grant, and the applicable countries or
regions of the Territory to which the applicable grant of rights would apply, together with such information and data in Metagenomi&#146;s or its applicable Affiliate&#146;s Control that would be reasonably useful for Moderna to determine wither to
exercise its right under this Section&nbsp;4.2.2 (Right of First Negotiation) (the &#147;<B>Discontinued Target ROFN Notice</B>&#148;). Moderna shall have a right of first negotiation on the terms and conditions set forth in this Section&nbsp;4.2.2
(Right of First Negotiation). In the event Moderna wishes to exercise its right of first negotiation with respect to such Discontinued Target identified in the Discontinued Target ROFN Notice, it shall do so in writing (the &#147;<B>Discontinued
Target ROFN Exercise Notice</B>&#148;) no later than [***] after Moderna&#146;s receipt of the applicable Discontinued Target ROFN Notice (the &#147;<B>Discontinued Target ROFN Exercise Period</B>&#148;). Upon Metagenomi&#146;s receipt of the
applicable Discontinued Target ROFN Exercise Notice, Metagenomi and Moderna shall negotiate in good </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
faith to attempt to reach agreement on the terms of a collaboration and license agreement for the Discontinued Target in the applicable countries or regions of the Territory similar to the terms
related to DT Moderna Research Programs in this Agreement as if the Discontinued Target were a DT Moderna Target. If (A)&nbsp;the Parties do not enter into such collaboration and license agreement within [***] of Metagenomi&#146;s receipt of the
applicable Discontinued Target ROFN Exercise Notice (the &#147;<B>Discontinued Target ROFN Negotiation Period</B>&#148;), (B) Moderna fails to respond during the applicable Discontinued Target ROFN Exercise Period, or (C)&nbsp;Moderna notifies
Metagenomi that it elects not to exercise such negotiation right, Metagenomi or its applicable Affiliate shall be free to seek to enter into an agreement granting rights to the Discontinued Target in the countries or regions in the Territory with
the Third Party, each as identified in the applicable Discontinued Target ROFN Notice; provided that in the event Metagenomi or its applicable Affiliate does not enter into such an agreement within [***] from (x)&nbsp;in the case of clause (A),
expiration of the applicable Discontinued Target ROFN Negotiation Period, or (y)&nbsp;in the case of clauses (B)&nbsp;and (C), expiration of the applicable Discontinued Target ROFN Exercise Period (or earlier delivery of notice by Moderna to
Metagenomi that it elects not to exercise such negotiation right), Metagenomi shall thereafter be obligated to, prior to entering into any such agreement, resubmit the Discontinued Target ROFN Notice and enter into good faith negotiations with
Moderna regarding such rights as specified above in this Section&nbsp;4.2.2 (Right of First Negotiation) at Moderna&#146;s request, so long as the applicable Discontinued Target ROFN Period has not expired. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.3 <B>DT Target Evaluation Plan</B>. Within [***] after the Effective Date, the Parties shall promptly establish a research program to
advance Base Editing technology towards achieving the Base Editing Knockout Readiness and to evaluate the Reserved DT Targets (the &#147;<B>DT Target Evaluation Program</B>&#148;). The Research activities in the DT Target Evaluation Program shall
follow a research plan and budget detailing principal objectives and the activities to be undertaken by both Parties, which includes: (a)&nbsp;the responsibilities of the Parties, and (b)&nbsp;a timeline showing the key activities and timeframes in
which such activities are expected to be completed (the &#147;<B>DT Target Evaluation Plan</B>&#148;). Moderna shall have the right to modify or amend the DT Target Evaluation Plan, provided that any modifications or amendments to the DT Target
Evaluation Plan shall be subject to review by the JRC and approval by the JSC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.4 <B>DT Moderna Research Plan</B>. Upon written request
by Moderna at any time during the DT Moderna Research Term, the Parties shall promptly establish a research program to discover and advance Licensed Product candidates within the DT Field (each, a &#147;<B>DT Moderna Candidate</B>&#148;) Directed
Against a Reserved DT Target selected by Moderna in its sole discretion in such written request (each Reserved DT Target so selected by Moderna, a &#147;<B>DT Moderna Target</B>&#148;) in order to advance such DT Moderna Candidates to IND Filing
(the &#147;<B>DT Moderna Research Program</B>&#148;; together with the DT Target Evaluation Program, the &#147;<B>DT Programs</B>&#148;). Notwithstanding the foregoing, upon the earlier of completion of the DT Target Evaluation Program or [***]
after the Effective Date, the Parties shall establish DT Moderna Research Programs for each then-current Reserved DT Target. To facilitate the foregoing, the Parties shall jointly propose a research and development plan and budget detailing
principal objectives and the activities to be undertaken by both Parties in such DT Moderna Research Program, which includes: (a)&nbsp;the responsibilities of the Parties, (b)&nbsp;a timeline showing the key activities and timeframes in which such
activities are expected to be completed, and (c)&nbsp;the criteria for a [***] (the &#147;<B>DT Moderna Research Plan</B>&#148;; together with the DT Target Evaluation Plan, the &#147;<B>DT Plans</B>&#148;). The initial DT Moderna Research Plan
shall be reviewed by the JRC and approved by the JSC. Moderna shall have the right to modify or amend the DT Moderna Research Plan, provided that any modifications or amendments to the DT Moderna Research Plan shall be subject to review by the JRC
and approval by the JSC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.5 <B>Obligations During the DT Moderna Research Term</B>. Each Party shall use
Commercially Reasonable Efforts to perform and complete (itself or through its Affiliates or by permitted subcontracting) its obligations under the DT Plans. Neither Party shall be required to perform any work which is not contemplated by any DT
Plan, unless such additional work is reflected in a mutually agreed amendment to the applicable DT Plan. Without limiting the generality of the foregoing, on a DT Moderna Research
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-DT</FONT></FONT> Moderna Research Program basis, each Party shall use Commercially Reasonable Efforts to perform and complete its activities under the DT Plans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.6 <B>DT Moderna Research Term Costs</B>. Metagenomi&#146;s Research Costs incurred under the DT Target Evaluation Plan and any DT Moderna
Research Plan shall, on an annual basis, first be credited against the Annual Research Funding Amounts. Upon fully consuming the Annual Research Funding Amount for any given year by Metagenomi&#146;s Research Costs (which, for the avoidance of
doubt, include Research Costs incurred under the RT Plans), Moderna shall pay Metagenomi for Metagenomi&#146;s Research Costs incurred under the DT Plans which are not covered by the Annual Research Funding Amount (the &#147;<B>DT Moderna Excess
Costs</B>&#148;) so long as the aggregate Research Costs incurred by Metagenomi in the DT Programs do not exceed the aggregate budgets therefor set forth in the DT Plans (the &#147;<B>DT Moderna Research Budgets</B>&#148;), provided <I>that</I>
Moderna&#146;s obligation to compensate Metagenomi for DT Moderna Excess Costs shall be subject to Metagenomi&#146;s obligation to provide reports describing all of Metagenomi&#146;s Research Costs incurred under the DT Target Evaluation Plan and
any DT Moderna Research Plan, including any DT Moderna Excess Costs. Within [***] after the end of each Calendar Quarter, Metagenomi shall send such a report to Moderna describing all of Metagenomi&#146;s Research Costs incurred under the DT Target
Evaluation Plan and any DT Moderna Research Plan, including any DT Moderna Excess Costs, for such Calendar Quarter. Moderna may reasonably request additional supporting documentation for Metagenomi&#146;s Research Costs described in such reports and
Metagenomi shall provide such documentation (e.g. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> cost breakdowns and general allocation of FTEs). No later than [***] after receipt of any such invoice
from Metagenomi, Moderna shall make payment of undisputed amounts for the DT Moderna Excess Costs for such Calendar Quarter. Reimbursement of any DT Moderna Excess Costs in excess of the DT Moderna Research Budgets shall be subject to approval by
the JSC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.7 <B>Subcontractors for the DT Plans</B>. Subject to the remainder of this Section&nbsp;4.7 (Subcontractors for the DT Plans),
each Party may engage subcontractors to perform its obligations under the applicable DT Plan. In all cases, such Party shall ensure that (a)&nbsp;it remains responsible for the work allocated to such subcontractors to the same extent it would if it
had done such work itself, (b)&nbsp;the subcontractor undertakes in writing obligations of confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> regarding Confidential Information that are at least as protective as those undertaken by
such Party with respect to Confidential Information pursuant to Article 11 (Confidentiality), and (c)&nbsp;the subcontractor undertakes in writing to assign or exclusively license back (with the right to sublicense through multiple tiers) all
intellectual property with respect to all Results and all other intellectual property arising out of such subcontracted activities, in each case in the course of performing any such work under the applicable DT Plan to such Party such that such
Party shall </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Control such intellectual property. Without limiting the generality of the foregoing, each Party may subcontract any of its obligations under the applicable DT Plan to a university or academic
institution on reasonable and customary terms, provided <I>that</I>, (a)&nbsp;such Party shall use reasonable efforts to ensure that such subcontracting relationship is consistent with, and such university or academic institution abides by, the
terms and obligations set forth in this Section&nbsp;4.7 (Subcontractors for the DT Plans) (or such revisions to such terms or obligations as the Parties may mutually agree) and (b)&nbsp;neither the U.S. government nor any agency thereof has funded
or will fund any part of such subcontracting relationship. The engagement of any subcontractor in compliance with this Section&nbsp;4.7 (Subcontractors for the DT Plans) shall not relieve either Party of its obligations under the applicable DT Plan
or this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.8 <B>Records and Reports</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.8.1 <B>Records</B>. Metagenomi and Moderna shall maintain, or cause to be maintained, during the DT Moderna Research Term and for a
reasonable period of time thereafter that is consistent with industry standards, complete and accurate written (or electronic) records of its activities under each DT Plan in sufficient detail and in a good scientific manner appropriate for
scientific, patent and regulatory purposes, which records shall reasonably reflect all work performed by or on behalf of such Party under the applicable DT Plan (the &#147;<B>DT Moderna Records</B>&#148;). Moderna may request a copy of any DT
Moderna Records of Metagenomi. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.8.2 <B>Reports</B>. Metagenomi and Moderna shall report on a Calendar Quarter basis to the other Party
through the JRC its Results in conducting activities under the DT Plans (the &#147;<B>DT Moderna Results</B>&#148;). In addition, for each DT Program, each Party shall provide the JRC with, on a Calendar Quarter basis during the DT Moderna Research
Term, all DT Moderna Results generated by or on behalf of such Party in performance of its activities under the applicable DT Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.8.3
<B>Ownership; Confidentiality</B>. Each Party shall own all rights, title and interest (including all intellectual property rights) in and to the DT Moderna Results and the DT Moderna Records generated by or for it in accordance with
Section&nbsp;8.1.2 (Ownership of Intellectual Property). The DT Moderna Results and DT Moderna Records constitute Confidential Information and shall in each case be subject to the rights and obligations of the Parties under this Agreement, including
Article 11 (Confidentiality) and the licenses granted hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.9 <B>DT Option</B>. On a DT Moderna Research <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-DT</FONT></FONT> Moderna Research Program basis, in the event this Agreement has not expired or been terminated with respect to such DT Moderna Research Program, Metagenomi
hereby grants to Moderna the right, but not the obligation, to exercise an exclusive option, exercisable at any time during the Term but no later than [***] (the &#147;<B>DT Option Period</B>&#148;) to obtain the licenses set forth in
Section&nbsp;5.15 (License to Moderna Upon Exercise of the DT Option) with respect to such DT Moderna Research Program (the &#147;<B>DT Option</B>&#148;). Moderna may exercise the DT Option up to two (2)&nbsp;times for a total of two (2)&nbsp;DT
Moderna Targets under this Agreement, each with respect to a DT Moderna Research Program at its own choosing in its sole discretion. No later than [***] after the beginning of the DT Option Period for each DT Moderna Research Program, Metagenomi
shall (a)&nbsp;provide to Moderna the Data Package for such DT Moderna Research Program, and (b)&nbsp;afford reasonable access during normal business hours to Metagenomi&#146;s personnel by Moderna and its
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
representatives as Moderna may reasonably request to assist Moderna in deciding whether to exercise the DT Option. Moderna may exercise the DT Option with respect to a DT Moderna Research Program
by delivering a DT Option exercise notice in respect of such DT Option to Metagenomi at any time during the Term prior to the expiration of the DT Option Period for such DT Moderna Research Program (the date of such delivery, the &#147;<B>DT Option
Exercise Date</B>&#148;). Within [***] after the DT Option Exercise Date, Moderna shall pay the DT Option Fee for such DT Moderna Research Program to Metagenomi. For clarity, on a DT Moderna Research <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Program-by-DT</FONT></FONT> Moderna Research Program basis, after Moderna exercises its DT Option with respect to such DT Moderna Research Program, Moderna shall be solely responsible and have sole authority for all
Development (including IND Filing), Manufacturing and Commercialization of all Licensed DT Products for such DT Moderna Research Program, and Moderna shall use Commercially Reasonable Efforts to Develop and Commercialize one or more Licensed DT
Products for each such DT Moderna Research Program. For the avoidance of doubt, Moderna may exercise the DT Option with respect to such DT Moderna Research Program during the DT Option Period, regardless of whether the applicable DT Moderna Research
Plan has been put in place and whether the activities under the applicable DT Moderna Research Plan have been completed or carried out at all. If Moderna does not exercise the DT Option during the DT Option Period, then Metagenomi shall have no
further obligation to Moderna with respect to such DT Moderna Research Program. Notwithstanding anything herein to the contrary, if Moderna exercises an RT Option and a DT Option with respect to the same target, then the DT Option Fee or the RT
Option Fee, as applicable, for the later exercise shall be reduced by [***] and the two applicable Programs will be treated as one for purposes of Moderna&#146;s Commercially Reasonable Efforts obligations. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Article 5 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LICENSES;
EXCLUSIVITY; MANUFACTURE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.1 <B>RT Research Term License</B>. On an RT <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Program-by-RT</FONT></FONT> Program basis, each Party agrees to grant, and hereby grants, the other Party, during the RT Research Term, a nonexclusive license under such Party&#146;s Background Technology and RT Program
Technology (including RT Results and RT Records generated by or for such Party in conducting activities under all RT Plans) (collectively, such Party&#146;s &#147;<B>RT Research Licensed Technology</B>&#148;), to carry out the other Party&#146;s
activities under the RT Plan in such RT Program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.2 <B>RT Preclinical Research Technology Transfer</B>. On an RT <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-RT</FONT></FONT> Program basis: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.2.1 from time to time during the
Term for such RT Program, each Party shall provide to the other Party such Party&#146;s RT Research Licensed Technology to be used based on the applicable RT Plan or as utilized under such RT Program in such Party&#146;s possession or Control but
was not previously provided in form and by means to be mutually agreed by the Parties; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.2.2 during the Term for such RT Program,
such Party shall reasonably cooperate with the other Party to facilitate the technology transfer of such Party&#146;s RT Research Licensed Technology to be used based on the applicable RT Plan or as utilized under such RT Program to the other Party.
Such cooperation shall include providing the other Party with reasonable access by teleconference or <FONT STYLE="white-space:nowrap">in-person</FONT> at such Party&#146;s facilities to appropriate personnel from such Party to provide the other
Party with technical assistance and consultation in connection with the transfer of such Party&#146;s RT Research Licensed Technology for such RT Program. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing provisions of this Section&nbsp;5.2 (RT Preclinical Research Technology
Transfer) or anything else herein to the contrary, Moderna&#146;s obligation to transfer its RT Research Licensed Technology to Metagenomi under this Section&nbsp;5.2 (RT Preclinical Research Technology Transfer) shall be limited to the RT Research
Licensed Technology that Moderna determines at its sole discretion is necessary or reasonably useful for Metagenomi to carry out its activities under the applicable RT Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.3 <B>DT Moderna Research Term License</B>. On a DT
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-DT</FONT></FONT> Program basis, each Party agrees to grant, and hereby grants, the other Party, during the DT Moderna Research Term, a
<FONT STYLE="white-space:nowrap">non-exclusive</FONT> license under such Party&#146;s Background Technology and DT Program Technology (including DT Moderna Results and DT Moderna Records generated by or for such Party in conducting activities under
all DT Plans) (collectively, such Party&#146;s &#147;<B>DT Moderna Research Licensed Technology</B>&#148;), to carry out the other Party&#146;s activities under the DT Plan in such DT Program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.4 <B>DT Moderna Research Term Technology Transfer</B>. On a DT
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-DT</FONT></FONT> Program basis: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.4.1 as soon as reasonably
practicable but in any event no less than [***] after the initiation of such DT Program, each Party shall provide to the other Party with such Party&#146;s DT Moderna Research Licensed Technology to be used based on the applicable DT Plan or as
utilized under such DT Program in such Party&#146;s possession or Control as of the Effective Date in form and by means to be mutually agreed by the Parties; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.4.2 from time to time during the Term for such DT Program, such Party shall provide to the other Party such Party&#146;s DT Moderna Research
Licensed Technology to be used based on the applicable DT Plan or as utilized under such DT Program in such Party&#146;s possession or Control but was not previously provided in form and by means to be mutually agreed by the Parties; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.4.3 during the Term for such DT Program, such Party shall reasonably cooperate with the other Party to facilitate the technology transfer of
such Party&#146;s DT Moderna Research Licensed Technology for such DT Program to the other Party. Such cooperation shall include providing the other Party with reasonable access by teleconference or <FONT STYLE="white-space:nowrap">in-person</FONT>
at such Party&#146;s facilities to appropriate personnel from such Party to provide the other Party with technical assistance and consultation in connection with the transfer of such Party&#146;s DT Moderna Research Licensed Technology for such DT
Program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing provisions of this Section&nbsp;5.4 (DT Moderna Research Term Technology Transfer) or anything else herein to the
contrary, Moderna&#146;s obligation to transfer its DT Moderna Research Licensed Technology to Metagenomi under this Section&nbsp;5.4 (DT Moderna Research Term Technology Transfer) shall be limited to the DT Moderna Research Licensed Technology that
Moderna determines in its sole discretion is necessary or reasonably useful for Metagenomi to carry out its activities under the applicable DT Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.5 <B>DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program License</B>. Metagenomi
agrees to grant, and hereby grants, to Moderna, during the Term, a <FONT STYLE="white-space:nowrap">co-exclusive</FONT> license (with Metagenomi and its Affiliates) under the Metagenomi Licensed DT <FONT STYLE="white-space:nowrap">Co-Co</FONT>
Technology, to Exploit all applications of the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Target in the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program, including all DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Candidates in such
DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program, for any use in the DT Field in the Territory during the Term, provided that (i)&nbsp;Moderna shall only exercise such license to carry out its activities under the DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Plans for such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program; and (ii)&nbsp;Metagenomi shall only practice its rights under the <FONT STYLE="white-space:nowrap">co-exclusively</FONT> licensed
Metagenomi Licensed DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Technology to carry out its activities under the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Plans for such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program. Moderna
agrees to grant, and hereby grants, to Metagenomi, during the Term, a license under the Moderna Licensed DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Technology, to carry out Metagenomi&#146;s activities under the DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Plans for the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program. Such license shall be <FONT STYLE="white-space:nowrap">non-exclusive</FONT> prior to DC Nomination and
<FONT STYLE="white-space:nowrap">co-exclusive</FONT> (with Moderna and its Affiliates) after DC Nomination with respect to the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product nominated in such DC Nomination, and shall not include the right
to Manufacture or have Manufactured the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product other than the rights of Moderna set forth in Section&nbsp;5.23 (Manufacture). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.6 <B>DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Research Technology Transfer</B>. With respect to the DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Program: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.6.1 as soon as reasonably practicable but in any event no less than thirty
(30)&nbsp;days after the Effective Date, each Party shall provide to the other Party with such Party&#146;s Licensed DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Technology for such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program in
such Party&#146;s possession or Control as of the Effective Date in form and by means to be mutually agreed by the Parties; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.6.2 from
time to time during the Term, such Party shall provide to the other Party such Party&#146;s Licensed DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Technology for such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program in such Party&#146;s
possession or Control but was not previously provided in form and by means to be mutually agreed by the Parties; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.6.3 during the
Term, such Party shall reasonably cooperate with the other Party to facilitate the technology transfer of such Party&#146;s Licensed DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Technology for such DT
<FONT STYLE="white-space:nowrap">Co-Co</FONT> Program to the other Party. Such cooperation shall include providing the other Party with reasonable access by teleconference or <FONT STYLE="white-space:nowrap">in-person</FONT> at such Party&#146;s
facilities to appropriate personnel from such Party to provide the other Party with technical assistance and consultation in connection with the transfer of such Party&#146;s Licensed DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Technology for
such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing provisions of this Section&nbsp;5.6 (DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Research Technology Transfer) or anything else herein to the contrary, (a)&nbsp;Moderna&#146;s obligation to transfer its Licensed DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Technology to Metagenomi
under this Section&nbsp;5.6 (DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Research Technology Transfer) shall be limited to its Licensed DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Technology that Moderna determines in its sole discretion
is necessary or reasonably useful for Metagenomi to carry out its activities under the applicable DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Plans, and (b)&nbsp;Metagenomi&#146;s obligation to transfer its Licensed DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Technology to Moderna under this Section&nbsp;5.6 (DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Research Technology Transfer) shall be limited to its Licensed DT
<FONT STYLE="white-space:nowrap">Co-Co</FONT> Technology that Metagenomi determines in its sole discretion is necessary or reasonably useful for Moderna to carry out its activities under the applicable DT
<FONT STYLE="white-space:nowrap">Co-Co</FONT> Plans, provided, however, notwithstanding anything herein to the contrary, (i)&nbsp;in the event of an <FONT STYLE="white-space:nowrap">Opt-Out</FONT> by Metagenomi pursuant to Section&nbsp;6.8 <FONT
STYLE="white-space:nowrap">(Opt-Out</FONT> Right), the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
foregoing clause (b)&nbsp;shall no longer apply with respect to the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program from which Metagenomi has exercised the
<FONT STYLE="white-space:nowrap">Opt-Out</FONT> Right, and Metagenomi shall transfer or otherwise provide all of its Licensed DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Technology to Moderna in accordance with Sections 5.6.2 (DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Research Technology Transfer), 5.6.3 (DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Research Technology Transfer), and 5.17 (Metagenomi Licensed Collaboration Technology Update); and (ii)&nbsp;in the event
of an <FONT STYLE="white-space:nowrap">Opt-Out</FONT> by Moderna pursuant to Section&nbsp;6.8.1 <FONT STYLE="white-space:nowrap">(Opt-Out</FONT> Right) prior to DC Nomination in such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program, the
foregoing clause (a)&nbsp;shall continue to apply but the scope of the Moderna Licensed DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Technology under this Section&nbsp;5.6 (DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Research Technology
Transfer) shall be expanded to additionally include Moderna&#146;s DT Moderna Research Licensed Technology being Exploited by Moderna as of the expiration of the Initial DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Research Term. Notwithstanding
the foregoing provisions of this Section&nbsp;5.6.3 (DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Research Technology Transfer) or anything else herein to the contrary, Metagenomi acknowledges, understands and agrees that no CMC or
Manufacturing-related <FONT STYLE="white-space:nowrap">Know-How</FONT> shall be provided by Moderna to Metagenomi under this Agreement, including this Section&nbsp;5.6.3 (DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Research Technology
Transfer). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.7 <B>Sublicensing</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.7.1 <B>Rights to Grant Licenses and Sublicenses in the Territory</B>. Except as permitted under this Section&nbsp;5.7 (Sublicensing),
without the prior approval of the other Party, neither Party shall grant a sublicense of the rights granted to such Party under Section&nbsp;5.5 (DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program License), to Develop, Manufacture, perform
Medical Affairs with respect to, or Commercialize the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products in the Territory. If either Party wishes to grant a license or sublicense (as applicable) to a Third Party to Develop, Manufacture,
perform Medical Affairs with respect to, or Commercialize any DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product in the Territory (except as permitted under this Section&nbsp;5.7 (Sublicensing)), then such Party shall notify the other Party
through the JSC, and the other Party shall review such proposal and determine whether to approve the extension of rights to such licensee or sublicensee. Following any such approval by the applicable JSC subcommittee of a proposed licensee or
sublicensee in the Territory, unless otherwise agreed by the applicable JSC subcommittee, such Party shall have the right to lead discussions with potential licensees or sublicensees, negotiate terms, and execute the agreement with such licensee or
sublicensee, provided that such Party shall provide the final form of any such agreement to the applicable JSC subcommittee for the applicable JSC subcommittee&#146;s approval prior to execution thereof. In addition, the Parties shall coordinate
through the applicable JSC subcommittee with respect to the performance or any such licensees or sublicensees, as applicable, to ensure the efficient Development, Manufacture, performance of Medical Affairs with respect to, and Commercialization of
the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products throughout the Territory. Notwithstanding the foregoing, if a Party has exercised its <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Right pursuant to Section&nbsp;6.8 <FONT
STYLE="white-space:nowrap">(Opt-Out</FONT> Right), then the foregoing restrictions on sublicensing shall not apply and, subject to Section&nbsp;6.8.3 (Right of First Offer After <FONT STYLE="white-space:nowrap">Opt-Out),</FONT> the Primary Party
shall have the right to sublicense the rights granted under Section&nbsp;5.5 (DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program License) without the prior approval of the <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Party, provided,
however, notwithstanding anything herein to the contrary, in the event Moderna exercises its <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Right pursuant to Section&nbsp;6.8 <FONT STYLE="white-space:nowrap">(Opt-Out</FONT> Right), Moderna shall
retain its right to Manufacture under Section&nbsp;5.23 (Manufacture). Notwithstanding anything herein to the contrary, Metagenomi shall not grant a sublicense of the rights granted to it under Section&nbsp;5.5 (DT
<FONT STYLE="white-space:nowrap">Co-Co</FONT> Program License) to Manufacture any DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products in the Territory. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.7.2 <B>Costs and Income from Sublicensing Activities in the Territory</B>. The External
Costs incurred in connection with the negotiation of an agreement with any such Third Party licensee or sublicensee (including legal costs and attorneys&#146; fees) in the Territory as approved by the JSC shall be shared equally by the Parties as
Other Operating Expenses in accordance with Section&nbsp;7.4 <FONT STYLE="white-space:nowrap">(Co-Co</FONT> Products Profit and Loss Share). Any Licensing Income received from such Third Party licensee or sublicensee with respect to the Development,
Manufacture, Commercialization or Medical Affairs activities performed by such Third Party licensee or sublicensee in the Territory shall be shared by the Parties as part of the Operating Profits or Losses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.7.3 <B>Sublicense Agreements</B>. Each sublicense to a Third Party granted by a Party pursuant to this Section&nbsp;5.7 (Sublicensing) shall
(a)&nbsp;be subject and subordinate to this Agreement, (b)&nbsp;be consistent with the terms of this Agreement, (c)&nbsp;include obligations of confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> applicable to the Confidential
Information of the other Party that are at least as stringent as those set forth in Article 11 (Confidentiality), and (d)&nbsp;include terms that are consistent with and no less restrictive with respect to the intellectual property provisions set
forth in this Agreement, unless, in each case, the Parties agree otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.8 <B>Responsibility for Sublicensees</B>. Notwithstanding
any sublicense, the Party that grants rights to such licensee or sublicensee (as applicable) shall remain primarily liable to the other Party for the performance of all of its obligations under, and such Party&#146;s compliance with all provisions
of, this Agreement. Each Party agrees that it shall be fully responsible and liable for any breach of the terms of this Agreement by any of its licensees or sublicensees (as applicable) to the same extent as if such Party itself has committed any
such breach. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.9 <B>Subcontracting for DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Plans</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.9.1 <B>Subcontracting Rights</B>. Either Party may engage a Third Party to perform services on a fee for service basis in connection with
the performance of its obligations or exercise of its rights under the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Plans in the Territory; provided that (a)&nbsp;any subcontractor engaged to perform Development activities with respect to a DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Product must be set forth in the Development Plan for such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product, (b)&nbsp;any subcontractor engaged to perform Medical Affairs with respect to a DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Product in or for the Territory must be set forth in the Medical Affairs Plan for such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product, and (c)&nbsp;any subcontractor engaged to perform
Commercialization activities with respect to a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product in or for the Territory must be set forth in the Commercialization Plan for such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.9.2 <B>Subcontracting Requirements</B>. No subcontracting by either Party in accordance with Section&nbsp;5.9.1 (Subcontracting Rights)
shall relieve the subcontracting Party of its obligations under this Agreement or any liability hereunder. Each agreement with any Third Party subcontractor engaged in accordance with Section&nbsp;5.9.1 (Subcontracting Rights) must (a)&nbsp;be
consistent with the terms of this Agreement, (b)&nbsp;include obligations of confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> applicable to the Confidential Information of the other Party that are at least as stringent as those
set forth in Article 11 (Confidentiality), and (c)&nbsp;include terms that are consistent with the intellectual property provisions set forth in this Agreement. As soon as reasonably practicable thereafter each Party shall provide the other Party
with a copy of any executed agreement with a Third Party subcontractor that shall perform Development, Manufacturing, Commercialization, or Medical Affairs activities under this Agreement in the Territory (which copy may be redacted to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
remove provisions that are not necessary to monitor compliance with this Section&nbsp;5.9 (Subcontracting for DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Plans)). <B>Schedule E </B>(Approved
Subcontractors) sets forth a list of <FONT STYLE="white-space:nowrap">pre-approved</FONT> subcontractors that may be engaged by either Party to perform activities hereunder in the Territory. Each Party shall remain directly responsible for any
uncured material breach of this Agreement by a subcontractor and shall terminate promptly any such subcontractor with notice to the other Party of such termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.10 <B>Third Party <FONT STYLE="white-space:nowrap">In-Licenses</FONT> in the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program</B>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.10.1 <B>Existing <FONT STYLE="white-space:nowrap">Co-Co</FONT> <FONT STYLE="white-space:nowrap">In-Licenses</FONT></B>. The Parties
agree that the agreements listed on <B>Schedule F </B>(Existing <FONT STYLE="white-space:nowrap">Co-Co</FONT> <FONT STYLE="white-space:nowrap">In-Licenses)</FONT> are existing <FONT STYLE="white-space:nowrap">in-licenses</FONT> entered into by each
Party that relate or pertain to the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program. Each stipulates and agrees that the rights and licenses granted to it under this Agreement are subject to the applicable terms of all such existing <FONT
STYLE="white-space:nowrap">in-licenses</FONT> of the other Party as such terms exist on the Effective Date with respect to the other Party&#146;s Licensed DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Technology that is being sublicensed
thereunder, and such Party hereby agrees to comply with those terms. The Party that is a party to such an existing <FONT STYLE="white-space:nowrap">in-license</FONT> has provided to the other Party a true and correct copy of such <FONT
STYLE="white-space:nowrap">in-license</FONT> prior to the Effective Date. Each Party further stipulates and agrees that the other Party&#146;s ability to comply with its obligations, and grant rights and licenses to such Party, under this Agreement
may be limited by requirements and restrictions imposed on the other Party under such existing <FONT STYLE="white-space:nowrap">in-licenses,</FONT> and notwithstanding any provision to the contrary set forth in this Agreement, the other Party shall
not be required to take any action that would cause it to be in breach of any such existing <FONT STYLE="white-space:nowrap">in-license.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.10.2 <B>Future DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> <FONT STYLE="white-space:nowrap">In-Licenses</FONT></B>. Except as otherwise
expressly provided herein, each Party shall have the right, in its sole discretion, to independently negotiate, obtain and maintain rights to use any and all Patents or <FONT STYLE="white-space:nowrap">Know-How</FONT> held by a Third Party (whether
through acquisition or license) that relates or otherwise pertains to the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program. Subject to the provisions of this Agreement, each Party shall be responsible for all obligations under the agreements
with the relevant Third Parties to acquire such rights. Such agreements shall be referred to as &#147;<B><FONT STYLE="white-space:nowrap">Co-Co</FONT> Moderna <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements</B>&#148; in the event such
Party is Moderna (or any of its Affiliates) and &#147;<B><FONT STYLE="white-space:nowrap">Co-Co</FONT> Metagenomi <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements</B>&#148; in the event such Party is Metagenomi (or any of its
Affiliates). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.10.3 <B><FONT STYLE="white-space:nowrap">Co-Co</FONT> Moderna <FONT STYLE="white-space:nowrap">In-License</FONT>
Agreements</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <B><FONT STYLE="white-space:nowrap">Co-Co</FONT> Moderna <FONT STYLE="white-space:nowrap">In-License</FONT>
Agreements</B>. Notwithstanding any provision in this Agreement to the contrary, during the Term for the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program, Moderna shall have the right to determine, in its sole discretion, whether any Patents
or <FONT STYLE="white-space:nowrap">Know-How</FONT> under any <FONT STYLE="white-space:nowrap">Co-Co</FONT> Moderna <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement can and should be sublicensed to Metagenomi for such DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Program. If Moderna determines that any such Patents or <FONT STYLE="white-space:nowrap">Know-How</FONT> can and should be sublicensed to Metagenomi for such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT>
Program, then Moderna shall disclose to Metagenomi the terms of such <FONT STYLE="white-space:nowrap">Co-Co</FONT> Moderna <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement (including by providing a copy of such <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Moderna <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement to Metagenomi), subject to applicable confidentiality obligations and reasonable redaction of provisions that do not relate to the potential
use of such Patents and <FONT STYLE="white-space:nowrap">Know-How</FONT> for the performance by Metagenomi of its existing or future activities in the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program. After Metagenomi has had an opportunity
to review the terms of such <FONT STYLE="white-space:nowrap">Co-Co</FONT> Moderna <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement and has agreed in writing to be subject to such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
terms, (i)&nbsp;such Patents and <FONT STYLE="white-space:nowrap">Know-How</FONT> shall be deemed &#147;Controlled&#148; by Moderna or its Affiliates for purposes of this Agreement and shall be
included in the Moderna Licensed DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Technology, (ii)&nbsp;the Parties shall allocate any royalty or other payment obligations to the applicable Third Party in connection with such Patents or <FONT
STYLE="white-space:nowrap">Know-How</FONT> in accordance with Section&nbsp;5.10.3(b) (Payments under <FONT STYLE="white-space:nowrap">Co-Co</FONT> Moderna <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements), and (iii)&nbsp;Metagenomi
stipulates and agrees that the rights and licenses granted to it under this Agreement are subject to the applicable terms of such <FONT STYLE="white-space:nowrap">Co-Co</FONT> Moderna <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement, and
Metagenomi hereby agrees to comply with those terms. Metagenomi further stipulates and agrees that Moderna&#146;s ability to comply with its obligations, and grant rights and licenses to Metagenomi, under this Agreement may be limited by
requirements and restrictions imposed on Moderna under such <FONT STYLE="white-space:nowrap">Co-Co</FONT> Moderna <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement, and notwithstanding any provision to the contrary set forth in this
Agreement, Moderna shall not be required to take any action that would cause it to be in breach of any such <FONT STYLE="white-space:nowrap">Co-Co</FONT> Moderna <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement. If Moderna does not
notify Metagenomi of a <FONT STYLE="white-space:nowrap">Co-Co</FONT> Moderna <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement, then no Patents or <FONT STYLE="white-space:nowrap">Know-How</FONT> under such
<FONT STYLE="white-space:nowrap">Co-Co</FONT> Moderna <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement shall be deemed &#147;Controlled&#148; by Moderna or its Affiliates for purposes of this Agreement, and they shall be excluded from
the Moderna Licensed DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <B>Payments under
<FONT STYLE="white-space:nowrap">Co-Co</FONT> Moderna <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements</B>. In the event the subject matter of a <FONT STYLE="white-space:nowrap">Co-Co</FONT> Moderna
<FONT STYLE="white-space:nowrap">In-License</FONT> Agreement is broader than the Patents and <FONT STYLE="white-space:nowrap">Know-How</FONT> thereunder that is included in the Moderna Licensed DT <FONT STYLE="white-space:nowrap">Co-Co</FONT>
Technology pursuant to Section&nbsp;5.10.3(a) <FONT STYLE="white-space:nowrap">(Co-Co</FONT> Moderna <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements), the Parties shall negotiate in good faith and reasonably allocate to Metagenomi the
obligation to pay that portion of Moderna&#146;s Third Party Payment under such <FONT STYLE="white-space:nowrap">Co-Co</FONT> Moderna <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement that is attributable to Metagenomi&#146;s exercise of
its licenses or rights to such Patents or <FONT STYLE="white-space:nowrap">Know-How,</FONT> subject to Section&nbsp;5.10.5 (Metagenomi Payments for Certain Technology). A disagreement between the Parties on such payment allocation shall be resolved
in accordance with Section&nbsp;13.4 (Baseball Arbitration). In the event a Party exercises the <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Right under Section&nbsp;6.8 <FONT STYLE="white-space:nowrap">(Opt-Out</FONT> Right), from and after the <FONT
STYLE="white-space:nowrap">Opt-Out</FONT> Date, the Primary Party shall pay [***] of Moderna&#146;s Third Party Payment under such <FONT STYLE="white-space:nowrap">Co-Co</FONT> Moderna <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement,
subject to Section&nbsp;7.11.2(d) (Third Party Payments). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.10.4 <B><FONT STYLE="white-space:nowrap">Co-Co</FONT> Metagenomi <FONT
STYLE="white-space:nowrap">In-License</FONT> Agreements</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <B><FONT STYLE="white-space:nowrap">Co-Co</FONT> Metagenomi <FONT
STYLE="white-space:nowrap">In-License</FONT> Agreements</B>. Notwithstanding any provision in this Agreement to the contrary, during the Term for the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program, Metagenomi shall have the right to
determine, in its sole discretion, whether any Patents or <FONT STYLE="white-space:nowrap">Know-How</FONT> under any <FONT STYLE="white-space:nowrap">Co-Co</FONT> Metagenomi <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement can and should
be sublicensed to Moderna for such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program. If Metagenomi determines that any such Patents or <FONT STYLE="white-space:nowrap">Know-How</FONT> can and should be sublicensed to Moderna for such DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Program, then Metagenomi shall disclose to Moderna the terms of such <FONT STYLE="white-space:nowrap">Co-Co</FONT> Metagenomi <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement (including by
providing a copy of such <FONT STYLE="white-space:nowrap">Co-Co</FONT> Metagenomi <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement to Moderna), subject to applicable confidentiality obligations and reasonable redaction of provisions that
do not relate to the potential use of such Patents and <FONT STYLE="white-space:nowrap">Know-How</FONT> for the performance by Moderna of its existing or future activities in the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program. After
Moderna has had an opportunity to review the terms of such <FONT STYLE="white-space:nowrap">Co-Co</FONT> Metagenomi <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement and has agreed in writing to be subject to such terms, (i)&nbsp;such
Patents and <FONT STYLE="white-space:nowrap">Know-How</FONT> shall be deemed &#147;Controlled&#148; by Metagenomi or its Affiliates for purposes of this Agreement and shall be included in the Metagenomi Licensed
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Technology, (ii)&nbsp;the Parties shall allocate any royalty or other payment obligations to the applicable Third Party in connection with such
Patents or <FONT STYLE="white-space:nowrap">Know-How</FONT> in accordance with Section&nbsp;5.10.4(b) (Payments under <FONT STYLE="white-space:nowrap">Co-Co</FONT> Metagenomi <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements), and
(iii)&nbsp;Moderna stipulates and agrees that the rights and licenses granted to it under this Agreement are subject to the applicable terms of such <FONT STYLE="white-space:nowrap">Co-Co</FONT> Metagenomi
<FONT STYLE="white-space:nowrap">In-License</FONT> Agreement, and Moderna hereby agrees to comply with those terms. Moderna further stipulates and agrees that Metagenomi&#146;s ability to comply with its obligations, and grant rights and licenses to
Moderna, under this Agreement may be limited by requirements and restrictions imposed on Metagenomi under such <FONT STYLE="white-space:nowrap">Co-Co</FONT> Metagenomi <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement, and notwithstanding
any provision to the contrary set forth in this Agreement, Metagenomi shall not be required to take any action that would cause it to be in breach of any such <FONT STYLE="white-space:nowrap">Co-Co</FONT> Metagenomi
<FONT STYLE="white-space:nowrap">In-License</FONT> Agreement. If Metagenomi does not notify Moderna of a <FONT STYLE="white-space:nowrap">Co-Co</FONT> Metagenomi <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement, then no Patents or <FONT
STYLE="white-space:nowrap">Know-How</FONT> under such <FONT STYLE="white-space:nowrap">Co-Co</FONT> Metagenomi <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement shall be deemed &#147;Controlled&#148; by Metagenomi or its Affiliates for
purposes of this Agreement, and they shall be excluded from the Metagenomi Licensed DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Technology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <B>Payments under <FONT STYLE="white-space:nowrap">Co-Co</FONT> Metagenomi <FONT STYLE="white-space:nowrap">In-License</FONT>
Agreements</B>. In the event the subject matter of a <FONT STYLE="white-space:nowrap">Co-Co</FONT> Metagenomi <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement is broader than the Patents and
<FONT STYLE="white-space:nowrap">Know-How</FONT> thereunder that is included in the Metagenomi Licensed DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Technology pursuant to Section&nbsp;5.10.4(a) <FONT STYLE="white-space:nowrap">(Co-Co</FONT>
Metagenomi <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements), the Parties shall negotiate in good faith and reasonably allocate to Moderna the obligation to pay that portion of Metagenomi&#146;s Third Party Payment under such <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Metagenomi <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement that is attributable to Moderna&#146;s exercise of its licenses or rights to such Patents or
<FONT STYLE="white-space:nowrap">Know-How,</FONT> subject to Section&nbsp;5.10.5 (Metagenomi Payments for Certain Technology). A disagreement between the Parties on such payment allocation shall be resolved in accordance with Section&nbsp;13.4
(Baseball Arbitration). In the event a Party exercises the <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Right under Section&nbsp;6.8 <FONT STYLE="white-space:nowrap">(Opt-Out</FONT> Right), from and after the
<FONT STYLE="white-space:nowrap">Opt-Out</FONT> Date, the Primary Party shall pay [***] of Metagenomi&#146;s Third Party Payment under such <FONT STYLE="white-space:nowrap">Co-Co</FONT> Metagenomi <FONT STYLE="white-space:nowrap">In-License</FONT>
Agreement, subject to Section&nbsp;7.11.2(d) (Third Party Payments). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.10.5 <B>Metagenomi Payments for Certain Technology</B>.
Notwithstanding the foregoing provisions of this Section&nbsp;5.10 (Third Party <FONT STYLE="white-space:nowrap">In-Licenses</FONT> in the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program), if and to the extent any Patents or <FONT
STYLE="white-space:nowrap">Know-How</FONT> under a <FONT STYLE="white-space:nowrap">Co-Co</FONT> Metagenomi <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement is necessary or reasonably useful to Exploit any Gene-Editing proteins
(including the making or using thereof), that are the preferred choice for the applicable DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products, by reference to scientific merit, manufacturing ease, clinical safety and effectiveness,
patentability and other relevant factors, Metagenomi shall bear [***] of the Third Party Payments under such <FONT STYLE="white-space:nowrap">Co-Co</FONT> Metagenomi <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement attributable to each
Party&#146;s Exploitation thereof in the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program; provided that, from and after Metagenomi <FONT STYLE="white-space:nowrap">Opts-Out</FONT> of the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT>
Program, Moderna shall bear [***] of the Third Party Payments attributable to its continued Exploitation of the Patents and <FONT STYLE="white-space:nowrap">Know-How</FONT> under the <FONT STYLE="white-space:nowrap">Co-Co</FONT> Metagenomi <FONT
STYLE="white-space:nowrap">In-License</FONT> Agreement, subject to Section&nbsp;7.11.2(d) (Third Party Payments), provided further that, notwithstanding anything else herein to the contrary, and without prejudicing Moderna&#146;s rights under
Section&nbsp;7.11.2(d) (Third Party Payments), [***] of such Third Party Payments may be deducted from any royalty payments to Metagenomi under Section&nbsp;7.11.2 <FONT STYLE="white-space:nowrap">(Opt-Out</FONT> Royalties) for the applicable DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Product provided such deduction may not result in a reduction in excess of [***] of the royalties that otherwise would have been due and payable to Metagenomi under Section&nbsp;7.11.2 <FONT
STYLE="white-space:nowrap">(Opt-Out</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Royalties). In addition, notwithstanding anything else herein to the contrary, and without prejudicing Moderna&#146;s rights under Section&nbsp;7.11.2(d) (Third Party Payments), from and after
Metagenomi <FONT STYLE="white-space:nowrap">Opts-Out</FONT> of the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program, [***] of Moderna&#146;s Third Party Payments under any and all <FONT STYLE="white-space:nowrap">Co-Co</FONT> Moderna <FONT
STYLE="white-space:nowrap">In-License</FONT> Agreements for Patents or <FONT STYLE="white-space:nowrap">Know-How</FONT> necessary to Exploit any Gene-Editing proteins (including the making or using thereof) due to the Metagenomi Gene-Editing
proteins being Covered by such Patents or <FONT STYLE="white-space:nowrap">Know-How</FONT> or due to the Metagenomi Gene-Editing proteins being materially less efficacious than the Third Party Gene-Editing proteins, may be deducted from any royalty
payments to Metagenomi under Section&nbsp;7.11.2 <FONT STYLE="white-space:nowrap">(Opt-Out</FONT> Royalties) for the applicable DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product provided such deduction may not result in a reduction in excess
of [***] of the royalties that otherwise would have been due and payable to Metagenomi under Section&nbsp;7.11.2 <FONT STYLE="white-space:nowrap">(Opt-Out</FONT> Royalties). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.10.6 <B>Moderna Payments for Certain Technology</B>. Notwithstanding the foregoing provisions of this Section&nbsp;5.10 (Third Party <FONT
STYLE="white-space:nowrap">In-Licenses</FONT> in the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program), if and to the extent any Patents or <FONT STYLE="white-space:nowrap">Know-How</FONT> under a
<FONT STYLE="white-space:nowrap">Co-Co</FONT> Moderna <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement is necessary or reasonably useful to Exploit any <FONT STYLE="white-space:nowrap">mRNA-LNP</FONT> Technology (including the making or
using thereof), that are the preferred choice for the applicable DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products, by reference to scientific merit, manufacturing ease, clinical safety and effectiveness, patentability and other relevant
factors, Moderna shall bear [***] of the Third Party Payments attributable to each Party&#146;s Exploitation thereof in the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program, provided that, from and after Moderna <FONT
STYLE="white-space:nowrap">Opts-Out</FONT> of the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program, Metagenomi shall bear [***] of the Third Party Payments attributable to its continued Exploitation of the Patents and <FONT
STYLE="white-space:nowrap">Know-How</FONT> under the <FONT STYLE="white-space:nowrap">Co-Co</FONT> Moderna <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement, subject to Section&nbsp;7.11.2(d) (Third Party Payments). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.11 <B>Third Party <FONT STYLE="white-space:nowrap">In-Licenses</FONT> in RT Programs</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.11.1 <B>Existing RT <FONT STYLE="white-space:nowrap">In-Licenses</FONT></B>. The Parties agree that the agreements listed on <B>Schedule G
</B>(Existing RT <FONT STYLE="white-space:nowrap">In-Licenses)</FONT> are existing <FONT STYLE="white-space:nowrap">in-licenses</FONT> entered into by each Party that relate or pertain to the RT Programs. Each stipulates and agrees that the rights
and licenses granted to it under this Agreement are subject to the applicable terms of all such existing <FONT STYLE="white-space:nowrap">in-licenses</FONT> of the other Party as such terms exist on the Effective Date, and such Party hereby agrees
to comply with those terms. The Party that is a party to such an existing <FONT STYLE="white-space:nowrap">in-license</FONT> has provided to the other Party a true and correct copy of such <FONT STYLE="white-space:nowrap">in-license</FONT> prior to
the Effective Date. Each Party further stipulates and agrees that the other Party&#146;s ability to comply with its obligations, and grant rights and licenses to such Party under this Agreement may be limited by requirements and restrictions imposed
on the other Party under such existing <FONT STYLE="white-space:nowrap">in-licenses,</FONT> and notwithstanding any provision to the contrary set forth in this Agreement, the other Party shall not be required to take any action that would cause it
to be in breach of any such existing <FONT STYLE="white-space:nowrap">in-license.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.11.2 <B>Future RT <FONT
STYLE="white-space:nowrap">In-Licenses</FONT></B>. Except as otherwise expressly provided herein, each Party shall have the right, in its sole discretion, to independently negotiate, obtain and maintain rights to use any and all Patents or <FONT
STYLE="white-space:nowrap">Know-How</FONT> held by a Third Party (whether through acquisition or license) that relates or otherwise pertains to the RT Programs. Subject to the provisions of this Agreement, each Party shall be responsible for all
obligations under the agreements with the relevant Third Parties to acquire such rights. Such agreements shall be referred to as &#147;<B>RT Moderna <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements</B>&#148; in the event such Party is
Moderna (or any of its Affiliates) and &#147;<B>RT Metagenomi <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements</B>&#148; in the event such Party is Metagenomi (or any of its Affiliates). </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.11.3 <B>RT Moderna <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements</B>.
Notwithstanding any provision in this Agreement to the contrary, on an RT <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-RT</FONT></FONT> Program basis, during the RT Research Term, Moderna shall have the right to
determine, in its sole discretion, whether any Patents or <FONT STYLE="white-space:nowrap">Know-How</FONT> under any RT Moderna <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement can and should be sublicensed to Metagenomi for such RT
Program. If Moderna determines that any such Patents or <FONT STYLE="white-space:nowrap">Know-How</FONT> can and should sublicensed to Metagenomi for such RT Program, then Moderna shall disclose to Metagenomi the terms of such RT Moderna <FONT
STYLE="white-space:nowrap">In-License</FONT> Agreement (including by providing a copy of such RT Moderna <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement to Metagenomi), subject to applicable confidentiality obligations and reasonable
redaction of provisions that do not relate to the potential use of such Patents and <FONT STYLE="white-space:nowrap">Know-How</FONT> for the performance by Metagenomi of its existing or future activities under the RT Plan. Upon such disclosure,
(i)&nbsp;such Patents and <FONT STYLE="white-space:nowrap">Know-How</FONT> shall be deemed &#147;Controlled&#148; by Moderna or its Affiliates for purposes of this Agreement and shall be included in Moderna&#146;s RT Research Licensed Technology and
(ii)&nbsp;subject to Section&nbsp;5.11.5 (Metagenomi Payments for Certain Technology), Moderna shall pay all (subject to Section&nbsp;7.9.4 (Third Party Payments)) Third Party Payments under such RT Moderna
<FONT STYLE="white-space:nowrap">In-License</FONT> Agreement. After Metagenomi has had an opportunity to review the terms of such RT Moderna <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement and has agreed in writing to be subject to such
terms (provided that Metagenomi may only object to being subjected to such terms if it would have a material impact on Metagenomi&#146;s business outside the collaboration contemplated by this Agreement), Metagenomi stipulates and agrees that the
rights and licenses granted to it under this Agreement are subject to the applicable terms of such RT Moderna <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement, and Metagenomi hereby agrees to comply with those terms. Metagenomi further
stipulates and agrees that Moderna&#146;s ability to comply with its obligations, and grant rights and licenses to Metagenomi, under this Agreement may be limited by requirements and restrictions imposed on Moderna under such RT Moderna <FONT
STYLE="white-space:nowrap">In-License</FONT> Agreement, and notwithstanding any provision to the contrary set forth in this Agreement, Moderna shall not be required to take any action that would cause it to be in breach of any such RT Moderna <FONT
STYLE="white-space:nowrap">In-License</FONT> Agreement. If Moderna does not notify Metagenomi of an RT Moderna <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement, no Patents or <FONT STYLE="white-space:nowrap">Know-How</FONT> under such RT
Moderna <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement shall be &#147;Controlled&#148; by Moderna or its Affiliates for purposes of this Agreement, and they shall be excluded from Moderna&#146;s RT Research Licensed Technology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.11.4 <B>RT Metagenomi <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements</B>. Notwithstanding any provision in this Agreement to
the contrary, on a RT <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-RT</FONT></FONT> Program basis, during the RT Research Term, Metagenomi shall disclose to Moderna all RT Metagenomi
<FONT STYLE="white-space:nowrap">In-License</FONT> Agreements (including by providing a copy of such RT Metagenomi <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement to Moderna). Metagenomi shall use reasonable efforts to ensure that any
such rights acquired under any RT Metagenomi <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement are freely sublicensable to Moderna hereunder, provided if Metagenomi (or any of its Affiliates) is unable to obtain the right to grant a
sublicense to Moderna for any RT Program under all intellectual property rights licensed to Metagenomi (or its Affiliate) under such RT Metagenomi <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement, then Metagenomi (or its Affiliate) shall
exclude any such intellectual property rights for the applicable RT Program from the scope of such RT Metagenomi <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement and shall promptly notify Moderna that it has entered into such RT
Metagenomi <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement. In the event Moderna so elects, and to the extent such Patents and <FONT STYLE="white-space:nowrap">Know-How</FONT> are sublicensable, (i)&nbsp;the applicable Patents and <FONT
STYLE="white-space:nowrap">Know-How</FONT> under </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such RT Metagenomi <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement shall be deemed &#147;Controlled&#148; by Metagenomi or its Affiliates for purposes of this Agreement as part of
Metagenomi&#146;s RT Program Technology and (ii)&nbsp;subject to Sections 5.11.5 (Metagenomi Payments for Certain Technology), 5.11.6 (Moderna Payments for Certain Technology) and 7.9.4 (Third Party Payments), Moderna shall pay all Third Party
Payments under such RT Metagenomi <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement. Moderna stipulates and agrees that the rights and licenses granted to it under this Agreement are subject to the applicable terms of such RT Metagenomi <FONT
STYLE="white-space:nowrap">In-License</FONT> Agreements, and Moderna hereby agrees to comply with those terms. Moderna further stipulates and agrees that Metagenomi&#146;s ability to comply with its obligations, and grant rights and licenses to
Moderna, under this Agreement may be limited by requirements and restrictions imposed on Metagenomi under such RT Metagenomi <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements, and notwithstanding any provision to the contrary set forth
in this Agreement, Metagenomi shall not be required to take any action that would cause it to be in breach of any such RT Metagenomi <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.11.5 <B>Metagenomi Payments for Certain Technology</B>. Notwithstanding the foregoing provisions of this Section&nbsp;5.11 (Third Party <FONT
STYLE="white-space:nowrap">In-Licenses</FONT> in RT Programs), if and to the extent any Patents or <FONT STYLE="white-space:nowrap">Know-How</FONT> under an RT Metagenomi <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement is necessary to
Exploit any Gene-Editing proteins (including the making or using thereof) that are the preferred choice for the applicable Licensed RT Products, by reference to scientific merit, manufacturing ease, clinical safety and effectiveness, patentability
and other relevant factors, Metagenomi shall bear [***] of the Third Party Payments attributable to each Party&#146;s Exploitation thereof in the applicable RT Programs. Moderna shall bear [***] of the Third Party Payments attributable to each
Party&#146;s Exploitation of any Patents or <FONT STYLE="white-space:nowrap">Know-How</FONT> under an RT Moderna <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement necessary to Exploit any Gene-Editing proteins (including the making or
using thereof), in each case where such Patents or <FONT STYLE="white-space:nowrap">Know-How</FONT> is necessary either due to the Metagenomi Gene-Editing proteins being covered by such Patents or <FONT STYLE="white-space:nowrap">Know-How</FONT> or
due to the Metagenomi Gene-Editing proteins being materially less efficacious than the Third Party Gene-Editing proteins, subject to Section&nbsp;7.9.4 (Third Party Payments), provided that, notwithstanding anything else herein to the contrary, and
without prejudicing Moderna&#146;s rights under Section&nbsp;7.9.4 (Third Party Payments), [***] of such Third Party Payments may be deducted from any royalty payments to Metagenomi under Section&nbsp;7.9 (Royalties on Products Directed Against an
RT Target) and for the applicable Licensed RT Product provided such deduction may not result in a reduction in excess of [***] of the royalties that otherwise would have been due and payable to Metagenomi under Section&nbsp;7.9 (Royalties on
Products Directed Against an RT Target). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.11.6 <B>Moderna Payments for Certain Technology</B>. After Moderna exercises the RT Option for
such RT Program, the Patents and <FONT STYLE="white-space:nowrap">Know-How</FONT> elected by Moderna pursuant to Section&nbsp;5.11.4 (RT Metagenomi <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements) shall automatically be included in
Metagenomi&#146;s Licensed RT Technology with respect to such RT Program. Subject to Section&nbsp;5.11.5 (Metagenomi Payments for Certain Technology), in the event the subject matter of the relevant RT Metagenomi
<FONT STYLE="white-space:nowrap">In-License</FONT> Agreement is broader than such Patents and <FONT STYLE="white-space:nowrap">Know-How,</FONT> the Parties shall negotiate in good faith and reasonably allocate to Moderna the obligation to pay that
portion of Metagenomi&#146;s Third Party Payment under the applicable RT Metagenomi <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement that is attributable to Moderna&#146;s exercise of its licenses or rights to such Patents or <FONT
STYLE="white-space:nowrap">Know-How</FONT> after Moderna exercises the RT Option. Moderna&#146;s such payment obligations are subject to Section&nbsp;7.9.4 (Third Party Payments) as if such payments constituted Moderna&#146;s payments to a Third
Party contemplated by Section&nbsp;7.9.4 (Third Party Payments), provided Moderna shall pay Metagenomi additional payments to reflect the effect of Section&nbsp;7.9.4 (Third Party Payments) had Moderna been the Party to such RT Metagenomi <FONT
STYLE="white-space:nowrap">In-License</FONT> Agreement and paid all payments to the Third Party thereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.12 <B>Third Party <FONT STYLE="white-space:nowrap">In-Licenses</FONT> in DT Programs</B>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.12.1 <B>Existing DT <FONT STYLE="white-space:nowrap">In-Licenses</FONT></B>. The Parties agree that the agreements listed on
<B>Schedule H </B>(Existing DT <FONT STYLE="white-space:nowrap">In-Licenses)</FONT> are existing <FONT STYLE="white-space:nowrap">in-licenses</FONT> entered into by each Party that relate or pertain to the DT Programs. Each stipulates and agrees
that the rights and licenses granted to it under this Agreement are subject to the applicable terms of all such existing <FONT STYLE="white-space:nowrap">in-licenses</FONT> of the other Party as such terms exist on the Effective Date, and such Party
hereby agrees to comply with those terms. The Party that is a party to such an existing <FONT STYLE="white-space:nowrap">in-license</FONT> has provided to the other Party a true and correct copy of such
<FONT STYLE="white-space:nowrap">in-license</FONT> prior to the Effective Date. Each Party further stipulates and agrees that the other Party&#146;s ability to comply with its obligations, and grant rights and licenses to such Party under this
Agreement may be limited by requirements and restrictions imposed on the other Party under such existing <FONT STYLE="white-space:nowrap">in-licenses,</FONT> and notwithstanding any provision to the contrary set forth in this Agreement, the other
Party shall not be required to take any action that would cause it to be in breach of any such existing <FONT STYLE="white-space:nowrap">in-license.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.12.2 <B>Future DT <FONT STYLE="white-space:nowrap">In-Licenses</FONT></B>. Except as otherwise expressly provided herein, each Party shall
have the right, in its sole discretion, to independently negotiate, obtain and maintain rights to use any and all Patents or <FONT STYLE="white-space:nowrap">Know-How</FONT> held by a Third Party (whether through acquisition or license) that relates
or otherwise pertains to the DT Programs. Subject to the provisions of this Agreement, each Party shall be responsible for all obligations under the agreements with the relevant Third Parties to acquire such rights. Such agreements shall be referred
to as &#147;<B>DT Moderna <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements</B>&#148; in the event such Party is Moderna (or any of its Affiliates) and &#147;<B>DT Metagenomi <FONT STYLE="white-space:nowrap">In-License</FONT>
Agreements</B>&#148; in the event such Party is Metagenomi (or any of its Affiliates). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.12.3 <B>DT Moderna <FONT
STYLE="white-space:nowrap">In-License</FONT> Agreements</B>. Notwithstanding any provision in this Agreement to the contrary, on a DT <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-DT</FONT></FONT> Program basis, during
the DT Moderna Research Term, Moderna shall have the right to determine, in its sole discretion, whether any Patents or <FONT STYLE="white-space:nowrap">Know-How</FONT> under any DT Moderna <FONT STYLE="white-space:nowrap">In-License</FONT>
Agreement can and should be sublicensed to Metagenomi for such DT Program. If Moderna determines that any such Patents or <FONT STYLE="white-space:nowrap">Know-How</FONT> can and should be sublicensed to Metagenomi for such DT Program, then Moderna
shall disclose to Metagenomi the terms of such DT Moderna <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement (including by providing a copy of such DT Moderna <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement to Metagenomi),
subject to applicable confidentiality obligations and reasonable redaction of provisions that do not relate to the potential use of such Patents and <FONT STYLE="white-space:nowrap">Know-How</FONT> for the performance by Metagenomi of its existing
or future activities under the DT Plan. Upon such disclosure, (i)&nbsp;such Patents and <FONT STYLE="white-space:nowrap">Know-How</FONT> shall be deemed &#147;Controlled&#148; by Moderna or its Affiliates for purposes of this Agreement and shall be
included in Moderna&#146;s DT Moderna Research Licensed Technology and (ii)&nbsp;subject to Section&nbsp;5.12.5 (Metagenomi Payments for Certain Technology), Moderna shall pay all (subject to Section&nbsp;7.10.4 (Third Party Payments)) Third Party
Payments under such DT Moderna <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement. After Metagenomi has had an opportunity to review the terms of such DT Moderna <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement and has agreed
in writing to be subject to such terms (provided that Metagenomi may only object to being subjected to such terms if it would have a material </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
impact on Metagenomi&#146;s business outside the collaboration contemplated by this Agreement), Metagenomi stipulates and agrees that the rights and licenses granted to it under this Agreement
are subject to the applicable terms of such DT Moderna <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement, and Metagenomi hereby agrees to comply with those terms. Metagenomi further stipulates and agrees that Moderna&#146;s ability to
comply with its obligations, and grant rights and licenses to Metagenomi, under this Agreement may be limited by requirements and restrictions imposed on Moderna under such DT Moderna <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement, and
notwithstanding any provision to the contrary set forth in this Agreement, Moderna shall not be required to take any action that would cause it to be in breach of any such DT Moderna <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement. If
Moderna does not notify Metagenomi of a DT Moderna <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement, no Patents or <FONT STYLE="white-space:nowrap">Know-How</FONT> under such DT Moderna <FONT STYLE="white-space:nowrap">In-License</FONT>
Agreement shall be &#147;Controlled&#148; by Moderna or its Affiliates for purposes of this Agreement, and they shall be excluded from Moderna&#146;s DT Moderna Research Licensed Technology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.12.4 <B>DT Metagenomi <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements</B>. Notwithstanding any provision in this Agreement to
the contrary, on a DT <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-</FONT></FONT> DT Program basis, during the DT Moderna Research Term, Metagenomi shall disclose to Moderna all DT Metagenomi <FONT
STYLE="white-space:nowrap">In-License</FONT> Agreements (including by providing a copy of such DT Metagenomi <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement to Moderna). Metagenomi shall use reasonable efforts to ensure that any such
rights acquired under any DT Metagenomi <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement are freely sublicensable to Moderna hereunder, provided if Metagenomi (or any of its Affiliates) is unable to obtain the right to grant a sublicense
to Moderna for any DT Program under all intellectual property rights licensed to Metagenomi (or its Affiliate) under such DT Metagenomi <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement, then Metagenomi (or its Affiliate) shall exclude
any such intellectual property rights for the applicable DT Program from the scope of such DT Metagenomi <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement and shall promptly notify Moderna that it has entered into such DT Metagenomi <FONT
STYLE="white-space:nowrap">In-License</FONT> Agreement. In the event Moderna so elects, and to the extent such Patents and <FONT STYLE="white-space:nowrap">Know-How</FONT> are sublicensable, (i)&nbsp;the applicable Patents and <FONT
STYLE="white-space:nowrap">Know-How</FONT> under such DT Metagenomi <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement shall be deemed &#147;Controlled&#148; by Metagenomi or its Affiliates for purposes of this Agreement as part of
Metagenomi&#146;s DT Program Technology and (ii)&nbsp;subject to Sections 5.12.5 (Metagenomi Payments for Certain Technology), 5.12.6 (Moderna Payments for Certain Technology) and 7.10.4 (Third Party Payments), Moderna shall pay all Third Party
Payments under such DT Metagenomi <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement. Moderna stipulates and agrees that the rights and licenses granted to it under this Agreement are subject to the applicable terms of such DT Metagenomi <FONT
STYLE="white-space:nowrap">In-License</FONT> Agreements, and Moderna hereby agrees to comply with those terms. Moderna further stipulates and agrees that Metagenomi&#146;s ability to comply with its obligations, and grant rights and licenses to
Moderna, under this Agreement may be limited by requirements and restrictions imposed on Metagenomi under such DT Metagenomi <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements, and notwithstanding any provision to the contrary set forth
in this Agreement, Metagenomi shall not be required to take any action that would cause it to be in breach of any such DT Metagenomi <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.12.5 <B>Metagenomi Payments for Certain Technology</B>. Notwithstanding the foregoing provisions of this Section&nbsp;5.12 (Third Party <FONT
STYLE="white-space:nowrap">In-Licenses</FONT> in DT Programs), if and to the extent any Patents or <FONT STYLE="white-space:nowrap">Know-How</FONT> under a DT Metagenomi <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement is necessary to
Exploit Gene-Editing proteins (including the making or using thereof) that are the preferred choice for the applicable Licensed DT Products, by reference to scientific merit, manufacturing ease, clinical safety and effectiveness, patentability and
other relevant factors, Metagenomi shall bear </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
[***] of the Third Party Payments attributable to each Party&#146;s Exploitation thereof in the applicable DT Programs. Moderna shall bear [***] of the Third Party Payments attributable to each
Party&#146;s Exploitation of any Patents or <FONT STYLE="white-space:nowrap">Know-How</FONT> under a DT Moderna <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement necessary to Exploit any Gene-Editing proteins (including the making or
using thereof) in each case where such Patents or <FONT STYLE="white-space:nowrap">Know-How</FONT> is necessary either due to the Metagenomi Gene-Editing proteins being covered by such Patents or <FONT STYLE="white-space:nowrap">Know-How</FONT> or
due to the Metagenomi Gene-Editing proteins being materially less efficacious than the Third Party Gene-Editing protein, subject to Section&nbsp;7.10.4 (Third Party Payments), provided that, notwithstanding anything else herein to the contrary, and
without prejudicing Moderna&#146;s rights under Section&nbsp;7.10.4 (Third Party Payments), [***] of such Third Party Payments may be deducted from any royalty payments to Metagenomi under Section&nbsp;7.10 (Royalties on Products Directed Against a
DT Moderna Target) for the applicable Licensed DT Product provided such deduction may not result in a reduction in excess of [***] of the royalties that otherwise would have been due and payable to Metagenomi under Section&nbsp;7.10 (Royalties on
Products Directed Against a DT Moderna Target). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.12.6 <B>Moderna Payments for Certain Technology</B>. After Moderna exercises the DT
Option for such DT Program, the Patents and <FONT STYLE="white-space:nowrap">Know-How</FONT> elected by Moderna pursuant to Section&nbsp;5.12.4 (DT Metagenomi <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements) shall automatically be
included in Metagenomi&#146;s Licensed DT Moderna Technology with respect to such DT Program. Subject to Section&nbsp;5.12.5 (Metagenomi Payments for Certain Technology), in the event the subject matter of the relevant DT Metagenomi <FONT
STYLE="white-space:nowrap">In-License</FONT> Agreement is broader than such Patents and <FONT STYLE="white-space:nowrap">Know-How,</FONT> the Parties shall negotiate in good faith and reasonably allocate to Moderna the obligation to pay that portion
of Metagenomi&#146;s Third Party Payment under the applicable DT Metagenomi <FONT STYLE="white-space:nowrap">In-License</FONT> Agreement that is attributable to Moderna&#146;s exercise of its licenses or rights to such Patents or <FONT
STYLE="white-space:nowrap">Know-How</FONT> after Moderna exercises the DT Option. Moderna&#146;s such payment obligations are subject to Section&nbsp;7.10.4 (Third Party Payments) as if such payments constituted Moderna&#146;s payments to a Third
Party contemplated by Section&nbsp;7.10.4 (Third Party Payments), provided Moderna shall pay Metagenomi additional payments to reflect the effect of Section&nbsp;7.10.4 (Third Party Payments) had Moderna been the Party to such DT Metagenomi <FONT
STYLE="white-space:nowrap">In-License</FONT> Agreement and paid all payments to the Third Party thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.13 <B>License to Moderna
Upon Exercise of the RT Option</B>. On an RT Preclinical Research <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-RT</FONT></FONT> Preclinical Research Program basis, upon Moderna&#146;s exercise of the RT Option
(pursuant to Section&nbsp;3.9 (RT Option)) with respect to the RT Target under such RT Preclinical Research Program, effective as of the applicable License Effective Date, all RT Candidates in such RT Preclinical Research Program shall become
Licensed RT Products in such RT Preclinical Research Program, and Metagenomi agrees to grant and hereby grants to Moderna an exclusive (even as to Metagenomi and its Affiliates) license, with the right to sublicense through multiple tiers, under
Metagenomi&#146;s Background Technology, Metagenomi&#146;s RT Program Technology with respect to such RT Preclinical Research Program, and all other Metagenomi Program Technology and Metagenomi&#146;s interest in any Joint IP, in each case relevant
to such RT Preclinical Research Program (collectively, the &#147;<B>Licensed RT Technology</B>&#148;), to Exploit all applications of the RT Target in such RT Preclinical Research Program, including all Licensed RT Products in such RT Preclinical
Research Program, for any use in the Territory in the RT Field during the Term (the &#147;<B>RT License</B>&#148;). During the Term, Metagenomi shall ensure that it Controls all <FONT STYLE="white-space:nowrap">Know-How</FONT> or Patents claiming or
Covering Gene Editing conceived, discovered, invented or created by or on behalf of Metagenomi (including jointly with others) so as to be able to grant </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Moderna the foregoing license. For clarity, on an RT Preclinical Research <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-RT</FONT></FONT> Preclinical Research
Program basis, with respect to the RT Target in the RT Field in an RT Preclinical Research Program for which Moderna has not exercised an RT Option by the end of the applicable RT Option Period, (i)&nbsp;the foregoing license does not grant and
shall not grant any rights to Moderna with respect to such RT Target in the RT Field, and (ii)&nbsp;Metagenomi shall retain all rights to Metagenomi Program Technology and Metagenomi&#146;s interest in any Joint IP (a)&nbsp;with respect to such RT
Target in the RT Field and (b)&nbsp;with respect to any Field other than the RT Field, except as expressly set forth herein otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.14 <B>RT Technology Transfer</B>. On an RT Preclinical Research
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-RT</FONT></FONT> Preclinical Research Program basis: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.14.1
as soon as reasonably practicable but in any event no less than thirty (30)&nbsp;days after the RT Option Exercise Date for such RT Preclinical Research Program, Metagenomi shall provide to Moderna with (i)&nbsp;one (1) electronic copy of all of
Metagenomi&#146;s RT Records and RT Results created or generated in all RT Programs as of the RT Option Exercise Date; (ii)&nbsp;one (1) electronic copy of all documents, data or other <FONT STYLE="white-space:nowrap">Know-How</FONT> in
Metagenomi&#146;s possession or Control as of the RT Option Exercise Date that describes or contains the Licensed RT Technology; (iii)&nbsp;all Materials within the Licensed RT Technology in Metagenomi&#146;s possession or Control as of the RT
Option Exercise Date, and (iv)&nbsp;the RT Target and Licensed RT Products in such RT Preclinical Research Program designed, created, synthesized or otherwise Manufactured by or on behalf of Metagenomi as of the RT Option Exercise Date; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.14.2 following the receipt of the RT Option Fee for such RT Preclinical Research Program, from time to time during the Term, Metagenomi
shall provide to Moderna one (1)&nbsp;electronic copy of all documents, data or other <FONT STYLE="white-space:nowrap">Know-How</FONT> in Metagenomi&#146;s possession or Control that describes or contains the Licensed RT Technology and all Materials
within the Licensed RT Technology in Metagenomi&#146;s possession or Control for such RT Preclinical Research Program but was not previously provided; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.14.3 following the receipt of the RT Option Fee for such RT Preclinical Research Program, during the Term, Metagenomi shall reasonably
cooperate with Moderna to facilitate the technology transfer of the Licensed RT Technology, RT Candidates and the RT Target in such RT Preclinical Research Program to Moderna to enable the Development, Manufacture or Commercialization of such RT
Candidates and the RT Target in the RT Field in the Territory. Such cooperation shall include providing Moderna with reasonable access by teleconference or <FONT STYLE="white-space:nowrap">in-person</FONT> at Metagenomi&#146;s facilities to
appropriate personnel from Metagenomi to provide Moderna with technical assistance and consultation in connection with the transfer of such Licensed RT Technology, RT Candidates and RT Target. Metagenomi shall provide such cooperation for no
additional consideration during the RT Research Term, and for [***] thereafter. After the expiration of such [***] period, Moderna shall reimburse Metagenomi for its reasonable costs to provide such cooperation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.15 <B>License to Moderna Upon Exercise of the DT Option</B>. On a DT Moderna Research <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-DT</FONT></FONT> Moderna Research Program basis, upon Moderna&#146;s exercise of the DT Option (pursuant to Section&nbsp;4.9 (DT Option)) with respect to the DT Target under such
DT Moderna Research Program, effective as of the applicable License Effective Date, all DT Moderna Candidates in such DT Moderna Research Program shall become Licensed DT Products, and Metagenomi agrees to grant and hereby grants to Moderna an
exclusive (even as to Metagenomi and its Affiliates) license, with the right to sublicense through multiple tiers, under Metagenomi&#146;s Background Technology, Metagenomi&#146;s DT Program Technology with respect to such DT Moderna Research
Program, and all other Metagenomi Program Technology and Metagenomi&#146;s interest in any Joint IP, in each case relevant to such DT Moderna Research Program (collectively, the &#147;<B>Licensed DT Moderna Technology</B>&#148;), to Exploit all
applications of the DT Moderna Target in such DT Moderna Research Program, including all Licensed DT Products in such DT Moderna Research Program, for any use in the Territory in the DT Field during the Term (the &#147;<B>DT License</B>&#148;).
During the Term, Metagenomi shall ensure that it Controls all <FONT STYLE="white-space:nowrap">Know-How</FONT> or Patents claiming or Covering Gene Editing conceived, discovered, invented or created by or on behalf of Metagenomi (including jointly
with others) so as to be able to grant Moderna the foregoing license. For clarity, on a DT Moderna Research <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-DT</FONT></FONT> Moderna Research Program basis, with respect to
the DT Moderna Target in the DT Field in a DT Moderna Research Program for which Moderna has not exercised a DT Option by the end of the applicable DT Option Period, (i)&nbsp;the foregoing license does not grant and shall not grant any rights to
Moderna with respect to such DT Target in the DT Field, and (ii)&nbsp;Metagenomi shall retain all rights to Metagenomi Program Technology and Metagenomi&#146;s interest in any Joint IP (a)&nbsp;with respect to such DT Target in the DT Field, and
(b)&nbsp;with respect to any Field other than the DT Field except as expressly set forth herein otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.16 <B>DT Technology
Transfer</B>. On a DT Moderna Research <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-DT</FONT></FONT> Moderna Research Program basis: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.16.1 as soon as reasonably practicable but in any event no less than thirty (30)&nbsp;days after the DT Option Exercise Date for such DT
Moderna Research Program, Metagenomi shall provide to Moderna with (i)&nbsp;one (1) electronic copy of all of Metagenomi&#146;s DT Moderna Records and DT Moderna Results created or generated in all DT Programs as of the DT Option Exercise Date;
(ii)&nbsp;one (1) electronic copy of all documents, data or other <FONT STYLE="white-space:nowrap">Know-How</FONT> in Metagenomi&#146;s possession or Control as of the DT Option Exercise Date that describes or contains the Licensed DT Moderna
Technology; (iii)&nbsp;all Materials within the Licensed DT Moderna Technology in Metagenomi&#146;s possession or Control as of the DT Option Exercise Date; and (iv)&nbsp;the DT Moderna Target and Licensed DT Products in such DT Moderna Research
Program designed, created, synthesized or otherwise Manufactured by or on behalf of Metagenomi as of the DT Option Exercise Date; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.16.2
following the receipt of the DT Option Fee for such DT Moderna Research Program, from time to time during the Term, Metagenomi shall provide to Moderna one (1)&nbsp;electronic copy of all documents, data or other
<FONT STYLE="white-space:nowrap">Know-How</FONT> in Metagenomi&#146;s possession or Control that describes or contains the Licensed DT Moderna Technology and all Materials within the Licensed DT Moderna Technology in Metagenomi&#146;s possession or
Control for such DT Moderna Research Program but was not previously provided; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.16.3 following the receipt of the DT Option Fee for such DT Moderna Research Program,
during the Term, Metagenomi shall reasonably cooperate with Moderna to facilitate the technology transfer of the Licensed DT Moderna Technology, Licensed DT Products and the DT Moderna Target in such DT Moderna Research Program to Moderna to enable
the Development, Manufacture or Commercialization of such Licensed DT Product and the DT Moderna Target in the DT Field in the Territory. Such cooperation shall include providing Moderna with reasonable access by teleconference or <FONT
STYLE="white-space:nowrap">in-person</FONT> at Metagenomi&#146;s facilities to appropriate personnel from Metagenomi to provide Moderna with technical assistance and consultation in connection with the transfer of such Licensed DT Moderna
Technology, Licensed DT Products and DT Moderna Target. Metagenomi shall provide such cooperation for no additional consideration during the DT Moderna Research Term, and for [***]. After the expiration of such [***] period, Moderna shall reimburse
Metagenomi for its reasonable costs to provide such cooperation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing provisions of this Section&nbsp;5.16 (DT Technology
Transfer), Metagenomi&#146;s obligations under this Section&nbsp;5.16 (DT Technology Transfer) and Section&nbsp;5.17 (Metagenomi Licensed Collaboration Technology Update) with respect to Licensed DT Moderna Technology shall be limited to
(i)&nbsp;Licensed DT Moderna Technology that comes into the Control of Metagenomi or any of its Affiliates prior to the [***] of the expiration of the DT Moderna Research Term (including, for the avoidance of doubt, prior to or during the DT Moderna
Research Term), (ii) any and all improvements to such Licensed DT Moderna Technology that comes into the Control of Metagenomi or any of its Affiliates within [***] after the expiration of the DT Moderna Research Term, and (iii)&nbsp;in the event
there is any fundamental issue with any of the foregoing Licensed DT Moderna Technology, as reasonably determined by Moderna, that prevents Moderna from Exploiting Licensed DT Products in such DT Moderna Research Program, any Licensed DT Moderna
Technology that may resolve such issue and that comes into the Control of Metagenomi or any of its Affiliates within [***]n (10)&nbsp;years after the expiration of the DT Moderna Research Term, in each case ((i)-(iii)), including any and all Patents
within Licensed DT Moderna Technology that Cover the Licensed DT Moderna Technology in each of (i)-(iii), and any and all Patents claiming priority, directly or indirectly, to the foregoing Patents, regardless of when any of the foregoing Patent is
filed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.17 <B>Metagenomi Licensed Collaboration Technology Update</B>. Without prejudice to any other obligations of Metagenomi under
this Agreement, during the Term, Metagenomi shall (a)&nbsp;provide regular and detailed updates to Moderna and the JSC regarding developments relating to Metagenomi&#146;s Background Technology and Metagenomi Licensed Collaboration Technology
(including any improvements or modifications thereto) that may have applicability to the Research, Development or Commercialization of any Products, which updates shall be (i)&nbsp;no less frequently than quarterly prior to the [***] of the
Effective Date, (ii)&nbsp;on a biannual basis after the [***] of the Effective Date and continuing until the expiration of the Research Term, and (iii) [***] thereafter, and (b)&nbsp;provide Moderna with reasonable access by teleconference or <FONT
STYLE="white-space:nowrap">in-person</FONT> at Metagenomi&#146;s facilities to appropriate personnel from Metagenomi to provide Moderna with technical assistance and consultation in connection with such updates or to otherwise support the
advancement of the applicable Program. For the avoidance of doubt, to the extent within the definitions of Metagenomi&#146;s Background Technology or Metagenomi Licensed Collaboration Technology, as the case may be, such developments shall be
automatically included in the licenses granted to Moderna under this Article 5 (Licenses; Exclusivity; Manufacture) without any action on the part of or additional consideration from Moderna. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.18 <B>Collaboration Materials Transfer</B>. If either Party is required to transfer to the
other Party any Collaboration Materials pursuant to an applicable Program Plan, the terms of this Section&nbsp;5.18 (Collaboration Materials Transfer) shall apply. The transferring Party shall provide the other Party with the applicable
Collaboration Materials in accordance with the Program Plan. Any Collaboration Materials provided pursuant to the Program Plan shall be accompanied by a material transfer record substantially in the form of <B>Schedule I </B>attached hereto
(&#147;<B>Material Transfer Record</B>&#148;). Each such Material Transfer Record shall be signed by an authorized representative of the providing Party, and then signed by an authorized representative of the receiving Party and returned to the
providing Party. The receiving Party shall use the Collaboration Materials solely to conduct the activities contemplated under the Program Plan and for no other purpose. The receiving Party shall not sell, transfer, disclose or otherwise provide
access to the Collaboration Materials without the written consent of the providing Party, except that the receiving Party may allow access to the Collaboration Materials to its Affiliates and its and their respective employees and officers who
require such access to perform its activities under this Agreement and solely for purposes consistent with this Agreement; provided that the receiving Party binds such Affiliates, employees and officers by written agreement to retain and use the
Collaboration Materials only in a manner that is consistent with the terms of this Agreement and the applicable Material Transfer Record. THE COLLABORATION MATERIALS ARE PROVIDED &#147;AS IS.&#148; NO REPRESENTATIONS OR WARRANTIES, EXPRESS OR
IMPLIED, OF ANY KIND, ARE GIVEN BY THE PROVIDING PARTY WITH RESPECT TO ANY OF THE COLLABORATION MATERIALS, INCLUDING THEIR CONDITION, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. The receiving Party acknowledges the experimental nature of
the Collaboration Materials and that accordingly, not all characteristics of the Collaboration Materials are necessarily known. The Collaboration Materials transfer to be undertaken under this Section&nbsp;5.18 (Collaboration Materials Transfer)
shall be overseen by a Working Group established for such purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.19 <B>No Other Rights and Retained Rights</B>. Nothing in this
Agreement shall be interpreted to grant a Party any rights under any intellectual property rights owned or Controlled by the other Party, in each case, that are not expressly granted herein, whether by implication, estoppel, or otherwise. Metagenomi
shall not practice the Moderna Licensed Collaboration Technology other than as expressly licensed and permitted under this Agreement. Any rights not expressly granted to Metagenomi by Moderna under this Agreement with respect to the Moderna Licensed
Collaboration Technology are hereby retained by Moderna, and Moderna hereby expressly retains the right (on behalf of itself, its Affiliates, and its licensees) to (a)&nbsp;Manufacture the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products
worldwide, and (b)&nbsp;perform Moderna&#146;s other obligations under this Agreement. Moderna shall not practice the Metagenomi Licensed Collaboration Technology other than as expressly licensed and permitted under this Agreement. Any rights not
expressly granted to Moderna by Metagenomi under this Agreement with respect to the Metagenomi Licensed Collaboration Technology are hereby retained by Metagenomi. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.20 <B>RT Exclusivity</B>. During the RT Research Term and within [***] thereafter (collectively, the &#147;<B>RT Exclusivity
Period</B>&#148;), except as otherwise required under or expressly set forth in this Agreement, Metagenomi and its Affiliates shall not, itself or with or through any Third Party, nor authorize, (sub)license (including granting any option, covenant
not to sue, or other like right thereto) or otherwise enable any Third Party to, directly or indirectly, design, identify, research, manufacture, develop, commercialize or otherwise exploit any candidate or product in the RT Field. After the
expiration of the RT Exclusivity Period, for the remainder of the Term of this Agreement, on a RT <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Target-by-RT</FONT></FONT> Target basis, except as otherwise required under this
Agreement, Metagenomi and its Affiliates shall not, itself or with or through any Third Party, nor </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
authorize, (sub)license (including granting any option, covenant not to sue, or other like right thereto) or otherwise enable any Third Party to, directly or indirectly, design, identify,
research, manufacture, develop, commercialize or otherwise exploit in the RT Field any candidate or product Directed Against any RT Targets with respect to which Moderna has exercised the RT Option. During the RT Research Term, except as otherwise
required under this Agreement, Metagenomi and its Affiliates shall not, itself or with or through any Third Party, nor authorize, (sub)license (including granting any option, covenant not to sue, or other like right thereto) or otherwise enable any
Third Party to, directly or indirectly, design, identify, research, manufacture, develop, commercialize or otherwise exploit any Guide or Donor Template that is specific to any RT Candidate (and, for clarity, excluding Guides and general homology of
Donor Templates that are used generally to <FONT STYLE="white-space:nowrap">knock-in</FONT> a gene but are not specific to the corresponding target). During the Term, except as otherwise required under this Agreement, Metagenomi and its Affiliates
shall not, itself or with or through any Third Party, nor authorize, (sub)license (including granting any option, covenant not to sue, or other like right thereto) or otherwise enable any Third Party to, directly or indirectly, design, identify,
research, manufacture, develop, commercialize or otherwise exploit any Guide or Donor Template that is specific to any Licensed RT Product from any RT Preclinical Research Program for which Moderna has exercised an RT Option (and, for clarity,
excluding Guides and general homology of Donor Templates that are used generally to <FONT STYLE="white-space:nowrap">knock-in</FONT> a gene but are not specific to the corresponding target). The obligations and restrictions in this Section&nbsp;5.20
(RT Exclusivity) shall not apply to any New Affiliate of Metagenomi, provided that such New Affiliate is not utilizing the applicable Metagenomi Licensed Collaboration Technology or Moderna Licensed Collaboration Technology with respect to the
activity that would otherwise be restricted under this Section&nbsp;5.20 (RT Exclusivity). Notwithstanding the foregoing provisions of this Section&nbsp;5.20 (RT Exclusivity), after [***], the term &#147;RT Field&#148; for purposes of this
Section&nbsp;5.20 (RT Exclusivity) shall no longer include BEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.21 <B>DT Exclusivity</B>. During the DT Moderna Research Term and
within [***] thereafter (collectively, the &#147;<B>DT Exclusivity Period</B>&#148;), except as otherwise required under this Agreement, Metagenomi and its Affiliates shall not, itself or with or through any Third Party, nor authorize, (sub)license
(including granting any option thereto) or otherwise enable any Third Parties to, directly or indirectly, design, identify, research, manufacture, develop, commercialize or otherwise exploit any candidate or product in the DT Field Directed Against
any of the Reserved DT Targets or any of the DT Moderna Targets that is not a Discontinued Target. After the expiration of the DT Exclusivity Period, for the remainder of the Term of this Agreement, on a DT Moderna <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Target-by-DT</FONT></FONT> Moderna Target basis, except as otherwise required under this Agreement, Metagenomi and its Affiliates shall not, itself or with or through any Third Party, nor authorize, (sub)license (including
granting any option thereto) or otherwise enable any Third Party to, directly or indirectly, design, identify, research, manufacture, develop, commercialize or otherwise exploit any candidate or product Directed Against any DT Moderna Targets in the
DT Field with respect to which Moderna has exercised the DT Option. Until the first anniversary of the Effective Date, except as otherwise required under this Agreement, Metagenomi and its Affiliates shall not, itself or with or through any Third
Party, nor authorize, (sub)license (including granting any option, covenant not to sue, or other like right thereto) or otherwise enable any Third Party to, directly or indirectly, design, identify, research, manufacture, develop, commercialize or
otherwise exploit in the in vivo Gene Editing field any Guide or Donor Template that is specific to any DT Moderna Candidate (and, for clarity, excluding Guides and general homology of Donor Templates that are used generally to <FONT
STYLE="white-space:nowrap">knock-in</FONT> a gene but are not specific to the corresponding target). After </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the first anniversary of the Effective Date and during the remainder of the DT Moderna Research Term, except as otherwise required under this Agreement, Metagenomi and its Affiliates shall not,
itself or with or through any Third Party, nor authorize, (sub)license (including granting any option, covenant not to sue, or other like right thereto) or otherwise enable any Third Party to, directly or indirectly, design, identify, research,
manufacture, develop, commercialize or otherwise exploit in the in vivo Gene Editing field any Guide or Donor Template specific to any DT Moderna Candidate Directed Against any Reserved DT Target or DT Moderna Target (and, for clarity, excluding
Guides and general homology of Donor Templates that are used generally to <FONT STYLE="white-space:nowrap">knock-in</FONT> a gene but are not specific to the corresponding target). During the Term, except as otherwise required under this Agreement,
Metagenomi and its Affiliates shall not, itself or with or through any Third Party, nor authorize, (sub)license (including granting any option, covenant not to sue, or other like right thereto) or otherwise enable any Third Party to, directly or
indirectly, design, identify, research, manufacture, develop, commercialize or otherwise exploit any Guide or Donor Template specific to any Licensed DT Product from any DT Moderna Research Program for which Moderna has exercised a DT Option (and,
for clarity, excluding Guides and general homology of Donor Templates that are used generally to <FONT STYLE="white-space:nowrap">knock-in</FONT> a gene but are not specific to the corresponding target). The obligations and restrictions in this
Section&nbsp;5.21.1 (DT Exclusivity) shall not apply to any New Affiliate of Metagenomi, provided that such New Affiliate is not utilizing the applicable Metagenomi Licensed Collaboration Technology or Moderna Licensed Collaboration Technology with
respect to the activity that would otherwise be restricted under this Section&nbsp;5.21 (DT Exclusivity). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.22 <B>DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Target Exclusivity</B>. During the Term of this Agreement, except as otherwise required under this Agreement, Metagenomi and its Affiliates shall not, itself or with or through any Third Party, nor authorize,
(sub)license (including granting any option thereto) or otherwise enable any Third Party to, directly or indirectly, design, identify, research, manufacture, develop, commercialize or otherwise exploit in the DT Field any candidate or product
Directed Against the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Target, or any Guide or Donor Template specific to any DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Candidates or DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products
(and, for clarity, excluding Guides and general homology of Donor Templates that are used generally to <FONT STYLE="white-space:nowrap">knock-in</FONT> a gene but are not specific to the corresponding target). [***]. For clarity, Metagenomi&#146;s
obligations under this Section&nbsp;5.22 (DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Target Exclusivity) shall continue to apply in the event Metagenomi exercises its <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Right under Section&nbsp;6.8
<FONT STYLE="white-space:nowrap">(Opt-Out</FONT> Right). Notwithstanding anything herein to the contrary, in the event Moderna exercises its <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Right under Section&nbsp;6.8
<FONT STYLE="white-space:nowrap">(Opt-Out</FONT> Right), its obligations under this Section&nbsp;5.22 (DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Target Exclusivity) with respect to the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Target
and the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products in the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program shall terminate, effective as of the applicable <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Date. The obligations
and restrictions in this Section&nbsp;5.22 (DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Target Exclusivity) shall not apply to a New Affiliate of a Party, provided that such New Affiliate is not utilizing the Metagenomi Licensed Collaboration
Technology or the Moderna Licensed Collaboration Technology with respect to the activity that would otherwise be restricted under this Section&nbsp;5.22 (DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Target Exclusivity). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.23 <B>Manufacture</B>. Except as expressly set forth otherwise in this Agreement or in any Program Plan, Moderna shall be responsible for
Manufacturing and supply of all <FONT STYLE="white-space:nowrap">non-GMP</FONT> and GMP mRNA Constructs and LNP formulated Candidates and Products for all Research, Development, and Commercialization activities contemplated under this Agreement or
any Program Plan. All decisions concerning such Manufacturing are within the sole discretion of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Moderna. Upon the first DC Nomination under a given DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program, the Parties shall enter a supply agreement to facilitate the activities related to
clinical supply contemplated under the applicable Development Plan (a &#147;<B>Clinical Supply Agreement</B>&#148;). No later than [***] prior to the anticipated First Commercial Sale of a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product in
the Territory, the Parties shall enter a supply agreement to facilitate the activities related to commercial supply contemplated under the applicable Commercialization Plan (a &#147;<B>Commercial Supply Agreement</B>&#148;). The Parties may also
enter to one or more quality agreements in conjunction with the foregoing. [***]. Notwithstanding anything herein to the contrary, Moderna may in its sole discretion cease performance of the Manufacturing activities (including any related CMC
Activities), if Moderna determines in its sole discretion that there is a Safety Concern with respect to a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product or Metagenomi Licensed DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Technology.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.24 <B>Government Approvals</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.24.1 <B>Efforts</B>. Each Party will use its commercially reasonable good faith efforts to eliminate any concern on the part of any
Governmental Authority regarding the legality of the RT License or the DT License prior to their becoming effective, under any Antitrust Law, including, if required by federal or state antitrust authorities, promptly taking commercially reasonable
steps to secure government antitrust clearance, including cooperating in good faith with any government investigation, including by making an appropriate response to any request (including a second request) by a Governmental Authority for documents
or information. Notwithstanding the foregoing, this Section&nbsp;5.24.1 (Efforts) and the term &#147;commercially reasonable good faith efforts&#148; do not require that either Party (a)&nbsp;offer, negotiate, commit to or effect, by consent decree,
hold separate order, trust or otherwise, the sale, divestiture, license or other disposition of any capital stock, assets, rights, products or businesses of either Party or their respective Affiliates, (b)&nbsp;agree to any restrictions on the
businesses of either Party or their respective Affiliates, or (c)&nbsp;pay any amount or take any other action to prevent, effect the dissolution of, vacate, or lift any decree, order, judgment, injunction, temporary restraining order, or other
order in any suit or proceeding that would otherwise have the effect of preventing or delaying the transactions contemplated by the RT License or the DT License. For purposes of this Section&nbsp;5.24 (Government Approvals), &#147;<B>Antitrust
Laws</B>&#148; means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the rules and regulations promulgated thereunder (the &#147;<B>HSR Act</B>&#148;), and any other laws of the U.S. (or a state or territory thereof) or any
other Governmental Authority that are designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.24.2 <B>Antitrust Filings</B>. On a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Program</FONT></FONT>
basis, at the written request of Moderna during the applicable RT Option Period or DT Option Period, each Party will, or will cause their applicable Affiliate(s) to, prepare and file with the U.S. Federal Trade Commission (&#147;<B>FTC</B>&#148;)
and the Antitrust Division of the U.S. Department of Justice (&#147;<B>DOJ</B>&#148;) any HSR Filing required of such Party under the HSR Act and any other filings, notices, applications or other submissions required of such Party under Antitrust
Laws (collectively, &#147;<B>Antitrust Filings</B>&#148;), in each case the necessity of which has been determined in the reasonable opinion of Moderna with respect to the transactions contemplated by a RT License or DT License with respect to such
Program. The Parties will cooperate with one another to the extent necessary in the preparation of any such Antitrust Filings. Each Party will be responsible for its own costs, expenses, and filing fees associated with any Antitrust Filing;
provided, further, that the Parties will equally share all </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
fees (other than penalties that may be incurred as a result of actions or omissions on the part of a Party, which penalties will be the sole financial responsibility of such Party) required to be
paid to any Governmental Authority in connection with making any such Antitrust Filing. In the event that the Parties make any Antitrust Filing(s) under this Section&nbsp;5.24.2 (Antitrust Filings), but (a)&nbsp;FTC or DOJ obtains a preliminary
injunction under the HSR Act against the Parties to enjoin the transactions contemplated by the RT License or the DT License, as applicable, or any other Governmental Authority enjoins the transactions contemplated by the RT License or the DT
License, as applicable, in accordance with Antitrust Laws, or (b)&nbsp;the HSR Clearance Date has not occurred and any other applicable antitrust clearances have not been obtained on or prior to three hundred and sixty-five (365)&nbsp;days after the
beginning of the RT Option Period or the DT Option Period, as applicable, then within thirty (30)&nbsp;days after the earlier to occur of (a)&nbsp;or (b), Moderna may exercise the RT Option or the DT Option, as applicable, again, with respect to a
different RT Target or a different DT Moderna Target, as applicable, and the applicable RT Preclinical Research Program or DT Moderna Research Program will continue. Notwithstanding anything to the contrary contained herein, except for the terms and
conditions of this Section&nbsp;5.24.2 (Antitrust Filings), the RT License or the DT License (including any and all of Moderna&#146;s obligations, including payment obligations, thereunder), will not be effective until the &#147;<B>License Effective
Date</B>,&#148; which is agreed and understood to mean the later of (i)&nbsp;the applicable RT Option Exercise Date or DT Option Exercise Date, or (ii)&nbsp;if a determination is made by Moderna pursuant to this Section&nbsp;5.24.2 (Antitrust
Filings) that any Antitrust Filing(s) is required, the receipt of any such required antitrust clearance(s). As used herein: (1) &#147;<B>HSR Clearance Date</B>&#148; means the earliest date that all applicable waiting periods under the HSR Act with
respect to the transactions contemplated by the applicable RT License or DT License have expired or have been terminated; and (2) &#147;<B>HSR Filing</B>&#148; means a filing by the Parties or their ultimate parent entities as that term is defined
in the HSR Act with the FTC and the DOJ of a Notification and Report Form for Certain Mergers and Acquisitions (as that term is defined in the HSR Act) with respect to the matters under the applicable RT License or DT License together with all
required documentary attachments thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.24.3 <B>Information Exchange</B>. Each Party will, in connection with any Antitrust Filing:
(a)&nbsp;reasonably cooperate with each other in connection with any communication, filing or submission and in connection with any investigation or other inquiry, including any proceeding initiated by a private party; (b)&nbsp;keep the other Party
or its counsel informed of any communication (and if in writing, provide a copy to the other Party or its counsel) received by such Party from or given by such Party to the FTC, the DOJ or any other Governmental Authority or in connection with any
proceeding by a private party, in each case regarding the transactions contemplated by any RT License or DT License; (c)&nbsp;consult with each other in advance of any meeting or conference with the FTC, the DOJ or any other Governmental Authority
or, in connection with any proceeding by a private party, with such private party, and to the extent permitted by the FTC, the DOJ or such other Governmental Authority or such private party, give the Parties or their counsel the opportunity to
attend and participate in such meetings and conferences; and (d)&nbsp;permit the other Party or its counsel to review in advance any submission, filing or communication (and documents submitted therewith) intended to be given by it to the FTC, the
DOJ or any other Governmental Authority, or, in connection with any proceeding by a private party, to such private party; provided, that (i)&nbsp;materials may be redacted to remove references concerning the valuation of the business of Moderna or
any Program, and (ii)&nbsp;neither Party is required to share with the other Party its HSR Filing and the documents produced by such Party in response to Items 4c or 4d of its HSR Filing. The Parties, as each deems advisable and necessary, may
designate any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
competitively sensitive material to be provided to the other under this Section&nbsp;5.24.3 (Information Exchange) as &#147;Antitrust Counsel Only Material&#148;. Such materials and the
information contained therein will be given only to the outside antitrust counsel of the recipient and will not be disclosed by such outside counsel to employees, officers or directors of the recipient unless express permission is obtained in
advance from the source of the materials (Moderna or Metagenomi, as the case may be) or the applicable Party&#146;s legal counsel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.24.4
<B>Assistance</B>. Subject to this Section&nbsp;5.24 (Government Approvals), at the reasonable request of Moderna, the Parties will cooperate and use respectively all reasonable efforts to make all other registrations, filings and applications, to
give all notices and to obtain as soon as practicable all governmental or other consents, transfers, approvals, orders, qualifications, authorizations, permits and waivers, if any, and to do all other things necessary or desirable for the
consummation of the transactions as contemplated by an RT License or DT License in accordance with applicable Antitrust Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.25
<B>Payments</B>. Payments payable under this Article 5 (Licenses; Exclusivity; Manufacture) shall be invoiced by the Party entitled to such payment on a [***] basis to the other Party by delivering an invoice to the other Party within [***] after
the end of each applicable Calendar Quarter for the payment due in connection with such Calendar Quarter. No later than [***] after receipt of any such invoice from such Party, the other Party shall make payment of undisputed invoiced amounts for
such Calendar Quarter. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Article 6 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COLLABORATION ACTIVITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.1 <B>Lead Party</B>. Subject to the remainder of this Article 6 (Collaboration Activities) and Article 2 (Governance And Joint Steering
Committee), with respect to the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program and DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products, the Parties acknowledge and agree that each respective Party will lead the following activities
(the &#147;<B>Lead Party</B>&#148;): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.1.1 <B>Moderna as Lead Party</B>. Moderna shall be the Lead Party for the following in the <FONT
STYLE="white-space:nowrap">Ex-U.S.</FONT> countries: Development (including Clinical Trials), Medical Affairs, Regulatory Filings and Commercialization activities related to DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.1.2 <B>Metagenomi as Lead Party</B>. Metagenomi shall be the Lead Party for Development (including Clinical Trials but subject to
Section&nbsp;2.10.2(a) (Decision-making for DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Plans)), Medical Affairs, Regulatory Filings and Commercialization activities related to DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products solely in
the U.S.; provided that Moderna may appoint [***] of all medical science liaisons in accordance with Section&nbsp;6.6.2 (Performance of Medical Affairs) and fifty percent (50%) of the deployed Sales Force in the U.S. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.2 <B>DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Plans</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.2.1 Promptly after the Effective Date, the Parties shall establish a program to discover, Research, Develop and Commercialize DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Products within the DT Field Directed Against the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Target (the &#147;<B>DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program</B>&#148;). To that end, the
Parties shall jointly propose, as applicable, (i)&nbsp;a research plan and budget (the &#147;<B>DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Research Budget</B>&#148;) detailing principal discovery and Research activities to be undertaken by
both Parties in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
discovery and Research of DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Candidates, which includes the criteria for DC Nomination (the &#147;<B>DT <FONT STYLE="white-space:nowrap">Co-Co</FONT>
Research Plan</B>&#148;); (ii) on a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-DT</FONT></FONT> <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product basis, for
clarity, subsequent to DC Nomination, a Development plan and budget detailing principal Development objectives and the activities to be undertaken by both Parties in the Development of such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product in
the Territory (the &#147;<B>Development Plan</B>&#148;); (iii) on a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product- <FONT STYLE="white-space:nowrap">by-DT</FONT> <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product basis, a written plan
for the specific Medical Affairs activities to be performed by the Parties for such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product in the Territory (the &#147;<B>Medical Affairs Plan</B>&#148;); and (iv)&nbsp;on a DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-DT</FONT></FONT> <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product basis, if applicable, a global Commercialization Plan for
such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product (the &#147;<B>Commercialization Plan</B>&#148;; together with the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Research Plan, the Development Plan(s) and the Medical Affairs Plan(s),
the &#147;<B>DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Plans</B>&#148;). Each DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Plan shall include: (a)&nbsp;the responsibilities of the Parties, and (b)&nbsp;a timeline showing the key
activities and timeframes in which such activities are expected to be completed. The initial DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Research Plan appended in <B>Schedule O </B>(DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Research
Plan) shall be presented by the Parties to the JSC for approval within [***] after the Effective Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.3 <B>DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Product Research Activities</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.3.1 <B>DT <FONT STYLE="white-space:nowrap">Co-Co</FONT>
Research Plan</B>. The initial DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Research Plan shall be reviewed by the JRC and presented to the JSC for approval. Each Party will have the right to propose modifications or amendments to the DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Research Plan, provided that any modifications or amendments to the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Research Plan shall be subject to review by the JRC and approval by the JSC. Each Party
shall use Commercially Reasonable Efforts to perform and complete (itself or through its Affiliates or by permitted subcontracting) its obligations under the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Research Plan. Neither Party shall be
required to perform any work which is not contemplated by the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Research Plan, unless such additional work is reflected in a mutually agreed amendment to the DT
<FONT STYLE="white-space:nowrap">Co-Co</FONT> Research Plan. Without limiting the JRC&#146;s rights to review and discuss and the JSC&#146;s rights to approve the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Research Plan and update thereto, the
Party to whom a particular Research activity is allocated under the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Research Plan shall have the right, without seeking JRC review or JSC approval, to make operational decisions with respect to the
performance of such Research activity to the extent consistent with the then-current DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Research Plan. Without limiting the generality of the foregoing, each Party shall use Commercially Reasonable
Efforts to reach a DC Nomination during the Initial DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Research Term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If there is no DC Nomination by the
end of the Initial DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Research Term, the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program will expire at the end of the Initial DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Research Term,
regardless of whether Moderna has exercised its <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Right with respect to such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program prior to the end of the Initial DT
<FONT STYLE="white-space:nowrap">Co-Co</FONT> Research Term, unless the Parties have expressed their mutual wish to continue with the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program and negotiated and agreed on whether to revise the DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Research Plan, in each case prior to the end of the Initial DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Research Term. After the expiration of the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program,
neither Party shall use, nor allow or enable any others to use, any Program Technology specific to the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Target in such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program in the DT Field for
[***], provided that the foregoing shall not apply to Moderna in the event it has exercised its <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Right prior to the expiration of the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.3.2 <B>Eligible <FONT STYLE="white-space:nowrap">Co-Co</FONT> Research Costs</B>. Subject
to the last sentence of Section&nbsp;7.3 (Research Funding), the Parties shall share [***] the Eligible <FONT STYLE="white-space:nowrap">Co-Co</FONT> Research Costs of all Research activities incurred by or on behalf of either Party that are set
forth in the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Research Budget; provided that to the extent that any Research Budget Overspend is not an Allowable Overrun, within [***] after the end of the appliable Calendar Quarter, the JSC shall
determine if such Overspend was caused by circumstances within the relevant Party&#146;s reasonable control, then, unless otherwise approved by the JSC, such Party shall be solely responsible for such Overspend (and the other Party shall not be
responsible for any portion of such Overspend), and if the JSC determines that such Overspend was caused by circumstances outside of the relevant Party&#146;s reasonable control or is otherwise approved by the JSC, then each Party shall be
responsible for [***] of the Overspend. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.4 <B>DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product Development Activities</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.4.1 <B>Overview</B>. The Lead Party shall lead the conduct of each standalone Clinical Trial in its respective Region with respect to the DT
<FONT STYLE="white-space:nowrap">Co-Co</FONT> Products in the Territory. In the case of international multi-site Clinical Trials involving at least one site in each of the U.S. and at least one country
<FONT STYLE="white-space:nowrap">Ex-U.S.,</FONT> the Parties will discuss and agree which Party would lead the conduct for such Clinical Trial taking into consideration the capabilities of each Party to operationally lead such Clinical Trial. Except
as expressly set forth otherwise in the Development Plan, Moderna shall be responsible for all CMC Matters and Manufacturing related to the clinical supply of DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products. Notwithstanding anything to the
contrary in this Agreement, the Parties may elect to conduct Development activities jointly and allocate specific operational activities in accordance with the Development Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.4.2 <B>Diligence</B>. Moderna and Metagenomi shall each use Commercially Reasonable Efforts to perform all obligations allocated to such
Party under each Development Plan for each DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product in the Territory. The applicable Development Plan shall specify which Party shall lead the conduct of each Clinical Trial set forth in the applicable
Development Plan and all Clinical Trials and Development activities shall be conducted as set forth in the Development Plan for each DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product in the Territory. Subject to Section&nbsp;6.4.7 (New
Development) and Section&nbsp;6.4.8 (Combination Products), the Parties shall not perform any Development activities in the Territory for any formulation, Indication, or Combination Product with respect to any DT
<FONT STYLE="white-space:nowrap">Co-Co</FONT> Product other than those formulations, Indications, or Combination Products set forth in the applicable Development Plan in accordance with this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.4.3 <B>Development Plans</B>. The initial Development Plan, which will set forth in reasonable detail the anticipated Development activities
for the applicable DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products in the Territory and the corresponding Development Budget, shall be reviewed by the JDC and presented to the JSC for approval. Subject to comments and proposed changes by
the other Party, each Party will be responsible for the Development Plan for such Party&#146;s respective Region. The development plans for each Region will be incorporated into the overall Development Plan. On at least a [***] basis during the Term
(or more frequently as may be required), the JDC shall review and update each Development Plan and corresponding Development Budget based on the currently available information and data, including to add (a)&nbsp;any New Collaboration Development
Activities that have not yet been included in the Development Plan and Development Budget for a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product, including the proposed timelines and budget for such New Collaboration Development Activities
set forth in the applicable New Development Proposal approved by JDC (as may be amended by the JDC), or (b)&nbsp;any applicable new formulations or Indications pursuant </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to Section&nbsp;6.4.7(a) (New Development Activities) or new Combination Products proposed by the JDC in accordance with Section&nbsp;6.4.8 (Combination Products). The JDC shall review, discuss,
and determine whether to present any such update to any Development Plan or Development Budget for approval by the JSC. Each such update to a Development Plan and corresponding Development Budget shall become effective and shall supersede the
previous Development Plan and corresponding Development Budget upon approval thereof by the JSC. Notwithstanding any provision to the contrary set forth in this Agreement, if either Party proposes to include Development activities for a DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Product for a particular formulation or Indication in the applicable Development Plan because those Development activities are required or requested by a Regulatory Authority in the Territory, then the JSC
shall approve the inclusion of such Development activities in the applicable Development Plan (and corresponding Development Budget). Without limiting the JDC&#146;s rights to review and discuss and the JSC&#146;s rights to approve each Development
Plan and update thereto, the Party to whom a particular Development activity is allocated under the Development Plan shall have the right, without seeking JDC review or JSC approval, to make operational decisions with respect to the performance of
such Development activity to the extent consistent with the then-current Development Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.4.4 <B>Development Cost Sharing</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <B>Eligible Development Costs</B>. The Parties shall [***] the Eligible Development Costs of all Development activities for DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Products in the Territory incurred by or on behalf of either Party that are set forth in the Development Budget; provided that to the extent that any Development Budget Overspend is not an Allowable Overrun,
within [***] after the end of the appliable Calendar Quarter, the JSC shall determine if such Overspend was caused by circumstances within the relevant Party&#146;s reasonable control, then, unless otherwise approved by the JSC, such Party shall be
solely responsible for such Overspend (and the other Party shall not be responsible for any portion of such Overspend), and if the JSC determines that such Overspend was caused by circumstances outside of the relevant Party&#146;s reasonable control
or is otherwise approved by the JSC, then each Party shall be responsible for [***] of the Overspend. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <B>Quarterly Reconciliation of
Development Costs for DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products</B>. With respect to each DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product, no later than [***] after the end of each Calendar Quarter, each Party shall deliver
to the other Party a written report of the Eligible Development Costs incurred by or on behalf of such Party in connection with the performance of Development activities during such Calendar Quarter (for Moderna, the &#147;<B>Moderna Development
Cost Share Notice</B>&#148; and for Metagenomi, the &#147;<B>Metagenomi Development Cost Share Notice</B>&#148;). For each Calendar Quarter: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(i) If the actual amount set forth in the Metagenomi Development Cost Share Notice exceeds the actual amount set forth in the Moderna
Development Cost Share Notice, then no later than [***] after Moderna&#146;s receipt of the Metagenomi Development Cost Share Notice for such Calendar Quarter, Moderna shall pay to Metagenomi [***] of the difference between the actual amount set
forth in the Metagenomi Development Cost Share Notice and the actual amount set forth in the Moderna Development Cost Share Notice for such Calendar Quarter, such that each Party bears [***] of the aggregate Eligible Development Costs incurred by or
on behalf of the Parties during such Calendar Quarter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(ii) If the actual amount set forth in the Moderna Development Cost Share Notice exceeds
the actual amount set forth in the Metagenomi Development Cost Share Notice, then no later than [***] after Metagenomi&#146;s receipt of the Moderna Development Cost Share Notice for such Calendar Quarter, Metagenomi shall pay to Moderna [***] of
the difference between the actual amount set forth in the Moderna Development Cost Share Notice and the actual amount set forth in the Metagenomi Development Cost Share Notice for such Calendar Quarter, such that each Party bears [***] of the
aggregate Eligible Development Costs incurred by or on behalf of the Parties during such Calendar Quarter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.4.5 <B>Development
Reports</B>. At each JDC meeting, (a)&nbsp;Moderna and Metagenomi shall each provide the JDC with a written report summarizing the Development activities for the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products conducted by or on behalf of
each Party since the last JDC meeting, including (i)&nbsp;patient enrollment and the ongoing status of all Clinical Trials, in each case, under any Development Plan and (ii)&nbsp;the status of each pending and proposed Regulatory Filing set forth in
the Development Plan for each DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product in the Territory, to the extent not already provided, and without limiting the obligations under Section&nbsp;6.5 (Regulatory Affairs), (b) Metagenomi shall
provide the JDC a summary of the progress and results of Metagenomi Development activities for the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product, and (c)&nbsp;Moderna shall provide the JDC a summary of the progress and results of Moderna
Development activities for the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product. Each Party shall also promptly provide written notice to the other Party, through the JDC or Alliance Managers, of any significant Development events in the
Territory (<I>e.g.</I>, Clinical Trial initiation or completion, clinical holds, and Regulatory Approvals) that the reporting Party reasonably believes is of interest to the other Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.4.6 <B>Assumed Development Activities</B>. If either Party has defaulted on its obligations to perform one or more Development activities
allocated to such Party under a Development Plan in a manner that delays the performance of such matters for a period of more than [***] beyond the timeline set forth in such Development Plan, then the other Party shall provide such defaulting Party
with written notice regarding such failure to perform, and upon receipt of such notice the defaulting Party shall have a [***] period to commence the performance of such Development activities in accordance with the terms hereof and the applicable
Development Plan (the &#147;<B>Development Activities Cure Period</B>&#148;), in any case subject to Section&nbsp;6.5.1(c) (CMC Matters). If (a)&nbsp;the defaulting Party has not commenced performance of such Development activities during the
applicable Development Activities Cure Period, (b)&nbsp;the defaulting Party notifies the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Party in writing that the defaulting Party anticipates that it shall be unable to perform such
Development activities, or (c)&nbsp;the defaulting Party does not perform such Development activities in accordance with the applicable Development Plan or otherwise in accordance with this Section&nbsp;6.4 (DT
<FONT STYLE="white-space:nowrap">Co-Co</FONT> Product Development Activities), within a reasonable period of time in accordance with the terms hereof, then, in each case ((a)-(c)), the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Party
may, upon written notice to the defaulting Party, assume those Development activities that are the subject of such default by the defaulting Party (the &#147;<B>Assumed Development Activities</B>&#148;). In connection with the defaulting
Party&#146;s failure to perform such activities or default of such obligations and the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Party&#146;s assumption thereof: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) the defaulting Party shall work collaboratively and in good faith with the <FONT
STYLE="white-space:nowrap">non-defaulting</FONT> Party, and make its personnel reasonably available to the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Party, in each case, in order to (a)&nbsp;transfer of any applicable technology,
materials, or contracts with subcontractors to the other Party that are necessary or reasonably useful for the performance of the applicable Assumed Development Activities, and (b)&nbsp;provide such other assistance so as to enable the <FONT
STYLE="white-space:nowrap">non-defaulting</FONT> Party to assume performance of the applicable Assumed Development Activities; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) the <FONT
STYLE="white-space:nowrap">non-defaulting</FONT> Party shall thereafter have the right to make operational decisions with respect to the performance of such Assumed Development Activities to the extent consistent with the then-current Development
Plan; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) the JDC shall update the applicable Development Plan to allocate performance of the Assumed Development Activities to the <FONT
STYLE="white-space:nowrap">non-defaulting</FONT> Party; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) for the avoidance of doubt, Eligible Development Costs incurred in
connection with the performance of Assumed Development Activities shall be shared [***] by the Parties as set forth in Section&nbsp;6.4.4(a) (Eligible Development Costs). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.4.7 <B>New Development</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <B>New Development Activities</B>. If either Party proposes to Develop in the Territory, (a)&nbsp;a new formulation of any DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Product or (b)&nbsp;any DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product for a new Indication (including any different patient population or line of therapy, which shall be deemed to be a different
Indication for purposes of this Section&nbsp;6.4.7 (New Development)), in each case ((a) and (b)), other than the formulations and Indications set forth in the applicable Development Plan for such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT>
Product ((a) and (b), &#147;<B>New Development</B>&#148;), then the proposing Party shall present to the JDC, to review and discuss, a proposal to add such New Development to the Development Plan, for the applicable DT
<FONT STYLE="white-space:nowrap">Co-Co</FONT> Product, including the countries in which such activities would be conducted and the allocation of performance of such activities between the Parties (a &#147;<B>New Development Proposal</B>&#148;). Each
New Development Proposal shall describe in reasonable detail the applicable <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies, and Clinical Trials, in each case, that the
proposing Party desires to conduct as part of such New Development, including a synopsis of the trial or activities, the proposed enrollment criteria, the number of patients to be included, the endpoints to be measured, and the statistical design
and powering (the &#147;<B>New Development Activities</B>&#148;), as well as a proposed timeline and budget and an analysis of the business opportunity and revenue potential for such New Development Activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <B>JDC and JSC Decision Regarding New Development Activities</B>. No later than sixty (60)&nbsp;days after receipt thereof from the
proposing Party, the JDC shall review, discuss, and determine whether to present to the JSC for approval, each New Development Proposal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) If the JSC approves a New Development Proposal, upon such an approval, then: (i)&nbsp;the New Development Activities set forth in such
New Development Proposal shall be deemed &#147;<B>New Collaboration Development Activities</B>&#148; for purposes of this Agreement and (ii)&nbsp;the JDC shall update the Development Plan for such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT>
Product to include such New Collaboration Development Activities for those countries agreed by the JSC, including the proposed timelines and budget, in each case, for such New Development Activities set forth in such New Development Proposal (as may
be amended by the JDC and approved by the JSC). Any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
New Development Activities included in a Development Plan pursuant to this Section&nbsp;6.4.7 (New Development) shall be deemed to be Development activities for all purposes under this
Section&nbsp;6.4 (DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product Development Activities). If the JSC does not approve a New Development Proposal, then the New Development Activities proposed in the New Development Proposal shall not be
included in any Development Plan, and the proposing Party shall not conduct such New Development Activities in the Territory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.4.8
<B>Combination Products</B>. [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.4.9 <B>Standards of Conduct; Development Records</B>. Moderna and Metagenomi shall perform, and
each shall ensure that their Affiliates and licensees and permitted sublicensees (as applicable), and subcontractors perform, all Development activities under each Development Plan, as the case may be, in a good scientific manner, in accordance with
GLP, GMP, and GCP, as applicable, and in compliance with Applicable Laws. Each Party and its Affiliates shall maintain written or electronic records, in sufficient detail, in a good scientific manner (in accordance with GLP, GCP, and GMP, as
applicable), and appropriate for regulatory and patent purposes, and that are complete and accurate in all material respects and reflect all Development work performed and results achieved, in each case, by or on behalf of such Party and its
Affiliates under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.4.10 <B>Access to Data</B>. In addition to its adverse event and safety data reporting obligations set
forth in Section&nbsp;6.5.7 (Pharmacovigilance and Adverse Event Reporting), each Party shall promptly provide the other Party with copies of all data and results and all supporting documentation (<I>e.g.</I>, protocols, Investigator&#146;s
Brochures, case report forms, analysis plans) Controlled by such Party that are generated by or on behalf of such Party or its Affiliates, sublicensees, or subcontractors, if applicable, in the Development of each DT
<FONT STYLE="white-space:nowrap">Co-Co</FONT> Product, to the extent necessary or reasonably useful for the performance of the other Party&#146;s Development activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.5 <B>Regulatory Affairs</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.5.1 <B>Regulatory Responsibilities</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <B>Territory</B>. Pursuant to the Development Plan, the Parties shall collaborate on a regulatory strategy for DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Products in the Territory, subject to Section&nbsp;6.5.1(c) (CMC Matters). The JDC shall review and discuss, the overall strategy for obtaining, supporting, and maintaining Regulatory Approval of each DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Product in the Territory (which strategy shall be reflected in each Development Plan) and the JDC shall oversee the implementation of and discuss the progress regarding the same. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <B>Regulatory Responsibilities</B>. Subject to [***] and on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Region-by-Region</FONT></FONT> basis, the Regulatory Responsible Party shall lead all regulatory matters relating to the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products in
accordance with the Development Plan. The Regulatory Responsible Party may file for in its name, and shall own, all Regulatory Documentations with respect to each DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product in the applicable country in
the Region. Subject to this Section&nbsp;6.5 (Regulatory Affairs) and on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Region-by-Region</FONT></FONT> basis, the Regulatory Responsible Party shall have the sole right to
(a)&nbsp;oversee, monitor, and coordinate all regulatory actions, communications and filings with, and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
submissions to, each Regulatory Authority in the Region with respect to each DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product; (b)&nbsp;interface, correspond, and meet with each
Regulatory Authority in the Region with respect to each DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product; and (c)&nbsp;seek and maintain all Regulatory Approvals in the Region with respect to each DT
<FONT STYLE="white-space:nowrap">Co-Co</FONT> Product. In addition, notwithstanding any provision to the contrary set forth in this Agreement, the Regulatory Responsible Party shall (i)&nbsp;not be required to delay any actions, communications, or
filings with, or submissions to any Regulatory Authorities in the Region in a manner that affects such Regulatory Responsible Party&#146;s ability to comply with any Regulatory Authority requirement or deadline or Applicable Laws in the Territory or
that would delay receipt of Regulatory Approval for a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product in the Territory and (ii)&nbsp;have final say on the content of all Regulatory Filings (including Material Communications) with Regulatory
Authorities in the Region. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) <B>CMC Matters</B>. Notwithstanding anything to the contrary in this Agreement: (i)&nbsp;Moderna shall be
solely responsible for all CMC Matters under this Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(i) Moderna is not required to disclose to Metagenomi or any of its
Affiliates any CMC Matters or any information related to the design of mRNA Constructs (including any applicable bioinformatics technology); and (iii)&nbsp;unless authorized in writing by Moderna, Metagenomi or its Affiliates shall not have the
right to access, review, use, copy, distribute or retain any Moderna&#146;s Confidential Information related to CMC Matters or the design of mRNA Constructs (including any applicable bioinformatics technology). In the event Metagenomi or any of its
Affiliates receive any knowledge or information regarding CMC Matters or the design of mRNA Constructs related to this Agreement from a Regulatory Authority or another Third Party, Metagenomi or its Affiliates shall immediately convey such knowledge
or information directly to Moderna and promptly and properly delete or destroy all records and documentation regarding any such CMC Matters or mRNA Construct design in its possession, or return them to Moderna, in each case as instructed by Moderna
in writing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) <B>Cooperation and Coordination</B>. At the Regulatory Responsible Party&#146;s request, the other Party shall
diligently cooperate with the Regulatory Responsible Party in connection with any Regulatory Filings and other regulatory compliance related activities with respect to the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products, including
harmonization of any Regulatory Documentation and Regulatory Filings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.5.2 <B>Communications with Regulatory Authorities</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <B>Prompt Disclosures</B>. Subject to Section&nbsp;6.5.1(c) (CMC Matters), each Party shall inform the other Party within [***], or such
shorter time as is necessary to comply with the reporting requirements of any applicable Regulatory Authority or under Applicable Laws, of notification of any action by, or notification or other information that it receives (directly or indirectly)
from any Regulatory Authority in the Territory to the extent such information: (a)&nbsp;raises any material concerns regarding the safety or efficacy of a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product; (b)&nbsp;indicates or suggests a
potential material liability of either Party to Third Parties in connection with a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product; (c)&nbsp;is reasonably likely to lead to a clinical hold, recall, market withdrawal, or field alert with
respect to a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product; or (d)&nbsp;relates to expedited and periodic reports of adverse events with respect to a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product, or DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Product complaints, and may have an adverse impact on the receipt or maintenance of Regulatory Approval or the continued </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Commercialization of a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product. The Parties shall reasonably cooperate with and assist each other in complying with regulatory obligations and
communications, including by providing to the applicable Regulatory Responsible Party, within two (2)&nbsp;Business Days after a request, such information and documentation that is in the other Party&#146;s possession as may be necessary or helpful
for such Regulatory Responsible Party to prepare a response to an inquiry from a Regulatory Authority in the Territory with respect to a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product. Each Party shall also promptly provide the other Party
with a copy of all correspondence received from a Regulatory Authority in the Territory specifically regarding the matters referred to above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <B>Other Material Communications</B>. To the extent not provided pursuant to Section&nbsp;6.5.2(a) (Prompt Disclosures), subject to
Section&nbsp;6.5.1(c) (CMC Matters), and on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Region-by-Region</FONT></FONT> basis, the Regulatory Responsible Party shall provide the JDC for its review and discussion a brief
description in English of the principal issues raised in each Material Communication with Regulatory Authorities with respect to any DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product in the Region promptly after receipt thereof, but in any
event within fifteen (15)&nbsp;Business Days after receipt thereof. The Regulatory Responsible Party shall allow the other Party a reasonable opportunity to review and comment on the Regulatory Responsible Party&#146;s proposed response to any
Material Communications with any Regulatory Authority in the Region with respect to any DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product in advance of the transmission of such response, and the Regulatory Responsible Party shall reasonably
consider all comments timely provided by the other Party in connection therewith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) <B>Other Disclosures</B>. In addition to its
obligations under this Agreement, each Party shall promptly disclose to the other Party the following regulatory information, subject to Section&nbsp;6.5.1(c) (CMC Matters): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(i) <B>Regulatory Actions</B>. All material information Controlled by such Party pertaining to actions taken by Regulatory Authorities
related to a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product in the Territory, including any notice, audit notice, notice of initiation by Regulatory Authorities of investigations, inspections, detentions, seizures, or injunctions
concerning a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product in the Territory, notice of violation letter (<I>i.e.</I>, an untitled letter), warning letter, service of process, or other inquiry; provided that a Party shall be entitled to
redact those portions thereof to the extent not related to a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(ii)
<B>Regulatory <FONT STYLE="white-space:nowrap">Non-Compliance</FONT></B>. All information Controlled by such Party pertaining to notices from Regulatory Authorities in the Territory of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with
Applicable Laws in connection with a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product, including receipt of a warning letter or other notice of alleged material <FONT STYLE="white-space:nowrap">non-compliance</FONT> from any Regulatory
Authority relating to a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product; provided that a Party shall be entitled to redact those portions thereof to the extent not related to a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.5.3 <B>Regulatory Meetings</B>. The Regulatory Responsible Party shall provide the other Party with reasonable advance notice of all
substantive meetings with the Regulatory Authorities in the applicable Region pertaining to the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product, or with as much advance notice as practicable under the circumstances. Upon the other
Party&#146;s request, the Regulatory Responsible Party shall include the other Party in the preparation and strategy for such substantive meeting and in any discussions and actions relating to the outcome thereof. Notwithstanding any provision to
the contrary set forth in this Section&nbsp;6.5.3 (Regulatory Meetings), (a) if required by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the applicable Regulatory Authority at any meeting with such Regulatory Authority, then attendance by the other Party shall be permitted; (b)&nbsp;attendance by the representatives of the other
Party shall not prevent participation of a representative of the Regulatory Responsible Party for the applicable DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product due to restrictions imposed by Regulatory Authorities on the number of
attendees; and (c)&nbsp;the Regulatory Responsible Party for the applicable DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product shall not be obligated to change the schedule of such meeting in order to accommodate the schedule of the other
Party&#146;s representatives. The <FONT STYLE="white-space:nowrap">non-Regulatory</FONT> Responsible Party shall strictly follow the applicable Regulatory Responsible Party&#146;s instructions with respect to any such meeting that it attends, and
shall not discuss the contents of any such meeting with any Third Party or Regulatory Authority except as required by Applicable Laws or authorized by the Regulatory Responsible Party in writing. If either Party requires an interpreter or other
translation services in connection with its participation in any such meeting with Regulatory Authorities, then the requiring Party shall be responsible for the costs of such translation services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.5.4 <B>Regulatory Filings</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <B>Regulatory Filings</B>. Subject to Section&nbsp;6.5.1(c) (CMC Matters), the Regulatory Responsible Party for each Region shall provide
the other Party with a copy of all proposed Regulatory Filings to be filed with or submitted to any Regulatory Authority in the Region for the applicable DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product for the other Party&#146;s review and
comment sufficiently in advance of, but in any event, unless not practicable, at least [***] prior to, the Regulatory Responsible Party&#146;s filing or submission thereof, and the Regulatory Responsible Party for the Region shall reasonably
consider incorporating any reasonable comments received from the other Party into such Regulatory Filings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <B>Other Submissions</B>.
In addition, the Regulatory Responsible Party for each Region shall provide the other Party with written notice of each of the following events with regard to each applicable DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product throughout the
Region (to the extent not already provided pursuant to Section&nbsp;6.5.4(a) (Regulatory Filings)), subject to Section&nbsp;6.5.1(c) (CMC Matters): within a reasonable period of time, but in any event, unless not practicable, at least [***],
following the occurrence thereof (a)&nbsp;the submission of any applications for Regulatory Approval of such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product to any Regulatory Authority in the Region, and (b)&nbsp;receipt of or denial of
Regulatory Approval for such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product (or inquiries from the applicable Regulatory Authority related to the Regulatory Approval process); provided that the Regulatory Responsible Party shall inform the
other Party of any such event under (a)&nbsp;or (b) prior to public disclosure of such event by the other Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) <B>CMC Filings</B>.
Notwithstanding anything to the contrary in this Section&nbsp;6.5 (Regulatory Affairs), Moderna shall be responsible for all <FONT STYLE="white-space:nowrap">CMC-related</FONT> components of all Regulatory Filings for the DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Products in the Territory. If not previously prepared and filed, Moderna will, at Metagenomi&#146;s written request, prepare and file with the FDA a DMF containing required CMC information for DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Products in the U.S. Metagenomi and its Affiliates may refer to such DMF in any Regulatory Filing made in connection with obtaining or maintaining a Regulatory Approval for applicable DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Product in the U.S. [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.5.5 <B>Costs of Regulatory Affairs</B>. [***]. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.5.6 <B>Right of Reference</B>. Subject to the rules of the relevant Regulatory Authority
and the terms of this Agreement, each Party hereby grants to the other Party a &#147;Right of Reference,&#148; as that term is defined in 21 C.F.R. &#167; 314.3(b) (or any successor rule or analogous Applicable Laws recognized outside of the U.S.)
to, and a right to copy, access, and otherwise use, all information and data relating to the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products in any Regulatory Filings or Regulatory Approval Controlled by such Party during the Term, solely
for the other Party&#146;s or its Affiliates&#146; use in the Development and Commercialization of the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products in their respective Region during the Term in accordance with this Agreement. All such
information and data contained in any such Regulatory Filings or Regulatory Approvals shall be considered Confidential Information of such Party and subject to the terms of Article 11 (Confidentiality). If requested by the other Party, such Party
shall provide a signed statement to this effect in accordance with 21 C.F.R. &#167; 314.50(g)(3) (or any successor rule or analogous Applicable Laws outside of the U.S.) to give effect to the intent of this Section&nbsp;6.5.6 (Right of Reference).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.5.7 <B>Pharmacovigilance and Adverse Event Reporting</B>. The Parties shall cooperate with regard to the reporting and handling of
safety information involving the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products in accordance with the Applicable Laws, regulatory requirements, and regulations on pharmacovigilance and clinical safety. The Regulatory Responsible Party
for a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product in a given Region shall be responsible for all processing of information related to any adverse events for such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product for the Region.
Each Party shall provide to the other Party the relevant safety information it receives (either directly or indirectly) related to a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product within such time to ensure that all regulatory requirements
and timelines are met in the respective territories. The Parties shall negotiate in good faith and enter into a Pharmacovigilance Agreement, which shall define the pharmacovigilance responsibilities of the Parties and include safety data exchange
procedures governing the exchange of information affecting the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products (<I>e</I>.<I>g</I>., Serious Adverse Events, emerging safety issues) to enable each Party to comply with all of its legal and
regulatory obligations related to such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products (the &#147;<B>Pharmacovigilance Agreement</B>&#148;). Moderna shall own and maintain the global safety database for all DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Products provided that the Pharmacovigilance Agreement shall provide Metagenomi access to such database and real time notifications and reporting of adverse events, as needed for pharmacovigilance obligations.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.5.8 <B>Recalls, Withdrawal, or Field Alert of a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <B>Notification and Determination</B>. In the event that any Governmental Authority threatens in writing or initiates any action to
remove a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product from the market (in whole or in part) in the Territory, the Party receiving notice thereof shall notify the other Party of such communication immediately, but in no event later than
two Business Days after receipt thereof. Notwithstanding the foregoing, in all cases the Regulatory Responsible Party for a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product in a Region shall determine whether to initiate any recall,
withdrawal, or field alert of such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product in the applicable Region, including the scope of such recall or withdrawal (<I>e.g.</I>, a full or partial recall, or a temporary or permanent recall) or
field alert. Before the Regulatory Responsible Party initiates a recall, withdrawal, or field alert for a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product in a Region, as applicable, the Parties shall use reasonable efforts to promptly meet
and discuss in good faith the reasons therefor, provided that such discussions shall not delay any action that such Regulatory Responsible Party reasonably believes should be taken in relation to any actual or potential recall, withdrawal, or field
alert. In the event of any such recall, withdrawal, or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
field alert, the Regulatory Responsible Party for the applicable Region shall determine the necessary actions to be taken and shall implement such action. Without limiting the foregoing, either
Party shall have the right to propose that a recall, withdrawal, or field alert for a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product should be initiated by such Party, but the Regulatory Responsible Party for the applicable Region shall
have the right to make the final decision as to whether or not to initiate the recall, withdrawal, or field alert. Notwithstanding the foregoing, if a recall, withdrawal, or field alert is reasonably necessary due to a Manufacturing issue related to
a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product, Moderna shall promptly notify Metagenomi of such issue and provide relevant information on such Manufacturing issue. Upon written request by Moderna for such recall, withdrawal, or field
alert, such request to include the scope of the recall or withdrawal, as applicable, Metagenomi (if Metagenomi is the Regulatory Responsible Party for the applicable Region), shall initiate such recall, withdrawal, or field alert in accordance with
Moderna&#146;s request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <B>Cost Allocation</B>. [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.6 <B>Medical Affairs</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.6.1 <B>Medical Affairs Plans</B>. No later than [***] before the submission of the first Regulatory Filing seeking the first Regulatory
Approval for a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product, the Medical Affairs Working Group shall prepare and submit to the JDC a Medical Affairs Plan for such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product in the Territory
for the following [***], including the corresponding Medical Affairs Budget. The Medical Affairs Plan shall contain a [***] rolling annual plan for the Medical Affairs activities for the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product in
the Territory. Subject to comments and proposed changes by the other Party, each Party will be responsible for the Medical Affairs Plan for its respective Region. The Medical Affairs Plans for each Region will be incorporated into the overall
Medical Affairs Plan. The JDC shall prepare, review, discuss and determine whether to present each Medical Affairs Plan and Medical Affairs Budget, including the allocation of activities between the Parties set forth therein, to the JSC for
approval. On an annual basis during the Term (or more frequently as may be required), the JDC shall review and update, or have a Party review and update, each Medical Affairs Plan and Medical Affairs Budget based on the currently available
information and data, including for any applicable new formulations or Indications that that were added to a Development Plan pursuant to Section&nbsp;6.4.7(b) (JDC and JSC Decision Regarding New Development Activities) or new Combination Products
approved by the JSC in accordance with Section&nbsp;6.4.8 (Combination Products), in each case, that are not included in the then-current Medical Affairs Plan for the applicable DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product. The JDC shall
review and discuss and determine whether to present any such update to the Medical Affairs Plans and Medical Affairs Budgets to the JSC for approval. Each such update to a Medical Affairs Plan and corresponding Medical Affairs Budget shall become
effective and shall supersede the previous Medical Affairs Plan and corresponding Medical Affairs Budget upon approval thereof by the JSC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.6.2 <B>Performance of Medical Affairs</B>. The Lead Party shall lead the performance of Medical Affairs activities in its respective Region
for each DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product, and, without seeking JDC review or approval, shall have the right to make operational decisions with respect to the performance of such Medical Affairs activities to the extent
consistent with the then-current Medical Affairs Plan provided that Moderna may appoint up to [***] of all medical science liaisons for the U.S. Notwithstanding anything to the contrary herein, the Parties may elect to conduct Medical Affairs
activities jointly and allocate specific operational activities in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
accordance with the Medical Affairs Plan. If a particular Medical Affairs activity is allocated to both Parties to perform jointly under a Medical Affairs Plan, then both Parties shall conduct
such activity in collaboration with each other as directed by the JDC. Each Party shall use reasonable efforts in the Territory to cobrand all sponsorships, booths, and similar activities in accordance with branding terms set forth in the applicable
Commercialization Plan and to the extent the same are solely related to the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products and such cobranding is permitted under Applicable Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.6.3 <B>Medical Affairs Costs</B>. [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.6.4 <B>Assumed Medical Affairs Activities</B>. If either Party has defaulted on its obligations to perform one or more Medical Affairs
activities allocated to such Party under a Medical Affairs Plan in a manner that delays the performance of such matters for a period of more than [***] beyond the timeline set forth in such Medical Affairs Plan, then the other Party shall provide
such defaulting Party with written notice regarding such failure to perform, and upon receipt of such notice the defaulting Party shall have a [***] period to commence the performance of such Medical Affairs activities in accordance with the terms
hereof and the applicable Medical Affairs Plan (the &#147;<B>Medical Affairs Activities Cure Period</B>&#148;). If (i)&nbsp;the defaulting Party has not commenced performance of such Medical Affairs activities during the applicable Medical Affairs
Activities Cure Period, (ii)&nbsp;the defaulting Party notifies the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Party in writing that the defaulting Party anticipates that it shall be unable to perform such Medical Affairs activities, or
(iii)&nbsp;the defaulting Party does not perform such Medical Affairs activities in accordance with the applicable Medical Affairs Plan or otherwise in accordance with this Section&nbsp;6.6 (Medical Affairs), within a reasonable period of time in
accordance with the terms hereof, then, in each case ((i)-(iii)), the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Party may, upon written notice to the defaulting Party, assume those Medical Affairs activities that are the subject of such
default by the defaulting Party (the &#147;<B>Assumed Medical Affairs Activities</B>&#148;). In connection with the defaulting Party&#146;s failure to perform such activities or default of such obligations and the
<FONT STYLE="white-space:nowrap">non-defaulting</FONT> Party&#146;s assumption thereof: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) the defaulting Party shall work
collaboratively and in good faith with the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Party, and make its personnel reasonably available to the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Party, in each case, in order to
(i)&nbsp;transfer of any applicable technology, materials, or contracts with subcontractors to the other Party that are necessary or reasonably useful for the performance of the applicable Assumed Medical Affairs Activities, and (ii)&nbsp;provide
such other assistance so as to enable the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Party to assume performance of the applicable Assumed Medical Affairs Activities; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Party shall thereafter have the right to make operational decisions with
respect to the performance of such Assumed Medical Affairs Activities to the extent consistent with the then-current Medical Affairs Plan; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) the JDC shall update the applicable Medical Affairs Plan to allocate performance of the Assumed Medical Affairs Activities to the <FONT
STYLE="white-space:nowrap">non-defaulting</FONT> Party; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) for the avoidance of doubt, Eligible Medical Affairs Costs incurred in
connection with the performance of Assumed Medical Affairs Activities shall [***]. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.6.5 <B>Medical Affairs Updates</B>. At each meeting of the JDC, each Party shall provide
to the applicable JDC a summary of the Medical Affairs activities performed by such Party for the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products in the Territory during the period since the last JDC meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.6.6 <B>Standards of Conduct; Compliance</B>. Each Party shall perform, or shall ensure that each of its Affiliates, sublicensees, and
subcontractors perform, all Medical Affairs activities in a professional and ethical business manner and in compliance with Applicable Laws, the Approved Labeling, and any applicable Medical Affairs Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.7 <B>Commercialization</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.7.1 <B>Commercialization Plan</B>. No later than [***] prior to the anticipated First Commercial Sale of a DT
<FONT STYLE="white-space:nowrap">Co-Co</FONT> Product in the Territory, Moderna and Metagenomi shall prepare and submit to the JCC, an initial Commercialization Plan for such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product, which will set
forth a reasonably detailed description of anticipated Commercialization activities for the applicable DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products in the Territory, including the corresponding Commercialization Budget. The
Commercialization Plan shall also contain a [***] rolling annual plan for the global Commercialization activities for the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product in the Territory and the Commercialization Budget shall include a
[***] financial forecast reflecting reasonably anticipated Commercialization Costs in accordance with the Commercialization Plan. Subject to comments and proposed changes by the other Party, each Party will be responsible for the Commercialization
Plan for its respective Region. The Commercialization Plans for each Region will be incorporated into the overall Commercialization Plan. The Commercialization Plan may discuss certain matters on an <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Indication-by-Indication</FONT></FONT> basis and shall address (to the extent applicable given the stage of Commercialization and estimated anticipated First Commercial Sale)&nbsp;(a) the Product Marks, global usage
guidelines for the Product Marks, global key positioning, and messaging strategy for such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product in such Indication, and guidelines for the Product Materials prepared in accordance with
Section&nbsp;6.7.9 (Product Materials) and (b)&nbsp;the general pricing and market access strategy (including discounts, rebates and other price reductions) globally and for each DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product for such
Indication in each country in the Territory. The JCC shall prepare, review, and discuss, and the JSC shall review, discuss, and determine whether to approve, each Commercialization Plan for a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product.
Moderna shall have the sole right to select the Product Marks for each DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product to be used in Moderna&#146;s Region and included in the applicable Commercialization Plan and may decide to develop and
adopt certain distinctive colors, logos, images, symbols, and trade dress to be used (in addition to the Product Marks) in connection with the Commercialization of each DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product in Moderna&#146;s
Region. The Parties shall jointly select the Product Marks for each DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product to be used in Metagenomi&#146;s Region and included in the applicable Commercialization Plan and may jointly decide to
develop and adopt certain distinctive colors, logos, images, symbols, and trade dress to be used (in addition to the Product Marks) in connection with the Commercialization of each DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product in
Metagenomi&#146;s Region. The JCC shall prepare, review, and discuss, and the JSC shall review, discuss, and determine whether to approve, each Commercialization Plan and Commercialization Budget. On an annual basis during the Term (or more
frequently as may be required), the JCC shall review and update each Commercialization Plan and Commercialization Budget based on the currently available information and data, including for any applicable new formulations or Indications that that
were added to a Development Plan pursuant to Section&nbsp;6.4.7(b) (JDC and JSC Decision Regarding New Development Activities) or new Combination Products approved by the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
JSC in accordance with Section&nbsp;6.4.8 (Combination Products), in each case, that are not included in the then-current Commercialization Plan for the applicable DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Product. The JSC shall review, discuss, and determine whether to approve any such update to the applicable Commercialization Plan and corresponding Commercialization Budget. Each such update to a
Commercialization Plan and corresponding Commercialization Budget shall become effective and shall supersede the previous Commercialization Plan and corresponding Commercialization Budget upon approval thereof by the JSC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.7.2 <B>Commercialization Activities</B>. The Parties shall Commercialize the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products in
the Territory in accordance with the Commercialization Plan for each DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product. The Lead Party shall lead the performance of Commercialization activities in its respective Region, and, without seeking
JCC review or approval, shall have the right to make operational decisions with respect to the performance of such Commercialization activities to the extent consistent with the then-current Commercialization Plan provided that Moderna may appoint
up to fifty percent (50%) of the deployed Sales Force for the U.S. Notwithstanding anything to the contrary herein, the Parties may elect to conduct Commercialization activities jointly and allocate specific operational activities in accordance with
the Commercialization Plan. Without limiting the generality of the foregoing, in connection with the Commercialization of the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products in its respective Region, The Lead Party shall be solely
responsible for (a)&nbsp;receiving, accepting, and filling orders for the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products, (b)&nbsp;handling all returns of the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products, (c)&nbsp;controlling
invoicing, order processing, and collection of accounts receivable for the sales of the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products, (d)&nbsp;booking and recording sales of the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products
in its books of account, and (e)&nbsp;distributing and managing inventory of the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products. If a particular Commercialization activity is allocated to both Parties to perform jointly under a
Commercialization Plan, then both Parties shall coordinate to jointly conduct such activity in collaboration with each other. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.7.3
<B>Commercialization Costs and Expenses</B>. [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.7.4 <B>Assumed Commercialization Activities</B>. If either Party has defaulted on
its obligations to perform one or more Commercialization activities allocated to such Party under a Commercialization Plan in a manner that delays the performance of such matters for a period of more than [***] beyond the timeline set forth in such
Commercialization Plan, then the other Party shall provide such defaulting Party with written notice regarding such failure to perform, and upon receipt of such notice the defaulting Party shall have a [***] period to commence the performance of
such Development activities in accordance with the terms hereof and the applicable Commercialization Plan (the &#147;<B>Commercialization Activities Cure Period</B>&#148;). If (a)&nbsp;the defaulting Party has not commenced performance of such
Commercialization activities during the applicable Commercialization Activities Cure Period, (b)&nbsp;the defaulting Party notifies the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Party in writing that the defaulting Party anticipates
that it shall be unable to perform such Commercialization activities, or (c)&nbsp;the defaulting Party does not perform such Commercialization activities in accordance with the applicable Commercialization Plan or otherwise in accordance with this
Section&nbsp;6.7 (Commercialization), within a reasonable period of time in accordance with the terms hereof, then, in each case ((a)-(c)), the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Party may, upon written notice to the defaulting
Party, assume those Commercialization activities that are the subject of such default by the defaulting Party (the &#147;<B>Assumed Commercialization Activities</B>&#148;). In connection with the defaulting Party&#146;s failure to perform such
activities or default of such obligations and the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Party&#146;s assumption thereof: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) the defaulting Party shall work collaboratively and in good faith with the <FONT
STYLE="white-space:nowrap">non-defaulting</FONT> Party, and make its personnel reasonably available to the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Party, in each case, in order to (i)&nbsp;transfer of any applicable technology,
materials, or contracts with subcontractors to the other Party that are necessary or reasonably useful for the performance of the applicable Assumed Commercialization Activities and (ii)&nbsp;provide such other assistance so as to enable the <FONT
STYLE="white-space:nowrap">non-defaulting</FONT> Party to assume performance of the applicable Assumed Commercialization Activities; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)
the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Party shall thereafter have the right to make operational decisions with respect to the performance of such Assumed Commercialization Activities to the extent consistent with the
then-current Commercialization Plan; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) the applicable JSC subcommittee shall update the applicable Commercialization Plan to allocate
performance of the Assumed Commercialization Activities to the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Party; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d)
[***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.7.5 <B>Pricing Matters; Pricing and Reimbursement Approvals; Information Sharing; Pricing Strategy</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Moderna shall be responsible for preparing the overall pricing strategy for the Territory, including establishing various pricing bands
for each country in the Territory, which is to be included in the Commercialization Plan subject to JCC review and JSC approval. Metagenomi shall have the right to comment, which Moderna shall consider in good faith in Moderna&#146;s proposed
pricing strategy. The Regulatory Responsible Party will be responsible for all Pricing Matters in its respective Region within the guidelines, such as pricing bands, set by the overall pricing strategy; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The Regulatory Responsible Party shall be solely responsible for negotiating, obtaining, and maintaining all Pricing and Reimbursement
Approvals for the DT CoCo Products in any country or regulatory jurisdiction in its respective Region where required in its own name or in the name of its Affiliate, subject to JSC approval; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Upon either Party&#146;s reasonable request, but subject to local anticompetition laws and any obligations of confidentiality between a
Party and any Third Party, the Parties, through the JCC, shall discuss key market research and relevant sections of DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product national reimbursement dossiers (or their equivalent) in the Territory, as
well as other relevant Commercialization information regarding the Territory collected or prepared by or on behalf of such Party relating to each DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product that such Party agrees to share with the JCC
for discussion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.7.6 <B>Commercialization Reports</B>. At each meeting of the JCC, each Party shall provide to the JCC a summary of the
Commercialization activities performed by such Party for the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products in the Territory, during the period since the last JCC meeting. In addition, at each meeting of the JCC following the First
Commercial Sale of a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product in a country in a Region, the respective Lead Party shall present sales forecasts, sales performance reports, and other information for such DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Product in such country in the Region. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.7.7 <B>Commercialization Diligence Obligations</B>. Following receipt of Regulatory
Approval of a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product in a country within the Territory each Party shall use Commercially Reasonable Efforts to perform, or cause to be performed, the activities for such DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Product assigned to it in the applicable Commercialization Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.7.8 <B>Standards of Conduct;
Compliance</B>. Each Party shall perform, or shall ensure that each of its Affiliates, sublicensees, and subcontractors perform, all Commercialization activities in a professional and ethical business manner and in compliance with Applicable Laws,
the Approved Labeling, and any applicable Commercialization Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.7.9 <B>Product Materials</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <B>Creation; Ownership; Use</B>. Unless otherwise agreed by the Parties or as otherwise set forth in the Commercialization Plan, the Lead
Party shall create and develop all Product Materials in accordance with the Approved Labeling, applicable Regulatory Approvals, and Applicable Laws for all countries in its respective Region and submit such Product Materials to the JCC for review,
discussion, and approval. The Lead Party shall own all rights, title, and interests in and to any Product Materials for the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products for its respective Region, excluding any Moderna Housemarks or
Metagenomi Housemarks as may be. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <B><FONT STYLE="white-space:nowrap">Co-Branding</FONT> of Product Materials</B>. [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.7.10 <B>Product Marks</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <B>Ownership; Trademark License</B>. [***] inures to the benefit of Moderna, regardless of which Party uses Moderna Housemarks in which
Region, and (ii)&nbsp;Metagenomi reserves all rights, title or interests in and to Metagenomi Housemarks, and all goodwill developed by virtue of the use of Metagenomi Housemarks inures to the benefit of Metagenomi, regardless of which Party uses
Metagenomi Housemarks in which Region. Upon a Party&#146;s reasonable request from time to time, the other Party shall provide to such Party for its review all materials that include any Product Marks, provided that all subsequent uses of any
materials already provided to such Party for review may be used without additional review. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <B>Use</B>. Each Party agrees that it and
its Affiliates and Sublicensees shall Commercialize each of the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products in the Territory in a manner consistent with the Commercialization Plan and shall ensure that all DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Products that are sold bearing the Product Marks are of a high quality consistent with industry standards for global pharmaceutical and biologic therapeutic products. Metagenomi agrees that it and its
Affiliates and Sublicensees shall (a)&nbsp;not use any Product Marks in a way that might materially prejudice their distinctiveness or validity or the goodwill of Moderna therein and shall include the trademark registration symbol <SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> or <SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> as appropriate; (b)&nbsp;ensure that each use of the Product Marks is in accordance with the guidelines with respect to manner of
use set forth in the Commercialization Plan; (c)&nbsp;not directly or indirectly, attack, dispute, or contest the validity of or ownership of such Product Marks anywhere in the Territory or any registrations issued or issuing with respect thereto;
(d)&nbsp;not use any trademarks or trade names so resembling any of such Product Marks as to be likely to cause confusion or deception; and (e)&nbsp;place and display the Product Marks on and in connection with the DT
<FONT STYLE="white-space:nowrap">Co-Co</FONT> Products in a way that acknowledges Moderna&#146;s role in discovering the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products and that such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product
is under license from Moderna. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) <B>Required Use</B>. On a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-DT</FONT></FONT> <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product basis, Metagenomi shall promote and sell such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products in
the U.S. only under the applicable Product Marks for such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products as set forth herein and in the applicable Medical Affairs Plan, Commercialization Plan, and if a sublicensee is approved pursuant to
Section&nbsp;5.7.1 (Rights to Grant Licenses and Sublicenses in the Territory) then such sublicensee&#146;s trademarks, and no other Trademarks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) <B>Registration, Maintenance, and Enforcement</B>. [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.7.11 <B>Patent Marking</B>. [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.7.12 <B>Copyright License</B>. [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.8 <B><FONT STYLE="white-space:nowrap">Opt-Out</FONT> Right</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.8.1 <B><FONT STYLE="white-space:nowrap">Opt-Out</FONT> Right</B>. With respect to the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT>
Program, (a)&nbsp;Metagenomi may, at any time during the Term of the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program, and (b)&nbsp;Moderna may, at any time during the Term of the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program (in
the case of (a), Metagenomi shall be the &#147;<B><FONT STYLE="white-space:nowrap">Opt-Out</FONT> Party</B>&#148; and in the case of (b), Moderna shall be the &#147;<B><FONT STYLE="white-space:nowrap">Opt-Out</FONT> Party</B>&#148;), elect to <FONT
STYLE="white-space:nowrap">opt-out</FONT> of its obligations under such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program (the &#147;<B><FONT STYLE="white-space:nowrap">Opt-Out</FONT> DT <FONT STYLE="white-space:nowrap">Co-Co</FONT>
Program</B>&#148;) (in the case of Moderna being the <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Party, subject to Section&nbsp;6.8.2(e) (Effects of <FONT STYLE="white-space:nowrap">Opt-Out)),</FONT> and the other Party (the &#147;<B>Primary
Party</B>&#148;) shall have the right to continue the Development and Commercialization activities in the <FONT STYLE="white-space:nowrap">Opt-Out</FONT> DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program in the Territory (&#147;<B><FONT
STYLE="white-space:nowrap">Opt-Out</FONT></B>,&#148; and such right to <FONT STYLE="white-space:nowrap">Opt-Out,</FONT> the &#147;<B><FONT STYLE="white-space:nowrap">Opt-Out</FONT> Right</B>&#148;). Metagenomi may exercise its <FONT
STYLE="white-space:nowrap">Opt-Out</FONT> Right by providing written notice to Moderna of such election at any time during the Term of the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program, and Moderna may exercise its <FONT
STYLE="white-space:nowrap">Opt-Out</FONT> Right by providing written notice to Metagenomi of such election at any time during the Term of the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program. Any exercise by either Party of its <FONT
STYLE="white-space:nowrap">Opt-Out</FONT> Right in accordance with the foregoing sentence shall become effective [***] after the delivery of the written notice (the &#147;<B><FONT STYLE="white-space:nowrap">Opt-Out</FONT> Date</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.8.2 <B>Effects of <FONT STYLE="white-space:nowrap">Opt-Out</FONT></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.8.3 <B>Right of First
Offer After <FONT STYLE="white-space:nowrap">Opt-Out</FONT></B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">[***] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.9 <B>Preservation of Program Assets</B>. On a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Program</FONT></FONT> basis, except as otherwise permitted under this Agreement, during the Term of such Program, Metagenomi (i)&nbsp;shall not and shall ensure that its
Affiliates do not, (a)&nbsp;assign, transfer, convey or dispose of, or enter into any agreement with any Affiliate or Third Party to assign, transfer, convey or dispose of (or agree to do any of the foregoing), the Collaboration Targets, any
Candidates or Products, or any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the Metagenomi Licensed Collaboration Technology, including its interest in any Program Technology, in each case in connection with such Program (the &#147;<B>Metagenomi Program
Assets</B>&#148;), or (b)&nbsp;license, option or grant to any Affiliate or Third Party, or agree to license, option or grant to a Third Party, any rights to or otherwise encumber any Metagenomi Program Assets, in each case ((a)-(b)) that would
impair or conflict in any respect with any of the rights or licenses granted or to be granted to Moderna hereunder, (ii)&nbsp;shall, under Article 5 (Licenses; Exclusivity; Manufacture), transfer or otherwise provide the most advanced version of the
Metagenomi Licensed Collaboration Technology to Moderna or the JSC, as applicable, and (iii)&nbsp;shall include such most advanced version of the Metagenomi Licensed Collaboration Technology in the applicable Program Plan. Without limiting the
generality of the foregoing, until the end of the Research Term, Metagenomi will not <FONT STYLE="white-space:nowrap">spin-off</FONT> or agree to <FONT STYLE="white-space:nowrap">spin-off</FONT> (by any means) any Patents or <FONT
STYLE="white-space:nowrap">Know-How</FONT> relevant to the licenses granted by Metagenomi hereunder into any Affiliate of Metagenomi (at the time of such spin) without ensuring that any newly invented Patents or
<FONT STYLE="white-space:nowrap">Know-How</FONT> arising (directly or indirectly) from the practice of any such spun Patents or <FONT STYLE="white-space:nowrap">Know-How</FONT> (or improvements thereto) remain &#147;Controlled&#148; by Metagenomi
under this Agreement. For clarity, Metagenomi&#146;s obligations under this Section&nbsp;6.9 (Preservation of Program Assets) shall continue to apply in the event Metagenomi exercises its <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Right under
Section&nbsp;6.8 <FONT STYLE="white-space:nowrap">(Opt-Out</FONT> Right). With respect to each DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program, except as otherwise permitted under this Agreement, during the Term of such DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Program, Moderna shall not and shall ensure that its Affiliates do not, (A)&nbsp;assign, transfer, convey or dispose of, or enter into any agreement with any Affiliate or Third Party to assign, transfer,
convey or dispose of (or agree to do any of the foregoing), the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Target, any Candidates or Products, or any of the Moderna Licensed DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Technology,
including its interest in any Program Technology, in each case in connection with such Program (the &#147;<B>Moderna Program Assets</B>&#148;), or (B)&nbsp;license, option or grant to any Affiliate or Third Party, or agree to license, option or
grant to a Third Party, any rights to or otherwise encumber any Moderna Program Assets, in each case ((A)-(B)) that would impair or conflict in any respect with any of the rights or licenses granted or to be granted to Metagenomi in such DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Program. For clarity, Moderna&#146;s obligations under this Section&nbsp;6.9 (Preservation of Program Assets) shall continue to apply in the event Moderna exercises its
<FONT STYLE="white-space:nowrap">Opt-Out</FONT> Right under Section&nbsp;6.8 <FONT STYLE="white-space:nowrap">(Opt-Out</FONT> Right). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.10 <B>Safety Concern</B>. Notwithstanding anything to the contrary herein or in the applicable DT
<FONT STYLE="white-space:nowrap">Co-Co</FONT> Plan for a given DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program, if, at any time during or after the Term of such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program, Moderna reasonably
believes that there is a Safety Concern with respect to a Product in such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program, then Moderna will immediately (and in any event within five (5)&nbsp;Business Days after the date it determines there
is a Safety Concern) provide written notice to Metagenomi of such Safety Concern, following which neither Party may conduct any further Development or Commercialization activities with respect to the Product that gave rise to the Safety Concern
until such Safety Concern is resolved; provided that if the Parties do not mutually agree how to resolve such Safety Concern within a [***] period, then Moderna shall have the right to determine whether there will be any further Development or
Commercialization activities with respect to such Product, and the extent of those activities, including the right to cease or suspend or cause the cessation or suspension of the conduct of any ongoing or future Clinical Trials of the Product, and
in the event Moderna determines that there will be no further Development or Commercialization activities with respect to the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product in such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program,
the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program shall terminate with respect to such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product to the extent it has not already expired or been terminated otherwise, and the Parties shall
cooperate with each other to wind-down their respective existing activities with respect to such Product. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Article 7 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FEES, ROYALTIES, &amp; PAYMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.1 <B>Upfront Payment</B>. As partial consideration for the rights granted by Metagenomi to Moderna pursuant to the terms of this Agreement,
within [***] of the Effective Date, Moderna shall pay to Metagenomi (i)&nbsp;a <FONT STYLE="white-space:nowrap">non-refundable,</FONT> <FONT STYLE="white-space:nowrap">non-creditable,</FONT> unencumbered cash payment equal to forty million Dollars
($40,000,000) (the &#147;<B>Upfront Payment</B>&#148;) and (ii)&nbsp;the first payment of the Annual Research Funding Amount as described in Section&nbsp;7.3 (Research Funding), provided that, promptly (and in no event later than [***]) after the
Effective Date, Metagenomi provides Moderna with a properly completed and signed IRS Form <FONT STYLE="white-space:nowrap">W-9</FONT> and an invoice for each of items (i)&nbsp;and (ii). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.2 <B>Convertible Note</B>. Pursuant to those convertible note financing agreements (collectively, &#147;<B>Convertible Note
Instruments</B>&#148;) entered into by the Parties dated as of even date herewith, and in accordance with the terms and conditions set forth therein, Moderna shall purchase convertible notes from Metagenomi in the amount of thirty million Dollars
($30,000,000) in principal converting to equity at the next Qualified Financing, as defined in the Convertible Note Instruments, on the terms and conditions set forth therein. The Convertible Note Instruments shall further provide that Moderna shall
have the right to designate one (1)&nbsp;observer to Metagenomi&#146;s Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.3 <B>Research Funding</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.3.1 As additional consideration for the rights and license granted herein, Moderna shall pay Metagenomi an amount of five million Dollars
($5,000,000) within [***] after the Effective Date and at least five million Dollars ($5,000,000) within [***] after each anniversary of the Effective Date (each, the &#147;<B>Annual Research Funding Amount</B>&#148;), for Metagenomi&#146;s Research
Costs under the RT Technology Research Plan, the RT Preclinical Research Plans, the DT Target Evaluation Plan and the DT Moderna Research Plans. Notwithstanding the above or anything else herein to the contrary, should the Annual Research Funding
Amount for a specific year after the Effective Date not be fully consumed by Metagenomi&#146;s Research Costs incurred under the RT Technology Research Plan, the RT Preclinical Research Plans, the DT Target Evaluation Plan and the DT Moderna
Research Plans during such year, Metagenomi shall promptly notify Moderna of same after the applicable anniversary of the Effective Date, and Moderna may credit its own DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Research Costs under the DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Research Plans for such year against any remainder of the Annual Research Funding Amount for such year. Any remaining DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Research Costs thereafter shall be subject
to sharing with Metagenomi pursuant to 6.4.4 (Development Cost Sharing). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.3.2 <B>Research Funding Audit</B>. In accordance with
Section&nbsp;7.6 (Accounting; Audit), Moderna may audit any invoices and expense reports provided by Metagenomi under Section&nbsp;3.5 (RT Research Term Costs) and Section&nbsp;4.6 (DT Moderna Research Term Costs). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.4 <B><FONT STYLE="white-space:nowrap">Co-Co</FONT> Products Profit and Loss Share</B>.
Subject to Sections 6.8 <FONT STYLE="white-space:nowrap">(Opt-Out</FONT> Right), Moderna and Metagenomi shall share in Operating Profits or Losses with respect to Commercialization activities, Medical Affairs activities, the activities set forth
under Other Operating Expenses and other related activities for the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products in the Territory as follows: Each Party shall bear (and be entitled to) fifty percent (50%) of such Operating Profits or
Losses (the &#147;<B>Profit and Loss Share</B>&#148;). <B>Schedule J </B><FONT STYLE="white-space:nowrap">(Co-Co</FONT> Products Profit and Loss Share) sets forth the procedures for reporting of actual results for each Calendar Quarter and review
and discussion of potential discrepancies, reconciliation, reasonable forecasting, and other finance and accounting matters, and to the extent such matters are not set forth in <B>Schedule J </B><FONT STYLE="white-space:nowrap">(Co-Co</FONT>
Products Profit and Loss Share), the JSC shall determine such matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.5 <B>Apportionment of Costs</B>. If any Commercialization Costs,
Development Costs, External Costs, Medical Affairs Costs, Cost of Sales, or Other Operating Expenses benefit both (a)&nbsp;a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product in the Territory, and (b)&nbsp;any other product or activities of a
Party outside of this Agreement, then the applicable Party incurring such costs shall apportion such costs in a manner that fairly and reasonably reflects the benefit to the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product in the Territory
and the other products or activities of such Party outside of this Agreement, as applicable. Each Party shall keep records of the total costs incurred and the apportionment pursuant to the records required under Section&nbsp;7.6 (Accounting; Audit).
At the request of the other Party, the Party making the apportionment shall provide reasonable additional supporting documentation and make its personnel reasonably available to answer any questions, and if the other Party disputes the
apportionment, then the JSC shall review, discuss, and determine what percentage of the total costs in question can be included as Commercialization Costs, Eligible Development Costs, Cost of Sales, Eligible Medical Affairs Costs, or Other Operating
Expenses, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.6 <B>Accounting; Audit</B>. Each Party agrees to keep full, clear, and accurate records in accordance with
U.S. GAAP, consistently applied, for a period of at least [***] after the relevant payment is owed pursuant to this Agreement, setting forth Research Costs (including Eligible <FONT STYLE="white-space:nowrap">Co-Co</FONT> Research Costs, RT Excess
Costs, DT Moderna Excess Costs), Development Costs (including Eligible Development Costs), Medical Affairs Costs (including Eligible Medical Affairs Costs) Manufacturing Costs, Commercialization Costs, Other Operating Expenses, royalties, sales of
the Products, and other amounts payable to the other Party hereunder in sufficient detail to enable amounts owed or payable to the other Party hereunder to be determined. Each Party further agrees to permit its books and records to be examined by an
independent accounting firm selected by the other Party and reasonably acceptable to the audited Party to verify the accuracy of any of the foregoing; provided that such independent accounting firm is subject to written obligations of
confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> applicable to each Party&#146;s Confidential Information that are at least as stringent as those set forth described in Article 11 (Confidentiality). Such audit shall not be
(a)&nbsp;performed more frequently than [***], (b) conducted for any Calendar Year more than [***] after the end of such year, or (c)&nbsp;repeated for any Calendar Year or with respect to the same set of records (unless a discrepancy with respect
to such records is discovered during a prior audit). Such examination is to be made at the expense of the auditing Party, except in the event that the results of the audit reveal an underpayment or overcharge by the audited Party of [***] or more
during the period being audited, in which case reasonable audit fees for such examination shall be paid by the audited Party. The underpaid Party shall be entitled to recover any shortfall in payments as determined by such audit, plus interest
thereon, calculated in accordance with Section&nbsp;7.15 (Default Interest). If such examination of records reveals any overpayment by a Party, then the other Party shall credit the amount overpaid against future amounts due to the other Party by
the overpaying Party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.7 <B>Disputed Payments</B>. If a Party disputes an invoice or other payment obligation
under this Agreement, then such Party shall timely pay the undisputed amount of the invoice or other payment obligation, and the Parties shall resolve such dispute in accordance with Section&nbsp;13.4 (Baseball Arbitration). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.8 <B>Milestone Payments</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.8.1 <B>General</B>. Moderna shall pay to Metagenomi certain milestone payments (&#147;<B>Milestone Payments</B>&#148;) set forth in this
Section&nbsp;7.8 (Milestone Payments): within [***] following the receipt of an invoice from Metagenomi for the applicable Milestone Payment in respect of (i)&nbsp;the first achievement of an RT Technology Milestone during the RT Research Term or
Base Editing Correction Readiness during the Initial RT Research Term or Base Editing Knockout Readiness during the DT Moderna Research Term, pursuant to Section&nbsp;7.8.2 (Technology Milestone Fees), (ii) the first Product for each RT Preclinical
Research Program achieving an RT Target development and regulatory milestone event set forth in Section&nbsp;7.8.3 (RT Target Development Milestones) (the &#147;<B>RT Target Development and Regulatory Milestone Event</B>&#148;), (iii) the first
Product for each DT Moderna Target achieving a DT Moderna Target development and regulatory milestone event set forth in Section&nbsp;7.8.5 (DT Target Development Milestones) (the &#147;<B>DT Moderna Target Development and Regulatory Milestone
Event</B>&#148;), (iv)&nbsp;the first occurrence of all Products Directed Against a given RT Target collectively achieving the sales milestone events set forth in Section&nbsp;7.8.4 (RT Target Sales Milestones) (the &#147;<B>RT Target Sales
Milestone Events</B>&#148;), and (v)&nbsp;the first occurrence of all Products Directed Against a given DT Moderna Target collectively achieving the sales milestone events set forth in Section&nbsp;7.8.6 (DT Moderna Target Sales Milestones) (the
&#147;<B>DT Moderna Target Sales Milestone Events</B>&#148;). For clarity, the maximum number of each RT Target Development and Regulatory Milestone Event achievable is ten (10) (i.e., only once per each RT Target subject to this Agreement), and the
maximum number of each DT Moderna Target Development and Regulatory Milestone Event achievable is two (2) (i.e., only once per each DT Moderna Target subject to this Agreement). Each Milestone Payment made under this Section&nbsp;7.8 (Milestone
Payments) shall be <FONT STYLE="white-space:nowrap">non-</FONT> refundable, <FONT STYLE="white-space:nowrap">non-creditable</FONT> and not subject to <FONT STYLE="white-space:nowrap">set-off</FONT> hereunder. Notwithstanding anything else herein to
the contrary, any pharmaceutical product (A)&nbsp;Developed with the intent to be Commercialized as a single-priced pharmaceutical product, (B)&nbsp;Commercialized as a single-priced pharmaceutical product, in each case of (A)&nbsp;and (B), by or on
behalf of Moderna or any of its Affiliates or Sublicensees, which comprises two or more Licensed RT Products, each Directed Against a different RT Target, shall be deemed one Licensed RT Product Directed Against only one RT Target, for purposes of
this Section&nbsp;7.8 (Milestone Payments), and any pharmaceutical product, (C)&nbsp;Developed with the intent to be Commercialized as a single-priced pharmaceutical product, or (D)&nbsp;Commercialized as a single-priced pharmaceutical product, in
each case of (C)&nbsp;and (D), by or on behalf of Moderna or any of its Affiliates or Sublicensees, which comprises two or more Licensed DT Products, each Directed Against a different DT Moderna Target, shall be deemed one Licensed DT Product
Directed Against only one DT Moderna Target, for purposes of this Section&nbsp;7.8 (Milestone Payments). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.8.2 <B>Technology Milestone Fees</B>. The Milestone Payments to be made by Moderna to
Metagenomi pursuant to Section&nbsp;7.8.1 (Milestone Payments, General) with respect to first achieving an RT Technology Milestone described below during the RT Research Term, or Base Editing Correction Readiness described below during the Initial
RT Research Term, or Base Editing Knockout Readiness described below during the DT Moderna Research Term are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Technology</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Milestone Event</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Achieved During the</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>RT Research Term,</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>the Initial RT</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Research Term or</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>the DT Moderna</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Research Term, each</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>as applicable</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maximum<BR>Total<BR>Payment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Milestone<BR>Payment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The maximum total amount payable under this Section&nbsp;7.8.2 (Technology Milestone Fees) shall not exceed seventy-five
million Dollars ($75,000,000). Metagenomi shall provide prompt written notice to the JSC upon achievement of an RT Technology Milestone during the RT Research Term, upon achievement of Base Editing Knockout Readiness during the DT Moderna Research
Term, and upon achievement of Base Editing Correction Readiness during the Initial RT Research Term, in each case together with sufficient data and other information for the JSC to confirm such achievement. The JSC shall notify Metagenomi and
Moderna of its confirmation within [***] after receiving the written notice from Metagenomi. Metagenomi shall send an invoice for the applicable Milestone Payment within [***] after receiving the confirmation from the JSC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.8.3 <B>RT Target Development Milestones</B>. The Milestone Payments to be made by Moderna to Metagenomi pursuant to Section&nbsp;7.8.1
(Milestone Payments, General) with respect to the first Product for each RT Preclinical Research Program to achieve the applicable RT Target Development and Regulatory Milestone Event described below during the Term are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>RT Target Development and Regulatory Milestone Events</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Milestone<BR>Payment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The maximum total amount payable under this Section&nbsp;7.8.3 (RT Target Development Milestones) shall not exceed one hundred
million Dollars ($100,000,000) per RT Target subject to this Agreement pursuant to Section&nbsp;7.8.1 (Milestone Payments, General). For clarity, no Milestone Payment is payable for subsequent or repeated achievements of the same RT Target
Development and Regulatory Milestone Event with respect to the same Licensed Product (including formulations), or any subsequent Licensed Products with respect to an RT Target for which an RT </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Target Development and Regulatory Milestone Event has occurred (see, e.g., the following example set forth in the remainder of this Section&nbsp;7.8.3 (RT Target Development Milestones)). By way
of example and not limitation, assume that a Licensed Product achieves the first RT Target Development and Regulatory Milestone Event for the first (1<SUP STYLE="font-size:75%; vertical-align:top">st</SUP>) RT Target, and immediately after the
Initiation of the Phase II Clinical Trial for such Licensed Product, Moderna decides to discontinue the Development of such Licensed Product Directed Against that RT Target. In such case, Moderna would pay Metagenomi the Milestone Payment
corresponding to the first RT Target Development and Regulatory Milestone Event set forth in the table above upon the attainment of such first RT Target Development and Regulatory Milestone Event by such Licensed Product. Then, assume that a
different Licensed Product for the same RT Target achieves the first RT Target Development and Regulatory Milestone Event. In such case, no Milestone Payment is due upon the attainment of the first RT Target Development and Regulatory Milestone
Event with respect to the second Licensed Product, and Moderna would pay Metagenomi the Milestone Payments corresponding to the second RT Target Development and Regulatory Milestone Event set forth in the table above upon the attainment of such
second RT Target Development and Regulatory Milestone Event by such second Licensed Product. With respect to each RT Target Development and Regulatory Milestone Event that has two potential options of either (i)&nbsp;or (ii) in the table above, if
the first achievement is for the RT Target Development and Regulatory Milestone Event under clause (ii), and if there is a subsequent achievement for the clause (i)&nbsp;version of the same RT Target Development and Regulatory Milestone Event, then
upon the occurrence of such subsequent achievement the difference between the amount of clauses (i)&nbsp;and (ii) shall be payable. By way of example, if the first Pricing and Reimbursement Approval in the United Kingdom is obtained for a Licensed
Product Directed Against a particular RT Target in an Orphan Indication (a clause (ii)&nbsp;occurrence), then [***] would be owing in accordance with the table above, and if subsequently Pricing and Reimbursement Approval in the United Kingdom is
obtained for a Licensed Product Directed Against the same RT Target in a <FONT STYLE="white-space:nowrap">Non-Orphan</FONT> Indication, then an additional [***] would be due [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moderna shall provide prompt written notice to Metagenomi upon achievement of an RT Target Development and Regulatory Milestone Event. Metagenomi shall send
an invoice for the applicable Milestone Payment within sixty (60)&nbsp;days after receiving the written notice from Moderna. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.8.4 <B>RT
Target Sales Milestones</B>. The Milestone Payments to be made by Moderna to Metagenomi pursuant to Section&nbsp;7.8.1 (Milestone Payments, General) with respect to the first occurrence of all Licensed Products Directed Against a given RT Target
collectively achieving the below RT Target Sales Milestone Events are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="19%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>RT Target Sales Milestone Event</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Milestone&nbsp;Payment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First Calendar Year in which annual Net Sales of all Licensed Products Directed Against such RT
Target in the Territory exceed [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First Calendar Year in which annual Net Sales of all Licensed Products Directed Against such RT
Target in the Territory exceed [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First Calendar Year in which annual Net Sales of all Licensed Products Directed Against such RT
Target in the Territory exceed [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First two consecutive Calendar Years in each of which annual Net Sales of all Licensed Products
Directed Against such RT Target in the Territory exceed one and [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The maximum total amount payable under this Section&nbsp;7.8.4 (RT Target Sales Milestones) shall not exceed
two hundred million Dollars ($200,000,000) per RT Target subject to this Agreement pursuant to Section&nbsp;7.8.1 (Milestone Payments, General). If more than one RT Target Sales Milestone Event is achieved in the same Calendar Year, Moderna shall
pay Metagenomi all Milestone Payments for such RT Target Sales Milestone Events achieved in such Calendar Year in accordance with this Section&nbsp;7.8.4 (RT Target Development Milestones). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moderna shall provide prompt written notice to Metagenomi upon achievement of an RT Target Sales Milestone Event. Metagenomi shall send an invoice for the
applicable Milestone Payment within sixty (60)&nbsp;days after receiving the written notice from Moderna. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.8.5 <B>DT Moderna Target
Development Milestones</B>. The Milestone Payments to be made by Moderna to Metagenomi pursuant to Section&nbsp;7.8.1 (Milestone Payments, General) with respect to the first Product for each DT Moderna Target achieving a DT Moderna Target
Development and Regulatory Milestone Event described below during the Term are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="19%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>DT Moderna Target Development and Regulatory Milestone
Events</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Milestone&nbsp;Payment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The maximum total amount payable under this Section&nbsp;7.8.5 (DT Moderna Target Development Milestones) shall not exceed one
hundred million Dollars ($100,000,000) per DT Moderna Target subject to this Agreement pursuant to Section&nbsp;7.8.1 (Milestone Payments, General). For clarity, no Milestone Payment is payable for subsequent or repeated achievements of the same DT
Moderna Target Development and Regulatory Milestone Event with respect to the same Licensed Product (including formulations), or any subsequent Licensed Products with respect to a DT Moderna Target (or multiple targets that include the same DT
Moderna Target) for which a DT Moderna Target Development and Regulatory Milestone Event has occurred (see, e.g., the following example set forth in the remainder of this Section&nbsp;7.8.5 (DT Moderna Target Development Milestones)). By way of
example and not limitation, assume that a Licensed Product achieves the first DT Moderna Target Development and Regulatory Milestone Event for the first (1<SUP STYLE="font-size:75%; vertical-align:top">st</SUP>) DT Moderna Target, and immediately
after the Initiation of the Phase II Clinical Trial for such Licensed Product, Moderna decides to discontinue the Development of such Licensed Product Directed Against that DT Moderna Target. In such case, Moderna would pay Metagenomi the Milestone
Payment corresponding to the first DT Moderna Target Development and Regulatory Milestone Event set forth in the table above upon the attainment of such DT Moderna Target Development and Regulatory Milestone Event by such Licensed Product. Then,
assume that a different Licensed Product for the same DT Moderna Target achieves the first DT Moderna Target </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Development and Regulatory Milestone Event. In such case, no Milestone Payment is due upon the attainment of the first DT Moderna Target Development and Regulatory Milestone Event with respect to
the second Licensed Product, and Moderna would pay Metagenomi the Milestone Payment corresponding to the second DT Moderna Target Development and Regulatory Milestone Event set forth in the table above upon the attainment of such second DT Moderna
Target Development and Regulatory Milestone Event by such second Licensed Product. With respect to each DT Moderna Target Development and Regulatory Milestone Event that has two potential options of either (i)&nbsp;or (ii) in the table above, if the
first achievement is for the DT Moderna Target Development and Regulatory Milestone Event under clause (ii), and if there is a subsequent achievement for the clause (i)&nbsp;version of the same DT Moderna Target Development and Regulatory Milestone
Event, then upon the occurrence of such subsequent achievement the difference between the amount of clauses (i)&nbsp;and (ii) shall be payable. By way of example, if the first Pricing and Reimbursement Approval in the United Kingdom is obtained for
a Licensed Product Directed Against a particular DT Moderna Target in an Orphan Indication (a clause (ii)&nbsp;occurrence), then [***] would be owing in accordance with the table above, and if subsequently Pricing and Reimbursement Approval in the
United Kingdom is obtained for a Licensed Product Directed Against the same DT Moderna Target in a <FONT STYLE="white-space:nowrap">Non-Orphan</FONT> Indication, then an additional [***] would be due [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moderna shall provide prompt written notice to Metagenomi upon achievement of a DT Moderna Target Development and Regulatory Milestone Event. Metagenomi shall
send an invoice for the applicable Milestone Payment within [***] after receiving the written notice from Moderna. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.8.6 <B>DT Moderna
Target Sales Milestones</B>. The Milestone Payments to be made by Moderna to Metagenomi pursuant to Section&nbsp;7.8.1 (Milestone Payments, General) with respect to the first occurrence of all Licensed Products Directed Against a given DT Moderna
Target collectively achieving the below DT Moderna Target Sales Milestone Events are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="19%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>DT Moderna Target Sales Milestone Event</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Milestone&nbsp;Payment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First Calendar Year in which annual Net Sales of all Licensed Products Directed Against such DT
Moderna Target in the Territory exceed [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First Calendar Year in which annual Net Sales of all Licensed Products Directed Against such DT
Moderna Target in the Territory exceed [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First Calendar Year in which annual Net Sales of all Licensed Products Directed Against such DT
Moderna Target in the Territory exceed [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First two Consecutive Calendar Years in each of which annual Net Sales of all Licensed Products
Directed Against such DT Moderna Target exceed one and [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The maximum total amount payable under this Section&nbsp;7.8.6 (DT Moderna Target Sales Milestones) shall not exceed two
hundred million Dollars ($200,000,000) per DT Moderna Target subject to this Agreement pursuant to Section&nbsp;7.8.1 (Milestone Payments, General). If more than one DT Moderna Target Sales Milestone Event is achieved in the same Calendar Year,
Moderna shall pay Metagenomi all Milestone Payments for such DT Moderna Target Sales Milestone Events achieved in such Calendar Year in accordance with this Section&nbsp;7.8.6 (DT Moderna Target Sales Milestones). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moderna shall provide prompt written notice to Metagenomi upon achievement of a DT Moderna Target Sales
Milestone Event. Metagenomi shall send an invoice for the applicable Milestone Payment within sixty (60)&nbsp;days after receiving the written notice from Moderna. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.9 <B>Royalties on Products Directed Against an RT Target</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.9.1 <B>Royalties</B>. Subject to the remainder of this Section&nbsp;7.9 (Royalties on Products Directed Against an RT Target), on an RT <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Target-by-RT</FONT></FONT> Target basis, Moderna shall pay Metagenomi royalties as set forth below on aggregate annual Net Sales of Licensed Products Directed Against an RT Target with
respect to which Moderna has exercised the RT Option pursuant to Section&nbsp;3.9 (RT Option) in the Territory, as calculated by multiplying the applicable royalty rate set forth below by the corresponding portion of aggregate annual Net Sales of
such Licensed Products in the Territory, during the period of time, on a Licensed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Licensed</FONT></FONT> Product and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, beginning on the First Commercial Sale of any such Licensed Product in such country and continuing until the latest of: (a)&nbsp;the expiration or abandonment of the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> Valid Claim of a Patent within the Licensed RT Technology in such country [***], contained in such Licensed Product; (b)&nbsp;ten (10) years after the First
Commercial Sale of such Licensed Product in such country; and (c)&nbsp;expiration of the Regulatory Exclusivity in such country with respect to such Licensed Product (the &#147;<B>RT Royalty Term</B>&#148;). Notwithstanding anything else herein to
the contrary, any pharmaceutical product Commercialized as a single-priced pharmaceutical product by or on behalf of Moderna or any of its Affiliates or Sublicensees, which comprises two or more Licensed RT Products, each Directed Against a
different RT Target, shall be deemed one Licensed RT Product Directed Against only one RT Target of Moderna&#146;s choosing, for purposes of this Section&nbsp;7.9 (Royalties on Products Directed Against an RT Target), provided that the RT Royalty
Term for such Licensed RT Product shall be the longest of the RT Royalty Terms for each of the Licensed RT Products in such pharmaceutical product if they were separate Licensed RT Products. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Aggregate Annual Net Sales of all Licensed Products Directed Against
an RT Target in the<BR>Territory</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Royalty&nbsp;Rate</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">For that portion of aggregate annual Net Sales of all Licensed Products Directed Against such RT
Target less than or equal to [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">For that portion of aggregate annual Net Sales of all Licensed Products Directed Against such RT
Target greater than one hundred and [***] and less than or equal to [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">For that portion of aggregate annual Net Sales of all Licensed Products Directed Against such RT
Target greater than [***] and less than or equal to [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">For that portion of aggregate annual Net Sales of all Licensed Products Directed Against such RT
Target greater than [***] and less than or equal to [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">For that portion of aggregate annual Net Sales of all Licensed Products Directed Against such RT
Target greater than [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.9.2 <B>Valid Claim</B>. On a Licensed <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Product-by-Licensed</FONT></FONT> Product and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, with respect to a Licensed Product Directed Against an RT Target that
is subject to royalties under this Section&nbsp;7.9 (Royalties on Products Directed Against an RT Target), at any time during the RT Royalty Term when no Valid Claim (including in the event of expiration) of any Patent within the Licensed RT
Technology Covers such Licensed Product in a country, the royalty rates provided in Section&nbsp;7.9.1 (Royalties) for such Licensed Product shall immediately be reduced in such country by [***] and shall remain so reduced for the remainder of the
RT Royalty Term for so long as there is no such Valid Claim. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.9.3 <B>Biosimilar Products</B>. On a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">country-by-country</FONT></FONT> and Licensed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Licensed</FONT></FONT> Product basis, with respect to a Licensed Product Directed Against an RT
Target that is subject to royalties under this Section&nbsp;7.9 (Royalties on Products Directed Against an RT Target), from and after the first Calendar Year in which a Biosimilar Product is sold in a given country and has achieved (i) [***] unit
sales in such country in the market segment in which such Licensed Product competes in such country, the royalties payable pursuant to Section&nbsp;7.9.1 (Royalties) for such Licensed Product shall be reduced in such country by [***] of the
royalties otherwise payable under Section&nbsp;7.9.1 (Royalties) and (ii) [***] unit sales in such country in the market segment in which such Licensed Product competes in such country, the royalties payable pursuant to Section&nbsp;7.9.1
(Royalties) for such Licensed Product shall be reduced in such country by [***] of the royalties otherwise payable under Section&nbsp;7.9.1 (Royalties). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.9.4 <B>Third Party Payments</B>. Without prejudicing Moderna&#146;s right under Section&nbsp;5.11.3 (RT Moderna <FONT
STYLE="white-space:nowrap">In-License</FONT> Agreements), if Moderna or any of its Affiliates or sublicensees <FONT STYLE="white-space:nowrap">in-licenses</FONT> any intellectual property from a Third Party that is necessary or reasonably useful to
conduct the Research, Development, Commercialization, making, having made, use, keeping, importation, exportation, offering for sale, sale or other Exploitation of a Licensed RT Product in the Territory that is subject to royalties under this
Section&nbsp;7.9 (Royalties on Products Directed Against an RT Target) or milestone payments to Metagenomi under Sections 7.8.2 (Technology Milestone Fees) through 7.8.4 (RT Target Sales Milestones), Moderna may deduct [***] of any and all
milestone, royalty, and other payments (including required reimbursement for costs incurred in connection with enforcement or other actions and required sharing of certain recoveries) paid by it to such Third Party from any royalty payments to
Metagenomi under this Section&nbsp;7.9 (Royalties on Products Directed Against an RT Target) or milestone payments to Metagenomi under Sections 7.8.2 (Technology Milestone Fees) through 7.8.4 (RT Target Sales Milestones) for each Licensed RT
Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.9.5 <B>Cumulative Reductions Floor</B>. In no event will the aggregate amount of royalties due to Metagenomi for a Licensed
Product Directed Against an RT Target in a country in the Territory in any given Calendar Quarter during the RT Royalty Term for such Licensed Product Directed Against an RT Target in such country be reduced by more than [***] of the amount that
otherwise would have been due and payable to Metagenomi in such Calendar Quarter for such Licensed Product Directed Against an RT Target in such country as a result of the reductions set forth in Section&nbsp;7.9.2 (Valid Claims), Section&nbsp;7.9.3
(Biosimilar Products) and Section&nbsp;7.9.4 (Third Party Payments), except in the event of Section&nbsp;5.11.5 (Metagenomi Payments for Certain Technology) or Section&nbsp;7.9.3(ii) (Biosimilar Products), which, for clarity, may result in up to
[***] reduction of the royalties. Moderna may carry forward any such reductions permitted in accordance with Section&nbsp;5.11.5 (Metagenomi Payments for Certain Technology), Section&nbsp;7.9.2 (Valid Claims), Section&nbsp;7.9.3 (Biosimilar
Products) and Section&nbsp;7.9.4 (Third Party Payments) that are incurred or accrued in a Calendar Quarter but that are not applied against royalties due to Metagenomi for such Licensed Product Directed Against an RT Target in such country in such
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Calendar Quarter as a result of the foregoing floor and apply such amounts against royalties due to Metagenomi for such Licensed Product Directed Against an RT Target in such country in any
subsequent Calendar Quarter (subject to the minimum floor set forth in this Section&nbsp;7.9.5 (Cumulative Reductions Floor)) until the amount of such reduction has been fully applied against royalties due to Metagenomi for such Licensed Product
Directed Against an RT Target in such country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.10 <B>Royalties on Products Directed Against a DT Moderna Target</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.10.1 <B>Royalties</B>. On a DT Moderna <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Target-by-DT</FONT></FONT> Moderna
Target basis, Moderna shall pay Metagenomi royalties as set forth below on aggregate annual Net Sales of Licensed Products Directed Against a DT Moderna Target with respect to which Moderna has exercised the DT Option pursuant to Section&nbsp;4.9
(DT Option) in the Territory, as calculated by multiplying the applicable royalty rate set forth below by the corresponding portion of aggregate annual Net Sales of such Licensed Products in the Territory, during the period of time, on a Licensed <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Licensed</FONT></FONT> Product and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, beginning on the First Commercial
Sale of any such Licensed Product in such country and continuing until the latest of: (a)&nbsp;the expiration or abandonment of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> Valid Claim of a
Patent within the Licensed DT Moderna Technology in such country [***], contained in such Licensed Product; (b)&nbsp;ten (10) years after the First Commercial Sale of such Licensed Product in such country; and (c)&nbsp;expiration of the Regulatory
Exclusivity in such country with respect to such Licensed Product (the &#147;<B>DT Moderna Royalty Term</B>&#148;). Notwithstanding anything else herein to the contrary, any pharmaceutical product Commercialized as a single-priced pharmaceutical
product by or on behalf of Moderna or any of its Affiliates or Sublicensees, which comprises two or more Licensed DT Products, each Directed Against a different DT Moderna Target, shall be deemed one Licensed DT Product Directed Against only one DT
Moderna Target of Moderna&#146;s choosing, for purposes of this Section&nbsp;7.10 (Royalties on Products Directed Against a DT Moderna Target), provided that the DT Moderna Royalty Term for such Licensed DT Product shall be the longest of the DT
Moderna Royalty Terms for each of the Licensed DT Products in such pharmaceutical product if they were separate Licensed DT Products. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Aggregate Annual Net Sales of all Licensed Products Directed Against
a DT Moderna Target in the<BR>Territory</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Royalty<BR>Rate</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">For that portion of aggregate annual Net Sales of all Licensed Products Directed Against a DT
Moderna Target less than or equal to [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">For that portion of aggregate annual Net Sales of all Licensed Products Directed Against a DT
Moderna Target greater than [***] and less than or equal to [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">For that portion of aggregate annual Net Sales of all Licensed Products Directed Against a DT
Moderna Target greater than [***] and less than or equal to [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">For that portion of aggregate annual Net Sales of all Licensed Products Directed Against a DT
Moderna Target greater than [***] and less than or equal to [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">For that portion of aggregate annual Net Sales of all Licensed Products Directed Against a DT
Moderna Target greater than [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.10.2 <B>Valid Claim</B>. On a Licensed <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Product-by-Licensed</FONT></FONT> Product and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, with respect to a Licensed Product Directed Against a DT Moderna
Target that is subject to royalties under this Section&nbsp;7.10 (Royalties on Products Directed Against a DT Moderna Target), at any time during the DT Moderna Royalty Term when no Valid Claim (including in the event of expiration) of any Patent
within the Licensed DT Moderna Technology Covers such Licensed Product in a country, the royalty rates provided in Section&nbsp;7.10.1 (Royalties) for such Licensed Product shall immediately be reduced in such country by [***] and shall remain so
reduced for the remainder of the DT Moderna Royalty Term for so long as there is no such Valid Claim. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.10.3 <B>Biosimilar Products</B>.
On a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> and Licensed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Licensed</FONT></FONT> Product basis, with respect to a
Licensed Product Directed Against a DT Moderna Target that is subject to royalties under this Section&nbsp;7.10 (Royalties on Products Directed Against a DT Moderna Target), from and after the first Calendar Year in which a Biosimilar Product is
sold in a given country and has achieved (i) [***] unit sales in such country in the market segment in which such Licensed Product competes in such country, the royalties payable pursuant to Section&nbsp;7.10.1 (Royalties) for such Licensed Product
shall be reduced in such country by [***] of the royalties otherwise payable under Section&nbsp;7.10.1 (Royalties) and (ii) [***] unit sales in such country in the market segment in which such Licensed Product competes in such country, the royalties
payable pursuant to Section&nbsp;7.10.1 (Royalties) for such Licensed Product shall be reduced in such country by [***] of the royalties otherwise payable under Section&nbsp;7.10.1 (Royalties). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.10.4 <B>Third Party Payments</B>. Without prejudicing Moderna&#146;s right under Section&nbsp;5.12.3 (DT Moderna <FONT
STYLE="white-space:nowrap">In-License</FONT> Agreements), if Moderna or any of its Affiliates or sublicensees <FONT STYLE="white-space:nowrap">in-licenses</FONT> any intellectual property from a Third Party that is necessary or reasonably useful to
conduct the Research, Development, Commercialization, making, having made, use, keeping, importation, exportation, offering for sale, sale or other Exploitation of a Licensed DT Product in the Territory that is subject to royalties under this
Section&nbsp;7.10 (Royalties on Products Directed Against a DT Moderna Target) or milestone payments to Metagenomi under Sections 7.8.5 (DT Moderna Target Development Milestones) or 7.8.6 (DT Moderna Target Sales Milestones), Moderna may deduct
[***] of any and all milestone, royalty, and other payments (including required reimbursement for costs incurred in connection with enforcement or other actions and required sharing of certain recoveries) paid by it to such Third Party from any
royalty payments to Metagenomi under this Section&nbsp;7.10 (Royalties on Products Directed Against a DT Moderna Target) or milestone payments to Metagenomi under Sections 7.8.5 (DT Moderna Target Development Milestones) and 7.8.6 (DT Moderna Target
Sales Milestones) for each Licensed DT Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.10.5 <B>Cumulative Reductions Floor</B>. In no event will the aggregate amount of
royalties due to Metagenomi for a Licensed Product Directed Against a DT Moderna Target in a country in the Territory in any given Calendar Quarter during the DT Moderna Royalty Term for such Licensed Product Directed Against a DT Moderna Target in
such country be reduced by more than [***] of the amount that otherwise would have been due and payable to Metagenomi in such Calendar Quarter for such Licensed Product Directed Against a DT Moderna Target in such country as a result of the
reductions set forth in Section&nbsp;7.10.2 (Valid Claims), Section&nbsp;7.10.3 (Biosimilar Products) and Section&nbsp;7.10.4 (Third Party Payments), except in the event of Section&nbsp;5.12.5 (Metagenomi Payments for Certain Technology) or
Section&nbsp;7.10.3(ii) (Biosimilar Products), which, for clarity, may result in up to [***] reduction of the royalties. Moderna may carry forward any such reductions permitted in accordance with Section&nbsp;5.12.5 (Metagenomi Payments for Certain
Technology), Section&nbsp;7.10.2 (Valid Claims), Section&nbsp;7.10.3 (Biosimilar Products) and Section&nbsp;7.10.4 (Third Party Payments) that are incurred or accrued in a Calendar </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Quarter but that are not applied against royalties due to Metagenomi for such Licensed Product Directed Against a DT Moderna Target in such country in such Calendar Quarter as a result of the
foregoing floor and apply such amounts against royalties due to Metagenomi for such Licensed Product Directed Against a DT Moderna Target in such country in any subsequent Calendar Quarter (subject to the minimum floor set forth in this
Section&nbsp;7.10.5 (Cumulative Reductions Floor)) until the amount of such reduction has been fully applied against royalties due to Metagenomi for such Licensed Product Directed Against a DT Moderna Target in such country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.11 <B><FONT STYLE="white-space:nowrap">Opt-Out</FONT> Milestones and Royalties</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.11.1 <B><FONT STYLE="white-space:nowrap">Opt-Out</FONT> Milestones</B>. With respect to each DT
<FONT STYLE="white-space:nowrap">Co-Co</FONT> Program for which the <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Party has exercised its <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Right pursuant to Section&nbsp;6.8 <FONT
STYLE="white-space:nowrap">(Opt-Out</FONT> Right), the Primary Party shall pay to the <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Party, certain milestone payments set forth in this Section&nbsp;7.11.1
<FONT STYLE="white-space:nowrap">(Opt-Out</FONT> Milestones) (the &#147;<B><FONT STYLE="white-space:nowrap">Opt-Out</FONT> DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Milestone Payments</B>&#148;) within sixty (60)&nbsp;days following the
receipt of an invoice from the <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Party for the applicable <FONT STYLE="white-space:nowrap">Opt-Out</FONT> DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Milestone Payment in respect of (a)&nbsp;the
first DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product in such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program achieving a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product development and regulatory milestone event set forth
in Section&nbsp;7.11.1(a) <FONT STYLE="white-space:nowrap">(Opt-Out</FONT> DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product Development and Regulatory Milestone Events) (the &#147;<B><FONT STYLE="white-space:nowrap">Opt-Out</FONT> DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Product Development and Regulatory Milestone Events</B>&#148;), and (b)&nbsp;the first occurrence of all DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products Directed Against the DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Target in such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program collectively achieving the sales milestone events set forth in Section&nbsp;7.11.1(b) <FONT STYLE="white-space:nowrap">(Opt-Out</FONT> DT
<FONT STYLE="white-space:nowrap">Co-Co</FONT> Product Sales Milestone Events) (the &#147;<B><FONT STYLE="white-space:nowrap">Opt-Out</FONT> DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product Sales Milestone Events</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <B><FONT STYLE="white-space:nowrap">Opt-Out</FONT> DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product Development and Regulatory
Milestone Events</B>. The <FONT STYLE="white-space:nowrap">Opt-Out</FONT> DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Milestone Payments to be made by the Primary Party to the <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Party pursuant to
Section&nbsp;7.11.1 <FONT STYLE="white-space:nowrap">(Opt-Out</FONT> Milestones) with respect to the first DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product in such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program achieving a DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Product Development and Regulatory Milestone Event described below during the Term are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="37%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Opt-Out</FONT> DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product Development and
Regulatory</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Milestone Event</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Opt-Out&nbsp;DT&nbsp;Co-Co&nbsp;Milestone&nbsp;Payment</FONT></FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Primary Party shall provide prompt written notice to the <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Party upon
achievement of an <FONT STYLE="white-space:nowrap">Opt-Out</FONT> DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product Development and Regulatory Milestone Event. The <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Party shall send an invoice
for the applicable <FONT STYLE="white-space:nowrap">Opt-Out</FONT> DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Milestone Payment within [***] after receiving the written notice from the Primary Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <B><FONT STYLE="white-space:nowrap">Opt-Out</FONT> DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product Sales Milestone Events</B>.
The <FONT STYLE="white-space:nowrap">Opt-Out</FONT> DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Milestone Payments to be made by the Primary Party to the <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Party pursuant to Section&nbsp;7.11.1 <FONT
STYLE="white-space:nowrap">(Opt-Out</FONT> Milestones) with respect to the first occurrence of all DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products Directed Against the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Target of such <FONT
STYLE="white-space:nowrap">Opt-Out</FONT> DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program collectively achieving the below <FONT STYLE="white-space:nowrap">Opt-Out</FONT> DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product Sales
Milestone Events are as follows: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="37%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B><FONT STYLE="white-space:nowrap">Opt-Out</FONT> DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Product Sales Milestone Event</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Opt-Out&nbsp;DT&nbsp;Co-Co&nbsp;Milestone&nbsp;Payment</FONT></FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First Calendar Year in which annual Net Sales of all DT
<FONT STYLE="white-space:nowrap">Co-Co</FONT> Products Directed Against the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Target in the Territory exceed [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First Calendar Year in which annual Net Sales of all DT
<FONT STYLE="white-space:nowrap">Co-Co</FONT> Products Directed Against the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Target in the Territory exceed [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First Calendar Year in which annual Net Sales of all DT
<FONT STYLE="white-space:nowrap">Co-Co</FONT> Products Directed Against the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Target in the Territory exceed [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First two consecutive Calendar Years in each of which annual Net Sales of all DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Products Directed Against the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Target in the Territory exceed [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The maximum total amount payable under this Section&nbsp;7.11.1 <FONT STYLE="white-space:nowrap">(Opt-Out</FONT> Milestones)
shall not exceed two hundred million Dollars ($200,000,000) per DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Target. If more than one <FONT STYLE="white-space:nowrap">Opt-Out</FONT> DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product Sales
Milestone Event is achieved in the same Calendar Year, the Primary Party shall pay the <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Party all <FONT STYLE="white-space:nowrap">Opt-Out</FONT> DT <FONT STYLE="white-space:nowrap">Co-Co</FONT>
Milestone Payments for such <FONT STYLE="white-space:nowrap">Opt-Out</FONT> DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product Sales Milestone Events achieved in such Calendar Year in accordance with this Section&nbsp;7.11.1 <FONT
STYLE="white-space:nowrap">(Opt-Out</FONT> Milestones). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Primary Party shall provide prompt written notice to the
<FONT STYLE="white-space:nowrap">Opt-Out</FONT> Party upon achievement of an <FONT STYLE="white-space:nowrap">Opt-Out</FONT> DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product Sales Milestone Event. The
<FONT STYLE="white-space:nowrap">Opt-Out</FONT> Party shall send an invoice for the applicable <FONT STYLE="white-space:nowrap">Opt-Out</FONT> DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Milestone Payment within sixty (60)&nbsp;days after
receiving the written notice from the Primary Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.11.2 <B><FONT STYLE="white-space:nowrap">Opt-Out</FONT> Royalties</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <B>Royalties</B>. The Primary Party shall pay the <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Party, on a DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-DT</FONT></FONT> <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, royalties as set forth below on annual Net Sales of such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products Directed Against the DT
<FONT STYLE="white-space:nowrap">Co-Co</FONT> Target in the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program in the Territory, as calculated by multiplying the applicable royalty rate set forth below by the corresponding portion of annual
Net Sales of such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product in such country, until the latest to occur of (i)&nbsp;the date of expiration of the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> Valid Claim of any Patents within the Licensed DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Technology licensed by the
<FONT STYLE="white-space:nowrap">Opt-Out</FONT> Party to the Primary Party under Section&nbsp;5.5 (DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program License) that Cover the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">composition-of-matter</FONT></FONT> or use of at least one (1)&nbsp;mRNA Construct, or a Gene Editing protein encoded by a mRNA Construct, contained in such DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Product in such country in the Territory, (ii)&nbsp;the date of expiration of marketing or Regulatory Exclusivity for such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product in such country in the
Territory, or (iii)&nbsp;the date that is ten (10)&nbsp;years from First Commercial Sale of such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product in such country in the Territory (the &#147;<B><FONT STYLE="white-space:nowrap">Opt-Out</FONT>
Royalty Term</B>&#148;): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="22%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>If <FONT STYLE="white-space:nowrap">Opt-Out</FONT>
Occurs</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Opt-Out&nbsp;Royalty&nbsp;Rate</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <B>Valid Claim</B>. On a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-DT</FONT></FONT> <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT>
basis, with respect to a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product that is subject to royalties under this Section&nbsp;7.11.2 <FONT STYLE="white-space:nowrap">(Opt-Out</FONT> Royalties), at any time during the <FONT
STYLE="white-space:nowrap">Opt-Out</FONT> Royalty Term when no Valid Claim (including in the event of expiration) of any Patents within the Licensed DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Technology licensed by the <FONT
STYLE="white-space:nowrap">Opt-Out</FONT> Party to the Primary Party Covers such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product in a country, the royalty rates provided in Section&nbsp;7.11.2(a) (Royalties) for such DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Product shall immediately be reduced in such country by [***] and shall remain so reduced for the remainder of the <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Royalty Term for so long as there is no such
Valid Claim. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) <B>Biosimilar Products</B>. On a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> and DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-DT</FONT></FONT> <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Product basis, with respect to a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product that is subject to royalties under this Section&nbsp;7.11.2 <FONT STYLE="white-space:nowrap">(Opt-Out</FONT>
Royalties), from and after the first Calendar Year in which a Biosimilar Product is sold in a given country and has achieved (i) [***] unit sales in such country in the market segment in which such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT>
Product competes in such country, the royalties payable pursuant to Section&nbsp;7.11.2(a) (Royalties) for such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product shall be reduced in such country by [***] of the royalties otherwise payable
under Section&nbsp;7.11.2(a) (Royalties) and (ii) [***] unit sales in such country in the market segment in which such Licensed Product competes in such country, the royalties payable pursuant to Section&nbsp;7.11.2(a) (Royalties) for such DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Product shall be reduced in such country by [***] of the royalties otherwise payable under Section&nbsp;7.11.2(a) (Royalties). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) <B>Third Party Payments</B>. If the Primary Party or any of its Affiliates or sublicensees
<FONT STYLE="white-space:nowrap">in-licenses</FONT> any right to any intellectual property from a Third Party that is necessary or reasonably useful to conduct the Research, Development, Commercialization, making, having made, use, keeping,
importation, exportation, offering for sale, sale or other Exploitation of an applicable DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product in the Territory that is subject to royalties under this Section&nbsp;7.11.2 <FONT
STYLE="white-space:nowrap">(Opt-Out</FONT> Royalties) (or milestone payments under Sections 7.11.1(a) <FONT STYLE="white-space:nowrap">(Opt-Out</FONT> DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product Development and Regulatory Milestone
Events)) or 7.11.1(b) <FONT STYLE="white-space:nowrap">(Opt-Out</FONT> DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product Sales Milestone Events), the Primary Party may deduct [***] of any and all milestone, royalty, and other payments
(including required reimbursement for costs incurred in connection with enforcement or other actions and required sharing of certain recoveries) paid by it to such Third Party (which, for the avoidance of doubt, include the Primary Party&#146;s
Third Party Payment pursuant to the last sentence of Sections 5.10.3(b) (Payments under <FONT STYLE="white-space:nowrap">Co-Co</FONT> Moderna <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements) and 5.10.4(b) (Payments under <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Metagenomi <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements), respectively, Moderna&#146;s Third Party Payment pursuant to Section&nbsp;5.10.5 (Metagenomi Payments for Certain Technology) and
Metagenomi&#146;s Third Party Payment pursuant to 5.10.6 (Moderna Payments for Certain Technology), as applicable) from any royalty payments to the <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Party under this Section&nbsp;7.11.2 <FONT
STYLE="white-space:nowrap">(Opt-Out</FONT> Royalties) or milestone payments under Sections 7.11.1(a) <FONT STYLE="white-space:nowrap">(Opt-Out</FONT> DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product Development and Regulatory Milestone
Events) or 7.11.1(b) <FONT STYLE="white-space:nowrap">(Opt-Out</FONT> DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product Sales Milestone Events) for each such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) <B>Cumulative Reductions Floor</B>. In no event will the aggregate amount of royalties due to the
<FONT STYLE="white-space:nowrap">Opt-Out</FONT> Party for a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product in a country in the Territory in any given Calendar Quarter during the <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Royalty Term
for such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product in such country be reduced by more than [***] of the amount that otherwise would have been due and payable to the Primary Party in such Calendar Quarter for such DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Product in such country as a result of the reductions set forth in Section&nbsp;7.11.2(b) (Valid Claims), Section&nbsp;7.11.2(c) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(Biosimilar Products) and Section&nbsp;7.11.2(d) (Third Party Payments), except in the event of Section&nbsp;5.10.5 (Metagenomi Payments for Certain Technology) or Section&nbsp;7.11.2(c)(ii)
(Biosimilar Products), which, for clarity, may result in up to [***] reduction of the royalties. The Primary Party may carry forward any such reductions permitted in accordance with Section&nbsp;7.11.2(b) (Valid Claims), Section&nbsp;7.11.2(c)
(Biosimilar Products) and Section&nbsp;7.11.2(d) (Third Party Payments) that are incurred or accrued in a Calendar Quarter but that are not applied against royalties due to the <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Party for such DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Product in such country in such Calendar Quarter as a result of the foregoing floor and apply such amounts against royalties due to the <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Party for such DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Product in such country in any subsequent Calendar Quarter (subject to the minimum floor set forth in this Section&nbsp;7.11.2(e) (Cumulative Reductions Floor)) until the amount of such reduction has been
fully applied against royalties due to the <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Party for such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product in such country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.12 <B>Payment; Reports; Royalty Minimum</B>. Royalty payments due under this Article 7 (Fees; Royalties, &amp; Payments) shall be
calculated, reported and invoiced for each Calendar Quarter. Within [***] after the end of each Calendar Quarter, Moderna (or the Primary Party, as the case may be) shall provide Metagenomi (or the <FONT STYLE="white-space:nowrap">Opt-Out</FONT>
Party, as the case may be) a report setting forth Net Sales and royalty for each applicable Product in the Territory or <FONT STYLE="white-space:nowrap">Ex-U.S.,</FONT> as applicable, in such Calendar Quarter. Metagenomi (or the <FONT
STYLE="white-space:nowrap">Opt-Out</FONT> Party, as the case may be) shall send an invoice for the applicable royalty payment within [***] after receiving the report from Moderna (or the Primary Party, as the case may be). The applicable royalty
payments shall be paid within [***] following the receipt of the invoice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.13 <B>Method of Payment; Foreign Exchange</B>. Unless
otherwise agreed by the Parties, all payments due under this Agreement shall be paid in Dollars by wire transfer or electronic funds transfer of immediately available funds to an account designated by the payee; provided that each Party shall only
be required to disburse funds to the payee&#146;s jurisdiction of incorporation or to a jurisdiction in which the payee has a significant business presence. For any currency conversion required in determining the amount of payments due hereunder,
such conversion shall be made as follows: (a)&nbsp;when calculating Net Sales, the amount of such sales in foreign currencies shall be converted into Dollars using the average rate of exchange over the applicable Calendar Quarter as reported in The
Wall Street Journal, Internet U.S. Edition at www.wsj.com, as of the last day of the applicable reporting period (or, if unavailable on such date, the first date thereafter on which such rate is available), and (b)&nbsp;when calculating all other
sums due under this Agreement, the amount in foreign currencies shall be converted into Dollars using the average rate of exchange for the applicable month as reported in The Wall Street Journal, Internet U.S. Edition at www.wsj.com, as of the last
day of the applicable month (or, if unavailable on such date, the first date thereafter on which such rate is available). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.14 <B>Records
and Audits</B>. Each Party shall keep, and shall cause its Affiliates and Sublicensees to keep, complete and accurate records which may be necessary to ascertain properly and to verify the royalty payments due hereunder. Such records shall be kept
for such period of time required by Applicable Laws. Within the Term, the other Party shall not more than once each year have the right to have its independent, certified public accountant inspect such Party&#146;s records for the purpose of
determining the accuracy of royalty payments for a period covering not more than [***] following the Calendar Quarter to which they pertain. No period shall be audited more than once. The other Party shall submit an audit plan, including audit
scope, to such Party for its </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approval, which shall not be unreasonably withheld, conditioned or delayed, prior to audit implementation. The independent, certified public accountant selected shall keep confidential any
information obtained during such inspection and shall report to the Parties only the amounts of Net Sales and royalties due and payable. Such audits may be exercised during normal business hours upon reasonable prior written notice to such Party. If
determined that additional royalties are owed, or that royalties were overpaid, during such period, such Party shall pay the other Party the additional royalties or the other Party shall pay such Party the overpaid royalties, as applicable, within
[***] of the date the independent, certified public accountant&#146;s written report is received by the paying Party. The fees charged by the accounting firm of such accountant shall be paid by the auditing Party unless any additional royalties owed
exceed [***] and [***] of the royalties paid for the royalty period subject to the audit, in which case the audited Party shall pay the reasonable fees of such accounting firm. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.15 <B>Default Interest</B>. If and to the extent that either Party fails to make any payment hereunder when due in accordance with the
applicable provisions of this Agreement (excluding any payment made due to a good faith error identified via an audit conducted by an independent, certified public accountant pursuant to Section&nbsp;7.14 (Records and Audits)), such Party shall pay
to the other Party default interest at a rate of [***] as from the due date (as reported in <I>The Wall Street Journal</I> (Eastern U.S. edition)) or the maximum rate allowable by Applicable Law, whichever is less. Interest shall be paid on a simple
annual interest rate. From and after the Effective Date, the Parties shall meet in good faith and agree on an appropriate replacement for the LIBOR rate to be used in substitution hereunder (with such agreed replacement to be appropriately
documented in writing and termed as expressly superseding the operation of this Section&nbsp;7.15 (Default Interest)), with such agreed replacement to be implemented prior to the [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.16 <B>Taxes</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.16.1
<B>Partnership Tax Matters</B>. Each Party shall be solely responsible for the payment of all taxes imposed on its share of income arising directly or indirectly from the collaborative efforts of the Parties under this Agreement. The Parties intend
that the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program gives rise to a partnership solely for U.S. federal and applicable state and local income tax purposes, and shall be governed by the terms of <B>Schedule M </B>(Partnership Tax
Matters) with respect to the tax matters set forth therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.16.2 <B>Cooperation and Coordination</B>. Except as set forth in
Section&nbsp;7.16.1 (Partnership Tax Matters) or <B>Schedule M </B>(Partnership Tax Matters) with respect to the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program, the Parties acknowledge and agree that it is their mutual objective and intent
to minimize, to the extent feasible and in compliance with Applicable Laws, taxes payable with respect to their collaborative efforts under this Agreement and that they shall use reasonable efforts to cooperate and coordinate with each other to
achieve such objective. Each Party shall provide the other with reasonable assistance to enable the recovery, as permitted by Applicable Law, of withholding taxes resulting from payments made under this Agreement, such recovery to be for the benefit
of the Party bearing such withholding tax. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.16.3 <B>Payment of Tax</B>. Except as set forth in Section&nbsp;7.16.1 (Partnership Tax
Matters) or <B>Schedule M </B>(Partnership Tax Matters) with respect to the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program, the upfront, milestones, royalties and other amounts payable by one Party to the other Party under this Agreement
(each, a &#147;<B>Payment</B>&#148;) shall be paid free and clear of any and all taxes, except for any withholding taxes required by Applicable Law. Except as provided in this Section&nbsp;7.16.3 (Payment of Tax), the payee shall be solely
responsible for paying any and all taxes (other than withholding taxes required by Applicable Law to be deducted from Payments and remitted by the payor) levied on account of, or measured in whole or in part by reference to, any Payments it
receives. The payor shall deduct or withhold from the Payments any taxes that it is required by Applicable Law to deduct or withhold. Notwithstanding the foregoing, if the payee is entitled under any applicable tax treaty to a reduction of rate of,
or the elimination of, applicable withholding tax, it may deliver to the payor or the appropriate Governmental Authority (with the assistance of the payor to the extent that this is reasonably required and is expressly requested in writing) the
prescribed forms necessary to reduce the applicable rate of withholding or to relieve the payor of its obligation to withhold such tax and the payor shall apply the reduced rate of withholding or dispense with withholding as the case may be;
provided that the payor has received evidence, in a form satisfactory to the payor, of the payee&#146;s delivery of all applicable forms (and, if necessary, its receipt of appropriate governmental authorization) at least [***] prior to the time
Payments are due. If in accordance with the foregoing, the payor withholds any amounts of tax, it shall pay to the payee the balance when due, make timely payment to the proper tax authority of the withheld amount and send to the payee proof of such
payment within [***] following such payments. If the paying party failed to deduct or withhold tax required by Applicable Law, the payee shall indemnify and hold harmless the paying party from any such taxes and further, shall assist the paying
party with regard to all procedures required in order to obtain relief and, if appropriate, reimbursement by tax authorities (including providing proof, if applicable, that the appropriate tax has in fact been paid by the payee) or, in case tax
authorities will not reimburse withholding tax to the paying party, the payee will immediately pay to the paying party (for remittance to the appropriate taxing authority to the extent not previously paid to such authorities by the paying party) the
amount of such tax not previously paid by the payee to the appropriate taxing authority. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Article 8 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INTELLECTUAL PROPERTY </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.1
<B>Ownership of Intellectual Property</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.1.1 <B>Inventorship</B><I>.</I> Inventorship as between the Parties shall be determined in
accordance with U.S. patent laws. All such determinations shall be documented to ensure any patent applications and patents reflect appropriate inventorship. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.1.2 <B>Ownership of Intellectual Property</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Except as expressly set forth herein otherwise, as between the Parties, any and all Results and
<FONT STYLE="white-space:nowrap">Know-How,</FONT> whether patentable or not, conceived, discovered, invented or created in the course of performing the activities or exercising their rights under this Agreement solely by a Party or jointly by the
Parties, their Affiliates, or Third Parties acting on its or their behalf, and all intellectual property rights inherent therein and appurtenant thereto, including all Patents, copyrights, trademarks, and trade secrets arising therefrom
(collectively, &#147;<B>Program Technology</B>&#148;) shall be owned in accordance with inventorship rules under U.S. patent law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Notwithstanding anything herein to the contrary, Metagenomi shall solely own all right,
title and interest to any Program Technology [***] (collectively, &#147;<B>Metagenomi Program Technology</B>&#148;). Moderna hereby assigns, transfers and conveys to Metagenomi, or its designee, all of Moderna&#146;s worldwide right, title and
interest in and to any and all Metagenomi Program Technology. Metagenomi agrees to grant and hereby grants Moderna and its Affiliates a perpetual, irrevocable, worldwide, royalty-free, sublicensable (through multiple tiers of sublicensees),
transferable (solely in accordance with Section&nbsp;14.7 (Assignment)), <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license, under all Metagenomi Program Technology to the extent pertaining to [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Notwithstanding anything herein to the contrary, Moderna shall solely own all right, title and interest to any Program Technology [***]
(&#147;<B>Moderna Program Technology</B>&#148;). Metagenomi hereby assigns, transfers and conveys to Moderna, or its designee, all of Metagenomi&#146;s worldwide right, title and interest in and to any and all Moderna Program Technology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) Notwithstanding anything herein to the contrary, any Program Technology discovered, invented, conceived or created during the applicable
Research Term that is neither Metagenomi Program Technology nor Moderna Program Technology shall be jointly owned by Moderna and Metagenomi (&#147;<B>Joint IP</B>&#148;). Each Party shall and hereby does assign to the other Party an undivided <FONT
STYLE="white-space:nowrap">one-half</FONT> interest in such first Party&#146;s right, title, and interest in and to all Joint IP made by or on behalf of such first Party. Subject to the licenses granted hereunder and the other terms and conditions
of this Agreement, each Party may exercise its ownership rights in and to Joint IP, including the right to license and sublicense or otherwise to exploit, transfer or encumber its ownership interest, throughout the world, without an accounting or
obligation (including paying royalties) to, or consent required from, the other Party. At the reasonable written request of a Party, the other Party shall take such further actions to confirm that no such accounting is required or to otherwise
effect the foregoing regarding Joint IP. Each Party agrees to hold Joint IP (and any <FONT STYLE="white-space:nowrap">Know-How</FONT> therein) in confidence subject to the same permitted disclosures set forth in Article 11 (Confidentiality) (applied
<I>mutatis mutandis</I> to the Joint IP consistent with each Party&#146;s rights to exploit the Joint IP) and shall not disclose such <FONT STYLE="white-space:nowrap">Know-How</FONT> to a Third Party unless under terms of confidentiality that
preserve the Parties&#146; ability to pursue Patents as set forth hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.1.3 <B>Assignment Obligation</B>. Each Party shall cause
all employees, independent contractors, consultants, and others who perform activities for such Party under this Agreement to be under an obligation to assign to such Party their rights in and to any Program Technology and all intellectual property
rights therein, except where Applicable Laws requires otherwise and except in the case of governmental, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">not-for-profit</FONT></FONT> and public institutions that have standard
policies against such an assignment (in which case a Party shall obtain a suitable license, preferably exclusive, or right to obtain such a license). Each Party shall use reasonable efforts to promptly disclose to the other Party all Program
Technology, including any invention disclosures, or other similar documents, submitted to it by its employees, agents or independent contractors describing such Program Technology, and all information relating to such Program Technology to the
extent necessary or useful for the preparation, filing and maintenance of any Patent with respect to such Program Technology. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.2 <B>Patent Prosecution and Maintenance</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.2.1 <B>Generally</B>. Subject to the remainder of this Section&nbsp;8.2 (Patent Prosecution and Maintenance), each Party shall control the
Prosecution and Maintenance of Patents that such Party Controls (other than Control obtained pursuant to a grant of rights under this Agreement). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.2.2 <B>Patents Within Metagenomi&#146;s Background Technology</B>. As between the Parties, Metagenomi shall have the first right, but not
the obligation, to Prosecute and Maintain any Patents within Metagenomi&#146;s Background Technology, at its sole expense. Metagenomi shall keep Moderna reasonably informed of the status of all Patents relevant to an applicable Program and shall
promptly provide Moderna with all material correspondence received from any patent authority in connection therewith. In addition, Metagenomi shall provide Moderna with drafts of all proposed material filings and correspondence to any patent
authority with respect to any such Patents for Moderna&#146;s review with reasonable time for Moderna to provide comments prior to the submission of such proposed filings and correspondences, and Metagenomi shall consider Moderna&#146;s reasonable
comments in good faith. Notwithstanding anything herein to the contrary, in connection with such Prosecution and Maintenance, Metagenomi shall take all reasonable steps to ensure that such Patents Cover the applicable Products. Metagenomi shall
notify Moderna of its intention to suspend or cease any Prosecution and Maintenance of any such Patents. Metagenomi shall provide such notice at least [***] prior to any filing or payment due date in connection with such Patents. In such event,
Metagenomi shall permit Moderna, at Moderna&#146;s discretion and at its sole expense, to continue Prosecution and Maintenance of such Patents, subject to the foregoing information sharing obligation and review and comment rights applied <I>mutatis
mutandis</I>. The Parties shall in good faith cooperate through the JPC (or as otherwise agreed in an applicable Working Group or by the Parties) to effect the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.2.3 <B>Program Patents Exclusively Licensed to Moderna</B>. As between the Parties, Moderna shall have the first right, but not the
obligation, to Prosecute and Maintain any Program Patents licensed exclusively to Moderna by Metagenomi under this Agreement, and Moderna shall bear the cost of such Prosecution and Maintenance. [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.2.4 <B>Joint Patents</B>. Subject to Section&nbsp;8.2.3 (Program Patents Exclusively Licensed to Moderna), the JPC shall determine which
Party has the first right, but not the obligation, to Prosecute and Maintain all Joint Patents. [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.2.5 <B>Cooperation of the
Parties</B>. Each Party shall cooperate fully with the other Party, through the JPC, in the Prosecution and Maintenance of Patents under this Section&nbsp;8.2 (Patent Prosecution and Maintenance) at its own cost (except as expressly set forth
otherwise in this Article 8 (Intellectual Property)), including by: (a)&nbsp;executing all papers and instruments, or requiring its employees or contractors, to execute such papers and instruments, to enable the other Party to apply for and to
Prosecute and Maintain such Patents in any country as permitted by this Section&nbsp;8.2 (Patent Prosecution and Maintenance) and (b)&nbsp;promptly informing the other Party of any matters coming to such Party&#146;s attention that may affect the
Prosecution and Maintenance of any such Patents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.3 <B>Infringement by Third Parties</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.3.1 <B>Notice</B>. Each Party shall notify the other within [***] of becoming aware of any alleged or threatened infringement by a Third
Party of any of the Program Patents or Patents within either Party&#146;s Background Technology, which infringing activity involves the using, making, importing, offering for sale or selling any (i)&nbsp;Product, any (ii)&nbsp;Biosimilar Product
with respect thereto, or (iii)&nbsp;for each Collaboration Target, otherwise involving such Collaboration Target and Gene Editing in such Collaboration Target&#146;s respective field, i.e., in the DT Field or the RT Field, as applicable, in each
case ((i) through (iii)) in the applicable DT Field or RT Field in the Territory, and any related declaratory judgment, opposition or similar action alleging the invalidity, unenforceability or
<FONT STYLE="white-space:nowrap">non-infringement</FONT> of any of the Program Patents or Patents within either Party&#146;s Background Technology (collectively &#147;<B>Infringement</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.3.2 <B>Generally</B>. Subject to the remainder of this Section&nbsp;8.3 (Infringement by Third Parties), each Party shall have the sole
right to bring and control any legal action in connection with any Infringement of Patents claiming inventions that such Party Controls (other than Control obtained pursuant to a grant of rights under this Agreement). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.3.3 <B>Patents Within Metagenomi&#146;s Background Technology</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) As between the Parties, Moderna shall have the first right to bring and control any legal action in connection with any Infringement of
any Patents within Metagenomi&#146;s Background Technology, where such Infringement relates to [***]. Moderna shall keep Metagenomi reasonably informed of the status of such enforcement efforts for such Patents. Metagenomi may, at its own expense,
be represented in any such action by counsel of its own choice with respect to the enforcement of any such Patents. If Moderna does not bring such legal action within a commercially reasonable period of time (but not less than [***]) after the
notice provided pursuant to Section&nbsp;8.3.1 (Notice), Metagenomi may bring and control any legal action in connection with such Infringement of such Patents at its own expense as it reasonably determines appropriate so long as Moderna does not
reasonably object to such action. In such case, Metagenomi shall keep Moderna reasonably informed of the status of such enforcement efforts for such Patents, and Moderna may, at its own expense, be represented in any such action by counsel of its
own choice with respect to the enforcement of such Patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) As between the Parties, Metagenomi shall have the first right to bring
and control any legal action in connection with any Infringement of any Patents within Metagenomi&#146;s Background Technology, where such Infringement relates to [***], in each case at Metagenomi&#146;s own expense (and, for clarity, whether or not
such Infringement falls within the scope of any license granted to Metagenomi hereunder). Metagenomi shall keep Moderna reasonably informed of the status of such enforcement efforts for such Patents. Moderna may, at its own expense, be represented
in any such action by counsel of its own choice with respect to the enforcement of any such Patents. If Metagenomi does not bring such legal action within a commercially reasonable period of time (but not less than [***]) after the notice provided
pursuant to Section&nbsp;8.3.1 (Notice), Moderna may bring and control any legal action in connection with such Infringement of such Patents at its own expense as it reasonably determines appropriate so long as Metagenomi does not reasonably object
to such action. In such case, Moderna shall keep Metagenomi reasonably informed of the status of such enforcement efforts for such Patents, and Metagenomi may, at its own expense, be represented in any such action by counsel of its own choice with
respect to the enforcement of such Patents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.3.4 <B>Program Patents Exclusively Licensed to Moderna</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.3.5 <B>Joint
Patents</B>. Subject to Section&nbsp;8.3.4 (Program Patents Exclusively Licensed to Moderna), the JPC shall determine which Party has the first right, but not the obligation, to bring and control any legal action in connection with any Infringement
of any Joint Patents, subject to either Party electing to so enforce at the enforcing Party&#146;s sole expense. The enforcing Party shall keep the other Party reasonably informed of the status of such enforcement efforts for such Joint Patents and
shall consider in good faith such other Party&#146;s comments thereon. The enforcing Party shall provide the other Party with drafts of all material papers to be filed with the court and shall in good faith incorporate all reasonable comments
thereto by such other Party before filing such papers. The other Party may, at its own expense, be represented in any such action by counsel of its own choice. If the enforcing Party does not bring such legal action within a commercially reasonable
period of time (but not less than [***]) after the notice provided pursuant to Section&nbsp;8.3.1 (Notice), the other Party may bring and control any legal action in connection with such Infringement of any such Program Patents at its own expense as
it reasonably determines appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.3.6 <B>Biosimilar Applications</B>. Notwithstanding the foregoing provisions of this
Section&nbsp;8.3 (Infringement by Third Parties), if either Party or any of their Affiliates receives a copy of a Biosimilar Application naming a Product as a reference product or otherwise becomes aware that such a Biosimilar Application has been
filed (such as in an instance described in Section&nbsp;351(1)(9)(C) of the PHSA), such Party shall promptly notify the other Party. If either Party receives any equivalent or similar certification or notice in the U.S. or any other jurisdiction,
either Party shall, promptly, notify and provide the other Party copies of such communication. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) For all Licensed Products, Moderna,
and for all DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products, the Party designated by the JSC, (in either case, the &#147;<B>Designated Party</B>&#148;) shall designate pursuant to Section&nbsp;351(l)(1)(B)(ii) of the PHSA the outside
counsel and <FONT STYLE="white-space:nowrap">in-house</FONT> counsel who shall receive confidential access to the Biosimilar Application. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The Designated Party shall have the right, after consulting with the other Party, to list any Program Patents or Patents within either
Party&#146;s Background Technology, insofar as they meet the statutory requirements pursuant to Section&nbsp;351(l)(1)(3)(A), Section&nbsp;351(l)(5)(b)(i)(II), or Section&nbsp;351(l)(7) of the PHSA, to respond to any communications with respect to
such lists from the filer of the Biosimilar Application, and to negotiate with the filer of the Biosimilar Application as to whether to utilize a different mechanism for information exchange other than that specified in Section&nbsp;351(l) of the
PHSA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) The Designated Party shall have the right, after consulting with the other Party, to identify Program Patents or Patents
within either Party&#146;s Background Technology to list, or respond to relevant communications under any equivalent or similar listing to those described in the preceding Section&nbsp;8.3.6(b) (Biosimilar Applications) in any other jurisdiction
outside of the U.S. If required pursuant to Applicable Law, upon the Designated Party&#146;s request, the other Party shall assist in the preparation of such list and make such response after consulting with the Primary Party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) The Parties recognize that procedures other than those set forth above in this
Section&nbsp;8.3.6 (Biosimilar Applications) may be applicable to Biosimilar Applications that are not governed by the PHSA. As a result, in the event that the Parties acting in good faith mutually determine that certain provisions of Applicable
Laws in the U.S. or in any other country in the Territory are applicable to actions taken by the Parties with respect to Biosimilar Applications under this Section&nbsp;8.3.6 (Biosimilar Applications) in such country, the Parties shall comply with
any such Applicable Law in such country in exercising their rights and obligations with respect to Biosimilar Applications under this Section&nbsp;8.3.6 (Biosimilar Applications). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.3.7 <B>Enforcement Costs for <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products</B>. Except as expressly set forth herein, all Internal
Costs and External Costs incurred by the Parties in connection with any suit or other action brought by a Party under this Section&nbsp;8.3.7 (Enforcement Costs for <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products) with respect to any
Infringement regarding a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product in the Territory shall be considered &#147;<B>Shared Patent Enforcement Costs</B>&#148; that shall be shared [***] between the Parties as an Other Operating Expense in
accordance with Section&nbsp;7.4 <FONT STYLE="white-space:nowrap">(Co-Co</FONT> Products Profit and Loss Share). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.3.8 <B>Allocation of
Recoveries for <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products</B>. Any recoveries resulting from enforcement action relating to a claim of Infringement regarding a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product in the Territory,
whether by settlement or judgment, shall be allocated as follows: [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.3.9 <B>Allocation of Recoveries for Licensed Products</B>. Any
recoveries resulting from enforcement action relating to a claim of Infringement regarding a Licensed Product, whether by settlement or judgment, shall [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.3.10 <B>Allocation of Recoveries in All Other Infringements</B>. [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.3.11 <B>Cooperation</B>. At the request and expense of the Party bringing an action under this Section&nbsp;8.3 (Infringement by Third
Parties), the other Party shall provide reasonable assistance in connection therewith, including by executing reasonably appropriate documents, cooperating in discovery and joining as a party to the action if required by Applicable Laws to pursue
such action. In connection with any such enforcement action, the Party bringing the action shall not enter into any settlement admitting the invalidity or <FONT STYLE="white-space:nowrap">non-infringement</FONT> of, or otherwise impairing the other
Party&#146;s rights in the applicable Patents without the prior written consent of the other Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.4 <B>Defense and Settlement of
Third Party Claims</B>. Each Party shall promptly notify the other in writing of (a)&nbsp;any allegation by a Third Party that the activity of either of the Parties pursuant to this Agreement infringes or may infringe the intellectual property
rights of such Third Party, including any inter partes review proceeding at the U.S. Patent and Trademark Office or foreign equivalent patent office (each a &#147;<B>Third Party Claim</B>&#148;), or (b)&nbsp;any declaratory judgment action that is
brought naming either Party as a defendant and alleging invalidity of any of the Program Patents other than in response to an Infringement action under Section&nbsp;8.3 (Infringement by Third Parties) (each a &#147;<B>Third Party Patent
Challenge</B>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.4.1 <B>Responsibility to Defend a Third Party Claim</B>. Each Party that is named as a
defendant in a Third Party Claim proceeding shall have the right to defend itself in such proceeding. The other Party shall reasonably assist the defending Party in defending such proceeding and cooperate in any such litigation at the request and
expense of the defending Party. The defending Party shall provide the other Party with prompt written notice of the commencement of any such proceeding and shall keep the other Party apprised of the progress of such proceeding and shall promptly
furnish the other Party with a copy of each pleading, communication, or other document relating to the alleged infringement that is received by such Party and shall consider reasonable input from the other Party during the course of the proceeding.
If the defending Party is Metagenomi, then Moderna shall be entitled to attend any substantive meetings, hearings, or other proceedings related to such claim (to the extent relevant, together with its own counsel, at its own expense). If the
defending Party is Moderna, then Metagenomi shall be entitled to attend any substantive meetings, hearings, or other proceedings related to such claim (to the extent relevant, together with its own counsel, at its own expense). If both Parties are
named as defendants in any such proceeding brought by a Third Party, both Parties may defend such proceeding and the Parties shall reasonably cooperate with respect to such defense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.4.2 <B>Right to Defend and Settle a Third Party Patent Challenge</B>. The prosecuting Party shall have the first right, but not the
obligation, to control the defense of any Third Party Patent Challenge relating to any Patent for which it is the prosecuting Party and to compromise, litigate, settle, or otherwise dispose of any such challenge, provided that if the prosecuting
Party notifies the <FONT STYLE="white-space:nowrap">non-prosecuting</FONT> Party that it declines to exercise such first right, then the <FONT STYLE="white-space:nowrap">non-prosecuting</FONT> Party shall have the right to control such defense and
to compromise, litigate, settle or otherwise dispose of such challenge. The Party defending the Third Party Patent Challenge shall keep the other Party timely informed of the proceedings and filings, and provide the other Party with copies of all
material communications, pertaining to each Third Party Patent Challenge. The Party defending the Third Party Patent Challenge shall not settle, stipulate to any facts, or make any admission with respect to any Third Party Patent Challenge without
the other Party&#146;s prior written consent (not to be unreasonably withheld, conditioned or delayed) if such settlement, stipulation, or admission would (a)&nbsp;adversely affect the validity, enforceability or scope, or admit infringement, of any
of the Program Patents; (b)&nbsp;give rise to liability of the other Party or its Affiliates; or (c)&nbsp;otherwise impair the other Party&#146;s or any of its Affiliates&#146; rights in the Program Patents under this Agreement. Upon the defending
Party&#146;s request, the other Party shall reasonably cooperate with the defending Party, to the extent necessary to defend the Third Party Patent Challenge. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.4.3 <B>Costs, Damages, and Recoveries</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <B>Costs of Defending Patent Challenges</B>. Each Party shall bear its own Internal Costs related to any Third Party Patent Challenge,
and each Party shall be responsible for [***] of the External Costs incurred with respect to any Third Party Patent Challenge of a Patent relating to a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product in the Territory and such External Costs
shall be considered &#147;<B>Shared Patent Defense Costs</B>&#148; that shall be shared [***] between the Parties as an Other Operating Expense in accordance with Section&nbsp;7.4 <FONT STYLE="white-space:nowrap">(Co-Co</FONT> Products Profit and
Loss Share). The other Party shall reimburse the Party defending such Third Party Patent Challenge for its share of such External Costs pursuant to the preceding sentence either (i)&nbsp;through the Operating Profits or Losses reimbursement
procedure set forth in Section&nbsp;7.4 <FONT STYLE="white-space:nowrap">(Co-Co</FONT> Products Profit and Loss Share) or (ii)&nbsp;within thirty (30)&nbsp;days of receiving the defending Party&#146;s invoice therefor, as applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <B>Licensed Products</B>. Subject to Article 10 (Indemnification), with respect to any
Third Party Claim for allegedly infringing activities conducted with respect to a Licensed Product in the Territory, the Party against whom such claim was brought shall bear [***] of such cost, damages, or recovery. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) <B><FONT STYLE="white-space:nowrap">Co-Co</FONT> Products</B>. Subject to Article 10 (Indemnification), with respect to any Third Party
Claim for allegedly infringing activities conducted with respect to a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product in the Territory, (i)&nbsp;the Internal Costs and External Costs in defending and any damages paid by the defending Party
shall be considered &#147;<B>Shared Infringement Defense Costs</B>&#148; that will be shared [***] between the Parties as an Other Operating Expense in accordance with Section&nbsp;7.4 <FONT STYLE="white-space:nowrap">(Co-Co</FONT> Products Profit
and Loss Share) and (ii)&nbsp;any recoveries obtained shall be considered Net Sales of the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product in the Territory, if applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) <B>Other Damages and Recoveries</B>. Subject to Article 10 (Indemnification), with respect to any Third Party Claim other than claims
described in Section&nbsp;8.4.3(b) (Licensed Products) or Section&nbsp;8.4.3(c) <FONT STYLE="white-space:nowrap">(Co-Co</FONT> Products), the Party against whom such claim was brought shall bear [***] of such cost, damages, or recovery. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.5 <B>Patent Extension</B>. [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.6 <B>Unified Patent Court</B>. In the event that Unified Patent Court Agreement enters into force during the Term of this Agreement, the JPC
shall be solely responsible for making all decisions regarding Patents, including decisions regarding the <FONT STYLE="white-space:nowrap">opting-out</FONT> or <FONT STYLE="white-space:nowrap">opting-in</FONT> of existing European Patents into the
jurisdiction of the Unified Patent Court or the registration of European Patents with Unitary Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.7 <B>Common Interest</B>. All
information exchanged between the Parties regarding the prosecution, maintenance, enforcement, and defense of Patents under this Article 8 (Intellectual Property) shall be the Confidential Information of the disclosing Party. In addition, the
Parties acknowledge and agree that, with regard to such prosecution, maintenance, enforcement, and defense the interests of the Parties as collaborators and licensor and licensee are to obtain the strongest patent protection possible, and as such,
are aligned and are legal in nature. The Parties agree and acknowledge that they have not waived, and nothing in this Agreement constitutes a waiver of, any legal privilege concerning the Patents under this Article 8 (Intellectual Property),
including privilege under the common interest doctrine and similar or related doctrines. Notwithstanding anything to the contrary set forth in this Agreement, to the extent a Party has a good faith believe that any information required to be
disclosed by such Party to the other Party under this Article 8 (Intellectual Property) is protected by attorney-client privilege or any other applicable legal privilege or immunity, such Party shall not be required to disclose such information and
the Parties shall in good faith cooperate to agree upon a procedure (including entering into a specific common interest agreement, disclosing such information on a &#147;for counsel eyes only&#148; basis or similar procedure) under which such
information may be disclosed without waiving or breaching such privilege or immunity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.8 <B>Trademarks</B>. Moderna shall have the right
to select, and shall be free, in its sole discretion, to use and to register in any trademark office in the Territory, any Trademark for use with a Licensed Product. As between the Parties, Moderna shall own all right, title and interest in and to
any such Trademarks adopted by Moderna for use with a Licensed Product, and is responsible for the registration, filing, maintenance and enforcement thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Article 9 </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>REPRESENTATIONS, WARRANTIES AND COVENANTS </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.1 <B>Mutual Representations and Warranties</B>. Each of Moderna and Metagenomi represent and warrant, as of the Effective Date, that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.1.1 it is duly organized and validly existing under in the Applicable Laws of the jurisdiction of its incorporation or formation, as
applicable, has full corporate, limited liability company or other power and authority, as applicable, to enter into this Agreement and to carry out the provisions hereof, and has sufficient facilities, experienced personnel or other capabilities
(including via Affiliates or Third Parties) to enable it to perform its obligations under this Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.1.2 it is duly authorized to
execute and deliver this Agreement and to perform its obligations hereunder, and the individual executing this Agreement on its behalf has been duly authorized to do so by all requisite corporate, limited liability company or other action, as
applicable; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.1.3 this Agreement is legally binding upon it and enforceable in accordance with its terms (except as the
enforceability thereof may be limited by bankruptcy, bank moratorium or similar laws affecting creditors&#146; rights generally and laws restricting the availability of equitable remedies and may be subject to general principles of equity whether or
not such enforceability is considered in a proceeding at law or in equity) and the execution, delivery and performance of this Agreement by it have been duly authorized by all necessary corporate action and do not and shall not: (a)&nbsp;conflict
with, or constitute a default or result in a breach under, any agreement, instrument or understanding, oral or written, to which it is a party or by which it may be bound, or violate any Applicable Law; or (b)&nbsp;require any consent or approval of
its stockholders or similar. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.2 <B>Metagenomi Representations and Warranties</B>. Metagenomi represents and warrants to Moderna that, as
of the Effective Date: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.2.1 <B>No DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Target or Reserved DT Targets Encumbered</B>. There
are no DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Target or Reserved DT Targets that are subject to an agreement between Metagenomi or any of its Affiliates and a Third Party of any kind or Metagenomi&#146;s (or its Affiliates&#146;)
commitment to negotiate an agreement with a Third Party that would prevent, limit or conflict with the inclusion of the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Target or Reserved DT Targets under this Agreement on an exclusive basis or
licenses granted herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.2.2 <B>Metagenomi Not Developing Products Against RT Targets in the RT Field or DT Targets in the DT
Field</B>. Metagenomi itself is not (and none of its Affiliates is) developing any products Directed Against or that work through, or are based on, and has granted no rights to any Third Party with respect to, any RT Target within the RT Field or
any DT Target within the DT Field. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.2.3 <B>No Grants That Conflict with This Agreement</B>. Metagenomi or its Affiliates have
not granted, and shall not grant during the Term, any rights (or other encumbrances) to any Third Party to Metagenomi Licensed Collaboration Technology that would prevent, limit or conflict with the rights and licenses granted to Moderna hereunder.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.2.4 <B>Control over <FONT STYLE="white-space:nowrap">Know-How</FONT> and Patents</B>. Metagenomi has Control over all <FONT
STYLE="white-space:nowrap">Know-How</FONT> and Patent rights owned by it or its Affiliates as of the Effective Date that are necessary or reasonably useful for the Research, Development, Manufacturing (including formulation), Commercialization or
other Exploitation of the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products as known to be contemplated under this Agreement as of the Effective Date. To Metagenomi&#146;s knowledge, the Regents of the University of California
(&#147;<B>UC</B>&#148;) has no right and has no reason to claim any right in any such <FONT STYLE="white-space:nowrap">Know-How</FONT> or Patent rights that would prevent, limit or conflict with the rights and licenses granted to Moderna hereunder.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.2.5 <B>Existing Patents</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) To Metagenomi&#146;s knowledge, all Patent rights contained in the Metagenomi Licensed Collaboration Technology existing as of the
Effective Date that are issued or subject to a pending application for issuance (the &#147;<B>Existing Patents</B>&#148;) are listed on <B>Schedule K </B>and all such Existing Patents are: (i)&nbsp;to the extent issued (unless otherwise indicated on
<B>Schedule</B><B></B><B>&nbsp;K </B>(Existing Patents)), subsisting and not invalid or unenforceable, in whole or in part; (ii)&nbsp;solely and exclusively owned by Metagenomi, free of any encumbrance, lien or claim of ownership by any Third Party;
(iii)&nbsp;to the extent subject to a pending application for issuance, being diligently prosecuted in the respective patent offices in which such applications have been filed in accordance with Applicable Laws and Metagenomi and its Affiliates have
presented all relevant references, documents and information to the relevant patent examiner at the relevant patent office; and (iv)&nbsp;filed and maintained properly and correctly, and no applicable fees applicable thereto when due and payable, as
may be or have been extended, have gone unpaid. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) To Metagenomi&#146;s knowledge, neither Metagenomi nor any of its Affiliates have
taken any action that would render any invention claimed in the Existing Patents unpatentable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) The Existing Patents represent all
Patents in the Metagenomi Licensed Collaboration Technology that relate to the DT Targets, the Products (anticipated as of the Effective Date), or the Exploitation thereof as of the Effective Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) To Metagenomi&#146;s knowledge, other than the rights granted under this Agreement, no rights or licenses are required under any Patent
rights Covering Gene Editing to practice the Metagenomi Licensed Collaboration Technology as contemplated in the Program Plans as of the Effective Date, or to Research, Develop, Manufacture (including to formulate), Commercialize or otherwise
Exploit the Products as contemplated herein by reason of the incorporation of Metagenomi Licensed Collaboration Technology in such Products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) None of the Metagenomi Licensed Collaboration Technology is subject to any existing royalty or other payment obligations to any Third
Party under any agreement or understanding entered into by Metagenomi or its Affiliates, and Metagenomi has no knowledge of any obligation to pay any royalties or other amounts to any Third Party by reason of Moderna&#146;s use thereof as
contemplated under this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) Metagenomi has not given any written notice to any Third Party asserting infringement
by such Third Party of any of the Metagenomi Licensed Collaboration Technology and, to Metagenomi&#146;s knowledge, there is no unauthorized use, infringement or misappropriation of the Metagenomi Licensed Collaboration Technology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.2.6 <B>No Third Party Agreements</B>. There are no licenses, terms of use or other agreements or arrangements with Third Parties regarding
any Metagenomi Licensed Collaboration Technology or other materials contemplated to be provided by Metagenomi to Moderna hereunder (or the Exploitation of any of the foregoing), to which Metagenomi or its Affiliate is a party or is otherwise bound,
that are inconsistent with or diminish the rights and licenses granted to Moderna under this Agreement, or Metagenomi&#146;s own right to Exploit them pursuant to this Agreement. Without limiting the generality of the foregoing, none of the
metagenomic data or sequence libraries used by Metagenomi to date is subject to any terms of use that are inconsistent with or diminish the rights and licenses granted to Moderna under this Agreement, or Metagenomi&#146;s own right to Exploit them
pursuant to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.2.7 <B>Litigation and Actions Relating to Intellectual Property</B>. Metagenomi or any of its Affiliates:
(a)&nbsp;have not received any written notice of any threatened claims or litigation seeking to invalidate or otherwise challenge the Metagenomi Licensed Collaboration Technology, including any Patents within the Metagenomi Licensed Collaboration
Technology, or Metagenomi&#146;s or its Affiliates&#146; rights therein; and (b)&nbsp;are not aware of any pending or threatened action, suit, proceeding or claim by a Third Party asserting that Metagenomi or any of its Affiliates is infringing or
has misappropriated or otherwise is violating any Patent right, trade secret or other proprietary right of any Third Party as would reasonably be expected to impair the ability of Metagenomi to fulfill any of its obligations under this Agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.2.8 <B>Other Material Claims and Actions</B>. There are no claims, actions or proceedings pending or, to Metagenomi&#146;s or any of
its Affiliates&#146; knowledge, threatened by any Third Party; nor, to Metagenomi&#146;s or any of its Affiliates&#146; knowledge, are there any formal inquiries initiated or written notices received that may lead to the institution of any such
legal proceedings, in each case (or in aggregate) against Metagenomi or its properties, assets or business, which if adversely decided, would, individually or in the aggregate, have a material adverse effect on, or prevent Metagenomi&#146;s ability
to conduct the Research or to grant the licenses or rights granted to Moderna under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.2.9 <B>No Government Funding</B>.
The inventions claimed or Covered by the Patents within the Metagenomi Licensed Collaboration Technology: (a)&nbsp;were not conceived, discovered, developed or otherwise made in connection with any research activities funded, in whole or in part, by
the federal government of the U.S. of America or any agency thereof; (b)&nbsp;are not a &#147;subject invention&#148; as that term is described in 35 U.S.C. &#167; 201(e) and (c)&nbsp;are not otherwise subject to the provisions of the Patent and
Trademark Law Amendments Act of 1980, as amended, codified at 35 U.S.C. &#167;&#167; <FONT STYLE="white-space:nowrap">200-212,</FONT> as amended, as well as any regulations promulgated pursuant thereto, including in 37 C.F.R. Part 401. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.2.10 <B>Regulatory Documentation</B>. To the extent that Metagenomi and its Affiliates
have generated, prepared, maintained and retained any Regulatory Documentation under this Agreement that is required to be maintained or retained pursuant to and in accordance with, to the extent applicable, good laboratory and clinical practice and
Applicable Laws, all such information is true, complete and correct in all material respects and what it purports to be. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.2.11 <B>Data
Protection and Data Privacy</B>. Metagenomi and its Affiliates&#146; have complied with all Applicable Laws related to data protection and data privacy and has provided all legally required privacy notices to, and obtained appropriate consents,
including research informed consents, from data subjects (&#147;<B>Notices and Consents</B>&#148;), and the Notices and Consents permit the use of the data as currently and previously used and processed by Metagenomi and shall permit the licensing
and transfer of all such personal data of data subjects to Moderna as contemplated in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.2.12 <B>Confidentiality</B>.
Metagenomi and its Affiliates have used commercially reasonable efforts to protect the confidentiality of those parts of the Metagenomi Licensed Collaboration Technology that constitute confidential or proprietary information of Metagenomi. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.3 <B>Moderna Representations and Warranties</B>. Moderna represents and warrants to Metagenomi that, as of the Effective Date: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.3.1 <B>No Grants That Conflict with This Agreement</B>. Moderna or its Affiliates have not granted, and shall not grant during the Term, any
rights (or other encumbrances) to any Third Party to Moderna Licensed Collaboration Technology that would prevent, limit or conflict with the rights and licenses granted to Metagenomi hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.3.2 <B>Control over <FONT STYLE="white-space:nowrap">Know-How</FONT> and Patents</B>. Moderna has Control over all <FONT
STYLE="white-space:nowrap">Know-How</FONT> and Patent rights owned by it or its Affiliates as of the Effective Date that are necessary or reasonably useful for the Research, Development, Manufacturing (including formulation), Commercialization or
other Exploitation of the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products as known to be contemplated under this Agreement as of the Effective Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.3.3 <B>No Third Party Agreements</B>. There are no license or other agreements with Third Parties regarding the Exploitation of any Moderna
Licensed Collaboration Technology or other materials contemplated to be provided by Moderna to Metagenomi hereunder, to which Moderna or its Affiliate is a party that is inconsistent with or diminishes the rights and licenses granted to Metagenomi
under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.3.4 <B>Litigation and Actions Relating to Intellectual Property</B>. Moderna or any of its Affiliates:
(a)&nbsp;have not received any written notice of any threatened claims or litigation seeking to invalidate or otherwise challenge the Moderna Licensed Collaboration Technology, including any Patents within the Moderna Licensed Collaboration
Technology, or Moderna&#146;s or its Affiliates&#146; rights therein; and (b)&nbsp;are not aware of any pending or threatened action, suit, proceeding or claim by a Third Party asserting that Moderna or any of its Affiliates is infringing or has
misappropriated or otherwise is violating any Patent right, trade secret or other proprietary right of any Third Party as would reasonably be expected to impair the ability of Moderna to fulfill any of its obligations under this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">9.3.5 <B>Other Material Claims and Actions</B>. There are no claims, actions or proceedings
pending or, to Moderna&#146;s or any of its Affiliates&#146; knowledge, threatened by any Third Party; nor, to Moderna&#146;s or any of its Affiliates&#146; knowledge, are there any formal inquiries initiated or written notices received that may
lead to the institution of any such legal proceedings, in each case (or in aggregate) against Moderna or its properties, assets or business, which if adversely decided, would, individually or in the aggregate, have a material adverse effect on, or
prevent Moderna&#146;s ability to conduct the Research or to grant the licenses or rights granted to Metagenomi under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">9.3.6 <B>No Government Funding</B>. The inventions claimed or Covered by the Patents within the Moderna Licensed Collaboration Technology:
(a)&nbsp;were not conceived, discovered, developed or otherwise made in connection with any research activities funded, in whole or in part, by the federal government of the U.S. of America or any agency thereof; (b)&nbsp;are not a &#147;subject
invention&#148; as that term is described in 35 U.S.C. &#167; 201(e) and (c)&nbsp;are not otherwise subject to the provisions of the Patent and Trademark Law Amendments Act of 1980, as amended, codified at 35 U.S.C. &#167;&#167; <FONT
STYLE="white-space:nowrap">200-212,</FONT> as amended, as well as any regulations promulgated pursuant thereto, including in 37 C.F.R. Part 401. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">9.3.7 <B>Regulatory Documentation</B>. To the extent that Moderna and its Affiliates have generated, prepared, maintained and retained any
Regulatory Documentation under this Agreement that is required to be maintained or retained pursuant to and in accordance with, to the extent applicable, good laboratory and clinical practice and Applicable Laws, all such information is true,
complete and correct in all material respects and what it purports to be. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">9.3.8 <B>Data Protection and Data Privacy</B>. Moderna and its
Affiliates&#146; have complied with all Applicable Laws related to data protection and data privacy and has provided all legally required privacy notices to, and obtained appropriate consents, including research informed consents, from data subjects
(&#147;<B>Notices and Consents</B>&#148;), and the Notices and Consents permit the use of the data as currently and previously used and processed by Moderna and shall permit the licensing and transfer of all such personal data of data subjects to
Metagenomi as contemplated in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">9.3.9 <B>Confidentiality</B>. Moderna and its Affiliates have used commercially reasonable
efforts to protect the confidentiality of those parts of the Moderna Licensed Collaboration Technology that constitute confidential or proprietary information of Moderna. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.4 <B>Covenants</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">9.4.1
<B>Employees, Consultants and Contractors</B>. Each Party represents, warrants and covenants that it and its Affiliates have obtained from each of its and their respective former and current employees, consultants and contractors, and shall obtain
from each of its and their respective future employees, consultants and contractors, in each case who have conceived, discovered, invented or created or who may conceive, discover, invent or create any of such Party&#146;s Licensed Collaboration
Technology, written agreements containing obligations of confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> and an assignment to such Party or its applicable Affiliates of all of such Person&#146;s rights to such Licensed
Collaboration Technology such that no such employee, contractor or consultant shall retain any rights thereto that would prevent or conflict with the other Party&#146;s rights of ownership, license or use thereof or thereto, as the case may be,
contemplated under this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">9.4.2 <B>Debarment</B>. Each Party represents, warrants and covenants to the other Party
that neither it nor its officers, employees, agents, consultants or any other person used by such Party in the performance of the respective Research and Development activities under this Agreement is: (a)&nbsp;debarred or disqualified under the
U.S. Federal Food, Drug and Cosmetic Act; (b)&nbsp;listed by any government or regulatory agencies as ineligible to participate in any government healthcare programs or government procurement or
<FONT STYLE="white-space:nowrap">non-procurement</FONT> programs (as that term is defined in 42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7b(f)),</FONT> or excluded, debarred, suspended or otherwise made ineligible to participate in any
such program; or (c)&nbsp;convicted of a criminal offense related to the provision of healthcare items or services, or is subject to any such pending action. Each Party shall not during the Term knowingly, employ or use, directly or indirectly,
including through Affiliates the services of any such person. In the event that either Party becomes aware of the debarment or disqualification or threatened debarment or disqualification of any person providing services to such Party, directly or
indirectly, including through Affiliates or, in the case of Moderna, Sublicensees, which directly or indirectly relate to activities contemplated under this Agreement, such Party shall promptly notify the other Party in writing and such Party shall
cease employing, contracting with, or retaining any such person to perform any such services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">9.4.3 <B>The Regents of the University of
California</B>. Metagenomi represents and warrants that none of the Metagenomi Licensed Collaboration Technology in existence as of the Effective Date is <FONT STYLE="white-space:nowrap">in-licensed</FONT> from UC. In the event that Metagenomi <FONT
STYLE="white-space:nowrap">in-licenses</FONT> from UC any <FONT STYLE="white-space:nowrap">Know-How</FONT> or Patent rights during the Term of this Agreement that Covers or otherwise relates to any <FONT STYLE="white-space:nowrap">Know-How</FONT>
conceived, discovered, invented or created, in each case as of the Effective Date, by any director, employee, consultant or contractor of Metagenomi as of the Effective Date in their capacity as employee, consultant, contractor or student of UC or
during their course of employment, consulting, contractor, or student relationship with UC, Metagenomi hereby covenants that it and its Affiliates shall (i)&nbsp;assume all payment obligations under such
<FONT STYLE="white-space:nowrap">in-licenses,</FONT> notwithstanding anything else herein to the contrary, (ii)&nbsp;ensure that such <FONT STYLE="white-space:nowrap">in-licenses</FONT> are fully sublicensable to Moderna, (iii)&nbsp;expressly make
Moderna an intended third-party beneficiary to such <FONT STYLE="white-space:nowrap">in-licenses,</FONT> and (iv)&nbsp;ensure that in the event of termination of such <FONT STYLE="white-space:nowrap">in-licenses,</FONT> Moderna shall become a direct
licensee of UC with respect to the <FONT STYLE="white-space:nowrap">Know-How</FONT> and Patent rights <FONT STYLE="white-space:nowrap">in-licensed</FONT> from UC to the extent Moderna has rights to such
<FONT STYLE="white-space:nowrap">Know-How</FONT> or Patent rights under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">9.4.4 <B>Open Source Software</B>. Metagenomi
represents, warrants and covenants that any deliverable that Metagenomi provides to Moderna and its Affiliates under this Agreement does not and will not include any open source, copyleft or community source code (including but not limited to any
libraries or code, software, technologies or other materials that are licensed or distributed under any General Public License, Lesser General Public License or similar license arrangement or other distribution model described by the Open Source
Initiative at www.opensource.org). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.5 <B>Compliance</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">9.5.1 <B>Compliance with this Agreement</B>. Each of the Parties shall, and shall cause their respective Affiliates to, comply in all
material respects with the terms of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">9.5.2 <B>Compliance with Applicable Laws</B>. Each Party covenants to the other that
in the performance of its obligations under this Agreement, such Party shall comply with, and shall cause its Affiliates and its and its Affiliates&#146; employees and contractors to comply, with all Applicable Laws. No Party shall, or shall be
required to, undertake any activity under or in connection with this Agreement which violates, or which it believes, in good faith, may violate, any Applicable Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">9.5.3 <B>Compliance with Party-Specific Regulations</B>. In carrying out their respective obligations under this Agreement, the Parties agree
to cooperate with each other as may reasonably be required to help ensure that each is able to fully meet its obligations with respect to all judgments, decrees, orders or similar decisions issued by any Governmental Authority specific to a Party,
and all consent decrees, corporate integrity agreements, or other agreements or undertakings of any kind by a Party with any Governmental Authority, in each case as the same may be in effect from time to time and applicable to a Party&#146;s
activities contemplated under this Agreement (the &#147;<B>Party-Specific Regulations</B>&#148;). Neither Party shall be obligated to pursue any course of conduct that would result in such Party being in material breach of any Party-Specific
Regulation applicable to it; provided that in the event that a Party refuses to fulfill its obligations under this Agreement in any material respect on such basis, the other Party shall have the right to terminate this Agreement in accordance with
Section&nbsp;12.2 (Termination for Material Breach or Insolvency or Patent Challenge) however, under such circumstances, such termination shall be the sole remedy for such terminating Party and such terminating Party shall not be entitled to any
other remedy under law or equity. All Party-Specific Regulations are binding only in accordance with their terms and only upon the Party to which they relate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">9.5.4 <B>Compliance with Internal Compliance Codes</B>. All Internal Compliance Codes shall apply only to the Party to which they relate. The
Parties agree to cooperate with each other to help ensure that each Party is able to comply with the substance of its respective Internal Compliance Codes and, to the extent practicable, each Party shall operate in a manner consistent with its
Internal Compliance Codes applicable to its performance under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">9.5.5 <B>Compliance with Anti-Corruption Laws</B>. In
connection with this Agreement, the Parties shall comply with all applicable local, national, and international laws, regulations, and industry codes dealing with government procurement, conflicts of interest, corruption or bribery, including, if
applicable, the U.S. Foreign Corrupt Practices Act of 1977, as amended, and any laws enacted to implement the Organisation of Economic Cooperation and Development Convention on Combating Bribery of Foreign Officials in International Business
Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">9.5.6 <B>Prohibited Conduct</B>. Without limiting the other obligations of the Parties set forth in this Section&nbsp;9.5
(Compliance), each Party covenants to the other that, as of the Effective Date and in the performance of its obligations under this Agreement through the expiration or termination of this Agreement, such Party and, to its knowledge, its Affiliates
and its and its Affiliates&#146; employees and contractors, in connection with the performance of their respective </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
obligations under this Agreement, have not made, offered, given, promised to give, or authorized, and shall not make, offer, give, promise to give, or authorize, any bribe, kickback, payment or
transfer of anything of value, directly or indirectly through Third Parties, to any Government Official for the purpose of: (a)&nbsp;improperly influencing any act or decision of the Person or Government Official; (b)&nbsp;inducing the Person or
Government Official to do or omit to do an act in violation of a lawful or otherwise required duty; (c)&nbsp;securing any improper advantage; or (d)&nbsp;inducing the Person or Government Official to improperly influence the act or decision of any
organization, including any government or government instrumentality, to assist any Party in obtaining or retaining business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.6
<B>Disclaimer</B>. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATIONS OR EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY, QUALITY, FITNESS FOR A
PARTICULAR PURPOSE, NONINFRINGEMENT, OR VALIDITY OF PATENT CLAIMS. NOTHING IN THIS AGREEMENT SHALL BE CONSTRUED AS A REPRESENTATION MADE OR WARRANTY GIVEN BY EITHER PARTY THAT EITHER PARTY SHALL BE SUCCESSFUL IN OBTAINING ANY PATENTS OR THAT ANY
PATENTS SHALL ISSUE BASED ON A PENDING APPLICATION. WITHOUT LIMITING THE RESPECTIVE RIGHTS AND OBLIGATIONS OF THE PARTIES EXPRESSLY SET FORTH HEREIN, EACH PARTY SPECIFICALLY DISCLAIMS ANY GUARANTEE THAT THE PRODUCTS SHALL BE SUCCESSFUL, IN WHOLE OR
IN PART. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Article 10 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEMNIFICATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.1
<B>Indemnity</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">10.1.1 <B>By Metagenomi</B>. Subject to Section&nbsp;10.1.3 (Procedure), Metagenomi shall defend, indemnify and hold
harmless Moderna and its Affiliates, and their respective directors, officers, employees and agents (each, a &#147;<B>Moderna Indemnitee</B>&#148;) from and against any and all costs, fees, expenses, losses, liabilities and damages, including
reasonable legal expenses and attorneys&#146; fees (collectively, &#147;<B>Losses</B>&#148;) to which any Moderna Indemnitee may become subject as a result of any claim, demand, action or other proceeding by any Third Party (a
&#147;<B>Claim</B>&#148;) to the extent such Losses arise out of: (a)&nbsp;the gross negligence or willful misconduct of Metagenomi or its Affiliates in connection with its activities under this Agreement; or (b)&nbsp;the breach of this Agreement by
Metagenomi or the breach of representations, warranties and covenants made hereunder by Metagenomi; except, in each case, to the extent such Losses result from (i)&nbsp;matters subject to clause (a)&nbsp;or (b) of Section&nbsp;10.1.2 (By Moderna) or
(ii)&nbsp;a Moderna Indemnitee&#146;s negligence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">10.1.2 <B>By Moderna</B>. Subject to Section&nbsp;10.1.3 (Procedure), Moderna shall
defend, indemnify and hold harmless Metagenomi, its Affiliates, and their respective directors, officers, employees and agents (each, an &#147;<B>Metagenomi Indemnitee</B>&#148;) from and against any and all Losses to which any Metagenomi Indemnitee
may become subject as a result of any Claim to the extent such Losses arise out of: (a)&nbsp;the gross negligence or willful misconduct of Moderna or its Affiliates in connection with its activities under this Agreement; or (b)&nbsp;the breach of
this Agreement by Moderna or the breach of representations, warranties and covenants made hereunder by Moderna; except, in each case, to the extent such Losses result from (i)&nbsp;matters subject to clause (a)&nbsp;or (b) of Section&nbsp;10.1.1 (By
Metagenomi) or (ii)&nbsp;an Metagenomi Indemnitee&#146;s negligence. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">10.1.3 <B>Procedure</B>. A Party that intends to claim indemnification under this Article
10 (Indemnification) (the &#147;<B>Indemnitee</B>&#148;) shall promptly notify the Indemnitor (the &#147;<B>Indemnitor</B>&#148;) in writing of any Claim in respect of which the Indemnitee intends to claim such indemnification. The failure to
deliver written notice to the Indemnitor within a reasonable time after the commencement of any action with respect to a Claim shall only relieve the Indemnitor of its indemnification obligations under this Article 10 (Indemnification) if and to the
extent the Indemnitor is actually and materially prejudiced thereby. The Indemnitor has sole control of the defense or settlement thereof. The Indemnitee shall cooperate fully with the Indemnitor and its legal representatives in the investigation of
any action with respect to a Claim covered by this indemnification. The Indemnitee may participate at its expense in the Indemnitor&#146;s defense of and settlement negotiations for any Claim with counsel of the Indemnitee&#146;s own selection. The
Indemnitor shall not settle any Claim without the prior written consent of the Indemnitee, not to be unreasonably withheld, conditioned or delayed. So long as the Indemnitor is actively defending the Claim in good faith, the Indemnitee shall not
settle or compromise any such Claim without the prior written consent of the Indemnitor. If the Indemnitor does not assume and conduct the defense of the Claim as provided above: (a)&nbsp;the Indemnitee may defend against, consent to the entry of
any judgment, or enter into any settlement with respect to such Claim in any manner the Indemnitee may deem reasonably appropriate (and the Indemnitee need not consult with, or obtain any consent from, the Indemnitor in connection therewith); and
(b)&nbsp;the Indemnitor shall remain responsible to indemnify the Indemnitee as provided in this Article 10 (Indemnification). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.2
<B>Losses in the Territory</B>. All Losses arising from any Third Party Claim relating to the Exploitation of a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product in the Territory, including fees and disbursements to counsel, incurred by
either Party in connection with the defense of any such Third Party Claim brought in the Territory, shall be shared [***] by the Parties as an Other Operating Expense in accordance with Section&nbsp;7.4 <FONT STYLE="white-space:nowrap">(Co-Co</FONT>
Products Profit and Loss Share), provided that, such Other Operating Expenses shall not include Losses of a Party or its Affiliate to the extent such Losses are: (a)&nbsp;caused by a breach of this Agreement by such Party or Affiliate; or
(b)&nbsp;caused by the negligence or willful misconduct of such Party or its Affiliate, and any such Losses described in clause (a)&nbsp;or (b) shall not be applied to the Operating Profit or Loss as Other Operating Expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.3 <B>Insurance</B>. During the Term, each Party shall maintain such types and amounts of liability insurance (including, with respect to
Moderna, self-insurance) as is normal and customary in the industry generally for similarly situated parties and adequate to cover its obligations under this Agreement, and each Party shall, upon request, provide the other Party with a certificate
of insurance in that regard, along with any amendments and revisions thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Article 11 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIALITY </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.1
<B>Confidential Information</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">11.1.1 <B>Confidential Information</B>. In connection with this Agreement, a Party may disclose to the
other Party certain confidential information of such disclosing Party (such confidential information, &#147;<B>Confidential Information</B>&#148;). For clarity, all Results in a Program and all records of each Party&#146;s activities in a Program
constitute Confidential Information, provided, that (a)&nbsp;any confidential information initially disclosed by a Party that is to be solely owned by the other Party in accordance with this Agreement shall be the Confidential Information of such
other Party (and the owning Party shall be deemed the disclosing Party, and the initially disclosing Party shall be deemed the receiving Party, with respect thereto and regardless of the Party initially disclosing the same), (b) any confidential
information Controlled by Metagenomi or any of its Affiliates to the extent solely relating to (i)&nbsp;a DT Moderna Target in the DT Field, (ii)&nbsp;a RT Target that is selected in accordance with Section&nbsp;3.9 (RT Option) in the RT Field, or
(iii)&nbsp;an RT Candidate, a DT Moderna Candidate or a Licensed Product, or the Exploitation of any of the foregoing (i)-(iii), shall be deemed Confidential Information of Moderna (and Moderna the disclosing Party, and Metagenomi the receiving
Party, with respect thereto and regardless of the Party initially disclosing the same), and (c)&nbsp;any confidential information Controlled by either Party or any of its Affiliates to the extent solely relating to the DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Target in the DT Field, a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Candidate or a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product or the Exploitation thereof shall be deemed Confidential
Information of both Parties. Without limiting the foregoing, the terms of this Agreement are the Confidential Information of both Parties and shall be treated confidentially by each of the Parties, subject to the exceptions set forth in
Section&nbsp;11.1.6 (Disclosure of Agreement). Information exchanged by the Parties pursuant to the Mutual Confidentiality Agreement shall be governed by such Mutual Confidentiality Agreement; provided that any such information that is subsequently
exchanged by the Parties under this Agreement shall, from that time, be governed by the terms of this Agreement. Notwithstanding anything herein to the contrary, Metagenomi shall not disclose any Results or Data Package to the extent related to the <FONT
STYLE="white-space:nowrap">mRNA-LNP</FONT> Technology without Moderna&#146;s prior written consent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">11.1.2 <B>Restrictions</B>. A Party
(the &#147;<B>Receiving Party</B>&#148;) that receives Confidential Information from the other Party (the &#147;<B>Disclosing Party</B>&#148;) shall keep all the Disclosing Party&#146;s Confidential Information in confidence with the same degree of
care with which the Receiving Party holds its own confidential information (but in no event less than a commercially reasonable degree of care). A Receiving Party shall not use the Disclosing Party&#146;s Confidential Information except in
connection with the performance of its obligations and exercise of its rights under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">11.1.3 <B>Exceptions</B>. The
obligations of confidentiality and restriction on use of Confidential Information under Section&nbsp;11.1.2 (Restrictions) do not apply to any information that the Receiving Party can prove by competent written evidence: (a)&nbsp;is now, or
hereafter becomes, through no act or failure to act on the part of the Receiving Party, generally known or available to the public; (b)&nbsp;is known by the Receiving Party at the time of receiving such information, other than by previous disclosure
of the Disclosing Party, or its Affiliates, employees, agents, consultants, or contractors; (c)&nbsp;is hereafter furnished to the Receiving Party without restriction by a Third Party who has no obligation of confidentiality or limitations on use
with respect thereto, as a matter of right; or (d)&nbsp;is independently discovered or developed by the Receiving Party without the use of Confidential Information belonging to the Disclosing Party. Specific information shall not be deemed to be
within any of the foregoing exclusions merely because it is embraced by more general information falling within those exclusions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.1.4 <B>Permitted Disclosures</B>. The Receiving Party may disclose Confidential
Information belonging to the Disclosing Party as expressly permitted under this Agreement or if and to the extent such disclosure is reasonably necessary in the following instances: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Prosecution and Maintenance of Patents as permitted under this Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Regulatory Filings for Product that such Party has a license or right to develop hereunder in a given country or jurisdiction; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) prosecuting or defending litigation as permitted under this Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) made in response to a valid order of a court or other Governmental Authority or to comply with Applicable Laws (including securities
laws); provided that the Receiving Party shall, to the extent permitted by Applicable Laws, first have given notice to the Disclosing Party and given the Disclosing Party a reasonable opportunity, at the Disclosing Party&#146;s expense, to quash
such order or to obtain a protective order or seek confidential treatment; and provided further that the Confidential Information disclosed in response to such court or governmental order shall be limited to that information which is legally
required to be disclosed in response to such court or governmental order or to comply with Applicable Laws; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) in response to a valid
request by a U.S., state, foreign, provincial, or local tax authority, in which case either Party may disclose, a copy of this Agreement (including any Schedules, ancillary agreements and amendments hereto); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) disclosure to its and its Affiliates&#146; employees, consultants, contractors and agents, and to Sublicensees, in each case on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">need-to-know</FONT></FONT> basis in connection with the Research, Development, making, having made, use, keeping, import, export, offering for sale, selling, or otherwise Exploiting of
Products in the RT Field or DT Field (as applicable) in the Territory, and Commercialization of the Products in accordance with the terms of this Agreement, in each case under written obligations of confidentiality and
<FONT STYLE="white-space:nowrap">non-use</FONT> at least as stringent as those herein; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) to the extent otherwise necessary or
reasonably useful for a Receiving Party to exploit the licenses granted to it under this Agreement; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) disclosure to <I>bona
fide</I> potential and actual investors, acquirers, and other financial partners solely for the purpose of evaluating or carrying out an actual or potential investment or acquisition, in each case under written obligations of confidentiality and <FONT
STYLE="white-space:nowrap">non-use</FONT> at least as stringent as those herein; provided that with respect to disclosure to actual or <I>bona fide </I>potential investors, such disclosure is under a written obligation of confidentiality that is
consistent with market terms, including a shorter period of time during which such information must be held confidential. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, if a Party is required to make a disclosure of the other Party&#146;s
Confidential Information pursuant to Section&nbsp;11.1.4(c) or (d) (Permitted Disclosures), it shall, except where impracticable, give reasonable advance notice to the other Party of such disclosure and use efforts to secure confidential treatment
of such Confidential Information at least as diligent as such Party would use to protect its own Confidential Information, but in no event less than reasonable efforts. Any information disclosed pursuant to Section&nbsp;11.1.4(c) or (d) (Permitted
Disclosures) remains Confidential Information and subject to the restrictions set forth in this Agreement, including the foregoing provisions of this Article 11 (Confidentiality). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.1.5 <B>Public Domain Information and Residual Knowledge</B>. Nothing in this Agreement shall prevent a Party from using any <FONT
STYLE="white-space:nowrap">Know-How</FONT> that is in the public domain. Except to the extent a Party has granted exclusive or <FONT STYLE="white-space:nowrap">co-exclusive</FONT> rights to the other Party under this Agreement (including as and to
the extent such rights survive this Agreement), each Party grants to the other Party a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license to use, outside the scope of this Agreement and for any purpose, any
<FONT STYLE="white-space:nowrap">Know-How</FONT> or Confidential Information shared in the performance of this Agreement by such Party solely to the extent such <FONT STYLE="white-space:nowrap">Know-How</FONT> or Confidential Information has been
retained (without intentional memorization) in intangible form in the minds of such Party&#146;s employees (or its Affiliates&#146; employees) who have had access to such <FONT STYLE="white-space:nowrap">Know-How</FONT> or Confidential Information
pursuant to the terms of this Agreement and without reference to any tangible copies of such <FONT STYLE="white-space:nowrap">Know-How</FONT> or Confidential Information; provided that this provision shall not be deemed in any event to provide any
right to infringe the Patent rights of the other Party or of Third Parties that have licensed or provided materials to the other Party; provided, further, that a Party&#146;s use of such <FONT STYLE="white-space:nowrap">Know-How</FONT> or
Confidential Information is on an &#147;as is, where is&#148; basis, with all faults and all representations and warranties disclaimed and at such Party&#146;s sole risk. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.1.6 <B>Disclosure of Agreement</B>. Notwithstanding the foregoing, either Party or its Affiliates may disclose the relevant terms of this
Agreement: (a)&nbsp;to the extent required or advisable to comply with the rules and regulations promulgated by the U.S. Securities and Exchange Commission or any equivalent governmental agency in any country in the Territory, provided that such
Party shall submit a confidential treatment request in connection with such disclosure and shall submit with such confidential treatment request only such redacted form of this Agreement as may be mutually agreed in writing by the Parties;
(b)&nbsp;upon request from a Governmental Authority (such as a tax authority), provided the disclosing Party uses reasonable efforts to ensure the Governmental Authority maintains such terms as confidential; (c)&nbsp;to applicable licensors, solely
to the extent necessary to comply with the terms of any Third Party license agreement, the rights under which are sublicensed to the other Party under this Agreement; and (d)&nbsp;to the extent necessary to perform obligations or exercise rights
under this Agreement, to any Sublicensee, collaborator or potential Sublicensee or potential collaborator of such Party, provided that any Sublicensee, collaborator or potential Sublicensee or collaborator agree in writing to be bound by obligations
of confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> no less protective of the Disclosing Party than those set forth in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.1.7 <B>Survival</B>. Each Party&#146;s obligations under this Section&nbsp;11.1 (Confidential Information) apply during the Term and
continue for three (3)&nbsp;years thereafter with respect to Confidential Information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.2 <B>Publicity</B>. On November&nbsp;2, 2021, the Parties shall issue a joint press
release in the form attached hereto as <B>Schedule N </B>(Joint Press Release). Except as permitted under Section&nbsp;11.1.4 (Permitted Disclosures) or Section&nbsp;11.1.6 (Disclosure of Agreement), neither Party shall issue any press release or
public statement disclosing information relating to this Agreement or the transactions contemplated hereby or the terms hereof without the prior written consent of the other Party; provided however, that neither Party shall be prevented from
complying with any duty of disclosure it may have pursuant to Applicable Laws or pursuant to the rules of any recognized stock exchange or quotation system subject to the restrictions set forth in Sections 11.1.4 (Permitted Disclosures) and 11.1.5
(Public Domain Information and Residual Knowledge). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.3 <B>Publication</B>. The following restrictions shall apply with respect to
disclosure by any Party of Confidential Information in any publication or presentation with respect to the Programs, the Collaboration Targets, the Products or their testing: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.3.1 both Parties acknowledge that it is their policy for the studies and results thereof to be registered and published in accordance with
their internal guidelines; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.3.2 a Party (&#147;<B>Publishing Party</B>&#148;) shall provide the other Party with a copy of any
proposed material publication or presentation at least [***] (or [***] in the case of a manuscript) prior to submission for publication so as to provide such other Party with an opportunity to recommend any changes it reasonably believes are
necessary to continue to maintain the Confidential Information disclosed by the other Party to the Publishing Party in accordance with the requirements of this Agreement. The incorporation of such recommended changes shall not be unreasonably
refused; and if such other Party notifies (&#147;<B>Publishing Notice</B>&#148;) the Publishing Party in writing, within such [***] period (or [***] period in the case of a manuscript) after receipt of the copy of the proposed publication,
presentation, or manuscript, that such publication or presentation in its reasonable judgment (i)&nbsp;contains an invention, solely or jointly conceived or reduced to practice by the other Party, for which the other Party reasonably desires to
obtain patent protection or (ii)&nbsp;could be expected to have a material adverse effect on the commercial value of any Confidential Information disclosed by the other Party to the Publishing Party, the Publishing Party shall prevent such
publication or delay such publication for a mutually agreeable period of time. In the case of inventions, a delay shall be for a period reasonably sufficient to permit the timely preparation and filing of a patent application(s) on such invention,
and in no event less than [***] from the date of the Publishing Notice. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Article 12 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TERM&nbsp;&amp; TERMINATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.1 <B>Term</B>. This Agreement commences on the Effective Date and, unless terminated earlier as provided in this Article 12 (Term and
Termination), shall continue on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-</FONT></FONT> Program basis as follows: (a)&nbsp;with respect to the RT Technology Research Program, until the end of the RT Research
Term; (b)&nbsp;with respect to an RT Preclinical Research Program, (i)&nbsp;in the event no RT Option has been exercised within the RT Option Period for such RT Preclinical Research Program, until the expiration of the RT Option Period, or
(ii)&nbsp;in the event an RT Option has been exercised within the applicable RT Option Period for such RT Preclinical Research Program, on a Licensed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Licensed</FONT></FONT>
Product and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, until the expiration of the applicable RT Royalty Term; (c)&nbsp;with respect to the DT Target Evaluation Program, until the end of
the DT Moderna Research Term; (d)&nbsp;with respect to a DT Moderna Research Program, (i)&nbsp;in the event no DT Option has been exercised within the DT Option Period for such DT Moderna Research Program, until the expiration of the DT Option
Period, or (ii)&nbsp;in the event a DT Option has been exercised within the applicable DT Option Period for such DT Moderna Research </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Program, on a Licensed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Licensed</FONT></FONT> Product and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, until the expiration of the applicable DT Moderna Royalty Term; and (e)&nbsp;with respect to the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program, on a DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-DT</FONT></FONT> <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, (i)&nbsp;in the event neither Party <FONT STYLE="white-space:nowrap">Opts-Out</FONT> within the time allowed under Section&nbsp;6.8.1 <FONT STYLE="white-space:nowrap">(Opt-Out</FONT>
Right), until neither Party (or its Affiliates, Sublicensees or assignees) continue to Commercialize such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product in such country; or (ii)&nbsp;in the event either Party
<FONT STYLE="white-space:nowrap">Opts-Out</FONT> within the time allowed under Section&nbsp;6.8.1 <FONT STYLE="white-space:nowrap">(Opt-Out</FONT> Right), until the expiration of the applicable <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Royalty
Term, provided that, in each case of (i)&nbsp;and (ii), in the event there is no DC Nomination in the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program by the end of the Initial DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Research Term,
this Agreement will expire with respect to such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program at the end of the Initial DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Research Term, subject to the last paragraph of Section&nbsp;6.3.1
(DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Research Plan) (the &#147;<B>Term</B>&#148;). Upon the expiration of the Term with respect to (A)&nbsp;a Licensed Product in an RT Preclinical Research Program in a country in accordance with clause
(b)(ii) of the immediately preceding sentence, the licenses granted to Moderna under Section&nbsp;5.13 (License to Moderna Upon Exercise of the RT Option) with respect to such Licensed Product and such country shall survive and become perpetual,
fully- paid and royalty-free; (B)&nbsp;a Licensed Product in a DT Moderna Research Program in a country in accordance with clause (c)(ii) of the immediately preceding sentence, the licenses granted to Moderna under Section&nbsp;5.15 (License to
Moderna Upon Exercise of the DT Option) with respect to such Licensed Product in such country shall survive and become perpetual, fully-paid and royalty-free; and (C)&nbsp;a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product in the DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Program in a country in accordance with clause (e)(ii) of the immediately preceding sentence, the licenses granted to the Primary Party under Section&nbsp;5.5 (DT <FONT STYLE="white-space:nowrap">Co-Co</FONT>
Program License) with respect to such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product in such country shall survive and become perpetual, fully-paid and royalty-free. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.2 <B>Termination for Material Breach or Insolvency or Patent Challenge</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12.2.1 <B>Material Breach</B>. On a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Program</FONT></FONT> basis,
subject to Section&nbsp;12.2.2 (Disputes Regarding Material Breach), each Party (the &#147;<B><FONT STYLE="white-space:nowrap">Non-Breaching</FONT> Party</B>&#148;) shall have the right to terminate this Agreement with respect to such Program upon
written notice to the other Party (the &#147;<B>Breaching Party</B>&#148;) if the Breaching Party materially breaches its obligations under this Agreement with respect to [***], after receiving written notice from the
<FONT STYLE="white-space:nowrap">Non-Breaching</FONT> Party identifying such material breach by the Breaching Party in reasonable detail, fails to cure such material breach within [***] from the date of such notice (or, if such breach cannot be
cured within [***] from the date of such notice, if the Breaching Party has not commenced or is not diligently continuing in good faith efforts to cure such breach; provided that, in any event, such breach must be cured within [***] from the date of
such notice) (such [***] period, the &#147;<B>Cure Period</B>&#148;). For the avoidance of doubt, (i)&nbsp;each Party has all rights and may seek all available remedies under Applicable Laws in the event of a breach of this Agreement by the other
Party, regardless of whether such breach constitutes a material breach that could give rise to termination of this Agreement, and (ii)&nbsp;if a material breach giving rise to termination under this Section&nbsp;12.2.1 (Material Breach) is specific
to any one (1)&nbsp;or more Programs, then the <FONT STYLE="white-space:nowrap">Non-Breaching</FONT> Party&#146;s right to terminate under this Section&nbsp;12.2.1 (Material Breach) shall be limited to such affected Programs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12.2.2 <B>Disputes Regarding Material Breach</B>. If the Parties reasonably and in good
faith disagree as to whether there has been a material breach, then the Breaching Party that disputes whether there has been a material breach may contest the allegation in accordance with Article 13 (Governing Law; Dispute Resolution), and the
applicable Cure Period shall be tolled upon the initiation of such dispute resolution procedures. If, as a result of such dispute resolution process, it is finally determined pursuant to Article 13 (Governing Law; Dispute Resolution) that the
Breaching Party committed a material breach of this Agreement, then the applicable Cure Period shall resume and unless such alleged breach was cured during the pendency of such Cure Period (once resumed), this Agreement shall terminate effective as
of the expiration of such Cure Period. This Agreement shall remain in full force and effect during the pendency of any such dispute resolution proceeding and all Cure Periods. Any such dispute resolution proceeding shall not suspend any obligations
of either Party hereunder and each Party shall use reasonable efforts to mitigate any damages. Any payments that are made by one Party to the other Party pursuant to this Agreement pending resolution of the dispute shall be promptly refunded if it
is determined pursuant to Article 13 (Governing Law; Dispute Resolution) that such payments are to be refunded by one Party to the other Party. If, as a result of such dispute resolution proceeding, it is determined that the Breaching Party did not
commit such material breach (or such material breach was cured in accordance with Sections 12.2.1 (Material Breach) or 12.2.2 (Disputes Regarding Material Breach)), then no termination of this Agreement shall be effective, and this Agreement shall
continue in full force and effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12.2.3 <B>Termination for Insolvency</B>. To the extent permitted by Applicable Laws, either Party may
terminate this Agreement in its entirety upon providing written notice to the other Party on or after the time that such other Party files or institutes a bankruptcy, reorganization, liquidation, or receivership proceeding or upon the appointment of
a receiver or trustee over all or substantially all property of the other Party, or upon an assignment of a substantial portion of the assets of the other Party for the benefit of creditors; provided that in the case of any involuntary bankruptcy
proceeding, such right to terminate shall only become effective if the other Party consents to the involuntary bankruptcy or such proceeding is not dismissed within [***] after the filing thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12.2.4 <B>Termination for Patent Challenge</B>. Metagenomi shall have the right, upon written notice to Moderna, to terminate this Agreement
on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Program</FONT></FONT> basis if Moderna directly or indirectly (whether alone, or in concert with or for the benefit of any Third Party) challenges, opposes, seeks to
invalidate or render void or unenforceable any Patent included within the Metagenomi Licensed Collaboration Technology in such Program, through a declaratory judgment, post grant review, inter partes review, or any other action or proceeding, except
to the extent required by Applicable Law, court order or bona fide judicial process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.3 <B>Moderna Option to Continue in Lieu of
Termination</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12.3.1 <B>Payment Reductions in Lieu of Termination</B>. For a given RT Target or DT Moderna Target (and any related
Program or Licensed Products), with respect to Metagenomi&#146;s material breach of any of its obligations under this Agreement with respect thereto as determined pursuant to Section&nbsp;12.2.1 (Material Breach) (and after completion of the process
set forth in Section&nbsp;12.2.2 (Disputes Regarding Material Breach) if invoked), Moderna shall have the right, at its option and by written notice to Metagenomi, in lieu of exercising its right to terminate this Agreement with respect to such
Collaboration Target under Section&nbsp;12.2.1 (Material Breach), to instead continue this Agreement with respect to such Collaboration Target (and related Program and Licensed Products) in accordance with its terms, and in which case: (a)&nbsp;at
Moderna&#146;s </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
option, the JSC will coordinate wind-down of Metagenomi&#146;s activities with respect to such RT Program or DT Program, and (b)&nbsp;from and after such time as Moderna delivers such written
notice to Metagenomi, any and all amounts thereafter payable by Moderna for a Licensed Product applicable to such Collaboration Target hereunder (including Milestone Payments and royalties) shall be reduced by fifty percent (50%) (and for clarity,
any floors on any such Milestone Payments and royalties hereunder will also be lowered by fifty percent (50%)). Notwithstanding the foregoing, Moderna&#146;s exercise of its rights under this Section&nbsp;12.3.1 (Payment Reductions in Lieu of
Termination) with respect to a Collaboration Target shall not affect the Parties&#146; respective rights and obligations (including, without limitation, Milestone Payments and royalties) with respect to any other Collaboration Targets (or any
related Program or Licensed Products). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12.3.2 <B>Profit-share Reduction in Lieu of Termination</B>. For a given DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Target (and related Program and DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products), with respect to Metagenomi&#146;s material breach of any of its obligations under this Agreement with respect thereto
as determined pursuant to Section&nbsp;12.2.1 (Material Breach) (and after completion of the process set forth in Section&nbsp;12.2.2 (Disputes Regarding Material Breach) if invoked), Moderna shall have the right, at its option and by written notice
to Metagenomi, in lieu of exercising its right to terminate this Agreement with respect to such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Target under Section&nbsp;12.2.1 (Material Breach), to instead continue this Agreement with respect to
such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Target (and related Program and DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products) in accordance with its terms, and in which case, Moderna may elect, on a one time basis, by providing a
written notice to Metagenomi, to seek to adjust the Profit and Loss Share for one or more DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products for such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Target in the Territory and, to fairly
compensate Moderna for the damages arising from such material breach. Moderna will have the right to propose the adjustment, and the Parties will discuss in good faith, and if the Parties cannot mutually agree, then such adjustment shall be resolved
pursuant to Section&nbsp;13.3 (Arbitration). It is understood that such adjustment would provide Moderna with additional share of the net profits (but not more than 75% of the total net profits) for the DT
<FONT STYLE="white-space:nowrap">Co-Co</FONT> Products, to Moderna, for a period of time as may be appropriate and agreed by the Parties (or pursuant to Section&nbsp;13.3 (Arbitration), as applicable). The profit adjustment may be, with respect to
the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Target, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, or for the entire Territory, and the adjustment shall not apply to the
sharing of any Development Costs. If Moderna so elects, then this Agreement shall continue to be in force with respect to such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Target (and related Program and DT
<FONT STYLE="white-space:nowrap">Co-Co</FONT> Products), provided that the foregoing shall not limit any other rights that Moderna may have under this Agreement with respect to Metagenomi&#146;s material breach, including to seek specific
performances pursuant to Section&nbsp;13.5 (Equitable Relief; Remedy for Breach of Exclusivity). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12.3.3
<B><FONT STYLE="white-space:nowrap">Know-How</FONT> Transfer</B>. Within thirty (30)&nbsp;days following Moderna&#146;s election not to terminate this Agreement under this Section&nbsp;12.3 (Moderna Option to Continue in Lieu of Termination),
Metagenomi shall disclose or deliver to Moderna, to the extent not previously provided, copies of all data and information in Metagenomi&#146;s (or its Affiliates&#146;) possession relating to the applicable Program which is reasonably necessary for
Moderna&#146;s Research, Development or Commercialization of the applicable Products (including for regulatory purposes and to otherwise undertake Program activities that would otherwise have been performed by Metagenomi and regardless of the stage
of any such activities). Upon Moderna&#146;s reasonable request, Metagenomi shall: (a)&nbsp;provide reasonable technical assistance to Moderna during such disclosure or delivery set forth in the preceding sentence; and (b)&nbsp;make its employees
and nonemployee consultants reasonably available at their respective places of employment to consult with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Moderna on issues arising in the course of Moderna&#146;s Research, Development or Commercialization and in connection with any request related to a Product from any Regulatory Authority,
including regulatory, scientific, technical and clinical testing issues. The <FONT STYLE="white-space:nowrap">Know-How</FONT> transfer to be undertaken under this Section&nbsp;12.3 (Moderna Option to Continue in Lieu of Termination) shall be
overseen by a Working Group established for such purposes, which Working Group may put in place a technology transfer plan expressly identifying <FONT STYLE="white-space:nowrap">Know-How</FONT> Controlled by Metagenomi or its Affiliates to be
transferred and the timing for such transfer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.4 <B>Termination for Convenience by Moderna</B>. Moderna may, at any time in its sole
discretion and without cause, terminate this Agreement with respect to an RT Program or a DT Program upon at least: (a)&nbsp;sixty (60) days&#146; prior written notice to Metagenomi if a First Commercial Sale has not occurred for the Products in
such Program; or (b)&nbsp;one hundred eighty (180)&nbsp;days&#146; prior written notice to Metagenomi if a First Commercial Sale of a Product in such Program has occurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.5 <B>Termination for Convenience by Primary Party</B>. Subject to the remainder of this Section&nbsp;12.5 (Termination for Convenience by
Primary Party), the Primary Party may, at any time in its sole discretion and without cause, terminate this Agreement with respect to the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program upon at least [***] prior written notice to the <FONT
STYLE="white-space:nowrap">Opt-Out</FONT> Party. Upon receiving the written notice from the Primary Party, and within such [***] period, the <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Party may elect to opt into the DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Program to continue the Development and Commercialization activities in the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program in the Territory by providing written notice to the Primary Party of such
election (&#147;<B><FONT STYLE="white-space:nowrap">Opt-In</FONT></B>,&#148; and such right to <FONT STYLE="white-space:nowrap">Opt-In,</FONT> the &#147;<B><FONT STYLE="white-space:nowrap">Opt-In</FONT> Right</B>&#148;). The exercise by the <FONT
STYLE="white-space:nowrap">Opt-Out</FONT> Party of its <FONT STYLE="white-space:nowrap">Opt-In</FONT> Right in accordance with the foregoing sentence shall become effective [***] after the delivery of the written notice to the Primary Party (the
&#147;<B><FONT STYLE="white-space:nowrap">Opt-In</FONT> Date</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12.5.1 If the <FONT STYLE="white-space:nowrap">Opt-Out</FONT>
Party exercises its right to <FONT STYLE="white-space:nowrap">Opt-In</FONT> with respect to the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program pursuant to this Section&nbsp;12.5 (Termination for Convenience by Primary Party), then
(i)&nbsp;the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program shall not terminate, (ii)&nbsp;from and after the <FONT STYLE="white-space:nowrap">Opt-In</FONT> Date, all rights to lead or manage any of the activities conducted by the Primary
Party as of the proposed date of termination set forth in its written notice to the <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Party under this Section&nbsp;12.5 (Termination for Convenience by Primary Party) shall be assumed by, and assigned
to, the <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Party, and (iii)&nbsp;the <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Party shall be referred to as the &#147;<B><FONT STYLE="white-space:nowrap">Opt-In</FONT> Party</B>&#148; hereafter in
this Section&nbsp;12.5 (Termination for Convenience by Primary Party). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12.5.2 Subject to Section&nbsp;12.5.3 (Termination for Convenience
by Primary Party), after the <FONT STYLE="white-space:nowrap">Opt-In</FONT> Party exercises the <FONT STYLE="white-space:nowrap">Opt-In</FONT> Right with respect to the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program pursuant to this
Section&nbsp;12.5 (Termination for Convenience by Primary Party), (i) the license of the Licensed DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Technology with respect to the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program from the <FONT
STYLE="white-space:nowrap">Opt-In</FONT> Party to the Primary Party under Section&nbsp;6.8.2 (Effects of <FONT STYLE="white-space:nowrap">Opt-Out)</FONT> shall immediately terminate as of the <FONT STYLE="white-space:nowrap">Opt-In</FONT> Date, and
the license of the Licensed DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Technology with respect to the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program from the Primary Party to the <FONT STYLE="white-space:nowrap">Opt-In</FONT> Party
under Section&nbsp;5.5 (DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program License) shall immediately become effective again and immediately become exclusive (subject to applicable Antitrust Filings and related government approvals or
clearances, provided that the Parties shall reasonably cooperate with each other in connection with the Antitrust Filings); (ii) the <FONT STYLE="white-space:nowrap">Opt-In</FONT> Party shall have sole authority and be solely responsible for all
Development and Commercialization activities and related costs in the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program, provided that in any event Moderna would </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
retain the decision-making power with respect to issues related to CMC Matters, Manufacturing, and the application of Moderna&#146;s technology to any of such activities; (iii)&nbsp;the Parties
shall agree upon a written transition plan (an &#147;<B><FONT STYLE="white-space:nowrap">Opt-In</FONT> Transition Plan</B>&#148;) setting forth all of the wind-down and other activities necessary or reasonably useful to transition all Development,
Commercialization, and Medical Affairs activities, and any accompanying technology transfer activities (including the assignment of any applicable Data Packages), for clarity excluding any transfer of any consulting services with respect to the DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Program (collectively, the &#147;<B><FONT STYLE="white-space:nowrap">Opt-In</FONT> Transition Activities</B>&#148;); (iv) each Party shall carry out the <FONT STYLE="white-space:nowrap">Opt-In</FONT>
Transition Activities assigned to it in the <FONT STYLE="white-space:nowrap">Opt-In</FONT> Transition Plan and be responsible for its own costs with respect to such <FONT STYLE="white-space:nowrap">Opt-In</FONT> Transition Activities; (v)&nbsp;the
Primary Party shall assign and transfer (where applicable) to the <FONT STYLE="white-space:nowrap">Opt-In</FONT> Party all Regulatory Documentations specific to all DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products in the DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Program, and shall grant the <FONT STYLE="white-space:nowrap">Opt-In</FONT> Party a right of reference to all other Regulatory Documentations with respect to such DT
<FONT STYLE="white-space:nowrap">Co-Co</FONT> Products necessary for the further Development and Commercialization thereof, in each case subject to Moderna retaining <FONT STYLE="white-space:nowrap">CMC-related</FONT> components of such Regulatory
Documentations and all other Moderna&#146;s Confidential Information related to CMC Matters, as set forth in the applicable <FONT STYLE="white-space:nowrap">Opt-In</FONT> Transition Plan; and (vi)&nbsp;each Party shall submit to the applicable
Regulatory Authority any filings, letters, and other Regulatory Filings and documentation necessary to effect such assignment and transfer as soon as practicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12.5.3 Notwithstanding the foregoing provisions of this Section&nbsp;12.5 (Termination for Convenience by Primary Party), after Metagenomi
exercises its <FONT STYLE="white-space:nowrap">Opt-In</FONT> Right with respect to the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program pursuant to this Section&nbsp;12.5 (Termination for Convenience by Primary Party), (i) the license of the
Metagenomi Licensed DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Technology with respect to the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program from Metagenomi to Moderna under Section&nbsp;6.8.2(b) (Effects of <FONT
STYLE="white-space:nowrap">Opt-Out)</FONT> shall become <FONT STYLE="white-space:nowrap">co-exclusive</FONT> but Moderna shall only practice its rights under the <FONT STYLE="white-space:nowrap">co-exclusively</FONT> licensed Metagenomi Licensed DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Technology to perform its obligations pursuant to Section&nbsp;5.23 (Manufacture), and (ii)&nbsp;the license of the Moderna Licensed DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Technology with respect to
the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program from Moderna to Metagenomi under Section&nbsp;5.5 (DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program License) shall become effective again and immediately become <FONT
STYLE="white-space:nowrap">non-exclusive</FONT> after DC Nomination with respect to the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product nominated in such DC Nomination, provided that (A)&nbsp;Metagenomi may only keep Exploiting Moderna
Licensed DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Technology being Exploited by Metagenomi as of Metagenomi&#146;s prior <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Date, and the Exploitation of any other Moderna Licensed DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Technology shall be subject to Moderna&#146;s express prior written consent, and (B)&nbsp;Metagenomi may only Exploit <FONT STYLE="white-space:nowrap">mRNA-LNP</FONT> Technology of Moderna or any of its
Affiliates and not of any Third Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12.5.4 Notwithstanding anything herein to the contrary, in the event Moderna exercises its <FONT
STYLE="white-space:nowrap">Opt-In</FONT> Right pursuant to this Section&nbsp;12.5 (Termination for Convenience by Primary Party), the JSC and its subcommittees, except to the extent required by the <FONT STYLE="white-space:nowrap">Opt-In</FONT>
Transition Plan to facilitate the <FONT STYLE="white-space:nowrap">Opt-In</FONT> Transition Activities, shall immediately disband, for clarity, solely with respect to such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12.5.5 Notwithstanding anything herein to the contrary, in the event Metagenomi exercises its <FONT STYLE="white-space:nowrap">Opt-In</FONT>
Right pursuant to this Section&nbsp;12.5 (Termination for Convenience by Primary Party), then Section&nbsp;6.5.1(c) (CMC Matters) and Section&nbsp;5.23 (Manufacture) shall remain in force. After Metagenomi has exercised such <FONT
STYLE="white-space:nowrap">Opt-In</FONT> Right, the Parties will use Commercially Reasonable Efforts to negotiate and enter a supply agreement and a quality agreement covering the supply of Candidates and Products for Research, Development, and
Commercialization, as applicable, for such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12.5.6 Notwithstanding anything herein to the contrary, in the event Metagenomi exercises
its <FONT STYLE="white-space:nowrap">Opt-In</FONT> Right pursuant to this Section&nbsp;12.5 (Termination for Convenience by Primary Party), if not previously prepared and filed, Moderna will, at Metagenomi&#146;s written request, prepare and file
with Regulatory Authorities in jurisdictions where Metagenomi is seeking Regulatory Approval of a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product, a DMF containing required CMC information for such DT
<FONT STYLE="white-space:nowrap">Co-Co</FONT> Product&#146;s Regulatory Approval. Metagenomi and its Affiliates may refer to such DMF in any Regulatory Filing made in connection with obtaining or maintaining a Regulatory Approval for such DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Product. Moderna will, on written request by Metagenomi or its Affiliate, provide to such requesting party and to any specified Regulatory Authority a letter, in the form reasonably required by such requesting
party, acknowledging that the requesting party has a right of reference to any such DMF. Notwithstanding that the foregoing provisions of this Section&nbsp;12.5.6 (Termination for Convenience by Primary Party) provide the mechanism for Regulatory
Authorities to have required access to Moderna&#146;s CMC information, in the event that the procedures set forth in the foregoing provisions of this Section&nbsp;12.5.6 (Termination for Convenience by Primary Party) are not available in a
particular country or are not sufficient to satisfy a Regulatory Authority&#146;s requirements, at Metagenomi&#146;s request, the Parties will discuss such requirements and use Commercially Reasonable Efforts to secure agreement from the Regulatory
Authority for it to receive required access to all necessary CMC information directly from Moderna in a manner that minimizes the disclosure of such CMC information and protects the confidential and proprietary nature of such CMC information.
Notwithstanding the foregoing provisions of this Section&nbsp;12.5.6 (Termination for Convenience by Primary Party), Moderna shall have no obligation to comply with Metagenomi&#146;s or its Affiliates&#146; written request that Moderna prepare and
file a DMF with, or otherwise provide CMC information to, any Regulatory Authority in any jurisdiction with respect to which Moderna has a material concern regarding the protection of its intellectual property rights in connection with any
Regulatory Filing or otherwise seeking or maintaining any Regulatory Approval in such jurisdiction, and upon written request by Moderna, Metagenomi shall, and shall cause its Affiliates and its and their Sublicensees to, refrain from preparing or
submitting any Regulatory Filing, or otherwise obtaining or maintaining any Regulatory Approval, for any DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product in such jurisdictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.6 <B>Effects of Termination</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12.6.1 <B>Effects of termination generally</B>. Subject to the remainder of this Section&nbsp;12.6 (Effects of Termination), upon termination
of this Agreement with respect to a Program, with respect to Products within such Program, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Product</FONT></FONT> basis: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <B>Licenses</B>. All licenses granted hereunder with respect to such Product will terminate; provided <I>that</I> such licenses will
continue as necessary for the Parties to complete the orderly wind-down of their activities under this Agreement in accordance with Applicable Law and as otherwise required in accordance with Section&nbsp;12.6.1(b) (Wind Down). With the exception of
such wind-down activities, each Party shall immediately cease and shall cause its Affiliates, Sublicensees and contractors, each as applicable, to immediately cease, all Research, Development, Manufacturing and Commercialization activities with
respect to such Product. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <B>Wind-Down</B>. Promptly following receipt by the applicable Party of a notice of
termination under Section&nbsp;12.2 (Termination for Material Breach or Insolvency or Patent Challenge) or Section&nbsp;12.4 (Termination for Convenience by Moderna) or Section&nbsp;12.5 (Termination for Convenience by Primary Party) if the <FONT
STYLE="white-space:nowrap">Opt-Out</FONT> Party does not exercise the <FONT STYLE="white-space:nowrap">Opt-In</FONT> Right, the Parties will begin to wind-down their respective activities under this Agreement with respect to such Product. The
Parties will establish an appropriate Working Group to coordinate such wind-down. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) <B>Destruction of Confidential Information</B>.
Each Receiving Party shall destroy (at the Disclosing Party&#146;s written request) all such Confidential Information of the Receiving Party in its possession as of the effective date of expiration or termination (with the exception of one copy of
such Confidential Information, which may be retained by the legal department of the Receiving Party to confirm compliance with the <FONT STYLE="white-space:nowrap">non-use</FONT> and <FONT STYLE="white-space:nowrap">non-disclosure</FONT> provisions
of this Agreement), and any Confidential Information of the Disclosing Party contained in its laboratory notebooks or databases, provided that each Receiving Party may retain and continue to use such Confidential Information of the Disclosing Party
to the extent necessary to exercise any surviving rights, licenses or obligations under this Agreement. Notwithstanding the foregoing, a Receiving Party shall not be required to destroy any computer files created during automatic system back up that
are subsequently stored securely by it and not readily accessible to its employees, consultants, or others who received the Disclosing Party&#146;s Confidential Information under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12.6.2 <B>Reversion</B>. Upon termination of this Agreement with respect to a Program by Metagenomi under Section&nbsp;12.2.1 (Material
Breach), with respect to any Product within such Program impacted by Moderna&#146;s material breach (a &#147;<B>Reversion Product</B>&#148;), the following will occur: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) any licenses and rights granted by Metagenomi to Moderna with respect to the Reversion Product shall revert to Metagenomi, provided that
such licenses and rights will continue as necessary as otherwise required under this Section&nbsp;12.6.2 (Reversion); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) in the case
the Reversion Product is a DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product, [***]; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) effective on the effective date of
termination for such Reversion Product, Moderna hereby assigns to Metagenomi or its designee all Regulatory Filings (except DMFs), Regulatory Approvals, Pricing and Reimbursement Approvals, copies of material correspondence and conversation logs, <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> and clinical study reports, clinical study protocols, and all data (in the format in which is maintained by Moderna), in each case, that are related to the Reversion Product and Controlled by Moderna or
its Affiliates as of the effective date of termination. Moderna shall take all steps necessary to transfer to Metagenomi or its designee ownership of all such assigned Regulatory Filings (except DMFs), Regulatory Approvals and Pricing and
Reimbursement Approvals, including submitting to each applicable Regulatory Authority a letter or other necessary documentation (with a copy to Metagenomi) notifying such Regulatory Authority of the transfer of such ownership of each Regulatory
Filing, Regulatory </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Approval and Pricing and Reimbursement Approval. If it is not feasible under Applicable Laws for Moderna to transfer to Metagenomi any such Regulatory Filings, Regulatory Approvals, and Pricing
and Reimbursement Approvals, Moderna shall hold such Regulatory Filings, Regulatory Approvals, and Pricing and Reimbursement Approvals in its name for the benefit of Metagenomi and shall grant, and hereby does grant to Metagenomi an exclusive,
royalty-free license and right of reference to use such Regulatory Filings, Regulatory Approvals, and Pricing and Reimbursement Approvals in connection with Exploitation of the Reversion Product and authorize Metagenomi or its designee to conduct
regulatory activities with appliable Regulatory Authorities relating to such Regulatory Filings, Regulatory Approvals, and Pricing and Reimbursement Approvals; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) Moderna shall be entitled, during the [***] following the effective date of termination of this Agreement with respect to a Reversion
Product, to finish any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">work-in-progress</FONT></FONT> and to sell any inventory of such Reversion Product and shall pay Metagenomi the amounts applicable to such sales of such
Reversion Product in accordance with the terms and conditions of this Agreement. Thereafter, Moderna shall cease selling any such Reversion Product, and Metagenomi shall have the right, in its sole discretion and upon written notification to
Moderna, to purchase from Moderna any or all of the inventory of such Reversion Product held by Moderna as of the date of such notice at a price equal to Moderna&#146;s Manufacturing Costs for such Reversion Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12.6.3 <B>Conduct During Termination Notice Period</B>. Following any notice of termination permitted under this Article 12 (Term&nbsp;&amp;
Termination) other than any termination pursuant to Section&nbsp;12.2.1 (Material Breach), during any applicable termination notice period (the applicable &#147;<B>Termination Notice Period</B>&#148;), each Party shall continue to perform all of its
obligations under this Agreement then in effect in accordance with the terms and conditions of this Agreement. In such circumstances, each Party shall also continue to bear its share of all applicable costs incurred during the Termination Notice
Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12.6.4 <B>Transition Agreement</B>. In connection with the termination of this Agreement, the Parties shall enter into a written
agreement (the &#147;<B>Transition Agreement</B>&#148;) that would include other reasonable terms and conditions, including terms allocating costs and expenses, describing the Parties&#146; indemnification obligations, setting forth the
Parties&#146; obligations with respect to unauthorized sales, and setting forth other coordination obligations. If, despite such efforts, the Parties are unable to agree upon such terms and conditions within [***] from the effective date of the
termination, either Party may refer the dispute for resolution by arbitration in accordance with Article 13 (Governing Law; Dispute Resolution), and the arbitrator shall have the authority to require the Parties to execute a Transition Agreement in
the form approved by the arbitrator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12.6.5 <B>Sublicense Survival</B>. Any permitted sublicense granted by a Party or its Affiliate to a
Third Party under the licenses granted to such Party under this Agreement shall survive the termination of this Agreement; provided that, in the case where termination of this Agreement for such Party&#146;s uncured material breach pursuant to
Section&nbsp;12.2.1 (Material Breach), such Sublicensee did not cause such uncured material breach. If permitted under such a surviving sublicense, effective upon termination of this Agreement, such sublicense shall become a direct license from
Metagenomi to such Sublicensee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.7 <B>Survival</B>. Expiration or termination of this Agreement shall not relieve the
Parties of any obligation or right accruing prior to such expiration or termination. Except as set forth below or elsewhere in this Agreement, the obligations and rights of the Parties under the following provisions of this Agreement shall survive
expiration or termination of this Agreement: Article 1 (Definitions) (to the extent the definitions are used in surviving provisions); Sections 3.7.1 (Records), 3.7.3 (Ownership; Confidentiality), 4.8.1 (Records), and 4.8.3 (Ownership;
Confidentiality); the second and third last sentences of Section&nbsp;5.18 (Collaboration Materials Transfer); Sections 5.19 (No Other Rights and Retained Rights), 5.25 (Payments); 7.6 (Accounting; Audit), 7.7 (Disputed Payments), 7.13(Method of
Payment; Foreign Exchange), 7.14 (Records and Audits), 7.15 (Default Interest), 7.16 (Taxes), 8.1 (Ownership of Intellectual Property), 8.2.1 (Generally), 8.3.2 (Generally), 8.7 (Common Interest), 8.8 (Trademarks), and 9.6 (Disclaimer); Articles 10
(Indemnification) and 11 (Confidentiality); Sections 12.6 (Effects of Termination), 12.7 (Survival), and 12.8 (Bankruptcy Code); Article 13 (Governing Law; Dispute Resolution); and Sections 14.1 (Entire Agreement; Amendment), 14.2 (Limitation of
Liability), 14.3 (Independent Contractors), 14.4 (Notices), 14.5 (Severability), 14.6 <FONT STYLE="white-space:nowrap">(Non-Use</FONT> of Names), 14.13 (Waivers), 14.15 (Interpretation), 14.18 (No Third Party Beneficiary Rights), 14.19
(Construction), 14.20 (Cumulative Remedies), 14.21 (Extension to Affiliates), and 14.22 (Other Activities). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.8 <B>Bankruptcy Code</B>.
If this Agreement is rejected by a Party as a debtor under Section&nbsp;365 of the U.S. Bankruptcy Code or similar provision in the bankruptcy laws of another jurisdiction (the &#147;<B>Code</B>&#148;), then, notwithstanding anything else in this
Agreement to the contrary, all licenses and rights to licenses granted under or pursuant to this Agreement by the Party in bankruptcy to the other Party are, and shall otherwise be deemed to be, for purposes of Section&nbsp;365(n) of the Code (or
similar provision in the bankruptcy laws of the jurisdiction), licenses of rights to &#147;intellectual property&#148; as defined under Section&nbsp;101(35A) of the Code (or similar provision in the bankruptcy laws of another applicable
jurisdiction). The Parties agree that a Party that is a licensee of rights under this Agreement shall retain and may fully exercise all of its rights and elections under the Code, and that upon commencement of a bankruptcy proceeding by or against a
Party under the Code, the other Party shall be entitled to a complete duplicate of, or complete access to (as such other Party deems appropriate), any such intellectual property and all embodiments of such intellectual property, if not already in
such other Party&#146;s possession, shall be promptly delivered to such other Party: (a)&nbsp;upon any such commencement of a bankruptcy proceeding upon written request therefor by such other Party, unless the bankrupt Party elects to continue to
perform all of its obligations under this Agreement; or (b)&nbsp;if not delivered under the foregoing clause (a), upon the rejection of this Agreement by or on behalf of the bankrupt Party upon written request therefor by the other Party. The
foregoing provisions of this Section&nbsp;12.8 (Bankruptcy Code) are without prejudice to any rights a Party may have arising under the Code. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Article 13 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B><B>GOVERNING LAW; DISPUTE RESOLUTION</B><B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.1 <B>Governing Laws</B>. This Agreement is governed by and shall be construed in accordance with the laws of the State of New York, without
reference to its conflict of laws principles. The United Nations Convention of International Contracts on the Sale of Goods (the Vienna Convention) does not apply to this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.2 <B>Disputes</B>. The Parties recognize that controversies or claims arising out of,
relating to, or in connection with this Agreement may arise from time to time. It is the objective of the Parties to establish procedures to facilitate the resolution of disputes in an expedient manner by mutual cooperation and without resort to
litigation. To accomplish this objective, the Parties shall follow the procedures set forth in this Article 13 (Governing Law; Dispute Resolution) to resolve any dispute. If any dispute, claim or controversy of any nature arising out of or relating
to this Agreement, including any action or claim based on tort, contract or statute, or concerning the interpretation, effect, termination, validity, performance or breach of this Agreement (each, a &#147;<B>Dispute</B>&#148;), arises between the
Parties, either Party may refer the Dispute to Executive Officers of each Party for resolution within [***] of a written request by either Party to the other Party. Each Party, within [***] after a Party has received such written request from the
other Party to so refer such Dispute, shall notify the other Party in writing of the Executive Officer to whom such Dispute is referred. If, after an additional [***] after the notice of Dispute, such Executive Officers have not succeeded in
negotiating a resolution of the Dispute, and a Party wishes to pursue the matter, each such Dispute, controversy or claim that is not an &#147;Excluded Claim&#148; (defined in Section&nbsp;13.6 (Excluded Claims)) shall be submitted for binding
arbitration administered by the International Chamber of Commerce (&#147;<B>ICC</B>&#148;) pursuant to its Arbitration Rules in effect at the time such Dispute arises (the &#147;<B>ICC Arbitration Rules</B>&#148;). The option to arbitrate under this
Article 13 (Governing Law; Dispute Resolution) shall extend to any claims by or against the Parties and their respective Affiliates and any agents, principals, officers, directors, or employees of either of the Parties or their respective
Affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.3 <B>Arbitration</B>. Any arbitration that the Parties decide to pursue shall be conducted by a single neutral arbitrator
experienced in the business of pharmaceuticals. If the issues in dispute involve scientific, technical or commercial matters, the arbitrator chosen hereunder may engage experts that have educational training or industry experience sufficient to
demonstrate a reasonable level of relevant scientific, medical and industry knowledge, as necessary to help resolve the dispute. The Parties shall select the arbitrator promptly following the initiation of the arbitration. If the Parties are unable
or fail to agree upon the arbitrator within [***] following the initiation of arbitration, the arbitrator shall be appointed by ICC. The arbitration shall be conducted in New York, New York, and all proceedings and communications shall be in
English. Except to the extent necessary to enforce a legal right or as may be required by law, neither a Party nor an arbitrator may disclose the existence, content, or results of an arbitration without the prior written consent of both Parties.
Each Party shall bear its own costs and expenses and attorneys&#146; fees and an equal share of the arbitrator&#146;s fees and any administrative fees of arbitration. Any arbitration findings or rulings made under this Section&nbsp;13.3
(Arbitration) shall be final and binding on the Parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.4 <B>Baseball Arbitration</B>. Any Disputes over any amounts invoiced under
this Agreement, Disputes over matters set forth in Sections 2.10.2 (Decision-making for DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Plans), 5.10.3(b) (Payments under <FONT STYLE="white-space:nowrap">Co-Co</FONT> Moderna <FONT
STYLE="white-space:nowrap">In-License</FONT> Agreements), 5.10.4(b) (Payments under <FONT STYLE="white-space:nowrap">Co-Co</FONT> Metagenomi <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements) and 12.6.2(b) (Reversion), shall be submitted
to and finally resolved by the following provisions in this Section&nbsp;13.4 (Baseball Arbitration). The Parties shall promptly designate in writing a single mutually acceptable arbitrator experienced in the licensing, development, and
commercialization of pharmaceutical products, who is independent of each Party (i.e., not a current or former employee, consultant, officer, or director or current stockholder of either Party or their respective Affiliates and who does not otherwise
have any current or previous business relationship with either Party or their respective Affiliates). If the Parties cannot agree on an arbitrator within [***] after referral of such matter, the arbitrator shall be selected by the President of
Greater Boston Chamber of Commerce. The arbitration shall </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be conducted in accordance with the ICC Arbitration Rules to the extent consistent with this Section&nbsp;13.4 (Baseball Arbitration). Within [***] of the arbitrator&#146;s appointment, each
Party shall prepare and deliver to both the arbitrator and the other Party its last, best offer for the applicable unresolved terms and a memorandum in support thereof. The Parties shall also provide the arbitrator with a copy of the relevant
provisions of this Agreement. Each Party may submit to the arbitrator (with a copy to the other Party) a rebuttal to the other Party&#146;s support memorandum and shall at such time have the opportunity to amend its last such offer based on any new
information contained in the other Party&#146;s support memorandum. Within [***] after the arbitrator&#146;s appointment, the arbitrator shall select from the two (2)&nbsp;proposals provided by the Parties the proposal such arbitrator believes is
the most consistent with the intent of the Parties when this Agreement was entered into provided the arbitrator may not alter the terms of this Agreement. The decision of the arbitrator shall be final and binding on the Parties. The foregoing
&#147;baseball-style&#148; arbitration shall be the exclusive remedy of either Party if the Parties cannot agree on any Disputes over any amounts invoiced under this Agreement, or Disputes over matters set forth in Sections 2.10.2 (Decision-making
for DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Plans), 5.10.3(b) (Payments under <FONT STYLE="white-space:nowrap">Co-Co</FONT> Moderna <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements), 5.10.4(b) (Payments under <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Metagenomi <FONT STYLE="white-space:nowrap">In-License</FONT> Agreements) and 12.6.2(b) (Reversion). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.5 <B>Equitable Relief; Remedy for Breach of Exclusivity</B>. Nothing in this Article 13 (Governing Law; Dispute Resolution) shall preclude
either Party from seeking equitable relief or interim or provisional relief from a court of competent jurisdiction, including a temporary restraining order, preliminary injunction or other interim equitable relief, concerning a dispute either prior
to or during any arbitration if necessary to protect the interests of such Party or to preserve the status quo pending the arbitration proceeding. Therefore, in addition to its rights and remedies otherwise available at law, including the recovery
of damages for breach of this Agreement, such <FONT STYLE="white-space:nowrap">Non-Breaching</FONT> Party shall be entitled to seek (a)&nbsp;equitable relief, specifically including, but not limited to, both interim and permanent restraining orders
and injunctions and (b)&nbsp;such other and further equitable relief as the court may deem proper under the circumstances. Any final judgment resolving a Dispute may be enforced by either Party in any court having appropriate jurisdiction. For the
avoidance of doubt, nothing in this Section&nbsp;13.5 (Equitable Relief; Remedy for Breach of Exclusivity) shall otherwise limit a Breaching Party&#146;s opportunity to cure a material breach as permitted in accordance with Section&nbsp;12.2.1
(Material Breach). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.6 <B>Excluded Claims</B>. As used in this Article 13 (Governing Law; Dispute Resolution), the term
&#147;<B>Excluded Claim</B>&#148; means any dispute, controversy or claim that concerns: (a)&nbsp;the validity, enforceability or infringement of any patent, trademark or copyright; or (b)&nbsp;any antitrust, antimonopoly or competition law or
regulation, whether or not statutory. Any Excluded Claim may be submitted by either Party to any court of competent jurisdiction over such Excluded Claim. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Article 14 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MISCELLANEOUS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.1
<B>Entire Agreement; Amendment</B>. This Agreement, including the Schedules hereto, sets forth the complete, final and exclusive agreement and all the covenants, promises, agreements, warranties, representations, conditions and understandings
between the Parties hereto along with the Convertible Note Instruments, with respect to the subject matter hereof and supersedes, as of the Effective Date, all prior and contemporaneous agreements and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
understandings between the Parties with respect to the subject matter hereof, including the Mutual Confidentiality Agreement. The Parties hereby agree to terminate the Mutual Confidentiality
Agreement as of the Effective Date, and that all confidential information that was disclosed by the Parties pursuant to the Mutual Confidentiality Agreement shall be deemed Confidential Information disclosed under, and subject to, the terms and
conditions of this Agreement. The foregoing may not be interpreted as a waiver of any remedies available to either Party as a result of any breach, prior to the Effective Date, by the other Party of its obligations under the Mutual Confidentiality
Agreement. No subsequent alteration, amendment, change or addition to this Agreement shall be binding upon the Parties unless reduced to writing and signed by an authorized officer of each Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.2&nbsp;&nbsp;&nbsp;&nbsp;<B>Limitation of Liability</B>. TO THE EXTENT PERMITTED BY APPLICABLE LAW, NEITHER PARTY MAY RECOVER FROM THE
OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES IN CONNECTION WITH THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES; PROVIDED, HOWEVER, THAT THIS SECTION 14.2 (LIMITATION OF LIABILITY) SHALL NOT BE
CONSTRUED TO LIMIT EITHER PARTY&#146;S INDEMNIFICATION OBLIGATIONS UNDER ARTICLE 10 (INDEMNIFICATION), METAGENOMI&#146;S LIABILITY IN CONNECTION WITH A BREACH OF ITS EXCLUSIVITY OBLIGATIONS UNDER SECTIONS 5.20 (RT EXCLUSIVITY), 5.21 (DT EXCLUSIVITY)
OR 5.22 (DT <FONT STYLE="white-space:nowrap">CO-CO</FONT> TARGET EXCLUSIVITY), MODERNA&#146;S LIABILITY IN CONNECTION WITH A BREACH OF ITS EXCLUSIVITY OBLIGATIONS UNDER SECTION 5.22 (DT COCO TARGET EXCLUSIVITY), OR EITHER PARTY FROM ITS LIABILITY
FOR ANY DAMAGES BASED UPON SUCH PARTY&#146;S BREACH OF ITS OBLIGATIONS UNDER ARTICLE 11 (CONFIDENTIALITY). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.3&nbsp;&nbsp;&nbsp;&nbsp;<B>Independent Contractors</B>. The relationship between Moderna and Metagenomi created under this Agreement is
solely that of independent contractors. This Agreement does not create any agency, distributorship, employee-employer, partnership, joint venture or similar business relationship between the Parties. Neither Party is a legal representative of the
other Party, and neither Party can assume or create any obligation, representation, warranty, or guarantee, express or implied, on behalf of the other Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.4&nbsp;&nbsp;&nbsp;&nbsp;<B>Notice</B>. Any notice required or permitted to be given under this Agreement must be in writing, in English.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder must be in writing and shall be deemed given and effective if: (a)&nbsp;delivered by hand or by overnight courier with tracking capabilities;
(b)&nbsp;mailed postage prepaid by first class, registered, or certified mail; or (c)&nbsp;delivered by facsimile or electronic mail followed by delivery via either of the methods set forth in clauses (a)&nbsp;and (b) of this Section&nbsp;14.4
(Notice), in each case, addressed as set forth below unless changed by notice so given: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="18%" VALIGN="top" ALIGN="left">If&nbsp;to&nbsp;Metagenomi:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Metagenomi, Inc. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="18%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">1545 Park Avenue </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="18%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Emeryville, CA 94608 </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="18%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Attn: Jian Irish </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="18%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">E-mail:</FONT> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="18%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">with a copy (which shall not constitute notice) to: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="18%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Metagenomi, Inc. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="18%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">1545 Park Avenue, </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="18%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Emeryville, CA 94608 </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="18%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Attn: Legal Department </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="18%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">E-mail:</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="18%" VALIGN="top" ALIGN="left">If&nbsp;to&nbsp;Moderna:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">ModernaTX, Inc. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="18%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">200 Technology Square </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="18%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Cambridge, MA 02139 </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="18%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Attn: General Counsel </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="18%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">E-mail:</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="18%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">with a copy (which shall not constitute notice) to: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="18%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">ModernaTX, Inc. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="18%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">200 Technology Square </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="18%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Cambridge, MA 02139 </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="18%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Attn: Shaun Ryan </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="18%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">E-mail:</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Party shall also provide a copy of any notice (via <FONT STYLE="white-space:nowrap">e-mail</FONT> if available) to the other Party&#146;s
Alliance Manager. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.5 <B>Severability</B>. If, for any reason, any part of this Agreement is adjudicated invalid, unenforceable, or
illegal by a court of competent jurisdiction, such adjudication shall not, to the extent feasible, affect or impair, in whole or in part, the validity, enforceability, or legality of any remaining portions of this Agreement. All remaining portions
shall remain in full force and effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.6 <B><FONT STYLE="white-space:nowrap">Non-Use</FONT> of Names</B>. Metagenomi shall not use the
name, trademark, logo, or physical likeness of Moderna or its respective officers, directors or employees, or any adaptation of any of them, in any advertising, promotional or sales literature, without Moderna&#146;s prior written consent.
Metagenomi shall require its Affiliates to comply with the foregoing. Moderna shall not use the name, trademark, logo, or physical likeness of Metagenomi or its officers, directors or employees, or any adaptation of any of them, in any advertising,
promotional or sales literature, without Metagenomi&#146;s prior written consent. Moderna shall require its Affiliates and Sublicensees to comply with the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.7 <B>Assignment</B>. Neither Party may assign or transfer this Agreement or any rights or obligations hereunder without the prior written
consent of the other, except that a Party may make such an assignment or transfer without the other Party&#146;s consent to: (a)&nbsp;its Affiliate, provided that such Party shall remain primarily liable for any acts or omissions of such Affiliate;
or (b)&nbsp;to an Acquirer in connection with a Change of Control, subject to Section&nbsp;14.9 (Metagenomi Change of Control). Any permitted assignee shall, in writing to the <FONT STYLE="white-space:nowrap">non-assigning</FONT> Party, expressly
assume performance of such assigning Party&#146;s rights and obligations. Any permitted assignment is binding on the successors of the assigning Party. Any assignment or attempted assignment by either Party in violation of the terms of this
Section&nbsp;14.7 (Assignment) is null, void and of no legal effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.8 <B>Acquisition of Existing Competing Programs</B>. If, after the Effective Date, any
Third Party becomes an Affiliate of a Party that such Party controls (as such term is defined in the definition of &#147;Affiliate&#148;, and for clarity, excluding a New Affiliate) as a result of a merger, acquisition, consolidation, asset sale, or
other similar transaction (whether in a single transaction or series of related transactions), and, as of the closing date of such transaction, such Third Party is engaged in (a)&nbsp;the Development or Commercialization of any compound or product;
or (b)&nbsp;the licensing, conveyance, sublicensing or other grant of rights in Patents or <FONT STYLE="white-space:nowrap">Know-How</FONT> with respect to such any compound or product, in each case of (a)&nbsp;and (b) that would, if conducted by
such Party, cause such Party to breach its exclusivity obligations set forth in Section&nbsp;5.20 (RT Exclusivity), Section&nbsp;5.21 (DT Exclusivity), Section&nbsp;5.22 (DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Target Exclusivity) (any such
activities in (a)&nbsp;and (b), a &#147;<B>Competing Program</B>&#148;), then continuation of the relevant Competing Program shall not be a breach of this Agreement provided that such Party provides the other Party with written notice of such
transaction promptly, but no later than [***] following the earlier of the first public announcement of such transaction or the execution of a definitive agreement relating to such transaction (if such disclosure is not prohibited under Applicable
Laws), and such Party does (or causes such Affiliate to), within [***] after the closing of such transaction, with mutual agreement with the other Party, either: (i)&nbsp;complete a Divestiture of such Competing Program; (ii)&nbsp;cease and
terminate the Competing Program, subject to any commercially reasonable wind-down provisions, including with respect to Clinical Trials; or (iii)&nbsp;offer to include the Competing Program into this Agreement; provided that the actions in clauses
(i) &#150; (iii) will not have to occur if such Third Party has <FONT STYLE="white-space:nowrap">pre-existing</FONT> license or contractual obligation that would prohibit the Third Party from taking the actions in clauses (i) &#150; (iii). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.9 <B>Metagenomi Change of Control</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">14.9.1 <B>Notification of Change of Control</B>. If Metagenomi undergoes a Change of Control at any time before expiry of the Research Term,
Metagenomi shall provide Moderna with written notice of such Change of Control of Metagenomi promptly, but no later than [***] following the earlier of the first public announcement of such Change of Control or the execution of a definitive
agreement relating to such Change of Control (if such disclosure is not prohibited under Applicable Law or by the terms of any written agreement between Metagenomi and any Third Party), which notice shall describe in reasonable detail the nature of
the transaction and the identity of the Acquirer (a &#147;<B>Change of Control Notice</B>&#148;). If Metagenomi undergoes such a Change of Control, then Section&nbsp;14.9.2 (Effects of Change of Control) shall apply. For the avoidance of doubt, a
Change of Control of Metagenomi shall not in any way limit or alter Moderna&#146;s rights in accordance with Section&nbsp;12.3 (Moderna Option to Continue in Lieu of Termination). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">14.9.2 <B>Effects of Change of Control</B>. On a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Program</FONT></FONT> basis, following a Change of Control of Metagenomi at any time before expiry of the Research Term for such Program, Moderna may elect, at its sole
discretion, whether the Research Transfer Scenario (in subsection (a)&nbsp;below) or the Research Continuance Scenario (in subsection (b)&nbsp;below) shall apply to such Change of Control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <B>Research Transfer Scenario</B>. The &#147;<B>Research Transfer Scenario</B>&#148; means that Metagenomi shall, on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Program</FONT></FONT> basis, transfer to Moderna all ongoing Research and Development activities (including the data and results for such Program), if any, being conducted by or
on behalf of Metagenomi or any of its Affiliates, or if no Research or Development activities remain ongoing at the time of such Change of Control, the following shall apply: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(i) Metagenomi shall promptly disclose or deliver to Moderna, to the extent not previously
provided, copies of all data, results, and information in Metagenomi&#146;s (or its Affiliates&#146;) possession constituting <FONT STYLE="white-space:nowrap">Know-How</FONT> included in the Metagenomi Licensed Collaboration Technology, which is
reasonably necessary or useful for Moderna&#146;s Exploitation of the Candidates and the Products (including for regulatory purposes) in such Program, and upon Moderna&#146;s reasonable request and at Moderna&#146;s expense, Metagenomi will:
(A)&nbsp;provide reasonable technical assistance to Moderna during such disclosure or delivery set forth in the preceding sentence for a period not longer than [***]; and (B)&nbsp;make its employees and
<FONT STYLE="white-space:nowrap">non-employee</FONT> consultants reasonably available at their respective places of employment to consult with Moderna on issues arising in the course of Moderna&#146;s Exploitation or in connection with any request
related to a Product from any Regulatory Authority, including regulatory, scientific, technical and clinical testing issues, preparation and submission of Regulatory Filings, and assistance in responding to requests from Regulatory Authorities (the
&#147;<B><FONT STYLE="white-space:nowrap">Know-How</FONT> Transfer</B>&#148;). The <FONT STYLE="white-space:nowrap">Know-How</FONT> Transfer to be undertaken under the foregoing shall be overseen by a Working Group established for such purposes,
which Working Group may put in place a transfer plan expressly identifying <FONT STYLE="white-space:nowrap">Know-How</FONT> owned or Controlled by Metagenomi or its Affiliates to be transferred and the timing for such transfer; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(ii) the JSC shall be immediately disbanded, and all approval rights of the JSC, or final decision making authority granted to a Party
pursuant to this Agreement, shall become approval rights of the corresponding Party (<I>i.e.</I>, mutual agreement by the Parties or final decision making authority by a Party). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <B>Research Continuance Scenario</B>. The &#147;<B>Research Continuance Scenario</B>&#148; means, on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Program-by-Program</FONT></FONT> basis, that Metagenomi shall continue the Research and other activities, if any, being conducted under the applicable Program Plan, and the Program and this Agreement shall continue in the
same manner as prior to the Change of Control, and in which case: (i)&nbsp;Moderna will maintain all of its rights under this Agreement; and (ii)&nbsp;Metagenomi shall continue to comply with its diligence obligations hereunder, with the same level
of diligence applied to such activities after the consummation of such Change of Control as compared to prior to the consummation of such Change of Control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.10 <B>Acquirer Engaged in Competing Program</B>. On a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Program</FONT></FONT> basis, if a Party undergoes a Change of Control at any time before expiry of the Term for such Program and, as of the closing date of such Change of
Control transaction or thereafter, the Acquirer (or any of its Affiliates) is engaged in a Competing Program, then such Party shall implement (as of the closing of such transaction or the engagement in the Competing Program, if later than the
closing of such transaction) and enforce Firewalls for the duration of the Firewall Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.11 <B>Firewalled Programs</B>. Promptly
following the first to occur of any of the following events in relation to an Acquirer of a Party during the Term: (a)&nbsp;the effective date of a Change of Control of such Party to an Acquirer with a Competing Program, or (b)&nbsp;DC Nomination
(if applicable), in either case (a)&nbsp;or (b) that results in the Acquirer&#146;s program with respect to the applicable Collaboration Target becoming a Competing Program, or (c)&nbsp;the initiation of a Competing Program by an Acquirer of such
Party (each of (a), (b), and (c), with respect to such Competing Program, the &#147;<B>Firewall Event</B>&#148;), such Party shall implement and enforce Firewalls between the applicable Program and the Competing Program for the duration of the
applicable Firewall Period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.12 <B>Firewall Audits</B>. In the event a Party is obligated to implement and enforce
Firewalls under this Agreement, the other Party shall have the right, through a designated Third Party auditor reasonably acceptable to such Party, to audit such Party&#146;s (and, as applicable, its Affiliates&#146;) obligations under this
Agreement regarding implementation and enforcement of such Firewalls for purposes of confirming compliance with the Firewalls, identifying any vulnerabilities or breaches and requiring such Party (or its Affiliates) to promptly remediate any <FONT
STYLE="white-space:nowrap">non-compliance</FONT> identified by such audit. In connection with such audit, duly authorized representatives of the other Party&#146;s designated auditor may make an <FONT STYLE="white-space:nowrap">on-site</FONT> visit
to such Party (or its Affiliate) for the purpose of conducting such audit. The other Party may conduct such audits from time to time as reasonably necessary to confirm such Party&#146;s compliance with such Firewall requirements no more than [***]
or more frequently if the other Party reasonably believes at any time that such Party is not in compliance with such Firewall requirements; provided that if the auditor identifies a breach of the Firewall, the other Party will be entitled to up to
[***] additional audits within the same Calendar Year to verify that appropriate action has been taken to remedy the breach of the Firewall. Any audits described under this Section&nbsp;14.12 (Firewall Audits) shall be conducted during such
Party&#146;s regular business hours, for a duration only as reasonably necessary to confirm such Party&#146;s compliance with the applicable Firewall requirements, and shall not unreasonably interfere with or impede such Party&#146;s business
operations. The other Party shall provide such Party with written notice of such audit at least [***] prior to such requested audit (or such shorter period as may be designated by the other Party if the other Party reasonably believes at any time
that such Party is not in compliance with such Firewall requirements). All such audits shall be conducted at the other Party&#146;s cost and expense. If the auditor identifies any breach of the Firewall, the other Party or the auditor will notify
such Party, and such Party will promptly (and will use reasonable efforts to ensure its Affiliates promptly) take all action necessary to remedy such breach, and will provide the other Party with reasonable assurance that such action has been taken,
at such Party&#146;s sole expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.13 <B>Waivers</B>. The failure of a Party to insist upon strict performance of any provision of
this Agreement or to exercise any right arising out of this Agreement shall neither impair that provision or right nor constitute a waiver of that provision or right, in whole or in part, in that instance or in any other instance. Any waiver by a
Party of a particular provision or right shall be in writing, shall be as to a particular matter and, if applicable, for a particular period of time and shall be signed by such Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.14 <B>Force Majeure</B>. Neither Party shall be responsible to the other for any failure or delay in performing any of its obligations
under this Agreement or for other nonperformance hereunder (excluding, in each case, the obligation to make payments when due) if such delay or nonperformance is caused by strike, fire, flood, earthquake, accident, war, act of terrorism, pandemics,
act of God or of the government of any country or of any local government, or by any other cause unavoidable or beyond the control of any Party hereto. In such event, such affected Party shall use Commercially Reasonable Efforts to resume
performance of its obligations and shall keep the other Party informed of actions related thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.15 <B>Interpretation</B>. The captions and headings to this Agreement are for convenience
only, and are to be of no force or effect in construing or interpreting any of the provisions of this Agreement. Unless specified to the contrary, references to Articles, Sections or Schedules mean the particular Articles, Sections or Schedules to
this Agreement and references to this Agreement include all Schedules hereto. In the event of any conflict between the main body of this Agreement and any Schedule hereto, the main body of this Agreement shall prevail. Unless context otherwise
clearly requires, whenever used in this Agreement: (a)&nbsp;the words &#147;include&#148; or &#147;including&#148; shall be construed as incorporating, also, &#147;but not limited to&#148; or &#147;without limitation&#148;; (b) the word
&#147;or&#148; is used in the inclusive sense (i.e., &#147;and/or&#148;); (c) the word &#147;day&#148; or &#147;year&#148; means a calendar day or year unless otherwise specified; (d)&nbsp;the word &#147;notice&#148; means notice in writing (whether
or not specifically stated) and shall include notices, consents, approvals and other written communications contemplated under this Agreement; (e)&nbsp;the words &#147;hereof,&#148; &#147;herein,&#148; &#147;hereby&#148; and derivative or similar
words refer to this Agreement as a whole and not merely to the particular provision in which such words appear; (f)&nbsp;the words &#147;shall&#148; and &#147;will&#148; have interchangeable meanings for purposes of this Agreement;
(g)&nbsp;provisions that require that a Party, the Parties or a committee hereunder &#147;agree,&#148; &#147;consent&#148; or &#147;approve&#148; or the like shall require that such agreement, consent or approval be specific and in writing, whether
by written agreement, letter, approved minutes or otherwise; (h)&nbsp;words of any gender include the other gender; (i)&nbsp;words using the singular or plural number also include the plural or singular number, respectively; (j)&nbsp;references to
any specific law, rule or regulation, or article, section or other division thereof, shall be deemed to include the then-current amendments thereto or any replacement law, rule or regulation thereof; (k)&nbsp;the phrase <FONT
STYLE="white-space:nowrap">&#147;non-refundable,</FONT> <FONT STYLE="white-space:nowrap">non-creditable&#148;</FONT> shall not prohibit, limit or restrict either Party&#146;s right to obtain damages in connection with a breach of this Agreement; and
(l)&nbsp;neither Party shall be deemed to be acting on behalf of the other Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.16 <B>Expenses</B>. Each Party shall pay its own
costs, charges and expenses incurred in connection with the negotiation, preparation and execution of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.17 <B>Further
Assurances</B>. Moderna and Metagenomi hereby covenant and agree without the necessity of any further consideration, to execute, acknowledge and deliver any and all documents and take any action as may be reasonably necessary to carry out the intent
and purposes of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.18 <B>No Third Party Beneficiary Rights</B>. This Agreement is not intended to and shall not be
construed to give any Third Party any interest or rights (including any Third Party beneficiary rights) with respect to or in connection with any agreement or provision contained herein or contemplated hereby, except for Third-Party Indemnitees or
as otherwise expressly provided for in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.19 <B>Construction</B>. The Parties hereto acknowledge and agree that:
(a)&nbsp;each Party and its counsel reviewed and negotiated the terms and provisions of this Agreement and have contributed to its revision; (b)&nbsp;the rule of construction to the effect that any ambiguities are resolved against the drafting Party
shall not be employed in the interpretation of this Agreement; and (c)&nbsp;the terms and provisions of this Agreement shall be construed fairly as to all Parties hereto and not in a favor of or against any Party, regardless of which Party was
generally responsible for the preparation of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.20 <B>Cumulative Remedies</B>. No remedy referred to in this Agreement is intended to be
exclusive unless explicitly stated to be so, but each shall be cumulative and in addition to any other remedy referred to in this Agreement or otherwise available under law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.21 <B>Extension to Affiliates</B>. Except as expressly set forth otherwise in this Agreement, each Party shall have the right to extend the
rights and immunities granted in this Agreement to one or more of its Affiliates. All applicable terms and provisions of this Agreement, except this right to extend, shall apply to any such Affiliate to which this Agreement has been extended to the
same extent as such terms and provisions apply to the Party extending such rights and immunities. For clarity, a Party extending the rights and immunities granted hereunder shall remain primarily liable for any acts or omissions of its Affiliates.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.22 <B>Other Activities</B>. Except as expressly provided in this Agreement, each Party may: (a)&nbsp;engage in research,
manufacturing, development or commercialization activities that utilize technologies similar to or involve products competitive with those contemplated under this Agreement; and (b)&nbsp;use any publicly available information and research results
(including any publicly available information of the other Party) to the same extent as Third Parties generally are legally permitted to do so. Except as expressly provided in this Agreement, nothing in this Agreement, including any obligation to
promote Products or any restriction on the use of Confidential Information, shall create: (i)&nbsp;any obligation not to research, develop, manufacture, commercialize or otherwise exploit any product; or (ii)&nbsp;any obligation to utilize a Sales
Force for Products separate from sales forces for other products. Each Party has limited resources, and as a result it is anticipated that personnel assigned to the activities contemplated under this Agreement may also participate in other
activities that may utilize technologies similar to or involve products competitive with those contemplated under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.23
<B>Counterparts; Electronic Signatures</B>. This Agreement may be executed in any number of counterparts, each of which is deemed an original, but all of which together constitute one instrument. This Agreement may be executed and delivered
electronically and upon such delivery such electronic signature shall be deemed to have the same effect as if the original signature had been delivered to the other Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature page follows</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>, the
Parties have caused this Agreement to be executed as of the Effective Date by their duly authorized representatives. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>M<SMALL>ETAGENOMI</SMALL>, I<SMALL>NC</SMALL>.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Brian Thomas</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Brian Thomas</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: CEO</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>M<SMALL>ODERNA</SMALL>TX, I<SMALL>NC</SMALL>.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Stephen Hoge</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Stephen Hoge</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: President</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[SIGNATURE PAGE TO STRATEGIC COLLABORATION AND LICENSE AGREEMENT] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Target </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">PH1 </P></TD></TR></TABLE> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Schedule A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Manufacturing Cost </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Manufacturing
Cost</B>&#148; means [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of this Schedule B, &#147;<B>Direct Costs</B>&#148; equals the sum of the following as incurred for DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Candidates or DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products, as applicable: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of this Schedule B, &#147;<B>Indirect Costs</B>&#148; equals the sum of the following as incurred for DT
<FONT STYLE="white-space:nowrap">Co-Co</FONT> Candidates or DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products, as applicable: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Schedule B-1 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule C </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain Technology Milestones </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Schedule C-1 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule D </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Reserved DT Targets </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Schedule D-1 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule E </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Approved Subcontractors </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***]. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Schedule E-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule F </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Existing <FONT STYLE="white-space:nowrap">Co-Co</FONT> <FONT STYLE="white-space:nowrap">In-Licenses</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***]. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Schedule F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule G </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Existing RT <FONT STYLE="white-space:nowrap">In-Licenses</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***]. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Schedule G-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule H </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Existing DT <FONT STYLE="white-space:nowrap">In-Licenses</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***]. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Schedule H-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Material Transfer Record </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For clarity, defined
terms used herein and not defined herein have the meanings ascribed to such terms in the Agreement. This Material Transfer Record may be executed in one or more counterparts, including by facsimile, email or PDF exchange, each of which shall be
deemed to be an original as against any party whose signature appears thereon, but all of which together shall constitute but one and the same instrument. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Direction of Transfer: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To Moderna, from Metagenomi </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To Metagenomi, from Moderna </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="29%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="70%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Description&nbsp;of&nbsp;Collaboration&nbsp;Material:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In signing below, the Moderna representative and the Metagenomi representative acknowledge that they understand and shall
abide by the terms and conditions under which the Collaboration Material is provided. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Moderna Representative
Signature</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Metagenomi Representative
Signature</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Moderna Representative Name</P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Metagenomi Representative
Name</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Moderna Representative
Title</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Metagenomi Representative
Title</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Date</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Date</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Schedule I-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule J </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Co-Co</FONT> Products Profit and Loss Share </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This <B>Schedule J </B><FONT STYLE="white-space:nowrap">(Co-Co</FONT> Products Profit and Loss Share) covers financial planning, accounting policies and
procedures to be followed in determining the <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products Profit and Loss Share with respect to the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Products in the Territory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. <B>Principles of Reporting</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.1 Each
Party shall provide a report of the results of its operations for the applicable period with respect to Commercialization, Medical Affairs and other related activities in the Territory for each DT <FONT STYLE="white-space:nowrap">Co-Co</FONT>
Product, which report shall include the cost categories set forth below. Following receipt of each such report from the Parties, Moderna shall generate a consolidated report, for each DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product in the
Territory, based on the foregoing financial information provided by each Party, which report shall be in the following format (the &#147;<B>P&amp;L</B>&#148;): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Cost Category</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Moderna</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Metagenomi</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net Sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>less</I> Cost of Sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>plus</I> Licensing Income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>less</I> Eligible Medical Affairs Costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>less</I> Commercialization Costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>less</I> Other Operating Expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">= Operating Profits or Losses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.2 <B>Standards</B>. It is the intention of the Parties to interpret each of the definitions used in the
P&amp;L in a manner that is consistent with this <B>Schedule J <FONT STYLE="white-space:nowrap">(Co-Co</FONT> Products Profit and Loss Share) </B>and applicable U.S. GAAP principles; it being understood and agreed that &#147;Operating Profits or
Losses&#148; shall be calculated in accordance with applicable U.S. GAAP principles. Each Party agrees to provide reasonable supporting documentation to ensure that each Party&#146;s accounting methodologies are reasonable and consistently applied.
Reasonable methodologies may include a standard rate or some other appropriate basis for allocating costs. Notwithstanding anything herein to the contrary, in no event shall either Party be obligated to recognize revenue for its own purposes in a
manner that is contrary to the U.S. GAAP principles used by such Party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Schedule J-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.3 <B>Accounting Procedures</B>. Each Party shall record and account for its Eligible
Medical Affairs Costs, Commercialization Costs or Other Operating Expenses, in each case, in a manner that allocates costs to the extent possible to a specific activity in the applicable Medical Affairs Budget, Commercialization Budget or specific
category of Other Operating Expenses. For purposes of determining Net Sales, Licensing Income, Cost of Sales, Eligible Medical Affairs Costs, Commercialization Costs, or Other Operating Expenses, any expense allocated by either Party to a particular
category under the definition of Net Sales, Licensing Income, Cost of Sales, Eligible Medical Affairs Costs, Commercialization Costs, or Other Operating Expenses shall not be allocated to any other category under the definition of Net Sales,
Licensing Income, Cost of Sales, Eligible Medical Affairs Costs, Commercialization Costs, or Other Operating Expenses, respectively. Each Party shall determine Net Sales, Licensing Income, Cost of Sales, Eligible Medical Affairs Costs,
Commercialization Costs, and Other Operating Expenses using its standard accounting procedures, consistently applied and consistent with U.S. GAAP principles, to the maximum extent practicable as if the applicable DT
<FONT STYLE="white-space:nowrap">Co-Co</FONT> Product were a solely-owned product of such Party (provided that the application of such procedures results, on balance, in outcomes that are fair and equitable to both Parties taking into consideration
the interests of both Parties as reflected in this Agreement). The Parties recognize that such procedures may change from time to time and that any such changes may affect the calculation of Net Sales, Licensing Income, Cost of Sales, Eligible
Medical Affairs Costs, Commercialization Costs, or Other Operating Expenses. Where the change is or would be material to the other Party, the Party proposing to make the change shall provide the other Party with an explanation of the proposed change
and an estimate of the effect of the change on the relevant cost or expense category. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.4 If necessary, a Party shall make the
appropriate adjustments to the financial information it supplies under this <B>Schedule J </B><FONT STYLE="white-space:nowrap">(Co-Co</FONT> Products Profit and Loss Share) to conform with the format of reporting results of operation required for
the P&amp;L. The Parties understand that all Net Sales of each DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product shall be booked in accordance with the Selling Party&#146;s U.S. GAAP principles and otherwise in accordance with
Section&nbsp;1.121 (Net Sales). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. <B>Frequency of Reporting</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to prepare the consolidated P&amp;L, each Party shall submit to the other Party a financial statement of such Party&#146;s Commercialization and
Medical Affairs activities, Net Sales, Licensing Income, Cost of Sales, Eligible Medical Affairs Costs, Commercialization Costs, and Other Operating Expenses in the format of the P&amp;L within [***] after the end of [***]. Each such individual
P&amp;L shall specify in reasonable detail all categories of actual costs related to Eligible Medical Affairs Costs, Commercialization Costs and Other Operating Expenses, and, upon a Party&#146;s request the other Party shall promptly provide any
invoices or other supporting documentation for any External Costs or with respect to which documentation is otherwise reasonably requested. Within [***] after the last day of each Calendar Quarter, Moderna shall prepare a reconciliation report and
send it to Metagenomi. Within [***] after the end of each Calendar Quarter, the Parties shall agree on a consolidated P&amp;L for the applicable Calendar Quarter and for such Calendar Quarter, a consolidated reporting of the Operating Profits or
Losses, the calculation of the Operating Profits or Losses, and the applicable sharing and determination of the corresponding cash settlement in an agreed format (such report, the &#147;<B>Consolidated Report</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Within [***] after the end of each Calendar Quarter, whichever Party is owed a payment shall prepare an invoice for such payment and deliver such invoice to
the other Party. The paying Party shall pay such invoice within [***] after receipt of the invoice. For clarity, the first P&amp;L prepared with respect to each DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product shall be prepared for the first
Calendar Quarter in which either Party incurs Eligible Medical Affairs Costs, Commercialization Costs, or Other Operating </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Schedule J-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Expenses (regardless of whether such Eligible Medical Affairs Costs, Commercialization Costs, or Other Operating Expenses are incurred before or after Regulatory Approval for any DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Product). In addition to the above, within [***] after the last day of the [***] of every Calendar Quarter, each Party shall submit to the other Party a report, with respect to each DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Product, setting forth the P&amp;L representing for each DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product (if any) the actual Net Sales, Cost of Sales, Licensing Income, Eligible Medical Affairs Costs,
Commercialization Costs, and Other Operating Expenses recognized by such Party in such just-completed two month period as well as an estimate of expected Net Sales, Cost of Sales, Licensing Income, Eligible Medical Affairs Costs, Commercialization
Costs, and Other Operating Expenses to be recognized in the third month of the current Calendar Quarter for each such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product (if any). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. <B>Financial Records</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each Party shall keep all
financial records and reports required by this <B>Schedule J <FONT STYLE="white-space:nowrap">(Co-Co</FONT> Products Profit and Loss Share) </B>in accordance with the U.S. GAAP principles to the extent applicable hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. <B>Operating Profits or Loss Sharing</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.1 The Parties agree to share the Operating Profits or Losses with respect to Commercialization activities, Medical Affairs activities, and
the activities related to Other Operating Expenses for each DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product (whether such Commercialization activities, Medical Affairs activities, and the activities related to Other Operating Expenses were
conducted before or after Regulatory Approval for each DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product) as set forth in Section&nbsp;7.4 <FONT STYLE="white-space:nowrap">(Co-Co</FONT> Products Profit and Loss Share) of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.2 Each Party is entitled to [***] of the Operating Profits or Losses for a given Calendar Quarter. If, taking into account the Net Sales,
Cost of Sales, Licensing Income received, and Eligible Medical Affairs Costs, Commercialization Costs, and Other Operating Expenses incurred by the Parties as outlined in the P&amp;L for such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product,
in each case, in such Calendar Quarter, an amount is due from one Party to the other to effect the Profit and Loss Share, then at the time the applicable Consolidated Report is delivered to Moderna, Metagenomi shall make a payment to Moderna for an
amount such that Metagenomi shall be bearing [***] of the Operating Profits or Losses for the applicable Calendar Quarter. Metagenomi shall make payment in full to Moderna [***] after the date of an invoice therefor from Moderna. Likewise, if with
respect to such Calendar Quarter, a balancing payment is due from Moderna to Metagenomi to effect the Profit and Loss Share, then, [***] after the applicable Consolidated Report is delivered to Metagenomi, Moderna shall pay Metagenomi an amount such
that Metagenomi shall receive [***] of the Operating Profits or Losses for the applicable Calendar Quarter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.3 Disputes </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event any invoiced payment that is not otherwise subject to a good faith dispute is made after the date specified in Paragraph 4.2 of this <B>Schedule
J <FONT STYLE="white-space:nowrap">(Co-Co</FONT> Products Profit and Loss Share)</B>, the paying Party shall pay the additional amounts or the receiving Party shall reimburse such excess payments, as applicable, with interest from the date
originally due as provided in Section&nbsp;7.15 (Default Interest) of this Agreement, and the remaining, disputed portion of any such payment shall be paid within [***] after the date on which the JSC, using good faith efforts, resolves the dispute,
or as escalated in accordance with Section&nbsp;2.10 (Decisions) with respect to the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Schedule J-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. <B>Start of Operations and Effective Accounting Date Termination</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.1 The Profit and Loss Share shall commence on the Effective Date. For clarity, Cost of Sales, Eligible Medical Affairs Costs,
Commercialization Costs, and Other Operating Expenses incurred prior to Regulatory Approval of each DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product are chargeable to the applicable Profit and Loss Share in accordance with U.S. GAAP
principles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.2 The Profit and Loss Share shall continue until this Agreement is terminated or expires. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6. <B>Audits</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The record keeping and audit provisions set
forth in Section&nbsp;7.6 (Accounting; Audit) of this Agreement shall apply with respect to all amounts payable by either Party to the other Party under the Profit and Loss Share, including with respect to the calculation of Eligible Medical Affairs
Costs, Commercialization Costs, Other Operating Expenses, Licensing Income, Cost of Sales and Net Sales with respect to the performance of Commercialization activities, Medical Affairs activities and the activities under Other Operating Expenses for
each DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product in the Territory. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Schedule J-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule K </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Existing Patents </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Schedule K-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule L </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RT Technology Research Plan </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Schedule L-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule M </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Partnership Tax Matters </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.1. <B>Constructive Partnership, Tax Treatment</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.1.1. Metagenomi and Moderna (the &#147;<B>Partners</B>,&#148; and each a &#147;<B>Partner</B>&#148;) acknowledge that the rights and
obligations imposed on each of them pursuant to this Agreement that relate to the allocation of Profits and Loss Share pursuant to Article 7 (Fees, Royalties, &amp; Payments), any other sharing of profits and losses from the Commercialization of the
Products within the Field in the Territory, and the collaborative relationship formed between them in connection therewith, in each case solely in connection with the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program, gives rise to a
partnership for U.S. federal (and, to the extent applicable, state and local) income tax purposes (the &#147;<B>Partnership</B>&#148;), which will commence upon DC Nomination in such DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program (the
&#147;<B>Partnership Commencement Date</B>&#148;). The activities of the Partners on or after the Partnership Commencement Date with respect to the Commercialization of the Product within the Field in the Territory and the rights related thereto in
the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program (the &#147;<B>Shared Rights</B>&#148;) shall be deemed to be conducted in and held by the Partnership. The Partnership shall not, and shall not be deemed to, have any interest or rights
relating to Product outside the Field or outside the Territory (with respect to the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program) or otherwise under this Agreement other than with respect to the Shared Rights. The Partnership, and the
rights and obligations set forth in this Schedule M, shall remain in existence for so long as this Agreement remains in full force and effect (provided this Agreement has not been terminated in its entirety, in accordance with Article 12 of this
Agreement or otherwise) or until the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program is terminated pursuant to Section&nbsp;1.8 of this Schedule M, if such termination occurs prior to the termination of the Agreement in its entirety. Prior
to the commencement of the Partnership, the Parties may mutually and in good faith determine that it is desirable to affect the arrangement between Metagenomi and Moderna with respect to the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program
as two or more Partnerships for U.S. federal income tax purposes, rather than as a single Partnership, each between Metagenomi or a Metagenomi Affiliate, as one partner, and Moderna or a Moderna Affiliate, as the second partner; provided, however,
that, unless otherwise mutually agreed to by Metagenomi and Moderna, an Affiliate that is a foreign person for U.S. federal income tax purposes may only be a partner in any Partnership if the use of such foreign Affiliate shall not adversely impact
the second partner. Metagenomi and Moderna shall cooperate in a reasonably prompt manner in order to effect any amendments to this Schedule M or this Agreement required or advisable as a result of the preceding sentence. The Parties further
acknowledge that the arrangement described in this Agreement (including this Schedule M) shall be treated by the Parties as a partnership solely for U.S. federal and applicable state and local income tax purposes and is not intended to constitute a
partnership for any <FONT STYLE="white-space:nowrap">non-tax,</FONT> <FONT STYLE="white-space:nowrap">non-U.S.,</FONT> or any other purpose. The Partners agree not to take any tax position, whether in a tax return or otherwise, that is inconsistent
with this Schedule M, other than pursuant to Section&nbsp;1.7 of this Schedule M. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.1.2. For U.S. federal income and other applicable tax
purposes, on the Partnership Commencement Date Metagenomi shall be treated as contributing to the Partnership its undivided interest in the Metagenomi Licensed DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Technology and its portion of the
Commercialization rights with respect to the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Product in the Territory (with respect to the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program) under this Agreement, and Moderna shall be treated
as contributing to the Partnership its undivided interest in the Moderna Licensed DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Technology and its portion of the Commercialization rights with respect to the DT
<FONT STYLE="white-space:nowrap">Co-Co</FONT> Product in the Territory (with respect to the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program) under this Agreement, each as a Capital Contribution in exchange for an interest in the
Partnership. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Schedule M-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.2. <B>Definitions</B>. Capitalized terms used, but not defined, herein will have the
meanings ascribed to them in this Agreement. For purposes of this Schedule M: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) &#147;<B>Book</B>&#148; means the method of accounting
prescribed for compliance with the capital account maintenance rules set forth in <FONT STYLE="white-space:nowrap">Section&nbsp;1.704-1(b)(2)(iv)</FONT> of the Treasury Regulations, as distinguished from any accounting method which the Partnership
may adopt for other purposes such as financial reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) &#147;<B>Capital Account</B>&#148; has the meaning set forth in
Section&nbsp;1.3.1 of this Schedule M. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) &#147;<B>Capital Contribution</B>&#148; means, for each Partner, such Partner&#146;s cash or
property contributed (or deemed contributed) to the Partnership. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) &#147;<B>Code</B>&#148; means the U.S. Internal Revenue Code of
1986, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) &#147;<B>Fiscal Year</B>&#148; means the calendar year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) &#147;<B>Gross Asset Value</B>&#148; means, with respect to any asset of the Partnership, the asset&#146;s adjusted basis for U.S. federal
income tax purposes, adjusted to reflect any adjustments required or permitted by Sections <FONT STYLE="white-space:nowrap">1.704-1(b)(2)(iv)(d)</FONT> through (g), (m) and (s)&nbsp;of the Treasury Regulations, as determined by the Partnership
Representative and mutually agreed upon by the Partners; provided that, in the case of any asset contributed to the Partnership, the initial Gross Asset Value of such property shall be equal to the fair market value of such asset as of the date of
contribution, as determined by the Partnership Representative and mutually agreed upon by the Partners. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) &#147;<B>Net Income</B>&#148;
and &#147;<B>Net Losses</B>&#148; mean the Book income, gain, loss, deductions and credits of the Partnership in the aggregate or separately stated, as appropriate, as of the close of each Taxable Year on the Partnership&#146;s tax return filed for
U.S. federal income tax purposes (or as of any other applicable time of the relevant Taxable Year). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) &#147;<B>Partnership
Representative</B>&#148; has the meaning set forth in Section&nbsp;1.6.1 of this Schedule M. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) &#147;<B>Profit Share</B>&#148; has the
meaning set forth in Section&nbsp;1.4.1 of this Schedule&nbsp;M. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) &#147;<B>Shared Rights</B>&#148; has the meaning set forth in
Section&nbsp;1.1.1 of this Schedule&nbsp;M. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) &#147;<B>Taxable Year</B>&#148; means the Partnership&#146;s Fiscal Year, or such other
year as may be required by Section&nbsp;706 of the Code. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Schedule M-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) &#147;<B>Treasury Regulations</B>&#148; means regulations (whether in final, proposed or
temporary form) promulgated by the U.S. Department of the Treasury under the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.3. <B>Capital Accounts; Formation of the
Partnership</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.3.1. The Partnership shall maintain a separate capital account for each Partner according to the rules set forth in <FONT
STYLE="white-space:nowrap">Section&nbsp;1.704-1(b)(2)(iv)</FONT> of the Treasury Regulations (a &#147;<B>Capital Account</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.3.2. Each Partner&#146;s Capital Account: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) shall be increased by (A)&nbsp;the Capital Contributions by such Partner to the Partnership after the Partnership
Commencement Date, as determined by the Partnership Representative and mutually agreed upon by the Partners (net of liabilities secured by the contributed property that the Partnership is considered to assume or take subject to under
Section&nbsp;752 of the Code), and (B)&nbsp;such Partner&#146;s distributive share of Net Income and other items of income and gain allocated to such Partner after the Partnership Commencement Date; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) shall be decreased by (A)&nbsp;the amount of money distributed (or deemed distributed) to such Partner by the Partnership
after the Partnership Commencement Date, (B)&nbsp;the fair market value of property (as determined by the Partnership Representative and mutually agreed upon by the Partners) distributed (or deemed distributed) to such Partner by the Partnership
(net of liabilities secured by the distributed property that the Partner is considered to assume or take subject to under Section&nbsp;752 of the Code) after the Partnership Commencement Date and (C)&nbsp;such Partner&#146;s distributive share of
Net Losses and other items of loss and deduction allocated to such Partner after the Partnership Commencement Date; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) other adjustments shall be made to the Capital Accounts of the Partners to accord with the regulations promulgated under
Section&nbsp;704(b) of the Code as determined by the Partnership Representative and mutually agreed upon by the Partners. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.3.3. As of
the Partnership Commencement Date, the initial Capital Account of each Partner shall be equal to the Capital Contribution of each such Partner pursuant to Section&nbsp;1.1.2 of this Schedule M. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.4. <B>Distributions</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.4.1. <B><FONT STYLE="white-space:nowrap">Non-Liquidating</FONT> Distributions</B>. In the event that assets of the Partnership are deemed to
be distributed other than in liquidation of the Partnership, such assets shall be deemed to be distributed in accordance with the payments comprising the share of Operating Profit or Losses between Metagenomi and Moderna under Section&nbsp;7.4 <FONT
STYLE="white-space:nowrap">(Co-Co</FONT> Products Profit and Loss Share) of this Agreement (the &#147;<B>Profit Share</B>&#148;), unless otherwise determined by the Partnership Representative and mutually agreed upon by the Partners. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Schedule M-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.4.2. <B>Liquidating Distribution</B>. In the event that the Partnership is terminated
pursuant to Section&nbsp;1.8 of this Schedule M, then the assets of the Partnership shall be distributed (or deemed to be distributed) in liquidation of the Partnership in accordance with the Profit Share, and the requirements under Section&nbsp;5.6
of this Agreement shall be deemed to occur after such distribution and in exchange for payments required pursuant to Section&nbsp;7.11 of this Agreement, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.4.3. <B>Withholding for Taxes</B>. Subject to the provisions of Section&nbsp;7.16.3 of this Agreement, any Partner is authorized to withhold
from payments made to the other Partner that are treated as distributions described in Section&nbsp;1.4.1 or Section&nbsp;1.4.2 of this Schedule M to the Partners, and with respect to allocations pursuant to Section&nbsp;1.5 of this Schedule M to
the Partners, and to pay over to any federal, state or local government, any such taxes as are required to be deducted or withheld under any provision of Applicable Law. Any amounts so withheld shall be treated as distributed pursuant to
Section&nbsp;1.4.1 or Section&nbsp;1.4.2 of this Schedule M, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.5. <B>Allocations, Section</B><B></B><B>&nbsp;704(c)</B>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.5.1. Except as required by Section&nbsp;1.5.2 or Section&nbsp;1.5.3 of this Schedule M, the Net Income or Net Loss for any Taxable Year
shall be allocated to the Partners in such a manner so that the Capital Account of each Partner equals (as of the end of such allocation period and to the fullest extent possible) the amount that would be distributed to such Partner if all
properties of the Partnership, including cash, were sold for cash equal to their respective Gross Asset Values, all liabilities allocable to such properties were then due and were satisfied according to their terms, all minimum gain chargebacks
required by this Agreement and the Treasury Regulations were made, all obligations of Partners to contribute additional capital to the Partnership were satisfied and all remaining proceeds from such sale were distributed pursuant to the order and
priority of Section&nbsp;1.4.2 of this Schedule&nbsp;M. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.5.2. <B>Special Allocations</B>. Notwithstanding Section&nbsp;1.5.1 of this
Schedule M, the Partnership Representative may, if mutually agreed upon by the Partners, specially allocate any costs or expenses that are disproportionately borne by one Partner to such Partner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.5.3. <B>Regulatory Allocations</B>. In the event any Partner unexpectedly receives any adjustments, allocations or distributions described
in Sections <FONT STYLE="white-space:nowrap">1.704-1(b)(2)(ii)(d)(4),</FONT> <FONT STYLE="white-space:nowrap">1.704-1(b)(2)(ii)(d)(5)</FONT> or <FONT STYLE="white-space:nowrap">1.704-1(b)(2)(ii)(d)(6)</FONT> of the Treasury Regulations, items of
income (including gross income) and gain shall be specially allocated to such Partner in an amount and manner sufficient to eliminate the deficit balance in such Partner&#146;s Capital Account (in excess of (i)&nbsp;the amount such Partner is
obligated to restore upon liquidation of the Partnership or upon liquidation of such Partner&#146;s interest in the Partnership and (ii)&nbsp;such Partner&#146;s share of the Minimum Gain (as defined in
<FONT STYLE="white-space:nowrap">Section&nbsp;1.704-2</FONT> of the Treasury Regulations)) created by such adjustments, allocations or distributions as quickly as possible. Additionally, there are hereby incorporated herein such special allocation
provisions governing the allocation of income, deduction, gain, and loss for U.S. federal income tax purposes as may be necessary under, and in the manner required by, the Treasury Regulations to ensure that this Schedule M complies with all
requirements of <FONT STYLE="white-space:nowrap">Section&nbsp;1.704-2</FONT> of the Treasury Regulations relating to &#147;minimum gain&#148; and &#147;partner nonrecourse debt minimum gain&#148; and the allocation and chargeback of <FONT
STYLE="white-space:nowrap">so-called</FONT> &#147;nonrecourse deductions&#148; and &#147;partner nonrecourse deductions&#148;, including a &#147;qualified income offset&#148;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Schedule M-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.5.4. Except as otherwise provided in this Section&nbsp;1.5.4 and in Section&nbsp;1.5.5 of
this Schedule M, for U.S. federal income tax purposes, all items of income gain, loss, deduction and credit shall be allocated among the Partners in the same manner the corresponding Book item was allocated pursuant to Section&nbsp;1.5.1 or
Section&nbsp;1.5.2 of this Schedule M. In the case of contributed property, items of income, gain, loss, deduction and credit, as determined for U.S. federal income tax purposes, shall be allocated first in a manner consistent with the requirements
of Section&nbsp;704(c) of the Code to take into account the difference between the Gross Asset Value of such property and its adjusted tax basis at the time of contribution. If the Gross Asset Value of any asset of the Partnership is adjusted
pursuant to the terms of this Schedule M, then subsequent allocations of income, gain, loss, deduction and credit, as determined for U.S. federal income tax purposes, shall be allocated with respect to such assets so as to take into account such
adjustment in the same manner as under Section&nbsp;704(c) of the Code and the Treasury Regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.5.5.
Metagenomi and Moderna shall mutually and in good faith agree on the method under Section&nbsp;704(c) of the Code and the Treasury Regulations to be utilized by the Partnership prior to the Partnership Commencement Date. For the sake of clarity, the
allocations required by Section&nbsp;1.5.4 and this Section&nbsp;1.5.5 of this Schedule M are solely for purposes of U.S. federal and applicable state and local income taxes and will not affect the allocation of Net Income or Net Losses as between
the Partners or any Partner&#146;s Capital Account. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.6. <B>Tax Reports, Tax Elections and Partnership Representative</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.6.1. To the extent permitted under Applicable Law, the Partnership intends to elect out of the application of Subchapter C of Chapter 63 of
the Code (i.e., the partnership audit rules) and any applicable state or local equivalent. For any applicable Taxable Year (or portion thereof) where the Partnership is able to so elect, the Partners agree to cooperate to share information relevant
to the matters addressed by this Schedule M and agree not to take any position on any tax return applicable to the matters addressed by this Schedule M that may be materially adverse to the other Partner without the consent of the other Partner, not
to be unreasonably withheld, delayed or conditioned. To the extent required after giving effect to the first sentence of Section&nbsp;1.6 of this Schedule M, the Partnership hereby designates Moderna to act as the &#147;partnership
representative&#148; of the Partnership within the meaning of Section&nbsp;6223 of the Code (along with any state or local equivalent, the &#147;<B>Partnership Representative</B>&#148;), and the Partnership Representative shall have the authority to
appoint the &#147;designated individual&#148; within the meaning of Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;301.6223-1(b)(3).</FONT> If the Partnership is unable to elect out of the partnership audit rules, the Partnership
Representative is authorized and required to represent the Partnership in connection with all examinations of the Partnership&#146;s affairs by U.S. federal (and any applicable state) income tax authorities, including resulting administrative and
judicial proceedings, to make any elections in connection therewith that are mutually agreed upon by the Partners, and to incur expenses for professional services and costs associated therewith, which shall be equally borne by each of Metagenomi and
Moderna; provided, that the Partnership Representative shall notify Metagenomi of any such administrative and judicial proceedings involving the Partnership and shall provide Metagenomi the opportunity to jointly participate in any such matters.
Metagenomi agrees to cooperate with the Partnership Representative as reasonably requested by the Partnership Representative with respect to the conduct of such proceedings. The Partnership Representative will, with mutual agreement by the Partners,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Schedule M-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
determine whether the Partnership (either on its own behalf or on behalf of the Partners) will contest or continue to contest any tax deficiencies assessed or proposed to be assessed by any
taxing authority provided, however, that the Partnership Representative shall not (i)&nbsp;agree or consent to compromise or settle such matters or (ii)&nbsp;take any action that disproportionately adversely affects Metagenomi, without the mutual
agreement of the Partners. Any deficiency for taxes imposed on any Partner (including penalties, additions to tax or interest imposed with respect to such taxes) will be paid by such Partner, and if paid by another Partner, will be recoverable from
the Partner on which such deficiency was imposed (including by offset against distributions otherwise payable to such Partner). The Partners agree to cooperate in good faith to notify each other regarding any tax notices or audits relating to the
Partnership and to provide any information or documentation reasonably requested by the Partnership Representative in connection with its duties under this Section&nbsp;1.6.1 of this Schedule M. In no event shall the Partnership Representative
require the Partners to file an amended tax return. A Partner&#146;s obligation to cooperate with the Partnership Representative and to indemnify and make payments to another Partner under this Section&nbsp;1.6.1 of this Schedule M will survive the
termination, dissolution, liquidation and winding up of the Partnership and the transfer, assignment or liquidation of a Partner&#146;s interest in the Partnership. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.6.2. The Partnership Representative shall prepare and file, or cause to be prepared and filed, all necessary U.S. federal, state or local
income tax returns for the Partnership. The Partnership Representative shall have such tax returns prepared by a &#147;big four&#148; accounting firm, which initially shall be Ernst&nbsp;&amp; Young, such accounting firm to be chosen with
Metagenomi&#146;s consent, and the cost of the preparation of such tax returns shall be equally borne by each of Metagenomi and Moderna. At least 60 days before the due date (including extensions) of any such tax return, the Partnership
Representative shall submit a copy of such tax return to Metagenomi for its review and comment. The Partners shall mutually agree on the preparation of such tax returns, making any required changes no fewer than 10 days prior to the due date of such
tax return. Within 180 days after the end of each Taxable Year, the Partnership Representative shall cause the Partnership to furnish Metagenomi with an IRS Form <FONT STYLE="white-space:nowrap">K-1</FONT> for such Taxable Year. In addition, the
Partnership shall deliver or cause to be delivered not later than the 15th day after the end of each Taxable Year to a requesting Partner all information necessary for the preparation of such Partner&#146;s U.S. federal income tax returns and any
state, local and other income tax returns that such Partner is required to file. Furthermore, the Partnership Representative shall jointly determine with Metagenomi regarding any matter for which the Partnership Representative is responsible or over
which the Partnership Representative has discretion under this Schedule M, including without limitation the preparation of any tax return or the making of any election hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.6.3. The Partners shall jointly determine whether to make or revoke any available election pursuant to the Code. Each Partner will, upon
request, use reasonable efforts to supply the information necessary to give proper effect to any such election. The Partners hereby agree to cooperate in good faith regarding any matters related to any tax elections or tax reporting positions of the
Partnership. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Schedule M-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.7. <B>Tax Position</B>. Unless otherwise required by Applicable Law, no Partner will take
a position on such Partner&#146;s U.S. federal or other applicable income tax returns, in any claim for refund or in any administrative or legal proceedings that is inconsistent with this Agreement (including this Schedule M) or with any information
return filed by the Partnership. If any Partner believes that such a position is required by Applicable Law, such Partner must immediately notify the other Partner in writing, citing such Applicable Law or any interpretation thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.8. <B>Termination of Partnership</B>. With respect to the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program, the Partnership shall
terminate upon the earlier of (i)&nbsp;the expiration or termination of the DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Program, or (ii)&nbsp;an <FONT STYLE="white-space:nowrap">Opt-Out</FONT> by either Party from the DT <FONT
STYLE="white-space:nowrap">Co-Co</FONT> Program. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Schedule M-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule N </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Joint Press Release </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Metagenomi and Moderna Establish Collaboration to Develop Next-Generation </B><B><I>In Vivo</I></B><B> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Gene Editing Therapeutics </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>The collaboration will combine Metagenomi&#146;s next-generation CRISPR-based and other novel gene editing
systems with Moderna&#146;s mRNA and LNP technologies to accelerate the development of in vivo gene editing therapeutics</I> </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Multi-year research collaboration funded by Moderna covering a series of undisclosed disease targets</I>
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Metagenomi to receive <FONT STYLE="white-space:nowrap">up-front</FONT> cash payment, equity investment, and
research funding, with potential for additional research, milestone and royalty payments</I> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EMERYVILLE, CA and CAMBRIDGE, MA. --
Metagenomi, Inc., a genetic medicines company with a versatile portfolio of next-generation gene editing tools, and Moderna Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that
the two companies have entered into a strategic research and development collaboration focused on advancing new gene editing systems for <I>in vivo</I> human therapeutic applications. The collaboration will utilize Metagenomi&#146;s novel gene
editing tools and leverage Moderna&#146;s mRNA platform, as well as lipid nanoparticle (LNP) delivery technologies, with the goal of developing curative therapies for patients with serious genetic diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Metagenomi has demonstrated the power of its proprietary metagenomics approach that mines the Earth&#146;s natural environment to discover
next-generation gene editing tools and has developed discovery capabilities with the potential to address multiple diseases,&#148; said Eric Huang, PhD, General Manager&nbsp;&amp; Chief Scientific Officer, Moderna Genomics (mGx). &#147;Their
discovery platform and expertise will expand Moderna Genomics&#146; ongoing efforts to develop innovative <I>in vivo</I> gene editing therapies to address a significant unmet medical need. This collaboration represents another milestone on our
journey to create transformational genome-engineering based medicines.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Gene editing has the potential to provide a cure for millions of
patients living with genetic disease. Our partnership with Moderna is designed to accelerate the creation of genetic medicines using Metagenomi&#146;s naturally derived, compact, modular and precise gene editing systems,&#148; said Brian C. Thomas,
PhD, CEO and <FONT STYLE="white-space:nowrap">Co-Founder</FONT> of Metagenomi. &#147;This partnership will enhance our shared vision to forge transformative therapeutics for patients.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Unlocking the therapeutic potential of gene editing requires a long-term commitment to develop the best technologies for both <I>in vivo</I> delivery
and gene repair,&#148; said Jak Knowles, MD, CBO at Metagenomi. &#147;We share Moderna&#146;s goal to develop mRNA-based medicines, and we are thrilled to partner with them.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Schedule N-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About the Collaboration </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the collaboration, Metagenomi and Moderna will advance a series of <I>in vivo </I>gene editing therapeutics against undisclosed targets.
Metagenomi will utilize its vast toolbox of gene editing systems in combination with Moderna&#146;s mRNA and LNP technologies, to deliver next-generation therapies for genetic diseases. Metagenomi will receive an upfront cash payment and is eligible
to receive certain target option exercise fees as well as development, regulatory and commercial milestone payments, plus tiered royalties on net sales of any products that are commercialized by Moderna. Moderna has also agreed to make an equity
investment in Metagenomi in the form of a convertible note. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Metagenomi </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Metagenomi is a gene editing company committed to developing potentially curative therapeutics by leveraging a proprietary toolbox of next-generation gene
editing systems to accurately edit DNA where current technologies cannot. Our metagenomics-powered discovery platform and analytical expertise reveal novel cellular machinery sourced from otherwise unknown organisms. We adapt and forge these
naturally evolved systems into powerful gene editing systems that are ultra-small, extremely efficient, highly specific and have a decreased risk of immune response. These systems fuel our pipeline of novel medicines and can be leveraged by
partners. Our goal is to revolutionize gene editing for the benefit of patients around the world. For more information, please visit https://metagenomi.co/. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Moderna </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 10 years since its inception, Moderna
has transformed from a science research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property
portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed. Moderna maintains alliances with a broad range
of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna&#146;s capabilities have come together to allow the
authorized use of one of the earliest and most- effective vaccines against the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moderna&#146;s
mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases,
cardiovascular diseases and autoimmune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past six years. To learn more, visit www.modernatx.com. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Schedule N-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Moderna Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including
regarding: the collaboration between Moderna and Metagenomi to accelerate the development of gene editing technologies; the financial structure for that collaboration and potential for payments; and the potential development of genetic medicines
using gene editing systems. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks,
uncertainties, and other factors, many of which are beyond Moderna&#146;s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other
factors include those other risks and uncertainties described under the heading &#147;Risk Factors&#148; in Moderna&#146;s most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed with the U.S. Securities and Exchange
Commission (SEC) and in subsequent filings made by Moderna with the SEC, which are available on the SEC&#146;s website at <U>www.sec.gov</U>. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any
forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna&#146;s current expectations and speak only as of the date hereof.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Metagenomi Contacts </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investor: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Simon Harnest </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CIO, SVP Strategy </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">simon@metagenomi.co </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(917)
<FONT STYLE="white-space:nowrap">403-1051</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Media: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ashlye Hodge </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sr. Marketing and Communications Specialist </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ashlye@metagenomi.co </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(510)
<FONT STYLE="white-space:nowrap">734-4409</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Moderna Contacts </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investor: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lavina Talukdar </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Senior Vice President&nbsp;&amp; Head of Investor Relations </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lavina.Talukdar@modernatx.com </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(617) <FONT
STYLE="white-space:nowrap">209-5834</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Medias: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Colleen Hussey </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Director, Corporate Communications </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Colleen.Hussey@modernatx.com </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(617) <FONT
STYLE="white-space:nowrap">335-1374</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Schedule N-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule O </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DT <FONT STYLE="white-space:nowrap">Co-Co</FONT> Research Plan </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Schedule O-1 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>3
<FILENAME>filename3.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.7</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.7 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT
TREATS AS PRIVATE OR CONFIDENTIAL. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>C<SMALL>OLLABORATION</SMALL> <SMALL>AND</SMALL> L<SMALL>ICENSE</SMALL> A<SMALL>GREEMENT</SMALL>
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>B<SMALL>ETWEEN</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>M<SMALL>ETAGENOMI</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AND </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I<SMALL>ONIS</SMALL> P<SMALL>HARMACEUTICALS</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>D<SMALL>ATED</SMALL> N<SMALL>OVEMBER</SMALL>&nbsp;10, 2022 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Article&nbsp;1 Overview</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.1.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Drug Discovery Program</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.2.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Development and Commercialization</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.3.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Co-Development and Co-Commercialization</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.4.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Exploratory Research</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.5.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Governance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.6.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Purpose</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Article&nbsp;2 Collaboration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.1.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Selection of Collaboration Targets</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.2.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Drug Discovery Program</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.3.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Exploratory Research Program</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.4.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Conduct of Collaboration Activities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.5.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Cost of Collaboration Activities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.6.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Collaboration Program Records and Reports</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.7.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Ionis Proprietary Toolbox of Chemical Modifications</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Article&nbsp;3 Licenses; Exclusivity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.1.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>License Grants to Ionis</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.2.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>License Grants to Metagenomi</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.3.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Subcontractors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.4.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Technology Transfer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.5.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Implied Licenses</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.6.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Exclusivity</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Article&nbsp;4 Governance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.1.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Joint Steering Committee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.2.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Subcommittees</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.3.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Joint Research Committee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.4.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Alliance Managers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.5.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Additional Participants</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.6.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Decision-Making</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Article&nbsp;5 Co-Development and Co-Commercialization Options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.1.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Co-Development and Co-Commercialization Options</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.2.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Development and Commercialization of the Co-Co Products; Opt-Down Right</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.3.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Escalation Procedure</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.4.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Metagenomi Opt-Out</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Article&nbsp;6 Development and Commercialization of the Ionis Products</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.1.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Development</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.2.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Commercialization</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Article&nbsp;7 Regulatory Affairs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.1.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Regulatory Responsibility</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.2.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Right of Reference</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.3.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Regulatory Support</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Article&nbsp;8 Manufacturing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.1.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Metagenomi Manufacturing Responsibilities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.2.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Development Supply Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.3.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Commercial Supply Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.4.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Ionis&#146; Assumption of Manufacturing Responsibilities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.5.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Manufacturing After the Metagenomi Supply Term</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Article&nbsp;9 Consideration; Financial Terms</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.1.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Upfront Payment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.2.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Wave 2 Target Selection Fee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.3.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Option Exercise Fee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.4.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Ionis Product Milestone Payments</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.5.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Ionis Products for [***] Target Populations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.6.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Ionis Product Royalty Payments</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.7.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Existing In-License Agreements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.8.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>New In-License Agreements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.9.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Payment Obligations Under Certain In-License Agreements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.10.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Metagenomi Product Economics</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.11.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Other Payments</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.12.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Right to Offset</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.13.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Records and Audits</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.14.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Currency of Payment; Non-Refundable Payments</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.15.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Late Fees</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.16.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Currency Restrictions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.17.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Withholding Taxes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Article&nbsp;10 Intellectual Property</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.1.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Ownership of Inventions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.2.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Patent Prosecution</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.3.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Patent Enforcement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.4.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Defense of Claims Brought by Third Parties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.5.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Patent Listing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.6.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Common Ownership Legislation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.7.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Patent Term Extension</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.8.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Recording</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.9.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Unitary Patent System</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.10.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Trademarks</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.11.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Common Interest</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Article&nbsp;11 Confidentiality</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.1.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Confidential Information</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.2.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Use of Name</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.3.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Residual Knowledge</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.4.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Public Announcements and Subsequent Disclosures</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.5.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Publications</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Article&nbsp;12 Representations, Warranties, and Covenants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.1.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Mutual Representations and Warranties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.2.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Additional Representations of Metagenomi</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.3.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Covenants of Metagenomi</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.4.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Additional Representations of Ionis</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.5.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Covenants of Ionis</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.6.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Warranty Disclaimer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Article&nbsp;13 Indemnification; Limitation of Liability; Insurance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.1.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Indemnification of Metagenomi by Ionis</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.2.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Indemnification of Ionis by Metagenomi</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.3.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Losses for the Co-Co Products</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.4.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Conditions to Indemnification</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.5.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Limited Liability</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.6.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Insurance Obligations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Article&nbsp;14 Term and Termination</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.1.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Term</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.2.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Termination</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.3.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Effects of Termination</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.4.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Confidential Information</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.5.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Surviving Provisions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Article&nbsp;15 Miscellaneous</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.1.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Dispute Resolution</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.2.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Designation of Affiliates</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.3.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Patent Disputes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.4.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Injunctive Relief</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.5.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Governing Law</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.6.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Cumulative Remedies</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.7.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Notices</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.8.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Amendment; Waiver</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.9.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Assignment and Successors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.10.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Rights in Bankruptcy</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.11.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Force Majeure</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.12.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Interpretation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.13.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Integration</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.14.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Severability</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.15.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Further Assurances</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.16.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Counterparts</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.17.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Relationship of the Parties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U>Schedules</U>:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Schedule<U> 1.114</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Schedule<U> 1.146</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Licensed Patent Rights</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Schedule<U>&nbsp;1.166</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Schedule<U> 1.175</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Metagenomi Platform Patent Rights</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Schedule<U>&nbsp;2.1.1(a)</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Schedule<U> 2.2</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***] Drug Discovery Plan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Schedule<U> 2.3.1</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Exploratory Research Plan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Schedule<U> 8.2</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Development Supply Agreement Key Terms</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Schedule<U> 11.4</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release(s)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Schedule<U> 12.2</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Metagenomi Disclosure Schedule</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Schedule<U> 12.4</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Ionis Disclosure Schedule</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COLLABORATION AND LICENSE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This <B>C<SMALL>OLLABORATION</SMALL> A<SMALL>ND</SMALL> L<SMALL>ICENSE</SMALL> A<SMALL>GREEMENT</SMALL></B><SMALL></SMALL> (this
&#147;<B>Agreement</B>&#148;) is entered into as of November&nbsp;10, 2022 (the &#147;<B>Effective Date</B>&#148;), by and between Ionis Pharmaceuticals, Inc., a Delaware corporation, having its principal place of business at 2855 Gazelle Court,
Carlsbad, CA 92010 <B>(</B>&#147;<B>Ionis</B>&#148;<B></B>), and Metagenomi, Inc., a Delaware corporation, having its principal place of business at 1545 Park Avenue, Emeryville, CA 94608 (<B></B>&#147;<B>Metagenomi</B>&#148;<B></B>). Metagenomi and
Ionis are sometimes referred to herein individually as a <B>&#147;Party&#148;</B> and collectively as the <B></B>&#147;<B></B><B>Parties.</B>&#148;<B></B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">WHEREAS, Metagenomi is a biopharmaceutical company that controls certain patent rights, know-how, technology, and expertise with respect to
gene editing; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">WHEREAS, Ionis is a biopharmaceutical company focused on developing and commercializing pharmaceutical and
biopharmaceutical products; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">WHEREAS, Metagenomi and Ionis desire to enter into a collaboration to utilize Metagenomi&#146;s and
Ionis&#146; expertise and each Party&#146;s platform to perform research services and other activities focused on the (a)&nbsp;discovery and development of therapeutics, and (b)&nbsp;advancing certain gene editing technologies to enable improved
performance, novel mechanisms, and novel delivery strategies; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">WHEREAS, Metagenomi desires to grant to Ionis, and Ionis desires to
receive from Metagenomi, an exclusive license under the Licensed Technology to Exploit Licensed Systems and Licensed Products under the terms and conditions set forth herein. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, the Parties agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Article&nbsp;1 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Overview
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Parties intend to undertake a strategic research collaboration under this Agreement, consisting of drug discovery and exploratory
research activities to advance new medicines using gene editing strategies, with the goal of discovering novel medicines for Ionis to Develop and Commercialize on its own or to co-Develop and co-Commercialize with Metagenomi. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Drug Discovery Program</B>. The Parties intend that, under this Agreement, the Parties will seek to
discover therapeutic products directed to specific genetic targets selected by Ionis under a Drug Discovery Program and pursuant to a Drug Discovery Plan for each specific genetic target, as permitted by this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Development and Commercialization</B>.<B></B> For each Drug Discovery Program, once the Parties
identify a candidate that is suitable for Development, as between the Parties, Ionis will be responsible for Development and Commercialization of products resulting from such Drug Discovery Program either on its own or, if Metagenomi exercises its
option, together with Metagenomi. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Co-Development and Co-Commercialization</B>. Metagenomi will have an exclusive option to co-Develop
and co-Commercialize products with Ionis under a limited number of Drug Discovery Programs. For any such option exercised by Metagenomi, the Parties will enter into a separate Co-Development and Co-Commercialization Agreement, as set forth herein.
Metagenomi will have a right to opt-out of such co-Development and co-Commercialization at specific times, as set forth herein. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Exploratory Research</B><B></B>. The Parties will also conduct an Exploratory Research Program under
this Agreement. The Parties intend that, under the Exploratory Research Program, the Parties will conduct collaborative research pursuant to an Exploratory Research Plan to jointly optimize Guide RNA and select delivery technologies and such other
activities as agreed upon by the Joint Research Committee in accordance with this Agreement. Any such improvements resulting from the Parties&#146; exploratory research under this Agreement will be incorporated into the Parties&#146; drug discovery
collaboration. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Governance</B><B></B>. The Parties have agreed to form (a)&nbsp;a Joint Steering Committee to
coordinate, oversee, and monitor the Parties&#146; activities under this Agreement; and (b)&nbsp;a Joint Research Committee reporting to the JSC to coordinate, oversee, and monitor the Parties&#146; research and drug discovery activities under this
Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Purpose</B>. The purpose of this<U> Article 1</U> (Overview) is to provide a high-level overview of the
roles, responsibilities, rights, and obligations of each Party under this Agreement, and therefore this<U> Article 1</U> (Overview) is qualified in its entirety by the more detailed provisions of this Agreement set forth below.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Article&nbsp;2 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Collaboration </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>2.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Selection of Collaboration Targets</B><B>. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>2.1.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Wave 1 Targets</B>.<B> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Initial Wave 1 Target</B>.<B></B> The first Collaboration Target will be [***], as set forth on <U>Schedule
2.1.1(a)</U> ([***]) (&#147;[***]&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Second Wave 1 Target</B>. Within [***] of the Effective Date, the Parties will mutually agree on the second
gene target as a Collaboration Target (the &#147;<B>Second Wave 1 Target</B>&#148;). The Second Wave 1 Target will be a target for which a Licensed Product would be delivered only to [***]. If the Parties do not agree on a Second Wave 1 Target
within such [***] period, then the Parties will mutually agree on an additional period to determine a second gene target to be the Second Wave 1 Target. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Additional Wave 1 Target Selection</B>. At any time during the period commencing on the Effective Date and
ending on the date that is [***] following the Effective Date (&#147;<B>Additional Wave 1 Target Selection Period</B>&#148;), Ionis may, in its sole discretion, but subject to <U>Section&nbsp;2.1.4</U> (Encumbrance Check), select up to two
additional gene targets as proposed Collaboration Targets by providing written notice to Metagenomi (each such notice, the &#147;<B>Additional Wave 1 Target Notice</B>&#148;), which notice will identify the proposed target (&#147;<B>Additional Wave
1 Target</B>&#148;). The Additional Wave 1 Targets will be targets for which a Licensed Product would be delivered only to [***] or only to [***]; <I>provided</I> that no more than one Additional Wave 1 Target will be a target for which a Licensed
Product would be delivered to [***]. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>2.1.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Wave 2 Target Options</B>. If, at any time during the Drug Discovery Term, (a)&nbsp;an IND for any Licensed
Product directed to a Wave 1 Target is filed with the applicable Regulatory Authority or (b)&nbsp;the Parties achieve [***] for a [***] under the Exploratory Research Activities (the &#147;<B>Wave 2 Target Selection Period</B>&#148;), then Ionis
may, in its sole discretion, but subject to <U>Section&nbsp;2.1.4</U> (Encumbrance Check), select up to four additional gene targets as proposed Collaboration Targets by providing written notice to Metagenomi (each such notice, a &#147;<B>Wave 2
Target Notice</B>&#148;), which notice will identify the proposed target (&#147;Wave 2 Target&#148;). Each Wave 2 Target will be a target for which a Licensed Product would be delivered only to [***] or only to [***], or any other [***] that has, at
the time of the Wave 2 Target Notice for such Wave 2 Target, achieved [***]. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>2.1.3</B>.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Target Substitutions</B>. On a Drug Discovery Program-by-Drug Discovery Program basis, Ionis will have the
right to substitute the Collaboration Target for a Drug Discovery Program in accordance with this <U>Section&nbsp;2.1.3</U> (Target Substitutions). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Discretionary Substitutions</B>. At any time before [***] (the &#147;<B>Target Substitution
Period</B>&#148;), Ionis may, in its sole discretion, but subject to <U>Section&nbsp;2.1.4</U> (Encumbrance Check), replace the Collaboration Target for such Drug Discovery Program by providing written notice to Metagenomi, which notice will
identify the proposed replacement gene target. Ionis may substitute (i)&nbsp;up to two Wave 1 Targets other than [***] and (ii)&nbsp;up to two Wave 2 Targets that become Collaboration Targets, in each case ((i) and (ii)), for any reason. Any
Collaboration Target that is substituted out pursuant to this <U>Section&nbsp;2.1.3(a)</U> (Discretionary Substitutions) will [***]. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Substitutions for Technological Infeasibility</B>. If the JSC determines that it is technologically
infeasible to Develop a Development Candidate for a Collaboration Target (&#147;<B>Technological Infeasibility</B>&#148;), then Ionis may, in its sole discretion, but subject to <U>Section&nbsp;2.1.4</U> (Encumbrance Check), substitute such
Collaboration Target by providing written notice to Metagenomi, which notice will identify the proposed replacement gene target. There is no limit on the number of replacements Ionis may make pursuant to this <U>Section&nbsp;2.1.3(b)</U>
(Substitutions for Technological Infeasibility) and any substitutions that are for Technological Infeasibility will not count towards the number of substitutions Ionis can make pursuant to <U>Section&nbsp;2.1.3(a)</U> (Discretionary Substitutions).
Any Collaboration Target that is substituted out pursuant to this <U>Section&nbsp;2.1.3(b)</U> (Substitutions for Technological Infeasibility) will not be eligible to be selected as a Proposed Replacement Target except as set forth in
<U>Section&nbsp;2.1.3(c)</U> (Substitutions After Resolution of Technological Infeasibility). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Substitution After Resolution of Technological Infeasibility</B>. If a Collaboration Target is substituted
out for Technological Infeasibility pursuant to <U>Section&nbsp;2.1.3(b)</U> (Substitutions for Technological Infeasibility) and, during the Drug Discovery Term and within [***] from when such substitution occurred, Metagenomi later reasonably
believes that it can resolve the issue that led to the Technological Infeasibility, then Metagenomi will notify Ionis, which notice will include a description of the approach Metagenomi intends to take to resolve the Technological Infeasibility.
Subject to clauses (i)&nbsp;and (ii)&nbsp;of <U>Section&nbsp;2.1.4(a)</U> (Encumbered Targets), Ionis will have the right to substitute a current Collaboration Target for such previous Collaboration Target by providing written notice to Metagenomi
within [***] of receipt of notice from Metagenomi that it believes it can solve the issue that led to the Technological Infeasibility. There is no limit on the number of replacements Ionis may make pursuant to this <U>Section&nbsp;2.1.3(c)</U>
(Substitutions After Resolution of Technological Infeasibility) and any substitutions that are as a result of resolution of a Technological Infeasibility will not count towards the number of substitutions Ionis can make pursuant to
<U>Section&nbsp;2.1.3(a)</U> (Discretionary Substitutions). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Substitution Procedure</B>. Any written notice provided by Ionis to Metagenomi pursuant to
<U>Section&nbsp;2.1.3(a)</U> (Discretionary Substitutions), <U>Section&nbsp;2.1.3(b)</U> (Substitutions for Technological Infeasibility), or <U>Section&nbsp;2.1.3(c)</U> (Substitutions After Resolution of Technological Infeasibility) will be a
&#147;<B>Replacement Target Notice</B>&#148; and the proposed replacement gene target identified in any Replacement Target Notice will be a &#147;<B>Proposed Replacement Target</B>&#148;. Each Replacement Target Notice will specify which current
Collaboration Target should be removed as a result of such replacement, and, unless otherwise agreed by the Parties, each Proposed Replacement Target will be a target for which a Licensed Product would be delivered to the same tissue as the
Collaboration Target subject to the substitution. Promptly after such Proposed Replacement Target becomes a Collaboration Target pursuant to <U>Section&nbsp;2.1.4(c)</U> (Effects if a Proposed Target is Available), Metagenomi will re-allocate the
resources dedicated to the Drug Discovery Program for the Collaboration Target that was removed as a result of the substitution to the Drug Discovery Program for the new Collaboration Target as soon as practicable, but in any event within [***]
after such Proposed Replacement Target becomes a Collaboration Target pursuant to <U>Section&nbsp;2.1.4(c)</U> (Effects if a Proposed Target is Available). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>2.1.4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Encumbrance Check</B>.<B> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Encumbered Targets</B>. Metagenomi will notify Ionis within [***] after Metagenomi&#146;s receipt of an
Additional Wave 1 Target Notice, a Wave 2 Target Notice, or a Replacement Target Notice if, at the time of receipt of such notice, (i)&nbsp;Metagenomi is then engaged in <I>bona fide</I> discussions with a Third Party for an agreement, [***],
pursuant to which Metagenomi would grant to such Third Party conflicting rights to Develop or Commercialize products directed to such Proposed Target such that Metagenomi could not grant Ionis the rights or licenses granted to Ionis hereunder with
respect to such Proposed Target, (ii)&nbsp;Metagenomi is contractually obligated to grant, or has granted, to a Third Party conflicting rights to Develop or Commercialize products directed to such Proposed Target such that Metagenomi could not grant
Ionis the rights or licenses granted to Ionis hereunder with respect to such Proposed Target, as evidenced by a binding written agreement, or (iii)&nbsp;the Proposed Target is the subject of an active <I>bona fide</I> then ongoing internal research
and development program at Metagenomi, as evidenced by [***] (each of (i)&nbsp;through (iii), a &#147;<B>Pre-Existing Restriction</B>&#148; and such Proposed Target, an &#147;<B>Encumbered Target</B>&#148;). Notwithstanding the foregoing, a
Collaboration Target that has been substituted out for Technological Infeasibility but for which Ionis later selects as a Proposed Replacement Target pursuant to <U>Section&nbsp;2.1.3(c)</U> (Substitutions After Resolution of Technological
Infeasibility) will only be an Encumbered Target if the foregoing clause (i)&nbsp;or clause (ii)&nbsp;applies with respect to such Proposed Replacement Target. If Metagenomi does not notify Ionis within such [***] period that the Proposed Target is
an Encumbered Target, then Ionis may provide a second notice to Metagenomi indicating that the Proposed Target will be deemed Available if Metagenomi does not respond to such second notice within [***]. If Metagenomi (x)&nbsp;notifies Ionis that a
Proposed Target is Available or (y)&nbsp;does not provide notice that a Proposed Target is an Encumbered Target </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="23%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
within the original [***] or within [***] after Ionis&#146; second notice, then, in either case ((x) or (y)), such Proposed Target will be deemed to be Available, at which point
<U>Section&nbsp;2.1.4(c)</U> (Effects if a Proposed Target is Available) will apply. If a Proposed Target is an Encumbered Target, then Ionis may select another Proposed Target (and another if such other Proposed Target is an Encumbered Target and
so on) until such time that Ionis selects a Proposed Target that is Available, at which point <U>Section&nbsp;2.1.4(c)</U> (Effects if a Proposed Target is Available) will apply. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Expiration of Pre-Existing Restrictions</B>. On [***], Ionis will use good faith efforts to [***], to
facilitate its activities pursuant to <U>Section&nbsp;4.1.5(b)</U> (Specific Responsibilities of the JSC), [***]. If at any time during the Additional Wave 1 Target Selection Period, the Wave 2 Target Selection Period, or the Target Substitution
Period, as applicable, any Pre-Existing Restriction that precluded Ionis from selecting a Proposed Target as a Collaboration Target later expires, terminates, or is otherwise modified such that such Proposed Target would no longer be an Encumbered
Target, and at such time (i)&nbsp;Ionis has not designated the maximum amount of Collaboration Targets as permitted under this Agreement, or (ii)&nbsp;Ionis has designated all Collaboration Targets as permitted under this Agreement, but Ionis has
not exhausted its right to substitute existing Collaboration Targets as permitted under <U>Section&nbsp;2.1.3(a)</U> (Discretionary Substitutions), <U>Section&nbsp;2.1.3(b)</U> (Substitutions for Technological Infeasibility), or
<U>Section&nbsp;2.1.3(c)</U> (Substitution After Resolution of Technological Infeasibility) (such time period prior to the occurrence of both (i)&nbsp;and (ii), the &#147;<B>Target Selection and Substitution Period</B>&#148;), then Metagenomi will
notify Ionis of such expiration, termination, or modification unless Ionis has notified the JSC that it is no longer interested in pursuing that Encumbered Target as a Collaboration Target. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Effects if a Proposed Target is Available</B>. If Ionis confirms in writing to Metagenomi that a Proposed
Target should be deemed to be a &#147;Collaboration Target&#148; under this Agreement within [***] of a Proposed Target being deemed Available pursuant to <U>Section&nbsp;2.1.4(a)</U> (Encumbered Targets), then (i)&nbsp;such Proposed Target will be
deemed a &#147;Collaboration Target&#148; as of the date of such notice, (ii)&nbsp;the Parties, through the JRC, will develop a Drug Discovery Plan for such Collaboration Target in accordance with <U>Section&nbsp;2.2.2</U> (Additional Drug Discovery
Plans), (iii)&nbsp;if the Proposed Target was a Wave 2 Target, then Ionis will pay any Wave 2 Target Selection Fee in accordance with <U>Section&nbsp;9.2</U> (Wave 2 Target Selection Fee) and, if applicable, the Drug Discovery Term will be extended
pursuant to <U>Section&nbsp;2.2.7</U> (Drug Discovery Term), and (iv)&nbsp;if the Proposed Target was a Proposed Replacement Target, then the Collaboration Target that was substituted out will no longer be a &#147;Collaboration Target&#148;. If
Ionis does not respond within [***] of a Proposed Target being deemed Available pursuant to <U>Section&nbsp;2.1.4(a)</U> (Encumbered Targets), then such Proposed Target will not be deemed a &#147;Collaboration Target&#148;. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>2.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Drug Discovery Program. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>2.2.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Initial Drug Discovery Plan</B>. The principal Development objectives for each Drug Discovery Program will
be set forth in a written plan that includes: (a)&nbsp;the specific activities to be performed by each Party through selection of a Development Candidate for such Drug Discovery Program, including the Gene Editing modality within the Field for such
Development Candidate, (b) the estimated timelines for the performance of such activities, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
and (c)&nbsp;the Development Candidate selection criteria (each such plan, as may be updated from time to time, a &#147;<B>Drug Discovery Plan</B>&#148; and the activities to be performed by the
Parties thereunder, the &#147;<B>Drug Discovery Activities</B>&#148;). In addition, each Drug Discovery Plan will include a written budget pursuant to which Metagenomi will perform the Drug Discovery Activities allocated to Metagenomi under such
Drug Discovery Plan, which budget will include (i)&nbsp;the number of FTEs to be dedicated by Metagenomi under such Drug Discovery Plan, and (ii)&nbsp;any Out-of-Pocket Costs expected to be incurred by Metagenomi in the performance of such Drug
Discovery Activities on a line-item basis (each such budget, a &#147;<B>Drug Discovery Budget</B>&#148;). The initial Drug Discovery Plan agreed to by the Parties for [***] is attached hereto as <U>Schedule 2.2</U> ([***] Drug Discovery Plan).
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>2.2.2</B>.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Additional Drug Discovery Plans</B>. No later than [***] after (a)&nbsp;the Parties agree on the Second Wave
1 Target pursuant to <U>Section&nbsp;2.1.1(b)</U> (Second Wave 1 Target) or (b)&nbsp;a Proposed Target is deemed a Collaboration Target under this Agreement pursuant to <U>Section&nbsp;2.1.4(c)</U> (Effects if a Proposed Target is Available), which
period shall be appropriately extended for the Parties to undertake the process described in <U>Section&nbsp;2.2.4</U> ([***] for Additional Drug Discovery Plans), if applicable, in each case, the Parties will develop, through the JRC, a Drug
Discovery Plan for such Collaboration Target (an &#147;<B>Additional Drug Discovery Plan</B>&#148;) in accordance with this <U>Section&nbsp;2.2.2</U> (Additional Drug Discovery Plans). The JRC will submit each proposed Additional Drug Discovery Plan
to the JSC for the JSC to review, discuss, and determine whether to approve. Unless otherwise agreed by the Parties, the content of each Additional Drug Discovery Plan will be consistent in scale and scope to that set forth in the Drug Discovery
Plan for [***] attached hereto as <U>Schedule 2.2</U> ([***] Drug Discovery Plan). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>2.2.3</B>.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Amendments to the Drug Discovery Plans</B>. At least [***] during the Drug Discovery Term, or upon either
Party&#146;s request, the JRC will develop and propose updates to each Drug Discovery Plan; <I>provided</I> that in no event will those updates include [***] the applicable Collaboration Target unless such [***] pursuant to <U>Section&nbsp;2.2.5</U>
(Development of [***] for a Drug Discovery Program). Any proposed updates to a Drug Discovery Plan will be submitted to the JSC for approval. The JSC will review, discuss, and determine whether to approve any such proposed update to a Drug Discovery
Plan. Each such update to a Drug Discovery Plan will become effective and will supersede the previous Drug Discovery Plan for the applicable Drug Discovery Program upon approval thereof by the JSC. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>2.2.4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>[***] for Additional Drug Discovery Plans</B>.<B> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>New</B> [***]. At each JSC meeting during the Target Selection and Substitution Period, Metagenomi will use
good faith efforts to notify Ionis if it reasonably believes that [***] (each such [***]). In addition, [***]. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Selection of </B>[***]<B></B>. The JSC will discuss and determine the [***] for the Second Wave 1 Target and
each Proposed Target that is deemed a Collaboration Target under this Agreement pursuant to <U>Section&nbsp;2.1.4(c)</U> (Effects if a Proposed Target is Available) from the [***], and, subject to <U>Section&nbsp;2.2.4(c)</U> (Incremental
Development Costs), such [***] will be set forth in the applicable Additional Drug Discovery Plan determined pursuant to <U>Section&nbsp;2.2.2</U> (Additional Drug Discovery Plans). For clarity, if the JSC selects for inclusion in an Additional Drug
Discovery Plan [***], then <U>Section&nbsp;2.2.4(c)</U> (Incremental Development Costs) is not applicable and [***] for the applicable Drug Discovery Program. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Incremental Development Costs</B>. If, in connection with the JRC&#146;s discussion and development of an
Additional Drug Discovery Plan, Ionis is considering, in good faith, selecting [***] for the applicable Drug Discovery Program and such [***], then Ionis will notify Metagenomi (an &#147;<B>Initial Interest Notice</B>&#148; and the [***] identified
in such notice, a &#147;[***]&#148;). If Metagenomi reasonably believes that the costs to progress a Drug Discovery Plan for the applicable Collaboration Target with the [***] are more than [***] of the costs to progress a Drug Discovery Plan for a
[***] (the difference between the costs to progress a Drug Discovery Plan for a [***] <I>versus</I> the costs to progress a Drug Discovery Plan for the [***], the &#147;<B>Incremental Development Costs</B>&#148;), then Metagenomi will notify Ionis
of such Incremental Development Costs (an &#147;<B>Increased Cost Notice</B>&#148;) within [***] of receipt of the Initial Interest Notice. For a period of [***] from Ionis&#146; receipt of the Increased Cost Notice, the Parties will use
Commercially Reasonable Efforts to negotiate, in good faith, economic terms that compensate Metagenomi for the Incremental Development Costs. If the Parties are unable to mutually agree on such financial compensation during such [***] period, then,
at Ionis&#146; election, (i)&nbsp;Ionis may select a different [***] and the process set forth in this <U>Section&nbsp;2.2.4(c)</U> (Incremental Development Costs) will continue to apply until (1)&nbsp;the Parties agree on financial terms to
compensate Metagenomi for the applicable Incremental Development Costs for [***], (2)&nbsp;Metagenomi does not provide an Increased Cost Notice for a [***], or (3)&nbsp;the [***], or (ii)&nbsp;Ionis may select a [***]. If the Parties mutually agree
on the economic terms [***] or if Metagenomi has not provided an Increased Cost Notice to Ionis for a [***] as set forth above, then, in either case, such [***] will be set forth in the applicable Drug Discovery Plan, [***], and such mutually agreed
economic terms will be set forth in a written agreement between the Parties. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>2.2.5</B>.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Development of </B>[***]<B> for a Drug Discovery Program</B>. If either Party wishes to Develop a Licensed
Product comprising a [***] that is not already set forth in the Drug Discovery Plan for such Drug Discovery Program, then such Party may propose such additional activities to the other Party and the Parties will discuss whether to amend such Drug
Discovery Plan or create a separate Drug Discovery Program for such [***]. If the Parties agree to include the additional [***] in the Drug Discovery Program, then the Parties will enter into a mutually acceptable amended Drug Discovery Plan that
includes the additional [***]. For clarity, neither Party will have any obligation to agree to amend a Drug Discovery Plan to include any additional [***] that were not set forth in the initial Drug Discovery Plan for the applicable Drug Discovery
Program. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>2.2.6</B>.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Delivery of Development Candidate; Development Candidate Report</B>. The objective of each Drug Discovery
Plan will be to identify both a lead and a backup candidate for development that each meet the development candidate criteria set forth in such Drug Discovery Plan. No later than [***] after completion by the Parties of all Drug Discovery Activities
set forth under the applicable Drug Discovery Plan with respect to each Collaboration Target, or such earlier time mutually agreed upon by the Parties, each Party will deliver to the JSC a report summarizing all results, information, and data that
were generated in connection with the performance of the Drug Discovery Activities under such Drug Discovery Plan, including information regarding any therapeutic agents that meet the development candidate criteria (each, a &#147;<B>Development
Candidate Report</B>&#148;). Following receipt of the Development Candidate Reports, and at such earlier times that the Parties have exchanged data and results regarding any therapeutic agent that meets the development candidate criteria set forth
in the applicable Drug Discovery Plan, the JSC will review and discuss such Development Candidate Reports and other data and results, and Ionis may, in its sole discretion, elect to designate one or more such therapeutic agents as Development
Candidates hereunder (regardless of whether any such therapeutic agents meet the development candidate criteria). </P></TD></TR></TABLE> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>2.2.7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Drug Discovery Term</B>. On a Drug Discovery Program-by-Drug Discovery Program basis, the Drug Discovery
Activities for a Drug Discovery Program will be performed by or on behalf of the Parties during the period commencing on the selection of a Collaboration Target for such Drug Discovery Program and, unless this Agreement is earlier terminated with
respect to such Collaboration Target, expiring upon the earlier of (a)&nbsp;completion of all Drug Discovery Activities set forth in the Drug Discovery Plan for such Drug Discovery Program and presentation to the JSC of such Drug Discovery
Activities, (b)&nbsp;the fifth anniversary of the Effective Date, and (c)&nbsp;selection of a Development Candidate for such Drug Discovery Program (the &#147;<B>Drug Discovery Term</B>&#148;); <I>provided</I> that (x)&nbsp;if one or more Wave 2
Targets become Collaboration Targets in accordance with <U>Section&nbsp;2.1</U> (Selection of Collaboration Targets) as a result of the Parties achieving Enabled Delivery for the tissue that such Wave 2 Target is delivered to and less than two years
are remaining in the Drug Discovery Term for such Wave 2 Target, then clause (b)&nbsp;will be extended to the earlier of (i)&nbsp;the time that Metagenomi completes all of its activities under the applicable Drug Discovery Plan for such Wave 2
Target, and (ii), with Metagenomi&#146;s consent, not to be unreasonably withheld, delayed, or conditioned (taking into account whether it is substantially likely that a Development Candidate will be identified and designated for such Wave 2 Target
during any extended Drug Discovery Term and the resources that Metagenomi will need to reasonably allocate to applicable Drug Discovery Term activities), the seventh anniversary of the Effective Date. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>2.3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Exploratory Research Program. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>2.3.1</B>.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Exploratory Research Plan</B>. The principal Development objectives to enable improved Guide RNA, [***]
delivery strategies, and any other Development activities that the JRC agrees to include pursuant to any amendment under <U>Section&nbsp;2.3.2</U> (Amendments to the Exploratory Research Plan) (the &#147;<B>Exploratory Research Program</B>&#148;)
will be set forth in a written plan that includes: (a)&nbsp;the specific activities to be performed by each Party and (b)&nbsp;the estimated timelines for the performance of such activities (such plan, as may be updated from time to time, the
&#147;<B>Exploratory Research Plan</B>&#148; and the activities to be performed by the Parties thereunder, the &#147;<B>Exploratory Research Activities</B>&#148;). In addition, the Exploratory Research Plan will include a written budget pursuant to
which Metagenomi will perform the Exploratory Research Activities allocated to Metagenomi under such Exploratory Research Plan, which budget will include (i)&nbsp;the number of FTEs to be dedicated by Metagenomi under the Exploratory Research Plan,
and (ii)&nbsp;any Out-of-Pocket Costs expected to be incurred by Metagenomi in the performance of such Exploratory Research Activities on a line-item basis (the &#147;<B>Exploratory Research Budget</B>&#148;). The initial Exploratory Research Plan
is set forth on <U>Schedule 2.3.1</U> (Exploratory Research Plan). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>2.3.2</B>.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Amendments to the Exploratory Research Plan</B>. At least annually during the Exploratory Research Term no
later than [***] of each Calendar Year, or upon either Party&#146;s request, the JRC will develop and propose updates to the Exploratory Research Plan or Exploratory Research Budget for the next fiscal year, or such other period as the Parties may
mutually agree, and will submit any such proposed change to the JSC. Additionally, at any time during the Exploratory Research Term, the JRC may develop and propose <I>ad hoc</I> updates to the Exploratory Research Plan or Exploratory Research
Budget </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
based on the then-current results and data. The JSC will review, discuss, and determine whether to approve any such proposed change to the Exploratory Research Plan or Exploratory Research
Budget. Each such update to the Exploratory Research Plan or Exploratory Research Budget will become effective and will supersede the previous Exploratory Research Plan or Exploratory Research Budget upon approval thereof by the JSC.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>2.3.3</B>.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Exploratory Research Term</B>. The Exploratory Research Activities will be performed by or on behalf of the
Parties during the period commencing on the Effective Date and, unless this Agreement is earlier terminated with respect to the Exploratory Research Program, expiring upon the earlier of (a)&nbsp;completion of all Exploratory Research Activities set
forth in the Exploratory Research Plan, and (b)&nbsp;the fifth anniversary of the Effective Date (the &#147;<B>Exploratory Research Term</B>&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>2.4</B>.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Conduct of Collaboration Activities</B>. Each Party, directly or through its Affiliates or, subject to
<U>Section&nbsp;3.3</U> (Subcontractors), Subcontractors, will use Commercially Reasonable Efforts to conduct the Drug Discovery Activities and Exploratory Research Activities (collectively, the &#147;<B>Collaboration Activities</B>&#148;) assigned
to it under the applicable Drug Discovery Plan or Exploratory Research Plan (collectively, the &#147;<B>Collaboration Program Plans</B>&#148;) and in a professional and timely manner. Each Party will, and will require its Affiliates and
Subcontractors to, perform its obligations under the Collaboration Program Plans in compliance with Applicable Law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>2.5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Cost of Collaboration Activities. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>2.5.1</B>.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Reimbursement by Ionis</B>. Ionis will reimburse Metagenomi for all (a)&nbsp;Internal Costs and
(b)&nbsp;Out-of-Pocket Costs (provided with reasonable supporting documentation), in each case ((a) and (b)), actually incurred by Metagenomi in the performance of the Exploratory Research Activities during the Exploratory Research Term to the
extent in compliance with both the Exploratory Research Plan and the amounts budgeted therefor in the Exploratory Research Budget [***] (such amount, the &#147;<B>Metagenomi Exploratory Research Costs</B>&#148;) up to $10,000,000 in the aggregate
(the &#147;<B>Reimbursement Cap</B>&#148;). If the aggregated Metagenomi Exploratory Research Costs during the Exploratory Research Term are <I>less</I> than the Reimbursement Cap, then Ionis will also reimburse Metagenomi for all (1)&nbsp;Internal
Costs and (2)&nbsp;Out-of-Pocket Costs (provided with reasonable supporting documentation), in each case ((1) and (2)), actually incurred by Metagenomi in the performance of the Drug Discovery Activities during the Exploratory Research Term to the
extent in compliance with both the applicable Drug Discovery Plans and the amounts budgeted therefor in the applicable Drug Discovery Budgets [***] (&#147;<B>Metagenomi Drug Discovery Costs</B>&#148;) up to [***]. In each Calendar Quarter during the
Exploratory Research Term, unless and until Ionis&#146; aggregated payments under this <U>Section&nbsp;2.5.1</U> (Reimbursement by Ionis) reach the Reimbursement Cap, Ionis will pay Metagenomi $500,000 to cover the Metagenomi Exploratory Research
Costs and, if applicable, the Metagenomi Drug Discovery Costs for such Calendar Quarter (such amount, the &#147;<B>Quarterly Reimbursement Payments</B>&#148;), within [***] following receipt of an invoice from Metagenomi therefor. No later than
[***] following the conclusion of each [***] during the Exploratory Research Term, Metagenomi will provide to Ionis a written report of all Metagenomi Exploratory Research Costs and Metagenomi Drug Discovery Costs incurred by or on behalf of
Metagenomi during the applicable [***] (such reports, the &#147;<B>Metagenomi Collaboration Cost Reports</B>&#148;). If the amount set forth in the Metagenomi Collaboration Cost Report for a [***], then no further action is required by the Parties,
except that [***]. If the amount set forth in the Metagenomi Collaboration Cost Report for [***], then [***]under this <U>Section&nbsp;2.5.1</U> (Reimbursement by Ionis). For clarity, Ionis will have the right to [***]. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>2.5.2</B>.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Cost of Other Collaboration Activities</B>. Except with respect to amounts reimbursed by Ionis pursuant to
<U>Section&nbsp;2.5.1</U> (Reimbursement by Ionis), Metagenomi will be responsible for all costs and expenses incurred by or on behalf of Metagenomi in the performance of the Collaboration Activities allocated to Metagenomi in the applicable
Collaboration Program Plans, including in the performance of all Drug Discovery Activities after the expiration of the Exploratory Research Term. In addition, Ionis will be responsible for all costs and expenses incurred by or on behalf of Ionis in
the performance of the Collaboration Activities allocated to Ionis in the applicable Collaboration Program Plans. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>2.6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Collaboration Program Records and Reports. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>2.6.1</B>.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Records</B>. Each Party will maintain, or cause to be maintained, records of its Collaboration Activities in
sufficient detail and in a good scientific manner appropriate for scientific, patent, and regulatory purposes, which records will reasonably reflect the work performed by such Party under each Collaboration Program Plan. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>2.6.2</B>.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Collaboration Program Reports</B>. During the Collaboration Term, in advance of each meeting of the JSC
(unless otherwise agreed by the JSC), each Party will submit to the JSC for its review and discussion written materials that include a reasonably detailed summary of the Collaboration Activities performed by or on behalf of such Party during the
most recently completed Calendar Quarter, which summary will include an estimate of the number of personnel that are performing Collaboration Activities for such Party in such Calendar Quarter (each, a &#147;<B>Collaboration Program
Report</B>&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>2.7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Ionis Proprietary Toolbox of Chemical Modifications. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>2.7.1</B>.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Option Grant</B>. If any Ionis Proprietary Toolbox of Chemical Modifications is necessary or reasonably
useful for Metagenomi to practice any Metagenomi Collaboration Technology or Joint Collaboration Technology (such Intellectual Property Rights, &#147;<B>Ionis Background Technology</B>&#148;), then Metagenomi will have an option to obtain the
license set forth in <U>Section&nbsp;3.2.3(a)</U> (Ionis Background Technology License Grant) to Exploit up to eight Metagenomi Products in the Field (&#147;<B>Ionis IP Option</B>&#148;). [***]. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>2.7.2</B>.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Option Exercise</B>. Metagenomi may exercise an Ionis IP Option by providing written notice to Ionis
(&#147;<B>Option Exercise Notice</B>&#148;) at any time during the period commencing on [***] and ending on [***] after the expiration of the [***] of the Effective Date (the &#147;<B>Option Term</B>&#148;), which notice will identify one or more
targets that Metagenomi proposes to designate as Metagenomi Targets to which the applicable Metagenomi Product will be directed (each, a &#147;<B>Proposed Metagenomi Target</B>&#148; and such notice, a &#147;<B>Proposed Metagenomi Target
Notice</B>&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>2.7.3</B>.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Encumbrance Check</B>.<B></B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Encumbered Targets</B>. Ionis will notify Metagenomi within [***] after Ionis&#146; receipt of a Proposed
Metagenomi Target Notice if, at the time of receipt of such notice, (i)&nbsp;[***], (ii)&nbsp;[***], or (iii)&nbsp;[***] (each of (i)&nbsp;through (iii), a &#147;<B>Pre-Existing Ionis Restriction</B>&#148; and such Proposed Metagenomi Target, an
&#147;<B>Encumbered Proposed Metagenomi Target</B>&#148;). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B></B>(b)<B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Effects if a Proposed Metagenomi Target is not an Encumbered Proposed Metagenomi Target</B>. If Ionis
does not notify Metagenomi within [***] after Ionis&#146; receipt of a Proposed Metagenomi Target Notice that the applicable Proposed Metagenomi Target is an Encumbered Proposed Metagenomi Target, then Metagenomi may provide a second notice to Ionis
indicating that the Proposed Metagenomi Target will be deemed a &#147;Metagenomi Target&#148; if Ionis does not respond to such second notice within [***]. If Ionis (i)&nbsp;notifies Metagenomi that a Proposed Metagenomi Target is not an Encumbered
Proposed Metagenomi Target or (ii)&nbsp;does not provide notice that a Proposed Metagenomi Target is an Encumbered Proposed Metagenomi Target within the original [***] period or within [***] after Metagenomi&#146;s second notice (such date, the
&#147;<B>Ionis IP Option Effective Date</B>&#148;), then, in either case, (A)&nbsp;the Proposed Metagenomi Target will automatically be deemed to be a &#147;Metagenomi Target&#148; under this Agreement with no further action by the Parties, and
(B)&nbsp;the license to Metagenomi under <U>Section&nbsp;3.2.3(a)</U> (Ionis Background Technology License Grant) will be effective with respect to Metagenomi Products for such Metagenomi Target. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>2.7.4</B>.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">I<B>onis Background Technology Transfer</B>. On a Metagenomi Target-by-Metagenomi Target basis, no later than
[***] after the Ionis IP Option Effective Date for each Metagenomi Target, Ionis will transfer to Metagenomi all Ionis Background Technology that is necessary or determined by Ionis in good faith to be reasonably useful, in each case, for Metagenomi
to Exploit the applicable Metagenomi Product for such Metagenomi Target in the Field. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Article&nbsp;3 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Licenses; Exclusivity </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>3.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>License Grants to Ionis. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>3.1.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Collaboration Activities License</B>.<B> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Collaboration Activities License Grant</B>. Subject to the terms of this Agreement, Metagenomi hereby grants
to Ionis and its Affiliates a non-exclusive, royalty-free license, with the right to sublicense through multiple tiers (subject to <U>Section&nbsp;3.1.1(b)</U> (Sublicensing by Ionis)), under the Licensed Technology to perform (or have performed in
accordance with this Agreement) all Collaboration Activities allocated to Ionis under each Collaboration Program Plan during the Collaboration Term. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Sublicensing by Ionis</B>. Ionis may grant sublicenses of any rights granted by Metagenomi under
<U>Section&nbsp;3.1.1(a)</U> (Collaboration Activities License Grant) through multiple tiers to any of its Affiliates or to one or more Subcontractors that are not [***]. Each such sublicense will be consistent with the terms of this Agreement and
will require such Sublicensee to comply with all applicable terms of this Agreement. Ionis will remain responsible for its Sublicensees&#146; compliance with the applicable terms of this Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>3.1.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Exclusive Exploitation License</B>.<B> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Exclusive Exploitation License Grant</B>. Subject to the terms of this Agreement, Metagenomi hereby grants
to Ionis and its Affiliates an exclusive, royalty-bearing license, with the right to sublicense through multiple tiers (subject to <U>Section&nbsp;3.1.2(c)</U> (Sublicensing by Ionis)), under the Licensed Technology to Exploit all Licensed Systems
and Licensed Products solely in the Field in the Territory. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Limitations</B>. Notwithstanding the license granted to Ionis pursuant to <U>Section&nbsp;3.1.1(a)</U>
(Collaboration Activities License Grant) and <U>Section&nbsp;3.1.2(a)</U> (Exclusive Exploitation License Grant), subject to the terms of this Agreement, Metagenomi will retain non-exclusive rights under the Licensed Technology in the Field in the
Territory for the sole purpose of performing the Metagenomi Activities or fulfilling its obligations under this Agreement, in each case, either itself or through its Affiliates, or Subcontractors. For clarity, Metagenomi will retain all rights under
the Licensed Technology and Licensed Systems for use outside of the Field. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Sublicensing by Ionis</B>. Ionis may grant sublicenses of any rights granted by Metagenomi under
<U>Section&nbsp;3.1.2(a)</U> (Exclusive Exploitation License Grant) through multiple tiers to any of its Affiliates or to one or more Sublicensees without the consent of Metagenomi; <I>provided</I> that such Sublicensees are not [***]. Each such
sublicense will be consistent with the terms of this Agreement and will require such Sublicensee to comply with all applicable terms of this Agreement. Ionis will remain responsible for its Sublicensees&#146; compliance with the applicable terms of
this Agreement. Promptly following Ionis&#146; grant of a sublicense to a Sublicensee, Ionis will notify Metagenomi of such sublicense. Upon Metagenomi&#146;s written request, Ionis will provide Metagenomi with a fully-executed copy of any agreement
reflecting any such sublicense (excluding any sublicense with an Affiliate of Ionis&#146; or any Third Party acting on Ionis&#146; behalf), which may be reasonably redacted to exclude Ionis&#146; proprietary information, other competitively
sensitive information, or any other information not necessary for Metagenomi to verify compliance with the preceding sentence, which copy will be treated as Ionis&#146; Confidential Information. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>3.1.3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Unblocking License</B>.<B> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Unblocking License Grant</B>. Subject to the terms of this Agreement, including the license granted pursuant
to <U>Section&nbsp;3.1.2(a)</U> (Exclusive Exploitation License Grant), Metagenomi hereby grants to Ionis and its Affiliates a [***] non-exclusive license, with the right to sublicense through multiple tiers (subject to <U>Section&nbsp;3.1.3(b)</U>
(Sublicensing by Ionis)), under Metagenomi&#146;s interest in the Joint Collaboration Technology [***] in the Unblocking Field in the Territory. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Sublicensing by Ionis</B>. Ionis may grant sublicenses of any rights granted by Metagenomi under
<U>Section&nbsp;3.1.3(a)</U> (Unblocking License Grant) through multiple tiers to any of its Affiliates or to one or more Sublicensees to which Ionis grants a license to [***]. Each such sublicense will be consistent with the terms of this Agreement
and will require such Sublicensee to comply with all applicable terms of this Agreement. Ionis will remain responsible for its Sublicensees&#146; compliance with the applicable terms of this Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>3.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>License Grants to Metagenomi. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>3.2.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Metagenomi Activities License</B>.<B> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Metagenomi Activities License Grant.</B> Subject to the terms of this Agreement, Ionis hereby grants to
Metagenomi a non-exclusive, royalty-free license, with the right to sublicense through multiple tiers (subject to the provisions of <U>Section&nbsp;3.2.1(b)</U> (Sublicensing by Metagenomi)), under the Ionis Licensed Technology solely to perform the
Collaboration Activities assigned to Metagenomi under the Collaboration Program Plans ( the &#147;<B>Metagenomi Activities</B>&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Sublicensing by Metagenomi</B>. Metagenomi may grant sublicenses of any rights granted by Ionis under
<U>Section&nbsp;3.2.1(a)</U> (Metagenomi Activities License Grant) through multiple tiers to any of its Affiliates or to one or more Subcontractors that are not [***]. Each such sublicense will be consistent with the terms of this Agreement and will
require such Sublicensee to comply with all applicable terms of this Agreement. Metagenomi will remain responsible for each Sublicensee&#146;s compliance with the applicable terms of this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>3.2.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Unblocking License</B>.<B> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Unblocking License Grant</B>. Subject to the terms of this Agreement, Ionis hereby grants to
Metagenomi and its Affiliates a [***] non-exclusive license, with the right to sublicense through multiple tiers (subject to <U>Section&nbsp;3.2.2(b)</U> (Sublicensing by Metagenomi)), under Ionis&#146; interest in the Joint Collaboration Technology
[***] in the Unblocking Field in the Territory. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Sublicensing by Metagenomi</B>. Metagenomi may grant sublicenses of any rights granted by Ionis under
<U>Section&nbsp;3.2.2(a)</U> (Unblocking License Grant) through multiple tiers to any of its Affiliates or to one or more Sublicensees to which Metagenomi grants a license to [***]. Each such sublicense will be consistent with the terms of this
Agreement and will require such Sublicensee to comply with all applicable terms of this Agreement. Metagenomi will remain responsible for its Sublicensees&#146; compliance with the applicable terms of this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>3.2.3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Ionis Background Technology License</B>.<B> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Ionis Background Technology License Grant</B>. Subject to <U>Section&nbsp;2.7</U> (Ionis Proprietary
Toolbox of Chemical Modifications), effective upon the Ionis IP Option Effective Date for a Metagenomi Target, Ionis hereby grants to Metagenomi a non-exclusive, royalty-bearing license with the right to grant sublicenses through multiple tiers
(subject to <U>Section&nbsp;3.2.3(b)</U> (Sublicensing by Metagenomi)) under the Ionis Background Technology solely to Exploit Metagenomi Products for such Metagenomi Target in the Field. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Sublicensing by Metagenomi</B>.<B></B> Metagenomi may grant sublicenses of any rights granted by Ionis under
<U>Section&nbsp;3.2.3(a)</U> (Ionis Background Technology License Grant) through multiple tiers to any of its Affiliates or to one or more Sublicensees to which Metagenomi grants a license to Exploit the Metagenomi Products; <I>provided</I> that
such Sublicensees are not [***]. Each such sublicense will be consistent with the terms of this Agreement and will require such Sublicensee to comply with all applicable terms of this Agreement. Metagenomi will remain
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="23%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
responsible for its Sublicensees&#146; compliance with the applicable terms of this Agreement. Promptly following Metagenomi&#146;s grant of a sublicense to a Sublicensee, Metagenomi will notify
Ionis of such sublicense. Upon Ionis&#146; written request, Metagenomi will provide Ionis with a fully-executed copy of any agreement reflecting any such sublicense (excluding any sublicense with an Affiliate of Metagenomi), which may be reasonably
redacted to exclude Metagenomi&#146;s proprietary information, other competitively sensitive information, or any other information not necessary for Ionis to verify compliance with the preceding sentence, which copy will be treated as
Metagenomi&#146;s Confidential Information. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>3.3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Subcontractors</B><B>.</B> Each Party and its Affiliates may perform any of its obligations under
this Agreement through one or more Subcontractors; <I>provided</I> that (a)&nbsp;neither Party nor its Affiliates will engage any subcontractor that has been debarred by any Regulatory Authority; (b)&nbsp;the subcontracting Party remains fully
responsible for the work allocated to, and payment to, such subcontractors to the same extent it would if it had done such work itself; (c)&nbsp;the subcontractor undertakes in writing obligations of confidentiality and non-use applicable to the
Confidential Information that are at least as stringent as those set forth in<U> Article 11</U> (Confidentiality) other than the term of any such confidentiality obligation, which will be customary for the nature of the Subcontractor;
(d)&nbsp;require such Subcontractor and its personnel to assign (or, if such Party, after using Commercially Reasonable Efforts, cannot obtain an assignment, then to grant a perpetual license) to such Party of all rights, title, and interests in and
to any Patent Rights or Know-How created, conceived, or developed in connection with the performance of subcontracted activities; <I>provided</I> that such Subcontractor and its personnel will not be required to assign its rights, title, and
interests to any of its background intellectual property or improvements thereto; (e)&nbsp;the subcontracting Party will be liable for any act or omission of any Subcontractor that is a breach of any of the subcontracting Party&#146;s obligations
under this Agreement as though the same were a breach by the subcontracting Party; (f)&nbsp;each Party will use good faith efforts to identify in writing to the other Party any Subcontractor that it engages to perform Collaboration Activities and
will only engage Subcontractors to perform the Collaboration Activities to the extent and in a manner consistent with such Party&#146;s engagement of subcontractors for other internal Development programs; (g)&nbsp;Ionis [***]; and
(h)&nbsp;Metagenomi [***]. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>3.4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Technology Transfer. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>3.4.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Initial Transfers</B>. On a Collaboration Target-by-Collaboration Target basis, no later than (a)&nbsp;for
[***] after the Effective Date and (b)&nbsp;for each new Collaboration Target, [***] after the applicable target becomes a Collaboration Target pursuant to <U>Section&nbsp;2.1.1(b)</U> (Second Wave 1 Target) or <U>Section&nbsp;2.1.4(c)</U> (Effects
if a Proposed Target is Available), each Party will transfer to the other Party all Ionis Licensed Technology or Licensed Technology (as applicable), with respect to [***], as of the Effective Date, or, with respect to Collaboration Targets that
become such after the Effective Date, at the time that a target becomes a Collaboration Target, in each case, that is [***] to perform the activities allocated to the non-transferring Party under the Drug Discovery Plan for the applicable
Collaboration Target. In addition, each Party will transfer to the other Party all Ionis Licensed Technology or Licensed Technology (as applicable) that is [***] for the non-transferring Party to perform the activities allocated to the
non-transferring Party under the Exploratory Research Plan no later than [***] after the Effective Date. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>3.4.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Additional Transfers</B>. Following the initial transfers described in <U>Section&nbsp;3.4.1</U> (Initial
Transfers), (a)&nbsp;promptly after [***] and (b)&nbsp;[***], Metagenomi will provide prompt updates to Ionis regarding any Licensed Know-How not previously transferred to Ionis that is [***] for Ionis to continue Exploiting the Licensed Systems and
Licensed Products, in each case, that relate to the Development Candidates being Exploited, or that Ionis, at such time, intends to Exploit, under this Agreement. During the Term, as reasonably requested by Ionis, Metagenomi will promptly provide
Ionis with any information specifically identified by Ionis and included in the Licensed Technology that is [***] for Ionis to Exploit the Licensed Systems or Licensed Products that relate to the Development Candidates being Exploited, or that
Ionis, at such time, intends to Exploit, and has not previously been transferred to Ionis under this Agreement. Metagenomi will provide such information to Ionis within [***] after Ionis&#146; request. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>3.4.3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Assistance by Metagenomi Personnel</B>. To assist with the transfer of Licensed Know-How under this
<U>Section&nbsp;3.4</U> (Technology Transfer) and Ionis&#146; Exploitation thereof in accordance with the terms of this Agreement during the Term, Metagenomi will make its personnel reasonably available to Ionis during normal business hours to
transfer such Licensed Know-How to Ionis and respond to Ionis&#146; reasonable inquiries with respect thereto. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>3.4.4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Costs of Support</B>. On a Collaboration Program-by-Collaboration Program basis, Metagenomi will provide the
first [***] FTE hours of technology transfer, or technical or regulatory assistance under this <U>Section&nbsp;3.4</U> (Technology Transfer), <U>Section&nbsp;7.2.2</U> (Assistance; Support) and <U>Section&nbsp;7.3</U> (Regulatory Support) for a
Collaboration Program at Metagenomi&#146;s cost and expense. On a Collaboration Program-by-Collaboration Program basis, for any such assistance in excess of [***] FTE hours for a Collaboration Program, Ionis will reimburse Metagenomi for its
reasonable, documented Internal Costs with respect thereto within [***] of receipt of a reasonably detailed invoice therefor. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>3.5</B>.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>No Implied Licenses</B>. Except as expressly provided in this Agreement, neither Party will be deemed to
have granted the other Party any license or other right with respect to any Intellectual Property Rights of such Party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>3.6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Exclusivity</B>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>3.6.1</B>.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Exclusivity Obligations</B>. Subject to <U>Section&nbsp;3.6.2</U> (Acquisition of Distracting Product) and
<U>Section&nbsp;3.6.3</U> (Change of Control), except in the performance of its obligations or exercise of its rights under this Agreement, neither Party nor any of its Affiliates will work independently or for or with any Third Party (including the
grant of any license to any Third Party) to: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">on a Drug Discovery Program-by-Drug Discovery Program basis, (i)&nbsp;during the Drug Discovery Term for a Drug
Discovery Program, Develop or Commercialize any product that targets the Collaboration Target in the Exclusivity Field, and (ii)&nbsp;until the earlier of the (1)&nbsp;[***] period after the expiration of the Drug Discovery Term for a Drug Discovery
Program or (2)&nbsp;[***] period after the Effective Date, clinically Develop or Commercialize any product that targets a Collaboration Target in the Exclusivity Field that is actively being Developed by Ionis under this Agreement for such Drug
Discovery Program; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">on a Co-Co Program-by-Co-Co Program basis, during the period commencing on the date [***] and expiring [***],
Develop or Commercialize any product that targets the Collaboration Target for such Co-Co Program in the Exclusivity Field. For clarity, the limitations set forth in this <U>Section&nbsp;3.6.1</U> (Exclusivity Obligations) will not apply to any
Collaboration Target that is substituted out in accordance with <U>Section&nbsp;2.1.3</U> (Target Substitutions). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>3.6.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Acquisition of Distracting Product</B>. Notwithstanding the provisions of <U>Section&nbsp;3.6.1</U>
(Exclusivity Obligations), if a Party or any of its Affiliates (such Party, the &#147;<B>Distracted Party</B>&#148;) acquires rights to Develop or Commercialize a product in the Field as the result of a merger, acquisition, or combination with or of
a Third Party (where such Party is not the acquired entity) other than a Change of Control (each, an &#147;<B>Acquisition Transaction</B>&#148;) and, on the date of the closing of such Acquisition Transaction, such product is being Developed or
Commercialized and such activities would, but for the provisions of this <U>Section&nbsp;3.6.2</U> (Acquisition of Distracting Product), constitute a breach of <U>Section&nbsp;3.6.1</U> (Exclusivity Obligations) (such product, a &#147;<B>Distracting
Product</B>&#148;), then the Distracted Party or such Affiliate will, within [***] after the closing of such Acquisition Transaction notify the other Party in writing of such acquisition and either: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">request that such Distracting Product be included in this Agreement on terms to be negotiated, in which case,
the Parties will discuss the matter in good faith for a period of no less than [***] and, if the Parties are unable to reach agreement on the terms on which such Distracting Product would be included hereunder within such period, then the Distracted
Party will elect to take the action specified in either <U>Section&nbsp;3.6.2(b)</U> or <U>Section&nbsp;3.6.2(c)</U> below; <I>provided</I> that the time periods specified in such clauses will be tolled for so long as the Parties are engaged in good
faith discussion under this <U>Section&nbsp;3.6.2(a)</U>; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">notify the other Party in writing that the Distracted Party or its Affiliate will [***], in which case, within
[***] after the closing of the Acquisition Transaction, the Distracted Party or its Affiliate will [***]; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">notify the other Party in writing that it [***], in which case, within [***] after the other Party&#146;s
receipt of such notice, the Distracted Party and its Affiliates will [***]. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:16%; text-indent:7%; font-size:10pt; font-family:Times New Roman">During the discussion
period under <U>Section&nbsp;3.6.2(a)</U>, prior to the time of [***] to <U>Section&nbsp;3.6.2(b)</U>, or prior to the [***] pursuant to <U>Section&nbsp;3.6.2(c)</U>, as applicable, the Distracted Party and its Affiliates will segregate all
activities relating to the Distracting Product from the Exploitation of the Licensed Systems or Licensed Products under this Agreement, including ensuring that (i)&nbsp;no personnel involved in performing Development or Commercialization activities
with respect to such Distracting Product have access to non-public plans or information relating to the Development or Commercialization of Licensed Systems or Licensed Products under this Agreement (except that [***]), and (ii)&nbsp;no personnel
involved in performing Development or Commercialization activities with respect to Licensed Systems or Licensed Products under this Agreement have access to non-public plans or information relating to the Development or Commercialization of such
Distracting Product (except that [***]). The procedures set forth in clauses (i)&nbsp;and (ii)&nbsp;above will be referred to as &#147;<B>Firewall Procedures</B>&#148; for the purposes of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>3.6.3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Change of Control</B>. If there is a Change of Control involving a Party (where such Party is the
acquired entity), then: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the obligations of <U>Section&nbsp;3.6.1</U> (Exclusivity Obligations) will not apply to any product that is
controlled by the relevant acquirer or its Affiliates and that exists prior to the closing of such Change of Control; provided that (i)&nbsp;the acquired Party and the acquirer and its Affiliates existing immediately prior to the effective date of
such Change of Control [***], (ii)&nbsp;the acquirer and its Affiliates existing immediately prior to the effective date of such Change of Control [***], and (iii)&nbsp;no personnel who were employees or consultants of the acquired Party or its
Affiliates at any time prior to or after the Change of Control will [***]; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if Ionis is the acquired entity and the acquiring entity is a [***], then Ionis will ensure that the acquiring
entity establishes and implements Firewall Procedures to segregate and protect Confidential Information related to the Licensed Systems and Licensed Products from access to or use by the acquiring party other than as permitted by this Agreement; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if Metagenomi is the acquired entity and the acquiring entity is an [***], then Metagenomi will ensure that the
acquiring entity establishes and implements Firewall Procedures to segregate and protect Confidential Information related to the Licensed Systems, Licensed Products, and Ionis Background Technology from access to or use by the acquiring party other
than as permitted by this Agreement. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Article&nbsp;4 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Governance </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>4.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Joint Steering Committee</B><B>. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>4.1.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Formation and Purpose of the JSC</B>. Promptly, but no later than [***] after the Effective Date, the
Parties will establish a Joint Steering Committee (&#147;<B>JSC</B>&#148;), which JSC will coordinate, oversee, and monitor the Parties&#146; activities hereunder in accordance with this <U>Section&nbsp;4.1</U> (Joint Steering Committee). The JSC
will have the responsibilities set forth herein and will have no further responsibilities (a)&nbsp;with respect to the Exploratory Research Program, upon the expiration of the Exploratory Research Term, and (b)&nbsp;with respect to any Drug
Discovery Program, upon the expiration of the Drug Discovery Term for such Drug Discovery Program. Upon the latest to occur of (a)-(b), the JSC will be dissolved. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>4.1.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Membership</B>. Each Party will designate [***] representatives with appropriate expertise and seniority to
serve as members of the JSC, and who have the authority to bind such Party with respect to matters within the purview of the JSC. Each Party may replace its JSC representatives at any time upon written notice to the other Party. Metagenomi will
designate one of its JSC members as one of the co-chairpersons of the JSC and Ionis will designate one of its members as the other co-chairperson of the JSC. Every [***] the co-chairpersons will alternate serving in the role of &#147;lead
co-chairperson.&#148; The lead co-chairperson or his or her designee, in collaboration with the Alliance Managers, will be responsible for calling meetings, preparing and circulating an agenda in advance of each meeting, and preparing and issuing
minutes of each meeting within [***]thereafter. Such minutes will be deemed finalized unless any JSC member objects to the accuracy of such minutes no later than [***] after receipt of such minutes. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>4.1.3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Meetings</B>. The JSC will meet in person, by videoconference, or by teleconference at least once each
[***], unless otherwise agreed by the Parties, on such dates and at such times and places as agreed to by the members of the JSC. The Alliance Manager of each Party will attend each meeting of the JSC as a non-voting participant. Each Party will be
responsible for all of its own expenses in participating in any JSC meeting. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>4.1.4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Meeting Agendas</B>. Each Party will disclose to the other Party the proposed agenda items at least
[***] in advance of each meeting of the JSC. Notwithstanding the foregoing, under exigent circumstances requiring JSC input, a Party may provide its agenda items to the other Party within a lesser period of time in advance of the meeting, or may
propose that there not be a specific agenda for a particular meeting, so long as such other Party consents to such later addition of such agenda items or the absence of a specific agenda for such JSC meeting. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>4.1.5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Specific Responsibilities of the JSC</B>. The responsibilities of the JSC will be to:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">oversee the overall strategic relationship between the Parties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">review, discuss, and determine whether it is technologically infeasible to Develop a Development Candidate for
a given Collaboration Target, as described in <U>Section&nbsp;2.1.3(b)</U> (Substitutions for Technological Infeasibility); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">review, discuss, and determine whether to approve each Drug Discovery Plan, and any updates thereto, pursuant
to <U>Section&nbsp;2.2.2</U> (Additional Drug Discovery Plans) and <U>Section&nbsp;2.2.3</U> (Amendments to the Drug Discovery Plans); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">discuss and determine the [***] for the Second Wave 1 Target and each Proposed Target that is deemed a
Collaboration Target under this Agreement pursuant to <U>Section&nbsp;2.1.4(c)</U> (Effects if a Proposed Target is Available), as described in <U>Section&nbsp;2.2.4(b) </U>(Selection of Gene Editing Modalities); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">review and discuss each Development Candidate Report and any other data or results provided by Metagenomi
regarding therapeutic agents that meet the development candidate criteria set forth in a Drug Discovery Plan, pursuant to <U>Section&nbsp;2.2.6</U> (Delivery of Development Candidate; Development Candidate Report); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">review, discuss, and determine whether to approve any updates to the Exploratory Research Plan or Exploratory
Research Budget, pursuant to <U>Section&nbsp;2.3.2</U> (Amendments to the Exploratory Research Plan); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">review and discuss each Collaboration Program Report, pursuant to <U>Section&nbsp;2.6.2</U> (Collaboration
Program Reports); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">review and discuss the Regulatory Strategy for each Licensed Product, as described in <U>Section&nbsp;7.1</U>
(Regulatory Responsibility); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">coordinate the wind-down of any Terminated Products in the Terminated Countries to the extent the JSC is still
in effect at the time of the applicable termination notice, pursuant to <U>Section&nbsp;14.3.1</U> (Wind-Down); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">perform such other functions as appropriate to further the purposes of this Agreement as determined by the
Parties. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>4.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Subcommittees</B> . From time to time, the JSC may establish and delegate duties, including any
responsibilities of the JSC set forth in <U>Section&nbsp;4.1.5</U> (Specific Responsibilities of the JSC), to operational subcommittees (each, a &#147;<B>Subcommittee</B>&#148;) on an &#147;as-needed&#148; basis to oversee particular projects or
activities, which delegations will be reflected in the minutes of the meetings of the JSC. Such Subcommittees may be established on an <I>ad hoc</I> basis for purposes of a specific project, for the life of a Licensed Product, or on such other basis
as the JSC may determine, and will be constituted and will operate as the JSC may determine; <I>provided</I> that each Subcommittee will have equal representation from each Party and decision making will be by consensus, with each Party&#146;s
representatives on the applicable Subcommittee collectively having one vote on all matters brought before the Subcommittee. Each Subcommittee and its activities will be subject to the direction, review, and approval of, and, unless otherwise
determined by the JSC, will report to, the JSC. For each Subcommittee, Ionis will designate one of its Subcommittee members to serve as the chairperson of such Subcommittee. The chairperson or his or her designee, in collaboration with the Alliance
Managers, will be responsible for calling meetings, preparing and circulating an agenda in advance of each meeting, and preparing and issuing minutes of each meeting within [***] thereafter. Such minutes will not be finalized until all Subcommittee
members have had an adequate opportunity to review and confirm the accuracy of such minutes. Each Party may replace its representatives on each such Subcommittee at any time upon written notice to the other Party. The Alliance Manager of each Party
(or his or her designee) will attend each meeting of each Subcommittee as a non-voting participant. Each Subcommittee and its activities will be subject to the oversight of, and will report to, the JSC. Any disagreement between the representatives
of the Parties on a Subcommittee will be referred to the JSC for resolution in accordance with <U>Section&nbsp;4.6</U> (Decision-Making). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>4.3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Joint Research Committee</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>4.3.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Formation and Purpose of the JRC</B>. Promptly, but no later than [***] after the creation of the JSC, the
Parties will establish a Joint Research Committee (&#147;<B>JRC</B>&#148;), which JRC will coordinate, oversee, and monitor the Parties&#146; research activities hereunder in accordance with this <U>Section&nbsp;4.3</U> (Joint Research Committee).
The JRC will be deemed a &#147;Subcommittee&#148; as described in <U>Section&nbsp;4.2</U> (Subcommittees). The JRC will have the responsibilities set forth herein and will dissolve upon the earlier of (a)&nbsp;the dissolution of the JSC,
(b)&nbsp;the expiration of the Collaboration Term, or (c)&nbsp;by mutual agreement between the Parties. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>4.3.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Membership</B>. Each Party will designate [***] representatives with appropriate expertise and seniority to
serve as members of the JRC, and who have the authority to bind such Party with respect to matters within the purview of the JRC. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>4.3.3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Specific Responsibilities of the JRC</B>. The responsibilities of the JRC will be to: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">coordinate the Collaboration Activities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">develop, discuss, and submit to the JSC to further review, discuss, and determine whether to approve each Drug
Discovery Plan, and any updates thereto, pursuant to <U>Section&nbsp;2.2.2</U> (Additional Drug Discovery Plans) and <U>Section&nbsp;2.2.3</U> (Amendments to the Drug Discovery Plans); </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">develop, discuss, and submit to the JSC to further review, discuss, and determine whether to approve any
updates to the Exploratory Research Plan or Exploratory Research Budget, pursuant to <U>Section&nbsp;2.3.2</U> (Amendments to the Exploratory Research Plan); and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">perform such other functions as determined by the JSC. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>4.4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Alliance Managers</B> . Each of the Parties will appoint a single individual to coordinate
communications regarding the activities under this Agreement (each, an &#147;<B>Alliance Manager</B>&#148;). The role of the Alliance Manager is to act as a single point of contact between the Parties to ensure a successful relationship under this
Agreement. The Alliance Managers will attend any JSC meetings. Alliance Managers will be non-voting participants in all JSC meetings that they attend; <I>provided</I>, <I>however</I>, that an Alliance Manager may bring any matter to the attention of
the JSC if such Alliance Manager reasonably believes that such matter warrants such attention. Each Party will designate its initial Alliance Manager promptly after the Effective Date and each Party may change its designated Alliance Manager at any
time upon written notice to the other Party. Any Alliance Manager may designate a substitute to temporarily perform the functions of that Alliance Manager by written notice to the other Party. Each Alliance Manager may also: (a)&nbsp;be the point of
first referral in all matters of conflict resolution; (b)&nbsp;provide a single point of communication for seeking consensus between the Parties regarding key strategy and plan issues; (c)&nbsp;identify and bring disputes to the attention of the JSC
in a timely manner; and (d)&nbsp;plan and coordinate cooperative efforts. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>4.5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Additional Participants</B><B></B>. Other employees of either Party or any of its Affiliates may
attend meetings of the JSC or any Subcommittees as non-voting participants with prior written notice to the other Party (including via email notification). In addition, with the consent of each Party, consultants, representatives, or advisors may
attend meetings of the JSC or any Subcommittees as non-voting observers; <I>provided</I>, <I>however</I>, that such Third Party participants and observers are under written obligations of confidentiality and non-use applicable to the Confidential
Information of each Party that are at least as stringent as those set forth in<U> Article 11</U> (Confidentiality). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>4.6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Decision-Making</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>4</B><B>.6.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Committee Decisions</B>. Each Party&#146;s representatives on the JSC will, collectively, have one vote (the
&#147;<B>Party Vote</B>&#148;) on all matters brought before such committee for a decision by consensus. The JSC will make decisions as to matters within its jurisdiction by unanimous Party Vote, which Party Vote will be reflected in the minutes of
the committee meeting. No vote will be binding on either Party unless each Party has at least one representative in attendance. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>4.6.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Scope of Committee Authority</B>. For the avoidance of doubt, matters that are specified in this<U> Article
4</U> (Governance) only to be reviewed and discussed (as opposed to reviewed, discussed, and approved) do not require any agreement or decision by either Party and are not subject to the voting and decision-making procedures set forth in this
<U>Section&nbsp;4.6</U> (Decision-Making). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>4.6.3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Escalation</B>. If the representatives of Metagenomi and Ionis are unable to agree on or resolve any matter
requiring the approval of the JSC after the use of good faith efforts, within [***] after the JSC first considers such matter then, at the election of either Party, such Party may refer such matter to the Party&#146;s respective Executive Officer.
The Executive Officers will use good faith efforts to resolve any such disagreement so referred to them as soon as practicable, and any final decision that the Executive Officers agree to in writing will be conclusive and binding on the Parties. If
the Executive Officers are unable to resolve any such disagreement so referred to them within [***] following such referral (or such longer period as the Executive Officers may agree upon), then: </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Ionis Final Decision-Making Authority</B>. Ionis will have the right to make the final decision regarding
[***]. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Resolution by Baseball Arbitration</B>. Except for those matters set forth in <U>Section&nbsp;4.6.3(a)</U>
(Ionis Final Decision-Making Authority), either Party may refer the matter for resolution pursuant to <U>Section&nbsp;15.1.3</U> (Expedited Dispute Resolution). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>4.6.4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>General Authority</B>. The JSC and any Subcommittees will have solely the powers expressly assigned to them
in this<U> Article 4</U> (Governance) and elsewhere in this Agreement. In conducting themselves on the JSC, any Subcommittees, and as Alliance Managers, and in exercising their rights under this<U> Article 4</U> (Governance), all representatives of
each Party will consider diligently, reasonably, and in good faith all input received from the other Party, and will use good faith efforts to reach unanimity, where required, on all matters before them. Notwithstanding anything to the contrary set
forth in this Agreement, the JSC, and any Subcommittees will not have the right to make any decisions: (a)&nbsp;to amend, modify, or waive compliance with any term or condition of this Agreement; (b)&nbsp;in a manner that negates any consent right
or other right specifically allocated to a Party under this Agreement; (c)&nbsp;to resolve any dispute involving the breach or alleged breach of this Agreement; (d)&nbsp;to resolve a matter if the provisions of this Agreement specify that agreement
of the Parties, including consent of each Party, is required for such matter; (e)&nbsp;in a manner that a Party reasonably believes would require it to perform any act that would cause such Party to violate any Applicable Law or the requirements of
any Regulatory Authority, or otherwise breach any of its obligations hereunder; or (f)&nbsp;that otherwise expand the rights or reduce the obligations of either Party under this Agreement. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Article&nbsp;5 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Co-Development and Co-Commercialization Options </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>5.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Co-Development and Co-Commercialization Options</B><B></B>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>5.1.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Option Grant</B>. Ionis hereby grants to Metagenomi the exclusive option to co-Develop and co-Commercialize
with Ionis the Licensed Products under a Drug Discovery Program (a &#147;<B>Co-Co Option</B>&#148;), which Co-Co Option may be exercised for (a)&nbsp;[***], (b)&nbsp;no more than one of the other three Drug Discovery Programs for the Wave 1 Targets,
and (c)&nbsp;no more than two Drug Discovery Programs for the Wave 2 Targets that become Collaboration Targets. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>5.1.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Option Period</B>. On a Drug Discovery Program-by-Drug Discovery Program basis, Metagenomi may exercise a
Co-Co Option for a Drug Discovery Program by delivering written notice to Ionis of such exercise at any time during the [***] after the selection of [***] for such Drug Discovery Program (such notice, the &#147;<B>Co-Co Option Notice</B>&#148;, and
such [***], the &#147;<B>Co-Co Option Period</B>&#148;). Notwithstanding the foregoing, Metagenomi may terminate the Co-Co Option Period for a Drug Discovery Program early by providing written notice to Ionis at any time during such [***] that
Metagenomi does not elect to exercise its Co-Co Option for such Drug Discovery Program and, upon Ionis&#146; receipt of any such written notice the Co-Co Option Period for such Drug Discovery Program, the Co-Co Option Period for such Drug Discovery
Program will be deemed to have expired </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
and Metagenomi may not thereafter exercise the Co-Co Option for such Drug Discovery Program. No more than [***] at Metagenomi&#146;s request during the Co-Co Option Period for a Drug Discovery
Program, Ionis will provide Metagenomi with [***] (&#147;<B>Option Package</B>&#148;). For clarity, Ionis will not be required to generate any additional data or information that is not in existence as of the date of Metagenomi&#146;s request for an
Option Package. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>5.1.3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Option Exercise</B>. If Metagenomi decides to exercise the Co-Co Option for a particular Drug Discovery
Program, then it will deliver written notice to Ionis of such determination during the applicable Co-Co Option Period, which notice will indicate the Drug Discovery Program for which Metagenomi elects to exercise the Co-Co Option, and (a)&nbsp;the
Drug Discovery Program for which Metagenomi is exercising its Co-Co Option will automatically be deemed a &#147;Co-Co Program&#148; and all Licensed Products under such Drug Discovery Program will automatically be deemed &#147;Co-Co Products,&#148;
(b)&nbsp;Metagenomi will pay Ionis the Option Exercise Fee for such Co-Co Program pursuant to <U>Section&nbsp;9.3</U> (Option Exercise Fee), and (c)&nbsp;the Parties will enter into a Co-Development and Co-Commercialization Agreement for such Co-Co
Program in accordance with <U>Section&nbsp;5.2</U> (Development and Commercialization of the Co-Co Products; Opt-Down Right). Any Drug Discovery Program for which Metagenomi does not exercise a Co-Co Option prior to the expiration of the applicable
Co-Co Option Period will automatically be deemed an &#147;Ionis Program&#148; and all Licensed Products under such Drug Discovery Program will automatically be deemed &#147;Ionis Products&#148; and Ionis will have sole control under the Development
and Commercialization of such Ionis Products in accordance with<U> Article 6</U> (Development and Commercialization of the Ionis Products). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>5.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Development and Commercialization of the Co-Co Products; Opt-Down Right</B> . On a Co-Co
Program-by-Co-Co Program basis, promptly after Metagenomi exercises a Co-Co Option for a Co-Co Program, the Parties will negotiate in good faith the terms of a worldwide, co-exclusive (with Ionis) co-Development and co-Commercialization agreement
(the &#147;<B>Co-Development and Co-Commercialization Agreement</B>&#148;), which terms and conditions will be reasonable and customary for agreements of this type and will include a requirement that the Parties share all future Development,
Commercialization, and other Exploitation costs and all future profits with respect to the applicable Co-Co Products, with the Parties bearing the share of such costs 50:50 and Ionis being responsible for booking and recording revenue and on terms
to be specified in the Co-Development and Co-Commercialization Agreement; <I>provided</I>, that [***]. Each Co-Development and Co-Commercialization Agreement will include: (i)&nbsp;the right for Metagenomi to, upon written notice to Ionis, reduce
its share of any costs borne under the applicable Co-Co Program from 50% to any percentage between 50% and 25% and Ionis&#146; share of such costs will increase accordingly (such option, the &#147;<B>Opt-Down Right</B>&#148;); <I>provided</I> that
Metagenomi will continue to bear 50% of the costs of any then-ongoing Clinical Trials through the completion of any such ongoing Clinical Trials, (ii)&nbsp;each Party will receive a share of profits equal to the percentage of costs funded by such
Party following the exercise of the Opt-Down Right based on the percentage of costs that Metagenomi commits to funding in its notice of exercise of its Opt- Down Right, and (iii)&nbsp;Metagenomi may only exercise the Opt-Down Right during the period
beginning no earlier than [***] and no later than [***] prior to the [***]. Until the Parties execute the Co-Development and Co-Commercialization Agreement, Ionis will continue to conduct and will be solely responsible for, and continue to have sole
and exclusive control over, the Development and Manufacture of the applicable Co-Co Products. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>5.3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Escalation Procedure</B>. If the Parties, despite their good faith negotiations, are unable to agree
on the terms and conditions of any Co-Development and Co-Commercialization Agreement within [***] of the date of the applicable Co-Co Option Notice (or such longer time as mutually agreed by the Parties), then either Party may refer those terms and
conditions to which they have not mutually agreed to the Executive Officers, who will use reasonable efforts to reach agreement on such terms and conditions. If such Executive Officers are unable to reach consensus with respect to such terms and
conditions within [***] after such referral, then either Party may notify the other Party of its intent to invoke dispute resolution under <U>Section&nbsp;15.1.3</U> (Expedited Dispute Resolution). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>5.4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Metagenomi Opt-Out</B><B></B>. On a Co-Co Program-by-Co-Co Program basis, Metagenomi will have the
right to opt-out of its rights and obligations under this Agreement to the extent related to the Exploitation of the Co-Co Products under such Co-Co Program and the applicable Co-Development and Co-Commercialization Agreement for a Co-Co Program
(each such right, an &#147;<B>Opt-Out Right</B>&#148;). Metagenomi may exercise the Opt-Out Right for a Co-Co Program by providing written notice to Ionis of such election no later than [***] after [***] (the &#147;<B>Opt-Out Period</B>&#148;). If
Metagenomi exercises the Opt-Out Right for a Co-Co Program during the applicable Opt-Out Period pursuant to this <U>Section&nbsp;5.4</U> (Metagenomi Opt-Out), then from and after the date that is the later of (a)&nbsp;[***] following the date on
which [***] or (b)&nbsp;[***] (the &#147;<B>Opt-Out Date</B>&#148;), (i)&nbsp;the applicable Co-Development and Co-Commercialization Agreement will terminate and Ionis will have sole control over, and sole decision-making authority with respect to,
at its cost and expense, the Development, Commercialization, and other Exploitation of the Licensed Products under such Drug Discovery Program, (ii)&nbsp;the Licensed Products under such Drug Discovery Program will be deemed to be &#147;Ionis
Products&#148; and such Drug Discovery Program will be deemed to be an &#147;Ionis Program&#148;, in each case, from and after the Opt-Out Date, (iii)&nbsp;Ionis will thereafter pay any Ionis Product Development Milestone Payments, Ionis Product
Regulatory Milestone Payments, Ionis Product Sales Milestone Payments, and Ionis Royalties, in each case, that accrue as a result of the Exploitation of the applicable Ionis Products from and after the Opt-Out Date (<I>provided</I> that Ionis will
not be required to pay the first Ionis Product Development Milestone Payment, Ionis Product Regulatory Milestone Payment, or Ionis Product Sales Milestone Payment, as applicable, to accrue as a result of the Exploitation of the applicable Ionis
Products after the Opt-Out Date), (iv)&nbsp;Ionis will not be responsible for any Ionis Product Development Milestone Payments, Ionis Product Regulatory Milestone Payments, or Ionis Product Sales Milestone Payments that accrued prior to the Opt-Out
Date, and (v)&nbsp;Metagenomi will continue to bear its share of the costs of any Clinical Trials for the applicable Ionis Products that are ongoing as of the Opt-Out Date through the completion of such Clinical Trials. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Article&nbsp;6 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Development and Commercialization of the Ionis Products </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>6.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Development</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>6.1.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>General</B>. On an Ionis Program-by-Ionis Program basis, from and after expiration of the Drug
Discovery Term for an Ionis Product, Ionis will have sole control over, and sole decision-making authority with respect to, at its cost and expense, the Development of, and the performance of all Medical Affairs with respect to, such Ionis Product
in the Field in the Territory. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>6.1.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Reporting for the Ionis Products</B>. On an Ionis Program-by-Ionis Program basis, during the period
after [***], [***] per [***], Ionis will provide Metagenomi with a reasonably detailed report regarding the status of Ionis&#146; Development of the Ionis Products for such Ionis Program. At Metagenomi&#146;s reasonable request, no more than [***]
per [***], the Parties will meet to discuss the Development of the Ionis Products. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>6.1.3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Development Diligence for the Ionis Products</B>.<B></B> Ionis (acting directly or through one or
more Affiliates or Sublicensees) will use Commercially Reasonable Efforts to Develop and seek Regulatory Approval for at least [***] in [***]. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>6.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Commercialization. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>6.2.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>General</B>.<B></B> Ionis will have sole control over, and sole decision-making authority with
respect to, at its cost and expense, the Commercialization of the Ionis Products in the Field in the Territory. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>6.2.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Commercialization Diligence for the Ionis Products.</B> Following receipt by or on behalf of Ionis of
Regulatory Approval for an Ionis Product in a country, Ionis (acting directly or through one or more Affiliates or Sublicensees) will use Commercially Reasonable Efforts to Commercialize such Ionis Product in such country. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Article&nbsp;7 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Regulatory Affairs </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>7.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Regulatory Responsibility. </B>From and after the Effective Date, as between the Parties, Ionis will be
responsible for the preparation and submission of all Regulatory Submissions (including all meetings with Regulatory Authorities in connection with the same) for all Licensed Products, but, for clarity, not including Regulatory Submissions that
relate to proprietary Metagenomi components of Licensed Products to which Ionis will have a right of reference pursuant to <U>Section&nbsp;7.2</U> (Right of Reference),<B> [***]; </B><I>provided</I><B></B> that Metagenomi will assist Ionis or any of
its Affiliates or Sublicensees in its efforts to prepare and submit any such Regulatory Submissions in accordance with this<U> Article 7</U> (Regulatory Affairs). Ionis or any of its Affiliates or Sublicensees may file all such applications in its
own name (or in the name of its designee) and will own and control all such applications. On a Drug Discovery Program-by-Drug Discovery Program basis, at Ionis&#146; request at any time after a Development Candidate is selected for a Drug Discovery
Program, the JSC will discuss a high-level regulatory strategy for such Drug Discovery Program (&#147;<B>Regulatory Strategy</B>&#148;), which strategy will leverage Metagenomi&#146;s expertise with Regulatory Submissions for products that are
similar to the Licensed Product. For clarity, the JSC will not have any approval rights with respect to the Regulatory Strategy for any Drug Discovery Program and Ionis will have sole control over, and sole decision-making authority with respect to,
the Regulatory Submissions for the Licensed Products. Notwithstanding the foregoing, if Metagenomi exercises the Co-Co Option for one or more Drug Discovery Programs in accordance with <U>Section&nbsp;5.1</U> (Co-Development and Co-Commercialization
Options), then all Regulatory Submissions with respect to any Co-Co Product will be prepared in accordance with the terms set forth in the applicable Co-Development and Co-Commercialization Agreement.<B> </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>7.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Right of Reference. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>7.2.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Grant.</B> Metagenomi will grant, and hereby does grant, to Ionis and its Affiliates and Sublicensees a
&#147;Right of Reference,&#148; as that term is defined in 21 C.F.R. &#167; 314.3(b) (or any successor rule or analogous Applicable Law recognized outside of the United States), to all Regulatory Submissions (including any drug master files)
submitted by or on behalf of and Controlled by Metagenomi or any of its Affiliates that are necessary or reasonably useful to support any Regulatory Submissions for a Licensed Product to be made by Ionis, its Affiliates, or Sublicensees in the Field
in the Territory. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>7.2.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Assistance; Cooperation.</B> Ionis and its Affiliates and Sublicensees may use such right of reference
solely for the purpose of seeking, obtaining, supporting, and maintaining Regulatory Approval for the Licensed Products in the Field in the Territory. Metagenomi will use Commercially Reasonable Efforts to take such actions as may be reasonably
requested by Ionis to give effect to the intent of this <U>Section&nbsp;7.2</U> (Right of Reference), including, if requested by Ionis, (a)&nbsp;providing a signed statement that Ionis may rely on, and that the applicable Regulatory Authority may
access, Metagenomi or its Affiliate&#146;s Regulatory Submissions in support of Ionis&#146; application for Regulatory Approval for any Licensed Product, and (b)&nbsp;subject to the data sharing requirements under any privacy- related Applicable
Law, providing Ionis with any underlying raw data or information submitted by Metagenomi or its Affiliates to the Regulatory Authority with respect to the applicable Regulatory Submissions. Internal Costs incurred by Metagenomi in performing any
activities requested by Ionis pursuant to this <U>Section&nbsp;7.2.2</U> (Assistance; Cooperation) will be reimbursed in accordance with <U>Section&nbsp;3.4.4</U> (Costs of Support). </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>7.3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Regulatory Support. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>7.3.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Access to Data.</B> Metagenomi will use Commercially Reasonable Efforts to assist Ionis or any of its
Affiliates or Sublicensees in its efforts to prepare and submit any Regulatory Submissions to obtain, support, or maintain Regulatory Approvals for all Licensed Products in the Field in the Territory, including by providing Ionis with all data,
written reports, and other documentation generated by or on behalf of Metagenomi under the Drug Discovery Programs that is necessary or reasonably useful to support any Regulatory Submissions for a Licensed Product, as well as any necessary samples
and materials. Unless otherwise noted in the Development Supply Agreement or the Commercial Supply Agreement, the costs of Metagenomi providing such support will be reimbursed in accordance with <U>Section&nbsp;3.4.4</U> (Costs of Support).
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>7.3.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Review of Regulatory Submissions.</B> Ionis may (but, for clarity, is not required to) provide drafts of any
INDs or other Regulatory Submissions for the Licensed Products to Metagenomi prior to submission to the applicable Regulatory Authority for Metagenomi to review and provide comments. Metagenomi will use Commercially Reasonable Efforts to review and
provide any such requested comments in a timely manner and the costs of such support will be reimbursed in accordance with <U>Section&nbsp;3.4.4</U> (Costs of Support). </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Article&nbsp;8 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Manufacturing </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>8.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Metagenomi Manufacturing Responsibilities. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>8.1.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Metagenomi Supply Term.</B> Subject to <U>Section&nbsp;8.4</U> (Ionis&#146; Assumption of Manufacturing
Responsibilities), on a Drug Discovery Program-by-Drug Discovery Program basis, commencing on [***] until [***], or such other period as mutually agreed upon by the Parties (the &#147;<B>Metagenomi Supply Term</B>&#148;), Metagenomi will Manufacture
(a)&nbsp;all applicable Licensed Systems and certain components of the applicable Licensed Products (consistent with those components that Metagenomi manufactures for its own products) (collectively, the &#147;<B>MG Manufactured
Components</B>&#148;), in each case, that are needed by Ionis for use in its Development activities pursuant to the terms of a development supply agreement (the &#147;<B>Development Supply Agreement</B>&#148;) to be entered into between the Parties
and (b)&nbsp;all MG Manufactured Components needed by Ionis for use in its Commercialization activities pursuant to the terms of a commercial supply agreement (the &#147;<B>Commercial Supply Agreement</B>&#148;) to be entered into between the
Parties. Under the Development Supply Agreement and the Commercial Supply Agreement, Metagenomi will provide the MG Manufactured Components at a cost that represents the Cost of Goods for such MG Manufactured Components <I>plus</I> 15% (the
&#147;<B>Supply Price</B>&#148;). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>8.1.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Requested CMO.</B> If Metagenomi is, at any point during the Metagenomi Supply Term, Manufacturing any MG
Manufactured Components without engaging a CMO, then Ionis may, upon written notice to Metagenomi, require Metagenomi to engage a CMO mutually agreeable to the Parties to conduct Manufacturing under this Agreement (such CMO, the &#147;<B>Requested
CMO</B>&#148;). Within [***] of Metagenomi&#146;s receipt of such notice requesting Metagenomi engage a Requested CMO, Metagenomi will in good faith negotiate and enter into a written agreement with such Requested CMO for the purposes of
Manufacturing the MG Manufactured Components (such agreement, the &#147;<B>Requested CMO Contract</B>&#148;) and conduct a transfer of the Manufacturing Know-How to such Requested CMO and otherwise facilitate implementation of such Manufacturing
Know-How, in each case, in a manner consistent with Metagenomi&#146;s rights and obligations with respect to the Manufacturing Technology Transfer described in <U>Section&nbsp;8.5</U> (Manufacturing After the Metagenomi Supply Term). Metagenomi will
ensure that the Requested CMO Contract is expressly and freely assignable to and assumable by Ionis without the consent of the Requested CMO. Metagenomi will provide a draft of the Requested CMO Contract to Ionis prior to executing such Requested
CMO Contract for review and comment and will incorporate Ionis&#146; reasonable comments. If Metagenomi does not engage the Requested CMO within [***] of its receipt of notice requiring the engagement of such Requested CMO, then Ionis may terminate
the Metagenomi Supply Term and assume all Manufacturing responsibilities for the MG Manufactured Components. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>8.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Development Supply Agreement. </B>At such time as directed by the JSC, the Parties will negotiate in good
faith the terms of the Development Supply Agreement, and a related quality agreement, which agreements will govern the terms and conditions of the Manufacturing of the MG Manufactured Components for Development purposes; <I>provided</I> that if
Ionis needs any MG Manufactured Components for its Development activities prior to the Parties entering into the Development Supply Agreement, then Metagenomi will supply such MG Manufactured Components on a per-batch basis and Ionis will pay
Metagenomi on a per-batch basis at the Supply Price for each such batch. The Development Supply Agreement and the related quality agreement will include terms and conditions consistent with the principles set forth on <U>Schedule 8.2</U>
(Development Supply Agreement Key Terms).<B> </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>8.3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Commercial Supply Agreement. </B>At such time as directed by the JSC, the Parties will negotiate in good
faith the terms of the Commercial Supply Agreement, and a related quality agreement, which agreements will govern the terms and conditions of the Manufacturing of the MG Manufactured Components for Commercialization purposes. The Commercial Supply
Agreement and the related quality agreement will include terms and conditions consistent with the principles set forth on <U>Schedule 8.2</U> (Development Supply Agreement Key Terms), with such modifications that are reasonable and appropriate for a
commercial supply.<B> </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>8.4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Ionis&#146; Assumption of Manufacturing Responsibilities. </B>If, (a)&nbsp;[***], or (b)&nbsp;[***], then,
in either case, [***]. For clarity, [***].<B> </B></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>8.5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Manufacturing After the Metagenomi Supply Term. </B>If Ionis assumes all Manufacturing responsibilities for
the MG Manufactured Components in accordance with <U>Section&nbsp;8.1.2</U> (Requested CMO) or [***] or the Metagenomi Supply Term otherwise expires, then from and after such date, Ionis will have<B> </B>sole control over and sole decision-making
authority with respect to, at its cost and expense, all Manufacturing activities for the MG Manufactured Components; <B></B><I>provided</I><B></B> that, at Ionis&#146; request, Metagenomi will continue to Manufacture and supply MG Manufactured
Components to Ionis pursuant to the Development Supply Agreement or Commercial Supply Agreement (as applicable) until the earlier of [***] or [***]. Promptly upon Ionis&#146; request after expiration of the Metagenomi Supply Term, Metagenomi will,
if and as requested, assign the Requested CMO Contract to Ionis and effect a transfer to Ionis or its designee(s) (which designee may be an Affiliate or a Third Party manufacturer, and which Third Party manufacturer may be a primary, backup, or
second manufacturer of such MG Manufactured Component) of all Licensed Know-How that is necessary or reasonably useful to enable the Manufacture of each MG Manufactured Component (the &#147;<B>Manufacturing Know-How</B>&#148;) and to facilitate
implementation of the Manufacturing Know-How at facilities designated by Ionis (such transfer and implementation, as more fully described in this <U>Section&nbsp;8.5</U> (Manufacturing After the Metagenomi Supply Period), the &#147;<B>Manufacturing
Technology Transfer</B>&#148;). Metagenomi will provide all reasonable assistance requested by Ionis to enable Ionis (or its Affiliate or designated Third Party manufacturer, as applicable) to implement the Manufacturing Know-How at the facilities
designated by Ionis. If reasonably requested by Ionis, such assistance will include [***]. Without limiting the foregoing, in connection with the Manufacturing Technology Transfer, Metagenomi will cause all appropriate employees and representatives
of Metagenomi and its Affiliates to meet with employees or representatives of Ionis (or its Affiliate or designated Third Party manufacturer, as applicable) at the applicable manufacturing facility at mutually convenient times to assist with the
working up and use of the Manufacturing Know-How and with the training of the personnel of Ionis (or its Affiliate or designated Third Party manufacturer(s), as applicable) to the extent reasonably necessary to enable Ionis (or its Affiliate or
designated Third Party manufacturer(s), as applicable) to use and practice the Manufacturing Know-How. Each Party will be responsible for its own costs and expenses incurred in conducting the Manufacturing Technology Transfer.<B>
</B></P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Article&nbsp;9 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consideration; Financial Terms </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>9.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Upfront Payment</B>. Ionis will pay Metagenomi a one-time upfront payment of $80,000,000 (the
&#147;<B>Upfront Payment</B>&#148;) no later than [***] after the Effective Date. The Upfront Payment is non- creditable and non-refundable.<B> </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>9.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Wave 2 Target Selection Fee</B>. On a Wave 2 Target-by-Wave 2 Target basis, promptly following the
designation of a Wave 2 Target as a Collaboration Target in accordance with <U>Section&nbsp;2.1.4(c)</U> (Effects if a Proposed Target is Available), Metagenomi will invoice Ionis for the applicable amount set forth in <U>Table 9.2</U>, which amount
will be based on the applicable scenario for selection of such Wave 2 Target (each such payment, a &#147;<B>Wave 2 Target Selection Fee</B>&#148;). Ionis will pay such Wave 2 Target Selection Fee no later than [***] after receipt of such invoice.
For clarity, each Wave 2 Target Selection Fee is only payable once for each Wave 2 Target that is designated as a Collaboration Target.<B> </B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="3" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><U>Table 9.2</U> &#150; Wave 2 Target
Selection Fee</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Wave 2 Target Selection Scenario</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Wave&nbsp;2&nbsp;Target</B><br><B>Selection Fee</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Scenario 1</B>: If the Wave 2 Target is a target [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Scenario 2</B>: If the Wave 2 Target is a target [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Scenario 3</B>: If the Wave 2 Target is a target [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order for Scenario 2 of <U>Table 9.2</U> to apply, Metagenomi must
(a)&nbsp;[***] and (b)&nbsp;[***]. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>9.3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Option Exercise Fee</B>. On a Drug Discovery Program-by-Drug Discovery Program basis, if Metagenomi
exercises a Co-Co Option for a Drug Discovery Program during the applicable Co-Co Option Period in accordance with <U>Section&nbsp;5.1.3</U> (Option Exercise), then Metagenomi will reimburse Ionis in accordance with the terms set forth in this
<U>Section&nbsp;9.3</U> (Option Exercise Fee), which reimbursement will be equal to 50% of the Internal Costs and Out-of-Pocket Costs incurred by Ionis in the conduct of the Drug Discovery Activities for such Drug Discovery Program prior to the
exercise of the Co-Co Option for such Drug Discovery Program <B></B><I>minus</I><B></B> 50% of the Internal Costs and Out-of-Pocket Costs incurred by Metagenomi in the conduct of the Drug Discovery Activities for such Drug Discovery Program prior to
the exercise of the Co-Co Option for such Drug Discovery Program if such amount is a positive number (such amount, the &#147;<B>Option Exercise Fee</B>&#148; for such Drug Discovery Program). No later than [***] after the date on which Metagenomi
exercises a Co-Co Option for a Drug Discovery Program, each Party will deliver to the other Party a written report, with reasonable supporting documentation, that sets forth the Internal Costs and Out-of-Pocket Costs incurred by or on behalf of such
Party in connection with performance of the Drug Discovery Activities for such Drug Discovery Program (to the extent in accordance with the applicable Drug Discovery Plan) (each, a &#147;<B>Development Cost Share Notice</B>&#148;). Promptly after
delivery of each Development Cost Share Notice, Ionis will invoice Metagenomi for the Option Exercise Fee (if any) and Metagenomi will pay the Option Exercise Fee no later than [***] after receipt of Ionis&#146; invoice.<B>
</B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>9.4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Ionis Product Milestone Payments. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>9.4.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Ionis Product Development Milestone Payments.</B> Subject to the terms and conditions of this Agreement,
including <U>Section&nbsp;9.5</U> (Ionis Products for [***] Target Populations), (a)&nbsp;with respect to the [***] set forth below, on an Ionis Program- by-Ionis Program basis and (b)&nbsp;with respect to the [***] set forth below, on an Ionis
Product-by-Ionis Product basis, Ionis will pay one-time milestone payments to Metagenomi of the amounts set forth in <U>Table 9.4.1</U> (each, an &#147;<B>Ionis Product Development Milestone Payment</B>&#148;) upon the first achievement by Ionis or
any of its Affiliates or Sublicensees of each of the development milestone events set forth in <U>Table 9.4.1</U> (each, an &#147;<B>Ionis Product Development Milestone Event</B>&#148;) for each Ionis Program or Ionis Product (as applicable);
<I>provided</I> that, with respect to the [***] set forth below, on an Ionis Program-by-Ionis Program basis, if more than one Ionis Product for the same Ionis Program achieve an Ionis Product Development Milestone Event, then [***]. Each Ionis
Product Development Milestone Payment is payable only once for each Ionis Program or Ionis Product (as applicable), regardless of the number of times the corresponding Ionis Product Development Milestone Event is achieved for such Ionis Program or
Ionis Product (as applicable). If Ionis or its Affiliates or Sublicensees achieve all of the Ionis Product Development Milestone Events for an Ionis Product, then the Ionis Product Development Milestone Payments payable by Ionis under this
<U>Section&nbsp;9.4.1</U> (Ionis Product Development Milestone Payments) for such Ionis Product will not exceed $29,000,000. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="44%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="3" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><U>Table 9.4.1</U> &#150; Ionis Product
Development Milestones</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Ionis Product Development</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Milestone Event</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Ionis&nbsp;Product&nbsp;Development&nbsp;Milestone&nbsp;Payment</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>9.4.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Ionis Product Regulatory Milestone Payments.</B> Subject to the terms and conditions of this Agreement,
including <U>Section&nbsp;9.5</U> (Ionis Products for [***] Target Populations), on an Ionis Product-by-Ionis Product basis, Ionis will pay one-time milestone payments to Metagenomi of the amounts set forth in <U>Table 9.4.2</U> (each, an
&#147;<B>Ionis Product Regulatory Milestone Payment</B>&#148;) upon the first achievement by Ionis or any its Affiliates or Sublicensees of each of the regulatory milestone events set forth in <U>Table 9.4.2</U> (each, an &#147;<B>Ionis Product
Regulatory Milestone Event</B>&#148;) by an Ionis Product. Each Ionis Product Regulatory Milestone Payment is payable only once for each Ionis Product, regardless of the number of times the corresponding Ionis Product Regulatory Milestone Event is
achieved for an Ionis Product. If Ionis or its Affiliates or Sublicensees achieve all of the Ionis Product Regulatory Milestone Events for an Ionis Product, then the Ionis Product Regulatory Milestone Payments payable by Ionis under this
<U>Section&nbsp;9.4.2</U> (Ionis Product Regulatory Milestone Payments) for such Ionis Product will not exceed $60,000,000. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="42%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="3" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><U>Table 9.4.2</U> &#150; Ionis Product
Regulatory Milestones</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Ionis Product Regulatory</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Milestone Event</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Ionis&nbsp;Product&nbsp;Regulatory&nbsp;Milestone&nbsp;Payment</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>9.4.3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Ionis Product Sales Milestone Payments.</B> Subject to the terms and conditions of this Agreement, including
<U>Section&nbsp;9.5</U> (Ionis Products for [***] Target Populations), on an Ionis Product-by-Ionis Product basis, Ionis will pay one-time milestone payments to Metagenomi of the amounts set forth in <U>Table 9.4.3</U> (each, an &#147;<B>Ionis
Product Sales Milestone Payment</B>&#148;) upon the first achievement by Ionis or any of its Affiliates or Sublicensees of each of the sales milestone events set forth in <U>Table 9.4.3</U> (each, an &#147;<B>Ionis Product Sales Milestone
Event</B>&#148;) for an Ionis Product. Each Ionis Product Sales Milestone Payment is payable only once for each Ionis Product, regardless of the number of times the corresponding Ionis Product Sales Milestone Event is achieved for an Ionis Product.
If Ionis or its Affiliates or Sublicensees achieve all of the Ionis Product Sales Milestone Events for an Ionis Product, then the Ionis Product Sales Milestone Payments payable by Ionis under this <U>Section&nbsp;9.4.3</U> (Ionis Product Sales
Milestone Payments) for such Ionis Product will not exceed $250,000,000. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="37%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="3" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><U>Table 9.4.3</U> &#150; Ionis Product
Sales Milestones</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Ionis Product Sales Milestone Event</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Ionis&nbsp;Product&nbsp;Sales&nbsp;Milestone&nbsp;Payment</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">1.&#8195;&#8201;The first Calendar Year in which the aggregate Net Sales for an Ionis Product
exceed [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">2.&#8195;&#8201;The first Calendar Year in which the aggregate Net Sales for an Ionis Product
exceed [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">[***]</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">3.&#8195;&#8201;The first Calendar Year in which the aggregate Net Sales for an Ionis Product
exceed [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">4.&#8195;&#8201;The first Calendar Year in which the aggregate Net Sales for an Ionis Product
exceed [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">[***]</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>9.4.4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Notice; Payment; Skipped Milestones.</B> Ionis will provide Metagenomi with written notice upon the
achievement of each Ionis Product Development Milestone Event, Ionis Product Regulatory Milestone Event, and Ionis Product Sales Milestone Event, such written notice to be provided (a)&nbsp;with respect to any Ionis Product Development Milestone
Event or Ionis Product Regulatory Milestone Event within [***] after such achievement and (b)&nbsp;with respect to any Ionis Product Sales Milestone Event, on or prior to the date of delivery of the Ionis Royalty Report under
<U>Section&nbsp;9.6.4</U> (Ionis Royalty Reports) for the Calendar Year in which such milestone event is first achieved. Following receipt of such written notice, Metagenomi will promptly invoice Ionis for the applicable milestone payment and Ionis
will make the appropriate milestone payment within [***] after receipt of such invoice; <I>provided</I> that with respect to the first Ionis Product Development Milestone Event (for selection of the first Development Candidate for an Ionis Program),
Metagenomi may only invoice Ionis after [***], and Ionis will have no obligation to make any payment with respect to such Ionis Product Development Milestone Event unless [***] and Metagenomi provides Ionis with an invoice for the applicable amount.
Each Ionis Product Development Milestone Event is intended to be successive. If any Ionis Product Development Milestone Event does not occur with respect to an Ionis Product for an Ionis Program, then such skipped milestone event will be deemed to
have been achieved upon the achievement of the next successive milestone event with respect to an Ionis Product for such Ionis Program. Payment for any such skipped milestone that is owed in accordance with the provisions of the foregoing sentence
will be due concurrently with the payment for the next successive Ionis Product Development Milestone Event. If more than one Ionis Product Sales Milestone Event occurs with respect to an Ionis Product in the same Calendar Year, then payments with
respect to all applicable Ionis Product Sales Milestone Events will be paid for such Calendar Year. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>9.5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Ionis Products for [***] Target Populations</B>. If an Ionis Product is intended to treat target populations
with [***] (each such population, [***] &#147;[***]<B> Target Population</B>&#148;), then Ionis will notify Metagenomi and [***], in each case, for such Ionis Product, [***].<B> </B></P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>9.6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Ionis Product Royalty Payments. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>9.6.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Ionis Royalty Rates.</B> Subject to the terms and conditions of this Agreement, including the provisions of
<U>Section&nbsp;9.6.2</U>. (Adjustments to Ionis Royalties), on an Ionis Product-by- Ionis Product basis, Ionis will pay Metagenomi royalties based on the aggregate Annual Net Sales of each Ionis Product at the rates set forth in <U>Table 9.6.1</U>.
On an Ionis Product- by-Ionis Product and country-by-county basis such royalties will be payable until the expiration of the applicable Royalty Term for each Ionis Product in such country. The royalty payments made pursuant to this
<U>Section&nbsp;9.6.1</U> (Ionis Royalty Rates), the &#147;<B>Ionis Royalties</B>&#148; and the rates set forth in <U>Table 9.6.1</U>, the &#147;<B>Ionis Royalty Rates</B>.&#148; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="3" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><U>Table 9.6.1</U> &#150; Royalty Rates for
Ionis Products</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Annual Net Sales of an Ionis Product in the
Territory</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><I>Royalty</I></B><br><B><I>Rate as a</I></B><br><B><I>Percentage</I></B><br><B><I>of Net</I></B><br><B><I>Sales</I></B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Portion of Annual Net Sales of each Ionis Product that is less than or equal to [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Portion of Annual Net Sales of each Ionis Product that is greater than [***], and less than or
equal to [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">[***]</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Portion of Annual Net Sales for each Ionis Product that is greater than [***], and less than or
equal to [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Portion of Annual Net Sales of each Ionis Product that is greater than [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">[***]</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:15%; font-size:10pt; font-family:Times New Roman">By way of example only, if the Annual Net Sales for an Ionis Product are [***] for a given Calendar Year, then
the Ionis Royalties payable with respect to such Annual Net Sales for such Ionis Product in such Calendar Year, subject to adjustment as set forth in <U>Section&nbsp;9.6.2</U> (Adjustment to Ionis Royalties) would be: [***] + [***] + [***] + [***] =
[***]. For the avoidance of doubt, the obligation to pay Ionis Royalties will be imposed only once with respect to the same unit of an Ionis Product. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>9.6.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Adjustments to Ionis Royalties. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Expiration of Valid Claims.</B> Subject to <U>Section&nbsp;9.6.3</U> (Cumulative Effect of Ionis Royalty
Reductions), on an Ionis Product-by-Ionis Product and country-by-country basis in the Territory, if during the Royalty Term for an Ionis Product in a given country there is no Valid Claim of a Royalty Bearing Patent Right Covering such Ionis Product
in such country, then commencing in the first Calendar Quarter after the date on which this <U>Section&nbsp;9.6.2(a)</U> (Expiration of Valid Claims) applies and for the remainder of the Royalty Term for such Ionis Product in such country, the
Annual Net Sales for such Ionis Product in such country will be reduced by [***] for purposes of calculating the Ionis Royalties owed under <U>Section&nbsp;9.6.1</U> (Ionis Royalty Rates). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Biosimilar Product.</B> Subject to <U>Section&nbsp;9.6.3</U> (Cumulative Effect of Ionis Royalty
Reductions), if, on an Ionis Product-by-Ionis Product and country-by-country basis, a Biosimilar Product with respect to an Ionis Product is approved for sale in a country, then commencing in the Calendar Quarter in which such approval was obtained
and continuing for the remainder of the Royalty Term for such Ionis Product in such country, the Annual Net Sales for such Ionis Product in such country will be reduced by [***] for purposes of calculating the Ionis Royalties owed under
<U>Section&nbsp;9.6.1</U> (Ionis Royalty Rates). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Third Party Payments.</B> Subject to <U>Section&nbsp;9.6.3</U> (Cumulative Effect of Ionis Royalty
Reductions), Ionis will be entitled to credit against the Ionis Royalties due to Metagenomi in a given Calendar Quarter [***] of (i)&nbsp;[***] that are actually paid by Ionis or any of its Affiliates or Sublicensees to any Third Party in
consideration for rights under any Patent Right, Know-How, or other intellectual property owned or controlled by such Third Party (whether by acquisition or license) (such rights, &#147;<B>Third Party IP</B>&#148;) that is acquired or licensed by
Ionis or any of its Affiliates or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="23%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Sublicensees after the Effective Date, and [***] useful for Ionis or any of its Affiliates or Sublicensees to Exploit a Development Candidate as such Development Candidate exists as of the date
of expiration of the Drug Discovery Term for the applicable Drug Discovery Program, and (ii)&nbsp;[***] (such amount in (i)&nbsp;or (ii), the &#147;<B>Third Party Payment</B>&#148;). Notwithstanding the foregoing, Third Party Payment shall exclude
[***]. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>9.6.3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Cumulative Effect of Ionis Royalty Reductions.</B> In no event will the royalty reductions for Ionis
Products permitted under <U>Section&nbsp;9.6.2(a)</U> (Expiration of Valid Claims), <U>Section&nbsp;9.6.2(b)</U> (Biosimilar Product), or <U>Section&nbsp;9.6.2(c)</U> (Third Party Payments), alone or together, reduce the Ionis Royalties due to
Metagenomi for an Ionis Product in a given Calendar Quarter by more than [***] of the applicable Ionis Royalties that would otherwise be owed on the Annual Net Sales of such Ionis Product. If Ionis would, but for the restriction set forth in this
<U>Section&nbsp;9.6.3</U> (Cumulative Effect of Ionis Royalty Reductions), have the right to reduce the Ionis Royalties due to Metagenomi by more than [***], then [***]. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>9.6.4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Ionis Royalty Reports.</B> Commencing on the First Commercial Sale of an Ionis Product and for so long as
Ionis Royalties are due under this Agreement, no later than (a)&nbsp;[***] prior to the start of each Calendar Year, Ionis will deliver a written good faith nonbinding estimate to Metagenomi of the projected Net Sales for the upcoming Calendar Year,
(b)&nbsp;[***] after the end of each Calendar Quarter, Ionis will deliver a written good faith non-binding estimate to Metagenomi of the Net Sales in the relevant Calendar Quarter and the Ionis Royalties payable on such Net Sales, and (c)&nbsp;[***]
after the end of each Calendar Quarter, Ionis will deliver a written report (each, an &#147;<B>Ionis Royalty Report</B>&#148;) to Metagenomi specifying on an Ionis Product-by-Ionis Product and country- by-country basis: (i)&nbsp;Net Sales in the
relevant Calendar Quarter; (ii)&nbsp;to the extent such Net Sales include sales not denoted in US Dollars, a summary of the then-current exchange rate methodology(ies) used for the calculation of Net Sales in accordance with <U>Section&nbsp;9.14</U>
(Currency of Payment; Non-Refundable Payments); (iii)&nbsp;the Ionis Royalties payable on such Net Sales; and (iv)&nbsp;if applicable, the Ionis Product Sales Milestone Payments owed to Metagenomi in the relevant Calendar Quarter. All Ionis Royalty
Reports will be the Confidential Information of Ionis. Ionis will pay the Ionis Royalties for each Calendar Quarter no later than [***] after receipt of an invoice from Metagenomi, which invoice will be provided promptly following Metagenomi&#146;s
receipt of each Ionis Royalty Report from Ionis pursuant to this <U>Section&nbsp;9.6.4</U> (Ionis Royalty Reports). For clarity, the submission by Metagenomi of an invoice to Ionis based on an Ionis Royalty Report will be without prejudice to
Metagenomi&#146;s right to dispute an Ionis Royalty Report or to audit an Ionis Royalty Report pursuant to <U>Section&nbsp;9.13</U> (Records and Audits). </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>9.7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Existing In-License Agreements. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>9.7.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Effective Date Licensed Technology; Existing Metagenomi In-License Agreements</B>. Metagenomi hereby
represents and warrants that none of the Licensed Technology Controlled by Metagenomi as of the Effective Date is in-licensed or acquired by Metagenomi under agreements with Third Party licensors or sellers. On a Collaboration
Target-by-Collaboration Target basis, if any Patent Rights or Know-How, as of the date a Proposed Target becoming a Collaboration Target pursuant to <U>Section&nbsp;2.1.4(c)</U> (Effects if a Proposed Target is Available), have been acquired or
in-licensed by Metagenomi and if solely owned by Metagenomi without any encumbrance or restriction on licensing, would constitute Licensed Technology as a result of such Proposed Target becoming a
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Collaboration Target pursuant to <U>Section&nbsp;2.1.4(c)</U> (Effects if a Proposed Target is Available) (any such agreement, an &#147;<B>Existing Potential Metagenomi In-License
Agreement</B>&#148;), then Metagenomi will, within [***] of the applicable Proposed Target becoming a Collaboration Target, provide Ionis with (a)&nbsp;notice and a copy of such Existing Potential Metagenomi In-License Agreements (which may be
redacted to exclude provisions thereof that would not be applicable to Ionis as a licensee or sublicensee (as the case may be)), and (b)&nbsp;any disclosures that would be made against the representations and warranties in <U>Section&nbsp;12.2</U>
(Additional Representations of Metagenomi) if such Existing Potential Metagenomi In-License Agreements were to become Metagenomi In-License Agreements. If Ionis provides written notice, within [***] of receipt of such information from Metagenomi,
that it would like to have any such Existing Potential Metagenomi In-License Agreement included in the licenses granted under this Agreement and be subject to the terms of such Existing Potential Metagenomi In-License Agreement that are applicable
to a licensee or sublicensee (as the case may be) thereunder, then such intellectual property rights described in such notice will automatically be deemed included in the Licensed Technology, and such Existing Potential Metagenomi In-License
Agreement will be considered a Metagenomi In-License Agreement. Except as otherwise provided in this Agreement, as between the Parties, Metagenomi will be responsible for all payments that arise under any license or other agreement to which
Metagenomi or its Affiliate is a party, including any Metagenomi In-License Agreement, in connection with this Agreement, including with respect to the Development, Manufacture, and Commercialization of Licensed Products. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>9.7.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Existing Potential Ionis In-License Agreements</B>. With respect to any Patent Rights or Know-How that are
the subject of an Ionis IP Option and are in-licensed or acquired by Ionis from any Third Party as of the applicable Ionis IP Option Effective Date (any such agreement, an &#147;<B>Existing Potential Ionis In-License Agreement</B>&#148;), Ionis
will, within [***] of the applicable Ionis IP Option Effective Date, provide Metagenomi with notice and a copy of each such Existing Potential Ionis In-License Agreement (which may be redacted to exclude provisions thereof that would not be
applicable to Metagenomi as a licensee or sublicensee (as the case may be)). If Metagenomi provides written notice, within [***] of receipt of such information from Ionis, that it would like to have any such Existing Potential Ionis In-License
Agreement included in the licenses granted under this Agreement and be subject to the terms of such Existing Potential Ionis In-License Agreement that are applicable to a licensee or sublicensee (as the case may be) thereunder, then such
intellectual property rights described in such notice will automatically be deemed included in the Ionis Background Technology and such Existing Potential Ionis In-License Agreement will be considered an Ionis In-License Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>9.8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>New In-License Agreements. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>9.8.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Proposed New In-License Agreements.</B> Either Party (an &#147;<B>Acquiring Party</B>&#148;) may, during the
Term, acquire or in-license rights to additional intellectual property from a Third Party that, if solely owned by such Party, without any encumbrance or restriction on licensing, would constitute Licensed Technology (if such Acquiring Party is
Metagenomi) or Ionis Background Technology (if such Acquiring Party is Ionis) (any such agreement entered into by Metagenomi, a &#147;<B>Proposed New Metagenomi In-License Agreement</B>,&#148; any such agreement entered into by Ionis, a
&#147;<B>Proposed New Ionis In-License Agreement</B>,&#148; and any Proposed New Metagenomi In-License Agreements or Proposed New Ionis In-License Agreements, a &#147;<B>Proposed New In-License Agreement</B>&#148;). Any such Proposed New In-License
Agreement will be freely licensable or sublicensable to the non-Acquiring Party </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
to the same extent that Licensed Technology or Ionis Background Technology (as applicable) is licensed to the non-Acquiring Party hereunder (including the right to grant sublicenses through
multiple tiers) and will not (a)&nbsp;impose any material restrictions or obligations on the non-Acquiring Party as a licensee or sublicensee or (b)&nbsp;disadvantage the non-Acquiring Party, in each case ((a) and (b)), as compared to any other
potential licensee or sublicensee under such Proposed New In-License Agreement. The Acquiring Party will [***] include in any such Proposed New In-License Agreement that is an in-license a provision pursuant to which [***]. Promptly following
execution of a Proposed New In-License Agreement, the Acquiring Party will provide the non-Acquiring Party with a copy of such Proposed New In-License Agreement (which may be redacted to exclude provisions thereof that would not be applicable to the
non-Acquiring Party as a licensee or sublicensee (as the case may be)). </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>9.8.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Acceptance of a Proposed In-License Agreement.</B> If the non-Acquiring Party provides written notice,
within [***] of receipt of a Proposed New In-License Agreement, that it would like to have such intellectual property rights included in the licenses granted under this Agreement and be subject to the terms of such Proposed New In-License Agreement
that are applicable to a licensee or sublicensee (as the case may be) thereunder, then such intellectual property rights described in such notice will automatically be deemed included in the Licensed Technology (if such Acquiring Party is
Metagenomi) or Ionis Background Technology (if such Acquiring Party is Ionis) (any such Proposed New Metagenomi In-License Agreement with respect to intellectual property rights that are included in the Licensed Technology pursuant to this sentence,
a &#147;<B>New Metagenomi In-License Agreement</B>,&#148; any such Proposed New Ionis In-License Agreement with respect to intellectual property rights that are included in the Ionis Background Technology pursuant to this sentence, a &#147;<B>New
Ionis In-License Agreement</B>&#148; and any New Metagenomi In-License Agreement or New Ionis In-License Agreement, a &#147;<B>New In-License Agreement</B>&#148;). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>9.9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Payment Obligations Under Certain In-License Agreements. </B>Any payment obligations arising under the
Metagenomi In-License Agreements or the Ionis In-License Agreements that are directly a result of the Development, Manufacture, or Commercialization of a Licensed Product or Metagenomi Product (as applicable) in the Field by or on behalf of the
non-Acquiring Party or any of its Affiliates or Sublicensees, after application of all available reductions to and deductions from such payment obligations under the applicable agreement (but, for the avoidance of doubt, excluding [***] will be paid
by [***] and reimbursed by the [***] in accordance with this <U>Section&nbsp;9.9</U> (Payment Obligations Under Certain In-License Agreements), but, with respect to [***], subject to [***] pursuant to <U>Section&nbsp;9.6.2(c)</U> (Third Party
Payments). Except as set forth in the immediately preceding sentence, [***] will be responsible for [***] under such agreements (including [***]). [***] will provide the [***] with a reasonably detailed invoice for any payments made by the [***]
under a Metagenomi In-License Agreement or Ionis In-License Agreement that are [***] pursuant to this <U>Section&nbsp;9.9</U> (Payment Obligations Under Certain In-License Agreements) within [***], and [***] will pay the undisputed portion of such
invoices within [***] of receipt thereof. For clarity, the [***] and its Affiliates will be [***] under a Metagenomi In-License Agreement or Ionis In-License Agreement one time only. Notwithstanding the foregoing, the [***] may, in its sole
discretion, notify [***] that it elects to abandon its payment obligations under this <U>Section&nbsp;9.9</U> (Payment Obligations Under Certain In-License Agreements) with respect to a Metagenomi In-License Agreement or Ionis In-License Agreements,
whereupon such agreement will no longer be deemed to be a Metagenomi In-License Agreement or Ionis In-License Agreements under this Agreement (as applicable) and the [***] will no longer be responsible for such payment obligations from and after the
date of such notice.<B> </B></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>9.10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Metagenomi Product Economics. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>9.10.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Metagenomi Product Milestone Payments.</B> If Metagenomi exercises the Ionis IP Option in accordance
with <U>Section&nbsp;2.7</U> (Ionis Proprietary Toolbox of Chemical Modifications), then, on a Metagenomi Product-by-Metagenomi Product basis, Metagenomi will pay one-time milestone payments to Ionis of the amounts set forth in <U>Table 9.10.1</U>
(each, a &#147;<B>Metagenomi Product Milestone Event</B>&#148;) upon the first achievement by Metagenomi or any of its Affiliates or Sublicensees of each of the milestone events set forth in <U>Table 9.10.1</U> (each, a &#147;<B>Metagenomi Product
Milestone Payment</B>&#148;) for a Metagenomi Product. Each Metagenomi Product Milestone Payment is payable only once for each Metagenomi Product, regardless of the number of times the corresponding Metagenomi Product Milestone Event is achieved for
a Metagenomi Product. If Metagenomi or its Affiliates or Sublicensees achieve all of the Metagenomi Product Milestone Events for a Metagenomi Product, then the Metagenomi Product Milestone Payments payable by Metagenomi under this
<U>Section&nbsp;9.10.1</U> (Metagenomi Product Milestone Payments) for such Metagenomi Product will not exceed [***]. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="69%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="39%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="3" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><U>Table 9.10.1</U> &#150; Metagenomi
Product Milestones</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Metagenomi Product Milestone Event</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Metagenomi&nbsp;Product&nbsp;Milestone&nbsp;Payment</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>9.10.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Notice; Payment; Skipped Milestones.</B> Metagenomi will provide Ionis with written notice upon the
achievement of each Metagenomi Product Milestone Event within [***] after such achievement and will pay Ionis within [***] after receipt of an invoice from Ionis. Each Metagenomi Product Milestone Event is intended to be successive. If any
Metagenomi Product Milestone Event does not occur with respect to a Metagenomi Product, then such skipped milestone event will be deemed to have been achieved upon the achievement of the next successive milestone event with respect to such
Metagenomi Product; <I>provided</I> that the [***] Metagenomi Product Milestone Event shall not be deemed to have been achieved upon the achievement of the [***] Metagenomi Product Milestone Event. Payment for any such skipped milestone that is owed
in accordance with the provisions of the foregoing sentence will be due concurrently with the payment for the next successive Metagenomi Product Milestone Event. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>9.10.3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Metagenomi Royalties.</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Metagenomi Royalty Rates</B>. Subject to the terms and conditions of this Agreement, including the
provisions of <U>Section&nbsp;9.10.3(b)</U> (Adjustments to Metagenomi Royalties), on a Metagenomi Product-by-Metagenomi Product and country-by-country basis, Metagenomi will pay Ionis an amount equal to [***] of the Net Sales of the applicable
Metagenomi Product in a country in the Territory by Metagenomi and its Affiliates and its Sublicensees until the expiration of the applicable Metagenomi Royalty Term for such Metagenomi Product in such country. The royalty payments made pursuant to
this <U>Section&nbsp;9.10.3(a)</U> (Metagenomi Royalty Rates), the &#147;<B>Metagenomi Royalties</B>&#148; and the rate set forth in this <U>Section&nbsp;9.10.3(a)</U> (Metagenomi Royalty Rates), the &#147;<B>Metagenomi Royalty Rate</B>.&#148;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Adjustment to Metagenomi Royalties</B>. On a Metagenomi Product-by- Metagenomi Product and
country-by-country basis in the Territory, if during the Metagenomi Royalty Term for a Metagenomi Product in a given country there is no Valid Claim of a Patent Right within the Ionis Background Technology Covering such Metagenomi Product in such
country, then commencing in the first Calendar Quarter after the date on which this <U>Section&nbsp;9.10.3(b)</U> (Adjustments to Metagenomi Royalties) applies and for the remainder of the Royalty Term for such Metagenomi Product in such country,
the Net Sales for such Metagenomi Product in such country will be reduced by [***] for purposes of calculating the Metagenomi Royalties owed under <U>Section&nbsp;9.10.3(a)</U> (Metagenomi Royalty Rates). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>9.10.4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Metagenomi Royalty Reports</B>. Commencing on the First Commercial Sale (applied <I>mutatis mutandis</I>) of
a Metagenomi Product and for so long as Metagenomi Royalties are due under this Agreement, no later than (a)&nbsp;[***] prior to the start of each Calendar Year, Metagenomi will deliver a written good faith non-binding estimate to Ionis of the
projected Net Sales for the upcoming Calendar Year, (b)&nbsp;[***] after the end of each Calendar Quarter, Metagenomi will deliver a written good faith non-binding estimate to Ionis of the Net Sales in the relevant Calendar Quarter and the
Metagenomi Royalties payable on such Net Sales, and (c)&nbsp;[***] after the end of each Calendar Quarter, Metagenomi will deliver a written report (each, a &#147;<B>Metagenomi Royalty Report</B>&#148;) to Ionis specifying on a Metagenomi
Product-by-Metagenomi Product and country-by-country basis: (i)&nbsp;Net Sales in the relevant Calendar Quarter; (ii)&nbsp;to the extent such Net Sales include sales not denoted in US Dollars, a summary of the then-current exchange rate
methodology(ies) used for the calculation of Net Sales in accordance with <U>Section&nbsp;9.14</U> (Currency of Payment; Non-Refundable Payments); and (iii)&nbsp;the Metagenomi Royalties payable on such Net Sales. All Metagenomi Royalty Reports will
be the Confidential Information of Metagenomi. Metagenomi will pay the Metagenomi Royalties for each Calendar Quarter no later than [***] after receipt of an invoice from Ionis, which invoice will be provided promptly following Ionis&#146; receipt
of each Metagenomi Royalty Report from Metagenomi pursuant to this <U>Section&nbsp;9.10.4</U> (Metagenomi Royalty Reports). For clarity, the submission by Ionis of an invoice to Metagenomi based on a Metagenomi Royalty Report will be without
prejudice to Ionis&#146; right to dispute a Metagenomi Royalty Report or to audit a Metagenomi Royalty Report pursuant to <U>Section&nbsp;9.13</U> (Records and Audits). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>9.11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Other Payments.</B> With respect to any amounts owed under this Agreement by one Party to the other
for which no other invoicing and payment procedure is otherwise specified in this Agreement, a Party will provide an invoice, together with reasonable supporting documentation, to the other Party for such amounts. The owing Party will pay any
undisputed amounts within [***] of receipt of the invoice, and any disputed amounts owed by a Party will be paid within [***] of resolution of the dispute in accordance with <U>Section&nbsp;15.1</U> (Dispute Resolution). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>9.12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Right to Offset.</B> Ionis will have the right to offset any amount owed by Metagenomi to Ionis that
are (a)&nbsp;[***], or (b)&nbsp;[***], in each case, against any payments owed by Ionis to Metagenomi under this Agreement. Such offsets will be in addition to any other rights or remedies available under this Agreement and Applicable Law. For
clarity, the foregoing right to offset will only apply to [***]. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>9.13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Records and Audits. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>9.13.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Books and Records.</B> Each Party will keep (and will cause its Affiliates and Sublicensees to keep)
complete and accurate books and records pertaining to (a)&nbsp;in the case of Ionis, all Internal Costs and Out-of-Pocket Costs incurred in connection with the performance of the Drug Discovery Activities, Net Sales of Ionis Products, any amounts
paid under any Ionis In-License Agreement, and any costs shared by the Parties for the Co-Co Products pursuant to a Co-Development and Co-Commercialization Agreement (the &#147;<B>Ionis Records</B>&#148;) and (b)&nbsp;in the case of Metagenomi, all
Internal Costs and Out-of-Pocket Costs incurred in connection with the performance of the Collaboration Activities, Net Sales of the Metagenomi Products, any amounts paid under any Metagenomi In-License Agreement, and any costs shared by the Parties
for the Co-Co Products pursuant to a Co-Development and Co-Commercialization Agreement (the &#147;<B>Metagenomi Records</B>&#148;), in each case ((a) and (b)), in reasonable detail to permit the other Party to confirm the accuracy of all payments or
costs reported for at least the preceding [***]. During the Term and for a period of [***] thereafter, each Party (the &#147;<B>Auditing Party</B>&#148;) may, upon written request and subject to this <U>Section&nbsp;9.13</U> (Records and Audits),
cause a nationally-recognized independent accounting firm (the &#147;<B>Auditor</B>&#148;), that is reasonably acceptable to the other Party (the &#147;<B>Audited Party</B>&#148;) to inspect the relevant records of such Audited Party and its
Affiliates to verify the payments made and amounts reported by the Audited Party and the directly related reports, statements, and books of accounts, as applicable. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>9.13.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Audit Procedure.</B> Before beginning its audit, the Auditor will execute a written agreement
acceptable to the Audited Party by which the Auditor agrees to keep confidential all information reviewed during the audit, which agreement will contain terms of non-disclosure and non-use no less stringent than those set forth in this Agreement,
but otherwise will be reasonable and customary for the purposes of an audit of this nature. The Auditor will have the right to disclose to the Auditing Party only its conclusions regarding any payments owed under this Agreement. Each Party and its
Affiliates will make their records available for inspection by the Auditor during regular business hours at such place or places where such records are customarily kept, upon receipt of reasonable advance notice from the Auditing Party. The records
will be reviewed solely to verify the Audited Party&#146;s compliance with the payment obligations and financial terms of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>9.13.3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Frequency; Overpayments and Underpayments.</B> Such inspection right will not be exercised more than
[***] and not more frequently than [***] with respect to records covering any specific period of time. In addition, the Auditing Party will only be entitled to audit the books and records of the Audited Party for the [***] prior to the [***] in
which the audit request is made. The Auditing Party agrees to hold in strict confidence all information received and all information learned in the course of any audit or inspection, except to the extent necessary to enforce its rights under this
Agreement or to the extent required to comply with any Applicable Law or judicial order. The Auditor will provide its audit report and basis for any determination to the Audited Party at the time such report is provided to the Auditing Party before
it is considered final. If the final result of the inspection reveals an underpayment or overpayment by either Party, then the underpaid or overpaid amount will be settled promptly plus interest due on any underpayments in accordance with
<U>Section&nbsp;9.15</U> (Late Fees). The Auditing Party will pay for such inspections, as well as its expenses associated with enforcing its rights with respect to any payments hereunder; unless such audit reveals an underpayment of amounts owed
to, or an overpayment of amounts owed by, the Auditing Party of more than [***] of the amount that was owed by the Audited Party or owed to the Audited Party, as applicable, with respect to the relevant period, in which case, the Audited Party will
reimburse the Auditing Party for the reasonable expense incurred by the Auditing Party in connection with the audit. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>9.14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Currency of Payment; Non-Refundable Payments.</B> All amounts to be paid pursuant to this Agreement
will be made in United States Dollars and will be paid by wire transfer in immediately available funds to a bank account designated by the receiving Party. The rate of exchange to be used in computing the amount of currency equivalent in U.S.
Dollars owed to a Party under this Agreement will be the paying Party&#146;s then-current standard exchange rate methodology employed for the translation of foreign currency sales into U.S. Dollars in accordance with its Accounting Standards and
consistently applied during the period. Any provisions of this Agreement that describe a payment as non-refundable will be without prejudice to either Party&#146;s right to bring a claim for breach of this Agreement, misrepresentation, or any other
claim permissible under Applicable Law, including seeking recovery of payments made and damages for loss. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>9.15.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Late Fees.</B> If a Party does not receive payment of any undisputed sum due to it on or before the due date
set forth under this Agreement, then simple interest will thereafter accrue on the sum due to such Party from the due date until the date of payment at a per-annum rate of [***] or the maximum rate allowable under Applicable Law, whichever is lower.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>9.16.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Currency Restrictions.</B> If, by reason of Applicable Law in any country, it becomes impossible or
illegal for a Party to transfer, or have transferred on its behalf, payments owed to the other Party hereunder, then such Party will promptly notify the other Party of the conditions preventing such transfer and such payments will be deposited in
local currency in the relevant country to the credit of the other Party in a recognized banking institution designated by the other Party or, if none is designated by the other Party within a period of [***], in a recognized banking institution
selected by the transferring Party, as the case may be, and identified in a written notice given to the other Party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>9.17.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Withholding Taxes</B>.<B> </B>Either Party (a <B></B>&#147;<B></B><B>Withholding Party</B>&#148;) may
withhold from payments due to the other Party (a &#147;<B>Non-Withholding Party</B>&#148;) amounts for payment of any withholding tax that is required by Applicable Law to be paid to any taxing authority with respect to such payments, which will be
remitted in accordance with Applicable Law. The Withholding Party will provide to the Non-Withholding Party all relevant documents and correspondence, and will also provide to the Non-Withholding Party any other cooperation or assistance on a
reasonable basis as may be necessary to enable the Non-Withholding Party to claim exemption from such withholding taxes and to receive a refund of such withholding tax or claim a foreign tax credit. The Withholding Party will give proper evidence
from time to time as to the payment of any such tax. The Parties will cooperate with each other in seeking deductions under any double taxation or other similar treaty or agreement from time to time in force. Such cooperation may include the
Withholding Party making payments from a single source in the U.S., where possible. Notwithstanding the foregoing, [***]. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Article&nbsp;10 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Intellectual Property </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>10.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Ownership of Inventions. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>10.1.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Background Intellectual Property.</B> As between the Parties, and subject to the licenses granted
under this Agreement, each Party retains all rights, title, and interests in and to all Intellectual Property Rights that such Party owns or Controls as of the Effective Date or that it develops or otherwise acquires after the Effective Date outside
the performance of the activities under this Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>10.1.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>By Inventorship.</B> For purposes of determining ownership under this <U>Section&nbsp;10.1.2</U> (By
Inventorship), inventorship will be determined in accordance with United States patent laws (regardless of where the applicable activities occurred). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Metagenomi Collaboration Technology</B>. Metagenomi will be the sole owner of any Know-How
discovered, developed, invented, or created solely by Metagenomi or its Affiliates or Third Parties acting on its or their behalf, in each case, in the performance of activities under this Agreement (&#147;<B>Metagenomi Collaboration
Know-How</B>&#148;) and any Patent Rights that Cover the Metagenomi Collaboration Know-How (&#147;<B>Metagenomi Collaboration Patent Rights</B>&#148; and together with the Metagenomi Collaboration Know-How, the &#147;<B>Metagenomi Collaboration
Technology</B>&#148;), and will retain all of its rights thereto, subject to any rights or licenses expressly granted by Metagenomi to Ionis under this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Ionis Collaboration Technology</B>. Ionis will be the sole owner of any Know-How discovered,
developed, invented, or created solely by Ionis or its Affiliates or Third Parties acting on its or their behalf, in each case, in the performance of activities under this Agreement (&#147;<B>Ionis Collaboration Know-How</B>&#148;) and any Patent
Rights that Cover the Ionis Collaboration Know-How (&#147;<B>Ionis Collaboration Patent Rights</B>&#148; and together with the Ionis Collaboration Know-How, the &#147;<B>Ionis Collaboration Technology</B>&#148;), and will retain all of its rights
thereto, subject to any rights or licenses expressly granted by Ionis to Metagenomi under this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Joint Collaboration Technology</B>. Any Know-How discovered, developed, invented, or created jointly
by (i)&nbsp;Ionis, its Affiliates, or Third Parties acting on its or their behalf and (ii)&nbsp;Metagenomi, its Affiliates, or Third Parties acting on its or their behalf, in each case, in the performance of activities under this Agreement
(including in any meeting of the JSC or any Subcommittee) (such Know-How, &#147;<B>Joint Collaboration Know-How</B>&#148;), and any Patent Rights that Cover such Joint Collaboration Know-How (&#147;<B>Joint Collaboration Patent Rights</B>,&#148; and
together with the Joint Collaboration Know-How, the &#147;<B>Joint Collaboration Technology</B>&#148;), will be owned jointly by Ionis and Metagenomi on an equal and undivided basis, including all rights thereto, subject to any rights or licenses
expressly granted by one Party to the other Party under this Agreement. Except as expressly provided in this Agreement, neither Party will have any obligation to account to the other for profits with respect to, or to obtain any consent of the other
Party to license or exploit, Joint Collaboration Technology by reason of joint ownership thereof, and each Party hereby waives any right it may have under the laws of any jurisdiction to require any such consent or accounting. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>10.1.3</B><B>.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Disclosure.</B> During the Term, (a) Ionis will promptly disclose to designated Metagenomi personnel
(including Metagenomi scientific and intellectual property personnel) in writing, and will cause its Affiliates to so disclose, the discovery, development, invention, or creation of any Ionis Collaboration Know-How or Ionis Collaboration Patent
Right and (b)&nbsp;Metagenomi will promptly disclose to designated Ionis personnel (including Ionis scientific and intellectual property personnel) in writing, and will cause its Affiliates to so disclose, the discovery, development, invention, or
creation of any Metagenomi Collaboration Know-How or Metagenomi Collaboration Patent Rights. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>10.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Patent Prosecution. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>10.2.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Ionis-Prosecuted Patent Rights</B>.<B></B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As between the Parties, Ionis will have the first right, but not the obligation, to control the Prosecution and
Maintenance of all Product-Specific Patent Rights, all Joint Collaboration Patent Rights, and all Ionis Collaboration Patent Rights (&#147;<B>Ionis-Prosecuted Patent Rights</B>&#148;). Ionis will be the &#147;Prosecuting Party&#148; with respect to
all Ionis-Prosecuted Patent Rights. Ionis will be responsible for and pay all future costs and expenses incurred in connection with the Prosecution and Maintenance of the Ionis-Prosecuted Patent Rights. Ionis will keep Metagenomi reasonably informed
as to material developments with respect to the Prosecution and Maintenance of the Ionis-Prosecuted Patent Rights and will provide Metagenomi a reasonable opportunity to review and comment on substantive communications from any patent authority in
the Territory regarding the Ionis- Prosecuted Patent Rights, as well as drafts of any substantive filings or responses to be made to such patent authorities in advance of submitting such filings or responses. Ionis will consider Metagenomi&#146;s
comments regarding such communications and drafts in good faith but is not required to implement such comments. In addition, Ionis will provide Metagenomi with (i)&nbsp;copies of all final substantive filings and responses made to any patent
authority with respect to the Ionis-Prosecuted Patent Rights in a timely manner following submission thereof and (ii)&nbsp;notice in advance of abandoning any such Ionis-Prosecuted Patent Rights. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If, during the Term, Ionis decides that it is no longer interested in the Prosecution and Maintenance of a
particular Product-Specific Patent Right or Joint Collaboration Patent Right, then it will promptly provide written notice to Metagenomi of such decision; provided that any such notice will be at least [***] in advance of any time based deadlines by
which an action must be taken to establish or preserve any such Patent Right. Unless Ionis decides to no longer Prosecute and Maintain a particular Product-Specific Patent Right or Joint Collaboration Patent Right for strategic reasons, Metagenomi
may, upon written notice to Ionis, assume the Prosecution and Maintenance of such Patent Right at Metagenomi&#146;s sole cost and expense. In such event Metagenomi will be responsible for 100% of the costs and expenses of the Prosecution and
Maintenance of such Patent Right, and Metagenomi will thereafter be the &#147;Prosecuting Party&#148; with respect thereto for all purposes under this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>10.2.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Metagenomi-Prosecuted Patent Rights.</B> As between the Parties, Metagenomi will have the sole right,
but not the obligation, to control the Prosecution and Maintenance of the Licensed Patent Rights and Metagenomi Collaboration Patent Rights, in each case, that are not Product-Specific Patent Rights (such Patent Rights, the &#147;<B>Metagenomi-
Prosecuted Patent Rights</B>&#148;) in accordance with this Agreement. Metagenomi will be the &#147;Prosecuting Party&#148; with respect to all Metagenomi-Prosecuted Patent Rights. Metagenomi will be responsible for and pay all future costs and
expenses incurred in connection with the Prosecution and Maintenance of the Metagenomi-Prosecuted Patent Rights. Metagenomi will keep Ionis reasonably informed as to material developments with respect to the Prosecution and Maintenance of the
Metagenomi-Prosecuted Patent Rights and will provide Ionis a reasonable opportunity to review and comment on substantive communications from any patent authority in the Territory regarding the Metagenomi-Prosecuted Patent Rights, as well as drafts
of any substantive filings or responses to be made to such patent authorities in advance of submitting such filings or responses. Metagenomi will consider Ionis&#146; comments regarding such communications and drafts in
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
good faith but is not required to implement such comments. In addition, Metagenomi will provide Ionis with (a)&nbsp;copies of all final substantive filings and responses made to any patent
authority with respect to the Metagenomi-Prosecuted Patent Rights in a timely manner following submission thereof and (b)&nbsp;notice in advance of abandoning any such Metagenomi-Prosecuted Patent Rights. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>10.2.3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Cooperation.</B> The non-Prosecuting Party will (a)&nbsp;obtain and deliver to the Prosecuting Party
any necessary documents for the Prosecuting Party to exercise its rights to prepare, prosecute, defend, and maintain all Patent Rights pursuant to this <U>Section&nbsp;10.2</U> (Patent Prosecution), (b)&nbsp;render all signatures that will be
necessary in connection with all such patent filings, and (c)&nbsp;assist the Prosecuting Party in all other reasonable ways that are necessary for the issuance of those Patent Rights for which such Prosecuting Party is responsible, as well as for
the Prosecution and Maintenance of such Patent Rights. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>10.2.4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Coordination in Prosecution.</B> Notwithstanding Metagenomi&#146;s right to Prosecute and Maintain
the Metagenomi-Prosecuted Patent Rights, the Parties will, and will cause their Affiliates to, cooperate and implement reasonable patent filing and prosecution strategies (including filing divisionals, continuations or otherwise) so that, to the
extent reasonably feasible, Product-Specific Patent Rights and other Licensed Patent Rights are pursued in mutually exclusive patent applications. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>10.3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Patent Enforcement. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>10.3.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Notification.</B> Each Party will use reasonable efforts to promptly notify the other in the event of
any actual, likely, or suspected infringement of any Ionis-Prosecuted Patent Right or Metagenomi-Prosecuted Patent Right (an &#147;<B>Infringement</B>&#148;), including any Infringement that arises as a result of the making, using, offering to sell,
selling, or importing of a product that would be competitive with a Licensed System or Licensed Product (a &#147;<B>Competitive Infringement</B>&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>10.3.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Competitive Infringements</B>.<B> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ionis will have the first right, but not the obligation, to institute, prosecute, and control a Proceeding to
enforce the Ionis-Prosecuted Patent Rights against any Competitive Infringement at its own expense. If Ionis fails to initiate a Proceeding within a period of 90 days after written notice of a Competitive Infringement is first provided by a Party
under <U>Section&nbsp;10.3.1</U> (Notification), then Metagenomi will have the right to initiate and control a Proceeding to enforce the applicable Patent Right against such Competitive Infringement by counsel of its own choice; provided that if
Ionis notifies Metagenomi during such 90-day period that it is electing in good faith not to institute any Proceeding to enforce Ionis-Prosecuted Patent Rights against such Competitive Infringement for strategic reasons, then Metagenomi will not
have the right to initiate and control any Proceeding to enforce such Patent Rights against such Competitive Infringement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Metagenomi will have the first right, but not the obligation, to institute, prosecute, and control a Proceeding
to enforce the Metagenomi-Prosecuted Patent Rights against any Competitive Infringement at its own expense. If Metagenomi fails to initiate a Proceeding within a period of 90 days after written notice of a Competitive Infringement is first provided
by a Party under <U>Section&nbsp;10.3.1</U> (Notification), then Ionis will have the right to initiate and control a Proceeding to </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="23%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
enforce the applicable Patent Right against such Competitive Infringement by counsel of its own choice; provided that if Metagenomi notifies Ionis during such 90-day period that it is electing in
good faith not to institute any Proceeding to enforce Metagenomi-Prosecuted Patent Rights against such Competitive Infringement for strategic reasons, then Ionis will not have the right to initiate and control any Proceeding to enforce such Patent
Rights against such Competitive Infringement. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>10.3.3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Proceedings for Infringements other than Competitive Infringements.</B> During the Term,
(a)&nbsp;Metagenomi will have the sole right, but not the obligation, to initiate a Proceeding against any Infringement that is not a Competitive Infringement with respect to any Licensed Patent Rights, at Metagenomi&#146;s sole discretion and at
Metagenomi&#146;s sole cost and expense and (b)&nbsp;the Parties will jointly agree upon any initiation of a Proceeding against any Infringement that is not a Competitive Infringement with respect to any Joint Collaboration Patent Right;
<I>provided</I> that neither Party will unreasonably withhold its agreement to initiate any such Proceeding with respect to any Joint Collaboration Patent Right (as applicable) upon the reasonable request of the other Party. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>10.3.4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Collaboration.</B> Each Party will provide to the enforcing Party reasonable assistance in any Proceeding
brought under this <U>Section&nbsp;10.3</U> (Patent Enforcement), at such enforcing Party&#146;s request and expense, including to be named in such action if required by Applicable Law to pursue such action. The enforcing Party will keep the other
Party regularly informed of the status and progress of such enforcement efforts, will reasonably consider the other Party&#146;s comments on any such efforts, including determination of litigation strategy and filing of material papers to the
competent court. The non-enforcing Party will be entitled to separate representation in such matter by counsel of its own choice and at its own expense, but such Party will at all times cooperate fully with the enforcing Party. The enforcing Party
will not settle any Proceeding that it brought under <U>Section&nbsp;10.3.2</U> (Competitive Infringements) in any manner that would limit the rights of the other Party or impose any obligation on the other Party, without the prior written consent
of the other Party, which consent will not be unreasonably withheld, conditioned, or delayed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>10.3.5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Expenses and Recoveries.</B> Any amount recovered in any Proceeding under this
<U>Section&nbsp;10.3</U> (Patent Enforcement), including any amount recovered in any settlement of such Proceeding, will first be used [***] and will thereafter be for (a)&nbsp;with respect to any Competitive Infringement, the benefit of [***];
<I>provided</I>, <I>however</I>, that to the extent any such amount is [***] then such amount will, [***] and (b)&nbsp;with respect to any Infringement that is not a Competitive Infringement, for the benefit of [***]. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>10.4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Defense of Claims Brought by Third Parties.</B> If any Third Party brings a claim or otherwise
asserts that a Licensed Product or Licensed System infringes such Third Party&#146;s Patent Rights or misappropriates such Third Party&#146;s Know-How (each, a &#147;<B>Third Party Infringement Claim</B>&#148;), then the Party first having notice of
the claim or assertion will promptly notify the other Party in writing. Subject to [***], [***] will have the sole right, but not the obligation, to undertake and control the defense or settlement of any Third Party Infringement Claim using counsel
of its choice, at its cost and expense. If [***] is named as a defendant in such suit, [***] will have the right to participate in such defense and settlement with its own counsel, at its cost. [***] will not enter into any settlement of any Third
Party Infringement Claim that is instituted or threatened to be instituted against [***] without [***] prior written consent, which will not be unreasonably withheld, conditioned, or delayed; except that such consent will not be required if such
settlement includes a release of all liability in favor of [***] or an assumption of any unreleased liability by [***]. As </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
requested by [***], [***] will provide reasonable cooperation and assistance to [***] in connection with [***] control of the defense or settlement of a Third Party Infringement Claim. Such
cooperation and assistance will include executing all necessary and proper documents and taking such actions as will be appropriate to allow [***] to control the defense and settlement of such Third Party Infringement Claim. [***] will reimburse
[***]; except that [***] will have no obligation to [***] will keep [***] reasonably informed of the progress of any Third Party Infringement Claim. To the extent reasonable, both Parties will cooperate in good faith to (a)&nbsp;ensure that [***]
and (b)&nbsp;[***]. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>10.5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Patent Listing.</B> Ionis will have the sole right, but not the obligation, to determine which Ionis-
Prosecuted Patent Rights will be listed in connection with the Regulatory Approval for a Licensed Product pursuant to 21 U.S.C. &#167; 355(b)(1)(G), any similar statutory or regulatory requirement enacted in the future regarding biologic products,
or any similar statutory or regulatory requirement in any non-U.S. country or other regulatory jurisdiction. The Parties will discuss and mutually agree on which Metagenomi-Prosecuted Patent Rights will be listed in connection with the Regulatory
Approval for a Licensed Product pursuant to 21 U.S.C. &#167; 355(b)(1)(G), any similar statutory or regulatory requirement enacted in the future regarding biologic products, or any similar statutory or regulatory requirement in any non-U.S. country
or other regulatory jurisdiction. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>10.6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Common Ownership Legislation.</B> Notwithstanding anything to the contrary in this<U> Article 10</U>
(Intellectual Property), neither Party will have the right to make an election under the Common Ownership Legislation when exercising its rights under this<U> Article 10</U> (Intellectual Property) without the prior written consent of the other
Party, which will not be unreasonably withheld, conditioned, or delayed. With respect to any such permitted election, the Parties will use reasonable efforts to cooperate and coordinate their activities with respect to any submissions, filings, or
other activities in support thereof. The Parties acknowledge and agree that this Agreement is a &#147;joint research agreement&#148; as defined in the Common Ownership Legislation. Notwithstanding the foregoing, the other Party&#146;s consent under
this <U>Section&nbsp;10.6</U> (Common Ownership Legislation) will not be required in connection with an obviousness-type double patenting rejection in any patent application claiming a Licensed System, Licensed Product, or uses thereof.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>10.7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Patent Term Extension. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>10.7.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Ionis-Prosecuted Patent Rights.</B> Ionis will be solely responsible for obtaining patent term
restoration for the Ionis-Prosecuted Patent Rights in any country in the Territory under any statute or regulation equivalent or similar to 35 U.S.C. &#167; 156, where applicable to a Licensed Product. Ionis will determine which relevant
Ionis-Prosecuted Patent Rights will be extended (including by filing supplementary protection certificates and any other extensions that are now or in the future become available). Metagenomi will abide by Ionis&#146; determination and cooperate, as
reasonably requested by Ionis, in connection with the foregoing (including by providing appropriate information and executing appropriate documents). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>10.7.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Metagenomi-Prosecuted Patent Rights.</B> The Parties will mutually agree on the strategy for
obtaining patent term restoration for the Metagenomi-Prosecuted Patent Rights in any country in the Territory under any statute or regulation equivalent or similar to 35 U.S.C. &#167; 156, where applicable to a Licensed Product. The Parties will
mutually agree on which relevant Metagenomi-Prosecuted Patent Rights will be extended (including by filing supplementary protection certificates and any other extensions that are now or in the future become available) and will cooperate with each
other in connection with the foregoing (including by providing appropriate information and executing appropriate documents). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>10.8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Recording</B>. If Ionis deems it necessary or desirable to register or record this Agreement or
evidence of this Agreement with any patent office or other appropriate Governmental Authority in one or more jurisdictions in the Territory, then Metagenomi will reasonably cooperate to execute and deliver to Ionis any documents accurately
reflecting or evidencing this Agreement that are necessary or desirable, in Ionis&#146; reasonable judgment, to complete such registration or recordation. Ionis will [***] in complying with the provisions of this <U>Section&nbsp;10.8</U>
(Recording). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>10.9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Unitary Patent System</B>. Ionis will have the exclusive right to opt-in or opt-out of the EU Unitary Patent
System for all Licensed Patent Rights and Joint Collaboration Patent Rights. For clarity, &#147;to opt-in or opt-out&#148; refers to both the right to have a European patent application or an issued European patent registered to have unitary effect
within the meaning of Regulation (EU) No 1257/2012 of December&nbsp;17, 2012 as well as the Agreement on a Unified Patent Court as of February&nbsp;19, 2013; and to the right to opt-in or opt-out from the exclusive competence of the Unified Patent
Court in accordance with Article 83(3) of that Agreement on a Unified Patent Court. Without limiting the generality of the foregoing, unless a Party or its Affiliate has expressly opted-in to the EU Unitary Patent System with respect to a given
Patent Right, the other Party will not initiate any action under the EU Unitary Patent System without such Party&#146;s prior written approval, such approval to be granted or withheld in such Party&#146;s sole discretion. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>10.10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Trademarks</B><B></B>. As between the Parties, all trademarks and trade dress rights used in
connection with the Commercialization of the Licensed Products in the Field in the Territory will be owned exclusively by Ionis. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>10.11</B><B>.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Common Interest</B><B></B>. All information exchanged between the Parties regarding the Prosecution
and Maintenance, and enforcement and defense, of the Patent Rights under this<U> Article 10</U> (Intellectual Property) will be deemed Confidential Information of the disclosing Party. In addition, the Parties acknowledge and agree that, with regard
to such Prosecution and Maintenance, and enforcement and defense of the Patent Rights under this<U> Article 10</U> (Intellectual Property), the interests of the Parties as collaborators and licensor and licensee are to obtain the strongest patent
protection possible, and as such, are aligned and are legal in nature. The Parties agree and acknowledge that they have not waived, and nothing in this Agreement constitutes a waiver of, any legal privilege concerning the Patent Rights under this<U>
Article 10</U> (Intellectual Property), including privilege under the common interest doctrine and similar or related doctrines. Notwithstanding anything to the contrary contained herein, to the extent a Party has a good faith belief that any
information required to be disclosed by such Party to the other Party under this <U>Article 10</U> (Intellectual Property) is protected by attorney-client privilege or any other applicable legal privilege or immunity, such Party will not be required
to disclose such information and the Parties will in good faith cooperate to agree upon a procedure (including entering into a specific common interest agreement, disclosing such information on a &#147;for counsel eyes only&#148; basis or similar
procedure) under which such information may be disclosed without waiving or breaching such privilege or immunity. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Article&nbsp;11 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidentiality </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>11.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Confidential Information</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>11.1.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>General.</B> Each Party will maintain all Confidential Information disclosed to it or its representatives
(the &#147;<B>Receiving Party</B>&#148;) by or on behalf the other Party (the &#147;<B>Disclosing Party</B>&#148;) in strict confidence during the Term of this Agreement and for a period of [***] after the expiration or termination of this
Agreement; <I>provided</I> that any Confidential </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Information of either Party that constitutes a trade secret will continue to be subject to the terms of this<U> Article 11</U> (Confidentiality) in perpetuity, so long as such information remains
a trade secret. Each Party will use all such disclosed Confidential Information only to the extent necessary for purposes of this Agreement, including exercising the licenses and rights hereunder, and will not disclose such Confidential Information
to any Third Party without the prior written consent of the Disclosing Party, except as permitted under this Agreement. Each Party will notify the other Party promptly on discovery of any unauthorized use or disclosure by a Party of the other
Party&#146;s Confidential Information, including the other Party&#146;s trade secrets. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>11.1.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Confidential Information of Each Party</B>. All information disclosed prior to the Effective Date pursuant
to the Confidentiality Agreement between the Parties dated [***] (the &#147;<B>Confidentiality Agreement</B>&#148;), by Metagenomi to Ionis will be Confidential Information of Metagenomi and by Ionis to Metagenomi will be Confidential Information of
Ionis. All Ionis Royalty Reports and reports identifying Ionis Product Development Milestone Events, Ionis Product Regulatory Milestone Events, and Ionis Product Sales Milestone Events will be considered Confidential Information of Ionis. All
Metagenomi Royalty Reports and reports identifying Metagenomi Product Milestone Events will be the Confidential Information of Metagenomi. The Product-Specific Know-How, Joint Collaboration Know-How, and the non-disclosed terms of this Agreement
will be the Confidential Information of each Party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>11.1.3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Exceptions to Confidentiality</B>. The following information will not be Confidential Information of the
Disclosing Party, and accordingly the obligations of each Receiving Party imposed by <U>Section&nbsp;11.1.1</U> (General) will not apply to any such information that: (a)&nbsp;was known to the Receiving Party without an obligation to keep such
information confidential prior to the Effective Date other than as a result of disclosure under any other agreement between the Parties, including the Confidentiality Agreement (as demonstrated by documentary evidence); (b)&nbsp;is or becomes
generally available to the public through means other than an unauthorized disclosure by the Receiving Party, its Affiliates, or any agents to whom it or they disclosed such information; (c)&nbsp;was or subsequently is disclosed to the Receiving
Party without restriction by a Third Party having a <I>bona fide </I>right to disclose such Confidential Information without breaching any obligation to the Disclosing Party; or (d)&nbsp;is developed independently by the Receiving Party without
benefit of or recourse to any of the Disclosing Party&#146;s Confidential Information (as demonstrated by documentary evidence). For clarity, (i)&nbsp;specific aspects or details of Confidential Information will not be deemed to be within the public
domain or in the possession of the Receiving Party merely because the Confidential Information is embraced by more general information in the public domain or in the possession of the Receiving Party; and (ii)&nbsp;any combination of Confidential
Information will not be considered in the public domain or in the possession of the Receiving Party merely because individual elements of such Confidential Information are in the public domain or in the possession of the Receiving Party unless the
combination and its principles are in the public domain or in the possession of the Receiving Party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>11.1.4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Permitted Disclosures</B>. The Receiving Party may disclose Confidential Information of the Disclosing Party
to the extent (and solely to the extent) that such disclosure is reasonably necessary in the following instances: </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="91%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(a)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">(i)&nbsp;&nbsp;the prosecution and maintenance of Licensed Patent Rights and Joint Collaboration Patent Rights, in each case, in accordance with the terms of this Agreement; or (ii)&nbsp;Regulatory Submissions and other filings with
Governmental Authorities (including Regulatory Authorities), as necessary for the Exploitation of a Licensed Product;</TD></TR>
</TABLE></DIV> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">disclosure of the existence and applicable terms of this Agreement and the status and results of Exploitation
of one or more Licensed Products to actual or <I>bona fide</I> potential investors, acquirors, Sublicensees, lenders, and other financial or commercial partners (including in connection with any royalty factoring transaction), and their respective
attorneys, accountants, banks, investors, and advisors, solely for the purpose of evaluating or carrying out an actual or potential investment, acquisition, sublicense, debt transaction, or collaboration; <I>provided</I> that, in each such case,
(i)&nbsp;such Persons are bound by obligations of confidentiality, non-disclosure, and non-use provisions at least as restrictive or protective of the Parties as those set forth in this Agreement or otherwise customary for such type and scope of
disclosure, and (ii)&nbsp;that any such disclosure is limited to the maximum extent practicable for the particular context in which it is being disclosed; <I>provided</I> that in no event will a disclosure of Confidential Information under this
<U>Section&nbsp;11.1.4(b)</U> be made, with respect to Ionis as the Receiving Party, to a [***] or with respect to Metagenomi as the Receiving Party, to an [***], in each case, without the prior written consent of the other Party;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to comply with Applicable Law (whether generally or in pursuit of an application for listing of securities)
including the United States Securities and Exchange Commission or equivalent foreign agency or regulatory body, or otherwise required by judicial or administrative process; <I>provided</I> that in each such event, as promptly as reasonably
practicable and to the extent not prohibited by Applicable Law or judicial or administrative process, such Party will notify the other Party of such required disclosure and provide a draft of the disclosure to the other Party reasonably in advance
of such filing or disclosure for the other Party&#146;s review and comment. The non-disclosing Party will provide any comments as soon as practicable, and the disclosing Party will consider in good faith any timely comments provided by the
non-disclosing Party; <I>provided</I> that the disclosing Party may or may not accept such comments in its sole discretion. Confidential Information that is disclosed in order to comply with Applicable Law or by judicial or administrative process
pursuant to this <U>Section&nbsp;11.1.4(c)</U>, in each case, will remain otherwise subject to the confidentiality and non-use provisions of this<U> Article 11</U> (Confidentiality) with respect to the Party disclosing such Confidential Information,
and such Party will take all steps reasonably necessary, including seeking of confidential treatment or a protective order for a period of at least [***] (to the extent permitted by Applicable Law or Governmental Authority), to ensure the continued
confidential treatment of such Confidential Information, and each Party will be responsible for its own legal and other external costs in connection with any such filing or disclosure pursuant to this <U>Section&nbsp;11.1.4(c)</U>;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to prosecute or defend litigation so long as there is [***] prior written notice given by the Receiving Party
before filing, and to enforce Patent Rights in connection with the Receiving Party&#146;s rights and obligations pursuant to this Agreement; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to allow the Receiving Party to exercise its rights and perform its obligations hereunder; <I>provided</I> that
such disclosure is covered by terms of confidentiality and non-use at least as restrictive as those set forth herein. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">If and whenever any Confidential Information is disclosed in accordance with this
<U>Section&nbsp;11.1.4</U> (Permitted Disclosures), such disclosure will not cause any such information to cease to be Confidential Information except to the extent that such disclosure results in a public disclosure of such information (other than
by breach of this Agreement). </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>11.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>No Use of Name</B>. Neither Party will use the other Party&#146;s name, logo, or Trademarks in any
promotional materials or advertising without the prior written consent of the other Party, except as provided under this Agreement or required by Applicable Law, in which case the Party disclosing such name, logo, or Trademarks will give advance
notice of such use and otherwise comply with <U>Section&nbsp;11.1.4(c)</U>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>11.3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Residual Knowledge</B>. Notwithstanding any provision to the contrary set forth in this Agreement, a
Receiving Party will not be liable for the use of any knowledge, technique, experience, or Know-How that is retained in the unaided memory of any officers, directors, agents, contractors, or employees of such Receiving Party after having access to
such Confidential Information (&#147;<B>Residual Knowledge</B>&#148;), <I>provided</I> that such officer, director, agent, contractor, or employee (a)&nbsp;has not intentionally memorized such Residual Knowledge, (b)&nbsp;is not aware at the time of
use that such Residual Knowledge is the Confidential Information of the Disclosing Party, and (c)&nbsp;has not been directed or encouraged by the Receiving Party to memorize such Residual Knowledge. Any use made by the Receiving Party of any such
Residual Knowledge is on an &#147;as is, where is&#148; basis, with all faults and all representations and warranties disclaimed and at its sole risk. For clarity, no license under any Patent Right is granted pursuant to this
<U>Section&nbsp;11.3</U> (Residual Knowledge). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>11.4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Public Announcements and Subsequent Disclosures</B>. Except as may be expressly permitted under
<U>Section&nbsp;11.1.4</U> (Permitted Disclosures), neither Party will make any public announcement regarding this Agreement without the prior written approval of the other Party, except for either Party&#146;s references to the other as the
licensor or licensee (as applicable) or a collaboration partner under this Agreement. For clarity, Ionis may make scientific publications or public announcements concerning Ionis&#146; Exploitation of any Licensed Product under this Agreement
pursuant to <U>Section&nbsp;11.5.1</U> (Ionis Publications); <I>provided</I> that, except as permitted under <U>Section&nbsp;11.1.4</U> (Permitted Disclosures), Ionis will not disclose any of Metagenomi&#146;s Confidential Information in any such
publication or announcement without obtaining Metagenomi&#146;s prior written consent to do so. The Parties may each issue, or, by agreement of the Parties, may jointly issue, a press release announcing the signing of this Agreement after the
Effective Date. The press release(s) to be issued by the Parties on or after the Effective Date will be substantially in the form of the press release(s) attached hereto as <U>Schedule 11.4</U> (Press Release(s)). After the issuance of any such
press release or any other permitted public disclosure by a Party, each Party may make subsequent public disclosures reiterating such information without having to obtain the other Party&#146;s prior consent and approval so long as the information
in such press release or other public announcement remains true, correct, and the most current information with respect to the subject matters set forth therein. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>11.5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Publications</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>11.5.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Ionis Publications.</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">During the Collaboration Term, Ionis will submit to Metagenomi for review any proposed academic, scientific, or
medical publication or public presentation related to any Licensed System or Licensed Product or to any activities conducted pursuant to this Agreement. Metagenomi will review such publication or presentation for purposes of determining whether any
portion of the proposed </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="23%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
publication or presentation contains Metagenomi&#146;s Confidential Information. Ionis will submit written copies of such proposed publication or presentation to Metagenomi no later than [***]
before submission for publication or presentation (or [***] in advance in the case of an abstract). Metagenomi will provide its comments with respect to such publications and presentations within [***] after its receipt of such written copy (or
[***] in the case of an abstract). Metagenomi will have the right: (i)&nbsp;to require the removal of its Confidential Information from any such publication or presentation and (ii)&nbsp;to request a reasonable delay in publication or presentation
in order to protect patentable information. If Metagenomi requests such a delay, then Ionis will delay submission or presentation for a period of [***] after its provision of the copy of the proposed publication or disclosure to enable patent
applications protecting Metagenomi&#146;s rights in such information. Ionis will comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unless otherwise agreed in a Co-Development and Co-Commercialization Agreement, after the Collaboration Term,
Ionis will have the right upon at least [***] prior written notice to Metagenomi, without any required consent or review from Metagenomi but subject to this<U> Article 11</U> (Confidentiality), to publish or publicly disclose the scientific results
of any activities conducted with respect to any Licensed System or Licensed Product or any other activities conducted pursuant to this Agreement; <I>provided</I> that if Metagenomi reasonably believes that such disclosure would adversely affect the
use of any Licensed System for applications outside of the Field, then Ionis will reasonably consider any comments to such disclosure provided by Metagenomi in such [***] period. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>11.5.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Metagenomi Publications</B>. During the Term, Metagenomi will not publish or publicly disclose the
scientific results of any activities it conducts that are specific to the Licensed System or Licensed Product in the Field, or any other activities conducted pursuant to this Agreement and exclusively licensed to Ionis, in each case, without the
prior written consent of Ionis (such consent not to be unreasonably withheld, conditioned, or delayed). </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Article&nbsp;12 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Representations, Warranties, and Covenants </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>12.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Mutual Representations and Warranties</B>. As of the Effective Date, Metagenomi and Ionis each hereby
represents and warrants to the other as follows: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.1.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">It is a corporation duly organized, validly existing, and in good standing under the laws of the jurisdiction
of its organization, and has all requisite power and authority, corporate or otherwise, to execute, deliver, and perform this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.1.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The execution and delivery of this Agreement and the performance by it of the transactions contemplated hereby
have been duly authorized by all necessary corporate action and will not violate (a)&nbsp;such Party&#146;s certificate of incorporation or bylaws (or equivalent charter or organizational documents), (b)&nbsp;any agreement, instrument or contractual
obligation to which such Party is bound, (c)&nbsp;any requirement of any Applicable Law, or (d)&nbsp;any order, writ, judgment, injunction, decree, determination, or award of any court or Governmental Authority presently in effect applicable to such
Party. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.1.3</B><B>.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">It is not under any obligation, contractual or otherwise, to any Person that conflicts with or is inconsistent
in any respect with the terms of this Agreement or that will impede the diligent and complete fulfillment of its obligations hereunder. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.1.4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">There is no action or proceeding pending or, to the knowledge of such Party, threatened that could reasonably
be expected to impair or delay the ability of such Party to perform its obligations under this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.1.5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All consents, approvals, and authorizations from all Governmental Authorities or other Third Parties required
to be obtained by such Party in connection with this Agreement, including the grant of any licenses, have been obtained. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>12.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Additional Representations of Metagenomi</B>. As of the Effective Date and the date on which each new target
becomes a Collaboration Target pursuant to <U>Section&nbsp;2.1.1(b)</U> (Second Wave 1 Target) or <U>Section&nbsp;2.1.4(c)</U> (Effects if a Proposed Target is Available) (unless otherwise noted below), Metagenomi further represents and warrants to
Ionis, that, except as set forth on <U>Schedule 12.2</U> (Metagenomi Disclosure Schedule) (which schedule may be updated each time a target becomes a Collaboration Target): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.2.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To Metagenomi&#146;s Knowledge, the practice of the Warranty Technology and the Metagenomi Platform as
contemplated by this Agreement will not (a)&nbsp;constitute misappropriation of any Know-How of any Third Party, or (b)&nbsp;infringe any Patent Rights of any Third Party. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.2.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Metagenomi Controls all Patent Rights and Know-How owned or in-licensed by Metagenomi that are necessary to
Exploit licensed systems discovered using the Metagenomi Platform in the Field. For purposes of this <U>Section&nbsp;12.2.2</U>, &#147;licensed systems&#148; mean a Gene Editing protein and a Guide RNA that is designed to modulate a target.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.2.3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Metagenomi is the sole and exclusive owner or, if applicable, exclusive licensee, of all Warranty Technology,
all of which is free and clear of any liens, charges, restrictions, and encumbrances (other than licenses granted to Third Parties that are not inconsistent with the options, rights, and licenses granted to Ionis hereunder), and neither any
assignment, license, sublicense, or other grant of any interest in or options to the Warranty Technology granted by Metagenomi or its Affiliates to any Third Party, nor any assignment, license, sublicense, or other grant of any interest in or
options to the Warranty Technology granted by any Third Party to Metagenomi or its Affiliates conflicts with the options, rights, and licenses granted to Ionis hereunder, and Metagenomi is entitled to grant all rights and licenses under the Warranty
Technology that it purports to grant to Ionis under this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.2.4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><U>Schedule 1.146</U> (Licensed Patent Rights) sets forth a true, correct, and complete list of all
Licensed Patent Rights as of the Effective Date. To the extent a Licensed Patent Right is omitted from <U>Schedule 1.146</U> (Licensed Patent Rights) as of the Effective Date, Metagenomi agrees and covenants to add such omitted Licensed Patent Right
to <U>Schedule 1.146</U> (Licensed Patent Rights), and that any such added Licensed Patent Right is deemed included in the licenses granted to Ionis pursuant to <U>Section&nbsp;3.1</U> (License Grants to Ionis) as of the Effective Date;
<I>provided</I> that, for clarity, any Patent Right that otherwise meets the definition of Licensed Patent Rights will be deemed a Licensed Patent Right and included in the licenses granted to Ionis pursuant to <U>Section&nbsp;3.1</U> (License
Grants to Ionis) from the time such Patent Right existed whether or not it is included on <U>Schedule 1.146</U> (Licensed Patent Rights). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.2.5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All issued Patent Rights within the Warranty Technology are in full force and effect and, to Metagenomi&#146;s
Knowledge, have been Prosecuted and Maintained from the respective patent offices in accordance with Applicable Law. Metagenomi has not received any written claims from any Third Party that any such issued Patent Rights are invalid or unenforceable.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.2.6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">With respect to the Patent Rights within the Warranty Technology, each patent properly identifies each and
every inventor of the claims thereof as determined in accordance with the laws of the jurisdiction in which such patent is issued or such application is pending, Metagenomi has obtained assignments from any and all inventors of all inventorship
rights relating to such Patent Rights, all such assignments of inventorship rights relating to such Patent Rights have been properly executed and recorded in the relevant U.S. and foreign patent offices, and each such inventor has complied in all
material respects with all applicable duties of candor and good faith in dealing with any patent office, including the duty to disclose to any applicable patent office all information known to be material to patentability. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.2.7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To Metagenomi&#146;s Knowledge, no circumstances or grounds exist that would invalidate, reduce or eliminate,
in whole or in part, the enforceability, validity or scope of any Patent Rights within the Warranty Technology. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.2.8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Other than the Metagenomi In-License Agreements (if any), there is no agreement between Metagenomi or any of
its Affiliates and any Third Party pursuant to which Metagenomi or its Affiliate has acquired Control of any of the Licensed Technology, and no Third Party has any rights, title, or interests in or to, or any license under, any of the Licensed
Technology. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.2.9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All Metagenomi In-License Agreements (if any) are in full force and effect. Neither Metagenomi nor its
Affiliates nor, to Metagenomi&#146;s Knowledge, the Third Party licensor in a Metagenomi In-License Agreement is in default with respect to a material obligation under such Metagenomi In-License Agreement, as applicable, and no such party has
claimed or has grounds upon which to claim that the other party is in default with respect to any obligation or permit, termination, modification, or acceleration under any Metagenomi In-License Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.2.10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Metagenomi and its Affiliates have taken commercially reasonable measures consistent with industry practices to
protect the secrecy, confidentiality, and value of all Warranty Technology that constitutes trade secrets under Applicable Law (including requiring all employees, consultants, and independent contractors to execute binding and enforceable agreements
requiring all such employees, consultants, and independent contractors to maintain the confidentiality of such Warranty Technology) and, to Metagenomi&#146;s Knowledge, such Warranty Technology has not been used, disclosed to, or discovered by any
Third Party except pursuant to such confidentiality agreements and to Metagenomi&#146;s Knowledge, there has not been a breach by any party to such confidentiality agreements. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.2.11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Warranty Technology have not been created pursuant to, and are not subject to, any funding agreement with
any Governmental Authority or any Third Party, and are not subject to the requirements of the Bayh-Dole Act or any similar provision of any Applicable Law. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.2.12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To Metagenomi&#146;s Knowledge, no Third Party has infringed, misappropriated, or otherwise violated, or is
currently infringing, misappropriating, or otherwise violating any Warranty Technology, and neither Metagenomi nor its Affiliates have brought any claim or sent any notice alleging any such infringement, misappropriation, or violation.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.2.13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">There are no judgments or settlements against Metagenomi or any of its Affiliates, any pending or, to
Metagenomi&#146;s Knowledge, threatened claims or litigation in writing, or written offers for Metagenomi to acquire or license any Third Party Intellectual Property Rights, in each case, in connection with the Warranty Technology or the practice
thereof, or relating to the transactions contemplated by this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.2.14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Metagenomi has not employed (and has not used a Subcontractor that has employed) any Person debarred by the FDA
(or subject to a similar sanction of EMA or foreign equivalent), or any Person that is the subject of an FDA debarment investigation or proceeding (or similar proceeding of EMA or foreign equivalent), in any capacity in connection with this
Agreement, the Warranty Technology, or the Metagenomi Platform. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>12.3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Covenants of Metagenomi</B>. Metagenomi covenants to Ionis as follows: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.3.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Metagenomi and its Affiliates will maintain Control of all Licensed Technology and Licensed Systems owned by
Metagenomi or its Affiliates at any time during the Term. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.3.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Metagenomi and its Affiliates will not grant or permit to be attached, any lien, security interest, or other
encumbrance with respect to any Licensed Technology which would adversely affect the rights granted to Ionis hereunder. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.3.3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Neither Metagenomi nor any of its Affiliates will effect any corporate restructuring or enter into any new
agreement or otherwise obligate itself to any Third Party, in each case, in a manner that conflicts with or otherwise adversely affects the options, rights, and licenses granted to Ionis hereunder. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.3.4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Metagenomi will maintain and not breach, and will cause its Affiliates to maintain and not breach, the
Metagenomi In-License Agreements, if any, or any license agreements that come into effect after the Effective Date pursuant to which Ionis receives a sublicense hereunder. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.3.5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[***]. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.3.6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[***]. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.3.7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Metagenomi will, and will ensure that its Affiliates, Sublicensees, and Subcontractors, obtain agreements from
any and all Persons involved in or performing any Development by or on behalf of Metagenomi that assign such Persons&#146; rights, title, and interests in and to any Licensed Technology to Metagenomi prior to any such person performing such
activities. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.3.8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Metagenomi will, and will ensure that its Affiliates, comply with Applicable Law in connection with the
performance of its and its Affiliates&#146; activities under this Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.3.9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Metagenomi will not, and will ensure that its Affiliates will not, take any action or enter into any agreement
with any Third Party that conflicts with or in any way relinquishes or otherwise diminishes the rights granted to Ionis under this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.3.10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In performing under this Agreement, Metagenomi and its Affiliates agree to comply with all applicable
anti-corruption laws, including the Foreign Corrupt Practices Act of 1977, as amended from time-to-time; the anti-corruption laws of the Territory; and all laws enacted to implement the Organization for Economic Cooperation and Development
Convention on Combating Bribery of Foreign Officials in International Business Transactions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.3.11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Metagenomi will not directly or indirectly offer or pay, or authorize such offer or payment of, any money, or
transfer anything of value, to improperly seek to influence: (a)&nbsp;any elected or appointed government official (e.g., a member of a ministry of health); (b)&nbsp;any employee or person acting for or on behalf of a Governmental Authority;
(c)&nbsp;any political party officer, employee, or person acting for or on behalf of a political party or candidate for public office; (d)&nbsp;an employee or person acting for or on behalf of a public international organization; or (e)&nbsp;any
person otherwise categorized as a government official under local law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.3.12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Neither Metagenomi nor its Affiliates will export, transfer, or sell any Licensed Product to any country or
territory except in compliance with Applicable Law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.3.13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Metagenomi will not, to Metagenomi&#146;s Knowledge, engage directly or indirectly, in any capacity in
connection with this Agreement any Person who either has been debarred by the FDA, is the subject of a conviction described in Section&nbsp;306 of the FD&amp;C Act or is subject to any such similar sanction. Metagenomi will inform Ionis in writing
promptly if it or any Person engaged by Metagenomi or any of its Affiliates who is performing services under this Agreement or any ancillary agreements is debarred or is the subject of a conviction described in Section&nbsp;306 of the FD&amp;C Act,
or if any action, suit, claim, investigation or legal or administrative proceeding is pending or, to Metagenomi&#146;s Knowledge, is threatened, relating to the debarment or conviction of Metagenomi, any of its Affiliates or any such Person
performing services hereunder or thereunder. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.3.14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Metagenomi will not, and will cause its Affiliates and Sublicensees not to, use or practice the Ionis
Background Technology, including the Ionis Proprietary Toolbox of Chemical Modifications, except in accordance with this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>12.4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Additional Representations of Ionis</B>. As of each Ionis IP Option Effective Date, Ionis represents and
warrants to Metagenomi that, except as set forth on <U>Schedule 12.4</U> (Ionis Disclosure Schedule) (which schedule may be updated each time a Proposed Metagenomi Target becomes a Metagenomi Target): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.4.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To Ionis&#146; Knowledge, the practice of the Ionis Background Technology as contemplated by this Agreement
will not (a)&nbsp;constitute misappropriation of any Know-How of any Third Party, or (b)&nbsp;infringe any Patent Rights of any Third Party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.4.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ionis is the owner, or licensee, of all Ionis Background Technology, all of which is free and clear of any
liens, charges, restrictions, and encumbrances (other than licenses granted to Third Parties that are not inconsistent with the options, rights, and licenses granted to Metagenomi hereunder), and neither any assignment, license, sublicense, or other
grant of any interest in or options to the Ionis Background Technology granted by Ionis or its </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Affiliates to any Third Party, nor any assignment, license, sublicense, or other grant of any interest in or options to the Ionis Background Technology granted by any Third Party to Ionis or its
Affiliates conflicts with the options, rights, and licenses granted to Metagenomi hereunder, and Ionis is entitled to grant all rights and licenses under the Ionis Background Technology that it purports to grant to Metagenomi under this Agreement.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.4.3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Ionis Background Technology have not been created pursuant to, and are not subject to, any funding
agreement with any Governmental Authority or any Third Party, and are not subject to the requirements of the Bayh-Dole Act or any similar provision of any Applicable Law. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.4.4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To Ionis&#146; Knowledge, no Third Party has infringed, misappropriated, or otherwise violated, or is currently
infringing, misappropriating, or otherwise violating any Ionis Background Technology in a manner that would be reasonably likely to adversely affect Metagenomi, and neither Ionis nor its Affiliates have brought any claim or sent any notice alleging
any such infringement, misappropriation, or violation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.4.5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">There are no judgments or settlements against Ionis or any of its Affiliates, any pending or, to Ionis&#146;
Knowledge, threatened claims or litigation in writing, or written offers for Ionis to acquire or license any Third Party Intellectual Property Rights, in each case, in connection with the Ionis Background Technology or the practice thereof, or
relating to the transactions contemplated by this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.4.6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ionis has not employed (and has not used a Subcontractor that has employed) any Person debarred by the FDA (or
subject to a similar sanction of EMA or foreign equivalent), or any Person that is the subject of an FDA debarment investigation or proceeding (or similar proceeding of EMA or foreign equivalent), in any capacity in connection with this Agreement or
the Ionis Background Technology. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>12.5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Covenants of Ionis</B>. Ionis covenants to Metagenomi as follows: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.5.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Neither Ionis nor any of its Affiliates will effect any corporate restructuring or enter into any new agreement
or otherwise obligate itself to any Third Party, in each case, in a manner that conflicts with or otherwise adversely affects the options, rights, and licenses granted to Metagenomi hereunder. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.5.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ionis will, and will ensure that its Affiliates, comply with all Applicable Law in connection with the
performance of its and its Affiliates&#146; activities under this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.5.3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ionis will not, and will ensure that its Affiliates will not, take any action or enter into any agreement with
any Third Party that conflicts with or in any way relinquishes or otherwise diminishes the rights granted to Metagenomi under this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.5.4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In performing under this Agreement, Ionis and its Affiliates agree to comply with all applicable
anti-corruption laws, including the Foreign Corrupt Practices Act of 1977, as amended from time-to-time; the anti-corruption laws of the Territory; and all laws enacted to implement the Organization for Economic Cooperation and Development
Convention on Combating Bribery of Foreign Officials in International Business Transactions. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.5.5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ionis will not directly or indirectly offer or pay, or authorize such offer or payment of, any money, or
transfer anything of value, to improperly seek to influence: (a)&nbsp;any elected or appointed government official (e.g., a member of a ministry of health); (b)&nbsp;any employee or person acting for or on behalf of a Governmental Authority;
(c)&nbsp;any political party officer, employee, or person acting for or on behalf of a political party or candidate for public office; (d)&nbsp;an employee or person acting for or on behalf of a public international organization; or (e)&nbsp;any
person otherwise categorized as a government official under local law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.5.6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Neither Ionis nor its Affiliates will export, transfer, or sell any Licensed Product to any country or
territory except in compliance with Applicable Law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.5.7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ionis will not, to Ionis&#146; Knowledge, engage directly or indirectly, in any capacity in connection with
this Agreement any Person who either has been debarred by the FDA, is the subject of a conviction described in Section&nbsp;306 of the FD&amp;C Act or is subject to any such similar sanction. Ionis will inform Metagenomi in writing promptly if it or
any Person engaged by Ionis or any of its Affiliates who is performing services under this Agreement or any ancillary agreements is debarred or is the subject of a conviction described in Section&nbsp;306 of the FD&amp;C Act, or if any action, suit,
claim, investigation or legal or administrative proceeding is pending or, to Ionis&#146; Knowledge, is threatened, relating to the debarment or conviction of Ionis, any of its Affiliates or any such Person performing services hereunder or
thereunder. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.5.8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ionis will not, and will cause its Affiliates not to, use or practice the Licensed Technology, except in
accordance with this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>12.6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Warranty Disclaimer</B>. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES ANY
REPRESENTATION OR EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTIES OF TITLE, NON-INFRINGEMENT, MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE. IN PARTICULAR, IONIS DOES NOT MAKE ANY REPRESENTATION
OR EXTEND ANY WARRANTY THAT THE LICENSED SYSTEMS OR LICENSED PRODUCTS WILL BE SUCCESSFULLY DEVELOPED OR COMMERCIALIZED HEREUNDER. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Article&nbsp;13 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Indemnification; Limitation of Liability; Insurance </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>13.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Indemnification of Metagenomi by Ionis</B>. Subject to <U>Section&nbsp;13.4</U> (Conditions to
Indemnification), Ionis will defend, indemnify, and hold harmless Metagenomi and its Affiliates, Sublicensees, Subcontractors, and their respective employees, officers, and directors (&#147;<B>Metagenomi Indemnitees</B>&#148;) from and against any
and all liability, damage, loss, cost, or expense of any nature (including reasonable attorney&#146;s fees and litigation expenses) (&#147;<B>Losses</B>&#148;) incurred or imposed upon the Metagenomi Indemnitees in connection with any claims, suits,
actions, demands, proceedings, causes of action, or judgments resulting from a Third Party claim (&#147;<B>Third Party Claims</B>&#148;) arising out of or relating to: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>13.1.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Exploitation of any Licensed System or Licensed Product by or on behalf of any Ionis Indemnitee other than
(a)&nbsp;claims by one or more Third Parties relating to patent infringement arising out of the practice of the Licensed Patent Rights in accordance with this Agreement, (b)&nbsp;claims by Third Parties relating to misappropriation of trade secrets
or other Intellectual Property Rights arising out of the practice of the Licensed Know-How in accordance with this Agreement, or (c)&nbsp;Losses shared pursuant to <U>Section&nbsp;13.3</U> (Losses for the Co-Co Products); </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>13.1.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the breach by any Ionis Indemnitee of any term of this Agreement; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>13.1.3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the negligence or willful misconduct of any Ionis Indemnitee except, in each case (<U>Section 13.1.1</U>
through <U>Section&nbsp;13.1.3</U>), to the extent that any such claim results or arises from a matter for which Metagenomi is obligated to indemnify Ionis under <U>Section&nbsp;13.2</U> (Indemnification of Ionis by Metagenomi).
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>13.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Indemnification of Ionis by Metagenomi</B>. Subject to <U>Section&nbsp;13.4</U> (Conditions to
Indemnification), Metagenomi will defend, indemnify, and hold harmless Ionis and its Affiliates, Sublicensees, and Subcontractors, and their respective employees, officers, and directors (&#147;<B>Ionis Indemnitees</B>&#148;) from and against any
and all Losses incurred or imposed upon the Ionis Indemnitees or any one of them in connection with one or more Third Party Claims arising out of or relating to: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>13.2.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any claim that the composition of matter [***] of a Gene Editing protein to edit gene targets (but not to edit
the Collaboration Targets specifically) infringes or misappropriates any issued Patent Right or other Intellectual Property Right owned or possessed by any Third Party; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>13.2.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Exploitation of any Licensed System that is included within a Licensed Product by any Metagenomi
Indemnitee, other than Losses shared pursuant to <U>Section&nbsp;13.3</U> (Losses for the Co-Co Products) and any amounts [***]; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>13.2.3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Exploitation of any Licensed System or Licensed Product by or on behalf of any Metagenomi Indemnitee prior
to the Effective Date and after termination of this Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>13.2.4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Exploitation of any Metagenomi Product by or on behalf of any Metagenomi Indemnitee; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>13.2.5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the breach by any Metagenomi Indemnitee of any term of this Agreement; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>13.2.6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the negligence or willful misconduct of any Metagenomi Indemnitee except, in each case (<U>Section 13.2.1</U>
through <U>Section&nbsp;13.2.6</U>), to the extent that any such claim results or arises from a matter for which Ionis is obligated to indemnify Metagenomi under <U>Section&nbsp;13.1</U> (Indemnification of Metagenomi by Ionis).
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>13.3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Losses for the Co-Co Products</B>. All Losses incurred by either Party arising from any Third Party Claim
relating to the Exploitation of the Co-Co Products will be shared by the Parties pursuant to the Co-Development and Co-Commercialization Agreement; <I>provided</I> that the Parties will not share Losses of a Party or its Affiliates to the extent
such Losses are (a)&nbsp;caused by a breach of this Agreement by a Party or Affiliate or (b)&nbsp;caused by gross negligence or willful misconduct of a Party or its Affiliate. As will be further set forth in the applicable Co-Development and
Co-Commercialization Agreement, if either Party learns of any Third Party Claim with respect to Losses covered by this <U>Section&nbsp;13.3</U> (Losses for the Co-Co Products), such Party will provide the other Party with prompt written notice
thereof, and the Parties will confer with respect to how to respond to such Third Party Claim and how to handle such Third Party Claim in an efficient manner. In the absence of such an agreement, each Party will have the right to take such action as
it deems appropriate. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>13.4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Conditions to Indemnification</B>. Any Person seeking indemnification under this Article 13
(Indemnification; Limitation Of Liability; Insurance) (the &#147;<B>Indemnitee</B>&#148;) will give prompt written notice of the indemnity claim to the indemnifying Party and promptly provide a copy to the indemnifying Party of any complaint,
summons, or other written or verbal notice that the Indemnitee receives in connection with any such claim. An Indemnitee&#146;s failure to deliver written notice will relieve the indemnifying Party of liability to the Indemnitee under this<U>
Article 13</U> (Indemnification; Limitation Of Liability; Insurance) only to the extent such delay is prejudicial to the indemnifying Party&#146;s ability to defend or settle such claim. The indemnifying Party will have the right to assume and
control the defense of the indemnification claim at its own expense with counsel selected by the indemnifying Party and reasonably acceptable to the Indemnitee; <I>provided</I>, <I>however</I>, that an Indemnitee will have the right to retain its
own counsel that is reasonably acceptable to the indemnifying Party, with the fees and expenses to be paid by the indemnifying Party, if representation of such Indemnitee by the counsel retained by the indemnifying Party would be inappropriate due
to actual or potential differing interests between the Indemnitee and any other party represented by such counsel in such proceedings. The indemnifying Party will act reasonably and in good faith with respect to all matters relating to such claim.
If the indemnifying Party does not assume the defense of the indemnification claim as described in this <U>Section&nbsp;13.4</U> (Conditions to Indemnification), then the Indemnitee may defend the indemnification claim but will have no obligation to
do so. The Indemnitee will not settle or compromise the indemnification claim without the prior written consent of the indemnifying Party, and the indemnifying Party will not settle or compromise the indemnification claim in any manner which would
have an adverse effect on the Indemnitee&#146;s interests (including any rights under this Agreement or the scope, validity, or enforceability of any Patent Rights, Confidential Information, or other rights licensed to Ionis by Metagenomi
hereunder), without the prior written consent of the Indemnitee, which consent, in each case (by the indemnifying Party or the Indemnitee, as the case may be), will not be unreasonably withheld, conditioned, or delayed. The Indemnitee will
reasonably cooperate with the indemnifying Party at the indemnifying Party&#146;s expense and will make available to the indemnifying Party all pertinent information under the control of the Indemnitee, which information will be subject to<U>
Article 11</U> (Confidentiality). The indemnifying Party will not be liable for any settlement or other disposition of the claims by the Indemnitee if such settlement is reached without the written consent of the indemnifying Party pursuant to this
<U>Section&nbsp;13.4</U> (Conditions to Indemnification). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>13.5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Limited Liability</B>. NEITHER OF THE PARTIES NOR THEIR RESPECTIVE AFFILIATES OR SUBLICENSEES WILL BE
ENTITLED TO RECOVER FROM THE OTHER PARTY OR ITS AFFILIATES OR SUBLICENSEES ANY SPECIAL, INCIDENTAL, INDIRECT, CONSEQUENTIAL, OR PUNITIVE DAMAGES OR DAMAGES FOR LOSS OF PROFIT, LOST OPPORTUNITY, LOST DATA OR COST OF PROCUREMENT OF SUBSTITUTE GOODS OR
SERVICES IN CONNECTION WITH THIS AGREEMENT, ITS PERFORMANCE OR LACK OF PERFORMANCE HEREUNDER, WHETHER LIABILITY IS ASSERTED IN CONTRACT, TORT (INCLUDING NEGLIGENCE AND STRICT PRODUCT LIABILITY), INDEMNITY OR CONTRIBUTION, AND IRRESPECTIVE OF WHETHER
THAT PARTY OR ANY REPRESENTATIVE OF THAT PARTY HAS BEEN ADVISED OF, OR OTHERWISE MIGHT HAVE ANTICIPATED THE POSSIBILITY OF, ANY SUCH LOSS OR DAMAGE, OR ANY LICENSE GRANTED HEREUNDER, EXCEPT TO THE EXTENT THE DAMAGES RESULT FROM (A)&nbsp;A
PARTY&#146;S WILLFUL MISCONDUCT OR GROSS NEGLIGENCE UNDER THIS AGREEMENT, (B)&nbsp;A BREACH OF THE OBLIGATIONS OF A PARTY UNDER <U>ARTICLE 11</U> (CONFIDENTIALITY) OR UNDER <U>SECTION 3.6</U> (EXCLUSIVITY), OR (C)&nbsp;AMOUNTS REQUIRED TO BE PAID AS
PART OF A CLAIM FOR WHICH A PARTY PROVIDES INDEMNIFICATION UNDER <U>ARTICLE 13</U> (INDEMNIFICATION; LIMITATION OF LIABILITY; INSURANCE). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>13.6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Insurance Obligations</B>. Each Party will, at its own expense, procure and maintain during the Term and for
a period of [***] thereafter, insurance policies, including product liability insurance when applicable, adequate to cover its obligations hereunder and that are consistent with normal business practices of prudent companies similarly situated. Such
insurance will not be construed to create a limit of a Party&#146;s liability with respect to its indemnification obligations under this<U> Article 13</U> (Indemnification; Limitation of Liability; Insurance). Each Party will provide the other Party
with written evidence of such insurance. Notwithstanding any provision to the contrary set forth in this Agreement, Ionis may self-insure, in whole or in part, the insurance requirements described above. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Article&nbsp;14 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Term
and Termination </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>14.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Term</B>. This Agreement will commence on the Effective Date and, unless otherwise terminated pursuant to
<U>Section&nbsp;14.2</U> (Termination), will continue (a)&nbsp;with respect to the Ionis Programs, on an Ionis Product-by-Ionis Product and country-by-country basis until the expiration of all applicable Royalty Terms for an Ionis Product in a
country, (b)&nbsp;with respect to the Co-Co Programs for which Metagenomi has not exercised its Opt-Out Right in accordance with <U>Section&nbsp;5.4</U> (Metagenomi Opt-Out), on a Co-Co Program-by-Co-Co Program basis until the Parties cease all
Exploitation for the Co-Co Products that are the subject to such Co-Co Program, and (c)&nbsp;with respect to the Metagenomi Products, on a Metagenomi Product-by-Metagenomi Product and country-by-country basis until the expiration of the Metagenomi
Royalty Term for a Metagenomi Product in a country (the &#147;<B>Term</B>&#148;). On a Licensed Product-by-Licensed Product and country-by-country basis, effective upon the expiration of the Royalty Term for a Licensed Product in a country (but not
upon any earlier termination of this Agreement for any reason), the licenses granted to Ionis will each become fully paid-up, royalty-free, irrevocable, and perpetual in such country with respect to such Licensed Product. On a Metagenomi
Product-by-Metagenomi Product and country-by-country basis, effective upon the expiration of the Metagenomi Royalty Term for a Metagenomi Product in a country (but not upon any earlier termination of this Agreement for any reason), the licenses
granted to Metagenomi will each become fully paid-up, royalty-free, irrevocable, and perpetual in such country with respect to such Metagenomi Product. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>14.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Termination</B>. This Agreement may be terminated as follows: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>14.2.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Termination for Convenience by Ionis</B>. Ionis may terminate this Agreement (either in its entirety
or on a Licensed Product-by-Licensed Product basis), for convenience by providing written notice of its intent to terminate to Metagenomi, in which case, such termination will be effective 90 days after Metagenomi&#146;s receipt of such written
notice. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>14.2.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Termination for Material Breach</B>.<B> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Ionis&#146; Right to Terminate</B>. If Metagenomi is in material breach of this Agreement, then Ionis may
deliver written notice of such material breach to Metagenomi. If the breach is curable, then Metagenomi will have [***] following its receipt of such written notice to cure such breach (except to the extent such breach involves the failure to make a
payment when due, in which case such breach must be cured within [***] following Metagenomi&#146;s receipt of such written notice). If Metagenomi fails to cure such breach within such [***] or [***] period, as applicable, or the breach is not
subject to cure, then Ionis may terminate this Agreement solely with respect to those Licensed Products to which such material breach relates, or in its entirety if such material breach relates to all Licensed Products, by providing written notice
to Metagenomi, in which case, this </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="23%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Agreement will terminate on the date on which Metagenomi receives such written notice; <I>provided</I>, <I>however</I>, that if (A)&nbsp;the relevant breach does not involve Metagenomi&#146;s
failure to make a payment when due and is curable, but not reasonably curable within [***], and (B)&nbsp;Metagenomi is making a <I>bona fide</I> effort to cure such breach, then Ionis&#146; right to terminate this Agreement on account of such breach
will be suspended for up to an additional [***] so long as Metagenomi is continuing to make such <I>bona fide</I> effort to cure such breach. If such breach is successfully cured during the applicable cure period, then Ionis will no longer have the
right to terminate this Agreement on account of such breach. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Metagenomi&#146;s Right to Terminate</B>. If Ionis is in material breach of this Agreement, then Metagenomi
may deliver written notice of such material breach to Ionis. If the breach is curable, then Ionis will have [***] following its receipt of such written notice to cure such breach (except to the extent such breach involves the failure to make a
payment when due, in which case such breach must be cured within [***] following Ionis&#146; receipt of such written notice). If Ionis fails to cure such breach within the [***] or [***] period, as applicable, or the breach is not subject to cure,
then Metagenomi may terminate this Agreement in its entirety by providing written notice to Ionis, in which case this Agreement will terminate on the date on which Ionis receives such written notice; <I>provided</I>, <I>however</I>, that if
(i)&nbsp;the relevant breach does not involve Ionis&#146; failure to make a payment when due and is curable, but not reasonably curable within [***], and (ii)&nbsp;Ionis is making a <I>bona fide</I> effort to cure such breach, then Metagenomi&#146;s
right to terminate this Agreement on account of such breach will be suspended for up to an additional [***] so long as Ionis is continuing to make such <I>bona fide</I> effort to cure such breach. If such breach is successfully cured during the
applicable cure period, then Metagenomi will no longer have the right to terminate this Agreement on account of such breach. Notwithstanding the foregoing, any license granted to Ionis under this Agreement may not be terminated under this
<U>Section&nbsp;14.2.2(b)</U> (Metagenomi&#146;s Right to Terminate) if (A)&nbsp;the material breach does not involve the failure to make any material and undisputed portion of a payment due to Metagenomi under<U> Article 9</U> (Consideration;
Financial Terms) and (B)&nbsp;such license is necessary to make, have made, use or sell a Licensed Product for which a Clinical Trial has been Initiated. Termination pursuant to this <U>Section&nbsp;14.2.2(b)</U> (Metagenomi&#146;s Right to
Terminate) will not relieve Ionis from liability and damages to Metagenomi for default, and the Parties agree that if monetary damages are available to Metagenomi as a reasonable remedy for any default hereunder, then such monetary remedy will
constitute the exclusive remedy for such default in lieu of termination of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Disputes Regarding Material Breach</B>. Notwithstanding the foregoing, if the alleged breaching Party in
<U>Section&nbsp;14.2.2(a)</U> (Ionis&#146; Right to Terminate) or <U>Section&nbsp;14.2.2(b)</U> (Metagenomi&#146;s Right to Terminate) disputes in good faith the existence or materiality of any breach, or failure to cure any breach, and provides
written notice to the non-breaching Party of such dispute within the relevant cure period, then the non-breaching Party will not have the right to terminate this Agreement in accordance with <U>Section&nbsp;14.2.2(a)</U> (Ionis&#146; Right to
Terminate) or <U>Section&nbsp;14.2.2(b)</U> (Metagenomi&#146;s Right to Terminate), as applicable, unless and until the relevant dispute has been resolved in accordance with <U>Section&nbsp;15.1</U> (Dispute Resolution). During the pendency of such
dispute, all the terms of this Agreement will remain in effect and the Parties will continue to perform all of their respective obligations hereunder. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>14.2.3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Termination for Insolvency</B>. If Metagenomi makes an assignment for the benefit of creditors, appoints or
suffers appointment of a receiver or trustee over all or substantially all of its property, files a petition under any bankruptcy or insolvency act, or has any such petition filed against it that is not discharged within [***] after the filing
thereof (each, an &#147;<B>Insolvency Event</B>&#148;), then Ionis may terminate this Agreement in its entirety by providing written notice of its intent to terminate this Agreement to Metagenomi, in which case, this Agreement will terminate on the
date on which Metagenomi receives such written notice. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>14.3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Effects of Termination</B>. In the event of any early termination of this Agreement by a Party pursuant to
<U>Section&nbsp;14.2</U> (Termination), effective as of the effective date of termination, the following provisions will apply with respect to the Terminated Products in the Terminated Countries: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>14.3.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Wind-Down</B>. During the applicable termination notice period, unless otherwise agreed by the Parties, the
Parties will begin to wind-down their respective activities under this Agreement to the extent related to the Terminated Products in the Terminated Countries. The JSC will coordinate the wind-down of each Party&#146;s efforts under this Agreement
with respect to the Terminated Products in the Terminated Countries, or, if the JSC has disbanded, then the Parties will establish an appropriate committee to coordinate such wind-down. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>14.3.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Termination of Rights and Licenses</B>. Other than as expressly set forth herein, including those provisions
that this Agreement expressly provides will survive such termination and subject to <U>Section&nbsp;14.3.8</U> (Sublicense Survival), all rights and licenses granted from one Party to the other hereunder will immediately terminate with respect to
the Terminated Products in the Terminated Countries; <I>provided</I> that such licenses will continue as necessary for the Parties to complete the orderly wind-down of their activities under this Agreement in accordance with Applicable Law and as
otherwise required in accordance with <U>Section&nbsp;14.3.1</U> (Wind-Down). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>14.3.3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Termination of Payment Obligations</B>. All payment obligations with respect to the Terminated Products in
the Terminated Countries hereunder will terminate, other than those that are accrued and unpaid as of the effective date of such termination. For any payment obligations that are accrued and unpaid as of the effective date of termination, an invoice
must be provided no later than [***] after the effective date of termination. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>14.3.4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Sell-Off Right</B>. For a period not to exceed [***] following the effective date of termination, Ionis will
have the right to sell or otherwise dispose of the Terminated Products in the Terminated Countries on hand at the time of such termination or in the process of Manufacturing; <I>provided</I> that any revenue obtained from such disposal will be
treated as Net Sales and the provisions of<U> Article 9</U> (Consideration; Financial Terms) will apply to such Net Sales and, if such sales result in the achievement of any Ionis Product Sales Milestone Event, then the applicable Ionis Product
Sales Milestone Payment will be payable. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>14.3.5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Assignment of Regulatory Submissions</B>. Except with respect to any termination by Ionis under
<U>Section&nbsp;14.2.2(a)</U> (Ionis&#146; Right to Terminate), Ionis will, as promptly as practicable, transfer to Metagenomi possession and ownership of all Regulatory Approvals solely relating to the Exploitation of any Terminated Product in the
Terminated Countries. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>14.3.6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Reversion for Terminated Products other than Combination Products</B>.<B></B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Reversion License Grant</B>. Upon Metagenomi&#146;s written request no later than 30 days following the
effective date of termination and agreement by the Parties of the applicable royalty rate pursuant to <U>Section&nbsp;14.3.6(c)</U> (Reversion Royalties), Ionis will grant and agrees to grant to Metagenomi, an exclusive, royalty-bearing (solely as
provided in <U>Section&nbsp;14.3.6(c)</U> (Reversion Royalties)), right and license, with the right to grant sublicenses through multiple tiers, under Patent Rights and Know-How Controlled by Ionis or its Affiliates to the extent such Patent Rights
or Know-How are actually being used on the date of such termination by the Parties in the Development, Commercialization, or other Exploitation of the Terminated Products in the Terminated Countries as such Terminated Products exist as of the
effective date of termination, solely to Exploit such Terminated Products in the Terminated Countries; <I>provided</I> that, if any such Terminated Products are Combination Products, then such license will not include any license or other rights
with respect to any Other Product that is Covered by Patent Rights Controlled by Ionis or any of its Affiliates and Metagenomi will not obtain a license to any such Other Product other than pursuant to <U>Section&nbsp;14.3.7</U> (Reversion for
Certain Combination Products) (such license grant, the &#147;<B>Reversion License</B>&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Third Party Reversion IP</B>. With respect to any Patent Rights or Know-How that are the subject of the
Reversion License that are in-licensed by Ionis from Third Parties, Ionis will notify Metagenomi of such Patent Rights or Know-How that are sublicensable to Metagenomi under the Reversion License (which notice will describe the terms and conditions
of any Third Party agreements that are applicable to the grant to Metagenomi of the Reversion Licenses under such Patent Rights or Know-How (any such agreement, a &#147;<B>Reversion IP In-License Agreement</B>&#148;), including applicable payment
terms). If Metagenomi elects to receive a sublicense under any Reversion IP In-License Agreement, then Metagenomi will notify Ionis in writing and Metagenomi will be responsible for (i)&nbsp;making all payments (including royalties, milestones, and
other amounts) that are payable by Ionis to the Third Parties under each Reversion IP In-License Agreement with respect to and allocable to the Patent Rights and Know-How that are the subject of the Reversion License and arising out of the
Exploitation of the Terminated Products in the Terminated Countries by making such payments directly to Ionis and, in each instance, Metagenomi will make the requisite payments to Ionis and provide the necessary reporting information to Ionis in
sufficient time to enable Ionis to comply with its obligations under each Reversion IP In-License Agreement, and (ii)&nbsp;complying with any other obligations included in each Reversion IP In-License Agreement that are applicable to the grant to
Metagenomi of the Reversion License under the applicable Patent Rights or Know-How (<I>provided</I> that Ionis has notified Metagenomi of such obligations), and the granting by Metagenomi of a sublicense under the Reversion Licenses will not relieve
Metagenomi of its obligations under subclauses (i)&nbsp;and (ii). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Reversion Royalties</B>. The licenses granted to Metagenomi in <U>Section&nbsp;14.3.6(a)</U> (Reversion
License Grant) will be royalty-bearing, and Metagenomi will pay Ionis, on a Calendar Quarter basis, the royalty rates that are agreed to by the Parties at the time of Metagenomi&#146;s written request delivered pursuant to
<U>Section&nbsp;14.3.6(a)</U> (Reversion License Grant). With respect to the royalty rates to be agreed to by the Parties pursuant to this <U>Section&nbsp;14.3.6(c)</U> (Reversion Royalties), the Parties will
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="23%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
take into account, among other things, (i)&nbsp;[***], (ii)&nbsp;[***], (iii)&nbsp;[***], and (iv)&nbsp;[***], and if the Parties have not reached agreement on such financial terms within [***]
after such effective date of termination, then either Party may refer such matter for resolution pursuant to <U>Section&nbsp;15.1.3</U> (Expedited Dispute Resolution). </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>14.3.7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Reversion for Certain Combination Products</B>. If (a)&nbsp;any of the Terminated Products are Combination
Products that are required, by the approved labeling for such Terminated Product, to be promoted as a Combination Product and the Other Product for such Terminated Product is exclusively Controlled by Ionis, such that Metagenomi is not able to
otherwise acquire such Other Product, and (b)&nbsp;there is no approved label regarding the promotion of the Terminated Product that is not a Combination Product (any such Terminated Product meeting the requirements of (a)&nbsp;and (b), a
&#147;<B>Terminated Combination Products</B>&#148;), then upon Metagenomi&#146;s written request no later than [***] following the effective date of termination for such Terminated Combination Products, the Parties will enter into good faith
negotiations for up to [***] regarding the grant of a non-exclusive, royalty-bearing right and license, with the right to grant sublicenses through multiple tiers, under Patent Rights and Know-How Controlled by Ionis or its Affiliates to the extent
such Patent Rights or Know-How are actually being used on the date of such termination by the Parties in the Development, Commercialization, or other Exploitation of the Terminated Combination Products in the Terminated Countries as such Terminated
Combination Products exist as of the effective date of termination, solely to Exploit such Terminated Combination Products in the Terminated Countries. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>14.3.8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Sublicense Survival</B>. Any sublicense granted hereunder by Ionis will, at the Sublicensee&#146;s option,
survive such termination on the condition that the relevant Sublicensee is not in material breach of any of its obligations under such sublicense. In order to effect this provision, at the request of the Sublicensee, Metagenomi will enter into a
direct license with the Sublicensee on terms that are substantially the same terms as the applicable terms of this Agreement; <I>provided</I> that Metagenomi will not be required to undertake obligations in addition to those required by this
Agreement, and Metagenomi&#146;s rights under such direct license will be consistent with its rights under this Agreement, taking into account the scope of the license granted under such direct license. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>14.4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Confidential Information</B>. Upon the expiration or termination of this Agreement with respect to a
Terminated Product in a Terminated Country, the Receiving Party will return (or, as directed by the Disclosing Party, destroy) all Confidential Information of the Disclosing Party related to such Terminated Product in such Terminated Country to the
Disclosing Party that is in the Receiving Party&#146;s possession or control (other than any Confidential Information required to continue to exercise a Party&#146;s rights that survive such expiration or termination of this Agreement);
<I>provided</I>, <I>however</I>, copies may be retained and stored solely for the purpose of determining a Party&#146;s obligations under this Agreement, subject to the non-disclosure and non-use obligation under <U>Article 11</U> (Confidentiality).
In addition, the Receiving Party will not be required to return or destroy Confidential Information contained in any computer system back-up records made in the ordinary course of business. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>14.5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Surviving Provisions</B>. Subject to the other terms and conditions regarding the termination and survival
of obligations under this Agreement in the event of expiration or termination of this Agreement, upon expiration or termination of this Agreement, all provisions of this Agreement will cease to have any effect, except that the following provisions
will survive any such expiration or termination for any reason for the period of time specified therein, or if not specified, then they will survive indefinitely: <U>Section&nbsp;2.5.1</U> (Reimbursement by Ionis) (solely with respect to obligations
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
accrued, but not yet paid, as of the effective date of termination of this Agreement); <U>Section&nbsp;3.1.3</U> (Unblocking License); <U>Section&nbsp;3.2.2</U> (Unblocking License);
<U>Section&nbsp;3.5</U> (No Implied Licenses); <U>Section&nbsp;9.4</U> (Ionis Product Milestone Payments), <U>Section&nbsp;9.6</U> (Ionis Product Royalty Payments), <U>Section&nbsp;9.9</U> (Payment Obligations Under Certain In-License Agreements),
and <U>Section&nbsp;9.10 (</U>Metagenomi Product Economics) (in each case, solely with respect to obligations accrued, but not yet paid, as of the effective date of expiration or termination of this Agreement); <U>Section&nbsp;9.11</U> (Other
Payments); <U>Section&nbsp;9.12</U> (Right to Offset); <U>Section&nbsp;9.13</U> (Records and Audits) (solely for [***] after termination or expiration of this Agreement); <U>Section&nbsp;9.14</U> (Currency of Payment; Non-Refundable Payments)
through <U>Section&nbsp;9.17</U> (Withholding Taxes); <U>Section&nbsp;10.1.1</U> (Background Intellectual Property); <U>Section&nbsp;10.1.2</U> (By Inventorship); <U>Section&nbsp;10.2</U> (Patent Prosecution) (solely with respect to Joint
Collaboration Patent Rights); <U>Section&nbsp;10.3</U> (Patent Enforcement) (solely with respect to Joint Collaboration Patent Rights); <U>Section&nbsp;11.1</U> (Confidential Information) through <U>Section&nbsp;11.4</U> (Publication Announcements
and Subsequent Disclosures); <U>Section&nbsp;12.6</U> (Warranty Disclaimer); <U>Section&nbsp;13.1</U> (Indemnification of Metagenomi by Ionis) through <U>Section&nbsp;13.5</U> (Limited Liability); <U>Section&nbsp;13.6</U> (Insurance Obligations)
(solely for [***] after expiration or termination of this Agreement); <U>Section&nbsp;14.1</U> (Term) (solely in the event of expiration and with respect to the last two sentences); <U>Section&nbsp;14.3</U> (Effects of Termination);
<U>Section&nbsp;14.4</U> (Confidential Information); this <U>Section&nbsp;14.5</U> (Surviving Provisions);<U> Article 15</U> (Miscellaneous); and <U>Appendix 1</U> (Definitions) (as applicable). Termination or expiration of this Agreement (either in
its entirety or with respect to one or more Licensed Products) will not relieve either Party of any liability that accrued hereunder prior to the effective date of such termination or expiration, preclude either Party from pursuing all rights and
remedies it may have hereunder or at law or in equity with respect to any breach of this Agreement nor prejudice any rights that will have accrued to the benefit of any Party prior to such termination or expiration. The remedies provided in this<U>
Article 14</U> (Term and Termination) are not exclusive of any other remedies a Party may have in law or equity. </TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Article&nbsp;15 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Miscellaneous </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>15.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Dispute Resolution</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>15.1.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Escalation</B>. In the event of any dispute, claim, controversy, or cause of action asserted by a Party
against the other Party or by the Metagenomi Indemnitees against Ionis or by the Ionis Indemnitees against Metagenomi arising out of or related to this Agreement or performance of this Agreement (other than matters within the purview of the JSC,
which will be resolved as set forth in <U>Section&nbsp;4.6</U> (Decision-Making)) (a &#147;<B>Claim</B>&#148;), including any alleged breach of this Agreement or claim for indemnification pursuant to<U> Article 13</U> (Indemnification; Limitation Of
Liability; Insurance), such Party may, by written notice to the other Party, refer such matter to the Parties&#146; respective officers designated below for attempted resolution (each, an &#147;<B>Executive Officer</B>&#148;): </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">For Ionis:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer (or such other senior executive designated by Ionis for such purpose)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">For Metagenomi:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer (or such other senior executive designated by Metagenomi for such purpose)</TD></TR>
</TABLE></DIV> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>15.1.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Arbitration</B>. Except as otherwise expressly set forth in this Agreement, if such Executive Officers do
not resolve the dispute within [***] after receipt of such request, then, either Party may at any time after such [***] period submit such Claim to be finally settled by arbitration administered in accordance with the procedural rules of the
American Arbitration Association (the &#147;<B>AAA</B>&#148;) in effect at the time of submission, as modified by </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
this <U>Section&nbsp;15.1.2</U> (Arbitration) (the &#147;<B>Arbitration</B>&#148;). The Arbitration will be governed by the Applicable Law of the State of New York. The Arbitration will be heard
and determined by three arbitrators who are retired judges or attorneys with at least 20 years of relevant experience, each of whom will be impartial and independent and will not have worked for or on behalf of either Party for at least [***]. Each
Party will appoint one arbitrator and the third arbitrator will be selected by the two Party-appointed arbitrators, or, failing agreement within [***] following appointment of the second arbitrator, by the AAA. Such Arbitration will take place in
New York, NY. The Arbitration award so given will, absent an appealable error under applicable AAA procedural rules, be a final and binding determination of the Claim, will be fully enforceable in any court of competent jurisdiction, and will not
include any damages expressly prohibited by <U>Section&nbsp;13.5</U> (Limited Liability). Ionis will pay the fees, costs, and expenses for the arbitrator it chooses, Metagenomi will pay the fees, costs, and expenses for the arbitrator it chooses,
and the Parties will share payment of the fees, costs and expenses for the third arbitrator. Except in a proceeding to enforce the results of the Arbitration or as otherwise required by Applicable Law or securities exchange, neither Party nor any
arbitrator may disclose the existence, content, or results of any Arbitration hereunder without the prior written consent of both Parties. The Parties will instruct the arbitrators to complete the Arbitration within [***] after selection of the
first arbitrator by a Party and each Party will use reasonable efforts to complete such arbitration proceedings within such time period. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>15.1.3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Expedited Dispute Resolution</B>. If the Executive Officers fail to reach agreement on any Expedited Dispute
within [***] of submission of such Expedited Dispute to the Executive Officers, then either Party may notify the other Party of its intent to invoke dispute resolution under this <U>Section&nbsp;15.1.3</U> (Expedited Dispute Resolution) and such
Expedited Dispute will be resolved by binding arbitration in accordance with this <U>Section&nbsp;15.1.3</U> (Expedited Dispute Resolution) except that the procedures for the conduct of such arbitration will be modified as follows:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The arbitration will be conducted by a single neutral arbitrator selected by the Parties or, failing agreement
by the Parties, by the AAA in accordance with the procedural rules of the AAA. Such arbitrator will be a retired judge or attorney with at least 20 years of relevant experience, who will be impartial and independent and will not have worked for or
on behalf of either Party for at least [***]. The arbitrator will have the authority to engage one or more Third Party experts who are expert in the subject matter of the dispute to advise the arbitrator in rendering his or her decision (each, a
&#147;<B>Third Party Expert</B>&#148;), and the costs of such Third Party Expert(s) will be included in the costs of the arbitration. The arbitrator will seek to obtain the mutual agreement of the Parties regarding such Third Party Expert(s), but
absent such agreement, such Third Party Expert(s) will be selected by the arbitrator. Each Third Party Expert will be a disinterested individual who is not affiliated with either Party or its Affiliates or a Sublicensee and who has expertise and
experience with respect to the subject matter of the Expedited Dispute, as determined by the arbitrator. Neither the Third Party Expert nor any of the Third Party Expert&#146;s former employers will be or have been at any time an Affiliate,
employee, officer or director of, or a consultant for, either Party or any of its Affiliates or a Sublicensee. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Within [***] of appointment of the arbitrator (and selection of the Third Party Expert(s)) in accordance with
this <U>Section&nbsp;15.1.3</U> (Expedited Dispute Resolution), the Parties will submit their written positions regarding the Expedited Dispute to the other Party and the arbitrator. Each Party may submit a revised written position to the arbitrator
within [***] of receiving the other Party&#146;s written position. If so requested by the arbitrator, each Party will make oral or other written submissions to the arbitrator in accordance with procedures to be established by the arbitrator;
<I>provided</I> that the other Party will have the right to be present during any oral submissions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The arbitrator will render a decision in writing within [***] (or such other time period as the Parties may
agree) after receipt of the last Party&#146;s written position, which decision will be in accordance with the applicable provisions of this Agreement, and such decision will be conclusive and binding on the Parties. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding anything to the contrary herein, the arbitration under this <U>Section&nbsp;15.1.3</U>
(Expedited Dispute Resolution) will be conducted as a &#147;baseball arbitration&#148; type proceeding. The arbitrator will select one of the Party&#146;s position as his or her decision, based on what is most reasonable and equitable to each of the
Parties under the circumstances and in light of the terms set forth in this Agreement, and will not have the authority to render any substantive decision other than to so select one Party&#146;s position as initially submitted, or as revised in
accordance with the foregoing, as applicable. The arbitrator may fashion such detailed procedures as the arbitrator considers appropriate to implement this intent. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Parties will instruct the arbitrator to complete all arbitration proceedings within [***] after selection
of the arbitrator and each Party will use reasonable efforts to complete such arbitration proceedings within such time period. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>15.1.4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Tolling</B>. The Parties agree that all applicable statutes of limitation and time-based defenses (such as
estoppel and laches), as well as all time periods in which a Party must exercise rights or perform obligation hereunder, will be tolled once the dispute resolution procedures set forth in this <U>Section&nbsp;15.1</U> (Dispute Resolution) have been
initiated and for so long as they are pending, and the Parties will cooperate in taking all actions reasonably necessary to achieve such a result. In addition, during the pendency of any Claim under this Agreement initiated before the end of any
applicable cure period, including under <U>Section&nbsp;14.2.2</U> (Termination for Material Breach), (a)&nbsp;this Agreement will remain in full force and effect, (b)&nbsp;the provisions of this Agreement relating to termination for material breach
with respect to such Claim will not be effective, and (c)&nbsp;neither Party will issue a notice of termination pursuant to this Agreement based on the subject matter of the arbitration, until the arbitral tribunal has confirmed the material breach
and the existence of the facts claimed by a Party to be the basis for the asserted material breach; <I>provided</I> that if such breach can be cured by (i)&nbsp;the payment of money, the defaulting Party will have an additional [***] within its
receipt of the arbitral tribunal&#146;s decision to pay such amount (or such later date if specified in the arbitral tribunal&#146;s decision) or (ii)&nbsp;the taking of specific remedial actions, the defaulting Party will have a reasonably
necessary period to diligently undertake and complete such remedial actions within such reasonably necessary period or any specific timeframe established by such arbitral tribunal&#146;s decision before any such notice of termination can be issued.
Further, with respect to any time periods that have run during the pendency of the Claim, the applicable Party will have a reasonable period of time or any specific timeframe established by such arbitral tribunal&#146;s decision to exercise any
rights or perform any obligations affected by the running of such time periods. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>15.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Designation of Affiliates.</B> Each Party may discharge any obligations and exercise any rights under this
Agreement through delegation of its obligations or rights to any of its Affiliates; <I>provided</I> that the delegating Party will remain primarily responsible for such obligation. Each Party hereby guarantees the performance by its Affiliates of
such Party&#146;s obligations under this Agreement, and will cause its Affiliates to comply with the provisions of this Agreement in connection with such performance. Any breach by a Party&#146;s Affiliate of any of such Party&#146;s obligations
under this Agreement will be a breach by such Party, and the other Party may proceed directly against such Party without any obligation to first proceed against such Party&#146;s Affiliate. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>15.3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Patent Disputes. </B>Notwithstanding <U>Section&nbsp;15.1.2</U> (Arbitration), if a dispute arises between
the Parties under this Agreement with respect to the inventorship, interpretation, scope, validity, enforceability, applicability or term of any Patent Right, then such dispute will not be resolved pursuant to <U>Section&nbsp;15.1.2</U>
(Arbitration), but instead may be brought by either Party in the federal courts in the State of New York.<B> </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>15.4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Injunctive Relief. </B>Notwithstanding anything to the contrary set forth in this Agreement, the Parties
each stipulate and agree that (a)&nbsp;the other Party&#146;s Confidential Information includes highly sensitive trade secret information, (b)&nbsp;a breach of <U>Section&nbsp;3.6</U> (Exclusivity) or<U> Article 11</U> (Confidentiality), in each
case, may cause irrevocable harm for which monetary damages would not provide a sufficient remedy, and (c)&nbsp;in such case of a breach of <U>Section&nbsp;3.6</U> (Exclusivity) or <U>Article 11</U> (Confidentiality), the non-breaching Party will be
entitled to equitable relief (including temporary or permanent restraining orders, specific performance or other injunctive relief) from any court of competent jurisdiction. In addition, and notwithstanding anything to the contrary set forth in this
Agreement, in the event of any other actual or threatened breach hereunder, the aggrieved Party may seek equitable relief (including temporary or permanent restraining orders, specific performance or other injunctive relief) from any court of
competent jurisdiction without first submitting to the dispute resolution procedures set forth in <U>Section&nbsp;15.1</U> (Dispute Resolution).<B> </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>15.5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Governing Law</B><B></B>. This Agreement will be governed by and construed in accordance with the
laws of the State of New York without taking into consideration any choice of law principles that would lead to the application of the laws of another jurisdiction. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>15.6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Cumulative Remedies</B>.<B></B> The rights and remedies of the Parties under this Agreement are
cumulative and not exclusive and, accordingly, are in addition to and not in lieu of any other rights and remedies of the Parties at law or in equity. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>15.7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Notices.</B> Any notice or report required or permitted to be given or made under this Agreement by
either Party to the other will be in writing and delivered to the other Party at its address indicated below or to such other address as the addressee will have theretofore furnished in writing to the addressor by hand, courier or by registered or
certified airmail (postage prepaid), in writing, by registered or certified airmail (postage prepaid): </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="69%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>If to Ionis:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ionis Pharmaceuticals, Inc.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2855 Gazelle
Court</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Carlsbad, CA 92010</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attention: Chief Business
Officer</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Copy to (which copy will not constitute notice):</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attention: General Counsel</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="69%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>If to Metagenomi:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Metagenomi, Inc.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1545 Park Avenue</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emeryville CA 94608</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attention: Brian C. Thomas</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Copy to (which copy will not constitute notice):</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Copy to</P></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">All notices will be deemed effective: (a)&nbsp;if by courier, on the Business Day of delivery as evidenced by
the courier&#146;s receipt (or if delivered or sent on a non-Business Day, then on the next Business Day); or (b)&nbsp;if sent by registered or certified airmail, on the Business Day of receipt as evidenced on the return receipt. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>15.8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Amendment; Waiver</B>. This Agreement (including all exhibits and attachments to this Agreement
except as set forth in <U>Section&nbsp;2.2.3</U> (Amendments to the Drug Discovery Plans) or <U>Section&nbsp;2.3.2</U> (Amendments to the Exploratory Research Plan)), may be amended, modified, superseded, or cancelled only by a written agreement
between the Parties, and any of the terms of this Agreement may be waived only by a written instrument executed by each Party or, in the case of waiver, by the Party or Parties waiving compliance. The delay or failure of either Party at any time or
times to require performance of any provisions will in no manner affect the rights at a later time to enforce the same. No waiver by either Party of any condition or of the breach of any term contained in this Agreement, whether by conduct, or
otherwise, in any one or more instances, will be deemed to be, or considered as, a further or continuing waiver of any such condition or of the breach of such term or any other term of this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>15.9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Assignment and Successors</B>. Neither Party may assign or transfer this Agreement in whole or in
part or the licenses granted under this Agreement without the other Party&#146;s prior written consent <I>unless</I> such assignment is to (a)&nbsp;a Third Party successor or purchaser of all or substantially all of the assets or businesses to which
this Agreement relates whether pursuant to a sale of assets, merger, or other transaction, in which case the assigning Party will provide prior written notice to the other Party and need not obtain the other Party&#146;s consent or (b)&nbsp;an
Affiliate of such Party, in which case the assigning Party will provide prior written notice to the other Party and need not obtain the other Party&#146;s consent; <I>provided</I> that, in either case, the assigning Party remains fully liable for
the performance of its obligations hereunder by such assignee. Each Party will also have the right to sell, assign, and convey its rights to receive royalties from Net Sales of Licensed Product (with respect to Metagenomi) and Metagenomi Products
(with respect to Ionis) and related rights to receive royalty reports and conduct audits of the other Party, its Affiliates and Sublicensees to Third Party purchasers of royalty interests. Any other assignment of this Agreement by a Party requires
the prior written consent of the other Party. An assignment to an Affiliate will terminate, and all rights so assigned will revert to the assigning Party, if and when such Affiliate ceases to be an Affiliate of the assigning Party. For clarity, any
assignment in violation of this <U>Section&nbsp;15.9</U> (Assignment and Successors) will be null, void, and of no legal effect. This Agreement will be binding upon and inure to the benefit of the Parties and their respective legal representatives,
successors and permitted assigns. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>15.10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Rights in Bankruptcy. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>15.10.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All rights and licenses now or hereafter granted by one Party to the other Party under or pursuant to this
Agreement, including, for the avoidance of doubt, the licenses granted to Ionis pursuant to <U>Section&nbsp;3.1</U> (License Grant to Ionis), are, for all purposes of Section&nbsp;365(n) of the U.S. Bankruptcy Code, licenses of rights to
&#147;intellectual property&#148; as defined in the U.S. Bankruptcy Code. Upon the occurrence of any Insolvency Event with respect to a Party granting a license (the &#147;<B>Licensing Party</B>&#148;), the Licensing Party agrees that the other
Party (the &#147;<B>Licensee</B>&#148;), as licensee of such rights under this Agreement, will retain and may fully exercise all of its rights and elections under the U.S. Bankruptcy Code. Without limiting the generality of the foregoing, the
Parties intend and agree that any sale of a Licensing Party&#146;s assets under Section&nbsp;363 of the U.S. Bankruptcy Code will be subject to Ionis&#146; rights under Section&nbsp;365(n), that the Licensee cannot be compelled to accept a money
satisfaction of its interests in the intellectual property licensed pursuant to this Agreement, and that any such sale therefore may not be made to a purchaser &#147;free and clear&#148; of the Licensee&#146;s rights under this Agreement and
Section&nbsp;365(n) without the express, contemporaneous consent of the Licensee. The Licensing Party will, during the Term, create and maintain current copies or, if not amenable to copying, detailed descriptions or other appropriate embodiments,
to the extent feasible, of all intellectual property licensed under this Agreement. Each Party acknowledges and agrees that &#147;embodiments&#148; of intellectual property within the meaning of Section&nbsp;365(n) include laboratory notes and
notebooks, cell lines, laboratory samples, product samples and inventory, research studies and data, all Regulatory Approvals (and all applications for Regulatory Approval) and rights of reference therein, marketing advertising and promotional
materials, the Licensed Technology, and all information related to the Licensed Technology. If (a)&nbsp;a case under the U.S. Bankruptcy Code is commenced by or against a Licensing Party, (b)&nbsp;this Agreement is rejected as provided in the U.S.
Bankruptcy Code, and (c)&nbsp;the Licensee elects to retain its rights hereunder as provided in Section&nbsp;365(n) of the U.S. Bankruptcy Code, the Licensing Party (in any capacity, including debtor-in-possession) and its successors and assigns
(including a trustee) will: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">provide the Licensee with all such intellectual property (including all embodiments thereof) held by the
Licensing Party and such successors and assigns, or otherwise available to them, immediately upon Ionis&#146; written request. Whenever the Licensee or any of its successors or assigns provides to Ionis any of the intellectual property licensed
hereunder (or any embodiment thereof) pursuant to this <U>Section&nbsp;15.10.1</U>, the Licensee will have the right to perform the Licensing Party&#146;s obligations hereunder with respect to such intellectual property, but neither such provision
nor such performance by the Licensee will release the Licensing Party from liability resulting from rejection of the license or the failure to perform such obligations; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">not interfere with the Licensee&#146;s rights under this Agreement, or any agreement supplemental hereto, to
such intellectual property (including such embodiments), including any right to obtain such intellectual property (or such embodiments) from another entity, to the extent provided in Section&nbsp;365(n) of the U.S. Bankruptcy Code.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>15.10.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All rights, powers and remedies of the Licensee provided herein are in addition to and not in substitution for
any other rights, powers, and remedies now or hereafter existing at law or in equity (including the U.S. Bankruptcy Code) in the event of the commencement of a case under the U.S. Bankruptcy Code with respect to the Licensing Party. The Parties
intend the following rights to extend to the maximum extent permitted by Applicable Law, and to be enforceable under U.S. Bankruptcy Code Section 365(n): </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the right of access to any intellectual property rights (including all embodiments thereof) of the Licensing
Party, or any Third Party with whom the Licensing Party contracts to perform an obligation of the Licensing Party under this Agreement, and, in the case of any such Third Party, which is necessary for the Manufacture, use, sale, import, or export of
Licensed Systems and Licensed Products; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the right to contract directly with any Third Party to complete the contracted work. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>15.11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Force Majeure</B>. Neither Party will be held liable or responsible to the other Party nor be deemed
to be in default under, or in breach of any provision of, this Agreement for failure or delay in fulfilling or performing any obligation (other than a payment obligation) of this Agreement to the extent such failure or delay is due to force majeure.
For purposes of this Agreement, &#147;<B>Force Majeure</B>&#148; is defined as any cause beyond the reasonable control of the affected Party and without the fault or negligence of such Party, which may include acts of God; material changes in
Applicable Law; war; civil commotion; destruction of production facilities or materials by fire, flood, earthquake, explosion or storm; labor disturbances; epidemic; pandemic; quarantine; and failure of public utilities or common carriers. The
Parties agree the effects of the COVID-19 pandemic that is ongoing as of the Effective Date (including related government orders) may be invoked as a Force Majeure for the purposes of this Agreement, even though the pandemic is ongoing, only to the
extent those effects are not reasonably foreseeable by the Parties as of the Effective Date. Notwithstanding the foregoing, a Party will not be excused from making payments owed hereunder due to any Force Majeure circumstances affecting such Party.
In the case of a Force Majeure, the Party affected by such Force Majeure will immediately notify the other Party of such inability and of the period for which such inability is expected to continue. The Party giving such notice will thereupon be
excused from such of its obligations under this Agreement as it is thereby disabled from performing for so long as it is so disabled for up to a maximum of [***], after which time the Parties will promptly meet to discuss in good faith how to best
proceed in a manner that maintains and abides by the Agreement. To the extent possible, the Party affected by such Force Majeure will use reasonable efforts to minimize the duration of any Force Majeure. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>15.12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Interpretation</B>. The Parties acknowledge and agree that: (a)&nbsp;each Party and its counsel
reviewed and negotiated the terms and provisions of this Agreement and have contributed to its revision; (b)&nbsp;the rule of construction to the effect that any ambiguities are resolved against the drafting Party will not be employed in the
interpretation of this Agreement; and (c)&nbsp;the terms and provisions of this Agreement will be construed fairly as to each Party and not in a favor of or against either Party, regardless of which Party was generally responsible for the
preparation of this Agreement. In addition, except as otherwise explicitly specified to the contrary, (i)&nbsp;references to a section, schedule or exhibit means a section of, or schedule or exhibit to this Agreement, unless another agreement is
specified, (ii)&nbsp;the word &#147;including&#148; (in its various forms) means &#147;including without limitation,&#148; (iii)&nbsp;the words &#147;shall&#148; and &#147;will&#148; have the same meaning, (iv)&nbsp;references to a particular
statute or regulation include all rules and regulations thereunder and any predecessor or successor statute, rules or regulations, in each case as amended or otherwise modified from time-to-time, (v)&nbsp;words in the singular will be held to
include the plural and vice versa, and words of one gender will be held to include all genders as the context requires, (vi)&nbsp;references to a particular Person include such Person&#146;s successors and assigns to the extent not prohibited by
this Agreement, (vii)&nbsp;references to &#147;days&#148; will mean calendar days, unless otherwise specified, (viii)&nbsp;the word &#147;or&#148; will not be exclusive, unless the context otherwise requires, (ix)&nbsp;the titles and headings
contained in this Agreement are for reference purposes only and will not affect in any way the meaning or interpretation of this Agreement, (x)&nbsp;the terms &#147;hereof,&#148; &#147;hereby,&#148; &#147;hereto,&#148; and derivative or similar
words refer to this entire Agreement, including any schedules or exhibits hereto, and (xi)&nbsp;unless otherwise specified, &#147;$&#148; is in reference to United States Dollars. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>15.13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Integration</B>. This Agreement, together with all exhibits and schedules attached hereto and each
Co-Development and Co-Commercialization Agreement, any Development Supply Agreement, and any Commercial Supply Agreement, sets forth the entire agreement with respect to the subject matter hereof and thereof and supersedes all other agreements and
understandings between the Parties with respect to such subject matter, including the Confidentiality Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>15.14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Severability</B>. Each Party hereby agrees that it does not intend to violate any public policy,
statutory or common laws, rules, regulations, treaty, or decision of any government agency or executive body thereof of any country or community or association of countries. If one or more provisions of this Agreement be or become invalid, then the
Parties will substitute, by written agreement, valid provisions for such invalid provisions, which valid provisions in their economic effect are sufficiently similar to the invalid provisions such that it can be reasonably assumed that the Parties
would have entered into this Agreement with such valid provisions. If the Parties are unable to agree upon such alternative valid provision, then the invalidity of one or several provisions of this Agreement will not affect the validity of this
Agreement as a whole, unless the invalid provisions are of such essential importance to this Agreement such that it is to be reasonably assumed that the Parties would not have entered into this Agreement without the invalid provisions.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>15.15.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Further Assurances</B>. Each of Ionis and Metagenomi agrees to duly execute and deliver, or cause to
be duly executed and delivered, such further instruments and do and cause to be done such further acts and things, including, the filing of such additional assignments, agreements, documents and instruments, as the other Party may at any time and
from time-to-time reasonably request in connection with this Agreement or to carry out more effectively the provisions and purposes of, or to better assure and confirm unto such other Party its rights and remedies under, this Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>15.16.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Counterparts</B>. This Agreement may be executed in counterparts, all of which taken together will be
regarded as one and the same instrument. Counterparts may be delivered via electronic mail, including Adobe&#153; Portable Document Format (PDF) or any electronic signature complying with the U.S. Federal ESIGN Act of 2000, and any counterpart so
delivered will be deemed to be original signatures, will be valid and binding upon the Parties, and, upon delivery, will constitute due execution of this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>15.17.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Relationship of the Parties</B>. In entering into this Agreement and performing their respective
duties and obligations with respect to the Agreement, the Parties are acting, and intend to be treated, as independent entities, and the activities and resources of each Party will be managed by such Party, acting independently and in its individual
capacity. The relationship between the Parties is that of independent contractors, and neither Party will have the power to bind or obligate the other Party in any manner. Nothing contained in this Agreement will be construed or implied to create an
agency, partnership, joint venture, fiduciary, or employer-employee relationship between the Parties. Except as otherwise expressly provided in this Agreement, neither Party may make any representation, warranty or commitment, whether express or
implied, on behalf of or incur any charges or expenses for or in the name of the other Party. Neither Party will hold itself out, or take any action, contrary to the terms of this <U>Section&nbsp;15.17</U> (Relationship of the Parties), and neither
Party will become liable due to any such representation, warranty, commitment, act or omission made by the other Party contrary to the provisions of this <U>Section&nbsp;15.17</U> (Relationship of the Parties). Subject to the terms of this
Agreement, the activities and resources of each Party will be managed by such Party, acting independently and in its individual capacity. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I></I>[<I>Remainder of page intentionally left blank.</I>]<I> </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly
authorized representatives. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>METAGENOMI, INC.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>IONIS PHARMACEUTICALS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Brian Thomas</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Brett Monia</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Brian Thomas</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Brett Monia</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Chief Executive Officer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Chief Executive Officer</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I></I>[<I>Signature Page to Collaboration and License Agreement</I>]<I> </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Appendix 1 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Definitions </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this Agreement, whether used in the singular or plural, the following terms will have the meanings set forth
below: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>AAA</B>&#148; has the meaning set forth in <U>Section&nbsp;15.1.2</U> (Arbitration).
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Accounting Standards</B>&#148; means United States Generally Accepted Accounting Principles, as
generally and consistently applied throughout a Party&#146;s organization. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Acquiring Party</B>&#148; has the meaning set forth in <U>Section&nbsp;9.8.1</U> (Proposed New
In-License Agreement). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Acquisition Transaction</B>&#148; has the meaning set forth in <U>Section&nbsp;3.6.2</U>
(Acquisition of Distracting Product). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Additional Drug Discovery Plan</B>&#148; has the meaning set forth in <U>Section&nbsp;2.2.2</U>
(Additional Drug Discovery Plans). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Additional Wave 1 Target</B>&#148; has the meaning set forth in <U>Section&nbsp;2.1.1(c)</U>
(Additional Wave 1 Target Selection). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Additional Wave 1 Target Notice</B>&#148; has the meaning set forth in
<U>Section&nbsp;2.1.1(c)</U> (Additional Wave 1 Target Selection). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Additional Wave 1 Target Selection Period</B>&#148; has the meaning set forth in
<U>Section&nbsp;2.1.1(c)</U> (Additional Wave 1 Target Selection). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Affiliate</B>&#148; means, as of any point in time and for so long as such relationship
continues to exist with respect to any Person, any other Person that controls, is controlled by, or is under common control with such Person. For purposes of this <U>Section&nbsp;1.9</U> (Affiliate), the term &#147;control&#148; (including, with
correlative meaning, the terms &#147;controlled by&#148; and &#147;under common control with&#148;), means the possession, directly or indirectly, of more than 50% of the voting stock or other ownership interest of such Person, or the possession,
directly or indirectly, of the power to direct or cause the direction of the affairs or management and policies of such Person or the power to elect or appoint more than 50% of the members of the governing body of such Person. The Parties
acknowledge that in the case of certain entities organized under the laws of certain countries outside the United States, the maximum percentage ownership permitted by Applicable Law for a foreign investor may be less than 50%, and that in such case
such lower percentage will be substituted in the preceding sentence; <I>provided</I> that such foreign investor has the power to direct the management and policies of such entity. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Agreement</B>&#148; has the meaning set forth in the Preamble. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Alliance Manager</B>&#148; has the meaning set forth in <U>Section&nbsp;4.4</U> (Alliance
Managers). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>[***]</B>&#148; means any amount that is less than [***], on a year to date basis, set forth in
the Exploratory Research Budget or a Drug Discovery Budget (as applicable) for such Calendar Year; <I>provided</I> that such amount is not incurred as a result of any breach by Metagenomi of this Agreement. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Annual Net Sales</B>&#148; means, with respect to an Ionis Product, the aggregate Net Sales of
such Ionis Product sold by Ionis, its Affiliates, or Sublicensees in the Field in the Territory during a Calendar Year and only during the Royalty Term for such Ionis Product in the applicable country. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Applicable Law</B>&#148; means applicable (with respect to the particular activity, task, or
obligation under this Agreement to which such term applies) laws, statutes, rules, regulations, and other pronouncements having the effect of law of any Governmental Authority that may be in effect from time to time, including for clarity any
applicable rules, regulations, guidelines, or other requirements of any Regulatory Authority that may be in effect from time to time. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.15.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Arbitration</B>&#148; has the meaning set forth in <U>Section&nbsp;15.1.2</U> (Arbitration).
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.16.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Audited Party</B>&#148; has the meaning set forth in <U>Section&nbsp;9.13.1</U> (Books and
Records). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.17.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Auditing Party</B>&#148; has the meaning set forth in <U>Section&nbsp;9.13.1</U> (Books and
Records). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.18.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Auditor</B>&#148; has the meaning set forth in <U>Section&nbsp;9.13.1</U> (Books and Records).
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.19.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Available</B>&#148; means, with respect to a Proposed Target, that such Proposed Target is not
an Encumbered Target. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.20.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>[***]</B>&#148; has the meaning set forth in <U>Section&nbsp;2.2.4(a)</U> (New [***]).
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.21.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Biosimilar Product</B>&#148; means, with respect to a particular Licensed Product in a
particular country, a product on the market in such country commercialized by any Third Party that is not a Sublicensee and that did not purchase such product in a chain of distribution that included any of Ionis or its Affiliates or Sublicensees,
that (a)&nbsp;is approved by the applicable Regulatory Authority, under any then-existing laws and regulations in the applicable country pertaining to approval of generic or biosimilar biologic products, as a &#147;generic&#148; or
&#147;biosimilar&#148; version of such Licensed Product, which approval uses such Licensed Product as a reference product and relies on or references information in the MAA for such Licensed Product, or (b)&nbsp;is otherwise recognized by the
applicable Regulatory Authority as a biosimilar or interchangeable product to such Licensed Product. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.22.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>BLA</B>&#148; means a biologics license application that is submitted to the FDA for a Licensed
Product, pursuant to 21 C.F.R. &#167; 601.2. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.23.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Business Day</B>&#148; means any day, other than Saturday, Sunday, or any day on which banking
institutions in California are authorized or required by Applicable Law to remain closed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.24.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>C.F.R.</B>&#148; means the U.S. Code of Federal Regulations. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.25.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Calendar Quarter</B>&#148; means each period of three consecutive calendar months ending on
March&nbsp;30,&nbsp;June&nbsp;30,&nbsp;September&nbsp;30, or December&nbsp;31, except that the first Calendar Quarter of the Term will commence on the Effective Date, and the last Calendar Quarter of the Term will end on the effective date of the
termination or expiration of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.26.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Calendar Year</B>&#148; means each period of 12 consecutive calendar months commencing on
January&nbsp;1 and ending on December&nbsp;31, except that the first Calendar Year of the Term will commence on the Effective Date, and the last Calendar Year of the Term will end on the effective date of the termination or expiration of this
Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.27.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Change of Control</B>&#148; means, with respect to a Party, (a)&nbsp;a merger, reorganization,
combination, or consolidation of such Party with a Third Party that results in the holders of beneficial ownership of the voting securities or other voting interests of such Party (or, if applicable, the ultimate parent of such Party) immediately
prior to such merger, reorganization, combination, or consolidation ceasing to hold beneficial ownership of more than 50% of the combined voting power of the surviving entity or the ultimate parent of the surviving entity immediately after such
merger, reorganization, combination or consolidation, (b)&nbsp;a transaction or series of related transactions in which a Third Party, together with its Affiliates, becomes the beneficial owner of 50% or more of the combined voting power of the
outstanding securities or other voting interest of such Party, (c)&nbsp;the sale, lease, exchange, contribution, or other transfer (in one transaction or a series of related transactions) to a Third Party of all or substantially all of such
Party&#146;s assets, or (d)&nbsp;a liquidation or dissolution of such Party or any direct or indirect parent of such Party. Notwithstanding the foregoing, an initial public offering, a <I>bona fide</I> venture capital financing, a SPAC transaction,
or reverse-merger transaction, in each case, of Metagenomi, will not be considered a Change of Control of Metagenomi. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.28.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Claim</B>&#148; has the meaning set forth in <U>Section&nbsp;15.1.1</U> (Escalation).
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.29.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Clinical Trial</B>&#148; means any clinical trial in humans that is designed to generate data
in support or maintenance of an IND or MAA. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.30.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>CMO</B>&#148; means a contract manufacturing organization. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.31.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;[***]&#148; means [***]. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.32.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Co-Co Option</B>&#148; has the meaning set forth in <U>Section&nbsp;5.1.1</U> (Option Grant).
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.33.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Co-Co Option Notice</B>&#148; has the meaning set forth in <U>Section&nbsp;5.1.2</U> (Option
Period). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.34.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Co-Co Option Period</B>&#148; has the meaning set forth in <U>Section&nbsp;5.1.2</U> (Option
Period). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.35.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Co-Co Products</B>&#148; means any Licensed Products that are the subject of a Co-Co Program.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.36.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Co-Co Program</B>&#148; means each Drug Discovery Program for which Metagenomi exercises a
Co-Co Option in accordance with <U>Section&nbsp;5.1</U> (Co-Development and Co-Commercialization Options). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.37.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Co-Development and Co-Commercialization Agreement</B>&#148; has the meaning set forth in
<U>Section&nbsp;5.2</U> (Development and Commercialization of the Co-Co Products; Opt-Down Right). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.38.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Collaboration Activities</B>&#148; has the meaning set forth in <U>Section&nbsp;2.4</U>
(Conduct of Collaboration Activities). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.39.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Collaboration Program</B>&#148; means (a)&nbsp;the Exploratory Research Program and
(b)&nbsp;each Drug Discovery Program. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.40.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Collaboration Program Plans</B>&#148; has the meaning set forth in <U>Section&nbsp;2.4</U>
(Conduct of Collaboration Activities). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.41.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Collaboration Program Report</B>&#148; has the meaning set forth in <U>Section&nbsp;2.6.2</U>
(Collaboration Program Reports). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.42.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Collaboration Target</B>&#148; means, as applicable, any of (a)&nbsp;[***], (b)&nbsp;the Second
Wave 1 Target, and (c)&nbsp;the Proposed Targets that Ionis designates in accordance with <U>Section&nbsp;2.1.4(c)</U> (Effects if a Proposed Target is Available). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.43.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Collaboration Term</B>&#148; means (a)&nbsp;with respect to a Drug Discovery Program, the
applicable Drug Discovery Term for such Drug Discovery Program and (b)&nbsp;with respect to the Exploratory Research Program, the Exploratory Research Term. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.44.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Combination Product</B>&#148; has the meaning set forth in <U>Section&nbsp;1.190</U> (Net
Sales). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.45.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Commercial Supply Agreement</B>&#148; has the meaning set forth in <U>Section&nbsp;8.1.1</U>
(Metagenomi Supply Term). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.46.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Commercialization</B>&#148; or &#147;<B>Commercialize</B>&#148; means with respect to any
product, any and all activities directed to the marketing, promotion, patient services, distribution, pricing, reimbursement, pharmacovigilance, import, export, offering for sale, and sale of such product, including seeking and maintaining any
required Pricing Approval, but excluding any activities directed to Manufacturing, Development, or Medical Affairs. &#147;<B>Commercialize</B>,&#148; &#147;<B>Commercializing</B>,&#148; and &#147;<B>Commercialized</B>&#148; will be construed
accordingly. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.47.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Commercially Reasonable Efforts</B>&#148; means with respect to the efforts to be expended by
any Person with respect to any objective, reasonable, diligent, and good faith efforts to accomplish such objective. With respect to Ionis&#146; obligations set forth in <U>Section&nbsp;6.1.3</U> (Development Diligence for the Ionis Products) and
<U>Section&nbsp;6.2.2</U> (Commercialization Diligence for the Ionis Products), &#147;<B>Commercially Reasonable Efforts</B>&#148; means that level, caliber, and quality of efforts and resources reasonably and normally used by biopharmaceutical
companies of similar size to Ionis as to a potential or actual product with similar commercial potential and at a similar stage of product life, taking into account with respect to each applicable Licensed System or Licensed Product, (a)&nbsp;issues
of safety, efficacy, and product profile, (b)&nbsp;likelihood of receiving Regulatory Approval (including, for clarity, Pricing Approval) of the applicable Licensed Product, (c)&nbsp;regulatory structure involved, (d)&nbsp;feedback provided by any
Regulatory Authority, including relating to proposed or approved labeling, (e)&nbsp;competitiveness in the marketplace and anticipated or actual profitability of the product (including based on the Pricing Approval and the cost of goods thereof,
where applicable), (f)&nbsp;proprietary position, and (g)&nbsp;other scientific, technical, and business factors deemed relevant by Ionis. &#147;<B>Commercially Reasonable Efforts</B>&#148; will be determined on a country-by-country basis in the
relevant countries and [***]. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.48.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Common Ownership Legislation</B>&#148; means the legislation on conditions for patentability
and novelty, as codified at 35 U.S.C. &#167; 102(c) (Common Ownership Under Joint Research Agreements). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.49.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Competitive Infringement</B>&#148; has the meaning set forth in <U>Section&nbsp;10.3.1</U>
(Notification). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.50.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Confidential Information</B>&#148; means (a)&nbsp;the existence and terms of this Agreement,
and (b)&nbsp;with respect to each Party, Know-How, materials, and other proprietary information including data and all other scientific, pre-clinical, clinical, regulatory, Manufacturing, marketing, financial, and commercial information or data that
is disclosed, made available to, or provided by or on behalf of such Party to the other Party or to any of the Receiving Party&#146;s employees, consultants, Affiliates, or Sublicensees, whether or not specifically marked or designated by the
Disclosing Party as confidential; <I>provided</I> that, notwithstanding the foregoing, Product-Specific Know-How will be deemed the Confidential Information of Ionis during the Term and thereafter following any expiration, but not termination, of
this Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.51.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Confidentiality Agreement</B>&#148; has the meaning set forth in <U>Section&nbsp;11.1.2</U>
(Confidential Information of Each Party). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.52.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Control</B>&#148; or &#147;<B>Controlled</B>&#148; means the possession by a Party (whether by
ownership, license, or otherwise other than pursuant to this Agreement) of, (a)&nbsp;with respect to any materials or other tangible Know-How, the legal authority or right to physical possession of such materials or tangible Know-How, with the right
to provide such materials or tangible Know-How to the other Party on the terms set forth herein, (b)&nbsp;with respect to Patent Rights, Regulatory Approvals, Regulatory Submissions, intangible Know-How, or other intellectual property, the legal
authority or right to grant a license, sublicense, access, or right to use (as applicable) to the other Party under such Patent Rights, Regulatory Approvals, Regulatory Submissions, intangible Know-How, or other intellectual property on the terms
set forth herein, in each case ((a) and (b)), without breaching or otherwise violating the terms of any arrangement or agreement with a Third Party in existence as of the time such Party or its Affiliates would first be required hereunder to grant
the other Party such access, right to use, license, or sublicense, and (c)&nbsp;with respect to any product, the legal authority or right to grant an exclusive license or sublicense under Patent Rights that Cover such product or Know-How that
relates to such product; <I>provided</I> that (i)&nbsp;any Know-How or Patent Rights in-licensed or acquired by Metagenomi or its Affiliates under an Existing Potential Metagenomi In-License Agreement or a Proposed New Metagenomi In-License
Agreement will not be deemed &#147;Controlled&#148; by Metagenomi unless and until such agreement becomes a Metagenomi In-License Agreement under <U>Section&nbsp;9.7.1</U> (Effective Date Licensed Technology; Existing Metagenomi In-License
Agreements) or <U>Section&nbsp;9.8.2</U> (Acceptance of a Proposed New In-License Agreement) (and only for so long as it remains a New Metagenomi In-License Agreement hereunder) and (ii)&nbsp;any Know-How or Patent Rights in-licensed or acquired by
Ionis or its Affiliates under an Existing Potential Ionis In-License Agreement or a Proposed New Ionis In-License Agreement will not be deemed &#147;Controlled&#148; by Ionis unless and until such agreement becomes an Ionis In-License Agreement
under <U>Section&nbsp;9.7.2</U> (Existing Potential Ionis In-License Agreements) or <U>Section&nbsp;9.8.2</U> (Acceptance of a Proposed New In-License Agreement) (and only for so long as it remains an Ionis In-License Agreement hereunder).
Notwithstanding the foregoing, a Party and its Affiliates will not be deemed to &#147;<B>Control</B>&#148; any of the foregoing (a)&nbsp;&#150; (c)&nbsp;that are owned or controlled by a Third Party described in the definition of &#147;Change of
Control,&#148; or such Third Party&#146;s Affiliates (other than an Affiliate of such Party prior to the Change of Control), (x)&nbsp;prior to the closing of such Change of Control, except to the extent that any such Patent Rights or Know-How were
developed by such Third Party prior to such Change of Control using or incorporating such Party&#146;s or its pre-existing Affiliate&#146;s Know-How or Patent Rights, or (y)&nbsp;after such Change of Control to the extent that such Patent Rights or
Know-How are developed or conceived by such Third Party or its Affiliates (other than such Party) after such Change of Control without using or incorporating such Party&#146;s or its pre-existing Affiliate&#146;s Know-How or Patent Rights and are
not developed or conceived by personnel who were employees or consultants of such Party or its pre-existing Affiliates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.53.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Cost of Goods</B>&#148; or &#147;<B>COGS</B>&#148; means, with respect to any Licensed Product
or Licensed System supplied by Metagenomi to Ionis pursuant to<U> Article 8</U> (Manufacturing): 100% of: (a)&nbsp;[***]; and (b)&nbsp;[***]. The Cost of Goods will exclude any amounts incurred due to gross negligence or willful misconduct of
Metagenomi, its Affiliates, or any Third Party. All components of Cost of Goods will be allocated on a basis consistent with the Metagenomi&#146;s Accounting Standards and consistent with the cost accounting policy applied by Metagenomi to other
products that it produces. For clarity, the Cost of Goods will not include any cost or expense already paid for by Ionis pursuant to this Agreement or any other agreement between the Parties or their Affiliates. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.54.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Cover</B>,&#148; &#147;<B>Covers</B>,&#148; or &#147;<B>Covered</B>&#148; means, as to a
compound or product and Patent Right, that, in the absence of a license granted under, or ownership of, such Patent Right, the making, using, keeping, selling, offering for sale, or importation of such compound or product would infringe such Patent
Right or, as to a pending claim included in such Patent Right, the making, using, keeping, selling, offering for sale, or importation of such compound or product would infringe such Patent Right if such pending claim were to issue in an issued
patent without modification. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.55.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Development</B>&#148; or &#147;<B>Develop</B>&#148; means, with respect to any product, any and
all internal and external research, development, pharmacovigilance activities, and regulatory activities regarding such product, including (a)&nbsp;research, process development, non-clinical testing, toxicology, non- clinical activities,
IND-enabling studies, and Clinical Trials, and (b)&nbsp;preparation, submission, review, and development of data or information for the purpose of submission to a Regulatory Authority to obtain authorization to conduct Clinical Trials and to obtain,
support, or maintain Regulatory Approval of such product, but excluding any activities directed to Manufacturing, Medical Affairs, or Commercialization. Development will include research, development, and regulatory activities for additional
presentations or indications for a product after receipt of Regulatory Approval of such product, including Clinical Trials initiated following receipt of Regulatory Approval or any Clinical Trial to be conducted after receipt of Regulatory Approval
that was mandated by the applicable Regulatory Authority as a condition of such Regulatory Approval with respect to an approved indication (such as post-marketing approval studies and observational studies, if required by any Regulatory Authority in
any country in the Territory to support or maintain Regulatory Approval for a product in such country, including any phase IV studies). &#147;<B>Develop</B>,&#148; &#147;<B>Developing</B>,&#148; and &#147;<B>Developed</B>&#148; will be construed
accordingly. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.56.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Development Candidate</B>&#148; means a therapeutic agent that is selected by Ionis for further
Development and Commercialization in accordance with its customary internal process and pursuant to <U>Section&nbsp;2.2.6</U> (Delivery of Development Candidate; Development Candidate Report). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.57.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Development Candidate Report</B>&#148; has the meaning set forth in <U>Section&nbsp;2.2.6</U>
(Delivery of Development Candidate; Development Candidate Report). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.58.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Development Cost Share Notice</B>&#148; has the meaning set forth in <U>Section&nbsp;9.3</U>
(Option Exercise Fee). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.59.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Development Supply Agreement</B>&#148; has the meaning set forth in <U>Section&nbsp;8.1.1</U>
(Metagenomi Supply Term). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.60.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Disclosing Party</B>&#148; has the meaning set forth in <U>Section&nbsp;11.1.1</U> (General).
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.61.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Distracted Party</B>&#148; has the meaning set forth in <U>Section&nbsp;3.6.2</U> (Acquisition
of Distracting Product). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.62.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Distracting Product</B>&#148; has the meaning set forth in <U>Section&nbsp;3.6.2</U>
(Acquisition of Distracting Product). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.63.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;[***]&#148; means, with respect to a Distracting Product, [***]. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.64.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Drug Discovery Activities</B>&#148; has the meaning set forth in <U>Section&nbsp;2.2.1</U>
(Initial Drug Discovery Plan). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.65.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Drug Discovery Budget</B>&#148; has the meaning set forth in <U>Section&nbsp;2.2.1</U> (Initial
Drug Discovery Plan). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.66.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Drug Discovery Plan</B>&#148; has the meaning set forth in <U>Section&nbsp;2.2.1</U> (Initial
Drug Discovery Plan). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.67.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Drug Discovery Program</B>&#148; means, on a Collaboration Target-by-Collaboration Target
basis, the program of Development undertaken for a Collaboration Target, as set forth in the applicable Drug Discovery Plan for such Collaboration Target. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.68.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Drug Discovery Term</B>&#148; has the meaning set forth in <U>Section&nbsp;2.2.7</U> (Drug
Discovery Term). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.69.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Effective Date</B>&#148; has the meaning set forth in the Preamble. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.70.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>EMA</B>&#148; means the European Medicines Agency or any successor agency or authority thereto.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.71.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;[***]&#148; has the meaning set forth in Section&nbsp;3 ([***]) of the Exploratory Research Plan
attached hereto as <U>Schedule 2.3.1</U> (Exploratory Research Plan). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.72.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B></B><B>Encumbered Proposed Metagenomi Target</B><B></B>&#148; has the meaning set forth in
<U>Section&nbsp;2.7.3(a) </U>(Encumbered Targets).<B> </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.73.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Encumbered Target</B>&#148; has the meaning set forth in <U>Section&nbsp;2.1.4(a)</U>
(Encumbered Targets). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.74.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Encumbrance</B>&#148; means any and all liens, encumbrances, charges, mortgages, security
interests, hypothecations, easements, rights-of-way or encroachments of any nature whatsoever. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.75.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>European Union</B>&#148; or &#147;<B>EU</B>&#148; means (a)&nbsp;all countries or territories
that are officially part of the European Union, as constituted from time to time, and (b)&nbsp;the United Kingdom. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.76.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Exclusivity Field</B>&#148; means, with respect to a Drug Discovery Program, (a)&nbsp;[***] and
(b)&nbsp;any [***]. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.77.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Executive Officer</B>&#148; has the meaning set forth in <U>Section&nbsp;15.1.1</U>
(Escalation). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.78.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Existing Potential Ionis In-License Agreement</B>&#148; has the meaning set forth in
<U>Section&nbsp;9.7.2</U> (Existing Potential Ionis In-License Agreements). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.79.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Existing Potential Metagenomi In-License Agreement</B>&#148; has the meaning set forth in
<U>Section&nbsp;9.7.2</U> (Effective Date Licensed Technology; Existing Metagenomi In-License Agreements). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.80.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Expedited Dispute</B>&#148; means any dispute (a)&nbsp;that a Party elects pursuant to
<U>Section&nbsp;4.6.3(b)</U> (Resolution by Baseball Arbitration) to refer to resolution pursuant to <U>Section&nbsp;15.1.3</U> (Expedited Dispute Resolution), (b)&nbsp;regarding the determination of any final definitive terms of any Co-Development
and Co-Commercialization Agreement pursuant to <U>Section&nbsp;5.2</U> (Development and Commercialization of the Co-Co Products; Opt-Down Right), (c)&nbsp;regarding the royalty rate or royalty term for any reversion royalty pursuant to
<U>Section&nbsp;14.3.6(c)</U> (Reversion Royalties), or (d)&nbsp;regarding any other provision of this Agreement that the Parties agree to designate as an Expedited Dispute. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.81.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Exploit</B>&#148; means, with respect to any product, to Develop, have Developed, make, have
made, use, have used, perform Medical Affairs, have performed Medical Affairs, offer for sale, have offered for sale, sell, have sold, export, have exported, import, have imported, Manufacture, have Manufactured, Commercialize, have Commercialized,
or otherwise exploit such product. &#147;<B>Exploitation</B>&#148; and &#147;<B>Exploiting</B>&#148; will be construed accordingly. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.82.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Exploratory Research Activities</B>&#148; has the meaning set forth in <U>Section&nbsp;2.3.1</U>
(Exploratory Research Plan). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.83.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Exploratory Research Budget</B>&#148; has the meaning set forth in <U>Section&nbsp;2.3.1</U>
(Exploratory Research Plan). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.84.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Exploratory Research Plan</B>&#148; has the meaning set forth in <U>Section&nbsp;2.3.1</U>
(Exploratory Research Plan). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.85.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Exploratory Research Program</B>&#148; has the meaning set forth in <U>Section&nbsp;2.3.1</U>
(Exploratory Research Plan). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.86.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Exploratory Research Term</B>&#148; has the meaning set forth in <U>Section&nbsp;2.3.3</U>
(Exploratory Research Term). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.87.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>FDA</B>&#148; means the United States Food and Drug Administration and any successor agency or
authority thereto. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.88.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>FD&amp;C Act</B>&#148; means the United States Food, Drug, and Cosmetic Act, as amended, and
the rules and regulations promulgated thereunder, as may be in effect from time to time. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.89.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Field</B>&#148; means, with respect to a given Drug Discovery Program, [***].
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.90.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Firewall Procedures</B>&#148; has the meaning set forth in <U>Section&nbsp;3.6.2</U>
(Acquisition of Distracting Product). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.91.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>First Commercial Sale</B>&#148; means on a Licensed Product-by-Licensed Product and
country-by-country basis, the first sale of a Licensed Product by Ionis, its Affiliate, or its Sublicensee to a Third Party resulting in a Net Sale in a particular country; <I>provided</I> that the following will not constitute a First Commercial
Sale: (a)&nbsp;any sale of a Licensed Product to a Ionis Affiliate or Sublicensee; (b)&nbsp;any sale of a Licensed Product for use in Clinical Trials, pre-clinical studies, or other Development activities at below market price; (c)&nbsp;the disposal
or transfer of a Licensed Product for a <I>bona fide</I> charitable purpose; or (d)&nbsp;compassionate use and &#147;named patient sales.&#148; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.92.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;[***]&#148; means, with respect to an Ionis Program and an Ionis Product Development Milestone
Event, [***]. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.93.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Force Majeure</B>&#148; has the meaning set forth in <U>Section&nbsp;15.11</U> (Force Majeure).
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.94.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>FTE</B>&#148; has the meaning set forth in <U>Section&nbsp;1.95</U> (FTE Rate).
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.95.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>FTE Rate</B>&#148; means an annual rate of $[***] for the time of an employee for a full-time
equivalent (&#147;<B>FTE</B>&#148;) person year (consisting of a total of 1,800 hours per annum) carrying out research, scientific, or technical work under this Agreement, prorated on a daily basis. Without limiting the foregoing, the FTE Rate will
be adjusted annually for each Calendar Year after the Calendar Year ending December&nbsp;31, 2022 to be equal to the FTE Rate for the preceding Calendar Year [***]. The FTE Rate [***]. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.96.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Gene Editing</B>&#148; means [***]. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.97.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Governmental Authority</B>&#148; means any arbitrator, court, judicial, legislative,
administrative or regulatory authority, commission, department, board, bureau, or body, or other government authority or instrumentality or any Person exercising executive, legislative, judicial, regulatory, or administrative functions of or
pertaining to government, whether foreign or domestic, whether federal, state, provincial, municipal, or other. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.98.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Guide RNA</B>&#148; means any single- or double-stranded polynucleotide (including any
analogue, variant, or mimic thereof) used for genome sequence site-specific targeting of a Gene Editing protein. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.99.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Increased Cost Notice</B>&#148; has the meaning set forth in <U>Section&nbsp;2.2.4(c)</U>
(Incremental Development Costs). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.100.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Incremental Development Costs</B>&#148; has the meaning set forth in
<U>Section&nbsp;2.2.4(c)</U> (Incremental Development Costs). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.101.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>IND</B>&#148; means an investigational new drug application filed with the FDA with respect to
a Licensed Product, or an equivalent application filed with the Regulatory Authority of a country in the Territory other than the U.S. (such as an application for a Clinical Trial authorization in the EU). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.102.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Indemnitee</B>&#148; has the meaning set forth in <U>Section&nbsp;13.4</U> (Conditions to
Indemnification). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.103.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Infringement</B>&#148; has the meaning set forth in <U>Section&nbsp;10.3.1</U> (Notification).
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.104.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Initial Interest Notice</B>&#148; has the meaning set forth in <U>Section&nbsp;2.2.4(c)</U>
(Incremental Development Costs). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.105.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Initiation</B>&#148; means, with respect to any Clinical Trial, the date on which the first
subject in such trial receives his or her initial dose in such Clinical Trial. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.106.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Insolvency Event</B>&#148; has the meaning set forth in <U>Section&nbsp;14.2.3</U> (Termination
for Insolvency). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.107.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Intellectual Property Rights</B>&#148; means any Know-How, Patent Rights, Trademarks,
copyrights, trade secrets, and any other intellectual property rights however denominated throughout the world. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.108.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Internal Costs</B>&#148; means, for any period, the product obtained by multiplying
(a)&nbsp;the actual total FTEs (or portion thereof) devoted to the performance of activity under this Agreement during such period, by (b)&nbsp;the applicable FTE Rate. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.109.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Ionis</B>&#148; has the meaning set forth in the Preamble. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.110.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Ionis Background Technology</B>&#148; has the meaning set forth in <U>Section&nbsp;2.7.1</U>
(Option Grant). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.111.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Ionis Collaboration Know-How</B>&#148; has the meaning set forth in
<U>Section&nbsp;10.1.2(b)</U> (Ionis Collaboration Technology). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.112.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Ionis Collaboration Patent Rights</B>&#148; has the meaning set forth in
<U>Section&nbsp;10.1.2(b)</U> (Ionis Collaboration Technology). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.113.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Ionis Collaboration Technology</B>&#148; has the meaning set forth in
<U>Section&nbsp;10.1.2(b)</U> (Ionis Collaboration Technology). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.114.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[***] </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.115.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Ionis Field</B>&#148; means all therapeutic, prophylactic, palliative, analgesic, and
diagnostic uses in humans utilizing oligonucleotides that bind to RNA, which such oligonucleotides are subject to a Valid Claim of a Patent Right Controlled by Ionis. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.116.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Ionis Indemnitees</B>&#148; has the meaning set forth in <U>Section&nbsp;13.2</U>
(Indemnification of Ionis by Metagenomi). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.117.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Ionis In-License Agreement</B>&#148; means (a)&nbsp;any Existing Potential Ionis In-License
Agreement that becomes an Ionis In-License Agreement pursuant to <U>Section&nbsp;9.7.2</U> (Existing Potential Ionis In-License Agreements) and (b)&nbsp;any New Ionis In-License Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.118.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Ionis IP Option</B>&#148; has the meaning set forth in <U>Section&nbsp;2.7.1</U> (Option
Grant). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.119.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Ionis IP Option Effective Date</B>&#148; has the meaning set forth in
<U>Section&nbsp;2.7.3(b)</U> (Effects if a Proposed Metagenomi Target is not an Encumbered Proposed Metagenomi Target). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.120.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Ionis&#146; Knowledge</B>&#148; means the knowledge, after reasonable investigation (including
consultation with Ionis&#146; outside intellectual property counsel), of the following: [***] as of the applicable date. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.121.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Ionis Licensed Know-How</B>&#148; means all Know-How that is Controlled by Ionis or any of its
Affiliates as of the Effective Date or during the Term (other than Joint Collaboration Know-How) that is necessary or reasonably useful to perform the Metagenomi Activities. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.122.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Ionis Licensed Patent Rights</B>&#148; means any Patent Rights Controlled by Ionis or any of
its Affiliates that Cover any Ionis Licensed Know-How. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.123.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Ionis Licensed Technology</B>&#148; means Ionis Licensed Know-How and Ionis Licensed Patent
Rights. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.124.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Ionis Product Development Milestone Event</B>&#148; has the meaning set forth in
<U>Section&nbsp;9.4.1</U> (Ionis Product Development Milestone Payments). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.125.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Ionis Product Development Milestone Payment</B>&#148; has the meaning set forth in
<U>Section&nbsp;9.4.1 </U>(Ionis Product Development Milestone Payments). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.126.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Ionis Product Regulatory Milestone Event</B>&#148; has the meaning set forth in
<U>Section&nbsp;9.4.2</U> (Ionis Product Regulatory Milestone Payments). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.127.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Ionis Product Regulatory Milestone Payment</B>&#148; has the meaning set forth in
<U>Section&nbsp;9.4.2 </U>(Ionis Product Regulatory Milestone Payments). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.128.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Ionis Product Sales Milestone Event</B>&#148; has the meaning set forth in
<U>Section&nbsp;9.4.3</U> (Ionis Product Sales Milestone Payment). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.129.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Ionis Product Sales Milestone Payment</B>&#148; has the meaning set forth in
<U>Section&nbsp;9.4.3</U> (Ionis Product Sales Milestone Payment). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.130.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Ionis Products</B>&#148; means any Licensed Products that are the subject of an Ionis Program.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.131.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Ionis Programs</B>&#148; means each Drug Discovery Program for which Metagenomi does not
exercise its Co-Co Option prior to the expiration of the applicable Co-Co Option Period or which Metagenomi opts out in accordance with <U>Section&nbsp;5.4</U> (Metagenomi Opt-Out). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.132.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Ionis Proprietary Toolbox of Chemical Modifications</B>&#148; [***] that is Covered by an Ionis
Toolbox Patent. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.133.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Ionis-Prosecuted Patent Rights</B>&#148; has the meaning set forth in
<U>Section&nbsp;10.2.1(a)</U>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.134.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Ionis Records</B>&#148; has the meaning set forth in <U>Section&nbsp;9.13.1</U> (Books and
Records). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.135.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Ionis Royalties</B>&#148; has the meaning set forth in <U>Section&nbsp;9.6.1</U> (Ionis Royalty
Rates). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.136.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Ionis Royalty Rates</B>&#148; has the meaning set forth in <U>Section&nbsp;9.6.1</U> (Ionis
Royalty Rates). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.137.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Ionis Royalty Report</B>&#148; has the meaning set forth in <U>Section&nbsp;9.6.4</U> (Ionis
Royalty Reports). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.138.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Ionis Toolbox Patent</B>&#148; means any Patent Right Controlled by Ionis as of the Effective
Date or during the Collaboration Term that [***]. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.139.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Joint Collaboration Know-How</B>&#148; has the meaning set forth in
<U>Section&nbsp;10.1.2(c)</U> (Joint Collaboration Technology). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.140.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Joint Collaboration Patent Rights</B>&#148; has the meaning set forth in
<U>Section&nbsp;10.1.2(c)</U> (Joint Collaboration Technology). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.141.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Joint Collaboration Technology</B>&#148; has the meaning set forth in
<U>Section&nbsp;10.1.2(c)</U> (Joint Collaboration Technology). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.142.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Joint Research Committee</B>&#148; or &#147;<B>JRC</B>&#148; has the meaning set forth in
<U>Section&nbsp;4.3.1</U> (Formation and Purpose of the JRC). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.143.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Joint Steering Committee</B>&#148; or &#147;<B>JSC</B>&#148; has the meaning set forth in
<U>Section&nbsp;4.1.1</U> (Formation and Purpose of the JSC). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.144.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Know-How</B>&#148; means any information and materials, including records, discoveries,
improvements, modifications, processes, techniques, methods, assays, chemical or biological materials, designs, protocols, formulas, data (including physical data, chemical data, toxicology data, animal data, raw data, clinical data, and analytical
and quality control data), dosage regimens, control assays, product specifications, marketing, pricing and distribution costs, inventions, algorithms, technology, forecasts, profiles, strategies, plans, results in any form whatsoever, know-how and
trade secrets (in each case, patentable, copyrightable or otherwise). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.145.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Licensed Know-How</B>&#148; means any Know-How that is Controlled by Metagenomi or any of its
Affiliates as of the Effective Date or during the Term (including Metagenomi Collaboration Know-How, but excluding Joint Collaboration Know-How) that is necessary or reasonably useful to (a)&nbsp;perform the activities under any Collaboration
Program Plan or (b)&nbsp;Exploit any Licensed System or Licensed Product. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.146.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Licensed Patent Right</B>&#148; means any Patent Right Controlled by Metagenomi or any of its
Affiliates as of the Effective Date or during the Term (including Metagenomi Collaboration Patent Rights, but excluding Joint Collaboration Patent Rights) that are necessary or reasonably useful to (a)&nbsp;perform any activities under any
Collaboration Program Plan or (b)&nbsp;Exploit any Licensed System or Licensed Product. The Licensed Patent Rights as of the Effective Date are set forth on <U>Schedule 1.146</U> (Licensed Patent Rights); <I>provided</I> that any Patent Right that
otherwise meets this definition will be deemed a Licensed Patent Right even if such Patent Right is not included on <U>Schedule 1.146</U> (Licensed Patent Rights). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.147.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Licensed Product</B>&#148; means any therapeutic product, medical therapy, preparation or
substance, comprising or employing a Licensed System, in any form or formulation, and whether alone or together with one or more other therapeutically active ingredients, delivery devices, or other components. All Licensed Products comprising the
same Licensed System will be considered the same Licensed Product under this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.148.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Licensed Systems</B>&#148; means, with respect to a Drug Discovery Program, (a)&nbsp;a Gene
Editing protein and a Guide RNA that (i)&nbsp;is designed to modulate the Collaboration Target for such Drug Discovery Program and (ii)&nbsp;either (A)&nbsp;was discovered or Developed by Metagenomi prior to the designation of such Collaboration
Target or (B)&nbsp;is discovered or Developed pursuant to the Drug Discovery Plan for such Drug Discovery Program, including any Development Candidate for such Drug Discovery Program or (b)&nbsp;any modification or derivative of any Gene Editing
protein or Guide RNA described in clause (a). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.149.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Licensed Technology</B>&#148; means all Licensed Know-How and Licensed Patent Rights and
Metagenomi&#146;s interest in the Joint Collaboration Technology. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.150.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Licensee</B>&#148; has the meaning set forth in <U>Section&nbsp;15.10.1</U>.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.151.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Licensing Party</B>&#148; has the meaning set forth in <U>Section&nbsp;15.10.1</U>.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.152.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Losses</B>&#148; has the meaning set forth in <U>Section&nbsp;13.1</U> (Indemnification of
Metagenomi by Ionis). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.153.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>MAA</B>&#148; means any new drug application or other marketing authorization application, in
each case, filed with the applicable Regulatory Authority in a country or other regulatory jurisdiction (and all supplements and amendments thereto), which application is required to commercially market or sell a pharmaceutical or biologic product
in such country or jurisdiction, including (a)&nbsp;all New Drug Applications and BLAs submitted to the FDA in the United States in accordance with the FD&amp;C Act with respect to a pharmaceutical product, (b)&nbsp;all MAAs submitted to
(i)&nbsp;the EMA under the centralized EMA filing procedure in the EU or (ii)&nbsp;a Regulatory Authority in any EU country if the centralized EMA filing procedure is not used to gain Regulatory Approval in such country, (c)&nbsp;all New Drug
Applications submitted to the National Medical Products Administration, or (d)&nbsp;any analogous application or submission with any Regulatory Authority in any other country or regulatory jurisdiction. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.154.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Major European Markets</B>&#148; means each of France, Germany, Spain, Italy, and the United
Kingdom. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.155.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Major Market</B>&#148; means each of Japan, the Major European Markets, and the US.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.156.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Manufacture</B>&#148; or &#147;<B>Manufacturing</B>&#148; means with respect to any product,
any and all activities directed to manufacturing, processing, packaging, labeling, filling, finishing, assembly, quality assurance, quality control, analyses, testing and release, shipping, supply, or storage of such product (or any raw materials,
components or process steps involving such product or any companion diagnostic), placebo, or comparator agent, as the case may be, including qualification, validation, and scale-up, pre-clinical, clinical, and commercial manufacture and analytic
development, product characterization, and stability testing, but excluding any activities directed to Development, Medical Affairs, or Commercialization. &#147;<B>Manufacturing</B>&#148; and &#147;<B>Manufactured</B>&#148; will be construed
accordingly. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.157.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Manufacturing Know-How</B>&#148; has the meaning set forth in <U>Section&nbsp;8.5</U>
(Manufacturing After the Metagenomi Supply Term). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.158.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Manufacturing Technology Transfer</B>&#148; has the meaning set forth in
<U>Section&nbsp;8.5</U> (Manufacturing After the Metagenomi Supply Term). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.159.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Medical Affairs</B>&#148; means any and all activities customarily conducted by the medical
affairs department of a pharmaceutical or biotechnology company commercializing products similar to the Licensed Products, including communications with key opinion leaders, medical education, symposia, advisory boards (to the extent related to
medical affairs or clinical guidance), activities performed in connection with patient registries, and other medical programs and communications, including educational grants, research grants (including conducting investigator-initiated studies),
patient advocacy, and charitable donations to the extent related to medical affairs and not related to activities that involve the promotion, marketing, sale, or other Commercialization of a product and that are not conducted by or on behalf of a
Party&#146;s or any of its Affiliates&#146; medical affairs departments. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.160.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Metagenomi</B>&#148; has the meaning set forth in the Preamble. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.161.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Metagenomi Activities</B>&#148; has the meaning set forth in <U>Section&nbsp;3.2.1(a)</U>
(Metagenomi Activities License Grant). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.162.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>&#147;Metagenomi Collaboration Cost Reports</B>&#148; has the meaning set forth in
<U>Section&nbsp;2.5.1 </U>(Reimbursement by Ionis). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.163.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Metagenomi Collaboration Know-How</B>&#148; has the meaning set forth in
<U>Section&nbsp;10.1.2(a) </U>(Metagenomi Collaboration Technology). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.164.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Metagenomi Collaboration Patent Rights</B>&#148; has the meaning set forth in
<U>Section&nbsp;10.1.2(a) </U>(Metagenomi Collaboration Technology). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.165.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Metagenomi Collaboration Technology</B>&#148; has the meaning set forth in
<U>Section&nbsp;10.1.2(a) </U>(Metagenomi Collaboration Technology). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.166.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>[***]</B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.167.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Metagenomi Drug Discovery Costs</B>&#148; has the meaning set forth in
<U>Section&nbsp;2.5.1</U> (Reimbursement by Ionis). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.168.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>&#147;</B><B>Metagenomi Exploratory Research Costs</B>&#148; has the meaning set forth in
<U>Section&nbsp;2.5.1</U> (Reimbursement by Ionis). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.169.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Metagenomi Field</B>&#148; means all therapeutic, prophylactic, palliative, analgesic, and
diagnostic uses in humans through the use of the Metagenomi Platform. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.170.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Metagenomi In-License Agreements</B>&#148; means (a)&nbsp;any Existing Potential Metagenomi
In-License Agreement that becomes a Metagenomi In-License Agreement pursuant to <U>Section&nbsp;9.7.1</U> (Effective Date Licensed Technology; Existing Metagenomi In-License Agreements) and (b)&nbsp;any New Metagenomi In-License Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.171.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Metagenomi Indemnitees</B>&#148; has the meaning set forth in <U>Section&nbsp;13.1</U>
(Indemnification of Metagenomi by Ionis). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.172.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Metagenomi&#146;s Knowledge</B>&#148; means the knowledge, after reasonable investigation
(including consultation with Metagenomi&#146;s outside intellectual property counsel), of the following: the [***] or, in each case, their functional equivalent. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.173.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Metagenomi Platform</B>&#148; means Metagenomi&#146;s proprietary Gene Editing proteins and
Guide RNAs specifically claimed in a Valid Claim of a Patent Right Controlled by Metagenomi. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.174.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Metagenomi Platform Know-How</B>&#148; means any Know-How within Metagenomi Platform as of the
Effective Date or during the Term. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.175.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Metagenomi Platform Patent Rights</B>&#148; means any Patent Rights Controlled by Metagenomi or
its Affiliates as of the Effective Date or during the Term that Cover any Metagenomi Platform Know-How. The Metagenomi Platform Patent Rights Controlled by Metagenomi or any of its Affiliates as of the Effective Date are listed in <U>Schedule
1.175</U> (Metagenomi Platform Patent Rights); <I>provided</I> that any Patent Right that otherwise meets this definition will be deemed a Metagenomi Platform Patent Right even if such Patent Right is not included on <U>Schedule 1.175</U>
(Metagenomi Platform Patent Rights). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.176.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Metagenomi Platform Technology</B>&#148; means the Metagenomi Platform Patent Rights and the
Metagenomi Platform Know-How. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.177.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Metagenomi Product</B>&#148; means any therapeutic product, medical therapy, preparation or
substance, comprising or employing a Metagenomi System and discovered by Metagenomi, in any form or formulation, and whether alone or together with one or more other therapeutically active ingredients, delivery devices, or other components. All
Metagenomi Products comprising the same Metagenomi System will be considered the same Metagenomi Product under this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.178.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Metagenomi Product Milestone Event</B>&#148; has the meaning set forth in
<U>Section&nbsp;9.10.1</U> (Metagenomi Product Milestone Payments). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.179.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Metagenomi Product Milestone Payment</B>&#148; has the meaning set forth in
<U>Section&nbsp;9.10.1</U> (Metagenomi Product Milestone Payments). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.180.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Metagenomi-Prosecuted Patent Rights</B>&#148; has the meaning set forth in
<U>Section&nbsp;10.2.2</U> (Metagenomi-Prosecuted Patent Rights). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.181.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Metagenomi Records</B>&#148; has the meaning set forth in <U>Section&nbsp;9.13.1</U> (Books and
Records). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.182.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Metagenomi Royalties</B>&#148; has the meaning set forth in <U>Section&nbsp;9.10.3(a)</U>
(Metagenomi Royalty Rates) </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.183.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Metagenomi Royalty Rate</B>&#148; has the meaning set forth in <U>Section&nbsp;9.10.3(a)</U>
(Metagenomi Royalty Rates) </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.184.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Metagenomi Royalty Report</B>&#148; has the meaning set forth in <U>Section&nbsp;9.10.4</U>
(Metagenomi Royalty Reports). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.185.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Metagenomi Royalty Term</B>&#148; means, on a Metagenomi Product-by-Metagenomi Product and
country-by-country basis, the period during the Term ending on the latest of (a)&nbsp;[***] following the First Commercial Sale (applied <I>mutatis mutandis</I>) of a Metagenomi Product in a country, (b)&nbsp;the expiration of the last Valid Claim
of a Patent Right within the Ionis Background Technology Covering such Metagenomi Product in such country, or (c)&nbsp;the expiration of any applicable Regulatory Exclusivity obtained for such Metagenomi Product in such country.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.186.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Metagenomi Supply Term</B>&#148; has the meaning set forth in <U>Section&nbsp;8.1.1</U>
(Metagenomi Supply Term). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.187.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Metagenomi System</B>&#148; means a Gene Editing protein and a Guide RNA that is designed to
modulate a Metagenomi Target. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.188.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Metagenomi Target</B>&#148; means each target for which Metagenomi exercises an Ionis IP Option
pursuant to <U>Section&nbsp;2.7</U> (Ionis Proprietary Toolbox of Chemical Modifications). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.189.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>MG Manufactured Components</B>&#148; has the meaning set forth in <U>Section&nbsp;8.1.1</U>
(Metagenomi Supply Term). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.190.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Net Sales</B>&#148; means the gross invoiced amount for (a)&nbsp;Ionis Products sold by Ionis,
its Affiliates, or Sublicensees or (b)&nbsp;Metagenomi Products sold by Metagenomi, its Affiliates or Sublicensees, in each case ((a) and (b)&nbsp;(the &#147;<B>Selling Party</B>&#148;)), to the extent recognized in the ordinary course of business
as revenue by the Selling Party on an accrual basis in accordance with United States Generally Accepted Accounting Principles or, in the case of non-United States sales, other applicable accounting standards after deduction of the following amounts:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">normal and customary trade, quantity or prompt settlement discounts (including initial launch stocking
discounts, chargebacks, and allowances) actually allowed, <I>provided</I> that such discounts are not applied disproportionately to such Licensed Product or Metagenomi Product when compared to the other products of the Selling Party;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">amounts repaid or credited by reason of rejection, returns or recalls of goods, rebates or <I>bona fide</I>
price reductions determined by the Selling Party in good faith; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">rebates and similar payments made with respect to sales paid for by any Governmental Authority such as, by way
of illustration and not in limitation of the Parties&#146; rights hereunder, Federal or state Medicaid, Medicare or similar state program in the United States or equivalent governmental program in any other country; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">refunds or clawbacks of a portion of payments previously paid by the Selling Party for not achieving a
predetermined metric or term in an outcome-based contracts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any invoiced amounts that are not collected by the Selling Party, including bad debts, (applied to Net Sales in
the period in which such receivables are written off), provided that any such amounts subsequently collected will be included in Net Sales for the period collected; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">excise taxes, value added taxes, sales taxes, consumption taxes and other similar taxes (excluding any income,
franchise, or withholding taxes), customs duties, customs levies and import fees imposed on the sale, importation, use or distribution of the Licensed Product, including fees paid pursuant to Section&nbsp;9008 of the Patient Protection and
Affordable Care Act that the Selling Party allocate to sales of the Licensed Product or Metagenomi Product (as applicable) in accordance with such Selling Party&#146;s standard policies and procedures consistently applied across its products, as
applicable; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an allowance for transportation costs, distribution expenses, special packaging, insurance charges, and storage
and warehousing costs. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net Sales (including any deductions) will be calculated using the Selling
Party&#146;s internal audited systems used to report such sales as adjusted for any of the items above not taken into account in such systems, fairly applied and as employed on a consistent basis throughout such Selling Party&#146;s operations. To
the extent any accrued amounts used in the calculation of Net Sales are estimates, such estimates will be trued-up to actuals (including that, for any estimates of deductions that are later decreased, the difference will be added back to Net Sales).
In no event will any particular amount identified above be deducted more than once in calculating Net Sales (<I>i.e</I>., no &#147;double counting&#148; of deductions). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the case of any sale or other disposal of a product between or among such Party or its Affiliates or Sublicensees for
resale, Net Sales will be calculated only on the value charged or invoiced on the first arm&#146;s-length sale thereafter to a Third Party (other than a Sublicensee). In the case of any sale that is not invoiced or is delivered before invoice, Net
Sales will be calculated at the time all the revenue recognition criteria under such Party&#146;s Accounting Standards are met. In the case of any sale or other disposal for value, such as barter or counter-trade, of any Licensed Product or
Metagenomi Product (as applicable), or part thereof, other than in an arm&#146;s-length transaction exclusively for money, Net Sales will be calculated on the value of the non-cash consideration received or the fair market price (if higher) of such
Licensed Product(s) or Metagenomi Product(s) (as applicable) in the country of sale or disposal. Notwithstanding the foregoing, the following will not be included in Net Sales: (1)&nbsp;sales between or among a Party and its Affiliates or
Sublicensees (but Net Sales will include sales to the first Third Party (other than a Sublicensee) by a Party or its Affiliates or Sublicensees); and (2)&nbsp;any named patient sales or any sale or other distribution at cost or less than cost for
use in any Clinical Trial, for <I>bona fide </I>charitable purposes, test marketing program, or for compassionate use. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Solely for purposes of calculating Net Sales, if the Selling Party sells a Licensed Product or Metagenomi Product (as
applicable) in the form of a combination product containing a Licensed System or Metagenomi System (as applicable) and one or more other therapeutically or prophylactically active ingredients or delivery devices that is not a Licensed System or
Metagenomi System (as applicable) (&#147;<B>Other Product</B>&#148;) (whether combined in a single formulation or package, as applicable, or formulated separately but packaged under a single label approved by a Regulatory Authority and sold together
for a single price) (such combination product, a &#147;<B>Combination Product</B>&#148;), Net Sales of such Combination Product for the purpose of determining the payments due to the other Party pursuant to this Agreement will be calculated by
[***]. If the gross selling price of a Licensed Product or Metagenomi Product (as applicable) containing such Licensed System or Metagenomi System (as applicable) in such country when sold separately in finished form (<I>i.e.</I>, without the other
active ingredients or delivery device) can be determined but the gross selling price of the Other Product in such country cannot be determined, then Net Sales in such country for purposes of determining royalty payments will be calculated by [***].
If such separate sales are not made in a country, then Net Sales will be calculated by [***]. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a license agreement or collaboration agreement that is negotiated in an
arm&#146;s length transaction with an Sublicensee includes a definition of &#147;Net Sales&#148; that differs in any material respect from the definition contained in this <U>Section&nbsp;1.190</U> (Net Sales), then the Parties will discuss such
material differences and will use reasonable efforts to negotiate in good faith any reasonable modifications to this <U>Section&nbsp;1.190</U> (Net Sales) that are necessary to avoid any ambiguity in the calculation of the royalty payment due to a
Party under this Agreement for sales of Licensed Products or Metagenomi Products by such Sublicensee. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.191.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;[***]&#148; means [***]. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.192.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>New In-License Agreement</B>&#148; has the meaning set forth in <U>Section&nbsp;9.8.2</U>
(Acceptance of a Proposed New In-License Agreement). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.193.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>New Ionis In-License Agreement</B>&#148; has the meaning set forth in <U>Section&nbsp;9.8.2
</U>(Acceptance of a Proposed New In-License Agreement). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.194.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>New Metagenomi In-License Agreement</B>&#148; has the meaning set forth in
<U>Section&nbsp;9.8.2</U> (Acceptance of a Proposed New In-License Agreement). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.195.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Non-Withholding Party</B>&#148; has the meaning set forth in <U>Section&nbsp;9.17</U>
(Withholding Taxes). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.196.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Opt-Down Right</B>&#148; has the meaning set forth in <U>Section&nbsp;5.2</U> (Development and
Commercialization of the Co-Co Products; Opt-Down Right). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.197.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Opt-Out Date</B>&#148; has the meaning set forth in <U>Section&nbsp;5.4</U> (Metagenomi
Opt-Out). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.198.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Opt-Out Period</B>&#148; has the meaning set forth in <U>Section&nbsp;5.4</U> (Metagenomi
Opt-Out). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.199.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Opt-Out Right</B>&#148; has the meaning set forth in <U>Section&nbsp;5.4</U> (Metagenomi
Opt-Out). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.200.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Option Exercise Fee</B>&#148; has the meaning set forth in <U>Section&nbsp;9.3</U> (Option
Exercise Fee). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.201.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Option Exercise Notice</B>&#148; has the meaning set forth in <U>Section&nbsp;2.7.2</U> (Option
Exercise). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.202.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Option Package</B>&#148; has the meaning set forth in <U>Section&nbsp;5.1.2</U> (Option
Period). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.203.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Option Term</B>&#148; has the meaning set forth in <U>Section&nbsp;2.7.2</U> (Option Exercise).
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.204.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Other Product</B>&#148; has the meaning set forth in <U>Section&nbsp;1.190</U> (Net Sales).
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.205.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Out-of-Pocket Costs</B>&#148; means, with respect to certain activities hereunder, direct
expenses actually paid or payable by a Party or its Affiliates to Third Parties and specifically identifiable and incurred to conduct such activities, but excluding any costs that are included in the FTE Rate. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.206.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Party</B>&#148; has the meaning set forth in the Preamble. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.207.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Party Vote</B>&#148; has the meaning set forth in <U>Section&nbsp;4.6.1</U> (Committee
Decisions). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.208.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Patent Rights</B>&#148; means all rights, title, and interests in and to (a)&nbsp;all national,
regional, and international patents and patent applications filed in any country of the world including provisional patent applications and all supplementary protection certificates, (b)&nbsp;all patent applications filed either from such patents,
patent applications, or provisional applications or from an application claiming priority to any of the foregoing, including any continuation, continuation-in part, divisional, provisional, converted provisionals and continued prosecution
applications, or any substitute applications, (c)&nbsp;any patent issued with respect to or in the future issued from any such patent applications, including utility models, petty patents, design patents and certificates of invention, and
(d)&nbsp;any and all extensions or restorations by existing or future extension or restoration mechanisms, including revalidations, reissues, reexaminations and extensions (including any supplementary protection certificates and the like) of the
foregoing patents or patent applications. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.209.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Payments</B>&#148; has the meaning set forth in <U>Section&nbsp;9.17</U> (Withholding Taxes).
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.210.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Person</B>&#148; means an individual, sole proprietorship, partnership, limited partnership,
limited liability partnership, corporation, limited liability company, business trust, joint stock company, trust, incorporated association, joint venture or similar entity or organization, including any Governmental Authority (or any department,
agency, or political subdivision thereof). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.211.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Phase III Clinical Trial</B>&#148; means a Clinical Trial that the FDA permits to be conducted
under an open IND and that is performed to gain evidence with statistical significance of the efficacy of such product in a target population, and to obtain expanded evidence of safety for such product that is needed to evaluate the overall
benefit-risk relationship of such product, to form the basis for approval of an MAA by a Regulatory Authority and to provide an adequate basis for physician labeling, in a manner that meets the requirements of 21 C.F.R. &#167; 312.21(c), as amended
(or its successor regulation), or, with respect to any other country or region, the equivalent of such a Clinical Trial in such other country or region. Notwithstanding anything to the contrary set forth in this Agreement, treatment of patients as
part of an expanded access program, compassionate sales or use program (including named patient program or single patient program), or an indigent program, in each case, will not be included in determining whether or not a Clinical Trial is a Phase
III Clinical Trial or whether a patient has been dosed thereunder. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.212.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Pivotal Clinical Trial</B>&#148; means any (a)&nbsp;Phase III Clinical Trial, or (b)&nbsp;other
Clinical Trial of a product on a sufficient number of patients, the results of which, together with prior data and information concerning such product, are intended to be or otherwise are sufficient, without any additional Clinical Trial, to meet
the evidentiary standard for demonstrating the safety, purity, efficacy, and potency of such active substance of such product established by a Regulatory Authority in any particular jurisdiction, as evidenced by finalized meeting minutes or another
written statement from such Regulatory Authority, and that is intended to support, or otherwise supports, the filing of an MAA by a Regulatory Authority in such jurisdiction (including any bridging study). Notwithstanding any provision to the
contrary set forth in this Agreement, treatment of patients as part of an expanded access program, compassionate sales or use program (including named patient program or single patient program), or an indigent program, in each case, will not be
included in determining whether or not a Clinical Trial is a Pivotal Clinical Trial or whether a patient has been dosed thereunder. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.213.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Pre-Existing Ionis Restriction</B>&#148; has the meaning set forth in
<U>Section&nbsp;2.7.3(a)</U> (Encumbered Targets). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.214.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Pre-Existing Restriction</B>&#148; has the meaning set forth in <U>Section&nbsp;2.1.4(a)</U>
(Encumbered Targets). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.215.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Pricing Approval</B>&#148; means, in any country where a Governmental Authority authorizes
reimbursement for, or approves or determines pricing for, pharmaceutical products, receipt (or, if required to make such authorization, approval or determination effective, publication) of such reimbursement authorization or pricing approval or
determination. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.216.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Proceeding</B>&#148; means any action, suit, litigation, arbitration, proceeding (including any
civil, criminal, administrative, investigative or appellate proceeding), prosecution, contest, hearing, inquiry, inquest, audit, examination or investigation that is, has been or may in the future be commenced, brought, conducted or heard at law or
in equity or before any Governmental Authority. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.217.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Product-Specific Know-How</B>&#148; means any Licensed Know-How that specifically relates to
(a)&nbsp;a Licensed System or Licensed Product, (b)&nbsp;any method of making a Licensed System or Licensed Product, or (c)&nbsp;the use of a Licensed System or Licensed Product and no other products that are not Licensed Systems or Licensed
Products. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.218.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Product-Specific Patent Right</B>&#148; means any Licensed Patent Right that specifically
claims (a)&nbsp;a Licensed System or Licensed Product, (b)&nbsp;any method of making a Licensed System or Licensed Product, or (c)&nbsp;the use of a Licensed System or Licensed Product and no other products that are not Licensed Systems or Licensed
Products. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.219.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Proposed Metagenomi Target</B>&#148; has the meaning set forth in <U>Section&nbsp;2.7.2</U>
(Option Exercise). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.220.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>&#147;</B><B>Proposed Metagenomi Target Notice</B>&#148; has the meaning set forth in
<U>Section&nbsp;2.7.2</U> (Option Exercise). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.221.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;[***]&#148; has the meaning set forth in <U>Section&nbsp;2.2.4(c)</U> (Incremental Development
Costs). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.222.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Proposed New In-License Agreement</B>&#148; has the meaning set forth in
<U>Section&nbsp;9.8.1</U> (Proposed New In-License Agreements). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.223.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>&#147;</B><B>Proposed New Ionis In-License Agreement</B>&#148; has the meaning set forth in
<U>Section&nbsp;9.8.1</U> (Proposed New In-License Agreements). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.224.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>&#147;</B><B>Proposed New Metagenomi In-License Agreement</B>&#148; has the meaning set forth in
<U>Section&nbsp;9.8.1 </U>(Proposed New In-License Agreements). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.225.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Proposed Replacement Target</B>&#148; has the meaning set forth in <U>Section&nbsp;2.1.3(d)</U>
(Substitution Procedure). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.226.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Proposed Target</B>&#148; means any (a)&nbsp;Additional Wave 1 Target, (b)&nbsp;Wave 2 Target,
or (c)&nbsp;Proposed Replacement Target. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.227.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Prosecuting Party</B>&#148; means, with respect to any Patent Right, the Party that is
responsible for the Prosecution and Maintenance of such Patent Right pursuant to <U>Section&nbsp;10.2.1</U> (Ionis- Prosecuting Patent Rights) or <U>Section&nbsp;10.2.2</U> (Metagenomi-Prosecuted Patent Rights), as applicable. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.228.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Prosecution and Maintenance</B>&#148; or &#147;<B>Prosecute and Maintain</B>&#148; means, with
regard to a Patent Right, the preparing, filing, prosecuting, and maintenance of such Patent Right, as well as handling re-examinations and reissues with respect to such Patent Right, together with the conduct of interferences, derivation
proceedings, the defense of oppositions, post-grant patent proceedings (such as <I>inter partes</I> review and post grant review), and other similar proceedings with respect to the particular Patent Right. For clarity, &#147;<B>Prosecution and
Maintenance</B>&#148; or &#147;<B>Prosecute and Maintain</B>&#148; will not include any other enforcement actions taken with respect to a Patent Right. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.229.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>&#147;</B><B>Quarterly Reimbursement Payments</B>&#148; has the meaning set forth in
<U>Section&nbsp;2.5.1</U> (Reimbursement by Ionis). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.230.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Receiving Party</B>&#148; has the meaning set forth in <U>Section&nbsp;11.1.1</U> (General).
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.231.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Regulatory Approval</B>&#148; means, with respect to a particular country or other regulatory
jurisdiction in the Territory, any approval of an MAA or other approval, product, or establishment license, registration, or authorization of the applicable Regulatory Authority necessary for the commercial marketing or sale of a pharmaceutical or
biologic product in such country or other regulatory jurisdiction, including, where applicable, Pricing Approval. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.232.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Regulatory Authority</B>&#148; means, with respect to a country in the Territory, any national
(e.g., the FDA), supra-national (e.g., the European Commission, the Council of the European Union, or the EMA), regional, state or local regulatory agency, department, bureau, commission, council or other Governmental Authority involved in the
granting of Regulatory Approvals or Pricing Approvals for pharmaceutical products in such country or countries. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.233.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Regulatory Exclusivity</B>&#148; means, with respect to a Licensed Product or Metagenomi
Product (as applicable) in a country, any data exclusivity rights or other exclusive right, other than a Patent Right, granted, conferred, or afforded by any Regulatory Authority in such country or otherwise under Applicable Law with respect to such
Licensed Product or Metagenomi Product (as applicable) in such country, which either confers exclusive marketing rights with respect to a product or prevents another party from using or otherwise relying on the data supporting the approval of the
Regulatory Approval for a product without the prior written authorization of the Regulatory Approval holder, as applicable, such as new chemical entity exclusivity, exclusivity associated with new Clinical Trials necessary to approval of a change
(e.g., new indication or use), orphan drug exclusivity, non-patent-related pediatric exclusivity, or any other applicable marketing or data exclusivity, including any such periods under national implementations in the EU of Article 10 of Directive
2001/83/EC, Article 14(11) of Parliament and Council Regulation (EC) No 726/2004, Parliament and Council Regulation (EC) No 141/2000 on orphan medicines, Parliament and Council Regulation (EC) No 1901/2006 on medicinal products for pediatric use and
all international equivalents. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.234.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Regulatory Strategy</B>&#148; has the meaning set forth in <U>Section&nbsp;7.1</U> (Regulatory
Responsibility). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.235.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Regulatory Submissions</B>&#148; means any regulatory application, submission, notification,
communication, correspondence, registration, Regulatory Approval, and other filing, made to, received from or otherwise conducted with a Regulatory Authority related to Developing, Manufacturing, obtaining marketing authorization, or otherwise
Commercializing a product in a particular country or jurisdiction, including all INDs, CTAs, BLAs, MAAs, and all applications for Regulatory Approval together with all supplements or amendments to any of the foregoing. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.236.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Reimbursement Cap</B>&#148; has the meaning has the meaning set forth in <U>Section&nbsp;2.5.1
</U>(Reimbursement by Ionis). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.237.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Replacement Target Notice</B>&#148; has the meaning set forth in <U>Section&nbsp;2.1.3(d)</U>
(Substitution Procedure). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.238.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Requested CMO</B>&#148; has the meaning set forth in <U>Section&nbsp;8.1.2</U> (Requested CMO).
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.239.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Requested CMO Contract</B>&#148; has the meaning set forth in <U>Section&nbsp;8.1.2</U>
(Requested CMO). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.240.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Residual Knowledge</B>&#148; has the meaning set forth in <U>Section&nbsp;11.3</U> (Residual
Knowledge). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.241</B><B>.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Reversion IP In-License Agreement</B>&#148; has the meaning set forth in <U>Section&nbsp;14.3.6(b)</U>
(Third Party Reversion IP). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.242.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Reversion License</B>&#148; has the meaning set forth in <U>Section&nbsp;14.3.6(a)</U>
(Reversion License Grant). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.243.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Royalty Bearing Patent Rights</B>&#148; means, with respect to any Licensed Product, all
Licensed Patent Rights that Cover such Licensed Product and that are listed in the then-current edition of the FDA&#146;s Purple Book in connection with the Regulatory Approval of such Licensed Product, or in equivalent patent listings in any other
country within the Territory. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.244.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Royalty Term</B>&#148; means, on a Licensed Product-by-Licensed Product and country-by-country
basis, the period during the Term ending on the latest of (a)&nbsp;12 years following the First Commercial Sale of a Licensed Product in a country, (b)&nbsp;the expiration of the last Valid Claim of the Royalty Bearing Patent Rights Covering such
Licensed Product in such country, or (c)&nbsp;the expiration of any applicable Regulatory Exclusivity obtained for such Licensed Product in such country. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.245.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Second Wave 1 Target</B>&#148; has the meaning set forth in <U>Section&nbsp;2.1.1(b)</U>
(Second Wave 1 Target). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.246.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Selling Party</B>&#148; has the meaning set forth in <U>Section&nbsp;1.190</U> (Net Sales).
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.247.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Subcommittee</B>&#148; has the meaning set forth in <U>Section&nbsp;4.2</U> (Subcommittees).
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.248.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Subcontractor</B>&#148; means a Third Party contractor engaged by a Party to perform certain
obligations or exercise certain rights of such Party under this Agreement on a fee-for-service basis (including Third Party Distributors, contract research organizations, or contract manufacturing organizations). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.249.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Sublicensee</B>&#148; means a Third Party to whom a Party or any of its Affiliates grants a
sublicense under the licenses granted to such Party under this Agreement, as permitted herein, excluding all Subcontractors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.250.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Supply Price</B>&#148; has the meaning set forth in <U>Section&nbsp;8.1.1</U> (Metagenomi
Supply Term). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.251.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Target Selection and Substitution Period</B>&#148; has the meaning set forth in
<U>Section&nbsp;2.1.4(b) </U>(Expiration of Pre-Existing Restrictions). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.252.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Target Substitution Period</B>&#148; has the meaning set forth in <U>Section&nbsp;2.1.3(a)</U>
(Discretionary Substitutions). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.253.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Technological Infeasibility</B>&#148; has the meaning set forth in <U>Section&nbsp;2.1.3(b)</U>
(Substitutions for Technological Infeasibility). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.254.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Term</B>&#148; has the meaning set forth in <U>Section&nbsp;14.1</U> (Term).
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.255.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Terminated Combination Products</B>&#148; has the meaning set forth in
<U>Section&nbsp;14.3.7</U> (Reversion for Certain Combination Products). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.256.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Terminated Country</B>&#148; means (a)&nbsp;any country in the Territory with respect to which
this Agreement is terminated or expires pursuant to<U> Article 14</U> (Term and Termination), and (b)&nbsp;in the event of termination or expiration of this Agreement in its entirety, all countries in the Territory. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.257.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Terminated Products</B>&#148; means (a)&nbsp;any Licensed Product with respect to which this
Agreement is terminated or expires pursuant to<U> Article 14</U> (Term and Termination), and (b)&nbsp;in the event of termination or expiration of this Agreement in its entirety, all Licensed Products. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.258.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Territory</B>&#148; means all countries of the world and all territories and possessions
thereof. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.259.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Third Party</B>&#148; means any Person other than a Party or an Affiliate of a Party.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.260.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Third Party Claims</B>&#148; has the meaning set forth in <U>Section&nbsp;13.1</U>
(Indemnification of Metagenomi by Ionis). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.261.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Third Party Distributor</B>&#148; means any Third Party that distributes (but does not Develop
or Manufacture) a Licensed Product directly to customers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.262.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Third Party Expert</B>&#148; has the meaning set forth in <U>Section&nbsp;15.1.3(a)</U>.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.263.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Third Party Infringement Claim</B>&#148; has the meaning set forth in <U>Section&nbsp;10.4</U>
(Defense of Claims Brought by Third Parties). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.264.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Third Party IP</B>&#148; has the meaning set forth in <U>Section&nbsp;9.6.2(c)</U> (Third Party
Payments). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.265.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Third Party Payment</B>&#148; has the meaning set forth in <U>Section&nbsp;9.6.2(c)</U> (Third
Party Payments). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.266.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Trademarks</B>&#148; means all registered and unregistered trademarks, service marks, trade
dress, trade names, logos, insignias, symbols, designs, and all other indicia of ownership, and combinations thereof. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.267.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;[***]&#148; has the meaning set forth in <U>Section&nbsp;2.1.1(a)</U> (Initial Wave 1 Target).
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.268.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;[***] <B>Target Population</B>&#148; has the meaning set forth in <U>Section&nbsp;9.5</U> (Ionis
Products for [***] Target Populations). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.269</B><B>.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Unblocking Field</B>&#148; means [***]. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.270.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>United States</B>&#148; or &#147;<B>U.S.</B>&#148; means the United States of America and all
of its districts, territories and possessions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.271.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Upfront Payment</B>&#148; has the meaning set forth in <U>Section&nbsp;9.1</U> (Upfront
Payment). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.272.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Valid Claim</B>&#148; means, with respect to a particular country, (a)&nbsp;a claim of any
issued and unexpired patent in such country whose validity, enforceability, or patentability has not been terminated by any of the following: (i)&nbsp;irretrievable lapse, abandonment, revocation, dedication to the public, or disclaimer; or
(ii)&nbsp;a holding, finding, or decision of invalidity, unenforceability, or non-patentability, from which decision no appeal can be further taken, or (b)&nbsp;a claim within a patent application in such country that has not been pending for more
than seven years from the earliest date to which such claim or the applicable patent application is entitled to claim priority and which claim has not been revoked, cancelled, withdrawn, held invalid, or abandoned. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.273.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Warranty Technology</B>&#148; means (a)&nbsp;with respect to any representation or warranty
made as of the Effective Date, (i)&nbsp;the Metagenomi Platform Technology in the Field, and (ii)&nbsp;the Licensed Technology that is necessary or reasonably useful to Exploit Licensed Systems and Licensed Products in the Field that are directed to
[***], and (b)&nbsp;with respect to any representation or warranty made as of the date on which each new target becomes a Collaboration Target pursuant to <U>Section&nbsp;2.1.1(b)</U> (Second Wave 1 Target) or <U>Section&nbsp;2.1.4(c)</U> (Effects
if a Proposed Target is Available), the Licensed Technology that is necessary or reasonably useful to Exploit Licensed Systems and Licensed Products in the Field that are directed to such Collaboration Target. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.274.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Wave 1 Target</B>&#148; means each (a)&nbsp;[***], (b)&nbsp;the Second Wave 1 Target, and
(c)&nbsp;any Additional Wave 1 Target that Ionis designates in accordance with <U>Section&nbsp;2.1.4(c)</U> (Effects if a Proposed Target is Available). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.275.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Wave 2 Target</B>&#148; has the meaning set forth in <U>Section&nbsp;2.1.2</U> (Wave 2 Target
Options). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.276.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Wave 2 Target Notice</B>&#148; has the meaning set forth in <U>Section&nbsp;2.1.2</U> (Wave 2
Target Options). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.277.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Wave 2 Target Selection Fee</B>&#148; has the meaning set forth in <U>Section&nbsp;9.2</U>
(Wave 2 Target Selection Fee). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.278.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Wave 2 Target Selection Period</B>&#148; has the meaning set forth in <U>Section&nbsp;2.1.2</U>
(Wave 2 Target Options). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.279.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Withholding Party</B>&#148; has the meaning set forth in <U>Section&nbsp;9.17</U> (Withholding
Taxes). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule 1.114 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule 1.146 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Licensed Patent Rights </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule 1.166 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule 1.175 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Metagenomi Platform Patent Rights </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***]
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule 2.1.1(a) </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>[***] </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule 2.2 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>[***] </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule 2.3.1 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exploratory Research Plan </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attached<I>.</I> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule 8.2 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Development Supply Agreement Key Terms </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule 11.4 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Press Release(s) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attached<I>.</I> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule 12.2 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Metagenomi Disclosure Schedule </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***]
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule 12.4 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Ionis Disclosure Schedule </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>4
<FILENAME>filename4.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.8</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.8 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT
TREATS AS PRIVATE OR CONFIDENTIAL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEVELOPMENT, OPTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AND LICENSE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BY AND BETWEEN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>METAGENOMI, INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>and
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">AFFINI-T</FONT> THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>June&nbsp;14, 2022 </B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>DEFINITIONS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>GRANT OF LICENSES; EXCLUSIVITY</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Grant of Licenses to <FONT STYLE="white-space:nowrap">Affini-T</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Exclusivity</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Grant of Licenses to Metagenomi</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Potential <FONT STYLE="white-space:nowrap">Co-Development</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>GOVERNANCE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Establishment of Joint Steering Committee; Governance Term</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Membership</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Meetings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Responsibilities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Dispute Resolution</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Alliance Managers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Project Leaders</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>RESEARCH ACTIVITIES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Research Plan</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Conduct of Research Plan</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Compliance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Record Keeping</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Target Termination</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>DEVELOPMENT ACTIVITIES; REGULATORY ACTIVITIES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Responsibility for Development</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Engagement of Third Party Contractors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Development Diligence</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Progress Reports</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Regulatory Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">Know-How</FONT> Sharing; Cooperation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>COMMERCIALIZATION OF PRODUCTS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Responsibility for Commercialization of Licensed Products</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Commercialization Diligence</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Compliance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>MANUFACTURE AND SUPPLY</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Metagenomi Reagents Supply</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Agreement Resolution</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>CONSIDERATION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Equity Grant</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Option Exercise Payments</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Milestone Payments</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Payment of Royalties; Royalty Rates; Accounting and Records</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-i- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(continued) </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>TREATMENT OF CONFIDENTIAL INFORMATION; PUBLICITY</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Confidentiality</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Publicity</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Permitted Publication</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Use of Proprietary Materials</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>INTELLECTUAL PROPERTY RIGHTS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Metagenomi <FONT STYLE="white-space:nowrap">In-Licensed</FONT> IP</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Ownership of Agreement IP</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>FILING, PROSECUTION AND MAINTENANCE OF PATENT RIGHTS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Patent Prosecution</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Third Party Infringement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Defense of Claims</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>TERM AND TERMINATION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Term</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Termination</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Consequences of Termination</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Surviving Provisions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>REPRESENTATIONS AND WARRANTIES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Mutual Representations and Warranties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Additional Representations, Warranties and Covenants of Metagenomi</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Warranty Disclaimer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Warranty of Success</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>INDEMNIFICATION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Indemnification of Metagenomi by <FONT STYLE="white-space:nowrap">Affini-T</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Indemnification of <FONT STYLE="white-space:nowrap">Affini-T</FONT> by Metagenomi</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Conditions to Indemnification</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Limited Liability</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>MISCELLANEOUS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Governing Law</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Notices</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Binding Effect</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Headings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Counterparts</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Amendment; Waiver</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Purposes and Scope</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-ii- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(continued) </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Assignment and Successors; Change of Control</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Force Majeure</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Interpretation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Entire Agreement; Severability</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Further Assurances</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Expenses</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.14</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Intellectual Property</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.15</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Performance by Affiliates</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Table of Schedules: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Schedule 4.1 - Research Plan for [***] </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Schedule
8.1(a) - Initial Restricted Stock Agreement </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Schedule 8.1(b) - Milestone Restricted Stock Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Schedule 9.4 - Form of Materials Transfer Record for Proprietary Materials </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Schedule 13.2.4 - Existing Patents </B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-iii- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEVELOPMENT, OPTION AND </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LICENSE AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This
DEVELOPMENT, OPTION AND LICENSE AGREEMENT (this &#147;<B>Agreement</B>&#148;) is entered into as of June&nbsp;14, 2022 (the &#147;<B>Effective Date</B>&#148;) by and between<B> </B>Metagenomi, Inc. (&#147;<B>Metagenomi</B>&#148;), a Delaware
corporation having a place of business at 1545 Park Ave., Emeryville CA 94608, and <FONT STYLE="white-space:nowrap">Affini-T</FONT> Therapeutics, Inc., a Delaware corporation having a place of business at 343 Arsenal St., Watertown, MA 02472
(&#147;<B><FONT STYLE="white-space:nowrap">Affini-T</FONT></B>&#148;). Each of Metagenomi and <FONT STYLE="white-space:nowrap">Affini-T</FONT> is sometimes referred to individually herein as a &#147;<B>Party</B>&#148; and collectively as the
&#147;<B>Parties</B>&#148;. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Metagenomi is a gene editing company that owns or otherwise controls patent rights and
<FONT STYLE="white-space:nowrap">know-how</FONT> related to gene editing; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, <FONT STYLE="white-space:nowrap">Affini-T</FONT> is a
biotech company developing immune cell receptor-based therapies, preventative treatments and diagnostics; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Parties previously
entered into an amended and restated side letter on May&nbsp;28, 2021 and effective as of December&nbsp;23, 2020 (the &#147;<B>A&amp;R Side Letter</B>&#148;), a Stock Issuance Notice and Restricted Stock Agreement dated December&nbsp;23, 2020
(collectively, the &#147;<B>Existing RSA</B>&#148;) and an MFN waiver letter dated August&nbsp;5, 2021 (the &#147;<B>MFN Waiver</B>&#148;); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Parties wish to have Metagenomi identify, develop or optimize certain Metagenomi Reagents using Metagenomi&#146;s proprietary
technology to be used by <FONT STYLE="white-space:nowrap">Affini-T</FONT> to develop and commercialize gene edited <FONT STYLE="white-space:nowrap">TCR-based</FONT> therapeutic products in the Fields in the Territory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the mutual covenants contained herein, and for other good and valuable consideration, the Parties hereto,
intending to be legally bound, hereby agree as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>1. <U>DEFINITIONS</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever used in this Agreement with an initial capital letter, the terms defined in this Article 1 shall have the meanings specified herein
and therein.<B> </B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.1 &#147;<B>A&amp;R Side Letter</B>&#148; is defined in the Preamble. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.2 &#147;<B>Affiliate</B>&#148; means, with respect to either Party, any Person that directly or indirectly controls, is controlled by or is
under common control with such Party; for purposes of this definition, the term &#147;control&#148; (including, with correlative meaning, the terms &#147;controlled by&#148; or &#147;under common control with&#148;) means direct or indirect
ownership of more than fifty percent (50%), including ownership by trusts with substantially the same beneficial interests, of the voting and equity rights of such Person, firm, trust, corporation, partnership or other entity or combination thereof,
or the power to direct the management of such Person, firm, trust, corporation, partnership or other entity or combination thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.3 &#147;<B>Affini-T</B>&#148; is defined in the Preamble. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.4 &#147;<B>Affini</B><B>-T Agreement IP</B>&#148; is defined in Section&nbsp;10.2.1(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.5 &#147;<B><FONT STYLE="white-space:nowrap">Affini-T</FONT> Agreement <FONT STYLE="white-space:nowrap">Know-How</FONT></B>&#148; is defined
in Section&nbsp;10.2.1(b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.6 &#147;<B><FONT STYLE="white-space:nowrap">Affini-T</FONT> Agreement Patent Rights</B>&#148; is defined in
Section&nbsp;10.2.1(b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.7 &#147;<B><FONT STYLE="white-space:nowrap">Affini-T</FONT> Background IP</B>&#148; means <FONT
STYLE="white-space:nowrap">(a)&nbsp;Know-How</FONT> Controlled by <FONT STYLE="white-space:nowrap">Affini-T</FONT> on or prior to the Effective Date, or that <FONT STYLE="white-space:nowrap">Affini-T</FONT> comes to Control outside of this Agreement
during the Term, that is necessary for Metagenomi to perform its obligations under this Agreement, and (b)&nbsp;Patent Rights Controlled by <FONT STYLE="white-space:nowrap">Affini-T</FONT> on or prior to the Effective Date, or that <FONT
STYLE="white-space:nowrap">Affini-T</FONT> comes to Control outside of this Agreement during the Term, that Cover the <FONT STYLE="white-space:nowrap">Know-How</FONT> described in the foregoing clause (a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.8 &#147;<B>Affini-T Clinical Target</B>&#148; means, as of the Effective Date, each of [***] and, in each case, including any modification,
translation, variation or mutation thereof; provided, that <FONT STYLE="white-space:nowrap">(i)&nbsp;Affini-T</FONT> may replace up to [***] pursuant to Section&nbsp;2.1.2(e); (ii) at any given time, the total number of <FONT
STYLE="white-space:nowrap">Affini-T</FONT> Clinical Targets may not exceed six (6); and (iii)&nbsp;each specifically identified target (i.e., the foregoing (a)&nbsp;through (f) and any replacement target added pursuant to Section&nbsp;2.1.2(e)) will
include genetic variants thereof [***] are deemed one <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target). For the purposes of this definition: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>[***]</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of
the foregoing targets shall cease to be an <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target in the case of termination with respect to such target pursuant to Sections&nbsp;2.1.2(a) or 12.2 or in the case of replacement of such
target pursuant to Section&nbsp;2.1.2(e). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.9 &#147;<B><FONT STYLE="white-space:nowrap">Affini-T</FONT> Indemnitees</B>&#148; is defined
in Section&nbsp;14.2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.10 &#147;<B><FONT STYLE="white-space:nowrap">Affini-T</FONT> Indemnity Claims</B>&#148; is defined in
Section&nbsp;14.2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.11 &#147;<B><FONT STYLE="white-space:nowrap">Affini-T</FONT> IP</B>&#148; means
<FONT STYLE="white-space:nowrap">Affini-T</FONT> Background IP and <FONT STYLE="white-space:nowrap">Affini-T</FONT> Agreement IP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.12
&#147;<B><FONT STYLE="white-space:nowrap">Affini-T</FONT> Patent Rights</B>&#148; means all <FONT STYLE="white-space:nowrap">(a)&nbsp;Affini-T</FONT> Agreement Patent Rights and (b)&nbsp;Patents Rights that are included within <FONT
STYLE="white-space:nowrap">Affini-T</FONT> Background IP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.13 &#147;<B>Agreement</B>&#148; is defined in the Preamble. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.14 &#147;<B>Agreement Dispute</B>&#148; is defined in Section&nbsp;15.1.4. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.15 &#147;<B>Agreement IP</B>&#148; means, as applicable, <FONT STYLE="white-space:nowrap">Affini-T</FONT> Agreement IP or Metagenomi
Agreement IP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.16 &#147;<B>Agreement <FONT STYLE="white-space:nowrap">Know-How</FONT></B>&#148; means all
<FONT STYLE="white-space:nowrap">Know-How</FONT> identified, conceived, discovered, created, reduced to practice or otherwise Developed in the course of conducting activities under this Agreement (e.g., Metagenomi Research Activities). Agreement <FONT
STYLE="white-space:nowrap">Know-How</FONT> is either <FONT STYLE="white-space:nowrap">&#147;Affini-T</FONT> Agreement <FONT STYLE="white-space:nowrap">Know-How&#148;</FONT> or &#147;Metagenomi Agreement
<FONT STYLE="white-space:nowrap">Know-How&#148;.</FONT> </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.17 &#147;<B>Agreement Patent Rights</B>&#148; means Patent Rights that Cover Agreement <FONT
STYLE="white-space:nowrap">Know-How.</FONT> Agreement Patents Rights are either <FONT STYLE="white-space:nowrap">&#147;Affini-T</FONT> Agreement Patent Rights&#148; or &#147;Metagenomi Agreement Patent Rights&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.18 &#147;<B>Alliance Manager</B>&#148; is defined in Section&nbsp;3.6. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.19 &#147;<B>Annual Net Sales</B>&#148; means the cumulative worldwide Net Sales of an applicable Licensed Product in a given Calendar Year.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.20 &#147;<B>Applicable Laws</B>&#148; means any national, international, federal, state or local laws, treaties, statutes, ordinances,
rules and regulations, including any rules, regulations, guidance, guidelines or requirements of any Regulatory Authority, national securities exchange or securities listing organization, that are in effect from time to time during the Term and
apply to a particular activity or Party hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.21 &#147;<B>Available</B>&#148; is defined in Section&nbsp;2.1.2(e). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.22 &#147;<B>Bankruptcy Code</B>&#148; means the U.S.&nbsp;Bankruptcy Code, as amended from time to time, and the rules and regulations and
guidelines promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.23 &#147;<B>BLA</B>&#148; means a Biologics License Application, as defined in the FDCA and
regulations promulgated thereunder, or any successor application or procedure required to sell a Licensed Product in the United States.<B> </B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.24 &#147;<B>Business</B><B> Day</B>&#148; means any day other than: (a)&nbsp;a Saturday, Sunday, or day on which commercial banks in
(i)&nbsp;Boston, Massachusetts or (ii)&nbsp;San Francisco, California are authorized or required by Applicable Law to remain closed; or (b)&nbsp;December&nbsp;25 through January 1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.25 &#147;<B>Calendar Quarter</B>&#148; means the period beginning on the Effective Date and ending on the last day of the calendar quarter
in which the Effective Date falls, and thereafter each successive period of three (3)&nbsp;consecutive calendar months ending on March&nbsp;31, June&nbsp;30, September&nbsp;30 and December 31; provided, that, the final Calendar Quarter shall end on
the last day of the Term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.26 &#147;<B>Calendar Year</B>&#148; means the period beginning on the Effective Date and ending on
December&nbsp;31 of the calendar year in which the Effective Date falls, and thereafter each successive period of twelve (12)&nbsp;months commencing on January&nbsp;1 and ending on December 31; provided, that, the final Calendar Year shall end on
the last day of the Term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.27 &#147;<B>Change of Control</B>&#148; means, with respect to a Party, (a)&nbsp;a merger or consolidation of
such Party with a Third Party that results in the voting securities of such Party outstanding immediately prior thereto, or any securities into which such voting securities have been converted or exchanged, ceasing to represent at least fifty
percent (50%) of the combined voting power of the surviving entity or the parent of the surviving entity immediately after such merger or consolidation, (b)&nbsp;a transaction or series of related transactions in which a Third Party, together
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with its Affiliates, becomes the beneficial owner of fifty percent (50%) or more of the combined voting power of the outstanding securities of such Party, or (c)&nbsp;the sale or other transfer
to a Third Party of all or substantially all of such Party&#146;s assets or all or substantially all of such Party&#146;s assets to which this Agreement relates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.28 &#147;<B>Claim</B>&#148; means a Metagenomi Indemnity Claim or an <FONT STYLE="white-space:nowrap">Affini-T</FONT> Indemnity Claim, as
applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.29 &#147;<B>Clinical</B><B> Trial</B>&#148; means human clinical trials, including Pivotal Trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.30 &#147;<B>CoC Affiliate</B>&#148; is defined in Section&nbsp;2.2.3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.31 &#147;<B>Combination Product</B>&#148; means any Licensed Product sold in combination with or includes one or more Other Components. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.32 &#147;<B>Commercial License</B>&#148; means, on an <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Target-by-Affini-T</FONT></FONT></FONT> Clinical Target basis, individually or collectively, an Exclusive License and/or a
<FONT STYLE="white-space:nowrap">Non-Exclusive</FONT> License with respect to such <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target, as applicable (based on whether an Option for an Exclusive License and/or a <FONT
STYLE="white-space:nowrap">Non-Exclusive</FONT> License is being elected by <FONT STYLE="white-space:nowrap">Affini-T).</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.33
&#147;<B>Commercialization</B>&#148; or &#147;<B>Commercialize</B>&#148; means any and all activities directed to the offering for sale and sale of a Licensed Product including activities directed to marketing, promoting, detailing, distributing,
importing, selling and offering to sell that Licensed Product, and seeking pricing approvals and reimbursement approvals (in each case, as and to the extent applicable) for that Licensed Product in the Territory, and interacting with Regulatory
Authorities regarding the foregoing. When used as a verb, &#147;to<B> Commercialize</B>&#148; and &#147;<B>Commercializing</B>&#148; means to engage in Commercialization, &#147;<B>Commercialized</B>&#148; has a corresponding meaning, and
&#147;<B>Commercial</B>&#148; means activities in connection with any of the foregoing.<B> </B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.34 &#147;<B>Commercially Reasonable
Efforts</B>&#148; means the [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.35 &#147;<B>Commercial Quality Agreement</B>&#148; is defined in Section&nbsp;7.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.36 &#147;<B>Commercial Supply Agreement</B>&#148; is defined in Section&nbsp;7.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.37 &#147;<B>Competing Activities</B>&#148; is defined in Section&nbsp;1.69. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.38 &#147;<B>Competing</B><B> Business</B>&#148; is defined in Section&nbsp;4.2.1(e). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.39 &#147;<B>Competing Acquiror</B>&#148; means [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.40 &#147;<B>Compulsory License</B>&#148; means, with respect to a Licensed Product, in a country or territory, a license or rights granted
to a Third Party by a Governmental Authority within such country or territory to sell or offer for sale such Licensed Product in such country or territory under any Patents Controlled by Metagenomi, <FONT STYLE="white-space:nowrap">Affini-T</FONT>
or their respective Affiliates, without direct or indirect authorization from Metagenomi, <FONT STYLE="white-space:nowrap">Affini-T</FONT> or their respective Affiliates, for example a right granted pursuant to requests under 30&nbsp;August 2003 WTO
decision. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.41 &#147;<B>Confidential Information</B>&#148; means (a)&nbsp;with respect to Metagenomi,
all information Controlled by Metagenomi and Metagenomi&#146;s Proprietary Materials; and (b)&nbsp;with respect to <FONT STYLE="white-space:nowrap">Affini-T,</FONT> all information Controlled by <FONT STYLE="white-space:nowrap">Affini-T</FONT> and <FONT
STYLE="white-space:nowrap">Affini-T&#146;s</FONT> Proprietary Materials, that are, in either case, disclosed or provided by or on behalf of a Party (the &#147;<B>Disclosing Party</B>&#148;) to the other Party (the &#147;<B>Receiving Party</B>&#148;)
or to any of the employees, directors or agents of, or consultants/service providers to, the Receiving Party; provided, that, none of the foregoing shall be deemed Confidential Information if the Receiving Party demonstrates by contemporaneous
credible written documentation that: (1)&nbsp;as of the date of disclosure, it is known to the Receiving Party or its Affiliates, other than by virtue of a prior confidential disclosure to such Receiving Party; (2)&nbsp;as of the date of disclosure
it is in the public domain, or it subsequently enters the public domain through no fault of the Receiving Party; (3)&nbsp;it is obtained by the Receiving Party from a Third Party having a lawful right to make such disclosure free from any obligation
of confidentiality to the Disclosing Party of which the Receiving Party should be reasonably aware; or (4)&nbsp;it is independently developed by or for the Receiving Party without reference to or use of any Confidential Information of the Disclosing
Party. For clarity, any combination of Confidential Information shall not be considered in the public domain or in the possession of the Receiving Party merely because individual elements of such Confidential Information are in the public domain or
in the possession of the Receiving Party unless the combination and its principles are in the public domain or in the possession of the Receiving Party. Notwithstanding anything herein to the contrary, (i)&nbsp;the terms of this Agreement shall
constitute Confidential Information of each Party, and (ii)&nbsp;Confidential Information Controlled by Metagenomi or any of its Affiliates exclusively relating to a Licensed Product or the exploitation thereof, and is not generally related to
Metagenomi&#146;s platform or have applicability beyond a Licensed Product (&#147;<B>Product Information</B>&#148;) shall be deemed to be Confidential Information of <FONT STYLE="white-space:nowrap">Affini-T</FONT> (and <FONT
STYLE="white-space:nowrap">Affini-T</FONT> the Disclosing Party, and Metagenomi the Receiving Party, with respect thereto and regardless of the Party initially disclosing the same). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.42 &#147;<B>Content</B>&#148; is defined in Section&nbsp;9.2.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.43 &#147;<B>Control</B>&#148; or &#147;<B>Controlled</B>&#148; means with respect to any Proprietary Materials, <FONT
STYLE="white-space:nowrap">Know-How,</FONT> Patent Rights, or other intellectual property rights, that a Party or any of its Affiliates has the legal authority or right (whether by ownership or license) to grant to the other Party a license,
covenant not to sue, sublicense, access, or right to use (as applicable) under, in and to such Proprietary Materials, <FONT STYLE="white-space:nowrap">Know-How,</FONT> Patent Rights, or other intellectual property rights, on the terms and conditions
set forth herein, in each case without violating any obligations of the granting Party owed to a Third Party, breaching the terms of any agreement with a Third Party or subjecting the granting Party to any fee or charge. Notwithstanding the
foregoing, any New Affiliate of a Party shall not be considered an Affiliate of such Party for the purposes of this definition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.44
&#147;<B>Cover</B>&#148; or &#147;<B>Covered</B>&#148; or &#147;<B>Covering</B>&#148; means, with respect to a Licensed Product or component thereof, that the Manufacture, use, offer for sale, sale, import or export of such Licensed Product or
component thereof in a particular country by an unlicensed Person would infringe a Valid Claim. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.45 &#147;<B>Data</B><B>
Package</B>&#148; is defined in Section&nbsp;4.1. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.46 &#147;<B>Development</B>&#148; or &#147;<B>Develop</B>&#148; means, with respect to a
Licensed Product, all <FONT STYLE="white-space:nowrap">non-clinical</FONT> and clinical drug development activities that are not Metagenomi Research Activities through and including the performance of Clinical Trials with respect to that Licensed
Product, and the preparation and filing of Regulatory Filings and all regulatory affairs related to the foregoing. When used as a verb, &#147;<B>Developing</B>&#148; means to engage in Development and &#147;<B>Developed</B>&#148; has a corresponding
meaning. For clarity, &#147;<B>Development</B>&#148; shall not include any Commercialization activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.47 &#147;<B>Development
Quality Agreement</B>&#148; is defined in Section&nbsp;7.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.48 <B>&#147;Development Supply Agreement</B>&#148; is defined in
Section&nbsp;7.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.49 &#147;<B>Disclosing Party</B>&#148; is defined in Section&nbsp;1.41. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.50 &#147;<B>Disputed Matter</B>&#148; is defined in Section&nbsp;3.5.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.51 &#147;<B>DMF</B>&#148;<B> </B>means a Drug Master File maintained with a Regulatory Authority in any country within the Territory.<B>
</B>For the purposes of this Agreement, there are two <FONT STYLE="white-space:nowrap">sub-types</FONT> of DMF: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Affini-T-Relevant</FONT></FONT> DMF</B>&#148; is defined in Section&nbsp;5.5.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>MG DMF</B>&#148; means a DMF that is both Controlled by Metagenomi and covers a Metagenomi Reagent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.52 &#147;<B>Drug Approval Application</B>&#148; means, with respect to a Licensed Product in any country in the Territory, an application
for Marketing Authorization for such Licensed Product in such country, including a BLA or a counterpart of a BLA (or the equivalent filing(s) outside of the United States) in any country in the Territory and all renewals, supplements and amendments
to any of the foregoing.<B> </B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.53 &#147;<B>Effective Date</B>&#148; is defined in the Preamble. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.54 &#147;<B>EMA</B>&#148; means the European Medicines Agency or any successor agency or authority thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.55 &#147;<B>Escrow Agent</B>&#148;<B> </B>is defined in Section&nbsp;2.1.2(d). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.56 &#147;<B>Escrow Materials</B>&#148; is defined in Section&nbsp;2.1.2(d). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.57 &#147;<B>European Union</B>&#148; or &#147;<B>EU</B>&#148; means the countries of the European Union as constituted from time to time,
and any successor thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.58 &#147;<B>Exclusive Field</B>&#148; means the treatment, prevention or diagnosis of any human cancer using
products with any engineered Primary TCR alpha/beta T Cells. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.59 &#147;<B>Exclusive License</B>&#148; is defined in
Section&nbsp;2.1.2(b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.60 &#147;<B>Exclusive Option</B>&#148; is defined in Section&nbsp;2.1.2. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.61 &#147;<B>Exclusively Licensed Product</B>&#148; means a
<FONT STYLE="white-space:nowrap">TCR-based</FONT> therapy, preventative treatment, or diagnostic for humans that (a)&nbsp;contains or comprises Primary TCR alpha/beta T Cells, (b)&nbsp;is directed to an
<FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target with respect to which an Exclusive Option has been exercised, and (c)&nbsp;is derived from <I>ex vivo</I> application of a Metagenomi Reagent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.62 &#147;<B>Executive Officers</B>&#148; means the [***], or a designee thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.63 &#147;<B>Existing RSA</B>&#148; is defined in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.64 &#147;<B>Extended Term</B>&#148; is defined in Section&nbsp;12.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.65 &#147;<B>FCPA</B>&#148; is defined in Section&nbsp;4.3.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.66 &#147;<B>FDA</B>&#148; means the United States Food and Drug Administration, or any successor agency or authority thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.67 &#147;<B>FDCA</B>&#148; means the United States Federal Food, Drug, and Cosmetic Act, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.68 &#147;<B>Field</B>&#148; means collectively or individually, as applicable, the Exclusive Field and the
<FONT STYLE="white-space:nowrap">Non-Exclusive</FONT> Field. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.69 &#147;<B>Firewalls</B>&#148; means (a)&nbsp;with respect to Metagenomi,
effective walls and screens (whether technical or physical) established between personnel working on Metagenomi Research Activities, on the one hand, and personnel performing any research, development, manufacturing or commercialization of any
therapeutic, diagnostic or preventative product directed to an <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target in the Exclusive Field on behalf of the CoC Affiliate or engaging in a Competing Business (&#147;<B>Competing
Activities</B>&#148;), on the other hand, to ensure that no nonpublic information, materials (such as lab notebooks, document management systems or other documented or memorialized <FONT STYLE="white-space:nowrap">Know-How)</FONT> or <FONT
STYLE="white-space:nowrap">non-personnel</FONT> resources relating to any <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target or Licensed Product in the Exclusive Field, or any information, materials or
<FONT STYLE="white-space:nowrap">non-personnel</FONT> resources relating to the Commercial License, or to <FONT STYLE="white-space:nowrap">Affini-T</FONT> IP, are accessible by Metagenomi (or CoC Affiliate) personnel performing Competing Activities.
Notwithstanding the foregoing, Metagenomi personnel that manage or supervise multiple programs at Metagenomi will not be subject to the Firewall themselves; provided that, Metagenomi shall keep all laboratory notebooks, information, materials and
records of Metagenomi Research Activities separately from the other laboratory notebooks, information, materials and records of any Competing Activities and shall ensure that any such manager or supervisor personnel is obligated to segregate the
information between Metagenomi Research Activities and Competing Activities (e.g. have such information saved or located separately and cannot be viewed at the same time); and (b)&nbsp;with respect to
<FONT STYLE="white-space:nowrap">Affini-T,</FONT> effective walls and screens (whether technical or physical) established between personnel working on any Licensed Product, on the one hand, and personnel of a Competing Acquiror, on the other hand,
to ensure that no nonpublic information, materials (such as lab notebooks, document management systems or other documented or memorialized <FONT STYLE="white-space:nowrap">Know-How)</FONT> or <FONT STYLE="white-space:nowrap">non-personnel</FONT>
resources relating to any Licensed Product, or any information, materials or <FONT STYLE="white-space:nowrap">non-personnel</FONT> resources relating to the Commercial License, or to Metagenomi IP, are accessible by Competing Acquiror personnel.
Notwithstanding the foregoing, Competing Acquiror personnel that manage or supervise multiple programs at Competing Acquiror and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap">Affini-T</FONT> will not be subject to the Firewall themselves; provided that, <FONT STYLE="white-space:nowrap">Affini-T</FONT> shall keep all laboratory
notebooks, information, materials and records of Licensed Products separately from the other laboratory notebooks, information, materials and records of the Competing Acquiror and shall ensure that any such manager or supervisor personnel is
obligated to segregate the information between Licensed Product and those of the Competing Acquiror (e.g. have such information saved or located separately and cannot be viewed at the same time). &#147;<B>Firewall</B>,&#148; when used as a verb,
means to implement Firewalls. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.70 &#147;<B>First Commercial Sale</B>&#148; means, with respect to a Licensed Product in any country in
the Territory, the date of the first sale, transfer or disposition by <FONT STYLE="white-space:nowrap">Affini-T,</FONT> an Affiliate or Sublicensee to a Third Party in that country after Marketing Authorization for such Licensed Product has been
received in that country; provided, that, the following shall not constitute a First Commercial Sale: (a)&nbsp;any sale, transfer or disposition of a Licensed Product at no more than a de minimis charge for academic research, preclinical, clinical,
or regulatory purposes; (b)&nbsp;any sale, transfer or disposition of a Licensed Product in connection with any patient assistance programs or for a bona fide charitable purpose, including compassionate use or &#147;named patient sales&#148; or to
physicians or hospitals for promotional purposes (including free samples to a level and in an amount which is customary in the industry or which is reasonably proportional to the market for such Licensed Product); or (c)&nbsp;any sale, transfer or
disposition of a Licensed Product for use in Clinical Trials, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies or other research or Development activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.71 &#147;<B>Force Majeure</B>&#148; means any occurrence beyond the reasonable control of a Party that prevents or substantially interferes
with the performance by such Party of any of its obligations hereunder, including by reason of any act of God, flood, fire, explosion, earthquake, casualty or accident, pandemic, epidemic or other health crisis, or war, revolution, civil commotion,
act of terrorism, blockage or embargo, or any injunction, law, order, proclamation, regulation, ordinance, demand or requirement of any government or of any subdivision, authority or representative of any such government. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.72 &#147;<B>Gene Edits</B>&#148; means <I>ex vivo</I> gene edits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.73 &#147;<B>Good Clinical Practices</B>&#148; or &#147;<B>GCP</B>&#148; means all applicable current Good Clinical Practice standards for
the design, conduct, performance, monitoring, auditing, recording, analysis and reporting of Clinical Trials, including, as applicable, (a)&nbsp;as set forth in the ICH, E6 and any other guidelines for good clinical practice for trials on medicinal
products in the Territory, (b)&nbsp;the Declaration of Helsinki (2004)&nbsp;as last amended at the 52nd World Medical Association in October 2000 and any further amendments or clarifications thereto, (c)&nbsp;U.S. Code of Federal Regulations Title
21, Parts 50, 54, 56, 312 and 314, as may be amended from time to time, and (d)&nbsp;the equivalent Applicable Laws in any relevant country, each as may be amended and applicable from time to time and in each case ((a)-(d)), that provide for, among
other things, assurance that the clinical data and reported results are credible and accurate and protect the rights, integrity, and confidentiality of trial subjects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.74 &#147;<B>Good Laboratory Practice</B>&#148;<B> </B>or<B> </B>&#147;<B>GLP</B>&#148;<B> </B>means the then-current standards for
laboratory activities for pharmaceuticals, as set forth in the FDA&#146;s Good Laboratory Practice regulations as defined in 21 C.F.R. Part 58 or the Good Laboratory Practice principles of the Organization for Economic
<FONT STYLE="white-space:nowrap">Co-Operation</FONT> and Development (&#147;<B>OECD</B>&#148;), and such standards of good laboratory practice as are required by the European Union and other organizations and governmental agencies in countries in
which a Licensed Product is intended to be sold, to the extent such standards are not less stringent than the United States Good Laboratory Practice. </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.75 &#147;<B>Good Manufacturing Practice</B>&#148;<B> </B>or<B>
</B>&#147;<B>GMP</B>&#148;<B> </B>means all applicable current Good Manufacturing Practices including, as applicable: (a)&nbsp;the principles detailed in the US Current Good Manufacturing Practices, 21 C.F.R. Parts 4, 210, 211, 601, 610 and 820; (b)
European Directive 2003/94/EC and Eudralex 4; (c) the principles detailed in the WHO TRS 986 Annex 2, TRS 961 Annex 6, and TRS 957 Annex 2, and TRS 99 Annex 2; (d) ICH Q7 guidelines; and (e)&nbsp;the equivalent Applicable Laws in any relevant
country, each as may be amended and applicable from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.76 &#147;<B>Good Research Practices</B>&#148; or
&#147;<B>GRP</B>&#148; means all applicable current Good Research Practices including, as applicable, (a)&nbsp;the Research Quality Association (RQA), 2014, Quality in Research Guidelines for Working in
<FONT STYLE="white-space:nowrap">Non-Regulated</FONT> Research, (b)&nbsp;the World Health Organization (WHO) Quality Practices in Basic Biomedical Research Guidelines, and (c)&nbsp;the equivalent Applicable Laws if any, in any relevant country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.77 &#147;<B>Governance Term</B>&#148; is defined in Section&nbsp;3.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.78 &#147;<B>Government Official</B>&#148; means: (a)&nbsp;any officer or employee of: (i)&nbsp;a government, or any department or agency
thereof; (ii)&nbsp;a government-owned or controlled company, institution, or other entity, including a government-owned hospital or university; or (iii)&nbsp;a public international organization (such as the United Nations, the International Monetary
Fund, the International Committee of the Red Cross, and the World Health Organization), or any department or agency thereof; (b)&nbsp;any political party or party official or candidate for public or political party office; and (c)&nbsp;any person
acting in an official capacity on behalf of any of the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.79 &#147;<B>Governmental Authority</B>&#148; means any
multi-national, federal, state, local, municipal, provincial or other governmental authority of any nature (including any governmental division, prefecture, subdivision, department, agency, bureau, branch, office, commission, council, court or other
tribunal). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.80 &#147;<B>[***]</B>&#148; is defined in Section&nbsp;8.3.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.81 &#147;<B>ICH</B>&#148; is defined in Section&nbsp;4.3.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.82 &#147;<B>IND</B>&#148; means (a)&nbsp;an Investigational New Drug Application, as defined in the FDCA and regulations promulgated
thereunder, or any successor application or procedure required to initiate clinical testing of a Licensed Product in humans in the United States; (b)&nbsp;a counterpart of an Investigational New Drug Application that is required in any other country
or region in the Territory before beginning clinical testing of any Licensed Product in humans in such country or region; and (c)&nbsp;all supplements and amendments to any of the foregoing.<B> </B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.83 &#147;<B>Indemnified Party</B>&#148; is defined in Section&nbsp;14.3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.84 &#147;<B>Indemnifying Party</B>&#148; is defined in Section&nbsp;14.3. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.85 &#147;<B>Infringement</B>&#148; is defined in Section&nbsp;11.2.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.86 &#147;<B>Infringement Notice</B>&#148; is defined in Section&nbsp;11.2.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.87 &#147;<B>Infringement Response</B>&#148; is defined in Section&nbsp;11.2.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.88 &#147;<B>Initial Term</B>&#148; is defined in Section&nbsp;12.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.89 &#147;<B>Initial RSA</B>&#148; is defined in Section&nbsp;8.1.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.90 &#147;<B>iPSC</B>&#148; means induced pluripotent stem cells. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.91 &#147;<B>JSC</B>&#148; is defined in Section&nbsp;3.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.92 &#147;<B><FONT STYLE="white-space:nowrap">Know-How</FONT></B>&#148; means, collectively, inventions, discoveries, improvements, trade
secrets and proprietary methods, whether or not patentable, including: (a)&nbsp;methods of manufacture or use of, and structural and functional information pertaining to, chemical compounds and materials and (b)&nbsp;compositions of matter, data,
formulations, processes, techniques, cell differentiation techniques and protocols, cell growth techniques and protocols, cell handling, cell assays, <FONT STYLE="white-space:nowrap">know-how</FONT> and results, including preclinical,
pharmaceutical, toxicological and clinical data. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.93 &#147;<B>Letter of Authorization</B>&#148; means a written statement by the DMF
holder permitting a Regulatory Authority to refer information in the DMF in support of another party&#146;s submission, as referenced at 21 C.F.R. &#167;314.420(d). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.94 &#147;<B>Licensed Product</B>&#148; means an Exclusively Licensed Product or a <FONT STYLE="white-space:nowrap">Non-Exclusively</FONT>
Licensed Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.95 &#147;<B>Losses</B>&#148; is defined in Section&nbsp;14.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.96 &#147;<B>Major European Market</B>&#148;<B> </B>means each of United Kingdom, Germany, France, Spain, and Italy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.97 &#147;<B>Manufacture</B>&#148;<B> </B>or &#147;<B>Manufactured</B>&#148; or &#147;<B>Manufacturing</B>&#148; means any and all activities
related to the production, manufacture, formulation, finishing, packaging, labeling, shipping and holding of any Licensed Product, or other product or therapy, or any component, intermediary or precursor thereof, and including process development,
process qualification and validation, <FONT STYLE="white-space:nowrap">scale-up,</FONT> <FONT STYLE="white-space:nowrap">pre-clinical,</FONT> <FONT STYLE="white-space:nowrap">non-clinical,</FONT> clinical and commercial manufacture,
characterization, quality assurance and quality control, including testing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.98 &#147;<B>Marketing Authorization</B>&#148; means, with
respect to a Licensed Product, the Regulatory Approval required by Applicable Laws to sell such Licensed Product in a country or region in the Territory. For purposes of clarity, (a) &#147;<B>Marketing Authorization</B>&#148; in the United States
means final approval of a BLA permitting marketing of such Licensed Product in interstate commerce in the United States; (b) &#147;<B>Marketing Authorization</B>&#148; in the European Union means marketing authorization for such Licensed Product
granted either by an individual country or the EMA; (c) &#147;<B>Marketing Authorization</B>&#148; in the United Kingdom means marketing authorization for such Licensed Product granted by the UK Medicines and Healthcare products Regulatory Agency
and (d) &#147;<B>Marketing Authorization</B>&#148; in other countries means marketing authorization for such Licensed Product granted by the competent authority of such other country.<B> </B> </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.99 &#147;<B>Metagenomi</B>&#148; is defined in the Preamble. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.100 &#147;<B>Metagenomi Agreement IP</B>&#148; is defined in Section&nbsp;10.2.1(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.101 &#147;<B>Metagenomi Agreement <FONT STYLE="white-space:nowrap">Know-How</FONT></B>&#148; is defined in Section&nbsp;10.2.1(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.102 &#147;<B>Metagenomi Agreement Patent Rights</B>&#148; is defined in Section&nbsp;10.2.1(a)(ii). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.103 &#147;<B>Metagenomi Background IP</B>&#148; means all Patent Rights and <FONT STYLE="white-space:nowrap">Know-How</FONT> Controlled by
Metagenomi or its Affiliates on or prior to the Effective Date, or that Metagenomi comes to Control outside of this Agreement during the Term, that (a)&nbsp;Cover any Metagenomi Reagent, or Gene Edit using Metagenomi Reagents, (b)&nbsp;are otherwise
necessary or useful to make, use, sell, import or practice any Metagenomi Reagents, or Gene Edit using Metagenomi Reagents, or (c)&nbsp;are otherwise necessary to make, use, sell, import or practice, any Licensed Product; provided that in the case
of this clause (c)&nbsp;if the applicable Patent Rights or <FONT STYLE="white-space:nowrap">Know-How</FONT> are not owned by Metagenomi or its Affiliates, then such Patent Rights or <FONT STYLE="white-space:nowrap">Know-How</FONT> shall only be
included as Metagenomi Background IP in accordance with Section&nbsp;10.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.104 &#147;<B>Metagenomi Indemnitees</B>&#148; is defined in
Section&nbsp;14.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.105 &#147;<B>Metagenomi Indemnity Claims</B>&#148; is defined in Section&nbsp;14.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.106 &#147;<B>Metagenomi</B> <B><FONT STYLE="white-space:nowrap">In-Licensed</FONT> IP</B>&#148; means Patent Rights or <FONT
STYLE="white-space:nowrap">Know-How</FONT> Metagenomi <FONT STYLE="white-space:nowrap">in-licenses</FONT> after the Effective Date that are necessary to make, use, sell import or practice any Licensed Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.107 &#147;<B>Metagenomi IP</B>&#148; means Metagenomi Background IP and Metagenomi Agreement IP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.108 &#147;<B>Metagenomi Patent Rights</B>&#148; means all (a)&nbsp;Metagenomi Agreement Patent Rights and (b)&nbsp;Patents Rights that are
included within Metagenomi Background IP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.109 &#147;<B>Metagenomi Reagent</B>&#148; means each of (a) [***], or (b) [***] , and (c)
[***] For clarity, Metagenomi Reagents shall include [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.110 &#147;<B>Metagenomi Reagent Improvement</B>&#148; means [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.111 &#147;<B>Metagenomi Research Activities</B>&#148; means activities undertaken by or on behalf of Metagenomi under a Research Plan to
identify, develop and optimize Metagenomi Reagents to implement Gene Edits for use in developing and commercializing gene edited <FONT STYLE="white-space:nowrap">TCR-based</FONT> products.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.112 &#147;<B>Milestone</B>&#148; means the earlier of the date upon which (a)&nbsp;an <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Affini-T-Relevant</FONT></FONT> DMF that has been approved by the JSC is submitted to the FDA, or (b)&nbsp;an IND that references a MG DMF is accepted by the FDA as evidenced by no
objection by the FDA within [***]after the date of submission of such IND (or any amended submission if such amendment restarted the applicable [***]period). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.113 &#147;<B>Milestone RSA</B>&#148; is defined in Section&nbsp;8.1.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.114 &#147;<B>MFN Waiver</B>&#148; is defined in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.115 &#147;<B>Net Sales</B>&#148; means [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.116 &#147;<B>New
Affiliate</B>&#148; means a Third Party that becomes an Affiliate of a Party after the Effective Date through or after a Change of Control of such Party, other than (i)&nbsp;such Party, or (ii)&nbsp;any Affiliates of such Party immediately before
the consummation of such Change of Control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.117 &#147;<B><FONT STYLE="white-space:nowrap">Non-Exclusive</FONT> Field</B>&#148; means
the treatment, prevention or diagnosis of any human cancer using products with engineered Other Immune Cells. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.118 &#147;<B><FONT
STYLE="white-space:nowrap">Non-Exclusive</FONT> License</B>&#148; is defined in Section&nbsp;2.1.2(c). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.119 &#147;<B><FONT
STYLE="white-space:nowrap">Non-Exclusive</FONT> Option</B>&#148; is defined in Section&nbsp;2.1.2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.120 &#147;<B><FONT
STYLE="white-space:nowrap">Non-Exclusively</FONT> Licensed Product</B>&#148; means a <FONT STYLE="white-space:nowrap">TCR-based</FONT> therapy, preventative treatment, or diagnostic for humans that (a)&nbsp;contains or comprises Other Immune Cells,
(b)&nbsp;is directed to an <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target with respect to which a <FONT STYLE="white-space:nowrap">Non-Exclusive</FONT> Option has been exercised, and (c)&nbsp;is derived from <FONT
STYLE="white-space:nowrap">ex-vivo</FONT> application of a Metagenomi Reagent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.121 &#147;<B>OECD</B>&#148; is defined in
Section&nbsp;1.74. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.122 &#147;<B>Option</B>&#148; is defined in Section&nbsp;2.1.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.123 &#147;<B>Option Exercise Fee</B>&#148; is defined in Section&nbsp;8.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.124 &#147;<B>Option Period</B>&#148; means, with respect to a given <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target in a
given Field, the time period beginning on the Effective Date and ending at the earlier of: (a)&nbsp;the end of the Initial Term, or if applicable, the Extended Term or (b)&nbsp;ninety (90) days following the date on which <FONT
STYLE="white-space:nowrap">Affini-T</FONT> files an IND for a Licensed Product directed to such <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target. For clarity, there are two (2)&nbsp;Option Periods per
<FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target: one (1)&nbsp;for the Exclusive Option and one (1)&nbsp;for the <FONT STYLE="white-space:nowrap">Non-Exclusive</FONT> Option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.125 &#147;<B>Other Components</B>&#148; means any (i) [***], or (ii) [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.126 &#147;<B>Other Immune Cells</B>&#148; means (a)&nbsp;TCR natural killer (NK) cells derived from iPSC immune cells or (b)&nbsp;TCR T
cells derived from donor-derived or iPSC immune cells. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.127 &#147;<B>Partial Termination</B>&#148; is defined in Section&nbsp;12.2.1 and
Section&nbsp;12.2.2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.128 &#147;<B>Party</B>&#148; and &#147;<B>Parties</B>&#148; are defined in the Preamble. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.129 &#147;<B>Patent Costs</B>&#148; means the costs and expenses incurred by a Party
(including reasonable external attorneys&#146; fees) in the conduct of Patent Prosecution or Patent Defense activities, as the case may be, for which that Party is responsible in accordance with this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.130 &#147;<B>Patent Defense</B>&#148; means the responsibility for defending any interference, declaratory judgment action, opposition,
derivation, <I>inter partes</I> review, post-grant review, reexamination, reissue, or other Third Party challenge or similar proceeding alleging the invalidity, unenforceability or <FONT STYLE="white-space:nowrap">non-infringement</FONT> of any
Patent Rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.131 &#147;<B>Patent Prosecution</B>&#148; means the responsibility for preparing, filing and prosecuting patent
applications (of all types) for any Patent Rights, and for maintaining any Patent Rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.132 &#147;<B>Patent Rights</B>&#148; means
the rights and interests in and to issued patents and pending patent applications (which, for purposes of this Agreement, include certificates of invention, applications for certificates of invention and priority rights) in any country or region,
including all provisional applications, substitutions, continuations, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part,</FONT></FONT> divisions, renewals, all letters patent granted thereon, and all reissues, <FONT
STYLE="white-space:nowrap">re-examinations</FONT> and extensions thereof, and all foreign counterparts of any of the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.133
&#147;<B>PDF</B>&#148; is defined in Section&nbsp;15.5. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.134 &#147;<B>Person</B>&#148; means an individual, sole proprietorship,
partnership, limited partnership, limited liability partnership, corporation, limited liability company, business trust, joint stock company, trust, incorporated association, joint venture or similar entity or organization, including a government or
political subdivision, department or agency of a government. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.135 &#147;<B>Pivotal Trial</B>&#148; means, with respect to any Licensed
Product, a single randomized, placebo or active controlled human clinical trial of a Licensed Product on sufficient numbers of patients that is designed to demonstrate statistically that such Licensed Product is safe and efficacious for its intended
use, to evaluate the risk-benefit relationship of such Licensed Product, and to define warnings, precautions and adverse reactions that are associated with such Licensed Product in the dosage range to be prescribed, as described in 21 C.F.R.
&#167;312.21(c) or corresponding foreign regulations, and that is intended to support a complete application for Regulatory Approval of such Licensed Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.136 &#147;<B>Plan Budget</B>&#148; is defined in Section&nbsp;4.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.137 [***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.138
&#147;<B>Product Information</B>&#148; is defined in Section&nbsp;1.41. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.139 &#147;<B>Project Leader</B>&#148; is defined in
Section&nbsp;3.7. </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.140 &#147;<B>Proprietary Materials</B>&#148;<B> </B>means<B> </B>(a)<B></B>&nbsp;any
tangible chemical, biological or physical materials that are Controlled and furnished by the Transferring Party to the Recipient Party, whether or not specifically designated as proprietary by the Transferring Party, or (b)&nbsp;any tangible
chemical, biological or physical materials that are generated, conceived or reduced to practice in the conduct of the Research Plan; provided, that &#147;Proprietary Materials&#148; does not include any Licensed Product or Metagenomi Reagents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.141 &#147;<B>Quality Agreement</B>&#148; means a document developed, approved, and updated by the Parties that sets forth the quality
expectations, responsibilities, rights (including, as applicable and agreed upon, audit requirements) and requirements relating to the Manufacture and supply of Metagenomi Reagents, as executed hereunder, or relating to supply of Metagenomi Reagents
for Clinical Trials or Commercialization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.142 &#147;<B>Receiving Party</B>&#148; is defined in Section&nbsp;1.41. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.143 &#147;<B>Recipient Party</B>&#148; is defined in Section&nbsp;9.4. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.144 &#147;<B>Recovery</B>&#148; is defined in Section&nbsp;11.2.5. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.145 &#147;<B>Regulatory Approval</B>&#148; means, with respect to any country or region in the Territory, any approval, establishment
license, registration or authorization of any Regulatory Authority required for the Manufacture, use, storage, importation, exportation, transport or distribution of any Licensed Product for use in such country or region.<B> </B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.146 &#147;<B>Regulatory Authority</B>&#148; means any national, international, regional, state or local regulatory agency, department,
bureau, commission, council or other governmental entity with authority over the distribution, importation, exportation, Manufacture, use, storage, transport, clinical testing, pricing, sale or reimbursement of any Licensed Product in the
Territory.<B> </B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.147 &#147;<B>Regulatory Filing</B>&#148; means, collectively: (a)&nbsp;any IND, CTA, Drug Approval Application,
establishment license application, DMF, application for designation as an &#147;Orphan Drug&#148; under the Orphan Drug Act, for &#147;Fast Track&#148; status under Section&nbsp;506 of the FDCA (21 U.S.C. &#167; 356) or for a Special Protocol
Assessment under Section&nbsp;505(b)(4)(B) and (C)&nbsp;of the FDCA (21 U.S.C. &#167; 355(b)(4)(B)) and all other similar filings (including counterparts of any of the foregoing in any country or region in the Territory); (b) all supplements and
amendments to any of the foregoing; and (c)&nbsp;all data and other information contained in, and correspondence relating to, any of the foregoing.<B> </B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.148 &#147;<B>Regulatory</B><B> Representative</B>&#148; is defined in Section&nbsp;5.5.3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.149 &#147;<B>Replacement Notice Response</B>&#148; is defined in Section&nbsp;2.1.2(e). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.150 &#147;<B>Replacement Notice</B>&#148; is defined in Section&nbsp;2.1.2(e). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.151 &#147;<B>Replacement Right</B>&#148; is defined in Section&nbsp;2.1.2(e). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.152 &#147;<B>Requesting Party</B>&#148; is defined in Section&nbsp;9.2.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.153 &#147;<B>Research Costs</B>&#148; is defined in Section&nbsp;4.2.3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.154 &#147;<B>Research Plan</B>&#148; is defined in Section&nbsp;4.1. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.155 &#147;<B>Research Plan Completion</B>&#148; is defined in Section&nbsp;4.2.1(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.156 &#147;<B>Retention Period</B>&#148; is defined in Section&nbsp;8.4.4. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.157 &#147;<B>Reviewing Party</B>&#148; is defined in Section&nbsp;9.2.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.158 &#147;<B>Royalty Term</B>&#148; means with respect to a Licensed Product, on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, the period beginning on the date of First Commercial Sale of such Licensed Product in such country and ending on the later of (a)&nbsp;date of expiration or invalidation of the last
to expire Valid Claim of a Metagenomi Patent Right in such country that Covers [***] in such country that is included within the Commercial License, (b) [***] after the date of First Commercial Sale of such Licensed Product in such country, and
(c)&nbsp;expiration of all regulatory exclusivities for such Licensed Product in such country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.159 &#147;<B>Sublicenseable Metagenomi <FONT
STYLE="white-space:nowrap">In-Licensed</FONT> IP</B>&#148; is defined in Section&nbsp;10.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.160 &#147;<B>Sublicensee</B>&#148; means
any Third Party to which <FONT STYLE="white-space:nowrap">Affini-T</FONT> or its Affiliate grants a sublicense under the Commercial License. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.161 &#147;<B>Supply Failure</B>&#148; is defined in Section&nbsp;2.1.2(d). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.162 &#147;<B>TCR</B>&#148; means <FONT STYLE="white-space:nowrap">T-cell</FONT> receptor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.163 &#147;<B>Term</B>&#148; is defined in Section&nbsp;12.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.164 &#147;<B>Territory</B>&#148; means every country and territory in the world. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.165 &#147;<B>Third Party</B>&#148; means a Person other than <FONT STYLE="white-space:nowrap">Affini-T</FONT> and Metagenomi and their
respective Affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.166 &#147;<B>Third Party License</B>&#148; is defined in Section&nbsp;8.4.2(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.167 &#147;<B>Third Party Payments</B>&#148; is defined in Section&nbsp;8.4.2(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.168 &#147;<B>Transferring Party</B>&#148; is defined in Section&nbsp;9.4. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.169 &#147;<B>United States</B>&#148; or &#147;<B>U.S.</B>&#148; means the United States of America and its territories and possessions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.170 &#147;<B>Upstream Agreement</B>&#148; is defined in Section&nbsp;10.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.171 &#147;<B>Valid</B><B> Claim</B>&#148; means either (a)&nbsp;a claim of an issued and unexpired patent that has not been revoked or found
to be unpatentable, invalid or unenforceable by a court or other government agency of competent jurisdiction, or (b)&nbsp;a claim of a pending patent application, which claim was filed in good faith, has not been pending for more than [***] and has
not been abandoned or finally disallowed without the possibility of appeal or refiling of such application. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2. <U>GRANT OF LICENSES; EXCLUSIVITY</U>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1 <B><U>Grant of Licenses to <FONT STYLE="white-space:nowrap">Affini-T</FONT></U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1.1 <U>Research License</U>. Metagenomi hereby grants <FONT STYLE="white-space:nowrap">Affini-T</FONT> and its Affiliates a <FONT
STYLE="white-space:nowrap">non-exclusive,</FONT> fully <FONT STYLE="white-space:nowrap">paid-up,</FONT> royalty-free, worldwide license, with the right to grant sublicenses, under, in and to Metagenomi IP for
<FONT STYLE="white-space:nowrap">Affini-T</FONT> to conduct research and Development activities involving Metagenomi Reagents and Licensed Products directed to the applicable <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target in each
Field prior to Option exercise and expiration of the Option Period (on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Field-by-Field</FONT></FONT> basis) for purposes of determining whether
<FONT STYLE="white-space:nowrap">Affini-T</FONT> will exercise either or both of its Options with respect to any such <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target(s). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1.2 <U>Commercial License</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) On an <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Target-by-Affini-T</FONT></FONT></FONT> Clinical Target basis, Metagenomi hereby grants <FONT STYLE="white-space:nowrap">Affini-T</FONT> (i)&nbsp;an exclusive option to obtain an Exclusive License (&#147;<B>Exclusive
Option</B>&#148;) and (ii)&nbsp;a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> option to obtain a <FONT STYLE="white-space:nowrap">Non-Exclusive</FONT> License (&#147;<B><FONT STYLE="white-space:nowrap">Non-Exclusive</FONT>
Option</B>&#148;, and individually or collectively, as applicable, with the Exclusive Option, &#147;<B>Option</B>&#148;), in each case of (i)&nbsp;and (ii), with respect to each <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target. <FONT
STYLE="white-space:nowrap">Affini-T</FONT> may, at its sole discretion, exercise one or both of its Options (i.e., on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Field-by-Field</FONT></FONT> basis) with respect to an <FONT
STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target by providing written notice to Metagenomi during the Option Period applicable to such <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target and such Field by identifying the
applicable <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target and stating whether an Exclusive License and/or a <FONT STYLE="white-space:nowrap">Non-Exclusive</FONT> License is being taken with respect to such <FONT
STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target. <FONT STYLE="white-space:nowrap">Affini-T</FONT> may exercise its Option for an Exclusive License or <FONT STYLE="white-space:nowrap">Non-Exclusive</FONT> License with respect to a given <FONT
STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target at the same time or at different times; provided, that any such Option exercise must occurring during the applicable Option Period with respect to such
<FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target and Field. During the Term, Metagenomi shall not license or otherwise dispose of any Metagenomi IP (including undertaking any such actions that would result in any given Patent Rights
and <FONT STYLE="white-space:nowrap">Know-How</FONT> no longer qualifying as Controlled by Metagenomi only as result of such actions) in any manner that is or could be inconsistent with the Option rights granted to
<FONT STYLE="white-space:nowrap">Affini-T.</FONT> Upon the expiration of the Option Period for an <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target, if <FONT STYLE="white-space:nowrap">Affini-T</FONT> has not exercised either Option
with respect to such <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target, then such <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target shall cease to be an <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Upon <FONT STYLE="white-space:nowrap">Affini-T&#146;s</FONT> exercise of an Exclusive Option with respect to a given <FONT
STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target, Metagenomi shall grant, and hereby does grant, to <FONT STYLE="white-space:nowrap">Affini-T</FONT> and its Affiliates, without further action from either Party an exclusive (even as to
Metagenomi), royalty-bearing (as set forth in Section&nbsp;8.4), sublicensable (through multiple tiers), worldwide license under all applicable Metagenomi IP to research, Develop, Manufacture or have Manufactured (including the Manufacture of
Metagenomi Reagents, subject to Section&nbsp;2.1.2(d) and, as applicable, the Development Supply Agreement and Commercial Supply Agreement), use, Commercialize and otherwise fully exploit any <FONT STYLE="white-space:nowrap">TCR-based</FONT>
therapy, preventative treatment, or diagnostic for humans that (A)&nbsp;is directed to such <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target, (B)&nbsp;contains or comprises Primary TCR alpha/beta T Cells, and (C)&nbsp;is derived from
<I>ex vivo</I> application of a Metagenomi Reagent (the &#147;<B>Exclusive License</B>&#148;). </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Upon <FONT STYLE="white-space:nowrap">Affini-T&#146;s</FONT> exercise of a <FONT
STYLE="white-space:nowrap">Non-Exclusive</FONT> Option with respect to a given <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target, Metagenomi shall grant, and hereby does grant, to <FONT STYLE="white-space:nowrap">Affini-T</FONT> and
its Affiliates, without further action from either Party a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> royalty-bearing (as set forth in Section&nbsp;8.4), sublicensable (through multiple tiers), worldwide license under all applicable
Metagenomi IP to research, Develop, Manufacture or have Manufactured ( including the Manufacture of Metagenomi Reagents, subject to Section&nbsp;2.1.2(d) and, as applicable, the Development Supply Agreement and Commercial Supply Agreement), use,
Commercialize and otherwise fully exploit any <FONT STYLE="white-space:nowrap">TCR-based</FONT> therapy, preventative treatment, or diagnostic for humans that (A)&nbsp;is directed to such <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical
Target, (B)&nbsp;contains or comprises Other Immune Cells, and (C)&nbsp;is derived from <I><FONT STYLE="white-space:nowrap">ex-vivo</FONT></I> application of a Metagenomi Reagent (the &#147;<B><FONT STYLE="white-space:nowrap">Non-Exclusive</FONT>
License</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, the Parties acknowledge and agree that the nature of the Licensed Products is such that <FONT
STYLE="white-space:nowrap">Affini-T</FONT> may inadvertently contravene the Commercial License granted by Metagenomi to <FONT STYLE="white-space:nowrap">Affini-T</FONT> under Sections 2.1.2(b) or 2.1.2(c) by way of an
<FONT STYLE="white-space:nowrap">off-target</FONT> effect whereby a given Licensed Product or Metagenomi Reagent interacts with a target (that it was not intentionally directed against) other than an <FONT STYLE="white-space:nowrap">Affini-T</FONT>
Clinical Target and that any such unintentional contravention shall not constitute a breach of this Agreement nor give rise to any infringement claims by Metagenomi related to such Licensed Product(s). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) Metagenomi shall supply to <FONT STYLE="white-space:nowrap">Affini-T</FONT> its requirements of Metagenomi Reagents in accordance with
the Development Supply Agreement and the Commercial Supply Agreement, as applicable; [***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) [***],
<FONT STYLE="white-space:nowrap">Affini-T</FONT> shall be entitled to [***] <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Targets with respect to which <FONT STYLE="white-space:nowrap">Affini-T</FONT> has not exercised its Option
(&#147;<B>Replacement Right</B>&#148;) by providing a written notice to Metagenomi (&#147;<B>Replacement Notice</B>&#148;). <FONT STYLE="white-space:nowrap">Affini-T</FONT> will be entitled to exercise its Replacement Right no more than [***]period.
Within[***] after receipt of a Replacement Notice, Metagenomi shall notify <FONT STYLE="white-space:nowrap">Affini-T</FONT> in writing (&#147;<B>Replacement Notice Response</B>&#148;) whether, as of the date of the Replacement Notice, the proposed
target in the Replacement Notice is Available (as defined below) for an Exclusive License or a <FONT STYLE="white-space:nowrap">Non-Exclusive</FONT> License and any other limitations that would apply if
<FONT STYLE="white-space:nowrap">Affini-T</FONT> were to add such target as an <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target hereunder and subsequently exercise its Option with respect to such target. If the Replacement Notice
Response provides that the proposed target is not Available for an Exclusive License or <FONT STYLE="white-space:nowrap">Non-Exclusive</FONT> License, then <FONT STYLE="white-space:nowrap">Affini-T</FONT> will be free to provide a Replacement Notice
for another proposed target. If the proposed target is Available for an Exclusive License or a <FONT STYLE="white-space:nowrap">Non-Exclusive</FONT> License, then <FONT STYLE="white-space:nowrap">Affini-T</FONT> shall have [***] from its receipt of
a Replacement Notice Response to determine whether it desires to have such target added as an <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target hereunder, by providing a written response to Metagenomi identifying the <FONT
STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target to be replaced and affirming the addition of such target as an <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target; provided that if such target is only Available for a <FONT
STYLE="white-space:nowrap">Non-Exclusive</FONT> License (and not Available for an Exclusive License), then <FONT STYLE="white-space:nowrap">Affini-T</FONT> acknowledges and agrees that by affirming the addition of such target <FONT
STYLE="white-space:nowrap">Affini-T</FONT> will only be able to exercise the <FONT STYLE="white-space:nowrap">Non-Exclusive</FONT> Option for such target. If such [***]period expires without a response from
<FONT STYLE="white-space:nowrap">Affini-T,</FONT> or <FONT STYLE="white-space:nowrap">Affini-T</FONT> provides a written response that it does not desire to add such target, then such target shall not become an
<FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target. As used herein &#147;<B>Available</B>&#148; means that (i)&nbsp;the proposed target [***], (ii) the proposed target [***], and (iii)&nbsp;the proposed target [***]. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1.3 <U>Retention of Rights</U>. Notwithstanding the license granted in Section&nbsp;2.1.1,
Metagenomi retains the rights under the Metagenomi Agreement Patent Rights as necessary to conduct its Development and Manufacturing responsibilities with respect to Licensed Products hereunder in accordance with this Agreement (including any
Metagenomi Research Activities). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1.4 <U>Rights of Reference</U>. Solely for the purpose of obtaining or maintaining Regulatory Approval
for a Licensed Product, Metagenomi hereby grants <FONT STYLE="white-space:nowrap">Affini-T</FONT> the right to cross-reference Metagenomi&#146;s or its Affiliate&#146;s Regulatory Filings and Regulatory Approvals anywhere in the world to the extent
such Regulatory Filings and Regulatory Approvals relate to Licensed Products (or components thereof) and are Controlled by Metagenomi or its Affiliates, and to access any data and <FONT STYLE="white-space:nowrap">Know-How</FONT> therein and use such
data and <FONT STYLE="white-space:nowrap">Know-How</FONT> in connection with the performance of <FONT STYLE="white-space:nowrap">Affini-T&#146;s</FONT> obligations and exercise of <FONT STYLE="white-space:nowrap">Affini-T</FONT> rights under this
Agreement. In furtherance of the foregoing, Metagenomi shall (or shall cause an applicable Affiliate to) provide a signed statement to this effect, if requested by <FONT STYLE="white-space:nowrap">Affini-T,</FONT> in accordance with U.S. 21 C.F.R.
&#167;314.50(g)(3) or the equivalent as required in any country or region of the Territory, or otherwise provide appropriate notification of such right of <FONT STYLE="white-space:nowrap">Affini-T</FONT> to the applicable Regulatory Authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.2 <B><U>Exclusivity</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.2.1 <U><FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Targets <FONT STYLE="white-space:nowrap">Pre-Option</FONT></U>. On an <FONT
STYLE="white-space:nowrap">Affini-T</FONT> Clinical <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Target-by-Affini-T</FONT></FONT></FONT> Clinical Target basis, until the earlier of
(a)&nbsp;exercise of an Exclusive Option for such <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target; <FONT STYLE="white-space:nowrap">(b)&nbsp;Affini-T&#146;s</FONT> written notice to Metagenomi that it does not desire to exercise its
Exclusive Option for such <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target; and (c)&nbsp;expiration of the Option Period with respect to the Exclusive Option for such <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target;
Metagenomi shall not, and shall ensure that none of its Affiliates, (i)&nbsp;engage in the discovery, research, Development, Manufacture, Commercialization or other exploitation of any therapeutic, diagnostic or preventative <I>ex vivo </I>gene
edited product directed to such <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target in the Exclusive Field or (ii)&nbsp;work with any Third Party, including through a grant of any (sub)license to any Third Party, to discover, research,
Develop, Manufacture, Commercialize or otherwise exploit any therapeutic, diagnostic or preventative <I>ex vivo</I> gene edited product directed to or associated with such <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target in the
Exclusive Field. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.2.2 <U><FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Targets Post-Option</U>. Upon exercise of an
Exclusive Option with respect to a given <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target, except as necessary to perform its obligations hereunder, Metagenomi shall not, and shall ensure that none of its Affiliates, (i)&nbsp;engage
in the discovery, research, Development, Manufacture, Commercialization or other exploitation of any therapeutic, diagnostic or preventative <I>ex vivo </I>gene edited product directed to such <FONT STYLE="white-space:nowrap">Affini-T</FONT>
Clinical Target in the Exclusive Field or (ii)&nbsp;work with any Third Party, including through a grant of any (sub)license to any Third Party, to discover, research, Develop, Manufacture, Commercialize or otherwise exploit any therapeutic,
diagnostic or preventative <I>ex vivo</I> gene edited product directed to or associated with such <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target in the Exclusive Field. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.2.3 <U>Change of Control</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) In the event that Metagenomi or its Affiliate acquires or is acquired by a Third Party (by merger, sale, consolidation, reorganization or
other change of control (including a Change of Control)), such acquired Party/acquiring Third Party (the &#147;<B>CoC Affiliate</B>&#148;) shall not be deemed to be in violation of Section&nbsp;2.2.1 or Section&nbsp;2.2.2 if such CoC Affiliate
(a)&nbsp;covenants in writing to <FONT STYLE="white-space:nowrap">Affini-T</FONT> that from and after the closing of such acquisition, it will not use, reference or otherwise exploit, directly or indirectly, any
<FONT STYLE="white-space:nowrap">(i)&nbsp;Affini-T</FONT> IP (or other Confidential Information of <FONT STYLE="white-space:nowrap">Affini-T,</FONT> including Product Information) that is provided by <FONT STYLE="white-space:nowrap">Affini-T</FONT>
under this Agreement for any purpose, or (ii)&nbsp;Metagenomi Agreement IP for any purpose that would result in a breach of Section&nbsp;2.2.2; (b) establishes and enforces, along with Metagenomi, Firewalls for as long as Metagenomi performs
Metagenomi Research Activities; and (c)&nbsp;independently discovers, researches, Develops, Manufactures or Commercializes any therapeutic, diagnostic or preventative product directed to an <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical
Target in the Exclusive Field without any aid, use or other exploitation of any <FONT STYLE="white-space:nowrap">Affini-T</FONT> IP (or other Confidential Information of <FONT STYLE="white-space:nowrap">Affini-T,</FONT> including Product
Information) or Metagenomi Agreement IP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) In the event that <FONT STYLE="white-space:nowrap">Affini-T</FONT> or its Affiliate is
acquired by a Competing Acquiror (by merger, sale, consolidation, reorganization or other change of control (including a Change of Control)), <FONT STYLE="white-space:nowrap">Affini-T</FONT> shall cause such Competing Acquiror to establish and
enforce Firewalls during the Term.&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.3 <B><U>Grant of Licenses to Metagenomi</U></B>. For so long
as any Research Plan is being performed, <FONT STYLE="white-space:nowrap">Affini-T</FONT> hereby grants Metagenomi and its Affiliates a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> fully <FONT STYLE="white-space:nowrap">paid-up,</FONT>
royalty-free, worldwide license, with the right to grant sublicenses, under, in and to <FONT STYLE="white-space:nowrap">Affini-T</FONT> IP solely for Metagenomi to perform its Development obligations under, and in accordance with, each Research
Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.4 <B><U>Potential <FONT STYLE="white-space:nowrap">Co-Development</FONT></U></B>. The Parties will discuss the
potential for <FONT STYLE="white-space:nowrap">co-development</FONT> and <FONT STYLE="white-space:nowrap">co-commercialization</FONT> of one or more <FONT STYLE="white-space:nowrap">TCR-based</FONT> therapeutic products that embody <I>ex vivo</I>
engineered TCR immune cells made using Metagenomi Reagents based Gene Edits and (a)&nbsp;are directed to targets other than the <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Targets<U> </U>in the Exclusive Field or (b)&nbsp;are directed
to any targets, including <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Targets, in the <FONT STYLE="white-space:nowrap">Non-Exclusive</FONT> Field. Any such <FONT STYLE="white-space:nowrap">co-development</FONT> and <FONT
STYLE="white-space:nowrap">co-commercialization</FONT> relationship would be governed by a separate <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">co-development/co-commercialization</FONT></FONT> agreement to be negotiated and
agreed to by the Parties in each Party&#146;s sole and absolute discretion. For clarity, neither Party is obligated to <FONT STYLE="white-space:nowrap">co-develop</FONT> such other products or enter into any such further agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>3. <U>GOVERNANCE</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1 <B><U>Establishment of Joint Steering Committee</U></B><B><U>; Governance Term</U></B>. Within [***] after the Effective
Date, Metagenomi and <FONT STYLE="white-space:nowrap">Affini-T</FONT> shall establish a joint steering committee (the &#147;<B>JSC</B>&#148;). The JSC shall have and perform the responsibilities set forth in this Article 3; provided, that, the JSC
shall conduct its activities in good faith and shall not have any authority to amend this Agreement without the mutual written agreement of both Parties. Unless otherwise agreed by the Parties, the term for the JSC shall commence as of the date upon
which it is established and continue until the earlier of (a) [***] or (b) [***] (&#147;<B>Governance Term</B>&#148;); provided that, the Governance Term with respect to any given Licensed Product will end upon the initiation of a Pivotal Trial with
respect to such Licensed Product. From and after the expiration of the Governance Term, this Article 3 shall have no further force or effect, including on a Licensed
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Licensed</FONT></FONT> Product basis in accordance with the proviso in the foregoing sentence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.2 <B><U>Membership</U></B>. Each Party shall designate in writing, in its sole discretion, three (3)&nbsp;representatives to
represent it on the JSC. The JSC may change its size from time to time by mutual written consent of the Parties (which consent may be withheld by either Party at its sole discretion) and each Party may replace its representatives at any time upon
written notice to the other Party. Each Party shall appoint one or more of its representatives to serve as a <FONT STYLE="white-space:nowrap">co-chairperson</FONT> of the JSC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.3 <B><U>Meetings</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.3.1 <U>Schedule of Meetings; Agenda</U>. [***], without limitation, the planning needs for each Research Plan and the responsibilities of
the JSC. Special meetings of the JSC may be convened by any member upon [***] written notice to the other members; provided, that (a)&nbsp;notice of any special meeting may be waived at any time, either before or after the special meeting and
(b)&nbsp;attendance of any member at a special meeting shall constitute a valid waiver of notice of such member. Meetings of the JSC may be held in person or by teleconference or videoconference; provided, that, any meetings held in person shall
alternate between the respective offices of the Parties or be held at other locations as may be mutually agreeable to the JSC members. Each Party may invite representatives, presenters or experts of such Party or of its Affiliates as it determines
is appropriate, subject to the other Party consenting to such attendance, which consent will not be unreasonably withheld, conditioned or delayed; provided, that any such guest attendees (i)&nbsp;shall not vote or otherwise participate in the
decision-making process of the JSC and (ii)&nbsp;are bound by obligations of confidentiality and <FONT STYLE="white-space:nowrap">non-disclosure</FONT> consistent with Article 9. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.3.2 <U>Voting; Decisions</U>. At each JSC meeting, the representatives of a Party shall have one (1)&nbsp;collective vote on all matters
before the JSC at such meeting. All decisions of the JSC shall be made by unanimous vote, subject to Section&nbsp;3.5. The JSC may also act by written consent signed by at least [***]<B> </B>designated by each Party. Whenever any action by the JSC
is called for hereunder during a time period in which the JSC is not scheduled to meet, the Parties may call a special meeting or circulate a written consent to the JSC in order to enable the JSC to address, and if agreed, take, the action in the
requested time period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.3.3 <U>Meeting Minutes</U>. With the sole exception of specific items of any JSC meeting
minutes to which the JSC cannot agree and which are escalated as provided in Section&nbsp;3.5, definitive minutes of all meetings of the JSC shall be finalized [***] after the meeting to which the minutes pertain, as follows: (a)&nbsp;within [***]
after each JSC meeting, <FONT STYLE="white-space:nowrap">Affini-T&#146;s</FONT> Alliance Manager shall prepare and distribute to all members of the JSC draft minutes of the meeting; (b)&nbsp;the JSC members shall then [***] after receiving such
draft minutes to provide comments thereon to the JSC <FONT STYLE="white-space:nowrap">co-chairpersons;</FONT> (c)&nbsp;upon the expiration of such [***] period, the <FONT STYLE="white-space:nowrap">co-chairpersons</FONT> shall have an [***] to
finalize the minutes; (d)&nbsp;if no comments are received by the JSC <FONT STYLE="white-space:nowrap">co-chairpersons</FONT> within the [***], the minutes shall be deemed final; and (e)&nbsp;the JSC members shall each sign and date the final
minutes. The signature of the JSC members upon the final minutes shall indicate each Party&#146;s assent to the minutes. If at any time during the preparation and finalization of JSC meeting minutes, the Parties do not agree on any issue with
respect to the minutes, such issue shall be resolved by the Executive Officers pursuant to Section&nbsp;3.5. The decision resulting from this escalation process shall be recorded by the <FONT STYLE="white-space:nowrap">co-chairpersons</FONT> in
amended finalized minutes for said meeting and if no resolution can be reached than the disagreement shall be reflected in the minutes accordingly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.3.4 <U>Expenses</U>. Metagenomi and <FONT STYLE="white-space:nowrap">Affini-T</FONT> shall each bear all expenses of their respective JSC
representatives related to their participation on the JSC and attendance at JSC meetings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.4 <B><U>Responsibilities</U></B>. The JSC
responsibilities will include: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.4.1 overseeing initiation of, progress of, reviewing, approving, amending and updating (as appropriate),
each Research Plan; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.4.2 discussing Metagenomi&#146;s performance of the Metagenomi Research Activities; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.4.3 reviewing and discussing Metagenomi&#146;s supply abilities with respect to each Metagenomi Reagent to be utilized in a Licensed
Product; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.4.4 approving each <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Affini-T-Relevant</FONT></FONT> DMF for
submission; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.4.5 establishing or abolishing other such working groups or subcommittees, as needed to further the purposes of this
Agreement, as mutually agreed by the Parties in writing at the JSC; provided that each such working group or subcommittee shall report to the JSC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.5 <B><U>Dispute Resolution</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.5.1 <U>Generally</U>. The JSC members shall use reasonable efforts in good faith to reach agreement on any and all matters within its
responsibility. If, despite such reasonable efforts, agreement on a particular matter that is within the responsibility of the JSC cannot be reached by the JSC within[***] after the JSC first meets to consider such matter or such later date as may
be mutually acceptable to the Parties (each such matter, a &#147;<B>Disputed Matter</B>&#148;), the Parties shall refer such Disputed Matter to the Executive Officers of the Parties who shall promptly initiate discussions in good faith to resolve
such Disputed Matter, and if not resolved by the Executive Officers within [***] from the date the Disputed Matter is first referred to the Executive Officers, then, subject to the limitations set forth in Section&nbsp;3.5.2, the Executive Officer
of <FONT STYLE="white-space:nowrap">Affini-T</FONT> shall have the right to make the final decision on such Disputed Matter, but shall only exercise such right in good faith after full consideration of the positions of both Parties. </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.5.2 <U>Limitations</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <FONT STYLE="white-space:nowrap">Affini-T</FONT> cannot exercise its final decision making authority to (i) [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) If any Disputed Matter involves a matter outside of the decision making authority of the JSC, then such Disputed Matter shall be resolved
in accordance with Section&nbsp;15.1 except as otherwise expressly set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.6 <B><U>Alliance Managers</U></B>.
Each Party will appoint an individual designated as the alliance manager (&#147;<B>Alliance Manager</B>&#148;). The Alliance Managers will attend each JSC meeting but will not be a member of the JSC and will be the main point of contact for each
Party to exchange information and facilitate communication for general matters concerning this Agreement or Research Plans, to provide support to the JSC and such other committees and working groups as the JSC may establish and to coordinate the
communication and feedback from each Alliance Manager&#146;s organization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.7 <B><U>Project Leaders</U></B>. Each Party
will appoint a project leader for each Research Plan (each a &#147;<B>Project Leader</B>&#148;). The Project Leaders will be responsible for the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> exchange of
information and communication in connection with its assigned Research Plan(s) and will be the first contact person for the other Party for operational and scientific matters with regard to such Research Plan. The Project Leaders will routinely
report on the progress of its assigned Research Plan(s) to the JSC. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>4. <U>RESEARCH ACTIVITIES</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.1 <B><U>Research Plan</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.1.1 <U>Initial Research Plan</U>. <B></B>From time to time during the Term, <FONT STYLE="white-space:nowrap">Affini-T</FONT> may draft and
propose to the JSC and the JSC shall promptly ([***]) upon receipt of such proposal, consider and subject to Section&nbsp;3.5, approve research plan(s) for Gene Edits describing the applicable Metagenomi Research Activities (each, a
&#147;<B>Research Plan</B>&#148;). As of the Effective Date, the Parties have agreed to the Research Plan for [***] attached hereto as Schedule 4.1. Each Research Plan will include a description of all Metagenomi Research Activities to be performed
thereunder, a budget for the conduct of such Metagenomi Research Activities (&#147;<B>Plan Budget</B>&#148;), a timeline for Metagenomi&#146;s performance, key milestones and progress/data/discovery reporting requirements, deliverables, one or more
success criteria with respect to such Research Plan and the required contents of the final report and data package to be delivered to <FONT STYLE="white-space:nowrap">Affini-T</FONT> upon completion of the Research Plan (the &#147;<B>Data
Package</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.1.2 <U>Quarterly Review of Research Plan</U>. During each Calendar Quarter JSC meeting, the JSC shall review the
contents of each Research Plan, progress under each Research Plan and discuss and mutually agree on any amendment or update (as appropriate) for such Research Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.2 <B><U>Conduct of Research Plan</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.2.1 <U>Metagenomi Responsibilities</U>. <B></B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Metagenomi shall use Commercially Reasonable Efforts to perform the Metagenomi Research Activities and deliver to <FONT
STYLE="white-space:nowrap">Affini-T</FONT> the Metagenomi Reagents (including, as and to the extent applicable, [***] in the quality and amounts provided in the applicable Research Plan and the Data Package in accordance with the timelines set forth
in the applicable Research Plan, and to commit such resources (including employees, agents, consultants, facilities, equipment and materials) as are necessary to comply with such diligence obligation. Metagenomi shall use Commercially Reasonable
Efforts to perform its obligations under each Research Plan until such Research Plan has been completed or terminated in accordance with the terms of the Agreement.<B> </B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Without limiting Metagenomi&#146;s supply and transfer obligations under Section&nbsp;4.2.1(a) and the Development Supply Agreement and
Quality Agreement, upon Metagenomi&#146;s completion of its obligations, including delivery of all deliverables, and achievement of all success criteria (or all success criteria are achieved except for those expressly waived by <FONT
STYLE="white-space:nowrap">Affini-T</FONT> in writing or those that Metagenomi demonstrates to <FONT STYLE="white-space:nowrap">Affini-T&#146;s</FONT> satisfaction that Metagenomi has used Commercially Reasonable Efforts to achieve without success),
set forth in a given Research Plan, Metagenomi shall notify <FONT STYLE="white-space:nowrap">Affini-T</FONT> in writing of such completion and submit to <FONT STYLE="white-space:nowrap">Affini-T</FONT> the Data Package for such Research Plan (the
&#147;<B>Research Plan Completion</B>&#148;). <FONT STYLE="white-space:nowrap">Affini-T</FONT> acknowledges and agrees that Metagenomi is not providing any guarantee that all success criteria in a Research Plan will be met, and Research Plan
Completion will be achieved when all work under the Research Plan has been completed and all success criteria has been achieved, except for those success criteria expressly waived by <FONT STYLE="white-space:nowrap">Affini-T</FONT> in writing or
those that are demonstrated to <FONT STYLE="white-space:nowrap">Affini-T&#146;s</FONT> satisfaction have been the subject of Metagenomi&#146;s Commercially Reasonable Efforts to achieve without success. Within [***] after <FONT
STYLE="white-space:nowrap">Affini-T&#146;s</FONT> receipt of such notice and Data Package, the JSC shall meet to discuss the Data Package. If <FONT STYLE="white-space:nowrap">Affini-T</FONT> does not believe Research Plan Completion has been
achieved, it shall so notify Metagenomi and the Parties will discuss in good faith the status of the activities under the Research Plan. <FONT STYLE="white-space:nowrap">Affini-T</FONT> may request any reasonable updates or additional information
with respect to the Data Package that are reasonably necessary for <FONT STYLE="white-space:nowrap">Affini-T</FONT> to exercise its rights under this Agreement with respect to the applicable Metagenomi Reagents. If
<FONT STYLE="white-space:nowrap">Affini-T</FONT> notifies Metagenomi that such Data Package contains inaccuracies or lacks necessary information generated under the Research Plan or is otherwise not complete, the Parties shall confer in good faith
with respect to any changes or additions recommended by <FONT STYLE="white-space:nowrap">Affini-T,</FONT> including the performance by Metagenomi of reasonable additional Metagenomi Research Activities that will be reflected in an updated Research
Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Metagenomi shall assign such scientific and technical personnel and allocate such other resources as are reasonably necessary
for performing the activities as are assigned to it in each Research Plan and shall perform such activities in accordance with all Applicable Laws (including GRPs and GLPs) in each case to the extent applicable to performance of the relevant
Research Plan activities by Metagenomi, the terms and conditions of this Agreement, and within generally accepted professional standards. Metagenomi shall be solely responsible for the safety and health of its employees and consultants, and for
compliance with all Applicable Laws related to health, safety and the environment, including providing its employees </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and consultants with all required information and training concerning any potential hazards involved in performing such activities and any precautionary measures to protect its employees and
consultants from any such hazards. Metagenomi shall reasonably train its personnel assigned to perform activities under this Agreement to ensure compliance with each Research Plan and shall ensure that any personnel so assigned shall be capable of
professionally and competently performing the activities assigned to Metagenomi in each Research Plan. <B></B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) Except as set forth
below in Article 7, in performing the Metagenomi Research Activities, Metagenomi shall not have the right to subcontract any of such activities without the prior written consent of <FONT STYLE="white-space:nowrap">Affini-T;</FONT> provided that
Metagenomi shall cause its subcontractors to comply with the provisions of this Agreement in connection with such performance.&nbsp;Metagenomi shall execute a formal written agreement with any such permitted subcontractor governing the provision of
services by such subcontractor. Each such subcontractor agreement shall (i)&nbsp;require such subcontractor to comply with the terms and conditions of this Agreement (including those provisions governing intellectual property, confidentiality and
audit rights) and (ii)&nbsp;prohibit such subcontractor from further subcontracting. Metagenomi&#146;s execution of such a subcontractor agreement shall not relieve Metagenomi of any of its obligations under this Agreement. Metagenomi shall remain
jointly and severally liable to <FONT STYLE="white-space:nowrap">Affini-T</FONT> for any performance or <FONT STYLE="white-space:nowrap">non-performance</FONT> of any such subcontractor, and Metagenomi hereby expressly waives any requirement that <FONT
STYLE="white-space:nowrap">Affini-T</FONT> exhaust all right, power or remedy, or proceed against any such subcontractor, prior to proceeding directly against Metagenomi. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) In the event that Metagenomi or its Affiliate is conducting any discovery, research, development, manufacture, commercialization or other
exploitation of any therapeutic, diagnostic or preventative <FONT STYLE="white-space:nowrap">TCR-based</FONT> therapy directed to an <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target other than under this Agreement (&#147;<B>Competing
Business</B>&#148;), Metagenomi shall establish and enforce Firewalls between such activities and personnel (subject to the terms of Section&nbsp;1.69) performing Metagenomi Research Activities under this Agreement for so long as Metagenomi performs
Metagenomi Research Activities. For clarity, Metagenomi and its Affiliates shall not reference, use or otherwise exploit any <FONT STYLE="white-space:nowrap">Affini-T</FONT> IP (or other Confidential Information of
<FONT STYLE="white-space:nowrap">Affini-T,</FONT> including Product Information) in conducting or pursuing the Competing Business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.2.2
<U><FONT STYLE="white-space:nowrap">Affini-T</FONT> Responsibilities</U>. In support of Metagenomi&#146;s activities under each Research Plan, <FONT STYLE="white-space:nowrap">Affini-T</FONT> will provide Metagenomi, subject to Article 9, with
access to <FONT STYLE="white-space:nowrap">Know-How</FONT> (including data and other information) that is Controlled by <FONT STYLE="white-space:nowrap">Affini-T</FONT> that is necessary or reasonably useful for the performance of such Metagenomi
Research Activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.2.3 <U>Research Plan Costs</U>. <FONT STYLE="white-space:nowrap">Affini-T</FONT> will pay all reasonable costs
actually incurred by Metagenomi for the performance of Metagenomi Research Activities under each Research Plan (&#147;<B>Research Costs</B>&#148;); provided that, <FONT STYLE="white-space:nowrap">Affini-T</FONT> is not obligated to pay any costs and
expenses that exceed the Plan Budget set forth in the applicable Research Plan and Metagenomi shall not be obligated to provide any services or materials for which it will not be paid under the applicable Plan Budget; provided, further, that in the
case it appears that the Plan Budget will be exceeded, the Party identifying such issue shall promptly notify the other Party and the Parties shall discuss in good faith any reasonable adjustments to the Plan Budget. [***] Metagenomi will submit to <FONT
STYLE="white-space:nowrap">Affini-T</FONT> a detailed invoice, including the Metagenomi Research Activities completed and the actual Research Costs incurred in connection with each such Metagenomi Research
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Activity pursuant to the Plan Budget as well as appropriate receipts for passthrough costs for the Research Costs that Metagenomi [***] and <FONT STYLE="white-space:nowrap">Affini-T</FONT> will
pay all undisputed invoices (or portions thereof) within[***] of receipt of such invoice pursuant to Section&nbsp;8.4.5(c); provided that <FONT STYLE="white-space:nowrap">(i)&nbsp;Affini-T</FONT> may reasonably request Metagenomi to provide
additional details, documents or support in connection with any invoice and <FONT STYLE="white-space:nowrap">(ii)&nbsp;Affini-T</FONT> shall pay all disputed invoices within[***] following resolution of a dispute by the Parties regarding any
invoice. <FONT STYLE="white-space:nowrap">Affini-T</FONT> shall have the right to audit Metagenomi&#146;s Research Costs by way of Section&nbsp;8.4.4 applied <I>mutatis mutandis</I> (with appropriate substitution/replacement of relevant Party and
subject matter references). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.3 <B><U>Compliance</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.3.1 <U>Applicable Laws</U>. Metagenomi shall perform the Metagenomi Research Activities in compliance with all Applicable Laws. For clarity,
with respect to each activity performed under the Research Plan that will or would reasonably be expected to generate any results, data, or analyses to be submitted to a Regulatory Authority in support of an IND, each Party shall comply with the
regulations and guidance of the FDA that constitute GRP, GLP or GMP (or, if and as appropriate under the circumstances, International Conference on Harmonization (&#147;<B>ICH</B>&#148;) guidance or other comparable regulation and guidance of any
Regulatory Authority in any country or region in the Territory). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.3.2 <U>Compliance with Anti-Corruption Laws</U>. In connection with
this Agreement, each Party will comply with all applicable local, national, and international laws, regulations, and industry codes dealing with government procurement, conflicts of interest, corruption or bribery, including, if applicable, the U.S.
Foreign Corrupt Practices Act of 1977, as amended (&#147;<B>FCPA</B>&#148;), and any laws enacted to implement the OECD Convention on Combating Bribery of Foreign Officials in International Business Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.3.3 <U>Prohibited Conduct</U>. In connection with this Agreement, neither Party has made, offered, given, promised to give, or authorized,
and neither Party will not make, offer, give, promise to give, or authorize, any bribe, kickback, payment or transfer of anything of value, directly or indirectly, to any person or to any Government Official for the purpose of: (a)&nbsp;improperly
influencing any act or decision of the Person or Government Official; (b)&nbsp;inducing the Person or Government Official to do or omit to do an act in violation of a lawful or otherwise required duty; (c)&nbsp;securing any improper advantage; or
(d)&nbsp;inducing the Person or Government Official to improperly influence the act or decision of any organization, including any government or government instrumentality, to assist Metagenomi or <FONT STYLE="white-space:nowrap">Affini-T</FONT> in
obtaining or retaining business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.3.4 <U>Certain Standards Applicable to Metagenomi Work</U>. All research done by Metagenomi for <FONT
STYLE="white-space:nowrap">non-regulated</FONT> work under this Agreement will be conducted in accordance with the Research Plan, GRP, and all applicable data privacy and security laws and regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.3.5 <U>Compliance Audits</U>. Without limiting Section&nbsp;8.4.4 (which is specific to financial audits) and other Sections
cross-referencing to Section&nbsp;8.4.4, <FONT STYLE="white-space:nowrap">Affini-T</FONT> shall have the right to audit Metagenomi and the facility(ies) where Metagenomi is performing activities under any Research Plan, including reviewing such
documents and records, as is reasonably necessary for assessing Metagenomi&#146;s performance of the Research Program. Such audit and document review shall be conducted during business hours no more than [***] and only upon [***]advance notice
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by <FONT STYLE="white-space:nowrap">Affini-T</FONT> and the mutual agreement of the Parties as to the specific date and time for such audit; provided, however, that in the case of audits for
cause, the [***] audit limit shall not apply and <FONT STYLE="white-space:nowrap">Affini-T</FONT> shall request such audit upon at least [***] advance written notice. It is understood that <FONT STYLE="white-space:nowrap">Affini-T</FONT> undertakes
no obligation to inspect, audit or qualify the facility(ies) and any inspection conducted hereunder is for <FONT STYLE="white-space:nowrap">Affini-T&#146;s</FONT> sole interest without undertaking any obligation or liability to Metagenomi or any
other person or entity. Any audit under this Section&nbsp;4.3.5 conducted by or on behalf of <FONT STYLE="white-space:nowrap">Affini-T</FONT> shall not relieve Metagenomi from any of its obligations or liabilities under this Agreement. <FONT
STYLE="white-space:nowrap">Affini-T</FONT> shall not have the right in connection with any such audit to obtain access to information or materials that are (a)&nbsp;solely related to Metagenomi&#146;s collaboration with Third Parties, or
(b)&nbsp;related to Metagenomi Background IP that is not licensed to or expected to be licensed to <FONT STYLE="white-space:nowrap">Affini-T</FONT> under this Agreement (e.g. nuclease systems that are not currently utilized under a Research Plan).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.4 <B><U>Record Keeping</U></B>. For so long as any Research Plan is being performed and for [***] thereafter, each
Party shall maintain complete and accurate records (paper or electronic as applicable) of its research and Development activities under the Research Plans in sufficient detail, including in sufficient detail for purposes of making patent filings, in
good scientific manner, or otherwise in a manner that reflects all work done and results achieved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.5 <B><U>Target
Termination</U></B>. At any time during the Term, if <FONT STYLE="white-space:nowrap">Affini-T</FONT> conclusively determines in good faith that it will not be Developing or Commercializing any Licensed Products with respect to a particular <FONT
STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target, then <FONT STYLE="white-space:nowrap">Affini-T</FONT> shall promptly notify Metagenomi of such conclusive determination and such <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical
Target shall cease to be an <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target under this Agreement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>5. <U>DEVELOPMENT
ACTIVITIES; REGULATORY ACTIVITIES</U> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.1 <B><U>Responsibility for Development</U></B>. As between the Parties, <FONT
STYLE="white-space:nowrap">Affini-T</FONT> shall have the sole right and responsibility, at its sole cost and expense, for the conduct of all Development activities applicable to any Licensed Product in the Territory, including the Manufacture and
supply of such Licensed Product in such quantities as required for such Development activities pursuant to this Agreement (subject to Metagenomi&#146;s Manufacturing rights and obligations under Article 7). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.2 <B><U>Engagement of Third Party Contractors</U></B>. <FONT STYLE="white-space:nowrap">Affini-T,</FONT> and its Affiliates
and Sublicensees, shall have the right to engage Third Party contractors to perform any of its Development activities. <FONT STYLE="white-space:nowrap">Affini-T</FONT> shall cause its contractors to comply with the provisions of this Agreement in
connection with such <FONT STYLE="white-space:nowrap">performance.&nbsp;Affini-T</FONT> shall execute a formal written agreement with its contractor governing the provision of services by such contractor. Each such contractor agreement shall require
such contractor to comply with the applicable terms and conditions of this Agreement (including those provisions governing intellectual property, confidentiality and audit rights). <FONT STYLE="white-space:nowrap">Affini-T&#146;s</FONT> execution of
such a contractor agreement shall not relieve <FONT STYLE="white-space:nowrap">Affini-T</FONT> of any of its obligations under this Agreement. <FONT STYLE="white-space:nowrap">Affini-T</FONT> shall remain jointly and severally liable to Metagenomi
for any performance or <FONT STYLE="white-space:nowrap">non-performance</FONT> of any such contractor, and <FONT STYLE="white-space:nowrap">Affini-T</FONT> hereby expressly waives any requirement that Metagenomi exhaust all right, power or remedy,
or proceed against any such contractor, prior to proceeding directly against <FONT STYLE="white-space:nowrap">Affini-T.</FONT> </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.3 <B><U>Development Diligence</U></B>.<B> </B>Upon <FONT
STYLE="white-space:nowrap">Affini-T&#146;s</FONT> exercise of its Exclusive Option or <FONT STYLE="white-space:nowrap">Non-Exclusive</FONT> Option with respect to a given <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target, <FONT
STYLE="white-space:nowrap">Affini-T</FONT> will use Commercially Reasonable Efforts during the Term to Develop, including seeking Regulatory Approval for, at least one (1)&nbsp;Exclusive Licensed Product or Nonexclusive Licensed Product, as
applicable, directed to such <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.4 <B><U>Progress
Reports</U></B>. From the date of the Option exercise until [***], <FONT STYLE="white-space:nowrap">Affini-T</FONT> shall provide Metagenomi an annual written update on the progress of its efforts to Develop Licensed Product(s) with respect to such <FONT
STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target, including a high-level summary of material (a)&nbsp;Clinical Trials completed, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(b)&nbsp;work-in-progress,</FONT></FONT>
(c)&nbsp;current schedules or anticipated events or milestones, and (d)&nbsp;transaction(s) involving Licensed Products, which summaries shall include relevant activities conducted and being conducted by
<FONT STYLE="white-space:nowrap">Affini-T&#146;s</FONT> Affiliates or Sublicensees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.5 <B><U>Regulatory Matters</U></B>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.5.1 <U>Regulatory Filings Generally</U>. As between the Parties, <FONT STYLE="white-space:nowrap">Affini-T</FONT> shall have the sole
right and responsibility for (i)&nbsp;preparing, filing and maintaining all Regulatory Filings for Licensed Products in the Territory and (ii)&nbsp;reporting to Regulatory Authorities all adverse, including serious, events occurring in any Clinical
Trial conducted by or on behalf of <FONT STYLE="white-space:nowrap">Affini-T</FONT> related to Licensed Products, to the extent required by Applicable Laws. Metagenomi shall prepare and file with the FDA a MG DMF (or an amendment to a <FONT
STYLE="white-space:nowrap">pre-existing</FONT> MG DMF) containing pertinent chemistry manufacturing control (CMC) information regarding the Metagenomi Reagents required for <FONT STYLE="white-space:nowrap">Affini-T&#146;s</FONT> IND submissions
(each such MG DMF, an &#147;<B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Affini-T-Relevant</FONT></FONT> DMF</B>&#148;); provided that <FONT STYLE="white-space:nowrap">Affini-T</FONT> shall notify Metagenomi at [***] to <FONT
STYLE="white-space:nowrap">Affini-T&#146;s</FONT> first anticipated IND filing (or foreign equivalent) for a Licensed Product, including through an update at the JSC, and Metagenomi shall file such an <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Affini-T-Relevant</FONT></FONT> DMF at [***]to the date of such anticipated IND filing, subject to JSC approval to so file. Metagenomi hereby grants <FONT STYLE="white-space:nowrap">Affini-T</FONT> or its designee a right
of reference to all MG DMFs in any Regulatory Filing related to the use of the Metagenomi Reagents for a Licensed Product. Metagenomi shall provide <FONT STYLE="white-space:nowrap">Affini-T</FONT> a copy of any MG DMF submission that also qualifies
as an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Affini-T-Relevant</FONT></FONT> DMF at [***] prior to the date of such anticipated IND filing; provided that <FONT STYLE="white-space:nowrap">Affini-T</FONT> shall not have the
right to download copies of such <FONT STYLE="white-space:nowrap">Affini-T</FONT> Relevant DMF. <FONT STYLE="white-space:nowrap">Affini-T</FONT> shall have the right, but not the obligation, to provide comments and feedback with respect to such
proposed DMF submission. Metagenomi shall consider <FONT STYLE="white-space:nowrap">Affini-T&#146;s</FONT> comments and feedback in good faith, including amending a <FONT STYLE="white-space:nowrap">pre-existing</FONT> DMF as appropriate, and shall
provide subsequent iterations of each such <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Affini-T-Relevant</FONT></FONT> DMF until <FONT STYLE="white-space:nowrap">Affini-T</FONT> has no further comments or feedback and then the <FONT
STYLE="white-space:nowrap">Affini-T</FONT> Relevant DMF shall be submitted to the JSC for approval. After Metagenomi or its Affiliate submits an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Affini-T-Relevant</FONT></FONT> DMF to
a Regulatory Authority (following JSC approval to so submit), and upon <FONT STYLE="white-space:nowrap">Affini-T&#146;s</FONT> written request [***] prior to an anticipated IND filing (or foreign equivalent) for such Licensed Product, Metagenomi
shall provide to such Regulatory Authority a Letter of Authorization (letter of access or other foreign equivalent) advising such Regulatory Authority that <FONT STYLE="white-space:nowrap">Affini-T</FONT> has a right of reference with respect to,
and permitting such Regulatory Agent the right to reference, the applicable DMF. Upon <FONT STYLE="white-space:nowrap">Affini-T&#146;s</FONT> request, Metagenomi shall update such Letter of Authorization (letter of access or other foreign
equivalent) to grant such right of reference to <FONT STYLE="white-space:nowrap">Affini-T&#146;s</FONT> successor or permitted assign. </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.5.2 <U>Licensed Product-Related Regulatory Interactions</U>. <FONT
STYLE="white-space:nowrap">Affini-T</FONT> shall be solely responsible for any communications with any Regulatory Authorities regarding the Licensed Products. In the event that Metagenomi receives any communication from a Regulatory Authority
regarding a Licensed Product, Metagenomi shall refer such Regulatory Authority to <FONT STYLE="white-space:nowrap">Affini-T</FONT> and shall not otherwise communicate with such Regulatory Authority without
<FONT STYLE="white-space:nowrap">Affini-T&#146;s</FONT> prior written consent. <FONT STYLE="white-space:nowrap">Affini-T</FONT> shall have the right to require that Metagenomi make available (at Metagenomi&#146;s cost and expense) an appropriate
representative to be present, as a silent observer (except as <FONT STYLE="white-space:nowrap">Affini-T</FONT> may expressly authorize otherwise), during a meeting or substantive telephone conference call with any Regulatory Authorities relating to
Metagenomi Reagents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.5.3 <U>Regulatory Consultation</U>. Each Party will appoint a representative to discuss regulatory matters related
to Metagenomi Reagents and Licensed Products with the other Party on a Calendar Quarter basis (each, &#147;<B>Regulatory Representative</B>&#148;), until such time as the Parties agree (each at its own discretion) in writing that such meetings will
no longer be held. Such meetings may take place in person or by tele-/video-conference as the Regulatory Representatives may agree between themselves. The Regulatory Representatives shall discuss interactions and filings with Regulatory Authorities
relating to: (a)&nbsp;with respect to Metagenomi and Metagenomi Reagents, for so long as there are outstanding Research Plans, all Metagenomi Reagents that are subject of any such Research Plans, and thereafter, all Metagenomi Reagents that are
incorporated into one or more Licensed Products; or (b)&nbsp;with respect to <FONT STYLE="white-space:nowrap">Affini-T,</FONT> Metagenomi Reagents for using Gene Edits to Manufacture Licensed Products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.6 <B><U><FONT STYLE="white-space:nowrap">Know-How</FONT> Sharing; Cooperation</U></B>. Promptly after the Effective Date
(and in no event longer than [***]after the Effective Date), and from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">time-to-time</FONT></FONT> thereafter, Metagenomi shall disclose or deliver to
<FONT STYLE="white-space:nowrap">Affini-T</FONT> copies of all <FONT STYLE="white-space:nowrap">Know-How</FONT> in Metagenomi&#146;s or its Affiliate&#146;s possession (and will use reasonable efforts to obtain all data and information in
Metagenomi&#146;s contract researcher&#146;s possession) relating to the Development and Commercialization of Licensed Products to the extent necessary or useful for <FONT STYLE="white-space:nowrap">Affini-T&#146;s</FONT> performance or exercise of
its rights under this Agreement, including [***]. Metagenomi shall promptly notify <FONT STYLE="white-space:nowrap">Affini-T</FONT> regarding [***].<B> </B>Upon <FONT STYLE="white-space:nowrap">Affini-T&#146;s</FONT> reasonable request, Metagenomi
will provide technical assistance to <FONT STYLE="white-space:nowrap">Affini-T</FONT> during such disclosure or delivery set forth in the preceding sentences. Metagenomi shall, [***] reasonably cooperate with
<FONT STYLE="white-space:nowrap">Affini-T</FONT> in the Development of any Licensed Products, including making its employees and <FONT STYLE="white-space:nowrap">non-employee</FONT> consultants reasonably available to consult with <FONT
STYLE="white-space:nowrap">Affini-T</FONT> on issues arising during <FONT STYLE="white-space:nowrap">Affini-T&#146;s</FONT> Development and in connection with any request related to a Licensed Product or its Development from any Regulatory
Authority, including regulatory, scientific, technical and clinical testing issues. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>6. <U>COMMERCIALIZATION OF PRODUCTS</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.1 <B><U>Responsibility for Commercialization of Licensed Products</U></B>. As between the Parties, <FONT
STYLE="white-space:nowrap">Affini-T</FONT> shall be responsible for the Commercialization of Licensed Products in the Territory,<B> </B>including (a)&nbsp;the conduct of all <FONT STYLE="white-space:nowrap">pre-marketing,</FONT> marketing,
promotion, sales, distribution, import and export activities (including securing reimbursement, sales and marketing and conducting any post-marketing trials or databases and post-marketing safety surveillance); (b) reporting of all adverse,
including serious, events to Regulatory Authorities if and to the extent required by Applicable Laws; (c)&nbsp;the timing for the launch of Licensed Products and for submitting applications for reimbursement with respect to Licensed Products in any
country in the Territory; and (d)&nbsp;booking all sales of Licensed Products in the Territory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.2
<B><U>Commercialization Diligence</U></B>. Upon <FONT STYLE="white-space:nowrap">Affini-T&#146;s</FONT> exercise of its Exclusive Option or <FONT STYLE="white-space:nowrap">Non-Exclusive</FONT> Option with respect to a given <FONT
STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target and subject to obtaining Regulatory Approval for an Exclusive Licensed Product or Nonexclusive Licensed Product, as applicable, directed to such
<FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target, <FONT STYLE="white-space:nowrap">Affini-T</FONT> shall use Commercially Reasonable Efforts during the Term to Commercialize at least one (1)&nbsp;Exclusive Licensed Product or
Nonexclusive Licensed Product, as applicable, directed to such <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.3 <B><U>Compliance</U></B>. <FONT STYLE="white-space:nowrap">Affini-T</FONT> shall perform its Commercialization activities
in compliance in all material respects with all Applicable Laws. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>7. <U>MANUFACTURE AND SUPPLY</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.1 <B><U>Metagenomi Reagents </U></B><B><U>Supply</U></B>. Metagenomi shall define, subject to the terms and conditions of
this Agreement, and the Development Supply Agreement and Development Quality Agreement, or the Commercial Supply Agreement and Commercial Quality Agreement, as applicable, the strategy and plans to manufacture Metagenomi Reagents supplied by
Metagenomi and shall keep <FONT STYLE="white-space:nowrap">Affini-T</FONT> informed on the progress therefor. Subject to Section&nbsp;2.1.2(d), Metagenomi will supply, and <FONT STYLE="white-space:nowrap">Affini-T</FONT> will purchase from
Metagenomi, all of the Metagenomi Reagents ordered by <FONT STYLE="white-space:nowrap">Affini-T</FONT> to be used for Gene Edits in the manufacture of Licensed Products for <FONT STYLE="white-space:nowrap">pre-clinical</FONT> research use pursuant
to one or more Research Plans and clinical Development use pursuant to the Development Supply Agreement and Quality Agreement. The Parties will enter into a supply agreement (the &#147;<B>Development Supply Agreement</B>&#148;) and a Quality
Agreement for Development purposes (the &#147;<B>Development Quality Agreement</B>&#148;) within[***] after <FONT STYLE="white-space:nowrap">Affini-T&#146;s</FONT> exercise of its first Option unless mutually extended by the Parties in writing. Upon
<FONT STYLE="white-space:nowrap">Affini-T&#146;s</FONT> request, to be made at a logical time based on JSC discussions with respect thereto (but, in any event, prior to filing for Drug Approval Application) for a Licensed Product, the Parties shall
amend the Development Supply Agreement (the &#147;<B>Commercial Supply Agreement</B>&#148;) and Development Quality Agreement (the &#147;<B>Commercial Quality Agreement</B>&#148;) to cover the supply of Metagenomi Reagents for Commercial purposes
within [***] of such request. The Development Supply Agreement and Development Quality Agreement will include supply amount, cost (for development supply, to be set at Metagenomi&#146;s manufacturing costs therefor (as will be further defined) plus
a reasonable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap">mark-up</FONT> to be set forth in the Development Supply Agreement, and for commercial supply, the Parties will agree on reasonable fixed tier pricing to be set
forth in the Commercial Supply Agreement), quality requirements, appropriate supply contingency plans, define supply defaults and remedies therefor, and certain manufacturing and scale up matters and other terms and conditions typically contained in
a contract manufacturing services agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.2 <B><U>Agreement Resolution</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.2.1 <U>Development Supply Agreement Finalization</U>. If the Parties have not entered into a Development Supply Agreement within [***] after
<FONT STYLE="white-space:nowrap">Affini-T&#146;s</FONT> exercise of its first Option or such later date as mutually extended by the Parties in writing, the finalization of such Development Supply Agreement shall be finally resolved by binding
arbitration. [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.2.2 <U>Development Quality Agreement Finalization</U>. If the Parties have not entered into a Development Quality
Agreement within [***] after <FONT STYLE="white-space:nowrap">Affini-T&#146;s</FONT> exercise of its first Option or such later date as mutually extended by the Parties in writing, the finalization of such Development Quality Agreement shall be
finally resolved by binding arbitration. [***] </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>8. <U>CONSIDERATION</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.1 <B><U>Equity Grant</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.1.1 <U>Initial Equity Grant</U>. In partial consideration of Metagenomi entering into this Agreement,
<FONT STYLE="white-space:nowrap">Affini-T</FONT> will, promptly following the Effective Date, issue 719,920 shares of <FONT STYLE="white-space:nowrap">Affini-T&#146;s</FONT> common stock to Metagenomi or its Affiliate in accordance with the terms of
that certain restricted stock agreement, in substantially the form attached hereto as <U>Schedule 8.1(a)</U> (the &#147;<B>Initial RSA</B>&#148;), to be executed by the Parties contemporaneously with the execution of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.1.2 <U>Milestone Equity Grant</U>. In partial consideration of Metagenomi entering into this Agreement,
<FONT STYLE="white-space:nowrap">Affini-T</FONT> will issue an additional 933,650 shares of <FONT STYLE="white-space:nowrap">Affini-T&#146;s</FONT> common stock to Metagenomi or its Affiliate in accordance with the terms of that certain restricted
stock agreement, in substantially the form attached hereto as <U>Schedule 8.1(b)</U> (the &#147;<B>Milestone RSA</B>&#148;), to be executed by the Parties promptly following the achievement of the Milestone. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.2 <B><U>Option Exercise Payments</U></B>. Within [***] after providing a written notice identifying an <FONT
STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target(s) with respect to which <FONT STYLE="white-space:nowrap">Affini-T</FONT> wishes to exercise its Option for either an Exclusive License, a Non-Exclusive License or both, Metagenomi shall
submit an invoice to <FONT STYLE="white-space:nowrap">Affini-T</FONT> pursuant to Section&nbsp;8.4.5(c) and <FONT STYLE="white-space:nowrap">Affini-T</FONT><B> </B>shall, within [***] of receipt of such invoice, make the following up to <FONT
STYLE="white-space:nowrap">two-times</FONT> (once for each Field), on an <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Target-by-Affini-T</FONT></FONT></FONT> Clinical Target basis (and corresponding to whether an Exclusive License, a
<FONT STYLE="white-space:nowrap">Non-Exclusive</FONT> License or both is/are taken with respect to such <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target), payments to Metagenomi (&#147;<B>Option Exercise Fee</B>&#148;): <B></B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Option for Commercial License in a Field</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option&nbsp;Exercise<BR>Fee&nbsp;for&nbsp;Exclusive<BR>License</B><br><B>($ US Dollars)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option&nbsp;Exercise<BR><FONT STYLE="white-space:nowrap">Fee&nbsp;for&nbsp;Non-</FONT></B><br><B>Exclusive&nbsp;License</B><br><B>($ US Dollars)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of First Option in a Field</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of Second Option in a Field</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of Third Option in a Field</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of Fourth Option in a Field</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of Fifth Option in a Field</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of Sixth Option in a Field</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.3 <B><U>Milestone Payments</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.3.1 <U>Development Milestones</U>. <FONT STYLE="white-space:nowrap">Affini-T</FONT><B> </B>shall notify Metagenomi within [***] after the
first achievement of each of the following Development milestone events with respect to each <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target once for each Field. Metagenomi shall submit an invoice to
<FONT STYLE="white-space:nowrap">Affini-T</FONT> for the applicable payment pursuant to Section&nbsp;8.4.5(c) and <FONT STYLE="white-space:nowrap">Affini-T</FONT> shall, within [***] of receipt of such invoice, make the following payments once for
each Field, on an <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Target-by-Affini-T</FONT></FONT></FONT> Clinical Target basis (and
corresponding to whether the Licensed Product achieving the relevant milestone is an Exclusively Licensed Product or a <FONT STYLE="white-space:nowrap">Non-Exclusively</FONT> Licensed Product). Each Development milestone shall be payable only once
for each <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target in each Field once for each Field regardless of the number of Exclusively Licensed Products or <FONT STYLE="white-space:nowrap">Non-Exclusively</FONT> Licensed Products
associated with such <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target that achieve such milestone event. In the event a Licensed Product is directed to more than one <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target,
such Licensed Product shall only trigger payment of applicable Development milestone amounts for a single <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target. <B></B> </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="17%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Development Milestone Event in a Field</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exclusively&nbsp;Licensed<BR>Product Milestone<BR>Payment</B><br><B>($ US Dollars)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-Exclusively</FONT><BR>Licensed&nbsp;Product<BR>Milestone<BR>Payment</B><br><B>($ US Dollars)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Development Milestone Event in a Field</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exclusively Licensed</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Product Milestone</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Payment</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>($ US
Dollars)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-Exclusively</FONT><BR>Licensed&nbsp;Product<BR>Milestone<BR>Payment</B><br><B>($ US Dollars)</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Maximum Total Development Milestone Payments</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">$18,750,000 for each <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target if all Development Milestones were achieved by an Exclusively Licensed Product and a
<FONT STYLE="white-space:nowrap">Non-Exclusively</FONT> Licensed Product both directed to such <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target [***]</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the purposes of this Section&nbsp;8.3.1, &#147;<B>[***]</B>&#148; means the earlier of (a) [***], (b)
[***], or (c) [***]. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.3.2 <U>Regulatory Approval Milestones</U>. <FONT STYLE="white-space:nowrap">Affini-T</FONT><B>
</B>shall notify to Metagenomi within [***] after the first achievement of each of the following Regulatory Approval milestone events with respect to each <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target once for each Field.
Metagenomi shall submit an invoice for the applicable payment to <FONT STYLE="white-space:nowrap">Affini-T</FONT> pursuant to Section&nbsp;8.4.5(c) and <FONT STYLE="white-space:nowrap">Affini-T</FONT> shall, within [***] of receipt of such invoice,
make the following payments once for each Field, on an <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Target-by-Affini-T</FONT></FONT></FONT> Clinical Target basis (and corresponding to whether the Licensed Product achieving the relevant milestone is
an Exclusively Licensed Product or a <FONT STYLE="white-space:nowrap">Non-Exclusively</FONT> Licensed Product). Each Regulatory Approval milestone shall be payable only once for each <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target
in each Field regardless of the number of Exclusively Licensed Products or Non-Exclusively Licensed Products associated with such <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target that achieve such milestone event. In the event a
Licensed Product is directed to more than one <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target, such Licensed Product shall only trigger payment of applicable Regulatory Approval milestone amounts for a single <FONT
STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target.&nbsp;&nbsp;&nbsp;&nbsp;<B> </B> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Regulatory Approval Milestone Event in a Field</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exclusively<BR>Licensed&nbsp;Product<BR>Milestone<BR>Payment</B><br><B>($ US Dollars)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-Exclusively</FONT><BR>Licensed&nbsp;Product<BR>Milestone<BR>Payment</B><br><B>($ US Dollars)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Regulatory Approval Milestone Event in a Field</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exclusively</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Licensed Product</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Milestone</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Payment</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>($ US Dollars)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-Exclusively</FONT><BR>Licensed&nbsp;Product<BR>Milestone<BR>Payment</B><br><B>($ US Dollars)</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Maximum Total Regulatory Approval Milestone Payments</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">$40,625,000 for each <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target if all Regulatory Approval Milestones were achieved by an Exclusively Licensed Product and a
<FONT STYLE="white-space:nowrap">Non-Exclusively</FONT> Licensed Product both directed to such <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target [***]</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.3.3 <U>Commercial Sales Milestones</U>. On a <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Target-by-Affini-T</FONT></FONT></FONT> Clinical Target basis, <FONT STYLE="white-space:nowrap">Affini-T</FONT><B> </B>shall notify and pay to Metagenomi
within [***] after the first achievement of each of the following Commercial sales milestone events as determined by aggregating Net Sales of all Licensed Products directed to a given <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target
(i.e., all Exclusively Licensed Products and <FONT STYLE="white-space:nowrap">Non-Exclusively</FONT> Licensed Products directed to a given <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target). Metagenomi shall submit an invoice to <FONT
STYLE="white-space:nowrap">Affini-T</FONT> for the applicable payment pursuant to Section&nbsp;8.4.5(c) and <FONT STYLE="white-space:nowrap">Affini-T</FONT> shall, within [***] of receipt of such invoice, make the following <FONT
STYLE="white-space:nowrap">one-time</FONT> payments. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Commercial Sales Milestone Event</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Milestone&nbsp;Payment</B><br><B>($ US Dollars)</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Maximum Total Commercial Sales Milestone Payments</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">$250,000,000&nbsp;for&nbsp;each<BR><FONT STYLE="white-space:nowrap">Affini-T&nbsp;Clinical&nbsp;Target</FONT><BR>[***]</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event [***] or more Commercial sales milestone events are achieved in the same Calendar Year, <FONT
STYLE="white-space:nowrap">Affini-T</FONT> shall pay to Metagenomi each Commercial sales milestone payment corresponding to the respective Commercial sales milestone event. For the avoidance of doubt, each Commercial sales milestone payment shall be
payable one time upon the first achievement of the corresponding Commercial sales milestone event, regardless of the number of times such Commercial sales milestone event may be achieved.<B> </B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once the Royalty Term with respect to a given Licensed Product and country has expired, the Net Sales of such Licensed Product in such country
shall not count towards cumulative Net Sales for purposes of this Section&nbsp;8.3.3. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.3.4 <U>Notice of Missing Payment</U>. If Metagenomi believes any of the foregoing
milestone event (Development, Regulatory Approval or Commercial sale) has occurred and it has not received payment of same from <FONT STYLE="white-space:nowrap">Affini-T,</FONT> it shall so notify <FONT STYLE="white-space:nowrap">Affini-T</FONT><B>
</B>in writing and shall provide to <FONT STYLE="white-space:nowrap">Affini-T</FONT><B> </B>documentation or other information that supports its belief. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.4 <B><U>Payment of Royalties; Royalty Rates; Accounting and Records</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.4.1 <U>Payment of Royalties</U>.<B> </B>On a Licensed
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Licensed</FONT></FONT> Product and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, during the applicable Royalty
Term for such Licensed Product and country, <FONT STYLE="white-space:nowrap">Affini-T</FONT> shall pay Metagenomi tiered royalties on the worldwide Annual Net Sales of such Licensed Product at the royalty rates set forth below. No more than one
royalty payment shall be due per Licensed Product per Calendar Quarter during the Royalty Term for such Licensed Product. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Annual Net Sales Thresholds</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>(Determined on an <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Target-by-</FONT></FONT></B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B><FONT
STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target basis)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exclusively<BR>Licensed&nbsp;Product</B><br><B>Royalty Rate</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-Exclusively</FONT><BR>Licensed&nbsp;Product<BR>Royalty Rate</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Annual Net Sales of all Licensed Products directed to a given [***] is less than [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Annual Net Sales of all Licensed Products directed to a given [***]is equal to or greater than
[***]but less than [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Annual Net Sales of all Licensed Products directed to a given [***]is equal to or greater than
[***]but less than [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Annual Net Sales of all Licensed Products directed to a given [***]Target is equal to or greater
than [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Once the Royalty Term with respect to a given Licensed Product and country has expired, the Net Sales of such
Licensed Product in such country shall not count towards cumulative Net Sales for purposes of establishing Net Sales tiers pursuant to this Section&nbsp;8.4.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.4.2 <U>Adjustments to Royalty Payments</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Notwithstanding anything to the contrary in Section&nbsp;8.4.1, if any Licensed Product is sold in a country and [***], then the
royalties shall be [***], continuing until [***] with respect to such Licensed Product and such country at issue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) If <FONT STYLE="white-space:nowrap">Affini-T,</FONT> or any of its Affiliates or
Sublicensees, is a party to a (sub)license from one or more Third Parties, including any Third Party license to Patent Rights which Cover, or <FONT STYLE="white-space:nowrap">Know-How</FONT> which relates to a given Licensed Product (or its use or
manufacture), because it is necessary or useful for <FONT STYLE="white-space:nowrap">Affini-T,</FONT> its Affiliate or Sublicensee to avoid infringement of such Patent Right or misappropriation of such
<FONT STYLE="white-space:nowrap">Know-How</FONT> in the Development, Manufacture, Commercialize or other exploitation of a Licensed Product in a given country (each such Third Party license is referred to herein as a &#147;<B>Third Party
License</B>&#148;), then, [***] of any payments owed by <FONT STYLE="white-space:nowrap">Affini-T</FONT> or any of its Affiliates or Sublicensees to any such Third Party for such a Third Party License (collectively, the &#147;<B>Third Party
Payments</B>&#148;) shall be creditable against royalties payable to Metagenomi under Section&nbsp;8.4.1; provided, that in no event will such credit reduce the royalties payable to Metagenomi for a given Calendar Quarter by [***]; provided,
further, that if additional reductions would be possible but for the foregoing [***], then such amounts may be rolled forward to reduce future royalty payments. Notwithstanding the foregoing, if the Third Party License is necessary or useful for <FONT
STYLE="white-space:nowrap">Affini-T,</FONT> its Affiliate or Sublicensee to avoid infringement of one or more Patent Rights or misappropriation of <FONT STYLE="white-space:nowrap">Know-How</FONT> as a result of exploitation of Metagenomi IP or the
Metagenomi Reagents in accordance with the terms of this Agreement, then [***] of any Third Party Payments in connection with such Third Party License shall be creditable against payments to Metagenomi under Sections 8.3 and 8.4.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) If <FONT STYLE="white-space:nowrap">Affini-T</FONT> is required to grant a Compulsory License to a Third Party with respect to a Licensed
Product, as applicable in any country, and such Third Party actually sells such Licensed Product in such country under such Compulsory License, with a royalty rate lower than the applicable royalty rate provided by this Section&nbsp;8.4, then the
Parties shall share all amounts actually received by <FONT STYLE="white-space:nowrap">Affini-T</FONT> or its Affiliates or Sublicensees from any Compulsory License in consideration of the sale of a Licensed Product less any withholding tax or other
taxes as may be required under Applicable Law and actually withheld from such payment due to <FONT STYLE="white-space:nowrap">Affini-T,</FONT> its Affiliate or Sublicensee, as applicable, [***] with
<FONT STYLE="white-space:nowrap">Affini-T&#146;s</FONT> share included in the royalty payments and reports made pursuant to Section&nbsp;8.4.3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.4.3 <U>Payment Dates and Reports</U>. <FONT STYLE="white-space:nowrap">Affini-T</FONT> shall provide a report showing the Net Sales of each
Licensed Product and calculation of the amount of royalty due to Metagenomi within [***] after the end of each Calendar Quarter in which a sale of such Licensed Product occurs, commencing with the Calendar Quarter in which [***]. Metagenomi shall
submit an invoice to <FONT STYLE="white-space:nowrap">Affini-T</FONT> based on such royalty report pursuant to Section&nbsp;8.4.5(c) and <FONT STYLE="white-space:nowrap">Affini-T</FONT> shall pay such royalty payments within [***] after receipt of
invoice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.4.4 <U>Records; Audit Rights</U>. <FONT STYLE="white-space:nowrap">Affini-T</FONT> and its Affiliates and Sublicensees
involved in booking sales of the Licensed Product shall keep and maintain for [***] from the end of the Calendar Year in which Net Sales occurred (the &#147;<B>Retention Period</B>&#148;) complete and accurate records of gross sales and Net Sales
by, as applicable, <FONT STYLE="white-space:nowrap">Affini-T</FONT> and its Affiliates and Sublicensees of each Licensed Product, in sufficient detail to allow royalties to be determined accurately. Metagenomi shall have the right during the
applicable Retention Period to appoint at its expense a nationally recognized independent certified public accountant reasonably acceptable to <FONT STYLE="white-space:nowrap">Affini-T</FONT> to audit the relevant records of <FONT
STYLE="white-space:nowrap">Affini-T</FONT> and its Affiliates and Sublicensees to verify that the amount of such payment was correctly determined. <FONT STYLE="white-space:nowrap">Affini-T</FONT> and its Affiliates and Sublicensees shall each make
its records available for audit by such nationally recognized independent certified public accountant during regular business hours at such place or places where such records are customarily kept, upon [***]written notice from Metagenomi. Such audit
right shall not be exercised by Metagenomi more than once in any Calendar Year or more than once with respect to sales of a particular Licensed Product in a particular period and such audit shall not unreasonably
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
interfere with or impede <FONT STYLE="white-space:nowrap">Affini-T&#146;s</FONT> or its Affiliate&#146;s or sublicensee&#146;s business operations. All records made available for audit shall be
deemed to be Confidential Information of <FONT STYLE="white-space:nowrap">Affini-T.</FONT> The results of each audit, if any, shall be provided to and are binding on both Parties absent manifest error; provided, that,
<FONT STYLE="white-space:nowrap">Affini-T</FONT> shall be provided an opportunity to discuss the findings of any such audit with the auditor prior to disclosure of the results thereof to Metagenomi. In the event there was an underpayment by <FONT
STYLE="white-space:nowrap">Affini-T</FONT> hereunder, <FONT STYLE="white-space:nowrap">Affini-T</FONT> shall promptly (but in any event no later than [***] after <FONT STYLE="white-space:nowrap">Affini-T&#146;s</FONT> receipt of the report so
concluding) make payment to Metagenomi of any shortfall. Metagenomi shall bear the full cost of such audit unless such audit discloses an underreporting by <FONT STYLE="white-space:nowrap">Affini-T</FONT> of [***] or at least [***] of the aggregate
amount of royalties payable in any Calendar Year, in which case <FONT STYLE="white-space:nowrap">Affini-T</FONT> shall reimburse Metagenomi for [***]. In the event there was an overpayment by <FONT STYLE="white-space:nowrap">Affini-T</FONT>
hereunder, <FONT STYLE="white-space:nowrap">Affini-T</FONT> may, at its discretion, credit such overpayment in the next royalty payment or request Metagenomi to and Metagenomi shall promptly (but in any event no later than [***] after
Metagenomi&#146;s receipt of the report so concluding) make repayment to <FONT STYLE="white-space:nowrap">Affini-T</FONT> of any such overage. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.4.5 <U>Payments; Withholding Tax</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) All payments made by <FONT STYLE="white-space:nowrap">Affini-T</FONT> under this Article 8 shall be made by wire transfer from a banking
institution in US Dollars in accordance with instructions given in writing from time to time by Metagenomi; provided however that <FONT STYLE="white-space:nowrap">Affini-T</FONT> will, or its vendor on behalf of
<FONT STYLE="white-space:nowrap">Affini-T,</FONT> will disburse payments only to Metagenomi&#146;s jurisdiction of incorporation or to a jurisdiction in which Metagenomi has a significant business presence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) If Applicable Laws require withholding of income or other taxes imposed upon any payments made by
<FONT STYLE="white-space:nowrap">Affini-T</FONT> to Metagenomi under this Agreement, including any value added tax or sales tax, <FONT STYLE="white-space:nowrap">Affini-T</FONT> shall (i)&nbsp;make such withholding payments as may be required,
(ii)&nbsp;subtract such withholding payments from such payments, (iii)&nbsp;submit appropriate proof of payment of the withholding taxes to Metagenomi within a reasonable period of time, and (iv)&nbsp;promptly provide Metagenomi with all official
receipts with respect thereto. <FONT STYLE="white-space:nowrap">Affini-T</FONT> shall render Metagenomi reasonable assistance in order to allow Metagenomi to obtain the benefit of any present or future treaty against double taxation which may apply
to such payments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) All invoices required to be submitted to <FONT STYLE="white-space:nowrap">Affini-T</FONT> under this Agreement
shall be submitted by Metagenomi to Bill.com or such other vendor designated by <FONT STYLE="white-space:nowrap">Affini-T</FONT> in writing from time to time. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>9. <U>TREATMENT OF CONFIDENTIAL INFORMATION; PUBLICITY.</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.1 <B><U>Confidentiality</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.1.1 <U>Confidentiality Obligations</U>. Metagenomi and <FONT STYLE="white-space:nowrap">Affini-T</FONT> each recognizes that the other
Party&#146;s Confidential Information and Proprietary Materials constitute highly valuable assets of such other Party. Metagenomi and <FONT STYLE="white-space:nowrap">Affini-T</FONT> each agrees that, during the Term and for an additional [***]
after termination or expiration of this Agreement, (a)&nbsp;subject to Section&nbsp;9.1.2, it will not disclose, and will cause its Affiliates not to disclose, any Confidential Information or Proprietary Materials of the other Party, (b)&nbsp;it
will not use, and will cause its Affiliates not to use, any Confidential Information or Proprietary Materials of the other Party, except as expressly </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
permitted in this Agreement, (c)&nbsp;it shall not attempt to reverse engineer, deconstruct or in any way determine the structure or composition of any of the other Party&#146;s Proprietary
Materials, and (d)&nbsp;it will use the same efforts to protect the other Party&#146;s Confidential Information as it does to protect its own similar Confidential Information (but, in any event, no less efforts than a reasonable Person in the
industry would use to protect similar information). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.1.2 <U>Limited Disclosure</U>. Each Disclosing Party agrees that disclosure of its
Confidential Information or any transfer of its Proprietary Materials may be made by the Receiving Party to any employee, director or agent of, or consultant to, such Receiving Party or to other Third Parties to enable such other Party to exercise
its rights (including <FONT STYLE="white-space:nowrap">Affini-T&#146;s</FONT> right to fully exploit any Commercial License granted to it) or to carry out its responsibilities under this Agreement; provided, that, any such disclosure or transfer
shall only be made to Persons who are bound by written obligations of confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> at least as strict as those described in Article 9. In addition, each Disclosing Party agrees that the
Receiving Party may disclose Confidential Information of the Disclosing Party (a)&nbsp;on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">need-to-know</FONT></FONT> basis to such Receiving Party&#146;s professional, legal and
financial advisors, (b)&nbsp;as reasonably necessary in connection with an actual or potential (i)&nbsp;permitted license or sublicense of such Receiving Party&#146;s rights hereunder, (ii)&nbsp;financing of such Receiving Party in a public or
private offering, or (iii)&nbsp;merger, acquisition, consolidation, share exchange or other similar transaction involving such Receiving Party and any Third Party, (c)&nbsp;to any Third Party that is or may be engaged by a Receiving Party to perform
services in connection with the Research Plan (or perform services in connection with carrying out Development or Commercialization activities) as necessary to enable such Third Party to perform such services, (d)&nbsp;as reasonably necessary to
file, prosecute or maintain Patent Rights, or to file, prosecute or defend litigation related to Patent Rights, in accordance with this Agreement, (e)&nbsp;as reasonably necessary for Regulatory Filings or interactions with Regulatory Authorities,
in each case relating to the Licensed Products, or (f)&nbsp;as required by Applicable Laws (including securities laws or regulations and the applicable rules of any public stock exchange in the case of any initial public offering or subsequent
public offering or in response to rules or guidance of the United States Internal Revenue Service or other taxing authority, or in other legal processes, including by the rules or regulations of the United States Securities and Exchange Commission
or similar regulatory agency in a country other than the United States or of any stock exchange or other securities trading institution); provided, that, in each case of clauses (a) &#150; (c) any such disclosure or transfer shall only be made to
Persons who are bound by written obligations of confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> consistent with those described in Article 9 (or industry standards in the case of a disclosure pursuant to clause (b)(ii)). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.1.3 <U>Requirement to Cooperate to Enable Accurate Public Disclosure</U>. To the extent either Party discloses to the other Party any
Confidential Information which is a fact, result or event relating to the Metagenomi Research Activities or the Development, Manufacture or Commercialization of any Licensed Product that the Receiving Party in good faith reasonably believes is
insufficient to allow the Receiving Party to fully understand the materiality of such Confidential Information for purposes of determining whether the Receiving Party is required to disclose, to any Governmental Authority or publicly, any such
Confidential Information in order to comply with Applicable Laws (including securities laws or regulations and the applicable rules of any public stock exchange), the Disclosing Party agrees to discuss such Confidential Information with the
Receiving Party and provide any additional information reasonably necessary to enable the Receiving Party to assess the materiality, and the accuracy and completeness, of such information for such public disclosure purposes as the case may be, which
additional information shall be treated as the Disclosing Party&#146;s additional Confidential Information and shall be treated in accordance with the terms hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.2 <B><U>Publicity</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.2.1 <U>Press Releases</U>. The Parties shall, upon such timing as the Parties jointly agree, issue a joint press release with respect to
this Agreement, and each Party may make subsequent public disclosure of the contents of such press release without further approval of the other Party. Subject to the foregoing, except as otherwise permitted under this Article 9, neither Party shall
issue a press or news release or make any similar public announcement related to the Research Plan or the terms and conditions of this Agreement without the prior written consent of the other Party.&nbsp;If a Party determines the need to make an
announcement related to this Agreement (as distinct from a publication related to a Licensed Product, which is subject to Section&nbsp;9.2.2) is required by Applicable Laws, it shall, to the extent reasonably practicable and permitted, give the
other Party at least [***] advance notice of the text of the announcement so that the other Party will have an opportunity to comment upon the announcement. With respect to any such public disclosure, except for the initial press release described
above, the requesting Party (the &#147;<B>Requesting Party</B>&#148;) shall provide the other Party (the &#147;<B>Reviewing Party</B>&#148;) with a draft of the Content (as defined in the next sentence) of the draft press release or public
disclosure for review, at least [***] (if practicable under the circumstances, or if not practicable, such shorter time) in advance of the issuance of the press release or filing. The word &#147;<B>Content</B>&#148; in this Section&nbsp;9.2.1 means
any information relating to the activities contemplated by this Agreement and does not include any other business information of the Requesting Party or information pertaining to the &#147;safe harbor&#148; provisions of the U.S. Private Securities
Litigation Reform Act of 1995 relating to &#147;forward-looking statements.&#148; The Reviewing Party may notify the Requesting Party of any reasonable objections or suggestions that the Reviewing Party may have regarding the Content in the proposed
public disclosure provided for review, and the Requesting Party shall reasonably consider any such objections or suggestions that are provided in a timely manner. The Requesting Party shall use diligent and good faith efforts to adopt the reasonable
requests of the Reviewing Party with respect to its Confidential Information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.2.2 <U>Right to Publish/Present</U>.
<B></B>Notwithstanding the foregoing or anything to the contrary in this Agreement, except as set forth in the last sentence of this Section&nbsp;9.2.2, <FONT STYLE="white-space:nowrap">Affini-T</FONT> shall have the sole right to publish or
publicly present all results or any and all milestone events achieved with respect to the research (including arising from or relating to the Metagenomi Research Activities), Development, Manufacture or Commercialization of any Licensed Product;
provided, that, to the extent such publication contains Metagenomi&#146;s Confidential Information, <FONT STYLE="white-space:nowrap">Affini-T</FONT> shall submit a draft of any proposed press release, manuscript, abstract or speech to Metagenomi at
least [***] prior to any such submission for publication and at least [***] prior to any such oral presentation and Metagenomi shall have the right to notify <FONT STYLE="white-space:nowrap">Affini-T</FONT> in writing within such [***]or [***], as
applicable, period if it reasonably determines that such draft contains Confidential Information of Metagenomi, in which case <FONT STYLE="white-space:nowrap">Affini-T</FONT> shall remove such Confidential Information from the proposed press
release, manuscript, abstract or speech. Subject to the foregoing portion of this Section&nbsp;9.2.2, Metagenomi shall have the right to publish or present without the prior written consent of <FONT STYLE="white-space:nowrap">Affini-T</FONT> so long
as no Confidential Information of <FONT STYLE="white-space:nowrap">Affini-T</FONT> is included in any such publication or presentation (including no Product Information). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.3 <B><U>Permitted Publication</U></B>. Notwithstanding Section&nbsp;9.2,
either Party may include in a public disclosure, without prior delivery to or approval by the other Party, any information which has previously been included in a public disclosure pursuant to Section&nbsp;9.2. A Party relying on this
Section&nbsp;9.3 shall bear the burden of establishing that information has previously been included in a public disclosure that has been approved pursuant to Section&nbsp;9.2 or published or publicly disclosed by the other Party. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.4 <B><U>Use of Proprietary Materials</U></B>. From time to time during the Term, either Party (the &#147;<B>Transferring
Party</B>&#148;) may supply the other Party (the &#147;<B>Recipient Party</B>&#148;) with Proprietary Materials of the Transferring Party for use in connection with this Agreement. Any Proprietary Materials being provided to Recipient Party shall be
accompanied by a Materials Transfer Record substantially in the form of <U>Schedule 9.4</U>, which shall be signed by an official representative of both Parties. In connection with the receipt of any Proprietary Materials from the Transferring
Party, each Recipient Party hereby agrees that (a)&nbsp;it shall not use such Proprietary Materials for any purpose other than exercising its rights or performing its obligations hereunder; (b)&nbsp;it shall use such Proprietary Materials only in
compliance with all Applicable Laws; (c)&nbsp;it shall not transfer any such Proprietary Materials to any Third Party without the prior written consent of the Transferring Party; (d)&nbsp;the Recipient Party shall not acquire any rights of
ownership, or title in or to, such Proprietary Materials as a result of such supply by the Transferring Party; and (e)&nbsp;upon the expiration or termination of this Agreement, the Recipient Party shall, if and as instructed by the Transferring
Party, either destroy or return any such Proprietary Materials that are not the subject of the grant of a continuing license hereunder; provided, that each Recipient Party may retain the Proprietary Materials of the Transferring Party for the sole
purpose of fulfilling regulatory requirements or industry best practices, including archived encapsulated cells from nonclinical GLP and clinical studies. EACH PARTY ACKNOWLEDGES THAT THE PROPRIETARY MATERIALS ARE BEING SUPPLIED WITH NO WARRANTIES,
EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE PROPRIETARY MATERIALS WILL NOT INFRINGE ANY PATENT OR PROPRIETARY RIGHTS OF ANY THIRD PARTY. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>10. <U>INTELLECTUAL PROPERTY RIGHTS</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.1 <B><U>Metagenomi <FONT STYLE="white-space:nowrap">In-Licensed</FONT> IP</U></B>. If Metagenomi knows or should have
knowledge of any Metagenomi <FONT STYLE="white-space:nowrap">In-Licensed</FONT> IP that Metagenomi has a right to sublicense (&#147;<B>Sublicenseable Metagenomi <FONT STYLE="white-space:nowrap">In-Licensed</FONT> IP</B>&#148;), or <FONT
STYLE="white-space:nowrap">Affini-T</FONT> becomes aware of any Metagenomi <FONT STYLE="white-space:nowrap">In-Licensed</FONT> IP, then Metagenomi or <FONT STYLE="white-space:nowrap">Affini-T,</FONT> as applicable, shall promptly notify the other
Party in writing of any such Metagenomi <FONT STYLE="white-space:nowrap">In-Licensed</FONT> IP (i.e., Sublicenseable Metagenomi <FONT STYLE="white-space:nowrap">In-Licensed</FONT> IP in the case of Metagenomi, and Metagenomi <FONT
STYLE="white-space:nowrap">In-Licensed</FONT> IP in the case of <FONT STYLE="white-space:nowrap">Affini-T),</FONT> including, in the case of Metagenomi providing a general description of the relevant Sublicenseable Metagenomi <FONT
STYLE="white-space:nowrap">In-Licensed</FONT> IP and any applicable financial terms (if <FONT STYLE="white-space:nowrap">Affini-T</FONT> initiates this process, then Metagenomi shall promptly respond to
<FONT STYLE="white-space:nowrap">Affini-T&#146;s</FONT> initial notice advising whether such Metagenomi <FONT STYLE="white-space:nowrap">In-Licensed</FONT> IP is Sublicenseable Metagenomi <FONT STYLE="white-space:nowrap">In-Licensed</FONT> IP and,
if it is, with such information). Upon receipt of any such notice from Metagenomi (including a subsequent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
notice if Metagenomi is to provide information following an initial notice from <FONT STYLE="white-space:nowrap">Affini-T),</FONT> <FONT STYLE="white-space:nowrap">Affini-T</FONT> shall have the
right to request, and Metagenomi shall provide, a copy of the license agreement and any amendments thereto with respect to such Sublicenseable Metagenomi <FONT STYLE="white-space:nowrap">In-Licensed</FONT> IP (the &#147;<B>Upstream
Agreement</B>&#148;) and answer any reasonable questions with respect to such Upstream Agreement and Sublicenseable Metagenomi <FONT STYLE="white-space:nowrap">In-Licensed</FONT> IP. Following such discussions,
<FONT STYLE="white-space:nowrap">Affini-T</FONT> shall have the right to include such Metagenomi <FONT STYLE="white-space:nowrap">In-Licensed</FONT> IP as Metagenomi Background IP hereunder upon written notice to Metagenomi subject to <FONT
STYLE="white-space:nowrap">Affini-T</FONT> agreeing to be subject to any pass-through obligations or limitations applicable to <FONT STYLE="white-space:nowrap">Affini-T&#146;s</FONT> exercise of such rights, including responsibility for payment
obligations to the extent solely attributable to the rights granted to <FONT STYLE="white-space:nowrap">Affini-T.</FONT> To the extent Sublicenseable Metagenomi <FONT STYLE="white-space:nowrap">In-Licensed</FONT> IP is included as Metagenomi
Background IP, Metagenomi shall comply with all terms and conditions of, and shall maintain in full force and effect each relevant Upstream Agreement related to such Sublicenseable Metagenomi <FONT STYLE="white-space:nowrap">In-Licensed</FONT> IP
and shall not terminate or amend any such Upstream Agreement in a way that could have an adverse effect on <FONT STYLE="white-space:nowrap">Affini-T&#146;s</FONT> rights without <FONT STYLE="white-space:nowrap">Affini-T&#146;s</FONT> prior written
consent, such consent not to be unreasonably withheld or delayed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.2 <B><U>Ownership of Agreement IP</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.2.1 <U>General</U>. As between the Parties, all right, title and interest in any Agreement <FONT STYLE="white-space:nowrap">Know-How</FONT>
and Agreement Patent Rights, shall be owned as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Metagenomi shall solely own all (i)&nbsp;Agreement <FONT
STYLE="white-space:nowrap">Know-How</FONT> that solely (1)&nbsp;relates to the identification, characterization, composition of matter, and manufacture of Metagenomi Reagents, or (2)&nbsp;constitutes an improvement to Metagenomi Background IP
(collectively (1)&nbsp;and (2), &#147;<B>Metagenomi Agreement <FONT STYLE="white-space:nowrap">Know-How</FONT></B>&#148;), and (ii)&nbsp;Patent Rights that Cover Metagenomi Agreement <FONT STYLE="white-space:nowrap">Know-How</FONT>
(&#147;<B>Metagenomi Agreement Patent Rights</B>&#148;) (collectively (i)&nbsp;and (ii), &#147;<B>Metagenomi Agreement IP</B>&#148;); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <FONT STYLE="white-space:nowrap">Affini-T</FONT> shall solely own all (i)&nbsp;Agreement <FONT STYLE="white-space:nowrap">Know-How</FONT>
that is not Metagenomi Agreement <FONT STYLE="white-space:nowrap">Know-How</FONT> (&#147;<B><FONT STYLE="white-space:nowrap">Affini-T</FONT> Agreement <FONT STYLE="white-space:nowrap">Know-How</FONT></B>&#148;), including all Agreement <FONT
STYLE="white-space:nowrap">Know-How</FONT> that constitutes an improvement to <FONT STYLE="white-space:nowrap">Affini-T</FONT> Background IP, and (ii)&nbsp;Patent Rights that Cover <FONT STYLE="white-space:nowrap">Affini-T</FONT> Agreement <FONT
STYLE="white-space:nowrap">Know-How</FONT> (&#147;<B><FONT STYLE="white-space:nowrap">Affini-T</FONT> Agreement Patent Rights</B>&#148;) (collectively (i)&nbsp;and (ii), &#147;<B><FONT STYLE="white-space:nowrap">Affini-T</FONT> Agreement
IP</B>&#148;).</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.2.2 Notice, Assignments, Assistance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Each Party shall (i)&nbsp;promptly notify the other Party of any Agreement <FONT STYLE="white-space:nowrap">Know-How</FONT> made by or on
behalf of itself and that is to be owned by the other Party, and (ii)&nbsp;hereby assigns, transfers and conveys to the other Party, or its designee, all of such Party&#146;s worldwide right, title and interest in and to any and all Agreement IP
that is to be owned by such other Party in accordance with Section&nbsp;10.2.1, including any and all moral rights and intellectual property rights inherent therein and appurtenant thereto, including all Patent Rights, copyrights, trademarks, <FONT
STYLE="white-space:nowrap">Know-How</FONT> and trade secrets and the rights to apply for the same. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Upon the request and at the reasonable expense of the other Party, each Party shall
execute and deliver any and all instruments and documents and take such other acts as may be necessary or desirable to document the assignment and transfer described in Section&nbsp;10.2.2(a) or to enable such other Party to secure its rights in the
applicable Agreement IP, including providing any necessary powers of attorney for such purpose.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.2.3 <U>CREATE Act</U>. Notwithstanding
anything to the contrary in this Article 10, neither Party shall have the right to make an election under the Cooperative Research and Technology Enhancement Act of 2004, 35 U.S.C. 103(c)(2)-(c)(3) (the &#147;<B>CREATE Act</B>&#148;) when exercising
its rights under this Article 10 without the prior written consent of the other Party. With respect to any such permitted election, the Parties shall coordinate their activities with respect to any submissions, filings, or other activities in
support thereof. The Parties acknowledge and agree that this Agreement is a &#147;joint research agreement&#148; as defined in the CREATE Act. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>11. <U>FILING, PROSECUTION AND MAINTENANCE OF PATENT RIGHTS</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.1 <B><U>Patent Prosecution</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.1.1 <U>Metagenomi </U><U>Patent </U><U>Prosecution Rights</U>. Subject to the last sentence of this Section&nbsp;11.1.1, Metagenomi shall
be solely responsible (but not obligated) for the Patent Prosecution of the Metagenomi Agreement Patent Rights. <FONT STYLE="white-space:nowrap">Affini-T</FONT> shall cooperate with and reasonably assist Metagenomi in connection with
Metagenomi&#146;s Patent Prosecution of the Metagenomi Agreement Patent Rights (including review and providing comments for responses to office actions or official actions from worldwide patent offices), including by obtaining assignments to reflect
chain of title consistent with the terms of this Agreement. All Patent Costs incurred by Metagenomi in connection with the Patent Prosecution of such Patent Rights shall be the sole responsibility of Metagenomi. If Metagenomi decides to cease
prosecution of or to allow to lapse any Metagenomi Agreement Patent Right, it shall inform <FONT STYLE="white-space:nowrap">Affini-T</FONT> of such decision promptly and, in any event, so as to provide
<FONT STYLE="white-space:nowrap">Affini-T</FONT> a reasonable amount of time to meet any applicable deadline to establish or preserve such Patent Rights. <FONT STYLE="white-space:nowrap">Affini-T</FONT> shall have the right, but not the obligation,
to assume sole responsibility for continuing the prosecution of such Patent Rights and paying any required Patent Costs to maintain such Patent Rights or defend such Patent Rights. If <FONT STYLE="white-space:nowrap">Affini-T</FONT> notifies
Metagenomi that it desires to assume responsibility for any such Metagenomi Agreement Patent Right, then <FONT STYLE="white-space:nowrap">Affini-T</FONT> will have the right to undertake the Patent Prosecution with respect to such Patent Right in
Metagenomi&#146;s name and such Patent Right shall cease to be a Metagenomi Patent Right for purposes of determining the Royalty Term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.1.2 <U>Metagenomi&#146;s Patent Defense Rights</U>. Metagenomi will notify <FONT STYLE="white-space:nowrap">Affini-T</FONT> within [***] of
becoming aware of any declaratory judgment, opposition, or similar action alleging the invalidity, unenforceability or <FONT STYLE="white-space:nowrap">non-infringement</FONT> of any of the Metagenomi Agreement Patent Rights in the Territory.
Metagenomi shall only be primarily responsible (but not obligated) for the Patent Defense of Metagenomi Agreement Patent Rights. At Metagenomi&#146;s reasonable expense, <FONT STYLE="white-space:nowrap">Affini-T</FONT> shall cooperate with and
assist Metagenomi in all reasonable respects, in connection with Metagenomi&#146;s Patent Defense activities. All Patent Costs incurred by Metagenomi in connection with the Patent Defense of such Patent Rights shall be the sole responsibility of
Metagenomi. If Metagenomi decides to cease such Patent Defense with respect to any such Patent Right, it shall inform <FONT STYLE="white-space:nowrap">Affini-T</FONT> of such decision promptly and, in any event, so as to provide <FONT
STYLE="white-space:nowrap">Affini-T</FONT> a reasonable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
amount of time to meet any applicable deadline to defend or preserve such Patent Rights. <FONT STYLE="white-space:nowrap">Affini-T</FONT> shall have the right, but not the obligation, to assume
sole responsibility for continuing such Patent Defense (and thereafter the prosecution of such Patent Rights). If <FONT STYLE="white-space:nowrap">Affini-T</FONT> notifies Metagenomi that it desires to assume responsibility for any such Patent
Defense, then <FONT STYLE="white-space:nowrap">Affini-T</FONT> will have the right to undertake the Patent Defense with respect to such Patent Right in Metagenomi&#146;s name. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.1.3 <U><FONT STYLE="white-space:nowrap">Affini-T</FONT> Prosecution Rights</U>. As between the Parties,
<FONT STYLE="white-space:nowrap">Affini-T,</FONT> at its sole expense, shall be solely responsible for the Patent Prosecution of all <FONT STYLE="white-space:nowrap">Affini-T</FONT> Patent Rights. Metagenomi shall cooperate with and assist <FONT
STYLE="white-space:nowrap">Affini-T</FONT> in all reasonable respects in connection with <FONT STYLE="white-space:nowrap">Affini-T&#146;s</FONT> Patent Prosecution of such Patent Rights, including by obtaining assignments to reflect chain of title
consistent with the terms of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.1.4 <U><FONT STYLE="white-space:nowrap">Affini-T</FONT></U><U>&#146;</U><U>s Patent
Defense Rights</U>. <FONT STYLE="white-space:nowrap">Affini-T</FONT> will notify Metagenomi within [***] of becoming aware of any declaratory judgment, opposition, or similar action alleging the invalidity, unenforceability or <FONT
STYLE="white-space:nowrap">non-infringement</FONT> of any <FONT STYLE="white-space:nowrap">Affini-T</FONT> Patent Rights in the Territory. <FONT STYLE="white-space:nowrap">Affini-T</FONT> shall be responsible for the Patent Defense of such <FONT
STYLE="white-space:nowrap">Affini-T</FONT> Patent Rights. Metagenomi shall cooperate with and assist <FONT STYLE="white-space:nowrap">Affini-T,</FONT> at <FONT STYLE="white-space:nowrap">Affini-T&#146;s</FONT> reasonable expense, in all reasonable
respects in connection with <FONT STYLE="white-space:nowrap">Affini-T&#146;s</FONT> Patent Defense activities. All Patent Costs incurred by <FONT STYLE="white-space:nowrap">Affini-T</FONT> in connection with the Patent Defense of such <FONT
STYLE="white-space:nowrap">Affini-T</FONT> Patent Rights shall be, as between the Parties, the sole responsibility of <FONT STYLE="white-space:nowrap">Affini-T.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.1.5 <U>I</U><U>nformation and Cooperation</U>. Metagenomi shall (a)&nbsp;promptly provide <FONT STYLE="white-space:nowrap">Affini-T</FONT>
with copies of all patent applications with respect to Metagenomi Agreement Patent Rights to be filed pursuant to Section&nbsp;11.1.1 and other material submissions and correspondence with the applicable patent offices, at least [***] (unless the
circumstances require otherwise) prior to undertaking any filing for review and comment by <FONT STYLE="white-space:nowrap">Affini-T</FONT> and (b)&nbsp;provide <FONT STYLE="white-space:nowrap">Affini-T</FONT> and its patent counsel with an
opportunity to consult with Metagenomi and its patent counsel regarding the filing and contents of any such application, amendment, submission or response, during such review period and as may otherwise be agreed by the Parties. The advice and
suggestions of <FONT STYLE="white-space:nowrap">Affini-T</FONT> and its patent counsel shall be taken into consideration in good faith by Metagenomi and its patent counsel in connection with such filing; provided, that, if <FONT
STYLE="white-space:nowrap">Affini-T</FONT> fails to timely provide any comment before the proposed filing or response date, Metagenomi&#146;s obligations under this Section&nbsp;11.1.4 shall be deemed to have been fulfilled. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.2 <B><U>Third Party Infringement</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.2.1 If (a)&nbsp;Metagenomi becomes aware of any suspected infringement of any Metagenomi Patent Rights or misappropriation of any Agreement
<FONT STYLE="white-space:nowrap">Know-How,</FONT> in each case with respect to the use by a Third Party of the Metagenomi Reagents to make Gene Edits directed to an <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target in the Exclusive
Field (&#147;<B>Infringement</B>&#148;); or <FONT STYLE="white-space:nowrap">(b)&nbsp;Affini-T</FONT> becomes aware of an Infringement, then that Party shall promptly notify the other Party of such Infringement of which it is aware (each, an
&#147;<B>Infringement Notice</B>&#148;). The Parties shall promptly meet to discuss any Infringement and the strategy for patent enforcement with respect to that Infringement; provided, that, at the request of either Party, the Parties shall first
execute a common interest agreement before any such meetings or exchange of detailed information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.2.2 Metagenomi shall have the first right, but not the obligation, to address any such
Infringement in the Territory with respect to the Metagenomi Agreement IP, taking reasonable steps, which may include the institution of legal proceedings or other action, and to compromise or settle such Infringement (each, an &#147;<B>Infringement
Response</B>&#148;); provided, that: (A)&nbsp;Metagenomi shall keep <FONT STYLE="white-space:nowrap">Affini-T</FONT> reasonably informed about any such Infringement Response and <FONT STYLE="white-space:nowrap">Affini-T</FONT> shall provide all
reasonable cooperation to Metagenomi in connection with such Infringement Response; (B)&nbsp;Metagenomi shall not take any position with respect to, or compromise or settle, any such Infringement that relates to any Metagenomi Agreement IP in any
way that is reasonably likely to adversely affect the scope, validity or enforceability of any <FONT STYLE="white-space:nowrap">Affini-T</FONT> Agreement IP, the Commercial License or any Licensed Product, without the prior consent of <FONT
STYLE="white-space:nowrap">Affini-T,</FONT> which consent shall not be unreasonably withheld, conditioned or delayed; and (C)&nbsp;if Metagenomi does not intend to or does not take any action to prosecute or defend an Infringement of Metagenomi
Agreement IP within [***] after the date of the Infringement Notice, or ceases to diligently pursue an Infringement Response with respect to such an Infringement of Metagenomi Patent Rights, it shall promptly inform
<FONT STYLE="white-space:nowrap">Affini-T</FONT> in such a manner that such Infringement Response will not be prejudiced and <FONT STYLE="white-space:nowrap">Affini-T</FONT> shall have the right, but not the obligation, to assume sole responsibility
to prosecute or defend an Infringement of such Patent Rights and paying all future costs associated with such Infringement Costs.<B> </B>All costs, including attorneys&#146; fees, relating to an Infringement Response from Metagenomi shall be borne
solely by Metagenomi. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.2.3 Each Party shall have the right to participate and be represented by counsel that it selects, in any
Infringement Response instituted or continued under Section&nbsp;11.2.2 by the other Party. If a Party with the right to initiate an Infringement Response under Section&nbsp;11.2.2 to eliminate an Infringement lacks standing to do so and the other
Party has standing to initiate such action, then the Party with the right to initiate an action under Section&nbsp;11.2.2 may name the other Party as plaintiff in such action or may require the Party with standing to initiate such Infringement
Response at the expense of the other Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.2.4 In any Infringement Response instituted under this Section&nbsp;11.2, the Parties
shall cooperate with and reasonably assist each other in all reasonable respects. Upon the reasonable request of the Party instituting that Infringement Response, the other Party shall join such Infringement Response and shall be represented using
counsel of its own choice, at the requesting Party&#146;s expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.2.5 Any settlements, damages or monetary awards
(&#147;<B>Recovery</B>&#148;) recovered by either Party pursuant to any Infringement Response shall, after reimbursing the Parties for their reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT>
expenses in making such recovery (which amounts shall be allocated pro rata if insufficient to cover the totality of such expenses), be [***]or[***] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.3 <B><U>Defense of Claims</U></B>. If any action, suit or proceeding is brought against either Party or any Affiliate of
either Party alleging the misappropriation or infringement of the <FONT STYLE="white-space:nowrap">Know-How</FONT> or Patent Rights of a Third Party by reason of the research, Development, Manufacture or Commercialization of any Licensed Product or
component thereof, including receipt of any notices of infringement under 35 U.S.C. &#167; 271(e)(2), 42 U.S.C. &#167; 262(1), or 42 U.S.C. &#167; 262(1)(9)(C), such Party shall notify the other Party within [***] of the earlier of (a)&nbsp;receipt
of service of process in such action, suit or proceeding, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
or (b)&nbsp;the date such Party becomes aware that such action, suit or proceeding has been instituted. To the extent such action, suit or proceeding does not relate to Metagenomi Reagents, <FONT
STYLE="white-space:nowrap">Affini-T</FONT> shall have the sole right but not the obligation to control and defend such action, suit or proceeding at its sole expense. To the extent such action, suit or proceeding relates to Metagenomi Reagents, the
Parties shall meet as soon as possible to discuss the overall strategy for defense of such matter and except as unanimously agreed by the Parties, <FONT STYLE="white-space:nowrap">(i)&nbsp;Affini-T</FONT> shall have the right but not the obligation
to control and defend such action, suit or proceeding at its sole expense; (ii)&nbsp;Metagenomi shall have the right to engage separate counsel at its own expense in any such action, suit or proceeding; and (iii)&nbsp;the Parties shall cooperate
with each other in all reasonable respects in any such action, suit or proceeding. Each Party shall promptly furnish the other Party with a copy of each communication relating to the alleged infringement or misappropriation and a Metagenomi Reagent
that is received by such Party including all documents filed in any litigation </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.4 <B><U>Patent Term Extension</U></B>.
The Parties shall cooperate with each other in obtaining patent term extensions or supplemental protection certificates or their equivalents in any country in the Territory where applicable to any Patent Right Covering a Licensed Product. Such
cooperation shall include diligently and timely conferring and coordinating with respect to such matters to ensure compliance with applicable filing deadlines and agreeing on procedures to be followed by the Parties to ensure such compliance. In the
event that elections with respect to obtaining such patent term extension are to be made or the Parties otherwise disagree, <FONT STYLE="white-space:nowrap">Affini-T</FONT> shall have the right to make the election or decision solely with respect to
any <FONT STYLE="white-space:nowrap">Affini-T</FONT> Patent Rights, and Metagenomi shall retain the right with respect to an election or decision with respect to the Metagenomi Patent Rights; provided that, Metagenomi shall consider any input from <FONT
STYLE="white-space:nowrap">Affini-T</FONT> with respect to the decision to extend Metagenomi Patent Rights in good faith. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>12. <U>TERM
AND TERMINATION</U> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.1 <B><U>Term</U></B>. This Agreement shall commence on the Effective Date and shall continue
in full force and effect, unless otherwise terminated pursuant to Section&nbsp;12.2, until the fifth year anniversary of the Effective Date (the &#147;<B>Initial Term</B>&#148;); provided that, if <FONT STYLE="white-space:nowrap">Affini-T</FONT>
exercises an Exclusive Option<B> </B>with respect to any <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target during the Initial Term, then the Initial Term shall be extended by five (5)&nbsp;years (the &#147;<B>Extended Term</B>&#148;)
to allow <FONT STYLE="white-space:nowrap">Affini-T</FONT> to exercise its Option with respect to other <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Targets. Following the expiration of the Extended Term, if any, this Agreement shall
survive, on an <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Target-by-Affini-T</FONT></FONT></FONT> Clinical Target basis, with respect
to each <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target for which <FONT STYLE="white-space:nowrap">Affini-T</FONT> has exercised its Option during the Initial Term or Extended Term until the earlier of (i)&nbsp;termination of such <FONT
STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target in its entirety under Section&nbsp;12.2 and (ii)&nbsp;the last day of the Royalty Term for the last Licensed Product associated with such <FONT STYLE="white-space:nowrap">Affini-T</FONT>
Clinical Target (collectively, the Initial Term, Extended Term (if any) and foregoing survival, the &#147;<B>Term</B>&#148;). Upon the expiration of the Royalty Term with respect to a given Licensed Product, country, and Field, the Commercial
License granted to <FONT STYLE="white-space:nowrap">Affini-T</FONT> shall be retained as fully <FONT STYLE="white-space:nowrap">paid-up,</FONT> irrevocable and perpetual licenses with respect to such Licensed Product, country, and Field. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.2 <B><U>Termination</U></B>. This Agreement, a given <FONT
STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target or a Licensed Product may be terminated as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12.2.1 <U>Unilateral Right
to Terminate</U>. <FONT STYLE="white-space:nowrap">Affini-T</FONT> may terminate this Agreement (a)&nbsp;in its entirety, or (b)&nbsp;on (i) a Research <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Plan-by-Research</FONT></FONT>
Plan basis, (ii)&nbsp;an <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Target-by-Affini-T</FONT></FONT></FONT> Clinical Target basis, or
(iii)&nbsp;a Licensed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Licensed</FONT></FONT> Product basis (terminations under this subclause (b), a &#147;<B>Partial Termination</B>&#148;), effective at any time by
providing not less than sixty (60)&nbsp;days&#146; prior written notice to Metagenomi. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12.2.2 <U>Termination for Breach</U>. If a Party
materially breaches this Agreement, then the <FONT STYLE="white-space:nowrap">non-breaching</FONT> Party may provide the breaching Party with a written notice specifying the nature of the breach, and stating its intention to terminate this Agreement
if such breach is not cured; provided, that, this Agreement may only be terminated in its entirety pursuant to this Section&nbsp;12.2.2 if the material breach materially and adversely impacts this Agreement as a whole, otherwise such termination
must be specific to the impacted Research Plan, <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target or Licensed Product, as such specifically impacted subject matter(s) are noted in the notice of breach (also, a &#147;<B>Partial
Termination</B>&#148;). If the material breach is not cured by the allegedly breaching Party within [***] after the receipt of such notice or if such other breach is curable but cannot be cured within the [***]period, the allegedly breaching Party
fails to commence actions during such [***]period to cure such breach and thereafter fails to use Commercially Reasonable Efforts to promptly cure such breach, then, in each case, the <FONT STYLE="white-space:nowrap">non-breaching</FONT> Party shall
be entitled, without prejudice to any of its other rights under this Agreement, and in addition to any other remedies available to it by law or in equity, to terminate this Agreement by providing written notice to the other Party. If the allegedly
breaching Party in good faith disputes such material breach or the failure to cure or remedy such material breach, such Party shall, within [***] of receipt of written notice from the other Party of termination (a)&nbsp;provide written notice of
that dispute putting forward in reasonable detail the rationale for disputing the alleged breach to the notifying Party and (b)&nbsp;initiate a proceeding in accordance with Section&nbsp;15.1, in which case, such termination shall not be effective
until [***] after the proceeding has concluded; provided that the breaching Party shall have [***] after such proceeding to cure the breach and during the pendency of any such proceeding the Parties shall continue performing their respective
obligations, and exercising their respective rights, under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12.2.3 <U>Termination for Insolvency</U>. Either Party shall
have the right to terminate this Agreement in its entirety upon immediate written notice if the other Party (i)&nbsp;applies for or consents to the appointment of, or the taking of possession by, a receiver, custodian, trustee or liquidator of
itself or of all of a substantial part of its property, (ii)&nbsp;makes a general assignment for the benefit of its creditors, (iii)&nbsp;commences a voluntary case under the Bankruptcy Code of any country, (iv)&nbsp;files a petition seeking to take
advantage of any Applicable Laws relating to bankruptcy, insolvency, reorganization, <FONT STYLE="white-space:nowrap">winding-up,</FONT> or composition or readjustment of debts, (v)&nbsp;fails to controvert in a timely and appropriate manner, or
acquiesce in writing to, any petition filed against it in any involuntary case under the Bankruptcy Code of any country, (vi)&nbsp;takes any corporate action for the purpose of effecting any of the foregoing, (vii)&nbsp;has a proceeding or case
commenced against it in any court of competent jurisdiction, seeking (A)&nbsp;its liquidation, reorganization, dissolution or <FONT STYLE="white-space:nowrap">winding-up,</FONT> or the composition or readjustment of its debts, (B)&nbsp;the
appointment of a trustee, receiver, custodian, liquidator or the like of all or any substantial part of its assets, or (C)&nbsp;similar relief under the Bankruptcy Code of any country, or an order, judgment or decree approving any of the foregoing
is entered and continues unstayed for a period of [***], or (viii)&nbsp;has an order for relief against it entered in an involuntary case under the Bankruptcy Code of any country and, in any of (i)&nbsp;through (vii) above, the application,
assignment, commencement, filing, or corporate action continues unstayed for, or is not otherwise discharged or withdrawn on or before, a period of [***]. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12.3 <B><U>Consequences of Termination</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12.3.1 If this Agreement is terminated in its entirety or subject to a Partial Termination by <FONT STYLE="white-space:nowrap">Affini-T</FONT>
pursuant to Section&nbsp;12.2.2 or Section&nbsp;12.2.3 or by Metagenomi pursuant to Section&nbsp;12.2.3, Metagenomi shall cease performing all applicable Metagenomi Research Activities. Upon <FONT STYLE="white-space:nowrap">Affini-T&#146;s</FONT>
written request, Metagenomi will discuss in good faith (a)&nbsp;granting to <FONT STYLE="white-space:nowrap">Affini-T</FONT> a research use license with respect to any applicable Metagenomi Background IP, and/or (b)&nbsp;a transfer of all complete
or incomplete deliverables, reports and data with respect to the terminated Research Plan(s), <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target(s) or Licensed Product(s), in each case of (a)&nbsp;and (b), on commercially reasonable
terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12.3.2 If this Agreement is terminated in its entirety or subject to a Partial Termination by
<FONT STYLE="white-space:nowrap">Affini-T</FONT> pursuant to Section&nbsp;12.2.1, or by Metagenomi pursuant to Section&nbsp;12.2.2, Metagenomi shall cease performing all applicable Metagenomi Research Activities.
<FONT STYLE="white-space:nowrap">Affini-T</FONT> shall be responsible for any <FONT STYLE="white-space:nowrap">non-cancellable</FONT> costs incurred in accordance with an applicable Research Plan (and the subject of which costs cannot be reasonably
allocable to other activities being conducted by Metagenomi). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12.3.3 Subject to the foregoing Section&nbsp;12.3.1 and
Section&nbsp;12.3.2, all rights and licenses granted by one Party to the other under Article 2 will terminate with respect to the terminated subject matter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12.3.4 Notwithstanding the foregoing, with respect to a Licensed Product on a Licensed <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Product-by-Licensed</FONT></FONT> Product basis or with respect to all Licensed Products directed to such an <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target on an
<FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Target-by-Affini-T</FONT></FONT></FONT> Clinical Target basis, in the event that <FONT
STYLE="white-space:nowrap">Affini-T</FONT> has the right to terminate this Agreement in accordance with Section&nbsp;12.2.2 as a result of a breach under Section&nbsp;2.1.2 (Commercial License), 2.2
<FONT STYLE="white-space:nowrap">(Non-Compete),</FONT> 4.2.1 (Metagenomi Responsibilities), 4.3 (Compliance), 9.1 (Confidentiality), 13.2.1 (No Claims), 13.2.3 (Ownership), 13.2.4 (Completeness) or 14.2 (Indemnification), and such breach resulted in
a material adverse effect on the potential or actual development or commercialization of such Licensed Product(s) or such <FONT STYLE="white-space:nowrap">Affini-T</FONT> Clinical Target(s), then, in lieu of exercising such termination right, <FONT
STYLE="white-space:nowrap">Affini-T</FONT> shall have the right, by way of written notice to Metagenomi, to continue this Agreement in accordance with its terms subject to [***] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.4 <B><U>Surviving Provisions</U></B>. Termination or expiration of this Agreement for any reason shall be without prejudice
to: (a)&nbsp;the survival of rights specifically stated in this Agreement to survive, including as set forth in this Section&nbsp;12.4; (b) the rights and obligations of the Parties provided in Sections 2.1.4 (only for expiration and not
termination), 4.4 (for the period set forth therein), 5.5.2 (first two sentences only and only for expiration and not termination), 8.4.4 (for the period set forth therein), 8.4.5, 10.2.2(b), 12.3 (as applicable) and 12.4<B> </B>and Articles 1, 9
(for the period set forth in 9.1.1), 14 and 15 (excluding Section&nbsp;15.8) (including all other Sections or Articles referenced in any such Section or Article), all of which shall survive such termination except as provided in this Article 12; and
(c)&nbsp;any other rights or remedies provided at law or equity which either Party may otherwise have. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>13. <U>REPRESENTATIONS AND WARRANTIES</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.1 <B><U>Mutual Representations and Warranties</U></B>. Metagenomi and <FONT STYLE="white-space:nowrap">Affini-T</FONT> each
represents and warrants to the other, as of the Effective Date, as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">13.1.1 <U>Organization</U>. It is a corporation or company
duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization, and has all requisite power and authority, corporate or otherwise, to execute, deliver and perform this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">13.1.2 <U>Authorization</U>. The execution and delivery of this Agreement and the performance by it of the transactions contemplated hereby
have been duly authorized by all necessary corporate action and will not violate (a)&nbsp;such Party&#146;s certificate of incorporation or bylaws, (b)&nbsp;any agreement, instrument or contractual obligation to which such Party is bound in any
material respect, (c)&nbsp;any requirement of any Applicable Laws, or (d)&nbsp;any order, writ, judgment, injunction, decree, determination or award of any court or Governmental Authority presently in effect applicable to such Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">13.1.3 <U>Binding Agreement</U>. This Agreement is a legal, valid and binding obligation of such Party, enforceable against it in accordance
with its terms and conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">13.1.4 <U>No Inconsistent Obligation</U>. It is not under, and will not become subject to, any obligation,
contractual or otherwise, to any Person that conflicts with or is inconsistent in any respect with the terms of this Agreement or that would impede the diligent and complete fulfillment of its obligations hereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.2 <B><U>Additional Representations, Warranties and Covenants of Metagenomi</U></B>. Metagenomi further represents and
warrants to <FONT STYLE="white-space:nowrap">Affini-T,</FONT> as of the Effective Date, as follows:</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">13.2.1 <U>No Claims</U>.<B> </B>There
are no claims, judgments or settlements against Metagenomi pending, or threatened that invalidate or seek to invalidate Metagenomi&#146;s rights in any Metagenomi Background IP. To Metagenomi&#146;s knowledge, the exploitation of the Metagenomi
Reagents and Metagenomi Background IP and use of Metagenomi Reagents by <FONT STYLE="white-space:nowrap">Affini-T</FONT> in accordance with the terms of this Agreement, including as used in connection with
<FONT STYLE="white-space:nowrap">Affini-T&#146;s</FONT> further research, Development, Manufacturing or Commercialization of Licensed Products, will not infringe on the rights of any Third Party, including any Third Party intellectual property
rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">13.2.2 <U>No Conflict</U>. Metagenomi has not granted any right, license or interest in or to the Metagenomi Patent Rights that
is inconsistent with the licenses and rights granted to <FONT STYLE="white-space:nowrap">Affini-T</FONT> under this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">13.2.3 <U>Ownership</U>. Metagenomi is the sole and exclusive owner of the Metagenomi
Reagents, Metagenomi Background IP, and Metagenomi Patent Rights, and, in each case, has the ability to grant to <FONT STYLE="white-space:nowrap">Affini-T</FONT> the rights granted to <FONT STYLE="white-space:nowrap">Affini-T</FONT> under this
Agreement, and such ownership is free and clear of all encumbrances, security interests, options and licenses. None of the Metagenomi Reagents or Metagenomi Patent Rights is subject to any existing royalty or other payment obligations to any Third
Party under any agreement or understanding entered into by Metagenomi or its Affiliates, and to Metagenomi&#146;s knowledge of any obligation to pay any royalties or other amounts to any Third Party by reason of
<FONT STYLE="white-space:nowrap">Affini-T&#146;s</FONT> use thereof as contemplated by this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">13.2.4 <U>Completeness</U>. The
intellectual property licensed to <FONT STYLE="white-space:nowrap">Affini-T</FONT> hereunder represents all of the intellectual property rights that are being used by Metagenomi or its Affiliates, or that are necessary or useful, for the
exploitation of the Metagenomi Reagents internally referred to by Metagenomi, as of the Effective Date, as [***]. The Patent Rights set forth in Schedule 13.2.4 represents all patents that, as of the Effective Date, Metagenomi or its Affiliates
Control, and that (a)&nbsp;Cover the Metagenomi Reagents internally referred to by Metagenomi, as of the Effective Date, as [***], Gene Edit using such Metagenomi Reagents or, to Metagenomi&#146;s knowledge, Licensed Products made using such
Metagenomi Reagents, or (b)&nbsp;are otherwise necessary or useful to make, use, sell, import or practice such Metagenomi Reagent, Gene Edit using such Metagenomi Reagents, or, to Metagenomi&#146;s knowledge, Licensed Products incorporating such
Metagenomi Reagents, such schedule shall be updated from time to time by Metagenomi on and after the Effective Date. For each Metagenomi Reagent (other than the Metagenomi Reagents internally referred to by Metagenomi, as of the Effective Date, as
[***]), simultaneously with providing the Data Package in connection with such Research Plan, Metagenomi shall provide to <FONT STYLE="white-space:nowrap">Affini-T</FONT> a written statement that represents and warrants that, except as disclosed in
such written statement, the representations and warranties of Metagenomi set forth in this Section&nbsp;13.2.4 are true and correct with respect to such Metagenomi Reagent as of the date of such written statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">13.2.5 <U>No Interference</U>. The Metagenomi Patent Rights are not the subject of any interference proceeding and there is no pending or
threatened action, suit, proceeding or claim by a Third Party challenging Metagenomi&#146;s ownership rights in, or the validity or scope of, such Patent Rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">13.2.6 <U>No Litigation</U>. There is no claim, action, suit, proceeding, complaint or investigation pending before any court or
administrative office or agency or, except with respect to disclosures provided in a letter from Simren Delaney at Metagenomi to Head of Legal at <FONT STYLE="white-space:nowrap">Affini-T</FONT> of even date herewith, to Metagenomi&#146;s knowledge,
currently threatened against, Metagenomi or any of its Affiliates, with respect to any of the Metagenomi Background IP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">13.2.7 <U>No
Third Party Infringement</U>. Metagenomi has not initiated or been involved in any proceedings or claims in which it alleges that any Third Party is or was infringing or misappropriating any Metagenomi Background IP nor have any such proceedings
been threatened by Metagenomi. To Metagenomi&#146;s knowledge, no Person is infringing or threatening to infringe or misappropriating or threatening to misappropriate any of the Metagenomi Background IP. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">13.2.8 <U>Assignment by Employees, Agents and Consultants</U>. All employees and agents of,
and consultants to, Metagenomi are obligated to assign to Metagenomi their rights in and to any inventions arising out of their work at Metagenomi either pursuant to written agreement or by operation of law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">13.2.9 <U>No Government Funding</U>. The inventions and <FONT STYLE="white-space:nowrap">Know-How</FONT> included within Metagenomi Background
IP (a)&nbsp;were not conceived, discovered, developed, or otherwise made in connection with any research activities funded, in whole or in part, by the federal government of the U.S. or any agency thereof, (b)&nbsp;are not a &#147;subject
invention&#148; as that term is described in 35 U.S.C. Section&nbsp;201(f), and (c)&nbsp;are not otherwise subject to the provisions of the Bayh-Dole Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">13.2.10 <U>Absence of Debarment</U>. None of Metagenomi, its officers, employees, agents, consultants or any other person Metagenomi intends
to use in the performance of the Metagenomi Research Activities has been or is (a)&nbsp;debarred, convicted, or is subject to a pending debarment or conviction, pursuant to section 306 of the United States Food Drug and Cosmetic Act, 21 U.S.C.
&#167; 335a, (b)&nbsp;listed by any government or regulatory agencies as ineligible to participate in any government healthcare programs or government procurement or <FONT STYLE="white-space:nowrap">non-procurement</FONT> programs (as that term is
defined in 42 U.S.C. <FONT STYLE="white-space:nowrap">1320a-7b(f)),</FONT> or excluded, debarred, suspended or otherwise made ineligible to participate in any such program, or (c)&nbsp;convicted of a criminal offense related to the provision of
healthcare items or services, or is subject to any such pending action. Metagenomi agrees to inform <FONT STYLE="white-space:nowrap">Affini-T</FONT> in writing promptly if Metagenomi or any person who is performing Metagenomi Research Activities is
subject to the foregoing, or if any action, suit, claim, investigation, or proceeding relating to the foregoing is pending, or to the best of Metagenomi&#146;s knowledge, is threatened. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">13.2.11 <U>Disclosure</U>. Metagenomi has made available to <FONT STYLE="white-space:nowrap">Affini-T</FONT> all toxicology studies, clinical
data, process and analytical development information, material filings and material correspondence with Regulatory Authorities, and all other material information in its possession or control relating to the Metagenomi Reagents internally referred
to by Metagenomi, as of the Effective Date, as [***], and, to Metagenomi&#146;s knowledge, all such information is complete and accurate in all material respects. For each Metagenomi Reagent (other than the Metagenomi Reagents internally referred to
by Metagenomi, as of the Effective Date, as [***]), simultaneously with providing the Data Package in connection with such Research Plan, Metagenomi shall provide to <FONT STYLE="white-space:nowrap">Affini-T</FONT> a written statement that
represents and warrants that, except as disclosed in such written statement, the representations and warranties of Metagenomi set forth in this Section&nbsp;13.2.11 are true and correct with respect to such Metagenomi Reagent as of the date of such
written statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">13.2.12 <U>No Human Materials</U>. If pursuant to this Agreement Metagenomi provides to
<FONT STYLE="white-space:nowrap">Affini-T</FONT> any biological materials that consists of human tissues, cells or blood products or was directly obtained from human tissues, cells or blood products, then Metagenomi shall ensure that it has obtained
and maintained the informed consent required under state and federal law from the donor of the tissue for the research and development, information disclosure, handling, storage and any other use associated with the human tissue, cells or blood
products to be conducted under this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.3 <B><U>Warranty Disclaimer</U></B>. EXCEPT AS OTHERWISE EXPRESSLY
PROVIDED IN THIS AGREEMENT, NEITHER PARTY MAKES ANY WARRANTY WITH RESPECT TO ANY <FONT STYLE="white-space:nowrap">KNOW-HOW,</FONT> RIGHTS OR OTHER SUBJECT MATTER OF THIS AGREEMENT AND EACH PARTY HEREBY DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED,
INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.4 <B><U>No Warranty of
Success</U></B>. Nothing contained in this Agreement shall be construed as a warranty, either express or implied, on the part of either Party that (a)&nbsp;the Metagenomi Research Activities, or development of Metagenomi Reagents on behalf of <FONT
STYLE="white-space:nowrap">Affini-T</FONT> will be successful, (b)&nbsp;the Development or Commercialization of any Licensed Product will be successful, or (c)&nbsp;any Licensed Product will be commercially exploitable in any respect. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>14. <U>INDEMNIFICATION</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.1 <B><U>Indemnification of Metagenomi by <FONT STYLE="white-space:nowrap">Affini-T</FONT></U></B>. <FONT
STYLE="white-space:nowrap">Affini-T</FONT> shall indemnify, defend and hold harmless Metagenomi, its Affiliates, their respective employees, directors, agents, officers and consultants (collectively, the &#147;<B>Metagenomi Indemnitees</B>&#148;),
against all liabilities, damages, losses and expenses (including reasonable attorneys&#146; fees and expenses of litigation) (collectively, &#147;<B>Losses</B>&#148;) incurred by or imposed upon the Metagenomi Indemnitees, or any of them, as a
direct result of claims, suits, actions, demands or judgments of Third Parties, including personal injury and Licensed Product liability claims (collectively, &#147;<B>Metagenomi Indemnity Claims</B>&#148;), arising out of (a)&nbsp;any breach of
this Agreement (including any representation or warranty hereunder) by <FONT STYLE="white-space:nowrap">Affini-T</FONT> or any <FONT STYLE="white-space:nowrap">Affini-T</FONT> Indemnitee or Sublicensee,<B> </B>(b)&nbsp;the gross negligence or
willful misconduct of <FONT STYLE="white-space:nowrap">Affini-T</FONT> or any <FONT STYLE="white-space:nowrap">Affini-T</FONT> Indemnitee or Sublicensee, or (c)&nbsp;the Development or Commercialization of a Licensed Product by <FONT
STYLE="white-space:nowrap">Affini-T</FONT> or any <FONT STYLE="white-space:nowrap">Affini-T</FONT> Indemnitee or Sublicensee (expressly excluding any such activities conducted by or on behalf of Metagenomi or liabilities for which Metagenomi is
liable as the manufacturer under the Development Supply Agreement or Commercial Supply Agreement); provided, that (i)&nbsp;any <FONT STYLE="white-space:nowrap">Affini-T</FONT> Indemnity Claims or Losses for which Metagenomi has an obligation to
indemnify <FONT STYLE="white-space:nowrap">Affini-T</FONT> Indemnitees pursuant to Section&nbsp;14.2 shall be excluded and with respect to which claim or Losses each Party shall indemnify the other to the extent of their respective liability for
such Losses, <FONT STYLE="white-space:nowrap">(ii)&nbsp;Affini-T</FONT> has no obligation to indemnify with respect to Losses arising out of the infringement or misappropriation of Third Party&#146;s intellectual property rights as a result of the
exploitation of Metagenomi IP or the Metagenomi Reagents, in each case provided such exploitation is within the scope of the licenses granted to <FONT STYLE="white-space:nowrap">Affini-T</FONT> hereunder, and
<FONT STYLE="white-space:nowrap">(iii)&nbsp;Affini-T&#146;s</FONT> indemnification obligations shall be limited to the extent that it is increased by Metagenomi&#146;s or any Metagenomi Indemnitee&#146;s negligence. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.2 <B><U>Indemnification of
<FONT STYLE="white-space:nowrap">Affini-T</FONT> by Metagenomi</U></B>. Metagenomi shall indemnify, defend and hold harmless <FONT STYLE="white-space:nowrap">Affini-T,</FONT> its Affiliates, their respective employees, directors, agents, officers
and consultants (collectively, the &#147;<B><FONT STYLE="white-space:nowrap">Affini-T</FONT> Indemnitees</B>&#148;), against all Losses incurred by or imposed upon the <FONT STYLE="white-space:nowrap">Affini-T</FONT> Indemnitees, or any of them, as
a direct result of claims, suits, actions, demands or judgments of Third Parties, including personal injury and Licensed Product liability claims (collectively, &#147;<B><FONT STYLE="white-space:nowrap">Affini-T</FONT> Indemnity Claims</B>&#148;)
arising out of (a)&nbsp;any breach of this Agreement (including any representation or warranty hereunder) by Metagenomi or any Metagenomi Indemnitee, or (b)&nbsp;the gross negligence or willful misconduct of Metagenomi or any Metagenomi Indemnitee;
provided, that (i)&nbsp;any Metagenomi Indemnity Claim or Losses for which <FONT STYLE="white-space:nowrap">Affini-T</FONT> has an obligation to indemnify any Metagenomi Indemnitees pursuant to Section&nbsp;14.1 shall be excluded and with respect to
which claims or Losses each Party shall indemnify the other to the extent of their respective liability for such Losses, and (ii)&nbsp;Metagenomi&#146;s indemnification obligations shall be limited to the extent that it is increased by <FONT
STYLE="white-space:nowrap">Affini-T</FONT> or any <FONT STYLE="white-space:nowrap">Affini-T</FONT> Indemnitees negligence. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.3 <B><U>Conditions to Indemnification</U></B>. A Person seeking recovery under this Article 14 (the &#147;<B>Indemnified
Party</B>&#148;) in respect of a Claim shall give prompt notice of such Claim to the Party from whom indemnification is sought (the &#147;<B>Indemnifying Party</B>&#148;); provided, that the Indemnifying Party is not contesting its obligation under
this Article 14, shall permit the Indemnifying Party to control any litigation relating to such Claim (including selecting counsel) and the disposition of such Claim; and further provided, that the Indemnifying Party shall (a)&nbsp;act reasonably
and in good faith with respect to all matters relating to the settlement or disposition of such Claim as the settlement or disposition relates to such Indemnified Party and (b)&nbsp;not settle or otherwise resolve such claim without the prior
written consent of such Indemnified Party (which consent shall not be unreasonably withheld, conditioned or delayed) unless such settlement fully releases the Indemnified Party without any liability, loss, cost or obligation incurred by the
Indemnified Party (in which case prior consent shall not be required). Each Indemnified Party shall cooperate with the Indemnifying Party in its defense of any such Claim in all reasonable respects and shall have the right to be present in person or
through counsel at all legal proceedings with respect to such Claim (with any such counsel being at its own sole cost and expense). If the Indemnifying Party does not assume and conduct the defense of the Claim as provided above, (i)&nbsp;the
Indemnified Party may defend against, consent to the entry of any judgment, or enter into any settlement with respect to such Claim in any manner the Indemnified Party may deem reasonably appropriate (and the Indemnified Party need not consult with,
or obtain any consent from, the Indemnifying Party in connection therewith), and (ii)&nbsp;the Indemnifying Party shall remain responsible to indemnify the Indemnified Party as provided in this Article&nbsp;14. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.4 <B><U>Limited Liability</U></B>. EXCEPT IN CONNECTION WITH A PARTY&#146;S GROSS NEGLIGENCE OR WILLFUL MISCONDUCT, NEITHER
PARTY SHALL BE LIABLE TO THE OTHER PARTY OR ANY OF ITS AFFILIATES FOR ANY SPECIAL, PUNITIVE, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES, INCLUDING LOST PROFITS OR LOST REVENUES, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES.
NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION&nbsp;14.4 IS INTENDED TO OR SHALL LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER SECTION&nbsp;14.1 OR&nbsp;14.2. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>15. <U>MISCELLANEOUS</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">15.1 <B><U>Governing Law</U></B><B><U> </U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">15.1.1 <U>Governing Law</U>. This Agreement shall be governed by and construed in accordance with the laws of the State of New York (U.S.A.),
without regard to the application of principles of conflicts of law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">15.1.2 <U>Jurisdiction and Venue</U>. Subject to Section&nbsp;15.1.3
and 15.1.4, any legal suit, action, or proceeding arising under, out of or in connection with this Agreement (including any subsequent amendment) or the matters contemplated hereunder, including any dispute, controversy or claim with respect to the
validity, enforceability, construction, performance or breach hereof, shall be instituted exclusively in the United States District Court for the Southern District of New York or the courts of the State of New York located in the city of New York
and County of New York, and each Party irrevocably submits to the exclusive jurisdiction of such courts in any such suit, action, or proceeding and waives any objection based on improper venue or forum <I>non conveniens</I>. Service of process,
summons, notice, or other document by mail to such Party&#146;s address set forth in Section&nbsp;15.2 shall be effective service of process for any suit, action, or other proceeding brought in connection with this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">15.1.3 <U>Equitable Relief</U>. Notwithstanding anything to the contrary, each of the Parties hereby acknowledges that a breach or threatened
breach of their respective obligations under this Agreement may cause irreparable harm and that the remedy or remedies at law for any such breach may be inadequate. Each of the Parties hereby agrees that, in the event of any such breach or
threatened breach, in addition to all other available remedies hereunder, the <FONT STYLE="white-space:nowrap">non-breaching</FONT> Party shall have the right, through any court of competent jurisdiction, to seek equitable relief to enforce the
provisions of this Agreement, and each Party irrevocably submits to the exclusive jurisdiction of such courts in any such suit, action, or proceeding and waives any objection based on improper venue or forum non conveniens. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">15.1.4 <U>Agreement Dispute</U>. It is the desire of the Parties to establish procedures to facilitate the resolution of any dispute,
controversy, or claim between the Parties that may arise from time to time pursuant to, arising out of or in connection with this Agreement (excluding such matters as are the subject of the JSC&#146;s responsibilities under Article 3), including any
Party&#146;s rights or obligations hereunder or any questions regarding the formation, existence, validity, enforceability, performance, interpretation, tort, breach or termination hereof (each, an &#147;<B>Agreement Dispute</B>&#148;), in an
expedient manner by mutual cooperation and without resorting to litigation. To accomplish this objective, the Parties shall use reasonable efforts in good faith to resolve any Agreement Disputes. If, despite such reasonable efforts, agreement on a
particular Agreement Dispute cannot be reached by the Parties within [***] after the Parties first consider such Agreement Dispute, the Parties shall refer such Agreement Dispute to the Executive Officers of the Parties who shall promptly initiate
discussions in good faith to resolve such Agreement Dispute, and if not resolved by the Executive Officers within [***] from the date the Agreement Dispute is first referred to the Executive Officers, then each Party is free to pursue any remedy at
law or in equity available to such Party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.2 <B><U>Notices</U></B>. All notices and communications shall be in
writing and delivered personally or by internationally-recognized overnight express courier providing evidence of delivery or mailed via certified mail, return receipt requested, addressed as follows below, or by email or facsimile confirmed
thereafter by any of the foregoing, or to such other address as may be designated from time to time by written notice given in accordance with this Section&nbsp;15.2. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="22%" VALIGN="top" ALIGN="left"><FONT STYLE="white-space:nowrap">If&nbsp;to&nbsp;Affini-T:</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Affini-T</FONT> Therapeutics, Inc. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="22%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">87 Greendale Ave. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="22%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Needham, MA 02494 </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="22%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Attention: CEO </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="22%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">With an electronic copy by email to: </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">With a copy to </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(that shall not
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">constitute notice): </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="22%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Affini-T</FONT> Therapeutics, Inc. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="22%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">2940 11th Ave. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="22%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Los Angeles, CA 90018 </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="22%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Attention: Head of Legal </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="22%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">With an electronic copy by email to: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">With a copy to </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(that shall not
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">constitute notice): </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="22%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Morgan Lewis Bockius LLP </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="22%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">110 North Wacker Drive </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="22%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Chicago, IL 60606-1511 </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="22%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Attention: Benjamin H. Pensak </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="22%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">With an electronic copy by email to: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="22%" VALIGN="top" ALIGN="left">If&nbsp;to&nbsp;Metagenomi:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Metagenomi, Inc. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="22%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">1545 Park Avenue </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="22%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Emeryville CA 94608 </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="22%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Attention: CEO </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="22%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">With an electronic copy by email to: </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">With a copy to </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(that shall not
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="22%" VALIGN="top" ALIGN="left">constitute&nbsp;notice):</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Metagenomi, Inc. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="22%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">1545 Park Avenue </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="22%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Emeryville CA 94608 </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="22%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Attention: VP of Legal, Chief of Staff </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="22%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">With an electronic copy by email to: </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">With a copy to </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(that shall not
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="22%" VALIGN="top" ALIGN="left">constitute&nbsp;notice):</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fenwick&nbsp;&amp; West LLP </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="22%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">555 California Street, 12<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Floor </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="22%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">San Francisco, CA 94104 </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="22%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Attention: Jake Handy </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="22%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">With an electronic copy by email to: </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise expressly provided in this Agreement or mutually agreed by the Parties
in writing, any notice, communication or document (excluding payment) required to be given or made shall be deemed given or made and effective upon actual receipt or, if earlier, (a) [***]after deposit with an internationally-recognized overnight
express courier with charges prepaid, or (b) [***]after mailed by certified, registered or regular mail, postage prepaid, in each case addressed to a Party at its address stated above or to such other address as such Party may designate by written
notice given in accordance with this Section&nbsp;15.2. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.3 <B><U>Binding Effect</U></B>. This Agreement shall be binding
upon and inure to the benefit of the Parties and their respective legal representatives, successors and permitted assigns. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.4 <B><U>Headings</U></B>. Article, section and subsection headings are inserted for convenience of reference only and do not
form a part of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.5 <B><U>Counterparts</U></B>. This Agreement may be executed simultaneously in two or
more counterparts, each of which shall be deemed an original and both of which, together, shall constitute a single agreement. Each Party may execute this Agreement by facsimile transmission or in Portable Document Format
(&#147;<B>PDF</B>&#148;)&nbsp;sent by electronic mail. In addition, facsimile or PDF signatures of authorized signatories of any Party will be deemed to be original signatures and will be valid and binding, and delivery of a facsimile or PDF
signature by any Party will constitute due execution and delivery of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.6 <B><U>Amendment; Waiver</U></B>.
This Agreement may be amended, modified, superseded or canceled, and any of the terms of this Agreement may be waived, only by a written instrument executed by each Party or, in the case of waiver, by the Party or Parties waiving compliance. The
delay or failure of either Party at any time or times to require performance or to exercise any right arising out of any provisions shall in no manner affect the rights at a later time to enforce the same. Any waiver by a Party of a particular
provision or right shall be in writing, shall be as to a particular matter and, if applicable, for a particular period of time and shall be signed by such Party. No single or partial exercise of any right, power or privilege will preclude any other
or further exercise of such right, power or privilege or the exercise of any other right, power or privilege. No waiver by either Party of any condition or of the breach of any term contained in this Agreement, whether by conduct, or otherwise, in
any one or more instances, shall be deemed to be, or considered as, a further or continuing waiver of any such condition or of the breach of such term or any other term of this Agreement. Except as expressly set forth in this Agreement, all rights
and remedies available to a Party, whether under this Agreement or afforded by Applicable Law or otherwise, will be cumulative and not in the alternative to any other rights or remedies that may be available to such Party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.7 <B><U>Purposes and Scope</U></B>. The Parties hereto understand and
agree that the relationship between the Parties described in this Agreement is limited to the activities, rights and obligations as set forth in this Agreement. Nothing in this Agreement shall be construed (a)&nbsp;to create or imply a general
partnership between the Parties, (b)&nbsp;to make either Party the agent of the other for any purpose, (c)&nbsp;to alter, amend, supersede or vitiate any other arrangements between the Parties with respect to any subject matter not covered
hereunder, (d)&nbsp;to give either Party the right to bind the other, (e)&nbsp;to create any duties or obligations between the Parties except as set forth herein, or (f)&nbsp;to grant any direct or implied licenses or any other rights other than as
set forth herein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.8 <B><U>Assignment and Successors; Change of Control</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">15.8.1 <U>Generally</U>. Neither this Agreement nor any obligation of a Party hereunder may be assigned by either Party without the written
consent of the other Party, which consent shall not be unreasonably withheld, conditioned or delayed, except that each Party may assign this Agreement and the rights, obligations and interests of such Party without such consent (a)&nbsp;in whole or
in part, to any of its Affiliates, or (b)&nbsp;in whole, but not in part, in connection with a Change of Control of such Party (whether this Agreement is actually assigned or is assumed by the acquiring party by operation of law (e.g., in the
context of a reverse triangular merger). Subject to the terms and conditions hereof, no right of a Party shall be diminished and no obligation of a Party increased as a result of an assignment by the other Party hereunder, including as a result of a
Change of Control of the other Party. This Agreement is intended for the benefit of the Parties and their respective successors and permitted assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person,
other than the Parties and their respective successors and permitted assigns. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">15.8.2 <U>Metagenomi Change of Control</U>. In the event of
a Change of Control of Metagenomi prior to delivery of all Data Packages for each Research Plan, Metagenomi shall provide notice to <FONT STYLE="white-space:nowrap">Affini-T</FONT> of such Change of Control within [***] after the date upon which the
Change of Control closes or otherwise becomes public, and, if the merger partner for such Change of Control has a Competing Business, then following such Change of Control, <FONT STYLE="white-space:nowrap">Affini-T</FONT> shall have the right to
limit the information or reports otherwise required to be provided to Metagenomi or the JSC hereunder to only that which is essential to ensure <FONT STYLE="white-space:nowrap">Affini-T&#146;s</FONT> compliance with its obligations hereunder and <FONT
STYLE="white-space:nowrap">Affini-T</FONT> shall have the right to refrain from including in such information or reports commercially sensitive information of <FONT STYLE="white-space:nowrap">Affini-T</FONT> (as
<FONT STYLE="white-space:nowrap">Affini-T</FONT> may determine at its sole discretion). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.9 <B><U>Force Majeure</U></B>.
Neither <FONT STYLE="white-space:nowrap">Affini-T</FONT> nor Metagenomi shall be liable for failure of or delay in performing obligations set forth in this Agreement, and neither shall be deemed in breach of its obligations, if such failure or delay
is due to a Force Majeure. In the event of such Force Majeure, the Party affected shall use Commercially Reasonable Efforts to cure or overcome the same and resume performance of its obligations hereunder. Notice of a Party&#146;s failure or delay
in performance due to Force Majeure must be given to the other Party within [***] after its occurrence. All delivery dates under this Agreement that have been affected by Force Majeure shall be tolled for the duration of such Force Majeure. If a
Force Majeure persists for more than [***], then the Parties will discuss in good faith the modification of the Parties&#146; obligations under this Agreement in order to mitigate the delays caused by such Force Majeure. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.10 <B><U>Interpretation</U></B>. The Parties hereto acknowledge and agree
that: (a)&nbsp;each Party and its counsel reviewed and negotiated the terms and provisions of this Agreement and have contributed to its revision; (b)&nbsp;the rules of construction to the effect that any ambiguities are resolved against the
drafting Party shall not be employed in the interpretation of this Agreement; and (c)&nbsp;the terms and provisions of this Agreement shall be construed fairly as to each Party and not in a favor of or against either Party, regardless of which Party
was generally responsible for the preparation of this Agreement. In addition, unless a context otherwise requires, wherever used, the singular shall include the plural, the plural the singular, the use of any gender shall be applicable to all
genders, the word &#147;or&#148; is used in the inclusive sense (and/or) and the word &#147;including&#148; is used without limitation and means &#147;including without limitation&#148;. Unless otherwise specified, references in this Agreement to
any Article shall include all Sections, subsections and paragraphs in such Article, references to any Section shall include all subsections and paragraphs in such Section, and references in this Agreement to any subsection shall include all
paragraphs in such subsection. The words &#147;herein,&#148; &#147;hereof&#148; and &#147;hereunder&#148; and other words of similar import refer to this Agreement as a whole and not to any particular Section or other subdivision. The phrase <FONT
STYLE="white-space:nowrap">&#147;non-refundable,</FONT> <FONT STYLE="white-space:nowrap">non-creditable&#148;</FONT> is not intended to limit either Party&#146;s rights to pursue or obtain damages arising from a breach of this Agreement. All
references to days in this Agreement shall mean calendar days, unless otherwise specified. Unless the context requires otherwise, (i)&nbsp;any definition of or reference to any agreement, instrument or other document herein will be construed as
referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein or therein), (ii)&nbsp;any
reference to any Applicable Laws herein will be construed as referring to such Applicable Laws as from time to time enacted, repealed or amended, (iii)&nbsp;any reference herein to any person will be construed to include the Person&#146;s successors
and permitted assigns, (iv)&nbsp;any reference herein to the words &#147;mutually agree&#148; or &#147;mutual written agreement&#148; will not impose any obligation on either Party to agree to any terms relating thereto or to engage in discussions
relating to such terms except as such Party may determine in such Party&#146;s sole discretion, (v)&nbsp;all references herein to Sections or Schedules will be construed to refer to Sections and Schedules to this Agreement, (vi)&nbsp;except as
otherwise expressly provided herein all references to &#147;$&#148; or &#147;dollars&#148; refer to the lawful money of the U.S., and (vii)&nbsp;the words &#147;copy&#148; and &#147;copies&#148; and words of similar import when used in this
Agreement include, to the extent available, electronic copies, files or databases containing the information, files, items, documents or materials to which such words apply. This Agreement has been prepared in the English language and the English
language shall control its interpretation. In addition, all notices required or permitted to be given hereunder, and all written, electronic, oral or other communications between the Parties regarding this Agreement shall be in the English language.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.11 <B><U>Entire Agreement; Severability</U></B>. This Agreement, the
Existing RSA, the A&amp;R Side Letter, MFN Waiver and the Initial RSA and Milestone RSA executed in accordance with Section&nbsp;8.1 set forth the entire agreement with respect to the subject matter hereof and thereof and supersede all other
agreements and understandings between the Parties with respect to such subject matter. There are no covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written, between the Parties with respect
to the subject matter of this Agreement other than as are set forth in this Agreement and any other documents delivered pursuant hereto or thereto. If any provision of this Agreement is or becomes invalid or is ruled invalid by any court of
competent jurisdiction or is deemed unenforceable, it is the intention of the Parties that the remainder of the Agreement shall not be affected. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.12 <B><U>Further Assurances</U></B>. Each of Metagenomi and <FONT STYLE="white-space:nowrap">Affini-T,</FONT> upon the
request of the other Party and without further consideration, will do, execute, acknowledge, and deliver or cause to be done, executed, acknowledged or delivered all such further acts, deeds, documents, assignments, transfers, conveyances, powers of
attorney, instruments and assurances as may be reasonably necessary to effect complete consummation of the transactions contemplated by this Agreement, and to do all such other acts, as may be necessary or appropriate in order to carry out the
purposes and intent of this Agreement. The Parties agree to execute and deliver such other documents, certificates, agreements and other writings and to take such other actions as may be reasonably necessary in order to consummate or implement
expeditiously the transactions contemplated by this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.13 <B><U>Expenses</U></B>. Each of the Parties will bear
its own direct and indirect expenses incurred in connection with the negotiation and preparation of this Agreement and, except as set forth in this Agreement, the performance of the obligations contemplated hereby and thereby. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.14 <B><U>Intellectual Property</U></B>. The Parties acknowledge and agree that the licenses granted by the Parties and all
other rights granted under or pursuant to this Agreement are and shall otherwise be deemed to be, for purposes of Section&nbsp;365(n) of the Bankruptcy Code (or analogous provisions of the bankruptcy laws of any Governmental Authority), licenses of
rights to &#147;intellectual property&#148; as defined under Section&nbsp;101(35A) of the Bankruptcy Code (or analogous foreign provisions), and that this Agreement is an executory contract governed by Section&nbsp;365(n) of the Bankruptcy Code (or
analogous foreign provisions) in the event that a bankruptcy proceeding is commenced involving either Party. <FONT STYLE="white-space:nowrap">Affini-T,</FONT> as the licensee of such rights under Article 2, shall retain and may fully exercise all of
its rights and elections under the Bankruptcy Code. The foregoing provisions of this Section&nbsp;15.14 are without prejudice to any rights the Parties may have arising under the Bankruptcy Code or other Applicable Laws. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.15 <B><U>Performance by Affiliates</U></B>. Subject to Section&nbsp;2.2.3 and Section&nbsp;4.2.1(e), as applicable, either
Party may discharge any obligation and exercise any right hereunder through any of its Affiliates. Each Party shall remain jointly and severally liable to the other Party for any performance or non-performance of any such Affiliate, and each Party
hereby expressly waives any requirement that the other Party exhaust all right, power or remedy, or proceed against any such Affiliate, prior to proceeding directly against such Party<U>.</U></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[SIGNATURE PAGE FOLLOWS] </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly
authorized representatives. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><FONT STYLE="white-space:nowrap">AFFINI-T</FONT> THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jak Knowles</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jack Knowles</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">CFO</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">June&nbsp;14, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>METAGENOMI, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Brian C. Thomas</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Brian C. Thomas</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">CEO</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">June&nbsp;14, 2022</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[SIGNATURE PAGE TO DEVELOPMENT OPTION AND LICENSE AGREEMENT] </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g425213g00a13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g425213g00a13.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[29T4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )EB^F!8X0DE-! 0      &4< 5H  QLE1QP!6@ #&R5'' (   )_]QP"
M4  (4E(Q,3<U-S(< @4 /$UI8W)O<V]F="!0;W=E<E!O:6YT("T@1W)A<&AI
M8W,@9F]R($)U<VEN97-S(%-E8W1I;VX@7S4N<'!T>  X0DE-!"4      !"'
M+D4\@(IX%U#:&E%_6<'..$))300Z      #E    $     $       MP<FEN
M=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4
M    0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M
M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\
M;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N
M=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT
M   0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O
M;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP
M $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B
M;V]L      !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P
M  ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'8Z9F
M   *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=0
M0P    !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
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M_P  .$))300-       $    'CA"24T$&0      !    !XX0DE- _,
M  D           $ .$))32<0       *  $          CA"24T#]0
M2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:
M    !@       0 U     0 M    !@       3A"24T#^       <   ____
M_________________________P/H     /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H   X0DE-! @      !     !   "0    D
M.$))300>       $     #A"24T$&@     #-0    8              ?@
M  .5          $                          0             #E0
M ?@                      0                         0     0
M     &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M    5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P
M ?@     4F=H=&QO;F<   .5    !G-L:6-E<U9L3',    !3V)J8P    $
M      5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L
M;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O
M1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(
M  9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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MU@ !     -,M2% @(
M                    $6-P<G0   %0    ,V1E<V,   &$    ;'=T<'0
M  'P    %&)K<'0   ($    %')865H   (8    %&=865H   (L    %&)8
M65H   )     %&1M;F0   )4    <&1M9&0   +$    B'9U960   -,
MAG9I97<   /4    )&QU;6D   /X    %&UE87,   0,    )'1E8V@   0P
M    #')44D,   0\   (#&=44D,   0\   (#&)44D,   0\   (#'1E>'0
M    0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY
M  !D97-C         !)S4D="($E%0S8Q.38V+3(N,0              $G-2
M1T(@245#-C$Y-C8M,BXQ
M                          !865H@        \U$  0    $6S%A96B
M                    6%E:(        &^B   X]0   Y!865H@
M8ID  +>%   8VEA96B         DH   #X0  +;/9&5S8P         6245#
M(&AT=' Z+R]W=W<N:65C+F-H               6245#(&AT=' Z+R]W=W<N
M:65C+F-H
M         &1E<V,         +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@
M8V]L;W5R('-P86-E("T@<U)'0@              +DE%0R V,3DV-BTR+C$@
M1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M          !D97-C         "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I
M;VX@:6X@245#-C$Y-C8M,BXQ               L4F5F97)E;F-E(%9I97=I
M;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M            =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X    !
M6%E:(       3 E6 %    !7'^=M96%S          $
M       "CP    )S:6<@     $-25"!C=7)V        !      %  H #P 4
M !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!> &, : !M '( =P!\ ($
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M 7YB?L)_(W\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
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MA'9Q=>S]=S>_OM@"1V #WX , & #3R^D< & #OWTP FO7Z>C7JXZX 7 "<-
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MB+15:D1K55$6Y52M%/I'-=X+D=O*B\QL&_?Z=_9C\#(;]^_J]> #H[@'OTP
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MJ#A\FT( 0\[QI[<2OBDT1;<J_*4[F7<@[J(<W;B?CU?H(:<BO]Y5_5SAU#B
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M="TRM%&F%O/2TDF-S0WH:DZ4L#/QH0^J?O)T?80R[ZB/7\=LRNGI ?5@!_L
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M\E-0/P;%XTP,*+7Q=I9FY$62E* ;.- /U3UXZA =!LEEYII$0'0:J9KF3YP
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MWEJ$-/\ ;'A@#<< & # !W[]_P H!W[[8 , '?OW]NP!W[^OZ0P 8 , & #
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g425213g00a14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g425213g00a14.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1OL4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &]"^<2 X0DE-! 0      &T< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<<
M @   G_W' )0  A24C$Q-S4W,AP"!0 \36EC<F]S;V9T(%!O=V5R4&]I;G0@
M+2!'<F%P:&EC<R!F;W(@0G5S:6YE<W,@4V5C=&EO;B!?-2YP<'1X #A"24T$
M)0      $'EN*7^M@RK?P'K6#4FQUSPX0DE-!#H      .4    0     0
M    "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T
M    26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R
M:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC
M# !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0
M  !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$
M.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P
M  !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#
M8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;
M    16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $
M  !21T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M            0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M          !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q
M=)S @         IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0
M<P    !09U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&
M(U)L=                %-C;"!5;G1&(U!R8T!9            $&-R;W!7
M:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M#&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M      MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ !
M [_^-0 "  $X0DE-!"8       X             /X   #A"24T$#0
M!    !XX0DE-!!D       0    >.$))30/S       )           ! #A"
M24TG$       "@ !          (X0DE- _4      $@ +V9F  $ ;&9F  8
M      $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0
M  $ +0    8       $X0DE- _@      '   /______________________
M______\#Z     #_____________________________ ^@     ________
M_____________________P/H     /____________________________\#
MZ   .$))300(       0     0   D    )      #A"24T$'@      !
M   X0DE-!!H      S4    &              (#   #M@         !
M                      $              [8   (#
M      $                         $     $       !N=6QL     @
M  9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M      !,969T;&]N9P          0G1O;6QO;F<   (#     %)G:'1L;VYG
M   #M@    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I
M9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4
M>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P
M  $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M         $)T;VUL;VYG   " P    !29VAT;&]N9P   [8    #=7)L5$58
M5     $       !N=6QL5$585     $       !-<V=E5$585     $
M  9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (
M8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E
M2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI
M8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    1
M15-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M      IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M       +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M       X0DE-!!$       $! #A"24T$%       !     \X0DE-! P
M$4,    !    H    %<   '@  "C(   $2< &  !_]C_[0 ,061O8F5?0TT
M O_N  Y!9&]B90!D@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3
M$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+
M#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,
M# P,# P,# P,# P,# P,#/_  !$( %< H ,!(@ "$0$#$0'_W0 $  K_Q $_
M   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
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MQ:'L8]K&WMN?Z@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0 !!0$! 0             ' 00%!@@" PG_Q !6$0 ! P(# @4/!@@+" ,
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M=EY2GSNV"+ZNV/\ JX^7[]OU<(M?#$BQ\DI+@C8,*4<G-DS,F)#CQWRQ%D=
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M&$"E=7AD/XO?,Z7J@T\Q&<26 CXL/U%SFR\FJ^]%4TL\CA 92X,N>,:&C+F
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M@+G2Y WK-\&>#XKAV+5\M?AM;1128<8V255-- QTG5-.[(UTC&@NRM<[*-;
MG<$DNKYKJ;K^XM);;Z>ZY:M@1-7ZUW?)M.J(%A>!4_:9.VVG1-3KU:L2WYC0
M9HZ!%$K?L>JE9T.3-C-T8^('O16#Y'#\4\O1KZ=+?;]JFL6L;\X\V_\ =??X
M+V408FMNHB@:RG@=QQ^H'<!H2#WJ)U+8H2MXW&#*VQCJAWB:18MB5C3NQZ9?
M8D786L)NHOW$;B^:B5C4X(<9C##U*8>C#["^-WW>K[572XMT>S7>+<][Z%/I
MUFT#J@V&0T&:UQ\,JS&!:9V#-VW&I!K8;9X <-7[I@9?ET#%/V;3AIS;M,J2
M-KG]<P;RW? -A2#L%=?!$%'W/=%=?CX]7K5!;PZCHTUOKS>CU+Z;3IF=3ZYU
M7O*";UF>_NZ18S4!".<ZA-P#J[5%]/\ J29"L*];U+<-9N-FH\;;R;Q$F#ZO
M-7*BVZ>DJ1C1P0::5#4Y_#IR\WVW\'@5=--V[7<#H3RVWV]*G[I-NV-::U*U
M?()H9>&M9T1NY#;(=B6BQ0+4W5Q2+!#/V6 Q%@V$U&+8ELE3<.+'BE9R'YT=
MAIE]#::JAWGP^!.=PJ*IWK M$XMM\1L37=NCP6NG/7G4< VN.QLJ\Z@L$?(:
MN=/&Z2LP00#Z$W>$N@\'2Y8N9)&3!X>7@D<@HK1:1+C6& @BM7@/)DP84A&<
MJ2_$CO)5G*E94EUE#F,Y4I#:E9SC.,YRIMM6<^.4)S^]P1?5V]F,8[?%\GY.
M$7QQ1H^$^0DPH,.)(+3$$"K\:,RP\2G-P88MN;/=:0A<R6@:.'CT29"G'DP8
M,.(E>(\5AMLB^S&,>S&.WK\.WK^/A$P6\<?QYT]9QV[?N^!<?EU[LK..WW]O
M"*N;J1\J3;-$[NV!J:!J*NV*'3"4&"P9F6DE DSD3 @PMEQV(P)D-,J;604S
MA*'EX4EI*\YPI6<8(M_UG]1&PRG0?J+=]+-&M7VB^V>D3YF:<?(09$.&7K]J
ME21*"D;,*7)A*>BQG%I<0A+CC#2U-]VTYP1,)Y*G>6Y-G;VO 38NT+W>!$/5
M),I$&6BSEC<&,1;ME1BMSF8T^4^TU)1&ERF$/(3AQ+4AUO"L)<7C)%?EG&.V
M>^/#QS^W'R\(N>6S]4G4'#M%BA1MK6AF)$/EHL9A+T3S&H[!&0RRTC&8F<^:
MVVA*,=\YSC&,=\YSR?Z;9?9]]+3R.PNF+W4\3W.M)JYT;7$D!]KDDDZ:E8A\
M\P>XB0@!QL--U]P%M;;BI9^4L6IT=HYQQ2EN+C7)Q:L^.5*4Q4%+5GY<JSW]
MF/'/-5X-@!+C@&X.H@!S &K%E<5VHC\+R>4CL=?!O2@\F/V]X=O=N_\ .]/]
M?_Y.P>KY.?#A*_3X3\U6?M4_K^PA5HK6DM?>W?\ ]6[?HK*+79P]*J]CN-BD
M+A@*H"+60W+:CO2W(H@' D$R4A$6,V[)DJ9AQ7G$L1VG'WLIPVRVMQ24YCBE
MIIJRIIZ2G:'SU4\-- PN:P.FGD;%&TO<0UH<]S07.(:V]R0 2KQ[@QKGN-FL
M:7.-B;!H))L+DZ#<!<\B@G1O*E]%NQ[G5*!4MDFB%INMB#U6N07M>WN"U,-G
MI[ P9%<FS0#$.(A^9)9;5)E/,QV4JRX\XA"5*QNU;P9[8X?1U=?5X;%'345/
M-55#Q7T+RR&"-TDC@QE0Y[B&-)#6M+G;@"2 K%F*44CV1LE<7O<UC08I1=SB
M !<L %R1J2 J3O+/W6X@.L"!! VRS!(*M/TN1F&)/%1L7+[IJW)<>S'ARV6<
MNK2VC"W/,\]24(2I6<)3VF;@=HJ.?9)[YZ2GFD.+UK<\M/#*X 0TA#<SV.-M
M387M>Y N23A\8>]M6,KWM'$LT:X@=D_F(5NWD?#!8[T5U@@;*$3,]=YV"VN:
M5G2B,Q3;1SS6D*DS'7GLH;1VPVC*_-0GP3C&/#D4<+444&V-1'#%'"P4- <D
M4;8V F$EQ#6 -!OO-KW&MRLKA))HFDN+CQDFI-SV6[S*S8L7& A\@J8G1AHZ
M+AO,F;+=2S'9PZ\VPWEQU><)1Y[SK;2>^<=UK2G'CG'(YIZ:>KF93TT,D\\F
M81Q1-+WORM<]V5HU-FM<X\P!/(KNJJZ:A@DJJR>*FIHLIDGF>&1LSO;&W,]Q
M &9[VM%][G ;RDZ)V%1[!.0,"6@*4(O(=6U#A3F'Y"T-(RXZI+;:LYREM&,K
M7G'_ "4XSG/JY>U6#8M11&>KPZKIX&EK72RPN9&'/.5H+B-"XD 7T)-E84>/
MX)B$[::BQ2AJJAS7.;#!41R2.:P9G$-:22&M!)YAJJW=SNNIVE=L(==2G!ES
M&$X<5C&,>@8\.V,]L?'X=N3GLJUIV>PDEK2>I1J0/UW]"YQVTD>-J<: >X 5
MAL XC^;CON/.K$]3YSG6E&RK/?.:P'SG.<]\YSF$SXYS\?Q]_'X^0EM$ ,>Q
M< 6 Q"JL-UOE7;AS<W)S:+H;94D[-X$2;DX51$D[R>(9J4F-W;]UWT^ !%EV
M1+*0Q9LQ[QP7!0M\J\J?[AE$/-=98SA337N:&_GTN?WOGX2CUJQRYV;V7Q;:
MJJGH\'CADGIJ?JF433L@:(N,9%<.?H3GD8+#6QNK?:C:[!MCZ2GK<:DJ(X*J
MIZEB-/ ZH<9N*?-9S6D%K<D;CFYP!O*3&C^JO474,3.B-;3SDR978$4B3P5!
MRA+;<:9(<C,9:<D*SAY:G6UXRA&.Z4X\[.>V<<O-I=B,?V3AI9\8BIXHZR1\
M4!AJ63ESXV![KAFK0 X:G0G0*RV6V^V=VQGJZ?!):J22BBCFG%12OIP&2O+&
MEI<3F.8&X&X:KE[+>%[*_P!KIN?;_IASV^OU\[3IM<,@^A1^J 67"=3W5GO_
M ,0EZ-!4.^Q=A[&,>@9\/^:;_P!Q/. ']F[QG>TK]'F=@WQ6^P+U^3Z>>5Z1
MPBHXZP>M#J$U+U#WR@T:WCQ58!HK61T!ZL5LDZSDC50A27E4P@,D2W<.39LA
MQ.'7E8;2O#:,)0A*<=)\'_!SLGCNRF&8KB=!+/6U1K..E;75D+7<375,$=HX
M9F1MM'$QNC021<W)7+?"/PF[8[.[8XKA.%8E%!0THH3#"^@H9RWC\/I9Y+R3
M0/D=>61[AF)L#8$  )VO)_=4^ZM[[-N%;V99X9P0(HSAN!'C  0E;))-@"P,
M.Y?%#X;KJ?<LU]&6G%J;\Y6%^;YR4YY@>%38?9O9C!\.K,&HI*:HJ,3%-*]]
M755 =%U+4RY<L\LC0<\;3F !L"+V)"V'@AV]VGVLQS$J+&ZZ.JIZ;"G543&T
M=)3%LPJZ:(.S4\4;CUDKP6N<6Z@VN!:0/5+U=2^F#<.DX]KB@X_3_8:'N:U;
MMN4B"5EV*A(JAS3M3UV=&9@S\1W@A.Z[.@U*P0%A"4YR19 1:+-%P0I9!"";
MZVZ"?1;[UT);0^$>PW]BCE1>L/J=V)03A$LSK+45YUQ3]N[$O=>QK<ULDP<A
M4OJ3W;IV#4J?69NZ-;-/.:TKNIX$S<M@^%4I9(Q; F:V-JK16!%<7W]&OMZ.
MCXY:D#2VX\_)H#KZ4X_5QU>;<U2:Z?6]+"ZP;%;;UU;+D]FTT686BS3.+[TY
M477 @Q8U[?UO!U)5+&5W<Y L5Z)P=B*KDIP*\FM3T,2HT][-;GX^-%0 :[^3
M=T^WP:72/VAU==0.AJ!U6VN]673MS*ZNV4WI;4<('IK8--"JMQ#1&O-Y-W/9
M9?.Y-@J^"M?#6RQ,30<%BLR;'(K@L.*LX\]:AT%L+ZZCFW<MK\^OJY56P-K
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MFI+-FX\U.<$P7_3$ORDEFN7+DZU5ZF@S9LAS%F2^>3L0T,M;/;L; &U]+WN
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MS$Q+CPR$O,:?B5$3AE24,)0^^EWAB;'<4D=59ZEI%7&()[4U(.,A8)&M:,L
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M'4#Y0&RNHJ&EI'2-:;M;(ZGBC+P"20'$@$DC4J/6H-"=%6Q;U:J)9.F"FA;
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M'A!;?#)/L"B\<^&G [+:*:?"FHL6:/01#6BEFJ]9A$AX83*")V1A>)@B%*E
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M250[M=1UMA^8%1.NL"Y; 'R7[@>C6=4!D8S,%UX%.N[6O*0Q>X0IJM;;EQJ
M8D[(I$TQ7"^67R:S#)$H]R],>M]NZSKVN$#H]'1KT@)L&HC-1AMB'=76BN#Y
M@NO%:Q!%N#6(L.&,GS@LH3#=@-R01"= B21LE<4A#(MOHC157TA6,C127YYX
MJ\1)6*P%"1.Q%Y$X]8S]V,B8UGLL@G<B%6CW6WW \!@6D^?(CG[(56Z2D/S)
M#KA$^G"(QXXQGX^$7Y\_'CZ_#]?;X^$7ZX1'"(X18QG&?5\7Z\?9PBSZL?-C
7\W"(X18SGMC.<_?U8X19X1'"(X1?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g425213g00k01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g425213g00k01.jpg
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M  (1 0,1 ?_$ !X  0 " P$! 0$!           &!P0%" ,) 0(*_\0 7A
M 04  @$"! ($!PH'"@L)! $" P4&  <1$A,(%!4A%C$7(B,R05%55I?5U@DD
M)3-789.4E=<F)S1"=):8-38W4G%R=Y&SM$-%5&*!H;:WT]3P4V1V>)*QM;C1
M_\0 ' $!  (# 0$!              (# 00%!@<(_\0 6Q$  @$# P(#! ,*
M"0<("0,% 0(#  01!1(A$S$&05$4(C)A4G&!!Q4C0I&3H='3\#-38G*2E+'!
MTD-456-S@N$6)#0U=:*RLP@7E;2UPM35\24F=(.VP\3B_]H # ,!  (1 Q$
M/P#_ '\<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2
MG%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4KSEEB@CDFGDCAAB8Z2665[8
MXXV-3RY\DCU1K&-1%5SG*B(B>55$XI6&EO5*GE+.O5%^Z*AHWA4_C_QO%*AR
M]H8Y'>AQ%ZQ?,B>7XS:,;YCD6)R^MV?1GA7(JQN]7IEC_;1*^%4?Q3/ZOW_?
M^RI2)H*8T4<R&Q'9"5!$1$PMS@"FQS,21C2 CFCFB3(UR)*,6/"1"_S'-%'(
MUS44K:QRQS,;+#(R6-Z>621O;(QR(JHJM>U5:Y/**GE%7[HJ<4K5V!LT)U8
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M5I&A^]FF6$5PMG96EE8,@A@#O%UG>:7HK/6M]<"5$][E2\S8J' ?8BNLJZU
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MA$@6=T([$C8XDHDTAR(JJKIS#9B"R97*JN?,1/+-(Y5<][G*J\O50JA1DA0
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M^SGQ$?$WWC1:$.7LSX=^K>K*KK#$;#5:L; F8;7Y[::C=33X?/W=4+>7.EM
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MHDFQT*HOGK;6M5%\(BF954<GIC7RBMT*JB>7N;]T1?,3U\>E8U>I4P^H)_\
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M+ZBI;.L\:HU\+(5OTEDD1SFM1C&.<YSV(U%5[45]ZQ_I+2_ZTW[&F_\ D/\
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M69NT)]H@MH[6R-Q-+<>T% AOUM555MH+B5G,ES$ !'M"[B6&.:0VUI."V90
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M_P#"Z%__ #0S?_Z52_\ Z^_.S9_]!U3_ +&C_P#[AT[O^_;%4#^$;_;_ /\
MK"K^QYCSZ:,N0A27S/8Y\JDP%O\ 7\J*CXY)1XH8TDB>CHGQ.:Z:%S%BG>Z9
MCUYQJOJN=YW;0YF=E+1$5-OI_JEH"8!9$W%>#5C9_.VVIOCRR*VBNSRV UM0
M\9L%16V,[[(T(5S6*]_I^.>-?NPZ)X=G31]%GTS5/$9U'4K.ZLM0GU:QL]-M
M]#T#4_$NM7MU/I^BZQ>W26=AI;VZP:5I]_,^HW=I;LJ$R%?>^'O >HZK&U_J
M$5Y9:3[+:7$-S:Q65S/=RZEJEGI&GV\,=UJ-A;P-/=7JRF2]NK6-;2WN)@6
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MX->R>&D?8VQ,D!"A4M%6PT\Q]U=.1K'!5M4%86=C+ L0X,[Y?;221NY(0,Q
M).,84>K$C"J.Y9B /,XK#.BC+;5R !WSG^2,G<Q] #WX4<555WC+;NW(7_7.
MQJ=%)U/K\U<YS3&;Q<W5ZG4A6PZQQ2UV/KLO(135\T4OZQ&D/RFJK)&.B;F!
M36#VD-L$ESI\D5S9ZC<VU_;2)+;W=H8Q+;RHX8.LQCZ>]<$ +%)&RGEB"15,
ML<=U%)!-#NMYE*R(SR(S(V=R#8XD16!QNZB3+CW"I :HI/\ !/U(5A*3K ^R
MVUKUYFW4LE%CKN]@NJ.MGJ!SQ7EQC65<2\@^SBMK:6ULC)2+*R.LS3; PR1\
M38=?4NKK$LEQJL\M_<3,KS3S%$:61 521DMTAA0HA*!8HHX]@5"A1$"S$%FU
MI::?<Z;I&H6%B\LEO::II&F:E&))K>2U:2=[VTGGO'6*60PF]FN/9IG:YM^E
M<'JU='6?3V>ZKFT$M#<[*S9H2X"IAM1J;70AUORX\0L4%*&?-(+3C-@@@'^7
MKH18%%%!'6)6!PJFI:V4-FTS1/.>NRLZS7$TR*R@J#$LKL(@5PI6/:N$4!1B
MK L")''!:VUJL:!#[/&8^IAF*M+EFWNJMTU<^\(4BASTX8E2V.;E*<4IQ2G%
M*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2L0\X*K!-L[(J *OKA"3SS2I&PC!AB0
MO(**(E>J,B@'@CDEED<J-9&QSG*B(O,@$D  DD@ #N2> !\R:P2 "2<  DD]
M@!R2?JJ']9OO"<32VFC<>VYT*'ZDH"R]SYRABU-F9H0<K,DGAS5R-=9"9AJI
M'$CVU*2K#$Z1S$G+M$C*N-J80%>S; %+_P"^07_WJC'N* MG+98@^6XDA?\
M=!"_9FIWRNITXI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5@6M56WE9
M84MR"+9U-L$576=:=!&2&> ;"\<L,H>5KHYAR()'Q31/:K7L>YKD5%YE6*D,
MI(92""."".016" P((!!&"#R"#W!%5GFK(_)W$'6FP+(LQ+"(IO7>IM)7ES:
M>L$&E)+R%^:0KW%;?.UT,Q"R&/>7LLN+-I(I;&SI]LZJM<!U,J #&.J@& A)
MP'4>4;' P.$<[<!6CS!25(1LG/P,>=V.2K'Z8'//+KEADA\2L++V8,I+V;;3
M303F*3"',+DU'#A<JOD#&]K,12I"^5[WM=)(^6-JLC8]&L57ZY#$_&P Q@!8
MP./GL+'/8Y)/'&"23>64@#IH"!@L#)ECZG+E<_S0H^50+M//"6V=IL?K##[_
M #>PU=70W!1X^=1*F=9";O)V4@GX>>!8HW8T^;I6 $CL&*FM8IR7210O#*T-
M3T:UUS3;K3+Z2Z]GF6*1C;7$MI.6MKF&YC FM6B;IAXE::!Q);7<*R6EY#<6
MD\\,F89TMYH99+2RO45P&MM0M8KRTDRK!3);SJZEU?:\,J%)[6<1W5K+#<PP
MRI3AWP(]'VJ3P6ZZVVK'6-/8 4QMW&E;2+29RMR8#*-@H(I-1(#05D%72E5Q
M(L^9":P7,NJ(6.9(&DZ>NEZ9I*6L20Z9;6UJETB*NH7<5I;I:P-J-Z!U;V=8
M(T1KF4FX;:&,FXDEJ9@UJ""SUFSM-4TZPBOXM&TN[C<Z9X>749I+BX/A^RAD
MAATEA/++-![($6"21WC4%C5Z=,](=>]"YD_(];U/T:CLKEMZ2&UT;8?GHJ"A
MRXZP##Q#ABMBH<Q2"3?+#Q/L"QB+FR>7<V=F>7?:6D-E&T4.X(SER&(X)5$P
M-JJ  J*.V2068EB2>?9Z;I>F(\.DZ99Z5;.87:UL5ECMS+#:6UD)A'+--LDE
MAM(6G*,JRS=2=EZLLC-;G-JMROY>QDC'1R-:]CVN8]CVHYCV.16N:YKD5'-<
MBJCFJBHJ*J*GA>*53%<]_45D!G2WN7JVX-'K<C8RN5T?7MN=.P>NP]C,Y5]C
M(VA4L86#,F<@](?*-A5DA%)QP:WG\,"X_A5!+C^,4<F0#S=1S(!RPS)R1(:J
M'X([?\F3A?Y!)^ ^BD_ 3V/N>:"KI_/\^45;55]3^:>HM^O9?+9.M+J;+5K5
M\HC\;(,-<X%XZR*A!4-?D;*KS)EE,U5-T.=OO$L[X)9773>\RR_QJ[SV^/)6
M3MP,NI< =E=>!FJX^ 4_BSM'\W 9/F<*0I)[LK=ZLH@X(1T3"C!1GS^OV6$$
M10NF]I&K)[39'M63VT>Q7^A%]".:KO'J3S35E1JVW>9I2&#&E'RR/':2UU70
M:"\'2-TWL(UY=)5V L9'N?=1'S-*2+Q.L*0*DBJ5#SM9U5;$,L;.GF.,C:L3
M"K'K;52F>W,UT#X_47EU(=#Z(_$S5\Q1QI%)*C&+"Y<$ ]P#Y\@'GUYJ2NZ?
M [+V/NL5Y'8\$=O*MJ)E^J+(>(L?,X]&GC@M:L]%7 'OB$]" ,E@+#&L()!_
M1&V&.>*.:-&1,]*-8Q$B8T*",HAC"A1&54H%#;PNPC;M#^^%QC=[V,\U:;JZ
M)+&YN"Q=Y"W6DR9) 0\A.[.]P2'?XF'#$BJ]7$OP2M^JXBD[1Q\#RGMMP<G0
MIV1GX3(WL/?:4-?7"5F[KE'E*2>;+!56J49@5?!C]I:DEVO-M2C%3&WL\JLK
M+AF$>Y055D?.Z)P#A2Q91N;\)&N%JCK7$<<D1EEDAE79*@=OPB!@X66,$),H
M8!L;<Y"D(S#=5HX@;KHVO&OL$%F7!J/])CL*,$*"8=E=(^":G+6*&(P(RM(2
M4:PJCFP' &QRBGC0E0R1LUWBVR%W0"4@ N5&\K@;??[LN -N"5(P1QBLB5G0
M()&:,,S!-Q*!V.7;;G =B!O. Q(][FO+9Y$VT(!U.5*%J=YGX9HZDXOW6UEU
M6S/9,;D=0@\<L\V>M9(V/83#"0;G[-@U[60$2C$5UC9&X&4<$QL1N QN4]@Z
M9XW#/8D!A[I(X(K92?>7 <=B>Q'T6\]I^7(.",]CL\=KPM?73D1BE5-O5&/J
M--F[+VFV^9O8(89R*JR9"^2&3U#DC'UMB)+/67E,;77M,6;4601<^'0H<9#*
M1E'&=KJ>Q&<'N""" 58%6 8$#*.'!\B#AE/=6]#^@@CA@0RD@@U#0!VYG?:'
M)2N6#.]F!V&LSKO;A>/7ZL:(<+>4L,1,3JV)+D>:JV]97*,81<6\W9=R>V0<
M=Z<L8[XE?NT1$;YS[R')C)YR=N&C8\!5Z2CDU #8[+V63+KZ!QPX_P![AP/,
M]0FL#"Y/%[K#YJUUV'Q=KHHJH[/Z="\Q3DPBZ>M+(HMY5C,)$F:P&+45MP&R
M*%5%=!$C8/(SVHNK<6EJTVY[>&0H287DBC=UCD4E2K,I9=T;^]@C(8@]S5\-
MQ.H2199$D7!W([(RR1Y4E2I!!4@A2#D#MQ5%UL607'4FB(ZZZ_N):OX?,QV1
M>5#\7EQ?Q'N+J84CJ8811ZAKX"V6E%LJRK&!:U'E78L<<$DS!6I?][[-)'1+
M:"/?<B'*Q(,10,6);W1N"%TD4M\!4D$$FJI;NXN44W,TMQMCDGV32-*.K<HL
M3,-Y;:\T<?1D(&9$"H^Y54599O6V,RDG7&2S6-P4?8EI-),3K \'E BJVBK$
MJ2.SMI$#!5-!#(N725N<!B''E%!T&MS[GUY%( 9 S+*DSO/*N\1[NF9"7<-)
ME417;+C@;FP062-AG.*([P1>S0N8TG*M-'&=D<G3[R21KM1R-VU25.UI!QC-
M7\>?19*C+LK$D"BH*4.8LPJ=\8H((D*.DFFE>OI:U/*N<J_=\LCO"(^5Z(ZM
M5+$(BY)("JH[D]@ *D2%!)(  R2>  *KJGJ+3L*SK]CL*\JKS=65#983"64+
MQRT+@>DH.XW ,J(YF@8Y&DY;*E-5,<GM7%Q$[;**+BKF98E*1D%V!$D@.1@]
MXXS]'R=Q_"?"OX/)D@ 7(9AA0<HA[Y\G<>OT5/P]V]_ 2(%_B*AUO:"KU[L[
MP?0["@TF<N\^[/RUWLC]<8_+%J1$3M,Y8.FB*K+@9X1$*"SM]J1_O02)SJ21
MV]Y9:8!J%G;R6UK-!+%<"[#J[:A>W"D=*UE1E,<\9!#YR2I (H"59\HQ!8$$
M8P1L5?7(.5/<>G>M!V1VEV378^R/%J+OK2<=H$OXLT>5P=I35TOU 9)13![+
MN>E&F@LX7.K(7_.B%1DDQ3#I+*C!G\F^T*>_MVM[/Q1;:9.S1LEW80--<+TW
M#M'T]1T>_MFBF53%-_S<3"-G,$]O+LE38M[J"VD$MQ91W48!5HKB6:.(AQMW
M;K:>VE61"=T1ZQCWA3+%*FZ-JK.LN[.SCNOM4%4;^C!R&@:8\DSI>IS]ULLR
MY]$:?2F!6_?U<?3165SGQB2["+/TY!3!P?IGC.2VU9IO,:K]SFQUN^T.^U?Q
M-$]_X;E7V"_L9KS3[FYMWNM*O[VVOVM+1K::/4+S1-*ENVLK;36VVTUI"(K"
M]N[67H6_B"]LX;JWTV*.UL]08/J%I/:Q7L,SI%?6L/LQN]US:K;6>IWT=OU)
M;B07+P7DDDSVT:U="[OO%7M<W#V3&+5^AT*]>4TCFW2$M?[Z3I\04?KK7"*X
M?Y7V(R6D-0SYM\;_ )*/UCZ9,6_!Z[H:KMQA[;4Y&WYX;<JQC;MXV;<Y][>!
M[M<TR0YX@N N\'!EC)V>:[A"!O/D^W \XS4ASTVFT'9>,N3L3J,]79GK+?T-
ME:W\.="%,N=#?]3E 0UP53JM(8UL\&4NB7-G<Z,6.&**0R:65BOWG2&UTFXM
MS?VEW<3WVG3!;5;H#9;6VJ)-(1/!&$7?=1!4ZDC>\>2%+52"6<':P 5Q[V.Y
M*8'!/H:O?G'JRJRSO[#M+LP7\OF*7KNZ\?Q_.1:JG]?_ -/X>]/G_P"9_FY:
MW,,1]&E7\FQO_FJM<=20>>$)^T,/[J\=G_P@VO7N+3]<(8PSLC1QJGK'F Q;
MPX<S7$^W^U&+FW=SGM142/6.(IN&MH?,K8I8ES'[L<LGF0(E]09,ER/4"-71
MO3J*:/[SHGH3(WH0F H/H=Y5A_,/I4,.U8Q5[9=CD"SW-=GK _KCJ#-!N9\[
MLMP1/,#JK>LCG5L49$]A7$Y"OM#((!\SF,WO=A/:MQ.B/-'F$(41 [2X$L[^
M21X!C5L>@.\@$[W>) O44 P+ DR$$A28XE\V<\,1]H*@GX55VSL8FIQ1  ]<
MY^\U^\NZ];^V?#<;G3R+)$!\TGI$K*"CCE;\Q!G:-L\5'DZ:*-QILLKSRH['
M6:&ZL+2#$RLJ1J=JY6-.YQW+-C@NV-SMV&,#"*H$U 0%G(W'EVYQGL H.<*.
MRJ/K.68DZF&CM^TI8[+;5Y-+@(Y&3TO79[%BL=,C'(^"\[*@\JD8<BHV6HZY
M<KQQH/2?N5.NBHLMB\[EAR$(:3\:4=D]5B/F?I2^O$>%&^3&#(<N,)Y(>[?.
M3Y>B>7=\DA4N3E%6U$M/NLMCW"07EHD5E9),ZIH:\0Z[T]V@RL^:6CR](-8:
M"Y0-LC)3G5E:4P$=7%&.@&9)*V:1O)G:.!C<Q(5%SVW.Q"KGL,D9/ R:@SJF
M-QY/90"6;^:HRQ^>!QW.!45^8[0V/V%&AZHH9$\*99-J=-V,3&OEKU#K!Y;/
M#9.5KFI.$=9&=A*4-+[-CF:8QCFLGB*/N>LWH-RQ _-CMD<>H CP>SL*Q^$;
M_5CYX9R.>PY13V()W\<%0:D6:Z^S&7,FMQ!)[+2ECJ*?KM"83?:LT9\C)Y G
MWEE).6'4.*9\U#GJIU?G*^=[UJZ@&-4C2+RNXVDX0'(11M0'UVC@MC@L<N?Q
MF)K*HJG<!EL8W,2S8],G) ^0P/05->5U.G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*
M<4IQ2G%*<4IQ2G%*<4JK.U_\+5=#@F>7+V/I LW9,_>B7(B0%:3=0&(SS/$'
M=9&CMLHPN%&N'M=)5)[T#Y62MNA]TM+_ !2%A_/.$CQ\U=A)CS5&[XQ5<G("
M?3;:?YHRSY^14%<^185:?*:LIQ2J)V!>JL^QSL]6=A7&&I:CKVJT:I45V,G0
MZUL]'>57FP-U>2U,@PS8JX6-B!11)&Z2661DZ^EJ=F#V6#3!=2V,%Y-)?RVX
M,\MXBI'';PR *MK<VX)+2-DONXP!BJSDOM#%0%!X"\DDCG<K>GEBH[HDN\B"
M+8:GXD-!00'!G&@LLTZ:&(/@K*]]I8?3QG].^_82!@L<1-$%'/(UGI\-57L1
MWE?$GW0/!/@^WCN?$\OAK0XYX;^>U74=4U"VGO4TNS>_U 6-L^JBXO9+6TC:
M:6*UCED"E!L+21JW8TCP]KFO2O%HVGZCJ31R6L4QM+;JQV[7LZVUK[3*L1BM
MEGG81H\[QH6W>]A6(T&<H^]=C2BZ6@[POAJFT4A]=!?9##55P/$.?,+)%:5Q
M?4@Y YD7R\H\D2Q1M=*B%1N= YD3MCPSXPT3Q7H>G^(-,T 0V6HI*\,.J6_B
M'2]0A,%Q-:S17>GWM]%=6TL<\$J%)8QD*'0M&RL:M8TB[T34KK2[R>&2XM&1
M9)+.YM;VUD$D231O!=6X>&:-XY$8,C'&2K88,!8@> [906!+#N_7O-1B?,N#
MJ^J(Q5D\KY6!D_3DLK6>/'A))'.\^55?X$[OM]G_ *$T_P#/ZM_]RKF[6_C'
M_)'^SK6%P;W(:3K)Q?:.ITH6EWQ65N:2ZI^N6 2A)BMM=LFA,SV"S=M$3$?0
M 21OC+BC]"S0RQ3,?YYL1-97EMJ6-,M;:2VLEN8I8)M09PXOK* @K<7L\3*8
MYW!!C)S@@@BL88%??8@D@@A,$;6/DH/<#SKH;G#JRJ[O-R-G,Z5JK<I\%6TP
M,8(43,VUK=&RVTPL-0"'4U9Q9UC8%2FP01QACN6;]8E8AX?6V'SWBCQ1I/@_
M1Y]<UEKOV2*:TM8X=.T^]U74;R\O[F*SLK+3]-TZ"YO;V[NKF:.**"W@D?EG
M;;&CNO5T;1K[7K^/3=/6 SO'/.TEU=6]E:06]K"]Q<7%U>7<D-M;00PQN[R3
M2(O 49=E4QS/:6S[.DMC,U?ZW+U5,=+4P'SX^D%J-+($>6*;8TC[UEQ93PC'
M &5)?S#:US/9]R,%/?'.DY?@[QSIWC==7GTG3->MM.TO4)M/M]5U;3?8+#7&
MMKF[L;NYT1GF>XN+:TO[&[LK@W5O93I-$&$#030S2;FO^'+OPZ;&.^O-,FNK
MVTCNI;*QNQ=7.FB:*&Y@AU$+&L44T]K<P7$0@FN(VC?:9%ECEC2Q:JMOP()(
MC=*MW+).Z5I-C3@P2PQK%%&@L3*A]9 L#71OF1T\4Q*RSRHXA84@AA]K7GJV
MH[BTGGA)E'E1D(\D:P#2#JBRO):]'^X42CT\0L5OI]'I\N\^KRGI4K-XI3BE
M.*4XI3BE.*5'M3F*O7TA5%;LG0<APY Y8<RBV559 $1&U5U4&L19 +BGL(!K
M&K.B19!31X9D1R-5KI(Y1@R]QD8/(((P58>:L"0P/!!(K#*&&#_Q!'((/D0>
M0?(U&<7I[5QQ>%VCH&;>C$0QAT$+1:[<9MLT8L&RHH$560JDTL .MH6.>1D[
M^:(>3WZ"YR5YH9N@P)(\]-CC!Y,;=]C?D)1OQU!/#*ZK%6.2C?&O.?)U^FOV
M\,O=6X/NE6;&[D_8=>6]P[_$9&RR>_.:G[TE9UUL*'=6D,?\/NSUV>*AA\(Y
M?=>SPUR^&KF#F55\Y \0_G2HT:G[&<'^\=ZQ+\!/DI5S]4;*Y_0IJT.4U93B
ME1ZM()M%L94+)&C&M"P8HTBK7)Z!?;8KD<SYQ5:Z59%8LSXI_1Z4E'A<BHJE
M8MMF["T>U\6QT].C8DC5E2M!&QZHZ1?=<AM$<ONKZT:JM<UOICC_ %?**KE*
MQX\:V6KM:6\O;?5U=R'+76(&F'S]@(57DCRBF!3BQ48HY I\$TD9D!,4T<['
M+&K4C56+D$J0RD@@@@C@@@Y!!\B#R*P0""" 01@@]B*A&;L+?KW0UW7VKMS;
MC/V[)X.N-;;R_,GSO%9'*F&T]D]B2F:.O$2>6AO3YI#-=3#NCLI"=13VEKH[
MF42*9$ #*,RH.PYQU$'DA)]Y1PC'C",%2M28R$8D@\1L>_\ ,8^; ?"3RP!S
ME@2VVT'_  :[+R6G;^I7;4&3K?0O3]UMD$MEI^OK J:7]B($*0[:YN-L;HYK
M*\V] (K2'1CMBPOOQ.GG&>JOU'"2 #S)'3<^2K&QXYK)]V16YPXV-Z9&60GT
M'QK\RP'I4M*(D_%-<+[JI$H+YTA4ES4=)Z3V.>T5(7,E<UK6(^9TT2Q(YK6L
MD]QWHIJ?GW[>7ZZT&\[<ZTZP)H!.P-G29*?3NM4I$N2'#1F,I!&&VL[Y_;=
M&(''.)#(:=*,(ZPL*NKCF?9VM<(5K3WEK:M$MQ/'"TQ81!VP7*+N8+]0Q]I
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M"JI8@'X=_$IVI<;2JU/Q ]?:/XF^K;[3?#?;TE-U[#H>QA3\KM[GO+)= B:
M#I_-FF!V.I$K]>9?YZ:DJ3;2RG=2W58YY[1'-^>2:C:ZK=KK6EZG=RP3Z-.8
M8[74Y);'VE;Z'3]RP6T[6KRJ)G.5RQDV/D.HQ[/Q/XSU%/\ T0?$T2>%+/P]
MK,_W0])T*+4[WP190?=)TR+5(;J5H8-7%@WB1,W=K;W%I#:SGJV3F&)&AN&0
M_6WJCN;#=SX,"^R6HSUU938K):+1TM3< 6%GF)-IEQ]#5B7H(I$I-7.2-/*H
M\1D<+I5'(:Q'.'F1GO;6[ANHPT<L;NJ1-,B.K-$TL8D574$E"0<@'T/H:^;:
M+K=AK=G!<6=W;3R-:6-S<P0S1R2VIOK9;F))T1BT3.A;:'"D[6 Y5L7/S:KL
M4XI3BE.*4XI4:OGS(9G61I.L;[=GOK$IJ1HQL;E9\Q\HU8EC]ST^E#E:)[GH
M_6]_V6N4_?\ ?]^*X*[HVE6/V;: ZN5FG'IM%>VOX-U6DACP@4.=ZI)*RP!&
M<D'F<#97MA<K;4M\J>JVOIX:T=9BJP1H/X%^ZYXOTZW^Z+J=GXEE'B&#2-=U
MK4QX3\2>((HO!EI%H'W,[BY\.64V@/#(UGJ&LZAJIU+2=;X.J:S/#I]N9+G3
M[;V/].>!="NY?"EI/HZ'29+[3-.L_OYI&EN_B&=]3\810ZM<1ZFLJ"XM=/M;
M#V2_T[M9:?&]U*$ANIO:/HUS]]5^8ZQR_P#DA7_1YO\ V;N*5D<4IQ2G%*<4
MIQ2N4;?X)?ANT0M@'I<7>::"PBHQ?.C[+[0NR*VMRXFT#RU/1&V6R(,H:?+1
M]A[*7-UM00&+1EW*F5L8Q-=4R@3ZC#L0._95'?&>P\\#/U5HMIUH^0\;/G:/
M?FF8@()0BJ3(2H032; I 4D%<%5(@S_AN^"*W[!U/7"X*A)[)MC=;O\ 0$1E
M[=FD0G8Y&3'[*G%["B.CEKABL;NHB+3JNGTXPU76;*NV4F1!30UUZ;G=)@')
MP, ?8<@X^L8SCG!&>XJ!M-.:5XNDG68R2L<R!\O'LD ESQ^#D!:%7PHD63IC
M<K'IFNZ;ZYJ;F&^KL\H=@-V+?]L!MAM[QM<!O]5D;'$Z:^KZ9;):BO2_I;BZ
M)N*L,&"FL=->7FU*KY=C<V=Z5#)]?+'V @@?9@?8 .W%;8MX@P8+@B9YQAFP
M)9(VC=@N=HWJ[E@!M9W:0CJ,6-G<Q5U0?3]:8#:'#V>KR-'?6 @GR(QMB#'.
M5"%[SR/E63JB2?+I/)),V)7*QLDCWM1'/<J[MMJ-]9HT5K=301N^]DC<A2^
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MMK@8&#! 5X(L<0H808T40XHHT4< \$;(HHV1L:U,5< % 50%50 J@   #
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M 7BH,I1';.9'PH;L SD*@4<[55F!QR3R3DDFM7B]_P!@%8W'E9/J/)A98Z@
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MJ/4=Q,GLK%B0"0I8_1! )^0+$#/ID@9[D=ZFBJS -(L8.??<.5'';$:.W/\
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M+,2Q  S@ #*H%R<EF/Q,>Y]!Z #R   [XR237&KP]KMK"[-MBX?E+E1<<%!
M#H'-I>IC903MV.)YI8Y9]AV4H24%N9$37#4% E+/2EOM:$V;3V),L84*#E<R
M$D#WIAD1D\_!$"648.YMVX;6&R#QLY))&#A1WXC."X''Q28P3QA<8.1[W/\
MJNLMIH?B9S';I>=M9,AE1;D $!E87)<_)DG=)VU(- .D" QPTEWUEJ[$1KSH
M$B_'UDC4E<KN6I<HEJ\(#[W*DG"[<XG5SG.X;EE0'CGIC.*@T#-.LI*[5!
M)R0>D5!XQ[K1L1S^.1706LR-IHM33;W/-?4VPU5FRU'O:^YB-&N,E>FD5-:G
MR%9:"!B7N.W?:^.T]BQUC, R^JC:P&PE"5T=4<JK&8W#$$O\./AD0!B<D9*R
M1P.HX!VL"1GFQT8L'4@$!>^>Z,<#@=F5Y%8]QD$ D<8][CZBOL?DIK:2CSFM
MUR7'7UP'"2+?];=OV$=W/:$U$\]=-5!T6QD8=)+7WJQ!7&FO=%D[,?25?8HM
M #E9"RY W.B;9%/PRP*5VA@"&+1\<KRJ*CJ4:(L8L@!P3A6;<A'>.4Y)(.",
M.><-PS%E(8.!6HS4^JR=O<!4M4+'HJ]9;C:=3!3L S^O$+*<I/9?2A-L4T:A
M*O"I'SWV0LK".B_%4LP=Z?26]K-V)K9.$<*68[3[L<QY9"!Q%<  %@HX60#=
MLY4,JB),*64D #</>>,<!AD_A(LG@G\9"<;N"5)WO?\ F=11Z^JCN* WYL1T
MTPL\<HY(-A6V K_;.J;BJ.A&LJ:YKIO(]E46@HEB 0UT!8T,K5;S6=&0[6&#
MW&"""#V92,AE/<,"01V-7JP894Y';T(([@@X((\P0"/,5O\ D:S5);(AXG<.
M+*B?[<@W2??)$;_V:^A\.FZ'D8_Q+^R7TN:B_M/V?V_7_5\\ZL/_ %'J/_:N
MC?\ NFNU _PB_P R3_Q1U:E(P=]4(^-L<C',D<R14">KV+-(K7^L!C07>I/"
M^H-K15\^1T2)6)SE5,=A^_\ ;S^6L;2Z/+8RG(T.MN:7-T8LP L]M=&"5P#"
M[4\6IJ@_F"GQ1O-M;4T*KK V.<58V1@@ <4Y9,$+[[:VN+R9;>T@EN9W#LL4
M$;2R%8HVEE?:@)V11(\LKD;8XT>1RJ*Q$7=(U+R.J*"H+.P5<LP51DD#+,P5
M1W9B%&20*V@)%=9A"6-?(,6">-"8&5"C'PD#$1ME@GB<B?K1RQO:]J_PHJ<J
M='C=XY%*/&S(ZL,%64D,I'J""#6000"#D$ @CL0>0?MJINX&M;FJM&M1J?IF
MZ*7PU$1//Z5NN_OX3QSIZ/\ ])N/^RM:_P#A-[49/A'\^/\ \Q:V_:R-'JLG
M<L:BF4O9W6S0U<B*UJ:O75G7MLCD7\TESVQN1U3^'WO2[RU7(NA#RSKY-%*3
MC^0AE7_OQK6)>RGCB2/N,_$X0_\ =8U5@N5FM.J:ZM#J8+W3=,F:7!QYXY@T
MDFSQU \G+FXR_B,5@LD?:?645)=0BGR)2Q:.PR6C,@)$IQX76E]LQ8MM6<))
MN&0(W;#B1,9/X&7<N1[Q4.@(+&JPN8P,;FBW)@XRRKE2I[#\(F#@\;BK'.!4
MUZQU$#HJ_&G6DV@J;7/Q:3K#56#B")=IU_/$,YH-M+8-0Z779&(X&NODLVR&
MWE072:0@DFX.U %#"9.\@&U@VR9!_DY1GD8XV28++MX5@R !0A:43<!"=P*[
MHV/=H^.#GDLF0&SR00QY+ :74=7LH0X8J.AEUF"!)0^# "'2U6HP!;(Y8H[W
MI+30&UI^<D#@F(%_!L5O5"CULZP8JYS@X3\KII)+N/O-LE("]4@%)!]&X0@A
MNP._:Q)'X17)WKAH]H&T;D'X@.&3T,39!7TV[@ /@(QM;/SFVT%5507#3#>V
M^OGOG@344U2Z/LO,SB2N@/KMIA@0 )KPNG)A*"MF9NEJ-M4G,'HC^MSCQ;>\
M;AXU+%2!!+@'8Q_!.",@I(20H88*[F:-AEA* 56LJ[  \R1G\8 B1<=PZ  D
M@\':H8'@H2":EN8O@IXR;+-"$:R@NYK*X#TN=FS,]22]U@;*2)[R:!A9!HA$
MRUSEE%9-[PL@[V0_*/;'JOO201M%)_*;W %X) 8,ZOS@8VHP]Y3G&2+EVL-P
M=<$X'Q'CL2"JD8![@G=G. <'$-R]YW'!V%V&W3X>WFP;3*R/!V ]QCYSK",Q
MC'&J751Z 9E(!22HHT<ROM;&YCF>>6VO>*P*7R&D:9XIL_$.NWNJ:W#JFAWK
MJVD:>EJ8+G3E9DVP.PF2UZ-K&LB=18I;J]:7K3S(8EA/6N;[3[JSM;6'2$TZ
MXM$42Z@M^]U]\B$?K22VS6226TLLIC,*+=S6Z(I&(2S8PS>R>]GYTR:O^'PD
M34+77A5>$?V#D3Z5A8!#HZH(\P,L,Q9K2'VY)D#$DA$D?(T,JV@@^9E]<0Y<
M("B(>H.MAI=A7/2)@S"760;=X$JF,[\"3:O4UT&FK=V[L]]<::#:^V(8[>PU
M4[XP;M;.-9=4L'6WE#I#+<7D+7*=)V@MS)*EO;66L='9BULVFSA-!;,J4=9Q
MNGJ9P&GDN%?**"^ONK:61L"PR-<^5R,^R*V5_K;Y*6SM()P!E]JHK''.U!+*
MRX/DS'^<:UY^@9':V$B0,[&**=Q)<1QY]P3R1Q10O(1\1B&W.0.,$S#DJIIQ
M2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*
M<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*@6PV4M*0%G,Z!'H=U>0RRTM"L[AA
M!0XGMA)TFG/CBG=2Y:LDD8A9WL3F'$+'4485E<E#!/L2/<"[';&I&YL9))[*
M@XW.1V&0 ,EB%!-09\851N=NP\A_*8_BJ/,\D]E!) KWQV,BS#;"QL#Y-#L-
M X:?4ZLJ!HY%I*(DWR5=7AI*0RCRU*A)4.=S8Q$P]=&28<85:Z*VO[ZX22;\
M #:BYV(#D+G&23QN=L#>Y +8  "JJKE5VY).6;XF[9QV 'DH_%7/'))+%F,V
MY74JJW$_X9V?9NO_ 'AW6E/U[3$1*GRIE1@13";&=OGRY3 ]]K-WGCG?JL5:
M$>)K/,+I9;I/=2)/DTI'F&E( ^PQ)&P_G56G+R-Y9" ^1" Y^T.SJ?YM5^OP
M_P!D[-TF0F[,LCLWG(PXJ2LM,9A[)@;*Z2)X#G2$T[G$$BK!%[9<J+.BM<K7
M-61_JZ=SJ5G=S33W&DP/+.[23%;N^17=CN8[5F  +>\%[ @<<"K(6GMR&@N)
M(F"-&'C(1MCH8W7<N#M=&9'&<,A*MD$@Q*T^$++7D[2;NSSMQ.UMC&DUKU'U
M?82+!;MB;:BO<7G9E>)8^P.XT5ZN@*>..^>-[H(E9R[*V\-::;AM.\)Z/I[7
MD@FNVL4>T-U,-PZUR8-AFE]YOPDFY\LQSDDG&J=37/9_OW*VL>R0/:VIU4+J
M)M;:789+>V-X)C!!)TX^I%%LC?8FY3M&/X%^#[*!.>\.RSPLDK!XY91^I>L(
M9ID&,6P8LTT>>;)*]YJ_-$22.<\F=K))W2/8U4VI)='F4)-H%E,@! CFFNI8
MP"2>(Y)&0<L6R!DL222:6)DTME?3)6TUT,Y1]/5;)T]IR;C8UL(F43Y/5"D!
M]S;@=QS,@.@K2K)C+K^R2Q)XK'ZM&^##8=B,L49%'\TUB5/H]Q4AC<JJU?5(
MU)%\O\JM*1^'XV#Q^&-+C=7$BNG51UD!!ZBLK!@^0&W@[MP!SD B][N_E&V6
M_NY%Z?2VR3R.O2SGI[68@1YYV8VY\JS(@+S$FWN4SNE(UW:':%TS5V-[;U=4
M/7XNF#SV>QLFLMJRG'"#<$"#FQ!<Y2+Z3MAJ)'!MF#HPM/?YS:N;F.[%LWLZ
M6MM90&VCBCDD<R%KBXNBN^5G;<TER^]L[8XP."Y17U#E<JIW2.=V2.%& NX@
M#L, *.[-QV#%;CRV8J\A2"T52V=PX[B""3#9OFK*VLSR)3;6ZMS%:QYUQ<6,
MY-C9FO:UQ)A,TOI8US6-YSN78LV,G  '    55'DJ@  >0%350H 'SR3R22<
MDD^9)Y)]:H'XFWNNJ?.]?PO<R75/N))4>JH+*AC*WK'..F]/ZRRU797:_7VG
M@^[4C9GB"4>V4>/SLVGNL\F,[ ,>HQNF;ZPT4,J'^<.*IN/>"I]+/Z<1K^22
M1&'\W/E73K6M8UK&-:QC&HUC&HC6M:U/#6M:B(C6M1$1$1$1$3PB>.:E;%0+
M39"\MK:MM,YM#<4^"97W+*JAS-C)I8$@=#$';%7U59DL&%5H\@J5<E:3$]DJ
M/*EAG= F&W%652%+#&_!+IP1F/)Z889R.I'*NX+E2NY6FCJF[=$DNY=HWF0;
M#N5MZ].2/+84IA]R;78[=X1UYG[)^#&O[:2[GW7;G8UE;7N6JJ"6X!?0TAU1
M;9?0OU.)VN4FJ*@1<=K<A>.CL*RRS'TJ PL*L,O0KDVN$)BW=%U?7M"]G6TU
MJ:XAMWNG$6H:=HDXG%['T+J*\]GTNS6[@FMLVQ@N$>-86E5%5I78Z]Y;6=ZD
MBR6YB>0P_AH+B=)8U@D,J='J/+'$^\[NHL8?*H<[EW&4='_"I4] 6.LM<;O]
MO<V6XESBZFUWUL;M;>Y@R\%NRL<;97!KR9[%9;PYAMS,^2U."8"*29(@ SH^
M=)'U;V]OSTX9K^Y>ZN$M88K> N\LLK)';HIA@B'5,<45ND*0Q+''&%5 #H:?
MHFDZ5+=7-A:RQ7>H=)M2NI;Z]NI+Z6!I3'+(EU/-#$X$\H;V:*'<'"<116\4
M/0[(K2MC2RT.CJUK:N$XZP(?71U4$4$,)"_-D&S64L @P8;WR%R2,2/Q$LJO
MAC1_+ &) SN).,;3N)/8#!QWX'!)^NNLY4Y(78 !QNRHP#DG<">>_P 6!@?/
M,#^IZ/M/]EG"++(]<2KZ9]?&V6OUFV&_^$BQ$4K&$YG-&?XE-R7%'>VH?S).
M'"KA2\[V"NQM2'X\/+]#ND9_UGTG'\6#M4X$A)#151EI/A)5#W;LSC^1]%2/
MQ_B/= .'JS:*AILQ5!T=!6BU-2"V1HP0<:1Q,=--(03,]?O).465-,6:9.^4
MHXR><PN:8F>65]+,S$LQ))[D_+@?8!@ =@  .*L "C   'D/GR?M)Y)[D\GF
MHO;Z,.X364%0TPHW+D9L>X*'$,(#&/M)AK-]4Q]=/$;/:5M(^ONK0$=T$@U9
M=TTWS']^N]G)0JJL< /DJ// .-V/HDY /F5;TK 8$LHYVX!..,GR^L#!(\@1
MZU5=W\5/2E3DKJXSNYSF^NZ7/W%D!BL;<"W6HOS*:.2&*KKZRO4LN-UK8QQ
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MS0RQD/'( 4="&5BI!K56M#4:_-V=#;1J556_SL;WC$2#D1+\_*0'8UAXSV$
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MJ.TJ9J[(&VX!88W8]X#D$*?Q=P.&(P2/=SM+ Q*AL;N<<X_%)X()'G@C(!R
M><9 (M2%]TV&)I ]9*0V*-)Y83"H(I9D8B2R10/ (?#&]_J<R)Q$[HVJC'32
MJU7NA4JB.SU5I5U@%9GA12-QJ3B*/,!3I,97AE0K,MCI;A(E"E7-Y<&*6XM/
M5-7NLI6 9H R*]OZ:(BR- Q+.2(T&YR.Y]$7@^^Y]U>#CER-JMB#L0 %&68[
M5XR ?-F_DJ.3VSPH.6%1HL%N- PO5N4GD)MM);%6%U:VL8QYY.>K+""_[-V%
MY&L$0IECJ+"S&SY!,$$,8NFWU;90 I7A2C1SSU#)*X]U5 51D ,05BC4\D!
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M)GF(DA'BDN8P0SJ N<D2"NUM30&'%?1&W()^(V',;G$<F,GOL<9V28Y^')#
M DHS #=M(.IX=1EDS@?24_$GEWP"I\F )XR#X6E95]F4.<VN.N4J[\,:2UP^
MN:#,^0'Z@R'ZA1Z"GG?7EG9ZW42"OV.0L)*\QI ,!$$U!L<]17=)E28F9)%W
M*3MD3/?'9E;D!ER2C@$8)&&1F5A42!74E6'*MCD9[JPXRI[,IQ@\C# $::&.
MM[1@=!:0FX/M;!2^U/+5E037^/-LV>8SZ2R)":+JNO\ 6MKD("=85DE#IQZY
M0-#1UVJSEI29[)W0G(Q)#)VW A) /)E!RDB9Y ;<A.58HRLV.)!SE)$]#[RD
M^8.,,CXR,@JP&& 92%WN<VEC!;#XOL 4*FV$S9TI[ !)HLKOH!(7D3G924N8
MB<&TC#BE-M\19%DWE&R$Z4,W39X)FJ-B\8VF2(ED&-P/QQDG #X !!. L@ 5
ML@$*QV#*N<A'P'\B/A?')*Y)(..2A.X<XW*-QLOE564XI7XYS6M<YSD:UJ*Y
MSG*B-:U$\JYRKX1$1$5555\(GW7COVI4;_&>/_G9FO\ ;M7_ /FN;'LEW_FU
MQ^9D_P -8R/4?E%8=AI<):@'5AVFS$X-B&2 9 ^]J_3,*9"\<B)W]]?NR0R/
M8O\ F<O,BUNP01;7&001^!D[CGZ-8)4@@D8((/([&N?J;<4<>)^&_>&ZBC=;
M 5V*HM<_ZO7K9S5G8V8K\X:!(,I'K;&WL2;"W5PDC8WAC4!!#W-:-+%)LM9W
M/4NH_9;C!,C)^!DP&B8N#\/\4)%7ODN/D12&]R!RPR @;MDB10I']/83]7RJ
MW=T7DM9GIP MOEZJ^!(%N\K>.N*V=:/45,J%TUB^*,Z&4@'YAOR5W71D0-NL
M^9;41,J!69+741VUTC FUN"I!5UZ,GO(W##X>#CE3@[6"L.0*M?## 8 CE3D
M<,.Q[]O(CS4D=B:B<-P1JZ6A[MP]<LNGK0BJ';8\ P<R;15=':'!ZG#L/C6&
MOM-'B]%%=&8*W<YM8>?]2K0;*LSV]L[J,\;0N]K,"H)#HSJR%"Z@QR%2-RI(
MA7J+C(&"06C"U#.X"95.\ JR>; $Y3/8E6R4/8G(! <FKMIKNJT-/7:"E.A/
MIK8$>RKSX5<V$@(J)LT,R)*V.2+S&Y/<BF9'-"]'1S1QR,>QNJRE6*L,,I((
M/D1^_P!1\JM5@P#*<@C((\Q4:U='DMB(+%8V,(MA6$*?G]%4V8P.AS=G[;HF
MV=%9M61PTSX7O&-%FC)JKJNE*IKZNM:0XZN)DCLA)&"",,I&5=?1AYCS!X*G
M#*0P!&&4,.<@@Y5AP5/J#Z_(Y!'!!!(JLZ_L:@)=<]>]I'Y#1A*&6*NE:RNE
MS&NKFDMKBJG29LN0A:;312/=#95;8K'-W0S%MZ8X99K'+YR3;!B2)BAR/<)(
M=&[Y1A\2<>ZV0ZGW6!P'>(W'*.H88^+ VL/0J<X;U'(/<'NHSP_JV/&BL>O+
M\;>8M[5D;A[W10.O*\9CE63\![.X*5Y+4<V=HV6W1LE?)-.,+6[3&T5;#6RR
MW1R\2 1OCB15]TG_ %B*./F\8!X),;L21C:R?!EE^@Q]X#CX&/ISA7X)( =
M,&Q\CNLUMARY*(YSC:R2."[HSX):[04!4ON+$-=4IC8C@%(;%)* 3)$H-L(U
MMC4%GULPYDM;QLF-PX895@<JP]58<''8CNIX8 @BIJZMG!Y'# \,I]"#R/EY
M$<@D<U+^0J5.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.
M*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE5UKMA8#V,.+Q0XEKO+ -A
MRH:V:6AQE)/+,,S6[%19AY_DGS#E09[.#%"7.VM RJ^M(K*>LU.KRUJ1@@R2
M$K&IQQPTC=]D>01G'+.05C!!(9BB/6SD'8F"Y&>>R#Z38YQ]$<%R" 0 S#<9
M#'U^0"*CA(+MKBW*^IZ736KH9;S37#H8X'V5G-!# .Q(X(H0ZVL!'$IZ.K'$
MIZ0"OJ@A1(HNY<C. JC"(.%1<YP!R>Y)))+,268EB34E4*.Y)/+,>['U.,#Y
M    8    J6\A4JB]5ZV:+5K*CV-DGI4&62 R)DL:54:.=!.0]12F)/[T;OD
M(VMAE9(PA[YE5(U//\G]_P"_?\GG*.*5\POB,[=I=-HNO]UFNQ.Q\L)T=VYV
MYG.PZ+$]B75%FKTGK;H;N3MPS-]@TE'-%4:%X%]U-FWFU9LUG%%06UG43NB=
M<GP1?,$\0W&O:BI>P\0: NB:W?64D<TMS:P:G':V>LW(:1(XTM+M#+H\$^VW
MN+Z'V*\B4SA[B2*/['X3US0_#_W,?N]7-O#]S_QA+I_W-4U+[X7FC:3KVK^$
MM7C\5^#O#]XNF7UQUK[0K^'2_%^I(Y1+*Y35;.VN=A?3H6;EC^YV=@%S]]=2
M8=]#VC25.7^$30].(S=9*WH( =!TSW?IXJG-WTAZ>U6]E"8J[89H,M,JV8%:
M@)<OJ&FAD?Z+19V-W!$4F54TU[8]6-D*RV]VY"L2Q"R]-LO%@E0%.[! /X>^
MYGJ+MKVE6!M]7@AM/!4^BXU"SGMECN=$\0W"PVUPTO$6JI8SA[BT8]6.(1N?
M<8,?O)SUM??JT6ETE3DJ0Z_NYWP@ MA:K8()2S33#"(0:VJJP!VR%6=Q<6)(
ME735044QUI:&"5X4$Q1,,3Y(C.P51DGU.  !DDD\!5 )8G@ $G@5%F"*68X
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MQBQB'W-W/@A) JGDNFLG\$</_%,1D_[-^ ^?)"%DY"J)#EJCN9/X3!7^,4<
M9_'7DKQC+#*]R=@P*M84H4X48X$D<P(R"$H0L6:,@4H4B-LL!(Q$+GQ3P3Q/
M9+#-$]T<D;FO8YS7(JU$$$@@@@X(/!!'<$>1%6]^U>_,4IQ2G%*<4IQ2G%*<
M4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2
MG%*T\5E.44; %%7D,"E;#)(MDYKVRJW]I%-#$"0H\T4C7M6*217.C]J9/#9F
MHBE:.^=V$])&9H?(1(\56,FN+&X=+"8Y94]UK!:AT4D,;5A>V-_A7O;(UZHQ
M6J@=^>1YCMFG[YJMJ$A.H0#(-=:XD>0VKTVTN;0S2'$;C9G9X  O3ZDV&6E%
MEN/I=/%"PL>FKF5^=JHZ&BI:ZHSX-55C8GN4!!E=$PCE(\@8CB&]Q&A)9@@.
MYB-S9.YR68DZ<]W9V"L;FXBB/1N+G$DB]:6*UC$MU*D>>I*((RK2=)6$:LHP
MH*@V;B]E6;S-9399^48[+[;,5.OS5I!*8BV%'>UX%M4F*(;7 $CH976(Y"1S
ML81%ZO;FA9(CD;&*1)HXY8SE)421#@C*.H93@\C((.#R*G97=OJ%G:7]I)U;
M6]MH+NVEVLO4M[F))H9-KA77?&ZMM90PSA@#D5,.3K9J,6N*QU[:UUY=Y;/6
M]S4*]U7:V=-7GV-=[K/;D0(PH>4@5LC?2LC(9&->^.)[D5\4;FQ95;&Y5;';
M< <?5GM60S*&"L0&&U@"0&7(;:V.XW*IP<C(![@5B6/7>!N!WB6^+RUL+)&'
M%(/9T-8?"]M?,I(7KC*&E:YXQ"^_$]45[)4;(CO4UJHV)C&Q<8VXVC&TG)7&
M.Q))QVSS5B7$\3!HYI8V!=@R2.C!G4*[ JP(+JJJY!RRJ <@ 5$E^'SH92I#
M5Z4ZG4N8DPN4E>N\BLTI-A'-$?+)(M1ZGN.:1.XSRJH3+/--,CY99'NE%^ 2
M:.'\#'<#%PD7X-)QAQB94PLHQ)(,.&&'<=F;.G[+;9=O9X-T@82'I1YD#.TC
M!SMRX:1WD8-D%V9SEB34IH.M>N\H5$=FL+D:$Z!LC8CZC.U-><WWHO8(D^<&
M$C)68J'Q&7.LJS%L1K29)4:U$I2WMXV#QP0HP! 9(D5@" " RJ" 0 #@\@ >
M5;4DDDSR23.\LDUQ+=RR2,TCRW4P"S7,CL2SW$JJ!+,Q,D@ #L0!4M,,$KA"
MK"P*&! !&G,-.,GB%$#$%B=.2443.YD(XP\+'S3SS/9%%$QTDCFL:JI> 20
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M0<9,;30NT98##-&59E)5B5)!I0SX)OA8L08JX[I;'EBP8>XZX@CG%(E4?&:
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M0/>Y@^\" N,W(,)M\F4^XR9I<DD A!"Q+#99JXFAB(D3.:L!9*BW\BG+7R2
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M6-K$-3GC9-/CU.7[W6<ERZL+9KF[N-B0V;R;2UPI8-%N: 2OL5N =?\ %?\
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ML;ZI[?V4WKB]<4LT3U8JLD7[HBE0?;936ZJ:DE".R]0_/7U9HJ@R8&X/M@+
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M945G=@JJ"S,Q"JJJ,EF)P   222  ,FHLRHK.[!54%F9CA551EF)/   R3P
M,DUP)L/[HWD*76#$Y+(Z+?=5G=1'Z2IT%/F=4%=7G<!FUMLMC>J8ELZL:KI#
MK]F9NG*R\0>R?):YBQ"&(IRIR.>5?Q?I'M*Q07MG<(]F;A$CN(O:))3-+%$B
MQEP0CF"8;BO+ %=P#[?G]]XXEMIQ<VNAZM?Z$VE221W\6EZE&TVOO>O;66A]
M2:V2WM[BX6!R8[AEG/M-E-'&T$I<]^8;<9WL/+Y_69HZ(JNT6=SVF%A62-#A
M:[3U MW4I8B(]9@B)P"XI4A(8Q_[WA%1%7GI8)XKB*.6)U=)(XY5*L#[DJ!T
M)P3\2D$>1'(R*]M8WUOJ%M!=6SADN+>WN51L"6..ZA6>(31YW1N8W!VN >_I
M4E,_Q+/^E _^^C\NK<K*XI3BE.*4XI3\_P ^*5H6Y7-,]7IH:A$?*LST^GBJ
MU\BQ+"JN:L:M<CF.=ZF*BL=(]\RM69[GK':O/NKSWX'/U\?,_EJ6]^/>;W>%
M]X\#(.!SQR >/,#TJ-S]2=6%([YGKC#$>NK*I'K-E:21SZ@Z7WRZUSWA*YP4
M\RNE>.JK%[CWO1J.>]7:TEA8RJR2V5I*CQO"Z26T+J\4N>K$RLA#1R9.]""K
MY.X')JU+JYC $=Q.@$D<P"32*!+$28I0 PQ)&23&X]Y"25(S6-^ACJ#YF(Q.
MK>O6EP6;;F$EN.S[)HK5D*CML(Y&UZ.84D+G,]UJHY5<YR^7N<Y=U&:*-8HV
M:.)$6)(T)2-8T^"-44A51/Q4 "KY 5KN!+MZH$FQS(G4&_8Y[NN[.UCYL,$G
MG-3\*O!K85'KPQ@8'2/F6$6&.")99%17O5D36M]2^&M\^/LQK&)X8QK4@ !P
M  .^  .?7BI$D]R3Y<G/ [#[*S.9K%%1%145/*+]E1?R5/XEXI47DQ&-F>Q\
MV4SDKHYW$QK+2UTGMD/%0)\L:/'5(W.$1('*Q$1T?V5%\JO,JS)G82NXACM)
M7++\).,9*^1/(\JF)' (#N 4,9 8@&,MO,9&<%"_OE?A+>]C/-8+>M.NVM1C
M<)D&M:),"U&YVI;Z0IY'2RBM5!$5L"R.<]L351C'.<L:-]3O-AGG.<S2G.<Y
MD<YW !LY;G<  ?4 9J2S3)\$TJ>\C^[(Z^_'_!OP1[T?XC=U_%(K9IC\HUSG
MMS5$QSYH)W.95!,<Z49K60/560-5?:8QK&M_=1J*WPJ.<BZYC0DL40LQRS%1
MDGU)QDGYFH]63MU'QR/C;L221W\R23ZDD]S6Y$!" C=""(,'$^1\KHQ88X&.
ME>OE\BLB:UJN=X1%54\^$:U/U6HB3P!V&*@!CM65Q2G%*<4IQ2G%*<4IQ2G%
M*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4I
MQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2OQ
M6M7SY:B^45J^41?+5_-J^?X%_A3\EXI3TM\^?2WRKO4J^$\^KT^CU>?S]7H_
M5\_GZ?U?R^W%*_%C8J*U6,5JHYJHK45%:]?+VJBIX5'K]W(OV<OY^>*5_7A/
MO]OS_/\ S_\ EXI3BE:BRH:NW=YL1WDM6&0:2)22HQYQIHY8Y1B1XIV0$02L
MF>DL4T;V2_J>XCO;9Z8NBR*R.H='4JZ,-R.K AE=3E64@D%6!!!((P34E9D8
M,I*LI#*PX96!!#*W=6! (*D$$ @\5!F=+=61CL$CQ%$P9D2Q,A8+Z6-9YD5B
MHC7(B/@;,1&.]/UH(B"8HE;'/*U_GI_!_A&YN%N[GPMX;N+I=FVXGT/2YI@8
MQ,(R))+5FW1BYN!&V<H+B8(1U9-W7C\1^((5V0ZYJ\*[BP6'4KR(!B8R2-DR
MXW&*(MC 8Q1$Y,:%?X9TCU+&3.;%@,U$638@6\Y45=%&1+95@S Z\R29GID>
M0(+&@X\KG*^*)7QL<UKW(O532]-CBB@CL+.."!8D@@CMHD@A2!!' D,*H(XD
MAC58X5C55B151 JJ *!K.L DC5M34M'/$S+?W2,T5S*\]S$S+*"T=Q/++-/&
MQ*2S2222!G=F,W SE35^A 82((XY)9FP)86#Q5EFE;*Z1XLA3AI'M>UJQ.DB
M<Z)&HD:M1.;H4#./,Y))).3W.22?7\I]:T'DDD(:1WD8 *&=BQVCL,L2< <
M=@.!6\YFH4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI
?3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g425213g00s01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g425213g00s01.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1@44&AO=&]S:&]P(#,N,  X0DE-! 0
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M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L            IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ "4S,P  0 ! )3,S  !  $X0DE-
M!"8       X             /X   #A"24T$#0      !    %HX0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$1       $     (   )    "0
M   X0DE-!!X       0     .$))300:      -!    !@             !
M$    K     & &< ,  P ', ,  Q     0                         !
M              *P   !$                      !
M         !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   !$     !29VAT;&]N9P   K     &<VQI8V5S5FQ,
M<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M       '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E
M3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E
M5'EP90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M    5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P
M 1      4F=H=&QO;F<   *P     W5R;%1%6%0    !        ;G5L;%1%
M6%0    !        37-G951%6%0    !       &86QT5&%G5$585     $
M      YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
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M 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$
M 04! 0$! 0$          0 " P0%!@<("0H+$  !! $# @0"!0<&" 4###,!
M  (1 P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U
M%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?56
M9G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1  (" 0($! ,$!08'!P8%-0$  A$#
M(3$2!$%187$B$P4R@9$4H;%"(\%2T? S)&+A<H*20U,58W,T\24&%J*R@P<F
M-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:F
MML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\ ]522224I))))2DDDDE*2
M2224I))))2DDD'-RZ<+#OS+R13C5ONL(U.UC38^!_5:DI,J=76>DWY]G3:<N
MFS.I$V8S7@V-'>63^;^?^XL3ZH_7K%^LU^1C-QGXE]#1:UCG!X?43LW[V!NR
MQKOIU?\ @EBX'ZK#_P!>77_X=SO^IRTEID-*ULTWOKM]9NO87UU?3B9MM-&(
M<<5T,,5$/;7;9Z]7T;][K'?SB[WZQ_6WI'U;;2>H&QUF03Z=5+=[]K8]2TZM
M:VMFYOYW_%KR[_&#_P"+C-_K8O\ Y[I6S_C?_P"4^F_\1;_U=:*WB(XSV+Z9
MB96/FXM67BO%F/D,;0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                            _^+__TE#0U]04D]&24Q%  $)OLS^_AX
M"(!P041"10(0  !P<G1R0TU92TQA8B 'T  ' !H !0 I #5A8W-P05!03
M  !!1$)%                     0  ]M8  0    #3+4%$0D4
M                                                      ID97-C
M    _    '1C<')T   !<    "MW='!T   !G    !1!,D(P   !L   H@9!
M,D(R   !L   H@9!,D(Q  "CN   H@9",D$P  %%P  ".+1",D$Q  -^=  "
M.+1",D$R  6W*  ".+1G86UT  ?OW   D)%D97-C         !I5+E,N(%=E
M8B!#;V%T960@*%-73U I('8R
M
M         '1E>'0     0V]P>7)I9VAT(#(P,# @061O8F4@4WES=&5M<RP@
M26YC+@  6%E:(        +5:  "\9P  DC!M9G0R      0#"0   0
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M_H;MA]N(RHFXBJ:+E8R#C7&.8(].D#V1+)(;DPJ3^I3IE=F6R9>ZF*>9DYJ
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MN7U2DHL9/'W&CO#UA7JJNEW=67J?M$C$IWJSKHNK?'KPJ3V1XGM,I$YWLGO
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MB'Q02H?+AW8T=H=YAP4.^HE6AKO81X\(FY+#+HTRF'NM@8N&E9>7'HH3DOV
M%XCHD+YH4X?FCKQ/6X<3C/\SG8;"C!T.%(@HB836Z8Y*IA7!T8QXHB:L)(K4
MGG.5THEHFPI^YH@RE^IG2X<^E2U.?89ODLPRV88<D<$-3H<EB/_5IXVQL,?
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MDW1@"[&[D95.Z*S6D"8\PZB2CVDHUZ5CD!L0!*7ABM0  (Q>@ "/Q\%0H&*
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M<'S#>HIWNWT[>Q9<]GW#>ZH_UGYX?%P;%G_1?0_P7'F0A._9.GH'@^C!<7J
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MFAM0.'WYEPLT7GXRE5\.>WZ B<K8\WWSN>K#R'V.M(&MVGT^KS&7/'T8JB"
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M?W<;?:Z2?ZL$EZQ)@'4  (,A@ ![<,?HB11M?<)SAYY?%[T1AF=0);?4A85
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MG-,<>*C@DT &AZ7KA&H  (,<@ !ZW,2=KSYM/K[AJY-?";DXJ%M0*K/,IC-
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MKGU0"G2.JDDT8W3]HR@.]'2?BAS6%7\.<;;!Y7\0<LJL]'\=<\^7'W\U=-&
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MM*"D=X5ZPYW!=^EIY)L1>%Y7_)B;>.=$W9:">7HOZI4J>>T5II;4>=P  (4
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M!:6*I+UKYZ'DH<Y;^)YBGR-+2ILYG3DYBIB9G*PE\Y;+F7(-2I<YB/P  (
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M!;)Q@[!BQJX]@O%3RJHX@F9#R::6@A0R<J.D@? >I*)B@A8&MJ%_@>0  (
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MT*\KJ59AA*K!IEU29*:"H^M"D**MHL,QE)^/G_,>=IW)E)D'H)O%A2@  (
M@ !RK\5(;-YEI<"L;;18';PY;I])T[?L;Y4Z=;0!<($I4[$T<2T4EK'I<+@
M *LI='L  (  @ !RHL1W='!EP[^Q=(M8.KL$=-5)\;:&=4 ZEK)V=;\IC:]_
M=B$5%:_$=;L #ZGI>.<  (  @ !RH\,Z>[AEJKYR>T58)KFU>OU)UK4D>O<Z
MB+$#>Q(IGJWR>S@5;JW>>P0 HZ?3?2X  (  @ !RE<'M@MIE@+TF@?A7Y[AJ
M@4))J+/2@,PZ9J^M@)8IG*R*@) 5KZPP@,P!(:7X@,0  (  @ !R=L#2B@ME
M7[P'B,A7P+=%A[9)=;*HAMHZ4:YSAE$IGJM'ADD5[:JOAI !D:15@0\  (
M@ !R4;_YD6AE2KL?C\M7LK9.CE1)9[&HC2(Z0:ULC%XIJ*HAC(46)ZE8BX,!
M\:+J@5   (  @ !R,+]0F--E/[IBEN!7KK5_E0I)8[#/DXTZ/ZR0DL(IMJDX
MDP<68*@MCR$"1Z&T@8H  (  @ !R$[[3H&!E/;G,GAI7L;35F^Y)9+ 6FCHZ
M.JO2F;8IMZA]F'D6A:=-CSH"C:"S@;H  (  @ !Q_KYVJ#9E0[E0I:)7N[1#
MHRA):Z]WH6LZ1:LIH%$IT*?*G$46J*:/CU("NI_S@=@  (  @ #9M7&!;*K%
M#G+7;C>OOW0;;[>9FW5)<2V"K'9K<J-JZW>*=!M2!7B@=8(V>GF@=L 2 GIY
M=JW7MV]7=][#<'#<>$>N27)!>+>82W./>32!='32>;YIQW8.>E%0ZW<T>M8U
M:'@A>SX0SGC">JW5XFV$@QW!I&\;@F>LM7"9@<*6S'( @4F ''->@.IHDW2R
M@)Q/V77E@$HT;':\?^\/P'=!?R+4&6OJCDJ_U6V.C)"J[F\9BO"5.G"7B75^
ML'(.B#%G5W-VAP1.S'2TA>(S@'5RA-L.UG7S@S#2>FJ4F6^^.VQ ELRI5&W6
ME#^3KF]>D=5]4G#BCY1F)7)>C9%-SG.DBZ@RI71'BA@.#G34AJC1)FF*I)V\
MZVLXH2.H FS/G:J286Y<FE%\'&_HERIE"G%HE#],XW*VD:8QX',_C\X-97/C
MB0[0%6BYK]2[W6IGJXJFZVOYIRN126V%HN=[&&\8GN9D)G"?FS-,&7'HE^\Q
M.G):EA0,V7,;B+#/1V@?NQ6[$&G+M@&F#&M3L,.07FS6JYAZ+VYJIL9C5V_X
MHFU+<'%#GL@PJG&7FY ,9W)YB&+.N6>\QF"Z@&EAP'VE86K:NF./G&Q-M&!Y
M;6W:KL]BIV]HJ>]*SG"NIE P&G#KG^X,#''WB"7*6GGD:XNW?7ID;4NCP7KF
M;NN/ GMH<'1Y57ON<?IBM7Q\<W]*TGT5=.XOX7W0=AX+.7]D=C?(Z7?H=CRV
M5WB1=N2BI'DM=X.-['G$>")X0GI=>,IAKWK_>7I)V7NB>AHN]7Q)>I *:WVQ
M>JC'978J@.2TKG;F@(>A''>5@"R,<WA#?^AV\GCU?[E@A7FM?YA(SWI:?W,N
M!WKE?T )MGPS?M;%TW2EBWJS"W5KBC.?>'8GB/*+ W;DA\1UHG>NAK]?7WAX
MA=!'U7DMA.\M,'F<A#0)&7KH@G?$6W-=EA.QEW0JD_:>!'3PD=F)EW6WC\UT
M97:)C>%>2'=FC"U&[7@@BITL;'ARB8H(DWG,A9/#)');H,*P8G,LG=><SG/R
MFMZ(:'2^E_1S2G67E3-=2W9TDJY&&W<TD(LKO7=KCWH((GC=A8#"*W&/JWZO
M9G)AI\R;S7,CH_F':'/NH#-R773/G*Q<?76QF79%:G9IEM$K+':'E5<'Q'@7
MA4#!;G#XMDVNI'''L=F:^G*!K3&&CG-$J)-QAW0FI$U;O741H(Q$SG7)G< J
MKG7'FB,'>'=VA0W \'"4P3:N%W%>O .:4G()MHF%UG*^L1YPU7.9K"M;'G2$
MJ A$.W4[I1 J*G4CG(('.W;VA.2[;H*4:IRJ,8(X;'B7ZX'Y;BJ$>8'1;[]O
M_(&Y<4U:<(&X<ME#@('==$<I!(*!=5,%/(.[=HVZ3("]=+.I$("-=8V6LX!E
M=E:#3X!+=Q=NY8!"=]U9<(!0>*9"DX!X>5HH+H#\><@$R((,>M*Y''\.?LVG
MPG[Y?K>5F'[??IR")'[8?H9MSW[<?H-8>7[X?HU!NG\G?I(G;G^.?GP$8H"1
M?I*WO'V4B-6F7'V&A^Z4#GU\AOZ R7V!AA5LD'V?A4Q787W,A)A S'W_@_8F
MJ'Y$@X0$"7](@=2V;7Q9DN&E"WQ0D3B2OWQ0CW]_A'Q=C<AK=WR C"U6:'R^
MBL<__GSTB9 E_WT8B08#OGXO@HBU57MBG0RC\WM>FJ.1J'M>F!Y^=7MNE9MJ
M>7N5DSQ5BGO/D1X_1GP)CW4E:'P/CP #?GU!@ERT=7J>ITFC#7J=I":0O'J9
MH-5]BGJGG8AIH'K4FG54SGL2E[\^K'L^E<8D['LJE" #27Q]@CFSS'H+L:"B
M6'H,K<:/^'G_J:]\PGH$I9EHW'HQH=U4&GIYGKH^&7JCG.0D?WIJF%(#'GO=
M@ARS7'FGO""ATGFGMYB/5GF-LKY\%'F#K>EH.7FHJ9=3C'GNID$]EWH:HWPD
M"WG-F%\"_'M>@@2LV(N]:=J<^8J :[N+_8E^;7!YP(BI;PAF:8?Q<)A1[(=B
M<B0[Z(<@<X4AL8?U=$X  (>!=R2K\XH"<V6<!XCX=%6*[H@,=3)XN8<_=@AE
M<8:-=N)1!X8&=[P[$87 >'@@]H9J>,<  (65>Q6J\(AJ?-N:U8=[?/F)V8:8
M?0MWG87:?2%D<84T?490*82X?74Z481R?9D@583T?9   (/F?HJIT8;VAEJ9
MI(8/A;>(D(4^A0!VBX2&A%-C>8/M@\-/7(-Y@TDYIH,X@N,?QH.8@K@  ()O
M@ "HI87#C]N8F(3@CHJ'@X07C2)U8H-GB[9B;X+6BF1.:X)UB4HXX8(RB&X?
M,H)FB'L  ($N@ "GJX37F7Z7EH/ZEWZ&@8,PE5QT;X* DS-AC('QD3!-JH&&
MCW@X18%%CE(>M8%8C=T  ( @@ "FXH0<HS*6R(-%H(B%K8)VG:QSF8'"FLI@
MQ($WF"9- (#-E?(WQX!VE+H>48!LDE<  (  @ "F2H./K0B6(X*^J;J$^('G
MIB9RX8$FHHQ@$H"7GU9,4X YG-DW-W_?F[4=^'^GE$0  (  @ "EXX,MMQJ5
MI()@LS.$7H%\KNMR/("IJJ!??( 0IN]+UW^OI'HVS7]8H7D=GG\-E <  (
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M (WBC!![^(Q>BNEK"(KVB;]9+8FUB+)&'(B^A]PQ68@7AU 7L(C&AU@  (
M@ ":4HZ@EE&+/XT&E)A[-XM^DL1J-8H4D/!87HC5CT9%;8?4C?$PRX<IC4T7
M28>LC 4  (  @ "9I(WOGX**AXQ:G3!Z>8K-FK5I>HE>F#U7K8@AE@I$U8<<
ME%LP7H97D_06_X:RCXT  (  @ "9'(UHJ,R)]8O8I>EYW(I$HLUHW(C)G[=7
M$H>(G0]$0(:+FTDOYH6]FBD6OH7ACV$  (  @ "8O8T(LE:)A(M[KO%Y5HG<
MJSEH3HA2IY!6D8<&I)1#U88$HO8OAH4XGQT6:X5(CR@  (  @ "0V)[A:,R"
MUYQ,:HUSWYH";#1CQ)?O;<52AY8+;TD_[)2&<+$K2I/H<;,0;);><2\  (
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M%Y9XD<MP 90\D$!@"I(?CKI/,Y SC6 ])8Z?C&HI(HVVC%T/BX[ B9$  (
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MWJ36<4=GK:'G<BQ8@9\G<Q9(,)RK<_XV9YK#=,LB*YI'=1X(@)MT=3$  (
M@ ""EJ:6>&AU/Z.(>*)G(J"3>.57[YW2>3U'L)M4>: V )EG>?XAZYC,>A4(
MG9EG>J<  (  @ "" *5"@%!TD*(Z@ !F7Y].?[973IR,?X)'')H8?VDUBY@I
M?U\AH9=U?U@(KI>+?Y,  (  @ "!9*0EB$=S\*$DAWAEM9X\AJU6GYMYA?%&
MEICZA5PU&Y</A0(A6I9"A10(O)7?@]$  (  @ " V*-+D%]S:*!.CQEE+IUA
MC<M6%9J8C(]&$Y@2BX@TR)8'BO$A*Y4DBV((S)1@A?,  (  @ " ;:*0F(=R
M]Y^9ELYDN)RHE0)5G9G:DTU%II=1D?(T=Y4\D5LA%90>D.@(XI,.A@(  (
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M8*W8=QM< JI'=V!-H*;K=\,^**/L>"TM$*''>(08[J'I>%0"7IWY>E@  (
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ML:DMFSM:,J6&F59+V*(&EZ,\E)[LEK4KZYR3EG88NYO&D+D#B993@F0  (
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M8;=F?!Y0A[-=>^E"\J]W>]XT+:P4>_ CDZGR>_@/9ZKB>]@  )MH?Z$  (
M@ !I>KHQ@W]=-;8C@MI05K(5@DM"M*XK@=<T%*JW@9HCE*B%@9X/J:DP@:X
M )IL@    (  @ !I3KD\BKM='K4<B<E01+$ B-Q"GJT-B! S_*F1AY(CG:<Z
MA\ /YJ>KAK@  )F0@    (  @ !I*;A_D?Y=%+1'D,A0/[ 8CX)"E*P;CFPS
M\:B;C>$CIZ8RCD40(J99BND  )C?@    (  @ !I#;?SF5E=%[.>E^901*]9
MEE5"DJM-E0@SY*?'E+8CG*5>D\P0/Z59BOP  )A(@    (  @ !H^K>/H.M=
M([,3GTE04:ZUG7Q"EJJ;G"4SZ:<+FVXCL:24F"(05J2#BPP  )>R@    (
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M9H&(=XN!78$[>"MP$H$#>,!=P(#>>55*.(#7>>0U!8#S>D\;-X&:>BP  (
M?CJ?9H 9@"60,W_=@"* %W^G@ -O$W]Y?]Y<VW]D?\))@']F?ZTT>']^?Y0:
MRG_A?U<  (  @ ">.WZPB7V/)'Y]B,]_!WY0A_]MY'XKAQU;UGX>ADI(D7XR
MA9DSLGY"A0T:.7Y9A0P  (  @ "=1'V0DNZ.)'UED95^"GTZD ]L\GT9CG=:
M]7T.C/A'UWT9B[$S''TDBMT9QWS[BF8  (  @ "<?7RJG&>-67R&FFE]/7Q7
MF"YL)GPTE>1:-'PND\E'-'PXD@HRI7PKD289<7O'CMD  (  @ ";Y7O[I?.,
MMGO<HU5\CGNGH&MK=WMYG7)9B7MQFLE&CWN#F,,R'WMME_D9('K$D/T  (
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M"XBR?B1T\H?!?C5DZH;B?CM3J88N?D=!+H6I?E4LRX5V?E02N8:@?@8  (
M@ "1,(A,ALR##X=3AE=S_(9KA<-C]862A1U2]839A(% G(1<A PL6X0@@[\2
M=X3H@X8  (  @ "05X<[C[Z"5(9*CK)S0X5@C7=C(H2%C"=2)(/,BO _\H-$
MB@ KTH+]B9X2'X-GB#H  (  @ "/J(9BF+6!FH5XEQ=RA82)E3EB9X.IDT91
M;8+RD8H_58)ED$(K;X'[D!T1Y8(>C!D  (  @ "/((6\H;Z!"839GY9QZ8/A
MG1MAS(+TFHM0U8(WF%H^N8&REO0J\($ZED81LH$1B_<  (  @ ".OH5%JO>
MEX1EJ%=Q8X-BI45A/X)BHB%06(&7GY@^5H$*GF4JFX".FS41<8!%B\L  (
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M*I"QA =H^(\8@Z%9QHV:@S%)J(Q!@LDX!8M1@H<D.(K^@F<*[8KQ@>X  (
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M$Z F9)5@JYWN9J!2()OG:(I"6)H>:DXPXIC^:\,<@9G!;#\#WYBA;+X  (
M?]!Y_*%!:GMMH)[,:^)@-)Q_;4%1N9I=;I5" 9B ;](PHY=*<-0<9I?/<0<$
M()80<=(  (  @ !Y:Y^B<EAL[IU"<R%?G9KT<^91(9C1=*Q!@I;R=6@P1)6Q
M=?X<-I8%=?L$4I/%=TT  (  @ !XQ)X0>AUL,IN[>F%>S9EX>IQ0?)=8>MQ
M[)6!>QTOTY0\>T\;]Y1G>S$$=)' ?$P  (  @ !X&YR_@>]KB)IR@;E>'I@U
M@79/R)83@2U :)0T@/@O9)+O@-P;M9+U@-@$CH_]@)T  (  @ !WAINZB=]J
M^IESB3A=DY<PB'5/.I4)AZT_XI,BAP<O&9&YAK$;CY&=AQ8$J(YV@R8  (
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MNJD;:H]4_:9&:^%'0*.@;2HX-Z%@;E,G/Z Q;QL2<:(M;HH  )<M<VD  (
M@ !M%ZJ!<+-A.:>3<7-4F*2T<C=&WJ(#<P$W[9^Y<[HG&YYR="X2DJ 3<Y@
M )6@>#   (  @ !LH:CJ> A@KZ8#>%-3_:,L>)Q&:J!Z>.\WB9XS>4$FW9S<
M>6P2EYXR>/4  )0P?&,  (  @ !L**>0?VQ@.*2O?U!3@:'9?RM%XY\F?P0W
M,9S0?O0FG9MP?O(2DIR&?N,  )+H@    (  @ !KO::'AO)?V:.EAG=3):#'
MA>1%A9X+A5 VV)NKA.4F;YHHA-42DIL#A+@  )'&@    (  @ !K9*6WCGU?
MD:+2C:]2WY_GC+)%.IT>B[LVAIJ\BQLF.YDEBTH2I9FHB:$  )#;@    (
M@ !K)*4/EA!?5*(FE/52G)\SDY]$\YQ?DEDV0)GTD;,EZ9AAD;P2@IBMC(,
M ) G@    (  @ !J\*2AG>-?5J&DG*A2F9Z8FO=$V)NBF58V,YD7F,\E_)=J
MEN<2JI>IC)X "X^*@ @  (  @ !AL[A\8(E5]+5\8E))H;*09!@\8:_#9<,M
MNZV,9R4<DJU$9[@(7*ZD9VL  )-8<M@  (  @ !A,+>19]M5Q[1/:0))DK$5
M:C@\;ZX+:V8MY:N?;&0<\*L*;+H(\:P);&D  )(7=VX  (  @ !@ZK8+;NQ5
M=[*_;Y))7:]R<$4\0ZQ1<0<MUJG.<:<=%*D%<<D)7*FE<9T  )#A>X   (
M@ !@JK1D==A5);$:=AE(_:W0=F$\!*JK=KHMJJ@@=PL=%Z<R=P8)J*=Z=S@
M (^_?Q8  (  @ !@:++U?-)4Z:^L?+](OJQ=?*T[N:DT?)PMCJ:5?*(=&:6.
M?)D)ZJ6(?1D  ([!@    (  @ !@+K':@_%4QZZ!@Y=(HZLD@RH[FZ?Q@L$M
M;Z5(@H,=):00@J *)Z/,@CD  (WC@    (  @ !?_;#\BQ14M:V-BGU(F*H?
MB;P[BZ;AB0@M7:0QB+8=*Z+>B2 *9:)*AH@  (TS@    (  @ !?V;!7DD94
MLJS+D7Y(F*E(D'8[A:7YCXDM2Z-!CV4=&*'LCKP*?*$?AQ<  (R<@    (
M@ !?P:_=F:!4NZPLF+U(HZB1EX$[AZ4TEH0M4J)MEBT=,Z$!DTX*DJ BAR8
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M>G>O8;J&-'A<9'1TIWD49OMA\'G3:6=.!GJ;:[<XBWMF;;\>RWP[;M,  (
M<F"D>'1Y:(V56G54:HZ% 78E;&ESBW;V;B=@[G?+;]5-(GBC<6PWPWEF<L<>
M*'G8<U$  (  =P6C-G(7<E"4 G,?<VZ#Y'0.='1R:'3X=69?['7@=E-,1G;'
M=S8W$7>%=^T=G7>2> <  (  >QBAQ&_U>_>2C7$7?$^"6'(??(QQ&7,>?+E>
MN'0E?.E+/'4>?1@V-775?38<\W5W?0,  (  ?J*@;&XFA9R1.&]:A3N!"'!U
MA+=OU'&#A!]=M'*4@Y!*57.?@Q<U?'1-@JT<:G.%@F\  (  @ "?4&ROCU:0
M(&WOCCY_^&\3C/=NS7 LBYU<O7%%BE5)C7),B38TVW+RB&,;[W'+B$L  (
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M1GTY::1Z 7UD:X=ID7V<;4U7[7WC;OY$^WY!<(\P.7Z]<<D6-G^S<;L  (
M>F>6.7K7<+Z( 7L@<@%XY7MB<R=H>'NP=#=6^GP(=3I$+WQP=BDOEWS;=M@5
MQ7U(=H4  (  ??.5!7C$>>>&O'DJ>G)WEWF%>MMG>7GA>SE6$'I.>XY#<7K
M>]PO"7L;? H59GL=>Z8  (  @ "3TW<'@PZ%KG=_@O-VA'?J@K!F37A2@E)5
M'WC'@?M"EGE(@;0N5WF2@784Z7E-@5,  (  @ "2U'6DC$N$J78FBX=UA':7
MBI%E6'<&B8-4.G=^B(-!X'?VAZXMQG@PART4@7?&AJ8  (  @ "2!W2"E8F#
MVW4,E"-TMW5]DGQDD77ND,%3?79LCRE!07;BC>$M6G;\C5,4.79^BQ8  (
M@ "1:G.@GLR#-W0PG,IT"W2>FGACYW4(F!-2UW6&E?- H78 E&8LVG8'D_X3
M]75WC7X  (  @ "0_7+]J!R"NG./I8IS?7/THI-C5711GX]24W3&G/U ,W4Y
MFVHL;'4SF8P3BW2TC3<  (  @ "++(A^7?!^$8>M8,=OTX<=8VI@1X:X9=M/
M=(9Q:"<]*X9F:CLHO(;M:[D.!HC^:T<  (  >=.*488T9JU].H6D:+5N[(4M
M:II?<X3.;&).NH2*;@\\CX1\;X\H0(3?<(\-UX9);_4  (  ?5B)7H0';U-\
M'8.D<*-M[8-"<=M>=X+S<OI-WX*[= L[V(*Q=/HGLX+W=8<-GH/G=.\  (
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MYWS[F41IL'RWEU]:>7QOE6)*27Q&D[(XTWPTDK$E@GOFDDH,RWPGB*8  (
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M1(KN=JIAWHGY=U13A8D3=_%#UXA=>'LRHX?V>.<>W8A&>.T&?(>2>;\  (
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M4H6^G<M>ZH2XF\90@H.EF:)!-H+"F"4PAH(FE[8=@8&OD_,&?8$4A&,  (
M@ !QKYO87+)E\9GW7T)9.YA@8;1+3I;\8_L\"I7:9@<JXI5]9YX6+I>%9\<
M ),-:;\  (  ?TIP]YH.9(QE9YA'9F]8M):B:$!*X94C:?@[MI/J:X,JKY-N
M;*L6,)47;)0 +Y"^;K8  (  @ !P3Y@3;$)DHI9J;8Y8#I3+;LQ*/Y--;_L[
M-)(1<0DJ5I&"<<H6%9+<<84 <XYP=#,  (  @ !ODY8Q<^-CT926=*U7*Y,'
M=65)C9&/=A(ZF9!;=J@IY8_!=PD5WI#9=JT HHQK>40  (  @ !NUY2;>Y!C
M%Y,,>^)6<9&"?!U(T) )?$,Z$H[/?&<I=8XQ?'P5G(\.?#H PXJJ?:8  (
M@ !N,I-;@UIB?)'6@SY5W)!(@OM(.X[*@J$YA(V&@E8I,(R^@C<5=HUD@F@
MX(DG@)<  (  @ !MK))/BR=A]9#5BJ%55(]%B>1'LXV_B14Y!HQVB'8HSXN=
MB%$5=8OCB 0! X??@*\  (  @ !M0I&+DPIAL9 7DC55$HYYD0%':8S3C[$X
MO(MTCM,H<(J>CP05&8K'C* !&H;1@+X  (  @ !L[Y#XFPYA7X]]F?A4N8W4
MF%]'$(P@EK$X<HJQE=$H.8G%E2<4_(G)CC !)X8#@,@  (  @ !E8J976[!:
M$J0?7A5-\*(C8&5 JZ!;8HTQ\I\%9&@@YY\398H+^Z&[91H  (V4;=(  (
M@ !DLZ3,8R=9IJ*.9/%-DZ!M9K! ;)Y[:%8QTIS_:;\@\YS5:HH,3Y[Z:?T
M (O[<LP  (  @ !D*Z+H:G59#*"X:[A-&9Z4;/$_^)R:;AXQ?YL1;QH@T)K!
M;Y4,?9QL;P8  (I[=Z(  (  @ !CG:$'<:M8:Y[B<GI,:)S)<SP_=9K1<_4Q
M$9E(=(T@D)C>=,,,CIH9=%4  (D4>^4  (  @ !C#I]N>/!7X9U3>5A+WIL[
M>:T^XYD_>>PPM)>I>B<@39<M>C$,CI@!>BH  (?1?YP  (  @ !BD)XL@%97
M<9P6@&%+=9GX@$@^?)?S@!HP599.?_H@)96B?_@,E98>@!$  (:T@    (
M@ !B)ITMA[]7&9L8AWE+))CPAO@^*);<AF8O^I4RA@X?YI1MAD0,K)1TA0T
M (7.@    (  @ !AU9Q>CRM6S)I*CIM*TY@<C;X]V)7]C-LOKI1$C'8?BY-^
MC*\,B9,EB'H  (4A@    (  @ !AE9O+ELU6OYFNEB1*Q9=LE.\]O94HDZPO
MJY-*DV<?L9);D>\,OY'LB)\  (2<@    (  @ !9([&M6F1.&J]27(U"9*T9
M7JHUG*L88)XG+*GC8B,5DZMA8F@#1:FV8UH  (CG<?T  (  @ !8<+!G87U-
MNJWB8QM"(ZMJ9+DU?ZDN9CHG.J>]9V 5ZJC/9W #TJ:_:%$  (>@=K(  (
M@ !8"*Z2:&A-2JP+:9!!T*F):K0U.*<X:\XG&*6L;)H6"J9S;'P$.:/S;7@
M (9G>MT  (  @ !7KJRG;SI,WZHF;_U!5Z>H<+DTYZ55<6TFWZ.\<>P6"J1.
M<:L$A*%<<OP  (5!?HH  (  @ !74JK]=AQ,BJB"=HI!!*7_=NHTBJ.F=S,F
MNJ'U=VT6":)==RD$PI\&>.$  (0^@    (  @ !6_ZFM?2-,4*<J?4I U:2=
M?4XT7J(W?3\FDJ!T?3,6&Z"7?18$_YSO?A8  (->@    (  @ !6NJB@A"U,
M*:82A!9 N:-U@\<T0:$"@VPF=)\T@T<6'9\M@X<%/ILA@GH  (*M@    (
M@ !6A:?2BT-,$Z4RBOU JJ*#BF<T,I_^B<\F79XAB<H5_YX1B38%39FK@Y8
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M9V>F?SQX,VE>?T9G^&KY?SE6QFR(?RQ$.6WM?R@P&FZ>?QX74FX&?O   (
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M)WE27 ERMWGA7RAB_GJ$8A-2 7LQ9-0_G7OO9UXK/'S%:5L0WGY0:6   (
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M1VWCA7IM#F[_A0Q=QW )A()-?W$'@_\[XW';@YDH6W'_@V4/6G.A@OH  (
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M:'[*8U]FU'[M9;58%W\>9^=("W]@:?(V<'_*:[DB9X"$;,D(WX'I;)H  (
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M9G40BMYB#'6)BA!3I77QB2A$-'98B%TS7':@A]D@2G8[B \(<GC8A54  (
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MK(4^:;-;"X3I:V9-(X2A;/D]^(1X;F0M!X2A;WT9 (69;Z "3H43<38  (
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MUWTOCW)717T CF=)JGRUC3PZ]7Q\C& JI'Q1C#P7D'NTBUL"GWUJ@<8  (
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M7HR>;O]/8HO)<"I"98L%<3PS[(J <B C;XJ8<IT/-XO/<@X  (*\>)H  (
M@ !EKXM]=4Q:EHJ\=A5.FXGQ=L)!GHDN=U S9HB?=\@C XBB=_T/#(E3=Y0
M (%.?.4  (  @ !D]XGB?/!9[HDP?4M. (AG?7M!"8>??8TRWH<$?9DBV8;,
M?:,/"X<2?;4  ( ;@    (  @ !D6HB(A(M94H?FA'=-:(<@A"] =H94@] R
M6H6P@XHB@(58@XD/,X4A@T<  (  @    (  @ !CWH> C$59#8;OB^5-+X8?
MBR1 /X4LBCLR+X1GB; B-H0&B@$.Y8.@A_(  (  @    (  @ !C?(:QE!E8
MK88ADWQ,RX5-DE,_X81/D08QXX-SD&XB H+MD"H.VX)=B@L  (  @    (
M@ !<X)[Q5=]20IU96)]&P)P(6T4Y^9K[7;@KB9I]7[X:29O-8+@&A)Q*800
M (.C;4D  (  @ !<!IS=71U1K)M97U5&-YGT87DYE9C 8W(K49@490P:4)D1
M9;0&WYC=9>,  ((0<C$  (  @ !;7YJ%9$-0]9D;9?Q%GY>]9Z(Y!9:$:28J
MZI7%:E8:)I:':K4'%Y6<:N0  ("7=Q0  (  @ !:MIA :UI0.);G;)Y$T967
M;<XX:I1A;N,J:I.?;[$9W90S;\X'+I*Q<",  (  >V4  (  @ !:#)9,<H%/
MDI4$<UM$,).W=!PWQI)\=+<J I&K=2T9E)(<=2$',9 J==X  (  ?RX  (
M@ !9<Y2W><A/!I-]>D-#L9(N>I4W49#I>L,IF) $>M\9<9 M>LP'.XWX>]$
M (  @    (  @ !8\)-K@1-.EI(^@3M#3)#J@2,V[8^7@.PI+HZE@,X9((ZI
M@.L'4(P<@.   (  @    (  @ !8B))<B&!.+Y$ZB#M"YX_FA\0VD(Z&AS8H
MW(U^AP88MXUSAT<'*XJCA-D  (  @    (  @ !8-Y&.C^5."9!RCZ-"PX\5
MCLXV;XV0C=LHXHQ7C<(8^8P(C*$'<HE4A0D  (  @    (  @ !0IJIA5$U&
M8JB85M([3:<-63TN[*7D6VD@AJ797/<.EZBC70@  * (8'P  (  <2X  (
M@ !/QJB46RI%Q*;,73<ZOZ4>7S(NA:/!8/<@6Z-M8BL.QZ6R8@<  )UL914
M (  =?@  (  @ !//:938>]%+:268XXZ0:+K91@N$:%^9GD@$Z$'9U8.T:+A
M9PH  )K>:>X  (  >CP  (  @ !.QZ0+:*=$HZ)9:=XYI*"V:P$MH9]);  ?
MP)Z_;)$.QJ _;"@  )AW;RL  (  ??\  (  @ !.2Z(+;W%$*Z!K<$XY,Y[%
M<1$M*YU,<:0?C)RE<?8.P)W9<8X -98 =0D  (  @    (  @ !-UZ!J=F!#
MRI[3=O XY)TH=U4LZYN>=Y$?6)K7=YP.V)NI=UX <9/:>E0  (  @    (
M@ !-<Y\3?55#?YV#?:(XJYO/?; LMYHW?9X?)IE=?8P.T9GE?;4 L)()?LX
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MGEU#:69\3U_U:UQKS&)^;3Q:/&3B;PE'=V;[<+PS*V@M<BX:NF>1<L\  (
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M>U%MED1VB%3%E$EFD5?;DE)5G5JWD)-#C%SZCRTP+%UXCGP8N5\YC.T  (
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M4V%H<-=P_F.K<B5AH67&<UA0_F?#='@_&VEC=8 K<6GK=D42DFQ'=@P  (
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MJE>]FY]L@EIGF59=7ES2EPA-15\#E18[^F"/D],I"5_ODV@1)&7OBY<  (
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M2&9S=V-EW&@^>")78&G=>,%'SVM:>50VI&QX>=,C;6PY>A4+"G&;>F4  (
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M!'IB5H]@#7L 6?91UWNP72E"1WQH8!\P_WU!8JX<XGYL9",$A(#I9.T  (
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M;VR/?1-:VFW/?5I-,F[B?7X^:F_.?9PN '!2?;T:X6^(?<($F'@\?H(  (
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MD'_!72%49H '7]!'$(!58E,X0X"Y9) G=(%K9D02UX+[9E\  ($):F(  (
M?S9JA'Q38B-?;WS+9%Y3=GTR9GQ&+GV0:&XWBWWX:B<FZGZ*:V<2E'^):S\
M (  ;WH  (  @ !I;7EF:?A>3GH$:Z%247J%;2U%2WKW;I@VOWMH;\XF3'O;
M<*$2.7R/<$@  (  =/X  (  @ !H8W;5<=-=5'>0<O5177@E<_5$47BB=-$V
M(WD+=8TER'E@=@,1]7GX=9X  (  >>(  (  @ !G<W2@><5<<'5X>F)0B'8>
M>M5#FG:=>R4U?W;_>V0E?7<?>Y(1UW>Y>V   (  ?@D  (  @ !FKG+(@;-;
MRW.]@=M/]G1K@<5#"W3C@8PTZ74Y@6,D]W4O@601J77:@8D  (  @    (
M@ !F$G%)B9I;-')-B55/8G,!B+U"@G-TB 4T9W.[AXLD<G.)AYL12W1JAL$
M (  @    (  @ !EF' 6D89:OG$HD.I.ZW'@C]M"$W)+CK,T"W)^C@(D+W(A
MCC81$7,_BO   (  @    (  @ !@IHQO49A6!XOM5-Q*=XNI5_T]G(N56N0O
M&HO7764>"(TI7OH)@(YJ7RD  (  :6D  (  ?G!?CXE26/Y5*XD16[M)JHC>
M7E4\]8C$8+PNH8CN8L8=R8GY8_@)I(JH8_T  (  ;BD  (  @ !>GX9!8&-4
M+88Q8IA(UX879*\\+X8$9I8N!88D:"D=8H;U:/T)HX=1:.L  (  <V0  (
M@ !=L(-H9\E3,H-W:7I'U8-Q:PT[9X-J;'HM58.);9P<XX0D;A@)AH1G;@P
M (  >%L  (  @ !<QH#H;SU23H$2<'%&]($<<84ZBX$5<F\LP($G<RT<9X&.
M<V,)88'C<XH  (  ?*P  (  @ !;]'['=L11B'\*=X5&/7\?>!PYW7\7>(XL
M(W\4>.(<)7\H>/$)6G^T>9D  (  @    (  @ !;/'SP?CU0UWU/?I)%F7UO
M?K0Y1WUD?K<KFWU/?KH;T7TD?L0)C7W2?S,  (  @    (  @ !:K'MYA<M0
M='OYA<Y%1GP;A7@Y!GOQA/TK;WNVA,,;C7M:A1L)4GQ<@]\  (  @    (
M@ !:.WI*C6Q0!7K7C2M$V7K_C&TXIWK-BY(K)WIUBT@;8GG9BS()3'LJADD
M (  @    (  @ !4I9;<4#U*C)7Q4U4_B95/5DHS)I4"6/HDSY5W6Q82[YA2
M6Z@!@I2E78T  (  ;10  (  @ !3GI/]5S])O)-$6> ^Q9*G7%TRB))$7ILD
M9Y*(8$\2V)3G8)D!U)$*8FD  (  <?@  (  @ !2RY$,7C](W)!Y8&<^"H_L
M8FTQV(^'9#DCY(^O98<2FY&D98X"!HW+9V<  (  =N0  (  @ !2 (Y"94!(
M!HW(9O$]*(U+:($Q+XSI:>$C5(T!:M 22HZ3:IT"'XKP;*0  (  >SP  (
M@ !1.8O(;%5'1(MI;98\:XKW;K4P=(J/;YXBXXJ*<#T1_HN^;^8"+8AX<EH
M (  ?P8  (  @ !0@HFK<X!&F8EG=%P[THC]=0TOZHB,=8\B:8AH==<1XHD?
M=8@"1895>$H  (  @    (  @ !/XH?B>JE&#(>X>RT[6(=4>W4O@(;5>Y<B
M!(:3>Z81J(;E>XL"<(2"?5<  (  @    (  @ !/8(9C@<1%B(92@? ZV(7V
M@=<O#(5P@:<AFX41@:81+X48@<,"88,1@74  (  @    (  @ !.^(4TB3-%
M6H5&B4 ZN83SB+TO$(0XB!0A[8.#B!H1Y(,=AR0"UX&T@>P  (  @    (
M@ !(6*)Q3E\^WZ$\44(T::!G4_8H6: H5DX9PZ%S5[\(HZ,;6&4  )&47^0
M (  <'H  (  @ !'1Y_F5/X]^)[L5W<S>)X:6<4GCYVO6[P919ZA7-@(IY]S
M75D  ([<9'X  (  =5$  (  @ !&FYT-6YT]-)PM7:PRPIMO7XXFVYKY8208
MPYN]8>H(EYO.8E   (Q#:5$  (  >:D  (  @ !&!YH\8CH\A)EO8]PQ]IB\
M958F0)A'9HL81YCM9P8(@)A,9U\  (G>;GP  (  ?8   (  @ !%9)>X:.@[
MW9<,:BDQ7I98:T EJ)72; H7^Y9,;$L(=94/;*\  (?&="\  (  @    (
M@ !$Q963;[X[2I4*<*<PY)1;<5\E3).^<=,7N)0 <= (DI(I<F0  (80>6<
M (  @    (  @ !$.Y/"=IPZSY-:=SDP@I*N=Y8D^)(!=[P7:)(>=YD(@H_2
M>)L  (2R?<H  (  @    (  @ !#R9)!?9 Z;9'V?>TP,I%/??@DPY"(?=H7
M0I!S?<@(4HWP?G@  (-%@    (  @    (  @ !#@)$$A,8Z)9#.A/0O\9 R
MA+,DF8]9A&472H\%A(<(A8Q9@U@  ()Q@    (  @    (  @ ">^U/53=6/
MR%<(4AV !%HB5E!O7%TL6F-=I6 97E%*OV*U8A$V<61C98$>7V.69_0!>WV
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MU5B[6OYU+5NV7DIE?UZ-8794HV$Q9'A"@&-J9THNN61=:;<63F9@:MH  (
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M?D<&APUNETM$AFU?GD\>A<U/E%)^A4,^6%34A-\KFU1,A,0455VBA/H  (
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MM%M;8M]J+5X<96-;7&"C9\5+:6+H:@,Z"V2A; TFN622;9D.$VN';<4  (
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MTDP*C,-DJD^VB[)6=U+XBIQ')U6JB;@VA%<*B2LD-U;"B6(-)6G(AS8  (
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MFE[::;Y>Y&%$:Y=1.V-R;5A"%V5+;NLQ;69E<$4>6&7><0$'#G03<<X  (
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M+5'MD:):L%3UD$M-+U>"CN(^F%EAC=(NBEF4C7D<0%N>C1D&G733A'D  (
M@ !PT7%S3>)E!G*34:18>'/-555*T74&6-X[S78M7" JYW=#7MD6G7@P8!8
MIW[F8EH  (  >-IO#VSK5=QCNVYJ61-77V_<7"Y)Z7$V7R$[#7)J8= J4G-:
M9 ,60W0)9-< SGZD9R$  (  ?(1MEFBG7?=B4FIX8)%6-FPC8Q%(V&V=96DZ
M)F[=9X@IFF^?:3<5QW!]::T X'Z&;"H  (  ?[QL-62T9A=@^&;$:!)4XFB<
M:?='WFHV:[TY1FN$;4TH\&P1;H(576UN;JD \WYE<98  (  @ !JXV$C;D9?
MN&-F;Z13NV5D<.U&RF<7<A8XHVAN<R(H;6C#<^<5&VK)<]H!$WXN=QX  (
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MW'JX4/A.!WN(5()! WQD5]TR='U,6MLAE'Z 70T,S("@77@  (  99T  (
M>[1C177"5-]8J';!6 ),_7>Z6P5 *GBD7=@QR'F"8%,A''IG8A$,M'RL8CT
M (  :D@  (  ?O1A\7&G7(-777+N7Q=+[G0289 _+W4/8]<P^G7F9= @@79X
M9QX,?'E!9QH  (  ;U8  (  @ !@L&W59#)6&V]19C1*L'"7:!T^-W&L:=\P
M'G)^:UD?U7*S;#\,,'98;"   (  =-$  (  @ !?A&I<:^A5 VP$;5])I&UI
M;KP]+&Z+;_,O>&]/</D?2V\=<8@+_G/0<6X  (  >;(  (  @ !>=F=&<[)4
M!FD9=*1(OFJ<=70\:FO'=B(NSVQT=K ? VO;=OT+]'&9=Q\  (  ?=,  (
M@ !=F&23>WA32V:5>_-(&V@S?#H[TFE??&(N,VGH?(L>>FD=?*P+UV_"?3T
M (  @    (  @ !<YV)*@S)2I&1M@T%'?68A@P<[0V=,@K,MJV>S@HH=[&;J
M@K<+BFY<@GL  (  @    (  @ !<8F!MBNQ2)F*JBJ5&_V1NB?4ZS&65B2TM
M2V78B,P=J&4FB2H+66T^AJH  (  @    (  @ !8\X-<3&!.JX.63]U#A(0$
M4SXW"H2:5F$HO(6 60(75H>)6EP$<8?56Z(  (  :34  (  ?AI7>'].4WQ-
MA'_55HI">8!@67$V+(#Q7!LH$X&Q7DD6\8,S7T,$C80(8&X  (  ;?$  (
M@ !62'M:6K-,5'P?74!!>WS)7ZHU/GU?8=<G4WX"8Y$6:W[[9"\$BH"V958
M (  <R0  (  @ !5*W>B8?5+,7B28_U 5GE59>0T6'GW9YHFB'I_:.85TWKX
M:2\$<WW<:F\  (  >"   (  @ !4&G0Y:4=**752:LX_578O;#8S8G;0;6PE
MXG<W;E@51W>$;EX$6GMI;^,  (  ?'(  (  @ !3)G$L<*M)0W)O<;L^A'-D
M<J8RH70&<V<E-W0]<^L5!72'<],$8GE#==\  (  @    (  @ !246YW> I(
M<V_G>*D]Q'#V>1HQ]7&6>6LDH7&;>9\4HG(F>8 $D'A*>W,  (  @    (
M@ !1IFPG?W1'[VW,?[@]6&[W?[$QJ&^)?XTD96]2?XD40G Z?[ $7'BB@"<
M (  @    (  @ !1)6H_AO)';VP!AND\W&U!AG@Q.6W.A?,D$6UDA=L4$&ZD
MA;@$47BU@NL  (  @    (  @ !,[XV@2M=#8(UJ3C8XU8V#46DLO8W_5$0>
M58]?5E<,@)'=5O8  (F*7#0  (  ;*T  (  @ !+DXG+491".(GF5(LWM8H7
M5U KQ8I_6;X=F8N86VP,.8T56]8  (9.8-\  (  <8X  (  @ !*A87Z6&=!
M'(9+6NDVO(:473PJUX;S7SL<W(?48(0+Y(B>8+\  (-49;H  (  =H@  (
M@ !)C8)47T= %X+(84\UJX,C8RLJ 8.!9+\<((0Q9:L+B(2W9<(  ("J:MX
M (  >NL  (  @ !(FW[Q9CP_)W^/9\XTPG_^:3<I'H!/:E<;E8#!:O@+.X%@
M:OT  (  <'D  (  ?KX  (  @ !'NGOB;4P^37RP;G S_GTV;V@H<7U]<"(:
M^WVF<&P+$WZ&<(<  (  =E4  (  @    (  @ !&^'DQ=%T]E7HM=1TS7'K+
M=:<GYGL%=@,:<GKG=A,*U'PV=FP  (  >T<  (  @    (  @ !&3W;0>VP\
MZW@#>] RO7B\>_@G77CM?  9^GB$>_L*;7IO?*T  (  ?W@  (  @    (
M@ !%TW3;@KP\AW9$@N R;W<@@I\G.G<Y@DL:)'9R@EL*SGBU@@8  (  @
M (  @    (  @ ! F9E%2*LWLIBM2^4MHYB43M0AJIE143L2>9PR4E,#4IF^
M5&   (2R7XH  (  < T  (  @  _-Y6\3P0V5)6.4=DL+)695&(@2Y9 5F81
M;IBA5R\#"94563\  (&N9$   (  =0$  (  @  ^09(657@U.I(95^$K'I(^
M6@(?.I+76Z 0H)3#7!\"TI#/7BX  (  :2,  (  >70  (  @  ];XY]6_TT
M4(Z?7?8J&([57ZD>9X]D8.@/_Y#782H"JHT&8SH  (  ;E8  (  ?5@  (
M@  \FHL48IHS=(MI9"8I1(NM970=F8PB9DL/IXT09F<"F8G%:(<  (  = 0
M (  @    (  @  [RX?R:5TRIHB':H$HD(CE:VL=!HE":_$//XFD:]8"IH<#
M;C   (  >3L  (  @    (  @  [%84I<"DQ](7^<.\G^(9W<7D<C8:_<;0.
MYX:N<88"EH3%=%,  (  ?9@  (  @    (  @  Z?(*[=PHQ78//=WPG=H1E
M=ZX<+H27=Z@.HX1)=Y(";H,">BL  (  @    (  @    (  @  Z#8"J?B<P
MYX'V?D\G"X*L?C$;XX+,?@$.D8)<?BX"B8&(?O\  (  @    (  @    (
M@    /__  #__P  __\  &UF=#(     ! ,)   !
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MA\1]PL"?AL-]<*F,A>9]59)2A2I]=7L'A(9]QF/$@_%^-4R/@WA^Z362@RB
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MD!%]_RG0BQQ_Q*]<K5*"9I[4J-F!@HX&I(2 T'S^H%" 6FN_G#* (EI]F ^
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M@>)\[#-\@@1^=>#A@HZ"J<Q<@A>!YK<2@;.!/Z$H@66 P8KI@2N :W2@@0F
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MDH-^V)Z$D&U^DXNVCGI^<GB%C*)^>64UBME^I5(4B0]^YS\[AT=_6RTKA72
M#,%9DZ*(?Z^BD6^'0)U[CUJ&$HJOC7>%&W>6B["$1&1EB?R#BE%HB$:"US[!
MAI2"-BSTA->!G<!%DI.1V*Y\D&R/NIQ+CF6-JHFGC'V+QW:>BLR*#6.1B2F(
M8E#"AX>&KSY0A>^$\BS%A$N#$+\GD;Z;)JUTCYB8,9L\C9>548B+B\"2B76H
MB@Z/UV+%B("--5 IANV*=CWMA62'D"R<@]*$8KXGD1ND<ZQVCOB@JYI"C/B<
MZ(>ABR69-737B7B5BV(2A^>1W$^FAF*.#CV9A.N)_BQY@VN%CKU.D)BMKJNE
MCGBI#9ESC':D8(;:BJ2?MG0HB/Z;$F&%AW.66$\YA>F1;#U5A(*,-2Q<@Q6&
MDKR?D#&VV:KZCA.Q5YC#C!"KM88MBCFF!W.(B):@6F#_AQ>:E$[;A924CCT;
MA"R.+BQ%@LZ'<+P9C]^_]ZIRC<:YAI@NB\"RVX66B>6L%W,!B$&E4V"3AL:>
M=$Z&A4^753SA@_./WRPR@I6()[4.GSUU,J1CG"AUSI-BF3=V>H'QEF5W17 L
MDZ-X.EY&D.%Y7DR=CA%ZJ#LVBRQ\1"JMB!Y^5+0'GBE]_*.CFQ1]MY*NF"=]
MCH%$E5M]BF]^DJ1]LEVCC_)^ 4P*C3)^:CK4BF!_"RJ=AV5_[K,=G1>&O**M
MF@V%H)'1ER"$H(!DE&*#T6ZRD;F#*5SSCQF"GTM^C&F"'SI]B:F!NRJ/AL&!
M:[(IG"F/8J&JF26-?Y#"ED&+O'][DWZ*%&W=D.2(G%Q%CE&'+4K]B[&%O#HQ
MB02$2BJ#AC&"R+%,FTN8'Z#%F%&5=(_7E7:2XGZ/DKN08FT7D!2-^UN@C92+
MI4J%BP.).#GLB&R&LBIYA;2$ [!TFJN@VJ &E["=98\=E-*9^GW.DAF6H6QB
MCX"34EL*C/R/_TH;BG>,D3FPA^^(\BIPA4J%&*^[FBZI>9]1ES6E.HYIE%6@
M\WTED9V<LFO.CPF8=5J3C(F4)DG%B?V/K#F"AX2*^2IIA/*&"*\AF<ZQ_IZ]
MEM2LZXW4D_*GOGR3D3:BB&M(CJ2=5%HCC"Z8!TEZB:62ASE;ARN,Q"ICA*J&
MTJZJF8&Z=IY&EHBT@8U4DZ.N67P2D..H'&K7CE"AX5G+B]V;CDDVB6&5"CDP
MAO*.22I>A'"'>*<!J+ITP9=^I-QU6X>XH1YV#'>;G75VXF<YF<YWYE;$EAEY
M'$:ADD5Z>#;@CD1\*B@OB?Y^2*8RI\1]"I;SH^!\SX<VH!U\MW<:G'-\R6:U
MF-%]"U9)E2=]>$8WD5Y^ 3:HC6U^R"A+B3A_T:5_IK^%/98SHN2$.H:-GQZ#
M6'9JFWR"K&84E^."*E7!E$>!RD71D(R!>C9XC*N!3"ADB(J!.Z3&I<^-6Y5F
MH?R+GH6QGCZ* '6JFIF(CF5GEPZ'1E4WDWV&$$5QC]"$VS9,B_^#KRAZA_*"
MA:0$I1&5:I2FH3^2^(3NG860I73GF>..<63(EDJ,2E2YDLB*.T4=CR6(&#8H
MBV2%ZBB-AW"#JZ-CI&.=CY0'H)B:8(1/G-Z70W1.F3R4.60\E::1-U1*DAF.
M.$34CH.+)S8(BMF']2B<AP&$K*+/H^6EEI.*H!>AI(/4G%:=M'//F*^9SF/&
ME2*5\E/MD9^2"427C@*. #7OBF>)SRBIAJ:%B:).HXBM>I,1G[>HP(-=F_*C
M]7-=F$:?*V-?E+J:9U.8D4&5D$1@C:>0EC7;B@N+;BBTAEN&0J'HHS^U2)*N
MGVJON(+VFZ&I_W+XE_*D/F,)E&6>AU-7D.Z8OT0SC5^2US7$B<^,RBB\AA^&
MV9FLLFQT:8L\K<=T^GR=J3IUK6V^I+-VC%ZPH!IWG4^BFV!XXD#^EG9Z3S+<
MD41\%"7VB[=^/)D:L8M\/(KEK-Q\ 7Q*J$)[]&UIH[%\&%Y6GQ=\<D]1FF-\
M^T"_E8!]HS+1D%M^C"8\BN-_MIBAL(F#ZHI=J^*"]GO2IT*"*FSHHK2!G5WA
MGB"!/D[SF7>!!D""E)^ XC+'CXJ YR9ZBBF!$)@BKY:+>XG)JO2)VWLNIEJ(
M8FQ9H<>'&UUBG3^& TZ2F*&% 4!'D]2$!C*_CM*#'R:OB8B"1Y>8KLZ3 XD\
MJB^0NGJ<I9>.EVO'H0:,EESMG'6*L4XZE^2(X4 3DR&'!S*XCBZ%+R;<B/Z#
M6Y<0KC6:AHB^J9.7D'HCI/>4M&M5H&61]%R'F]2/0DWPES6,D3_JDGV)V#*S
MC9Z'$"<"B(J$2Y:KK:6A\(A:J0:>17G"I&J:J&KYG]B7'5PXFTJ3F4VXEJZ0
M"S_-D>:,:C*PC1R(NB<AB"J%%Y9'K4:I-X@:J*"DS'F&H_6@66JUGU&;\5OU
MFL*7F4U^ECJ3.#^KD8..P3*OC+N*,B<[A]R%PI7TK/RP88?0J$VK*7D]HYRE
MU&IQGO6@AEN_FF6;44U:E=Z6%#^8D320QS*OC'F+;"=/AYV&3(T1O%)T''^B
MMN-TH'(6L81U461DK!=V-U:<IG]W5$CKH*YXJSN\FIAZ*B\PE"-\ B0!C4E^
M,(R_NWA[@G]]M@%[0G'PL(U[.V0YJPU[;U9MI6Q[WTC&GYU\A3NKF8M]3"]2
MDR-^5R1NC&1_GHR$NFZ"LG\NM/^!QW&IKX2!#&/IJ@* FE8FI&. 74B4GIR
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M"5L-KH&-PDZ@I]:+F$*4H/R)@S=*F>:'=2T'DHR%>R1HBQ:#JH"]P/F;8G1
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M=&F(&KB%=7^&Q*)]=I6%J(PK=[.$KW6_>.*#RU]D>B:"XDDT>Y6!]3-P?4R
MY.$H<?R4C<PS<R.2"+;4=$:/I:#]=7&-:XK8=JR+:G2@=_>)<UY]>5>':4B
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MA75]B"M^A$-^LK=ZC?F"RZ<$C&."/Y7[BN&!MH0LB86!2W(+B#N ^5_-AP2
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M?:6'A9?F?:2&BH7W?;2%D7.=?>&$KV$P?B6#U$[_?GN"]#T:?OJ"!"P9?Z*
M\KB2?'^1_*?V?'^0.9:K?(N.8(3,?*J,>W*B?.2*G&!>?46(R$YB?;6&WCRV
M?D^$S"OR?Q&"=K>&>Y.;@:;L>YJ8ZI6F>ZF6)X/2>]"33W'!?!:0<U^C?("-
MDDW8?0J*FSQ=?;R'8RO2?I6#T+:O>MBD[J82>N2A?Y3)>O*=S8+[>QN9]W$
M>VZ6'5\&>^:2,4UE?'B.'CP5?4")PBNW?BV$_K8,>DNN.*5F>EJI[901>F2E
M1()#>HB@9G!3>N&;@EYP>VN6BDSV? J18#O6?-N+X"N@?=>& ;6A>>RW5Z3F
M>?RR*I-Z>?JL?8&D>A2FC&_">FN@E%WY>ON:B$R6>ZJ41CN3?(N-L2N/?9.&
MUZ]FBSMJLJ!.B?1LJ)!9B.!N?G^#A^YP1VXIAP=R(UR@ABET(TM7A5%V23I
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MB*]]WR60A@I^T)+[F3J"%X7$EJZ!M7@-E"V!4VGKD;6 _UMPCTJ P$T#C-V
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ML$*"<%M1JR^!X%!TI=N!9T7!H%.!&#M0FJ: Z#&CE,: PRCCCL2 MR&CB-Z
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MALB%TGI'A=*%*VP"A.6$;EU\A R#L4[;@U:# T">@JN"4#+@@A^!DR9N@::
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M.7R]F!V6E7&7E9Z4J&7;DN^23EG&D"J/M4VZC7V-(D'NBNV*F#;8B%6(%2R
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M<'B$XH8Q<<6$4W:)<QN#KF:4=):#"U9R=D6"<D:[>!2!UC=T>B&!,"E9?&F
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M-YKZ?4=HOXW3?6MJZ7^_?9]L^G#S?>)O!6&F?CAQ'E(W?J5S5$,C?RIUJS2
M?]YX02<,@,9[*IGP>R9QAXRD>WMRX'Z\>\YT)F_Z?#)U9V#9?*MVM%&8?4%X
M%D*X??%YCS1.?M)[+B<=?^5\^YC/>39Z/XMW>:UZTWV,>B%[3&\8>I][P6 4
M>S]\.5$%>_Q\P$):?-5]4C0E?>-]]2<L?Q]^II>O=YB"W8I\>"6"NGR2>+&"
M;FX0>4B""5]*>@"!IE!=>N:!3$'F>^6 \3/N?1> DB<Y?G6 *9:_=DZ+;XF+
M=NJ*C7NJ=X.)<6TY>"N(,EZ*>/B&[$_2>?&%IT&(>Q&$7C/!?&:"_"=#?>2!
M@)7_=4&3V(C,=>J2-7KQ=HJ016R*=SZ.)EWM>!Z+_4]8>2R)S$%">ER'C3.C
M>]"%*R=,?6R"J95L='&<#X@U=2.9J7I5=<66WFOV=GN3UUUC=VB0Q4[>>(^-
MID#P>=**=C.%>U6'&R=3?0F#I94&<]JD!H?!=)*@WGG4=3"=,6MV=>*9.ESV
M=M*5.$Z+> 21*D"I>5R-!C-7>O>(O2=9?+J$=8^7A^]?J8-WAQ%BKW:(AFEE
MEFC-A=MH;UJ8A5)K6$Q%A,]N:3Y;A%=QIC#E@_UU/"2E@\MY0H[+A<EH$(*R
MA2YJ0'6XA*9L7F@6A"QN>UG_@[IPJDO1@UAR^CX/@P-U;##0@M%X("36@L-[
M(8WI@\!P48&L@U9QP'35@NMS(6<\@HUT@5E-@CMU\4M+@?UW>3VZ@<]Y&C"V
M@<1ZY24!@=I\W(SM@>]X<("B@9YY+G/!@5!YV&9J@0AZ>5B8@-I[)4K&@,%[
MWCUI@+A\IC"<@-1]@R4G@0Y^<HOZ@%" @7^[@!F E'+E?^* A665?[. 7E@<
M?Y2 .TIM?Z" (3TY?[R "C"3?_]_]25&@%]_WXLH?QF(CW\&?O*']7(Z?L.'
M(V3I?IN&*U=L?I&%+DGP?JZ$.#SF?NB#0#!S?TR"-B5A?\N!((I_?AJ0;GY:
M??^/)7&4?=2-BV1.?;6+P5;=?;N)[DF#?>F(%SRP?C&&.3!C?K*$/R5W?U""
M-8GZ?528%GW5?4*6''$.?1B3N&/0?/B1$E9H?0B.8DD9?4R+JCQM?:2(ZC!5
M?C2&"26)?NR#'HF8?,.?A'UL?+:<W'"<?(B9I6-@?&.6'%8,?'.2B$C6?,&.
M[CPW?2V+2# W?=2'BB67?IR#WH.ED)Q?<WA:CPIB8VQGC:ME1E_+C%IH*5+0
MBOUK(47(B9IN1#D[B#=QE"T\AN5U/B*)A:]Y2X+MCJUG6'>\C4]IA&O'C %K
MK5]%BKAMWU)EB6MP)T5_B"1RE#D7AM]U)BU*A;!W_2+6A)M[%X(QC+YO%7;E
MBXMPD&L3BE1R"5Z;B2%SB5'@A^]U'D4BALAVSSCHA:9XG2U0A)MZFB,:@ZA\
MOX%@BO9VKG8(B=MWB&HOB+YX5EWTAZ!Y)U%4AH]Z D3$A8IZ\3BYA(Q[\BU3
M@Z9]$"-5@M5^08"3B7%^,'51B&A^<FF#AUQ^F5U"AE)^KE#MA4U^QT1ZA&M^
M\CB7@XY_(BU:@LQ_7".'@B!_F7_>B#F%K72FAT.%3&CAAC^$O5RZA3B$#5!Y
MA$*#6$1+@VB"M3A_@JR"&"U=@@^!<B.P@8B QW],AT:-!70UAEZ,"FAWA5J*
MOUP_A$^)0$_]@V>'P4/I@J&&3CA:@>^$WRU:@7&#5R/3@0J!RG[8AHR4)W/!
MA:N2D&@"A*60A5O4@Y>.-$^<@K.+YD.+@@&)GC@@@5Z'7BU9@.Z% 2/O@*."
MHWY_A@&;%'-EA2*8Y&>?A!>6$EMU@P.2YD]/@AR/P4-7@7&,I3@#@.")CRU3
M@(B&9B0%@%&#57@SF69?*6V_ES)B"&+!E2%DZ5<ZDP5GUDMOD,1JWC^OCFQN
M%S1]C AQ?2GIB:IU/2"JAVAY4'>.E[AFGVU&E:5HQ6).DY!J]U;BD6UM/$LR
MCS-OGS^0C/%R+#1^BJ=TWRH7B&EWVB$2AD9[#7;WE>%MX6R9D^]O96'"D>MP
M\%9@C]9RD4K3C;-T2C]8BXYV*#1RB65X(RH\ATIZ4R%MA4A\I'9.E"!T^6OB
MDD%UZ6$"D%1VV%72CE9WTTIAC%%XX#\2BDMZ!S19B$1[0RI5ADQ\HR&[A&U^
M$W6FDJ=\ &M D-E\86!ECOE\LU4[C0=\_4G_BQ1]5S[-B2]]Q#0\AT9^/2IF
MA6Y^R"'^@[%_6G43D7Z"_&JYC[Z"SU_IC>.">U3%B_:"$$F9B@Z!JCZBB"^!
M530KAF2!"RIUA*Z P"(U@Q2 =W2;D(:)RFI#CM2)"U]WC/V(#%19BQ2&YTD]
MB3:%PSYGAV>$JC0KA9^#FRJ(A F"@2)C@I*!:G0\C]&0;&H(CBF/*%\_C$J-
M=%0>BD^+?4D)B&^)DCXMAK>'MC0#A0:%Z2J4@X&$"R*(@BB"-7/RCTF6UFG!
MC9Z5"%[UB[F2FE/9B;F/UTC3A]B-(CX+AB6*?S/VA(:'["J;@QF%4B*F@=."
MVVU"HF]>L&-XGZ1A@%E:G-9D8T[FF=IG8D1,EJ)JASG1DT%MXB_UC\EQ:2;/
MC$MU0A\'B/)Y5&RIH/QEO6,<GC1GXED/FU!J(TZVF$1L@T0VE0QO"CG8D;QQ
MP3 <CEMTGB<?BOMWOA^(A\)[ FPQGSILC6*9G(5N'5BLF:QOPDY>EJEQB4/^
MDX5S<#G%D$]U@3 QC0QWL2=AB<]Z%!_WAKE\BFNUG7QS,&(1FMAT.5@=F!%U
M3$W\E2)V=T.TDAEWOCFBCP%Y(S YB]YZH">5B,5\02!7A=5]ZFLXG !YPV&<
MF6QZ2E>MEJ]ZS$V-D\M[4$-VD--[[CE^C=I\I3 YBM5]:B>]A]Y^12"IA1-_
M(FK*FM: 2V$]F$R 4E=8E9* .DU DK* %$,VC\1__#EHC--__# \B>N ""?>
MAQ: &R#MA'" ,&IMF>F&I&#SEV:&+%<7E*J%=$T!D<F$GD+YCN6#TSE&C .#
M&3!'B2&";B?^AFN!OR$E@^F!%6HGF2J,OV"REJR+PU;6D_"*:4S&D0V(WT+'
MCBV'7CD5BUV%ZS WB(2$CB@>A=V#*R%2@WR!U&GOF**2LF"GEB*125;+DUF/
M.TRRD&",W$+%C76*F3DJBJV(<S!0A_2&9R@VA6^$6B%V@R6"<&*LJ\I>&EE]
MJ'-@UU WI.-CO4;1H/%FT#UIG*5J&30XF!UMG2NUDW=Q32/ZCL=U11V5BE1Y
M56(5JI!DP5DOIR)FX5 $HV=I,$:]GUQKKSUQFPIN8C1?EHYQ2RO\D?MT6B1H
MC6AWHQXMB19Z^&&]J-YK)%C4I71LO$_%H<!N>$:+G;AP:CU=F7=RAS1ME1-T
MU2PQD)QW0"3%C"QYV1ZPB )\<V%PIQIQ5EA]H[QR<T]IH!5SJ493G"-U"3T[
ME_IVDC1MD[5X/2Q7CU]Z 241BQ5[YA\@AQ5]Q6$CI9)W>%@XHD%X(4\IGJ)X
MTT83FKEYE#TEEJ5Z?C1LDGU[ABQVCD=\G251BB-]RA]_ADM^[V#=I%U]DE@*
MH0Y]RD\&G7%][47TF8U^$#T-E81^2C1UD6E^I"R5C5%_#B6(B5)_@A_/A:-_
M\&"CHV:#>E?JH!6#04[PG'6"T47@F)2"3SS[E):!X31UD(N!B2RTC'Z!126Y
MB**!!B 0A1B RF!VHJB)*E?8GT^(@$[EFZB'>$76E\2&2CSND\R%+S1HC]>$
M*BR\B]N#/B7@B!&"5R!$A*B!?V!9HAB.I%?3GJ^-AT[BFO^+X473EQ>* #SS
MDR&(-#1YCS>&@RS*BU"$[27UAY^#:2!NA$Z"$;=98K=:Z:;W95Y>6)8K9_9A
MN83.:HUE#7+^;3IH9V$ < UKVT]&<PUO>3W<=EMS:"UQ>@IWX[5R7VIE5*5^
M8F1GN93@94-J%X.L:!YL=7'[:Q%NVV ?;BUQ6TZ,<7AS^SU==1-VX"U&>0YZ
M++.I7(%OI*/.7[EQ 9-Q8M5R7()69>MSQ7#3:1MU/%\K;'IVR$W2< IX;#SG
M<^UZ0"TA>"M\5;'D6>EYQJ(9759Z*Y'-8*%ZE8#Y8^M[!V^B9UI[C5XV:O9\
M(TT>;L9\Q3QY<NE]@BT =V-^6[!!5ZN#Q*"76T6#1)!@7KR"P7^?8B^"0&Z4
M9<R!R5U6::2!9$Q];:V _CP9<@B G2SD=K2 -Z[E5=.-J9];68^,2(\]72:*
MUGZ38+Z)76VA9(&'Z%R<:'^&>TOT;+V%"SO%<4F#ARS,=A^!XZW.5$^79IY=
M6">5'XY36]22MWV[7X>00VS=8VV-TUO[9Y"+7TN&:_&(VCN$<*B&-"RY=:*#
M6ZS[4R&@YYV<5PN=LHV:6L::3WT-7HB6VVP\8H>3;5MM9LV/]DL>:U",8SM,
M<".(FRRI=3N$GJQS4DFJ#)T85CREV(T36?BA<WR(7;^= 6O%8<N8F%L-9B:4
M(DK*:L./ACL/;[6*K2R<=.B%K*K<:@Q:K)OZ:_U>-8QV;?%AGGP\;^YD\VN$
M<@1H4%JA=#]KRTH+=J1O=#G2>5-S=2JN?%IX *E:9O!DDYK=:31G'(MW:V1I
MDWM;;9EL FJ\;^AN>EGZ<F1Q#DF,=0]SQCF%> IVQRJ?>UIZ,*?,9"5N5IE!
M9J9OZXH-:0UQ=7H*:WIR_VF?;@9TEUD2<,)V1$C><ZYX##D?=NEZ!2J1>G9\
M/Z8W8:AW[9>Q9%EXH8B-9NYY27C2:8IY[6B.;%%ZGU@Z;TA[84A%<G%\,CC(
M=>E]'RJ%>:Q^*:2_7X&!:9938EJ!1X<_91F!#W>59]V RV>>:L^ CE=T;?Z
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M=W&"D6L >!F"4UZI>,F!]5(F>9R!F$6I>IV!1CFJ>\. ^2Y0?1N JB1??HV
M6(%A=7J*3G8F=D&)E6I7=O:(E%X/=[B':E&<>*.&/$5">;Z%$CE\>OF#ZBY(
M?'6"LR1[?@N!=(#5='F1P'6>=4^06VG1=@V.E5V4=M>,F%$L=]2*ED3?>0J(
ME#E >ER&DBY!>^V$?"22?:&"9(!L<[>8[W4T=)>6Y&EB=5F45%TK=B61?%#7
M=RF.H$2D>&Z+Q3D0>=J(YRXF>X:%_"2D?4R#*7MYB<%::7#DB.9=S66VB#1A
M*5GMAXYDB$W*AN!H 4&EAC5KJ38%A91O@BL'A1)SN2%DA+=X3WJ;AUQB'G N
MAL%DSF4*AB]G>EEBA9]J+TUBA1!L_4%CA(QO\S7NA!9S$BLC@\)V?"&]@Y%Z
M*7G$A0MIMV]&A*5KO&1,A#9MOUBT@\=OQTS>@UUQYD$,@P9T)37)@KUVA2LU
M@I9Y'"(*@H][W7CA@N]Q-&Y;@JQRF&-@@E]S\E@$@A%U3DQ,@=)VN4"J@:5X
M/#6:@8EYU2L]@8][E2)-@:Y]:G@'@2)XG6V.@/IY9&*;@,=Z%E=%@)-ZO4O9
M@&Q[;4!5@&Q\+S5R@'A\_BM&@*=]X2*&@.Y^S'=&?YM_]&S=?X^ 'F'[?W"
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M?<M^TE*R?@%^^TEM?B%_$4 D?E!_,#<H?IA_7R[0?O1_GR<$?XE_W""=@"N
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MA/V!@4J/A&B!5$)<@Z*!$CHT@MV Y3)0@C> RBL_@9. Q"3;@3* L!^7@0R
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MC*"#?4+TBSV# #OEB6N":S3]AW^!_"Y1A;R!J2A4A!N!:2+]@M&!(!ZY@=>
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M3Y=^<78X5(-^FFCH67Y^O5M*7K5^Y4V:9#A_'4!=:?]_8C/$<!!_MRB>=B&
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M?O]_EA[A?_V  U+@=W&"'DO,>/:"%T2@>A^!OSUQ>NV!6#95>Z.!&B]H?'R
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M@)Z &QX%@,2 5   __\  /__  #__P  ;69T,0     #!"$   $
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MYN?HZ.GIZNOK[.SM[N[O[_#P\?+R\_/T]/7V]O?W^/CY^?K[^_S\_?W^_O\
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M,O^F0$O_L#E8^;TQ8N?.+6G0X"1_N<\WEZ?"4JF>NF:UFK5SNYBS?;Z7LH/
ME+&%P9"PA<.-KX7$B:Z&Q8:NA\:&KH?&AJZ'QH:NA\:&KH?&AJZ'QH:NA\:&
MKH?&AJZ'QH:NA\:&KH?&AJZ'QH:NA\:&KH?&AJZ'QH:NA\:&KH?&_ZLS,O^J
M.TG_MC)3\,<J6MC>(6;"WR2"K<X\F)_#5J>9O&BREK=UN)2T?;V3LX.^D;*%
MOXZRAL"+L8;!B+"'PH:PB,.&L(C#AK"(PX:PB,.&L(C#AK"(PX:PB,.&L(C#
MAK"(PX:PB,.&L(C#AK"(PX:PB,.&L(C#AK"(PX:PB,.&L(C#_ZTQ,O^P,T7X
MP"E,W]8C3<?H(&JSWB:$H<]!EI?&6:23P&JLD+QULH^Y?;:/MX.XC+:$NHJU
MA;R(M(:]AK.'OH2SB+^$LXB_A+.(OX2SB+^$LXB_A+.(OX2SB+^$LXB_A+.(
MOX2SB+^$LXB_A+.(OX2SB+^$LXB_A+.(OX2SB+^$LXB__Z\O,O^Y*3_HSAX_
MS.8;4K?N(6VEWBR#E])%DI#+6YV,Q6NEB\)UJHJ_?*V'OG^PA+R L8.\@K*!
MNX.S?[J$M'ZZAK5^NH:U?KJ&M7ZZAK5^NH:U?KJ&M7ZZAK5^NH:U?KJ&M7ZZ
MAK5^NH:U?KJ&M7ZZAK5^NH:U?KJ&M7ZZAK5^NH:U_[(J,O'&'#/1XA0ZO/,;
M5JCN)FV8X35_CMA*C(C0796&S&N;A,ETH(''>*-^Q7NE?,1]IGO$?J=YPX"H
M>,*"J7?"@ZIWPH.J=\*#JG?"@ZIWPH.J=\*#JG?"@ZIWPH.J=\*#JG?"@ZIW
MPH.J=\*#JG?"@ZIWPH.J=\*#JG?"@ZIWPH.J^KX<*-;=#B/ \!0_K/T>5YSP
M+6J/Y3YYAMY.@X'87XM_U&N0>M%PE'?/=)=USG>8<\UYFG+->YMQS'V;<,M_
MG&_+@)UORX"=;\N G6_+@)UORX"=;\N G6_+@)UORX"=;\N G6_+@)UORX"=
M;\N G6_+@)UORX"=;\N G6_+@)UORX"=V=(+&,3M#BFP_19!G_\D59'T-66'
MZT9P?^54>7OA87]VW6B$<MMNAV_9<8EMV'2+:]AWC&K6>8UIUGJ.:-5\CF?5
M?H]GU7Z/9]5^CV?5?H]GU7Z/9]5^CV?5?H]GU7Z/9]5^CV?5?H]GU7Z/9]5^
MCV?5?H]GU7Z/9]5^CV?5?H]GU7Z/_Z,Y*O^?1D#_G5!5^J!09>^C477DI%.&
MVJ);EM"@9:3(G7"PQ9Q[M<*<@[F_FHF^O)6+PKJ0C,6XC(_)MHB2S+.$E\^R
M@9_2K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_
MHM.M?Z+3K7^BTZU_HM.M?Z+3_Z,Y*O^?1D#_G5!5^J!09>^C477DI%.&VJ);
MEM"@9:3(G7"PQ9Q[M<*<@[F_FHF^O)6+PKJ0C,6XC(_)MHB2S+.$E\^R@9_2
MK7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M
M?Z+3K7^BTZU_HM.M?Z+3_Z,Y*O^?1D#_G5!5^J!09>^C477DI%.&VJ);EM"@
M9:3(G7"PQ9Q[M<*<@[F_FHF^O)6+PKJ0C,6XC(_)MHB2S+.$E\^R@9_2K7^B
MTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3
MK7^BTZU_HM.M?Z+3_Z,Y*O^?1D#_G5!5^J!09>^C477DI%.&VJ);EM"@9:3(
MG7"PQ9Q[M<*<@[F_FHF^O)6+PKJ0C,6XC(_)MHB2S+.$E\^R@9_2K7^BTZU_
MHM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^B
MTZU_HM.M?Z+3_Z,Y*O^?1D#_G5!5^J!09>^C477DI%.&VJ);EM"@9:3(G7"P
MQ9Q[M<*<@[F_FHF^O)6+PKJ0C,6XC(_)MHB2S+.$E\^R@9_2K7^BTZU_HM.M
M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_
MHM.M?Z+3_Z,Y*O^?1D#_G5!5^J!09>^C477DI%.&VJ);EM"@9:3(G7"PQ9Q[
MM<*<@[F_FHF^O)6+PKJ0C,6XC(_)MHB2S+.$E\^R@9_2K7^BTZU_HM.M?Z+3
MK7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M
M?Z+3_Z,Y*O^?1D#_G5!5^J!09>^C477DI%.&VJ);EM"@9:3(G7"PQ9Q[M<*<
M@[F_FHF^O)6+PKJ0C,6XC(_)MHB2S+.$E\^R@9_2K7^BTZU_HM.M?Z+3K7^B
MTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3
M_Z,Y*O^?1D#_G5!5^J!09>^C477DI%.&VJ);EM"@9:3(G7"PQ9Q[M<*<@[F_
MFHF^O)6+PKJ0C,6XC(_)MHB2S+.$E\^R@9_2K7^BTZU_HM.M?Z+3K7^BTZU_
MHM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3_Z,Y
M*O^?1D#_G5!5^J!09>^C477DI%.&VJ);EM"@9:3(G7"PQ9Q[M<*<@[F_FHF^
MO)6+PKJ0C,6XC(_)MHB2S+.$E\^R@9_2K7^BTZU_HM.M?Z+3K7^BTZU_HM.M
M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3_Z,Y*O^?
M1D#_G5!5^J!09>^C477DI%.&VJ);EM"@9:3(G7"PQ9Q[M<*<@[F_FHF^O)6+
MPKJ0C,6XC(_)MHB2S+.$E\^R@9_2K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3
MK7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3_Z,Y*O^?1D#_
MG5!5^J!09>^C477DI%.&VJ);EM"@9:3(G7"PQ9Q[M<*<@[F_FHF^O)6+PKJ0
MC,6XC(_)MHB2S+.$E\^R@9_2K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^B
MTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3_Z,Y*O^?1D#_G5!5
M^J!09>^C477DI%.&VJ);EM"@9:3(G7"PQ9Q[M<*<@[F_FHF^O)6+PKJ0C,6X
MC(_)MHB2S+.$E\^R@9_2K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_
MHM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3_Z,Y*O^?1D#_G5!5^J!0
M9>^C477DI%.&VJ);EM"@9:3(G7"PQ9Q[M<*<@[F_FHF^O)6+PKJ0C,6XC(_)
MMHB2S+.$E\^R@9_2K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M
M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3_Z,Y*O^?1D#_GD]4^J%.9.^D
M3W7EIE&%VJ58E=&B8J/)GVVOQ9]WM<*>@+F_G8B^O)F)P[F4B\>VCXW+LXJ0
MS[&&EM2N@Z#7IX&AU:>!H=6G@:'5IX&AU:>!H=6G@:'5IX&AU:>!H=6G@:'5
MIX&AU:>!H=6G@:'5IX&AU:>!H=6G@:'5_Z,Y*O^@1D#_GDY4^J)-9/"E3G3E
MJ$^$VZ=5E-*E7Z'*HVFMQ:)TM,*A?;F_H(6^NYV(P[B8B<BUDXO-L8Z.TZZ)
MEMBGA9W:H86@UJ&%H-:AA:#6H86@UJ&%H-:AA:#6H86@UJ&%H-:AA:#6H86@
MUJ&%H-:AA:#6H86@UJ&%H-:AA:#6_Z,Y*O^@1D#_GTU4^Z-,9/"G3'3FJ4Z#
MW*I3DM*I6Z#+IF:KQJ5PL\.E>KB_I(*]NZ*'P[B=A\FSF(G/L)2.U:N2E]J@
MBIS<FXF?V)N)G]B;B9_8FXF?V)N)G]B;B9_8FXF?V)N)G]B;B9_8FXF?V)N)
MG]B;B9_8FXF?V)N)G]B;B9_8_Z,X*O^@14#_H$Q4^Z1+8_&H2W/FJTR#W:U0
MD=2L6)[,JF*IQZILL<2J=K; JGZ\O*B$PKBDALFSH8C/K)R-U:.6E-J:D9S<
MEHZ>V):.GMB6CI[8EHZ>V):.GMB6CI[8EHZ>V):.GMB6CI[8EHZ>V):.GMB6
MCI[8EHZ>V):.GMB6CI[8_Z0X*O^@14#_H$M3^Z5*8_&I27+GK4J!WK!-D-6P
M59S.L%ZGR;!HK\:R<[/#LGRXO;" P;:L@LFNIX7/I:&*U9R<D=J5F9S<D92>
MV9&4GMF1E)[9D92>V9&4GMF1E)[9D92>V9&4GMF1E)[9D92>V9&4GMF1E)[9
MD92>V9&4GMF1E)[9_Z0X*O^@14#_H4I3^Z9(8O*K2''HKTB W[-*CM:U49K0
MMEJDS+AEJ\J]<:[!N7NVM[* P*ZLA,BFJ(7.G:2'U)2@CMB.GYG;C)N>V8R;
MGMF,FY[9C)N>V8R;GMF,FY[9C)N>V8R;GMF,FY[9C)N>V8R;GMF,FY[9C)N>
MV8R;GMF,FY[9_Z0X*O^A14#_HDE3_*='8?*M1G#ILD9_X+='C-F[3I?3OU>?
MT,5CI,7 <*VZN'FWL+* P*FMA<>@J(3-EZ6%THZAB=>'H)+9AZ&<V(>AG-B'
MH9S8AZ&<V(>AG-B'H9S8AZ&<V(>AG-B'H9S8AZ&<V(>AG-B'H9S8AZ&<V(>A
MG-B'H9S8_Z0W*O^A1$#_HTA2_*E%8?.N1&_JM4-]XKQ$B=S"2I/8RE29RL9B
MI+R];K"RMGBYJK& P:2MA<>;J83,DZ:$T(JCA]2#HH[6@J*6UH*BEM:"HI;6
M@J*6UH*BEM:"HI;6@J*6UH*BEM:"HI;6@J*6UH*BEM:"HI;6@J*6UH*BEM:"
MHI;6_Z4W*O^A1$'_I$92_:I$8/2Q0F[KN$%[Y,%"AM_,1HW3SU*7P<1AI[.[
M;;.KM7B[I;& P9^NA,:8JX3*D*B$SHBFAM&"I(S3@*22TX"DDM. I)+3@*22
MTX"DDM. I)+3@*22TX"DDM. I)+3@*22TX"DDM. I)+3@*22TX"DDM. I)+3
M_Z4W*O^A1$'_I451_JQ"7_6T/VSMO#YXY\= @>#61H?)S5&:N,)@JJRZ;;6E
MM7B\H+& P9NNA,65K(3(CJJ$RX>HALZ"IXO/?Z:/T'^FC]!_IH_0?Z:/T'^F
MC]!_IH_0?Z:/T'^FC]!_IH_0?Z:/T'^FC]!_IH_0?Z:/T'^FC]!_IH_0_Z4V
M*O^B0T'_IT-0_ZX_7?>W/&GPPCMSYM _>=/9/XJ^RU&=K\!AK*6Y;K:@M7F\
MG+*!P)BOA,.2KH3&C*R%R(>JA\J"J8K,?ZF.S7^ICLU_J8[-?ZF.S7^ICLU_
MJ8[-?ZF.S7^ICLU_J8[-?ZF.S7^ICLU_J8[-?ZF.S7^ICLU_J8[-_Z8V*O^B
M0D'_J4!/_[([6_F].&7LRSAMW-PU>,?6/HZSR5*@I\!CK9^Y<+::M7J\F+*!
MOY2QA<*/KX7$BZZ&Q8:MA\>"K(K(?ZN-R7^KC<E_JXW)?ZN-R7^KC<E_JXW)
M?ZN-R7^KC<E_JXW)?ZN-R7^KC<E_JXW)?ZN-R7^KC<E_JXW)_Z<U*O^C0D'_
MK#Q-_[<V5_+%,U_AUC9CS>,Q?+K3/Y&IR%2AG\!EK9FZ<K66MGNZE+."OI*R
MA<"-L8;!B;"'PX:OB,2"KHK%@*Z,Q8"NC,6 KHS%@*Z,Q8"NC,6 KHS%@*Z,
MQ8"NC,6 KHS%@*Z,Q8"NC,6 KHS%@*Z,Q8"NC,6 KHS%_Z@T*O^F/C__L3=*
M^;XP4N?/+U71XBQHP.$P?ZW20I.@R%>AF,%GJY2\<[*2N'RWD+:"NHZTA;R+
MLX:^B+*'P(6QB<&#L8K!@;",PH&PC,*!L(S"@;",PH&PC,*!L(S"@;",PH&P
MC,*!L(S"@;",PH&PC,*!L(S"@;",PH&PC,*!L(S"_ZDR*O^K.#W_N"]%[L@I
M2-;?)5+#["ELL=\Q@J'219*7REJ?D<-IIXZ_=*V-O'RQB[J!M(BY@[:%N(2X
M@[>&N8&VA[I_M8F[?K6+O'ZUB[Q^M8N\?K6+O'ZUB[Q^M8N\?K6+O'ZUB[Q^
MM8N\?K6+O'ZUB[Q^M8N\?K6+O'ZUB[Q^M8N\_ZLP*O^Q+SCVPB8\W-H?.\;K
M(U>S["IOH]\U@I;42I"/S5V:B\AKH8G$=::&PGNJ@\!^K(&_@*Y_OH*P?;V#
ML7N\A;)ZNX>S>;N(LWF[B+-YNXBS>;N(LWF[B+-YNXBS>;N(LWF[B+-YNXBS
M>;N(LWF[B+-YNXBS>;N(LWF[B+-YNXBS_ZTN*OZ[)3#CTAHMR>@;0;;W(UJE
M["YOEN$\?XS83XN'TE^3A,ULF8'*=)Y^R'BA>\=[HWG&?:1XQ7^E=L2!IG7#
M@Z=TPX2H<\*&J7/"AJESPH:I<\*&J7/"AJESPH:I<\*&J7/"AJESPH:I<\*&
MJ7/"AJESPH:I<\*&J7/"AJESPH:I_[0D)>S*%B/-Y1,LN?8;1J?Z)EN8[C5L
MC.5$>H3>4X. V6**?-5LCWC2<9-UT'65<\]XEW'.>IAPS7R9;\U^FF[,@)MM
MS(*<;,N$G&S+A)QLRX2<;,N$G&S+A)QLRX2<;,N$G&S+A)QLRX2<;,N$G&S+
MA)QLRX2<;,N$G&S+A)QLRX2<]<$5&='?#!B\\Q,QJO\>1YK\+%F.\CQGA.I+
M<GWE6'IYX&. =-YJA'#;;X=MVG.):]EVBFK8>(MIUWJ,:-9\C6?6?HYFU8".
M9=6!CV75@8]EU8&/9=6!CV75@8]EU8&/9=6!CV75@8]EU8&/9=6!CV75@8]E
MU8&/9=6!CV75@8]EU8&/TM(*";_H#1VM_Q4SG?\C19#_,U2%]T-??O%1:'?L
M7&]PZ6)T:^=G=VCE;7EFY'![9>-S?6/B=GUBX7A^8N%Y?V'A>W]@X'V 7^!_
M@5_@?X%?X'^!7^!_@5_@?X%?X'^!7^!_@5_@?X%?X'^!7^!_@5_@?X%?X'^!
M7^!_@5_@?X%?X'^!_Z Y(?^<1C;_FE%*_YU26?>?5&GMH%=XXY]<A]J<9Y72
MF7"AS)9[J\:4A+/$DXNVPH^/NL"+DKR^AY6_O8.8P;R!F\.[?J#$NGRFQK=Z
MK,:U>JS&M7JLQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&M7JL
MQK5ZK,:U>JS&_Z Y(?^<1C;_FE%*_YU26?>?5&GMH%=XXY]<A]J<9Y72F7"A
MS)9[J\:4A+/$DXNVPH^/NL"+DKR^AY6_O8.8P;R!F\.[?J#$NGRFQK=ZK,:U
M>JS&M7JLQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&M7JLQK5Z
MK,:U>JS&_Z Y(?^<1C;_FE%*_YU26?>?5&GMH%=XXY]<A]J<9Y72F7"AS)9[
MJ\:4A+/$DXNVPH^/NL"+DKR^AY6_O8.8P;R!F\.[?J#$NGRFQK=ZK,:U>JS&
MM7JLQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&M7JLQK5ZK,:U
M>JS&_Z Y(?^<1C;_FE%*_YU26?>?5&GMH%=XXY]<A]J<9Y72F7"AS)9[J\:4
MA+/$DXNVPH^/NL"+DKR^AY6_O8.8P;R!F\.[?J#$NGRFQK=ZK,:U>JS&M7JL
MQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&
M_Z Y(?^<1C;_FE%*_YU26?>?5&GMH%=XXY]<A]J<9Y72F7"AS)9[J\:4A+/$
MDXNVPH^/NL"+DKR^AY6_O8.8P;R!F\.[?J#$NGRFQK=ZK,:U>JS&M7JLQK5Z
MK,:U>JS&M7JLQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&_Z Y
M(?^<1C;_FE%*_YU26?>?5&GMH%=XXY]<A]J<9Y72F7"AS)9[J\:4A+/$DXNV
MPH^/NL"+DKR^AY6_O8.8P;R!F\.[?J#$NGRFQK=ZK,:U>JS&M7JLQK5ZK,:U
M>JS&M7JLQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&_Z Y(?^<
M1C;_FE%*_YU26?>?5&GMH%=XXY]<A]J<9Y72F7"AS)9[J\:4A+/$DXNVPH^/
MNL"+DKR^AY6_O8.8P;R!F\.[?J#$NGRFQK=ZK,:U>JS&M7JLQK5ZK,:U>JS&
MM7JLQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&_Z Y(?^<1C;_
MFE%*_YU26?>?5&GMH%=XXY]<A]J<9Y72F7"AS)9[J\:4A+/$DXNVPH^/NL"+
MDKR^AY6_O8.8P;R!F\.[?J#$NGRFQK=ZK,:U>JS&M7JLQK5ZK,:U>JS&M7JL
MQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&_Z Y(?^<1C;_FE%*
M_YU26?>?5&GMH%=XXY]<A]J<9Y72F7"AS)9[J\:4A+/$DXNVPH^/NL"+DKR^
MAY6_O8.8P;R!F\.[?J#$NGRFQK=ZK,:U>JS&M7JLQK5ZK,:U>JS&M7JLQK5Z
MK,:U>JS&M7JLQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&_Z Y(?^<1C;_FE%*_YU2
M6?>?5&GMH%=XXY]<A]J<9Y72F7"AS)9[J\:4A+/$DXNVPH^/NL"+DKR^AY6_
MO8.8P;R!F\.[?J#$NGRFQK=ZK,:U>JS&M7JLQK5ZK,:U>JS&M7JLQK5ZK,:U
M>JS&M7JLQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&_Z Y(?^=1C;_FE!*_YY16?>@
M4FCMH59XY*%:AMN>9)32FVZ@S)AXJL:5@;+$E8FVP9&.NK^,D+V]B)/ O(27
MP[J!F\6Y?J#'N'RGR+)[JLBP>ZK(L'NJR+![JLBP>ZK(L'NJR+![JLBP>ZK(
ML'NJR+![JLBP>ZK(L'NJR+![JLBP>ZK(_Z X(O^=1C?_FT]*_Y]/6?BB4&CN
MHU-WY:17A=RB8)/3GFJ?S9MTJ<>8?;'$EX:VP92,NK^/CKZ\BI+"NH:5Q;B"
MFLBW?Z#+M'RGS*Q\J<JJ?:G*JGVIRJI]J<JJ?:G*JGVIRJI]J<JJ?:G*JGVI
MRJI]J<JJ?:G*JGVIRJI]J<JJ?:G*_Z X(O^=13?_G$Y*_Z!.6/BC3V?OI5%V
MY:95A-VE79'4HF:=S9]PJ,B<>K#$FH*VP9B*NKZ2C+^[C8_$N(B3R+:#F<RT
M@*'/K'VESZ9^I\RD?ZC+I'^HRZ1_J,ND?ZC+I'^HRZ1_J,ND?ZC+I'^HRZ1_
MJ,ND?ZC+I'^HRZ1_J,ND?ZC+_Z$X(O^=13?_G4U)_Z%,6/FE36;OIT]UYJE3
M@]ZH6I#5IF*<SZ-LILF@=J[%GG^UP9R'NKZ7BL"ZD(W&MHN2R[2(FLZRAJ31
MIH"DT:"!I\V?@:?,GX&GS)^!I\R?@:?,GX&GS)^!I\R?@:?,GX&GS)^!I\R?
M@:?,GX&GS)^!I\R?@:?,_Z$X(O^>13?_GDQ)_Z)+5_FF3&;PJ4YTYZM1@M^K
M5X[7JE^:T*AII,NE<ZS&HWRSPJ"$N;Z<B,"YEHS&M9&2RZ^-F,^JBJ'2H(2C
MTYN$ILZ:A*?-FH2GS9J$I\V:A*?-FH2GS9J$I\V:A*?-FH2GS9J$I\V:A*?-
MFH2GS9J$I\V:A*?-_Z$X(O^>13?_GDM)_Z-*5_JG2V7PJTQSZ*U/@."O5(W9
MKER8TJUFH<VK<*G(JGFPPZ>!M[ZAA,"UFXG&KI6/S*B1E<^BCI[2FHFBTY:'
MI<^5AZ;.E8>FSI6'ILZ5AZ;.E8>FSI6'ILZ5AZ;.E8>FSI6'ILZ5AZ;.E8>F
MSI6'ILZ5AZ;._Z$W(O^>1#?_GTI)_Z1)5OJH263QK$MRZ;!-?^&S48O:LUJ5
MU+-CGL^S;J7+LWBKPZQ\M[BE@;^OGH;&J)F,RZ&5DM";DIO3E8ZBU)&,I="1
MBZ;.D8NFSI&+ILZ1BZ;.D8NFSI&+ILZ1BZ;.D8NFSI&+ILZ1BZ;.D8NFSI&+
MILZ1BZ;._Z$W(O^>1#?_H$E(_Z5(5ONJ2&3RKDEQZK),?>*V3XG<N%>2UKIA
MFM.];:#)N'6KOK!ZMK.I?[^JHH3&HIV*RYN:D,^5EYG2D)6BU(V0I=",D*;/
MC)"FSXR0IL^,D*;/C)"FSXR0IL^,D*;/C)"FSXR0IL^,D*;/C)"FSXR0IL^,
MD*;/_Z$W(O^>1#?_H$E(_Z9'5?NK1V/SL$APZ[5*?.2Z3H;>OU6/VL-@E=+$
M;9S%NW.JN;-XMJZM?;^EIX+%G:*(RY:?CL^/G);2BYRBTXB5I-")E*7/B92E
MSXF4I<^)E*7/B92ESXF4I<^)E*7/B92ESXF4I<^)E*7/B92ESXF4I<^)E*7/
M_Z(W(O^?1#?_H4A(_Z=&5?RL16+TLD9N[+A(>N:_3(/AQU.*W,UBCL[(;)O
MOW&JM+=WM:FQ?+Z?K('%EZ>&RI"DC,Z*HI71AJ*ATH2;I="%FJ7/A9JESX6:
MI<^%FJ7/A9JESX6:I<^%FJ7/A9JESX6:I<^%FJ7/A9JESX6:I<^%FJ7/_Z(V
M(O^?0S?_HD9'_ZA$5/VN0V'UM41L[KQ&=^G$2W_CSU2$V=1EB,C+:YJZPG"I
MKKIWM*.T?+V:KX'#DJR%R(NIBLR$IY+/@*:<T("CI<^ H:;.@*&FSH"AILZ
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MK,9]GJS&?9ZLQGV>K,9]GJS&?9ZLQGV>K,9]GJS&_Z U&O^=0B[_HD(\_ZI
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MDE$W_Y=31?^95U/]F5M@]9AA;>V5:'GEDG*$WX]\CMJ,A9;5AXN<T8.0H<^
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MY4ACK.)-<I_?5'^3V5V*B=)GDX/-<)I]R7>?>,9]I'3$@Z=PPHBI;L&.JVS
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M8O=S@VCT;XQN\6R3<N]JFG7M9Z!X[&6E>NMDJGSJ8J]]Z6&U?NA@NW_H7\.
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MM%0_W;-;2="L8EG&I&IFO)UQ<K27=WRLD7Z%IHR&C*"(C9&:A966EH*>FI*
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M?XJ[GWZ*R)Y_B<F=@(C*G("(RYN B,N;@(C+FX"(RYN B,N;@(C+FX"(RYN
MB,N;_X$B!O^)+@__F345_Z(X&_^I.B#[L#TD\+A"*.:_2BK=PT\TSKU61L*V
M7E:WL&5DK:EK<*2D<7J<GWB#E)M^BHZ7AI"(E8Z5@I*6F7Z0H)QZCZN>>(^X
MGW>0R9YYCLJ=>HS+FWN,RYM[C,N;>XS+FWN,RYM[C,N;>XS+FWN,RYM[C,N;
M_X$B!O^++0[_FS04_Z0W&?^L.![XM#HA[;U (^3&22/7QTPSR<%51;VZ7%6R
MM&-CJ*YI;Y^I;WF6I7:"CJ%\B8>=@X^!FXN4?)B4F'>7G9MSEJB=<9:UGG"6
MQIURE,J<=)++FW61RYIUD<N:=9'+FG61RYIUD<N:=9'+FG61RYIUD<N:_X(B
M!O^-+ W_G303_Z8T&/^O-1OTN#<<Z<,^'.#-11_1RTLRQ,540[B_6U.MN6%A
MHK1H;9FO;G>0JW2 B*=ZAX&D@8U[HHF2=:"1EG">FYEMG::;:IVSG&F>PYQK
MG,N;;IC,FF^7S)EOE\R9;Y?,F6^7S)EOE\R9;Y?,F6^7S)EOE\R9_X,A!O^0
M*PW_H#,1_ZDR%?VS,1?POC07Y<L[%=K4/QW+STDPOLE20K+$65&GOV!?G+IF
M:Y*V;'6)LG)^@:]XA7JL?XMTJH>0;ZB/DVJGF99GIJ289*:QF6.GP9EDI<V8
M9Z#-F&B?S9=HG\V7:)_-EVB?S9=HG\V7:)_-EVB?S9=HG\V7_X0A!O^3*0O_
MHC /_ZTN$OBX+!+KQB\0X-4X"]+:/1S%U$@NN,]00*S*6$^@Q5Y=E<%D:(N]
M:G*#NG!Z>[=V@72U?8=NLX6+:+*.CV2QF))AL*.47K"PE5VQOY5=L="48*K0
ME&&HT)1AJ-"48:C0E&&HT)1AJ-"48:C0E&&HT)1AJ-"4_X8A!O^7* K_IBP-
M_[$H#O+ )@SCT"@'U-\R"\G?/AF]VT<LL=9//:315DR9S5Q9CLEB983&:&Y[
MQ&]V=,%U?&W ?()HOH2&8[V-B5^\EXQ;O**.6;ROCUB]OHY7OM2.6;;3CUJT
MTY!:M-.06K33D%JTTY!:M-.06K33D%JTTY!:M-.0_X@A!O^<)PC_JB<*_+@A
M">G*&P75WB $R>4P#[[C/1VTX48LJ-Y..IS:54B1UEM5AM-A8'S09VETSFYP
M;<UU=F?+?'MBRX1^7LJ-@EK*EX17RJ.&5<JOAE3+OH93S-6&5,39B%7!V8E5
MP=F)5<'9B57!V8E5P=F)5<'9B57!V8E5P=F)_XT=!?^B)0;_L!\%\L(4 ]G;
M#@')YB 'O>@O%++G.B*GY4,QF^-*/I#A4$J&WU=4?-Y>773=961LVVQJ9MMT
M;V':?'-<V81V6=F.>579F'M3VJ-\4=JP?5#;OGU0W--\4-3@?E'0X']1T.!_
M4=#@?U'0X']1T.!_4=#@?U'0X']1T.!__Y4: _^I'P/[NA("U,T+ ,GF#P*\
M[2 +L.TN&:7L.2>:ZT(UC^I)087I4$M[Z%=3<NA=6FKG8V!DYVIE7^=R:5OG
M>FQ7YX)N4^>+<5#GE7).Z)]T3.BJ=4OHM79*Y\-V2NC==DODX'5+Y.!U2^3@
M=4ODX'5+Y.!U2^3@=4ODX'5+Y.!U_YT6 ?^Q$@'3PPD Q]$* +OR$02O\R$/
MH_,N'9GS.2J.\T(VA/-*07OS4DER\U=0:?-<5F/S8UI=\VE>6?-P857S=V-2
M\W]F3_*'9TWPCVE+[YAK2N^@;$GNJ6U([K-M1^W ;D;MQVY&[<=N1NW';D;M
MQVY&[<=N1NW';D;MQVY&[<=N_Z</ -.Z!P#%QP< NM8) *WZ$P:B^B(2E_HO
M'XW[.BN#_$,U>OU,/G']445H_59+8?Y;3US^8E-7_FA65/UO6%'[=5I.^GQ<
M3/F#74KXBE](]Y%@1_:984;VH&)%]:=C1/2Q9$/TM61#]+5D0_2U9$/TM61#
M]+5D0_2U9$/TM61#]+5DUK($ ,2^!@"WS 8 K-P) :#_%@B5_R44B_\R'X+_
M/"EY_T4R;_]*.6?_3S]?_U5#6O];1U7_84I2_V=,3_]L3DW_<D]+_WA12?]^
M4D?_A%-%_XM40_^154+^F%9!_9Y70/VF6$#\J5A _*E80/RI6$#\J5A _*E8
M0/RI6$#\J5A _*E8QK@$ +;$! "JTP4 GO(- I3_&@F*_R@3@?\T'7?_/"5M
M_T(L9?]',EW_3397_U,Z4_]9/4__7S],_V1!2O]I0TC_;D1&_W-%1/]Y1D+_
M?D=!_X1(/_^*23[_D$H]_Y5+//^<3#S_GTP\_Y],//^?3#S_GTP\_Y],//^?
M3#S_GTP\_Y],M[P# *G+ @"<VP, DO\0 HG_'0B _RH0=?\Q&&O_.!]B_SXD
M6_]$*53_2BQ0_U$O3/]7,DG_7#-&_V U1/]E-D+_:3=!_VXX/_]S.3W_=SH\
M_WP[._^"/#G_ASTX_XP]-_^3/C;_E3XV_Y4^-O^5/C;_E3XV_Y4^-O^5/C;_
ME3XV_Y4^JL0  )S2  "/YP( AO\1 GS_&P5Q_R0+:/\K$5__,A=7_SD;4?\_
M'DS_1B%(_TTC1?]2)4+_5R= _ULH/O]?*3S_8RHZ_V<K.?]K+#?_;RPV_W0M
M-?]X+C3_?2XR_X(O,?^(,#'_BC Q_XHP,?^*,#'_BC Q_XHP,?^*,#'_BC Q
M_XHP_VHD!/]I,@K_;#X4_W9&'O][32G_?%4S_WI=/?]V9D;_<6Y-_VUY5/]J
MA%K^9HU?^V.58OEAG&7X7Z)H]UZH:O9<K6OU6[-L]%JY;O-9P6[S6,EO\EC4
M<.]8X'#I6>1PXUKF<-Q=Z'#<7>APW%WH<-Q=Z'#<7>APW%WH<-Q=Z'#<7>AP
M_VHD!/]I,@K_;#X4_W9&'O][32G_?%4S_WI=/?]V9D;_<6Y-_VUY5/]JA%K^
M9HU?^V.58OEAG&7X7Z)H]UZH:O9<K6OU6[-L]%JY;O-9P6[S6,EO\EC4<.]8
MX'#I6>1PXUKF<-Q=Z'#<7>APW%WH<-Q=Z'#<7>APW%WH<-Q=Z'#<7>AP_VHC
M!/]I,0K_;CX4_W=%'O]\32C_?E0S_WQ<//]Y9$7_<VU._V]X5?]K@EK]:(M?
M^V648_EBFV;W8*%I]EZG:_5=K6ST7+-N\UJZ;_)9P7#R6<IQ\5C8<>Q9X7'F
M6N1QX%SG<=A=Z''87NAQV%[H<=A>Z''87NAQV%[H<=A>Z''87NAQ_VLC!/]J
M,0K_<3P4_WI#'?^ 2RC_@5,R_X!://]\8D7_=VI._W%T5?]N?UO]:HE@^F:2
M9/ADF6CV8:!K]5^G;?->K6_R7+-P\ENZ<?%:PW+P6<US[EG=<^A:XG3A7.5S
MV5[F<]!?YW307^=TT%_G=-!?YW307^=TT%_G=-!?YW307^=T_VPC!/]K,0K_
M<SL4_WU"'?^"2B?_A%$R_X-9._^ 8$7_>VA-_W1Q5?]P?%O\;(=A^6B09O=E
MF&GU8Y]L\V&F;_)?K''Q7;-R\%R[=.];Q77O6M!UZEK?=N)<XG;;7^5UT6#F
M=LIAY7?*8>5WRF'E=\IAY7?*8>5WRF'E=\IAY7?*8>5W_VTB!/]L,0O_=CH4
M_X!!'?^%2"?_B$\Q_X=7._^$7D3_?V9-_WAN5?]S>5S\;H1B^6J-9_9GEFOT
M9)YN\F*E<?%@K'/O7K1U[EV\=NY;QW?M6]9XY5S@>-Q?XWC28.1XRV'D><1C
MXWK$8^-ZQ&/C>L1CXWK$8^-ZQ&/C>L1CXWK$8^-Z_VXB!/]M,0O_>#@3_X,_
M'/^)1R;_BTXP_XM5.?^(7$/_@V-,_WUK5/]V=5S\<H!B^&V*9_5IE&SS9IQP
M\6.D<^]AK'7N7[1W[5V^>>Q<RWKH7-QZWE_A>M)AXWO*8N)\Q&/B?;YEX7V]
M9>%]O67A?;UEX7V]9>%]O67A?;UEX7V]9>%]_VXB!/]N, O_>S<3_X8^'/^,
M127_CTPN_X]3./^-6D'_B&%+_X-I4_I\<5OW=GQB\W&':/!MD&WM:9EQZF:A
M=>ACJ7CF8;)ZY&"[>^)?QWS@7]I]U&+A?<ICX'[#9.!_O6;?@+=GWX"W9]^
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M@EBOW8)8K]V"6*_=@EBOW8)8K]V"_X07 O^9' +_JA\#];D5 M[-# #0WQ(
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MB# P_X\P+O^6,2W_GC(M_YXR+?^>,BW_GC(M_YXR+?^>,BW_GC(M_YXRI,(
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MID<\^[%(._N^23K\STDY_.-).?SC23G\XTDY_.-).?SC23G\XTDY_.-)QZT
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M)2;_H28E_Z<F)?^G)B7_IR8E_Z<F)?^G)B7_IR8E_Z<FG\   )'-  "#VP
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M@Q@E_XX9)/^8&B/_H!HB_ZH;(?^M&R'_K1LA_ZT;(?^M&R'_K1LA_ZT;FKX
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M!_]C.P[_9486_V50'?]A623_760K_UIP,/]6?#7_4X<Y_U"1//].FC__3:)
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M8V2,]&-DC/1C9(ST8V2,]&-DC/1C_W$0 ?^"#P#_D0T WI\) -.J"0#,LPD
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MH2TY\JXN./*^+S?ST"\W\^<O-O'S+S;Q\R\V\?,O-O'S+S;Q\R\V\?,ON:<
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M$![_H! >_Z@1'?^Q$1W_L1$=_[$1'?^Q$1W_L1$=_[$1E;P  (;'  !YTP
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M6')Z_%AR>OQ8<GK\6')Z_%AR>OQ8_V<1 ?]U#P#_@PX ](X- -N9"@#4H0L
MS*05 ,*D)P.XHC8*L)Y"%:>:3!^@EU0IF9-<,9.08SB-C6H_B(IQ1(.(>$E^
MAG]->H2(47:"D55S@9M8;X"F6FU_M%QK?\5<:X#?7&N \EIK@/M9;'[\6&U^
M_%AM?OQ8;7[\6&U^_%AM?OQ8_VD0 ?]X#@#_A0P XI(( -6;"0#.HPD QZ@2
M +VH)0*TIC0)JZ) $Z.?2AZ;FU(GE)A:,(Z583>(DF@]@I!O0WZ.=DAYC'U,
M=8J%4'&(CE1MAYE7:H:D66>%L5MEA<);987<6V6%\%IFA?M99X/\6&>#_%=G
M@_Q79X/\5V>#_%=G@_Q7_VP. /][# #RB0D V94& ,^>" #)I@@ P:L0 +BK
M(@*OJC((IJ<^$IZD2!R6H5$ECYY8+HB;7S6"F68\?99M07B4=$9SDGM+;Y"#
M3VN/C%)GCI959(VB6&&,KUE?C,!:7XS965^,[EE?C/M888K]5V&)_5=AB?U7
M88G]5V&)_5=AB?U7_V\, /]_"0#?C0, TI@& ,JB!@#"J08 NJ\. +*P( &I
MKB\&H:P\$)BI1AJ1IT\CB:16+(.B73-]GV0Y=YUK/W*;<41NFGE(:9B!3&67
MBE!AE9137I6@55N4K5=:E+U869345UF4[%=9D_E66Y'^55N0_E5;D/Y56Y#^
M55N0_E5;D/Y5_W,) /6$! #8D0, S)P% ,.E!0"[K00 L[,, *NU' &CM"P%
MF[(Y#I*P1!>*K4T@@ZM4*7VI7#!WIV(V<:5I/&RD;T%HHG=%9*%_25^?B$Q<
MGI)/6)Z>4E:=JU-4G;Q44YW15%.=ZU-3G/A35)K_4U29_U-4F?]35)G_4U29
M_U-4F?]3_W@& .&)  #0E@( QJ$# +RI P"SL $ J[@( *2Z& "<NBD#E+DV
M"XRW012$M4H=?+-2)7:Q6BQPKV R:ZYG.&:M;CQBJW5 7JI]1%JIADA6J)%*
M4ZB=35&GJDY/J+I/3JC/3TZGZ4]-IO=/3:7_3TZD_T].I/]/3J3_3TZD_T].
MI/]/^G\  -B.  #)FP$ OJ4" +2M 0"KM0  H;\$ )O!% "4P24"C, S"(2_
M/A%\O4@9=;Q0(6^Z6"=JN5\M9;AE,F"W;#9<MG0Z6+5\/E6TA4%1M)!$3K.<
M1DRSJ4A*L[E(2;3.2$FSZ4A(L?9)2+#_2DBP_TI(L/]*2+#_2DBP_TI(L/]*
MXH8  ,Z4  #"H0  MJD  *NQ  "AN@$ F,,% )#)$ "*R2 !@\DO!7O(.PUT
MQT44;L9.&VC%5B%CQ%TG7L-D*UK":R]6P7(S4\%[-D_ A#E,P(\\2L";/D?
MJ#]&P+A 1<#-0$7 Z#]$OO9!0[W_0D.\_T-#O/]#0[S_0T.\_T-#O/]#UHT
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M(S7NSR,T[N8C-.OU(S3K^",TZ_@C-.OX(S3K^",TZ_@CLZ4  *:M  "9MP
MC<$  (#+  !UU0$ :>$& &3S$0!>\QP!6?0F E3T, 1/]3@&2_5 "$?V1PI$
M]DX,0?=5#C_W7 \\]V,1.OAJ$S?X<Q0U^'T6,_F(%S'YE!@O^J$9+OJO&BW[
MOAHL^\\;*_OG&RO[ZQLK^^L;*_OK&RO[ZQLK^^L;J*H  )JT  "-OP  @,D
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M2W]K_TM_:_]+?VO_2W]K_TM_:_]+_UX0 ?]K#@#_=@X ^X - .J(#0#;CPP
MT)(5 ,>2)P*^CS8(MHQ"$:Z(31JHA%8BHH!>*IQ]93"7>FPUDW=S.H]U>SZ,
M<X)"B'*+1H5PDTF";YU,?VZH3GUNM4][;<90>F[@4'EO\DYY;_Y->6__3'EO
M_TMY;_]+>6__2WEO_TMY;_]+_V / /]M#0#_>0P [H,+ -N+"0#4D0H S)43
M ,*5)0*YDS0'L8]!$*J,2QFCB%0AG81<*9>!8R^2?FHUCGQQ.8IZ>#V&>(!"
M@W:(17]UD4E\<YM,>7*F3G9RLU!U<L-0<W+=4'1S\$]T<_U-='/_3'1S_TQT
M<_],='/_3'1S_TQT<_],_V(. /]O# #\>PH WH8& -6." #/E D QY@1 +Z8
M(P&UEC(&K9,_#Z:021B?C%(@F(E:*).&82Z.@V@TB8%O.85_=CV!?7Y!?7N&
M17IYCTEV>)E,<W>D3G%WL5!O=L%0;G?94&YW[T]N=_Q.;G?_36]W_TQO=_],
M;W?_3&]W_TQO=_],_V0- /]R"@#P?@8 VH@% -"0!P#*EP@ PIL0 +F;(0&Q
MFC &J9<]#J&41Q>:D5 ?E(U8)XZ+7RV)B&8SA(9M.("$=#U[@GM!>("$171_
MC4AQ?9=+;7RB3FM\KT]I>[Y0:'S54&A\[4]I?/M.:7S_36I[_TQJ>_],:GO_
M3&I[_TQJ>_],_V8* /]U" #A@0( U(L% ,N3!@#$F@8 O9X. +6?'P&LGBX%
MI)L[#)V81166E4X>CY-6)8F072R$CF0R?XMK-WJ*<CQVB'E <H:!1&^%BD=K
M@Y5*:(*@366!K$YC@;Q/8H'13V*!ZTYC@?E-8X'_3&2 _TMD@/]+9(#_2V2
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MIT=2F;9(49G*2%&8YDA1E_5(49?_1U&6_T=1EO]'49;_1U&6_T=1EO]']G<
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M-4.[XC1"N?,U0;C]-T"W_S= M_\W0+?_-T"W_S= M_\WSHL  +^8  "RH0
MIZD  )RP  "1N   AL " 'O(!P!TRQ( <,PB 6O+, -FRSP'8<M%#%S*3A%8
MRE855,I=&5')9!Q.R6P?2\ET(DC(?B1%R(@G0\B5*$'(HBH_R+$K/LG$*S[)
MX2H^Q_(K/<;\+3S%_RX\Q?\N/,7_+CS%_RX\Q?\NQ),  +:?  "II@  G:X
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M$2?U\1$G]?$1)_7Q$2?U\1$G]?$1HZ@  ):R  "(NP  >\4  &_.  !BUP
M5MX  $[P!P!*^A  1OL9 $+[(@$__"H!._TR CC].0(U_C\#,OY& S#_3 0N
M_U,%*_]:!2G_8@8G_VL&)/]V!R/_@@@A_Y ((/^="1__JPD>_[H)'?_)"1S_
MW0D<_]T)'/_="1S_W0D<_]T)F+   (JZ  !\Q   ;\T  &+8  !5W@  2>0
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M-/\A_S@J O\_)P+_0R8"_T8I O]),@/_23P%_TA'!_]&4PO_1%\/_T)J$O]
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M&0#R<A\ YG0F =UT,0+3<3\(RVU+#\5I5A? 9F =NV-I(K=@<2>T7GDKL5R
M+JY;B#&L68\SJEB7-:=7GS>E5Z@YHU:S.J%6P#N?5M(\G5;I/)M7^#R:5_\\
MF5C_.YA8_SN86/\ZF%C_.IA8_SJ86/\Z_U(2 ?]<#@#_9A  _VT1 /IS% #K
M=Q@ X'D? -1Y+0++=CP'Q')(#KYO4Q:X:UP=LVAE(J]E;2>L8W4KJ6%\+Z9?
MA#*C7HLUH5V3-YY<FSF<6Z0[F5JO/9=:NSZ66LP_E%KE/Y);]3Z16_\^D%S_
M/9!<_SR/7/\\CUS_/(]<_SR/7/\\_U41 /]?#0#_:0X _W$. /5W$ #F>Q$
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M06AXJD-F>+A$97C,165XYT1E>/=#9GC_0F9X_T%F>/] 9GC_0&9X_T!F>/]
M_V0# .YQ  #8?   RX4" ,., P"[D0, LY0) *R6& "EEB@"G90V!Y:200Z0
MCTH5BHU2'(2+6B)_B6 G>X=G+'>%;C!S@W4T;X)]-VR!ACMI?Y ^9GZ;06-^
MJ$-A?;9$8'W)1%]]Y4-@??9"8'W_06%]_T!A??] 87W_0&%]_T!A??] _V<
M .-T  #2?P  QX@! +Z/ @"VE0$ KI@& *::%0"?FB8"F)DS!I&7/PR+E4@4
MA9-0&G^16"!ZCU\E=HUE*G*+;"YNBG,R:HA[-F:'A#ECAHX\8(69/UV$ID%;
MA+1"6H3'0UJ$XT):@_1!6X/_0%N#_T!;@_\_6X/_/UN#_S];@_\__VH  -YX
M  #-@P  PHP  +F3  "PF   IYT" *"?$@"9GR,!DYXQ!8R=/ N%FT82?YE.
M&'J75AYUEETC<)1C*&R2:BQHD7$P99!Y-&&.@C=>C8PZ6HR7/5B,I#]6B[)
M5(O%0%2+X4!4BO,_58K^/U6)_SY5B?\^58G_/E6)_SY5B?\^[V\  -9\  #(
MAP  O9$  +28  "JG   H*(  )FD$ "3I2 !C*0N X6C.0E_HD,/>:!,%G2?
M4QMOG5H@:IQA)6:::"ECF6\M7YAW,%N7@#18EHHW5965.5*5HCM0E+ ]3Y3#
M/4^4WSQ/D_(\3Y+]/$^2_SQ/D?\\3Y'_/$^1_SQ/D?\\Y'0  ,^!  #"C
MN)8  *V<  "CH0  F*@  )"J#0"+JQL A:LJ GZJ-@9XJ4$,<JA)$FVG41AI
MIE@<9*1?(6"C9B5=HFTI6:%U+%:A?B]3H(@R3Y^3-4V?H#=+GJ\X2I[!.$F>
MW3A)G? X29S\.$F;_SE)F_\Y29O_.4F;_SE)F_\YVWH  ,B'  "\D@  L9H
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M(CB__R0XO_\D.+__)#B__R0XO_\DO9$  +";  "DH@  F*H  (RQ  " N0
M=;\  &K&! !>S @ 6<\2 %?0(0!5T"X!4= Y D[00P1+T$P&2=!3"$;06PM#
MT&,-0=!K#S[0=1$\T8 3.M&,%#C1FA8VT:D7-=&[%S32TA<UT.P6-,_W&#/.
M_QHSSO\:,\[_&C/._QHSSO\:LYD  *:A  ":J0  CK$  (&Y  !UP   :L<
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M!!;_Y 06_^0$DZX  (6W  !XP   :LD  %W2  !0V0  1-\  #KD   U]P,
M,O\, "[_$@ K_QH */\A ";_)P C_RT (/\S ![_.0$<_S\!&?]% 1?_30$5
M_U4!$_]? 1'_:@(0_W@"#O^' @[_E@(-_Z0"#/^P @S_O@(,_\("#/_" @S_
MP@(,_\("A[8  'F_  !KR0  7M,  %#;  !#X   ..4  "_P   K_P  )_\(
M "3_#@ A_Q, 'O\9 !O_'@ 8_R, %?\H !/_+0 1_S( $/\X  [_/P ,_T8!
M"O]/ 0?_60$$_V4! ?]R 0#_@0$ _X\! /^; 0#_IP$ _ZD! /^I 0#_J0$
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MVD.1&=A"F1K50I\;TT&F'-%!KAW/0;<>SD'!'LQ!T!_)0N4?Q4+S(<)!_B/
M0?\DOD'_)+U!_R6]0?\EO4'_);U!_R6]0?\E_T(8 ?])$P#_4!0 _U89 /]9
M( '_6B@!]UHR N]8/03H54D'XU-5"MY18 [93FH2U$QT%M!+?!C.280;S$B,
M',I'DQ[(1YH?QD:A(<1&J2+"1;$CP46\([]%R22]1M\EN4;O)K9&^R>T1O\H
MLT;_*+)&_RBQ1O\HL4;_*+%&_RBQ1O\H_T85 /]-$0#_51( _UL6 /]>&P#Y
M8",![V L >9>-@/?7$0%V%E0"M%76P_,5&44R%)N&,50=QO#3W\=P$Z&'[Y-
MCB&\3)4CNDN<)+A*I":V2JPGM$JV*+-)PRFQ2=8IKDKJ*JM*^"NI2O\KJ$O_
M*Z=+_RNG2_\KITO_*Z=+_RNG2_\K_TD2 /]0#@#_61  _U\2 /]C%@#R91T
MYV4E -YD,0'48C\%S6!+"L==5@_"6F 5OEAI&;M6<1RX5'D?ME.!(K-2B"2Q
M4) FKU"7**U/GRFK3J@KJ4ZR+*=.OBVF3LXNHT[F+J%/]2Z?3_\NGD__+IU/
M_RZ=4/\NG5#_+IU0_RZ=4/\N_TP0 /]4#0#_70X _V,/ /EG$0#K:14 WVH<
M --J+ '+:#L$Q65'";]B4@^Z8%P5MEUE&;);;1VO674AK%A\(ZI6@R:G58LH
MI523*J-3FRRA4Z,NGU*M+YU2N3";4LDQF5+B,9=3\C&64_\QE53_,914_S"4
M5/\PE%3_,)14_S"45/\P_T\. /]8"P#_8 L ^V8, /!K#0#D;0X UFX6 ,QO
M* '$;3<$O6M$";=H3P^R95@5KF)A&JI@:1ZG7G AI%UX):%;?R>?6H<JG%F.
M+)I8ERZ85Z PE5:J,I-6M3.15L4TD%;=-(Y7\#2-5_TSC%C_,XQ8_S*,6/\Q
MC%C_,8Q8_S&,6/\Q_U$, /];"0#_8P@ ZVH' -UN" #8<0H SW(3 ,9S)0&^
M<C0#MW!!"+%M3 ZL:E44IV=>&:-E91Z@8VTBG&%T)9I@>RB77H,KE%V++9)<
MDS"/6YPRC5JF-(M:LC6)6L$VAUK6-H9;[3:%6_LUA5S_-(1<_S.$7/\SA%S_
M,X1<_S.$7/\S_U,* /]=!@#U9@0 WVT# -5R!@#0=0D R781 ,!W(@"X=C$#
ML70^!ZMQ20ZF;E(4H6Q;&9UI8AV99VHBEF9Q)9-D>"B08W\KC6&'+HI@D#"(
M7YDSA5^C-8->KS:!7KXX@%[1.']?ZC=^7_HV?F#_-7Y@_S1^8/\T?F#_-'Y@
M_S1^8/\T_U4( /]@! #H:0  VG # -!U!0#*> < PWH/ +M['P"S>B\"K'@\
M!Z9U1@VA<U 3G'!8&)=N8!V3:V<AD&IN)8UH=2B*9WPKAV:$+H1DC3&!8Y8T
M?V.A-GQBK3=Z8KLY>6+..7ACZ#AX8_@W>&3_-GAD_S5X9/\U>&3_-7AD_S5X
M9/\U_U<% /]B 0#A;   U'," ,MX! #%>P4 OGT- +9^'0"O?BP"J'PY!J%Y
M1 R<=TX2EW16&))R71R.<&0@BFYK)(=L<BB$:WHK@6J"+GYIBC%[:)0T>&>?
M-G9FJCAT9KDY<V;+.G)FYCER9_<X<F?_-W)H_S9R:/\U<FC_-7)H_S5R:/\U
M_UD" /9E  #=;@  SW8! ,=[ P# ?P0 N8 , +&"&@"J@BH"HX W!9U]0@N7
M>TL1DGA4%XUV6QN)=&(@A7)I)(%Q<"=^;W<K>VY_+GAMB#%V;)(T<VN<-G!J
MJ#AN:K<Z;6K).FQJY#IM:_4X;6O_-VUK_S9M:_\V;6O_-FUK_S9M:_\V_UL
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M.5QYW3E=>?$X77C^-UYX_S9>>/\U7GC_-5YX_S5>>/\U]60  -QP  #*>@
MP(,  +:)  "NC0  I(\  )V1$ "7DB  D9$N XJ0.0>$CD,,?XU,$GJ+4Q=U
MB5H;<8AA(&Z&:"-JA6\G9X1W*V.#?RY@@HDQ78&4,UN H399?Z\W5W_ .%=_
MVC=7?_ W6'[]-EA^_S58?O\U6'[_-5A^_S58?O\UZ6@  -1T  #&?@  NX<
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M+D:6_RY&EO\N1I;_+D:6_RY&EO\NT7<  ,&$  "VC@  JI4  *";  "5GP
MBJ0  'VI  !WJQ  <ZL> &^L+ %JJS<$9:M!!V&J20M=J5$/6JE8$U>H7Q93
MIV894*=N'$VF=A]*I8$A2*6,)$6EF29#I*@G0J2X*$&DSB=!H^HG0*+X*$"A
M_RE H/\I0*#_*4"@_RE H/\IR7X  +J+  "OE   HYH  )B@  "-I0  @JH
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M$B['_Q(NQ_\2KI<  *&>  "5I0  B:T  'RT  !PNP  9,$  %G&  !.RP,
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M8@ )_V\ "/]_ 0?_D $%_Z !!/^N 03_O $#_\<! __' 0/_QP$#_\<!@[0
M '6]  !GQ@  6L\  $O5   _W   ,^$  "GE   A[   'OT  !K_!0 7_PP
M%?\0 !+_%  0_QD #O\>  W_(P +_R@ "/\N  ;_-0 #_ST  /]&  #_40
M_UT  /]K  #_>P  _XL  /^9  #_I0  _ZP  /^L  #_K   _ZP _R<L ?\J
M*@'_*RH!_RHN ?\F- +_)3\"_R-+ _\A6 /_(&0$_QYP!/\=>P3_'84%_QV.
M!?\=E@7_'9P&_QVB!O\<J ;_'*X'_QRT!_\<NP?_',,'_QS.!_\=WP?_'>L'
M_!WU!_D=_@;W'O\']QW_"/8=_PGV'?\)]AW_"?8=_PGV'?\)_RDJ ?\L)P'_
M+B<!_RTJ ?\L,@'_*ST"_RE) _\G50/_)6$$_R-M!/\B> 7_(H(%_R&+!O\A
MDP;_(9H'_R&@!_\AI0?_(:L(_R&Q"/\AN C_(<$(_R'+"/PAW CY(>D(]B'T
M"/,B_0?R(O\)\2+_"O$A_POP(?\+\"'_"_ A_POP(?\+_RPF ?\P) '_,2,!
M_S$F ?\R+P'_,3H"_R]& _\M4@/_*UX$_REI!?\H=07_)W\&_R>(!_\FD ?_
M)I8(_R:="/XFHPG])JD)_":O"?LFM@GZ)KX)^";("?8FV0GR)N@)[R?S">TG
M_0KK)O\+ZB;_#>DF_PWH)O\.Z";_#N@F_P[H)O\._R\C ?\S( '_-1\!_S<C
M ?\X+ '_.#<"_S9" O\T3@/_,EH$_S!E!?\N< ;^+7L'_"V$"/HLC GX+),)
M]RR9"O8KH KT*Z8*\RNL"_(KLPOQ*[L+[RO&"^XLU OJ+.8+YBSR"^0L_ WB
M+/\/X2S_$. L_Q#?+/\1WRS_$=\L_Q'?+/\1_S,? ?\W&P'_.AH!_ST@ ?\_
M* '_/S(!_ST^ O\[20/_.54$^S=A!O<U; ?U-'8(\C-_"? RAPKO,H\+[3*6
M"^PQG SJ,:(,Z3&I#.@QL WF,;D-Y3'##>,RT0W?,N4,W#+Q#]@Q_!'5,?\2
MTC'_$]$Q_Q30,?\4T#'_%- Q_Q30,?\4_S<; ?\[%P#_/Q8 _T,< /]&) '_
M1BX!_T0Y OQ"1 /V/U $\3U<!NT\9P?J.W$)Z#IZ"N4Y@POC.(L,XCB2#> W
MF0W?-Y\.W3>F#MLWK0_9-K80US;!$-4VSA#1-^,1S3?Q$\HW^Q7(-_\6QC?_
M%\4W_QC$-_\8Q#?_&,0W_QC$-_\8_SL7 /] $P#_11, _TD8 /],( #_3"D!
M^DLS ?)(/@+L1DH$YT16!N-#8@C?06P*W$!U#-D_?@W5/H8/TSV-$-$]E!'/
M/)L2S3RB$\P\J13*.[$4R#N[%<<[R!;%/-P6P3SM%[X\^1F[//\:NCS_&[D\
M_QNX//\;N#S_&[@\_QNX//\;_SX4 /]$$ #_2A$ _T\4 /]1&P#[4B, \5$M
M >E/. 'B344#W$M1!=9)7 C11V8+SD9P#LM%>!#(1( 2QD.'%,1"CA7#0I46
MP4&<%[]!I!B]0*P9O$"V&KI PAJX0-(;M4'H&[)!]AVP0?\>KD'_'JU!_QZL
M0?\>K$'_'JQ!_QZL0?\>_T(1 /]'#0#_3PX _U,1 /]6%0#S5QP Z%8E .!5
M,0'74S\"SU),!<I05PG&3F$-PTQJ$,!*<A*]27H5NTB"%KE'B1BW1Y 9M4:7
M&[-&GQRQ1:<=L$6Q'JY%O!^L1<P?JD7C(*=&\R&E1O\AHT;_(J)&_R&B1O\A
MHD;_(:)&_R&B1O\A_T4. /]+"@#_4PP _U<- /E:$ #K6Q0 WUH< -1:*P#,
M6CL"QEA(!<%64PF\5%P-N5)E$;50;12S3W47L$Y\&:Y-A!JL3(L<JDN2'JA*
MFA^F2J,AI$FL(J-)N".A2<8DGTK>))U*\"2;2OTEF4O_))E+_R282_\DF$O_
M))A+_R282_\D_T@, /]/" #_5@@ ]5L) .E>"@#D7@T U5\5 ,M@)P#$7S8"
MOEY#!;A;3@FT65@.L%=A$JQ5:16J5' 8IU-X&J52?QRB488>H%".()Y/EB*<
M3I\CFDZH)9A.LR:73L(GE4[6)Y-.[">13_LGD$__)Y!0_R:/4/\FCU#_)H]0
M_R:/4/\F_TH) /]3!0#X6@0 XE\# -IB!@#48PD S6,2 ,1E(P"\93("MF-
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MJBQ]6K<M?%K)+GI:XRYZ6_4M>ES_+'E<_RMZ7/\J>ES_*GI<_RIZ7/\J_U$
M /);  #>9   SVH  ,=N @# < 0 NG , +)Q&@"K<2D!I7 W Y]N0@>:;$L,
MEFI4$9)H7!6.9F,8BV5I&XAC<!Z%8G@A@F%_)(!@B"9]7Y$I>U^<*WA>IRUV
M7K4N=5[&+W1>X2]T7_,N=%__+'1@_RMT8/\K=&#_*W1@_RMT8/\K_U,  .A>
M  #99P  RVT  ,-Q 0"[<P( M7,) *UU%P"G=2<!H70T YMR/P>5<$D+D6Y2
M$(QL612):F 8A6EG&X)H;AY_9G4A?65])'IDA29W9(\I=6.:*W)BI2UP8K,O
M;V+$+VYBWB]N8_(N;F/^+6YC_RQN8_\K;F/_*VYC_RMN8_\K_U4  .5@  #3
M:0  R'   +]T  "W=P$ L'<' *AX%0"B>20 G'@R I9V/0:1=$<+C')/#XAP
M5Q.$;UX7@&UD&GUL:QUZ:W,@=VIZ(W1I@R9R:(TI;V>7+&UGHRYK9K$O:6;!
M,&EFVS!I9_ O:6?]+6EG_RQJ9_\K:F?_*VIG_RMJ9_\K_E@  .%C  #/;
MQ',  +MX  "S>@  JWH$ *1[$@">?"( F'PO I)Z.P6,>$4*AW=-#H-U51)_
M<UP6>W)B&GAP:1UU;W @<FYX(V]M@29M;(LI:FR6*VAKH2YF:Z\O9&J_,&-K
MV#!C:^\O9&O\+61K_RUE:_\L96O_+&5K_RQE:_\L]%L  -UF  #+;P  P'8
M +=[  "O?@  IGX! )]_$ "9@!\ DX M HU_.06(?4,)@WM+#7YZ4Q)Z>%H6
M=G=A&7-U9QQP=&X?;7-V(FIR?R9H<8DH97"4*V)PH"U@;ZTO7V^]+UYOU"]>
M;^TO7V_[+5]O_RQ@;_\L8&__+&!O_RQ@;_\LZUX  -AI  #'<@  O'D  +-_
M  "K@@  H8(  )F##@"4A!T CH0K 8B#-@2#@D (?H!)#'E_41!U?5@4<GQ?
M&&Y[91MK>FP>:'ET(F5X?25B=X<G8':2*EUUGBQ;=:LN6G2[+UEUT2]9=.PN
M673Z+5IT_RQ:=/\K6G3_*UIT_RM:=/\KYF$  -%M  ##=@  N7T  *^#  "F
MA@  G(8  )2(# ".B1D B8DH 8.)- -^ASX'>89'"W2%3P]PA%83;8)=%VF!
M8QIF@&H=8W]R(&!^>B-=?80F6GR/*5A[G"M6>ZDL5'NY+5-[SBU4>NHM5'KY
M+%1Y_RM5>?\J57G_*E5Y_RI5>?\JX64  ,QQ  "_>@  M((  *N'  "AB@
ME8L  (V-"0"'CA8 @H\D 7V/,0)XCCL%<XU$"6^,3 UKBE019XE:%62(81AA
MAV@;7H9P'EN%>"%8A((D582-)E*#FBE0@J<J3X*W*TZ"S"M.@N@K3H'X*D^
M_RI/@/\I3X#_*4^ _RE/@/\IVVH  ,=U  "Z?P  L(<  *:,  "<CP  CY$
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M(#R;_R \F_\@PGP  +6(  "ID   GI8  ).;  "'GP  >Z0  &^H  !CK 0
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MA (DU)0"(M2F B'5N0(AU=("(-/K B#2]@,?T?\$']'_!!_1_P0?T?\$GYL
M )2B  "'J0  >;$  &VX  !@O@  5,,  $G'   ^RP  -= ! "W5!@ EVPL
M)-X2 "/>'  BWR4 (> N "#@-P ?X4  'N%* !WB4P <XUX &^-J !KD>  8
MY(@!%^6: 1;FK $5YL !%.?= 1/E[P$3X_H!$^/Z 1/C^@$3X_H!EJ(  (FI
M  ![L0  ;KD  &'   !4Q@  2,H  #W/   STP  *MD  "+> @ >ZPH '.P0
M !OM%P 9[1\ %^XF !7N+0 4[S4 $_ ] !'P1@ 0\5  #_);  [R:0 -\W@
M#/2*  OUG  *]:X "?;"  GVV0 (]>T "/7M  CU[0 (]>T BZD  'VR  !O
MN@  8L(  %7)  !'S@  .](  #'8   GW0  '^$  !GH   6^ 8 %/H- !+[
M$@ 0_!< #OP=  W](P ,_2D "OXP  C_.  &_T$  _],  #_6   _V8  /]W
M  #_B0  _YL  /^K  #_NP  _\X  /_/  #_SP  _\\ ?[(  '&Z  !CPP
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MKAV22;L>D$G,'HY*Y1Z-2O8>BTO_'HM+_QV*2_\=BDO_'8I+_QV*2_\=_T4
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M)'96VB1U5^\D=5?](W58_R)U6/\A=5C_(758_R%U6/\A_TT  .57  #37P
MR&0  +]G  "W:   L6<' *EH% "C:20 GF@R 9EG/02494<'D&1/"HQB5PV(
M85X0A5]E$X->;!: 77,8?5UZ&GM<@QUY6XP?=EN7(71:HB-R6J\D<5J_)7!:
MU25O6^TE;UO\(V];_R)O6_\B;UO_(6];_R%O6_\A^D\  .%:  #/8@  Q&<
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M)&!F_R-@9O\C86;_(F%F_R)A9O\BZ%@  --C  #$:P  N7$  +!U  "G=P
MGG4  )9V#0"0=QD BW@G (9W,P*!=CT$?'5&!WAS3@MU<E4.<7%<$6YP8Q1K
M;VH6:6YQ&69N>AQC;8,>86R.(5]KFB-=:Z<E6VNW)EIKRB9::^<E6VOW)%MJ
M_R-<:O\B7&K_(EQJ_R)<:O\BXUL  ,YF  # ;@  MG0  *QY  "C>P  F'D
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MA1  >88> '6'*P%QAS8";88_!&F%1P=EA$\*8H-6#5^#7 ]<@F,26H%K%5>
M<QA4?WT:47^('$]^E!]-?J(@2WVQ(4I]Q")*?>$A2WST(4M[_R!+>_\@2WO_
M($M[_R!+>_\@T&<  ,!R  "T>P  JH(  *"&  "5B   AX@  'R*  !VC X
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M'0!;GBD 6)XT 56>/0)2G44#4)U-!4V=5 =+G%L)2)QC"T:<:PU#FW4/09N
M$3Z:C1,\FIL4.IJK%3F:O14YFMD5.9CO%CF7_!8XEO\7.)7_%SB5_Q<XE?\7
MNWH  *^%  "DC   F)$  (V5  "!F@  =9T  &B@  !;I   5J4, %.F%P!1
MIR, 3Z<O $RG. %*IT$!2*=) D:G4 1#IU@%0:=?!C^F: @]IG(*.J9]"SBF
MB@TVI9D.-*6I#S.ENP\SI=0/,Z3N#S*B^Q RH?\1,J'_$3*A_Q$RH?\1M((
M *B,  "=D@  DI<  (:<  !YH0  ;:4  &&I  !5K   2Z\% $>P$ !%L!P
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M !G.K@$8SL4 &,WD !C,] $8ROP!&,K_ AC*_P(8RO\"FYD  (^?  ""I@
M=:T  &BS  !<N0  4+T  $3!   YQ   ,,@  "C, 0 @T 8 &=4+ !;7$  5
MV!D %=DB !39*P 3VC0 $]H] !+;2  1W%, $=U? !#=;0 0WGX #M^1  [@
MI  -X+@ #.#2  O?[0 ,WO< #-W[  S=^P ,W?L DI\  (6G  !WK@  :K4
M %V\  !0P0  1,4  #C)   NS0  )=$  ![5   6V@$ $=X& !#G#0 .YQ(
M#>@9  SH(0 +Z2D "NHQ  GJ.P 'ZT4 !>M1  3K7@ #ZVX  >N   #JE
MZJ<  .N\  #KT@  Z^D  .SO  #L[P  [.\ AZ<  'FO  !KMP  7KX  %'%
M  !#R0  -\T  "W1   CU@  &]L  !/?   .XP  #.X"  KV"@ ']@X !?82
M  /V&   ]1X  /4E  #U+@  ]3<  /9"  #V3@  ]ET  /9N  #V@0  ]I4
M />G  #WMP  ^,<  /C0  #XT   ^-  >Z\  &VX  !@P   4L@  $3-   W
MT0  *]<  "'<   8X   $>0   SG   '[P  !/H   '_ P  _P@  /\-  #^
M$   _A0  /\:  #_(0  _RD  /\S  #_/@  _TL  /];  #_;   _X   /^2
M  #_H0  _ZT  /^S  #_LP  _[, _QPF /\<) #_&B4 _Q4G /\1+@#_$#H
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M.[P/H#O-#YX[YA";//41FCS_$9D\_Q&8//\1F#S_$9@\_Q&8//\1_SH! /]
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M%HI%W!:(1O 6AD;]%H9&_Q:%1_\5A4?_%85'_Q6%1_\5_S\  .Q(  #=3P
MSU,  ,95  # 4P, NU$, +-2&0"M4RD J%,V :-20@*?44L$G%!4!IE/7 B6
M3F,*E$UJ#)%,<0Z/2W@/C4M_$8M*AQ*)2I 4ATF:%85)I1>#2;$8@DG &(%*
MUAE_2NT8?DO\&'Y+_Q=]2_\7?4O_%GU+_Q9]2_\6_T,  .9,  #64P  R5@
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M&VI7_QIJ5_\9:U?_&6M7_QEK5_\9ZTP  -A6  #(7@  O&(  +-E  "K90
MHV(  )QB#@"68QP D60I (QC-0&(8C\#A&%(!8!@4 =]7U<)>EY="W==9 UU
M7&L0<UQR$G!;>Q1N6X07;%J/&&I:FAIH6J<<9EJV'65:R!UE6N0=95KV'&5:
M_QME6O\:95K_&65:_QEE6O\9Z$\  --9  #$80  N68  +!H  "G:0  GF4
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M&E=F_QI79O\:VUD  ,=B  "Z:@  KW   *9S  ":<P  CW   (=Q!0"!<A$
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MC!-$@9H50H"I%D& NA9 @-(607_M%D%^^Q9!??\607W_%D%]_Q9!??\6PFH
M +5U  "J?0  GX(  )*#  "%A   >84  &J)  !DB@, 8(P0 %V-&P!;CB<
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M""Z@LP@NH,D(+I_G""V=]PDMG/\*+9O_"BV;_PHMF_\*KX   *.)  "7C@
MC9,  '^5  !RF   9IP  %N@  !/I   1:<  #ZI#  \JA0 .JH? #FJ*0 X
MJS( -ZL[ #6K0P TK$L ,JQ3 3&L7 $OK&8"+:QQ BNL?P,JK(X#**R>!">L
ML 0FK,4$)JOD R6I]00EJ/\%):?_!26G_P4EI_\%IXD  )N/  "1E   A)D
M 'B>  !KH@  7Z8  %.J  !(K0  /;   #2S P OM0X +;46 "RU(  KMBD
M*K8R "FW.@ HMT, )[=, ":X50 DN%\ ([AK "*X> $@N(@!'[B9 1VYJP$<
MN< !'+C? 1RV\@$;M?P"&[3_ ANT_P(;M/\"GX\  )25  "(FP  >Z$  &ZF
M  !BJP  5K   $JS   _M@  -;D  "R\   DOP8 '\(- !W"%  <PAX &\,F
M !K#+P 9Q#@ &,1! !?$2@ 6Q54 %<5A !3&;P 3QG\ $L:1 !''I  0Q[D
M#\?4 !#&[@ 0Q/H $,/_ !##_P 0P_\ EY8  (N<  !^H@  <:D  &2O  !8
MM   2[@  $"[   UO@  *\$  "/%   ;R0$ %,P& !#0"P .T1$ #=$9  W1
M(0 ,T2H #-$T  O2/@ *TDD "=-5  G38@ (TW( !M2$  74F  $U*L  ]7
M  '5W  !U>T  =7V  '5]@ !U?8 CIT  ("D  !SJP  9K$  %FX  !,O0
M/\   #3#   JQP  (<H  !G.   2T@  #=8!  G;!0 &W T !-P1  /=&  !
MWB   -XH  #?,0  X#P  .%'  #B5   XV,  .-T  #DB   Y)L  .6N  #E
MP0  Y=4  .;G  #FYP  YN< @Z0  '6L  !HLP  6KL  $W!  ! Q   ,\@
M "C,   ?T   %]0  !#9   +W0  !>$   #D    Y0<  .8-  #G$0  Z!8
M .D=  #J)0  ZRX  .TY  #O10  \%,  /%D  #Q=@  \HH  /.<  #SK0
M]+L  /3(  #TR   ],@ =ZT  &JU  !<O0  3\0  $#)   SS0  )]$  !W6
M   4W   #N    CC   !Y@   .H   #N    [@   .\$  #P"@  \0X  /,2
M  #T&   ]B   /@J  #Z-0  _4,  /Y2  #_8P  _W8  /^)  #_F@  _Z8
M /^P  #_L   _[  _Q8C /\5(0#_$2$ _PTD /\)*P#_!C< _P-$ /\ 40#_
M %T _P!H /\ <@#_ 'L _P"# /\ B@#_ )$ _P"6 /\ G #_ *$ _0"F /L
MK #Y +, ]P"[ /4 Q0#S -$ \@#D /$ \0#O /H [@#_ .X _P#M /\ [0#_
M .T _P#M /\ _QD@ /\8'0#_%1T _Q ? /\.*0#_##0 _PI! /\'30#_!5D
M_P1D /\$;@#_ W< _P.  /\#AP#_ XT _0*3 /L"F0#Y IX ]P*D /4"J@#S
M ;  \0&X .\!P@#M <\ ZP'C .H![P#H OL YP3_ .8%_P#F!O\ Y@;_ .8&
M_P#F!O\ _QP; /\;&0#_%Q@ _Q4= /\3)0#_$3  _Q ] /\.20#_#%4 _PM@
M /\+:@#]"W, ^PM\ /D*@P#W"HH ]0J0 /0*E@#S"IL \0JA .\)IP#M":X
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M /\E"P#_* P _RD0 /\H%@#^)B  ]"0K .PA. #F($0 X1]0 -T?6P#9'F4
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M!J0PX@:A,/,'GS#_")XQ_PB=,?\(G#'_")PQ_PB<,?\(_S   /\U  #O.
MXCH  -LY! #6-0D SC03 ,8V(@"_.#$ NC@_ +8X2@&S.%0!L#== JTW9 *K
M-FP#J39S!*@V>02F-8 %I#6'!:,UCP:A-9<'GS6@!YXUJ@B<-;8(FS7%"9DU
MW0F6-N\*E#;]"I,W_PJ2-_\*DC?_"I(W_PJ2-_\*_S,  /8Z  #D/P  V$(
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M$7A&_Q!X1O\0>$;_#WA&_P]X1O\/\#\  -])  #-3P  P5,  +A4  "Q4@
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M$F%6_Q)A5O\2X$T  ,M6  "]70  LF$  *AC  "=80  E5T  (U>"0"'7A,
M@U\@ ']?+ ![7S<!=UY  G1>2 -Q74\$;UQ6!6Q<7 =J6V,):%MK"V9:<PUD
M6GP/8EJ'$6!9DQ)>6: 475FN%5M9OQ9;6=@66UGO%5M9_11<6?\37%G_$EQ9
M_Q)<6?\2W%   ,=9  "Z8   KV0  *1E  "99   D&   (AA!@""8A$ ?F,=
M 'IC*@!V8S0!<V(] 6]B1@)L84T$:F%4!6=@6@=E8&$(8U]I"F%?<0Q?7GH.
M75Z%$%M>D1)979X46%VL%5==O1967=465EWN%5==_!177?\35UW_$E==_Q)7
M7?\2UE,  ,1<  "W8P  K&@  *!H  "59P  BF,  (-E @!]9@\ >&8: '1G
M)P!Q9S( ;F<[ 6MF0P)H9DL#9652!6-E609A9%\(7F1G"EQC;PQ:8W@.6&.#
M$%9BCQ)48IP34V*J%5)BNQ518M(546'M%5)A^Q128?\34V'_$E-A_Q)38?\2
MT58  ,!?  "S9@  J6L  )QK  "0:@  A6<  'UI  !W:@T <VL7 &]K) !L
M;"\ :6PX 69K00)C:TD#86M0!%YJ5P9<:ET'6FEE"5AI;0M5:'8-4VB!#U%G
MC1%/9YH23F>I%$UGN11,9\\43&;K%$UF^Q--9O\23F7_$DYE_Q).9?\2S%H
M +QC  "P:@  I6\  )AN  ",;0  @&P  '=M  !Q;@L ;6\4 &EP(0!F<2P
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M#CQ[LPX\>\@./'KF#CQY]PX\>/\./'C_#CUW_PX]=_\.O&@  *]R  "D>0
MEGH  (AZ  !\>@  <'P  &-_  !<@@  5X0+ %.%% !1AB  3X8J $Z'- !,
MASP!2H=$ 4B'2P)&AU,"1(9: T*&8@1 AFP&/H5V!SN%@P@YA9$*.(2@"S:$
ML0LVA,8+-H/D"S:"]@LV@?\,-H#_##: _PPV@/\,MF\  *IX  "??P  D'X
M (-_  !W@   :X(  %Z'  !5B@  3HP& $J.$ !(CQH 1X\E $60+P!$D#@
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M 1ZD[P$>HOL"'J'_ AZA_P(>H?\"HH8  )>,  "+CP  ?9$  &^4  !CF
M5YT  $VA  !#I0  .*@  #"K   HK@< )*\0 ".O%P AKR$ (+ I !^P,0 >
ML#H ';%" !RQ3  ;L58 &K%A !FR;P 8LGX %K*0 !6RH@ 4LK8 $[+. !.Q
MZP 3K_D $Z[_ 1.N_P$3KO\!FHT  )"2  "$EP  =9H  &B?  !;HP  4*@
M $6L   [L   ,;(  ">U   @N   &+H' !2\#@ 3O!4 $KP> !&])@ 1O2X
M$+TW !"^00 .ODP #KY7  V^90 ,OW0 "[^&  J^F0 (OJP ![["  >^WP (
MOO  "+WZ  B]_  (O?P DY0  (>9  !ZGP  ;*4  &"J  !3KP  1[,  #RV
M   QN   )[L  !^^   7P0  $<0!  S("  (R0X !\D4  ;)'  %R20 !,HL
M  /*-@ "RD   ,M,  #+60  RV@  ,MY  #,C   RY\  ,NS  #+R   S.(
M ,SO  #,\0  S/$ BIH  'RA  !OIP  8JT  %6S  !(N   .[L  #"^   F
MP0  '<0  !7(   /RP  "LX   32 @  TPH  -,/  #4%   U1H  -8B  #7
M*@  V30  -H_  #<2P  W%H  -UJ  #=?0  W9$  -VD  #>M@  WL@  -[>
M  #>X@  WN( ?Z(  '&I  !DL   5K<  $F\   \P   +\0  "3'   ;RP
M$\\   W2   'U@   -L   #>    WP,  . )  #A#@  XA(  .,7  #E'@
MYB<  .@Q  #J/0  [$L  .Q:  #M;   [H   .Z4  #NI0  [K0  .["  #N
MQ@  [L8 =*H  &:R  !8N0  2\   #W%   OR0  ),T  !G1   1U@  "]L
M  />    X0   .4   #H    Z0   .H   #K!@  [0L  .\/  #P$P  \AH
M /0C  #W+@  ^3L  /M*  #\6P  _6T  /V   #^DP  _J(  /ZM  #^KP
M_J\ _Q ? /\.'0#_"AT _P$@ /\ * #_ #4 _P!! /\ 3@#_ %H _P!E /\
M;@#_ '< _P!_ /X A@#\ (P ^P"2 /D EP#X )P ]P"B /8 IP#U *T \P"U
M /( O0#Q ,D [P#< .X ZP#M /< [ #_ .L _P#J /\ Z@#_ .H _P#J /\
M_Q,< /\1&0#_#1D _P8< /\#)0#_ #$ _P ^ /\ 2@#_ %8 _P!A /\ :P#]
M ', ^@![ /< @P#U (D ] "/ /( E #Q )D \ "? .X I #M *L [ "R .H
MN@#H ,8 YP#6 .4 Z #D /4 XP#^ .( _P#A /\ X0#_ .$ _P#A /\ _Q48
M /\3% #_#Q0 _PT9 /\+(@#_""T _P0Y /\!1@#_ %$ _@!< /H 9@#V &\
M\@!W .\ ?@#M (4 ZP"+ .H D0#H )8 YP"< .8 H0#D *@ XP"O .$ N #?
M ,, W0#1 -L Y@#9 /, UP#] -4"_P#4 O\ U /_ -0#_P#4 _\ _Q@3 /\5
M$ #_$@\ _Q(5 /\1'0#_#B@ _PPT /\*00#Y"$P ]097 /$&80#M!FH Z05R
M .8%>@#D!8$ X@6' . &C0#?!I( W0:8 -L&G@#9!J4 UP:M -0&M0#2!L
MT ?/ ,X(Y0#,"?0 R@O_ ,@,_P#'#/\ QPS_ ,8,_P#&#/\ _QL. /\9# #_
M& T _Q@1 /\7& #_%"( ^Q$N /,0.@#M#D8 Z U2 .4-7 #A#64 W@UM -L-
M=0#8#7P U0V" -,-B0#1#8\ T V5 ,X-G #-#J, RPZK ,D.M #(#L  Q@[/
M ,,0Y@# $?4 O1+_ +P2_P"[$O\ NA+_ ;H2_P&Z$O\!_Q\* /\<! #_'P@
M_Q\- /\=$@#X&AL [A8F .84,P#@$S\ VA-+ -035@#0$U\ SA1H ,L4;P#)
M%'< QQ5] ,85A #$%8H PQ61 ,$6F # %I\ OA:G +P7L "[%[P N1?+ +<8
MX@"S&?(!L1K_ :\;_P&N&_\!KAO_ :T;_P&M&_\!_R($ /\B  #_)0( _"0'
M /<A# #L'1( X1H< -@:*@#0&S@ RQU% ,<=4 ##'EH P!YB +X>:@"\'W$
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M!8TQ_P6-,?\%C#'_!8PQ_P6,,?\%_RT  .HU  #<.@  SCT  ,8\  # -P(
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M"FM&_PIK1O\*Y4   ,])  #!3P  M5(  *M2  "A3P  FTH  )1*# "/2Q<
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MC0M95)H-6%2G#E95N ]65<P/5E7I#E95^0U65?\-5U3_#%=4_PQ75/\,T4T
M ,!6  "S7   IUX  )I=  "/7   AE@  ']9  !Y6@T =%L7 '%;(P!N6RX
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M#$ABL@U'8L<-1V+D#4AA]@Q(8?\,2&#_"TE@_PM)8/\+Q%@  +5@  "J9@
MFV8  (UF  ""90  =F0  &YE  !H9@4 8V<0 &!H&@!=:24 6VHO %EJ. !7
M:D !56I' 5-J3@)1:E4#3VE=!$UI9 5+:6T&26AX!T=HA E&:)(*1&>A"T-G
ML0Q"9\4,0F?B#$)F]0Q#9O\+0V7_"T-E_PM#9?\+OUP  +%D  "F:@  EFD
M (EI  !]:0  <6D  &=J  !B; $ 76T- %EN%@!7;R$ 57 K %-P-0!1<#T
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M<@  :',  %QV  !4>0  3GL% $I]#P!(?A@ 1G\C $5_+ !#@#4 0H ] $&
M10 _@$P!/8!4 3R 7 (Z?V4".']O S9_? 0T?XH$,G^:!3%^J@8P?KT&,'[:
M!C!]\ 8P>_T&,'O_!C!Z_P8P>O\&L&P  *1U  "4=0  AG4  'EV  !N=P
M8WD  %=]  !/@0  1X0  $*&#  _AQ, /8@= #R()P [B3  .HDX #B)0  W
MB4@ -HE/ #2)6 $SB6$!,8EL 2^)> (MB8<"+(F7 RJ(IP,IB+H#*8C4 RF&
M[@,IA?P$*83_!"F$_P0IA/\$JG0  )Y[  ".>@  @'H  '1[  !H?@  78$
M %*%  !)B0  08P  #F0!0 UD0\ ,Y(7 #*2(0 QDBD ,),R "Z3.@ MDT$
M+)-* "N44@ JE%P *)1G ">4<P$EE((!))23 2*3I $AD[<!()// 2&2[ $@
MD/H"((__ B"/_P(@C_\"I'P  )>   "'?P  >X   &Z"  !BA0  5XD  $V.
M  !"D@  .I8  #*9   JG D *)T1 ":=&0 EG2( ))XJ ".>,@ BGCH (9Y"
M "">2P ?GU4 'I]@ !R?;0 ;GWP &I^- !B?GP 7G[( %I_) !:>Z  6G/<
M%IO_ 1>;_P$7F_\!G8,  (^&  ""A@  =(<  &>+  !;CP  4),  $:8   \
MG   ,Z   "NC   CI@  '*@+ !JI$0 8J1@ %ZDA !:J*0 5JC$ %*HY !.J
M0P 3JTT $JM8 !&K90 0JW0 #JN&  ZKF0 -JZP #*O!  RJWP ,J?( #:C\
M  VH_P -J/\ EHH  (F,  !ZC0  ;)$  &"5  !4F@  29\  #^C   UIP
M*ZH  ".N   ;L   %+,!  ^U"@ -MA  #+86  NV'P *MB< ";8O  BV.0 '
MMT, !K=/  2W6P #MVH  K=[  "WC@  MZ$  +:T  "VRP  MN4  +7Q  "U
M]P  M?< CY$  (&4  !REP  99P  %BA  !,I@  0:L  #>O   LL@  ([4
M !JX   3NP  #KT   G !0 #P0T  ,$1  #!%P  PAX  ,(F  #"+P  PSD
M ,1$  #$4   Q%X  ,5O  #%@0  Q94  ,6H  #%O   Q-$  ,3F  #$[@
MQ.X AI@  'F>  !KHP  7:D  %"N  !$LP  -[8  "RY   BO   &;\  !'"
M   ,Q0  !L@   #+    S <  ,P-  #-$0  S18  ,X=  #/)   T"T  -(X
M  #41   U%(  -5A  #5<P  UH<  -:;  #6K0  U[\  -C.  #8W0  V-T
M>Z   &ZF  !@K0  4[,  $6X   XO   *[\  "'"   7Q@  $,D   K,   "
MT    -0   #7    V    -H%  #;"P  W X  -X3  #?&0  X2$  .,J  #E
M-@  YT,  .=3  #H9   Z7<  .F,  #JGP  ZJX  .JZ  #JPP  ZL, <*@
M &*O  !5M@  1[P  #G    LQ   (,@  !;,   .T   !]0   #9    W0
M .$   #C    Y    .8   #G 0  Z0<  .L,  #L$   [A4  / =  #S)P
M]C,  /=#  #X5   ^68  /EZ  #ZC@  ^IX  /NI  #[L   ^[  _PL; /\'
M&0#_ !D _P < /\ )0#_ #( _P _ /\ 2P#_ %< _P!B /\ :P#_ ', _0![
M /L @@#Z (@ ^ "- /< D@#V )@ ]0"= /0 H@#S *D \0"P .\ N #N ,,
M[ #1 .L Y@#I /, Z #^ .@ _P#H /\ Z #_ .@ _P#H /\ _PX8 /\*%0#_
M 10 _P 8 /\ (@#_ "X _P [ /\ 1P#_ %, _0!> /H 9P#W &\ ]0!W /,
M?@#R (0 \ ") .\ CP#N )0 [ ": .L GP#I *4 Z "L .8 M #D +\ XP#,
M .$ X@#? /  W@#[ -X _P#= /\ W0#_ -P _P#< /\ _Q 3 /\-$0#_!A
M_P(5 /\ '@#_ "D _P V /\ 0@#Z $X ] !9 /$ 8@#N &L [ !R .H >0#H
M '\ YP"% .4 BP#D )  X@"6 .$ G #? *( W0"I -H L0#8 +L U0#( -(
MW0#1 .T T #Y ,\ _P#. /\ S0#_ ,T _P#- /\ _Q$/ /\.#0#_# T _PL2
M /\'&0#_ B0 _P P /8 / #O $D Z@!3 .< 70#D &8 X0!M -\ = #= 'L
MVP"! -D A@#6 (P U "2 -( F #0 )X S@"F ,P K@#* +@ R #$ ,8 UP#%
M .H PP#W ,( _P#! ?\ P +_ , "_P#  O\ _Q0+ /\0!@#_$ D _Q . /\.
M% #_"AX ]08I .L$-@#C T( WP-. -L$5P#6!&  TP1H - $;P#.!78 S 5\
M ,H%@@#)!8@ QP6. ,8%E #$!9L P@6C , &JP"^!K4 O0;" +L(U "Z">D
MMPOX +4,_P"T#/\ M S_ +0,_P"T#/\ _Q<$ /\4  #_%@, _Q0) /\1#@#R
M#A4 Z PA -X*+@#6"SL T Q' ,P,40#)#%H Q@UB ,0-:@#"#7$ P UW +\-
M?0"]#H, O Z* +H.D0"Y#I@ MPZ@ +8.J0"T#[0 L@_! +$0U "N$>L JQ+Z
M *D2_P"H$_\ IQ/_ *<3_P"G$_\ _QH  /\;  #Y&P  ZQD  .44!@#E$ X
MV0X7 ,\1)@#($C0 Q!-  +\42P"\%%0 N15= +<59 "U%6L M!5Q +(5> "Q
M%GX KQ:% *X6C "L%I0 JQ>< *D7I@"G&+  IAB] *08SP"B&N< GQKW )T;
M_P&<&_\!G!O_ 9L;_P&;&_\!_QT  /<A  #H)   W24  -0A 0#/&P@ RA<1
M ,(:( "\'"T MQTZ +,>10"P'D\ K1Y7 *L>7P"I'V8 J!]L *8?<P"E'WD
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M WPQ_P-\,?\#[2\  -LW  #)/0  OCX  +,\  "L.   IS,$ *(R$0"=-!T
MF34J )4U-0"2-4  CS5) (TU4 "+-5< B35> 8<U9 &%-&L!A#1R H(T>0*
M-(("?C2+ WTTE@-[-:$$>36N!'@UO@5W-M0%=C;M!70W_ 5T-_\$=#?_!'0W
M_P1T-_\$YS4  -(]  ##0@  N$0  *Q"  "D/@  GSD  )HX#@"4.AD D#HF
M (T[,0"*.SL ASM$ (0[3 "".U,!@#I: 7XZ8 %].F<">SIN GDZ=0)W.GX#
M=CJ(!'0ZDP1R.IX%<3JK!6\[NP9N.\\&;3OJ!FT\^@9L//\%;#S_!6P\_P5L
M//\%XCD  ,Q"  "^1P  L4@  *5&  "=0P  ES\  )(^"P"-/Q4 B3\A (5
M+0""0#< ?T!  'U 2 ![0$\!>4!6 7<_70%U/V,"<S]J G$_<@-P/WH#;C^$
M!&P_D 5K/YP&:3^I!F@_N =G0,P'9D#H!V9 ^09E0/\&94#_!F5 _P5E0/\%
MW#X  ,=&  "Y2P  K$P  *!*  "71P  D4,  (M#" "&0Q( @D0> 'Y$*0![
M130 >44] '9%10!T1$P!<D13 7!$60%N1& ";$-G FM#;P-I0W<$9T.!!69#
MC09D0YD&8D.G!V%$M@A@1,H(8$3F"%]%^ =?1?\'8$7_!F!$_P9@1/\&UD$
M ,-)  "V3@  IT\  )M-  "22P  C$<  (5'! " 1Q  ?$@: 'A()@!U23
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M"%%0L0E04,0)4%#A"5!0] A14/\'44__!U%/_P913_\&R4L  +E3  "K5P
MG%8  (]5  "%5   ?%   '51  !P4@D :U,2 &A4'0!E5"< 8E0Q &!4.0!>
M5$$ 7%1( 5I43P%95%8!5U1= E9490-45&X$4E1X!5%4A 9/5)$'3E2@"$Q4
MKPA,5,()2U3?"4Q4\PA,4_\'3%/_!TU3_P9-4_\&Q4X  +96  "G6@  F%D
M (M8  "!5P  =U0  '!5  !J5@8 9E<0 &)7&@!@6"0 75@N %M9-P!963\
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M!SUA[P8]8?T&/F#_!CY@_P8^8/\&N5D  *MA  ":80  BV$  ']A  !T80
M:6$  %]B  !99   5&8) %%G$0!.9QH 3&@D $MI+0!):38 2&D^ $9J10!%
M:DP 0VI4 4)J7 % :64"/FEO CQI>P,[:8D$.6F8!3AHJ 4W:+H%-VG3!3=H
M[@4W9_P%.&;_!3AF_P4X9O\%M%X  *=E  "590  AF0  'IE  !O90  9&8
M %EH  !2:@  36P$ $EN#@!';A8 16\@ $1P*0!"<#( 07 Z $!Q0@ _<4D
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M B)]_P(B??\"I7$  )-Q  "#<0  =G$  &QR  !@=0  5G@  $Q\  !#@
M.X,  #.&   MB0H *HH1 "F+&0 GBR( )HLJ "6,,0 DC#D (XQ" "*-2@ A
MC50 ((U> !^-:P =C7D '(V* !N-G  9C:X &(S$ !B,XP 9BO4 &8G_ 1F(
M_P$9B/\!G7<  (QV  !]=@  <G<  &5Y  !:?   4(   $:$   \B0  -(P
M "V0   EDP( 'Y4, !V6$@ <EAH &Y<B !J7*@ 9ES( &)@Z !>80P 6F$T
M%9A8 !289  3F', $9B$ !"8E@ 0F*D #IB_  Z7W0 /EO( $)7\ !"4_P 0
ME/\ E7T  (5\  !X?   :WX  %^!  !4A@  2HH  $"/   VDP  +9<  "::
M   >G0  %Z # !*B#  0HQ( $*,9  ^C(0 .I"D #J0Q  VD.@ ,I$4 "Z10
M  JD7  )I&H !Z1[  :CC@ $HZ$  J.T  .BRP #HN8  Z'S  .A^P #H?L
MC8,  '^"  !QA   9(<  %B,  !-D0  0I8  #B:   OG@  )J(  !ZE   7
MJ   $:L   RN!P 'KPT  Z\2  *O&0 !KR$  *\I  "P,@  L#P  +!'  "P
M4P  L&$  +!Q  "P@P  KY<  *^J  "OOP  KMD  *[K  "N]   KO0 AXD
M 'B*  !JC@  79,  %&8  !%G0  .Z(  #"F   GJ@  'JX  !:Q   0M
M"[8   6Y P  N@H  +H.  "Z$P  NQD  +LA  "\*   O#$  +T\  "^2
MOE8  +YE  "^=P  OHP  +Z?  "]LP  OL<  +[>  "]ZP  O>L ?Y(  '"5
M  !BF@  59\  $FE   ]JP  ,J\  "BT   >M@  %;D   Z\   )OP   L(
M  #$    Q00  ,8*  #&#@  QQ(  ,@8  #)'P  RB<  ,PP  #./   SDD
M ,]9  #/:@  SWX  ,^3  #/I@  S[@  ,_(  #/VP  S]L =YP  &BA  !;
MIP  3JX  $&T   TMP  *+H  !V]   3P   #<0   ;'    R@   ,X   #0
M    T0   -("  #3"   U0P  -80  #9%0  VQP  -TD  #@+P  XCP  .-+
M  #D7   Y&\  .6#  #EF   Y:D  .6V  #EPP  Y<, ;*4  %^L  !1L@
M1+D  #6\   HP   ',0  !+(   ,RP   \\   #3    V    -P   #?
MWP   .$   #C    Y ,  .8(  #H#0  Z1$  .P8  #N(@  \2X  /,\  #T
M30  ]5\  /9S  #WAP  ]YD  /BE  #XL   ^+  _P,7 /\ %0#_ !4 _P 8
M /\ (P#_ "\ _P \ /\ 2 #_ %0 _P!> /\ 9P#] &\ ^P!V /D ?0#X (,
M]@"( /4 C@#T ), \@"8 /$ G@#P *0 [@"K .T LP#K +T Z@#+ .@ X0#G
M /$ Y@#] .4 _P#D /\ Y #_ .0 _P#D /\ _P<3 /\ $0#_ !$ _P 5 /\
M'P#_ "L _P W /\ 1 #^ $\ ^@!: /< 8P#T &L \@!R /  >0#O '\ [0"$
M .L B@#J (\ Z "4 .< F@#E *  Y "G .( KP#@ +D W@#& -P V@#: .P
MV #Y -8 _P#6 /\ UP#_ -@ _P#8 /\ _PH0 /\##@#_  T _P 2 /\ &@#_
M "8 _  R /< /P#T $H \0!5 .T 7@#J &8 Z !N .4 = #C 'H X@"  .
MA0#> (L W "0 -L E@#8 )P U0"C -, JP#1 +4 S@#! ,P T0#+ .< R0#U
M ,@ _P#( /\ R #_ ,@ _P#( /\ _PP, /\&" #_ @H _P / /\ %0#\ "
M\0 L .P .0#I $4 Y0!/ .$ 60#> &$ VP!H -< ;P#4 '4 T@![ -  @ #.
M (8 S ", ,L D@#) )@ QP"@ ,4 J ## +$ P0"\ +\ RP"] ., O #R +L
M_0"[ /\ N@#_ +H _P"Z /\ _PX% /\)  #_"04 _P8+ /\!$ #P !D Y@ E
M .$ ,@#< #\ U@!) -$ 4P#. %L RP!C ,@ :@#& '  Q0!V ,, >P#! ($
MP "' +X C@"\ )0 NP"< +D I "W *X M0"Y +, R "Q -\ L 'O *\!^P"N
M O\ K0/_ *T#_P"M _\ _Q   /\.  #_#0  ]@L# /('"@#B 1$ VP(= -(#
M*P#, S< R 1# ,0$30#!!%8 O@5= +P%9 "Z!6L N 5Q +<%=@"U!7P LP:#
M +(&B0"P!I$ KP>9 *T'H0"K!ZL J0BW *@)Q@"F"MT I0OP *,,_0"B#?\
MH0W_ *$-_P"@#?\ _Q$  /P2  #L$P  XA,  -L/ P#6"0L S@@4 ,8*(@#
M##  O T\ +@-1@"U#4\ L@Y7 + .7P"N#F4 K0YK *L.<0"J#G@ J Y^ *</
MA0"E#XT I ^6 *(0GP"@$*D GQ"U )T1Q0";$=X F1+Q )<3_P"6%/\ E13_
M )44_P"4%/\ _Q4  .T;  #@'P  TA\  ,D;  #$% 4 P1 . +H2&P"T$RD
ML!0U *P50 "I%4D IA52 *0660"B%F  H19F )\6; ">%G( G!9Y )L7@ "9
M%X@ F!>1 )88FP"4&*8 DQFR )$9P0"0&M@ C1ON (L<_0"*'/\ BAS_ (D<
M_P")'/\ ]!T  .0E  #3*0  QRH  +PF  "V(   M!D+ *X:%0"H'", I!TO
M *$>.@">'D0 FQY, )D>5 "7'UL E1]A )0?9P"2'VT D1]T (\@? ".((0
MC""- (H@EP")(:( AR&N (8BO0"%(M$!@B/K 8$D^P& )/\!?R3_ 7\D_P%_
M)/\!["4  -LM  #),0  O#$  +$N  "K*0  IR0% *,C$0">)!T FB4J )8F
M-0"3)C\ D29' (\F3P"-)E8 BR=< (DG8@"()VD AB=O (4G=P"#)W\ @2>)
M 8 HDP%^*)X!?2FK 7LIN0%Z*<T!>"KH 7<K^0%V*_\!=BO_ 74K_P%U*O\!
MY2P  - T  #!.   LS@  *@U  "B,0  G2T  )DJ#@"4*Q@ D"PD (TM, "*
M+3H ARU# (4M2@"#+5$ @2Y8 ( N7@!^+F0 ?2YK 'LN<P%Y+GL!>"Z% 78N
MCP%T+YL!<R^H G$OM@)P,,D";S#E FXQ]P)M,?\";3'_ FTQ_P)M,?\"WS(
M ,DY  "[/@  K#T  *$Z  ":-P  E3,  ) Q"@",,10 AS(@ (0S*P"!,S4
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M UL_KP1:/\$$6C_=!%D_\@19/_\#63__ UD__P-9/_\#S#\  +Q&  "K2
MG$<  )%&  "(1   @D   'P_  !W0 P <T 5 &]!( !L02H :D$S &A!.P!F
M0D, 9$)* &-!4 !A05< 8$)> 5Y"90%=0FX"6T)X EI"A -80I #5T*>!%9#
MK0150[\$5$/:!%1#\0140_X#5$/_ U1#_P-40_\#R$(  +A)  "G2P  F$H
M (U)  "#1P  ?4,  '9#  !Q1 H ;402 &I%'0!G12< 9$4P &)%. !@13\
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M!$9/[01&3OP$1D[_ T=._P-'3O\#O4P  *Y2  "<40  C5$  (%1  !W4
M;DP  &=.  !B3P  75 - %I0% !741X 55$G %-1, !14C@ 4%(_ $Y21@!-
M4DT 3%-5 $I370%)4V4!2%-O D93>P)%4XD#0U.7 T)3IP1!4[@$05//!$%3
M[ 1!4OL#0E+_ T)2_P-"4?\#ND\  *I4  "85   B50  'U3  !S4P  :5$
M &)2  !<4P  6%0* %15$@!251L 3U8D $Y6+0!,5S4 2U<\ $I71 !(5TL
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M C)@_P(R8/\"KEP  )M=  "*70  ?%T  '!=  !F70  7%X  %)@  !,8@
M164  $%F"@ ^9Q$ /&@: #MH(@ Y:2L .&DR #=J.@ V:D$ -6I) #1J4@ S
M:EL ,6IE #!J< $N:GX!+6J. 2QJGP$K:K !*FK& 2IIY0$J:/8"*V?_ BMG
M_P(K9_\"J6$  )5@  "$8   =V   &QA  !B80  6&,  $YF  !':   0&L
M #IN!0 V;PX -' 5 #-P'@ R<28 ,'$N "]Q-0 N<CT +7)% "QR30 K<E<
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M8P 5AG$ %(:! !*&DP 1AJ8 $86[ !"%U@ 1@^\ $8+[ !*"_P 2@?\ D6X
M (%M  !T;@  :6X  %UP  !3<P  27<  $!\   W@   +X,  ">'   AB@
M&HT& !6/#0 3D!, $I : !*0(@ 1D"H $)$R !"1.P /D40 #I%/  V17  ,
MD6H "Y%Z  J1C0 (D)\ !Y"S  >/R0 'C^8 !X[T  B-_  (C?\ B7,  'MS
M  !O<P  8W4  %=X  !-?0  0X$  #F&   PB@  *(X  "&1   :E0  $Y<
M  Z:"  +G X "9P3  B<&@ 'G"( !IPJ  2<,P #G#T  IU(  "=5   G6(
M )QR  "<A   G)<  )NJ  ";OP  FML  )KL  ":]0  F?@ @GD  '9Y  !H
M>@  7'X  %&"  !&AP  /(P  #*1   IE0  (9D  !F=   2H   #J,   FF
M!0 #IPP  *<0  "G%0  J!P  *@C  "H*P  J30  *D_  "I2P  J5D  *EH
M  "I>@  J8X  *FA  "HM0  J,L  *?D  "G[P  I_, ?8   &^!  !AA
M58D  $F.   ^E   -)D  "J>   AH@  &:8  !*I   -K   !Z\   "R
MLP<  +,,  "S$   M!4  +0;  "U(@  MBL  +<U  "W0   N$X  +A=  "X
M;@  N((  +B7  "XJ@  M[X  +?2  "WY@  M^H =H@  &>+  !:D   3I8
M $*<   WH@  +*<  "*K   9KP  $;,   NV   $N0   +P   "^    O@
M +\&  # "P  P0\  ,(3  ##&0  Q"   ,4I  #'-   R$(  ,E1  #)8@
MR74  ,F*  #)GP  RK$  ,K!  #)T0  R=D ;I,  &"8  !3G@  1J0  #JK
M   OL   )+4  !FX   0O   "K\   '!    Q    ,@   #*    R@   ,P
M  #- P  S@@  - -  #1$   TQ8  -8>  #:*   W30  -Y#  #?5   WV<
M .!\  #@D0  X*0  ."R  #@O@  X,, 9I\  %FF  !,K0  /[0  #*X   D
MO   &+\  !##   (QP   ,H   #-    T0   -4   #8    V0   -L   #=
M    WP   .$$  #C"@  Y0X  .<3  #J'   [2<  / U  #Q1@  \E@  /-K
M  #S@   ])0  /2C  #TK@  ]+( _P 3 /\ $0#_ !$ _P 5 /\ 'P#_ "P
M_P Y /\ 10#_ %  _P!: /X 8P#[ &L ^0!R /< > #U 'X ] "$ /( B0#Q
M (X \ "3 .X F0#M )\ [ "F .H K@#H +@ Y@#% .4 VP#C .T X@#[ .(
M_P#A /\ X0#_ .$ _P#A /\ _P 0 /\ #@#_  T _P 2 /\ &P#_ "@ _P T
M /X 00#[ $P ]P!6 /0 7P#Q &8 [P!M .P = #J 'H Z0!_ .< A0#F (H
MY0"/ ., E0#A )L X "B -X J@#; +0 V0#  -8 T #3 .@ T@#W -$ _P#1
M /\ T #_ -  _P#0 /\ _P - /\ "0#_  H _P / /\ %@#[ "( ]P O /0
M.P#P $< [0!1 .D 6@#E &( X@!I .  ;P#> '4 W !Z -H @ #8 (4 U0"+
M -, D0#1 )< SP"> ,T I@#+ *\ R0"Z ,< R0#% .( Q #R ,, _@#" /\
MP0#_ ,( _P#" /\ _P,& /\  0#_  8 _P , /D $0#Q !T ZP I .< -@#C
M $$ WP!+ -L 5 #5 %P T@!C ,\ :@#- '  RP!U ,D >P#( (  Q@"& ,4
MC ## ), P0": +\ H@"] *L NP"V +D Q "W -H M@#M +0 ^@"T /\ M #_
M +0 _P"T /\ _P0  /\   #_    _P & .P #0#E !8 W@ B -< +P#1 #L
MS0!% ,H 3@#& %< Q !> ,$ 9 "_ &H O0!P +P =0"Z 'L N0"! +< AP"U
M (X LP"5 +( G@"P *< K@"R *P OP"J -$ J #H *@ ]P"G /\ IP#_ *8
M_P"F /\ _P8  /\%  #Q P  Z    .$ !P#5 !  S0 ; ,< )P## #, OP ^
M +P 2 "Y %$ M@!8 +0 7P"R &4 L !J *\ < "M '8 K !\ *H @@"I (D
MIP"1 *4 F@"C *0 H0"N *  NP"> <T G0+F )P$] ";!/\ F@7_ )H%_P"9
M!?\ _PH  /$.  #D$   V0\  ,X+  #( PL P@ 3 +P"'P"W RP LP0W + %
M0@"M!DH J@92 *@'60"F!U\ I0=E *,':P"B"'$ H AW )\(?@"="(4 FPF.
M )H)EP"8"J$ E@JL )4+N@"3"\P D@SE ) -]@"/#O\ C@[_ (X._P"-#O\
M]A$  .87  #6&P  QQD  +X5  "Y$   MPH- +$+%P"L#20 J XP *4..P"B
M#D0 GP], )T/4P";#UH F@]@ )@09@"7$&P E1!R ),0>0"2$($ D!"* (\1
ME "-$9\ BQ&J (H2N "($LL AA/F (44]P"#%?\ @Q7_ ((5_P""%?\ [1H
M -PA  #*)0  NR(  +$?  "K&@  J10& *42$0"@%!X G!4J )D5-0"6%CX
ME!9' )(63@"0%E4 CA=; (P780"+%V< B1=M (@7= "&&'P A1B& (,9D "!
M&9L @!JG 'X:M0!]&\< ?!SB 'H=]0!Y'?\ >!W_ '@=_P!X'?\ Y2(  - I
M  "_+   L"H  *<G  "@(P  G1\  )H:#@"5'!@ D1TD (X>+P",'CD B1Y!
M (<?20"%'U  @Q]6 ((?7 " 'V( ?Q]I 'T@< !\('@ >B"! 'DAC !W(9<
M=2*D '0BL@!S(\, <B/? ' D\P!O)/\ ;R3_ &XD_P!N)/\ W2D  ,@P  "W
M,@  J#   )XN  "7*@  DR<  ) C"@",(Q, B"0? (0E*@"")30 @"8] 'TF
M1 !\)DL >B92 '@F6 !W)EX =29E '0G; !R)W0 <2=] &\HB !N*)0 ;"BA
M &LIKP%J*< !:2K; 6<J\0%G*_\!9BO_ 68J_P%F*O\!U"\  ,(V  "O-@
MH34  )8T  "0,   BBT  (<J!@"#*1  ?RH: 'PK)0!Y*R\ =RPX '4L0 !S
M+$< <2Q- ' L5 !N+%H ;2QA &LM: !J+7  :"UZ &<NA0!E+I$!9"Z> 6(O
MK %A+[T!83#5 6 P[P%?,/T!7S#_ 5\P_P%?,/\!S30  +P[  "I.@  FSH
M ) X  ")-0  @S(  '\P 0![+PX =S 6 '0P(0!Q,2L ;S$T &TQ/ !K,4,
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M DX^Z0)-/OH"3C[_ 4X]_P%./?\!P#\  *Y#  "<0P  CD,  ()"  !Z0
M<ST  &T\  !H/04 9#T. &$^%P!>/B$ 7#XI %H^,0!8/CD 5SY  %4_1@!4
M/TT 4S]5 %) 7 !00&4 3T!O 4Y!>@%-08<!2T&6 4I!I0))0K4"24++ DE"
MZ ))0OD"24'_ DE!_P%)0?\!O4,  *I%  "810  BD4  ']%  !V0P  ;T
M &A   !C00$ 7T$- %Q!% !90AT 5T(F %5"+@!30C8 44(] $]"0P!/0TL
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M 3M,_P$\3/\!LTT  )Y,  "-3   ?TP  '1,  !J3   8$H  %E+  !43
M4$T% $Q.#@!)3Q4 1T\> $5/)@!$4"X 0E U $%0/0! 440 /U%+ #Y14P ]
M4EP /%)F #I2<@ Y4G\!.%*. 3=2G@$V4J\!-5+$ 352X@$V4O4!-E'_ 390
M_P$W4/\!KD\  )E/  ")3P  >T\  '!/  !F3P  7$X  %1/  !/40  2E(!
M $93# !#5!( 050; $!5(P ^52L /58R #Q6.@ [5D$ .E9) #E740 X5UH
M-E=C #57;P T5WP!,U>, 3%7G $P5ZT!,%?" 3!7X $P5O0!,5;_ 3%5_P$Q
M5?\!J%(  )52  "$4@  =U(  &Q2  !B4@  6%,  $]4  !)5@  1%<  $!9
M"  ]6A  .UH7 #E;(  X6R< -UPO #9<-@ U7#X -%Q& #-=3@ Q75< ,%UA
M "]=;  N77H +%V) "M=F@$J7:L!*EV_ 2E=W@$J7/(!*EO^ 2M;_P$K6O\!
MHU4  (]5  !_50  <E4  &=6  !>5@  5%<  $Q9  !%6P  /UT  #I?!  V
M8 T -&$3 #)B'  Q8B, ,&(K "]C,@ N8SH +6-" "QC2@ J9%, *61= "AD
M:0 G9'8 )F2& "5DEP D9*D (V2] ")DV@ C8_$ (V+] 21A_P$D8?\!G%@
M (E8  !Z60  ;ED  &-9  !:6@  4%P  $A>  !!8   .F,  #1F   O: H
M+&D0 "II%P I:A\ *&HF "=J+@ F:S4 )6L] "1K1@ C:T\ (FQ9 "!L90 ?
M;'( 'FR" !ULE  <;*8 &VNZ !IKU  ;:NX '&G\ !QH_P <:/\ E5P  (-<
M  !U7   :5T  %]=  !67@  3&$  $-D   \9P  -6H  "]M   H< 0 (W(-
M "%R$@ @<QH 'W,A !YS*  ==#  ''0X !MT0  :=$H &714 !=U8  6=6X
M%75^ !1UD  3=*( $G2V !%TSP 2<^P $G+Z !-Q_P 3<?\ CF   'U@  !O
M80  96$  %MB  !19   2&<  #YK   W;@  ,'$  "EU   B>   ''L' !=]
M#@ 6?1, %7T; !1^(@ 3?BH $GXQ !%^.@ 1?D0 $'].  ]_6@ .?V@ #7]X
M  Q_B@ +?IT "GZP  E]Q@ *?>0 "GST  M[_0 +>O\ AF4  '=E  !J90
M868  %9H  !,:P  0F\  #ES   Q=P  *GH  "-^   <@0  %80  !"'"  -
MB0X #(D4  R)&P +B2, "HDK  F),P (B3T !HE(  6)5  $B6$  HEQ  &)
M@P  B98  (BI  "'O@  A]H  (;L  "&]0  AOH ?FH  '%J  !G:P  6VP
M %!P  !&=   /'@  #-]   J@0  (X4  !R(   5C   $(\   R2!@ &DPP
M I,1  "4%@  E!T  )0D  "5+   E34  )5   "53   EED  )9I  "5>@
ME8X  )2A  "4M0  D\P  )+F  "2\@  DO< >'   &UP  !@<@  5'4  $EY
M   _?@  -8,  "R(   CC0  &Y$  !24   /EP  "IH   2= P  G@D  )\.
M  "?$@  H!<  * =  "A)0  HBT  *(W  "C0P  HU   *-?  "C<0  HX0
M **9  "BK0  H<(  *'<  "AZP  H/( <W8  &9W  !9>P  38   $*%   X
MBP  +I   "25   ;F@  %)X   ZA   )I    J<   "J    JP0  *L*  "L
M#0  K1$  *T6  "N'   KR0  + M  "Q.0  L48  +)5  "R9@  LGD  +*.
M  "QHP  LK<  +'*  "QX   L>D ;'X  %^"  !2AP  1HT  #N3   PF0
M)IX  !RC   3IP  #:L   >N    L@   +4   "W    N    +D"  "Y"
MN@P  +L0  "\%   O1L  +\C  #!+0  PCH  ,))  ##6@  PVP  ,2"  #$
MEP  Q*L  ,2\  #$RP  Q-H 98D  %B.  !+E0  /YL  #.B   HJ   ':T
M !2Q   -M@  !KD   "\    OP   ,,   #$    Q0   ,8   #'    R00
M ,H)  #+#0  S1$  ,\8  #2(0  U2T  -8\  #830  V5\  -IS  #:B@
MVYX  -NN  #;N@  W,, 7I8  %&<  !$HP  .*H  "RQ   @MP  %;L   V^
M   $P@   ,4   #)    S0   -    #2    T@   -4   #6    V0   -L
M  #>!0  X H  .(/  #E%@  Z"   .PM  #M/@  [5$  .YE  #O>@  [X\
M /"?  #PJP  \+, _P 0 /\ #@#_  X _P 2 /\ '0#_ "D _P U /\ 00#_
M $T _@!6 /L 7P#X &8 ]@!M /0 = #R 'D \0!_ /  A #N (D [0"/ .L
ME0#J )L Z "B .8 J@#E +, XP#  .$ T@#@ .H WP#Y -T _P#= /\ W0#_
M -X _P#> /\ _P - /\ "@#_  D _P / /\ & #_ "0 _@ Q /L /0#X $@
M] !2 /  6@#M &( ZP!I .D ;P#G '4 Y0!Z ., ?P#B (4 X "* -X D #<
M )8 V@"= -@ I0#5 *\ T@"Z -  R@#. ., S0#T ,L _P#+ /\ RP#_ ,L
M_P#+ /\ _P ( /\  P#_  4 _P , /P % #W !\ \@ K .\ -P#K $( YP!,
M .0 50#@ %T W0!D -H :@#8 '  U0!U -( >@#0 (  SP"% ,T BP#+ )(
MR0"9 ,< H0#% *H PP"U ,$ PP"_ -H O@#N +T _ "\ /\ O #_ +P _P"\
M /\ _P   /\   #_    ^0 ' /$ $ #J !H Y  E -\ ,0#; #P UP!' -(
M4 #. %< RP!> ,D 90#& &H Q0!P ,, =0#! 'H P "  +X A@"\ (T N@"4
M +D G "W *4 M0"P +, O0"Q ,\ KP#H *X ^ "N /\ K0#_ *T _P"M /\
M_P   /\   #]    [@ ! ., # #: !0 T0 ? ,P *P#( #8 Q0!  ,( 2@"_
M %( O !9 +H 7P"X &4 M@!J +0 ;P"S '4 L0!Z +  @0"N (@ K0"/ *L
MF "I *$ IP"K *4 N "C ,@ H@#B *$ \P"@ /X H #_ *  _P"@ /\ _P
M /8   #J    X    -, !@#)  \ P@ 8 +T ) "Y "\ M@ Z +0 0P"Q $P
MK@!3 *P 60"J %\ J0!D *< :@"F &\ I !U *, >P"A (( H "* )X DP"<
M )T F@"G )@ M "6 ,, E0#< )0 [P"3 /L DP#_ ), _P"2 /\ ^04  .H+
M  #<#0  RPH  ,(%  "\  H M@ 1 +$ ' "N "@ J@ S *< /0"D $4 H@!-
M *  4P"> %D G !? )L 9 ": &H F !P )< =@"5 'X DP"& )(!CP"0 9D
MC@*D (P"L0"+ \  B076 (@&[0"(!_H APC_ (8(_P"&"/\ [P\  -X4  #*
M%0  O!(  +,0  "N#   JP8- *<#%0"B!2  GP<L )P(-@"9"#\ EPE' )4)
M3@"3"50 D0I: ) *7P"."F4 C0IK (L*<@"*"WD B N" (<+C "%#)< @PRB
M ($-L " #<  ?PW8 'T.[P!\#_T >P__ 'L0_P![$/\ YA<  -$>  "]'0
MKQP  *89  "A%0  GA $ )T-#P"8#AD E XE )$/+P"/$#D C!!! (H02 "(
M$$\ AQ!5 (406P"$$6$ @A%G ( 1;@!_$74 ?1%^ 'P2B !Z$I0 >!*@ '<3
MK@!U$[X =!35 ',5[@!Q%OT <1;_ '$6_P!P%O\ W!\  ,8E  "S)0  I2,
M )PA  "6'@  DAD  )$4"P"-%!0 B14? (86*0"#%C, @1<\ ( 70P!^%TH
M?!=0 'H75@!Y&%P =QAB '88:0!T&'$ <QEZ '$9A !O&I  ;AJ= &P;JP!K
M'+L :AS0 &D=[ !H'OL :![_ &<>_P!G'O\ T28  +TJ  "K*@  G2H  ),H
M  "-)0  B"(  (8=!@"#&Q  ?QP: 'P=) !Z'2X =QXV '8>/@!T'D4 <A]+
M '$?40!O'U@ ;A]> &P?90!K(&T :2!V &@A@0!F(8T 92*: &,BJ !B([@
M82/- & DZ0!@)/H 7R3_ %\D_P!?)/\ RBP  +8O  "D+P  EB\  (PM  "%
M*@  @"@  'TD  !Z(@T =B,5 ',C( !Q)"D ;R0R &TD.@!K)4$ :B5' &@E
M30!F)50 925: &0F80!B)FD 829R %\G?0!>)XH 72B7 %LII0!:*;4 6BK*
M %DJYP!8*O@ 6"K_ %@J_P!8*O\ Q3$  *\S  ">,P  D#,  (8R  !_+P
M>2T  '4J  !R* H ;R@2 &LI&P!I*24 9RHM &4J-0!C*CT 8BI# & J2@!?
M*U  7BM7 %PK7@!;+&8 62QO %@M>@!7+8< 5BZ5 %0NHP!3+[, 4R_' %(O
MY0!2+_< 4B__ %(O_P!2+_\ P38  *HV  "9-@  BS8  ($U  !Y,P  <S$
M &\O  !K+@8 :"T0 &0N& !B+B$ 8"\J %XO,0!<+SD 6R]  %DO1@!8+TT
M5S!3 %8P6P!4,6, 4S%L %(R=P!1,H0 3S.2 $XSH0!-,[$ 333% 4PTXP%,
M-/8 3#3_ $PT_P!,,_\ NSD  *8Y  "5.0  ASD  'PY  !T-P  ;C0  &DS
M  !E,@( 83(- %XR% !<,QX 6C,F %@S+@!6,S4 530\ %,T0P!2-$H 4310
M % U6 !.-6  339J $PV=0!+-X( 2C>0 $DXGP!(.+ !1SC# 4<XX0%'./4!
M1SC_ 4<X_P%'./\!MSL  *(\  "1/   @SP  '@\  !P.@  :C<  &0V  !@
M-@  7#8+ %DW$@!6-QH 5#<C %(W*P!0-S( 3S@Y $TX0 !,.$< 2SA. $HY
M50!).5X 2#IH $<Z<P!&.X  13N. $0\G@!#/*X!0CS" 4(]WP%"//,!0CS_
M 4(\_P%"._\!LST  )X^  "-/@  ?SX  '4^  !L/0  9CH  & Y  !;.@
M5SH( %,[$ !1.Q@ 3CL@ $P[* !+.R\ 23PV $<\/0!'/$0 1CU+ $4]4P!$
M/EP 0SYF $(_<0!!/WX 0#^- #] G  ^0*T!/4#  3U W0$]0/(!/4#_ 3X_
M_P$^/_\!KD   )I   ")00  ?$$  '%!  !H0   83P  %L]  !6/@  4CX%
M $X_#@!,/Q4 23\= $= )0!&0"P 1$ S $- .@!"04( 04%) $!!40 _0EH
M/D)C #U#;P \0WP .T.+ #I$FP Y1*L!.42^ 3A$VP$Y1/$!.4/^ 3E#_P$Y
M0_\!JD(  )9#  "&0P  >$,  &Y#  !E0P  74   %9   !10@  34(" $E#
M# !&0Q( 1$0: $)$(@!!1"H /T4Q #Y%.  ]13\ /$9' #M&3P Z1E< .4=A
M #A';  W1WH -DB) #5(F0 T2*H -$B] #-(V0 T2/  -$?] #1'_P U1O\
MID0  ))%  ""1@  =48  &I&  !A10  640  %%$  !,1@  2$<  $1'"@!!
M2!  /TD8 #U)(  \22< .DHN #E*-@ X2CT -TM$ #9+3  U2U4 -$Q? #-,
M:@ R3'< ,4R& #!,EP O3:@ +DV[ "Y-U0 N3.\ +TS] "]+_P P2_\ H4<
M (Y(  !^2   <4@  &9)  !=2   54@  $Q)  !'2@  0DL  #],!@ [30X
M.4X5 #=.'0 V3R0 -4\K #-/,P R4#H ,5!" #!02@ O45( +E%< "U19P L
M474 *U&$ "I2E0 I4J8 *5*Y "A2T@ I4>X *5#\ "I0_P J3_\ G$H  (E*
M  !Z2P  ;4L  &-,  !:3   44P  $A-  !#3P  /5   #E2 @ U4PP ,U02
M #%4&0 P52$ +E4H "U5+P L5C< *U8^ "I61@ I5D\ *%=9 "=79  F5W(
M)5>! "17D@ C5Z0 (E>W ")7SP B5^P (U;Z "-5_P D5?\ EDT  (1.  !U
M3@  :4X  %]/  !63P  35   $52   _4P  .58  #-8   O6@@ *UL/ "I;
M%0 H7!T )UPD "9<*P E7#, )%TZ "-=0P B74P (5U6 "!>80 ?7FX 'EY^
M !U>CP <7J$ &UZT !I=S  ;7>D &USY !Q;_P <6_\ D%$  'Y1  !P40
M9%(  %M2  !24P  2E0  $%7   [60  -5L  "Y>   H8 , )&(, ")C$0 A
M8Q@ 'V0@ !YD)P =9"X '&0V !ME/@ :94< &651 !AE70 796H %F5Z !5E
MBP 499X $V6Q !)ER  29.< $V/W !1B_P 48O\ B50  'A5  !K50  8%8
M %=6  !/5P  1ED  #U<   V7P  ,&(  "ED   C9P  '6H' !EL#@ 8;!,
M%FT: !5M(0 4;2D %&TP !-M.0 2;D( $6Y, !!N6  /;F4 #FYU  UNAP -
M;IH #&VM  MMP@ +;.  #&OS  UK_0 -:O\ @ED  ')9  !F60  7%H  %1:
M  !*7   05\  #EC   Q9@  *FD  "1L   =;P  %W(  !)U"0 /=P\ #G<4
M  YW&P -=R, #'<J  MW,P *=SP "7='  AW4@ '=U\ !7=O  1W@  #=Y0
M 7:G  !VNP !==4  73K  )T]@ "=/P >UT  &U=  !B7@  65X  $Y@  !%
M8P  /&<  #-K   K;@  )'(  !YU   7>0  $GP   U_!@ )@0P !8$1  .!
M%@ "@1T  8$D  "!+0  @C8  ()   ""3   @ED  ()H  "">0  @HT  (&@
M  " M   @,L  '_G  !^\@  ?OD =&(  &AB  !>8@  4V0  $EG   _:P
M-G   "UT   E>   'GP  !>    1@P  #88   B)!  "BPH  (L.  "+$P
MC!@  (P?  "-)@  C2\  (XY  ".1   CE$  (Y@  ".<0  CH4  (Z9  "-
MK0  C,,  (S?  "+[@  B_8 ;F@  &1G  !8:0  36P  $)Q   X=@  +WL
M "9_   >A   %H@  !",   ,CP  !I(   "5    E@<  )<,  "7#P  F!,
M )D8  ":'P  FR8  )LP  "<.P  G$@  )Q7  "<:   G'L  )R0  ";I0
MF[H  )K0  ":YP  FO$ :FT  %YO  !1<@  1G<  #M\   Q@@  )X<  !Z,
M   6D0  $)4   J9   $G    *    "B    HP$  *,&  "D"P  I0X  *82
M  "G%P  J!X  *HF  "K,0  JSX  *Q-  "L70  K'   *R%  "LFP  JZ\
M *O#  "KV0  JN@ 9'4  %=Y  !+?@  /X0  #2*   ID   'Y8  !:;   0
MGP  ":,   &G    J@   *X   "P    L    +$   "R P  M @  +4-  "V
M$   MQ4  +D=  "[)@  O#,  +U!  "]4@  O60  +YY  "^D   O:0  +VW
M  "]Q@  O=< 7'\  %"%  !$BP  .)(  "R9   AGP  %Z0  !"I   )K@
M +(   "V    N0   +T   "_    OP   ,    #!    PP   ,0%  #&"@
MQPX  ,D3  #+'   SB8  - U  #110  TE<  -)K  #3@@  TY<  -.I  #2
MN   TL0 58P  $F3   ]F@  ,*(  "6H   :K@  $;0   FY    O0   ,$
M  #$    R    ,L   #-    S0   ,\   #0    T@   -0   #8    V@8
M -T,  #@$0  XQH  .8G  #G.   Z$H  .E=  #J<@  ZX@  .N;  #LJ
M[+( _P - /\ "P#_  L _P 0 /\ &@#_ "8 _P R /\ /0#_ $@ ^P!2 /@
M6@#V &( \P!I /$ ;P#P '4 [@!Z .P ?P#K (0 Z0"* .@ D #F )8 Y "=
M .( I0#A *\ WP"[ -T RP#; .8 V0#W -@ _P#8 /\ UP#_ -< _P#4 /\
M_P ( /\ ! #_  0 _P - /\ %0#^ "$ ^@ L /< . #T $, \ !- .T 50#J
M %T YP!D .0 :@#B '  X !U -X >@#= '\ VP"% -D BP#5 )$ TP"9 -$
MH #/ *H S0"U ,L Q #) -T R #Q ,< _P#& /\ Q@#_ ,8 _P#' /\ _P
M /\   #_    _P * /@ $0#Q !P [  G .D ,@#F #T X@!' -T 4 #9 %@
MU0!? -( 90#0 &H S@!P ,P =0#* 'H R0!_ ,< A0#% (P PP"4 ,$ G "_
M *4 O0"P +L O0"Z -  N #K +< ^P"V /\ M@#_ +8 _P"V /\ _P   /\
M  #]    \P % .D #@#A !8 VP A -4 +0#1 #< S@!! ,H 2@#' %( Q !9
M ,( 7P#  &4 O@!J +P ;P"[ '0 N0!Z +< @ "V (< M ". +( EP"P *
MK@"J *T MP"K ,@ J0#C *@ ]0"G /\ IP#_ *< _P"F /\ _P   /X   #Q
M    Y0   -< "@#- !$ QP < ,( )@"_ #$ O  [ +H 1 "W $P M !3 +(
M60"Q %\ KP!D *T :0"L &\ J@!T *D >@"G ($ I@") *0 D0"B )L H "E
M )X L@"= ,$ FP#: )H [P"9 /T F #_ )@ _P"8 /\ _0   /    #A
MT0   ,8 ! "]  T MP 5 +, ( "P "L K0 U *L /@"H $8 I@!- *0 5 "C
M %D H0!? *  9 "> &D G0!N )L =0": 'L F "# )8 C "5 )8 DP"A )$
MK0"/ +L C0#/ (P Z0"+ /@ C #_ (P _P", /\ \P(  .('  #,!P  OP0
M +<   "Q  @ JP 0 *< &0"D "0 H  N )X -P"< $  F@!' )@ 3@"6 %0
ME0!9 ), 7@"2 &0 D !I (\ ;P"- '8 BP!^ (H B "( )( A@"= (4 J0"#
M +@ @0#* (  Y0"  /4 ?P#_ '\ _P!_ /\ Z T  - 0  "^$   L0X  *@-
M  "C"   H (, )P $P"8 !T E0 G )( ,0"0 #D C@%! (P!2 "* DX B0)4
M (<"60"& E\ A -D (,#:P"! W( @ 1Z 'X$A !]!8X >P6: 'D&IP!X!K4
M=@?( '4(XP!U"?0 = K_ ',*_P!S"O\ W14  ,07  "Q%P  I18  )P3  "6
M$0  E T$ ),(#0".!Q4 BPD@ (@)*@"%"C, @PL[ ($+0@" "TD ?@M/ 'T,
M5 ![#%H >@Q@ '@,9P!W#&X =0UV '0-@ !R#8P < V9 &\.I@!M#K4 ; [)
M &L/Y@!J$/< :1#_ &D0_P!I$/\ T!T  +D>  "H'@  FQT  )(;  "+&0
MB!4  (<1!P"%#A  @0\: 'X0) ![$"T >1 V '<1/0!V$40 =!%* ',14 !Q
M$58 <!%< &X28@!M$FH :Q)S &D3?0!H$XD 9A.6 &44HP!C%;, 8A7& &(6
MXP!A%O8 8!?_ & 7_P!@%_\ QR(  + C  "?)   DB,  (DB  ""(   ?AT
M 'P9  !Z%0T =Q45 '06'P!Q%B@ ;Q<P &X7. !L%S\ :Q=% &D82P!H&%$
M9AA8 &487@!C&68 8AEO & 9>0!?&H4 71N2 %P;H0!;'+  6AS# %D=X !8
M'O0 6![_ %@>_P!8'O\ OR<  *DH  "9*   BR@  ((G  ![)0  =B,  ',@
M  !Q' D ;AP1 &L<&@!I'2, 9QTL &4=,P!C'CH 8AY! & >1P!?'DT 7AY4
M %P?6P!;'V( 62!K %@@=@!6(8( 52&0 %0BG@!3(JX 4B/  %$CW0!1)/(
M423_ %$D_P!1(_\ N2L  *,L  "3+   ABT  'PL  !T*@  ;R@  &LE  !I
M(@4 9B$. &,B%@!A(A\ 7R,G %TC+P!<(S8 6B,] %DD0P!7)$H 5B10 %4D
M5P!3)5\ 4B5H %$F<P!/)G\ 3B>- $THG !,**P 2RF^ $LIV@!**?$ 2BG_
M $LI_P!+*?\ LRX  )XO  ".,   @3   '<O  !O+@  :BL  &4J  !C)P$
M7R<, %PG$P!:)QL 6"@D %8H*P!5*#( 4R@Y %(I0 !0*48 3RE- $XI5 !-
M*EP 3"IE $HK< !)*WP 2"R+ $<MF@!&+:H 12Z\ $4NU@!%+N\ 12[^ $4N
M_P!%+?\ KC$  )HR  "),P  ?#,  '(S  !K,0  92\  & M  !=+   62P)
M %8L$ !4+!@ 4BP@ % L* !.+2\ 32TV $PM/ !*+4, 22U* $@N40!'+ED
M1B]C $4P;0!#,'H 0C&) $$QF !!,J@ 0#*[ #\RTP _,NX 0#+] $ R_P!
M,O\ JC,  )8U  "&-0  >38  &XU  !F-0  83(  %PP  !7,   5# & %$P
M#@!.,!4 3#$= $HQ)0!(,2P 1S$R $8Q.0!$,4  0S)' $(R3P!!,U< 0#-@
M #\T:P ^-7@ /36' #PVE@ [-J< .S:Y #HVT0 Z-NT .S;\ #LV_P [-O\
MIC8  )(W  "".   =3@  &LX  !C-P  738  %<S  !3-   3S0# $LT# !)
M-!( 1C4: $4U(@!#-2D 034O $ U-@ _-CT /C9$ #TW3  \-U4 .SA> #HX
M:0 Y.78 .#F% #<ZE0 W.J4 -CJX #4ZSP V.NP -CK[ #8Y_P W.?\ HC@
M (XY  !^.@  <CL  &@[  !?.@  63D  %,V  !.-P  2C@  $8X"@!$.1
M03D7 #\Y'P ^.28 /#DM #LZ-  Z.CL .3M" #@[2@ W.U, -CQ< #4\9P T
M/70 ,SV# #,^DP R/J0 ,3ZV #$^S0 Q/NH ,3[Z #(]_P R/?\ GCL  (L\
M  ![/   ;CT  &0]  !</0  53P  $XZ  !).P  13P  $$]!P ^/0X /#T5
M #H^'  Y/B, -SXJ #8_,0 U/S@ -#]  #- 2  R0%  ,4!: #!!90 O07(
M+D*! "U"D0 M0J( +$*U "M"RP L0ND +$+Y "U!_P M0?\ F3T  (<^  !W
M/P  :S\  &%   !9/P  4C\  $D^  !$/P  0$   #Q!!  Y0@T -T(2 #5#
M&0 S0R$ ,D,H #%$+P P1#8 +T0] "Y%10 M14X +$58 "M&8P J1F\ *49^
M "A&CP G1Z$ )D>S "9'R0 F1N< )T;X "A%_P H1?\ E4   ()!  !S0@
M9T(  %Y"  !50@  3D(  $5"   _1   .T4  #=&   T1PH ,4@0 "](%@ N
M21X +$DE "M)+  J23, *4HZ "A*0@ G2DL )DM5 "5+8  D2VT (TM\ ")+
MC0 A3)\ (4RQ "!,QP @2^8 (4OW ")*_P B2O\ D$,  'Y$  !O1   9$4
M %I%  !210  2D8  $%'   \2   -TD  #)+   N30< *TX. "E.$P G3QH
M)D\A "5/*  D3S  (U W ")0/P A4$@ (%!2 !]170 >46H '5%Y !Q1B@ ;
M49P &E&O !E1Q0 94>0 &E#V !M/_P <3_\ BD8  'E'  !K1P  8$@  %9(
M  !.2   1TD  #Y+   Y3   ,TX  "Y0   H4P( )%0+ ")5$  @518 'U8>
M !Y6)  =5BP '%8S !M7.P :5T0 &5=. !A760 76&8 %5AU !18AP 46)H
M$U>L !)7P@ 25^$ $U;T !15_P 45?\ A$D  '1*  !F2P  7$L  %-+  !+
M3   1$T  #Q/   U40  +U0  "E6   D60  'EL' !I=#0 871( %UT9 !9>
M(  57B< %%XN !->-P 27D  $5]* !%?50 07V( #U]Q  Y?@P -7Y8 #5^I
M  Q>O@ ,7MH #5WP  U<_  .7/\ ?DT  &Y.  !B3@  6$\  $]/  !(4
M0%(  #A4   P5P  *EH  "1=   ?7P  &6(! !-E"0 19@\ $&84  ]F&P .
M9R( #6<I  UG,@ ,9SL "V=%  IG4  )9UT !V=L  9G?0 %9Y  !&:C  )F
MMP #9<\ !&7I  1D]0 $9/P =U$  &E2  !=4@  5%(  $Q3  !#50  .U@
M #-;   K7@  )6$  !]D   99P  $VH   ]M!@ +< P "' 1  =P%@ %<!T
M!' D  -P+  "<#4  ' _  !P2@  <%<  '!E  !P=@  <(H  &^>  !OL@
M;L@  &WE  !M\@  ;?D <%8  &-6  !95@  _^+__TE#0U]04D]&24Q%  0)
M45<  $=8   ^6P  -E\  "YB   F9@  'VH  !EM   3<   #G,   MV!  %
M> L  7@/  !Y$P  >1D  'D?  !Z)@  >B\  'HY  !Z1   >E   'I?  !Z
M<   >H,  'J8  !ZK   ><(  'C?  !X[P  =_< :EL  %];  !66P  3%P
M $)@   Y8P  ,&@  "AL   @<   &70  !-W   .>P  "7X   2! @  @@@
M (,-  "#$   A!0  (49  "&(   AB@  (<Q  "'/   ATD  (=7  "':
MAWL  (>0  "&I0  A;H  (73  "$Z@  A/0 96   %Q@  !180  1F0  #QI
M   R;0  *7(  "%W   9>P  $H    V#   (AP   HH   "-    C@0  (X)
M  "/#0  D!   )$4  "2&0  DR   )0I  "5,P  E4   )9.  "67P  E7(
M )6(  "5G0  E+(  )3(  "3X@  D^X 864  %9F  !*:@  /VX  #5T   K
M>0  (7\  !F$   1B0  #(T   :1    E    )@   ":    FP   )P"  "=
M!P  G@L  )\.  "A$@  HA@  *,@  "E*0  IC8  *9$  "F50  IF@  *9]
M  "FE   I:D  *2]  "DT0  I.0 6VP  $]P  !#=0  .'L  "V!   CAP
M&8T  !&2   +EP  !)P   "@    HP   *8   "H    J0   *H   "L
MK00  *X)  "P#0  L1$  +,7  "U(   MBL  +<Z  "W2P  N%P  +AQ  "X
MB   N)T  +BQ  "WP@  M]  5'8  $A\   \@@  ,8D  ":0   ;EP  $IT
M  RB   #IP   *L   "N    L@   +8   "X    N    +H   "[    O0
M +X   # !0  P0L  ,,0  #&%@  R2   ,HN  #+/@  S%   ,QD  #->@
MS9$  ,VD  #-M   S<  38,  $&*   UD0  *9D  !Z@   3I@  #*P   .Q
M    M@   +H   "^    P@   ,8   #(    R    ,H   #+    S0   ,X
M  #0    T@$  -4(  #9#@  W14  .$A  #B,0  Y$,  .56  #F:P  YH(
M .>6  #GI0  YK  _P ) /\ !0#_  8 _P . /\ %@#_ "$ _P M /\ . #]
M $, ^0!- /4 50#R %T \ !C .X :0#L &\ Z@!T .D >@#G '\ Y@"% .0
MBP#C )$ X0"9 -\ H0#< *H V@"V -< Q@#5 .$ TP#T -( _P#1 /\ T0#_
M ,\ _P#* /\ _P ! /\   #_  $ _P , /\ $@#Z !T ]@ H /, ,P#P #X
M[ !( .@ 4 #E %@ X@!> -\ 9 #= &H VP!O -D = #6 'H U !_ -( A0#0
M (P S@"3 ,P G #) *4 QP"P ,8 O@#$ -0 P@#N ,$ _@#  /\ P #_ +\
M_P"^ /\ _P   /\   #_    ^@ ' /$ #P#K !@ Y@ C .( +@#@ #@ VP!"
M -4 2P#1 %( S@!9 ,L 7P#) &4 QP!J ,8 ;P#$ '0 P@!Z ,$ @ "_ (8
MO0". +L E@"Y *  MP"J +8 MP"T ,H L@#F +$ ^ "P /\ KP#_ *\ _P"P
M /\ _P   /\   #W    Z@ " .$ # #7 !, T  = ,P * #) #( Q@ \ ,(
M10"_ $T O !3 +H 60"X %\ MP!D +4 :0"T &X L@!T +$ >@"O (  K0"(
M *P D0"J )H J "E *8 L0"D ,$ HP#< *$ \@"A /\ H #_ *  _P"A /\
M_P   /<   #H    V0   ,L " ## !  O0 8 +D (@"V "P M  V +( /P"O
M $< K !- *L 5 "I %D IP!> *8 8P"E &@ HP!N *( = "@ 'H G@"" )P
MBP"; )4 F0"? )@ K "6 +H E #/ ), ZP"2 /L D@#_ )( _P"1 /\ ]P
M .<   #3    Q@   +L  @"S  P K0 2 *H ' "G "8 I  P *, . "@ $
MG@!' )P 3@": %, F0!8 )< 70"6 &, E0!H ), ;@"2 '0 D !\ (\ A0"-
M (\ BP": (H IP"( +4 A@#' (4 Y "$ /4 A #_ (, _P"# /\ [    -,
M  #! 0  M    *P   "F  < H  . )T %@": "  EP I )4 ,@"3 #H D0!!
M (\ 2 "- $T C !3 (L 6 ") %T B !C (< :0"% &\ @P!W (( @ "  (H
M?@"6 'T HP![ +  >@#" 'D W0!X /$ =P#] '@ _P!X /\ W@H  ,0+  "R
M#   I@L  )T(  "9!   E0 * )$ $0". !D BP C (D + "' #0 A0 [ (,
M0@"" $@ @ !. '\ 4P!] %@ ? !> 'L 9 !Y &H > !R '8 >P!T (8 <P"2
M '$ GP!P *T ;@"^ &T!U@!M NT ; /Z &P#_P!L _\ SA   +<1  "F$@
MFA$  )$0  "+#@  B0L# (<%# "$ 1, @0$< 'X")0!\ RX >@,V '@$/ !W
M!$, =05( '0%3@!S!50 <059 ' &7P!N!F8 ;09N &L'> !J!X, : B0 &<)
MG0!E":P 9 F\ &,*U !C"^P 8@SZ &(,_P!B#/\ PQ8  *T7  "=&   D!@
M (<6  "!%   ?1$  'P.!@!\"@X > H6 '4+'P!R"R@ < PP &\,-P!M##X
M; Q$ &L-2@!I#4\ : U5 &<-7 !E#6, 8PYK &(.=0!@#H$ 7PZ. %T/G !<
M$*L 6Q"] %H0U@!9$?  61'] %D1_P!9$?\ N1L  *4=  "4'@  B!X  'X=
M  !X&P  =!@  '$5  !Q$0D ;Q 1 &P0&0!I$"( 9Q$J &81,@!D$3D 8Q$_
M &(110!@$DL 7Q)1 %T26 !<$E\ 6A-H %D3<@!7%'T 5A2+ %05F0!3%:D
M4A:Z %$6T@!1%^T 41?] %$7_P!1%_\ LB   )XB  ".(@  @2,  '<B  !P
M(0  ;!X  &D;  !G& 0 9A4. &,6%0!A%AX 7Q8F %T6+0!<%S0 6A<[ %D7
M00!8&$< 5AA- %485 !3&%P 4AED %$9;@!/&GH 3AN( $T;EP!+'*8 2ARX
M $H=SP!)'>L 21W[ $D=_P!*'?\ K"0  )@E  "()@  >R<  '$F  !J)0
M9B,  &(A  !@'@  7AP+ %L;$@!9'!H 5QPB %4<*0!4'#  4QTW %$=/0!0
M'4, 3QU* $T>40!,'E@ 2Q]A $D?:P!(('< 1R"% $8AE !$(J0 1"*V $,B
MS !#(^D 0R/Z $,C_P!#(O\ IB<  ),I  "#*@  =BH  &TJ  !E*0  8"<
M %PE  !9(P  5R$' %4A#P!2(18 4"$> $XA)0!-(BP 3"(S $HB.0!)(D
M2")& $<C30!%(U4 1"1> $,D:0!")74 0":# #\FD@ ^)Z, /B>T #TGR@ ]
M*.@ /2CY #TG_P ^)_\ HBH  (XK  !_+0  <BT  &@M  !A+   7"L  %@H
M  !4)@  428$ $XE#0!,)1, 2B8: $@F(@!')BD 128O $0F-@!#)SP 02=#
M $ G2P _*%, /BE< #TI9@ \*G( .RJ! #HKD  Y*Z$ ."RR #<LR  W+.8
M."SX #@L_P X+/\ G2P  (HN  ![+P  ;S   &4P  !=+P  6"X  %,K  !0
M*@  3"H  $DJ"P!&*A$ 1"H7 $(J'P!!*B4 /RHL #XK,P ]*SD /"M  #LL
M2  Z+%  .2U9 #@N9  W+G  -B]_ #4OCP T,)\ ,S"Q #(PQP R,.4 ,S#W
M #,P_P T+_\ F2\  (<Q  !W,@  :S(  &(R  !:,@  5#$  $\O  !++0
M1RX  $0N" !!+@X /RX4 #TN'  [+B( .2\I #@O+P W+S8 -C ^ #4P1@ U
M,4X -#%7 #,R8@ R,FX ,3-] # SC0 O-)X +C2P "TTQ0 M-., +C3V "\S
M_P O,_\ E3$  (,S  !T-   :#4  %XU  !7-   430  $LR  !&,0  0C(
M #\R!0 \,@T .3,2 #@S&0 V,R  -#,F #,S+0 R-#0 ,30[ # U0P P-4P
M+S95 "XV8  M-VP +#=[ "LWBP J.)P *3BN "@XPP H..( *3CU "HW_P J
M-_\ DC0  '\U  !Q-@  93<  %LW  !4-P  338  $<V  !"-0  /38  #HV
M @ W-PL -#<0 #(W%@ Q.!T +S@D "XX*P M.3( +#DY "LY00 J.DD *CI3
M "D[7@ H.VH )SMY "8\B0 E/)L )#RM ",\P@ C/.  )#ST "4[_P E._\
MC38  'PX  !M.0  8CD  %@Z  !1.0  2CD  $0Y   ].0  .3H  #4[   R
M.P@ +SP. "T]%  L/1H *CTA "D]*  H/B\ )SXV "8^/@ E/T< )#]0 "-
M6P B0&@ (4!V "! AP ?09D 'T&K !Y!P  >0=X 'T#S !] _@ @/_\ B3D
M '@Z  !I.P  7CP  %4\  !-/   1SP  $ \   X/0  -#X  #!    M004
M*D(, "="$0 F0Q@ )$,> "-#)0 B0RP (40S "!$.P ?1$0 'D5. !U%60 <
M164 &T5T !I%A0 91I< &4:I !A&O@ 71=P &$7Q !E$_0 :1/\ A#P  ',]
M  !F/@  6S\  %(_  !*/P  1#\  #U    V00  ,4,  "Q$   G1@$ )$<*
M "%(#P @210 'DD; !U)(@ <22D &THP !I*.  92D$ &$I+ !=+50 62V(
M%4MQ !1+@@ 32Y0 $DNG !)+O  12]D $DKP !-*_  42?\ ?S\  &]   !A
M00  5T(  $Y"  !'0@  04(  #I#   R10  +4<  "A)   C2P  'DT& !M/
M#0 84!$ %U 7 !90'@ 54"4 %% L !-1-  243T $5%' !%14@ 045\ #U)M
M  Y2?@ -49$ #5&D  Q1N  ,4=$ #5#L  U0^@ .3_\ >4,  &I$  !=1
M4T4  $M%  !$10  /D8  #9(   O2@  *4P  "1/   ?40  &E,  !16"0 1
M5PX $%@3 !!8&0 /6"  #E@H  U8,  -6#D #%A#  M83@ *6%H "%AH  =8
M>0 &6(P !5B?  18LP $5\H !5?F  57\P &5OP <T8  &1'  !92   4$@
M $A(  !!20  .DH  #)-   K4   )5(  "!5   :6   %5H  !!=!@ ,8 P
M"F 0  E@%0 (8!P !V C  5@*P $8#0  V ]  %@20  8%4  &!C  !@<P
M8(8  %^:  !?K@  7\0  %[B  !>\   7O@ ;$H  %]+  !52P  3$P  $5,
M   ]3@  -5   "Y3   G5@  (%D  !I<   57P  $&(   UE!  (9PL  V<.
M  !H$P  :!@  &@?  !I)@  :2X  &DX  !I0P  :4\  &E=  !I;0  :8
M &F4  !HJ0  :+\  &?<  !F[@  9O< 9D\  %I/  !13P  2D\  $%1   X
M5   ,%<  "A;   A7@  &F(  !1E   0:   #&L   =N P !< D  ' -  !Q
M$   <10  '(:  !S(0  <R@  ',Q  !S/   =$@  '-6  !S9@  <WD  '..
M  !SHP  <KD  ''2  !QZP  </0 85,  %93  !/4P  154  #M8   R7
M*F   ")D   ;:   %&P   ]O   +<@  !G8   !Y    >@8  'H*  ![#@
M?!$  'T5  !^&P  ?R(  ( J  " -0  @$$  (!/  " 7P  @'$  ("&  "
MG0  ?[(  '[*  !^Y0  ??$ 7%@  %18  !)6@  /UT  #5A   L90  (VH
M !MO   4<P  #G<   E[   #?P   ((   "$    A@$  (8&  "("@  B0T
M (H0  "+%0  C!L  (XB  "/+   CS@  (]&  "/5@  CV@  (]^  "/E0
MCJL  (W!  "-W   C.L 65T  $Y?  !#8@  .&8  "YL   D<0  ''<  !1\
M   .@0  "(4   ")    C0   )    "2    DP   )0   "6 P  EP@  )@,
M  ":#P  FQ,  )T:  "?(P  H"X  * \  "@3   H%X  *!T  "?C   GZ(
M )^W  ">RP  GN  4V0  $=H   \;0  ,7,  "=Y   =?P  %(4   V+   &
MD    )0   "8    G    )\   "A    H@   *0   "E    IP   *@$  "J
M"0  K T  *T2  "P&0  LB,  +(Q  "R0@  LE0  +)I  "R@   LI@  +&L
M  "ROP  L<X 3&X  $!S   U>@  *H$  !^(   5C@  #I4   ::    GP
M *0   "H    K    *\   "Q    L0   +,   "U    M@   +@   "Z
MO 8  +X,  # $0  PQD  ,4F  #%-P  QDD  ,9=  #'<@  QXH  ,B?  #(
MKP  R+P 1GH  #F!   NB0  (I   !>8   /GP  !Z4   "J    KP   +,
M  "W    O    +\   #!    P@   ,0   #%    QP   ,D   #+    S0
M ,\#  #2"@  UA   -P:  #=*@  WCP  -]0  #@90  X7L  .&1  #BH@
MXJT _P " /\   #_  , _P , /\ $P#_ !T _P H /X ,P#[ #X ]P!( /,
M4 #P %< [0!> .L 9 #H &D YP!O .4 = #C 'D X@!_ .  A0#> (P W "3
M -D G #6 *8 TP"Q -$ P #/ -H S@#Q ,P _P#+ /\ RP#_ ,8 _P#! /\
M_P   /\   #_    _P ( /L $ #V !D \@ D .\ +@#M #D Z !" ., 2P#@
M %( W0!9 -D 7P#6 &0 TP!I -$ ;@#/ '0 S@!Y ,P ?P#* (8 R ". ,8
ME@#$ *  P@"K ,  N0"^ ,T O #J +L _ "Z /\ N@#_ +H _P"V /\ _P
M /\   #^    ]  $ .L #0#D !0 WP ? -L *0#8 #, TP ] ,X 10#* $T
MQP!3 ,4 60## %\ P0!D +\ :0"] &X NP!S +H >0"X (  M@"( +0 D "R
M )H L0"E *\ L@"M ,0 K #A *L ]@"J /\ J@#_ *H _P"J /\ _P   /T
M  #N    X@   -4 "@#- !$ QP 9 ,0 (P#! "T OP W +L /P"W $< M0!.
M +( 4P"P %D KP!> *T 8P"L &@ JP!M *D <P"H 'H I@"! *0 B@"C )0
MH0"? )\ K "> +L G #2 )L [@": /\ F@#_ )D _P"9 /\ _@   .X   #>
M    RP   ,$ !0"Y  T M  4 +$ '@"N "< JP P *H .0"G $$ I !( *(
M30"A %, GP!8 )X 70"= &( FP!G )H ;0"8 ', EP![ )4 A "4 (X D@"9
M )  I@". +0 C0#( (P Y@"+ /D B@#_ (H _P"+ /\ \    -L   #'
MN@   +    "H  H I  0 *  & "= "$ FP J )H ,P"8 #L E@!! )0 2 "2
M $T D0!2 (\ 5P". %P C !A (L 9P"* &X B !U (< ?@"% (@ @P"4 ((
MH "  *\ ?P#  'X W0!] /( ?0#_ 'T _P!] /\ X    ,8   "U    J@
M *(   ";  4 E0 - )( $P"0 !P C0 D (L +0"* #0 B  [ (8 0@"% $<
M@P!- (( 4@"! %< ?P!< 'X 8@!] &@ >P!P 'H >0!X (, =@"/ '4 G !T
M *H <@"Z '$ T0!P .P < #[ '  _P!P /\ S00  +<&  "G!P  FP8  ),$
M  ".    B@ ( (8 #P"$ !8 @0 > '\ )P!] "X ?  V 'H / !Y $( =P!'
M '8 3 !U %( <P!7 '( 70!Q &, ;P!K &X = !L 'X :P"* &D F !H *8
M9P"V &8 RP!E .< 90#W &4 _P!E /\ P P  *L-  ";#@  CPX  (8-  "!
M"P  ?@<! 'P!"P!Y !$ =P 8 '4 (0!S "D <0 P &\ -@!N #P ; !" &L
M1P!J $T :0!2 &@ 6 !F %\ 90!G &, < !B 7H 8 &' %\"E0!> J, 7 .S
M %P#QP!;!.0 6P7T %L&_@!;!O\ M1   *$2  "1$P  A1,  'P2  !V$0
M<PX  '(,! !Q!PT ;@02 &P$&P!I!2, 9P4J &8&,0!D!C< 8P8] &('0P!A
M!TD 7P=. %X(50!="%P 6PEC %H);0!8"G@ 5PJ% %8+DP!4"Z( 4PNS %(,
MQP!2#.0 40WU %$-_P!1#?\ K14  )D7  ")&   ?1D  '08  !M%P  :A0
M &<1  !G#@< 9@P. &,,%0!A#!T 7PPE %T-+ !<#3, 6PTY %H-/P!8#44
M5PU+ %8.40!5#ED 4PYA %(.:P!0#W8 3A"# $T0D@!,$*( 2Q"R $H1R !)
M$>4 21'W $D2_P!)$?\ I1D  )(<  "#'0  =AX  &T=  !F'   8AH  %\7
M  !>% $ 7A$* %L0$0!9$1@ 5Q$@ %41)P!4$2X 4Q$T %$1.P!0$D$ 3Q)'
M $X23@!,$E4 2Q-> $D39P!(%', 1A2  $45CP!$%9\ 0Q:P $(6Q0!"%^,
M0A?V $(7_P!"%_\ GQT  (P@  !](0  <2(  &@B  !A(0  7!\  %D<  !7
M&0  518& %05#@!1%10 3Q8< $X6(P!,%BH 2Q8P $H6-P!)%ST 1Q=# $87
M2@!%&%( 0QA: $(99 !!&7  /QI] #X;C0 ]&YT /!RN #L<PP ['.$ .QWU
M #L<_P \'/\ FB$  (<C  !X)   ;"4  &,E  !<)   5R,  %,@  !1'@
M3QP" $T;# !+&A$ 2!L8 $<;( !%&R8 1!LM $,<,P!"'#D 0!Q  #\=1P ^
M'4\ /1Y8 #P>8@ Z'VT .1][ #@@BP W(9L -B&M #4AP0 U(=\ -2'S #8A
M_P V(?\ EB,  (,F  !T)P  :"@  %\H  !8)P  4R8  $\D  !,(@  22
M $<@"0!$'P\ 0A\5 $ @'  _(", /B I #P@+P [(38 .B$] #DA1  X(DP
M-R)5 #8C7P T(VL ,R1Y #(EB0 Q)9H ,"6K # FOP O)MP ,";R # F_P Q
M)?\ D28  '\H  !Q*@  92H  %PJ  !5*@  3RD  $LH  !()0  1"0  $$D
M!0 _) T /202 #LD&0 Y)!\ -R0F #8D+  U)3, -"4Z #,F00 R)DH ,2=3
M # G70 O*&D +BEW "TIAP L*9@ *RJJ "HJO0 J*MH *RKQ "LJ_@ L*?\
MC2@  'PJ  !M+   8BT  %DM  !1+0  3"P  $<K  !#*   /R@  #PH @ Y
M* L -R@0 #4H%@ S*!P ,B@C # H*0 O*3  +RHW "XJ/P M*T< +"M1 "LL
M6P J+&< *2UU "@MA0 G+9< )BZH "4NO  E+M@ )B[P "8N_0 G+?\ BBL
M '@M  !J+@  7R\  %8O  !.+P  2"X  $,M   _+   .RP  #<L   T+ D
M,BP. # M$P N+1H +2T@ "LM)P J+BT *BXU "DO/0 H+T4 )S!. "8P60 E
M,64 )#%S ",Q@P B,I4 (3*G "$RNP @,M0 (3+O "(Q_  B,?\ ABT  '4O
M  !G,   7#$  %,Q  !+,0  13$  $ P   [,   -C   #,P   P,08 +3$-
M "LQ$0 I,A< *#(> "<R)  E,RL )3,R "0S.@ C-$, (C1, "$U5P @-6,
M'S5Q !XV@0 =-I, '#:E !LVN0 ;-M( '#;M !TV^P =-?\ @C   '$R  !C
M,P  630  % T  !)-   0C,  #TS   W,P  ,30  "XU   K-0( *#8+ "4W
M$  D-Q4 (C<; "$X(@ @."@ 'S@P !XX-P =.4  '#E) !LZ5  :.F  &3IN
M !@Z?P 7.Y$ %SND !8[MP 5.]  %CKL !<Z^@ 8.?\ ?3(  &TT  !@-0
M538  $TV  !&-@  0#8  #HV   T-@  +C@  "HY   F.@  (SL( " \#@ >
M/1( '3T8 !P]'P ;/B4 &CXM !D^-  7/CT %C]' !4_40 4/UX %#]L !-
M?  20(\ $4"B !% M@ 00,X $3_K !(_^0 2/O\ >34  &DW  !<.   4CD
M $HY  !#.0  /3D  #<Y   Q.@  *SP  "<]   B/P  'D$$ !I""P 80Q
M%T,5 !5$&P 41"( $T0I !-$,0 21#H $45# !!%3@ 015L #D5I  Y%>0 -
M18P #46?  Q%L@ +1<D #$7E  U$]@ -1/\ =#D  &4Z  !8.P  3SL  $<\
M  ! /   .CP  #0\   N/@  *$   "-"   ?1   &D8  !5("  22@T $4H2
M !!*&  /2QX #DLE  U++0 -2S8 #$M   M+2@ *2U8 "4MD  A+=  '2X<
M!4N:  1+K@ $2L0 !4K@  5*\  &2?H ;CP  & ]  !4/@  2SX  $0^   ]
M/@  -S\  #%    J0@  )$4  !]'   :20  %4P  !%.!0 .40L "U$0  I1
M%  )41L "%$B  =1*0 %43( !%([  -21@ !4E(  %)?  !2;P  4H$  %&6
M  !1J0  4;\  %#<  !0[@  4/< :$   %M!  !000  2$$  $%!   [0@
M-$,  "U%   F2   ($L  !M-   64   $5,   Y5!  *6 H !E@.  )8$@
M61<  %D=  !9)0  62T  %DV  !900  64T  %I:  !::0  67P  %F0  !9
MI0  6+H  %C5  !7[   5_8 8T0  %9%  !-10  144  #]%   W1P  +TD
M "A,   B3P  &U(  !95   16   #5H   E= P $7PD  & -  !@$   810
M &$9  !B(   8B<  &(Q  !B.P  8D<  &)5  !C9   8G8  &*+  !BH
M8;8  &'/  !@Z@  8/4 74@  %))  !*2   0T@  #I*   R30  *E   "-3
M   <5P  %EH  !%=   -8   "&,   -F 0  9P8  &@+  !I#@  :A$  &L5
M  !L&P  ;2(  &TJ  !M-   ;4   &U.  !M70  ;6\  &V$  !LF@  ;+
M &O(  !KY@  :O, 6$T  $Y-  !(3   /DX  #51   L5   )%@  !U<   6
M8   $&0   QG   ':P   6X   !P    <@,  '('  !S"P  =0X  '81  !W
M%@  >!P  'DC  !Z+0  >CD  'I'  !Z5@  >6@  'I\  !YE   >*H  'C!
M  !WWP  =^\ 5%$  $Q1  !"4@  .%4  "]9   F7@  'F(  !9G   0:P
M"V\   5S    =P   'H   !\    ?@   '\"  " !@  @0H  (,-  "$$0
MAA4  (@<  "))0  BC   (H^  ")30  B5\  (ES  "(BP  B*(  (>Y  "'
MT0  AN@ 4E8  $=7   \6@  ,E\  "AD   ?:0  %F\  !!T   *>0   GT
M  "!    A0   (@   "*    C    (T   "/    D 0  )((  "3#   E1
M )<5  "9'0  FR<  )LT  ";1   FE8  )IJ  "9@@  FIH  )BP  "8QP
ME]X 2UP  $!@   U90  *VH  "%Q   7=P  $'T   F#   !B    (P   "1
M    E0   )@   ":    FP   )T   "?    H    *(   "D!0  I@H  *@.
M  "J%   K1T  *TJ  "M.0  K4L  *U?  "M=P  K)   *NG  "KN@  J\L
M168  #EK   N<0  (W@  !E_   0A@  "8T   "3    F    )T   "A
MI0   *@   "K    JP   *X   "O    L0   +,   "U    MP$  +D'  "\
M#0  OQ,  ,(?  #"+@  PD   ,)4  #!:P  P8,  ,";  #!K0  P;P /G(
M #)X   G@   '(@  !*0   *EP   )T   "C    J    *T   "R    M@
M +D   "[    O    +X   #     P@   ,0   #&    R    ,L   #.!0
MT0T  -84  #7(P  V#4  -E)  #:7@  VW4  -N,  #<GP  W*L _P   /\
M  #_    _P ) /\ $ #_ !D _@ D /P +P#Y #D ] !# /  2P#M %( Z@!9
M .< 7P#D &0 X@!I .  ;@#> ', W !Y -H ?P#7 (8 U ". -$ E@#/ *$
MS "L ,H NP#( -( Q@#N ,8 _P#% /\ Q0#_ +\ _P"Z /\ _P   /\   #_
M    _@ % /< #@#R !4 [@ ? .L *@#I #0 XP ] -X 10#9 $T U !3 -$
M60#. %X S !C ,H : #) &T QP!S ,4 >0## (  P0"( +\ D "] )L NP"F
M +D M "W ,@ M@#F +4 ^P"T /\ M #_ +, _P"N /\ _P   /\   #X
M[0   .4 "P#= !$ UP : -( ) #/ "X RP W ,< 0 ## $< P !. +X 4P"\
M %D N@!> +@ 8P"V &@ M0!M +, <P"Q 'D KP"! *T B@"K )0 J0"@ *@
MK0"F +X I0#; *0 ] "D /\ HP#_ *, _P"B /\ _P   /8   #F    UP
M ,L !@#$  X O@ 5 +L 'P"Y "@ MP Q +0 .@"P $$ K0!( *L 3@"I %,
MIP!8 *8 7 "D &$ HP!G *$ ; "@ ', G@!Z )T @P"; (X F0"9 )< I@"6
M +8 E0#, )0 ZP"3 /T DP#_ ), _P"3 /\ ]P   .0   #0    P0   +<
M @"O  L JP 1 *< &0"E "( HP K *( ,P"? #L G !" )L 2 "9 $T EP!2
M )8 5P"5 %L DP!A )( 9@"0 &T CP!T (T ?0", (< B@"3 (@ H "' *\
MA0#" (4 X@"$ /< A #_ (0 _P"$ /\ Y0   ,T   "\    KP   *8   ">
M  < F@ . )8 % "4 !T D@ E )$ +0"0 #4 C0 \ (P 0@"* $< B !, (<
M40"& %8 A !; (, 8 "! &< @ !N 'X =P!] ($ >P"- 'H F@!X *D =P"Z
M '8 TP!V .\ =@#^ '4 _P!U /\ T    +L   "K    GP   )<   "0  (
MBP + (@ $ "& !< A  @ (( )P"! "\ ?P U 'T / !\ $$ >P!& 'D 2P!X
M %  =P!5 '8 6P!T &$ <P!I '$ <0!P 'L ;@"' &T E0!K *, :@"T &H
MR0!I .@ :0#Y &D _P!I /\ P    *P   "< @  D (  (@   "#    ?P &
M 'L #0!Y !( =P : '8 (@!T "D <P P '$ -@!P #P ;P!! &T 1@!L $L
M:P!0 &H 5@!H %P 9P!D &4 ; !D '8 8P"" &$ D !@ )\ 7P"O %X PP!>
M .$ 7@#T %T _P!= /\ M <  * )  "0"P  A L  'P*  !W!P  = 0  '$
M"0!O  \ ;0 5 &L ' !I ", :  J &< ,0!E #8 9  \ &, 00!B $8 8 !,
M %\ 4@!> %@ 70!? %L : !: '( 6 !^ %< C !6 )L 50"K %0 O@!4 -H
M4P#O %0 ^P!4 /\ J0T  )8.  "'$   >A   '(0  !L#@  :0P  &<) P!F
M! L 9  0 &( %P!@ !X 7@ E %T *P!< #$ 6@ W %D / !8 $( 5P%' %8!
M3@!5 E0 4P)< %(#90!1 V\ 3P1[ $X$B@!-!9D 3 6I $L%O !*!M0 2@?M
M $H'^0!*!_\ H1   (X2  !^%   <Q0  &H4  !D$P  8!$  %X/  !=#04
M70D- %H&$@!8!QD 5@<@ %4')P!3!RT 4@@S %$(. !0"#X 3PE$ $X)2@!,
M"5$ 2PI9 $H*8@!("VT 1PMZ $8,B !$#)@ 0PRI $(-O !"#=4 0@WN $(-
M^P!"#?\ FA0  (<6  !X&   ;!D  &,9  !=&   618  %83  !4$0  5 X(
M %,-#@!1#10 3PT; $T-(@!,#2@ 2PTN $H-- !)#3H 1PY! $8.1P!%#D\
M1 Y7 $(/80!!$&P /Q!Y #X0B  ]$9@ .Q&I #L1O  Z$=8 .A'P #H2_0 [
M$?\ DQ@  ($:  !S'   9QT  %X=  !8'   4QL  % 8  !.%@  3!,# $P1
M"P!*$!  2!$7 $81'@!%$20 1!$J $(1, !!$3< 0!(] #\21  ]$DP /!-4
M #L37@ Y%&D .!1V #<5A0 V%98 -!:G #06N@ S%M, ,Q;N #06_  T%O\
MCAL  'P=  !N'P  8R   %H@  !3(   3AX  $H=  !(&@  1A@  $46!P!#
M%0X 0143 #\5&@ ^%2  /14G #L5+0 Z%C, .18Z #@600 W%TD -1=1 #08
M6P S&68 ,AES # :@P O&I0 +ANE "T;N  M&]  +1OL "X;^P N&_\ BAX
M '@@  !J(@  7R,  %8C  !/(@  2B$  $8@  !#'@  01L  #\: P ]&@P
M.QD1 #D9%@ W&AT -AHC #4:*0 T&C  ,QLV #$;/@ P'$8 +QQ/ "X=60 M
M'60 +!YQ "L?@0 J'Y( *1^D "@@MP G(,X )R#K "@@^@ I'_\ AB   '0C
M  !G)   7"4  %,E  !,)0  1R0  $(C   _(0  /1\  #H>   W'@D -1X.
M #,>$P Q'AH ,!X@ "\>)@ N'RT +1\S "P@.P K($, *B%, "DA5@ H(F(
M)B)O "4C?P D(Y  (R.B "(DM0 B),P (B3I ",D^0 D(_\ @B,  '$E  !C
M)@  62<  % H  !))P  0R<  #\F   [)   ."(  #4B   R(@8 ,"(- "XB
M$0 L(A< *B(= "DB(P H(RH )R,Q "8D.  E)4$ )"5* ",F5  B)F  (2=M
M " G?0 ?)X\ 'BBA !XHM  =*,H '2CH !XH^  ?)_\ ?B4  &XG  !@*0
M5BD  $TJ  !&*@  02D  #PH   W)P  -"8  # F   M)@, *R<+ "@G$  G
M)Q0 )2<: "0G(0 C*"< (B@N "$I-@ @*3X 'RI( !XJ4@ =*UX '"MK !LK
M>P :+(T &2R? !@LL@ 8+,D &"SG !DK]P :*_\ >B<  &HJ  !=*P  4RP
M $HL  !#+   /BL  #DK   T*@  ,"H  "LJ   I*P  )BL( ",L#@ B+!(
M("P8 !\L'@ >+24 '2TL !PM,P ;+CP &BY% !DO4  8+UP %R]I !8P>0 5
M,(L %#"> !0PL0 3,,< $S#E !0P]@ 5+_\ =BH  &<L  !:+0  4"X  $@N
M  !!+@  .RX  #8M   Q+0  +"T  "<O   D+P  (3 % !\Q#  <,1  &S(5
M !HR'  9,B( &#(I !<S,0 6,SD %3-# !0T30 3-%D $C1G !$U=P 1-8D
M$#6< ! UL  .-<8 #S3D ! T]0 0-/\ <BP  &,N  !7,   33   $4P   ^
M,   .#   #,P   O,   *3$  "0R   A,P  '34" !HV"0 7-PX %3<3 !0X
M&0 3.!\ $C@F !(X+@ 1.38 $#E  ! Y2P ..5< #CID  TZ=  ,.H8 ##J9
M  LYK  *.<$ "CG>  LY\0 ,./P ;B\  %\Q  !3,@  2C,  $(S   [,P
M-C,  #$R   L,P  )S0  "$V   =.   &3D  !4[!@ 2/0P $#X0 ! ^%0 .
M/AP #CXC  T^*@ ,/C, ##X\  L_1P */U( "#]@  <_;P &/X$ !3^4  0_
MJ  #/KP !#[7  4^[  %/O< :3,  %LT  !0-0  1S4  #\U   Y-0  -#4
M "XU   I-P  (S@  !X[   :/   %C\  !)!!  .0PH #$0.  I$$P )1!D
M"$0@  =$)P &1"\ !40X  -%0@ "14X  $5;  !%:@  17P  $60  !$I
M1+D  $31  !$Z@  0_4 9#8  %<W  !,.   0S@  #PX   W.   ,3@  "LY
M   E.P  (#T  !I    60@  $D0   Y'!  +20D !TH-  1+$0 !2Q8  $L<
M  !+(P  2RL  $LT  !+/@  3$D  $Q7  !,9@  3'<  $N,  !+H0  2[4
M $K.  !*Z0  2O4 7SH  %([  !(.P  0#L  #H[   T.P  +CP  "<^   B
M00  '$,  !9&   220  #DL   M. P '4 @  E$,  !1$   4A,  %,8  !3
M'P  4R8  %,O  !3.0  4T4  %-2  !380  4W(  %.'  !2G   4K$  %'*
M  !1YP  4?0 63X  $X^  !%/@  /CX  #@^   P0   *4(  "-$   =1P
M%TH  !)-   .4   "U,   95 @  5P<  %@+  !9#@  6A$  %H5  !;&@
M7"$  %PJ  !<-   7#\  %Q-  !<6P  7&P  %R!  !;EP  6ZT  %K%  !:
MY   6?, 5$(  $I"  !"0@  /$(  #1#   L1@  )4D  !Y,   73P  $E,
M  Y6   *60  !5L   !>    8 0  &$(  !B#   8PX  &01  !E%@  9AP
M &<C  !G+0  9SD  &=&  !G50  9V8  &=Z  !FD0  9:@  &7   !DW@
M9/  3T8  $=&  ! 10  -T<  "]*   F30  'U$  !A5   260  #5P   A@
M   "8P   &8   !H    :@   &L$  !L"   ;0P  &\.  !P$@  <A<  ',=
M  !T)@  =#(  '0_  !T3@  <U\  '1R  !SB@  <J$  '&X  !QU   <.P
M3$H  $5*   [2P  ,DX  "E2   @5@  &%L  !)?   -9   !V@   !K
M;P   '(   !U    =@   '<   !Y @  >@8  'P*  !^#@  @!$  ((6  "$
M'@  A"D  (0V  "$10  A%8  (-J  "#@0  @ID  (&Q  " R0  @.4 2DX
M #]0   U4P  *U<  ")<   98@  $F<   QL   %<0   '4   !Y    ?0
M ($   "#    A0   (8   "(    B0   (L$  "-"   CPT  )(0  "4%@
MEB   )8L  "6.P  EDP  )5@  "5=@  E)   ).G  "2O0  DM4 1%4  #E9
M   O70  )&,  !II   2;P  #'4   1[    @    (4   ")    C0   )$
M  "3    E    )8   "8    F@   )P   ">    H 8  *(+  "E$   J!<
M *DC  "I,0  J4,  *E6  "H;0  IH<  *>>  "FLP  I<< /EX  #)C   G
M:@  '7   !-X   ,?P   X4   "+    D0   )8   ";    GP   *(   "D
M    I0   *<   "I    JP   *T   "P    L@   +4"  "W"0  NQ   +X8
M  "^)@  OC@  +Y+  "]80  O'H  +N4  "ZJ0  NKD -VH  "MP   @>
M%H    V(   %CP   )8   "<    H@   *<   "L    L    +,   "V
MMP   +D   "[    O0   +\   #"    Q0   ,@   #*    S@@  -(0  #5
M&P  U2P  -1   #45P  TVX  -2&  #4FP  TZL _P   /\   #_    _P %
M /\ #@#_ !4 _  @ /D *@#V #0 \0 ] .T 1@#I $T Y@!3 .0 60#A %X
MW@!C -P : #9 &X U0!S -, >0#0 (  S@"( ,L D0#) )P Q@"G ,0 MP#"
M ,P P #L +\ _P"^ /\ O0#_ +< _P"R /\ _P   /\   #_    ^@ ! /,
M"P#M !( Z  ; .4 )0#D "X WP X -@ 0 #2 $< S@!. ,L 5 #( %D Q@!>
M ,0 8P#" &< P !M +\ <P"] 'H NP"! +D BP"V )4 M "A +( KP"P ,(
MK@#C *X ^@"L /\ K0#_ *D _P"F /\ _P   /\   #R    Y@   -T !P#2
M  X S0 6 ,H ( #( "D Q0 R ,  .@"\ $( N0!( +< 3@"U %, LP!8 +$
M70"P &( K@!G *P ; "J ', J0![ *< A "E (X HP": *$ J "? +D G@#2
M )T \@"< /\ G0#_ )P _P"9 /\ _    .X   #=    S    ,$  @"Z  P
MM@ 2 +( &@"P ", KP L *T - "I #P I@!" *0 2 "B $T H !2 )X 5P"=
M %L G !@ )H 9@"9 &P EP!T )4 ?0"3 (< D0"3 )  H0". +$ C0#& (P
MZ "+ /T C #_ (P _P", /\ [0   -@   #%    MP   *P   "F  @ H0 .
M )\ %0"= !X FP F )H +@"7 #4 E0 \ ), 0@"1 $< D !, (X 40"- %4
MBP!: (H 8 ") &8 AP!M (4 =@"$ (  @@", (  F@!_ *D ?0"\ 'P W !\
M /4 ? #_ 'P _P!\ /\ V0   ,$   "Q    I    )P   "4  , D  , (T
M$0"+ !@ B0 @ (D * "' "\ A0 V (, / "" $$ @ !& '\ 2P!] $\ ? !4
M 'L 6@!Y &  > !G '8 < !U 'H <P"& '$ DP!P *( ;P"T &X S !N .T
M;@#^ &X _P!N /\ Q    *\   "@    E    (P   "&    @0 ( 'X #@!\
M !0 >P ; 'D (@!X "D =P P '4 -@!T #L <@!  '$ 10!P $H ;P!/ &T
M5 !L %L :P!B &D :@!H '0 9@"  &4 C@!C )T 8@"M &$ P@!A .0 80#X
M &$ _P!A /\ M    *    "1    A@   'X   !Y    =0 # '$ "P!O !
M;0 6 &P '0!K "0 :P J &D , !H #8 9@ [ &4 0 !D $4 8P!* &$ 3P!@
M %8 7P!= %T 90!< &\ 6@!Z %D B !8 )@ 5P"H %8 NP!6 -@ 5@#Q %8
M_P!6 /\ J $  )0%  "%!P  >@<  '(&  !L!   :0$  &< !P!D  T 8P 1
M &$ & !@ !\ 7P E %X *P!= #  6P V %H .P!9 $  6 !% %< 2P!6 %$
M50!8 %, 80!2 &H 4 !V $\ A !. ), 30"D $P M@!, ,T 3 #K $P ^@!,
M /\ G0D  (L+  !\#0  < T  &@-  !B#   7PH  %T& 0!< 0D 6@ . %@
M$P!7 !D 5@ @ %4 )@!3 "L 4@ Q %$ -@!0 #L 3P!! $X 1P!- $T 2P!5
M $H 70!) &< 1P!S $8 @ !% )  1 "A $, L@!# ,@ 0P#F $, ]0!# /\
ME0T  (,/  !T$   :1$  & 1  !:$   5@X  %0-  !3"@0 4P8+ %$#$ !/
M 14 3@$; $P!(0!+ 2< 2@(L $D",@!( C< 1P,] $4#0P!$ TH 0P11 $($
M6@! !60 /P5P #X&?@ ]!HX / >? #L'L0 Z!\8 .@?C #H'\P Z"/P CA
M 'P2  !N%   8A4  %H5  !4%   4!,  $T1  !+#@  2PT& $H*# !)"!$
M1P@6 $4('0!$"", 0@@H $$)+@! "3, /PDY #X*0  ]"D< / I/ #H+6  Y
M"V, . QO #8,?@ U#(X - V? #,-L0 R#<< ,@WC #(-]  R#?X B!,  '<5
M  !I%P  7A@  %48  !/&   2A8  $<5  !%$P  0Q " $,." !"#0X 0 T2
M #\-&  ]#1\ / TD #L-*@ Y#3  . XW #<./0 V#D4 -0Y- #,/5P R#V(
M,1!N "\0?0 N$(X +1&@ "P1L@ K$<@ *Q'F "L1]@ L$?\ @Q8  '(9  !D
M&@  61L  %$;  !+&P  1AH  $(8   _%P  /A0  #P2!  [$0H .A 0 #@0
M%0 W$!L -1$A #01)P S$2T ,A$S # 1.@ O$D( +A)+ "T35  K$U\ *A1L
M "D4>P H%(P )Q6> "85L  E%<8 )17D "45]@ F%?\ ?AD  &X;  !@'0
M5AX  $T>  !''@  0AT  #X<   Z&@  .!@  #<6   U%0< -!0- #(4$@ P
M%!< +Q0= "T4(P L%2H *Q4P "H5-P I%C\ *!9( "<74@ F&%T )!AJ ",9
M>0 B&8H (1F< " 9KP ?&<0 'QGB " 9]  @&?\ >AL  &H>  !='P  4R
M $H@  !$(   /A\  #H>   W'0  -!P  #(9   P&00 +A@+ "P8$  J&!0
M*1@: "<8(  F&28 )1DM "0:-0 C&CT (AM& "$;4  @'%L 'QUH !X==P =
M'8@ '!Z; !L>K0 :'L, &A[@ !H=\P ;'?\ =QT  &<@  !:(0  4"(  $@B
M  !!(@  .R(  #<A   S(   ,!\  "T=   K'0  *!T( "8=#@ E'1( (QT7
M "$='0 A'20 (!XJ !\>,@ >'SH '1]# !P@30 ;(5D &B%F !DA=0 8(H<
M%R*9 !8BK  5(L$ %2+? !4A\@ 6(?X <R   &0B  !7(P  320  $4E   ^
M)   .20  #0C   P(@  +"(  "DA   F(0  )"$& "(A#  @(1  'B$5 !TB
M&P ;(B$ &R(H !HC+P 9(S@ &"1! !<D2P 6)5< %25D !0F<P 3)H4 $B:8
M !$FJP 1)L  $";= !$E\0 2)?T <"(  &$D  !4)@  2B8  $(G   \)@
M-B8  #$E   M)0  *20  "8D   B)0  'R4# !TF"@ ;)@X &2<2 !@G&  7
M)Q\ %B<E !4H+0 4*#4 $RD^ !(I20 1*54 $2IB ! J<0 /*H, #BJ6  XJ
MJ0 -*KT #2K7  TJ[@ .*?L ;"0  %TF  !1*   2"@  $ I   Y*   -"@
M "\H   K)P  )R<  "(H   >*0  &RH  !@K!P 6*PT %"P1 !,L%@ 2+!P
M$2TC ! M*@ 0+3( #RX\  XN1@ -+E( #2Y?  PO;@ ++W\ "B^2  DOI0 )
M+KD ""[0  DNZ0 *+O< :"<  %HI  !.*@  12L  #TK   W*P  ,2H  "TJ
M   I*@  )"H  " K   ;+0  &"X  !4O!  2,0H $#(.  \R$P .,AD #3(@
M  TR)P ,,B\ "S,X  HS0@ ),TX "#-;  8T:@ %-'L !#..  ,SH@ ",[8
M C/-  ,SYP $,O, 9"H  %8L  !++0  0BT  #HM   T+0  +RP  "LL   F
M+   (BT  !TO   9,0  %3(  !(T P /-@D ##@-  HX$0 ).!8 "#@=  <X
M)  &."P !#@T  ,X/@ ".4H  #E7   Y90  .7<  #F+   XGP  .+,  #C*
M   XY@  -_( 7RT  %(N  !(+P  /S   #@O   R+P  +2\  "DO   D,
M'S$  !HS   5-0  $C<   \Y P ,.P@ "#T-  4^$  #/A0  #X:   ^(0
M/B@  #XQ   _.P  /T8  #]3   _80  /W,  #^'   ^G   /K   #W'   ]
MY   /?( 6C   $XR  !$,@  /#(  #4R   P,0  *S$  "8R   @-   &S8
M !8X   2.P  #ST   P_ P (00@ !$,,  !##@  1!(  $46  !%'0  120
M $4M  !&-@  1D(  $9.  !&70  1FX  $6"  !%F   1*T  $3$  !#XP
M0_( 530  $HU  !!-0  .34  #,T   N-   *#4  "(W   =.@  %SP  !(_
M   /00  #$0   A& 0 #2 8  $D*  !*#0  2Q   $P4  !-&0  3B   $XH
M  !.,@  33T  $Y*  !.6   36D  $U]  !,E   3*H  $O!  !+X0  2O(
M4#@  $8X   ].   -S@  #$W   J.0  )#L  !X]   80   $T,   ]&   +
M20  !TL   ).    4 0  %$(  !2"P  4PX  %01  !5%0  5AL  %<C  !7
M+   5S@  %=$  !74@  5F,  %9W  !6C@  5:4  %2]  !3W0  4_  2SP
M $(\   [.P  -3L  "T\   F/P  'T(  !E%   32   #DL   M/   %40
M %0   !7    6 $  %H%  !;"   7 P  %T.  !?$0  8!8  &(=  !B)@
M8C$  &(^  !A3   85T  &%P  !@B   8*   %^W  !>U   7>X 1T   #\_
M   Z/P  ,4   "E#   A1@  &DH  !-.   .40  "E4   18    6P   %X
M  !A    8P   &0!  !E!   9P@  &@+  !J#@  ;!(  &X7  !O(   ;RH
M &\V  !N10  ;E4  &YH  !M?P  ;9@  &RP  !KR@  :N@ 1$0  #Y#   U
M1   *T<  "-+   ;3P  $U0   Y8   (7    F    !D    9P   &L   !M
M    ;P   '    !R    = (  '4&  !W"@  >0X  'P2  !^&   ?R(  '\N
M  !_/0  ?DT  'UA  !]=P  ?)   'NH  !ZP   >=\ 0T<  #E)   O3
M)5   !Q5   46P  #F    =E    :@   &X   !R    =@   'D   !\
M?@   '\   "!    @P   (4   "' P  B@@  (P-  "/$0  DAD  )(E  "2
M,P  DD0  )%7  "0;0  CX8  (Z?  "-M0  C,T /4X  #)1   H5@  'EP
M !5B   .:   !VX   !T    >0   'X   ""    A@   (D   ",    C@
M )    "2    E    )8   "8    FP   )X&  "A#   I!$  *8;  "F*0
MICH  *5-  "E8@  I'L  *.4  "AJP  H;\ -E<  "Q<   A8@  %VD   ]P
M   '=P   'X   "$    B@   (\   "4    F    )L   ">    GP   *(
M  "D    I@   *@   "K    K0   +    "S!   MPP  +L2  "['P  NS
M +M#  "Z6   N7   +>+  "WH0  M[, ,&(  "5I   :<   $'@   F
MB    (\   "6    FP   *$   "F    J@   *X   "P    L0   +0   "V
M    N    +L   "]    P    ,,   #'    RP,  ,\,  #3%0  TB4  -(X
M  #13@  T&4  ,]^  #-E@  S*D _P   /\   #_    _P # /\ "P#\ !$
M^0 ; /< )0#S "\ [@ X .D 0 #F $@ X@!. -\ 5 #< %D V0!> -4 8P#3
M &@ T !M ,X <P#+ 'H R "" ,8 C ## )< P "C +X L@"\ ,@ N@#J +D
M_P"X /\ L0#_ *H _P"G /\ _P   /\   #[    ]@   .T !P#G  \ X@ 6
M -\ ( #> "D V0 S -$ .P#, $( R !( ,4 3@#" %, P !8 +X 70"\ &(
MN@!G +D ;0"W '0 M0![ +( A0"P )  K@"< *P J@"I +T IP#> *8 ^0"E
M /\ HP#_ )T _P"; /\ _0   /8   #K    WP   -$  P#*  P Q0 2 ,,
M&P#  "0 O@ L +D -0"V #P LP!# +  2 "N $X K !2 *L 5P"I %P IP!A
M *8 9P"D &T H@!T *  ?0"> (@ G "5 )H HP"8 +0 E@#- )4 \0"4 /\
ME0#_ )  _P". /\ \P   .8   #1    P@   +@   "Q  @ K0 / *H %@"H
M !X J  G *8 +P"B #8 GP \ )T 0@"; $< F0!, )< 40"6 %4 E !: ),
M8 "1 &8 D !N (X =@", ($ B@"- (@ FP"& *P A0#! (0 Y@"# /T A #_
M (, _P"! /\ Y    ,L   "Z    K    *(   "<  0 F  , )8 $0"4 !D
MDP A )( * "/ #  C0 V (L / ") $$ B !& (8 2P"% $\ A !4 (( 6@"!
M &  ?P!G 'X ;P!\ 'H >@"& '@ E !W *0 =0"W '0 U !S /0 = #_ '0
M_P!T /\ RP   +8   "F    F@   )(   "*    A@ ( (, #@"! !0 @0 ;
M (  (P!_ "H ?0 P 'L -@!Z #L > !  '< 10!U $D = !. ', 5 !Q %H
M< !A &X :0!M ', :P!_ &D C0!H )T 9P"N &8 QP!E .H 9@#_ &8 _P!G
M /\ N    *0   "5    B@   ($   !\    =@ $ '0 # !R !  <0 6 '
M'0!P "0 ;@ J &T , !K #4 :@ Z &D /P!H $0 9P!) &4 3@!D %0 8P!;
M &$ 8P!@ &T 7@!Y %T AP!; )8 6@"H %D O0!9 -\ 60#X %H _P!: /\
MJ    )4   "'    >P   ',   !N    :@ ! &< " !E  X 9  2 &, & !C
M !\ 8@ E &$ *@!? #  7@ U %T .@!< #X 6P!$ %D 20!8 $\ 5P!6 %8
M7@!4 &@ 4P!S %$ @0!0 )$ 3P"B $X M0!. -  3@#P $X _P!/ /\ G
M (D   ![ P  < ,  &@#  !B 0  7P   %T ! !;  L 60 / %@ % !7 !D
M5P @ %8 )0!5 "H 4P P %( - !1 #D 4  _ $\ 1 !. $L 30!2 $L 6@!*
M &, 20!O $< ? !& (P 10"= $4 L !$ ,< 1 #H $0 ^@!% /\ D@0  ( '
M  !Q"@  9@H  %X*  !9"0  50<  %0$  !2  < 4  , $\ $ !. !4 30 ;
M $P ( !+ "8 2@ K $D , !( #4 1P Z $8 0 !% $8 0P!. $( 5@!! %\
M0 !K #X >  ] (@ / "9 #P JP \ ,$ .P#@ #L ]  [ /\ B0H  '@,  !J
M#@  7PX  %<.  !1#@  30P  $L+  !*" ( 200) $@ #0!& !$ 10 6 $0
M' !# "$ 0@ F $$ *P _ #$ /@ V #T /  \ $, .P!* #H 4@ Y %P . !H
M #8 =0 U (4 - "6 #0 J  S +P ,P#8 #, [P S /L @@T  '$/  !D$
M61$  %$1  !+$0  1Q   $0.  !"#0  00L% $$'"P _!0X /@,2 #P"&  [
M AT .@,B #D#*  X RT -P,R #8$.0 U!#\ - 5' #,%4  Q!EH , 9F "\'
M<P N!X, +0>5 "P'IP K![H *P?2 "L'ZP K!_< ?1   &P1  !?$P  5!0
M $P4  !&%   0A,  #X2   \$   .@X! #H-!@ Z"@P . D0 #8(%  U"!D
M- D? #())  Q"2D , DO "\*-@ N"CT +0I% "P+3@ K"UD *0QE "@,<P G
M#(, )@V5 "4-IP D#;L (PW2 ",-ZP C#?< >!(  &@4  !;%@  41<  $@7
M  !"%@  /18  #D5   W$P  -1$  #,0 P S#@@ ,@T- # -$0 O#18 +0T;
M "P-(0 K#2< *@TM "D.-  H#CL )PY$ "4.3@ D#UD (Q!E "$0<P @$(0
M'Q"6 !X0J0 =$+T '!#8 !T0[@ =$/D <Q0  &06  !7&   31D  $49   _
M&0  .A@  #47   R%@  ,!4  "X3   M$00 +! * "L0#@ I$!( *! 8 "80
M'@ E$"0 )! J ",1,0 B$3D (1%" " 22P >$E8 '1-C !P3<0 :$X( &125
M !@4IP 7%+L %Q/4 !<3[@ 8$_H <!8  & 9  !4&@  2AL  $(<   \&P
M-AL  #(:   O&0  +!@  "H6   H% $ )A,' "43#  C$Q  (A,5 " 3&@ ?
M$R$ 'A0G !T4+@ <%38 &Q4_ !H620 9%E0 &!=A !87<  5&($ %!B3 !,8
MI@ 2&+H $A?2 !(7[  3%_H ;!D  %T;  !1'0  1QT  #\>   Y'0  -!T
M "\<   K&P  *!H  "89   D&   (A<$ " 7"@ >%PX '!<2 !H7%P 9&!X
M&1@D !@9+  7&30 %AH] !4:1P 4&U( $QM? !(<;@ 1''\ $!R2 ! <I0 /
M'+D #AS0  X;Z@ /&_@ :1L  %H=  !.'P  11\  #T@   V'P  ,1\  "T>
M   I'0  )1T  ",<   @&P  '1L! !L;!P 9' T %QP0 !8<%0 5'!L %!TB
M !,=*0 2'C$ $1XZ !$?10 0'U  #R!=  X@;  -('P #2"/  P@H@ +(+4
M"R#*  L@Y0 ,'_0 91T  %<?  !,(0  0B$  #HA   T(0  +R$  "H@   F
M'P  (Q\  " >   ='@  &2   !8@!  4( L $B$. !$A$P 1(AD $"(?  \B
M)@ .(R\ #B,W  TC00 ,)$T "R19  HD9P ))'@ ""2+  <DG@ ')+$ !B3'
M  8CXP '(_$ 8A\  %0A  !)(P  0",  #@C   R(P  +",  "@B   D(0
M(2$  !XA   :(0  %B,  !,D P 1)0@ #R8-  XG$0 -)Q8 #"<=  LG(P *
M)RL "2@T  @H/@ '*$D !BA5  4I9  $*70  RF'  (IFP !**\  "C%  $H
MX0 !)_  7B(  %$D  !&)0  /24  #4E   O)0  *B0  "8D   B(P  'R,
M !LD   8)0  %"8  !$H P /*0@ #"P,  HL$  (+!0 !RP:  8L(0 %+"@
M RTP  (M.@ !+44  "U2   N8   +G$  "V$   MF0  +:T  "S"   LX
M+/  6B0  $TF  !#)P  .B<  #,G   M)P  *"8  "0F   A)@  '28  !DG
M   5*0  $2L   \L P -+@< "3 ,  8Q#@ #,1(  3(7   R'@  ,B4  #(M
M   R-@  ,T(  #-.   S70  ,VT  #.!   RE@  ,JL  #'!   QWP  ,?
M5B<  $HI   _*@  -RH  # J   K*0  )R@  ",H   >*0  &BH  !8L   2
M+@  #S    TQ @ *- < !34+  (V#@  -Q   #@4   X&@  ."(  #@J   Y
M,P  .3X  #E*   Y60  .6D  #E]   XDP  .*@  #>_   WW@  -O  42L
M $8L   \+   -"P  "XL   J*P  )2L  " L   ;+0  %R\  !,Q   0,P
M#34   DW @ %.@8  3L*   \#0  /0\  #X2   _%P  0!X  $ E  ! +P
M0#H  $!&  ! 5   0&4  #]X   _CP  /J8  #Z]   ]W   /?  32X  $(O
M   Y+P  ,B\  "TN   H+@  (B\  !TP   8,@  $S4  ! W   ,.@  "3P
M  4^    000  $((  !#"P  1 T  $80  !'%   2!D  $@A  !(*@  2#4
M $A!  !(3P  2&   $=S  !'B@  1J(  $6Y  !%V0  1/  2#(  #XR   V
M,@  ,#$  "LQ   E,@  'S0  !DV   3.0  $#P   P_   (0@   T0   !&
M    2 (  $H%  !+"   3 L  $X.  !/$0  414  %(<  !2)0  4C   %(\
M  !12@  45H  %%M  !0A   3YT  $ZU  !-T@  3>X 0S8  #LV   T-0
M+S0  "<U   A.   &CL  !0^   000  #$0   ='   "2@   $T   !/
M40   %,"  !4!0  50@  %<+  !9#@  6Q$  %T7  !='P  72H  %TV  !<
M1   7%0  %MG  !;?@  6I<  %FO  !8RP  5^H /SD  #@Y   S.   *SD
M ",\   </P  %4,  !!'   +2@  !4X   !1    5    %<   !:    7
M %T   !?    8 0  &('  !D"P  9@X  &@2  !K&0  :R,  &HN  !J/
M:DT  &E?  !H=0  9X\  &:H  !EP@  9., /3T  #<\   N/0  )4   !U$
M   620  $$T   I1   $50   %H   !=    8    &,   !F    :    &H
M  !K    ;0   &\"  !Q!@  = H  '8.  !Y$P  >QL  'LG  !Z-0  >44
M 'A9  !X;0  =X8  ':?  !UMP  =-( /$$  #)"   H10  ($H  !=.   0
M5   "ED   )>    8P   &<   !K    ;P   '(   !U    =P   'D   ![
M    ?0   '\   ""    A ,  (<)  "*#@  CA,  (\>  ".*P  CCL  (U.
M  "+8P  BGP  (J5  "(K0  A\4 -D<  "Q+   B3P  &54  !!;   *80
M 6<   !M    <@   '<   ![    ?P   (,   "&    B    (H   "-
MCP   )$   "4    EP   )H!  "=!P  H0T  *44  "D(0  I#$  *-$  "B
M60  H'   )^+  "=H@  G;< ,%   "55   ;6P  $F(   MI   !<    '<
M  !]    @P   (@   "-    D0   )4   "8    F@   )P   "?    H0
M *,   "F    J0   *P   "P    M <  +@.  "Z&   NB<  +DY  "X3@
MMV4  +9^  "UE@  LZL *5L  !YB   4:0  #'$   )Y    @0   (D   "/
M    E@   )L   "@    I    *@   "K    K    *\   "R    M    +8
M  "Y    O    ,    #$    R    ,T'  #2$   TAT  -$O  #01   SUL
M ,US  #+C0  RJ$ _P   /\   #[    ^@   /P " #X  \ ]0 7 /0 ( #Q
M "H ZP S .8 .P#B $, W@!) -H 3P#6 %0 TP!9 -  7@#. &, RP!H ,D
M;@#& '4 PP!] ,$ A@"^ )( NP"> +D K@"V ,, M #H +, _P"O /\ I0#_
M )X _P"; /\ _0   /<   #R    \    .<  P#A  P W  2 -@ &P#6 "0
MT@ M ,P -@#& #T P@!# +\ 20"\ $X N@!3 +@ 6 "V %T M0!B +, 9P"Q
M &X KP!V *P ?P"J (H J "7 *4 I@"C +D H0#9 *  ^0"> /\ F #_ )(
M_P"/ /\ \P   .P   #C    TP   ,@   #!  D O0 / +L %@"Y !\ MP G
M +, +P"O #< K  ] *H 0P"H $@ I@!- *0 4@"C %8 H0!; )\ 80"> &<
MG !O )H > "7 (, E0"0 ), G@"1 +  D #( (X \ "- /\ B@#_ (4 _P""
M /\ YP   -T   #&    N    *X   "H  0 I0 , *$ $@"A !D H  B )\
M*0"; #  F  W )8 /0"3 $( D@!' )  2P"/ %  C0!5 (P 6@"* &$ B !H
M (< < "% 'L @P"( ($ E@!_ *< ?0"\ 'P XP!\ /T ? #_ '@ _P!V /\
MU@   ,    "O    HP   )D   "3    CP ) (T #@"+ !0 B@ < (H (P"(
M "H A0 P (, -@"" #L @ !  '\ 10!^ $H ? !/ 'L 5 !Z %H > !A '8
M:0!U ', <P"  '$ C@!O )\ ;@"R &T SP!L /0 ; #_ &L _P!I /\ P
M *L   ";    CP   (<   "     ?  $ 'H # !X !$ >  7 '@ '@!W "0
M=0 J ', , !Q #4 <  Z &X /P!M $0 ; !) &L 3@!J %0 : !; &< 8P!E
M &T 9 !X &( AP!@ )< 7P"J %X P@!> .D 7@#_ %X _P!= /\ K    )D
M  "*    ?P   '<   !Q    ;0   &H " !I  X :  2 &< & !G !\ 9P E
M &4 *@!C "\ 8@ T &$ .0!@ #X 7P!# %X 2 != $X 6P!5 %H 70!8 &<
M5P!R %4 @0!4 )$ 4P"C %( N !1 -P 40#Y %( _P!2 /\ G0   (L   !\
M    <0   &D   !D    8    %X !0!<  L 6P / %L % !: !D 6@ ? %D
M)0!7 "H 5@ O %4 - !4 #@ 4P ] %( 0P!0 $D 3P!0 $X 6 !- &( 2P!M
M $H >@!) (L 2 "= $< L0!' ,P 1@#P $< _P!' /\ D    'X   !P
M9@   %X   !9    5@   %,  0!2  @ 4  - $\ $ !/ !4 3@ : $X ( !-
M "4 3  J $H +@!) #, 2  X $< /@!& $0 10!+ $0 4P!# %T 00!H $
M=0 _ (4 /@"7 #T JP ] ,, /0#F #T ^P ^ /\ AP   '4#  !H!@  70<
M %4&  !0!@  3 0  $H!  !)  0 1P * $8 #@!% !$ 10 6 $0 &P!# "
M0@ E $$ *@!  "\ /P T #X .@ ] $  .P!' #H 3P Y %D . !D #< <0 V
M ($ -0"3 #0 I@ T +L - #= #0 ]0 U /\ ?@8  &T)  !@"P  5@P  $X,
M  !("P  1 H  $((  ! !0$ /P$' #X "P ]  X /  2 #L %P [ !P .@ A
M #D )0 W "H -@ P #4 -0 T #P ,P!# #( 3  Q %4 , !@ "\ ;0 N 'T
M+0"/ "P H@ L +8 + #0 "P [@ L /P =PH  &<,  !:#@  4 X  $D.  !#
M#@  /@T  #L,   Y"P  . D# #<%"  V @T -0$0 #0 $P S !@ ,@ = #$
M(@ P "< +P L "X ,@ M #@ + !  "L 20 J %( *0!= "@ :P G 7H )@&,
M "4 GP E +( )0#* "4 Z  E /< <@T  &(.  !6$   3!$  $01   ^$0
M.1   #8/   S#@  ,0T! # +!0 P" H +P8- "X%$0 L!!0 *P,9 "H#'@ I
M R, * 0I "<$+P F!34 )04] "0%1@ C!E  (@9< "$':0 @!WD 'P>+ !X'
MG0 >![  '0;& !T&XP =!?, ;0X  %X1  !2$@  2!,  $ 3   Z$P  -1(
M #$1   N$   + \  "H. P J#0< *0L+ "@)#@ G"1$ )0@6 "0(&P C"2
M(@DF "$)+  @"C, 'PH[ !X+1  ="T\ ' Q; !L,:0 :#'D & R+ !@,G@ 7
M#+  %@S% !8,X0 6"_  :1   %H2  !.%   114  #T5   W%0  ,10  "T3
M   J$@  *!$  "80 0 D$ 0 (PX( ",-#  B# \ ( P3 !\,&  >#1T '0TC
M !P-*@ ;#3( &@XZ !@.1  7#E  %@]< !4/:@ 3$'L $A"- !$0H  1$+,
M$ _) ! /Y  1#_( 91(  %<4  !+%@  0A<  #H7   T%P  +Q8  "H5   G
M%   )!,  "(3   @$@, 'A$& !T0"0 <$ T &P\0 !D0%0 8$!L %Q A !80
M*  5$3  %!$Y !,10P 2$DX $1): ! 2:0 0$WD #A.,  X3G@ -$[$ #1+%
M  P2X0 -$O$ 8A0  %06  !)&   /QD  #<9   Q&0  +!@  "@7   D%@
M(18  !\5   <% ( &A,$ !D2!@ 7$@L %1(. !02$@ 3$Q@ $A,? !$3)@ 1
M%"T $!0V  \500 .%4P #A97  T690 ,%W4 "Q>'  H7F@ )%JT "!;!  @6
MW0 )%>X 7Q8  %$8  !&&@  /1H  #4;   O&@  *AH  "49   B&   'Q@
M !P7   9%@$ %Q8# !46!  3%@D $18- ! 7$0 /%Q8 #A<<  X8(P -&"H
M#!DS  P9/  +&D< "AI3  D:80 '&W$ !AN#  4;EP $&JH  QJ_  ,9V@ $
M&>P 7!@  $X:  !#'   .AP  #,<   L'   )QP  ",;   @&@  '1D  !H9
M   7& $ %1@" !(9!  0&P< #AL,  T<$  ,'!, "QP9  H<'P )'2< "!TO
M  <>.0 &'D, !!Y0  ,?7@ "'VX  1^    ?E0  'JD  !Z]   =V   '>P
M6!H  $L<  !!'@  .!X  # >   J'@  )1T  "$<   >'   &QL  !@;   6
M&P$ $QL" !$<!  .'@< #!\+  H@#@ ((!( !B$7  4A'0 $(20  B(L  $B
M-0  (D   "--   C6@  (VL  "-^   CDP  (J<  "*\   AUP  (>T 51T
M $@?   ^(   -2   "X@   H(   (Q\  " >   ='0  &AT  !8=   3'@
M$1\"  X@!  -(@< "B0+  8E#0 $)1   B84   F&@  )B$  "<I   G,@
M)ST  "=)   H5P  *&<  "=[   GD   )Z4  ":[   FU@  )>T 42   $4A
M   [(@  ,B(  "PB   F(0  (B$  !X@   ;'P  &"   !0@   1(@  #R,
M  TE P *)@8 !B@*  ,I#0  *P\  "P2   L%P  +!X  "PF   M+P  +3D
M "U&   M5   +60  "UW   LC0  +*0  "NZ   KU@  *NX 32(  $$D   X
M)   ,"0  "DD   D(P  (2(  !TB   9(@  %2,  !(D   /)@  #2@   HJ
M @ &+ 4  BX)   O"P  , X  #(0   S%0  ,QL  #,B   S*P  ,S8  #-"
M   S4   ,V   #-S   RB@  ,J$  #&X   PU@  ,.\ 224  #XF   T)P
M+2<  "@F   C)0  'R0  !LE   6)@  $B@  ! J   -+   "BX   8P 0 "
M,@0  #0'   U"@  -PP  #@.   Z$@  .A<  #H?   Z)P  .C(  #H^   Z
M3   .EP  #IO   YA@  .)X  #BV   WU   -N\ 1"D  #HI   Q*0  *RD
M "8H   B)P  '2@  !@I   3*P  $"X   TP   ),@  !34   $W    .0(
M #L%   \"   /@L  #\-  !!$   0Q0  $,;  !#(P  0RX  $,Y  !#1P
M0E<  $)J  !!@0  0)H  #^R   ^SP  /N\ /RP  #8L   O+   *BL  "4J
M   ?*P  &2T  !0O   0,@  #34   @X   $.@   #P    _    00   $,"
M  !%!0  1@@  $@+  !*#@  3!$  $T6  !-'@  32@  $TT  !,0@  3%$
M $MD  !+>P  2I0  $FM  !(R@  1^P .S   #,O   M+P  *"T  "(O   ;
M,0  %30  ! W   -.@  "#T   )     0P   $8   !(    2@   $P   !.
M 0  3P0  %$'  !3"P  50X  %@2  !9&0  6"(  %@N  !7/   5TL  %9>
M  !6<P  58T  %2G  !2P@  4N8 .#,  #$R   L,0  )3(  !TU   6.
M$3P   Q    '1    $<   !*    30   %    !3    50   %<   !9
M6@   %P#  !>!P  80L  &0.  !F$P  9QP  &8G  !F-   940  &17  !D
M:P  8H4  &&?  !@N0  7MP -3<  # U   H-P  (#H  !@]   10@  #$8
M  9*    3P   %,   !6    60   %P   !?    80   &0   !E    9P
M &D   !L 0  ;@8  '$+  !T#P  =Q4  '<@  !V+0  =CT  '5/  !T8P
M<WL  '*5  !PKP  ;\D -3H  "L[   B/P  &D,  !)(   ,30  !5(   !7
M    7    &    !D    :    &L   !N    <0   ',   !U    =P   'H
M  !\    ?P   (($  "&"@  B@\  (P7  "+)   BC,  (E%  "'6P  AG(
M (6+  "#I0  @KP +T   "5$   <20  $TX   U4   $6@   &$   !F
M:P   &\   !T    >0   'T   "     @P   (4   "'    B@   (P   "/
M    D@   )8   "9 @  G@D  *(0  "B&@  H2D  * [  "?4   G6<  )J!
M  ":F0  F:\ *4D  !].   55   #EL   5B    :0   '    !W    ?0
M ((   "&    BP   (\   "3    E0   )<   ":    G0   *    "C
MI@   *H   "N    L@   +<*  "[$0  NA\  +DP  "W10  M5P  +1T  "Q
MC@  KZ0 (E0  !A;   08@  !VH   !S    >P   ((   ")    D    )4
M  ":    GP   *,   "F    J    *L   "N    L    +,   "V    N@
M +T   #"    QP   ,P!  #3"P  U!4  -,F  #1.@  T%$  ,UH  #+@0
MRI8 _    /8   #R    \0   /, !0#T  P \@ 3 /  ' #M "4 Z  N .(
M-@#> #X V0!$ -0 2@#1 $\ S@!4 ,L 60#) %X Q@!C ,0 :0#! '  O@!X
M +P @0"Y (T M@": +, JP"Q ,  KP#F *X _P"E /\ F@#_ )0 _P"/ /\
M]    .P   #H    YP   -\   #9  D T@ 0 ,\ %P#/ "  S  H ,8 , #
M #< O  ^ +D 1 "W $D M0!. +, 4P"Q %< KP!= *T 8@"K &D J0!Q *<
M>@"E (4 H@"3 *  H@"= +8 FP#4 )D ^0"6 /\ C0#_ (@ _P"$ /\ Z
M -\   #9    R0   +\   "X  0 M0 - +, $@"Q !H L  B *T *@"I #$
MI@ X *0 /0"B $, H !( )X 3 "< %$ FP!6 )D 7 "7 &( E0!I ), <@"1
M 'T CP"+ (T F@"+ *P B0#% (@ [@"& /\ ?P#_ 'H _P!X /\ V0   ,T
M  "[    K@   *4   "?    G  ) )D #P"9 !4 F0 = )@ ) "4 "L D0 Q
M (X -P", #P BP!! (D 1@"( $L A@!0 (4 50"# %L @@!B (  :P!^ '4
M? "" 'H D@!X *, =P"Y '8 X !U /\ <@#_ &X _P!L /\ QP   +4   "E
M    F0   (\   ")    A0 $ (0 # "" !$ @@ 7 (( '@"  "4 ?@ K 'P
M,0!Z #8 >0 [ '< 0 !V $0 =0!) ', 3P!R %4 < !< &\ 9 !M &X ; !Z
M &H B@!H )L 9P"O &8 S !E /4 9 #_ &$ _P!@ /\ M    *    "0
MA0   'T   !W    <P   '  " !O  X ;P 2 &\ & !O !\ ;0 E &L *@!I
M #  :  T &< .0!F #X 90!# &, 2 !B $X 80!5 %\ 7@!> &< 7 !S %L
M@@!9 ), 6 "F %< OP!7 .H 5P#_ %8 _P!4 /\ H0   (X   !_    =0
M &P   !H    9    &$ ! !@  L 7P / %\ $P!? !D 7P ? %T )0!< "H
M6P O %D ,P!8 #@ 5P ] %8 0P!5 $D 4P!0 %( 6 !1 &$ 4 !M $X >P!-
M (P 3 "? $L M0!* -P 2@#Z $H _P!* /\ D@   (    !R    9P   %\
M  !:    5P   %4  0!3  < 4@ , %( $ !2 !0 4@ : %$ 'P!/ "0 3@ I
M $T +@!, #, 2P X $H /0!) $, 2 !* $8 4@!% %P 1 !G $, =0!" (8
M00"8 $  K@!  ,L /P#R $  _P!  /\ A0   '0   !G    70   %4   !/
M    3    $H   !(  0 1P * $< #0!& !$ 1@ 5 $8 &@!% !\ 1  D $,
M*0!" "T 00 S #\ .  ^ #X /0!% #P 3@ [ %< .@!B #D ;P X (  -P"3
M #8 IP V ,  -@#H #8 _@ V /\ ?    &L   !> @  5 ,  $T#  !' P
M0P$  $$    _  $ /@ ' #T "P ]  X /  1 #P %@ \ !H .@ ? #D )  X
M "D -P N #8 ,P U #H - !! #, 20 R %, ,0!> #  :P O 'L +@". "T
MH@ M +@ +0#= "T ^  N /\ <P$  &0%  !7!P  30@  $8(  ! "   .P<
M #@%   W P  -@ $ #4 "  T  P -  / #0 $@ S !8 ,@ ; #$ (  P "0
M+P I "X +P M #8 +  ] "L 10 J $\ *0!: "@ 9P G '< )@") "8 G0 E
M +, )0#/ "4 \  F /\ ;08  %X)  !2"P  2 P  $ ,   Z"P  -@L  #(*
M   P"   +@8" "X#!@ M  H +  - "P $  K !, *@ 7 "D '  H "  )P E
M "8 *P E #( )  Y ", 0@ B $L (@!7 "$ 9  @ ', 'P"% !\ F0 > *X
M'@#' !X Z0 ? /H : D  %D,  !-#0  0PX  #P.   V#@  ,0T  "T-   J
M#   * L  "<)!  F!@@ )@0+ "4##@ D 1  ) $4 "(!&  A 1T (0 B "
M*  ? "X '@$V !T!/P < 4D &P%4 !H!80 : 7  &0&" !@ E@ 8 *H & #!
M !@ X0 8 /0 8PP  %4.  !)#P  0!   #@0   R$   +0\  "D.   F#@
M(PT  "(, P @"P8 ( D) !\'#  >!@X '@41 !P%%0 ;!1H &@4? !H%)0 9
M!2L & 4S !<&/  6!D8 %@92 !4'7P 4!VX $P>  !('E  2!J< $@6\ !($
MV0 2 ^\ 7PX  %$/  !&$   /!$  #41   O$0  *A$  "80   B$   ( \
M !T. @ <#04 &@T' !H+"@ 9"@T & D0 !<)$@ 6"1< %0D< !0)(@ 4"BD
M$PHQ !(*.@ 2"T4 $0M1 ! ,7P /#&X #@R   X,E  -"Z< #0NZ  T*T@ -
M"NH 7 \  $X1  !#$@  .A,  #(3   L$P  )Q(  ",1   ?$0  '!   !H0
M @ 8#P0 %@X' !4."0 4#0L $PP- !(,$  2#!0 $0P: !$-(  0#2@ #PTP
M  X..P -#D8 #0Y1  P/7@ +#VT "@]_  D/DP )#Z8 " ZY  @.T  '#N@
M6!$  $L2  ! $P  -Q0  # 4   I%   )10  "$3   =$@  &A(  !<1 @ 5
M$04 $Q ' !(0"0 1#PH $ X,  X.#@ .#Q( #1 8  T0'@ ,$"4 #! M  L1
M-@ *$4$ "1%-  @26@ '$FH !A)\  42D  $$J0  Q&X  ,1SP "$>@ 51(
M $D4   ^%0  -18  "T6   G%@  (A4  !X4   ;%   &!,  !42 P 3$@4
M$A$' ! 1"0 /$0H #1$+  P2#@ +$A$ "A(5  D3&P )$R( "!,J  <4,P %
M%#X !!5*  ,56  "%6<  15Z   5C@  %:,  !2W   4SP  $^D 4A0  $86
M   [%P  ,A<  "L7   E%P  (18  !P6   9%0  %A0! !03!  2$P8 $1((
M  \2"  .$PD #!0*  H5#0 (%A  !A83  46&0 $%Q\  Q<G  (8,  !&#L
M !E'   950  &60  !EW   9C   &*(  !BW   7SP  %^H 3Q8  $,8   Y
M&0  ,!D  "D9   C&0  'Q@  !L7   8%@  %14" !,5!0 1% 8 $!0&  X5
M!P ,%@@ "A<*  <9#  $&@X  AL2  $;%@  &QT  !PD   <+0  '#@  !U$
M   =4@  '6(  !UU   =B@  '*   !RV   ;T   &NL 3!@  $ :   V&P
M+1L  "8;   A&@  '1D  !D9   7&   %!<# !(6!  0%P0 #A<$  P9!0 *
M&@< !QP)  ,="P  'PT  " 0   @%   (1H  "$B   A*@  (34  ")!   B
M3P  (E\  ")R   AB   (9\  ""V   ?T0  '^T 2!H  #T<   S'0  *QT
M "0=   @'   '!L  !@:   6&0$ $QD! !$9 0 .&@$ #!P"  H= P ''P4
M R$(   B"@  ) P  "8.   F$@  )A@  "<?   G)P  )S(  "<^   G2P
M)UP  "=N   FA0  )IT  "6T   DT0  (^X 1!T  #D?   P'P  *!\  ",>
M   >'0  &QP  !@;   4'   $1P   X=   -'P  "B$   8B 0 #) 0  "8&
M   H"   *@L  "L-   M$   +14  "T<   M)   +BX  "XZ   N2   +5@
M "UJ   M@0  +)H  "NR   JT   *>\ 0"   #8A   M(0  )B$  "$@   =
M'P  &AX  !8>   2'P  #R$   TB   *)   !B8   (H    *P(  "T$   O
M!@  , D  #(,   T#@  -1(  #48   U(   -2H  #4V   U0P  -5,  #1F
M   T?   ,Y8  #*O   QS0  ,.\ /",  #(D   J)   )",  " B   <(0
M%R$  !,C   0)0  #2<   DI   %*P   2X    P    ,@   #0!   V!
M. 8  #H)   \#0  /A   #X4   ^'   /B8  #XQ   ^/P  /4X  #UA   \
M=P  .Y$  #JK   YR0  ..T -R<  "\G   H)@  (R4  !\D   9)0  %"8
M ! H   -*P  "2X   4P    ,P   #4    X    .@   #P    ^ 0  0 ,
M $('  !$"@  1@T  $D1  !)%P  2"$  $@L  !'.@  1TD  $9;  !%<0
M1(L  $.E  !"PP  0>@ -"H  "PJ   G*   (B<  !PH   6*@  $2T   TP
M   ),P   S8    Y    /    #X   !!    0P   $8   !(    2@   $P#
M  !.!@  4 H  %,.  !4$P  5!P  %,G  !3-   4T,  %)5  !1:@  4(,
M $^>  !-N0  3.  ,"T  "LL   F*P  'RP  !@N   2,@  #34   @Y   "
M/0   $    !#    1@   $D   !,    3@   %$   !3    50   %<   !9
M 0  7 8  %\*  !B#@  8Q4  &,?  !B+   83P  &!.  !?8@  7GL  %R6
M  !;L   6<\ +S   "HO   B,   &C,  !,W   ..P  "#\   %$    2
M $P   !/    4@   %4   !8    6P   %T   !@    8@   &0   !F
M:0   &T%  !P"P  =!   '08  !S)0  <C0  ')%  !P60  ;W$  &V+  !K
MI@  :L  +C,  "4U   =.   %#P   Y!   '1P   $P   !1    50   %D
M  !=    80   &4   !H    :P   &T   !O    <@   '0   !W    >@
M 'X   ""!   A@L  (H1  ")'   B"L  (8]  "$4@  @V<  (&!  !_FP
M?K( *3H  " ]   60@  #T@   A.    5    %H   !@    9    &D   !N
M    <@   '8   !Z    ?0   (    ""    A0   (@   "+    C@   )(
M  "6    FP,  * ,  "B$P  H"$  )\S  "=1P  FEX  )AW  "7CP  E:<
M(T,  !E(   13@  "54   !<    8P   &H   !Q    =@   'L   "
MA@   (H   ".    D0   ),   "6    F0   )P   "@    HP   *<   "K
M    L    +8$  "\#0  NA<  +DH  "W/   M%(  +)J  "OA0  K9P '$X
M !-4   +7    60   !L    =    'P   "#    B0   (\   "4    F@
M )\   "B    I    *<   "J    K@   +$   "T    N    +P   #!
MQP   ,T   #4!0  V!   -4>  #3,0  T$@  ,U?  #+=@  R(X
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MY.7FY^CIZNOL[>[O\/'R\_3U]O?X^?K[_/W^_VUF=#$      P0A   !
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MA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VO?
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ME]Z2G9?>DIV7WNW$#!/SQ1(O],(94NJ]'WS*K#RLQJM5L\*H:KF^J7>_NJJ
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MFW^YP)N(O;Z9B<"\E8K#NI&+QKB-C<BWBH_*MHB1S+6%D\VT@Y;/LX&9T+.
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MD*>$SXRFA=")IH;1AJ6'TH2EBM*!I8W2@*6/TH"EC]* I8_2@*6/TH"EC]*
MI8_2@*6/TH"EC]* I8_2@*6/TH"EC]* I8_2@*6/TNS!"PSUPA(D]L$:1/>]
M(6K:M"F6S;PHJ;N[0[.NM6&\J+%SP:6N?\6AK83'FZR#R9:K@\J1JH3+CJF$
MS(NIA<V(J(;.AJB'SH.HB<Z!IXS/@*>-SX"GC<^ IXW/@*>-SX"GC<^ IXW/
M@*>-SX"GC<^ IXW/@*>-SX"GC<^ IXW/@*>-S]_$"0ORQ1 C\\060_3!'&G>
MPA6/P< CK*^Y3+:FM&6]HK)UP*"P@,.=KH3%EZV$QI.MA,>/K(3(C*N%R8FK
MALJ'JX;*A:J(RH.JB<N!JHO+@*J,RX"JC,N JHS+@*J,RX"JC,N JHS+@*J,
MRX"JC,N JHS+@*J,RX"JC,N JHS+@*J,R]K%" KKR0TB[L@20N_&%6C0T@J'
ML;XOKJ6X5+B?M6B\G;-VOYNQ?\&9L(3"E*^$PY"OA<2-KH7%BJZ&QHBMAL:'
MK8?&A:V(QX.MB<>!K8O'@*R+QX"LB\> K(O'@*R+QX"LB\> K(O'@*R+QX"L
MB\> K(O'@*R+QX"LB\> K(O'@*R+Q]7&" G9S H@Y<\-0-C5"U^]U@N(I<0T
MIIRW6KB9M6N[E[1WO9:S?[Z5LH7 D;&%P8ZQA<&+L(;"B;"'PHBPA\.&L(C#
MA:^)PX.OBL2"KXO$@:^+Q(&OB\2!KXO$@:^+Q(&OB\2!KXO$@:^+Q(&OB\2!
MKXO$@:^+Q(&OB\2!KXO$@:^+Q-+(" ?3SPH=U=0+/<+9"V.KWA"#F\XSF93$
M4Z:1OF>OD+ITM)"W?;F1M82\CK.&OHRRAK^*LH? B+*(P(:QB,&%L8G!A+&*
MP8*QB\&!L8S"@+&,PH"QC,* L8S"@+&,PH"QC,* L8S"@+&,PH"QC,* L8S"
M@+&,PH"QC,* L8S"@+&,PL[*" ;.T0H<QM<*0:_J#F&=YAQXD-HRB(O23)2)
MRU^<B,9NHXC#>*B%P'RK@[]_KH"]@;!_O(.Q?;R$LGR[AK-[NX>T>KJ(M'FZ
MB;5XN8NU>+F,MGBYC+9XN8RV>+F,MGBYC+9XN8RV>+F,MGBYC+9XN8RV>+F,
MMGBYC+9XN8RV>+F,MLG+" ;(T@DBL]\)0J#\%5J3\"AJB^8Y=X3?28*!V%N+
M@--ID7S0<99YS7::=LMZG73*?9YRR7^@<<B!H7#'@Z)OQX6C;L:&HVW&B*1L
MQ8JE;,6+I6S%BZ5LQ8NE;,6+I6S%BZ5LQ8NE;,6+I6S%BZ5LQ8NE;,6+I6S%
MBZ5LQ8NE;,6+I<3.!PJWV0<FH_L./9;_'DZ-^B];AO(_9X#K3G%[Y5MY=N!E
M@''=;(1NVG*(:]EWBVG7>HUGUGZ.9M6 CV74@I!DU(218].&D6+3B9)ATHN3
M8=*,DV'2C)-ATHR38=*,DV'2C)-ATHR38=*,DV'2C)-ATHR38=*,DV'2C)-A
MTHR38=*,D_^Q& G_L2,>_ZXQ.O^I/EGMHDMYV9I<E\B5<K#%E7VUPY>%N,&7
MB[N_DXR]OH^.P+R,C\*[B9+$NH:4Q;F#EL:Y@9G'N(";R+A^GLFW?:+*MWRG
MRK1[J<JT>ZG*M'NIRK1[J<JT>ZG*M'NIRK1[J<JT>ZG*M'NIRK1[J<JT>ZG*
MM'NIRO^Q& G_L2,>_ZXQ.O^I/EGMHDMYV9I<E\B5<K#%E7VUPY>%N,&7B[N_
MDXR]OH^.P+R,C\*[B9+$NH:4Q;F#EL:Y@9G'N(";R+A^GLFW?:+*MWRGRK1[
MJ<JT>ZG*M'NIRK1[J<JT>ZG*M'NIRK1[J<JT>ZG*M'NIRK1[J<JT>ZG*M'NI
MRO^Q& G_L2,>_ZXQ.O^I/EGMHDMYV9I<E\B5<K#%E7VUPY>%N,&7B[N_DXR]
MOH^.P+R,C\*[B9+$NH:4Q;F#EL:Y@9G'N(";R+A^GLFW?:+*MWRGRK1[J<JT
M>ZG*M'NIRK1[J<JT>ZG*M'NIRK1[J<JT>ZG*M'NIRK1[J<JT>ZG*M'NIRO^Q
M& G_L2,>_ZXQ.O^I/EGMHDMYV9I<E\B5<K#%E7VUPY>%N,&7B[N_DXR]OH^.
MP+R,C\*[B9+$NH:4Q;F#EL:Y@9G'N(";R+A^GLFW?:+*MWRGRK1[J<JT>ZG*
MM'NIRK1[J<JT>ZG*M'NIRK1[J<JT>ZG*M'NIRK1[J<JT>ZG*M'NIRO^Q& G_
ML2,>_ZXQ.O^I/EGMHDMYV9I<E\B5<K#%E7VUPY>%N,&7B[N_DXR]OH^.P+R,
MC\*[B9+$NH:4Q;F#EL:Y@9G'N(";R+A^GLFW?:+*MWRGRK1[J<JT>ZG*M'NI
MRK1[J<JT>ZG*M'NIRK1[J<JT>ZG*M'NIRK1[J<JT>ZG*M'NIRO^Q& G_L2,>
M_ZXQ.O^I/EGMHDMYV9I<E\B5<K#%E7VUPY>%N,&7B[N_DXR]OH^.P+R,C\*[
MB9+$NH:4Q;F#EL:Y@9G'N(";R+A^GLFW?:+*MWRGRK1[J<JT>ZG*M'NIRK1[
MJ<JT>ZG*M'NIRK1[J<JT>ZG*M'NIRK1[J<JT>ZG*M'NIRO^Q& G_L2,>_ZXQ
M.O^I/EGMHDMYV9I<E\B5<K#%E7VUPY>%N,&7B[N_DXR]OH^.P+R,C\*[B9+$
MNH:4Q;F#EL:Y@9G'N(";R+A^GLFW?:+*MWRGRK1[J<JT>ZG*M'NIRK1[J<JT
M>ZG*M'NIRK1[J<JT>ZG*M'NIRK1[J<JT>ZG*M'NIRO^Q& G_L2,>_ZXQ.O^I
M/EGMHDMYV9I<E\B5<K#%E7VUPY>%N,&7B[N_DXR]OH^.P+R,C\*[B9+$NH:4
MQ;F#EL:Y@9G'N(";R+A^GLFW?:+*MWRGRK1[J<JT>ZG*M'NIRK1[J<JT>ZG*
MM'NIRK1[J<JT>ZG*M'NIRK1[J<JT>ZG*M'NIRO^Q%PG_LB(>_ZXP.O^I/5GL
MHTIYV)M;F,>5<K'%EWNUPYB#N,&9BKN_E8N^O9&,P;N.CL.ZBI#%N8>2Q[B$
ME<FW@IC*MH";R[9^GLRU?:/,LWRGS:]\J,NO?*C+KWRHRZ]\J,NO?*C+KWRH
MRZ]\J,NO?*C+KWRHRZ]\J,NO?*C+KWRHR_^R%PG_LB$>_Z\O.O^J/%GLI$EZ
MV)M:F<:6<;+$F'BUPIF!N<";B+R^EXJ_O)2+PKJ0C<6YC(['MXB1R;:%E,NU
M@Y?-M(&:SK1_G\^S?J3/KGVFSJM]J,RK?:C,JWVHS*M]J,RK?:C,JWVHS*M]
MJ,RK?:C,JWVHS*M]J,RK?:C,JWVHS/^R%@G_LR$>_[ N.O^K.UGLI$AZUYQ9
MFL:7;[+$F7:VPIM_N<"<A[V]FHG NY:*P[F2B\:WCHW)MHJ/S+2'DLZSA);0
MLH&:T;* G]*N?Z/2JG^ESZ9_I\VF?Z?-IG^GS:9_I\VF?Z?-IG^GS:9_I\VF
M?Z?-IG^GS:9_I\VF?Z?-IG^GS?^S%@G_LR >_[ M.O^K.EGLI4=ZUIQ9FL:8
M;;+$FG2VPIQ]N;^=A;V]G(C!NYB)Q;B4BLBVD(O+M(R.SK.(D=&QA973L(.:
MU+""H-6J@:+3IH&ET*.!I\VC@:?-HX&GS:.!I\VC@:?-HX&GS:.!I\VC@:?-
MHX&GS:.!I\VC@:?-HX&GS?^S%0C_M" >_[$M.O^L.5GKI49[UIQ8F\:9:[+$
MG'*VPIU[N;^?@[Z\GHC"NIJ(QK>6B<JUDHK-LXZ,T+&*C].OAY36KH6:V*N#
MG]>F@Z+4HH.DT)^#ILV?@Z;-GX.FS9^#ILV?@Z;-GX.FS9^#ILV?@Z;-GX.F
MS9^#ILV?@Z;-GX.FS?^T%0C_M!\>_[$L.O^L.5GKID5[U9U8F\>::;+$G7"V
MPI]YNK^@@KZ\GXC"N9R(Q[:8B,NTE(G/L9"+TZ^,CM:MB9/9K(>;VZ:&GMFB
MA:'5GH6DT9R%ILZ<A:;.G(6FSIR%ILZ<A:;.G(6FSIR%ILZ<A:;.G(6FSIR%
MILZ<A:;.G(6FSO^T% C_M!\=_[$L.O^M.%GKID5[U9U7G,>;9[+$GFZVPJ!W
MNK^A@+Z[H8C#N)Z'R+6:A\VREXC1L).*U:V/C=FKC)/=J(J;WJ*(GMF>B*'5
MFX>DT9F'ILZ9AZ;.F8>FSIF'ILZ9AZ;.F8>FSIF'ILZ9AZ;.F8>FSIF'ILZ9
MAZ;.F8>FSO^T% C_M1X=_[(K.O^M.%KKID1[U9U7G,><9;+$GVRUPJ%UNKZB
M?K^[HX?$N*"'R;2=A\ZQF8C3KI:)V*N3C-RHD)+AHXZ:WYZ,GMJ:BZ'5EXJD
MT9:)ILZ6B:;.EHFFSI:)ILZ6B:;.EHFFSI:)ILZ6B:;.EHFFSI:)ILZ6B:;.
MEHFFSO^T% C_M1X=_[(J.O^M-UKKIT-\U9Y5G<>=8[+$H&JUPJ-SNKZD?+^[
MI(7$MZ*'RK.?A]"PG8?5K)J)VZF8C."EEY/FGI2:WYF1G=J6CZ#6E(VCTI.,
MI<^3C*7/DXRESY.,I<^3C*7/DXRESY.,I<^3C*7/DXRESY.,I<^3C*7/DXRE
MS_^U$PC_M1X=_[,J.O^N-EKKIT-\U9]3G<>>8++%HFBUPJ5PNKZF>K^[IH/%
MMZ6'R[.BA]&OH(?7JIZ)W*2;B^"=F8[CFIN9X)66G-N3DZ#7D9&CTY"/I<^0
MCZ7/D(^ESY"/I<^0CZ7/D(^ESY"/I<^0CZ7/D(^ESY"/I<^0CZ7/D(^ES_^U
M$PC_MAT=_[,I.O^N-EKKJ$)\U:!1G<>?7K'%I&2UPJ=MN;ZI=[^[J8'$MJB(
MR[&EA]&KHH?7I9^(VYZ=B-V7FXO@DIN3WY*<G-R/F)_7CI6BTXV3I-"-DZ30
MC9.DT(V3I-"-DZ30C9.DT(V3I-"-DZ30C9.DT(V3I-"-DZ30C9.DT/^U$PC_
MMAT=_[0I.O^O-5KJJ$%\U:).G,>A6K'%IF"TPJIIN;^M<[Z[KGW$M*J'RZVE
MAM&GHH;5H*"&V)F?AMN2G8G=C9V.W8R>F-N,GI_8BYJBU(J7I-&*EZ31BI>D
MT8J7I-&*EZ31BI>DT8J7I-&*EZ31BI>DT8J7I-&*EZ31BI>DT?^V$@C_MQP=
M_[0H.?^P-%KJJ4!]U:1)G,BD5;#&JENSPZ]CM\"S;+VVKGS%L*F'S*FFAM"C
MI(74G**$UI6AA=B/GX?:BI^+VX>?DMJ(H9S7B)^AU(><I-&'G*31AYRDT8><
MI-&'G*31AYRDT8><I-&'G*31AYRDT8><I-&'G*31AYRDT?^V$@C_MQL=_[4G
M.?^P,UKJJCY]UJA$F\FH3Z_'L%.RQ;A9M;FS;;^QK7W&K*J&RZ6GA<^?IH31
MF*2$TY*CA-6,HH;7B*&*UX6ACM>#HI;6A*2?U(2BH]&$HJ/1A**CT82BH]&$
MHJ/1A**CT82BH]&$HJ/1A**CT82BH]&$HJ/1A**CT?^W$0?_N!H<_[8E.?^Q
M,5KJJSQ^UZP[F<JM1*W)N46NO;A9N+*R;\"LKG[&J*N%RJ&IA,V;IX//E::#
MT(^EA-**I(;3AJ.(U(.CC-2!HY'4@*29TX"FH=& IJ'1@*:AT8"FH=& IJ'1
M@*:AT8"FH=& IJ'1@*:AT8"FH=& IJ'1@*:AT?^X$ ?_N1D<_[<D.?^S+UKI
MK3E^V;0OELRX,JG"O4"PL[9=NJRQ<<&GKG[%I*R%R)VK@\J7J8/,DJB$SHVG
MA,^)IX;0A::(T(*FB]& IH[1?J:4T'VGFL]]IYK/?:>:SWVGFL]]IYK/?:>:
MSWVGFL]]IYK/?:>:SWVGFL]]IYK/?:>:S_^Y#P?_NA<<_[DB.?^U+5KLLS!Z
MW< ?D,G#(:BUNDBTJ[5BO*:R<\"CKW[#H*Z$QIFL@\B4JX3)CZJ$RHNJA<N(
MJ8;,A:F(S8*HBLV J(W.?JB1S7RIELU\J9;-?*F6S7RIELU\J9;-?*F6S7RI
MELU\J9;-?*F6S7RIELU\J9;-?*F6S?R[#@?\O!4;_KL?./^W*5KPO21TW],.
MAKG!*JJJN4^VI+5EO*"R=+^>L7_"FZ^$PY:NA,61K83&C:V%QXJLALB'K(?)
MA:N(R8*KBLJ JXS*?JN/RGRKDLI\JY+*?*N2RGRKDLI\JY+*?*N2RGRKDLI\
MJY+*?*N2RGRKDLI\JY+*?*N2RO&]# ;YOA(:^KX;-_RZ)5KGSA-HR-D+B:W#
M,J>AN%:XG;5HNYNS=;Z9LG_ F+&$P9.PA<*/KX7#C*^&Q(FNAL6&KH?%A*Z(
MQH.MBL:!K8O&?ZV.QWVMD,=]K9#'?:V0QWVMD,=]K9#'?:V0QWVMD,=]K9#'
M?:V0QWVMD,=]K9#'?:V0Q]_ " 7UP@\9]L(6-N[(%5#-W QFM=H/B*+)-J":
MOE:PE[=JN96U=KR4M'Z^E+.$OY"RA<"-L8;!BK&&P8BQA\*&L(C"A+")PH.P
MBL.!L(O#@*^-PWZOC\-^KX_#?J^/PWZOC\-^KX_#?J^/PWZOC\-^KX_#?J^/
MPWZOC\-^KX_#?J^/P]G"!P7DQPL8[\@0--':"T6ZZ0YHIMX8@IC1-Y61R%.A
MC\)EJ8Z^<JZ-O'NRC+J!M8FX@K>'N(2XA;>%N8.VAKJ"MH>Z@;6(NX"UB;M^
MM8J\?;2,O'RTC;U\M(V]?+2-O7RTC;U\M(V]?+2-O7RTC;U\M(V]?+2-O7RT
MC;U\M(V]?+2-O=3$!P36RPD5T]0+)[WB#$FI]!1EF>8E>([<.8:(U$^0AL]@
MEX3,;9R#R76@?\=XHGW&>Z1ZQ7VF><2 IW?#@:AVPH.I=<*$JG3!AJMSP8>K
M<L")K'&_BZUQOXNM<;^+K7&_BZUQOXNM<;^+K7&_BZUQOXNM<;^+K7&_BZUQ
MOXNM<;^+K<_&!P+0S0D2P-D)+*SW#TB;^AY<C^\Q:X;G0G: XE!^?MU?A7O9
M:8IWU6Z/=--SDG'1=Y1PT'J6;L]]EVW.?YELS8&9:\V#FFK,A9MIS(><:,N)
MG6?*C)UGRHR=9\J,G6?*C)UGRHR=9\J,G6?*C)UGRHR=9\J,G6?*C)UGRHR=
M9\J,G<K(" '"T@<3KN8)+9W_%4&1_RA0A_HY7('S2&9\[51N=^A>=7'D97IM
MX6M^:M]P@6C>=81FW'B%9=M[AV/:?HABVH&)8=F#BF#9A8I@V(>+7MB*C%[6
MC8U>UHV-7M:-C5[6C8U>UHV-7M:-C5[6C8U>UHV-7M:-C5[6C8U>UHV-7M:-
MC<3*!P.QV@05G_\-*)+_'3>)_RY#@O\]3GS]2U=W^%9?;_-=96CP8FID[6EN
M8>MO<5_I<W-=Z'=U7.=[=EOF?G=:YH!X6>6#>5CEA7I8Y(AZ5^2+>U;CCGQ6
MXXY\5N..?%;CCGQ6XXY\5N..?%;CCGQ6XXY\5N..?%;CCGQ6XXY\5N..?/^J
M' 7_JB<7_Z<V+_^B1$KZG5)EZI=??MR3;I//DGBEQI*"M,22B;;#D8ZXP8Z0
MNL"*DKR_AY2]OH26O[Z"F<"]@)O!O7Z>P;Q]H<*\>Z3"O'JHP[QYK<.X>:_"
MN'FOPKAYK\*X>:_"N'FOPKAYK\*X>:_"N'FOPKAYK\*X>:_"N'FOPO^J' 7_
MJB<7_Z<V+_^B1$KZG5)EZI=??MR3;I//DGBEQI*"M,22B;;#D8ZXP8Z0NL"*
MDKR_AY2]OH26O[Z"F<"]@)O!O7Z>P;Q]H<*\>Z3"O'JHP[QYK<.X>:_"N'FO
MPKAYK\*X>:_"N'FOPKAYK\*X>:_"N'FOPKAYK\*X>:_"N'FOPO^J' 7_JB<7
M_Z<V+_^B1$KZG5)EZI=??MR3;I//DGBEQI*"M,22B;;#D8ZXP8Z0NL"*DKR_
MAY2]OH26O[Z"F<"]@)O!O7Z>P;Q]H<*\>Z3"O'JHP[QYK<.X>:_"N'FOPKAY
MK\*X>:_"N'FOPKAYK\*X>:_"N'FOPKAYK\*X>:_"N'FOPO^J' 7_JB<7_Z<V
M+_^B1$KZG5)EZI=??MR3;I//DGBEQI*"M,22B;;#D8ZXP8Z0NL"*DKR_AY2]
MOH26O[Z"F<"]@)O!O7Z>P;Q]H<*\>Z3"O'JHP[QYK<.X>:_"N'FOPKAYK\*X
M>:_"N'FOPKAYK\*X>:_"N'FOPKAYK\*X>:_"N'FOPO^J' 7_JB<7_Z<V+_^B
M1$KZG5)EZI=??MR3;I//DGBEQI*"M,22B;;#D8ZXP8Z0NL"*DKR_AY2]OH26
MO[Z"F<"]@)O!O7Z>P;Q]H<*\>Z3"O'JHP[QYK<.X>:_"N'FOPKAYK\*X>:_"
MN'FOPKAYK\*X>:_"N'FOPKAYK\*X>:_"N'FOPO^J' 7_JB<7_Z<V+_^B1$KZ
MG5)EZI=??MR3;I//DGBEQI*"M,22B;;#D8ZXP8Z0NL"*DKR_AY2]OH26O[Z"
MF<"]@)O!O7Z>P;Q]H<*\>Z3"O'JHP[QYK<.X>:_"N'FOPKAYK\*X>:_"N'FO
MPKAYK\*X>:_"N'FOPKAYK\*X>:_"N'FOPO^J&P7_JB<7_Z<U+_^C1$KZG5%E
MZ9=>?MN4;93/DG>FQ9*!M,23B+;#DHVXP8^/NL"+D;R_B).^OH66O[V"F,&\
M@)O"O'Z>PKQ]H<.[>Z3$NWJIQ+IYK<2U>:[#M7FNP[5YKL.U>:[#M7FNP[5Y
MKL.U>:[#M7FNP[5YKL.U>:[#M7FNP_^K&P7_JR87_Z@T+_^D0TKYGE!EZ9A=
M?]J5:97-E'2HQ91^M,25AK;"E8RYP9&.N[^-D+V^B9*_O8:4P;R#E\.[@9K$
MNGZ=Q;I]H<:Z>Z7&N7JJQK5ZK,:Q>JW$L7JMQ+%ZK<2Q>JW$L7JMQ+%ZK<2Q
M>JW$L7JMQ+%ZK<2Q>JW$L7JMQ/^K&@7_JR47_ZDT+_^D0DKYGT]FZ)E<@-J6
M9I;,E7&IQ95\M,26@[?"EXNZP).,O+Z/CK^]BY#!O(>3P[J$EL6Y@9G&N7^=
MQ[A]H<BX?*;)M7JJR;![J\>L>ZW%K'NMQ:Q[K<6L>ZW%K'NMQ:Q[K<6L>ZW%
MK'NMQ:Q[K<6L>ZW%K'NMQ?^L&07_K"06_ZDS+_^E04KYGT]FZ)E;@=F88Y;,
MEF^JQ99YM,.7@;?!F(FZOY6+O;Z1C<"\C8_"NHB2Q;F%E<>X@IC)MW^=RK9]
MHLNV?*C+L'NIRJQ\JLBH?:S%J'VLQ:A]K,6H?:S%J'VLQ:A]K,6H?:S%J'VL
MQ:A]K,6H?:S%J'VLQ?^L&07_K"06_ZHR+_^E04OYH$YGYYI9@=F989?+EVVK
MQ9=WM,.9?[?!FH>[OY>*OKV3C,&[CH[$N8J0Q[B&D\FV@IC+M7^=S;1^H\ZQ
M?*;.K'VHRZA]JLFE?JS&I7ZLQJ5^K,:E?JS&I7ZLQJ5^K,:E?JS&I7ZLQJ5^
MK,:E?JS&I7ZLQO^L&07_K2,6_ZHR+_^F0$OXH$UGYYQ7@=F:7I?+F&JLQ9ET
MM,.:?;?!FX6[OIF)O[R5BL*ZD(S%N(R/R+:'DLNT@Y?.LX"=T+)_I-&L?J7/
MJ'ZGS*1_J<FA@*S&H8"LQJ& K,:A@*S&H8"LQJ& K,:A@*S&H8"LQJ& K,:A
M@*S&H8"LQO^M& 7_K2,6_ZLQ+_^F/TOXH$UGYYU5@=F<7)?*F6BLQ9IRM,.<
M>KC G(.[OIR)O[N7B<.YDXO'MXZ-R[2)D,ZRA);1L8&=TZR HM.G@*70I("G
MS:"!J<J>@:O&GH&KQIZ!J\:>@:O&GH&KQIZ!J\:>@:O&GH&KQIZ!J\:>@:O&
MGH&KQO^M& 7_K2(6_ZLQ+_^G/TOXH4QGYYY3@=F=69?*FV6LQ9QOM,.=>+C
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MJ:G,<:VJS'"RJ\MPMJO+;[RKR'# J\1QP*K$<<"JQ'' JL1QP*K$<<"JQ''
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M=JN4N&^KJ;IRI;6Z=YVUN7J9MK=]EK>V?I.YM'^1NK* D+NQ@)"[L8"0N[&
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M:TCOL&Q'[K=L1^ZW;$?NMVQ'[K=L1^ZW;$?NMVQ'[K=L1^ZW;-VO  #%O 0
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M?%'.X']2QMZ!4\3>@5/$WH%3Q-Z!4\3>@5/$WH%3Q-Z!4\3>@?^2# #_H T
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M_YE '?^<1B?_G4PQ_)U2._2<647MF6!/YI1H6=^.<V/5AGUNS7^'>,9XD8#
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M@[*9@X3+F(2#SI:$@]"4A(+2DH2!TY"$@=2.A(#6C(2 UHR$@-:,A(#6C(2
MUHR$@-:,A(#6C/]W$@'_=!L#_X(>!/^4)PC_H#(-_Z<T$_JN.!COM3T<YKQ&
M(=R_3"S.N50_P[%=4+>J95^MI&QLHYUT=YF8?(&1DX:*B8^2D8*,GY9]BJ^8
M>HO'F'R)SI9]B-"4?H;2DG^%TY!_A-2.@(/6C("#UHR @]:,@(/6C("#UHR
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M_YH1 /^M% #:O@H T<T* ,OD$ '!Y"4'M^,U$ZWA0"&CWDDOE]M2/HO764N
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M8TG2\F-)TO)C2=+R8TG2\F-)TO)C2=+R8_Z5  #4J0  PK4# +7! P"JSP4
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M4_]=&P+_628#_U,Q!O]4.0C_74(0_V)+&O]B52/_8%\L_U]K-/]<=SO_68)
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M2R30IE0UQI]>1+R99E*TDF]=K(QW9Z2'@&^>@HIWF'Z4?9)[H(&->JV$BGG
MA8AZW(2'>MV"AGK?@(9ZX'Z%>N)\A7GC>H5YY'F%>>1YA7GD>85YY'F%>>1Y
MA7GD>?]J%0'_:QL"_WL7 O^*' +_F"8%_Z(P"/6H,PSKKCD0XK-!%-:Q1R/*
MJU(TP*1<0[:>9%&MF&Q<I9)T9IV-?6^6B(9VCX61?8J"G(*%@*J%@7^\AH"
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M<%FCZW!9H^MP6:/K<%FCZW!9H^MP6:/K</]W#P'_C0@ WJ " ,^N!0#$N04
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M:FF)\&AIB?!H:8GP:&F)\&AIB?!H:8GP:/]G$@'_>0P _XH* -^:! #3I@<
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M6DZM^EI.K?I:3JWZ6O]_  #<DP  RJ(  +RL 0"QM0  J, # )_+!@"6V0L
MD> ; 8K?+ :"WSD.>=Y#%W'=32!JW%8H8]M?+UW:9S58V7$Z4]E[/D_9B$)+
MV99%2-FF1T;:NDA%V]M'1-CT24+3_TU$R?]/1<+_4$>[_U)'N_]21[O_4D>[
M_U)'N_]21[O_4N:*  #/FP  OZ<  +*P  "GNP  G,8# )/1!@"+Z@X A>@?
M G[H+09VZ#@.;NA!%F;G2AU?YU(C6>=;*57G9"U0YVTQ3.=X-4GGA#A&Z)$Z
M0^B@/$#ILCX_ZLL^/NCO/CWF_S\]X/]"/]?_1$#._T9 SO]&0,[_1D#._T9
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M" __G @._ZP)#O^["0W_TPD-_],)#?_3"0W_TPD-_],)#?_3"9&\  "!R0
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M7Q0!_VP1 ?]X$P'_@1<!_X@= ?*/)0+GDR\$WI4X"=.0117*BU$BPH5;+KN
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M /]^$ #_B!$ ]9$4 .B8&0#=GB !T9XQ!\>:0!.^E4P@MI!6+*Z+8#>GAFA
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M7'1Y^EMU>?M:=7G[6G5Y^UIU>?M:=7G[6O]=$P'_; T _WL+ /:("0#<DP8
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M5U^-_%=?C?Q77XW\5_]J"@#_?   W(P  ,V8  ##HP, NJH" +.S 0"LO H
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M'"O_XQTJ_/H=*OK_'2KW_QPJ]_\=*O?_'2KW_QTJ]_\=*O?_';.C  "DJP
ME[8  (G!  ![RP  ;]8  &/?  !;]08 5?\0 %#_&0%+_R,"1O\L T+_- 0^
M_SP%.O]#!C?_2P<T_U,(,?];"2[_9 HK_V\,*/]\#2;_BPXD_YP0(O^N$2'_
MQ1(@_^D3'__\$Q[__Q,>__\3'O__$Q[__Q,>__\3'O__$Z:I  "8LP  BK\
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M2 ?_.U4+_SEB#_\W;Q/_-7T7_S.*&?\RE1O_,9X=_S"G'O\PKQ__,+<@_R_
M(?\ORR+_+]PB_R_J(_\O]2/_+_XC_R__(O\P_R+_,/\C^S/_)?4U_R7P-_\F
M\#?_)O W_R;P-_\F\#?_)O\\)@+_.2T"_S\L O]#+0/_1#($_T,Y!?]#10?_
M0E(+_T!?$/\^:Q7_.W@8_SF%&_\WD![_-YH@_S:C(?\UJR+_-;,C_S2\)/\T
MQB7_--0E_S3F)O\T\2;_-/LF_S7_)?XU_R;Z-O\H\SC_*>PZ_RGF//\JYCS_
M*N8\_RKF//\JYCS_*O\])0+_/2H"_T,H O]'*0/_22T$_THV!?]*00?_24T,
M_T=:$?]%9Q;_0G0:_T" '?\^C"#_/94B_SR>)/\[IB;_.ZXG_SJW*/\ZP2C_
M.LTI_SKA*?XZ[BG[.ODI]SO_*?8Z_ROP._\MZ#W_+N$__R[;0?\NVT'_+MM!
M_R[;0?\NVT'_+O\^)0+_028"_T@D O],)0+_3RD#_U(S!?]1/@?_44D,_T]6
M$O],8A?_2F\<_T=[(/]%AB/_0Y$E_T*:)_]!HBG_0:HJ_4"R*_Q O"S[/\@M
M^#_;+?1 ZRWP0/<M[4#_+^L__S'D0?\RVT/_,]%$_S/+1O\SRT;_,\M&_S/+
M1O\SRT;_,_] ) +_12,"_TP@ O]2(0+_5B8#_UDO!/]9.@?_648,_U91$O]4
M71C_46H=_DYU(?Q,@27Y2HLH]TF5*_5'G2SS1Z8N\D:N+_!%N##O1<0Q[473
M,>A&Z#'E1O8RXD7_-=]$_S;31_\WRDC_.,1*_SB_2_\WOTO_-[]+_S>_2_\W
MOTO_-_]!(P'_21\!_U$< ?]7' +_7","_V L _]@-@;_8$$+_UY-$?U;6!CX
M6&0=]%5P(_%3?"?N4(8KZT^0+NE-F3#G3*$RY4RJ,^-+M#3B2\ UX$O/-=M+
MYC;52O0XT4K_.LY*_SS$3/\\O4W_/+A/_SRT3_\[M$__.[1/_SNT3_\[M$__
M._]"(@'_3!P!_U48 ?]<&0'_8R "_V8H _]H,@7_:#T)^F9($/1C4Q?N8%\=
MZEUK(^9:=BCB5X$MWU6+,-Q3E#/949TVU5"F.--/KSK03[L[SD[)/,M/X3W'
M3_(^PT__0,!/_T&W4?]!L5+_0*U3_T"J5/\_JE3_/ZI4_S^J5/\_JE3_/_]&
M'P'_4!D!_UD5 ?]B%P'_:!T!_VPD O]O+@/Y;S@'\6Y$#NMK3A7E:%L<WV1G
M(]I@<2K477LOT%N%-,Q8CCC)5Y<[QU6@/<14J3_"4[1!OU/"0KU3UD.Y4^U$
MME/]1;-4_T6L5O]$IU?_1*18_T.A6/]"H5C_0J%8_T*A6/]"H5C_0O]('0'_
M4Q8!_UT2 ?]F% '_;1D!_W(A ?MU*0+R=C,%Z78^"^)S2A+;;U<:TFMB(\UG
M;"O(9'8QQ&%_-\!>B3N]7)(^NEN:0;=9I$2U6*Y&LE>[1[!7S4BM6.A(JECZ
M2:=9_TBA6O](G5O_1YM<_T:97/]%F5S_19E<_T697/]%F5S_1?]+&@'_5Q,!
M_V$0 /]K$@#_<A8 _W@< ?5[) 'K?2T#XGXY!]E[1A#0=E,:R7%>),-M:"R^
M:G$SNF=[.+9D@SVR8HQ!KV"51:Q>GT>I7:E*IERV2Z1<QTRB7.)-GUWW3)Q>
M_TR87_]*E6#_29-@_TB18/]'D6#_1Y%@_T>18/]'D6#_1_].& '_6A$!_V0.
M /]O$ #_=A, _'T7 .^!'@'DA"<"VX0T!="!0P_(?$\9P7A:([MS9"RU<&TS
ML6QV.JUJ?S^I9XA#I6611Z)CFTJ?8J5-G&&Q3YE@P5"78-Q0E6'S3Y-B_TZ0
M8_],CF3_2XQD_TJ+9/](BV3_2(MD_TB+9/](BV3_2/]0%@'_7!  _V@- /]R
M#@#_>A  ]H$2 .F&%P#>BB !THHP!,F&0 [!@DT9NGU7([1Y82RN=6HTJ7)R
M.J1O>T"@;(1$G6J-2)EHETR59Z%/DF:M49!EO5*.9=13C&;P48MG_U"(9_].
MAVC_3(9H_TN%9_])A6?_285G_TF%9_])A6?_2?]2% '_7PX _VL+ /]U# #Y
M?@T \(4. ..+$ #6CQH S(XN!,.+/0V[ATH8M(-5(JU^7BNG>V<SHG=O.IUT
M>$"9<H!%E6^)29%MDTV-;)Y0BFJJ4X=JN52%:L]4A&ON4X-L_U&";/]/@6O_
M38!K_TR :_]*@&O_2H!K_TJ :_]*@&O_2O]4$@'_80P _VX* /UX"0#H@@@
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M3&QY_TQL>?],;'G_3/]># #_; $ YGH  -:&  #+CP( Q)<$ +Z=! "XH@X
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M+S_']3 ]Q/\S.\/_-3R^_S8]N/\W/;C_-SVX_S<]N/\W/;C_-]&&  # E0
MLI\  *6G  ":KP  CK<  (._  !XQP, ;L\' &77#0!CV!T 8-@M EO8.@17
MV$8)4]A0#4_861%+UV(51]=L&$37=QM!UX0>/MB3(#S8HR$[V;<B.MK5(CK6
M\B,WU/\G-M+_*331_RLVRO\M-LK_+3;*_RTVRO\M-LK_+<60  "VG0  J*4
M )RM  "/M@  @[X  '?'  !LSP( 8M8' %KD#@!8Y!P 5.0I 5#D-0-,Y3\%
M2.5)!T7E4PI"YEP-/^9F#SSF<1(ZYWX4-^>,%C7GG!<SZ*X9,NG&&3+HZADQ
MY?X9+^3_'"[D_QXMXO\@+>+_("WB_R MXO\@+>+_(+J:  "JHP  G:L  )"T
M  "#O0  =\8  &O/  !?U@  5-X$ %'P$ !-\!L 2O F 4;Q, )"\CH#/O)#
M!#OS2P4X\U0'-O1="#/T: DP]70++O6!#"SVD0XJ]J(/*/>W$"?XUA$G]O01
M)O/_$2;Q_Q$E\?\3)?'_$R7Q_Q,E\?\3)?'_$ZVA  "@J0  DK,  (2\  !V
MQ@  :<\  %W8  !1WP  2>X$ $;\#@!"_1< /OXA #O^*@$W_S,"-/\Z C#_
M0@,M_TH#*_]3!"C_7 4E_V8%(O]S!B#_@P<?_Y0('?^F"!S_O @;_^()&O_Y
M"1K__PD9__\)&?__"1G__PD9__\)&?__":*G  "3L0  A;L  ';&  !IT
M6]H  $[@  !#Y0  /OL! #K_#  V_Q, ,O\; "__(P K_RH!*/\Q 23_-P$A
M_S\"'_]& AS_3@(9_U@#%O]C Q/_< ,2_X$$$?^3!!#_IP0/_[T%#O_@!0[_
M]@4.__\%#O__!0[__P4.__\%#O__!96O  "&N@  =\4  &C0  !:VP  3.$
M $#G   W\P  ,O\  "[_!P J_PX )O\3 "/_&@ ?_R  &_\F !C_*P$5_S(!
M$O\X 1#_0 $._T@!#/]2 0G_70(&_VL"!/]] @+_D (!_Z," /^V @#_S0,
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M/)%;_SN/6_\ZCUO_.H];_SJ/6_\ZCUO_.O],$@#_5@T _V ) /]H"@#Z;PP
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M8_\]@F/_/()C_SR"8_\\@F/_//]0#P#_6P< _V8# .QO @#<=@, U'P' -&
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M/G=J_SYW:O\^=VK_/O]4# #_7P  \FP  -UV  #0?0( R8,$ ,2'!@"_BA
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M  #D<0  SWX  ,.(  "YD0  L)<  *>;  ">H0  F*,3 ).C)0&-HC0&AJ%
M#8"?2A5YG5,<=)M:(V^98BAJF&HN9I9R,F&5?#==E(8Z69*3/E:2H4!3D;)!
M4I+)0E*1ZT%2D/] 4H__/U6+_SY6B/\]5X?_/5>'_SU7A_\]5X?_/?EG  #=
M=@  R8,  +V-  "SE0  J9L  *"@  "6IP  CZD/ (NJ(0&%J3 $?Z@\"GBG
M1Q)SI5 8;:-8'FBB8"1DH6<I7Z!P+EN>>3)7G80V4YR1.5"<GSM.F[ ]3)S'
M/4R;ZCQ,F?\\3)C_/$V5_SQ/D?\[4(__.U"/_SM0C_\[4(__.^MM  #3?
MPXD  +>3  "LF@  HI\  )FE  ".JP  A; + (&Q&P!\L2L"=[ X!W&O0PUK
MKDT49JU5&6&L71Y=JV4C6:IN)U6I=RM1J((O3:>/,DJGGC5(IZ\V1Z?&-D:F
MZ39%I/XW1:/_-T:@_S=(G/\W29K_-TF:_S=)FO\W29K_-^)T  #*@P  O(\
M +"8  "EG@  FZ0  )"K  "%L0  >K@$ ':Y% !RN24!;;DS!&BX/PACN$D.
M7K=2$UJV6AA6MF(<4K5K($ZT=21+M( G2+..*D6SG2Q"LZXM0;/%+D&SZ2U
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M'3'*_Q\PR?\A+\C_(2_(_R$OR/\A+\C_(;Z/  "OF@  HJ$  ):I  "*L
M?;@  '&_  !FQ@  6\P" %#2!P!'V@P 1MP8 $7<)P!$W34!0=U  C_>2P,]
MWE4$.M]?!CC?:0<UWW8),^"$"S'@E POX:8-+N&\#BWBX XMWO@/*]W_$BK<
M_Q0IVO\6*-K_%BC:_Q8HVO\6*-K_%K.8  "EH   F:<  (NP  !^N   <<
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M @?__P('__\"!___ I&M  ""N   <\(  &3,  !6U0  2-T  #OB   PYP
M)^X  "/_   @_P0 '/\, !G_$0 6_Q8 $_\; !'_(0 ._R< #?\N  K_-@ '
M_SX !/](  #_5   _V(! /]S 0#_AP$ _YT! /^R 0#_R@$ _^H! /_S 0#_
M\P$ __,! /_S 82W  !TP0  9<P  %;8  !'WP  .>4  "WJ   C[@  '/T
M !C_   5_P  $?\$  __"P -_PX "?\1  ;_%0 #_QH  /\@  #_)@  _RX
M /\W  #_00  _TT  /]<  #_;0  _X(  /^6  #_J   _[H  /_#  #_PP
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M)ZY&_R>J1_\FITC_)J=(_R:G2/\FITC_)O] % #_2 X _TX+ /]5#@#_61$
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M+X5;_R^%6_\OA5O_+_]+# #_5   ^UX  .)E  #8:P$ SVX% ,QP" #&<A(
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M.UM\XSI;?/HX7'O_-UU[_S5>>?\T7W?_,U]W_S-?=_\S7W?_,_Y<  #A:@
MS74  ,!^  "VA@  KHL  *6.  ";D0  E9,1 )"4(@&+DS$#A9(]"7^12 ]Z
MCU$6=8U9&W&,8"!LBF@E:(EP*62'>2UAAH,Q786/-%J$G#97@ZPX58._.56#
MX3A5@ODW5H+_-5:!_S18?_\S67W_,EE]_S)9??\R67W_,N]@  #;;@  QWH
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M*T*<_RQ"F_\L1)?_*T27_RM$E_\K1)?_*]=R  ##@   MHP  *J4  "?F0
ME)X  (FC  !^J   <*X  &JP#@!HL1T 9;$L 6&Q. -=L$,&6;!,"E6O5 Y2
MKUT13JYE%4NN;QA(K7D;1:V&'D*LE2 _K*4B/JVY(SVMV"(]J_4C/*G_)3NG
M_R8[IO\F.Z3_)CND_R8[I/\F.Z3_)LQZ  "[B   KI(  **9  "7G@  C*0
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M#2/0_PTCT/\-(]#_#:Z6  "@G0  E*0  (:L  !YM   ;+L  &#"  !4Q@
M2,L  #[0   UU00 +=T* "SA$P KXA\ *>,J "CD-0 GY#\ )N5* "3F50 C
MYF$!(>=N 2#G?@(>Z) "'>FD AOIO (:ZN("&N;\ AGE_P,9Y/\$&./_!1CC
M_P48X_\%&./_!:.=  "6I   B*P  'JU  !LO0  7\0  %/*  !'S@  /-,
M #+:   JWP  )>X) "/P$0 A\1D '_$B !WR*P ;\S0 &?0^ !?T2  5]5(
M$_9? !+V;@$1]X !$/B4 0_YJ@$.^<8!#OGM 0WV_P$-]/\!#?/_ 0WS_P$-
M\_\!#?/_ 9FC  "+K   ?+4  &V^  !?Q@  4LT  $72   YV   +]X  ";B
M   ?Z@  '/L& !G_#@ 7_Q, %/\: !+_(0 0_R@ #O\P  W_.0 +_T, "?].
M  ;_7  $_VP  O^   '_E@  _ZT  /_*  #_\   __\  /__  #__P  __\
M /__ (VK  !]M0  ;K\  &#(  !2T   0]<  #?=   KX@  (N8  !GJ   5
M^0  $O\  !#_"  ._PX #/\1  G_%@ &_QP  _\B  #_*@  _S,  /\]  #_
M20  _U<  /]I  #_?@  _Y4  /^L  #_QP  _^@  /_Z  #_^@  __H  /_Z
M ("U  !POP  8<D  %+3  !#VP  ->$  "GF   >Z@  %>X  !#X   ._P
M"_\   C_   $_P8  /\*  #_#@  _Q$  /\5  #_&P  _R,  /\K  #_-@
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M#](L_Q#1+/\0SRS_$,XM_Q#.+?\0SBW_$/\R&0#_-Q0 _SH1 /\\$@#_/QD
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M'II'_QZ:1_\>FD?_'O] #0#_1@0 _TP  /A2 @#H500 X54( .)5#0#551D
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M,6EGW#!I9_4N:6?_+&EG_RIJ9_\I:F;_*&IF_R=J9O\G:F;_)_]0  #G6P
MTV8  ,5N  "[<P  LW<  *MY  "D> , G7H4 )A[)0&3>S0#CGI !XEX2@V$
M=E,2@'5;%WQS8AMX<FH?=7%R(G)O>R9O;H4I;&V0+&ELG"YF;*HP9&R\,6-L
MV3!C;/0O8VS_+61L_RMD:_\I96K_*&5J_RAE:O\H96K_*/U3  #C7P  SFD
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M*U)\_RE3>_\H5'K_)U1Z_R=4>O\G5'K_)^A>  #0:P  P'8  +1^  "KA0
MH8D  )>+  ")C0  @X\( 'Z0%P![D2<!=I$T W*0/P9MCTD+:8Y1#V6-61-B
MC& 77HMH&UN*<1Y7B7LA5(B&)%&'E"=/AJ(I38:T*DN&S"I+A>XI3(3_*4R#
M_RA,@_\G38'_)DZ!_R9.@?\F3H'_)N%C  #)<   NWL  +"$  "FB@  FXX
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M'#>?_QPWG_\<-Y__',1X  "UA0  J8\  )V5  "2F@  AI\  'JC  !NJ
M8JP  %6P  !0L@X 3K(; $VS* !+LS4 2;,_ 4:S20)$LU($0;-;!C^S9 @\
MLV\*.K-[##>SB@XULIH/,[.M$#*SQ1 RLND0,;#^$C"N_Q0OK?\5+ZS_%B^L
M_Q8OK/\6+ZS_%KN!  "NC@  H94  )::  ")H   ?:8  '&K  !EKP  6;0
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M IZ:  "2H0  A*D  ':Q  !HN   6[\  $[$  !"R   -\P  "W0   DU0
M'-L  !7?!0 4Z0X $NH4 !'K'0 0ZR8 #NPP  [M.@ -[D8 "^Y3  KO8@ )
M\'0 "/&)  ?RH  %\KH !/'D  +Q_0 "[_\  ^W_  /M_P #[?\  ^W_ )6A
M  "&J0  >+(  &FZ  !;P@  3<@  $#,   TT0  *M8  "';   9X   $N0
M  _P 0 -^0H "_H/  G[%0 '^QP !/PD  '\+   _#<  /Q"  #\4   _&$
M /UU  #\C   _*0  /S!  #\ZP  _/\  /W_  #]_P  _?\  /W_ (FI  !Y
ML@  :KL  %S$  !.S   /]$  #+7   GW0  '>$  !7E   .Z   "O$   C]
M   %_P,  ?\)  #_#@  _Q(  /\7  #_'P  _R<  /\Q  #_/@  _TT  /]?
M  #_=0  _XT  /^F  #_P@  _^<  /_\  #__P  __\  /__ 'RS  !LO
M7<8  $[/   _U@  ,=T  "7B   :Y@  $>H   SN   %\@   /\   #_
M_P   /\   #_!0  _PH  /\.  #_$@  _Q@  /\A  #_*P  _SD  /]*  #_
M70  _W,  /^,  #_I   _[D  /_4  #_W@  _]X  /_> /\8+ #_&2D _QDH
M /\5*P#_$#  _PLX ?\#1 '_ %$!_P!> ?\ ; '_ '@!_P"" ?\ C '_ )0!
M_P"< /\ H@#_ *@ _P"O /\ M@#_ +X _P#( /\ UP#_ .< _P#S /\ _0#_
M /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\;*0#_'28 _QPE /\9
M)P#_$RP _PXT /\+0 '_"$X!_P5; ?\#: '_ G0!_P)_ ?\"B '_ I$!_P*8
M ?\"GP'_ :4 _P&L /\!L@#_ ;H _P'$ /\!T0#_ .0 _P#Q /\ _ #\ ?\
M_ +_ /P#_P#\!/\!_ 7_ ?P%_P'\!?\!_ 7_ ?\?)@#_(2( _R A /\>(P#_
M&"< _Q,P /\1/ '_#DH!_PU7 ?\+8P'_"F\!_PIZ ?\*A '_"HT!_PJ4 ?\*
MFP'_"J(!_PJH ?\*KP'_"K<!_PK  /\*S #_"N  ^PKO /<*^@#U"_\!]0S_
M ?0-_P'T#?\"] W_ O0-_P+T#?\"] W_ O\B(@#_)!T _R0< /\B'0#_'B(
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M#+LL_PR[+/\,NRS_#/\Q$0#_-0P _S8' /\Z"P#_/!  _SL5 /@Y'P#O-RL
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M2[,>BTO%'HE+XAZ'3/<>ADS_'85,_QR%3?\:A4S_&85,_QF%3/\9A4S_&?]
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M(WA5UR-W5?(B=E;_('96_Q]V5O\==E;_''96_QMV5O\;=E;_&_]%  #L3@
MVE@  ,E>  "_8@  MV0  +%C  "K80@ I&,7 )]D* ":93<"EF1#!9%C30B.
M854,BF!=$(=?91.$7FP6@5UT&7Y<?1Q\6X8>>5J1('=:G2)T6:HD<EFZ)7%9
MTB5P6O C;UK_(F]:_R!P6O\><%K_'7!:_QQP6O\<<%K_'/](  #G4@  TUL
M ,5B  "[9@  LV@  *QH  "E9@4 GV<4 )II)0"5:30"D&A !(QG2@B(9E,,
MA&5;$(%D8A-^8VH6>V)R&7AA>AQV8(0><U^.(7!>FB-N7J@E;%VX)6I>SB9I
M7NXD:5[_(FI>_R!J7O\?:E[_'FI>_QUJ7O\=:E[_'?E*  #C50  SU\  ,%E
M  "W:@  KVP  *=L  "?:@$ F6L1 )1M(@"0;C$!BVT]!(=L1P>#:U +?VI8
M#WQH8!-X9V<6=F=O&7-F>!QP98$>;62,(6ICF"-H8J8E9F*V)F1BS"9D8NPE
M9&+_(V1B_R%E8O\?96+_'F5B_QUE8O\=96+_'?),  #?6   RF(  +UI  "S
M;@  JW   *)P  "9;@  DW 0 (]R'P"*<BX!AG([ X)Q10=]<$X+>FY6#G9M
M7A)S;&45<&MM&&UJ=1MJ:7\>9VF*(65HEB-B9Z0E8&>T)E]GR29>9^HE7F?^
M(U]G_R%?9O\?8&;_'F!F_QY@9O\>8&;_'N]/  #:7   QF4  +IM  "P<@
MIW4  )UT  "4<P  C70- (EV' "%=RL!@7<X WQV0P9X=4P)='14#7%S6Q%N
M<F,4:W%K%VAP<QIE;WP=8FZ'(%]ME")=;*(D6FRR)5ELQR58;.@E66S](UEK
M_R%::_\?6VO_'EMJ_QY;:O\>6VK_'NM3  #38   PFD  +9Q  "L=@  HWD
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M3W7_'4]U_QU/=?\=3W7_'=]<  #(:   N7(  *YZ  "E@   FH(  (Z"  "
M@P  >84" '2&$0!QB"  ;H@N 6J(.0)GAT,%8X=,"&"&4PM=A5L.6H1C$5>$
M:Q14@W4748* &DZ!C1Q+@9L>28&L'TB P2!'@.,?1W_Z'DA^_QY(??\=27S_
M'$E\_QQ)?/\<27S_'-9A  #";@  M'@  *J   "?A0  E(<  (B'  ![B0
M<(P  &N.#0!HCQH 9H\I &*0-0%?CS\#7(](!5F.4 A6CE@+4XU@#E",:!!-
MC'(32HM]%DB*BAA%BID:0XJJ&T**OQM!BN$;08CY&T&&_QM!A?\;0H7_&D*$
M_QI"A/\:0H3_&LUG  "\=   KWX  *6&  ":B@  CHP  (*-  !UD   9Y0
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M#;6   "HBP  G)$  )&6  "%G   >*   &NE  !?J   4ZP  $BO   ]L@
M-K4+ #2U%0 SMB$ ,K8L #&W-P PMT$ +[A+ "ZX50 LN& !*KAM 2FY>P(G
MN8T");F? R2YM ,CN=(#([?T!"*U_P4AM/\&(;/_!R&R_P<ALO\'(;+_!ZV*
M  "@D0  E9<  (B=  ![HP  ;J@  &&M  !5L0  2K0  #^W   TNP  *[X#
M "3"#  BPA0 (L,? "'#*@ @Q#0 '\0_ ![%2@ =QE8 ',9C !O'<P :QX4
M&<>9 !C(K@ 7R,L %\;Q 1?$_P$6P_\"%L'_ Q;!_P,6P?\#%L'_ Z.1  "8
MF   BYX  'VE  !PJP  8K$  %:V  !*N0  /KT  #3    JQ   (L@  !G,
M!  3T H $=(1 !#2&@ 0TR4 #],P  [4/  .U$@ #=56  W590 ,UG@ #-:-
M  O8I  *V+X "=GF  K6_@ +U/\ "]+_  O2_P$+TO\!"]+_ 9J8  ".GP
M@*8  '*M  !DM   5[H  $F_   ]P@  ,L8  "C)   ?S0  %]$  !'6   ,
MVP4 "-X+  ;?$0 %WQH !. D  +A+@ !XCH  .-'  #D5@  Y&<  .5[  #F
MD@  YJH  .?(  #G\   Z/\  .C_  #H_P  Z/\  .C_ )&?  ""IP  =*\
M &6W  !7O@  2<,  #S'   PRP  )<\  !S4   4V0  #MT   GA   "Y0
M .D&  #I#0  Z1$  .H8  #K(0  [2L  .\W  #Q10  \E8  /-H  #S?@
M])<  /6P  #VT   ]_,  /?_  #W_P  ]_\  /?_ (6G  !VL   9K@  %C!
M  !*R   .\P  "[1   CU@  &=P  !'@   ,XP  !.<   #J    ]0   /0
M  #U!0  ]0L  /8/  #V%   ^!T  /HG  #\-   _T,  /]5  #_:0  _X$
M /^:  #_L@  _\\  /_M  #_^0  __D  /_Y 'BP  !HN@  6<,  $O+   [
MT0  +=@  "'=   6X@  #N8   CJ    [0   /    #X    _P   /\   #_
M    _P   /\&  #_#   _Q   /\8  #_(@  _S   /]   #_4P  _VD  /^!
M  #_F0  _Z\  /_#  #_U0  _]4  /_5 /\3* #_$R4 _Q$E /\-)P#_!BT
M_P U /\ 00#_ $\ _P!< /\ :0#_ '0 _P!^ /\ B #_ )  _P"7 /\ G0#_
M *0 _P"J /\ L #_ +< _P#  /\ S #_ -\ _P#L /\ ^ #_ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\6)0#_%B( _Q0A /\0(P#_"B@ _P P
M /\ /0#_ $L _P!8 /\ 9 #_ '  _P!Z /\ A #_ (P _P"3 /\ F@#_ *
M_P"F /\ K0#_ +0 _P"\ /X R #] -D ^P#I /H ]@#Y /\ ^ #_ /@ _P#X
M /\ ^ #_ /D _P#Y /\ ^0#_ /\:(@#_&AX _Q@= /\3'@#_#B( _PHL /\'
M.0#_ T8 _P!3 /\ 8 #_ &L _P!V /\ ?P#_ (@ _P"/ /\ E@#_ )T _P"C
M /X J0#\ +  ^@"Y /< Q #U -( \P#F /( ] #Q /\ \ #_ .\ _P#O /\
M[P#_ /  _P#P /\ \ #_ /\>'0#_'AD _QP7 /\7& #_$QX _Q$H /\.- #_
M#$$ _PI. /\(6P#_!V8 _P9Q /\&>@#_!H, _@:+ /P&D@#Z!ID ^ :? /8&
MI@#T!JT \@:U / %P #M!<X ZP7D .D&\P#F"/\ Y0K_ .0+_P#D"_\!Y O_
M >0+_P'D"_\!Y O_ ?\A& #_(1, _R 1 /\;$@#_'!H _QHD /\6+P#_$SP
M_Q%) /\050#\#F$ ^0YK /8.=0#T#GX \@Z& / .C@#N#I4 [0Z; .L.H@#J
M#JH Z ZS .8/O0#E#\P X0_C -T0\P#9$?\!UA+_ =03_P'3$_\"TA/_ M(3
M_P+2$_\"TA/_ O\E$P#_)1  _R0- /\C#@#_(Q0 _R(> /\?*0#_'#4 ^1E#
M /083P#O%UL [!=F .D7< #F%WD Y!>! .(7B0#@%Y$ WQ>8 -T7GP#;%Z<
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M"/\O" #_,0  _S4  /8W  #J-@( YS,( .0O#P#9+AL SS$L ,DS/ #$-$D
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M50.D1%X%H41F!Y]#;@B=0W8*FT)^"YE"A@V708\.E4&9#Y-!I!&10; 2D$'
M$HY!V1*+0?$2B4+_$HA"_Q&(0O\0AT+_$(="_P^'0O\/AT+_#_\X  #S/0
MXT<  -),  #(3@  P$T  +M* @"V1PX L$D= *M++0"F3#L!HDQ' IY+402;
M2UH&F4IB")9):@J427$,DDAY#H](@@^-1XL1BT>5$HE&H!2'1JP5A4:[%H1&
MT1:"1^X6@$?_%7]'_Q1_1_\2?T?_$7]'_Q%_1_\1?T?_$?\[  #N0P  W$P
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M&6I5_Q=J5?\6:E7_%6M5_Q1K5?\4:U7_%/)#  #?3P  RU@  +U=  "S80
MJV(  *)@  ";7   E5X0 )!@'P",82X B&$Z H1@102!8$X&?E]6"7M>70MX
M764.=EQL$'-<=!-P6WT5;EJ(%VM:E!EI6:$;9UFP'&59PQQD6>,<9%GZ&F19
M_QAD6?\795G_%659_Q1E6?\495G_%.]&  #:4@  QEL  +IA  "P90  IF8
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M%E9E_Q569?\55F7_%>)1  #*70  NV8  *]L  "F<0  F7   (YO  "#;@
M?7 % 'AR$@!U<R$ <G,O 6]S.@)L<T0$:7),!F9R5 AC<5L+8'!C#5UP:Q!;
M;W036&Y_%55NBQ=3;9D946VH&D]MNQM.;=D:3FST&4]K_QA/:_\74&K_%E!J
M_Q50:O\54&K_%=U5  #%80  MVH  *QQ  "B=0  E'0  (ET  !\<P  =G4
M '%W$ !O>!T ;'DK &EY-P%F>4 #8WE)!6!X40===U@)6W=@#%AV: Y5=7$1
M4G5\$U!TB!9-=)<72W.F&$ESN1E(<]4927+S&$EQ_Q=*<?\62G#_%4MP_Q1+
M</\42W#_%-1:  # 9@  LV\  *AV  "=>0  CW@  (1X  !W>0  ;WP  &I]
M#0!G?AD 9'\F &* ,@%?@#T"7(!& UI_3@57?U4'5'Y="5)]90Q/?6\.3'QY
M$4I\AA-'>Y0517ND%D1[MQ9#>](60WKR%D-Y_Q5#>/\41'?_%$1V_Q-$=O\3
M1';_$\U?  "[:P  KG0  *1\  "7?@  BGT  ']^  !R?P  9H,  &&$" !>
MAA, 7(<A %J'+@!8AS@!58=" E.'2@-0AU(%3H9:!TN&8@E)A6P+1H5W#4.$
M@P]!A)(1/X2B$CV$M1,\A,\3/(+P$CR!_Q(]@/\2/7__$CU^_Q$]?O\1/7[_
M$<5F  "U<0  JGL  )^"  "2@@  A8(  'F#  !MA@  7XH  %B- 0!4C@\
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M R>EK00FI<8#)J3K!"6B_P4EH/\&))__!B2>_P<DGO\'))[_!Z]^  "CB
MEXX  (V3  !^E0  <)@  &.;  !7GP  3*(  $*F   XJ0  +ZP# "JN#@ I
MKA@ **\C ">O+0 FL#< );!! "2P2P CL58 (K%C "&Q<0 ?L8( 'K*4 1RR
MJ0$;LL$!&['G 1NO_@(:K?\"&JS_ QJK_P,:J_\#&JO_ ZB(  ";CP  D90
M (2:  !VGP  :*(  %NE  !/J0  1*T  #FP   OLP  )K8  !ZY!0 8NPX
M%[L6 !>\(  6O"H %;TU !2]0  3ODL $KY8 !*^9P 1OW@ $+^, !# H@ .
MP+H #L#A  ^]^P /O/\ $+K_ 1"Z_P$0NO\!$+K_ 9^/  "4E0  AYL  'FA
M  !KIP  7JP  %*Q  !%M   .K8  "^Y   EO   ';\  !7#   /Q@4 "\H-
M  G*%  (RAT !\HG  ?*,@ &RSX !<M+  3,6@ #S&H  LQ^  ',E   S*L
M ,W(  #,[0  S/\  ,O_  '*_P !RO\  <K_ )>6  "*G   ?*,  &ZJ  !@
ML   4K8  $6Y   YO   +K\  "/#   ;Q@  $\H   W-   (T0   =0)  #4
M#@  U14  -8>  #8)P  V3$  -L^  #<2P  W5L  -YN  #>A   WYL  -^T
M  #>V0  W_<  -__  #?_P  W_\  -__ (V=  !_I0  <*P  &&S  !3N@
M1;\  #C"   LQ@  (<D  !C-   0T0  "]4   3:    W@   . !  #A"0
MX@X  .03  #E&P  YR0  .DO  #K/   [4L  .Y=  #N<0  [XD  /"B  #P
MO   \.,  ._Y  #P_P  \/\  /#_ (&E  !RK0  8[4  %2]  !&Q   -\@
M "K,   ?T   %=4   [:   'W@   .(   #F    Z0   .H   #L    [@4
M .\,  #Q$   \Q<  /4@  #X*P  ^SD  /U*  #^7@  _W0  /^-  #_I@
M_\   /_A  #_]0  __4  /_U '2N  !EMP  5L   $?(   XS0  *M(  !W8
M   3W0  #.(   /F    Z0   .P   #P    \P   /0   #V    ^    /H
M  #]!P  _PT  /\2  #_&P  _R@  /\W  #_2@  _UX  /]V  #_CP  _Z8
M /^Z  #_T0  _]$  /_1 /\/) #_#B( _PLA /\#) #_ "D _P R /\ /@#_
M $P _P!9 /\ 90#_ '  _P!Z /\ A #_ (P _P"2 /\ F0#_ )\ _P"E /\
MJP#_ +( _P"Z /\ Q0#_ -, _P#G /\ ] #_ /\ _@#_ /\ _P#^ /\ _@#_
M /X _P#^ /\ _@#_ /\1(0#_$!X _PT= /\''P#_ ", _P M /\ .@#_ $@
M_P!5 /\ 80#_ &P _P!V /\ ?P#_ (< _P". /\ E0#_ )L _P"A /\ IP#^
M *X _0"V /P P #[ ,T ^0#B /@ \ #W /P ]@#_ /4 _P#U /\ ]0#_ /4
M_P#U /\ ]0#_ /\5'0#_$QH _Q 9 /\+&0#_ !T _P I /\ -@#_ $, _P!0
M /\ 7 #_ &< _P!Q /\ >@#^ (, _ "* /H D0#Y )< ^ "= /< HP#U *H
M] "R /( NP#Q ,@ [P#< .X [ #M /H ZP#_ .H _P#J /\ Z@#_ .H _P#J
M /\ Z@#_ /\8&0#_%A4 _Q,3 /\.$P#_"QH _P<D /\", #_ #X _P!+ /\
M5P#_ &( _ !L /@ =0#U 'X \@"% /$ C #O ), [@"9 .P H #K *8 Z0"N
M .< MP#F ,, Y #4 .( Z0#A /< WP#_ -T _P#= /\ W0#_ -T _P#= /\
MW0#_ /\;$P#_&A  _Q8. /\2#@#_$A4 _P\? /\,*P#_"3@ _P9% /L#40#W
M EP \@)F .X"< #J G@ YP*  .8#AP#D XX X@.5 .$#G #?!*, W02K -L$
MM #8!<  U@70 -,&YP#0"/@ S@K_ ,P+_P#+#/\ RPS_ ,L+_P#+"_\ RPO_
M /\?$ #_'@L _QH' /\9"P#_&!$ _Q89 /\2) #Z$#  \PX^ .X-2@#I#%8
MY0QA .(,:@#>#7, VPU[ -D-@P#6#8H U V1 -(-F0#0#J  SPZI ,T.LP#+
M#K\ R@_0 ,81Z0#"$OD OQ/_ +T3_P&\$_\!O!/_ ;P3_P&[$_\!NQ/_ ?\B
M# #_(00 _R   /\A!0#_'PP _QP1 /88' #L%2@ Y1,V -\20P#9$T\ TQ1:
M - 59 #-%FT RQ9U ,D7?0#'%X4 Q1B, ,08E #"&9P P!FE +X9KP"]&KL
MNQK+ +@;Y0&T'/8!LAW_ K =_P*O'?\"KAW_ JX=_P*N'?\"KAW_ O\F!@#_
M)0  _R8  /LG  #Q)0, \"$+ .@<$@#>&1T U!LM ,T=/ #('TD Q2!5 ,$A
M7P"_(F@ O")P +HC> "Y(W\!MR.' ;4CCP&T))<!LB2@ ;$DJ@*O)+8"K27&
M JLEWP*H)O,#I2;_ Z,F_P.B)O\$H2;_ Z$F_P.A)O\#H2;_ _\I  #_*
M]BT  .<P  #?+P  V2L$ -8B"@#.(Q8 QB8G , H-@"[*D0 N"M/ +4L60"R
M+&(!L"QJ :XM<@&L+7H"JBV! JDMB@*G+9(#I2V; Z0MI02B+;$$H"W !)\M
MV 2<+N\%F2[_!I<O_P:6+_\&E2[_!94N_P65+O\%E2[_!?\L  #_+@  ZC4
M -TY  #1.0  RC8  ,<O!@#!+1$ NC A +0R,0"P-#X K#5* *DU5 &G-5T!
MI#5E J(U;0*@-70#GS5\!)TUA 2;-8T%FC27!I@TH0:6-*T'E#6["),UT B0
M->P(CC;^"(PV_PB+-O\(BS;_!XHU_P>*-?\'BC7_!_\O  #R-   XCP  -)!
M  #'0@  P$   +LZ 0"V-@X L#D< *H[+ "F/#H HSU& )\]4 &=/5D"FCUA
M Y@]: 26/' %E#QW!I(\@ >1/(@'CSN2"(T[G0F+.ZD*B3NW"X@[R@N%/.@+
M@SS["X(\_PJ!//\*@3S_"8$\_PB!//\(@3S_"/\S  #L.@  VD,  ,I'  "_
M20  MT<  +%"  "M/@H ID 7 *)")P">0S4 FD1" 9=$3 &41%4"D4-= X]#
M9 6-0VL&BT)S!XE">PB'0H0*A4&."X-!F0R!0:4-?T&S#GY!Q@Y\0>0.>D+Y
M#7E"_PQX0O\+>$+_"WA"_PIX0?\*>$'_"O8V  #F0   T4@  ,--  "Y3@
ML4T  *E)  "D108 GT83 )I((P"623( DDH^ 8]*2 *,2E$#BDE9!(=)8 6%
M26@'@TAO"(%(=PI_1X +?4>*#7I'E0YX1J(/=D:P$'5&PA!S1N 0<D?W#W%'
M_PYQ1_\-<4?_#'%'_PMQ1O\+<4;_"_,Y  #@1   S$P  +Y1  "T4P  JE(
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M#E]3_PU?4_\-7U/_#>=$  #/4   OU@  +-=  "H7P  G%T  ));  "+6
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M#=%4  "^7@  L6<  *9M  "7;   BFL  ']K  !S:P  ;6T  &AN# !E<!<
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M"CE^K LW?L,+-WWF"S=[_ LW>O\+-WG_"CAX_PHX>/\*.'C_"KYD  "P;P
MI7@  )9Y  "'>0  >WD  '!Z  !D?   6(   %"#  !+A0H 2(84 $>'( !%
MB"L 1(@U $.(/@!!B4<!0(E/ 3Z(6 (\B&$#.HAL!#>(> 4UB(<&,XB8!S*'
MJ@<PB, ',(?D!S"%^P@P@_\(,(+_"#"!_P@P@?\(,('_"+=K  "J=@  H'\
M )!^  ""?@  =G\  &J   !>@P  4X<  $J+  !!C@( /9 . #N0&  ZD2,
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M !*H]0 3I_\!$Z7_ 1.E_P$3I/\!$Z3_ :.&  "7C   C9$  'V2  !ME0
M8)@  %2<  !(H   /J0  #2G   JJP  (:X  !FQ   2LP< #[40  ZU%P .
MM2$ #;4K  VU-@ ,MD$ "[9.  JV7  )MFP "+9_  >VE  &MJH !;;%  :V
MZ@ 'M?\ "+3_  BS_P )LO\ ";+_ )J-  "0DP  A)@  '2<  !EH   5Z0
M $NH  ! K   -;   "JS   AM0  &+@  !&[   ,O@( !L +  + $0 !P1D
M ,$B  #"*P  PC8  ,-"  ##4   Q%\  ,1Q  #$AP  Q)T  ,2U  #$V@
MQ/8  ,/_  ##_P  P_\  ,/_ ).4  "'F@  >*   &JF  !<K   3[$  $&U
M   UMP  *;H  !^]   6P   $,,   K&   #R@   ,P%  #,#   S1$  ,X8
M  #.(0  T"H  -$U  #30P  U%(  -1C  #5>   U8\  -6G  #6P@  UND
M -;]  #6_P  UO\  -;_ (J;  ![H@  ;*D  %ZP  !0M@  0KH  #2]   H
MP0  '<0  !3'   -RP  !LX   #2    UP   -D   #:!0  W L  -T0  #?
M%0  X1T  .,G  #E,P  YT(  .A4  #H9P  Z7X  .F7  #JKP  ZLX  .OO
M  #K_@  Z_\  .O_ 'VC  !NJP  7[(  %&Z  !"P   -,,  "?'   ;RP
M$L\   O3   "V    -T   #A    Y    .4   #G    Z0   .L'  #M#0
M[Q$  /$9  #T)   ]S$  /E!  #Z50  ^FH  /N$  #[G0  _+8  /S2  #]
M[0  _?0  /WT '&L  !AM0  4KT  $3$   TR0  )LT  !K2   0V   "-T
M  #A    Y0   .@   #L    [P   /$   #S    ]0   /<   #Y 0  ^P@
M /X.  #_%0  _R$  /\O  #_00  _U8  /]M  #_AP  _Z   /^V  #_R@
M_]0  /_4 /\+( #_!QX _P = /\ ( #_ "4 _P N /\ .P#_ $D _P!6 /\
M8@#_ &T _P!V /\ ?P#_ (< _P". /\ E #_ )H _P"@ /\ I@#_ *T _P"U
M /\ O@#_ ,L _P#A /\ \ #^ /T _0#_ /T _P#] /\ _0#_ /P _P#Y /\
M^0#_ /\-'0#_"QH _P09 /\ &@#_ !\ _P J /\ -P#_ $4 _P!1 /\ 7@#_
M &@ _P!R /\ >@#_ (( _P") /\ D #_ )8 _P"< /X H@#\ *D ^P"P /D
MN0#X ,8 ]@#9 /4 ZP#T /D \P#_ /( _P#S /\ \P#_ /, _P#S /\ \P#_
M /\0&0#_#A4 _P@4 /\ % #_ !D _P E /\ ,@#_ $  _P!, /\ 60#_ &,
M_@!M /P =0#Z 'T ^0"$ /< BP#V )$ ] "7 /, G@#R *0 \ "L .X M #M
M ,  ZP#/ .D Y@#H /4 Y@#_ .< _P#F /\ Y0#_ .4 _P#E /\ Y0#_ /\2
M% #_$!  _PP/ /\#$ #_ !4 _P @ /\ + #_ #H _P!' /H 4P#W %X ] !G
M /$ < #O '@ [0!_ .L A@#J (P Z "3 .< F0#E *  XP"G .$ L #? +H
MW0#) -L X #8 /  UP#^ -4 _P#4 /\ TP#_ -, _P#3 /\ TP#_ /\5$ #_
M$@P _PX) /\+# #_"1( _P,: /\ )@#] #, ] !  .\ 30#K %@ Z !A .4
M:@#B '( X !Z -X @ #< (< V@". -@ E0#4 )P T@"C -  K #. +8 S #$
M ,H V0#( .T QP#[ ,4 _P#$ ?\ PP'_ ,0!_P#$ ?\ Q '_ /\8"P#_%04
M_Q   /\0!@#_#PT _PP4 /P''P#Q RL YP Y .( 1@#> 5$ V@); -4"9 #2
M VP SP-T ,T$>P#+!(( R@2) ,@%D #&!9@ Q 6@ ,(&J0#!!K0 OP;! +T(
MU0"[">P N O] +8,_P"U#?\ M W_ +0-_P"T#?\ M W_ /\;!0#_&   _Q<
M /\6  #[$P8 ^A . .X,%@#C"2( V@DP -,*/@#."TH R@Q5 ,<-7@#%#6<
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M I H_P*/*/\"CB?_ HXG_P*.)_\"CB?_ O\F  #R*0  XS$  -(T  #(-
MP#   +LI @"X(PX L28< *PH*P"H*C@ I"M$ *$L3@"?+5< G2U? )LM9P&9
M+6X!F"YU 98N?0*4+H8"DRZ0 I$NF@./+J8#C2ZS XPNQ0.*+^$$AR_V!(4O
M_P2$+_\#A"__ X,O_P.#+_\#@R__ _LI  #K,0  V3@  ,D\  "_/   MCD
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M!FI!_P9J0?\%:D'_!>TW  #60@  Q$D  +=-  "K30  H$H  )A'  "30@
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M!]I&  ##4   M5@  *A;  "96@  C5@  (17  ![5   =E8! '%7#P!N61L
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M"D9BJ@M$8K\+1&+A"T1A^0I$8/\)1&#_"$5?_P=%7_\'15__!\A2  "X7
MJV0  )MD  ",8P  @&,  '9C  !J8@  8V0  %]F!@!;9Q$ 66@= %=I*0!6
M:C, 5&H\ %)J10%0:DP!3FI4 DQJ7 -*:F4$2&EO!49I>@=$:8@(0FB8"4!H
MJ0H_:+T*/FC>"3YG]PD^9O\(/V7_!S]E_P<_9/\'/V3_!\-7  "S80  IVD
M )9H  "'9P  >V<  '%G  !E:   7&H  %AL 0!4;@X 4F\8 %!O) !.<"X
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M<   <G   &=Q  !<<P  47<  $IZ  !"?0, /WX. #U_&  \?R, .X M #J
M-@ Y@3\ .(%( #:!4  U@5H!,X%D 3&!< $O@7\"+8&/ RR!H0,J@;8#*8'2
M RE_\P,I??\#*7S_ RE[_P,I>_\#*7O_ [%J  "E=   E78  (5U  !X=0
M;74  &%W  !7>@  3'X  $.!   [A0  -8@) #*)$0 QB1L ,(DE "^*+P N
MBC@ +8M! "R+2@ JBU0 *8M? "B+:P FBWH!)(N+ 2.+G@$BB[,!(8S. 2&*
M\0$@B/\"((;_ B"%_P(AA?\"(87_ JMR  "A?   CWL  (!Z  !S>@  9GP
M %M_  !0@@  1H8  #R*   TC0  +)$  ":3#  DE!, (Y0< "*5)@ AE2\
M()4X !^60@ >EDP '998 !R69  :EW0 &9>& !B7F0 7EZX %9?) !:5[@ 6
MD_\!%I+_ 1:1_P$6D/\!%I#_ :5[  "9@P  B8$  'N   !L@@  7X0  %2(
M  !)BP  /Y   #64   MEP  )9H  !V> 0 6H P %*$2 !2A&P 3H24 $J$N
M !&B.  1HD, $*)/  ^B7  .HVL #:-]  VCD@ ,HZ< "J+   NBY@ ,H/X
M#9__  V>_P -G?\ #9W_ )Z$  "2B0  @X@  '.(  !EBP  6(X  $R2  !!
MEP  -YL  "Z>   DH@  '*4  !6H   /JP0 "JX,  >M$@ &K1L !:TD  2N
M+@ "KCD  :Y%  "N4@  KF$  *YS  "NAP  KIT  *ZT  "NU0  K?0  *W_
M  "L_P  J_\  *O_ ):+  ",D   >Y   &N2  !=E@  4)H  $2?   YHP
M+Z<  "6K   <K@  %+$   ZT   )MP   ;@)  "X#@  N10  +D<  "Z)0
MNB\  +LZ  "\1P  O%8  +QG  "\>P  O)$  +RI  "\Q   O.L  +O^  "[
M_P  N_\  +O_ )"2  "#F   <YL  &.?  !5HP  1Z@  #NM   PL0  );0
M !NW   2N@  #+T   6_    PP   ,0"  #%"@  Q0X  ,84  #'&P  R"0
M ,HN  #,.@  S4D  ,U9  #-;   SH,  ,Z;  #-M0  SMH  ,[V  #-_P
MS?\  ,W_ (:9  !WH   ::8  %JL  !,L@  /K8  #"Y   DO   &;\  !'"
M   *Q0   LD   #,    T    -$   #2 0  TP@  -4-  #7$0  VA@  -PA
M  #?+   X3H  .)*  #C70  Y'(  .2+  #EI0  Y<   .7F  #E^   Y?\
M .7_ 'JA  !KJ0  7*\  $VV   _O   ,+\  "/#   7QP  #\H   ?.
MT0   -8   #<    WP   .    #B    Y    .8#  #H"0  Z0X  .P5  #N
M'@  \2L  /0Z  #U30  ]F$  /=Y  #XDP  ^*T  /G&  #YY   ^?,  /GS
M &VJ  !>L@  3[H  $#!   QQ0  (LD  !;.   -T@  !-@   #=    X0
M .0   #H    ZP   .T   #O    \0   /,   #V    ^ ,  /H+  #]$0
M_QL  /\I  #_.P  _T\  /]F  #_?P  _YD  /^O  #_PP  _]8  /_6 /\$
M' #_ !D _P 9 /\ ' #_ "( _P K /\ . #_ $8 _P!3 /\ 7@#_ &D _P!R
M /\ >@#_ (( _P") /\ CP#_ )4 _P"; /\ H0#_ *@ _P"O /\ N0#_ ,4
M_P#9 /X [ #] /L ^P#_ /L _P#[ /\ ^@#_ /0 _P#P /\ \ #_ /\'& #_
M 14 _P 4 /\ %@#_ !L _P F /\ - #_ $( _P!. /\ 6@#_ &0 _P!M /\
M=0#_ 'T _P"$ /\ B@#] )  _ "6 /H G0#Y *, ^ "K /< M #U +\ ] #.
M /, Y@#Q /8 \ #_ .\ _P#O /\ [@#_ .X _P#J /\ Z@#_ /\+% #_!A$
M_P 0 /\ $ #_ !8 _P B /\ +@#_ #P _P!) /\ 5 #^ %\ ^P!H /D < #W
M '@ ]0!_ /, A0#R (L \ "2 .\ F #M )\ [ "F .H K@#H +D YP#' .4
MW@#C /  X@#^ .  _P#@ /\ X0#_ .$ _P#A /\ X0#_ /\-$ #_"0T _P$,
M /\ # #_ !( _P < /\ * #\ #8 ^0!# /8 3@#R %D [P!B .P :P#J '(
MZ !Y .8 @ #D (8 X@", .$ DP#? )H W0"A -L J@#8 +0 U0#  -( TP#0
M .H S@#Z ,T _P#- /\ S0#_ ,P _P#, /\ S #_ /\0# #_# < _P," /\
M" #_  X _P 6 /8 (@#P "\ [  \ .D 2 #E %, X0!< -X 90#; &P UP!S
M -0 >@#2 (  T "' ,X C@#, )4 R@"= ,@ I0#& *\ Q "[ ,( RP#  .4
MO@#U +T _P"\ /\ O #_ +P _P"\ /\ O #_ /\1!0#_#@  _PH  /\( 0#_
M! H ^  0 .D &@#C "@ W@ U -D 00#3 $P SP!6 ,L 7P#) &8 Q@!N ,0
M= #" 'L P0"" +\ B0"] )  O "8 +H H0"X *L M@"W +0 QP"R .  L0'R
M *\"_P"N _\ K03_ *T$_P"M!/\ K03_ /\4  #_$   _P\  /(-  #J"@
MZ0,) -T $@#4 !\ S0$M ,@".@#$ T4 P -0 +T$60"[!6$ N05H +<&;P"U
M!G8 M =] +('A "Q"(P KPB5 *T)G@"K":@ J@JU *@*Q0"F"]\ I WT *(.
M_P"@#O\ GP[_ )\._P"?#O\ GP[_ /\7  #_$P  [Q@  .09  #;%@  TA "
M ,\)"P#("!8 P0HD +P,,@"W#3X M Y) +$.4P"O$%L K1!C *L0:@"I$7$
MJ!%X *81@ "E$8@ HQ*1 *$2FP"@$Z8 GA.S )P3PP";%-X EQ;T )46_P"4
M%_\ DQ?_ )(7_P"2%O\ DA;_ /\:  #T'0  Y2,  -4E  #*)   PAT  +X6
M! "[$!  M!,= *\5*P"K%C@ IQA# *4930"B&58 H!I= )X;90"=&VP FQQS
M )H<>P"8'(, EQV- )4=EP"3'J( DAZO ) >OP"/']@ C"#Q 8D@_P&((/\!
MAR#_ 8<@_P&&(/\!AB#_ ?H>  #K)@  VBT  ,HP  "^+@  M2@  + B  "N
M&PP J!T7 *,?)@"?(3, G"(^ )DC2 "7)%$ E219 ),E8 "2)6< D"9N (XF
M=@"-)G\ BR:( 8HGDP&()YX!AB>K 80GNP&#*-$!@"CN 7XI_P%]*?\!?"C_
M 7PH_P%\*/\!?"C_ ?4D  #C+@  SS4  ,$X  "T-@  JS$  *4L  "B)@8
MGB83 )DH(0"5*BX DBLY (\L1 "-+4P BRU4 (DN7 "'+F, ABYJ 80N<@&"
M+GH!@2^$ 7\OCP)]+YH">R^G GHOMP)X+\P"=C#J G4P_@)S,/\"<S#_ G,O
M_P)S+_\"<R__ O J  #<-0  QSL  +H_  "L/   HC@  )PS  "8+P  E2X0
M ) P' ",,BD B3,U (8T/P"$-4D @C51 ( U6 !^-5\!?35F 7LV;@%Y-78"
M>#6  G8UBP-T-9<#<C:D W VM 1O-L@$;3;G!&PV_ -K-O\#:S;_ FHV_P)J
M-?\":C7_ NHP  #3.@  PD$  +-#  "E00  FSX  )4Z  "0-@  C#4- (@W
M& "$."4 @3HQ '\[/ !\.T4 >CQ- '@\50%W/%P!=3QC 7,\:@)Q/',"<#Q\
M VX[AP-L.Y0$:CNA!&@[L05G/,4%93SE!60\^@1D//\#8SO_ V,[_P-C._\"
M8SO_ N4U  #-/P  O48  *Y'  "?10  E4,  (Y   ")/   A#P* ( ]% !]
M/B( >C\N 'A . !U04( <T%* ')!40%P05D!;D%@ FQ!9P)J07 #:$%Y V=!
MA 1E09$%8T&?!6%!K@9@0<(&7D'B!EY!^05=0?\$74#_ UU _P-=0/\#74#_
M ]\Y  #(0P  N4H  *E+  ";20  D$<  (A$  "#00  ?D$& 'I"$0!V0QX
M=$4J '%%-0!O1C\ ;49' &M&3P%J1E8!:$9= F9&90)D1FT#8D9V!&!&@@1>
M1HX%7$6<!EM%K 991K\'6$;?!EA&]P571?\$5T7_!%=$_P-81/\#6$3_ ]H]
M  #$1P  M4X  *1.  "63   BTL  (-)  !]10  >$8" '1'$ !P2!L ;DDG
M &M*,@!J2SP :$M$ &9+3 %D2U,!8DM: F!+8@)?2VH#74MT!%M*?P592HP%
M5TJ:!E5*J@=42KT'4TK<!U)*]@922O\%4DG_!%))_P-22/\#4TC_ ]1!  #
M2P  LE$  *!0  "23P  ATX  'Y,  !X2   <DH  &Y+#0!K31@ :$XD &9.
M+P!D3SD 8D]" &%020%?4%$!75!8 EM/8 )93V@#5T]R!%5/?0533XH%4DZ8
M!E!.J =.3KL'34[9!TU.]09-3O\%34W_!$U-_P1.3/\#3DS_ \Y$  "\3@
MKE0  )Q3  ".4@  @U$  'I0  !R30  ;$\  &A0"P!E414 8U(A &%3+ !?
M4S8 750_ %M41P!:5$X!6%16 59470)45&8#4E-O U!3>P1.4X@%3%.7!DM3
MIP=)4[H'2%/5!TA2\P9(4O\%2%'_!$E1_P1)4/\#25#_ \I(  "Y4@  JE<
M )A6  "*50  ?U0  '93  !L40  9U,  &)4" !?5A( 75<> %M7*0!96#,
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M!3AB[P0X8?\$.&#_ SA?_P,Y7O\#.5[_ [Q5  "M7P  G&   (M?  !]7P
M<E\  &A?  !=8   56(  $]D  !+9@H 26<2 $=H'0!%:"< 1&DQ $-I.0!"
M:D( 0&I* #]J4@ ]:EL!/&IE 3IJ< (X:GX"-FF- S1IGP,S:;(#,6G+ S%H
M[0,Q9_\#,6;_ S)E_P,R9/\#,F3_ [=;  "I9   EF0  (9C  !X8P  ;6,
M &1D  !990  4&@  $EK  !#;00 0&X. #YO&  ];R( /' K #IP-  Y<3T
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M 1E__P$9?O\!&7[_ :9P  "5<P  A'(  '9Q  !K<0  7G,  %1V  !)>0
M/WT  #>!   OA   )X@  ""+!0 ;C0X &HT5 !F-'@ 8CB< %XXP !:..0 5
MCD, %(]/ !./6P 2CVH $8][ !"/CP /CZ0 #H^[  V/X  .C?H #XO_ !"*
M_P 0B?\ $(G_ *%Z  ".>0  ?G<  ')W  !D>   6'L  $U^  !"@@  .88
M "^*   GC@  ()$  !B5   2F 4 #IH.  V:%  ,FAT "YHF  N:,  *FCL
M"9I&  B:4P &FV$ !9IR  2:A@ "FIL  )JQ  &9SP "F?   IC_  27_P %
MEO\ !9;_ )F!  "'?P  >GX  &M^  !=@0  4(4  $6)   [C0  ,9(  "B6
M   ?F0  &)T  !&@   ,HP( !J4*  &E$   I18  *8?  "F*   IC(  *<]
M  "G2@  IU@  *=H  "G?   IY$  *:H  "FPP  I>D  *7\  "E_P  I/\
M *3_ )&'  ""A@  <H8  &.(  !5C   29$  #V6   RF@  *)X  !^B   7
MI@  $*D   NL   $KP   +$&  "Q#   LA$  +(7  "S'P  LR@  +0R  "U
M/P  M4T  +5=  "U<   M88  +6=  "UM@  M=P  +3W  "T_P  M/\  +3_
M (N/  !ZC@  :I$  %N5  !-F@  0)\  #6D   JJ   (*P  !:P   /M
M";<   &Y    O0   +X   "^!@  OPP  , 0  #!%@  PAT  ,,G  #%,@
MQD   ,91  #'8P  QW@  ,>1  #'J0  Q\<  ,?L  #'_@  Q_\  ,?_ (.7
M  !QF@  89X  %*C  !%J0  .*X  "RS   @MP  %KH   Z]   &P    ,,
M  #'    R0   ,H   #,    S0,  ,X)  #0#@  TA,  -0;  #8)0  VS(
M -U"  #=5   WFD  -Z!  #>G   W[4  -_9  #?\P  W_\  -__ '>?  !H
MI@  6:T  $JS   [N   +;L  !^_   4P@  #,8   /)    S    -    #5
M    V0   -H   #<    W@   .    #B!0  Y L  .<0  #J&   [20  / R
M  #Q1   \E@  /-O  #TB@  ]*0  /2_  #TWP  ]/,  /3T &JH  !;KP
M3+<  #V]   MP0  '\8  !/*   +S@   -(   #7    W    .    #E
MYP   .D   #K    [0   .\   #Q    \P   /8'  #Y#@  _!8  /\B  #_
M,P  _T<  /]=  #_=@  _Y$  /^I  #_O@  _]@  /_; /\ & #_ !8 _P 5
M /\ & #_ !X _P G /\ -@#_ $, _P!/ /\ 6@#_ &0 _P!M /\ =0#_ 'T
M_P"$ /\ B@#_ )  _P"6 /\ G #_ *, _P"K /\ M #^ +\ _0#/ /L YP#Z
M /@ ^0#_ /D _P#Y /\ ]0#_ .X _P#I /\ YP#_ /\ % #_ !$ _P 1 /\
M$@#_ !< _P C /\ ,0#_ #X _P!* /\ 5@#_ &  _P!H /\ < #_ '@ _0!^
M /P A0#Z (L ^0"1 /@ F #W )X ]0"F /0 K@#R +D \0#' .\ X #N /(
M[ #_ .P _P#L /\ ZP#_ .4 _P#@ /\ W@#_ /\#$ #_  X _P - /\ #0#_
M !, _P > /\ *P#_ #@ _P!% /X 4 #[ %H ^ !C /4 :P#S '( \0!Y .\
M?P#N (8 [ ", .H D@#I )D YP"@ .8 J0#D +, X0#  .  TP#> .L W #[
M -L _P#: /\ V@#_ -D _P#4 /\ T@#_ /\'#0#_  D _P & /\ "0#_  \
M_P 8 /L )0#X #( ]0 _ /( 2@#M %0 Z@!= .< 90#D &P X@!S .  >@#>
M (  W "& -H C0#7 )0 U "; -( I #/ *T S0"Y ,L R0#) .0 R #V ,8
M_P#% /\ Q@#_ ,< _P#' /\ QP#_ /\*!@#_ 0  _P   /\ ! #_  L ]  2
M .\ 'P#J "P Y0 X .( 0P#= $X V0!7 -0 7P#1 &< S@!M ,P = #* 'H
MR "  ,8 AP#% (X PP"6 ,$ G@"_ *@ O0"S +H P@"Y -L MP#P +4 _P"V
M /\ M0#_ +4 _P"U /\ M0#_ /\,  #_!   _P   /X   #V  , Z  - .
M%P#9 "0 T0 Q ,T / #* $< Q@!1 ,, 60#  &  O@!G +P ;@"Z '0 N0![
M +< @@"U (D LP"1 +( F@"P *0 K@"O *P O0"J -  J #K *< ^P"F /\
MI@#_ *4 _P"E /\ I0#_ /\-  #_!P  ] D  .H)  #B!   V@ ' ,\ $0#(
M !P P@ I +X -0"[ $  MP!* +0 4P"R %L L !B *X : "L &\ JP!U *D
M?0"H (0 I@"- *0 E@"C *  H0"K )\!N0"= \P G 3H )H&^0"9!_\ F C_
M )<(_P"7"/\ EPC_ /\0  #W$   Z!0  -P5  #.$0  Q@T  ,($"P"\ !0
MMP$A +(#+@"N!3H JP9$ *@(30"F"%4 I E< *(*8P"@"FH GPMQ )T+> "<
M"X  F@R) )D,DP"7#)X E0VJ )0-N "2#<P D [J (X0_ ",$/\ BQ#_ (L0
M_P"+$/\ BA#_ /L3  #M&@  W2   ,PA  "_'0  MQ<  +,1  "R"PT JPT9
M *<.)@"C#S, GQ ^ )T11P":$5  F!)7 )827@"5$V4 DQ-L )(3<P"0%'P
MCQ2% (T5CP"+%9H BA6G (@6M0"&%LD A!?G ((8^P" &?\ ?QG_ '\9_P!_
M&/\ ?QC_ /4:  #D(P  SRD  , J  "S)@  JB(  *4<  "D%0@ H!03 )L6
M(0"7&"T E!DX )$:0@"/&TL C1Q2 (L<60")'6  B!UG (8>;P"%'G< @Q^
M ((?BP" 'Y< ?B"C 'T@L@![(,4 >2'D '<B^0!V(O\ =2+_ '0A_P!T(?\
M="'_ .\A  #;*P  QS$  +8Q  "I+@  H"H  )LF  "8(0$ E1X0 ) @&P"-
M(2@ B2,S (<D/0"%)$8 @R5. ($F50!_)EP ?B9C 'PG:P![)W, >2=\ '@H
MAP!V*), ="B@ 7(HKP%Q*<$!;RG@ 6TI]P%L*?\!:RG_ 6LI_P%K*/\!:RC_
M >@H  #0,@  P#@  *XW  "A-0  F#(  )(M  ".*0  BR<, (<H%P"#*B,
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M EL[IP)9.[@#6#O2 U<[\0)6._\"5CO_ E8Z_P%6.O\!5CG_ =0W  # 00
MKT0  )U#  "00@  A4   'X^  !Y.P  =#H  '$Z#@!M/!@ :STD &D^+P!G
M/S@ 93]  &1 2 !B0$\ 84!7 %] 7@%=0&8!7$!O 5I >@)80(<"5D"5 E1
MI -30+8#4D#/ U% [P-00/_B__])0T-?4%)/1DE,10 &"?\"4#__ E __P)1
M/O\!43[_ <\[  "]10  JD<  )E&  "+10  @40  'E"  !T/@  ;S\  &M
M# !G014 94(A &-#*P!A0S4 7T0^ %Y$10!=14T 6T54 %E%7 %8160!5D5M
M 51%> )2184"4423 T]$HP--1;0#3$7, TM%[0-+1/\"2T3_ DM#_P),0O\"
M3$+_ LH_  "Y2   IDH  )5)  "'2   ?4<  '5%  !N0@  :4,  &5$"0!B
M11, 7T8> %U'* !<2#( 6D@[ %E)0P!724H 5DE2 %1)60%326$!44EK 4])
M=@)-28("2TF1 TI)H0-(2;,#1TG* T9)[ -&2/\"1DC_ D='_P)'1O\"1T;_
M L9#  "V3   HDP  )%,  "$2P  >4H  '!)  !I1@  9$<  %])!@!<2A
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M CI7FP(X5ZT"-U?$ C=7YP(W5OT"-U7_ C=4_P(W4_\".%/_ KI/  "I5@
ME54  (54  !X5   ;50  &14  !85   4E8  $Y7  !*60D 1UH1 $9:&P!$
M6R4 0ULN $)<-@!!7#X /UQ& #Y=3P ]75< .UUA #I=; $X77D!-EV( 31=
MF0(S7:L",5W" C%<Y0(Q6_P",5K_ C%9_P(R6?\!,EC_ ;94  "D60  D%@
M (!8  !S5P  :5<  &!8  !460  3EL  $A=  !#7P0 0& . #YA%P ]82
M.V(I #IB,@ Y8CH .&-" #=C2P V8U0 -&-= #-C:  Q8W8!+V.% 2YCE@$L
M8ZD!*V._ 2ICXP$J8OL!*F#_ 2M?_P$K7_\!*U[_ ;%9  ">7   BUP  'M;
M  !O6P  95L  %Q<  !17@  26   $-B   \90  .&<* #5H$@ T:!L ,VDD
M #)I+0 Q:34 +VH] "YJ1@ M:D\ +&I9 "MK90 I:W( *&N" "9KDP D:Z<
M(VN] ")JX  C:?D!(V?_ 2-F_P$C9O\!)&7_ :Q@  "88   A6   '9?  !J
M7P  86   %=@  !-8P  1&8  #UH   V:P  ,&X$ "QP#@ J<14 *7$> "AQ
M)@ G<B\ )G(W "5R0  D<DH (G)4 "%S8  @<VT 'G-] !USD  ;<Z, &G.Y
M !ESW  :<?< &G#_ !MO_P ;;O\!&VW_ :9F  "190  ?V0  '%D  !F9
M760  %)F  !(:0  /VP  #=O   P<P  *78  ")Y"  ?>Q  'GL7 !Q['P ;
M>R@ &GLP !E\.0 8?$, %WQ. !9\6@ 5?&< %'UX !)]BP 1?9\ $'VU  ]]
MU0 0>_4 $7G_ !%X_P 2=_\ $G?_ )YK  "*:@  >FD  &UI  !B:0  5VH
M $QM  !#<   .70  #%X   I>P  (G\  !N"   4A0D $880 !&&%P 0AQ\
M$(<H  Z',0 .ASL #8=&  R'4P +AV$ "H=Q  F'A  'AY@ !H:N  6&R0 &
MA>P !X3_  B#_P )@O\ "8+_ )5Q  "#;P  =&X  &EN  !<;P  4'(  $9U
M   \>0  ,GT  "J!   BA0  &XD  !2,   /CP, "I(+  :2$0 $DA@  I(@
M  &2*0  DC,  ),^  "32P  DUD  )-I  "3>P  DI   )*F  "1OP  D>4
M )#Z  "/_P  C_\  (__ (UW  !]=0  <'0  &)U  !5>   27P  #^    T
MA   *XD  "*-   :D0  $Y0   Z7   )FP   9T(  "=#@  G1,  )X:  ">
M(@  GRL  )\U  "@0@  H%   *!?  "@<0  H(<  )^=  "?M0  GMH  )WV
M  "=_P  G/\  )S_ (9]  !X?   :7P  %M_  !.@P  08@  #:,   LD0
M(Y8  !J:   2G@  #:$   :D    IP   *D#  "I"@  J@X  *L3  "L&0
MK2(  *XK  "O-P  KT4  *]4  "O9@  KWL  *Z4  "NJP  KLD  *[O  "M
M_P  K?\  *W_ (&$  !QA   88<  %.+  !&D   .98  "Z;   CH   &J0
M !*H   ,K   !*\   "R    M@   +<   "W @  N @  +D-  "Z$@  NQ@
M +TA  "^*P  P#@  ,!(  # 6@  P6X  ,&&  #!H   P;H  ,'C  # ^0
MP/\  ,#_ 'F-  !HD   690  $N:   ]H   ,:4  "6K   :KP  $;,   NX
M   "NP   +X   #!    Q    ,4   #&    QP   ,@%  #*"P  S \  ,X5
M  #0'P  TRL  -4Z  #53   UF   -AW  #8D@  V*P  -G)  #9[   V?L
M -C_ '"9  !@G@  4:0  $.J   UL   *+8  !RZ   1O@  "<$   #%
MR    ,L   #/    T@   -,   #6    V    -L   #=    WP<  .(-  #E
M$P  Z!T  .PJ  #M/   [5$  .YG  #O@0  [YP  /"W  #PTP  \.P  /#T
M &>F  !8K0  2;0  #JZ   JO@  ',(  !#&   'R@   ,X   #2    U@
M -P   #@    XP   .0   #F    Z    .L   #M    [P   /("  #U"@
M^!$  /P<  #_+   _S\  /]5  #_;@  _XH  /^D  #_N@  _]$  /_A /\
M% #_ !( _P 2 /\ % #_ !D _P E /\ ,@#_ #\ _P!+ /\ 5@#_ &  _P!H
M /\ < #_ '@ _P!_ /\ A0#_ (L _P"1 /\ F #_ )X _@"F /T K@#\ +D
M^@#( /D X@#X /0 ]P#_ /8 _P#V /\ [P#_ .< _P#B /\ W@#_ /\ $0#_
M  X _P . /\ #P#_ !0 _P @ /\ +0#_ #H _P!& /\ 40#_ %L _P!C /X
M:P#\ ', ^@!Y /D @ #W (8 ]@", /4 D@#S )D \@"@ /  J0#N +, [0#!
M .L U@#J .X Z0#^ .< _P#G /\ Y0#_ -T _P#5 /\ T0#_ /\ #0#_  H
M_P ( /\ "0#_ !  _P ; /\ * #_ #4 _P!  /H 2P#V %4 \P!> /$ 9@#N
M &T [ !T .L >@#I (  YP"& .8 C0#D ), X@"; .  HP#> *T W "Y -H
MR@#7 .8 U #X -( _P#2 /\ T@#_ ,X _P#) /\ Q@#_ /\ " #_  , _P
M /\  P#_  T _  6 /< (@#S "X [P Z .P 10#H $\ Y !8 .$ 8 #> &<
MVP!M -D = #5 'H TP"  -$ AP#/ (X S0"5 ,L G@#) *< QP"S ,4 P@##
M -P P0#Q +\ _P"_ /\ O@#_ +X _P"] /\ NP#_ /\   #_    _P   /\
M  #V  @ [@ 1 .< &P#A "< W0 S -D /@#3 $D SP!2 ,L 60#( &$ Q@!G
M ,0 ;0#" ', P !Z +\ @ "] (@ NP"0 +D F "X *( M0"M +, NP"Q ,X
ML #J *\ _ "M /\ K0#_ *X _P"N /\ K@#_ /\"  #_    _0   /(   #H
M    W@ , -, %0#, "$ R  L ,0 . #! $( O0!+ +H 4P"X %H M@!A +0
M9P"R &T L !T *\ >@"M (( K "* *H DP"H )T I@"H *0 M0"B ,8 H0#C
M )\ ]@"> /\ G@#_ )X _P"> /\ G@#_ /\&  #[    [@4  .($  #5
MRP & ,, #P"] !D N  E +0 ,0"Q #L K@!% *P 30"I %4 IP!; *4 8@"D
M &@ H@!N *$ =0"? 'P G@"% )P C@": )@ F "D )8 L "5 ,$ DP#< )(
M\@"1 /\ D #_ )  _P"/ /\ CP#_ /T*  #P#@  X1$  ,X0  #"#0  NP<
M +< "@"Q !( K  > *@ *0"E #0 H@ ^ )\ 1P"= $\ FP!6 )D!7 "7 6,
ME@)I )0"< "3 W@ D0.  ) $B@".!)4 C 6A (H%K@")!KX APC8 (8)\ "$
M"O\ @PO_ (,+_P"#"_\ @PO_ /80  #F%P  TAP  , :  "S%@  K!(  *@-
M  "F!PT H@46 )T'(@"9"2X E@HX )0+00"2#$H D Q1 (X-6 ",#5X BPUE
M (D-; "(#G0 A@Y] (4.AP"##I, @0^? ( 0K0!^$+X ?1#; 'H1] !X$O\
M=Q+_ '<2_P!W$O\ =Q+_ .\7  #;(0  QB0  +0C  "H(   H!P  )L7  "9
M$00 F X0 ),0&P"/$2< C!(R (D3/ "'$T0 A11, (,44P"!%5H @!5@ 'X6
M: !]%F\ >Q9X 'D7@P!X%X\ =AB< '08J@!S&;L <AG4 &\:\0!N&_\ ;1O_
M &T:_P!M&O\ ;1K_ .<@  #0*0  O"L  *LJ  ">*   EB0  ) @  "-'
MC!<, (@8%@"$&B( @1LM 'X<-P!\'4  >AU( 'D>3P!W'E4 =A]< '0?8P!S
M'VL <2!T ' @?P!N(8L ;"&8 &LAIP!I(K@ :"+/ &8B[@!E(_\ 9"/_ &0B
M_P!D(O\ 9"'_ . F  #(+P  M#$  *,P  "6+@  C2L  (<H  "$)   @B (
M 'X@$@![(AX >",I '4D,P!S)3P <25# ' F2P!N)E( ;2=9 &LG8 !J)V@
M:2AQ &<H>P!E*(@ 9"F5 &(II !@*;4 7RG+ %XJ[ !<*O\ 7"G_ %PI_P!<
M*?\ 7"C_ -@L  ##-0  K34  )TT  "0,P  AC$  ( M  !\*P  >2@# '8G
M$ !R*1H <"HE &TK+P!K+#@ :BQ  &@M1P!G+4X 92Y5 &0N70!C+F4 82]N
M %\O> !>+X0 7"^2 %HOH0%9+[(!6##( 58PZ0%5,/X!52__ %4O_P!5+O\
M52[_ - Q  "].@  J#D  )<X  "*-P  @#8  'HR  !U,   <BX  &XN#0!K
M+Q8 :3 A &8Q*P!D,C0 8S(] &$S1 !@,TL 7S12 %TT6@!<-&( 6C1K %DU
M=0!7-8( 5360 50UGP%2-; !437& 5 UYP%/-?T!3S7_ 4\T_P%/-/\!3S/_
M <LV  "X/0  HSP  )(\  "%.P  >SH  '0W  !O-0  ;#,  &@T"@!E-1,
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M0P  FD(  (I"  !]00  <T   &L_  !E/   8#P  %P^! !9/@\ 5S\8 %5
M(@!302L 4D$T %!"/ !/0D, 3D)+ $U#4@!+0UH 2D-D $A#;@!'0WL!14.)
M 4-#F0%"0ZL!0$/  3]#X0$_0_D!/T+_ 3]!_P% 0?\!0$#_ ;]!  "J10
MED4  (9%  !Y1   ;T0  &="  !@/P  6T$  %="  !40PT 4405 $]%'P!.
M12@ 3$8Q $M&.0!*1T$ 24=( $A'4 !&1U@ 14=A $-(; !"2'@!0$B' 3Y(
MEP$\2*D!.TB^ 3I(WP$Z1_@!.D;_ 3I%_P$[1?\!.T3_ ;M%  "F2   DD<
M ()'  !V1P  :T<  &-&  !;0P  5D4  %)'  !.2 H 3$D2 $I)' !(2B4
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M "E7U@ I5O4 *57_ "I4_P$J4_\!*E+_ :]1  "840  A5$  '90  !J4
M8%   %A1  !.4@  1U,  $%5   [6   .%D* #5:$0 T6AH ,ULB #);*P Q
M6S, +UP[ "Y<0P M7$P +%Q6 "M=8  I76T *%U\ "9=C@ D7:$ (UVU ")=
MT@ B7/, (EO_ "-:_P C6?\ )%C_ *A5  "25   @%0  '%4  !F5   7%0
M %15  !*5@  0U@  #Q;   V70  ,& % "UA#@ K814 *F(= "EB)0 H8BX
M)V,V "9C/@ E8T< (V-1 ")D7  A9&D 'V1Y !YDB@ <9)X &V2S !EDS@ :
M8_$ &V'_ !M@_P <8/\ '%__ *%9  ",6   >U@  &U8  !B6   65@  %!9
M  !'6P  /EX  #=@   Q8P  *F8  "1I"0 A:A  (&H7 !]J(  >:R@ '6LP
M !QK.0 ;:T( &FQ, !EL6  7;&4 %FQT !1LA@ 3;)H $FRO !%LR@ 1:^\
M$FG_ !-H_P 3:/\ $V?_ )E=  "%70  =5P  &A<  !>7   55P  $M>  !"
M80  .60  #)G   K:@  )&T  !YP 0 7<PL %701 !1T&  3="$ $G4I !%U
M,@ 1=3L $'5&  ]U4@ .=5\ #75N  QU@0 +=94 "G6J  ATPP )=.< "G/]
M  MQ_P ,<?\ #'#_ )%B  !_80  <&$  &1A  !:80  3V(  $5E   \:
M,VP  "MO   D<@  '78  !=Y   1? 0 #7\,  M_$@ *?QD "7\B  A_*@ &
M?S0 !7\_  1_2P "?U@  7]G  !_>0  ?XX  '^C  !^NP  ?>   'WW  !\
M_P  >_\  'O_ (EG  !X9P  :V8  &%F  !49P  26D  #]M   U<0  +'4
M "1Y   =?   %H   !"#   ,A@( !HD*  &)#P  B10  (H;  "*(P  BRP
M (LW  "+0P  BU   (M?  "+<0  BX8  (N<  "*LP  B=,  (CS  "(_P
MA_\  (?_ ()M  !S;   :&P  %IM  !.;P  0G,  #AW   N>P  )8   !V$
M   5B   $(P   N/   $D@   )0&  "5#   E1   )85  "7'   F"0  )@N
M  "9.0  F4<  )E6  "9:   F7T  )F4  "8JP  E\@  );N  "6_P  E?\
M )7_ 'MT  !O<P  87,  %-V  !&>@  .W\  #"$   FB   '8T  !22   .
ME@  "9D   &<    H    *$   "B!@  H@P  *00  "E%   I1P  *<D  "H
M+P  J#T  *E,  "I7@  J7(  *B)  "HH@  J+P  *?E  "F^P  IO\  *7_
M '=[  !H>P  67X  $N"   ^AP  ,HT  ">2   =EP  %)P   Z@   'I
M *@   "K    K@   *\   "P    L00  +,*  "T#@  M1,  +8;  "X)
MNC$  +I   "Z4@  NV4  +M]  "ZEP  NK$  +K2  "Z\P  N?\  +G_ &^#
M  !?A@  48L  $.0   VEP  *IT  !^B   5IP  #:P   6P    M    +<
M  "[    O@   +\   #     P0   ,,!  #$!P  Q0T  ,<1  #*&0  S20
M ,XS  #/1   T%@  -!N  #1B   T*0  -#!  #1Y@  T?@  -'_ &>/  !7
ME   29H  #NA   NIP  (:T  !:S   .N   !KP   #     PP   ,8   #+
M    S0   ,X   #0    T0   -0   #6    V@(  -P)  #?#P  XQ<  .8D
M  #G-@  Z$D  .E?  #J>   ZY0  .NO  #KS   [.@  .SV %^>  !0I
M0JL  #2R   FN0  &;X   ["   $Q0   ,H   #-    T0   -@   #;
MWP   .    #B    Y    .8   #I    ZP   .X   #Q!0  ]0T  /D6  #\
M)0  _3D  /Y/  #_9P  _X(  /^=  #_M0  _\L  /_D /\ $0#_  \ _P /
M /\ $0#_ !8 _P B /\ +P#_ #L _P!' /\ 4@#_ %L _P!D /\ ; #_ ',
M_P!Z /\ @ #_ (8 _P", /X DP#] )D ^P"A /H J0#X +0 ]P#" /8 V@#U
M /$ ] #_ /, _P#S /\ Z0#_ .  _P#8 /\ TP#_ /\ #@#_  L _P * /\
M"P#_ !$ _P = /\ *@#_ #8 _P!! /\ 3 #_ %8 _@!? /L 9@#Y &T ]P!T
M /4 >@#T (  \@"& /  C0#O )0 [0"; .P I #J *X Z0"Z .< S0#E .D
MY #[ ., _P#B /\ W@#_ -$ _P#, /\ R #_ /\ "0#_  0 _P ! /\ ! #_
M  X _P 8 /\ ) #] #  ^P [ /< 1@#S %  [P!9 .P 8 #J &< YP!N .8
M= #D 'H X@"  .  AP#> (X W "5 -H G@#6 *@ U "S -$ PP#/ -\ S@#T
M ,P _P#+ /\ RP#_ ,4 _P"_ /\ O #_ /\  @#_    _P   /\   #]  L
M]P 3 /$ '@#M "H Z@ U .< 0 #B $H W0!2 -D 6@#5 &$ T@!G -  ;0#.
M ', S !Z ,H @ #( (< Q@"/ ,0 F #" *$ P "M +X NP"\ -  N@#M +D
M_@"X /\ N #_ +< _P"S /\ L #_ /\   #_    _P   /D   #N  4 Y0 .
M -X & #8 ", T@ N ,\ .0#+ $, QP!, ,0 5 #! %L OP!A +P 9P"[ &T
MN0!S +< >@"U ($ M ") +( D@"P )L KP"G *P M "K ,8 J0#D *< ^ "F
M /\ I@#_ *4 _P"E /\ I #_ /\   #_    ]0   .H   #>    T  * ,@
M$@#" !T O@ H +L ,P"Y #T M0!& +( 30"P %4 K0!; *P 80"J &< J !M
M *< <P"E 'H I "" *( C "@ )8 GP"A )T K@"; +X F0#8 )< \0"6 /\
ME@#_ )< _P"7 /\ EP#_ /\   #U    YP$  -0   #)    P  $ +@ #@"S
M !8 KP A *L + "H #8 I@ _ *, 1P"A $\ GP!5 )T 6P"; &$ F@!G )@
M;@"7 '4 E0!] )0 A@"2 )$ D "< (X J0", +@ BP#- (D ZP"( /T B #_
M (@ _P"( /\ B #_ /D&  #I#   U X  ,,,  "W"0  L (  *L "0"F !
MH@ : )X )0"; #  F  Y )8 00"4 $D D@!0 )  5@". %P C0!B (L :0"*
M '  B !X (< @0"% (P A "8 (( I0"  +0 ?@#( 'T!YP!\ OD >P/_ 'L$
M_P![!/\ >P3_ /$.  #>%0  Q14  +04  "I$0  H0X  )X*  "; PP EP 3
M ), '@"0 2D C0(S (H#/ "(!$, A@5+ (4&40"#!E< @@=> ( '9 !_"&P
M?0AT 'P(?@!Z"8D > F6 '<*HP!U"K, <PO' '(,Y@!P#?L < W_ &\-_P!O
M#?\ ;PW_ .@6  #0'@  N1T  *D<  "=&@  E18  ) 3  "/#@, C@H. (D+
M%P"&#", @PTM ( --@!^#CX ? Y& 'L.30!Y#U, >!!: '8080!U$&@ <Q!Q
M '$1>P!P$8< ;A&4 &P1H@!K$K( :1+' &@3YP!F$_T 913_ &44_P!E$_\
M91/_ -\>  #&)   L"0  * C  "4(0  BQ\  (8;  "#%P  @A(( '\1$@!\
M$AT >10H '84,0!T%3H <A9! '$62 !O%T\ ;A=6 &P770!K&&0 :1AM &@9
M=P!F&8, 9!F0 &,:GP!A&J\ 8!K$ %X;Y !='/L 7!S_ %P;_P!<&_\ 7!O_
M -4E  "]*@  J"D  )@I  ",*   @R4  'TB  !Y'P  >!L# '89#P!R&A@
M;QPC &T=+0!K'34 :1X] &@>1 !F'TL 91]2 &,@60!B(&$ 82!I %\A<P!=
M(7\ 7"&- %HBG !9(JP 5R+  %8CX0!5(_D 5"/_ %0B_P!4(O\ 5"+_ ,TK
M  "V+@  HBX  )(N  "%+0  ?"L  '8H  !R)@  ;R,  &TA# !J(A4 9R,?
M &4D*0!C)#$ 8B4Y & F00!?)D@ 729/ %PG5@!;)UT 62=F %@H< !6*'P
M5"B* %,IF0!1*:H 4"F^ $\IW@!.*?< 32G_ $TI_P!-*/\ 3BC_ ,@P  "P
M,@  G#(  (PR  " ,0  =C   ' M  !K*P  :"D  &8H"0!C*!$ 8"D< %XJ
M)0!<*RX 6RLV %DL/0!8+$0 5RU, %4M4P!4+5L 4RUC %$N;@!0+GH 3BZ(
M $POEP!++Z@ 22^[ $@OVP!(+_8 1R__ $<N_P!'+?\ 2"W_ ,0T  "K-0
MES4  (<U  ![-0  <C0  &LR  !F+P  8BX  %\M!0!<+A  6B\8 %@P(@!6
M,"L 53$S %,Q.@!2,D( 43)) % R4 !.,U@ 33-A $LS:P!*,W< 2#2% $<T
ME0!%-*8 0S2Y $(TU@!"-/0 0C3_ $(S_P!",O\ 0C+_ , X  "G.   DS@
M (,X  !W.   ;3<  &8V  !A,P  73(  %DR @!7,PT 5#05 %(U'P!1-2@
M3S8P $XV. !,-S\ 2S=& $HW3@!).%8 1SA? $8X:0!$.'4 0SB# $$YDP!
M.:0 /CFX #TYTP \.?, /#C_ #TW_P ]-_\ /3;_ +L[  "B.P  CSL  '\[
M  !S.P  :CH  &(Y  !=-P  6#8  %0W  !1. L 3SD3 $TY' !+.B4 2CHM
M $@[-0!'.SP 1CQ$ $4\2P!$/%, 0CQ< $$]9P _/7, /CV! #P]D0 Z/:,
M.3VV #@]T0 W/?( -SS_ #@[_P X._\ .#K_ +8]  ">/@  BSX  'P^  !O
M/@  9CT  %X]  !8.P  4SH  $\[  !,/ @ 23T1 $<^&0!&/R( 1#\J $,_
M,@!"0#H 04!! $! 20 ^05$ /4%: #Q!9  Z07  .$%_ #=!CP U0J$ -$*T
M #)"S@ R0?  ,D#_ #- _P S/_\ -#[_ +%   ":0   AT   'A!  !L00
M8D   %M   !4/P  3C\  $I   !&004 1$(. $)#%@! 0Q\ /T0G #Y$+P \
M1#< .T4^ #I%1@ Y14X .$98 #9&8@ U1FX ,T9\ #%&C0 P1I\ +D:S "U&
MS  M1N\ +47_ "Y$_P N0_\ +D/_ *Q#  "60P  @T,  '1#  !H0P  7T,
M %=#  !00P  2$,  $1%  !!1@$ /D<, #Q($P Z2!P .4DD #A)+  V230
M-4H[ #1*0P S2DP ,DI5 #!+7P O2VL +4MZ "Q+BP J2YT *$NQ "=+R@ G
M2^T )TK_ "A)_P H2/\ *4?_ *=&  "11@  ?T8  '!&  !E1@  6T8  %1&
M  !,1P  1$@  #]*   [2P  -TP) #5-$  S3A@ ,DX@ #%/*  P3S  +T\X
M "Y/0  L4$@ *U!2 "I07  H4&@ )U!W "50B  D4)L (E"O "%0R  @4.L
M(4__ ")._P B3?\ (TW_ *%)  ",20  >DD  &Q*  !A2@  6$H  %!*  !)
M2P  0$P  #M.   U4   ,5($ "U3#0 L5!0 *E0< "E5)  H52P )U4S "95
M/  E5D4 )%9. ")660 A5F4 'U9T !Y6A0 <5I@ &U:L !E6Q0 95ND &E7_
M !M4_P ;4_\ '%+_ )M-  "&30  =4T  &A-  !=30  5$T  $U.  !%3P
M/%$  #93   Q50  *U@  "9:"0 C6Q  (EL7 "%<'P @7"< 'UPN !U<-P <
M74  &UU* !I=50 876$ %UUP !5=@0 4794 $UVJ !%=P@ 17>< $EO^ !-:
M_P 36O\ %%G_ )11  " 40  <%$  &11  !940  45$  $E2  !!4P  .%8
M #)9   K6P  )5X  !]A P :8PP &&01 !=D&0 69"$ %60I !1E,0 393H
M$F5$ !%E4  095T #V5K  YE?0 -99$ #&6E  IDO  *9.  "V/Y  QB_P -
M8?\ #6'_ (U5  !Z50  :U4  %]5  !650  3E4  $17   \60  -%P  "Q?
M   F8@  'V4  !EH   3:P4 $&T-  YN$@ -;AH #&XB  QN*P +;C0 "FX^
M  AN2@ ';E< !FYE  1N=@ ";HH  &V?  !MM@  ;-8  &SS  %K_P ":O\
M VK_ (5:  !T6@  9EH  %Q9  !360  2%H  #]=   V8   +F,  "9G   ?
M:@  &6T  !-Q   .= , "G<*  5W$  !=Q4  '<<  !W)   >"T  '@W  !X
M0P  >%   'A>  !X;P  >(0  'B9  !WL   =LT  '7P  !U_P  =/\  '3_
M 'Y?  !N7P  8EX  %E>  !-7P  0F(  #EE   P:   )VP  !]P   8=
M$G<   U[   (?@   H (  "!#0  @1$  ((7  "#'@  @R8  (0P  "$.P
MA$@  (17  "$:   A'P  (23  "#J@  @L4  ('K  "!_@  @/\  (#_ '=E
M  !I9   7V,  %)D  !'9P  /&L  #%O   H<P  ('<  !A\   1?P  #(,
M  :'    B@   (P#  ","0  C0X  (X1  "/%P  D!X  )$G  "2,@  DC\
M )).  "27P  DG,  )*+  "1H@  D;P  )#E  "/_   CO\  ([_ '%K  !F
M:@  6&L  $MM   _<0  -'8  "I[   @@   %X4  !")   +C0  !)$   "5
M    F    )D   ": P  FP@  )P-  ">$0  GQ8  * >  "B*   HC4  *-$
M  "C50  HVD  **   "BF@  H;,  *#8  "@]@  G_\  )__ &YQ  !?<@
M474  $1Y   W?@  +(0  "&*   7CP  $)0   J9   !G0   *    "D
MIP   *@   "I    J@   *P&  "M"P  KQ   + 5  "R'@  M"D  +0Y  "T
M2@  M5T  +5S  "UC@  M:@  +3&  "S[0  LO\  ++_ &9Z  !7?0  28(
M #R'   OC@  (Y0  !B:   0GP  ":0   "I    K0   +    "T    MP
M +@   "Y    NP   +P   "^ @  P @  ,(.  #$%   QQX  ,@L  #)/0
MRE   ,IF  #*?P  RIL  ,JX  #*W0  RO4  ,K_ %Z&  !/BP  09$  #.8
M   GGP  &Z4  !&K   )L    +4   "Y    O0   ,$   #&    R    ,D
M  #+    S    ,X   #0    T@   -0%  #9#   W1(  .$>  #B+@  XT(
M .17  #E;P  YHP  .:H  #EQ0  Y><  .;V %:4  !(FP  .J(  "RI   ?
ML   $[8   N\    P0   ,4   #)    S0   -(   #6    V@   -L   #>
M    X    .(   #D    YP   .D   #M    \ H  /01  #X'P  ^3(  /I(
M  #[7P  _'H  /V7  #]KP  _<<  /WD /\ #@#_  T _P , /\ #@#_ !,
M_P > /\ *@#_ #8 _P!" /\ 30#_ %< _P!? /\ 9P#_ &X _P!T /\ >@#_
M ($ _0"' /P C0#Z )0 ^0"< /< I0#U *\ ] "\ /, SP#Q .P \ #^ .\
M_P#O /\ XP#_ -< _P#. /\ R@#_ /\ "@#_  8 _P $ /\ " #_ !  _P 9
M /\ )0#_ #$ _P ] /\ 1P#^ %$ ^P!9 /D 80#V &@ ] !N /, = #Q 'H
M[P"! .X AP#L (X Z@"6 .@ GP#F *D XP"U .( Q@#@ ., WP#X -T _P#=
M /\ U #_ ,D _P#" /\ O@#_ /\  P#_    _P   /\  0#_  T _P 4 /T
M( #Z "L ]P V /, 00#O $L [ !4 .@ 6P#F &( XP!H .$ ;@#? '0 W !Z
M -H @0#8 (@ U "0 -( F #/ *( S0"N ,L O #) -, QP#P ,8 _P#$ /\
MQ #_ +L _P"V /\ LP#_ /\   #_    _P   /\   #W  @ \  0 .L &@#G
M "4 Y  P .$ .P#< $4 U0!- -$ 50#. %L RP!B ,D 9P#' &T Q0!S ,,
M>@#! ($ OP") +T D@"[ )P N0"G +< M0"U ,@ LP#F +( ^P"Q /\ L #_
M *X _P"J /\ IP#_ /\   #_    _@   /$   #E  ( W  - -, % #- !\
MR@ J ,< - #$ #X P !' +P 3@"Z %4 MP!; +4 80"S &< L@!M +  <P"N
M 'H K "" *H BP"H )4 IP"@ *4 K0"C +X H0#; *  ] "? /\ G@#_ )\
M_P"= /\ FP#_ /\   #\    [@   .    #0    Q0 ( +X $ "Y !D M0 C
M +, +@"P #< K0!  *H 2 "H $\ I0!5 *, 6P"B &  H !F )\ ; "= ',
MFP![ )H A "8 (X E@": )4 IP"3 +< D0#, )  [ "/ /\ C@#_ (X _P".
M /\ CP#_ /P   #O    VP   ,D   "]    M0 " *X # "I !, I0 = *(
M)P"@ #$ G0 Z )H 0@"8 $D E@!/ )0 50"3 %L D0!@ )  9P". &T C0!U
M (L ?@") (D B "5 (8 H@"% +$ @P#$ ($ Y "  /D ?P#_ (  _P"  /\
M@ #_ /0"  #@"0  QP@  +<'  "L P  I@   *  !P";  \ F  7 )4 (0"2
M "H CP S (T / "+ $, B0!) (< 4 "& %4 A !; (, 80"! &@ @ !P 'X
M>0!\ (0 >P"0 'D G0!X *P =@"^ '4 W0!S /0 <P#_ ', _P!S /\ <P#_
M .D-  #/$   N1   *D0  ">#@  EPL  ),&  "0  L C  1 (D &@"& "0
M@P N ($ -@!_ #X ?0!$ 'P 2P!Z %$ >0!7 '< 70!V &0 = !L ',!=0!Q
M 8  ;P*- &X"F@!L ZH :P.[ &D$U@!H!O$ : ?_ &<'_P!G!_\ 9P?_ -\4
M  ##%P  KA<  )X6  "3%0  BQ(  (80  "$# ( @P8- ( #% !\!1X >0<H
M '<(, !U"#@ <PE  '()1@!P"DP ;PI3 &T+60!L"V$ :@MI &D,<@!G#'X
M9@R+ &0-F0!B#:D 80V[ & -V !>#O, 70[_ %T._P!=#O\ 70[_ -0<  "Y
M'0  I!X  )4=  ")'   @1H  'L7  !X$P  >! & '<-#P!S#A@ < XB &X/
M*P!L$#, :A [ &D00@!G$4D 9A%/ &015@!C$ET 81)F & 2;P!>$GL 7!.(
M %L3EP!9$Z< 5Q2Z %84U0!5%?, 5!7_ %05_P!4%?\ 5!3_ ,HB  "P(@
MG2,  (TC  "!(@  >2$  ',>  !O&P  ;A<  &T3# !J%!0 9Q4> &46)P!C
M%B\ 81<W & 7/@!>&$4 71A+ %P94@!:&5H 61EB %<:; !6&G< 5!J% %(;
ME !1&Z0 3QNW $X;T !-'/$ 3!S_ $P<_P!-'/\ 31O_ ,,F  "J)P  EB<
M (<H  ![)P  <B8  &PD  !H(0  9AX  &0;" !B&Q$ 7QP: %T=(P!;'BL
M6AXS %@?.@!7'T$ 5B!( %0@3P!3(%< 42%? % A:0!.(70 32&" $LBD0!)
M(J( 2"*T $<BS0!&(^\ 12/_ $4B_P!&(O\ 1B'_ +PJ  "D*P  D2L  ((L
M  !V*P  ;2H  &8I  !B)@  7R0  %TB! !;(0X 6"(6 %8C'P!4)"@ 4R0P
M %(E-P!0)3X 3R9% $XF3 !,)E0 2R=< $DG9@!()W$ 1B=_ $4HCP!#**
M02BR $ HRP _*.T /RC_ #\H_P! )_\ 0"?_ +<M  "?+@  C"\  'TO  !Q
M+P  :"X  &$M  !=*P  6B@  %<G  !4)PP 4B@3 % I' !.*24 32HL $LJ
M- !**SL 22M" $@L20!&+%$ 12Q: $0L9 !"+6\ 0"U] #\MC0 ]+9X /"VP
M #HMR  Z+>L .BW_ #HM_P Z+/\ .BS_ +(P  ";,0  B#(  'DR  !M,@
M9#(  %TQ  !8+P  52P  %$L  !/+0D 3"T1 $HN&0!)+R( 1R\J $8P,0!%
M,#@ 0S _ $(Q1P!!,4\ 0#%7 #XQ80 ],FT .S)[ #DRBP X,IP -C*O #4R
MQP T,ND -#+_ #4Q_P U,?\ -3#_ *TS  "6-   A#4  '4U  !I-0  8#4
M %DT  !4,P  4#   $PQ  !),08 1S(/ $4S%@!#,Q\ 0C0G $ T+@ _-38
M/C4] #TU1  \-DP .C95 #DV7P W-FL -C9X #0WB0 R-YH ,3>M "\WQ0 O
M-^@ +S;^ # U_P P-?\ ,#3_ *DV  "2-@  @#<  '(X  !F.   73<  %8W
M  !0-@  2S0  $<U  !$-@, 03<- #\X%  ^.!P /#DD #LY+  Z.3, .3HZ
M #@Z0@ V.DH -3I3 #0[70 R.V@ ,#MV "\[AP M.YD +#NL "H[PP I.^8
M*CK] "HZ_P K.?\ +#C_ *0X  "..0  ?#H  &XZ  !C.@  6CH  %,Z  !-
M.@  1C@  $(Z   _.P  /#P+ #H\$0 X/1D -STA #8^*0 T/C  ,SXW #(_
M/P Q/T< ,#]0 "X_6@ M0&8 *T!T "E A  H0)< )D"J "5 P0 D0.4 )#_\
M "4^_P F/?\ )CW_ )\[  "*/   >#T  &H]  !?/0  5CT  $\]  !)/0
M0CT  #P^   Y/P  -D$( #1!#P R0A8 ,4(> "]#)0 N0RT +4,T "Q$/  K
M1$0 *D1- "A$6  G16, )45Q "-%@@ B194 ($6H !]%OP >1., 'T3[ !]#
M_P @0O\ (4'_ )H^  "%/P  =$   &=   !<0   4T   $Q   !&0   /D$
M #A#   T10  ,$8# "U'#0 K2!( *D@: "E((@ H22D )TDQ "5).0 D24$
M(TI* ")*50 @2F$ 'TIO !U*?P ;2I( &DJF !A*O0 72N  &$GZ !E(_P :
M1_\ &D?_ )5"  " 0@  <$,  &-#  !80P  4$,  $E#  !"1   .T4  #5'
M   P20  *TL  "9-"0 D3A  (DX6 "%/'0 @3R4 'T\L !Y/-0 =3ST '%!'
M !I040 94%T %U!K !90?  44(\ $U"D !%0N@ 14-X $4_X !)._P 33?\
M%$W_ (]%  ![1@  :T8  %]'  !51P  34<  $9'   _1P  -TH  #%,   K
M3@  )E   "!3 P <50P &E81 !E6&  75B  %E8G !56,  45CD $U=" !)7
M30 15UD $%=H  ]7>0 .5XP #5>@  M7M@ +5M0 "U;T  Q5_P -5/\ #E/_
M (A)  !V2@  9TH  %M*  !12@  2DH  $-*   [3   ,TX  "Q1   F5
M(58  !M9   57 < $5X- !!>$P 07AH #EXB  Y>*@ -7C, #%X]  M>2  *
M7E0 "%YB  =><P %7H8  UZ;  )>L0 "7<P  EWN  -<_P $6_\ !5O_ (%.
M  !P3@  8DX  %=.  !.3@  1TX  #Y/   V40  +E0  "=7   A6@  &UT
M !5@   08P, #&8+  AG$  &9Q4 !6<<  1G)  "9RT  6<W  !G0@  9TX
M &=<  !G;0  9X   &:5  !FK   9<<  &7K  !D_   9/\  &/_ 'I2  !J
M4P  75(  %12  !+4@  0E,  #E5   P6   *%L  "%?   :8@  %&4  !!H
M   ,:P$ !FX)  !O#@  ;Q(  &\8  !P'P  <"<  '$P  !Q.P  <4@  '%6
M  !Q9@  <7D  '&/  !PIP  ;\$  &_G  !N_   ;?\  &W_ '-8  !E5P
M6E<  %%6  !&5P  /%H  #)=   J80  (F0  !IH   4;   #F\   IR   $
M=@   '@%  !X"P  >0X  'H3  ![&0  ?"   'TI  !],P  ?4   'U.  !]
M7@  ?7(  'V(  !\H0  ?+H  'OB  !Z^@  >?\  'C_ &U=  !@7   5UP
M $M=  ! 7P  -6,  "MG   C:P  &F\  !-S   .=P  "'L   )^    @@
M (,!  "$!@  A0L  (8/  "($P  B1D  (HA  "+*P  BS<  (Q&  "+5@
MBVD  (N   "+F0  BK,  (G8  "(]P  B/\  (?_ &AC  !>8@  46(  $1E
M   X:0  +FX  "1S   :>   $WT   V!   &A0   (D   "-    D    )(
M  "2    E 4  )4*  "7#@  F!(  )H8  ";(0  G"T  )T\  "=3   G%\
M )QV  ";D0  FZL  )K)  ":\   F?\  )C_ &5I  !7:0  26P  #UQ   P
M=@  )7P  !N!   2AP  #(P   21    E0   )D   "=    H    *$   "B
M    I    *4!  "G!P  J0P  *H1  "M&   KR(  *\P  "O00  KU0  *]K
M  "NA0  KJ$  *Z^  "MY@  K/P  *S_ %YQ  !/=   0GD  #5_   HA0
M'8P  !.2   ,F    YT   "B    I@   *H   "N    L    +$   "S
MM    +8   "X    N@0  +P*  "^$   P1<  ,,D  ##-0  Q$D  ,1>  #%
M=P  Q9,  ,6O  #%T0  P_(  ,/_ %9\  !'@@  .H@  "R/   @E@  %)T
M  VC   #J0   *X   "R    MP   +L   "_    P@   ,(   #%    Q@
M ,@   #*    S0   ,\   #2"   U0X  -L8  #=)P  WCH  -]0  #@:
MX(0  .&A  #AO0  X>(  .#T $Z+  ! D@  ,ID  "6A   8J   #J\   6U
M    N@   +\   #$    R    ,X   #1    U    -4   #8    V@   -T
M  #?    X@   .0   #G    ZP4  .\.  #T&0  ]2L  /9!  #W6   ^'(
M /F0  #YJP  ^,0  /CA /\ "P#_  @ _P ) /\ # #_ !( _P : /\ )@#_
M #( _P ^ /\ 2 #_ %( _P!: /\ 8@#_ &D _P!O /\ =0#^ 'L _ "! /L
MB #Y (\ ]P"7 /4 H #S *H \@"W .\ R0#M .8 [ #[ .L _P#K /\ W0#_
M ,X _P#& /\ P@#_ /\ ! #_    _P   /\ !0#_  T _P 5 /\ (0#_ "P
M_P X /\ 0P#] $P ^0!4 /< 7 #T &, \@!I /  ;P#N '4 [ ![ .H @@#H
M (D YP"1 .0 F@#B *0 X "P -T P #: -P V #T -4 _P#3 /\ RP#_ ,$
M_P"[ /\ MP#_ /\   #_    _P   /\   #_  H _0 1 /D &P#V "< ]  R
M /  / #L $8 Z !. .0 5@#A %P W@!C -P : #9 &X U0!T -( >P#0 ((
MS0"* ,L DP#( )T Q@"H ,0 MP#! ,P P #K +X _P"] /\ O0#_ +0 _P"N
M /\ JP#_ /\   #_    _P   /H   #R  4 Z@ . .4 %@#@ "$ W0 K -L
M-@#3 #\ S@!( ,H 3P#' %8 Q !< ,( 80#  &< O@!M +P <P"Z 'H N ""
M +8 BP"T )8 L@"A +  KP"N ,$ K0#@ *L ]P"J /\ J0#_ *8 _P"A /\
MGP#_ /\   #_    ]P   .@   #<    T  * ,H $0#% !L P@ E +\ +P"\
M #@ N !! +4 2 "R $\ L !5 *X 6P"L &$ J@!F *@ ; "G ', I0![ *,
MA "A (X GP": )T IP"; +@ F@#0 )D [P"8 /\ EP#_ )8 _P"4 /\ D@#_
M /\   #V    Y    -(   #%    NP % +4 #@"P !4 K  ? *H *0"H #(
MI0 Z *( 0@"@ $D G@!/ )P 50": %H F !@ )8 9@"5 &P DP!T )( ?0"0
M (< C@"3 (P H0"+ +  B@#% (@ Y@"' /L A@#_ (< _P"' /\ A@#_ /@
M  #E    S0   +T   "S    J@   *, "@"? !$ FP 9 )D (P"7 "P E0 T
M )( / "0 $, C@!) (P 3P"* %0 B0!: (< 8 "& &8 A !N (, =P"! ($
M?P"- 'X FP!\ *H >P"\ 'H VP!X /4 > #_ '@ _P!X /\ > #_ .T   #1
M @  NP(  *P!  "B    FP   )8 !0"1  T C0 4 (L '0"( "8 A@ N (0
M-@"" #T @ !# 'X 20!] $\ ? !5 'H 6P!Y &$ =P!I '4 <0!T 'P <@"(
M '$ E@!O *4 ;@"V &T S@!L .X :P#_ &L _P!K /\ :P#_ -\+  #"#
MK@P  )X,  "3"P  C <  (@"  "%  D @0 0 '\ %P!\ "  >@ H '@ , !V
M #@ =  ^ ', 1 !Q $H < !0 &X 5@!M %T ; !D &H ;0!H '< 9P"$ &4
MD@!D *$ 8P"R &$ R0!@ .D 8 #\ &  _P!@ /\ 8 #_ - 0  "V$0  HA(
M ),2  "($0  @ \  'P-  !Y"0$ > ,+ '4 $0!S !H <  C &X!*P!L 3,
M:@(Y &D#0 !G T8 9@1, &4$4@!C!5D 8@5A & %:@!?!G0 70:! %P'CP!:
M!Y\ 60>P %<'Q@!6">< 5@K[ %4*_P!5"O\ 5@K_ ,85  "M%P  F1@  (H8
M  !_%P  =A8  '$3  !N$   ;0T% &T)#0!J"10 9PH= &4*)@!C"RX 8@PU
M & ,/ !?#$( 7@U( %P-3P!;#58 60U> %@.: !6#G, 50Z  %,.CP!1#I\
M4 ZQ $X.R !-$.H 31#] $T0_P!-$/\ 31#_ +P;  "E'   DAT  (,>  !W
M'0  ;QP  &D:  !F%P  9!0  &00" !B#Q  7Q 8 %T0(0!;$2D 6A$Q %@2
M. !7$CX 5A)% %023 !3$U, 41-; % 390!.%'  3!1] $L4C !)%)P 1Q6N
M $85Q0!%%>@ 11;^ $46_P!%%?\ 117_ +4?  ">(0  BR(  'PB  !Q(@
M:"$  &(?  !?'0  7!H  %L7 @!:%0T 5Q84 %46'0!4%R4 4A@M %$8- !/
M&#L 3AE" $T92 !+&E  2AI8 $@:8@!'&FT 11MZ $,;B0!"&YH 0!NL #\;
MP@ ^'.4 /1S\ #X<_P ^&_\ /AO_ *\C  "8)   AB4  '<F  !L)@  8R4
M %TD  !9(@  5A\  %0=  !3' L 41P2 $X=&@!-'2( 2QXI $H>,0!)'S<
M1Q\^ $8@10!%($T 0R!5 $(@7P! (6H /R%W #TAAP [(9@ .2&J #@BP  W
M(N, -R+[ #<B_P X(?\ ."'_ *HF  "4)P  @2D  ',I  !G*0  7RD  %@H
M  !4)@  42,  $\B  !,(@< 2B(0 $@B%P!'(Q\ 120F $0D+@!")#0 024[
M $ E0P _)4H /293 #PF7  Z)F< .29U #<GA  U)Y8 -">H #(GO@ Q)^$
M,2?Y #(F_P R)O\ ,R7_ *4I  "/*@  ?2P  &\L  !D+0  6RP  %4K  !0
M*@  3"@  $HF  !')P0 1"<- $(H% !!*!P /RDC #XI*P ]*3( /"HY #LJ
M0  Y*D@ ."M0 #8K6@ U*V4 ,RMR #$K@@ P+)0 +BRG "PLO  K+-X +"SX
M "PK_P M*O\ +2K_ *$L  "++0  >2X  &LO  !@+P  6"\  %$N  !,+@
M2"P  $4K  !!*P  /RP+ #TL$0 [+1D .BXA #DN*  W+B\ -B\V #4O/@ T
M+T4 ,R]. #$P6  P,&, +C!P "PP@  J,)( *3"E "<PN@ F,-P )C#W "<O
M_P H+_\ *"[_ )PN  "',   =C$  &@R  !=,@  53(  $XQ  !(,0  1#
M $ O   \,   .C$) #<Q$  V,A8 -3(> #,S)0 R,RP ,3,S # T.P O-$,
M+31, "PT5@ J-6$ *35N "<U?@ E-9  (S6C "(UN0 A-=D (33V "(T_P C
M,_\ (S+_ )@Q  "#,P  <C0  &4T  !:-0  434  $LT  !%-   0#0  #HS
M   W-   -#4& #(V#@ P-Q, +S<; "XW(@ M."D *S@Q "HX.  I.4  *#E)
M "8Y4P E.5\ (SEL "$Z?  @.HX 'CJB !PZMP ;.=4 '#GU !TX_P =./\
M'C?_ ),T  !_-@  ;C<  &$W  !7-P  3C<  $@W  !"-P  /#<  #4X   R
M.0  +SH" "P["P J/!$ *3P8 "@]'P F/28 )3TN "0]-0 C/CT (CY& " ^
M4  ?/EP '3]I !L_>0 :/XP &#^@ !8_M0 5/M( %C[S !<]_P 8//\ &#S_
M (XW  !Z.   :CD  %XZ  !3.@  2SH  $4Z   _.@  .3H  #(\   N/@
M*4   "9!"  D0@X (D(4 "%"&P @0R, 'T,J !Y#,@ <0SH &T1# !I$30 8
M1%D %T1G !5$=P 31(H $D2> !%$LP 01-  $$/R !%"_P 20O\ $T'_ (D[
M  !V/   9CT  %H]  !0/0  2#T  $(]   \/0  -CX  "]    J0@  )40
M "%& P =2 P &TD1 !E)%P 821X %TDF !9)+@ 52C8 %$I  !-*2@ 12E8
M$$ID  ]*=  .2H< #4J;  Q*L  *2LH "TGL  Q(_P -1_\ #4?_ (,^  !Q
M/P  8D   %9   !-0   14   #]    Y00  ,D(  "M%   F1P  (4D  !Q+
M   63@< $U . !)0$P 14!D $% A  ]0*0 .4#$ #5 [  U11@ +45$ "E%?
M  E1;P '4($ !5"6  -0JP "4,4  T_H  -/^P %3O\ !DW_ 'U"  !K0P
M740  %)$  !*1   0T,  #Q$   U10  +D<  "=*   A3   '$\  !=1   2
M5 , #E<*  M8$  *6!4 "%@<  =8)  &6"P !5@V  -80  !6$P  %A:  !8
M:0  6'P  %B1  !7IP  5\   %;E  !6^0  5?\  %7_ '9'  !F1P  64@
M $]'  !'1P  0$<  #A(   P2@  *4T  ")0   <4P  %E4  !%8   -6P(
M"5X)  1?#@  7Q(  %\8  !@'P  8"<  & P  !@.P  8$<  &!4  !@8P
M8'8  &"+  !?H@  7[L  %_B  !>^0  7?\  %W_ &]+  !A3   54P  $Q+
M  !$2P  .TP  #).   K40  (U0  !Q7   66P  $5X   U@   (8P   F8'
M  !G#   9P\  &@3  !I&0  :B$  &HI  !J-   :D   &I-  !J70  :F\
M &J%  !JG0  :;8  &C=  !H]P  9_\  &;_ &E1  !<4   4E   $I/   _
M4   -5,  "U6   D60  '5T  !9@   09   #&<   9J    ;@   &\#  !P
M"   <0T  '(0  !T%   =1L  '8C  !W+   =S@  '9&  !V5@  =F@  '9^
M  !VEP  =;$  '33  !S]0  <_\  '+_ &-6  !850  4%0  $15   Y6
M+UL  "9?   =8P  %6<  !!L   *<   !',   !V    >@   'P   !\ P
M?@@  '\,  "!$   @A0  (0;  "%)   AB\  (8]  "&30  A5\  (5U  "%
MCP  A*D  (/)  ""\0  @?\  (#_ %];  !66@  25L  #U>   R80  )V8
M !YK   5<   #G4   EY   !?@   ($   "%    B    (H   "+    C0$
M (X&  "0"P  D0\  ),4  "5&P  ER8  )<T  "71   EU8  )9L  "5A@
ME:(  )3!  "3Z@  DO\  )+_ %UA  !/80  0F0  #9I   J;@  'W0  !5Y
M   .?P  !X0   ")    C@   )(   "6    F    )H   ";    G0   )\
M  "A P  HP@  *4-  "G$P  J1P  *HH  "J.0  JDL  *IA  "I>@  J)D
M *BU  "GW0  I_@  *;_ %9H  !(;   .G   "YV   B?0  %X0   Z*   '
MD    )8   ":    GP   *,   "G    J@   *L   "M    KP   +$   "S
M    M0   +@%  "Z#   O1(  , <  # +0  P$   +]5  "_;@  OHL  +ZH
M  "^R0  O>\  +S^ $YT  ! >0  ,G\  "6'   9C@  $)4   ><    H@
M *<   "L    L    +4   "Y    O    +T   "_    P0   ,,   #&
MR    ,H   #- @  T L  -42  #6(0  US0  -A)  #98   VGP  -J:  #;
MM0  V]D  -OR $:"   XB0  *Y   !V8   2H   "J<   "N    M    +D
M  "^    P@   ,@   #+    S@   ,\   #2    U    -8   #:    W0
M -\   #B    Y@   .H*  #O$P  \"4  /(Z  #S40  ]&L  /2)  #UI0
M];\  /7= /\ !@#_  , _P % /\ "P#_ !  _P 7 /\ (@#_ "T _P Y /\
M1 #_ $T _P!5 /\ 70#_ &0 _P!J /\ < #] '8 ^P!\ /D @P#W (H ]0"2
M /, FP#P *8 [@"S .L Q #I .0 YP#Y .8 _P#E /\ TP#_ ,< _P"_ /\
MNP#_ /\   #_    _P   /\  @#_  L _P 2 /\ '0#_ "@ _P S /\ /@#\
M $< ^ !/ /0 5P#Q %T [@!C .P :0#J &\ Z !U .8 ? #D (, X@"+ -\
ME0#< )\ V0"K -4 NP#2 -0 SP#R ,T _P#, /\ Q0#_ +H _P"T /\ L #_
M /\   #_    _P   /\   #_  8 ^0 / /4 %P#S "( \0 M .T -P#G $
MX@!) -\ 4 #; %< UP!= -0 8P#1 &@ SP!N ,P =0#* 'P R "$ ,4 C0#"
M )@ P "D +T L@"[ ,8 N0#H +@ _0"W /\ M@#_ *T _P"G /\ HP#_ /\
M  #_    _P   /4   #K  $ Y  , -X $P#9 !P TP F -$ , #, #H R !"
M ,0 2@#  %  O0!6 +L 7 "Y &$ MP!G +4 ;0"S '0 L0!\ *\ A0"M )
MJ@"< *@ J@"F +L I0#: *, ]0"C /\ H@#_ )X _P": /\ EP#_ /\   #^
M    [P   -\   #0    QP ' ,$ #P"\ !< N0 @ +< *@"U #, L  [ *T
M0P"K $D J !/ *8 50"D %H HP!@ *$ 9@"? &T G0!T )P ?0": (@ F "4
M )8 H@"4 +( D@#) )$ ZP"1 /\ D #_ )  _P", /\ B@#_ /P   #L
MV0   ,<   "Z    L0 " *L # "G !( I  ; *$ ) "@ "P G@ U )L / "8
M $, E@!) )0 3P"2 %0 D !: (\ 7P"- &8 BP!M (D =@"( (  A@", (0
MF@"" *H @0"^ (  X "  /D ?P#_ '\ _P!_ /\ ?@#_ /$   #8    P@
M +,   "H    H    )D !P"5  X D@ 5 )  '@". "8 C0 N (H -@"' #T
MA0!# (0 20"" $X @0!4 '\ 60!^ &  ? !G 'H ;P!Y 'H =P"& '4 E !T
M *, <@"U '( SP!Q /$ < #_ '  _P!P /\ <0#_ .$   #$    L    *(
M  "7    D0   (L  @"&  L @P 1 ($ & !_ "$ ?0 I 'P , !Y #< >  ]
M '8 0P!T $D <P!. '( 5 !P %H ;P!B &T :@!K '0 :@"  &@ C@!G )T
M90"O &4 Q@!D .@ 9 #] &, _P!C /\ 9 #_ ,\%  "V!P  HP@  )0(  ")
M!P  @@,  'X   ![  8 =P . '4 $P!R !L <0 C &\ *P!M #( ;  X &H
M/@!I $0 9P!) &8 3P!E %8 8P!= &( 90!@ &\ 7P![ %T B0!< )D 6P"J
M %D OP!9 .$ 6 #X %@ _P!8 /\ 60#_ ,(,  "J#0  EPX  (D.  !]#@
M=@T  '$*  !O!@  ;0 * &L $ !I !8 9P > &4 )@!C "T 80 S &  .0!?
M #\ 70!% %P 2P!; %( 6@!9 %@ 8@!7 &P 50!X %, A@!2 )8 40"G %
MNP!/ =L 3@+T $X#_P!.!/\ 3@/_ +@0  "A$@  CA,  '\3  !T$P  ;!(
M &<0  !E#@  8PL# &,&# !A!!$ 7@,9 %P$(0!;!2@ 608O %@&-0!6!SL
M50=" %0'2 !3"$\ 40A6 % )7P!."6D 30EV $L*A !)"I0 2 JF $<*N@!&
M"M@ 10OS $4,_P!%#/\ 10S_ + 4  "9%@  AQ@  '@9  !M&   91<  %\6
M  !<$P  6A$  %H.!@!:# T 5PP4 %4,' !3#20 4@TK % -,0!/#C@ 3@X^
M $T.10!+#DT 2@Y5 $@/7@!'#V@ 10]U $,0A !!$)4 0!"F #X0NP ]$-P
M/1'V #T1_P ]$/\ /A#_ *D9  "2&P  @1P  '(=  !G'0  7QP  %D;  !5
M&0  4Q8  %(3  !2$0H 4! 0 $X1& !,$2  2A(G $D2+@!($S0 1Q,[ $43
M0@!$$TD 0Q12 $$46P _%&4 /A5R #P5@0 Z%9( .!6D #<5N0 U%=@ -1;U
M #86_P V%O\ -Q7_ *,<  "-'@  >R   &TA  !B(0  6B$  %0?  !0'@
M31L  $P9  !+%@8 218. $<7%0!%%QP 1!@D $(8*@!!&#$ 0!DX #\9/P ]
M&48 /!I/ #H:6  Y&F, -QMO #4;?@ S&Y  ,ANB # ;MP O&], +QSS "\;
M_P P&_\ ,!O_ )T?  "((@  =R,  &DD  !>)   5B0  % C  !+(@  2"
M $8=  !%' ( 0QP, $$<$@ _'1D /ATA #P>)P ['BX .A\U #D?/  W'T0
M-A], #0@5@ S(&  ,2!M "\@?  M(8X +"&@ "HAM0 I(=  *2'R "DA_P J
M(/\ *R#_ )DB  "$)0  <R8  &4G  !;)P  4R<  $PF  !')0  1"0  $(A
M   _(0  /2$) #LA$  Y(A8 ."(> #8C)0 U(RL -"0R #,D.0 R)$$ ,"1*
M "\E4P M)5X *R5K "HE>@ H)8P )B6? "0ELP C)<X (R7P "0E_P E)/\
M)23_ )0E  " )P  ;RD  &(J  !7*@  3RH  $DI  !$*   0"<  #TF   Z
M)0  -R8& #4F#@ T)Q0 ,B<; #$H(@ P*"D +R@P "TI-P L*3\ *RE' "DI
M40 H*EP )BII "0J>  C*HH (2J= !\JL@ >*LP 'BKO !\I_P @*?\ (2C_
M ) H  !\*@  ;"L  %\L  !4+   3"P  $8L  !!*P  /"L  #@J   U*@
M,BL# # K#  N+!$ +2P8 "PL'P J+28 *2TM "@M-  G+CP )BY% "0N3P C
M+EH (2]G !\O=@ =+X@ '"^; !HOL  8+\H &"[M !DN_P ;+?\ &RW_ (PK
M  !X+0  :"X  %LO  !1+P  22\  $,O   ^+@  .2X  #0N   P+@  +2\
M "LP"@ I,1  )S$5 "8Q'  E,B, )#(J ",R,0 A,SD (#-" !\S3  =,U<
M&S-D !HT=  8-(8 %C2: !0SK@ 3,\@ $S/L !0S_P 5,O\ %C'_ (<N  !T
M+P  93$  %@Q  !.,@  1C(  $ Q   [,0  -C$  #$Q   K,P  *#0  "4U
M!@ C-@T (382 " W&0 ?-R  'C<G !TX+@ ;.#8 &C@_ !DX20 7.54 %3EB
M !0Y<0 2.80 $3F8 ! YK0 ..,< #CCK ! X_P 0-_\ $3;_ (,Q  !P,@
M830  %4T  !+-   1#0  #TT   X-   ,S0  "TU   H-P  )#D  " Z @ =
M.PL &SP0 !D]%0 8/1P %STC !8]*P 5/C, %#X\ !(^1@ 1/E( $#Y?  \^
M;P ./H$ ##Z5  L^J0 */L$ "CWD  L]^P ,//\ #3O_ 'TT  !K-@  73<
M %$W  !(-P  03<  #LW   U-P  ,#<  "HY   E.P  (#T  !P_   7008
M%$,- !)#$@ 10Q@ $4,? !!$)P /1"\ #D0Y  U$0P ,1$X "T1;  E$:@ '
M1'P !D20  1#I0 "0[T  T/@  -#]@ $0O\ !D'_ '@X  !G.0  63H  $XZ
M  !%.@  /CH  #@Z   S.@  +3L  "<]   A0   '$(  !=$   31@, #TD*
M  U*#P ,2A0 "TH;  E*(P (2BL !THT  5*/@ $2DD  DI6  !*90  2G<
M $J+  !*H0  2;D  $G=  !)]0  2/\  $C_ '(\  !B/0  53X  $H^  !"
M/0  /#T  #8]   O/@  *4   "-"   =10  %T<  !-*   /3 ( "T\)  =0
M#0 #41$  %$7  !1'@  428  %$O  !1.0  440  %)1  !28   47(  %&'
M  !1G0  4;4  %#8  !0]0  3_\  $__ &Q   !=00  44$  $=!  ! 0
M.4   #)!   J0P  )$8  !Y(   72P  $DX   Y1   +4P$ !E8'  !7#
M6!   %@3  !9&0  6B$  %HI  !:,P  6C\  %I,  !:6@  6FP  %J!  !9
MF0  6;$  %C1  !8]   5_\  %?_ &5%  !810  344  $5$   ^1   -44
M "U'   E2@  'DT  !A0   24P  #E8   I9   $7    %X$  !?"0  8 T
M &$0  !B%0  8QL  &0C  !D+0  9#@  &1%  !D5   9&8  &1[  !CDP
M8ZT  &+,  !A\@  8?\  &#_ %]*  !32@  2DD  $-(   Y20  +TP  "=/
M   ?4@  &%4  !)9   -70  "&    )C    9@   &@!  !I!0  :@H  &L-
M  !M$0  ;A8  ' =  !Q)@  <3$  ' ^  !P3@  <%\  '!S  !OC0  ;Z<
M &[&  !M[P  ;/\  &S_ %I/  !03@  2$T  #U.   S40  *50  "!8   8
M7   $6    QD   &:    &L   !O    <@   '0   !U    =P0  '@)  !Z
M#0  ?!   'T6  !_'@  @"@  ( U  " 10  ?U8  ']K  !_A   ?J   'V^
M  !\Z0  >_\  'K_ %94  !.4P  0E0  #=6   L6@  (E\  !AC   1:
M"VT   -R    =@   'H   !]    @    (,   "$    A@   (<"  ")!P
MBPP  (T0  "0%@  DA\  )(L  "2.P  DDT  )%B  "1>@  CY<  (^T  ".
MX0  C/L  (S_ %59  !(6@  .UT  "]A   D9@  &6P  !%R   *=P   GT
M  ""    A@   (L   ".    D0   ),   "5    EP   )D   ";    G00
M )\*  "B#P  I!8  *8A  "F,0  ID,  *57  "D<   HXX  *.K  "AT
MH/4  )__ $YA  ! 9   ,VD  "=N   ;=0  $7P   N#    B0   (X   "3
M    F    )T   "A    I    *4   "G    J0   *L   "M    L    +(
M  "U"   N X  +P6  "\)0  O#<  +M,  "Z9   N8$  +>B  "WP   M^H
M +?\ $9K   Y<   *W<  !]_   3A@  "XX   &5    FP   *$   "F
MJP   +    "S    MP   +<   "Z    O    +\   #!    Q    ,<   #*
M    S04  -$.  #4&0  U"L  -1   #36   TW0  -.2  #2L   TM,  -+R
M #YY   Q@   (X@  !>1   -F0   Z    "G    K@   +,   "X    O0
M ,(   #&    R@   ,H   #-    SP   -(   #5    V0   -T   #?
MXP   .<%  #K#P  [!\  .TS  #N2P  [V0  .^"  #PGP  \;D  /'8 /\
M  #_    _P $ /\ "0#_  X _P 5 /\ '@#_ "D _P T /\ /P#_ $@ _P!0
M /\ 6 #_ %X _P!E /T :P#[ '$ ^0!W /@ ?@#V (4 \P"- /$ EP#N *(
MZP"O .@ P #F .  XP#X .( _P#; /\ RP#_ ,$ _P"Y /\ M #_ /\   #_
M    _P   /\   #_  D _P 0 /\ &0#_ ", _P N /T .0#Y $( ]0!* /(
M4@#N %@ ZP!> .D 9 #F &H Y !P .( =@#? 'T W0"& -D CP#5 )H T0"G
M ,X M@#+ ,X R0#P ,< _P#% /\ NP#_ +0 _P"M /\ J0#_ /\   #_
M_P   /\   #[  ( ]@ - /$ $P#M !X [  H .D ,@#C #L W0!$ -@ 2P#3
M %$ T !8 ,T 70#+ &, R0!H ,8 ;P#$ '8 P@!^ +\ AP"\ )( N@"? +<
MK0"U ,$ L@#D +$ _0"O /\ K #_ *4 _P"@ /\ G #_ /\   #_    ^P
M .X   #D    W  ( -, $ #/ !@ RP B ,D *P#& #0 P0 ] +T 1 "Z $L
MMP!1 +4 5@"R %P L !A *X 9P"L &X J@!V *@ ?P"F (H HP"6 *$ I0"?
M +8 G0#1 )P \P"; /\ G #_ )8 _P"3 /\ D #_ /\   #V    YP   -,
M  #&    O0 # +@ #0"S !, L0 < *\ )0"N "X J0 V *8 /0"C $0 H0!*
M )\ 3P"= %4 FP!: )H 8 "8 &8 E@!N )0 =P"2 ($ D ". (X G ", *T
MB@## (D Z "( /\ B0#_ (< _P"% /\ @@#_ /,   #C    S    +P   "P
M    IP   *$ " ">  \ FP 6 )D 'P"8 "< E@ O ), -P"1 #T C@!# (P
M20"+ $X B0!4 (< 60"% &  A !G (( ;P"  'H ?@"& 'P E !Z *0 >0"X
M '@ V !W /< > #_ '@ _P!W /\ =0#_ .8   #+    MP   *@   ">
ME@   (\ ! "+  P B  2 (< &0"% "$ A  I (( , !_ #< ?0 ] 'P 0P!Z
M $@ >0!- '< 4P!V %D = !A '( :0!Q ', ;P!_ &T C0!L )T :@"O &D
MR !H .T :0#_ &D _P!I /\ :0#_ -(   "X    I0   )<   "-    A@
M ($   !\  @ >0 . '< % !V !P =  C ', *P!Q #$ ;P W &X /0!L $,
M:P!( &H 3@!H %0 9P!; &4 8P!C &T 8@!X &  AP!? )8 70"H %T O@!<
M .0 7 #[ %P _P!< /\ 7 #_ ,(   "J 0  F ,  (D$  !_ @  >    '0
M  !P  0 ;0 , &L $0!I !< :  > &8 )0!E "P 8P R &( . !@ #T 7P!#
M %X 20!< $\ 6P!6 %H 7@!8 &@ 5P!S %4 @0!4 )$ 4@"C %$ MP!1 -8
M40#U %$ _P!1 /\ 4@#_ +8'  "?"0  C0L  'X,  !S"P  ; H  &@'  !E
M P  8P ' &$ #0!? !, 70 : %P (0!; "< 60 M %@ ,P!6 #D 50 _ %0
M10!3 $L 40!2 %  6@!/ &0 30!O $P ?0!* (T 20"? $@ L@!' ,P 1P#O
M $8 _P!' /\ 1P#_ *P,  "5#@  @Q   '40  !K$   8P\  %X.  !;#
M6@D" %D$"@!7  \ 50 5 %, ' !2 ", 40 I $\ +P!. #4 30$[ $P!00!*
M D@ 20)/ $@"5P!& V$ 10-M $,#>@!" XL 0 .< #\#KP ^ \@ /03J #T%
M_  ]!O\ /@;_ *00  ".$@  ?!,  &X4  !D%   7!,  %82  !3$0  40X
M % ,!0!0"0P 3P<1 $T'%P!+"!\ 20@E $@)*P!'"3$ 1@DX $0*/@!#"D4
M0@I- $ +50 _"U\ /0MK #P+>0 Z#(H . R< #<,KP U#,< -0SI #4-_0 U
M#?\ -@S_ )T3  "'%0  =A<  &D8  !>&   5A@  % 7  !-%0  2A,  $D1
M  !)#@< 2 T. $8-$P!$#1H 0PXA $(.* ! #BX /PXU #X//  ]#T, .Q!+
M #H05  X$%X -A!K #00>0 R$(H ,1"< "\0L  M$,D +1'L "T1_P N$?\
M+Q#_ )<6  ""&0  <1L  &0<  !9'   41P  $P;  !'&@  1!@  $,5  !"
M$P( 01(+ $ 1$  ^$A< /!(> #L3)0 Z$RL .!,R #<3.0 V%$  -!1( #,4
M40 Q%%P ,!5H "X5=P L%8@ *A6: "@5K@ G%<< )A7J "<5_P H%?\ *17_
M )$:  !]'   ;1X  & ?  !6'P  3A\  $@>  !#'0  0!P  #X:   ]&
M.Q<' #D6#@ X%Q0 -A<; #48(@ S&"@ ,A@O #$9-@ P&3T +AE& "T:3P K
M&ED *AIF "@:=  F&H8 )!J9 "(:K0 A&L4 (!KH "$:_@ B&O\ (QK_ (T=
M  !Y'P  :2$  %PB  !2(@  2B(  $0A   _(0  /"   #D>   X&P  -1P$
M #0<#0 R'!( ,!T8 "\='P N'24 +1XL "L>,P J'CL *1]# "<?30 F'U<
M)!]D "(?<@ @'X0 'Q^7 !T?JP ;'\, &Q_G !L?_0 ='_\ 'A[_ (D@  !U
M(@  92,  %DD  !/)0  1R4  $$D   \(P  .",  #4B   S(   ," ! "XA
M"@ L(1  *R$5 "HB'  H(B, )R(I "8C,  E(S@ (R-! "(D2@ A)%4 'R1A
M !TD<  ;)(( &225 !<DJ@ 6),$ %23E !8D_  7(_\ &2/_ (4B  !Q)
M8B8  %8G  !,)P  1"<  #XG   Y)@  -28  #$E   N)   *R4  "DE!P G
M)@X )283 "0G&0 C)R  (B<G "$H+@ @*#8 'B@^ !TH2  ;*5, &2E? !@I
M;@ 6*8  %"F4 !(IJ  1*<  $2CD !$H^P 3*/\ %"?_ ( E  !N)P  7R@
M %,I  !)*@  0BD  #LI   V*0  ,B@  "XH   J*   )BD  "0J!  B*PP
M("L1 !\L%@ =+!T '"PD !LM*P :+3, &"T\ !<M10 6+E  %"Y= !(N;  1
M+GX $"Z2  XNIP -+;T #2W?  TM^0 .+/\ $"S_ 'PH  !J*@  6RL  % L
M  !&+   /RP  #DL   T*P  +RL  "LK   F+   (BX  !\O   <, D &C$.
M !DQ$P 7,1H %C(A !4R*  4,C  $S(Y !(S0P 1,TX $#-;  XS:0 -,WH
M##..  HSH@ (,KD "#+9  @R]  *,?\ "S'_ '<K  !F+0  6"X  $TO  !#
M+P  /"X  #8N   Q+@  +2X  "DN   C,   'S(  !LS   7-04 %#8, !(W
M$0 1-Q8 $3<= ! X)  /."P #C@U  TX/P ,.$H "SA7  DX90 '.'8 !3B*
M  ,XGP !-[4  3?3  (W\0 #-O\ !3;_ ',N  !B,   5#$  $DQ  !!,0
M.3$  #0Q   O,   *S   "4R   @,P  &S8  !<X   3.@( $#P)  T]#@ ,
M/1, "ST9  H](0 )/2D "#TQ  8^.P %/D8  SY2  $^80  /G(  #Z&   ]
MG   /;(  #W0   \\   //\  #S_ &TR  !=,P  4#0  $8T   ^-   -S0
M #(S   M,P  )S0  "(V   =.   &#H  !0]   0/P( #4$(  E##0 &1!$
M T06  )$'0  1"0  $0M  !$-@  1$$  $1.  !$7   1&T  $2!  !$F
M0Z\  $/-  !"\   0O\  $+_ &@V  !8-P  3#@  $,X   [-P  -38  # V
M   I-P  (SD  !X[   8/0  $T   !!"   -10$ "$<'  -)#   20\  $H3
M  !+&0  2R   $LH  !+,@  2ST  $Q)  !,5P  2V@  $M]  !+E   2JP
M $K*  !)[P  2?\  $G_ &(Z  !4.P  23L  $ [   Y.@  ,SD  "PZ   E
M/   'S\  !E!   31   $$<   Q)   (3    D\%  !0"@  4 T  %$0  !2
M%0  5!L  %0C  !4+   5#<  %1$  !44@  5&,  %1W  !4CP  4Z@  %+&
M  !2[0  4?\  %'_ %P_  !//P  13\  #X^   W/0  +SX  "=    @0P
M&48  !-)   /3   "T\   92    5    %<"  !8!P  60L  %H.  !;$0
M718  %X=  !?)@  7S$  %X]  !>3   7ET  %YQ  !=B0  7:,  %S!  !;
MZP  6O\  %K_ %9$  !+0P  0T(  #Q!   R0@  *44  "%(   :2P  $TX
M  Y2   *50   UD   !;    7@   &    !B @  8P8  &4*  !F#@  :!$
M &H7  !K'P  :RD  &LV  !K10  :U8  &IJ  !J@@  :9T  &B[  !GYP
M9O\  &7_ %%(  !(2   048  #='   L2@  (TT  !M1   350  #ED   A=
M   !80   &0   !G    :@   &P   !N    <    '(%  !S"0  =0T  '<1
M  !Z&   >R$  'LN  !Z/0  >DX  'EB  !Y>0  >)8  '>S  !UX   =/P
M '/_ $Y-  !'3   .TT  #!/   F4P  '%@  !-<   -80  !F8   !J
M;P   '(   !V    >0   'P   !]    ?P   ($   "# @  A@<  (@,  "+
M$0  CA@  (XD  ".,P  C40  (Q8  "+;P  BHP  (FJ  "(SP  AO<  (7_
M $U1  !!4P  -%4  "E:   >7P  %&4   UJ   %<    '8   ![    ?P
M (,   "'    B@   (T   ".    D0   ),   "5    F    )H%  "=#
MH!$  *,:  "C*   HCH  *%.  "@90  H($  )Z@  "=P0  F^X  )K_ $99
M   Y7   +6$  "%G   6;@  #G4   5[    @0   (<   "-    D@   )8
M  ":    G0   )\   "A    I    *8   "H    JP   *X   "Q P  M L
M +@1  "Y'@  N2\  +A#  "W6@  M78  +27  "TM0  L>(  +#\ #]D   Q
M:0  )6\  !AW   /?P  !H<   ".    E    )H   "@    I0   *H   "N
M    L0   +(   "U    MP   +H   "\    OP   ,,   #&    R0   ,X*
M  #2$P  TB,  -$W  #03P  SFH  ,V*  #*JP  R\L  ,OO #=Q   I>
M'8   !&)   (D0   )H   "A    IP   *T   "S    N0   +X   #"
MQ0   ,8   #)    S    ,X   #2    U0   -H   #>    X0   .4   #J
M"P  ZQ<  .HK  #J0P  ZEX  .IZ  #KF0  Z[4  .O5 /\   #_    _P !
M /\ !P#_  T _P 2 /\ &P#_ "4 _P O /\ .@#_ $, _P!+ /\ 4P#_ %H
M_0!@ /L 9@#Z &L ^ !R /8 > #T (  \0") .\ D@#L )T Z0"J .8 O #C
M -P WP#W -T _P#, /\ O@#_ +4 _P"P /\ K0#_ /\   #_    _P   /\
M  #_  8 _P - /\ % #_ !\ _P I /L ,P#W #T \P!% .\ 30#L %, Z !9
M .4 7P#C &4 X !J -T <0#: '@ U@"  -( B@#/ )4 S "B ,@ L@#% ,D
MP@#M ,  _P"[ /\ L #_ *@ _P"D /\ H0#_ /\   #_    _0   /H   #X
M    \  ) .P $0#H !D YP C .4 +0#> #8 U@ ^ -$ 1@#- $P R@!2 ,@
M6 #% %T PP!C ,  :0"^ '  O !X +D @0"W (T M ": +$ J0"N +P K #A
M *H _ "H /\ H #_ )D _P"6 /\ E #_ /\   #Y    \@   .<   #;
MT0 $ ,H #0#' !0 Q  = ,( )@"_ "\ NP W +< /P"T $4 L0!+ *X 40"L
M %8 J@!< *@ 80"F &@ HP!P *$ >0"? (0 G0"1 )H H "8 +$ E@#, )4
M\0"4 /\ D0#_ (L _P"( /\ A@#_ /<   #L    W@   ,D   "\    M
M *\ "@"K !  J0 7 *@ ( "G "@ H@ P )\ . "< #X F@!$ )@ 2@"6 $\
ME !5 ), 6@"1 &$ CP!H (T <0"+ 'L B0"( (< EP"% *@ @P"^ ($ Y "
M /\ @ #_ 'P _P![ /\ >0#_ .D   #7    P0   +$   "F    G0   )<
M!0"4  T D@ 2 )  &@"/ "( C@ J (L ,0") #@ AP ^ (4 0P"# $@ @0!.
M '\ 5 !^ %H ? !A 'H :0!X ', =@!_ '4 C@!S )\ <0"S '  T !O /8
M;P#_ &\ _P!M /\ ; #_ -H   "_    K    )X   "3    C    (4   ""
M  D ?P / 'X %0!] !P ?  D 'H *P!W #$ =0 W '0 /0!R $( <0!( &\
M30!N %, ; !: &L 8@!I &P 9P!X &8 A@!D )< 8@"J &$ P@!@ .L 80#_
M &$ _P!A /\ 8 #_ ,4   "M    FP   (T   "#    ?    '<   !R  4
M<  , &X $0!L !< ;  > &L )0!I "P 9P Q &8 -P!D #T 8P!" &( 2 !@
M $X 7P!5 %T 70!< &8 6@!R %D @ !7 )  5@"C %4 N0!4 -X 5 #[ %0
M_P!5 /\ 50#_ +8   "?    C0   '\   !U    ;@   &D   !F  $ 8P )
M &$ #@!@ !, 7P 9 %X ( != "8 6P L %H ,@!8 #< 5P ] %8 0P!5 $D
M4P!0 %( 6 !1 &$ 3P!L $X >@!, (H 2P"< $H L0!) ,X 20#S $D _P!)
M /\ 2@#_ *H!  "4!0  @@<  '0(  !J"   8P8  %X$  !;    60 % %<
M# !6 !  5  5 %, &P!2 "( 40 H %  +0!. #, 30 X $P /@!+ $4 2@!,
M $@ 5 !' %T 1@!H $0 =0!# (4 00"8 $  JP!  ,4 /P#J #\ _P!  /\
M0 #_ * (  "*"P  >0T  &P-  !A#0  6@T  %4+  !2"0  4 8  $\"" !.
M  T 3  2 $L %P!* !X 20 C $< *0!& "\ 10 T $0 .@!" $$ 00!( $
M4  ^ %H /0!D #P <@ Z (( .0"4 #@ IP W +X -@#C #8 ^0 V /\ -P#_
M )@-  "##@  <A   &41  !;$0  4Q   $X0  !*#@  2 T  $<* P!'!PH
M100. $0"$P!" AH 00(@ $ #)0 ^ RL /00Q #P$-P [!#X .@5% #D%3@ W
M!5< -@5B #0&<  R!H  ,0:2 # &I0 O!;L +@7= "X&]0 M!_\ +@?_ )$0
M  !]$0  ;!,  %\4  !5%   3A0  $@3  !$$@  01   $ .  ! #08 0 H,
M #X)$  \"18 .PH< #D*(@ X"B@ -PLN #8+-0 U"SL ,PM# #(,3  P#%8
M+PQA "T,;P K#'\ *@R2 "@,I0 G#+L )0S= "4-]0 F#?\ )PW_ (L2  !W
M%   9Q8  %L7  !1&   21<  $,7   _%0  /!0  #H2   Y$0$ .0\( #@.
M#0 W#A( -0X8 #0.'P R#B4 ,0\L # /,@ O$#H +1!" "P02P J$%4 *!!A
M "80;P D$(  (Q"3 "$0IP ?$+T 'A#@ !X1]P ?$/\ (!#_ (84  !S%P
M8QD  %<:  !-&P  11H  $ :   [&0  .!@  #46   T%   ,Q($ #(2"P Q
M$A  +Q(5 "T2'  L$R( *Q,I "H3,  H$S< )Q0_ "842  D%%, (A1? " 5
M;0 ?%7X '161 !L5I0 9%;L &!7> !@5^  9%/\ &A3_ ((7  !O&@  7QP
M %,=  !*'0  0AT  #P=   W'   -!L  #$:   O&0  +A8  "P7"  K%@X
M*1<3 "@7&0 G&"  )1@F "08+0 C&#0 (AD] " 91@ >&5$ '1E= !L::P 9
M&GP %QJ/ !4:HP 4&;H $AG; !,9]@ 4&?\ %1C_ 'T:  !K'0  7!\  % @
M  !'(   /R   #D?   T'P  ,1X  "T=   K'   *1L  "<;!0 E&PP )!P1
M "(<%@ A'!T (!TC !\=*@ >'3( '!XZ !L>1  9'DX %QY; !8>:0 4'WH
M$AZ- !$>H@ 0'K@ #A[8  \>]0 0'?\ $1W_ 'H=  !G'P  62$  $TB  !$
M(@  /"(  #8B   R(0  +B$  "H@   G(   )!\  "(@ @ @( H 'B$/ !TA
M%  <(1H &R(A !DB)P 8(B\ %R(X !4C00 4(TP $B-8 !$C9P 0(W@ #B.+
M  TCGP ,([0 "R/0  LB\  ,(O\ #2'_ '8?  !D(@  5B,  $LD  !!)
M.B0  #0D   O(P  *R,  "@C   D(P  (",  !TD   ;)0< &28- !<F$0 6
M)A< %2<> !0G)0 3)RP $B<U !$H/P 0*$H #BA6  TH9  ,*'0 "BB'  DH
MFP ')[$ !2?,  8G[  ')OX "";_ '$B  !@)   4R8  $@G   _)P  -R8
M #$F   M)@  *24  "4E   B)0  '2<  !DH   6*@0 %"L+ !(L$  1+!0
M$"P; ! L(@ .+"D #BTR  TM.P ++48 "BU2  @M8  &+7  !"V#  (MF
M+*X  "S)   LZP !*_P  BO_ &TE  !=)P  3R@  $4I   \*0  -2D  "\H
M   K*   )R<  ",G   ?*   &RH  !<L   3+@( $# (  XQ#0 -,1( ##$7
M  LQ'@ *,28 "#(N  <R-P %,D(  S).  $R7   ,FP  #)_   RE0  ,:P
M #''   PZ@  ,/P  ##_ &@I  !8*@  3"L  $$L   Y+   ,BL  "TK   I
M*@  )2H  " K   <+   %RX  !,P   0,@( #C0'  HW#  '-Q  !3<4  ,W
M&P "-R(  #<J   X,P  .#X  #A*   X6   .&@  #A\   WD@  -ZD  #;%
M   VZ@  -OT  #7_ &,L  !4+@  2"\  #XO   V+@  ,"X  "LM   G+0
M(BT  !TO   8,0  %#,  ! U   .-P$ "CH'  8["P "/ X  #T2   ^%P
M/AX  #XF   ^+P  /CH  #Y&   ^5   /F0  #YW   ^CP  /:<  #W#   \
MZ0  //T  #O_ %XP  !0,0  1#(  #LR   T,0  +C   "DO   D,   'C(
M !DT   4-@  $#D   T[   */0  !4 %  !!"@  0@T  $,0  !$%   11H
M $8B  !&*P  1C4  $9!  !&3P  1E\  $9S  !%B@  1:0  $3   !#Z
M0_X  $+_ %@T  !+-0  034  #DU   R-   +3,  "8T   @-0  &C@  !0Z
M   0/0  #4    E"   $10   $<#  !(!P  2@L  $L.  !,$0  3A4  $\<
M  !/)0  3R\  $\\  !/2@  3UH  $YM  !.A0  3:   $R\  !+YP  2_X
M $K_ %,Y  !'.0  /CD  #<X   Q-P  *3<  "$Y   ;/   %3\  !!"   ,
M10  !T@   )*    30   $\   !1!   4@<  %0+  !5#@  5Q$  %D7  !:
M'P  62D  %DV  !91   650  %AG  !8?P  5YH  %:W  !5XP  5/T  %3_
M $X]  !#/0  /#P  #4[   L/   )#X  !Q!   51   $$@   M+   %3@
M %$   !4    5P   %D   !;    70(  %X&  !@"P  8@X  &02  !G&
M9R(  &8N  !F/   9DT  &5@  !E=P  9),  &.Q  !AW0  8/P  %__ $E"
M  !!00  .C\  #!    F0P  'D8  !5*   03@  "E(   -6    6@   %T
M  !@    8P   &4   !G    :0   &L!  !M!0  ;PH  '(.  !U$@  =QL
M '8F  !V-0  =48  '19  !T;P  <XL  '*I  !PS0  ;_<  &[_ $9&  !
M10  -48  "I(   @3   %U$  !!6   )6@   5\   !C    :    &L   !O
M    <@   '4   !W    >0   'L   !]    @ ,  (,(  "&#0  B1,  (H=
M  "**P  B3P  (A/  "&9@  A8$  (2@  ""P@  @?   '__ $9+   Z3
M+D\  "-3   86   $%X   ED    :0   &\   !T    >    'P   "!
MA    (<   "(    BP   (X   "0    DP   )8   "9!P  G0T  *$4  "@
M(0  H#$  )Y$  "=6P  G'8  )F6  "9M0  EN4  )7^ #]2   R50  )EH
M !M@   19P  "6T   !T    >P   ($   "&    BP   )    "4    EP
M )D   "<    GP   *$   "D    IP   *H   "M    L08  +4-  "X%@
MMR8  +8Y  "U4   M&H  +*)  "PJ@  KL\  *WU #=<   K80  'F@  !-P
M   +>    (    "'    C@   )4   ":    GP   *0   "H    K    *T
M  "P    LP   +4   "X    NP   +\   ##    QP   ,L%  #1#@  T1L
M - N  #/10  S5\  ,M^  #)G@  R+X  ,7I "]I   C<   %GD   V!   !
MBP   ),   ";    H@   *@   "N    M    +@   "]    P    ,(   #%
M    R    ,L   #.    T0   -8   #;    WP   .0   #H!@  ZQ$  .HC
M  #J.@  Z50  .=R  #EDP  X[,  ./4 /\   #_    _P   /\ ! #_  L
M_P 0 /\ %P#_ "$ _P K /\ -0#_ #X _P!' /\ 3@#_ %4 _ !; /H 80#X
M &8 ]@!M /0 <P#R 'L [P"$ .T C@#J )D Y@"G ., N0#? -4 VP#W -8
M_P#  /\ L@#_ *H _P"E /\ H@#_ /\   #_    _@   /P   #\  , _@ +
M /\ $0#_ !H _0 D /D +@#T #@ \ !  .P 2 #I $X Y@!4 .( 6@#? %\
MW !E -@ :P#4 '( T ![ ,T A0#* )$ QP"> ,, K@#  ,4 O0#K +L _P"P
M /\ I #_ )P _P"8 /\ E0#_ /\   #Z    ]    /$   #R    Z@ % .<
M#@#B !4 X0 > .$ * #8 #$ T  Y ,L 0 #( $< Q0!- ,( 4P"_ %@ O0!>
M +L 9 "Y &L M@!S +0 ? "Q (@ K@"5 *L I "H +@ I@#< *, ^P"? /\
ME0#_ (\ _P"+ /\ B0#_ /D   #O    YP   -\   #/    R    ,$ "@"_
M !$ O  8 +L (0"Y "H M  R +$ .@"N $  JP!& *@ 3 "F %$ HP!6 *$
M7 "? &, G0!J )L <P"9 'X E@", )0 FP"2 *T D #' (X \ "- /\ A@#_
M (  _P!] /\ ? #_ .T   #@    T0   +\   "S    J@   *8 !0"B  T
MH0 3 *  &P"? ", FP K )@ ,@"5 #D DP _ )$ 1 "/ $H C@!/ (P 50"*
M %L B !C (8 :P"$ '8 @@"" (  D@!^ *, ? "Z 'H X0!Y /\ =P#_ '(
M_P!P /\ ;P#_ -T   #+    M@   *<   "=    E    (X  0"+  H B0 0
M (@ %0"' !T AP E (0 + "" #( ?P X 'T /0![ $, >0!( '@ 3@!V %0
M=0!; ', 8P!Q &X ;P!Z &T B0!L )H :@"N &D S !H /8 9P#_ &4 _P!D
M /\ 8P#_ ,H   "T    H0   ),   ")    @@   'L   !X  4 =@ , '4
M$0!T !@ <P ? '( )0!P "P ;@ R &P -P!J #P :0!" &@ 2 !F $X 90!5
M &, 70!B &8 8 !R %X @ != )( 6P"E %H O@!9 .D 60#_ %D _P!8 /\
M6 #_ +D   "B    D    (,   !Y    <0   &T   !I  $ 9@ ) &4 #@!D
M !, 8P 9 &, ( !A "8 8  L %X ,0!< #< 6P \ %H 0@!8 $@ 5P!/ %8
M5P!4 &  4P!L %$ >0!0 (H 3P"> $X M !- -H 30#[ $T _P!- /\ 30#_
M *H   "4    @@   '4   !K    9    &    !=    6@ % %@ # !7 !
M5@ 5 %8 &P!5 "$ 4P G %( + !1 #$ 3P W $X /0!- $, 3 !* $H 4@!)
M %L 2 !F $8 <P!% (0 1 "7 $, K !" ,D 0@#Q $( _P!# /\ 0P#_ )X
M  ")    > ,  &H$  !A!   6@,  %4!  !2    4  " $X "0!-  T 3  1
M $L %P!* !P 20 B $@ )P!' "T 10 R $0 . !# #X 0@!% $$ 30 _ %8
M/@!A #T ;@ [ 'X .@"1 #D I@ X +\ . #H #@ _P Y /\ .0#_ )4#  "
M!P  ;PD  &(*  !8"P  40H  $P(  !)!@  1P,  $8 !@!$  L 0P / $(
M$P!! !@ 00 > #\ (P ^ "D /0 N #L -  Z #H .0!! #@ 20 W %( -@!=
M #0 :@ S 'H ,@", #$ H0 P +@ +P#> "\ ^0 O /\ , #_ (P)  !X#
M: T  %P.  !2#@  2PX  $4-  !!#   /PH  #X( @ ]! @ / $- #L $  Z
M !4 .0 : #@ (  V "4 -0 K #0 ,  S #< ,@ ^ #$ 1@ O %  +@!: "T
M9P K '< *@") "D G0 H +, )P#1 "< \@ G /\ )P#_ (8,  !R#@  8Q
M %81  !-$0  11$  $ 0   \#P  .0X  #<-   V"P0 -@@* #4&#@ T!1(
M,@07 #$%'  P!2( +P4H "X&+@ M!C0 *P8\ "H&1  I!TX )P=9 "8'90 D
M!W4 (P>' "('FP @!K  ( ;+ !\%[0 ?!OX 'P?_ ( .  !M$0  7A(  %(3
M  !($P  01,  #L3   W$@  -!$  #(0   P#P$ , T& # +"P O"A  +0H4
M "P+&0 J"Q\ *0LE "@,*P G##( )@PZ "0,0P C#$T (0U8 " -90 >#74
M' V( !H-G  9#;$ & S* !<,ZP 7#?P & S_ 'L1  !I$P  6A4  $X6  !%
M%@  /18  #@5   S%0  ,!0  "T3   K$@  *A # "H/"  I#@T * X1 "8.
M%@ E#QT ) \C ",/*0 A$#$ (! Y !X00@ =$$P &Q!8 !D09@ 7$'8 %1")
M !00G@ 2$+, $1#. !$0[@ 2$/X $A#_ '<3  !E%0  5Q<  $L8  !"&0
M.AD  #08   P%P  +!<  "D6   G%0  )A0! "42!  C$@L (A(/ "$2%  @
M$AH 'A,@ !T3)P <$RX &A,V !D40  7%$H %A16 !049  2%'0 $12' ! 4
MG  .%+$ #13*  T4ZP .$_X #A/_ ',5  !A&   4QH  $@;   _&P  -QL
M #(:   M&@  *1D  "88   D&   (A<  " 6 0 >%@@ '18- !L7$@ :%Q<
M&1<= !@8)  6&"L %1@T !08/0 2&4@ $1E4 ! 98@ .&7( #1F$  P9F  *
M&:T "1C&  D8YP )&/H "A?_ &\8  !>&@  4!P  $4=   \'0  -1T  "\=
M   J'   )AL  ",;   A&@  'AH  !P:   :&P4 &!L, !8<$  5'!4 %!P;
M !,<(@ 2'2D $1TQ ! =.P .'44 #1Y1  P>7@ *'FT "1Z   <>E  %':H
M QW"  ,=Y@ $'/@ !1S_ &L:  !;'0  31X  $(?   Z'P  ,A\  "T?   H
M'@  )!X  "$=   >'0  '!T  !@>   5'P( $R ) !(A#@ 0(1( $"$8  XA
M'P .(B8 #2(N  PB-P *(D$ "2)-  <B6@ %(FD  R)\  $BD0  (J@  "'
M   AY0  (/@  "#_ &<=  !7'P  2B$  $ A   W(@  ,"$  "HA   F(
M(B   !\?   <'P  &2   !8A   2(P( $"0'  XF#  ,)A  "R85  HF'  )
M)B( ""8J  8G,P $)ST  R=)  $G5@  )V8  "=Y   GCP  )J8  ":_   E
MY   )?D  "3_ &,@  !4(@  1R,  #TD   T)   +B,  "@C   D(@  (2(
M !XA   :(@  %R,  !,D   0)@( #B@'  LJ"P (*PX !BL3  0K&  "*Q\
M 2PG   L,   +#H  "Q%   L4P  +&,  "QV   LC   *Z0  "N^   JY
M*OH  "G_ %\C  !0)0  1"8  #HF   R)@  *R8  "8E   C)   'R0  !LD
M   7)0  %"<  !$I   .*P( "RT&  <O"P $, X  # 1   Q%0  ,1P  #$C
M   R+   ,C8  #)"   R3P  ,E\  #)R   QB0  ,:(  #"\   PY   +_L
M "__ %HG  !,*   0"D  #<I   O*0  *2@  "4G   A)@  '"<  !@H   4
M*@  $2P   XN   +, $ !S(%  ,T"0  -0P  #8/   W$@  .!@  #@@   X
M*   .#(  #D]   Y2P  .5L  #AN   XA0  -Y\  #>Z   VY   -?P  #7_
M %4J  !(+   /2P  #0L   M*P  *"H  "0I   >*@  &2L  !0M   1+P
M#3$   HT   '-@   C@$   Z!P  .PH  #T-   ^$   0!0  $ ;  ! )
M0"X  $ Y  ! 1P  0%8  $!I  ! @   /YL  #ZW   ]XP  //P  #S_ % O
M  !#+P  .2\  #(O   L+0  )RP  " M   :+P  %3$  !$S   --@  "3@
M  4[    /0   $ !  !!!   0P<  $4+  !&#@  2!$  $H6  !*'@  2B@
M $HT  !)0@  25$  $ED  !(>P  2)<  $>T  !&X   1?P  $3_ $HS   _
M,P  -C,  # Q   J,   (S$  !PS   6-0  $3@   T[   (/@   T$   !#
M    1@   $@   !*    3 0  $X'  !/"P  40X  %02  !5&0  52(  %0N
M  !4/   5$L  %->  !3=   4I   %&N  !0UP  3_L  $[_ $4W   \-P
M-38  "\T   F-0  'C<  !<Z   1/0  #$$   =$    2    $H   !-
M4    %,   !5    5P   %@"  !;!@  70L  %\.  !B$P  8AL  &(G  !B
M-   844  &!7  !@;0  7XD  %VG  !<S   6O@  %G_ $$\   Z.P  -#D
M "HZ   A/   &$   !%#   ,1P  !DL   !/    4P   %8   !9    7
M %\   !A    8P   &4   !G 0  :@4  &T*  !P#@  <Q4  '(@  !R+0
M<3T  '!/  !O90  ;H   &V?  !KP0  :?$  &C_ #]    Y/@  +C\  "1"
M   :1@  $DH   Q/   $5    %@   !=    80   &4   !H    :P   &X
M  !Q    <P   '4   !X    >P   'X#  "!"@  A0\  (<7  "&)   A30
M (1&  ""70  @78  '^6  !^M@  ?.<  'K_ #]$   S10  *$@  !U,   3
M4@  #%<   -=    8P   &@   !M    <0   '8   !Z    ?@   ($   "#
M    A@   (D   "+    C@   )(   "5 0  F0D  )X0  ">&@  G2D  )P\
M  ":4@  F&P  ):+  "4J@  DM0  )#Z #A+   L3@  (%,  !59   -8
M V<   !N    =    'H   "     A    (H   ".    D@   )4   "7
MF@   )T   "@    HP   *<   "K    KP   +0)  "X$   MQX  +4P  "S
M1@  L6   *]^  "LH   J\$  *GN #%5   D6P  &&$   YI   %<0   'D
M  "!    B    (\   "4    F@   )\   "D    J    *D   "L    KP
M +,   "U    N0   +T   #!    Q@   ,L   #1"@  TQ0  -$E  #0.P
MS50  ,IQ  #(D@  Q;,  ,/> "EB   <:0  $7$   =[    A    (T   "5
M    G0   *,   "I    KP   +0   "Y    O    +X   #"    Q0   ,@
M  #,    T    -0   #:    WP   .0   #J    [@P  .T:  #L+P  ZDD
M .AE  #FA@  Y*4  .+& /\   #_    _P   /P  0#\  @ _@ . /\ % #_
M !T _P F /\ , #_ #H _P!" /\ 20#^ %  ^P!6 /D 7 #V &( ] !H /(
M;P#P '8 [0!_ .H B0#G )4 Y "C .  M0#; -  U0#V ,H _P"V /\ J #_
M )\ _P": /\ E@#_ /\   #[    ]@   /,   #S    ]@ ) /H #@#] !8
M^P @ /< *@#R #, [0 [ .D 0P#F $D X@!/ -X 50#; %L U@!@ -( 9P#/
M &X S !V ,D @ #& (P P@": +\ J@"[ ,$ N #I +8 _P"G /\ F@#_ )(
M_P"- /\ B@#_ /H   #Q    Z@   .<   #G    Y  ! .  "P#; !$ V@ :
M -L (P#1 "P R@ T ,8 .P#" $( OP!( +P 3@"Z %, N !9 +8 7P"S &8
ML0!N *X =P"L (, J0"1 *8 H0"C +4 H #8 )X ^P"5 /\ BP#_ (4 _P"
M /\ ?@#_ .\   #C    V@   -,   #&    OP   +D !@"W  X M  4 +0
M'0"S "4 K@ M *L - "G #L I !! *$ 1@"? $P G0!1 )L 5P"9 %X EP!E
M )4 ;@"3 'D D "' (X EP", *D B0#$ (@ [P"% /\ ? #_ '8 _P!S /\
M<@#_ .    #0    Q@   +8   "I    H0   )T  0"9  H F  0 )@ %@"7
M !X E  F )$ +0"/ #0 C  Z (H /P"( $4 AP!* (4 4 "# %8 @0!> (
M9@!^ '$ ? !] 'D C0!W *  =0"V ', WP!R /\ ;@#_ &D _P!G /\ 90#_
M ,P   "^    JP   )T   "3    B@   (4   ""  4 @  - '\ $0!_ !@
M@  @ 'T )@!Z "T =P S '4 . !T #X <@!# '  20!O $\ ;0!6 &P 7@!J
M &@ : !U &< A !E )8 9 "K &( R0!A /8 8 #_ %P _P!; /\ 6@#_ +T
M  "I    EP   (D   !^    >    ',   !O  $ ;0 ) &P #@!K !, :P 9
M &H ( !H "8 9@ L &4 ,@!C #< 8@ \ &  0@!? $@ 70!/ %P 5P!: &$
M60!M %< >P!6 (X 50"B %, NP!2 .D 4@#_ %  _P!/ /\ 3P#_ *T   "8
M    A@   '@   !N    9P   &,   !@    70 % %P "P!; !  6P 5 %L
M&P!: "$ 6  F %8 + !4 #$ 4P V %( / !1 $( 3P!) $X 40!- %L 2P!F
M $H = !) (4 2 "9 $< L0!& -@ 1@#\ $4 _P!% /\ 10#_ )\   ")
M>    &P   !B    6P   %8   !3    40 " $\ " !/  T 3@ 1 $X %@!-
M !P 3  A $H )@!) "P 2  Q $< -P!% #T 1 !$ $, 3 !" %4 0 !@ #\
M;@ ^ 'X /0"2 #P J0 [ ,< .P#S #L _P [ /\ / #_ ),   !^    ;@
M &$   !8    40   $P   !)    1P   $4 !0!$  L 0P . $, $@!# !<
M0@ = $  (@ _ "< /@ L #T ,@ [ #@ .@ _ #D 1P X %  -P!; #4 :  T
M '@ ,P", #( H@ Q +P ,0#G #$ _P R /\ ,P#_ (D   !V P  9@4  %D'
M  !0!P  208  $,%  !  P  /@$  #P  P [  @ .@ - #H $  Y !0 .0 9
M #< '@ V ", -0 H #0 +@ S #0 ,@ [ #  0P O $P +@!7 "T 9  L ',
M*P"' "H G  I +4 *0#< "D ^P I /\ *@#_ ($$  !N"   7PH  %,+  !*
M"P  0@L  #T*   Y"0  -@@  #4%   T @8 ,P * #( #@ Q !$ ,0 5 #
M&@ O !\ +@ D "P *@ K #  *@ W "D /P H $D )P!4 "8 8  D &\ (P""
M "( EP A *X (0#, "$ \P A /\ (@#_ 'L)  !H#   6@T  $X.  !%#@
M/0X  #@-   S#0  , P  "X+   M"0, +08( "P$#  K @\ *@$2 "D!%P H
M 1P )P A "8 )P E "T )  T ",!/0 B 48 (0%1 !\!70 > 6P ' %_ !L
ME  : *H &@#% !H ZP 9 /\ &@#_ '4,  !D#@  50\  $H0  ! $   .1
M #,0   O#P  + X  "D.   G#0$ )PP% "<*"@ F" T )0<0 "0&%  B!AD
M(08? " ')  ?!RL '@<R !T'.@ <"$0 &@A/ !D(7  7"&L %@A] !4'D0 4
M!Z< $P:_ !(%Y  2!?H $@7_ '$.  !?$   41$  $82   ]$@  -A(  # 2
M   K$0  *!$  "40   C$   (@X$ "$-!P A# L ( L. !\+$@ ="Q< ' P<
M !L,(@ :#"D &0PQ !@,.0 6#4, %0U/ !,-7  2#6L $ U^  \-D@ .#:<
M#0R^  T,X  -#/4 #0S_ &T0  !<$0  3A,  $,4   Z%   ,A0  "T4   H
M$P  )1,  "(2   @$0  'A$# !P0!0 <#P@ &P\, !H.$  9#Q0 %P\: !8/
M(0 5$"@ %! P !(0.0 1$$0 $!!0  X070 -$&L #!!\  L0D  )$*4 "!"\
M  <0WP '$/0 !P__ &D1  !8%   2Q4  $ 6   W%@  ,!8  "H6   F%0
M(A4  !\4   =$P  &A," !D2!  7$@8 %A(* !42#@ 4$A( $A(8 !$3'@ 1
M$R4 $!,N  X3-P -%$  #!1+  L46  )%&< !Q1X  84C0 $%*,  Q.[  (3
MW0 !$O0  A+_ &43  !5%@  2!<  #T8   T&   +1@  "@8   C%P  (!<
M !T6   :%0  &!4" !85!  4%04 $A8( !$6#0 0%Q  #A<5  X7&P -%R(
M#!<I  L8,@ )&#P !QA'  485  $&&,  AAU  $8BP  %Z$  !>Y   7W0
M%O4  !;_ &$6  !2&   11H  #L:   R&@  *QH  "4:   A&0  'A@  !L8
M   8%P  %A<" !07 P 2& 4 $!D'  X;"P ,&P\ "QL3  H;&  ('!\ !QPF
M  4<+P $'#@  AQ$   =40  '6   !UR   <B   '*   !NY   ;W@  &O8
M !K_ %X8  !/&@  0AP  #@<   O'0  *1P  ",<   ?&P  '!H  !D9   7
M&0$ %!D" !(: P 0&P0 #AT'  P>"P )'PX !B 1  4@%@ #(!P  2$C   A
M*P  (34  "%    A3@  (5T  "%O   AA@  ()X  ""X   ?W@  'O@  ![_
M %H;  !+'0  /QX  #4?   M'P  )QX  "(=   >'0  &QP  !@;   5&P
M$AP  ! = @ .'P0 #"$&  DB"@ %(PT  B00   E$P  )1D  "8@   F*
M)C(  "8]   F2@  )EH  "9L   F@P  )9P  "6W   DWP  (_D  "/_ %4>
M  !'(   /"$  #(A   K(0  )2   " ?   ='@  &AT  !8>   3'@  $"
M  XA   ,(P( ""4%  4G"0  * L  "H.   K$0  +!8  "P=   L)0  +"X
M "PZ   L1P  +%8  "QI   L@   *YH  "JU   IWP  *?L  "C_ %$B  !$
M(P  ."0  "\D   H(P  (R(  !\A   <(   %R   !,A   0(P  #B0   LF
M   (*   !"H$   L!P  +@D  # ,   Q#P  ,Q,  #,9   S(0  ,RH  #,U
M   S0P  ,U(  #-E   R>P  ,I<  #&S   PW@  +_L  "[_ $PE   _)@
M-2<  "TF   G)0  (B0  !XC   9(P  %"0  !$F   .*   "RH   <L   #
M+P   #$"   S!   -0<  #<*   Y#0  .A   #L5   ['0  .R8  #LQ   [
M/@  .TX  #M@   Z=P  .9(  #BP   WVP  -OP  #7_ $<I   [*@  ,BH
M "LI   E)P  (28  !LG   5*   $2H   XL   *+P  !C$   $T    -@
M #@    [ 0  /00  #\'  !!"@  0PX  $41  !%&   12$  $4L  !$.0
M1$@  $1;  !#<0  0HT  $&K  ! T@  /_H  #[_ $(M   X+@  +RT  "DK
M   D*@  '2H  !<L   1+@  #3$   DT   $-P   #H    \    /P   $$
M  !$    1@   $@#  !*!P  3 L  $X.  !0$P  4!P  % G  !/-   3T,
M $]5  !.:@  388  $RD  !*R@  2?@  $C_ #XR   U,0  +B\  "DN   @
M+@  &3$  !(S   .-P  "3H   (]    0    $0   !'    20   $P   !/
M    40   %,   !5 0  6 8  %H+  !=#@  7Q4  %X@  !>+   73P  %Q.
M  !;8P  6GX  %B=  !7P   5?(  %3_ #HV   S-   +3(  "0S   ;-@
M$SD   X]   (00   $4   !)    3    %    !3    5@   %D   !;
M70   &    !B    90   &@%  !K"P  ;Q   &\8  !N)0  ;30  &U&  !K
M6P  :G4  &B4  !FM@  9.D  &+_ #@Y   R-P  *#D  !X[   5/P  #D0
M  =)    30   %(   !6    6@   %X   !B    90   &@   !K    ;0
M '    !S    =@   'D   !]!   @0L  (41  "$'0  @BP  ( ^  !^5
M?FL  'N*  !ZJ@  =]8  '7] #@]   L/@  (D$  !=&   /2P  !U$   !7
M    7    &(   !F    :P   &\   !T    >    'L   !^    @    (,
M  "&    B@   (T   "1    E@,  )L,  "=$P  FR$  )HS  "720  E&(
M )-_  "0H   CL4  (SS #%$   E2   &DT  !!3   (6@   &$   !H
M;@   '0   !Y    ?P   (0   ")    C0   )$   "3    E@   )D   "=
M    H    *0   "H    K    +(#  "W#0  MQ<  +4H  "R/@  L%8  *QS
M  "JE   J;0  *7E "I/   >5   $EL   IB    :@   ',   ![    @@
M (D   ".    E    )H   "?    I    *8   "I    K0   +    "S
MMP   +L   #     Q0   ,L   #1!   U0X  -,=  #0,@  S4L  ,IF  #&
MAP  PJD  ,'+ ");   68@  #&L   %T    ?0   (<   "0    EP   )X
M  "D    JP   +$   "V    N@   +P   #     Q    ,@   #+    SP
M -0   #:    X    .8   #K    \08  / 3  #N)P  [#\  .I;  #G>@
MY)L  ."[ /\   #[    ]@   /,   #T  4 ]@ , /H $0#_ !D _P B /\
M+ #_ #4 _P ] /\ 10#\ $P ^@!2 /< 6 #U %X \P!D /$ :@#N '( [ !Z
M .D A0#E )$ X0"@ -T L@#8 ,X T@#V ,$ _P"M /\ G@#_ )8 _P"0 /\
MC #_ /H   #R    [    .D   #I    [  % /( # #X !( ]P ; /4 )0#P
M "X ZP W .8 /@#B $4 W0!+ -@ 4 #3 %8 T !< ,T 8@#* &H R !R ,4
M? #" (@ O@"6 +H J "W +\ M #H *X _P"= /\ D #_ (@ _P"# /\ @ #_
M /    #E    W@   -H   #;    W    -@ !P#1  X T0 5 -( '@#+ "<
MQ0 O ,  -P"] #T N@!$ +< 20"U $\ L@!5 +  6P"N &$ K !I *D <P"G
M '\ I "- *$ G@"> +( FP#5 )D _ ", /\ @@#_ 'L _P!V /\ = #_ .(
M  #3    R@   ,<   "\    M@   +   0"O  L K  1 *T & "M "  J  H
M *0 +P"@ #8 G0 \ )L 0@"9 $< EP!- )4 4P"3 %D D0!A (\ :@", '4
MB@"# (@ E "& *< @P#" (( \ !\ /\ <P#_ &T _P!J /\ : #_ ,\   #!
M    N0   *T   "@    F    )0   "1  8 D  - )  $@"/ !D C@ A (L
M* "( "\ A@ U (0 .@"" $  @ !% 'X 2P!\ %( >@!9 '@ 8@!V &P = !Y
M '( B0!Q )T ;P"T &T WP!L /\ 90#_ &  _P!> /\ 7 #_ +X   "Q
MH    )(   ")    @@   'P   !Z  $ >  ) '< #@!X !0 =P : '0 (0!R
M "< <  M &X ,P!L #@ :P ^ &D 1 !H $H 9@!1 &0 6@!C &0 80!P %\
M?P!> ), 70"I %P R !; /< 5P#_ %0 _P!2 /\ 40#_ +    "?    C0
M '\   !T    ;@   &H   !F    90 $ &, "P!C !  8P 5 &, &P!A "$
M7P G %T + !< #( 6@ W %D /0!7 $, 5@!+ %4 4P!3 %P 4@!H %  =P!/
M (D 3@"? $T N@!, .D 2P#_ $D _P!' /\ 1P#_ *(   "-    ?    &X
M  !E    7@   %D   !7    50 ! %0 !P!3  T 4P 1 %0 %@!2 !L 40 A
M $\ )@!. "L 3  Q $L -P!* #T 20!$ $< 3 !& %8 1 !A $, < !" ($
M00"7 $  KP _ -< /P#_ #X _P ] /\ /@#_ )0   !_    ;P   &,   !9
M    40   $T   !*    2    $< ! !'  H 1@ . $8 $0!' !8 10 < $0
M(0!" "8 00 K $  ,0 ^ #< /0 ^ #P 1P Z %  .0!; #@ :0 W 'H -@"/
M #4 IP U ,8 - #U #0 _P T /\ -0#_ (@   !T    90   %@   !/
M2    $,    _    /0   #P  @ \  < .P , #L #P [ !( .@ 7 #D '  W
M "$ -@ F #4 +  T #( ,P Y #$ 00 P $L +P!6 "X 8P M ', + "( "P
MH  K +L *P#J "L _P K /\ + #_ '\   !L    70$  %$"  !( P  0 ,
M #L"   W    -    #,    R  4 ,@ ) #( #0 Q !  ,0 3 #  &  O !T
M+0 B "P *  K "X *@ U "D /0 H $8 )P!1 "8 7@ E &X ) "" ", F0 C
M +, (@#> "( _P C /\ ) #_ '<   !E!   5@8  $L'  !""   .@@  #4'
M   P!@  +04  "P#   K  , *@ ' "D "P I  X *0 1 "@ %0 G !D )@ >
M "4 )  D "H (P Q "( .0 A $, ( !. !\ 6@ > &D '0!\ !P DP ; *P
M&P#- !L ]@ ; /\ ' #_ ' %  !?"   40H  $8+   ]"P  -0L  # +   K
M"@  * D  "4(   D!P( (P0& ",""0 B 0P (@ / "$ $@ @ !8 'P ; !X
M(  = "8 '  N !L -@ : #\ &0!* !@ 5P 7 &8 %@!X !4 CP 5 *8 % ##
M !0 [@ 4 /\ %0#_ &L(  !;"P  30P  $(-   Y#0  ,0T  "P-   G#0
M(PP  "$,   ?"P$ '@H% !T("  =!@L ' 4- !P$$  ;!!0 &008 !D$'@ 8
M!", %P0K !8$,P 5!#P % 1' !,#5  2 V, $0-U ! "B@ 0 :( #P"\  \
MY0 / /X $ #_ &<+  !7#0  20X  #X/   U#P  +@\  "@/   D#@  ( X
M !T.   ;#0$ &0T$ !@,!P 8"PD %PD, !<)#@ 6"1( %0D6 !0)&P 3"2$
M$@DH !(),  1"3H $ E%  \)4@ ."6$ #0ES  P(B  +")\ "@>W  H&VP *
M!?8 "@3_ &,-  !3#@  1A   #L1   R$0  *Q$  "40   A$   '1   !H/
M   8#P$ %@X$ !4.!P 4#0D $PT+ !,,#0 2#!  $0P4 ! ,&0 0#!\ #PPG
M  X-+P -#3D # U%  L-40 )#6  " UQ  8-A@ %#9T ! RT  ,,T@ "#/$
M @O_ %\.  !0$   0Q$  #@2   O$@  *!(  ",2   >$0  &Q$  !@1   5
M$ ( %! % !(0!P 1#PD $ \* ! .#  .#@X #@\2  T/%P ,$!T #! D  H0
M+  )$#8 "!!!  803@ %$%T  Q!O  $0A   $)P   ^T   .U   #O,   [_
M %P0  !-$@  0!,  #84   M%   )A0  "$3   <$P  &1(  !82   4$0,
M$A$& !$1"  0$ H #A +  T1"P ,$0T "Q(1  H2%0 )$AH "!(A  83*0 %
M$S,  Q,^  (32P  $UH  !-L   3@@  $IL  !*T   1UP  $?4  !'_ %@2
M  !)%   /14  #,6   K%@  )!4  !\5   :%   %Q0  !03 0 3$@0 $1('
M ! 2"0 .$@D #1()  L3"@ )% T !Q4/  86$P $%A@  Q8?  (6)P  %S
M !<[   72   %U@  !=J   6@   %ID  !6T   5V0  %/<  !/_ %44  !&
M%@  .A<  # 8   H&   (A<  !T6   9%@  %A4  !,4 P 2$P8 $!,'  \3
M!P -% < "Q4(  D6"0 && P  QH.  $:$0  &A8  !L<   ;)   &RT  !LX
M   ;1@  '%4  !MG   ;?0  &Y<  !JS   9VP  &/D  !?_ %$6  !#&
M-QD  "X:   F&@  (!D  !L8   8%P  %18! !,5!0 1%00 #Q4$  T6!  +
M%P4 "1D&  8:"  "' H  !X-   @$   (!,  " 9   @(0  (2H  "$U   A
M0@  (5(  "!D   @>@  'Y4  !^Q   >VP  '?H  !S_ $T9   _&P  -!P
M "L<   D'   'AL  !H:   7&   %!<" !(7 @ 0& $ #1D!  L: @ (' ,
M!1T$  (?!@  (0@  ",+   E#@  )A$  "86   F'@  )R<  "<R   G/P
M)DX  "9@   F=P  )9(  "2O   CV@  (OL  "'_ $@=   \'@  ,1\  "@>
M   B'@  '1P  !D;   6&@  $AH  ! ;   -'   "QT   @?   $(0   2,"
M   E!   )P8  "D)   L#   +@\  "X3   N&@  +B,  "XN   N.P  +DH
M "U<   M<@  +(X  "NL   JU   *?L  "C_ $0@   X(0  +B$  "8A   @
M(   '!X  !@=   4'0  $!X   X?   +(0  !R,   ,E    )P   "D    L
M 0  +@,  # &   S"@  -0T  #81   V%P  -A\  #8I   V-@  -D4  #57
M   U;0  -(D  #*H   QSP  ,/H  "__ #\D   T)   *R0  "0C   ?(0
M&R   !8@   1(0  #B,   HE   &*    BH    M    +P   #(    T
M-P   #D#   [!@  /@H  $ .  !!$@  01H  $ E  ! ,0  0$   #]2   ^
M9P  /8(  #RB   ZQP  .?@  #C_ #HH   P*   *2<  ",E   ?(P  &"0
M !(E   .*   "BH   4M    ,    #,    V    .    #L    ^    0
M $(   !% @  1P8  $H*  !-#@  314  $P?  !,*P  2SH  $I,  !)80
M2'P  $>;  !%OP  0_,  $+_ #8L   M*P  )RD  ",G   ;*   %"H   XM
M   *,   !#,    W    .@   #T   !     0P   $8   !(    2P   $T
M  !0    4P$  %8&  !9"P  6Q   %L9  !:)0  630  %A&  !76@  570
M %23  !2M0  4.H  $__ #,P   L+@  )RP  !XM   6+P  $#(   HV   #
M.@   #\   !"    1@   $D   !,    3P   %(   !5    6    %H   !=
M    8    &,   !G!@  :PP  &P2  !K'@  :RP  &D]  !G4@  9FH  &2)
M  !AJP  7]P  %W_ #$S   L,0  (C(  !DU   1.0  "CT   )"    1P
M $P   !0    5    %@   !;    7P   &(   !E    :    &L   !N
M<0   '4   !Y    ?08  ((-  ""%@  @"0  'XU  !\20  >V$  'A_  !V
MGP  <\8  '#W #$V   F.   '#L  !)    +10   DL   !1    5@   %L
M  !@    90   &D   !N    <@   '8   !Y    ?    'X   ""    A0
M (D   ".    DP   )@&  "<#@  FQH  )@K  "60   DED  )%S  "-E0
MB[4  (CH "L^   @00  %4<   U-   "5    %L   !A    :    &X   !S
M    >0   'X   "#    B    (P   "/    D@   )4   "9    G0   *$
M  "E    J@   +    "W!P  N!$  +4A  "R-0  KTT  *II  "HB   IJ@
M *+1 "-(   83@  #E0   1<    9    &T   !U    ?    (,   ")
MCP   )4   ";    H    *,   "F    J0   *T   "Q    M0   +D   "^
M    Q    ,H   #2    V@H  -86  #2*0  SD$  ,I<  #%?   PIT  ,&]
M !Q5   17   !V4   !N    =P   '\   "(    D    )@   "?    I0
M *T   "S    N    +H   "^    P@   ,8   #*    S@   -,   #:
MX    .<   #M    \P   /0.  #R'@  [S8  .Q1  #H;@  Y)   -^Q
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M______________________________________\
M 0,$!08("0H+#0X/$1(3%!87&!H;'!T?("$B)"4F*"DJ*RTN+S R,S0V-S@Y
M.SP]/D!!0D1%1D=)2DM-3D]04E-455=865M<75Y@86)C969G:6IK;&YO<'%S
M='5W>'EZ?'U^@(&"@X6&AXB*BXR.CY"1DY25EIB9FIR=GI^AHJ.DIJ>HJJNL
MK:^PL;.TM;:XN;J[O;Z_P<+#Q,;'R,G+S,W/T-'2U-76U]G:V]W>W^#BX^3F
MY^CIZ^SM[O#Q\O3U]O?Y^OO\_O__________________________________
M____________________                      $#! 4&" D*"PT.#Q$2
M$Q06%Q@:&QP='R A(B0E)B@I*BLM+B\P,C,T-C<X.3L\/3Y 04)$149'24I+
M34Y/4%)35%576%E;7%U>8&%B8V5F9VEJ:VQN;W!Q<W1U=WAY>GQ]?H"!@H.%
MAH>(BHN,CH^0D9.4E9:8F9J<G9Z?H:*CI*:GJ*JKK*VOL+&SM+6VN+FZN[V^
MO\'"P\3&Q\C)R\S-S]#1TM35UM?9VMO=WM_@XN/DYN?HZ>OL[>[P\?+T]?;W
M^?K[_/[_____________________________________________________
M_P ! @,$!08'" D*"PP-#@\0$1(3%!46%Q@9&AL<'1X?("$B(R0E)B<H*2HK
M+"TN+S Q,C,T-38W.#DZ.SP]/C] 04)#1$5&1TA)2DM,34Y/4%%24U155E=8
M65I;7%U>7V!A8F-D969G:&EJ:VQM;F]P<7)S='5V=WAY>GM\?7Y_@(&"@X2%
MAH>(B8J+C(V.CY"1DI.4E9:7F)F:FYR=GI^@H:*CI*6FIZBIJJNLK:ZOL+&R
ML[2UMK>XN;J[O+V^O\#!PL/$Q<;'R,G*R\S-SL_0T=+3U-76U]C9VMO<W=[?
MX.'BX^3EYN?HZ>KK[.WN[_#Q\O/T]?;W^/GZ^_S]_O]M9G0Q      ,$(0
M 0                    $                    !     0(#! 4&!P@)
M"@L,#0X/$!$2$Q05%A<8&1H;'!T>'R A(B,D)28G*"DJ*RPM+B\P,3(S-#4V
M-S@Y.CL\/3X_0$%"0T1%1D=(24I+3$U.3U!14E-455976%E:6UQ=7E]@86)C
M9&5F9VAI:FML;6YO<'%R<W1U=G=X>7I[?'U^?X"!@H.$A8:'B(F*BXR-CH^0
MD9*3E)66EYB9FIN<G9Z?H*&BHZ2EIJ>HJ:JKK*VNK["QLK.TM;:WN+FZN[R]
MOK_ P<+#Q,7&Q\C)RLO,S<[/T-'2T]35UM?8V=K;W-W>W^#AXN/DY>;GZ.GJ
MZ^SM[N_P\?+S]/7V]_CY^OO\_?[_  $! @(# P0$!08&!P<(" D)"@L+# P-
M#0X/#Q 0$1$2$Q,4%!46%A<7&!D9&AH;'!P='AX?(" A(B(C)"0E)B8G*"DI
M*BLL+2TN+S Q,C(S-#4V-S@Y.CL\/3X_0$)#1$5&2$E*3$U/4%)355=86EQ>
M8&)D9FAJ;6]Q='9Y?'Z!@X:)BXZ0DI67F9N=GZ&CI:>HJJRMK["RL[6VM[FZ
MN[R]O\#!PL/$Q<;'R,G*R\S-S<[/T-'2TM/4U=;6U]C9V=K;V]S=W=[?W^#A
MX>+CX^3EY>;FY^CHZ>GJZ^OL[.WN[N_O\/#Q\O+S\_3T]?;V]_?X^/GY^OO[
M_/S]_?[^_P ! 0(" P,$! 4&!@<'" @)"0H+"PP,#0T.#P\0$!$1$A,3%!05
M%A87%Q@9&1H:&QP<'1X>'R @(2(B(R0D)28F)R@I*2HK+"TM+B\P,3(R,S0U
M-C<X.3H[/#T^/T!"0T1%1DA)2DQ-3U!24U576%I<7F!B9&9H:FUO<71V>7Q^
M@8.&B8N.D)*5EYF;G9^AHZ6GJ*JLK:^PLK.UMK>YNKN\O;_ P<+#Q,7&Q\C)
MRLO,S<W.S]#1TM+3U-76UM?8V=G:V]O<W=W>W]_@X>'BX^/DY>7FYN?HZ.GI
MZNOK[.SM[N[O[_#P\?+R\_/T]/7V]O?W^/CY^?K[^_S\_?W^_O__I24&_Z0P
M#O^F.AC_L4,C_[M+,O_!547^PUY:\L1E<.3";(;7NG"9S+)TJL.K=K>]IGG"
MMZ%]R[&=@M.KFHG<I9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:E
MEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>;_I24&_Z0P#O^F
M.AC_L4,C_[M+,O_!547^PUY:\L1E<.3";(;7NG"9S+)TJL.K=K>]IGG"MZ%]
MR[&=@M.KFHG<I9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7F
MI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>;_I24&_Z0P#O^F.AC_
ML4,C_[M+,O_!547^PUY:\L1E<.3";(;7NG"9S+)TJL.K=K>]IGG"MZ%]R[&=
M@M.KFHG<I9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5
MYJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>;_I24&_Z0P#O^F.AC_L4,C
M_[M+,O_!547^PUY:\L1E<.3";(;7NG"9S+)TJL.K=K>]IGG"MZ%]R[&=@M.K
MFHG<I9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67
ME>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>;_I24&_Z0P#O^F.AC_L4,C_[M+
M,O_!547^PUY:\L1E<.3";(;7NG"9S+)TJL.K=K>]IGG"MZ%]R[&=@M.KFHG<
MI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:E
MEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>;_I24&_Z0P#O^F.AC_L4,C_[M+,O_!
M547^PUY:\L1E<.3";(;7NG"9S+)TJL.K=K>]IGG"MZ%]R[&=@M.KFHG<I9>5
MYJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7F
MI9>5YJ67E>:EEY7FI9>5YJ67E>;_I24&_Z0P#O^F.AC_L4,C_[M+,O_!547^
MPUY:\L1E<.3";(;7NG"9S+)TJL.K=K>]IGG"MZ%]R[&=@M.KFHG<I9>5YJ67
ME>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5
MYJ67E>:EEY7FI9>5YJ67E>;_I24&_Z0P#O^F.AC_L4,C_[M+,O_!547^PUY:
M\L1E<.3";(;7NG"9S+)TJL.K=K>]IGG"MZ%]R[&=@M.KFHG<I9>5YJ67E>:E
MEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67
ME>:EEY7FI9>5YJ67E>;_I24&_Z0P#O^F.AC_L4,C_[M+,O_!547^PUY:\L1E
M<.3";(;7NG"9S+)TJL.K=K>]IGG"MZ%]R[&=@M.KFHG<I9>5YJ67E>:EEY7F
MI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:E
MEY7FI9>5YJ67E>;_I24&_Z0P#O^F.AC_L4,C_[M+,O_!547^PUY:\L1E<.3"
M;(;7NG"9S+)TJL.K=K>]IGG"MZ%]R[&=@M.KFHG<I9>5YJ67E>:EEY7FI9>5
MYJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7F
MI9>5YJ67E>;_I24&_Z0P#O^F.AC_L4,C_[M+,O_!547^PUY:\L1E<.3";(;7
MNG"9S+)TJL.K=K>]IGG"MZ%]R[&=@M.KFHG<I9>5YJ67E>:EEY7FI9>5YJ67
ME>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5
MYJ67E>;_I24&_Z0P#O^F.AC_L4,C_[M+,O_!547^PUY:\L1E<.3";(;7NG"9
MS+)TJL.K=K>]IGG"MZ%]R[&=@M.KFHG<I9>5YJ67E>:EEY7FI9>5YJ67E>:E
MEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67
ME>;_I24&_Z0P#O^F.AC_L4,C_[M+,O_!547^PUY:\L1E<.3";(;7NG"9S+)T
MJL.K=K>]IGG"MZ%]R[&=@M.KFHG<I9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7F
MI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>;_
MI24&_Z0P#O^F.AC_L4,C_[M+,O_!547^PUY:\L1E<.3";(;7NG"9S+)TJL.K
M=K>]IGG"MZ%]R[&=@M.KFHG<I9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5
MYJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>;_I24&
M_Z0P#O^F.AC_L4,C_[M+,O_!547^PUY:\L1E<.3";(;7NG"9S+)TJL.K=K>]
MIGG"MZ%]R[&=@M.KFHG<I9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67
ME>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>;_I24&_Z0P
M#O^F.AC_L4,C_[M+,O_!547^PUY:\L1E<.3";(;7NG"9S+)TJL.K=K>]IGG"
MMZ%]R[&=@M.KFHG<I9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:E
MEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>;_I24&_Z0P#O^F
M.AC_L4,C_[M+,O_!547^PUY:\L1E<.3";(;7NG"9S+)TJL.K=K>]IGG"MZ%]
MR[&=@M.KFHG<I9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7F
MI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>;_IB4&_Z0P#O^G.AC_
MLD,B_[Q+,O_#5$7\QEU:\<AD<>/&:H?6P&^;R[ARK,*Q=+J[K7?$M*E[S:NC
M?]2BGH7;F9J.X9F:CN&9FH[AF9J.X9F:CN&9FH[AF9J.X9F:CN&9FH[AF9J.
MX9F:CN&9FH[AF9J.X9F:CN&9FH[AF9J.X9F:CN'_IB4&_Z4P#O^H.A?_LT,B
M_[Y+,?_%5$7YR5Q;[\UC<>/,:8C5QFV<R;]PKKVV<KJTL'7#JZIXRJ*E?-&9
MH8'8D)V)W9"=B=V0G8G=D)V)W9"=B=V0G8G=D)V)W9"=B=V0G8G=D)V)W9"=
MB=V0G8G=D)V)W9"=B=V0G8G=D)V)W9"=B=W_IB4&_Z4P#O^J.A?_M4,B_\!+
M,?W(4T7VS5M;[=%A<N'09XG1RVN=PL!NK;:W<;BLL7/!HZQVR)JH><Z2I'[4
MB:"%V(F@A=B)H(78B:"%V(F@A=B)H(78B:"%V(F@A=B)H(78B:"%V(F@A=B)
MH(78B:"%V(F@A=B)H(78B:"%V(F@A=C_IR4&_Z4P#O^K.A?_MD,A_\%+,?K+
M4D3ST5I:ZME@<M[698G+S&J<N\%MJZ^Y<+:EM'*^G*]TQ)2K=\J+IWO/A*2!
MU(2D@=2$I('4A*2!U(2D@=2$I('4A*2!U(2D@=2$I('4A*2!U(2D@=2$I('4
MA*2!U(2D@=2$I('4A*2!U(2D@=3_IR4&_Z8P#O^M.A;_N$(A_L1*,/?.4D3P
MUEA:Y^!><M;:9(C$S6F:M,-LJ*B[;[*>MG"ZEK)RP(ZN=L:&JGK*?Z=_SG^G
M?\Y_IW_.?Z=_SG^G?\Y_IW_.?Z=_SG^G?\Y_IW_.?Z=_SG^G?\Y_IW_.?Z=_
MSG^G?\Y_IW_.?Z=_SG^G?\[_J"4&_Z<P#O^N.1;_ND(@^\9*+_3344/KW5=:
MX^9<<<[;9(>]SVF8KL5KI:*^;J^8N6^VD+5QO(BQ=,&!KGC%>ZQ]R7NL?<E[
MK'W)>ZQ]R7NL?<E[K'W)>ZQ]R7NL?<E[K'W)>ZQ]R7NL?<E[K'W)>ZQ]R7NL
M?<E[K'W)>ZQ]R7NL?<G_J"0&_Z<P#?^P.17_O4(?]\E*+^_84$+FXU59W.A;
M<,;=8X6VT6B5I\AKH9S!;:J3O&^QBKEQMH2U=+M]LG>_=[!\PG>P?,)WL'S"
M=[!\PG>P?,)WL'S"=[!\PG>P?,)WL'S"=[!\PG>P?,)WL'S"=[!\PG>P?,)W
ML'S"=[!\PG>P?,+_J20%_Z@P#?^S.13^P$(>\\U*+>G=3T#AZ5-9T^I;;[_?
M8X*OTV>1H<MJG9;%;:6-P&^KAKUQL'^Z<[5ZMW>X=+5[NW2U>[MTM7N[=+5[
MNW2U>[MTM7N[=+5[NW2U>[MTM7N[=+5[NW2U>[MTM7N[=+5[NW2U>[MTM7N[
M=+5[NW2U>[O_JB0%_ZDO#?^V.!/YQ$$=[=))*^+C34#;[U)8RNU:;;?A8G^H
MUF>-F\]JEY');9^(Q6^E@L)QJ7N_=*UVO7>P<;M[LW&[>[-QNWNS<;M[LW&[
M>[-QNWNS<;M[LW&[>[-QNWNS<;M[LW&[>[-QNWNS<;M[LW&[>[-QNWNS<;M[
MLW&[>[/_JR0%_ZLO#?^Z.!+SR4$;Y-I)*-CH3$#.\U%7P.]9:Z[D87J@W&>&
ME-1KD(O/;I>$S'"<?<ESH'C&=:-SQ'BF;L)\J6["?*ENPGRI;L)\J6["?*EN
MPGRI;L)\J6["?*ENPGRI;L)\J6["?*ENPGRI;L)\J6["?*ENPGRI;L)\J6["
M?*G_K20%_[ O"_O . _JT$$7VN)&*,SN3$'#^5!5M?-89J7I8727X6=^C=MK
MAH77;XQ_U'*1>M%UE'7/>)=QS7N:;,Q^G&S,?IQLS'Z<;,Q^G&S,?IQLS'Z<
M;,Q^G&S,?IQLS'Z<;,Q^G&S,?IQLS'Z<;,Q^G&S,?IQLS'Z<;,Q^G&S,?IS_
MKR,$_[8M"?'(-@S=W#T3S>I&*L'V2T"V_T]1JO=88)OO86N/Z&ATA>1M>W_@
M<8!YWG2#==QXAG+:>XENV'Z+:]:"C6O6@HUKUH*-:]:"C6O6@HUKUH*-:]:"
MC6O6@HUKUH*-:]:"C6O6@HUKUH*-:]:"C6O6@HUKUH*-:]:"C6O6@HW_L2,$
M^K\L!N/4+P?.YCL6P?-%*[3_23VH_TY,GOU76)'V86&&\6EI?^UO;GGJ=')U
MZ'=U<>=Z=V[E?7EKY(![:>.$?&GCA'QIXX1\:>.$?&GCA'QIXX1\:>.$?&GC
MA'QIXX1\:>.$?&GCA'QIXX1\:>.$?&GCA'QIXX1\:>.$?&GCA'S_M2(#Z\LB
M M#C)P?"\3H9M/Y"*J;_1CF;_TU%DO]63X;^8E9^^FI<=_=P8'/U=6-O\WAE
M;?)\9VKQ?VAH\()J9N^%:V;OA6MF[X5K9N^%:V;OA6MF[X5K9N^%:V;OA6MF
M[X5K9N^%:V;OA6MF[X5K9N^%:V;OA6MF[X5K9N^%:V;OA6OVPAL!U-\1 <+O
M)@NU_#H:I_\^)YG_1#.-_TL]A?]517S_84MU_VI/</]P4FS_=51J_GE6:/U\
M5V;\?UAD_():8_N&6V/[AEMC^X9;8_N&6V/[AEMC^X9;8_N&6V/[AEMC^X9;
M8_N&6V/[AEMC^X9;8_N&6V/[AEMC^X9;8_N&6V/[AEO4SPH Q.T2 K7[)@VH
M_S89F?\[(XS_02R _THT>/]3.G'_7S]L_VE#:/]O167_=$=C_W=(8O][26'_
M?DI?_X%*7O^$2U[_A$M>_X1+7O^$2U[_A$M>_X1+7O^$2U[_A$M>_X1+7O^$
M2U[_A$M>_X1+7O^$2U[_A$M>_X1+7O^$2U[_A$O_GR(%_YTM#/^>.!7_J$$>
M_[%)*_^V4SS_N%U/^[9F8^ZT;W?BK'6)V*1[F<Z;?Z;(DX2QPHV(N;Z(C+^Z
M@Y'%MW^7R[1]H,^N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YY
MI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-'_GR(%_YTM#/^>.!7_J$$>_[%)
M*_^V4SS_N%U/^[9F8^ZT;W?BK'6)V*1[F<Z;?Z;(DX2QPHV(N;Z(C+^Z@Y'%
MMW^7R[1]H,^N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N
M>:31KGFDT:YYI-&N>:31KGFDT:YYI-'_GR(%_YTM#/^>.!7_J$$>_[%)*_^V
M4SS_N%U/^[9F8^ZT;W?BK'6)V*1[F<Z;?Z;(DX2QPHV(N;Z(C+^Z@Y'%MW^7
MR[1]H,^N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31
MKGFDT:YYI-&N>:31KGFDT:YYI-'_GR(%_YTM#/^>.!7_J$$>_[%)*_^V4SS_
MN%U/^[9F8^ZT;W?BK'6)V*1[F<Z;?Z;(DX2QPHV(N;Z(C+^Z@Y'%MW^7R[1]
MH,^N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFD
MT:YYI-&N>:31KGFDT:YYI-'_GR(%_YTM#/^>.!7_J$$>_[%)*_^V4SS_N%U/
M^[9F8^ZT;W?BK'6)V*1[F<Z;?Z;(DX2QPHV(N;Z(C+^Z@Y'%MW^7R[1]H,^N
M>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YY
MI-&N>:31KGFDT:YYI-'_GR(%_YTM#/^>.!7_J$$>_[%)*_^V4SS_N%U/^[9F
M8^ZT;W?BK'6)V*1[F<Z;?Z;(DX2QPHV(N;Z(C+^Z@Y'%MW^7R[1]H,^N>:31
MKGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N
M>:31KGFDT:YYI-'_GR(%_YTM#/^>.!7_J$$>_[%)*_^V4SS_N%U/^[9F8^ZT
M;W?BK'6)V*1[F<Z;?Z;(DX2QPHV(N;Z(C+^Z@Y'%MW^7R[1]H,^N>:31KGFD
MT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31
MKGFDT:YYI-'_GR(%_YTM#/^>.!7_J$$>_[%)*_^V4SS_N%U/^[9F8^ZT;W?B
MK'6)V*1[F<Z;?Z;(DX2QPHV(N;Z(C+^Z@Y'%MW^7R[1]H,^N>:31KGFDT:YY
MI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFD
MT:YYI-'_GR(%_YTM#/^>.!7_J$$>_[%)*_^V4SS_N%U/^[9F8^ZT;W?BK'6)
MV*1[F<Z;?Z;(DX2QPHV(N;Z(C+^Z@Y'%MW^7R[1]H,^N>:31KGFDT:YYI-&N
M>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YY
MI-'_GR(%_YTM#/^>.!7_J$$>_[%)*_^V4SS_N%U/^[9F8^ZT;W?BK'6)V*1[
MF<Z;?Z;(DX2QPHV(N;Z(C+^Z@Y'%MW^7R[1]H,^N>:31KGFDT:YYI-&N>:31
MKGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-'_
MGR(%_YTM#/^>.!7_J$$>_[%)*_^V4SS_N%U/^[9F8^ZT;W?BK'6)V*1[F<Z;
M?Z;(DX2QPHV(N;Z(C+^Z@Y'%MW^7R[1]H,^N>:31KGFDT:YYI-&N>:31KGFD
MT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-'_GR(%
M_YTM#/^>.!7_J$$>_[%)*_^V4SS_N%U/^[9F8^ZT;W?BK'6)V*1[F<Z;?Z;(
MDX2QPHV(N;Z(C+^Z@Y'%MW^7R[1]H,^N>:31KGFDT:YYI-&N>:31KGFDT:YY
MI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-'_GR(%_YTM
M#/^>.!7_J$$>_[%)*_^V4SS_N%U/^[9F8^ZT;W?BK'6)V*1[F<Z;?Z;(DX2Q
MPHV(N;Z(C+^Z@Y'%MW^7R[1]H,^N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N
M>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-'_GR(%_YTM#/^?
M.!7_JD >_[-)*_^Y4CS_NUQ/^KIE9.VX;7CAL'.+U:AYG,R??:K%EX&UOY&%
MOKJ,B<6VAX_,LH.6TJ^!H-:G?J+3IWZBTZ=^HM.G?J+3IWZBTZ=^HM.G?J+3
MIWZBTZ=^HM.G?J+3IWZBTZ=^HM.G?J+3IWZBTZ=^HM/_GR(%_YXM#/^@-Q3_
MJT >_[1)*_^[4CS_O5M0^KYD9.R\;'G@M7*-TZUWGLJD>JW"G'ZYO):"P[>0
MA\JRBXS2KH>5V*:#G=JA@J'5H8*AU:&"H=6A@J'5H8*AU:&"H=6A@J'5H8*A
MU:&"H=6A@J'5H8*AU:&"H=6A@J'5H8*AU:&"H=7_H"(%_YXM#/^A-Q3_K$ =
M_[9(*_^]43S_P%I0^L%C9>S!:GK>N7"/TK%UH<BH>+# H7N\N9M_Q[26A,^P
ME(W5JY&7VJ")G-R:B*#7FHB@UYJ(H->:B*#7FHB@UYJ(H->:B*#7FHB@UYJ(
MH->:B*#7FHB@UYJ(H->:B*#7FHB@UYJ(H-?_H"(%_YXM#/^B-Q3_K4 =_[=(
M*O^_43S_PEI0^<1B9>O%:7O>OFZ0T;9SH\:N=K.^IWG N*-_R;2AAL^LG(W5
MHY:4VIJ1G-R5CI_8E8Z?V)6.G]B5CI_8E8Z?V)6.G]B5CI_8E8Z?V)6.G]B5
MCI_8E8Z?V)6.G]B5CI_8E8Z?V)6.G]C_H"(%_Y\M#/^C-Q3_KD =_[A(*O_!
M4#S^Q5E0]\A@9NO*9WS=PVV1S[QQI<6T=+6]L'G MJQ_R*ZGA<^EH8K5G)R1
MVI69G-R/E)_8CY2?V(^4G]B/E)_8CY2?V(^4G]B/E)_8CY2?V(^4G]B/E)_8
MCY2?V(^4G]B/E)_8CY2?V(^4G]C_H2(%_Y\M#/^D-Q3_L#\<_[I(*O_#4#O[
MR%A0]<M?9NG/9GS<R6N2SL-OIL&Z<K6VLG; K*Q[R*2H?\Z<I(74E*"-V(V?
MF=N*G)_8BIR?V(J<G]B*G)_8BIR?V(J<G]B*G)_8BIR?V(J<G]B*G)_8BIR?
MV(J<G]B*G)_8BIR?V(J<G]C_H2(%_Z M#/^F-A/_L3\<_[M(*?[&3SOXRU=0
M\M!>9N?49'W:SVF3R,5MIKJ[<+2MLW._HZUVQYJH>LV2I7_2BJ*&UX2@D=F$
MHIS7A**<UX2BG->$HIS7A**<UX2BG->$HIS7A**<UX2BG->$HIS7A**<UX2B
MG->$HIS7A**<UX2BG-?_H2(%_Z M#/^G-A/_LS\<_[U'*?S(3COUSE9/[M5=
M9N3:8GW3TFB2P<9LI+.\;[&FM7*\G*]TQ).K=\J+IWO/@Z2!U'VBB]9[HY75
M>Z.5U7NCE=5[HY75>Z.5U7NCE=5[HY75>Z.5U7NCE=5[HY75>Z.5U7NCE=5[
MHY75>Z.5U7NCE=7_HB$%_Z M#/^H-A+_M#\;_[]'*/G+3CKRTU5/ZMQ;9N#@
M87W,TV>1N\AKHJR^;J^@MW"XE;)SP(VN=L6%JGK*?JA_SGBFA]%UI8_2=:6/
MTG6EC])UI8_2=:6/TG6EC])UI8_2=:6/TG6EC])UI8_2=:6/TG6EC])UI8_2
M=:6/TG6EC]+_HB$%_Z$L"_^J-A+_MCX;_<)'*/7-3CGNV51.YN-99=CB8'O%
MU6:/M,IJGZ7!;:N9NF^TD+5RNXBQ=<"!KGC%>JQ]R72JA,MQJ8O,<:F+S'&I
MB\QQJ8O,<:F+S'&IB\QQJ8O,<:F+S'&IB\QQJ8O,<:F+S'&IB\QQJ8O,<:F+
MS'&IB\S_HR$%_Z(L"_^L-1'_N3X:^<5')_#133CIX%),XNE79,[D7WJ]UV:,
MK<QJFY_$;*>3OF^OBKEQM8.V=+I\LW>^=K%\PG&O@L1NKH?&;JZ'QFZNA\9N
MKH?&;JZ'QFZNA\9NKH?&;JZ'QFZNA\9NKH?&;JZ'QFZNA\9NKH?&;JZ'QFZN
MA\;_I"$%_Z,L"_^O-1#_O#X8],E&)>K833;BYT],W.]58\;F7WBTVF6)I=!I
MEIC(;*&-PV^HA;]QKGZ[=+)XN7>V<[=[N6ZU@+QKM(6^:[2%OFNTA;YKM(6^
M:[2%OFNTA;YKM(6^:[2%OFNTA;YKM(6^:[2%OFNTA;YKM(6^:[2%OFNTA;[_
MI2$$_Z0L"_^S-0_[P3X7[<]&(N'?2S38ZT],S_-48KSH7G2KWF2$G=1ID)'.
M;9F'R6^@@,5RI7K"=*ETP'BL<+Y[KVN\@+)HNX2S:+N$LVB[A+-HNX2S:+N$
MLVB[A+-HNX2S:+N$LVB[A+-HNX2S:+N$LVB[A+-HNX2S:+N$LVB[A+/_IB$$
M_Z@K"O^X- WSQST4Y-A%'M;F237+\4Y,Q/=37['L77"AXF1]E=MIAXK5;H^"
MT'&5>\UTFG;+=YUQR7F@;<=]HFG%@:5FQ(6F9L2%IF;$A:9FQ(6F9L2%IF;$
MA:9FQ(6F9L2%IF;$A:9FQ(6F9L2%IF;$A:9FQ(6F9L2%IF;$A:;_J" $_ZXJ
M"/R_,POISSP0U^%"'LKM236_^$U*M_M26Z;Q76F8Z65TC.)J?8/=;X1\VG.)
M=]=WC'/5>H]OTWV1;-& E&C0A)9ESX>79<^'EV7/AY=ESX>79<^'EV7/AY=E
MSX>79<^'EV7/AY=ESX>79<^'EV7/AY=ESX>79<^'EV7/AY?_JB #_[4I!O#(
M,0?:W3,,R^I"(;[V2#6R_TQ&J?]159OW76".\&5JA>ML<7WG<79WY'9Z<^)Y
M?6_A?']LWX"!:=Z#@V?=AX5EW(F&9=R)AF7<B89EW(F&9=R)AF7<B89EW(F&
M9=R)AF7<B89EW(F&9=R)AF7<B89EW(F&9=R)AF7<B8;_K1\#^;\E ]_6(@++
MZ#(/OO1!(K#_13.D_TI!G/]138_^75:%^69>??1N9';R<VAR[WAK;NY\;6SM
M?V]J[()P9^J%<F7JB7-CZ8QT8^F,=&/IC'1CZ8QT8^F,=&/IC'1CZ8QT8^F,
M=&/IC'1CZ8QT8^F,=&/IC'1CZ8QT8^F,=&/IC'3_MAP"Z,T4 <SF'02^\S$2
ML?\^(J/_0B^6_T@ZC?]01(3_7$M[_V=1=/YN5F_\<UEL^WA;:?E\76?X?UYF
M^(-?9/>&8&+VB6%A]HQB8?:,8F'VC&)A]HQB8?:,8F'VC&)A]HQB8?:,8F'V
MC&)A]HQB8?:,8F'VC&)A]HQB8?:,8F'VC&+SQ \ SMH+ +WS'0>Q_S(4H_\Z
M'Y7_/RJ)_T8S@/]/.GC_6T!Q_V9%;/]M2&C_<TIF_W=,9/][36+_?TYA_X)/
M8/^%4%[_B5%>_XM17O^+45[_BU%>_XM17O^+45[_BU%>_XM17O^+45[_BU%>
M_XM17O^+45[_BU%>_XM17O^+45[_BU',RPD ON8, :__'@FD_S 3E?\U'(?_
M/"1\_T0K<_]-,6S_6#5G_V,Y8_]K.V'_<3U?_W4^7?]Y/US_?$!;_W]!6O^"
M05G_AD)8_XA"6/^(0EC_B$)8_XA"6/^(0EC_B$)8_XA"6/^(0EC_B$)8_XA"
M6/^(0EC_B$)8_XA"6/^(0EC_B$+_F1\%_Y8K"_^5-A+_H#X:_ZA')O^N433_
MKUM%_ZUE5_BI;VCMHWAYXYM_A]N2A934BXR>SX61ILN E:S'?)FQQ7F>M<)V
MH[G =*J\O7&ROKEOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^Q
MO[EOL;^Y;[&_N6^QO[EOL;__F1\%_Y8K"_^5-A+_H#X:_ZA')O^N433_KUM%
M_ZUE5_BI;VCMHWAYXYM_A]N2A934BXR>SX61ILN E:S'?)FQQ7F>M<)VH[G
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MM38/^<$_%^[.1B/DW$PRW>=/2<_H5E[ Y%URLMYD@J/4:9&5RVV<B<5PI7_
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M;47_BWA/_X:$6?R"CF'W?99H]'B=;O%THW/N<:EW[&ZN>NILLWWI:KE_YVC
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M ]#C,@S%[$ =NO%'+[#O2S^E[5%.FNM:6H_J8F6%Z&IN?>=R=77C>'MOX'Z
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M%/^50QS_FDPG_YE8,_^68S__DFY,_XYZ5_R)A6+UA(]K\'Z7<^QYGGKH=*6
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MW()1V=R"4=G<@E'9W(+_CQ,"_Z03 ?ZX$@#6S L S.01 <#O)@>U]3@5JO1
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M)3S_F24[_YXF._^>)CO_GB8[_YXF._^>)CO_GB8[_YXF._^>)CO_GB:KP0
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M14O_OD9*_]!'2?_<1TG_W$=)_]Q'2?_<1TG_W$=)_]Q'2?_<1TG_W$?1K@
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M117_=4\<_W9=(_]S;"K_<'HQ_VV'-O]KE#O_:9\__VBH0O]FL$7_9+A'_V/
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M;4S;W&Q-V.QJ3L_P9T[/\&=.S_!G3L_P9T[/\&=.S_!G3L_P9T[/\&?_CPL
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M,#[_S3 ^_\TP/O_-,#[_S3 ^_\TP/O_-,#[_S3"[L0  K+P  )_)  "3V0
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MJ#4+Z:T]$]^O1A[2J5$OQZ):/[Z;8TRUE6I7KH]R8*>+>6BAAX%NG(.(=)>
MD'B2?9E\CGRB@(MZK8*(>KN#AWK-@X=\XGR'?.=UAGSL;H9\\&F&?/!IAGSP
M:89\\&F&?/!IAGSP:89\\&G_9QP"_W49 O^%&0+_DA\"_YPE _NE+ 7PK#0)
MYK([$-NS1!W-K4\NPZ99/KF?84NPF6A6J)1P7Z&/=V>;BWYNEHB&<Y"%CGB,
M@I9\B("@@(1_JX*!?[B#?W_*A(&!X7V!@>9V@8#K;X" [VJ @.]J@(#O:H"
M[VJ @.]J@(#O:H" [VK_:!P"_W@7 O^'& +_E!T"_Y\C _BI*@3LL3$'XK<Y
M#=6W0AS)L$XMOJI7/;2C7TJKGF=5HYAN7YR4=6:6D'QMD(V#<XN*BWB&B)1\
M@8:>@'V$J()[A+6$>83'A'J&X'][A>9W>X7K<'N$[FM[A.YK>X3N:WN$[FM[
MA.YK>X3N:WN$[FO_:1L"_WH6 O^*%P+_EQP"_Z,A O2M)P/HM2X%WKTU"M"Z
M0!O$M$PLNJY6.Z^H7DFFHF54GIUL79>9<V:0E7ELBI*!<H60B7=_C9)\>XN;
M?W>*IH)TB;.#<HK$@W2,X']TB^5X=8GJ<7:([6QVB.UL=HCM;':([6QVB.UL
M=HCM;':([6S_:QH"_WT4 O^-%@'_FAH!_Z8> ?"Q(P+DNRD#V<(P"<N]/QG
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M44CA_$](X?Q/2.'\3TCA_$](X?Q/2.'\3TCA_$_AF0  S:D  +ZS @"SO@,
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M_S3_5",#_U M!/]9+07_7S '_V,V"O]F0 [_9DH3_V55&?]C91[_87,C_UZ
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M7U6N^EM6K?M:5JW[6E:M^UI6K?M:5JW[6E:M^UK_?@D \I$" -:A @#*K04
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M3]):IU'/6;!3S5BZ5,M8QE7)5]I6Q5?L5<-;^4_"7O]*P%__1KU@_T*Z8/]
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M7&>2_5=GD?]29Y'_4F>1_U)GD?]29Y'_4F>1_U+_;@X _W\) /&.!0#9FP4
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M24ZY_TE.N?])3KG_24ZY_TGOA0  U)4  ,>C  "ZK $ L+0  *>_ P">R08
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M"1?_APD6_Y0)%?^?"A3_J@H4_[,*%/^S"A3_LPH4_[,*%/^S"A3_LPJ3NP
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M47> _TQW@/]'=X#_1G> _T9W@/]&=X#_1G> _T;_9 \ _W() /]_" #EC 4
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M1F"6_T9@EO]&8);_1F"6_T;_< , ZX$  -:/  #*F@$ P:,# +FJ @"QL@$
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M&3/TL1DR]<4:,?7B&C'T\1DQ\?X9,?'_&3'Q_QDQ\?\9,?'_&3'Q_QFRI
MI:L  )BV  "+P   ?LH  ''5  !EW@  7O4* %G\$P!3_!X!3OPG DK], -%
M_3D%0?U !C[^2 <[_D\)./]7"C;_7@LS_V<,,?]P#2[_? XL_XD/*_^6$"G_
MI! H_[01)__'$2?_X1$F__(1)O_V$2;_]A$F__81)O_V$2;_]A&GJ0  F;,
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M181O_S^%</\[AG'_.(9Q_SB&<?\XAG'_.(9Q_SC_6P\ _V<( /]S" #S?0@
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M/&^!_SQO@?\\;X'_/&^!_SS_9 @ _W(  .%_  #3B0$ RI(# ,.8! "]G@0
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M,4&_NC%!P-(Q0;[N,$&]_2]!O/\N0;S_+4&\_RU!O/\M0;S_+4&\_RW.B@
MOY@  +&@  "FJ   F[   )"X  "%OP  >L<$ &_/"0!KT14 9]$F 6/1- 1>
MT$ (6=!*#%7/4Q!1SUL43L]C&$O.:QM(SG4>1<Y_($+.C") SIDD/LZH)CS.
MNB8\S]0F/,WO)3O,^R4[R_\E.\K_)3O*_R4[RO\E.\K_)3O*_R7#DP  M9X
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M"R'_X LA_?(*(/S\"B#\_ H@_/P*(/S\"B#\_ JBIP  E;$  (>[  !YQ@
M;,\  %_9  !2WP  2.@  $/_"  __Q  ._\9 #?_(0 T_RD!,/\P 2W_-P(J
M_SX")_]$ B7_2P,B_U,#(/]< QW_9@0;_W($&?^ !1?_CP46_Y\&%?^O!A3_
MP 84_]8&$__I!A/_Z083_^D&$__I!A/_Z0:7KP  B+H  'K%  !LSP  7MH
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M-99>_S&67_\MEF#_*I9@_RJ68/\JEF#_*I9@_RK_4@\ _UP* /]F"0#_;@H
M]G0, .]X#@#A>Q( U'P@ ,I[,P3!=T$+NG1-$[1P6!NN;&$AJ6II)Z9G<2NB
M97@OGV2 ,YQBB#:989 XEE^9.Y1>HCV17JT_CUV[0(U=S4&,7N@_C6'Y.(UB
M_S..9/\PCF3_+(YE_RR.9?\LCF7_+(YE_RS_50X _U\& /]I!@#T<@8 XG@&
M -M\"0#9?PP S8$= ,1_, .[?#\*M'A+$JUU51JH<5XAHVYF)I]L;BN;:G4O
MF&A],Y5GA#:298PYCV25/(QCGSZ)8JI AV&W0H5AR4*$8N1!A63W.X9F_S6'
M9_\QAVC_+H=I_RV':?\MAVG_+8=I_RW_5PP _V$$ /YL P#D=0$ VWL% -.
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M,'QP_S!\</\P?'#_,'QP_S#_6P@ _V8  .=R  #:>P  SX(# ,F'!0#$B@8
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MEC$%EY,^#)"02!2*CE$;A(M9(7^)8"=[AV<K=X5N,'.$=31O@GTW:X&'.VB
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M.T^6M#Q.ELD\3I;H.D^6^391EO\S4I;_,%*6_S!2EO\P4I;_,%*6_S#F<@
MT(   ,*,  "XE@  K9P  *.A  "9I@  CJT  (BN$0"#KB(!?:TQ!'>L/0IR
MJD<0;*E/%F>H5QMCIUX?7Z9E)%ND;2=8I'4K5*-_+E&BB3%.H98T2Z&D-DFA
MM#9(H<@W2*#G-4F@^3)*G_\P2Y__+DN?_RU+G_\M2Y__+4N?_RW=>0  R88
M +R2  "QF@  IJ   )RF  "1K   AK(  'VV#0!YMAT =;8L F^U.09JM$,+
M9;-,$6"R5!9<L5L:6+!C'E6O:R%1KW,E3JY]*$NMB"I(K94M1:VC+D2MLR]#
MK<@O0JSG+T.K^2U$J_\K1*K_*42J_RE$JO\I1*K_*42J_RG1@   P8T  +68
M  "IGP  GJ4  ).L  "(L@  ?;@  '&^!@!NOQ4 :K\F 6:_,P-AOC\'7;Y(
M"UF]40]5O5D34;Q@%TZ\:!I+NW$=2+M['T6ZAR)"NI0D0+JB)CZZLR8]NL@F
M/;KH)CVX^24]M_\D/;;_(SVV_R,]MO\C/;;_(SVV_R/'B   N94  *R=  "A
MI   EJL  (JR  !_N0  <[\! &C&!0!@R@X 7LH= %O*+ %7RC@#5,I#!5#*
M3 A-R54+2LE=#D?)9A%$R6\40<EY%C_(A1@\R),:.LBB&SG)LQPXR<D<.,CH
M'#?'^1PWQ?\<-L3_'#;$_QPVQ/\<-L3_'#;$_QR^D0  L)L  *2C  "8J@
MC+(  ("Y  !TP   :,<  %W-!0!3TPH 3]<2 $W8(@!+V#  2=@\ D;81@-$
MV4\$0=E8!C_980@\V6L*.MEV##?9@@XUVI /--J@$#+:L1$QV\<1,=KG$3#8
M]A(PUO\3+]3_$R_4_Q,OU/\3+]3_$R_4_Q.SF@  IJ$  )JI  "-L0  @+H
M '3!  !HR0  7,\  %+5 P!(W @ 1>42 $/E'@!!YBH /N8U 3OG/@$YYT<"
M-^=0 S3H600RZ&(%,.AM!B[I>0<LZ8<(*^J6"2GJIPHHZKH*)^O6"B?I\ HG
MY_T))N;_"B;F_PHFYO\*)N;_"B;F_PJHH   G*<  (^P  ""N0  =,(  &C*
M  !;T0  3]<  $7=   ^[@D //(1 #GS&P V\R4 -/0N #'T-P$N]3\!+/5'
M 2GV3P(G]E<")?=A R/W; ,A^'H$'_B)!![YF@4<^:L%&_K !1KZW@4:^?(%
M&O?]!1GV_P49]O\%&?;_!1GV_P6>I@  D:\  (.Y  !UP@  9\L  %K3  !-
MV@  0M\  #CE   U^P< ,?\/ "[_%@ K_Q\ *?\F "7_+0 C_S0 (/\[ 1[_
M0P$;_TL!&?]3 1;_70(4_VH"$O]X A'_B (0_YH"$/^K P[_O@,._]4##O_M
M P[_\ ,.__ ##O_P P[_\ .3K@  A+@  ';"  !GS   6M4  $S<   _X0
M->8  "WT   J_P( )O\+ "/_$0 @_Q< '?\= !G_(P 6_RD %/\O !+_-0 0
M_ST #O]% 0S_3@$*_U@!!_]E 07_= $#_X4! O^6 0'_I@$ _[4! /_& 0#_
MR@$ _\H! /_* 0#_R@&&MP  =\$  &C,  !:UP  2]X  #[D   RZ0  )^T
M "/_   ?_P  &_\% !?_#  4_Q  $?\4  __&  -_QT "_\B  C_*  %_RX
M O\U  #_/0  _T<  /]2  #_7@  _VT  /]^ 0#_C@$ _YL! /^I 0#_JP$
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M(JY+_Q^N3/\=K4S_&ZU-_QJM3?\:K4W_&JU-_QK_1Q$ _T\- /]6# #_7 X
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M# #A;!  TVT> ,EL,0+":D 'NV=,#;5D5Q.P86 9K%]I':A=<2&E7'@DHEJ
M)Z!9ARJ=6) LFU>8+IE6HC"65:PRE%6Y,Y-5RC.15>4SD5?W+9%9_RF16O\E
MD5O_(Y%;_R&16_\AD5O_(9%;_R'_3PL _U<" /]A @#J: $ WFT$ -AP" #5
M< L RW(; ,)Q+@*Z;ST&M&Q)#:YI5!.I9UT9I&1E':%B;2&=870EFE]\*)A>
M@RN578LMDEN4,)!;GC*-6J@TBUFU-8I9QC:(6>$VB%ST,(A=_RN)7O\HB5__
M)8E?_R.)7_\CB5__(XE?_R/_40D _UH  /5D  #@;   UW$# -!T!@#-=0D
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M-UUZLSA<>L<Y7'KE-UY[^#)?>_\N8'S_*V%\_REA?/\I87S_*6%\_RGU8@
MWF\  ,QZ  # @P  MXD  *^.  "FD0  G9(& )>3%P"1DR@!BY(V!86000M_
MCDH1>HQ2%G6*6AMQB&$?;8=H(VJ&;R=FA'<K8X. +F""BC%=@98T6H&C-EB
MLC=6@,4W5H#C-EB!]S%9@?\M6X+_*EN"_RE;@O\I6X+_*5N"_RGL9@  V',
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M*T6;]"E&FO\G1YK_)4>:_R1'FO\D1YK_)$>:_R34=P  PH0  +:/  "KE@
MH9P  ):@  "+I0  ?ZH  '2N!0!OKQ0 ;*\D &BO,@)DKCT%7ZU&"5NL3PU8
MK%815*M>%%&J9A=.JFX:2ZEX'4BI@R!%J(\B0ZB=)$&HK25 J, E/ZC?)3^F
M]"- I?\B0*7_(4"D_R! I/\@0*3_($"D_R#*?@  NXL  *^5  "DFP  F:$
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M#"G-_PTIS?\-*<W_#2G-_PVNF   HI\  ):F  ")K@  ?+8  &^]  !CPP
M5\@  $S-  !"T@, .=D) #7?$  TWQL ,N G #'A,@ PX3T +N)' "WB4 $K
MXEH!*N-E BCC<0(FY'\#)>2/ R/EH00BY;0$(>7-!"#D[ 0@XOL$'^'_!1_@
M_P4?X/\%'^#_!1_@_P6DG@  F*4  (NN  !]M@  <+X  &/&  !6RP  2]
M $#5   VW   +^4' "WM$  K[A@ *>XB "?O*P E[S0 (_ \ "'P10 ?\4X
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M  #_U@""M0  <[\  &3)  !6TP  1]L  #K@   NY0  (^D  !KM   5_0
M$O\  !#_ @ ._PD "_\-  C_$  $_Q,  ?\8  #_'@  _R0  /\K  #_,P
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M#= S_PS.,_\,S33_"\PT_PO,-/\+S#3_"\PT_PO_.18 _SX2 /]!$ #_11,
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M%YU,_Q:=3/\6G4S_%IU,_Q;_1PL _TT" /]4 @#W6@0 ZUT' .=="P#A7!
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M+FIFLR]I9L8P:&;D+VIH]REK:?\E;&G_(FQJ_R!L:O\@;&K_(&QJ_R#_5P
MY&(  -)L  #&<P  O7@  +5[  "M?   I7P* )]]&@"9?"H!DWLX!(UY0PF(
M=TP.@W54$G]S6Q9[<F(9>'!I'75O<"!R;G@C;VV!)FQLBREJ;)<L9VNC+F5K
MLB]D:\0P8FOA+V1L]BIF;?\F9FW_(V=N_R!G;O\@9V[_(&=N_R#V60  X&4
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M+5-\\BE5?/\E5GS_(E=\_R!7?/\@5WS_(%=\_R#E9   SW   ,%Z  "V@P
MK8D  *.,  "9C@  C8\  (:0#@"!D1T ?9 L 7B/. 1SCD((;HU+#&J,4Q!G
MBEH48XEA%V"(:!M=AW >6H9Y(5:%@R14A8\F482<*$^$JBI-A+PJ3837*DV#
M\2=/@_\D4(/_(E"#_Q]0@_\?4(/_'U"#_Q_>:0  R74  +R   "RB   J(T
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M&3R?_Q@\G_\8/)__&#R?_QC$?   MHD  *J2  "?EP  E9P  (FA  !]I@
M<:H  &2N  !:L0@ 5[$4 %6R(P!3LC !4+([ DVR1 -+L4T%2+%5!T6Q70E#
ML64+0+!O#3ZP>@\[L(<1.:^6$S>OIA0VK[@4-;#1%#6N[Q0TK?X4-*S_%#2K
M_Q0TJ_\4-*O_%#2K_Q2[A0  KY   *.7  "8G0  C*,  ("H  !TK0  :+(
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M A?:_P*@G   E*,  (>K  !YLP  ;+H  %_!  !2Q@  1LH  #O.   QTP
M*=D  "'>!0 >Z X '>@5 !OI'@ 9Z2< &.HP !;J.0 5ZT, %.Q. !+L6@ 1
M[6< $.YW !#NB@ .[YX #O"S  WPS0 ,[^P #.W\  SK_P ,Z_\ #.O_  SK
M_P"7HP  B:L  'NT  !MO   7\0  %+*  !%S@  .=,  "_8   EW0  '>$
M !CL @ 6]PL %/<1 !'X%P 0^!X #ODE  WY+0 +^C4 "?L_  ?[2@ $_%<
M _UF  +^=P  _8L  /V?  #\M0  _-$  /SM  #\_   _/T  /S]  #\_0"+
MJP  ?;0  &Z]  !@Q@  4LT  $32   WV   +-T  "+A   9Y0  $^H  !#Z
M   ._P8 #?\,  K_$  '_Q0 !/\:  '_(   _R<  /\P  #_.@  _T4  /]3
M  #_8@  _W4  /^*  #_GP  _[,  /_'  #_Y0  _^4  /_E  #_Y0!_M
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M ?(3_P'Q$_\"\!3_ O 4_P+P%/\"\!3_ O 4_P+_*A\ _RP< /\L&P#_*QT
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M";HS_PFZ,_\)NC/_";HS_PG_.1  _ST+ /] "0#_1 T _T81 /]%&0#W1",
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M_Q3_1P  ^$\  .17  #570  S&   ,5@ @#!7@4 NET1 +-?(P"L7S,!IEY
M Z%<2P>=6E0*F5E<#I989!&35FL3D%5R%HY4>AB+5((:B5.*'(=2E!Z%4IX?
M@U&J(8%1N")_4<LB?E+G(7Y3^1U^5/\:?E7_%WY5_Q9^5?\5?E7_%7Y5_Q7_
M2@  [E(  -Y;  #/80  QF0  +]E  "Z8P( LV(/ *QC( "F8S !H&(] YMA
M2 :67U$*DEY9#8]<81&,6V@3B5IO%H99=AB$6'X:@E>''']7D!]]5ILA>U:G
M(GE6M2-W5L<D=E;D)'97]Q]W6/\;=UG_&7=9_Q=W6?\6=UG_%G=9_Q;_3
MZ58  -E?  #+90  P6@  +II  "T:   K6<- *9H' "@:"T!FF<Z Y5E10:0
M8TX*C&)7#8EA7A"&7V43@UYL%H!=<QA^7'L:>UR#'7E;C1]V6I@A=%JD(W):
MLB1Q6L0E;UKA)7!;]B!Q7/\<<5W_&G%=_QAQ7?\7<5W_%W%=_Q?]3P  Y5D
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M)E]G\2)@:/\>86C_'&)H_QIB:/\98FC_&6)H_QGL5P  V6(  ,=K  "\<@
MLW<  *IY  "A>0  EW<! )!X$0"+>"$ AG@O 8%W.P1\=44'>'1-"G1R50YQ
M<5P1;G!C%&MO:A9H;G$99FYZ'&-MA!Y@;(\A7FR<(UQKJB5::[LF66S3)EIL
M[R-;;/\?7&W_'%UM_QI=;?\976W_&5UM_QGH6@  TF8  ,-O  "X=@  KWL
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M&DM^_QE,?O\83'[_&$Q^_QC59P  PW,  +9\  "LA   HHD  )B+  "-C0
M?(T  '6.! !OCQ( ;9 A &F0+@%ECSD"8HY"!%Z.2P=;C5(*6(Q9#%:+80]3
MBV@24(IQ%$V)>Q=*B8<92(B5&T:(HQU$B+0=0XC*'4.'ZAQ$AOL:1(;_&$6&
M_Q=%A?\7187_%T6%_Q?-;0  O7@  +&"  "GB@  G(X  )*0  "&DP  >94
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M#2^E_PVVA   JHX  )Z4  "4F0  AYX  'NC  !OJ   8ZP  %>O  !+L@
M0;4& #ZV$0 ]MAX .[8I #JW-  YMSX -[=' #:W4 $TMUH!,K=D C"W;P,N
MMWP$++>+!2JWG 4IMZX&*+C%!2BWY@4GM?D')K/_!R:R_P@FLO\()K+_"":R
M_PBOC0  HI0  )>:  "+H   ?J8  '&K  !EL   6;0  $VW  !"NP  .+X!
M "_""0 MPQ( +,,> "O#*0 JQ#, *<0] "C%1P GQ5$ )L5< "7&:  CQG8!
M(L:& 2#&F $?QJL!'L?! 1[&Y $=Q/@"',+_ QS!_P,<P?\$','_!!S!_P2E
ME   FIH  (ZA  "!IP  <ZX  &>T  !:N0  3KT  $+    XPP  +\<  ";+
M!  >T H &]$1 !K2&@ 9TB4 &-,O !C3.@ 7U$0 %M10 !7570 4U6L $]9\
M !+7CP 1V*0 $-F[ !#9W@ 0U?, $-/_ !#2_P$0T?\!$-'_ 1#1_P&<F@
MD:$  (.H  !UL   :+<  %N]  !.P0  0L4  #?(   MS   )-   !S5   5
MV@4 $.(+ !#C$0 .Y!H #N0C  WE+0 ,Y3< "^9"  KF3P )YUT ".=M  ;F
M@  %YI4 !.:K  +FQ  !YN8  .?Y  #G_P  YO\  .;_  #F_P"3H0  A:D
M '>Q  !IN0  6\   $[&  !!R@  -<X  "K2   AU@  &=L  !+?   -XP
M"_$(  GS#@ '\Q, !/(:  +R(@  \BH  /(T  #R/P  \DP  /)<  #R;0
M\H(  /*8  #SK0  \\8  /3E  #T]@  ]/L  /3[  #T^P"'J0  >;(  &JZ
M  !<P@  3LD  $#.   STP  *-@  ![=   5X0  #^0   KH   %\P   _T!
M  #\"   ^PT  /L1  #[%@  _!X  /PF  #\,   _3P  /Y)  #^6@  _FT
M /^"  #_F   _ZP  /_   #_V   _^0  /_D  #_Y ![L@  ;+L  %W$  !/
MS0  0-(  #+9   FW@  &^(  !+F   ,Z@  !>T   #T    _P   /\   #_
M    _P0  /\)  #_#@  _Q(  /\8  #_(0  _RL  /\W  #_1@  _U@  /]K
M  #_@   _Y4  /^F  #_LP  _[L  /^[  #_NP#_&R8 _QPD /\:) #_%2<
M_Q M /\*-@#_!4, _P%0 ?\ 7@'_ &L!_P!V ?\ @0#_ (H _P"2 /\ F@#_
M *  _P"F /\ K #_ +( _P"Y /\ P@#_ ,T _P#? /\ [ #_ /@ _P#_ /T
M_P#] /\ _0#_ /T _P#] /\ _0#_ /T _P#_'R, _Q\A /\>(0#_&2, _Q,I
M /\.,@#_#$  _PE- ?\'6@'_!&<!_P-S ?\#?0'_ X<!_P./ /\"E@#_ IP
M_P*B /\"J #_ J\ _P&V /\!O@#_ <D _P'; /\ Z@#\ /8 ^ #_ /<"_P#W
M _\ ]@3_ /8$_P#V!?\ ]@7_ /8%_P#_(A\ _R(< /\A' #_'A\ _Q@D /\5
M+P#_$CP _Q!) /\.5@'_#&(!_PMN ?\+>0'_"X(!_PN+ ?\+D@'_"ID!_PJ?
M /\*I0#_"JL _PJR /\*NP#]"L8 ^PK4 /<*YP#S"O0 \ K_ .\+_P#N#/\
M[0S_ >T,_P'M#/\![0S_ >T,_P'_)1L _R88 /\E%P#_(1@ _R A /\>*P#_
M&C< _Q=% /\440'_$EX!_Q%I ?\1= '_$7T!_Q"& ?T0C@'\$)4!^A"; ?D0
MH0'W$*@!]A"O ?00MP#S$,( \1#0 .T0Y0#H$?( YA'^ >02_P'C$O\!XA+_
M >(2_P'A$O\!X1+_ >$2_P'_*18 _RH3 /\I$@#_)Q, _R@< /\G)P#_(S,
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M!Z<S_P?_-P< _SH  /\^  #Z00$ \4$& /$_#0#F/!( VSH? - [,0#*/$
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M%(]#NA6-0\T5BT3H%8I%^A*)1O\0B4;_#HA&_PV(1O\-B$;_#8A&_PW_0
M\D<  .-/  #44P  RU4  ,14  # 4 0 N4\1 +)0(@"L43( IU$_ J)02@.>
M3U,%FTY<")A-8PJ53&H,DTMQ#9%*>0^.2H 1C$F)$HI)DA2(2)P5ADBH%H5(
MM1>#2,<8@4CD&(%*]Q6 2O\2@$O_$(!+_P^ 2_\.@$O_#H!+_P[_0P  [$L
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M'6M6\!IK5_\7:UC_%&Q8_Q)L6/\1;%C_$6Q8_Q'Q2P  WU8  ,Q>  # 9
MMV<  *YH  "G9@  GV(& )AC% "29"0 C6,R 8EB/0*$84<$@6!/!WU?5@EZ
M7ET+=UUD#75<:Q!S7',2<%M[%&Y;A1=L6I 9:EJ<&VA9JAQF6KH=95K1'65:
M[AME6_X79EO_%69<_Q-G7/\29US_$F=<_Q+M3@  VED  ,AA  "\9P  LVH
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M%E=H_Q189_\36&?_$UAG_Q/A6   RV,  +UK  "R<@  J78  *!X  "6=P
MB',  (%S"P!\=!< >'0F '1T,@%P<ST";7-&!&IR3@=G<54)9'!<"V%P8PY?
M;VH07&YS$EIN?!57;8@756R4&5-LHQM1;+,<4&S('$]LYQM1;/H846S_%5)L
M_Q12;/\34FS_$U)L_Q/<7   QV<  +EO  "O=@  I7L  )Q\  "1?   @G@
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M$$" _Q#&:P  MW8  *Q_  "BA0  EXD  (R+  "!C0  <XX  &6/  !=CPD
M6I 4 %B0(0!6D2T 4Y X 5&000).D$D#3)!0!$J/6 5'CV '18YI"4*.<PM
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M!2VDEP8LI*D&*Z2]!BJDW@8JHO4'*:'_!RF@_P@IG_\(*9__""F?_PBQ@@
MI8L  )J1  "0E@  @YH  ':?  !JH@  7J8  %*I  !&JP  /*T  #6O#  S
ML!4 ,K A #&P*P OL#4 +K$^ "VQ2  LL5$ *[%; "FQ9P$GL70!)K&# 22Q
ME (CL:8"(K*[ B&RVP(AK_,#(*[_ R"M_P0?K/\$'ZS_!!^L_P2JBP  G9$
M ).7  "'G   >J(  &VG  !@JP  5:\  $FQ   ^M   ,[<  "JZ P DO T
M(KT5 "&](  AO2H (+TS !^^/0 >OD< ';Y2 !R_7@ :OVP &;]\ !B_C@ 7
MP*$ %L"V !3 TP 5OO$ %;S_ 16[_P$4NO\"%+K_ A2Z_P*AD@  EI@  (J>
M  !]I   ;ZH  &*O  !6M   2K<  #ZZ   SO0  *L   "'$   9QP4 $\L+
M !',$@ 1S!L $,PE  _-+P .S3H #LU&  W-4@ -SF  #,YP  O.@P *SI<
M"<ZL  C.Q@ (SN@ ",W[  G+_P )R_\ "<O_  G+_P"8F   C9X  '^E  !Q
MK   9+,  %>Y  !*O0  /L   #+#   HQ@  '\H  !?-   1T0  #-8%  C9
M#  &V1( !=H;  3:)  #VRX  =LY  #<10  W5(  -YB  #><P  WH@  -^=
M  #?LP  W\X  .#N  #?^@  W_\  -__  #?_P"/GP  @:8  '.N  !EM0
M6+T  $K"   ]Q0  ,<D  ";,   =T   %-0   [9   )W0   ^$   #C!P
MXPT  .02  #E&0  YB(  .<K  #I-@  ZT,  .Q2  #L8@  [78  .Z,  #N
MH0  [[<  ._1  #OZP  \/8  /#V  #P]@"$IP  =:\  &>W  !9OP  2\8
M #S*   OS@  )-(  !K8   2W   #.    7C    YP   .L   #K    [04
M .X+  #P$   \14  /,>  #T)P  ]S,  /E   #Z40  ^V,  /QW  #]C0
M_:,  /ZV  #^R0  _]\  /_?  #_WP!WL   :+D  %K!  !,R@  /,\  "[4
M   BV@  %]X  !#B   )Y@   .D   #L    \    /8   #V    ]P   /@
M  #Z!P  ^PT  /T1  #_&0  _R,  /\O  #_/@  _T\  /]B  #_=P  _XT
M /^?  #_K@  _[H  /^Z  #_N@#_%B, _Q4A /\2(0#_#B0 _P8J /\ ,P#_
M $$ _P!. /\ 7 #_ &@ _P!T /\ ?@#_ (< _P"/ /\ E@#_ )P _P"B /\
MJ #_ *X _P"U /\ O0#_ ,< _P#6 /\ YP#^ /, _@#^ /T _P#\ /\ ^P#_
M /L _P#[ /\ ^P#_ /L _P#_&B  _QD> /\6'@#_$"  _PHE /\$, #_ #T
M_P!+ /\ 6 #_ &0 _P!P /\ >@#_ (, _P"+ /\ D@#_ )@ _P"> /\ I #_
M *H _P"Q /T N0#[ ,, ^@#0 /@ XP#W /$ ]@#\ /0 _P#T /\ \P#_ /,
M_P#S /\ \P#_ /, _P#_'1P _QP9 /\9&0#_%!L _PXA /\,+ #_"3D _P5&
M /\"4P#_ %\ _P!K /\ =0#_ 'X _P"& /\ C@#_ )0 _@"; /P H0#Z *<
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M /\<(P#_&"\ _Q0[ /\220#\$%4 ^ ]@ /0/:@#Q#W0 [PY\ .T.A #K#HL
MZ0Z2 .<.F0#F#J  Y ZG .(.KP#@#K@ W@[% -P.V@#6$.P TA'Z ,\2_P#-
M$O\!S!+_ <L3_P'*$_\!RA+_ <H2_P'_)P\ _R<, /\E"0#_)@T _R43 /\C
M' #_("@ ^QPU /4:0@#O&$\ ZA=: .8690#C%FX X!9W -X6?P#<%H< V1:.
M -86E0#4%IP TA>C - 7JP#.&+4 S!C! ,L8T@#'&N@!PQOX < ;_P&^'/\!
MO1S_ KP<_P*\&_\"O!O_ KP;_P+_*PP _RL% /\K P#_+0D _RP. /\I%0#W
M)B  [B,M .<A.@#A'T@ VQ]4 -4@7P#1(&@ SB!Q ,PA>0#*(8$!R"&( <8A
MCP'$(98!PR&> <$BI@&_(J\!O2*[ KPCR@*Y(^,"M23T K,D_P.Q)/\#KR3_
M Z\D_P.N)/\#KB3_ ZXD_P/_+P8 _R\  /\R  #_,P( ^3(( /<O#@#K*Q8
MX2<B -@G,@#0*4$ RRI. ,8J60##*F(!P"IK ;TJ<P&[*GH"N2J" K@JB0*V
M*I "M"J8 [,JH0.Q*JH#KRNU!*XKQ 2L*]L$J"SO!*8L_@6D+/\$HRW_!*(M
M_P2B+/\$HBS_!*(L_P3_,@  _S,  /DX  #I.0  XCD  -XU!P#>+@T T2\;
M ,DQ+ ##,SL O3-( +DT4P&V,UP!LS-E K S;0*N,W0#K#)[ ZLR@P2I,HH$
MIS*3!:4RFP:D,J4&HC*P!Z RO@>?,M$'G#/J!YHS^P>8-/\'ES3_!I8T_P:6
M-/\%EC3_!98T_P7_-0  _S@  .H^  #?0@  U4(  ,\_ P#-. @ Q3@5 +TZ
M)@"W.S8 LCQ# *X\3@&J.U<"ISM@ Z4Z9P.C.F\$H3IV!9\Y?0:=.84'FSF-
M!YDXE@B8.* )ECBK"I0XN J3.<H+D3GE"X\Z]PJ-.O\)C#O_"(P[_P>,._\'
MC#O_!XP[_P?_.   \3X  .-%  #420  RTH  ,5'  #!000 NC\1 +-!(0"M
M0C$ J$,^ *1#20&@0E,"G4%; YM!8@280&H%ED!Q!I0_> >2/W\(D#^("H\^
MD0N-/IL,BSZF#8D^LPV(/L0.AC_@#H0_] V#0/\+@T#_"H) _PF"0?\(@D'_
M"()!_PC_/   ZT,  -Q*  #,3P  PU   +Q.  "W20$ L48. *I(' "D22P
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M$F]-J1-N3;D4;$W.%&Q-ZQ-L3OT0;$__#FQ/_PQL3_\+;$__"VQ/_PON10
MW%   ,E7  "]7   M%X  *Q>  "D6P  G%8$ )56$@"05R$ BU@O (=7.P&#
M5D0"?U9- WQ55 5Z5%L&=U1B"'53: ES4W +<5)X#6]2@@]M48T1:U&9$FE1
MIA1G4;859E'+%652Z11E4OL19E/_#V93_PUF4_\,9E/_#&93_PSJ20  U5,
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M%E5>XQ567O<25E[_$%=>_PY77O\-5U[_#5=>_PW>4P  R%T  +MD  "P:@
MIFT  )UN  "3;0  A6<  'YG"0!X9Q4 =&<C '%H+P!N9SD!:V=" FAF2@-E
M9E(%8V58!F!E7PA>9&<*7&1O#%IC>0Y88X0056*1$E-BGQ-28JX546+"%5!B
MX1518O8246+_$%)B_PY28O\-4F+_#5)B_PW95@  Q&   +=H  "L;@  HW$
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M#D%S_PU!<_\,07/_#$%S_PS&9   MVX  *MV  "B?   EW\  (R!  "!@0
M<H   &5_  !=?P@ 67\3 %> ( !5@"L 4X$V %& /@%/@$8"38!. DM_50-)
M?UT%1G]F!D1^< A"?GL)/WZ("SU]EPP\?:<-.GVZ#CI^U@TZ?/$-.GO_##I[
M_PLZ>O\+.GK_"SIZ_PO :0  LG0  *=\  "=@0  DH0  (>&  ![AP  ;H<
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M!"*9_P2L@0  H(@  )6.  "+D@  ?Y8  '*:  !EG0  6:   $ZC  !"I
M-Z8  "ZH!0 IJ0\ **D8 ">J(@ FJBP ):HU "2J/P CJD@ (JM3 "&K7@ @
MJVH 'JMY !VKBP ;JYT &JNQ !FKR@ 9JNP!&:C] 1BG_P(8IO\"&*;_ ABF
M_P*EB0  F8\  (^4  "#F0  =9X  &BB  !<I@  4*D  $2L   YK@  +[
M ":S   >M08 &;</ !BW%P 7MR$ %K<J !6W-  4N#X $[A) !*X5  2N6(
M$;EQ !"Y@P /N9< #KFL  VYQ  -N.< #K;[  ZU_P .M/\ #K3_  ZT_P"<
MD   DI4  (:;  !YH   :Z8  %ZK  !2KP  1K(  #JU   OMP  );H  !V]
M   5P   $,,&  O&#@ *Q14 "<4>  C%*  'Q3( !L8]  7&20 %QE<  \9F
M  +&=P !QHL  ,:@  #%M@  QM(  ,7O  #%_   Q?\  ,7_  #%_P"5E@
MB9P  'NC  !MJ0  8*\  %.T  !&N   .KL  "Z^   DP0  &\0  !/'   .
MR@  ",X!  '0"@  T!   - 6  #1'@  TB<  -,Q  #4/   U4D  -98  #6
M:0  UGP  -:2  #6IP  UK\  -;@  #6\P  UOX  -;_  #6_P",G0  ?J0
M &^K  !AL@  5+D  $:]   YP0  +<0  "+'   9RP  $<X   S2   %U0
M -L   #< P  W0H  -X/  #?%   X1P  .(D  #D+@  YCH  .=)  #H60
MZ&L  .F!  #IF   Z:T  .G%  #IX@  Z?(  .GU  #I]0" I0  <:T  &.U
M  !5O   1\(  #G&   LR@  (,X  !;2   /U@  "-L   #?    XP   .4
M  #G    Z $  .H'  #K#0  [1$  .\8  #Q(0  \RL  /8X  #W2   ^%H
M /EM  #ZA   ^IL  /JO  #ZP@  ^MH  /K?  #ZWP!TK@  9;8  %:^  !(
MQ@  .<L  "O0   ?U   %-H   W?   %XP   .8   #I    [0   .\   #Q
M    \P   /4   #V @  ^ D  /H.  #]$P  _QP  /\H  #_-@  _T<  /]:
M  #_;@  _X4  /^:  #_JP  _[D  /^\  #_O #_$2  _Q > /\,'@#_!"$
M_P G /\ , #_ #X _P!, /\ 60#_ &4 _P!P /\ >@#_ (, _P"+ /\ D@#_
M )@ _P"> /\ I #_ *H _P"P /\ N #_ ,( _P#. /\ X@#^ /  _0#[ /L
M_P#[ /\ ^P#_ /H _P#Z /\ ^@#_ /H _P#_%!P _Q(: /\.&@#_"!P _P A
M /\ +0#_ #H _P!( /\ 50#_ &$ _P!L /\ =@#_ '\ _P"' /\ C@#_ )0
M_P": /X H #] *8 _ "L /L M #Y +T ^ #) /< W #U .P \P#X /, _P#R
M /\ \0#_ /  _P#P /\ \ #_ /  _P#_%Q@ _Q46 /\1%0#_#!< _P4= /\
M* #_ #8 _P!# /\ 4 #_ %P _P!G /\ <0#_ 'H _ "" /H B0#X )  ]P"6
M /4 G #T *( \P"H /$ L #P +@ [@## .P TP#J .< Z0#U .< _P#F /\
MY0#_ .4 _P#E /\ Y0#_ .4 _P#_&A, _Q@1 /\4$ #_#Q$ _PT9 /\*) #_
M!3  _P$^ /\ 2P#_ %< _@!B /H ; #U '4 \@!] /  A #N (L [ "1 .L
MEP#I )X YP"D .8 K #D +0 X@"_ .  S0#> ., W #R -H _0#8 /\ U@#_
M -4!_P#5 ?\ U0+_ -4"_P#_'A  _QP- /\7"P#_%0X _Q05 /\1'P#_#BH
M_PLX /T(10#X!E$ ] 1< .X$9@#J!&\ Y@-W .0$?P#B!(8 X 2, -X$DP#=
M!9H VP6@ -@%J #5!;$ T@6[ - &R0#.!^  S CQ ,D*_P#'"_\ Q@S_ ,4,
M_P#%#/\ Q0S_ ,4,_P#_(0P _R & /\< P#_'0H _QL0 /\8& #_%", ]A$P
M .\./@#J#DH Y0U6 .$-8 #=#6D V0UQ -4->0#3#8$ T0V( ,\-CP#-#I8
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M ILE_P+_+   _RT  .TR  #B-   VC,  -,N P#2)0H R247 ,$G)P"[*38
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M!X,YK0>".;P(@3G3"'\Z[@A].OX'?#O_!GP[_P5\._\%?#O_!7P[_P7T-P
MY4   -)'  #%2@  O$L  +5)  "O0P  J3X+ *(_%P"=0"8 F$$T )1!/P"1
M04D!CD%1 8M 60*)0& #AT!G X4_;02#/W4%@3]]!G\^AP=]/I$(>SZ<"7H^
MJ0EX/K@*=S_-"G4_Z@IT0/P(=$#_!W1 _P9S0/\&<T#_!G- _P;Q.P  WT4
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M#F!-X0Y@3?8,8$[_"F!._PE@3O\(8$[_"&!._PCC1P  S5   +Y7  "S6P
MJET  *%=  "86@  C5,  (92# " 4Q@ ?%,E 'E4,0!U5#P <U-$ 7!33 )M
M4E,":U)9 VE28 1G46@&95%P!V-1>0AA480*8%"1#%Y0G@U<4*T.6U' #EI1
MW@]:4?4,6E+_"EM2_PE;4?\(6U'_"%M1_PC?2@  R5,  +M:  "P7P  IF$
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M"TQ=_PI,7?\)3%W_"$Q=_PC/5   OEX  +%E  "G:@  G6T  )1M  ");
M>&4  &]D  !I9 X 9609 &)D)0!@93  7F4Z %QE0@%:94H"6&11 E9D6 -4
M9%\$4F1G!5!C<0=.8WL)3&.("DICEPM(8Z8,1V.X#49CT0U&8^\,1F+_"D=B
M_PE'8O\)1V+_"$=B_PC*6   NF(  *YI  "C;@  FG$  )!R  "$<0  =&L
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M!C5T_P:Y:   K7$  *)Y  "8?@  C8   (*!  !V@@  :8$  %N!  !1@0
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M ""8AP ?F)D!'9BL 1R8PP$<E^4!')7Z 1N4_P$;D_\"&Y/_ AN3_P*G?P
MG(8  )&+  "'CP  >I(  &V5  !AF   59L  $F=   ]G@  ,Y\  "JA   A
MHPH 'Z,1 !ZC&@ =I"0 '*0M !ND-@ :I#\ &:1* !BD50 6I6$ %:5P !2E
M@0 3I90 $J6H !&EOP 0I.( $:+X !&A_P 1H/\!$:#_ 1&@_P&@A@  E8P
M (R1  !_E0  <9H  &2>  !8H0  3*0  $"F   UIP  *JD  "*L   9K@
M$K ) !"Q$  0L1@ #K$B  ZQ*P -L34 #;%   RQ2P +L5@ "K%G  BQ>  '
ML8L !;&@  2PM0 $L-  !+#O  6O_@ &KO\ !J[_  :N_P"8C@  CY,  (*8
M  !UG0  9Z(  %JG  !.JP  0:T  #6O   KL0  (;0  !BV   1N0  #;P#
M  >^#  #O1(  ;T9  "^(@  OBL  +XV  "^00  OTX  +]<  "_;0  OX
M +Z5  "^J@  OL(  +WD  "]]@  O?\  +W_  "]_P"2E   A9H  'B@  !J
MI@  7*L  $^P  !"LP  -;8  "JX   @NP  %[X  !#!   +Q   !,<   #)
M!P  R0T  ,D2  #*&0  RR(  ,LK  #--0  SD$  ,Y0  #/8   SW(  ,^'
M  #/G0  S[,  ,_.  #/ZP  SO@  ,[^  #._@"(FP  >J(  &RH  !>KP
M4+4  $*Y   UO   *;\  !["   5Q@  #LD   C,    T    -,   #5
MU@8  -@,  #9$0  VQ8  -P?  #>*   X#0  .)!  #B40  XV,  .-W  #D
MC@  Y*0  .2Z  #EU   Y>H  .7S  #E\P!\HP  ;JH  &"R  !1N0  0[X
M #7"   HQ@  ',D  !/-   ,T0  !-4   #:    W@   .$   #B    Y
M .4#  #G"0  Z0X  .L2  #M&@  [R0  /(Q  #T00  ]%,  /5F  #U?
M]I,  /:I  #WO   ]\X  /??  #WWP!PK   8;0  %.[  !%PP  -L<  "?,
M   ;T   $=4   K;    WP   .(   #E    Z0   .P   #M    \    /$
M  #S    ]00  /<*  #Z$   _!8  /\A  #_+@  _T   /]3  #_:   _X
M /^6  #_J   _[8  /^_  #_OP#_#1P _PH; /\"&P#_ !X _P D /\ +@#_
M #P _P!* /\ 5@#_ &, _P!M /\ =P#_ '\ _P"' /\ C@#_ )0 _P": /\
MH #_ *8 _P"L /\ M #_ +T _P#) /X W0#] .T _ #Z /L _P#Z /\ ^0#_
M /H _P#Z /\ ^@#_ /H _P#_$!D _PT7 /\&%@#_ !@ _P > /\ *@#_ #<
M_P!% /\ 4@#_ %X _P!I /\ <@#_ 'L _P"" /\ B0#_ )  _@"6 /T G #\
M *$ ^P"H /D KP#X +@ ]@## /0 T@#S .< \@#V /  _P#O /\ \ #_ .\
M_P#O /\ [@#_ .X _P#_$A0 _P\2 /\+$@#_ !( _P : /\ )0#_ #, _P!
M /\ 30#_ %D _P!D /T ;0#[ '8 ^0!] /< A #U (L ] "1 /, EP#Q )T
M\ "C .X J@#L +, Z@"] .@ RP#G .$ Y0#Q ., _0#C /\ X@#_ .$ _P#A
M /\ X #_ .  _P#_%!  _Q$. /\-#0#_!P\ _P(5 /\ ( #_ "T _P Z /\
M1P#Y %, ]0!> /( : #P '  [0!X .L ?P#I (4 Z ", .8 D@#E )@ XP"?
M .$ I@#? *X W "X -H Q0#6 -D U #L -( ^0#1 /\ SP#_ ,X _P#. /\
MS@#_ ,X _P#_%PP _Q0( /\/!0#_#@L _PP1 /\'&@#_ 28 _  T /0 00#M
M $T Z0!8 .8 8@#C &H X !R -X >0#; (  V0"& -8 C0#3 ), T0": ,\
MH0#- *H RP"S ,D OP#& -  Q0#H ,, ]@#! /\ P +_ +\#_P"_ _\ OP/_
M +\#_P#_&P8 _Q<  /\4  #_$P4 _Q$- /\.% #Y"A\ \ 8L .8#.0#@ T8
MW -1 -8$6P#2!&0 SP5L ,P%<P#*!7H R 6! ,8%AP#%!HX PP:6 ,$&G0"_
M!J8 O0:P +L'O "Y",T N KE +4+]P"S#?\ L0W_ + -_P"P#O\ KP[_ *\.
M_P#_'@  _QL  /\;  #Z&@  ]18% /81#0#K#A4 X@LB -@+,0#0##X RPU*
M ,<-50#$#EX P0YF +\.;0"]#G0 NP][ +D/@@"W$(H MA"1 +00F@"R$*,
ML!&M *\1N@"M$<H JA+E *<4]P"E%?\ HQ7_ *(5_P"B%?\ HA7_ *(5_P#_
M(@  _R   / C  #F)   X"$  -P9!0#;$ P T!$9 ,@3*0#"%3< O19$ +D7
M3@"U%U< LQA@ + 89P"N&&X K!EU *L9? "I&80 J!J, *8:E "D&IX HQNH
M *$;M "?',4 GAS? )H=\P&8'O\!EQ[_ 98?_P&5'_\!E1__ 94?_P'_)@
M]"<  .8M  #:+P  SRT  ,HG  #''P@ P1P3 +H>(@"T'S$ KR ] *LA2 "H
M(E( IB): *,C8@"A(VD H"-O )XC=P"<(WX FR.& )DDCP&7))D!EB2C 90D
ML &2);\!D276 8XF[P&,)_\"BR?_ HHG_P*))_\"B2?_ 8DG_P'Z*0  [#
M -TV  #-.   Q#<  +XR  "Z*P( M24. *XG'0"H*2L I"HX * J0P"=*TP
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M!F\ZX@9N.O<%;CO_!&T[_P1M._\#;3K_ VTZ_P/J.0  U4(  ,1(  "Y2P
MKTL  *=)  "?1   F#X! )$\$ ",/1T B#XJ (0_-0"!/S\ ?C]( 'P_3P%Z
M/U8!>#]= 78^9 )T/FL"<CYS W ^? -O/H<$;3Z3!6L^H 9J/JX&:3_ !V<_
MW@=G/_4&9D#_!69 _P1F0/\$9C__!&8__P3E/0  ST8  +],  "T3P  JE
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M!E5,_P953/\%54S_!55,_P752   PE$  +57  "J6P  H%P  )=<  "-60
M@5,  '=/! !Q3Q  ;E < &I0* !H4#( 95 [ &-00P!A4$H!7U!1 5U06 )<
M4%\"6E!G UA0<0174'L%55"(!E-0E@=24*4(4%"W"5!0S@E/4.T(4%#_!U!0
M_P904/\%4%#_!5!0_P702P  OU0  +):  "G7@  G6   )1@  ")70  ?%<
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M!4%<_P7#5@  M%\  *AF  ">:@  E6T  (IM  !_;   ;V<  &1D  !;8@4
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M C-RB0,Q<IH#+W*L RYRP0,N<N,#+G'X RYP_P,N;_\#+F__ RYO_P.S9@
MIV\  )UV  "3>@  B'P  'Y]  !R?0  9'P  %=[  !,>@  0GD# #QY#@ Z
M>A< .7HA #AZ*@ W>S, -GL[ #1[1  S>TP ,GM5 #![7P O>VH!+7MW 2M[
MAP$J>Y@"*'NJ B=[OP(F>^$")GKW B9X_P(F>/\")W?_ B=W_P*N;   HW8
M )E\  ".?P  A((  'B#  !LA   7X0  %&$  !'A   /(0  #.$"0 PA!$
M+X0: "V$)  LA2T *X4U "J%/@ IA4< *(90 ">&6@ FAF8 )(9S ".&@P A
MAI4 ((:G 1Z&O $>AMX 'H3U 1Z"_P$>@O\!'H'_ 1Z!_P&H=   GGT  )."
M  ")A0  ?H@  '&*  !EBP  6(P  $R-  ! C@  -HX  "R/   ED P (Y 3
M "*0'  AD"4 ()$N !^1-@ >D4  '9%) !R15  :D6  &9%N !B1?@ 6DI
M%9*D !21N0 3D=@ $X_T !2._P 4C?\ %(S_ 12,_P&C?0  F(,  (Z(  "$
MC   =X\  &F1  !=DP  4)4  $67   YF   +ID  "6:   =FP( %IT, !6=
M$P 4G1L $YTD !*=+0 1GC< $9Y! !">3  /GE@ #IYG  V>=P ,GHH "YV>
M  J=L@ )G<P "9SL  J;_@ +FO\ "YG_  N9_P"<A   D8H  (B.  ![D@
M;98  &"9  !4G   2)\  #R@   PH0  )J,  !VE   5IP  $*D%  NK#0 (
MJA, !ZH;  :J)  %JBX !*HX  *J1  !JE   *I>  "J;@  JH$  *J5  "I
MJ@  J<$  *CD  "H]@  I_\  *?_  "G_P"5BP  C)   '^5  !QF@  8YX
M %:B  !*I@  /:@  #&J   FJP  ':T  !2P   .L@  ";4!  *V"@  M@\
M +85  "W'0  MR4  +<O  "X.0  N$8  +A4  "X9   N'8  +B+  "WH
MM[8  +?3  "V[P  MOP  +;_  "V_P"/D@  @I<  '2=  !FH@  6*<  $NL
M   ^KP  ,;$  ":S   <M@  $[@   V[   &O@   ,$   #"!   P@L  ,,0
M  #$%0  Q!P  ,4D  #&+@  R#H  ,E'  #)5P  R6D  ,E]  #)E   R*H
M ,C#  #(Y   R/0  ,C]  #(_0"%F0  =Y\  &BF  !:JP  3;$  #^U   Q
MN   );H  !J]   1P   "\,   /'    R@   ,T   #.    SP,  - )  #1
M#@  TQ(  -49  #7(@  VBT  -TY  #>20  WEH  -]N  #?A0  WYP  -^R
M  #>RP  WN8  -_T  #?] !YH0  :Z@  %RO  !.M0  0+L  #&^   DP0
M&<4  !#(   )S    ,\   #3    V0   -P   #=    WP   .$   #B!0
MY L  .80  #H%@  ZB   .TK  #P.@  \4L  /%>  #R<P  \XL  /.B  #S
MM@  \\D  //A  #SX0!MJ@  7K$  %"Y  !!OP  ,L0  "3(   7S   #M
M  ;5    V@   -X   #B    Y@   .D   #J    [    .X   #P    \@
M /0&  #V#   ^1(  /P<  #_*0  _SH  /]-  #_8@  _W@  /^0  #_HP
M_[,  /_!  #_P0#_!QD _P$7 /\ %P#_ !H _P A /\ *P#_ #D _P!' /\
M5 #_ %\ _P!J /\ <P#_ 'L _P"# /\ B@#_ )  _P"6 /\ FP#_ *$ _P"H
M /\ KP#_ +@ _P#$ /X U0#\ .H ^P#X /H _P#Y /\ ^ #_ /@ _P#V /\
M\P#_ /$ _P#_"Q4 _P43 /\ $P#_ !0 _P : /\ )P#_ #0 _P!" /\ 3P#_
M %L _P!E /\ ;@#_ '8 _P!^ /\ A0#^ (L _0"1 /L EP#Z )T ^ "C /<
MJP#V +, ] "^ /, S #Q ., [P#S .X _P#M /\ [ #_ .L _P#L /\ [ #_
M .L _P#_#1$ _PD0 /\ #P#_ !  _P 6 /\ (@#_ "\ _P ] /\ 2@#_ %4
M_0!@ /H :0#X '$ ]@!Y /0 ?P#S (8 \0", .\ D@#N )@ [ "? .L I@#I
M *X YP"X .4 Q0#C -H X0#M -\ ^P#> /\ W0#_ -T _P#= /\ W0#_ -T
M_P#_#PT _PP+ /\#"0#_  P _P 2 /\ '0#_ "D ^P W /@ 1 #U %  \@!:
M .X 8P#L &L Z0!S .< >@#E (  XP"& .$ C #? ), W0"9 -L H0#9 *D
MU0"R -( O@#0 ,X S@#F ,P ]@#* /\ R@#_ ,D _P#( /\ R #_ ,@ _P#_
M$0@ _PT" /\'  #_!0@ _P . /\ %@#W "( [P P .L /0#H $D Y !4 .
M70#= &4 V0!M -4 <P#2 'H T "  ,X AP#, (T R@"4 ,@ FP#& *0 Q "M
M ,( N #  ,< O0#? +P \0"[ /X N0#_ +@ _P"X /\ N #_ +@ _P#_%
M_P\  /\-  #_#   _P<) /@!$ #H !H XP H -T -@#8 $( T@!- ,X 5P#*
M %\ QP!F ,4 ;0## '0 P0!Z +\ @0"] (@ NP"/ +D EP"W )\ M0"H +,
MLP"Q ,( KP#8 *X"[0"L _L JP7_ *H&_P"I!O\ J0;_ *D&_P#_%@  _Q(
M /<2  #L$0  Y@X  .4&" #= Q( U ,@ ,T$+0#(!#H PP5& +\%4 "\!E@
MN09@ +<'9P"U!VX LP=U +$(>P"O"(( K@F* *P)D@"J"9L J JE *8*L "E
M"[\ HPS4 *$-[0"?#OX G0[_ )P/_P";#_\ FP__ )L/_P#_&@  ]QD  .H>
M  #?'@  U1H  - 3 @#.# L QPL6 , -)0"Z#C( M@X_ +(/20"O$%( K!!:
M *H080"H$6@ IA%O *01=@"B$7T H1&% )\2C@"=$I< G!*B )H3K0"8$[P
MEQ30 )05[ "2%OT D!?_ (\7_P".%_\ CA?_ (X7_P#Z'0  [B,  -\H  #0
M*@  QR<  ,$A  "]&04 N1(0 +(5'@"M%BP J!<X *080P"A&4P GQE4 )P:
M7 ":&F( F1II )<;< "5&W< E!M_ )(<B "0')( CQR= (T=J0"+';< BA[*
M (@?YP"&(/H A"#_ 8,@_P&#(/\!@B#_ 8(@_P'U)   Y2P  -,Q  #&,P
MO#$  +8M  "P)0  K!T, *8>& "A("8 G"$R )DB/0"5(D< DR-/ )$C5@"/
M(UT C21D (LD:P"))'( B"1Z (8D@P"$)8T @R68 8$EI & )K(!?B;% 7TG
MX@%[)_<!>2C_ 7@H_P%X*/\!>"C_ 7@H_P'O*P  W3,  ,HY  "^.P  M#H
M *TV  "F+P  H2@' )LG$P"6*"  D2DM (XJ. "+*T( B"M* (8K4@"$*U@
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M U\Z_P)?.O\"7SK_ E\Z_P+=.P  QT,  +E)  "N2P  I$P  )M*  "210
MB3\  ($Z"0![.A0 =SL@ '0\*P!R/#4 ;ST^ &T]1@!K/4T :3U3 &@]6@!F
M/6$!9#UI 6,]<@%A/7T"8#V) EX]E@-=/J4#6SZV!%H^S 1:/^P$63_^ UD_
M_P-9/_\"63__ ED^_P+6/P  PT<  +5,  "J4   H%   )=/  ".2P  A$4
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M TI+_P/(20  N%$  *Q7  "A6P  F%P  (Y<  "#60  =E,  &M.  !D30H
M7TP3 %Q-'@!:32@ 6$TQ %9-.@!434$ 4TY( %).3P!03E<!3TY? 4U.: %,
M3G,"2D]_ DE/C0-'3YT$1D^N!$5/PP1$4.0$1$_Y!$5/_P-%3_\#14[_ T5.
M_P/$3   M54  *E;  "?7@  E6   (M@  " 7@  <E<  &=3  !>40< 65$1
M %=1&P!4424 4E(O %%2-P!/4C\ 3E)& $U330!,4U4 2E-= 4E39@%'4W "
M15-] D13BP-"4YL#052L!$!4P00_5.($/U3X T!3_P- 4_\#0%/_ T!2_P/
M4   LE@  *9>  "<8@  DF4  (AE  !]8@  ;EP  &-9  !95@, 5%8. %%6
M& !/5B( 35<L $Q7- !*5SP 25A$ $A82P!'6%, 15A; 4189 %"6&X!0%A[
M C]8B0(]6)D#/%BJ SM9OP,Z6> #.ECW SI8_P,[5_\#.U?_ SM7_P.\5
MKEP  *-C  "99P  D&D  (5I  !Y9P  :V(  &!@  !570  3EL, $M;% !)
M7!\ 1UPH $9=,0!%73D 0UU! $)=2 !!7E  0%Y8 #Y>80$\7FP!.UYX CE>
MAP(W7I<"-EZI S5>O0,T7]T#-%[U S5=_P(U7?\"-5S_ C5<_P*X60  JF$
M *!G  "6;   C&X  (%N  !V;   9VD  %QF  !19   2&() $1B$0!"8AL
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M "!UMP ?==( 'W3Q !]S_P$?<O\!(''_ 2!Q_P&I:P  GG,  )1Y  "*?
M@'X  '1_  !G?P  6G\  $U^  !#?@  .'T  "]] @ H?0T )GT4 "1]'  C
M?B4 (GXM "%^-@ A?C\ 'W]( !Y_4@ =?UX '']K !I_>@ 9?XP %W^? !9_
MLP 5?\X %7[O !9\_P 6>_\ %GO_ !=[_P"D<@  FGH  (]_  "%@@  >X0
M &V&  !@AP  5(<  $B(   \B   ,H@  "B(   @B 4 &HD. !F)%0 8B1T
M%XHF !:*+@ 5BC< %(I! !.*3  2BU@ $8ME !"+=0 /BX< #HJ;  V*KP ,
MBL@ #(GJ  V'_  .A_\ #H;_  Z&_P"?>P  E($  (J%  " B   <XL  &6-
M  !9CP  3)   $&2   TD@  *I(  "&3   9E   $I8&  Z7#@ -EQ4 #)<=
M  R7)@ +ER\ "I<Y  F71  (EU  !I=>  67;@ #EH   9:4  "5J   E;X
M )3@  "4]   D_\  9+_  &2_P"8@@  CH@  (6,  !WCP  :I(  %V5  !0
MF   1)H  #B;   LG   (IT  !F>   2H   #:("  >C"P !HQ   *,7  "C
M'P  HR<  *,Q  "D/   I$@  *16  "D90  HW<  *.+  "CH   HK8  *'2
M  "A\   H/L  *#_  "@_P"1B@  B8X  'N2  !MEP  8)L  %.>  !&H0
M.:,  "VD   CI@  &:@  !&J   ,K   !:X   "O!P  KPT  *\1  "P&
ML"   +$H  "Q,@  LCX  +),  "R6P  LFP  +*!  "QEP  L:P  +#&  "P
MZ   K_<  *__  "O_P",D   ?Y4  '&:  !CGP  5:0  $>H   ZJ@  +:P
M "*N   8L   $+,   JU   "N    +L   "[    O <  +P-  "]$0  OA8
M +\>  # )P  P3(  ,)   ##3P  PV   ,-T  ##BP  PZ$  ,.X  #"UP
MPN\  ,+Z  #!_@"!EP  <YT  &6C  !7J   2:T  #NQ   MLP  (;8  !:Y
M   .NP  ![X   #!    Q0   ,<   #(    R0   ,H%  #+"P  S0\  ,X4
M  #0'   TR8  -8R  #800  V%,  -EF  #9?   V90  -FK  #9PP  V>$
M -GP  #9] !VGP  9Z8  %FL  !+L@  /+<  "ZZ   AO0  %<    W$   %
MQP   ,H   #.    T@   -4   #6    V0   -L   #=    WP<  .$,  #C
M$0  YAD  .DD  #L,@  [4,  .Y6  #O:P  [X0  .^<  #OL@  [\8  ._=
M  #OY !JJ   6Z\  $RV   ^O   +\   "#$   4R   #,P   +0    U
M -D   #>    X@   .4   #F    Z    .D   #L    [@   / "  #R"0
M]0\  /@7  #\(P  _S,  /]&  #_6@  _W$  /^)  #_GP  _[$  /_   #_
MQ@#_ !4 _P 4 /\ % #_ !< _P = /\ * #_ #< _P!$ /\ 40#_ %P _P!F
M /\ ;P#_ '< _P!^ /\ A0#_ (L _P"1 /\ EP#_ )T _P"D /\ JP#_ +0
M_@"_ /T S@#[ .8 ^0#V /@ _P#W /\ ]P#_ /< _P#P /\ [ #_ .D _P#_
M Q( _P 0 /\ $ #_ !$ _P 7 /\ ) #_ #( _P _ /\ 3 #_ %< _P!A /\
M:@#_ '( _P!Y /T @ #\ (8 ^@", /D D@#X )@ ]@"? /4 I@#T *X \@"Y
M /  Q@#N -X [0#P .L _@#J /\ Z0#_ .D _P#G /\ XP#_ .  _P#_!PX
M_P - /\ "P#_  P _P 3 /\ 'P#_ "P _P Z /\ 1@#^ %( ^P!< /@ 90#U
M &P \P!T /$ >@#O ($ [@"' .P C0#J ), Z0": .< H0#F *D XP"S .$
MOP#? -  W0#I -H ^0#9 /\ UP#_ -4 _P#5 /\ U0#_ -0 _P#_"0H _P$%
M /\  P#_  D _P 0 /\ &0#[ "8 ]P T /0 0 #R $P [@!6 .H 7P#G &<
MY !N .( = #@ 'L W@"! -P AP#: (T U@"4 -0 FP#1 *, SP"M ,P N #*
M ,< R #@ ,8 \P#% /\ PP#_ ,, _P## /\ PP#_ ,, _P#_"P$ _P,  /\
M  #_  , _P + /, $@#N !\ Z@ M .8 .@#B $4 W@!/ -D 6 #4 &  T0!H
M ,X ;@#, '0 R@![ ,@ @0#& (< Q ". ,( E@#  )X O@"G +L L@"Y ,
MMP#4 +4 [ "S /L LP#_ +( _P"R /\ L0#_ +$ _P#_#0  _P8  /\#  #W
M    ]  # .< #0#@ !@ V@ E -, ,@#. #X R@!) ,8 4@## %H P !A +X
M: "\ &X N@!T +@ >P"V ($ M "( +( D "P )D K@"B *P K0"J +H J #+
M *8 Y@"E /< I #_ *, _P"B /\ H@#_ *( _P#_$   ^PP  .\.  #F#0
MWPD  -H !@#0 !$ R0 = ,0 *@"_ #< NP!" +< 2P"T %0 L@!; *\ 8@"M
M &@ JP!N *D =0"H 'L I@"# *0 BP"B )0 H "> )X!J "< K4 FP/& )D%
MX@"8!O0 E@C_ )4)_P"4"?\ E G_ )0)_P#\$0  \14  .,9  #6&0  S!4
M ,<0  #$!PH O0,4 +<$(0"R!BX K@@Z *H)1 "G"4T I I5 *(*7 "@"F(
MG@MI )P+;P";"W8 F0Q^ )<,A@"6#)  E R: )(-I@"1#;, CPW% (T.X@"+
M$/8 B1#_ (@1_P"'$?\ AQ'_ (<1_P#V&0  YR   -8D  #()0  OR(  +D<
M  "T% $ L0T. *H.&0"E#R< H1 S )T1/@":$4< F!)/ )425@"3$EP D1)C
M ) 3:0".$W  C!-X (L3@0")%(L AQ26 (85H@"$%;  @Q;! ($7W0!_&/0
M?1G_ 'P9_P!\&?\ >QG_ 'L9_P#O(0  W2D  ,HM  "^+P  M2P  *XG  "H
M(   HQ<( )X6$P"9%R$ E!DM )$:. ".&D$ BQM) (D;4 "'&U< A1Q> (0<
M9 ""'&L @!QS '\=? !]'88 ?!Z1 'H>G@!X'ZL =Q^\ '8@U !T(?  <B'_
M '$B_P!Q(?\ <2'_ '$A_P#H*   TC   ,(U  "W-P  K34  *4Q  ">*P
MF"," )(>$ "-(!L B2$G (8B,@"#(SP @2-$ 'XC2P!\)%( >R19 'DD7P!W
M)&8 =B5N '0E=P!S)8$ <2:- &\FF0!N)J< ;2>X &PGS@%J*.T!:2G_ 6@I
M_P%H*?\!:"C_ 6@H_P'A+@  RS8  +P[  "Q/0  IST  )\Y  "7,P  CRT
M (@G# "#)Q8 ?R@B 'PI+0!Y*C< =RH_ '4J1P!S*TX <2M4 ' K6P!N*V(
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M 5,Y_P'-/   O$0  *])  "D3   FDP  )%+  "'1@  ?4   ',[  !L. T
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M 4=%B %&19@"14:I D1&O0)#1MP"0T;U D-&_P)#1O\!0T7_ 4-%_P'!1P
MLD\  *94  "<5P  DE@  (A8  !^50  <4\  &9*  !<1@4 5T8/ %1&& !1
M1B( 3T8K $Y&,P!,1SH 2T=! $I'20!)2%  2$A8 $=(80!%26P 1$EX 4))
MA@%!298!0$JG C]*NP(^2]@"/DKS CY*_P(^2?\!/TG_ 3])_P&]2@  KU(
M *-8  "96P  D%T  (9<  ![60  ;5,  &)/  !73 $ 44H- $Y*%0!,2Q\
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M 2Y9M0$M6<\!+5GO 2Y8_P$N5_\!+E?_ 2Y6_P&R5P  I5\  )ME  "1:0
MAVH  'QJ  !Q:   8V4  %AB  !-7P  0UT" #Q;#0 Z7!0 .%P= #=<)@ U
M72X -%TV #-=/@ R748 ,5Y. #!>5P O7F( +5YN "Q??0 J7XX *5^@ "A?
MLP$G7\P )U_M 2=>_P$G7?\!*%W_ 2A<_P&M7   HF0  )AJ  ".;@  @V\
M 'EO  !N;@  8&L  %1I  !)9P  /V4  #5C"0 R8Q$ ,&,9 "]D(0 N9"D
M+60Q "QD.0 K94( *F5* "AE5  G95\ )F9K "1F>@ C9HL (F:= "!FL0 ?
M9LD 'V;K "!E_@ @9/\ (&/_ 2%C_P&I8@  GFH  )5P  "*<P  @'4  '5U
M  !I=   7'(  $]Q  !$;P  .FX  #!M P I; T )VP4 "9L'  E;20 )&TL
M "-M-  B;3T (6Y& "!N4  >;EL '6YG !QN=@ :;H< &6^: !AOK@ 6;\8
M%F[I !=M_  8;/\ &&O_ !AK_P"D:0  FG$  )!V  "&>0  ?'L  '%[  !D
M>P  5WH  $IY   _>   -7@  "MW   B=@< '78/ !QW%@ ;=QX &G<F !EW
M+@ 8=S< %WA  !5X2@ 4>%8 $WAC !)X<@ 1>(, $'B7  ]XJP .>,, #G?F
M  YV^@ /=?\ $'7_ !!T_P"?<0  E7@  (M\  ""?P  =X$  &J"  !=@@
M4((  $2"   X@@  +H(  "2"   <@@  %(() !&#$  0@Q8 $(,>  Z#)P .
M@S  #8,Y  V#1  ,@U  "X-=  F#;  (@WX !H.1  6"I0 #@KL !(';  2!
M\@ %@/\ !G__  9__P":>0  D'X  (:#  !]A0  ;X<  &*)  !5B@  28L
M #V,   QC   )HP  !V-   5C@  #X\#  J0#  &D!$ !(\8  ./(  !CRD
M (\R  "0/0  D$D  (]6  "/90  CW8  (^*  ".GP  CK0  (W/  ",[@
MC/L  (O_  "+_P"4@   BX4  (*)  !TC   9H\  %F1  !,DP  0)4  #26
M   HE@  'I<  !68   /F@  "IL   *<"0  G X  )P3  "<&@  G"(  )TK
M  "=-0  G4   )U.  "=7   G6X  )R!  "<EP  G*P  )O&  ":Z   F?D
M )G_  "8_P".B   AHP  'B0  !JE   7)<  $^:  !"G0  -IX  "F?   ?
MH0  %:(   ZD   (I@   *@   "I!   J0H  *D.  "I$P  JAH  *HB  "K
M*P  K#8  *Q$  "L4P  K&,  *QW  "KC@  JZ0  *N\  "JW@  J?0  *G]
M  "I_P")C@  >Y,  &V7  !?G   4:   $2D   VI@  *J@  !ZI   4JP
M#:X   :P    L@   +4   "U    M0,  +8)  "W#@  N!(  +@9  "Z(0
MNRL  +PX  "]1P  O5@  +UK  "]@0  O9D  +VP  "]S   O.H  +SW  "[
M_@!^E0  <)L  &*@  !3I0  1JH  #BM   JKP  'K$  !.T   ,MP   [D
M  "\    OP   ,(   #"    PP   ,0   #&!@  QPP  ,@0  #*%@  S"
M ,\K  #0.@  T4L  -%>  #2<P  THL  -*D  #3NP  T]@  -/M  #3]@!S
MG0  9*,  %:I  !'KP  .;,  "JV   =N0  $KP   J_    PP   ,8   #)
M    S0   ,\   #0    T@   -0   #6    V0(  -L(  #>#@  X1,  .0=
M  #H*@  Z#P  .E/  #I9   ZGP  .N5  #KK   Z\(  .S5  #LY0!FI@
M6*P  $FS   [N0  *[P  !W    1Q   "<@   #,    SP   -,   #9
MW0   .    #A    XP   .4   #G    Z@   .P   #N!   \0L  /42  #X
M'   ^RL  /T^  #^4P  _FH  /^#  #_FP  _ZX  /^^  #_R@#_ !( _P 0
M /\ $0#_ !, _P 9 /\ )@#_ #0 _P!! /\ 30#_ %@ _P!B /\ :P#_ ',
M_P!Z /\ @0#_ (< _P"- /\ DP#_ )D _P"@ /\ IP#^ *\ _ "Z /H R0#Y
M .$ ^ #S /< _P#V /\ ]0#_ /$ _P#I /\ Y #_ .$ _P#_  \ _P - /\
M#0#_  X _P 4 /\ (0#_ "X _P \ /\ 2 #_ %, _P!= /\ 9@#^ &T _ !U
M /L >P#Y (( ^ "( /< C@#V )0 ] "; /, H@#Q *H [P"T .T P0#K -4
MZ@#L .@ _ #G /\ Y0#_ .8 _P#@ /\ V0#_ -0 _P#_  L _P ( /\ !@#_
M  D _P 0 /\ ' #_ "D _P V /\ 0@#[ $X ]P!7 /0 8 #R &@ [P!O .T
M=@#L 'P Z@"" .@ B #G (X Y0"5 ., G #A *0 WP"N -T N0#: ,H UP#D
M -0 ]@#1 /\ T #_ -  _P#/ /\ RP#_ ,< _P#_  , _P   /\   #_  0
M_P - /H %@#V ", \P P /  / #M $< Z0!1 .4 6@#B &( WP!I -T ;P#:
M '8 V !\ -0 @@#2 (@ T "/ ,T E@#+ )X R0"H ,< LP#% ,$ P@#8 ,
M[P"_ /X O@#_ +T _P"\ /\ O #_ +P _P#_ @  _P   /\   #_    ]  '
M .T $0#H !P XP I -\ -0#; $$ U@!+ -$ 5 #- %P R@!C ,@ :0#& &\
MPP!U ,$ >P"_ (( O@"( +P D "Z )@ N "B +4 K "S +D L0#+ *\ YP"N
M /@ K #_ *L _P"L /\ K #_ *L _P#_!   _P   /8   #N    YP   -\
M# #6 !4 SP B ,H +@#' #H PP!$ ,  30"\ %4 N0!< +< 8P"U &D LP!O
M +$ =0"O 'L K0"" *L B@"I )( IP"< *4 I@"C +, H0## )\ W@"> /(
MG0#_ )P _P"< /\ FP#_ )L _P#_!P  ]@D  .D+  #?"@  U00  ,X !0#&
M !  P  : +L )P"W #( LP ] +  1@"M $\ J@!6 *@ 7 "F &, I !H *(
M;P"A '4 GP!\ )T A "; (T F0"7 )< H@"5 *X DP"] )$ TP"0 .T CP#\
M (X _P"- ?\ C0'_ (T!_P#Y#@  ZA(  -P5  #-%0  Q!$  +X,  "Z @H
MM  2 *X '@"J "H I@ U *( /P"@ $@ G0%0 )L"5@"9 EP EP-C )4#:0"3
M V\ D01V ) $?P".!8@ C 62 (H&G@"(!JH A@>Z (4(SP"$"NL @@O\ ($,
M_P" #/\ @ S_ ( ,_P#Q%0  X!T  ,T@  #!(0  N!T  +$7  "L$   J D-
M *('%@"="2, F0HN )4+. "3#$$ D Q) (X-4 ",#5< B@U= (@-8P"'#6H
MA0YQ (,.>@""#H0 @ Z/ 'X/FP!\#Z@ >Q"X 'H0S@!X$>P =A+_ '42_P!T
M$_\ =!/_ '03_P#H'@  TR8  ,,J  "X*@  KB@  *<C  "@'   FQ,# )8/
M$ "0$!L C!$G (D2,@"&$SL A!-# ((42P" %%$ ?A17 'P47@![%64 >15L
M '<5= !V%GX =!:* '(7E@!Q%Z0 ;QBT &X8R0!M&>@ :QK\ &H;_P!J&_\
M:AO_ &H;_P#@)@  RBT  +PQ  "P,P  IS$  )\L  "7)@  D!\  (H7# "%
M&!8 @1DB 'X:+ ![&S8 >1L^ '<<10!U'$P <QQ3 '$=60!P'6  ;AUG &T>
M< !K'GH :AZ% &@?D@!G'Z  92"P &0AQ0!C(>0 8B+Z &$B_P!A(O\ 82+_
M &$B_P#7+   PS0  +8X  "J.0  H3@  )@U  "0+P  B"@  ( A" ![(!(
M=R$= '0B)P!Q(C$ ;R,Y &TC00!K(T@ :2-. &@D50!F)%L 921C &,E:P!B
M)74 826! %\FC@!>)IT 72>M %LHP0!;*.  6BGW %DI_P!9*?\ 62G_ %DH
M_P#/,@  OCD  +$]  "F/P  G#\  ),\  "*-@  @3   'DJ P!R)@\ ;B<9
M &LH(P!I*"P 9BDU &4I/ !C*4, 82I* & J40!>*E< 72I? %PK: !:*W(
M62Q] %@LBP!6+9H 52VJ %0NO0!3+MP 4B_U %(O_P!2+O\ 4B[_ %(N_P#*
M-@  NCT  *U"  "B1   F$0  (]!  "%/   >S<  '(Q  !K+ P 9RT5 &0M
M'P!A+B@ 7RXQ %TN.0!<+T  6B]& %@O30!7+U0 5C!< %4P9 !3,6X 4C%Z
M %$QB !0,I< 3C*H $TSNP!---@ 3#3S $PT_P!,-/\ 3#/_ $PS_P#&.@
MMD(  *E&  ">20  E4D  (M'  "!0@  =ST  &TW  !D,@D 8#(2 %TR' !:
M,B4 6#,M %8S-0!5,SP 4S1# %(T2@!1-%$ 4#19 $\U80!--6P 3#9W $LV
MA0!*-Y4 2#>F $<XN %'.-,!1CCQ 48X_P%&./\ 1CC_ $8W_P#!/@  LD4
M *9*  "<30  DDT  (A+  !^1P  <T(  &D]  !?-P8 6C80 %<W& !4-R(
M4C<J % W,@!/.#D 33A  $PX1P!+.$X 2CE6 $DY7P!(.FD 1SIU $4[@P!$
M.Y, 0SRD 4(\M@%!/= !03WP 4$]_P%!//\!03S_ 4$\_P"^0@  KTD  *-.
M  "94   CU$  (50  ![3   ;T8  &5"  !:/0( 5#L. %$[%0!/.Q\ 33LG
M $L[+P!)/#8 1SP] $<\1 !&/4L 13U4 $0^7 !#/F< 0C]S $ _@0 _/Y$
M/D"B #U M0$\0<X!/$'N 3Q!_P$\0/\!/$#_ 3T__P&Z10  K$P  *%1  "7
M5   C54  (-4  !X40  ;$L  &%'  !60@  3T , $P_$P!)0!P 1T D $9
M+ !$0#, 0T Z $)!0@!!04D 0$)1 #]"6@ ^0V4 /4-Q #M#?P Z1(\ .42@
M #A%LP$W1<L!-T7L 3=%_P$W1/\!.$3_ 3A#_P"W20  J5   )Y5  "46
MBUD  (!8  !V5@  :%   %U,  !32   2D4) $9$$0!$1!D 0D0B $%%*0 _
M13$ /D4X #U%/P \1D< .T9/ #I'6  Y1V( .$AN #9(?  U2(T -$F> #-)
ML0 R2<D ,4GK #))_@ R2/\ ,DC_ #-(_P"T3   IU0  )Q9  "27   B%T
M 'Y=  !S6@  954  %M2  !03@  1DH% $!)#@ ^218 /4D> #M*)@ Z2BX
M.4HU #A+/0 W2T0 -DM- #1,5@ S3&  ,DQL #%->@ P38L +DV< "U.KP L
M3L< +$[I "Q-_0 M3?\ +4S_ "U,_P"P4   I%@  )E=  "/80  AF(  'MA
M  !P7P  8EL  %A8  !.50  0U$! #M/#  X3Q, -D\; #5/(P T4"L ,U R
M #)0.@ Q4$( ,%%* "Y14P M4ET +%)I "M2>  I4H@ *%.: "=3K0 F4\4
M)E/G "93_  G4O\ )U'_ "=1_P"L50  H%P  )9B  "-9@  @V<  'AF  !M
M90  8&$  %5>  !*6P  /U@  #56"  Q51  ,%87 "Y6'P M5B< +%8O "M7
M-@ J5SX *5=' "A74  F6%H )5AG "18=0 C688 (5F8 "!9JP ?6<( 'UGE
M !]8^@ @6/\ (%?_ "%7_P"H6@  G6(  )-G  "*:P  ?VP  '5L  !J:P
M76@  %%E  !&8P  .V   #%> P J70T *%T3 "9=&P E7B, )%XJ "->,@ B
M7CH (5Y# "!?3  ?7U< 'E]C !Q@<0 ;8(( &6"5 !A@J0 78,  %F#B !=?
M^0 87O\ &5[_ !E=_P"D8   F6@  )!N  "&<   ?'(  ')R  !F<0  6&X
M $QL  !!:P  -FD  "UG   C9@@ 'V8/ !UF%0 <9AT &V8E !IF+0 99S4
M&&<^ !=G2  69U, %6A? !-H;@ 2:'\ $6B2 !!HI@ /:+T #FC@ !!G]P 0
M9O\ $67_ !%E_P"?9P  EF\  (QS  ""=@  >'@  &UX  !@=P  4W8  $9T
M   [<P  ,7(  "=Q   ><0  %G * !-P$  3<!< $G ? !%Q)P 0<2\ $'$X
M  YQ0@ .<4X #7%;  QQ:0 +<7H "G&-  AQH0 &<;8 !G#2  =P[P (;_\
M"6[_  EN_P";;P  D74  (=Y  !^?   ='X  &9^  !9?@  37X  $!]   U
M?0  *GP  "%\   8?   $7P$  Q\#  *?!$ "7P9  A\(0 '?"D !GPR  1\
M/0 #?$@  7Q5  !\8P  ?'0  'R'  ![G   >[$  'K+  !YZP  >?H  'G_
M  !X_P"6=P  C'P  (.   !Y@P  ;(0  %Z%  !1A@  18<  #F'   MAP
M(X<  !J'   2AP  #8@!  :)"@ !B0\  (D4  "(&P  B",  (DL  ")-@
MB4(  (A.  "(70  B&T  (B!  "'E0  AZL  (;$  "%Y@  A/@  (3_  "$
M_P"0?@  AX,  'Z'  !QB0  8XL  %:-  !)CP  /)$  #"1   DD0  &I(
M !*3   -E   !I4   "6!@  E@P  )40  "6%0  EAT  )8D  "6+@  ECD
M )9&  "650  EF4  )9X  "5C@  E:0  )2\  "3WP  D_4  )+_  "2_P"+
MA@  @XH  '6-  !GD   690  $R7   _F0  ,IH  ":;   ;G   $IT   R?
M   $H    *(   "C 0  HP<  *,,  "C$   I!4  *0<  "E)0  IB\  *8\
M  "F2P  IEL  *9N  "EA   I9L  *2S  "CT   H^\  *+\  "B_P"&C0
M>)$  &J5  !<F0  3IT  $&@   SH@  )J,  !NE   1IP  "JD   &K
MK0   *\   "P    L    + %  "Q"P  L@\  +,4  "T&P  M20  +<P  "W
M/P  MU   +=B  "W>   MY   +:I  "VP@  MN0  +;U  "U_@![DP  ;9@
M %^=  !0H@  0J8  #2I   FJP  &JT  !"O   )L@   +0   "W    N@
M +P   "]    O@   +X   #  @  P0@  ,(-  #$$@  QAD  ,DD  #*,@
MRT,  ,M5  #,:@  S(,  ,R<  #+M0  S,X  ,SI  #,]@!PFP  8:$  %*F
M  !$JP  -K   ">R   :M0  $+@   >[    O@   ,$   #$    R    ,L
M  #+    S0   ,X   #0    T@   -4#  #8"@  VQ   -X8  #B)   XS4
M .1(  #E7   YG,  .:-  #FI0  YKP  .;3  #GYP!CI   5:H  $:P   X
MM0  *+D  !J\   /P   !<0   #'    RP   ,\   #4    V    -P   #=
M    WP   .$   #C    Y0   .@   #J    [08  /$.  #U%@  ^"4  /DX
M  #Y30  ^F,  /M\  #\E0  _*H  /R[  #]RP#_  \ _P . /\ #@#_ !
M_P 6 /\ (P#_ #  _P ] /\ 20#_ %0 _P!> /\ 9@#_ &X _P!V /\ ? #_
M (( _P") /\ CP#_ )4 _@"; /T HP#[ *L ^@"U /D PP#W -L ]@#P /0
M_P#S /\ \@#_ .P _P#B /\ W #_ -8 _P#_  P _P ) /\ " #_  H _P 2
M /\ '@#_ "L _P X /\ 1 #_ $\ _P!9 /X 80#\ &D ^@!P /@ =P#W 'T
M]@"# /0 B0#R (\ \0"6 .\ G0#M *4 [ "O .H O #H ,T Y@#H .0 ^@#C
M /\ X@#_ .  _P#5 /\ S@#_ ,L _P#_  8 _P ! /\   #_  0 _P . /\
M&0#_ "4 _0 R /L /@#W $D \P!3 /  7 #N &, [ !J .H <0#H '< Y@!]
M .0 @P#B (D X "0 -X EP#< )\ V0"I -8 M #3 ,0 T #> ,X \P#, /\
MRP#_ ,H _P#( /\ P@#_ +X _P#_    _P   /\   #_    ^P + /8 $P#Q
M "  [0 L .H . #G $, XP!- .  5@#< %T V0!D -4 :P#2 '$ T !V ,X
M? #, (, R@") ,@ D0#& )D Q "C ,$ K0"_ +L O0#/ +L ZP"Y /P MP#_
M +< _P"V /\ M #_ +$ _P#_    _P   /\   #V    [@ % .< #P#A !D
MVP E -4 ,0#2 #P S@!& ,H 3P#' %< Q !> ,$ 9 "_ &H O0!P +L =@"Y
M 'P N "# +8 B@"S ), L0"< *\ IP"M +, JP#% *D X0"G /4 I@#_ *4
M_P"D /\ I #_ *0 _P#_    _    /$   #H    X    -0 "P#, !, QP ?
M ,( *@"_ #4 O  _ +@ 2 "U %  LP!7 +  7@"N &0 K !I *L ;P"I '4
MIP!\ *4 A "C (P H0"6 )\ H0"= *T F@"\ )@ T@"7 .X E0#^ )0 _P"5
M /\ E0#_ )4 _P#\ 0  \ 4  .,'  #5!0  S    ,4 ! "^  X N  7 +,
M(P"O "X JP X *D 00"F $H HP!1 *$ 5P"? %T G0!C )L :0": &\ F !V
M )8 ?0"4 (8 D@"0 )  FP". *< C "V (H R0"( .< AP#Y (< _P"& /\
MA@#_ (8 _P#T#   Y!   -$2  #%$0  O0X  +8(  "Q  @ JP 1 *8 &P"A
M "8 G@ Q )H .@"8 $, E0!* ), 40"1 %< CP!= (X 8P", &D B@!P (@
M=P"& (  A "+ (( E@"  *, ?@"Q 'T Q ![ N$ >@/U 'H%_P!Y!?\ > ;_
M '@&_P#J$P  UAH  ,8=  "Z'   L1D  *H3  "D#0  GP4, )D % "5 !\
MD0(I (T#,P"+!#P B 5$ (8&2P"$!E$ @@=7 ($'70!_!V, ?0AJ 'L(<@!Z
M"'P > F& '8)D@!T"J  <PJO '$+P0!P#-\ ;PWV &X._P!M#O\ ;0[_ &T.
M_P#A'   RR,  +PF  "Q)@  J"0  * >  "9&   DQ " (X+#@"("Q< A PB
M ($-+ !^#34 ? X] 'H.10!X#DL =PY1 '4/6 !S#UX <1!E ' 0;@!N$'<
M;!"" &L0CP!I$9T :!&M &82P !E$M\ 9!/V &,4_P!C%/\ 8A3_ &(4_P#6
M)   PRH  +4N  "J+P  H"T  )@H  "0(@  B1L  ((3" !]$1( >1(< '83
M)P!S%#  <10X &\5/P!M%48 ;!5, &H64P!H%ED 9Q9A &46:0!D%W( 8A=^
M &$8BP!?&)D 7AFI %P9O !<&M@ 6AOS %H<_P!9'/\ 61S_ %D<_P#-*@
MO3$  *\U  "D-@  FS0  )(Q  ")*P  @24  'D= P!S& X ;QD8 &P:(@!I
M&RL 9QLS &4<.P!D'$$ 8AU( & =3@!?'54 71U< %P>9 !;'FX 61]Y %@?
MAP!6()8 52"F %0AN !3(=( 4B+Q %(C_P!2(_\ 4B+_ %(B_P#(+P  N#8
M *LZ  "@/   ECL  (TX  "#,@  >BT  '(F  !J( P 9B 3 &,A'0!A(28
M7R(O %TB-@!;(CT 6B-$ %@C2@!7(U$ 52-8 %0D80!3)&H 425V % E@P!/
M)I, 3B>C $PGM0!,*,X 2RCN $LI_P!+*/\ 2RC_ $LH_P##-   LSL  *<_
M  "<00  DD   (D^  !_.0  =3,  &PM  !C)P@ 7B81 %PF&0!9)R( 5R<K
M %4H,@!4*#D 4BA  %$H1@!0*4T 3BE5 $TI70!,*F< 2RIS $DK@ !(*Y
M1RRA $8MLP!%+<L 12[L $0N_P!$+O\ 12W_ $4M_P"^.   L#\  *1#  "9
M10  CT4  (5#  ![/@  <3D  &<T  !>+@0 6"L. %4K%@!2+!\ 4"PG $\L
M+P!-+38 3"T\ $HM0P!)+4H 2"Y2 $<N6@!&+V0 12]P $,P?@!",(T 03&>
M $ RL0 _,L@ /S/J #\S_@ _,O\ /S+_ #\R_P"[/   K4,  *%'  "620
MC$D  (-(  !X1   ;3X  &,Y  !:-   4C , $\P$P!,,!P 2C D $DQ*P!'
M,3( 1C$Y $0Q0 !#,D< 0C)/ $$S6 ! ,V( /S1M #XT>P ]-8L /#:< #LV
MKP Z-\8 .3?H #DW_  Z-_\ .C;_ #HV_P"W0   JD8  )Y+  "430  BDX
M (!,  !U2   :D,  & ^  !6.0  334) $DT$0!'-1D 134A $,U* !!-2\
M0#4V #\V/0 ^-D4 /3=- #PW50 [.&  .CAK #DY>0 X.8D -SJ; #4ZK0 U
M.\0 -#OF #0[^P U._\ -3K_ #4Z_P"T0P  ITH  )Q.  "240  B%(  'Y0
M  !S30  9T@  %Q$  !2/P  2#H& $0Y#P!!.18 /SD> #XY)@ \.2T .SHT
M #HZ.P Y.T( .#M* #<\4P V/%T -3UI #0]=P S/H< ,3Z9 # _JP O/\(
M+S_D "\_^@ P/_\ ,#[_ # ^_P"Q1P  I$T  )E2  "/50  AE8  'Q5  !Q
M4@  9$P  %E)  !/10  14 # #\^#0 \/A, .CX; #D^(P W/BH -C\Q #4_
M.  T/T  ,T!( #) 40 Q05L ,$%G "Y"=0 M0H4 +$.7 "M#J@ J0\  *43B
M "I#^0 J0_\ *T+_ "M"_P"N2@  H5$  )=6  "-60  @UH  'E:  !N5P
M85(  %=.  !-2P  0T<  #I#"@ V0Q$ -$,8 #-#(  R1"< ,40O #!$-@ O
M13T +45& "Q%3P K1ED *D9D "E'<@ H1X, )D>5 "5(J  D2+X (TC@ "1(
M]P E1_\ )4?_ "9'_P"J3P  GU4  )1:  "+7@  @5\  '=>  !K7   7U@
M %55  !+40  0$T  #5*!P P20X +DD5 "U)'0 L220 *THK "I*,P H2CL
M)TM# "9+3  E2U8 )$QB "-,<  A3(  ($V3 !]-I@ >3;L '4[= !Y-]@ >
M3/\ 'TS_ "!+_P"G4P  G%H  ))?  "(8P  ?F0  '1C  !I80  7%X  %);
M  !'6   /%4  #)2 @ J4 P )T\2 "90&0 E4"  )% H "-0+P B43< (5%
M "!120 >4E, '5)? !Q2;0 :4WT &5.0 !A3I  64[D %5/9 !93]  74O\
M&%'_ !E1_P"C60  F&   (]E  "%:   >VD  '%I  !F9P  660  $UA  !"
M7P  .%P  "Y:   E6 @ (%<. !Y7%  =5QP '%@C !M8*P :6#, &5@\ !A8
M10 665  %5E; !19:0 36GH $EJ- !%:H0 06K< #EK5 !!9\P 06?\ $5C_
M !%8_P"?7P  E68  (QK  "";0  >&X  &YO  !B;0  56H  $AH   ^9@
M,V4  "EC   @80$ && + !5@$  48!< $V > !)@)@ 28"X $6$W !!A0  /
M84L #F%8  UA9@ ,8G8 "V*)  IAG0 )8;( "&'+  AAZP )8/T "E__  M?
M_P";9@  DFT  (AQ  !^<P  =74  &IT  !<<P  3W(  $-P   X;P  +6X
M "1L   ;:P  $VL$  YJ#  -:A( #&H9  MJ(0 *:BD "6HR  AJ/  ':T<
M!6M3  1K80 ":W$  &J$  !JF   :JT  &G&  !IYP  :?@  &C_  !H_P"7
M;0  C7,  (1W  ![>@  <'L  &-[  !6>@  27H  #UY   Q>   )W<  !UV
M   5=@  #W8"  EV"@ $=@\  '85  !V'   =B0  '4L  !U-@  =4$  '5.
M  !U7   =6P  '5^  !TDP  =*@  '/   !SXP  <O<  '+_  !Q_P"2=0
MB7H  (!^  !V@   :8$  %N"  !.@@  08(  #6#   I@@  'X$  !:!   0
M@@  "H(   *#!P  @@T  ((1  ""%P  @AX  ((F  ""+P  @CL  ()'  ""
M50  @64  (%X  "!C0  @*(  '^Z  !_W0  ?O0  'W_  !]_P"-?   A($
M 'N$  !NA@  8(@  %**  !%BP  .8P  "R,   AC   %XP  !"-   )C@
M H\   "0 P  CPD  (\.  "/$@  D!@  ) ?  "0*   D#(  ) _  "030
MD%T  (]P  "/A0  CIP  (ZS  "-T   C/   (O^  "+_P"(A   @(@  '*+
M  !DC0  5I   $B3   [E0  +I8  "*6   7EP  #Y@   B9    FP   )T
M  "=    G0,  )T)  "=#0  GA$  )X7  "?'P  GRD  * U  "@0P  H%0
M *!F  "?>P  GI,  )ZK  "=Q@  G>D  )SY  "<_P"#BP  =8X  &>2  !9
ME@  2YD  #V<   PG@  (Y\  !>@   .H@  !Z0   "F    J    *H   "J
M    J@   *L!  "K!P  K P  *T0  "N%@  KQX  +$I  "Q.   L4@  +%:
M  "Q;P  L8@  +&@  "PN@  K]T  *_R  "O_0!XD0  :I8  %R:  !-GP
M/Z,  #&F   CIP  %ZD   ZK   %K@   +    "R    M0   +<   "W
MN    +D   "Z    O ,  +T)  "^#@  P!0  ,,>  #%*P  Q3P  ,9.  #&
M8@  QGH  ,:4  #&K0  QL@  ,7E  #%\P!LF0  7IX  $^D  !!J   ,JP
M "2O   6L0  #;0   .W    N@   +T   #     Q    ,8   #&    R
M ,D   #+    S    ,X   #0!@  TPT  -@3  #<'@  WBT  -]   #@5
MX6L  .&%  #AGP  X;<  .'/  #AY@!@H0  4J<  $.M   TL@  );4  !>Y
M   -O    ;\   ##    QP   ,H   #/    TP   -8   #7    V@   -P
M  #?    X0   .,   #F    Z0$  .P+  #P$@  \Q\  /0Q  #V1@  ]UP
M /AT  #XCP  ^:8  /FX  #XR0#_  T _P + /\ "P#_  X _P 3 /\ 'P#_
M "P _P Y /\ 10#_ %  _P!9 /\ 8@#_ &H _P!Q /\ =P#_ 'X _P"$ /X
MB@#] )  _ "7 /H G@#Y *< ]P"Q /8 O@#U -( \P#L /$ _@#P /\ \ #_
M .8 _P#< /\ T@#_ ,T _P#_  < _P $ /\  @#_  8 _P 0 /\ &P#_ "<
M_P S /\ /P#_ $H _@!4 /L 70#Y &0 ]P!K /4 <@#S '@ \@!^ /  A #O
M (H [0"1 .P F0#J *$ Z "K .8 M@#D ,< X@#C .  ]P#> /\ W0#_ -D
M_P#, /\ Q0#_ ,$ _P#_    _P   /\   #_  $ _P - /\ %@#\ "( ^0 N
M /8 .0#S $4 [P!. .P 5P#I %X Y@!E .0 ; #B '( X !W -\ ?@#= (0
MVP"+ -@ D@#5 )L T@"D ,\ KP#- +X RP#5 ,D [P#' /\ Q0#_ ,0 _P"^
M /\ N #_ +4 _P#_    _P   /\   #^    ]P ) /$ $0#K !P YP H .0
M,P#A #X W0!( -@ 40#3 %@ T !? ,X 90#, &L R@!Q ,@ =P#& 'T Q "$
M ,( C #  )0 O@"> +L J "Y +8 MP#( +4 Y@"S /H L0#_ +  _P"P /\
MK #_ *D _P#_    _P   /H   #Q    Z  # .  #0#8 !8 T0 B ,T +0#*
M #< Q@!! ,( 2@"_ %( O0!9 +H 7P"X &4 MP!J +4 < "S '8 L0!] *\
MA0"M (T JP"7 *D H0"G *X I0"^ *( V "@ /( GP#_ )X _P"> /\ G@#_
M )P _P#_    ]P   .L   #A    U@   ,L "0#% !$ OP ; +L )@"W #$
MM  Z +$ 0P"N $L JP!2 *D 6 "G %X I@!D *0 :0"B '  H !V )X ?@"<
M (8 F@"0 )@ FP"6 *< E "V )( R@"0 .D CP#\ (X _P"- /\ C #_ (T
M_P#X    Z0(  -L#  #, 0  Q    +T  @"V  T L  5 *L ( "G "H I  T
M *$ / "> $0 G !+ )H 4@"8 %@ E@!= )4 8P"3 &D D0!P (\ =P"- (
MBP"* (D E0"' *$ A0"O (, P0"! .  @ #U '\ _P!_ /\ ?P#_ '\ _P#N
M"@  W X  ,H0  "^#@  M0L  *\#  "I  < HP 0 )X & "9 ", E@ L ),
M-0"0 #X C@!% (P 2P"* %$ B !7 (8 70"% &, @P!J ($ <0!_ 'H ?0"$
M 'L CP!Y )P =P"J '4 NP!T -0 <@#P '( _P!R /\ <0#_ '$ _P#C$0
MS1<  +\9  "S&0  JA4  *,0  "="@  EP$* )$ $@"- !L B0 E (4 +P"#
M #< @  ^ 'X 10!] $L >P!1 'D 5P!X %T =@!D '0!:P!R 70 < )_ &X"
MBP!L Y@ :P.F &D$MP!H!<X 9P?L &8(_0!F"?\ 90G_ &4)_P#6&@  Q"
M +8C  "K(P  H2   )D;  "2%   C X! (8'#0" !!0 ? 8> 'D'* !V"#
M= @X '()/P!P"44 ;PI, &T*4@!L"E@ :@M? &@+9P!G"W  90QZ &,,AP!B
M#)4 8 VD %\-M@!>#<X 7 [M %P/_P!;$/\ 6Q#_ %L0_P#-(0  O"@  *\K
M  "D*P  FBD  )(D  ")'P  @A@  'L1!0!U#0\ <0T7 &X.(0!K#BH :0\R
M &<0.0!E$$  9!!& &,030!A$%, 7Q%: %X18@!<$6L 6Q%V %D2@P!8$I(
M5A.B %43M !4$\L 4Q3L %(5_P!2%O\ 4A7_ %(5_P#&*   MBX  *DR  "?
M,@  E3$  (PM  "#)P  >B$  '(:  !K$PL 9Q,3 &04' !A%"4 7Q4M %T5
M- !<%3L 6Q9" %D62 !8%D\ 5A=6 %477@!3%V< 4AAR % 8?P!/&8X 3AJ?
M $P:L !+&\< 2QOI $H<_0!*'/\ 2AS_ $H<_P#!+0  L30  *4W  ":.
MD#<  (<T  !]+P  ="D  &PC  !D' < 7AD0 %L:& !9&R$ 5QLI %4;, !4
M'#< 4AP] %$<1 !/'4L 3AU2 $T=6@!+'F, 2AYN $D?? !''XL 1B"< $4A
MK@!$(<0 0R+F $,B_ !#(O\ 0R+_ $,B_P"\,@  K3@  *$\  "7/@  C3T
M (,Z  !Y-0  ;S   &8J  !>) ( 5R - %0@% !1(!T 3R$E $XA+ !,(3,
M2R(Z $DB0 !((D< 1R). $8C5P!$(V  0R1K $(D>0!!)8@ /R:9 #XFJP ]
M)\$ /2?C #TH^@ ]*/\ /2?_ #TG_P"X-@  JCT  )Y   "40@  BD(  ( _
M  !V.P  ;#8  &(P  !9*@  424+ $TE$0!+)1D 224A $<F* !%)B\ 1"8V
M $,F/0!")T0 02=+ #\H5  ^*%T /2EI #PI=@ [*H8 .2N7 #@KJ0 W++\
M-RS@ #<L^  W+/\ -RS_ #@L_P"U.@  IT   )Q$  "11@  AT8  'U$  !S
M0   :#L  %\V  !5,0  3"L' $<I#P!%*A8 0RH> $$J)0 _*BP /BLS #TK
M.0 \*T$ .RQ( #HL40 Y+5L ."YF #8N<P U+X, -"^5 #,PIP R,+T ,3'>
M #$Q]P R,?\ ,C#_ #,P_P"Q/@  I$0  )E(  "/2@  A4H  'M)  !P10
M94   %L[  !2-@  2#$$ $(N#0 _+A, /2X; #LN(@ Y+RD ."\O #<O-@ V
M,#X -3!& #0Q3P S,5D ,C)D #$R<0 P,X$ +S23 "XTI@ L-;L +#7; "PU
M]0 M-?\ +33_ "XT_P"N00  HD@  )=,  "-3@  @TX  'E-  !N2@  8D4
M %A   !./   13<  #TS"P Y,Q$ -S,8 #8S'P T,R8 ,S,M #(T-  Q-#P
M,#5$ "\U3  N-E8 +39B "PW;P K-W\ *CB1 "@XI  G.;D )CG8 "<Y]  H
M.?\ *#C_ "DX_P"K10  GTL  )1/  "+4@  @5,  '=2  !L3P  7TD  %9&
M  !,0@  0CT  #@X"  T. \ ,C@5 #$X'0 O."0 +C@K "TY,@ L.3D *SI!
M "HZ2@ I.U0 *#M? "<\;0 E/'T )#V/ ",]H@ B/;< (3[4 "$^\P B/?\
M(SW_ ",\_P"H20  G4\  ))3  ")5@  ?U<  '56  !J4P  74\  %-,  !*
M2   0$0  #9 !0 O/0T +3T3 "L]&@ J/B$ *3XH "@^+P G/C< )C\_ "0_
M2  C0%( (D!= "%!:@ @07H 'D&- !U"H  <0K4 &T+1 !M"\0 <0O\ '4'_
M !Y!_P"E30  FE,  )!8  "&6P  ?5P  ');  !G6   6U0  %%2  !(3@
M/4H  #-'   J0PL )D,0 "5#%@ D0QX (T0E ")$+  A1#0 ($4\ !Y%10 =
M14\ '$9: !M&:  91G@ &$>* !='G@ 61[, %$C. !5'[P 61_\ %T;_ !=&
M_P"B4@  EU@  (U=  "$8   >F$  '!@  !E7@  65H  $]8  !$5   .5$
M "].   F2P8 ($H. !Y*$P =2AH '$HA !M+*  :2S  &4LX !=+0@ 63$P
M%4Q7 !1,90 3374 $DV( !%-G  03;$ #D[,  ]-[@ 03?\ $4S_ !%,_P">
M5P  E%T  (MB  "!90  =V8  &UF  !C9   5F$  $I>   _6P  -5@  "M6
M   B5 $ &E(* !92$  54A8 %%(= !-2)  24BP $5(T !%2/@ 04T@ #U-4
M  Y38@ -5'( #%2$  M4F  )5*T "%3%  E4YP *4_L "U+_  M2_P";70
MD60  (AH  !^:P  =&P  &ML  !?:@  4F<  $5D   Z8@  ,&   "9>   =
M70  %5L% !!:#  .6A$ #EH8  U;(  ,6R< "ULP  I;.@ )6T4 !UM1  9;
M7@ $6VT  UN   %;E   6Z@  %O   !:X@  6O8  5K_  )9_P"79   CFL
M (1N  ![<   <G(  &=Q  !9<   3&X  $!L   U:P  *FD  "%G   89@
M$68!  QE"@ '90\ !&44  -D&P "9",  &0L  !D-0  9$   &1,  !D6@
M9&D  &1[  !DCP  8Z0  &.[  !BW0  8O0  &+_  !A_P"3;   B7$  (!U
M  !X=P  ;7@  &!W  !2=@  1G4  #ET   N=   (W(  !IQ   2<0  #7$
M  9Q"   < T  ' 2  !P%P  ;Q\  &\F  !O,   ;SL  &]'  !O5   ;V0
M &]U  !NB@  ;:   &VV  !LU@  :_(  &O_  !K_P".<P  A7@  'U[  !S
M?0  97X  %A^  !+?@  /GX  #)^   F?0  ''P  !-\   -?   !GT   !]
M!0  ? L  'P/  !\$P  ?!D  'PA  !\*0  ?#0  'M   ![3@  >UX  'MO
M  !ZA   >IH  'FQ  !XS@  =^\  ';^  !V_P")>@  @7\  'B"  !K@P
M784  $^&  !"AP  -8@  "F'   =AP  %(<   V(   &B0   (H   "*
MB08  (D,  ")#P  B1,  (D:  "*(@  BBP  (HX  "*1@  B58  (EH  ")
M?   B)0  (>K  "&Q@  A>H  (7[  "$_P"%@@  ?88  &^(  !ABP  4XT
M $6/   XD0  *Y$  !^2   4D@  #9,   24    E@   )<   "8    EP
M )<%  "7"P  F X  )@3  "9&@  F2(  )HN  ":/0  F4T  )E>  "9<P
MF(L  )BC  "7O   EN(  );W  "5_P" B0  <HP  &2/  !6DP  2)8  #J9
M   LF@  'YL  !2<   ,G@   Y\   "A    HP   *4   "E    I0   *4
M  "F @  IP@  *<-  "H$0  J1D  *LC  "K,0  JT$  *Q3  "L9P  JX
M *J:  "JLP  JM   *GO  "I^P!UCP  9Y0  %F8  !*G   /)\  "VB   @
MHP  $Z4   NG   !J0   *L   "N    L0   +(   "R    LP   +0   "U
M    M@   +@$  "Y"P  NQ   +T8  "_)   OS4  ,!'  # 6P  P'(  ,"-
M  #!I@  P,$  +_C  "^\P!JEP  6YP  $VA   ^I0  +ZD  "&K   3K0
M"[    "S    M0   +@   "\    OP   ,$   #!    PP   ,0   #&
MQP   ,D   #+    S@@  -$/  #5&   V"<  -DY  #:30  VV0  -M^  #<
MF0  W+   -S)  #<XP!=GP  3Z4  $"J   RKP  (K(  !2U   *N    +L
M  "_    PP   ,8   #+    S@   -$   #1    U    -8   #9    VP
M -X   #@    Y    .<&  #K#@  [QD  / J  #R/P  \U4  /1M  #TB
M]*$  /2V  #TQP#_  D _P & /\ !P#_  P _P 1 /\ ' #_ "@ _P T /\
M00#_ $P _P!5 /\ 70#_ &4 _P!L /\ <@#^ '@ _ !^ /L A #Z (L ^0"2
M /< F0#V *( ] "L /, N0#Q ,L \ #H .X ^P#M /\ [ #_ .$ _P#2 /\
MR0#_ ,0 _P#_  $ _P   /\   #_  0 _P . /\ %P#_ ", _P O /\ .P#]
M $8 ^@!0 /< 6 #T %\ \@!F /  ; #O '( [0!X .P ?@#J (4 Z0", .<
MDP#E )P XP"F .$ L0#? ,$ W0#= -L ] #9 /\ U@#_ ,\ _P#$ /\ O0#_
M +D _P#_    _P   /\   #_    _P + /P $P#W !X ]  J /( -0#N $
MZ0!* .8 4@#C %D X !@ -X 9@#< &P V@!R -< > #4 'X T@"% -  C0#.
M )4 S "? ,D J@#' +@ Q0#- ,, ZP#  /X OP#_ +X _P"V /\ L #_ *T
M_P#_    _P   /\   #Y    \@ & .L #P#F !D X0 D -X +P#: #D TP!#
M ,\ 3 #, %, R0!: ,< 8 #% &8 PP!K ,$ <0"_ '< O0!^ +L A@"Y (X
MMP"8 +4 HP"S +  L0#" *X X "L /< JP#_ *H _P"H /\ HP#_ *  _P#_
M    _P   /4   #K    X0   -8 # #/ !, R@ > ,8 *0#" #, OP ] +L
M10"X $T M@!4 +, 6@"Q %\ L !E *X :@"L '  JP!W *D ?P"G (< I0"1
M *, G "@ *D G@"X )P S@": .X F0#_ )< _P"6 /\ E@#_ ), _P#]
M\0   .4   #9    S0   ,0 !@"]  \ MP 8 +, (@"P "P K0 V *D /@"G
M $8 I !- *( 4P"@ %D GP!> )T 9 "; &H F@!P )@ =P"6 (  E "* )$
ME0"/ *( C0"P (L PP") ., B #Y (8 _P"& /\ A@#_ (8 _P#S    XP
M -$   #%    O0   +8   "N  L J  2 *0 ' "@ "8 G  O )H -P"7 #\
ME0!& )( 3 "1 %( CP!8 (T 70"+ &, B@!J (@ <0"& 'D A "# (( CP!_
M )L ?@"I 'P NP!Z -4 > #R '@ _P!W /\ =P#_ '< _P#G!P  T0P  ,,-
M  "X#   K@@  *@   "B  4 FP . )8 %0"2 !\ C@ H (L ,0"( #D A@!
M (0 1@"" $P @ !2 '\ 5P!] %T >P!C 'H :P!X ', =@!] '0 B !Q )4
M< "D &X M !L ,H :P#J &H _ !J /\ :@#_ &H _P#:$   QA0  +@6  "M
M%0  I!(  )P.  "6!P  D  ) (H $ "% !@ @0 A 'X *@![ #( >0 Y '<
M0 !U $8 <P!, '( 40!P %< ;@!> &T 90!K &X :0!W &< @P!E )$ 8P"?
M &( KP!@ ,0 7P#D %\!^ !> O\ 7@+_ %X"_P#.&   O1T  + @  "E'P
MFQP  ),7  "+$0  A P  'X$"P!Y !( =0 ; '( (P!O "L ;0$S &L!.@!I
M D  9P-& &8#3 !D!%( 8P19 &$$8 !?!6D 7@5S %P&?P!:!HT 60>< %<(
MK0!6",$ 50GA %0+]@!4"_\ 5 O_ %0+_P#&'P  MB4  *DH  ">*   E"4
M (LA  "#&P  >Q0  '0. P!N"0T :0@4 &8)'0!D"B4 8@HM & +- !>"SH
M70M  %L,1P!:#$T 6 Q4 %<-7 !5#60 5 UO %(->P!0#HH 3PZ: $X.K !,
M#\( 3!#C $L0^0!+$/\ 2Q'_ $L0_P"_)@  L"L  *0O  "9+P  CRT  (8I
M  !])   =!X  &P7  !E$0< 7PX0 %P/%P!:$!\ 6! G %80+@!4$#4 4Q [
M %(10@!0$4@ 3Q%0 $X15P!,$F  2Q)K $D2> !($X< 1A.7 $44J0!$%+X
M0Q7? $,6^ !#%O\ 0Q;_ $,6_P"Z*P  JS$  * T  "5-0  BS0  ($Q  !X
M*P  ;R8  &8@  !>&0$ 5Q0- %04$P!1%!L 3Q4C $X5*@!,%3$ 2Q8W $D6
M/@!(%D0 1Q=, $475 !$%UT 0QAG $$8= ! &8, /QJ4 #T:I@ \&[L .QO;
M #L<]@ \'/\ /!S_ #P<_P"U,   J#8  )PY  "1.P  ASH  'XW  !S,@
M:BT  &$G  !9(0  41L) $P9$ !*&A< 2!H? $8:)@!%&RT 0QLS $(;.@!!
M'$$ 0!Q( #X<4  ]'5D /!YD #L><0 Y'X  .!^2 #<@I  V(+@ -2'6 #4A
M]  U(O\ -2'_ #8A_P"R-   I#H  )D^  "//P  A3\  'L\  !P.   9S(
M %TM  !4*   3"(% $8?#@!#'Q0 01\; #\?(@ ^("D /2 P #L@-@ Z(3T
M.2%% #@B30 W(E< -B-B #0C;@ S)'X ,B2/ #$EH@ O);8 +R;2 "\F\@ O
M)O\ ,";_ # F_P"O.   HCX  )9"  ",0P  @D,  'A!  !N/0  8S@  %HS
M  !1+@  2"@! $ D#  ](Q$ .R08 #DD'P X)"8 -B0L #4E,P T)3H ,R9"
M #(F2@ Q)U0 ,"=? "\H;  N*'L +"F- "LJH  J*K0 *2K/ "DK\  J*_\
M*BK_ "LJ_P"L/   GT(  )1&  "*1P  @$<  '9%  !L0@  83T  %<X  !.
M,P  1"X  #PI"0 W*!  -2@5 #,H'  R*", ,"@I "\I,  O*C< +BH_ "TK
M2  L*U( *RQ= "HL:@ H+7D )RV+ "8NG@ E+K, )"_- "0O[@ E+_\ )2__
M "8N_P"I/P  G44  )))  "(2P  ?DP  '1*  !J1P  7D(  %0]  !+.0
M030  #@O!@ R+0T ,"T3 "XM&0 M+2  *RTG "HN+@ I+C4 *2\] "@O1@ G
M,$\ )3!; "0Q:  C,7< (C*) "$RG0 ?,[$ 'C/+ !XS[0 ?,_\ (#/_ "$R
M_P"F0P  FDD  )!-  "&3P  ?%   '-/  !H3   7$8  %)#  !)/P  /SL
M #8V @ N,@P *S(1 "DR%P H,AX )C(D "4S*P D,S( (S0Z "(T0P A-4T
M(#58 !\V90 >-G4 '#>' !LWFP :-Z\ &3C( !DXZP :./\ &S?_ !LW_P"C
M1P  F$T  (Y1  "$4P  >U0  '%3  !F4   6DP  %!)  !'10  /4$  #,]
M   J.0D )3<. ",W%  B.!L (3@B " X*  ?.#  'CDX !TY00 <.DL &CI6
M !D[8P 8.W( %CN% !4\F0 4/*T $SW& !,]Z0 4//T %3S_ !8[_P"@2P
ME5$  (M5  ""6   >5D  &Y8  !D5@  6%$  $Y/  !%2P  .D<  #!#   G
M0 4 (#X- !T^$0 </A< &SX> !H^)0 9/BT &#\U !8_/@ 5/T@ %$!3 !-
M8  207  $4&" !!!EP /0:P #D+$  Y"YP /0?P $$'_ !! _P"=4   DU8
M (E:  " 70  =EX  &Q=  !B6P  5E<  $Q5  !!40  -DX  "Q+   C2
M&T4) !=$#P 51!0 %$4; !-%(@ 212D $44Q !%%.P 01D4 #T90  Y'7@ -
M1VT #$=_  M'DP )1Z< "$>^  A'X  )1_8 "D;_  M&_P":50  D%L  (=@
M  !]8@  <V,  &IB  !@80  4UX  $=:   \5P  ,E4  "A2   ?4   %TX$
M !%,#  /3!$ #DP7  Y,'@ -324 #$TN  M--P *34( "4U-  =.6@ &3FD
M!$Y[  ).CP !3J0  $VZ  !-VP !3?(  4W_  ),_P"66P  C6(  (1F  !Z
M:   <6D  &AI  !<9P  3V0  $)A   W7P  +5P  "-:   :6   $E<!  U6
M"0 )50X !U43  95&@ $52(  U4J  )5-   53X  %5*  !65P  5F4  %5W
M  !5BP  5:   %6V  !4U   5/$  %/]  !3_P"38@  BF@  (!L  !W;@
M;V\  &-N  !6;   26H  #UH   R9@  )V4  !UC   58@  #F$   E@"  #
M8 T  %\1  !?%P  7QX  %\F  !?+P  7SH  %]%  !?4P  7V$  %YR  !>
MAP  79P  %VR  !<SP  7.\  %O]  !;_P"0:@  AF\  'UR  !U=   :G4
M %UT  !/<P  0G(  #9P   K;P  (&X  !=M   0;   "FP   )K!@  :PL
M &H/  !J%   :AH  &HA  !I*@  :30  &E   !I3@  :5P  &EM  !H@@
M:)@  &>N  !FR@  9>T  &7\  !D_P"+<0  @G8  'IY  !P>P  8GL  %5[
M  !(>@  .WH  "]Z   C>0  &7@  !%W   *=P   W<   !W @  =P@  '8-
M  !V$   =A4  '8;  !V(P  =BX  '4Z  !U1P  =58  '5H  !T?   =)(
M '.J  !RQ   <>D  '#[  !P_P"&>0  ?WT  '9_  !H@0  6H(  $R"   _
M@P  ,H0  "6#   :@P  $8,   J#   "@P   (0   "%    A ,  (,(  "#
M#0  @Q   (,5  "$'   A"8  (0R  "$/P  @T\  (-@  ""=0  @HP  (&D
M  " O0  ?^,  '[Y  !^_P""@   >H0  &R&  !>B   4(H  $*+   UC0
M)XT  !N-   1C@  "HX   "/    D0   )(   "2    D@   )(!  "2!P
MD@P  )(0  "3%0  DQT  )0H  "4-@  E$4  )-7  "3:P  DX(  )*<  "1
MM@  D-@  (_S  "/_P!^AP  <(H  &&-  !3D   19,  #>5   IE@  ')<
M !&8   )F0   )L   "<    G@   *    "@    H    *    "A    H00
M *()  "C#@  I!0  *4=  "F*@  ICH  *9,  "E8   I7@  *62  "DK
MI,D  */K  "B^@!SC@  9)$  %:5  !'F0  .9P  "J>   =H   $:$   BC
M    I0   *<   "I    K    *X   "N    K@   *\   "P    L0   +(
M  "S!@  M0T  +<3  "Y'@  N2X  +I   "Z5   NVH  +J%  "YH0  N;L
M +K>  "Y\@!GE0  6)D  $J>   [H@  +*8  !VH   1J@  !ZP   "O
ML0   +0   "X    NP   +P   "\    O@   +\   #     P@   ,0   #&
M    R ,  ,L+  #/$@  T2   -$R  #21@  TUT  -1V  #4D@  U:L  -7$
M  #4X@!;G0  3*(  #VG   OK   'Z\  !&Q   'M0   +@   "[    O@
M ,(   #'    R@   ,P   #,    S@   -    #2    U0   -@   #;
MWP   .(   #F"P  ZQ,  .PD  #M.   [DX  .]G  #P@@  \)P  /"R  #Q
MQ0#_  , _P ! /\ ! #_  D _P / /\ & #_ "0 _P P /\ / #_ $< _P!1
M /\ 60#_ &  _0!G /P ;0#Z ', ^0!Y /@ ?P#V (4 ]0", /, E #R )T
M\ "G .X LP#L ,0 ZP#A .H ^ #I /\ YP#_ -D _P#+ /\ P@#_ +T _P#_
M    _P   /\   #_    _P , /\ % #_ "  _P K /X -P#Z $( ]@!+ /(
M4P#P %L [@!A .P 9P#J &T Z !S .< >0#E '\ XP"& .$ C@#? )8 W0"@
M -L K #8 +L U #1 -, \ #0 /\ S@#_ ,@ _P"] /\ M@#_ +( _P#_
M_P   /\   #_    _0 ( /< $ #S !H [P F .T ,0#H #L XP!% .  30#<
M %4 V0!; -8 80#3 &< T0!L ,\ <@#- '@ RP!_ ,D AP#' )  Q0": ,,
MI0#  +( O@#% +P Y0"Z /L N #_ +< _P"P /\ J0#_ *4 _P#_    _P
M /X   #U    [  # .4 #0#? !4 V@ @ -0 *@#0 #4 RP ^ ,@ 1P#% $X
MP@!5 ,  6P"^ &$ O !F +H ; "X '( M@!X +4 @ "S (@ L0"2 *X G@"L
M *H J0"[ *@ U0"F /, I #_ *, _P"A /\ FP#_ )@ _P#_    ^P   /
M  #E    V    ,X "0#' !$ P@ : +X ) "[ "X MP X +0 0 "Q $@ K@!.
M *P 5 "J %H J0!? *< 90"E &L I !Q *( > "@ ($ G@"+ )P E@"9 *,
MEP"R )8 QP"3 .@ D@#^ )$ _P"0 /\ C0#_ (L _P#Y    ZP   -T   #/
M    Q@   +P ! "U  T L  5 *P '@"H "@ I0 Q *( .0"? $$ G0!( )L
M3@"9 %, EP!9 )8 7@"4 &0 D@!J )  <0". 'H C "# (H CP"( )P A@"J
M (0 O "" -P @0#V (  _P!_ /\ ?P#_ 'X _P#L    V@   ,D   "^
MM@   *X   "G  D H0 0 )P & "8 "( E0 J )( ,@"0 #H C0!! (L 1P")
M $T AP!2 (8 6 "$ %T @@!D ($ :P!_ ', ?0!] 'L B !X )4 =@"C '4
MM !S ,P <0#M '  _P!P /\ < #_ '  _P#?!0  R@H  +P+  "Q"0  J 0
M *$   ";  , E  , (\ $P"* !L AP D (0 + "! #, ?P Z 'T 00![ $<
M>0!, '< 4@!V %< = != '( 9 !P &T ;P!V &P @@!J (\ :0"= &< K@!E
M ,, 9 #D &, ^@!C /\ 8@#_ &, _P#0#@  OQ(  +(3  "G$@  G1   )4+
M  "/ P  B0 ' (( #@!^ !4 >@ > '8 )0!T "T <0 T &\ .@!N $  ; !&
M &H 3 !I %( 9P!8 &8 7P!D &< 8@!Q &  ? !> (D 7 "8 %L J0!9 +P
M6 #< %@ ] !8 /\ 5P#_ %< _P#&%@  MAH  *H=  "?'   E1D  (T4  "%
M#P  ?@D  '<!"@!R !  ;@ 7 &H 'P!H "< 90 N &0 - !B #L 8 !  %\
M1@!= $P 7 !3 %H 6@!8 &( 5P!L %4 =P!3 (4 4@"4 % !I0!/ ;@ 3@+2
M $T$\ !-!?\ 307_ $T%_P"_'0  L"(  *,E  "9)0  CR(  (4=  !]&
M=1(  &X- @!G!@P 8P,1 %\"&0!= R$ 6P0H %D$+P!7!34 5@4[ %0&00!3
M!D< 409. % '50!.!UX 30AG $L(<P!)"8$ 2 F2 $<*HP!%"K8 1 O0 $0,
M[P!##?\ 0PW_ $0-_P"Y)   JBD  )XL  "4+   BBH  ( F  !W(0  ;AL
M &84  !?#P4 60L- %4*$P!3"QL 40LB $\,*0!-#"\ 3 PV $L-/ !)#4(
M2 U) $8-40!%#EH 1 YD $(.< ! #G\ /P^0 #X0H@ \$+8 .Q#1 #L1\0 [
M$?\ .Q'_ #P1_P"T*0  IB\  )HR  "0,@  AC$  'PM  !R*   :2,  &$=
M  !9%@  41$( $P/$ !*$!8 2! = $80) !%$"L 0Q$Q $(1-P!!$3X 0!%%
M #X230 ]$E8 /!)A #H3;0 Y$WP -Q2- #84GP U%;, -!7- #,6[@ T%O\
M-!;_ #06_P"O+@  HC0  )<W  ",.   @C8  '@T  !N+@  92H  %PD  !4
M'@  3!@$ $84#0!"%!( 0!09 #\4(  ]%2< /!4M #L5-  Y%CH .!9" #<6
M2@ V%U, -1=> #,8:@ R&7D ,!F* "\:G0 N&K$ +1O* "T;[  M'/\ +AO_
M "X;_P"L,@  GS@  )0[  "*/   @#P  '8Y  !K-   8B\  %DJ  !0)0
M1Q\  $ :"@ \&1  .AD6 #@9'0 V&B, -1HI #0:,  S&C< ,AL^ #$;1P O
M'%  +AU; "T=9P L'G8 *AZ( "D?FP H'ZX )R#' "8@Z@ G(/X *"#_ "@@
M_P"I-@  G3P  )(_  "'00  ?4   '0^  !I.@  7S4  %8P  !-*P  1"4
M #L@!P V'@X ,QX3 #(>&0 P'B  +QXF "X?+0 M'S0 +" [ "L@1  J(4X
M*2%8 "<B90 F(G0 )2.% ",CF0 B)*T (23% "$EZ  B)?T (B3_ ",D_P"F
M.@  FC\  (]#  "%10  >T0  ')#  !G/P  73H  %,V  !*,0  02P  #@F
M P Q(PP +B(1 "PB%@ J(AT *2(C "@C*@ G(S$ )B0Y "4E00 D)4L (R96
M "(F8P A)W( 'R># !XHEP =**L &RG# !LIY@ <*?L '2G_ !XH_P"C/@
MF$,  (U'  "#20  >DD  '!'  !F1   6C\  %$[  !'-P  /C(  #4M   L
M* D *"</ "<G%  E)QH )"<A ",H)P B*"X (2DV " I/P ?*DD 'BI4 !TK
M8  ;*V\ &BR! !DLE0 7+:D %BW! !8MY  7+?H &"W_ !DM_P"A00  E4<
M (M+  ""30  >$T  &Y,  !D20  6$0  $]   !&/0  /3@  #,T   J+P8
M)"P- "$L$@ @+!@ 'RT> !XM)0 =+2P '"XT !LN/  :+T8 &"]1 !<P7@ 6
M,&T %3%_ !,QDP 2,:@ $3*_ !$RX@ 2,OD $S'_ !,Q_P">10  DTL  (E/
M  " 40  =E(  &U0  !B3@  5DD  $U&  !$0P  .S\  #$Z   G-@, 'S(+
M !PR$  ;,A4 &3(; !@R(@ 7,RD %C,Q !4T.@ 4-$0 $S1/ !(U7  1-6L
M$#9]  \VD0 .-J8 #3>\  TWW0 --O8 #C;_  \V_P";20  D4\  (=3  !^
M5@  =58  &I5  !@4P  54\  $Q,  !"20  .$4  "Y!   D/0  '#H( !8X
M#@ 5.!( %#@8 !,Y'P 2.28 $3DN ! Y-P /.D$ #CI,  T[60 -.V@ "SMZ
M  H[C0 )/*( !SRX  <\U0 (//  "3O_  H[_P"83@  CE0  (58  !\6P
M<EL  &A:  !>6   4U4  $E2   ^3@  -$L  "I'   A1   &$(# !) "P 0
M/Q  #C\5  X_'  -0", #$ K  M -  *0#X "4%*  =!5@ &064 !$%V  -!
MB@ !09\  $&T  !!T  !0>X  4'\  ) _P"55   C%D  (->  !Y8   <&
M &9@  !=7@  45L  $57   Z5   +U$  "5/   <3   %$H   Y("  +1PX
M"$<2  ='&0 &1R  !4@H  -(,0 "2#L  $A'  !(4P  2&(  $AS  !(A@
M2)L  $BQ  !'S   1^T  $?[  !'_P"26@  B6   (!C  !W90  ;F8  &5F
M  !99   3&   $!=   U6P  *ED  "!7   750  $%,   M2!P %40T  5 1
M  !0%@  4!T  % E  !0+@  4#@  %!#  !04   4%X  %!O  !0@P  3Y@
M $^N  !.R0  3NL  $W[  !-_P"/80  AF8  'UI  !T;   ;&T  &%K  !3
M:0  1F<  #ID   O8P  )&$  !I?   27@  #%P   9<!@  6PL  %H/  !:
M$P  6AD  %DA  !9*0  63,  %D_  !93   65H  %EK  !8?@  6)0  %>K
M  !7Q0  5ND  %7[  !5_P",:   @FT  'IP  !R<@  9W(  %IQ  !,<
M/VX  #-M   H:P  '6H  !1H   -9P  !V<   !F P  9@D  &4-  !E$0
M9!4  &0<  !D)   9"X  &0Z  !C1P  8U4  &-F  !C>@  8I   &&G  !@
MP0  7^8  %_Z  !>_P"';P  ?W0  'AW  !N>   8'@  %)W  !%=P  .'8
M "MV   @=   %G,   YS   '<@   '(   !R    <04  '$*  !Q#@  <!$
M ' 7  !P'@  <"<  ' S  !O0   ;U   &]@  !N=   ;HL  &VB  !LO
M:^(  &KX  !I_P"#=P  ?'L  '-]  !E?@  5W\  $E_   \?P  +X   ")_
M   7?@  #WX   =^    ?P   '\   !_    ?@   'X%  !^"@  ?@T  'X1
M  !^%P  ?B   'XK  !].0  ?4@  'U9  !\;0  ?(0  'N<  !ZM@  >=H
M 'CU  !W_P" ?P  =X(  &F#  !;A0  388  #^(   RB0  )(D  !B)   /
MB0  !XH   "+    C    (T   "-    C    (P   ", P  C @  (T-  "-
M$0  C1<  (XB  ".+P  CC\  (U0  "-9   C'L  (R5  "+K@  BLT  (GO
M  ")_P![A0  ;8@  %Z*  !0C0  0H\  #21   FD@  &9,   Z4   &E0
M )8   "8    F@   )L   ";    FP   )L   ";    G    )T%  "="P
MGA   )\7  "@)   H#0  *!&  "@60  GW   )^*  ">I0  GL(  )WH  "<
M^0!PC   88\  %.2  !$E@  -ID  ">;   9G   #YT   6?    H0   *,
M  "E    J    *D   "I    J0   *H   "K    K    *T   "N 0  L D
M +(/  "S&   M"<  +0Y  "U30  M&0  +1^  "SF@  L[0  +/5  "S\ !D
MDP  59<  $>;   XGP  *:(  !JD   .I@  !*@   "K    K0   +    "T
M    M@   +@   "X    N0   +H   "\    O0   +\   #     PP   ,4'
M  #)#P  RAH  ,LL  #,0   S58  ,YO  #-BP  S*@  ,S"  #,X@!8FP
M2:   #JE   LJ0  '*L   ^N   $L0   +0   "W    N@   +X   ##
MQ@   ,@   #(    R@   ,L   #-    SP   -(   #5    V0   -T   #A
M!0  Y@\  .<>  #H,@  Z4@  .I@  #K>P  ZY<  .RN  #LP@#_    _P
M /\   #_  8 _P - /\ %0#_ "$ _P L /\ . #_ $, _P!, /X 5 #[ %L
M^@!B /@ : #V &X ]0!T /0 >@#R (  \0"' .\ CP#M )< ZP"A .D K0#G
M +T Y0#8 .0 \P#B /\ X #_ -  _P#$ /\ O #_ +8 _P#_    _P   /\
M  #_    _P ) /\ $0#_ !P _0 G /D ,@#U #T \0!& .T 3P#K %8 Z !<
M .8 8@#D &@ XP!N .$ <P#? 'D W0"  -H B #8 )$ U "; -( I@#/ +0
MS #) ,D Z0#( /\ QP#_ ,$ _P"W /\ KP#_ *L _P#_    _P   /\   #_
M    ^  % /( #@#N !< Z@ B .8 + #A #< W0!  -@ 20#3 %  T !6 ,X
M7 #, &( R@!G ,@ ;0#& ', Q !Y ,( @0#  (H O@"4 +P GP"Y *P M@"^
M +0 W0"S /< L0#_ +  _P"H /\ H@#_ )X _P#_    _P   /D   #O
MY@   -\ "P#6 !( T  < ,P )@#( #  Q  Z ,  0@"] $H NP!0 +@ 5@"V
M %L M0!A +, 9@"Q &P L !R *X >@"L (( J0", *< F "E *4 HP"T *
MRP"? .X G0#_ )P _P"9 /\ E #_ )$ _P#_    ]@   .H   #=    SP
M ,< !@#   \ NP 7 +< ( "S "H L  S *T .P"J $, IP!) *4 3P"C %4
MH@!: *  7P"> &4 G0!K )L <@"9 'L EP"% )0 D "2 )T D "L (X OP",
M .( BP#Z (D _P") /\ A@#_ (, _P#T    Y    -0   #(    OP   +4
M 0"N  L J0 2 *4 &P"A ", G@ L )L - "8 #P E@!# )0 20"2 $X D !3
M (X 60"- %X BP!D (D :P"' ', A0!] (, B "! )4 ?P"D 'T M0![ ,\
M>0#Q '@ _P!W /\ =P#_ '4 _P#E    T0   ,,   "X    KP   *@   "@
M  8 F@ . )4 %0"1 !X C@ F (L +0"( #4 A@ \ (0 0@"" $< @ !- '\
M4@!] %@ >P!> 'D 90!X &T =@!V ', @0!Q (X ;P"= &T K@!L ,0 :@#G
M &D _0!H /\ : #_ &D _P#5 P  PP<  +8(  "K!@  H@   )L   "4
MC0 * (@ $ "# !@ ?P @ 'P )P!Z "X =P U '4 .P!T $$ <@!' '  3 !O
M %( ;0!8 &L 7P!I &8 9P!P &4 >P!C (@ 8@"7 &  IP!> +L 70#< %P
M]@!< /\ 6P#_ %L _P#)#0  N1   *P1  "A$   EPT  (\(  "(    @@ %
M 'L #0!W !( <P : &\ (0!L "@ :@ O &@ -0!G #L 90!! &, 1@!B $P
M8 !2 %\ 60!= &$ 6P!J %D =0!7 (( 50"1 %0 H@!3 +4 40#/ %  [P!0
M /\ 4 #_ %  _P"_%   L!@  *0:  "9&0  CQ8  (<1  !_#0  =P8  '$
M" !K  X 9P 4 &0 &P!A "( 7@ I %T +P!; #4 60 [ %@ 00!6 $8 50!-
M %, 5 !2 %P 4 !E $X < !, 'T 2P"- $D G@!( +  1P#' $8 Z0!& /L
M1@#_ $4 _P"X&P  JB   )XB  "3(@  B1\  ( :  !W%0  ;Q   &@+  !A
M! H 70 0 %D %@!6 !T 5  C %( *@!0 #  3P U $X .P!, $$ 2P!( $D
M3P!' 5< 1@%A $0"; !# GD 00.) $ #F@ ^!*T /03$ #P%Y0 \!_@ / ?_
M #P'_P"R(@  I2<  )DI  ".*0  A"<  'LC  !Q'@  :1@  &$2  !:#0,
M4P@, $\%$0!,!1< 2@8> $@&) !'!BH 10<P $0'-@!#"#T 00A# $ (2P ^
M"5, /0E= #L*:  Z"G8 . N' #<+F0 U"ZP - S" #,,Y  S#?D ,PW_ #0-
M_P"M)P  H"P  )4O  "++P  @"X  '<J  !M)0  9"   %P:  !4%   3 \&
M $8,#0!##!( 00P8 #\,'P ^#"4 / TK #L-,@ Z#3@ . T_ #<.1P V#E
M- Y: #,.9@ Q#W0 , ^% "X0F  M$*L +!## "L1Y0 L$?H +!'_ "T1_P"J
M+   G3$  )(T  "'-0  ?30  '0Q  !J*P  8"<  %@A  !/&P  1Q8  $ 1
M"0 [$ \ .1 4 #<0&P V$"$ -! G #,1+0 R$30 ,1$[ # 10P N$DT +1)7
M "P28P J$W$ *1." "<4E0 F%*D )17  "05XP E%OH )A;_ "85_P"F,0
MFC8  (\Y  "%.@  >SD  '$V  !G,0  72T  %0H  !,(@  0QT  #L7!0 U
M% T ,A,1 #$4%P O%!T +A0D "P4*@ K%3$ *A4X "D60  H%DH )Q=4 "87
M8  D&&\ (QB  "$9DP @&:< 'QF^ !X:X  ?&O@ (!K_ " :_P"C-   F#H
M (T]  "#/@  >3T  &\[  !E-P  6S(  %(M  !)*   0",  #@> 0 P&0H
M+!@/ "H8%  I&!H )Q@@ "89)P E&2T )!HU ",:/@ B&T< (1M2 " <7@ ?
M'6P '1U^ !P=D0 :'J4 &1Z\ !@?W0 9'_8 &A__ !L>_P"A.   E3T  (M!
M  "!0@  =T(  &U   !C/   63<  $\S  !&+@  /2D  #4D   M( < )QT-
M "4=$@ C'1< (1T= "$=)  @'BL 'QXR !X?.P ='T4 '"!/ !HA7  9(6H
M&")[ !8BCP 5(J, %".Z !,CV@ 4(_4 %2/_ !8C_P">/   DT$  (E$  !_
M1@  =48  &Q$  !B00  5SP  $TX  !$-   /#   #,K   J)@, (R(+ " A
M$  >(14 '"(; !LB(0 :(B@ &B,P !DC.  8)$( %B5- !4E60 4)F@ $R9Y
M !(FC0 1)Z( $">X  XGU@ 0*/0 $2?_ !$G_P"<0   D44  (=(  !]2@
M=$H  &I)  !@1@  54$  $P^  !#.@  .C8  #$R   H+0  ("D) !LG#@ 9
M)Q( &"<8 !8G'P 5*"4 %"@M !,H-@ 2*4  $BE+ !$J5P 0*F8 #BMW  XK
MBP -+)\ #"RU  LLSP ,+.\ #2S_  TK_P"91   CTD  (5,  !\3@  <T\
M &E.  !>2P  4T<  $I$  !"0   .3T  "\X   E-   '3 % !8M#  4+!
M$RT5 !(M'  1+2, $"TJ  \N,P .+CT #2](  TO50 ,,&, "C!T  DPB  (
M,9P !C&Q  8QRP &,>L !S#\  @P_P"72   C4T  (-1  !Z4P  <50  &=2
M  !=4   4DP  $E*  ! 1@  -4(  "L^   B.@  &C<! !(T"0 /,PX #C,3
M  TS&0 -,R  ##0H  LT,0 *-3L "#5&  <U4@ %-F  !#9Q  (VA   -ID
M #:O   VR   -N@  #;Y  $U_P"430  BE(  (%6  !X6   ;UD  &58  !;
M50  45(  $=/   \3   ,4@  "=$   >00  %C\  ! \!P +.@T "3H1  @[
M%P &.QX !3LF  0[+@ ".S@  3Q#   \3P  /%X  #QN   \@0  /)<  #RL
M   [Q0  .^<  #OX   [_P"14@  B%@  ']<  !V70  ;5X  &-=  !:7
M3E@  $)4   W40  +4X  "-+   :20  $D8   U$!@ '0PP  T,0  !#%0
M0QL  $,C  !#*P  0S4  $-   !#30  0UL  $-K  !#?@  0Y0  $*J  !"
MPP  0>8  $'Y  !!_P".6   AEX  'UA  !S8P  :V0  &)C  !780  25T
M #U:   R6   )U4  !Y3   540  #D\   E-!0 "30L  $P.  !,$P  2Q@
M $L?  !+*   2S(  $L]  !+20  2U<  $MG  !*>P  2I   $FG  !)P
M2.0  $CX  !'_P"+7P  @V0  'IG  !Q:0  :6H  %YI  !09@  0V0  #=A
M   L7P  (5T  !A;   060  "E@   -7 P  5PD  %8-  !5$   514  %0;
M  !4(P  5"T  %0Y  !410  5%,  %1D  !3=P  4XT  %*D  !1O0  4.(
M %#X  !/_P"(9P  ?VL  '=N  !O<   97   %=N  !*;   /6L  #!I   E
M:   &F8  !%D   +8P  !&(   !B 0  808  & +  !@#@  7Q(  %\7  !?
M'@  7B@  %XS  !>0   7D\  %Y?  !=<@  78@  %R@  !;N0  6M\  %GW
M  !8_P"$;@  ?'(  '5U  !K=@  774  $]T  !"<P  -7,  "AR   =<
M$V\   QN   $;@   &X   !N    ; (  &P'  !K"P  :PX  &L2  !J&0
M:B(  &HM  !J.@  :4D  &E:  !I;   :(,  &>;  !FM0  9=@  &3U  !D
M_P" =0  >GD  '![  !B>P  5'P  $9\   Y?   +'P  !][   4>@  #7H
M  1Z    >@   'H   !Z    >0   'D!  !X!@  > L  '@.  !X$P  >!H
M '@E  !X,@  =T$  '=2  !W90  =GP  '65  !TKP  <\X  '+Q  !Q_P!^
M?0  =8   &>!  !8@@  2H,  #R$   NA0  (84  !6%   -A0   X4   "&
M    AP   (@   "(    AP   (<   "'    AP0  (<)  "'#@  B!,  (@<
M  "(*0  B#@  (=*  "'70  AG,  (:-  "%IP  A,4  (/L  ""_@!XA
M:H8  %R(  !-B@  /XP  #&.   CCP  %H\   V0   "D0   )(   "3
ME0   )8   "6    E@   )8   "6    EP   )<   "7!P  F T  )D3  ":
M'P  FBT  )H_  ":4@  FF@  )F#  "9GP  F+H  )?B  "6^ !MB@  7XT
M %"0  !!DP  ,Y8  "27   6F   #9D   &;    G0   )\   "A    I
M *4   "D    I0   *4   "F    IP   *@   "I    J@0  *P,  "N$P
MKB$  *XS  "N1P  KET  *YV  "NDP  KJX  *W-  "L[P!AD0  4Y4  $28
M   UG   )I\  !>A   -HP   *4   "G    J@   *P   "P    L@   +0
M  "S    M    +4   "W    N    +D   "[    O0   +\!  ##"P  Q14
M ,4E  #&.0  QT\  ,=H  #&A0  QJ(  ,:\  #&W@!5F0  1YT  #BB   I
MI@  &:@   VK    K0   +$   "T    MP   +H   "_    P0   ,0   ##
M    Q0   ,8   #(    R@   ,T   #/    T@   -8   #;    X P  .$8
M  #C*P  Y$$  .5:  #F=   YI$  .6L  #EQ #_    _P   /\   #_  $
M_P * /\ $@#_ !T _P H /\ - #_ #X _0!( /H 4 #W %< ]0!= /0 8P#R
M &D \ !O .\ = #M 'L ZP"! .D B0#H )( Y@"< .0 J #B +< WP#- -P
M[@#9 /\ V0#_ ,H _P"^ /\ M0#_ +  _P#_    _P   /\   #_    _P &
M /\ #P#\ !@ ^  C /0 +@#P #@ ZP!" .@ 2@#E %$ X@!8 .  70#> &,
MW !H -D ;@#6 '0 U ![ -$ @@#/ (L S0"5 ,H H0#( *\ Q0#! ,( XP#
M /L P #_ +L _P"P /\ J #_ *0 _P#_    _P   /\   #[    \P ! .T
M# #H !, XP > .  * #: #( TP \ ,\ 1 #, $L R0!1 ,8 5P#$ %T P@!B
M ,$ 9P"_ &T O0!T +L >P"Y (0 MP". +0 F0"R *< KP"W *T T "K /(
MJ@#_ *D _P"A /\ FP#_ )< _P#_    _P   /0   #I    X    -4 " #.
M !  R0 8 ,4 (@#! "L O  U +D /0"V $4 LP!+ +$ 40"O %8 K@!; *P
M80"J &8 J0!M *8 = "D 'P H@"& *  D@"> )\ G "N )D PP"7 .< E@#_
M )4 _P"2 /\ C0#_ (H _P#\    \    .,   #4    R    +\  P"Y  T
MLP 3 *\ ' "L "4 J0 N *4 -@"C #X H !$ )X 2@"= %  FP!5 )D 6@"7
M %\ E@!F )0 ; "2 '4 D !^ (X B@"+ )< B0"F (< N "% -8 A #V ((
M_P"! /\ ?@#_ 'P _P#M    W0   ,P   #!    N    *X   "G  D H@ 0
M )X %P": !\ EP G )0 +P"1 #< CP ] (T 0P"+ $D B0!. (@ 4P"& %D
MA !? (( 90"  &T ?@!W 'P @@!Z (\ > "> '4 KP!S ,< <@#L '$ _P!P
M /\ < #_ &X _P#=    R0   +P   "Q    J0   *$   "9  , DP , (X
M$@"* !D AP A (0 *0"! #  ?P W 'T /0![ $( >0!( '@ 30!V %( = !8
M '( 7P!Q &< ;P!P &P >P!J (@ : "7 &8 J !E +P 8P#A &( ^@!A /\
M80#_ &$ _P#- 0  O 4  *\%  "E @  G    )0   "-    A@ ( ($ #@!\
M !0 >  ; '4 (P!R "D <  P &X -@!M #P :P!! &D 1P!H $P 9@!2 &0
M60!C &  80!I %\ = != ($ 6P"0 %D H0!7 +0 5@#0 %4 \@!5 /\ 5 #_
M %4 _P#!#   L@X  *8/  ";#@  D@L  (D%  ""    >P " '4 "P!P !
M;  6 &@ '0!F ", 8P J &$ , !@ #8 7@ [ %T 00!; $8 6@!, %@ 4P!6
M %L 5 !D %( ;@!1 'L 3P"* $T FP!, *X 2P#& $H Z@!) /X 20#_ $D
M_P"Y$@  JA8  )X7  "4%@  BA,  ($0  !Y"P  <0,  &L !@!E  T 80 1
M %T & !: !X 6  D %8 *@!4 #  4P V %$ .P!0 $$ 3@!' $T 3@!+ %8
M20!? $< :0!& '8 1 "% $, EP!! *D 0 "_ #\ X@ _ /@ /@#_ #\ _P"R
M&0  I!X  )@?  ".'P  A!P  'H8  !R$@  :@X  &((  !< 0@ 5P . %,
M$P!0 !D 3@ ? $P )0!* "L 2  P $< -@!& #P 1 !" $, 20!! %$ /P!:
M #X 90 \ '( .@"! #D DP X *4 -@"Z #8 VP U /0 -0#_ #4 _P"L(
MGR0  )0F  "))@  ?R0  '4@  !L&P  9!4  %P0  !4# $ 3@8* $H"#P!'
M !0 1  : $( ( !  "4 /P K #X!,0 \ 3< .P(^ #D"10 X TT -@-6 #4$
M80 S!&X ,05^ # %D  O!:, +0:X "P&U  L!_  + C_ "P(_P"H)0  FRH
M ) L  "&+0  >RL  '(G  !H(@  7QT  %<7  !/$@  2 X$ $$*"P ^!Q
M.P85 #D'&P X!R$ -@@F #4(+  S"#( ,@DY #$)00 O"4D +@I3 "P*7@ K
M"VP *0M\ "@,CP F#*( )0RW "0,TP C#?  ) W_ "4-_P"D*@  F"\  (TR
M  "#,@  >3$  &\N  !E*0  7"0  %,?  !+&0  0Q,  #P0!@ U#0P ,PP1
M #$,%@ O#!P +@TB "T-*  K#2X *@TU "D-/0 G#D8 )@Y0 "0.7  C#VH
M(@][ " 0C@ ?$*( '1"W !P0U  =$?( '1'_ !X1_P"A+P  E3,  (HV  "
M-P  =C8  &TS  !C+P  62H  % E  !((   /QH  #@5   P$0@ +! . "H0
M$@ H$!@ )Q > "40)  D$"H (Q$R "(1.@ A$4, (!). !X26@ =$V@ &Q-X
M !H3BP 8%*  %Q2U !84T0 6%?$ %Q7_ !@4_P">,P  DS<  (@Z  !^.P
M=#L  &LX  !A-   5R\  $XK  !%)@  /2$  #0<   M%P4 )A,, ",3$  B
M$Q4 (!,: !\3(0 >%"< '10O !P5-P ;%4$ &A9+ !D65P 7%V4 %A=V !08
MB0 3&)X $ABS !$9S@ 1&>\ $AG_ !,9_P"<-@  D3L  (8^  !\/P  <S\
M &D]  !?.0  534  $PP  !#+   .B<  #(B   J'@$ (AD) !X7#@ <%Q(
M&A<7 !D8'@ 9&"0 &!DL !<9-  6&CX %1I) !,;50 2&V, $1QT ! <AP /
M'9P #AVQ  T=RP -'>P #AW_  \=_P"9.@  CS\  (1"  ![1   <4,  &A"
M  !>/@  4SH  $HV  !!,@  .2T  #$I   H)0  (" & !H=#  7'!  %1P5
M !0=&P 4'2( $QTI !(>,@ 1'SP $!]& ! @4P .(&$ #2%Q  PAA0 +(ID
M"B*N  DBQP )(N< "B+[  LA_P"7/@  C$,  (-&  !Y2   <$@  &=&  !<
M1   4C\  $D[  ! .   .#0  "\P   G+   'B<# !8C"@ 2(0X $2$3 ! B
M&0 0(B  #R(G  XC+P -)#D #"1$  LE4  *)5X "29O  <F@@ &)I8 !":L
M  ,FQ  $)N4 !";W  8F_P"50@  BD<  (%*  !X3   ;TP  &5+  !;2
M4$0  $=!   _/@  -SL  "TV   D,0  &RT  !,J!P /* T #2<1  TH%@ ,
M*!T "R@E  HI+0 )*3< !RI"  8J3@ $*UP  RML  $K?P  *Y0  "NI   K
MP0  *^,  "OV   J_P"21@  B$L  ']/  !V40  ;5$  &-0  !:30  3TH
M $='   ^1   ,T   "D\   @.   %S0  !$Q!0 ,+PP "2X0  <N%0 &+QL
M!2\C  ,O*P ",#4  # _   P3   ,5D  #%I   Q?   ,9$  #&G   POP
M,.$  ##U   O_P"02P  AE   'U4  !U5@  :U8  &)5  !84P  3E   $5-
M   Z20  +T4  "5"   </@  %#L   XY!0 )-PL !#8/  $V$P  -AD  #8@
M   V*0  -C(  #<]   W20  -U<  #=G   W>0  -X\  #:E   VO0  -N
M #7U   U_P"-4   A%8  'Q:  !R6P  :5L  &!;  !760  3%8  $!2   U
M3@  *DL  "!(   71@  $$,   M!!  $0 H  #\.   ^$0  /A8  #X=   ^
M)@  /B\  #XZ   ^1@  /E0  #YD   ^=@  /8P  #VC   \NP  /-X  #OU
M   [_P"*5P  @EP  'E?  !P80  :&$  %]A  !47@  1UL  #I7   O50
M)5(  !M0   230  #$L   9* P  20D  $@-  !'$   1Q0  $8:  !&(@
M1BP  $8W  !&0P  1E$  $9@  !%<P  18D  $2@  !$N   0]P  $+U  !"
M_P"(70  ?V(  '=E  !N9P  9V@  %MF  !.8P  06$  #1>   I7   'UH
M !57   .5@  !U0   !3 0  4@8  %$+  !1#@  4!$  $\6  !/'@  3R<
M $\R  !//P  3TT  $Y=  !.;P  3H4  $V=  !,M0  2]@  $KU  !*_P"%
M90  ?&D  '1L  !M;@  8FT  %1K  !':0  .F<  "UE   B9   &&(  !!@
M   )7P   %X   !>    70,  %P(  !;#   6@\  %H3  !9&0  62(  %DM
M  !9.@  64@  %A8  !8:P  5X$  %>9  !6L@  5=(  %3T  !3_P"!;
M>7   '-S  !H<P  6G(  $QQ   _<   ,F\  "5N   :;   $6L   EJ
M:@   &D   !I    :    &<#  !F"   9@P  &8/  !E%   91P  &4G  !D
M-   9$,  &13  !D90  8WL  &*4  !AK0  8,T  %_Q  !>_P!]=   =W<
M &YY  !?>0  47D  $-Y   V>   *7@  !QW   1=@  "G4   !U    =0
M '8   !U    =    '0   !S @  <P<  ',,  !R$   <A4  '(@  !R+
M<CL  '%,  !Q7P  <70  '".  !OJ   ;L8  &SM  !K_P![>P  <GX  &1^
M  !5?P  1X   #F!   K@@  'H$  !*!   *@0   ($   ""    @P   (,
M  "#    @@   ((   ""    @@   ((%  """@  @@\  ((7  ""(P  @C(
M ()#  "!5@  @6P  ("&  !_H0  ?KT  'WF  !\_ !V@@  :(,  %F%  !+
MAP  /(D  "Z*   @BP  $XL   J+    C    (T   "/    D0   )(   "1
M    D0   )$   "1    D0   )(   "2 @  DPD  )0/  "4&0  E"<  )0X
M  "43   DV(  )-\  "3F   DK,  )'8  "0]@!JB   7(H  $V-   _D
M,)(  "&4   4E0  "I8   "7    F0   )L   "=    GP   *    "@
MH    *    "A    H@   *,   "D    I0   *8'  "H$   J!P  *@M  "I
M0   J58  *EO  "IBP  J*@  *?'  "F[ !?CP  4)(  $&6   SF0  (YP
M !2=   *GP   *$   "C    I@   *@   "L    K@   *\   "O    L
M +    "R    LP   +0   "V    MP   +H   "]!P  OQ   +\?  # ,P
MP$D  ,!B  # ?@  P)L  ,"W  "_V !3EP  1)L  #6?   FHP  %J4   NG
M    J@   *T   "P    LP   +8   "[    O0   ,    "_    P0   ,(
M  #$    Q@   ,@   #*    S    ,\   #3    V@<  -L3  #=)0  WCL
M -]3  #@;@  WXP  -VI  #=P@#_    _P   /\   #_    _P ' /\ $ #_
M !D _P D /\ +P#\ #H ^0!# /4 2P#S %( \0!9 .\ 7@#M &0 ZP!I .D
M;P#G '4 Y@!\ .0 A #B (T X "7 -T H@#: +$ U0#% -( Z #0 /\ SP#_
M ,0 _P"X /\ KP#_ *D _P#_    _P   /\   #_    _P " /L #0#W !4
M\P ? .\ *0#J #0 Y@ ] .( 10#> $P VP!3 -@ 6 #4 %X T@!C -  :0#.
M &X S !U ,H ?0#( (4 Q@"0 ,( FP#  *D O@"Z +L V0"Y /< N #_ +0
M_P"I /\ H@#_ )T _P#_    _P   /\   #V    [@   .< "@#A !$ W  :
M -< (P#0 "X RP W ,< /P#$ $8 P0!- +\ 4@"] %@ NP!= +D 8@"X &@
MM@!N +0 =0"Q 'X KP"( *T DP"J *$ J "Q *8 R "D .T H@#_ *( _P";
M /\ E0#_ )$ _P#_    _    .X   #C    V    ,T !0#&  X P0 5 +T
M'@"Y "< M0 P +( . "O $  K !& *H 3 "H %$ IP!6 *4 6P"C &$ H0!G
M )\ ;@"> '8 FP"  )D C "7 )D E "H )( O "0 -\ C@#[ (X _P"+ /\
MA@#_ (, _P#X    Z0   -P   #,    P0   +@   "R  H K  1 *@ & "E
M "$ H@ I )X ,@"< #D F0 _ )< 10"5 $H E !0 )( 50"0 %H CP!@ (T
M9P"+ &\ B0!X (8 A "$ )$ @@"@ (  L@!] ,P ? #Q 'L _P!Z /\ =P#_
M '4 _P#F    TP   ,8   "[    L0   *<   "A  4 FP - )< $P"3 !L
MD  C (P *P"* #( B  X (8 /@"$ $0 @@!) ($ 3@!_ %, ?0!9 'L 8 !Y
M &@ =P!Q '4 ? !S (D < "8 &\ J0!M +\ :P#F &H _P!I /\ :0#_ &<
M_P#3    PP   +4   "K    HP   )L   "2    C  * (< $ "# !8 ?P =
M 'T ) !Z "L >  R '8 . !T #T <@!" '$ 2 !O $T ;0!3 &P 60!J &$
M: !J &8 = !D ($ 80"1 %\ H@!> +8 7 #5 %L ]P!; /\ 6@#_ %H _P#%
M    M@(  *D"  "?    E@   (X   "'    @  % 'H # !U !$ <0 8 &X
M'@!K "4 :0 K &< ,0!F #< 9  \ &, 00!A $< 7P!- %X 4P!< %L 6@!D
M %@ ;@!6 'L 5 "* %( FP!1 *X 4 #( $\ [@!. /\ 3@#_ $T _P"["@
MK T  * -  "5#   C @  (,"  !\    =0   &X " !I  X 90 3 &( &0!?
M !\ 70 E %L *P!9 #$ 6  V %8 .P!5 $$ 4P!' %$ 3@!0 %4 3@!> $P
M: !* '4 2 "$ $< E0!% *@ 1 "_ $, Y !" /P 0@#_ $( _P"R$0  I10
M )D5  ".$P  A!$  'L-  !S"   ;    &4  P!?  L 6P / %< % !4 !H
M40 ? $\ )0!. "L 3  P $L -@!) #P 2 !" $8 2 !% %  0P!9 $$ 8P _
M &\ /@!^ #P D  [ *, .@"X #D V0 X /4 . #_ #@ _P"L%P  GQL  ),=
M  ")'   ?QD  '45  !L$   9 P  %T&  !6  8 40 , $T $ !* !4 1P :
M $4 ( !$ "8 0@ K $$ ,0 _ #8 /@ ] #P 1  [ $L .0!4 #< 7P V &L
M- !Z #( C  Q )X , "S "\ S@ O .\ +@#_ "X _P"G'@  FB(  (\D  "$
M)   >B$  '$=  !G&   7Q,  %<.  !0"@  20,( $4 #0!! !$ /@ 6 #P
M&P Z "$ .0 F #< +  V #( -  X #, /P Q $< , !0 "X 6P M &< *P!V
M "H B  H )P )P"P "8 R0 E .H )0'[ "4!_P"B(P  EB@  (LJ  "!*@
M=R@  &TE  !D(   6QL  %(5  !+$   0PP" #T'"0 Y PX -@$2 #,!%P Q
M 1P , $B "\")P M BT + ,T "H#.P I!$, * 1- "8%6  E!64 (P9T "(&
MA@ @!IH 'P>N !X'Q@ =!^< '0CX !T)_P"?*   DRT  (@O  !^+P  ="X
M &HK  !A)@  6"$  $\<  !'%P  /Q(  #@.!  Q"PH +@@. "L'$@ I!Q<
M* @= "<((P E""D ) DP ",)-P A"D  ( I* !\+50 ="V( &PQR !H,A0 8
M#)D %PRM !8,Q@ 5#>8 %0WY !8-_P"<+0  D#$  (8T  !\-   <C,  &@Q
M  !?+   52<  $PC  !$'0  /!@  #03   M$ 8 )@T+ "0,#P B#!, (0P9
M !\,'P >#24 '0TL !L--  :#CT &0Y' !<.4P 6#F$ % ]Q !,0A  2$)@
M$1"N ! 0Q@ 0$.@ $!#[ !$0_P"9,0  CC4  (0X  !Z.0  <#@  &<V  !=
M,@  4RT  $HH  !")   .1\  #$:   J%0$ (Q$' !T0#0 ;#Q  &0\5 !@0
M&P 7$"$ %A I !40,0 4$3H $Q%% !(240 1$E\ $!)O  X3@@ .$Y8 #1.K
M  L3P@ +%., #!3Z  T3_P"7-0  C#D  ((\  !X/0  ;ST  &4Z  !;-P
M4C(  $DN  ! *@  -R4  "\A   H'   (!@# !D4"@ 5$@X %!(2 !,3&  2
M$Q\ $10F !$4+@ 0%#@ #Q5"  X63P -%EP #!=L  L7?P )&), "!BH  88
MOP '&.  !QCU  D8_P"5.   BCT  (!   !W00  ;4$  &0_  !:/   4#@
M $<S   ^,   -BL  "XG   G(P  'Q\  !<:"  2%PT $!<1  \7%@ .&!P
M#A@C  T9+  ,&C4 "QI   H;3  )&UH !QQI  4<?  $'9$  AVF  $=O  "
M'-T  ASR  ,<_P"3/   B$$  ']$  !U10  ;$4  &-$  !900  3ST  $8Y
M   ^-@  -3(  "XN   E*@  '24  !0A!  /'0L #1T0  P=%  +'1H "AXB
M  @>*@ ''S, !B ^  0@2@ #(5<  2%G   A>0  (8X  "&D   AN@  (=L
M "'R   @_@"00   AD4  'U(  !T2@  :TH  &))  !81@  3D(  $4_   ]
M/   -3D  "LT   B+P  &2L  !(H!  -) H "2,.  8C$@ %(QD !"0@  (D
M*  !)3$  "4\   E2   )E4  "9E   F=P  )HP  ":B   FN0  )MD  "7R
M   E_@".10  A$D  'M-  !S3P  :D\  &!.  !72P  34@  $1%   \0@
M,3T  "<Y   >-0  %3(   \N P *+ H !2L.  $J$0  *A8  "H>   J)@
M*R\  "LY   K10  +%,  "QB   L=0  +(H  "N@   KMP  *]8  "KR   J
M_P",20  @DX  'I2  !Q5   :%0  %]3  !640  3$X  $-+   W1P  +4,
M ",_   :/   $C@   PV P &,PD  #(-   R$   ,10  #$;   Q(P  ,2P
M #(W   R0P  ,E   #)@   R<@  ,H<  #&>   QM0  ,-0  ##R   O_P")
M3P  @%0  'A7  !O60  9ED  %Y9  !55P  25,  #Y/   R3   *$@  !Y%
M   50@  #D    @] @ !/ @  #L,   Z#P  .1(  #D8   Y(   .2D  #DT
M   Y0   .4X  #E=   Y;P  .(4  #B<   WLP  -](  #;R   U_P"'50
M?UH  '9=  !M7P  95\  %U?  !27   1%@  #A5   M4@  (D\  !A,   0
M2@  "D@   -& 0  108  $0*  !##0  0A   $$5  !!'0  028  $$Q  !!
M/0  04H  $%:  !!;   0($  #^9   _L0  /M   #WR   \_P"$7   ?&
M '-C  !L90  9&8  %ED  !+80  /EX  #);   F60  '%8  !)4   ,4@
M!%$   !/    3@,  $T(  !,#   2PX  $L2  !*&0  2B(  $HL  !*.0
M2D<  $I6  !):   27X  $B6  !'KP  1LT  $7Q  !$_P"!8P  >6<  ')J
M  !K;   8&L  %)I  !$9@  -V0  "IB   ?8   %5X   U=   &6P   %H
M  !9    6    %<$  !6"   5@P  %40  !4%   5!T  %0G  !4-   5$(
M %-2  !39   4GD  %*2  !1JP  4,H  $_O  !._P!^:@  =VX  '!Q  !F
M<0  6'   $IO   \;0  +VP  ")J   7:0  #F<   9F    90   &4   !E
M    8P   &(   !B!   80@  &$-  !@$   8!<  & A  !?+@  7SP  %]-
M  !>7@  7G0  %V-  !<IP  6\4  %KM  !9_P![<@  =78  &MW  !==@
M3W8  $%U   S=0  )G0  !ES   0<@  !W$   !Q    <0   '$   !Q
M;P   &\   !N    ;@(  &X(  !M#   ;1$  &T:  !M)@  ;#4  &Q&  !K
M6   :VT  &J&  !IH0  :+X  &?H  !F_@!Y>@  <'P  &%\  !3?0  1'T
M #9^   H?@  &WT  !!]   '?0   'T   !]    ?@   '\   !^    ?0
M 'T   !\    ?    'P   !\!@  ? P  'P2  !\'0  ?"P  'P\  !\3P
M>V4  'M^  !ZF@  >;8  'C?  !W^@!S@   98$  %:#  !(A   .88  "N'
M   =AP  $8<   >(    B    (D   "*    C    (T   "-    C    (P
M  ",    C    (P   "-    C00  (X,  ".$P  CR$  (XR  ".1@  CEL
M (UT  "-D   C*T  (O.  "*\P!HA@  6H@  $N+   \C0  +8\  !Z0   1
MD0  !Y(   "3    E0   )<   "9    FP   )P   ";    FP   )P   "<
M    G0   )X   ">    GP   *$#  "B#   HA8  *,F  "C.@  HT\  *-H
M  "BA@  HJ(  *+   "AZ !<C0  39   #^3   PE@  (9D  !*:   'FP
M )T   "@    H@   *0   "H    J@   *L   "J    JP   *P   "M
MK@   *\   "Q    L@   +0   "W 0  N0T  +D:  "Z+0  ND,  +I;  "Z
M=P  NY0  +NQ  "YT@!0E0  09@  #*<   CH   $Z(   BD    IP   *H
M  "L    KP   +(   "W    N0   +L   "Z    O    +T   "_    P
M ,(   #$    Q@   ,D   #-    T@$  -0/  #5'P  US4  -A-  #8:0
MUX8  ->C  #6O0#_    _P   /\   #_    _P # /\ #0#_ !4 _P @ /P
M*P#X #4 ]  _ /  1P#N $X ZP!4 .D 6@#G %\ Y0!D ., :@#A '  WP!V
M -T ?@#; (< V "1 -, G0#/ *L S0"] ,L X #) /L QP#_ +T _P"Q /\
MJ0#_ *, _P#_    _P   /\   #_    _    /8 "P#Q !$ [0 ; .D )0#D
M #  WP Y -H 00#5 $@ T0!. ,\ 5 #- %D RP!> ,D 8P#' &D Q0!O ,,
M=P#  '\ O@"* +L E0"X *, M@"T +0 S0"R /( L #_ *P _P"C /\ G #_
M )< _P#_    _P   /H   #Q    Z    .  !@#9  X T@ 6 ,X 'P#( "D
MQ  R ,  .@"] $$ N@!( +@ 30"V %, M !8 +( 70"P &( K@!I *P ;P"J
M '@ J "" *8 C@"D )L H0"K )\ P "= .8 FP#_ )H _P"4 /\ C@#_ (H
M_P#_    ]@   .@   #<    S@   ,8  0"_  L N@ 1 +8 &@"R "( K@ K
M *H - "H #L I0!! *, 1P"A $P GP!1 )X 5@"< %P F@!B )D : "7 '
ME0!Z )( A@"0 ), C0"B (L M0") -, AP#W (8 _P"$ /\ ?P#_ 'P _P#R
M    XP   -(   #%    N@   +$   "K  < I0 . *$ % "> !P F@ E )<
M+0"4 #0 D@ Z )  0 ". $4 C0!* (L 4 ") %4 B !; (8 80"$ &D @@!R
M '\ ?0!] (L >P": '@ JP!V ,0 = #K ', _P!S /\ < #_ &X _P#?
MS    +\   "T    JP   *$   ":  ( E  + )  $ ", !< B  > (4 )@"#
M "T @0 S '\ .0!] #\ >P!$ 'D 20!X $X =@!4 '0 6@!S &( < !K &X
M=0!L (, :@"2 &@ HP!F +@ 9 #> &, ^P!B /\ 8@#_ &  _P#,    O
M *\   "E    G0   )0   ",    A@ ' ($ #0!\ !( >  9 '4 'P!S "8
M<0 M &\ ,@!M #@ :P ] &H 0@!H $@ 9P!. &4 5 !C %L 80!D %\ ;@!=
M 'L 6P"* %D FP!7 *\ 5@#+ %4 \@!4 /\ 5 #_ %0 _P"^    L    *0
M  "9    D    (@   "!    >0 " ', "@!O  \ :P 4 &< &@!E "  8P F
M &$ + !? #( 7@ W %P / !; $( 60!' %< 3@!6 %4 5 !> %( : !0 '0
M3@"# $P E0!* *@ 20#  $@ Z !' /\ 1P#_ $< _P"T"0  I@L  )L,  "0
M"@  A@4  'X   !V    ;P   &@ !0!C  P 7P 0 %L %0!8 !H 5@ A %0
M)@!3 "P 40 Q %  -@!. #P 30!" $L 2 !) %  2 !8 $8 8@!$ &X 0@!]
M $  C@ _ *( /0"X #T W0 \ /@ / #_ #P _P"L$   GQ(  )02  ")$0
M?P\  '8,  !N!0  9@   &   0!9  @ 50 - %$ $0!. !8 2P ; $D (0!(
M "8 1@ K $4 ,0!# #8 0@ \ $  0P ^ $L /0!3 #L 70 Y &D -P!X #8
MB0 T )P ,P"Q #( S@ R /$ ,0#_ #$ _P"F%@  FAD  (X:  "$&@  >A8
M ' 2  !H#@  7PH  %@#  !1  0 3  * $@ #@!$ !( 00 6 #\ &P ] "$
M/  F #H +  Y #$ -P W #8 /@ T $8 ,P!/ #$ 60 O &4 +@!S "P A0 K
M )@ *@"M "D Q@ H .H * #^ "@ _P"A'   E2   (HA  !_(0  =1\  &P:
M  !C%@  6A$  %(-  !+!P  1  & $  "P \  \ .  2 #8 %P T !P ,P A
M #$ )P P "P +@ S "T .@ K $( *@!+ "@ 50 F &$ )0!P "0 @0 B )4
M(0"I "  P0 @ .0 'P#Y !\ _P"=(@  D28  (8H  !\)P  <B4  &DB  !?
M'0  5Q@  $X3  !&#@  /PL  #@%!P T  P ,0 0 "X $P L !@ *@ = "D
M(@ G "@ )@ N "0 -@ C #X (@!' "  4@ ? %X '0!M !P ?@ : )( &0"G
M !@ O0 7 -\ %P'U !<"_P":)P  CBL  (0M  !Y+0  <"L  &8H  !=)
M5!\  $L:  !#%   .Q   #0- @ M"0D *04- "8#$  D 1, (@(9 "$"'@ @
M B0 '@,J !T#,@ ;!#H &@5$ !D%3P 7!EP %@9J !0'?  3!Y  $@>E !$'
MNP 0!]L $ CR ! )_P"7*P  C"\  ($Q  !W,@  ;C$  &0N  !;*@  424
M $D@  ! &P  .!8  #$2   I#@0 (PP) !\)#0 =!Q  &P<5 !D(&@ 8""
M%PDG !8)+@ 5"C< $PI! !(+30 1"UH $ MI  X,>P .#)  #0RE  P-NP +
M#=D "PWQ  P-_P"5+P  BC,  '\V  !V-@  ;#4  &,S  !9+P  4"L  $<F
M   ^(0  -AT  "X8   G$P  (! % !D."@ 5# X % P1 !,,%@ 2#!P $0TC
M ! -*P /#30 #@X_  T.2@ ,#U@ "P]G  H0>0 ($(T !Q"B  80N  %$-0
M!1#O  80_P"2,P  B#<  'XZ  !T.P  :SH  &$X  !8-0  3C   $4L   ]
M)P  -2,  "T?   F&@  'A8! !<3!@ 1$ L #@X.  X/$P -$!D #1 @  P0
M*  +$3( "A$\  @22  '$E4 !A-E  03=@ #$XL  12@   3M@  $]$  !/N
M   3^P"0-@  ACL  'P^  !S/P  :C\  & ]  !7.0  338  $0Q   \+@
M-"H  "PF   E(@  'AX  !8: @ 0%0D #!,.  H3$@ )%!< "!0?  <5)@ &
M%2\ !!8Z  ,61@ !%U,  !=B   8=   &(D  !B?   8M0  %]   !?M   7
M^P"..@  A#\  'M"  !R0P  :$,  %]"  !6/P  3#L  $,W   [-   ,S
M "PL   D*0  &R0  !,? @ -&PD "1D-  89$0 $&18  AD=  $:)   &BT
M !LX   ;1   '%$  !Q@   =<@  '8<  !R=   <LP  ',X  !OM   ;_ ",
M/@  @D,  'E&  !P2   :$@  %Y&  !51   2T   $,]   [.@  ,S<  "HR
M   @+0  %RD  ! E @ +(@D !2 -  $?$   'Q0  !\;   @(@  ("L  "$V
M   A00  (4\  "%>   B<   (H4  "&;   AL@  (<T  "#M   ?_ "*0P
M@$@  'A+  !O3   9DT  %U+  !420  2D8  $)#   Z0   +SL  "4W   <
M,P  $R\   TL @ '*0@  2<,   F#@  )1(  "89   F(0  )BD  "8S   G
M/P  )TT  "=<   G;0  )X(  ">9   FL   )<P  "7N   D_0"(2   ?TP
M '90  !N40  95(  %Q1  !33P  2DP  $%)   U1   *T   "$\   7.0
M$#8   HR 0 #, <  "\+   N#@  +1$  "T6   M'@  +2<  "TQ   M/0
M+4H  "U9   M:P  +8   "R7   LKP  *\L  "KN   J_@"%30  ?5(  '55
M  !L5P  8U<  %M6  !350  1U$  #M-   P20  )48  !Q#   3/P  #3T
M  8Z    . 4  #<)   V#0  -0\  #04   T&P  -"0  #0N   T.@  -$<
M #17   T:   -'T  #.5   RK0  ,<H  #'N   P_P"#4P  >U@  '-;  !J
M70  8ET  %M=  !/6@  0E8  #92   J3P  ($P  !9)   .1P  "$0   !"
M    00,  #\'   ^"P  /0X  #T1   \&   /"$  #PK   \-P  /$0  #Q3
M   \90  .WH  #J2   ZJP  .<@  #CM   W_P"!6@  >5X  '%A  !I8P
M8F0  %=B  !)7@  /%L  "]8   D50  &5,  !!1   *3P   4T   !,
M2@   $D$  !("   1PP  $8/  !&%   11P  $4G  !%,P  14   $50  !$
M80  1'8  $./  !"J   0<8  $#L   __P!^80  =F4  &]H  !H:@  76D
M $]F  !"9   -&$  "A?   =70  $EL   M9   "6    %8   !6    5
M %,   !2!   40D  % -  !0$   3Q@  $\B  !/+@  3SP  $]+  !.70
M3G(  $V+  !,I0  2\(  $GJ  !(_P![:0  =&P  &YO  !D;P  56T  $=L
M   Y:@  +&D  "!G   490  #60   -B    8@   &$   !@    7P   %X
M  !=    7 0  %P)  !;#0  6Q(  %L<  !:*   6C8  %I&  !96   66T
M %B%  !7H   5KT  %7H  !3_@!Y<   <W0  &EU  !;=   3',  #YS   P
M<@  (W$  !9O   -;@  !&T   !M    ;0   &T   !L    :P   &H   !I
M    :0   &D#  !H"0  : X  &@5  !G(0  9R\  &<_  !F4@  9F8  &5_
M  !DF@  8[<  &+A  !A_ !W>   ;7H  %]Z  !0>@  0GH  #-[   E>P
M&'H   YY   $>0   'D   !Y    >@   'H   !Z    >    '@   !W
M=P   '<   !W 0  =P@  '<.  !W&   =R8  '8V  !V20  =5\  '5W  !T
MDP  <Z\  '+3  !Q]P!Q?@  8W\  %2   !%@@  -H,  "B$   :A   #H,
M  2$    A    (4   "&    B    (D   "(    AP   (<   "'    AP
M (<   "(    B    (@'  ")$   B1P  (DL  "(/P  B%4  (AM  "'B0
MAJ<  (7'  "$[P!FA   5X8  $B(   YB@  *HP  !N-   /C0  !(X   "0
M    D0   ),   "5    EP   )@   "6    EP   )<   "7    F    )@
M  "9    F@   )L   "=!P  G1$  )TA  "=,P  G4D  )QB  "<?P  G)P
M )RY  ";X@!:BP  2XX  #R1   MDP  'I4  !"6   $F    )H   "<
MG@   *$   "D    I@   *<   "F    IP   *<   "H    J0   *H   "L
M    K0   *\   "Q    LPD  +,5  "T)P  M#T  +55  "U<   M(X  +2L
M  "TS !-D@  /Y8  "^:   @G0  $9\   6A    HP   *8   "I    K
M *\   "S    M0   +<   "V    MP   +@   "Z    NP   +T   "_
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M____________________________________________
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M1TE*2TU.3U!24U155UA96UQ=7F!A8F-E9F=I:FML;F]P<7-T=7=X>7I\?7Z
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M________J#4          %S3____________________________?0T
M     %36___________________________N?44          $34________
M___________________\JF0O @  !"(W25C.________________________
M____Z:1K02@_8W^5I[K:_______________________________5LJRRS.3Z
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________ENY=W8LC_________________
M________________VYYG-@H  HS________________________________(
M?S\%     %[/_____________________________]F!.0       #RJ____
M_________________________YY,         ".0____________________
M________W&\:         !!]^?__________________________KT@
M      !O[O__________________________A!,           !DYO______
M___________________L40            !7WO______________________
M__^X%0            !(UO________________________]T%
M   XS_________________________FB6A,            CQ?__________
M_______________?FUPL           -NO__________________________
M[[%]53DB$0<! A$BLO______________________________W[^EF9B:H*R]
MVO__________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____X[Z=@'S[________________________________\K>$5S . !VL____
M___________________________2BDP5      !R\___________________
M_________]9_-@        !+R?__________________________^I$^
M       OJ___________________________P%H            :E?______
M____________________C20            (A/______________________
M___G7@              =_________________________^T)0
M    :O________________________]]                6_3_________
M______________TK                3.O______________________Z4
M                /.'______________________S ,
M+=G_____________________F8IA)P              )]?_____________
M_________^V^B54G            )=S__________________________LJ=
M=EU*/#(M+# Y1][_______________________________WFW=;2T-/9Y/__
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________OU+O6____________________
M_____________^>XCVI++Q5O_______________________________DH6<T
M!P     \R?___________________________]:".P         2E_______
M____________________[84Q            ;_______________________
M____ID(             4.'________________________L:0
M    -\G_______________________^S+P              (K;_________
M______________]Y                $*?_______________________(T
M                 )G______________________ZD
M (S______________________T8                  '______________
M________WP                   '3_____________________EP
M             &K_____________________S@                   &/_
M_____________________RDB 0               &'_________________
M_____[FC@%<W%P           &C___________________________K3KI2&
M?'5Q<')W@93_________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________V[J=@FEIT_______
M________________________R)-E/1D    =GO______________________
M_____]N.3!,         ;O__________________________VWPL
M    1=?_________________________BRH             (K3_________
M_______________"1                Y?_______________________]]
M 0               '_______________________^<V
M &K______________________YT                  %C_____________
M_________T8                  $?X____________________Z0
M             #7I____________________E@                   "7;
M____________________O                    !C.________________
M____ZP                    _"_____________________P
M          JY_____________________R<                   JU____
M_________________W                    VY____________________
M_^"<C'!50C,F&Q0/#0X2&B:_____________________________^>38TL[,
MR\S/UN#\____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________Z].\X________________________________]*IA65(
M+!(!A?____________________________&K<3P/        3^#_________
M________________U7\U            '[+________________________C
M=1T              (G_______________________^0(P
M &?______________________]5#                 $CV____________
M_________XH                  "[=_____________________S@
M             !?(____________________O@                    2V
M____________________G                     "E________________
M____N@                    "3____________________W
M          ""_____________________P                    !T____
M_________________Q,                   !H____________________
M_T(                   !@_____________________WH
M      !=_____________________]$                   !A________
M______________\D                  !F_______________________)
MK)F)?79Q;&EG9F=K<'J,________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________XL6JD7EA=___________________________
M___=IG=0+ P     ,<3_________________________X)).$P
M (_________________________2<!T              &#_____________
M_________^YO#P               #?B_____________________Y8<
M             !3 _____________________T                    "C
M____________________K@                    ")________________
M____G@                    !R____________________O
M          !?____________________V@                    !-____
M________________^@                     [____________________
M_PX                    J^?___________________S,
M       ;Z?___________________UX                    /V_______
M_____________X\                    &T/___________________]
M                    RO____________________\K
M    R/____________________^                     R___________
M___________W%@$%!0,!       !!@T8R________________________.OA
MV,_,S<_0TM37W.+J____________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________________________':
MQO______________________________\<:CA&A-,A@ %:O_____________
M_____________[E\1A@          ''________________________7?"\
M             #OC_____________________]]D"0                RU
M_____________________W0#                  "-________________
M____Q14                   !J____________________F0
M          !+____________________M@                     P_?__
M________________UP                     9Y___________________
M]@                     %T____________________PX
M        P?___________________R\                     K_______
M_____________U(                     GO___________________WD
M                    CO___________________Z4
M    @/___________________]@                     =/__________
M__________\V                    ;?____________________]\
M                :?_____________________7#0
M:/______________________<                   8?______________
M_________U \1DY465UA9&AL<'9^B?______________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____[]6[HXMS6I7___________________________B_CF1!(04      %+\
M_______________________WG588             !?!________________
M_____^5L%@                "-_____________________V,
M          !>____________________G0                     U_/__
M________________H0                     1V?__________________
MR@                      N___________________[@
M        H?___________________PP                     BO______
M_____________RT                     =O___________________TT
M                    9/___________________V\
M    4O___________________Y0                     0/__________
M_________[P                     ,/___________________^H.
M                (O____________________]$
M%?____________________^!                    "_7_____________
M_______("P                   NS_____________________7@
M             .7_____________________R1P                  -K_
M_____________________YT!              <.%\7_________________
M_______5N;S!Q\[5V^'F[?3[____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________XW\__________________
M____________[,:EB&U4.R$' #+>________________________UY)9*0
M          "@______________________^)-@                !G____
M_________________V8                    R]O__________________
ME0                     #R/__________________IP
M        H/__________________UP                      ?/______
M_____________P                      7O___________________R4
M                    0____________________T@
M    +/___________________VH                     &/__________
M_________XL                     !?/__________________Z\
M                 .'__________________]4
M ,____________________\D                     +[_____________
M______]4                     *[___________________^+
M             )_____________________+#@                   )+_
M____________________5P                   (;_________________
M____J@H                  'G______________________VT
M         &;_______________________=5                 $7_____
M____________________:B,K-3]*56!J=7Z'D9S_____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________^C/MIV#:4ZY____
M_____________________^RR@UPZ'0(       ![____________________
M___%;2D               ! _____________________X,;
M       'R___________________D@                      F/______
M____________I                       :O__________________W0
M                    0?___________________PX
M    '?___________________SD                      .C_________
M_________V                       ,[__________________X4
M                 +?__________________Z@
M */__________________\L                      )#_____________
M_____^\6                     'W___________________\^
M             &S___________________]I                     %K_
M__________________^9                     $G_________________
M___2%@                   #G_____________________6
M         "G_____________________H@                   !G_____
M________________]58                   3_____________________
M_[LO                  #X______________________^K*0
M      #/________________________R4<     !Q,@+CY2:(3M________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________]-7)____________________________^M*PDG==
M0B@,  !*________________________Q7U%%P             1V/______
M_____________\10                    G___________________H@P
M                    :/__________________E
M    -O__________________V@                      !^S_________
M_________Q4                      ,3__________________T@
M                 *+__________________W4
M (/__________________YT                      &G_____________
M_____\,                      %+__________________^</
M             #[___________________\S                     "O_
M__________________]8                     !C_________________
M__^!                      7___________________^L
M          #____________________>(@                    #R____
M________________7                     #?____________________
MGP                    #,____________________Z$H
M      "W_____________________Z 6                  "<________
M______________]Z @                !W________________________
M>@L               5,_________________________Z)7:'2 C9RKO-#G
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________^WC________________________
M___2HWI8.BDC'!8.!@  G_____________________^L4@X
M    :?__________________Y$,                     -/__________
M________>0                       ./_________________S0
M                 ++__________________Q,
M (7__________________T\                      %W_____________
M_____X,                      #K__________________[(
M             !S__________________]L#                      +_
M__________________\J                      #[________________
M__]/                      #G__________________]T
M          #4__________________^;                      # ____
M_______________$!P                    "M___________________P
M,P                    ":____________________9P
M      "&____________________HP                    !R________
M____________XT0                   !<_____________________Y$&
M                  !!_____________________^M?
M   =_______________________*2P                  ____________
M____________RU<   P8)#$_3F!TBZ?'___________________________7
MY_+_________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________KU,W'PKZZM[.PK:FHI?___________________]U^4S\P
M(QD1"0(          -O_________________=@
M *?_________________N@                       '7_____________
M_____P<                      $;__________________TX
M             !K__________________XP                       #]
M_________________\$                       #;________________
M__$9                      "^__________________]$
M          "D__________________]K                      "-____
M______________^1                      !Y__________________^W
M                      !F___________________>(0
M      !3____________________2@                     _________
M____________=P                     K____________________K H
M                   6____________________YT4
M    _____________________XH                     ____________
M_________]9-                    _?____________________^G+@
M                U?______________________F"H           88+45@
MX/_______________________ZAC=(&/G*N[S>+Z____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______GR[>IG96.B82 ?'AT<&QH99#_________________O&I(+1D*
M             #'__________________P                        /_
M_________________T(                       #<________________
M_XX                       "R_________________\X
M          "-__________________\I                      !K____
M______________]:                      !.__________________^&
M                       T__________________^N
M       >___________________4%P                     *________
M___________Z/0                      ____________________90
M                    ____________________C@
M    ____________________O!D                     [___________
M________\4X                     V/___________________XL
M                O____________________\Q#
MH?____________________^1&0                  >O______________
M_______R= H                17_______________________Z'03'RPX
M15-B<H6;M-+U___________________________7Z/3_________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________________________OW\_'N[.OK[/'_________________
M_]FRF8=Y;61=5E%+1D$\.#(M*"/$_________________TLE"P
M          "2_________________X@                       !F____
M_____________]<                        ]__________________\S
M                       8__________________]L
M        __________________^=                        ________
M___________)#                       ]O_________________Q-0
M                    W___________________6P
M    R___________________@@                      M___________
M________J08                     H___________________TR\
M                C?___________________UX
M=____________________Y,'                    7O______________
M_____\U#                    0/____________________^'$
M            '/_____________________87@                   /__
M____________________OTX       X<+#Y2:H:ER/__________________
M_____\)\C)JGML76Z/W_________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________^[AU\_)P[ZZMK&MJ:>FIJ>N_________________[Z&
M;5M,0#<O*"(<%A +!      4_________________]<%
M        __________________\T                        ]O______
M__________]V                        TO________________^P
M                    LO_________________A)
M    EO__________________40                      ?/__________
M________>0                      9O__________________H
M                4?__________________QR,
M//__________________[DL                     )_______________
M_____W0                     $/___________________Z,6
M             /___________________]A,                     /__
M__________________^(#P                   /__________________
M___+4P                   /______________________I3@
M  D=-$YKC/_______________________YDY0U%?;GV.H+7+Y?__________
M___________________K^?______________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________KS+FLH9F1BX:!?'AT<&MH9F9H\?________________]A13(C
M& X&                GO________________]^
M    =?_________________#                        4O__________
M_______[-P                      ,O__________________:@
M                %O__________________E@
M /__________________OQL                      /______________
M____YD(                      /___________________VD
M             /___________________Y "                     /__
M_________________[DL                     /3_________________
M_^A<                     -G___________________^1&
M         +S____________________*4P                   )W_____
M________________F"X             $"E&9L3_____________________
M[G\=#!HH-T97:7Z5K\SN_________________________^>@JKG(V.G\____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________?7PZ^;BW]O8U-+1T-+7X/__________
M_______.GHI\<6EA6U913$A#/CHV,B\N,?_________________2)1$#
M                 /__________________0@
M /__________________?0                       /______________
M____L L                      /;_________________W3D
M             -S__________________V(                      ,7_
M_________________XD                      *__________________
M_Z\B                     )G__________________]9(
M         (+___________________]R                     &G_____
M______________^A*                    $[____________________3
M7                    #/_____________________EBX
M !4R4G?_____________________X'(3   !#Q\O0EAPBZC([/__________
M_____________\IO;GZ.GK##V.__________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________^>#2R,"ZM;"LJ*6BGYV;FYR@I_______________
M____@F162T,\-C K)R(=&!,."00  -3_________________D@
M             *W_________________S!X                      (O_
M________________^U(                      &W_________________
M_X                       %'__________________ZD;
M         #K__________________]!"                     "/_____
M______________5H                      S___________________^/
M%                     #___________________^X/@
M      #____________________E;0,                   #_________
M____________GS<              ! O4'3_____________________W7(4
M      87*D%:=92VVO_______________________[Q81%1D=8::K\CC____
M___________________________2S>'Q____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________\^_K[_?______
M________________[KFHG9:/BH:"?WMX=G1R<W5X?Y#_________________
MZT\Z,"@A&Q40"P<"         "/__________________VD
M          #__________________YL*                      #_____
M_____________\@Y                      #___________________!C
M                      #___________________^*#@
M      #___________________^P-                     #_________
M___________56P                    #_____________________A1H
M                  /L____________________L4D              !@Y
M78'_____________________Y7L>       ,(3A2;X^SV?______________
M_________[M8*3E)6FR E[#-[?____________________________^SGK3%
MU^O_________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________Z[^?AW-G6U-+0T-#1T]G@Z_?_____
M_____________[B*?G=Q;&AD85Y;65A75UE>97'__________________[\Q
M'Q80"@4               #__________________^U6
M      #H__________________^"!                     #,________
M__________^K+P                    "S___________________25P
M                  ";___________________W?!
M  "%____________________HC<                 !2N4____________
M________RV$"            #"Q0=I[1____________________]8TP
M   -(SM7=IF^Y?_______________________\-C&"H[3%]TC:?&Y_______
M______________________^H?Y:HN]#G____________________________
M_________?__________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________=SL6_O+FVM+.QLK*UN<#)U>/_________
M__________^7;&1>65513TQ*2$=&2$M066:A__________________^G)@X'
M @                !6___________________.4
M   Z___________________T>0L                    A____________
M________GS(                    .____________________Q%@
M           (,5J$____________________Z7\?           &)TMQFL+I
M_____________________Z=)      (7+TIHBJ[5_/__________________
M_____]-U'B8X2EYUCZO+[_____________________________^N<H68K,+;
M]O__________________________________W^______________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________O[*JIJ.AH)^?H:.FK+3 S=WL____________
M________BEI33TM(1D1#0D%"0T=.66E]____________________GBX&
M                ____________________PU8                  !5!
M____________________YWL:              DT8(NT________________
M_____Y\_          0E2G&9PNO______________________\9F#P   !,J
M1&*#I\WU_________________________^N.-2L^46B!G;S>____________
M__________________^^=G^4J<'<^?______________________________
M____TMCS____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________V\O#O[^_Q\_C]________
M____________________^+"?FI>6EI:8FY^DK+;"T>'N________________
M_____HY02D=%1$1$149'2U%::(.I_____________________Z9! 0
M    !S9CC[KA_____________________\9E"@      !"=,<YS$[/______
M_________________^6(+P  $RI$8H*FS/3_________________________
M__^K4#9*87N6M-;Z_______________________________2AWR8L<OI____
M________________________________U,[M________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________MY>/CY.;H[?'Y____________
M__________________VQE)*2E9F=HZFRO-#M________________________
M__^=4T=)35%68'.*K];\__________________________^R5@ :-5!MBZ[2
M]______________________________-;SY?>YFWU_G_________________
M_______________NGX.FPN'_____________________________________
MX\[K________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________________
M
M
M                                              #_____________
M____________________________________________________________
M____________________________________________________________
M_____________________________________P    #_X4&W:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60]
M(E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS
M.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 W
M+C(M8S P," W.2XQ8C8U83<Y+" R,#(R+S V+S$S+3$W.C0V.C$T(" @(" @
M(" B/@H@(" \<F1F.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G
M+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@(" @(" \<F1F.D1E<V-R
M:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7 ](FAT
M=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B"B @(" @(" @(" @('AM;&YS
M.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(*(" @(" @(" @
M(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O
M(@H@(" @(" @(" @("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+VUM+R(*(" @(" @(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z
M+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT(R(*
M(" @(" @(" @(" @>&UL;G,Z<W12968](FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B"B @(" @(" @(" @('AM;&YS
M.G1I9F8](FAT=' Z+R]N<RYA9&]B92YC;VTO=&EF9B\Q+C O(@H@(" @(" @
M(" @("!X;6QN<SIE>&EF/2)H='1P.B\O;G,N861O8F4N8V]M+V5X:68O,2XP
M+R(*(" @(" @(" @(" @>&UL;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N861O
M8F4N8V]M+W!H;W1O<VAO<"\Q+C O(CX*(" @(" @(" @/'AM<#I#<F5A=&5$
M871E/C(P,C,M,#8M,C=4,3,Z,3$Z-#@K,#4Z,S \+WAM<#I#<F5A=&5$871E
M/@H@(" @(" @(" \>&UP.D-R96%T;W)4;V]L/E!38W)I<'0U+F1L;"!697)S
M:6]N(#4N,BXR/"]X;7 Z0W)E871O<E1O;VP^"B @(" @(" @(#QX;7 Z36]D
M:69Y1&%T93XR,#(S+3 V+3(W5#$S.C,T.C$Q*S U.C,P/"]X;7 Z36]D:69Y
M1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T841A=&4^,C R,RTP-BTR-U0Q
M,SHS-#HQ,2LP-3HS,#PO>&UP.DUE=&%D871A1&%T93X*(" @(" @(" @/'!D
M9CI0<F]D=6-E<CY!8W)O8F%T($1I<W1I;&QE<B Q,"XP+C @*%=I;F1O=W,I
M/"]P9&8Z4')O9'5C97(^"B @(" @(" @(#QD8SIT:71L93X*(" @(" @(" @
M(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<]
M(G@M9&5F875L="(^36EC<F]S;V9T(%=O<F0@+2!0<F]J96-T(%1O($MA;&]N
M("T@1%)3($9O<FT@4RTQ(%-H96QL(%]'4"!$<F%F=" V+C(V+C(S7W-E;G0@
M=&\@<')I;G1E<B!V,CPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^
M"B @(" @(" @(#PO9&,Z=&ET;&4^"B @(" @(" @(#QD8SIC<F5A=&]R/@H@
M(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:3YR
M<C4P,#<S-#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @
M(" @(#PO9&,Z8W)E871O<CX*(" @(" @(" @/&1C.F9O<FUA=#YI;6%G92]E
M<'-F/"]D8SIF;W)M870^"B @(" @(" @(#QX;7!-33I);G-T86YC94E$/GAM
M<"YI:60Z,6)B-S,S960M86$S-"TP-S0V+6(T,SDM.#=A96,T,#$T-S4V/"]X
M;7!-33I);G-T86YC94E$/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YA
M9&]B93ID;V-I9#IP:&]T;W-H;W Z-F4Q-V$R96(M93DT-BUA9C0W+3@W.60M
M-60T.3DW.&(R-3%C/"]X;7!-33I$;V-U;65N=$E$/@H@(" @(" @(" \>&UP
M34TZ3W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z,65E-#!C,F0M,S,S."TT
M8S1E+6)C-3<M8CEC9&4Y-3)E.34S/"]X;7!-33I/<FEG:6YA;$1O8W5M96YT
M240^"B @(" @(" @(#QX;7!-33I(:7-T;W)Y/@H@(" @(" @(" @(" \<F1F
M.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V
M960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN
M<W1A;F-E240^>&UP+FEI9#HQ964T,&,R9"TS,S,X+31C-&4M8F,U-RUB.6-D
M93DU,F4Y-3,\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IW:&5N/C(P,C,M,#8M,C=4,3,Z,S,Z-#DK,#4Z,S \+W-T179T
M.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT
M/D%D;V)E(%!H;W1O<VAO<" R,RXU("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A
M<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO
M<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA
M8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM
M<"YI:60Z-S4P.#8X8S8M9&5A9BTW8S0U+6(P-C,M-&(Y,#4V.&-D,V8S/"]S
M=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE
M;CXR,#(S+3 V+3(W5#$S.C,T.C$Q*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T
M;W-H;W @,C,N-2 H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG
M960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.F%C=&EO;CYC;VYV97)T960\+W-T179T.F%C=&EO;CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.G!A<F%M971E<G,^9G)O;2!A<'!L
M:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T
M179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYD97)I=F5D/"]S=$5V
M=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S
M/F-O;G9E<G1E9"!F<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H
M;W @=&\@:6UA9V4O97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @
M(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z,6)B-S,S960M86$S-"TP-S0V
M+6(T,SDM.#=A96,T,#$T-S4V/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(S+3 V+3(W5#$S.C,T.C$Q*S U
M.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F
M='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @,C,N-2 H5VEN9&]W<RD\+W-T
M179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC
M:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP34TZ
M2&ES=&]R>3X*(" @(" @(" @/'AM<$U-.D1E<FEV961&<F]M(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T4F5F.FEN<W1A;F-E
M240^>&UP+FEI9#HW-3 X-CAC-BUD96%F+3=C-#4M8C V,RTT8CDP-38X8V0S
M9C,\+W-T4F5F.FEN<W1A;F-E240^"B @(" @(" @(" @(#QS=%)E9CID;V-U
M;65N=$E$/GAM<"YD:60Z,65E-#!C,F0M,S,S."TT8S1E+6)C-3<M8CEC9&4Y
M-3)E.34S/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z
M;W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z,65E-#!C,F0M,S,S."TT8S1E
M+6)C-3<M8CEC9&4Y-3)E.34S/"]S=%)E9CIO<FEG:6YA;$1O8W5M96YT240^
M"B @(" @(" @(#PO>&UP34TZ1&5R:79E9$9R;VT^"B @(" @(" @(#QT:69F
M.D]R:65N=&%T:6]N/C$\+W1I9F8Z3W)I96YT871I;VX^"B @(" @(" @(#QT
M:69F.EA297-O;'5T:6]N/C,P,# P,# O,3 P,# \+W1I9F8Z6%)E<V]L=71I
M;VX^"B @(" @(" @(#QT:69F.EE297-O;'5T:6]N/C,P,# P,# O,3 P,# \
M+W1I9F8Z65)E<V]L=71I;VX^"B @(" @(" @(#QT:69F.E)E<V]L=71I;VY5
M;FET/C(\+W1I9F8Z4F5S;VQU=&EO;E5N:70^"B @(" @(" @(#QE>&EF.D-O
M;&]R4W!A8V4^-C4U,S4\+V5X:68Z0V]L;W)3<&%C93X*(" @(" @(" @/&5X
M:68Z4&EX96Q81&EM96YS:6]N/C8X.#PO97AI9CI0:7AE;%A$:6UE;G-I;VX^
M"B @(" @(" @(#QE>&EF.E!I>&5L641I;65N<VEO;CXR-S(\+V5X:68Z4&EX
M96Q91&EM96YS:6]N/@H@(" @(" @(" \<&AO=&]S:&]P.D-O;&]R36]D93XT
M/"]P:&]T;W-H;W Z0V]L;W)-;V1E/@H@(" @(" @(" \<&AO=&]S:&]P.DE#
M0U!R;V9I;&4^52Y3+B!796(@0V]A=&5D("A35T]0*2!V,CPO<&AO=&]S:&]P
M.DE#0U!R;V9I;&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D
M9CI21$8^"CPO>#IX;7!M971A/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ 5P#< P$1  (1
M 0,1 ?_$ !X  0 " 04! 0             )"@@#!08'"P0"_\0 1!   00"
M @$# P %!P8/    ! (#!08!!P ("0H1$A,4%187(3%1(SE!87>1MB(W5VAT
M@20I,S0U1DAQL;.WP>'P\?_$ !L! 0 !!0$                $ 0(#!08'
M_\0 1A$  @$# P(#! 8&!@@'     0(#  01!1(A,4$&$U$B87&!%#*1H;'!
M%2,S<M'P%C5#<X+Q)4)25'2RPN$T-D1BDI.T_]H # ,!  (1 Q$ /P"_QQ2G
M%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2HXO+=VAV-TU\>
M?8_L3J-<<QLFD0-5CZA(2H@\B'"RUYV#4Z"W/JCC&"09$B!9L[LN$">.\ 4:
M$.R<TZ*MYM62)0\BJ>ASGWX!/N]/\^AU&NWLVGZ5=W<&/.C6-8R0&"M++'%N
MVG@E=^0"""0,@C-5H_3U^7+N]V4[LR'7'LIM^1W32+YK6YVB)(L\/71IJGV>
MF,ARK)$-)P,7#NXBI2-5( R,4:@X;#^(\H) 3C12B9$\2*FY1M((& 3C!X[Y
M)^VN1\*Z[J-YJ+6EY.;B*6&1U+J@:.2/#>RR*OLE205.0.",8YNA7_9FM]40
M.;3M+8-(UK6,%, YL=_M<#3H+!I6<I&#S+V(^.C_ +HE6,I8'^X^L\K&<-H5
MG&>1 ">@)^ S7H,LT4"[YI8X4R!OE=8UR> -SD#)/09YKE4;)1TQ'A2T0>%*
MQ4D*P='2<:4P='GA%-I>&,",%<=&*%(96AU@AAQQIUM25MK4E6,YI5X8, RD
M,I (8'((/0@C@@^XU]O%5IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<
M4IQ2G%*<4IQ2G%*<4IQ2O-F[X>:OR+T3R3[VE*/V$M-3I^A]^["UQ2M2PKN!
M]6%T_7MY*KK$=:J>Y]:/M)5C%KS+\]+3*2Y3[D\_$07%"K8&'GQPQF,97VF'
M)ZD'W>E>1:GXAU6/5[HQW<D:6UU-%' I_4%(9&4*\8P&+A?;=LL23@JO MC^
M?&;=LWA/[&V0AA K]@J_7J;>&:4IQL=V6W=J$]QAM:L84M#*R%-H4K&%*2G&
M<XQG.>1H/VRXZ>UC_P"+5W/B9B_AZZ<\%ULV..Q:YMSQGTSWJI#Z8K^=<H7]
MC^Y_\+H_?R7<_LC\1^-<-X-_KJ+_ (>Y[_\ M'V?/T^S++U;E[MQ?<KKQK5^
M?DG*+!=;0+K%U?[ES$0-:K/LO8T).3V \*PRN2-B:K  +*6A3J!8]#+:D(6Y
MA=EJ/98]]V/NJ9XYED.HVL6\^6EFLBKDX#R2S*S8'<K$HS[O0FINO2S7NW7/
MQF2<7:)Z1FPM=]CMD4>FM2)+I68&IIJ6MK8U! K>6M34</.VN=,%%3E+0WW[
MC3*$-82G&&Y $G QE03[SDC/3W>_X]AT?@N6232&5V+"&[ECCSGV4\N*3:,]
M@TC8QP!C&.E61.1ZZZG%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%
M*<4IQ2G%*<4JG5ZI'OKV4T#8^N?771&T+IIZ"NU/L>S[W8]=V20J=ILSHMA3
M7:[ +GX184['0\0J.E)$H8"488F"I$3[]ES$4-C,NVC5@S, <' !'3C[\YY[
M5P/C/4[RU>TM;6:2W62-YI'B9D=\/L5=ZX90N"2 1DD9Z '/STV7</?';OH_
M=">P-UDMCVG3NZ)364#=["0LZUS%3Q3:?:8YBSRSN,DS<C%E3YX3,P>X_)%
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M*;E7) CQD9)'&>>.O'YG@\XZ5Q?@R"5M6695S#%!.'=2"%9E0*&YRA;<-FX
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M3N*FQ%NW%TX\%Z6B9HH^NP:H0V :(0389&2KT';]'"DF1PJYPIR,MWY&>/\
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M:CZ--XGBL(AIEG!):,TC)(RV^YV\Q@Y8O<Q.6#*5!90< =0 3R$#H1YOM_\
MDXZW]W>QG5&"HUCJ>X-!R.R+;KNZ:1@06J51+A$LRMAD8..V[8),^09IC!<:
M8J.8?*DHR-&#'!>)0KZ]/,A6)T5B<AL @YR1\!W^P\].:O&F>(KK6+34;NQ$
M;)<6IFDB>V0"**10S%5N7<GR\AMN2P  !Z'NWU@?_2G0_P#V'L'G/]?\OJ+]
M_P#\\I:?VG^'_JJ1X[^MIG[MY^$%6T^E&<XZ9=2<XQ[YQUBT+G&/?V]\XU55
M/;'O_1[_ ,>17^NW[S?B:[C3OZOL<?[G:X_^A.]4F_3]1L9M#S?=E[]MQ*'-
MF05>[+7^"$EWFYHUG8TQM:!KMC<9DR6GG'Y&,KMGM;"9-IUI]]A9*L.*;=6A
M4R?B!0.GLCTXVG^ XKSOPN%F\1WDDYS,JWLJAO:/G-/&CX)R<JLD@)XXQ[JM
M*^=6JU>U^*'N2S:8P"19@M=Q]IA'#D-_4C+17[=73H"3CR%>SHI[1R$#H6.M
M#A0Y1,:Y]44X@=Z-"2)4QW.#[P?7UKL_$L<;Z)J'F $)")%)XVNDBE"#Q@YX
M]X)7D$@U?>ETK;HCTN/D+*IC?U)%_?TK%RBL/J'6W49DKK/%71Q+B"@\J]JL
M9+)6QA;J2FE.#+$+0\H9R0^/I*9]!Z=<-CX]O2N-T]G7P=JQ3DF\*MR!^K?Z
M&LG.0.48\?=VJ5OTG-;H(70K;MIA&@EW^>[)6.+O9B6VLR2(^ H]%=J,8^_A
MA#^(\<:9E) (93[[+94I(OM8;<(?3G'=$[P.VWCWG)R?^];OP0D0TRX=0#(U
MXZR,0-Q58HMBDXS@!B0O0$D]S6'_ *OJM45J.Z3V] D.ULLT_<-=).;6PW/&
MTB.&I$D(*4A*L$$Q,;.R13H3CR5L@ERAR1U-K/)P[?:Y]OTX^WG^?\Z@^.TB
MVZ=)[/G$SIG(W&)?+;'[H9B03P"2.YSBQZC6TV]/5'P^4G"2FZ$[UF#M*U)8
M,0$9;Q];Z>B6TODX<Q'D%1T,0XH1A;>3 VI0QQ"TLG.85=;8S(1UR!GW9)P1
M[R,]^E0O%LD@LM CY\LVGF=\&18;91ZC*JQQQG#'L2*RWTAMSU0-*TUJJHZA
MZ=Z+"U77-=4V'UTP,QHH9E-*"KX#-:7AAW?(CZ%O1"17W<$"C$*=<<40RT^I
MQ&+66VR<NV<G/)X^[/N[U.MI_&4=O EO86P@6*-8L+:C]4$41GF\'^J!G(R?
M0&OD\-WCR\G>DO*C/=M.R_7$/3=#VG!;O<VA(5:\:I54FIF^^UE&AHZH4W8-
MLED1K]W!C"1(U(S@D:Z,R^Z4RD1M+B:2,Q;%;)7;CKGCCJ0,\=?YQ;H&E:Q;
M:T;V[M!;Q3"Z,YCD@\L-, X01QRR,%,JC:,8! )(Q6-OCDU_6;WZG?LV;906
M9'.O=W=TM@5X8EA@@9NRQ]IL<!&'NMDLNXP[%HL9,G'/,Y9?%E1 2V7DY8^"
MZR'%LF.X0'[,]O>/X\U%TF&.7QA=EP#Y-QJ,R@@$%Q+(BD@@_5\QF!X]H YX
M%3!>JO!"(\:=4-?#%?,C^T.L\@%O#LN$A9)INSF"<B/K0IT;)#.<LOY96C+K
M6<MN?)&?;F*V_:?X3^5;[QJ =)B) )%]!@D=,QS9Q\>]0)=L;G=V?3,>-Z#%
MDI95;L/9+9,7:,HR4X.0%6;GV%)JD,<2G.6T@#$,_<@QK^?H./Q0C[+7U(UI
M36= /I$AZ^R#\,XS\/3UZ_"N8O9)!X0TA1NVM>2A\9P5CDNBH8],9 (!X]D$
M#V<U;8\$M+I5,\4O4!-*C8T!NTT$ZY68F/RTXY+W.?LTV]9)&3);RI9$B@UK
M\:YA]:G01XX:+QAIH!IEN+,297SG@X&?0?EW^==SX:CCCT2P\L !XC(Y'.Z1
MW;>2>YR,<_5 "]% JK#Y\HL'3?G)Z_;%TDA#>TK)$=:=D3D=#.+AB2-G1^QI
M>JPB7CVEMI;-GZU5*HT48C+>?I/?5(^;CCSKDF#)@8'I[0YYXP#WZ 'M]_-<
M7XG M_$=K+;C]?(ME,=IVYG$S1H/BZ1H#Z@GCEL[1YU*Y#7+SX:7J-F :DZ_
M:G^GM=L$61E66)"'F[4'&R@#V4*2K+109+X[F4J3G*',^RL9_;RZ']@2.P<^
MG3)_GOZ5;XC19/$T,;J&1VT]74\Y5CAE^8R/?\*M[>8N+C"O%EWA!*CP2 Q.
MO-Q*%$?%8=%&*B!QSXHAAAQ"FF7HPX,0P!U"4K#*%'(84VZRVM,.+]JG[PKN
MM?5?T+J(*@@6DA ('! !4CC P0",8Q@8Q@8AO])#0J]']->QNS6 V/TJM79-
MZER<AD87!*H&CZTHDS"A8,2PDU8[9]\GG_M72'!FW7LNL--.O$*=RW1]L#T4
M?:2:T/@:)1I]W-@>8]WY9.!G9'#$RC/7&96."<#/%1?^:< (/U#O6]\45@=V
M3M/2@^0<:;2A1AB;_&@)*(4G&/JOX# #&^HKW7]$9E&<_%"<8S0_^'/P?Y=?
M\ZTWB%0/%=G@#VI-.)XZGSE'/KP/LXZ 5^O5>?SA_5_/^K!3<?W[PVW_ /?[
M\_T<I;?LG_>;_E6J^-?ZUM?^!A]?]ZN,_P _EFK^P/\ S(/_ &4?_P E'(->
MG+T'P'X548]3-T/[>=Q-E]3YCK+HBY[AC*/1MGQML,JN(G+,&=,S]3)BQC?R
M4I'KPX8."6\U])+J?BPOY*3GVQF5;.B;][!<[<=3TW9/ ]]<-XPTR^OY;%K2
MVDG6**<2%-N$+-&5SN(/(!(P#T[=:L34?KZ#LCQ_T3K!N2 >"&MG4RFZ:V+7
MS$MY.ARC=3Q=4GQ<J:<6AF5A#_KK&)&?^0LB$T2*^EQIMW$?<5?<IY#9!^==
M4EJ)M+CL[A2!)8QV\RGJN8%1QWPRG/(Z$9!S5,[Q%^#?MSKCR7:_N/:#2=BJ
M&ENN]DM.PH^\ROXI5<V!;*&>J/ULU ?9R<@2XS)6,B+NHR2QVF7H.#+9><PZ
MZVT[,EF0QD*02P (] >OI\.,_G7GVA>'+^+6(9+VV=+>T=Y1(^#'*\1Q"$(8
MDY<B49 &$(/)P9[?4A]6.PG;CI5JO7?6[5=DVY=83LM5;A*UVKXC\G!5D'6F
MU8<N8>_(F@,?:L2<W$AK^+RG?JG,^S>4_-2<$#*C[F( VD9/J<5U'BVRN[[3
MH(;2!KB1;M)&1,9""&9"WM%1PSCWY((& :Y9U:\=DWN;P6:WZ!]F*U*ZKO4K
MK"V0TF',""&S>N+T+MFVW2AV-P44QQ@ER)D<0$R^&-(-?DHMTB,64.DQW*#2
M8G,BG(W9^((P?MYJ^RTEKCPW%IEVA@E:*0$-AFAE^D231/[)P=I*-@,"5.,C
M-0<=69'SU>& 6U=8JGTM/[8:8>L,U9*:94ZI=MHU"/D9)P!)\S4;5K@AJ;K\
M1-X&P<13[G$19;<F2;(L1X);\DHO,WDS>V7VMCG) /S!Z_$=:YRS/B;P^KV4
M>G&^@\QGC,:2SQ@MU9)(2&0-]8I(B$-N8 $DG(;H#TO\O/<;R#Q'D)[R6/9_
M5:B01D<6O7D58)O6D[<J_5W\'U73$9K6.FTS,%J]!ISA=H>O[+ID\U^786U*
MS$V9+@62/$B&- &)ZGJ,GJ0?4<8QQ]]2]+L->O\ 5%U34GFLHEVDPJS0M(J,
M6CMQ"&W+#EB9/.R6RP.6.Y<Z_46>,C>7?[36F;KUMA0[CM+0,W<G"=?OS 4+
M)6ZEW@."Q+8K)4P8#!O3T+(UB,,1%GEAO2@#QK4:2Y),"QDG;;R+&6#<!L8/
MH1GKWP>GN/H,UL?%>CW.IVUO):*)9[5I,Q%E0O'*$#E"Q"%E**2K$97.TY 5
ML5?&KMKU!E=W9U8T5V-Z^EU3J7468#7ETL,EK77X$C$:^J-,)AX)PRPQ,XX>
M@EMR+A17CA@E/D+4I2T9RZM6:R"#:Q5B6Z@9/))Y[?/K4/1Y_%*W%E;7=J4L
M4"Q2,88E98DB*H2X?.054$A<FL7_ "">,#O]T-\B9WD;\:% F=IUVX72?OKE
M/HE=_2R=HUHO[)PNP:38=:1SR)BU:ZM+TI+2$:;7 G&8 8_ !:8,J#AI@[)'
M)')'Y<A (& 2<9ZX(/8@>I![ ]*@ZKH^IZ7JIU;1X7G221I?+BC$C1/-D31/
M$#ODBD+,5*#V V/9V*QWGM+)^>SRU]:MBZVN_48;JQI^F0HMJLU*56K14]C=
MAKE72FCZM1:_![!F\SQ,6N<0!.$90-#5T%R)2<;.S!P<?!$T3R(F!#[F.0#V
M /KCCIGX^E7WI\3:Y:2Q26(LH(U$CQ[)$ENI$.Y(T65MQPP#8VJ@*@ER<+4E
M/@OZ"['HOB_WWU,[KZ;L5 1N+;VUA)ZD698+$I)4"YZUUS7$RX;\88>T,M9<
M;*8CBDNX(%/C4D);3EMM2L<S@RJZ-G !S[P3Z_*MMX;TN:+1[NRU&W>+Z3<3
MAXW(W-%)#"A8%2<9(;:<Y!&>U17:T\57G1\5>\-EI\<,W4=PZ:OKJO\ A$M:
MM4QT5/10+KWZ./7G7FUK!7$Q-\A6"76?S5.+,'>9RZS^65'ENQ+>4RP2@>;E
M2/<3UZX(Z]C@XK2PZ-XET6YF_112XMY2>=\ #J&8KYL,[ILE4-C=&S XY.#L
M$:GF_P!$]W:<SH;>GD=WK5[KV@W&5<HF"T?1W8MVK:<U#31H!T!8B8$86!9.
MG;3/R;!J(9LX9Y<<DHFR6*0>)Q$WPLF66,$(,'<>K'ISSGIR/>3C K4^([74
M(Q;76KW*R7MP75+>+;Y<$$0!'*@*&9W(.W(.,EG(]FUCWQ\7,EY(/%AU4UQ7
M7X^F]A]+Z=TY:-6F6]!D7'XEU:LK$+=-?6IQ(A!\,#8A!AL.DI!<(B[)7X)X
MIK(3![#L6.3RY&)S@Y! ^/7Y<UVNIZ,VK:+8Q(1'=V\%N\!DRJ[C BR1.<%E
M##'(&5=$)! (,1^E.ZGJ)>F.E1.IA7CON6W#]703-!U[M4G4M_V"[ 0,2$F*
M@!T6C6\L=0[^'!#-,-Q,BX8XI0; X\H08EK/OF9(')82!<\D<#/P!P?C@9^=
M:&WU'Q7IUN+$Z5+.T*B**<P22[% VH \),,@7HK$G*A0V<<R >#7QV^0;4>V
M=I]R.^FV=D0-DVO^D,F'U_*V&7)"S]KNAJ)"=V5M*M0$N_1P9$9K+PE8K#0C
MQ\6^6LPM$&N) CWK)I(RH2-1@$>UCX\*<]^^1GMQSG;^&]+U2"6XOM3ED5[A
MBXMVF<DN^XO)+&DA@&=WLJR&12H(,>"K]$>/3H?V\U5Y\>UG9[8>B+G5=!W:
MW=L3ZKL^2Q$_H]-B7B\YDZD^)D>3?/\ IS@&<DA?5";5]/\ Y5+6?V<K)(A@
M101N 3(^ P?^_P ?C432=-OX/$U[>36LD=M(]]Y<S;=CB6;?&1@Y&]3D9'J#
MSG$B?J)>LV^.U_0>%UAUVUG8=KWX?L#KRTO5BM?8?D6Z_%5J_B2,JK\B:"/]
ML(3*1[+GL_ESYE-?%"L?+*<<#*DF6.!M(S]E;;Q79W-[IBPVD+SRK=PR%$QG
M8JR@GD@8!89QD\],<UTUU9\5UAW_ .![6G0KM#6);3&V(]_8UCA5SH(TA-ZQ
MV"QNC8=FH]E=!!D<L%C&PDV@>2$9D$+,K5AD!4N,D/)4W<TH6;>IRH 'Q&.>
MHX]W^=1K+1'NO#,6F7B-;W ,SJ7 9H91<2O&^ W(*L P##*.PZU$MULN7J"O
M$+69OJ?5NF<EV:U1$%6&0UM*0=!N.WZE6R)PIP]^1J=NU?("2 \ ?*$OS;U,
MN0P$DR<6;ED:'606A>5O(F(<OM/?) )^.21\QFM':2>*-!5[)+ WD WO$5AD
MN(T+$DF.2 Y"LQWE)0K9)X3)KO7QR^)KO/VR[VQ_DV\I44]3'X:T [ J>K;&
MVP!<K'::VP,WKL%ZF D/8USKJ@.CA$@0<Z\U9)$F"$!/A%"2!LV3:\J(GEQ<
M\8W=O?\ $GG)Z?E*TG0]2OM2&KZTICVR"5(7.)'=%Q%F,$^3'%[.%;:QV#V2
M#N.AY7/'MW0W=YKM)]B=3]>[S>-*5R=ZIDS>PX?$+^"CF*1;H\^U.OY+EAC?
MC""-./F? 1><(1G+6',^V,UBD182I8;L/P<]\X_[5;K>EZA<^(H+F"TDDMU:
MP8S+M**(W_6$Y8'V ,GC\LV5O)QK6][C\?G;O5FL:U(7'8-\T==:W4*M$_0S
M)3LY(@9:"C0L$O#C_<$.?Y+?U7VD>_[UX_?R-&0KJQ. &!)]WRKL-8AEN-+O
MX(4,DLMM*D:+C+,5X49XR3ZD?$5&WZ;OJQV#ZC])]IZZ[(ZLLFI+M-=FK;<8
MJNVC$?@\VLG:RU-#"3#/XXT]C[1^4@I<)'R>2[]4%[Y-X3\%*OG97DRIR-H&
M?MK4>$K*ZL=.FANX7@E:\>0(^W)0P0(&!4D8W(P]>.14;GE;\?G<W=_FPT#V
M)U1U]O%WTG5ICJF_/[$A\0V8*,9I-\9E+6Z1DJ5&-PF$ QDDSX"+SAM.<M8<
MS[8SFBD182I8!L/QSWSCM6HUO2]0N?$=I=P6LDEM&]B7E7;M412AI,Y8'V5Y
M/'3IFM#U&?CY[G=L^[77[8W7+K[>-LTFK=?ZO5K!8JPF&R!%V +;6RITJ*)S
M(RH+_P!RQ$R\8>OZ;2V_HEM>R\K^24T@D18V5F )8D#GNH'XBGBS2]0O=1MI
M;2TEGC6TCC9T* *ZSSN5.Y@<X9">,8(P<\5<P$2I @J%IRE:!V4J3G]Z5):3
MA2<_UXSC.,\B5WXZ#X"OHXJM.*4XI3BE.*4XI3BE.*4XI3BE.*4XI59;M?I;
MU)$]V.W',=6NR>H*KUXD;O*E:AKLWG4/Y>'I;F6_Q@1_YK3$[+?<L_RGS^_F
M) C]OLLE?[,XDJUOM4,I+8Y(SU^.1]U<?>VWBYKNX:RO+=+1I6-NCF$LL9Q@
M'=;,01SP6;'J>M8Q:%]/SW"[)=H(+M3Y>>QL#MM^N2<6?C6=7ES[23;!("24
M;%U"5DT0E2JE$U\HC+I9==H\63]^P86*C,*4:4;BYIU5=L*[<]R.G/SR?CZ\
M=*A6WA:_O+U;W7KI)RA4^2C%_,"DE8V;9&D<0/5(T.X$_5).;@3333#3;++:
M&664(::::0EMMIMM.$H;;0G&$H0A.,)2E.,)2G&,8QC&.1*[VM3BE.*4XI3B
5E.*4XI3BE.*4XI3BE.*4XI3BE?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g425213g01a01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g425213g01a01.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1>D4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %XB^8"0X0DE-! 0      "(< 5H  QLE1QP"   "   < E  #E-A<F%H
M($YO;VYB97)G.$))300E       01N=-3E+[S@,ES\^Y">ROM#A"24T$.@
M   !*P   !     !       +<')I;G1/=71P=70    '     $-L<E-E;G5M
M     $-L<E,     4D="0P    !.;2 @5$585     @ 0P!) $4 ( !2 $<
M0@       $EN=&5E;G5M     $EN=&4     0VQR;0    !-<$)L8F]O; $
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M!@!! %  1  M #(       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q ;%%H@
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M0DE-!!D       0    >.$))30/S       )           ! #A"24TG$
M    "@ !          $X0DE- _4      $@ +V9F  $ ;&9F  8       $
M+V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $ +0
M  8       $X0DE- _@      '   /____________________________\#
MZ     #_____________________________ ^@     ________________
M_____________P/H     /____________________________\#Z   .$))
M300(       0     0   D    )      #A"24T$1       $     (   )
M   "0      X0DE-!!X       0     .$))300:      -!    !@
M       "9P  !9<    & &< ,  Q &$ ,  Q     0
M       !              67   "9P                     !
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M;&]N9P   F<     4F=H=&QO;F<   67     W5R;%1%6%0    !
M;G5L;%1%6%0    !        37-G951%6%0    !       &86QT5&%G5$58
M5     $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$58
M5     $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@
M  =D969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N
M    !V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L
M;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U
M='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT
M3W5T<V5T;&]N9P      .$))300H       ,     C_P        .$))3001
M       ! 0 X0DE-!!0       0    $.$))300,      S3     0   *
M  !%   !X   @6    RW !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4
M9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,
M#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.
M%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,
M# P,# S_P  1" !% * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
M         P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)
M"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$
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M%P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M-4568F9H<G2"AY26F*C(X55C9&5S=H22I+>XQL?3U?_$ !P! 0 !!0$!
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ME=G-FKJ81?A11-(@G5.1,A>G4ZABD('40 .IC" !U$0 .H^(B >8Y!( ))
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M^O3;X_I3>()J))B/1,H9F:?=5+BOJ=.H(]4O!0I]G5OMJ%PWXLK,/:)AP!!
M,?QNJCE3>6'$00UCB,[_ #M]NSFKCYLU=3")A$PB81,(F$3")A$PB81,(F$3
M")A$PBZ:Q2#*)@Y>3DG2#*/CXUZ^?/'2A4FS1FT;*KN7+A8_0B2*")#J*J'$
M"D(4QC#T <Q;VHRE:7%6H[A92HU*CW?LL8TN<Z!D\+03'PS"@D!KBX@ ,>22
M8 '"9)\%CGXU2;")VTC+2+QLRBXW@UH.3?OW*I$6K-@U<69PZ=N%CF B3=N@
MF9990XE(1(ACF$"@(YYMH%:G0Z275Q5>&4*7030[E[\D"C3JWKGO( )AK8=
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M+:51RLW(S>LC@\(9FB")U%%$B@/4R!Q*&<KT4Z07G1Z^%]:T*=7UNUL+ N>
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M^:P$NC)@#B.-SAO^*U^N$&U:;6N4T]/RSYTC%[%>VRM511-BY6.[E;G<ZTO
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MFFL=I%L07.<&K!!1591%HCW$4SK*F*0IU#B;*IWE>[KZ:VM6?6%G4%M:A_\
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M[9M,IF^YF9LL] E9Q4871^_69G;@)!BL*0.'^L&K1,?1)*&ZK+I%$"B'>ZB
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MI%AUY^]J!PJW)N6(MFM]I3MD@F]$2AG#Y/4>Y8\J4D4TR!FPHRE 8N3=WUI
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M]N^%\7/.OC,J0Y272P"/66[OYV&T@Z^LQ)&R'0?B8( *BQ>X'EW?T1@*4!'
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MJM$',-A]-LM;(&,<@!VQF=U;9'G-QH*Z64-=; !15KX@/T,-I"/=9Q:S1QU
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MK^HBJ8=8;3 A11EEG)PZ_$L3B!41*<1 I@Z" !U-X#70]&'3:BUP?I=#-!M
M1J%O +:A>79(S'ZD9)@NA4T^C^J,<]QH EP@#K&XRTG))[.R28QO'T:<[N,I
M$$BGND^4Q7+0YP'5^U.\4A)UR\,;ZVE#U$K=0IQ+X")>@%[QP[N2?1ETV+*3
M1I=L>K<YT_*%O!E]9^,'8UR)QADD2Z!<&AZI_JP&3_G69F?W9WW[<C<[N,?J
MZQ?CM/\ ?.6-[O75^U0,((.'"BH@(4KIT(0Y1ZB8 $.@%Z]1Z7J?HSZ:>W_%
MMO[36M,WUO[):T-GF#M,2-X)@20T35 &S;-QO-9O<([I[8,F %P)?GOQ89D7
M?/-@R[%F678+&<O-;[,:-R)F5%)/O++U!-,#*+*)HIE,8#JJ'*0A3&$"C:9Z
M,.FC'EWR90=^(ZL 7UO'%UPJ8)=(:&\XGBQP\U;&@ZH'%WJ[1D$#K&QB,3R\
M".\'<+F*<Z^,GHT.EVL @#Z+7, :PVI]8BV6>BJ;H--#KW2JD$!+U[W7IX>(
MC ]&/38N'\64!P['Y0MOU7-<0X#:8Y$D$B >0:#JDM/J[01D_C&YCE,GMG>,
M&)7I8#M#..,,W=L6U[G$VDXC!,9HHZJVDJ=5A'7&/M'<2.:D"9!1)U&L7!ED
MC )T4CH^(J&+F9;>CKIO:,KM9IM MK-MF. O[<2+?4*M])XA'M%[*<3B"Z2/
M9-ZEHVJTF5&BW!ZP03UC,-#FO CQ8TXS/,B0LIG8R\G--[<Y(35/HMBE9.PM
M=)V%\X9O:7=Z^B1HTNU:.X4^$+%78MBH<@/F@@W(Z.N<JAC)E4]$KW>X]&W0
M_I!T?U)U?5;.G0I,TCY.8YES2K%[C=U+CCX:<]6 T@%KADD@$QG;Z%IMW97-
M6K<TQ3#Z 8T<372X.!(D'8 "#$DF,Q)V>RATZAU$?'S$.G]B ?N!]WKGMK1!
M=XC^RT?8NK[.[[R?M7ZRI$PBB%R.X.<?N5%NUY=]MPUF=SNN4UHYB>MW&?JK
M*T59S:ZA>G5%OK&&=MV]PI#JXT*GV)>O2I5&IY"";?7 W7>H.B+B<\Y#6L;Q
M&W_7M@[.U3IMILK4^P=7P%VW!;H:B4EK;+U39NOUYO)6"5,0B13O'153I,TG
MD@+5%RJU9N#)"3)!AS'0#P.X@#EL[21X<P0>],C()!QD8.#*Z+LXFM#8\'^,
M5)I^R]2;F3U7I;7.J;%>M.6V*OU!D+90*A#5VQ)0MCCR)@Z;I2#)0R)7K5A(
M W41.Z8ME%!3"GF2<DDF8',DQCD)@=P23&Y/B3].WP^*FYZDS^Q&WWA+^)DJ
M(W[_ #Y[$]29_8C;[PE_$PD>..\_3V^]/4F8_P!J-OO"7NZ?ZW\O/SPI3U)F
M']J-O:/](2^?_6840/HCW+#?SNF=#'YR]G/9K=R?XLZFD>-&RMKWJ^Z\VMN"
MJTC8DY ;4TU/ZWJ(U*KR7>-(K+V*3;K+%F7$(U/'$5<L'3QRF5N($C(,=L8G
MN/B,'N3P)!G=OAVQL1@]NRS&$9L%"%.1LU.0Y2F*<J*)@,40 2F 0()1 0\0
M,'@(#U >@X,'D.[N\%,N_:,]LY^F5]/4F?V(V^\)?Q<*('GSOG)W/-/4F?V(
MV^\)?Q<) \[X[]T]29_8C;[PE\G_ %GR!A2N*]")CV;I^^".9,F3=9V\>NBM
MF[9HU;)F67=.'"H$200;I$.LJLJ8J:1"&4.8I2B(%$3Y\[[%8?NS??:0#DKV
MB<S1^2G&#=+WD)R'8[NJ52TUMNM["N%:HL9K:CT!XK<X.- JD2X3L4,N7O1J
MDQ&$1=L05DDG;@6I"'Q/U3OYQX]BS%^ILQ_M1M]X2_B84QYDIZDS^Q&WWA+^
M+A$]29_8C;[PE_$PH  [?B3]95!8LAZ=6C;P_P#B$OXF,\B1X1]H*E0+[3%3
M62_"'DEK>\;;TOH]WNK3^QM1TJX;MN\+KJE!=+M3YB*A&KV>D2J*@4JR_K;I
M.+8R<BDR0<.48]P"0D%GF2X[2[D.0Q&!. A)W))(SVG?O5U.%SG7\EQ6T!'4
M:_ZTVU%4W4>O=?O+QJVRQ%VI$M/T6HPM9GS0EBBA,@];)RD<X]'Z<C=Z5(R?
MK;1LL8R)&<29(VG/#S@8&!RYI).Y)!&QF(R=CXY4H?4F?V(V^\)?Q/N>["B/
M'XE/4F?V(V^\)?Q,*8\R?/GO*>I,_L1M]X2_B841X_$IZDS^Q&WWA+]XF$CE
MY[%AQY;3>@G/:4]G_<)[D_Q7U_,\;AY"LKWJJ_[CJE7VO+NM]ZU@JEKM"LTU
MVH91ZNYE6WISH2KN'74:.6R\2G(JKD2,3EX><DS[RLQH,V8@ @U;" @ ]?0)
M>(>_IW/;A2J^I,_L1M]X2_B82.?VGZMD]29_8C;[PE_%PB>I,_L1M]X2_B84
M$3YCZEP916#AHU_+RYXJ,BHMFXD9.2D#,V3".CV21W#Q\^>.A2;-&;1NFHX<
MN7"J:""*9U5CE3(8P$@#ZLG[^WZ5A[[+$-,1.R^T&3IG)/C#O.4WMS/V?R8K
M4!H_;-=V+/5?6ERB*9 1!;E%QY$5XB42D81RD\*P+*PR(KLTT9A95;T18C)[
MX\?/9[T^/CD9S]&#OC;>5F0%@R'I_P R-O ?]@2^YXD$.GS?:R<\B1V]_C*J
M!(V)'@8518LA\?5&W7W^@2Z_=[F$D]I^)^]/467V(U^\)?Q/R\L*,]IGMD]A
M',]Y3U%EUZ^J-NOG_2$OXO\ F]F$S,R9\3]'9[EC8[6V/US9> W(O3MLW)HS
M0\UO+75@UI0[9O:^0^MZ2K;)9KZ=FU=3;Y)RZ-W$6RSA=.*CI)ZF@F=<&IDR
M',#SY\.221S/+F3MM S]"E]QUG=>7+1^KI?7MRH&S:PWI-=@FMUUW/P]PI\R
M[KL6V@Y0\-88A1PQ?HH23!VV4,0Y5DE4CHN4D5R*)$))/,_$CXB?H*O2+%D(
M?\Z-O=U] CU#YNI!Z8DC8IGM..\\I[^\JA6#(O\ :K<1\?$4$>OC\Q \O(,B
M),G)Y$Q(!Y [PAR9,D]LF?\ #NV7Z]29_8C;[PE_%R45!8LQ\VK?I[O0I 'X
MBXSR)'<#@^/:FV9CW^86''?\]H-3M6>'=YE>3W%FI3&DM6\@M6VS3MLV_5(7
M<LA;][HZT6U^T@J&N857?K:5><'60D'D9)G+(19HN/DR/#B0"0-Y/[1WS]'T
M>"<1/:<[S&Q$]^(^CXYCO460A_SHU'P_V!']XG[F%,GM/Q/G//M06+(?[4;?
M:02\/;X?68[^?;L5$D<S\2?K/G/:@L60_P!J-OO"7L_\'\?G\N3)[3\2ID]I
MY\^U/467V(V\NG](2\A\_P"QR-\G)[\J#G==18)*K5:$E;)9WT#7J[!,'4K-
MSLXXCXJ'B(M@@HZ?2,G)/SH,F#%FV257=NW2R2#=!-1550A"&,!1 'GP[? +
M$]V3_P!!V);\Q8&D<B>-F^);8_,S>O(YDRT7M&O['<UG7NV):)5JJ%M:QY47
M,1,D&,=(2"*2+R)1<]U)G+O>\/=>=U*R\^I,_L1M]X2_B82/,GQ\_#9/4F?V
M(V^\)?Q<*(\^?._:4]29_8C;[PE_%P@ &WG[O<GJ3/[$;?>$OXF$B!'GX[K%
M#VT$'K>_\"MM:*LV\N/^@;3N-2F1=$L._=B1&LJI(2-3V)3;K+M4I9VBZ?+K
MDA8-V4"1D:^,1==J1T"""QEBCX2G/Z\GO[_/9S&2K7=KU]L>DUNZZ[LM/OM,
MGHQ!U V^F2L19:Q.-$^\V,ZB)R(6=QT@V!=!9$56KA0I54E$CB50AR@2 <_?
M]7+[^\+VGJ3/[$;?>$OXN$CR23]:>I,_L1M]X2_B82!]OO/-/4F?V(V^\)?Q
M<) \^\?:GJ;/[%;?>$OW.YX^6$\[_;Y[5A@O4EH=YVR6GMHJ<HN*D?)T7B[L
M7C1+Z0D=P59MO-UM.^[(K%M@8]AKTPF45*>*CE$#M7+Y"=%VNW0:PBZ2_IP*
M?/GP69_U)G]B-OO"7\7"B/L^CS]?:506+,? 6C;SZ_TA+^)D$3$$B"#B.7B"
MD#/?OS\[J@,&0"(^JMQ 0 .@H(B =/=]9U\?;U$?(,GVIDO<1R:2.$=X$3)Y
MR3]:JDQ$F,X!(W\\E7U)E]B-O:'](2]OG_8823VGXG[UY^U3U+HM<FKA=9>M
M5&J5R/<RU@LUE>QD) 0<6S3,J[DI>7DE&S"/8MDBF4<.G;A)!(@"910H!UPH
M,DY)^)[_ +^7VF<7'9$,M45W2VXJ'3-^\==^S"W*/D=M]\ZT-LN#V4QK]7W9
MMVTWFE-+ 9BF@ZB)7X&D$V[UNLU.Q+(-GB$?(2"3<7 OH^/;//S@("8W.<]^
M>V/I^Y99O4&7V(V^\)?N]SK^/]T>J3^T[XGZML?XR5,GM/Q508L@_M1M]M!+
M[7]A[/9DR3N2?>DGM/Q/G]^=T]19?8C7[PE[^O\ K/?D))[3\57U)GUZ^J->
MOO\ 5TNO^)A1F29=/;)QX=BQ.]L>QU7;^(<II>V;XX[Z!M>PK_J&<J$GOW9,
M'K*!F&VK]PZ^V#:T&#UZDY?OG*,#".$4R,(]RD1\]CT7ZS)NZ]9(]WGS/Q*2
M01!.([=N6_>!\!/)9.J99:)L&K0=TH4[5;K3K''(25>M54D8JP5R<C5@'T+Z
M(F8I9W'2+-02F*1PT<K)"8IB=_O$, $DXR<=Y'GP7I_467V&U_\ )TOXG[N$
MSVGX[>'8OT5JV3-WTD$4C]!*)TTDR&$HB!A*)BE >Z(E 1#VB #D$3S(\$.=
M\YG.<GQV7(R43")A$PBP8]NU>M6ZVTAH:[7^%VNM9*YN]Y*:RMVJ9O6L+)TF
MS-=4;&5E7*R.X:??M<VB6LM3).U&D4B:JKV0M5WF8&.KSR+F3-7Z!%V/89V*
MCVS1^^;%6VMAD+?,[X+);3V%);$UKL^ V/:W^J]</8R5J]FT]KW5FM4 KU2<
MU^GVFOUNCQAH&Z0-@8RCV9DR.9-R4<_C]G?]GPYYO<*4PB814'R'YA^3\?LP
MBTPNU4VMI.K\S^3^O@;[7JB5T803G?T&MN?B]K>G;>0A=(UA_(&B%-PZ&VEM
M*K/;?1!AM?:O"G6*'C]D["@;=&5L:U/P,G,N8/A(^F?#[93SVK<*UN$4&O*&
M$'&24)"!3*N$/#3)5RR\3%? C'X/C)4KE15P628-/0M7P+JJ+ Z25]*H<_>,
M,^?,HO:81,(F$5B^4)JF7C3R%-?*]8+;1PT?M8;E5:F=5.TV:J_$6>^,%?K:
MB)B*IS\S$^MQT.HF<AR2#EN8IBB "!%JR=D7MG46SN<&F6@$V_=9&DTG;]4T
MF%@VMQHM;?5)8NCPZMFL$C6>/FB]6SECU!8ZC))42B[?NEKG:[+7Y&3K:%:;
MV5LC.)$6X<'B #TZ=0#P]WR815PB81,(L ?;P[&UCJFI\:+S:XK;"-^@KIL5
MUKF\ZML.I(1[5RA3$ MD*6.W?1-CZ_N-FN489HPI]04K/QCDW3*2<0$O&G9.
MP<D\^?/-7R[$N4I,UQ:V!*U-"2>33[D'?'.RKLKL;7^UZWLG8*U=I"DC=*/=
M]54+6.N9.MKPYH2$50J=%@&4=/P<VQ=)/)!!U(.2<_M\^>SFLQ6$3")A%0W@
M CUZ?/U_>\?FZ>/7V#Y81:2G:*;:T'"\RN5FKG<1N>/J%CV ,[OK6B.Z>,5+
MBMNOH:E43XT(U1O?-$7W>4%;-D1;^#C],4:MW^#<[5<PE[D*-)5 ]?<*J//G
MS]JCSYCS]:W88_T7J#'T*:B*/J;;T*2W>!5)+T)/1IJ@<QC@H0G0I^\8QN\
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MV4 =@9<(X\CM>F:?L]WK;1Y7*E=8VM3/QJ9SKB7DFLN3SYV\5D"*     =
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MO'.8X]3&$1(,?O7*PB81,(F$3")A%\UDB+)J)G#J50AB&#J(=2F 0,'4H@(
M("(> _+Y@&$5MM-Z>UYH'6-0T[JBOEJVNZ'&J1%5KY)"5E2QD>H]=2!T D)M
M])2KKO.WKE85'KYPJ J"4#@F4A"D5S<(F$3")A$PB81,(F$3")A$PB81,(F$
M3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB8
M1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")
MA$PB81,(F$5!,4H"(B =//J(!Y^7G[^GA[\B>6YWC$QVHOGZ4OO)]LY0'SZ9
M;-4#!X6GL<]K7#Q$XG<=Q'@@GGOW+]E,4WD(#T\^@@/0?</3+@((D$$=HR$7
MZR43")A%01  ZB(!\X] ^[D$[@1(B9GFB_ JE#KXDZ=>G7OE_A_%E!J 8)9@
MP?;:,^_;P.47[ 0'Q 0$/+J @/C[O#+B*N$3")A$PB81,(F$5!$ \Q / 1\1
MZ> >8_,'M]V1(VY[@<RB^8+%'VD^V<H?OY;-0#!AIDX<]H,<C$['EE,\_=X*
MI5"F$0[Q>H?]< ]?E#Y,K:[B$P0,YD$$=H(.WPV*C/=Y\[_0OIE2E,(F$3")
MA$PB81,(F$3")A$PB81,(H"[G[23C3H3D5.\7=C2EEB]KQ'&.T\KF#!*)8J1
M=MUY3#VX]A@:G(KR[8TCL!I'4BPS1*VZ;1[=>&9*OD98X(.DVY1V?='T'*OS
M1.4V@=@U.H6V)VK0X]"YNJU#Q\+-W*JL+$QN%KH3+9T7KZ8BBS3@S&_A1'Z%
MH<U(%5I5.$!26316BR@],4^?/T*V$KV@/%5"?T["53;%/VBUW1M:S::A[1JR
MW4N[U&IW:HZWM6U9QKL"?BK*9K6&K.HT^6<**'!VZ3<*, 69I,W)WJ!.WS]$
M?>KAGYA<3D]<AN%3DUH FIS6+XHDV6;<% "A&M74O6MA;1GP@OAT ,4XQ(/A
M?@D8JHH F(&PHGSX[=_QVSXJS"_:3<3EMXK\=ZSL.-O&SV%XU+0YB(JLS4G#
M>*?;GJ\Y<*C,@ZEK+$#/5U&$AD5IM_44;$XCEYZ :%8N7#MT1B4KDL>TGX7R
M.T;SK%IOO62R6M-8M-IWO9J6P]?JZ@JL6\OR^MTZW.WU*UG81-U2LJ!4EZ_)
M(-#$;NF1RNC.')&N$\^>WR%,^NV:NVZ B+55)Z%L]8L$<SF(&Q5^493,'-Q,
M@@FY8R<3+1Z[AA(Q[UNJFNU>-%U6[A$Y%$CG(8HC!, X)CD-T7;@J7VB4/?U
M.4.GVNOAE'6#G#8W#GM!'B),)Y^Y/2E]Y/OA?X<CK6]K.S\XWSE$]*7WD^^%
M_AQUK?VF?^(U$]*7WD^^%_AQUK?VJ9_]8W[815!0HCTZE\O88#?:\.O\/3QZ
M94'@R9; Q@AV?$?5$HOIE:)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3
M")A%01Z=.O3IU'J(CTZ> CX>_P L)GEY"_)#E/U[H@(!T\0'J @/7^#*0Z26
MP06Q(\9B#SV]W-1F3M'+M[Y7[RI2F$3")A$PB81,(F$3"+%[VS<S-U[LU^3,
MQ7)Z=K,RWB]<H-9NM3,G7YMD1]N+7K!V+"8AW3*38J.&+MTU54:.D5#(+JI]
M[NG, X=_4J4;&^JTGNIU:5E=U:;VX<U].@]S"#W$=\[<U8NB6V]9S20YM-[F
MD<BUI(^D+43^#Y@>GYY.[S> >([ZW1U\ #Q'\W@>/AU$??XY\W#IQTK: !K5
MT!V<-ON3)_S1YGDO%#TJUP.>!?/: ]S0UO"  '$1D=D<S)DSO&Q'_H?B9L+W
M5G+^*FK5<+2TKO*2.BX(]RMUEN3R*C'.@=.S*[!E(6B4EG[=DI*R3]\+5-R"
M .7:ZI2 90W7W'H;>W-]T=TZ]NJAJW-S5NA6J$-!?P7%=K7$- '$6L:"?BO5
MNCES6O='M+NX=QUZHJ=8X" XLJ.:'0,2>9YF>TSL%YUBWB81,(K!<JWSV-XP
M\CI"->.H^08Z'VV\8OV+A5H^8O&U!L"S9XS=H'37:NFRQ"+-W"!R*H+$(JD<
MARE'+;A)+<P[@!C&'.#3!CLGG/V2-_<?H!*T(:,G8Y*CU.2?;0WBY?2%5@WK
MQR;?.Y047=NHELNX7.!;R4H'46.=0W=*  )A[H '0,^<;WIITHHWUU1HZQ<4
MJ5*ZKTJ=-C* :QC*SV-: :1,!H &>2\5O>E&N,O;EC+U[&-KU&L:T -8T.(
M:#)VY# P28D+=%[(Z<G+-V:'"FP6:;F+)/R^@Z4\EIVP2;V9FI1X=JH"CN2E
M9%=R_?NU>Z JN7;A990?KCJ&$>H_1U-Q=3:XY)B?C'U97M V'F>_W]G)9%LN
M*4PB81,(F$3")A%8[DR]>1W';?;^/=N6#]CI3:;QB^9+*-7K-XUI$VNV=-'2
M)B+-W#=9,BJ*R)RJI*%*HF8IB@8+5220 2TD0'-P]LO8"6NY$@[C((!$(1Q
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M6VDGRRVFWUFDGJIPKQT+2-(GU^N@3:.MXQ1B:V'UL&U"H*R0_#XJ%N_K97P
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M/C]);3?/X&1TYQ$:,)MDUH\ZNYB'SF(T,PDV[.213.T<KQKUF_116.=H[;N
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M0SC$2WNG$YDYA=/^&_1G_9U7LS3I?1[>?I7Z!KL$>O7LK=[]/,!^+O$8!\_
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M_ 9Z1L?Q]822/]-:AW_S>[.QV..=7X;]&1CY.JGD/Q=/QWXNX]^\C94,TV
M#U[*[>X '41$:]Q& 0#QZB(FWQTZ!Y^/0 \A\NH5T_0=Z1 ^F7:_9!K7M+G,
MUJ_>_A!!/ UPAS@)+09#B!)RH/37HQ4#F_)M5P<"T@4Z8D&06B78D'>">_<+
M6?2[)KM&"K3"OT@-^,5_8K1*-NMFT&84V<K8I"38)G3-L[N$418N4T#)E$4T
MC@)$S"0J9C?8&FM=:Z996E<E[K6VHT'M@15JL'MU2XO#B3!/$0)B/'N^B7ID
MZ!:1H&G6=]T?NGW5.G<==6%K9W+S^5.X 6U"U[B&.#?;:V .)HX1(M?>^$7+
M+C7?-!7C>O&&RZ5JDEM5Q6V%GFI/5[YH^GG6NKY(MH8B5)N5ADP7<,HQ\[(9
MPS29]UDH!G +B@FIRWI J-=T3U0M8*9 MR3C(-U1D')YGG Y=J\U]/OI(Z)=
M-N@E72M"TJ[M;FE>TKNJ]]A;6?%0;0N*1:VK1)<YPJU:;BP@-(;.[05PM#]G
M/S@W%K*+V3K/AO<-BT:USMY>UZZQ\WIM!I/-&]YL<>LZ1;V6_P 3-HD1?,G;
M3N/8]LIWT#"4IB=PQ^DTI]-NEZ6>K:XG3+,$@- D4R?VLS(@D2?!=QZ.O2_T
M'Z/="] T?5-'NKB]L;3JZU:GI]G=]9)+F\52J0\$!S0 0-B=@2KO?4F^T=\P
MX WX0]_P_P ?P]OLZ[/'J'R]?+[F; 5:>W4C&9EHSX\??@]NV,KLSZ>?1QN-
M"OP,?Z%T\F3YQ*ZBQ=D7VD4I7IV-:<!+XB\DHMTS:+C8M )@W<+ME$TUQ.GL
MXRB8 J8IS'( F*'UP!U ,5*C>!O#2:"&O!RTSQ-@!T/)@$]G?WK5ZUZ;/1Y?
MZ-JEG0T2_IW-Y:/H6M0Z-8MZFLYA;U@<)<R7$20.(3( Y;)= K>TZ[1*77IC
MLL]YNI6 J-:A)-9*"XCN$E)"*A6+)ZJDX5WJDLL11PB=0JZJ9#G Y3'(503%
M#Y U+T*^D&^U#4+NET@LFLJ73C1I]?=4A3IEQ/"*C?F@@_/9(;NO,:/3;HPR
MC2INL*SJK8#G&FPEQ@3+B>Z8G,[D03ZSU38(C_6KM[A\]>XC=.H^_P#/W#P#
MW>77IX=.N8/\!GI%D Z]8<_]-Z@,9S@3X;#';"O_ (;=&9 ^3JN<9ITS$<_G
M')[]Y[@K4;*T9R$WE9N/E9UMPQWCQ6F*[R3U/>Y;?JL#Q.%76M8J[^07FK"R
M9M]B;!+*/VJ+E+U:,=U&;9.CB/K+)4J929Z%Z-/1ITOZ)](FZIK>J6U[8&VJ
M4G6U'4+J[XZCPW@>]E=O"T,]HM<(.2.P+G>E'2?1]3TI]KI]FZA6J5*1ZQS&
M-(:#GA+7$B?UML;=BV M(4"^:VI1JWL;=URY 6()A\_^/MYKFO:M-@P=(M"M
M80(O6=4IM;]2CC(K*H.31 R2QWBP.G:Z:;<J7T$T$""9.3SYDD#,G QO\-AY
MM]D#>>05X,E$PB810N[0KC?<.7/#[<O'B@SM<K-OV)'U5&#G+<63-7&+JN7R
MKVXPR@0S5Y)"@X;P"S4/56ZJ@*KIF$"D QLQKN@+JWKV[G.IMKTGT2]@XG 5
M&N83'. Z0# G<Q*HJL%2F^F<![',)[G""M?HO8C=H(4"A]%#B /0O< ?6]R@
M/UH 4!$/BEX> = 'KT']$/3V>7'T4:?)G5;YV9GU:VS\:H,\I(Y<UP7\'U@2
MXB_NZ8<]SN!H:6@N<7$ Q,$G)// *S =E1P>V_PAU]O2"W1:M<VVT;<W.VV6
MU4UK\9A@HJ,:ZRH5!3CUU+3&QKY1\9:GN'IS)I';@B\1(50#E,0OH&B:13T/
M2K;3*-5]RVU?5>VI68UCB:U5]4F&2T.;QEN"< 9DKL=-L*>F6E*SI/<^G2;
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M'2WS,/8[/IW6%<HTY.UTKTL'*R,0@9-P\BRR2#5^#)0Q@]$+MNBMT >^F4?
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M-'L"0$I/5-D6>69PI//W+-?1GUT?4ZNO=BQ%<@;NZB6R]FAJE-25DK,;*J%
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K(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A4N/")B<PO_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g425213g01a17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g425213g01a17.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1>\4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %Z"^8$@X0DE-! 0      #@< 5H  QLE1QP"   "   < E  "$1E<V@@
M4F%J' (% !=0;W=E<E!O:6YT(%!R97-E;G1A=&EO;CA"24T$)0      $!4F
M] /\ZW4.FJ(YR6#3;TLX0DE-!#H      .\    0     0      "W!R:6YT
M3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90
M  !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE
M5$585     8 00!0 $0 +0 R       /<')I;G10<F]O9E-E='5P3V)J8P
M  P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M    0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-
M!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M    0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N
M0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M     $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M    4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!O
MX            $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M            0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL
M0'+            *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G
M4',     4&=00P    !,969T56YT1B-2;'0               !4;W @56YT
M1B-2;'0               !38VP@56YT1B-0<F- 60           !!C<F]P
M5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M  QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M       +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      !  E,S,  $
M @"4S,P  0 ".$))300F       .             #^    X0DE-! T
M  0   !:.$))3009       $    'CA"24T#\P      "0           0 X
M0DE-)Q        H  0         ".$))30/U      !( "]F9@ ! &QF9@ &
M       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4
M   ! "T    &       !.$))30/X      !P  #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@  #A"24T$"       $     $   )    "0      X0DE-!$0      !
M   "   "0    D      .$))300>       $     #A"24T$&@     #00
M  8              ED   =1    !@!G #  ,0!A #$ -P    $
M                 0             '40   ED
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   ED     4F=H=&QO;F<   =1
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   )9     %)G:'1L;VYG   '40    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $    !#A"24T$#      -%@
M  $   "?    ,P   >   %^@   ,^@ 8  '_V/_M  Q!9&]B95]#30 "_^X
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M5:="#Y?DZI^P8OIY++X
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! ?_  !$( , "5P,!$0 "$0$#$0'_Q  >   # 0 #  ,!
M    " D'!08* 0,$ O_$ '80   % P(#! 4## @-# X(!P$#! 4& @<1""$
M,4$)$E%A$Q05%G$7@9$8&2(F)R@V-S@YH? E*3)W>+'!T0HC)#5&1TA79W:V
MX?$T0D1255989FB'E;<:151B97)T=8:6EZ:GM2HS0V.%DJ2R@H24HJ6SM/_$
M !T! 0 " P$! 0$            !!@(#!P4(! G_Q !:$0 ! @0#!0,&"0@%
M"@8! P4! A$  R$Q!$%1!08287&!D? 3(C*AL<$'%",S-4+1X?$5)#0V4G)S
M=!8E0V*R)D135&-D=8*2LPA598.3HD6%H\(7&':DP__:  P# 0 "$0,1 #\
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M:VAE:'.%('A*JGAK=&V5+,E!*0]*6A3U*FE>A8M;0O0O7O=_!CN\3UR0^O2
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MUUR<>*-#<<(F#A"#A"#GRX0@X0@X0@X0@X0CKM,OB=4DJAP2>/C+J47M*N+
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M$M5S^B--B1ZB+V#T]10^-IE:TV5-F41?HFEQ0JR#:#8*T@MQ!\Q5Q>]/ +Q
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MI&76[CM]52QBC5VJ+JQ)[1J92R6I77)?D)D!1IC9*TEIS69U:2Z'-33654F
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MC K,R6,J)VEBJ=6QK94ZW(0O):2J,1Y@HK)5%1Y!54"F@ZH*BLTB&:LU7>C
MX/"(PBL+AT8?RA4%\%7(K5QS %*,"UX@=]7KW>,JEJ&%PUS7PU4U:Y+[6[MS
MJINK9Z"0"+V9-8XK!T,#.;@62R)+7-Z6G5R.(O2VI0H5DT5B/K7< !JIHIII
MI  ]#8.S]FS=E2IV(P4K$39V(7+5,65!2$A:@%)"3H .PF]02.)1226HS 7
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M2I"P'\T@H5)4E7FE7I);.*03Y.0F[':YU)!=)1=&BFX%(4T=WNX"W#SL !L
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MP8\1$..A8ND[&',*E%-KA)'=7L=^4>G]1-7'%8FQ;/34LSOVQ1?LBA^^HU=
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M!5Q[,GX%=N[PX:1M;";;VGA\-B>(HE89>&F!!#%06<8L*>K)X"0P+MYKU?\
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MZ'TI04HY(OK,% K>ZUE92A(72EI)I'-0HS!/"JE->IMSOV=T(=VG6?KB<3\
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MZ:?N:3QXYO\ 0RGT].8!VOX#B)6X4&NY9\Z@5]]HE_.=H),^7X*2/X;,RO\
M7 ].+G( \O)K_:*!U=\V:](RF\337%/)RVTS9AH/Q%XI),Q$?Z'2IQTT%Q3&
M_/+$Q9VQGEY!C?X<4=  WSF?\4QM6_VLRE3K07U'/5+K)3SEAO\ HH:-URTB
M>3 /[ ,7DSMGS?L>1^GP^&^V,W>96;B!5W&3/;.QTZ<JQM5\Q)(IYM[GT@V@
M/BE8J-V'PYMOK/'D'U8\O <"/2V=L<\_(0^?/Q&G;[4VGAW_ -3D4L[N/O'2
M,$6_#UM$6]/?X&2?']^>^N>O]MN8CGRVVVQRWSR"ZXCYO!@M^@X9S1_1+.X
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MH4'/ 00.UA3K6P>T6_<1>W%X/&G;2L9Y56)XL,G%RTI6C#D422E2QQN+))2
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M=V^_Y Q=?[67_B%G;J\;59,Y\Y-;9&GN[*4AV.U,P&I73L'V.:;176$0$0R
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MEOXY\=O/./<7^A[4J*87$\[RU7#9._8XRC&9Z!%!5%@/V@6=NPYM2D5%[<#
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M]KY4I0?FE.\W^(6_!_L>\1.@HA[W:D0Q_=>:H1VY;W@DG@'Z=N+K*_0\"?\
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M-U_HG_\ 4%-;,"E:/<>*Y0I,A_#O3>/,?JL--GAM]U:/^/CD0Z>&=\<>XO\
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M>U,9)8FG]LD7&515[DU>/4?IES]3E87/]YNV?T>YC+C]''R-MCZ6VG_/XO\
M[\R/Z$;-;\GX%O\ 4\-_V4>/9&X<>='[8.$(F5VKT<C<CTO&%2Z'1"4,3;-X
M<Z&JI>X-#<E;5B9_;Z436E4*WF-2(HZ:5&&1(P^"2-LEY)3F/L^E836J2UH>
M/'V_;#(Z)D[>ETFV#3-;D<[MY%N60I*O/8O=HPPJBDVGT0,HJ%AJ,M)4%2,B
MI0L6K%9)!:U:M6*U)RDU"-\G 1489+0G0H:84,;>PEU3G570VA&?9JGVZ+A7
M0(5T(@;/61554"%5)'?$! 0X0/CW>NT2W[(_Y"O<'5I]30=%C[%?5E7#"W!L
M)/-51>IB"WUK &II/.K,--3@M!73557754)P&=X1'A$9Z4]OOLW:SY0#T[@(
M0!V =ONKWOV$<XQ=Z:_-RP.W7.XACCM!^;D9>8CL^3#!F/>W,!HF7Z*Z];_8
M]>NC@Y-=I$R/:::0-N<(U,;!ML$#9M]MN=6,? .O%?V_3=_%6I-EL7_OC-GZ
M=VL0H%T\E@J.8HH6<O4WJUZ0P?:WY#6]I3 =OO=;YC\,SBWGAT$,=/@ <?GW
M/_0<;_,I_P"PGQ<]8U+](:</;<^+Z0A-R@Q;6X6X_@1+ Z;?L&O#SQL/SB&,
MB(CFR(/YS)I=^5RH9@#-P[$\XW ]>>7M\/S%+0( QV%:?Q^MSI\  ;A]PZ@/
MGW ?+KD $ XYPO\ 6:;3_P#)GI\Z7&7N]48D>:QLW*GX<NS*(XPL<Q&+#CG&
MF 1Y]6E(.W+8?FQ\<\=*QGSF,S\Z7_A-.OOL\;?J#,<1TT/5KOK7I%%NR* 1
MU4ZNA_P/Z=?C^$=Z?H#?SWQ\>*?O>#\7V8VBO4$GOL:GO,8>.O2%JUEC^V,:
MJPY_:IIV\,?@$Y<_AGXYQU'CT=@?0,FWZ:OJ?/-J\M#$RSYQIJ/4+^!DQ,)9
MJ3'%JE8YW&:6I#&W]]2&59__ +>+ BO&<A)Q#G3Y!= "!;H.MWT3A\F2SD<+
M%ZEE#H+5[<KQ>GMMM]'\&#F(ZHM.6 \?MY(#^4 ^?CGFZ/TS*?\ T4_V!HS4
M0"DGGIR]C9?<9'<QKZ8JJY> 5"/QY<\]-]]^+NX /69R/IGN]G:P.U5> @OY
M@!ZLS,U\[ O9[FM'8KA]Q#4AMC[\.ZF1SMO%K=]>GS8\^@C3-[:X_"_\.PM#
MT5ZKT^^-*:*F&MP?5I]E_9$Z"[2_4B !O]5WJAQG8!'Y8))S'X;<PZ]-PNZ&
M. V8,TX%)4UQ4-R]>9H(V5+$.S()+EJA0 MJXME0Y1K=CP^_[T!#T"[5S _^
M"DXV\LX^G''X=JUV)M5F<HPYLU!-)4;FSUYAHQ512')<$\G'"<FZ,*>J'9[9
MNG[X/L_Q -OOF0\=@A$+$/Y0'X=./"W0'F;4.LJ6S&X<:9./:](Q4/E$ZD#U
M$_;6$"=0#V8NWYMZW8=\?U(:&WCT$<\QZ<6Q%9R#_M$UR+J%"*],S0.0&,9F
MB".7K T%K](O/V06?K:FCW]Z)N\O^VKM]/Q^/'-MX?IS:-:^6MEZ*:\_&L0C
MT$_NI]@BDG'CQE!PA$B^U.:ZGM+95$XMS\I;2I*]*6@(''WV?W$->!:3R7!Q
MCD$9*F#T;E$VRHE^CTO735.VL3W672XQEY U-2#QXZ_;6T0U2=6\>SNBLK4
M V-^*E58>I),5K@"E;6'JY>*U=(4T=U54&!/I[E(@;W\T@/")$85JI<;+--A
M+BK]0:&.N5J"&>GWC22N-GRUC,/,5$%,E2MA3-;R<LJ+>ZV^M/50WG^KJ*2E
M%0ETE"92B-/#>.V)IV0K"GL+[2BFJ[E :)()Z&HOO% )=44;_L@[M05%@91G
M:D0$"Q[H8Y!5M\534;N;85(7Y.:G"(*%:'XQ+<N X8/KR%XO_P %B$S/A#W1
M0N5)Q"%;:PH,G$UD+ ,RBPQ) J:?6 =GB1Q.FBQ%11555KXJ-0ET5#4*.H>]
M4(9$1#OTCOS'//.-L<4]*)KIF3=I;60Z@N8J5M?:DI*"2%+5*0,1Y) 2"?)H
M3+\FE@G@X0 ?L5"Y<H(2=D[!"982.'\E;,F#@0P*>.9LLS%H8$<2YG&1YRYA
M+JBTG9.1YFBEOKR1V-MY+.Q--TTI;>UH\T)$="F%1M4=2G*'(%TF*#ZSJN[W
M1J,,J&KO5#2(>_N9,G*7MB5-5BIIPV.\BJ=C-H3,7/XN +"2E20D.E04X) !
MH7,?.OP^RI,K:FZ_DY$C#*7NTDS).&P6!PLE*T8_$(4 <)*EE10H%))N0 *0
MC4JQ\N&I\0SOJ.N3GF'(QL  #(Y /H'KG?CNNS_H_"5^HK.K,@EF;,,:$](_
MG+O5^L6W'_\ -L2#E>3AKMS;5LJ/'>M.7Y:&F(0#_95V0\\?)D[Y'(?,&^,X
MY8VXT;4^CYW_ "OUX@X;*N4>KN!7>?!/?R&(Y_MO>]:OIHQ;]G:Z?E;Z0<_W
ME-0H@&^,>\EHOAY!X^?&_=']"VDU!Y23?7B&?7EV:?1B1YZV?T"SW;DW47SL
M*O$Q;][65NX ?WLYSC&?][;D/AD.O0?AX6G#?/(!>G$?_HH:D:YBHSJ8R'HK
M-?14!;ET=@:F@YAFBZFNP 'L:K@=?O7;7 'G_4T&$-QY (@ =!'?CG>S*[R2
M^>T)VISF"E*NU,HU6EC5A<#4'*G7[XD/2'V-(#TIIY#Y!U#'SX^'%_FEITYO
M]+-#&Q F*'N/0-]4&-A^J/[J!3(D"P-*$BE\KU-4NQ3#-MM6O3.L*7C\0"V%
MJ/YM\_-OCBE;WD':&$_DTBPN%JO]M^R,$>@/WC[$^ZL6HXJL91\#N _ >(-B
MVD(DA?#L^KK7)O3<FYL7N%;QI:IV[MCL2V2&.O[@Y(:D,=:6.LFM2A<DZ>NF
MNIL$^D*2\@!H4XR%0CSO';K;8F[6VEM#!S=E"7M!<I7!B94TSD"5AY4DA2D
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M \>/!^"WSMOXDNP5LU9 T^5E%^R@I?LCEGPQ?J7BC9I\OVCN^R)'K_\ 4:K
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M<L_57Z;,[#C\:T? ,\QW\,X <8$./<4WQ/:E_P!&Q&;WE*+N]*'O=R]\)C%
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M0+9O7I4-RE!/DRFX021^T=7L"=* TL<FOTACCM--'X]0@^I@.7/,$9AR/S@
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MJ'L2+*%&TT@(Z*8*!U%%7?HS[IHPJIIJJI#-/,.]W0_0&*=OZ3_1+;[$@_$
M01<?+RW[Z1??@O)'P@[I*%T[:PC=77]@RSA/2;46\J)+$8PA_P#JJ.\-)BP-
MQHI'(?U3GH(AS\N7'"3L_!J05F4HS5)*RORT]^,A^-O*,#Q%V9M Q8?58V]M
M9+)3C%I2D!* $R_12U*I)+  .2[.[WBD?9P-#:R1B]B!K34(T15S4 %$%C4-
M%'>A,?,J !KJKK'-5557V5=5-(U!2&  ,=3^#:3+E2=X4)!9>W5I*RI2E5P<
MDD@J-Z 5!8'H#P;X:\3/Q.T-U)L^:J8L;MRV)X1_G4XUX4AZDW+ES4DQ(BXE
M(5:@]4V0"H U&W($,TAL J$ CX;AD!QOGC[[W6 .[&[Z2I2DJV9)F@$GS53%
M3$* X6\UI*2RG(/$7K3^6OPM$_TUVH*D)(9Z ,I5@&#U M6@;,Z1I*IQK=TT
M!N/],NUOW:0'(VT>@JJ$ I -P  '/,=]QIW\O?\ 2C^B.T735.(PW"25$CB7
M+<'SFL2+4YDN/>^ XC^E4SS0_P 4F'B)(/HJ]9(&=;4C1^UTS]5QI"Y?B7U$
M!GEG[9;1 &.>WV/GC?'')MT6^([2/]^1SLW/)R+\H^O+3#2Z:N2X?E2X.F8/
M29%^PS92[G+\64Y\/][;E\_SX\N+5AR/+( S*CI]171\G%ZOE&=DJ/\ <-=<
MNRS,&M2L74UU"(=C7/\ ^"[:_P N:6#ATQG81' YWZ=..=[+_625_P 1G'M"
MIA<OI>H%LKQK/H YLGJ+>*1(<.5.<Y[M(C\1I#;X!G]'%_F/Y6<U"9TVA&96
M2:L-+?<8VGZKU'"BKU8I!Y-T8#5Q>J'8I[6VU:AM@-84O -^@VOM0'7XYQX?
M./%)WO &T,(V>#3V><L1@GT =2?4P\=V0BU/%6B8.$(.$(.$(ZO-'22LD8=W
M2'Q>F:21&068U1>MZ21VEX.J4$EF)Q>EY1Z1O[B>LY0!IY)E%8D@2 !48%0(
M1V:@:AII&NGN5C32-5 5=X*:A !JI[P  5=T<AWL!G&<!PA']<(0<(0<(0<(
M1E=]%)*.R=X5:DRHE.EM=/U)YU#L+#4421%'8TVNE\I*/J9JJ**:J@=@(.%N
MQZX!1@D]P40<O'+W^[.$5[)R,OT;TVOE3^S$,1C_ '.?9 VMZ=_CSZ26U*XY
M$DZ<2*8ZZ/I#6D ]*I+0H7)[<WLY 6E='534I<1II0SOE;MOIT[=(IV)98YR
M70.>>::1SG&<Y#?D'/P#P#A$Q*C50KNZ/:#]GDB<&BWY5D2[D72/CSVD=WXR
MY:F>UZ=[JT.[>Z,9K87&D\5*:Q+-1N"9V.=3%HF%&HZ"L5B(!"G_ &;L[5$9
M #A.99R^3EJ'VY5 Y0@?:<B/UQ&)CXZ.6T-MQP%Y9$(8\^8;B/3GQT/=:NQ,
M4[4QUJO21))ID#2E^A<1BAO+)M5!</HHW !+ES44[80"]8"$28N>!NQ8WS_M
MQP7 ]>G+KGX\6(%T8O\ DF_Q#V.2Y/*X9,;@3R=^^K>RO7E%\^UKS\CUDOX1
ML(^CW2GN/GY#^CRX\#X+/I_$$W_)4PFE7$R42]O#Z1RSX8OU*Q7\>7_B2WV1
M)!?LD5!S'U98 B/0/1&;B.=L".!VS]._T EN)!<-QIIF*L]!R894;SJF/B^@
MFR;@^50'/77J='YBYJ  9[#R2AG ?4(S<,B(;"%MGO..?ECZ0Y ''S1MG]>L
M79ORP'IRDW\6:/Z#[LM_1_9'\C*Y_M=>[LB.,, 0A<3W'(11@$/F9T8@'CT\
M?\UQF'SYE:\1N:9@"M!E=NT!H]I%DT(#Y/2N5R['+U15GL4JA%%K;R(_E*,/
M,<_VE;=]?F_DXI^]_P _L_E@DMWCWP8"9,9KBV=V\-$E(D&)7J R&.]JIU*B
M ],?*[)=AW#<,@&XY\PSQ:Y/Z'LP7_,TW%1YS%CZWUM6^,GYLT;SKYV+7!OG
M>EAD&\[.X/VRB&>(Z4KV> \KA6A#GD>7@&WT;^1O-]#2FRQI[_)H!IIVEXR?
MSSTH#>K'0?;V-'QVA8!]<AGOEI<LC@/_ $XN_P \CR#X=>8\1NO]$FU<?,!_
MZ+7/6P#:F) ^40:V4>5"-:<K.;.*PI<AR,XTX8$<!JPTV>//Y5H]@1#]'+PV
MX]U8_,]I:)PV)8:#R4P4K0B,5@<.=T G/TQGTUS>*A]M_P M V_]U(]9#8=_
MD8N"&WS;Y#.V=PXIVYP\_'?P976JYC$:7=\AE&; S98RXCW-:N?OB8$[P,%F
M> Q]JDCSX9]CK,\]N0ARQM\_%SPY:=)%?G3JQ]'.C]O7I$VJ9Q.24@<@Y;V=
MQSBD4SV_H=*@ ZZ#(J.0'_P$Q!M\ V\,=/"BHIOFL?\ JN-'=-77QK&$OYI/
M\,-R'!T[>6M'B>;#CW?8^0A[&:_#_N C<!$.8CR''7RXO4VLW$TS%A6X%L\C
M3*A%#&8+R6>B?1K8$U&=Q0/GV14?L/\ \6^L['761,*0Z;A;.V7ZAN(\4S?:
MNT\-_)R"QH<Q8]1IRJ1&,N@8  #3H/'NB+>GO\#)-M_;GOM_UMS'?YOW/Z@(
M77$%T8-A48+#!\CYI<%A75M'YN1]=Z><NXYTKT%]&%!#W=FJ&>TZ7X 0SHFE
M@ '7:],,#QQ@<#UY;CSWK^]E-CX7(?&P7[%OEV^QQ&7]H6JR$N*6(!\<Z7:.
MB:Q]^T]U9>/R:Z:A^/VHO^_QZ;>._/C]&[GT'A=1B<19\C4?<T2FB9E*N&%*
MV\'[8PI8 _+OHM'G]^;8W >8N#J/S\MP^(\N7IXU_B&T/Y.:";4X5/J=2[Z:
M$QK4[@&I%>KD<F;(&O.*4=M3^.+L^1#I+M0.!S_@Q;QVWR&!WSR$>G%7W.)$
MG:ZA12488).:>+RC]A:P-2*TOD %3)0(<!?,OU[GZYFD2WOOCY$[M (8S;>:
M!CED/=YPP'(>0A\-_AQ;L*H^7PU2PFRP11@.--\ZW[HF:!\K1_2 N:5=@[:7
MJXSCU>:--M(FEWE^3W9SEG'XOH_X[\<DQU,;BQIB)W_<5&**(2.7OAD^/RQG
M!PA$W^U;4%I]&<UJ%'%5:FJ56Z*;JIH"L(^B<#9HSEIEZM0GJH2H13U5"!:]
MX[S(E$P3'*GT.!!$9CQX'3-HW70\U)F32381J1J8^K2([?MM"<^+/+E(F*HF
MLY4<70B?7>LQ>[5DTF 2L7G5>C4KRU1B:FA+4112B891_3O"IC>4T<7(VJ0'
MM:\EC<W!%6Y(&YW,2FT-JY:W%J$AB](D5U$GJ$="I-4I)HK)I/)&L#*4/'?$
MU.S+:;CLJ'6DUW=EL=G-R$>M6X1,MED3BY\,CCVYC;BT]8*VJ+JGB0*&@@$Q
MA!(IS'E<-1A59GI*0K[@0]\F?Q]G*(\>OW5CSKZ=\?)\\#MGY5KV[\A#[K\T
MS\VW41Z\MN.TEO)R'OP(JYHZ1:EC0 6;/,3+LIG9CITK=S<N?92&MTB?G,]'
MXAG'N1J7'.?^(;/X8Z"'4>G/D%>V]] XIQ3RTKN<5O:_XQBJZ!D9B07Z*I[S
M8ELH8'M;L?5NZ4O'ZG6^?T>_%O/G^'AOGF'&C<^F QUZXI(;,?((S>O.]GC7
M,]('^Z?;I"%W*#[FMPL;![D2S&W+]@UP=?#81Z[?-Q9)?Z3(<.6=F%?2)Y7[
M>3QN%AF=>ZWKR^ZS[>-7UBLC.1_:YTXXV' #8XOIG'\G( WSGFZJ;S3!IM-D
MY-\J;.:>ZKQA9-[:WU;.XHU;VRB.4,S[I180ZQIA\L_L4DWY;;_R[CCCI6+I
M-Q9_O2_9J-,NVAC<X*$_O&M* COL'\"**]D3^51JZY_B?TZ^ AGWCO/X9_D\
MN?%3WN?XKLP<YA[T#[N3:6C -4<WYU<TI;6IRTJM6LO\XQJLW#'NIIU'E_Q"
M<@Q](\_'EMQ^[=_Z"D*^LG&K8YCSSX[8F6_$>UJWI9A09&UM3=+-2?XJ509'
M>;6J^&]TX;T .F/G^;BPI^N;-)Q#Y_V"[,?<_(/71-!\FHT>@S_;&='IX8Q>
MGMMOR/H/_"BTX_Y<$<<[W1^F93?Z*?[G^V-ANFK5/CW=L2.VS5R_=U9SGGWM
MOY ^.//B^2K'7CF-6@\XV85YN32HC8L@,=$)=JY6\4'2*U=BSO8[4>/CK!NH
M/+&WNK;O'QVXI&]_TEAR,MG88=_'G73GZH_/+%9@_OGG[7]\1-@H?;;J1$.7
MU7FJ'GT^[!)!#KGE\V0^;BZRJX/ _P BBCM]9-.79V5I&]'S9IDGVW^V^<:U
M8\ '7YH"';/RM7-ISX?<3F_/Z?/GRWX_#M4'\A[4-3YN%Y5\JH5UUK6T8*])
M/_,>=1HYNV5-"S"'9[9L?O@NS_IP/]TN._(/M(A@8SM^GY\=?"W0+(VKIY*7
M[0.N>M-(Q/SB1GYO,>D6I]V72$#=<^RUW3+>M >E6Z0WEG]/7EQ;D,9R*'YQ
M)Y>D,PXR:[7Y/F3YI#T:G1BW+6T7F[((?VM31[G^]$V]/_"CK^G?X^.^>.;;
MQ?3FT6']N=?V4L&[^@Y$1"/13^ZGV"*2<>-&4'"$28[5Z(/TXAMDXZT^J)D#
MA/GE,^NSA;N43UM0H:F"H\LMRKA,'N%)VI+6I3EJJ4B5A0MTA6H438[R1J2_
MTM8B/7R[NGKBJ[27Z)J;2N\76!:!(6%92441584D%TA46BJ$:DA=0!FA-4.2
M*1 H=Z.$2/&<9I?5FGS_ &FF[7;*;-MNYF>RJ*FN6NT4)FR!M+(P>X%G1H]T
M9B7 5S>6J0%U5N!/JABFE732;61276AHW@<O5$P=.0U4]B39+TE0UU?450,,
MTTX$1"*(Z!'NC4.,C]D(=X>Z&=QQO3=_7_HGM\!ZX!+-KY=%6Y 7#F+W\&+?
MT^W5*F2!MC"DDFC.L7RRS%ZVA?2JJJB"1IHKI"HDO C3C(#0 @(CN @ !N/0
M!'CC(3\C0.3*<<CPT:E#76_?'TF5><'R-?.%1V*Y9@^Z'S[/*L 9+WT8$1"Y
M[>&_0!@\<P(YQL.^.Z ]=^.C?!N24;?XG!_+Z[T_S.47&9>H#]EHXU\,;G&[
MJ_\ ^-RP7JWYU/)[7-7O8Q'NXFVH'5*/4=1EQP'KR/;\?HX^^]U!_DMNX?\
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M)E(7,7PI(!(2A*B6>S/IG$A7!V:Q1J@H<V^L?5U("%*Q-7L92-&P4F".]0@
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M:DQ !$TO0%(?04!!LY=Q;NCH>L<?VSW5EMM\FNFKKMM$9!\!W#'41^ \;]W
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M(9\? ,@/0.8\5S=#YO:M6^3EYWJ/N';<T:"WE!R"3_\ 9J_CW9H [!EK7?\
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M*D2PHY,HHI-+H,II-*KII,HHK  JII$$(Y( "D II  I          P   ;
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M5>\:B_ -6!IV>SL[+1(:@!"FG/\ M0'Z0 ?Y?UY\7^8&F3@/]+,+,Q]-1N:
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MM9RB0(5Z<]0ZJ"4OJR!0::<L0]#<9'J+1!>O93H<_9G35VAT@II -J0IZX
MV'YMOHX1/2)U=IQ<:!6ST[LR^X5OG"XD><[QVM,H8VN4'0XXAZA4A"ZC&ZF.
MZ5N=%%9:5U@*6D&^A(*=<<<20Y*4396K5DAYOHTO:E[VUSB*Y%O98CD:OZLH
MH6B-+5HTJNDD"P5)B% 4#W*AH XJ@P*!JIS34-(58&JD1I$0$0$0'/$!*;@
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M*2:S"BC*R@J"BJLLNJJD:J*1!$-X]W2K]8^_A$Q^!Q:VUW3@D=6]$Y)0.)4
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M.S2NH$Q(O2554UU)U% #2-1=55%%0@%5(B-(;XR H1SE-(44TTTABFD   \
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M*2 2(BO)_&7WQNR/LT;"H+2W(LVE=9F7%KIF6_<9*=W(/6N)D=O#"S6Z2L]
MPGV8WNCD:20<Y4TMQB$A210M9$;.M,4*#D*O?PQO7MC.%O8_Z7W 2ZU;_==6
M=28G-.4.4BCKV>O,(4R\VNMSK>HDX Y5JD4]E;4IJ6TG5&)7(M52-#L@0.*9
M3[/'AND*\N[[XJDG(*2D$)B:0H)3DED%4!RH**HI++I#RIHI /FX1,?;PA!P
6A!PA!PA!PA!PA!PA!PA!PA!PA'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g425213g01a99.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g425213g01a99.jpg
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M-R!H86ER;&EN92!R=6QE<R!C:&%N9V5D('1O(# N,C4N)B-X03LF(WA!.^*
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M!Q8B4Y+!%1A459.5TM36X2-"4F*4EM7Q)#,V8W6BPO_:  P# 0 "$0,1 #\
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MZ#_^S#K!_P#!]=?_ )[.T?@V[_R&R?X>5^P=Q_!%U?FZQ?X:3^P3O5%&4O1
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MP6<>D\HDT>,+-UT6B'!\P$!/&) #'B9$,-9OW(QBUYZ\M22V+8J([*P0, 8
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MFB,+(V8]G@ZLX7)HR\,:F;Q+(P>.L[0'2-@H#C8^8HM-1A8&'6-"4LJT;:?
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MSQVNH5/LUU_L*EOM%]D",I;Q\I&97N,^NV\:F\%EH&P8$>?A/71NQL6)FL5
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BZ=<<EWD;C8IR12;.U56R(ANKK2G1]R2\QT]@@8 P!@'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g425213g01b01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g425213g01b01.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[18>4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %@*^5C0X0DE-! 0      "(< 5H  QLE1QP"   "   < E  #E-A<F%H
M($YO;VYB97)G.$))300E       01N=-3E+[S@,ES\^Y">ROM#A"24T$.@
M   !*P   !     !       +<')I;G1/=71P=70    '     $-L<E-E;G5M
M     $-L<E,     4D="0P    !.;2 @5$585     @ 0P!) $4 ( !2 $<
M0@       $EN=&5E;G5M     $EN=&4     0VQR;0    !-<$)L8F]O; $
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M!@!! %  1  M #(       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q ;%%H@
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M0DE-!!D       0    >.$))30/S       )           ! #A"24TG$
M    "@ !          $X0DE- _4      $@ +V9F  $ ;&9F  8       $
M+V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $ +0
M  8       $X0DE- _@      '   /____________________________\#
MZ     #_____________________________ ^@     ________________
M_____________P/H     /____________________________\#Z   .$))
M300(       0     0   D    )      #A"24T$1       $     (   )
M   "0      X0DE-!!X       0     .$))300:      -!    !@
M       "7@  !9<    & &< ,  Q &( ,  Q     0
M       !              67   "7@                     !
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M;&]N9P   EX     4F=H=&QO;F<   67     W5R;%1%6%0    !
M;G5L;%1%6%0    !        37-G951%6%0    !       &86QT5&%G5$58
M5     $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$58
M5     $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@
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M       ! 0 X0DE-!!0       0    $.$))300,      M-     0   *
M  !$   !X   ?X    LQ !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4
M9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,
M#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.
M%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,
M# P,# S_P  1" !$ * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
M         P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)
M"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$
M @(! @0$ P0%!@<'!@4U 0 "$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X<
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0'_P  1" $! EX# 1$  A$! Q$!_\0 'P !  $$ P$! 0
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & ,%,DFN.>?9^QC!4, 8 P!@# &
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M_P > 2'8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@#N >T>V"F237%-\>SGVFJ;U3M,6N&Y$Q^]MT4786UZSJ>#AI]SO*O=/SC
MSL?7U8J">PI^S04#<;Q;N3%"EY6*UJS?QK>1^JJFRL'$+M'-N2\I25D4FXJ^
M3T?L-JEDH55FT5*8#E4;(*%,4$RE,4Z1# 8I4C'2* @(" )G.F #V(8Q>PB!
M]. 0^=;?_!+U9_EP\(O^D12LAK/?O\N03!Y(& , 8 P!@# & , 8 P!@# &
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MWAA^?&,/+S^S'IX\@;0N2!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M(@FZ7*H!'AUM_P#!+U9_EP\(O^D12ODR'V>GS=_BXCOZ28/) P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M$AIC4*?./B:"&YR<FM;WX[DL3R$JIJR;Z@(*';3J7U5*(M2"!G7>&]*\3SS
M1. O)W\WSDFT-@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MRX.$7_2(I7M^+^/ 7?/?'Q\"83 & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@'B62Q0U1@)FT6)Z6-@
MJ_&NY>7D#I+KD9QS%$[ATY,BV26<*E11(8XD0145, =B$,80 ?:A0JW5>E;T
M(.I6KU(TJ4$XQ<ZDVHQCF3C%9;2S)I+M:1Y5ZU*VHU;BM/91HPE4JS:DU&$$
MY2DU%.3PDWA)OR(]L! 0 0]@AW#Y!SQ/7F, 8 P!@# & , 8 P!@# & , 8
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ME86-TW/+>9=9<U%E**VJ*QE.4J]6E8QNN9JXDF"#HOH &;+/&Z2Y1E'*K*,
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M#J\NXI3N^MW))>"VNCT7#9MR]_A:EN<EMV-8>Y8S/S5C81@# & , 8 []O\
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MR/H'6FNDD:$9?8:M&YKRCA/=4HV\(4Y*6&\1A7JK":B]V6LI&T5GST=S& ,
M8 P!@# & 12=7+8]QUYH>CGJ$L$4:<V2S:28BQ8/?26\?#2<JT3_ -7-G()>
M4^:H+^)'RS'\'EJ"9,QBCT7W-;&UOM8NU<T^LZFPJ2I^-..USG&G-^)*.<PE
M*/C92SE8:R:'T_OKJRTRV\&J=7UUW&-3Q82W1@E.*\>,L8DD_%2;Y$,^L;/
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MWO1JM.MI.F5*4XU(.QMHJ47E-PHPA-9\L9QE%^1IHO;F),F, 8 P!@# & ,
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M=-:D5B+<_P!@1*NLJ$I%WV5!0)2[QQZK%&96Z2!7^V@_LC84IEX"G]L!P]4
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M2KU0V5/U6@V*\5^H$EYRE1EKLT#%JV./CU!DV[E)OXG?OW^D$?O1.;<@B/\
M>K7:FH-9ZUK= BZAIA\%&UEH37K>M[FUQ9]@$V#J&DO-)7*Y/+3JJA1DU6Y&
M,D-ANVUE;W*T6T (N9R].F[]_P!@_7W[\B?? & , 8!!%S<U=M=+F1;.3UBT
MOPNO>C]*Z5T;7:#)<L*I%U=W/W_9-]V=5K9 T7D+#05QLE+F8YU):[CHV%N-
M!M=4>R5W1+"NJN_=2DFL!,GIJ/?1.IM;14EK2N:9?QE)K<>YU+3Y.,F:IK=1
ME%-6PTFMRT+$P41(0E;!((J,=1L+%,EF;9(S9@U2$J) +E8 P!@'S/2N3,W9
M60-S/#-5RM"O .+07(I'! '0)@*@MQ5$@+@0!.*7B H>+M@&J!T_:!RLH_/R
MA:PO'$?6.CIVM*CMO;R$)I;B)5J+)5*1UK:Z5:MW42V46USFZ?JJE]VR#RCZ
M[3@X^.K:6JWSM"V1L5/2,^10._?XS;(P!@# & 16=7+5N^]L\>*G :&XYZUY
M2O8_84C,W+5&SHO5\I&.HA'5&S6%1L,63:LI"0R,A6=K2&OIA^$1,1T^_K36
M>AVJRC62>MU@/,Z1L)L2+U%M)_96E-DM>SFQ(5?46RZ]0M*ZYG-GP<+KFH52
MT24]7]"'/15(>GW& E]=4&05(TL*E0J;!A*,DT(Y@Z> 2S8 P!@# -8?JW:*
MY75_E!3=W:^I?#.9U[O>VZ6XTPNR+-Q<H>R=[TJ1V/::S0IZF;#?; O\$UNV
MN[?6']Q11D:M%2MH;Q+M>@&AH..=DN[8._=FRU58IW!5>MPC]:+</H>!AXIZ
MX@X<E>A5W<?'MVCE:'@$W3XD'%JK(G/'PY'KPD8T,BR*Z< @"IP/>P!@# +0
M\@FEZD-$;G8:PJ]6NVQWNK+\TH=-O"+5S3;7;W-6E$:[7;4V?*H,7->F98[6
M.EV[U=NS78.%TG2Z*!U%2!W\I!STX]![BT7RKJ-'<U_CFM"U;4=SLFWZMK#C
MCI/3<WQK7V[&ZZFM=05@E*C;K/>";?VHYK$T%\@X:2M&JWU8HT.YAK$@:%C&
M2T=^_;Q^3 -B3) P!@# (ANJ?QZVQR*D>.->J=*TK)ZUJLAMN\W[8VZM,ZZW
M75]:VBJU"-G=<#;(&\3\).0NKK@K&VB"OT]KA.5M[9R%63!HC&*/':(%X.EU
M-[:M7&9[<]OZIU]IV6O6W=GWNIU/585%S07VO;I-DLM3N%9GZ:RCX^WQEU:R
M:UF:VV2:I6*<1DDW,^4LEYQ2B%W[]_F4C."1@# & :_UTX_;X:<W]EO9[4W2
MHH8;SV/#QVH;YL30MILNV^2M:K39MMY_$O'L;LQFL?96MRZ_;3=D6?5M&+?R
M%7@+C'K/DVI6<1'#S<?E^D&P#D@8 P!@%*7FBTS9M0L6O]B56 N]'ML6YA+/
M4K3%,YNOST2\)X',?*Q4@BNS>M52]A,DLD< ,4IR^$Y"F #%WBKPOUQQ3G-M
M2%(@==QL5<+20NLXNGZOJU%<ZIU"C#P:S?3S>9A4?=*RP2>PR7;8QWLFJFJM
M.7B0%9N=1N1RJ''C\GZS,W & , 8 P!@# & , #W[#V]OQ=_9W_'@$$6AN$G
M)]#E99M\W[C-TN]:OZSO66,WV)5>.=D4V]L37:Z[23+LRE79ELIXUK-YGXN7
MD(N2=V*MLY=A:F,N=PA*PZ[.1D0)W< 8 P!@IGR]?D3\OE&"H8 P"-KJ'<!]
M)<LZ]7]MV_0<!O[=7'6O;!G],Z]LDE%Q%9V=,2U1EVK/5%]=S+=:/&FV&PGA
MY('9EHQ] SL9'2[&99(DD4'P&7O'K4-"T9IVC:WUOK"KZ;K,1$)OAUM344D:
MY5IR>.:<LT?' @HJDL0+ _D3J.DU#E=*F.X*8P* . 7HP!@# & 4G)T2F3-O
MJU_E:Q"R%VI$?9(JH6EVP06G*W&W D42TL8>0.07#%K/D@X<LJB@<I'@1K(%
M@-Y"?8"K, 8 P!@# */I^OZ1KY*Q(T>JP=42MUMGK[9TX*/;QQ)ZZ6AP1U8[
M1*%;D(#R;FG*::\E(+>)=TJ0IU3F$.^ 5A@# & , H^^:^H^T:R[I>Q:I!76
MIOWL+(O:[9(YO*Q#I_7)N.LD"[79.B*(*+Q$_$QDPP4,43-I!@U<IB"B)# !
M6& , 8 P!@%(EH-*+?%-H%J\(&Q5JFC0U;H#!#ZHCTQO+KSZ-8-)^'TD85.;
M<KRA6'C\CTY0SCP^9V$ *NP!@# & <&*!BB4P )3 )3 /K 0$.P@(?<$/4.
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M,O&,)1)%42BJDD_:I.TTE!((D%1,JH$.)1$HF ?"(AV'-R-CYGIX P!@# &
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M2Y9QCCC*,KINL:?JZK.PK2JJ@X*KFE4I[744W#[9&.<[)<LXQQYHF&S-F4&
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MYY7:HXW[,YGL-D,-NO5[4AQP>1(ZST'NS<S<B,5#[70=!+N]2T&YM8!8QWJ
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M^Y_EBCQ65BSJ/U_;\\?9Y^ -N3JI&#L-ZX"CZP-Z]$[^'[(/64WKY#^T!["
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MZMSY\?'Y,<>+6S7\*+Q=^\7*T/\ \#',OZ#,[ =('PHO%W[Q\K?S&.9?T&8
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M[I73OQ4O?SI0_N9J"]R^X?+5Z+Y<K.I\]=+AZ?G./KS]57]OO ?M_P#<5O\
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MG;-)XRGAXP_*==Z%4ZE+15&K"=.7A=P]M2#A+#V8;C))\5YC9AS?S;1@# &
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M;):42KD;&IOU6:;ER1JHZ*J=N1PL5(2%5.!@+DX P!@# & , 8 P!@# & ,
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M!U2.']I1ES5ZWVZ7>M485U581CKJWKSVU&EBO#36T,[U/$$C!>7EL]NS]A"
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M(R1<0DBOMEE8(,DROL.OK:8V&,QJ%E7)JKPD_)[::)0B@4:,BE;O4))9_**
MW=5ZQQ=BC3O898ST@$AP"!@ P#W*8 , @/J$!#N @(?$(#WP#G & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , H[8-]J>KJ59MAWJ<BZS3J
M?$N9RQV";D&D3$1$4S #.G\C)/U4&;)H@0?&JX<K)I)E 1,< SVMZ$KFO3H0
M:4JLE&+?)-YXO'9P/*O55"E4JN,I*$=SC'X3XI87GXF#?PKO +]U/HCU=_\
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MI53=MI0CF%?D8:K02T54B5^NQ4? E8.0+FUSI^:DA[%<KQ/W;;NP]B;#A[_
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M(0A1]1"E*'?UCV*  '?MV]?8/7\V"F327%9X_2=L%0P!@# & , 8 P!@# &
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M[&\ZC5AAI"$7M?"]@C)MS-%GC;86VEG#9-42@==!(VCT2**D* BF0RR0&,
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M(T!Q\U.PGH]VRT]?56Z,?-ZJN4A9J13%*"YN+:PUY\YV/'JQLA$NH[]_E?S
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2E[68F<F/]BP7_#!__;+X)/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g425213g01b17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g425213g01b17.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[3%:4&AO=&]S:&]P(#,N,  X0DE-! 0
M    ,3Z^$F!CA"24T$!       0!P!6@ #&R5'' %:  ,;)4<< @   @  '
M)0  A4:6T@4GEA;AP"!0 74&]W97)0;VEN="!0<F5S96YT871I;VXX0DE-!"
M4      !!#8B<E/-U'P,.[H!FY4R6<.$))300Z      #O    $     $
M    MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
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MYU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M  5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M     08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&
M]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6
M=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M
M 0 2P    !  $!+     $  3A"24T$)@      #@             _@   .$
M))30/R       *  #_______\  #A"24T$#0      !    %HX0DE-!!D
M    0    >.$))30/S       )           ! #A"24TG$       "@ !
M        (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9
MF:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M$X0DE- _@      '   /____________________________\#Z     #___
M__________________________ ^@     __________________________
M___P/H     /____________________________\#Z   .$))300(
M 0     0   D    )      #A"24T$'@      !      X0DE-!!H      S
M4    &              -E   #JP         !
M    $              ZL   -E                      $
M              $     $       !N=6QL     @    9B;W5N9'-/8FIC
M   0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M          0G1O;6QO;F<   -E     %)G:'1L;VYG   #JP    9S;&EC97
M-6;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;V
MYG          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4V
MQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4V
MQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q
M  !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;V
MYG   #90    !29VAT;&]N9P   ZL    #=7)L5$585     $       !N=6
MQL5$585     $       !-<V=E5$585     $       9A;'1486=415A4
M   0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4
M   0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V
M1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E
M1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T<V
M5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=7
M1S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M    $! #A"24T$%       !     HX0DE-! P     )K\    !    H    )
M0   '@  $5@   )J, &  !_]C_X@Q824-#7U!23T9)3$4  0$   Q(3&EN;P
M(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U
M)'0@               0  ]M8  0    #3+4A0("
M                                           !%C<')T   !4    #
M-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "&
M   !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M96
M%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/   "
MQB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L97
M1T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-B
MTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                  6%E:(
M   /-1  $    !%LQ865H@                     %A96B        !OH@
M  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M"VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M  %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                !D97-C         "Y)14,@-C$Y-C
M8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M   "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('
M-21T(                             9&5S8P         L4F5F97)E;F
M-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M  +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C
M$                                  '9I97<      !.D_@ 47RX $,
M\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
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M@+X0OY#!(,*@Q##%P,=0R.#*<,P S9#/,-#0TF#4 -6@UT#8X-J0W##=X-^
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MX-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,#
MP,# P,# P,# P,# P,#/_  !$( )0 H ,!(@ "$0$#$0'_W0 $  K_Q $_
M !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
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M1 L>QS6%Q<
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MM?$W0U)397)T=K*S)U:$A9.5TD9B8Y*4HZ2E9AB"@Z+4_]H # ,!  (1 Q$
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MSIK5CT\1MK=:D';9#3KS*;N;([Z<_.NUG8]<F,O#VE,ZSA<(6^E=.?:3#J^
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MI"?E\^^7BHIV/'"R=GD A/D3S^8V H]:_J7\+22W@X1<;\3\VUOK:Q0O<>M
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M[ V !KU)(T3HDCJ3M2J?9/T3"A>V<0)!\+Q/B!5": I2YS5$ U#6!Q/QFO\
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M1D:\):]MP5 !(HBIP0E ?Y(/1CZIHUB&.C&.C&5UWT;.1K22/]BD'?&^9R8
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MH,1ZJ>,\7R5-?Y\HRGSL;/W=G21H#0^! "5$?$<:X')Y&Z*V51P0M $HA4(
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MF(GE4)G04*$HE@=4?B3$C_2I\TI+>UH2$$$<;21X^2?4 )YWS]XA/ESOXC7
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M"*55 2*@%2ML7/!=_JA+#(7I3.B^BF]>V(?TZX\V/5]*$%/B!Q;DQHG\CZ_
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M1EBOQI9YUS@2\.*^.$ZX^>$7>!2I"AE\BP,H@ '#V8=C:@?LMOCA142/$"%
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M.G:=:*BVM..D%5>(4$[-Y&5/. I7HS9UZ^=G"=<F,I7VG-OV'<LQ@N.R1-V
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MEW!<DV*+63D:$U/?1C:X)N5:0SB[)YLWN*]7L/08O;WN2A1N.[7$U-TD/TX
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ME1;T:2Z]:O5J(IT:5&F@U*E:I560BG2IH!6NHI00E *E$ $]=@!>(#H))(
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M<57( -?T@R1V!H$FW+6Y&N->GIQ^9^%XO<S #0;& /\ 6R=R3\CX'E;G%#=
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M16S^5\;!2$86)!Y&O@1KE1 2/O=:KJ77A:2)7O<)].)UK3/H7D/V]8J)A )
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MJFN#\9\*\O2/[0A;6L/B=,%G_)<UEEVJ^M#NR]+<Y\^((!&B5$@!!)T M2?
M@;!3LDCR2D>ZH> J>75R5-:&B<^VVS;7-%L:](*+8FA H$5"J9JB*#X)[TE0
MZOV"(_Q\%'W=G".1CM.@%I^D[0 /CX[WP"3Y>A&SM12(RULUT4%#XTDC_P"W
M,WOM3)#M5MRT$ &/!$3M*9J E.%!2@"#E79520TW/TD-/G0[.$'>E5\_[&@=
MZ1A8Z&R-$^.M@A6CQL>0ZU?4N.^TDMX.$7*"IQ.^Y%W-]O6*A&$ V/;ZH%)3
MM*G)DF:GGJ])3KR%0#P4K1204D$GQ*BE>J?D@!)3S[ODD#94 F=E%[E/3R50
MW6U*V:,P$)6U*$H@&8_!!"6WFJ$)>D]B;S[.7"IWO<[EL[Y^.6;S/Q_XD;!.
MR#HCJJVL[CGB?S6'_L^6/+TM-VA2^]V27^<G!1,IR.%H3>_/6K4XN\$)'=KW
M/+\M^7<-FD>1"B 4Y)N4^6R"$C@@@+!/D#M("M60T=XOX&J^)L,VK62@K0%>
M:P7=2'L6 &*XC6IQ"<2Y 2:BI<%U#:[I(!LCP&9[)2$]YO:4/).SW)8.&]^Z
M0<G6V3K?N[45#A*CY$#>_$ZZM)ZZ-:0^1,5RJ#VC'Z:9^<BW=@U,8PK/XQD0
M$LG;4,JO*0@W&@*MT8>J:M85CHQCHQE2=[P!R[$#DJ^H4-Z;)&INYM$ #?&R
MHZ4.$\CG?5&/=*UT^P]$5W1;#R*A5&)8TAK8!2IW#8&L5JG7WM3/EB9/_P 2
M0ZCHS:'?EO6P-@>0 /(T2DDE6]Z)T2"HE0!(^'5?!MNBD!0:I<V5%#MS1%!
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MB 5[&\M:(%"%62 KV3_M*"4:[/;]&D^]K(. 0/+9^Z/M@\2 O^,'DD:5HGR
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M.;*\KSH,ZZZ;ZK:-.K<Z&RH.C5?H,;&4>Z_MG<1-O3M'/&*EQ%USSRV+>?\
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&,8Z,;__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g425213g01m21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g425213g01m21.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1WX4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '=R^=D0X0DE-! 0      %@< 5H  QLE1QP"   "P7 < E  "')R,S4W
M-CDX' (% #=-:6-R;W-O9G0@4&]W97)0;VEN=" M($=R87!H:6-S(&9O<B!"
M=7-I;F5S<R!396-T:6]N(%\U.$))300E       00+\9.60E?J=_K2?K]SAO
M"3A"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /<')I
M;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M#W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4
M<       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0
M<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P
M<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O
M;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
M3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O
M;VP      $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B
M0&_@            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M         $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M             %)S;'15;G1&(U!X;$!Y            "G9E8W1O<D1A=&%B
M;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C
M4FQT                5&]P(%5N=$8C4FQT                4V-L(%5N
M=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R
M;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M   -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M    .$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$)@      #@
M           _@   .$))300-       $    'CA"24T$&0      !    !XX
M0DE- _,       D           $ .$))32<0       *  $          CA"
M24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M 0 R     0!:    !@       0 U     0 M    !@       3A"24T#^
M    <   _____________________________P/H     /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H   X0DE-! @      !     !   "
M0    D      .$))300>       $     #A"24T$&@     #-0    8
M         TL   2E          $                          0
M       $I0   TL                      0
M   0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P   TL     4F=H=&QO;F<   2E    !G-L:6-E<U9L3',    !
M3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M!V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I
M;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M    26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O
M<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   -+
M %)G:'1L;VYG   $I0    -U<FQ415A4     0       &YU;&Q415A4
M 0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .
M8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       )
M:&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=
M  EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.
M;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M      QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
M     #A"24T$*       #     (_\        #A"24T$$0       0$ .$))
M3004       $    "#A"24T$#      390    $   "@    <0   >   -/@
M   320 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_; (0
M# @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,
M# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\  $0@
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MU*D
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                          #_
MX4 4:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@8F5G
M:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX
M;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B
M92!835 @0V]R92 U+C,M8S Q,2 V-BXQ-#4V-C$L(#(P,3(O,#(O,#8M,30Z
M-38Z,C<@(" @(" @("(^"B @(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^"B @(" @
M(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM
M;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(^"B @(" @
M(" @(#QX;7 Z0W)E871E1&%T93XR,#(S+3 V+3,P5#$Q.C$T.C,V*S U.C,P
M/"]X;7 Z0W)E871E1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y0
M4V-R:7!T-2YD;&P@5F5R<VEO;B U+C(N,CPO>&UP.D-R96%T;W)4;V]L/@H@
M(" @(" @(" \>&UP.DUO9&EF>41A=&4^,C R,RTP-BTS,%0Q,3HU-CHP,RLP
M-3HS,#PO>&UP.DUO9&EF>41A=&4^"B @(" @(" @(#QX;7 Z365T861A=&%$
M871E/C(P,C,M,#8M,S!4,3$Z-38Z,#,K,#4Z,S \+WAM<#I-971A9&%T841A
M=&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R
M:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIP9&8](FAT
M=' Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B/@H@(" @(" @(" \<&1F.E!R
M;V1U8V5R/D%C<F]B870@1&ES=&EL;&5R(#$P+C$N,38@*%=I;F1O=W,I/"]P
M9&8Z4')O9'5C97(^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \
M<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN
M<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B/@H@(" @
M(" @(" \9&,Z8W)E871O<CX*(" @(" @(" @(" @/')D9CI397$^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D^<G(S-3<V.3@\+W)D9CIL:3X*(" @(" @(" @
M(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+V1C.F-R96%T;W(^"B @(" @(" @
M(#QD8SIT:71L93X*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M9&5F875L="(^36EC<F]S;V9T(%!O
M=V5R4&]I;G0@+2!'<F%P:&EC<R!F;W(@0G5S:6YE<W,@4V5C=&EO;B!?-3PO
M<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z
M=&ET;&4^"B @(" @(" @(#QD8SIF;W)M870^:6UA9V4O97!S9CPO9&,Z9F]R
M;6%T/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C
M<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP34T]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B"B @(" @(" @(" @
M('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y
M<&4O4F5S;W5R8V5%=F5N=",B"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C
M(CX*(" @(" @(" @/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI9#HX04(S0S!%
M13!%,3=%13$Q.44T0SDQ1CDU0D,X-C8V0SPO>&UP34TZ26YS=&%N8V5)1#X*
M(" @(" @(" @/'AM<$U-.D1O8W5M96YT240^>&UP+F1I9#HR,SDP-D,U1# Y
M,3=%13$Q.44T0SDQ1CDU0D,X-C8V0SPO>&UP34TZ1&]C=6UE;G1)1#X*(" @
M(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YX;7 N9&ED.C(S.3 V
M0S5$,#DQ-T5%,3$Y131#.3%&.35"0S@V-C9#/"]X;7!-33I/<FEG:6YA;$1O
M8W5M96YT240^"B @(" @(" @(#QX;7!-33I(:7-T;W)Y/@H@(" @(" @(" @
M(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I
M;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.FEN<W1A;F-E240^>&UP+FEI9#HR,SDP-D,U1# Y,3=%13$Q.44T0SDQ
M1CDU0D,X-C8V0SPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @
M(" @/'-T179T.G=H96X^,C R,RTP-BTS,%0Q,3HU-#HP.2LP-3HS,#PO<W1%
M=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E
M;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W
M87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\
M+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z
M86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX
M;7 N:6ED.C@Y0C-#,$5%,$4Q-T5%,3$Y131#.3%&.35"0S@V-C9#/"]S=$5V
M=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR
M,#(S+3 V+3,P5#$Q.C4V.C S*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H
M;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @
M(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z86-T:6]N/F-O;G9E<G1E9#PO<W1%=G0Z86-T:6]N/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYF<F]M(&%P<&QI8V%T
M:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO<W1%=G0Z
M<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F1E<FEV960\+W-T179T.F%C
M=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G!A<F%M971E<G,^8V]N
M=F5R=&5D(&9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T
M;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I
M;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.FEN<W1A;F-E240^>&UP+FEI9#HX04(S0S!%13!%,3=%13$Q.44T0SDQ
M1CDU0D,X-C8V0SPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @
M(" @/'-T179T.G=H96X^,C R,RTP-BTS,%0Q,3HU-CHP,RLP-3HS,#PO<W1%
M=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E
M;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W
M87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\
M+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP34TZ2&ES=&]R>3X*
M(" @(" @(" @/'AM<$U-.D1E<FEV961&<F]M(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @/'-T4F5F.FEN<W1A;F-E240^>&UP+FEI
M9#HX.4(S0S!%13!%,3=%13$Q.44T0SDQ1CDU0D,X-C8V0SPO<W12968Z:6YS
M=&%N8V5)1#X*(" @(" @(" @(" @/'-T4F5F.F1O8W5M96YT240^>&UP+F1I
M9#HR,SDP-D,U1# Y,3=%13$Q.44T0SDQ1CDU0D,X-C8V0SPO<W12968Z9&]C
M=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)
M1#YX;7 N9&ED.C(S.3 V0S5$,#DQ-T5%,3$Y131#.3%&.35"0S@V-C9#/"]S
M=%)E9CIO<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#PO>&UP34TZ1&5R
M:79E9$9R;VT^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F
M.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIP
M:&]T;W-H;W ](FAT=' Z+R]N<RYA9&]B92YC;VTO<&AO=&]S:&]P+S$N,"\B
M/@H@(" @(" @(" \<&AO=&]S:&]P.D-O;&]R36]D93XT/"]P:&]T;W-H;W Z
M0V]L;W)-;V1E/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z
M4D1&/@H\+W@Z>&UP;65T83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,  0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( ,H!'0,!$0 "$0$#
M$0'_Q  >  $  @(" P$             " H'"0,& 0(%!/_$ % 0   & @$
M PD,!@8)! ,   (#! 4&!P !" D1$A,4(3<X=G>RMA48,3,V67-UE[2UUQ8C
M-7%TL1<B05%AU"0G*$9'5UB8U24R-$)$H;/_Q  < 0$  04! 0
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M80]E'\C37/TG?B@@GI$*]G'S-/OMR;3=\;Y,IQ[ALYO67XPS<ZLT@YS$C*,
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MON9V?6#V\/:Q_.T%64_X\[Z4SUQ9*%G$;U6[$,.<6>@>0_#K]^OYY1VA=2[
M6=:D\5=:^8,.]G&W(SVKRI:7?ZS>)#+MT)J38?IL.QXA5<:/E\X=!-# F5)4
M9RT*-8NV!0L'LM.#N"$A0HWH8P[UVM%["'?5VMZZ]92S[.K+4J6TE#%Z:H<U
M[T9EL9BUB8N7*D<UN9/KQ/$DK(6J^1V2U%1,<%7.NC1B:L.>72%3Z-<?U[IT
M?RRL)_R$#+8F0EC]NM4J;HON''N.PRI:09LZ-)SG5,F[WT22I>T80(C'!4F
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MCW6M/L-8Q!0_1. RNSK(N6KILZQ1SE*Y*_M4:8(>>YO\C]P7EP"RIFQI4K]
M20Z.=D3+K0Y"S*QYKR<7\JXVP5=3MRUMR<7TLY/D!B#$LGDXK%R@[O1D)B$,
ME]?S0V;3)Q8ILC,<=N2I [,BLMJ=8XXM:4#;1@# & 1$K#RR^67HPXK>M>V
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M*:FZ JN40*@8]=$=/B".)RNZ96P/\X2W(RL[GW_(2Y^O1-):(L8"V]FV:,(
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M@V]QM'O;/)86-5QV]7^*FE^\XD^F1A]L>IJ[KJ6\BXE%G5'4KO-FMM[NA6.
MM!5M9$B/VD7MJ-8F-6;VE*=VQ$K4CT0L5)TRE2;F^5L4GHI*BDIZ:6T8H)FT
M;YVHF3(]F"-]*B)(QCW(U'HU[$<B(CG-3[YMNU4Q1'*Y&*J92(O1\<-"JFI3
MJG'VBF>(*EMYR^O8U$.2MO16.ZO1?%G5W<&55(DJ=,:XI6E,L='!L0IS%R<E
M0MVU:V6K6$!,,6K]%@5&_"@L^*%[K0FIH(K4K(*=*^2!SW1NECA:U6QY;E1&
M-7%J*U$5Z(UTBO<B.*O<J_>HY58U5R$7!,WUX89]?UZ,5-[71F_*VT_-V/\
MXFMS1N$KW:R^WG\MA<4FE^INU3;]G)"]*PG)3R@;F]),O_&E><3MOE>TN^3^
M8I":^O.Z\GC-H;P\PEF+-8& 6%NC^\F*'_7$N]HU^==NIR'2]>IWB4ESP4<R
M;-[>T-]F,W<B/$-<?HUF7X"NR^MWD6UO#JS=Y#9[V<V+P>#VCNLI53R,;=":
MDV$(':5UKM&5*'*1\>3]*7ZX<],X[>LW:A[CX[=9;Y9OV.U?5J'[J5DK&<1O
M5;L0GQ!["'LH_D::Y^D[\4$$](A7LX^9I]]N3:;OC?)E./<-G-ZR_&&;G5FD
M'.8D91@$Q.!GE/0#^'E/LJ\YL5U>7*3JU'D2'1."KGO979U^XU!8DSKQ+P8!
M$FY.#_'>^YF;/[+9;&728YM0-)A\8ON^J[:]H6W1ND@0QRO+*BT< >'1QFC5
MH&H*U5UAVJ4'; #80.V41Q5ICC:?)%%3-DV;C984V$O>Y=;UNV@ TMH&M,0Z
M0E6A.9B4S" )P5;4#9P(!K="*"M$H"F3Z* D5@# & 1$K#RR^67HPXK>M>V
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M(-N[?:[$U.;X[\:>4:!I9F]:ZN:Y10\X 0B;FY,:K6JSQ[0]0"4Z8DTXP6_
M$ !;_LS=EOM=I/\ ,4_-2UW]J6_J\W^C]YO]1ZLR&U9"T-3^R\:N43BSOC:A
M=VIP3T/.1IUS:YI2EJ%80/O'7;)4I3RCBA:\ @#UO"7VNTO^8I^>EKO[4>KS
M?Z/WF_U$\.$]E2>DW^=N$_XX<M&Y,^L[0C;A)..5CN6S3TBU2>>$84+6<(K0
M2S0;T(>M!%O>]:WUZZLT:^]NV7;$%"RSZKUA\$TKI$]#419+7,:C5QFAC1V*
MIA@U55.E"YIXWL5ZO3#')PSHN.G'0J_4;#O?H1C_ )"<PO\ M;MC_P 'G.RY
M-'UTM]N32V[(EK!QAY4J6223.0O34>=04\2FFH'%R4*4QAB<]N <2,11@=B+
M,"$8-[ZA:UO6]9S"U+M6Q4VC6U$-,QT4U3+)&Y9X&JK'/56KDND1R8IT*B*G
M2A&"\_!O?"TKPVU7T=ELEI:RTJNIIY%K[.C5\4LSWL<K)*IKVXM5%R7M:Y-"
MHBF#W]-:$6/C:9_XX\FFL^7R)/$HV4JHZ;%C>)&K;G1W3M*/6T/ZU6:VLKHL
M"7KP[(1'C^ &\L?N4MS\59^L4Z[)%_D8-."F_*XXV3$F"8IC:5F9U^&:K7/K
MP3-I.Q?H3>?_ $M\I?L*F_\ D<?<I;GXJS]9I_\ RE/\*K\_DB/_ )*S/[PV
M]\2>0QE24A'(1->//+I#(6YQD*A4F2\:+/<"0%.#RK6)=A5)&<T@>QD&@$+0
M1[V#>]A%K0M;UG0[OT=10V73TU2Q(YF.F5S4<UZ(CYI'M^^8JM7%KD5<%S8X
M+GQ1)$<']CVA85UZ*S;3A2GK(9:QTD22Q3(ULM3))&OI('R1KBQR+@CU5,<%
MP7%#)UP<K6R8558T48^/_+X]YD<+DC*UDG<8;43E&KW)J5)$I9B@UD"42 9Q
MH-"-,$$ -;V(6]:UEW:L$E59EH4T+<N:>BJH8FXHW*DDA>QC5<Y4:U%<J(JJ
MJ(F.*J9R\%)/76%;%%2L])4U5FUE/!'E,9ERRP/9&W+D<QC<ISD3*>YK4QQ5
M40T-_P!'5]_]+7*+[#)O_D,X6EQ+U(B)]'Q9O][1_P!P1<7@KONJJOT,F?\
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MTVLI&4H*,:FUQ@E?1(MK7[/_ *IJTM5#E:L1J?\ 4;(6)P:_6 ,RF&==.?\
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M([ 'O8N4WSCEZ_8GQ)_([ 'O8N4WSCEZ_8GQ)_([ 'O8N4WSCEZ_8GQ)_([
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MO6LK?8 ]/30B<W&&O;FB*9%[Q&U*LDTQH=%+0K5-QB]%LE5WHH.)";H)@M;
MV3-__P !%U?!WHF__B#!1,<$QTX9]9^O!48 P!@# & , @[TE$*L&Q.#')"'
M5BTO<CE+Q MZ.B<9--)DDUB*%[:'*Q()'1D&%'"?9Q7Z.3Q)H**&$P]P>4Y
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@HPP"8HH(QZ $(>V+6Q=G6@]?5K6L ^A@# & , 8!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g425213g01m24.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g425213g01m24.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1H@4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &@2^9F X0DE-! 0      %P< 5H  QLE1QP"   "   < E  "')R-3 P
M,#<X' (% #M-:6-R;W-O9G0@4&]W97)0;VEN=" M($=R87!H:6-S(&9O<B!"
M=7-I;F5S<R!396-T:6]N(#8N<'!T>#A"24T$)0      $+=/7OP.7Y COMVU
MUV4'-&@X0DE-!#H      .4    0     0      "W!R:6YT3W5T<'5T
M!0    !0<W138F]O; $     26YT965N=6T     26YT90    !#;')M
M#W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $
M      ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4
M= !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL
M=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !
M   2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB
M<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
M     $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN
M=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P    !29" @
M9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@(&1O=6)
M;^            !"<F1456YT1B-2;'0               !";&0@56YT1B-2
M;'0               !2<VQT56YT1B-0>&Q ?"            IV96-T;W)$
M871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15
M;G1&(U)L=                %1O<"!5;G1&(U)L=                %-C
M;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L
M  YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M        #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO
M;F<      #A"24T#[0      $ "4S,P  0 ! )3,S  !  $X0DE-!"8
M  X             /X   #A"24T$#0      !      X0DE-!!D       0
M   >.$))30/S       )           ! #A"24TG$       "@ !
M  $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M      $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE-
M _@      '   /____________________________\#Z     #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z   .$))300(       0
M 0   D    )      #A"24T$1       $     (   )    "0      X0DE-
M!!X       0     .$))300:      -!    !@             #_P  !8P
M   & &< ,  Q &T ,@ T     0                         !
M      6,   #_P                     !
M !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !2
M8W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T
M;VUL;VYG   #_P    !29VAT;&]N9P  !8P    &<VQI8V5S5FQ,<P    %/
M8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '
M9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90
M  !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P
M(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   _\
M4F=H=&QO;F<   6,     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M        37-G951%6%0    !       &86QT5&%G5$585     $       YC
M96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH
M;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M"79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0
M   +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO
M;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M    #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M    .$))300H       ,     C_P        .$))3001       ! 0 X0DE-
M!!0       0    ".$))300,      ]@     0   *    !S   !X   UZ
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M_/\ V;9[_P"EK4PLB^TWLR&L;918&'TR2T@LKNGWAO\ I5953#_I.=_Q[?\
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M:\-P#ZT
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ V@$O P$1  (1 0,1 ?_$ !X
M 0 " @(# 0             '" 8)! 4! @,*_\0 -1   00# 0  !0$( @(!
M!0$ !0,$!@<  0(($1(3%!4)%A@W67B6N-@7(2(Q02,D)3)A8__$ !L! 0$
M P$! 0             ! @,%! 8'_\0 /Q$  @$# 04$" 0$! <!      $"
M P01(042,4%1$V%Q@084(I&AL<'P%3)"T3-2X?$6(R1B!S5#<H*#HI/_V@ ,
M P$  A$#$0 _ /W>V':595$ ZE=KV+!*QB_"W+;N26%+H_"P'+CKCM3E#HQ)
M" T?I;I--3OE+;C2G7''?6N=ZYWO0'2U?>U(7>S>D*6N2JK>8#>N."+VL+"B
M,^:#^U-]<I\/7,4+ED6O7?7'?/'*_:>^M\]:YUO?._@!D\^>S@=#9&\K4!'I
M1/4!B^XF!ELB>Q.,$37?RIM$CTC&@900$BD^N]N'KEA'RSS:"/:39FHLIQOD
M#75!/37H>VZ7\:!P!>KXA>OIA.P",VGJD'.GX+"HQ5 XTZEAB(URXG# D5*F
MC>X9&@8XY.M,@S60E)&0<FU0C8 8%TUX]WTR=- _2GJ*]INY\\025TY7-N4^
M+MIW=EE%:PDDZALG+P6X2]45LSAM>\V?%B,6$62/ D[ EVG\YDQ.%(\M(2(=
M&G#S<Q9AIX_#&GAKKIWZO31.S%7>TZ8.T-1MO7/8]44.9N&!,)+J+6!9D5C"
M:)]F@U:341'7LJ(@UY$.C<B56&Z)MVO'2K;M@Y=-VBCWA#0GQ74L77]GUK;(
M1:3578<&LN.-B*X=Q(*_E@"9!$"S5!JZ<BUBL<($F"1%NU?,G"[+MQRY10>-
M55$N4W"778&<X P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!
M@# & , 8!KZO0]2E0W\UMJ\//,;?)E8@RCD+]...&=C+0O@*F6*&(]+XP[%.
MI=2\1;JN?R96QH0*D4$[';[+VS(88F($?=.(XZ?#K]\.O0K+XE8'O0]HP^Y;
M9@Z\U*A:HC-B=VS(//+.B'U1WD<)+H&:@HJT8Z)C[F^Z*(1MV2=.#+:46U"R
M381&BKBR)JC,&C,&*]/?U3T^C\5SY&Y_!"BC3QH9B-6^=XO6%O<Q6S?-!J2D
MH18A^!<2V.2 7-F,F$3")SFO6LOB[HK'# Z1H.TN LZCI<?)8Q&3;<OMJS?A
MR8??WRSXIF,!O$4_KYR#G=0^AFL6O9\(M03;UE2^H&,Y 6CU;EB.[6*ET:^8
M3J%\1$O!IH_(<U5I.4'@T:BA!Y&9,&F_/38BU%RNGA]\^_J^A:^JZ)KVIJGK
M.GA E$]&ZKAH2%@'TL;,39MVU#CVS)8J4>KM-<KF#:[?HH:=((MTW9)PNOI%
M/GKA/@1ZMOJ0IY48,1EI^^V0UDT'LD?8('Z+1BW1:-4OJ>)_'"O?TFZ'":2?
MSJ=]J=_)QKYN^^N]_'KK>]BOA'P^K+G8(, 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & :X_1_B$_=]WZLH<<J]J/-C*/&.91+8*_
M/7+36Z3LPY8W9+SY,6Y=JVBI"P-&>1!/M9NR_9\JQ0E2_<R0^G$T!<Z<_?W8
MZ?7AE<RUU>>?*VJ69RB6UDR)P=C,T5UI)74>+.654NI&X>HO7$W&5W\>X[%9
MB_ZX<\'C$/:Q_F6J$')&8-CYE$<28B$W8 P!@# *>>8?XN?J ?U@Q[_"3QM@
MKX1\/JRX>"# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@%<K2NNR8-+OV7@OE^U;P;) !ALC(H!/?.$?8"E2CTPT1$OQ-KW=7<KX
M<Z3#J.^'Z4?5!NTE_HL"KIZQ*-F N.]+W_1$$U,7N.P/9A6PIU2LVHJ*C_,:
M4,8QJP+'H^2&SL@5M3DXH='QFH;8LE5L*;CM;'JGC"(Q/IWO0]!1;KX\:!^*
M?O\ JD; \$& , 8!3SS#_%S]0#^L&/?X2>-L%?"/A]67#P08 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , TP_J*1Z[10OW+^S%9Q
MPM7_ *A\40_SX*MB5WE4M11:OIXU3].A%.I5NQI""==C]?\ ,<7>MG(W:NW.
MDGS5OKMVERGT*L::<'E_#Y8)^\YO+<N;TSKTK(ZE85U5ZOF-K5L5-L;?JZV&
MDR,]V;J5*D [^L3IT?R)18)=I?=K.?IJN>>DDNNM\]? 0V08!4;V%Z#.>>8E
M6A40ZKF*L[#ML/6DAMVY2#L=3]*""<2FLE;S>PU61, JX9'#T5"U?%V#B41%
M@1G]A1)B[DK+;A%H_%2\^[KJO[\'PX%>:V]@7]Z#'U;&:;BM,A[!D%23NY9?
M*YB[F\BJ@Q%(_:QVIJM(5CH)U&Y(1BOH7N-&+)A\U**JI16N?P[Y2/39Z<;<
M)!C''[>-4^]:97CPYW4H*ZPUZTA55SHL-Q-.RX4%E*L9*D&KA['";UHG^;C;
MAZGI%N0<1TQR]#.'S9--!VJSVY23336XXT)P[^_K\R(_+BJ2]L^_E4%4UDNO
M8,?^51+OE1/KX>)?&VM_+WQO?._AO6];^&]_#>MZW_WK!7P7A]67'P08 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , U*WY,?+['W
M685]B%(P\BU:>=*C)4%$;)BK^5P0?-K$GUZ-;=GP<.J$-@'$]Y 0BLHRB=7;
MZ-1B/+OV(E=FTF!SD@*D\:+F^'3"QGSSX^1S/(TRH17V9<D<\D.@:5&S>C(E
M9DWC$&CI&.5R#O43/#<7(2,&&4$B0H.3SV$/P6IHB%;()'^X<$./F_9?LF0?
M TUQ6O?T6,>[P_IM>P0J_P"CZ/EMJE*1FT!D$.&3.B+')V""!V3&7\LKZ4]F
MZ]F-=/F9=D*+ABH0X,'S%P7BLO&K/G(-^U7:*B"# P]X3#[^.?O]RML#\6W5
M2;F/SRG;6JEO:ST#<T<LAM**ND2=2.V5N79([X"]U]#X[/F1R*,:BEDNDPB,
M 'LE+-Y3&CI!(T1%&-M2[47/7N^&G?R^/N+"0OQ?Y\"TY35/V!6%=7>UI:##
MH: DMMUU"YF:<+<-&/,C/\<G Q%N'?2\LS_.&VHCEJR4>]\<<)?1:MN4PSTT
M\# _%\(AE=3GW?#J^B,8@D1$>P1'XF*PT *C$<%_?>,/'Q%[^.!A&C$8R^\(
M.W3YU]LU2^X>.7#I7YUUE.^@?+P^K+U8(, 8 P!@# & , 8 P!@# & , 8 P
M#B/W[$4Q>$R;UH.&CFKA\0(/W"+1DQ9-$NUW3MXZ<=IH-FK9!-19PX64X212
MX[44[YXYWO64(3J3A3IPE4J5)1A3IPBY3G.3W8PA&*<I2E)I1C%-MO"38;23
M;>$M6WP2ZLUF><_>UO7?/+R%K^.[>U7\#E X?7TNC2T+24/@B#!-TR=&.Y_-
M82#*+FA^VDQ$/X$6D@OJ,2,)SWM5OL?(9)^A;>]"ME;'L=BU5Z6;*E?7UM4J
M7UI7C>25O7IU)1G"DK&RO*U.-&HIV=6%]2MZOK-O6:47VE"W\5&ZJ59UEZO4
MW(22A)./MI\_;E%:Z23BVMUK/5VS[]!DFV^M$///HQA\JNDM[XAD4-Z_]?':
MG.XO.SNNTN?^_CWQ\WQWKX<ZZWO7Q^96PZ<OX>W=@U-,ZW=U1\O]394,/N>/
MF;^U?.E57#],7Q_[9,]=^F8NCO6G]9^C6&]JZ2^&O.=P&-:W\?AM3?4;B1OC
MZ7/_ +VIKK>MZ_[Y^;'^'KE_P]H;!J:9_P"?[)I>7^HNZ+SW<2]M'G"JO_35
M?7^6#7+EGEU.:EZ9K13?7U1%V,=<K?0WT3\S>D!:>U/C\/\ Q4?U0W3ZX_\
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M_ES?P*D7[:'ZEP.PJ,[J7SO5Y*!NY.1W9H<#:/$Q*%A3<0X=;%&3TJA5:CX
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M<AB*UEO;4[:FZ=/>:<G)N3RVWPZ)822T2SQ>I;;/EST# & , 8 P!@# & ,
M8 P!@# & , 8!4'WC8S>K/*]DRDAW5+4$[>UW!Y69O((G)Z?BD*M"SX96DTF
MUC198L 1E45A,5EI>5E(NX.A6LA2#_AWA8:T>+O4!5Q_;CW8\2 _T]X13==/
M)\ IKT1XIMH<58BC9V,^3ZHK6N"3-^BKMBSDDP=0:X+,?&1_+3K\.$1+-VB
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M<I3G.3<ISE)MRE)N4FVVVV;4DDDDDDL)+1)+@DN21S<P*, 8 P!@# & , 8
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MG64U8/:V=244C+7-BQ.%/1?!K*U>J6.?/AIKGITP9+^GO$H%7SZ?QBMEZX8
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MQL[3,*C/#Z30^4@!:,FY?.G07H/-8F[CZY7IT35%AH]5C'=GGPX_?$V+X(,
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MQ(0:;G-ISEQQPBN4(Z)[JYMI.;]II+$8SEG'-@P!@# & , 8 P!@# & , 8
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M3Q)YE>7$87%;L;?"$9-]I46)-8C#.53CTZ.<N,Y?^"T696&SAFT8 P!@# &
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M]V?S ?5O]B>%_P#37 '[M]V?S ?5O]B>%_\ 37 '[M]V?S ?5O\ 8GA?_37
M()\XUYZ*MZLEYG)/>_IAD42M._H1R@&KWQ"W8[%59?5E5?'U]IO/(3]?;]T
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MJ_95<^Y?5+ZCKI_0G+]V^[/Y@/JW^Q/"_P#IKD _=ONS^8#ZM_L3PO\ Z:X
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MV)$6H<<X/EQX=!^6>[ZTR%LE2+ALFZ(N]\=Z:L4.E'+C?'6DDN]\[^ 'W-@
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M[^[0512426Y[3XZT!RC=/5')6@,?(ZMKD^PC!QY)HTR-PB,E6D>DA%^N4(2
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MBD7"1UU)S/7U/F+R)P(8LUC1/?UE?B_)=N76_JJ?%7_SZ^(&98 P!@# & ,
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M]+:#!FU8H;4[5VBS;HMDMJJ;UM13::/''&U.]ZUOOO>OFZWK7S;W@'*P!@#
0& , 8 P!@# & , 8 P#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g425213g11m20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g425213g11m20.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2@>4&AO=&]S:&]P(#,N,  X0DE-! 0
M    * *^$"0CA"24T$!       6!P!6@ #&R5'' (   +!<!P"4  (<G(S-3
M<V.3@< @4 -TUI8W)O<V]F="!0;W=E<E!O:6YT("T@1W)A<&AI8W,@9F]R($
M)U<VEN97-S(%-E8W1I;VX@7S4X0DE-!"4      !! OQDY9"5^IW^M)^OW.&
M\).$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M  4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<F
MEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0
M!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E
M!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G
M!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V
M]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
M!,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F
M]O;       0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6
M) ;^            !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M          0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M              4G-L=%5N=$8C4'AL0'=6V1         *=F5C=&]R1&%T86
M)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B
M-2;'0               !4;W @56YT1B-2;'0               !38VP@56
MYT1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W
M)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M    UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M     X0DE- ^T      ! !=6V1  $  @%U;9$  0 ".$))300F       .
M           #^    X0DE-! T       0   !X.$))3009       $    'C
MA"24T#\P      "0           0 X0DE-)Q        H  0         ".$
M))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M    !P  #_____________________________ ^@     ______________
M_______________P/H     /____________________________\#Z
M#_____________________________ ^@  #A"24T$"       $     $
M)    "0      X0DE-!!X       0     .$))300:      ,U    !@
M         #Q   !DP          0                         !
M        9,   #Q                      !
M   !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M!28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $
M)T;VUL;VYG   #Q     !29VAT;&]N9P  !DP    &<VQI8V5S5FQ,<P
M%/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9V
MEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90
M    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&
M]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   \0
M  4F=H=&QO;F<   9,     W5R;%1%6%0    !        ;G5L;%1%6%0
M !        37-G951%6%0    !       &86QT5&%G5$585     $
MYC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
MEH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M  "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'
M0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $
MYO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M      #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M      .$))300H       ,     C_P        .$))3001       ! 0 X0D
ME-!!0       0    '.$))300,     !V,     0   *    !@   !X   M
M   !UP !@  ?_8_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E
M)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0     245#('-21T(
M        $  /;6  $     TRU(4" @
M                                 18W!R=    5     S9&5S8P   8
M0   !L=W1P=    ?     48FMP=    @0    4<EA96@   A@    49UA96@
M   BP    48EA96@   D     49&UN9    E0   !P9&UD9    L0   "(=G
M5E9    TP   "&=FEE=P   ]0    D;'5M:0   _@    4;65A<P  ! P
M D=&5C:   !#     ,<E120P  !#P   @,9U120P  !#P   @,8E120P  !#
MP   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87
M)D($-O;7!A;GD  &1E<V,         $G-21T(@245#-C$Y-C8M,BXQ
M         2<U)'0B!)14,V,3DV-BTR+C$
M                                       %A96B        #S40 !
M   1;,6%E:(                     !865H@        ;Z(  #CU   #D%
MA96B        !BF0  MX4  !C:6%E:(        "2@   /A   ML]D97-C
M       !9)14,@:'1T<#HO+W=W=RYI96,N8V@              !9)14,@:'
M1T<#HO+W=W=RYI96,N8V@
M                      9&5S8P         N245#(#8Q.38V+3(N,2!$96
M9A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="               N245#(#
M8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M                       &1E<V,         +%)E9F5R96YC92!6:65W:6
MYG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$              "Q2969E<F
M5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M                        !V:65W       3I/X %%\N !#/%  #[<P !!
M,+  -<G@    %865H@      !,"58 4    %<?YVUE87,          0
M                    */     G-I9R      0U)4(&-U<G8        $
M    4 "@ / !0 &0 > ", *  M #( -P [ $  10!* $\ 5 !9 %X 8P!H &
MT <@!W 'P @0"& (L D "5 )H GP"D *D K@"R +< O #! ,8 RP#0 -4 VP
M#@ .4 ZP#P /8 ^P$! 0<!#0$3 1D!'P$E 2L!,@$X 3X!10%, 5(!60%@ 6
M<!;@%U 7P!@P&+ 9(!F@&A :D!L0&Y <$!R0'1 =D!X0'I ?(!^@(# @P"%
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MH,0PQ<#'4,C@RG#, ,V0SS#0T-)@U #5H-= V.#:D-PPW>#?@.$PXN#DD.9
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MJ/JP*K=:OIK%RLT*U$K;BN+:ZAKQ:OB[  L'6PZK%@L=:R2[+"LSBSH
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MC&(6P+!L 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P"COJG"NA\FWZ"+0\G?_  ^R'CM,@P-I
MXS4\VW$FG_*4U],3L4-O5H6PJ<IT]?[CNVHQF;Y6C9*V>3ELD%+'Y.<VMH0
M>RXW<";;XW/-&6Y5.ZN XN\.KYIONDK;8BY(KK(]T9FLJQ?_  TWPG1O=E0M
MI8%YKKZ)J*0.4MK1:C(+9HV=!T0P*P@7)8 P!@# (+<.?69S]_?/<?\ Z\\?
M, G3@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!X&RK&9*KBJB82)
M!(E[2D6-Z)07&&);(G(HQS5%H4IHFYO"-3M-M6<008<$&PE#.*[_ &!%L6@/
M;I3]*DR=3HH\C2@@H_1"HH1"DG1I83/)*"1?WBCR^]W#2Q?2 S0@[^G6 ?O@
M# & , Q3;T\D5>,#,\1R,MDH/<YC$XH>C<Y ='2TH9:^)(\D7EJB65\VHVF<
MG%$(],).3VI-J#0';-* 2:!E0&Q[ #9@=!'L(=C"$6Q!"/>M=X(1;"'8M:WV
MZT+80[WKZ=AU]6 ?U@# & , 8 P!@# & , 8 P!@# /F^[V_3V=NO^?9VZP"
M+?*&_GFA=\=],K V/_\ ;1RBJ:@W;TDK5)?0C-8FI!M:_M^TH1><.;=MF*\U
M2J>Q*=Y8SRPM:"'M E+@# & , @MPY]9G/W]\]Q_^O/'S )TX P!@# & ?-[
MUKZ]ZU^W?9_O@#6];^G6];U_SUO6_P#; /N , 8 P!@# & , 8 P!@# & ,
M8 P"KGJ,\M5%%)8Y6I<+3R(B?-9+\:ZF/!K>:W"C4I:EA:8M,!"J"HTJ$CT
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M87Z7/^.X?V0W_N+-5@;Q7+\:7W3D;T&^+$7XV[W59;GD_+_& , 8 P!@# &
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M7DLO!R?*J>8K'65HA,862!"XM1KH->K4N4FV:<0J"L5GI_(@V[&Z!LL !_\
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MG4J]0['\167P:0Y%<8\4)TJ+NYBI-,W):EZYI-GJS"_2Y_QW#^R&_P#<6:K
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ME^-+[IR-Z#?%B+\;=[JLMSR?E_C & , QU;JIV05=83DQ/"Q@>6F&R-X:WA
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M):EZYI-GJS"_2Y_QW#^R&_\ <6:K WBN7XTONG(WH-\6(OQMWNJRW/)^7^,
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MG*X^T";?1'.Z-OKDM#X=%?,37GS@#A=QZ/#WCC)N:.4F(.I6;; ;$^6@=F#
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MKFDV>K(O\!O5UR@]RDO@DPS181X'?.8C[JJ(3HFXFQOU<S9;@1BX>>TO5'O
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M;[,DS?5:2Q$L0A\^D:=H=AMS_!0@?8?+R49),N;B0J(V8ZF'@ -\_E^(+^\
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MH8:3BFL]9_9C,:]'[VKEWPMEGB,>S8Z6N2K.LZ3NYS#9N&+S+^TPB%OVP?\
M4:/^8XLEO^4V^S[?AR'C_P ;_JO^8E_U@O:L0_"^*?G7S(EHEY+.ZQJNS$>N
M\\,_\4?O<7D\ /8XH/W,%XRZY2F/>6%_Z8S9H#?V_@5/S:>]2K7K-^L6F/<J
M0^.I\H72!Y6V\W4=J(Y)W37'&%^JZ_;(#R[!]T1+OBR'YGCN?,?(.7GEVQAX
M:/[.5Q]H$V^B.)TD/6'=WPA7^*(L^, \)N71HN\<8]SGQSBGV=?M,1"7BQ[5
MU'_&*%?,R#([9N4-#UBWO5*JP!YP<*>T]J^)0%Y_++G%7%2W1#X"Z.5NLZ^
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MR \NP?=$2[XLA^9X[GS'R#EYY=L8>&C^SE<?:!-OHCB=)#UAW=\(5_BB+/C
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MWB4*4/A?I<F^WJ0?1_";WP&6^R_>RS5,]6M#%^QX_#>&\-)GX7PN6];EGO\
M?Y??J^[TY&2^?_$?FI9=MTK.9O,N+;>YVY8,-X]MJ*+LUM#1-!ZQAG4I32)<
M8Z.8CE)194?4HSD9&BAB&H3F 'K0#>]JL+:0ZG#%L_9L-M@JVK425"RR5#XU
MSD1J*S>MB=J3>ZEWV:YKJ349:NV1U<OA72O8N]:W)J-5/W<]>O\ $LGI.I^H
MI2-5PNJ69^X7/39"6K;2C=')JO A<M)VK4J]&J24SF(@LWO*1 WHK>P;T'6]
M:UV]FH?>[H^]W:NNLD+:=];*DKH6/5[6*D;(\D<YK55,F(J9HB^G/QGN@B2"
M&.%%5R1MWJ*NI5UKK7(@7U+^/_..90ENO&>R;B@E(K@47B!+'$VBX!&N?]HE
MBQB*$JS%3JZ=PC;:L?R%8RPEBT>G(-+T()@P;#";YAZ"]OIWS5$L'T=LC6I&
MUB[[?JU55=\GW;W[BL-(6BNW:0JNW55==*NWNMU/-31LIH89$E;-*V5SG+(Y
M%145B(B)]V:J971<".>"+C"Z<706'Q''&G23ZDQDH%'KET]E'Z<D#CYL6BT\
M^9"*\H@ 7Y01NA>3,%ON][6A9^-P["VRNLOTF58G/W_AE:Q)$7PJ2Y;U$WN6
M:9?>N2YZS##HEML6 JC 276L=1U%=].6N6")*AKO#PS^#2-'^#RSA1N^557)
M5U9ZS"?3BXT<WV" J;U@LJXI')[589?##6*4L]O^6:28[.'F-*%@%34ZZ >8
MJ4QPQ446(L(0$*0%B%Y0L0A?-EPY!9)*B2&IFF6HC;&J2-8F]1KE<CDWJ>/-
M<LEU?V^<!Z([;@.KN571W:LKG7*@=0/94011I$Q9&R>$:L;UWSD5J)DJ(G\T
M,44?P%YE1_EC+&-HL3C"HD?'0RD[1-4.$?M<+/(Q3UPF;BVM0"T[MYVC"WF0
M%04M/V,W9P' @1(0[),"+PTF#:6DKH:YM;4/?#4).C',C1JN1V^WJJB9Y+GX
MTR7(C=DW/]FLE\ME\AOUQFFMEQI;BR"2FIVQROIIV3I&YS7JYK7.8B*Y$543
M[E/4\T>'G-.P.2E0O$LFW%M _P#)6:JJY0E,#);1C5&5,%IV4S7TFJVX.NE:
MTEP05^:@\B5HD1*QP*.T(1!)@19KMA.FNU8ZMDJYX7JR-B,C9&YJ)&U&HN;D
MS7/)%7/_ +9&SQGH2M.,\0U>(:J]5]'/5QTT;Z>"G@DB9]%IXZ=BM<]Z.57-
MC1[LTRWRJB:BTRK:^ZC565U"ZY;7CA2YH(5'6V.I'%:UWF2K6D-J<*<M2H))
M=!E%FFA#H0P%BV (M[T'?9V:R24E.E)304S7*]M/%'$CW(B.<D;4;OE1-2*N
M6>2:BUK#:([#9;7989GSQ6NBIZ*.:1J-?*RG8D:/>UJJUKG(F:HBY(OB*].H
M/Q[YQ3!XK&SYO)>)Z4]]GE24 @;8RT7"(M.?9=A!8$,@5'.3MWC"6Q7(MJ52
M,H 3#TZ?N$FA-'K>K:P1I2N&![94VREM='71U%:^M=)4331.:Y\,$*QHD:*B
MM1(&N1V:+FJHNHJ[2+H7M>D6\TMYK;U7VV6EMT=N;!2T]/-&]D5355*2N=-^
M\CE6J>U6I^[DU%])F"5\+>>9G%U!0"F<\0]1J'.#C+2GTE@N?TRL&4>]O TH
MTPWGS,H(AN1I(3-&#WH)0!;+[PM]GQ3Z3Z^GQK68U2UTCJJLHTHW42SR^ 8U
ML%/ CTE1OA%=E3M<J*B)FYR)EJ4_:K0Q:ZK1[;M'KKS7MHK=<GW)EP;!3K52
MR/GK)UC=$J^":W.L<W-%SR8U?&JF-N!_'#G.BX^IK,ATHXF;:.4E-0Z0&-<B
M9[CVX19NED8-<TZ4)[<[Z3KEB,F1"*/'W"2#3DH=E[" >\_<7:4*_%M18JBH
MM=)1NL5:M="V&::1M0]9*=^\D61N;&HM.U,VJJY.5<LT0_<$:&+7@BDQ/1TM
MYKZUN)K8ELJ'U$%/&ZEC2.KB62%(U5KWY5;ER?J_<:F>M57$_%?AIS29^0MF
M.L<FW%HU[XO6JS1%26\,=MZ;)0O?JJA]@ 6D;1N^E*%*G16 2W"*,\L:-6W&
MG!%Y$T 0[K$6FJZ8CLEQLD]EH::*X0I!)-%4U#Y(T21DB.:U[4:Y<VHFO),L
M_$I'L*[G>RX5Q%:,108AN=7-:JGZ5%3S4M*R*5R1R1;U[F+OT3)ZK^[]Z)XM
M9W/(?BUSPE_+VM&9WLWC8VRJ\F.VYHQ+V9!<8FN$)ZD25V0X-R/:E\"XZT]Z
MFZ89 D8DI9 TBO9X!Z/+T'7V'2I^P[10VK_Z2L->M#$Z)*VJ9OJF;?2/DWSU
M\"N3DW^]3]YV:(AL\3:$FXDOMTO2XWQ-;4N=0D[J"BFWM+!E%'%X.)/#-_<_
M<WV2M\:JB(A>=Q]:>1S!'#&3D NIQR4,Z!B:XPMJ<F<E"5IT"$25Q527<V6*
MS1K5)A28Y/M"9L']]3YP(8MEBRK:N?Z555-5X-D7TFHFG\%&F4<7AI'2>#8B
M(B(QF^WK41$U(FI/$7304OT&AHJ+PTE1]#I*:E\/,N<L_P!'A9#X:5<USDDW
MF_>N:YN<NLD+GG/6, 8 P!@# & , 8!\[==N]?YZ^O /N , 8 P#&IM,U ?8
M9-NG577)UKIT?H\BS385&S+ )0:(\UTC*F(VW<A+2Z2]J;1 7'1>D^]D:#Y+
M>P; R5@'P6N\$0?_ .0=Z_\ SKLP##W'^G&OC_3D$IQE>7"0-<$:CFI&\NI*
M8AP7EG.*UQ$:I)1A F+'HQ:,O020Z#W !WO7>WO /D+IQLA=N77;B5Y<%KE=
M8:W"ZM"@E,! R:K>.+HX@VW'%!TH.])$+AJ5GG0A>3.  )'=!O>M@)]3C9/;
M-HRS5;RX('"C'^;/[2UIB4QB)].FT">8$K3N1IH1'D%(4;R:X)A)!!&-4066
M;VDB%K /UOZH6V_J4M*E'EW7L#5:4(?X0X/;62F4.+4D?T!J Y<B(5A$E-4I
MP&[,*+/#LH0M:T/Z, RPF)TF3D)]"V+1!)1.A;^L6B@!!K>^SZ.W>@]N^SLU
MV_5K6OHP#BNS>!V:W)K,,$46Y(%: PT&M;&6!6G,3B,!H6MAV, 3-B#H6MAV
M+6M;^CMP#'5%U4WT72]4TNTNJU]:ZIKZ)5\W/3D4G(<'5%$F1$QIG!:2E"%,
M4J5DH@'GEIPA) 8,02]:!K6 <*M:=;*UFMZS5"\KW-5>MCM%CNZ)82F+3L2Y
MHK*!5D4W-HR A,/2'(($C=##%>QG:6N"HH(M$%E:T!^<IIEKE-WU)=RAZ<$K
MK4D4M.*-K&02F$W.Z>T_T*](*UYY@=JBCVK]"DOF($X@EF^?*?.-;\F5@'[W
MQ3[9?%7OM7O#PO86]]<H@Y'.C82F/6D&1"9Q^9IBBRE81IQ 6*H^2B4;&'8@
M)E!HRMZ-"#>@,O\ [< QW;M>(K=JFRZI<G%4T-UEP*7P%>ZH2R3ES8BE\?<(
M^I7HRE 1)S52,EP&H3EGAV2,TL 3-;!L6L ]+$V F*1:-19,H-5IXTP,S 0J
M/" !RDEF;DS<4H."7K1833@)@F&!!K0 C%O0==W6L QW3E.-E.%6:4V/+@\Z
MLVX)U<*_;@2F)VV.<Z.0G*V=%YL$/E&]#M" *8X_O*1Z,%Y46]ZUV ?FX4RV
M.'(**\@C'IP+>8K4DVJ--'@$IMM:MMFTM@\N5NYZ@0=K KT*J#I$B8DL>DXR
M%RD9NMF%E=@'(NRH&V[(JPQ5U>%[(G8;0J&T"53<2F//4.%0V=%+.;6LT*H(
MBPHGA?%$[6O-!KS@E&K/-3;T> O> 9?P##W(*GFSD%2-I4B\O*^/--I0E_A+
MB^-1*90Y-21^0FH3ER(A8$24U2G ;L99:@.RA"UK0M=F 9=*+T4264'>]Z++
M 6'>_KWH =!UO?9_GOL[=]G^> 8?HVFVRC8B^1!I>7!]3/EFVS9IJQR)3$*"
M%]LV-);&<FPL"0(2Q(VE=)5#<A-'K9YJ1,28H$(X0]X'B/[;:>;6V^Y=?8'E
M>:\2ZIX'4ZE@&2FTUHVV!RVP98C=B#PATK&N7J+!6I%11@MIRR&]*,K7E##M
MX!^=N4TUVXY4XY.3RX- Z<N%@N%L+0$IC@/+FP1R6QPEF<-J0"$2WGD2U2I-
M.3;"I"<D(  6@#,[0,RX!AGD!3+7R JQZJQY>G"/M[T\0IX-=6LA*H6DF0J;
MQV;I2"RE@1I]EKE<=(0J!"#L1:92:85V&A!O0?V,S8!AKC_337Q_J:-5.S/+
MA(&Z-*Y2K(=G0E*G7*12F7/TN4 .)1A G"%(I?CD9&P!UL2=.4,SM,$/>P/U
MBU/MD6N>V[G3O"]4Z6W&JLC3DRG$I@-[015FIQIO5(3BPZ5''.NINJ\]"I$(
M!7F*;S?0?*&ZV!^%DTPUV3/Z'GZYZ<&U90\]D,]9V]&0F-2ORR0UK-*U.0.9
MAX=G)TR=#-%;F48DV$T2M$G*'O9 S=; S/@&&;MIEKNUDA+(ZO3@QE0FW:MM
MU(>VDICS%KE5LO;I@WM"D*H(@ 0.JIN+1K32M:4%)S!C3B";H.\ RNZ( .C8
MXMAA@B@.*!6@&:#6MC+ K3F)Q& "+^[L0-&;$'0OHWO6M;^C ,=495;=1E,5
M53#0ZK7UKJJO8C7K<].12<AP=4418D+$F<%I"0(4Q*I84A"H/+3AT2 TP02]
M:!K6L X%;4XV5M.;UG*%Y<'-7>M@LE@NZ%82F*3,*UDK6$5J2W-AA =&GI3T
M$(2.1ABO8C@K%RDH&]$ *UH#^993+7++LIZ[%+TX)'6GHO;<7;&0@E,-N>4]
MMA@07)4X'F!VJ).:=0))YB%,((#O/U/G';Y,KL S+@%9'(GJ2DT-9%\05NXT
M7):S+QAKJ!6_>T^AKE7J%@AM:3A'(G +NVH)+*FA^E;^TH8J^N!\69&TU6I;
MVU6I"K)WI*4K PE?O4%E$NXV<R8XFJ>X^,EHM'!.UN3E%2>1/,/-=91 "(T\
M-S5-V-5!I(^K(3,8Z^G,2Q;%7WS5]9@NS2HV,2C9Y"8"O1COZS=1WD"X\4KK
MYSR&#U+P>O-_Y2+.5JV3)3ZPNE74C;+Z%<ZG/M)K9;6:I<XJ1/CVH,9B#H.H
MBWF#B4?MQ"F%H#.;KR_Y!UWP(O\ H"Y;)?4?+REJ4J^SZUNUM./8W>^:%FTI
MAB6.VTSJBQ=X,SC1CFJK>WD2<XPY-)$I#Z/M;Y:A%CY^?G^P,Z=13D;?0K?9
MZ[XP64").G#VJB>9UZLJ=T;T8[A\@[>85YQD7:5GEF'%V;#V6V9 O2E!$<4K
M:82H"#>U9)Q($K.0?/4< XKR/DU4U9O]AP%7Q&E')*"V=YTREUT%Y"W1T^!P
M:4:+=?TF3KY'N2@>%*I S*&MO96%\$M<4J@HL& 1&M:!MG%*OJRY!\E.9G4/
M>K*6C:9U8EFT\=,9C2#,8@,97>4,S_2,:B4DIZ!U&L)<#(^UZ>XUZ6"T!,7E
MR8Y_1GNNGH_V^?O!/>:<YH!"8#S.L%;%)6N:^%2],@FZ5)Z,TLEVU-302W2S
MHKH]:64 &V6>MS;L+L-$/3DC6=H=)_)&C P@X\Y([7-MW=747C5[7Q<TAY#,
M56UW2)+E 4J$QX2\;JTMV1G0)Z=CXTT0JK8W$9"ED,S=YR]K5Q<M<7,MI K+
M<VMOT!%F!=0U15U\<X9G=%56Y"9DY6#Q"I&N^-\IE$&])*;2?JJL%^4HXM+5
M,UU4S?#7=D95LR<9^;)&EG&QM"M6Y%!=TI;6-\^[_P!?*@LYXG<O(KRH160W
MI(PX0&Q:=E#9$[,@3A)H7-@,JU_CZ&4QMT9II7C])(?*(_(&->6H0.+8YA4$
M*DS@VN;>WKT)Q& 1LC'4HDLYKVQK;B'#ZW558PB<RNM&B;R>QJ'K]DF$N@MB
M2*NY@N3J9G8[0".P!@<(TM.4S:1"1%JU6_1+4T."H A[ PDX=5JQK$3<3W[C
MKQI?YNV6KR:L;CO;K(;85.'JF*8UQ7]D2!WA,0E95ADQ1]4J38NW3-FG[6N<
MX:ZP]"O;@'IY"[-R,/YZ/YZA_8S!$N=+;&V[4)KR#WWR1NRQN1W+&(0VKWA]
MK=O?4"&B;)<62QW,^9N"J+0R(TU!EBEI888:]*E\E4IG6/,_DGET,5J"?T$B
M*:YB[NH+&A8:+MAJE#5<4II&^XJ]"AA3EQQEL7AQLQTX3Q0EDZEND45DJ-3&
M@Q*00%5)4SVFES&X: F*VM*2@32P!@$,>?CWR1C/%RTY+Q?ET#K^>QB(RV5N
MTZG#(LE!D6B44ATADCLOAT8*T!J?)JI4-;>ULA$F4D1Y#IP4NZ\IQ$W$M*\#
MM::OQ:=2/#IYGC9-I1*+ZJN#.C],V")&KXO'GTVG"+#D,FL1U:R4[1"&-T.1
MK4:!<H)3MY[ZO0-"0HH2@L( *TZ(ZL\)LF2<O;E>+'=$<!8(;9[OQ$I!XK^0
MQ5KM6NN-T8?W^P+CC-BOL3;6NP7ZQ7=$O4M\:C$N<RXK73*SN*QJ*<UKT>D
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MQ*C7J&Z?=@T=.8='D=%5')G^,JWM*YQTE[TY2-C(&3YHH\@Y"),, MFP!@#
M(46-PP9;$7<U5JB=NS6+F=2D6I=[ 0S(E&H(AB\*GL,)?6D1BLO;RK5DSM2O
M,1+?-""C6\DD!P@'F# !Y>[^!+!=:=^3KK&>F$+[PFLSA88)&Q(%FTS'9)L;
M-53P&CEA'E'=J_1PH)#,+NHE6E1GE59?DP]X#IKGZ>$<M%Y?'^.V<_5PXV#Q
M.EW$:X@M3 WNR"T84Y1Y2UP"2O"%2N1E(I=5KJXO3G'G,G:@Q6V/SM&U8P-Y
MQ)A#Y4'"YC]-.LN8M)U%5T@F4B@DPI0,:1PNVXLB3;DFF! D9FJ9Q!V;S%*=
M*Z1*Q&9G(3/[$I5;2%."9H>"-&*V=-H8'91GIB\65<ON2RK[K&M.3=G7+:+Q
M/W2<VY5\1?W2.L VUHCL-K:-A=TST)NB<'C#$VM3>22H+VO5[<'A62!:XJ.T
M#D4WP&05- G[C^JM)=-N)#RRWS%".-SY!XZ3'VV&W1*BG]JB">5DGFR+3!6C
M2NE40C2!.)(G4L+^E"J**4,2,PX##DEZ<M_RJIW#B\\\\IF[<5')I3P]5$GV
MEX$]W8.M4HR2R*_-O%4Y!+6IR6Q.2U%RMQKY7+MHRB]J7-2L\HM, Y/(SIER
MZZU/)F/POE;*:?J/ETEB:FZH W5C$I>[KI-$85'*^)=(M-WAQ1JXXSR2+PV*
M-\M8/1"\Q>!K5":7=C-=E1H \1[2:=.<+G9TNOFO+RD=:7HNNY+=4!G!$.8I
M.TPTU50<!X^3*"/<1=EA2*:PZ;Q6!(G)R+-7,+PVNYB-0T.B4QK :J Q,\=)
ME1/!6I,[?Y,R"SKQL&UJ>NV/6.\U)7NHQ7D\IR%RVO&=L;*H6>E8K(:Y=8;,
MGE@<XA(3E2XQ(K5+=243X<4[I@)Q\5>.#CQTBTI;7^<,,]DLQDPI$ZN<4J&O
MZ4BK624WI&UNC\;A<"1ZTG:4!*4Q5M1(GZ3O:IR<'%2-U+3GE(DX$8IGTTF]
M_P"/=64FQV\8WN=/<DYQR6C$@EM;1ZP8:]R*;3ZT)N;&IW5CPZ)&25,3+NTG
M%,R&#=D*YO>&5DDZ0Y.O3>0P#SL;Z8S_  B 19JAW)5Q;[3AW+Z4\PV6RW"H
M8:>R@E\\KY\KF7Q$ZLV9RC\?+BA[+*'X4?);5S<>PB&TD]YP"VFF+P/5[Z<R
M^,JH_/*CY O]<WI$;AY+6<P64? V&5L*N/<IYT*>6-5\NKY>YHDDAC!3HF8S
MF5Q2/S&^-KBPHG),K*"<L0J ,N4?Q%EU(FI7E!R"D\CF<VNB2W9R9E+M"8B4
M9?ST^08$(:XV6VIRO-ZPBD.1M,/W&$,5-4JTZ&*IVYP7.!CDXKS0)OX P#&E
MT0$^UJ=MBKDSF4RJ;)K2=P%.\GI1K2&D^8Q9UCI3F<B+.3&*RD!CB%48E H3
MC4 *V4$XH0]&! PPT4-8;#3?'VB6N>Q?4"@U8H:DO#2N*.1KY8T2;JA40!-N
M"NB>1)=0%TW)0M\A,6K4\EWMK(/:BRRE!H5X0(.PWIHW \LG'JD^1-WUG8G&
M+BFTO[/5\9A-2N<(LZ=I5=4RVD(P&UI4JFCY'B2F"N9J]IG='"XVTI9<_;2N
MBT#>D)VV"?/S_O\ *@R+2W!B_P!AFO&H'(#D1#K9J7A>0Z"H"/QJL'*&SB2/
MXH&Z55$YC=DF7321-+X^0RN7U\:$A$08(T@>'UT421P"7L)#42!:?@# (T7/
M02VU;DXHVFEDR5E3\;[)G<]7LQ[8<M.EA$QIV<U<4VI%I:U,!H-0*9>2\F*C
MDR\"@A"8B"248H"I* P5R[XZ\P>0E7VY5M><E*_JEEGTZAVV)4FK64[?45))
M6 I/957R"2L=AL[R:ZV$^@/#J;1,Z*N[#%5JUH;M%N)I+PF P\GX,\EC*ZIM
MJ3V=QBK2P.)LY89CQ1.J"BIRQUC&6X,,E5=3J"V1#'ZVWMSDT;F<*EKBV>=1
M^01QY:G+R,@\[7N) .\!*SB?QQFM+*KHL>X; 9+-O7D//FZ=65)(G%U<,A#6
MEC,39H-!X1!XXY/<D=D4;BT:8R=><N[ZX.3N]N3T[J1)]K@I20)@X P"/&N/
MK=KE:+E1J2+?2^^/NJ!_1#S CT;Z.#8P[$U)-N?E_.O/MJ1^C-H-)M)_(:\X
M\OY3_P O ,/3?C;RF>VF%J85SMFD*GL97V22]ORNFZWE$-FD6G$D.>(XUO-<
MGB:T*:0UDT@;8_$Y<W/2=0K3I%JA_;'/;LH(* SCQJH*-<9*9B5.1=X?)(EC
MPWYT>)7)S4ITCF$OF$C=IC-)>^"0ID:$#E)96_/#PH3($B9 A\["A0)R4:8@
ML(&=\ 8 P"%%<<;K4IBM.2[)5]FP]%95SWS;MX0:5RB#.+Y&(2KLMV;7!(T/
M\72R=K628+,0C4)SE"1[9@+#3BCPIR@$B(- BI;/3NOV5ZY5UC7W("M(QQVY
MORI3,KX:9+4+I)+8C3M*X7%8!:*:J941-VZ-E(9?'HBA$P;F4:>SX*Y*E:E&
M)X) E3$ ?M8'3CN5S)O2E*TY"12%\/\ E!-P3BX8*[5NZ2"XF4Q_0QUNMF-U
MC8I4S;8^VL]L)X[HQQ622'/;E&%;[(E+.-2-:CTW@6Y(4:9N1(V]&2!.D0I4
MZ-*07K02R4R4H!!!)8=:UH("R@! '6M:UH(=:UK .5@'"<TFU[<O0A,T4):C
M5)=&[#L>B]J"1E:'L&MAV+0=C[VPZ$'>]:[.W7UX!#BA>.MN<=>+_$_CU [.
MA9RVBFFNH;9$G?8(YKTE@0.)L2MLD#=%VLF4(SH@_/:S36K;7A<M?R&LA,J3
MG-ZT2D!I($4^-'"3F?2]K3^QK%O+C'<;G=LP.7W?8#U2%EI;>D]>@4K"V&LH
ML^;N51$X3$H<Q*M-$6C[5%/0*8WSIX<6YR>7%>O4 =C6/3QNB,*N/U23SD%$
M9CQ"XH68WV=2L!;JT<F6W791"S'DVFXE9U@'3-QC;M'*D-=DQ[<?'(8Q.,F/
MCL;$Z"1!0K0N0%M^ , C5R\H-=R<H"84LW29+$%<G>*Z="Y M;#7A,C#!K+A
M\_.)&WD+6\TX3B3%S&PL859>DQJP"D83@$B), [BU87?LM<'U'6MR1RK8TY5
M1(F%H6AKI++9I';=5NB(Z,SU,L?'<4:<8NT-)2U"YPU?'1'NBA2!42^H-E "
M$"/]"<8;W;>02[D]RDMNM[$LMNIP-$P1GIVN'JN(8RPY;*44SE+^^%R:8S9\
M?)5)WYJ:!%D@<D3'&VY"8C;TBM0N5. @)^X P!@# & , 8 P!@# & , 8!$6
MP.?7"JJI\JJZQN45)PV?MZM&WNT8?I\PHE[$O<1 "@0R$1BOS:.K%@C2])DS
MX>WG&]\.P V'>MX!+-,I3K4Y"Q(>2J2*B2E"92G- <G4)S@!,)/(.*$(LXDT
ML03"C2Q" 8 01@%L.];V!T+?,HDZR:0PQLDK&X2Z))65;*8RC=42E]CJ.2%+
M#X^J>FHH\:YM(>R6]<:U&JR"@+RTB@Q,(P!(]Z Z?^TZ#_VGZIKTX7_:1N"[
MLK4;\U7>5W"M/WZ,[>_/?-O1OD]/G_H=I?///N]O1OFWF^_*X![W & 8OM+=
MT::V[^Q0NL3'OS_?I?5H'2HEKTU^;F=W;<**$'J]K_.O(]NE(0I_-_*;T+RF
M@ZV!A#O\^/U;B)_&W)_08/W5Z5_)/U'?Y\?JW$3^-N3^@P-7I7\D_4=_GQ^K
M<1/XVY/Z# U>E?R3]1W^?'ZMQ$_C;D_H,#5Z5_)/U'?Y\?JW$3^-N3^@P-7I
M7\D_4=_GQ^K<1/XVY/Z# U>E?R3]1W^?'ZMQ$_C;D_H,#5Z5_)/U'?Y\?JW$
M3^-N3^@P-7I7\D_4=_GQ^K<1/XVY/Z# U>E?R3]1W^?'ZMQ$_C;D_H,#5Z5_
M)/U'?Y\?JW$3^-N3^@P-7I7\D_4=_GQ^K<1/XVY/Z# U>E?R3]1W^?'ZMQ$_
MC;D_H,#5Z5_)/U'?Y\?JW$3^-N3^@P-7I7\D_4=_GQ^K<1/XVY/Z# U>E?R3
M]3YL?/GL^A-Q#[?_ '6W)K7A^\#5]RK^67]U)9-GI+T:W^F=(=._F27TKILV
M?MMTX^0+\^TW[5:TIVBTI\KYKM1K1^R/)[.UHSO:P?AAFT1<E]/2#5+$T:9'
M?1@=N8K/43TEZT\^=*>_I"&*ICT.VSS+S381*!:5>=;4ZV'R6BMX&K[_ '9_
MW0QIW^?'ZMQ$_C;D_H,'[J]*_DGZCO\ /C]6XB?QMR?T&!J]*_DGZCO\^/U;
MB)_&W)_08&KTK^2?J._SX_5N(G\;<G]!@:O2OY)^H[_/C]6XB?QMR?T&!J]*
M_DGZCO\ /C]6XB?QMR?T&!J]*_DGZCO\^/U;B)_&W)_08&KTK^2?J._SX_5N
M(G\;<G]!@:O2OY)^H[_/C]6XB?QMR?T&!J]*_DGZCO\ /C]6XB?QMR?T&!J]
M*_DGZCO\^/U;B)_&W)_08&KTK^2?J._SX_5N(G\;<G]!@:O2OY)^H[_/C]6X
MB?QMR?T&!J]*_DGZCO\ /C]6XB?QMR?T&!J]*_DGZCO\^/U;B)_&W)_08&KT
MK^2?J=LP#YM[?&?4H3\6M1OTFA]/[85EL">],WG)?I+;0%P0A0"<M)/*^9:6
M""EVH\GY<6B^]@:ON5?RR_NI*G!^# & , 8 P!@# & , \=8OZ4?V?SK]".[
M^FGZ'2;]$>_W>Y^D_H5;Z![_ '^P'=]*^:=[O_W>SM[WT=N 4C<;%K&U=(Z+
M/O'=-QQ<9['JX?G_ )8L?):,.DK+D5P,L>>5_))@MEI;'M@D>[*=;'3.J18;
M,3U)&F\90!(U#88V=T#UD!Y\V X5-S!GC^_06ODE4=._C3R6K./I6UL0,4+E
M-H439LQ=MH2W 8U+O'2I9&F1K96QP-5EE!1 :BO*&JQ@, Q?).;-^-CZ]L[$
M_5_#9-:[7TNH%_;2]01C.058Y<H(E9+A/+!E 2MMH9.(M>PI8]73%)'(,<:)
M=)F=(8$+8K7)5(&#N1EZ<A.&/)_D5)2+Y9N45B0KAE2\?A<F>X57S'+:Q3W9
MRP8H0J<[/9XFX02O7I+&1.9\NBYBP<$1*T!9+=*W!,V%'2,Y\_/C!-_CS9O-
MF4RRUZCL&SY% 6%FCM,S^)W7>\:XH[LUG=G:R!-\OK5UKJC[1=XVLA]DQML-
M;J]FCJU1]S:716]HR5,I7-J#>/GY^?1_,%T&OJUV_7_G@# & , 8 P!@# &
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M!" 0C  2I3EB*3D%"[.\6246+L^KO  $.^S_ -NW7T8!^V , 8 P!@# & ,
M8 P!@# & , 8 P"F2]: Y[3KFF.[U56<:;XI2H!,YW$^NI[?T\K-L@,I.92R
MY9;<UB#50]AMTLM0YQ4K6B'/"I\&W0B.$:-8FXA]=%SH$"X]N&O,;T!CJG3)
M'0Q$E&Y)42DQ8C3+QD $L3I%9J=(:J3$J-F%D*3$J8P\H(#1IR1"V6$#F8 P
+!@# & , 8 P#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g425213g11m21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g425213g11m21.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[26@4&AO=&]S:&]P(#,N,  X0DE-! 0
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M<')I;G1E<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,
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M      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0
M     %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6)
M;^            !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M             $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X
M;$![!#UP        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !0
M9U!S     %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N
M=$8C4FQT                4V-L(%5N=$8C4')C0%D            08W)O
M<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P
M   ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M        "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "
M  $#O_XU  (  3A"24T$)@      #@             _@   .$))30/R
M   *  #_______\  #A"24T$#0      !    !XX0DE-!!D       0    >
M.$))30/S       )           ! #A"24TG$       "@ !          (X
M0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M  $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M     '   /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H
M /____________________________\#Z   .$))300(       0     0
M D    )      #A"24T$'@      !      X0DE-!!H      S4    &
M          1(   'IP         !                          $
M        !Z<   1(                      $
M    $     $       !N=6QL     @    9B;W5N9'-/8FIC     0
M %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M0G1O;6QO;F<   1(     %)G:'1L;VYG   'IP    9S;&EC97-6;$QS
M 4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M  =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG
M:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   $2
M  !29VAT;&]N9P  !Z<    #=7)L5$585     $       !N=6QL5$585
M  $       !-<V=E5$585     $       9A;'1486=415A4     0
M#F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0
M"6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0
M   )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L
M=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4
M3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
M       ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG
M       X0DE-!"@       P    "/_         X0DE-!!$       $! #A"
M24T$%       !     @X0DE-! P     &M\    !    H    %H   '@  "H
MP   &L, &  !_]C_X@Q824-#7U!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R
M4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M         0  ]M8  0    #3+4A0("
M                                 !%C<')T   !4    #-D97-C   !
MA    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G6%E:
M   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q    (AV
M=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $#
M "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#   $
M/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA
M<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M         !)S4D="($E%0S8Q.38V+3(N,0
M                                        6%E:(        /-1  $
M   !%LQ865H@                     %A96B        !OH@  ./4   .0
M6%E:(        &*9  "WA0  &-I865H@        )*    ^$  "VSV1E<V,
M        %DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%0R!H
M='1P.B\O=W=W+FEE8RYC:
M                      !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E
M9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)14,@
M-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                        9&5S8P         L4F5F97)E;F-E(%9I97=I
M;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E9F5R
M96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                         '9I97<      !.D_@ 47RX $,\4  /MS  $
M$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P         !
M                     H\    "<VEG(     !#4E0@8W5R=@        0
M    !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@
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M)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB\&-#8Y=CZV1
M9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(:@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0'_P  1" #S ;,# 1$  A$! Q$!_\0 '@ !  (# 0$! 0$
M          @)!@<*!0$$ @/_Q !H$   !@(! 0($#@T%!A /   " P0%!@<
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M5M4\C;C6SXR+XZD4HTXB'!Z1N+U]>3U QB[N.:'B/%N-DT3V79\-NB"RRY3
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M%KKT$R-(M==;UOIM GWKKK>M;UO\^MZUO7DWKKD@]O & , 8 P!@# & , 8
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MM(2RRB\Y99["J/TM2]O\OU[_ ,<._P#V!FA_H5B?]_9_YZO^B4/_ ,%M)_\
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M_P!,$C -27[[!UP?NTFWT<<< V0R_B9I]S$'R4K /3P!@# & , 8 P!@# &
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MZ.J_$S,U[+G\.W_Z,2^-\SU:#=IB/WK;FK&3X#^UQ_\  \]R6Y9OQ?PP!@#
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MK\3,S7LN?P[?_HQ+XWS/5H-VF(_>MN:L9/@/[7'_ ,#SW);EF_%_# & , 8
MP!@# & , 8 P!@# & , KLY \);6LZ]YI>E.\M9)Q[7V704"X^V#&T%/5K9S
M=((S7<LN25L3FF6SDLQ8R.6S;LE*)4%NT LXDA :(6S2M=T1U:Y3VN'O$V_>
M+K-7E?RCF5(+OINK:K8*JAE;O5&U5!CD#9$&5CCD2<E4SB9(9&X+&=D9=)#2
MU1HRG,Q48J6[$>67O 2?*LO DLOS_=XB?."1@# (A=H#YC7+W^'"X_H&^9#W
M>N/.@2CC?K=8/<5J^0D9(/:P#4+G8,K16XQUP1"D"IE>F!SDFI8.5A3J$S>S
M*6A Y W'MLAHS5(5[VA+3%A=0 /(TH/&82(L!)H&WL 8 P#G*YM^<]:/]=8O
MHNR94&E/'5YXZ7P]$X\X3>_;&OOVOP5N6H=GCYM[7[ZY1\K)S>-$.):7E[CW
MR]>"+O,M_/K[I(DY<V<LX8!4%VF<A?VF35N@:WMV;D+C%Y"6X(D+BK2I%Y9C
M@02,M8G(- 2I ,D8BAA. ,(RQ;+%K8-[UNO]-+BXH5[!4:]:BI4JSDJ56=-2
M:G#)RU)+-KP9YY> Y^X:+^^L[[!(VEY=6T:EI=.<;>O5HJ;5:"3DJ<HJ32;6
MW/8>MV9\ED;^Z6R6^O[R\EHV^'^*%NKFM< )?"'R )GBX%1QH2>^$HO0_!Z#
MWM !K?J!UK7TT+N*]=W_ &:O6K:JH:O9:DZFKFZN>KKR>6?ARRSV9[D??@6O
MKV\JZ0*[N[FZ5.GA_8U<5ZM90UI7>MJJI*2CGJK/++/)%L^;X7T, _(O0HW1
M"L;7!,4L0."50B6I#P:,(5)%10R%*<X&_4&4<2,99@-^H( MZWZF\ T#Q?C;
M#':P-TQM*)KTMGMJ;5Z1DZ*\8VW6?,&E!X7>O5%I&V(DB!,'?WI"1,0G+T$H
MH = 2)P!@&B.3_F]7#[Q'SY-O,9C/%=]YM6Z.1K&FG>GI#Z*N^B9SK5/[*-<
M>_J)_/J#*?PWC&P\]M>GIG'^CO'^">E;#XJD=3X?)K]6OBR\SN<^X!\%Y-_J
MW\6 <G,C]<+][LNGRX_*&K]TU?*R]XX)ON[;SSJXZ:9T\4E[#=4?NXA/T<;<
MNW#N+['S.UZ"!VYHWWO8%Z'PWX.B;/SV&:& <Z?.3SGK*_:1SZ*LN4_I1QY>
M?L>@IG'_  H]^^,?@O@;8M"[.OS;F_WX2G^V29O6B7$U+RU;WD7AP0=YE#TA
M?]) G5FS%H# *6.T^]D:M?>8N^>E65OIQW78^;U.D1S=PW\;8+Z.J_$S,U[+
MG\.W_P"C$OC?,]6@W:8C]ZVYJQD^ _M<?_ \]R6Y9OQ?PP!@# & , 8 P!@#
M & , 8 P!@# & , 8!XTB,7%1]\-:P&F.1;.YC;@$!T,X:X"(X20!(=ZWH1@
ME&B] #O738MZU@%,?9HV#/")5"J\Y1S;G>Q<J'^A=2][K/E+NOP5--#VE?%D
M=DR^EQP1I4%F[ALB=FAN.:'V1(9&T,<I1'K8Z84M"L31X?#U_P!NN>T;+YY<
MTJ(<N(G+2&)3[9V^JZ,N&.DZ4<=.0J-I]%!Q!\;PZ-D:NKR(\0@\9]03N>Z%
MM("?YV-:%+_+8>WVK]S3!:?&1:%&X^+77H)D:MZZZWK?3:!/O776^F]?JWKK
MD@]@S>PEF"UY= %O7Z]!WO!#>2;Y%F<TSYR1O4$M5NP;/E.G)L&\LR!;X]_.
M4K4K<2#U2$DSN:[B<\YM0F& UKU1I2M]==WIE-UL>QB-6K&.(7"2J5$DG'))
M2:2[4XXNM.]+X7=>$<?Q!1A7JPBE6V**FTEEEEN2VY9KP,Z(*L<5SO6E?.KF
MI-6N+E"XRO7K#Q=XY4L5LR,]2H.%TUWC3CC!F#%TUU$+>^F6W93E4L[2<Y.4
MYVU"<Y/?*4J49-O[6WF^4ZUP6M4N,'PJO6G*I6K8=95:M23SE.I4MJ<ISD_#
M*4FVWX6V9YGI,F, YRN;?G/6C_76+Z+LF5!I3QU>>.E\/1./.$WOVQK[]K\%
M;EJ'9X^;>U^^N4?*R<WC1#B6EY>X]\O7@B[S+?SZ^Z2).7-G+.& 4U=J%Z\*
MJ][3]\Z)<KG3CNC#_(U_?@<Y\.'&& ^9W?3TST^RY_&]Q>Y\,^423/KH-OQ'
MQ6_/5/1P&_6Z1^3PWWKPN"RP3H08 P#2/'GV,2O?Y</_ .7YU@&[L 8!HCD_
MYO5P^\1\^3;S&8SQ7?>;5NCD:QIIWIZ0^BKOHF<ZU3^RC7'OZB?SZ@RG\-XQ
ML//;7IZ9Q_H[Q_@GI6P^*I'4^'R:_5KXLO,[G/N ?!>3?ZM_%@')S(_7"_>[
M+I\N/RAJ_=-7RLO>.";[NV\\ZN.FF=/%)>PW5'[N(3]'&W+MP[B^Q\SM>@@=
MN:-][V!>A\-^#HFS\]AFA@'.GSD\YZROVD<^BK+E/Z4<>7G['H*9Q_PH]^^,
M?@O@;8M"[.OS;F_WX2G^V29O6B7$U+RU;WD7AP0=YE#TA?\ 20)U9LQ: P"E
MCM/O9&K7WF+OGI5E;Z<=UV/F]3I$<W<-_&V"^CJOQ,S->RY_#M_^C$OC?,]6
M@W:8C]ZVYJQD^ _M<?\ P//<EN6;\7\, 8 P!@# & , 8 P!@# & , 8 P!@
M# & >6]M87QF=F8:UR;0.S:M;1.+,M-;7= %<F,3"6-3B1O1Z!Q2Z-V<B6$[
MT:E4@*/+^^!K (5T?PO>:WM9@N.VN2=N\F9G7U>O]65*KLYMK]E+@40EKC'7
M&7*CPP**QH4QFTHW$(LB>)I)A*W$Q"S!)2$)#7%V/7@97V@/F-<O?X<+B^@;
MYD/\USH$HXWZW6#W%:OD)&2#UCO[T;^S'_F[P1+<_$^8Y.7_ /'KU[K./RP[
M*$K_ %];RM3WY'!=YW=<^<U>DD=0--^Q'6'O B'S"@R\+#N&R\TMNA@=O:/\
M18+Z*P_X2D;)SUF7& <Y7-OSGK1_KK%]%V3*@TIXZO/'2^'HG'G";W[8U]^U
M^"MRU#L\?-O:_?7*/E9.;QHAQ+2\O<>^7KP1=YEOY]?=)$G+FSEG# *:NU"]
M>%5>]I^^=$N5SIQW1A_D:_OP.<^'#C# ?,[OIZ9Z?9<_C>XO<^&?*))GUT&W
MXCXK?GJGHX#?K=(_)X;[UX7!98)T(, TI>UY1R@HBDF$G;'=U0+'I,R%IV8*
M42D*A4F6*@&CTL4)B_ A B,"+H9L?>&#H'IWA:QV)XE1PJW5S7A4G!U%32I*
M+EK24I+MI16647GM-;THTFLM%,.AB5]1N*]*=S"V4+90=37J0J34GV2<(ZJ5
M-I[<\VMF6;46^)/*R$31<VT^V,DC(?%SQ94F+<59;>%L E=Y=)IF2G'LI8:I
MT>4@=24QG=(V7XT69H A%=TS>/PW22RQ.Z5I0I7$:CA.:E4C!1RADWMC.3S:
M>S8:[HWPEX/I/BE+"K.SOZ->K2K55.XC05)1HPE.2;A5G+-J.SZ.6;2>18?F
MPEC# -$<G_-ZN'WB/GR;>8S&>*[[S:MT<C6--.]/2'T5=]$SG6J?V4:X]_43
M^?4&4_AO&-AY[:]/3./]'>/\$]*V'Q5(ZGP^37ZM?%EYG<Y]P#X+R;_5OXL
MY.9'ZX7[W9=/EQ^4-7[IJ^5E[QP3?=VWGG5QTTSIXI+V&ZH_=Q"?HXVY=N'<
M7V/F=KT$#MS1OO>P+T/AOP=$V?GL,T, YT^<GG/65^TCGT59<I_2CCR\_8]!
M3./^%'OWQC\%\#;%H79U^;<W^_"4_P!LDS>M$N)J7EJWO(O#@@[S*'I"_P"D
M@3JS9BT!@%+':?>R-6OO,7?/2K*WTX[KL?-ZG2(YNX;^-L%]'5?B9F:]ES^'
M;_\ 1B7QOF>K0;M,1^];<U8R? ?VN/\ X'GN2W+-^+^& , 8 P!@# & , 8
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MD9G6/O?/WE@N9WMO5M;FCW&N(Q.E2!<2-.J(\,GXP%'E>%),&#PA)I9H.O>
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MDMK0[/VG"Z2E_<I1(%NMJ#3S?"NC^\.;HHZF;!I0L-T6$LON%A RS & , 8
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M[EX'QP>I#8TEE<B\7'L@O92'T5\13"[XDR8G9INQR#;& , 8 P!@# & , 8
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MEH$2(E(B9G7K[07<X P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
=# & , 8 P!@# & , 8 P!@# & , 8 P!@# /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g425213g12u12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g425213g12u12.jpg
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ME9;4(D&3(R08)3)10F$9)C,V4G&!L<$*)S1&<I'_Q  < 0$!  ,! 0$!
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MA$*ZJ;;<L:@]UA"\4A$#9S19;AY3E%YF]LHR&O$*0T/BAA.C>K#7[8<IY0^
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M>^?&>&6?]E:[DN^I]?D?. )VRGCN*5SA^_SY@#]&V5%5/R-1>F,S 077P0X
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MF.2UEX;[P_##]B>_^M3$N^K H+W9]"=AB5.FN_$^+#6O@R_ZS@RTHS+P\56
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M;'LTI3J;T  +9%@AN+O5R@VQ<%F(+-+:<<1J5;]&SF/6:G<KPV:\D<L>N^"
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MDORT_;YN(=OM^7M)WBSW-TCFILNLD!92R$,@6R;%J^8Y^62BC<-K4%]UN,8
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MJU&39!IF;P[(WUW2^(@4PK:C80I0^HTF!('=&O#="H?6_-8L JOXFYK"TZ%
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MWL5PE9KDP-5AD%(T8>HU<R_>_>F'HW(#&2#<Q'R2GU!9[G*K,I1A9&%OODU
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M'PKAFH+(#7L,>*<"QS495EKH)<+>NL'.:'I32COL9=5ZDO'"*P9V]*EF2PN
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MAMZI]@;)1^%2F-V9GY=JSR6)"3(SBRL@"/G^H?N%Q\Z](O9M'>O70C5[3&%
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M(M9M-;D\DOTZRQ?<PQ11ZS:8SK)K]ALO#-I89C*GTNKA]1XF'&6%S63!+26
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M1:<>^RS[FMWK([@O07H2'S#V8M7EF10;NBC1Y(#4$5V"A,UU(=#"PZA:I>^
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MRSHWL(IG]>8-0]+?2@=6K9;+0MH0!>TWKJO+=KI@@<K25!"@RL?8RM<"T&S
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M\I,S:Z!VC4'^%?T*7^<JOIO_ %?T@T[LTK<<S/\ IX7MQSMFJT_AYOY7#_\
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M$\(N&>O#9CS#/IB2/;Y?5KGY_+/R_P#U?+/\?XXS_'^[.<>")S4(#@01(/\
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MG^&<9QGY9QG^&<>,LD47REKF=9]?Q^,?KYQG.V)Y_JB^6WU8Q!G,F?TL?/\
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ME; IM:3X>K$%&DV2])D4&1KO!,>N=)FML_6(34Z<P2*P.<B95>9VI[5 20@
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MD-U3.W="LT2\JFNB!BDM;M:)TUF^=\RE$ ''G;T/V(YZ&(@S&G[J=Y;.KJ%
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M!5\J: W0[U$=HM(E37@A&?EZL8>+A<,Y,D!4(+=NG+-Y>5]UI"93XMIZ970
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M.NVN(\U?IVQMT7#8%0M=6V;3J$!H._6JN=:=X!SL.Z&FP:/J#8,ATVF[7_\
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MM?5#))%[>7(3D;WMYGGI9,B)[?R>KRFG2:&I.BZ]5,[,,L#VP4'/7E,LC?>
MR6R$7L7*RY)PFYE2H0##?;6_?H+&DQG5O:L#Y^0G"&)Y6_GAWCT5$%N$?$AD
M3 I6/J[!+T8N,7A[-6JO4EP>#;Q/KKQD&N-P891?^8J0U7"=W@[TPO\ 5VJN
MT3C^XU:\=Y+U-= @%8*26R;6X>4DZ&Y],HD+8/VJYY[C,W3B!/U^9#0I?O\
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M:YI:BKFB2J5-(9Y<E=@E/%^I-("+[$J]68I+$*T^J<IIK\_B:FP\;C,7A\0
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MT7BB6N)\=N]3L;B ;V^DWB#QG19O2363&=M,YSC&VVF<YQG'\=-LZ[?+Y_\
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M22;Z10UZE>S;M3R1P5X99I---O'$8BCA:-3$8AXIT:+"^I4()#6C,PT%QY
MDFP!*U<=C<+LW"8C'XZLW#X3"4GU\17>'%M.DP2YQ#0YQC@UK7.<2 T$D!>;
MUEYX?\0M1(-_&*Y:J0X^07+>#] 794>LK94ODU/)"'LQXL4M*45,=6GWBU_<
M0L_%:)CK5;76E/5O=+\+;>V1M&D? QCW[]1[:E)['T6X*H SP*E0U*>ZY^(
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MLBU@+@B2?KGRG=M-LCR6-2GBS3<T5 *CZCOK87-8P'!N8T@$O<Q@Q0:_=!?
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MS3;<:*H<TODV^D'<GRL3"N'V9CFX#\+,_+5FOP>*K5*[=UP=1:[&,JL=4&;
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M[I)_T=XMJ>@]TOH.I]D^Z;O\#7/]TD_Z.\6U/0>Z7T'4^R?=-W^!KG^Z2?\
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M:/\ 2^B;761)VUUET_0A^B3&,;Z_HQ?+./T]/DMJ>@]TOH.I]E]1#RU>>.S
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M$<[HOPW<EL&ZFKV!M.]@(3ZO[%$MRI]FKGJ;&FN-6Z9H#P[*&ID(' ]^;OV
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MH$07$/G]4-/<6'UB)<!H7Y%[6ENPR[P47W5CM;Y+YYLPVR>#D,8_0AH5@?\
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M=^$-2EGKBX+,LD-#2S;^UCBVMV=I2*0^$3PB>$3PBCVJDKZM<KUJOA\.<R_
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M\3EZ?2>35?JZ$O'&.W'^>ZA!D?Z-5VF[RH]OZQ5'@2K5%F_SPF1YI4<1"B$
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MS>ZB:=-O!*=F4?=FGMYUMG%]IO7ZYFI)#3N4L,BS]K'4SO0OQ2W-MZ_RU/\
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MY:DGBY%9%;E+0I34LG"A(B([?^7V/4VN5,/5KUF]G>6=@M/O:NW%^CC+2!>
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M&_\ )\0=#T*2-1U"?N]3_FA=_P!;&_\ )\0=#T*2-1U"?N]3_FA=_P!;&_\
M)\0=#T*2-1U"?N]3_FA=_P!;&_\ )\0=#T*2-1U"?N]3_FA=_P!;&_\ )\0=
M#T*2-1U"?N]3_FA=_P!;&_\ )\0=#T*2-1U"?N]3_FA=_P!;&_\ )\0=#T*2
M-1U"?N]3_FA=_P!;&_\ )\0=#T*2-1U"?N]3_FA=_P!;&_\ )\0=#T*2-1U"
M?N]3_FA=_P!;&_\ )\0=#T*2-1U"?N]3_FA=_P!;&_\ )\0=#T*2-1U"?N]3
M_FA=_P!;&_\ )\0=#T*2-1U"?N]3_FA=_P!;&_\ )\0=#T*2-1U"?N]3_FA=
M_P!;&_\ )\0=#T*2-1U"?N]3_FA=_P!;&_\ )\0=#T*2-1U"?N]3_FA=_P!;
M&_\ )\0=#T*2-1U"?N]3_FA=_P!;&_\ )\0=#T*2-1U"?N]3_FA=_P!;&_\
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MO4_YH7?];&_\GS*#H>A7I(U'4)^[U/\ FA=_UL;_ ,GQ!T/0I(U'4)^[U/\
MFA=_UL;_ ,GQ!T/0I(U'4)^[U/\ FA=_UL;_ ,GQ!T/0I(U'4)^[U/\ FA=_
MUL;_ ,GQ!T/0I(U'4)^[U/\ FA=_UL;_ ,GQ!T/0I(U'4)^[U/\ FA=_UL;_
M ,GQ!T/0I(U'4)^[U/\ FA=_UL;_ ,GQ!T/0I(U'4)^[U/\ FA=_UL;_ ,GQ
M!T/0I(U'4)^[U/\ FA=_UL;_ ,GQ!T/0I(U'4)^[U/\ FA=_UL;_ ,GQ!T/0
MI(U'4)^[U/\ FA=_UL;_ ,GQ!T/0I(U'4)^[U/\ FA=_UL;_ ,GQ!T/0I(U'
M4)^[U/\ FA=_UL;_ ,GQ!T/0I(U'4)^[U/\ FA=_UL;_ ,GQ!T/0I(U'4)^[
MU/\ FA=_UL;_ ,GQ!T/0I(U'4)^[U/\ FA=_UL;_ ,GQ!T/0I(U'4)^[U/\
MFA=_UL;_ ,GQ!T/0I(U'4)^[U/\ FA=_UL;_ ,GQ!T/0I(U'4)^[U/\ FA=_
MUL;_ ,GQ!T/0I(U'4)^[U/\ FA=_UL;_ ,GQ!T/0I(U'4)^[U/\ FA=_UL;_
M ,GQ!T/0I(U'4)^[U/\ FA=_UL;_ ,GQ!T/0I(U'4)^[U/\ FA=_UL;_ ,GQ
M!T/0I(U'4)^[U/\ FA=_UL;_ ,GQ!T/0I(U'4)^[U/\ FA=_UL;_ ,GQ!T/0
MI(U'4)^[U/\ FA=_UL;_ ,GQ!T/0I(U'4)^[U/\ FA=_UL;_ ,GQ!T/0I(U'
M4)^[U/\ FA=_UL;_ ,GQ!T/0I(U'4)^[U/\ FA=_UL;_ ,GQ!T/0I(U'4)^[
MU/\ FA=_UL;_ ,GQ!T/0I(U'4)^[U/\ FA=_UL;_ ,GQ!T/0I(U'4)^[U/\
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M%M'>E(K<"<K0'AO1[756)4H]UZ5SY$H)C[3(\W0:X/K](2^6&Y?YN"M-LSO
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MU*\N+CFH<M?O3!:[#;A'5JLAB2,?L2# / WS$Q,3$SG;)7>H=HY8\QJ6J\\
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M,%4EB+%)AVO[7O:E+Y_+1[A5Y9]>O11V-9=-6,(99>F.?VP!Q$>R#Q^X;[:
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M5ZLT$I3;4=%MO=VU@R2#E%]%(J'7>8D9-*\;TL4[TM!G,1"BYBD%,R@DTP2
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M/<LFYS#,U]!9G(DG++@?Y\NW#(1LB;X!R!BJ\YHEDNG/3Y-2IC.?U8")L?7
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M"?U5AB^A* N+-?8DWG+/*!F.%K<-=5T&;X;4S<<V.&.Y7X-BI:\U,XT"G%@
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M;*E>9S\U:2AIF*%)]?GE/?SD66S_  ;GE_D_&>9\Y+WJI,THIP00=OC_ -;
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M1JU6TW&G3!?CW84QO6I@M@Y_KAUS^DD&!!MV,)MS$8AE%[J-%IJ[7J[/(&_
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M]>>*.'6W_P"CM\M:>V^LD/R^O.<ZX_\ IV^6V-+$5F-;BYH,?N"B7 _]7><
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M!Q6QGK9QI Y4(8K*#T5OZ50OSBN?R$VLHJE<@*_"]"'**R4/G5556BVV3;8
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M+J@?7B<31I5:[W9EP>YI-)LW93I;E.E84VMB5MT\#A6,:TT:=1S<JE1C7OF
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M9$B?U"E=L^PMC"_5B)-WJ6G+MT(6'\4*%B>]^_[9K]LE28%I.GH"U J5%[,
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M";.QU>E6J"FS$4\)B'X?>+]PS693=3#6.!#SO0S==O1!7FZK39.\]C2!)!<
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M5+-0-&?9$_1(#)1X#26\ OU_;)^M#9ZQ>3%BE12I=+DVM$K*?)R\_P!O98)
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M .8+_:5FN0T@(.H?DK3TAL A-J,J@3O;:7[?0[52L;6W_G5L!I^0MF1_0L2
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MY^Y"Z2R3O4"@ L:FHM(@DZZ1T%NX!/EZ+*X](EYBX3ZV<C?.@-VY[U\3U<)
M^I55.#,)<\(7 H4R?#F3ZBS'D&^4L"I)ZA[GA-1<!M.[;'U6..K;MPS$FY,
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M+JBJX)]G\F)(2DC+G&5\UL-MV#OB4FJW2.D@^4$D<A'S'4_93MVH69JS=,Z
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MR*6!Q6)_P[#M?1PU:L*>'+L.UWATG/ +Z0IF9;8EA.4-WC?T8ZHY[6N<[=)
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MFQGF+:&W9I;"<$A)@>.)%I\O69^T?.,.7OBC\]*S0SV^/]CE$,UNJ=0Y5H&
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M#GJ"$W8.DA%,S25X'44]KG) 4KTP+\S1I#NGC\WZ46M+!6^N7/A,V];VRS7
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MG9Z6[GSFBL+9,BVK8VM$5@\.,<<[>>AOH#P"X&;I'P];%Y6!7>.<KOK1 )O
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&PB>$7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g425213g17k03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g425213g17k03.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1]Z4&AO=&]S:&]P(#,N,  X0DE-! 0
M    'UZ^@# X0DE-! 0      $@< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<<
M @   @  ' )0  A4:6T@4GEA;AP"!0 74&]W97)0;VEN="!0<F5S96YT871I
M;VXX0DE-!"4      !!"2?(2Q1RH\=@5/H8JC;9L.$))300Z      #O
M$     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN
M=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M      MP<FEN=&5R3F%M951%6%0    & $$ 4 !$ "T ,@      #W!R:6YT
M4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <
M"G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@
M  EP<F]O9D--64L .$))300[      (M    $     $      !)P<FEN=$]U
M='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;
M4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O
M;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP
M $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M        1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M     %)S;'15;G1&(U!X;$!RP           "G9E8W1O<D1A=&%B;V]L 0
M  !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M            5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C
M0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T
M0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O
M<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))
M30/M       0 )3,S  !  $ E,S,  $  3A"24T$)@      #@
M   _@   .$))30/R       *  #_______\  #A"24T$#0      !    %HX
M0DE-!!D       0    >.$))30/S       )           ! #A"24TG$
M    "@ !          (X0DE- _4      $@ +V9F  $ ;&9F  8       $
M+V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $ +0
M  8       $X0DE- _@      '   /____________________________\#
MZ     #_____________________________ ^@     ________________
M_____________P/H     /____________________________\#Z   .$))
M300(       0     0   D    )      #A"24T$1       $     (   )
M   "0      X0DE-!!X       0     .$))300:      -!    !@
M       $;   !V@    & &< ,0 W &L ,  S     0
M       !              =H   $;                      !
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M;&]N9P  !&P     4F=H=&QO;F<   =H     W5R;%1%6%0    !
M;G5L;%1%6%0    !        37-G951%6%0    !       &86QT5&%G5$58
M5     $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$58
M5     $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@
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M       ! 0 X0DE-!!0       0    @.$))300,     !2N     0   *
M  !@   !X   M    !22 !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4
M9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,
M#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.
M%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,
M# P,# S_P  1" !@ * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
M         P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)
M"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$
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M@961TIWHUMIK=0ZL%A:"XCVM<UNU F@3V1*7#$R["U/Z5U.VQ[W4MK/?9F9
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M?^<6L6O8QQZV[TW%EC\,
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                 /_A3>)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O #P_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP
M0V5H:4AZ<F53>DY48WIK8SED(C\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O
M8F4Z;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#<N,BUC,# P
M(#$Q-BYD964S83<W+" R,#(R+S Y+S Q+3$S.C4W.C X(" @(" @(" B/@H@
M(" \<F1F.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO
M,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N
M(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7 ](FAT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"\B"B @(" @(" @(" @('AM;&YS.G!D9CTB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(*(" @(" @(" @(" @>&UL
M;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(@H@(" @
M(" @(" @("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O
M,2XP+VUM+R(*(" @(" @(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT(R(*(" @(" @
M(" @(" @>&UL;G,Z<W12968](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"]S5'EP92]297-O=7)C95)E9B,B"B @(" @(" @(" @('AM;&YS.G!H;W1O
M<VAO<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W O,2XP+R(*(" @
M(" @(" @(" @>&UL;G,Z=&EF9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]T:69F
M+S$N,"\B"B @(" @(" @(" @('AM;&YS.F5X:68](FAT=' Z+R]N<RYA9&]B
M92YC;VTO97AI9B\Q+C O(CX*(" @(" @(" @/'AM<#I#<F5A=&5$871E/C(P
M,C,M,#<M,#-4,C,Z,3(Z-#DK,#4Z,S \+WAM<#I#<F5A=&5$871E/@H@(" @
M(" @(" \>&UP.D-R96%T;W)4;V]L/D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I
M;F1O=W,I/"]X;7 Z0W)E871O<E1O;VP^"B @(" @(" @(#QX;7 Z36]D:69Y
M1&%T93XR,#(S+3 X+3 R5#$S.C(T.C(R+3 W.C P/"]X;7 Z36]D:69Y1&%T
M93X*(" @(" @(" @/'AM<#I-971A9&%T841A=&4^,C R,RTP."TP,E0Q,SHR
M-#HR,BTP-SHP,#PO>&UP.DUE=&%D871A1&%T93X*(" @(" @(" @/'!D9CI0
M<F]D=6-E<CY-:6-R;W-O9G3"KB!0;W=E<E!O:6YTPJX@,C Q-CPO<&1F.E!R
M;V1U8V5R/@H@(" @(" @(" \9&,Z8W)E871O<CX*(" @(" @(" @(" @/')D
M9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D^5&EM(%)Y86X\+W)D9CIL
M:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+V1C.F-R96%T
M;W(^"B @(" @(" @(#QD8SIT:71L93X*(" @(" @(" @(" @/')D9CI!;'0^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M9&5F875L="(^
M4&]W97)0;VEN="!0<F5S96YT871I;VX\+W)D9CIL:3X*(" @(" @(" @(" @
M/"]R9&8Z06QT/@H@(" @(" @(" \+V1C.G1I=&QE/@H@(" @(" @(" \9&,Z
M9F]R;6%T/FEM86=E+V5P<V8\+V1C.F9O<FUA=#X*(" @(" @(" @/'AM<$U-
M.DEN<W1A;F-E240^>&UP+FEI9#IF.#$Q.&%A,RUA-68V+34X-#$M.6-D,2TU
M8C(T,60W834S,F,\+WAM<$U-.DEN<W1A;F-E240^"B @(" @(" @(#QX;7!-
M33I$;V-U;65N=$E$/F%D;V)E.F1O8VED.G!H;W1O<VAO<#HV,#-A-3-A-BTR
M938R+3AB-#(M.&(Q,"TS-C4U9F$U965F8F0\+WAM<$U-.D1O8W5M96YT240^
M"B @(" @(" @(#QX;7!-33I/<FEG:6YA;$1O8W5M96YT240^>&UP+F1I9#HQ
M.3=B960T,RUC-&4Q+3$Q-&(M.65E92UA-V(P9#!C93=E,3$\+WAM<$U-.D]R
M:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @
M(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C$Y-V)E9#0S+6,T93$M
M,3$T8BTY965E+6$W8C!D,&-E-V4Q,3PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @
M(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,RTP-RTP-%0P,#HP-3HS
M,BLP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P(#(S+C4@*%=I;F1O=W,I
M/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^
M<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.FEN<W1A;F-E240^>&UP+FEI9#HV-#@P,C8V8BUF-#9A+6$R-# M.6(U,2UD
M960P.34Q,S)F8S@\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IW:&5N/C(P,C,M,#@M,#)4,3,Z,C0Z,C(M,#<Z,# \+W-T
M179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G
M96YT/D%D;V)E(%!H;W1O<VAO<" R,RXU("A7:6YD;W=S*3PO<W1%=G0Z<V]F
M='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^
M+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F-O;G9E<G1E9#PO
M<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE
M=&5R<SYF<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@
M:6UA9V4O97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N
M/F1E<FEV960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.G!A<F%M971E<G,^8V]N=F5R=&5D(&9R;VT@87!P;&EC871I;VXO=FYD
M+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A;65T
M97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#IF.#$Q
M.&%A,RUA-68V+34X-#$M.6-D,2TU8C(T,60W834S,F,\+W-T179T.FEN<W1A
M;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C,M,#@M
M,#)4,3,Z,C0Z,C(M,#<Z,# \+W-T179T.G=H96X^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<" R,RXU
M("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @
M(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @
M(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @
M(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @(" @(" \>&UP34TZ1&5R:79E
M9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \
M<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED.C8T.# R-C9B+68T-F$M83(T,"TY
M8C4Q+61E9# Y-3$S,F9C.#PO<W12968Z:6YS=&%N8V5)1#X*(" @(" @(" @
M(" @/'-T4F5F.F1O8W5M96YT240^>&UP+F1I9#HQ.3=B960T,RUC-&4Q+3$Q
M-&(M.65E92UA-V(P9#!C93=E,3$\+W-T4F5F.F1O8W5M96YT240^"B @(" @
M(" @(" @(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^>&UP+F1I9#HQ.3=B
M960T,RUC-&4Q+3$Q-&(M.65E92UA-V(P9#!C93=E,3$\+W-T4F5F.F]R:6=I
M;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/"]X;7!-33I$97)I=F5D1G)O;3X*
M(" @(" @(" @/'!H;W1O<VAO<#I#;VQO<DUO9&4^-#PO<&AO=&]S:&]P.D-O
M;&]R36]D93X*(" @(" @(" @/'!H;W1O<VAO<#I497AT3&%Y97)S/@H@(" @
M(" @(" @(" \<F1F.D)A9SX*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QP:&]T
M;W-H;W Z3&%Y97).86UE/F$\+W!H;W1O<VAO<#I,87EE<DYA;64^"B @(" @
M(" @(" @(" @(" @(#QP:&]T;W-H;W Z3&%Y97)497AT/F$\+W!H;W1O<VAO
M<#I,87EE<E1E>'0^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @
M(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @(" @(" @/'!H;W1O<VAO<#I,87EE<DYA;64^9#PO<&AO=&]S
M:&]P.DQA>65R3F%M93X*(" @(" @(" @(" @(" @(" @/'!H;W1O<VAO<#I,
M87EE<E1E>'0^9#PO<&AO=&]S:&]P.DQA>65R5&5X=#X*(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<&AO=&]S:&]P
M.DQA>65R3F%M93YE/"]P:&]T;W-H;W Z3&%Y97).86UE/@H@(" @(" @(" @
M(" @(" @(" \<&AO=&]S:&]P.DQA>65R5&5X=#YE/"]P:&]T;W-H;W Z3&%Y
M97)497AT/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(#QP:&]T;W-H;W Z3&%Y97).86UE/F(\+W!H;W1O<VAO<#I,
M87EE<DYA;64^"B @(" @(" @(" @(" @(" @(#QP:&]T;W-H;W Z3&%Y97)4
M97AT/F(\+W!H;W1O<VAO<#I,87EE<E1E>'0^"B @(" @(" @(" @(" @(#PO
M<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'!H;W1O<VAO<#I,87EE
M<DYA;64^8SPO<&AO=&]S:&]P.DQA>65R3F%M93X*(" @(" @(" @(" @(" @
M(" @/'!H;W1O<VAO<#I,87EE<E1E>'0^8SPO<&AO=&]S:&]P.DQA>65R5&5X
M=#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @
M(" @(" \<&AO=&]S:&]P.DQA>65R3F%M93Y'96YO;64@161I=&EN9R!%9F9I
M8VEE;F-Y(&-O<'D@,SPO<&AO=&]S:&]P.DQA>65R3F%M93X*(" @(" @(" @
M(" @(" @(" @/'!H;W1O<VAO<#I,87EE<E1E>'0^1V5N;VUE($5D:71I;F<@
M169F:6-I96YC>3PO<&AO=&]S:&]P.DQA>65R5&5X=#X*(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<&AO=&]S:&]P
M.DQA>65R3F%M93Y'96YO;64@161I=&EN9R!%9F9I8VEE;F-Y/"]P:&]T;W-H
M;W Z3&%Y97).86UE/@H@(" @(" @(" @(" @(" @(" \<&AO=&]S:&]P.DQA
M>65R5&5X=#Y'96YO;64@161I=&EN9R!%9F9I8VEE;F-Y/"]P:&]T;W-H;W Z
M3&%Y97)497AT/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(#QP:&]T;W-H;W Z3&%Y97).86UE/D=E;F]M92!%9&ET
M:6YG($5F9FEC:65N8WD@8V]P>3PO<&AO=&]S:&]P.DQA>65R3F%M93X*(" @
M(" @(" @(" @(" @(" @/'!H;W1O<VAO<#I,87EE<E1E>'0^1V5N;VUE($5D
M:71I;F<@169F:6-I96YC>3PO<&AO=&]S:&]P.DQA>65R5&5X=#X*(" @(" @
M(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<&AO
M=&]S:&]P.DQA>65R3F%M93Y'96YO;64@161I=&EN9R!%9F9I8VEE;F-Y(&-O
M<'D@,CPO<&AO=&]S:&]P.DQA>65R3F%M93X*(" @(" @(" @(" @(" @(" @
M/'!H;W1O<VAO<#I,87EE<E1E>'0^1V5N;VUE($5D:71I;F<@169F:6-I96YC
M>3PO<&AO=&]S:&]P.DQA>65R5&5X=#X*(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<&AO=&]S:&]P.DQA>65R3F%M
M93Y'96YO;64@161I=&EN9R!%9F9I8VEE;F-Y/"]P:&]T;W-H;W Z3&%Y97).
M86UE/@H@(" @(" @(" @(" @(" @(" \<&AO=&]S:&]P.DQA>65R5&5X=#Y'
M96YO;64@161I=&EN9R!%9F9I8VEE;F-Y/"]P:&]T;W-H;W Z3&%Y97)497AT
M/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(#QP:&]T;W-H;W Z3&%Y97).86UE/DME>2!P;'5R:7!O=&5N8WD@;6%R
M:V5R<SPO<&AO=&]S:&]P.DQA>65R3F%M93X*(" @(" @(" @(" @(" @(" @
M/'!H;W1O<VAO<#I,87EE<E1E>'0^2V5Y('!L=7)I<&]T96YC>2!M87)K97)S
M/"]P:&]T;W-H;W Z3&%Y97)497AT/@H@(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(#QP:&]T;W-H;W Z3&%Y97).86UE
M/E!E<F-E;G0@;V8@0V5L;',\+W!H;W1O<VAO<#I,87EE<DYA;64^"B @(" @
M(" @(" @(" @(" @(#QP:&]T;W-H;W Z3&%Y97)497AT/E!E<F-E;G0@;V8@
M0V5L;',\+W!H;W1O<VAO<#I,87EE<E1E>'0^"B @(" @(" @(" @(" @(#PO
M<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI"86<^"B @(" @(" @(#PO<&AO
M=&]S:&]P.E1E>'1,87EE<G,^"B @(" @(" @(#QP:&]T;W-H;W Z1&]C=6UE
M;G1!;F-E<W1O<G,^"B @(" @(" @(" @(#QR9&8Z0F%G/@H@(" @(" @(" @
M(" @(" \<F1F.FQI/GAM<"YD:60Z,3DW8F5D-#,M8S1E,2TQ,31B+3EE964M
M83=B,&0P8V4W93$Q/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D)A9SX*
M(" @(" @(" @/"]P:&]T;W-H;W Z1&]C=6UE;G1!;F-E<W1O<G,^"B @(" @
M(" @(#QP:&]T;W-H;W Z2&ES=&]R>3XR,#(S+3 W+3 S5#(S.C4V.C0R*S U
M.C,P)B-X.3M&:6QE($=R87!H:6-S(&9O<B!"=7-I;F5S<R!396-T:6]N+3@N
M<&1F(&]P96YE9"8C>$$[,C R,RTP-RTP-%0P,#HP-3HS,BLP-3HS,"8C>#D[
M1FEL92!#.EQ5<V5R<UQ$96QT85Q$97-K=&]P7'9I=F5K7&<Q-VLP,RYP<V0@
M<V%V960F(WA!.SPO<&AO=&]S:&]P.DAI<W1O<GD^"B @(" @(" @(#QT:69F
M.D]R:65N=&%T:6]N/C$\+W1I9F8Z3W)I96YT871I;VX^"B @(" @(" @(#QT
M:69F.EA297-O;'5T:6]N/C,P,# P,# O,3 P,# \+W1I9F8Z6%)E<V]L=71I
M;VX^"B @(" @(" @(#QT:69F.EE297-O;'5T:6]N/C,P,# P,# O,3 P,# \
M+W1I9F8Z65)E<V]L=71I;VX^"B @(" @(" @(#QT:69F.E)E<V]L=71I;VY5
M;FET/C(\+W1I9F8Z4F5S;VQU=&EO;E5N:70^"B @(" @(" @(#QE>&EF.D-O
M;&]R4W!A8V4^-C4U,S4\+V5X:68Z0V]L;W)3<&%C93X*(" @(" @(" @/&5X
M:68Z4&EX96Q81&EM96YS:6]N/C$X.38\+V5X:68Z4&EX96Q81&EM96YS:6]N
M/@H@(" @(" @(" \97AI9CI0:7AE;%E$:6UE;G-I;VX^,3$S,CPO97AI9CI0
M:7AE;%E$:6UE;G-I;VX^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \
M+W)D9CI21$8^"CPO>#IX;7!M971A/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@!:@)? P$1
M  (1 0,1 ?_$ !\  0 !! (# 0             *!@<("00% @,+ ?_$ '\0
M   & 0,!! ,&"0\4# D("P$#! 4&!P( "!$A"1(Q01,5410687&!D1<V.%5W
MH;'3\!@B-#=4<Y.4E;6VM\'1U0HC)"4G*#(S-4924U=U=I*STM3A)D)#1$5'
M5F>7LK3Q&6-D972#AI:X2&9RA(6'I,588H*CI::GPL3'U__$ !T! 0 " @,!
M 0             '" 4& 00) @/_Q !H$0 ! @,% @8)#0H*!P4'!0   1$"
M R$$!08Q05%A!Q(V<8'P$S(U='61H;&S%!46(R4S-')SM+7!T0@B)"9%4E5V
MX?$W0D-$4U1BE;+3%U9C9&6#E$9FA*.E)X*%HL74U9*3I,/2_]H # ,!  (1
M Q$ /P"?QH"*[16X/=MEL"8]U5JS+=(YN$QM';G%VJ9/5Y5.F@,KPF&^ZOZT
M=<X;#H!%2;"AA22,@:RO2*7*#$,ECZE^9C P*><5"8#.+9SVI-G[DMWK+M[E
M4/IN+M\A9]V3R[P9B>)NJO2C5FW>V8G6T;AEVM3RC11YNE$[9G[*P"L&XI./
MJ-R:@1H,V[%*_OP&'G9Q]HQ8C[N:L]9N:W18*J=34]><]E1,XE%7Y-L!?HIN
MN;*P@:JQH''8\P2+9.^)H<^-,5:::GLEL!58ZE6KD)S\@D$=5D.@&3T8[7>6
MRO>EN0VQHVW;P@@]95YO#>8A:[K,YLUM,.E^TEUB<>?R[SP>V1E>4,7R=GYU
M.ESM&XDG8&1-''+&!S.U$298]I0,K[0OK<*DNZCVZI$,"LQIG&R2Y+7D[.AL
MPZ&UZHD#3+-OA+)8<-DAE?3ESD*)"FE[VFC*52E:BG!D?A7+%'N@LLO0&']&
M=H%:+;7E<XRZ:UXR.4S8Z4/DMW;BI*Y$5L0\_P#@^]O-^.T=3)6UPC"!CG%L
M2>;2!0S($+FG;"$S'.9<0R2)T2DQIP M:W=H?N;?Z1N&X#UL:;8]=#"U-T6:
M&Y5(\951\ZEW8YQS>8F<Z[>E:D&_"*,$[C+P66Q.[*:].+K,E<BR?&L67U.^
M ;/J7W7V)-]QZK:\\PUL3/L#CBNRIG+<A=3$[E2S_#:Y44U)VT<S<229)/I[
M+)]$%ON@Q0@,5T+9QR%(0![=[C P&GW:!;C;MK7<G%(@S1>E5S*<G9VJ1HY9
M$EUE5FG+W6QC;\XQJ6QB$WFNL]HE,NC+F\/R"8+XE32J%/#2],#2C>5Z=FF&
M3KUTZ^-UZ[2I'[<9>U$7+N)E$A=Y'=3?!-STEJ^!59%WBP&GW3%:@[*!RW2H
M8B@9'"639O?W2931P %J\UD4REVEBPU_=7*0%-<+C<8 N;.M^<YB<+160V/M
M*[DU,+"[7HHC:Y-I"$1EID-VFO-V-\,DZ18JEC<G>4;GBE*R-(E,D+][BQCF
MYC3'G-9C&4P%%Y=I5N'4UU,I8TPBC%9E9UKNNM]W?L9.P2A@L2([98+MZGN3
M1&2*:NVX6&"OTF.N9]A"K-YLB9G,1\6038YB4)7O&()^/LRUZYZ@RK@.YZTV
MNO\ M!)O,%,4N"1[7YK:*V#5#7+%G')T$4C%6MUB0J(/I&4@DRQ4Z38I0"6.
M/1S,A-<C!7+DI#DD,2(T'(,:XIVE%I26)M!C\=MKK7!VGTXCQ%XR^PH6YTPX
M((E2\/MA)#BOH57I:;;'+/DZF5KFEB;W:TEBHR&1%YLPN)JS3TT#P=>O74%I
MMIF\N_Y*W[.RGRT8XW,EA6QMSK.WGVU"UTG<)H;/>RLK;<@4DC[RND<:0PJ0
M2JR%2U*B2H$BPY]FCJA<_<BSW8]QQ^#FZ]>NTKVH^T-O/&NZBD_O#C<UAX0O
M;*AD#!FY2U_NB92>^*.F5AIQ9),H69-1Z]GD$5:VG!,ZL#FNEY$@5FBN85K0
M2+YP_7H5?J49>;KXRZ54[[YA<$#W4XG2BBIL-5[,(+N%:Y7MWDL@,3,LGL^.
MWHN75J]NJMY?3&Z3P+&LV;+!W3&MCNKP>T[ZMC$7.4)F5+R"O=NF\*V;%MV-
M0J31^!$UW(9;:56,1S<;)5%@)WVIZQK:Q0E4A>7%Q.9')'(4\N>F)4R)65$M
M0+&IN?\ U\OP=U;(T@4%MX9K4'M,=U]</^Z#</,ZTHRL]N=BPZNY3)(0JBZI
MXO8B]TLK;I 2VU\UNC@Q,_O5CRJ)(D[HA/:53>48K6.99AA6?&O[?JR!AE26
M\68/5PYR&V-\=C1[=HFW;WQ6DA[,A@K>*3=%]!^!K[!Q@$-;:X9XLCM*,I9)
M74?B-IH=W#K*E,)/7R$IN79K69>2RE\@LE!.UZW(;LV/;ZZ)V2-4T2LWD[86
M-\7U'83'(<%T2MZI=Q<ADU$6:T)9/)GUFE<)=H#'53WF_(H:M?15H\CH1%5;
M4J0G@7N[-KM2;IGDRV'[9+E,@4E47-M.IF5GV"YR\R17?/9W(-O"VW9%+G^.
M,2]8YQ=O]WL+LS&'2R",\+=2R\G=#;8R8]+71X$D70#0#0$;)?<NZAT/[6NV
M7.7[F%E=;89?O6CL >XK<U20ZJ(NDKC;BUR>*0P(05%U-PXR5J>I"8[L\W:U
MQB-M=#V-9GD?ZF6)S>.N:]=GEZ7-UI]OD*WK[M:;:.W*4EMS<HO4C:WRR[*#
MH$Z*S21S95N3?8C/]KJ&[%^YI,D+2(XJX5J]R<T^OV!SSQS%6^M#LH6K#%ZG
M)H;.06\9][UZD=KT\5.][@'8BI46ZB>U&NJE4\UGBJ;JIC>T5+9*073;B$<+
MM.+5^AL8EPE>&]%78BIE?L/<<--A".-.R=P1@5+N/[5B?4MO7D*VJ;"HZY-M
M\BVW["K @M7/,_P:YE:!6X3<=954/LCVND,+.O.L"6+V-WAK^[)W):M:4C3&
M&E*E;"39 L=6\#8)NFW&6.Q;<^T'?(%/ZK]^>WQR;V&!#6DB6N$U@RA;7M72
M_!HN5.]-2QLC,Z6KY:XN*!,TI'5L" NT6<3<<W<UQ3% 8SVIO0W)U-?5@GSF
MMU*LR%IVM]C5$5S9R^8(GL&79EO<N4]M3/":OHFM>5\ZD50QMO%D71YS):5R
M5M>6[%<O2$),G7K^T=<OKU^HZ0S?3N"M&YJWKZJ[0VTRD^,6$@S56!5ZF7R.
MF[%:Y9LUW.VZJCTE8T4N6KE7O2DE?1](A(9I]F&3DB22MP/0J14P)N \H?VC
MUML49LRW54/":L-M7=%:VIR#+'1Q6GP^Z[<V!;/+GH"H4SJE((3HZ^G-F2NS
M(^]OBI"2I3RZ51T],*?%T/2B!E+NZWN6MMVN2J*HB];Q"3F2>$-$S>7&1R^!
MP=-.G-;8S!7ZVNZS5V-;5;@5)46+J#P8>THK6=B%;[!&!1"L2Y.#\E='F^T&
M,;%+MSKI84(7R&\15L4AWJ;\S)$QLX68P LB>VQNL>+5U!VW));)C8QQEM20
M[W<>P-[/A&W]Z]5O\S8Y0])WE>_MNX'<M7: 3]XJJ5E&OM1Q9;%:&1&)J[E<
MWEB3<K/E"[8RV;E,KE@CJBR5BKCZ>1.BF&DYJHOBF48Q&9S-39K9(FG" F@<
M65]I]<L5>+Z:6>J8(X)*9K>Q'1L:)1/H6CFF;E7=216?M,YE;.1;"JU5L)G;
MJ_IF8C%%1S8F;6E^B4MPGCX4]'M:0"_L9W3WPX[CJUJN8RVDXDQM=VW;1UB&
MD1=Y2)+1D,8K2HK4K\B JI!/161*2K6&RE#7C',U,P4NCE''MW(P4MQI38TN
MO7KXTJ"AK1[2.UZ_O_<'7+11C5,(Y2+5:'N6+)9G VVUI3E7VV7#< V35LCA
MMFJK*=8W,)"8DJ]O9F"@W1&F+=$,WPL-P-(<H2C LVQ[QKKEUVO3)&[EJ:RS
ME\^@L3ATAIEU?WZED3HOV([P[R,,SBI,G<CY!@$J@480/4<SFZQ.[*6=HE."
MI@=A+C3(!5M;[W;VD[MMY88W**CGLXONIMFQ+I/#<) KJIGD5KP3M YW,GIK
M@$9F(EX2)D7[:6:-R%$@EK<#PXYKD"G*/$LK8D;6W=UH#VQ;M29W+%5,K#6.
MDX*98C]L0C.=3RV0R VTYXDW=+(%[[K.J/,E6W%NE?UGG*WN*(05Q9PP>)+"
M9HJ>I%'<(Z2R/KKXPGV^?IZ[,BK;@WHW97%W;J(+7#3"'/&M5MCS 3[,<I<\
M-A3#3VS;;;>)\?CC0R.35BP&3!WL=R8U!Y:DU"SJ#CYJ8WOJW!5'G8#&'M!]
M\&[NF=S];2RB?6S]1;7V<UB[C[[IYK1('21)8ROL*(04;;@IHMV:Q=-:34SE
M@FZUK]+@@?X'&YFWX(_62I 9@!9VG^V0W"-Y&T^J7Y-1SI*9<R]F37;^9;4D
MD:"]KJ=]Y$ B#[/-PT B\>(:V%SKJ!O#LIB+N*9.:DRFA3MFN>V8U&UQ5] I
MAE[<>^J:VY$2Z\G3;5/;(SKOM#'THTA<NA!Q%R;5KGK:&UUM\?V$AY)P33R3
M1&</,KSC*5,DEZR"(8A(,4!IBEZ=EX&5BWM5=RK=6XVG)8EM9K:OIKOZFVR^
M"6384LGS3 JU8:O?+L22JU[[>3<DB!H+E)M;1Z#P)C:75$WF2Y]%T>I&G2KV
M^/$@6JH+M$MP>Y2JM^5]'R N!*V'LK(E=]=1&%N*MUAU>6DDG7:!Q55-(?G(
M4?NM0N>4]00-:J4NB7NJLF9 !B @K#W/KCKKDZ/T[/W@H^B-\%^S.I8;*[UM
MJ?L^Y!RWG]GA4\EVYMCPC@K?6]&V?,8,AB%C-KHTM>:VXH[N1971;.YM+U&"
M5@=52QSJ9O;8L3$W(MPY!9&@.U3W1T]3LUM"8OCE=ZM36>PJ/)G&T7Y*F@-6
M.MUWEOHC4SMZ:KUKS#6XAM/:JT@D74>M)E#VQP>RX8WK9,SDYYG& ;;]BF_[
M<=O(N)DC:^JZ<KRM&+;+35X6<L3S)UF,O6/UR/\ ?D1C:"LW&-JG*"N\-<EE
M.HYBF?EKN>>GBSP4VX%NKDN!P:@-Q.@&@&@&@,6M\DWE59[+-W-CP5[4QJ;0
M';->DSB$B18D9K&&3QBL9.],+REP5$J$N2EL=$25:3BH3GD"83B!I1A8Y8"!
MI>9;]W/TI6FPJR+ 1;L9=)KJN<E69"9I>M7S!3:K:S;#-Q=QX-\8:*BBJ8D8
M[.)9'V],A@$SR,<D\B2Q=Y#+!2R%$K +I[2>U3M;=%#-UHN65-$.-0;&J_W,
M,,JVXMDYM1TBT[LQJNXYTK)Z@TMR:<Y185/N5;-[$\1!O4IQ?Y40O:UI["M5
MJ(_'P*/['G?3+9XGMY#N<W,,\U1J#-G3/73F\VM5=MQTVVK]ADFR>84QW#7,
M4@++A8$TF3-WL]MRM@6/E0E)VTI#(7]ME9.#4!>>@NU&G5XP[<G,%KWLJJT:
M]JR[[%AD1FES3C.>4R-06Y,*DQRW?1U%#0(AT<<5,;2R1W=&!U;WMGP6Y,+;
M&)%AC[Y2@+Q;JK]W(PJRK2;::11N6,C9V?TCML_%18N,-:XA+$[],R$MBQ,W
MZ'LV.EBXM(@3@B;5IK,A.3H4>1AXY*C,BP+%9=H/8]=HI2WKGRLV(U"$XDN5
MA[@)&_80^3O5:[5-G]E(:6B(MB]E+8K"MIXNN3/3$B;S'K-N:H/,GYFK^:K5
M+@E:@+=S?>WN7249NCFHO["VL\V9+KPK-6T'/I4]J.81K856FXEL71UY4K#&
M88DB>390A11W-F,=TKJN3R3.4'E'J&%.\W7KIEJX-FE/[GIS9.Y6TMO"^%M#
M>KH0N9JK=?DOK3$DA-+'Z..FUK",X*SQ*6YV-5*V6O\ ,U.1JDABD\,6,B/#
M$M9CFF UMF[Z]R>Z:FI"UQ]!%:+6/=N;*& U[8):P.LUA$?OO=BQTY-:AE[=
M5FX-;9\.FJ!H'%.X3-R2TQ)S0SGT5:H="Y1'T,H) JMQW/7E0\JOZR96]*+<
MS;;.WB>]>($OLZC,.8(O0,"KPN+M;JRJ9#-VA%'FLEW-?I6_1Z.HG0HM/)9.
MJ0R%W4DE$A]16]H[^I_729/,FQWIN_S8G6VZ%S*?*(FKPW5'(U$ 7[3,&]YE
MR)^>7./,.$%QN-]7356%E2AIC,5C+J]F2^.J'Q^88H!3QG:5[A CIT@*K^FL
MT$$JZ]+AF;CA(&F2);(BE)VS44#,;X IJ:W[6B,&>)"VV0]I5N3O/;(RB,QA
MBAN6MKJB<A,;G.#(B*;M+:B.U/>9=<X5P.Y[$VW6%NB1-E?P5K&#+FYCJN=3
M5N@['.2E4HE!S24NC+,UR 'Y8F;#QA9Y3P>4[FAF\KP,99!VEMOJJV6DN>-#
MU8X*(YN><VVZ)/.XBJK>?YTE#JD>&*!U^;5=S6ZQ1.WILX6P\HV]L5698SJP
M):@E,G3P:5EN>#"Q =QMQW6W<_3NA(\]6;%6J%S.?N, FYUC$K'V03J2IMG>
MV*UF)JADC62AA215_?7J=2M0VQQL;'?)P<R7)U]PN/I5B4L</1]S]5*,KKM,
MKW:*9C-C'U='K'BK1&X1#DL,;7*8NUUSN>.?9?I]^Y"HJ4J#7)O<E3F^-2VL
M"F[WJKGE].D**1^[TZUG.:)$.2]'XNB83/;MVB#\GF%*6,HVQ[6/HJQ6S-ML
MHD"2-21YDM-6A/C6U(\Y/TH/8'&+KHBA:$SFS/SDJR$?7YN#,XJ\HRQ!U\9?
MNB=U=J6%?*&O9?'Z_2P69*=YZ&%'QT)$7+FC/:!?T$ILQ7*%;FXJVAY"?(IX
M4[ F:6YG&-JF',!5/9+\!3#PBNW-XL@:<^RJWO[A;<W;U?!;'W$.EG-%@13>
M9G,X$FM*J[>7,[W5ER(&VMG:9UI%H!#Y[M5;&N(8.3.RK))*9\V6FL7MA8)V
M52>WFCR"4OED&..60AD(8XCD(8XY9Y" !R(8XX@.6673ICB Y9#T !$0#0&O
MEB[0S:ZY54TSMU8K:B<;7/UPHT\0>=N=N*)2V,FW^4BS6-9+I"&&#/#HR5K%
M7;-J-<I\X($K R/3LBCKLN;IFG<6)"!9"K)3V;-46M8NX6K8[:2RRW&3YU1Z
MW2PK=38B=7,+E!'<TDK#;U!GMMD4;)=']&@26C9,8HF.IT[*RMF<CFA36TLZ
MHQ$!D>Q;Y=G,E<XJA8']:YFV^J:RL'%-3-E@U9.3K8$DJ6'H[*>38(6WPIVE
M]C0Y_A,%06(I9'"3OC>6@8B%62QN]U 6;B.^O:@\!';A-K%3 6*QFJSE+B]2
M^C[&:+S>9-&;NI[;82B;X"S5&\NDU:9?+;7C,>4/!4L!Y+5&MC"5&'G%%,38
M2'7K^PNY(>T1VBQ.+H)L\2.:$M),1F$CD (*)N=V>ZPBL(FCS7,KRMEA9Z^7
M/E2%(+$B+_"O5T]0QXYPD<8>DK>G5EL#F>B H#>P2]/4\V]4WA0$-GD:MF>N
M#%")>AW6W%MGF$:G$<J2R9L]8KSJ:JUT? BPP""KFE**:;*<'5U6M:)?&D*9
MJ2NY '?UC=[XI9VT*GVH1_/:5$9?,*0BDH8IVT(Y@U(Z6,D=1*I<%-*84G:6
MZGT$@@SG!&MU2V6X3;&)XMDARK[!A4J$Z("TG9W[KZIW N-K68SPB%1AZF=6
M5+?%@61#MR+SN7C+$R3-)+G5KIN=3>2L<9QIN85-A@_/"RAF9"3"X6URQ1(F
M0M&9('8#0+CJ>T4VVK9#"VJ$,TA=%5@2Z#93<R9599E3N3;6\RK6]I]!KA1H
M)[7+2ML9@>4^WR1MT<R9_2@I3XBJ(<"3$)+>K ]S]VCVW[!K@LF@D?GLVQEM
MD5>SJ6TRGK=C$\,B-P1">.$$MV!P5YK7&9VE')217[K'(ZZPYI5M[ODE=$F+
MV1BRJDPNOC'7KY^DK]JWR[1L#*\11M^=U37/\*K71QZC-,6@LA[&Z[A)*FBM
M9,\UDK5!#([6<QG;^[8)O>U.U\;D:3W1DID"!O)5)S%*F?B4'[(+BGV<SO:'
MTA4542>);;X\SL4L)FDO=J\Q?+(FC P6@\PQB4Q^NI\D9F&.U5(8W*'I>HC[
MJ,LDDQ:& M,RDLCN\J'7KU0&(\Z[3J05'%:9F\\I*@H@]WY0,LW'-K*Y[J!8
M7N3PZ')JESCE=0)2^T$S'V=?,I3VMFDC%9$$M2'-8RY(4,N58NHF( ,KE>ZF
M!-^Z""[4SJL%''9/"6Z693M;@U(F&+W$_MTTLJ(T\X1,6W/(B=NE=5I8UG+5
MX+R3&0IF:"STIRJ4MJL .DK"_+AO2*1";03;3#&6H;FC:V8T#8[[-2Y(J0YH
MH[G(:DF5WU4WP^.FP.*SAH;6\^.K818%B2:.YKXRV/;2QK5:G!G R$V]V*QW
MY2\7L ^$(XDK=<Y+%YA!U&2!W+B4\K>4R*L;"B.#HF2)4KTDBTUC$GCS>\D(
MT93F@2%KB4:(M9[E+ ]E-;9J9H/&2_0TC3LB/EZ5G;7Y?*YU/[*=E+''?6XQ
MZ+IGBRI1+75KB#"9() H9HDUK$<<;5C\^+DC84L=W$]2!>\M A)RPS)1)"LR
M\S#2\RTQ)>6!AQ>)1IF&6. #CF:5A@69F AEF7CCAD(XX@  >>"1*6H/6%ID
M^"M3@24I58$EXJ%!:?TGN<L\_'$#3<"/2F^AP,RRQ*](9W Q[^7(''Q:6K%S
MS>L6QOQ>3$F* QVQ1)@<\T.)GI<4>:\"_=623$T ,Q3Y&B2!@=\, RZZ ])3
M"QD!F!+*TD@:Y&/)@%-R,L#'<[$<#77,,"0#-R-P$<#%V7*K/$1QR-$!$- >
M2=C94BA,L2L[6F5HD'JI&J3MZ0E0D:_28F^K4QY9.)I"#TN.)GN,K+!/Z3''
M/T?> !T!VF@&@&@-)%^]J^91.&X*RL]N.<XVOT_NE@^SQZ?(N\*5-LV+<#R6
MTJ+GE$<KI-%ES<\0VKVQRPCA"%4[^O["E32\(4I[(V("E"D#".:=H3L)2;M4
M5ZH]LL@M"REEV6K7>W:0P:\IA)8W=ETUY26UM!3<CK6CS#TU0)[#MZ+[K6R!
MM$^.:,':#Q&,.\D<I(L;CS\6L#<C!MR-CH-X<<V\[@*0@5>/UQ;?EEMTS.H-
M,U$[R6&UUG VV\Z5FKJXPZ*'^OH3)9TVR"*O3,7G'9?#E>:K)O9WEG6D*@.6
MHW9[*7 '2=*&[-P&NU,?2Q*7&;>K"59S!1A,%=:1G';\^F5YGE;7N:9NRJ,M
M)E1*Y(6CR>\5Z?,IA?$SFM H9Z[1*J<;%AL:B\21R"N[)SJ%8\V$['N<15,^
M=@'[NF&5X2Z"2"'$/Z%^J];L_7Q^1,<A%M>R7!U4L[@E9E,1R3N8&653VE3>
MZZM5DSAC>[OL'DA2M@5#-ZYF=?.+LVNL=)- PMHGT=C3\K8WN*2DD]M>4:4Q
MM<&MX.*2+<C/=I!(&$,)O+9CMRQG,4V^,TGE<V-M.N(X_G3MUNQ[/F8++TK?
M:E*WB$77<Z>786$PT>]6(D9'EB@\G=V*/NJK-DS!D42Q4Z* /0JWB;+)J]4U
M*;.03%?8487-LBAL;J^";I;)JQLF4P<IO#ZP.5I([5T:@LELJ1?0QD335A<Z
MA.,O:'] I;(&!*A6VN+J!=4_M#]LRM2A>G-6LDL<<$\(>:F-A57739-E/2^4
MUW85ANN*VM6:GSGV&.L=B==S!2M(3K7=U0D,SXBE26)NJ8II6@5NX[[]J3?)
M&N-))'(I&J=U\<;F9ZA5.VG-8@X3&QH$5:D;@Z&;16#NT4-LB55PYH9LG@^#
MQ[[%<>>FI>>V!B\(<5(%JXGVB6W:4,M8V,OBDGC<8MBF*^E4%:W6I;5<;Q7!
M9\S?HA&X*55\=JU[S5L;TX,&?J9R8I<[I'XXPE<@938LJ:)2Z 7).WS[1<SX
M<X%/+\[%6/'ZT]%(FJD+6>FIA:[8G"FO*RCUIR%N@"M!5[A)YZ2YQIMBEEK(
MTY)7I"XIU[:A,+R',"Z\HW TC'[::Z<>@>5TW,<(VO5K&NKIS)X9#)!*25Y$
M,QG5E,D4<X%7LEDJ=M4$QXB6R1D=5A!S7@5C@4_,7K(#&R0=HC1"G&-R.IV=
M983P^RQJA2M4^QF85<X90>15I=-GQ"?Q9PFL'2*9[6\M6TN_M,;?XT*J+.IX
MKW1"[GY-H)EH%\(UN6V[ME6-%A2>55?7*M#2Z&_9;""7YA6RB"Q(ZOQL-_=3
M8ZUDDR96D98ZZ.:PUQ21THY>A.4*B4@ O$K,#H&S>1M731=/*Q7O$1;"J_E]
ML AD5-V/#']NA4'F;-"I&^J(R]PEK?4>1,GL5L!O3BWXK7]!)C9$Q%.3&K5N
M8@8;V;=VT><7IM<L6)578<[=)IN"=JC]_C\U;I*XI**8[=&2<3!^L15$4T2R
MJ2Q7.M)%$U+;$I9)H^3'F=U95\NPL%K:JH,<6<#*5M[07:0_%NBA&Y3TUZR0
M5\XMD87;>;N;IY837<><O;JX75Q#76MTDILUOFS;6<P<4*N&MCXE)BD1>'YX
M-;V!E7+$@%9X;S=L9\MKJ,@_O0/UELD-]2JE-3V4E01Q%9D@7QB QRRW]9"R
M&RI7B;S!D7Q6/P^REL5>G*5HL&$&H'8]"F4 4E/][^TNNK%D5=2$B;.$[KIY
M"!*DL0VXW+/2RI6VU['+M"O8F^PVMGUID$I;JP>V^S\XI%G%P<6^*M;U(3D:
M=/&W8U$!UT@WV[(VMX);')_R<T+JN+4DS-KI6QI)6ZZ5/U,J;K%E^B4TP-?!
MCIXOI%.,S5Q[-_&2F1<],4H1B:?BCT![(?O>H>>VFU4V7'GE$VV'754VC6J:
M0UU.&:3SPJR)E>[<Z.[E4S_!FZ3Q"&Q!-2228NEG2Y(WQD$LWCA[BK:#E[ =
M(./-1NN77> U[_=GB]M3'L#C+7,9/(8C!(XPLFWZXE<@L'"P&.R)7!7.&QA)
M763Q-*ZES/7%FN3%.V9 O@:K"//IN3X4&669W(*LL^Y9LAM9_K*C=O45N.4U
MC6L,L>P5<GL%!5^#8SRMZF"6O(5 %&4#G&<FGKH;7LL<TK6]F06'Q_ AA,<9
MFB.?<10@6I2;MW09;8"5\VTL;/0D1O&J]L\TF.<X;U%B-,MMF,4Z\1%1*Z8-
MK](Q#"4,MON-0N0GM-IR-U8UASG(,(XL8RG%4D=>O[042Z]HD?!L[_3RFC(C
M'I13,/K*1K6ADN5EDV<.8["M0*OB;/N4=8O!%Q%(.K*G</HC/+1'<;C3M5=(
M9<[M"AV7,>#:\ 9H;6KZ+W)TZTVJ6QMK#[MDL^BII+!(SYA%')57\YD$%6/T
M,EBR/1%;)(B^*X^>XL#PNBL>5JT!Y>1K41W0R, R'T T T!:V\;5@]%TS:]T
MV88>77=3UU,[%G&25"#HJRBD-CS@_OQ:1L$<0<51S:@4E)D&66.*P_,M..6(
M&#D &ON';\9 %?/-C;V-H;OM>H;.HV2U838IDR9KZ87%FF;JSPMEJV31^"11
M-)(O><EPFS BCE:Q9HGA<KQ=W%@8Y"L=T636L P0C.]795LE72V1;-:(?[ :
M)]0C594LF4_M:ZD%C(#JOW?U1M 3T%((_?[-+[&K=%5+M>DD?4$)5XL#?'E3
M4O9TL138R49"G W!TANUVPWJEMXNE#'N3-U*/SZ;+C6VE;)9FEZ?8X\R-G>G
M*LUCI!FQMMU6CE$/D3"8Y5B?*S<I$U^X,3<E:MM!6!9%D[0#9.W54QWTYQF8
MP%JO&HB;WG)2C;98ZR6-5:Y I:T<NO(J&0-^%G8G1<#DQQ&0RM::Q3D4SJI@
MSG(65(X.!(%XSM\6VTY*M<DQEE/N/T1)O3"4MAV]W=)'2426M7"2MMED1)J9
MJZ7N\SAL <8K($4PF<<1NL'9W!.2W*'L7)U:TBX"PMEWIV?.Z$J"QJ1N4_F9
M#Q$TDYAZNM&/<E"RGI)8-0%6DAK=;*ZJ21?UI,I_3J!NE)-#O[LHDTB92HUF
M9#3EY\:*. J2&;^=NBV&UN_##9+$X!8E24E,*WA(T_:KC;JI;<OT56.*0WZ#
ML;JUT+Q0*F*H'=-'WQ@DCZD?4:<S,M BB)\3D<K YM?[H]D%;.Y"R!R&<.:W
M<.^U+,GR>90_<!9B8R17](FZ TLPV-8K\R2<BKE3XZ*TD=A=:3%[B:6$-V()
M$T:C38<3@I N!-;FM6'[IX+04?H>H72*6K&9M;6-D.%RO<;?BX_4;Y2K%/G1
MX@B.A7Y$IEZ%QMIF.AR/W^')GY)'CSW.110_-*G+ LZNWQV$V4/*MVF6U8A3
MMZ"D+@OFMY4VVDWFSMSCL&KA^LN,K[5ABB HT58L]P1V-B6R/$>E]HNC&N>(
MRWR^/-JM>L):0*RVY[T:QL:M+NGTH;:AA%?[<DV2N36-3]EH+LH8^+KX<3/)
M!G%K'9X1"?=KW&$N)J6PH>EBF*QG= :RL3G8YU38%@4P\]HUM<BZ@Q+DU/D;
MA$ C]FJKL/F]3656,BI6/P"J6ZZ,T[C5\LKEKE3LG?8BN0/)3>TMV( B/0KB
M"5^:E.2('<RGM$*"A[C&U;5%K'7IY+8DI@]H("*/N9LMV%N48I9SMUJ>76EO
MH8&6E)FY]AC6WJVUV*8"VW"-J#74EQ/*9ER$D"X*#>+M'<9Q!Z<9G?-V4267
MQJ)P1P9JDGCE4RBQ9+79]R,$2:K-10PZKD,W-K7/*>"R>^1,\(6186L4DD&J
M,B]!U\9;:S]T%BQV%;K[@@-&U?-JHVEKY7B*26SUS@\FG;_3=?GR^UY3&%K7
M7%@-C1C$3RB:SB;4XM1;C(Y$U29R5R.*L34SD2("S]K[]CZTE$?INW**H),Z
M3"L*PG+U7;/N0%?/9PQ71.I[4+?$]O\ 7[U143=+QF[3%XB*U_CB<^$9ITCZ
MCC:!P4D>C<5#KUIUV4!5M26?MNVZ[EKGVNP^M)0QQ1MKM;-+ OJ;6--[23R"
MP(!#(C+Y#1R]QLAVF$N,5PBC+$AEBLC5A(SV7-D?)84U1]*M;7]8O O' KNW
M,63&&Z41[:_"X2EL2LW&RJ3D#_:8R)(4:N.87]K@]\M3)!V1PJJ26(P.92U.
MXP%RNIA8WA [8/RQ<J:6A#*@,@]O\ZA5O5- +HA<83Q=%:$1994<V9H&U*]-
M2IR38GN,??3VXL"5+I'W7):TN.91IR;)P1J<TYAA66)F0%Z= 8(/?9_UNZM*
MYH06C=T5*6J-P#;BMBTAA*!U1UKN<DR.;V]3R5P5U\X'C"'B:(29.RO*D5-H
MQ1Q 28Y8C:W<(0 Z*PMBQ#?5C)&-ODO6PN>P^]6>_8A,92X9JG-DE2:O<ZE>
MRF)U1,JYL9\GJNU3DPG&R*#6&R9I7=Z(6159FX(EK,Z\P*%I3LM*DKPVE)I-
M']SEMNUB0U*Y))TK5%ST$V?F.VI[=D<//=IM'IE9K&3%IQ8\@]"OBM@QEYFK
M46A16.KE*0K%"6!=]#V?M-I5$5,4R6S75+ I6_R:"MJ][C6".*I9#N.I[=.H
MBR(QOB"%>Y1Y':]*QM0@,D"YXD6# [2-E52!7@H:%#*!CCN3[,U^LLZ3LU,V
MTHJ^'W,Q6I%;Y%8>YJG^2LMLWK-;Z=<2\4A&;4]M<:E%G6*3$(V65"7)(3(,
MD4AG<GBJA[B+R;ZO(#95-*IB\\E]0S9[,=,'BDYB^3B&X(59*=$8]2"NII5Z
M_%Z(,2GF+D6,:G;WFG((.1F%N>"%5D>84G,3'@6/1[-X.VR90O:[$N)KKTZP
M95;)5&-DM:6^J$EDS96^/$FDI)22,E3XY Y2B2/LUS@:Z>K*S*F+D:_%0O!2
M0C!,!VM4[/:>IUG<XU$R9"?%9%259T3+HN\N:18QS&/53#CZ[CDJD21,V(LU
M%@+H#FCADDDJ(Y#B_1QCC3:K;_11ME%"!8DSLV*S+R!\/L^Z)M-&*)0Z(05X
ML:51YT1QUDK*"WO ZV8#DC#"V#)R:F-KW"3K)U<U^2R7R55BTN+_ "-S7HCC
ME@%05!V?\#@".J'>:3^RK-L6K&ZD$3-*I(^LV934VT5&)PQP^%,R=OC#28?"
MD*ZS)R[F*I"+Q8#ZJ<T.<HF[R#0WE)P/QF[.BFHUC%&^,S>Y(]%(\\4G)GF$
MMDJCN$;L&5[>YLVSFKI+-Q40Y0^*')I6L[4T.I,=>HXU21@:69&^MRY2S-2U
M(!>QJHUV8+GN6:-$B;0K3<%'6A58\,/;5>,B1VI'8NTURDG,8D>"_-"6W2&L
MV.-QN01]P9<Q2N$+87IJ<<<G%\1G@4=)-CU)2N+0V(/(S$QM@.W1;MGBJI+(
M"D3NT0X]WJN1-4L0NB5M*5(;,BDDIJ"R.)2]OR2"QOC=FY)V_)0*;)*;[.O7
MS#]_G^TX"S81MW<YXX6X[L3F[7.X7-![RRN-<<SC8R.4P!KB$;9V1K>DS&G3
MM<)60N')X,\Q="WDI7&+OTK2B84ND"MPT![(OM#2U,0WG5-8]@&H:V:Y8&WZ
MGY_)2UE%U.\R-K<FI+@6U15C8+ E,78D3JO:H[&IM.I8W1!B5YM<*(CN*-F.
M:@+S;>Z>(H:H8G6.,@52YQ:#)&^RF8+41#8JF,]GLK?+ L67FM24T]*T>^J=
MRB1/^#0F//3M1;C@WD'GE)L#<P+SZ : : : : : : : : UB-/9W%86[:9DD
MFQ+UMUF.ZV![](+"$*=0T3ZOMT$94L1TI:U3X<6[,<KIN;.3#A,%#+F@9) T
MO[J\MJ9>H;%92E.Z_:"W[?V'>P-K1RUC10B7)X=+97N!F@09/*2DL9BC_N+;
MZ:1RA9!<$C.G>(F9"UM#U^_U4<UO!:N!OJ)0K;U)Q -R1M O_ MH=@(=V<3O
M^T+>-L.(4#0R^A=M\?<T8JI\<$^P@#E;]OW5,"4S*T2*QI,O@;3%VA'&HTUL
MJ&,(CWA:<KD$B<"D('@[=G+2[]7SG4[Y,K:>ZQ3J&%365>OC]$WV$TH9&9XG
ML=B]XD4>80O8)%BV2)(E1I N-OM,2(>3G R1PAJYT9%P'8L79W4#'E4"7-RF
M=IEE>)H,4S'-STRQPLY7 W+<4\M[H8BBD:84#0L<'?=#:#@O(B:6.-:(W*.$
M1INCZ-DP3* *KV^[.HWMG,(25G8TZPCKE-)78$_8'9# 4Z.P),_0B(P)H,7H
M8?#(?'(\CC[7$$3PH]Z<<97>83$]9+IF\OCXZ/ZIZ M_'^S4VVQ>5S.4LB20
M-V<PFK?/ :V]/ VHAA>T]\Q/<BYEHGYI@J&;2)O?K2AC,N4)K#E<USC["*R+
MP8Z)L:D4> =>O[2KH7L*HZ!E,Q3&IG.6+%**CEJ(5S^@/R%UI666!,H=B>);
M(1Z1(8[V3(L7DD PS7(\&XDDY&8F,.4 <*!]GW0]=/48?H^JGN2Z)FGG-8.$
MA;U)&6:B!VU71GNK MB3Y' $?N>7YXA@84(.!;.I$1+1'IU@'5Q?L[J:AK[!
M5\<F5O-L8@<OJVR$=;E2E@R@[Y9]154PTG%[ D16<1RDJEW55K&&%C?F1NDK
M7"'-P;$\K"*)Y=WWW,#FPSL_*:AAU1GE2:SGXVCFBO8U7>3Z^1H?5<3JB7/T
MMKZ,K :(@T"Z(([D_FL6*Y<)K\Z,B!!ZY=W!X!:[K7U L+-NS=?PFT%0U%:Z
MF#TH2X4DZ6C&%JMR42.9K:/O]]OIE.<LDB3%M>\URU[,B[;FW*8"+,WE@?,O
MHL-:5BC#$!FL][:8R[6VMMIOG5GQ(R2*8DX6+ HC(VUH@=I.L#1J&Z)N4W(%
M@4RO/) UFI6AV;HU+(XR3)E9V5CG#7)&9OP09@8Z5]V7NV>M&A$Q1K"6IFMG
MD#&\QXA/C F,QE;HQ!K-KV/1G-7%8"P*Y,@;8_;4L R13@^46&\JL&,R135W
M(94:;$#+-)0M<H*[3UTA;#D"=+62:IT\R;\TS;8R>+I(H5#4QR::-R1*[)'D
MAG()]"XI<R/0*BRSB2"\,,"L0,,P[*Z@RHLBBB"<W&QH\V^Q&25G1ATKB+$S
M>-V;*X#-Y%&G*-QZL6V$1)C"45E$'8A)5D5K[-4I(?<WHYWSF$MS>P,CF[:!
M3Z"-U;$C29"Z,%2RJWY;'V]T=$R@IS67>RV>P3IOD?HFY.+@TG-EMRPEN2IA
M0')!]6Y&JE/N4T%(%F6OLY*R:W!!)?HP;@7*P(LT5$PUA8KQ*H.X2BIFBCBK
M5;J]1PTC.N<8PY"FC=U61$Y$JG\=FRZ9,4C5>^E2ZNN);GB!W^?9[4>IM:N;
MG=76=R.P("TP%M7R.7+(A,9#8"FL9 _2J%/<MF,IA;O.FEV;)!)718L^AK*:
M_;'] #;&9 VND19FA@1 7)4;1JJ4V ZV48?*PD3Q=[Q?ZS#!X2 W>_M[VO%[
M1EA1246H3,&$*I*Q/(;Q49*,)7R\9+LT@^JM 6!.[,"AS&UCBZ><7:WUZPJF
MA]35LAE\;PB2J<-&WL[;"$^6Y'0H^29OKA4YN*-R:$TA2P51)B@F6$0*DAJE
MP/ O2IV74^;;L&O-(IF;395?US7M0LSZU/B-/[MJZ 9V'D; )"F,:#R7V*3G
MZ([@=.F9?B8C<'6-0*2LI;!*X4Q/J8"VM*=FSMTH1PA;A \).G&NIS&)K"DH
ME0-G3M!<+KRVJQBT97YQ&"1I9+6IJC5TS3TL@FBN1V*]+O4ATAG#N0S)DH@7
MHM7;"P69,7&>M5E6Y4,IDL'0UG/G2I)&QL9U@P!I<7]T8X^_C(8O*A:EL>62
MR691V:0D8G8+$7)W@ELEB8LU-BE HENV.5BWSATDPS6V5T.=K0A%T*J66R5A
M&K#K-K>(P"(0:4+P2Q-+8K^,;3UA"'] Q2BPWR,C+V%!)U#*>Z)4AR<#HSM@
M5:.&*XZ06?>TJ>D;3$6&M)1)ILR.TGIIG@=IQBZ8DDA3P?$0/DIS38\)ASZ8
MZ7&%I/#PGC+:QOS@Z,9SJWN0&25-U QTM%%T9:'R3RI:^2N43J5R^9*VQ7)Y
M9,9BZG.[^_.P,+1'HZB,4J#<"$S;'8^QLC<A3)4B!L3EE#WP+L: : : I2=P
M:)6=")A6\]8D,H@\_C#]#)C&W/#(UN?XO)FM4ROS,N+PRPSR2.36M5(SPPSP
M,]&=D.&>&?&0 :T#NQZVROM<3*J[+G^Y2Z8E(:VCE1Q%';MR+)EC3T A\SCE
M@Q9GK)&>S)F<E8S2V&Q%>$AFS7-9&ZH(VVQQ]=76,YN#.N=>O7ZP<='V-&T%
M'$T,2*.LPE*FKETK1:L;GJ'L!KLUO.XFMMSKD[*&J.0-HC#:\'6-5431)R8X
MP,D>;H>2JC[:PI/2)UJ4#(G;KL(I3;)<5X7A 72P'2:7WD5A+PED@;7!N2HB
MI+));@E38M3"R.<C6%/$J="DDHL5SG$T;F MMBK;)4<9;4K5@!;YY[,ZH7BM
MD=4!:E]M$1"D\-MTA*8Y3"&]?-*(:'-Y=(%6TH6!71OID%:&2!Z1120-)31,
MUS6[O#;-I)+TKRZEK .QN/9C)3837C9MMGYE=3.O[1NR?IY2_.CB2\JFW<.^
M3B66?%TK\T-;BE0LSA+)BF<2TBZ'O:K%NCK0G9G:,2M"U3IJ ZFB>S(HBD9#
M4<\2JG5ZGM:5[6,3=G,6B')D,TE584TTT:U3U:XK8V[V6SJCH0S($AD39[+3
MPA0J0-CTZQYUDJ/-\4 7'A&P^I82IJ5=C*++DBZE&BIXY!5<A>8R)B:,T?G;
MQ59,#C@QQ!C)<DD>9[GDC 8L.*Q>7AN:HZH>'-<\IG5U>'U QMD79JO3?/JV
M0U):A\*HAC?MLLHL*(JU+HID4U>]KUKD6?%5;V"5/@UR!:]$MK+$<%R)7!TC
M,UH"EDE9+,S;8NBC8&Q]WJF+O=MP6Z5N;I[\*\@5F5RP%$JB<&;./VN]UB_R
MC-P0Y)<SU+A@NJ6+8M:DM8G*2)S'4LY.JR6%&)0,65G9\52XP60U&OL6\5-*
M.$ M.N(A3H35F30BK8[;T3D,'DI<+S11--*70&>+2I^9H&VV3); C\!0KL$T
M596U.W-)2 "["_:74;G$MQ, 6DR4R"[GB%7T28F2_G(6I*ZNL)0P.12.&&-Y
M*1SB+_)VII:71[6-CAB2=+&_WVHTJ*0.;XO=0,3+H[,"(636VX5"3;-GRNY;
MS@5C1I59%J/;"J2B]3JE4=&)USBRU_#86W-S6TPYJ:"2444;67(5R4]X,]T.
MRY<J5 9"1[9+6K3)3YU()G:5A6$ND;Y(W:=35^CISX[B[5"OHY"RJDL=B<<C
MR5CC4!<E9+(D:&-M/-?E*V3/RM[>G-U5K@6J*FTI6)=GI3\(EE</\=FUPHXY
M5TZB%J1VL1E+!G %-I0VE_H HYZ\)_>@$G5N+I7&):5Z84\H10I5(L,Y>GBZ
M23*%3F<!6..UDQ8EW9UF_2DMPV_[JT<S7+XP@2&-,Z@$CM.&$PBUTT?DF6;@
MU.$=E>):B;-7N]F+=(W,WF0AF:]LB]M0L@'?SO:)5-A/:N3O!\K12;*,T9'F
M.0-#LA2ND/5[=9W,;%K*5Q4]0T+,$,H12"=/Y#V>K*<&B11]09&W9F4,JUW1
M.0=>8HXG8%MM*G"2T<XJI4VH5<LQNISLQ5DTG323/$Z;95&GZ'2AS%F IYK?
M.!RQ37*2)*$H%)86T1Q#@K%P94SIH#RCFTUXJ9CP"GKFL)P?87 %];T(Q74\
MA-:LI=@=CF0C+(N,15#!Y199K U,;<B855GS:4RI.VMWO>;9FP(GZ1+EP&0-
M)U2Q4;4=<T_&U:YQ9JYB#)%$KLZY%9.SV8U(BB%K\[Y)RRD^3L^K@4O#IDG*
M*(R7K5&1)110X%X@70T T!X&8CF7GAB9F5EGAECB:6& F%CEB( 9@!N!A8YX
M"/>Q PLS <@#OX98\XB!I??F7=:Q90=D)<]RK_*&B86$@IE_-/GZUB<Y0EWQ
MRQ.L>=Q:J)ID<6-@KCMA&,*XOG9J%)7V40,D6->(DTK][";$.<R*V;97:3#Y
M+E@AM=0&3'4'K5/NH7VBV/HW1E$7'/<"=&E$V;7:0Y0T7X8CBRX11,%/F/7O
MKSK(W%C ?2.O[\P9BU[,)=+$DEP>66.-;K%I<[1-:6V/+FXMZHQN(;U9:U*>
MK9&Y3A@<G<2L<R34W>+.*,#$PS#+$0 N!WGK^T-?Z:5_)_O/05ZKKXO+Y!WG
MO^T-?Z:5_P"AZ"O5=/%Y/*.\]_VAK_32O_0] .\]_P!H:_TTK_T/0#O/7]I:
M_P!-*_\ 1- !R>N>A#7Q\*I7S_V/XM ?G>>_[0U?II7X?I/[7V] ?O>>_P"T
M-?Z:5_Z'H!WGO^T-?Z:5^'Z3^U]O0#O/?]H:_@_DI7_H?[^@'>>_[0U?II7_
M *'H!WGO^T-7Z:5_Z'H!WGOR(:_TTK#_ /PQT [SU_:&OX?Y*5_Z'H#W$9.0
MF![J*0XE<#R)!Z@PSG_:\8F)R\>!\_QP"'ESH#G: : : : : : : : : PU>
M-\M/,[1F]9L=H*4R!RMGWS),H*J9GN&PJC7J/,5I6G)X]*5C ^)8+%5<OB9Y
MI:%O<9LYH9"@5LL-<2RG#W"!<VF-QL&O-2]IXHV2UIP;62-S%E5RII2-:2<5
MU,W&4M4.L:(F)'1RS/B\E7PJ3%MR=\+8I20G0)7)TC;<U/D>7.P%^PRQ$.0R
MQ$/: @(?:'0'[R'M#YPT Y#VA\X: <A[0^<- .0]H?.&@'(>T/G#0#D/:'SA
MH!R'M#YPT Y#VA\X: <A[0^<- .0]H?.&@'(>T/G#0#D/:'SAH!R'M#YPT Y
M#VA\X: _>0'P'G0#0#0#0#0#0#0#0#0&,,KW702,2.60I/$K0D\ZC4PB4$;8
M<R0\$+O/)',(K*INB*@:J8.<58'AJ;HG!9J].TD7/35&RB(L[IT+LO7%$)5
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M?+5;QL<"K!.DQ03(%6"**%5AB15AB6%:*J$1CZ.MY#_QTV[U]MFS;[?\O.@
M/S!SQX\:A+UWO9%5KTM[,BUM=I1W_P"8KYUR5\F*:>R3$?\ K%?_ /?5Y_\
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MU]<N;;DA="E.UZF]IW%5=9N%"5BU(+!L2&0M:Z(W!W.5MZ632!O9U"Y*2>F
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M.1T!R= - - >&9A98X 9GA@)F8%EAGECB.9@@.088<B'>S'''(0QQYR$,1$
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MD2L[YE<^'2][WNRVX:@NV]KTNV"=9;UBG0W?>-LL,,Z*7.N]((IL-EG2DFK
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M+G5,MBIMIGM_[%0Q27NLF0I$Y:DSZ!<J 2S3Q38]WW[5SWL@- E0(\<<!B.
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M-(G'XQ3D8JV)2AA>U,F=8K+,#8E.W(#8)=]W0V@80$[FQ3VK;CGQHC;<VQU
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MA[HZ" ]!#VZP_L@N1%5%O6Q(J45%GP(RY-5=QIR\(.!T547%=Q.E%]T;/_\
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MB$:Z^W^4J+5E;)\$LO>\GT<)Z*W;W.L'>5E]!+*OUV#NC0$<OMV_IJVU>?\
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M^IR/[SH#E)D"%$.8HT21()G= P4R8D@3 PY[H9^BPP[W=[V7=[W/'>'CCD=
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M8P>L%?UC=?T9DZ?'_+C[G.@+(;FURG+;;N#QR9G$O'*C[8#(PPUG' L!@3^
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M1^8GCJ'/]1W#S_\ 4=!^ >H>>@+(;FG<DS;=N#+!&ZXCG2%KX!D8U+L"\>]
MW_'O9YY$ACA@'/.660@&(<B(@ <ZQ][=RKS\'VSYM-,!BSDMB5L_6"^6_NZT
MD%WCXA#CR\_M^?L'GV\ZKFZ5T7M5=MC9HE.A&HCLYY^^5&TU7QZ[]:N>.?\
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M487GGQUZMS>,$:[MC5!2K>4H-)$SN#5,# /2$GI\^<5$B >2SRRS,0Z]!'
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M56AYQ1I[9,77CQ>/C+2KJE*52B+1JG.C_5_8^>.!>&P!#QY#W:2 ^/M#J(?
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M.3WW# PLS#).&6&0 !V*5]8USHZ,B)Y:ECTR8H\WIH2N*10Z-&#B5D>WY.B
MD[-6@Q7$X9G(\E910*2L<C"!SPQ$0 \5C^PM[HTL:][:$+T_>[/4;.L<D:9T
M>?5Y JE_JEO..P5N/N%, J%GN,D[W,0 G'=PL.]H#M] - =-[XX\  (OK, "
M\^]P!]:(>!D/>'#U$ ^GX%Y[X#CZK_)W> <?0<AQH#K1GD&Q;GUWRF<3Q:8N
MM-;9,Z#(F<&Z.N)&16)[>^K16>YFA:3D>3B:E<#4YY>1Q09EXB9@ @=IA(&$
MQWPC^#VT9OQK6#V4R8.2+)W,91/!*#O@V@<*W-K%2()P<,212">($@=Z00QT
M!V&:I+@I)1YJ2,%:DH\].ES.+Q4GD)<B,%1Q) Y ::4FS5)L3S,,<L"<E!&)
MF6(G%AD![] >E0H3HTYZM6>2E2I235"E2H-P(3ITY.&1AQYYQN6)91)1>.1A
MIIF6.!>&.66608@(Z XK4[-3\VHGEC<V]Y:').6K;G5J6IG%M7I#0[Q2E$N1
MF')52<W'\<6<0:87F'7'(0T!QFZ11]X7.[8TOK,Z.4?4E(GYO;G-$N7,BP\D
M%!*1W2)CS5#:I.(RQ/*(6EDFF$Y 9A@. AEH#G+UZ%K1*W)S6I&YN0)CEBY>
MO4$I$2)(F+R-4*E:I1F60F3$%89FG'G&8%%%XY9YY8XXB( $"]"ZHDCFV+4C
MDW."8E8@<$"DE8B6I%)>)J=4D5I\S"%*8\K/$TD\DS,HTO+'/#++$0$0.7H!
MH!H!H!H!H!H!H!H!H#$>FMHT6JQ,]-3](UEFQ\8= *NA3#)V%C2H8;5=6NLQ
M>8)&# ;B,!D;PU*INZ)EDJ< (5.3>VQXK- 0N1.+B\!UZ^,O4@I6HFL%0-U:
M0E%[N5 M79)XXUEYK5@)4J'%6K,Q3=]2IQ0HD2/$X[+,S%(D2IL<@)3E88 =
M XUIMWES2G:W:%U))V*4%J 2-SBSQ5Z:9$4TY^[%8)TBDE2C=RVW-+[J4 46
MHQ1YI_3F^C$GO8_$R7+FP12YL$$R")&B@F0PQP1(BHK10Q(J*B*RU1:L?C:+
M/9[5)CL]JD2;3(F(B3)%HE03I,Q$B2)$CES(8H(T2*%(D2*%6B1%2J(6M(VY
M;#%+.@D*:D]J2A@=7(IE:WPB!50:SN3P>KS0$M*!S+;,D2QR.7%F(BD"<\Q4
M8K+S3X%"=AE@'5];;N_J%B_Z61_EF,]CF'OT%<W]UV'_ ""NF[:WM8ARO&3-
M.W^C(JN:"52G"0-U:0AC5M9 I3B5JC%V3,Z4Y$2*(Q04J-!05@*4P[ [+T.>
M8#]R[#8I,:3)5CLLJ9"_%CEV>5!'"Z*BM%# D2.BJBLM454R4_:SW+<UDG06
MBRW3=EFM$OC=CGV>P663.E\:&*"+B39<J&.'C01101<6)'ABBA5T546MFJOZ
M??6U$\L<4@3RT.2<M8W.K4VLKBVKTAV/>)5(ER0LY*J3FXB&19Y!IA6>(\XY
M"'77:,F<DJH*L),/-*KZ(X&*<L<S\P8F\1,RQ 0Q$>2! . $0Z  == =(OK^
MAUR)U0.D4K!8W"O)B3VB7ML;4(A<WO!$F3QEU3*"\R!7NY;PW)R697A[H7X.
MJ(K!,;BN(Q-XBAACAB@CA2*&)%ABAB1(H8H8D988D5T5%15145%145E/B9+@
MFP1RIL$$R5,@BES)<R%(X)D$:+#'!'!$BPQ010JL,4,2*D2*J*BHI:4=MNQ+
M B1JQH_:MBEAQAA,N5#7]58D18THD%!I,C.%K MC,+3Y >86YY)<L"1 W( P
M$,M=/UMN[^H6+_I9'^68GV.8>_0-S?W78?\ (.X;=M.S%OD#(2ST9MN0RHY+
MA*(V4VU[6Z:0&HD!Z?/"1,F"5JP<<TJ)2<DSP=T "4F/-3Y HP,S*$?J"P6"
M7%#'!8K)!'"J10QP6:3#%#$F2PQ) BHJ:*BHJ'W*N&XY,R"=)N:Z94V5'#,E
M395W6.7,EQP*D4,<$<$E(H(X8D188H51851%144NZ96E5$G)DQT+A92A9D;@
MD(,9VDLY5F25D<=BF*R)#,_(HG'(TW$K'(2RL<C,@# !$.V98]^57UF5AEGG
M!HB667B.6>>;&V8X888 .666661 !CCCB B(B(!B "(B !H#JV:"TS)6Q,]1
MZ,U\_LSAB9FC=F9"Q.K8MPP-,(-R2KT.)Z11A@<6:28)1N>.)F&9>0AECD
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M38(Y<R"&9+F0Q03)<<*1P1P1HL,<$<,2+#%#%"JPQ0Q(J1(JHJ*BEL"MKNR
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MHY2ETQZO):R,9@%I9.MC5KRR O*Z+KU[4WO\>1/;:N7XI3S4Z@#7@G[,^ZX
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M9!^--.5I0W,G&7LL8G3HCL*30I/%Z\8D[37DL*>DK= 7509*[9]N]Q5C#V]
MZV,?7R8;7LN?.L"8&RMY67(V*:OJ=U;6B7R1+741:6UX1Y%N!AHU7&84T)4K
MFG;S<I [-JN6O8'2; -N5Q;;(D^PVS%[.L;BHW7C82L22-#+':960R82L+2M
MI8Y)J_@JMG;++.<8LXH8@Z&2%>SO#=)'-2YBK?E1ZX#81H#2=8W9A67,722R
M2/VZ=#E$EW'VE=:&)MXY&,T+GL^G\U0(MQC(\XY$.>=E,]&.<9AB*()BFUG2
MJ\)"OQ>#'1X.<, .[RVE;@&IFESRR4'MP2N9L7I"$P2J2UT'>X!#)!!$<R9I
M';K<873M<+9RW15IE3DMK"!VP[2!<Y220NJ]R=H&B0(41H'?5]L'G42O6FYE
M"G=UJN UO'F1[>#W9_K^?3=SF#-M1RVMQV+HG/"LR) IC;*T@SS%^;7>;C7Z
MF8PQ [-,&<#I6K.B#KUV=>D9?,U!2YKW%TS<3_)4%A.$)H/<%5,QL=Y8XQ&Y
MT_'6'9E"S2!-0MT18&EH,C[$B@<T)RQ)!)@C5J$JGW*K6/#@KP R?DK7F]QR
M0,I>"<PQW9'5KP+5G+DZ0S->@/28X*E#8>F<B$^0FAB<<WJ4ZXHL<LTAY2C$
MLS$#0@W[1-\U?N#)758DFP..O-<W4;%S87=2B%-U?V0S0_;#!J@E]MV#4])U
M\BNEOAKTT2U5 (=8\,?91+*M87U-.WF2&FFP!$!E6;M5W",K#.X[#H?2R6R0
ME.X>=QO=?G-'Z/6O*S+@?I(^,\6Y9X*N?(,]Y,\EPKMYE2]^G3%"6.'1&2PJ
M+/CF2RLL! H+#:7O,D[PE8IG+9+G3$I07]#)I!77=I:,O=FBJ+)8)HRQQE1/
M*N,HSY'8J)"\1=&WR^=K+"21DQO<#&7U:Z-ILNGX&7^QS;W8=!Q2V#;+>FY2
M^6M:V$_11=D31-&S0=B:ZTKJLFEG)302&0"'E.KLGKX)7(2X[%TK:F>']2A+
M<) :C.D+J!F[H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!
MH!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!
MH!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!
MH!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!
MH!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!
MH!H!H!H!H!H!H!H!H!H!H!H".Q2/:J[@;'VR9;CID_UHQ%J)S2D2RA46V=;A
MTH,!]F;M(31(8)[2LRZHG5=I(UD?=G3%:I@#UBNBZYQ3OV2%X!@/C3RY@;!-
MO7::5;N0NB)U%$:DN^/MME,M_2>I;9ES97:2N;-C&V^Q&2J[">V MGL=[GC2
M49,WGW*Q(Y?"(XX.#:E%V.2HTZI)@:!C9V?7:5W=NNW*R.JK'@E>1J!NU<W!
M8]?/$<8YNPXG)ZNOLNH4B""6)*7USAVZN*/+"I1RQ]MBH&F,Q>%N2UIC;JWG
M*7YO,Q YZ#M,;.L;?52E$U]3YS%0KMN WO[?)5.WA_BCO*;/FVT*K'=RDJ"+
M1$I<A=($C162A!"R.STK7IY@S)S%BS&,IUC6+@!F)/\ =Z[P-7M*<7ZH;.CC
M;N$0RY9+Z\-KJ0V-=%>K&>N,9F@CZ^+TVJGB4MV:W++)JEBI =(V)'Z$S%.Z
M8]XI5F!CI17:5KY^W1,E_KN2RZQ++R@[5 *JKR&MD0<5#S*'K=DN4J%\HM6V
M6A C(;J[VR/K_(6J4-4)5QEQ09-:!9,G:4I&2-.O6O7:#V0+M/B)S,'-2GIZ
MP4%2OS-1R"(2AP;(<D=H)/[=DUVP9$S6RV868J<%2-UF-8M30VY0!GD(L.+J
M*R2JDZ-3[I;@+M;<=^[%;+/M^B,KB$E1W=;,4IUW=V5C:FLB.8M]C;9T^X!R
MMQGP62M<Z):60N260580[+\E,@*LQMQBV36L3G)WU2!0%P]J%!8LDW51VLX#
M*YA8&WJM=Q,A:%:M5! A\EG.WB-GN<O8'!"FL B<QYG;',EP3^MI/'HPDDI4
M3E9$56."O**A)@.IB^\J]&FRG.,6VQ90Z+0T[:%!GIX6U_!W13(YS>J<QVF#
MBHQB6XQSRB"4A-GBUHBT228-L:!K<WC$R<"K;FK("Z2[?PU%Q:H[(?*VM&GJ
MUL60,KNV2:PX;#Y(CFE5OE'77<J=\:3X3<)ZF#.*5CJ@7AX2R)K?96RIUS(S
M*Z[S,E!K[$P*6C7:C5S-(^VN<,H^[94_N[XXM;?$&1=1ZU8:WMU32&Y37PR4
M%W+]#\D@N*Q5];%C/E+1DS;+$93.N92D3DTO#@!?6D]W22X)'?0G5X_0ZLJ=
M:Z]DK-9KN[QM6CF<8GE01:WBW#.-M;JLDL?6(&22X&9(E[;F68C+*RS5$NF:
MEI2 69K?M/*MMQKCV5>U-;TEE\VET/BT"@:!54![G*\)I7MAVHA>,9,GM8^O
MH^6R0>JIRY2UBD\O:)9'UC6WMQ[ <;)(T8[ 6@K'M*+%D<4J][7T^OG$DL-5
MMH;W:%Q=#&H)G"B[_MK<E7R=Z-D<SM=<5(ER0BE$B53#RF-D+97<<U8S*0-T
MA-+A8%XXKVBD8-DF,->J_LN39I;'1PZ3V+'HM!HM"8:186]6[=F-5)W5D=[E
MD4P=#C;#J46UY=(VC>!6LJY)/E3#$"W!="HR'E+I4-O=B-_SF)PQBJ^U8@BL
MFF9/?]63>9)H'C%I_5<<F,.AA4@;R(Y/7^3,RQ]4SEA?FEAE+ PNF,;5DJG8
MIJ<S,FDD"T6WOM'HM;!E*1QQK^S%2FS#:HARJVRXI!8?7>=FVIML_%-L#,$-
M"Z+ GK"0M@J9P(5X$Y2]LC\A]Q,YTH=4:H'T ,1G7M=[';KA>J:+J$Q2]-W:
MM(MD2:595C:R>IS:741=I=,W-9<QAWT-45Z9.BX_+"-GOY8$L )W8V&9(Q%8
M8!8^)=LYN?1Q=Y:+3J:GXEN"GGT#F.H*9F43OBG!A,QO*]F2DD;W,)M)T<MK
M^^=N\,.E4?>':^*7F+,>[O!R2+%UVSIY(TR9.!FY87:+63LKC$HPWN0^OK+?
M6BT&"'-,MVD/<;88VCC$CKE=8!+]=$<OZUF%#0;@2+(\,4<12FT7;"SEBF/#
M"\<U#BJ0H0-N;8XIG=M;W9%EWT;FA2.*3/G#+OIEJ<M21EWBLS"\N\4;@/)9
MAF \\X9Y8\9"!SM - - :&7'M)[\43/M!"0?*TB<2V=.^Z-K96)-M-W"V"^O
MK-1]*$6&RR===>%K0V@,7XQY<T_NZN'-TC#P]-[3DW)G!B-DC:\H@,A(%VL%
M9R:PZVJT:FNY_P 9?;U7;9W&\6F.5PRU&1N(GM#H+_6P\QF<;?<+);4K+"5Z
M54Y+DT8D+*D<E63&WR)^,2"X*@+6,?:57>Y=I HVM*8%7Q-&Y;B95MS2R[%B
MFY0"Y1S;FENHI]2;@#GW*H'^SEDES60U?M=;HJ39C"U(ULJ6/9R%L58Y@7MG
MG:A1&%[\&[9$DI6S)7FGD=1P><6Q'TYZUCA<SO"+/DN@A2AD2,ZO!5$D[6V-
M>$NE:^1,9C$HD*7- QOS>U2%>T@59NHWE6Y3-.5?:$'H"2>^&3;EE=62.J+$
M3M^<]>:UAY%L/<L?J^30.6/K4JE<XB%6'OU.IG%T/)=??%'TDE:6E2M4D-X%
M@('VD%KW?9ZV"55&*V9XI;MNP2([7K,EK7,79(?4R^J=P-B2.WIS%4CU&E$M
M-F>&W&3N=,1.-/T0P?89-85('B0%9DO"3 #OYQO>W ,U%6)9,/\ H3RUXHIY
MMIHL/U31^Y%;(9:\0^*PN=UXP?0-<3HS,J,:Y5%IC@HL>SII-)U#*JR)CKB7
MA,&B8BIC &9=I;P:TJFM;4G+L0_O+M4=&R>\W^/L$:EJYF<V.+P ; 4-\=L8
M8WA WHY<W9$)V\]"]'Y'&'@(I<3"%*<D"SM.[TE:2C[VM?<P)T2?:&@J.W[#
M@B*G)17#S$:W=X:YRQE4M1$GL><FV,A>ACDJ:X_*\1@"I>ZQ]T9Y#!8<\MR]
MN2@=;'^TFA<]8S"ZYIJW)=8>*FR\#H"TJ*C<#T+#5<-KN92R=%RTFURJ\D\7
M;R+;KIAQ31&9O,C4S!^41CU,0J8I I:F0*%I/M")U.W2AF!?5JN;K[@L.KZ]
MEKI$44=A+)5:^7[!H%O"=5R;&3VB_OEDH##9&Z&I343)#UK2Q)'>.^JY%((_
M'7.S ,EZ.WH0R^*JM*THY YM'OH3GKR)%!9@]U*S3@H]'&$<LQ;WE']$P]EK
MI]% MQ1.+!;3Y '-A<DZG)\)0,HI'M6!C%?/:(O395\0NRB6Y,FJ=UJ&\[0.
MFMD4U;4O1RB8T^KC29EHII(@;DR%QAUL<I?+7-AM@Q;-(>M:H>I<H6R3UJ4'
MN2$#NF_>O<LA>DL\8HE7Z2H5VXJ ;7D==2!%(T=O#++#JV)2ENGKE+R'XQ@:
MFYIL&;-,9<Z^"NUZ_*OVYTL@N;X*34T0* J7:[N[L^>6XKHO<0;25<V?&&5U
M;7B'-T@:6Z;3>R%.2.9)6&!Q)-9UAILT-<U$:VR>Q<FF3SO%6%APQ9@Y1)P9
M9I$&L#RMKM$6F&PZWWV)5!8;L$4CVZ%%4\T><X"EKVU[2VK,TM56/"T!15A%
M39G(:G"#S4"7*41R,(I$WP&8',*X[,8L,E L#O*W_P!V[2Z-I2:*$<=76;+-
MJ.[*[)!%I16R8YG?9I0-#(;2:6Y>[1"]#2:^:@=5/<<$3"-K92)$8+8G?8J:
M0#V:S!C>':E;Z%<$=W&+T7&K&;"K2I.,H-PD%VU;DC8Y[T+"J:PY_9)T;VL/
MTN:;EN!^IV21&)Q61N-8S]Q83&NQ$\FS*3#%'=H4@7)KKM(]UVZ)8VQ?:^5L
MP3OM?;1(WN:N*;V4[W/]#29R&2V!:5?):ZK4AV057.:[961QIV5XV7.[*8'5
M364@6I(BX1%Z4-"YW6@9LT?VB]>W'N67;3SH!+HG9C37+3.SY"KD59.5<RG)
M1#8#,7<*M5)9R78UBPI&GL!(WL]L--9D5Q(G%ADJ)'("5C<2F6 =.R=J1M_?
MIVTUBDC-I$SUX31Y*3'53)&<5">:NFXY!MFDU9JCRI>:F"=UK+G=HF$^:R3C
MD;963FEF#>XNA7I4A0%HD?:1V,[U=+Y/'*;='HR)T%M"NMKL):AB3"RST[<C
M;C_7RV+H:L37!*)'%'4M#%7S",XN$X>FP']N=L7][0LZ>-+YD!EBIWJ,I-<Q
M&9)Z;ME?*Y?N#?-L9-4)CJQQE[1:4><YHV.F#L\J;%3U_P"]<@(.YN@/[9,7
M(<V=4@/+09+LE+<E Q\G?:KUTVL>XLVLJKG5D22A8E;<E3H\'VMVABF!]'V(
MRUA8S>8X835Q?(3DTR1X-5M/OWC3$LF4?8I ZPM"_P"2 M(I K.=]IY2M=6%
M8E;2.#V:+_54<D;E.BVH:W=C624Q;;X?N5>(.:U(;$-?,U)-?DX-9<VQ; K
MZ=+6Z)%3;)8M*.T!VZ#?HL?K'JBN&3;K:")WF6X5=0M@E2E_JAO65IGEMD/W
M11Z6B6S6&_M\J;WF!*6E<>W,KIDXM9"&6HE)0R9NC<?E@'2U/VBL0F<5K9W6
M0FQI(SO*?;Q'[%MIFBL,B$'A%D[ED$;45A&'B%.-ORV;HSWM1-(*4Z!%CK&9
M(GE/8P#C*UJ7"1N# Z^/+K]H+@T]OWK.TZVL&U7N#694,4KN@8!NA<\[%1PY
M2N<*,LF.SZ1QN9($U?3*<XEGY)ZOFZ=?&W$Y#(D9S6FSS;LB71$9F!9FT-^M
M@F9UQ!:\HVP8#:\PN[;S#Y#'K+2U2^N#!4]XM=B2=DGS81&[L+BSD>]IJFG$
M,!N43$EWB\A:7=<X,#BA2L8R%S N796X&^W"=[GF:E,:=8V3:1$XP[2=%;K-
M*EJZVY7(:],M8UB:),PS&-(*EA2.)GLC+A9#A&[2S/E2^2#G#B44$-32D#SC
MF_1)/8^_R:M]O5W3*/QV-)5+I*$N-<-<=;)ZX4$R;AD5?.V#W8#9*FXW"+R:
M.QQQEZB+80UOF[RDCQSSW\52E,!CA=/:JMU?1#:B:2U5Q7=D78FVUV=;,/N&
MPHPE(JNAKLM^#58J=VM8S2=,5)Y<\F2MW?X7@0IP:VN%P6?32<$M1D6+B;VY
M@7SOW<M>3'.;434 P-<YCM-QREH[*4:2+GSUX.L"Z)FWODA<V*)M,FB#Y/7.
MF:$1(9]C6,9E#.]3W"UF$6]9DI:4J->!2\=[22,M%=>^"81B0V6Y0& RZTMP
M4IJ.'KX/'Z;K6+6;,ZYRE,]K>]I%#;7BTJ)&"2QREU1-;7/)=$#X3.&\A;)2
MT4573%U^P%XL-VRRSY%>]/TC&A8+AH4UI262^7.E2(JNK/!^E:0IF>7XZ.RH
MMSEV4AJ+!\O&&,$?<&M*[1I$QL$ZF%6/<E)% !3L:WF.\<VGG;C[.AZ^;H"+
M">8DQOM3QT8O';"@N5C*X;#+R1MUCS#W)7E7R)B!',EC_*IXX,*.,9!)6V0N
M[*YLQJH#AINT 0G/$V.&D9^L@[56&U*<5[(V.45&^K[.E.[>9N$ KJO6A"W6
M*<SMZ]5*\&]G*E"V1!">\ED;NX2)NC:2//<G I9=VCK*AF);.JJBVT;@E<7:
MNG"HS8S6Q\[5VECN%V_[?F@4$\*O3"!D1X9)>K,:)1Z8](YL7NV3C+&;U,GC
MTD?M\G6@.0W]HNPN<B9TC16%HOZ^79P2$,-3HH]7;=-&:U7FR=VE<RAO?IZZ
MW43!5C2T/FU>6MJO%N2E-[82E;Y"U2N9I)5DV1(#LHOVEM7S<J'/$1J:ZGN%
M227[<*YD$W+05TC:*ZL?<^IAI<#ATN;E]CII&J5,B*?11PFKO#V:4Q]JP?6U
M,TNK\K,6$H -CN@&@&@&@&@&@&@&@&@&@/P1#$!RR$,<<0$<LA$    .1$1'
MH  '41'H : P&B;%V=\GVPPNJ8I(J5<-KK19K<PP=G*LW$J*!:U;VAC9#6P-
M3\LE)+JXR9ELIA+E"1F%V5'.()B5&"5<P*2L3P,8=OFQ_:5M?W9W#O#'<Y!W
M5X2,UDGFQI9E1=>L54L>XFPF29/KI-'B&(H\J=RW1]C:1GAKG*,6I'F6<]+%
M)<@F#T[R-4!?-HV2=F;''A_;V2"5"SO-^,TICQ#.@L]X2*'R,MTV33^=QJIF
M8J<8!#(PGGC FDDTC]1I(XS"]-6)\@199I1QP \(-'^S+EMQ8;E*YA.WUWL6
M>([-D2W<M&&V*D$@Z-RB+TM8*1RL8A2DR9Y?*BYXRQU>3AFG7RY*:0I6J%AF
M+2<H OY'V_:#6L3VY9-$LJR/Q"N8DX,VVMT<+21GMX1%-"\&9U&'OSW*E.4W
M1IX0DQ]8.BE=(3B6PG-T4+,<O2+! P7W?51M9@RBNJ.8H'>=:3R?2Z(N%;SB
MF:FG%D$.K_ $5Z3LB)H)0D<,7:/.C:PS2Z9([*85+(-+R69Z6I%$D/C2]5'7
M(#NZ<9-AE.L\9V^H8O/Y.T1*3PZJU%W/%?SE'6$LNF@'R8R9GC 3V.MS/7*:
M5QB>.DZ0D-<<2-L+)G(N%6ISSY,TIXFD J+9,.URS+HQN.JC9P@D#!M1I^ T
M5!)[5#W5V4+V>O:G-X@[A#U<D1B^62Q2B01TP#)6YO;DI9,&A$S>KF0UQ7K)
M('7JQ<N5L>P4Z6R!>K/B<Q<]SC],]O\ -T$3LE[DL/,=[ @DT46,#Y$62:FP
MVMW:61>I),T3>=L[''Y4[KV$4#T\J%Q9^1;]WC!5E@3#9(PY);!DS]7;LCDE
MUUI&'J8M,R2N[!';3JR-/<C@1\Y=4,C%FB9<*C[&O6*LGC-(D)(S3&O:526I
M+,T!XQO;YL2KIUB#(UH:U0NKTJ8YM7$=D5HN,@,/:4K)*:XBR.N(]+)FZE)J
MN;FFWI5&(M 8BA)K%L.GBHADCB=>ZD99 6T4M&TRAI+*X)%*)MZ=C2S 5/IG
M((EG/+?]X!]BQ156C+!052&>O,W5+U%4J'A2U02.-KG%JVKDLEW.(AQ<BBGK
MX"C8ENCV3U>3';1C57;@(LBM2A,I!F434MVN+2?MUI%FKUG(L^65Z5D[-1;#
M'XQ.H6S)[!51I3,':,DXLQCBN:V04:8"M$U7]G^AL:,[.VYF=2YQ+(>T[D8,
MF;9S<_K".QJ* ZPF''UW<"67@\UDF1L+A-6J"5S!IA&FX('C8R>/QW&+Y2HH
MX"W49SV#/L<"LZIHJS'1@<8^SM=+K(<U6573%<*K;$_S^SX=&=N]U/LL@K"=
M)(R^22QI'"W=#/HHEES,ID;FSR-^@[4M6( ,JJ;J+:=:U?L]L5M 4I\:L]1$
M9X)R\R5MCN+_  B^YIN/9B) SN;I@O8I-"MQ$TG<H>V!62F4MDM5.T;>$N;8
MW$LZ4"AML_9^P?;9<\ON=LG4FEKJ\1650&),;BW,[,R0>$3.P$MD/C"VM[*4
M0UE$>OVQGP;&^-M<2BK40C7+D<5PD,EE#X\\=>ODZJ"^L-VF;>*^315)#JR:
MF-/")-#9E%2B'.1'@SR:OZJSI&'.I.2QX4YG',=6&9P\@I5D>F/19"K6$*73
M^3]<@X9VSS;4H,5FGU2RG9+MR!6[I9Z5QD1F"C<80TI6,JSS2\GD2\G3%I1I
MD0M/<][6910#FRY&99YY 6GCG9C[#(JR6-&FC;3 \HY:D4S@<M8'@Z1R1E*@
MN4@PEA<*AS7(GQU15M$4LK*32EOC=<D11G;9(@;'U C3.C4VJDH'$S[+[8B9
M5ZFGL]O[/G!W"8+)Z\X93"QQEDBE+C&3H4Y.$HL?WX_1%E"=SA9YL/<FB02I
MR95\4R".JF\UG++1X 9UM;6W,C8W,K.A2MC0T(4C6UMJ$@M*A;FY G+2(4*-
M,3C@4G2I$Q12=.05CB6227@7ACCCB  !SM - - :ZS9#M$2.^X7;S]"Q_&"[
MA;P>JNO628$K/H=69?MTU$8Y6'$1=S)9A)\'!-549:2)L]QQJ;(5'UJI''6Y
M\]^:&4-C(!C:?V=6T-3OAK7=>FW 11O.C22(WE7U,M!=+MON]!5]0G5#'IR3
M/T"%/9,MK%DBF93FN7NKD]YJ'- UDN<V-B;.TQE#QN1N8&9RW:#L>(N>3[EE
M]>UXFM4DE184IERB6NB9G:%<KB2^%*+75Q/.2EP./RJ0PML=8[G:Q4>02AS9
M$+DC]\IR<A6&/(+=-56=FS#Y]MVF3#7]&.TNB,>>*_I>X4H,4U&&-&W^+N28
MUM=;27.;N:4Y5\QN[VU-3K)7A>_,1[F](R%Z)2O7^F NT_,6T&G(JS-#@=#&
M])6%FV'=\.B.<[-<)5C<*C"7S2:JXRU.TIS>GR5J1LJ2*BXGD8I1HRY4C2I&
MI"A%I+3@<I^K[:'>3\]1YZP@SU8<S9X)+G)B;IV>P6PRIZUQ<<(1*F,J+2=M
MF]>O,)RF3J@2RJ('1]U;LWU2@.=1Q5@5F!8^:5CV9V$ A2&6R.K"87A8,KJ9
MGDR:]9&0X2V?V:K2++%K.P+&8[ PDUDJ; 6,K:JLN&V=))(WR@UG:CYHW+?5
MC?DG=?&#-%VF='+6B<P-[EU5J&**-J")63#W*0Q/-LC#3+$>+4UQN;,2A8*=
MC0R1 KP;FYI?$J4EW2J<$J4A04=CAD!9."5ELOKN#9PB.+ZX6PO= C"/ID\S
MM1396=XLAL;R8D418'ZQ9A*GB;Q5OB1YK8P0]A<UT>8V14I)9&I"E6*?3 =:
M7M.V;2.)QV'X-:60MF)\ALEG=ANRQWB;/[<Y-+/"Y:YN5D96(IL&:0)RCJ>-
MPR2LC[)WJ"KH\@C,8=6PUK;&5 F XL3JC8DY+(7&H YU@>\M-C1^;P=O@]R+
M,9&-@4E3L:IM+DTY1R<8O;D$6I%!'8/,8N!BME=86K]S3EG<TKZN,< .TK1F
MV/4O%K$10B84^W1)X=0;+(SDEP(YNV)SF1$N9$<->'">S&1XQ^/1AO:79I9:
M^P4MT9BR5&[HFA@;2\' L0/*1N>TW<_!FZ7V"^H5$"@Y\\7N4?EEC/\ 7T2,
M985/7FN)0X6C!$<N8XI-:[PEL#<$:0JS&B00X_%'D84EP%4I+S YSA!MF:>W
MVZ]G)VJ])9JACQM%N=E-GXI&1>@;X6LBI5T%P;.6%0-Q>VZN$RZ+)[FSC*B1
MH($D/CQ,K)C:7)$4!1,>CNTP=QE9$L]='!-'F,SF[:5N!"^J'RM+/6/3W(W.
MPU#.^-,T=FZ4SJ-YV\_2%I+G+)[H;HS8,A7U.N4,R.98,@%3&4#LL=K#NI08
M@@CE.G6)S-#<L6RLQV5IXG'+>:B\+#>5-<#,#&"J%UGM27%3,IG'XY$GV9X%
MFN+R].)QAZDP#A7!7FQ#<)%JY4VZXTU.X>Y0VQ:OJUQ66BE2,L@A]N,[74]B
M1F).K-+F]-),)0W*V>&JLT"EQ<$RY:@2-RA&[*R<C0+53:8[$MV9#I0,\CA4
MMAM 6NIAJ.7B_&1=EK:R*MK=PD#J\1JS8K-V>=P)1$XP:\1%=*\5L;S7JCGR
M/D+75JS=31 I6;;3.R&GD1KZ,RJ/[8S(E3E>O#/$B6RVD,7*;:G6.C9(),T2
M=UC4[9ULRKET?9(V2"4-T\72",NSY*"WI[)5.4CS5+P+N,5;;#:\W S&]RXU
M *PMF&@Q5^,YDDHRB,.S"5U]7*=$?7D?=)017B=Q<X8K@$)<9-&XVVR)>E2M
MT44N"M#[F(4 5RBHS9,VW60K11ZH$U]H+@>MPA+;A)T7T0$UO6%6;A!WB>#&
M<GT7(%\GK9C="P39M8M"HAE62=*@];-9KP0!3,LI39C6\1*DIL30F,,3@+)3
MR.-Q*;RE7@\Q2F; REK#$<XDBF2=LF+W5<YP=7!$L>4KG*(;DKEC=@XH&]YD
M*!<!4,_?]H%9M<B7OKC#%2VH;7SO&019@E&+Y,HK:TT6*4JB7N$51O\ F\)%
M[B,_6K#$+@E+:BT#QDM);\",$V> %H[%:]@\.C%E6@Y,22<P*]8)<),Y>H+*
MY-8%>N$95NS*=<"2,M;/,5D/@SK-9,L;W.7JJY;X\[2N7->;W(5RB0M92W #
MQ3Q3L])/.W./R94SM]DR2O;*CC["[*MJ;I'R6P6 IGO;1-+$D4=?Y\H;Y')#
MHBV.D$*NE])66DX0 3T><KQ:2%Q"4#)!]H[;6N<WJ7NC:R-SO [0C5S222M\
M]?XTOB%CPJI6FOVA_D#LS2=L.8R,*4]6QM\8',]-&Y) G$TJ3M#LU/:W-:!C
M$?%>SSA]J[2V"+,$:D,ML%J1ME"(X'8:QWA#C%J09U.4=GC\R?1"30JP?H:@
M[%-,$F#JT3J=L#HYE9Q#,DIJ<E[.'53*"'P3:U!G*35G%BZT1/#'2%?UE-*_
M/E*)X<VJA:\3RXB!,LKBKR\N*M)#FM)/9<22Z/*##!V3/BDMS<' HM-B0!BN
M0;V>U%*:N9HTW%R8F:NT?NVN9BPS"97$E6N$"LNI=KT06H[%=)G)U9[)"9+N
M5B,6BL/P>E,0C+"Z24UG9$)+:M*S O\ 6+36SS<(Y2F?S485,LX0C502UG-C
MM)V9XV<RQ0Q6^+:]OQLA<P:(Q-8U&LG)R<5,%N%"_,3,0[O!AK.F3/+F"L#K
MUT%V0925XW0+WJIRQ0O2EBD4Z.M8M/52><$QH:F4JWZ/>^\NH\;22PU1]#'*
M4.3%]$%+%C<82#L6T#@V: ]<HBVR.J:F*J:>O-<-==4G$XQ;V$<GUD+9)((7
M :NG#78$.EIJZ42=XG^4(B<S8F;*/8'KE4=*P;VZ'H$QC0"=BR J6-;>J$L2
MK)8B-5%VU"[NLE;?:N;)9%DG<7.3N#LV.L(DD/F\!4L#HPJ*Y98]#8O74CB[
MJWR%A8H:P 6\FN:90N/ MBOVY]GZICAJQR)K8V-4(N?F:=/*JY7OW&V*7B5$
M3Z4QS<4_9ST,K!3N\U/*F,CC=]KI4C<I(LS?'1O/7KSU!X%F7]=V9TUBUDGS
MM&UQ*!V>IE%?V//9)-)C7S+9:Y]W5RB%+HV]3IKFK8Z28URO&%/IL:,5N)R=
MI@3BXI&16T5R^R-H, R&1QO:6OK/&CGR2.S+%EEGKH]%VZQK\L='8SI/XI)T
MJ1"MK.Q9+9RBU\3\'U(DQBI\/EJ4\"CA1MR=.2O4I#P.2EV\;*I*ZO-8LK?"
M%+Q'JMB5(2"N8G:+XA7L,%KMX1S6OT3M#8W,TI[3+:^>UZ62P6PU;:GLB&+'
M;-RCDJ;,W<\U4!5<:V5;8XEFTGLE7)L%K*]X29&Z.4HF[\\G23&QX!;IL@=7
ME]DKDZOKVMLNKX+,G1U>UC@N=GIB YS/5EN+N4O J1JVKT R2%ME356[8CD#
M/),)>VN6#E(,S4LC+E5Q3?!TP+-=S$^9N,JO^X'@"C2<TWIYNO)$GW*A9R&X
M#%M^[,JGG"Z*MLN/2!\A<+JY?3SVW5(PHD.+"O?J(?5<CKAQ5/1YF;BL-;W0
MQ"6K<9$1))44RH#XQ&I1&8R_21H=P-DV@&@&@&@&@&@&@&@&@&@ @ @(" "
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M!H!H!UY^#K\?/3C]WGY- - -  Y\_M: : : : : : : : : : : : : : :
M: : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
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M9G@9CB)R%6I39\X9 )1V8=.>0P6)K3/LEQV^T6:;%)GRH)*RYD"HD4*Q6F3
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MY=*Y>Z-F=%S]^AZ5HJ57)=CH;1@CECA=<_=ZZE3_ *V3O\>3I2I.1U88OR-
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ME_<%^WS9.@+OZ Q\W8=-M%Z?8PEWZT*=:]BSDS?W@JV^@C-6QO3"&)/ UO\
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MZ>_99U_^J(PXX]GSATZ^W428R5?91?:9)ZLCJ[*GWD#-5-5V)14>BHI#F/\
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MZ;'R9$=ZD080Y5X;S[N77E7^>R>JDL;5KR[PT T T T T T T T T T T T
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M2)O70%Q6D)WTLE9:]^J2L%D7DK<LP+.O>Q\\<53>O:$R]"?B \&I5J9.I)R
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MVX_]ZVL>@@(\>P?'CV=.N8P_W=NG7W0LVU&]N3-\]N;YHKFTX(Y8X6JR)?\
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M?A4NBZ:KE5G<B#"'*O#?ARZ\^_)/5-Y+'U; N\- - - - - - - - - - -
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M,6#F>RM[FO=7%"U&K .S0)%SFX*TZ;(LI0L4FXY'9@=SH!H"T%(?2:]_9?W
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M.$.5>&_#EU^2V25WDL;5L"[HT T T T T T T T T T T T T T T T T T
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MOE4DG,JDD@]1L<7(<WV42YT>'QS4(HQ&(Y'4/NE;G@D9F-M1$X8X)^<@./3
M8^\]V_&ATM6]PXX#P"\+$ /N?)H/(:T.VU  VHPSH ?S<XMU#IQ_L+L+V?\
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MPM]K<#[;T\UW[TYUSH]#=.'/+#//?'_TPUG[8P#\451H^VUH(/MZ#)&[S^(
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M@@@A18HHXE5(888455541$5:$*?UHV?71M\?S<D\/9_3O'_7TZ#JOWK?>#?
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M_P!)T)_AO6RFVD)[M 0&4;S]QDBC/=D3 [6.XK&E\8AQ=VAS29I$..*IO<D
MJ$2Q/EEB..)Z<XTO++'(,<^@@$,WY=]OF7O>,<NPVR9!':IBP1P66?'!%"JT
MBACAEK#$BIJBJF\K3BVY[VGXDOB=(NJ\Y\F9:XXX)DFPVJ9+CA2&%$B@C@DQ
M0Q0JKH\,2HM6JALS[">8Q&M))N2.L>51JOR7=CK$II,FSZV17!S-1KYOFL+;
M\WU6AP6YI,%"?)3BF$S(C$\C(T,0-PYV/!-EM5GM%O6T6:T6=(I,E(5GR)DI
M(E2.)52%9D,/&5$5%H]%?GW7@ML%NL4^^8K98;79$F2K$DN*U66?9TF<6.TJ
MO$[-+EI$L*1(L20NJ<9'9%A*3W:RB,/NY*X'=DD;"\M+A,%:A YM3PW.#<M3
MY)4N.)Z1<C4G)U)0Y=X ,*-RP'+$0 1$!#468MNJ]9V);WG2;LO"=*F6R-8)
MLJQ6F9+C@6&!46"."6L,4*J_WR*J;'8B7'-Q7W:,77]/L]SWI/DS;?'%+G2;
MOM<R5,A['+:*"9!*6"*%69(D545F1:&:/9;V57,*D%R&S*P(3$RG!FA1: V3
M2IA8<%QB=;(\E&"/)T<$N*G,C$XK([$D3,B@-+$P,?28\[IP66&VV.??2VNQ
MVNRI,E6!):VJS3I"3%@BM?&XBS8($B6%%A6)$=4='1'0D#@8NR\KOM6((K?=
M]ML4,VSW<DJ*UV6?9TF+!,MBQ) LZ"!(EA2*%8D1U1%1V=#<3^*)V_?W=*<_
MZ3H3_#>IB)[- ';M3B%66S[:,*XF$6G^;.Y6OD[X0J0,\JS:\%R:O 19..#&
ML7"CQ5BE5 E%2!8'BF/]$.7H3.[H>-[-:;1!=OJ>SSY_$BM?'[!)F3N+QDL_
M%XW8X8N+QN*K.S\56R4B7A3L-NML-QI8K%:[9V.*\NR)9;/.G]CXZ6'B=D[#
M!'Q./Q8DAXR(D31(BT4TT[/4RA@W7;;'M](-965HO*KG-V=W4O)M;&MN13-F
M/6.#BO68DI$2),G+S4*52HTD@@HO(TTS##$1#4;INZ\(+TN^..P6V"""V6>*
M.*.RSX(8889T"Q+%%%+1(41*JL2HB(ZK1".,/W+?$J_[FF3+IO25*E7K8(YD
MV9=]K@@EP0VF5'%'''%)2&&&"%%XT4<7%1*JJ)E(I[4NSJUFQ-)A#;#@DM%N
M-L$7$(U+8^_"A!5A#02^[ :W%2*4%(ISP($[N =Z [T?>$K/N]_A4L5MMD-Q
M^I+':K7V.*\NR>IK/-G]CXZ6#B=D25!'Q4BXD7%XS/Q8EA=8:;?PT7;>-X)A
MWU!8+9;>Q+>O9?4EFG6CL?9$N[B=D[#!'Q./Q(^+QFXW%B9V5M=VW21QYIOV
MF71T?V5L;&^S84L<'%Q=D"-"A2)I"@-4*E:Q0I+3I4Q!8"8><>9@4467EGGG
MCAB(ZCO#ET7M*Q!<DR9=EY2Y4N];#,F3)MBM4$$$$-IE+%%''%)2&&&%$6**
M*)4A1$=51'(JPI<%^R,3X?G3KFO63*E7S=TR9-F7?:X)<N7!:Y2QQQS(I4,,
M$$,*+%%%$J)"B*JJR*2K(G9%=S[-<7!9["YH8UXI\W,N)RECD>;=@L$[%)FN
MQ9URS))BJR3*,4^2@"P/$@X"AR$K/NV?+CE:: : : : : : : : : : : :
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M!TE,OED]DKZ\)X^PQ)"L>)3.'J02)QR;8K%XY'&TM4YF%(6=D;T:<LO D1R
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M:UI4EJ^+V018;^C<L(Y-<H)#'5[?'*.^K3W(I\Q$\E(2FS;6IL2Y'F+0,J=
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MYDW(6]I;BST,>S6KDX+/7CJI: : ,O- - - - - - - - - - - - - - -
M- - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
M- <-8W-[C[D%P0HUPH%A+BA%8E(4^XG!,&8)UR3TV&?N=80!A@$JB>X>4!F8
M89XAGER!S- - - - - - - - - - - - - - - - - - - - - - - - - -
M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
( - - - ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g425213g18a19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g425213g18a19.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1^X4&AO=&]S:&]P(#,N,  X0DE-! 0
M    'YR^@)(X0DE-! 0      %H< 5H  QLE1QP"   "   < E  "')R,S<W
M,#$S' (% #E-:6-R;W-O9G0@4&]W97)0;VEN=" M($=R87!H:6-S(&9O<B!"
M=7-I;F5S<R!396-T:6]N+G!P='@X0DE-!"4      !#SCLQI\4MJV5.RR_8]
M[#?<.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      !  E,S,  $  0"4S,P  0 !.$))300F       .
M             #^    X0DE- _(       H  /_______P  .$))300-
M   $     #A"24T$&0      !    !XX0DE- _,       D           $
M.$))32<0       *  $          3A"24T#]0      2  O9F8  0!L9F8
M!@       0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U
M     0 M    !@       3A"24T#^       <   ____________________
M_________P/H     /____________________________\#Z     #_____
M________________________ ^@     ____________________________
M_P/H   X0DE-! @      !     !   "0    D      .$))301$       0
M     @   D    )      #A"24T$'@      !      X0DE-!!H      T$
M   &              (6   "50    8 9P Q #@ 80 Q #D    !
M                  $              E4   (6
M  $                         $     $       !N=6QL     @    9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M  !,969T;&]N9P          0G1O;6QO;F<   (6     %)G:'1L;VYG   "
M50    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M!W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN
M96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E
M96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   "%@    !29VAT;&]N9P   E4    #=7)L5$585
M  $       !N=6QL5$585     $       !-<V=E5$585     $       9A
M;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L
M;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R
M>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V56
M97)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L
M:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M  IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M   +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M   X0DE-!!$       $! #A"24T$%       !     <X0DE-! P     %.,
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M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
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M,!X=2\35]IJL+'/JLOI])SK:K:Z<JFRRS_!?H\CU)=4Z;F]7Z[5]IZ;8[IS
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M6P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M)"=55Y:DM=$9&B@R5%AETD=F9Y.7U=?_Q  < 0$  @,! 0$
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M/1OWE!S5%!-,DVT%(\1-1$ $! 0 0$-! 0U 0[A[P]6"+:!J Z!J " #H&H
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MLUUUWTQ8N"P.$Z,X\)A1C4N$U60>$:S+*:^6P5996531H<-/;-TQ/F1[=O\
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M]1[:&I)=KM.2&R"3?0CM-A15[KP;]HE8O"L$PO$7.T/-[E4<(/(4+,-#)\&
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4;E7S2DYEDGK3Z*+;!%L$6P1?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g425213g18b20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g425213g18b20.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1O@4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &\2^<0@X0DE-! 0      %H< 5H  QLE1QP"   "   < E  "')R,S<W
M,#$S' (% #E-:6-R;W-O9G0@4&]W97)0;VEN=" M($=R87!H:6-S(&9O<B!"
M=7-I;F5S<R!396-T:6]N+G!P='@X0DE-!"4      !#SCLQI\4MJV5.RR_8]
M[#?<.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      !  E,S,  $  0"4S,P  0 !.$))300F       .
M             #^    X0DE- _(       H  /_______P  .$))300-
M   $     #A"24T$&0      !    !XX0DE- _,       D           $
M.$))32<0       *  $          3A"24T#]0      2  O9F8  0!L9F8
M!@       0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U
M     0 M    !@       3A"24T#^       <   ____________________
M_________P/H     /____________________________\#Z     #_____
M________________________ ^@     ____________________________
M_P/H   X0DE-! @      !     !   "0    D      .$))301$       0
M     @   D    )      #A"24T$'@      !      X0DE-!!H      T$
M   &              *.   "7P    8 9P Q #@ 8@ R #     !
M                  $              E\   *.
M  $                         $     $       !N=6QL     @    9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M  !,969T;&]N9P          0G1O;6QO;F<   *.     %)G:'1L;VYG   "
M7P    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M!W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN
M96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E
M96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   "C@    !29VAT;&]N9P   E\    #=7)L5$585
M  $       !N=6QL5$585     $       !-<V=E5$585     $       9A
M;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L
M;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R
M>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V56
M97)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L
M:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M  IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M   +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M   X0DE-!!$       $! #A"24T$%       !     PX0DE-! P     $0P
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M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
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MWZ-EN0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M@FQ"81_,HGYG0R^8N009K,B3R'PQL+D5 OE<+$"94 4 4 4 4 4 4 4 4 4
M4 4 4 4 4 4!YA#A0(T7)"FBP9PV&8%*%!!PL#1H(IWGPL4N!EE84<,MX07\
M(S"PRQ![^#WR^/?<.Z C[Y/%4MDO%3/#"ER2<UG">.#@KP36& *E$DV8,#!.
M<<T1 ;@H80>>8:\,=)A)&>-E 0T7P+W%P R<T"35JKDEPC!K,GH$A1V IMQ3
M68DEF.)2:>H>*HC?3:>)J-I,3IK>D2Z9TR;V@Z'&T!T-+L%IP-V.X%W-CC/;
MS6F<JYJH&QE % 5% /F1B?\ (!K?Q05H"W: * * * * * * * * * * * *
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M17Y_*:PN/K=25]/Z]=:I8^]K+Q&BS,1SC1CB31_&K+SL!U@U8\O8% % % %
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M2$BN\/4_'D;OU.N^6;*[/8*"H)Z>Z$-R(T+@&\'PI&20C;:($FU#(D@.N>I
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M7YA4Q=,PR:\Q& ;0]1JFT(W.C.;%LD7F"60%O)TJS'>I$RUCX:R&KL5VN9)
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F9I)@RI!#9BW<IC!(7W(OI18![J * * * * * * * * * * __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g425213g18c21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g425213g18c21.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1S<4&AO=&]S:&]P(#,N,  X0DE-! 0
M    ',"^<V X0DE-! 0      %H< 5H  QLE1QP"   "   < E  "')R,S<W
M,#$S' (% #E-:6-R;W-O9G0@4&]W97)0;VEN=" M($=R87!H:6-S(&9O<B!"
M=7-I;F5S<R!396-T:6]N+G!P='@X0DE-!"4      !#SCLQI\4MJV5.RR_8]
M[#?<.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      !  E,S,  $  0"4S,P  0 !.$))300F       .
M             #^    X0DE- _(       H  /_______P  .$))300-
M   $     #A"24T$&0      !    !XX0DE- _,       D           $
M.$))32<0       *  $          3A"24T#]0      2  O9F8  0!L9F8
M!@       0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U
M     0 M    !@       3A"24T#^       <   ____________________
M_________P/H     /____________________________\#Z     #_____
M________________________ ^@     ____________________________
M_P/H   X0DE-! @      !     !   "0    D      .$))301$       0
M     @   D    )      #A"24T$'@      !      X0DE-!!H      T$
M   &              )4   "Q0    8 9P Q #@ 8P R #$    !
M                  $              L4   )4
M  $                         $     $       !N=6QL     @    9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M  !,969T;&]N9P          0G1O;6QO;F<   )4     %)G:'1L;VYG   "
MQ0    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M!W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN
M96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E
M96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   "5     !29VAT;&]N9P   L4    #=7)L5$585
M  $       !N=6QL5$585     $       !-<V=E5$585     $       9A
M;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L
M;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R
M>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V56
M97)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L
M:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M  IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M   +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M   X0DE-!!$       $! #A"24T$%       !     @X0DE-! P     $@@
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M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
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M6>NRK?>'>W"VV#]'NIWW?:/YO_!K2$P)T/@DI=)8OUDRZW=-NHIN<P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MN,75\"0R-39&559UE:&QL[31)28G,V74*&3!_\0 ' $!  (# 0$!
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M&FYF(+'!'2K]LX(OL=1)")YY7B$*4A";ETN$(0A0*4A2]3&1@4I2E  *4H
M%   "@ =NP!PBWQPB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<
M(J%_41T:HY-UG5.X2;:KR"[S!Z-$6QI><PR70A3B*_*]4>H4XF3,]%GHZP2=
M[GC9]H]:EH6EC# XG)/((B27M-AM%%C8,BLXZY*RC;>E+9(AP[KS-NC!Q-@7
M-<92L15(>(U&TP-L5B+Z:ZS-:I\OG\X2$-"WNI6BT52!NU1?S-.E;76&4ZM/
M1Y%%[T=Z]6H'HZA_O:LUFM:;B?B(:2E9K+$<EKJCK,<DRO%8U;.8B)OVM4JU
MT^5J^9UZP2&EYMK.DY]HN@S%ZM5<LJ2<@O7X,BM1X1:)ZB_F^@/KTZ7?YS&1
M\(M[<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"*D/K6CTHS8
M8X2DU30;-"5)2T](\K$,Y[08A7J6L&VZHZT&C7R[PC5S$X!2:5'FSJK05RM;
MZF1D35TY2'0L,](YL-4DB*>G5QB5TUV';.(S8J#EU$@ZE:V-Z1T"$W5]#NV$
MA)U.Q%L1Y7'NK?IB9U][55:8V=1=GF23L[6B.98]:GJRUE[$A,D7W>CRNH5G
M*7L<WW:J=0Y#7&7=#?*=;]?NT2V,K'0I!KIYC;>I?JLN";R/!('BS%#3&D(B
MG)(*LJI%.5W[^7(OLVOJTPZGPSZ?DK%/2,7'6Z]TMPO5*%>[FJ,GEC5PYT^1
M;M*I7)AVZJV=JLW\3<;>V05K4)9&#JK.9,+("44J1?4Z@';5_FE6?,G"+MD]
MVSI7=M'3=0JJ#EJYZE,A6;N$%2")%$5DCD434((E.0Q3%$0$!X1;^X1.$3A$
MX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$6#S>F9S6[I2\WL-\I\'H.CHV%QGU
M'E['$1UMNZ%39)25H6J=>=NTI6P)UV.71?31XIJZ+&-%".'@HHF _"+..$3A
M%S%PN07VNZWH5@T-_+RF9Y[47,JSFV]]].Z[4N$<Y[U+=1Z74+-P+S<>EVTZ
ME]RJY=YV%1T2<F')M>2N,H=MJNB6VP'JSF)(KP^L7-;YM6/V7):;763X++%-
MIY"SN+/ Q3BMWG/KWG]SSUL2OVBF72MV5A*2<5(R$JG8XN0KA$*XG!SU=L49
M9EV[8B^ITFU/9:=F#R)W-.!2N:EME7C<M<2I"##[A+1\.DQ$Q*#2:%!^Z?=:
M$A[0RD(I("0$O;OUT0;(MR*(U$],YUE\4X;YYML=5)E2AO,C^ZD=C[ K&6S^
M<@Y6(N=JN$&%Y(WL_49?'SBNV6Y;@=S'M;#.TFMC*9XZBBR,6^(I ;=A&95V
MLY]8XV%D$YVK:YTC0<0^/9[09!&/@]YQVL1Y%88LR6 7.G#MTVYSJ11A55 7
M9P%T/MN$4UN$4--8ZP"87>M.;:KB>KU_#<XS%OH!.HB(C&=SJUJEFL99;%;*
M1!TBI+R^C&EJK5JT\FW#Y2NBQ?B1>/;>+K[F?=8BDWGEZ@-/H5+TFJ&DCU>_
MU6 N=;4F8>3KTJM 6:+:S,.O(0,TU93$,[7CGC=9>+EF3.28G.+9\U;.DU42
M$68<(G")PB<(G")PB<(G")PB<(G"*%^M7#K?A;]H</E5#Z9Y2BS.>-H[I\G+
MW?=(C+(ZW0*]=)Z10U:&@J7(L&N;H$@(QNV^]F2&=6]T*+&?@+I1O#E\KS?7
M[:>_MP4HZ$K>%J145=-:5=AHRE;A3WIE2'TI)4YM;31Z V!&K/IME'3#J )*
M>Z@B5I1BV?F8@C[K3]L!S"7VHY5_99K=5:7'DEK?8X.KQ:CE-FG(V"491#$[
MM4BJB34KI^L@@+A1-%8Z:(']H<J2ABE$"&$/*-'@2[-TF(T*"PN#0^*]L-MX
M@D-O/(%2 2!6IH5B3L_(V="$>T)R6DH!>(8C3<>%+PC$<'.;#$2*YC;[@UQ#
M:U(:XTP5;^L:139KJOZ;Y:M6O%+I2XAKM1K[LTKIN)$O_3LXE:M#GJT1G;"3
MHLU8C--(64/!3Z;*S1*AX9LBO**/T$4TG&*;4LT4K:$D :T)FH.-,Z;_ !ID
M>0A:LZ5:,BA.D-BB\"6UM22%X T)'Y;&A!%1D01RJP6GZ/GEQ.>,I^@5:Z/X
MYFDL]+"6*%FGY4"B1O[N?(Q"QBH@LL)0.J#=! 5E/!,A $I ]H$Y*3+G-EYF
M7CN:+SFP8T.(YK:TJ0QQ(%<*G"N"S9*V;(M)[X=G6G9\_$AM#XC).<EYE[&$
MAH>]L&(\M:7$"\0!4@5JL\YDK9*AGJ>POI-R*\W&H[5Z@O5%F;74X'<)Y]E,
M/1L-L5:CLQZL.H=_I&AUMG/1W1S<[A&5NQ["X/"5Z2G;VO=XXGN*$C+*"KI)
M5T13 ZW:]BW4)TG2&VP%PBI=I&1=:E\\NT#>=5AHVTLG.AU0LGFL6^Q9.:O*
M-@UM1BMCT8ZJ-,M^D5JT6E$*G592WL6L$Z(O;TOY2OV/$+]<JD\:L:GH.L--
M&JN;(W33]#=X]6+_ (?B=NKM-E;?K]=JMSD7]IA9=CM)&!X1O!UB.U=A4JVX
MD8.!8R+LBLDX1:)ZB_F^@/KTZ7?YS.1\(O@]7LM*0?3QHDI"R3^(DVC:#,UD
M(QVNQ>MS'LL.D<4'391)=(3I*'2/X'+YIG.0W<IA 9'HE"A1](;.A1H<.-">
M^,'0XK&Q&.I+1B+S' M-" 148$ C$+RC$B$\@D&F8P.87+EK<!JL[>7%^S^W
M7%A=M0AHW)=8T@-FT.NW"H9,RCK69K/9<BV<2T(ST"!E)]8\*]-'LS%!^\!9
MU[-RZ.%R3.C]GO>YTO9TBUTRT2TS$NB$Z#+;G&_+2K!"B0A-,B/:6.N,)%"]
MYW)C5@B*[)SW&E7"M35V% XU!I0<IIR4JK>_3;L5U4T0M/L6A7Z\L*YDAH]%
M[>;5*664DW$0^JL:2<F'3Y84WL\]3*HO(R7L$E'+ITZ6[$!8Q.1/3JS9*2L2
M4^#RT"'$;.P(9C-@PF1GM;+S'K'L:TN+B Y^0<X D8!>\N]SHC@7.(ND@$DC
M,;"33/85=-RI%F)PB<(G")PB<(G")PBT)OURUJKUJ%]XICC\[>UKU1&\]#[!
M=Y&EPK;-'UB:MK[-1KN&CI:0<66.KPO'%<8K,R,7C]/LNHN*16#PBWDS>LY!
M CI@[;/FIQ,!'+-=)R@<2&$AP(LB<Z9A(8!*8 ,(E, @/80$.$41>O5TY9]+
M.CN&CA=JX(M40(NV5.@L0#W* (8"JIF(<H&*(E, &#R*(@/<![<B>G#WP]&;
M2?#>YCA\%HYCBUP^.2^3@01R8'+!0#6>]\/0NUGPWOAO#Y"CF.<UPK:,J#0M
M((J,#["1D2N4&7KNYNM6U2V5_3)"LQ=HQ^!J=$EG%HM5I&JWY@]LJBUB/FDJ
MLC3/8-49*.5]U-GA'LM[%5D](5NLN8U-LM6&)*1@173,9\O:$68FX8<(&[2S
MQ!:(+9V&YTS5P8YI!A@0[U68A<SPK:EVV=9<"8=.3467M6/-3T$&'*F8D7LE
M6-EV6I#<Z>O/W&.TL>S<X&Z7X0<\XVV^F&_MGOZ0$7:;2_M$HTS.80F)58%&
M;:8EVK2)2?2Q(@KEPUC@?.RK.TV2)U$F8+>YTE#$(!AD>@<Q$C:2.W\8072D
MZZ'!B1HD40V;I +&7GG?F&#=OW0YU"3F5-]5$Y$F-,WW7QVR[I*??"@1)B)'
M$-A=#,-A>^AB&&TANZ.:"ZEXAI-!8AZDWS 17UCU[\/_ ,/9/@[?A^3_ +?C
MY8.F?!#>N0?#C*Q]<O%&%VQ)[?\ L3FS;^"Y?''3P]FK!U&GE91*AQ6TS6<R
ML9:LCD[)4M5]C3H"&;.%K+8G3AVP2<N7D<9G'A76+5NK6G;E!_[=V\45)7_P
M]L-EGW6.C.E(<=KH4XV'&EJQG/(,*'=:;M'7M^7D1*%KMZN?#;;($*P!"@/F
MHMD2\[#B2MKPY><LPNG(\:*TRTJ(<-VY%D81G".^([X1=>PW&-O7M^E\7PTG
M1B=Q-XT1H7R,(B8>T^Q#N81^$3#\HB/RCW'DBT(^6SO56^,U61J1X:MGLN'Y
MN$KK.64NE%23UYS-5==63;,GVM9UB[/1^GS,8S9V>M]4%&P2K]1^6I:SK*%=
MR6"CK/TW;98Y*2JKY]H);3)T&^8Q9G<!KC&$9R-@740F<_(I@]06$FI'17J6
M8YH27MTHK9YS44QLR5\EYZQ7"Z=01]XNSI)Q@]%GM)@)B2M<]87=9L614D+=
MG3Y6)L-)"&E*W'2S BQ[TQVN=0V 6&FYYF2V2>]YI3B@VNGRUQZB[S;VLY6<
MXS5I FN,[U3XUAFO>[FF9C0(:K1[ZF+UF.S2*HK6F33JLDC6$816)&62)W\U
M4R]CE3'R.4O90_;P(/<0['/Y%\2C\8WD'8![APBT;U&?-] ?A_\ 73I=_G,Y
M'_P^7A%B/6C]&G3/S6!^U,)R3Z&\9+,Z<?RL=>4?U3^8=X7/7SH%:Q6 >G%\
M^-A^K>9_7]8Y -8O LMVC"\O,K)E?6.Z!^TU7<<I99Z<(G")PB<(G")PB<(M
M0ZU!UV5A(YT^AH62=IZ%D;11P[CV+QP0@:I3>[8ZRR*BI2@181]B8P !51'Q
M[''N1;49,&,:W*TCF;1@U()S$;,FZ+5N0QS"<YBHH$33*)SB)CB!0$QA$P]Q
M$1X10_Z_OHJ:3^_5#[:0'(CIUQ7M/]D\[+JOM:7$BU^G9_WC*KF]./<J7QQ/
MV(( 40-V2_9#C[,._P  ]Q,*GQ>Y?V3X1\O( Y^=L%:T% /T=\<.?::8;[.M
M5R&ZMUE3D,!4FZ"2:4/MQP-!6F:GWZ:WTE4/T&M7]'<G6KSC"WJ$Y]&^E_;S
M?7E@K1U/<<&]FSO])6&^I./_ * 17UCU_P#4]D_)^#]T/X?DY9.F?!#>N0?#
MC*T]<W%*#VQ)^!.>P]X^E42& H"'CY=O$HCY  ")A*43=OA'XOEY>/X?#Q^0
M>58?IR&?-W<GL7+)I7"M*#/.M!7+96M/92N*LU],'YS-(_05K^+_ #^Q^3M^
M#]WDUT(^6SO56^,U77J0X:MGLN'YN$KJN64NE%ST]3%NN3KJ"N%?IUDOE:S:
M69+Q>66>)3]3FU62FZ2\V/:$]AM-CK60.$<TF6!+\[:S690%QF$*!(9&C1"4
MLT=ECZ*23(K:>M^<>UKI;U2=8N$F_P!S6U47DBA?+!F<H^KPWNKIVB'J=UJ]
MRSV;B+_.5P\K#9RDUNU:0F+X_KD'(RB$;)/ ,119](V94G^G*^RI9NIVYP_U
M\LFXNL!+WRQO;;,S>'8C/3SBTVO3+-<+_;5:S8Y25S^BV>T3;B8F,7I^8.G2
M#54PMTR*,!NCOJL:R&W26VXY4.HY'1+I;[0WBZC?X5^VE=>OF T.F0.WMV&N
M.J6WIM9R2P5B:I%.CV3^4O6>URPMU*8QGT*NREY(BL:V*K[)%4K-236EU*6K
MD5JG2!'S\0IG<FI9YF68[MC3"6DBW@= 19I#)6!):8+YT@XILU?N:8IU>\AP
MBS3K1^C3IGYK _:F$Y)]#>,EF=./Y6.O*/ZI_,.\+GKYT"M8K /3B^?&P_5O
M,_K^L<@&L7@66[1A>7F5DROK'= ]X^GWYE=QREEGIPB<(G"+32&76E'?I#93
M[+H2]->94QSM# E0K_O7,+"TM#FP+:FV$L06S??J\8+DK*PJ31HL8=( %D=8
M$#MR+<O")PBU1NMDF:?C>FVFNO!CYVOTN?E8E\"*#@6C]FP66;+@@Z26;*BF
MH4IO9KI*)F[=CD,'P<PK2C1)>SYV/"==BPI:-$ANH'77M82TT<"TT(K0@@[0
M0M#I1.S-G:.VW/R<3<IJ4LV;F)>)=8^Y%APG.8ZX]KF.NN -'-(.1"Y>',WI
M,=':&USG6KUDK_7.HNN]3VG3=#?1Z,Q;]-@)2I2;E5ZI-L)E&-KL^2G0+*8K
M,(A&0#ILT.E]SO9.'J+JLH>EELL)<^/#C M>T-?!AMHXBC8@W-K'5835H)+'
M$$.:15<S2VM?32 \Q(MH0)MKH4:$V%'DY5K6/?#+61Q\'A07E\%SA$AASG0W
M.;=>QS:A3>Z(=0U97JRFGTOJ-[LS7J LZ$[>J_9YP\U66#NHYU(1$4WHT"[2
M,PH4>JC%,W4HQJJ<:WEI!,'3\JXD1(EL[$TAM6>M22E9B.QT&(8PB-;!A-+[
ML&+$:2X-J"'-;2[=%!0@DDF3Z#ZP=*K:THL>S+0M!D:3CNFVQX;9.4A.C792
M:CL+WPX+7-+'L9=W,L%UH!!JXFS;K^^BII/[]4/MI <W.G7%>T_V3SLNK/UI
M<2+7Z=G_ 'C*KF]./<J7QDQ[$$.Q"^)B_LB@^*H^!?,XB(F WDIV3,F3R ">
MS)S^ZHH,,J4%*BCG&CJ $G&H.^%TBAS:WD1U+K<0<,*-I3%U0XT <[ &I)(%
M!7"@GWZ:WTE4/T&M7]'<G&KSC"WJ,Y]J75H:GN.#>S9W^DK#?4G^8"*^L>O_
M *GLGRA^YW^'\ _N]N65IGP0WKD'PXRM/7+Q2A=L2?@3@R_GRTY51*H/D8!
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M6HVV<IV:1LCB.F1;:?U3H_EY*YBZS3[RH-[*[KC4V\C'2"^C(:$*D6_6/7G
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M3[ <X^ %_92CXI=Q.?P#R(/R)E]H8"&(H($()Q,>DM@Q&9PVC+$FFW9B3AD
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M&L@__P ^7\'\/+)TSX(;UR#X<96GKF/^Z4'VVQ)^!.'+^?\ =42&$O</$3B
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MW(*M.M<]ME>/)U?29.M1\Y:HF@S%DE*M6;386<9790BQCH!3C%LGN\W7YG#
MJEEUB7EZKFG39:7%TQ7#(=&DT""4S&E65S2,S/(E>S$-*ZG/E3SJEM&5HTR:
MCV4,=FU0E)$BG1PB<(G")PB<(JH>K_JDN>3:)LC%?6;%E33*\@SF]Y-0:;6\
M*G;/O$Y:):^-;7)#$;M/4X^GP=9DZ[4:6&4XS?J%IYY.PF+]W'4I?\Z)%$7[
M3?J'HRNBT;+X*(;M+0KK^A52]P59N=<DKC5X[-^LJO=-D#'6>N2%7L!V:.IU
M>7/>TVI#04H9J4D?5[*+=PC:"$4<8OU6M'.]L5Q&N8[9(&RYYT7.ZI5:IK[>
M9IV13V]M^LNYVA38KZM0X&2@KHWA,8I6?/J>Y(K'A<5ZH6,4AW%IDFZQ%8@;
M<- MH^GQ?8,[6CU7J/L:K?2,Y>-(:U27N6S=)6R[9!1K2],'JD>D2J6?/X]%
MP_@6:J5G24(LA(LXTJS.2(IK<(G")PB<(G"+6&W6RW4+&-=O6?U@]WOE+S"_
M6RDTQ-%VY4MUNKE4EIBMU@C=A_=RYY^99LHHJ++^ZU3.P(V_9C$X15FT+KEC
MZ5=6L;(;X[ZB,\EHO!W%HUVP!TY5S)Z&]UFV-:N:8B[;DL\QL5+82<A+.(J#
MS3<: SL2KVG3*T?I$JV1,>3>_OC[\I18,'J=6J6S2T7B!8Y]73VI.1GZI.ZO
MJT36LXK4;%]%G3]U")5:CV".R]9S8KE:935G;RIUNT_=QQ*-(&_6HLX2!B8F
M@L"+;G2%Z@-SVW7JMA%HSY@#E#+:])3E[&WP;>X2-G;8]D.B2UMELS3811XN
MEVEWH[EC$/H(SY!FJG6GAT",+;[FK1%L[IOW&>T7J<V*BQ'495]QI%#C;BQN
MD>T99Q!-J;J+716Z$+2<FBZP0U[FJWFU*<.:CM5JODO;8Q?31KL95IV-G6>A
MT^MD5B'")PB<(G"*)W7&L5'I:U,?OHE*LLJE3VK(89M:GDC<9-[?ZHTBLC0;
M45=K=52;A)+M,;<A4G+>RE:WM<T(NE)%;*%(H\^E!$7VM=-#^GZO89YUJM$M
ME5S_ $6A6 +6H[R&QT3I_P .J2521?6UX]<RJ-W@H>%WU>5AE?O9>R6S2"L$
M*[/Q>.2*S?A$X1.$3A$X1?SK-&CE1LJX;-UU6:HKM%%D4U5&JXIG2%9L<Y3&
M05%)11,5$A*<4SG)Y>)C )%Z P8@NHY!DT!RLH559P#9$%U52%0(1114">T.
MH0C9L0IS&$Q2MT"@( DF!2+\S1,69)R@:-CS(/3&.\1,S;BD[.98[@QG*8IB
M1<QEU5%C&5*<164.H(B<YC"1?V&3(84Q,0AA2,)TA,4!%,XD.D)TQ$.Y#"FH
MHF)B]A\#G)W\3& 2+WX1.$3A$X1.$3A%_#]S(T$G3<(]B"#U8[EXC[D0]D[<
M*"45%W2?L_!=8XD()U52G.82%$QA$H=B+V/'1ZB8(J,6:B(+(N 2.U0.F#AN
M"8-UP(8@E!9 $D@15 /-($TP(8H$+V(O=-FS27%RDU;)N1;I-!<)H)$7%J@8
MYD6PJE("@MT3*',DB)O9IF.<2% 3"(D7Y-XR-:+JN6L>Q;.5O(%G#=H@BNJ!
MS@H<%54TRJ*>9P YO(P^1P P]Q#OPB_NX1.$3A$X11=ZK,7O6\9\MGU=F*,-
M1FT5FM\I5U;Z9"J6YNC)0DU7757U?']&H&AY'9JO-PJ,I&VF )8UA,J=,L6V
M>),95@1:PZ0>CZ5Z=+-I-XGK?)R$II*R+QS4F>R=5^HP#&66!BE.6>PR_49O
MVIHWF[R[*"JT*TN+:DT22K]6KK.J1R1XM9[[K(IX\(G")PB<(G")PB<(G")P
:B<(G")PB<(G")PB<(G")PB<(G")PB<(O_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g425213g19a10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g425213g19a10.jpg
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M 0$! 0$! 0$!_\  $0@!FP(' P$1  (1 0,1 ?_$ !X  0 !! ,! 0
M       '!08("0$#! (*_\0 :Q    8! P$$! 8,"0<&"@0/ 0(#! 4&!P (
M$1(3%"$Q"14641@B05:1E1<C,E1887&!DY?2U!DD4E>6T=/8\"9"F*&QU=8E
M*#,U4]<G-#9#1$9B<L'A@Z2V\3A%2&-D969H<W>"A8>2H__$ !T! 0 !!0$!
M 0             % 0(#! 8'" G_Q !>$0 " 0," P0%" 8%!PD%! L! @,
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M.[.H2@VY=>%=>J9>9;2$,SL\03O:E=)SCUX\^=8?2D*.RAB5B>4!E*:A'\X
MD'!#84['!.V:BNR^D[R5CRBYZ<9 VO5M?,&'L,[9LZ5_'N*\_P AD"G7RI;H
M\G3>+*17W>2)[!6.IFDY"CIRN2CR3K,GC*39/(Q6*>PD])-G;Q>-KCEOL<[D
M>7/S_P"-6&Y=5DU1#O$2.0*DFI6$K%5&LQJ5;(.04(Q@@G-3WC[TBF(,B5G/
M>3HEHH3#&#]LV(-T8Y ]:D5>6.DY2IF4+J]BG-8-'('K4_36.,G<;)Q[B8DG
M:TV^<1;EI%/(E5)U3!]^2,>L8_&LBW",'<?,2))=6>:L'.",;%=.#N<DXZ;S
M;M$W$+[H<&5_*LM1'6*KC[0W^A9(Q5(3A;))8UR7BV^6+'5YISZ;"'KXROJV
MP5IXM'RAH*)"6AG4;+(L46SY'J$8^[[]ZOAD[V,/ITMEE9<YTNC%&7.!G# X
M.!D;X%6#)[]\'5DF<%+_ !>6<8A@/%LOF^V$R)BNUUIS.XA@9&7B9B_T=BNT
M5?62)CI&&<-73$C9I8$Q=Q*PPW=I:/6<4JAG11(6#IW:EVU*1X!G++SR!@[#
M?EMN*Z3;_,'HP-UD'D+EV-M=*RU3L(K8GD\6V1AEJQ9#R+7(VY4"*JU+<I)N
M9-K;*=)A:FDDNY8LH>$C+ YM2U?4KLVBQKC_ ([_ )Y[4[],-L^5=8].DZBS
M ,H Z@J=6>0 .K&DXO#9AN#F]S^$'&69^N%J;L^;-SV.64">*F(*19U_"FY7
M+&&:LI8(6?7<2L3;'M;H44_MT:Z% &5F<RS9!C'MTTF+<1CX _$9JL,AECUD
M8\<JXW&R2N@R#ODA03Z\["LK-4K+32E-*4TI32E-*4TI32E-*4TI32E07-;F
M]OU=GCUF9R[1V4TBN+5RU---UDF3DINA1O(/F_;1\>LD?DBZ3UTW.@8# L4@
ME-Q-P]F^/7$ N8>$WKPE=2N(6!=<9#1HV'D4C=2BL&_9S6(S1 Z3(H/+&>7M
M/(>O/+K4U,7S*39M9&->-9"/>H)NF3YBX1=LW;98@'1<-7*!U$'""I# =-5(
MYTU""!BF$! =0SH\3M'(C1R(Q5T=2CHRG!5E8!E8'8@@$'8BLH((R#D'<$<B
M/.K8R+?*SBO'UZR?='Y(JG8XIUFOELE#]/1&UJH0KVP3K\_48A>EI%Q[IP8#
M&* @GXF /$+:M9@BLS;*JEB?(*,G[A6H;;/Z07)S#9]NYR+N2DZG:,\;88QI
M?7,+6CU]I%3$;FO#M3S-A7'K)6"[C%JN8J[W*9VUMY)R#21F9_&SJ3FW"DB]
M=R"]Q R,9P=L^_'J]1]^*U(IW$,S2D&2+Q8&!D.@=% 'DS&+)QDH2=\UXZ=O
M$W!Q>S-'*5RR96+EDW9QO/C,/[TK)5X&GGK^2<),,G1L%9+I%M8V,+%5A(NW
MW+.-]P[A>LD@UFCFL/X-%V$6Z?M7M"-]ASY#\^O..IHLT@A#,ZL\,P2<@* R
M:@"^ ,+^K=93IY8(!Q6=FVG-5LO^.L]YZO<L9WC4V;,V_8<C&41&MU(?!^%'
M@XL0?ME6;5N_L 9 M6-KUE>'DIEV\>+PM\AF#-5K$,XYDV';'L'W[_QQ[JSQ
MNS+)(QRNM] P!A$\&W(G4RLX)/)@!MBM9*7I%\]5"9F=S65J?6V6.['Z.O$V
MX;%&#:1D&VST8::SEG.OU7':&0WSF@HFC[>P+=*[ W*R4Z!M*'JLLFK PC\S
M!HTEJZ1N,\CC/JP<]?5^>5:WI+C,K :3;QR(@8D9D<!=7AR#N 2 VW(><\QV
M[W+>5[EL[:/8N6QPH7TCMGP'=W==C\BUFBYUQ^W]'GN(SG%35?C<F5*F6]S3
MDK8M5XV3CY6*709Y+Q;, RDI%K',W)A&,^S(SS&X%7]\[M",%?\ *3&Q&H+(
MOH\D@(U '3G (Z,AW(JT:'Z1*R8ZP)B1VZQY*V>4RQMRNEWP2K>,H35KL61,
M]1&Y"J8'BL,6:XR,!WTXV"R9KP\K"S96KJ5+#/;0DTA';>J@=45 .,\B.G3&
M<^ZJ"X*HOASJB9H]3$ZI!((PA;'4NF#@G!.WAJ9Z'Z1"RWW=/+86A\3FD<>Q
MN<LO[>'EFBH_)SJQUJRX;QM9;I,9,N4B./2XIB<;S]OILWBV&C&V0'EH;S<M
M1IET"A;,\@H"F-L_ACIMMUWZ_P -[A<DRE-.5#O'D!L@HI)9CC2%+ J/$3DK
MYD"-OX1;/[/:]MAW.6[%&%L>TC<_7JID=*[2EJS-;L88(QU9\.P^1X?[.5HJ
M6'UWU;E['-OW, A9G45%8SJB"!U9NVOGX1C.=KC<@')&>G/'EO[3[JM](D[J
M*5D11*H;42Y6-3'K&LJAQD[9.E0.;9P&G_TB6<<AXHPU@V>Q7?K;2763=R^#
M<;3UMQ#0ZWF*ZGHE^6EPG0QY4['1\B1ECEGR#9JI#*(4V8=+$ JC5J(*F*)0
M"3GR)WY=.=9;AV5$*,REI$4E%5VPQWTAE8'U;5%>?-[ETVD8AQI8BS2.<%6=
M./D7(D=G&%M>-]TT_15[ZQA7<PKB/$N (>FXX:04?++1Z%KO\+0*NM)Q$?!2
MA$Y!W)V,M,#)Z>S<?$GU;>=623-"BG/>84LP<%92-0&=$<>E0 3XF"KD 'J:
MFU'<SG:\7/=C]B^@XE3Q=M<G;CBUU,WJY7%M>+AE:N8'IV822+.OP5/>0L;0
M$)G(5:ICLCJ?4L+ULPL=F9@@1*'AY1@8'/?[MR/?RY;>VK^]<F;2JZ(25)8M
MJ9A&LAP ,!<L%SG.Q..6<9:1OKW.DV_[8C&H>)<CYUMVPB3WP98E)NXV"C5*
M3I%/A,:BC!UX(2@R8M,D9+?WP7+HWJ=G2*$O$R8(H3C%U$-A8W//8X\_/UCR
M_P"%8UGE[N+PJSM;F=B254A0FVP/B8MGD%7!Y[5E)@3=I?-Q^:)F H=%ID3A
M*I8^PGD2>MEFM%@)DR5C]P6("Y(H\= TMA5U:VT7A7O#*SO)6Y#VC)8/5K#O
M+<QEQ&,^8./5^?=65)6D?PJHC"HQ))U^-=2@+C&W7)]U0%NDW2YYPSF+<+@J
M"M#0MNS9C+;J[V+O5JS7G8U+(.4<JH[9<KD7:K1@)VYAB"T6?&&=Y8MI"<;)
M0-MEF#TQ*]&(QJ8 ;>_/NW^_E\-O/'+*Z221@[ND9@. =+,_=/MCQ!"4D.<[
M$CD *HF2=V.>:OD7<=68JZ(EC,<>DY]&YMKJI5ZQ5%EVF(MP-7V:2&6:^Y6&
M$ 7KRS/<N7Y=*=<%/-08S*:=??1:,7%)LJX&W_=)]XS^%4:60-( VRW5O$-A
M\R1("XY=2['/,9V(P*S#VCY?ON4AW8FO$D$[]BO>#F?%%*0:1D3&K,:+3XNF
MNH"#Y8MV!)!RW6EWX!)RBBT@Z,N0KQ\<B28IT/3UC^)'\*S1.S=[JWT3.BX
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MZAM61E=W6YX>[CZLZ<WQD[J%O](9E_9"YVVEJM22&N8^QO@W)&1(K,#.RHL
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MVJ+PLV/"[546)-*R!(8H>\DN'))T0)%&IU."-"+OC/6L3>,-*V<CEDEL  X
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M'9=MP?('F">8WWW'MMPNW9ACMHX''K+O\4==5P=D=4R\VAVHEZ^Q764,E(I
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MW,/I%\[BVB,S(]PMGI+HFIE5NZ;Q:0FH-EAJ4&0LIXPA#R $*N[' (7.2"<
M[[8YC'7>MAK7>OMXEFTLXK5S=6LT0[%DLVKM9LK]5PMT=HF=JX-&(1YVJX 8
M$'RSQ!@J*:@E<])##K@&[&]HHFB6XLDM1,FM7N+FV0*N<>-1*T@9=M2!&<$@
M:=ZV_2(3G2Q;'T58_?C3]]33C3*E1RM$.9>JN78]P=@QE(R49+1LM%.S(D<)
MHO6:W4 %604*LV=-U7#)TF(BW<J]"@%A^(\,N^%3)#=JF9$[R*2)Q+%*@.EF
M1UQNK AE8(ZG&I1D9R(ZN"5/+8@C!'M!_?RJ1]1]7TTI32E-*4TI32E-*4TI
M32E-*4TI32E-*4TI4<9%R[C#$K)@_P F7RK49G+N_5\8M9IEE%%?N^ $Z+0'
M2R9UQ1(8%'!TRF3;)B"C@Z1/C:W[#A?$N*/)'PVQNKYXD[R46T+R]VG(,^D'
M&H[*/G,00H)VJQY(XP#(ZH"< L0,GR'Y]M8^V#%5ACLC4ZVXAJ-(>U]"-G)U
MM-2DTJ@G[:VM=<LA;+"\;H2%@MC0:\Y,C!LFT@"':.UQ.NV019&+.P<5MY>'
M7EKQ>\ODN&E@MVAB@#'T*T5>ZM+=&,=O:/Z0H,TC1:M** K,7-6E2'4JJD8)
MU$[AFZD[D@#.W7/,8K2GZ0CTJ]B8)90V9(TUW%7=RW<T^T99J\L\81A50E4E
MCDAZV+62EWE?F8%%1A/%"61=]A(ODF@*$1#O'H79;L-:VLG#^U?I<;V,#0\0
MM["[C1WQW6L">X#1Q"6*8@Q$18++'G!(([3@O9N.^X=)Q&]G$<#I=P&-% 8+
MI>W[Q'=@$E#L'@4JX+!%.0U:J\&[=)2\JU.PY$?.E:;(L)YQ 61Q!&D>ZCWQ
MRSCXV'D9PPK>SK=ZL91PV<@W*Q6<%-PR/(',,OQ[M#)?75_PRR1[%9F23TN&
M=EC+C2S2/W*D&5G*P2*S8Q@2ZC&,:O&NTC6]N_"^&E\V<=K;,1-%$\B0QQEY
M98[=47T@HH 52R[-E7PZ1[(9S;U.-\#>R^(*9#/+U3#*1[!N#%!G,SS%*52D
M)R,;N' -%"6=LD NHM)T8&LM7GJC^*(J_+*QS* [/7,2\<MY>+7<UN/U\-Q>
M:F+ M&_=M(-+%XEE6$L@P&C722 ,5YO=<5*W$MU+,\PN%CE/>/W@)P!NP);N
MI%!3O,ZX)T19 8T21_O#J.8IFSU' .0*TWK>1F:;V??/7;Q%M("A%E=3]<E7
MA(XSF/,FP!=ZJW<QO>2)/I^19@H1O_%FO5W?">!VHON.V5P]S87$RE8N[#Q1
MRR2JTD<+2!)-27)9D$V&$8.0S-J,;/>(+=KI9 5TF(X/SU)6"3(&"#+&D8=5
M*KF)64:ADU?<A+PK?%TW=(#$,+/9%@+O!8_?6NO-FZ\E$L6K&7659V,\6"TF
MHT*@P)#Q[<A^Y-2(L$#K 5@R04WNSMD8KZ*R;B5Q!8/9SW<=I.[&&0F2,(UN
M),1J5$I)8^-D)7206(UEEDBN(V](,B21-(5?."7=22IP!DL-;;9+%F;=B3-M
M?F:C5K9MUH\?!SE#G[=2*M-V9&70.H^92$J"<DBF\656$"N22,>H<R;9)HBT
M,BB5=-)5,R*,?<6LUU;<;NW>WO8+6\N$@,>D*ZQ%5+* N<:=!U,79F\2DKI-
M:XF9XKR23$K%V$04X &G&,<B=).//)Y%B:C:EUVS3><MP%OW"XK>4#&=8:OS
MUF79)OXB)-*'D&T# *QCYPLD6U'G(E)S(&=H)G8E=N!7>IM2.6Z1=ZZ:TAX-
MP6SX)?I>7MPR">%S'+((A&T\PD15)MQ#(5C",2^E0JEF5B:"ZE$,$%O*LCY4
ML#@L54DL&))T\SG.X]>*@_.".(LJ*4F"A+1*GR-&O'D2RQ]'E675/5G[AY99
M-)TDDR61)(RDHJQ4;@T>+2:\8>0[1L= K5PCN<*L[SAPO[A[6)+.;3</?MI0
MB\0R1QRJQ<,RPB69@)$[I)PC*=>I3)PRO%*49@L7= .Q(W/ZE2N2=AW<2J?F
MC3L,@YK)YTPMLS-&6>58*LI"M6K])*7*H*=0BDV:7<4UTUBE,X:5N'];NA:H
MIB\E G':"Q.2-RI>?W5A;<-1KF.9+]Y%]&M@55D=R7&H+D[1A)'<Y8MWA"E<
M"KX;F#0(C(SB4E&*$#OW+!F(<'*O<3")0Y;3 L.1G4QK6M=\1X?S,@Z8XK;W
M:Q7Z<(Z"69.TED&3*'>O5'4*BP1;IJ*&!>:7:E6D5TSIE6CD#-TB-WQ8XDKP
MOAO%^SDB-/>VW#[=Y1,Y=8;@&5%62XA;(C9#%%X9U60@.T*1D%F([+@_'[[A
M<HD[V&&SA,<G=!%/># 1G75@K'*BR=U%JW4G40(BS6=M;W=;@]F5GAL/5FYP
MU5PZXFO6V0"6.NPUPKC1S+N(JN7.VSA6;8EG>1\8@Q1+$1<'(-%7X(I-4TSO
MG3H@2MS8=F.V5O=<3GMKB]XG;J;:U6UGFL92]OKEAAMVD+0@.\CZY9$<(26<
MJJUZ#?0Q]J[..ZL7MX[[5(C=]#-WKQ1QR2PV]O#WL<8=W8"X>7Q(-3+C05/Z
M:=MN5*-!;7,*/MO]CK6?&KZURF/F%J.D\IC%E*OE[#:7M<(S?M)"8K":*Y4(
M" AI'XB*3J%5<KF:'(L?RGC=E<\1[1\9;C$5QP0):Q7[VRLEW(T42VUJEP[(
M\<5PVDFXGE098"8(H;EP%U877"76TN8BLZ@##%<%9"S*R.K.I3H,.1E=.1C;
M+'"5PMMP?9">3L;9XZ#+/L5*TVMT-ZEE8L[F(:'L%<33!% LA'0,P15)E+)@
MX2>%<J%2>.B(@<.=XQ:6EFG#XX);:6<VT@N7M)N_BF"S,+>Z))8QR7$)#/$2
MI32,HI)%848L7)! R, @@C89&_0'D>N??4^:A*OII2FE*:4II2FE*:4II2FE
M*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4K@1  $1\@ 1'\@:4K&7+.Z/'E
M BY=M 2#6]W5HB\3:5BNO&[I-"2;E.4J=CF4U#1E>:I+E K@'SDL@H4JA&+%
MVN )CT?"^S'$.(R1&>*2QLG,;/=7$;*6B8@YMH6 DN'*[KH4Q@D&1U7)K$\J
MH#@AF&?"#U Y,1\T>9/NS6AI6RW*YLI!UD1LQC860<R,Y),WSPJKX\F]DU97
MOZBJ94TX@4G2ZZX(HNE%B**E3!40+R;W9;:TLFCCL&>26-$@C=$P@B2,0B-0
M<F3**JY*@$#.,DU%EG<'O %4MJ*YWZD' Y<\Y )V]U=B*"N1&$U7J>FM*+&:
M=R4D^R<$A&IG!03ZW,PHF+<QD2#VBJ2)UWBH /9(*GZN+69>'R13W96,!PXB
MRIF?3OA80=0SR!(51U(VH,R95,D]3C89W\O+H,G?(%9G8!P-4ZM446%J50M#
MIZD\1=(.VY20B?:.72I^AFH(]X O68 5?BL *$2530:J 77'\>XW=7=VTEN&
MMDC>-DT.>^/A4#+KC VY( =R"S;ULQ0Z5(;<GU;#KGGOMMD_"KLGH-''13R,
M:Y%2.07X0[(AG"XG<@0C=DF3J,#A=P8Q&:""8@91<Z:9  Z@"&M#.;_]7,N)
M&7Q;@+X22S[ :0N[D[^$9)(YWD:%U+G&,;\_9N-_W\NE3I3XV2;QB$C/=F,_
M)-T57J:9Q42C$! 56T,U4$1ZD6(*&%=0!Z73]5VY*!$U$DTX&Y:,RNL.>Z5B
M$)V+XV,A'0MC('1< [YS>N<9.,GRS@8Z;^77UYJO.%T1<-T.\I)JJ"L0"@<@
MJ]0IC]R41Y P>?ES\G'(^&-00K-I) TG<'!&?.J^7Y_/YWVP8VL]<C)5)>)E
M4TI!L8Z:P#R(*H.4C]H@X24*(';O6JI2K(JIF Z*I2*%,!@#B0MYI(P)HV:-
M@"N.A0C!4CDRL#N",$9H0",'\^NJK5;&5!LM"S!S!+1G!C*$2Z4Y-DL8P-I)
ML0H]) 6$ITW2(=)6KQ-9(O*(MU%M>XA)821_,;;!.Z,/G(WGC(P>H(/,' =<
M\QC/K&^"!^_'(^ZH:RYBG$N:5GK*V5:,]= V02;6AD<K"U-CG*J1(B4B@)1<
ME;@4AP8/DWS/A0@G0Y HZF>%\4XKPA4>UN9>YU,6MW!>V8 @DF-OFZB2"Z%&
MV/BK%)#%*"'&XP0P/B'KSU'J;;;U5J@S'M;R9B07+VOKJW&F%.=1&3B6X!*,
M4RB)Q3E(Q(%5DSD* "HNR.X;G HJ*$;EY(3U'@_:;AW%=*7*BUO",-'(3W;D
M[9C<D CU/I;.V^V8R:VEB'@8LG,$8R/4>H]6Y'(;5E=AVJ-HG$[)A"R282TW
M$.'<E,D'O"OKZ0;',B['J'XR;'M4$T$>"IG10(8 !0ZIC<QQ:[:7BC/-&>ZB
MF58X>2]PCC*;=7P23G(9CG;&-R!0D. 3EADDG<D@Y)(WQD[>S<5MBV)1:)\.
MFM[U=)>VV:=DF5M(W*8K:.>U-TX@&D4U*81.+<K= TQVJAC'6<33A0HE0,BD
MEY5VYD8<9%JH*VEM!&UIJ.6=+I5G>5L#&HLPAP, + @W8$G=M\%-6Q8DANGS
M?" !SQL3OU)-9L:XVMBFE*:4II2FE*:4II2FE*:4II2FE*:4II2ODYR$*8YS
M%(0H"8QCF I2E .1$QA$    !$1$>  .1T^_IMOSI6'NX[!4+G*DW>;QN:H2
M.5)NE!C:+M<K,.5X]E5%I]&2M5;82#!&=1J[RP1RDC%O9N*AE90@KM.^=NW9
MH))]5V>XW-P.]LH.(F\CX7#>_*4MI%"JR/="W,5K<.DC0-=1PR=W*D$LXA\#
M!-)9B<$T0E1RH7O"AC#$L!I9LN 1G3J *D@$\L@XK4CO^W,9HVB4AOBS(.5V
MR<GFK"]_K\50L50#*'KV((]HG$5ZE/:=<)9%G;K Y9CZPC)Y=ZY0>O6)EG45
M%QKE)F8?0^RW!>!=II;CB%APUE;A'$[*Z:^XI=L]SQ=G:::^6YM8N\LX=64E
M@BB5D5M(EDD4N#.]G.'WLW$N'SO#Z18K=K%<*D)DAA=4,L0D(!<(P7299!W8
M(W"YR-,>UW!,]9 96B0F GH-O9)*.?.U@9E4;OE6:14P!.=7BK&B!CF*?M'I
MV$.Z='*B8QU@(5W,=H^T.N\6&*Q2?A<*VS791@YR5D<*5 ,$;HQB=&(PJ8\:
MZL))]K^T(FEDX=;XB18HI226;6!)J8$0@I^PK#0'F$1+&-5!89T8_P P1*57
MG,:.*W/B\JC]P:*7Y2090YAD7/#@KPI"J,#ORN7S=>%61F(V50=R"I#5U\B^
M+,[+=D\W-IQ&"YC%G.W?M&0R2LY5F8QJ26V?:XC=8HL/F$/%((X_,KEM5P9$
M:)&DBPZ@9+ 8 #8)CDW*R0S1LLT3)HD:8JA&Q"%FGM IM$DG5B>+,;;50>1R
MT2V([D6D2=LW<MXI8>0=+!'&<-VC Q73I2/ RS>-%%),J1HT65O/=720VT:2
M6TQBD[TZ5+J[!BOS@J-H+!" NG3J&,XYMFCN)+@-&&>*7?4V(W;.#(=@ 7 9
MG(4!CI)).28OA]N\=E#=%CC<3-W*^UNP5]C%M%J<I'J%;2JM:CW;-F+2Q%DH
M^180<FS.12:CE(AXG(.O6R2KL&\D8$YB7C<EAV?ON!0VUE/!/(["[#C5$+AT
M9]4'=R1R3(X(A<2H8T[I@NJ,9UY_U4$O=A&0%L888\3'(*GF1S !.< [D&I^
M@\25?!&28=O0FUS,WR%*@ZGE#.S/X]LFU=+F;,D@!)(AFR OG!G8/S+K(LS$
M6*X54$Q1AY^(W'%[*0WC6NJQC*PC0$=BR+J8[L0YT+H* *SY!4 "L(N&N;6?
MOA&K(N(^8.3@LW,G?&  .9'2IFS+6928AXYY6:M%3MD1D&R!'[A!H$G&QIB.
M!<=S>+=BJ1!8Y@0<)%<E("3A13L51Y$D;PR6..1TGN)(;=D8F-6?NY) 5TZT
M7*E@!E6*YRH 8==6PG6*1C)*57!(!R59N6XWY;8S@'W50\ZHTU/&C>JW"/>/
MF4H+-A'LF_#H"2#!$AT57:JQB%50;\" G,F<ZIP(9)(%0(9/)PCTKTXW%JZ+
M)&'=W?*YC<X(0#)5FV(W &^6WP;[+6UTTBLN 27.G&I6SG  QN>?/;?IFHNB
MMIE%J4K]F6HTIG$9LBZV:-A!;R2Y(1NX;QJD(G(%B5%5(H]@=P(]T5=N^MFJ
M]$CE8J*YG#HV_)VBO+F(<,NKQI.%2W DFS&O>LK2=\8^\ $@@6?Q!$ <)E 6
M72HR->!YC$6,EN6\1(\9&<Z=7,#/+J!@#UX>7?/&Y:CR5&GFN(7%RF[G+ST
M\;J,7$K'=]36BV3%DY5A#) U?B:0;+)BZ[O#+D2231%<4'HM^CM^"< OX[V"
M7B2V\%M%#,/&D;]V1([.!*"&3]4P;&91DL0NI 90I;]T(1F-5TNI#%2!XCD9
MR,%2WG@$Y/(U48;"^0<+QDV"U3@V$CD2P"_D_5CTCY_*)H-%P-'R"T.Y4,UK
MRSF265)&QJL>1RJD=CVC=H)12@N-RVG'Q&T=W,J6-N8];YBA5&8DL%D0,654
MU2L LLFJ-3)GQIOP7MK(ZZ68I""?$#X'U !T[TLK3(JA5:0,D:^-(V(8-BON
M*VYM+I5)=S%16/JL]8,)0)N0L+U)A./Y$Z:$DG&R#F+155/+,DRFD48!JW(H
M@Z?-^V[L_>-8%G 6-U-87MO-PM+R*U@D66YBB#,UVBKH$IA9F1M9("HJ*TB:
M0"I(2/K^"<<EX;>0S+->2H74B"V4/#W:90R)'(H3N_"4,KD:PI"'NPUQ)&GH
MSL\3F&=S=(PW;IR&K6VI.U/+'.GN-F)!5N*NR==%U VEY+N'[&,4L99*.8L&
M<0X*HDL@<$TFAS))/0ZCM-';\>[-3\7X='++Q>:V6VB$5FK7K6QN-%Q:B,+)
M*L+1L\C.I."/G $K7IW&+&SXYPOY80SS<36%-$4>O=$F*E7M0654"N\G>@=
M2[ @5^F/+&[J:Q]EB4JK6C^NL4U>F4:QWG(L$X>S5AKK/)SVR1U?N,56&$>[
M;3U+@'4 4;,Z;O#R""+XCQHR=MFK@#>3\*[*0<1X3%=-?=SQ.ZO+VWL+"=4A
MM[IN'1V\D]I+=-(K07EPEP?1E9%C8QE6=&==/E\L[12LAC.E%0R-@ED+EU!*
M8W52GBR0=_FX!-3UMEMUYON",97#)3!6.N\]66KV>27C#PJKE?M%DFTJ>'4(
MFI%&FF*;67&/.DD+,7HM^R2[/LRPO:*SLK#CG$[/ATG>64%RR0$2=\$7 +1"
M;)[WN7+1=YJ;7HU$DG)R0LSQ1LXPS*"VV-_/!Y9YXZ9J=]0M9::4II2FE*:4
MII2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2M:._G--DJH0^-XEZ^
MKT)+UN1LUKF&2BS1[,1:3I1DG7X]\B9-9)L4&KES8"-%4W*Z+F*9F5(S=NTG
M/HW8/@MM>&;B4R)<30W$=K:PN T<4I57-Q)&25+994MRX*JRRONZ(4U+F4J0
M@R%*EF('/&V W3U@=.>QQ6!5(>H6^@,0:LC1[*05.RKS<$"-G#E=!RX*0H-4
M#J)"4SANMP*9P**(**' @)F-KO+_ /R&]<R2!G3#3G5J #H#@,<-JTGD1L=M
M\C&O'XH\C8<@,8)Y]!S.<CEGGOFO23$L+-LVH7-9XY$CLK@*W'IR"+856X*$
M%&=?I(%,J5-03=31D=)$%2$5[^Z2X)JWY5GB=O0PB*8ROI#Z&?#8.J!"V%..
M3."2"? IWJT1@XU>?S1G<#JV-O=GWU)C)U'PK-",C(4(]BV*=-%JS9D9LVI$
MPY\$@*@0@"/CX%$3CR)A,83#J.>-YG:62;6[8)9GU,Q;/,Y)SOGGD ],5DV
MV4@>07"@<SSP -]O\:O6$O#QFR1:>J3]/VX2K*JM2D2,HLJH7M@(]%00,42@
M4J:0D+X=:Q1$0+I3V2,Y?O@=@,!6)("@'3E"-B#DDY\@>=9 Y Y8VSN1ZQY^
MKD/=ZJY4+X[L,TU&6AV1ZZ@HJ6'ZG2BAUY, ,EZY!N**Z/8J 91O&E!4 !(Z
MS\5%N]->[:]U8)!$QCE?O\#O %&D1G<QDZ@=2[,^QW 7 *MD'+,-L#D-]\^?
MD1T'O.^0*GB9=2:$4JX*FU1 I!,H**ZZPD2 IA#I,+9N(\\% P=)!#D0*8?
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M:Z!N;B%[2)&54M))PD$ER1%'+J9)46.3,.& *0KH"4ULA7 9\1G0"';)U2!
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M33,]K;5RY<LE55>"(HRL4>1BU%C" ("\*N(\)<#T/9;B)X=QNT8C5%=MZ#.
M"2([EE5751NS13".4* 2W=E0-ZQ3KJC;S4:ATW'K]F:T!4V.D7&X.ON&$1)+
M-Y!B[!-\1DOW-4YZP^3$QG(D[ AB@!43IJG(J4Y/$@%^,/OEY+$O ;A9)HPT
M;H=!==0 N8R,+G)WR05\.#SYU%QC]>F <'?.-@=)R/:-\@YY9Y<MEUBL^/\
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MX:IKU.4<0TB^E7Y) %)AC(EGYPJ#L5CIC*-!21DR))F8NU0%FB9,"$C5FS=
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MKD*H NIMSI4<AGED^TU#R.79Y&&6;4V 0,MT&3L,G;/F14-)YU<))"K*8LR
MP*1(BRIDE*6\*1,ZPM^H"C;VSHX$5#I4*5KVB?44QR 4P#KC_P!*W1=4_ >+
M0X"ECJX<ZJ&8J#_SY'8 \\)MD'JN>;7M P75/P7BT> &;0>&284MIR%/$$<X
M.S )J7(+*!55+GFED6!O(,+M%*BLX0$CBCV.0*"S4@*N$NUK[*:1$Z28@H(
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M*W.!C=20%'D?/7$7)G:YN&NM?I33RM<]Z")._9V:7O <8<N6+# P2=A6R
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M#:LZ1@J-1$WV?_\ :'[0\:X9=7LO . 1RV]]#;(L$G%F0QRVQGRZGB)*N&
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MFI8RCMDPTW-[JF20(M\Q1I2 )Q#G%E&,;XYS*"'4+$1Z0,8W241$" /27@H
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M=<ESR=MR3X1@#))P -@!G  Y"H9CEB<8R<X]?6NP2%'D!* @/@(" "'''''
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MK9?37:ZTB0C5H%P9-!7 U%<%@=]DJ].#\(C!1.$\*2)FU]VG#K)8]872'*B
M*7*Y4-C(&V3FK@D-A.TI\HDHG@Z@,!33*F8K.O1Y4U1*/5VBB:J*A>T'R'IZ
M0$ #D.>1&/CG5%*FUM),G(UVL&5SS P@./+RW\ZN/".%'GPOAF/_ .G66PZ
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M2 J$+U%ZBS'$.)2FXA>2V&>;R,HCTED":5'BP4;?0!@9;!.^M)W40TMI;F,
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M'BLLW?VT[7,4O?LKRLZ2R-^LUDLC=PQ,6(QD6VXGG2H095AI#0JH5D",N!A
M"J@  ;$9'BW-8L&P[?=E25CG>8C1K6/BSRBY[A<+Q6)L89C+R(R+]JV3@'TO
M-N&(/U%W$3 M&XQS)TZ=$CT6!'CDQL5OVW[$\+CD7A/>M)*(E%I:V5S#WTD4
M?=HSF=(H5D*!5EF=A(Z(ID+]VN!X=Q&5E$I38L=9D1RH<AFV0DXSNHV4$X&,
MX.X7#>)'$!0Z5C^HI*-Z[CRO)PC>8>N 1=O'H+N)%_*=FB1?LGLI,OGDCV*
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M$8@,N 64$@97IG\YJ#DXE<)+(@6+2CLJDJQ) 8C?Q#?;WU0R[O,NB( -#C
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M,7V6_GKD-W>7!Y$:)%@(!R >JYWD?'CR[;GPY'^H> U7Y)ML9[R7'4ZEQ_\
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M*0Z93@<SD50[<_W"8& X@)3*= ]EX[+W%R002X53C2&92Q()R N,J!N<8SD
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M+6"D%IJSOK;,R-@!A:UY5]"UFCP%9K#65=RTBP6EE>Z0Q"L>R5633- 6O&N
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M$;C/+H:S5L],B+$"$S43#)LGP*-9!LP:_&;N@+R(/&?059HHNF<X*$621\"
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M#&^*ULM<E.WQ5W#VU(V29D55G*DK+&1D5BMWA 3!N+%3K8M6Z0=16[8R";5
M1, -NL!,/HAL$B*HELUO%& HCC#)EE.=1D&'9B=RV2QQ\X X.ALP),N2=]1'
M(>6,[8]HQS]=1JKCQDJ9%121<*F;=9F8*HIG0;&45*L<4$05*FF50X<J%2 A
M3E$Q3 (#QK='$774!$HU'QE6.6P-.YQDX'+/+:K/1A]82.>,;=/7RVY<O*IB
MKSJP.YMBW5D.\,7"Z::L<VBFQ02:\@"QFPI 9R!D$0%0A3**]?2! *83!J,G
M,*PNPCTLH)$C2-NV#I#@X7#-L< 8YY%9!$<CQD^H+S^\^\XK>3A'T:]?K\(U
MMUNL+]GD*Q-BO9=!%DR>DKR;DO*<(T=+F4,=PW;"DA*.R#PNX3.V;&+&-V:!
M/!>TW;NYXK,UG;*!PNW;3"%=T])9#O<2@8R&;Q0H<!%.I@979JW1P@'#/,X;
M&ZZ$(!SGXBIY^ [6>./;B=\Q'GU='^X ]_XM<G\LR?4)]MOPJX\(C^OD]?AC
M]?F/6?;US7'P'*S\^9WZNC_Z]/EF3ZA/M-^%4^1X_KY/L1?R5R.QVLCQ_ES.
M^  '_5\?\GY]/EB3ZA/MM_$?NVI\CQ_7R>W1'\/FUQ\!RL_/F=^KH_\ KT^6
M9/J$^TWX4^1X_KY/L1?R4^ Y6?GS._5T?_7I\LR?4)]IOPI\CQ_7R?8B_DJZ
MJ3M&@:59XRS-;=+O5XSOO9MG#)DFDIWV/=QYNLZ8B<.@CLRA> 'DQ0 ? 1UB
MFXH\T3Q&% 'TY(9LC2P8;8'ECWUEAX8D,BR+,Y*ZMBJ '4I4YP!Y@^>WD:R]
MU%U)TTI32E-*4TI32E-*4TI5EY%IZ&0*-::6X=*L4[)#/(L'J)0.=HJX3$$'
M/9B(%6(@N":JK<P@1PF4Z!Q BAAUN</O&L+VUO402&VG270VP<*?$N?V25R
MP!*G# $@51AJ!4\B"/C6/%FC,;;9JNKG&SU]XZLD?'Q-??Q="1=#'2EIN$G"
M0:Y:C4W\DTA8M]9YSU:DX=K+1Y3IE34?NN2J*'G;>7B?:2Y7@EM<*MM))+<1
MR<0*=Y%;6<4TZ^EW<<3S2I:P][H0!R,D1CD!B;1"ID(.0 #H',MA3I7. 6)
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M"1I&L(Q=3BW:XD>1P))$U+'E\MI&>6EE:<M.T\DK3,&:1GU%LC&MG(+D  ;
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M DD55;LR1U]P5[2!S::[B)F#2@_VH49TJ NTBJ#G4H#:M^[P,U59 Q\> <$
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MU6[Y^;[B#CIY\N7N&U=\KE?&592%NM9H=,$ Z2L(8._&()?\PJ$8FJDD(>(
M!S)@ ^'@'&J!2>2GV[<O:3OT^[UXK@GFQY;@9.#G!V'3/7EGETJ,I'='2F_4
M6,AK!)G 1 IE4V4>B;CP 0.=TY6 H_)U-@'R\ U?H;S'JY_A5H QS/K QOY
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MFE*:4II2FE*:4II2NI5=%!-15=5-%)(AE%553E333(4.3'.<X@4I2AXF,80
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MCIUK/';S28*H-)SXN6=LC?&3G;=1BKD@-KK153OUWM#^9>*&ZUT(\3H)G,/
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M%NKFV#]X()GC#D %U4^%B!L"5(R!R.: Y (VS[ZJD@("HD ?= 4>1_*(=/\
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M'7\[U+6E5II2N.0]X?3I2@F /$1  \_$?D]_Y/QZ4JU9>R)-.I!KPJX !ZC
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M:4II2FE*:4II2FE*@'+6$(Z]]I.PJB<1;D2D,1V)C)M),4"@"*;X$P$R+@H
M4B$@B454P*0JQ%2$(*>[;7;0X1_''R(/-<]5Z$8QE3SZ8K!/;+-XU.B49.P.
M&YG!]>/\<YP(WH69YNIR@43+2+EHY:'(T:SKH@]LB7P(AZS4#DKUDH4.I&71
M%03%,!W K%$ZY)0:7421$,K;@ CW[<P?-3C?RJ,="I*.-++S/7RSZU_O XZ\
MJEC).**_DMB200408V C<IXRP->E1-PETBH@B^%#D'C(_44R:Q!%=N @=N<2
M"=)0&*G;EU&.OX^>=JM/4-L>8(]6"-NH',9Q@CGSJ$,89EL.-\VQ%.S"9V9I
M6J!,PL/,*AV_<FEOLE=7*X,Y'I._B51I*!$' <JMBIJ)F*/9=BG%WMB)G+6P
M57"!W0;!\L1L.0<A6R/VB-M\9F+.^,:*+ALIKT+(3\T$*3J/5<D8/0<SM@;1
M6CML^;(/&;A%TU<I$60<-U"JHK)*% Y%$E""8AR'*(&*8IA 0'P'4&002I!!
M4X((P01T-38(8 @Y! ((Y$'D0>1KT:I5::4II2FE*:4II2FE*:4II2FE*:4I
MI2FE*:4II2FE*:4II2FE*M.\51"ZU:5KJKM6-7=%;.XF8;$(H[@+!$O&\O7+
M"R34$$E'L!.L8^8:I+=3=9=D1)P11 ZB9E4(S^>O2L8;ONH;UFIDC^X(DRZ@
M=Q 62K)&56:5>RL *D]74,?I<N8F1[1O,U(ZB:2\W7)*(EE$T$GA$S2%C8M=
M-K8Z85/B/[3'HJ__ *QZ CS%:-[>K;+H7#3,-AMI3^\V2/(Z1MJ((VP:BC'.
M(Y2>E3Y&RNHM*3D@L#]E#/Q$_8G,('2=2R1@Z>H@=(M8P !)N0""X*)@[!+H
M!I1%BB&E% &PP-N8!Z[DY;<G?E7..Y=C)(2SL223S)YC/D ,#2-AY>5U99S0
MQHY%(*"!.4MZY 33;D#M6T1VI>$E7A4^14=CU$,UCB<*'\#K=FGT%6J%R/(#
MW<O(^[!\JL ).3N?4,^_;]PZXR1D5T[?L<S-38R]ELQ3(SMI%$XLU?!RR9IJ
M+N!,]#P CQ\X7,NH@'QD$R)%4Z5C*IIQE[.LK*B$%$SA@-F)ZJ>JCEGX;5*V
ML#11LS#2SX\.YP,\ST!//&^!CD361NM&MBFE*:4II2FE*:4II2FE*BS,N.W6
M4J#)4]G,(0JSR0KL@*KZ.&7B)!& L47/.(*>B0=L?6<!8$(Y2&F6)W)47,>]
M73<).VQEF;BC#4,9(]G[CY@]162-])Y9WV\P=OSMO6);#:7GQ@DLFGO"OJ -
MZ^G$0;-A#JQT'$.THBNQ"+QO!L+$U; V:LXZ99(1IE%44@E&TNU5:6!BI*.K
M2A(^>PWZ;8&V ,<A]_\ '-J4X\.>N^^?63C?/KY''J J ;3\SK=#AWNPR H_
M%_7W($4;3,E!M&T,W<?Q-I 35PDHUPH20+%/F<M*I/Y,Z\.DYDUY)\^?NE@0
M\];<CG?8^1Z;[Y./W"G>#'S0#N<CF ,;$'KCG@#!^_SY!V:VK)D; ,K#EP4G
M[+'L[0YBPM8VVN+.HWF'UK<J# V60R(XGHUJ]8V1I%3IGTC+/Y!G!,SLWD8N
M#%6*HT><98G"XSSYDGV;YWVV.V^,TU@<QY$ *<9R/+EY#F3G?;:K_P ,[;+S
MBV^DNDWG*?OR'JBYUAU!2L$BT:2,)8K_ #^18F3?*I2JX&N<--6)\S=SK9!"
M/DHA55DC!1A0;=TJJ:23J)R,8./,'^%6M*&&RZ<;\SY; 9SC8';&#[ZS U?6
MO32E=#ERBT1,NN<$TR\<F$#&$3"( 0I2E 3'.<P@4I" )S&$ *4?DN5&=@J*
M68]!SQU)Z #F22 !S/+-0,]>H&-M\^L[#WU;"\H_=#P@(L4/(H])5'IP_E&Z
M@.@AR #\0"+'X'J%0@_$"1BLXT&J0]Z_49Q$IVV! 5W]I*C)(QBLP4>6<^KV
M\OP]7GO5+49]OSWE5TXY .>V<+J%'Y1Y3,;L@#GQZ03 /#RUM*R)\U43G\Q%
M!!Y#Q!<G;KG_  NTXQA=^1V]?0C?VG-=Z:14R])"B!0_]D0$>/Q<>/R?[-5U
MCKSVZ@[^W.-O7BF#GES\CD?')_?UKLX'W#] _P!6FM?/^/[LBFD^1]V_[JI$
M],-Z]$/IEX@\7;,$@6628HD6<F*91-+[6555!$H%%0#JK.%T&S=$JCARNB@D
MHH5J&#@C.#C.VX&<;^?^',C.*>5;:&2>1)&2)=3+&H:1AD#P@E5YD99F"J/$
MQ"@D8\8VW(T2:L<QCFYW> @,F-99LI&5*R(/:/-RU?GF3)]6G</%VMK#.9L7
MPKNV@)Q*;X6K]D]A^]RZT6O,/[2X!]FVQSDY(.XR-A@[\SOD'PB X=VAL9[B
M;A]Y?6\'$UD!BM;A&L9I8)U22V>**Y6)I5<.R9B$A62.2+5*8FE?)W@?'P$.
M..? >/'\8@'N'C5VH>_&PVR?AG\^PUTA4CIM^'[O?BL:J866,%S%H67% ,EY
M#Z1:)V8S<1]J)#JZ1C9MDS$0-SU]FW(;GD#F4/R(S]YW/^2:S$#\G6&S&U#?
M\V3&TD#-N,8RQ&.6!1<8WQ\YMN9SG;& >>W//+RVJZL0B(XJQ\ \\A66/@/5
MR \J]74!C&,!N? P&$3 )1 PB(#K4XO_ /B=]_\ S+_> =MAMC!VV&=@*OC^
M:/6!]V/ASSCVGU5.M5(B)'RG'+D%DTS"//)6_9$.D4O/D4RO:B80XZCE$#<]
M!>.=ORV8ES^KT$@?W]3!B?6!IQML#MN36&8G5\<>_;]V/R-KNU'UAII2FE*:
M4II2FE*:4II2FE*:4H(<^ Z4!QN*CW(.-J[D6+[E+H=B\;D4&-EVY2@^CU3
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M-R5[QG"F(#"&[X1.%R+7&.X2YMLD?-N)6QX"#8> VQ&TBCP!=FD))$-PA/\
M:XSWDL,G/)$( QJVY#9CMO%V"Y5JF"!5EE#-A>N1*=(97!4J1$!]KN!*5A"W
M6(*/3QTW>;/QPS.F['M1QW25,=R20HU&(;'NN-1%L>BY^?+9R^?^20YV?:IX
M%:DZM2D!BP\3$%6DM" /UJ@86&X78':=O+-4&;V ;5YBSP5@<K580AC]W7B>
M]HN(B;04F,X+H>N&SJPN%%5XA26I2T&[;+MEXL]1:B4ZB,VN@AC/:?C[+@I<
MZ2'RI@0A@8>#:00;,[*T-VVV,^ES#'A.K4G[)\-N+B&>4H_<J4,)"O!,NJX9
M.]61LEH6EB>!P5:%H6T[2N&K+?9]@V&1*[ALBIT)\W8**C:ZID"S4><C +7\
M!M'TBPE8&Y]X6EFZ$/D>4@&#Q)Y'.+1>5^_M'",:J+O*W:7BTN4DX>]VK.J^
MC7%C!=12?K^.,D;I+::1"S2\/CN'&EQ;68,;!I1C:' XDWCG*-I(#Q3312+E
M;5#(KK*<R+W-PZZLKKN1J^82:[B?<5?MO2S&'SM SOV&["F]L260IE-Y)Y!Q
MR=Y)MAD+7EL4$2>N,6NUYN :.\NJ0U7+&W%[+,GL._@&BMB88.+\#L>-%Y>#
M3P?*=OW5LUG"5CL;[1$VFWX86;$7$%2"9UX8);D-:I&XFCF<0->E[-9R)'>*
MWHVA09W+22Q,H0/)<,HS);F1UC%UHC+2E@(V5==9RLJK(MDSO<<9 8I5*<44
MGHMFXB6-MA$"3!S2*BM8DF4G&&)"OE7)WK9OWF19I]N;N"J38Z:).2:ZC;"\
M1L7:ZA @DD6>2UF8Q#NU%S&T4OZY%4(6T1L<>,%@29Q0&P8V5E;Q#&EEP<$%
M6R%((.<YWVV\KJKT+E'OJZ2>1*ZD99H"AA''QSE,#94I2%X]KR<#_&C#R(B
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MC5MU66L6J$!Q[= )41IE+AP%T(^#4C:?$05D1.;5N^TUCZ+A>!<&DE[O(U<
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MR7[ON\/KT8+*/%WWHY&2V,B;P'IG?.*K"VX+$Z#[U:K9^AYZ\6K?8^J9H?\
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M !-PN5ER5S)-&@E.FLD*8@8TC'%*)T1+RHX;@=#@RB:!=54CYK ,C#?.,;[
M'S!SO5@8@Y!PZX*D<P0<]-LCU=#OR-9$;?\ ,K7*E7*1^JBC;(5--";9@(%,
MX+R)$95NGX"*#D"\+ 4!!%T!R#TD41 >:OK1K:7(R8G)*,!L#G="<;$;X'5?
M6#736-V+F/#$"5 -:Y&2-L./,';)Z$X.]9 ZTJWJ:4II2FE*:4II2FE*:4II
M2FE*:4H(\ (^[2E:^-QF097(UR8X5I3@QFR;],EB=(F,*"KM+D5TW D\X^'2
MZUG91$04<E,7I,9-+F?X9;")/29!XWVC!YJN<:AY%CRVR%&W.H'B5UWC^CH3
MH0_K"-PS#]G(Z+S._P [;!(Q4C,&57Q#1A3ZRMHB$:F</')@*#J3?G*':+&#
MP[9\_7 J2"0"($ 4D"=**0=,EN3YD[;>70>P9J(/B.WS1S.WQ\]^0'J&PK&V
MD5Z6SU>75XMB1R5&(< @QCC&-V"X(G!9K"H>76@F4X.)=R4 [=0_8^ K_:,%
MU.($T(?UC#F.8'+5[?H\R!ORWK;MX.\;6V>Z7 Y@AR-BHY[8W.?7[1G FF1(
MA$TRE(1,A4R$(4"D(0@ 4I"%#@I2E   "E      #PU"U)DYVZ9R!^[[MJ^]
M*I32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*5\G*!RF(8 ,4P
M"4Q3!R4P#X" A\H"'@(:;]"01R(V(]8/0CF".M54X(/YY5&KMLM$.Q0 1%$0
M$6IS<B55 #?<&ZO-5N'":GF80Z%? #CQ.13+<)K!\6PD .ZM@888_9;<KSZC
M<BMI""!YKOC(ZYV&.G(\]\[[5^3O-1(.M;N]PK;<DU>"PMC.R0\#+NHAU,+P
MZUAG8%M$VZ"03^.=>K0QY2=8II+(%>G8#%BJ0)/D_P!2<',UQV5X"W9]TUVK
MV\LT4<JPK,+>WG:6UF8XVNIA' Y8,5U]Z >Z&.;N B7MQZ4"(Y(RL;%2VG4R
M!74 <XQJ8#8DJ1UJS;G>MM,Q$3S2L1D=7HL8)FS"+:U!L6USCN,I>.XN 6C;
M _K$V6)?ISD%<GEJ>HS%=3=RE@5F>+.S6&'#<L[+M%%+ US+)<2=^[F5[IO1
MH4DO.(2SK);QW, E0PSV:6J-#<,D, A_R9QWQQR2V;*P0!04 P$\;%8X@I#&
M-M)#+(7W0%CKRX.FJ=7YK;;,RE*97-]7F&.V$17".()&E61K=8^2:P,7'W12
MQ7FHLHY[,.)J9]<3\"8?:IB+A-@BHUK# 5XI7)/%VABBO'LXYWOWEN2L[7D#
M6<B--+)9BWLKMY%A6&+N8)L^C/H+D-<R8D%%:S<QB0JL0"#3W;B12% D,DL:
MJ6U'4RZ0V3C.@ BJ]A>$K4ON'VXI;=P?&GT',(M<!9%M"BC20:*M@D9"2D)P
MR#<PO"]\5<(Q$?'PD<F+9LBH_.47RNOQ>:YBX#V@/:#0(&686FOT8!XV#%(X
MT@U$:/ J&:1YI"&9A'DH,ENL1N[4VN3@?K<:^F Q);8EAJ)50%&P75L:_6L(
M" CS[Q_)^;RU\KGF<<NE=2.0SY"@B(\<B(\!P'Y T\_7SQL/A3 YXW\^OQYU
MQ\@CY  <B(^7T_)^?2JU[V$<[D3 #<@ B(\&=*%$$"@/F*8^!G!@#D0*D/0
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M3/VCDO/(NU52F$Q4D@+$7<_?2$ ^!"0N#L?-O?\ N\JE[>'N8P2,.X\6>@Z
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MT3_?^G<R_52?8;\*:#YC[_PI\(_;O_/YA3]:M$_W_IW,OU4GV&_"F@^8^_\
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MN>T(DXIQ&9?T:=PLE]=R('':#@"!E624A6"LRE@ <%E)P2*G#[&F./YOJ/\
MT2@/]WZ_.XWEX"1Z9=[$_P#O,_\ M*ZOY2XA_GUW_K$O\]6/=X?'U,1AET\+
M0=E+,S,? IEA:YC]N9H_E7;=C' Z]?NX8!1=.''1VK87 (@F<S@$BBF)\L,]
MY,6'RC/'I1Y/UES=G4(QJ8+W?>;XW&0 >7K&[8S7UX\J-Q>:V[J&6?5+-=L'
M6&-Y9 O<K*0PC1CX@JG8!L[5YD5]O[B&DYUO6:*Y80TJV@)0&5$:2+QI8W:K
M5LE7"Q[""<OWD^1T];-5X=@V=2"#A9-)9N0X\ ,G%!(D9N;M6D0R)JNI0&B"
MLQER95 C*J6#D@8\\9-V..B6*!IKZ.2:W-U&9KIX(S;!7?T@RS2)&L&F-V[U
MG"%5U!L&K?)<MKBIR)MHZ@O%E6,3(-F[#'8OW3U*;"%&.;L&K.LKN9"46)8X
M!16%9)+S#-*9C57S%LF\0.?-IXP,YFO%"O(A+WCH 8N\+$DS$!?U4H#DA6[M
MRI(7%;!M.THSJDO8PLLT3F2\[L1M;M<),TK23((HE:SNU$TA6%VMYE21C&^F
MJ1<QMMG#R"</$XYD#1=8&XNS(TN.! *Z6-C9=:00=*PJ31T+2.F8=U(-&JZS
MV-)*QI9!NU.]; IC=N+)IUS7JZYA H-W+_:%G15P)=0!:-P&TZ6TMH+ $BR2
M#M%$$:22^0/<BT :Y?6MP9)8EBDC$I:)GDM[A(^\"B1H)@A/=OIM*$NV$)1>
M=2?XJKD&2M-(IU-&<5JCR<BT--0E8G6""=6@CR=S=]3>VQ+)9XUK:L<G* \9
MIO5BMRKJY77B*",B^N6[YG6/%Q=*IT/-&Q,KE85W@<@&345P0NXSEGMN,PK:
M$<3DD:]>980+JXCC*07%Y;-(;FX$-LH,EFY"&76$>-F5<LJ5I6V;:2FCRM*[
M3Y4LH_KD>S<Q.-BOV"BEH6B$HY?UFC7O5@MFX3T.M,'3>'-"(R3$90C51XV3
M5M4<6.K-Q=+I$I8->N&'=:]7A:4-OW4A0:?UFA])\)-8S;]H5#%[BZC*K<.5
MEOA&X%JDKR*8S-KUMW$ZVZ$![EX9$MEE96 K$#(;>;0^CXNOUFF2DE*$D%F3
M)'')4EE&T:QBI)=^OWJN($812[&=A'4;,2!VL5+HR\:>*>O >MQ4LD;BD09G
MN;I54#+&\D.[%U VE(+!HW#HA=T[M]0&U8YTX[:I))<7%W$D31*[->;!Y7FC
M6)2)B9)@]O<+)"@:2%H)A*J=S)IC^3R7M_BH]O(+8ICE2&@QF'Z"%&IPKPKH
ME=R'9'%=E"J+)D1L#)KC*QM7S)$ZZ;5X>,*JX*W>@X)G6+BCL5%],/UO=J6N
MKH*X,EO&LB$$YC8W43*QQJ75@ C%2$'#./W$IBCXB^3)W<9-[< 3*;OA=HD\
M8*:O1Y7XO:/'(ZKJ03X!>%HS)56:8GM,Q)1#?&%59'9(.W+1=Y4JR!)-"-LL
M[4Y4S<J+144SQ\O!*"JFH(B+*3B7(&*HY6;MM:2>_C57-]<G40"JW5P2NJ*.
M5,DLH.M)!C V*,-]C49<R<4M8DD?B-P^MPA5+F<E"T$%PA?)  DCG 7!)+1R
MC $>6O*0QKCDK!Z8N/Z0!@:.! 0J<  @/8G\0$(_D!#Y!#6-+V]#K_EEV?$O
M.YG\Q_\ $K33B7$-:9OKO&I<_P"42^8_O5MFV9VW8I6=I^V*KY%JV(&]\C]M
M&'IBQ#,X92DUWLD^Q=6[(G&)6(M(>QMDO4S$OD9B.ID7*REXG6RIW,?!O>A4
M2>R74EP+B<++(!WK8R[$8]6_+&_,#/PK]*.'R6WH5IWBJ7]&B9SH&22@//JW
MQZ9Z5D36\E; ++;IBIHXVPU&JL4:D:'?3&'JW&!9GMLL+&G!!Q\2]JJ$_'V2
M"NDM#5&<K<]%Q<ZSGI(&8QXBPDQ98#+=  ]\^,G8,V?5UQY_#ESQM"6S)(**
MH !U%1OGU<]N>>6U1'6+=MZR)NBVIV;!N/*W235O)&Z[',^O&T6M4^0F A,-
MMY&)G&BL"@!I:F6Z$DH>VTZ247[*2A)9D\,U:.^V;H2-D\K1W7>2,X ATAB3
M^V<XR?, 9P-MNM0_%GB:.,Q($QK#;8R-BIZ<_+F,GSK:_K/7/5&V8LD1V'\6
MWW)LHB5TUI=9DYLC$R_=0DW[= 2Q42#D4U>[GEI11G&IK=DKV2CHI^S4Z>@:
M,0H)/(#\CWU<JZF"^9^[K]U1!AS-MFW+4>/OV-D(:@U5XJJR7<6YA)V2W%D6
MI4R2+1& :+5R"8()'4[6(L 6*S-I!N9)1U LU@<,DZ*VL9&PZ9'QV!\_6:N9
M0APV2?5L/5ON3MS&![>M2V3&IW?QK+D')-D.'B0"6<:2BB;S$$D\9,Z0=5,!
M$>@L@L_4 O *+*F #:KCS)/OQ[ML<O7OZZM+>2@>[)^)S7:.(L<*AQ(59G/"
M/B92TN9"VK''WJ+V9Y++*&'Y3'4,(_*.F!Y9Z;[_ +Z%F/7X8'[JKM=HE(J"
MKE>ITZK5A=Z0B;U>OP$5#K/$TS"=--TK'M&ZC@B9S&,0BQCE(81$H (B.JX
MY "J$D[$D@<@235UZ52FE*:4II2FE*:4II2FE*:4K'O.^3YJD-X:"JIA2LE@
M4,9!X5,BJK%JFJF@46R2A3D,[>.%.Q0,<ABIE36, "H)!)NV=NLQ9I!E$P".
MA)SL=MQ@'(^.U:]S.T"KH)#OG? V4$;CUY\P?947R,GN*Q0W:WB3MZTTQ*Y;
M^MXU:3=RR" .% *5&0:ND$T034.8K?O#%13L53E IP Q%!WGM+25='<HF0=+
M(H5AMT8>KD#D$9]=:J7ERCZA,[$'=78E3OR;(& 2-\;[[>O8G0+:SO-0@K4R
M*":4PQ3<'0ZNH6[DOVIVV$?E[!P10@"/ F*!3" <ZYF>(P321'?0V ?,$ @^
M\$>^ND@E$\22@8U#<>1&Q'N(-7CK%6:FE*:4II2FE*HD^][G'+"4P@HJ'9I\
M#\;XW@(A^01#GCY/$1UDB74X\AN?=OCRWY5CE;2A/+.V?+/^&??BHJ#_ !_C
MPUN5%GU_C32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E
M-*4TI32E<&\OR" _0(:H=P1Y@U4<_:"/B#7X_KOD['-.S+N@K5RMT)7I?X4^
MY)RO$S#L6#WN$MENUOF#D452IJ@VD8]T@[9KD^(NV7271.)#E,/V)_1CQ[@5
MGV&X%;7O&N$VEQ$E\LUO=<1M+>9.\XE=2*'CEF21=4;HPRHRK @[@U\%?TW=
MC>U_%?Z3NTU_POLIVEXE872\$]'O^&\$XE>6DA@[/\,MI3%<VUO)$[13QR1M
MH9BDD;!AJ0K6.@Q.SMT=ZK.6^MVI=]&/HE1>VVMQ8UT6KUA&1A%FBTFHX.WE
M(^/B6K6,FTQ"98D4=F2D!5=N5%9\M_1[(9FN.,<!O'FBDA=[WCMI=N(Y(8+<
ME7GO'994@MTCBN%(N8U,A$NJ20OQ:<)_I@@6%++LKVRX=';SQW$</#.R5]PZ
M$RPW%U=JKQ6?#(4:VFN;N66>R=7L9L1K):A8+98:ID3+^*'=HV_FC,@5^09U
MS)SQ]+O E0=>KXTN)\CQ"<C*NS!PDFM(/V#,SMR8I57KU!,3BJX(!O,/_:!X
MCPWC7]&UYPW@O$;'BUZ_$N&/':</O8+ZY:.)W+OW4$LLK*@&7;2=SON<F:[!
M]A^VEG<=H'NNQ_:>TCD[.O!";C@'$K=9)CQW@4W<PJ]JNI^ZBEE$::B(XY&
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MY$\L'GOG?/D1TSDC;VXVJ@;,;2HM7[+17QQ*]KLH9\W0.(]96KS^+.DP*8?
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M=0KAMR @ @ -W*:9?,! @\"(@(!SW$XA'=N1RD"N/:=F]Y()/M%=+PV3O+5
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M9V*4K>56,VBEQ,.-0 $91P0Z$>J(]F]6(=)L950HE"6_JT[99P.%PG+2(/\
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MM?\ =Z?PFV[[^93;;^L;*7_!&GZ:\+_S;B'+/.TY#F?[7D*?UZ\+_P"SU_\
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M/P/E6P'6&M:FE*:4II2FE*\<@U*]8/69P*8CMHY;'*8.2B1P@HB8!#Y0$#B
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MOV:J:23.#$#.U-N+CMS'<+)Z+$2O$.T=UI)< MQFSCMIEZX2 1AH<C4SDA@
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M.JN@8Z#@XBJF8Y#%'7#-<S:FPY U'&R[ G8?-SL,#??;?>O2#Q2]3PK</I&
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=-,H%(F0A0 I"$* %*4H 4I0      UCY\ZR5_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g425213g20j89.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g425213g20j89.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2UL4&AO=&]S:&]P(#,N,  X0DE-! 0
M    +5"^$6 #A"24T$!       9!P!6@ #&R5'' %:  ,;)4<< @   @  '
M)0  AR<C4P,# W.!P"!0 [36EC<F]S;V9T(%!O=V5R4&]I;G0@+2!'<F%P:&
MEC<R!F;W(@0G5S:6YE<W,@4V5C=&EO;B V+G!P='@X0DE-!"4      ! U(P
M@@PMP9I^[3X+OB:/X?.$))300Z      #E    $     $       MP<FEN=$
M]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4
M  0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M95
M1%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P
M!F "  4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6
MT    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT
M 0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;V
MP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP      $
M-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V
M]L      !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P
M,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX            $
M)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT                0F
MQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'+
M *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P
M    !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
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M  .$))300-       $     #A"24T$&0      !    !XX0DE- _,
MD           $ .$))32<0       *  $          3A"24T#]0      2
M O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:
M  !@       0 U     0 M    !@       3A"24T#^       <   ______
M_______________________P/H     /____________________________
M\#Z     #_____________________________ ^@     ______________
M_______________P/H   X0DE-! @      !     !   "0    D      .$
M))300>       $     #A"24T$&@     #-0    8              N4
M)X          $                          0             ">    N
M4                      0                         0     0
M   &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M  5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   N
M4     4F=H=&QO;F<   )X    !G-L:6-E<U9L3',    !3V)J8P    $
M    5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;V
MYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V
M5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(
M9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M    !,969T;&]N9P          0G1O;6QO;F<   +E     %)G:'1L;VYG
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MU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*
M      #     (_\        #A"24T$$0       0$ .$))3004       $
M  $CA"24T$#      BN     $   "(    H    9@  /\    BG  8  '_V/
M_B#%A)0T-?4%)/1DE,10 ! 0  #$A,:6YO A   &UN=')21T(@6%E:( ?.
M( "0 & #$  &%C<W!-4T94     $E%0R!S4D="               !  #VU@
M !     -,M2% @(
M                  $6-P<G0   %0    ,V1E<V,   &$    ;'=T<'0
M'P    %&)K<'0   ($    %')865H   (8    %&=865H   (L    %&)865
MH   )     %&1M;F0   )4    <&1M9&0   +$    B'9U960   -,    AG
M9I97<   /4    )&QU;6D   /X    %&UE87,   0,    )'1E8V@   0P
M  #')44D,   0\   (#&=44D,   0\   (#&)44D,   0\   (#'1E>'0
M  0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY
M!D97-C         !)S4D="($E%0S8Q.38V+3(N,0              $G-21T
M(@245#-C$Y-C8M,BXQ
M                        !865H@        \U$  0    $6S%A96B
M                  6%E:(        &^B   X]0   Y!865H@        8I
MD  +>%   8VEA96B         DH   #X0  +;/9&5S8P         6245#(&
MAT=' Z+R]W=W<N:65C+F-H               6245#(&AT=' Z+R]W=W<N:6
M5C+F-H
M       &1E<V,         +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V
M]L;W5R('-P86-E("T@<U)'0@              +DE%0R V,3DV-BTR+C$@1&
M5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M        !D97-C         "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;V
MX@:6X@245#-C$Y-C8M,BXQ               L4F5F97)E;F-E(%9I97=I;F
M<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M          =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X    !6%
ME:(       3 E6 %    !7'^=M96%S          $
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M0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,#
MP,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01#
MP,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\  $0
M@ H "( P$B  (1 0,1 ?_=  0 "?_$ 3\   $% 0$! 0$!          ,  0
M($!08'" D*"P$  04! 0$! 0$          0 " P0%!@<("0H+$  !! $# @
M0"!0<&" 4###,!  (1 P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4
M,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$  @,! 0$              00#!0<& @C_Q !2$0 ! P(#!0,&"0<'"@<
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M3?KQ'?<-M?EO\^>")Z!IIRP1( TV\@&NW/Y\]-\$1IV[\-?AKMV\=]?AM@B
MVU'D(Z\0T[1^WNX=,$0.P<O$?GN ]G'!$!H/0=/.NGAM\ML$1H&W;T[NSIRW
MTU[=,$1S\ T\-=]?'?Y\<$2_1Z_]H?OP18[*(=$)NW%M$UBL;E[22K+<"6N4
M,;9(&XI>24>02M*1.R56FH5E$*E)):F@H#J"E!Y=%84&F4U$58;)GU]$Q&I
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M#UC@)52I<M-4$R]?L]5NR!H%,     -@  TV#0  .  '( #!%#/)S_;YL/\
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M7/G^Q5NWU_KXQCOR 6J0<//#'L_(3ZZJ?<*W[[#Z*KBS%('^N.6CN*IVQV(
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M,R\_C_I"&?S\<.'I\3[(1=7/G^Q5N#?:>,>XZ_Y*D'Q^SPQ[/R$C\M5)_P!
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MS1]UE3+ HRB8HX]RF02R>28M>9&H<P-#&C5FF.[X+:L+2'N)C<S)Q)J,<W5
MG 3@(H'6"O+F#N]GMN,E;<O3#E;C)UGK#7,NTHO)*:+E7SNA;=Q>K\12T;*P
MQ"V4P66HLLYHWF-S%PD2M;,+D.QC.M;4BIF2NI]7Y"(I;Y_F"+R3)[?!LF%P
MD-J&4N/-#P7<5P@[M<XJ)/T;ED?D42=$UMF)V97:X3M3*VIE(8X.C7#7+'HY
M PF('<E>8T+B+4&2#,C<F\CVJ9[I7I@<O>E4&?Y(VVZ090[F99)^QC"+QS6Q
MTU7R%7,LQM\V!U/8)];Y]8'^(M!+:]Q@]PC;@]&HTS\UHU;KP161CR[^FO\
M+OVP1'?YTX>?K@B6_9R\_=QUX=N"(T$.T1W'7AR#D <N&W?@B!#78>&"*&>3
MG^WS8?YYEZ.'_P A#..VWQXB."+JY\_V+-W;/&,./1ID(]/MQ[/R$^NJGW"O
MG'[;#<;*KB_HQ]MO&;!Q.1U%E3MCL5]=1_$".\Y'0R; :RVDQ.GHD^&HU%C<
MF(UG/@.,DVF^1$B)G3()< B.-^P9Q$W! )\<S-IWH]=1B]R.'ZP,O+_BU0/U
MY\=.'+3EOPA C%[.YX>OV?2@Z]UA^*V&",MJ?:;Z&PI8Y@?V(W5#_D')M_\
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M*MW3\_&3X@UR !Q[/R$^NJF?Z!6Y?KL/D>/JLJN+^B'VQST=U[1FJ=L=BU]
M.HS[9M/?;.2-9I'$R1D#EQB.?*3E 1B09SM?D( FQO-XO[I4&!PX:W.I%HMZ
MKYP5:;Z/7]5[D?O R\^/^IBG[.WMY:8Y7\(7Z7L[[O7SB;U1/B1IRMJMC@OF
MU,OG-R^SU/-2SS _L0NMS_J')OX4IQY+87UWLC_>.%_>M5BO]#4^P[U+Y_\
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M72732.A8-U5.H&-Y@TT>K7Q.U-HXRGYK%8W$XBD'!XIUJKGM#@" Z'$C> )
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M&B2FH 3:Z &M0< DD4_X1IH"66%5>V"+'9],$-O8)-9\YIE:UM@\2D<P<$:
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MS$*L$7,MQ;SC@3D+49ZH4M"VE,2I(,45HS:AI*54E4F>N*8VL!I+/T FNH!
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MT'4*4Z<BG1[8G2JKVQ7JTF 355[2C2DT:J: *J'70#!KJIH"@?TAJJII -1
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g425213g25i26.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g425213g25i26.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1L.4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &O*^:)@X0DE-! 0      &P< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<<
M @   @  ' )0  AR<C4P,# W.!P"!0 [36EC<F]S;V9T(%!O=V5R4&]I;G0@
M+2!'<F%P:&EC<R!F;W(@0G5S:6YE<W,@4V5C=&EO;B V+G!P='@X0DE-!"4
M     ! P0P[*A?9;E00KUX4;9]+W.$))300Z      #E    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P
M4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M     BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O
M;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M         $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M        0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'7@
M           *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M    4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2
M;'0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE
M;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC
M<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M   +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU  (  0._
M_C4  @ !.$))300F       .             #^    X0DE- _(       H
M /_______P  .$))300-       $     #A"24T$&0      !    !XX0DE-
M _,       D           $ .$))32<0       *  $          3A"24T#
M]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M     0!:    !@       0 U     0 M    !@       3A"24T#^
M<   _____________________________P/H     /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H   X0DE-! @      !     !   "0
M D      .$))300>       $     #A"24T$&@     #-0    8
M     H,   /^          $                          0
M   #_@   H,                      0                         0
M     0       &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T
M,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M
M;&]N9P   H,     4F=H=&QO;F<   /^    !G-L:6-E<U9L3',    !3V)J
M8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R
M;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@
M  UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   *#     %)G
M:'1L;VYG   #_@    -U<FQ415A4     0       &YU;&Q415A4     0
M     $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .8V5L
M;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R
M>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV
M97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M"V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE
M    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M  QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
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M[_J2N;' 728W_((_\+N_ZDKFQP$L6\_-1>B^KW]!=_QKOP
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MB@"%4101AJ,<%7)X,#4E0BJB'%Z'#%!K#=+@'BI5(CE[/8RE?(! &%N2</\
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M?D6%XSMVG@4 =@W<Y6MYIBMM/S(C .KY1%7M1;'42\B"G2550Z815"VV@X!
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MO5%$^Z$A]N<N_-@V^57=>O3;>O@^>Y[1&=ZL>3Q4Q4;NI16,2^E)K/269MY
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M7-6&\AFK3,B(4USP<Y.5?-5-*I!:I8"I4BJ;\*Z@.7*XP<DT" K4-0U5&9T
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M=LB' WJVT52FN(B(O!\?:,Q(5LI1J RK@E<'KQ;8<2H1%=2HJXJQ&X*#I%C
M)4HS(:,:.#7%P]8LQ= ^$&A?\%1_HP<=7 6UGAA_Z?O^?Q9?]7=Z/R\J:#)N
MI\=)NF1J>#-4I4TU3G>$^^\OQICS3RN-?]P-.*!;B,M1O'7$I-0[CU1S6Q?X
M7%?E#[\XU;TE)Y,CL@! )6FCY8H*(#$&<2SH5(#\Y;% BG,Q\]OO0E2E%-*'
M?T+@CF*:@(%J@K4;M:IBK"&.=SP_',U/)B0T?\J4>7'IMS7X0O(V4?[2^"N4
MEVT&8Y7C/N59]TIT"DT<Y$\L-#ZJAECL]/7AOMS.,^*?3MFQ.."FI'2/D][7
MA8LU+=:G),F64>OX8UB79[-U,*1#)M)P+IW"&A;!OTBEO9*V93"@ YTXBW*@
M2S9=&%,-#&3R,0CZ;JLQYHK.*O'HV9ZK1LQ#:1T^/:L)9AHE'Q2#(E47O)*R
M;F.8N(M//E6MG<*>)%7S!4J).WA>?QD*#]/,P[]S!'4*;E\*A%8917FKQJHG
MB421F-,*ZP4'Y/.:8<(L">6YI,R82KC$>41"S-$]+QR^&5Q)+X@.8=/M)9\:
M&1JLX94%<.6OG)T2L**.BBIEV[4A#5QZ<AXPTZK(1XJ9,>4E<NUV8GQ,I5$1
MP"-4L8<)Y&%YR:J\\*X<FC'L>3I8K3K;H_,%$9PK#V")8(D>.C>),7T.Y+GC
MN+:=-LH1S]RPE?+J(@49,Y7W65F27>CJ<T4>S2N@D-T"=+*5E260=WQ22_D3
M&'LJCB51?&SQ64/%.(GVV5ZBTDK",FF ID@["-B2)!%*\B:T=< C\XJR+UP5
MU4J&4DJ^&(Z53!TAEDDT9>T3%TV0Z:@CR6Z2.$_(A/E:P3\XT>M%TMBHSAB=
MZS!DL>>IN9R8@VS B3XE1&;-1+DUB'QV7F$6T:1+M^R#-(9^_?V'4(L#<^K[
MDJZX#0ARO<[23%KD@( (^UJFJT 1$0 1J( (B(!A4:"-D(6U?4\?ZD\D)D/_
M *+"V[3P*/WANX!3QUY7_.G5*X(^D15Z'CIB03X,J<H"<JX/415"VV4HARZ6
M7$#1ZJ0(QV*JHSY$5L"4Q:@ )IO"[7X^)7^=$/\ %HFT'PE*[!VF13O4Y5X\
MA]N?VW;NUO9JQXQKEQ9@F3($2JP^X1"@[ASV@([-&' VX-$Q'.4N??NL_.U2
MZ_X;CM?U:K>BK@/B5R+#XI=T!3\Q(Y>BKV)B$FK. OE%2,#QJ!G+C'<6$>6M
MEJ"48%GUJCT*DC$UCY0@+4/G2BM@@!KIK%]>Y^>,Y9:O8&]_2 C^FVA?" /O
M;<U*GOZ5?]/;]-.3#&,NY><G1AQ&&G&'M7$Y0Q:>?B9FIF ^U^K>G[!QO1MZ
M,<;<[V)Z9V5^T+I_OV<9]KYJTQ\"=L_!,<^EO0 !1%"'G"CD:H8YDXI"E%4*
M$+Y(#098,1DF );Z(9& 9GJ3I3<#5E0/175R<VH!K4M4C5%HW.X!XJ55Y^QG
MR 06Y'P_;:MT6O>$B_ZB\)5^Q2)*YE;.=*=T*4^;*M.2,M?TQDH68_N_(_D=
M1VL\!/35J<KA;%<O'7:/J]IW(+\^6FZ:$[6[""BU;673%4)4OTO$605#(N0+
M5P<]"946"U!C,"M,$Q<T #'I+Q4JTM-[E$8,5(4)R#&'ZW<O$5*WS.*=@UYC
M'IKGCG;@G"+TYM7Z;;?6B8L/,V7J2]442[H3[])=A_)<V[#9W3TVWKX/FN>T
M2BGOJQ3_ "S[L'C$OH6>1T\&9=RC+VH&K"][=#*$:8YA54%:.G-@ L8#_9@4
M1$2I?W$DQF4Y[XB#RV4_*$/:Q>0EVO#J186V?YN9%.#+HY98^Y23-*<.-+D,
M0H'* Z$@ +'2(S00 ![:T''MQ$*ZZV\WB@I3"G)I$Y"*;U_PA)E>4BC]&20;
M=UX)D?R>V:*^*MJI^DVZX9RU0OI$1>%[M:'#C!>264>W,8Q7BVPE7Q+@A10E
M1@11:O72+#-49%#5$.(Q0LN&Z+,70/A!H3_!4=?]5SGKZ;:QPP;@]?@ &[WQ
MK\;N[FJ+]F$9-U4VTA+^5H!X$P36O)F[O"?_ 'E]KYIYTAR&@XID._'B4M1O
M'7$H:'%C'-;%_A<5^4/OSC5O2<OD2X+*%W( N.%=R  F(((2H5BSYNCZ]9*D
M!_GM6B*:*&JC9(6#E5K4Q5RJ8NXQ?-G+! Z.B.QSN>.!S-3R:D/C*CXIGOMS
M?X0TXFRT*^,OF*_@777LG-FW)5G4(TO7,<FW9$46&AAHKC6HUZM&@.RH!I&W
M,HD(KI>@3%W(XEE$**\TE4ZHD,B3,L-2R+-4V;*10DRI.HZ'21 Q+Z%2T"8+
MMM=*<S/H1')TJ0+A\KE48GT.E">#,HHY=ET4A'B;B9XB8V[5+U*I0F3:44,M
M"8D0\W40F)8*N2\"CYR,)DA5"]@6I8+E(H17I=V?QZG<K<I;/DJ612D3RJ)E
M:Y&.@CZ&,(J@3#!N:';M6*#RBG3!IN_.NI<$*^GB4H8XO&G1; 2N>3,D0;I4
MX7$P O(1<QHZ)E,%WV%FLC4L7KF3)DMR^$*YX&AN?D"U@)OG<*5)^*,((]K"
M'<CAU#I#+"N?1\^M""M-NS2.X!'5JLA!7*FG@=O9GG2R$8H^_$1UY),?B;[C
MLLA&BKH'P3+KX?\ 1WDKI_YMDUJQUZMED(6S?4\?ZD#^*$S\C0W&=NU<"@NP
M;MF+6\C!EMY^L+SC-1%7HI;39)*0*+X(R>J'DJHBJ%MLJ!5U&+("V_?4O@V-
M0FC/@[CF72@;.-X7:_'Q*_SHA_BT3:#X3>@=IY=['ZTE,<ZGG:+MV\_9YF8G
MHF7+V^R'W-"  .T!]'&VW!8F8YRES[]UGYVJ7Y:CK>B[@3WC<];K=@Y#>)DI
MO%-48@DQ!3^7,WX4Q8&G&-= >C%1'EK981L%. !#*44#/'0IG%"KNK9I4(KG
M$99A<HOKW/RGMFK+S$>]JA(_72VA?"!Z.N8_ZX?[%NG,J1F7(^,F]0GE6457
M%%H.6&*SS'[C,U*:)?*V@YA7P'&Z:YACGMZ>=;$],[*_:%S_ 'BS7 QG6OFK
M7]7/]4QSZV]  L-P&X?A+D@2J@L4K$,0YWDH]2%E'7@#4906K19GW,/!YL,:
M4T<2J2MO<O\ :=['DANEP$0]JE4Z_9[&X;B$@'=IMR3A^OW6NJ_T?9[C\8O#
M\K&)*YIW(HOEFJLTI1\E18RM_0?N*EGG^1@/^AU']=K/ 3TU:8_$+9/\^[=L
M=T5OCV0H/#%=TW;?"=K=BS !0O@A5B]4W<F"Q15E-&05"<W7U%"P9=1U- 0$
M YB$#Q76KX@8ZJY3"H>D/UNY>(N5N?O/*0Q_F0J.GHT=%N!<(O3FU?IMO]<Q
M,V'F;+U)>J*)=T)&JSEWG[V#75_"KO'IK7U96WOX/?D>T/I5CT64Q[!0N:+&
M'??*D]6;5' 7V,ITI"][="1519<"H% ,$Z"L82HBI-C4XYKTA.F,RG/?"0>6
MRGX_#VQ[R?B]X>MA;H:_BYF;#%%/(K_4H>32:7!&)KK0.@U6.D1G(.W: B-
MQWUV[;><1V2)R$4WKQ_7"3*V&)0'_P!M$O':.-NZ<$P1P>V:Z+);(@H.^;=E
MJ%0/08!A$/>//VBN%#?W1AC6GL6*\6V'YRG-CD]*G/W,(L_-( J'"EPC8<W,
M:Q9BY_\ "$0FY1?HP<<9AOMK/#!^#]_P7O?G[ZNS8H[.J5C(NJBWD%5$PR'D
MSE:/F#JD/#?_ 'A]_-//^X/&C=;B,M1O'7$J:'<8YK(O\+BORA]^<:MZ2E7B
M NTH%0&XNY=PW&(,U1@I7$NM*H3G@JC6/GM] T0$E*G5#4HOV10U() "T'*,
M 4+/O"PQSN>.!S-33]C4> 8TQ[Z4>SC0&OF_PACP-EYFTOBAC66ZG+4\W/GW
M*LZ4XLKT5"1U 0T/#5CG3.E/6%=&(UZ;<RC/BF-_'V61DBX1/H^2<UYVF:BF
MY(B&"#DT>H1/K>7CPJG4@5$7S;*8Y?J=/$[!G+0U*(%8D3R-ACY,0I^3%D;,
M@NA98PZQ."Y"/GN1I5<D:8FVI9@I:8I2>3*FQ#K9RKIP+23*QFA- L]J>5J7
M@UDJ'5WB,C9*)6#@Q33U&I!-R][Q+/8>E20_-"YVI3X[CS%R=NW\(1HB7D#,
MQ7WD8E3)V4:?C#M-7E)K%,QKW#J D([A3:09 X6Y*27=V673#B\0PI$P;Q*.
M)XDN-DT7)]X9)=Y, OF0>I0T*4R;NW:OL]D(:=T5XRLA$9?7\_SA9"/S:?.F
M&&FVWKMEAD19%MIMEEAD0'DB#30M  "#?ZD0J \H0"E;(1CC[\1'.'[4F7Q-
M]QKV9T12HWB-%70*!=+NO!H]SM)7_9LF@RU!IT!Z$5A;-]3Q_J3R0F?D6%MV
MG@4^P; .G=;U3]?.O23D&32(J]CQI+-Q574#W!G+Q5"VV)X)+T.=2ZXYN23D
MH#1C@E0&#A7"LR$Z(P&]R\;PNU^/B5WG1#_%HFT'PE*[!VHY474[O*D=F?>=
M&B]=PEM9L$,QU-)N5L6&KT?<.0]-<1U:!'+M#9JX*2Q.2]$2\<Y2Y]^ZS\[5
M+\M1VKL[<;>B[@AN-S"'Y)=@2"4\U*2#_ N4:(.9IIJ>5,Q&J-C7445X\M;+
M!+J2R9##7.I4@B*$!D =<SCIE0("#%].Y^>,Y9:_8&^P_P"L!'QG3JPT+X0$
M&S;F WQZ6JU[A;L^<9=R![I.3C)6JN,F]I>&+3TI[3$U,,/:_5N6KP'&^KC"
MW.]B>F=E?M"Z?[]G&?:^;M/4G^J8Y];>@0PEU3=3%:%\*HF@A"%,QRSWX)7[
M7S@L))2J^"6UKD>GJ,  ,0COBU&>J946JB&YW *>U2JAT^SV,W_B$AUX8X:=
M&-N2</VVK=1_T$G[Q>-W4&:).YH;.9#^&]?FRNZN<7-%5XRU_3Q*%GG^1ZOX
M'4>K#JWVL\!/35HZ?$+;_?NW\87SS(]>7JFA.UNQ#12Z%6<,ZJ51.;!XC#S*
MXQJ[4"+UXP6^4"*X(0NA5R=Y6F"ME%5=&0J&4 8'34L8?K=R&LBY6^9Q3N^\
M4VCZ]>.%N"<(O3FU?IMM]>)BP\S9>I+U11+NA/OTEWJ]C!MVFSOZ;;U\'WR+
M:.??-BG^64YBAZ,8Q+YY=GZLW,RKHBY)587O;H2K4358?:@:M3A6,)"'"4+K
M[%K3!%.Z,RG/?"0>6RGX_#VLWE1=[P/["V/)W.9N0H@%.5(K*A,I_K2YGPN,
M%.BCG32.D5BO)#LZ_5O'U6\X1.0B>]=\(297E$H_1DDIV?3C;NG!,G^3VS<9
M>YVSMA>;=0^;5_A#WA.[6COQ@E?FRNV3F*\VV&K@$(IWDDAZ&CL>=EM4J0:#
MD !95%6<<SD68N?_  A$)N46&O[6#C#C?;6>&*_R>ORM\G1U_*[OHC-OB_=0
M.[2H5173^K-1U=U]T/"?_>7VQV\I_F#CGO\ 5;B,M1O'7$J:'<8YK8O\+B?R
MA]^=:MZ2 664%?)E-1EJ043*F9,0="2*J10UT 7I)W1\]OJE%0HA*H%#5J%P
M1G7"*)G5R14E"^YM79*F&-]SQ_'4U!_BQ(:</PI2<#]&/-_A#\G9?KWSZMV'
M7&?<OP]PZ23U%>6&B8;A'H$< T;-N(;L^91GQ3J]7? )[L<4@R"(09RI5!,Z
M(,"Y-J10GZ<E3(9,F,&\@H>&<37GRNHR$2J*>G,680\*GDX30"TF,J'S,2"4
M01\S!1K4,A&*[G6:JH_N>20/SXN0B:3IP@4<_E4@4 TJ3,NEK*6!1Z>)T6A3
MA;K Y,3J9JC*8<LBHHSF"\*$8Y.6#"%A&$E!MEKTR-CXPBAR&3:R@^Z6JXPB
M;IZ5@U!'S/@%$Q-)Q<_AR4G)Y<-D]X%.'RWA;W3@@=P"F7:M3,-(@Y,H5^LS
M-3.CI1'<L8-$EY46*A1%M.A^?=SOJN^$/+'+CYP](6K"/R?NF8AT]<--/6&'
MSIXY:;<O7CA\P#QD66FG+]TTP^<O  1%AZZ:9>.VP!MAMEMD!!"$6N)-D$NI
M;2K2,WY43.6UUU%7V;[3]=(HX04UIZF9H5'2CG,,D%PM$HY*EQ,*926C3*/&
M.+U28EBHAHA6*%(+2*C!?.8,]@ZETS0#"M.I.7#*F:XG'< ZTI%QI+%-[U.W
M3I#$D$7R[ACDLD.GX-:0,\C)>O)B%9FY*'S,$4G401N3!F+.BI/>"2]01!G%
M/3!ZHH8S:B'KVO.MF5\\ R:*6YH%7Y7:N@8)E36+#7/N5[DJZ[RZ<KW.TD^5
MR?V/*]K9-5I7&@#E6F&=1RI%86U?5\?ZD\D)GY&AK=IX%)]P;NJ^=O*)CX^=
M\J@ :IHD5>E[M,61)0^#4&.*E/?%4+;8"SHN+A"S(^)2C*#&,0[+2B.%JNY^
M<5$;PNU^/B5_G1#_ !:)M!\)4^X.U$+][$__ 'D<<V:_.>+UW7NUF"$0D?\
MUFKTIT0^X1J ].K :#VYAA6W!HF(YRES[]UGYVJ7/RW'<!LMZ*N! N-R^BW=
M4IYF1R5JRG100T0<P)FG/]::M3X15&?+>5!6/+6RT5$+*"F3+NS-'7)X^5JH
M4@$+7'3D"JPHJI%]>Y^#]TU9;4(]_2 DPWCHMH7P@>CKFZ_'@[?F+?MU,D9E
MR\Y-@LBHC5EI55"$PQ:>?B8FK7+VOU<&VG@2-]-*X=N=N=[$],;*_:%S_>+.
M,ZU\U:?JY_JF.?2WH 88,%HA1$?(@$58M6L*5I6J'%Z[U4$%*%=Q:I8!#B
MK'K2N99,:5JJC DE'&F -'8.L-SN C]RE4AI]GL:.[[ $&OHT4QWVY'P^'WU
MNI_]OL]_RB\58.[ZJL2=S\U-^L.8_!EHI+9(T9:_IXE2SS_(_D91VL\!?35I
M] M_]Z[:B%[\T/7'5,_)5<*PG:W8JN6I12=W)6B%5%%,6J%*Z3(G77"JLBX
ML;$U5&H23E54H0[H2I$%RT5ZL-<,$\G3!^MW+Q%RMT_:>4AM$.9#'IP'.W ^
M$/IS:OTVW^M$S8>9LO4EZHHEW0GWZ2[P_<P;;!P-G>_/7;>_@^7O/:*?I5CB
MB>+.[=&'??+D]29&7'+VEFA>]N@E@5)6H8!PU'7,Z51A&&'(0,X+JQP7#(:J
MY>,RG/?"0>6RGX_#VLWGY/> /T>VQH>YSU0JRO5T=7BLOE2K\Z5&J%#AM!DS
M#*.D4,&0 .O>.VG:'7;S>$3(#H3W1.0BB]?\(296 ?C$H_1HDQWCMU[K=UX)
MC_A[9KE.YVRA%_*;?/D1!@ZO$/>#X^T8+Q@053"7LYY1C7BVQ* HY<'(*IOI
M37&+"&NG0X5>>NE12S-S\:7A$)N473]K!P-.RVK\,'X/7]Q6P 08]]W=]<.0
M5QC*NS6UG5P:N@XDY3 BFYZ0\%_]Y?\ \T\I_F#;B4M1O'7$H:'<8YK8O\+B
MORA]^<:MZ3E:25S0%T=@@=4')F6%8(N:.J,NJE!4XUR#Q\]OJH==0$?%&>E$
MPJ84+)5B5YW;>N-(8YW/'\<S4QQ\&H_J&)4F/';E;FWPAGP-E_K+YTR77W5I
MSQGW(>65_!E'3,IZ0U>:&A[@W[\*?7CE2W,HSX^0P+B\V@8PK-8&#,RPPAWT
M''EQA#.8V!CH2(8%V_A8R$B6'L/$P[]VTT[?.'SMMT\8:%AMEID1"R$:@1LN
M9+77)?JUB7R0@):RW@HXZF <IM'%1Y%I\D?-%D"[.HA*(<D=&;I/%K<*3NHY
MZF$,1P!2V9-F9RZ)A.#<WC8U"$CFZE<)V?L#/*6T/<6F2K(Z\XMEVFIW$E\&
M-&\E.25RN3ZD3R8D&^2",D/,A0QI.GWAX2)]R@RB/5Q 7)I"%)E#)N 6K+Y4
ME='TKF7';?".A0L>F+\M+GYM!PQ::OH&%>F9?!QS1I"0!@\AW;<;!0ID\@RU
MX80\+$B\<N(YLO@&HMT[9?MP4*T\YAW6$?<%=/'&ZFJR$3T\?3T[*60C$GWX
MB.O))E\3?<>FR&^-%70*^Y+NO?XN\E=&?W-DUM]?S@A"V;ZGC_4GDA,_(L+;
MM7 H_>*[:6MZ6OY^>FKQ%7L>-GU$B:J!4Y,6S<X15"VUH<D1'J<5</5BCE\V
MQU&:JK4%0C%J.%8-D^\+M?CXE?YT0_Q:)M!\)$^X.U*%+L0H"*D\F*G3+18O
M6#6]FJA9B4)6HF1D&N>J0^YK]B.[C1QK#1P:)>.<I<^_=9^=JEV?MW'<;<[>
MB]GE;E<]+K=FJGB)1DRM2CK$'/6;UIW9TFS5\:\CQY:V5@[X %7>A4!VJ:*6
M1%IBS:A, JA%9#3% ZJE]>Y^>,Y9>8CW]("/TT^:VA?"!Z.N>7?LJ;N][?+>
M4C+N7ES>H5&1XTO6$ABL]!I)B:@?\WRMU8T(XWHSI]5N=[$],[*7^D+GK^46
M<9]KYNT]2?ZICGUMZ "L"R;L@U,B0^)J8ABCD8Y*K$O5W 4C# 06^D.;,B"I
MJ5R5-SYQ\J$8.ZK@*!,TYVRANEP#Q4JGS]C:C_D @P]=<<Z6Y'P_]+75_P#E
M]G^\7A^7V1)7+S4WZR;!$\&7MT81E;^GB4+//\BPU?8=1X:/1:SP$*;:M:?(
M+=SAX^[.!B1'U?/-#UY>5IFY83M;L2%W0T&+*'JN-"3R F(M0S*,=Z%BW2$S
M<A06H 2"P0N*AZG/,OCN1*J 6)4*#NIID--Y57Z7<JC(N5N-!%'E.. _[R !
MLQKHI79E;@?"+TYM7Z;;_7,3%AYFR]27JBBG="0^W278_P ES8.LU=_-;>_@
M^7O/:*5[YL=?Q9C#OJ<>S6G%F/;!T1GZ(7M;H-%!.+$JG.K%-:)BL8>1 9'
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MR9IIEA4RY0!@8>Z$8+'YTJH)]"PPFQ1&&B,2L7&0KQ>*E*%KX#$$(PX=T#2
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M(0:=.GL[==.G99"#J'/$-0;@SV;Z:K(05IB.&NNC@;(0>D1[:=%<-.S7A9"
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;UXV0@$:4##, XZ &ED(*AZ>S/?0=6FR$?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g425213g26g26.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g425213g26g26.jpg
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M0I&3TC(S-C=25%9AE]0E)G%U=I2AM#0U4V*!T=/_Q  < 0$!  (# 0$
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M8*XZ8UTD260;/4IQK]7&@O&KU\:3KGW*OD5%;):\37+;2;SDQ,;'A82&V$A
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M,@EK!XK/,8ZOVJ43CD;=*@YCJBWG73<Z>6NKC5ZR<<;>JIU[;V0?5<YM_3=
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MT;=&JB_'?*Z/7_1>@;^OLE'I_P#G.29*91KHL:>ZX2IYU0XKEODDG]_V:O\
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MD& G'''QNQ@# & , 8 P"H3'\O>S_JA47]\VQ,$UIT+YVEO<%& , 8 P!@#
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MZ+]+$\=WK+F('T,+[-GJ'@6?^JM_[%/^[C/1?I8GCN]8S$#Z&%]FSU#P+/\
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MTW,8G8AL5F6!8UC,N699TK*+^M%9#1TQ$5=*Q9F)?F(JKK5\1RF69CC,# &
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MS"Y1)E,W=TWEJBZ%1-1E^RI61@M<W^;AW0L9:'I5JE8MZ"*#@6<C'P3]VR=
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M, 8 P!@# &"51="HHR53:GA0HR@8 P!@'SJ'Z0_K# '4/TA_6& .H?I#^L,
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M , 8 Z!\?3S_ $X!I*F0@G,4A"F4'M',4H%$Y@#H!CB  )A   .H]1Z>7Q8
M$A#&(8Q"F,01$AA* F()@Z&$@B'4HB'D/00ZAY#Y8!JP"G6TN'K7;4M=VU@Y
M \AV>J-GJ$#96B(^TTYQKJUQZC!G%RU=;2\[0IG:5+J=GC6?@K-6*#L2KQ$B
M@[D?#-X]22D#NA:Z-VOC M\FV;HMDV:2"1&B2)&R;8I"@B1NF0$R(E3Z=D$R
MIE @$Z=D"@ =.F"&Z)"&,4QB%,8G42&$H"8@F#H82B(=2]0\AZ"'4/(?+ -6
M 5KY2UCC!):REK=RIJ>OI^A4"/E+-Z5NT"TF'];"/8+/G\A4G)&RUBCYT&+-
M51$U441FURHB1MVS% N"I70FO AJCZ>X ZVV]KAM3Z=K25W);O;&KKF;?O7V
MUK=&!48<DS.J0EEM$I;I*ED:QBH*]ZT?PZ3HYQ;)G5<J@D<,=^/H]1?G!"F/
M/VC7;97&*X4:G1URFXZRV'7D;M6 UP\28[&L>B%KY7O7A7:(LJY9BI9)S6(6
M6,;,6KI&4E&KEY&0IC33R/3."<<<4U%%*E6MLU&[ZWW?"T+E+;N-.C-\S"]%
MHNT8^Y6SD'%4"_\ ':P:XN-I@J3<EWVX9ZF5?94E%!7:U9".=@-8"1O#VO0S
MNKH5UDK.$\&G'P:R^"JZ=55KX-%-B=9</2.L]FW:@;?MB=IVMQCD]V<C;7N*
MOMF<#KP^QHBC>UJKT&#C+/7-D4S8$'7G%P;4Q&]/X5>'1L\&:79QLFXC91*9
MC@O''QJ3C7Z3J-04.W4'G)>6-NW/L#=#I]Q0H3MI+[!B-7Q#Z';DV_L)$T<P
M2U?KW7L<LT54*+DZDFQD'H+&$J3M-#HB FM.A?.AZ&X*, 8 P!@# ,3NMM8T
MNOO)MX4RZA.PVC8]'S=2LJZ-W3",:$\Q.NZ7$I  H&$A .J("5,V9*RK-C6M
M.PI.$J,1U8D>,_\ -RTM#[J/,1%U,A,JN-*N5K:HKD,1;EL0+#LZ-/QVNB.;
M=A2TLS\[.3<5;LO*P4Q5T2-$HB41;K;SU2C5*D+>W&PS$KJJIR:C>_V@[:;W
MIL=B *)T"$?)"+"FU]T!O*PJ1_\ ,8Q!,PA&H&<21@*90AVWARJMGG>=AV#8
MBOE[,LV%R=L5,'0)=V,6.JU1'3\^ZL17?.AL5E[NFU- DI6TXD2:LF!'5+?M
M=[)W*ZVH5'-LB7C-7D]E23T6B3$.!^0EH:*J0&K$F,+S59;JETRN4"MQE4JL
M:E&0T6CW:"!.IU55#CWCAV[7/U5=/7:PF7=NEC&566.8YA^( \DO+P92"R!
M8C(4-*-1-*KI5SETN<Y:JYRXJJU/I-GV?*67*09&2@M@R\!MUK4JKG*JU=$B
M/6KHD2(Y5<][E5SG*JJI0?F)OVXZ6V5KF!@]?OK>EL!5$(CT7LRV5UU*2R"A
MH96MJP44<6C4BCB2AWK5^B4@O5@.F?J=%R?/I.2-@R=LV=:,>//0I1TA>6-G
M;,E)EL*"ZD5LPDQ&:KW*C8<:&^&JKFVT5*(K4.<=ZL<VC+U[!.Z<F.C%$5$U
MIH6I82K:;L5T&+L>^7:,JJR3;*PFKXZ2D)"DULR1>TD>97?*'<W:>3$>RO)R
MYEFO: P((JIB0Q,#,VO+R>=E["8Z"UZJD:TXD.'#GIFN#LRD-$;(RZ_JPH*-
M?2EYR+5%[4AJM%?BB:&(M6ITUQ<M=:]19E%%)NDF@@DF@@B0J:2*)"II))D
M"D333(!2$(0H 4I"@!2@     9KBJKE57*KE555555555<5556JJJKBJJM57
M%3M-S(!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# *@<\JAK6T\3=XN]H:AJ&ZX2GZVNMO8TVYMDO1OI6*J\N1.31F2LGTI5
M563-R\%U9ZZD%AB8H\@M$B=T)$E K3CC60IQ"TN6B79A;H[WN-NTFZ>X3<#Q
M.X]CKV\/V[XC!\W!G?2;<M196I@JFDX=$4JZ02I2,78&8'(4N37I3HU^?T%P
MW^'X'I5E(, 8 P"H3'\O>S_JA47]\VQ,$UIT+YVEO<%& , 8 P#X(@4!$P@
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M'%"SA"%3*4A"E(0A0*0A0 I2E*'0I2E#H       !T /(,UKMUXXZ3L-6 ,
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MX(B:&M8W0QC$HUC$P:U$1#V-2ZU&IJ3^:]:XF3YYBC & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8!4)C^7O9_U0J+^^;8F 6]P!@$13+))2VLWHV6\( V:SZ!_!17>M&)G;
MF%.5JU4"K.2G06\*;LF,NY$2M^I5NG:$V;@([D,1O)Y!RO?*N;G)EC7Q&M9,
M5>]JSC%1S;[:]RRBNQ;HIBXL]#9-PV+RBXUDPD56R4T]J1$=!2&B/;+N1:HL
M2EU7(Y$5:X(2V7_!+YF-\$/,P=##Y!YF#H7H8?C$.R'0>OD'Q9A%TKZ,4\.)
ME$6J5VXFK & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P"H3'\O>S_JA47]\VQ, M[@# &
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MZB,8.KL(=PWK<9$R'C+%/NI0AF#CC!.-2#CU>'7LHA=C & , 8 P!@# & ,
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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MJ:*]B+Z4Z3#MK^R':/UI.;,UVB2?F]QZ]IVQ[2EKE6.6BU9A77<'-6)TV/,
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MZ$OM)_ .,WO[/B.>?JWWWX0]\X^A+[2?P#C-[^SXCGGZM]]^$/?./H2^TG\
MXS>_L^(YY^K???A#WSCZ$OM)_ .,WO[/B.>?JWWWX0]\X^A+[2?P#C-[^SXC
MGGZM]]^$/?./H2^TG\ XS>_L^(YY^K???A#WSCZ$OM)_ .,WO[/B.>?JWWWX
M0]\X^A+[2?P#C-[^SXCGGZM]]^$/?./H2^TG\ XS>_L^(YY^K???A#WSCZ$O
MM)_ .,WO[/B.>?JWWWX0]\X^A+[2?P#C-[^SXCGGZM]]^$/?./H2^TG\ XS>
M_L^(YY^K???A#WSCZ$OM)_ .,WO[/B.>?JWWWX0]\X^A+[2?P#C-[^SXCGGZ
MM]]^$/?./H2^TG\ XS>_L^(YY^K???A$;;5]D ]95<@J'ZI?0OMIVKHV)]*^
MWSTEX'O]UZ_'Q'@?:8P\5V>QT[KQC?M=?\8'3SY-91:UT(JZ-B+O.J-:N>:V
H%F+M^-+MO9VM*S$+&F;2OA0]H<Z381@# & , 8 P!@# & , 8!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g425213g27i06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g425213g27i06.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
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MP20-6"\],[G7O)#C!L@7L).+3@2P%@K$:HHF5"WFGW][G[^:R[NWKOS\7;_
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M^R.1]?R^@&)EDU,Z_?7[NIB[1K]]?NK^=?SA%E@I%)<.)+)1MM)09 (I1O\
ME"9L5J3I&_Y_=.G?3^=_QA%DL(F$3")A$PB81,(F$3")A$PB81,(F$3")A$P
MB81,(O*3K_E%SJF?4;Y/X]&+J%&7N\AJC- 5:5,TV1*,2G3VO5EO>OB2X_J!
M*U$9><;?F;C2-1&WML.:3W<:6%O"9XG/:)7=LYC2>\131R\Z->-.H;+QF>YX
M]I\, '36,#7*R9.?^WQYKT3!WR,5NAVIZ=;5(%/2$;0G:?>C4=+.U:WK^?\
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M _A7R+S8^(_#=.(FR?N6V-R'&74 GOM6O8E;2I3>W7'-,*T]5R.+NAX=#FB
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M1HVI1$A)CPH,5*U2)<IYMB.TXXO2=D )V L^ 5=].\J^/\KKR;89,2C]9?\
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ME->G('Y_?2UL+SKHM.ZQ3@M_H!5P]3K''W-KYW8HR)BFQJEJ3%,"6S@\;)(
MR;6D30AR*PZ(/"WXI<+-GBYD68\4<E-L(F$3")A$PB81,(F$3"+3ORU\J ?
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M+(W^VE26T:4MIWTUMYM"M.;V\G2G?/<3X>(/[Q"*B) >P<HR=@X?^$GF.CB
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MQ%*(K*(,J>-B-;E$H;3R_LD9RX4S)X87:=4KB&;]WNGF2-P#MT6CAK-/!N+
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M\;I+ \?#C$OTZ?0BOT7.X>!/);C7ZS69%KZ4*%U:]WSHT)B#/I!)J19[_P!
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MK!+\FU\<E.H190_U <-%7OWMO7E]_/HO;96!E2\<Q,MD=P,;&7R:F@-,9>7
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MD<_'W)0@Q/D6,]\+LQ$@Q('#Y;99XT^-Q+6$$:6Z;-BA1.]W\R3U-^!WSU.
M!+G$D4!;MAROZ;#_ &K#U^H4>+:)@@"'KQL4,<$'&YJQHLG*K=O%MN!!\?\
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M3LN+!]G'\)R<>**6+)=G,SG''<^1K)(W,QL:.+)#G$GMH7R,)#H]&ECAY?\
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M_IU^$:%0B$1;$EA"]%%GQ^SS^:G]8Y1S*E "%5J%"J5:K184'!$P(0$/&BB
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MRC6DMLL,MH;;1K7II*=?SO\ ?*;WOD>Z1[BY[W%SW'<N<XV2?,DK8   !L
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M/7>B-M^S\6?@#Z^33RKZ^C3]+)] K\ZSYJ1^7]-O7.XW'>B76-S/G$F_7JW
M!I5JL5];7/.A]/8'$;1. -4(+ E5[G,P(P:M5WKCDB]6RC5R$)F02=@/U8H
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M,(%.@QY]1I8FU*'P9]C)7GOX?.][K:OE158R/J8GW*S9+SOG/X6BV.J5.;S
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MZP^W[DI5['6U)]R=;]/76MX11"P%>9#+C08EI(4>!?RVK5#YA'/2 4:W$$Q
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MLGYKH6/@'C_;"T\_;>)\=LITB5;/E#5BYO2C):>;_&B@C1H@2)!I,R44_$
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MJ-*U_P#14\ZE:?77IM3'[;]4YV.#Q:I9)2-F,TM-<G.WV\]+2#X!RJ9CB(P
M2"76:\ #M74$\^@YE:PVXH0%B6U"MQD$B14,%A2)C:WXL-XR2C0%3GXZ'8ZY
M2833[LE,5+[&I3S3<=;["'5/([LKBUH(V+G-;9'Y=1 #JZAMV 0T'Q Y4& %
MQ!%D N/('8#NCH/(WMX=%T0,PS%/E*V8)M&TL"1AL>5U"8@2_BFRR,&3!G,1
M%:ANJ8>'ID1949F-[V).X[["G8WW4K7$Y[9'1O>).X'AVD-V+M.D@;&C1'ES
M!63FC1J:QS;=I+=[&U\Z'C7+EN;W!MBB&W -KC:VYZ0R;K<"8C>_1'I(VG4=
MW>M[]-*9D*0KW;UZI;VZC^[I:LT\1QQ/C/-7)$.T8>M"BX7X.:33;_, :L;S
MC/='(/\ 2[9U\JL4?A8 Y\S6UK:W/*+KIA$PB81,(F$3")A$PB81,(F$3"+2
MGCWF3R;H9[R8%1KY7I_^SGU-SG-\1&*1'%54P_9+& C0#'N=0F"XJ6#DQ]:>
M4E/RQ9+.M_+'=0CJR8L<PPF8SF&62 NE /)S(F/(=X'\PL[$]>:\[B<4T.XL
M_)+^QQ,P1,VO9\TL;:L^(;>^PKFMIFKL#?L0VM,R6W)Q<&Q8(&DN)W\X^1J6
MIMU*=;WO:5(ANKTI.]IWK_/]OWJ>ZR""2<D5%,87MHWJ&G<'ES<!2Z@SXCEQ
M8@!US8[<AAY6QVL[CT9X\RI?K>MZ]=;UO6_XWK?KK?\ SUE5700>1!]-UQ2Z
MVI:VTN(4XWZ>]&E:VI'KK6]>Y.M^J?76];UZZ_C>M_YZR2" "00#=$@T:V-'
MD:.QI0'-)+0X%S>8!%CU',+GD+)<$.-N:WMM:%Z2K:5;0K2M:5K]MIWZ;WZ;
MUO\ G7^6201S!%BQ8(L'D=^A6+7-=>EP=1(-$&B.8-<BN6]Z3K:E;UI.M;WO
M>]ZUK6M:]=[WO?[:UK7[[WO]M:R.?)22 "3L +)\ %^(6AQ.EH4E:%?OI2=Z
M4G?^F];WK>200:(((Y@BB/@4#@X M((/(C<%%*2A*EK4E"$ZVI2E;TE*4ZUZ
M[WO>_36M:U^^][_; !)  ))V  LD^  YH2 "20 !9)Y (E25ITI"M*2K7KI2
M=ZWK>OZZWK]MX((-$$$<P11'P* @@$$$'D0;!]"%^+<;;U[G%H;3O>DZ4M6D
MZ]RM^FM>N]ZUZ[W_ !K^=X#7.--!<>= $FAS-!0YS6BW$-%@630L[ >I7/\
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M)A$PB^,B0S%8=DR74,L,(4XZZXK24-MHUZJ4I6_VUK6O^>_XUZ[WK62 7$
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MU:L20Y1S>-$0R%LN 1"X,V>\Q1#0QU'4;#@&V>6XZ*L>7%O)A1WZ'"R7@70
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M'K[4_NMUQ6]);9;U_FMQ>TI3_EKUVI6])3O>MD4;I7MC8"7.-;;T.I/D!O\
M[K%SFM!<X@ <R5J-TWLK0,6^8LQ98H6IY$0<&@?([/+D)"O9!#"1\?TG'C,]
MS:&8L!A#SCSBE+0TPRE:T>OX1P4Y4H@Q('3S@&2669I;#!"T R3SR%ICQ\:,
M E\SR WEJ<YS6KS_ !;C6-PR!^3FS"&$'LXHF.:_(RIW@B+'Q(@2_(RI7;,A
MC#G.V.G3J*U2=WTBZ#2=PL]K+\X -)<6/K8,D+$1A$9SY$1OSMB^SE$3-B:>
M^RT2W!+0:]#DS)P#\<HB#>G%?43Y7!>$-$$.'B\4?&UIFXAFLDD;.X:-3\;&
M=*R'&PWZGB 2L?D.:QLQDTSB)GBH8?:7V@[7*?FY/!8'/(Q^'XLD<0@#@[NY
M>0V%\^9FQAL+LES'PX\<D\F)V+,C!DDDPC,0>IUC2^ZV;V;?CI=U_:2RG6VU
M2ZHVYK6_DWM/JS+-_P![UUI/O0OUU]IO:*CO:7AQ) X-P=MW6O"B O\ JAM@
MS"P=4.K8C^F__71NCV5XZ=(?[0\5_P FLMS9OR>\8)D#;QJ+C!'F",D#3VS-
M3CIH]34:(F%O:N[V;[G41]7O3T9KV;?V#7+9]&_?^^D3MM>Y&M;WM25,:UOU
M]-YCVEX6#?X/P:FN!H8<)&GM6N<T!LH'>AU,:=B'EKC8%+%OLM[0"%H/M#Q,
MR%E7[Y, U_8.TN=>.=F9+FNTMU6QA&H%UKN[B"]2=^[NUG^!,R2C:==*9]VV
M$EBC+"=*^77[_9#_ &J<UO\ O;D17?7T=WM.L^TO#2P <&X+= 6<* @=WO.&
MJ:Z<X$T.CFCH5D/9;CAD!?[0<7+6RNH^^S#5$'6VS[N0"8^X>Z[OTZM-M7"/
M$'K3%^3N]E]RT14N[WTEE'^*XS46G=[U\GHE/W4PV]O6O3:&5ZUZ>L-6DR/:
M;ANDUP?@P<2 "<*&@->18($_/0_& H :HYB;[1H!OLKQYN@?]0\5(T .TYDP
M[XBQ1J[V.=C,S->1O39H  #&[5'C"K RT#74.A$^A362PLC,JQT^+L5>=9&[
M<.+(VB2L=**UP-&;;'C4F(A*%"CDGWW2,>:Q#W&EXNXGP;BKX,67A^'BM=DQ
M2/GP8WQY4,+-/:.8(YWXTI+7/<(9X2Z9S&P0N8^4/#\.X_P..?.;Q+,S@,><
M^[YT\<V$9GMD=",J2:%D^+&R1N.PY4$[(X09\C()B8V)UXU,]!NKVK-1U#JU
M:Q<'0&[42PP=L31RE.:GQ62<<>Y'E0WF'''980XTS,%FQ$]QZ.T\W(C28=+B
M?"LGA>1'('1/AGC)Q,V,..#G0!YJ6"0 #M&.MF1"7NDQI=4$O>:'.[W!^-XO
M&<8Z!)CY,#A[[P_(+69V%.6M(CFC=H)C>QS7X\X:V/*AJ:*VE[63T-$Z.4-C
MH;35*6[+G,(UI;I[X_;MU.U;7M+'NTVEO2MKWKW;]B=^FO\ +.3D23QP2O<[
M'TM8ZRT2DV10!LZ022 .A*Z[&1/<UK2\6;HF/?>MM]Z'AOM8L\M^AOY+<")^
M8U!T3^%'WVAJGU0-2/3_ !/M%2DID;9]?^QMY.E^G_:UGE%U5W<(F$3")A$P
MB81,(F]:W_.M;]-^NO7_ "W_ %_UPB^*XT=Q+J%L,K0_KT?2MI"DO:UKTUIU
M.T[TYK6OV_OZ5^W[9% W8!OGMS]5B6,(<"UI#MG M!#AX.VW^-KC]I$^9J1]
MK'^>.UMAA[X6_F995Z>YEISV^]MI7IKU;0I*-^FO77[:Q0L&A8% UN!X ^":
M&:FNT-U-!:UVD:FM/-K35@'J :74V%#[8;B[$C-Q6I6IS4;<"+MAN;I>W-3&
MV=M?&B5IQ2EZD)3I[2][5I?NWO>1H90&AM Z@-(H.YZ@*H&][&ZUG'QRT,,$
M)8U_:M88F:1("7"0-TT'AQ)U@:K)-VONT/@,3))!F##9GS4,MS)S49EN9+1'
M3M,=$F2A&GGT,)WM+*75KTTG>](TG6\!K0XN#6ASJU.  <ZMA9YFAROET638
MHFR/E;'&V64-$DC6-$D@8*8'O #GA@V:'$Z1L*7<S);$PB81,(F$3")A$PB8
M1,(F$3")A$PB81,(F$3")A%PVTVIQ+NVT;=0E24.;0G;B$K]/<E*]Z]R4J]-
M>[6MZTKTUZ^OIK%#G6XY'POFHH6#0L6 :%@'F >8OJN.F&=)]FF6M(]_R>S3
M:-)^3:O?MSV^GI[]J_O>_P!/=[OW]?7]\4/#S^/BFEHV#0!>JJ'YKN_6][YW
MNN?L1[MJ]J?<K6DJ5[=>Y2=>OIK>_3UWK7KOTUO]M>N_ZX4_?W\ROW6M:UK6
MM:UK7[:UK6M:UK^FOZ?\L(OW")A%I/\ 4(L/FU5_%ZY&/I\4>C]"\F&"M7;K
M5;OLT/#&.U]\W%;M<P=^H[#4ZW*.0Q&W78,4]81L%37W3S?WQ!B$,FEDW38U
M776N:H'RL#^>EGX/XWD.<R)U.\C+=1(_/NY ^7FB2Z!0KU::O2^E6^[19.IR
MMO!:A:N2'^8TT[(ER)Z(?5G![,M;=@GN.E&UGPZ7SZUR];/HM<[]6O-.W4"R
MF$UCL<*R7?F'0NA1AL)ZP,6*L67KGC)YP641RN1,BRVG=R^27J\\AYF 'MZ1
M^#L NJ,0E:E,#GF2D5?2MMSUW'CRV!/QI;8^3/0O-D%V#HHKBPMYNE!?'ZPV
M7GC$>C&[?%O'06N;]MD-#F)T'E!X -O(OIPWCR1HFW]>I(DG5'# X?2+L:LL
M4A7"@5MXWOT\*%WZ[_MNM<NZ7;STF5NS\G!A.Z6"43IWF11YMLCTD# B6T%*
M$^:U<\>[,/)T#C(O59Z8P7H_C0X[8(/2N=@9HKI(,P)YR51,L5FJQ2--_+QK
MI?,^O,?%=VRW#SJ'60[:ZBQULY469,>CB.B63G<^OWMWF/Z\E3'KC(Y6#X9<
MOCND0\YJIM*A^-Y<Q/Y6RQ;55].GU6]DFU'E>U5OXWOZ4>9W^2VR\C)/D+5^
M,USHU%+]/*]R-<_K=((B>5!84JA +CNO&K<1O+E&MO%^NW&&,/7 <-HTE*ZA
M((PQQFNQK ]11\&PWNOD%>5#??8GD*YCIOZJO>$P?(@CU6\76X ^C!15EYQV
MTL*B%6+&,$P++8VO'4C58 T,8=T\*G,OPKNR#@2&&IX[[0]&]K+WWR5E#JVK
MH #Z]?7U6APRL?4XK?' Q,&_WA'0*=2S=F-<[,W;H'1&+HDAXQ<3@'F(/1;O
M,W:2-_,VFR=7L],I$I <?SSR I"*D!8<J4ANSV(LCIZ5OUKD+/0>@WYT?@M[
M.2P_)6^^0%W$=> ][K?#[J$I\FGF7+)%K8ZJ6GQ<M?+'X46 Y6+2_=!;'D-9
MY75#=SDV8%6X-YYW7:W7H\XP-)^JBQVKS_F_TV^)4!\@;+YL0?(.]6;FX_IT
MT-1(IZLU2OCJ;O\ LVB<PM9OPI?,]& G8',KM-OG6(@%[R<G"0KHSJ<X 1I,
M,4)XZ45.8A]!)M\?WW^'A?\ RL+7Y'G")MISH3@BRV<M"JDV^.2VJ?98PRZZ
MJ?-O$,M,HE;K=QK-,F5JP]:A5[K=,U#?H=-ECN@3C1&#7JQ-'ZBQBG8UT_Y/
M/TV\%F!M_P#J03K23!V!N;6]R->/$9+(3G:B[<2N]$+>+?\ ;!;:N:=XP2YP
MU9>6%;?Y(UB1 MG6S,]VH4P#:'>-(:$R;M:2$"MOK6W/S\*^.RN@-TCRP6-\
MZ*^'DMWRS>.P4O3.-$U@:P@GT+J!^KG.W5YR>)$00@V9/J?+^C<&I2!L=@")
MLMP@6N3*8C-$H\B(2AW?/G>WES];^"KSF<KR&CWKN'D!T@[U%RN<[\9;V,X[
M,Z120M2&GFA77^Y%QUUM_/M5?GDP+T$A1:OS%\^(9WSYDI7% IAD "DS(;08
MH^'.N7Z<SX\R+N_145P_R3\W.GS*E(KMV_65;3:" ZS&$4AZUP15@AC^/'#/
M,+4=YUXOB 4Y]=!LANW4"UMR>.52#:;=$KMIOUX>Y\=JTTI-#_;XT>9\K!Z%
M677NE?4-@3J:-L<'H9'[BSTQZ/.<Y)5'&;.2L=,\(+%9*-T*8 H[$"B\TK9#
MH_EX-BW6.U6"T&9S$4%-7HI8@"!/0B@UT\_'Q-?2A\?B(Q(Z#]3@)2!-IBQ[
MY:;,9K-(?L-1,\TH Z!4WK1X^.W3HI %JL\RD659WG/30SE?IHF=&O"I90T[
M5S57OY.2"BQ"G:ZZ7SW-\]^?7:Z^'@K]O%\\U(7.O&I=5D(?-6DK>D]&NFN=
M] D.Q)$8Y&WQL/?J:CQPF7<>$L-7>(HZF9C\CX9%_4H=J0,MO(A)<?!E%% W
MO7[_ *?N?5:@WEOSUL$+I=R%:[PWT8GRIU/K"I$4-%YKU4!X\_4&?F5'C4']
M(P!1VNC^G3^'5BN7QR)=C%R:LM7<:O)J>Z&EB2R%=:Y]=NK=^?J>?CT6PT^U
M^8]<NUG*4]J_M<Z@=5HY]J6=YJ$1N^TFP=.\;:5<B]SBFJP)-A6Q')+'UR^S
M855WSB4&-4]<F4S"$ABM?F%B*WOX<_ _O7-0O@_DGY)]>\,>G=,$=/(6[L *
M[<Q3'%U:D-6$T%"3J!R2VVNDAYU"\9KF(=L=KFG[;.#'T<AZP$H]8.U039)C
MY$4;NFBDT"-MOCOS%U>WI8Y=+4DE=O\ -*?.Z$J Q:'X7'NYT.C$ZC5::$(=
M$Z#"NM5N_<)M-8-@^3==IM1)TSG'5?&FBE+7:1%/Y\6ME*Z'")]/YXJUCKB*
M)0%;\[]/ ?O]-NBKEOHWU':N#EB*\OH5D*@.#==LHR7T3E94B5OO=!SWE4[(
MI:_TQP--9BMU^:"\<YO*997H/,*?;!)TB&KR^N:,1HM0@WO7AMZIMUKF+J^6
MWG?C?/X;+=WQ]F^4,+LEKK_6#]VN'-=Q^PL@3=OIM! )B.5#K D7S25$)46F
M4YN5)N7/SA29-U.;EQ",>LC2(B()>2:=,2H/W\A]_86\V%"\EN@2ZSJX= 2K
MQW[27F_FKPVT3&\%[.2'%">]=M;AD!Y6!6G1TV'.,3.:R(I2"^N!(9D-$(SZ
MH@QUZ/\ 3^'\7R8\3A\8XUB0LCCP6&-^=BL,43'<"#XWQN<"-,<7$&EAW#3*
MUWYW _(>)^SYES>(RC@^5,Z:7B+VO9!D$/EEC]J>QD:\$-.J;*X,6N;LPQPN
M!K'.B*JF53\LXO7C/W7\=H_\B/3QV[GK:@N^A I.]Z1JKZ4C?Z+066ECTTO2
M4;'>S3SZ&5V&\9S!'I/'\)SSC.!)S\/_ !G</E8T?GO4W*<PZNCP).EK1_TY
M&92[\#S#%[]&^O=,H#W8<8@D>-+J.DX#9&EM&V%T8%NI5[:IX5@+7E*\:N]1
MW$-C&S+KO"NU1D:E:I=#CR6]NOAF$2%_JF-<_P!VEJ^;:/NT*4W.9=>OXO%\
MIT^9IXYP]S7&5V.WW[ [K/?>(EI%\J@DPQIH4QK0"- JG-[/:8,(.X!E:F11
M1Y#FXV8"]QP.$1N+C&]KG2','$"!OJ=W@+>"L)1K_P CK=A%_J[F%NYZ5*RO
MQ0(GT#FMVJB2:I<NX;E PY^V5Y<(D0*5U$6 W2A9&4>M1$N$&BQ#LB$Y,'[<
M_*XMF0F.'B4>5#&0^6+&S,=[&N:,41RRPPR!P,<\8?'E.C+<?^J7RQ=H0_=P
M_!X7P[($V;PB?%?(6,AFEQIP71R.XBZ:%LDS)G.;-@S,A?A->'9\DV'!'#+(
M-<7HC DCB@]IZ&J/+A.:<:TG2VI*-.1WG(\B.ZI*GD*D19;+T>4G:U.-2V7F
MW=Z=1O/&Z6DEKFC>B[D 0X!S#1 II:6N;M^4@CNTOID3XWQQO@=;-VM(+26N
MB(8]A+"[O0O)9(W47,?;7@.#FKZ['#MZ_P#082OY_P#96->G[Z]/77Q_Z;_[
M]?QD%C#S:W_X1NWZ@>G(BJOKL!>1^9_S.]6:O>CL?6N7-/QH_6O_ $&'OU]?
M_96?V]-_TVWK>OW_ &]?]?VQHCW :WU( ]3R%]=JOJ+Z-3^A=U.]\JL"P>HK
MSOKNNAN%"WOU^RB?\/2*QK]O^3?_ /OW_KO,Q#&!^1I/4D [GG5\O04/);+=
MU<XGU/A6W(#T  ZT%775+)*HU.EGPU:&%GV94:/*?FN?CQH*!)TZA^P%I,42
M8E-BQJ],_>/M#9#,%M_9(FN*&A$9L7)N+#-(R-SG1!VH-$;&N=*^N[$W4Z-H
M<_?0#(PO>&QQETKV1O[' L&'B6<W%R,A\+7,=(T,C=/-D2,+:Q8&G(QQVV0T
MN;$.U;+)*&0X^K(DCC?37CCT2X$AQR#=FWI4"O-NHM-@.)#")=;+1![4^:B>
M[#CCQ)BL&(3NS <C T\\$0Y)@2WRU=W7[46W<0QX(YHG8P;<[QV,4(D>R:(N
M>UKFM#7O9.PU%*QY:V4@2L#,CM8&]WVQX=PGA[69>/)#B,E89XV0OE.)+A@D
M.GN4R2X65B$-BRXLJ2."2,.G8(LQN5BP5OV7H/("MFG5T11SU]NPAE]N3"IU
M$M=T/UN-.%V9Z(DW^D*_.(U!@A8DR9SC%@EPM61)H#:ALDF)=CR(OHN$S<4Q
M(-7O;</#EIS>VRH88)GLD@.IK)Y0R=PA'9QR,C<^%K9X'"-Q>T_GOC>/PGB,
MY9B<-DRLI@E;KB@D,L3'X_$G=XP,9)"]^<]^3-&<@^]F7&SF'(82Z/ASINKN
MDD$B'CIW24*8GC6M+9X+W.<C;2;7SQTGO>F:R[[MIK*+JK;7N]SFTZC(0IP@
MRV]LXCQO+9&8V\:P&2OC>=(S,!A:?=.(AE@.V)R'XA::L%C7?Y5JPO9V)SVN
MFX+EF..2  ^ZYSP]C<WA#Y-6ITFQQ8LYK@!9#Y&[EX"F#<@0D6RE7C1W;4_5
M=CM.I5X^]S<5HRGGPIA_6G=UA6EJW<T$6ON?>I*E:V22M3#J'UT/QG+<^_Q_
M!:T3.-#.PF@L/$I)!R<&Z1B%K*JM #18&^8]G&",#\$S=7NK6_\ =,P$3#A$
M$1Y#=WOK9"7$V9"9;-V>[.(5K6I>XOC1W?6MS2"HV]>.?>T^D91CL"X._;JG
M[4GW#9?--^SV^YKYD,J]JA$E,0WB^:[1?'L C3$)-7$\!HV@X2)+N4:KDCSK
MJ]W2'G)OE)[.Q6\LX-FCORN']PS;:#D>T#HPVVB@(I^%CP#8X6__ (/=]GF]
MIVVWM"=I1M"=H2I*D*2GVZ]J5(7K2D;UKTUM*M:4G>O3>M;UO6?)C=F]S9OK
MOZC9?910 KE6WHN>0I3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")
MA$PB81,(F$3")A$PB81,(F$3")A$PB81,(J;[!W:@<,;I,GH4DF/'WR[UOGX
MDI$'JFP(=AMIL77 #95Q#J'([$XT9'0]*C,S)#33LDD]&0)&%9\$G/[\%JE?
MOJ5\-K/,+_>ZF'OEYL52YM9>G@:$FIV"O$+;5@//;'?V;3^4F"9K(&@R&JR1
M#$KC-A2-"""$>@<AJ8(;*%(%D>?W\_+S'BK6[-YE\OX%<+96^DZ)-1:W3*?<
M6EU41:+98GX1ZO>1%V/R2(*!6&A8T+6J)XVWZSI(Q+08(DVQ9,8\"$D?TLQ<
M2 $\OOE_*C&_J"^/PVQ#:O;YECI1>P=?O7'JRR>#ZTBP$J'TVH\<FV:"N%)E
M*56"G2+W5*T(>TA91]1.07=&,5\!9RX0FD_2_OX;_P"^R[5$\^N$]+EPH-*A
M]*.3"(.T6J*Q&H!;>]U6I47DO22EBD.;7\,* [3^\\;)08\YR,6DR>@"@^QK
M9D=8QX0E$?8\2/V*P OZ@_)+6_'W3!IF:$].2+(7&QM2@50&N]+\I[%XG3J^
MX5$#;4^];*[T&EW!$6.W!U4#R@[3RKN'K,MVV0WW\TH]?]^5WZ41_"R\+ZA7
MCA/9"/,3[XE9QF.6:B2.=6J--'TZ:CCLH?T$Q%?@-NC:40%=[Y87C$WT_=ZC
MV&2/D#HY^O6,.))1]?3?<_\ 'WLNQU+SWX3Q*P=-"]5=LU.A<RM5>J$NQ3 Z
M9 >Q%3'(I_<BRZXN+*<D2XU2YR+)&#GS,,2I$N*T! Q#-B* Q!0FDFJZV?K7
MZKA*^H%X[P[-8*U)EWQI-:,GP92Q[Y]9-U1,RMVGKU#GN1C>HNV945Z^<+Z7
M3ATAEM22!@$V_&TL,2'%I)*//[Z?R/GZK&:^H#R9XL<;A ;B_7ZE1[';;A-E
MAY06RU^6)E\3EA13U4-QAS:X=HI'=Z3T"";>/0V88*?#B382"S\R$,)1_;SW
MO^"NB]]2;QG'(.3[ 6L=>KH^U@:^$LQ,$ZT+M@8UQ3FG>I-W#-J=20360%#Z
MO4)AM,R&P;:>*CXT$1.FSV8:2:3]_'^"M_,*%^:UK7KZ:UKUWZ[]->GKOTUK
MUW_7?IK6O7?^6M:_RPB_<(OA&BQH;*(\2.Q%CM^[;;$9IMAE&UK4XO:&FDI0
MGWN*4M7M3KW+4I6_7>][V1??")A$PB81,(OA'BQHC?PQ([$5GWN.?%':;9;^
M1YQ3KSGL;2E/O==6MQQ?I[EN*4M6]J5O>R+[:UK7KZ:UKUWZ[]-?SOTUKUW_
M %WZ:UKU_IK6$7[A$PB81,(F$6).!XQX7+%R_734IO6DN)_[;+R%:<9?1_\
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M*SR6#$L;VXY8KK'W/;?:VNR'P+K3E9*20RE?S];2S]^E?H%TP'@MXQUR%N!
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M6ZA,SD9YGUV/+P)B-?OI,E#T1W?_ "TF4WZ_Y>OR)]?Y_;^,O,XS$0!)$]A
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M*T].FD)$J@.+\2 >&Y<C0\:2&!C*%SFH]+!V5#)G:WL]&EC^S;3&,:V@,K(
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1F$3")A$PB81,(F$3")A%_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g425213g27n27.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g425213g27n27.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( ($"7P,!$0 "$0$#$0'_Q  >  $
M @,  P$!            !@<$!0@" PD!"O_$ $80  $$ P !  @"!P4$!PD
M  4" P0&  $'" D1$A,4%5>7%M47&!DAEM;8&B)66=<*(R5Q)#%!46&!D28G
M-%)5E:&GT__$ !P! 0$  @,! 0             ! @,$!08'"/_$ %(1  $#
M @,#!P<(!@@$! <   $  @,$$1(A,05!4083%&%QD? B5(&4H='4!Q4C4Y.Q
MP=(7)#+AX_$S-$)28F-DDA8E0T0F)S6T-F5R@X3$T__:  P# 0 "$0,1 #\
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MK=S\IZ.P?J**L-@&*/(N+]=NMH8Y\+,$SPX[).D!E$+MPY3H/5=BD) B ;L
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MG8L45)15,M/*Z#:>TYJB)L==)1&IJ8I.8BCIP(S/(Z&HJ7QQ7+F>2ZV99,,
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M-D54\W/,@IXHJV0OJWOGFI_HL6U&MA#7P2/=TTTCN:#9&M<US2<C'4@7-14
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M9%1_=5,&R&]KC[_-XY/UK:RMJ ^AD94BK:UCY:EODU#G%N/!3WR!\H,>#?\
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MG><;:7(#;6RZ&IVA43[/=#2QF61L4T[I"VX;9C74S&DW(U<!UK(;4?B8'4P
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M/KZ=&UOV5ITK7KU^!]^K?JW^_P#?GI1\F6WW .%1LNQ (^GJ="+^:+2-JR$
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M-/'GF@,LJ(I[B22FFY:6VA1 &8E1'8KB]QWV248>\,>:G1R U34Q>B8DP/\
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MZ"G@:6,=&2V$&[Y2Y[S+(YSC9[R2R,,C;:SW2))6OR #1B<XW<'9NMD,AA
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M?7MR/C5<402Q>33S,9'<D1RPF5L=S?#$62PN;'K9CB\,_986L#6-R_D'D/\
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M=(B^Z>3',R [JMD+QSBHYVPQN5@W[&VS#KPZOMR/ES,9_8.0?L%L+#K!.O
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MR+16EQ-\AG[-+]X]/6H<]>U;2\^%8._(\EF2G9NNQ(WE#7]5>YZAPN,R"-8
MM,#1\ -2+"8Y$5LL$$'#13(L+6SIBPUL6]<KC98HE%S.R+(F VSL,NWKZ^M/
M';XZK*5=D\78/8#PD[)Z#9ZS+3SB5S2VRA(\$_/N09N\T+HP-TBF9"77DMQ+
M%1Y8VP 9=;)U2XTB^7NH& .HI0=+$ ;>.WNU10&@^ ?*.?R:Q+'6OH,YZIKH
MVA3<ERD#X*8O.[=Y,V^M05#0%)#P(\1I_P IKP+E,#8\!I8NO4QN&W!?A&GS
MK$;W[/9;W(M"+]&_Q035#5/CVWJ3@TYS$]RB4^\8J2IS=?L/ _&KQVFS8[B*
M6VPDRU3/%NA%8K[D9V$BSFK?+='O"IH8,!$W.?L[2>OBG#J]Y/XJU:)XB4J@
M%NAE!EVZ/(U=:Y?ZA7XZR@ :YRRM].O]LZ?;H5 *@:V)-MS)%SMS\X88M!&R
MDPL(#68(Z2SN"1D%U_OO?6_;X[+9W*!\D\#JAQ:V@[S1^I]&'V469LTPG(9"
M\@A#+'7[Q7^ @[M4" (;S"$(@C;,[XV\[,S#0***M[!5^TRHEB9<L#JV!-^Z
MV_QWW1:&K^CAY'4 @:L"KMT"?5P=7$5^/6+6-Y1<:Z4G#/&>F^)\@_9@]BYE
M/AV)TWRCGU3:-5Z<W^#Y1V&0(MU]B.5D04W%J;"Y[>-]Q5OG?KNK*)>'%3E\
MLX]S4;T3HX.;Q!ZPKIE^C;HQ:SZBVZGW&AV41.&66E&Z0H%)K%X*P X>%5(4
M&LMCJ[%!M1!8CY;*E\[G/QU644=!^C^X?2[56KOSHKTRBV>J<GN/)1S\2]D[
M6!F#;B%XY6I%C.TGH:+A23-B'5WAU*"1=2:]H#/B,_$'09<J$II&KKG,96/4
M!]UD\>.]3@+XG58%0:#2H=YO:B%#[M9/(I%T>U3?GQ_H]WNE\N]X<+#6JBU4
M8P.Q$>EV^'H0"K@A(F#,A[&/QYT+4UX3?=]_XGT)[5@\H\/J?Q^FW*G5N^=#
MEILO(Z+P4 ?+*I+YKGO(.5AK@%Y=3JLB-2X@4AJD,WRTRXARZ![6=-327MV:
M>9CQX\9N>/>BT8CPL$B7>3.-]KZ\ZKAW+)?,.8S6X7'A9\ W*YE,Y6W9)-D"
M<H&&#L\>%GR; /KIR3/HB;QN+9IE4FO!Z_&$6_4,S<Z\>WT?BGCL\=?#MOMC
M_B#7WHO#A]*O-@I +QN !(/':DT I1BNAS]2J1NH50V=+.U^#U$J-;@EXN[;
M5PW3:P-NC ,>/(NQH4ZQ-G%^KMTTZLLNWNMO*^N1<U!\9Y5S?D=:?G2Z_P R
MHU5H8>:4<:>*3X%5"0@D<@5>9:9:?*$&X6II%]MEI#TU]]U+:-+TG416)A$P
MB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3
M")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81
M,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A
M$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F
M$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB
M81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"
()A$PB81?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g425213g28a10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g425213g28a10.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[15Z4&AO=&]S:&]P(#,N,  X0DE-! 0
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M;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0
M   !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "
M4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,
M8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0
M 0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP
M $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B
M;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L
M  !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P    ,
M4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX            $)L("!D
M;W5B0&_@            0G)D5%5N=$8C4FQT                0FQD(%5N
M=$8C4FQT                4G-L=%5N=$8C4'AL0&<9F:         *=F5C
M=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P    !,
M969T56YT1B-2;'0               !4;W @56YT1B-2;'0
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M300-       $    'CA"24T$&0      !    !XX0DE- _,       D
M      $ .$))32<0       *  $          CA"24T#]0      2  O9F8
M 0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:    !@
M     0 U     0 M    !@       3A"24T#^       <   ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@     ____________________
M_________P/H   X0DE-! @      !     !   "0    D      .$))300>
M       $     #A"24T$&@     #-0    8              ;(   /I
M      $                          0             #Z0   ;(
M                 0                         0     0       &YU
M;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P
M(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   ;(
M4F=H=&QO;F<   /I    !G-L:6-E<U9L3',    !3V)J8P    $       5S
M;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M      9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A
M=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N
M9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,
M969T;&]N9P          0G1O;6QO;F<   &R     %)G:'1L;VYG   #Z0
M  -U<FQ415A4     0       &YU;&Q415A4     0       $US9V5415A4
M     0      !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB
M;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0
M  ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M
M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E
M96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E
M=&QO;F<         "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S
M971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*
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M87$B$P4R@9$4H;%"(\%2T? S)&+A<H*20U,58W,T\24&%J*R@P<F-0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M @,! 0             &!P$% P0( @G_Q !<$0 " 0,!! ,(#0<'"00+
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MA55BI',0"B!%=5N/#;[^1B3RU5UN\KD;+T4\A.QX6R&=;5IFSMN*:FJUJU1
MS:AWS!BR?-)*9%:=-)$M$2C&/(HL<SG6CI)ZL$B-8W=2+9=%M?L"6R.M*<9,
M3*+*RT.ZU5M(QE?DHR*EWD1*6&"C8R619O9F+(88]VX,=-Z@X2*H@;K "KV
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M"#RYCZ!S#F/S!ZB <PYC\&8\WBX^?JZO7 -^9 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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MJL?N\"NO47GT\PY_%_AS9F_+;[Y^$YP]_D+O?_JQS3W/PWI7R/5?UK C%_\
M&O9SYLVC_7T4N2S<$G& , 8 P!@# & , 8 P!@# & , 8!H!@$1 !\P^# -<
M 8 P!@# & , 8!368V&G%[2IVL_<Y95>VU6VV=.4*LF5%FG5'M>9JM3H&+WB
MJCL9\ATU"G*5,&Q@,!NL.73J7:A>V]GN2;N*%Q64TUB*H2H1::?'PNFX8['X
MC65=2C2U:RTITI.=Y9WMVJV\E&FK.=M!TW'&9.H[E---*.YQYE2L[ALQ@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# -.H!'ES\\#*[37 &
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MU.CI5-9<D]Z%Q7A*IPQ&EF2;? K\ \P ?C#GFR-\, 8 P!@# & , 8 P!@#
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M:+C%."KZ%:5JN91BI2WZDG+PI2QRCA<"^;),3L8 P!@# & 17<9  7=S(WD
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M:O3Z!15.GQI.WRZG!3WL*"QER"Y*BQ!@# & , 8 P!@# & , 8 P!@# & ,
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MV17X1UR^BR7_ %M1L@>POPI<?(Y>FT*8[C_QDOOFFO\ >;(R.\M8])# & ,
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M*S$RR9"KC[DSL6Z[UN95#DY[OO.\(H1.5;&UJ=6HX4Y;SM])M:-1)-*,^_\
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M#(]7L%<?QV]]^,8)@68"P0IMFSSA2=.\:H$B3)R!E 5CPBW)%W!@1*<'??\
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M6H:I0&M8LUAIZAM>[+;P^I]<!,W-X=J@XB%EG?<1Z<+/BUI\"9ZH[= 3/%]
M^8/T8!K@# & , 8!;3QB1[24X9=QL'M=L%J;.*BY!2#K"Y4)9V*;ALJFJ43Q
M<ZDNQ8G3*^EF:\#/(/HEL]9KPDLBN>/< 6:]GXY>3>T-KV*7M%/VE+&HM&A
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M7K3%CNYQ5]H7:4V%-.$JXM.1T]'QD?7IB555LC511NJT56#MX\GCU\Y/'@#
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M(< ^*39N@=51%!)(ZQNM8R:92&6/TE)UJB4 %0_04I>L_4;I*4O/D4  #[X
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M2KO5Z,(04::3?A*K)Y>4DL&2UDP)2, 8 P!@# & , 8 P!@# & , 8 P!@#
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M5A[(HZVEL7B+C]?72Y)-[O9F;&2GZ<OJ%PM!NDH]NU8I('7.9=JU;N^8 X
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M#.?9_8N6AZC&_EJ,;G=I5:71*U=+/2I+>WG6J<8XRN'UX9EV98*Y+//K)X,
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & :
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M?/XJSQ=T96VTCL%-T62>-7/<MI,@3"L7'.WU^K\, Y1^"'C JCMD>/MUVO\
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M+#+SLM=9JVM%*^,T^2IC>):2!6<36D4*Z9H#R)KL+#,/&F644;&5Y"48+P<
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
? 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g425213g28a20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g425213g28a20.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2!N4&AO=&]S:&]P(#,N,  X0DE-! 0
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M;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0
M   !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "
M4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,
M8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0
M 0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP
M $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B
M;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L
M  !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P    ,
M4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX            $)L("!D
M;W5B0&_@            0G)D5%5N=$8C4FQT                0FQD(%5N
M=$8C4FQT                4G-L=%5N=$8C4'AL0&<$Q*         *=F5C
M=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P    !,
M969T56YT1B-2;'0               !4;W @56YT1B-2;'0
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M300-       $    'CA"24T$&0      !    !XX0DE- _,       D
M      $ .$))32<0       *  $          CA"24T#]0      2  O9F8
M 0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:    !@
M     0 U     0 M    !@       3A"24T#^       <   ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@     ____________________
M_________P/H   X0DE-! @      !     !   "0    D      .$))300>
M       $     #A"24T$&@     #-0    8              <$   0(
M      $                          0             $"    <$
M                 0                         0     0       &YU
M;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P
M(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   <$
M4F=H=&QO;F<   0(    !G-L:6-E<U9L3',    !3V)J8P    $       5S
M;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M      9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A
M=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N
M9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,
M969T;&]N9P          0G1O;6QO;F<   '!     %)G:'1L;VYG   $"
M  -U<FQ415A4     0       &YU;&Q415A4     0       $US9V5415A4
M     0      !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB
M;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0
M  ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M
M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E
M96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E
M=&QO;F<         "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S
M971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*
M#     (_\        #A"24T$$0       0$ .$))3004       $    "#A"
M24T$#      5O@    $   "@    1@   >   (-    5H@ 8  '_V/_B#%A)
M0T-?4%)/1DE,10 ! 0  #$A,:6YO A   &UN=')21T(@6%E:( ?.  ( "0 &
M #$  &%C<W!-4T94     $E%0R!S4D="               !  #VU@ !
M -,M2% @(
M            $6-P<G0   %0    ,V1E<V,   &$    ;'=T<'0   'P
M%&)K<'0   ($    %')865H   (8    %&=865H   (L    %&)865H   )
M    %&1M;F0   )4    <&1M9&0   +$    B'9U960   -,    AG9I97<
M  /4    )&QU;6D   /X    %&UE87,   0,    )'1E8V@   0P    #')4
M4D,   0\   (#&=44D,   0\   (#&)44D,   0\   (#'1E>'0     0V]P
M>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY  !D97-C
M         !)S4D="($E%0S8Q.38V+3(N,0              $G-21T(@245#
M-C$Y-C8M,BXQ
M                  !865H@        \U$  0    $6S%A96B
M            6%E:(        &^B   X]0   Y!865H@        8ID  +>%
M   8VEA96B         DH   #X0  +;/9&5S8P         6245#(&AT=' Z
M+R]W=W<N:65C+F-H               6245#(&AT=' Z+R]W=W<N:65C+F-H
M
M &1E<V,         +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R
M('-P86-E("T@<U)'0@              +DE%0R V,3DV-BTR+C$@1&5F875L
M="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M  !D97-C         "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@
M245#-C$Y-C8M,BXQ               L4F5F97)E;F-E(%9I97=I;F<@0V]N
M9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X    !6%E:(
M    3 E6 %    !7'^=M96%S          $                        "
MCP    )S:6<@     $-25"!C=7)V        !      %  H #P 4 !D '@ C
M "@ +0 R #< .P!  $4 2@!/ %0 60!> &, : !M '( =P!\ ($ A@"+ )
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M&SL
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0 # 0$! 0$            !!0<&! (( __$ %@1  (! P$$!0<%# 4&#04
M   ! @,$$04&$B$Q$Q1!4? '87&!D:'1%2(RL<$6%R,S-55TE+/3X?$(-#9U
MM"5$4U9SLB0F0D-25&5RA)*5H])%@Z*DU/_:  P# 0 "$0,1 #\ ^_C & ,
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M /S , K@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!Y
M*^4BN[*IEGH%N:.']6N,+(5VPL6LE)1#A[$2C<[5^T3DX=VPE&7J&ZBB1EV+
MQLN4IS 54 $0$#"$7Q T7$R-)E$J_/O76O\ V26O>V;[>YM R%;E0GJDSFVD
MK8WC6RL*7.E":IC&P(R36J2?5Y I,%Q$XL>/'CV [:V% G)+2A0 .HZ\W.(B
M  '7^W-;!\NOPZ?$1']8_' -AL 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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ME)I"2(F!N+@&O=O_ ,)32G^;O<_^V:VP#83 & , 8 P!@# & , 8 P!@# &
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M?OK"3H.Z#Q4++5ZH0[:NIC*ZZ6*FT=UV'CY!Z!$#IM"C).G0F32*J?JN)E!
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M;U]_4 Z=!^(AU^/3I\, NP!@# & , 8 P!@#  B ?' * 8INO0>O3X_JP"N
M, 8 P!@# ,>SM]0@M@4*AJL%UU[XTM[MJ^342*@P+4&44\<$7(?HJH+PLJF5
M+R^O8*9Q/T 0'/)5NE2NK6U<)-W4;B49IK=CU>$)-23X_.W\)KM2SSX5UQJ,
M+?4=.TZ5.4IZC"]G"HG%0I=2A1G-33XRZ3IHJ.[R:>>PR%GK+$8 P!@# & ,
M 8 P!@# & , 8 P!@# & , #\!Z?'[, UCW9L-NHPW%JHT<Y]8AQSN5_&6$Z
M/I#-G2$_7@C@1 ?.]019H9R900\KRS%*4PG W2FU*[@Z>H63C+>CI%S=.:?#
M=DJU''![W!P<GA/@T<SKNH0=#6]*Z.2J+9J^U#ILK<W)QN;94\8SOJ4'+.<-
M/'#F97U& !JW7'3_ -0ZC_/ ,!SVZ?\ U"S_ $6A^RB6NC_DG2_[NLN;S_FU
M+O,BY["Q-"N3'%W<^^-A5^;CMS4UAJJML&#AOI*]:OEK=4)6Y,WR[LMLM!H#
M8E)7MY$$Q9(QE8LA9*LQZS49 T6YD3IN4&/'G\>YOF.SA]?CS]_JXYW9K+27
MCZ[!,9]W&2$XSB8]K+OH:+4A(AY)(-4DGCF,AE7LDI%,%G!5%&D>I(/3-$#$
M0,Z7$GFF [H2E$>HA[^G3 ->[>';R3TKT_R=;H']77UFMOET_P!?\G3 ,U1]
MBAI.6FX)E)LW4Q731X3D:BL4[N*]K-1?1H/40'N1%ZT 7#?N_P",2_3#J "(
M?$:E.<ZE.,XN=)Q52*:<H;\=Z.\N:WH\5GFN)_&%Q0J5:U"G5A.M;.FJ].,D
MYTG5COTU4CSCOP^='/-<CMG"Q6Z1UE# 1-,AU%#F_O2$3*)SF,/V !2B(C[^
MGRSZ;23;Y)-OT(_K)J*<F\**;;?))<6^6>"3.LK\]$VB&B[% 2+66@YR/:2L
M/*,5"K,I&-?HD<LWS1<@B19LY;J$515*/:=,Y3!U >H_-.I3K4X5:4XU*=2,
M9TYQ:<9PDLQE%K@XR3337!KB?RH5Z-S1I7%O4A6H5Z<:M&K3:E3J4YQ4H3A)
M<)1G%J46LIIYSC!VYA$ ZA\_W!GT_P"7C*^L_L::\G+]3T(/5MA<6.(0A*;R
M;UTQM,HJ[(1E O8ER^4DVTDL(]K99BFJD=R100%,JA#&  'H-%J]S04+*HZL
M%3H:O:JM/>BHTI4Y2<U-MI1<$\R3?S4\M<,'%[57MG"AI%Q*YHJA:;6:5"ZJ
M.:4+>=*<^DC6DN%/HU*+FI?133EA'<\>++"-)[;]><RK)&:L'(#;CZ'C%%B%
M>23.*5A#23AHCU[E4F)7C07)R^Y('*/=_?@.?>E5:<:NH4G4BJE75+^5.#:4
MIQINEON*SEJ&]'>:6.*Y91_;9NYH0KZU;SJTXW%SM'K4Z%%R2G5IT)6_23IK
M.91@IP<VOH[\<\UG;/+LZX8 P!@# & , Q9=;BS/3=K%KDVW&Q4>M3OKP9*I
M*O*_,A5U9N,!RD8IP1<>F69/T2+$,51%5(XD$ANF>&YN(JC=NC4BZEO1K.2B
MTY4ZBH.I3WEQPVG&237%-/BFBLO;RF[/5E;5X.YL;:OTB@U*=M7ZH[BCOQX[
ML]R5.K%27&+B^3-=.)^W):ZV&]5>W7 )BPLZKI:R14,[5:E?(QDYI?7LM8I1
M%N@BD<S5Y:IIVX<K'[BE>O3)D\L@E2)5Z)?5+FM=4:]QTE6%'3JD*<G%2W*F
MG6M6K4BDDVI5ZLG*2X*4L<.!S>R>L5KZYO[2\O56N*=GH=S1H3<%55*XT33J
MUU64(I/<G=UY2E)YQ4J-)I82W>SHCMQ@# & , 8!U$_.Q-8AI*P3T@UB86':
M+/Y23?*E09L63<@J+NG*Q_T4D42 )U#F]Q2@(CGQ4J4Z-.=6K.-.G3BYSG)I
M1A&*S*4F^"27%M\D?QN+BA:T*MS<U84:%"$JE:M4DHTZ=."S*<Y/A&,5Q;?!
M+BS72@;,6M_)K<]1C;0E-5>EZZU0<(EHJ@JU@[;)SNRTK"14R9/.3D%V,= E
M=(*JF!--!L)"$$YQ/56MWUC5]0HPKJI1M[2Q_!Q:<:=>I4N^D[,J3A"FI)O*
MSRXG/:?J;N]I];LJ=U&O;6.FZ1^"A.,H4+RK7U57*>%^-E3IT.D6]P4(?-67
MG:++@Z<8 P!@# & , 8 P#%TQN364#.S57FKU6HRPUZ.93$U#NY)!&0BXN1?
MQD7'OGC8QO,1;.Y&9B6:"IP[3KOVJ9>IE0 ?'._LZ52I1J7-*-:E"-2K3E-*
M4(3G"G&4D\83G4IQ3>,N<>]%95UC2Z%Q6M*VH6M.YMJ5.O<4)58JI2HU:E*E
M3J5(<7&,ZE:E"+?!RJ17:F>4X\V:=M56N+^PRCB6=L=S;IK[-=P"13-X:O;)
ML4/"QR8))IAY,?&-&[1$3 94R:11544,(F'SZ97K7%.O.JW)QU#4:,>"6[2H
MW52%*/!+A&*45GLX<SR;/7->ZM+R=Q5E5G3UK6[:#EC,:%MJEU0MZ:PEPIT:
M<(+.9-++;?$SYEH7PP!@# & , URV%_A%<=?^B-V?]@T_*F[_*VD?[/4OV5N
M<QJ?]IMF/]AKW[&P,X)V2%6L3NJHRC)2PL(MG-/88JQ1?MHF0<.FC*060Z]Y
M&KIRR=H(*B %45;*E*(B00RR56FZDJ*G'I8QC.5/*WU"3DHR<>>[)QDD^UQ:
M[#H5<4)7$[558.XITH5YT<_A(T:DI0A4<<Y4)3A.,9<FXR7-,[W/Z']A@# &
M , 8 P!@# & , 8 P!@# & , 8 P"(;Q ]AN-?6+82D78TZ[8K/Q_HM6ANBK
M<CR7;RV[E&]EB623@B@+BYJ9YH'9$R"HFR]0L0R9DP.7@MJKIVE:\=.LJ5:M
MI%O1IKYN:BJ:G-5X1WD^/0NHVDLJ*D_^3E9!Y1M2EIU75'1NE;75ULW8VE#C
M%3K*KKDHW-*"DGO;UHZW2)+>5+?DL)-J3;4G_-=KC_J'4?\ L!AG96']1L_T
M:A^SB:=I'Y)TO^[K+_#4C(>>LL1@# & :Q[0DQA-ZZOFBH@X&)U)OF3! 3BF
M"XL?J\= B*H%.*8*^5V=X%,)0'N H].F?SJU.CIU*F$^CISJ8SC.Y%RQGL3Q
MC/8?RKU>AH5JV-[HJ52KNY:WNCA*>,I-K.,92;\SY& >.6[UKGR<O\8I7D6'
MUHZ6U+N!54DB=P$,HVI5);A!D S1'UA#?3,YO7F%L;JQ* -?XX?+Y;2=2=?6
MKJDZ2B[W3K/46]]2W'"VLXJG%+Z<7UAMR7_12YMXSW9S77?;4ZA0ZNJ7RKH>
MCZXY=)*70N-G805M'\'%5%B\^=4;@WN)J#3)!9W_ )%EO^C)#_8U\ZFK^*G_
M -UFA5_Q%;_95/\ <D8*XC] XO\ 'G_,MK4/_P")1/3_ %Y6Z#^1-(_NVR_P
M],HMD?[*[./OT/2W[;.B>VV7L96@N];M$XM.2"_;+AM?J'.Y.V-&)RL+8I89
M0A2HK Y,B:"*@#8QD2G*Y$XK$,F!#^B\N^JRLEN*?6KV%K])+=4Z-:IOKL>.
MC7!XRF\=C/;JFI/3IZ7%4NE^4=5M]-;W]SHE7HW%7I>3WG'H,;F%G>?SEC)
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M@E'H^JIJ2FW+?PTL+,FMCV&K [/USKLL61RG?(:]2IY0SDR9XTU-2@%2(%;
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M?\"/4_=\?5]9<TY;TM_-3%<9ZUY"N)NOMHEY,QJ>B=B"XCVLZ#\8A9P PP$
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MH45$^O[!6TG3RM6B+46=JNV,D<SM4"3X@" >\.@]?Z_S^[W?9[\ NP!@# &
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M,(>^!XK]!#W]-<[+Z?O^MC.&^^7%/\CS?_CEQ_\ 8.&^^71S^2:C7Z7%9_\
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MWMV6K44Q%VW449KJ&C=;R5KD7J;YI;QLBSV0-8J_"HIMS(?Q"96YUE!4 !,
M (CE[LYL]'9ZC<T8W,[GK%6-5RE35/=W8*"CA2DY<%G.5Q[&R\V>T&EL_;7%
MO2N)W*N*_3N=2$8.+4(P44HY7*///;RY$^&=*7XP!@# & 4$H&#H(=0^60TG
MS_EZ 4 A0]P!_./].21A=R]A0"$ 0$"^\/> ^_\ 7^O]8]?G]N"2_ & , 8
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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MO]D4&\O(HB:LHTI]PKUE=1J*RAT4E7Z$+)/56::JJ9TTSN")D.H0Y"B)BB&
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MON#A'R*UIHYO)N]L6^@N(JDM(>?+5I-S+&DHY<4&5A.^C212ZS1%RF5R=\U
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M./F);.+53V/1=/1=1VG*3$S98"T;%CHZ2L,\>T3CJBH[$M/U:GE[ JJLZEI
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MC=X]/MZ<JXOKT'W>[_A=S1?NU\BW^IE7_P!)L?LO\G@ZIK#_ ,]I?_ES[/\
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M KT#Y!@# & , 8 P!@# & , 8 P!@#H'R#^O_<'[L = ^08 Z!\@_K_W!^[
M& .@?(, 8 Z 'P  P"G0/D'S^'V_/ *] ^08 P!@# & .@?+ *= ^0?NP"N
K.@?+ '0/E@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g425213g29a65.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g425213g29a65.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( )@ L0,!$0 "$0$#$0'_Q  >  $
M @(# 0$!            !@<%" ,$"0(!"O_$ $X0  (" P "  (%!0H)" L
M  0% P8! @< " D1$A,4%2$6(C%16 H7&35!8767M-8D,C0X<7-WLK88&B-&
M4F*6U3-"0T1%5V-R@978_\0 ' $!  (# 0$!              $" P4&! <(
M_\0 51$  @$# @(%!@<+"04&!P   0(#  01!2$2,083(D%1!S)A<;'P%!52
M@9&AP0@70E97<H*5T=3A"189(S-BEK+5)"62D],8-#93E-)49&6CI./Q_]H
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M1K7J(HM&G<*?;S3\Q3L<]V_U;[> [O'U&L"QS*5WR1&JGMD\@,D$D$MQ9V;
M.QXP235E5CGWOHV;<V&Z?@\C*[3U1FL3L>R5.=9%=N86S@3KM%U"E7VB9@DA
MOU-!]CJJT3(ZVI7N8GJE,?([%L,$JJ-M_?Q[AL.[^/*K!9\J&)..JR<C&4,9
M<\\CB42 @  Y&VXQZU^17KIXI3Q2GBE?FVVNN,[;;8UUUQG.=MLXQC&,?ISG
M.?EC&,?RYSXI6.V9QR9SH%%*=OC/RSM#CZ(^N?\ OE;_ $8<?Z--I-OU:Y\5
M7B\-_5R^GE]&:CMFJ:RY*]EUP5I7"N H-M J.6B-((&BDC0]4RCD8CS8A8K#
MH(3%YPD(Y0)<,1(A$4T>DF%0P+*>+&.>,9Y;C.>\'P^W;#<4?-+3QKDEG=DY
M,=6/F5"?-R]L8UV*:-ZJJ8'D[:X_#&9RR)9<XQ^&,[?+'DG8D>!-2A)1">95
M2?60#5F^15J>*4\4IXI3Q2M:>55HNY^G?-J>!8&53.M?K33JT%:4V<ZMZT6]
MY<N5COU6<2P9PQ3S%:,0LZSP[8)'BSB6//RWUV&F7D>G:II^H2VL-]%8W]K>
M265Q_87D=M<1S/:S]EOZFX5#%)V6' [95N1U>J6,FJ:+J.F0WD^G2ZCI=W8Q
M:A;'%S8R7=I);I>6YXEQ/;-()HB&4AT7#+S'G/R3X5?4>=4;K%6.]H&9DO0<
MUO @*M2[&KDN4+.<^8JRB$V"4DTDV.; T'V/:+ 6<;RD2---]!XN_P#+1T^L
M/*CI&EZ9IFB#H_-87#W$E\\D4\\J,@3X"OP>&W(M"V)I.)VXI8X&6- C<?YP
MZ+_<_:_H.F=(;&;I[/.VL_ 1'#!;W4=DQM)WF>2^CDO'>624,$3J^'JL%G:<
M$(LUY1\-CH_/[_6[>1W^4,=$=]MES5ES<1P3IK'OKL%$08SR+$.9C;Z@W,T)
M&NPN\T>(-]M\;:_GS2^BUSI^HV=Z]^LJ6MQ',\(CD G6-@S0.3)CJI@#'*,'
M,;,,;UT/1GR-:OH>NZ;JTW2A6BL+F.XDBM(;E);A8SQ&V9I)P@AG ZN?B#\4
M3.O 201V:U\.SIM:N$+_ #[ O H(]V>VU@IPS$&ZQY-%*'P4)*P;3BP&2;3X
MD(WWD8X^69=?JY\[8V\_06J]/;#4-*NM/31!&]S;F!6>2%HH"R@"1 L*L6A.
M&AP$PRJ<KC%?=A;,K9XS@=ZY#'Z_M-?S=,_W)M[/.'38N+XB%4;R%L32MCWU
M(Z/ _89((DER>W'DNC#?5B7G;,YOR//Q]IDD_P ,)_\ 3;_->L]'U_PK6_%#
MDDFY4DDDY0\1[\G+9R>9]IYUU_\ FCGM3^WU0O\ P7T;^\_CK/1]?\*?$S_^
M>O\ RS_[J?\ -'/:G]OJA?\ @OHW]Y_'6>CZ_P"%/B9__/7_ )9_]U>NWI#\
M#3M_JEZZ77CEH]U6W0C[;U)9?PTL"2RA\VK@JVO%I)XUZQA:#66]@=RE1'-6
M>N@H6\2M6'A;)/!LSVT.O:5+K$$,45T;4Q2%R"&9) 5*X<*RG*\T.X&6&.UD
M<ATVZ!7O2K2K6PM=<?3FMKPW+(8Y'M;A3&8PLJ1RHW'$27B?M*.)P4RP=;8]
MCOA#]:[0?RZ-9[6,-,4?FVE4)"MBE\:! 0/97+?8BNX ?XR(!)"]&6:B&12E
MQCI!-]CYH)!P5OV?R9=/+'H'T<&AWND-JMPMS+.=1CDBBEF64+PPS+-'*_#;
M!>K@(E*]40O5H5)?::+T3NM)T;2])FU>74);"V:)[JX5\N6GFF"Q@R2,L4*R
MBWA5F9EABC&0,(NN?\ IV_\ :HK'_ANW?^>>?1/OXZ-^+-S_ .IM?^A6R^(9
M_P#XI/\ A?\ ;6Z58^%AU*N\-H/*RO9]G83ZG9+B]FU:K'?Y+!CVC1)H,LK8
M?W],:' LV3D%R9+^NU*.>LIAHUVGTXR_SSY4[E/*%KD.K6$*:'##:I;-;;2F
MYD1F;X9.T0A7X0580>8V((HEX\JW%Q/3?R;:CTKATQ+7I"UD+ W/';RQS26L
MAN.J(DC6.9"DL?5E265PRR'A,>&$E_H_12\I^7U2B3]O.;EH7=C;2ZG!L_N(
M:)YHKTA!3#?>DA(\06RV8C?,_P!/$Y34Z2'037Z6D^^\F'2"WZ V-]9WUE\<
M/=S)*ERK)%+;JH*_!D$R2YMV)Z[ 9,3,Y*L&7@YJ[\C&L3Z'I6ECIA*TEA<W
MT[I-#<&R5;P6X5+9%N>L3J3;LQX^(.]Q*R"+M"2Y^">O;GB-E;/GO1/OV)BG
MV5Q( 1C8X)YI"QB=3R8B"B-I9Q=1MX1,1#8WUU,(SDC33.\4W0=-.G-CTHL;
M:SMM&%D\%T+@W4KQ/*%$4D9ACZN)"$D,@>3B<@F).P3AEZ3R?>3?4.A>IW>H
M7G2$ZA'<V9M%L88IHX6=IHI1<3=;-(&>(1,D7#'Q 32?U@!*/MA]>P)_ 8;4
M2//_ +<W\9,X_7H+%M]+&?Y<?72Q_P ^OGS:OKF2<X&!W$\_H_;C[*_=5D6^
MV-S993Y,9^>,$9Q@?7/_ '!=,:PXQ_\ ?K)M_P![/BIQRSN1X^/JY>KPK(ZZ
MZZXQKKC&NN,?+&NN,8QC&/T8QC'X8Q_-CQ4UQ$?Y//\ ZF7_ '-O%0W(^H^R
MJ@]<_P#-[X1_L:YA_P $(_);F?6?;58_[./\Q?\ **N7R*O3Q2GBE/%*>*50
MO FJU#ZP<5>.#(%RA-P7G#5JP*W^K& 6KN>IC#C"),_/&D HL,L\V_RS]&/3
M;;^3R6YGUGVU2,XB0GD$4G_A%=>3VJ]>,0CRB]6K#;<P*@L0 :]N=96[(+J-
M8>W:@D*TM?"9-V>EDI58L=R#P $3M#4D3:RFZBI0"3HV#[^BHZV/Y8/F\M\\
M0++C&<Y4%MNX$\AFI#;^_<=H+2PJ+C>U->)J*E.ZM93"%CHEK(-A: ID6M@L
M6@4E?3,&YS('"]0Q9C-R@RHF<0.RS.2\14M(BDAF P 3G. "<#)Y#).V37,-
MWKC)C<9 +TNHSNS+S<^9B*HVX^QQ-^YU7S;5>ZH./\_K)G%3KJ\UL]&CUVRO
M%'WVGVUWSKILIUB9QQ#/$RX_O*,L/6 "3ZJ@J/VL];;U/2A*_P!'46(GH+_2
MK4^)>HLA$[&Q2UQ9<X%&^T:7$B8XFE.E-W$C;[+<ETED'<!LRULB-ILQ51+$
MV &!).%QG.<9P-L@XPWYO:Y;UWS?8CDBEG8$XE\D:L*H'<3[ K K-PL^ZL*@
MZ/=;3/(774#+?$8)]5M=>"SKL7]]VZIVNF(L,[767B8!0NH) ?)&21AFQPYS
MN 3MPD=^2"!D[5.EO8>9LCX%(][I<[0EXSK P8%L0,Y";*D$P>YKP^@1\TV[
MQ2#G!K-3M#HP7B9P06/%#^?XJP=>\C.2,9!W',;>'?G&*[MLZISRC,ZXDM5L
M4J'=P%M1E32R2R$N;,/2$!%IMFZ%4%$2P;;(D TS(Z($>>;6'$>FD>\\\$4B
MI9U4@,0"<D#O/",M@>@;FJN4>T_KN]L XJ_KM.UDS7'3$B5D?NE#692%F??J
M=X>ZA7@H+6AC1/"7M+=D+[<E"2MSF:04-8;/ Q[^OE5!)&6V=?-/?C&#N#GD
M1@Y!P< G&QJQV'8N6+)H1B;_ %:0B5C1U6\(#<5K*$7TPX99SS9M&KW,V2@W
M9F< MJ[5O@)6[8L5H*\R<IB%#.JY=1^$.:C8Y\XX7..0)( )V)(\:FV6>DF<
MZ@PRG;XSG&=HL8T&USC].-BI/HQ?A^J/,FWZM<Y\5.>X;^ST;_LSWT^S'D_B
M45@://Z1P?GC;./U;ER8^LS^K/U4</\ -M_+XJ,$C?;U<_G/[*[0X8PN,_40
MZ:;;?X^_X[2[YS^G.\N^=I-\_P OYVV?Q\5( '=^WZ>==GQ4T\4IXI7"1_D\
M_P#J9?\ <V\5#<CZC[*J#US_ ,WOA'^QKF'_  0C\EN9]9]M5C_LX_S%_P H
MJY?(J]/%*>*4\4IXI6MW(:N+=_4+F%+-)G#"M_K=2JN68+B/8H45_P Q6*2"
M1L3:[Q9G@B+WEAQ+IM'F377&^NVOSQF6YGUGVUC09B0>,:CZ5 K2M'\,WE%8
M5VEQSOO]YK#A@('4]+LN:)M]ZA74=7[5S%)6DIBDA02B+I7,>Q**=3&0;<)K
M7SN5\^;E[M8I+0FL>29);? N8W@RBR 3(T1*/@H_;"Y1L=EN3;X->%&LVBDF
MBO(6B1C%),DT31QNG'&8V=6X4=!($X2P92J CF#=G=O3/F/L2Z8V:V=!^[*D
MQJM6J%W@J.J]07?EU5M]6M@JSIMKC:3@VM*-N@WA0@M$FCBK%6!L:GL,0YLB
MR7'&>N(6'^M);"B/MDMCDH7)SC<@;\MMJSCJ+D%XYXY$V1FA='!(*L5=E9@3
MC& =QQ9Y'%51#Z%\<YO+3&]C]E;:H>JK=CHZY^_;\X2DV^YNSN2L^R61Q,S3
M_:F<_8">6J=[?LB.49$AM5I%"ET!=["XDD@D$8.2"#MC&V,<QCP[MMMJD0(O
M"3*<C<$E1DDJ7)VWX^$9QC8D9W&)SP[@?K7P]?RU)6._*7L/,.AZ] 2RV"_5
M-T^>-I_76#URW7V"P&,2G[P6-)IEHCP<<216Q(4=#K^X-"J];KZR,DY](Q]>
M??\ ;5DCC3@"R \+<0RP)),?5X)SD[;CPV484 5]WKT1JEXG<5P[I^U=A?R^
MSD^):PC#3]*:5?V9+ZR\M50?6?+R72TT.O7'LUJLJRM-*R2HU8HJ2;#HN<J7
M#:P5+KQ!"R\1&0O$.(@;$A2<D;;D#%4=83((&F19)%F98N)5F='+ER%+<3(K
M.Q\TJ"!R(),9>^F'*7EQ+L]Q[BA>60BR]59V&!Q&! *_EZ \H[Y1#;:X+=0T
M5E:\U8\TI"*KQ6=.UK&*56U5784V:=4G<+/6MG>LH=;2Y92 5=;>4J5QD%6"
M$8//(/IS4F.+B):5>++9!(&2Q4]H<6Y7A4#(Q@8(/.K6ZSZDT*YW;GUY3]6N
M?+^N4.IEHJBSI;0&,2.*/E_7.;*7"_G$^DR <A')U]Y9-)E2X70XU8F5M)B%
M((P\'DXU#!.)>(C(4D<1 .YQYQ&1S'*HDZCK8XS.L=P49HXPZAV4*Z%UB.25
M7C))5>'(4,=A5<R>D%9,+K)U?MS&KVFCH\1A'435M7UK"[1L)@3>EW.L#W@E
M@XOC"BLK#S1I9M+.GZ&SK-YO1YUSGM!E6>TS*R21A3)&RAQQH60J'7Q0D ,N
MXW&5Y?/11%(S".17:+*OU;*2KC8]8JL2) ,J02KX9LX)!&/IOP]%2(_G4<O<
M;;9T_-ZYQ:FJ:_9U4TTXU5XI9?7"V*5P,.;%&K6DO&WK4@W=LAD/VLK>[70H
MF<R76LZH:9^WUG.>9Y]_JK(+<94<;-P!!AAN AC(QZS&,G'X1W\W'ISC&-<8
MUUQC&,8^6,8QC&,8Q^C&,8_#&,?JQY%>JOWQ2GBE/%*>*4\4KA(_R>?_ %,O
M^YMXJ&Y'U'V54'KG_F]\(_V-<P_X(1^2W,^L^VJQ_P!G'^8O^45<OD5>GBE/
M%*>*4\4K6OD]4@O?I[S2CE,FB8:Y>M=,JI#A&3]C=*H+#R]:HE9*"\Z[X%:
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MZ]95ZRSMEF>-G<BUQ+IJ(N71@*EH2HTMJ[:+8)LK$^C=ZI51GX2H XBQ( R
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M- &;Q.V;UV($64*!VB.LBQE.0ME+5L.+Z;=+9NB-C:W<.G/?FYN&@9C*T$$
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9/Z0?\D_]*O@7_9:TG\NWDO\ _7K^]U__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>g425213g29b87.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g425213g29b87.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[3"\4&AO=&]S:&]P(#,N,  X0DE-! 0
M    ,*"^$D2#A"24T$!       0!P!6@ #&R5'' %:  ,;)4<< @   IYP'
M)0  A4:6T@4GEA;AP"!0 74&]W97)0;VEN="!0<F5S96YT871I;VXX0DE-!"
M4      ! SOA\!-O9J=[?06Z&@D$E(.$))300Z      #E    $     $
M    MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M   $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<F
MEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P
MP 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M  0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#
ML      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M  0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V
M)O;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M   $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M  4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M           $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M          0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0&
MB#"D         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4'
M,     4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B
M-2;'0               !38VP@56YT1B-0<F- 60           !!C<F]P5V
MAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
MQC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M     +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      !  Q!A2  $  0
M#$&%(  0 !.$))300F       .             #^    X0DE- _(
MH  /_______P  .$))300-       $    >#A"24T$&0      !    !XX0D
ME- _,       D           $ .$))32<0       *  $          CA"24
MT#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0
M R     0!:    !@       0 U     0 M    !@       3A"24T#^
M  <   _____________________________P/H     /________________
M____________\#Z     #_____________________________ ^@     __
M___________________________P/H   X0DE-! @      !     !   "0
M   D      .$))300>       $     #A"24T$&@     #-0    8
M       68   %@          $                          0
M     !8    68                      0
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M    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
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M]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=
MEV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M  "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;V
MYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M    QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
M   #A"24T$*       #     (_\        #A"24T$$0       0$ .$))30
M04       $    #SA"24T$#      F*P    $   "=    H    =@  2<
M F#P 8  '_V/_B#%A)0T-?4%)/1DE,10 ! 0  #$A,:6YO A   &UN=')21T
M(@6%E:( ?.  ( "0 & #$  &%C<W!-4T94     $E%0R!S4D="
M     !  #VU@ !     -,M2% @(
M                              $6-P<G0   %0    ,V1E<V,   &$
M  ;'=T<'0   'P    %&)K<'0   ($    %')865H   (8    %&=865H
M(L    %&)865H   )     %&1M;F0   )4    <&1M9&0   +$    B'9U96
M0   -,    AG9I97<   /4    )&QU;6D   /X    %&UE87,   0,    )'
M1E8V@   0P    #')44D,   0\   (#&=44D,   0\   (#&)44D,   0\
M (#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C:V%R9"
M!#;VUP86YY  !D97-C         !)S4D="($E%0S8Q.38V+3(N,0
M      $G-21T(@245#-C$Y-C8M,BXQ
M                                    !865H@        \U$  0
M$6S%A96B                      6%E:(        &^B   X]0   Y!865
MH@        8ID  +>%   8VEA96B         DH   #X0  +;/9&5S8P
M     6245#(&AT=' Z+R]W=W<N:65C+F-H               6245#(&AT='
M Z+R]W=W<N:65C+F-H
M                   &1E<V,         +DE%0R V,3DV-BTR+C$@1&5F87
M5L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@              +DE%0R V,3
MDV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M                    !D97-C         "Q2969E<F5N8V4@5FEE=VEN9R
M!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ               L4F5F97)E;F
M-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M                      =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,  03"P
M #7)X    !6%E:(       3 E6 %    !7'^=M96%S          $
M                 "CP    )S:6<@     $-25"!C=7)V        !
M %  H #P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!> &, : !M '
M( =P!\ ($ A@"+ )  E0": )\ I "I *X L@"W +P P0#& ,L T #5 -L X
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M2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,#
MP1# P,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A
M04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,#
MP,# P,_\  $0@ H "= P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
M        ,  0($!08'" D*"P$  04! 0$! 0$          0 " P0%!@<("0
MH+$  !! $# @0"!0<&" 4###,!  (1 P0A$C$%05%A$R)Q@3(&%)&AL4(C)!
M52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>
M/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1
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M?92S&]+[-ZMB2GL4EE8O766=.P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0'_P  1" "O *P# 1$  A$! Q$!_\0 '@   P$
M P$! 0$           @)!P$%!@,$"@+_Q !>$   !@$" @(*#08)!PH'   !
M P0%!@<"  @1(1(Q$Q05%C=!46%Q=@D7,S4V=8&1H;*SM? E)W)SL;0B)"8T
M0T:VP=$8(S)$98/Q0D535%5F@H6&X6)D9W1WDZ;_Q  < 0$  @,! 0$
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MZVYM=/S.OE+%.)?$#FI=<41?T,RB3LC=8XP&IUISPV+JXQO$8Z(0AI(M"&^
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M\SLNKKGL:FFU3# K6P[9II!"D%?S9^-6P]=/4)K>EK:MRW=AC4W9(O)<X P
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MQ5NIAX"9'QY_FM=>0=?P14:HJC^?Z%7_ /<L57_O&J]G%=0=&='ZPHA9=?\
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M>',Z&;[S1C#9#:D?'_0R'CQ]S^3^"'_#Y->W,FJH5'>U]=JQ>FZT-<5;J8>
MF1^/\USKR_\ 2*C5$T?^T%"_&&-/2-8.Q=0=&UH_6%$++K_\./U0U>[,AH&Y
M<AF1UF_&TG[V(^^EC_%T=_>G/5?Y?]6Y.];2/"Y6W1.D;U!XBO%[VP_.ZQ^H
M[7][R'CS_P#?]G+>R(\U/O;7WN:/CZK'3Y;6>.)=EJA)?=BNKW=)U_K</.'[
M=>P>]&WJ-;EK,=9<Y^?B0/;HDK6W7X$ISZF*/L2OQ]'7JD>0_/U ]I'B:75>
M]"= S6XTS41M7BN<J0;$N/<NR?,Y1OCQ#K $+N >+AY-5GE]UGDH6>3I4?\
MU\2MVA]&UKM^-I87O$ ?;H4]?P?9A\? 0[ 8/H 0X=7C >.N]D;5R&[]:_\
M%"%]>+%AI,/*&7H]M7'BETC7PC8/C]G_ 'T@/QYM>DI?5*5;^Z?=[!J[^U87
M=3[\IKO([ZX=RO\ !U!Z U0*ZZYT1&B+K'LPTIF=S26_-W.+;%YA+44;B0:Y
MFX)3<BV\L[+^"3FMS $V!N7\$O(T,QY!HB@E[%/)84MOB<1V&TQ1<5=&6+V"
MFG;U3E:6! 5-9@8AVS2J+UI*,91+)*C[HN<HG-O1MP3N)#)(G!]H]U=P9V@@
MQ>SMT770VV0G7>OHDD0-D(2NKD)2AQ7] &I7RC1%^=8!HI%0$< .%.>!(B(
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)>I0F.,8S+__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>g425213g29c87.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g425213g29c87.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2:.4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )G*^F$(X0DE-! 0      #$< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<<
M @   IYP' (%  UP<FEN=&UG<B!F:6QE #A"24T$)0      $,H_/;Y#^.\W
MC?LK8JZ:0,(X0DE-!#H      .4    0     0      "W!R:6YT3W5T<'5T
M    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#;')M
M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585
M  $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3
M &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB
M=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !
M       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O
M;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
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M9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L
M      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO
M;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O
M<&QO;F<      #A"24T#[0      $ .__C4  @ ! [_^-0 "  $X0DE-!"8
M      X             /X   #A"24T$#0      !    '@X0DE-!!D
M  0    >.$))30/S       )           ! #A"24TG$       "@ !
M      (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:
M  8       $ ,@    $ 6@    8       $ -0    $ +0    8       $X
M0DE- _@      '   /____________________________\#Z     #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z   .$))300(       0
M     0   D    )      #A"24T$'@      !      X0DE-!!H      S4
M   &              %Q   "<@         !
M  $              G(   %Q                      $
M            $     $       !N=6QL     @    9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<   %Q     %)G:'1L;VYG   "<@    9S;&EC97-6
M;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI
M8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI
M8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   !<0    !29VAT;&]N9P   G(    #=7)L5$585     $       !N=6QL
M5$585     $       !-<V=E5$585     $       9A;'1486=415A4
M 0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4
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M971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M  $! #A"24T$%       !     \X0DE-! P     '#H    !    H    %X
M  '@  "P0   '!X &  !_]C_X@Q824-#7U!23T9)3$4  0$   Q(3&EN;P(0
M  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'
M0@               0  ]M8  0    #3+4A0("
M                                         !%C<')T   !4    #-D
M97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "&
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M+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                6%E:(
M /-1  $    !%LQ865H@                     %A96B        !OH@
M./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$  "V
MSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M%DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                              !D97-C         "Y)14,@-C$Y-C8M
M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-2
M1T(                             9&5S8P         L4F5F97)E;F-E
M(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                                 '9I97<      !.D_@ 47RX $,\4
M  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M   !                         H\    "<VEG(     !#4E0@8W5R=@
M      0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D
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M8XS*C3&-F(W_CF:.SH\VCYZ0!I!N
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! ?_  !$( &P MP,!$0 "$0$#$0'_Q  >   " P # 0$!
M    " 4&!P($"0$#"O_$ &00   & 0(" P@*!A$1"0    $" P0%!@< $0@A
M$C$W$Q05-D%1=K4X87%T=8&1H;/!%A<TL;;P"1@B(R8H,S5$559SE+2WX?$D
M)2<R0T538V1E9H65EJ2ET494=X.$AI.FTO_$ !L! 0 " P$!
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M4$PW>5B9;BUN1#/I.JX$9JD4 )4M>U]<D@TOIRKHQV3L=2[UM&Q=ZJ,E(/%
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MO]X1/II94)K=C5]E=,7[_E-\I>8'UH'Y6<$ _/Y]5<*6XYX+Y&R_S3(\>I3
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M>B\/O\_7\?7SU5PYZXX&_P#H?51OS62!P8ZC?[(\+OLE?X?.VO'._P"Z5O\
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M6W)NKIIF4J:%!$>M),>6W,A?/N'DY;"(CR\^E+0<XY!7DH:5%+:9[;U% :U
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=V2"+1FT;))H-FZ2:*)")D*4"*4T1&B(T1&B+_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>g425213g29e65.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g425213g29e65.jpg
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M 00!! , !0(#! 8  0<($1(3% D5%B$7,2(8(S)!<20E)E)R@:'_Q  < 0$
M @,! 0$              0(#! 4&!PC_Q  ^$0 !! $"! ,&! 0%! (#   !
M  (#$2$$$@4Q05$3(F$&<8&1H? RL<'1%"-"X0<5,U+Q)$-3HA=B-'*2_]H
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MIQ1'I0RQW<!8)("U6&=W'V/6H^^@ KN"#3N5B-*I$B953*+(H?L+N^== >8
MZ<^EA0^74-&]WE8=HRT#:2=/U()L[YA9:0-H\I+3NI:GZ,_4RM] LUT"%V+'
M7-<7XW<Z%8JYQCH;TGKZK!5O,M@L5AY9*"^4KZ$JY:QV@_Z5IK$6["+U+"AX
M'-CI3CM/K%>/]7O"A^?46.=8QZ'WV,\A EU):7#(V,<TACO/;8R2TB-P%N,H
MHAQ V6P %SO>ZL3")"MUZ>8'3A!:<#$S"@DHL>X3%D9,".].'$7!*W!3DZ%)
M6[&EK&+6/7(:<5"6J-MO>ZK?%D G!H6#SOUK"OF%*81,(F$3")A%X8?J9=+_
M %(:5U#J(OQ_7>KFJ89\<!8]*GT?GB+;!K7HF'T/JG1RQX?+W5S.I)F?QOD9
M+FB@\A^5&W<>H<AB,#VS5A#M&+MVXNKOZ?\ )OW6M'4NU+7/$(>6F#R[6;JE
MW/=8-<RQA91L;GQU1.=@//?8?18GKWHQ':J#Z)LC=<B>FKDWO^)GV.:#P?.N
M^643Y^YQQ$%%XV("]!.])\X/T.XP[%4>OW^PF;;NXUZY5*MGX,&.FIK%??*[
MSC-]@KQ/DWR"1LAKQ3^$A@#9"(VL&RG%T>UUM<ZW;@0"%IC'[-^J3,Y-1>6=
M$Y]VVG](B]$-S>A="$\F=M!RU_?Z3Y-Z/4*57[1Q(M8:%3.<MT#KOHNE2+H\
M3EN:@^=8-7N$P=:[ 3%GIH<QG'(D=;'S&#CZ\UB#]46-:YKVNW'<=EDVZ%X:
M#&2UK0U\C=Q)_P!.G'<:,DU7U!^J4:KHHR:XZ($%_P ^Y&K)58/ >WR2 1^M
M'>!,?XI?F6D)2!)&/,;MG4VJWT6A$^BU^T  ,F<&L9.;7)Q-2FY_.P+P3CGZ
M>MGYV;+JB 2P ^;<!&_!!C\MN#01;GTYMM(%@FK5'-]"?J;T6LRW:/PXU961
M$+HL0?6;;S#K=G,D"D[GOLCH(2S3KB;M9:S3X &X\DX95!5680[LPUUD?4!$
MB/-L5 B#F+R?]O;TOI[_ )9M'2:EH.QA=6Z@YCR2=DS@2Z[H.;&T"C>^ADBO
MMZSZW^H9_P!-/G2V<S:Z9 ZX=7Z35;W.(\5ZS/D*F!*_=4^<5VZ@WCSN6M88
MH8FPJ6Z?"7RB<KYR=N<HH/GW:F\\EQ++'C&?0CMRZ]:_/Y6DS]1X<9;O#W>+
M>QCS5!WA;FF,D$TVPX,:76"X-RLFMGK?WQ#Z'UR, XO?%<[J?8><P*O E>9>
MOO\ 1+-1E7#TU2.D5ND%PU9L7*34W;G/N"7^M7@[;H//)O-.AE)YCH]-L]B#
M5ND30[CYBNG>L9/2[QFE+IM0'.J-Q:'M_P"V_<6W*UP;6YA/EC<UQ=MV.)+@
M2 W[FNX?J%6_R#ZCM!NE&J-V*N],YN+YK7>9\K[-%Z$#K;O:Z^(Z8,'QCG'K
M%'Z&%%\Y:ESA70.0!.R,3QDT^9A;(/Q X[<5D5GWX_7[Z7@D9-08926EKPYN
MT-:_<&[P' >0[J;=.8'W9JR HKZ3T_W?8[-!@U.O^@)5+IO/IT( (@\P]#U>
M5T-!CA?'[ F^W/IB*QQBS3K2SV4OUV@"Z7(J/-;B(@4$19R-0!HMR&R2A5^O
M*_??K7+-]>:JYTY.!)M##0VR#=<;#N+J8;#R]H:0UPH$@ YSV#Z*_48J\L8
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MDNLR#:0T@-(<VB0:Z%Z5_4MJH,2):YS=.@6B-3>@E7UGO,718*+5>46CU?\
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MO#@!1)%4":PKG7A3U)7*OS"ED[N(9I?/P'%P<BG$.N]%NX:2=YC</(U@/VX
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M^F#-Y7>K9V"RD>:3)%5FQGZD)YBAZ'TS^_PH6J1QS$L<7/;1&X%[B20(Z/F
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MYK3M).QQH+U"XU8+':^3\XLEO#6*O6DW3*\1L(:W0XH^S0#$D;'60:-P(8H
MS"(*D[<=?B;KU=?C[<TS*KH&4AX1#A;3"2UI(() )!P03W%"OD#W .%)>%9,
M(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$49=KZ2SQKC?6NOR LZ
MR1^4\ROG27ZZ+5]),^S1JJ5L[H4<K;;VDSBB!:H,16V7?B0^WO[;GQ].RJ]V
MQCWT3L:YU#F=H)H<\FL87Y#/%GZZGOB_>I/(_P#FL10[SP+V?TZN<R_BE)YB
M-JHSCY3I!,F/I>^=]"3?S-XZ$NH.P=JZE(N%.T$%K%V>O0BR#(]$]G(6BC1R
M+/.['KV]/NN1#KM0Z6'Q UT<[@RFM #"XD-VNWESMM>>V@ AP!L+]+'5>_\
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MS?TW+'$[<W^H;*!Y$K+\*^7Z$CZJ7\P(F$3")A$PB81,(F$5KFG HR7!@$C
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MSZ W)'U6;R#J]*'4.4<B.6KG'4'X$_H=;V0."U+%'%]K'(9^N?O">!)O:[<
M [<X->X;C46<L/+8]H;8MKZ+AR6.@_ 7I$14OP9G:212R2Z=4Q)Z1$[YUB&@
MZ>$<S\MQ+ N3/M5'OPU(&S=CY'U:T62*]2Y+]GJ5_F!Y.A+]QL#0.;';'0>M
MXNC9H84#3R4+>2=K0?YCQ9#8KYM<*<]CB?+EKB,;C7K)0H%E%4:EC+F^$DW
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M8[U,.W233;OSERG62T+,_N]@BA(R2:"=;%.6AB0-=.W//.OWP/KW5KG)&XN
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M?'^<CH IRPO=JU=DQ5%X;3"0BJYH!N4J6XK\?[B'D_E;C:6J1N'O_BVJ3_\
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M:@4I1"!4N8"Y!F5T!ZQ7RZFDT:@5>YU2M#15P 6>+T,B!"7>H0H<V3#02_'
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MQ=*16H4)C[WV(D5G\F3N;(^U':;_ ")F_M_,M[Z$:^[)W]IKY?<^IW?VV_\
MG_P3\0K4.WK\>Z[IC1D_5],=A/U/?D*^EIO7U2/K^Y]]7PG7R]]>]K^[OY7]
M>_J^KY_O"4.WWS_/*^J$(;3I#:$H3K:MZ2A.DIUM2MJ5O6DZUKY4K>U*W\?V
IK>][_O>\(NV$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>g425213g37a01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g425213g37a01.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1JJ4&AO=&]S:&]P(#,N,  X0DE-! 0
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M;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0
M   !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "
M4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,
M8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0
M 0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP
M $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B
M;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L
M  !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P    ,
M4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX            $)L("!D
M;W5B0&_@            0G)D5%5N=$8C4FQT                0FQD(%5N
M=$8C4FQT                4G-L=%5N=$8C4'AL0'E>^>         *=F5C
M=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P    !,
M969T56YT1B-2;'0               !4;W @56YT1B-2;'0
M  !38VP@56YT1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O
M;      .8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L
M;VYG          UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14
M;W!L;VYG       X0DE- ^T      !  E,S,  $  0"4S,P  0 !.$))300F
M       .             #^    X0DE-! T       0    >.$))3009
M   $    'CA"24T#\P      "0           0 X0DE-)Q        H  0
M       ".$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9
MF@ &       ! #(    ! %H    &       ! #4    ! "T    &       !
M.$))30/X      !P  #_____________________________ ^@     ____
M_________________________P/H     /__________________________
M__\#Z     #_____________________________ ^@  #A"24T$"
M$     $   )    "0      X0DE-!$0      !     "   "0    D
M.$))300>       $     #A"24T$&@     #00    8              [<
M  @+    !@!G #, -P!A #  ,0    $                          0
M           ("P   [<                      0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   [<     4F=H=&QO;F<   @+    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   .W
M     %)G:'1L;VYG   ("P    -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $    !CA"24T$#      /Y0    $   "@    2@   >
M (K    /R0 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_;
M (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01
M# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
M$0@ 2@"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,
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M/W/2W_I/T>KB?:/LM/VJ/M/IM]?;]'U('J;?H^W>DI,HO>UC'/>0UK02YQX
M')4DDE/(]<Z_TK/%)Z=]8,;% 9;781>6RVX,K]1OI_X?'K]6[%L_P>1Z?YGJ
M(%GUB);-?7\!CV,?75^G:6G<1Z=]_J8UCG65,]GI[O\ A/47:I)*>(=]8;"U
MS6?6' #'AY(]9N\.>]SXJN^S.])E53FUT_HKOH?X3U:[,:5_U@998UC?K!@M
MQV,JVQ>0\O8S;<Y^VMKWUVO<[V/N_,K^@L[,^L_UBNS+;L?/JPJ2Z:\6P,_1
ML; VY.^I]F_3]99ZGLM_15_X-=YTS-^W]/Q\WTT
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MUOK7>NH?:MGTH_G#RR+[7&P*6;8>G]C5.?.P8JSE)OU7502-(IQY5X.R,9V
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MQ%GSELBS*LY0;^.*ZI$S2+\BG'"M<_0&.E]EV)(&SV16.A[SK7H-[(F6>%O
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M99L5H]A4=3!%9R%'J2%!('T^D3RS7"IE,8AK/7BF*(@8IIF. Q1#R$# +D!
M0$!Z@(=0^/)HQ,HC8QLC1[C\#9_5B M]3-WN[9Z^;N )C=)F.'NE 0 3&Z./
M( $0 1'H'40Q\URNW^QLCOZ?@;._U>S$]IJ[:OD$W3)R@[;*@(I.&RR:Z"@
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M.4Y:T"OR^JRM'Q\56<LN,EKA0]P$8M+U*B(O[*C/;8"NO:K855J2=G1(9O\
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M<^(N19CXCY"8&1D%-IC6W&DY3UAR:$<(+&VAJ/+Z,O+M?2%*VLK8J'UU-KK
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MH0XW^U/8CO[NP[?JDZ780@'NJY%_+[GM>_+]4;/^_P"?W?;FD_EN_P &\/\
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MJ1D7)E7L@\4ZJ.G:RJQ_,W0.3>3Y+,Y?/R>2S[FNRLJPV6.?0>Y:T7OTUUJ
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M=@21V[CWF6"]Y?X;?'\]4?D_JW:_PP _P9??OO\ B_\ R7_(F_TB2?N;C?\
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M<VAWINLR$ O<$(QO.J/[#,SHN48A1XJQ(F$L[<E;@F=\Y,840(*G?#OB8"E
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M_=*NI2].BP$KL,-'1!&P#^8GUV)@][S!PV_YU>OVKPV_AKX_E^+,T^^_XO\
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M1R-B9%(M17%=Z+B.J6H&Z;$#L%<%>HZW/'#M[>"G4 %'=0=1 //7\9Y=?C$
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M/HP2"Y48>/D%$&[4[QJF==P5)(5%TTR&,<1 *^RVJH VV)6&.E+D#9'J!OX
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MO0621U%#D,8;)FO<^-BFT':FVM]^I="$!)]Y(4G>]$[]TZZ^3#BN*XKQG\I
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M5T,5ZU*-KWHVNI?RZ'U3J/-XW Y'YK\^Q*<KYCF4\AA^<@?YOFX_5Y&35O\
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M(Z[&[O8V@ &=F('8=I$W6VVUEV9CU :;W $=AV ]-G0]\WSH[_:]C_T-M_\
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M$QH+J"J\=F [I\^>.U7#Z0?.!*0%7;URNN8B:2?B>&DF0L]55%5$4*BC2JH
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18B,1&(C$1B(Q$8B,1&(G_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>g425213g41a01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g425213g41a01.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[2164&AO=&]S:&]P(#,N,  X0DE-! 0
M    )#J^DG0X0DE-! 0      #$< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<<
M @   @  ' (%  UP<FEN=&UG<B!F:6QE #A"24T$)0      $$N#VN(%BQ45
M4"!=N_=0* TX0DE-!#H      .4    0     0      "W!R:6YT3W5T<'5T
M    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#;')M
M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585
M  $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3
M &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB
M=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !
M       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O
M;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
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M9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L
M      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO
M;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O
M<&QO;F<      #A"24T#[0      $ "4S,P  0 " )3,S  !  (X0DE-!"8
M      X             /X   #A"24T$#0      !    '@X0DE-!!D
M  0    >.$))30/S       )           ! #A"24TG$       "@ !
M      $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:
M  8       $ ,@    $ 6@    8       $ -0    $ +0    8       $X
M0DE- _@      '   /____________________________\#Z     #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z   .$))300(       0
M     0   D    )      #A"24T$1       $     (   )    "0      X
M0DE-!!X       0     .$))300:      -!    !@             "H0
M J$    & &< -  Q &$ ,  Q     0                         !
M          *A   "H0                     !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG   "H0    !29VAT;&]N9P   J$    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   J$
M    4F=H=&QO;F<   *A     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    1.$))300,     !G3     0   *    "@   !X  !
M+    !FW !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L
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MJGEL%HP:VP
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
M$0@!(P$C P$1  (1 0,1 ?_$ !X  0 " @(# 0             '"08(! 4!
M PH"_\0 1A   00" @$"! ((! 0#!0D ! (#!08!!P ($1(3"105(18Q%R)!
M46%QD=$C,GBQ&"0XN"58H28H-%*!,S5"17*"LO#Q_\0 ' $! 0$  P$! 0
M          $"! 4& P<(_\0 0A$  0,# @,&!0(% P,# P4  0 " P0%$2$Q
M$D%1!A-A<8'P%)&AL<$BT0<5,N'Q(S-"%E)B)29#"!<D-41&<I+_V@ , P$
M A$#$0 _ /OXX1.$3A$X1.$3A$X1.$3A%\U':;L9V*HW;[O+K^%-V5K_ *M/
MW[IW&]D.U-9F@Y.1ZQZFN>FPXN:7K*JGR#A==E+'-%LFWC:$5$%!:IK#IUZ=
MCI.90(1&Y.<D:XSN#J-!R\3^=.:HP-=ST.WOP_N%(?;[46Q*YLFZ7NJU:Y;
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MMUTACB82:B:R3LJGS" 9EGCCFB8(XW\,A&">RLM3V3N]UH+;6-OG9ZHK:J*
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MR1B0AFADE2!2DI42:1AK#I1&4IR\^MQS*<95XYM978\(G")PB\*_+/\ +/\
MMPBK\^&1_P!++G^HCN#_ -UNX^!I]?J<I^P^@Q[_ "K!.$3A$X1.$3A$X1.$
M3A$X1.$3A$X1.$3A$X10QNO3<7N.MLQ))N8B4CR\&Q<LV.@C+3OH4TXP2WZF
MUO"O-J_60EU"DK2A:%>4^,_G7\2/X>47\0K/%02U)M];23BIHJ]L+9N[?P.C
M?'-&2QTD+V/.6MD80\-<"<87JNR?:FH[+7!U5'"*F":(PU%.YY9Q-+@X/C<,
MALC7-&"6D$$@Z%:U-=8]SZHB7+#H?; #%X]I.)>MVNOBF4.VC#/_ ## )+.,
MYF(PK",NCM28$H*^VE]:E>M*<-JZ3^'O\/[C_"ZBJ&T,M+VJ;7S-FN]OG$EI
MG>(F.CB?9:YLE1'3U,;7',5QAJ*6I=PM?)3 !XYW:KM-3=L:B-U0R:S.IHW1
M4-3&6UT3>-P>YMPIG-BDEB<X8XZ66.:(:M9+_2I>TYV/;O$VYK?9=/E-1[DC
MA5OF5&<7\Q!V-D=339$K0+/AMD.QQ^5.H>^16@.>$87[I49@=M12OU*@NMLN
MW?"WS3,J:8-=6VBXP?!7JVAQPWXRB+I&R0$X:RX4,U5;IB6B.IXWB,>,GI:R
MB,;:R)G!-D4U;2R?$6ZMX0"XTU2 TM> <NI:F."KC )?#PM+CL]SG+Y)PB<(
MG")PB<(G")PB<(G")PB^;_M56KI/V6Z5B0ZB&V'78.\]G6BO7H;XL)FER+-:
M)]$&-8E+B1+9%R4 *V#&PQ VN""E1U,64\H",!7)$N$_/ /([G;&_/4G78YR
M,]0%K/4C8#!!VW'+['HIL^&!0VJMNNY'-Z(D=6J>UN:+F;,^)#+]Q$&X58H!
MWZ:G7AUMGV8%2\M?,?BW K3@V!\Q27\8E5H76[[$:>0T..6AWUSZ:$(=L @Z
MY. =R.OS&-/OB]3FUE.$4-C]B="E;0=TD-N761&WV$../:R9NU><O#6&6?F'
MFUUI$AF52^R-CYET;(WS#8__ #"VDL_K\F1U"+VB]@M%';0+TD'N'6A6X 6,
MD&:Q8NE?=O(S26$$K]ZLH/S+(<;&=;)<9R+[S8SC;ZVTM+2O-12\K\L_RS_M
MPBK\^&1_TLN?ZB.X/_=;N/@?O]_?Y0_M]O?X5@G")PB<(G")PB<(G")PB<(G
M")PB<(G")PB<(G")PBCC96J*1MB'9B+C$I+4"2@^&EA'7 )V DV4KP/)PDP*
MIHZ-.'RM2FWAGD9QG\_/[.IN=GIKGW4CI*BCKJ8N=1W.@F?2U](]PPX1SQD%
M\+]!-2S"6EJ&@-GAD: !RZ6LDIN-G!#44TP GI*F-LU-,!L71N_ID;_\<\99
M/$23%(PDE1A'2^RM+I1'WHB0V9KICPV+?QAO>N==&]7I;1<8P5.538C"/2A<
M]'-*,PG'NR##R\K>YT3[O?+ >'M!3&ZVQIQ_U!:J8B>%F/\ <N]G@#GQXT#Z
MJV,EI_\ G)2TK,D=@RAH+A_^FS_"5)&?Y97398]W_;15\F&O'_;#6&.7_BV:
M=V\U,WRE$ 1DHU;*]F/F<8S%%KEP6F3_ #Z<>D;+KR,N.)RK"5MXQ[C:\^AQ
M*5><<[D]I.SX@I*EU[M3*>N(%'+)7TT;*EQP.&$OD;QN!.'-;ES3HX Z+A_R
MJYF2:(6^L=)3_P"^QE-,]T6^L@:P\(T."="-02%E:5)4G"DYPI*L84E2<XRE
M2<X\XSC./MG&<??&<?;./OCG<@@@$$$$ @@Y!!U!!&A!&H(W7!(()!!!!P0=
M""-P1R(7GE43A$X1.$3A$X1.$3A%25\0S5-"L&R>NO5O5?6_IR_>NQ]XW5LP
MO:'8_3L1?:%3IV#@:T9>YR.J0CD.]:]P;#0N#0T@F7$<D8RN&F23I;<8VEO)
M&P'B1T'/KU\\:Z*@Z$DZ ;9Y;>. ,G7EZKJ.B>J2.I'=&9ZVW?3'3!=UN77V
M:VA6-]=4=&1^CK(S5X*[U>!GJ%M:ICR4]D(67DY:(EZK(@S#<?+N0D@TZ!DD
M!+C<&CMMQODG3QY;], 9"<L^(!'SU^^GU5YG-J+BG+?:",<%1[A+8I"QV_'G
MUOH:6II'C]OJ<PE/C^/"+Y$^JS.S*KUDZ:]J-LT?K3>ZM<NY<.)/P(%0M8/:
M,/=%[VE9JBO;1&[!+FP[,VP"RO.MV/6I=7S"M44544^:2V#E+?R .AP#K@C&
MO0Y].IQ] OH=21DZC(R0&XW]D>/B5*-:KE9%^&_UBW>!#0O_ !2R/Q*:]+GW
MM((?Z1Y';LYVWM=5OD(?8,(^O$>JFYFH V'?,6.BNQ[(2F,!"LI13_2#IGBS
MIUR?GT0:D@_TXSC7&-"#OOS/JKX=K[4[CUN[R\/JCJA3]F489L+,3<Y;L' T
M8Z46\$PZ<AVLFU.3) P&:M\1"G#'<$H920GT)=PC&\G73RU&OVV6/4?7]E$G
MPI#)T_IS%&V:&8KUA+WIVQ)FH,:3;F1XF4?[0[==D(UF599':D6@3%OBMFML
M-(*0RDA+:$N80D-ML:G[E#CEM@>&P'V]Y5C_ "J)PB<(G")PB<(G")PB<(G"
M)PB<(G")PB<(G")PB<(O"DI5C*58PI*L9PI*L8SC.,_;.,XS]LXSC[9QG[9X
MWW153=FM-7('9Q,C3J#+R%5L6 2(W\(Q+QP <NXPTS*M&A1_N?1WB3&U'NF/
MCB1SZ7\N*)]]+V.?R7_&/^$':N_=I/YWV4MM+64%32L[^EIZF@M\E'50@]_,
MZ"IEIFS&J_3(98.]F?("V1O$&%W[5V#[=V6U6HVZ]5,]/4Q3.[F=\%35-G@D
MP(XQ)"R9T0IW%S1'+P1-8[B8=78WHZXSS<[J*J(<ETRLM!C.5^P-K4Y\]#S,
M6XIDF$DVW\)(;.C6\LL.9>1CYA&&RF5.,/M.K_H;L%&^+L7V9BDK#72Q6BD@
MFJ7<?$:B",0U,+Q)_J-DI:B.2FD9(!(R2%S7@.!"_+NT4C9;]=WL@%,U]?4/
M9 .$AL<CS)$YI;^DLEB>R9CF98YDC7-)!!4Y<]<NF3A$X1.$3A$X1.$3A%\V
M/Q0.JO6&J[;I2:1TU,[(]C=TIW1OLM-L[+[FUO4:Q#:?AHZ>NMJ!S$6@YD*Q
M%$V.-C*W#5J(CTY?,=PET09O.,X( ( !YD:G3GH!CY9'+KE;;G!U  P-0-<Z
M#/EOS76_""CHB![2HG2NJ&O>O9_8#J'';CH6P(+L9N?>$]MVC.VNGMOQ:T;
M-?C(UZC$2L>BPBR0[,['DR<>W"N%11$H[@-#IG!&1N>GI]_/7".VQG)! .F
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M,^D"E2<D(XC#%9E,.1GL.SU[C_B%9OB'1"C[86OO*.[6Z1P$U5-1-#:BG=G
M?<*=G#+3R ?^IT+HYF%\N _SUSMS^REP=&)#/V?K2V>AJ6@EE,RH<3'*-#P4
MDK_T2L__ &=3QL=PQYX;&VG6WFVWF7$.M.H2XTZVI*VW&UIPI"T+3G*5H6G.
M%)4G.<*QG&<9SC/.$002"""#@@Z$$;@CD0N:"",@Y!U!&Q'5?OD1.$3A$X1.
M$5/G:_MW\1'2/8&KQ=!Z<ZZM/6L=N[KG-I6?L+2Z/%3XPD-"D5PR9L%F!!"U
M*^'*$R V(^?:E\6MQ&6(HIG(RG'<N<0=O7EZ],=-2?!4 $;Z]/>Y/+;'/QF+
MK#O'N[N_=*3MJZ5T[I#0D+K$LTH"K[XIN][E;[S9I& .HTJ&;3! AZY56JJS
M/E>LY#R9U<@ 0"XIH=2L@2<?T^.-^?OYH0!USXC&GS/-60\THNNF)4&"B92;
MDW5,1L/'&RL@^EIU]3(4>,X64ZEEA#CSRFV&7%X:9;6ZYG&$-H4K.,9(ODLH
MWQ#=3=A_B<]-.Q%FWB7&CS<[V"UEKS0^8NYAQ^KZ+*4T:$UL=;P7(%L$_:VV
MK:>4;8"QGC!:U$-5JO/$"IC3B7L!P.NN^GARZ<\ZXSN/!?0M/"0,?\3G.^N3
MZ8&!UUZK-ZQ3*W&](>NW?,2*'SW,M?Q J]+6;;:,NYV'82+EVBG]76?5DI,I
M7B1-I0E"4JL-4EYQ<($%!AK: :($2\ER!QLXDCGN=//;Y:J#&2,X&,;XVQMO
MOK\RKZ]K=GME:[O$O4:_TR[)[9BHUL%0U\U_^B'\*3&3 F"WD1WXHVC7)OU
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M!5/L0Y+A:IUX;*5RY$0<-(3%'@#KP%'9E,"-"@6QP'Z\,H9M64P^$%*P -[
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M,.75!1L#YB?E\9+PYDCIDC<;ZDC0YY =3TU)Y7H#@;9QIIS!VU.GAC70:K[
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M!WZ8QD>H60E_&_\ AWB&;;#SM:PD9U+'@GJ(%UU='A-C9-BW)+ 6K'\1&$W
MX5;>(TUEK B1Y%QMI3F6<Y?Q.-OC[]\\?9.!VFF_[X]?3/T*]HOQNOAX%3.J
MX;]+4ZPK:<"=/(DR=>W-F(H'R48Q)?1]FG9B,HJ,X7EY8 8#R2?>D6'1LNHP
MIE;MXAU^VFF?>,ZZ)PNZ?/G^/0K'3_CN_#KCZ/<;R[L6\.LTZZD4URMCZMNK
MENL*!Y(>/S;JO"9BTKE:6XV^N31.>^QC$:,0\X.V\E#"W$.O+/+7^_@<)PNZ
M'?&H/OSZ+,&_C7_#H?NI=.%W>\6,-0F;\S=Q*5<2:%)COOJ:;K438VH931]O
M4SA!B85EC.5C.HRV0M[ULH<;?QGWTY_XRX'=#[QCYYT735SXXGP\+'!:QG,;
M1L\)^DR;D(1,38-<W*,FJ(J.8EWE2FQP%13N:Q"F+B4C@2*G"VBG9.+4C&&"
M7'F7&WKY^'/WZ)P.Z'W_ (/R*X!OQT_AWAUG9UEQL:Z%XUG9LUG,$'K"Z.V*
M^JP0$-B=UQ&*BV\V>N*68ISZLEX1O X99"FTM(:4\XQ_;3_'IG*<#NFWO[Z9
MV\<:K(GOC;?#D&OL)0R=XO"JGJE^*A+<52KB-262%.)2S3BYYZ&1AB\$-9=)
M:KGRRR,LCO86XA["&EN(?O['WV\4X7:::G;WU\-_!8N+\=KX=Q-*JUT_2%>A
M\6F[)I6*N3JR[-W&O^J1)C\VJSP>(M2XFFH;'Q(JFU//8^0('7@?+ZUCMN(>
MR/W^WY&7"[H>?(\O#<>H"R$GXW/P\!IS:,)G;4X]G6$$#.+E1M?7-Z&OOSL>
MZ?F(UJ>B(]-KF@\H0": T@7+1[R&$..I2\ZTXF]?>WOY[)P.UTVT/OWL5Q@_
MCA?#P,)U&-^E2QC9VV$6:EXO75S9&US\I&ID/E=J/?25)IYA+BOIPC+GSF'I
M#"D86D?'S/'$WKSQ[\/$9\$X7'D=L^_OY:K87JM\2'J=W*NU]UUH^]GRESU^
M7,9-@K!6INL&S]=A3H^,)O%31+B#XG::](2@(@TPQE&5ND-8<&:2ZTI8.!V]
M^\J$$;^'UY+>WFE$X1.$3A$X1.$3A$X1.$3\_P ^$57D'\+^H0NP8)_.\]K'
M]<:EO [LC3^J)0E-3KJ W =-2-HQ)HM+,"B^'U&.MLO*6N)HILVY"@SI27_+
MHPHPC>>'7.3OG'+/ATUUYK7$?7&,\_V\.OBK0E?EG^6?]N:657M\,P8=WJTZ
MIQAES.>Q/<#/J<:;7GSCM;N/TY\J3G[I\8\?N\?;[>.0?O\ ?WX]=4\]\#WK
MU4Z]P:1,WOJAV7I-,@%3EMN&B=K5NM0H# _STQ/S5'FXV(C1?<RTWDDTTA@9
MCW'$)]QQ.,K3C[X'8^15;H1YC[K/='ULNNZ7U# 3T4F/G8'5]"A9@ EEG)($
MI&56)"D0GLI]:?=&+'=9=]"U)RMO/A2L>,\#0=$.Y\S]U)_R8GCQ\J-XSGU9
MQ[#7CU>?5ZO'I\>?5]_/Y^?O^?*HO/R@F,Y5@4?U9QXSGV6_.<><Y\9SZ?/C
MSG.?'[\YX1:3]U]8VW8(/5UFC54B?53.YG7V_P!H1',#?^"TJK3DB189XO#B
MFL8 BQWFW"?;];GI7CT-+SYQR'EYC[C/I[Y*C?T/V*W7R$'GU8R(-G"_\V,L
M-9]7V\?K?J??[?;[^?M]ORY5%Y^4$\X5\J/YQC.,9]EOSC&?'G&,^GSC&?&/
M.,?;/C'[N$7CY(/QZ?E!O3Y]7CV&O'J]7J]7CT>//J_6\_GZOO\ GPBTOL^L
M[6;\0+46T!JL^]KV$ZJ[LI,S9TL#9C K58-FZ;F(.$(SE>'OG)",@9LP;"65
M-Y9!)]3B%>E*\Z\0Z8^6_P ]OLKR/F/L>7/SY>JW1^3$_5_Y4?\ 5QX3_@-?
MJX\>/"?U?MCQC&/&/V8YI1>/DQ/&<?*C>,Y\YQ[#7C.?/GSG'I\9SYQC/G/W
M\_?A%Y^3$\^KY4?U>/'J]AKSX\^?'GT^?'G[^/W\(M,^F^L[304=G\72JOP&
M;AV\W!>ZK@]@7.)>H3HE4;A9X'VE.^ CU!&)8]?MNXRRYZFT>?O!S\3XCI[R
M-U3R\OR5N9\F)^M_RHWZW^;_  &OUOMX_6_5^_V^WW\_;[?ERJ)\F)YQGY4?
MRG&<)S[#7E.,^/.,?J_;&?&/.,?NQ^[A%'NVZ\[.:IV9!Q$6V=*S- N4;& L
M,,^\9)2%>D10AVL*PE/O$%/-MHRI2<>M>,J5C'G.!V/O[(HPZ<4>;H74WK32
M;G +@;?4=$ZKK5GA3V!\'Q$["TN'CY2,,]K+B/F CF'V'L(<6CW4+]*E8^^8
M-AIR^7@J=SSU*V0P&'CQC HV,)^Z<88:QZ<^,X\X\(^WVSG'V_9G..51/D@\
MX5C(@V<*SY5CV&O"L_;[JQZ/&<_;'WSY_+'[N$6E7<O65LO\EU'?I=5(GT4;
MN#JV]VYP!@;_ ,#ID- W@:5G#LN+:SB/#(D06WO;]QSUD-^EI7WSB$9QX$%4
M<_$']_QIXK=7Y,3QC'RHWC&?.,>PUXQGSY\XQZ?&,^?OY_/S]^51>?DQ/O\
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M69.9&Q$2[K0PIOL<SDGEY9YZZGRQCESYJD8YYZ^!^V_3Z*1=\](-$;SHQM%
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M/[OM% U[5]L[!BPDL'W,^DQ+S+.22<H;<=CQ)24G"8UM3;>6FSU84G'A*4;
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M40T=<HHO($C5"3\F>PFQAFI4(1"86J2;)2IG(WN8RG'(9:KF^>.E9;ZQU3-
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MA+I49C&<G-#^,^.=+:;G#2-KI;?5QT;PPMJ7P2-A+9/]MQ>6X#9/_C<<-?\
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M<9&]R98'8+G,#L4]%5M9)9HH6S<=X?65;JHR0T]1!24EN>_O)&0RD_%5KFO
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MU\5H_)C56W6;;]G.V=LUW2<[O?KQ?%]CZAIV*8%B)FN4^\ !ZZEH*;JC]4_
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/?><*#\GZ$J6N%4X1?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>g425213g41a02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g425213g41a02.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2#L4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (-"^A  X0DE-! 0      #$< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<<
M @   @  ' (%  UP<FEN=&UG<B!F:6QE #A"24T$)0      $$N#VN(%BQ45
M4"!=N_=0* TX0DE-!#H      .4    0     0      "W!R:6YT3W5T<'5T
M    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#;')M
M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585
M  $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3
M &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB
M=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !
M       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O
M;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
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M9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L
M      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO
M;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O
M<&QO;F<      #A"24T#[0      $ .__C4  @ ! [_^-0 "  $X0DE-!"8
M      X             /X   #A"24T$#0      !    '@X0DE-!!D
M  0    >.$))30/S       )           ! #A"24TG$       "@ !
M      $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:
M  8       $ ,@    $ 6@    8       $ -0    $ +0    8       $X
M0DE- _@      '   /____________________________\#Z     #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z   .$))300(       0
M     0   D    )      #A"24T$'@      !      X0DE-!!H      S4
M   &              %Z   !O          !
M  $              ;P   %Z                      $
M            $     $       !N=6QL     @    9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<   %Z     %)G:'1L;VYG   !O     9S;&EC97-6
M;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI
M8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI
M8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   !>@    !29VAT;&]N9P   ;P    #=7)L5$585     $       !N=6QL
M5$585     $       !-<V=E5$585     $       9A;'1486=415A4
M 0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4
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M971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M  $! #A"24T$%       !     0X0DE-! P     %I@    !    H    (@
M  '@  #_    %GP &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@
M  '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,
M# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.
M#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M#/_  !$( (@ H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
M   #  $"! 4&!P@)"@L!  $% 0$! 0$!          $  @,$!08'" D*"Q
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M#_3]5]SOTK'NJ_6/5]3T/^M+T##SL+/I]?"OKR:9+?4J<'MD<MW-_.4D\4H
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M*NACI?2:OK!U>NTO^T-&-T\PSU
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #^ 2H# 1$
M A$! Q$!_\0 'P !  (" @,! 0            @)!PH%!@$#! (+_\0 /Q
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MFPM-.V]LS8SFE(%\KG9C:X-J#Z5Y*HXO012%WLC://3C7(9'2.$SK7REX+6
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MMH3S %GS9FLW3,(%56*80 :2QCAKB'!6LEQ?#*VEC><K9IF%\5^33*TO8UQ
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M9AO"*SOA%^%%$T4U%53D222(91510P$333(43'.<YA I2$* F,8P@!2@(B(
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M"1:)@TD);'Y*\65E2=7^.<+HN#U&<"FO6BR7L1UD?JND6!8)MW]W/GMKK?\
M8HJDO#SZ[R-I[$YC8XW0,)JUKPR\6NY:G//4]NH7B#;0QL+"S,VM2[%Y9I+I
M".8U]XO-M9*5FF;VZU686@F+FE'B6_M'0@#:QO:]SXZD6L=SX$)VK:'YR1.$
M3A$X1.$3A%6)>?UP77G^0CL9_6S#>$5G?")PB<(G")PB<(G")PB<(G")PB<(
MJ*.S;>1:;EH*$B#HO_WD73$KA110@,7K9!R@=KZS"4K=0%!,!4O(A3^L@@!R
MF /S(Z9X:N#I,XLCJ^O .).GIFS/>\"EJ8HIXG0YB0(GA^8-9]$',W<%;<<
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MH(IV1$0S05#P(0X1MEC>]CB]T8<!Z'&W1KAE#A-3BV!]?!)0L$M1222F:.6
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M]>!U\45E.Z[O1.NM%-HFBMKTZKI9>/A!2SS-;_JUA^-DP7%L8*IFU<M%D%D
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M?4G>':;A[G[>>W"\]9J\N)O@S85UZK2\.3756@@) 4VW<+9".H!\)!,O3JK
M&24$K@0!Z]>:; CGH#SU))^ %M.?N4[O"3L>,U;HY(:Y>K-2H?3YR[:U;>WU
MMMLG$L)^)T]/0+2A.Q^D/91<CN+) 1;=C&P\?+'1;MX1%F+%$$%R^LH</I6
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M+P8Q2%$QC%*4 \Q,80 H!^\1$0  _P"1'A%ZP<MC"!2N$#&'[ !5,1'Y>?R
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K6,C?SKY906!O>*U]W+]U)-];:D6)OW6VL/W5K7"XIPB<(G")PB<(G"+_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>g425213g41s00.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g425213g41s00.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[16"4&AO=&]S:&]P(#,N,  X0DE-! 0
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M;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M  !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$
M8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'0D,
M   #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M  !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!L1?/
M    "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S     %!G
M4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M            4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN
M=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E
M8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R
M;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU  (
M 3A"24T$)@      #@             _@   .$))30/R       *  #_____
M__\  #A"24T$#0      !    '@X0DE-!!D       0    >.$))30/S
M   )           ! #A"24TG$       "@ !          $X0DE- _4
M $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $
M6@    8       $ -0    $ +0    8       $X0DE- _@      '   /__
M__________________________\#Z     #_________________________
M____ ^@     _____________________________P/H     /__________
M__________________\#Z   .$))300(       ]     0   D    )
M"0  "1(!   PS0   #/X    #*,!  !H!P   &M"    G)(   "?R0    H@
M 0 X0DE-!!X       0     .$))300:      ,U    !@             !
MF@  !98          0                         !              66
M   !F@                     !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   !F@    !29VAT;&]N9P  !98    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   9H     4F=H=&QO
M;F<   66     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    7.$))300,      I?     0   *     N   !X   5D    I# !@
M ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1"  N * # 2(
M A$! Q$!_]T !  *_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+
M 0 !!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,
M,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C
M<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=4
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0'_P  1" "N E\# 1$  A$! Q$!_\0 '@   @(!!0$
M              D'" 8! @,$!0K_Q !N$   !@$# @($! X+"0@,#P ! @,$
M!08'  @1$B$),1,4%4$6(E%Q%S(U-SAA=':!D;&TM;8D-E)R=7>2H;+!T1@C
M)28S-#E"LR<H97.&EL3P&45&9&:"DY6BIL+A*41'4U978H2%HZ2EQ]?Q_\0
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M?*W8*38( T1D6YV*#QE7&=<M$T[3B,>+&=NYMRBM*34D9DW>:DND&V<3ELY
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M'@IC@,*XBJM[=Y/K.-J77L@O:1"8U=6Z%K\;&3:E K3CUF!IX.V:")DZ_$K
MD+*-2 C=$C9DB4GH6+--"%,*/HW:%MMAK_(Y2B,3U^,OTQ=%LBR]D8.9IJ[E
M;NX=)/%K+)-T)0C!])JKH("=5TT5(9)!!N)/5T4TBD4SO:34I&VUZ^/J_&N;
MC4X>R5^MV-5N R<-"V]> <V>-8K@("DUFUZM757Z? @L>'9#R'HNY%$%\VD[
M9\H71?(N0\(X]N-W>%A4I"R3\ VD)&49UU5JO"QDP=;E.8AF#ADS<)PDFF[B
M%'#1LX79*K()'(2,^.:P1EL;V_K9JRGGBYT>MY O>2,D4G)#)_9X!@Y/4']
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M-;JOSKJ(Q[9!FF8K=%-,I%CD'B[&=8CTXFM8[HM>BDIY&TI1D'48")CTK.V
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M2J]/4TL8+Z2M!(ET$HS,]1%J:-D7@^C("Z'0H*K0@"H!A'H$0X^-KTW1+0N
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M)CK KI8J8&+U2XEZ@((B7XO2' =0#SKPM'IKB:U6E2."IM]8]K=8.=,$AI<
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MI3.YIGSUJPGAN?4S+/W?3/S">U@/25\[HKEB_P 3#KEP7LD_X7>+DN3(W 9
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MVY\CENV;^ZXY22-A'"XOO,<(GKLR'"4M<Y[$&,YG(S(8[($E2:Z\NT>,4I"
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M1002*5-)(A$R% I0 *G,<_<5R-R?]4?>:E';] XW"R9OEIU5'C]XA*&#\?'
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MU<9'=.>43.:H8O8'E$V@@;;DB (OU)BY7K1A&MW+U=%F@1JF=118_HTDRD0
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MPW.OP]?AXUO3YN91L(M.^9ME('B#NC.ZI<S?:1 SM/$1O.^.,)@4O/Y!EI/
M"LA34HR D;%6Y-U*SEG3"YLIA[BNX.WD5,U1E5V\6F^9NU5V4@X:SR;?UE)5
M9LQ22$C<M#F.?N*Y6^R[?JB?_,V\[;\.*6KOS#C<')#_ *WP-JPB/RB5O*&
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M'2%1@&D,Y!L5FH",?*SJ8KJN4?6 3;I+N>K6S/\  K^-+;L7,WV3E.NR]_\
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M8(!UFAID R(=:X[-VQ6(\-TH#'94 >1 '504#J,8W!S(V#DP<B/[DO;R#CL
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MP\7#P*H9E_Z[.3/O\M/ZP/=>_P!$?JC1WV##?@,7#5^>J<_>Y,0I/^CPL/\
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MW;XQN20-RCK(I2EEL1E* %*7)R!2@ < !0H5]   /<  ' !J#FWG[BK-R?\
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M/&%OKG0(R[+\=ZMYX<0=5.R4'_A3"#_)BE3?S\<:\GZ1A..T>-^#J#_UBN?
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M=<P&5:II\)I)G4-RH ])>P?+:K@M(TZ7K:V#QV#9MJ8C"5&-$DM$E[&@$D0
M3>0J4-(8+$5#3HU15=E UF[ 9$@;#<#CG"4EOO$1W"OA$>1^"-='G[?JZO?S
M'\H_/K='0*?^CM&3K']+Q +HC6_M&R8V3NV9+BQ?SPV6%MUG*QOAN?4_*O\
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M/_+\!K_S_P"?)CG6K,=_O$I?;='_ ,NWWK)"V&$_W1V:P]R48U_SQ'[M;_\
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M30O$> ?96(1]WK5O_-*Q_8/X]:M]''TK3?U<!X8S\EW\;\W1^J[[S57S8?\
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M9T1,>WC(_P#+AN^)ZER80SK$'?XB_<835N0^4/QAK5J[JAO<*(#A#*O @/\
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M>!8 2UK8 (N"Z9H4J=!KVL!^6;DP,C(%@)M>_/<KLCC+( ^>X+(W_-C#W_\
M6W'\VL- SB^]<JQ^U82MULKLS5YK/^2UHJ>C'D4_32K>($53-'C<Z"Y4ED\:
M]21Q(?@JG?I'N'<-<^$Q-3!XO#XNEJE^'J"JQKP2TO:06ZP!:2 1) (G+(E"
M&D$.$@\8Y]J5KB+;_A;).;\GX>KF2\_,;5A-[#J3TI((X,/$O5'<DX9)G9M&
M5)>3\<1)VQ4] G;H2LGGV?\ A6LDFH@3/@]A4Z=Z9>RHQU/!:M1I9 IU@6AS
M2"0?7F\;23LL-G6;AZ6OK0[; )$6,?W01%HVYC8"K5[R,5QT;AVQY%RQE7/=
MKJV*V+ZW.HVAU3$"DV=J5-)"3=D0-06#<[9@S*9\]7=O&R#-BW=.CJ<)B4?/
M:$TSCM!5\15P3<,XXF X5Z=1P:)U@&EE6FZ <I<2<B2N=[:;VP66 S^,C;.R
M!O@J$]MV)L=AGN;@*+D?<+7+14HZ_)0%DL,7@QY6;JSHEH1QCE%2MHM:<]G2
M%I5VE&U:D!M$-7%'[ERC)5PDQ% 9\GD-*]*]+:6T?4P&+&%#*M1M1U2C3J-J
M#4<'-9#JKF!I(!)+2\F^ML7%2H46&0UQ(,W-A(B+#C<3SR64;A\"5R1RSCY#
M(%\W&S]DRX[G*= S-8K^'4*RV>TZDV:\-XV;=N**P2C9":A*Q+HP:"1'9GSU
M%95T9DQ;NW:%=$=*M+:'P;<'AFX)S&5ZM9KZE&KKQ4<7:IU:S08$ N #K3(R
M4UJ-&K9S2,C(C(;,NH3R$K*=E..(J9QW9;GBC*6:ZHE)6VPUBQ0-L8X"G7S2
MPX\F9>MOVR$O4JC9ZI)-R/D7J(/Z]89AB=4%&BKA.09/&C;IZ=TWCM.NPKL5
MZBF["->&>I8X!YJ027A]1^T"S=2P$1)F]%E*F/DM)M$DGM%A)',C/>JE9DQM
MM[Q?:,L(94RGN&J;^I'Q3-/)2::85BX.X2.=;)9X*KH4U\^IC9L^39S-9F@L
M<A(FBX2O,X^1>R$H1G"3B\=G*'3G3M&CAZ+6:/=3HT11)-&M+PQH;K$BO#3
MM  )-VKBJ4:3W!VJX.:) $29BYEIOE,9737,)X;D<>5JI15;S3>;!2XA59TR
MBY&+Q>NPF&+UV[DCE5E(>AL) [1TNZ,LBXC9!L843IF0<>C$HF\OI'&UM)8Z
MMC\0&"K6# YK&D-:6-:P%LDN]AK6W<;<;KG8 &@#9D29^&V1LY9*SNNFI1HB
M-$1HB-$1HB-$1HB-$1HB-$1HB-$1HBAW.6&:?GBC+T"[.Y5E#KRU<GDEX<T0
M9TC*U&QQ-KA'!V5@A[!7Y9NVF89@LO$S\',0\@D4[9['.$U!*$@D9*" <]E_
M'/@LCQA1*SBV@U/'=06>J5FC5R"J4)[2?GDWR,36XAE"QJ3MZH!3N'!&+) 5
MEC$(*RICKB4!4$1A ([2>U1;D_;-CW+UE=7J0F[C 6]2+H4;$VFG33!A(UM;
M&UBM]CK<M!!(1$Q'DE <WJS1TH,BQDF$E#2)HYPP$A>L9DQ&SXQ\/%(!,Y^9
M]_FRF/']'K^,Z+3L=51!=M6*+6(.HU]!TY4>.TH:O1K:*CB.WBW*SQT#1JEZ
MR[6$5G*_I%UC&44,884Y*M;'9_B&-L&,IQ"RWCU?$MIMEVJM>7GXA2%2MMNL
M-YLDO-KJG@/;[)R#W(%A;+MX.=A6,M%HPS*T-)U& BQ:S)B/CNC?_39"H&B;
M'?NV'D,CU9; %/N4J)5,MX]M^-+<X=EK5SAW4#-&C'A&4@5FY!,RHLW:B+A-
M%<H 0Q5!06*7_6(/<-0+$'<K&(-^'GS;:HCQ5MBQ+B#)U\RK5'\VK9LAN9M2
M2;RCR%/',36>X2]\GDF(Q\'&R\@:1M\Y*2B2]IEK&]B$W'L6ON8B!*2*"29[
M .Q  -O;Q\?.X19Y-0BI0.F8IR"(@!BCR B4PE-P/VC (#]L!U"E;"N$#'.F
M54ACI]SD >3%#D0Y$ [AW 0^<!T15KR!M<Q;D+,F-LV61Y8$KKC5-!*O(-'T
M.E&/"LI9698BY3>PKR79J-I5XHHZ4K$O7SSK4Z,+:!G()!K%I3)B-G(>=@40
M)VSOD_TV[>62LHNB5PD9(QC%*;I'J(/!@$IRG 0'@>!Y*'?\7?4*54"H;*<.
M8\L5#LD%+7IJACQC (Q-?>6-FO6Y"9JE<N52KEMG6AH<CU_9(:JWNS0K=9*1
M:Q*C-9BZ?1#J0A(E^QL7$SE?AE.<<]O,JNJ(.?'CMB /"^P&%/>1\<U7+E26
MHUD</CPQI2J33@L2[1:O!=U.SPUNA>I<S=P":)Y> 8G<IE3(+AH"R)3)E5 Y
M8!@SNWJ2+1EEEP6*XPP/3\1V[)=[C)RTS=CRH[AUK$_M,C%N 090#R?<P44Q
M)%0T*5="+4M4FS;RLZ,U9UHL(F%>S[N(@8)C'"2?/GX(  ;;?,^?>9Z><-ON
M,L\HHL\A+S!2(T^]TM(D5*HL "'R WAD)U0Z3AH\07=I>PHU5EZRDLSZB*H/
MV,@S<*M3@2)XQW>?@A ,</.>=N!6488Q?3L*T*+QQ2WKY[$1\C9)GUJ35C%'
M[Z5MMBEK;/OU48.-AH-BF^FYF2=MX^$AXF$8(J%91,<S8MT6Z<&Z",I\Y96M
MR$*6-%*-$1HB-$1HB-$1HBAK.N#ZEN"HBN/KFYE&40I+1$V1S$)PB[M&0A'Z
M,@Q.9G98:Q5V00!9$/2LYF"DVAC>C<IH)/FK-TW*/S\^/D+,<>T6&QI2ZO0Z
M\=Z>!J%>A*O"A).UY!^6)KT8VB(TKV0=**N7[HK%H@1P\<',NY5*994QE#F,
M+- //OW]I*B7+FV.D9AG_A9+3EQK%K;L:FSAK+3Y..82M>4I[B_'CW\1[5B)
MF.*\>,,F7&$DQ?1[Y!Q$RIDDD&[M%%XG()&2$ Y^=_;M4OT.CU_&U*JN/JFU
M,PJ]+@8BLUU@951<S&$@F3>.BV0KK'.LOZLR:H(BNL<ZRO1Z14YU#&,,*57Z
M5V?8YE[#4I]S8+P1.GY.L>7F$"21A5(-Q>;'<)"]*RBOK, O-QP,IZ3=II$K
MDW!GDX)9:MV-6;@UUV*DSL\[E$#W7O:WP4T94Q=7<OX[LF,K4K(IUNUPZ\'+
M&BW!6D@9BX*0BOJSHZ2Q45A*3XIQ24*!AY$AN #0$@R$@1!OSVQOWJ*\6[4,
M:XBR5?<I59S/JV#(3Z4?2S>17BACF!YVX3E_FTX\(V)C)!][2MUBE9,'5KD+
M/(1359."K[R'K[=&+(GW=T@=R@-C(G;WQSM;GQ5G-0K(T15ER#M3QSDK+M%S
M387MB2MN/S,#0[>.<1B,4X-$2LC-0YG8NHIY-,#,9"5>*.?@Q-5TMC:F2BK>
M6Q0S5I'-YDQ'F\?!5U1)/9P-[[B;VD*RPIB9$4A.;D4A3%0. -R)>D3AQV W
M^L''8!U"LJB$V4XF3NU2NZ<I=DW-6LCJU+PJ<TS+!6N6#+%LS?7_ (5(&BC/
M7;2EY,NL_9:LVC'\2""[DC>8-,M4B(ZL7&^P'8.4>Y5#0+YFV?B.9OS5@LG8
MZ@,LT:>Q]:#/2P-B2:H2(QRR;=X*31^UD4P07417*D85VB7)A2-\7D..XZ@&
M._O4D3YW+ \;;?:MC/)F4,KQT]:IVU981A6<^I8744NV81==EK3,P</%>S(>
M+=+,(AQ<9II&K6!S/2[&%]EUYM*I0,)$1K,3LMYM/Q0".6P=<^?S*[.;]OU
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M-&DL$RC9+0%7KTB_<0M3^%UE;H62V!7F4<%CGD4I66!T[114328CW>>/:5
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M?=?$:IN/Z_4;G<:=;:Q2[+EVU8LDYB<CU8F5IR-:HSBS(V:R5B18H2":4U8
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MG<'4.*1N'?\ %5A\YB)[NPKTW&V[<8Y.0RV_#,RO2 %ZAQ%M4+VY$>!*&#
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M(C1$:(C1$:(M! !\P ??W ![_+WT1;033   "$      *4   [    <  !V
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M*0I>/+I* <<^?D :(@4R&YZB$-SSSR4!YY\^>0[\^_1$%*4H !2E*    !0
M   \@   .P>X/=HBT%-,1 13((AY")2\A\P\=O,=$6[I+QQP''R<!Q^+RT1;
M?1I@/()DY'S'H+R/X>.=$6X2E$  0 0#R 0#@/FT1;033+STID#D>1X*4.1^
M4> \]$6HE*;Z8I3=N.X /;Y.X>7VM$6A4R%'DI"%'OW*4 'OQSW /?P'/R\!
M\@:(M^B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1;%. 34$>>
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M[L0Q-SJ^5<GKSLHTGK)6X^.J]0QEB>;GI<S$TS8'\G)M(:(C73]N#)] :8S
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M1!L14Z" @*+8ZA$2JG;I?'!- ZADB HH)2=1Q-HFJ+;8CN_KEDMOP9CP$#%
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MR2=E^.=\_P"@6/FVLX.0J<U3(+'E.J$/.1!X=<:?3*= .&B739?5'; &E?\
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5:(C1$:(C1$:(C1$:(C1$:(C1%__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>g425213g42a01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g425213g42a01.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1YX4&AO=&]S:&]P(#,N,  X0DE-! 0
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M;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0
M   !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "
M4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,
M8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0
M 0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP
M $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B
M;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L
M  !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P    ,
M4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX            $)L("!D
M;W5B0&_@            0G)D5%5N=$8C4FQT                0FQD(%5N
M=$8C4FQT                4G-L=%5N=$8C4'AL0'6ME8         *=F5C
M=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P    !,
M969T56YT1B-2;'0               !4;W @56YT1B-2;'0
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M300-       $    'CA"24T$&0      !    !XX0DE- _,       D
M      $ .$))32<0       *  $          CA"24T#]0      2  O9F8
M 0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:    !@
M     0 U     0 M    !@       3A"24T#^       <   ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@     ____________________
M_________P/H   X0DE-! @      !     !   "0    D      .$))300>
M       $     #A"24T$&@     #-0    8              H$   0?
M      $                          0             $'P   H$
M                 0                         0     0       &YU
M;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P
M(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   H$
M4F=H=&QO;F<   0?    !G-L:6-E<U9L3',    !3V)J8P    $       5S
M;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M      9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A
M=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N
M9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,
M969T;&]N9P          0G1O;6QO;F<   *!     %)G:'1L;VYG   $'P
M  -U<FQ415A4     0       &YU;&Q415A4     0       $US9V5415A4
M     0      !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB
M;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0
M  ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M
M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E
M96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E
M=&QO;F<         "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S
M971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*
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M=M>][&,]V'L;5N]&NIOJ^K8M;,R\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 /_A0!=H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME="!B96=I;CTB[[N_
M(B!I9#TB5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED(C\^"CQX.GAM<&UE=&$@
M>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#
M;W)E(#4N,RUC,#$Q(#8V+C$T-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @
M(" @(" @(CX*(" @/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S
M+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$
M97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP
M/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(CX*(" @(" @(" @/'AM
M<#I#<F5A=&5$871E/C(P,C,M,#8M,S!4,3$Z,30Z,S8K,#4Z,S \+WAM<#I#
M<F5A=&5$871E/@H@(" @(" @(" \>&UP.D-R96%T;W)4;V]L/D%D;V)E(%!H
M;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]X;7 Z0W)E871O<E1O;VP^"B @(" @
M(" @(#QX;7 Z36]D:69Y1&%T93XR,#(S+3 V+3,P5#$S.C0Q.C(U*S U.C,P
M/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T841A=&4^
M,C R,RTP-BTS,%0Q,SHT,3HR-2LP-3HS,#PO>&UP.DUE=&%D871A1&%T93X*
M(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I
M;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!D9CTB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(^"B @(" @(" @(#QP9&8Z4')O9'5C
M97(^06-R;V)A="!$:7-T:6QL97(@,3 N,2XQ-B H5VEN9&]W<RD\+W!D9CI0
M<F]D=6-E<CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C
M/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @
M(#QD8SIC<F5A=&]R/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @
M(" @(" @/')D9CIL:3YR<C,U-S8Y.#PO<F1F.FQI/@H@(" @(" @(" @(" \
M+W)D9CI397$^"B @(" @(" @(#PO9&,Z8W)E871O<CX*(" @(" @(" @/&1C
M.G1I=&QE/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @(" @(" @(" @(" @
M/')D9CIL:2!X;6PZ;&%N9STB>"UD969A=6QT(CY-:6-R;W-O9G0@4&]W97)0
M;VEN=" M($=R87!H:6-S(&9O<B!"=7-I;F5S<R!396-T:6]N(%\U/"]R9&8Z
M;&D^"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L
M93X*(" @(" @(" @/&1C.F9O<FUA=#YI;6%G92]E<'-F/"]D8SIF;W)M870^
M"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T
M:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7!-33TB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*(" @(" @(" @(" @>&UL
M;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]2
M97-O=7)C945V96YT(R(*(" @(" @(" @(" @>&UL;G,Z<W12968](FAT=' Z
M+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B/@H@
M(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED.C)$,#DS14(U,40Q
M-T5%,3$Y1#%%.3(V1D0V0S$Q.$$U/"]X;7!-33I);G-T86YC94E$/@H@(" @
M(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED.C V.#4U,44Y,3 Q-T5%
M,3$Y1#%%.3(V1D0V0S$Q.$$U/"]X;7!-33I$;V-U;65N=$E$/@H@(" @(" @
M(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z,#8X-34Q13DQ
M,#$W144Q,3E$,44Y,C9&1#9#,3$X034\+WAM<$U-.D]R:6=I;F%L1&]C=6UE
M;G1)1#X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @(" @(" @(" @(#QR
M9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS
M879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M:6YS=&%N8V5)1#YX;7 N:6ED.C V.#4U,44Y,3 Q-T5%,3$Y1#%%.3(V1D0V
M0S$Q.$$U/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z=VAE;CXR,#(S+3 V+3,P5#$R.C$U.C,P*S U.C,P/"]S=$5V=#IW
M:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!
M9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!
M9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%
M=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I
M;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI
M:60Z-T)#-#0Q-3,Q,S$W144Q,3E$,44Y,C9&1#9#,3$X034\+W-T179T.FEN
M<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C,M
M,#8M,S!4,3,Z-#$Z,C4K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#
M4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F9R;VT@87!P;&EC871I;VXO
M=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A
M;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IA8W1I;VX^9&5R:79E9#PO<W1%=G0Z86-T:6]N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYC;VYV97)T
M960@9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P('1O(&EM
M86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @(#PO
M<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS
M879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M:6YS=&%N8V5)1#YX;7 N:6ED.C)$,#DS14(U,40Q-T5%,3$Y1#%%.3(V1D0V
M0S$Q.$$U/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z=VAE;CXR,#(S+3 V+3,P5#$S.C0Q.C(U*S U.C,P/"]S=$5V=#IW
M:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!
M9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!
M9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%
M=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @
M(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED.C="
M0S0T,34S,3,Q-T5%,3$Y1#%%.3(V1D0V0S$Q.$$U/"]S=%)E9CII;G-T86YC
M94E$/@H@(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)1#YX;7 N9&ED.C V
M.#4U,44Y,3 Q-T5%,3$Y1#%%.3(V1D0V0S$Q.$$U/"]S=%)E9CID;V-U;65N
M=$E$/@H@(" @(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/GAM
M<"YD:60Z,#8X-34Q13DQ,#$W144Q,3E$,44Y,C9&1#9#,3$X034\+W-T4F5F
M.F]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/"]X;7!-33I$97)I=F5D
M1G)O;3X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!H;W1O
M<VAO<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W O,2XP+R(^"B @
M(" @(" @(#QP:&]T;W-H;W Z0V]L;W)-;V1E/C0\+W!H;W1O<VAO<#I#;VQO
M<DUO9&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D9CI21$8^
M"CPO>#IX;7!M971A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H\/WAP86-K970@96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ L0$D P$1  (1 0,1 ?_$
M !\  0 " @(# 0$            ("08'!0H! P0""__$ $D0  $$ @( !0("
M! D)!0D   4" P0& 0< " D1$A05$Q8A,1=!490*&2(C55AQD=,8)#(U-WBX
MU? F4F&8UB<V0E.!DJ>WP?_$ !P! 0 !!0$!               % @,$!@<!
M"/_$ #41  (#  (" @$"!0($!@,   $"  ,$!1$&$A,A% <Q%2)!4?!A<2.!
MH>$(%C*1T?$D,\'_V@ , P$  A$#$0 _ ._QQ$<1'$1Q$<1'$3BCBS388JY7
M&!LJP('3%!(QF5*A")!9,=S(]DI,A1)\R(/<E?21,DQ(,R2Q'RXXS%?<2EI5
MJ\W"FTYEJ?0*W-"7N]=+7!3\:VV(ECI67Z#NE=C*I)5&( .5A&%MN1>3LU5<
M<VF@;[<--6C;7C-JC2^2B^_-1=I2GW:BJ[11598%6RVM27%8)KO+NFK56':;
M70M*@1Y#>%ST@V1?O>PI0L:4UVW=L6H^9R.UK-*-!')-1;0$='#2,Q]B<M\I
M!%)CK\N5W^?<UCR5:]O'<)GKM\@W< +3R7(O35;QB\C^7HO-?$M:M#/A5:/C
MJML*V^UJU 3ZKP_H)X/RW+W<3Q'D7G6_3G\"X/SQLJ>/^-5:]63R5N!/#\=A
M_)\HSY'WK5S+-N33JS4I9G%>2_6UB]Y.;\05-5U=H*_VBAPQ<S;=C+.V ?\
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M"F'DY>0_[N+A;2%2!\U.$MI@^;XC1RR\>,_+;^).+DLVZUL+^IV54>WOBO\
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M"BX>M%G=U5%I[1V/Q#YLV@UK>I9'M7X_3I3[%RBMS;]1M"Y,_&W'=KR,6VT
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M\F]7[ >J9YF 7A/0);H:TU8D'LM<*(8?<5 .5\L,,BY6&IHR?$F,,OMHD>-
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M8V(Z!8N"$Z$U@]8[8$'Y.%R]+8F'9<R;*+*G7AQV\LR##K]D*BQ?QK@4+@%
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'B(XB.(G_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>g425213g42a02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g425213g42a02.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[3&44&AO=&]S:&]P(#,N,  X0DE-! 0
M    ,7B^$F9#A"24T$!       8!P!6@ #&R5'' %:  ,;)4<< @   HW '
M)0  AR<C,U-S8Y.!P"!0 W36EC<F]S;V9T(%!O=V5R4&]I;G0@+2!'<F%P:&
MEC<R!F;W(@0G5S:6YE<W,@4V5C=&EO;B!?-3A"24T$)0      $.%>M.JD&=
M%FLZOAK[CF0Z$X0DE-!#H      .4    0     0      "W!R:6YT3W5T<'
M5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#;'
M)M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585
M    $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 (
M!3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
MQB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M  0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V
M)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M   $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M!29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@(&
M1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@56
MYT1B-2;'0               !2<VQT56YT1B-0>&Q =/))P         IV96
M-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $
MQE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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ME-! T       0    >.$))3009       $    'CA"24T#\P      "0
M       0 X0DE-)Q        H  0         ".$))30/U      !( "]F9@
M ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M     ! #4    ! "T    &       !.$))30/X      !P  #___________
M__________________ ^@     _____________________________P/H
M   /____________________________\#Z     #___________________
M__________ ^@  #A"24T$"       $     $   )    "0      X0DE-!!
MX       0     .$))300:      ,U    !@             ">P   ]\
M       0                         !              /?   ">P
M                 !                         !     !        ;G
M5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W
M @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   ">P
M!29VAT;&]N9P   ]\    &<VQI8V5S5FQ,<P    %/8FIC     0      !7
M-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M      !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F
M%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6
MYD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<          $
MQE9G1L;VYG          !"=&]M;&]N9P   GL     4F=H=&QO;F<   /?
M   W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G951%6%
M0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-3&
M)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M
M  #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6
MT    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO<E1Y<&
M5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V
M5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='
M-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M ,     C_P        .$))3001       ! 0 X0DE-!!0       0    &.$
M))300,     ";D     0   *    !G   !X   P2   ";( !@  ?_8_^(,6$
ME#0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )
M8 ,0  86-S<$U31E0     245#('-21T(               $  /;6  $
M  TRU(4" @
M             18W!R=    5     S9&5S8P   80   !L=W1P=    ?
M 48FMP=    @0    4<EA96@   A@    49UA96@   BP    48EA96@   D
M     49&UN9    E0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P
M   ]0    D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#     ,<E
M120P  !#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W
M!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V
M,         $G-21T(@245#-C$Y-C8M,BXQ               2<U)'0B!)14
M,V,3DV-BTR+C$
M                   %A96B        #S40 !     1;,6%E:(
M            !865H@        ;Z(  #CU   #D%A96B        !BF0  MX
M4  !C:6%E:(        "2@   /A   ML]D97-C         !9)14,@:'1T<#
MHO+W=W=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=RYI96,N8V
M@
M  9&5S8P         N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7
M(@<W!A8V4@+2!S4D="               N245#(#8Q.38V+3(N,2!$969A=6
MQT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M   &1E<V,         +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B
M!)14,V,3DV-BTR+C$              "Q2969E<F5N8V4@5FEE=VEN9R!#;V
MYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M    !V:65W       3I/X %%\N !#/%  #[<P !!,+  -<G@    %865H@
M    !,"58 4    %<?YVUE87,          0
M*/     G-I9R      0U)4(&-U<G8        $      4 "@ / !0 &0 > "
M, *  M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L D
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MY+_MS_;?___^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ,"
M@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,#
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MW.?2UOZ'U/=O\ [%O\TDIMI*ITJSJ%N!59U.IM&8=WJULB!#G
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0'_P  1" "V 1P# 1$  A$! Q$!_\0 'P !  (" @,! 0
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MET-W86TLI4E4/6A3Q/%/KRX"V+(^)C>CQ6SJ->/=&0W98OU<=M:Y%C;%?%I
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ML)[+&0\I:"+8A JPA(Y8N))@P<Z+52:O/BB),@?++CY6L23/[G*; AE,4([
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MY'N\9DK9VU#-/'6D$57OAFD6*0<P(Z]\;D,.1PRA@.1PP]"#K?;[ 61QF/\
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M<M_5/1"[&/?[*OS]'AKCGSIJIIJ5?"]?U8/V3ZSR/=;CI/0\CG^(<&U&5O\
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M4]N7)+37 ]2\.^(NA &@WY $5#:',FS]@MG55=D9:4D#ZLJZ#KQKVDFL/!]
M?P'36CQKH=BO=JB,/1Z0?$$Y[?6=U3#U&:ES[[ZFO\@#1#%7)&8)O0Y+(*_T
M!BA0Z$:0Q]-'*&V(8*RB)K86K^Z7.88C:6Y"D<C23B7Q2"TTI6-9UB;M>*)>
M3"P42$-R70K2_FG\FY M7K&ZF0JQ02M-9%@5YDO/.R0BTL#B)X*Z=[5W""8A
MR7DC9=Q+UJN0JCUQ];1BV6#Y+WG.!IP%!J;:TB8:N*2T^JRGK C(*4#\6L*:
MMM<RU]2AC@ZU34L;*N%*GS;_ .<6'_8VE_FKQZM?M+]"^WOV&QW\4BUGF_O
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ME[X^_N7N7N Y&N:P/7.5]4;:KS/HV(Z RC<&RY=C=/3:1M4^Q0EP#;!:@PM
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MCCC:RW5SWR/<UK&M15<Y41$553S@'>FT&#*NZ-OLQ! 5<O0+$GT  $_))/H
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M$Z^%K)+LRSE..]7$<@;N[DX"\3)YO3Z,/KNH-LKC3&4$UOD_Z:!M"H9:4?\
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M_$Y#874K-9C=]9L#C+&RLCCX;EUD\3W9<UM^Q'7'B:5A(\%6Q(O*A2L3^O(
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M9HJ:BJH*NNHZ*LKZ6EIP1:RIJ*D(:NJZNM!@8,#7UP <<(@0(8T48XH@T44
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M-@U+7NI>5(K325P[E#Q*J^A/:[!21QVRME99X1CU+U8HI; -V).P2H7X4M&
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MT5V?);LUZL;=3-_HKV)HX49SMGIXP0-(RJ6(5B%![B 2!P#QFS_+'R#Y^?\
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MV^@'7N3N_#W*C6]DY6KG*B(U.@Y)7*J_PB(B6ZJJJO\ "(GRJK_">8P=P8$
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M%,387%71MA$)IQ0<U)85>C.*LM,R^BMK]*DYM;^TP!TT@X\5C2OB<4I!<EA
M9"./^GC&6+(EQ%9Y;4-083$R5TAHM-7N3R0V5M)9N>[3"#W=(JKHBSU"ID[I
M&F65$2@DD,/N<TZQP23>]VDF>2T(I:T49KFNT-?S1F43L\X9FCG![ J",HS-
MQ>[NKRNT&4"'/MZ3/'CWDUC<TN;?I"7W0<]"RAH2(FU-TT &V',O"9RE#AFE
MDJX11K(&67_A'892S:AN8^));-:G*EIY[-6DUV0V8GJ"I4D KVA##926T[R>
M)')K*B6(6;A_G3@AD@MR,D$UB-H!##/9%91 RSM9L*?+"9)(6C@54+LH$K,T
M4BCYO=-S<[.HP4T// 2S=I<W8]31O&K@[*&O>L7[C8V)\5D6!5QBP4]<?'%(
M><+!)83 BQOD*)@@EU<^UO5QEGK\6S,L<6+J[+PMBT))I(6F7RWX888C#'-.
MTCV9HB5AAD985ED8+'&SKNH]B'(;BH>RHL>TZT]G<61ZB[@HXLPU*]R.J3'C
MK=NW;2W8ITD@BH5;:I);M00M;DJP*S330Q22.Y8>7J\:19P/N,F=>TE$<B*&
M&R[H2C!"2)!I KNOL FG RN>--"?7%1)(Q_U1._S7>5SVC76C=S=;O@MQU+<
M,0DC<O!92,V$65)(70M'*H$BLDB_-/(/Q!@7\E#R(R2^SME9:,M<W<-OJY+C
MK\<\$]9['V#2R5+42M!/%-7=VAE56C8.A /''/72YM(7Q/GMCL#[*PU%J!FK
M>_?:UU;4&BV]KG9S[&NDK:NKJ!PF5Q<\P40T@2&0LA;&;-.2R25]X?966%>J
MFX$KJBP1[5R\<0C=Y%,:9O JC!Y'D9BZ@,6#%23RH"\ :L&6NF9OI4CCBJPR
M6X:XADDE1H8IPD<@DEEF9S(BJY8/V,6Y154A1&SD%Q<W8@QFB.MWWSIJQ]W2
M66<=1B9BXE>]Q]%3DNJ:]UN"#*GX\9DAES+-%#"=^X206(_S9#K-9LVNA74Z
M2Y+9:VVT,@;56>F:L=&R\1\U6L_NT)L0PM\Q93+:9U19?.R3(39_V:((8/:3
MZ.+62$5QOG%"">*SYVM0B4B.Q,OED\,D@^<R!(0K%H_&K1L-=VP&QW%EU_1T
MU[G[8+$3DJS"6<]6,.+]W)6(-/HT),A)E/>^^LCY3Z3]U#KX2*JK>14N/'ED
MG33)E\9BH-NT+-2W7DRL8!RT*6'>0+D8Y;-+LC9%A_,D,*PVO=Y9VCL3A+ A
M=0I_0+BMP;EN;KW3C\GB;]?;4E:XNV+LE&&*#R8%X<?F!/8CFDM=^3N6GLXS
MWZO2CGHT7FH&W$[RC9LV74NO5'M%08I0MJ/STNTQ5;15N:QS3,_IJB\I[XK7
M;#4;,KGNK'^C,W8H]23FZ_;<RL<Z $)HCIM6/J:VLAKG2P^$GVC9O"2@V32&
M_+8FM70EJG/!8K)3HTZ"92E(#;KNTZ6Y,?EXK4DDE6-:;4IICI[DGL+=6/B0
M0EHE0)&"KAE8R2/(8WX", I421%0 WS^_@4%^^VQV.9]G]=!E,_9W-?)UF^L
MMQ.#61V#0L<-:A5-@QJR3CRM.1]VV[$BK&'6I$6>+&B D'GGEBG/I[C,9?VP
MKY"W!5F7#P08I9;#0M)DGBEL0GYJ.IBXJFK(TYAKHUR-VF5T16VB;1W!N'#=
M.>CL>"Q5W(U7Q>,N;EFJTDMK6V_":E"VH[Y8I!9#9-<I!'26W>FCQ%B%*CQ2
MRR1X0[%?;JDRD4?-J@FWV5O:#5]4V$,,P<*,<<NX/+L$LC*^OA$F"JYZILY1
ML"L,LA$&28M8().UVU2Q-K(.<W82#&UH'EG9I)8VE+M'6B2$P1S2O(LEA;':
MD3<Q02%^R,.RREU R>Z,;@PFSZ$^1W#>O0U:(BKUIX:ZQ0V,C:GN+<LTZD=>
M2M1DHK+-:C*V;M<0B2=HHI+??1O<[FO]4>P[CG%/<1:8W2<K)49N8,T>DRN<
MT1M&)N-"+BHQY3]!I,%B['0:8'+1@FE6]O10U+:NSD(2N)BC>&,QYWABL9E+
M%>2I##F(Q(+D=:G=M58[3XZL;[-XJU7)7XJM1[C21I!!9:8S0A#*E*?:YR,F
M0L[ RD->S5:]M>2Z*MJN\=RHMNW6EDBL5759$LU8Y&66%U#++&RLI((/.>Y&
MOTVV](,#?ZE-1+<KWBRK?S-@ )6W-P#2/ZE455Q]@+ \P'DJ[6N#&-I36X/.
MO,J)@RI!9Y)7FE7 _(]Z57'^TENJO2%,0_E1Y"81T9&D@ADL9O8D\L!9\EF&
M$T,LCQV$^4;0CF61 RA1&NMKK<[R;*QCL6[OLEKJ&=0&95HY=0W"I$"&4 @]
MB\C@GU]=45<7N;F\ KSM#87!%]*VOEO*NTS,F<@S=U,(Z2THJKZZJO=8 5Y2
MN'B(E*N2/IB9++:DL*A=YL?]H"S9M^SWU&EN36GMOAL<UJO8HFFM*RV5Q9GJ
M5P:\!FAB?E%=I+3^@9K,@=3KS[(\,%?VI>DL=:.%8%SV5$$L5H639@&W\T(K
M$O$L@CDD4!F4+"O)*B)2I [QRW9[FYZ[H:R^SMM78J:PB?@+$NK'$A>W+7<6
M>T?Y),1,IKDO#)Q+N@2W#K)2:Q2I*]AHD#B&Z?,WB\34V_0GIW:TV5CBXS$,
M=AY&#9"LUVEV(Z)%^98EDJV_=GG5)Q&LQBD;M.^/$[AW/D-P;QI97#WJ>W)*
M=YMJW)Z4,*.,),^(S GFCL26>,E9DKY/$B_6I//2,[U!:KQ&8;-5KU/K@7M=
M68,T/<0X0[504-)546.CEQQ^*?QPG7D=*U.S*YW??>>WI4%_S\BIJ^E84G-$
MT6.(-S^A'W4$LU<HL/A7V=-D8Y,<V1CI-9L36+I%^.^,]'27%4Z*92L5'R4]
M?)+--B<BEI+%Y8K-5L>P34 T\XO+$0_B9PJJJ J8_"7,SN8V_P"-#1D"6/L[
M4Y5O)K7B]W-IN<S[(;:#'9RVNZV#KV\OMW.!50GLBR8VT=5%@Q.G)&F_<9![
M2POPXZ:.RMI7YA 4KW#64DK9\V#BL5?VY&^3NUJTSXBC4Q"33O"S9%Z+V(Y2
M$1T,*O7BJ2FRT%<+>\OF#P!3M-Q&X=SX?8_2*/;V'OY.G'MG;V3W/+5I164C
MP,%/$4+%1#--!(;CPW[67K)C%N9"1L)[K[FT-QI%N*Y'M>D8CTVXL3@'75:!
M;=*W-9NM7G<Z_3W.5ST0O2+BG)&$3&='AJ1=!OJK'8^VU)G/MH)G*G1&GR4C
M'I%;5<0V\?BKV\,XN2$$LD&,I38^G:M"I7N66EQ<-A7<W\69I*V.FO7H*B9.
M@]J:JD8L$<P34S]J>2:/J[G3%W &M@1(ZKWLB?(50J0"D@7ND"(7,4@4,25'
MW0BM^IKM-F9S[@NS&H-)'T/2<-HRX,_=U D&HK==K)J>'[.CID%I:T(^DM;1
M2-$'*+2UH2@G1S15@L3F0Y/TTQV.^6LW0GM5/DFIGK*RVH9W]SFH4!.Y-6?O
ML2O'9@A*5'4V9I/-$5,SGEIE]F+(Y6CTSW];P].S;S<N3Q5;&5HH(YIADLA4
MCI59I89'@K^&I/96U;]XE@K)7@F:>6&)6D6%/ +>]T6;",T8I]+J/V(RJOXR
M0A@RH;VJLF5%D>.(J&5_XY9H<EE6.@<=6S!DC2#REB/8^2;<%5J4]Q96&C+%
M8I&NMBF\4KRQM5L/%8KQ,Y[).^.*7P3*ZQS+*CK(J.& @?\ )(,CDLG[/W2:
MWFJ=BIEUZC"KEZUNN*KG)8[;NY:-Z58H9'B6K;L5I;-1ZL\M>6I-#+6L2Q.D
MK<L FJDY7L9]?=W5U9-UNRK1)+NKHJF>.BH.D6N>SDT(]%0T$,L5G05=;;N,
ME'G0Z4Z0P*2*OG%'BM)T-$ ZT;$%>.../R6F81/*X,LVV+TTW+2S3'E)7>,*
M"O:%"L"P).FZ8U/E2HM.""&/W.G(X@EGF4SSX^&Q9#-//8(:.>62'L#+XQ&$
M<&0.QP9ZX7%Q9]NS<5V?;QF!]8J!(\Z1G7 4U;4A= &$SUA77KJB!UI+=4<0
M=H3]5W91NF,F:,, P.6!FR.2S8GI[B6U+962.OEHQ3>DT-6"M&;,=.6"V:R>
M\-:JK'8D)MSKW2,(XX1&R#+$@AAL8EH(X2KR8]S86R)9I9G\#V8Y(!,PB$,Y
M>*,>",]J NSEU)WJ?:3H?7.:4_);GFC<5'2W7L#Z]X'HYVF=9D7<./Z9W'G/
M.K(3'50H+ZPBUL -4?#-9V]F&RE'9^4 )8'OA<)1$?\ J?WSJT&H5>P_M=[!
M>O>QZ5JF:O(]/;SC/>P'5-[ZYY'+PGU/+/6WF_'.DZ[E?0]MTP0:+2YSIW2=
MYC\=6-S=O*;7WM7M-#68G&F#X"YW\?G36'K#W1]K,@1A>3WLW2S^M]TTO&P<
MI567 ^74O2JRDU./[CN>@ZWDM-6]0L>5E8^V'Y!!EL/3]XTM+NN+V-J9I.YM
MT50^E!+::[@5[4^T)%/77LQ_7A^=<AR_3"O83HF*X;Q(K29:\QG6=3G2ZOI^
M3V?38PX;[GG.\?)<;>#U^@Z*+L2;5VLY]6RY@W.5Q#35T818YX8IPD\9(I@\
M)0Q,3D=$0//&V6&>-R?PZ.6-[9&*G\*UR*G\>--?3XTT\::]! HQ@\XA8\!0
MI4,HY(Q$,<XY \['1303PRM='-#-&YT<L4C7,D8YS'M5JJBM-<1F\MF,;3"9
MW(9RARF? ^]^#19NHKZ.F"_)GE*(_$K*L<4(;[Y,TQ,WV8&?=GEEF?\ 5)(]
MRM-45?JLV5?5[VYGL310(7YGUUB9(5-'!&^5;'VS>D;72.:U7JUCW_3\_/PU
MR_X>1EN+;N>W+N+(4=O8?)9JY#AMN6I:V+ISW9XZR7MU0M/)'71V2)99H8S(
MP"AY$7GDC7RZX(\GLZ[!6-6<_ER;X)"@L>!LW98Y( /IR1Z_#5.\>ES\S5?#
M<ULK4=]*NC+A>U'(B+]*JURHB_"HOPO\_"HOD9;BQN0VC>CQFZ:EC;N1FK1W
M(J69C;'6I*DLDT,5E(;0BD:!Y:\\:2!2I>&10>4/%:-I]&.K>_,;+F=E=-=[
M[KQ,%R7'39+;^VLME:45^&&"Q-3DLTJLT2V8H+5:5X2P=8YXG*A74GO7,KVF
MDZ3SR..S"?))N<BQC&SL5SWOT%>UK6HB_*JYRHB)_BJ^<3"97&/F<0B9"D[/
ME*"JB6869F-J(*JJKDEB2 !Q\2!].LSQWLY=?,3D*&4R?1KJ7C\;C+M7(9&_
M<V;GJ]2C1ISI9MW+4\M)8X*U6O')//-(RI%%&[L0JDZG9^HM#*3R7$PCPRSS
M2=*#^B*&-TLK_HRNK<[Z6,1SW?2QKG+\(OPUKG+\(B^9UUT@FL[9Q,->)YIG
MS\79'&I9V[<9E&/ ')]%!8_4 3K9/['VZ-N;.WEO7<FZ\YBMMX"AL207LUF[
MU;&8RF;6ZML4:OO-VW)%!#[Q<L05H/)(ODGFBB7EW537WZH4-Y+[(\9CCIK1
M\DFZIVL8T I7.<LCT1$3[7\JJK\(G^E?*BYK;&X[V)R%.GALE:M6:TD4%:O5
MFFFFE8?-CBB16=W8_!5!)^K5N.IWM"="\]T^W?AL)U@Z<9?+9+!W*F/QN.WC
M@KMZ[:E4>.O5JU[TDT\SGGLCC1F8\\ G6SO-C=8L<B)F+SY5COA?VLI/Y5/]
M/VO\?(?_ "I.IX]3T_W<!]). R7'X3^9]:X?E;&?].J_XY/_ (ZU*+?U>]C9
M+6SD9PSJCV/L#7L>W#:%S7,<3*YKFN0#X5JHJ*BHOPJ+\IY^B3&^T;T#@QU"
M"?K)TVBFAI58IHI-X8-)(I8X(TDC=&N!E='4JRD JP((Y&J-R[(W@TDC#:^>
M8%W*LN*N,""Q(*D0GD$>H(^(XXUA"VSE_169]+=4EK5VU4817V5:?7E#&@'"
M2N@*$+&EB;+ 0/,Q\4T4C6O8]KFN1%14\R.+KKT7GBCFAZJ]/Y8I462.1-V8
M5D=' 974BYP58$$$?$'6:TO9ZZ[9*G5R%#H_U(NT;L$5JI;K;.SL]>S7F19(
M9X98Z3))%(C*\<B,592&4D'G6?\ E7KKWKHN7=HL%QKI>QH'6A@+;G-8R_N:
MQ3!8QU)%0P &>#[XZ21_=B^OZX_K:KFHCD5=:OM6*_4#JJVX=BC[+L$=MX>D
M,OMPC+8XVZTETV*PN4C- 9H?+'Y8^_N3O3N [AK;Q[%V8Q71[HLNS^JN3H].
M=UC=N>RAVYO.U#MS-+C;R4!3O-CLJ]6T*MHP3""<Q>.4Q2!&)1N)$8?U)]H0
MDM4,]>^Q"K(H/V_R.>Z>+Z_H_,^OZ?KK6_5]/UL^KX_M]2?/]T\B;9^T]T5$
MR'O6 S$#2FMV>6A9C+=JR]Q!:,<\<CG@GXCZ]5;_ "2S/87J+=Z./L+*T-Y+
MB*F^TRK[:M0YE<>]V;:)IK<-!Y_=S:%2R8!+V^403&/N\;<?)U#U']H[+/BP
M5_KUV,Z9MN/*Z$7GFHGD2)H9['2*R.M<J,1TC&JY4^$5[45?Y\N#[,(.V]^Y
M.]N'_@6G+M;(58[63/N4#V9,IA94A6:QV(TKQP3.J!NXK&Y X4D:R<?M;<L<
MY:3 9A%\;#EL?: Y[DX']2^)]?Q'6#@_2[VY86*YWK/W%C&DPN>YW,M<UK6M
MD:KG.5:I$1$1/E5_P3_5Y9SKAN/ 9GI'U"Q6(S6+R63O[8R-:C0HWJ]FW;L2
M1@1PUZ\,CRRRL?N4168_0#JP_LW5;.WNO'2O-YVM/A\/C-XXNWD<IDH9*5"C
M5BD8R6+=JPL<,$* \M)(ZJO/J?761A/4#VJ'*&(G]=>T0P0$0S332<YU3(XH
MHI&ODE>]U8C6,8QJO<Y51&M155?A/-,LNQMZ=DO_ +,9[CM?C_@VWQ\#Q_Q?
MXM?H#EZT](Y8IHTZF;'=Y(I$C1=S8EF=W4A%51:)+,2 H YY/'QU?(WV8]>/
MA/GM?+_G_7LZ'_TWRIWV.Y[])\C^W4F'_P#36MG\J3JA_<_W?^X&2_F^J8^U
M^NO>^G];Z)T'G/&NF;C"Z_5VUYEM=E<7?WF<T-,<0Z4.TIK>N!(!L0"HU1\!
M0LTL,K?Y8]4\LMMC96\)=NX:2+;6<>-\?79'3'6BK*5]&4B/@@_01Z'5^.GW
M4KI_M+9&UMM;FWMM?;^X<)A:6/S&$R^<Q^/RF,OP1]L].]2LV([%:S$WS9(9
MHU=#Z,H.HJZSFG1,'=D9O:X;6970"Q#S$TU_06E79P1%PM(%DE#,&BGC81 ]
MDT+G,1)(W->U5:J+YSK&VMPU)3#9P^1KS *S1359HY & 92R.JGA@>0>/7XC
M7;W/:-Z!XZ=JM[K/TSIV4"L\%G>N @F574,A9);RMPRL"#QP001\=7$?I89C
M1E83JZCT%Q.UFMHD=]NN*=]*K33JB*GVOX^4_MY'.\]@;XSEBC)A]I[@RD=>
M"6.>2AB[EM(G>7O5)&AB<(S+RP4D$CUXU37VE^J'3C?6:VO:V7OK:FZZU#%7
M:]VQM_.X[+PU)Y;BR10V)*-B=89'C!=$<JQ4<@<>NN__ *FG).H:[@N9K<MS
MS8W]A#U.B,E!I\]9GE,$CR^QAD)= *-)(D$<L\,;Y%:C6OFC:J_+T1;,^PQ&
M_1WJ]F]S]5E/3G;ESI_F,)4S>\Q]CN+LYBUGMKW:V,@NY/W:O)>GIXZ_9BK(
MYE>"G9E52D+D40ZP03[@VU1I8*&7+VXLW7LR5L=&]N=*Z4<C$\S10!W$2R31
M(SD=H:1 2"PYH\I/57V5)M@8!N"]9GGDG^(X8<'HY)7JD;W*C&,KU<Y?I:JJ
MB(J_"*J_PBJFPOKIUHZ2;XZ3[TVILWJ5LG<^YLSCJ]?$8'!;DQ>3R^2GBR5*
MU)#2H5+,MFQ(E>":=EBC8K%%)(>%1B.![*^)R>TO:!Z9[CW1C[FWL#BLO?FR
M69S%:;'8RA#)@<M726W=LI'!7C>>:*%6D=0TDB(.690<Q5_J'[3!'A&&>N_9
MA1!"QR2B9^=:F* <>"5DLT\TKZQ&1Q11M=))(]4:QC5<Y41%7S59+L;>8BF)
MVQG0/%)R3C;?_,;X_:OHUO;L]9^DT]>Q!%U+V1++-!-%%$FYL2[R2R1LD<:(
MMLLSNY554 DL0 .=7P?[ICUX<B_':^7_ "O]OG:4'\_/^O\ .^/*H?8[GOTG
MR/\ X2;_ '-:W?RI.J']S_=_[@9+^;ZUY.W,?H.Q]5O:.*:WI;CH>PM*FVKH
M93*^RKCK\\D(X(N!CX"12AY(YQYX7OCEB>U['*UR+Y8K"8+-C#8D'&7E(QU(
M%3!(""*T8(((]"#R#J\>T.O?13:FU=M[7W-U:Z>;?W'M[!XO"YW YC=^#Q^6
MPV8QE*&ID<9DJ%F['9IWZ-N&6O:JSQI-!/&\<B*ZD"V;TO[GQKGGKYD\IO.G
MX;'Z4"RU,QM!I-+4TUN)$;H[(P.0BOL"H"H6%"30DCN?$U)8)8Y6*YCVJN.Y
MOH=UCW3DILUMOI?OO/8BRL*5\GB=L9>_1G>O$E>=8K5:K)"[0SQR0RA7)21&
M1@&4@46]H'JOTSW#U2SF5P._=IYG&3U,,D.0Q>=Q]ZG*\&)J13+'9K3R1.T4
MJ-'(%<E'5E;A@1K"_NAF=%[/ZG&7WKG1VW<J3,4)]1H[7E0!.YKZ*T,L?S1*
MZV*SL9\(!I(B*3 ,2^.66!%E8U6)\^9%M3H_U6VQ6MP;AZ=;SP<UJ99JT64V
M]DZ,D\2($>2)+%>-G1'^8S*" QX)YU/OLF]5^F>*VYNZ/);^VECI9<U1>)+N
M>QU5Y$6B0S(LUA"R@^A(!'/ISSJ,&*]1O:0.R*>7Z\]D&8X![&OGYWJ(FJ]2
M1G(U%?6M155K7+\?W^&JO^'DL;0V?NJK<M/:V]F8%>J55IL?90,WD3A06C )
M !/'/H#S]?$1?DCN[ML=0>ENQ<9L;<.'WAD:/4!;]RCMS(ULQ:JTOL<S=?WN
M>"C)/)%7$\T4/F91&)943N[G /8-SZF^SQN2NA _7_L!1,\0J0P0<_TTLLBL
M/%D<C&,KE<Y6L:YRHB+\-:J_V15\LGT1I7,+U3V?DLO5GQN.J6\@]J]=C:M5
MKK)A<C"C33RA8XU:62.,%F +NBCYS '3W4VIN:.U$[[?S"JO?R3CK7 Y4@?\
M5K#_ #/TX]L*[I'/K _UN[8$"#N,F8:85S760#"""W]?.221/)5MCA@@AC?+
M-+(YK(XV.>Y4:BKYL<RF\]HRXS(QQ[FP;R24+:(BY.HS.[UY%5542DLS,0
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MY^N1$_Z5_M_T_P#5YI"O?U[<_75C^&?4RQ_U./\ ZB_Z(UJ[>Q__ "@.U?\
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M 2.=O+HWU+Z?XN+-;PVK;PF,GNQ8Z*W/;Q<Z/=FAGGB@"4KUF4,\5:=PQC"
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M&/9 YA4L$SG.^ID;F?+O.?M::/:L%N#/L,;-;F2:O'+]L,L4:%'=3!Y5 5B
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MJ(Y$^%\KKB_9QZFT]_8K<4U7#?)M+=F-S,SKEXFE]SJ9>"Y*5A\7<TG@C8A
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1T\::>--/&FGC33QIIXTU_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>g425213g42c52.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g425213g42c52.jpg
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MX=']D@]W#3N2X4/DIQ/\TL!^S6G/(>U/AD^6G\.C^R0>[AIW)<*'R4XG^:6
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M*PIA*R41-0[%[=;6\3C:A$OJE8%8.L1%1*6):1Z22-4D0A0%7.WH*6)(N4#
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M(MON*\_*[PE\4&,YZI6ZI3%ELTHT9TYT\B&#US6J9%,Y*^82CLAT!C%VJR9
MD5*^YQ_5\AW!P[-+R;=6^V:<GJZQ92"]>B&.RS*X*F,KJPOD)8^C)E<V5!<,
M46UKY5 -]37#CP.,P[Q21SF1@(BR"58XT#38-9X%$DLS%-C%/*268&:1W10Q
M1%Z9OC_V2$(!R:/B[\UGS1V5HZO,K.[H:S"L*3V*&4M4;$]F([+%A<VJ:A\H
MJRM/@H*SQ-EA54C,+.K+X_A8T6,K.6"^JDBZ$V5[FSD$ &,91DLQ(8'HLQU%
M<O+.0Y7<29<2L8DEPQ6,OAE:*0LN*<R,N(+1*DBR(19\\** <GY4PAQ76WA[
MJ]<AAODGDI"O\2;>1=/E(RB3K92Z8=S=6\20[]2)R'>(URYKE@LV/H1I.C?[
M*_5<1;6[3LHUE D5F54R+*Q*62\-K*[ Y9(RY%T4ZA6)&4#4J 1:^QB8<;+@
M8HUE9L0$Y0#%I(X7&VPN,CPJ-EQ$RDQO) @?;R$E1,[!LV7T,[1S7D>4]'N_
MH=:N1^%O"?*N[G3B7Q#SIVCFO(\IZ/=_0Z9'X6\)\J9TXE\0\Z=HYKR/*>CW
M?T.F1^%O"?*F=.)?$/.M1.+#A[RSF]/%59I4G+4E@WLUU4M=J2:6 SROLI3$
MU[@8*<AXZ$M]&DWMCA;5)PTK6W+>4=$@YIFSGG$8[;QR@%SPDQYRT;,<JY5R
M[R)$)!)1@ 5!!T%P;7UL>7RGAI,8,-'#,L2B28RRAC>-6PTR(ZJDT+%TE9&C
M(8Y'"N5(4UK%8L'\=5'J65HC%$7?I!_:[;E2T4Q4MGJ8=RMCGLO<6=YKEA;1
M\K.5=FXBK$PFL DM%?>2O:U 9E[)NJ[.+0%DJ4IF4Q,4+IH%0-Z#W8!(%(N%
M-B")<I OH " 0PYTD/*D,>(3#.[&23$R1';P?RY'Q7*<L<@5I8@5D5\%M$9L
MHSLQ1S&\37TYQWQW.<AM4F:F0(G'B>8;9.+SR\/2):Q/:_)VFGRE.8/*B&:&
M<0PQK4ZDA=J;(/8N=6L5B[80]A7P:E86II9.@$60WCNQ0 "T@ (5@QS;,DLS
M96 (L-1M+&QS%>5#.+3.L'.9'+DX=I"C2Q-$IBYX$6"*(31,RN7?,KG![09J
ME99P%Q2S^0,JR]2CK82OSUCLSRJ%;VDT:D6.?8FX5H",!NR/)MS1Q MM#RF8
MB!T6XMW!W\D)"$L2+A^0J%0,IN% ;^6QUVDS'_3KZ+)\!T&TXK#XR2?$M$YR
M.\ABM.JC*<+R<BV&<%?YL.((%A8YFTS@MZ*=HYKR/*>CW?T.M7(_"WA/E7>S
MIQ+XAYT[1S7D>4]'N_H=,C\+>$^5,Z<2^(>=.T<UY'E/1[OZ'3(_"WA/E3.G
M$OB'G6GW$-P[Y;S)D_$JM7F)RD5&JT_*:=GLS!K.+RL-:Y2V8*E*:O78Z*ME
M54:6_M'7;V2%M$HSM4%7VKF1:2]9DT+$DU<9XB8T>\;,S,E@5T*A9 UR5/HY
MBMP"I;H(L:Y>/PTF+Q&%,<XABCBQ.TD#$LLC2X-HBBK-%:3)'.%D82H@+*T;
M"2QPK XKXY[6M>HZW-LD4J!E8_)LK7VS6UUP74;89NATYE4JZSLT+/6"Q/*_
M#WME;I..E3H5(5&<BV66KE;8K!6(W(PB&7*F8@H"=F^H#-F.4J!<J5%M=0=3
MH3I1Q\J2;9999(49<0T8&(A)61X8EBC$BR2.4282LK6BT8')&#LUZ^2Q-QZ-
MHQRK3^^-&-084V!95N?F*C/R;2G1<%PE*6E!'H;;$IN;]).HWBDB6<]WQH==
M60DF*X7*%9*U6<9+17%TO]<DA)!Z1,^7_2?1%X21E(L#Z)-Q4-'RH$.RED46
MA01O- [")4Y,VMOYRWF8KRBJOMT)8J=JBF-QM9P]X[S["(VQ[F:4NUEDU#T&
M)JYY:-A8INM!QN&L7IV:8=5>IREEB86R2>6N^4I-)ELT^GS@F2'E'E;"&<K8
M95!RB.,@>D6L'.ID>PNRJ2 F2WHCUB]ZZ>!7$)M6Q<[2-_)2/.T2@HN$PVT<
MQQ/(J2-B><9_YCCA8QY"=C^T<UY'E/1[OZ'6+(_"WA/E6_G3B7Q#SJ6QA9DK
MI(31,F4 Y]Q%@Z  ]S.'6(I;>'JU9$?,/1;I_P!)ZCZJJS+E/I+WCK]M;LZ[
ME<NFE*:4II2FE*:4II2FE*:4II2FE*:4J"H;:2:$Z0X<S&1-T0+B4A^1Q%AT
MAFW((*G3Y^4BXJ%%N"JB8$/V2)DU*G:4II2FE*:4II2FE*CN^IJY'?;9NMU\
MY$MO<S=?2*@*:?\ ;4 2$^R. E 0TI7)O]SH?W*7WQ#_ 'A?OR !#_VB !#>
M$H  AI3XU6TI32E-*5"DAV8.Q =A! X[]*BAMU>'IG!3(I_VU2B0/O@$-*5-
MTI32E-*4TI32E-*4TI32E-*4TI32E0Y$=H]^(#L(,W0[]*DAML@?KZ9P!D$=
MO^:L4R2?V:@"0#!I2I9?L0_J#WP'WOA#J'^L.K2E?=*4TI32E-*4TI4%V?E7
MC YQ)TCY0G*"QDP5VC9 _(8A2&!P <G2="<4RE,F"X'$Z)"'4J=I2FE*:4II
M2FE*:4J$U'=>2Z]]GJ8![JDIM_!S =N1, .AUCOT3@3*COTY1Z!9$I5*FZ4I
MI2FE*:4II2J+C[G7_N5?OB$^\-]^<!(3^T<!(7PF 0 =*5Q:=;5L.^^[='KY
MR*[^YEZ^D2 $U/[:8 0_V1  H@&E0-P]G[ZJD:5--*4TI32E-*5!=CLXB^O;
M=\H&W3(I[_P;(CMR*E$[CP;]"W$JQ=NG,;L=!<IE*G:4II2FE*:4II2FE*@M
M!W<2G7OL^3#;ID5-OX-CQVY$B@=OX=^A<"98V_3E-V.N@4JE3M*4TI32E-*4
MTI32E-*4TI32E-*4TI32E-*4TI32E-*4TI4%0VTDT+S&#=C(&Y 7*4AN5Q&!
MS&:B03K&)S;$7*<I6P'.F<AQ=$$BE3M*5'%XT!9=L+IL#AJV1>.D!72!9LT<
MG=)MW2Z7-SHMESL7I$5U"E25.T=%(8PMU0(J+BY%Q< $B^H!O8GU&QL?4>JN
M39RV>MF[QFX0=M':"3EJZ;*IKMG+9=,JJ#ANND8Z2R"R1RJ)*IF,FHF8IR&$
MH@(JD$$7!N#J"-Q'75;2E-*4TI4=W]R.? '[W6ZQ,F0 ]S-X3+ *10^$RH"F
M'A.'* Z4KDW^YT/!]I2\ D,'V!? 9/W,0_"3V@^$OM=M*?&JVE*:4II2H4C]
MPN^L ]P/UB=!, ZO")W/[W*'_B6 4P^^ZM*5-TI7P1 .L1  W .L=NL1  #^
ML1$  /?$0 .O2E?=*4TI32E-*4TI32E-*4TI32E0Y'^3W_6 ?O-UUF.B0H>X
M'ZQ.YW;D /?.X 42AUJ^T VE*MIW?J?'KJLW<\R2<-S"DNF'3*]&J3J.F8Z"
M*B?,0P"4X 8>0P"4P 8! ,>UCN5S"XWBKB-SN4_C8?K;]^VH)\I4 GV5E9AM
MX=TGO_DVUD'I;M?WZZ9'X3\*C*9=QND&ZEK8E#X11?[?]F@ZS+!*YLB%CIH"
M.G\:C*W5^E=<MG3$S<!%:ZQJ8!X=V\D.WO>\R'6TG)7*$GU,*[>PI\U5KI7'
M$M@QIOV1D6(2V\.[67';^OECAUM)]'>6I/J<GRM['B_O(*J74;R/WZZMYUQ@
M\-;+<'66(%$0WW S.=$0V\._+$FUL)]$OI$]LG)<YON].#^\HJNUCWYA^-_+
M_OT59TIQX<)+%9@+G-]>0*F[.*_*ULI" GV ]*'3D) * NETIDN5(3) "_0K
M H)D@24V$^A'TJ>V3D;$&^[^9AA?OF%4.)@%[R 6WZ-Y5U"WLC_!&WWZ;B$J
M2>W4.\=:^K\5?'6RO^'OTS;ZO(&+-_\ XF%Z/_7K&<=A!OF7N;Y:ZQ3V3?@0
M2$04XCZ>40\.\9;_ /RK@ZR#_#?Z;MJ/H]BS_P"KA.G_ .H_[54\HX(;\0G<
MQ_1:S'BCBXX;<XMYASBC+M6NA(!9JC-)1II!%Y&F?%6.R.[82+%D^2;NP;N2
MM70M^QG"C9RDDJ=1NL1/S_+?('+'T;;#IRYR?B.3CBE=L.9PI281E1((Y(V>
M-GCSH9$S9T#H64!U)V,/-%BPQP[B7(0'"WNM[VNI (!L;&UC8VW&LN=W]-^,
M#'\:WT6N%SB'M%^/E6SLI>!NZG=_3?C Q_&M]%ISB'M%^/E392\#=U.[^F_&
M!C^-;Z+3G$/:+\?*FREX&[JBM[Y42+/C'G612JNB'2$1W!0@,6:8G+T:('
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M*FREX&[J=W]-^,#'\:WT6G.(>T7X^5-E+P-W5$<WNHG6CS$G61BI.SJ*B [
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M&/\ QH^D<8 ')O(AM??#C^G_ .OK >28#ODE[TZP>#U5;BWL#/"XN(B?*N?
M$=OL9C'@!U;_  XZ'X=;"_XX_29!8<F<A?C#RAZ__P"8CKK$>1,,23M9]?7'
M_P#LZVHX7O8Q\#\**EL>T2QY)GI>XDC6TI+6V6KKI="/BSN56T?'H1%8AFB"
M!W#M5PY460<.5E"HATY$DBI:\-]-/IKRO].1@8^4TPF%@P!E>&# 12(C2S!%
M>65L1-B)&8*@5 K*BJ6]$LQ:M_D_"1<G&5H<SO+8,TIN0 20JA @ N;FX))
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M4#(@5I?-%;9/HUQ2:*>)CJ:_SYD)BU85AW'U@\NYIJO#F-&L5XL<E*/)6%M
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M;.=>F/7EW85VFV^7M:/\!;I(.]P>EON])TUTN16!6Y8$ 4YS.R$7RX9A&Y7
MD.25B0Y;XRRD65_Y9,@6.1MI<K.>*257KF1,7.[U6"I<-ERR"]PJZCL6OX20
MS?6Y?%EEI6)[)+2=4DK6S=7>)=Y$Q_/OJ_;6C%DBF,S$KQTM'L7CFHRBX-CZ
M0&;6]M1<"^MM#NZ .DUMS\]8I+"94_I))3AR(2IQ*- \4#%D+C:J9HG*OE%L
MP(8 G!-SC?9#Z]8[ ^;Y,GY>@0]]QU4BC6ZCCEY:[+7#XHPH[M^0:W -L+V%
MS7(8F1D,P-I1J[>W^2DG5C8-(:(ID+4&[V6D;,VN+&QZ38&[6&IZLMNC36Y-
M:T@Y55G82LT:RQ1^BD1=TV.'+RHHP[%!M1.&%YBQ<91&J7.],3)WUSE_,$5)
MA8%,:H8UQ6]I1Y&NQ:40A<7SK**60V,-(!&L7<T8L2WQN[?LIF0D6K1\\7;,
M%FA#2#1O4VRC=>YOKK;2VE_;_?HKIHTO.)@V?8B*!HRR@*')FVH#!02<HB)!
M)L;Y;:BNIF\,2TI*/WZ<^T.1XY6<$%XBX%P4JQQ.":@IB<@BD \@"00*)2@)
M2)AL0NF,.P<N7!NQ.H-[$WWZ[MW[M70$P  RG0 :6M5MK\/LVKS;3\4&^_A;
MN^K?;_P_@UMQ^AOUT.[UF]090018Z^SK)_O73N^&J?<$$I;)#EZQZQ;O1\(@
M/O%_!K>@Q:1,&*LU@!86&[UW_MYU7..HU9TCPBV=Z!P);8$G,&WMFD@.W7O[
MQ1UW<-](H(""</*V[<R#=[:QDW)/76.);@/N4@!P)>JPGS /V;&5';??X$]=
MO#_3;"0[\%B6TZ'B'1;K-8&C)! (U\ZQ+.>QE9 E3',EDJG)<P#L"D;-CX?A
MY4Q\&NM#_B/@8LM^3<6;6W2PC=?U^NL;8=B",P[C6$K)[$#D^4.D0F7:"B+I
M<R2?21DZ&QBH+N.LIBD.I[1 X<B!5E0WZ04P0(LJEUX/\6.3(BI/)6..4:VE
MP_\ <BM=\"[7LZB]N@]'_:L32/L&>8'HFY,WXV(!A$?;0EH';K$?>1_#\.NO
M%_C5R3& #R+RB;$[IL-T_C6F>293_P"+'NMN;K!ZO55FNO8#<T+B(ESQC N^
MWA@K7[PC\"'X=;D?^.G(Z"QY#Y2/_KX7U_>]=83R'*23MX]3?ZK5OUP)^QBY
M!X3.^$K9\S1%K3N@PA&E?@8N8:P,<>([.,K+K!(N .M+/"O2,P%!HW*@T:[+
M.'HKHD8?+/\ $SZ:X/Z='DH8/DLX \G\Y,F*Q+QR8J83[(+ NR6RP1F,R'-(
MY:1_16/(QEZW)&$?DTSEY-KMLMD6ZHI6Y+:WNQN!< :#6^EO0OO*27EYGYJX
M^EU\IYB_:+W&NWSL<![QY4[RDEY>9^:N/I=.8OVB]QISL<![QY4[RDEY>9^:
MN/I=.8OVB]QISL<![QY523PS)*'7($XV+T"H)"8S18"J"*"*_.GRKF$2 "P)
MB)P(;I"* !1*!3F<Q?M%[C3G8X#WCRJKWE)+R\S\U<?2Z<Q?M%[C3G8X#WCR
MIWE)+R\S\U<?2Z<Q?M%[C3G8X#WCRIWE)+R\S\U<?2Z<Q?M%[C3G8X#WCRIW
ME)+R\S\U<?2Z<Q?M%[C3G8X#WCRIWE)+R\S\U<?2Z<Q?M%[C3G8X#WCRKB?"
MTD0AS]O6AN0IC<I6B_,;E 1V+NL ;CML&X@&_A$/#IS%^T7N-.=C@/>/*OB>
M%Y)5--0)UJ4%"$.!3M%P.4#E W*8 6, &#?8P 80WWV$0Z].8OVB]QISL<![
MQY5S[RDEY>9^:N/I=.8OVB]QISL<![QY4[RDEY>9^:N/I=.8OVB]QISL<![Q
MY4[RDEY>9^:N/I=.8OVB]QISL<![QY4[RDEY>9^:N/I=.8OVB]QISL<![QY4
M[RDEY>9^:N/I=.8OVB]QISL<![QY524PS))G0(,XV-TZID@,1HL)4Q*@LOSJ
M\RY1 @@B*8"0#FZ0Z8"4"B8Y',7[1>XTYVO ?$/*JO>4DO+S/S5Q]+IS%^T7
MN-.=C@/>/*G>4DO+S/S5Q]+IS%^T7N-.=C@/>/*G>4DO+S/S5Q]+IS%^T7N-
M.=C@/>/*G>4DO+S/S5Q]+IS%^T7N-.=C@/>/*@X3DO+S(?ZVKCZ0=.8OVB]Q
MJ#BE(MD/>/*H$CAB109.%1FV1@(F81 &RX"/]6Y]0V"903G707W&L$TX$3^B
M?JVWCITK5'(F,)UTO!/H-K6):?I]M1FH@]FD)V(CV2R]?EH*0DFJD&WD%7;P
M(*S2L<V9R+,S$RKI9<Y4UFS)T72V.4L&?0@@Y5N39A8:D6U -P=W=7A\=,LC
MZ(;J2P).[T66^@.MB1;U[[U8->X:; \85^-:4O&T.M58*,K%4FZ[EG,]8LU6
MB:'&V:/QHG7[/!Q[6=BG2#:ZVV%LT@V?%?R-=L4M#R#BPQCQ:.-OPOE8#,Q+
M$D^BMB6U:XN01< @6Z+Z'43@E#,%" 6%@1(Z, BMD"LEF&C,"00;,1J#:MB!
MX4WCU2K@>@T*.A8.1Q4_<P,#G?B#@H"Q.:8[;6=Y:;M6X@C"&R)>(.YQ\>_@
M;#>49N4N"**;J^2B[EA&MV_2#7UZP>@=/0.H6/1NZ!7I5PZLJ'9J #$UA/.
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ME$T>_*!3&$S-T4"E0(Y,810. %*V4,1-P8? "!SD(J(@F8Q2F$04J67[$O\
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M:8WA;W8\J9,+Q#QFO@S^9!#[CDP_"$ S$?Q"R,'_ &TVF-X6'_IC^ZFH*88
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M'M(I3N1C(.%?N*G58.NK/(:L-E65;B'"D0Q9F5BJ^T77;0L<<19Q:*ZZ;%%
MJR@&$D[R3[3??OJR0PQ$F.*.,LJJ2B*I*H+(IR@>BH)"C<!NJ[I$O/'OR<@J
M<[)T7HP2,N*G,@H'(")#$.L)]^4$BG(901Y"F*(@(166I9?L2^][4.K_ *:4
MK[I2FE*:4II2FE*A.PW7C.K?9\H._1(J;?P;(!OSJF Z'AVZ5N!EC;] 8H-U
MES%4J;I2FE*:4II2FE*:4J$U)RKR0\@EZ1ZF?F%(R8*;1T>3G*<QC N <G1]
M*0"% R8H"43HG.=2INE*:4II2FE*:4JBX#=!<-A-NBH'*!1.)MR&#8" )1.(
M^ "@8!-X $!'?2E<6A>5HU+RB3E;H%Y!(*8EV2*'**9C&,F)=MA()C"7;E$P
MB&^E!N'_ &^'14C2E-*4TI32E-*5!=DYG$8;D$_1OE#\P(F5Z+>-D$^<3E.4
M&X#S]'TQRJ%,*@-P(!UR*$4J=I2FE*:4II2FE*ZN:_DMY_<F_1JDGU&]E8I_
M\I_8/U%:CS!.5_*&Y!+TCXI]Q3$G2;1S%/G PG,"P!R<G2%*F "04>03)&4/
MR9=Y]C?]8->)Q/UW]A_O5VTS[<G_ &R_I#62/ZZ^VMOD_P#S._\ 2MF6P"#=
M$!ZA!(G^D-=0;A[!7K8Q9%!ZA5"3DXV%CI"8F)!C$Q$2R=24I*R;M!A'1L<Q
M04=/7\@^=*)-F;)FV25<.G3A5-!N@FHJLH1,AC!-6) !)(  N2=  -Y)Z *X
MQ4K'3L7&S<.];R41,,&<K%R+10%FK^.D&Z;MB];*E]JJW=-EDET5"]1TU"F#
MJ'2I!N+C<=14_2E-*4TI32E-*4TI32E-*4TI32E-*4TI32E6G9;16*DNPDK7
M8H.LL%&<ZDE(6"0C(=B=1A']T4@D23DG;4A%&<! S4ZZ;)\X!#0TM+N3(,X5
M=4JQ.X7_ ';]2!56=$%W=4!O8LP4&RLYU)&Y59CU*K,= 35S$<ME2E.FX04(
M<2%(8BJ9RF,H0%4RE,4P@83IF*H0 $1,00.7<H@.E3<=8KK&]B@G<[(UEK+,
M7%@B(J'FY.(2<$.^8Q%@?6&,A9!P@41,FVDY"IV5FT4'J4<0<DF'MFR@ MI?
MHU'=:_ZBH#*6*!@6559EOJ%8L%)'42C@>M3U5QB+) 3XR(0LQ'R8Q,J]@Y(&
M;E-864O&@W%_'+\IAY'30';7LA/K%/IT@-L)R[R01^O?171KY6!LQ4V.YA:X
M]HN+^T5W'2I\Q2=(3F-]B7G+S&V+S#RAON/M?;=0#[7K\&HJUQU[]WKKGI2F
ME*CNR\S1T7EY^9NL7DY3GYMTS!R\B8E.?FWVY2&*<V^Q1 P@.E*L.3RKBZLL
MG:UCR10:\A"V*.H\PI-6^ B$HBZ2$!'6>/I\D:1DD>U]G>UJ4C+"SK[PZ<NX
M@I%A+)-5&#M!PI-B=P)TONZ.OV5B::% <\L2A7$;%G10LA4.$-SHY1E<(?2*
MD,!8@UV=/R+C[(:<PK0+U3KRE7I9Q 3ZM/L\)9DX.=:#L[A9@\*^>EC)9J/4
MXCGHH/$!ZE42Z$$;P1?=<6O4QRQ2YME)')D8JVS=7RL-ZME)RL.D&Q'55XZB
MLE-*5"DB=(P=DY.EYD#AT?1JJ\^X?8BFB8BIP'WRIF*8?  AI2K'89?Q+*IF
M6B\HXZDD2SE@K!E6%VK3Q,MEJ<.XL-IKQCMY-0H3E:@&CJ<L$2(]GPT.V<2<
MBW;,D5%RS8]1Z.@].[OZ*Q">!OJS1&SO&;2(;/&I=TT;ZZ*"SKO5020 +UT#
M'B*X?9/M6$;G7#<@,W&RTS"@QR=27?;>'@4Y):<E8OL><4[81L,C#3"LL^:=
M*UCDXJ2.\51*Q="DRL-ZG3?H>G=WU08O"FUL3ASF#,MIHSF5;YF'I:A<K9B-
M!E-[6-=\US%B-]+2,"QRGCEY.1#T(Z5AFMWK+B5C) 8>?L(,)".2DSO&3P8"
MJ6B<!JY137[3UN?D^3L*&D5VRQZCW?OK'?5AB("S()X2ZFS*)$+*<K/9E#7!
MR([6(OE1FW*2*CG+F*&9T4W>3L>M5'%GAZ2W3<72MH'7N=AKT=;H"HHD4DBF
M5L\Y4YB(M$/ $ TK)5V4CIMDT6C7K9RJL>H[B=QW#0GV Z$U)G@&^:(7=8Q>
M1!>1T#HF_P"NR,KJOUF1@P!!!J TSCA5^QD91CF#%SV,B' ,Y:1:9 J;AC&.
MQDFL,5K(NT98[=DX-+O644"+E1)09%VU8@47+A)(ZQZCW&H&)PY!83PE5-F(
ME0A3F"V)#6!S$+8ZYB!O-=W.Y+QQ5T5'-FR!2:ZW1KI[>LXG;7!1"*533>L(
MT]H45D'[=,E=)(RL6P/-&,$:5[),&HN07>-TU%CU'?;=T]7MJS30I<O+&@";
M0EG5;1@@%S<BR7(&;ZMR!>Y%=<IF/$22U*;JY4QPDXR2S5D<=(*7BLD6OT>A
MV%T[ZE)&E /:F:/;..Z5U!%?H)]L&7.<.RT.D6)O8$VWZ'3V]55YQ -G>>'^
M<,T/\Q/YJZ:Q^EZ8U&JW&HZQ74EX@<#'% I,VXC.9U,P%=; 7)--,+FP6J)?
M3]7@D "9$5IBR047)S4#&)\SV8B8Y](QR#AFT<+)LK<)W7W'=U^RHYUAM/ZB
M#5E0?S8]7=2R*/2U9U!95WLH) (!-=M(YCQ%#J-T9;*F.(M5V^ML6U2D;Q66
M2CF3H*@)7J.0(YE$C+/J6J()6UHF!G%<4$"3";,P@&F5NH]!W'<=Q_'HZZL9
MX%(#31 DR  R("3%I*!=M3&=)!O3_5:KIK-IK%U@F%HIMC@;;6I4BRD78JS+
MQ\]!22;=RLS<'82T4X=L'A$';=PU6,W<*%2<H+('$JJ1RE@@C0BQZC5T=)%#
MQNKHWU71@RFQ(-F4D&Q!&AW@BN^TJU0I(G21S\G)TG.R=$Z,2**@IS(*!R"F
MB8BRG-OR\B1RJ'WY2&*80$%*PU+9NCHMZ[9)P+QT1FNHVZ8SM)L*AD3F3.8$
M3(+&(43$'D Y^<2["<I#")0P).'8J%.AM<FVH-MUM-:SB D YAK;H-6TXXD&
M#<HB-4>&V#?JE40__P (??\ _P">]K>CAVA S6O;HOO_ !JIB(TN-U]U67*<
M845&%.8U&D%N3?J+.-B;[;_#&FV_[Z[V%^CDF*L!BD2XOK$QZOOBL3>C>^MK
M?&WG6)9[V1B!@BG,?%LNXY-]P):&:>^V_P ,,;X-=Z#_  _GG (Y3B6YMKAG
M/_\ F%86FRZ9;Z7W_P#'MK!5E]F(JM<Z3I,%V!UR (^TO$<EOL&_WU</MKMX
M?_"7%3VMRU M^O!2'I ^T#KK5DQZQ_\ AL="?K ;OPK#LE[/-2HT1 W#A:5=
MA$/:Y%B2^ =O?J@Z[$7^!V,DT_\ :'"C0'_\/E._=_[T*U7Y81/_  &.[_Q
M-YMPFL^<*WLME!XJL@/<?-,26>CS\+"O+<T.^G8JQ1TI',3H1#YN#U",CG$2
M_26G&;A$W8BR+EJF[;F=(G.1%QY#Z=?X<8_Z$<F8?E:3E#"\I867%I@I!'')
MAIHI98I98F".TJR1D02*Q#JZMD]!E+,FWR?CTQ\S0!&B<(9%N<RLJD!A< $$
M9EL+$$7U! !]#^_:Q\@._/4?H-?*>?#LSXA\M=GFK\2_'RIW[6/D!WYZC]!I
MSX=F?$/EIS5^)?CY4[]K'R [\]1^@TY\.S/B'RTYJ_$OQ\J=^UCY =^>H_0:
M<^'9GQ#Y:<U?B7X^5._:Q\@._/4?H-.?#LSXA\M.:OQ+\?*G?M8^0'?GJ/T&
MG/AV9\0^6G-7XE^/E4=',S!%1VH$ XW=."KCRNTRCN5JV:^Z"8AP.?9L&QB%
M1(!.0@IB<AUE7/AV9\0^6G-7XE^/E4COVL?(#OSU'Z#3GP[,^(?+3FK\2_'R
MIW[6/D!WYZC]!ISX=F?$/EIS5^)?CY4[]K'R [\]1^@TY\.S/B'RTYJ_$OQ\
MJ=^UCY =^>H_0:<^'9GQ#Y:<U?B7X^5._:Q\@._/4?H-.?#LSXA\M.:OQ+\?
M*N"N:F"B:B8P#K90AR#S/4A+L<HEZP*D0PAU]8 <HB'4!BCU@Y\.S/B'RTYJ
M_$OQ\JXH9I8(HHHA .=DDDT@Y7B12[)D H<I3)*&*7JZ@,<Y@#J$YAZQ<^'9
MGQ#Y:<U?B7X^55>_:Q\@._/4?H-.?#LSXA\M.:OQ+\?*G?M8^0'?GJ/T&G/A
MV9\0^6G-7XE^/E3OVL?(#OSU'Z#3GP[,^(?+3FK\2_'RIW[6/D!WYZC]!ISX
M=F?$/EIS5^)?CY4[]K'R [\]1^@TY\.S/B'RTYJ_$OQ\JCKYF8+*LU!@'&[1
MP9P',[(8VYFCIK[F)2IE(?9R.YE"+D%/G("0*'(LBY\.S/B'RTYH_$OQ\JD=
M^UCY =^>H_0:<^'9GQ#Y:<U?B7X^5._:Q\@._/4?H-.?#LSXA\M.:OQ+\?*G
M?M8^0'?GJ/T&G/AV9\0^6G-7XE^/E3OVL?(#OSU'Z#3GP[,^(?+3FK\2_'RK
MX.;F/O0#H1_"^1#_ +]CC^C3GR]F?$/*H.%8 DLNGMZZ@26:&B[%RB$ Y*)T
MC!S"_2';?\'8P?IU#XU64@(VHMJ1Y&L,V')B?TANZCT&]:_/+D@Z>O#ECS)]
MEN@6'98!$!*T;MMCB(&!0VS<! Q"HEY.0@IB<IU5.>TP;_21OZ;[S?J'4/Q)
M/M\3C("CL<P-P1NMUUY\^R_9#OE&]C(XEK=C"S7"BWF+[S0P=HHD_,UNUQ79
MW$%BB,DNU4W7G+&79=FQ#V0CWW8CE+LF-=O&CCG:KKIFWL)9ID) M<BQUUR,
M1W$:>NU8E#I!*Z,0PR$%;AA=T&A&NXF_=J*\D.*3,'$+'YPXQQDLX>R'UGV4
MV"XRG$1['7PYXV:Y1)PV7SA8;7*LM\;2:-'AX%3$=SQQ,T8+(ZS%8[/*LWW;
M--HN^:N7"$N1]UQ:RZ+E*^D3O#:@ZFW3NMZKUTIGGSX@[7&+CUQ(7!PH)>;M
M!==G=0!"T;*6,SN<RD'<5L<?\0>?>/>HG]DN<W=E<>(_@JRE[)M9.&*5JKRW
MWAP]X7KC3LB8HM%;F8MZH5^JTX?\CP5N<41:KL^U,$RME=JQ&J\$^G00L,C+
MZ-K!@I-^AM#?\1^SH+4Q#8P\]5MK+A)L>(" 6#X?*\+AE;TK0R*Q0@ *K*MO
MK$&3Q1Y3S*EC3,(3G%[><2XXQ[[-%[(]25J??;WQ94'%MQQ;2V>-V&+<7*Y^
MX>8&X67#4-CL[F07P[C]TU8T">E9)R=)H"%749.H%KCT0?1'0#;74V-@;[O[
MBLF(:7(]YWC1>4<6"LCXJ.-XP (TV\ 9H534QII&QZ#EL?U8^Q9Y)F,N^Q\\
M+&0IZHYGI$K/XU3(Y@N(2[2^2<OJ%AIV9@6UBMU]GH:NR]N"Y-(M"XUZ=>P,
M*=_5IZ$63BV")DVR6-MYW?AI\.CU^NNU@7,F$@=EE0F,769B\HL2MW9E4L6M
MF#%5)!!(%[5O[J*VZ:4II2FE*:4II2FE*:4II2FE*:4II2M;^([AY@^(V+I5
M>G)^>K(4RS/[["S-?00,\9V=G59ZM5YT99V8[-1.&D[0C9PA))E)0EE5@"0M
MCCI*N.I:+?65LI)M>XM^%P?[6]5[C6M7%85<4L:L[)LY=LK+:X<1R(IUT]$R
M![,&5LN5U9"P.!)3V/:F25P<70ET=M)27N2MRL*:56BA0=2[S,N7,P/+'"G(
M\2<P>1&"N4DJ;4LB'7E)FJU6M-VC9%X:1.+.VT-K6Z+?AE46]ARW(Z:U6Y+C
M9S)M""TFT;T%U8XB><NNOHRC;[-)3F9$0 7S&KCQ;P.US&=FKEH:W1R+NN\/
M##AK39UVLL*FP=5",E;A*M[KT2#^348Y9?.+,W6GKK'JMF\L[;S2Y8)DC8"-
M(>"]P1;>V;?[!;=N%M!T:=56@Y.2%T<2&Z8482RH$!C4N1)8$VF):[2"P8YO
M1 8!<6,?8S*8P:((-;^,4X;P\HV8O*Y08*#&KV$U-R;5:_8Z&W)(NF]3,QD,
MHO;G9(XI)(ENM5,QR[6=136M.FDS.T)WB_\ <7%P>O=INM<UA'(\8 M+E(5@
M"D2+D<I,BO'J<EC.9'7TL\D<1) 0ALA89]C[QIA.X4*Y5^S6"7D<=2XNX!6>
M:1KZ11@6-;S71*Q5"S)B=GHQ-9QUE:N4=J*1P6?1&**@I(BX=*O%"PSEKZ 7
MWVOKN_4B_5U6M67#\EPX>2*17=C$Q*Y@I.4)B(DCOO"I%.D8Z2L$9-S<UOSJ
ME=.FE*CO  S1T42@8#-UP$I@4,4P"D8.402$JH@/@$$C H(=1! VPZ4KS[D^
M Y9=_;[+6,]9!K%HN5KG;R641C(U *K8[?$9KK=AE:NK5UZ986\NWJV8F4/4
MYV9L,Q.U]/%V/6,@_L%692E3DKY]P(! %K:W-K$7/M OIK<[M".6W)GI2.F)
ME1Y)'DS95NCR+B$=D,>S<-LYPL;L[.FQB!9D!1MS,?8_9X^;VUNRD',@6VY
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M,[\3>(^=.YRO>0H;T6Q^@TV,791^!?*F=^)O$?.G<Y7O(4-Z+8_0:;&+LH_
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M10S9<$^9RQR+RM]'W@CY:Y/Q7)K8E6?#\YB*+,J%1)LY!=',99-HJL63.A8
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MSVVVG.(>T7X^5-E+P-W5Q:WFH$:MBFL$842H(E$I5E0*403* @ +EZ8  0V
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M]E,!_3&;:<RBXI.]?DH<3(=#E[CYUUTGARM(,'2I7\Z)B)&$ ,YC]MP^':,
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M>FG4>\>50799(KB+ 'K0G.^4*)2MG*0* $;(GY#D"0,#DH"4% 1.*92G3*X
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M<I5DMG4@=*W]DRPV'#G:^)25JUQAZG4K+B"O/(-TI7S6!ZGE3 >%>)-]+1Q
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M(SG49R!J2+]=[W'KU]OKK \?),,BQR+R?%+(%58W&'CD<+&($54:S-EB(A4
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M*$.1(?;G*8I1 5*EE^Q+_4'O[^]\(=0_UAX=*5]TI32E-*4TI32E079P*XC
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M^'TH0:CG+-/CFME;R+Z DI>0-#0\O&Q@LP7F&$S+),XIQ!N1D& Q$X1X,1/
M^9FA'L@5T@*DY3KINZM?TK6YYAK(3/&!("R,QRJRBWI!FLI4YERM?*UQE)N*
MJL>)C <D!RLLJU%=VDQ3DE8D'YB3Z3-6<3K2*BM=52).IJ+SSAI%(-CQQ7*S
MM_&II(G"38"Y93>UC^_7NH,7AFW31DVOEOZ5LV3ZGUM7(4"UR2H'UA<UXFL
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MOZNNK5D<Z8@B2F/)9"K;(I0W,*[WD  #P[^T'71@Y(Y3Q-MA@IY;[LB7_O\
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MY4V4O W=3NXJ'QAB_.2Z<XA[1?CY4V4O W=3NXJ'QAB_.2Z<XA[1?CY4V4O
MW=41S=*H=9@8D_&&*D[.HJ8'#8033%@]2 XBL'2% 55$T^9KLON<"F'L8S@!
M<XA[1?CY4V,O W=4ONXJ'QAB_.2Z<XA[1?CY4V4O W=3NXJ'QAB_.2Z<XA[1
M?CY4V4O W=3NXJ'QAB_.2Z<XA[1?CY4V4O W=3NXJ'QAB_.2Z<XA[1?CY4V4
MO W=7P;S4 Z^Z&,_Z."C_P!@ 1TYQ#VB]]-E)P-W5ULO=ZDI&NR$GXXQC(F
M"@MUB/X.K57GA*,!(I)%89HWV3^B=W]Q6K<I-12SZ1%-\V."ST#I"4Z.RA 8
MLTA. IE X@"B:B>[@16W(/*/8X(@'+D="39@=_3]X']-=-/QKQ.*C=7>ZD:$
M:CVU?=*=-SK)<JQ#;G+ML.^_6 ?IUGBU=2-1<?OV^K?6S@ <Y-C;77\*V?:_
M<R']T3_2&NHNX>P?I7K(_J+[*KZFKTTI32E-*4TI32E-*4TI32E-*4TI32E-
M*4TI32E:H\5^)<IY@K]&A,379G2)J M,W9Y=P_G)F$8V2")CVY5L*7(*UIHX
ML00]HGK+!1MADH9U$3%=KBDO8JO+L+S&5)<ME(%\PN"+?$&^O4 ;=!.AT)K3
MQL$\\<:P2"-ED+L2SJ'78RH(R4!8*[NH=E*NBW>-A*J$8<D<%<8X6U:6ALR0
MS6NR-S-8NT1[]=P1K8CF'+4Q%NX]KW'':2]>K>$I;$M(6Q&'<_2;E8(.;E)9
MW&R#!.SVN0R6U76W4.H>S>03?4B^E:S8;'[0LLZA&DS9=K+9/ZB=E8#9^DJX
M<P1F"ZQNRL201GD[#$F!>)ZIY"C;K:LBUM5%WPR5C%5O2&[7:\RDKF^M6/*,
M\&8NR;+6(M!_7E%KP8(K'9BP\+#HV&30:I(M*;5&#D64@@#_ %$C0"P-M.FV
MX:Z[O6:F##8Q)1(\J6.#2&0;225FQ*/,^WNZ"Z?S/1B]%5SL +1Q@XKK7##Q
MKU1JZ-7\O5N*?.26&S-TGF6<E69DG>W=,R*0$[0YEJ"1Y>86X9&?8>DI>0DD
M&<A1JKC^PQE/9+HV^4AWTYDX=!ZAJ+CNL,UM^I%ZPK@^44'H8A%-G;6:5QM#
M'-]<M%FD625H&9C9HDB<1@[1E.6<,X)XN:C<Z!.95S^WR#$5F7,TL+1O/61F
MA8JG&5G-=,C%W=<)7V<)(6:Q-'7#Y>K0I(+]#'WZ+R0>OOR1I8XUJAF4C1;'
MV#U$Z[]]P/5;IW9L/AL?')$TV*$JHQ#@,XSH$Q,:DID"EW!PLCW-A(LQ0VRY
M]_-4KJ4TI4=W]R.?_NZWWJ9_^&;[Q7W(W]E7W,W@/[41TI7E)9>![B,6(^LM
M%SRA7[E8<YY1N+]F6Q7.+ID9C'(%FXB(R/62C63244G\H16+<^H)J+*IP=91
ML6*L1PT4HUCJ&SM$AE#KN*Z90+V%[@+W"ZC=T7OOKB2<G8LYGCQ.21\3-(1G
MD6-897Q8!L,V>98<5TY4SPP*#EB5S&@.!G/T;2I-E8<A56UVNSQU IDZ1.]W
M^OM(NL0^+<5UZTWV&M:]2LT@\S+"7/'LTIA>Q*5.';8\8WVSW%=68LSI.(0%
MUZ!86ZAON38[M-=1TV L!>B<G8I8B'E221Q'&W\V5 J"&!'E639N3B%DA;F[
M[-!$)7D.9SEK>KAZQS<L>Q61U[VWK,=.W[*M@OA86D6><LE,@XQ]"5F!C&,
MG8*K5'T(LX:UTLK:VO02B,]>I*TWDD@S&VFK<!1B#:W0 -1;KZB;[]#IIWGH
MX6*2)9=J$#23O+EC=GC52J*H7.B%39+N/2#2%Y;C:9%V"U6MJH4CUL'?@'W
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MGMQ[7U<,@ZJPN ^_3V>RW3>M3[O[#IA2\J&4D,I929B83"(,RU+;VP" [=/
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M_P OE3G3\*_'SJ.CAJ"44=D-*2X @X*D00%@',46K9<1'9 XB/.L<NYBHFV
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M33_NTQ$A/L2")0 =*?O][ZD:4II2FE*:4II2H+L!%>,VWV!\H([(HJ@ =K9
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M5.5[HH8* ;=!-O2!N,S 7&_<!KI\16?!38UY%7$*]C#&9,V':)%?FN#<LCD
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M3,TN4B^9KN!EN"!8;[7.X7] .X#)OEL_I]_^K7RKF^*XS[P^==G;P</Y!3N
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M%S?%<9]X:;>#A_(M5NX#)OEL_I]_^K3F^*XS[P^=-O!P_D%.X#)OEL_I]_\
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M>+,_/E_5VEWX5\1^2FG6>X>=47!Y 6ZX T:&$450 H.UE!-N0W4"8QX H(^
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MHR)F'G+]FJ8GOA[Y45/T:RQ_77VUMX 19]'D)UWQJ.@].U/1ZO5ZZV0;'?\
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ML(.+\XJDID>_JG;G-!-0%NL98G\!R!MS&07;B',HN<Z?M%SCSH&15';HQ4%
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MG H>T+]CTGNFWP=)[?;[+VV^E/WU56TI32E-*5!DNM@[ZB#[@?J4!<2#U??
MU$' A\((B"@_>]>E*G:4II2FE*:4II2FE*:4II2FE*:4II2H4EUQS\-B#NR=
M=2@+B0?<%.HX-=G(D'[X&X].(;]#[IRZ4J87[$O]0>#?;P?AZ_Q]?PZ4K[I2
MFE*:4II2FE*A.R\R\8/(8W(^4-S%0%4$]XV0)SG4 Y0;%'GZ,%S%4 QU"MN0
M#. 4(I^_W_Q4W2E-*4TI32E-*4TI4%I]OD^H@?OY/K*"X&'^#8_K4Z8>C$_O
M +79#HP(!@[)!P(J5.TI32E-*4TI32E47'W.OX/M*OV7/R_8&\/1^Z;?#T?M
M]OL/;;:4KBS^Y&O44/WLAU%!0"A[D7J*"WNP%^ %?=-MND]MOI0;A^_UU[ZD
M:4II2FE*:4II2H#S[HBNH@_O]383 X$P?P9(]:8HB"93^\(N]V_1BH!0[*%L
M(*5/TI32E-*4TI32E=7-?R6\_N3?HU23ZC>RL4_^4_L'ZBM1I@/W_*]10W?E
M'VH+@(_P8P#<_2CT8FZM@%KLAR 0#!V2#@1Y,N\^QO\ K'[U_2O$XGZ[^P_W
MJ[J9]N3_ +9?TAK)']=?;6WR?_F'\?\ I-;,-?N9#^Z)_I#747</8/TKUL?U
M%]E5]35Z:4II2M>[1C?A2HZ#-U=*%P]U!M(.!9L'%HJV-X!!\[*3I!:LUI9B
MT3<N 3 3B@B8ZH$#F$O+UZFYZSWFL'-<-]G@]S'\M71^Y_P/\B>(_FWIOJ;2
MYZSWFG-<-]G@]S'\M=(GB7AE6LCRG)8NP<I;(^#C;,^K9*+1#3C2NS#^5BXJ
M<<1@179B45(R4%,L&;\Z0-G#N+?-TU#*ME2E7/6>\TYKAOL\'N8_EKN_W/\
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M6: 25,128K[9Q,QQ7,<BHY+-I.I^YJH9.21<E^3@ 4!);#"QD3:(#KH7C]-
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MKAOL\'N8_EI^Y_P/\B>(_FWIOJ;2YZSWFG-<-]G@]S'\M0I+ &!@CGXCA3$
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MG\P.;;3:#M!XAYTYIA_LT/N4^6N+7"W#D5JV*;$V$0,""(& *'20 !!,H"
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M;%"/9%YAZ2*Z(1 Y3%W:;M]B@!A[+!R <N25M;2-N.YST,+;CT#K_2O&XF!
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MPZX:Y+2EF5HUN0S%\_I%VU!R)F;@OI6;K_-WJRVRVQO;\<!]FQ5=D'M?4(7
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MY_QU_P!._P BT_KOO?[=/Z7[OYJ?QU_T[_(M/Z[[W^W3^E^[^:G\=?\ 3O\
M(M/Z[[W^W3^E^[^:G\=?]._R+3^N^]_MT_I?N_FI_'7_ $[_ "+3^N^]_MT_
MI?N_FJBJ.9@.W!11\0YEC @7IH1/IE>QUS&3Y"G*#C9 %E>A.50I>BZ<" =
MBA']=][_ &Z?TOW?S56_CK_IW^1:?UWWO]NG]+]W\U/XZ_Z=_D6G]=][_;I_
M2_=_-3^.O^G?Y%I_7?>_VZ?TOW?S4_CK_IW^1:?UWWO]NG]+]W\U?!'-8=?[
M_P#^@08_]@ 1T_KOO?[=0>;6-LM^CZW]ZA2!LR]A.>G!_P!%T9N?<D+MM_\
M*7?\6H;GMCFS6Z?J6K7FV&R>^7=Z]_1N]?7I6"G1KB+QQV6=P<P+_O@IE&9^
MB4Z!$03$A3""&Z(HJ]$0$P$%.G$@F6.<^@VVOZ5_Q"]?GO/7I7B<;L,S9+7U
MO];U]?1\/A65Z+VRZ9#I>?[,.;?HO#SE\.WX-_!K<A)S#-OS"VFMK'J]?XUD
MP&7-I];\=]M?5^^JMKVN_8R&_AZ%/?\ KY0UU5W#V#]*]5']1?95?4U>FE*:
M4II2FE*:4II2FE*:4II2FE*:4II2FE*:4JB9$3.$E^<P FBNCT>Y^4PKG;'
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B^DULPU^YD/[HG^D-=1=P]@_2O6Q_47V57U-7II2FE*__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>g425213g47c44.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g425213g47c44.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1EN4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &5*^9((X0DE-! 0      &$< 5H  QLE1QP"   "   < E  "')R,S<W
M,#$S' (% $!-:6-R;W-O9G0@4&]W97)0;VEN=" M($IU;'D@,BT@($=R87!H
M:6-S(&9O<B!"=7-I;F5S<R!396-T:6]N+G!P #A"24T$)0      $!VQ:EJM
MQ/YH?1@[OU24MD$X0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q <.            IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ ! [_^-0 "  $X0DE-
M!"8       X             /X   #A"24T$#0      !      X0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M T$    &              2H   %Z@    8 4P!4 %\ ,  T #<    !
M                      $             !>H   2H
M      $                         $     $       !N=6QL     @
M  9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M      !,969T;&]N9P          0G1O;6QO;F<   2H     %)G:'1L;VYG
M   %Z@    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I
M9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4
M>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P
M  $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M         $)T;VUL;VYG   $J     !29VAT;&]N9P  !>H    #=7)L5$58
M5     $       !N=6QL5$585     $       !-<V=E5$585     $
M  9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (
M8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E
M2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI
M8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    1
M15-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M      IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M       +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M       X0DE-!!$       $! #A"24T$%       !     0X0DE-! P
M#L0    !    H    'X   '@  #L0   #J@ &  !_]C_[0 ,061O8F5?0TT
M O_N  Y!9&]B90!D@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3
M$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+
M#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,
M# P,# P,# P,# P,# P,#/_  !$( 'X H ,!(@ "$0$#$0'_W0 $  K_Q $_
M   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
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MM\?_V@ , P$  A$#$0 _ /54DDDE*22224I))))2E3R.HLKJ=90!<*PU[R'
M#T]Q9;8U_N:[TMK_ &*'4\[[+6YYD4U OON8075AH]1N^H_28_;^\N+=;5U&
MUEG5;!BXKW.NQL$N(8&O+G>L^7.:^W<W]_\ G?YA2X\=ZG[ KQ.@=W)^M^"V
MUHIO=D"JQQ>W'J<\/80\,;ZC@VO=6[9O_P"M_I?YQ0K^N&$'M-M]E#6TD1D5
M.:'63[;'/K;;[?3;^C_\&]^Q9^-;A 5U_;,:OTWN8VTO%;;& -YI8YWI>O\
M\+_->E_PBMV]/N: (#JMPNM&IV-=+_L_HOW^MZMF_P!3;;5_.?Z.O8I?;B-"
M$<<>Q^UZ'%ZG7>YPT]/<VNJYK@YMCO\ ">EL+_T;/;[]W_GM75P&S*Z7ZF7T
M_?538'!^(XNK%E9&MU+7C=BY3??L]K_2_E^IL76='ZCB9%-3,8EU=C ^IH:X
M^FS_ $61:38W[0W_  E>_>HIXZU"=*L:ATTDDE$I22222E))))*4DDDDI__0
M]5258]2P 2#>V08.O@F_:>!_IV?>C158;22J_M/ _P!.S[TOVG@?Z=GWI4>R
MK#:257]I
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &H AH# 1$
M A$! Q$!_\0 '@ !  (" @,!              <(!08!"0(#! K_Q !K$
M!@(! 04#! D+#@D'"P4! @,$!08 !Q$($A,4(3$505$)%A@B%S535F%QD]+3
M(R4R0E1S@9&4H? 9)#1#15)8996QLL'"U#,V1$95<I+1\2978H66E^$G*#='
M2&-U>82&AZ6TM]76_\0 ' $!  (# 0$!              0% 0(#!@<(_\0
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M5:U:W(BW[QTK$(3A?''+%N0%BZ=IF68.E!*=DNJ0IS98:YIUOITEJ+<SHUQ
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M3STXHI#;JB6[NZ(D@+C#[=L# MM[R[74QJ2R ]@-:Z=8"F:2</T8&?G=A4Z
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M XRP138,B \%0>01W(PP/;/OX\L#-=PW1%UEU+J5LJT7M.NU^O;NK4(M*L+
MR47:P5KA(Q,0D'R#!TX4;Q<U"-C^(=('4<$,Q%>1CU6K=JX;M/F7I=Z.3>CM
MJUS:74CZ+)(1.LQ4/9NV6'5F]G?;OM(#MLVL DFXL&:MNXFMH7*R;;89,@8A
M0@4;BS.1PG&7+'"C&[@9J\]IK37;CVOS56OL<[KL0[,A*-H=^249+K(KIN%
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MPSR-)('=$+;D<[F(VNP( 8$U:6ERSRR1&50J]-7W 8W!6 $K\OTD*IOA3"S
M]-CLW!H,V/3KSU#4M%Y5]9U^'KZ+21D&"CAFG$QB;=K& U<!/V!^DU?+1T&D
MNL51V8B+AFX=/!6>*3[Y=52BN[6TTV0="]9+NTGB>=K:=!U DZEH75!+"\H3
M?)L60P0-'LDFN'D!7TEA=PZ7<)<27=TT[-$6"LXF<22=162%<\.,!%9#+(-K
M1QQ0HM4[Z3NI6]]"FX&ZFNZM7IJ1O$=786SHS</(SLK;&AYP15JE,>1KI!Q
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MZ;!P>001WSD'DFI>A$KIL3!F4O-?/P2#B34+IQGD>!&><9[#';<[<4#U:RI
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MM/XZ?C^5/LXZC#_G]7_Y2?\ 18]1N_X$GW#\Z>O6G\=../'\J?9RU']_U?\
MY2?]%CU&[_@2?</SIZ]:?QT_'\J?9RU']_U?_E)_T6/4KO\ @2?=3UZT_CI^
M/Y4^SEJ/[_J__*3_ *+'J5W_  )/NIZ]:?QT_P WY5S]G'4GW_5_^4G_ $7I
M^'TQZE=_P)/NIZ]:?QT\NY_+\>U<?9RU']_U?_E)_P!%CU&[_@2?<#_(T]>M
M/X\?WG\JY^SCJ3@!^?U?X'G_ )2?W>O]J_"&/4KO^!)]W^]/7K3^.GX_E7'V
M<M1_?]7_ .4G_18]2N_X$GW4]>M/XZ?YORI]G+4?W_5_^4G_ $6/4KO^!)]W
M^]/7K3^.GX_E[J?9RU']_P!7_P"4G_18]2N_X$GW4]>M/XZ?C^5/LXZD^_ZO
M^7G_ &2?]%F?4;O^ _X?G6?7K3^/']Y_*GV<M1_?]7_Y2?\ 19CU&[_@2?</
MSK'KUI_'3\?RJ$-RW'6NQW6MX52XUN5I+6YC)7Z*4EQ9IO(EM"R7LT7"8BBH
M_:(S!FIEF*0JF44,@J9$4T3JI76CM/IR:C,(Y(KUK/I6$HC#%)7FCZFPD$([
M1;@)#@ ;E+#=AM'O+1MHZ\9&[V@20""K#RYP<'[*BS79JPRMD<UV->*#8*-K
MVH6ZE4PSN4&96LD3:99%5 9B+>,3),PCJVW0KKI)<Z_BB%*FF99MVSGLM2O0
M]I*=/ANX+[4+NTO+T+&(5MI;:)E(BE1P7,MR6N%9<;3DG#8%86\ME8,UQ'[
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M>2:.U?TGTM+B56:*W>QLUFE7+%FCB,0=URK%BJD95B3P<8%O>E2XFRBG#,(
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M?CCBA7'GCSP1^C]N/?3Z3M+#^X-F_%W<9\>> YDA]>/Y_/W\XVMY8^/]>?\
MOX=ZSM/AGMGL?NXS^5<_2?I@_P!P;-Y<>J<5SZA_C+D?0!Y]0_SY*,/(GGL"
M?UX>/^P*3GN,>[^7(_7V9X'J>I@"/ZPV?U$/^#B_/CWC^N?GY^GPXX_%@*Q\
M1QWX/?R^/]2*;3Y$]_#']3_2GTGZ7Z# V<0XX\DXL/(/3^Z?IYC^'X@'IF2C
M>'\B?L\.?PK!4CP/W'R_E^/F!VI])ZE^H0-F$?WN+_&'K)@/J'(AQY_'D>,!
M6^'Q!]WCXY\/+N>* 9'8]^>/#\_]OM?2>I0^8P-FY]_ZE%^[T\O:7'GP'O\
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MW"CIN5[*H]ZNJ1$BA5W2!2]E,#?7R )DU". S+TQ:$-+T@S[8@R LRA6*Q\
M$D$*<Y/&*[HT5W KRG8T#9.P9]E<> 4D \ XX!)SDX @F@NHUG3=BU#:L0UG
ME)5L]C7D2XB$7:+1PU,[9,I4\1+J&;^,%5VBHH8JZ+AHLV*9(YOJ&+;7FY[N
MRN-.D:+ILCK*)"C,&VNT8DC )7:A !!1@2#CFIMQ;R-ZO/$54 AL@D!U[E0P
M'T<9&,8YXY[U(G>G%38U/3:&V%\W7K&R&9P,0E$/W]8D9@L:59@C+.4'11CY
M!RD<6\:D$)(F[7>M1,0KI)0MA)Z6P:1=JILQ<M<0G=(T@1U]H[HU*I*WM$>T
M,AL[6"-@ V9??("83LCC:5W1D$HC#E3(D;[5D6,X8@R)D;N5"DC7YG94#3=2
M2>L[G /(RYP$ ]AZ]9(2+:-%#/&H*D".L28R,2_1CB',LS[2\W,QR3,.X"O^
M.(DJKXSTABCEO3<]28)JTR(24WR!3MR[30Y@NH\$,=I5M[!6ME8"KNVLIWN8
M);62.2"62,20#+PJKN@,D$3I(D3$$,%,<3,1@71W!3U?0D;NW;&P(@-7MFUE
M4B7D"M*A7Q1D*FP> ^.JBYN*,L06CJ..#/EPG.IR#%RV159)=^ BS+[FQ@TG
MT7TJ6*\N)(>J9I(VE>19V&S;MM2GM+*"P.Z$)*LA5R5(W+]?1=%T+2Y5U5C
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MN?\ ^_Q\I7>,;UQY;%Q_*GR;9_PO\[_ZJ?1ATO\ >HI_EF:_W_,?*-U]=?\
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MRJPN9FL[)I+NZ:",1+-<"(-N,4)"EU1=P"E^5&36%H![:^R3V9R 3C'?())
MSR37Y\_E"NEIY,]0=]B^F;IUF&U1U^>M$O3W5#8\_*6-_>(-C<V=NML:JLZ4
M;UIZ /F,<^8(%@47$3)NY98'CPHA]=]$-2T^#0-/D])-8=YM26Z]5BO&2*"W
M2QN6MGM(9&"DW"^RT@9S+ME18QA :]=HNJZHZ7%C%>:8ZP)#';)K4UTSJK1L
M$>U=2R-TR0-D@:5\*JMM!6H#Z;NHZP5I_+TBJN:8V"3/ -W=C[*+:9:2CQ-@
MP+[/D%UT&*,; / ,9FY%NI&MI 2O68$4;PAXOSWI!H:Z1-#)9V]])%>74@EZ
MBF:;HAC(6$BC$<RQYPL@)."[8.14?TC]&Q;]"[F2XG^FTD:K));S,B&1I"!'
M(YWAB-DC&5T98X^!)');*PZ61VV#=O:-@NIY6OL0;01:<Z;6INZ-(%7/&1,<
M59=FD"JH(O9Y^(.&@,&Z2KN?3![)$1;V-EZ70:,VW2[*.<SA.M'DP)$%+;%C
M(#L[E6S/<3!Y'&-H0,JQ^(F5)(PR1+"LAD9I9QTR2H DGG(#'IQ,R0P1@A7D
M8+%O6,F3L!?S$9&46NZIHT6J^DZ6TA:RG,*&0E9-1G5XMG%/TT9$Y"N'IVTN
M12%55*D5  CG0(E*D1,$H=I.US=7.H7\B0I,\LK)S'$999 S'8,*B;RZQC.Y
MV&06Y9O,K;R1R&YD<K&ZEQ%G: )2QC)0D["8P)?:YRRDX.2:=;L0L>W+C4]"
M[PNY*$P:/23D!&()0B;HC%I%22,>Y;LDS(&F)23;(.HQ CITH9&:<.VZ2::J
M3AJ'LM)>'3;:YU?2;7UQBIAFD+2E-[2H9$9SN$21.0QVJ/FU4DD$$RXTM5A:
M>V'5G<X)W-EFWA<-GE44G/ Y4 @FIJZ6XE'6KB9AI=Z@AI>L05C-(/+6 HH%
MCT':\C[5M2KU(D&=(ZCI0R14T&Y2F4(*!"I LDI6Z_(;](IHT)U2XG@*+ -S
M=1E$?3MPIZRGV<$Y)QG<2Q!$34E.Q5!S.2F A.<Y]H+SGGRSVX/OV&,D.DW;
M5R:VEG]BEG581\LP15CZS7X].0=L9 ZK%"3;/(A)PFM+F[Q5N*[0@R+4"),@
M/VBJCR=?2+3K=[=QJ+3S('8/<3R&-7C 8QLLI4B+(W;7^;;+/V(KF8[F"V"C
M=+.P&=Q+%<@[L,3E=IQVQW!YR*L-L_7.FGM 67AM>:Y%&>5:-&,S$U&J@1$1
M6!QWGB$(XIC$5\*HS.D10IC&4,D82F 2C26-[J<=X!+>7^Z+<S127-U[0VE<
M;6D[C<'!V^ ()!!J):-,UQLDED&Q&9D=CSC@J1G'8Y_1QB=,W+55)5AM951D
MP%X<Z+:3F(6,AHUHE-28*2'LUV@Q*DZ$J"ZX,D%%2+]HXE$ACD**@==3MM1N
MEEU"Y9PF&,<4KRR/T4PF]"Y*^T 7(&WC@X.16;JWF?J39VH.T99LE5P ^/H\
M@9]WD <U0.9ZQ;98MCVO7NET;! N6L_9!>6)?V<LM.1\&\<)'<KQKV-%2'$X
M]ZZ44%0KTI1(W$$55A1+Z^+T9MK>RM[W56AF5H8-D*[P(7F1?9#I)B7'"@8*
MGZ7.,U:):I*D(DC5R$&%&<*<=@V1G/ P1CZ/?N=FZT=52NVZEK+<+C9L+'3U
M:AHVO3%:,15NX</'LRJX&>@TVKO@DBEXMOXL@-D$#MT$G",@0J9$!X>B^HQ:
M;<:AIJV$LD-Q+)/'<##*JK$%Z,VY?H'8=IW%MS;3&<EJYV2-'/+:+&RJ79ED
M/("X4;6('&.< GN>WB/.U]:\$%DBJO':G1"8G8V,CK).R\@T70DQ(1FW%BS2
M*R7>+&*L5&06>HN(M\"!SJ)I+K,DW"];-Z,7#6<TQU98EBES;0I"Y"EMS(T[
M(X: .ZM##(F]5F*+AV81U+ATN53MDN&,,9>2-5.PY4@MLR2A=%;>4?*[5#>P
MN2OLN%FK='?VZ&L-@;UAT\@Y=W7D)(6X-WZI"*/V<#(N$F;J#F(0CCQ/LB:?
MMEXPS-%R7O:?8&2XH>&N;Y+N-(;I0]XQ BGP%+KD[8G?@ Y.5()4]SLER#<0
M12O':RP1"=5FC5@FX,7X1I4P5GMYCP9XTQ)V8K=6S'=TO;]WO(['DH,UQB)^
M5DF45(M$WJZ*-<F4HIP8S,IUI&/8"ZL8)-DS%;.9MS(BDWX:G6(GXHB_O_17
MT>O(!-+?R02E# ML=KS/'TOGRI+;?FTE=2=I'S@Z@[@'ZYZ-:!'IXFNGG@B1
MYH0JY#(75A((TZC1QQ;G<96%%#NN]8P?:/?5T5_)7V#2\6?841:Z_>#;DH57
M7C9JT1\_4)#6T)+E;V%8BU.8R$DE/V)1NLP2$KV6;-(Y\S6;F1604545\7Z1
M^F]AJK"TNK6X@.EWD^^WMV@GCOY8MT*@73+&UO"K"0>Q&SM&PP0>*I/2O53K
M)2P:V2*&SN)2S=5G=YU+0[D950"(+N('TG+$L2 H%QM2TG3$<I+PML4F+R_F
MMJ/:50V!)!5S;5V,05"-FI^5C8MVR+'5Y*60DG_?NB"+",*4@'<G$@'H=92]
MGZ,]M;6]A'!I27E\ZQ]*S#RDR06\3NK"6Y,31IM7]I*2< 9QXU+&TX]@DDD+
MAFSQP20" .0>XY&,C.:N*'3%I?R'YJ*>[^[4R/IZ?\O'T]V>/&I76 =ZC(SQ
M&@[]^P'W=O("NGR;:=^F2?,NV1^-!Z8=+"(B-4/R/J/MF9_W[,_*5W]<?X%_
M*GR;9_PL^\N_YUQ]&'2WWJ'_ ,LS7^_X^4KOZX_P+^5/DVS_ (7^=_\ 57/T
M8=+?>HIZ<?;F:]/A_9_ICY2N_KKWS]!>_GV[T^3;/^%_G?\ U4^C#I;[U%/\
MLS7^_P#X S'RE=_77_ OY>\T^3;/^%_G?_54L5*H0%'ADJ_6F9F$4@LNX2;&
M<.'0E5<G[Q8W>NE551 Q_/LB?LE]P!D::9YW,DA!8@ D #@# X'N\:E111P(
M(XQM4$D#)/).3R>:V;.5=*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3
M%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*^=P\:,R@=VZ;M2&'@IG"Z2!
M1'X 94Q0$?(?(!YS(!/8$_ 9K!('<@?$@?SKS2707*!T5DEB&#DIDE"*%$/B
M!B"("'XAS&".XQ0$'L0?@<U[<5FF*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*53_JVT
M9-;D)I:2B*[7[RVUSM:.G;1KVV+-D:];*7.QC^JVCO1>IK,QEH..E3S4.*Z2
M@]ZU73;E,Z51(;U?HMK4.D'6(Y;B>Q;4-+D@MM0M59KBTO()$NK7;LP_2GDB
M$,VU@,,I8; Q$>XB,O2P%<)(&9&^BRD%6SG(R V1P>1BOHT_T=:\T^\V.HPL
M-UL\=L&I1^NTH:T3!'K:JZZB@F_9M.A72+="2<,8\E@?MF+V8>2$FTCRLV*#
MHB*'ZIIK'I;?:Q%8)+!96SV-U+?-+:Q&-KJ_FZ(ENYE+&-9)#;HSK$D<;2%V
M*EFXWMXA;2=5&8L"FS=A@@C8LBCC)"D_O$\8'8"OR<=8716XZ3X&:V7KLMFM
M&MK5L.Z:N8RL^BT4=TUK!O2E*PL)8DQ13E995BJ2-?/2,FR[!NJ06"CI8JA/
MNNBZ]'KS0Z=>O%%?KI]M?2Q0;D2<W*9W6Y?(=$#CJ)'E@Q&6QNS]2T36AZ0M
M+:W<$<#0*LJE)26FE5BKLJL@"!>#@&3OWP,U\.B>J:SZR9LJ]$PE<CI"SP"+
MMR[DG:WMB 1BBN&[).)2</"*ME)$Q6D\FLY(N8_@X:3=D=(,%GF>/U_T;DTR
M*[OK22:[:2Z=3BTW*%FD("JT'LK(A90Q*+'O.T!),JWD_2#T2!D>Y#3W$$=S
MO,20@QS"64>RS(H V;FA+>RA#S$L&FR.TND[2HG<QGS/?1ESN+^&C7$A'PK@
M'9FQ(-HW4AJ<V6533*J4D\XASV-3CO7@5>P.9'NV\HDBCYP=4.EE-*T4S%%=
M9Q($B*G,2NFW*HC/GV@$7#&1E0;A\]N;2X9IA<)):PQ2,$ZJ;')G#=:Z*'G(
MMQ(L*[1T_6($10T3$U_EM7$V[L4=L[%G9MA(1;ELJG!-8@2MGA*:V1?*M?$N
MG";B)BVBAD63M3N).1=OEW!E5TG(KNP^D6GI''HMK%H%G!%.O3N5N+P2X6 L
MJ//<.JB3>SM-)M#2(%:(HQ8XS&FLUB"BUP4]EL,XR>I(8X@!PI9]C2<>PL>T
MJ H53/NX-S668TO(4E>/9PM&F4GT-<;&DF!5CJ2**4JE$"Z=**MXQV* *&-V
MB*+.D2(%0.F7O2J<](M;3Y4BN4EZE[&T<EM:,PWJ50[F,:X=\9)V9R@&]P0R
M$0(["$W+S2L6<+F/VMH5$<PEP,*"I;"C_F+ ^)K5-6Z#U?6*[%#$V'V]7YCV
M/9G]O]K-'396PQ[!L"L<FG'E2;-T8$\JN5>,7,+XKA;L.G"G9,F6=J&O7MQ=
M3)+$(9X.M +7INK"!F!,N9,LW541[95'3(Q@9&:%MROW$P=U5-I'L994)QR2
MQ7 (R,A@!D\.M"')?7&IM-ZCN#]9"J2SE*:!W)NFL#(S-G?1:D/))'8I"B^?
M11W3PP.4VPI,T)$4&3A5;Q !OZ+7 M!J6IZC;IFYC^:VQJTR1VRRK-$0_*J^
MQ1M+Y9HB74#;4>RMYBLMY,@0N V.0XC0$$GC( (&1]+@'RS/NLX(F@D8^Q61
MBO8)EB1O!/95T8B+I^:%C/9)G I*"Y5CGJ)2.72BCQ,[Y8AC*=\HU724&BOK
MZ/6'EMX)XX8OG)Q&I+K&K2B1@S#:'4;D!5"%48)5<&LSHEVAAB<EBJ'*JQY8
MD9R1AE.TJ,$C=G(XQ53K7<I75M@O.]5M90<Y&W^QNX&Q&*HA$MURV&24E6R@
MR$<!Y&/%)2+1?(.5&YD9-5FY2>BLJ+A4M_ +6_BM=&&J212V<(EMTPTTA:W@
M;<BQ/E9"T9D!5"64<QCA14Y;=3%#'&YCFA57WG)( 80NQW85E!8*XR"N5.Y<
M#,C1MB-M:@5BPR,*XKKJ1=/HB1CEE47S-1!%ZI&Q,Y! X3;)O8Y:59J1#M$P
M-T4GPLT9!!LE-M'2?EKN[?3=5FT]+E7BD$4EM=QCIR1RRPI+&'0,^&;=L>-C
MW\2DJ5(BMS'+)N(=D!;: V-R\3PLV=REHVZ\+JNX1EV0EH&4QKM3:.IBZ_L5
M8FV)/G;0GOM.E1Y&)W[EFNZ?G1EH*'E_!*MCG:G45408'<,D)-C(QAC!&69B
M89*BTZZNUU=K59YGGFE:"<E^)X7]NX2X!WK-&BAI"CKN= I3IRL"MK9V%U+>
MVAMU22*Z*I*P*JH,:;8[AL$]*1 FV2103',&61I+>X 7K+O^W)+=%WJM.@Y^
M;86ETR84>O+2*B$<P7EIV15/'L+*_EI'NV*[61E"-DIHJ;=")6*1R=<Y&A)$
M/;6N@0,MSJ6IV44D<;K,BJ&FG>UM$5C($1227D623:,RW,>TSIU"<_3M#]&H
M]/@EO;N.V: R-<RXW-M@@08:%$A4JI*&383G!9=V-@7M=Z3ODKNH./T'OM?=
M6NZD3:$P>I#I2$M4Q!RMEAUH"95?VYRRMD6[E6U80MT6*<.R04D%&Z[I(DA(
MM6R2#5RI3:G_ .(&CQ:[HS:?>W/R=$MTNJS6T<RPND\'3MHVMG$9N!;2 3.0
M@95/3C+L"!!]+]4M-1@AM--;J*C=64JK10NZE#& KHA$J8<"0*-H<@.RLPKM
M:3ZB.JF,W?IC7MGUEJVFLMC32R"^JH^RRE\V3!Z[AF+H;#LJ?N$.$;2X&+AW
M)&#5@P%G(*3CQR:/;K@Y2.8OB#H'HO)HNL7]OJ6J7CZ=""-4>VCL=-FOYG7U
M?3H+.7J7EQ+,A9I'W((47J,-I&?$=:?JQ*R1KU"<QAF9P@7+2%L!5 ( "\DD
MX[Y(OK!5:AMY%W;JU U9*4F^\,\LD+'18/)0#*#WYEI5FEWKKMK$$5Q%<W>+
M$$51,H41SQ$UU?-&EI<W%TT4!PEM-)+LBX]D")SA,*1MPH]D\<&I8QR0!SW(
M'?[?&MPR+6:8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%
M*8I3%*8I3%*8I3%*8I3%*HALK>VYX^\V:KTV!3680TF9DS=,ZV_E7*Z::*:A
MC+*B+AN)A,<W(II)@   <?WUY:Z?;201RR;V9QE@'"@<G! "YQC&>>X.#WQ1
MW5_<1SR11[%5#A24W$\ G)S@<YQQVQX\G/Z9ZEY>P69.C[(CF\;+O5BM(V11
M:JQP^T! >S'2C%<W*"S@W9*V52(F J&(FHEPH50O.\TY8XS+!N(7ED)S[/BR
MGN=O[P(X[#)!SUL]1:600SA0S<*ZC R1D*1D\GD COBKH93U;TQ2N.0^(?QX
MI3M%_O@_C#%8R/,?>*X[9/[XO_:#_OS.#Y'[C3(\Q]XK2=CW%*ATBQ6PR9%S
MQ+$5&J!Q'L+O7"J;5BD?LB!N[,Z72[SLB!N[[79$!XSK;Q&::.+D;FP?, 9+
M?;@'[:XW$PAADE&&**2!D=SP,^[)&:ZUZ_3=A;W<R=MG+09NW\8JW(Y?F<."
M'< 4JAFD;'H*)(-F34BJ9#=@R29!.!$B*'!02^I18X0(XD 4#/ VD_WFX+9Y
MQGQY[9KRTLLDI+RR-DGMDX'&!A<X4#Q'?[36>-T[[&C1 \1<HT!( ]V";^;C
ME X\_(4FRP%_#]?CD?>.9.UL[D!R?W@K8^&<_KRQSH'*]I&'&/9)4G..^._O
M\L#QKZ"5+J:@.#1MIF71"< 4C2X'73$"FY /#R;E #>?GYI<\#P/EY#S,%LX
MPT,>1SGIJ/L! [>./<175+F=<$3R9[ !V(_PL<<X(SXY\ !7U$V9U4UH1!VV
MG)%%+@3"YKC"73$/(/K.H]HJH8OJ(B"_(#R B'&<FL+-_P#TPI_Y7(P.?#(Y
M[=P?#CDUW74;Q<8DW8\U0Y[]^"<>\$>(SQ68:=7^Q(93N+13HE8P" \'0DX1
MUV>>!Y!8ZZ8B/ B @@4!$! /(!XX/I,!^@\BGR&'![^X$8XSR?#SKNFK3CZ<
M:,#XY*$=OB#Y]AXXX%2-$=:53<"4LW49V.Y$ ,I'NF<F0.?4>RM[./P'P 3#
MZ\@'&1GTB1?H3(WEN5E^ ]G?R?ACO4A-7B(^<B=3GLI##!Q@Y.WS\NW-3)6^
MHK4=E$B:%K;13@_'#:>34B3 (F H%\0X#P)C"(AP!71A'D. R))8749(,18#
MQ3VACW>)^[CQQ4R._M9>T@7C.),(?Q./Z'P)J8V3]C)($=1SUH_;'#DCAFX1
M=('#_P!%5 YTS?P&'(C*RG#*5/DP(/W&I896&5((\P01^%?7F*S3%*8I3%*8
MI3%*8I55]QT.Q6W:M".9[=&E6=5^:B8R9IK]\U4H=[2<)2L=:95NT5(W<Q[]
M@V5B#&D$UF0'+X94$S.TCCZ;2+VVM=+OP$LFNEN8)98;R.-A?V)4Q26T3."R
MR1R,)ATR'P=PSL('-E+.H]H#:<,#]$C&,CL<^&?+XUL%(H,5K**M*6U;I5K$
MKL>XI2+@)N/B:] R$TX8M&:;=I#R+MRT=3,P>/&1?)H&'Q3X3G:LTRD$31[^
M^DU.6U^3+*YA73K,QJ(GEN9TA5WDW/-&H=(8=_2C9A[*<.QW#&R,827$A1BQ
M(8,4P2,8!!&,]SCN2:_/W?/D[)OJ'V1U:[YCIQ@PVMKF_P"R7<CI!I69):7=
M24.T<2^K6]>=*3A&RD/=X)K#J1TBBQ1,/+QO&-S!W0$^QQ>E]EH.G^CFE>HF
M:QU/3;%8=;ENP8T$S+%J+RP]$JL]A.T@9=WLY!=AEBUQIFN:A++:V=WJ+PV-
MO>0QR6T<$$8-NKD8FN%7UB2.2-F:0,2)!G. HQT^T78FY]1Q%NLY(N;HBL5*
M/(%&P.JH]9E0LUE(\;3-454D&1DDY1>!3E5B-53)/VK:,,83D[HHY=ZAZ.:1
MJ5Y%-#,TMS+:L(XUO%91$F +E.FYV %PBR)F)W<#DU[?5/1O3-4>)01,S1H6
MC%RP'1C.])QL.[B4QY]HJ2(]N-I)M]1NK))U6T(EPWEK/-6^1G.Q:I!VFW22
M9D:&5E(Y=(Y5'8RTBZE)-9P=8XF5</FPIK.$$6(YX6?1=6T*ROY9DMW=VVL!
M+))+T%8HKJR1E)%EW%RI93R[$ KMKP5_Z,7EI,96$20V:*?5XU9W95PL<BNJ
M;"H2&%@"1M^=4@'V:LKLG:]$VM2H;750FVLC)O)"(L5O\*0KD&-AF1A9^-BS
MB0A3.C,'+EU7W!"(<*,X]-JD?Q*G=H3_ $>@N+2X74;A'B+03QKU&,,O4O>E
M \XW$,%B6[9@[<ARN"=IQY@:9<P/+->0R0QH8TM^JA59(;0S$G##;MFZ"38&
M<M*Q/!!.S48*G6ZJ]UK7+BTEFL)(SMUGY=L=FDT<N[)%4F/.*H$66;F;1$B[
MFHU%4%Q!0(T%%! _:(31]9.JZO=WSX6*&Q-JD8DW+'$@MXP5<@ ;F61^1CJ2
M,,L%4U&:W^C<2QA6E*(N[(90EU?SDX'8R)'$Q\EX[&L5MJ(KLSH]:QUR2$UB
MDK;$LJ[(-GA&SARQBH6&?62%=.&2J3<.RYF4$SK+F,Y;+LC,SN$T3"D$OT8U
MB[GU!9979K 2,DL6Q)5AZP>V@D7<A;*S3)*^/9959BI\0AD%PUJ5&$MYY) <
MX+"[D:/G@^W%;RI@'L^<''&\0\W)5>*H5!V'=F4Q:;,ZAK2R\?/F>D39S\8[
M2C(J;?OU_P"PPBE:DLR%^9%FDC'O63=906B2ZM+>:C8'78KJS"VT#Q+'*H41
MAIFMQ%+*40#:'98SDJ&=@[G!8 :+!&XNY4B"QP"YA<")0X$<W6+QKR5VO'>)
M[/;?%WS@Q_;>H+5Z="VQ6)-1L\28Q<9#LCI1YI*-FG-1D%&*:":( H?VXTAF
MT(\75>-42N%()^8KCN9I5)3GI1=]<6-3<PEIGG@G"R)<*JHZQW +@.RK[)((
M967>"&5BIL(M*NYKFP,4+/U3-+(DF(P$N \DP.!Q TBSJN" IN(3R4!JG=]Z
MLW$G3JC6JTZ8'1I"4E)NU64JW83ZT"\;,WC-!DV2%!T1Y"I-^P[;G>G37:HP
M[9RU!6$.=*[D]&[K6KBYF9)K)5F$=O(Z82>8-AIU9MV+=)EV0A2Q=$1R5)VG
MUFG>B%TT]S-,)8DN=D,8Z;-$95+!IG=D*&,[1(I &YGG (20EJ\PM0VMU(Q-
M]V)2SRJ3B+N=29W@KBPH ZFK-L>0D8^G##H]B+7>/9.89R"4FQ8&643.HUD_
M"':MUU6/L;2PT;1KNQMKI8&N6L+R6"Y:W+*@LHXY+Z>0KO,.]=LG6=SDN4#;
MGV-ZNZ.G>B5K:&6VBO#F.WMD6-(V2,-&LTBES*)&&] %8*T@5QU%YK]'.DOD
M@M?5[4>K[IL&LP\CU9UQI$S5@EWEIL3JFO)YE8SRS=I)LVCE=@YDV->%I7'$
MVS8K-E7[,99%!PY$DB?Y3>_^(MT^IWL-O+,- F:6.)%@M_7$C:WZ74C9E#!#
M/F<0LX8*W3+@ K5!JWI%=W1N[2RFZ6G2MLC3I*CF':H= P =$E(8E<Y <@@9
M*UV+5S8^XAV_$4&?3UX_:C'NY&W1%-0GW1Z)% R%2'=R]GDE&[,[^4=@DDUA
MPC$UEFJAG("DD":H^6N-.TCY(FOX#J,;=1([2:\:!/7I=X$R16T89Q'&F2\O
M4(#C;RV5KRP9MP! [$L <[?+GW^_'%?=N'I.UWN>YL[]+6+950L9:L>C3;S7
M-WD:A\[:4I(C+#5[$9D115>+%\=54W@%8]VH5=1-1T<@) ERTGTHU#1[-[&&
MWTV[MS="^@34+&.[]4O1&(O6K?>0!+TP .H'0$ A02Q.DD"2,'+.K;=A*.4W
M+WVG&,C/-3K1Z15M;U."HU)AFE?JM:8)QL+#L@/X=FU3,8XAVU3JKKK++**N
M73IPJLZ=NEEG3E95=910U+>7EUJ%U/>WLSW%U<R&2:9\;G<X'90JJJ@!4555
M41555"@ =5544*HPJ@ #W#]<GQ/-;5D:MJ8I3%*8I3%*8I3%*8I3%*8I3%*8
MI3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*KY<KK48*:DD9>RP<
M>NFX,"C9Q)-B.2"!2#P9J"AG #P("(=UR///O\_3V8Q:PX'[@'Q//'QKR=\,
MW<_EO\>.,#S[<\9QW^-4KNTZPV1N2IA1^\7,W6B&9Y5N@H@9VLSD%7KA^':(
MDN+>/:&$I5UBE$2-U.R'=%2$TAR%BD+C@@C![88=LCOG \\$@<URA4F6,+](
M-R03QM).?@._OYKL&/*2!Q$1=KASZ@4XE /Q 7@ 'XB'F/GR(YY[8G@B_<#_
M #S^-7O5D^NWWUZ3/'9_([IP8!]0,LH(#^ 0[7&9  [ #P["M2[GNQ^^O#Q"
M_'9[];L_#O#\?Q=KC,_=VQV':L9/F?O->'>J?=#_ /;-[_7WXIDGN3]].\4^
MZ'_[1O\ OS.?A]P_*F3YG[S6GWZMC=*A.ULRW=J23,2M55!.9-%ZW53=LE#@
M'(]V#I!+O> $>[$_ "80#.D,G3D5_ 'G''!SGMSX_P!*TD7JQNA)]H<<]CW'
MX]\>'//:J0U#9%NTLK(U2=K@N6Y7BCD&+UPHP5;N#E(FJLQ>%0=(.6;HJ2:@
M"5)5(Y@[Q)4O;.!KQ"LH#(P(([CO@=LCS'(Y/;!%4SHR$HZD$'C[?(XP0?YY
M[=A*#/JEA3FX?U*4;EYX$S22:/>./@19!@/O$..T <>O(9DK@XW#WC!_GV\O
M#)^-: 9\SDG!'N]W?GWD8R*VMEU(:Y<\>(+/1XB(<^*C2+$#X<BQ>.CB <>?
MZGR//EFN"3@8/'GR/@".33:.X/CQG[.^.W?Q'QQFMO8;EUE("4$;='(G$ X*
M^2>QW'IR F?-FZ8&XX_;CY  "/QR01X?B#_(^?'QIM]XY]_P\\>>:W-M,5RP
M)B1G)P<TD<H<IH.V+\HE'@/K)D45#CS#D!+S\0#W8[>?<^![]S^OACN*8;/C
MG ^X]OU\?(UCGU"I4@F<CZHUQ8I_(3>QF"2O ^@E730(J ^?J50!#R\P], ]
M\$^\ G'W9P#Q3)'?R\1G(/O_ !Y\OLJ-)OIVUW*=L[!&3@5C<B!HY\=9L CY
M<F;R /  GESV4CHA\#%#S#.X\>..V<?9X>&!_7/.6X<# '(S_7@>>!Q49NNG
M^_5M0[FBW<YA^L)4R.Y"N/3!R ]@%6;ARV6'R#D3J-R"(>@!@['&)(U;/?(#
M#R[$<<>7/QK=7=?H2NA!SPS+Y]\'!/;PY^(KR:[3ZD]9]DDZWD)F-0#LB:;8
MEG&@D)[S3<>8S@@"4!^LL^Y#CDQ1$! (LEA:RYPFULGF,[<9&?HDX//N[9[<
M5+BU"ZC..IU !@"3#DXQXJ,]N<_[U+=3ZSH!V*;>Y5E[#J\]E1]#K%DF@&Y$
M!,=HX!LY1('J($6=G]1 OEQD"72'&3#(KX_<<;6^\9'GX#W$U81:LC<2QE?
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M <\K\#WX\^,8Q\<FL*VMG4?J 2E<*R<S"-Q^MXPHV>&[HO/ >*+WCZ-2XY$
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M3&""5)/;O@8';GL/ACOSX\5N2"Z+E(BZ"A%4E  Q#D,!BB'P\O00]#%'@Q1
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M]NPR0:W1<G/@/UC^OC_.M1*4" /F)C&$3'.<1,<YS#R8YS#YF,8>1$1_$
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M@>>.0/;R2Q28V[XI&B8!RJX+JRE5+%022!DC)K=&D5LQLRMVW*Q4@$@<L",
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MA*(Y[F:9!.ZR3;99&<=5T5$:3VO:*JJDY('-<YG6265U#!7=G <@L S$^T0
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M(%809/CPS>?F<'(QSQR3C/%2@4IU#D22(*BRIP323* B)SF] \O0H!R8YAX
MA"F,(@ 95\ %F(55&68G  'O_ #Q/ KHS!1DG'E\:DZ*CRQK)-L @93S4<*
M' *+GX[9@Y\^R' $3 ?V*92%\N.,I;B7K2,PR%[(">RCM]I[GWD]^YALQ8DG
M_;'Z\?&LCG&M:8I3%*8I3%*8I3%*8I59=X::+8T5[?56Y4[(V3[Z18H$[(SB
M*7!N_1*3C]=D"A]02AVWI !(1%<J0GL+6Z*GIR'*MP"?W3@\? \ #CR\C42X
MM]_MI@.!V ^E_OY^?@#FO@TCMXT\1&G6E<2V!L0R,9(.C 4TND@'9\(X$_ C
M+-R%[(";Z[U(HF-RY34[ZQ(P-W&#@^SG&#X_ ^=5I4DGOD$@YP.WAX<]_NY
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M#G]2R<NFWKG3@D(/RJYCL?G(QUG%QZK@Y;YL=<%,R;01A@=F2.PMY6Z&%_\
M,L5AY'M$/L.1X8;C)[^%'FY=<1]TUUKU[8T6]NVO#3<]1(=1J]!6:C*_'MY6
M26[T&XMV2A8]<7+9N_6:KO2-GP,TUSL714B:;?26M]>K 3;:=+##>2AEQ%).
MQ2,;<AG!<;24#!2R;RN]=V?5IC'-*%S' ZI(P(P&9BH \2 <9(X&1YUJQ^I/
M4Z=V&BGEY@'I;8GK\]B"IVDU"3V L!.ZHZE_+$#426@ZBB;,(P9?O E#DAA,
M$P<K 9'R)J/JGK8BC*>K&]$'K%OZX;('!NQ9]7UDVX'M=3IX,8,H!B]NMO4Y
MS'U-JXV=4)U$ZIB'>01YWE .<X[#/:MLU[N#7VTWMN846</-K4:5:0UC/[*F
M(YNV?OF))%J5FYE6#%*6;+,SE63D(LSR/4 >$W1Q 0R/>:;>V"6SWD/1%W&T
ML ZD3LR(^QMPC=S&P88*2!''<J*UFMYH!&95V=0%E&Y2< @'(4G;R>QP>_%;
MLI8(%$S@JLW$)&:$%1T5229D,V("XM1.X RP"B0'0"V$RG9 %P%'GO $N11%
M*=N(I#NX4A&(8XW84X]H[?:P,^S@]CFN8CD."$<@]B%8YXSQQSQS\.>U0O=>
MIK4^OK-.U>S/[,@XJT779NUS,=1+G.52J1%K5?(P<G9K5"P;^"@V#LT<]44>
M2#U!NS;MEG;U5NU3.J6SM=#U&]MXKFWC@9;B2>&VBDO+6&XN9;8(9DM[>65)
MI642)A40EV8*@9CBI$=E/*BN@3#LZQJTB))(R8W*B,P9B,C@"OH;]2NF7<?L
MR1:W!!RCIZWLZ-L1%!A)J/:_8I%Y',(]NHQ*S%V[9OG4JT(SE&*+F,<]ET*3
MLW@GG<:G1-462PC:T93J=LUW9%GC"S0(LCNP<MM5D6-BT;E9%]D,@WINQZG<
M;H5V8,Z&2+)&&55+-SG@JHR0<$<>=;F&UZ".T_L+A8&X[)^99M@_-L$7/??-
M0LN2$&1\7W/@>\]H*%)X'Q/CNY'Q7A_#<JA&^3[SU#Y4Z#>H>M>I^L97'K/3
M,O3VYWXV G?C9GV<[N*Y="7H>L;?FNIT]V1]+;N[=\8XSVSQXC,B9#KE3%*8
MI3&!Y?K] 4KH=WUUH]8U4^6)Z?-%4C1&V)?I5::YL,5L.1B*N^?L;@6X2E-:
M3NXVA&Z:BBM5TQ8G] @59;NP,V+,W=)'O$91$PJ5WQ8I3%*8I3%*U"Z:^H.R
M(MO![$I%0OL*T?HRK6(NE:A;3%MI1NBX;MY)O'SC)\T1?H-W;I!%XFB5PDBY
M<)$4*190INL4TT#%X)I87*E2T4CQL5)!*ED()4D D9P2 <<"M61'&'57'?#
M,/+L0?#(^!([5\MCUAK6X0L36[;KRC6BNP#AH[@H"Q5* FX6%=,$Q18N8F+D
MH]RQCG#-$QDFJS-!%1ND8R:)B$$0$D\\3M)'-+'(X(>1)'1W#<D,ZL&8$]\D
MY\:%$("E%('8%00/@","J^6'HMU7;.H2!ZBK)*6F8L-8F(VQ0%3=I4GYJQ<]
M#U=U4HEVC)I4Q/9"D3&Q[Y[(LZ6YOZ]!0LSI6S)U8)H$G:<Y-5N([)K)%C1'
M5D>4&7J,CN)&!4RF#<Q !E$(E* *7P!CB;:,S"8Y)&,+[( (&!R%#[0/W-VS
M/)7-2)LVK]-<)&4(-MT_3S>(:S$)JW6B=UJ53<L(^7NIT*W!4:GI2D8NC&'L
M8D;0K2%BB-D7R9$67<F2(0@0TNKJ,R&.YG0RL&E*32*9&!+!I"&!=@Q)!;)!
M).<UU,<9"@HA"C"@J" .. "..PK?1U9K$UL5OHZYH@WE<B*2US&H5\;8JFWC
M74,W35L0Q_M=0B$0]>12)3/!*G&NW+$@%:KJI'QZQ<=,0]>;HC)$75?I@E@Q
M(3=MY8!CQ]( ]QFL[$SNV+N^MM&>!@<XSVX^'':L$RT+HR-AIJN1VF-3L*]9
M$FB%B@F6NJ@UAIY"/D74PP1FHQ"'392B3&6>O)1FF^07(UD7;EZ@";E=54^Y
MO+MF1VNKDO'DQN9Y2R$J%)1BV5RH"G:1E0 > !6O2BP5Z<>#C(V+@X)(R,8.
M"21GQ)-9:4U'JF;:1+":UEKZ78P-@>6V#92E,KC]I#6J0D'$L_LL4W=QJJ,=
M8'TJ[=2;R9:$1D7,@Y7>+.3N%E%#:+<W"%F2XF4N@B<K+(I>-5"K&Q# LBJ
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M._=[+^5(?I,=*7^')_@;\JQN7ZR^/B/#O]WC3VE'?N]E_*D/TF8Z4G\-_P#
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M2F!I[=U-PT+H03$J(Z,0Z]#J%MU$(0;>O=OU#'\Y#URICEB!)4E#EF5@2=O
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MCJJJYQ2F*4Q2J!::=#N#KDZEMOM"E6IVB*33NDFH21 *JA)7<[\VW-YKLG
M "C%NYG5U/>D2%0J<[59EHL<KABHBFI5_<4IBE,4IBE,4IBE,4KKE^4H_P"(
MW2O_ /F =&__ /EF/Q3_ ''W\&NQK%*8I3%*8I3%*C&8^V;S]^'_ $2ADY/V
M:?W?ZG]<U63_ +5_B/Y"NK;K_I?3W./HJ;VQ5*%.6=AJ>TC#O;,E#'EFS%CM
MS2#%H1D,BZ0<=A,+79BMNZ*).Y?3P%.416*?V'HWZ1ZCHL;Q6MS=QP27D4\D
M5O*8D=A9WT3!O98$L3;.Q.!_9T&"<&H[Z$-6(<(FY%,.YHG?!<F=6)3'"BVD
MCP6&#."#DD51>^:NZ)8Z,V6NRUUIM%6)H7RB4BP%HA5041?:MVYK6!HJK'B1
M 0>1,9*2"%+$HE,6-7?>&[H@F ?00>G>N*UMU+[4I MQZ./(IN6!ECM;.Z74
M4Y1AB^E>&27=D;HU+J6P5U/H:)/9188^J#$C="8],ZG\[;.,N,FQ2-XVY&6D
M&T 9S\6S]8=%,1([91C]=Z?;IQ$=UPJQGL]"K 1LIKS4NIIJHC&@21* *1DI
M-RCBK"02B206D!0!(QC";-KZ=ZVHM!+>:E(RMH74)N2>LMM=W;WP.4)!O('A
MBE4D[EC4NQ4J!K_PAU22JP1];>(\V\IV>O#I6^!O )M&@=Y<;<[SC!SG9;CJ
M/HC83&S46>N-+D1AKWN*/8%;(U44TF4)T.U+8,4DP[+\ \(VN#YU*1W9[)2V
MM1R<H$<=I0>4'IYKRK;*][JC,L%HDK&Y)ZDBZW+<32$;,EI;)ELF/&%4 DH
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M_?,HR_SF36H]$ QQTHQG<H'0EX]9;UZ(\'_T+=?4R>?;8XXYK.7O4O1!''G
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MC$;>UTL<=^ODP_\ ]@!*^>*^W[)-$\6##YT17C!FX2M@W[XW>#.V2%+8X*+
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MCHJK<RQCIFQ2MTQ2F*4Q2F*5&,Q]LWO[\/\ HE_\<G)^S3^[_4U63?M7^/\
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M+;#&TE9:"T<!G#7=5:KE0V 5$6K?ED,C!U6$;LCM^Z-%+-U7# 45G"QS8)9
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M_H5I=#T*=]*73(PMOI/RE&ZPPN)R)9XELTWC/K<Q@=X4&%D&\+CIL*I ;FY
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M:UY&*30E'#U\P!HXD'QW$HZG?$PDW#$P202Q$I&2)+9.G [-LR[(F%S)OW*
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M4IBE,4IBE,4IBE,4K&242UDR!WP"FN0!!)REP"J?/N'R$%$Q'S,D<#$$?,
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MI3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I48S'VS><?=A_P!$O/\
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MI3%*8I3%*8I3%*8I3%*C&8^V;S]^'\/[4O\ 3\'IDY/V<?\ =_ZFJLF_:O\
M'^@K&YM7*F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F
M*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*5&^W:_\Y==VB.(0#N$H
M\\DT#L]HWBHHQ7Z8$\P^LJ5N=#W\E6,' @(@/>V?9,C9XR 1SR&X/(\C@_9G
MPKG,@>*1?';D?$$'^GF*A;IAGQ=UR<KJI^V>(D4Y!L41#R:2J0@<A $W(%3=
MM%CGX#@#.?/S,.73#!]_8\Y['SP!X\8[CFJ4\@'WGC&,9[8]W!Y\ZUGJ3C5H
MFPU"Y,@%-0R8LU%R (&(]B')7[%0PA^W.FY5 O/')6WD(@'EE1G*D\$]O#:1
MAO>> >V3S@"MD;;AAW0Y!YSD'*\CM[7GQY<BNQ>ISB5EK%?L"(@*<Q$1\AY<
M#V3N6R:BJ8\"(=I-4QTS  CP8HA[L\C*ACD>,_N,R_8#P?M&#7L8G$D:./WE
M5OO'/X^7'EQ6P9SK>F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4
MQ2F*4Q2F*4Q2F*4Q2HQF/MF\_?A_S!DY/V:?W?ZFJR;]J_Q_H/U[JQN;5RIB
ME,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IB
ME,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE>)RE.4Q#E Q#E$IBB'(&*8! Q1#W@
M("("'O#%*HCJ[FB;RF*NL(HM7CF9@D@.( !B=[[2AE Y#@3+)((D2]X^)[(<
M\AE^C[XD/&2JEC[P,$'WC[?'RJEE7;)(G/#':#SQG(QX=L_'C'C4Z[\@_;&M
MY55-/MKP;IG-(@''($04\*Z'XB4K%XX6-[P[KM#SV!YV'?X\=L_=CQXX\.<&
MN0YR/=YX[?'@CS\?&I"Z4+*$YJEI&J*=IU69)[%G()@,<&JQPD&AQ#U @@Z5
M1)R  /<& /3R\_J<>RY+8.)45^<]P2A[^/L@GOW')KTVER;[55SS&64\]ADE
M?AQBK,Y758TQ2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*
M4Q2F*4Q2F*5&4S]LWG[[_LER<G[./^[_ -3563_M7^(_D*QF;5RIBE,4IBE,
M4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,
M4IBE,4IBE,4IBE,4IBE,4IBE,4JB_4 W4J>U:]<&Q!*#M"*E ,7M!WCV#=E0
M7)Y>7)FR+(#  " @;S#DW(W%BVZ$KXHQ[ 9VMDGD^9R!X]_ 8-;>+B16/9EQ
MCGD@@??C'N[ X/:X+]HVGH5XRY(HSFXMPV P>8';R+,Z93 /]Z*:W;*(>8>0
MY(SX]L<_=W_0^PU#Y! X/]<C'?\ /BJ\]'<NM$W&Z4UT;LF<,0= F81#^OH-
M\9FX(0H_M^Z=*&. <#PCY@' \5NK)NBCD\4?:>W9U![]\DKVQ\"<5<:2^V26
M+GVEW GC)0[3\< @9&./"NPW*&KZF*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*
M4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2HRF/MF\_?A^']Z7X?A_A]V3D_9I_=_J:
MK)OVK_'^@_E6,S:N5,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4I
MBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE5=ZIH@'-
M4@9HI>5(J:,S,(>OAY5J<3<\AY@"[%N7X!V_+S$>)]B<.ZY^DF[X;2<\>>#D
M<CR[&HEZN8E8<E6Y['AN!QSX_ YQQV-25J67--ZYJ3U0W:5)%)QRHB;DQE(E
M16+,81X[7;.5H!S<^8B;@?/SRR( )QV[_?S_ %JK;OGP/;/CCC/X5 E45^:'
M541-,120E; LD8H (%.G:& +@7C@0$OBGI1*'[42AY_5#B/>QA[.3Q*H6YR3
ME"&R#QX ]^/=DFIUB^RZB(Q[9VD^Y@0<]\>UCOVSWXX[,\\M7J:8I3%*8I3%
M*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*C&8^V;W]^
M'_1+_3^G.3D_9I_=_J?OJLF_:O\ '^@K&YM7*F*4Q2F*4Q2F*4Q2F*4Q2F*4
MQ2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4
MQ2F*4Q2F*4Q2H?WS'>T=664"E QV16,D3G]KX.0:G5.''O*AWO/Q#D,DVC$3
MQ^1)7[".WVG ]Y-<;@%H7QX 'GG&&!^SG^M:7TV/0<Z\6:<B(QL_(H  B(@!
M%T6KPH%X'D $[A7D/B!AX\\N6[X]P^W@?9[N.*IV&,8[ 8S[\D_CW^WCBHRV
M^<:[O&I6!,W= <M8E#'#C@#L9-5HH/P\D6B8#Z^0^\.,T==T,JY[I(,>]@<<
M>.3D>9X%=86VRQ.> KISD>![\\CN#QX<]Z[00$! !#S 0Y ?B YY"O8TQ2F*
M4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*5&4Q]
MLWG[\/Q_O2_'_P /AY9.3]G'_=_ZFJLF_:O\?Z"L9FU<J8I3%*8I3%*8I3%*
M8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*
M8I3%*8I3%*8I3%*8I3%*U*^L@D:1;F0@)O$5R9(4 ]>\!@N=+CGW@H4@_P '
MQSK =LT9[>VOAGQ']:TD&8W'FC#\*K3TLO1-'7&/,81!%Y$O4R\_NIN]14,
M  #P/@TP'D./(/+U'+UN<'CQ'CGC'O/F?//G5(3Q@]\Y[^[M\<YS_7.:QO5$
MV,C)4F3*' F;2C43EX >6KABY3^L/F !XHXAZ^?(@ >>84=\\\@XY\1C QW)
MV_#SK(.0./HY/&/#&/+CGG')Q78[77P2=?@I(/20AHQ\'GSY.V2#@//@.?)3
MUX#GUX#/(R+MD=?JNR_<Q']*]FARB'S53]X!K,9I6U,4IBE,4IBE,4IBE,4I
MBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4J,IG[9O/WW_9+DY/V<?\
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7,4IBE,4IBE,4IBE,4IBE,4IBE,4K_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>g425213g50a51.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g425213g50a51.jpg
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M 0$! ?_  !$( )0 N ,!$0 "$0$#$0'_Q  >  $  @(# 0$!
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MC/\ J,?.<[/J4\O'9C./[B,?V*XPQZG:/!>9]Y(_D![:94=!N/B>0_ ?$\_
M=#5@21(3O380WS,E0^/J;3\]B&Y(><C,SI]PWC'G3&F5K4VW)F,#1[,I]"4N
M/M08;;BE(C,I1(4+T_GGI4$D]?Z#W <A\^%6]R:BG%*<4IQ2G%*<4K736UQ&
M:[Z2:#L U&)S U&Z=*M<2T0)"42,RAE9UI -3XP@<E;2IY-^+!=:@0DNMJE2
MU-,86C+G>Q(&2!XD#GTYUC>011/*P)6.-I&"C+$(I8A1WD@<AWGE51?RA6@F
MK!4:I*S8V[#?'>GYJGPQDF@V\?9/XQNR[7K"IO@+31+Y::<>B58E49]@V!-"
M6$C% U><(EP'C168H,Q;AM@GE@;L]01M )Y$ \P1CE7!^E+8-&A#AY3:B,#A
MR!_.Y7B0K)%(\;!#&7E*NP1"I&XG;73,Z_\ 1"YNL(<,5>B\G:]MNE1J_DX5
M3'S42:ALC5NM8)5Z <N@4R0$7M_=6LKM1?9B!82A+6EIC7@N*!B(A%42##NR
M2 -H&3SR,JQY$ G("D'/+(QX58:K #"%$C<=Y$0 1_\ XY880Q5Y 663SB&2
M/8KLT+B1E5<X[+;UW:_UYIZO;HN5%V?7ZY9-H7_5(X :5JG%I]>:R ;0L%M(
M=^#M277I(YEK3UY&!QT$\0M]F-P1PRN5@J\;$9EQPWSA6#^B#@Y'4J!SV^L=
M1W\SFI?4[>.!;B6*:)7FE@"YAW;X5F:0[>.5('F\@4+(79@ D;;EJRBW65TZ
M5^QV6HV*]S*_9*=B\NV<47H^PH+@8=K<# L]SL$N0_5$1$U(2")P"+5P2^JK
MEVY3;84L1?PII, $@9&,D 9(QDD@#.<9.#R."!S( K*U[:J[H92&CXI<&.9=
MHA0/(S;HQA%1@V_ZC9]!FK@EU=ZBCKTMD)*)6B%O>UVJG4PE&>K-0BQ2](-9
MKMM8-L;2LNOR3,\(;;F#'JR)'F+I-FCI\8569[\93>;;#Z7<5&3U/7IC /7Q
MZ>NJM?0#@;27%P[QH?0C :-MDFX3/$05;(**&D)!"H2*KX-Z0/09JPN"6'K@
MR)>ME=J86R2J3;(<0OBS4&C[''VQP;."Q"X"A(K=WCS9-QLD,2(1"&R##3KP
M*:*)S9,; >OGRY=Q(/M.1T&>OMQC74[9FP#)M+HBN8Y,-OBCE#[2NY8MD@8R
M.%7"EOJX8W'3>J#2=^E%X56M):9*KM8S<;,S/H.Q0"JI7E)).Q9MMS8:F*35
M'BL01/) 1MB4,*6$.R@T#A$!,F+,>@HPZCOP.8Y^SGS]>.G?6:.\MY2P1V)1
M.(X,4JE$.<%]Z+L+!2RJ^&=?24%2":GI76[K.TEI(/%?MP4M'D4I9,00Q6BE
MGBJO^J'MOB(D6@4^Q6C9D^4U68LB$E]-*8!6"P02H:E&[3+'K2[ 0@,<C&YL
M=<<F"\SC R?7R[\5C7489"%V2*RK%N5MI<<6 W  BC9Y6(CY9X85V#+&SD8-
M@4#K$Z;=GG1=9INT!\T\;'!2H865!VNJR2T2PB*F?#)'8M@$&B;-F@KY2C"!
M<9;A-H9:Z_.D0VHQ:$X])1AU'X$'&,CG@G','\#5XKZUF8)',"S!6565T)#*
MC+C>JY)62-MH]+:ZDC!%5XUU_P#3XDZ;KI4F4K9$/>1](:59)5,$0"7G+-MV
ML2[1ZR?N&8-:K8.3HC:<XXF^OU"RPX%;B-MUN05M5.&6">&W7D>6>63X8'3F
M3N'3(]?(XQ?25L&96+(5D$?IF-0<O.ADR9,(BFVF+<0HX"#T"SQJV5U+K,TS
M:ZSLFWJ7;08'5L,.:L+LJMNV4E(JEA*V *#M0^O:YDWBQMPII&J6-J: -"0]
MYK+(B3-N%2KT)4>0]#+M*@E<MR SWCNYXR?9D'N)K)%?0RI,X$@6 *[G87/#
M=G59 L)E8 F-\JRK(FTF1$&#7M1.JK5)J[ Z'6B1 L6+&J8'ER5@3HJ"'8V3
M3=@737-A7(.CQ,<W5[K$UI9A 4Y69)F,H^F! D)9;?D28==KD$A0!@X+'KC
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MKU5ADI$:F6NP@MLCHDRWV878C5%!!D0::J0NP0JB\MAM/&ARH _S8ST8'O;
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5O>6X>,SVLVWASP[TXD;,FX9S7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>g425213g50a52.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g425213g50a52.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[27&4&AO=&]S:&]P(#,N,  X0DE-! 0
M    ):J^ED(X0DE-! 0      #@< 5H  QLE1QP"   "   < E  "%1I;2!2
M>6%N' (% !=0;W=E<E!O:6YT(%!R97-E;G1A=&EO;CA"24T$)0      $(E,
M*T ^4D:PQ&_V$<%;PI<X0DE-!#H      .4    0     0      "W!R:6YT
M3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90
M  !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE
M5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O
M &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU
M;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0
M !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O
M;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O
M;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0               !"
M;&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M  IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M!!D       0    >.$))30/S       )           ! #A"24TG$
M"@ !          $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F
M  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M      $X0DE- _@      '   /____________________________\#Z
M  #_____________________________ ^@     ____________________
M_________P/H     /____________________________\#Z   .$))300(
M       0     0   D    )      #A"24T$'@      !      X0DE-!!H
M     S4    &              +,   "(P         !
M          $              B,   +,                      $
M                    $     $       !N=6QL     @    9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<   +,     %)G:'1L;VYG   "(P    9S
M;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E
M241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0
M  Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0
M  I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !2
M8W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T
M;VUL;VYG   "S     !29VAT;&]N9P   B,    #=7)L5$585     $
M  !N=6QL5$585     $       !-<V=E5$585     $       9A;'1486=4
M15A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'14
M15A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI
M9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#
M;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T
M3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG
M:'1/=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-
M!!$       $! #A"24T$%       !     4X0DE-! P     &U,    !
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M1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$
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M751>6: LLK9FO>_])[75W6>B^RGT_P!4L_G?46\L'._;QOO?6QXQ;7ULK#'
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MR/4KL.PVAX:7G0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MB48,.T+#E*=>V6.JHU_](1L>=<0C[EML+R8<+Z5BLYJ_;WDD[-#3U6FO;#2
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M9]-34E:PEL?T.:2N^"*.DXG/".>,NU"#6>/45%"'DMQB$) , G"(OQM3$&B
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M^:(EX>LQ4;,AO-:K.WS'$]N&Q&_%B-/E2)$2791N:0#>'D*<JUB-6U?8Q(K
MFU&I$XA/N(YN:[[JO;?2N$5Z-D<6/W!)):#HP-BC<GH,N"1I?ZCH[>A 5#F5
M*Z 0D3)QHG8Y>\Y9(BC?ID2+*>^S,B-SKN<6^(=V_BW,[05SP:/C$<]FCVFO
M.9J;<"1F8M0]&EACKSX.K?VMHOI%SX<4"'6_U6_3)) /L$4WS?O)Y-H=GQOG
M[ZNM :WM8;3EL\(T 1E-X&QE[1:G($UEN"Y:'CRIZ?.:E,DZA<*C-3#ECMP*
M1MTJ]:S;*.<.,]95 67J_=K@LMTXES5<SO3T>9.Y;+;W= ! FSBN?Z;9C:)O
M/@]%/;.T=#<MR B@H\6ER^>T-3-A2=(IH;(RI(Z5A)Y=<N&/:>2A=7WR8ZV%
M#&8^1=UB3=S@8^-4[F0"4INTP:.@8,CK>*MV=5&,%,ASH$MJRM/H%[%EA&5I
MO.WAT5543T54F!>\ODYG8<3P-JAM<[K.Z4]?-G!1[/L@9GR.-G*5;837DJ5Z
M^)&$3TX#1MQLM*\3&:V/.EK00A;IPPV)R:UYIAF/<+SH'WK*^W._9))T/7XT
MAM1KHJ/U %:G3GO,I""9=)491T.@J!-66SHI\+I"HK&ZFY$]K!,J.(H#J?=]
M@<EK-N%OY'I=W(<QN7!/2^MA\U6)\XP9RCCH=Y<$Z"U 6_B=%I9JV/LD3 [,
M$,X*NDZ(PF9J7I7PQDT==5%(O?!E7I1$S<=[?3Z%H#0T/B.66P.-BV>W:5SA
M[71$A$J;E^5%U1V;S)@IH:NKTN>,YUD-.N6%UK9</!?)KDLAOO<QMDS5$#.3
M]P).;8S(313MR <9)B]UL0E(_GN=:82>TXD\W6S#R@>8JH449SV;K&1A/1'Q
M@>:8C7(M?BO?KS'5E^< B^%ZKSXIU3H6RYOE*VT#Y9$<8P9F]E-"2+39?8Z>
M .!9N:<.#&D;TD2E=45#TJ,$M>_'<:162[/US*\*YEKNK;.(S:S^0',NSC<V
M+F.:4Y>N7*PL+G,R$K*EDUI-&:O#P8$375)2!6_4JL<U94<A%N\OT+)[#! ^
MG B]6WA]%DQ^W%'D<YM6?,DQ,9RJ2=\FHZ*/]-E98E9(C9(D^;'M1[%3T3YJ
MJHT??;C" 3/FX.0=UC9T%,[+QNI<R(2D_LU+4C3AP3=Q5^QJ6!!K6YO.EM64
MH;TIC# ;+UD,$QM:.:&*0ITZ];M9+>"O>CD-!?#C\]RSM)Z9]3/7-ZX3DQ%Q
MG)(=1I2^4$KNV1Z7[FTCB0(K>MR86OLX:F9JIK99/X<M4B5DCZI.X3Q6F#^_
M;E);'Z?H+\?U0;AQ//'=3Q^FN9@=+4ZOC)R-,0"M8"B./7C+BVP)% L&+SFL
M&94[IXC0VT*H3UY)WUR:Y^7,%6PP&ZSG3,1D^AY"ZA++[7/B=,!O)\46<49I
M17JKI6L=(V*PR&5([,'S<Z"RR2![OFQW@JEYQ/W$<X[_ "=)9SVR4L-Y=T$O
MSH[,3'/'P$B F.!Z'\U*^21AS(%726(0NBJK]F2G'$HH?#Z<J(1//T1'HBAW
M0<,&Z7BM-@M#.8JAM4)MAR%K/&2.=.U8;4:M2V(.B+%4D*)59/A8I7J=B.:O
M8BC>BN:CF.(JZ<G]GN,Y!T<=T #I-.9GHA^CK=?J+C"Q_3;CK)S&D=MO-*<9
M'4CM$9Q//<CG1 X:,%#18^G<>V&::U$ZL4GPGQ<=M8J)[/V0<ZI:':]QY%7M
MXOW/%;W2-6-ZU7N4I#IC0;C,O ,S6GL%AA2D0PM*O2S-08#L47UQ4>2S%B%7
M3B(WR$G>1\.:\16X%,;;>T_GVZ*:+4S%==FMSH=IE.B0;/,EJ,9;-Z[)X%_,
MZMP'5+""P*6@0QEHH"-A3@@R'*TRU]+%+YR0N@()@/AP=VSD= BB087^C*]N
MV'KKI\P"(:3K6:TE#?\ -M]NSWU#.0V /8'NBT*(<L("P)G,@=VFGT\^H#B0
MTE:<1J]")ITXQL]4?6(9 OA=WGPX3P>66-]B@[HXH'I.]Z302= ,&\-M^O ,
M8;#R8'H/1^8W*<&.V-QUS%TC5"\W/@<R$,LRT^6J'@HJJ$.52=6&:2V5K-2J
MK[!^=51P.BO3.UVK.!KAJ''"U_8"[UWC(@% 4HTP^+JV<U(%*U9@QDAFR=OH
M(K:ER^:E8$)$K-.*-K2C''D!7'O/S=+&?^B\X%F<]H#V'I'R7;Q=I-ERGJ.N
MT%:;1X'?A=9H^E G9FY5!L$9K-D^@Z<[=TP6EGIA-X1H"X-1WZ*^ ="2>/;7
MG[+5A/8B0/X9O8^F69+_ +Z!]Y-3F^VQVA#M'GBF/I&LY@,T+EBKR!!N6N9&
M_:'ZG.*XH/M7M9K+4Q2Y9O??M)68F^M>B8V3]D=+5YAL_<MAM2Q/?05C_<.9
M =5'3Y7N^@+CV8:?0EH*8NOH9[2Y:L)H%:0S0C<P9*AJARV!FO1I8>2=S:S^
M)5R7K5_H[^:U=JG5&=1[4_L%-F<@ =6ET.176YZEEQFN!T*=>&+#19LVVX!W
M&A#'KVM Z(N?J2T)29*:\*&VZI6=^N7RL^[_ $>W'[MK.OEU_67# ^JYMT T
M&M:ZD5AV_1^570-S,] TY<T!)Z=FFM)F0=+2R9P[GQND&CJH\F.EJPQ1,(LG
M1_T=WMIUU]36ESYHSH1]FV2QFBNFGN-<V-7NO'^XVS_/[K(&. &9NAG8RDMW
MXVI)JP#.T9OG -7ZY3"?SU?WS4:O>VWIO8-4$RON4,_S-XL(C9J+V>N6PM(6
M?W>8VA(E@F&Q 0:/:=I5@]ZF5,T[-(8/I'<SE; Z6[(P@ST3*G27GH+1$_;7
MW7E+<WRSVXZ =2]N0BUBJU3G.ENBGP",Q9.=:(]"Q8^ZX-^K5L6^KH<(+I47
M62UFAFPK H2I&RM*DY#><J\,OA3^A[!><4!V?ILZ5VNU:YY5 #.,D[^S'79^
M- \U4,BA83&T;6=F!DZK\^?)Y8M<WPG:&3N9EC$&2EZ"&-6DXSU[S6/BOZ/;
MDW/88J6/W/80 DC=BO\ 0 PO7C:(_JL]?H.AZ96;L_M,[#;IPP:/4FJBP8FU
MD8;.9M-RUN.<%!!1C)/'H/WZJ/I_1C>W*V2S$FCL[W89;%!Z.4R?.M(<$VL2
M*P8G1 M8"P%NK6S]0SI,OG#^6S%S/Q:HV;)"H,^-&52,8Q+=2V5UJGPLS%^V
M_I_*3!/F_&]*>YU[>P5G.LPV3KD<>0&T QO=II=X$S;;&?DT&3%A1)/0B\T.
MEEOS+$^I!5+#Z@T;30I(5JWEZ#.CYJ/_ .PIH>W:[G"7LR D>>62@C.Y7I=8
M#H<Z-&:@/A:>C(9\V?':4(3A-;(R3.70Q'1UY:L\$!5QJ_1,N#4QTI,L7U+M
M>W-74XL,WHCF>2H]/)VBV\A'/726[CQDUA+LUVU8CIOM!V0C[Z#:DU8=&2A@
MKR$XZK2-JM7M6IH(R!IMB?GA,'HFGZ*JO7N#]Q.;]O0S)$SX4P>CTNA6C=C"
MK61^:R8NI*3V._,+9DC1,YC1,;;Y?Z*26GMF@AK122R-:I$HK/O;RU3NI#BK
MP(J>U0Z=FN5,GJ] SDNR(&-/CPFRK'AW.'QPFKF0H4#M?]5,UKTSZ5:H2(K1
M?3IO<I1Y7X\6QN&-WFM][9?=L+]RE <:%#<,$%E,M%J81E+K>?UFZ%P6;%>"
MM4TV+%BJ]D!.B3_"XZ<A,E.ZD=%6RR2H]"?-]!CVXS4(VOOZPV$R?N$T)?$Z
M-Q'@W2JG.H,U!=&.(]!2Y92I7T>9<Z1(:XJ.6AK/O&W?A/4AQY>:5$;]!'$:
MG4:.3N\YUDF6.]S5PWH*C@W.)+W.KG2RW*:FPGV^8''26@SV@FR>A-A,01DK
M6"V2 Z6K=&$+T!IFA>RG.1H9BZ.2&S,4.,Z/3WH2+I7O5::'WB9\?1ZNNJQ!
MD'H.7"\V1FQ@XWGM-IBI':J:3)X66L,N?:B>CDE#I-<S,]RS6&42-$E.9DH_
M=SU2RU36?;FV#7<!X7A"=T3)Z@W4=SL9T&+&YRM5+:B:N4"5C<(R-J6(1\4L
M,-EK+A*W;KBJ4<4]RS:94B61Q2>N/J.B3W!3W8N]\GR78*_7%R53>0DS5#,P
M<]RQ%@,:ILE5'#GW[-F2>Y/7HUH&V;$CO\K865S6M8K6-*ZGK5%(>IC>XX/F
MVXVE'NC;UW+YDN<JU+?,<FVK8G'4Y;,<,ZQ6&R)'(YB(Y6.1R(OX]$4[CP/9
MWL8_^?LR(]K7(B<PR'X1S47QY6;S^_[*JJOCPBJOCSZ(H#M1O<LP:YH.K=T2
MS%M]W_"EV2?F641].JS&['3?<UD9.C76%L9VO7_RB*SZ4\JJBN1O@B8/\ =G
M_P!_Z?\ XL,?_P!+Z(ELZMW)>K7< O<F(/K8 ;L&W?Y997[M;5[1DP\E1S?N
M?H_;1UZ#96.^'U?JO7Y.5J>/19P -,;Q)W1,@TE0EYM7 X@*:KCNRK_X?9?[
M/_!;D/QX7RG_ 'Q_8J(J?W*GJL<#T6S[.1ZPJ%<ZI]SV4F_9=[C'4_A'HV@Q
M51:O,<HJVJ0>F(L0V[/UK#_%F9U^1)6QJV+PQGP8W\IZBY_?X\E.BV-[2.%$
MK\?>I99*5"Y;C8_F.11CGUJTL[6O^,WE6.6/XN1/"^'?A4]%<.@\_11CFHGN
M&XYUA-G=[I]E<U>0S>CM4ZW,LF^O6G-!Z1&>O"Z67ZKHXIK$C(W2*KEC:SY(
MCD<JD6%TZCW/"YR@;H]S;=FL[3GN:?#:YCDVQ-JZ_<Y_+W9T6*PQ_P!:O4+3
M3UT559]>.-)&N:J^":UKY8?\O^S_ ._].J_W_P L,?\ ]+Z(ET;H]R&=*P>&
MB[DR2CK &Y,6[TG,<FEJK+E9LNE6&NULWT5CL-/3).LC%<BP0N9X57>2E_#U
M_1TR8J<_[.B?GO\ .O\ C_+#'^5_T^)?'G^_PB)_<B>BJQN1G=S)MNNXC::B
MOKTPY+'M#F6 *6>M/JZ3+5S%FM;JCI9*DRU[:R)!,UD<GTGHR1'JWYJ1+CW&
M\M]M9W3YC;>Y.8*7'':4?$,1F=HR&WET/= *MFFD%44IOLQ:4\VE5&SDI+/V
MM4501%^U8^Q-(4Q\NV+"^7JX5: 7'_;]E^J0\Z)>X3J9DB,ZAR>V9S)W*A&A
M3/5\#BL,F'&E^IU^8U[$1LF*RF6,6@5#;C5-VIY:<E=8R5BA8(\B>,\M85J*
MJ6^U[GG"]!D!O-<OTS>=KXW'AZM()ENA\?#B<21S0Z_0F#7ZV[9RC*3ZI]26
M.!:3Y-.20@US[[X[;X_N&DPD<*EN@\R.+&2UFAX;[3-MTHY@Y-UK*.I.S]3P
ME@=0I6Z63=IM?%;TA %0T$^7=E;6QP80CI69L37,S%!0H\?;:J69D=)3*ZNU
MZRZS7IG"N,9 @%.:GJFK'\[L]EI;G.\G&!LOJ8;W5UT4>\M4,79'X@]U*G&6
MTHB?6:+/Y<S#\G1$I'2T0_WM=Q3V,^D[@?*M%QFO;#[?NXC(MWJ]YI^XM,B?
MX0R)[3DUSV@S-7+7-6.EH.=GZ&0/6]>$OGCPH[<V$5S11NA_32;(W,NLM%';
M <>S,>U3-J)@6N>>V/V^\[K@;'V>?><P\'!HM)1JWM-T$^+'Y6Q"P6YPRD8,
M%;XX&.M&["+1F@'UJ<UR=D5&!&M*]"QE=>S<:BYZ&]0GV@'-^%]NW.Q'..?9
M[:8$9%I*..UDW4:M*70YRKKS\(HM)59D;3(77*C(YOBR>1BHY'M1B.^FPJIE
M[A=9VJ7AO6([G'\Y3J/PFC;8M,ZI7M/@A4=-]25E?^#HOK.:WRJ1K+'\U_'S
M:B^?1 "2 +RW,TO]"FG%N^VM@B5.+YU6I$SPYW6JK5^*-1$7PF-=^_C^LB.<
MK7>6^7*GHM@LSO"%S,@?U)/&4N4FQ22[-T7K] OQ(B1X\$KMI];9+4CK=1JV
MG7+4O-ND0-K.7^$X&U6?1EEG6P_ZC42+Z7P^4B*@D0N30 OC(3J"NG8]@M-O
MMS861_.%S"[@." #%@'(<5J.,R_G]U1/RO$QOA/RO^VG0_9/RO\ ]5_^O_)Z
MU?>@P/6__P"NJ9KV/^$O%!,VFSD"9$,1)+7 "!R2* 3)EFE@$ZGUC0]_,7J7
M'1"7(>/@:TM"7J%2-B0-VNAD99993*O8_P"I(YT3X'1(YC6I(KO"HGI]Z$R!
MGG*Z]VO[37F[1X?M6QD0VD)A!/\ OAW(@6N$0>E[#\@)/5]?QSVW\^>)YI$5
M/"_[;-;]O_8Q4_Y/3?BHPX!WSO<+ V!=Q:1T-2*W,&;C2M:I3\2V'9VR=A^R
MX_GK2R]KV$MOY=3@K)6O.&YQ+%2-RY*=+;(?BSQ::L3)%>K$B8L:^=JX[2 0
M$3?> B$B"!<[XD&4N#,[8T.T[=(!-LEXSG(8WB";72)UFM(K&NHSH]_P3&)\
M_@Q7/1B*BO5J(BIY]%CNX1 TNBQS ;CP4)X3K.U1<5Y''3Y!G;E2/FF&95M/
MZI#5=9K,S0UD-AU9V/F? Z:-K9'0ODD=%\O@LCU1RH6-)<;W6I[[K.T28@.R
M[R'.TZ_\T>-/^O'U2"R[Z\?5L>^K!]-,A!X;;LMBK/F5SFUV2NG?&]L:IZ(G
M9_%_<_\ >7S7_&W7_P#@KT1)#4ZSM#N\<CEEY!GX[D6.ZTRI5;U&*2*S%+/S
MS[J5UI,>UE=U9K*ZMB?&Y;/UG(Q6NC<GHHPGG5YXF<\T[TV'<U1%_DMFORG^
M^W77_FQ7HJH/PPAI276O<99UF=J9<PICFD;Q5$XW15VUF8.LE>PA)@\8U[YT
M^2NA2HU8O@B.<Y7>I>??TN[410_W.^UG1>YO2B*)3HQ+!\ZSV#UP\?'E*H&Y
MI[FZV2,#7"MI=3F3P^@/#Y>*6 1=$OJ'H2)6Y/6MT4@BDEJF=_/-L<9G0KP!
M]GGN M],@W>SO8)APAUODO5S^P"=2Z;8H16L1B,#E]>.H\<MYV#!E[FGDRQV
M(2>-W4O JYVF5A52P6DUA!JG26&G4V]LWM7[)R;G8SF9@V["VA.%'Y9G4<#W
M#;=!OK=%D:-AM@'ROJF!N<[R=<I6K31RK1KW'BZ\RCJ4,D3ULQD/#0O?BS7W
MW+7[_P!L_;&:?=Z7+NS@ZI?EVQ\UH\WL]JPSU,;>Y\<"T<YHN*2"'<YK;V^4
MLC6V^AY\H,OV4'QVJM*K9NS4F%5KN7>USL^0EY[UH)G.6Y;6Y.+*K6XU#H]'
M6QUZE/RM,/M#)#1KDI+H7H!6U+2L_79FB==:H-HTK=NVB5DI 4].%T[UE])]
MK?N1ZEM,)M#YGD0PB%(XXY<;F76!D>=F =EL;TB&HD;^#+Z<[]SD'40+3@DY
MSR0P;:4(Z(9<H6ZHZL3+YPQUU4:RWLK[/CZ)"P*M8V$F,UXLYB_T[>& IT5Y
MSVXSFCN1[L?S-I&S2+4M11K,$[8+OC[![2[9]M*00)?'%3+5,TZ/9\5">W[V
MX\TXMKH=V[1<UHF\L4FAY=TZ]7LRT-.;^E=K7JV7OP6JEZM)#<JV&7;2R5YX
MG23R2*]ZD3"[EU?,:GC?3<Z &=%(F36+/C15&'DG4VRV[UL?/%7@B5^.8Q'2
M2*C6JYS6HOY543POHK"=V(18$'H5/6=KPK86M6MT'YLC:U43D?5E15^*.\?U
M<4J._*^%_*>%\HO[>?1;(8]Z(!F>(!W 9RSO08O( <TB.W=&#ZF3E*@@G122
M .GP&RJ0\FZ@U*0IN$W8IUR1),@SY1(0*T*RHSY.1]AJJWXM<Y)$'!$_R!#G
M.55[/@VU;-LFVB.TM (2&B+SG' 9DU# N7:IE-:U=^*3^JH'HB*[]D7DO3OR
MOC]O^Q)%5?ROX;Y7Q^?']VC[&??XR7[P>,^&."-HL^(BA'0@F8QDUTRL'!;@
M>([,?TE\!TBL$M\S @Z9!W)^GNAF+5M.?O3THVMR+I$E95L03.5S6L5KVI\O
M*>/6(V=C6KXY5+&ZCM>V!_*^.;?LUM'#]FU%M#O!WBWFX5(DZL0O:,:G[T^@
M)^_[\DZKX_"_UOZR8U6_U41?*^4\+ZV_:'^1[^Z\0V]G_G!RW?;R2ZX]T_.9
MY_5'&1/1QZ'.OZL^(67DG4W+>#7Z(*&G>B^ECI?$4[ZL[&-?\)$^B[Y,1/"K
MM7FQQF,@FZ$#N9<N54S#O:<5:"F:U>GT.2><61KP1IR3J2.EGFJ2P11,1<>B
M_-\DC6HU414155WA/SZ+$%LV8MP+\J$/Q44XSUS*YOD/+\\<'=#'F07/L>'*
MTIN3=2=)4)#L^/J7:CWQ8^2)TE>Q#+$_X2.;\F+\55%:JECI_?16!VOJ><TF
M/&#@@CHQ"[!T?DY>6"'DO4/DT:!Z9E#):Y\G9%K/I41M&U;E_K?/Z<#O@QSE
M:BE9:Q;V[)M?SUP/CRD'0%_;]N1]6_M7PG[XQ$_Y?S_9Y]%.1[>Z4&GZKF;O
M8^7Z2J*Z+(%!Y+IX\L03DG4FQ4;AV3$.%03-=CVS(Z]^F7G1JR-R)]J]'N:J
ML1Q#EY\0>DG?S#)O)W;!+^/MNA(OY_"\CZI_9X_[K^#OA_:G_=?OY3]T\>BJ
MB?'+BG>G=YUE,8?I@3Y7G\0:Z>S9_,/)N#XNK2)/J4M$-%WYHJEMWVTDZ5OH
MK,US&O<K'(A-:XW*Q_HB/1$>B(]$1X1/V3T1'A$_9/W_ "O^*_W^B(]$7E/%
M]:":%))8?JQ21)+ Y(YHOJ,<WZD+U1R,E9Y^4;E:J->B*J+X\>B)3\'&Z /R
M;'C-3(;F/4JQ*"_-HYYK1R=6FR7V]@E8L.=--8GJ+7F621?+FO:K48SXL:1:
M/W'5NE$>8GQ7,J-RT4)##,)&<.:C":.K18%(301YRS)&JM*$24=(<V>&6*U4
MK6;-FFY+;('L([&O#CYN?1.($MF0.*EOU'U""CJ2W*TTC)I:UI:T;IX'SL5S
M9'12N?&Z1KE1SFJOE?11A_9IM5I^_+CB55+K]+H=CM./O@(M$@D>[FJ5:PZA
MH[-0DV3?6W[5U<V-O19?-LJ9MT#M''JQA20X';%3#R#9XUM2%5<-4\HOC]U3
MQY\^%_P_/A?'^GPOC^[T14_PHGH4'N!)VG-,_P +Q-Z8_2DR2:^.$W^IG@%K
M!U(:IF./+P1 :;25$//E)R;;8F"Q;(**MV9:<Y8@#">.IYEWF1,LXL3TL7?,
M\_V8P5;,4"=O,&XAUK/V9*1F._\ IUA:;1]J)/J0V7V$C9&^-6R(KO#',<J.
M0LN6L-8*OX*#54NP"[SQ^C+/OJ"$$8S.=T=<9F\W5YTR:X;#ZB$_/F+RS:B-
M!MP?;%5C$I*[;C;75E6(C,4RYX.7G5Y=:R3EZ>)-$7\^LA+1R%PKH^8O$ZP>
MU-7K7 Z32PD&FXH4^5P7!#)]>2"1R0I,R*21DB,1$)P9YZ:^?F9SFD/;!!TR
MG):BZ.-++HK68IVMN8O1:>C2;NV:,]#='#XC9.Z'-1RT$BOQ&LM4'#(Q[Z%%
MD;ZK1\%,JIU[B*ULF""A:-#36+A2R5@KDPR;-P?.RR"IZ[3QNOA()CA*T-^X
M6QG1*24JEHNR*6P0H+6CM1$6VQP/1B>I:VU<):DSG+G+N7P4;AF:=1TF@'$-
M[$<DH#ECBBH$[E)0=PS#'"R:26Q425/#6-84'=F/[JVJJK#1A:464)QANK+7
MT9 52H9$RSK<D=.]6I:FU-O>G7Q@="EDE<<2C67-8:) L-\5F![R3TC;9HDR
MD]#S#F7D^9XWUQU"P*R68&6RU\]9H  ].P;*P2U2A>>M0KPRDB-:9K)J]VZ]
MBV+4,S6S1S2/9*B2-=Z*ZUJ:D;G?%//A5_*)X3QY\JOA/W5/W543]_1%#P/0
M\+J2=P-F]?G#Q4?(8BO#Q!>B0M5)L\;L9L]#8AK3R/BF":"K8"%HG(D@XI$^
MC;;#83Z?HG7&E1<>=V(F),5NB!\&)LT*1,N-'W2LZU15.[>JU+1.RU$<M<?!
M8ECDN3^%1?I0-D>C5^2HC?+D)R?IZD+P349M9BE9#X;[D'%]8U7_ %2C]</$
MK5>DA6+Z_P!0<QT:+(U]QL+58BN\^$54)IM?I>/\893[<7;32 EK')FUPEA"
MP_Z)B=_^YB%2K81A"1?[(ZKI7JGY\>BCZ[^7M62[V==EJ=F]3N:0#4MC(X9B
M-6T8&U[%"&PYK*\MR&6RR2I'.^2-L+[#8DD62-&JJO;Y(XU.C^RX@UV6M61]
M.MHP5BV6CEF%U8"P^:P1B@<K9Y:,,=ATEN.!R.;.^NV1L*M?]16_%?!'D_QY
MLW-=4V.3=5*WDTP!:0.1\)NY^L#OM0\K&M?)$4L?<_1'R,8Y'/9<?"YK%:YR
M(US5<1\C1_CBNS-?E9;$-2+2 9+=B%MB"I&8'/M35WPK8CGBKMLK-)#) BS,
MD8Q6.B_RJ.^FBN0C@2F&RERX:HM[#/#9B9/7D9/!*QLD,T3VR131/:CV2Q2,
M5S)(Y&.1S'M<K7M5'-545%]%5I/XKS*/+L4\&1X!J//-4G11P5JL63Y%T^OY
M'-^FGU/E<^BGP\.\_'\^BC\_7G3+0673-!R4-&S0)4+M<FQ9AEBK<JV82,+&
M)*Z>A-#*^.Y"V-R2K+7=(QK%^2JB>BN=?E<E388)$R<T5&B:\KTBCG)W:U&"
M254<Y(FRVI8HW2*UKG?!'*[XHKO'A%5"+6UMED;CWLIZ?/6W1Q+-(E8V+G='
M DC8G3R)%;<YD*2O9&Z1R(U)'-:JHKD\DIJ4E)55/SY\>$3RO_+_ ,WCT11A
M-CCOL+A;^)LX@H=8=2ODU,C$'4K;)4A=3M7?NOMJUE)5:Q:\TL<J/<UJL1R^
M/12C2RX#G=1UO(R%&:5L$5NM+,^LR['#'/$^22H]WQ9:C8UZN?7<[^JV=J+$
MKOQ\_/HC@\.3'1^%BE3(3/U4N&R@T-2?,R%+92[5'U5L3+\8H5L6Y8H?JRK_
M %(V*_Y/5$8Q%7PGHE*"EP&.%!Q7E6TN=ND)!%0Z'ME8DD6896)4K!"%(E:D
MBS4HIGV(TC5R?-7QM1OG^LJ>BJW?A/S^/W_?_'^S\_\ !^/1%QX3^Y/]2>B+
MG]O1%'-@'*:')Z4"#T-S)&30$L*%:D?6IW;^<(D*%BI3.TJ9".6A:MB;$T=^
MO7NQ2U9IJ[([$;XG/:I%\U?9][.^F^V;?X[.GM"/W&9R<?N=T,.^' *67C?0
M[1T/ ',YB+(V"[9LD#3ILX<V.H)3?6@C*3U&0W;C[+Y&-=**DDER22P#DDD"
M$"&$3N  A H  !( ++]X7M7[GU3=;G7\JH\R-$==SCG.5QYKH-\;%/R[0<]U
MFMTMJ2(>9YSOF6\SL9-")($I\K/F=?";R8J",M7IR1$!9302OA]D?;8<F%R<
MW.^!%RN"/D] :Z05T1IVJ]S5&;N^=ZA)CMW*S)R/S8;9Y\39BVSM N_C;J81
M%457?G8[\MEK6N"F-<&$NE,<;LEK>M>R3O\ L!_2"F(YG[=<D7Z+SD_D,7E(
MS$<^>XEH7;C2:JGI?![F6J"FF;Z,T.M](EP^=Q9ZD6S@RMFR<C9%/TBJV-/V
M,=OGU=8>? <6,YE'>Z*3;;4PX2:/]0E[4[:'L&4NT+W-I-2+T.7.GLV(-QV^
M@7<M3#Y2E;S@62P^I"':U-3K=RROYGO1;L+[&>D9&0GF &$X9<J:H1PF,1UB
MW:O4-1P2YSCGP?)ZN/G^='9RO)?NMT(HGN,/>H:#.T)]+LCEK7CK5>&:N9)V
MX'ST6N*7H+V.^Y(7JN=FYL/P=,+S(9QUF@Y#6T5!!':#_-QNNSA.\0-U>0BK
M\0MSM5%T[-Q]%L;HC/O!3*=]X.M]N8C*X2^$Q==[#N@ZD96MY;(>WKC.KTO)
MMCRXW9R .<S3YT-Z-VD%I#T^8?=$T+VB*#.1,T6;982YFJ-O1D'0B:F?SL[8
M:I1C?1QY<,9IX<8*]+]K?/1/ =\)9TB3G=2E!C]YE'TL_0)\ST'5HL5BZ-O-
M7K%NP")X/.FA=2\.A(&(;8T%"M A;MV)FQ$PNR[^[M7&2KQ5]EG:Z^2PV;EY
M;[?2!#EA3/$--K+^G,KH/=1 "ZL%V5P?O[-;'Q1@*FC'CY]>8@T46V8_I< <
M:UR9&,M:*%=:^5DM]FGN9L]=Y]W,([A?(H>,;)QWG?"L36/E<_> ]!W9V_VV
M$IL9W!J@#5:K!%J5%TP;'V<Y<TXSY5Z(8=(EQY2COQX?KJF3UPU0]]7.#_!Z
M7,FB=7-E^4=5JV.FBEL9P5-!TP)?-A!Q=P2]2O$Z8(/:IV2(9;5:2R4<)>OP
MA(NB)/E2]Z&<F:?+ S"BW>_Z/(OU':=/H<]BY'RKGO89^1C]@9IX>F1T$60Y
MP%W)$J"'@!K,W Y^DWMW!6[$O\15(T&A;]B=MBS'3JO*ZUKX;#M1W*3D0;VW
M;2E3M=J/98?Q+0=3#:*>J/LG#7+3EN]V$+2K!9[3(:; UPZ3"WK(.S 1>V@-
MORR34I9BF%P9[QUNZGDDS%[2^M_KG*MFGMS]LH@1S!H 9H.)!M81E!]/LT>=
M[#(NVUX]9P5?.K;R!$_43##3^+M%)@US26S)V F@*E5:U5 "'F2Y-;M: 4(%
M\']PWM>V SW?;/4<% 9[GF1@Y=IN-9E-$%Q.=X%4QE6(6&R_23D),PDPKLC:
MNEHA+&,5\P@C>'C++K\U('8)RSH['/7.BF&J+;?WK&*A_%\ZRUK^5V;VF0*8
M7<[+(%:X@QU&K3KB-S!+;PO1\9#N\BN))#I,^6"'*5OG71ZVJ$E)+!" 1<:X
MH.M?/CTX)[>T/VI:CC.J=T+I0?EDF]+>W/V\\UT)S"C(HYI]_P [K;V/HA*I
M;E!"+*!CLN@!_96?A7M$H![$(TJ[JD#/15?0+T1'HB/1$>B+%NW:@VG;(7[$
M52C1K3W+EN=Z1P5JM6)\]BQ-([\,BAA8^21[E1&M:JKZ(D')[J.(?P=@=Y1U
M1,]F>G-*OQ-G+XO<:H@9C!1S2&G_ *%G<Z3.T6BOMY8R"$!M5U6=GT)6ME5&
M*1<1^Z?BEPH+$A=">U%DP!R^FISX_GW0M<-:"V;;+\T0NELWER8P;$4CIVI(
MVD;=66&."9]F.%(W_$C^O9,8QU3 @.A8_E9C15:&^WPK1F\AGIH;GUS@W)I2
M?H)ZMEE=U%KQT9"K,^O/:BLS0O?+7BF9#,YA'UKS2R;[L^"V1](@'VEC4(2.
M;3/#Q^.RFPUYRY?YT8D ;:: !FP),T\3G"T2TKYU:*!EEDKI7O3_ '=7ZQ%O
M:'N1XJ5+9$*+W%0C;W5('>S-BF,.6!-UFFB)39RI9.QC%"B"IY@<H@@.9OT"
ME^6A9@K5))V)&I%.\IT;$[DCM1.1T5 ^0YUIG8W:5Q[GS?H.H8+&FI MJ7X)
M ^[".+#Y[#())FUW6/MYW1V(IHHR)6:_W)84;SOJF[P-\5TN7DQ^OC=")"&(
MZU>'9SV,[$[.V#2U;E2"S3CTXN:]+!#>;4=)+6>Q;<,U=F,46["8JL'P[K=L
MUA:;5M-CLMD!]RWM(+*!Y QVD0AA#W.3,W-282>=[H.L.>K)>$Y)7?U&N1W8
MG>?ZOQ=\5^7-G(J))Y\)\E7]G)^55$T_R Q.[F)W9\I]LU^R_P" /&C!!&#8
M,2"?S(W9L2[49]26A*^\CIHD]F,_9X/GW7-7,6A'20]B5]>)P8:\I:6V]W.F
MNC:^M$YL/PCE5TO]5R,:OS]0;3#>.G!SJ6%5#]!^, M_RBY$X8I3H_OAR*D*
M^Z7K?A?'#,KY\+X_VY)/W_XMU_YE_P!'J_R;/ \QVKY3R6</^G_C!B BCL88
M20(H@2\()8D2N$PMI@O<)V3>Z+39D'PK'U[^2'9P@1D(]CF@KR5M*\R@]M5]
M7F=I[W1J$MK8:^*-(WR1JQ'(JKZVV=K#:@Q0TO\ AGX!V7YKQCPBU\&VC^-:
M6@M8Q> U"T5\N%) ATVOXL]Q?]G%^=?\=Q+_ /Q+ZS7E*(Y#J?==F.NEAG#\
M%'#1T.GS,WWG:+L<RD,B?)Y<F^/Z?*I_-:2Z,LK5D5['RU7QK)'&YSF(1;71
M])[]E\^<TI'BF">.SP<D<OMJ=IO36G4A5.:]:;6ADY57CEL+!!(D,;YX6/D^
M+72L1?/HB?\ 0L0&A-"]+7;]$E0J7?MIT9*C&VX(["12(J*QZL21&N7Q\55O
ME$1%]%&QUKVP69!5K5D5*\$,".^/R2*-L:.^+6L;\OBB>?BQK6-\_P"Y:UK4
M\(B)Z*KW]$1Z(CT1'HB/1$EO<+SG1=>Y'K.79W0-RSM[$/R^A/M<K;U#$%2=
M.ONFA5=3O0?KM_)*8&!GVZ[Z<%^[!9M(^&%T4A%0;3^S+H8@J/B":X'TW 4=
MYL=R J;KJ>IX]H8K?3<A0#ZT?%I>.Y2E"\9'HATVDH#Z5.M6M_KY""W$UU:K
M.XBXQ7M(ZIS'6Y,I9L\\WL@G <CRR79NX]6Y$^A9Y_<T+VQP9'( KX/9#(*9
M:A0&6=.JWB[!<GZNU);UISBCUNYC/,TG6297;O:KTL_J@G0\UVM+&WQ8K3OY
MIH^H.$PR9_7:35XZW$&KQY#-YVM;R29$5J@<E>U'?/3V#<2RV[$<7EA*29Q1
MLFI,S]GYZ+(>SOIG$K-TSR&UC27WX[IF$=G"NKT^'F'X/6[U-GE"X';!\[HB
M8G6A%^I6.1((GK&5FBGKDJL]"%\Y'PP?K1;&3VW]YTPOC^5*=+QA.US(P'T5
MCKH@UH';S*:*&^:GT0RME;P\EC]TMT$1I9W.G=@T<0ST$5PNHFP3EA<A US<
MFPDIUPKVC[;CD^VI,[QKW@S/0,?K!*@@F$H%# X!AP&<+C=N^[CKT5QVD)C;
M%PO;%.K%+36Q7T+0D;A!92'E@7\O/KUTG9^>)S_B_NO-U&B90O0>C838 AN8
MIR324*0^EQ[(W![QU&LB/)3%\N2N1U1\=A7QVZZ?)UETD3-=K"8K..&'^Q@B
M XD27=X7;65AXCL-M;1&SLK+:K&TM(Q_:&""TA,40()G"'+8W)9OU:R/<YN/
MZ>K%7RU?Y1=-<OA4^2>?CE?'E//];\J[SY_M]>?#L]J!,VDBYG(LV&(RN8K[
M?9?5GT_9V$ .W38">\8N8$\P]TJ44VUU'GI_%G_PKTB-8K^[7Z4O+NAUYYOE
MC[3/%2K-F66+:L\HZ5M6.5T42+++X8CE2&PBC,GF6PQ>>)=C1S=*?#;?5'@-
MI:V40\0C %I!$9D ;L0>Y@"*GY3975O5%3^#NH-\I^Z<BZ;^/\?*Y3^S]_RJ
M?M_9ZQ_A1B8WY39JF>9F9BG)>B/JSP%PVW@S#";'+^].2D7M\ZGG<SUKL"F@
MW1:CKN2Y3]O$O*NDV+2I5GWT<CYJU;*RSUF.?(Q(7SQQLL*DBQ*](W?'LV2Q
MBLH"(I$EP,!A.>NGRGZLV_9_$/$HK?9B#9D'\@7!8F=3VE>KB?S_ ,#_ .0=
M*_XG>K?_  =ZZU^62;X;W/#T<B?AGH]#5\G5>S6V_0Y-T^TQ(KG5-=:A1TE?
M)2L9,D4K4G@>YLU>9'P3LCEC>Q"*1]9[OA;G+.DU(J/16S6L%L*\2S\CZC7A
M22;/D6,66Q/D8X*\2.<BR3SR1PQ-\OE>UJ*OHBL=E/\ L6S7_H /_P"[JWHB
MW_HB/1$>B(]$1Z(CT1(WW(S=&3C&U%\CH27.DZJE6Q61M(DR5<Z4V5^MFOXQ
M)RP132UQ.-K$[&G(SLBDD;6%/;%'),^-CBA^:Z[R7RGTG&.M9 ?S[D6RYK+9
MP_(]MTY^*+9/DA[W,9&MA.B8NL3RHN(*5;GBEDGDM._29[]4O5H4%U:H9B1O
MB)16/1!CC=P?CT]RNW,N:[D!L\&0ZYRC2LM4N0< !Q*3]MYCO-G[S*6=1 2A
M3;UC+X^?E4K/$7BE)S27Z+9NL\S6?TY?)77.BL+[J\?TG5%,B9WF"_59Q [H
MHW.,PW.2GN+YN1K&6@E'!=]@;-;+;#-ZDHR@]HC>92]2K@XV$!\YEB$6-0H&
M<SGH])MAW2?H:7W9]!K=&YAB+/1\IT /$W!3Y:S7IWN3\Y"W_:-F3+QU?J4X
MZR5);<-V#0C(Z!*YI+YZ9LZVYZUH.ZS=C)</UU$N8[7*>V+=K*YM+WMZ]LO:
M.7'6 L%EMYJ:^:(Y2S7>[15YBH^?+QYW9$N@71E> A.=Z'ELQH"'VMRM5&:"
M=A.];&M:9'SN)R;,]6N9\%"PYKWL:NIA<QN$[=%'M>=:;*ZZ /D!F9OYY]V#
MK89FS=H7 YLU=.QTH\1?:&,G^:':Y50=P%8OUKI>MZD[\;L,T/MY^MZWW,,E
MO<MQ+N!/39YF)QA(Q[>:&6SBXHWSF)#&8,9,7M=*N8TI$@6J2&K:C82A*Q*V
ML3)B[UFA*3H-@.%:C R,Q-P0X+XN+K@OK/\ K 5WY4J,7\H[\WZW[IX\?A9?
MQ_9^/'[_ +IZ(0+\7PG5\]8)!=)*BE[9[<7M*#O@PMT_YJE^KX;YY]=1OE/J
M_A%\JGG]O*HB_GQZ(&N9I"6N' 9*P'ZR'7RGZJ-_N7_/JO\ TOHCC$3I/R2$
MRQ<.GN([ ]2@U(W<]X\QKEOU?BKFW^E_-J+]7Q\F_.+Y)^Z(YB_LYODE2#-@
M#B,"/TGTIH,G[EAB?Z;]7_I?1'&(23X&6$QX[1-<4'-=_-SMSO#KU;RK7=;V
M3F.3S+^6N:Y'-5/PYJHJ*J>/1)"]GQ*DO8C A>2=/1"HU7+SW9M8B7JRJKW9
MPDC6HB2KY<[SX:GA555\(BJOHJX-"IWE/^Q?-_\ H /_ .[J_HBW_HB/1$>B
M(]$1Z(CT1<*B+^%3RGE%_P"%%\I_R_GT1<(UJ+Y1/S^?ROE5_*^5_*^?_P#2
M?A/QZ*,*:ZU79$1/PG_7S^?15'CS_P!?^O\ U_T)Z(L2"A2JOMRU:E:O+?L)
M;O200QQ27+200U4LVGQM:ZQ82M6KUTFE5\B0UX8OE\(HVM*,.S<EE>$__G_A
M_?SZ*H\)_<GY_?\ Q_;]_P"_]D]%" :^9U>M89"!M$*N@SXH>:#$H'5B HI4
M@OCKU=ZHKH;=.RR6"Q&Y6M562QN3RB+X\HB^BJJD=XUS.EV#'9:GR+B;<F>P
M^X*SU9>;A)#/Z^ OY:*C9DO_ $V0(+2N9L1R5(JC+,LRH]UQ&,:UI0EJF]AG
MEKCDO7C7%^4:S#Q%]EQ_C%W25M5T,':M!^; !XWX9S>:3-U/LJEFO=L01_8"
MJK'?6M3S2.1TCY9%D5RDK\'V2HU>1P>5E[=4DXIQTG= %@ [G[A?(*]RF#JF
M\:IV4GLT'CR=JY ,GKW;=N>NVC!<\415=M6>TV;T3UT&NQSH[I[87B'#]5S[
M+:9.-<H<5T>/!%I;,O.0=2"6Z1#U[:NDIO'06X:J6+$CFU7.8Z.-[FM<BN5R
MD',MQK1IM^ZSFJZ#^1Y_5!^-_;9CE(?7:?1Z"CI*8/C?.YLX0!X[1DG:4TM0
MZ+)FA]?]('U (Z.B7=*TF=HV++Y$BEE4AOG42FT]-F_).'L_&N+9?-CW ^=<
MMS-\J=AH0_I_*\@>TAB:6I>LM%9860'?I#BURU##-=OF6*-'AH2U^Y+5^DEZ
MN2C#%]<)\J7A)GF>%S!/4Y"KMN9</F(&M ;Q&FQ('G.,?7SMS-86+33:FN3B
MI624L5\HUL4K+-B<.\=H 246MD:ELB0\ZW=)Y3=?2J...)C(XF-CCC8UC&,1
M&L8QC4:QK6IX:UK6HC6HB(B(B(GX]%5W]$1Z(CT1'HB/1$>B(]$1Z(CT1'HB
M/1$>B(]$1Z(O!U:N^Q%;?!"ZU#'+##8=&QTT44RQNFCBE5%?&R5T42RM8J)(
ML<?S1?@WP1M8+F"O7JQ_2K00UXOJ2R_3@C9%']6>5\\\GP8C6_4FFDDFE?X^
M4DKWR/57N<JD73[.I\K+TK0(^XC4MO2)B/M(R/Z3$L.1OF9&1?Y-J2JY&L\,
M1$:B)Z(VM:%R]8H8H(HX(8V0P11LBBAB:V..**-J,CCC8Q$:QC&(C&,:B-8U
M$:U$1$3T18\0ZA Z!\%*I"^LRQ'7?%6AC? RY(R:VR%S&(L3;4T;);#6?%)I
M&-?(CG-14*,.[\_A8AG/@=%!%6/A1)NO!-]Q! 7'5",,%CZ;XOKPQVX9F13?
M2EEB^JQ&O^G+)'\OA(]%*KQIY?-CKOZC0 !J)#[&(9]]3&TZUS].@:UD%!;,
F,+)EI0L8QD-7Y_1B9'&UC&MC8C2,ZWOHB/1$>B(]$1Z(CT1?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>g425213g50a53.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g425213g50a53.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1<N4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %Q*^608X0DE-! 0      #@< 5H  QLE1QP"   "   < E  "%1I;2!2
M>6%N' (% !=0;W=E<E!O:6YT(%!R97-E;G1A=&EO;CA"24T$)0      $(E,
M*T ^4D:PQ&_V$<%;PI<X0DE-!#H      .4    0     0      "W!R:6YT
M3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90
M  !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE
M5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O
M &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU
M;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0
M !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O
M;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O
M;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0               !"
M;&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q >+
M  IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M!!D       0    >.$))30/S       )           ! #A"24TG$
M"@ !          $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F
M  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M      $X0DE- _@      '   /____________________________\#Z
M  #_____________________________ ^@     ____________________
M_________P/H     /____________________________\#Z   .$))300(
M       0     0   D    )      #A"24T$'@      !      X0DE-!!H
M     S4    &              %'   #'@         !
M          $              QX   %'                      $
M                    $     $       !N=6QL     @    9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<   %'     %)G:'1L;VYG   #'@    9S
M;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E
M241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0
M  Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0
M  I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !2
M8W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T
M;VUL;VYG   !1P    !29VAT;&]N9P   QX    #=7)L5$585     $
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M!!$       $! #A"24T$%       !     8X0DE-! P     #+P    !
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M1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$
M A$#$0 _ /54DDDE*22224I))))3"\.--@;.XM,;='3'YO\ *5$966&-UDP)
MFBZ9A:*22G&R.H=3],M927%S2/;5:TB?W7&?<M:JLUU-K+W6%H WO@N,?G.V
MAJFDDDD'8 -?*NR:@WT*?6F=QD#;^[I^<AG*SO3!&++R'DMW 0088W=^?N:K
MB22&F<G.F/LW?][ELQZ@_P#22+C6Y#Y]>OTS ( UY_-/\IJ.DDI22222E)))
M)*4DDDDI_]#TC(P+[<OUZ\FRICFAKZVDP(;>S=6TGTVN
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                     /_A0 ]H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O #P_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ<F53
M>DY48WIK8SED(C\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T
M82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T-38V
M,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI21$8@
M>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D9BUS
M>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70]
M(B(*(" @(" @(" @(" @>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M
M+W!D9B\Q+C,O(CX*(" @(" @(" @/'!D9CI0<F]D=6-E<CY-:6-R;W-O9G3"
MKB!0;W=E<E!O:6YTPJX@9F]R($UI8W)O<V]F=" S-C4\+W!D9CI0<F]D=6-E
M<CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I
M<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(^"B @(" @(" @(#QX;7 Z0W)E
M871O<E1O;VP^36EC<F]S;V9TPJX@4&]W97)0;VEN=,*N(&9O<B!-:6-R;W-O
M9G0@,S8U/"]X;7 Z0W)E871O<E1O;VP^"B @(" @(" @(#QX;7 Z0W)E871E
M1&%T93XR,#(S+3 W+3 S5# Y.C,U.C,V+3 W.C P/"]X;7 Z0W)E871E1&%T
M93X*(" @(" @(" @/'AM<#I-;V1I9GE$871E/C(P,C,M,#<M,#-4,3$Z,C Z
M-3,M,#<Z,# \+WAM<#I-;V1I9GE$871E/@H@(" @(" @(" \>&UP.DUE=&%D
M871A1&%T93XR,#(S+3 W+3 S5#$Q.C(P.C4S+3 W.C P/"]X;7 Z365T861A
M=&%$871E/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$
M97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP
M34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B"B @(" @(" @
M(" @('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O
M<U1Y<&4O4F5S;W5R8V5%=F5N=",B"B @(" @(" @(" @('AM;&YS.G-T4F5F
M/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52
M968C(CX*(" @(" @(" @/'AM<$U-.D1O8W5M96YT240^=75I9#HR-S-!-D$Q
M."TP,$,W+31$1$$M03@W-2U!045%14(V-D,U,S$\+WAM<$U-.D1O8W5M96YT
M240^"B @(" @(" @(#QX;7!-33I);G-T86YC94E$/GAM<"YI:60Z,$(X.$-#
M1C=#1#$Y144Q,4%&.3E!1#%%,3,X-#%$-4,\+WAM<$U-.DEN<W1A;F-E240^
M"B @(" @(" @(#QX;7!-33I/<FEG:6YA;$1O8W5M96YT240^=75I9#HR-S-!
M-D$Q."TP,$,W+31$1$$M03@W-2U!045%14(V-D,U,S$\+WAM<$U-.D]R:6=I
M;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @(" @
M(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C Y.#A#0T8W0T0Q.45%,3%!
M1CDY040Q13$S.#0Q1#5#/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z=VAE;CXR,#(S+3 W+3 S5#$Q.C(P.C0W+3 W.C P
M/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A
M<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z
M<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG
M960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S
M=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC
M94E$/GAM<"YI:60Z,$$X.$-#1C=#1#$Y144Q,4%&.3E!1#%%,3,X-#%$-4,\
M+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW
M:&5N/C(P,C,M,#<M,#-4,3$Z,C Z-3,M,#<Z,# \+W-T179T.G=H96X^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H
M;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N
M9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F9R;VT@87!P
M;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S
M=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^9&5R:79E9#PO<W1%
M=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R
M<SYC;VYV97)T960@9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S
M:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C!".#A#0T8W0T0Q.45%,3%!
M1CDY040Q13$S.#0Q1#5#/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z=VAE;CXR,#(S+3 W+3 S5#$Q.C(P.C4S+3 W.C P
M/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A
M<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z
M<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG
M960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T
M;W)Y/@H@(" @(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YX
M;7 N:6ED.C!!.#A#0T8W0T0Q.45%,3%!1CDY040Q13$S.#0Q1#5#/"]S=%)E
M9CII;G-T86YC94E$/@H@(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)1#YU
M=6ED.C(W,T$V03$X+3 P0S<M-$1$02U!.#<U+4%!145%0C8V0S4S,3PO<W12
M968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.F]R:6=I;F%L1&]C
M=6UE;G1)1#YU=6ED.C(W,T$V03$X+3 P0S<M-$1$02U!.#<U+4%!145%0C8V
M0S4S,3PO<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \+WAM
M<$U-.D1E<FEV961&<F]M/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @
M(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @
M>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(CX*
M(" @(" @(" @/&1C.G1I=&QE/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @
M(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UD969A=6QT(CY0;W=E
M<E!O:6YT(%!R97-E;G1A=&EO;CPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D
M9CI!;'0^"B @(" @(" @(#PO9&,Z=&ET;&4^"B @(" @(" @(#QD8SIC<F5A
M=&]R/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D
M9CIL:3Y4:6T@4GEA;CPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^
M"B @(" @(" @(#PO9&,Z8W)E871O<CX*(" @(" @(" @/&1C.F9O<FUA=#YI
M;6%G92]E<'-F/"]D8SIF;W)M870^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N
M/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @
M(" @("!X;6QN<SIP:&]T;W-H;W ](FAT=' Z+R]N<RYA9&]B92YC;VTO<&AO
M=&]S:&]P+S$N,"\B/@H@(" @(" @(" \<&AO=&]S:&]P.D-O;&]R36]D93XT
M/"]P:&]T;W-H;W Z0V]L;W)-;V1E/@H@(" @(" \+W)D9CI$97-C<FEP=&EO
M;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,  0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$(
M %  P@,!$0 "$0$#$0'_Q  >   !! ,! 0$             ! 4&!P(#" $)
M"O_$ #80  $% 0 !! (" 0(#!@<   0! @,%!@< "!$2$Q05%B$B%S$C)$$8
M)S,V5F%7<7*!E;+4_\0 &P$! 0$  P$!              $" P0%!@?_Q  X
M$0 ! @,%!P,# @0'       ! !$" R$$,4%181)Q@9&AT? %L<$BX?$&$P<7
M4M(4559BDI34_]H # ,!  (1 Q$ /P#]_'A$>$1X1'A$>$1X1'A$>$5.Z'3:
M>HZ-)751.?,KI\77G.I]1HVY8$0QMW:#OL #!<QH3[ HN%(QRAIG""B1"CR1
MH1(2_P#'(H1==VTE)$^6;+<^(2,G\54@ZJ=[JY/L17M^7.$_P]XU]O?^_P#)
M/Z_W\XHYH@#F&,U:@^;J>Z^CL'Z;M-OB$,%KLDO:E"<#,BCI"=CZ3LP'ZOK%
MUS$*H-#ZJ-%>EC8*LIJC'V^IT&4R(.QH=L/IC\\7J[ZGIQ[@*AML0"!;O =9
MME>$;/$/,R.1K_FG^#^."U01S!+$$8B.)# 4>]]W->W;OX?>H6'T6T>MQ^I>
MF3)%GE&;%(EQSO\ $1 31*:&&*2(#$YV@\3-C>NYJ8,VOJ*L"RLY+JQ"KPQ3
MKB8>$26U,''CB)L911_^ ,\R9CR'00^\<3I%C8JM:BKV5\"FC:ZF+&9JRT4E
M5;WC@6CM'IJ$*:QN+,HLJ$080 ,=DDLTKYIVN>K6*V&%LL\BMCB>Y"*FJ#U%
MU-Z;;0LS9XP537ZJV<8\M'S6 .9$>9\:L+\*-Q5B5#&YT]>^:!]>UT+GRD)*
MU$>#\J NZU3^HT2!\Z?P35/46MSM@\-(O:X-71.JVQQ4M6L"NM&5BV:/M"&D
M#L'@A?-&V9KE1E;48XY>SX.R/H<,/*#/N'R=ZBP5LF5L.0M2_N1KA+$.P"*J
MC&+H8,^OXY<#)'.G2:9[XA5@0DU1"G5T1E>V"R(-U\W4QW[T?S'.Z_/7($55
MNX;72;&IE/(J9:0P:<2 NOE(_+^EYU)4: =&DJ,(LCD NA&$-4>-83&$P(LK
M(V32S<KY^<E-/"(\(CPB/"(\(CPB/"(\(CPB/"(\(CPB/"(\(CPB/")KL*2E
MMW1.M:BKLW0(]L+K"O$-="UZM5[8E)AE6-'JUJO1BHCE:U5]_9/8B;OX9C__
M $GFO_P57_\ R^$6V#)Y46:(D;,Y\<B"1DL!$%-70S0RL5',EBEC&:^.1CD1
MS'L<US51%147PYN>F2*0>$1X1>*B.16N1'-<BHYJHBHJ*GLJ*B_TJ*G]*B_T
MJ>$0B(B(B(B(B(B(B>R(B?TB(B?TB(G](B?[>$7OA%BUC&*Y6M:U7N^;U:U$
M5[_9&_)WLB?)WQ:UOR7W7V:B>_LB>$67A$>$1X1'A$>$1X1'A$>$5+[[LX'/
M]MEL?99JZ+BU U/-!H!9JO\ 6P37?4.><I&!_&<8MG*4->=+SUB<Z0,8-E-^
M5.&6<8-.%$\\\QWI2M0XV6AKM$':<BFRT+ 1/$(GBAV88AM&&B-1ZY<'CM;<
MY6[SMNI-?J3*(>"K<9:W<5+F=7=9O?[32TXM*L&<SN7 SMOLQ9&6MN1;X[]1
M:EQ4<E]5BSE6XW7:X;TZ=.]78?+]'? VN5IS,E3UE=?#;8;</<!9TL]3>7%A
M] @V3-:^]@%SMI^LHP3K']HV"8X@^IJ*Z[LJHHO4]9^'-Q%SK*FF+876[NYR
M M5J"Y\O"=35]"5LJ;H"E/J+.T9CMECXJ\S)' YZTDN='?4>0&C=9FNEA(M%
M5ZWN;WV)Z!KZ6BTYQ>6EHV8O)J 1!I>LPZ9T5/GS\/7/%4BRK+#;C:/*./"A
ML1Q(\T;H27LJ9H7^$[MQ#=PMVZ]:?/<B3025HX^EHM#D*?4 6P]] !*3+IJ7
M;W5"!"'( 2.*,-!A+)=E<:"RSXF0A/K9YF63OV,%>58W8I[Y+ZM\3U7:_P &
M$K2ZXV&BORR]&R4HG$?RO*;0G'Z+!@:&RJ:&0O1AQ+3Z<8$JMKK(O.7H9KZP
M98YXVE,M?,/>YZ7J(:GUR8/(:JQS-IG[(Q\&F_4"/H"9KRPASM/H[JDW.YTU
M>'4_C9S.9:LS]GL(9(K6XGM,JZJ/)92S75<-,2_R_P \JKJV/J"P^.W_ #W!
M3RR6DNX*M!['05+XSL_@XQ00Y:4C;6(R3C4,>NMK.JH<S^RF#;:6!S4&?*D;
MD4BK7K'JTJ^;:VZQX&8$T5I5UEM.% 5IYJ,F\M*'%V_1;<6MA@S-\.E.-E,_
M>CPWQ9HR&["JL,L+6R?JKVUJ"H#_ #S;3-)S/5%IJK376.N>;Y6LT%.;(#&.
M3UN 4:]G?^F&#AS4UGAZTF\+;8WP#;D(,%Y-15O:>UAYA=94V!-URLKB?8M'
MU=3I+C"5^/$@RV#U(<HNQETTQ4&^H_Y!7"3CORF?8)." K6'.806Q"U6&'[(
MD2=Q16-TO< \TY[MNA6;17U^*R]WIS&&V8M*&\>FKYSY&E6QB/'KAW-@]IBW
MQ$.AC5SXA2I4C&E( 26A!)- !>2;@-2:!5/AO4=2ZWD&FZV=FK2F'R 815S0
MCV%7;S2.L\-D]_71UEQ]U;4D1D4VSIH9C3YJL.M.0Z*UF!A *GC*"JK2/UR\
M]DE'&3)ZY"R-;+S>.)TV:B:[I4=TVD7+(\B\A<V%)'J8^VEBB8P2"R:H:G4&
MD"IBH<OI[*3X[UE\AV(70SAY+:KCYGSZLZ%H66:5#92 BJ9;FXIZ:(6V)FL;
MC*L)I*Z_C2.(.&XT=15"EE'J<.$5((+&AQ!H1H7N4@ ]5/+#R>'AM*,')[L#
M8F4<<\E1\<K-5@0R$UVSEBM98:VQ=>D18X8<"2S0K3K(&.^0:"<R,HW10\?U
ML<H?IJK+'!:*L-OMG092H>6RG3[@M+?Z?(UFL,%;;?G5] FLS*T5@LXSCJHJ
M\IH[(04J'1!Y\G9^C^9X.GN[]5N6J+4NLBR]L>C+W94=:8[4\UI1[-><PZ.;
M<6#V:/;5!-+75;<M9-K3KV&N"NDD"-B*&J9IK(<B3T7K YM<:;FN7) N*<SK
M,LL^/G,/RA$;*&2MC,I;S3B5^C+MLFNAL":_.U-+=UPU[-?6$82@(T&YEK")
M?TGU68KFFT'Q-C1:"U-.NL_DJ\^NGSL%>7M-5"XFCSZ/M;NOFABE':Z4ZYFB
M97!MBL'QO+BH-1+1$4BY?ZCL#U35[+$U+IJW182NH#KV VRS=A7RR7 KY[ 2
MFN,]>759=.RQ'X];I"027AU]B:*)][YG2LA)YYYKBJ]*]86=K'W[;C ZFL_C
M9]G6V/WWF C?(2-LNB\_J?US"M8(MC'=:KEFM%<X57NHJME=H= RMHYK$ZJ(
MD]IZR<W6V9U(S Z@^WKKEV7*$!O<&3 _4BOQCK6H"LH-3+7F-KQ-W2%O(C(;
M*[\>[$F#&.I#AHR+L:-SGQQN?&L3W,:Y\2N:Y8W.:BNC5S%5CE8JJU7-56JJ
M>[55%1?"*,Z^UR%!3RWVV*I@::B5UTIUVT=T(,U1#-9(:*V=DDBFA0BS&0*(
MQYC%@=(.WYL]T*%L6X\_A^"HO<>JC@N'B@,L= *?-</@@>E?'7A$RQ$YVXOH
M'.*T)E .?+)64%B%#5UY9UW+;CMSX]9);_\ (M(XZMQ=DRYWU ^G+(T$.5K;
M$NNJ\KKX,#(#>@6T]A7Z236:BJ=+;%:"2:TG>DF<OMJ9?V9$TI&6]M<\LB$U
MDLA'=^MWMUW7.K(*&(N.@Z*[I>?9NTM,@/%SV6ZNMG:4[BZZPJ\MNI0THQ,I
M>5DHH\]I7(,44]YL1 Q2#H/!*Y)KEN[^<4).3UT^?B]@Z]AM==::P@=><XY;
MG& "N'*DZ);M$AAU#9W>XD+.>K$\EC*F2)29Q6SB1$$0AS-B/.;+,'W]&[H^
MAZ=TR9&NM,CH-5F\SRK$UIMD7-TF]G=T>\+@,MM[968UH5!*9@29AI3"<PZ4
MP(:,6N:W\9T$2O=*C*U'W]&[HYHX+C4%G?4:IUN#=-8V-3A;/F.')C,!GU84
M+=]915XZXN[RRCJOT\[BEC(AL+.IF%CCB=!) (1"0YL2-AG-1]0.;]D?0XXA
M\-=?'6X:RUN7*S62 YMBAF&U9 %8D/0+.2."NS5>"/&,61-SMQ<J,"<,/ LB
MD/>V+VE>GLBNB/H>G=0Q<LN(")SHW(\<VLZB:+C[4%O4-*:*1"W.VL< TK3\
M.]0*Z*K!,@:RM^MS9R&RMB^Q[IF7PHYK3J*J1QI?<RH6?K.88T>N?H&PMBBZ
M/>6!26/0=E$ATR$VF!E(:*3H-%+8F0(3],,3YFBC_&.$?R>>7H"<B.7=2/0Z
M7=T%/:Z:SP&.G&SE9:7DZC[VPG.:. !.0;^"D_.X&?E3"0R0L:X@=DJN;%+,
MR-SG(W("<B.7?X5L1M8C6JQC6(YK/Z:U&_XHWV:W^D3^FI_34_V1/Z3^O"JR
M<UKVN:]J.:Y%:YKD1S7-5/94<B^Z*BI_2HJ>RI_OX1,LPN<HJFWE('I*>C5E
ME:7TD\0-?5+'-')/;V-N^1L0BQRQ)++8EF+\7Q(]Y,BL1RH2@T5&Z'H/IBRH
M0CCC.:ECNK4HA@LO05^Q*&S]IG[G7?B25.0J[LX#,6&<KKF[^R<2"C+"9-.D
MDGY,:3$<9I%+T3TR:$&ALX[W,RUV%VLH-.M6-:5XM'K1M--@"PR :T05B017
MDKVG16(SZ=E;'#KB?C1"CWD1+TMT6#R5I==3PH.!@N(]]2YO3;Z:?1.I!3'W
M!5_55J@Q0A&+&?#/DB#S#$CADFFD!^Z4N."* 1YYSJC]%L,I@0FLP#^19UK-
MUF[ZHL"H-) AMI45]=65UDR[O5HFW)II(A(36GDD%&SS#H1,2V>&*16#Z@<W
M[(M+,]5<ZR]#31\;RD]2,7S[)A_D75=:GSS@F5N6QQ5H;8YQ23YJ-Q OXYY4
MTY8$+)'A)\T;$X'.!%":MA7 E0[GJ/RG/9C056(Z"7=<?R<V=+H=#<[($"XK
M8R+X6$ D^UD(:F<&:=9$QP/DC(*G;*XM(I7$QO:DK0JP9GS^SJF@)R6RBP4%
M)7M!&Y'D38W1WD2D6][7VA[P])8&6=O72FEY62>2N+(/(;("][AG0.; ]CXV
MHGDX'IW1,5AEZSK60I(3N2T,=*!+:_H8A].-4%TLCQK;,G+7/KL_[ MF%).C
M1@[TC<CH)G,26&+ZZH-S7^<;U*09B+P^W&7E.8*-QYI>6E,L[P LA$OL_2Z"
MUB$,(SI!<@EN#H!67"S/C?9%H6AD9#?C-,-&I>'PS;-,]#]_E.>:AHWZHS/F
M<YS6=MZ+)YX@$RNAJ#HTSQ5G=B 5 Q$-37D!#5IE,1/#7LC_  HOR(Y1_C)]
MB-8/OZ-W1ZMH^'YZ,K9\*JL^G7F$K*ZGI]\ =85^PM9LT!$%07EV^,\JGM)Y
M97$4(91E&J5@]@UEM'*',/\ )RP$QK\Y&$O7#0VH](F;@,U>.S%YO8-/5C9J
MMRJT-J_+T%/7QKC=)55L3J-8AB(P=T\K6C&ONKVPANYC462*,UXI9+$9BK7M
M0$87<.%42=N])A@-_I+[C,H5RW$H7/7:>LSO[K29VW.H8!(A22[T@*P(+T7<
MM12*62<TRK/9L5)(#K+"M+MB$@$N#=G0CB6SX X+JW&)I-!<]$NL+L\X)E[/
M49DZI4O)F:%Y89?(>8DB'163-;3I(.6)*/)"UPCGHU?FZ>17_P"--T.[Y*U>
MM%/5].;T/?,9NLFV9*K$++*O/#W,D:L6A^I&1?SY/K5B(]'JLDGV?)%1&?'_
M "48.]YQW:;L5N&%P^K7M\%-RQ=1%ZAH&LV^1=,_!8M7R.YY8+&L7\AWZ1,;
M$G0&JU['I*Y\BRO21'L:C(_K5TF8HF 88G'=HNS9K+#.,QXC#L[(H1BYO(UR
M"2F/ZB[IV75VTR"SI@M]]<J<]L4C;$FAYM]L;H?]0%5[WO6%S)4E8D:1O:L;
M_L1T>?W*&F(QT.BY8[###&(1'%4/AVT*764'42-[A62;;(_:T+7NAD;SRQ:U
MB?B522(^-=^Y9/FBM1JH^/ZU:JJC_?V2PQ")Z&BX+19Q)$)$1.T2&(&]_.J5
M;BKZ<ZRYNV7<Y-ZNZ"(D+F<\/C^J7^+ZM4D>B[Z3[6(Q)&_6BQJKGM?]GLQ6
M/V]^H;J#\+JI5TJGZ<W,0K-N\I*S^7\Y3X,YX=$[['=#RS8G_-=])_C'*K)'
ML^/O*QKHD?&KTD9$6_IE/TQG..@O)W>5G';B-6Z>&+GAT$DL*4)ZRQ1SNWLR
M0OD9\FLE=#,D;E1ZQR(BL=1>-XT17U'_ .''_P#0W_\ 5/(BS\(JF["3SS^/
MUM+TFEL+NGU=W!E@8:_,W6CE%M;X(ZKC+<^DKSYZ1B!%FCNN)?QHQXR)&)-[
MRJQQ#YQ\[+YXR?\ 9+B"(O *O:=2I3F4U1F<!95^K)J\P?:S)RZ[3_E0[FU&
MTL8NT?9E !UCK6GB=$15UT5O6QN ++B]PQ-]VM]-:\+TE(W7H].&N;C1\=U"
M6A6<=H8ZK3WK7P[9VXJZNW&LQ'G:=:,N^*O_ %#GY J\L5#N,U,^KFMI:W/1
M84KPCCHYK3"KXX!\7Q(IW%2V-OJMR5H><:RAASMUQOC]L ==YNRT\MK6V=OU
M(RJ.B)@UF=DB^T.5DDWY#"YIGR(]TD3FO:^]^W;QEK7[%>7X?46="P"OVF)=
M,M3N?ID;SBY;'&WZ\W]B/B7ICG2J]%;\')+$D?Q7W;)\T^ $,Q!O>]KGT.:U
M"'+:.HMW:TZMF>?I?KK,(>^JV7.2X1EYW>"LD(;OLXT=9)4Z9.[ZHY7LDEC:
MQ'2L:Z-LD2N21HD $@%V..ATR\P7K^B>ER_5O5K!Z;'-CDP6RTP28IL ABB@
M$3_4(8J$AKB1O7-72?43VHWG>^#*,YLHQ>*U(Q"08?1Q3+!/1'Q2I%*_HTS(
MY5C>[X2/AE:QWLYT;T16KQB944Q%YIQHOUBU?PEL$BS6B</6+7$9,B=-$)L\
MD"(RY<4;$B-P"S):WU8]S1K427E_LC43_P C:?\ Z(B?_$KS'[UWTFN#C)^6
MO-E[/\DO3?\ /;=_U;/_ 'KI[B$O5+OE6,N6:_#!I;5T]FHJ\ZNR/H>?8FE2
MQ)-_J7 LC&R2O1BK$U49\4=\E17+R@N <X06=V) -[!VNN"_ _5+'#Z?ZGZC
M8(8XIL-AMUKL<,R("&*9#9K1,DB.*$. 8Q!M$ L"6!8+71$]5"U'4AX-?A55
MNWK'3R2\ZNW)+,_F7.G?.)C>F,^F-(EBB6-SIE62-\J2(V5L46B7;0-\_*YK
M'Z=!:91F&9%"3$0PA!%*8G12?GI.I)ZOL':FUH[6=O/,.@CZ//FY^**)=)OE
MD81$;I-&XB1S_9621S"M8WW:Z.151S9@V_JW9=>W62&R3)8AC,>W!$7( ;9B
M 9AF_1= >%TUKEAAG8Z.>*.:-R.:Z.5C9&.:]CF/:YCT5JHYCW,<BI[.8YS5
M]T544BK&GXER;/Z<784>"SE3? 4[J&N(KP6BAUE6^S@N9!ZRGA5E/6OEM1H;
M"4H$" J0MKYW3K)-.Z0HPR'F._528+!8:MGJ"J[&90 G/M,90D!9ZH%GI&6,
M8D-@VHE@#9)6M.A !B,:&Z%"8PA&3(]H\*,*JN-SAZC+T%U=8ZMT(5H1-21P
M4F7N]\'3OF&$I<N$D.7QVAI@PQA*2LKPWR!L $#%":82KTAE;-03I=B!J<0A
M\\]UAH^<U]+1W&DI':^;5%AU$4ZR]$ZZ>-,^&=@\:D#U%Y/<$B5L1QD[6"AL
MG=$UZS*.S[)8CG3E#VYHY PXA]^'LSK.'F.<,I$UTC>@U^C/R@+R(R]STXBQ
M&484NS&JRJ47:M((E .LCD6K'.0F2>:45ABR.9*V&MX'(=EN";,@!V8MDQ .
MP#.--'O%=5JK.2U2T=9H[^/6R;07-%,GBK.B]-@CAFL6 V%A3A0S;,V9(Y3*
MRNA?\R9GRS!QO8YC7?7Y& N Y#7NM?OSG!_<B< C#'@D&!YV!I<[2:?3A;>F
MU<"70[1W="ZI7H*QYTPGSA%L=5(;!#8""!SN0CYO<UR/C_P5BK5F*;,F!HXB
M6N!/;[K3C\!)J(ZPG<5VOK"J^HR>D 2'I/5F?A::P!NA+T9J'Z:-625;OE#!
M$Y'S,#L&/,]I9F,CI.[' ::4X'=F>,$D.:: -F/9KFK7%-X.2+OM&#G--7[1
M:61-!8%O9MNPM@".RVXE3''I=EZF*L(99@5H-K&%%"I<9D49ONE>6-$L1G:_
M5B1<^YWNNQHO2\S:6&HFQ]KF-Z?CK74W.;L+Q.D]'DK5Q\G.A+D8DN*?6Q2S
M26>A,-SQ1,([ZJ%!'UZ/DL)DD8N1M_,ZZTX\,%TVB(B(B?TB(B(G_LG^WA5>
M^$6+FM>GQ>UKVK_NCD1R+_\ 945/"*MJ[C?+:C2!:VKPV?KKNMJ/T5;*$$T4
M"MK5MXKY8JZEA5E*"0MS#%9?GBU\)_Y;?M_)^3G_ "*,!=N\%RE ^.R(DP)(
MN6S@Q%9*1-6D#T=9#-7S%L"B*F!EC%:\24F.MKHR)('1OF8 $R17-%@2,JHY
M;\VS<Y<UV%#H:PZ*B"IF!9#2VN6@+KZ8FXL:NO8#6V=74MEC+N[1()YD@1%-
M5I!#8(V+$10;(\Q9H*JFT.S3?T6M"FT@B ?ZCZ]RUHTMR0$Q(9!]1803QV-;
M6UA:DM)>PEKF$,A#23\6$@)#X7C@]/A,U/R2OZ#07=3TB/<.&@TS4&#=N^CA
M@G"5<]9=4Y<3+&V#.FDKSVL@F+;&P(LZNEF!<0"^*201AY5=BRVRTV.T2K79
M9T<BT2(Q,DS81#MRXQ=$!%#%"XP<$#!0$#TQ\_O=5N<OHLCJ8L=$-&#4%_SC
MIC?VP9E56K8.*LI=.T AI<]C8!CBUD3YQ&U9*V,@TD@GY>=B'+W_ !^=Z]^/
M]:_JJ;!'+F>MVN*7,AB@CA(D 10Q PQ0EI0+$$APU+FH2FLO3!ST;HF?SP6)
MTQ&.-K))[:\7<]/?*&<H]_+%'&=%IDJX(HI:NL'(@+9^7*^Y%<*CV-F= V(<
MO?NNU_,']9_ZAMO_ !LW_G5A7O,V<]J*&GP+=Z[/ U]F-^"#K>CWI5:^!D$E
M3$$ )J05GB(FD*BDC*/%8Z1T+GG!#QD$,UE32C!@%\G/GS;3/G6F?&9L^T39
MD^=,B;:F39L9F3(XF8/''%%$6 #FC)/<\M-K,]7WU0S3D:O0+#9;*!=QU$L-
M;6+"S#LG'A'N8[B*"&TI:"J1) "#GUC%';7_ +.:-["U+M5HDP[$N;%!"Y+!
MF<\"WMQ*LWEV*!HQ'Z6:"[CTUY6AU5S)<W&HL&N&H["W<%^O!U%@8;6!$2V!
ME@/'/&-82#F0)8Q1SQ(/ 6)DZ;.,,4V.*.*$,#$P(!9Z!KV')6QX7&N7>M]
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MH6:Y"DA<3;DQBEQ$AQO$-;"^4.=&$1(KXT1: Y S+*J22A=-/@B:41S8F)9
MS&1$4&@G8PD2>$X.=K9+US4G$+@@*&F1$? 3#%/$YDD;')$49RR;[1C#[:,/
MEP5Q:!3U,QZYVZEM'5E?:&QQ5\UFEO$5,"A+)2XQ'._'BFG>]L:R*Y[B++)S
M]$5^CSM1!S*DKL1>#9D00"@O1@70R9?-:5D@@0UQ! ##&FB_#:-&U[?<59T>
MGW_5%6NU#]2/A1[]"W0'Y24V+<Z+6D9:ZK>4VKL[39K6@G6>:N+!!R[&[NXA
M5#@*M9%#*KC,J-80FPS)(A"C21MBE#CE<:CZD<F[H]6T!YOV2O2$]&2PS.<L
MX>96XFK/L:^2,ZBO9Q8$ HK*Y6240BWGB*25H#AOK=]?P^[[/DY&K&]@3NYG
M[ ]$Q WG@/FHZI3?V/3\G3@D0/YR\;]UD,X.&/3:$2$:+1Z>ERT,D3673HV0
MUS;5I+!F1M;)&,@S'0H])(P#\B>0=5)IZ[<8'-Z"QH0.45@E>#97Y-=3YBXJ
M(3B0*WYN?*@ENR+\B88$<7\F2*1[8HH6JCF1,8D3X4F%_P!5B1AR/S^>L^^"
M*;X?IM([X_;&U_Q]_P!\GO\ 'Y>WO[)[^WO[)X1,63N^JZBF_;I/SX)/VVCJ
M_H6JT<Z^^?T=K0+/]B7<7]%+6?E(SX?\%)DA^<GU_8^D-R!YAU 7YD<BREN*
MO;VVGV%;HF5/[#*Z>"B0BEC,@#-')R.5T\<ZCG3E3P31NT<@;VH1(Q[163-^
M"RNC8:[4/U(^$>_0MT!^5.?(JCPB/"(\(CPB/"(\(CPB/"(\(CPB^?GJ.VO!
M\IOCV;SEUK9W^>J*?JQFAK9:>O$N1<5.1:5X-[<%EQP!!PFU8\=(!;EU;=%I
MI@Z4=CHC3)Y"R2'(.3G$,*Z^$:*M[?L<, ^D?I/2CF["B$K(]$3&M' X\C/9
M*"[_ (C=B5(@N@6] S]MS/GR26CY**VJ*T&8L;/P3X^G$N"N%69L+L>@ 5[U
MFRK=W1[6FI,B?RUX':.2NIK:NH6U4NKR2[S+Y?*[^M2\SWZ@YMD/C3:^O^(-
ML)!GJVB59?:>"" .>]05K==Q&'"INH6O(5K=2QE_%S+HLC^J] G9'A->]\$P
M?-$BF:W/V#G12K%SJ*9(Y$16/6&6*1&JJLD8[V<F@SB@O&,7=E6OJ;M.C"]3
M4?$Z'Z(?^]GH:>\4:^WX7,%1/\&_TGOS=5]D_P"G]^2F0YQ?W(QS/3LN:L4N
MZ&S@HPO5=O / 9=111,J^:/1K([RQ:G^<O/))'*Y45SE<]?\E7V^+?9J9O+U
M%31RV5R^TL?H=AG62SSI@FF.;)ES(FF,-J*$$L&H*J-T%GT,;1=,9!U;90J[
M;@OF>E1S-[B)5YS@$^Z5).?/:QZ1I' C8&PQ?7#&Y8EF=+++F*(@@# :ZWUK
MQ7IV/],^ESH9QCAGDP3M@-.(I^W+-:5+DE]6P4EP[=O<=*U[S.J[?[Q\-A6H
M1#6<SCD?%)?]!<V&1B\\?!\(GL<^-S(62JZ:1)))&)$V((B8;@6/^[(5^DOE
MF-,5Y/K'HEBL5HDRY F"&.28XMN,Q%X8]D588'RJF>AHM2_8\S9)U3>2*MYH
M59(X#FB/@<W&7ZJZ+Z^=LC5SV(Z)R3,F;\'N5C6R(V1MAB)<$-3.*M&=W-VE
M*ZKPIUCE2S+;:^J(@U?!_=DY;_-:5:2L;+U/>S,=O.6,^$@/-&M1TG3L@QDJ
M+%SJ)_V0/<V>)%>L:RQL2:.6%7Q/W"SW8'$G YG'\,NO,D00P&*$GSF%*MYB
M] S$;*1W5N@RM9E-$YT,@7,TCE1M08JQO^OG,<GQ>B*URQO8_P!E7XO:[V<B
MF0YQ?)73;4]/@!/M;B="M: O^K/0T]PA51K0N8^R?\!BHB>_-U7V3W]D]U55
M3V]U5?[\4R'.+^Y&U/3LH/RK&W\N/1[>J;^!JZKH;?KB#YJK/=G0M0QTGO-S
MN63YS.:LTG^?P221R1,CB1D;*6>X70XQ9:'\XNH!J14Y9FM0>VBF/,J\JLN.
MMB&75IH)V=&KWNL[B.GB.E:_E7,7-C>RCJ:6N1D*+]<:Q@,D5J(LLDK_ '<L
M-T.[Y*HO._X"MCR*H\(CPB/"(\(CPB/"(\(CPB/"(\(F>\SU!IP5J])1U&@K
M72QSNK[NM#M05GA^2Q3**=#/ LL7R=]<BQ_)B.<C51'+[D3QX1-5W14VDKI:
MF^K K>LFE$(E!L!XR1GS@%PG!3+%(CF_:(:,.6-(B(^$B&*6-S7L:Y"*FZ[D
M>=,U.PBN\13/QTPM<%35Y]9GR0S/L"1MM- HB)8L$G?)(,2#>H8XB1))AWBB
M*P5Q2]_/ C0\MJ&ZC&,H,/4.H/S#OY6OX%$@"UKJ\ED'VO+?^YB-'/\ P906
MU,:P3QJ9&>YK4@5I&NO84IPOW-GI5V2/7<5R</\ &&X[GN6AABTP<U\,-G<Z
ML95*]9U.'(GLIQW5XTDDWY9!E6+8VJRPLB'$<A$TK"YA/M$(AAAGSX80P$,,
MV8(1"!0 "(  4N Y.G33\-YRZ@O_ .-<[R@NB,&DE!*%HZ!DS[5((1A"")+0
M P*1C(QQH"'DC$2(!#]4#?MC'1L88@'>%L6NUP@[-JM4+ESLVB:'+ .?K8E@
M YP %P"5R\3YU64QTM3@<F9I&T2BPGRT50(3;'!"D. _.<- &*C)3YI9EA8T
M<*"0LA88X(WN1+N#:!8CGSYI!FSYTPB@,<V9$0+V!,18/5@P?!-.!Y#FB<M2
MD;[GN636#3VSII'5%1]T3%L;$:O(:M<U1("2:-PJ$J)]7NLTT;XXE=)"TL;4
M?]<9WQ1%MU:;@DV1Y#3DFZR/:8'+2U<6B^[*_?64LDS@Q3YR@R8XJ^)&#BC-
MAJ)JS\^0JYBL(32R"FHX2 6ODX/8,/GX6=J(N#%$0PH8B0;\'KA?EQ39<<N8
M_505T.$SQ.5.OV)*0E!32@09AM3GT/ MVDGS6)DYYTFA@#D$%"9$LD9)DKAJ
MJ*KTR[/FI5SE^/OSX+?I^6ECWDC<G@\25GW2\]:QA@80DX0C+^^7>J,YRRN,
M(EHX\_ -&0P2$2*<H@!Y9T*CO.<SS0B]G.0<WGC=[8)69RFK#WN>#IN=YB+G
MSP39;AX@%1 K+8K]V43,7'*U#43\Q*=XK:QK7&DVEJ38R_$1J2SS@F-&:\_A
MOE750YG/Y<<H7.T]?3#FF+8&15XT8S2SE%%!4PGZVHLY/X8(0GW2*YZ#BCPH
A[ZX8VM*LWNGSPB/"(\(CPB/"(\(CPB/"(\(CPB/"+__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>g425213g55v25.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g425213g55v25.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2 X4&AO=&]S:&]P(#,N,  X0DE-! 0
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M4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <
M"G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@
M  EP<F]O9D--64L .$))300[      (M    $     $      !)P<FEN=$]U
M='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;
M4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O
M;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP
M $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M        1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M     %)S;'15;G1&(U!X;$!L,B3@        "G9E8W1O<D1A=&%B;V]L 0
M  !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M            5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C
M0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T
M0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O
M<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))
M30/M       0 [_^-0 "  $#O_XU  (  3A"24T$)@      #@
M   _@   .$))30/R       *  #_______\  #A"24T$#0      !    '@X
M0DE-!!D       0    >.$))30/S       )           ! #A"24TG$
M    "@ !          $X0DE- _4      $@ +V9F  $ ;&9F  8       $
M+V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $ +0
M  8       $X0DE- _@      '   /____________________________\#
MZ     #_____________________________ ^@     ________________
M_____________P/H     /____________________________\#Z   .$))
M300(       0     0   D    )      #A"24T$'@      !      X0DE-
M!!H      S4    &              %^   %HP         !
M              $             !:,   %^                      $
M                        $     $       !N=6QL     @    9B;W5N
M9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,
M969T;&]N9P          0G1O;6QO;F<   %^     %)G:'1L;VYG   %HP
M  9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2    !W-L
M:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU
M;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU
M;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG   !?@    !29VAT;&]N9P  !:,    #=7)L5$585     $
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M    H    "H   '@  !.P   %6D &  !_]C_X@Q824-#7U!23T9)3$4  0$
M  Q(3&EN;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5
M  !)14,@<U)'0@               0  ]M8  0    #3+4A0("
M                                                     !%C<')T
M   !4    #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R
M6%E:   "&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5
M '!D;61D   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #
M^    !1M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#
M   $/   " QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY
M."!(97=L971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)
M14,V,3DV-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M
M6%E:(        /-1  $    !%LQ865H@                     %A96B
M      !OH@  ./4   .06%E:(        &*9  "WA0  &-I865H@
M)*    ^$  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M            %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                          !D97-C         "Y)
M14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M             "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S
M<&%C92 M('-21T(                             9&5S8P         L
M4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
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M $H 3P!4 %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +(
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MU1CZ&2 911EK&9$9MQG=&@0:*AH
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MM_$9,S1'5%AB=(*$AI/"TM=#14A3>(>7HZ6GT]76_\0 ' $!  $% 0$
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MT/$U,R?/WLJ3*1CJ$P2C)J;=,$7#1PI<BHO,N??$@H;P*/ 3%G6AJK-[BHJ
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M*UF5;E$LAT%:/N*H-Z?()V^N*,[4NHZ*S*A6W19 49Q51X8K4J<6=T8SHQ4
M#S3 71%^!LQXC+5BW@V2\=!2U)/Y%3MQKK60JZLS[09B$4G/C(_)1Y,79#M
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M*UUI(.TD.5E6K)Q(IN7":/[J=)(Y4_IB4=<MP9/< #VY_>I>H[L7^'NM&/\
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MZZRV+0<)Q.001A]\<^RVJ'/CQSXF-5\*4=<V0[)H/E1IGK$Y@<^/F6[[9;-
M4Z$DK):)B,K]?AVIGLK-3#YO'1D<U(8I#.'CUV=)LW1 QRE%554A"B8 $0Y#
MGBBA0KW5:G;6M&I<W%9X92H46E]6H]VC&,&;G'@,IYK8CG-8TN>X-:T$N<3
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M6),T3+MTFX2,89H[5:,5U563<BP;\4EP]4PY4$75:ITU%1N7L?R<1$WVBO\
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M Q]$XC_!UE\K1H%S0(G\JSW@MK;Q!?O,,]?Q+3_GR%URKT>?GAL[Q_E!R_\
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M,25^T'EVO<]03%$?HB/8>HO_ !@X^.MYD@$%O#OU]O)1[@[^:_W2%MW^&/\
M>488_P#%KE_S@6G7)?23EMSC7_X'KL:94ZPSZ-L_JW>I[@M9'=EQ]M#N*Z>_
M[]V5?S_/NP=O=KI796/P8V=Y?(^&S_Y.A*B%_P#/*_8X#U3]JIO '/V<\+\]
MA^ROC;]MHC7LQV/D/&(T^3;^/_)U>:I9_.*'UA]@6UCXA7WFF>OXHQW[3PFN
M5>C_ //; /VEW\/<J7XG]'WGU3?:Y:>1O4WX1UUXWRAW^W)08Y@CFIJO!0[9
M9S,'^UO <?@"R<:TYTT_1&"_O2M_#O6?P+\M>?S&1Z ?;*]CQM?[>\#_ ,5K
MQ_/$'_BUYNA?YEC_ .VV?\,]4Q\'KK<\/!VCSR5!\'\ _P#=)_\ &'6[F:GN
M/V*/N_1_G#[5N<;'_O0]O?XM8'_DU=<>[;?G;C_[QK?^U3^P^9V_U31Z)"BA
MN/\ ;;:/XR3O\YN-;;L/FEK^RVW]BQ8VIY;N]5O@;[LN-?XVQ/\ RX:\>T'T
M)BG['6]U74/RK.\^PJ3'>!]PBRC\)2L_IG60#K56QHG'+(<Q=_V%996N)8X?
M\#Y[HC[5#H;L80#T[B'Y3GUNP:YZPV?6L*"2&]WMS4B>PGUR5_=5@?R>7/A^
ML0UK7I!\O"NPW7NTRLC9?I]P]I5 [Y.V3ZSQ[Z2T_.,]/=_P]^VO9L!GA5YF
M?GU5VIUZJB52],.88$P#F.1='P5A4 !R';WA[S?'X<\?DXX^K4](@&)&1XG[
MUCSG/;R4Y&#C";#6.1'C^U")]/>'L:8\?'CD?U>_OK06T!G',5, %MZ\2.(R
M?W:ZP!EDLY0:&40T20RF8DSF-">U0HV3^V*P#P'(SDL ]@'L5^N >O/N_./<
M=;TM!-O0$G*A1 ,YQN#(K$5#XSA @.R'*9)T*N5M\']^C' ]N?G.S 0X#CI\
MM<?=Q[P !^K\^L9M&(P7$A)^:O,DYY$0)Y2K[>#4 B,QI/..,\UE7XJ90'99
MD41YX--T I@Y[=(W2$,/ >OJ4./7U'M\(5T6#_//"W#,NMK\$$Y'^1UGC+GO
M<=8XKZXN3X!6(R+"R"-?&>P$GF0"8XZ>?4X$1[@ \!Z 4 +P ? .0$> #L'<
M1X]^NK0[F!KF8S[\N*A4-&6Z#&4F23'$F<R=2>:GV\$@@ QW#!QTA[;C(> $
M> _L6Z>G(CQSWY[^_6B>FPCK-FSK])P?-:?X=RDNS\N%UO:EK)[R<X])5&^+
M/FG,&/,^TZ&H&4LATB(<XPC9!S&5&YV*ML'+]2R69N=ZNVAY%FDJZ,@U02,N
M8HJ&32(F8PD(4I?OT2X/@^)[.WMQB6%8;?UF8M<4FU+RRM[ES:;*=(-8'5J;
MR "YSH! WG$JW'*]>C<4!1K5*4TS.X\MF<\P#![R)@*+4NZ;<R(<!N&S>')T
MP']]6\GY 3@''[I.GX^OIXY]!Y#MK:(V6V8F1LY@32 [-N$V+3IS% +"/OKW
M=<#=5W \ZA[N$<UMP;29R7L.V/!5@L$I(34Y-8OI\G+R\L\<2$C(OW4*U4<O
M'KUVJJY<N7"G4JLLNJHHH<QC&,(CKE+:JC1MMI<<M[>E3H4*6)W;*5*DQE.G
M38VLYK6,8P!K6M    R$ <(G%H2ZUMRXEQZIN9,G2<SQ5^BS$9Q].09E, F
M0,Y0*("!A#@0%0.![=PU'@*Q_P#IZNI_1G(& <LH.1'80O08'$>D ^@YCSA=
MR2L:H8A$WS0ZB@\$3(X1.<X_ I2G$1U?NU TN=2J- UEA.[G$F-!SF%0N:/T
MARU'WKZ57"2("950B1 X^FH($+W] ZC&*'(\]@]?JU8"2[=:USB-8!)UC(1G
M\<,U5?-\J,/^[6O_ *Y+_P#DU?NU/]55_P##<J2.8](7T-W3=T!A0726Z.GJ
M%(Y3]/5ST]728W CP/'/'/ _#0AP\ICV\MYI;/=.L<>\)/:#W9^Q?1JBJFB)
MHB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(H2=^(,G
M.Z;%"EGD=J]3F6M NC.J);FK93/FM8JD-QHRZTI4/LB85ML?!9'3ES*LWL+7
M9Y@\>PX1;IR[L":"257(IK&8\MR"'3QP7@2#R0?HE[D$ +R01YX'I#D/=HBP
M*WQ/,C8]A*EENO;ALHXFQ_%7BKP^5(>DI;9"D"F/T+ W&3KRN>L<S(KVF0MK
MJGQ3MDC;@45KII0]8KCZSE9I.R*_>U:3R!,X#QO*Y0GGEGNDA"*.Y*P29J0:
M:EV:TG('@']A^QHV:X]3LSBNC$FLR%*1"L-I_P"46\,=5BFBJ<BN)E:-R-,8
MWNL5B&Q5NHY.D:[),Z-:+?".K)6:_9'#<R<;,3, R>QSF89QZYBN3QZ;YL#D
MR9$U%!2$Y#$6-.!]J#6JX;5Q?FR)IET>KW60O$S8825N3N9OMME&;<LMD+(-
MCF%X^9FKW-O5) CY5N#6!CX5.$K\#%Q<'"QD8Q(O8VG5:OTIGGVKU:-3B(&)
MW'WE*/CTEG*Y&R:]5HKQ4I5GB[AR<#KN%5!%58X@8X@ @4  +#Y7F;[X56ZC
MO'M6K=O.^^PW#_C;NO\ /3G78VQOYJ;/?NBQ_L&* W_SVZ^OJ>\5;##?W8,2
M?C0QX'^%\4/](ZR^+?1.)]N'7X/<+2I 5EM^6I_\))'82,R.U;;6_?[SW/WX
MO9'^6L=<H;"?GE@'[:SW:BFN(?,+OZIWNN6FP0P=B]^>_P#2.NQ5KUXSGG]W
M]RF8\%K[N&6?Q6(?M9#ZTSTU?0>%_O"K_"U%G]GOG-;ZEGM"N/XW( ,[MU'X
M0F5!#\CJB&#])0'\FL?T+_-]H/KL-_L[U>G'OREH.!> ?.2%!*8  1 .P!QQ
M^8-;U;H.X>Q15WE/_GO]\K;B\,7[R3#8?%2] /\ ^(MLUR1TF?GQC?\ W9_R
MZT4\PC*PMXRDU9[9?4E:T^[WD=TNXCCL(Y<O0_E^<KT1UTILEGLSL_/^Z;#^
M'"BM]#;BYRR\(><N\_'=DJ0V^<_9XPISW'[+6./VRA=>K:$ 8#C1 C_)6(_P
M5=?"T<3=4>76,@?T@MKCQ!/O,<\_Q,2_GR$URET>_G?L]]>[^%*FN*?1]QW-
M]JTZC"'7Q[Q(A_)DO\6NQ(!S(G,CTN/WJ"'>@$$  .]]W8IKO!4^ZMFWC_8[
MK7[0CS^G6F.F?Z)P8#AB-P/_ $Y6>P S<52?]2/>"JOQMO\ 3_;U_>;)O\NI
M&L?T+>1M'_.PGV8DOKM!Y=KW/4$WO+_=%_XP:WDH]P=_-=[I6W=X8_WE.%__
M !>Y?M_:M<G=)/Y\8YW8?_ T5.L+^C;/ZMWON6LCNP[;H-Q7X[LJC_AW8-=,
M;*-!V7V>D?Z'PWG_ +%;J%W[G>&5L]7]G<J<P (#G/"XA_LK8V_;:)UZ<> &
M"8P!_NV__@JJOLI\(H3F>L/L"VL?$*^\TSU_%&._:>$URIT?_GM@'[2[^'N5
M,,3^C[SZIOM<M/ .KOU#S_E^ -=A;HRR&7++V*!;Y)$9#*1ES4U?@I?=9S./
MO#&\#Q]7^>,1UI;II^B,%_>E;^'>I'@7Y>][&,]@7L^-K_;W@?\ BM>/YX@]
M?#H5 -GC\_[99_P[U3:(D/M8RFEV<(^]0?<\$-\1,GQ^01'6[PT F-"(XJ.@
MD@3^N%N<;'_O0]O?XM8'_DU=<=;;?G;C_P"\:W_M6P;#YG;?5-44-P_MLLX_
M&QSH_P#ZFYUMNP^:6W9;6P]%%H6-J#QW'@7$#GD85;X&^[+C7^-L3_RX:\>T
M'T)BG['6]U74/RK.\^PJ3#>!]PFR?WSK7Z)QEQK56QGT[9=UU_8UEE+@D4W1
M^J[[%#L?^$/]T</R H?C6ZV_^UOVK#@>(P\P?L4B6PGUR5_=5@/_ ,NP?X@U
MK;I!\O"NTW7NTUD++]+N'M*H'?+]U"L_Q):?S].Z]G1_]%7G[;5_L:*MOM6=
MWVE85%]0_"'Z]3YVA[C[%X%.-@W[C..?XH1'\B2UH#'_ *;Q?]N?[C5GJ7Y(
M_5N4*=E_MBG_ ._LQ_."^M[6?S>C]31]P+"U/*?_ #A["KE;?/NSXX_C.T_Y
M);6-VDCY$Q$Q_P#3/'IC[5=;F*K8^,PLKO%3[;+,B? )['_(?5\\X;M^K4)Z
M+?SRPGA_)[_^!K<%]L7^87/?2]&_3GU+4TUU?NC=F,XGSQZ%!W..^1.6^1H-
M)4^_@D"/L&X<>>_MF,_Y)=-:$Z;LG;.1E])^L6BE6SF?A$YRUDK'_P 9?[X^
MC?7B&%'\IK1;1$?RCK.="X'X,W8X'%*SCVDV]JXGO))/G7EVC)%>B1P:[VQ[
M%$43JY[B''6GQ_ZP./=K;Y$1IH08XG=/W%1\N#FNB<HU[UN@[-"E-M+V[<AS
M^]#1OYD::XSVS:';5X_(G=Q>[<.P^$/S6PK0_P CH]M%L_U5$A8U5 L4_P *
M'#_-N6#L<WI[>X[>NMR6E-AMK>6C\C3]P+'5'NWW"<@<ADKG;>CF'-.-@,8Y
MO,LZ)3 )C"!@!HY, " CQV, "';GGW]QUBMHFCY#Q @ $6SS,:0]HRY:\(YJ
MZW<7UH<=X-8'-!B X%V8] ]"D5WB**$PI+G(<Y#A-UX ,0PE, ?*:0<=11 ?
M3L/?OK6FQ #\;MPX!P-"[<9SS##!\W8LG=$MHOC*0WUP?:HB0=NN_P#9+CL'
M_P!<I\0_\+6YC3IB(8W,@'Q0<CW^T9K#[[N?J'W*1[84JJI'Y,%1510?;*R(
M>8<Q^.$)KCCJ$>/4?36M=O0&U<-  'B78R &0?0].O%>^Q<3ULF8W/7O_<L(
M?$XW=[BL#Y^KE0Q1D=W4:V]QM!SCF,;PU9D"+2KN=M#-R[,M,PLBY 3MV#-/
MRR+%2*"0& @")A--.C79+9_'<"KW>*8?3N[AN(UZ#:CJMRQPI,HVSVM I5J;
M8#GOS+9SB3PQ6+WUU;7 90<YK328[( YESP3XP(!R R_O$<H>)1O8'O]G&2'
MGW?-BA 'Z:K_ $!_CV&>CO8L$@X+1\UQ? ^D7*Q8Q>_@?C7@]K:?VB?6MHS;
MI:Y^YX'Q!<+1)*2M@LN-ZE/3<DHD@B=[)24(U>/71D6B2#=(RRZASBFW122+
MSPFF0O!0Y;VEH4;':#&;2U9U5M:XC>4*%)N\[JZ5*H&L:-XN>[=&@<2X\3.:
MF5J\U+6VJ/,N?3#GNTDDYZ#AH-?L5SC6J *8>J>B.0["7Y29=A]! P"OR40'
MU 0Y >P\#K&^#W<!W4W!#@" VVJDP1,P 2-1P7VWF1D1V'>F<^Z/9Z5]#6RP
MCM8J#>7C%UE.R:*+]JJJH;CG@B::ACG$  1$"@/  (CV =4-*X:"YU&NT 9F
MI0J4V_UG- GSH#,QG&9A?1)2\?$E(O)2#2.0,)2%4>N4&J!E#%.8" JX.0AE
M!*4P@F41.)2&, "4IA#YL;5K5-RDRJ\]6'EE*D^H\>-NR"T. &41$SGQ"9#,
MF,XUR]&A\Y'J*\4MUJA@ 0M=>#GGL,S&\]AX]!=@/?CGT#L/PU]VVEZ1(M+L
M:^7;5P[(D9PR,]1V1Q0N9/Y1GG,?>O8C9J/ED55HN092:2"@I+*L73=VFFKP
M!O+.HV56*53I,4W080$"F*/<! 1^3V5Z3C3K4*U D2TUF[N\-/$!<'02#!,9
M]Q H"UWDN!YZG3S:'A$]J_9:48MSBDN^;(JAP)DEET4SAR "')3* ( (#R'/
M'/J&C6U7>32J.',"1K TG/TG2<TD1,Y<U^83<6(\#(L #X^UM_T<+<^_] ZN
M-*MQHU1GJ 1[0/\ 'TH"#H03J0-0.9' ?>%Z21@.7J*;J*8"F*//("4P<@("
M B @(<#R B ^X=6 $2#O C(AW//157ZZN1-$31$T1-$31$T1-$31$T1-$31$
MT1-$49;?;ANVINY^_9TH-TQ',05U=W%F]A[]9,T+.)"MS;O'JM-8.X%B[?TR
M)<XO9TZ<C*LI7HMJ5RE=;"\?F*]D7ZCTBDO1Z_+#S X./'5Z]QZ0Y$ ,(B "
M/N$>WIHBB\\5"4KTEA6NTMS;ZK6)1S?FRDU*2F6L<8IFJI2+'C3+]9G9F*FL
MI0UGH:,K<8<]AQG4B7> ^;DC9K,B@$]49!FWN=;(LB=ALS&V+:GB>PP[>22C
M)]C9)MHYFG]?DYN83E;M9WPV.<>U%9>GJS=G.N:QS!*:<*<WDI9TVJJ3> 1C
MVZ)%E_HBX$0#U$ _"(!^O21SUT[46'6"KU2(>U[A:]+W&JQ4^\W)VOV2#D;#
M$,9AT+VI4%%G[/&.7B3U<7:P"DV\I WGJ!Y:768.->AF'W]:D;JE97=6V#2X
MW%.VK/H!K'2]QK-8:8# "7$NAH!F(5HJ,#VM+V!Q(AI< 3GP!,GS+5PWD+H.
MMU>X19LNDN@IEJ["FL@H15(X!-NBB)%$Q,0P 8HE$2B/ @(#W ==?;&[U/9;
M9\.:0X818@M<"TC\0PY@B1Z%!+[.]NH_U]3WBK78B<H-,LXK<NED6S5KDJ@K
M.7+A0B*"""-LCEUEEUE!*FDDDB4555%#%(1,!4,(% 1UF,587X7B.X"Y[["]
M#6-!<YSG6KVAH S)),  23D,U\Z.=9N<0)]#8C4<X]2VM-]^0*"\VBYG9M;Q
M4'+RPXZD5:^T;V6%6<SJ82+=(3PR";TRLF0%4%TA,R(N4%$52<]29P#EC87#
M[]NV&#/=8WC66U\P7#W6U8-H'<<8K.+ *1AS3#RW(@\0IC?UZ)LKEHK4B74G
M;H%1A)(#A $YF01EQ!' K4'+P  'H/P]_P";\&NN5 73)U@QW'+T</4I@_!R
MFX6NYAR_+6"7BX*+;8L:@XDIA^TC(] 5;?"I) L\>JH-DO,5.1)/K4+UJ'*0
MO)C  Z>Z8Z%>YP?"J-O1JUZK\0JAE*C3?5J.(M*I(:Q@<YT $F <@3P6>P!S
M67%<N<UHZEF;B -1Q,!7!\9ZPP%GD-N4K6IR'L,8:*RL@62@Y-E+,#+(O\?@
MLB5XP7<-Q52[^:F"G63_ %8!KQ=#MO<6U+:*C<T*UO5%7#":5>D^E4 =2OMT
MEE1K7 .D08@R(7JQQS7&V+'-<-Z):01HXD2">P^CL4'H<\!SSSP'//KZ>_6[
M 0 )(T''L46(.\Z 8WWQ R\HK:Z\-"]T=ALSQA$OKE5&<K"-+W)3,8[L,0WD
M(B.^R%95/E"39K/".6#+RW#=3VITFDAT+HF\SI5()N4^DBPOJFV>+5F65W4I
M5W893HU66U9U.M4^3[8%E)X86U'RUP+6$NEKA$@J<X.]@L:0<]@(-8D.< 1X
MSR#!.61!'896N-NO?L9/<UG^3C'C21CGV5[LX8OV+A%VR>-UK"[517:NFYU$
M'"*J1@42514.0Z8@<HB40'71NRM-]+9S J55CZ51F%V+7TZC2Q['"@ 6N8X!
MS7 Y$$ @Y$*,7L/KW):=YIKO<"W,%LF"")$'@=%2V W"+;.6&7+E5)LW0RMC
MM9===0B2**25PACJ*JJJ"4B:9"%$YSG$I2E 3&$  1UZ=H&N?@>,,8"Y[L+Q
M !K07.)-G6  :))))   DD@!>>T&[=4>0J,,G2 YI)G3+.5M([^K[1GVT_/E
M5972IO+.E43HJ5QK8X=Q/)K-9J'4<HGATGAY BK8B:AUTS-P.B1,YE *!3"'
M+FP&'8A3VHV>NGV-XRVZ\GPA]K7;0AUL0T]<6"GXQR;XV9R&:F6*5:1L;A@J
M4RZ&^*'MWM3PF?4M14QOW3CXD0[_ (&Z7^+77!$@F2(WLN&IX*%<!_2]YRF.
M\'6W5.HY/S,YM=GKU8;N\?UU%JXL,U&PJ+E8E@$YTFZLDY;)K*%)](R:9C&*
M7Z0@ =]:@Z7;2[N\*P=EI:W%RYE_7+FV]&K6<UO@_E.%-KB!)B3E*SF"/8RX
MJN<YK1U31+G "9&4D@3V:JM/&FGX*8L> F\1-1,HX8P5\5>H1LBS>K,TI%Q1
M74>HZ2:K*G;IOVP^T,SK%(5T@/G(BHF/5K'=#-O7I4MH7U:%:DRH[#6TWU*3
MV,>ZD,3;4#'.: XTW0'AI)8Z Z"OICCF.=:@.:2:;R ""3(R($\>'/@H/>1Z
MBAP/<Q>__E!VUNV!NS.?+S\M=,U'^!_FN]TK;$\."^4:N[)\.GL%SJD$1LM<
M(MP>9L41&%0DSW2SOR1RQGKQ $GQV*J;PK0XE<&:*$< F*)RG'E?I#L+ZYVY
MQH6]E=UR^G8U&BC;UJI=3;:4:;JC=QCI8VIXA>):'^*3.2F^&U*;<-LPZHQI
M#' @N:""7N(!!.1(SC6%K9[I'K.2W*9_DHUVVD(]_F7)SQB^9+I.F;QJXN\Z
MLW<M72!U$'#=PB=-9%9$YTU4E"*$,8ABB/1FS#'T]G, I56NIU*>$X<RHQ[2
MQ]-[;.@US7M< YKFD$$. ((((D*(79!N[@C,;^1!D$1J",CKP5/X(<H-<V8?
M=NED6K5IE'';ATY<*$10;-T+C%++KN%E!*FBBBB4RJJJABD32*8YS 4HCKUX
MVUS\%Q9C Y[WX=?-8UH+G/<ZSJ@-:!)<22   220!FJVI#;BB20 *F9)  R&
MI.BVB=^&0*'9-FN? KMVJ,]T5J'9J?(MDAI3RW3JQQ2K9L?V%ZOTN'";=PH@
MB;A18B"QTRF*D<2\O;#X?B%KMM@!N+&\H37JO_'VU>E+&6]P'N'6,;XK2Y@<
M[1I<T&"X*78A4IU,/O"RHQX-( %KFN!/C& 03F<LM<UJ/CZC[M=9 &1D2)&<
M91.J@\CF/2%,OX,4Y"P^8,JMI:8BXMQ,4""9Q"$C(-&2TJ[+8!5,UCDG*R1W
MS@J8"H9!L554" )Q+T@(ZU!TRT*];!\)=1HU:K:.)5GU74Z;WBDSJ'C?J%H(
M8V2!O.@28F5GL"<T5[T%S0=RF,R-2UL#O*^SQE;=4[9=\)*5:SUZRD85RZ(/
MCU^:C9DC)928A_+1=FCG+D&RI_*4Z$UA(<WEGX >@W%O0Y:75I98[X7;7%J:
MEW9NI"XHU*'6-\'?+F"JUN^ 8!+9 D3P5FT)#JMONN#HH@$-(.Z1,S$P<]"H
M7N>"CVY^DF/YA$=;E@$S.@([NT'@5@ " )$>.-5N&;++]18[:_MWK$A=*DPL
MJ^.*RFC7GECAVLXJH[2,9HFE$KO"/SG<@H06Y"-Q,L!R"F!@,'/(NV=A?5=I
MMH;FE97=2W;B%P77%.WK/HM#8WBZJUAI@-_2)<(XPI_95*;;2V:ZHQKC3; <
M]H<9D@ $@GLR465JLU<<6VW$0GX18S2?GU70)2S!06R2<JX*HJN!'!O)23,8
M"G44Z2%$0 Q@$>-;6L;>X%G:$T*PW[>W#9IO >32:0&RT22)@ DD9PL=4J,W
MG#?;DYY\H3&]J>'K*K#!UOJ;/*N.Y9W:*XUBF]OBB.)-Q-QB,>@8%/,$JSU1
MT5LD8$P$XE.J4>@!-QT]]>3';6ZJ81B5*G;7#ZKK.MN4FT:KJCA$2VF&;QSR
MR!SRUR5:52F*C"7L #HDN:!,'(YQ/G4D>[S(5 6PA)-TKS3U%YES6GT0BG9H
M4ZLJR&?;)@\C4RO1.^:]:*Q <-051$R2A>ODA@#5^QV&X@,;MW.L;QK:)NV5
MG.M:X;1>:%7Q:I+ *;H<T[KRT^,W+,+)W-6GU;OQE,RUT#?;G(X9]Y'<HCOE
M^!,\4C@FX@7Z)EP68A),Q>)>3YBBWFMO/\Y/RDRF44ZR%Z"%,8_!0$0W+U%8
M-ZSJ:H8X-W7FF_<,D@0Z(,D@"#F2 -5B=]A:P;[9SD;PD3GF)R\\*0#8M>:1
M&LLIR<A<:JQC61JD5Y(O;##MF+0[D9Y)N5R[6>$;H&74'RT2JJ%%50>@@&,/
M&M<[>6-]5JX13I6=W5J/-V6LIVU9SW!K*6]NL:TN(;D3EEJ<H7NLZE)O6$U&
M  "2YS1$DZYY3''6%0.]N\TI_D&H2C&X55Y&O*6F1I(M;#$+L'1VU@G$W!&S
MQ)X9NN9!0Q4UBI*',D<Q2G IA ->[8.POJ6'7M*K9W=.HV]?OTWVU9M1@=1H
MEI<QS X!PS$C,9C+-4OJM.6'K&01D=YO,]O:L/@GH,'J,>,S% _6,B"++Y19
M^UJBN4IT03;>=YR@K$.0Z0%((J%.4Q.0, C.#1K%CG]35W0'2[JW[HB09,0(
M((,Z$$'1>'?9^NW^L/O4TN"LE8Y/A^FMR7^DG7@Z3&NII MJ@C+0[9!!LV6<
M2B8/Q/'H(N54FZJSLJ*::ZJ:1S H<I1T3C^&8E\M8BXX??!MQ?O%!W@E>*[C
M3W@VB>KBH2&D@,WB0"1H5G:52F:1(J,(#()#VD"2!F9RUXJ&RQ6FKJ2\Z_3L
MD HQ4L,PDD]+,QHM%51=K+ FFY!SY)U!1,54"$.)A3,!^.D0'6[;6VNFT:+#
M;UVU.HHDL=1J[P&X 26[N\/&RD@"01J%AGO82\A[(WAGO"#D=(F5<C UJK#'
M,N,CO;' ,R.+&P6;G=3,<W*NDL5=-%1$5G)/-354#RTCI]15#_0*(F#C7@V@
MMKFI@N)"G;UWD6]4$,I5'$%H!<#NM,$#,@Y@9Z*M"HP56R]@_I#[UE#XHU]H
MLGM*R36(VZ5.0LK>QTA)Q7F-CAW<X@JSND3[8FM$MWBC])1J*9_:2';E,@)#
M>:!.D>(7T8V%_2VJPFZJ65W3MC:WI%P^VK,H$/L:H816<P4R'$@-(=XQ( F5
M]L7J4_ ;AN^S>WZ0C>;,[],Q$S.[)[IX+5@]?374TC=B1.[$<9C2.:A3@>L.
M1\L\#^LIT/!HNU,J+//A;9;:Q6#/7N-O8BV&>BH4SOR6UO*M[*$D[;"X\H5D
M@4\H#] JI@;@3EYT?TR6-[>/V>-I9W5T*?REUAM[>K7%,.%J&[_5,=N[Q:X#
M>B2"!H5)< J4V"X#ZC&$M9 >YK28.<21,<>2LMXQ4M%R>Y"H?)DDPDC,L40R
M#LK!XW=BU57L-D>MTG(-U%!0469.6[M(BO291JN@N0!25(<V5Z&:-:CLS>BM
M2JTB[&;LM%5CV%S0VDR6[X$M#FELB0"TMU!"^.T):^XMX<'#JC):08/BG,B5
M$VGWX#WB9,>/?P!P$>WU!Z_#WZVTXB-1QX_\)4?@@/$'41EK!6XAM%R)C^&V
MC[?%9B]4Z)20QI481=62LT(Q30F64 P4>Q*IW3Y(J<HS3524<L#B#MN11,ZJ
M)"G*(\@;6X;B-;:S'VT;"]JN=B-Q7:*5K7>747W-3<K-#:9)I/+2&U!+'00"
M8*G]I6I"THDU:?BTV@R]HAP:"6G/(YB0<\PHHK'9*Z6QRB8S\*!WTJ^78E&5
M8@9X@Z?KBV6:E\_EPDX 0%!1$#D6 0\LQN=;@M+>X\%H_B*WB4F!_P"*?XA:
MT;P=XOBEL&08(C-8ZH]F^[QFZ\QR&>O'57/V_6>LM\TT$7%B@40CK$HY?BK+
MQZ8,6S)@\.]</!.X &J+0I#F=*K=";<I#&5,0"B(8C:*UN3@=Z&V]<[]#=9%
M*H2]SWL#6MAOC%Y,- DND 2<E=;5*?7N\=D"D)ES<H+IXZ#U#59^[M<B8_FL
M&3KV'O5.EF36P5ELZ=QEFA'[9NY</RJMVZZ[5\JDDNNDW74124.511-%8Y"F
M*F<0UML=AV(V^T=HVO87M$FQO"&UK6O3)@,!(#Z8)C>$D Q(YA9&YJTC0<14
MID& "'M()Y9%1.*62N(D145GX1)-V0YVJBLM'I$<D34\LYVYU'!2+%(H44S"
MF8P%. E$0$!#6Y30N':4*Q+'#> I/):8D!PW9$@@@&"00>*Q.\PYA[8/'>:!
MVP9C52-[$KA4&)LAPCRUUMI-O'E>!I#.9R+0E'7D,YI=?V:/5=%=K^0B)55?
M*1-Y:0@H?@@@.M;[>6=V_P"3J[+6X?1:RZ-2LRA5=287OH!H=4#2ULD$-WB"
M2"!F%[[*I2:ZHTU*>\=R 7M!,;\P"9,3GEEQA1-^+O8ZY:]RU8?UBP0ECCTL
M3UYFL_@95A,,T7:5CMRJK51S'KN$$W*:2Z*BB!C@J0BR1S% JA!-M+HFMZ]K
MLU<,N:%:W>_$[FHUE>D^B]S'6]F&O:VHUI+7;I#7 $&#$P0L#C3V/O 6/:\"
MBP$L<' .#JD@D$B1.FHE13]R  <"(A^3XC]>MF@ DR>$S/=E)Y:>98A;DVU6
M^T6)V\;>J[*W2IQM@<8DQVDA!2%BAV<PNH\K[$C1-&,<O$WJIW9SD(V(1 QE
MS'*5(#B8 'CW:G#K^KM'M!<T;*\K6[,5Q$ON:=M6?1;N7;R\NJM8ZF-QH)=+
MO%#23 "G-K6HLL[5CJU-KW40&L=4:'.\42&M)!,'* %$5)V&O'F)E!*=AE%F
MCV65=IDDV)E6Z:#U0%U7!"KB9%-$W(*G5 I4Q['$!UN>A;UQ;T"ZA5 =3IAI
M=2?#B6B "6P9R@#7*%X*U5O75 *C8RR#QRSX]RNMMUN-/9YAH4P]M5;:Q#2;
M72=2CJ<BT(YJJK#R8))N'JKHC9%10>03(HJ4QQ[% =8C:6RNJF#7U*G:W#ZS
MZ(+*3*%1U1X%6G):QK2YP'$@&)7TMJK!5:756@:9O &8/,]BN5XO]TIM@VW4
M1G!VRLS;QWE"O2[5K$SL5).7,0$!<V1I1N@S=+*K1WM::C07J93-O:4SH"KY
MI3$#"]$%E>4-H;M]Q:7-%E/#*]%[JUO5IM96ZZT?U3W/8T-J;A#]PD.W2'1!
ME5QFJSP7=;4;O%S2 'C>(SS !DB0<QQ!Y+6OX#I(' =B)AQQZ"!"@(<?$!Y
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M,H/PUU+K'O>&NK'$'5-P%Q#"]S=YQ &\XN)DF5]<?#:=6T+&- ZM[,@! @@
MZ$Q)YY0 H1AY[<#P/440_"!@$/TZW:V <],YUX@C@HZZ8,<I\PS/JX<=,UM7
M>'7B_'=KV48@"RX_I=D*]=6V:=A/5>"EP<2Z=QLL8637^4&2_FR*<:@A&IO3
M]3DD>W19E5!NF0@<K=(N)8K:[<XQX%?W5MU5*QI-ZFXK4R*3[6G5?2!IU:9%
M,U0VH6 [KGRX@O,J;X72I'#Z+GL#]]I(D#."0#GH1) )@@1E !6N+N?CV$1N
M0SW$13%C&1<9F/)3&.CHUJW9,6+-I<9AN@T:M6J""#=NW(D""""1 2133*1(
M 3 H:Z.V:J5*VSF UJSWU*M7",/?4J5'.?4>]UI1<Y[WN<XN<XN+BXF222<R
MHC>!HNJX;H'Z1 :(R '*,_N7A8*:-9#->(&#]LW=Q[S)U!:OF;M%)RU?-7-K
MBVZK1RW6(HDN@X(<R*R*Q#I*IG,10!(8P:].-/>S!,6>QSF/9AU\ZG482U['
MMM:K@YKFD.:YI +2""'01F,EM\YM_$%1IJ /:8T!!,S B,X$DP1Q6SYOHQ;C
M2I;-L^*U?'M'K:QJU%/C'@:I!Q!COV<_'H1[LQF#! 3.6A'[Q-HX,(K-B.W)
M4U$R+J@?F/83$\3NMLMGVWV(WEVX5JS#UUQ6JM#:EO6+FCK'NAKRP;S1 =N
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MJ$4 CE!%0H& #$#6]-GMN-E++ ,&M;O&K.A<4,.M+:M2>Y^]3JTJ&X\.W6&
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MNU05ZE5!20PZHL?I#OTIIF,/N#7FQG'<)N<+O[>CB%I4JUK:I3IL;6;+G.$
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M YY$1 H>HCR(\>G/U^OUZO:UK00T  DDQI)U,9Q/+15.9G,"(B<N_AGYD\D
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M+<N3 #Z9R5(';Z3]ZZ@@4../0!Y  Y^/(^_W^_1M)C&AK6M #B^&M#1O3.]
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MCM260,F<6%_3KK>'=K6Q*DJ9#;(/E:_'Q\>U 0-<]/:/LE4L_P##.=R%/I<
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:31$T1-$31$T1-$31$T1-$31$T1-$31%__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>47
<FILENAME>g425213g57a59.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g425213g57a59.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1^ 4&AO=&]S:&]P(#,N,  X0DE-! 0
M    'V2^@#8X0DE-! 0      %L< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<<
M @   @  ' )0 !M3=6)R86UA;FEA;B!-87)U=&AU<&%N9&EY86X< @4 %U!O
M=V5R4&]I;G0@4')E<V5N=&%T:6]N #A"24T$)0      $/<I3IWHI1\D^)_=
MJP0,*9<X0DE-!#H      .4    0     0      "W!R:6YT3W5T<'5T
M!0    !0<W138F]O; $     26YT965N=6T     26YT90    !#;')M
M#W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $
M      ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4
M= !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL
M=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !
M   2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB
M<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
M     $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN
M=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P    !29" @
M9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@(&1O=6)
M;^            !"<F1456YT1B-2;'0               !";&0@56YT1B-2
M;'0               !2<VQT56YT1B-0>&Q <V1RL         IV96-T;W)$
M871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15
M;G1&(U)L=                %1O<"!5;G1&(U)L=                %-C
M;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L
M  YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M        #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO
M;F<      #A"24T#[0      $ .__C4  @ ! [_^-0 "  $X0DE-!"8
M  X             /X   #A"24T$#0      !    '@X0DE-!!D       0
M   >.$))30/S       )           ! #A"24TG$       "@ !
M  $X0DE- _0      !( -0    $ +0    8       $X0DE- _<      !P
M /____________________________\#Z   .$))300(       0     0
M D    )      #A"24T$'@      !      X0DE-!!H      S4    &
M          (L   "?          !                          $
M         GP   (L                      $
M    $     $       !N=6QL     @    9B;W5N9'-/8FIC     0
M %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M0G1O;6QO;F<   (L     %)G:'1L;VYG   "?     9S;&EC97-6;$QS
M 4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M  =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG
M:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   "+
M  !29VAT;&]N9P   GP    #=7)L5$585     $       !N=6QL5$585
M  $       !-<V=E5$585     $       9A;'1486=415A4     0
M#F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0
M"6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0
M   )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L
M=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4
M3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
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M_*>>_$Q?3HH].OUEJ_63KW4>
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M$OO:A6=:(6J%;M8G!ZK6Z@+DY7&G1N%A7<Z6>B>X<1SH!7&1%TD=B<@'MG1
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MO.5]0 G]J#HI]]*B.3;S_AG]/^?^7]?1_P N1?[O_4N[>_9>O['_ ,U1+/\
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MSM5_;D:V%T0W5D9Z*-J]AJM7NTQC"-DL 7!F8;J+2)V/^):[ MW1'>?G)^H
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)........?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>48
<FILENAME>g425213g57a60.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g425213g57a60.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1VT4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '9B^=78X0DE-! 0      %L< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<<
M @   @  ' )0 !M3=6)R86UA;FEA;B!-87)U=&AU<&%N9&EY86X< @4 %U!O
M=V5R4&]I;G0@4')E<V5N=&%T:6]N #A"24T$)0      $/<I3IWHI1\D^)_=
MJP0,*9<X0DE-!#H      .4    0     0      "W!R:6YT3W5T<'5T
M!0    !0<W138F]O; $     26YT965N=6T     26YT90    !#;')M
M#W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $
M      ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4
M= !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL
M=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !
M   2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB
M<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
M     $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN
M=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P    !29" @
M9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@(&1O=6)
M;^            !"<F1456YT1B-2;'0               !";&0@56YT1B-2
M;'0               !2<VQT56YT1B-0>&Q <V1RL         IV96-T;W)$
M871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15
M;G1&(U)L=                %1O<"!5;G1&(U)L=                %-C
M;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L
M  YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M        #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO
M;F<      #A"24T#[0      $ .__C4  @ ! [_^-0 "  $X0DE-!"8
M  X             /X   #A"24T$#0      !    '@X0DE-!!D       0
M   >.$))30/S       )           ! #A"24TG$       "@ !
M  $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M      $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE-
M _@      '   /____________________________\#Z     #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z   .$))300(       0
M 0   D    )      #A"24T$'@      !      X0DE-!!H      S4    &
M              )3   $(P         !                          $
M            !",   )3                      $
M        $     $       !N=6QL     @    9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   )3     %)G:'1L;VYG   $(P    9S;&EC97-6;$QS
M     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M      =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/
M<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54
M>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   "
M4P    !29VAT;&]N9P  !",    #=7)L5$585     $       !N=6QL5$58
M5     $       !-<V=E5$585     $       9A;'1486=415A4     0
M    #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0
M    "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U
M;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F
M875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4
M    3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N
M9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L
M;VYG       X0DE-!"@       P    "/_         X0DE-!!$       $!
M #A"24T$%       !     0X0DE-! P     $PX    !    H    %H   '@
M  "HP   $O( &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_
MVP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,
M# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4
M$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_
M !$( %H H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0         #
M  $"! 4&!P@)"@L!  $% 0$! 0$!          $  @,$!08'" D*"Q   00!
M P($ @4'!@@% PPS 0 "$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R
M@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%
MM)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0 " @$"! 0#
M! 4&!P<&!34!  (1 R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3
M%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D
M]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$  A$#$0 _ .R?
MT7ZTMOR;,7K(I9=9:]E;ZO6VAYL?C_TAUGI>EOJH]*CTZ/3Q_5]/UK;E+(Z1
M];+:Z0SK;:[:GWO=8W': [?+<1AJW;7,QJGN_G-_Z3]-9ZUE5:D[K'5;NOYG
M1*&55NJQ3?3:]KR!N'IT6.?]"[]/_.4>FSV?]J+4#IV']?F7UG/ZAB.J#"'_
M */>-^QC6/\ 3KJPGO\ THW>W)H_PW^#MHHPTIG7TKZYNAUO7*V&7$L;BUO
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MZMGI^EZ?I>HND224X6%TKZSU9E5^5UEN10'S?1Z#&AS +ME=9;_-?SE#WO\
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M=&X%O_:FQGY[?S/1=P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M0E=YEM4*,C-A<7:!)"<T-7)WH;&S-U)B8W2"D9.V_\0 ' $!  (# 0$!
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M/0(Z-7N6+UXRV<)*;M'3AOLFMN!)_ ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
M' ' (U)TQ3QN?C+7,U/6I>T@C=!H&LHG!(N_GXAJUPYU;-ADR="E9$P;ML/'
M>$$6A%)-'#ISA/77"ZOM 8Q[U^H8DRG TC251$!UFEFQZR6#VMH:Z96$=9NL
MOFAJ<-5PJB$L+-7N<O&Q$\F_>(.LY<)+:JY]O@&R":OK0#*EYV#KN"A9NZCS
M&(N9D)B0 =*G$3%_#?+(PO(68]$NK'AWP;3X$*H\V&M/A6WP[9/W"7L@:?MU
MMZZ[HS)MO0=+;M[&SG-A(;59!MD9WG);8]G,R2R"SI*,Y.;;&L_.]7WJ6VV(
M_P#3,Y6R!K</ZD]<X);DTO:-5+#F5J3E&*-"4M6$-'K\,.AD#%UF#$0G#Q)=
M*!AM82%%@R B(:!AQ9!FCN2;.E=?;X!M#/KGU['ATXZPHFFF,?20DS5($SK"
M$-@Z;::J#%IDW3&(@]&6B$M5"AE9,CJAA,\H)&;E=7>S!KE(#U[4%1.Y>82#
M>E:EW/6&.+!Y^;VKB';%YP(/[BU#HN8$LALO),.-*! NY9B:6>MB.X@7L\26
MV8-,I 9$=3-/B,"L":IK87@"VBK,'@=!8NRP&9P7<VI"&HKX86E\N;0[>323
M>*H,_<I1[>0&]A&C/)9_EP![(]557Q%O&&D3K>!1AK"=9%I#&T>A\>"MXCI,
M'>Q"6Z1A$:.;)@-90_WW>R+45JTP;=[;.2>'2VV=\@:HOUOZ[N8XYA[FA:7<
M1)Y+%)X[BR]6P=6..IRLGLBM,W(10%L,7EBJ.VR2DB5:[&-T]MM-GF=<YQP#
M]T.O- MB!(LVHVGFY4S&OHPP30K.%I$"L/R(&Q_,4)/$PFKE]&L@ P<)\B=*
M*B_E H:-^%^"8M44@/U7Z_T,Y%1L$YI*HW .&ARL=AX9>MH:J*BD?.[(;FP<
M;'*!=F8(.9W:MMRHP6BU9$=FR&SM!;**>=0,EK3-/Z&)'(=:HK74_,#49DDM
M.:P6+X,2F10LFU-0X](R>!>'ILU$S#)D6C)0FNZ? 2;1J_%KM73=)70#X)TM
M3AH1& !FIJT+ 80;Q)88$)P2+/Q$1D>KEP]UD$8&NA2K, ;P\=NG>"HI%H_P
MY<N%\+^]64WV ]Y&K*Q, )7%"]<P,I%IX5<G9Q&B,0C[X!,S;W=DH\,2L,Y'
M*CI$5=J#!JCD@7;/':^X]ENJMOLT0RF!B!U&4F''.PXBG:L%"2#V-$WXL=7T
M28CGI*%E]I##B#MDV$)-G+V)G]MCD:=K);K@B^VQ(6HU>YROD#S/>O\ 0Q(.
MI'B-)5$_ +-HPS6!O:VAKH.JTA+LJ_AC508N%49;MHB^/''D80V0RD!=F2K@
M5JT6(O-U@(_LGIOUMM6O6U2R6K@@VK\2^#S0U7T$4>UK$9J1KAF('PT180.
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M/5O* U/W7\HF\F>-I*[9DZ/DZ%4ULG,^O]?,;<GCB&V_(6^H)S,.SE2A'\.
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ML +^< < YU>-W\C>V?\ :*]Y_P!O4EY"=7>/P0E>C?#XJ=%>20. . . . .
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M5FVZO+6B2K//Z2]8V/B=7:QKVQRS*CTFGB?RCA>[=K7)T:B\2[%;=R+Z=BC
ME"W:].G6O'+7?2;''(V"Q9<DJ6;E>39(*TK]XXY$79&I]-R(;OS=+(< < <
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M1$39$3V(B=#L6,9&QL<;&QQL:C6,8U&L8U$V1K6M1$:U$Y(B(B(G0_;DGT.
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M %W5G_>$K^SZ?<KKWY_%?O%?X=D"KR/Z3A?WH[^%90D+EB6@X X X X X X
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M4<JWXF+(R-K7<$F,QL[V[HB*C7S.=*Y$Y.D<KU17*JFY2Z=PF #?G$YET;B
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MDY/4:=?_ %#E5Z^WBLKO[?8/PQY]?RM+=EKO<O97H-/_ (8)OV;#^"O&]?\
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MK3K4B3]]QR*^G<I*QG=HK6HC+BR(YVZJZ-&[(CE<DA\L"U' ' ' ' ' ' '
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MEDBCT\HT.,#)EVI+4O9>V'C=! 3[3H":;]\S77VKF%RAH#%;)G]FTZ(N<XX
M%H#-(? IACJX,#ROM!%8E;+D"^AQ::5)$W9)J1&,73MKO-6S,#N[U:.%2: '
M7".'Q4KCP&4@G.'H22AA9\.\UUVUU=BC+% B/<ZZ[8QMKA=HY15QKMC&V,;^
MF<8SC@&9X X X X X X X X X X X X X X X X X X X X X X X X X X
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MW6KMN,'@196QCR:36K2\Z>D;#%*E; .#(=$#<(Z\0NY$:F&E;ETBDJ+1Z9@
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M3@^1LAHOL%8&LSWK9H)@PX0,R5ZWZ0MC7CB]6TJTVMC70I(-5H.F[?2$"/\
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MPJ@[A(-C2D7=P**Z,<I-G4&/R&R2J^JK5-*0)NPCXS- .IW ' ' ' ' ' '
M' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
#/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>49
<FILENAME>g425213g58b60.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g425213g58b60.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2(44&AO=&]S:&]P(#,N,  X0DE-! 0
M    (?B^AI8X0DE-! 0      $4< @   @  ' )0  AR<C,W-S Q,QP"!0 L
M36EC<F]S;V9T(%!O=V5R4&]I;G0@+2!-;V1E<FYA($=R87!H:6-S+G!P='@
M.$))300E       0"%C5*%567ZGO..J";B6BD3A"24T$.@      Y0   !
M   !       +<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E
M96YU;0    !);G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;
M   +<')I;G1E<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B
M:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7
M   !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L
M.$))300[      (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,
M   7     $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP
M $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B
M;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC
M 0       %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O
M=6) ;^            !";" @9&]U8D!OX            $)R9%15;G1&(U)L
M=                $)L9"!5;G1&(U)L=                %)S;'15;G1&
M(U!X;$!RP           "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0
M  !09U!S     %!G4$,     3&5F=%5N=$8C4FQT                5&]P
M(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D            0
M8W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P
M       ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO
M;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^
M-0 "  $#O_XU  (  3A"24T$)@      #@             _@   .$))300-
M       $     #A"24T$&0      !    !XX0DE- _,       D
M  $ .$))32<0       *  $          3A"24T#]0      2  O9F8  0!L
M9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:    !@
M 0 U     0 M    !@       3A"24T#^       <   ________________
M_____________P/H     /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H   X0DE-! @      !     !   "0    D      .$))300>
M   $     #A"24T$&@     #0P    8              Y<   ,'    !P!3
M %0 7P U #@ -@ P     0                         !
M  ,'   #EP                     !                         !
M   !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL
M;VYG   #EP    !29VAT;&]N9P   P<    &<VQI8V5S5FQ,<P    %/8FIC
M     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O
M=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M#6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !)
M;6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   Y<     4F=H
M=&QO;F<   ,'     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M    37-G951%6%0    !       &86QT5&%G5$585     $       YC96QL
M5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z
M06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E
M<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +
M8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4
M   )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M#&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M.$))300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
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MVT4U90&4RFBQSW,8SU,+(IH=]LOLJKR+;6[\;_!J_P!6
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( 28 ^ ,!$0 "$0$#$0'_Q  >  $
M @,!  ,!            " D&!PH% 0,$ O_$ $P0   & @$# @($"@4'# ,
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M^0<^#L$G@**D3#Q+@:UKO.B; & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@%<A>J/Q<-NA_I7XE;$Y*"V0.HK5<%ZR^1H=5V(N!ABJU-6-0H-$'4R(
M$(P5(*C<5%4TUE4CF[ &NLS33O42XT;PV@RU72;),#+V/Z2CKZ:EJ]*Q=9V4
M%,='8VP:9,NVR;:1&$>)G16*H9 [GP,HS*N0HC@:]]=AXG(#J3\=>..UI'3E
MX-=7]QK]5C[];4ZS5)";85*@OE?14N$Z]:E%)M$,%!#WHE$[A(G=4$3)E,8
MS^V?XR]3R=H]4/B_JFSP,-,R%LDZW+)4E=_LF'K+]:@0#?8B+9S3W#Z><$;I
M/4I=J\;.0-$$?@V25*+KTC 8I0(T[KZTFIJG:Z;4]+Z\O>WU'W)S77'FZS[.
M ?L*U#/;@HL:2+#2BY")2\_'LQ9NVK @>W73<&\UBF()< VF?J@:NUW6[G);
M#5L%WDH/9VY88K77%/DG25<I6J91LSG'MF?N"MXIJ[KI')22*0OA>/# 8[)L
ML4@C@F?5ZZ^#:_'OF<VY#<CK/2J.O$S6G#Z*HNW*/:&J2Z,A*!;7B*0D=)K@
M0Z1$T%0_%&3*=-4!*;[L%SUU<O@L$P!@# & , 8 P!@# .;2Z]3SE%!*\M=D
M1NRN+$?7N.O)>]:=K7'ZV2R3#:NP(&G34-$MS,&[9VK.FEK $BN,2+>..BNN
MB4.X) <X-:[QV9KE[:]RQESU3N/M<LVO:AL"+OE+D[D_U]5)B9E:K)-JI4=C
M['9-'$!19&6=I-U'DBLZ>),3.HUL[8(+F CAPD8# 4#0VV^L]JZ"NE0I.G-:
M[!V:H\Y"P^B+S9?HZ^C:S79)9U(-9Q&*DU2@C-S4>9H15%JW$S95(3B*W<.P
M$S]?1;#7F;1)U1M2:_U57KGL5:Q721DVMNL<JYUW3Y)Q%5ZF562.VDYR;>N2
MMXYH$4CXB[:$=J2"PIJF;M5 ((X&M?G^MQ\3.7JG)O<?).!@5(>3U7KQ/2TS
MJNSQA%DW%EK6TM:L+M\0>E7 IRCZSSQ0(9-,Y$NQ3E\@'M.OO^$UF">^4# &
M , 8 P!@# & , J.L?3=LUGU;N/6TE=ZH"&V.7M9Y"NW;>,DT#IU"&N$;8'M
M9<K$,"YY]=@R.S:OTS>T15,03?BP, @E_3WXZ]C%-(=/'D-4=D<=HC9^TM82
MO'SB),W2=TXUI<'/QNT+8\LDB]=1"6QWC_O (M81L_5;JI5\B99$Z::KCN83
M#@=?7?7GD:FY$\?N8NU^?/)2,T0MKFH:VVMQBK&J;_;]L5:U/VBD/845XZ<<
MZ\DX("M'%GCHUTNDG'R9SQY7!R+.4A*GD6ZKEPSOV\.Y>O-"<O'V7N[OSQ-3
M;EZ+/(&SGF:11-W426UB2K:<K>OI#9[W8KFQZWC]3UJ&@S1$-4X!TE17C:Q.
MHM:1>2CQF,F@+Y5)$X 4@ M_7LOAK@A;K[Z_';WDG5NFGNV X]U>BTK8^KS[
M3HO,?7_*VO2,]#6(M(D34UNR:.:U.(,#%FA4>HD>'2=MC@!%!; <?$I^[\>E
MM>H(^[$Z0?)Z;D+JX@MT:RG8'8-PY'V20HEH=;+@:A7'.])1D_86!HQJ3MN-
MFG:XDBZ0,WL0+1R@K)BD4"E,&/MKM]1X>/QX_!-[@'P#V%Q'LS*>NFPJG<B,
M]$5'4()UV+E(]55[6))-V,P?WPBF5NZ03 OH$^V14>_]7*"U7 & , 8 P!@#
M & , K(XS]-/3VK+EOS96W];:1VOLO:?)_9^\ZI?WVN8B1MM7K5R?Q[VN5I>
M>GF#F2]_7C-%A*JQ739IJ*^34"B)AP/8@_R&Z2W)?=.[K9<C;EUQ*5&;Y#ZL
MW;!3=R=[(>V^JP6NI]C.!KZ&JK-W] V#-<6?MT91HT(Z43,)G)A/\\ D%-].
MW>,;Q_HM&H6P]6_6C0>7(<EH^1LL-8OH1)L5I:6>.ZY)MXXQ9KWAFDH9-)XB
M<$P72*)OL"..[+7(>'M]R+E\Z0'*"7JT76(?=.KY^(<:XV12Y2KVASLR%I];
MGM@"[.I<("&JSQ!*PO&AGB@ UM)'"2?@GZ'B FR:7NU[J"??3DX*WWA>GL9.
M[WRK77Z7U3158BS5N-DX\69=1ZSCJ(]<OOB)A!099TR,^;%1[>B@<"*_C $<
MHUK[EGN , 8 P!@# & , BCSIVC;=)\/.1VVZ&[387+7>I[7:ZV[61!PFA*Q
M# SEL<R _)8?(OB5,1#S,(!W#OWQK7$$)J/U;]=U_6]GL7(K7.RM12-%T?1]
MQD^D,,0S[8E<LB$9'F>UZ-;F Z$JI./4R*0RQS*H-W!'!E!3*; 36E]S\X]8
MW6*D(9BQT_LJ5VZ;9-9UFRU/'((.9.3D[K$#-5F5CI@A!CW<,=H=%.:=$ !A
M7!E4G!3BEW,!F,AU3ZP;5I[=7=)[#E;]!7^X:PV-KJ25C*_]65TH,<UE[-&6
MNQ2"I6:1?ASUHXAE&K=Q\6!P0J14Q <#VM>]]:\;1VJ76786_<E<LI*,_@N)
M <6;5N.Z6^2;"-J@[C7;5'P+N+2: 8@/6S1VY)"(HI%*9^]?(.$SE(42B%L_
M3K-WU[K&: ?T;8%DL51OU;M--CZ1+0]!&-+)35V8[1GT*OKE*ON&O]%4E)Z?
M=-XMY&G'W$2Y,H"X*$3$PAK6NON,)NO4VW'![KXX4>3XWVS5=8N%AV&SW6.Q
M4DVSR!@J;7&L^G/U261-[.7B2)./!VLFB!U77=FGXG3,8P<??B96?K%ZABZB
M^OMNU'MZH5&;H$EL[3DM,P142[>JD5)M(M=*#3\A-'V-VH[3=Q4$\\G#]B(+
MD4*'<,#/AP7M^>!C+?K(PR4I9(>P<6-ZUQY1H"K;)O*LC'-0CZUINX%0^$7Q
MR\*'@JY(HY23?UY,OO&@ H<53 4>P$C:-U*=2["C-=?1^MV=6W[ WN710411
M(A;# R24<A.R-EE&_AY$@8NNOHN8>. (!2(R"!/4\NXX)G^?+MSOF6.8*, 8
M P!@$7.:^S[1I?BGO/:M+<%:VFBT60L$,N+<'0D=LUFP]DVP_P#:%3I&4311
M[@*BIBE 0$>^ 07USU;=?PFN9N9Y'Z]V-J*9J&CJ;NHBE@AR&6O]3LTC&U=M
M)0;- X&:R3NUR32-&)7.91%1T0XJ"0HY.2<_2_AZV!^=UUDM7D@8MG':>V9-
M[?F-EU[5[#4D2V0=2BTS<4/=U61+,$(+ T,^0,"3YX  $:]2<-5RB9$3#0>]
M.=6:IM==*66 T?L65O%=LE\J>RZ)*+Q==)K><UKX?2EE.3\@I[==98%4SU\C
M)JJ,P0PF3],"C@&HH;K MIG>U;G/H8[CN'\CPCF^2T[;WK,2W.&L<)>#5M>/
M(P]0/?)*K)FKK.-2*1=W+'(Y(J5(?3P-=>M=YLR%ZR^AG]5LCR2H^P8S8+-3
M6Z5*UHG'$D)G8BVXWRT?K-A7GK?^A_%9ER@H258*B*L)Z:AG/F4N 8K:.I_M
M*!Y Z.I5GX^VK4^N9>M[;GMWK7]N5M-UI'7#5%T66K+M(WM)V!<)G,F@N@B1
M1^Z5312%,2#Y/#5^/R3Q3L[M9<>I4YH9^TZN^JF=4L5OO6H]MT&-'4J^\]8)
MST&4CC:^MDETT2.*\4@_T>RK$.#TE;<=W?L3%<BH!1'M-:YW[+%\N-N/R:X6
MZT-?B5+8WM7%K>5:7UW2:ON'8IWS%F9C5-(W0B?T;OSAX4 *X6>K*&14@4B>
M[0%%8QE! @@%!*6A=1[5FPY/6]:@ZM:PN6P=[6?1!ZNN@0LA69BI5H;7+66<
M+X>3>LA%':"WD?#T5W+Q!N0XG,(@&>O[X_WP+$\ 8!BUOO-+U]$_'KW;*Y38
M3UTFOQ>T34=!1ON5Q$$6_O9-PV;^LJ("":?J>9Q#[(#@'Y938^OH/Z.?&;Q4
MHKZ7K)-ZI\1L,2S^DBZY 412@O<.T_BJBJ9@.F1EZXG*("4! < S/ & :.Y+
MZ4:\CM!;;T0]L#NJ--K4B9I;BR,&:$@\A4IA#T#OV[%RHD@Z50#[14554R'^
MX3!]^ 0IY =+G77(U!=A>K[.'C3<=H;0[1JWB&/FQ=0#J(?1EX17%R!A>E=0
MZ(N(@2@T<-UUVXKE*?R "&NS>E?ORM.-43>J=S,7VV/K^J%I?[.K.J*I3*MJ
MRF5BMN6)')-8A8W#"SF?O$FQ)<3S"+A[[@Y@23*7O@&S;3T: LC:K69SR*<3
M&X"[&V;M7:-ONNJH6UT?9-WVC%1<'*3OU6J6./AZZ^@HJ&8MJPJWDGX17BJ<
MI5!5^RUK7Y'FU;HD0$!4JYKZ3Y"SUDI :SV7JK8L)(Z^@DSWJN7JV,+M$J-7
MB4OYUA]4Y^+8+-G#--V,BV1,W7!$#B8'KWA<]:]>_B9O5ND!$-J==8:\;I3G
MK5(L]<HZYM-1U; Z_9Z_D=3V-M;*38W->8S,FWM=B:SC1%Q)2+YXS"11 R)D
M40-Y!/'GI->N=QFD_P!-G:>PIBBW?;O,&T[(V%6K99W<V]D];0#2D2FO;?!(
MP$U0*_0DII9E4A6003=$L#61?.R/ ,K[4?(0"@U:^Z.DG;ZY7:)M'E7:[Q0=
M34H])X^0)=>P4*[UNU-+,)!*5L,JWF7*FP)=JS9#$M74@WBRIM51,*9CE^T!
M*.^=/6'O0[Y%?:4Y'CO+0E6T6[]*!CUQKK.L V!.PM!4=E%ZZ=^W 3L%Q3;I
M>8@10>WS!/OZJ1HXJ\(K)']0K9O*JTT.TZZHU"UO":HUE!V:3A'(7V_IQ3&N
MWS>3*(@WKQK$(6NLPM?BD$W?A)&4:.3J 1,2$!K6D']\.OP[.'(NQP!@# &
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M4YAR-J3^1E*$[56J]GK\B>(L$<S='\Y"(!X0B@*1C\X%4<-CD$/5(14ABG*
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M4$+6U:L;*A78A&<9LEC.&K6229(D=((+&^TH1)0HD P]P[@( 8P !A S# &
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M#%5K>7(2#C1>+F<NQ8QNTIYNV%TY/W4<.!3( JK'$3*'$1$<#6M9%QV , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & 0OVKTZN"^\;U,[.V_P 5
M=*;%V#81:#.6^UTB*EIV5%BT18,Q?/G"1E7 MV;=!LD)Q$2HI)D ?$H  &4:
M,X/\1.,UCDK?Q_X[:IU%9YB,&%E)VBU./@I)]$F73<FCW+EHF511J+A)-84A
M'Q%0A3"'<, E1@# /,FOR-+?LQ__  JN 5.]$O\ ,F=?O%\E/YM6'MC2@MUP
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , \R:_(TM^
MS'_\*K@%3W1,_,G=?O%<D_YM6'!5^$]DU[ENF"# & , 8!_!E"$[>9R$[_=Y
M& O?_1W$,J(J\$5>Y%7V(JHG%43O5$/D3D OF)R@3MW\Q, %[?K\N_;M_?WR
M*BIDJ67J4MT7@MS^L 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@'F37
MY&EOV8__ (57 *GNB7^9.Z_>*Y*?S:L/Z_\ [^KY8T@UKN+=, 8 P!@'T.G*
M#)LX>.E2H-6B"KERL<>Q$4$$S*K*G$ $0*FF0QS" #\@'Y9^F,?(]D<;5<^1
MS6,:G%SWJC6M3M551$[5/R][8V/D>J-8QKGO<O!K6HKG*O8B(JJ4A<Z-UHW^
M^4I/2.P7$VU:5B1&83JLB]111<(/E5S&<^ MRF.5H!E/+[0 D'W_ '!GHCZ<
M[/RX7AM?_O\ AC*=\E9&L*UL<3G.8Z)K?V_S6RO2R)E=>Y32&W&-18C7TJX/
M7NGC92N;)^FDD8UKTD>Y=Y%W;JC;*JIRRN?;)\D-03?$ZN::EMW2S/=_PU:;
M+ 5EZ]?S[(R"TL,4^OK='LY&A%=^S+-'!RFL/FR\!$>X#KGZA8%74V.XE7LP
MY\.&.?$Z*=C&M@5%:UF\U&KDBR(YM]VRN:N>2F<[#XI33X+0TKZQLM:U)6R1
M.>KI$5'*Y&JJIFJ,5KK(JV1;+R)Z\;-JFIW'[BM7N0UJ+6]T[.K$)6F<'<I%
M$;9:[NC$.I)\Q023 3O7P1S)9\J<I2IIMRAZARG$I3:[37QKW,X)E8!\ (#W
M[" ]A[#V$![#^H?U#_<.2Z+>RHMELO8O4O4N:"RIQ3CFG:G6?P95(I3G,HF4
MB91.H8QR@4A  1$YS"( 4H  B)C" =@$>_8,HYVY]7,^MJ[:O42N&;EN[0/W
M J[59-PB80'L(%42,<@]A^0]C#V'Y#@'Z, 8 P!@%*W5GY[[SX8R6HF&G"4\
M"79E8'DTK:()6:4 T6X:(MTV@%?-"(D,"YQ5$2G,(@7Q$H=^^Y/I3L)@FV3,
M6?BZU=Z-\#(4IIDA3_*USG*Z['*J_MRY=G,Q_'L4J,,C@? V-RR/<CND1RI9
M$Y;KF\UZU[4(9:AZX-@MFI;9#;9L]*U!M:OQ-@M+#:;^FNIN@2+"(1378U4U
M392R4@$_+G.=N@[(\(U ">7B"@E(;ZNW7T;J,)9)B&S*5%;1M2-KJ!SDFK&+
M9[IIT?:-KH6-:BJEE>BWM=,TXL(VABK]V"H1L539SE5J*V)UE3=1JJJKO+?A
M?.R^,X.(O6'XO[*IB=9W1O:CQ>YJ='MD=@RK:'?UNA3DRH *N5J*99617=Q;
M8BJ"(G<G26,L)_ AR@(AKG_QYMK^ZVSM>JL<C'HU(7*QZHBHQ[4E56.LM]UR
M(MN1]MU;2,1%?41-1?XJYVZCN62NLCN]%7K+,(SD1HR9@&]HBMK4B0@G48WF
M47[6>9J@:+=."M6[XS<J@NDT%%S%(!U4"=@'U# "8"<,6K:*KPZIEHZZGEI:
MJ%V[+!,U6R,=U*GRBJG:=AKFO:US'(YKDNUS5NBHN:*BIE8W W<(/&Z#MJLF
MX;.44W#=PB<JB*Z"Q 42524*(E.FH0Q3D.41 Q1 0$0'.J?H^[ & , 8 P!@
M# *VN8?5*XV<*=D5K5^T2W.6L,I7V]WM:E0@%IEEK;7CJ44A4KW<UB&)[.!&
M324:>3<%W'F7R]+Q$!P,[*O5ZKU)K(F39-R:ECX0YI79=$AC3-6+.QJ$U:X2
M)=.H>6C3N8Z13:2#UNY%H[0."B*WI>!R]_$1$H@ %4/1?W#J.$X7N&DOM'7D
M8Y/R#Y&NBMW]SKK-<S9SM:P+-EP2<2*9Q2<(F(L@H!1(LD<JB9C%, Y$OG?K
MR[M7!;']?.C_ .V+5WZO^_M6_P 5_P#G[LI+]_DI\EWOI$P]B[@U>8>W?L%]
MJPCV_P! 2G_O^K]."GQ]?.C_ .V+5_W]O^_M6_Q3_P"?NP+_ 'X+KPXGQ]?.
MC_[8M7_[>U;_ !3 OJRE8O4+W\JF[H"6I=SM31;R+GFMA8T6WQKINX445;D1
M-*FBW3G[)D#*HD15\ 5(<_81[9N?Z48)A>*,Q*HK\/CJYJ.II74TLB/7HG(U
MS]U$16M55<UKEO?APM<U;]1<6Q##WT,%'5OIXJJ"=L\;$;_E:KMRRJY%7^*J
MW+A<IHWE&[$I^I(RYZMO5$0MUAD&+% KRV5YN]A&3B:&,EAE(^9E(U-(ZL>"
MSAJ59;T52&)Y=P'-NUNT6&P3UF'SS04M73/I48E:B=%(DKX7++$W?8LG1Q.>
MYMU8F^Q+K9%1=;4&"UE0VEJV4\\]%4,J5>ZE:_?:Z-KVMBD<QB[KGRHU%LBK
MN]M[5[S.MMDU!G3N4$'M:Q;'<[1C'B3B"J[=@RLE?D7L@ZK[=E9G55.^]"F0
MYF"LLK!(^Y!?UFCHHJ>IGRFP83MG2UCUEKL4P]M4E(L/0QTZNGBDCC9(R:E?
MTK:&EWGROA:LF\KNE<YUU1?NI45^S55!3=%1X;5-ITJ&3+*L[>@>USGL5E0B
M-6KG1$C21RL1J)NY(U%6[W>&T?HKQ1Z9%]B-H5J[[VUG=XU:P;,M,E2W.Q:]
M7DM<7=>R'D8VURL>"+M^5%HP5;R(MU55B-@\?<&(0WFW:;#(<&QW$L,IUD=#
M1U+H8W3):1[41%1SD5$5+WX*ET3);KF;IP.NEQ+"J.NF:QLE3$DCFQJBL:JN
M5+(Y%<CDLG%%LJYIED6/[*Y^V:N:>T7L73L3K?<K>\UROR5]</;]#Q$Q5QE8
M5!V1RO7(9P^=BNL]4!!PW01,BU5.8HF\"=\U)]2-O:#Z=;,5.T-<Q)W-EBIZ
M2CW]Q]742NLD;+(JV8U'2/5$R8U56QLWZ>;#U_U!VDIL HGK3M?')/55:L5\
M=+3Q-5722<OW+9C&WNYRHG,@5?.H+R#UY7-ARL*]J3J:M!Y*P-X^:F#&90@R
M+("$09*L5W#U%-@BV_HS--$7@J#YF0[FSPS@7UG^H[L5Q*GJZNJI:':RIJ,0
M9+#2.JI:-N(-9! F&O>_HJ>.%C$Z/I';D;VO<_\ <>UL6^C7TZDPV@FI4IY*
MO9:FAH)&SS?I8JR2@<M1.[$&-C6:1\V^YSUC8YSVJUK+HERAZS]1+GA9C6IQ
M.W>:J$INVI5=W4U(2R'4K:47!/48]P11L^<(H-FR-=%VPEXY,0D):4.1VNW(
MN'CGIF@^I$F&X7A>$TM5-7OV9J4PS:&IK6.7$*QE/36ITM'_ !J:B7<DDFLL
M"L1RHJ[V7G>I^F4>(U^(8G+!'0P[24DF);.04\D:4-,^6H1:AKY)E8JP4\*R
M-8S*=9-U$:ME+=;UU"=S\=N#'$MG&+4V,L^T]K?0BUSD1:H:/DJQ4%T".8BZ
M6./;/U7<$+QT4[=1F)"JN"$**Y2'6,&;^PVNCQ*@I*^'*.K@CG:ET56](U'*
MQ53)58Z[5ME=%5%-"XA1R8?6U=%-F^EGDA<MLG;CU:CK<D>EG)WHBG1!JSDM
MIRSZYI<_);?U^G(2M>C73TLK<JLQD!=&0*5<[IH$H -U%%2F4\! ! IBB8 $
M1#.Z=,V 7>^D3CV+N#6!A["/8+Y5Q'L'WC^5/T?IP#X^OC2']L6KO]O:MW_]
MOBO?_P!,$OW^2GQ]?.C_ .V+5_\ M[5O\4P4YH.OS<Z/<;3Q[D*G>:W9TF4#
M;FCM.NV*+F&K50\@P63,Y&.=N"(K*E\@)Z@E$Y"#V ?$<]-?Z?W_ /%VA8J-
M3_D4CM];7_\ 6]+77BB9+;DJW,/VL:]T5+N,<]4>^Z(QSK(J<51$NE\TS.:K
M8LG$L*H[6DY,&K%<R3=0J)45E7QUCB1*/1]4?324<J>)07,( D "H)B 43!O
MZLKZ&EC>M944\3=YL2,DEC:^1TO[61-1ZHJOE5VZU$M:][I953%L/I*O]1$L
M=-)>V]OO:]C(U3_NY;?N1J?]+?NX(BWLNFJ/J6W!<M=EB9TCV?N*[*,6CVZI
MJ]&S,Q+2[!!HK.6%H15HJ1DV6_&.I11)(Q$3?;$AA ,>K439VFEV@Q"LD=%0
MT<L^)1TT/1I62-?&OZFH= QRU$D$2+'&LR_Y<DWD:YV[]Z.9F)/FH8X6MM)T
M<#Y58_HDW'6W(I%1S$<K42T:+NHJJJ71$7H#>\:K?K??/&[6\K?=+/H>7U;?
MH:7#7&WH-K)V;8)XAZ[BH>[V LH1%)&L^23I5JN5)@_@&RC1NH=T<J8^-MNL
M;H]H=I\1Q:@Z3])4NB2%9&]&]R1Q-C5RLY([=WD1<[+FB*AF%! ^FHX()'(Y
M\4:,<J75,NJ^=K\.RV:W.BW:'/2A<4M5Z;K3T8C;]XEJRWKSGZKYZNR-=@9B
MNPC4%EILS>3.ZCX=90AFS19)!8ZJB?;L'D YK7:''(-G\-DKYF](Y%;'#%=$
M=-,[^++\;617.5$6R(JK9#:GTH^FV)?5/:^CV7H)OTD4C):JOKW1N>RBHH41
M9)53@Y[G.:R)BJF\Y;(BJEEK^VGUS);5&N;M<9;74<Z>,233BJME7J35)T[.
MJ@M 0C@XJE W9LB]2>N"]U3"<BB93&)VS7.'_4JKKJA*6/#VK+-*](GK?<CC
M62/<61&JKE:QBNWU1%5;HJ'K7:S_ $A[.;*X0[':S:>H_2T%%3K5TK5C9/75
M;*6IZ=*5\Z,C8^HJ&POA8YR-9&R7>1<D6 _);\(<Y)L)CC=;M.UC7M:IUVJA
M7]WU\K[>W6R;L+F*,\72BY%15)!A%1[D09,#E[.GSP"I+$+Y"!<JHMM::LJL
M0A2CJ8HL.7<GGD:C(D=TZ1*MU7>:NY>2R\&(KE1+9Z,VA_T]XK@.#;+5_P#O
MV$5];M7"ZIHL-I)72UC6-P]U9N*UO^)[5D1*9'M<JNJ%Z-MUNB;IU?\ A#NQ
M)].J6.UZWIC.L,(:-;[';N9?X/*UV=DIA9GZ,U&NS$EDI4K,B*[9M",GD6H*
MP@LX( ")<U8]KVM>QS7,<U'-<U45'-5+HY%1;65+*BW6Z'GF:&6GED@GC?%/
M#(Z*6*1JMDCD8Y6O8]JV<U[7(K7-5$5%2RYG3AJG>VL=P0%<EZA<ZG)/K% L
MI].O1UI@)>99M7:!%A*Y:1;]TH H>8$6,!?%,_V3^)@$ _9Q&X< 8 P#G@ZH
M'3AY8\@^0=[V)QS3U[,53DEQFBN+&V#W2?"$D=;0K"X.+(:]P3=1%;Z0'%NX
M!J,.U,@N*I!5!3L(XM?W&M>7L6;SO3IXF[#C*,?<.GZMLJV4[7%1UQ]*9U-Z
M=^\AZG$I1K1$XI.TB^CW*LH0IBB8 5$IC&P##8;I(].FO,0C87BMK>.8@X<.
M@:MF\DFB5=TH*KA0I D.P&54^T;M\N_;MV#Y8!ZG^2LZ?W^;+K__ %4E_P ?
M@%=G5$Z8''&(XJ23OCQQB8FV0&PM:)-AHB4O\?+"+6Z,3L'@",AYF9C%BX![
M_P"$&_F8WR# UK7R6&M>E;P!,V;BKQDH *"W1]0#(R7D!_2*!O+^GA]KR[]_
M[_\ UP/'V^WA^<S[O\E9T_O\V77_ /J9+_C\ ]-ATQ>"<6"A8WCK3&(*]O5!
MHK,MP4$O?Q$X(R9 ,)>X]N_?MW'MG:IJZNHT<E)65=*CU17I35$T"/5O!7]$
M]F]:ZVO>UU3F=>:EIJA6K44\%0K+[BS0QR[E^.ZKV*K;\[%<'52Z8_'53C$@
MYTEQE83%^=;PT*B^3K",N_F%ZD?9,(A;A<$4D%14C"5]1Z62$P"!&8J&^7B
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MIQ4G%#],+A3]$ZK6Y'1]=DX&OQS$D;!2Y5GK5@H1%(X^D*QS.4E0< *RJA'
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M$1[Y^72R.>DKI'OD145'O<KWHK52W[GJJY62V?+((EDMRZK);GR1">\)TI^
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MW1!UT%:>NG),2/G[---5[%0<\^8MZ]/S#!-5,SR*AI1\_;]Q*H@!B'*4"8&
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MUFC8T\G3X^;?R!JO67$@D+A*#B19L!5*"PMQ/V$ )>8 P!@# & , 8 P!@#
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M+0\)X/I"!KPG^%U_WQOQKM&+;MTEUA%50HG'O@$C, 8 P!@# & , 8 P!@#
$& ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>50
<FILENAME>g425213g61f03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g425213g61f03.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1D24&AO=&]S:&]P(#,N,  X0DE-! 0
M    &/:^8Y X0DE-! 0      #@< 5H  QLE1QP"   "   < E  "%1I;2!2
M>6%N' (% !=0;W=E<E!O:6YT(%!R97-E;G1A=&EO;CA"24T$)0      $(E,
M*T ^4D:PQ&_V$<%;PI<X0DE-!#H      /$    0     0      "W!R:6YT
M3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90
M  !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE
M5$585     < 00!0 $0 +0 M #(       ]P<FEN=%!R;V]F4V5T=7!/8FIC
M    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M 0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"
M24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M%P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#
M<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O
M;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $
M      !21T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B
M0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M              !";&0@56YT1B-2;'0               !2<VQT56YT1B-0
M>&Q <L            IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O<"!5
M;G1&(U)L=                %-C;"!5;G1&(U!R8T!9            $&-R
M;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M    #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ "4S,P
M 0 " )3,S  !  (X0DE-!"8       X             /X   #A"24T#\@
M    "@  ________   X0DE-! T       0   !:.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         "
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!$0      !     "   "0    D      .$))300>
M       $     #A"24T$&@     #00    8              Y(   =?
M!@!G #8 ,0!F #  ,P    $                          0
M   '7P   Y(                      0                         0
M     0       &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T
M,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M
M;&]N9P   Y(     4F=H=&QO;F<   =?    !G-L:6-E<U9L3',    !3V)J
M8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R
M;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@
M  UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   .2     %)G
M:'1L;VYG   '7P    -U<FQ415A4     0       &YU;&Q415A4     0
M     $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .8V5L
M;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R
M>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV
M97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M"V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE
M    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M  QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
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M .@IX^$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M      #_XO__24-#7U!23T9)3$4  0F^S/[^'@ (@'!!1$)% A   '!R=')#
M35E+3&%B( ?0  < &@ % "D -6%C<W!!4%!,     $%$0D4
M       !  #VU@ !     -,M041"10
M                                "F1E<V,   #\    =&-P<G0   %P
M    *W=T<'0   &<    %$$R0C    &P  "B!D$R0C(   &P  "B!D$R0C$
M *.X  "B!D(R03   47   (XM$(R03$  WYT  (XM$(R03( !;<H  (XM&=A
M;70 !^_<  "0D61E<V,         &E4N4RX@5V5B($-O871E9" H4U=/4"D@
M=C(
M                                                =&5X=     !#
M;W!Y<FEG:'0@,C P,"!!9&]B92!3>7-T96US+"!);F,N  !865H@
MM5H  +QG  "2,&UF=#(     ! ,)   !                     0
M              $   $   (   (D!!T%V@=I"-D*-@N%#,<-_P\Q$%X1BQ*W
M$^(5"Q8R%U<8>1F8&K4;TASO'B4?62"'(;(BVB/_)2,F1"=F*(8IIRK'*^@M
M""XH+T@P:3&),J8SPC3>-?LW&#@U.5$Z;3N)/*4]PC[>/_A!$4(I0T)$7$5U
M1H]'J4C#2=U*]TP232Q.0T]94&]1AE*<4[)4R57?5O98#5DC6CI;45QF77A>
MBE^;8*UAOF+/8^!D\68"9Q)H(VDS:D)K4FQ>;6=N<6]Z<(-QC'*4<YQTHW6J
M=K%WMWB]><-ZR'O-?,Y]S7[,?\N R8''@L6#PH2_A;N&MX>SB*Z)J8JDBYZ,
MF(V1CH:/>Y!PD6226)-,E$"5,Y8FEQF8#)C_F?*:Y)O6G,B=NYZMGY^@CJ%\
MHFJC5Z1%I3.F(*<.I_RHZJG7JL6KLZRAK8^N?:]KL%FQ1[(VLR2T$K4 M>VV
MVK?(N+6YH[J0NWZ\:[U9OD>_-< BP1#!_L+LP]K$Q\6UQJ/'D<A^R6S*6<M$
MS"[-&,X!SNO/U="^T:?2D--YU&'52=8QUQC8 -CFV<W:LMN8W'W=8MY'WRS@
M$.#TX=CBN^.>Y'OE5^8SYP[GZ.C!Z9KJ<>M([!WL\.W#[I;O=O!5\3/R#_+J
M\\/TG/5S]DGW'O?S^,;YE?IA^RG[Z_RG_5S^"_ZT_UK__P   >@#IP4L!H0'
MOPCG"@0+%@P<#1X.' \9$!<1%!(0$PL4!!3\%?,6YA?8&,P9UAK>&^$<X1W?
M'ML?UB#1(<LBQ".^)+@ELR:N)ZHHIBFB*J KGBR=+9HNE2^1,(TQB3*&,X,T
M@35_-G\W?SB .8(Z?SM^/'P]?#Y\/WU ?T&"0H5#B42-19)&F$>:2)M)G4J?
M2Z-,IDVJ3J]/M%"Z4<!2QU/.5-55UU;95]M8WEG@6N-;YUSJ7>U>\5_U8/AA
M_&, 9 -E 67_9OQG^FCX:?5J\VOP;.YMZV[H;^5PX7'><MISUG3-=<-VN7>O
M>*5YFWJ0>X5\>GUO?F1_6(!-@4&"-8,IA!R%$(7^ANV'VXC*B;B*IHN5C(.-
M<8Y@CTZ0/9$LDAN3"I/ZE.F5V9;)E[J8IYF3FH";;9Q:G4B>-I\EH!2A!*'U
MHN:CV*3*I;VFL:>FJ)NID:J'JW^L=ZUOKF>O8+!:L52R3[-,M$FU1K9%MT2X
M1;E&NDB[2KQ.O5*^5[]=P&/!:L)RPWO$A,6*QI#'ELB=R:7*K<NVS+_-R,[2
MS]S0YM'QTOO4!M42UA[7*M@WV43:4=M>W&O=>=Z&WY3@G.&BXJCCK>2RY;;F
MNN>]Z,#IP^K4Z^7L]>X$[Q+P(/$L\CCS0_1.]5GV8_=J^&[Y;_IL^V3\5OU$
M_B__%___   "!0/8!6@&Q@@&"3(*4@ME#'(-> YZ#WH0>A%Y$G43<!1H%5X6
M4A=%&#<9*1HT&ST<0!T_'CH?-" L(2,B&2,/) 0D^27N)N,GV"C,*<$JMBNK
M+)\MDRZ'+WPP<#%D,EDS331!-38V*S<A.!8Y"SH .O8[[3SC/=L^TS_+0,1!
MO4*W0[)$K$6F1J%'G$B7291*D$N.3(M-BDZ)3XA0B%&)4HA3B%2(58A6B5>*
M6(M9C5J/6Y%<DUV67IA?FV"=89]BH&.A9*-EI&:F9Z=HJ&FI:JIKJFRK;:MN
MJV^K<*EQJ'*E<Z-TH'6==IEWE7B1>8QZAWN"?'Q]=GYO?VF 88%:@E&#2(0^
MA36&*X<AB!>)#(H"BO>+[8SBC=B.S8_#D+F1KY*EDYR4DI6)EH"7>)APF6J:
M8YM>G%F=59Y2GU"@3Z%/HE"C4J15I5FF7Z=FJ&ZI>*J"JXZLG*VKKKNOS+#?
ML?.S";0@M3BV4;=LN(>YI+K"N^&] ;XAOT/ 9<&'PJK#SL3QQA7'.<A>R8+*
MILO*S.W.$,\RT%31=-*4T[+4S]7KUP;8'MDVVDS;8=QTW8?>F-^GX+/AON+'
MX\WDT>72YM#GS.C$Z;KJK.N;[(?M;^Y8[USP6_%6\DSS/?0J]1+U]O;6][/X
MC?EB^B_Z]/NQ_&;]$?VS_DW^X?]Q__\   '9 XT%"094!W\(E@FA"J0+GPR3
M#8(.< ]?$$P1-Q(A$PD3\!36%;L6GQ>#&($9?1IT&V8<51U!'BP?%R  (.HA
MTR*](Z8DD"5Z)F0G3B@Y*24J$"K]*^HLURW$+K$OGC",,7DR9S-5-$0U,C8B
M-Q$X 3CQ.>(ZTSO$/+4]ICZ8/XI ?4%O0F)#541)13Q&,$<C2!=)"TG_2O-+
MZ$S<3=!.Q4^Y4*U1H5*54XA4>E5M5E]745A#635:)EL87 E<^EWK7MQ?S&"]
M8:QBFV.)9'AE9F949T)H,&D>:@MJ^&OE;-)MOFZJ;Y9P@G%L<E9S0'0I=1)U
M^W;D=\UXMGF>>H9[;GQ6?3Y^)7\-?_2 VX'"@JB#C81RA5>&.X<@B 6(ZHG/
MBK.+F(Q]C6*.1X\MD!*0^)'>DL23JI21E7B68)='F"^9&)H!FNJ;U)R_G:J>
MEI^#H'&A7Z)/HS^D,*4BIA6G"*?]J/.IZJKBJ]NLU:W0KLNOQ[#$L<*RP;/!
MM,*UQ;;(M\VXT[G;NN.[[;SXO@2_$< @P3#"0,-2Q&;%>L:/QZ;(OLG6RO',
M#,TJSD?/8]" T9_2O]/@U0/6)]=,V'/9F]K$V^_=&MY&WW/@H>'/XP+D3>69
MYN?H-NF&ZMCL*^V [M?P,?&0\N_T3?6J]P3X6OFK^O;\.OU[_KO___\ @ "
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M@E*JZJ %@;FF+H?5@4ZAQF[]@0F=O%4?@..:,SB)@/.8.!(?@;R,0>0O@XO
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MY)PIJ]YYMHH0I]YYLG>*I!=YYF1'H)AZ4$_YG7-ZYCH?FO9[C2 IFIA\<0
ME=-_RJS.KRB"@YMHJN2!F8E^IMJ X';[HQ. 8V.HGYN )D]3G'^ (SETF@6
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MI(Y"M,* O7UBL 6 #6OSJXQ_GEFXIV1_<D9LHZY_@S%LH-Y_P1>PH3N N@
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MH(MPL42GI7J8K(*D$VDOJ 2A!5<EH]2>ET0YH B=22_$G/"<)Q<5G*B/FP
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MJ(%'O@B')W%>N)Z%W&#;LW6$\T^AKI^$63U2JEJ$&2DCITJ$3@^OJ$^$[@
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M]7_,NJ&LDV_VM1^HRU^-K^.EV$YWJPFD&CQOIKRB_RBSHU.;A1!LHT2+&P
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M%G5?QVR-&68@P7*+9U9VNYN*&D8DMBB)2#2UL6:(_B$LKDF)Y E=K9N&50
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MQ75%P\6PZF9DO9.L\E;RMZ.J9D;"LB6HWS6(K5:D,B)EJ=N700M'J+"'H
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MA)U\CN ?@J""O<KW@BF!][3=@<6!39W?@7F S(8C@4. =&VS@2F 0%0>@3"
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MBJEW?I-^B8YX"7TQB)=XLF8%A\5Y>DV>ARAZ23(XAR5[,0S6B21\>= \B_&
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M$2BJB66(YP5?B->#H;U'DF><A:K/D$Z9LI>9CF&7 X.5C*J4A6[9BRB205E
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ME5&M=7:%DLZI5F,@D).ERT[FCJ>C2CE9C0"A6R ,C)"5JP"]B1N @*P4FIS
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MYI"7HS64FG^IG\*2?VX"G(B0GUN<F8F.]D@LEOV-OS,FE0*-+QG(E2V,[0
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MQ(9]L+AT-W:0K*)TPF7OJ,5U;%1GI2MV,4&BH@AW RSPG_AWK!)NHAQWK
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M^8/+K&::2W/4J#B7U6,OI$&5K5'.H)23Y3]FG5F2PRM FPN3$Q(0F_*,-@
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M+GFYN@AZU&JNM3QZK%KTL*MZMDI/K&YZ[CA?J-5[0R0TIL=[@0J?J"Y\8@
MA;:  (?>O?*"Z7EBN/V!]&I>M":!+EJ6KX^ M4GVJTR =#@:IZR ;"03I8&
ME K?IH.!)@  A6N  (>7O.>*F'D!M_6)&VGGLR*'U%HLKH&&UTF4JD&&+3?/
MIIV%U2/RI%N&& L7I0>%40  A2F  (<^O J28'BEMQ:08FF$LD&.IEG K9Z-
M,TD_J4Z,'#>/I:R+EB/7HU:,/@M*H[F'H@  A/&  (;?NV*:4WA0MF>7UFDU
ML8B5G%EUK-^3O4CYJ(R253==I-.1QB/#HFN1Z MTHI2'OP  A,*  (:'NMZB
M7W@)M=J?9&CUL.^<KEDYK#Z::TC"I^R8VS<YI"R8JB.ZH9B6HPN<H92'V0
MA)J  (9-NF*JE7?5M5JG'FC&L&NC]ED/J[.A94B:IUZ?Y3<4HZ:?"B.JH/R8
M'0O H+2'\@  A'N  (8-NA&S/G? M/BO.6BWK_.K@UCUJR.HJ$B(IKVG.3<3
MHOVD#R/"H&"8+0OQH!V($P  A&&  'MNRS%R_6V9Q;9S-U]8P']SFE!SNX)T
M)T">MM]TRR]%LR%U9!L&L?AU:P-OL$UWB0  @R2  'MHRD!ZB&VKQ,)Z$5]>
MOVMYV5!PNDEYVD"9M8=Z#2]2L:AZ5AM'L#%Z7P0+KB]\1@  @R*  'MRR1*!
MV6V7PYZ V%]'OCV #U!.N0M_H$!]M#I_;2]0L$=_=QM]KI)_JP27K$F =0
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M,&T_OUNC_5[\N<&A+% 6M&&?%$!GKW6>62^-JU:<TQQXJ."30 :'I>N$:@
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MB(1]:;5)CHN"ZJ0,C0*"79(#BY*!TW[7BE.!:6K,B3>!&56[B$J XS\VAYZ
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M.Y;1E@F RH7ID]N 97/MD>6 '&$%D!U_\4T!CIA_WS=CC8%_UAUWC?Y_\P
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MNY*]DC&L"X&KD >H1F_'C@2DIUTMC$2ABDFFBL^?9#2TB9B=V1N+B8>2GP
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M2HD-GF.'1'D8FX:&4VA.F-F%A%: EG.$XT.3E&2$:B[>DO^$*Q4'E#Z$@
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M\(8[FVNQ*78BF'BM1F5!E:JIKE.TDRJG#D$OD1*E.BT.CWV>=A0"D R-AP
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M@WPTITV-#6T>H\&+M%U!H&**@4R)G4R)B3J-FL&([":4F3&(_PT_FER'/0
M@!J  (H0JD&6Q'NNII:4S6R8HP62[%RZGZ&1.4P)G(6/T3HRF=V.]"9;F#^/
M6PU"F2>(]P  @ "  (FHJ9Z?('M I?B<JVPFHF2:1EQ(GOV8&$NAF]Z67#GC
MF2Z5AB8VEUZ4W U*F!&(_   @ "  (E+J32GIWL%I8JDO6OGH>2ASEOXGF*?
M(TM*FSF=.3F*F)F<K"7SELN9<@U*ESF(_   @ "  (D#J.BP@GJ\I3.M*FN5
MH8*IP%NCG?:FO4K_FL6D^CE.F!^BQ"7(EE&9C U#EJ"(]P  @ "  ']RN?]M
M;''AM<!N:6.QL;UO<52KK>EP@$29JF!QC3,!IY-R>!Z[IM%RP06]IS]S;0
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M!G!/L*V20&((K'&0EU,"J&*/)D,EI*J.$C'^H9V-M1Z!H".-X <AGJ.$T@
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M<&7#O[%TBU@ZNP1TU4GQMH9U0#J6LG9UORF-KW]V(145K\1UNP /J>EXYP
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MTV4_NF*6X%>NM7^5"DECL,^3C3H_K)"2PBFVJ3B3!Q9@J"V/(0)'H;2!B@
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M'<&D;QN"9ZRU<)F!PI;,<@"!28 <<UZ ZFB3=+* G$_9=>6 2C1L=KQ_[P_
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MVISYBH!KNXO]B7YM<'G B*EO"&9IA_%PF%'LAV)R)#OHAR!SA2&QA_5T3@
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M?I>6@_J7?H:!@S"57'1O@H"3,V&,@?&1,$VJ@8:/>#A%@46.4AZU@5B-W0
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M6H\6D<AS37\4D"=T,VWZCJQU%%O$C5AU^4A5C$5VV3,HBZUWBAC]C0!W@P
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M@HJ'C%J=,'IYBLV:M6EZB5Z8/5>MB"&6"D35AQR46S!>AE>3]!;_AK*/C0
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MV8%UF;IZ$G)]EVUZ36)@E5-ZE5$]DVIZZ3[+D>%[0"I9D1Q[<1 &DR][)0
M@ "  ([/FLR"/8"2F&Z!VW&$EBV!>6&0E!.!)E![DC> ZCXJD+. PBG>C^*
MJ0_2D9* J@  @ "  (X F;2*J'_&EUF)N7"TE1V(QV"TDP>'WD_6D1R'##V;
MCZ"&>BEWCL&&/@^MD!:%>P  @ "  (U5F,:31W\7EGB1RW !E#R00& *DA^.
MND\SD#.-8#TECI^,:BDBC;:,70^+CL")D0  @ "  (S&F!B;]WZ:E<^9^&^"
MDXF7U%]ZD6"5N4Z>CW63\3REC>*2S2C/C-B2Q0]IC9V*:P  @ "  (Q5EYFD
MOWXBE5*B0V\ DP.?DU[VD,V<\4X=CMR:U#PFC4^9W"AKC#B8&@]+C*R*5P
M@ "  (P!ESVMQ'W#E/2JW&Z1DIJGJ%Z"D%:DD4VTCENB43O/C,:@]2@?BZ^;
M(0\<B_F*-P  @ "  (.)J1-H-W8\I?9IX&@5HQYK>%CBH'AL_DB+G@YN<C:R
MG#5OMR)>F^-P6@A8G:]P(   @ "  (,2I_)P9W7>I-9Q1V>MH>=R+%B!GR=S
M%D@PG*MS_C9GFL-TRR(KFD=U'@B FW1U,0  @ "  (*6II9X:'4_HXAXHF<B
MH)-XY5?OG=)Y/4>PFU1YH#8 F6=Y_B'KF,QZ%0B=F6=ZIP  @ "  (( I4*
M4'20HCJ  &9?GTY_ME=.G(Q_@D<<FAA_:36+F"E_7R&AEW5_6 BNEXM_DP
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M7')]GK>F[&0NFZ:D,E3ZF*VAI44"E@V@+3/9D_R>?""9DMB6"@CCD3N& @
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MX6A_JUB%+EL%I\^$ATRWI&V#\SURH62#CRR0GS*#:QC9GO>#OP+MFCN!^P
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MM%W.NT!H#E#CMY9I<$,CM 5JQC0JL.AK]",?KSYLH@XAL4AKXP  GP1SL
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MNUT>M1R)R5!$L0"(W$*>K0V($#/\J9&'DB.=ISJ'P _FIZN&N   F9"
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M?8\D?GV(SW\'?E"'_VWD?BN''5O6?AZ&2DB1?C*%F3.R?D*%#1HY?EF%#
M@ "  )U$?9"2[HXD?661E7X*?3J0#VSR?1F.=UKU?0Z,^$?7?1F+L3,<?22*
MW1G'?/N*9@  @ "  )Q]?*J<9XU9?(:::7T]?%>8+FPF?#25Y%HT?"Z3R4<T
M?#B2"C*E?"N1)AEQ>\>.V0  @ "  )OE>_NE\XRV>]RC57R.>Z>@:VMW>WF=
M<EF)>W&:R4:/>X.8PS(?>VV7^1D@>L20_0  @ "  )M]>W^OGXPY>V*L;GO\
M>R&HV6K>>N2E/%C^>M*B'489>N"@&C&O>L:=GQBX>?*0MP  @ "  )31CPQC
MDH;RC9UE\7?PC'EH(&>?BXEJ)U8;BKML%4,]BBIMX2YVBBEO1Q/(C)MO%
M@ !Z0)00C2UL>H8KB_=M_G<.BN5O:&;+B?1PP%59B25R"T*1B)-S/RW?B'UT
M'A-BBGUSK   @ !]MI,QBU]U1X4<BDUV#G88B4AVQ&74B&1W<%1]AY]X&D'7
MAQ-XN2U)ANYY'Q,#B']XF@  @ "  )(LB;A]^X0+B+)^)'3RA\%^-63JAN)^
M.U.IABY^1T$NA:E^52S+A79^5!*YAJ!^!@  @ "  )$PB$R&S(,/AU.&5W/\
MAFN%PV/UA9*%'5+UA-F$@4"<A%R$#"Q;A""#OQ)WA.B#A@  @ "  )!7ASN/
MOH)4ADJ.LG-#A6"-=V,BA(6,)U(D@\R*\#_R@T2* "O2@OV)GA(?@V>(.@
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MBGG/E1]M FN9DVEN9UQ%D=MOOTN\D'MQ!CF^CX%R)R5XCW9RR LND1AR10
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M1'7QCMV3\&>\C3N28EB&BZB0Q4AKBDV/:#<4B4*.F".>B+*.Q@K&B!V'20
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M6&SNG4)S(5^=FO1SYE$AF-%TK$&"EO)U:#!$E;%U_APVE@5U^P12D\5W30
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MZVI+F :8@US=E:Z6RTYSDV&5##\>D663UBYCC_N3TALPCXR1/035C!R#10
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M"&"OI@-X4U/]HRQXG$9JH'IX[S>)GC-Y02;=G-QY;!*7GC)X]0  E#!\8P
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MXU]6H:2<J%*9GIB:]T38FZ*95C8SF1>8SR7\EVJ6YQ*JEZF,G@ +CXJ "
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MTE3IKZQ\OTB^K%U\K3NYJ31\G"V.II5\HAT9I8Y\F0GJI8A]&0  CL&
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M4)0"<Q]S;H/D= YT=')H=/AU9E_L=>!V4TQ&=L=W-C<1=X5W[1V==Y)X!P
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MTXZ*:^.@5WY8;06=D6TU;AV:O%LV;T*8*T@P<%*6&3/1<-25'QLZ;S61>@
M@ "  )U4:?&LEXX(:SVI<GW!;%2E\FR7;5^B:UJE;GV?34>U;XJ= S-6;_^;
M>!K$;D>2&0  @ "  )A0?Y=>6HI)?W!A1GL8?WAC^&J6?YYF=EC8?]=HU47&
M@"YK#3#E@+YLWA:U@CUM-   @ !V7)=3?1MGF(E&?3EII'H!?61KAVF1?9QM
M35?M?>-N_D3[?D%PCS Y?KUQR18V?[-QNP  @ !Z9Y8Y>M=POH@!>R!R 7CE
M>V)S)VAX>[!T-U;Z? AU.D0O?'!V*2^7?-MVV!7%?4AVA0  @ !]\Y4%>,1Y
MYX:\>2IZ<G>7>85ZVV=Y>>%[.580>DY[CD-Q>L![W"\)>QM\"A5F>QU[I@
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M'(*Z<X^EBG-]<_2BDV-5=%&?CU)3=,:<_4 S=3F;:BQL=3.9C!.+=+2--P
M@ "  (LLB'Y=\'X1AZU@QV_3AQUC:F!'AKAEVT]TAG%H)STKAF9J.RB\ANUK
MN0X&B/YK1P  @ !YTXI1AC1FK7TZA:1HM6[LA2UJFE]SA,YL8DZZA(IN#SR/
MA'QOCRA A-]PCPW7ADEO]0  @ !]6(E>A =O4WP=@Z1PHVWM@T)QVUYW@O-R
M^DW?@KMT"SO8@K%T^B>S@O=UAPV>@^=T[P  @ "  (A/@A1WZ'KZ@<5XEVRX
M@7AY*EV$@3)YJ$T @0UZ'CLC@0=Z@2<L@3)ZJPUF@=%Z70  @ "  (=*@%:
MBWG]@!N HVO"?]^ EER+?Z: ;DQG?WN 23JH?WV +2;<?XZ $ U2?_Y_Z
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M9G':D)%@&F1ICW%BIE6ZCH-E!T6^C<-G.30?C7)I&Q_2CE9J%P9.CIEJ%
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M1&VYB!:%^V!>ARJ%AU(+AD*$^$*ZA7R$<3'RA/>$(!YNA/F$.P:1A#R"VP
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MC&5GF$=F;UBTEJ)H0$KAE2-I^#NVD^IK@RJODVYLJQ8PE1=LE  OD+YNM@
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M)V'UD-6*H554CT6)Y$>SC;^)%3D&C':(=BC/BYV(415UB^.(! $#A]^ KP
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M=5D,H+AKN$T9GI1L\3_XG)IN'C%_FQ%O&B#0FL%OE0Q]G&QO!@  BGMWH@
M@ "  &.=H0=QJUAKGN)R>DQHG,ES/#]UFM%S]3$1F4ATC2"0F-YTPPR.FAET
M50  B11[Y0  @ "  &,.GVYX\%?AG5-Y6$O>FSMYK3[CF3]Y[#"TEZEZ)R!-
MERUZ,0R.F %Z*@  A]%_G   @ "  &*0GBR 5E=QG!: 84MUF?B 2#Y\E_.
M&C!5EDY_^B EE:)_^ R5EAZ $0  AK2     @ "  &(FG2V'OU<9FQB'>4LD
MF/"&^#XHEMR&9B_ZE3*&#A_FE&V&1 RLE'2%#0  A<Z     @ "  &'5G%Z/
M*U;,FDJ.FTK3F!R-OCW8E?V,VR^NE$2,=A^+DWZ,KPR)DR6(>@  A2&
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M.DS?JB9O_4%7IZAPN33GI55Q;2;?H[QQ[!8*I$YQJP2$H5QR_   A4%^B@
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M?DP,I'J2(D"GH;J1530NGR.0I"9GG2^0F18FG/:-Y 5JF'"#J0  @8"
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MC8NC;NYE#WPQ<$%G:6NC<8QIH5GE<M%KOD;F= =MNC(X=/5O8!C2=,EOW
M@ !VR)B%:J%L((H_;$!MQWL1;;UO56J%;R9PQECN<(-R*$88<<ES=#&9<J5T
M?!AC<B9TDP  @ !ZXI<$: 5UF8C!:<MV?GF#:V=W1FDZ;.QW^5>^;FQXHT46
M;\)Y03#'<(EYMQ?*;^QYC   @ !^<96@9<9_#H=G9Z9_/'@S:5Y_1F?X:OE_
M.5;&;(A_+$0Y;>U_*# :;IY_'A=2;@9^\   @ "  )1[8^J(DH9,9=^("G<F
M9Z:'5F;W:5.&C%76:NV%S$-_;$Z%*R^(;.>$OQ;I;'*$P   @ "  )./8F*2
M$H5E9&:0V'9&9C:/9F8A9^V-XE4-:9*,?4+6:O2+5B\5:VJ*K!:=:R.)QP
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MM7Z]= EL>7![=.-N'6#E=;MOHE R=H]Q$CX:=UUR72H+=^US11 ]>1!RRP
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MN7G-:UB61&N5;'R4@5Q=;8F2J4PC;HZ1#SJJ;UN/]B> ;R>/[ \ <5"*)0
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MRG(.>@UR]V26>FAT!58N>KMT]T9;>R!UTS47>X=VB"%T>]1VT BR?7!W"P
M@ "  'V =XEZ2W#Y> MZW&.,>'E[254L>-I[F46T>3][X32+>:E\&R$9><!\
M( BJ>Z%\E@  @ "  'R/==>"WG L=FN"WV+-=N&"K51?=T:"7$3E=ZR"$#/R
M> *!WR"?=^.!U0B#>A^!7   @ "  'O+='&+:F]F=1"*WF(,=8F*$%.E=?&)
M*$0T=EB(73-<=J"'V2!*=CN(#PAR>-B%50  @ "  'LQ<U*3\&[.<_N2X&%S
M='.1?U,3=-60!$.C=3F.S#++=7J.*Q_<=.".#0AC=\Z%JP  @ "  'J^<GB<
M?&Y7<R>:_6#S<YN9$%*3<_*7#D,U=$F5@3)T='J5$A^!<[:2U@@L=PJ%A@
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MX&6Y@1UXD5D.@.IY(DM=@+=YF#R9@)-Y_"OH@*EZ0AA(@/]Z$P)N@41[P
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M"EW0DTA9]U&NDE5<Q411D95?8C5YD25AL"1RD:)C50]/E(QC)P  B EIF@
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M\%GNB3!]2TX B&=]>T$)AY]]C3+>AP1]F2+9ALQ]HP\+AQ)]M0  @!N
M@ "  &1:B(B$BUE2A^:$=TUHAR"$+T!VAE2#T#):A;"#BB* A5B#B0\SA2&#
M1P  @ "     @ "  &/>AX",15D-AN^+Y4TOAA^+)$ _A2R*.S(OA&>)L"(V
MA :* 0[E@Z"'\@  @ "     @ "  &-\AK&4&5BMAB&3?$S+A4V24S_AA$^1
M!C'C@W.0;B("@NV0*@[;@EV*"P  @ "     @ "  %S@GO%5WU)"G5E8GT;
MG A;13GYFOM=N"N)FGU?OAI)F\U@N :$G$IA!   @Z-M20  @ "  %P&G-U=
M'5&LFUE?548WF?1A>3F5F,!C<BM1F!1E#!I0F1%EM ;?F-UEXP  @A!R,0
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M$TZ6DCZ!.T-,D.J!(S;MCY> ["DNCJ6 SAD@CJF ZP=0C!R X   @ "
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M[T4MI)9CCCI!HNME&"X1H7YF>2 3H0=G5@[1HN%G"@  FMYI[@  @ !Z/
M@ "  $['I MHIT2CHEEIWCFDH+9K 2VAGTEL !_ GK]LD0[&H#]L*   F'=O
M*P  @ !]_P  @ "  $Y+H@MO<40KH&MP3CDSGL5Q$2TKG4QQI!^,G*5Q]@[
MG=EQC@ UE@!U"0  @ "     @ "  $W7H&IV8$/*GM-V\#CDG2AW52SKFYYW
MD1]8FM=WG [8FZEW7@!QD]IZ5   @ "     @ "  $USGQ-]54-_G8-]HCBK
MF\]]L"RWFC=]GA\FF5U]C [1F>5]M0"PD@E^S@  @ "     @ "  $TDG@.$
M64-*G'.$<3B!FK:$,BR9F0B#WQ\*F!*#Y ZJF'>#>P"UD)F >P  @ "
M@ "  $SQG2F+CT,HFY2+ACADF="+""R&F!"*CA\3EO.*KP[9EQZ(1 #=CV>
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M[(AU5UU[7WE)6FI[O6D>73Y\"E@"7^I\5D6.8BA\I#&M8QM\Y1FP8T1\[@
M@ !_$I5D48*$M8<\50&$9'@K6#&#^F@56R6#@E<,7>.#$D358"2"N3$:8/2"
M@1E(8:6"H0  @ "  )113VB.<X8_4P:-7W=#5D^,*V<_65J*\E9"7"N)U$0K
M7FZ(YC"I7Q2(4AC\8$V(20  @ "  ).!3;B8&H5[46V61':(5,6426:15]N2
M4E6=6K>0DT.,7/J/+3 L77B.?!BY7SF,[0  @ "  )+T3'>AEX3M4#>?!'7W
M4Y.<1&8'5JN9F54E68B724,L6\:5C2_)7!.4^QA97F:0=@  @ "  )%8::Q3
M8H.>:TQ7+W3S;/!:S&4;;I!>-U00<"-A>$&L<9AD@"UU<J5G"1/1<\9GQP
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M"'S27&J"!VZB7O*!WU]E84:!H$\G8V>!9#V=90N!.RI-922!+!'F:/>!.P
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M#G<W;S!? VF!<(1ASEJE<<UD<TJ"<P9F[3CA=")I)"4+=,AJM@N-=_=JJ@
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M)G%>8EJ'RF0/9$R'-%6N9@V&AD8]9YB%ZS5P:).%@B*D9Z2%B@K+;L^$0P
M@ "  'T*7I&0Y7"S8-2/]F-D8M".NU4,9)2-:T6?9AZ,4#349PJ+I2(N9=B+
MZ0JS;>J'/   @ "  'R+75>9DG R7ZB8(&+;8:662E2$8V24844I9.62UC1X
M9;Z2&R')9&*140IK;F2'"P  @ "  'C]>>Y2_FT$>F)6CV ->P!9]E'7>[!=
M*4)'?&A@'S#_?4%BKASB?FQD(P2$@.ED[0  @ !Y('>S=F!;2&OU=RA>+U\.
M=_)@[U#_>+ACA4&4>7UEYC!T>D=GZAR(>P5H\02;?BEIL@  @ !\P'9]<PUC
MEVJP=!=EU%W\=0EG\T_\=>IIZT"Y=K]KN"_%=WUM-1P0=\MMU@2<>\5NN0
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M1F8 :4.,L5EX:I:+S4OD:["*SCTH;).*!BS<;-^)NAHK:_:)S 29>#J#'
M@ "  '$59G&5C66$:!J4CECW:7"3(DME:H.1GCR]:UB0@"R*:X607QG0:K2.
MB 1L>(>"_0  @ "  &S%@ME2>V&"@LU5YU5(@O19+$?+@SE</3C6@Z%? 2?9
MA'AA+!+TAKMAE0  @SIEK@  @ !\ VN6?X1:3F"0?\%=(51F@ =?T$<0@%5B
M4SA#@+EDD"=T@6MF1!+7@OMF7P  @0EJ8@  @ !_-FJ$?%-B(U]O?,MD7E-V
M?3)F?$8N?9!H;C>+??AJ)R;J?HIK9Q*4?XEK/P  @ !O>@  @ "  &EM>69I
M^%Y.>@1KH5)1>H5M+45+>O=NF#:_>VAOSB9,>]MPH1(Y?(]P2   @ !T_@
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MAEJ^<2B0ZD[K<>"/VT(3<DN.LS0+<GZ. B0O<B&.-A$1<S^*\   @ "
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M/5).@1)P<4;T@1QQA3J+@15R;RS @2=S+1QG@8YS8PEA@>-SB@  @ !\K
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M/4J,E?%353^)E4]62C,FE0)8^B3/E7=;%A+OF%);J &"E*5=C0  @ !M%
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M@$:9B6=T7#O2B/UU#2_JB(QUCR)IB&AUUQ'BB1]UB )%AE5X2@  @ "
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M_CWXGNQ7=S-XGAI9Q2>/G:];O!E%GJ%<V BGGW-=60  CMQD?@  @ !U40
M@ "  $:;G0U;G3TTG"U=K#+"FV]?CB;;FOEA)!C#F[UAZ@B7F\YB4   C$-I
M40  @ !YJ0  @ "  $8'FCQB.CR$F6]CW#'VF+QE5B9 F$=FBQA'F.UG!@B
MF$QG7P  B=YN?   @ !]@   @ "  $5DE[AHZ#O=EPQJ*3%>EEAK0"6HE=)L
M"A?[EDQL2PAUE0]LKP  A\9T+P  @ "     @ "  $3%E9-OOCM*E0IPIS#D
ME%MQ7R5,D[YQTQ>XE !QT B2DBER9   AA!Y9P  @ "     @ "  $0[D\)V
MG#K/DUIW.3""DJYWEB3XD@%WO!=HDAYWF0B"C])XFP  A+)]R@  @ "
M@ "  $/)DD%]D#IMD?9][3 RD4]]^"3#D(A]VA="D'-]R A2C?!^>   @T6
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M56AZ$#,75F9ZLQP*6--[*@&Q?21]B)5G/:F ?H=K0M2 ;'B;1XN 7&C#2]R
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MZX!'4'-LIW'U5 %N5F*T5U)O\E(I6EEQ>$!J7*]RYRT370IT&!4X8;AT<P
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M'GL<0PR8%FU61XJ5]5Z&2Y*3\DZ@3PJ213V"4461'2KA4*V1$Q/?7FF-0
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MB'2J4_1SJF=!5RETN5C46@]ULDE<7)]VG3A,7DMW<25G78-X"0U^:3%X.@
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M$W &:PU1_&*Z;+=5TE1A;EA9@T3&;]U<^S./<2M@$Q_4<:QB.0<S=[9C$
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M(6E"6&EYQURP6RMZ3D\1799ZO$!47XE[(C '8%A[@QU/8(E[NP;6=')\Z@
M@ "  '/]4I&!N6A@5<^!QEOA6+&!IDY06S*!<S^@72:!3R]U7<2!2QT,7GZ!
MB ;8=&^!:0  @ "  ',]4$.*.6>O4Z.)N5LV5IZ(^$VS62J()S\'6Q:'AB[>
M6WR'01R=7.2'Q0;3='B$G0  @ "  '*S3G"2FF<M4>V1HEJP5/602TTO5X*.
MXCZ866&-TBZ*692->1Q 6YZ-&0:==-.$>0  @ "  '#1<7--XF4&<I-1I%AX
M<\U554K1=098WCO-=BU<("KG=T->V1:=>#!@%@"G?N9B6@  @ !XVF\/;.M5
MW&.[;FI9$U=?;]Q<+DGI<39?(3L-<FIAT"I2<UID Q9#= EDUP#.?J1G(0
M@ !\A&V6:*==]V)2:GA@D58V;"-C$4C8;9UE:3HF;MUGB"F:;Y]I-Q7'<'UI
MK0#@?H9L*@  @ !_O&PU9+1F%V#X9L1H$E3B:)QI]T?>:C9KO3E&:X1M32CP
M;!%N@A5=;6YNJ0#S?F5QE@  @ "  &KC82-N1E^X8V9OI%.[961P[4;*9Q=R
M%CBC:&YS(BAM:,-SYQ4;:LESV@$3?BYW'@  @ "  &G%7@-V@%[(8'9W4%+G
M8I9W_T7T9%QXD#?-9:-Y$2?99:IY>!2N:)IY9P$2?C![]   @ "  &C<6TM^
MJUWM7>-^]%(;8!]_#$4V8?)_"S<;8RM_$R='8MY_+Q1Q9KM_9@$D?A-_^@
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M@U==<NY?%TON=!)AD#\O=0]CUS#Z=>9ET""!=GAG'@Q\>4%G&@  @ !O5@
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M,E*D9&V#04=]9B&#!SM#9TR"LRVK9[."BAWL9NJ"MPN*;ER">P  @ "
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M]4LQ>))C_4!6>55EY#18>?=GFB:(>G]HYA73>OAI+P1S?=QJ;P  @ !X(
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M\D=O; &&Z3S<;4&&>#$Y;<Z%\R01;62%VQ00;J2%N 11>+6"ZP  @ "
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M/#\G?X]GSC3"?_YI-RD>@$]J5QN5@,%J^ L[@6!J_0  @ !P>0  @ !^O@
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MJS>RF*U+Y2VCF)1.U"&JF5%1.Q)YG#)24P-2F;Y48   A+)?B@  @ !P#0
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M73*FB(=J@2B0B.5K:QT&B4)K\0\_B:1KU@*FAP-N,   @ !Y.P  @ "
M@ "  #L5A2EP*3'TA?YP[R?XAG=Q>1R-AK]QM [GAJYQA@*6A,5T4P  @ !]
MF   @ "     @ "  #I\@KMW"C%=@\]W?"=VA&5WKAPNA)=WJ ZCA$EWD@)N
M@P)Z*P  @ "     @ "     @ "  #H-@*I^)S#G@?9^3R<+@JQ^,1OC@LQ^
M 0Z1@EQ^+@*)@8A^_P  @ "     @ "     @ "     __\  /__  #__P
M;69T,@     $ PD   $                    !
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MY+5^8XELS$!^78?,LYI^;H9FFMA^F(5#@AA^V81/:5I_+X-G4*Y_KX*A.!2
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MS@6"),#BM\:!5[E3H4J O['ZBM" 8:J[=&N +J-<7BF !YN52 * !Y,[,A>
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M@Z*N7_)YJIK\25YZ]I*[,OQ\=(F,YR=T5=)!T/9TV<F;NDQU:L#_HVYV)+B
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MMYR%BK8!I "$8Z_5D 2#:JFA>_R"JJ-W: N"%)TR5&F!AY:E00N!'H^G+E:
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M 82LHL^CY:66DXJ@%Z&D@]2<5IVT<\^8KYG.8\:5(I7R4^V1GY()1)>. HX
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MPYI_&7,YKX!_*'1.FLE_0'5HA:I_9':7<&)_EG?E6S-_V'E.1AZ /GKU,7Z
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M>)6 GHXV94N <8O34CN 48E2/VV 4X:@+6: <8.5P?6!VZ'UL#N!,IZ;G=*
MHILDBMN -)>D=[!_Z90I9(A_P)"N4:E_MXT;/PE_SHDZ+3=__X3DP1*!/:N;
MKUF F*=BG.V !*+VB?E_EYYQ=N=_5YGR8^5_.I5E42Y_,Y"M/K=_7HN=+1!_
MH(8)P&2 QK4JKJ: ); -G"U_BZJAB39_%J4)=C)^V9]X8T=^S)G74+A^TI0
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M''K+0N^.W7O,-$&+AGT&)LN("'Z G)F@R7_$CFJ=CG]I?\>:8'\B<(Z73'\
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MFG:#%9W-BGN"2)J*>>Z!EY<9:3F!#I.C6)B IY B2%F 5(R#.&^ .(BB*:6
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M-R.!P'GY*&N!Z'P^H["!P'=%E6B!<'@)AG^!(WB[=L" Z7EO9I^ OWHO5EJ
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MAK>%#92V>/6$&9)Z:J:#,Y *7#>"<8V33>.!T(L80 B!0XB0,J" [(7=)H^
MJ8,,DT>%7YZ!AC*$>9OB>&B#@9C3:A^"DY5^6[F!U)(A36Z!1HZ\/[B QHM*
M,HJ >(>I)IR 2X/ODNR$[Z8ZA<F$#J+E=^^##9[W::6"$YJO6U.!3Y9D32.
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M>9=\LVS(;:!] FZT8/-]7'"=4_-]R'*91NE^472Q.EY^]';H+G!_Q7E5(^.
MO7OV@_-Z+G++>(EZJ'04;(]['G5-8"Y[F'9^4TM\-'>Z1G1\['D*.A]]OWIN
M+F=^P7OU)!-_Y'V7@O)X1'J]=Y!XX'M9:Z9Y=7O87U5Z#WQ%4LAZQWRZ1A-[
MKGT[.>U\K7W(+F-]W7YF)#Q_*G\.@A5VO(*>=MAW<8*1:P!X&8)37JEXR8'U
M4B9YG(&81:EZG8%&.:I[PX#Y+E!]&X"J)%]^C8!8@6%U>HI.=B9V08F5:E=V
M]HB47@]WN(=J49QXHX8\14)YOH42.7QZ^8/J+DA\=8*S)'M^"X%T@-5T>9'
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MWV57?"=C5VA,:YQF]&M)6NAJQFYA2HQNT'&B.J5S-'4T*_=W\GD^J+U59VF
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M695V9DIBTI*&6-!FDH^;2V1JHHRR/HIN[(G ,DMS@H:V)W)X)X.QB@=RME6
M?DQSWEEQ<>=U*5U/9-!VCF$C5T9X"V4(2:9YK&D9/'I[=6UA+]=]A7(1)(%_
MU'='B+EO3UX%?35PV6$O<.5R;&1*8_5T#F=B5I9US6J*22-WMVW7/"=YRW%2
M+\)\)G4B)+=^M7E6AWUL-&9[>_!N#FCC;]YOWFL_8P=QOFV75=ISOF_]2)MU
M[G*".]AX2G4J+Z]Z['@3).9]N'M AC9I8F[C>K!K?7"-;JYMB'(G8C1OGG.^
M52QQWW5:2"5T47<..YIV\7C=+Z1YU7K:)0]\W'T"A/UF]7<Q>:1I0G@E;:UK
M?WC_82]MQGG)5'!P/'J91XMR\'M\.SEUS'QN+X1XZ'UZ)3)\'7Z9@_IDZG]G
M>*YG7G^D;,QIPG^W8&1L-W^R4\-NV7^N1QQQMW^W.O9TRG_++W!X&W_E)4][
M?8  @REC-H=I=^MERH;O;!EH388X7\)JY(5?4S-MKX2'1K)PMX.T.LAS[8+H
M+V=W;((4)6AZ]X$W@H9AU8\K=U%DA(W[:X-G'HQV7SIIS8K$4K=LN(D31D9O
MYX=F.H9S0(6]+UMVW(0!)7MZBH(_@A%@QY:;=MUCBI2\:PMF,I)G7LAH[X_7
M4EMK[8U*1@9O-HK".DYRL(@X+SEV;X6@)8MZ,X,8?M)Z?%6?= 1[ 5E]:)M[
ML%U17(]\<V$E4"!]0V400ZA^+&DJ-[%_-&U[+%> =7(T(EB!YW=??:9W2EV=
M<Q-X*V#'9[]Y%F/H6]UZ#6<-3Y=[%FI'0TM\0&VI-X1]BW$Z+&)_$74?(J2
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M21N"H64$/=&"OVDP,Q:"\6V1*0N#3W)4(&.#U'=S<KY_DET<:0Q_RF!&7J^
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MT'VN6W6("W5A4WN'?G9\2T>&NG>(0N^%T'B5.J:$X'FV,I^#_WKV*S&#-WQ
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M/EN#;F(--0.#FV;6+$V#VVO8)&*$0W$U'=6$Q';'84-_:E>W60-_W5M/4$>
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MG7[F-S&!;'[Y,22!#W\P*U2 RG]\)BB EG_1(9J GH ;'@6 Q(!4  #__P
M__\  /__  !M9G0Q      ,$(0   0                    $
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M:Y!ZT7"4=\]TEW7.=YASS7F:<LU[FW',?9MPRW^<;\N G6_+@)UORX"=;\N
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M0/^B25/\IT=A\JU&<.FR1G_@MT>,V;M.E]._5Y_0Q6.DQ<!PK;JX>;>PLH#
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MBZF*S(2GDL^ IIS0@*.ESX"AILZ H:;.@*&FSH"AILZ H:;.@*&FSH"AILZ
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MY)EGA]R6<9+5DWN<SY"$I,N.C*O(BI"PQ8>4M,.$F+?"@9NYP7^>NL%]HKO
M>Z:\P'FKO;]XLKV[>+.]NWBSO;MXL[V[>+.]NWBSO;MXL[V[>+.]NWBSO;MX
ML[V[>+.]NWBSO;MXL[W_G#@:_YI&+?^744'_FE-/_IQ57O6<6FSLFU]ZY)EG
MA]R6<9+5DWN<SY"$I,N.C*O(BI"PQ8>4M,.$F+?"@9NYP7^>NL%]HKO >Z:\
MP'FKO;]XLKV[>+.]NWBSO;MXL[V[>+.]NWBSO;MXL[V[>+.]NWBSO;MXL[V[
M>+.]NWBSO;MXL[W_G#@:_YI&+?^744'_FE-/_IQ57O6<6FSLFU]ZY)EGA]R6
M<9+5DWN<SY"$I,N.C*O(BI"PQ8>4M,.$F+?"@9NYP7^>NL%]HKO >Z:\P'FK
MO;]XLKV[>+.]NWBSO;MXL[V[>+.]NWBSO;MXL[V[>+.]NWBSO;MXL[V[>+.]
MNWBSO;MXL[W_G3@:_YI%+O^74$'_FU%/_YU47?6>6&OLG5UYY)MDAMR8;I+5
ME7B<T)*!I,N/B:O'C8^QQ8F3M<.%E[C"@IJZP7^>N\!]HKV_>Z>^OWFMOKMX
ML;ZV>;*^MGFROK9YLKZV>;*^MGFROK9YLKZV>;*^MGFROK9YLKZV>;*^MGFR
MOK9YLK[_G3@:_YI%+O^83T#_G5!._Y]27/:@56KMH%IXY9]@A=V<:I'6F'.;
MT)5]I,N2A:O'CXVQQ(R1ML*'E;G!@YF[OW^=OKY]HK^]>JC O'FOP;1YL,&P
M>K# L'JPP+!ZL,"P>K# L'JPP+!ZL,"P>K# L'JPP+!ZL,"P>K# L'JPP+!Z
ML,#_G3<:_YM%+O^93D#_GDY._Z%06_>B4VGNHU=WYJ)=@]Z?9H_7G&^:T9AY
MH\N5@JO'DHFQQ(Z/ML*)D[J_A)B]O8"=P+Q]H\*[>ZK$M'JMQ*U[KL.J>Z_!
MJGNOP:I[K\&J>Z_!JGNOP:I[K\&J>Z_!JGNOP:I[K\&J>Z_!JGNOP:I[K\'_
MGC<:_YM$+O^:34#_GTU-_Z).6_>D46COI55UYZ5:@M^C8HW8H&N8TIQUH<R9
M?JG(E8:PQ)*-ML&,D;N^AI:_O(&<P[I^I,6W?*O'K7NKQJ=\K<2D?:[#I'VN
MPZ1]KL.D?:[#I'VNPZ1]KL.D?:[#I'VNPZ1]KL.D?:[#I'VNPZ1]KL/_GC<:
M_YM$+O^;3$#_H$Q-_Z1-6OBF3V?PJ%-TZ*A7@."G7HS:I&B6TZ%QG\Z=>J?)
MF8.OQ96*M<&/C[N]B97!NH6=Q+:"I,>P@*K(IWVJR*)^K,6??Z[#GW^NPY]_
MKL.??Z[#GW^NPY]_KL.??Z[#GW^NPY]_KL.??Z[#GW^NPY]_KL/_GC<:_YM$
M+O^<2S__H4I,_Z5+6?FH3F;QJE%SZ:M5?^*K6XK;J664U:9NG<^C=Z7*GX"L
MQ9F&M+^3C+RXC9/!LHF9Q:Z&H<BJA*G)H8"IRIR!K,:;@:W$FX&MQ)N!K<2;
M@:W$FX&MQ)N!K<2;@:W$FX&MQ)N!K<2;@:W$FX&MQ)N!K<3_GC8:_YQ$+O^<
M2C__HDE,_Z9*6?FI3&7QK$]QZJY4?>.O68C=KF*1UJUKFM&J=:++I7VKP9V#
MM+F6B;RRD9#!K(R6QJ>)G<BCAZ;*FX.HRYB#J\>6A*W%EH2MQ9:$K<66A*W%
MEH2MQ9:$K<66A*W%EH2MQ9:$K<66A*W%EH2MQ9:$K<7_GC8:_YQ#+O^=23__
MHTA+_Z=)6/JK2V3RKDYPZ[%2>^2S5X7?M&".V;-JEM&Q=9[&J'NKO*"!M+.:
MA[RLE(W"II"4QJ"-F\F<BZ3+EH>HRY.'J\B2AZS%DH>LQ9*'K,62AZS%DH>L
MQ9*'K,62AZS%DH>LQ9*'K,62AZS%DH>LQ9*'K,7_GS8:_YQ#+O^>2#__HT=+
M_ZA(5_NM26/SL$QO[+10>>:X5H/ANUZ+VKMJDLVT<Y[!JWFJMZ1_M*Z=A+RF
MF(K!H)21QIJ1F,F6CZ'+D8RHS(^*JLB.BJS&CHJLQHZ*K,:.BJS&CHJLQHZ*
MK,:.BJS&CHJLQHZ*K,:.BJS&CHJLQHZ*K,;_GS8:_YQ#+O^>1S[_I$9*_ZI&
M5ORN2&+TLTMM[KA/=^B]57_AP5Z&UL!LCLBW<9V]KG>JLJ=]M*FA@KNAG(C!
MFIB/QI26ELF0E)_+C)*HS(J/JLF*CJS&BHZLQHJ.K,:*CJS&BHZLQHJ.K,:*
MCJS&BHZLQHJ.K,:*CJS&BHZLQHJ.K,;_GS8:_YQ#+O^?1C[_I45*_ZM%5?RP
M1F'VMDEK\+Q.=.?"57O?R&& T<-JC<2Z<)VXLG6IK:M[LZ.E@+N;H8;!E)V-
MQ8Z;E,B*F9W*AIFHRX:4JLF&DJO&AI*KQH:2J\:&DJO&AI*KQH:2J\:&DJO&
MAI*KQH:2J\:&DJO&AI*KQH:2J\;_GS4:_YU"+O^@13W_IT1)_ZU#5/ZS1%_W
MND=H[\%-<.7)5G7<SF1ZS,9IC;Z^;IRRMG2HI[!YLIZK?KJ5IH3 CJ.+Q(BA
MDL>$GYK)@)^GRH&:JLB"F*O&@IBKQH*8J\:"F*O&@IBKQH*8J\:"F*O&@IBK
MQH*8J\:"F*O&@IBKQH*8J\;_H#4:_YU"+O^A1#W_J$)(_Z]!4_^V0EWWOD9E
M[,=-:^/26&W6TV%ZQ\IGC+G";9NLO'*GH;9WL9BQ?;F/K8*^B*J)PX*HD,9]
MIYG(>J>ER7NBJ\A]GJS&?9ZLQGV>K,9]GJS&?9ZLQGV>K,9]GJS&?9ZLQGV>
MK,9]GJS&?9ZLQGV>K,;_H#4:_YU"+O^B0CS_JD!'_[(^4?VZ0%GSPT1@Z,].
M8]_<66?/V&!YP,]FBK+(:YJFPG"FF[QVKY&X>[>)M8&\@K*'P'VPCL-XKI;%
M=JVAQG6LK,9WIJW%=Z:MQ7>FK<5WIJW%=Z:MQ7>FK<5WIJW%=Z:MQ7>FK<5W
MIJW%=Z:MQ7>FK<7_H#0:_YY!+O^D0#O_K#U%_[4[3O>_/E7LRT19X=I/6M3?
M46S&VEI]N--BBZO.:9B?QG&DE<!WK8Z[?K2'MX.Y@;2'O7RRC+]YL9/!=K";
MPG2PIL)RL*W"<K"MPG*PK<)RL*W"<K"MPG*PK<)RL*W"<K"MPG*PK<)RL*W"
M<K"MPG*PK<+_H3,:_YY!+_^G/3K_L#I#_;HX2O#&.T_CU45.U>%&7\CB2W&Z
MW5*!K-5;CY_,9IN6QG"DC\!XJXJ\?[&$N8.U@+>'N'RVB[MYM)"\=[27O7:T
MH;UTLZ6^=+.EOG2SI;YTLZ6^=+.EOG2SI;YTLZ6^=+.EOG2SI;YTLZ6^=+.E
MOG2SI;[_HC,:_Z ^+O^J.3?_M#4_]L U1.?/.477WSQ0R>=!9+OE1G:LW$Z%
MG]-:DI7,9YR.QG&DBL)YJH6_?JZ O(*R?;J&M'JYBK9WN(ZX=;>3N7.WFKES
MMZ"Y<[>@N7.WH+ESMZ"Y<[>@N7.WH+ESMZ"Y<[>@N7.WH+ESMZ"Y<[>@N7.W
MH+G_HS(:_Z,Z+/^N-#3^NC$Z[<HP.]K=,C_*YSA5O.P]::WE1'F?VTZ'E--<
MDHW,:)N(R'*AA,1YIH#"?:I\P(&M>;Z%KW>]B+!TO(NR<KN0LW"[E;1ONIJT
M;[J:M&^ZFK1ONIJT;[J:M&^ZFK1ONIJT;[J:M&^ZFK1ONIJT;[J:M&^ZFK3_
MI# :_Z<U*O^T+S#TPRHQWM@K+<SF+D6]\C5:K>X[;)_D1'N3VU&'B]1>D(;/
M:IB"RW.=?LAXH7K&?*1WQ("F=<.#J'/"AJEQP8FK;\"-K&W DJULOY6M;+^5
MK6R_E:ULOY6M;+^5K6R_E:ULOY6M;+^5K6R_E:ULOY6M;+^5K6R_E:W_I2\:
M_ZTM)?R\)RCET"$DSN0D,[[Q+$JN^#-=H.T];9/D1WJ*W52%@]=AC'_2;))[
MSW*7=\UWFG3+>YQRRGZ><,F!H&[(A*%MQX>B:\:*HVG&CJ1HQ9&E:,61I6C%
MD:5HQ9&E:,61I6C%D:5HQ9&E:,61I6C%D:5HQ9&E:,61I6C%D:7_IRP:_[4E
M'^S)&AS0XADAO_ B.*_]*TV@^#5>D^Y!;(GF37>!X%B ?=QDAGC8:XMSU7&.
M<--UD6[2>9-LT7R4:M!_EFG/@I=HSX689LZ(F67-C)IDS8Z:9,V.FF3-CIID
MS8Z:9,V.FF3-CIIDS8Z:9,V.FF3-CIIDS8Z:9,V.FF3-CIK_KB06]<$7%-3?
M#A# [Q@FL/TC/*'_+4Z4^3I=B?%':('K4G%ZYEUX=.)D?7#?:X%MW7"$:MQT
MAFC;>(AFVGN)9=E]BF38@(MBV(.,8=:%C6#6B8Y?U8N.7]6+CE_5BXY?U8N.
M7]6+CE_5BXY?U8N.7]6+CE_5BXY?U8N.7]6+CE_5BX[^N18-U-(+!L+N#A:Q
M_!DJHO\E/93_,DR)_$!9@?9-8GKP6&ES[%]O;.ED<VCG:G9FY6]Y9.1S>F+C
M=GQAXWE]8.)[?E_A?GY>X8!_7>"#@%S@A8%;WXB!6]^(@5O?B(%;WXB!6]^(
M@5O?B(%;WXB!6]^(@5O?B(%;WXB!6]^(@5O?B('4R D#Q-<*![+[$!FC_QPK
ME?\H.XK_.$B!_T52>OQ26G+W66!K]%YD9O)D:&+P:6I@[FUL7NUQ;5SM=&Y;
M['9O6NQY<%GK>W%8ZWUQ6.I_<E?J@G-6Z81S5NF$<U;IA'-6Z81S5NF$<U;I
MA'-6Z81S5NF$<U;IA'-6Z81S5NF$<U;IA'/$S0@!M-T("Z3_$AJ7_Q\JB_\N
M-H'_/4%Y_TI)<?]24&G_6%5C_5U87_MC6USY9UU:^&M?6/=N8%?W<6%6]G1A
M5?9V8E3U=V-3]7EC4_1\9%+T?F11](!E4?2 95'T@&51](!E4?2 95'T@&51
M](!E4?2 95'T@&51](!E4?2 95'T@&7_EC,4_Y5#)?^243?_EU-%_YE74_V9
M6V#UF&%M[95H>>62<H3?CWR.VHR%EM6'BYS1@Y"ASX"5ILU]FJG+>YZKRGFA
MK<EWI:_(=:FPQW2NL<=SL[+&<[JRP76[LL%UN[+!=;NRP76[LL%UN[+!=;NR
MP76[LL%UN[+!=;NRP76[LL%UN[+_EC,4_Y5#)?^243?_EU-%_YE74_V96V#U
MF&%M[95H>>62<H3?CWR.VHR%EM6'BYS1@Y"ASX"5ILU]FJG+>YZKRGFAK<EW
MI:_(=:FPQW2NL<=SL[+&<[JRP76[LL%UN[+!=;NRP76[LL%UN[+!=;NRP76[
MLL%UN[+!=;NRP76[LL%UN[+_EC,4_Y5#)?^243?_EU-%_YE74_V96V#UF&%M
M[95H>>62<H3?CWR.VHR%EM6'BYS1@Y"ASX"5ILU]FJG+>YZKRGFAK<EWI:_(
M=:FPQW2NL<=SL[+&<[JRP76[LL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LL%U
MN[+!=;NRP76[LL%UN[+_EC,4_Y5#)?^243?_EU-%_YE74_V96V#UF&%M[95H
M>>62<H3?CWR.VHR%EM6'BYS1@Y"ASX"5ILU]FJG+>YZKRGFAK<EWI:_(=:FP
MQW2NL<=SL[+&<[JRP76[LL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!
M=;NRP76[LL%UN[+_EC,4_Y5#)?^243?_EU-%_YE74_V96V#UF&%M[95H>>62
M<H3?CWR.VHR%EM6'BYS1@Y"ASX"5ILU]FJG+>YZKRGFAK<EWI:_(=:FPQW2N
ML<=SL[+&<[JRP76[LL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!=;NR
MP76[LL%UN[+_EC,4_Y5#)?^243?_EU-%_YE74_V96V#UF&%M[95H>>62<H3?
MCWR.VHR%EM6'BYS1@Y"ASX"5ILU]FJG+>YZKRGFAK<EWI:_(=:FPQW2NL<=S
ML[+&<[JRP76[LL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!=;NRP76[
MLL%UN[+_EC,4_Y5#)?^343?_EU-%_YE64OV96V#UF&!M[99G>>63<83?D'N.
MVHV$EM6(BIS1A)"BSX"5ILQ]F:G+>YVLR7FAKLAWI:_(=JJQQW2NLL=SM++$
M=+JROW6ZLK]UNK*_=;JROW6ZLK]UNK*_=;JROW6ZLK]UNK*_=;JROW6ZLK]U
MNK+_EC,4_Y9#)?^54#?_F5%$_YM44OZ<6%_UFUUL[9ED>.:6;(/?DW:-VH^
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M8>;$5F?>R6)MSL%G?\&Y;8ZVL7*;JZIXIJ*E?JZ9H(2UDIV+NHR:D[Z'F)O
MA)>DPH*6K\*#D[# A)&ROH21LKZ$D;*^A)&ROH21LKZ$D;*^A)&ROH21LKZ$
MD;*^A)&ROH21LK[_FS,4_YI!)O^?0C/_ID ]_ZU 1_^T0D_WNT=7[<--7>3,
M6&#9S6!LR<5F?KR]:XVPM7&:I:]VI9RJ?*V3IH*TC**)N8:@D+V!GIF_?9ZB
MP7N>K\%]F;# ?Y:ROG^6LKY_EK*^?Y:ROG^6LKY_EK*^?Y:ROG^6LKY_EK*^
M?Y:ROG^6LK[_G#,4_YI!)O^@03+_J#\\_[ ^1?^W04WTP$53ZLE.5N+56E?2
MT5YKQ,ED?;;!:HRJNV^9G[5TI):P>JR-K("RAJF'MW^GCKMZII:^=Z6@OW2F
MK;]WH;&_>IVROGJ=LKYZG;*^>IVROGJ=LKYZG;*^>IVROGJ=LKYZG;*^>IVR
MOGJ=LK[_G3,4_YM!)O^B/S'_JCPZ_[,\0ON[/DGPQD1-YM)/3=S<5U;,U5UJ
MOLUC>[#':(NDP6V7F;QSHH^X>*J&M'ZP?[*%M7FPC+ATKY6[<:Z?O&ZOJ[UQ
MJK.\=*6SO'2EL[QTI;.\=*6SO'2EL[QTI;.\=*6SO'2EL[QTI;.\=*6SO'2E
ML[S_G3,4_YM )O^D/##_K3DX_[8Y/_7!/$/ISD1$WMU-1]+@4UC%VUQHM]-A
M>JG-9HF<R&N5D<1QGXC =J=_O7VM>+N$L7.ZB[1ON)2W;+>=N&JWJ+EIMK:X
M;:^UN6VOM;EMK[6Y;:^UN6VOM;EMK[6Y;:^UN6VOM;EMK[6Y;:^UN6VOM;G_
MGC(4_YT^)?^G.2[_L38U^[PV.NW).CS@VD0ZTN)'3,?B35ZYWE1NK-E;?)_4
M8HB4T&B3BLQOFX+'=Z)\PWZH=L"$K'*^BJ]OO)&Q;;R8LFN[H;-JNZVR9[JV
MM&>ZMK1GNK:T9[JVM&>ZMK1GNK:T9[JVM&>ZMK1GNK:T9[JVM&>ZMK3_GS(4
M_Z Z)/^J-"S_M3(Q\\,R,^/4.##3X3P_QNA"4KGE2&.LXDURG]]4?Y/978J)
MTF>3@\UPFGW)=Y]XQGVD=,2#IW#"B*ENP8ZK;,"4K&J_FZUIOZ6M:+^NK6B_
MKJUHOZZM:+^NK6B_KJUHOZZM:+^NK6B_KJUHOZZM:+^NK6B_KJW_H# 4_Z,V
M(O^O,"C[O"TKZ,TL*-7@,##'Z3A$N>P^5ZSI16>>YTMUDN!3@(G97HF"U&B1
M?-!QEGC,=YMTRGV><,B"H6['AZ-KQ8NE:<20IFC$EJ=FPYZH9<.EJ&7#I:AE
MPZ6H9<.EJ&7#I:AEPZ6H9<.EJ&7#I:AEPZ6H9<.EJ&7#I:C_H2\4_Z@O'_^U
M*B+PQB0AV-TC(,CI+36Z\C5)K/$\6I[P0VF2Z$QUB.%5?X';88=[UVJ-=M-Q
MD7+1=Y5OSWR7;,V FFK,A9MHRXF=9LJ-GF7)DI]CR9B@8LB>H6+(GJ%BR)ZA
M8LB>H6+(GJ%BR)ZA8LB>H6+(GJ%BR)ZA8LB>H6+(GJ'_HRT4_ZXI&OB_(!K>
MUA@3R>@B);KT*SJL^#1-GO<\7)+Q1FF(Z5!S?^-9>WK?9()TW&N&<-EQBFW6
M=HUJU7N/:--_D6;2@Y)DT8>48]&*E6'0CY9@SY277L^9F%[/F9A>SYF87L^9
MF%[/F9A>SYF87L^9F%[/F9A>SYF87L^9F%[/F9C_IR@2_[<?$N;.$0W+YA46
MN_0A*JS^*SZ>_S1.DOH_7(CR2F9_[%5O>>A>=7+D9'MNX6M^:M]P@6C>=81E
MW'F%8]M]AV+:@8A@VH2)7]F'BEW8BXM<UY",6]:4C5O6E(U;UI2-6]:4C5O6
ME(U;UI2-6]:4C5O6E(U;UI2-6]:4C5O6E(W_L!X+[<8.",W;"PB[\Q4:K/\A
M+I[_+#^2_S=-A_U$6'_V3V%X\5EH<>U?;6KK9'%GZ&IT9.=O=V+E='E@Y'AZ
M7^-[>UWC?GQ<XH%]6^&$?EKAB']9X(R 6."/@5C@CX%8X(^!6."/@5C@CX%8
MX(^!6."/@5C@CX%8X(^!6."/@5C@CX'SO0T$S,\) ;WE# RL_Q<>GO\D+Y+_
M+SV'_SU)?_])4GC\5%IP^%I?:?1?9&3R96=A\&II7N]N:USN<FU;[79N6NQY
M;UCL?'!7ZWYP5NN!<57JA')4ZHAS4^F+=%/IBW13Z8MT4^F+=%/IBW13Z8MT
M4^F+=%/IBW13Z8MT4^F+=%/IBW3,Q@@ O=0( ZWU#@^?_QH?D_\G+8C_-#E^
M_T)#=_]-2F[_4U!G_UE58OQ>6%[[9%M;^6A=6?AL7E?W<&!6]W-A5?9V8E3U
M>&)3]7MC4O1]9%'T@&10\X-E3_.&9D_SAF9/\X9F3_.&9D_SAF9/\X9F3_.&
M9D_SAF9/\X9F3_.&9D_SAF:]RP8 KML&!)__$!"3_QT=B/\J*'[_.#)V_T0Z
M;?]+067_449?_U=)6_]=3%C_8DY5_V904_]J45+_;5)0_W!33_]R5$[_=51-
M_W=53?]Y54S^>U9+_GY72OV!5TK]@5=*_8%72OV!5TK]@5=*_8%72OV!5TK]
M@5=*_8%72OV!5TK]@5?_C2T._XP^'?^*3"[_DE,[_Y172/^57%3]DV)@]9%J
M:^^-<G;IB7Q_Y(6$AN" BXW<?)&2VGF7EMAVG)G5<Z";U'&EG=-OJ9_2;JZ@
MTFVSH=%LN:+1:\"CS6S%H\ANQJ+(;L:BR&[&HLANQJ+(;L:BR&[&HLANQJ+(
M;L:BR&[&HLANQJ+_C2T._XP^'?^*3"[_DE,[_Y172/^57%3]DV)@]9%J:^^-
M<G;IB7Q_Y(6$AN" BXW<?)&2VGF7EMAVG)G5<Z";U'&EG=-OJ9_2;JZ@TFVS
MH=%LN:+1:\"CS6S%H\ANQJ+(;L:BR&[&HLANQJ+(;L:BR&[&HLANQJ+(;L:B
MR&[&HLANQJ+_C2T._XP^'?^*3"[_DE,[_Y172/^57%3]DV)@]9%J:^^-<G;I
MB7Q_Y(6$AN" BXW<?)&2VGF7EMAVG)G5<Z";U'&EG=-OJ9_2;JZ@TFVSH=%L
MN:+1:\"CS6S%H\ANQJ+(;L:BR&[&HLANQJ+(;L:BR&[&HLANQJ+(;L:BR&[&
MHLANQJ+_C2T._XP^'?^*3"[_DE,[_Y172/^57%3]DV)@]9%J:^^-<G;IB7Q_
MY(6$AN" BXW<?)&2VGF7EMAVG)G5<Z";U'&EG=-OJ9_2;JZ@TFVSH=%LN:+1
M:\"CS6S%H\ANQJ+(;L:BR&[&HLANQJ+(;L:BR&[&HLANQJ+(;L:BR&[&HLAN
MQJ+_C2T._XP^'?^*3"[_DE,[_Y172/^57%3]DV)@]9%J:^^-<G;IB7Q_Y(6$
MAN" BXW<?)&2VGF7EMAVG)G5<Z";U'&EG=-OJ9_2;JZ@TFVSH=%LN:+1:\"C
MS6S%H\ANQJ+(;L:BR&[&HLANQJ+(;L:BR&[&HLANQJ+(;L:BR&[&HLANQJ+_
MC2T._XT^'?^,3"[_E%,[_Y561_^66U3]E6%@]I)H:^^/<'7IBWI_Y(>#A]^"
MBHW<?I"2V7J6E]9WFYK5=*"=TW*EG])PJ:'1;JZBT&VTH]!LNJ30;,*DRF[$
MI,1OQ*3$;\2DQ&_$I,1OQ*3$;\2DQ&_$I,1OQ*3$;\2DQ&_$I,1OQ*3_CBT.
M_XX^'?^.2R[_E5$Z_YA41_^86%/^F%Y?]I5D:N^2;'7ICG9^Y(J A]^%AX[;
M@(Z4V'R4F-5YFIS3=I^?T7.DHM!QJJ3/;Z^ESFZVILYMO:?*;L*GPW#"I[UQ
MPJ>]<<*GO7'"I[UQPJ>]<<*GO7'"I[UQPJ>]<<*GO7'"I[UQPJ?_CRT._XX^
M'O^02BW_ET\Z_YE11O^;5E+^FEM>]YAA:?"5:'3JD7%^Y(Y\AM^)A([;@XN4
MUW^2FM1[F)[2=YZAT'2DI,YRJJ;-<+&HS6^YJ<MOP:G#<<&IO'+ JK=SP*JW
M<\"JMW/ JK=SP*JW<\"JMW/ JK=SP*JW<\"JMW/ JK=SP*K_CRT._X\^'O^2
M2BW_F$TY_YM/1?^=4U'_G5A<^)M>:/&997+JE6U\Y)%WAM^,@8[;AXF5UH&0
MFM-]EI_0>9VCSG6CILURJZG,<+.JRV^]J\5ROZN]<[^LMG2^K+%UOJVQ=;ZM
ML76^K;%UOJVQ=;ZML76^K;%UOJVQ=;ZML76^K;%UOJW_D"T._Y ^'O^322W_
MF4PY_YU.1/^?45#_GU9;^9Y<9O*<8G'KF&E[Y91SA."/?8W;BH:4UH2-F])_
ME:#/>IRES7:CJ,MSJZO*<;6MQG&^K;YTO:ZV=;VNL':]KJQWO:ZL=[VNK'>]
MKJQWO:ZL=[VNK'>]KJQWO:ZL=[VNK'>]KJQWO:[_D"T._Y ^'O^522S_FTHX
M_YY,0_^A3T__HE1:^J%99?.@7V_LG69YYIAO@^"3>8S;CH*3UH>*F]*!DJ'/
M?)JFRGBBJL=UJZW#<[2OOW.\L+=UO+"P=[NPJGB[L*=YO+"G>;RPIWF\L*=Y
MO+"G>;RPIWF\L*=YO+"G>;RPIWF\L*=YO+#_D2T._Y$^'O^62"S_G$@W_Z!*
M0O^C34W_I%)8^Z578_2D76WNH6-WZ)YK@.*8=8G<DGZ2TXR'FLR&CZ'&@)>G
MP7R>K+UYIJ^Y=J^QMW:ZLJ]WNK*J>;JRI7JZLJ)[N[&B>[NQHGN[L:)[N[&B
M>[NQHGN[L:)[N[&B>[NQHGN[L:)[N['_D2T._Y$^'O^81RS_G4<W_Z%(0?^E
M2TS_IU!6_*A58?6H6VOMIV%TY:1I?MZ?<X?4F'V0RY&$FL2*C**^A).HN(":
MK;1\HK"P>JNSK7FUM*AZN;2D>[FTH'VYLYU]NK.=?;JSG7VZLYU]NK.=?;JS
MG7VZLYU]NK.=?;JSG7VZLYU]NK/_DBT._Y(^'O^81BO_GD8V_Z-'0?^G24O_
MJDY5^JM37O*L66CIK&!QXJEH>MFE<X/-G'J/Q96!FKV.B**WB)"IL827KJR
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M,?^/53S_CEM&_XMB4/^&:5G\@'%B]WM[:?-VA7#O<HYU[&Z5>>IKG'WH::.
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MG7%RM)=W?*R1?H6FC(:,H(B-D9J%E9:6@IZ:DH"GG8]_LIZ-@,&>C(#)GHN
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M5D']GE= _:980/RI6$#\J5A _*E80/RI6$#\J5A _*E80/RI6$#\J5C&N 0
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M?.!?VGW48N%]RF/@?L-DX'^]9M^ MV??@+=GWX"W9]^ MV??@+=GWX"W9]^
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M9TGEQF=(YM]G2N#L9TK?[&=*W^QG2M_L9TK?[&=*W^QG2M_L9TK?[&?_G T
MV[$& ,J]!P"_R@< M=H* *KO&06@\"@/EO U&XSP/R:"\$<Q>?!..7#O5$!H
M[UI&8>]@2UWO9T]8[VY25.]U55'P?5=.\(592_"/6TCQF5Q&\:->1/*O7T/R
MNU]"\\Q@0?/G8$'SZ&!!\^A@0?/H8$'SZ&!!\^A@0?/H8$'SZ&#>IP( R[8%
M +W!!0"RSP< I^H- 9WW' >4^"L2BO@V'('Y0"9X^D@O;_I--F?Z4SQ@^EA
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M:N-ZHVOD>:%KY'FA:^1YH6OD>:%KY'FA:^1YH6OD>:%KY'G_:"$$_V\D!?^
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M4D#M\5% [?%10.WQ44#M\5% [?%10.WQ44#M\5'4I0  Q+(# +:\ P"KR04
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M ?^9$0#SJ X U[4* ,_!"@#&Q1@ O,0J!;+".!&GOT0>GKM-*Y2X53:+M5Q
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M3$?<Q$Q&W-Y,1MKM3$38^4]#V/M/0]C[3T/8^T]#V/M/0]C[3T/8^T_;F@
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M)BK_NR<I_[XG*?^^)RG_OB<I_[XG*?^^)RG_OB>FM@  F,(  (O.  !^VP
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M6U"LP%M0K-I:3ZON6T^J^EM1IOI;4:;Z6U&F^EM1IOI;4:;Z6U&F^EO_@ D
MX9(! -&@! #&JP4 O+0$ +.] P"KQPL I,D< 9S(+ :3QSD/BL5$&8'#32-Z
MP50L<[];,VV^8CEGO&D^8KMP0UZZ=T=:N8!+5KF)3E.XE%!0N*!23;BN5$RX
MOU1+N=A42[?M5$JV^55*L_Y62K/^5DJS_E9*L_Y62K/^5DJS_E;ZAP( UI@
M ,FE P"]KP, L[@! *G"! "AS0@ FM 6 )+0* 2*SS8,@<Y!%7G,2AYRRU(F
M;,I:+6;)83)AR&@W7,=O/%C&=C]5QG]#4<6)14[%E$A+Q:!*2<6N2TC%OTM'
MQMA+1\7M2T;#^4U%PO].1<+_3D7"_TY%PO].1<+_3D7"_T[?D   S)\  +^J
M 0"SLP$ J;T" )_'!0"6T@D CMH2 (C;) * VC((>-D^$''82!AJUU ?9-98
M)5_57RI;U&<O5]1N,U/3=C90TW\Y3-.(.TK3E#Y'TZ _1=2N0$34OT%#U=A
M1-/L0$+2]D)!T?Y$0='^1$'1_D1!T?Y$0='^1$'1_D31F   PZ4  +6N  "I
MN   GL," )3-!@"*V0H A.,8 7WD)@-UY#((;N,\#V?C115AXTT;7.-5(%?C
M7214XV0G4.)K*DWB<RU*XWPP2..&,D7CD#1#XYPU0>2I-D#DN#<_Y<LW/^7D
M-S_C\S8]XOLX/>+[.#WB^S@]XOLX/>+[.#WB^SC&H0  MZL  *JT  ">O@
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M$1W_L1$=_[$1'?^Q$1W_L1&5O   AL<  'G3  !KX   7NT  %;_ P!/_PP
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M3G(E_TM]*?](B"S_1I(N_T6;,/]$HC+_0ZDS_T*P-/]"MS7_0;\V_T')-O]
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M65^,P%I?C-E97XSN65^,^UAABOU788G]5V&)_5=AB?U788G]5V&)_5?_;PP
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M2$BQ]DE(L/]*2+#_2DBP_TI(L/]*2+#_2DBP_TKBA@  SI0  ,*A  "VJ0
MJ[$  *&Z 0"8PP4 D,D0 (K)( &#R2\%>\@[#73'111NQDX;:,56(6/$72=>
MPV0K6L)K+U;!<C-3P7LV3\"$.4S CSQ*P)L^1\"H/T; N$!%P,U 1<#H/T2^
M]D%#O?]"0[S_0T.\_T-#O/]#0[S_0T.\_T/6C0  QIL  +BE  "MK@  HK8
M )B_ @"-R 8 @]$+ '_2&@!YTBH#<M(W"&S10@]FT4L58=!3&ES/6Q]8SV(C
M5,YI)U'.<2I-SGHM2LZ#,$C.CC)%SIHT0\ZH-4+.N#9!S\TU0<[H-4#-]3<_
MR_XY/LO_.3[+_SD^R_\Y/LO_.3[+_SG*E@  O*(  *^J  "CLP  F+P  (W&
M P""SP< >-D+ '/>& !NWB8":-XS!6+>/@I=WD@/6=Y0%%7>6!=1WF ;3MYG
M'DO=;R!(WG@C1MZ!)4/>C"=!WI@I/]ZF*C[?M2H]X,@J/=_C*CS=\2L[W/LM
M.MS]+CK<_2XZW/TN.MS]+CK<_2[ GP  L:<  *2P  "8N@  C<,  ('- @!V
MUP< ;N@/ &GH&P%CZ"<"7NDR!5CI.PA4Z40,3^I,#TSJ4Q))ZEL51NIB%T3K
M:AE!ZW(;/^M['3SKAAXZ[)$@..R>(3?MK"(V[;LC->[/(S3NYB,TZ_4C-.OX
M(S3K^",TZ_@C-.OX(S3K^".SI0  IJT  )FW  "-P0  @,L  '75 0!IX08
M9/,1 %[S' %9]"8"5/0P!$_U. 9+]4 (1_9'"D3V3@Q!]U4./_=<#SSW8Q$Z
M^&H3-_AS%#7X?18S^8@7,?F4&"_ZH1DN^J\:+?N^&BS[SQLK^^<;*_OK&RO[
MZQLK^^L;*_OK&RO[ZQNHJ@  FK0  (V_  " R0  =-,  &?>  !>\@@ 6?X1
M %/_&@%._R,"2?\K T7_,P1!_SH%/O]!!CO_1P<X_TX(-?]4"3/_6@DQ_V$*
M+_]I"RS_<@PJ_WT-*/^(#B;_E0\E_Z$0)/^N$2/_NA(B_\H2(O_0$B+_T!(B
M_] 2(O_0$B+_T!*<L@  CKP  (''  !ST0  9]T  %GC  !3_08 3?\. $C_
M%@!#_QX!/_\F CK_+0(W_S,#,_\Y S#_/P0N_T0$*_]*!2G_4 4G_U8&)/]=
M!B+_90<@_VX''?]Y"!O_A0@:_Y()&?^>"1C_J D7_[,)%_^W"1?_MPD7_[<)
M%_^W"1?_MPF0N@  @L4  '30  !GW   6.,  $WP  !'_P( 0O\, #S_$0 X
M_Q@!-/\? 3#_)0$L_RL"*?\P B7_-0(C_SH"(/\_ Q[_1 ,<_TD#&?]/ Q?_
M5@05_UX$$O]H!!'_<@4/_WX%#O^*!0[_E 4-_YX%#?^B!0W_H@4-_Z(%#?^B
M!0W_H@7_.2\"_SPP _]!,0/_1#0$_T0Z!O]$10C_15$,_T-=$?]!:1;_/G89
M_SR!'/\ZC![_.98@_SB>(?\WI2/_-ZLC_S:R)/\VN27_-L E_S7*)O\UUR;_
M->4F_S7O)O\U^";_-O\F_C;_)OPV_R;\-O\G^C;_*/HV_RCZ-O\H^C;_*/HV
M_RC_.2\"_SXO _]$+P/_1C($_T@X!O](0PC_2$\-_T=;$O]$9Q;_0G,:_S]_
M'?\]BA__/),A_SN;(_\ZHB3_.:DE_SFP)O\XMB;_.+XG_SC')_\XTRC_..,H
M_SCM*/XX]RC[./XG^3G_)_@X_RGX./\J]CC_*O8X_RKV./\J]CC_*O8X_RK_
M.B\"_T$L _]&+ /_2B\$_TPW!?]-00C_3$P-_TM8$O](9!?_1G ;_T-\'O]!
MAR#_/Y C_SZ8)/\]H"7_/:8F_SRM)_\\M"C_.[LI_SO$*?\[SRG^.^ J^SOK
M*O@[]2GV//XI]#S_*O,[_ROR._\L[SO_+>\[_RWO._\M[SO_+>\[_RW_/"T"
M_T0I O]**0/_3BP$_U$T!?]2/@C_4DH-_U!5$O]-81?_2FT;_TAX'_]%@R+_
M0XTD_T*5)O]!G2?_0*,H_T"J*?X_L2K]/[@K_#_!*_H_RROW/]PL]3_I+/$_
M]"OO/_TL[3__+>P^_R_K/O\PYS__,.<__S#G/_\PYS__,.<__S#_0"H"_T@F
M O].)@/_4BD#_U8R!?]7/ ?_5T<,_U51$O]271?_4&D<_TUT(/]*?R/]2(DF
M^T>1*/I&F2GX1: J]T2G*_5$K2ST0[4M\T.]+?)#R"[P0]<N[$/G+NE$\RWF
M0_PPY$+_,>-"_S+A0O\SW$/_--Q#_S3<0_\TW$/_--Q#_S3_0R<"_TLC O]2
M(@+_6"<#_UPO!/]=.0?_7D,,_UM.$?]86!?^560<^E)O(/=0>B3T380G\DR-
M*?!*E2OO29PM[4FC+NQ(JB_J1[$OZ4>Z,.='Q3#F1](PXDCE,-]'\C+;1_LT
MV$;_-=5&_S;21O\WS4C_-\U(_S?-2/\WS4C_-\U(_S?_1B0"_T\@ O]6'P+_
M720#_V$L!/]C-0;_9$ +_V)*$/I>5!;U6U\<\5AK(.Y5=27K4W\HZ%&(*^9/
MD2WD3I@OXDV@,.%,IS'?3*XRW4NW,]M+PC392L\UU4OD-=!+\#;-2OLXRDK_
M.LA*_SK&2_\[P4S_.\%,_SO!3/\[P4S_.\%,_SO_2B$"_U,= O];' +_8B("
M_V<I _]I,@7_:CP)^6A&#_)E4!7M85L:Z%YF(.1;<27A6'LIWE:$+-M4C"_8
M4I0RU%&;--)0HS703ZHWSDZR.,Q.O#G*3LDZR$[=.L1/[3O!3OD]OD[_/;Q.
M_SZZ3_\^ME#_/K90_SZV4/\^ME#_/K90_S[_31X"_U8: ?]?&@'_9R "_VPF
M O]O+@3Y<#@'\F]"#.ML2Q+E:5<9WV5B']IA;"74778JT%M^+\U9AS+*5X\U
MR%:6-\94G3G$4Z4[P5.M/+]2MSZ]4L,_O%+3/[E2Z#^U4O9!LU+_0;%3_T&O
M4_]!K%3_0:Q4_T&L5/]!K%3_0:Q4_T'_4!P!_UH7 ?]D& '_;!T!_W$C OUU
M*@/S=C,%ZW8]"N-S1P_<;U,7U&M>'\YF9R;*8W$KQF!Y,,)>@32_7(DWO5J1
M.KI9F#RX6* ^ME>H0+16LD*R5KU#L%7,0ZU6XT2K5O-$J%?^1*=7_T2E6/]$
MHEC_1*)8_T2B6/]$HEC_1*)8_T3_4QD!_UT4 ?]H%@'_<!H!_W8@ ?=Z)@+M
M?"X#Y'PX!]QZ1 W2=4\6RW!:'L9L8R;!:&PLO69U,;EC?36V880YLU^,/+!=
ME#^N7)M!JUND0ZE:K46G6KA&I5G'1Z-:WD>A6N]'GUO\1YU;_T>;7/]&FES_
M1II<_T::7/]&FES_1II<_T;_51<!_V 2 ?]K% '_=!< _WH< ?)_(@'G@2D"
MWH(S!--_0 S+>DP5Q'96'KYQ8"6Y;F@LM&MQ,K%H>3:M9H ZJF2(/:=BCT"E
M8)=#HE^@19]>J4>=7K1)FUW"2IE=UDJ77NQ*EE_Z295?_TF38/](DF#_1Y)@
M_T>28/]'DF#_1Y)@_T?_6!4!_V,1 ?]N$@#_=Q4 ^WX8 .V#'0#BAR,!UH<N
M \R#/0O%?TD4O7M3';=V726R<V4LK6]M,JEM=3>F:GP[HFB$/I]FC$&<991$
MF6.<1Y=BIDF48K!+DF&^3)!AT$R/8NA,CF/X2XUC_TJ,9/])BV3_28MD_TF+
M9/])BV3_28MD_TG_6A,!_V80 /]Q$0#_>A( ]X(4 .B'%P#=BQP T(LL \>(
M.PJ_A$<3N']1'+%[6B2L=V(KIW1J,:-Q<C:?;WD[FVV /YAKB$*5:9!%DFB9
M2(]FHDJ,9JU,BF6Z38AES$Z'9N9.AF?V3(9G_TN%:/]+A&C_2H1H_TJ$:/]*
MA&C_2H1H_TK_7!(!_V@/ /]T$ #_?1  \X40 .2+$0#6CQ< RXXJ L*,. FZ
MB$02LX1/&ZQ_6".G?& KH7AH,9UU;S:9<W8[E7%]/Y)OA4*.;8U%BVR62(AK
MH$N%:JI-@VFW3H%IR$^ :N-/@&OT3G]K_TQ_:_]+?VO_2W]K_TM_:_]+?VO_
M2W]K_TO_7A !_VL. /]V#@#[@ T ZH@- -N/# #0DA4 QY(G KZ/-@BVC$(1
MKHA-&JB$5B*B@%XJG'UE,)=Z;#63=W,ZCW5[/HQS@D*(<HM&A7"328)OG4Q_
M;JA.?6ZU3WMMQE!Z;N!0>6_R3GEO_DUY;_],>6__2WEO_TMY;_]+>6__2WEO
M_TO_8 \ _VT- /]Y# #N@PL VXL) -21"@#,E1, PI4E KF3- >QCT$0JHQ+
M&:.(5"&=A%PIEX%C+Y)^:C6.?'$YBGIX/89X@$*#=HA%?W6127QSFTQY<J9.
M=G*S4'5RPU!S<MU0='/P3W1S_4UT<_],='/_3'1S_TQT<_],='/_3'1S_TS_
M8@X _V\, /Q["@#>A@8 U8X( ,^4"0#'F!$ OI@C ;66,@:MDS\/II!)&)^,
M4B"8B5HHDX9A+HZ#:#2)@6\YA7]V/8%]?D%]>X9%>GF/279XF4QS=Z1.<7>Q
M4&]VP5!N=]E0;G?O3VYW_$YN=_]-;W?_3&]W_TQO=_],;W?_3&]W_TS_9 T
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M2U>/]TI7CO]*6([_25B._TE8CO])6([_25B._TG_<0$ X(   ,^,  #$E@(
MNYX" +*D  "IJ@4 HJP5 )NL)@*4JS0'C*H_#X6H2!=^IE >>*18)7.B7BMN
MH64P:I]L-&6><SEAG7L\7IN$0%J:CD-7F9I%5)FG1U*9MDA1F<I(49CF2%&7
M]4A1E_]'49;_1U&6_T=1EO]'49;_1U&6_T?V=P  V(4  ,F1  "_FP$ M*(
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M-T"W_S= M_\W0+?_-T"W_S?.BP  OY@  +*A  "GJ0  G+   )&X  "&P (
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M$2?U\1&CJ   EK(  (B[  ![Q0  ;\X  &+7  !6W@  3O ' $KZ$ !&^QD
M0OLB 3_\*@$[_3("./TY C7^/P,R_D8#,/],!"[_4P4K_UH%*?]B!B?_:P8D
M_W8'(_^"""'_D @@_YT)'_^K"1[_N@D=_\D)'/_="1S_W0D<_]T)'/_="1S_
MW0F8L   BKH  'S$  !OS0  8M@  %7>  !)Y   1/L% #__#@ [_Q4 ./\<
M #3_) $Q_RL!+?\Q 2K_-@(G_SP")?]" B/_2 (@_TX#'O]5 QS_70,9_V<$
M%_]R!!7_?P04_XP%$_^:!1+_I@41_[(%$?^\!1'_O 41_[P%$?^\!1'_O 6,
MN   ?<(  &_,  !BV   5-\  $?E   ^\0  .?\! #3_"P P_Q  +/\6 "G_
M'  F_R( (O\G 1__+ $<_S$!&O\V 1C_/ $5_T$!$_]( A'_3P(0_U<"#?]A
M @S_; (*_WD""?^& PC_D@,'_YT#!O^E P;_I0,&_Z4#!O^E P;_I0/_,3$"
M_S8N O\Z+P+_.S(#_SLY!/\[0P7_.4\'_SA<"O\V: W_-'00_S* $O\QBQ3_
M,)06_S";%_\OHA?_+Z@8_RZO&?\NM1G_+KP9_R[%&O\NSQK_+N :_R[K&O\N
M]!K_+OP:_"__&?LO_QKZ+O\;^B[_'/HN_QSZ+O\<^B[_'/HN_QS_,R\"_SDL
M O\]+0+_/C #_S\V!/\_007_/4T'_SQ9"O\Z90[_.'(1_S9]$_\UB!7_-)$7
M_S.9&/\SH!G_,J89_S*L&O\QLQK_,;H;_S'"&_\QS!O_,=T;_S'I&_TQ\QOZ
M,OL;^#+_&_<R_QSV,?\=]3'_'O4Q_Q[U,?\>]3'_'O4Q_Q[_-2P"_SPJ O]
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M%:QU5ANG<E\BHF]F)YYL;BR;:G4PEVA\,Y1GA#:198PYCF25/(QCGCZ)8JA
MAV*U0H5BQ4*$8MY#@V/Q0H)C_4&"9/] @F3_/X)D_S^"9/\_@F3_/X)D_S__
M60X _V0+ /]N"@#J=P@ VWT( -2""@#,A!( PX4D ;N#- 6S@$ ,K7Q+%*9Y
M5!NA=EPAG'-D)IAQ:RN4;W(OD6UY,XYK@3:+:HDYB&B2/(5GFS^"9J9!@&:R
M0WYFP41]9ME$?&?O0WQG_$%\:/] ?&C_0'QH_S]\:/\_?&C_/WQH_S__6PP
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M1&5X]T-F>/]"9GC_069X_T!F>/] 9GC_0&9X_T#_9 , [G$  -A\  #+A0(
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M/$^1_SQ/D?\\3Y'_/$^1_SSD=   SX$  ,*,  "XE@  K9P  *.A  "8J
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M)#B__R2]D0  L)L  *2B  "8J@  C+$  ("Y  !UOP  :L8$ %[," !9SQ(
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M!R;PEP<E\*<()/&X""/QS @B\N4((O#S""+O]0@B[_4((N_U""+O]0B>I@
MD:\  (2X  !WP0  :LD  %W0  !1UP  1MT  #_J!0 \]@X .?87 #;W(  S
M]R@ ,?@P "[Y-@$K^3T!*?I$ 2?Z2@(E^U("(_M: B#\8P,>_&X#'/U[ QO^
MB009_I@$&/^H!!?_MP06_\@$%O_@!!;_Y 06_^0$%O_D!!;_Y 23K@  A;<
M 'C   !JR0  7=(  %#9  !$WP  .N0  #7W P R_PP +O\2 "O_&@ H_R$
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M,Y%6Q3205MTTCE?P-(U7_3.,6/\SC%C_,HQ8_S&,6/\QC%C_,8Q8_S'_40P
M_UL) /]C" #K:@< W6X( -AQ"@#/<A, QG,E ;YR- .W<$$(L6U,#JQJ512G
M9UX9HV5E'J!C;2*<870EFF![*)=>@RN478LMDER3,(];G#*-6J8TBUJR-8E:
MP3:'6M8VAEOM-H5;^S6%7/\TA%S_,X1<_S.$7/\SA%S_,X1<_S/_4PH _UT&
M /5F! #?;0, U7(& -!U"0#)=A$ P'<B +AV,0.Q=#X'JW%)#J9N4A2A;%L9
MG6EB'9EG:B*69G$EDV1X*)!C?RN-88<NBF"0,(A?F3.%7Z,U@UZO-H%>OCB
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M.7)G]SAR9_\W<FC_-G)H_S5R:/\U<FC_-7)H_S7_60( ]F4  -UN  #/=@$
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M-EYX_S5>>/\U7GC_-5YX_S7U9   W'   ,IZ  # @P  MHD  *Z-  "DCP
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M+D:6_R[1=P  P80  +:.  "JE0  H)L  )6?  "*I   ?:D  '>K$ !SJQX
M;ZPL 6JK-P1EJT$'8:I)"UVI40]:J5@35ZA?%E.G9AE0IVX<3:9V'TJE@2%(
MI8PD1:69)D.DJ"="I+@H0:3.)T&CZB= HO@H0*'_*4"@_RE H/\I0*#_*4"@
M_RG)?@  NHL  *^4  "CF@  F*   (VE  ""J@  =;   &RS# !IM!@ 9;0G
M 6&T,P)>M#T$6K1&!U:S3@I3LU4-4+-<$$VR8Q-*LFL61[%T&$6Q?AI"L(H=
M0+"7'CZPIB \L+<@/+#,(#ROZ" [KO<A.JW_(CJL_R,ZK/\C.JS_(SJL_R/
MA@  LY(  *>9  "<GP  D*8  (2L  !YL0  ;;<  &&\!0!=O1( 6KX@ %B^
M+0%4OC@"4;Y"!$Z^2@9,OE((2;Y9"D:^8 Q$OF@.0;UQ$3^]?!,\O8@5.KV5
M%CB]I!<WO;48-KW*&#>\YQ<UN_89-;K_&C2Y_QLTN?\;-+G_&S2Y_QNXCP
MJI@  )^?  "3I@  AZP  'NS  !ON0  8[X  %C$! !0R P 3<@7 $S))0!*
MRC$ 1\H[ 47*1 )#RDP#0<I4!#[*7 8\RF0'.LMN"3C+> HVRX4,-,N2#3++
MH@XQR[(/,,S'#S#+Y0XOR?4/+LC]$2['_Q(NQ_\2+L?_$B['_Q*NEP  H9X
M )6E  ")K0  ?+0  '"[  !DP0  6<8  $[+ P!%T @ /M4. #W5&@ \UB8
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M A'ZLP(0^\8"$/O= A#[Z0(0^^D"$/OI A#[Z0*/JP  @;0  '.]  !FQ@
M6<T  $O3  ! V0  -=X  "SC   F\0  )/X* "'_$  ?_Q8 '/\< !G_(@ 7
M_R@ %?\N !/_-0 2_SP $/]#  [_3  -_U8 "_]B  G_;P (_W\!!_^0 07_
MH $$_ZX!!/^\ 0/_QP$#_\<! __' 0/_QP&#M   =;T  &?&  !:SP  2]4
M #_<   SX0  *>4  "'L   >_0  &O\% !?_#  5_Q  $O\4 !#_&0 ._QX
M#?\C  O_*  (_RX !O\U  /_/0  _T8  /]1  #_70  _VL  /][  #_BP
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M'ZQ%S!^J1>,@IT;S(:5&_R&C1O\BHD;_(:)&_R&B1O\AHD;_(:)&_R'_10X
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M+(%7]RN 6/\J@%C_*H!8_RF 6/\I@%C_*8!8_RG_3P( _5D  .)@  #59P
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M+&IG_RMJ9_\K:F?_*VIG_RO^6   X6,  ,]L  #$<P  NW@  +-Z  "K>@0
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MA(TF4H.:*5""IRI/@K<K3H+,*TZ"Z"M.@?@J3X#_*D^ _RE/@/\I3X#_*4^
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M(465I"-$E+,C0Y3((T.4Y2-#DO4D0Y'_)$.0_R1#D/\D0Y#_)$.0_R3*=0
MNX$  +"+  "DD0  FI4  (^9  "#G0  =*(  &ZC"P!JI!< 9J4E &.E,0%?
MI#L#6Z1$!5BD2PA5HU,+4J-:#4^B81!-HF@32J%Q%4>@>QA$H(8:0I^3'$"?
MHAT^G[(>/9_&'CV?XQT]G?0>/9S_'SR;_Q\\F_\@/)O_(#R;_R#"?   M8@
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M""K%V@@JQ/ (*<+["2C!_PHHP?\+*,'_"RC!_PNHE0  G9L  )&B  "$J0
M>*\  &NU  !?NP  5+\  $G#   _R 0 -LT) #/.$0 RSQP ,<\G ##0,0 O
MT#H +M%# "W13  KTE4 *M)? 2C3:0$GTW8!)=.$ B34E (BU*8"(=6Y B'5
MT@(@T^L"(-+V Q_1_P0?T?\$']'_!!_1_P2?FP  E*(  (>I  !YL0  ;;@
M &"^  !4PP  2<<  #[+   UT $ +=4& "7;"P DWA( (]X< "+?)0 AX"X
M(. W !_A0  >X4H '>)3 !SC7@ ;XVH &N1X !CDB $7Y9H!%N:L 17FP $4
MY]T!$^7O 1/C^@$3X_H!$^/Z 1/C^@&6H@  B:D  'NQ  !NN0  8<   %3&
M  !(R@  /<\  #/3   JV0  (MX" ![K"@ <[!  &^T7 !GM'P 7[B8 %>XM
M !3O-0 3\#T $?!& !#Q4  /\EL #O)I  WS>  ,](H "_6<  KUK@ )]L(
M"?;9  CU[0 (]>T "/7M  CU[0"+J0  ?;(  &^Z  !BP@  5<D  $?.   [
MT@  ,=@  "?=   ?X0  &>@  !;X!@ 4^@T $OL2 !#\%P ._!T #?TC  S]
M*0 *_C  "/\X  ;_00 #_TP  /]8  #_9@  _W<  /^)  #_FP  _ZL  /^[
M  #_S@  _\\  /_/  #_SP!_L@  <;H  &/#  !6RP  2-$  #K6   OW0
M)>$  !SE   4Z0  $?<   __ 0 -_PD "_\-  C_$  &_Q0  _\8  #_'@
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M"<TPV G),>H*QC'W#,,Q_P[!,?\/P#'_#[\Q_P^_,?\0OS'_$+\Q_Q#_-A,
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M&Y9&^!R51O\;E$;_&Y-&_QN31_\;DT?_&Y-'_QO_0@4 _TH! /)0  #A5 $
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M(G58_R%U6/\A=5C_(758_R'_30  Y5<  --?  #(9   OV<  +=H  "Q9P<
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M(F%F_R+H6   TV,  ,1K  "Y<0  L'4  *=W  ">=0  EG8- )!W&0"+>"<
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M7P  RFD  +QR  "R>   J7T  )]_  "2?@  BG\' (2 $P" @2$ >X$N 7>
M.0-R@$(%;G]*"&M^40MH?5@.9'Q?$6)[9A1?>FT77'EU&5EX?QQ7>(H>5'>6
M(5)VI")1=K,C4';&)%!VXR-0=?4C477_(E%T_R%1=/\A473_(5%T_R'88P
MQ6T  +AV  "N?0  I8(  )J#  "-@P  A(0# 'V%$ !YAAX =8<K 7&'-@)M
MAC\$:85'!V6$3PIB@U8-7X-<#UR"8Q):@6L55X!S&%1_?1I1?X@<3WZ4'TU^
MHB!+?;$A2GW$(DI]X2%+?/0A2WO_($M[_R!+>_\@2WO_($M[_R#09P  P'(
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M%3F:V14YF.\6.9?\%CB6_Q<XE?\7.)7_%SB5_Q>[>@  KX4  *2,  "8D0
MC94  (&:  !UG0  :*   %ND  !6I0P 4Z87 %&G(P!/IR\ 3*<X 4JG00%(
MITD"1J=0!$.G6 5!IU\&/Z9H"#VF<@HZIGT+.*:*#3:EF0XTI:D/,Z6[#S.E
MU \SI.X/,J+[$#*A_Q$RH?\1,J'_$3*A_Q&T@@  J(P  )V2  "2EP  AIP
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M 1C*_ $8RO\"&,K_ AC*_P*;F0  CY\  (*F  !UK0  :+,  %RY  !0O0
M1,$  #G$   PR   *,P! "#0!@ 9U0L %M<0 !78&0 5V2( %-DK !/:-  3
MVCT $MM( !'<4P 1W5\ $-UM !#>?@ .WY$ #N"D  W@N  ,X-( "]_M  S>
M]P ,W?L #-W[  S=^P"2GP  A:<  '>N  !JM0  7;P  %#!  !$Q0  .,D
M "[-   ET0  'M4  !;: 0 1W@8 $.<-  [G$@ -Z!D #.@A  OI*0 *ZC$
M">H[  ?K10 %ZU$ !.M>  /K;@ !ZX   .J4  #JIP  Z[P  .O2  #KZ0
M[.\  .SO  #L[P"'IP  >:\  &NW  !>O@  4<4  $/)   WS0  +=$  "/6
M   ;VP  $]\   [C   ,[@( "O8*  ?V#@ %]A(  _88  #U'@  ]24  /4N
M  #U-P  ]D(  /9.  #V70  ]FX  /:!  #VE0  ]Z<  />W  #XQP  ^-
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M ?\.>P'_#H0!_PZ+ ?\.D@'_#I@!_PZ= ?\.HP'^#J@!_ ZN ?L.M0#Z#KX
M^ [) /4.VP#R#NH [@[U .P._P'K#_\!Z@__ >H0_P'I$/\!Z1#_ >D0_P'_
M(A\ _R(< /\A' #_'R  _Q\I /\<- #_&D  _Q=, ?\56 '_%&,!_Q-N ?\3
M=P'^$X !_!.( ?H2C@'Y$I4!^!*: ?82H 'U$J8!]!*L ?,2LP'Q$KP!\!+'
M >T2V 'I$^@!YA/U >04_P'B%/\"X17_ N$5_P+@%?\"X!7_ N 5_P+_)1L
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M";(P^PJP,/\+KC#_"ZXP_PNM,/\+K3#_"ZTP_PO_,PP _S8& /\\"0#_/@P
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M%H5'_Q6%1_\5A4?_%85'_Q7_/P  [$@  -U/  #/4P  QE4  ,!3 P"[40P
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M(@";7"\ EUL[ I):10./64T&BUA5"(A77 J&5F,,@U5J#H%4<1!^5'@2?%.
M%'I2B19X4I08=E*?&712JQIR4KH;<5+-''!2Z!MP4_D:<%/_&G!3_QEP4_\8
M<%/_&'!3_QCO20  W5,  ,M:  # 7P  MV(  *]A  "H7@( H5\0 )M@'@"6
M8"P D6 X 8U>0@.)74L%A5Q2!X);60J 6F ,?5EG#GM8;A!X6'42=E=]%'17
MAQ9R5I$8;U:<&FY6J1ML5K@<:U;+'6I6YAQJ5_<;:E?_&FI7_QEK5_\9:U?_
M&6M7_QGK3   V%8  ,A>  "\8@  LV4  *ME  "C8@  G&(. )9C' "19"D
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M&EYBI!Q<8K(=6V+%'5MBX1U;8O0<6V+_&UQB_QI<8O\:7&+_&EQB_QK@50
MRU\  +UG  "R;   J7   )]O  "4;   C&T( (9N$P"";R$ ?6\M 7EO. )U
M;D$#<FU)!6YL4 =K:U<*:6M>#&9J90YD:6P186ET$U]H?A9=9XD86V>5&EEF
MHAM79K <5F;#'59FWQU69O,<5V;_&U=F_QI79O\:5V;_&E=F_QK;60  QV(
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M&49XU1E&=^\81W;\&$=V_QA'=?\71W7_%T=U_Q?)90  NF\  *YW  "D?0
MF'\  (M_  !^?P  <X$  &R#"0!HA!, 984@ &*&+ !?AC8!7(8_ EF%1@-7
MA4X%5(55!U*$7 E/@V,+38-K#4N"= ](@G\11H&,$T2!FA5"@*D608"Z%D"
MTA9!?^T607[[%D%]_Q9!??\607W_%D%]_Q;":@  M74  *I]  "?@@  DH,
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M"2V<_PHMF_\*+9O_"BV;_PJO@   HXD  )>.  "-DP  ?Y4  '*8  !FG
M6Z   $^D  !%IP  /JD, #RJ%  ZJA\ .:HI #BK,@ WJSL -:M# #2L2P R
MK%,!,:Q< 2^L9@(MK'$"*ZQ_ RJLC@,HK)X$)ZRP!":LQ00FJ^0#):GU!"6H
M_P4EI_\%):?_!26G_P6GB0  FX\  )&4  "$F0  >)X  &NB  !?I@  4ZH
M $BM   ]L   -+,# "^U#@ MM18 ++4@ "NV*0 JMC( *;<Z "BW0P GMTP
M)KA5 "2X7P CN&L (KAX 2"XB $?N)D!';FK 1RYP $<N-\!'+;R 1NU_ (;
MM/\"&[3_ ANT_P*?CP  E)4  (B;  ![H0  ;J8  &*K  !6L   2K,  #^V
M   UN0  ++P  "2_!@ ?P@T '<(4 !S"'@ ;PR8 &L,O !G$.  8Q$$ %\1*
M !;%50 5Q6$ %,9O !/&?P 2QI$ $<>D !#'N0 /Q]0 $,;N !#$^@ 0P_\
M$,/_ !##_P"7E@  BYP  'ZB  !QJ0  9*\  %BT  !+N   0+L  #6^   K
MP0  (\4  !O) 0 4S 8 $- +  [1$0 -T1D #=$A  S1*@ ,T30 "](^  K2
M20 )TU4 "=-B  C3<@ &U(0 !=28  34JP #U<   =7<  '5[0 !U?8  =7V
M  '5]@".G0  @*0  '.K  !FL0  6;@  $R]   _P   -,,  "K'   AR@
M&<X  !+2   -U@$ "=L%  ;<#0 $W!$  ]T8  '>(   WB@  -\Q  #@/
MX4<  .)4  #C8P  XW0  .2(  #DFP  Y:X  .7!  #EU0  YN<  .;G  #F
MYP"#I   =:P  &BS  !:NP  3<$  $#$   SR   *,P  !_0   7U   $-D
M  O=   %X0   .0   #E!P  Y@T  .<1  #H%@  Z1T  .HE  #K+@  [3D
M .]%  #P4P  \60  /%V  #RB@  \YP  /.M  #TNP  ],@  /3(  #TR !W
MK0  :K4  %R]  !/Q   0,D  #/-   GT0  '=8  !3<   .X   ".,   'F
M    Z@   .X   #N    [P0  / *  #Q#@  \Q(  /08  #V(   ^"H  /HU
M  #]0P  _E(  /]C  #_=@  _XD  /^:  #_I@  _[   /^P  #_L #_%B,
M_Q4A /\1(0#_#20 _PDK /\&-P#_ T0 _P!1 /\ 70#_ &@ _P!R /\ >P#_
M (, _P"* /\ D0#_ )8 _P"< /\ H0#] *8 ^P"L /D LP#W +L ]0#% /,
MT0#R .0 \0#Q .\ ^@#N /\ [@#_ .T _P#M /\ [0#_ .T _P#_&2  _Q@=
M /\5'0#_$!\ _PXI /\,- #_"D$ _P=- /\%60#_!&0 _P1N /\#=P#_ X
M_P.' /\#C0#] I, ^P*9 /D"G@#W J0 ]0*J /,!L #Q ;@ [P'" .T!SP#K
M >, Z@'O .@"^P#G!/\ Y@7_ .8&_P#F!O\ Y@;_ .8&_P#_'!L _QL9 /\7
M& #_%1T _Q,E /\1, #_$#T _PY) /\,50#_"V  _PMJ /T+<P#["WP ^0J#
M /<*B@#U"I  ] J6 /,*FP#Q"J$ [PFG .T)K@#K";8 Z G  .8)S0#D">(
MX@KP -\+^P#>#/\ W W_ -P-_P#;#?\!VPW_ =L-_P'_'Q< _QX3 /\;$@#_
M'!D _QLB /\8+ #_%3@ _Q-$ /X24 #Y$5L ]1!F /,0;P#P$'< [A!_ .P0
MA@#J$(P Z1"2 .@0F #F#YX Y0^E .,/K #A#[0 X ^^ -X/S #:$.$ U1'P
M -(2^P#/$O\!SA/_ <T3_P'-$_\!S!/_ <P3_P'_(A( _R(/ /\A#P#_(A0
M_R(< /\@)P#_'3( ^!L^ /(92P#N&%8 ZA=@ .<6:@#D%G( XA9Z . 6@@#>
M%H@ W!:/ -L6E0#9%IL UA:B -06J0#2%K$ T!>[ ,X7R0#,&-X R!GN <4:
M^P'#&O\"P1O_ L ;_P+ &_\"P!O_ L ;_P+_)@X _R4+ /\H# #_*1  _R@6
M /XF( #T)"L ["$X .8@1 #A'U  W1]; -D>90#5'FT TA]U - ??0#.'X,
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M")TQ_PB<,?\(G#'_")PQ_PC_,   _S4  .\X  #B.@  VSD$ -8U"0#.-!,
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M#WA&_P_P/P  WTD  ,U/  #!4P  N%0  +%2  "K3@4 I$X1 )Y/( "94"T
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M$FE1HQ-G4;$49E'#%652WA5E4O(495+_$V52_Q)E4O\295+_$F52_Q+D2@
MSU,  ,!:  "U7@  K&   *)>  ":60  DEH+ (U;%@"(7", A%PO (!;.@%]
M6T,">5I+ W994@1T6%@&<5A?!V]79@EM5VT+:U9U#6E6?@]G5HD19565$F-5
MH11B5:\5857!%F!5VQ9@5O$58%;^%&!6_Q-A5O\285;_$F%6_Q+@30  RU8
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M%5%BTA518>T54F'[%%)A_Q-38?\24V'_$E-A_Q+15@  P%\  +-F  "I:P
MG&L  )!J  "%9P  ?6D  '=J#0!S:Q< ;VLD &QL+P!I;#@!9FM! F-K20-A
M:U $7FI7!EQJ70=::64)6&EM"U5H=@U3:($/46>-$4]GFA).9ZD436>Y%$QG
MSQ1,9NL436;[$TUF_Q).9?\23F7_$DYE_Q+,6@  O&,  +!J  "E;P  F&X
M (QM  " ;   =VT  '%N"P!M;Q0 :7 A &9Q+ !D<38!87$^ 5YQ1@)<<$T#
M67!4!5=P6P95;V((4V]J"E!N<PQ.;GX.3&V*$$IMF!%);*<22&RX$T=LS1-'
M;.H32&OZ$DAK_Q)(:O\12&K_$4AJ_Q''7@  N&<  *QN  "A<@  DW(  (=Q
M  !Z<0  <7(  &MT!P!F=1$ 8W8= &!W* !>=S, 6W@\ 5EW0P)6=TL#5'=2
M!%)V6050=F '3G5H"$MU<0I)='P,1W2(#D5SE@]#<Z400G.V$4%SRQ%"<N@1
M0G+X$4)Q_Q!#</\00W#_$$-P_Q#!8P  LVP  *AS  ";=@  CG4  (%V  !U
M=@  :7@  &-Z @!>? X 7'T9 %E^) !7?R\ 57\X 5-_0 %0?T@"3GY/ TQ^
M5@1*?ET%2'UE!D9];@A#?'D*07R&"S][E T^>Z,./'NS#CQ[R X\>N8./'GW
M#CQX_PX\>/\./7?_#CUW_PZ\:   KW(  *1Y  "6>@  B'H  'QZ  !P?
M8W\  %R"  !7A L 4X44 %&&( !/ABH 3H<T $R'/ %*AT0!2(=+ D:'4P)$
MAEH#0H9B!$"&; 8^A78'.X6#"#F%D0HXA* +-H2Q"S:$Q@LV@^0+-H+V"S:!
M_PPV@/\,-H#_##: _PRV;P  JG@  )]_  "0?@  @W\  '>   !K@@  7H<
M %6*  !.C 8 2HX0 $B/&@!'CR4 19 O $20. !"D$  0)!' 3^03P$]D%8"
M.Y!? CF0: ,WCW,$-8^ !3./C@8QCYX',(ZO!R^.PP<OCN$'+XST""^+_P@O
MBO\(+XK_"2^*_PFP=@  I7\  )B$  "*A   ?84  '"'  !EB@  6HX  $^2
M  !&E0  09@, #Z8%  ]F1\ .YDH #J:,0 YFCH -YI" #::2@ UFE(!,YI:
M 3&:9 $OFF\"+9I[ BR:B@,JFIH#*9JL!"B:P 0GF=X#)Y?R!">6_04GE?\%
M)Y7_!2>5_P6I?@  GH4  )*)  "$B@  =HP  &J/  !>DP  5)<  $F;  !
MGP  -Z($ #*C#@ QHQ< ,*0A "ZD*@ MI#( +*4Z "NE0P JI4L *:54 "BE
M7@ FI6D ):5V 2.EA0$BI98!(*:H 1^ENP$>I=<!'J3O 1ZB^P(>H?\"'J'_
M AZA_P*BA@  EXP  (N/  !]D0  ;Y0  &.8  !7G0  3:$  $.E   XJ
M,*L  "BN!P DKQ  (Z\7 "&O(0 @L"D '[ Q !ZP.@ =L4( '+%, !NQ5@ :
ML6$ &;)O !BR?@ 6LI  %;*B !2RM@ 3LLX $['K !.O^0 3KO\!$Z[_ 1.N
M_P&:C0  D)(  (27  !UF@  :)\  %NC  !0J   1:P  #NP   QL@  )[4
M ""X   8N@< %+P. !.\%0 2O!X $;TF !&]+@ 0O3< $+Y!  Z^3  .OE<
M#;YE  R_=  +OX8 "KZ9  B^K  'OL( ![[?  B^\  (O?H "+W\  B]_ "3
ME   AYD  'J?  !LI0  8*H  %.O  !'LP  /+8  #&X   GNP  '[X  !?!
M   1Q $ #,@(  C)#@ 'R10 !LD<  7))  $RBP  \HV  +*0   RTP  ,M9
M  #+:   RWD  ,R,  #+GP  R[,  ,O(  #,X@  S.\  ,SQ  #,\0"*F@
M?*$  &^G  !BK0  5;,  $BX   [NP  ,+X  ";!   =Q   %<@   _+   *
MS@  !-("  #3"@  TP\  -04  #5&@  UB(  -<J  #9-   VC\  -Q+  #<
M6@  W6H  -U]  #=D0  W:0  -ZV  #>R   WMX  -[B  #>X@!_H@  <:D
M &2P  !6MP  2;P  #S    OQ   ),<  !O+   3SP  #=(   ?6    VP
M -X   #? P  X D  .$.  #B$@  XQ<  .4>  #F)P  Z#$  .H]  #L2P
M[%H  .UL  #N@   [I0  .ZE  #NM   [L(  .[&  #NQ@!TJ@  9K(  %BY
M  !+P   /<4  "_)   DS0  &=$  !'6   +VP   ]X   #A    Y0   .@
M  #I    Z@   .L&  #M"P  [P\  / 3  #R&@  ]",  /<N  #Y.P  ^TH
M /Q;  #];0  _8   /Z3  #^H@  _JT  /ZO  #^KP#_$!\ _PX= /\*'0#_
M 2  _P H /\ -0#_ $$ _P!. /\ 6@#_ &4 _P!N /\ =P#_ '\ _@"& /P
MC #[ )( ^0"7 /@ G #W *( ]@"G /4 K0#S +4 \@"] /$ R0#O -P [@#K
M .T ]P#L /\ ZP#_ .H _P#J /\ Z@#_ .H _P#_$QP _Q$9 /\-&0#_!AP
M_P,E /\ ,0#_ #X _P!* /\ 5@#_ &$ _P!K /T <P#Z 'L ]P"# /4 B0#T
M (\ \@"4 /$ F0#P )\ [@"D .T JP#L +( Z@"Z .@ Q@#G -8 Y0#H .0
M]0#C /X X@#_ .$ _P#A /\ X0#_ .$ _P#_%1@ _Q,4 /\/% #_#1D _PLB
M /\(+0#_!#D _P%& /\ 40#^ %P ^@!F /8 ;P#R '< [P!^ .T A0#K (L
MZ@"1 .@ E@#G )P Y@"A .0 J #C *\ X0"X -\ PP#= -$ VP#F -D \P#7
M /T U0+_ -0"_P#4 _\ U /_ -0#_P#_&!, _Q40 /\2#P#_$A4 _Q$= /\.
M* #_##0 _PI! /D(3 #U!E< \09A .T&:@#I!7( Y@5Z .0%@0#B!8< X :-
M -\&D@#=!I@ VP:> -D&I0#7!JT U :U -(&P #0!\\ S@CE ,P)] #*"_\
MR S_ ,<,_P#'#/\ Q@S_ ,8,_P#_&PX _QD, /\8#0#_&!$ _Q<8 /\4(@#[
M$2X \Q Z .T.1@#H#5( Y0U< .$-90#>#6T VPUU -@-? #5#8( TPV) -$-
MCP#0#94 S@V< ,T.HP#+#JL R0ZT ,@.P #&#L\ PQ#F , 1]0"]$O\ O!+_
M +L2_P"Z$O\!NA+_ ;H2_P'_'PH _QP$ /\?" #_'PT _QT2 /@:&P#N%B8
MYA0S . 3/P#:$TL U!-6 - 37P#.%&@ RQ1O ,D4=P#'%7T QA6$ ,05B@##
M%9$ P1:8 , 6GP"^%J< O!>P +L7O "Y%\L MQCB +,9\@&Q&O\!KQO_ :X;
M_P&N&_\!K1O_ :T;_P'_(@0 _R(  /\E @#\) < ]R$, .P=$@#A&AP V!HJ
M - ;. #+'44 QQU0 ,,>6@# 'F( OAYJ +P?<0"Z'W@ N1]^ +<?A0"V'XP
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M!8PQ_P7_+0  ZC4  -PZ  #./0  QCP  , W @"[,PT LS09 *XV)P"I-S0
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M"7@_I0IW0+(*=4##"W1 W0MS0?$+<D'_"G)!_PIR0?\)<D'_"7)!_PGI/
MU44  ,5+  "Z3@  L$X  *=+  "B1@  FT8. )9'&@"12"< CD@S (I(/0"'
M1T8!A$=. 8)&50* 1EP#?D5B!'Q%:01Z17 %>$1X!G9$@0AT1(L)<D26"G!$
MH@MO1*\,;D3 #&U%V0UL1>\,:T7]"VM&_PMK1O\*:T;_"FM&_PKE0   STD
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M#EM1S@]:4>H.6U'Z#5M1_PQ;4?\,6U'_"UM1_PO62@  PU,  +99  "K7
MGEH  )-9  "+5   A%8# 'Y6$ !Z5QH =E<F '-8,0!P5SH ;5=" 6I720)H
M5E "9E97 V167@1B564%8%5M!UY5=@A=58$*6U6-"UE4F@U85*<.5E6X#U95
MS ]65>D.5E7Y#595_PU75/\,5U3_#%=4_PS130  P%8  +-<  "G7@  FET
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M#$AA_PQ(8/\+26#_"TE@_PO$6   M6   *IF  ";9@  C68  ()E  !V9
M;F4  &AF!0!C9Q  8&@: %UI)0!;:B\ 66HX %=J0 %5:D<!4VI. E%J50-/
M:5T$36ED!4MI;09):'@'1VB$"49HD@I$9Z$+0V>Q#$)GQ0Q"9^(,0F;U#$-F
M_PM#9?\+0V7_"T-E_PN_7   L60  *9J  "6:0  B6D  'UI  !Q:0  9VH
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M!C!Z_P:P;   I'4  )1U  "&=0  >78  &YW  !C>0  5WT  $^!  !'A
M0H8, #^'$P ]B!T /(@G #N),  ZB3@ .(E  #>)2  VB4\ -(E8 3.)80$Q
MB6P!+XEX BV)AP(LB9<#*HBG RF(N@,IB-0#*8;N RF%_ 0IA/\$*83_!"F$
M_P2J=   GGL  (YZ  " >@  ='L  &A^  !=@0  4H4  $F)  !!C   .9 %
M #61#P SDA< ,I(A #&2*0 PDS( +I,Z "V300 LDTH *Y12 "J47  HE&<
M)Y1S 264@@$DE),!(I.D 2&3MP$@D\\!(9+L 2"0^@(@C_\"((__ B"/_P*D
M?   EX   (=_  ![@   ;H(  &*%  !7B0  38X  $*2   ZE@  ,ID  "J<
M"0 HG1$ )IT9 "6=(@ DGBH (YXR "*>.@ AGD( ()Y+ !^?50 >GV  ')]M
M !N??  :GXT &)^? !>?L@ 6G\D %I[H !:<]P 6F_\!%YO_ 1>;_P&=@P
MCX8  (*&  !TAP  9XL  %N/  !0DP  1I@  #R<   SH   *Z,  ".F   <
MJ L &JD1 !BI&  7J2$ %JHI !6J,0 4JCD $ZI# !.K30 2JU@ $:ME !"K
M=  .JX8 #JN9  VKK  ,J\$ #*K?  RI\@ -J/P #:C_  VH_P"6B@  B8P
M 'J-  !LD0  8)4  %2:  !)GP  /Z,  #6G   KJ@  (ZX  !NP   4LP$
M#[4*  VV$  ,MA8 "[8?  JV)P )MB\ "+8Y  >W0P &MT\ !+=;  .W:@ "
MMWL  +>.  "WH0  MK0  +;+  "VY0  M?$  +7W  "U]P"/D0  @90  '*7
M  !EG   6*$  $RF  !!JP  -Z\  "RR   CM0  &K@  !.[   .O0  "< %
M  /!#0  P1$  ,$7  #"'@  PB8  ,(O  ##.0  Q$0  ,10  #$7@  Q6\
M ,6!  #%E0  Q:@  ,6\  #$T0  Q.8  ,3N  #$[@"&F   >9X  &NC  !=
MJ0  4*X  $2S   WM@  ++D  "*\   9OP  $<(   S%   &R    ,L   #,
M!P  S T  ,T1  #-%@  SAT  ,\D  #0+0  TC@  -1$  #44@  U6$  -5S
M  #6AP  UIL  -:M  #7OP  V,X  -C=  #8W0![H   ;J8  &"M  !3LP
M1;@  #B\   KOP  (<(  !?&   0R0  "LP   +0    U    -<   #8
MV@4  -L+  #<#@  WA,  -\9  #A(0  XRH  .4V  #G0P  YU,  .AD  #I
M=P  Z8P  .J?  #JK@  ZKH  .K#  #JPP!PJ   8J\  %6V  !'O   .<
M "S$   @R   %LP   [0   'U    -D   #=    X0   .,   #D    Y@
M .<!  #I!P  ZPP  .P0  #N%0  \!T  /,G  #V,P  ]T,  /A4  #Y9@
M^7H  /J.  #ZG@  ^ZD  /NP  #[L #_"QL _P<9 /\ &0#_ !P _P E /\
M,@#_ #\ _P!+ /\ 5P#_ &( _P!K /\ <P#] 'L ^P"" /H B #X (T ]P"2
M /8 F #U )T ] "B /, J0#Q +  [P"X .X PP#L -$ ZP#F .D \P#H /X
MZ #_ .@ _P#H /\ Z #_ .@ _P#_#A@ _PH5 /\!% #_ !@ _P B /\ +@#_
M #L _P!' /\ 4P#] %X ^@!G /< ;P#U '< \P!^ /( A #P (D [P"/ .X
ME #L )H ZP"? .D I0#H *P Y@"T .0 OP#C ,P X0#B -\ \ #> /L W@#_
M -T _P#= /\ W #_ -P _P#_$!, _PT1 /\&$ #_ A4 _P > /\ *0#_ #8
M_P!" /H 3@#T %D \0!B .X :P#L '( Z@!Y .@ ?P#G (4 Y0"+ .0 D #B
M )8 X0"< -\ H@#= *D V@"Q -@ NP#5 ,@ T@#= -$ [0#0 /D SP#_ ,X
M_P#- /\ S0#_ ,T _P#_$0\ _PX- /\,#0#_"Q( _P<9 /\") #_ #  ]@ \
M .\ 20#J %, YP!= .0 9@#A &T WP!T -T >P#; ($ V0"& -8 C #4 )(
MT@"8 -  G@#. *8 S "N ,H N #( ,0 Q@#7 ,4 Z@## /< P@#_ ,$!_P#
M O\ P +_ , "_P#_% L _Q & /\0"0#_$ X _PX4 /\*'@#U!BD ZP0V .,#
M0@#? TX VP17 -8$8 #3!&@ T 1O ,X%=@#,!7P R@6" ,D%B #'!8X Q@64
M ,0%FP#"!:, P :K +X&M0"]!L( NPC4 +H)Z0"W"_@ M0S_ +0,_P"T#/\
MM S_ +0,_P#_%P0 _Q0  /\6 P#_% D _Q$. /(.%0#H#"$ W@HN -8+.P#0
M#$< S Q1 ,D,6@#&#6( Q UJ ,(-<0# #7< OPU] +T.@P"\#HH N@Z1 +D.
MF "W#J  M@ZI +0/M "R#\$ L1#4 *X1ZP"K$OH J1+_ *@3_P"G$_\ IQ/_
M *<3_P#_&@  _QL  /D;  #K&0  Y10& .40#@#9#A< SQ$F ,@2- #$$T
MOQ1+ +P45 "Y%5T MQ5D +45:P"T%7$ LA5X +$6?@"O%H4 KA:, *P6E "K
M%YP J1>F *<8L "F&+T I!C/ *(:YP"?&O< G1O_ 9P;_P&<&_\!FQO_ 9L;
M_P'_'0  ]R$  .@D  #=)0  U"$! ,\;" #*%Q$ PAH@ +P<+0"W'3H LQY%
M + >3P"M'E< JQY? *D?9@"H'VP IA]S *4?>0"C'X  HA^' * @CP"?()@
MG2"B )L@K &:(;D!F"'* 98BY &4(_4!DB/_ 9$C_P&0(_\!D"/_ 9 C_P'_
M(@  ZRD  -TN  #/+P  QRT  ,$G P"](@T MB,: + E* "L)C0 J"9  *4G
M20"B)U( H"=: )XG80"<)V< FR=M )DG= "8)WL!EB>" 94GBP&3)Y0!D2B>
M 9 HJ0&.*+4"C2G& HLIWP*)*O("ARK_ H8J_P*&*O\"ABK_ H8J_P+T*
MXS$  -$V  #%.   O#8  +8P  "R*PD JRP4 *8M(@"B+B\ GBXZ )LN1 "8
M+TT EB]5 )0N7 "2+F( D"YI 8\N;P&-+G8!C"Y^ 8HNA@*(+H\"ARZ: H4O
MI0.#+[(#@B_" X$PV@-_,.\#?3'^ WTQ_P-\,?\#?#'_ WPQ_P/M+P  VS<
M ,D]  "^/@  LSP  *PX  "G,P0 HC(1 )TT'0"9-2H E34U )(U0 "/-4D
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M2   I48  )U#  "7/P  DCX+ (T_%0")/R$ A4 M () -P!_0$  ?4!( 'M
M3P%Y0%8!=S]= 74_8P)S/VH"<3]R W _>@-N/X0$;#^0!6L_G 9I/ZD&:#^X
M!V= S =F0.@'9D#Y!F5 _P9E0/\&94#_!65 _P7</@  QT8  +E+  "L3
MH$H  )='  "10P  BT,( (9#$@""1!X ?D0I 'M%- !Y13T =D5% '1$3 %R
M1%,!<$19 6Y$8 )L0V<":T-O VE#=P1G0X$%9D.-!F1#F09B0Z<'842V"&!$
MR@A@1.8(7T7X!U]%_P=@1?\&8$3_!F!$_P;600  PTD  +9.  "G3P  FTT
M ))+  ",1P  A4<$ (!'$ !\2!H >$@F '5), !S23H <$E" &Y)20%L2% !
M:DA6 6A(70)F2&0"94AL V-(=01A1W\%8$>*!EY(EP==2*4(6TBT"%M(QPE:
M2.0(6DGV"%I)_P=:2/\&6DC_!EI(_P;110  OTP  +)2  "C40  EU   (U.
M  "&2@  @$H! 'I+#@!V3!< <DPC &],+0!M338 :DP_ &A,1@!F3$T!9$Q3
M 6),6@)A3&$"7TQI UY,<@1<3'P%6DR(!EE,E0=73*,(5DRR"%5,Q@E53.()
M54SU"%5,_P=53/\'5DS_!E9,_P;,2   O%   *]5  "@5   DU,  (E1  "!
M30  >DX  '5/# !P3Q4 ;5 @ &I0*@!G4#, 95 \ &-00P!A4$H!7U!1 5U0
M6 )<4%\"6E!G UE0< 174'H%55"&!E10DP=24*$(45"Q"5!0Q E04.$)4%#T
M"%%0_P=13_\'44__!E%/_P;)2P  N5,  *M7  "<5@  CU4  (54  !\4
M=5$  '!2"0!K4Q( :%0= &54)P!B5#$ 8%0Y %Y400!<5$@!6E1/ 5E45@%7
M5%T"5E1E U14;@125'@%452$!D]4D0=.5* (3%2O"$Q4P@E+5-\)3%3S"$Q3
M_P=,4_\'35/_!DU3_P;%3@  ME8  *=:  "860  BU@  (%7  !W5   <%4
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M!CY@_P:Y60  JV$  )IA  "+80  ?V$  '1A  !I80  7V(  %ED  !49@D
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M 2YY@P(M>9("*WBC BIXM0(J>,P"*G?J BIV^0,J=?\#*G3_ RIT_P.J:@
MFFT  (EL  !\;0  <&T  &9N  !;<0  4'4  $AX  !!>P  .GX% #9_#@ T
M@!8 ,X$@ #*!*  P@3  +X(X "Z"0  M@D@ +()0 "N"6@ J@F0 *()P ":"
M?P$E@H\!)(*@ 2."L@$B@LD!(H'G 2)_]P$B?O\"(GW_ B)]_P*E<0  DW$
M (-Q  !V<0  ;'(  &!U  !6>   3'P  $.    [@P  ,X8  "V)"@ JBA$
M*8L9 ">+(@ FBRH )8PQ "2,.0 CC$( (HU* "&-5  @C5X 'XUK !V->0 <
MC8H &XV< !F-K@ 8C,0 &(SC !F*]0 9B?\!&8C_ 1F(_P&==P  C'8  'UV
M  !R=P  97D  %I\  !0@   1H0  #R)   TC   +9   "63 @ ?E0P '982
M !R6&@ ;ER( &I<J !F7,@ 8F#H %YA# !:830 5F%@ %)AD !.8<P 1F(0
M$)B6 !"8J0 .F+\ #I?=  ^6\@ 0E?P $)3_ !"4_P"5?0  A7P  'A\  !K
M?@  7X$  %2&  !*B@  0(\  #:3   MEP  )IH  !Z=   7H , $J(, !"C
M$@ 0HQD #Z,A  ZD*0 .I#$ #:0Z  RD10 +I%  "J1<  FD:@ 'I'L !J..
M  2CH0 "H[0  Z++  .BY@ #H?,  Z'[  .A^P"-@P  ?X(  '&$  !DAP
M6(P  $V1  !"E@  .)H  "^>   FH@  'J4  !>H   1JP  #*X'  >O#0 #
MKQ(  J\9  &O(0  KRD  + R  "P/   L$<  +!3  "P80  L'$  +"#  "O
MEP  KZH  *^_  "NV0  KNL  *[T  "N] "'B0  >(H  &J.  !=DP  49@
M $6=   [H@  ,*8  ">J   >K@  %K$  !"T   +M@  !;D#  "Z"@  N@X
M +H3  "[&0  NR$  +PH  "\,0  O3P  +Y(  "^5@  OF4  +YW  "^C
MOI\  +VS  "^QP  OMX  +WK  "]ZP!_D@  <)4  &*:  !5GP  2:4  #VK
M   RKP  *+0  !ZV   5N0  #KP   F_   "P@   ,0   #%!   Q@H  ,8.
M  #'$@  R!@  ,D?  #*)P  S#   ,X\  #.20  SUD  ,]J  #/?@  SY,
M ,^F  #/N   S\@  ,_;  #/VP!WG   :*$  %NG  !.K@  0;0  #2W   H
MN@  ';T  !/    -Q   !L<   #*    S@   -    #1    T@(  -,(  #5
M#   UA   -D5  #;'   W20  . O  #B/   XTL  .1<  #D;P  Y8,  .68
M  #EJ0  Y;8  .7#  #EPP!LI0  7ZP  %&R  !$N0  -;P  "C    <Q
M$L@   S+   #SP   -,   #8    W    -\   #?    X0   .,   #D P
MY@@  .@-  #I$0  [!@  .XB  #Q+@  \SP  /1-  #U7P  ]G,  />'  #W
MF0  ^*4  /BP  #XL #_ Q< _P 5 /\ %0#_ !@ _P C /\ +P#_ #P _P!(
M /\ 5 #_ %X _P!G /T ;P#[ '8 ^0!] /@ @P#V (@ ]0". /0 DP#R )@
M\0"> /  I #N *L [0"S .L O0#J ,L Z #A .< \0#F /T Y0#_ .0 _P#D
M /\ Y #_ .0 _P#_!Q, _P 1 /\ $0#_ !4 _P ? /\ *P#_ #< _P!$ /X
M3P#Z %H ]P!C /0 :P#R '( \ !Y .\ ?P#M (0 ZP"* .H CP#H )0 YP":
M .4 H #D *< X@"O .  N0#> ,8 W #: -H [ #8 /D U@#_ -8 _P#7 /\
MV #_ -@ _P#_"A  _P,. /\ #0#_ !( _P : /\ )@#\ #( ]P _ /0 2@#Q
M %4 [0!> .H 9@#H &X Y0!T ., >@#B (  X "% -X BP#< )  VP"6 -@
MG #5 *, TP"K -$ M0#. ,$ S #1 ,L YP#) /4 R #_ ,@ _P#( /\ R #_
M ,@ _P#_# P _P8( /\""@#_  \ _P 5 /P ( #Q "P [  Y .D 10#E $\
MX0!9 -X 80#; &@ UP!O -0 =0#2 'L T "  ,X A@#, (P RP"2 ,D F #'
M *  Q0"H ,, L0#! +P OP#+ +T XP"\ /( NP#] +L _P"Z /\ N@#_ +H
M_P#_#@4 _PD  /\)!0#_!@L _P$0 /  &0#F "4 X0 R -P /P#6 $D T0!3
M ,X 6P#+ &, R !J ,8 < #% '8 PP![ ,$ @0#  (< O@". +P E "[ )P
MN0"D +< K@"U +D LP#( +$ WP"P >\ KP'[ *X"_P"M _\ K0/_ *T#_P#_
M$   _PX  /\-  #V"P, \@<* .(!$0#; AT T@,K ,P#-P#(!$, Q 1- ,$$
M5@"^!5T O 5D +H%:P"X!7$ MP5V +4%? "S!H, L@:) + &D0"O!YD K0>A
M *L'JP"I"+< J G& *8*W0"E"_  HPS] *(-_P"A#?\ H0W_ * -_P#_$0
M_!(  .P3  #B$P  VP\# -8)"P#."!0 Q@HB , ,, "\#3P N U& +4-3P"R
M#E< L Y? *X.90"M#FL JPYQ *H.> "H#GX IP^% *4/C0"D#Y8 HA"? * 0
MJ0"?$+4 G1'% )L1W@"9$O$ EQ/_ )84_P"5%/\ E13_ )04_P#_%0  [1L
M . ?  #2'P  R1L  ,04!0#!$ X NA(; +03*0"P%#4 K!5  *D520"F%5(
MI!99 *(68 "A%F8 GQ9L )X6<@"<%GD FQ>  )D7B "8%Y$ EAB; )08I@"3
M&;( D1G! ) :V "-&^X BQS] (H<_P"*'/\ B1S_ (D<_P#T'0  Y"4  -,I
M  #'*@  O"8  +8@  "T&0L KAH5 *@<(P"D'2\ H1XZ )X>1 ";'DP F1Y4
M )<?6P"5'V$ E!]G )(?;0"1'W0 CR!\ (X@A ",((T BB"7 (DAH@"'(:X
MAB*] (4BT0&"(^L!@23[ 8 D_P%_)/\!?R3_ 7\D_P'L)0  VRT  ,DQ  "\
M,0  L2X  *LI  "G) 4 HR,1 )XD'0":)2H EB8U ),F/P"1)D< CR9/ (TF
M5@"+)UP B2=B (@G:0"&)V\ A2=W (,G?P"!)XD!@"B3 7XHG@%]*:L!>RFY
M 7HIS0%X*N@!=ROY 78K_P%V*_\!=2O_ 74J_P'E+   T#0  ,$X  "S.
MJ#4  *(Q  "=+0  F2H. )0K& "0+"0 C2TP (HM.@"'+4, A2U* (,M40"!
M+E@ @"Y> 'XN9 !]+FL >RYS 7DN>P%X+H4!=BZ/ 70OFP%S+Z@"<2^V G P
MR0)O,.4";C'W FTQ_P)M,?\";3'_ FTQ_P+?,@  R3D  +L^  "L/0  H3H
M )HW  "5,P  D#$* (PQ% "',B  A#,K ($S-0!_,SX ?3-& 'LS30!Y,U0
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M!%D__P-9/_\#63__ UD__P/,/P  O$8  *M(  "<1P  D48  (A$  ""0
M?#\  '= # !S0!4 ;T$@ &Q!*@!J03, :$$[ &9"0P!D0DH 8T%0 &%!5P!@
M0EX!7D)E 5U";@);0G@"6D*$ UA"D -70IX$5D.M!%5#OP140]H$5$/Q!%1#
M_@-40_\#5$/_ U1#_P/(0@  N$D  *=+  "82@  C4D  (-'  !]0P  =D,
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M T=._P.]3   KE(  )Q1  "-40  @5$  '=0  !N3   9TX  &)/  !=4 T
M6E 4 %=1'@!542< 4U$P %%2. !04C\ 3E)& $U230!,4U4 2E-= 4E390%(
M4V\"1E-[ D53B0-#4Y<#0E.G!$%3N 1!4\\$05/L!$%2^P-"4O\#0E+_ T)1
M_P.Z3P  JE0  )A4  ")5   ?5,  '-3  !I40  8E(  %Q3  !85 H 5%42
M %)5&P!/5B0 3E8M $Q7-0!+5SP 2E=$ $A72P!'6%( 1EA: 4188P%#6&T!
M05AY D!8A@(^6)4#/5BE SQ8MP0\6,T$/%?J SQ7^@,]5O\#/5;_ SU6_P.V
M4P  I5<  )17  "%5@  >58  &]6  !E50  7%8  %=8  !260< 3EH0 $Q:
M& !*6R$ 2%PJ $=<,@!%7#H 1%U! $-=2 !"75  0%U8 #]=80$]76L!/%UV
M CI=A (Y79,".%VC S==M0,V7<L#-ESH S=<^0,W6_\#.%O_ SA:_P.R5P
MH%H  (]9  "!60  =5D  &M9  !@6@  5EL  %%=  !,7@( 2& - $5@% !$
M81X 0F(F $!B+@ _8C8 /F,^ #UC10 \8TT .V-5 #EC7@ X8V@!-F-T 35C
M@0$S8Y$",F.A C%CLP(Q8\@",6+G C%A^ (Q8?\",F#_ C)@_P*N7   FUT
M (I=  !\70  <%T  &9=  !<7@  4F   $QB  !%90  068* #YG$0 \:!H
M.V@B #EI*P X:3( -VHZ #9J00 U:DD -&I2 #-J6P Q:F4 ,&IP 2YJ?@$M
M:HX!+&J? 2MJL $J:L8!*FGE 2IH]@(K9_\"*V?_ BMG_P*I80  E6   (1@
M  !W8   ;&$  &)A  !88P  3F8  $=H  ! :P  .FX% #9O#@ T<!4 ,W >
M #)Q)@ P<2X +W$U "YR/0 M<D4 +')- "MR5P J<F$ *7)M "=R>P F<HL
M)'*< 2-RK@$C<L,!(W'B 2-P] $C;_\!(V[_ 2-N_P&A90  CF0  ']D  !R
M9   :&4  %YF  !4:0  26P  $)O   [<@  -'4  "YX"@ K>1$ *GD8 "EZ
M(0 G>B@ )GHP "5[.  D>T  (WM( ")[4@ A>UP ('MH !]\=@ =?(8 ''N8
M !M[J@ :>[\ &GO> !IY\@ ;>/X &W?_ 1MW_P&9:0  B&D  'EI  !M:0
M8VH  %EL  !/;P  17,  #UW   U>@  +GT  ">! P B@PT ((02 !^$&@ =
MA"( '(4J !N%,0 :A3D &85" !B&3  7AE8 %H9C !6&<0 4AH$ $H:3 !&&
MI@ 1A;L $(76 !&#[P 1@OL $H+_ !*!_P"1;@  @6T  '1N  !I;@  77
M %-S  !)=P  0'P  #>    O@P  )X<  "&*   :C08 %8\- !.0$P 2D!H
M$I B !&0*@ 0D3( $)$[  ^11  .D4\ #9%<  R1:@ +D7H "I&-  B0GP '
MD+, !X_)  >/Y@ 'CO0 "(W\  B-_P")<P  >W,  &]S  !C=0  5W@  $U]
M  !#@0  .88  #"*   HC@  (9$  !J5   3EP  #IH(  N<#@ )G!, ")P:
M  ><(@ &G"H !)PS  .</0 "G4@  )U4  "=8@  G'(  )R$  "<EP  FZH
M )N_  ":VP  FNP  )KU  "9^ "">0  =GD  &AZ  !<?@  48(  $:'   \
MC   ,I$  "F5   AF0  &9T  !*@   .HP  ":8%  .G#   IQ   *<5  "H
M'   J",  *@K  "I-   J3\  *E+  "I60  J6@  *EZ  "IC@  J:$  *BU
M  "HRP  I^0  *?O  "G\P!]@   ;X$  &&$  !5B0  28X  #Z4   TF0
M*IX  "&B   9I@  $JD   VL   'KP   +(   "S!P  LPP  +,0  "T%0
MM!L  +4B  "V*P  MS4  +=   "X3@  N%T  +AN  "X@@  N)<  +BJ  "W
MO@  M](  +?F  "WZ@!VB   9XL  %J0  !.E@  0IP  #>B   LIP  (JL
M !FO   1LP  "[8   2Y    O    +X   "^    OP8  , +  #!#P  PA,
M ,,9  #$(   Q2D  ,<T  #(0@  R5$  ,EB  #)=0  R8H  ,F?  #*L0
MRL$  ,G1  #)V0!NDP  8)@  %.>  !&I   .JL  "^P   DM0  &;@  !"\
M   *OP   <$   #$    R    ,H   #*    S    ,T#  #."   T T  -$0
M  #3%@  UAX  -HH  #=-   WD,  -]4  #?9P  X'P  ."1  #@I   X+(
M ."^  #@PP!FGP  6:8  $RM   _M   ,K@  "2\   8OP  $,,   C'
MR@   ,T   #1    U0   -@   #9    VP   -T   #?    X00  .,*  #E
M#@  YQ,  .H<  #M)P  \#4  /%&  #R6   \VL  /.   #TE   ]*,  /2N
M  #TL@#_ !, _P 1 /\ $0#_ !4 _P ? /\ + #_ #D _P!% /\ 4 #_ %H
M_@!C /L :P#Y '( ]P!X /4 ?@#T (0 \@") /$ C@#P ), [@"9 .T GP#L
M *8 Z@"N .@ N #F ,4 Y0#; ., [0#B /L X@#_ .$ _P#A /\ X0#_ .$
M_P#_ !  _P . /\ #0#_ !( _P ; /\ * #_ #0 _@!! /L 3 #W %8 ] !?
M /$ 9@#O &T [ !T .H >@#I '\ YP"% .8 B@#E (\ XP"5 .$ FP#@ *(
MW@"J -L M #9 ,  U@#0 -, Z #2 /< T0#_ -$ _P#0 /\ T #_ -  _P#_
M  T _P ) /\ "@#_  \ _P 6 /L (@#W "\ ]  [ /  1P#M %$ Z0!: .4
M8@#B &D X !O -X =0#< 'H V@"  -@ A0#5 (L TP"1 -$ EP#/ )X S0"F
M ,L KP#) +H QP#) ,4 X@#$ /( PP#^ ,( _P#! /\ P@#_ ,( _P#_ P8
M_P ! /\ !@#_  P ^0 1 /$ '0#K "D YP V ., 00#? $L VP!4 -4 7 #2
M &, SP!J ,T < #+ '4 R0![ ,@ @ #& (8 Q0", ,, DP#! )H OP"B +T
MJP"[ +8 N0#$ +< V@"V .T M #Z +0 _P"T /\ M #_ +0 _P#_!   _P
M /\   #_  8 [  - .4 %@#> "( UP O -$ .P#- $4 R@!. ,8 5P#$ %X
MP0!D +\ :@"] '  O !U +H >P"Y ($ MP"' +4 C@"S )4 L@"> +  IP"N
M +( K "_ *H T0"H .@ J #W *< _P"G /\ I@#_ *8 _P#_!@  _P4  /$#
M  #H    X0 ' -4 $ #- !L QP G ,, ,P"_ #X O !( +D 40"V %@ M !?
M +( 90"P &H KP!P *T =@"L 'P J@"" *D B0"G )$ I0": *, I "A *X
MH "[ )X!S0"= N8 G 3T )L$_P":!?\ F@7_ )D%_P#_"@  \0X  .00  #9
M#P  S@L  ,@#"P#" !, O (? +<#+ "S!#< L 5" *T&2@"J!E( J =9 *8'
M7P"E!V4 HP=K *((<0"@"'< GPA^ )T(A0";"8X F@F7 )@*H0"6"JP E0NZ
M ),+S "2#.4 D WV (\._P".#O\ C@[_ (T._P#V$0  YA<  -8;  #'&0
MOA4  +D0  "W"@T L0L7 *P-) "H#C  I0X[ *(.1 "?#TP G0]3 )L/6@":
M#V  F!!F )<0; "5$'( DQ!Y )(0@0"0$(H CQ&4 (T1GP"+$:H BA*X (@2
MRP"&$^8 A13W (,5_P"#%?\ @A7_ ((5_P#M&@  W"$  ,HE  "[(@  L1\
M *L:  "I% 8 I1(1 * 4'@"<%2H F14U )86/@"4%D< DA9. ) 650".%UL
MC!=A (L79P")%VT B!=T (88? "%&(8 @QF0 ($9FP" &J< ?AJU 'T;QP!\
M'.( >AWU 'D=_P!X'?\ >!W_ '@=_P#E(@  T"D  +\L  "P*@  IR<  * C
M  "='P  FAH. )4<& "1'20 CAXO (P>.0")'D$ AQ]) (4?4 "#'U8 @A]<
M ( ?8@!_'VD ?2!P 'P@> !Z(($ >2&, '<AEP!U(J0 ="*R ',CPP!R(]\
M<"3S &\D_P!O)/\ ;B3_ &XD_P#=*0  R#   +<R  "H,   GBX  )<J  "3
M)P  D",* (PC$P"()!\ A"4J ((E- " )CT ?29$ 'PF2P!Z)E( >"98 '<F
M7@!U)F4 ="=L '(G= !Q)WT ;RB( &XHE !L**$ :RFO 6HIP %I*ML!9RKQ
M 6<K_P%F*_\!9BK_ 68J_P'4+P  PC8  *\V  "A-0  EC0  ) P  "*+0
MARH& (,I$ !_*AH ?"LE 'DK+P!W+#@ =2Q  ',L1P!Q+$T <"Q4 &XL6@!M
M+&$ :RUH &HM< !H+7H 9RZ% &4ND0%D+IX!8B^L 6$OO0%A,-4!8##O 5\P
M_0%?,/\!7S#_ 5\P_P'--   O#L  *DZ  ";.@  D#@  (DU  "#,@  ?S !
M 'LO#@!W,!8 =# A '$Q*P!O,30 ;3$\ &LQ0P!J,4H :#)0 &<R5P!E,ET
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M 4X]_P' /P  KD,  )Q#  ".0P  @D(  'I   !S/0  ;3P  &@]!0!D/0X
M83X7 %X^(0!</BD 6CXQ %@^.0!7/D  53]& %0_30!3/U4 4D!< %! 90!/
M0&\!3D%Z 4U!AP%+098!2D&E DE"M0))0LL"24+H DE"^0))0?\"24'_ 4E!
M_P&]0P  JD4  )A%  "*10  ?T4  '9#  !O0   :$   &-! 0!?00T 7$$4
M %E"'0!70B8 54(N %-"-@!10CT 3T)# $]#2P!.0U( 341: $Q$8P!*1&T!
M245X 4A%A0%'190!146C D5&M )$1LD"1$;G D1%^ )$1?\"147_ D5%_P&Z
M1@  ID@  )1(  "&2   >T<  ')&  !J0@  8T,  %Y$  !:10L 5D42 %1&
M&P!11B, 3T8K $Y&,P!,1SH 2T=! $I'20!)2%  2$A8 $=(80!&26L 1$EV
M 4-)@P%"29(!04FB D!)LP(_2L<"/TKE C])]P) 2?\"0$C_ D!(_P&V20
MHDH  )%*  "#2@  =TH  &Y)  !E10  7D<  %E(  !520@ 44H0 $]*& !,
M2B$ 2DLI $E+,0!'2S@ 1DP_ $5,1@!$3$X 0TU6 $)-7P!!36@ 0$UT 3Y-
M@0$]39 !/$V@ 3M.L0(Z3L8".D[D CM-]@([3?\!.TS_ 3Q,_P&S30  GDP
M (U,  !_3   =$P  &I,  !@2@  64L  %1,  !0304 3$X. $E/%0!'3QX
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M 2I=JP$J7;\!*5W> 2I<\@$J6_X!*UO_ 2M:_P&C50  CU4  ']5  !R50
M9U8  %Y6  !45P  3%D  $5;   _70  .E\$ #9@#0 T81, ,F(< #%B(P P
M8BL +V,R "YC.@ M8T( +&-* "ID4P I9%T *&1I "=D=@ F9(8 )627 "1D
MJ0 C9+T (F3: "-C\0 C8OT!)&'_ 21A_P&<6   B5@  'I9  !N60  8UD
M %I:  !07   2%X  $%@   Z8P  -&8  "]H"@ L:1  *FD7 "EJ'P H:B8
M)VHN "9K-0 E:ST )&M& "-K3P B;%D (&QE !]L<@ >;(( '6R4 !QLI@ ;
M:[H &FO4 !MJ[@ <:?P '&C_ !QH_P"57   @UP  '5<  !I70  7UT  %9>
M  !,80  0V0  #QG   U:@  +VT  "AP!  C<@T (7(2 "!S&@ ?<R$ 'G,H
M !UT,  <=#@ &W1  !IT2@ 9=%0 %W5@ !9U;@ 5=7X %'60 !-TH@ 2=+8
M$73/ !)S[  2<OH $W'_ !-Q_P".8   ?6   &]A  !E80  6V(  %%D  !(
M9P  /FL  #=N   P<0  *74  ")X   <>P< %WT. !9]$P 5?1L %'XB !-^
M*@ 2?C$ $7XZ !%^1  0?TX #W]:  Y_:  -?W@ #'^*  M^G0 *?K  "7W&
M  I]Y  *?/0 "WO]  MZ_P"&90  =V4  &IE  !A9@  5F@  $QK  !";P
M.7,  #%W   J>@  (WX  !R!   5A   $(<(  V)#@ ,B10 #(D;  N)(P *
MB2L "8DS  B)/0 &B4@ !8E4  2)80 "B7$  8F#  ")E@  B*D  (>^  "'
MV@  ANP  (;U  "&^@!^:@  <6H  &=K  !;;   4'   $9T   \>   ,WT
M "J!   CA0  '(@  !6,   0CP  #)(&  :3#  "DQ$  )06  "4'0  E"0
M )4L  "5-0  E4   )5,  "660  EFD  )5Z  "5C@  E*$  )2U  "3S
MDN8  )+R  "2]P!X<   ;7   &!R  !4=0  27D  #]^   U@P  +(@  ".-
M   ;D0  %)0   ^7   *F@  !)T#  ">"0  GPX  )\2  "@%P  H!T  *$E
M  "B+0  HC<  *-#  "C4   HU\  *-Q  "CA   HID  **M  "AP@  H=P
M *'K  "@\@!S=@  9G<  %E[  !-@   0H4  #B+   ND   ))4  !N:   4
MG@  #J$   FD   "IP   *H   "K!   JPH  *P-  "M$0  K18  *X<  "O
M)   L"T  +$Y  "Q1@  LE4  +)F  "R>0  LHX  +&C  "RMP  L<H  +'@
M  "QZ0!L?@  7X(  %*'  !&C0  .Y,  #"9   FG@  '*,  !.G   -JP
M!ZX   "R    M0   +<   "X    N0(  +D(  "Z#   NQ   +P4  "]&P
MOR,  ,$M  #".@  PDD  ,-:  ##;   Q((  ,27  #$JP  Q+P  ,3+  #$
MV@!EB0  6(X  $N5   _FP  ,Z(  "BH   =K0  %+$   VV   &N0   +P
M  "_    PP   ,0   #%    Q@   ,<   #)!   R@D  ,L-  #-$0  SQ@
M -(A  #5+0  UCP  -A-  #97P  VG,  -J*  #;G@  VZX  -NZ  #<PP!>
ME@  49P  $2C   XJ@  ++$  ""W   5NP  #;X   3"    Q0   ,D   #-
M    T    -(   #2    U0   -8   #9    VP   -X%  #@"@  X@\  .46
M  #H(   ["T  .T^  #M40  [F4  .]Z  #OCP  \)\  /"K  #PLP#_ !
M_P . /\ #@#_ !( _P = /\ *0#_ #4 _P!! /\ 30#^ %8 ^P!? /@ 9@#V
M &T ] !T /( >0#Q '\ \ "$ .X B0#M (\ ZP"5 .H FP#H *( Y@"J .4
MLP#C ,  X0#2 .  Z@#? /D W0#_ -T _P#= /\ W@#_ -X _P#_  T _P *
M /\ "0#_  \ _P 8 /\ ) #^ #$ ^P ] /@ 2 #T %( \ !: .T 8@#K &D
MZ0!O .< =0#E 'H XP!_ .( A0#@ (H W@"0 -P E@#: )T V "E -4 KP#2
M +H T #* ,X XP#- /0 RP#_ ,L _P#+ /\ RP#_ ,L _P#_  @ _P # /\
M!0#_  P _  4 /< 'P#R "L [P W .L 0@#G $P Y !5 .  70#= &0 V@!J
M -@ < #5 '4 T@!Z -  @ #/ (4 S0"+ ,L D@#) )D QP"A ,4 J@## +4
MP0## +\ V@"^ .X O0#\ +P _P"\ /\ O #_ +P _P#_    _P   /\   #Y
M  < \0 0 .H &@#D "4 WP Q -L / #7 $< T@!0 ,X 5P#+ %X R0!E ,8
M:@#% '  PP!U ,$ >@#  (  O@"& +P C0"Z )0 N0"< +< I0"U +  LP"]
M +$ SP"O .@ K@#X *X _P"M /\ K0#_ *T _P#_    _P   /T   #N  $
MXP , -H % #1 !\ S  K ,@ -@#% $  P@!* +\ 4@"\ %D N@!? +@ 90"V
M &H M !O +, =0"Q 'H L "! *X B "M (\ JP"8 *D H0"G *L I0"X *,
MR "B .( H0#S *  _@"@ /\ H #_ *  _P#_    ]@   .H   #@    TP &
M ,D #P#" !@ O0 D +D +P"V #H M !# +$ 3 "N %, K !9 *H 7P"I &0
MIP!J *8 ;P"D '4 HP![ *$ @@"@ (H G@"3 )P G0": *< F "T )8 PP"5
M -P E #O ), ^P"3 /\ DP#_ )( _P#Y!0  Z@L  -P-  #+"@  P@4  +P
M"@"V !$ L0 < *X * "J #, IP ] *0 10"B $T H !3 )X 60"< %\ FP!D
M )H :@"8 '  EP!V )4 ?@"3 (8 D@&/ ) !F0". J0 C *Q (L#P ")!=8
MB ;M (@'^@"'"/\ A@C_ (8(_P#O#P  WA0  ,H5  "\$@  LQ   *X,  "K
M!@T IP,5 *(%( "?!RP G @V )D(/P"7"4< E0E. ),)5 "1"EH D I? (X*
M90"-"FL BPIR (H+>0"("X( APN, (4,EP"##*( @0VP ( -P !_#=@ ?0[O
M 'P/_0![#_\ >Q#_ 'L0_P#F%P  T1X  +T=  "O'   IAD  *$5  ">$ 0
MG0T/ )@.&0"4#B4 D0\O (\0.0",$$$ BA!( (@03P"'$%4 A1!; (0180""
M$6< @!%N '\1=0!]$7X ?!*( 'H2E !X$J  =Q.N '43O@!T%-4 <Q7N '$6
M_0!Q%O\ <1;_ ' 6_P#<'P  QB4  +,E  "E(P  G"$  )8>  "2&0  D10+
M (T4% ")%1\ AA8I (,6,P"!%SP @!=# 'X72@!\%U  >A=6 'D87 !W&&(
M=AAI '08<0!S&7H <1F$ &\:D !N&IT ;!NK &L<NP!J'-  :1WL &@>^P!H
M'O\ 9Q[_ &<>_P#1)@  O2H  *LJ  "=*@  DR@  (TE  "((@  AAT& (,;
M$ !_'!H ?!TD 'H=+@!W'C8 =AX^ '0>10!R'TL <1]1 &\?6 !N'UX ;!]E
M &L@;0!I('8 :"&! &8AC0!E(IH 8R*H &(CN !A(\T 8"3I & D^@!?)/\
M7R3_ %\D_P#*+   MB\  *0O  "6+P  C"T  (4J  " *   ?20  'HB#0!V
M(Q4 <R,@ '$D*0!O)#( ;20Z &LE00!J)4< :"5- &8E5 !E)5H 9"9A &(F
M:0!A)G( 7R=] %XGB@!=*)< 6RFE %HIM0!:*LH 62KG %@J^ !8*O\ 6"K_
M %@J_P#%,0  KS,  )XS  "0,P  AC(  '\O  !Y+0  =2H  '(H"@!O*!(
M:RD; &DI)0!G*BT 92HU &,J/0!B*D, 8"I* %\K4 !>*U< 7"M> %LL9@!9
M+&\ 6"UZ %<MAP!6+I4 5"ZC %,OLP!3+\< 4B_E %(O]P!2+_\ 4B__ %(O
M_P#!-@  JC8  )DV  "+-@  @34  'DS  !S,0  ;R\  &LN!@!H+1  9"X8
M &(N(0!@+RH 7B\Q %PO.0!;+T  62]& %@O30!7,%, 5C!; %0Q8P!3,6P
M4C)W %$RA !/,Y( 3C.A $TSL0!--,4!3#3C 4PT]@!,-/\ 3#3_ $PS_P"[
M.0  ICD  )4Y  "'.0  ?#D  '0W  !N-   :3,  &4R @!A,@T 7C(4 %PS
M'@!:,R8 6#,N %8S-0!5-#P 4S1# %(T2@!1-%  4#58 $XU8 !--FH 3#9U
M $LW@@!*-Y  23B? $@XL %'.,,!1SCA 4<X]0%'./\!1SC_ 4<X_P&W.P
MHCP  )$\  "#/   >#P  ' Z  !J-P  9#8  & V  !<-@L 63<2 %8W&@!4
M-R, 4C<K % W,@!/.#D 33A  $PX1P!+.$X 2CE5 $DY7@!(.F@ 1SIS $8[
M@ !%.XX 1#R> $,\K@%"/,(!0CW? 4(\\P%"//\!0CS_ 4([_P&S/0  GCX
M (T^  !_/@  =3X  &P]  !F.@  8#D  %LZ  !7.@@ 4SL0 %$[& !..R
M3#LH $L[+P!)/#8 1SP] $<\1 !&/4L 13U3 $0^7 !#/F8 0C]Q $$_?@!
M/XT /T"< #Y K0$]0, !/4#= 3U \@$]0/\!/C__ 3X__P&N0   FD   (E!
M  !\00  <4$  &A   !A/   6ST  %8^  !2/@4 3C\. $P_%0!)/QT 1T E
M $9 + !$0#, 0T Z $)!0@!!04D 0$%1 #]"6@ ^0F, /4-O #Q#?  [0XL
M.D2; #E$JP$Y1+X!.$3; 3E$\0$Y0_X!.4/_ 3E#_P&J0@  ED,  (9#  !X
M0P  ;D,  &5#  !=0   5D   %%"  !-0@( 24,, $9#$@!$1!H 0D0B $%$
M*@ _13$ /D4X #U%/P \1D< .T9/ #I&5P Y1V$ .$=L #='>@ V2(D -4B9
M #1(J@ T2+T ,TC9 #1(\  T1_T -$?_ #5&_P"F1   DD4  ()&  !U1@
M:D8  &%%  !91   440  $Q&  !(1P  1$<* $%($  _21@ /4D@ #Q))P Z
M2BX .4HV #A*/0 W2T0 -DM, #5+50 T3%\ ,TQJ #),=P Q3(8 ,$R7 "]-
MJ  N3;L +DW5 "Y,[P O3/T +TO_ #!+_P"A1P  CD@  'Y(  !Q2   9DD
M %U(  !52   3$D  $=*  !"2P  /TP& #M-#@ Y3A4 -TX= #9/)  U3RL
M,T\S #)0.@ Q4$( ,%!* "]14@ N45P +5%G "Q1=0 K480 *E*5 "E2I@ I
M4KD *%+2 "E1[@ I4/P *E#_ "I/_P"<2@  B4H  'I+  !M2P  8TP  %I,
M  !13   2$T  $-/   ]4   .5(" #53#  S5!( ,509 #!5(0 N52@ +54O
M "Q6-P K5CX *E9& "E63P H5UD )U=D "97<@ E5X$ )%>2 "-7I  B5[<
M(E?/ ")7[  C5OH (U7_ "15_P"630  A$X  '5.  !I3@  7T\  %9/  !-
M4   15(  #]3   Y5@  ,U@  "]:"  K6P\ *EL5 "A<'0 G7"0 )EPK "5<
M,P D73H (UU# ")=3  A758 (%YA !]>;@ >7GX '5Z/ !Q>H0 ;7K0 &EW,
M !M=Z0 ;7/D '%O_ !Q;_P"040  ?E$  '!1  !D4@  6U(  %)3  !*5
M05<  #M9   U6P  +EX  "A@ P D8@P (F,1 "%C&  ?9"  'F0G !UD+@ <
M9#8 &V4^ !IE1P 995$ &&5= !=E:@ 697H %66+ !1EG@ 39;$ $F7( !)D
MYP 38_< %&+_ !1B_P")5   >%4  &M5  !@5@  5U8  $]7  !&60  /5P
M #9?   P8@  *60  "-G   =:@< &6P. !AL$P 6;1H %6TA !1M*0 4;3
M$VTY !)N0@ 1;DP $&Y8  ]N90 .;G4 #6Z'  UNF@ ,;:T "VW"  MLX  ,
M:_, #6O]  UJ_P""60  <ED  &99  !<6@  5%H  $I<  !!7P  .6,  #%F
M   J:0  )&P  !UO   7<@  $G4)  ]W#P .=Q0 #G<;  UW(P ,=RH "W<S
M  IW/  )=T< "'=2  =W7P %=V\ !'>   -WE  !=J<  ':[  %UU0 !=.L
M G3V  )T_ ![70  ;5T  &)>  !97@  3F   $5C   \9P  ,VL  "MN   D
M<@  'G4  !=Y   2?   #7\&  F!#  %@1$  X$6  *!'0 !@20  ($M  ""
M-@  @D   (),  ""60  @F@  ()Y  ""C0  @:   ("T  " RP  ?^<  '[R
M  !^^0!T8@  :&(  %YB  !39   26<  #]K   V<   +70  "5X   >?
M%X   !&#   -A@  "(D$  *+"@  BPX  (L3  ",&   C!\  (TF  "-+P
MCCD  (Y$  ".40  CF   (YQ  ".A0  CID  (VM  ",PP  C-\  (ON  "+
M]@!N:   9&<  %AI  !-;   0G$  #AV   O>P  )G\  !Z$   6B   $(P
M  R/   &D@   )4   "6!P  EPP  )</  "8$P  F1@  )H?  ";)@  FS
M )P[  "<2   G%<  )QH  "<>P  G)   )NE  ";N@  FM   )KG  ":\0!J
M;0  7F\  %%R  !&=P  .WP  #&"   GAP  'HP  !:1   0E0  "ID   2<
M    H    *(   "C 0  HP8  *0+  "E#@  IA(  *<7  "H'@  JB8  *LQ
M  "K/@  K$T  *Q=  "L<   K(4  *R;  "KKP  J\,  *O9  "JZ !D=0
M5WD  $M^   _A   -(H  "F0   ?E@  %IL  !"?   )HP   :<   "J
MK@   +    "P    L0   +(#  "T"   M0T  +80  "W%0  N1T  +LF  "\
M,P  O4$  +U2  "]9   OGD  +Z0  "]I   O;<  +W&  "]UP!<?P  4(4
M $2+   XD@  +)D  "&?   7I   $*D   FN    L@   +8   "Y    O0
M +\   "_    P    ,$   ##    Q 4  ,8*  #'#@  R1,  ,L<  #.)@
MT#4  -%%  #25P  TFL  -."  #3EP  TZD  -*X  #2Q !5C   29,  #V:
M   PH@  ):@  !JN   1M   ";D   "]    P0   ,0   #(    RP   ,T
M  #-    SP   -    #2    U    -@   #:!@  W0P  . 1  #C&@  YB<
M .<X  #H2@  Z5T  .IR  #KB   ZYL  .RH  #LL@#_  T _P + /\ "P#_
M !  _P : /\ )@#_ #( _P ] /\ 2 #[ %( ^ !: /8 8@#S &D \0!O /
M=0#N 'H [ !_ .L A #I (H Z "0 .8 E@#D )T X@"E .$ KP#? +L W0#+
M -L Y@#9 /< V #_ -@ _P#7 /\ UP#_ -0 _P#_  @ _P $ /\ ! #_  T
M_P 5 /X (0#Z "P ]P X /0 0P#P $T [0!5 .H 70#G &0 Y !J .( < #@
M '4 W@!Z -T ?P#; (4 V0"+ -4 D0#3 )D T0"@ ,\ J@#- +4 RP#$ ,D
MW0#( /$ QP#_ ,8 _P#& /\ Q@#_ ,< _P#_    _P   /\   #_  H ^  1
M /$ ' #L "< Z0 R .8 /0#B $< W0!0 -D 6 #5 %\ T@!E -  :@#. '
MS !U ,H >@#) '\ QP"% ,4 C ## )0 P0"< +\ I0"] +  NP"] +H T "X
M .L MP#[ +8 _P"V /\ M@#_ +8 _P#_    _P   /T   #S  4 Z0 . .$
M%@#; "$ U0 M -$ -P#. $$ R@!* ,< 4@#$ %D P@!? ,  90"^ &H O !O
M +L = "Y 'H MP"  +8 AP"T (X L@"7 +  H "N *H K0"W *L R "I .,
MJ #U *< _P"G /\ IP#_ *8 _P#_    _@   /$   #E    UP * ,T $0#'
M !P P@ F +\ ,0"\ #L N@!$ +< 3 "T %, L@!9 +$ 7P"O &0 K0!I *P
M;P"J '0 J0!Z *< @0"F (D I "1 *( FP"@ *4 G@"R )T P0"; -H F@#O
M )D _0"8 /\ F #_ )@ _P#]    \    .$   #1    Q@ $ +T #0"W !4
MLP @ +  *P"M #4 JP ^ *@ 1@"F $T I !4 *, 60"A %\ H !D )X :0"=
M &X FP!U )H >P"8 (, E@", )4 E@"3 *$ D0"M (\ NP"- ,\ C #I (L
M^ ", /\ C #_ (P _P#S @  X@<  ,P'  "_!   MP   +$ " "K !  IP 9
M *0 ) "@ "X G@ W )P 0 ": $< F !. )8 5 "5 %D DP!> )( 9 "0 &D
MCP!O (T =@"+ 'X B@"( (@ D@"& )T A0"I (, N "! ,H @ #E (  ]0!_
M /\ ?P#_ '\ _P#H#0  T!   +X0  "Q#@  J T  *,(  "@ @P G  3 )@
M'0"5 "< D@ Q )  .0". 4$ C %( (H"3@") E0 AP)9 (8"7P"$ V0 @P-K
M ($#<@" !'H ?@2$ 'T%C@![!9H >0:G '@&M0!V!\@ =0CC '4)] !T"O\
M<PK_ ',*_P#=%0  Q!<  +$7  "E%@  G!,  )81  "4#00 DP@- (X'%0"+
M"2  B DJ (4*,P"#"SL @0M" ( +20!^"T\ ?0Q4 'L,6@!Z#&  > QG '<,
M;@!U#78 = V  '(-C !P#9D ;PZF &T.M0!L#LD :P_F &H0]P!I$/\ :1#_
M &D0_P#0'0  N1X  *@>  ";'0  DAL  (L9  "(%0  AQ$' (4.$ "!#QH
M?A D 'L0+0!Y$#8 =Q$] '811 !T$4H <Q%0 '$15@!P$5P ;A)B &T2:@!K
M$G, :1-] &@3B0!F$Y8 912C &,5LP!B%<8 8A;C &$6]@!@%_\ 8!?_ & 7
M_P#'(@  L",  )\D  "2(P  B2(  ((@  !^'0  ?!D  'H5#0!W%14 =!8?
M '$6* !O%S  ;A<X &P7/P!K%T4 :1A+ &@840!F&%@ 91A> &,99@!B&6\
M8!EY %\:A0!=&Y( 7!NA %L<L !:',, 61W@ %@>] !8'O\ 6![_ %@>_P"_
M)P  J2@  )DH  "+*   @B<  'LE  !V(P  <R   '$<"0!N'!$ :QP: &D=
M(P!G'2P 91TS &,>.@!B'D$ 8!Y' %\>30!>'E0 7!]; %L?8@!9(&L 6"!V
M %8A@@!5(9  5"*> %,BK@!2(\  42/= %$D\@!1)/\ 423_ %$C_P"Y*P
MHRP  ),L  "&+0  ?"P  '0J  !O*   :R4  &DB!0!F(0X 8R(6 &$B'P!?
M(R< 72,O %PC-@!:(ST 621# %<D2@!6)%  5217 %,E7P!2)6@ 429S $\F
M?P!.)XT 32B< $PHK !+*;X 2RG: $HI\0!**?\ 2RG_ $LI_P"S+@  GB\
M (XP  "!,   =R\  &\N  !J*P  92H  &,G 0!?)PP 7"<3 %HG&P!8*"0
M5B@K %4H,@!3*#D 4BE  % I1@!/*4T 3BE4 $TJ7 !,*F4 2BMP $DK? !(
M+(L 1RV: $8MJ@!%+KP 12[6 $4N[P!%+OX 12[_ $4M_P"N,0  FC(  (DS
M  !\,P  <C,  &LQ  !E+P  8"T  %TL  !9+ D 5BP0 %0L& !2+"  4"PH
M $XM+P!-+38 3"T\ $HM0P!)+4H 2"Y1 $<N60!&+V, 13!M $,P>@!",8D
M03&8 $$RJ ! ,KL /S+3 #\R[@! ,OT 0#+_ $ R_P"J,P  EC4  (8U  !Y
M-@  ;C4  &8U  !A,@  7#   %<P  !4, 8 43 . $XP%0!,,1T 2C$E $@Q
M+ !',3( 1C$Y $0Q0 !#,D< 0C)/ $$S5P! ,V  /S1K #XU>  ]-8< /#:6
M #LVIP [-KD .C;1 #HV[0 [-OP .S;_ #LV_P"F-@  DC<  ((X  !U.
M:S@  &,W  !=-@  5S,  %,T  !/- , 2S0, $DT$@!&-1H 134B $,U*0!!
M-2\ 0#4V #\V/0 ^-D0 /3=, #PW50 [.%X .CAI #DY=@ X.84 -SJ5 #<Z
MI0 V.K@ -3K/ #8Z[  V.OL -CG_ #<Y_P"B.   CCD  'XZ  !R.P  :#L
M %\Z  !9.0  4S8  $XW  !*.   1C@* $0Y$ !!.1< /SD? #XY)@ \.2T
M.SHT #HZ.P Y.T( .#M* #<[4P V/%P -3QG #0]=  S/8, ,SZ3 #(^I  Q
M/K8 ,3[- #$^Z@ Q/OH ,CW_ #(]_P">.P  BSP  'L\  !N/0  9#T  %P]
M  !5/   3CH  $D[  !%/   03T' #X]#@ \/14 .CX< #D^(P W/BH -C\Q
M #4_.  T/T  ,T!( #) 4  Q0%H ,$%E "]!<@ N0H$ +4*1 "U"H@ L0K4
M*T++ "Q"Z0 L0OD +4'_ "U!_P"9/0  ASX  '<_  !K/P  84   %D_  !2
M/P  23X  $0_  ! 0   /$$$ #E"#0 W0A( -4,9 #-#(0 R0R@ ,40O #!$
M-@ O1#T +D5% "U%3@ L15@ *T9C "I&;P I1GX *$:/ "='H0 F1[, )D?)
M "9&YP G1O@ *$7_ "A%_P"50   @D$  '-"  !G0@  7D(  %5"  !.0@
M14(  #]$   [10  -T8  #1'"@ Q2!  +T@6 "Y)'@ L224 *TDL "I),P I
M2CH *$I" "=*2P F2U4 )4M@ "1+;0 C2WP (DN- "%,GP A3+$ ($S' "!+
MY@ A2_< (DK_ ")*_P"00P  ?D0  &]$  !D10  6D4  %)%  !*1@  04<
M #Q(   W20  ,DL  "Y-!P K3@X *4X3 "=/&@ F3R$ )4\H "1/,  C4#<
M(E _ "%02  @4%( 'U%= !Y1:@ =47D '%&* !M1G  :4:\ &5'% !E1Y  :
M4/8 &T__ !Q/_P"*1@  >4<  &M'  !@2   5D@  $Y(  !'20  /DL  #E,
M   S3@  +E   "A3 @ D5 L (E40 "!5%@ ?5AX 'E8D !U6+  <5C, &U<[
M !I71  95TX &%=9 !=89@ 56'4 %%B' !18F@ 35ZP $E?" !)7X0 35O0
M%%7_ !15_P"$20  =$H  &9+  !<2P  4TL  $M,  !$30  /$\  #51   O
M5   *58  "19   >6P< &ET- !A=$@ 771D %EX@ !5>)P 47BX $UXW !)>
M0  17TH $5]5 !!?8@ /7W$ #E^#  U?E@ -7ZD #%Z^  Q>V@ -7?  #5S\
M  Y<_P!^30  ;DX  &).  !83P  3T\  $A0  ! 4@  .%0  #!7   J6@
M)%T  !]?   98@$ $V4) !%F#P 09A0 #V8;  YG(@ -9RD #6<R  QG.P +
M9T4 "F=0  EG70 '9VP !F=]  5GD  $9J,  F:W  -ESP $9>D !&3U  1D
M_ !W40  :5(  %U2  !44@  3%,  $-5   [6   ,UL  "M>   E80  'V0
M !EG   3:@  #VT&  MP#  (<!$ !W 6  5P'0 $<"0  W L  )P-0  <#\
M '!*  !P5P  <&4  '!V  !PB@  ;YX  &^R  !NR   ;>4  &WR  !M^0!P
M5@  8U8  %E6  #_XO__24-#7U!23T9)3$4 ! E15P  1U@  #Y;   V7P
M+F(  "9F   ?:@  &6T  !-P   .<P  "W8$  5X"P !> \  'D3  !Y&0
M>1\  'HF  !Z+P  >CD  'I$  !Z4   >E\  'IP  !Z@P  >I@  'JL  !Y
MP@  >-\  'CO  !W]P!J6P  7UL  %9;  !,7   0F   #EC   P:   *&P
M "!P   9=   $W<   Y[   )?@  !($"  """   @PT  (,0  "$%   A1D
M (8@  "&*   AS$  (<\  "'20  AU<  (=H  "'>P  AY   (:E  "%N@
MA=,  (3J  "$] !E8   7&   %%A  !&9   /&D  #)M   I<@  (7<  !E[
M   2@   #8,   B'   "B@   (T   ".!   C@D  (\-  "0$   D10  )(9
M  "3(   E"D  )4S  "50   EDX  )9?  "5<@  E8@  )6=  "4L@  E,@
M )/B  "3[@!A90  5F8  $IJ   _;@  -70  "MY   A?P  &80  !&)   ,
MC0  !I$   "4    F    )H   ";    G (  )T'  ">"P  GPX  *$2  "B
M&   HR   *4I  "F-@  ID0  *95  "F:   IGT  *:4  "EJ0  I+T  *31
M  "DY !;;   3W   $-U   X>P  +8$  ".'   9C0  $9(   N7   $G
M *    "C    I@   *@   "I    J@   *P   "M!   K@D  + -  "Q$0
MLQ<  +4@  "V*P  MSH  +=+  "X7   N'$  +B(  "XG0  N+$  +?"  "W
MT !4=@  2'P  #R"   QB0  )I   !N7   2G0  #*(   .G    JP   *X
M  "R    M@   +@   "X    N@   +L   "]    O@   , %  #!"P  PQ
M ,86  #)(   RBX  ,L^  #,4   S&0  ,UZ  #-D0  S:0  ,VT  #-P !-
M@P  08H  #61   IF0  'J   !.F   ,K    [$   "V    N@   +X   #"
M    Q@   ,@   #(    R@   ,L   #-    S@   -    #2 0  U0@  -D.
M  #=%0  X2$  .(Q  #D0P  Y58  .9K  #F@@  YY8  .>E  #FL #_  D
M_P % /\ !@#_  X _P 6 /\ (0#_ "T _P X /T 0P#Y $T ]0!5 /( 70#P
M &, [@!I .P ;P#J '0 Z0!Z .< ?P#F (4 Y "+ ., D0#A )D WP"A -P
MJ@#: +8 UP#& -4 X0#3 /0 T@#_ -$ _P#1 /\ SP#_ ,H _P#_  $ _P
M /\  0#_  P _P 2 /H '0#V "@ \P S /  /@#L $@ Z !0 .4 6 #B %X
MWP!D -T :@#; &\ V0!T -8 >@#4 '\ T@"% -  C #. ), S "< ,D I0#'
M +  Q@"^ ,0 U #" .X P0#^ ,  _P#  /\ OP#_ +X _P#_    _P   /\
M  #Z  < \0 / .L & #F ", X@ N .  . #; $( U0!+ -$ 4@#. %D RP!?
M ,D 90#' &H Q@!O ,0 = #" 'H P0"  +\ A@"] (X NP"6 +D H "W *H
MM@"W +0 R@"R .8 L0#X +  _P"O /\ KP#_ +  _P#_    _P   /<   #J
M  ( X0 , -< $P#0 !T S  H ,D ,@#& #P P@!% +\ 30"\ %, N@!9 +@
M7P"W &0 M0!I +0 ;@"R '0 L0!Z *\ @ "M (@ K "1 *H F@"H *4 I@"Q
M *0 P0"C -P H0#R *$ _P"@ /\ H #_ *$ _P#_    ]P   .@   #9
MRP ( ,, $ "] !@ N0 B +8 + "T #8 L@ _ *\ 1P"L $T JP!4 *D 60"G
M %X I@!C *4 : "C &X H@!T *  >@"> (( G "+ )L E0"9 )\ F "L )8
MN@"4 ,\ DP#K )( ^P"2 /\ D@#_ )$ _P#W    YP   -,   #&    NP "
M +, # "M !( J@ < *< )@"D #  HP X *  0 "> $< G !. )H 4P"9 %@
MEP!= )8 8P"5 &@ DP!N )( = "0 'P CP"% (T CP"+ )H B@"G (@ M0"&
M ,< A0#D (0 ]0"$ /\ @P#_ (, _P#L    TP   ,$!  "T    K    *8
M!P"@  X G0 6 )H ( "7 "D E0 R ), .@"1 $$ CP!( (T 30", %, BP!8
M (D 70"( &, AP!I (4 ;P"# '< @@"  (  B@!^ )8 ?0"C 'L L !Z ,(
M>0#= '@ \0!W /T > #_ '@ _P#>"@  Q L  +(,  "F"P  G0@  )D$  "5
M  H D0 1 (X &0"+ ", B0 L (< - "% #L @P!" (( 2 "  $X ?P!3 'T
M6 !\ %X >P!D 'D :@!X '( =@![ '0 A@!S )( <0"? '  K0!N +X ;0'6
M &T"[0!L _H ; /_ &P#_P#.$   MQ$  *82  ":$0  D1   (L.  ")"P,
MAP4, (0!$P"! 1P ?@(E 'P#+@!Z S8 > 0\ '<$0P!U!4@ = 5. ',%5 !Q
M!5D < 9? &X&9@!M!FX :P=X &H'@P!H")  9PF= &4)K !D";P 8PK4 &,+
M[ !B#/H 8@S_ &(,_P##%@  K1<  )T8  "0&   AQ8  ($4  !]$0  ? X&
M 'P*#@!X"A8 =0L? '(+* !P##  ;PPW &T,/@!L#$0 :PU* &D-3P!H#54
M9PU< &4-8P!C#FL 8@YU & .@0!?#HX 70^< %P0JP!;$+T 6A#6 %D1\ !9
M$?T 61'_ %D1_P"Y&P  I1T  )0>  "('@  ?AT  '@;  !T&   <14  '$1
M"0!O$!$ ;! 9 &D0(@!G$2H 9A$R &01.0!C$3\ 8A%% & 22P!?$E$ 71)8
M %P27P!:$V@ 61-R %<4?0!6%(L 5!69 %,5J0!2%KH 41;2 %$7[0!1%_T
M41?_ %$7_P"R(   GB(  (XB  "!(P  =R(  ' A  !L'@  :1L  &<8! !F
M%0X 8Q85 &$6'@!?%B8 718M %P7- !:%SL 61=! %@81P!6&$T 51A4 %,8
M7 !2&60 41EN $\:>@!.&X@ 31N7 $L<I@!*'+@ 2AW/ $D=ZP!)'?L 21W_
M $H=_P"L)   F"4  (@F  ![)P  <28  &HE  !F(P  8B$  & >  !>' L
M6QL2 %D<&@!7'"( 51PI %0<, !3'3< 41T] % =0P!/'4H 31Y1 $P>6 !+
M'V$ 21]K $@@=P!'((4 1B&4 $0BI !$(K8 0R+, $,CZ0!#(_H 0R/_ $,B
M_P"F)P  DRD  (,J  !V*@  ;2H  &4I  !@)P  7"4  %DC  !7(0< 52$/
M %(A%@!0(1X 3B$E $TB+ !,(C, 2B(Y $DB0 !((D8 1R-- $4C50!$)%X
M0R1I $(E=0! )H, /R:2 #XGHP ^)[0 /2?* #THZ  ]*/D /2?_ #XG_P"B
M*@  CBL  '\M  !R+0  :"T  &$L  !<*P  6"@  %0F  !1)@0 3B4- $PE
M$P!*)AH 2"8B $<F*0!%)B\ 1"8V $,G/ !!)T, 0"=+ #\H4P ^*5P /2EF
M #PJ<@ [*H$ .BN0 #DKH0 X++( -RS( #<LY@ X+/@ ."S_ #@L_P"=+
MBBX  'LO  !O,   93   %TO  !8+@  4RL  % J  !,*@  22H+ $8J$0!$
M*A< 0BH? $$J)0 _*BP /BLS #TK.0 \*T  .RQ( #HL4  Y+5D ."YD #<N
M<  V+W\ -2^/ #0PGP S,+$ ,C#' #(PY0 S,/< ,S#_ #0O_P"9+P  AS$
M '<R  !K,@  8C(  %HR  !4,0  3R\  $LM  !'+@  1"X( $$N#@ _+A0
M/2X< #LN(@ Y+RD ."\O #<O-@ V,#X -3!& #4Q3@ T,5< ,S)B #(R;@ Q
M,WT ,#.- "\TG@ N-+  +33% "TTXP N-/8 +S/_ "\S_P"5,0  @S,  '0T
M  !H-0  7C4  %<T  !1-   2S(  $8Q  !",@  /S(% #PR#0 Y,Q( .#,9
M #8S(  T,R8 ,S,M #(T-  Q-#L ,#5# # U3  O-E4 +C9@ "TW;  L-WL
M*S>+ "HXG  I.*X *#C# "@XX@ I./4 *C?_ "HW_P"2-   ?S4  '$V  !E
M-P  6S<  %0W  !--@  1S8  $(U   ]-@  .C8" #<W"P T-Q  ,C<6 #$X
M'0 O."0 +C@K "TY,@ L.3D *SE! "HZ20 J.E, *3M> "@[:@ G.WD )CR)
M "4\FP D/*T (SS" ",\X  D//0 )3O_ "4[_P"--@  ?#@  &TY  !B.0
M6#H  %$Y  !*.0  1#D  #TY   Y.@  -3L  #(["  O/ X +3T4 "P]&@ J
M/2$ *3TH "@^+P G/C8 )CX^ "4_1P D/U  (T!; ") :  A0'8 ($"' !]!
MF0 ?0:L 'D'  !Y!W@ ?0/, 'T#^ " __P").0  >#H  &D[  !>/   53P
M $T\  !'/   0#P  #@]   T/@  ,$   "U!!0 J0@P )T(1 "9#&  D0QX
M(T,E ")#+  A1#, ($0[ !]$1  >14X '459 !Q%90 ;170 &D6% !E&EP 9
M1JD &$:^ !=%W  81?$ &43] !I$_P"$/   <ST  &8^  !;/P  4C\  $H_
M  !$/P  /4   #9!   Q0P  +$0  "=& 0 D1PH (4@/ "!)%  >21L '4DB
M !Q)*0 ;2C  &DHX !E*00 82DL %TM5 !9+8@ 52W$ %$N" !-+E  22Z<
M$DN\ !%+V0 22O  $TK\ !1)_P!_/P  ;T   &%!  !70@  3D(  $="  !!
M0@  .D,  #)%   M1P  *$D  "-+   >308 &T\- !A0$0 74!< %E > !50
M)0 44"P $U$T !)1/0 144< $5%2 !!17P /4FT #E)^  U1D0 -4:0 #%&X
M  Q1T0 -4.P #5#Z  Y/_P!Y0P  :D0  %U$  !310  2T4  $1%   ^1@
M-D@  "]*   I3   )$\  !]1   :4P  %%8) !%7#@ 06!, $%@9  ]8(  .
M6"@ #5@P  U8.0 ,6$, "UA.  I86@ (6&@ !UAY  98C  %6)\ !%BS  17
MR@ %5^8 !5?S  96_ !S1@  9$<  %E(  !02   2$@  $%)   Z2@  ,DT
M "M0   E4@  (%4  !I8   56@  $%T&  Q@#  *8!  "6 5  A@'  '8",
M!6 K  1@-  #8#T  6!)  !@50  8&,  &!S  !@A@  7YH  %^N  !?Q
M7N(  %[P  !>^ !L2@  7TL  %5+  !,3   14P  #U.   U4   +E,  "=6
M   @60  &EP  !5?   08@  #64$  AG"P #9PX  &@3  !H&   :!\  &DF
M  !I+@  :3@  &E#  !I3P  :5T  &EM  !I@   :90  &BI  !HOP  9]P
M &;N  !F]P!F3P  6D\  %%/  !*3P  05$  #A4   P5P  *%L  "%>   :
M8@  %&4  !!H   ,:P  !VX#  %P"0  < T  '$0  !Q%   <AH  ',A  !S
M*   <S$  ',\  !T2   <U8  '-F  !S>0  <XX  '.C  !RN0  <=(  ''K
M  !P] !A4P  5E,  $]3  !%50  .U@  #)<   J8   (F0  !MH   4;
M#V\   MR   &=@   'D   !Z!@  >@H  'L.  !\$0  ?14  'X;  !_(@
M@"H  ( U  " 00  @$\  (!?  " <0  @(8  ("=  !_L@  ?LH  '[E  !]
M\0!<6   5%@  $E:   _70  -6$  "QE   C:@  &V\  !1S   .=P  "7L
M  -_    @@   (0   "& 0  A@8  (@*  ")#0  BA   (L5  ",&P  CB(
M (\L  "/.   CT8  (]6  "/:   CWX  (^5  ".JP  C<$  (W<  ",ZP!9
M70  3E\  $-B   X9@  +FP  "1Q   <=P  %'P   Z!   (A0   (D   "-
M    D    )(   "3    E    )8#  "7"   F P  )H/  ";$P  G1H  )\C
M  "@+@  H#P  *!,  "@7@  H'0  )^,  "?H@  G[<  )[+  ">X !39
M1V@  #QM   Q<P  )WD  !U_   4A0  #8L   :0    E    )@   "<
MGP   *$   "B    I    *4   "G    J 0  *H)  "L#0  K1(  + 9  "R
M(P  LC$  +)"  "R5   LFD  +*   "RF   L:P  +*_  "QS@!,;@  0',
M #5Z   J@0  'X@  !6.   .E0  !IH   "?    I    *@   "L    KP
M +$   "Q    LP   +4   "V    N    +H   "\!@  O@P  , 1  ##&0
MQ28  ,4W  #&20  QET  ,=R  #'B@  R)\  ,BO  #(O !&>@  .8$  "Z)
M   BD   %Y@   ^?   'I0   *H   "O    LP   +<   "\    OP   ,$
M  #"    Q    ,4   #'    R0   ,L   #-    SP,  -(*  #6$   W!H
M -TJ  #>/   WU   .!E  #A>P  X9$  .*B  #BK0#_  ( _P   /\  P#_
M  P _P 3 /\ '0#_ "@ _@ S /L /@#W $@ \P!0 /  5P#M %X ZP!D .@
M:0#G &\ Y0!T ., >0#B '\ X "% -X C #< ), V0"< -8 I@#3 +$ T0#
M ,\ V@#. /$ S #_ ,L _P#+ /\ Q@#_ ,$ _P#_    _P   /\   #_  @
M^P 0 /8 &0#R "0 [P N .T .0#H $( XP!+ .  4@#= %D V0!? -8 9 #3
M &D T0!N ,\ = #. 'D S !_ ,H A@#( (X Q@"6 ,0 H #" *L P "Y +X
MS0"\ .H NP#\ +H _P"Z /\ N@#_ +8 _P#_    _P   /X   #T  0 ZP -
M .0 % #? !\ VP I -@ ,P#3 #T S@!% ,H 30#' %, Q0!9 ,, 7P#! &0
MOP!I +T ;@"[ ', N@!Y +@ @ "V (@ M "0 +( F@"Q *4 KP"R *T Q "L
M .$ JP#V *H _P"J /\ J@#_ *H _P#_    _0   .X   #B    U0 * ,T
M$0#' !D Q  C ,$ +0"_ #< NP _ +< 1P"U $X L@!3 +  60"O %X K0!C
M *P : "K &T J0!S *@ >@"F ($ I "* *, E "A )\ GP"L )X NP"< -(
MFP#N )H _P": /\ F0#_ )D _P#^    [@   -X   #+    P0 % +D #0"T
M !0 L0 > *X )P"K #  J@ Y *< 00"D $@ H@!- *$ 4P"? %@ G@!= )T
M8@"; &< F@!M )@ <P"7 'L E0"$ )0 C@"2 )D D "F (X M "- ,@ C #F
M (L ^0"* /\ B@#_ (L _P#P    VP   ,<   "Z    L    *@ "@"D !
MH  8 )T (0"; "H F@ S )@ .P"6 $$ E !( )( 30"1 %( CP!7 (X 7 ",
M &$ BP!G (H ;@"( '4 AP!^ (4 B "# )0 @@"@ (  KP!_ ,  ?@#= 'T
M\@!] /\ ?0#_ 'T _P#@    Q@   +4   "J    H@   )L !0"5  T D@ 3
M )  ' "- "0 BP M (H - "( #L A@!" (4 1P"# $T @@!2 ($ 5P!_ %P
M?@!B 'T : ![ '  >@!Y '@ @P!V (\ =0"< '0 J@!R +H <0#1 '  [ !P
M /L < #_ '  _P#-!   MP8  *<'  ";!@  DP0  (X   "*  @ A@ / (0
M%@"! !X ?P G 'T +@!\ #8 >@ \ 'D 0@!W $< =@!, '4 4@!S %< <@!=
M '$ 8P!O &L ;@!T &P ?@!K (H :0"8 &@ I@!G +8 9@#+ &4 YP!E /<
M90#_ &4 _P# #   JPT  )L.  "/#@  A@T  ($+  !^!P$ ? $+ 'D $0!W
M !@ =0 A ', *0!Q #  ;P V &X / !L $( :P!' &H 30!I %( : !8 &8
M7P!E &< 8P!P &(!>@!@ 8< 7P*5 %X"HP!< [, 7 /' %L$Y !;!?0 6P;^
M %L&_P"U$   H1(  )$3  "%$P  ?!(  '81  !S#@  <@P$ '$'#0!N!!(
M; 0; &D%(P!G!2H 9@8Q &0&-P!C!CT 8@=# &$'20!?!TX 7@A5 %T(7 !;
M"6, 6@EM %@*> !7"H4 5@N3 %0+H@!3"[, 4@S' %(,Y !1#?4 40W_ %$-
M_P"M%0  F1<  (D8  !]&0  =!@  &T7  !J%   9Q$  &<.!P!F# X 8PP5
M &$,'0!?#"4 70TL %P-,P!;#3D 6@T_ %@-10!7#4L 5@Y1 %4.60!3#F$
M4@YK % /=@!.$(, 31"2 $P0H@!+$+( 2A'( $D1Y0!)$?< 21+_ $D1_P"E
M&0  DAP  (,=  !V'@  ;1T  &8<  !B&@  7Q<  %X4 0!>$0H 6Q 1 %D1
M& !7$2  51$G %01+@!3$30 41$[ % 200!/$D< 3A). $P250!+$UX 21-G
M $@4<P!&%(  116/ $05GP!#%K  0A;% $(7XP!"%_8 0A?_ $(7_P"?'0
MC"   'TA  !Q(@  :"(  &$A  !<'P  61P  %<9  !5%@8 5!4. %$5% !/
M%AP 3A8C $P6*@!+%C  2A8W $D7/0!'%T, 1A=* $484@!#&%H 0AED $$9
M<  _&GT /AN- #T;G0 \'*X .QS# #L<X0 ['?4 .QS_ #P<_P":(0  AR,
M '@D  !L)0  8R4  %PD  !7(P  4R   %$>  !/' ( 31L, $L:$0!(&Q@
M1QL@ $4;)@!$&RT 0QPS $(<.0! '$  /QU' #X=3P ]'E@ /!YB #H?;0 Y
M'WL .""+ #<AFP V(:T -2'! #4AWP U(?, -B'_ #8A_P"6(P  @R8  '0G
M  !H*   7R@  %@G  !3)@  3R0  $PB  !)(   1R ) $0?#P!"'Q4 0" <
M #\@(P ^("D /" O #LA-@ Z(3T .2%$ #@B3  W(E4 -B-? #0C:P S)'D
M,B6) #$EF@ P):L ,":_ "\FW  P)O( ,";_ #$E_P"1)@  ?R@  '$J  !E
M*@  7"H  %4J  !/*0  2R@  $@E  !$)   020% #\D#0 ])!( .R09 #DD
M'P W)"8 -B0L #4E,P T)3H ,R9! #(F2@ Q)U, ,"== "\H:0 N*7< +2F'
M "PIF  K*JH *BJ] "HJV@ K*O$ *RK^ "PI_P"-*   ?"H  &TL  !B+0
M62T  %$M  !,+   1RL  $,H   _*   /"@" #DH"P W*!  -2@6 #,H'  R
M*", ,"@I "\I,  O*C< +BH_ "TK1P L*U$ *RQ; "HL9P I+74 *"V% "<M
MEP F+J@ )2Z\ "4NV  F+O  )B[] "<M_P"**P  >"T  &HN  !?+P  5B\
M $XO  !(+@  0RT  #\L   [+   -RP  #0L"0 R+ X ,"T3 "XM&@ M+2
M*RTG "HN+0 J+C4 *2\] "@O10 G,$X )C!9 "4Q90 D,7, (S&# "(RE0 A
M,J< (3*[ " RU  A,N\ (C'\ "(Q_P"&+0  =2\  &<P  !<,0  4S$  $LQ
M  !%,0  0#   #LP   V,   ,S   # Q!@ M,0T *S$1 "DR%P H,AX )S(D
M "4S*P E,S( )#,Z ",T0P B-$P (357 " U8P ?-7$ 'C:! !TVDP <-J4
M&S:Y !LVT@ <-NT '3;[ !TU_P"",   <3(  &,S  !9-   4#0  $DT  !"
M,P  /3,  #<S   Q-   +C4  "LU @ H-@L )3<0 "0W%0 B-QL (3@B " X
M*  ?.#  'C@W !TY0  <.4D &SI4 !HZ8  9.FX &#I_ !<[D0 7.Z0 %CNW
M !4[T  6.NP %SKZ !@Y_P!],@  ;30  & U  !5-@  338  $8V  ! -@
M.C8  #0V   N.   *CD  "8Z   C.P@ (#P. !X]$@ =/1@ '#T? !L^)0 :
M/BT &3XT !<^/0 6/T< %3]1 !0_7@ 4/VP $T!\ !) CP 10*( $4"V !!
MS@ 1/^L $C_Y !(^_P!Y-0  :3<  %PX  !2.0  2CD  $,Y   ].0  -SD
M #$Z   K/   )ST  "(_   >000 &D(+ !A#$  70Q4 %40; !1$(@ 31"D
M$T0Q !)$.@ 114, $$5. !!%6P .16D #D5Y  U%C  -19\ #$6R  M%R0 ,
M1>4 #43V  U$_P!T.0  93H  %@[  !/.P  1SP  $ \   Z/   -#P  "X^
M   H0   (T(  !]$   :1@  %4@( !)*#0 12A( $$H8  ]+'@ .2R4 #4LM
M  U+-@ ,2T  "TM*  I+5@ )2V0 "$MT  =+AP %2YH !$NN  1*Q  %2N
M!4KP  9)^@!N/   8#T  %0^  !+/@  1#X  #T^   W/P  ,4   "I"   D
M10  'T<  !I)   53   $4X%  Y1"P +41  "E$4  E1&P (42( !U$I  51
M,@ $4CL  U)&  %24@  4E\  %)O  !2@0  498  %&I  !1OP  4-P  %#N
M  !0]P!H0   6T$  %!!  !(00  04$  #M"   T0P  +44  "9(   @2P
M&TT  !90   14P  #E4$  I8"@ &6 X  E@2  !9%P  61T  %DE  !9+0
M638  %E!  !930  6EH  %II  !9?   69   %FE  !8N@  6-4  %?L  !7
M]@!C1   5D4  $U%  !%10  /T4  #='   O20  *$P  ")/   ;4@  %E4
M !%8   -6@  "5T#  1?"0  8 T  & 0  !A%   81D  &(@  !B)P  8C$
M &([  !B1P  8E4  &-D  !B=@  8HL  &*@  !AM@  8<\  &#J  !@]0!=
M2   4DD  $I(  !#2   .DH  #)-   J4   (U,  !Q7   66@  $5T   U@
M   (8P   V8!  !G!@  : L  &D.  !J$0  :Q4  &P;  !M(@  ;2H  &TT
M  !M0   ;4X  &U=  !M;P  ;80  &R:  !LL   :\@  &OF  !J\P!830
M3DT  $A,   ^3@  -5$  "Q4   D6   '5P  !9@   09   #&<   =K   !
M;@   '    !R P  <@<  ',+  !U#@  =A$  '<6  !X'   >2,  'HM  !Z
M.0  >D<  'I6  !Y:   >GP  'F4  !XJ@  >,$  '??  !W[P!440  3%$
M $)2   X50  +UD  "9>   >8@  %F<  !!K   +;P  !7,   !W    >@
M 'P   !^    ?P(  ( &  "!"@  @PT  (01  "&%0  B!P  (DE  "*,
MBCX  (E-  ")7P  B7,  (B+  "(H@  A[D  (?1  "&Z !25@  1U<  #Q:
M   R7P  *&0  !]I   6;P  $'0   IY   "?0   ($   "%    B    (H
M  ",    C0   (\   "0!   D@@  ),,  "5$   EQ4  )D=  ";)P  FS0
M )M$  ":5@  FFH  )F"  ":F@  F+   )C'  "7W@!+7   0&   #5E   K
M:@  (7$  !=W   0?0  "8,   &(    C    )$   "5    F    )H   ";
M    G0   )\   "@    H@   *0%  "F"@  J X  *H4  "M'0  K2H  *TY
M  "M2P  K5\  *UW  "LD   JZ<  *NZ  "KRP!%9@  .6L  "YQ   C>
M&7\  !"&   )C0   ),   "8    G0   *$   "E    J    *L   "K
MK@   *\   "Q    LP   +4   "W 0  N0<  +P-  "_$P  PA\  ,(N  #"
M0   PE0  ,%K  #!@P  P)L  ,&M  #!O  ^<@  ,G@  ">    <B   $I
M  J7    G0   *,   "H    K0   +(   "V    N0   +L   "\    O@
M ,    #"    Q    ,8   #(    RP   ,X%  #1#0  UA0  -<C  #8-0
MV4D  -I>  #;=0  VXP  -R?  #<JP#_    _P   /\   #_  D _P 0 /\
M&0#^ "0 _  O /D .0#T $, \ !+ .T 4@#J %D YP!? .0 9 #B &D X !N
M -X <P#< 'D V@!_ -< A@#4 (X T0"6 ,\ H0#, *P R@"[ ,@ T@#& .X
MQ@#_ ,4 _P#% /\ OP#_ +H _P#_    _P   /\   #^  4 ]P . /( %0#N
M !\ ZP J .D - #C #T W@!% -D 30#4 %, T0!9 ,X 7@#, &, R@!H ,D
M;0#' ', Q0!Y ,, @ #! (@ OP"0 +T FP"[ *8 N0"T +< R "V .8 M0#[
M +0 _P"T /\ LP#_ *X _P#_    _P   /@   #M    Y0 + -T $0#7 !H
MT@ D ,\ +@#+ #< QP!  ,, 1P#  $X O@!3 +P 60"Z %X N !C +8 : "U
M &T LP!S +$ >0"O ($ K0"* *L E "I *  J "M *8 O@"E -L I #T *0
M_P"C /\ HP#_ *( _P#_    ]@   .8   #7    RP & ,0 #@"^ !4 NP ?
M +D * "W #$ M  Z +  00"M $@ JP!. *D 4P"G %@ I@!< *0 80"C &<
MH0!L *  <P"> 'H G0"# )L C@"9 )D EP"F )8 M@"5 ,P E #K ), _0"3
M /\ DP#_ ), _P#W    Y    -    #!    MP " *\ "P"K !$ IP 9 *4
M(@"C "L H@ S )\ .P"< $( FP!( )D 30"7 %( E@!7 )4 6P"3 &$ D@!F
M )  ;0"/ '0 C0!] (P AP"* ), B "@ (< KP"% ,( A0#B (0 ]P"$ /\
MA #_ (0 _P#E    S0   +P   "O    I@   )X !P":  X E@ 4 )0 '0"2
M "4 D0 M )  -0"- #P C !" (H 1P"( $P AP!1 (8 5@"$ %L @P!@ ($
M9P"  &X ?@!W 'T @0![ (T >@": '@ J0!W +H =@#3 '8 [P!V /X =0#_
M '4 _P#0    NP   *L   "?    EP   )   @"+  L B  0 (8 %P"$ "
M@@ G ($ +P!_ #4 ?0 \ 'P 00![ $8 >0!+ '@ 4 !W %4 =@!; '0 80!S
M &D <0!Q '  >P!N (< ;0"5 &L HP!J +0 :@#) &D Z !I /D :0#_ &D
M_P#     K    )P"  "0 @  B    (,   !_  8 >P - 'D $@!W !H =@ B
M '0 *0!S #  <0 V '  / !O $$ ;0!& &P 2P!K %  :@!6 &@ 7 !G &0
M90!L &0 =@!C (( 80"0 &  GP!? *\ 7@## %X X0!> /0 70#_ %T _P"T
M!P  H D  ) +  "$"P  ? H  '<'  !T!   <0 ) &\ #P!M !4 :P < &D
M(P!H "H 9P Q &4 -@!D #P 8P!! &( 1@!@ $P 7P!2 %X 6 != %\ 6P!H
M %H <@!8 'X 5P", %8 FP!5 *L 5 "^ %0 V@!3 .\ 5 #[ %0 _P"I#0
ME@X  (<0  !Z$   <A   &P.  !I#   9PD# &8$"P!D !  8@ 7 &  '@!>
M "4 70 K %P ,0!: #< 60 \ %@ 0@!7 4< 5@%. %4"5 !3 EP 4@-E %$#
M;P!/!'L 3@2* $T%F0!,!:D 2P6\ $H&U !*!^T 2@?Y $H'_P"A$   CA(
M 'X4  !S%   :A0  &03  !@$0  7@\  %T-!0!="0T 6@82 %@'&0!6!R
M50<G %,'+0!2"#, 40@X % (/@!/"40 3@E* $P)40!+"ED 2@IB $@+;0!'
M"WH 1@R( $0,F !##*D 0@V\ $(-U0!"#>X 0@W[ $(-_P":%   AQ8  '@8
M  !L&0  8QD  %T8  !9%@  5A,  %01  !4#@@ 4PT. %$-% !/#1L 30TB
M $P-* !+#2X 2@TT $D-.@!'#D$ 1@Y' $4.3P!$#E< 0@]A $$0;  _$'D
M/A"( #T1F  [$:D .Q&\ #H1U@ Z$?  .A+] #L1_P"3&   @1H  ',<  !G
M'0  7AT  %@<  !3&P  4!@  $X6  !,$P, 3!$+ $H0$ !($1< 1A$> $41
M) !$$2H 0A$P $$1-P! $CT /Q)$ #T23  \$U0 .Q-> #D4:0 X%'8 -Q6%
M #85E@ T%J< -!:Z #,6TP S%NX -!;\ #06_P".&P  ?!T  &X?  !C(
M6B   %,@  !.'@  2AT  $@:  !&&   118' $,5#@!!%1, /Q4: #X5(  ]
M%2< .Q4M #H6,P Y%CH .!9! #<720 U%U$ -!A; #,99@ R&7, ,!J# "\:
ME  N&Z4 +1NX "T;T  M&^P +AO[ "X;_P"*'@  >"   &HB  !?(P  5B,
M $\B  !*(0  1B   $,>  !!&P  /QH# #T:#  [&1$ .1D6 #<:'0 V&B,
M-1HI #0:,  S&S8 ,1L^ # <1@ O'$\ +AU9 "T=9  L'G$ *Q^! "H?D@ I
M'Z0 *""W "<@S@ G(.L *"#Z "D?_P"&(   =",  &<D  !<)0  4R4  $PE
M  !')   0B,  #\A   ]'P  .AX  #<>"0 U'@X ,QX3 #$>&@ P'B  +QXF
M "X?+0 M'S, +" [ "L@0P J(4P *2%6 "@B8@ F(F\ )2-_ "0CD  C(Z(
M(B2U "(DS  B).D (R3Y "0C_P""(P  <24  &,F  !9)P  4"@  $DG  !#
M)P  /R8  #LD   X(@  -2(  #(B!@ P(@T +B(1 "PB%P J(AT *2(C "@C
M*@ G(S$ )B0X "4E00 D)4H (R94 "(F8  A)VT ("=] !\GCP >**$ 'BBT
M !THR@ =*.@ 'BCX !\G_P!^)0  ;B<  & I  !6*0  32H  $8J  !!*0
M/"@  #<G   T)@  ,"8  "TF P K)PL *"<0 "<G%  E)QH )"<A ",H)P B
M*"X (2DV " I/@ ?*D@ 'BI2 !TK7@ <*VL &RM[ !HLC0 9+)\ &"RR !@L
MR0 8+.< &2OW !HK_P!Z)P  :BH  %TK  !3+   2BP  $,L   ^*P  .2L
M #0J   P*@  *RH  "DK   F*P@ (RP. "(L$@ @+!@ 'RP> !XM)0 =+2P
M'"TS !LN/  :+D4 &2]0 !@O7  7+VD %C!Y !4PBP 4,)X %#"Q !,PQP 3
M,.4 %##V !4O_P!V*@  9RP  %HM  !0+@  2"X  $$N   [+@  -BT  #$M
M   L+0  )R\  "0O   A, 4 'S$, !PQ$  ;,A4 &C(< !DR(@ 8,BD %S,Q
M !8S.0 5,T, %#1- !,T60 2-&< $35W !$UB0 0-9P $#6P  XUQ@ /-.0
M$#3U ! T_P!R+   8RX  %<P  !-,   13   #XP   X,   ,S   "\P   I
M,0  )#(  "$S   =-0( &C8) !<W#@ 5-Q, %#@9 !,X'P 2."8 $C@N !$Y
M-@ 0.4  $#E+  XY5P ..F0 #3IT  PZA@ ,.ID "SFL  HYP0 *.=X "SGQ
M  PX_ !N+P  7S$  %,R  !*,P  0C,  #LS   V,P  ,3(  "PS   G-
M(38  !TX   9.0  %3L& !(]#  0/A  $#X5  X^'  ./B, #3XJ  P^,P ,
M/CP "S]'  H_4@ (/V  !S]O  8_@0 %/Y0 !#^H  ,^O  $/M< !3[L  4^
M]P!I,P  6S0  % U  !'-0  /S4  #DU   T-0  +C4  "DW   C.   'CL
M !H\   6/P  $D$$  Y#"@ ,1 X "D03  E$&0 (1"  !T0G  9$+P %1#@
M T5"  )%3@  15L  $5J  !%?   19   $2D  !$N0  1-$  $3J  !#]0!D
M-@  5S<  $PX  !#.   /#@  #<X   Q.   *SD  "4[   @/0  &D   !9"
M   21   #D<$  M)"0 '2@T !$L1  %+%@  2QP  $LC  !+*P  2S0  $L^
M  !,20  3%<  $QF  !,=P  2XP  $NA  !+M0  2LX  $KI  !*]0!?.@
M4CL  $@[  ! .P  .CL  #0[   N/   )SX  ")!   <0P  %D8  !))   .
M2P  "TX#  =0"  "40P  %$0  !2$P  4Q@  %,?  !3)@  4R\  %,Y  !3
M10  4U(  %-A  !3<@  4X<  %*<  !2L0  4<H  %'G  !1] !9/@  3CX
M $4^   ^/@  .#X  #!    I0@  (T0  !U'   72@  $DT   Y0   +4P
M!E4"  !7!P  6 L  %D.  !:$0  6A4  %L:  !<(0  7"H  %PT  !</P
M7$T  %Q;  !<;   7($  %N7  !;K0  6L4  %KD  !9\P!40@  2D(  $)"
M   \0@  -$,  "Q&   E20  'DP  !=/   24P  #E8   I9   %6P   %X
M  !@!   80@  &(,  !C#@  9!$  &46  !F'   9R,  &<M  !G.0  9T8
M &=5  !G9@  9WH  &:1  !EJ   9<   &3>  !D\ !/1@  1T8  $!%   W
M1P  +TH  "9-   ?40  &%4  !)9   -7   "&    )C    9@   &@   !J
M    :P0  &P(  !M#   ;PX  ' 2  !R%P  <QT  '0F  !T,@  =#\  '1.
M  !S7P  ='(  '.*  !RH0  <;@  ''4  !P[ !,2@  14H  #M+   R3@
M*5(  "!6   86P  $E\   UD   ':    &L   !O    <@   '4   !V
M=P   'D"  !Z!@  ? H  'X.  " $0  @A8  (0>  "$*0  A#8  (1%  "$
M5@  @VH  (.!  ""F0  @;$  (#)  " Y0!*3@  /U   #53   K5P  (EP
M !EB   29P  #&P   5Q    =0   'D   !]    @0   (,   "%    A@
M (@   ")    BP0  (T(  "/#0  DA   )06  "6(   EBP  )8[  "63
ME6   )5V  "4D   DZ<  )*]  "2U0!$50  .5D  "]=   D8P  &FD  !)O
M   ,=0  !'L   "     A0   (D   "-    D0   ),   "4    E@   )@
M  ":    G    )X   "@!@  H@L  *40  "H%P  J2,  *DQ  "I0P  J58
M *AM  "FAP  IYX  *:S  "EQP ^7@  ,F,  "=J   =<   $W@   Q_   #
MA0   (L   "1    E@   )L   "?    H@   *0   "E    IP   *D   "K
M    K0   +    "R    M0(  +<)  "[$   OA@  +XF  "^.   ODL  +UA
M  "\>@  NY0  +JI  "ZN0 W:@  *W   "!X   6@   #8@   6/    E@
M )P   "B    IP   *P   "P    LP   +8   "W    N0   +L   "]
MOP   ,(   #%    R    ,H   #."   TA   -4;  #5+   U$   -17  #3
M;@  U(8  -2;  #3JP#_    _P   /\   #_  4 _P . /\ %0#\ "  ^0 J
M /8 - #Q #T [0!& .D 30#F %, Y !9 .$ 7@#> &, W !H -D ;@#5 ',
MTP!Y -  @ #. (@ RP"1 ,D G #& *< Q "W ,( S #  .P OP#_ +X _P"]
M /\ MP#_ +( _P#_    _P   /\   #Z  $ \P + .T $@#H !L Y0 E .0
M+@#? #@ V !  -( 1P#. $X RP!4 ,@ 60#& %X Q !C ,( 9P#  &T OP!S
M +T >@"[ ($ N0"+ +8 E0"T *$ L@"O +  P@"N ., K@#Z *P _P"M /\
MJ0#_ *8 _P#_    _P   /(   #F    W0 ' -( #@#- !8 R@ @ ,@ *0#%
M #( P  Z +P 0@"Y $@ MP!. +4 4P"S %@ L0!= +  8@"N &< K !L *H
M<P"I 'L IP"$ *4 C@"C )H H0"H )\ N0"> -( G0#R )P _P"= /\ G #_
M )D _P#\    [@   -T   #,    P0 " +H # "V !( L@ : +  (P"O "P
MK0 T *D / "F $( I !( *( 30"@ %( G@!7 )T 6P"< &  F@!F )D ; "7
M '0 E0!] ), AP"1 ), D "A (X L0"- ,8 C #H (L _0", /\ C #_ (P
M_P#M    V    ,4   "W    K    *8 " "A  X GP 5 )T '@"; "8 F@ N
M )< -0"5 #P DP!" )$ 1P"0 $P C@!1 (T 50"+ %H B@!@ (D 9@"' &T
MA0!V (0 @ "" (P @ ": '\ J0!] +P ? #< 'P ]0!\ /\ ? #_ 'P _P#9
M    P0   +$   "D    G    )0  P"0  P C0 1 (L & ") "  B0 H (<
M+P"% #8 @P \ (( 00"  $8 ?P!+ 'T 3P!\ %0 >P!: 'D 8 !X &< =@!P
M '4 >@!S (8 <0"3 '  H@!O +0 ;@#, &X [0!N /X ;@#_ &X _P#$
MKP   *    "4    C    (8   "!  @ ?@ . 'P % ![ !L >0 B '@ *0!W
M #  =0 V '0 .P!R $  <0!% '  2@!O $\ ;0!4 &P 6P!K &( :0!J &@
M= !F (  90". &, G0!B *T 80#" &$ Y !A /@ 80#_ &$ _P"T    H
M )$   "&    ?@   'D   !U  , <0 + &\ $ !M !8 ;  = &L ) !K "H
M:0 P &@ -@!F #L 90!  &0 10!C $H 80!/ &  5@!? %T 70!E %P ;P!:
M 'H 60"( %@ F !7 *@ 5@"[ %8 V !6 /$ 5@#_ %8 _P"H 0  E 4  (4'
M  !Z!P  <@8  &P$  !I 0  9P ' &0 #0!C !$ 80 8 &  'P!? "4 7@ K
M %T , !; #8 6@ [ %D 0 !8 $4 5P!+ %8 40!5 %@ 4P!A %( :@!0 '8
M3P"$ $X DP!- *0 3 "V $P S0!, .L 3 #Z $P _P"="0  BPL  'P-  !P
M#0  : T  &(,  !?"@  708! %P!"0!:  X 6  3 %< &0!6 "  50 F %,
M*P!2 #$ 40 V %  .P!/ $$ 3@!' $T 30!+ %4 2@!= $D 9P!' ', 1@"
M $4 D !$ *$ 0P"R $, R !# .8 0P#U $, _P"5#0  @P\  '00  !I$0
M8!$  %H0  !6#@  5 T  %,*! !3!@L 40,0 $\!%0!. 1L 3 $A $L!)P!*
M BP 20(R $@"-P!' ST 10-# $0#2@!#!%$ 0@1: $ %9  _!7  /@9^ #T&
MC@ \!Y\ .P>Q #H'Q@ Z!^, .@?S #H(_ ".$   ?!(  &X4  !B%0  6A4
M %04  !0$P  31$  $L.  !+#08 2@H, $D($0!'"!8 10@= $0((P!"""@
M00DN $ ),P _"3D /@I  #T*1P \"D\ .@M8 #D+8P X#&\ -@Q^ #4,C@ T
M#9\ ,PVQ #(-QP R#>, ,@WT #(-_@"($P  =Q4  &D7  !>&   51@  $\8
M  !*%@  1Q4  $43  !#$ ( 0PX( $(-#@! #1( /PT8 #T-'P \#20 .PTJ
M #D-,  X#C< -PX] #8.10 U#DT ,P]7 #(/8@ Q$&X +Q!] "X0C@ M$:
M+!&R "L1R  K$>8 *Q'V "P1_P"#%@  <AD  &0:  !9&P  41L  $L;  !&
M&@  0A@  #\7   ^%   /!($ #L1"@ Z$!  .! 5 #<0&P U$2$ -!$G #,1
M+0 R$3, ,!$Z "\20@ N$DL +1-4 "L37P J%&P *11[ "@4C  G%9X )A6P
M "45Q@ E%>0 )17V "85_P!^&0  ;AL  & =  !6'@  31X  $<>  !"'0
M/AP  #H:   X&   -Q8  #45!P T% T ,A02 # 4%P O%!T +10C "P5*@ K
M%3  *A4W "D6/P H%D@ )Q=2 "8870 D&&H (QEY "(9B@ A&9P (!FO !\9
MQ  ?&>( (!GT " 9_P!Z&P  :AX  %T?  !3(   2B   $0@   ^'P  .AX
M #<=   T'   ,AD  # 9!  N& L +!@0 "H8%  I&!H )Q@@ "89)@ E&2T
M)!HU ",:/0 B&T8 (1M0 " <6P ?'6@ 'AUW !T=B  <'IL &QZM !H>PP :
M'N  &AWS !L=_P!W'0  9R   %HA  !0(@  2"(  $$B   [(@  -R$  #,@
M   P'P  +1T  "L=   H'0@ )AT. "4=$@ C'1< (1T= "$=)  @'BH 'QXR
M !X?.@ ='T, '"!- !LA60 :(68 &2%U !@BAP 7(ID %B*L !4BP0 5(M\
M%2'R !8A_@!S(   9"(  %<C  !-)   124  #XD   Y)   -",  # B   L
M(@  *2$  "8A   D(08 (B$, " A$  >(14 '2(; !LB(0 ;(B@ &B,O !DC
M.  8)$$ %R1+ !8E5P 5)60 %"9S !,FA0 2)I@ $2:K !$FP  0)MT $27Q
M !(E_0!P(@  820  %0F  !*)@  0B<  #PF   V)@  ,24  "TE   I)
M)B0  "(E   ?)0, '28* !LF#@ 9)Q( &"<8 !<G'P 6)R4 %2@M !0H-0 3
M*3X $BE) !$I50 1*F( $"IQ  \J@P .*I8 #BJI  TJO0 -*M< #2KN  XI
M^P!L)   728  %$H  !(*   0"D  #DH   T*   +R@  "LG   G)P  (B@
M !XI   ;*@  &"L' !8K#0 4+!$ $RP6 !(L'  1+2, $"TJ ! M,@ /+CP
M#BY&  TN4@ -+E\ #"]N  LO?P *+Y( "2^E  DNN0 (+M  "2[I  HN]P!H
M)P  6BD  $XJ  !%*P  /2L  #<K   Q*@  +2H  "DJ   D*@  ("L  !LM
M   8+@  %2\$ !(Q"@ 0,@X #S(3  XR&0 -,B  #3(G  PR+P +,S@ "C-"
M  DS3@ (,UL !C1J  4T>P $,XX  S.B  (SM@ ",\T  S/G  0R\P!D*@
M5BP  $LM  !"+0  .BT  #0M   O+   *RP  "8L   B+0  '2\  !DQ   5
M,@  $C0#  \V"0 ,. T "C@1  DX%@ (.!T !S@D  8X+  $.#0  S@^  (Y
M2@  .5<  #EE   Y=P  .8L  #B?   XLP  .,H  #CF   W\@!?+0  4BX
M $@O   _,   ."\  #(O   M+P  *2\  "0P   ?,0  &C,  !4U   2-P
M#SD#  P["  (/0T !3X0  ,^%   /AH  #XA   ^*   /C$  #\[   _1@
M/U,  #]A   _<P  /X<  #Z<   ^L   /<<  #WD   ]\@!:,   3C(  $0R
M   \,@  -3(  # Q   K,0  )C(  " T   ;-@  %C@  !([   //0  ##\#
M  A!"  $0PP  $,.  !$$@  118  $4=  !%)   12T  $8V  !&0@  1DX
M $9=  !&;@  18(  $68  !$K0  1,0  $/C  !#\@!5-   2C4  $$U   Y
M-0  ,S0  "XT   H-0  (C<  !TZ   7/   $C\   ]!   ,1   "$8!  -(
M!@  20H  $H-  !+$   3!0  $T9  !.(   3B@  $XR  !-/0  3DH  $Y8
M  !-:0  37T  $R4  !,J@  2\$  $OA  !*\@!0.   1C@  #TX   W.
M,3<  "HY   D.P  'CT  !A    30P  #T8   M)   '2P   DX   !0!
M40@  %(+  !3#@  5!$  %45  !6&P  5R,  %<L  !7.   5T0  %=2  !6
M8P  5G<  %:.  !5I0  5+T  %/=  !3\ !+/   0CP  #L[   U.P  +3P
M "8_   ?0@  &44  !-(   .2P  "T\   51    5    %<   !8 0  6@4
M %L(  !<#   70X  %\1  !@%@  8AT  &(F  !B,0  8CX  &%,  !A70
M87   &"(  !@H   7[<  %[4  !=[@!'0   /S\  #H_   Q0   *4,  "%&
M   :2@  $TX   Y1   *50  !%@   !;    7@   &$   !C    9 $  &4$
M  !G"   : L  &H.  !L$@  ;A<  &\@  !O*@  ;S8  &Y%  !N50  ;F@
M &U_  !MF   ;+   &O*  !JZ !$1   /D,  #5$   K1P  (TL  !M/   3
M5   #E@   A<   "8    &0   !G    :P   &T   !O    <    '(   !T
M @  =08  '<*  !Y#@  ?!(  'X8  !_(@  ?RX  '\]  !^30  ?6$  'UW
M  !\D   >Z@  'K   !YWP!#1P  .4D  "],   E4   '%4  !1;   .8
M!V4   !J    ;@   '(   !V    >0   'P   !^    ?P   ($   "#
MA0   (<#  "*"   C T  (\1  "2&0  DB4  )(S  "21   D5<  )!M  "/
MA@  CI\  (VU  ",S0 ]3@  ,E$  "A6   >7   %6(   YH   ';@   '0
M  !Y    ?@   ((   "&    B0   (P   ".    D    )(   "4    E@
M )@   ";    G@8  *$,  "D$0  IAL  *8I  "F.@  I4T  *5B  "D>P
MHY0  *&K  "AOP V5P  +%P  "%B   7:0  #W    =W    ?@   (0   "*
M    CP   )0   "8    FP   )X   "?    H@   *0   "F    J    *L
M  "M    L    +,$  "W#   NQ(  +L?  "[,   NT,  +I8  "Y<   MXL
M +>A  "WLP P8@  )6D  !IP   0>   "8    "(    CP   )8   ";
MH0   *8   "J    K@   +    "Q    M    +8   "X    NP   +T   #
M    PP   ,<   #+ P  SPP  -,5  #2)0  TC@  -%.  #090  SWX  ,V6
M  #,J0#_    _P   /\   #_  , _P + /P $0#Y !L ]P E /, +P#N #@
MZ0!  .8 2 #B $X WP!4 -P 60#9 %X U0!C -, : #0 &T S@!S ,L >@#(
M (( Q@", ,, EP#  *, O@"R +P R "Z .H N0#_ +@ _P"Q /\ J@#_ *<
M_P#_    _P   /L   #V    [0 ' .< #P#B !8 WP @ -X *0#9 #, T0 [
M ,P 0@#( $@ Q0!. ,( 4P#  %@ O@!= +P 8@"Z &< N0!M +< = "U 'L
ML@"% +  D "N )P K "J *D O0"G -X I@#Y *4 _P"C /\ G0#_ )L _P#]
M    ]@   .L   #?    T0 # ,H # #% !( PP ; ,  ) "^ "P N0 U +8
M/ "S $, L !( *X 3@"L %( JP!7 *D 7 "G &$ I@!G *0 ;0"B '0 H !]
M )X B "< )4 F@"C )@ M "6 ,T E0#Q )0 _P"5 /\ D #_ (X _P#S
MY@   -$   #"    N    +$ " "M  \ J@ 6 *@ '@"H "< I@ O *( -@"?
M #P G0!" )L 1P"9 $P EP!1 )8 50"4 %H DP!@ )$ 9@"0 &X C@!V (P
M@0"* (T B "; (8 K "% ,$ A #F (, _0"$ /\ @P#_ ($ _P#D    RP
M +H   "L    H@   )P ! "8  P E@ 1 )0 &0"3 "$ D@ H (\ , "- #8
MBP \ (D 00"( $8 A@!+ (4 3P"$ %0 @@!: ($ 8 !_ &< ?@!O 'P >@!Z
M (8 > "4 '< I !U +< = #4 ', ] !T /\ = #_ '0 _P#+    M@   *8
M  ":    D@   (H   "&  @ @P . ($ % "! !L @  C '\ *@!] #  >P V
M 'H .P!X $  =P!% '4 20!T $X <P!4 '$ 6@!P &$ ;@!I &T <P!K '\
M:0"- &@ G0!G *X 9@#' &4 Z@!F /\ 9@#_ &< _P"X    I    )4   "*
M    @0   'P   !V  0 =  , '( $ !Q !8 <  = '  ) !N "H ;0 P &L
M-0!J #H :0 _ &@ 1 !G $D 90!. &0 5 !C %L 80!C &  ;0!> 'D 70"'
M %L E@!: *@ 60"] %D WP!9 /@ 6@#_ %H _P"H    E0   (<   ![
M<P   &X   !J  $ 9P ( &4 #@!D !( 8P 8 &, 'P!B "4 80 J %\ , !>
M #4 70 Z %P /@!; $0 60!) %@ 3P!7 %8 5@!> %0 : !3 ', 40"! %
MD0!/ *( 3@"U $X T !. /  3@#_ $\ _P"<    B0   'L#  !P P  : ,
M &(!  !?    70 $ %L "P!9  \ 6  4 %< &0!7 "  5@ E %4 *@!3 #
M4@ T %$ .0!0 #\ 3P!$ $X 2P!- %( 2P!: $H 8P!) &\ 1P!\ $8 C !%
M )T 10"P $0 QP!$ .@ 1 #Z $4 _P"2!   @ <  '$*  !F"@  7@H  %D)
M  !5!P  5 0  %( !P!0  P 3P 0 $X %0!- !L 3  @ $L )@!* "L 20 P
M $@ -0!' #H 1@!  $4 1@!# $X 0@!6 $$ 7P!  &L /@!X #T B  \ )D
M/ "K #P P0 [ .  .P#T #L _P")"@  > P  &H.  !?#@  5PX  %$.  !-
M#   2PL  $H( @!)! D 2  - $8 $0!% !8 1  < $, (0!" "8 00 K #\
M,0 ^ #8 /0 \ #P 0P [ $H .@!2 #D 7  X &@ -@!U #4 A0 T )8 - "H
M #, O  S -@ ,P#O #, ^P""#0  <0\  &00  !9$0  41$  $L1  !'$
M1 X  $(-  !!"P4 00<+ #\%#@ ^ Q( / (8 #L"'0 Z R( .0,H #@#+0 W
M S( -@0Y #4$/P T!4< ,P50 #$&6@ P!F8 +P=S "X'@P M!Y4 + >G "L'
MN@ K!]( *P?K "L']P!]$   ;!$  %\3  !4%   3!0  $84  !"$P  /A(
M #P0   Z#@$ .@T& #H*#  X"1  -@@4 #4(&0 T"1\ ,@DD #$)*0 P"2\
M+PHV "X*/0 M"D4 + M. "L+60 I#&4 * QS "<,@P F#94 )0VG "0-NP C
M#=( (PWK ",-]P!X$@  :!0  %L6  !1%P  2!<  $(6   ]%@  .14  #<3
M   U$0  ,Q # #,."  R#0T , T1 "\-%@ M#1L + TA "L-)P J#2T *0XT
M "@..P G#D0 )0Y. "0/60 C$&4 (1!S " 0A  ?$)8 'A"I !T0O0 <$-@
M'1#N !T0^0!S%   9!8  %<8  !-&0  11D  #\9   Z&   -1<  #(6   P
M%0  +A,  "T1!  L$ H *Q . "D0$@ H$!@ )A > "40)  D$"H (Q$Q "(1
M.0 A$4( (!)+ !X25@ =$V, '!-Q !H3@@ 9%)4 &!2G !<4NP 7$]0 %Q/N
M !@3^@!P%@  8!D  %0:  !*&P  0AP  #P;   V&P  ,AH  "\9   L&
M*A8  "@4 0 F$P< )1,, ",3$  B$Q4 (!,: !\3(0 >%"< '10N !P5-@ ;
M%3\ &A9) !D65  8%V$ %A=P !48@0 4&), $QBF !(8N@ 2%]( $A?L !,7
M^@!L&0  71L  %$=  !''0  /QX  #D=   T'0  +QP  "L;   H&@  )AD
M "08   B%P0 (!<* !X7#@ <%Q( &A<7 !D8'@ 9&"0 &!DL !<9-  6&CT
M%1I' !0;4@ 3&U\ $AQN !$<?P 0')( $!RE  \<N0 .'-  #AOJ  \;^ !I
M&P  6AT  $X?  !%'P  /2   #8?   Q'P  +1X  "D=   E'0  (QP  " ;
M   =&P$ &QL' !D<#0 7'!  %AP5 !4<&P 4'2( $QTI !(>,0 1'CH $1]%
M ! ?4  /(%T #B!L  T@?  -((\ #""B  L@M0 +(,H "R#E  P?] !E'0
M5Q\  $PA  !"(0  .B$  #0A   O(0  *B   "8?   C'P  (!X  !T>   9
M(   %B $ !0@"P 2(0X $2$3 !$B&0 0(A\ #R(F  XC+P .(S< #2-!  PD
M30 +)%D "B1G  DD>  ()(L !R2>  <DL0 &),< !B/C  <C\0!B'P  5"$
M $DC  ! (P  .",  #(C   L(P  *"(  "0A   A(0  'B$  !HA   6(P
M$R0# !$E"  /)@T #B<1  TG%@ ,)QT "R<C  HG*P )*#0 ""@^  <H20 &
M*%4 !2ED  0I=  #*8<  BF;  $HKP  *,4  2CA  $G\ !>(@  420  $8E
M   ])0  -24  "\E   J)   )B0  "(C   ?(P  &R0  !@E   4)@  $2@#
M  \I"  ,+ P "BP0  @L%  '+!H !BPA  4L*  #+3   BTZ  $M10  +5(
M "Y@   N<0  +80  "V9   MK0  +,(  "S@   L\ !:)   328  $,G   Z
M)P  ,R<  "TG   H)@  )"8  "$F   =)@  &2<  !4I   1*P  #RP#  TN
M!P ), P !C$.  ,Q$@ !,A<  #(>   R)0  ,BT  #(V   S0@  ,TX  #-=
M   S;0  ,X$  #*6   RJP  ,<$  #'?   Q\ !6)P  2BD  #\J   W*@
M,"H  "LI   G*   (R@  !XI   :*@  %BP  !(N   /,   #3$"  HT!P %
M-0L  C8.   W$   .!0  #@:   X(@  ."H  #DS   Y/@  .4H  #E9   Y
M:0  .7T  #B3   XJ   -[\  #?>   V\ !1*P  1BP  #PL   T+   +BP
M "HK   E*P  ("P  !LM   7+P  $S$  ! S   --0  "3<"  4Z!@ !.PH
M #P-   ]#P  /A(  #\7  ! '@  0"4  $ O  ! .@  0$8  $!4  ! 90
M/W@  #^/   ^I@  /KT  #W<   ]\ !-+@  0B\  #DO   R+P  +2X  "@N
M   B+P  '3   !@R   3-0  $#<   PZ   )/   !3X   !!!   0@@  $,+
M  !$#0  1A   $<4  !(&0  2"$  $@J  !(-0  2$$  $A/  !(8   1W,
M $>*  !&H@  1;D  $79  !$\ !(,@  /C(  #8R   P,0  *S$  "4R   ?
M-   &38  !,Y   0/   ##\   A"   #1    $8   !( @  2@4  $L(  !,
M"P  3@X  $\1  !1%0  4AP  %(E  !2,   4CP  %%*  !16@  46T  %"$
M  !/G0  3K4  $W2  !-[@!#-@  .S8  #0U   O-   )S4  "$X   :.P
M%#X  !!!   ,1   !T<   )*    30   $\   !1    4P(  %0%  !5"
M5PL  %D.  !;$0  71<  %T?  !=*@  738  %Q$  !<5   6V<  %M^  !:
MEP  6:\  %C+  !7Z@ _.0  .#D  #,X   K.0  (SP  !P_   50P  $$<
M  M*   %3@   %$   !4    5P   %H   !<    70   %\   !@!   8@<
M &0+  !F#@  :!(  &L9  !K(P  :BX  &H\  !J30  :5\  &AU  !GCP
M9J@  &7"  !DXP ]/0  -SP  "X]   E0   '40  !9)   030  "E$   15
M    6@   %T   !@    8P   &8   !H    :@   &L   !M    ;P(  '$&
M  !T"@  =@X  'D3  ![&P  >R<  'HU  !Y10  >%D  'AM  !WA@  =I\
M '6W  !TT@ \00  ,D(  "A%   @2@  %TX  !!4   *60   EX   !C
M9P   &L   !O    <@   '4   !W    >0   'L   !]    ?P   ((   "$
M P  APD  (H.  ".$P  CQX  (XK  "..P  C4X  (MC  "*?   BI4  (BM
M  "'Q0 V1P  +$L  ")/   950  $%L   IA   !9P   &T   !R    =P
M 'L   !_    @P   (8   "(    B@   (T   "/    D0   )0   "7
MF@$  )T'  "A#0  I10  *0A  "D,0  HT0  *)9  "@<   GXL  )VB  "=
MMP P4   )54  !M;   28@  "VD   %P    =P   'T   "#    B    (T
M  "1    E0   )@   ":    G    )\   "A    HP   *8   "I    K
M +    "T!P  N X  +H8  "Z)P  N3D  +A.  "W90  MGX  +66  "SJP I
M6P  'F(  !1I   ,<0   GD   "!    B0   (\   "6    FP   *    "D
M    J    *L   "L    KP   +(   "T    M@   +D   "\    P    ,0
M  #(    S0<  -(0  #2'0  T2\  -!$  #/6P  S7,  ,N-  #*H0#_
M_P   /L   #Z    _  ( /@ #P#U !< ]  @ /$ *@#K #, Y@ [ .( 0P#>
M $D V@!/ -8 5 #3 %D T !> ,X 8P#+ &@ R0!N ,8 =0## 'T P0"& +X
MD@"[ )X N0"N +8 PP"T .@ LP#_ *\ _P"E /\ G@#_ )L _P#]    ]P
M /(   #P    YP # .$ # #< !( V  ; -8 ) #2 "T S  V ,8 /0#" $,
MOP!) +P 3@"Z %, N !8 +8 70"U &( LP!G +$ ;@"O '8 K !_ *H B@"H
M )< I0"F *, N0"A -D H #Y )X _P"8 /\ D@#_ (\ _P#S    [    .,
M  #3    R    ,$ "0"]  \ NP 6 +D 'P"W "< LP O *\ -P"L #T J@!#
M *@ 2 "F $T I !2 *, 5@"A %L GP!A )X 9P"< &\ F@!X )< @P"5 )
MDP"> )$ L "0 ,@ C@#P (T _P"* /\ A0#_ (( _P#G    W0   ,8   "X
M    K@   *@ ! "E  P H0 2 *$ &0"@ "( GP I )L , "8 #< E@ ] ),
M0@"2 $< D !+ (\ 4 "- %4 C !: (H 80"( &@ AP!P (4 >P"# (@ @0"6
M '\ IP!] +P ? #C 'P _0!\ /\ > #_ '8 _P#6    P    *\   "C
MF0   ),   "/  D C0 . (L % "* !P B@ C (@ *@"% #  @P V (( .P"
M $  ?P!% 'X 2@!\ $\ >P!4 'H 6@!X &$ =@!I '4 <P!S (  <0". &\
MGP!N +( ;0#/ &P ] !L /\ :P#_ &D _P#     JP   )L   "/    AP
M (    !\  0 >@ , '@ $0!X !< >  > '< ) !U "H <P P '$ -0!P #H
M;@ _ &T 1 !L $D :P!. &H 5 !H %L 9P!C &4 ;0!D '@ 8@"' &  EP!?
M *H 7@#" %X Z0!> /\ 7@#_ %T _P"L    F0   (H   !_    =P   '$
M  !M    :@ ( &D #@!H !( 9P 8 &< 'P!G "4 90 J &, +P!B #0 80 Y
M &  /@!? $, 7@!( %T 3@!; %4 6@!= %@ 9P!7 '( 50"! %0 D0!3 *,
M4@"X %$ W !1 /D 4@#_ %( _P"=    BP   'P   !Q    :0   &0   !@
M    7@ % %P "P!;  \ 6P 4 %H &0!: !\ 60 E %< *@!6 "\ 50 T %0
M. !3 #T 4@!# %  20!/ %  3@!8 $T 8@!+ &T 2@!Z $D BP!( )T 1P"Q
M $< S !& /  1P#_ $< _P"0    ?@   '    !F    7@   %D   !6
M4P ! %( " !0  T 3P 0 $\ %0!. !H 3@ @ $T )0!, "H 2@ N $D ,P!(
M #@ 1P ^ $8 1 !% $L 1 !3 $, 70!! &@ 0 !U #\ A0 ^ )< /0"K #T
MPP ] .8 /0#[ #X _P"'    =0,  &@&  !=!P  508  % &  !,!   2@$
M $D ! !'  H 1@ . $4 $0!% !8 1  ; $, ( !" "4 00 J $  +P _ #0
M/@ Z #T 0  [ $< .@!/ #D 60 X &0 -P!Q #8 @0 U ), - "F #0 NP T
M -T - #U #4 _P!^!@  ;0D  & +  !6#   3@P  $@+  !$"@  0@@  $ %
M 0 _ 0< /@ + #T #@ \ !( .P 7 #L '  Z "$ .0 E #< *@ V #  -0 U
M #0 /  S $, ,@!, #$ 50 P &  +P!M "X ?0 M (\ + "B "P M@ L -
M+ #N "P _ !W"@  9PP  %H.  !0#@  20X  $,.   ^#0  .PP  #D+   X
M"0, -P4( #8"#0 U 1  -  3 #, &  R !T ,0 B #  )P O "P +@ R "T
M.  L $  *P!) "H 4@ I %T * !K "<!>@ F 8P )0"? "4 L@ E ,H )0#H
M "4 ]P!R#0  8@X  %80  !,$0  1!$  #X1   Y$   -@\  #,.   Q#0$
M, L% # ("@ O!@T +@41 "P$%  K QD *@,> "D#(P H!"D )P0O "8%-0 E
M!3T ) 5& ",&4  B!EP (0=I " '>0 ?!XL '@>= !X'L  =!L8 '0;C !T%
M\P!M#@  7A$  %(2  !($P  0!,  #H3   U$@  ,1$  "X0   L#P  *@X#
M "H-!P I"PL * D. "<)$0 E"!8 ) @; ",)(  B"28 (0DL " *,P ?"CL
M'@M$ !T+3P <#%L &PQI !H,>0 8#(L & R> !<,L  6#,4 %@SA !8+\ !I
M$   6A(  $X4  !%%0  /14  #<5   Q%   +1,  "H2   H$0  )A ! "00
M!  C#@@ (PT, "(,#P @#!, 'PP8 !X-'0 =#2, ' TJ !L-,@ :#CH & Y$
M !<.4  6#UP %0]J !,0>P 2$(T $1"@ !$0LP 0#\D $ _D !$/\@!E$@
M5Q0  $L6  !"%P  .A<  #07   O%@  *A4  "<4   D$P  (A,  " 2 P >
M$08 '1 ) !P0#0 ;#Q  &1 5 !@0&P 7$"$ %A H !41,  4$3D $Q%# !(2
M3@ 1$EH $!)I ! 3>0 .$XP #A.>  T3L0 -$L4 #!+A  T2\0!B%   5!8
M $D8   _&0  -QD  #$9   L&   *!<  "06   A%@  'Q4  !P4 @ :$P0
M&1(& !<2"P 5$@X %!(2 !,3&  2$Q\ $1,F !$4+0 0%#8 #Q5!  X53  .
M%E< #19E  P7=0 +%X< "A>:  D6K0 (%L$ "!;=  D5[@!?%@  41@  $8:
M   ]&@  -1L  "\:   J&@  )1D  "(8   ?&   '!<  !D6 0 7%@, %18$
M !,6"0 1%@T $!<1  \7%@ .%QP #A@C  T8*@ ,&3, #!D\  L:1P *&E,
M"1IA  <;<0 &&X, !1N7  0:J@ #&K\  QG:  09[ !<&   3AH  $,<   Z
M'   ,QP  "P<   G'   (QL  " :   =&0  &AD  !<8 0 5& ( $AD$ ! ;
M!P .&PP #1P0  P<$P +'!D "AP?  D=)P ('2\ !QXY  8>0P $'E   Q]>
M  (?;@ !'X   !^5   >J0  'KT  !W8   =[ !8&@  2QP  $$>   X'@
M,!X  "H>   E'0  (1P  !X<   ;&P  &!L  !8; 0 3&P( $1P$  X>!P ,
M'PL "B .  @@$@ &(1< !2$=  0A)  "(BP  2(U   B0   (TT  "-:   C
M:P  (WX  ".3   BIP  (KP  "'7   A[0!5'0  2!\  #X@   U(   +B
M "@@   C'P  (!X  !T=   :'0  %AT  !,>   1'P( #B $  TB!P *) L
M!B4-  0E$  ")A0  "8:   F(0  )RD  "<R   G/0  )TD  "A7   H9P
M)WL  ">0   GI0  )KL  ";6   E[0!1(   12$  #LB   R(@  +"(  "8A
M   B(0  'B   !L?   8(   %"   !$B   /(P  #24#  HF!@ &* H  RD-
M   K#P  +!(  "P7   L'@  +"8  "TO   M.0  +48  "U4   M9   +7<
M "R-   LI   *[H  "O6   J[@!-(@  020  #@D   P)   *20  "0C   A
M(@  '2(  !DB   5(P  $B0   \F   -*   "BH"  8L!0 "+@D  "\+   P
M#@  ,A   #,5   S&P  ,R(  #,K   S-@  ,T(  #-0   S8   ,W,  #**
M   RH0  ,;@  ##6   P[P!))0  /B8  #0G   M)P  *"8  ",E   ?)
M&R4  !8F   2*   $"H   TL   *+@  !C !  (R!   - <  #4*   W#
M. X  #H2   Z%P  .A\  #HG   Z,@  .CX  #I,   Z7   .F\  #F&   X
MG@  .+8  #?4   V[P!$*0  .BD  #$I   K*0  )B@  "(G   =*   &"D
M !,K   0+@  #3    DR   %-0   3<    Y @  .P4  #P(   ^"P  /PT
M $$0  !#%   0QL  $,C  !#+@  0SD  $-'  !"5P  0FH  $&!  ! F@
M/[(  #[/   ^[P _+   -BP  "\L   J*P  )2H  !\K   9+0  %"\  ! R
M   --0  "#@   0Z    /    #\   !!    0P(  $4%  !&"   2 L  $H.
M  !,$0  318  $T>  !-*   330  $Q"  !,40  2V0  $M[  !*E   2:T
M $C*  !'[  [,   ,R\  "TO   H+0  (B\  !LQ   5-   $#<   TZ   (
M/0   D    !#    1@   $@   !*    3    $X!  !/!   40<  %,+  !5
M#@  6!(  %D9  !8(@  6"X  %<\  !72P  5EX  %9S  !5C0  5*<  %+"
M  !2Y@ X,P  ,3(  "PQ   E,@  '34  !8X   1/   #$    =$    1P
M $H   !-    4    %,   !5    5P   %D   !:    7 ,  %X'  !A"P
M9 X  &83  !G'   9B<  &8T  !E1   9%<  &1K  !BA0  89\  &"Y  !>
MW  U-P  ,#4  "@W   @.@  &#T  !%"   ,1@  !DH   !/    4P   %8
M  !9    7    %\   !A    9    &4   !G    :0   &P!  !N!@  <0L
M '0/  !W%0  =R   '8M  !V/0  =4\  '1C  !S>P  <I4  '"O  !OR0 U
M.@  *SL  "(_   :0P  $D@   Q-   %4@   %<   !<    8    &0   !H
M    :P   &X   !Q    <P   '4   !W    >@   'P   !_    @@0  (8*
M  "*#P  C!<  (LD  "*,P  B44  (=;  "&<@  A8L  (.E  ""O  O0
M)40  !Q)   33@  #50   1:    80   &8   !K    ;P   '0   !Y
M?0   (    "#    A0   (<   "*    C    (\   "2    E@   )D"  ">
M"0  HA   *(:  "A*0  H#L  )]0  "=9P  FH$  )J9  "9KP I20  'TX
M !54   .6P  !6(   !I    <    '<   !]    @@   (8   "+    CP
M ),   "5    EP   )H   "=    H    *,   "F    J@   *X   "R
MMPH  +L1  "Z'P  N3   +=%  "U7   M'0  +&.  "OI  B5   &%L  !!B
M   ':@   ',   ![    @@   (D   "0    E0   )H   "?    HP   *8
M  "H    JP   *X   "P    LP   +8   "Z    O0   ,(   #'    S $
M -,+  #4%0  TR8  -$Z  #040  S6@  ,N!  #*E@#\    ]@   /(   #Q
M    \P % /0 # #R !, \  < .T )0#H "X X@ V -X /@#9 $0 U !* -$
M3P#. %0 RP!9 ,D 7@#& &, Q !I ,$ < "^ '@ O "! +D C0"V )H LP"K
M +$ P "O .8 K@#_ *4 _P": /\ E #_ (\ _P#T    [    .@   #G
MWP   -D "0#2 !  SP 7 ,\ ( #, "@ Q@ P ,  -P"\ #X N0!$ +< 20"U
M $X LP!3 +$ 5P"O %T K0!B *L :0"I '$ IP!Z *4 A0"B ), H "B )T
MM@"; -0 F0#Y )8 _P"- /\ B #_ (0 _P#H    WP   -D   #)    OP
M +@ ! "U  T LP 2 +$ &@"P "( K0 J *D ,0"F #@ I  ] *( 0P"@ $@
MG@!, )P 40"; %8 F0!< )< 8@"5 &D DP!R )$ ?0"/ (L C0": (L K ")
M ,4 B #N (8 _P!_ /\ >@#_ '@ _P#9    S0   +L   "N    I0   )\
M  "<  D F0 / )D %0"9 !T F  D )0 *P"1 #$ C@ W (P / "+ $$ B0!&
M (@ 2P"& %  A0!5 (, 6P"" &( @ !K 'X =0!\ (( >@"2 '@ HP!W +D
M=@#@ '4 _P!R /\ ;@#_ &P _P#'    M0   *4   "9    CP   (D   "%
M  0 A  , (( $0"" !< @@ > (  )0!^ "L ?  Q 'H -@!Y #L =P!  '8
M1 !U $D <P!/ '( 50!P %P ;P!D &T ;@!L 'H :@"* &@ FP!G *\ 9@#,
M &4 ]0!D /\ 80#_ &  _P"T    H    )    "%    ?0   '<   !S
M<  ( &\ #@!O !( ;P 8 &\ 'P!M "4 :P J &D , !H #0 9P Y &8 /@!E
M $, 8P!( &( 3@!A %4 7P!> %X 9P!< ', 6P"" %D DP!8 *8 5P"_ %<
MZ@!7 /\ 5@#_ %0 _P"A    C@   '\   !U    ;    &@   !D    80 $
M &  "P!?  \ 7P 3 %\ &0!? !\ 70 E %P *@!; "\ 60 S %@ . !7 #T
M5@!# %4 20!3 %  4@!8 %$ 80!0 &T 3@![ $T C !, )\ 2P"U $H W !*
M /H 2@#_ $H _P"2    @    '(   !G    7P   %H   !7    50 ! %,
M!P!2  P 4@ 0 %( % !2 !H 40 ? $\ ) !. "D 30 N $P ,P!+ #@ 2@ ]
M $D 0P!( $H 1@!2 $4 7 !$ &< 0P!U $( A@!! )@ 0 "N $  RP _ /(
M0 #_ $  _P"%    =    &<   !=    50   $\   !,    2@   $@ ! !'
M  H 1P - $8 $0!& !4 1@ : $4 'P!$ "0 0P I $( +0!! #, /P X #X
M/@ ] $4 / !. #L 5P Z &( .0!O #@ @  W ), -@"G #8 P  V .@ -@#^
M #8 _P!\    :P   %X"  !4 P  30,  $<#  !# 0  00   #\  0 ^  <
M/0 + #T #@ \ !$ /  6 #P &@ Z !\ .0 D #@ *0 W "X -@ S #4 .@ T
M $$ ,P!) #( 4P Q %X , !K "\ >P N (X +0"B "T N  M -T +0#X "X
M_P!S 0  9 4  %<'  !-"   1@@  $ (   [!P  . 4  #<#   V  0 -0 (
M #0 #  T  \ -  2 #, %@ R !L ,0 @ #  )  O "D +@ O "T -@ L #T
M*P!% "H 3P I %H * !G "< =P F (D )@"= "4 LP E ,\ )0#P "8 _P!M
M!@  7@D  %(+  !(#   0 P  #H+   V"P  ,@H  # (   N!@( +@,& "T
M"@ L  T +  0 "L $P J !< *0 < "@ (  G "4 )@ K "4 ,@ D #D (P!"
M "( 2P B %< (0!D "  <P ? (4 'P"9 !X K@ > ,< '@#I !\ ^@!H"0
M60P  $T-  !##@  / X  #8.   Q#0  +0T  "H,   H"P  )PD$ "8&"  F
M! L )0,. "0!$  D 10 (@$8 "$!'0 A "( (  H !\ +@ > 38 '0$_ !P!
M20 ; 50 &@%A !H!<  9 8( & "6 !@ J@ 8 ,$ & #A !@ ] !C#   50X
M $D/  ! $   .!   #(0   M#P  *0X  "8.   C#0  (@P# " +!@ @"0D
M'P<, !X&#@ >!1$ ' 45 !L%&@ :!1\ &@4E !D%*P 8!3, %P8\ !8&1@ 6
M!E( %0=? !0';@ 3!X  $@>4 !(&IP 2!;P $@39 !(#[P!?#@  40\  $80
M   \$0  -1$  "\1   J$0  )A   "(0   @#P  '0X" !P-!0 :#0< &@L*
M !D*#0 8"1  %PD2 !8)%P 5"1P % DB !0**0 3"C$ $@HZ !(+10 1"U$
M$ Q?  \,;@ .#(  #@R4  T+IP -"[H #0K2  T*Z@!<#P  3A$  $,2   Z
M$P  ,A,  "P3   G$@  (Q$  !\1   <$   &A " !@/!  6#@< %0X) !0-
M"P 3# T $@P0 !(,%  1#!H $0T@ ! -*  /#3  #@X[  T.1@ -#E$ # ]>
M  L/;0 *#W\ "0^3  D/I@ (#KD " [0  <.Z !8$0  2Q(  $ 3   W%
M,!0  "D4   E%   (1,  !T2   :$@  %Q$" !41!0 3$ < $A ) !$/"@ 0
M#@P #@X.  X/$@ -$!@ #1 >  P0)0 ,$"T "Q$V  H100 )$4T "!):  <2
M:@ &$GP !1*0  02I  #$;@  Q'/  (1Z !5$@  210  #X5   U%@  +18
M "<6   B%0  'A0  !L4   8$P  %1(# !,2!0 2$0< $!$)  \1"@ -$0L
M#!(.  L2$0 *$A4 "1,;  D3(@ ($RH !Q0S  44/@ $%4H  Q58  (59P !
M%7H  !6.   5HP  %+<  !3/   3Z0!2%   1A8  #L7   R%P  *Q<  "47
M   A%@  '!8  !D5   6% $ %!,$ !(3!@ 1$@@ #Q((  X3"0 ,% H "A4-
M  @6$  &%A, !189  07'P #%R<  A@P  $8.P  &4<  !E5   99   &7<
M !F,   8H@  &+<  !?/   7Z@!/%@  0Q@  #D9   P&0  *1D  ",9   ?
M&   &Q<  !@6   5%0( $Q4% !$4!@ 0% 8 #A4'  P6"  *%PH !QD,  0:
M#@ "&Q(  1L6   ;'0  '"0  !PM   <.   '40  !U2   =8@  '74  !V*
M   <H   '+8  !O0   :ZP!,&   0!H  #8;   M&P  )AL  "$:   =&0
M&1D  !<8   4%P, $A8$ ! 7!  .%P0 #!D%  H:!P '' D  QT+   ?#0
M(!   " 4   A&@  (2(  "$J   A-0  (D$  ")/   B7P  (G(  "&(   A
MGP  (+8  !_1   ?[0!(&@  /1P  #,=   K'0  )!T  " <   <&P  &!H
M !89 0 3&0$ $1D!  X: 0 ,' ( "AT#  <?!0 #(0@  "(*   D#   )@X
M "82   F&   )Q\  "<G   G,@  )SX  "=+   G7   )VX  ":%   FG0
M);0  "31   C[@!$'0  .1\  # ?   H'P  (QX  !X=   ;'   &!L  !0<
M   1'   #AT   T?   *(0  !B(!  ,D!   )@8  "@(   J"P  *PT  "T0
M   M%0  +1P  "TD   N+@  +CH  "Y(   M6   +6H  "V!   LF@  *[(
M "K0   I[P! (   -B$  "TA   F(0  (2   !T?   :'@  %AX  !(?   /
M(0  #2(   HD   &)@   B@    K @  +00  "\&   P"0  ,@P  #0.   U
M$@  -1@  #4@   U*@  -38  #5#   U4P  -&8  #1\   SE@  ,J\  #'-
M   P[P \(P  ,B0  "HD   D(P  ("(  !PA   7(0  $R,  ! E   -)P
M"2D   4K   !+@   #     R    - $  #8$   X!@  .@D  #P-   ^$
M/A0  #X<   ^)@  /C$  #X_   ]3@  /6$  #QW   [D0  .JL  #G)   X
M[0 W)P  +R<  "@F   C)0  'R0  !DE   4)@  $"@   TK   )+@  !3
M   S    -0   #@    Z    /    #X!  !  P  0@<  $0*  !&#0  21$
M $D7  !((0  2"P  $<Z  !'20  1EL  $5Q  !$BP  0Z4  $+#  !!Z  T
M*@  +"H  "<H   B)P  '"@  !8J   1+0  #3    DS   #-@   #D    \
M    /@   $$   !#    1@   $@   !*    3 ,  $X&  !0"@  4PX  %03
M  !4'   4R<  %,T  !30P  4E4  %%J  !0@P  3YX  $VY  !,X  P+0
M*RP  "8K   ?+   &"X  !(R   --0  "#D   (]    0    $,   !&
M20   $P   !.    40   %,   !5    5P   %D!  !<!@  7PH  &(.  !C
M%0  8Q\  &(L  !A/   8$X  %]B  !>>P  7)8  %NP  !9SP O,   *B\
M "(P   :,P  $S<   X[   (/P   40   !(    3    $\   !2    50
M %@   !;    70   &    !B    9    &8   !I    ;04  ' +  !T$
M=!@  ',E  !R-   <D4  '!9  !O<0  ;8L  &NF  !JP  N,P  )34  !TX
M   4/   #D$   ='    3    %$   !5    60   %T   !A    90   &@
M  !K    ;0   &\   !R    =    '<   !Z    ?@   (($  "&"P  BA$
M (D<  "(*P  ACT  (12  "#9P  @8$  '^;  !^L@ I.@  (#T  !9"   /
M2   "$X   !4    6@   &    !D    :0   &X   !R    =@   'H   !]
M    @    ((   "%    B    (L   ".    D@   )8   "; P  H P  *(3
M  "@(0  GS,  )U'  ":7@  F'<  )>/  "5IP C0P  &4@  !%.   )50
M %P   !C    :@   '$   !V    >P   (    "&    B@   (X   "1
MDP   )8   "9    G    *    "C    IP   *L   "P    M@0  +P-  "Z
M%P  N2@  +<\  "T4@  LFH  *^%  "MG  <3@  $U0   M<   !9    &P
M  !T    ?    (,   ")    CP   )0   ":    GP   *(   "D    IP
M *H   "N    L0   +0   "X    O    ,$   #'    S0   -0%  #8$
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M_____________________________________________________P
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M]/7V]_CY^OO\_?[_;69T,0     #!"$   $                    !
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MA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:]\ 0%?C
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MA*6*TH&EC=* I8_2@*6/TH"EC]* I8_2@*6/TH"EC]* I8_2@*6/TH"EC]*
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MF[%_P9FPA,*4KX3#D*^%Q(VNA<6*KH;&B*V&QH>MA\:%K8C'@ZV)QX&MB\>
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M<;^+K7&_BZUQOXNM<;^+K7&_BZUQOXNM<;^+K7&_BZUQOXNMS\8' M#-"1+
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MEU]^W)-ND\^2>*7&DH*TQ)*)ML.1CKC!CI"ZP(J2O+^'E+V^A):_OH*9P+V
MF\&]?I[!O'VAPKQ[I,*\>JC#O'FMP[AYK\*X>:_"N'FOPKAYK\*X>:_"N'FO
MPKAYK\*X>:_"N'FOPKAYK\*X>:_"_ZH<!?^J)Q?_IS8O_Z)$2OJ=4F7JEU]^
MW)-ND\^2>*7&DH*TQ)*)ML.1CKC!CI"ZP(J2O+^'E+V^A):_OH*9P+V F\&]
M?I[!O'VAPKQ[I,*\>JC#O'FMP[AYK\*X>:_"N'FOPKAYK\*X>:_"N'FOPKAY
MK\*X>:_"N'FOPKAYK\*X>:_"_ZH<!?^J)Q?_IS8O_Z)$2OJ=4F7JEU]^W)-N
MD\^2>*7&DH*TQ)*)ML.1CKC!CI"ZP(J2O+^'E+V^A):_OH*9P+V F\&]?I[!
MO'VAPKQ[I,*\>JC#O'FMP[AYK\*X>:_"N'FOPKAYK\*X>:_"N'FOPKAYK\*X
M>:_"N'FOPKAYK\*X>:_"_ZH<!?^J)Q?_IS8O_Z)$2OJ=4F7JEU]^W)-ND\^2
M>*7&DH*TQ)*)ML.1CKC!CI"ZP(J2O+^'E+V^A):_OH*9P+V F\&]?I[!O'VA
MPKQ[I,*\>JC#O'FMP[AYK\*X>:_"N'FOPKAYK\*X>:_"N'FOPKAYK\*X>:_"
MN'FOPKAYK\*X>:_"_ZH<!?^J)Q?_IS8O_Z)$2OJ=4F7JEU]^W)-ND\^2>*7&
MDH*TQ)*)ML.1CKC!CI"ZP(J2O+^'E+V^A):_OH*9P+V F\&]?I[!O'VAPKQ[
MI,*\>JC#O'FMP[AYK\*X>:_"N'FOPKAYK\*X>:_"N'FOPKAYK\*X>:_"N'FO
MPKAYK\*X>:_"_ZH;!?^J)Q?_IS4O_Z-$2OJ=467IEUY^VY1ME,^2=Z;%DH&T
MQ).(ML.2C;C!CX^ZP(N1O+^(D[Z^A9:_O8*8P;R F\*\?I["O'VAP[M[I,2[
M>JG$NGFMQ+5YKL.U>:[#M7FNP[5YKL.U>:[#M7FNP[5YKL.U>:[#M7FNP[5Y
MKL.U>:[#_ZL;!?^K)A?_J#0O_Z1#2OF>4&7IF%U_VI5IE<V4=*C%E'ZTQ)6&
MML*5C+G!D8Z[OXV0O;Z)DK^]AI3!O(.7P[N!FL2Z?IW%NGVAQKI[I<:Y>JK&
MM7JLQK%ZK<2Q>JW$L7JMQ+%ZK<2Q>JW$L7JMQ+%ZK<2Q>JW$L7JMQ+%ZK<2Q
M>JW$_ZL:!?^K)1?_J30O_Z1"2OF?3V;HF5R VI9FELR5<:G%E7RTQ):#M\*7
MB[K DXR\OH^.O[V+D,&\AY/#NH26Q;F!F<:Y?YW'N'VAR+A\ILFU>JK)L'NK
MQZQ[K<6L>ZW%K'NMQ:Q[K<6L>ZW%K'NMQ:Q[K<6L>ZW%K'NMQ:Q[K<6L>ZW%
M_ZP9!?^L)!;_J3,O_Z5!2OF?3V;HF5N!V9ACELR6;ZK%EGFTPY>!M\&8B;J_
ME8N]OI&-P+R-C\*ZB)+%N865Q[B"F,FW?YW*MGVBR[9\J,NP>ZG*K'RJR*A]
MK,6H?:S%J'VLQ:A]K,6H?:S%J'VLQ:A]K,6H?:S%J'VLQ:A]K,6H?:S%_ZP9
M!?^L)!;_JC(O_Z5!2_F@3F?GFEF!V9EAE\N7;:O%EW>TPYE_M\&:A[N_EXJ^
MO9.,P;N.CL2YBI#'N(:3R;:"F,NU?YW-M'ZCSK%\ILZL?:C+J'VJR:5^K,:E
M?JS&I7ZLQJ5^K,:E?JS&I7ZLQJ5^K,:E?JS&I7ZLQJ5^K,:E?JS&_ZP9!?^M
M(Q;_JC(O_Z9 2_B@36?GG%>!V9I>E\N8:JS%F72TPYI]M\&;A;N^F8F_O)6*
MPKJ0C,6XC(_(MH>2R[2#E\ZS@)W0LG^DT:Q^I<^H?J?,I'^IR:& K,:A@*S&
MH8"LQJ& K,:A@*S&H8"LQJ& K,:A@*S&H8"LQJ& K,:A@*S&_ZT8!?^M(Q;_
MJS$O_Z8_2_B@36?GG56!V9Q<E\J9:*S%FG*TPYQZN,"<@[N^G(F_NY>)P[F3
MB\>WCHW+M(F0SK*$EM&Q@9W3K("BTZ> I="D@*?-H(&IRIZ!J\:>@:O&GH&K
MQIZ!J\:>@:O&GH&KQIZ!J\:>@:O&GH&KQIZ!J\:>@:O&_ZT8!?^M(A;_JS$O
M_Z<_2_BA3&?GGE.!V9U9E\J;9:S%G&^TPYUXN,">@;R]GHC NYJ(Q+B5B<FU
MD(O-LHN/T;"&E=6NA)[7IX*AU*."I-&?@J?-G(.IRIJ#J\>:@ZO'FH.KQYJ#
MJ\>:@ZO'FH.KQYJ#J\>:@ZO'FH.KQYJ#J\>:@ZO'_ZT7!?^N(A;_JS O_Z<^
M2_BA2VCGGU&!V9]6E\J<8JS%G6RTPY]UN,"@?KR]H(?!NIV(QK>8B,NSDXG/
ML(Z-U*V)E-FHAIW:HH6AU9Z%I-&;A:;.F86IRI>%J\>7A:O'EX6KQY>%J\>7
MA:O'EX6KQY>%J\>7A:O'EX6KQY>%J\>7A:O'_ZX7!/^N(A;_K# O_Z<^2_BB
M2VCHH4^!V:!3E\J>7ZS&GVFTPZ%RN,"B?+R]HH3!N:"'Q[6<A\VREXC2KI.+
MV*J.D]^BBYS<G(F@UIF(H]*7B*;.E8BIRI2(J\>4B*O'E(BKQY2(J\>4B*O'
ME(BKQY2(J\>4B*O'E(BKQY2(J\>4B*O'_ZX7!/^N(1;_K"\O_Z@]2_BB2FCH
MHDV V:)0E\N@7*S&H66SPZ1NM\"E>+R\I8+"N*2'R+2@A\ZPG8C5JYF*W:67
MD^:;D9O=EH^@UY2-H].2C*;/D8NHRY"*J\B0BJO(D(JKR)"*J\B0BJO(D(JK
MR)"*J\B0BJO(D(JKR)"*J\B0BJO(_ZX6!/^O(1;_K2\O_Z@\2_>B26CHI$J
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MT8V'HLR,C:K'BI&QQ(B4ML.%EKC"@YFYPH&;N<%_GKK!?:&[P7NDN\!ZI[O
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MIU1]X:98BMJD8I;2H6NARYUUJ\::@+/"F(JZO(Z/PK:#F<NL?:;.HG^JR9V
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MB+6Y_YL1 ?^@)@K_GS8<_YQ$,?^C0S__J$-._ZU$6_BQ16CPMDATZ;M,?N/
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M>IFVMWV6M[9^D[FT?Y&ZLH"0N[& D+NQ@)"[L8"0N[& D+NQ@)"[L8"0N[&
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M_Z@G"O^U(@SQQ" ,X-4D"='A,!3'YCTDO>-&-++@3D2FW%92F===88S28V^
MSVMZ=,QSA&O*?HMBR(R17,B<E5G(L997R,Z66[O-F%ZRS)EAJ\R99*;-F6>B
MS9AGH,V79Z#-EV>@S9=GH,V79Z#-EV>@S9=GH,V7_XH. ?^+& /_GR$%_ZX@
M!OB]& ;CT1,$T.$>"<7J+AFZZ3HIL.=#.:3D2DB8XE!6C.!78H#=7VQVVVAU
M;-IR?6/8?H-<V(R(5]B=BU37L(U4V,V,5<O3CU? TI%:N-&37++1DU^LT9-@
MJM&38*K1DV"JT9-@JM&38*K1DV"JT9-@JM&3_XP. ?^/%@+_I1X#_[45 ]K*
M"P+0X0X"Q.L>#;CO+!VM[C<NHNQ /9?K2$J,Z4]6@>A68';G7FELYV5P9.9P
M=U[C?'Q9X(F 5MZ7@U/=IH11W+B%4=W4A%/0VH=4QMB)5K_7BEBXUHM9MM:+
M6;;6BUFVUHM9MM:+6;;6BUFVUHM9MM:+_XX- /^7$@'_K14!V;\) ,S."0##
MZPX$MO4>$:OU+"&A]#<PEO- /HOS2$J!\U!4=_-776WS761E\&9J7^UP;EKJ
M>G)6YX5V4^61>5'DGGM/XZQ\3>.]?$WCV7Q0V.!\4<[@?U+&WH%3Q-Z!4\3>
M@5/$WH%3Q-Z!4\3>@5/$WH%3Q-Z!_Y(, /^@#0#;MP8 RL,' ,#2"0"U]! &
MJ?L?%)_\+".4_#<QBOQ!/8']24=X_5%0;OU75V7Z7EQ@]F9A6_1O95;Q>&A3
M[X)K4.Z,;4[LEV],ZZ-Q2NJP<DGJP7)(ZMAR2^/D<D[8YG-.U>=T3M7G=$[5
MYW1.U>=T3M7G=$[5YW1.U>=T_Y8* -ZL @#+N@4 O<<& ++8" &G_Q((G/\A
M%I+_+B.)_SDO@/]".7?_2D)M_U!)9?]63E__7E-:_F565?QM6E+Z=5Q/^'Y?
M3/>'84KUD6)(])QD1O.F947RLV9$\L%G0_+49T7NYV=&Z^AG1NOH9T;KZ&=&
MZ^AG1NOH9T;KZ&=&Z^AG[J(  ,VT @"\O@0 K\T$ *3>!P&:_Q4)D/\D%8?_
M,"!^_SLJ=/]",FO_2#EC_TX_7?]50UC_74=3_V1*4/]K34W_<D]*_WE11_^"
M4T7_BU1#_I160?V>5T#]J%@__+-9/OR_6C[[T5H]^]M:/?O;6CW[VUH]^]M:
M/?O;6CW[VUH]^]M:TJT  +VX @"NQ0( H=4" );W"P*-_Q@(A/\F$7S_,1IQ
M_S@B:/\^*6#_12]:_TPS5/]3-U#_6CI,_V \2?]F/D;_;4!$_W1"0?][0S__
M@T4]_XQ&._^51SK_GDDY_Z=*./^Q2C?_ODLW_\)+-__"2S?_PDLW_\)+-__"
M2S?_PDLW_\)+O[,  *Z^  "@S0  DMX  (G_#0&!_QH%=_\C#&W_*A-D_S$9
M7/\X'E7_0")0_T@F3/]/*4C_52M$_ULM0O]A+S__9S$]_VTR._]S,SG_>C4W
M_X(V-?^+-S/_E#@R_YPY,?^D.C#_KSLP_[([,/^R.S#_LCLP_[([,/^R.S#_
MLCLP_[([L+@  *#'  "1V   A.\  'S_#0%O_Q$#9O\9!E[_(0I6_RD/4/\R
M$TO_.A9&_T$90O](&S__3AT\_U,>.?]9(#?_7B$U_V0B,_]I(S'_<"0O_W<E
M+?]^)BS_AR<J_X\H*?^7*2C_H"HH_Z,J*/^C*BC_HRHH_Z,J*/^C*BC_HRHH
M_Z,JH<(  )'1  ""X0  >/\  &S_" %@_PT"5_\1 T__& 5(_R &0_\I"#__
M,0H[_S@,./\^#C7_1 \R_TD0,/].$2[_4Q(L_U@3*O]=%"G_8Q4G_VD6)?]O
M%R3_=Q<B_WX8(?^%&1__CQH?_Y$:'_^1&A__D1H?_Y$:'_^1&A__D1H?_Y$:
M_V@9 O]D(P3_7R\&_UY $/]C2QK_9U0E_VA=+_]F9SG_9')!_V)]2/]@AT[_
M79!2_UN85O]:GEG_6*1;_U>J7?Y6L%_]5;5@_%2\8?Q4Q&+[4\UC^5+<8_92
MYF/Q4^IC[%3M8^96[V+@5_!CX%?P8^!7\&/@5_!CX%?P8^!7\&/@5_!C_VD8
M O]E(P3_8"X&_U] $/]F21K_:E,E_VM<,/]I93K_9W!"_V1[2?]BA4__7XY4
M_UV66/];G5O_6J-=_5BI7_Q7KV'[5K5B^E6\9/I5Q&7Y5,YE]U/=9O-3YF;N
M5>IFYU;M9>%8[F7;6>]FVUGO9MM9[V;;6>]FVUGO9MM9[V;;6>]F_VH8 O]F
M(@3_82X'_V _$/]I2!O_;5$F_VY;,/]L9#K_:6Y#_V=Y2_]D@U'_88Q6_U^5
M6O]=G%W]6Z)@^UJI8OI9KV3Y6+5E^5>\9_A6Q6CW5<]H]53@:?!5YFGI5^IH
MXEGL:-M:[6G36^YITUON:=-;[FG36^YITUON:=-;[FG36^YI_VH8 O]G(@3_
M8BX'_V,^$/]L1AO_<5 F_W)9,?]P8CO_;&M$_VEV3/]G@5+_9(M8_V&37/U?
MFV#[7:%B^ENH9?E:KF?X6;5H]UB\:?97QFKU5M%K\E7A;.Q7YVSD6>EKW%OK
M:]1<[&S-7>ULS5WM;,U=[6S-7>ULS5WM;,U=[6S-7>UL_VL7 O]H(0/_8RT'
M_V<\$/]P11O_=$XF_W97,?]T8#O_<&E%_VUS3?]J?E3_9HA:_F.17OMAF6+Y
M7Z!E^%VG:/9<K6KU6K1L]%F];?18QV[R5]1O[E?B;^99YF_=7.ENTUWJ;\U>
MZW#'7^MPQU_K<,=?ZW#'7^MPQU_K<,=?ZW#'7^MP_VP7 O]I(0/_92T'_VLZ
M$/]T0QO_>4PF_WI5,?]Y73S_=69%_W!P3O]M>U;_:H5<_&:/8?IDEV7W89]H
M]E^F:_1=K6WS7+1O\EJ]<?%9R7+O6-ISZ%KC<]Y=YG+37NASRU_H=,9@Z'3!
M8>ATP6'H=,%AZ'3!8>ATP6'H=,%AZ'3!8>AT_VT6 O]J( /_9BT'_V\X$/]X
M01K_?4HE_W]2,?]^6SS_>V-&_W9L3_]Q=U?^;8)>^VJ,8_AFE6CU9)UL\V&D
M;_)?K''P7;1S[UR_=>Y;RW;J6]UWX%WC=M-@Y7?*8>5XQ&+E>+YCY7BZ9.5X
MNF3E>+IDY7BZ9.5XNF3E>+IDY7BZ9.5X_VX6 O]K( /_:"P'_W,V$/]]/QK_
M@D<E_X10,/^$6#O_@6!%_WQI3_]V<E?^<7U?^6V(9?9JDFKS9IMO\6.C<N]A
MJW7M7[5X[%W!>>Q<T'KC7=][U&'B>\IBXGS"9.%]O&7A?;=FXGRS9^)\LV?B
M?+-GXGRS9^)\LV?B?+-GXGRS9^)\_W 5 ?]L'P/_:2P'_W<T#_^!/!G_AT4D
M_XI-+_^)53K_AUU%_X)E3_]\;EC]=GA@^'*$9_5MCFWQ:9AR[V:A=NQCJWGK
M8+9\Z5[$?N=>V'_88=]^RF/?@,%EWH&Y9]Z!M&C>@;!IWX"L:=]_K&G??ZQI
MWW^L:=]_K&G??ZQIWW^L:=]__W$5 ?]M'P/_:RL'_WLR#_^&.AC_C$,B_X]+
M+?^/4SC_C5I#_XEB3?^#:5?]?')@^'9_9_1QBF[P;)5T[6B?>>IDJGWH8;>
MYE_(@MUAVX/,9-R$P&;<A;AHVX6Q:MN%K6O<A*ELW8.F;-V"IFS=@J9LW8*F
M;-V"IFS=@J9LW8*F;-V"_W(4 ?]O'@/_;RD'_W\P#O^*.!?_D4$A_Y1*+/^5
M43;_DUA!_Y!@2_N+9U7UA&]?\'UZ9^MWA6_G<I!VXVV;?-YHIH':9;.$U6/$
MAL]DVH?!9]F(MVG8B:]KV(FJ;=F(IF[:AZ-NVH:@;]N%H&_;A:!OVX6@;]N%
MH&_;A:!OVX6@;]N%_W(4 ?]P'@/_<B@'_X(N#?^.-A;_E4 ?_YE(*?^93S3_
MF%4^^I9<2?229%/MC&M=YX5V9N%_@6_;>(QWTW*6?LUMH83):JV)Q6B[B\%H
MT(RV:]6-KFW5C:=OUHRC<-:+GW'8BIUQV8F;<MJ'FW+:AYMRVH>;<MJ'FW+:
MAYMRVH>;<MJ'_W,4 ?]P'0/_=28&_X8L#?^1-A7_F4 =_YQ&)_^=3#'\G5([
M])Q91>V98$_FE&A9WXYS8]6&?6[-?X=XQGB1@,!SFX>[;Z>,MFVTC[-LR)&L
M;M*1I7#3D*!RU(^<<]6-F736C)=TV(J6==F)EG79B99UV8F6==F)EG79B99U
MV8F6==F)_W03 ?]Q'0/_>"0&_XDK#/^5-1/_G#X;_Z!#)/^B22[WHU W[Z)6
M0>>A74K?G6=4U)5O8LN->&[#A8)YNW^,@K5YEHFO=:&.JG*ODJ9QP92A<]"4
MG'31DIAVTI&6=]./E'?5C9)WUHR1>-B*D7C8BI%XV(J1>-B*D7C8BI%XV(J1
M>-B*_W43 ?]R' /_>R,&_XPI"_^8-!+_GSP9_Z-!(ONF1BKRJ$TSZJE4/.*I
M6T37HV-3S)IL8L*3=6ZZBWYYLH6'@ZI_D8JD>YR0GGBJE)IVNY:7=\^6E'G0
ME)%ZT9*/>M.0CGK4CXUZU8V,>M>+C'K7BXQZUXN,>M>+C'K7BXQZUXN,>M>+
M_W43 ?]S' /_?2$%_XXI"O^;-!#_HCD7_Z8^'_>J1";NKDHNY;%2-=RO64'/
MJ&%2Q:!I8;N8<FZQD7IYJ8N#@Z&%C8N:@9B1E'ZEEI!\MIB-?<V7C'[/E8I^
MT).*?M*1B7[3CXE]U8V(?=:+B'W6BXA]UHN(?=:+B'W6BXA]UHN(?=:+_W82
M ?]T' /_@" %_Y$H"?^>,P__I#<5_JH[&_.O02+JM$@HXKE0+M2T5D#)K5]1
MOJ5G8+2>;VVJEW=XH9& @IF,BHN1AY61BX2BEH:#LIF#A,N8A(/.EH2#T)2$
M@M*2A('3D(2!U(Z$@-:,A(#6C(2 UHR$@-:,A(#6C(2 UHR$@-:,_W<2 ?]T
M&P/_@AX$_Y0G"/^@,@W_IS03^JXX&.^U/1SFO$8AW+],+,ZY5#_#L5U0MZIE
M7ZVD;&RCG71WF9A\@9&3AHJ)CY*1@HR?EGV*KYAZB\>8?(G.EGV(T)1^AM*2
M?X73D'^$U(Z @]:,@(/6C("#UHR @]:,@(/6C("#UHR @]:,_W@2 ?]U&P/_
MA1P$_Y<F!_^C+PO_JS 0];,T%.N[.A?BQ$08U<1(*\B]4SV\MEM.L;!C7::J
M:FJ<I'%VDI]Z@(F:@XF!EHZ0>9.<E722K)=QDL.8<Y'/EG:.T)1XB]*1>8K3
MD'J(U8Y[A]:,>X?6C'N'UHQ[A]:,>X?6C'N'UHQ[A]:,_W@2 ?]V&P/_B!L#
M_YHE!O^F*PG^KRP,\;DO#N;#-@_=S3P6SLA'*<+"43NVO%E,JK9A6Y^P:&B5
MJV]TBZ9W?H&B@(9YGXN-<9R9DFR;J95IF[^6:YG0E&Z4T9)QD=*1<X_4CW6-
MU8UVB]:+=HO6BW:+UHMVB]:+=HO6BW:+UHMVB]:+_WD1 ?]X&@+_C!D#_YXC
M!/^J)@;XM"4(Z\ H".'-, ?4TC<4R,U%)[O(3SFOPE=*H[U?6)BX9F6-LVUQ
M@Z]U>WJK?H-QJ(F*:J:6CV6EIY)BIKV28Z/2D6>=TY!JF-2/;975C6Z2UHQP
MD-B*<)#8BG"0V(IPD-B*<)#8BG"0V(IPD-B*_WL1 ?]\%P+_D!<"_Z(A _^N
M( 3RNQT$Y<H> ]K;) /,V342P--#)+3.33:HR55'G,1=59' 9&*&O&MM>[AS
M=G*U?'YJLX>%8[&5BEZPI8Q;L;R-6Z_5C5^GU8UCH=:,9IS7BVB9V(IJEMF(
M:I;9B&J6V8AJEMF(:I;9B&J6V8AJEMF(_WP0 ?^!% +_E14!_Z<= ORU%@+K
MQA !VML/ ,W@)03#WS8/N-M!(:S52S.@T5-#E,U:48G)8EU^QFEG=,-Q<&O!
M>WADOX9^7;Z4@EB]I856OKN&5;W;AEBSVH=<J]J'7Z;:AV&AVX9CG=N%8YW;
MA6.=VX5CG=N%8YW;A6.=VX5CG=N%_WX0 ?^'$0'_FA$ _ZT4 -J^"@#1S0H
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MERDH_Z(J)_^M*R;_N2PF_\DM)O_)+2;_R2TF_\DM)O_)+2;_R2TF_\DMJK<
M )K%  "+TP  ?>(  '7_!0!I_PP!7_\1 E?_%P-0_Q\%2?\F!T3_+@D__S8+
M._\]#3?_0P\S_TD1,/]/$B[_51,L_UL4*O]B%2?_:18E_W(7(_][&"'_AAD?
M_Y$:'O^<&Q[_I1P=_[ ='?^P'1W_L!T=_[ ='?^P'1W_L!T=_[ =G,   (S.
M  !\W@  </4  &7_  !:_P8!4?\- 4G_$0)#_Q<#/?\?!#C_)@4T_RT&,/\S
M!RW_.0<J_SX()_]#""7_20DC_TX)(?]4"1__6@H=_V$*&_]I"QG_<@P7_WP-
M%O^&#13_CPX4_YH/%/^:#Q3_F@\4_YH/%/^:#Q3_F@\4_YH/_UP< O]7)@/_
M43(&_TX\"/]711#_6TX9_UQ8(O];8RO_66\R_U=Z./]4A3W_4I!!_U"91?]/
MH$?_3J=)_TVN2_],M$S_2[M-_TK#3O])S4__2=U0_TCI4/](\E#[2?90]DOY
M4/!-^T_J3_M0YT_\4.=/_%#G3_Q0YT_\4.=/_%#G3_Q0_UP< O]8)@/_4C(&
M_U$Z"/]:0Q#_7TT9_U]7(_]>82O_7&TS_UEY.O]7A#__5(Y#_U*71_]0GTG_
M3Z9+_TZM3?]-M$__3+M0_TO#4?]+SE+_2M]2_TGJ4_U*\E/X2_93\4WX4NM/
M^E+E4/I3XE'Z4^)1^E/B4?I3XE'Z4^)1^E/B4?I3_UT; O]9)@/_4S$&_U0Y
M"/]=0A#_8DL:_V)5(_]@7RS_7VLT_UQW._]9@D#_5HQ%_U252/]2GDO_4:5.
M_U"L3_]/LU'_3KM2_TW$4_],SU3_2^!5_TOK5?I,\E7T3?95[%#X5.91^%7?
M4OE6W%/Y5MQ3^5;<4_E6W%/Y5MQ3^5;<4_E6_UX; O]:)0/_5#$&_U@W"/]A
M0!'_94D:_V93(_]D72W_8F@U_U]T//]<?T+_68I'_U:32_]4G$[_4Z10_U&K
M4O]0LU3_3[I5_T[$5O]-T%?_3>)8_$SM6/9.\ECN4/58YE/V6-]4]UG75?A9
MTU7X6=-5^%G35?A9TU7X6=-5^%G35?A9_U\: O];)0/_53 &_UPT"/]E/1'_
M:D<:_VM1)/]I6BW_9F0V_V-P/?]??$/_7(=)_UF13?]7FE#_5:)3_U.J5?]2
MLE?_4;I9_U#%6O]/TEO\3N1;^$_M7/!1\EOG5/1;WE7U7-56]EW.6/==RUCW
M7<M8]UW+6/==RUCW7<M8]UW+6/==_V : O]<) /_5B\%_V R"/]J.Q#_;T0:
M_W!.(_]O5RW_:V$V_V=L/O]C>$7_8(-+_UR.3_]:F%/_5Z!6_U:I6?]4L5O_
M4[I<_E'&7OQ0UE_Y4.=?\E+N7^=5\5_=5_)@TECS8<M9]6+%6_5BPUOU8L-;
M]6+#6_5BPUOU8L-;]6+#6_5B_V$9 O]=(P/_6BT%_V4O"/]O.!#_=$$9_W9+
M(_]U5"W_<5TV_VQG/_]H<T;_9'],_V"*4O]=E5;_6IY9_UBG7/Y6L%_]5+I@
M_%/'8OE2W&/S4^ACZ57N8]Y8\&306O%ER%SR9L)=\F:]7O)FNU[R9KM>\F:[
M7O)FNU[R9KM>\F:[7O)F_V(9 O]>(P/_7BH%_VDM"/]T-0__>CX8_WQ((O][
M42S_>%HV_W-C/_]M;4?_:7I._V2&5/]@D5C_79Q<_5JE8/M8L&+Z5KME^%7*
M9O54X&?L5NIGWUKM9]!<[VG&7>]JOU_O:KE@[VJU8>]JLV'O:K-A[VJS8>]J
MLV'O:K-A[VJS8>]J_V,8 O]@(@/_8B<%_VXJ!_]Y,@[_?SP7_X)&(?^"3RO_
M?U@U_WM@/O]U:4?_;W1.^VJ!5?AFC%OU8I=?\U^A8_!<JV;N6K9I[%G$:NE8
MVFOA6NIKT%WL;<5?[&Z\8>MOMF+L;[%C[&ZM9.QNJV3M;:MD[6VK9.UMJV3M
M;:MD[6VK9.UM_V08 O]A(@/_9B4$_W(G!_]^, W_A3L6_XA%'_^(32G_AE4S
M_X)>/?M]9D;V=G!.\G)\5>YMAUSJ:))BYF2<9N-AIFK@7[)MW5V_;]I=TW#2
M7NIPQ&#I<KIBZ'.S9.ASK67I<ZEFZ7*F9^IQI&?J<*1GZG"D9^IPI&?J<*1G
MZG"D9^IP_V47 O]B(0/_:2,$_W<E!O^"+PS_BCD4_XY#'?^/3";_C5,P^8I;
M.O.%8T3M?VQ-Z'EW5>-T@EW>;HUCV6F7:=-FH6[/8ZQQRV&Y=,AARG7%8>5V
MN63F=[!FY7>J:.9WI6GF=J)JYW6?:NASGFOI<YYKZ7.>:^ESGFOI<YYKZ7.>
M:^ES_V87 ?]C(0/_;2 $_WLC!?^'+@O_CS@2_Y-!&O^52B/ZE%$M\Y%9-^R-
M8$'EAVE*WX%T4]9Z?EW/=(AERF^1;,5KFW'!:*9UO6:R>+IEPGJW9=U[KFCC
M>Z=JXWNB:^1ZGFSE>)MMY7>9;>=VF&[G=9ANYW68;N=UF&[G=9ANYW68;N=U
M_V<6 ?]D( /_<!X#_WXB!?^++ G_DS<0_YA &/V:2"#TFDXI[)A5,^6573S=
MCV9'TXAO4\N!>5[%>X-FOW6,;KEQEG2U;J%XL&NL?*UJNWZJ:M)_I&S@?IYM
MX7V:;^)\EW#C>I5PY'F3<.5WDW'F=Y-QYG>3<>9WDW'F=Y-QYG>3<>9W_V@6
M ?]D( /_<QP#_X$@!/^.*PC_ES4._YT^%?B?1!SOH$LEYY]2+=^=6C?3E6-&
MRHYL4\.'=5Z[@7YGM7N(;Z]WD76J<YQZI7"H?J%OMH&>;\J"FW#>@99QWX"3
M<N%^D7/B?)!SXWJ.<^1YCG/E>(YSY7B.<^5XCG/E>(YSY7B.<^5X_VD6 ?]F
M'@/_=AH#_X0? _^2*@?_FS0,_J [$O.C01CJID@@XJ=/)]BB5C;,FF!%PY-I
M4KN-<EZSAGIGK(&$;Z9]C7:@>9A\FW:C@)=TL8.4=,6$D77=@X]VWH&-=N!_
MBW?A?8IWXGN)=N1ZB7;D>8EVY'F)=N1YB7;D>8EVY'F)=N1Y_VD5 ?]I'0/_
M>!D"_X<> _^5* ;_GC(*^J0W#^^H/13FK$0:W:U+)-"F5#7&GUY$O)EF4K22
M;UVLC'=GI(> ;YZ"BG>8?I1]DGN@@8UZK82*><"%B'K<A(=ZW8*&>M^ AGK@
M?H5ZXGR%>>-ZA7GD>85YY'F%>>1YA7GD>85YY'F%>>1Y_VH5 ?]K&P+_>Q<"
M_XH< O^8)@7_HC (]:@S#.NN.1#BLT$4UK%'(\JK4C3 I%Q#MIYD4:V8;%RE
MDG1FG8U];Y:(AG:/A9%]BH*<@H6 JH6!?[R&@(#;A8" W8. ?]Z!@'[@?X!]
MX7V ?>-[@'SD>H!\Y'J ?.1Z@'SD>H!\Y'J ?.1Z_VL5 ?]M&0+_?A4"_XT;
M O^;) /^I2P&\:PO".>S- O=NCH0T+5&(<6O43*ZJ5I"L*-B3Z>=:EN>F')E
MEI-Z;H^/@W:(BXY\@HB9@7R&IX5YAKF&=X?7A7B%W8-Z@]Z!>H+@?WN!X7U\
M@.-[?'_C>GQ_XWI\?^-Z?'_C>GQ_XWI\?^-Z_VL4 ?]P& +_@10!_Y 9 ?^?
M(@+ZJ28$[;$I!>*Z+P;6OS8/RKI$(+^T3S&TKEA JJA@3J&C9UJ8GF]DCYIW
M;8B6@'6 DHM[>H^6@'2.I(1QC;:%;X[1A7&+W8-SB=^!=8?@?G:%X7UWA.-[
M=X/D>G>#Y'IW@^1Z=X/D>G>#Y'IW@^1Z_VP4 ?]S%@+_A1,!_Y06 ?^B'@'U
MK2 "Y[@A MW#)@+0PS0-Q+Y"'KFY32^NLU8^I*Y>3)JI95>1I6UBB:%U:X"=
M?G)YFHAY<I>4?FV6HH)IE;.$9Y;-@VF3WH)LC]^ ;XSA?G"*XGQRB.-Z<H?D
M>7*'Y'ERA^1Y<H?D>7*'Y'ERA^1Y_VT3 ?]V$P'_B!(!_Y@3 /^G&0'OLQ8!
MXL 5 -7*'@')QS(,OL- '+.^2RRHNE0\GK5<292P8U6*K&M?@:ER:'FE>V]R
MHX5V:Z"1>V:?GW]BG[&!8)_*@&*<X']EE^%^:)/B?&J0XWMLC>1Y;8SE>&V,
MY7AMC.5X;8SE>&V,Y7AMC.5X_VX3 ?][$0'_C1  _YT0 /JL$0#:NPL U<D+
M ,W.&P'"S"\*M\D]&:S%22FAP%(XE[Q:1HVX85&#M6A;>K)P9'*O>6MKK(-Q
M9*N/=E^IGGI;J:]\6:K)?%JGXGM>H.-[89OC>F.7Y'EFE.5W9I+F=V:2YG=F
MDN9W9I+F=V:2YG=FDN9W_W 2 ?^ #@'_D@X \J,+ -FS"0#/O@D R\P) ,33
M%P"ZTBP'L,\[%J7,1B::R% UC\18087!7TU\OF=6<[QO7FNY=V5DN()K7K:.
M<%FUG7-5M:YU5+;(=5.SYW97J^9V6J3F=ER@YW5?G.=T8)KH=&":Z'1@FNAT
M8)KH=&":Z'1@FNAT_W(2 ?^&# #[F D V:D& ,ZU!P#&P0< P,\) +K;$P"Q
MVBD%I]@W$IS41"&2T4TPA\Y5/'W+74=TR650;,=M5V7%=EY>Q(%C6<..:%3#
MG6M1PZYL3\3(;4["[6U0N.MO4[#K<%6KZG!8INMP6:/K<%FCZW!9H^MP6:/K
M<%FCZW!9H^MP_W</ ?^-" #>H ( SZX% ,2Y!0"[Q08 M=,* *[A%@&FX2D&
MG> W$9/>0AV)W$PI?]I4-7777#]MU61(9=-L3U_2=E19TH%95-&.75#1G6!-
MTK!B2]/)8DK2[6)+R/)F3;_Q:$^X\&E1LO!I4J_O:5*O[VE2K^]I4J_O:5*O
M[VE2K^]I_W\* .V6  #2I@$ Q+(# +F\ P"PR08 J=@* *'G&0*9YRH)D.<W
M%(?F0A]]Y4HI=.11,VOC63IDXF%!7N)K1UCB=4M3X8!/3^*-4TOBFU5)XZQ7
M1^3$5T;CZ5=&W?991]#W7$G(]UY*P?9@2[WV8$N]]F!+O?9@2[WV8$N]]F!+
MO?9@_XD  -F>  #'K $ N;8" *[! P"ES@8 G.0, )7O'0.-[RP+A>\Y%7SO
M01YS[TDG:NY0+V+N5S5<[E\Z5NYH/U+N<4)-[WQ&2>^)24;PEDM#\*9-0/&Y
M3C_RVT\^\/=.0N;[3T/=^U%$U/Q31<_\5$7/_%1%S_Q41<_\5$7/_%1%S_Q4
MX94  ,NF  "[L   KKL! *+( @"8U04 D/@/ 8GX( 2"^"X+>?DW$W#Y/QMH
M^48B8/I-*%KZ5"U4^EPQ3_ME-4O[;3A'_'<[0_R#/3_]D#\\_9]!.OZO0SC_
MQD0W_^I%-OS]13OR_T0^ZO]$/N;_1C[F_T8^YO]&/N;_1C[F_T8^YO]&T)\
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M'1S_RAX<_^8?&__P'QO_\!\;__ ?&__P'QO_\!\;__ ?I+4  )7"  "&SP
M=]X  &OT  !B_P, 6?\+ 5'_$0%*_Q<"1/\? S__)@0Z_RT%-O\T!C+_.@<N
M_T (*_]&""C_3 DE_U()(O]9"B#_8@L=_VL,&O]V#1?_A X5_Y(/%/^@$!/_
MK1$3_[H1$__#$A/_PQ(3_\,2$__#$A/_PQ(3_\,2E[X  (;,  !WVP  :><
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MW%-'R/=52,#\6$JX^UE,LOM:3JWZ6DZM^EI.K?I:3JWZ6DZM^EI.K?I:_W\
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M-37S_S0W[/\V.>7_.#GE_S@YY?\X.>7_.#GE_S@YY?\XR)X  +:I  "HL@
MF[T  (_(  "#U   >>@' '/\$@%K_1T"9/TG!%[^,0A8_CL-4_]#$4W_2Q5)
M_U,81?]:&D'_8QT^_VP?._]V(3?_@B,T_Y E,O^?)S#_L"@N_\@I+?_J*BS_
M_RHL__\J+_G_*B_Y_RHO^?\J+_G_*B_Y_RHO^?\JN:8  *JN  "<N0  CL4
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M"0W_TPD-_],)#?_3"0W_TPD-_],)D;P  (')  !RUP  9.0  %3K  !+_P
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M6(AK_%B(:_Q8B&O\6(AK_%B(:_Q8_U0: ?]B$P'_;Q !_WL2 /^%% #ZC1D
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M246Y_TI'L_]+2:W_3$JK_TQ*J_],2JO_3$JK_TQ*J_],Z7\  -&0  #"G@
MM:<  *JO  "@N   EL$" (S+!P"$U0T @-4> 7G5+@5RU#P,;--'%&724!M?
MT5DA6M%B)U70:RQ1T'4P3<^!-$G/CC=&SYTY1-"N.T+0QCM#T.HZ0,W]/C[+
M_T! P_]"0;W_0T*Y_T1"N?]$0KG_1$*Y_T1"N?]$W8@  ,>8  "XHP  JZL
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M'"KW_QTJ]_\=*O?_'2KW_QTJ]_\=LZ,  *2K  "7M@  B<$  'O+  !OU@
M8]\  %OU!@!5_Q  4/\9 4O_(P)&_RP#0O\T!#[_/ 4Z_T,&-_]+!S3_4P@Q
M_UL)+O]D"BO_;PPH_WP-)O^+#B3_G! B_ZX1(?_%$B#_Z1,?__P3'O__$Q[_
M_Q,>__\3'O__$Q[__Q,>__\3IJD  )BS  "*OP  >\H  &[5  !@WP  5.<
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M3E64_TU8D/],68W_2UN*_TI;BO]*6XK_2EN*_TI;BO]*_V@  .5Y  #1AP
MQ9(  +N<  "QH@  J:D  *&Q @";LQ4 E;,H HZR-@F&L$(2?ZY,&WBL5"-R
MJEPJ;*AD,6>G;#9BI74[7:1_0%FCBD-5HI='4:&G24^ANDI.HME)3J#U24Z?
M_TE0F?])4I;_2%22_T=4DO]'5)+_1U22_T=4DO]'_VX  -Y_  #*C0  OI@
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M-CVX_S<]N/\W/;C_-SVX_S<]N/\WT88  ,"5  "RGP  I:<  )JO  ".MP
M@[\  'C' P!NSP< 9=<- &/8'0!@V"T"6]@Z!%?81@E3V% -3]A9$4O78A5'
MUVP81-=W&T'7A!X^V),@/-BC(3O9MR(ZVM4B.M;R(S?4_R<VTO\I--'_*S;*
M_RTVRO\M-LK_+3;*_RTVRO\MQ9   +:=  "HI0  G*T  (^V  "#O@  =\<
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M"1G__PD9__\)HJ<  ).Q  "%NP  =L8  &G0  !;V@  3N   $/E   ^^P$
M.O\, #;_$P R_QL +_\C "O_*@$H_S$!)/\W 2'_/P(?_T8"'/]. AG_6 ,6
M_V,#$_]P Q+_@001_Y,$$/^G! __O04._^ %#O_V!0[__P4.__\%#O__!0[_
M_P4.__\%E:\  (:Z  !WQ0  :-   %K;  !,X0  0.<  #?S   R_P  +O\'
M "K_#@ F_Q, (_\: !__(  ;_R8 &/\K 17_,@$2_S@!$/]  0[_2 $,_U(!
M"?]= @;_:P($_WT" O^0 @'_HP( _[8" /_- P#_[ , _^P# /_L P#_[ ,
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M1V5[_T1F>O]#9WC_06AV_S]H=O\_:';_/VAV_S]H=O\__UL$ /=I  #==@
MS8   ,.(  "[C@  M),! *V7"0"GF!H H)@L YF6.@J2E$42C))/&H:/5R*
MC5\H>XMG+G:);S-RAW<X;86!/&F$BT!F@I=#8H&E1F"!MD=>@<U'7H'O1E^!
M_T1@?_]"87W_06)[_S]C>O\_8WK_/V-Z_S]C>O\__UX  .EM  #6>0  R(0
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M/$^1_SM0C_\[4(__.U"/_SM0C_\[ZVT  --\  ##B0  MY,  *R:  "BGP
MF:4  (ZK  "%L L @;$; 'RQ*P)WL#@'<:]##6NN311FK5498:Q='EVK92-9
MJFXG5:EW*U&H@B]-IX\R2J>>-4BGKS9'I\8V1J;I-D6D_C=%H_\W1J#_-TB<
M_S=)FO\W29K_-TF:_S=)FO\WXG0  ,J#  "\CP  L)@  *6>  ";I   D*L
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M(2_(_R$OR/\AOH\  *^:  "BH0  EJD  (JP  !]N   <;\  &;&  !;S (
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M=P$+_XH""O^? @G_M0((_]4"!__T @?__P('__\"!___ @?__P('__\"D:T
M (*X  !SP@  9,P  %;5  !(W0  .^(  ##G   G[@  (_\  "#_!  <_PP
M&?\1 !;_%@ 3_QL $?\A  [_)P -_RX "O\V  ?_/@ $_T@  /]4  #_8@$
M_W,! /^' 0#_G0$ _[(! /_* 0#_Z@$ __,! /_S 0#_\P$ __,!A+<  '3!
M  !ES   5M@  $??   YY0  +>H  "/N   <_0  &/\  !7_   1_P0 #_\+
M  W_#@ )_Q$ !O\5  /_&@  _R   /\F  #_+@  _S<  /]!  #_30  _UP
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MXSJM%>(ZMA;@.\(6WSO2%MH[Z!?4.O8:T#K_',TZ_Q[+.O\>RCK_'\0[_Q_
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M.W-G_SAS:/\V<VC_-7-G_S-S9O\R<V;_,G-F_S)S9O\R_U$$ /]<  #B9P
MTG   ,=V  # >@  NGT" +1_# "M@1T IX$N J!_/ B:?4</E7I1%I!X6AR+
M=F(AAW1I)H-R<2M_<7HO?&^#,GANC35U;9@X<FRE.W!KM#QN:\D\;6OI.VUL
M_CEM;/\W;FS_-6YK_S1N:O\R;FK_,FYJ_S)N:O\R_U,  /1?  #>:@  S7,
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M-5YY_S1?=_\S7W?_,U]W_S-?=_\S_EP  .%J  #-=0  P'X  +:&  "NBP
MI8X  )N1  "5DQ$ D)0B 8N3,0.%DCT)?Y%(#WJ/419UC5D;<8Q@(&R*:"5H
MB7 I9(=Y+6&&@S%=A8\T6H2<-E>#K#A5@[\Y58/A.%6"^3=6@O\U5H'_-%A_
M_S-9??\R67W_,EE]_S)9??\R[V   -MN  #'>@  NX,  +*+  "HD   GY,
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M*T27_RM$E_\KUW(  ,.   "VC   JI0  )^9  "4G@  B:,  'ZH  !PK@
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MG04HV;$&)]K-!B?7[P8FU/\))=+_"R31_PPCT/\-(]#_#2/0_PTCT/\-KI8
M *"=  "4I   AJP  'FT  !LNP  8,(  %3&  !(RP  /M   #75!  MW0H
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M  #_K0  _\H  /_P  #__P  __\  /__  #__P  __\ C:L  'VU  !NOP
M8,@  %+0  !#UP  -]T  "OB   BY@  &>H  !7Y   2_P  $/\(  [_#@ ,
M_Q$ "?\6  ;_'  #_R(  /\J  #_,P  _ST  /])  #_5P  _VD  /]^  #_
ME0  _ZP  /_'  #_Z   __H  /_Z  #_^@  __H @+4  '"_  !AR0  4M,
M $/;   UX0  *>8  ![J   5[@  $/@   [_   +_P  "/\   3_!@  _PH
M /\.  #_$0  _Q4  /\;  #_(P  _RL  /\V  #_0P  _U,  /]E  #_>@
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M*X15_"J#5O\H@U;_)X)6_R6!5O\D@5;_)(%6_R2!5O\D_T<# /]/  #G6
MV6   ,UD  #&9@$ P68$ +MF#@"T:2  KFDQ JAH/P6C9DH*GV54#YIC7127
M8648DV!M')!>=1^.77TBBUR&)8A;D"B%6IHJ@UFF+(!9M"U_6<<N?5GF+7Q:
M^BQ[6O\J>UO_*'M;_R=[6O\F>EK_)7I:_R5Z6O\E_TD  /M2  #C7   TF,
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M*FIG_REJ9O\H:F;_)VIF_R=J9O\G_U   .=;  #39@  Q6X  +MS  "S=P
MJWD  *1X P"=>A0 F'LE 9-[- ..>D 'B7A*#81V4Q* =5L7?'-B&WAR:A]U
M<7(B<F][)F]NA2EL;9 L:6R<+F9LJC!D;+PQ8VS9,&-L]"]C;/\M9&S_*V1K
M_REE:O\H96K_*&5J_RAE:O\H_5,  .-?  #.:0  P7$  +=W  "O>P  IWT
M )Y]  "8?A$ DX B (Z ,0*)?SX&A'U(#']\41%[>ED6=WE@&G-W:!YO=G A
M;'5X)6ET@BAF<XXK8W*:+F!QJ"]><;HP77'4,%UQ\BY><?\L7G#_*U]P_RE@
M;_\H8&[_*&!N_RA@;O\H\54  -YB  #*;0  O74  +-[  "K@   HH(  )B!
M  "1@P\ C84? (B%+@*#A#L%?H-%"GJ!3@]U@%84<7]>&&Y]9AQJ?&T@9WMV
M(V-Z@"=@>8LJ77B8+%IWIBY8=[@O5W?1+U=W\2Y8=O\L6';_*EEU_RE:=/\H
M6G3_)UIT_R=:=/\G[5D  -=F  #%<0  N7H  *^   "FA   G88  )&'  "*
MB0P AHH; (*+*P%]BC@$>(E""'2(3 UOAU02;(5;%FB$8QID@VL>88)T(5V!
M?21:@(DH5W^6*E5^I"Q2?K8M47[.+5%][RQ2??\K4GS_*5-[_RA4>O\G5'K_
M)U1Z_R=4>O\GZ%X  -!K  # =@  M'X  *N%  "AB0  EXL  (F-  "#CP@
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MG1<ZIJ\8.:;'&#FEZA@XH_\:-Z'_&S>@_QPWG_\<-Y__'#>?_QPWG_\<Q'@
M +6%  "ICP  G94  )*:  "&GP  >J,  &ZH  !BK   5;   %"R#@!.LAL
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M B#/Y (?S?H#'LO_!![*_P4=R?\&'<G_!AW)_P8=R?\&J)0  )R:  "0H0
M@J@  '2O  !GM@  6[P  $[   !#PP  .<<  "_,   GT 0 ']8* !O:$  ;
MVQH &MLF !K<,0 9W3P &-U( !C>50 7WV( %N!R !7@A0 4X9H $^*Q !+C
MSP 2X/0 $M[_ 1'=_P$1V_\"$=O_ A';_P(1V_\"GIH  )*A  "$J0  =K$
M &BX  !;OP  3L0  $+(   WS   +=   "35   <VP  %=\% !3I#@ 2ZA0
M$>L= !#K)@ .[#  #NTZ  WN1@ +[E, "N]B  GP=  (\8D !_*@  7RN@ $
M\>0  O']  +O_P #[?\  ^W_  /M_P #[?\ E:$  (:I  !XL@  :;H  %O"
M  !-R   0,P  #31   JU@  (=L  !G@   2Y   #_ !  WY"@ +^@\ "?L5
M  ?['  $_"0  ?PL  #\-P  _$(  /Q0  #\80  _74  /R,  #\I   _,$
M /SK  #\_P  _?\  /W_  #]_P  _?\ B:D  'FR  !JNP  7,0  $[,   _
MT0  ,M<  "?=   =X0  %>4   [H   *\0  "/T   7_ P !_PD  /\.  #_
M$@  _Q<  /\?  #_)P  _S$  /\^  #_30  _U\  /]U  #_C0  _Z8  /_"
M  #_YP  __P  /__  #__P  __\ ?+,  &R\  !=Q@  3L\  #_6   QW0
M)>(  !KF   1Z@  #.X   7R    _P   /\   #_    _P   /\%  #_"@
M_PX  /\2  #_&   _R$  /\K  #_.0  _TH  /]=  #_<P  _XP  /^D  #_
MN0  _]0  /_>  #_W@  _]X _Q@L /\9*0#_&2@ _Q4K /\0, #_"S@!_P-$
M ?\ 40'_ %X!_P!L ?\ > '_ ((!_P", ?\ E '_ )P _P"B /\ J #_ *\
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M%YQ!_!>:0?\7F$'_%YA!_Q:70?\5ET'_%9=!_Q670?\5_SL& /\_  #Y1@
MY4L  -Q.  #3300 T4H) ,I*% #"32< O$XW ;=.10*R35 %KTQ:"*M+8PJH
M2FP-IDET#Z1)?!&A2(03GT>,%9U'E1>;1I\8F4:J&9=&N!J61LH;DT;F&Y%'
M^1N/1_\:CD?_&8Y'_QB-1_\8C4?_%XU'_Q>-1_\7_SX" /]#  #K2P  W5$
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M'W96_QUV5O\<=E;_&W96_QMV5O\;_T4  .Q.  #:6   R5X  +]B  "W9
ML6,  *MA" "D8Q< GV0H )IE-P*69$,%D6--"(YA50R*8%T0AU]E$X1>;!:!
M7709?EQ]''Q;AAYY6I$@=UJ=(G19JB1R6;HE<5G2)7!:\"-O6O\B;UK_('!:
M_QYP6O\=<%K_''!:_QQP6O\<_T@  .=2  #36P  Q6(  +MF  "S:   K&@
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M'F!F_QY@9O\>[T\  -I<  #&90  NFT  +!R  "G=0  G70  )1S  "-= T
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MFQY)@:P?2(#!($> XQ]'?_H>2'[_'DA]_QU)?/\<27S_'$E\_QQ)?/\<UF$
M ,)N  "T>   JH   )^%  "4AP  B(<  'N)  !PC   :XX- &B/&@!FCRD
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M$#2@W0\TG?<0,YS_$C.:_Q(SF?\3,YG_$S.9_Q,SF?\3O7<  *^#  "CBP
MF)$  (V5  "!F0  <YP  &>?  !;H@  3Z8  $>I" !$JA( 0ZH? $&K*P!
MJS< /ZQ! #VL2@$[K%,".:Q< S>L9P0UK',%,JR!!C"LD0<NK*,(+:RX"2RL
MV0@LJO4**ZC_"RJF_PPJI?\-*J7_#2JE_PTJI?\-M8   *B+  "<D0  D98
M (6<  !XH   :Z4  %^H  !3K   2*\  #VR   VM0L -+45 #.V(0 RMBP
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M  O4_P +TO\ "]+_ 0O2_P$+TO\!FI@  (Z?  " I@  <JT  &2T  !7N@
M2;\  #W"   RQ@  *,D  !_-   7T0  $=8   S;!0 (W@L !M\1  7?&@ $
MX"0  N$N  'B.@  XT<  .16  #D9P  Y7L  .:2  #FJ@  Y\@  .?P  #H
M_P  Z/\  .C_  #H_P  Z/\ D9\  (*G  !TKP  9;<  %>^  !)PP  /,<
M ##+   ESP  '-0  !39   .W0  ">$   +E    Z08  .D-  #I$0  ZA@
M .LA  #M*P  [S<  /%%  #R5@  \V@  /-^  #TEP  ];   /;0  #W\P
M]_\  /?_  #W_P  ]_\ A:<  ':P  !FN   6,$  $K(   [S   +M$  "/6
M   9W   $>    SC   $YP   .H   #U    ]    /4%  #U"P  ]@\  /84
M  #X'0  ^B<  /PT  #_0P  _U4  /]I  #_@0  _YH  /^R  #_SP  _^T
M /_Y  #_^0  __D >+   &BZ  !9PP  2\L  #O1   MV   (=T  !;B   .
MY@  ".H   #M    \    /@   #_    _P   /\   #_    _P8  /\,  #_
M$   _Q@  /\B  #_,   _T   /]3  #_:0  _X$  /^9  #_KP  _\,  /_5
M  #_U0  _]4 _Q,H /\3)0#_$24 _PTG /\&+0#_ #4 _P!! /\ 3P#_ %P
M_P!I /\ = #_ 'X _P"( /\ D #_ )< _P"= /\ I #_ *H _P"P /\ MP#_
M ,  _P#, /\ WP#_ .P _P#X /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\
M_P#_ /\ _Q8E /\6(@#_%"$ _Q C /\** #_ #  _P ] /\ 2P#_ %@ _P!D
M /\ < #_ 'H _P"$ /\ C #_ ), _P": /\ H #_ *8 _P"M /\ M #_ +P
M_@#( /T V0#[ .D ^@#V /D _P#X /\ ^ #_ /@ _P#X /\ ^0#_ /D _P#Y
M /\ _QHB /\:'@#_&!T _Q,> /\.(@#_"BP _P<Y /\#1@#_ %, _P!@ /\
M:P#_ '8 _P!_ /\ B #_ (\ _P"6 /\ G0#_ *, _@"I /P L #Z +D ]P#$
M /4 T@#S .8 \@#T /$ _P#P /\ [P#_ .\ _P#O /\ \ #_ /  _P#P /\
M_QX= /\>&0#_'!< _Q<8 /\3'@#_$2@ _PXT /\,00#_"DX _PA; /\'9@#_
M!G$ _P9Z /\&@P#^!HL _ :2 /H&F0#X!I\ ]@:F /0&K0#R!K4 \ 7  .T%
MS@#K!>0 Z0;S .8(_P#E"O\ Y O_ .0+_P'D"_\!Y O_ >0+_P'D"_\!_R$8
M /\A$P#_(!$ _QL2 /\<&@#_&B0 _Q8O /\3/ #_$4D _Q!5 /P.80#Y#FL
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M [LE_@2X)?\%MB7_!;4E_P:U)?\&M27_!;4E_P6U)?\%_RP- /\M!0#_+@$
M_S$% /\Q"P#]+Q  \2L8 .<I)0#?*#, V"A" -$J3P#-*UH R2ME <<K;@'$
M+'8"PBQ^ L LA@.^+(X#O2R6 [LLG@2Y+*<$N"RQ!;8LOP6U+=$%L2WJ!JXN
M^P>K+O\(J2[_"*@N_PBH+?\(J"W_"*@M_PBH+?\(_R\( /\Q  #_-0  ]C<
M .HV @#G,P@ Y"\/ -DN&P#/,2P R3,\ ,0T20# -54!O#5? KHU: *W-7 #
MM31X!+,T@ 6Q-(@&L#20!JXTF0>L-*((JS2L":DTN0FG-,H*I37E"J$U^ N?
M-?\,G37_#)TU_PN<-?\+G#7_"YPU_PN<-?\+_S," /\U  #V.@  Y3X  -Q
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M$8A"_Q"'0O\0AT+_#X="_P^'0O\/_S@  /,]  #C1P  TDP  ,A.  # 30
MNTH" +9'#@"P21T JTLM *9,.P&B3$<"GDM1!)M+6@:92F((EDEJ"I1)<0R2
M2'D.CTB"#XU'BQ&+1Y42B4:@%(=&K!6%1KL6A$;1%H)'[A: 1_\5?T?_%']'
M_Q)_1_\1?T?_$7]'_Q%_1_\1_SL  .Y#  #<3   S%$  ,%4  "Y5   M%$
M *Y-"P"H3QD HU$I )Y2-P&:4D,"EU%.!)115@:14%X)CD]F"XQ.;0V)3G4/
MATU^$85-AQ."3)$5@$R<%GY+J1=\2[@8>TO-&'E,ZQAX3/X7=TS_%7=,_Q1W
M3/\3=TS_$G=,_Q)W3/\2_SX  .A'  #54   QE8  +Q8  "T60  K58  *=3
M!P"A5!4 G%8E )A7- &45T "D%=*!(U64P:*55L)AU1C"X14:@Z"4W(0@%)Z
M$GU2@Q1[48X6>%"9&'90IAET4+4:<U#)&G%0Z!IP4?P8<%'_%W!1_Q5P4?\4
M<5#_$W%0_Q-Q4/\3]4   .1+  #/5   P5H  +==  "O7@  IUL  *%8 P";
M61( EELB ))<,0&.7#T"BEQ'!(=;4 :#6E@)@5E@#'Y99PY[6&\0>5=W$W96
M@!5T5HL7<E66&6]5HQIM5+(;;%3&&VI5YAMJ5?L9:E7_%VI5_Q9J5?\5:U7_
M%&M5_Q1K5?\4\D,  -]/  #+6   O5T  +-A  "K8@  HF   )M<  "57A
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MFQI69ZH;56>]'%1GW!Q49_8:5&;_&%5F_Q=59?\65F7_%59E_Q569?\5XE$
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M;P  J'8  )UY  "/>   A'@  '=Y  !O?   :GT- &=^&0!D?R8 8H R 5^
M/0)<@$8#6G].!5=_50=4?ET)4GUE#$]];PY,?'D12GR&$T=[E!5%>Z061'NW
M%D-[TA9#>O(60WG_%4-X_Q1$=_\41';_$T1V_Q-$=O\3S5\  +MK  "N=
MI'P  )=^  "*?0  ?WX  ')_  !F@P  880( %Z&$P!<AR$ 6H<N %B'. %5
MAT("4X=* U"'4@5.AEH'2X9B"4F%; M&A7<-0X2##T&$DA$_A*(2/82U$SR$
MSQ,\@O 2/('_$CV _Q(]?_\2/7[_$3U^_Q$]?O\1Q68  +5Q  "J>P  GX(
M )*"  "%@@  >8,  &V&  !?B@  6(T! %2.#P!2CQL 4(\G $^0,P!-D#T!
M2Y!% DF03@-&D%8$1(]?!4*/: <_CW,)/8Z "SJ.CPPXCJ --XZS#C:.S XV
MC>\.-8O_#C6)_P\UB/\/-H?_#S:'_P\VA_\/OFT  +!Y  "E@@  F8<  (R(
M  !_B   <HH  &:-  !:D0  4)4  $F7"0!'F!, 19@@ $29*P!#F38 09I
M $":2 $^FE$"/)I: CJ:9 ,WFF\%-9E]!C.9C <QF9T(+YFP""Z9R@@NF.T(
M+I;_"BV4_PHMD_\++9+_"RV2_PLMDO\+MG4  *J!  ">B   DXT  (:.  !X
MCP  :Y(  %^5  !4F0  29T  $"@   ZH@T .*,7 #>C(@ VI"T -:0W #2D
M00 SI4L ,:54 3"E7@$NI6H!+*5X BJEB ,HI9H#)Z6M!":EQ@,FI.L$):+_
M!26@_P8DG_\&))[_!R2>_P<DGO\'KWX  *.(  "7C@  C9,  'Z5  !PF
M8YL  %>?  !,H@  0J8  #BI   OK , *JX. "FN&  HKR, )Z\M ":P-P E
ML$$ )+!+ ".Q5@ BL6, (;%Q !^Q@@ >LI0!'+*I 1NRP0$;L><!&Z_^ AJM
M_P(:K/\#&JO_ QJK_P,:J_\#J(@  )N/  "1E   A)H  ':?  !HH@  6Z4
M $^I  !$K0  .;   "^S   FM@  'KD% !B[#@ 7NQ8 %[P@ !:\*@ 5O34
M%+U  !.^2P 2OE@ $KYG !&_>  0OXP $,"B  [ N@ .P.$ #[W[  ^\_P 0
MNO\!$+K_ 1"Z_P$0NO\!GX\  )25  "'FP  >:$  &NG  !>K   4K$  $6T
M   ZM@  +[D  "6\   =OP  %<,   _&!0 +R@T "<H4  C*'0 'RB< !\HR
M  ;+/@ %RTL !,Q:  /,:@ "S'X  <R4  #,JP  S<@  ,SM  #,_P  R_\
M <K_  '*_P !RO\ EY8  (J<  !\HP  ;JH  &"P  !2M@  1;D  #F\   N
MOP  (\,  !O&   3R@  #<T   C1   !U D  -0.  #5%0  UAX  -@G  #9
M,0  VSX  -Q+  #=6P  WFX  -Z$  #?FP  W[0  -[9  #?]P  W_\  -__
M  #?_P  W_\ C9T  '^E  !PK   8;,  %.Z  !%OP  .,(  "S&   AR0
M&,T  !#1   +U0  !-H   #>    X $  .$)  #B#@  Y!,  .4;  #G)
MZ2\  .L\  #M2P  [ET  .YQ  #OB0  \*(  /"\  #PXP  [_D  /#_  #P
M_P  \/\ @:4  '*M  !CM0  5+T  $;$   WR   *LP  !_0   5U0  #MH
M  ?>    X@   .8   #I    Z@   .P   #N!0  [PP  /$0  #S%P  ]2
M /@K  #[.0  _4H  /Y>  #_=   _XT  /^F  #_P   _^$  /_U  #_]0
M__4 =*X  &6W  !6P   1\@  #C-   JT@  '=@  !/=   ,X@   ^8   #I
M    [    /    #S    ]    /8   #X    ^@   /T'  #_#0  _Q(  /\;
M  #_*   _S<  /]*  #_7@  _W8  /^/  #_I@  _[H  /_1  #_T0  _]$
M_P\D /\.(@#_"R$ _P,D /\ *0#_ #( _P ^ /\ 3 #_ %D _P!E /\ < #_
M 'H _P"$ /\ C #_ )( _P"9 /\ GP#_ *4 _P"K /\ L@#_ +H _P#% /\
MTP#_ .< _P#T /\ _P#^ /\ _P#_ /X _P#^ /\ _@#_ /X _P#^ /\ _Q$A
M /\0'@#_#1T _P<? /\ (P#_ "T _P Z /\ 2 #_ %4 _P!A /\ ; #_ '8
M_P!_ /\ AP#_ (X _P"5 /\ FP#_ *$ _P"G /X K@#] +8 _ #  /L S0#Y
M .( ^ #P /< _ #V /\ ]0#_ /4 _P#U /\ ]0#_ /4 _P#U /\ _Q4= /\3
M&@#_$!D _PL9 /\ '0#_ "D _P V /\ 0P#_ %  _P!< /\ 9P#_ '$ _P!Z
M /X @P#\ (H ^@"1 /D EP#X )T ]P"C /4 J@#T +( \@"[ /$ R #O -P
M[@#L .T ^@#K /\ Z@#_ .H _P#J /\ Z@#_ .H _P#J /\ _Q@9 /\6%0#_
M$Q, _PX3 /\+&@#_!R0 _P(P /\ /@#_ $L _P!7 /\ 8@#\ &P ^ !U /4
M?@#R (4 \0", .\ DP#N )D [ "@ .L I@#I *X YP"W .8 PP#D -0 X@#I
M .$ ]P#? /\ W0#_ -T _P#= /\ W0#_ -T _P#= /\ _QL3 /\:$ #_%@X
M_Q(. /\2%0#_#Q\ _PPK /\). #_!D4 ^P-1 /<"7 #R F8 [@)P .H"> #G
M H  Y@.' .0#C@#B Y4 X0.< -\$HP#=!*L VP2T -@%P #6!=  TP;G - (
M^ #."O\ S O_ ,L,_P#+#/\ RPO_ ,L+_P#+"_\ _Q\0 /\>"P#_&@< _QD+
M /\8$0#_%AD _Q(D /H0, #S#CX [@U* .D,5@#E#&$ X@QJ -X-<P#;#7L
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M Z(F_P2A)O\#H2;_ Z$F_P.A)O\#_RD  /\H  #V+0  YS   -\O  #9*P0
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M#@"P.1P JCLL *8\.@"C/48 GSU0 9T]60*:/6$#F#UH!)8\< 64/'<&DCR
M!Y$\B >/.Y((C3N="8L[J0J).[<+B#O*"X4\Z N#//L+@CS_"H$\_PJ!//\)
M@3S_"($\_PB!//\(_S,  .PZ  #:0P  RD<  +])  "W1P  L4(  *T^"@"F
M0!< HD(G )Y#-0":1$(!ET1, 91$50*10UT#CT-D!8U#:P:+0G,'B4)["(="
MA J%08X+@T&9#(%!I0U_0;,.?D'&#GQ!Y YZ0OD->4+_#'A"_PMX0O\+>$+_
M"GA!_PIX0?\*]C8  .9   #12   PTT  +E.  "Q30  J4D  *1%!@"?1A,
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M[$$  -1,  ##5   MED  *Q<  "@6@  EU<  )%4  "+50P AE<9 (-8)P"
M630 ?5D_ 7I92 -W6% $=%A8!G)77P=O5V8);59N"VM6=PUH58$/9E6-$614
MFA)B5*D38%2Z%%]4TQ1>5/(37E3_$5]4_P]?5/\.7U/_#5]3_PU?4_\-YT0
M ,]0  "_6   LUT  *A?  "<70  DEL  (M8  "%6@H @5L6 'U<) !Z73$
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M$T]BS!-/8NT23V'_$4]A_Q!08/\.4&#_#E!@_PU08/\-V4\  ,-:  "T8P
MJ6D  )MH  "/9P  A&<  'EE  !S9P  ;VD. &QJ&P!I:R@ 9VPT &1L/0%B
M;$8"7VM.!%UK5@5::ET'6&IE"59I;@M3:7@-46B$#TYHDA!,9Z$22V>R$DEG
MR1))9^L226;_$$IF_P]*9?\.2V7_#4MD_PU+9/\-T50  +Y>  "Q9P  IFT
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M/G/]#3YR_PT^<?\,/W'_##]P_PP_</\,Q5X  +5I  "I<0  G'4  (UT  "
M=   =70  &EV  !>>0  6'P! %1]#@!2?AH 47\F $]_,0!-@#L 3(!# 4J
M2P)(?U0"1G]<!$-_905!?W &/WY\"#Q^B@DZ?IH*.7ZL"S=^PPLW?>8+-WO\
M"S=Z_PLW>?\*.'C_"CAX_PHX>/\*OF0  +!O  "E>   EGD  (=Y  ![>0
M<'H  &1\  !8@   4(,  $N%"@!(AA0 1X<@ $6(*P!$B#4 0X@^ $&)1P%
MB4\!/HA8 CR(80,ZB&P$-XAX!36(AP8SB)@',H>J!S"(P <PA^0',(7["#"#
M_P@P@O\(,('_"#"!_P@P@?\(MVL  *IV  "@?P  D'X  ()^  !V?P  :H
M %Z#  !3AP  2HL  $&. @ ]D X .Y 8 #J1(P YD2T .)(W #>20  VDDD
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M 1.D_P$3I/\!HX8  )>,  "-D0  ?9(  &V5  !@F   5)P  $B@   ^I
M-*<  "JK   AK@  &;$  !*S!P /M1  #K47  ZU(0 -M2L #;4V  RV00 +
MMDX "K9<  FV;  (MG\ ![:4  :VJ@ %ML4 !K;J  >U_P (M/\ "+/_  FR
M_P )LO\ FHT  )"3  "$F   =)P  &6@  !7I   2Z@  $"L   UL   *K,
M "&U   8N   $;L   R^ @ &P L  L 1  '!&0  P2(  ,(K  #"-@  PT(
M ,-0  #$7P  Q'$  ,2'  #$G0  Q+4  ,3:  #$]@  P_\  ,/_  ##_P
MP_\ DY0  (>:  !XH   :J8  %RL  !/L0  0;4  #6W   IN@  '[T  !;
M   0PP  "L8   /*    S 4  ,P,  #-$0  SA@  ,XA  #0*@  T34  --#
M  #44@  U&,  -5X  #5CP  U:<  -;"  #6Z0  UOT  -;_  #6_P  UO\
MBIL  'NB  !LJ0  7K   %"V  !"N@  -+T  "C!   =Q   %,<   W+   &
MS@   -(   #7    V0   -H%  #<"P  W1   -\5  #A'0  XR<  .4S  #G
M0@  Z%0  .AG  #I?@  Z9<  .JO  #JS@  Z^\  .O^  #K_P  Z_\ ?:,
M &ZK  !?L@  4;H  $+    TPP  )\<  !O+   2SP  "],   +8    W0
M .$   #D    Y0   .<   #I    ZP<  .T-  #O$0  \1D  /0D  #W,0
M^4$  /I5  #Z:@  ^X0  /N=  #\M@  _-(  /WM  #]]   _?0 <:P  &&U
M  !2O0  1,0  #3)   FS0  &M(  !#8   (W0   .$   #E    Z    .P
M  #O    \0   /,   #U    ]P   /D!  #["   _@X  /\5  #_(0  _R\
M /]!  #_5@  _VT  /^'  #_H   _[8  /_*  #_U   _]0 _PL@ /\''@#_
M !T _P @ /\ )0#_ "X _P [ /\ 20#_ %8 _P!B /\ ;0#_ '8 _P!_ /\
MAP#_ (X _P"4 /\ F@#_ *  _P"F /\ K0#_ +4 _P"^ /\ RP#_ .$ _P#P
M /X _0#] /\ _0#_ /T _P#] /\ _ #_ /D _P#Y /\ _PT= /\+&@#_!!D
M_P : /\ 'P#_ "H _P W /\ 10#_ %$ _P!> /\ : #_ '( _P!Z /\ @@#_
M (D _P"0 /\ E@#_ )P _@"B /P J0#[ +  ^0"Y /@ Q@#V -D ]0#K /0
M^0#S /\ \@#_ /, _P#S /\ \P#_ /, _P#S /\ _Q 9 /\.%0#_"!0 _P 4
M /\ &0#_ "4 _P R /\ 0 #_ $P _P!9 /\ 8P#^ &T _ !U /H ?0#Y (0
M]P"+ /8 D0#T )< \P"> /( I #P *P [@"T .T P #K ,\ Z0#F .@ ]0#F
M /\ YP#_ .8 _P#E /\ Y0#_ .4 _P#E /\ _Q(4 /\0$ #_# \ _P,0 /\
M%0#_ "  _P L /\ .@#_ $< ^@!3 /< 7@#T &< \0!P .\ > #M '\ ZP"&
M .H C #H ), YP"9 .4 H #C *< X0"P -\ N@#= ,D VP#@ -@ \ #7 /X
MU0#_ -0 _P#3 /\ TP#_ -, _P#3 /\ _Q40 /\2# #_#@D _PL, /\)$@#_
M QH _P F /T ,P#T $  [P!- .L 6 #H &$ Y0!J .( <@#@ 'H W@"  -P
MAP#: (X V "5 -0 G #2 *, T "L ,X M@#, ,0 R@#9 ,@ [0#' /L Q0#_
M ,0!_P## ?\ Q '_ ,0!_P#$ ?\ _Q@+ /\5!0#_$   _Q & /\/#0#_#!0
M_ <? /$#*P#G #D X@!& -X!40#: EL U0)D -(#; #/ W0 S01[ ,L$@@#*
M!(D R 60 ,8%F #$!:  P@:I ,$&M "_!L$ O0C5 +L)[ "X"_T M@S_ +4-
M_P"T#?\ M W_ +0-_P"T#?\ _QL% /\8  #_%P  _Q8  /L3!@#Z$ X [@P6
M .,)(@#:"3  TPH^ ,X+2@#*#%4 QPU> ,4-9P#"#F\ P0YV +\.?@"]#X4
MO ^- +H0E0"X$)T MQ"G +41L@"S$<  LA'5 *X3[@"K%/X J17_ *<5_P"G
M%?\ IA3_ :84_P&F%/\!_Q\  /\<  #Z'@  ZQX  .,<  #?%04 W@X- -,.
M& #+$2@ Q1,W , 41 "\%D\ N1=9 +<780"T&&D LQEQ +$9> "O&H  KAJ(
M *P;D "K&YD J1NC *<<K@"F'+P I!W/ *$>Z@&>'OP!G!__ 9L?_P&:'_\!
MFA[_ 9D>_P&9'O\!_R(  /\A  #L)P  X"H  -0I  #-)   RAP( ,09$@"]
M'"( MQXQ +,@/@"O(4D K2)3 *HC7 "H)&0 IB1L *0D<P"C)'H H26" : E
MBP&>)90!G26> 9LFJ@&9)K<!F";) I4GY@*2)_D"D"C_ H\H_P*.)_\"CB?_
M HXG_P*.)_\"_R8  /(I  #C,0  TC0  ,@T  # ,   NRD" +@C#@"Q)AP
MK"@K *@J. "D*T0 H2Q. )\M5P"=+5\ FRUG 9DM;@&8+G4!EBY] I0NA@*3
M+I "D2Z: X\NI@.-+K,#C"[% XHOX02'+_8$A2__!(0O_P.$+_\#@R__ X,O
M_P.#+_\#^RD  .LQ  #9.   R3P  +\\  "V.0  L#(  *PM"P"G+Q< HC$F
M )XS- ":-$  F#5* )4U4P"3-5L!D35B 8\U:0*--7$"C#5Y XHU@@.(-8L$
MAC66!(0UH@6"-:\%@37 !G\VW 9]-O0&>S;_!7LV_P5Z-O\$>C;_!'HU_P1Z
M-?\$]2T  .0W  #0/P  PD,  +=$  "M0   ISH  *,V!@"=-Q, F3DB )4Z
M+P"2/#L CSQ& (P\3P&*/%<!B#Q> H8\90*$/&T#@CQU!( \?01_/(<%?3R2
M!GL[G@=Y.ZP'=SN\"'8\U0AT//$(<SS_!W(\_P9R//\%<CS_!7([_P5R._\%
M\3(  -X]  #)1   O$@  +!)  "F1@  GT$  )L] 0"5/1  D3\= (U!*P"*
M0C@ AT-" (1#2P&"0U,!@$-; GY"8@-\0FD$>D)Q!7A">@9V080'=$&/"')!
MFPAP0:D);T&Y"FU!T IL0>X):T+_"&I"_P=J0?\&:D'_!FI!_P5J0?\%[3<
M -9"  #$20  MTT  *M-  "@2@  F$<  )-"  ".0PT B44: (9&* "#1S0
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M#5E/QPU93^@,6$_]"UA/_PE93_\(64[_!UE._P=93O\'WT,  ,=-  "X5
MK%D  )U7  "150  B%0  (%0  ![4@0 =U,1 '14'@!Q52L ;U8V &Q60 %J
M5D@!:%90 F965P-D5EX$8E5F!6!5;P==57@(6U2$"EE4D0M75* ,55.P#513
MQ0U34^8,4U/\"U-3_PE44O\(5%+_"%12_P=44O\'VD8  ,-0  "U6   J%L
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M"D1@_PE$8/\(15__!T5?_P=%7_\'R%(  +A<  "K9   FV0  (QC  " 8P
M=F,  &IB  !C9   7V8& %MG$0!9:!T 5VDI %9J,P!4:CP 4FI% 5!J3 %.
M:E0"3&I< TIJ901(:6\%1FEZ!T1IB A":)@)0&BI"C]HO0H^:-X)/F?W"3YF
M_P@_9?\'/V7_!S]D_P<_9/\'PU<  +-A  "G:0  EF@  (=G  ![9P  <6<
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M RE[_P,I>_\#L6H  *5T  "5=@  A74  'AU  !M=0  87<  %=Z  !,?@
M0X$  #N%   UB D ,HD1 #&)&P PB24 +XHO "Z*.  MBT$ +(M* "J+5  I
MBU\ *(MK ":+>@$DBXL!(XN> 2*+LP$AC,X!(8KQ 2"(_P(@AO\"((7_ B&%
M_P(AA?\"JW(  *%\  "/>P  @'H  '-Z  !F?   6W\  %""  !&A@  /(H
M #2-   LD0  )I,, "24$P CE!P (I4F "&5+P @E3@ 'Y9" !Z63  =EE@
M')9D !J7=  9EX8 &)>9 !>7K@ 5E\D %I7N !:3_P$6DO\!%I'_ 1:0_P$6
MD/\!I7L  )F#  ")@0  >X   &R"  !?A   5(@  $F+   _D   -90  "V7
M   EF@  '9X! !:@#  4H1( %*$; !.A)0 2H2X $:(X !&B0P 0HD\ #Z)<
M  ZC:P -HWT #:.2  RCIP *HL  "Z+F  R@_@ -G_\ #9[_  V=_P -G?\
MGH0  )*)  "#B   <X@  &6+  !8C@  3)(  $&7   WFP  +IX  "2B   <
MI0  %:@   ^K!  *K@P !ZT2  :M&P %K20 !*XN  *N.0 !KD4  *Y2  "N
M80  KG,  *Z'  "NG0  KK0  *[5  "M]   K?\  *S_  "K_P  J_\ EHL
M (R0  ![D   :Y(  %V6  !0F@  1)\  #FC   OIP  ):L  !RN   4L0
M#K0   FW   !N D  +@.  "Y%   N1P  +HE  "Z+P  NSH  +Q'  "\5@
MO&<  +Q[  "\D0  O*D  +S$  "\ZP  N_X  +O_  "[_P  N_\ D)(  (.8
M  !SFP  8Y\  %6C  !'J   .ZT  #"Q   EM   &[<  !*Z   ,O0  !;\
M  ##    Q (  ,4*  #%#@  QA0  ,<;  #()   RBX  ,PZ  #-20  S5D
M ,UL  #.@P  SIL  ,VU  #.V@  SO8  ,W_  #-_P  S?\ AID  '>@  !I
MI@  6JP  $RR   ^M@  ,+D  "2\   9OP  $<(   K%   "R0   ,P   #0
M    T0   -(!  #3"   U0T  -<1  #:&   W"$  -\L  #A.@  XDH  .-=
M  #D<@  Y(L  .6E  #EP   Y>8  .7X  #E_P  Y?\ >J$  &NI  !<KP
M3;8  #^\   POP  (\,  !?'   /R@  !\X   #1    U@   -P   #?
MX    .(   #D    Y@,  .@)  #I#@  [!4  .X>  #Q*P  ]#H  /5-  #V
M80  ]WD  /B3  #XK0  ^<8  /GD  #Y\P  ^?, ;:H  %ZR  !/N@  0,$
M #'%   BR0  %LX   W2   $V    -T   #A    Y    .@   #K    [0
M .\   #Q    \P   /8   #X P  ^@L  /T1  #_&P  _RD  /\[  #_3P
M_V8  /]_  #_F0  _Z\  /_#  #_U@  _]8 _P0< /\ &0#_ !D _P < /\
M(@#_ "L _P X /\ 1@#_ %, _P!> /\ :0#_ '( _P!Z /\ @@#_ (D _P"/
M /\ E0#_ )L _P"A /\ J #_ *\ _P"Y /\ Q0#_ -D _@#L /T ^P#[ /\
M^P#_ /L _P#Z /\ ] #_ /  _P#P /\ _P<8 /\!%0#_ !0 _P 6 /\ &P#_
M "8 _P T /\ 0@#_ $X _P!: /\ 9 #_ &T _P!U /\ ?0#_ (0 _P"* /T
MD #\ )8 ^@"= /D HP#X *L ]P"T /4 OP#T ,X \P#F /$ ]@#P /\ [P#_
M .\ _P#N /\ [@#_ .H _P#J /\ _PL4 /\&$0#_ !  _P 0 /\ %@#_ "(
M_P N /\ / #_ $D _P!4 /X 7P#[ &@ ^0!P /< > #U '\ \P"% /( BP#P
M )( [P"8 .T GP#L *8 Z@"N .@ N0#G ,< Y0#> ., \ #B /X X #_ .
M_P#A /\ X0#_ .$ _P#A /\ _PT0 /\)#0#_ 0P _P , /\ $@#_ !P _P H
M /P -@#Y $, ]@!. /( 60#O &( [ !K .H <@#H 'D Y@"  .0 A@#B (P
MX0"3 -\ F@#= *$ VP"J -@ M #5 ,  T@#3 -  Z@#. /H S0#_ ,T _P#-
M /\ S #_ ,P _P#, /\ _Q , /\,!P#_ P( _P ( /\ #@#_ !8 ]@ B /
M+P#L #P Z0!( .4 4P#A %P W@!E -L ; #7 ', U !Z -( @ #0 (< S@".
M ,P E0#* )T R "E ,8 KP#$ +L P@#+ ,  Y0"^ /4 O0#_ +P _P"\ /\
MO #_ +P _P"\ /\ _Q$% /\.  #_"@  _P@! /\$"@#X !  Z0 : ., * #>
M #4 V0!! -, 3 #/ %8 RP!? ,D 9@#& &X Q !T ,( >P#! (( OP") +T
MD "\ )@ N@"A +@ JP"V +< M #' +( X "Q ?( KP+_ *X#_P"M!/\ K03_
M *T$_P"M!/\ _Q0  /\0  #_#P  \@T  .H*  #I PD W0 2 -0 'P#- 2T
MR (Z ,0#10#  U  O019 +L%80"Y!6@ MP9O +4&=@"T!WT L@>$ +$(C "O
M")4 K0F> *L)J "J"K4 J K% *8+WP"D#?0 H@[_ * ._P"?#O\ GP[_ )\.
M_P"?#O\ _Q<  /\3  #O&   Y!D  -L6  #2$ ( SPD+ ,@(%@#!"B0 O PR
M +<-/@"T#DD L0Y3 *\06P"M$&, JQ!J *D1<0"H$7@ IA&  *41B "C$I$
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MG@&&)ZL!A">[ 8,HT0& *.X!?BG_ 7TI_P%\*/\!?"C_ 7PH_P%\*/\!]20
M .,N  #/-0  P3@  +0V  "K,0  I2P  *(F!@">)A, F2@A )4J+@"2*SD
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M!6<\Q05E/.4%9#SZ!&0\_P-C._\#8SO_ V,[_P)C._\"Y34  ,T_  "]1@
MKD<  )]%  "50P  CD   (D\  "$/ H @#T4 'T^(@!Z/RX >$ X '5!0@!S
M04H <D%1 7!!60%N06 ";$%G FI!< -H07D#9T&$!&5!D05C09\%84&N!F!!
MP@9>0>(&7D'Y!5U!_P1=0/\#74#_ UU _P-=0/\#WSD  ,A#  "Y2@  J4L
M )M)  "01P  B$0  (-!  !^008 >D(1 '9#'@!T12H <44U &]&/P!M1D<
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M!DU._P5-3?\$34W_!$Y,_P-.3/\#SD0  +Q.  "N5   G%,  (Y2  "#40
M>E   ')-  !L3P  :% + &51%0!C4B$ 85,L %]3-@!=5#\ 6U1' %I43@%8
M5%8!5E1= E149@-24V\#4%-[!$Y3B 5,4Y<&2U.G!TE3N@=(4]4'2%+S!DA2
M_P5(4?\$25'_!$E0_P-)4/\#RD@  +E2  "J5P  F%8  (I5  !_5   =E,
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M SE>_P,Y7O\#O%4  *U?  "<8   BU\  'U?  !R7P  :%\  %U@  !58@
M3V0  $MF"@!)9Q( 1V@= $5H)P!$:3$ 0VDY $)J0@! :DH /VI2 #UJ6P$\
M:F4!.FIP CAJ?@(V:8T#-&F? S-IL@,Q:<L#,6CM S%G_P,Q9O\#,F7_ S)D
M_P,R9/\#MUL  *ED  "69   AF,  'AC  !M8P  9&0  %EE  !0:   26L
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M<0 <A(( &X25 !J$J0 8A,$ &(/F !B!_0 9@/\!&7__ 1E^_P$9?O\!IG
M )5S  "$<@  =G$  &MQ  !><P  5'8  $EY   _?0  -X$  "^$   GB
M((L% !N-#@ :C14 &8T> !B.)P 7CC  %HXY !6.0P 4CT\ $X]; !*/:@ 1
MCWL $(^/  ^/I  .C[L #8_@  Z-^@ /B_\ $(K_ !")_P 0B?\ H7H  (YY
M  !^=P  <G<  &1X  !8>P  37X  $*"   YA@  +XH  ">.   @D0  &)4
M !*8!0 .F@X #9H4  R:'0 +FB8 "YHP  J:.P )FD8 ")I3  :;80 %FG(
M!)J&  *:FP  FK$  9G/  *9\  "F/\ !)?_  66_P %EO\ F8$  (=_  !Z
M?@  :WX  %V!  !0A0  18D  #N-   QD@  *)8  !^9   8G0  $:    RC
M @ &I0H  :40  "E%@  IA\  *8H  "F,@  IST  *=*  "G6   IV@  *=\
M  "GD0  IJ@  *;#  "EZ0  I?P  *7_  "D_P  I/\ D8<  (*&  !RA@
M8X@  %6,  !)D0  /98  #*:   HG@  'Z(  !>F   0J0  "ZP   2O
ML08  +$,  "R$0  LA<  +,?  "S*   M#(  +4_  "U30  M5T  +5P  "U
MA@  M9T  +6V  "UW   M/<  +3_  "T_P  M/\ BX\  'J.  !JD0  6Y4
M $V:  ! GP  -:0  "JH   @K   %K    ^T   )MP   ;D   "]    O@
M +X&  "_#   P!   ,$6  #"'0  PR<  ,4R  #&0   QE$  ,=C  #'>
MQY$  ,>I  #'QP  Q^P  ,?^  #'_P  Q_\ @Y<  '&:  !AG@  4J,  $6I
M   XK@  ++,  ""W   6N@  #KT   ;     PP   ,<   #)    R@   ,P
M  #- P  S@D  - .  #2$P  U!L  -@E  #;,@  W4(  -U4  #>:0  WH$
M -Z<  #?M0  W]D  -_S  #?_P  W_\ =Y\  &BF  !9K0  2K,  #NX   M
MNP  '[\  !3"   ,Q@   \D   #,    T    -4   #9    V@   -P   #>
M    X    .(%  #D"P  YQ   .H8  #M)   \#(  /%$  #R6   \V\  /2*
M  #TI   ]+\  /3?  #T\P  ]/0 :J@  %NO  !,MP  /;T  "W!   ?Q@
M$\H   O.    T@   -<   #<    X    .4   #G    Z0   .L   #M
M[P   /$   #S    ]@<  /D.  #\%@  _R(  /\S  #_1P  _UT  /]V  #_
MD0  _ZD  /^^  #_V   _]L _P 8 /\ %@#_ !4 _P 8 /\ '@#_ "< _P V
M /\ 0P#_ $\ _P!: /\ 9 #_ &T _P!U /\ ?0#_ (0 _P"* /\ D #_ )8
M_P"< /\ HP#_ *L _P"T /X OP#] ,\ ^P#G /H ^ #Y /\ ^0#_ /D _P#U
M /\ [@#_ .D _P#G /\ _P 4 /\ $0#_ !$ _P 2 /\ %P#_ ", _P Q /\
M/@#_ $H _P!6 /\ 8 #_ &@ _P!P /\ > #] 'X _ "% /H BP#Y )$ ^ "8
M /< G@#U *8 ] "N /( N0#Q ,< [P#@ .X \@#L /\ [ #_ .P _P#K /\
MY0#_ .  _P#> /\ _P,0 /\ #@#_  T _P - /\ $P#_ !X _P K /\ . #_
M $4 _@!0 /L 6@#X &, ]0!K /, <@#Q 'D [P!_ .X A@#L (P Z@"2 .D
MF0#G *  Y@"I .0 LP#A ,  X #3 -X ZP#< /L VP#_ -H _P#: /\ V0#_
M -0 _P#2 /\ _P<- /\ "0#_  8 _P ) /\ #P#_ !@ ^P E /@ ,@#U #\
M\@!* .T 5 #J %T YP!E .0 ; #B ', X !Z -X @ #< (8 V@"- -< E #4
M )L T@"D ,\ K0#- +D RP#) ,D Y #( /8 Q@#_ ,4 _P#& /\ QP#_ ,<
M_P#' /\ _PH& /\!  #_    _P $ /\ "P#T !( [P ? .H + #E #@ X@!#
M -T 3@#9 %< U !? -$ 9P#. &T S !T ,H >@#( (  Q@"' ,4 C@## )8
MP0"> +\ J "] +, N@#" +D VP"W /  M0#_ +8 _P"U /\ M0#_ +4 _P"U
M /\ _PP  /\$  #_    _@   /8  P#H  T X  7 -D ) #1 #$ S0 \ ,H
M1P#& %$ PP!9 ,  8 "^ &< O !N +H = "Y 'L MP"" +4 B0"S )$ L@":
M +  I "N *\ K "] *H T "H .L IP#[ *8 _P"F /\ I0#_ *4 _P"E /\
M_PT  /\'  #T"0  Z@D  .($  #:  < SP 1 ,@ ' #" "D O@ U +L 0 "W
M $H M !3 +( 6P"P &( K@!H *P ;P"K '4 J0!] *@ A "F (T I "6 *,
MH "A *L GP&Y )T#S "<!.@ F@;Y )D'_P"8"/\ EPC_ )<(_P"7"/\ _Q
M /<0  #H%   W!4  ,X1  #&#0  P@0+ +P % "W 2$ L@,N *X%.@"K!D0
MJ A- *8(50"D"5P H@IC * *:@"?"W$ G0MX )P+@ ":#(D F0R3 )<,G@"5
M#:H E VX )(-S "0#NH CA#\ (P0_P"+$/\ BQ#_ (L0_P"*$/\ ^Q,  .T:
M  #=(   S"$  +\=  "W%P  LQ$  +(+#0"K#1D IPXF *,/,P"?$#X G1%'
M )H14 "8$E< EA)> )4390"3$VP DA-S ) 4? "/%(4 C16/ (L5F@"*%:<
MB!:U (86R0"$%^< @AC[ ( 9_P!_&?\ ?QG_ '\8_P!_&/\ ]1H  .0C  #/
M*0  P"H  +,F  "J(@  I1P  *05" "@%!, FQ8A )<8+0"4&3@ D1I" (\;
M2P"-'%( BQQ9 (D=8 "('6< AAYO (4>=P"#'X  @A^+ ( ?EP!^(*, ?2"R
M 'L@Q0!Y(>0 =R+Y '8B_P!U(O\ ="'_ '0A_P!T(?\ [R$  -LK  #',0
MMC$  *DN  "@*@  FR8  )@A 0"5'A  D" ; (TA* ")(S, AR0] (4D1@"#
M)4X @295 '\F7 !^)F, ?"=K 'LG<P!Y)WP >"B' '8HDP!T** !<BBO 7$I
MP0%O*> !;2GW 6PI_P%K*?\!:RG_ 6LH_P%K*/\!Z"@  - R  # .   KC<
M *$U  "8,@  DBT  (XI  "+)PP AR@7 (,J(P" *R\ ?BPY 'PL0@!Z+4H
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M E8[_P)6._\"5CK_ 58Z_P%6.?\!U#<  ,!!  "O1   G4,  )!"  "%0
M?CX  'D[  !T.@  <3H. &T\& !K/20 :3XO &<_. !E/T  9$!( &) 3P!A
M0%< 7T!> 5U 9@%<0&\!6D!Z EA AP)60)4"5$"D U- M@-20,\#44#O U!
M_^+__TE#0U]04D]&24Q%  8)_P)0/_\"4#__ E$^_P%1/O\!SSL  +U%  "J
M1P  F48  (M%  "!1   >4(  '0^  !O/P  :T , &=!%0!E0B$ 8T,K &%#
M-0!?1#X 7D1% %U%30!;150 645< 5A%9 %616T!5$5X E)%A0)11),#3T2C
M TU%M -,1<P#2T7M TM$_P)+1/\"2T/_ DQ"_P),0O\"RC\  +E(  "F2@
ME4D  (=(  !]1P  =44  &Y"  !I0P  940) &)%$P!?1AX 74<H %Q(,@!:
M2#L 64E# %=)2@!625( 5$E9 5-)80%126L!3TEV DU)@@)+29$#2DFA TA)
MLP-'2<H#1DGL T9(_P)&2/\"1T?_ D=&_P)'1O\"QD,  +9,  "B3   D4P
M (1+  !Y2@  <$D  &E&  !D1P  7TD& %Q*$ !:2QL 6$PE %9,+P!533@
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M C=6_0(W5?\"-U3_ C=3_P(X4_\"ND\  *E6  "550  A50  'A4  !M5
M9%0  %A4  !25@  3E<  $I9"0!'6A$ 1EH; $1;)0!#6RX 0EPV $%</@ _
M7$8 /EU/ #U=5P [76$ .EUL 3A=>0$V78@!-%V9 C-=JP(Q7<(",5SE C%;
M_ (Q6O\",5G_ C)9_P$R6/\!ME0  *19  "06   @%@  '-7  !I5P  8%@
M %19  !.6P  2%T  $-?! ! 8 X /F$7 #UA(  [8BD .F(R #EB.@ X8T(
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M !MN_P$;;?\!IF8  )%E  !_9   <60  &9D  !=9   4F8  $AI   _;
M-V\  #!S   I=@  (GD( !][$  >>Q< ''L? !M[*  :>S  &7PY !A\0P 7
M?$X %GQ: !5\9P 4?7@ $GV+ !%]GP 0?;4 #WW5 !![]0 1>?\ $7C_ !)W
M_P 2=_\ GFL  (IJ  !Z:0  ;6D  &)I  !7:@  3&T  $-P   Y=   ,7@
M "E[   B?P  &X(  !2%"0 1AA  $887 !"''P 0AR@ #H<Q  Z'.P -AT8
M#(=3  N'80 *AW$ "8>$  >'F  &AJX !8;)  :%[  'A/\ "(/_  F"_P )
M@O\ E7$  (-O  !T;@  :6X  %QO  !0<@  1G4  #QY   R?0  *H$  "*%
M   ;B0  %(P   ^/ P *D@L !I(1  22&  "DB   9(I  "2,P  DSX  )-+
M  "360  DVD  )-[  "2D   DJ8  )&_  "1Y0  D/H  (__  "/_P  C_\
MC7<  'UU  !P=   8G4  %5X  !)?   /X   #2$   KB0  (HT  !J1   3
ME   #I<   F;   !G0@  )T.  "=$P  GAH  )XB  "?*P  GS4  *!"  "@
M4   H%\  *!Q  "@AP  GYT  )^U  ">V@  G?8  )W_  "<_P  G/\ AGT
M 'A\  !I?   6W\  $Z#  !!B   -HP  "R1   CE@  &IH  !*>   -H0
M!J0   "G    J0,  *D*  "J#@  JQ,  *P9  "M(@  KBL  *\W  "O10
MKU0  *]F  "O>P  KI0  *ZK  "NR0  KN\  *W_  "M_P  K?\ @80  '&$
M  !AAP  4XL  $:0   YE@  +IL  ".@   :I   $J@   RL   $KP   +(
M  "V    MP   +<"  "X"   N0T  +H2  "[&   O2$  +XK  # .   P$@
M ,!:  #!;@  P88  ,&@  #!N@  P>,  ,#Y  # _P  P/\ >8T  &B0  !9
ME   2YH  #V@   QI0  ):L  !JO   1LP  "[@   *[    O@   ,$   #$
M    Q0   ,8   #'    R 4  ,H+  #,#P  SA4  - ?  #3*P  U3H  -5,
M  #68   V'<  -B2  #8K   V<D  -GL  #9^P  V/\ <)D  &">  !1I
M0ZH  #6P   HM@  '+H  !&^   )P0   ,4   #(    RP   ,\   #2
MTP   -8   #8    VP   -T   #?!P  X@T  .43  #H'0  ["H  .T\  #M
M40  [F<  .^!  #OG   \+<  /#3  #P[   \/0 9Z8  %BM  !)M   .KH
M "J^   <P@  $,8   ?*    S@   -(   #6    W    .    #C    Y
M .8   #H    ZP   .T   #O    \@(  /4*  #X$0  _!P  /\L  #_/P
M_U4  /]N  #_B@  _Z0  /^Z  #_T0  _^$ _P 4 /\ $@#_ !( _P 4 /\
M&0#_ "4 _P R /\ /P#_ $L _P!6 /\ 8 #_ &@ _P!P /\ > #_ '\ _P"%
M /\ BP#_ )$ _P"8 /\ G@#^ *8 _0"N /P N0#Z ,@ ^0#B /@ ] #W /\
M]@#_ /8 _P#O /\ YP#_ .( _P#> /\ _P 1 /\ #@#_  X _P / /\ % #_
M "  _P M /\ .@#_ $8 _P!1 /\ 6P#_ &, _@!K /P <P#Z 'D ^0"  /<
MA@#V (P ]0"2 /, F0#R *  \ "I .X LP#M ,$ ZP#6 .H [@#I /X YP#_
M .< _P#E /\ W0#_ -4 _P#1 /\ _P - /\ "@#_  @ _P ) /\ $ #_ !L
M_P H /\ -0#_ $  ^@!+ /8 50#S %X \0!F .X ;0#L '0 ZP!Z .D @ #G
M (8 Y@"- .0 DP#B )L X "C -X K0#< +D V@#* -< Y@#4 /@ T@#_ -(
M_P#2 /\ S@#_ ,D _P#& /\ _P ( /\  P#_    _P # /\ #0#\ !8 ]P B
M /, +@#O #H [ !% .@ 3P#D %@ X0!@ -X 9P#; &T V0!T -4 >@#3 (
MT0"' ,\ C@#- )4 RP"> ,D IP#' +, Q0#" ,, W #! /$ OP#_ +\ _P"^
M /\ O@#_ +T _P"[ /\ _P   /\   #_    _P   /8 " #N !$ YP ; .$
M)P#= #, V0 ^ -, 20#/ %( RP!9 ,@ 80#& &< Q !M ,( <P#  'H OP"
M +T B "[ )  N0"8 +@ H@"U *T LP"[ +$ S@"P .H KP#\ *T _P"M /\
MK@#_ *X _P"N /\ _P(  /\   #]    \@   .@   #>  P TP 5 ,P (0#(
M "P Q  X ,$ 0@"] $L N@!3 +@ 6@"V &$ M !G +( ;0"P '0 KP!Z *T
M@@"L (H J@"3 *@ G0"F *@ I "U *( Q@"A ., GP#V )X _P"> /\ G@#_
M )X _P"> /\ _P8  /L   #N!0  X@0  -4   #+  8 PP / +T &0"X "4
MM  Q +$ .P"N $4 K !- *D 50"G %L I0!B *0 : "B &X H0!U )\ ? ">
M (4 G ". )H F "8 *0 E@"P )4 P0"3 -P D@#R )$ _P"0 /\ D #_ (\
M_P"/ /\ _0H  / .  #A$0  SA   ,(-  "[!P  MP * +$ $@"L !X J  I
M *4 - "B #X GP!' )T 3P"; %8 F0%< )<!8P"6 FD E )P ),#> "1 X
MD 2* (X$E0",!:$ B@6N (D&O@"'"-@ A@GP (0*_P"#"_\ @PO_ (,+_P"#
M"_\ ]A   .87  #2'   P!H  +,6  "L$@  J T  *8'#0"B!18 G0<B )D)
M+@"6"C@ E M! )(,2@"0#%$ C@U8 (P-7@"+#64 B0UL (@.= "&#GT A0Z'
M (,.DP"!#Y\ @!"M 'X0O@!]$-L >A'T '@2_P!W$O\ =Q+_ '<2_P!W$O\
M[Q<  -LA  #&)   M",  *@@  "@'   FQ<  )D1! "8#A  DQ ; (\1)P",
M$C( B1,\ (<31 "%%$P @Q13 ($56@" %6  ?A9H 'T6;P![%G@ >1># '@7
MCP!V&)P =!BJ ',9NP!R&=0 ;QKQ &X;_P!M&_\ ;1K_ &T:_P!M&O\ YR
M - I  "\*P  JRH  )XH  "6)   D"   (T<  ",%PP B!@6 (0:(@"!&RT
M?APW 'P=0 !Z'4@ >1Y/ '<>50!V'UP =!]C ',?:P!Q('0 <"!_ &XABP!L
M(9@ :R&G &DBN !H(L\ 9B+N &4C_P!D(_\ 9"+_ &0B_P!D(?\ X"8  ,@O
M  "T,0  HS   )8N  "-*P  AR@  (0D  ""( @ ?B 2 'LB'@!X(RD =20S
M ',E/ !Q)4, <"9+ &XF4@!M)UD :R=@ &HG: !I*'$ 9RA[ &4HB !D*94
M8BFD & IM0!?*<L 7BKL %PJ_P!<*?\ 7"G_ %PI_P!<*/\ V"P  ,,U  "M
M-0  G30  ) S  "&,0  @"T  'PK  !Y* , =B<0 '(I&@!P*B4 ;2LO &LL
M. !J+$  :"U' &<M3@!E+E4 9"Y= &,N90!A+VX 7R]X %XOA !<+Y( 6B^A
M 5DOL@%8,,@!5C#I 54P_@%5+_\ 52__ %4N_P!5+O\ T#$  +TZ  "H.0
MES@  (HW  " -@  >C(  '4P  !R+@  ;BX- &LO%@!I,"$ 9C$K &0R- !C
M,CT 83-$ & S2P!?-%( 731: %PT8@!:-&L 635U %<U@@!5-9 !5#6? 5(U
ML %1-<8!4#7G 4\U_0%/-?\!3S3_ 4\T_P%/,_\!RS8  +@]  "C/   DCP
M (4[  ![.@  =#<  &\U  !L,P  :#0* &4U$P!B-AX 8#<H %XW,0!=.#H
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M 3]#^0$_0O\!/T'_ 4!!_P% 0/\!OT$  *I%  "610  AD4  'E$  !O1
M9T(  & _  !;00  5T(  %1##0!11!4 3T4? $Y%* !,1C$ 2T8Y $I'00!)
M1T@ 2$=0 $9'6 !%1V$ 0TAL $)(> % 2(<!/DB7 3Q(J0$[2+X!.DC? 3I'
M^ $Z1O\!.D7_ 3M%_P$[1/\!NT4  *9(  "21P  @D<  '9'  !K1P  8T8
M %M#  !610  4D<  $Y("@!,21( 2DD< $A*)0!'2BX 1DLV $5+/@!#2T8
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M 2I3_P$J4O\!KU$  )A1  "%40  =E   &I0  !@4   6%$  $Y2  !'4P
M054  #M8   X60H -5H1 #1:&@ S6R( ,ELK #%;,P O7#L +EQ# "U<3  L
M7%8 *UU@ "E=;0 H77P )EV. "1=H0 C7;4 (EW2 ")<\P B6_\ (UK_ "-9
M_P D6/\ J%4  ))4  " 5   <50  &94  !<5   5%4  $I6  !#6   /%L
M #9=   P8 4 +6$. "MA%0 J8AT *6(E "AB+@ G8S8 )F,^ "5C1P C8U$
M(F1< "%D:0 ?9'D 'F2* !QDG@ ;9+, &63. !IC\0 ;8?\ &V#_ !Q@_P <
M7_\ H5D  (Q8  ![6   ;5@  &)8  !96   4%D  $=;   ^7@  -V   #%C
M   J9@  )&D) "%J$  @:A< 'VH@ !YK*  =:S  '&LY !MK0@ :;$P &6Q8
M !=L90 6;'0 %&R& !-LF@ 2;*\ $6S* !%K[P 2:?\ $VC_ !-H_P 39_\
MF5T  (5=  !U7   :%P  %Y<  !57   2UX  $)A   Y9   ,F<  "MJ   D
M;0  'G ! !=S"P 5=!$ %'08 !-T(0 2=2D $74R !%U.P 0=48 #W52  YU
M7P -=6X #'6!  MUE0 *=:H "'3#  ETYP *<_T "W'_  QQ_P ,</\ D6(
M ']A  !P80  9&$  %IA  !/8@  164  #QH   S;   *V\  "1R   ==@
M%WD  !%\!  -?PP "W\2  I_&0 )?R( "'\J  9_-  %?S\ !']+  )_6  !
M?V<  ']Y  !_C@  ?Z,  'Z[  !]X   ??<  'S_  ![_P  >_\ B6<  'AG
M  !K9@  868  %1G  !):0  /VT  #5Q   L=0  )'D  !U\   6@   $(,
M  R& @ &B0H  8D/  ")%   BAL  (HC  "++   BS<  (M#  "+4   BU\
M (MQ  "+A@  BYP  (JS  ")TP  B/,  (C_  "'_P  A_\ @FT  '-L  !H
M;   6FT  $YO  !"<P  .'<  "Y[   E@   '80  !6(   0C   "X\   22
M    E 8  )4,  "5$   EA4  )<<  "8)   F"X  )DY  "91P  F58  )EH
M  "9?0  F90  )BK  "7R   ENX  );_  "5_P  E?\ >W0  &]S  !A<P
M4W8  $9Z   [?P  ,(0  ":(   =C0  %)(   Z6   )F0   9P   "@
MH0   *(&  "B#   I!   *44  "E'   IR0  *@O  "H/0  J4P  *E>  "I
M<@  J(D  *BB  "HO   I^4  *;[  "F_P  I?\ =WL  &A[  !9?@  2X(
M #Z'   RC0  )Y(  !V7   4G   #J    >D    J    *L   "N    KP
M +    "Q!   LPH  +0.  "U$P  MAL  +@D  "Z,0  ND   +I2  "[90
MNWT  +J7  "ZL0  NM(  +KS  "Y_P  N?\ ;X,  %^&  !1BP  0Y   #:7
M   JG0  'Z(  !6G   -K   !;    "T    MP   +L   "^    OP   ,
M  #!    PP$  ,0'  #%#0  QQ$  ,H9  #-)   SC,  ,]$  #06   T&X
M -&(  #0I   T,$  -'F  #1^   T?\ 9X\  %>4  !)F@  .Z$  "ZG   A
MK0  %K,   ZX   &O    ,    ##    Q@   ,L   #-    S@   -    #1
M    U    -8   #: @  W D  -\/  #C%P  YB0  .<V  #H20  Z5\  .IX
M  #KE   ZZ\  .O,  #LZ   [/8 7YX  %"D  !"JP  -+(  ":Y   9O@
M#L(   3%    R@   ,T   #1    V    -L   #?    X    .(   #D
MY@   .D   #K    [@   /$%  #U#0  ^18  /PE  #].0  _D\  /]G  #_
M@@  _YT  /^U  #_RP  _^0 _P 1 /\ #P#_  \ _P 1 /\ %@#_ "( _P O
M /\ .P#_ $< _P!2 /\ 6P#_ &0 _P!L /\ <P#_ 'H _P"  /\ A@#_ (P
M_@"3 /T F0#[ *$ ^@"I /@ M #W ,( ]@#: /4 \0#T /\ \P#_ /, _P#I
M /\ X #_ -@ _P#3 /\ _P . /\ "P#_  H _P + /\ $0#_ !T _P J /\
M-@#_ $$ _P!, /\ 5@#^ %\ ^P!F /D ;0#W '0 ]0!Z /0 @ #R (8 \ "-
M .\ E #M )L [ "D .H K@#I +H YP#- .4 Z0#D /L XP#_ .( _P#> /\
MT0#_ ,P _P#( /\ _P ) /\ ! #_  $ _P $ /\ #@#_ !@ _P D /T , #[
M #L ]P!& /, 4 #O %D [ !@ .H 9P#G &X Y@!T .0 >@#B (  X "' -X
MC@#< )4 V@"> -8 J #4 +, T0## ,\ WP#. /0 S #_ ,L _P#+ /\ Q0#_
M +\ _P"\ /\ _P " /\   #_    _P   /T "P#W !, \0 > .T *@#J #4
MYP!  .( 2@#= %( V0!: -4 80#2 &< T !M ,X <P#, 'H R@"  ,@ AP#&
M (\ Q "8 ,( H0#  *T O@"[ +P T "Z .T N0#^ +@ _P"X /\ MP#_ +,
M_P"P /\ _P   /\   #_    ^0   .X !0#E  X W@ 8 -@ (P#2 "X SP Y
M ,L 0P#' $P Q !4 ,$ 6P"_ &$ O !G +L ;0"Y ', MP!Z +4 @0"T (D
ML@"2 +  FP"O *< K "T *L Q@"I .0 IP#X *8 _P"F /\ I0#_ *4 _P"D
M /\ _P   /\   #U    Z@   -X   #0  H R  2 ,( '0"^ "@ NP S +D
M/0"U $8 L@!- +  50"M %L K !A *H 9P"H &T IP!S *4 >@"D (( H@",
M *  E@"? *$ G0"N )L O@"9 -@ EP#Q )8 _P"6 /\ EP#_ )< _P"7 /\
M_P   /4   #G 0  U    ,D   #   0 N  . +, %@"O "$ JP L *@ -@"F
M #\ HP!' *$ 3P"? %4 G0!; )L 80": &< F !N )< =0"5 'T E "& )(
MD0"0 )P C@"I (P N "+ ,T B0#K (@ _0"( /\ B #_ (@ _P"( /\ ^08
M .D,  #4#@  PPP  +<)  "P @  JP ) *8 $ "B !H G@ E )L , "8 #D
ME@!! )0 20"2 %  D !6 (X 7 "- &( BP!I (H < "( '@ AP"! (4 C "$
M )@ @@"E (  M !^ ,@ ?0'G 'P"^0![ _\ >P3_ 'L$_P![!/\ \0X  -X5
M  #%%0  M!0  *D1  "A#@  G@H  )L## "7 !, DP > ) !*0"- C, B@,\
M (@$0P"&!4L A091 (,&5P""!UX @ =D '\(; !]"'0 ? A^ 'H)B0!X"98
M=PJC '4*LP!S"\< <@SF ' -^P!P#?\ ;PW_ &\-_P!O#?\ Z!8  - >  "Y
M'0  J1P  )T:  "5%@  D!,  (\. P"."@X B0L7 (8,(P"##2T @ TV 'X.
M/@!\#D8 >PY- 'D/4P!X$%H =A!A '40: !S$'$ <1%[ ' 1AP!N$90 ;!&B
M &L2L@!I$L< :!/G &83_0!E%/\ 913_ &43_P!E$_\ WQX  ,8D  "P)
MH",  )0A  "+'P  AAL  (,7  ""$@@ ?Q$2 'P2'0!Y%"@ =A0Q '05.@!R
M%D$ <19( &\73P!N%U8 ;!== &L89 !I&&T :!EW &89@P!D&9  8QJ? &$:
MKP!@&L0 7AOD %T<^P!<'/\ 7!O_ %P;_P!<&_\ U24  +TJ  "H*0  F"D
M (PH  "#)0  ?2(  'D?  !X&P, =AD/ '(:& !O'", ;1TM &L=-0!I'CT
M:!Y$ &8?2P!E'U( 8R!9 &(@80!A(&D 7R%S %TA?P!<(8T 6B*< %DBK !7
M(L  5B/A %4C^0!4(_\ 5"+_ %0B_P!4(O\ S2L  +8N  "B+@  DBX  (4M
M  !\*P  =B@  '(F  !O(P  ;2$, &HB%0!G(Q\ 920I &,D,0!B)3D 8"9!
M %\F2 !=)D\ 7"=6 %LG70!9)V8 6"AP %8H? !4*(H 4RF9 %$IJ@!0*;X
M3RG> $XI]P!-*?\ 32G_ $TH_P!.*/\ R#   + R  "<,@  C#(  ( Q  !V
M,   <"T  &LK  !H*0  9B@) &,H$0!@*1P 7BHE %PK+@!;*S8 62P] %@L
M1 !7+4P 52U3 %0M6P!3+6, 42YN % N>@!.+H@ 3"^7 $LOJ !)+[L 2"_;
M $@O]@!'+_\ 1R[_ $<M_P!(+?\ Q#0  *LU  "7-0  AS4  'LU  !R-
M:S(  &8O  !B+@  7RT% %PN$ !:+Q@ 6# B %8P*P!5,3, 4S$Z %(R0@!1
M,DD 4#)0 $XS6 !-,V$ 2S-K $HS=P!(-(4 1S25 $4TI@!#-+D 0C36 $(T
M] !"-/\ 0C/_ $(R_P!",O\ P#@  *<X  "3.   @S@  '<X  !M-P  9C8
M &$S  !=,@  63(" %<S#0!4-!4 4C4? %$U* !/-C  3C8X $PW/P!+-T8
M2C=. $DX5@!'.%\ 1CAI $0X=0!#.(, 03F3 $ YI  ^.;@ /3G3 #PY\P \
M./\ /3?_ #TW_P ]-O\ NSL  *([  "/.P  ?SL  ',[  !J.@  8CD  %TW
M  !8-@  5#<  %$X"P!/.1, 33D< $LZ)0!*.BT 2#LU $<[/ !&/$0 13Q+
M $0\4P!"/%P 03UG #\]<P ^/8$ /#V1 #H]HP Y/;8 .#W1 #<]\@ W//\
M.#O_ #@[_P X.O\ MCT  )X^  "+/@  ?#X  &\^  !F/0  7CT  %@[  !3
M.@  3SL  $P\" !)/1$ 1SX9 $8_(@!$/RH 0S\R $) .@!!0$$ 0$!) #Y!
M40 ]05H /$%D #I!<  X07\ -T&/ #5"H0 T0K0 ,D+. #)!\  R0/\ ,T#_
M #,__P T/O\ L4   )I   "'0   >$$  &Q!  !B0   6T   %0_  !./P
M2D   $9!!0!$0@X 0D,6 $!#'P _1"< /D0O #Q$-P [13X .D5& #E%3@ X
M1E@ -D9B #5&;@ S1GP ,4:- #!&GP N1K, +4;, "U&[P M1?\ +D3_ "Y#
M_P N0_\ K$,  )9#  "#0P  =$,  &A#  !?0P  5T,  %!#  !(0P  1$4
M $%& 0 ^1PP /$@3 #I('  Y220 .$DL #9)-  U2CL -$I# #-*3  R2E4
M,$M? "]+:P M2WH +$N+ "I+G0 H2[$ )TO* "=+[0 G2O\ *$G_ "A(_P I
M1_\ IT8  )%&  !_1@  <$8  &5&  !;1@  5$8  $Q'  !$2   /TH  #M+
M   W3 D -4T0 #-.&  R3B  ,4\H #!/,  O3S@ +D]  "Q02  K4%( *E!<
M "A0:  G4'< )5"( "10FP B4*\ (5#( "!0ZP A3_\ (D[_ ")-_P C3?\
MH4D  (Q)  !Z20  ;$H  &%*  !82@  4$H  $E+  ! 3   .TX  #50   Q
M4@0 +5,- "Q4%  J5!P *54D "A5+  G53, )E4\ "5610 D5DX (E99 "%6
M90 ?5G0 'E:% !Q6F  ;5JP &5;% !E6Z0 :5?\ &U3_ !M3_P <4O\ FTT
M (9-  !U30  :$T  %U-  !430  34X  $5/   \40  -E,  #%5   K6
M)EH) "-;$  B6Q< (5P? "!<)P ?7"X '5PW !Q=0  ;74H &EU5 !A=80 7
M77  %5V! !1=E0 37:H $5W" !%=YP 26_X $UK_ !-:_P 46?\ E%$  (!1
M  !P40  9%$  %E1  !140  25(  $%3   X5@  ,ED  "M;   E7@  'V$#
M !IC#  89!$ %V09 !9D(0 59"D %&4Q !-E.@ 2940 $650 !!E70 /96L
M#F5]  UED0 ,9:4 "F2\  IDX  +8_D #&+_  UA_P -8?\ C54  'I5  !K
M50  7U4  %95  !.50  1%<  #Q9   T7   +%\  "9B   ?90  &6@  !-K
M!0 0;0T #FX2  UN&@ ,;B( #&XK  MN-  *;CX "&Y*  =N5P &;F4 !&YV
M  )NB@  ;9\  &VV  !LU@  ;/,  6O_  )J_P #:O\ A5H  '1:  !F6@
M7%D  %-9  !(6@  /UT  #9@   N8P  )F<  !]J   9;0  $W$   YT P *
M=PH !7<0  %W%0  =QP  '<D  !X+0  >#<  'A#  !X4   >%X  'AO  !X
MA   >)D  '>P  !VS0  =?   '7_  !T_P  =/\ ?E\  &Y?  !B7@  65X
M $U?  !"8@  .64  #!H   G;   'W   !AT   2=P  #7L   A^   "@ @
M ($-  "!$0  @A<  (,>  "#)@  A#   (0[  "$2   A%<  (1H  "$?
MA),  (.J  ""Q0  @>L  ('^  " _P  @/\ =V4  &ED  !?8P  4F0  $=G
M   \:P  ,6\  "AS   @=P  &'P  !%_   ,@P  !H<   "*    C ,  (P)
M  "-#@  CA$  (\7  "0'@  D2<  )(R  "2/P  DDX  ))?  "2<P  DHL
M )&B  "1O   D.4  (_\  "._P  CO\ <6L  &9J  !8:P  2VT  #]Q   T
M=@  *GL  ""    7A0  $(D   N-   $D0   )4   "8    F0   )H#  ";
M"   G T  )X1  "?%@  H!X  *(H  "B-0  HT0  *-5  "C:0  HH   **:
M  "ALP  H-@  *#V  "?_P  G_\ ;G$  %]R  !1=0  1'D  #=^   LA
M(8H  !>/   0E   "ID   &=    H    *0   "G    J    *D   "J
MK 8  *T+  "O$   L!4  +(>  "T*0  M#D  +1*  "U70  M7,  +6.  "U
MJ   M,8  +/M  "R_P  LO\ 9GH  %=]  !)@@  /(<  "^.   CE   &)H
M !"?   )I    *D   "M    L    +0   "W    N    +D   "[    O
M +X"  # "   P@X  ,04  #''@  R"P  ,D]  #*4   RF8  ,I_  #*FP
MRK@  ,K=  #*]0  RO\ 7H8  $^+  !!D0  ,Y@  ">?   ;I0  $:L   FP
M    M0   +D   "]    P0   ,8   #(    R0   ,L   #,    S@   -
M  #2    U 4  -D,  #=$@  X1X  .(N  #C0@  Y%<  .5O  #FC   YJ@
M .7%  #EYP  YO8 5I0  $B;   ZH@  +*D  !^P   3M@  "[P   #!
MQ0   ,D   #-    T@   -8   #:    VP   -X   #@    X@   .0   #G
M    Z0   .T   #P"@  ]!$  /@?  #Y,@  ^D@  /M?  #\>@  _9<  /VO
M  #]QP  _>0 _P . /\ #0#_  P _P . /\ $P#_ !X _P J /\ -@#_ $(
M_P!- /\ 5P#_ %\ _P!G /\ ;@#_ '0 _P!Z /\ @0#] (< _ "- /H E #Y
M )P ]P"E /4 KP#T +P \P#/ /$ [ #P /X [P#_ .\ _P#C /\ UP#_ ,X
M_P#* /\ _P * /\ !@#_  0 _P ( /\ $ #_ !D _P E /\ ,0#_ #T _P!'
M /X 40#[ %D ^0!A /8 : #T &X \P!T /$ >@#O ($ [@"' .P C@#J )8
MZ "? .8 J0#C +4 X@#& .  XP#? /@ W0#_ -T _P#4 /\ R0#_ ,( _P"^
M /\ _P # /\   #_    _P ! /\ #0#_ !0 _0 @ /H *P#W #8 \P!! .\
M2P#L %0 Z !; .8 8@#C &@ X0!N -\ = #< 'H V@"! -@ B #4 )  T@"8
M ,\ H@#- *X RP"\ ,D TP#' /  Q@#_ ,0 _P#$ /\ NP#_ +8 _P"S /\
M_P   /\   #_    _P   /< " #P !  ZP : .< )0#D #  X0 [ -P 10#5
M $T T0!5 ,X 6P#+ &( R0!G ,< ;0#% ', PP!Z ,$ @0"_ (D O0"2 +L
MG "Y *< MP"U +4 R "S .8 L@#[ +$ _P"P /\ K@#_ *H _P"G /\ _P
M /\   #^    \0   .4  @#<  T TP 4 ,T 'P#* "H QP T ,0 /@#  $<
MO !. +H 50"W %L M0!A +, 9P"R &T L !S *X >@"L (( J@"+ *@ E0"G
M *  I0"M *, O@"A -L H #T )\ _P"> /\ GP#_ )T _P"; /\ _P   /P
M  #N    X    -    #%  @ O@ 0 +D &0"U ", LP N +  -P"M $  J@!(
M *@ 3P"E %4 HP!; *( 8 "@ &8 GP!L )T <P"; 'L F@"$ )@ C@"6 )H
ME0"G ), MP"1 ,P D #L (\ _P". /\ C@#_ (X _P"/ /\ _    .\   #;
M    R0   +T   "U  ( K@ , *D $P"E !T H@ G *  ,0"= #H F@!" )@
M20"6 $\ E !5 ), 6P"1 &  D !G (X ;0"- '4 BP!^ (D B0"( )4 A@"B
M (4 L0"# ,0 @0#D (  ^0!_ /\ @ #_ (  _P"  /\ ] (  . )  #'"
MMP<  *P#  "F    H  ' )L #P"8 !< E0 A )( *@"/ #, C0 \ (L 0P")
M $D AP!0 (8 50"$ %L @P!A ($ : "  '  ?@!Y 'P A ![ )  >0"= '@
MK !V +X =0#= ', ] !S /\ <P#_ ', _P!S /\ Z0T  ,\0  "Y$   J1
M )X.  "7"P  DP8  )  "P", !$ B0 : (8 ) "# "X @0 V '\ /@!] $0
M? !+ 'H 40!Y %< =P!= '8 9 !T &P <P%U '$!@ !O HT ;@*: &P#J@!K
M [L :036 &@&\0!H!_\ 9P?_ &<'_P!G!_\ WQ0  ,,7  "N%P  GA8  ),5
M  "+$@  AA   (0, @"#!@T @ ,4 'P%'@!Y!R@ =P@P '4(. !S"4  <@E&
M ' *3 !O"E, ;0M9 &P+80!J"VD :0QR &<,?@!F#(L 9 V9 &(-J0!A#;L
M8 W8 %X.\P!=#O\ 70[_ %T._P!=#O\ U!P  +D=  "D'@  E1T  (D<  "!
M&@  >Q<  '@3  !X$ 8 =PT/ ',.& !P#B( ;@\K &P0,P!J$#L :1!" &<1
M20!F$4\ 9!%6 &,270!A$F8 8!)O %X2>P!<$X@ 6Q.7 %D3IP!7%+H 5A35
M %45\P!4%?\ 5!7_ %05_P!4%/\ RB(  + B  "=(P  C2,  ($B  !Y(0
M<QX  &\;  !N%P  ;1,, &H4% !G%1X 918G &,6+P!A%S< 8!<^ %X810!=
M&$L 7!E2 %H96@!9&6( 5QIL %8:=P!4&H4 4AN4 %$;I !/&[< 3AO0 $T<
M\0!,'/\ 3!S_ $T<_P!-&_\ PR8  *HG  "6)P  AR@  'LG  !R)@  ;"0
M &@A  !F'@  9!L( &(;$0!?'!H 71TC %L>*P!:'C, 6!\Z %<?00!6($@
M5"!/ %,@5P!1(5\ 4"%I $XA= !-(8( 2R*1 $DBH@!((K0 1R+- $8C[P!%
M(_\ 12+_ $8B_P!&(?\ O"H  *0K  "1*P  @BP  '8K  !M*@  9BD  &(F
M  !?)   72($ %LA#@!8(A8 5B,? %0D* !3)#  4B4W % E/@!/)D4 3B9,
M $PF5 !+)UP 22=F $@G<0!&)W\ 12B/ $,HH !!*+( 0"C+ #\H[0 _*/\
M/RC_ $ G_P! )_\ MRT  )\N  ",+P  ?2\  '$O  !H+@  82T  %TK  !:
M*   5R<  %0G# !2*!, 4"D< $XI)0!-*BP 2RHT $HK.P!)*T( 2"Q) $8L
M40!%+%H 1"QD $(M;P! +7T /RV- #TMG@ \+;  .BW( #HMZP Z+?\ .BW_
M #HL_P Z+/\ LC   )LQ  "(,@  >3(  &TR  !D,@  73$  %@O  !5+
M42P  $\M"0!,+1$ 2BX9 $DO(@!'+RH 1C Q $4P. !#,#\ 0C%' $$Q3P!
M,5< /C%A #TR;0 [,GL .3*+ #@RG  V,J\ -3+' #0RZ0 T,O\ -3'_ #4Q
M_P U,/\ K3,  )8T  "$-0  =34  &DU  !@-0  630  %0S  !0,   3#$
M $DQ!@!',@\ 13,6 $,S'P!"-"< 0#0N #\U-@ ^-3T /35$ #PV3  Z-E4
M.39? #<V:P V-G@ -#>) #(WF@ Q-ZT +S?% "\WZ  O-OX ,#7_ # U_P P
M-/\ J38  )(V  " -P  <C@  &8X  !=-P  5C<  % V  !+-   1S4  $0V
M P!!-PT /S@4 #XX'  \.20 .SDL #HY,P Y.CH .#I" #8Z2@ U.E, -#M=
M #([:  P.W8 +SN' "T[F0 L.ZP *CO# "D[Y@ J.OT *CK_ "LY_P L./\
MI#@  (XY  !\.@  ;CH  &,Z  !:.@  4SH  $TZ  !&.   0CH  #\[   \
M/ L .CP1 #@]&0 W/2$ -CXI #0^,  S/C< ,C\_ #$_1P P/U  +C]: "U
M9@ K0'0 *4"$ "A EP F0*H )4#! "1 Y0 D/_P )3[_ "8]_P F/?\ GSL
M (H\  !X/0  :CT  %\]  !6/0  3ST  $D]  !"/0  /#X  #D_   V00@
M-$$/ #)"%@ Q0AX +T,E "Y#+0 M0S0 +$0\ "M$1  J1$T *$18 "=%8P E
M17$ (T6" ")%E0 @1:@ 'T6_ !Y$XP ?1/L 'T/_ "!"_P A0?\ FCX  (4_
M  !T0   9T   %Q   !30   3$   $9    ^00  .$,  #1%   P1@, +4<-
M "M($@ J2!H *4@B "A)*0 G23$ )4DY "1)00 C2DH (DI5 "!*80 ?2F\
M'4I_ !M*D@ :2J8 &$J] !=*X  82?H &4C_ !I'_P :1_\ E4(  (!"  !P
M0P  8T,  %A#  !00P  24,  $)$   [10  -4<  #!)   K2P  )DT) "1.
M$  B3A8 (4\= "!/)0 ?3RP 'D\U !U//0 <4$< &E!1 !E070 74&L %E!\
M !10CP 34*0 $5"Z !%0W@ 13_@ $D[_ !--_P 43?\ CT4  'M&  !K1@
M7T<  %5'  !-1P  1D<  #]'   W2@  ,4P  "M.   F4   (%,# !Q5#  :
M5A$ &588 !=6(  65B< %58P !16.0 35T( $E=- !%760 05V@ #U=Y  Y7
MC  -5Z  "U>V  M6U  +5O0 #%7_  U4_P .4_\ B$D  '9*  !G2@  6TH
M %%*  !*2@  0TH  #M,   S3@  +%$  "94   A5@  &UD  !5<!P 17@T
M$%X3 !!>&@ .7B( #EXJ  U>,P ,7CT "UY(  I>5  (7F( !UYS  5>A@ #
M7IL  EZQ  )=S  "7>X  US_  1;_P %6_\ @4X  '!.  !B3@  5TX  $Y.
M  !'3@  /D\  #91   N5   )U<  "%:   ;70  %6   !!C P ,9@L "&<0
M  9G%0 %9QP !&<D  )G+0 !9S<  &="  !G3@  9UP  &=M  !G@   9I4
M &:L  !EQP  9>L  &3\  !D_P  8_\ >E(  &I3  !=4@  5%(  $M2  !"
M4P  .54  #!8   H6P  (5\  !IB   490  $&@   QK 0 &;@D  &\.  !O
M$@  ;Q@  ' ?  !P)P  <3   '$[  !Q2   <58  '%F  !Q>0  <8\  '"G
M  !OP0  ;^<  &[\  !M_P  ;?\ <U@  &57  !:5P  458  $97   \6@
M,ET  "IA   B9   &F@  !1L   .;P  "G(   1V    > 4  '@+  !Y#@
M>A,  'L9  !\(   ?2D  'TS  !]0   ?4X  'U>  !]<@  ?8@  'RA  !\
MN@  >^(  'KZ  !Y_P  >/\ ;5T  &!<  !77   2UT  $!?   U8P  *V<
M "-K   :;P  $W,   YW   (>P   GX   ""    @P$  (0&  "%"P  A@\
M (@3  ")&0  BB$  (LK  "+-P  C$8  (M6  "+:0  BX   (N9  "*LP
MB=@  (CW  "(_P  A_\ :&,  %YB  !18@  1&4  #AI   N;@  )',  !IX
M   3?0  #8$   :%    B0   (T   "0    D@   )(   "4!0  E0H  )<.
M  "8$@  FA@  )LA  "<+0  G3P  )U,  "<7P  G'8  )N1  ";JP  FLD
M )KP  "9_P  F/\ 96D  %=I  !);   /7$  #!V   E?   &X$  !*'   ,
MC   !)$   "5    F0   )T   "@    H0   *(   "D    I0$  *<'  "I
M#   JA$  *T8  "O(@  KS   *]!  "O5   KVL  *Z%  "NH0  KKX  *WF
M  "L_   K/\ 7G$  $]T  !">0  -7\  "B%   =C   $Y(   R8   #G0
M *(   "F    J@   *X   "P    L0   +,   "T    M@   +@   "Z!
MO H  +X0  #!%P  PR0  ,,U  #$20  Q%X  ,5W  #%DP  Q:\  ,71  ##
M\@  P_\ 5GP  $>"   ZB   +(\  ""6   4G0  #:,   .I    K@   +(
M  "W    NP   +\   #"    P@   ,4   #&    R    ,H   #-    SP
M -((  #5#@  VQ@  -TG  #>.@  WU   .!H  #@A   X:$  .&]  #AX@
MX/0 3HL  $"2   RF0  ):$  !BH   .KP  !;4   "Z    OP   ,0   #(
M    S@   -$   #4    U0   -@   #:    W0   -\   #B    Y    .<
M  #K!0  [PX  /09  #U*P  ]D$  /=8  #X<@  ^9   /FK  #XQ   ^.$
M_P + /\ " #_  D _P , /\ $@#_ !H _P F /\ ,@#_ #X _P!( /\ 4@#_
M %H _P!B /\ :0#_ &\ _P!U /X >P#\ ($ ^P"( /D CP#W )< ]0"@ /,
MJ@#R +< [P#) .T Y@#L /L ZP#_ .L _P#= /\ S@#_ ,8 _P#" /\ _P $
M /\   #_    _P % /\ #0#_ !4 _P A /\ + #_ #@ _P!# /T 3 #Y %0
M]P!< /0 8P#R &D \ !O .X =0#L 'L Z@"" .@ B0#G )$ Y ": .( I #@
M +  W0#  -H W #8 /0 U0#_ -, _P#+ /\ P0#_ +L _P"W /\ _P   /\
M  #_    _P   /\ "@#] !$ ^0 ; /8 )P#T #( \  \ .P 1@#H $X Y !6
M .$ 7 #> &, W !H -D ;@#5 '0 T@![ -  @@#- (H RP"3 ,@ G0#& *@
MQ "W ,$ S #  .L O@#_ +T _P"] /\ M #_ *X _P"K /\ _P   /\   #_
M    ^@   /( !0#J  X Y0 6 .  (0#= "L VP V -, /P#. $@ R@!/ ,<
M5@#$ %P P@!A ,  9P"^ &T O !S +H >@"X (( M@"+ +0 E@"R *$ L "O
M *X P0"M .  JP#W *H _P"I /\ I@#_ *$ _P"? /\ _P   /\   #W
MZ    -P   #0  H R@ 1 ,4 &P#" "4 OP O +P . "X $$ M0!( +( 3P"P
M %4 K@!; *P 80"J &8 J !L *< <P"E 'L HP"$ *$ C@"? )H G0"G )L
MN ": -  F0#O )@ _P"7 /\ E@#_ )0 _P"2 /\ _P   /8   #D    T@
M ,4   "[  4 M0 . +  %0"L !\ J@ I *@ ,@"E #H H@!" *  20"> $\
MG !5 )H 6@"8 &  E@!F )4 ; "3 '0 D@!] )  AP". ), C "A (L L "*
M ,4 B #F (< ^P"& /\ AP#_ (< _P"& /\ ^    .4   #-    O0   +,
M  "J    HP * )\ $0"; !D F0 C )< + "5 #0 D@ \ )  0P". $D C !/
M (H 5 ") %H AP!@ (8 9@"$ &X @P!W ($ @0!_ (T ?@"; 'P J@![ +P
M>@#; '@ ]0!X /\ > #_ '@ _P!X /\ [0   -$"  "[ @  K $  *(   ";
M    E@ % )$ #0"- !0 BP = (@ )@"& "X A  V (( /0"  $, ?@!) 'T
M3P!\ %4 >@!; 'D 80!W &D =0!Q '0 ? !R (@ <0"6 &\ I0!N +8 ;0#.
M &P [@!K /\ :P#_ &L _P!K /\ WPL  ,(,  "N#   G@P  ),+  ",!P
MB (  (4 "0"! !  ?P 7 'P ( !Z "@ >  P '8 . !T #X <P!$ '$ 2@!P
M %  ;@!6 &T 70!L &0 :@!M &@ =P!G (0 90"2 &0 H0!C +( 80#) &
MZ0!@ /P 8 #_ &  _P!@ /\ T!   +81  "B$@  DQ(  (@1  " #P  ? T
M 'D) 0!X PL =0 1 ', &@!P ", ;@$K &P!,P!J CD :0-  &<#1@!F!$P
M9012 &,%60!B!6$ 8 5J %\&= !=!H$ 7 >/ %H'GP!9![  5P?& %8)YP!6
M"OL 50K_ %4*_P!6"O\ QA4  *T7  "9&   BA@  '\7  !V%@  <1,  &X0
M  !M#04 ;0D- &H)% !G"AT 90HF &,++@!B##4 8 P\ %\,0@!>#4@ 7 U/
M %L-5@!9#5X 6 YH %8.<P!5#H  4PZ/ %$.GP!0#K$ 3@[( $T0Z@!-$/T
M31#_ $T0_P!-$/\ O!L  *4<  "2'0  @QX  '<=  !O'   :1H  &87  !D
M%   9! ( &(/$ !?$!@ 71 A %L1*0!:$3$ 6!(X %<2/@!6$D4 5!), %,3
M4P!1$UL 4!-E $X4< !,%'T 2Q2, $D4G !'%:X 1A7% $45Z !%%OX 11;_
M $45_P!%%?\ M1\  )XA  "+(@  ?"(  '$B  !H(0  8A\  %\=  !<&@
M6Q<" %H5#0!7%A0 518= %07)0!2&"T 41@T $\8.P!.&4( 31E( $L:4 !*
M&E@ 2!IB $<:;0!%&WH 0QN) $(;F@! &ZP /QO" #X<Y0 ]'/P /AS_ #X;
M_P ^&_\ KR,  )@D  "&)0  =R8  &PF  !C)0  720  %DB  !6'P  5!T
M %,<"P!1'!( 3AT: $T=(@!+'BD 2AXQ $D?-P!''SX 1B!% $4@30!#(%4
M0B!? $ A:@ _(7< /2&' #LAF  Y(:H ."+  #<BXP W(OL -R+_ #@A_P X
M(?\ JB8  )0G  "!*0  <RD  &<I  !?*0  6"@  %0F  !1(P  3R(  $PB
M!P!*(A  2"(7 $<C'P!%)"8 1"0N $(D- !!)3L 0"5# #\E2@ ])E, /"9<
M #HF9P Y)G4 -R>$ #4GE@ T)Z@ ,B>^ #$GX0 Q)_D ,B;_ #(F_P S)?\
MI2D  (\J  !]+   ;RP  &0M  !;+   52L  % J  !,*   2B8  $<G! !$
M)PT 0B@4 $$H'  _*2, /BDK #TI,@ \*CD .RI  #DJ2  X*U  -BM: #4K
M90 S*W( ,2N" # LE  N+*< +"R\ "LLW@ L+/@ +"O_ "TJ_P M*O\ H2P
M (LM  !Y+@  :R\  & O  !8+P  42X  $PN  !(+   12L  $$K   _+ L
M/2P1 #LM&0 Z+B$ .2XH #<N+P V+S8 -2\^ #0O10 S+TX ,3!8 # P8P N
M,'  +#"  "HPD@ I,*4 )S"Z "8PW  F,/< )R__ "@O_P H+O\ G"X  (<P
M  !V,0  :#(  %TR  !5,@  3C$  $@Q  !$,   0"\  #PP   Z,0D -S$0
M #8R%@ U,AX ,S,E #(S+  Q,S, ,#0[ "\T0P M-$P +#16 "HU80 I-6X
M)S5^ "4UD  C-:, (C6Y "$UV0 A-/8 (C3_ ",S_P C,O\ F#$  (,S  !R
M-   930  %HU  !1-0  2S0  $4T  ! -   .C,  #<T   T-08 ,C8. # W
M$P O-QL +C<B "TX*0 K.#$ *C@X "DY0  H.4D )CE3 "4Y7P C.6P (3I\
M " ZC@ >.J( '#JW !LYU0 <.?4 '3C_ !TX_P >-_\ DS0  '\V  !N-P
M83<  %<W  !.-P  2#<  $(W   \-P  -3@  #(Y   O.@( +#L+ "H\$0 I
M/!@ *#T? "8])@ E/2X )#TU ",^/0 B/D8 (#Y0 !\^7  =/VD &S]Y !H_
MC  8/Z  %C^U !4^T@ 6/O, %SW_ !@\_P 8//\ CC<  'HX  !J.0  7CH
M %,Z  !+.@  13H  #\Z   Y.@  ,CP  "X^   I0   )D$( "1"#@ B0A0
M(4(; "!#(P ?0RH 'D,R !Q#.@ ;1$, &D1- !A$60 71&< %41W !-$B@ 2
M1)X $42S !!$T  00_( $4+_ !)"_P 30?\ B3L  '8\  !F/0  6CT  % ]
M  !(/0  0CT  #P]   V/@  +T   "I"   E1   (48# !U(#  ;21$ &4D7
M !A)'@ 7228 %DDN !5*-@ 42D  $TI* !%*5@ 02F0 #TIT  Y*AP -2IL
M#$JP  I*R@ +2>P #$C_  U'_P -1_\ @SX  '$_  !B0   5D   $U   !%
M0   /T   #E!   R0@  *T4  "9'   A20  '$L  !9.!P 34 X $E 3 !%0
M&0 04"$ #U I  Y0,0 -4#L #5%&  M140 *45\ "5%O  =0@0 %4)8  U"K
M  )0Q0 #3^@  T_[  5._P &3?\ ?4(  &M#  !=1   4D0  $I$  !#0P
M/$0  #5%   N1P  )TH  "%,   <3P  %U$  !)4 P .5PH "U@0  I8%0 (
M6!P !U@D  98+  %6#8  UA   %83   6%H  %AI  !8?   6)$  %>G  !7
MP   5N4  %;Y  !5_P  5?\ =D<  &9'  !92   3T<  $='  ! 1P  .$@
M #!*   I30  (E   !Q3   650  $5@   U; @ )7@D !%\.  !?$@  7Q@
M & ?  !@)P  8#   & [  !@1P  8%0  &!C  !@=@  8(L  %^B  !?NP
M7^(  %[Y  !=_P  7?\ ;TL  &%,  !53   3$L  $1+   [3   ,DX  "M1
M   C5   '%<  !9;   17@  #6    AC   "9@<  &<,  !G#P  :!,  &D9
M  !J(0  :BD  &HT  !J0   :DT  &I=  !J;P  :H4  &J=  !IM@  :-T
M &CW  !G_P  9O\ :5$  %Q0  !24   2D\  #]0   U4P  +58  "19   =
M70  %F   !!D   ,9P  !FH   !N    ;P,  ' (  !Q#0  <A   '04  !U
M&P  =B,  '<L  !W.   =D8  '96  !V:   =GX  ':7  !UL0  =-,  '/U
M  !S_P  <O\ 8U8  %A5  !05   1%4  #E8   O6P  )E\  !UC   59P
M$&P   IP   $<P   '8   !Z    ?    'P#  !^"   ?PP  ($0  ""%
MA!L  (4D  "&+P  ACT  (9-  "%7P  A74  (6/  "$J0  @\D  (+Q  "!
M_P  @/\ 7UL  %9:  !)6P  /5X  #)A   G9@  'FL  !5P   .=0  "7D
M  %^    @0   (4   "(    B@   (L   "- 0  C@8  ) +  "1#P  DQ0
M )4;  "7)@  ES0  )=$  "75@  EFP  )6&  "5H@  E,$  )/J  "2_P
MDO\ 76$  $]A  !"9   -FD  "IN   ?=   %7D   Y_   'A    (D   ".
M    D@   )8   "8    F@   )L   "=    GP   *$#  "C"   I0T  *<3
M  "I'   JB@  *HY  "J2P  JF$  *EZ  "HF0  J+4  *?=  "G^   IO\
M5F@  $AL   Z<   +G8  ")]   7A   #HH   >0    E@   )H   "?
MHP   *<   "J    JP   *T   "O    L0   +,   "U    N 4  +H,  "]
M$@  P!P  , M  # 0   OU4  +]N  "^BP  OJ@  +[)  "][P  O/X 3G0
M $!Y   R?P  )8<  !F.   0E0  !YP   "B    IP   *P   "P    M0
M +D   "\    O0   +\   #!    PP   ,8   #(    R@   ,T"  #0"P
MU1(  -8A  #7-   V$D  -E@  #:?   VIH  -NU  #;V0  V_( 1H(  #B)
M   KD   '9@  !*@   *IP   *X   "T    N0   +X   #"    R    ,L
M  #.    SP   -(   #4    U@   -H   #=    WP   .(   #F    Z@H
M .\3  #P)0  \CH  /-1  #T:P  ](D  /6E  #UOP  ]=T _P & /\  P#_
M  4 _P + /\ $ #_ !< _P B /\ +0#_ #D _P!$ /\ 30#_ %4 _P!= /\
M9 #_ &H _P!P /T =@#[ 'P ^0"# /< B@#U )( \P"; /  I@#N +, ZP#$
M .D Y #G /D Y@#_ .4 _P#3 /\ QP#_ +\ _P"[ /\ _P   /\   #_
M_P " /\ "P#_ !( _P = /\ * #_ #, _P ^ /P 1P#X $\ ] !7 /$ 70#N
M &, [ !I .H ;P#H '4 Y@!\ .0 @P#B (L WP"5 -P GP#9 *L U0"[ -(
MU #/ /( S0#_ ,P _P#% /\ N@#_ +0 _P"P /\ _P   /\   #_    _P
M /\ !@#Y  \ ]0 7 /, (@#Q "T [0 W .< 0 #B $D WP!0 -L 5P#7 %T
MU !C -$ : #/ &X S !U ,H ? #( (0 Q0"- ,( F #  *0 O0"R +L Q@"Y
M .@ N #] +< _P"V /\ K0#_ *< _P"C /\ _P   /\   #_    ]0   .L
M 0#D  P W@ 3 -D ' #3 "8 T0 P ,P .@#( $( Q !* ,  4 "] %8 NP!<
M +D 80"W &< M0!M +, = "Q 'P KP"% *T D "J )P J "J *8 NP"E -H
MHP#U *, _P"B /\ G@#_ )H _P"7 /\ _P   /X   #O    WP   -    #'
M  < P0 / +P %P"Y "  MP J +4 ,P"P #L K0!# *L 20"H $\ I@!5 *0
M6@"C &  H0!F )\ ;0"= '0 G !] )H B "8 )0 E@"B )0 L@"2 ,D D0#K
M )$ _P"0 /\ D #_ (P _P"* /\ _    .P   #9    QP   +H   "Q  (
MJP , *< $@"D !L H0 D *  + "> #4 FP \ )@ 0P"6 $D E !/ )( 5 "0
M %H CP!? (T 9@"+ &T B0!V (@ @ "& (P A ": (( J@"! +X @ #@ (
M^0!_ /\ ?P#_ '\ _P!^ /\ \0   -@   #"    LP   *@   "@    F0 '
M )4 #@"2 !4 D  > (X )@"- "X B@ V (< /0"% $, A !) (( 3@"! %0
M?P!9 'X 8 !\ &< >@!O 'D >@!W (8 =0"4 '0 HP!R +4 <@#/ '$ \0!P
M /\ < #_ '  _P!Q /\ X0   ,0   "P    H@   )<   "1    BP " (8
M"P"# !$ @0 8 '\ (0!] "D ?  P 'D -P!X #T =@!# '0 20!S $X <@!4
M '  6@!O &( ;0!J &L = !J (  : ". &< G0!E *\ 90#& &0 Z !D /T
M8P#_ &, _P!D /\ SP4  +8'  "C"   E @  (D'  "" P  ?@   'L !@!W
M  X =0 3 '( &P!Q ", ;P K &T ,@!L #@ :@ ^ &D 1 !G $D 9@!/ &4
M5@!C %T 8@!E &  ;P!? 'L 70") %P F0!; *H 60"_ %D X0!8 /@ 6 #_
M %@ _P!9 /\ P@P  *H-  "7#@  B0X  'T.  !V#0  <0H  &\&  !M  H
M:P 0 &D %@!G !X 90 F &, +0!A #, 8  Y %\ /P!= $4 7 !+ %L 4@!:
M %D 6 !B %< ; !5 '@ 4P"& %( E@!1 *< 4 "[ $\!VP!. O0 3@/_ $X$
M_P!. _\ N!   *$2  ".$P  ?Q,  '03  !L$@  9Q   &4.  !C"P, 8P8,
M &$$$0!> QD 7 0A %L%* !9!B\ 6 8U %8'.P!5!T( 5 =( %,(3P!1"%8
M4 E? $X):0!-"78 2PJ$ $D*E !("J8 1PJZ $8*V !%"_, 10S_ $4,_P!%
M#/\ L!0  )D6  "'&   >!D  &T8  !E%P  7Q8  %P3  !:$0  6@X& %H,
M#0!7#!0 50P< %,-) !2#2L 4 TQ $\.. !.#CX 30Y% $L.30!*#E4 2 ]>
M $</: !%#W4 0Q"$ $$0E0! $*8 /A"[ #T0W  ]$?8 /1'_ #T0_P ^$/\
MJ1D  )(;  "!'   <AT  &<=  !?'   61L  %49  !3%@  4A,  %(1"@!0
M$!  3A$8 $P1( !*$B< 21(N $@3- !'$SL 11-" $0320!#%%( 011; #\4
M90 ^%7( /!6! #H5D@ X%:0 -Q6Y #45V  U%O4 -A;_ #86_P W%?\ HQP
M (T>  ![(   ;2$  &(A  !:(0  5!\  % >  !-&P  3!D  $L6!@!)%@X
M1Q<5 $47' !$&"0 0A@J $$8,0! &3@ /QD_ #T91@ \&D\ .AI8 #D:8P W
M&V\ -1M^ #,;D  R&Z( ,!NW "\;TP O'/, +QO_ # ;_P P&_\ G1\  (@B
M  !W(P  :20  %XD  !6)   4",  $LB  !((   1AT  $4< @!#' P 01P2
M #\=&0 ^'2$ /!XG #L>+@ Z'S4 .1\\ #<?1  V'TP -"!6 #,@8  Q(&T
M+R!\ "TAC@ L(:  *B&U "DAT  I(?( *2'_ "H@_P K(/\ F2(  (0E  !S
M)@  92<  %LG  !3)P  3"8  $<E  !$)   0B$  #\A   ](0D .R$0 #DB
M%@ X(AX -B,E #4C*P T)#( ,R0Y #(D00 P)$H +R53 "TE7@ K)6L *B5Z
M "@EC  F)9\ )"6S ",ES@ C)?  )"7_ "4D_P E)/\ E"4  ( G  !O*0
M8BH  %<J  !/*@  22D  $0H  ! )P  /28  #HE   W)@8 -28. #0G%  R
M)QL ,2@B # H*0 O*#  +2DW "PI/P K*4< *2E1 "@J7  F*FD )"IX ",J
MB@ A*IT 'RJR !XJS  >*N\ 'RG_ " I_P A*/\ D"@  'PJ  !L*P  7RP
M %0L  !,+   1BP  $$K   \*P  ."H  #4J   R*P, ,"L, "XL$0 M+!@
M+"P? "HM)@ I+2T *"TT "<N/  F+D4 )"Y/ ",N6@ A+V< 'R]V !TOB  <
M+YL &B^P !@OR@ 8+NT &2[_ !LM_P ;+?\ C"L  '@M  !H+@  6R\  %$O
M  !)+P  0R\  #XN   Y+@  -"X  # N   M+P  *S * "DQ$  G,14 )C$<
M "4R(P D,BH (S(Q "$S.0 @,T( 'S-, !TS5P ;,V0 &C1T !@TA@ 6-)H
M%#.N !,SR  3,^P %#/_ !4R_P 6,?\ ARX  '0O  !E,0  6#$  $XR  !&
M,@  0#$  #LQ   V,0  ,3$  "LS   H-   )34& ",V#0 A-A( (#<9 !\W
M(  >-R< '3@N !LX-@ :.#\ &3A) !<Y50 5.6( %#EQ !(YA  1.9@ $#FM
M  XXQP ...L $#C_ ! W_P 1-O\ @S$  ' R  !A-   530  $LT  !$-
M/30  #@T   S-   +34  "@W   D.0  (#H" !T["P ;/!  &3T5 !@]'  7
M/2, %CTK !4^,P 4/CP $CY& !$^4@ 0/E\ #SYO  X^@0 ,/I4 "SZI  H^
MP0 */>0 "SW[  P\_P -._\ ?30  &LV  !=-P  43<  $@W  !!-P  .S<
M #4W   P-P  *CD  "4[   @/0  '#\  !=!!@ 40PT $D,2 !%#&  10Q\
M$$0G  ]$+P .1#D #41#  Q$3@ +1%L "41J  =$?  &1)  !$.E  )#O0 #
M0^   T/V  1"_P &0?\ >#@  &<Y  !9.@  3CH  $4Z   ^.@  .#H  #,Z
M   M.P  )ST  "%    <0@  %T0  !-& P /20H #4H/  Q*%  +2AL "4HC
M  A**P '2C0 !4H^  1*20 "2E8  $IE  !*=P  2HL  $JA  !)N0  2=T
M $GU  !(_P  2/\ <CP  &(]  !5/@  2CX  $(]   \/0  -CT  "\^   I
M0   (T(  !U%   71P  $TH   ], @ +3PD !U -  -1$0  41<  %$>  !1
M)@  42\  %$Y  !11   4E$  %)@  !1<@  48<  %&=  !1M0  4-@  %#U
M  !/_P  3_\ ;$   %U!  !100  1T$  $!    Y0   ,D$  "I#   D1@
M'D@  !=+   23@  #E$   M3 0 &5@<  %<,  !8$   6!,  %D9  !:(0
M6BD  %HS  !:/P  6DP  %I:  !:;   6H$  %F9  !9L0  6-$  %CT  !7
M_P  5_\ 944  %A%  !-10  140  #Y$   U10  +4<  "5*   >30  &%
M !)3   .5@  "ED   1<    7@0  %\)  !@#0  81   &(5  !C&P  9",
M &0M  !D.   9$4  &14  !D9@  9'L  &.3  !CK0  8LP  &'R  !A_P
M8/\ 7TH  %-*  !*20  0T@  #E)   O3   )T\  !]2   850  $ED   U=
M   (8    F,   !F    : $  &D%  !J"@  :PT  &T1  !N%@  <!T  '$F
M  !Q,0  <#X  '!.  !P7P  <',  &^-  !OIP  ;L8  &WO  !L_P  ;/\
M6D\  %!.  !(30  /4X  #-1   I5   (%@  !A<   18   #&0   9H
M:P   &\   !R    =    '4   !W!   > D  'H-  !\$   ?18  '\>  "
M*   @#4  (!%  !_5@  ?VL  '^$  !^H   ?;X  'SI  ![_P  >O\ 5E0
M $Y3  !"5   -U8  "Q:   B7P  &&,  !%H   +;0   W(   !V    >@
M 'T   "     @P   (0   "&    AP(  (D'  "+#   C1   ) 6  "2'P
MDBP  )([  "230  D6(  )%Z  "/EP  C[0  ([A  ",^P  C/\ 55D  $A:
M   [70  +V$  "1F   9;   $7(   IW   "?0   ((   "&    BP   (X
M  "1    DP   )4   "7    F0   )L   "=!   GPH  *(/  "D%@  IB$
M *8Q  "F0P  I5<  *1P  "CC@  HZL  *'0  "@]0  G_\ 3F$  $!D   S
M:0  )VX  !MU   1?   "X,   ")    C@   ),   "8    G0   *$   "D
M    I0   *<   "I    JP   *T   "P    L@   +4(  "X#@  O!8  +PE
M  "\-P  NTP  +ID  "Y@0  MZ(  +?   "WZ@  M_P 1FL  #EP   K=P
M'W\  !.&   +C@   94   ";    H0   *8   "K    L    +,   "W
MMP   +H   "\    OP   ,$   #$    QP   ,H   #-!0  T0X  -09  #4
M*P  U$   --8  #3=   TY(  -*P  #2TP  TO( /GD  #&    CB   %Y$
M  V9   #H    *<   "N    LP   +@   "]    P@   ,8   #*    R@
M ,T   #/    T@   -4   #9    W0   -\   #C    YP4  .L/  #L'P
M[3,  .Y+  #O9   [X(  /"?  #QN0  \=@ _P   /\   #_  0 _P ) /\
M#@#_ !4 _P > /\ *0#_ #0 _P _ /\ 2 #_ %  _P!8 /\ 7@#_ &4 _0!K
M /L <0#Y '< ^ !^ /8 A0#S (T \0"7 .X H@#K *\ Z #  .8 X #C /@
MX@#_ -L _P#+ /\ P0#_ +D _P"T /\ _P   /\   #_    _P   /\ "0#_
M !  _P 9 /\ (P#_ "X _0 Y /D 0@#U $H \@!2 .X 6 #K %X Z0!D .8
M:@#D '  X@!V -\ ?0#= (8 V0"/ -4 F@#1 *< S@"V ,L S@#) /  QP#_
M ,4 _P"[ /\ M #_ *T _P"I /\ _P   /\   #_    _P   /L  @#V  T
M\0 3 .T '@#L "@ Z0 R ., .P#= $0 V !+ -, 40#0 %@ S0!= ,L 8P#)
M &@ Q@!O ,0 =@#" 'X OP"' +P D@"Z )\ MP"M +4 P0"R .0 L0#] *\
M_P"L /\ I0#_ *  _P"< /\ _P   /\   #[    [@   .0   #<  @ TP 0
M ,\ & #+ "( R0 K ,8 - #! #T O0!$ +H 2P"W %$ M0!6 +( 7 "P &$
MK@!G *P ;@"J '8 J !_ *8 B@"C )8 H0"E )\ M@"= -$ G #S )L _P"<
M /\ E@#_ ), _P"0 /\ _P   /8   #G    TP   ,8   "]  , N  - +,
M$P"Q !P KP E *X +@"I #8 I@ ] *, 1 "A $H GP!/ )T 50"; %H F@!@
M )@ 9@"6 &X E !W )( @0"0 (X C@"< (P K0"* ,, B0#H (@ _P") /\
MAP#_ (4 _P"" /\ \P   .,   #,    O    +    "G    H0 ( )X #P";
M !8 F0 ? )@ )P"6 "\ DP W )$ /0". $, C !) (L 3@") %0 AP!9 (4
M8 "$ &< @@!O (  >@!^ (8 ? "4 'H I !Y +@ > #8 '< ]P!X /\ > #_
M '< _P!U /\ Y@   ,L   "W    J    )X   "6    CP $ (L # "( !(
MAP 9 (4 (0"$ "D @@ P '\ -P!] #T ? !# 'H 2 !Y $T =P!3 '8 60!T
M &$ <@!I '$ <P!O '\ ;0"- &P G0!J *\ :0#( &@ [0!I /\ :0#_ &D
M_P!I /\ T@   +@   "E    EP   (T   "&    @0   'P " !Y  X =P 4
M '8 ' !T ", <P K '$ ,0!O #< ;@ ] &P 0P!K $@ :@!. &@ 5 !G %L
M90!C &, ;0!B '@ 8 "' %\ E@!= *@ 70"^ %P Y !< /L 7 #_ %P _P!<
M /\ P@   *H!  "8 P  B00  '\"  !X    =    '  ! !M  P :P 1 &D
M%P!H !X 9@ E &4 + !C #( 8@ X &  /0!? $, 7@!) %P 3P!; %8 6@!>
M %@ : !7 ', 50"! %0 D0!2 *, 40"W %$ U@!1 /4 40#_ %$ _P!2 /\
MM@<  )\)  "-"P  ?@P  ',+  !L"@  : <  &4#  !C  < 80 - %\ $P!=
M !H 7  A %L )P!9 "T 6  S %8 .0!5 #\ 5 !% %, 2P!1 %( 4 !: $\
M9 !- &\ 3 !] $H C0!) )\ 2 "R $< S !' .\ 1@#_ $< _P!' /\ K P
M )4.  "#$   =1   &L0  !C#P  7@X  %L,  !:"0( 600* %< #P!5 !4
M4P < %( (P!1 "D 3P O $X -0!- 3L 3 %! $H"2 !) D\ 2 )7 $8#80!%
M VT 0P-Z $(#BP!  YP /P.O #X#R  ]!.H /07\ #T&_P ^!O\ I!   (X2
M  !\$P  ;A0  &04  !<$P  5A(  %,1  !1#@  4 P% % )# !/!Q$ 30<7
M $L('P!)""4 2 DK $<),0!&"3@ 1 H^ $,*10!""DT 0 M5 #\+7P ]"VL
M/ MY #H,B@ X#)P -PRO #4,QP U#.D -0W] #4-_P V#/\ G1,  (<5  !V
M%P  :1@  %X8  !6&   4!<  $T5  !*$P  21$  $D.!P!(#0X 1@T3 $0-
M&@!##B$ 0@XH $ .+@ _#C4 /@\\ #T/0P [$$L .A!4 #@07@ V$&L -!!Y
M #(0B@ Q$)P +Q"P "T0R0 M$>P +1'_ "X1_P O$/\ EQ8  ((9  !Q&P
M9!P  %D<  !1'   3!L  $<:  !$&   0Q4  $(3 @!!$@L 0!$0 #X2%P \
M$AX .Q,E #H3*P X$S( -Q,Y #840  T%$@ ,Q11 #$47  P%6@ +A5W "P5
MB  J%9H *!6N "<5QP F%>H )Q7_ "@5_P I%?\ D1H  'T<  !M'@  8!\
M %8?  !.'P  2!X  $,=  ! '   /AH  #T8   [%P< .18. #@7%  V%QL
M-1@B #,8*  R&"\ ,1DV # 9/0 N&48 +1I/ "L:60 J&F8 *!IT "8:A@ D
M&ID (AJM "$:Q0 @&N@ (1K^ "(:_P C&O\ C1T  'D?  !I(0  7"(  %(B
M  !*(@  1"$  #\A   \(   .1X  #@;   U' 0 -!P- #(<$@ P'1@ +QT?
M "X=)0 M'BP *QXS "H>.P I'T, )Q]- "8?5P D'V0 (A]R " ?A  ?'Y<
M'1^K !L?PP ;'^< &Q_] !T?_P >'O\ B2   '4B  !E(P  620  $\E  !'
M)0  020  #PC   X(P  -2(  #,@   P( $ +B$* "PA$  K(14 *B(< "@B
M(P G(BD )B,P "4C.  C(T$ (B1* "$D50 ?)&$ '21P !LD@@ 9))4 %R2J
M !8DP0 5).4 %B3\ !<C_P 9(_\ A2(  '$D  !B)@  5B<  $PG  !$)P
M/B<  #DF   U)@  ,24  "XD   K)0  *24' "<F#@ E)A, )"<9 ",G(  B
M)R< (2@N " H-@ >*#X '2A( !LI4P 9*5\ &"EN !8I@  4*90 $BFH !$I
MP  1*.0 $2C[ !,H_P 4)_\ @"4  &XG  !?*   4RD  $DJ  !"*0  .RD
M #8I   R*   +B@  "HH   F*0  )"H$ "(K#  @*Q$ 'RP6 !TL'0 <+"0
M&RTK !HM,P 8+3P %RU% !8N4  4+ET $BYL !$N?@ 0+I( #BZG  TMO0 -
M+=\ #2WY  XL_P 0+/\ ?"@  &HJ  !;*P  4"P  $8L   _+   .2P  #0K
M   O*P  *RL  "8L   B+@  'R\  !PP"0 :,0X &3$3 !<Q&@ 6,B$ %3(H
M !0R,  3,CD $C-# !$S3@ 0,UL #C-I  TS>@ ,,XX "C.B  @RN0 (,MD
M"#+T  HQ_P +,?\ =RL  &8M  !8+@  32\  $,O   \+@  -BX  #$N   M
M+@  *2X  ",P   ?,@  &S,  !<U!0 4-@P $C<1 !$W%@ 1-QT $#@D  \X
M+  ..#4 #3@_  PX2@ +.%< "3AE  <X=@ %.(H  SB?  $WM0 !-],  C?Q
M  ,V_P %-O\ <RX  &(P  !4,0  23$  $$Q   Y,0  -#$  "\P   K,
M)3(  " S   ;-@  %S@  !,Z @ 0/ D #3T.  P]$P +/1D "CTA  D]*0 (
M/3$ !CX[  4^1@ #/E(  3YA   ^<@  /H8  #V<   ]L@  /=   #SP   \
M_P  //\ ;3(  %TS  !0-   1C0  #XT   W-   ,C,  "TS   G-   (C8
M !TX   8.@  %#T  ! _ @ -00@ "4,-  9$$0 #1!8  D0=  !$)   1"T
M $0V  !$00  1$X  $1<  !$;0  1($  $28  !#KP  0\T  $+P  !"_P
M0O\ :#8  %@W  !,.   0S@  #LW   U-@  ,#8  "DW   C.0  'CL  !@]
M   30   $$(   U% 0 (1P<  TD,  !)#P  2A,  $L9  !+(   2R@  $LR
M  !+/0  3$D  $Q7  !+:   2WT  $N4  !*K   2LH  $GO  !)_P  2?\
M8CH  %0[  !).P  0#L  #DZ   S.0  +#H  "4\   ?/P  &4$  !-$   0
M1P  #$D   A,   "3P4  % *  !0#0  41   %(5  !4&P  5",  %0L  !4
M-P  5$0  %12  !48P  5'<  %2/  !3J   4L8  %+M  !1_P  4?\ 7#\
M $\_  !%/P  /CX  #<]   O/@  )T   "!#   91@  $TD   ],   +3P
M!E(   !4    5P(  %@'  !9"P  6@X  %L1  !=%@  7AT  %\F  !?,0
M7CT  %Y,  !>70  7G$  %V)  !=HP  7,$  %OK  !:_P  6O\ 5D0  $M#
M  !#0@  /$$  #)"   I10  (4@  !I+   33@  #E(   I5   #60   %L
M  !>    8    &("  !C!@  90H  &8.  !H$0  :A<  &L?  !K*0  :S8
M &M%  !K5@  :FH  &J"  !IG0  :+L  &?G  !F_P  9?\ 44@  $A(  !!
M1@  -T<  "Q*   C30  &U$  !-5   .60  "%T   %A    9    &<   !J
M    ;    &X   !P    <@4  ',)  !U#0  =Q$  'H8  ![(0  >RX  'H]
M  !Z3@  >6(  'EY  !XE@  =[,  '7@  !T_   <_\ 3DT  $=,   [30
M,$\  "93   <6   $UP   UA   &9@   &H   !O    <@   '8   !Y
M?    'T   !_    @0   (,"  "&!P  B P  (L1  ".&   CB0  (XS  "-
M1   C%@  (MO  "*C   B:H  (C/  "&]P  A?\ 35$  $%3   T50  *5H
M !Y?   490  #6H   5P    =@   'L   !_    @P   (<   "*    C0
M (X   "1    DP   )4   "8    F@4  )T,  "@$0  HQH  *,H  "B.@
MH4X  *!E  "@@0  GJ   )W!  ";[@  FO\ 1ED  #E<   M80  (6<  !9N
M   .=0  !7L   "!    AP   (T   "2    E@   )H   "=    GP   *$
M  "D    I@   *@   "K    K@   +$#  "T"P  N!$  +D>  "Y+P  N$,
M +=:  "U=@  M)<  +2U  "QX@  L/P /V0  #%I   E;P  &'<   ]_   &
MAP   (X   "4    F@   *    "E    J@   *X   "Q    L@   +4   "W
M    N@   +P   "_    PP   ,8   #)    S@H  -(3  #2(P  T3<  -!/
M  #.:@  S8H  ,JK  #+RP  R^\ -W$  "EX   =@   $8D   B1    F@
M *$   "G    K0   +,   "Y    O@   ,(   #%    Q@   ,D   #,
MS@   -(   #5    V@   -X   #A    Y0   .H+  #K%P  ZBL  .I#  #J
M7@  ZGH  .N9  #KM0  Z]4 _P   /\   #_  $ _P ' /\ #0#_ !( _P ;
M /\ )0#_ "\ _P Z /\ 0P#_ $L _P!3 /\ 6@#] &  ^P!F /H :P#X '(
M]@!X /0 @ #Q (D [P"2 .P G0#I *H Y@"\ ., W #? /< W0#_ ,P _P"^
M /\ M0#_ +  _P"M /\ _P   /\   #_    _P   /\ !@#_  T _P 4 /\
M'P#_ "D ^P S /< /0#S $4 [P!- .P 4P#H %D Y0!? ., 90#@ &H W0!Q
M -H > #6 (  T@"* ,\ E0#, *( R "R ,4 R0#" .T P #_ +L _P"P /\
MJ #_ *0 _P"A /\ _P   /\   #]    ^@   /@   #P  D [  1 .@ &0#G
M ", Y0 M -X -@#6 #X T0!& ,T 3 #* %( R !8 ,4 70## &, P !I +X
M< "\ '@ N0"! +< C0"T )H L0"I *X O "L .$ J@#\ *@ _P"@ /\ F0#_
M )8 _P"4 /\ _P   /D   #R    YP   -L   #1  0 R@ - ,< % #$ !T
MP@ F +\ +P"[ #< MP _ +0 10"Q $L K@!1 *P 5@"J %P J !A *8 : "C
M '  H0!Y )\ A "= )$ F@"@ )@ L0"6 ,P E0#Q )0 _P"1 /\ BP#_ (@
M_P"& /\ ]P   .P   #>    R0   +P   "T    KP * *L $ "I !< J  @
M *< * "B #  GP X )P /@": $0 F !* )8 3P"4 %4 DP!: )$ 80"/ &@
MC0!Q (L >P") (@ AP"7 (4 J "# +X @0#D (  _P"  /\ ? #_ 'L _P!Y
M /\ Z0   -<   #!    L0   *8   "=    EP % )0 #0"2 !( D  : (\
M(@". "H BP Q (D . "' #X A0!# (, 2 "! $X ?P!4 'X 6@!\ &$ >@!I
M '@ <P!V '\ =0". ', GP!Q +, < #0 &\ ]@!O /\ ;P#_ &T _P!L /\
MV@   +\   "L    G@   ),   ",    A0   (( "0!_  \ ?@ 5 'T ' !\
M "0 >@ K '< ,0!U #< =  ] '( 0@!Q $@ ;P!- &X 4P!L %H :P!B &D
M; !G '@ 9@"& &0 EP!B *H 80#" &  ZP!A /\ 80#_ &$ _P!@ /\ Q0
M *T   ";    C0   (,   !\    =P   '( !0!P  P ;@ 1 &P %P!L !X
M:P E &D + !G #$ 9@ W &0 /0!C $( 8@!( &  3@!? %4 70!= %P 9@!:
M '( 60"  %< D !6 *, 50"Y %0 W@!4 /L 5 #_ %4 _P!5 /\ M@   )\
M  "-    ?P   '4   !N    :0   &8  0!C  D 80 . &  $P!? !D 7@ @
M %T )@!; "P 6@ R %@ -P!7 #T 5@!# %4 20!3 %  4@!8 %$ 80!/ &P
M3@!Z $P B@!+ )P 2@"Q $D S@!) /, 20#_ $D _P!* /\ J@$  )0%  ""
M!P  = @  &H(  !C!@  7@0  %L   !9  4 5P , %8 $ !4 !4 4P ; %(
M(@!1 "@ 4  M $X ,P!- #@ 3  ^ $L 10!* $P 2 !4 $< 70!& &@ 1 !U
M $, A0!! )@ 0 "K $  Q0 _ .H /P#_ $  _P!  /\ H @  (H+  !Y#0
M; T  &$-  !:#0  50L  %()  !0!@  3P(( $X #0!, !( 2P 7 $H '@!)
M ", 1P I $8 +P!% #0 1  Z $( 00!! $@ 0 !0 #X 6@ ] &0 / !R #H
M@@ Y )0 . "G #< O@ V ., -@#Y #8 _P W /\ F T  (,.  !R$   91$
M %L1  !3$   3A   $H.  !(#0  1PH# $<'"@!%! X 1 (3 $("&@!! B
M0 ,E #X#*P ]!#$ / 0W #L$/@ Z!44 .05. #<%5P V!6( - 9P #(&@  Q
M!I( , :E "\%NP N!=T +@;U "T'_P N!_\ D1   'T1  !L$P  7Q0  %44
M  !.%   2!,  $02  !!$   0 X  $ -!@! "@P /@D0 #P)%@ ["AP .0HB
M #@**  W"RX -@LU #4+.P S"T, ,@Q, # ,5@ O#&$ +0QO "L,?P J#)(
M* RE "<,NP E#-T )0WU "8-_P G#?\ BQ(  '<4  !G%@  6Q<  %$8  !)
M%P  0Q<  #\5   \%   .A(  #D1 0 Y#P@ . X- #<.$@ U#A@ - X? #(.
M)0 Q#RP , \R "\0.@ M$$( +!!+ "H050 H$&$ )A!O "00@  C$), (1"G
M !\0O0 >$.  'A'W !\0_P @$/\ AA0  ',7  !C&0  5QH  $T;  !%&@
M0!H  #L9   X&   -18  #04   S$@0 ,A(+ #$2$  O$A4 +1(< "P3(@ K
M$RD *A,P "@3-P G%#\ )A1( "044P B%%\ (!5M !\5?@ =%9$ &Q6E !D5
MNP 8%=X &!7X !D4_P :%/\ @A<  &\:  !?'   4QT  $H=  !"'0  /!T
M #<<   T&P  ,1H  "\9   N%@  +!<( "L6#@ I%Q, *!<9 "<8(  E&"8
M)!@M ",8-  B&3T (!E& !X940 =&5T &QIK !D:?  7&H\ %1JC !09N@ 2
M&=L $QGV !09_P 5&/\ ?1H  &L=  !<'P  4"   $<@   _(   .1\  #0?
M   Q'@  +1T  "L<   I&P  )QL% "4;#  D'!$ (AP6 "$<'0 @'2, 'QTJ
M !X=,@ <'CH &QY$ !D>3@ 7'EL %AYI !0?>@ 2'HT $1ZB ! >N  .'M@
M#Q[U ! =_P 1'?\ >AT  &<?  !9(0  32(  $0B   \(@  -B(  #(A   N
M(0  *B   "<@   D'P  (B " " @"@ >(0\ '2$4 !PA&@ ;(B$ &2(G !@B
M+P 7(C@ %2-! !0C3  2(U@ $2-G ! C>  .(XL #2.?  PCM  +(]  "R+P
M  PB_P -(?\ =A\  &0B  !6(P  2R0  $$D   Z)   -"0  "\C   K(P
M*",  "0C   @(P  '20  !LE!P 9)@T %R81 !8F%P 5)QX %"<E !,G+  2
M)S4 $2@_ ! H2@ .*%8 #2AD  PH=  **(< "2B;  <GL0 %)\P !B?L  <F
M_@ ()O\ <2(  & D  !3)@  2"<  #\G   W)@  ,28  "TF   I)0  )24
M "(E   =)P  &2@  !8J!  4*PL $BP0 !$L%  0+!L $"PB  XL*0 .+3(
M#2T[  LM1@ *+5( ""U@  8M<  $+8,  BV8   LK@  +,D  "SK  $K_  "
M*_\ ;24  %TG  !/*   12D  #PI   U*0  +R@  "LH   G)P  (R<  !\H
M   ;*@  %RP  !,N @ 0, @ #C$-  TQ$@ ,,1< "S$>  HQ)@ (,BX !S(W
M  4R0@ #,DX  3)<   R;   ,G\  #*5   QK   ,<<  ##J   P_   ,/\
M:"D  %@J  !,*P  02P  #DL   R*P  +2L  "DJ   E*@  ("L  !PL   7
M+@  $S   ! R @ .- < "C<,  <W$  %-Q0  S<;  (W(@  -RH  #@S   X
M/@  .$H  #A8   X:   .'P  #>2   WJ0  -L4  #;J   V_0  -?\ 8RP
M %0N  !(+P  /B\  #8N   P+@  *RT  "<M   B+0  '2\  !@Q   4,P
M$#4   XW 0 *.@< !CL+  (\#@  /1(  #X7   ^'@  /B8  #XO   ^.@
M/D8  #Y4   ^9   /G<  #Z/   ]IP  /<,  #SI   \_0  ._\ 7C   % Q
M  !$,@  .S(  #0Q   N,   *2\  "0P   >,@  &30  !0V   0.0  #3L
M  H]   %0 4  $$*  !"#0  0Q   $04  !%&@  1B(  $8K  !&-0  1D$
M $9/  !&7P  1G,  $6*  !%I   1,   $/H  !#_@  0O\ 6#0  $LU  !!
M-0  .34  #(T   M,P  )C0  " U   :.   %#H  ! ]   -0   "4(   1%
M    1P,  $@'  !*"P  2PX  $P1  !.%0  3QP  $\E  !/+P  3SP  $]*
M  !/6@  3FT  $Z%  !-H   3+P  $OG  !+_@  2O\ 4SD  $<Y   ^.0
M-S@  #$W   I-P  (3D  !L\   5/P  $$(   Q%   '2    DH   !-
M3P   %$$  !2!P  5 L  %4.  !7$0  61<  %H?  !9*0  638  %E$  !9
M5   6&<  %A_  !7F@  5K<  %7C  !4_0  5/\ 3CT  $,]   \/   -3L
M "P\   D/@  '$$  !5$   02   "TL   5.    40   %0   !7    60
M %L   != @  7@8  & +  !B#@  9!(  &<8  !G(@  9BX  &8\  !F30
M96   &5W  !DDP  8[$  &'=  !@_   7_\ 24(  $%!   Z/P  ,$   "9#
M   >1@  %4H  !!.   *4@   U8   !:    70   &    !C    90   &<
M  !I    :P$  &T%  !O"@  <@X  '42  !W&P  =B8  '8U  !U1@  =%D
M '1O  !SBP  <JD  '#-  !O]P  ;O\ 1D8  $!%   U1@  *D@  "!,   7
M40  $%8   E:   !7P   &,   !H    :P   &\   !R    =0   '<   !Y
M    >P   'T   "  P  @P@  (8-  ")$P  BAT  (HK  ")/   B$\  (9F
M  "%@0  A*   (+"  "!\   ?_\ 1DL  #I,   N3P  (U,  !A8   07@
M"60   !I    ;P   '0   !X    ?    ($   "$    AP   (@   "+
MC@   )    "3    E@   )D'  "=#0  H10  * A  "@,0  GD0  )U;  "<
M=@  F98  )FU  "6Y0  E?X /U(  #)5   F6@  &V   !%G   );0   '0
M  ![    @0   (8   "+    D    )0   "7    F0   )P   "?    H0
M *0   "G    J@   *T   "Q!@  M0T  +@6  "W)@  MCD  +50  "T:@
MLHD  +"J  "NSP  K?4 -UP  "MA   >:   $W    MX    @    (<   ".
M    E0   )H   "?    I    *@   "L    K0   +    "S    M0   +@
M  "[    OP   ,,   #'    RP4  -$.  #1&P  T"X  ,]%  #-7P  RWX
M ,F>  #(O@  Q>D +VD  "-P   6>0  #8$   &+    DP   )L   "B
MJ    *X   "T    N    +T   #     P@   ,4   #(    RP   ,X   #1
M    U@   -L   #?    Y    .@&  #K$0  ZB,  .HZ  #I5   YW(  .63
M  #CLP  X]0 _P   /\   #_    _P $ /\ "P#_ !  _P 7 /\ (0#_ "L
M_P U /\ /@#_ $< _P!. /\ 50#\ %L ^@!A /@ 9@#V &T ] !S /( >P#O
M (0 [0". .H F0#F *< XP"Y -\ U0#; /< U@#_ ,  _P"R /\ J@#_ *4
M_P"B /\ _P   /\   #^    _    /P  P#^  L _P 1 /\ &@#] "0 ^0 N
M /0 . #P $  [ !( .D 3@#F %0 X@!: -\ 7P#< &4 V !K -0 <@#0 'L
MS0"% ,H D0#' )X PP"N ,  Q0"] .L NP#_ +  _P"D /\ G #_ )@ _P"5
M /\ _P   /H   #T    \0   /(   #J  4 YP . .( %0#A !X X0 H -@
M,0#0 #D RP!  ,@ 1P#% $T P@!3 +\ 6 "] %X NP!D +D :P"V ', M !\
M +$ B "N )4 JP"D *@ N "F -P HP#[ )\ _P"5 /\ CP#_ (L _P") /\
M^0   .\   #G    WP   ,\   #(    P0 * +\ $0"\ !@ NP A +D *@"T
M #( L0 Z *X 0 "K $8 J !, *8 40"C %8 H0!< )\ 8P"= &H FP!S )D
M?@"6 (P E "; )( K0"0 ,< C@#P (T _P"& /\ @ #_ 'T _P!\ /\ [0
M .    #1    OP   +,   "J    I@ % *( #0"A !, H  ; )\ (P"; "L
MF  R )4 .0"3 #\ D0!$ (\ 2@". $\ C !5 (H 6P"( &, A@!K (0 =@""
M (( @ "2 'X HP!\ +H >@#A 'D _P!W /\ <@#_ '  _P!O /\ W0   ,L
M  "V    IP   )T   "4    C@ ! (L "@") !  B  5 (< '0"' "4 A  L
M (( ,@!_ #@ ?0 ] 'L 0P!Y $@ > !. '8 5 !U %L <P!C '$ ;@!O 'H
M;0") &P F@!J *X :0#, &@ ]@!G /\ 90#_ &0 _P!C /\ R@   +0   "A
M    DP   (D   ""    >P   '@ !0!V  P =0 1 '0 & !S !\ <@ E '
M+ !N #( ;  W &H / !I $( : !( &8 3@!E %4 8P!= &( 9@!@ '( 7@"
M %T D@!; *4 6@"^ %D Z0!9 /\ 60#_ %@ _P!8 /\ N0   *(   "0
M@P   'D   !Q    ;0   &D  0!F  D 90 . &0 $P!C !D 8P @ &$ )@!@
M "P 7@ Q %P -P!; #P 6@!" %@ 2 !7 $\ 5@!7 %0 8 !3 &P 40!Y %
MB@!/ )X 3@"T $T V@!- /L 30#_ $T _P!- /\ J@   )0   ""    =0
M &L   !D    8    %T   !:  4 6  , %< $ !6 !4 5@ ; %4 (0!3 "<
M4@ L %$ ,0!/ #< 3@ ] $T 0P!, $H 2@!2 $D 6P!( &8 1@!S $4 A !$
M )< 0P"L $( R0!" /$ 0@#_ $, _P!# /\ G@   (D   !X P  :@0  &$$
M  !: P  50$  %(   !0  ( 3@ ) $T #0!, !$ 2P 7 $H ' !) "( 2  G
M $< +0!% #( 1  X $, /@!" $4 00!- #\ 5@ ^ &$ /0!N #L ?@ Z )$
M.0"F #@ OP X .@ . #_ #D _P Y /\ E0,  ( '  !O"0  8@H  %@+  !1
M"@  3 @  $D&  !' P  1@ & $0 "P!#  \ 0@ 3 $$ & !! !X /P C #X
M*0 ] "X .P T #H .@ Y $$ . !) #< 4@ V %T - !J #, >@ R (P ,0"A
M #  N  O -X +P#Y "\ _P P /\ C D  '@,  !H#0  7 X  %(.  !+#@
M10T  $$,   _"@  /@@" #T$"  \ 0T .P 0 #H %0 Y !H .  @ #8 )0 U
M "L -  P #, -P R #X ,0!& "\ 4  N %H +0!G "L =P J (D *0"= "@
MLP G -$ )P#R "< _P G /\ A@P  '(.  !C$   5A$  $T1  !%$0  0!
M #P/   Y#@  -PT  #8+!  V" H -08. #0%$@ R!!< ,04< # %(@ O!2@
M+@8N "T&-  K!CP *@9$ "D'3@ G!UD )@=E "0'=0 C!X< (@>; " &L  @
M!LL 'P7M !\&_@ ?!_\ @ X  &T1  !>$@  4A,  $@3  !!$P  .Q,  #<2
M   T$0  ,A   # / 0 P#08 , L+ "\*$  M"A0 + L9 "H+'P I"R4 * PK
M "<,,@ F##H ) Q# ",,30 A#5@ ( UE !X-=0 <#8@ &@V< !D-L0 8#,H
M%PSK !<-_  8#/\ >Q$  &D3  !:%0  3A8  $46   ]%@  .!4  #,5   P
M%   +1,  "L2   J$ , *@\( "D.#0 H#A$ )@X6 "4/'0 D#R, (P\I "$0
M,0 @$#D 'A!" !T03  ;$%@ &1!F !<0=@ 5$(D %!"> !(0LP 1$,X $1#N
M !(0_@ 2$/\ =Q,  &45  !7%P  2Q@  $(9   Z&0  -!@  # 7   L%P
M*18  "<5   F% $ )1($ ",2"P B$@\ (1(4 " 2&@ >$R  '1,G !P3+@ :
M$S8 &11  !<42@ 6%%8 %!1D !(4=  1%(< $!2<  X4L0 -%,H #13K  X3
M_@ .$_\ <Q4  &$8  !3&@  2!L  #\;   W&P  ,AH  "T:   I&0  )A@
M "08   B%P  (!8! !X6"  =%@T &Q<2 !H7%P 9%QT &!@D !88*P 5&#0
M%!@] !(92  1&50 $!EB  X9<@ -&80 #!F8  H9K0 )&,8 "1CG  D8^@ *
M%_\ ;Q@  %X:  !0'   11T  #P=   U'0  +QT  "H<   F&P  (QL  "$:
M   >&@  '!H  !H;!0 8&PP %AP0 !4<%0 4'!L $QPB !(=*0 1'3$ $!T[
M  X=10 -'E$ #!Y>  H>;0 )'H  !QZ4  4=J@ #'<(  QWF  0<^  %'/\
M:QH  %L=  !-'@  0A\  #H?   R'P  +1\  "@>   D'@  (1T  !X=   <
M'0  &!X  !4? @ 3( D $B$. ! A$@ 0(1@ #B$?  XB)@ -(BX #"(W  HB
M00 )(DT !R):  4B:0 #(GP  2*1   BJ   (<   "'E   @^   (/\ 9QT
M %<?  !*(0  0"$  #<B   P(0  *B$  "8@   B(   'Q\  !P?   9(
M%B$  !(C @ 0) < #B8,  PF$  +)A4 "B8<  DF(@ ()BH !B<S  0G/0 #
M)TD  2=6   G9@  )WD  ">/   FI@  )K\  "7D   E^0  )/\ 8R   %0B
M  !'(P  /20  #0D   N(P  *",  "0B   A(@  'B$  !HB   7(P  $R0
M ! F @ .* < "RH+  @K#@ &*Q, !"L8  (K'P !+"<  "PP   L.@  +$4
M "Q3   L8P  +'8  "R,   KI   *[X  "KD   J^@  *?\ 7R,  % E  !$
M)@  .B8  #(F   K)@  )B4  ",D   ?)   &R0  !<E   4)P  $2D   XK
M @ ++08 !R\+  0P#@  ,!$  #$5   Q'   ,2,  #(L   R-@  ,D(  #)/
M   R7P  ,G(  #&)   QH@  ,+P  ##D   O^P  +_\ 6B<  $PH  ! *0
M-RD  "\I   I*   )2<  "$F   <)P  &"@  !0J   1+   #BX   LP 0 '
M,@4  S0)   U#   -@\  #<2   X&   ."   #@H   X,@  .3T  #E+   Y
M6P  .&X  #B%   WGP  -[H  #;D   U_   -?\ 52H  $@L   ]+   -"P
M "TK   H*@  )"D  !XJ   9*P  %"T  !$O   -,0  "C0   <V   ". 0
M #H'   ["@  /0T  #X0  ! %   0!L  $ D  ! +@  0#D  $!'  ! 5@
M0&D  $"    _FP  /K<  #WC   \_   //\ 4"\  $,O   Y+P  ,B\  "PM
M   G+   ("T  !HO   5,0  $3,   TV   ).   !3L    ]    0 $  $$$
M  !#!P  10L  $8.  !($0  2A8  $H>  !**   2C0  $E"  !)40  260
M $A[  !(EP  1[0  $;@  !%_   1/\ 2C,  #\S   V,P  ,#$  "HP   C
M,0  '#,  !8U   1.   #3L   @^   #00   $,   !&    2    $H   !,
M!   3@<  $\+  !1#@  5!(  %49  !5(@  5"X  %0\  !42P  4UX  %-T
M  !2D   4:X  %#7  !/^P  3O\ 13<  #PW   U-@  +S0  "8U   >-P
M%SH  !$]   ,00  !T0   !(    2@   $T   !0    4P   %4   !7
M6 (  %L&  !="P  7PX  &(3  !B&P  8B<  &(T  !A10  8%<  &!M  !?
MB0  7:<  %S,  !:^   6?\ 03P  #H[   T.0  *CH  "$\   80   $4,
M  Q'   &2P   $\   !3    5@   %D   !<    7P   &$   !C    90
M &<!  !J!0  ;0H  ' .  !S%0  <B   '(M  !Q/0  <$\  &]E  !N@
M;9\  &O!  !I\0  :/\ /T   #D^   N/P  )$(  !I&   22@  #$\   14
M    6    %T   !A    90   &@   !K    ;@   '$   !S    =0   '@
M  ![    ?@,  ($*  "%#P  AQ<  (8D  "%-   A$8  ()=  "!=@  ?Y8
M 'ZV  !\YP  >O\ /T0  #-%   H2   '4P  !-2   ,5P   UT   !C
M:    &T   !Q    =@   'H   !^    @0   (,   "&    B0   (L   ".
M    D@   )4!  "9"0  GA   )X:  "=*0  G#P  )I2  "8;   EHL  )2J
M  "2U   D/H .$L  "Q.   @4P  %5D   U@   #9P   &X   !T    >@
M (    "$    B@   (X   "2    E0   )<   ":    G0   *    "C
MIP   *L   "O    M D  +@0  "W'@  M3   +-&  "Q8   KWX  *R@  "K
MP0  J>X ,54  "1;   880  #FD   5Q    >0   ($   "(    CP   )0
M  ":    GP   *0   "H    J0   *P   "O    LP   +4   "Y    O0
M ,$   #&    RP   -$*  #3%   T24  - [  #-5   RG$  ,B2  #%LP
MP]X *6(  !QI   1<0  !WL   "$    C0   )4   "=    HP   *D   "O
M    M    +D   "\    O@   ,(   #%    R    ,P   #0    U    -H
M  #?    Y    .H   #N#   [1H  .PO  #J20  Z&4  .:&  #DI0  XL8
M_P   /\   #_    _  ! /P " #^  X _P 4 /\ '0#_ "8 _P P /\ .@#_
M $( _P!) /X 4 #[ %8 ^0!< /8 8@#T &@ \@!O /  =@#M '\ Z@") .<
ME0#D *, X "U -L T #5 /8 R@#_ +8 _P"H /\ GP#_ )H _P"6 /\ _P
M /L   #V    \P   /,   #V  D ^@ . /T %@#[ "  ]P J /( ,P#M #L
MZ0!# .8 20#B $\ W@!5 -L 6P#6 &  T@!G ,\ ;@#, '8 R0"  ,8 C #"
M )H OP"J +L P0"X .D M@#_ *< _P": /\ D@#_ (T _P"* /\ ^@   /$
M  #J    YP   .<   #D  $ X  + -L $0#: !H VP C -$ + #* #0 Q@ [
M ,( 0@"_ $@ O !. +H 4P"X %D M@!? +, 9@"Q &X K@!W *P @P"I )$
MI@"A *, M0"@ -@ G@#[ )4 _P"+ /\ A0#_ (  _P!^ /\ [P   .,   #:
M    TP   ,8   "_    N0 & +< #@"T !0 M  = +, )0"N "T JP T *<
M.P"D $$ H0!& )\ 3 "= %$ FP!7 )D 7@"7 &4 E0!N ), >0"0 (< C@"7
M (P J0") ,0 B #O (4 _P!\ /\ =@#_ ', _P!R /\ X    -    #&
MM@   *D   "A    G0 ! )D "@"8 !  F  6 )< '@"4 "8 D0 M (\ - ",
M #H B@ _ (@ 10"' $H A0!0 (, 5@"! %X @ !F 'X <0!\ 'T >0"- '<
MH !U +8 <P#? '( _P!N /\ :0#_ &< _P!E /\ S    +X   "K    G0
M ),   "*    A0   (( !0"   T ?P 1 '\ & "  "  ?0 F 'H +0!W #,
M=0 X '0 /@!R $, < !) &\ 3P!M %8 ; !> &H : !H '4 9P"$ &4 E@!D
M *L 8@#) &$ ]@!@ /\ 7 #_ %L _P!: /\ O0   *D   "7    B0   'X
M  !X    <P   &\  0!M  D ;  . &L $P!K !D :@ @ &@ )@!F "P 90 R
M &, -P!B #P 8 !" %\ 2 != $\ 7 !7 %H 80!9 &T 5P![ %8 C@!5 *(
M4P"[ %( Z0!2 /\ 4 #_ $\ _P!/ /\ K0   )@   "&    >    &X   !G
M    8P   &    !=  4 7  + %L $ !; !4 6P ; %H (0!8 "8 5@ L %0
M,0!3 #8 4@ \ %$ 0@!/ $D 3@!1 $T 6P!+ &8 2@!T $D A0!( )D 1P"Q
M $8 V !& /P 10#_ $4 _P!% /\ GP   (D   !X    ;    &(   !;
M5@   %,   !1  ( 3P ( $\ #0!. !$ 3@ 6 $T ' !, "$ 2@ F $D + !(
M #$ 1P W $4 /0!$ $0 0P!, $( 50!  &  /P!N #X ?@ ] )( / "I #L
MQP [ /, .P#_ #L _P \ /\ DP   'X   !N    80   %@   !1    3
M $D   !'    10 % $0 "P!#  X 0P 2 $, %P!" !T 0  B #\ )P ^ "P
M/0 R #L .  Z #\ .0!' #@ 4  W %L -0!H #0 >  S (P ,@"B #$ O  Q
M .< ,0#_ #( _P S /\ B0   '8#  !F!0  60<  % '  !)!@  0P4  $ #
M   ^ 0  /  # #L "  Z  T .@ 0 #D %  Y !D -P > #8 (P U "@ -  N
M #, -  R #L , !# "\ 3  N %< +0!D "P <P K (< *@"< "D M0 I -P
M*0#[ "D _P J /\ @00  &X(  !?"@  4PL  $H+  !""P  /0H  #D)   V
M"   -04  #0"!@ S  H ,@ . #$ $0 Q !4 ,  : "\ 'P N "0 +  J "L
M,  J #< *0 _ "@ 20 G %0 )@!@ "0 ;P C (( (@"7 "$ K@ A ,P (0#S
M "$ _P B /\ >PD  &@,  !:#0  3@X  $4.   ]#@  . T  #,-   P#
M+@L  "T) P M!@@ + 0, "L"#P J 1( *0$7 "@!'  G "$ )@ G "4 +0 D
M #0 (P$] "(!1@ A 5$ 'P%= !X!;  < 7\ &P"4 !H J@ : ,4 &@#K !D
M_P : /\ =0P  &0.  !5#P  2A   $ 0   Y$   ,Q   "\/   L#@  *0X
M "<- 0 G# 4 )PH* "8(#0 E!Q  ) 84 "(&&0 A!A\ ( <D !\'*P >!S(
M'0<Z !P(1  :"$\ &0A< !<(:P 6"'T %0>1 !0'IP 3!K\ $@7D !(%^@ 2
M!?\ <0X  %\0  !1$0  1A(  #T2   V$@  ,!(  "L1   H$0  )1   ",0
M   B#@0 (0T' "$,"P @"PX 'PL2 !T+%P <#!P &PPB !H,*0 9##$ & PY
M !8-0P 5#4\ $PU< !(-:P 0#7X #PV2  X-IP -#+X #0S@  T,]0 -#/\
M;1   %P1  !.$P  0Q0  #H4   R%   +10  "@3   E$P  (A(  " 1   >
M$0, '! % !P/"  ;#PP &@X0 !D/%  7#QH %@\A !40*  4$#  $A Y !$0
M1  0$%  #A!=  T0:P ,$'P "Q"0  D0I0 ($+P !Q#?  <0]  '#_\ :1$
M %@4  !+%0  0!8  #<6   P%@  *A8  "85   B%0  'Q0  !T3   :$P(
M&1($ !<2!@ 6$@H %1(. !02$@ 2$A@ $1,> !$3)0 0$RX #A,W  T40  ,
M%$L "Q18  D49P '%'@ !A2-  04HP #$[L  A/=  $2]  "$O\ 91,  %46
M  !(%P  /1@  #08   M&   *!@  ",7   @%P  '18  !H5   8%0( %A4$
M !05!0 2%@@ $18- ! 7$  .%Q4 #A<;  T7(@ ,%RD "Q@R  D8/  '&$<
M!1A4  088P "&'4  1B+   7H0  %[D  !?=   6]0  %O\ 818  %(8  !%
M&@  .QH  #(:   K&@  )1H  "$9   >&   &Q@  !@7   6%P( %!<# !(8
M!0 0&0< #AL+  P;#P +&Q, "AL8  @<'P ''"8 !1PO  0<.  "'$0  !U1
M   =8   '7(  !R(   <H   &[D  !O>   :]@  &O\ 7A@  $\:  !"'
M.!P  "\=   I'   (QP  !\;   <&@  &1D  !<9 0 4&0( $AH# ! ;!  .
M'0< #!X+  D?#@ &(!$ !2 6  ,@'  !(2,  "$K   A-0  (4   "%.   A
M70  (6\  "&&   @G@  (+@  !_>   >^   'O\ 6AL  $L=   _'@  -1\
M "T?   G'@  (AT  !X=   ;'   &!L  !4;   2'   $!T"  X?!  ,(08
M"2(*  4C#0 ")!   "43   E&0  )B   "8H   F,@  )CT  "9*   F6@
M)FP  ":#   EG   );<  "3?   C^0  (_\ 51X  $<@   \(0  ,B$  "LA
M   E(   (!\  !T>   :'0  %AX  !,>   0(   #B$   PC @ ()04 !2<)
M   H"P  *@X  "L1   L%@  +!T  "PE   L+@  +#H  "Q'   L5@  +&D
M "R    KF@  *K4  "G?   I^P  */\ 42(  $0C   X)   +R0  "@C   C
M(@  'R$  !P@   7(   $R$  ! C   .)   "R8   @H   $*@0  "P'   N
M"0  , P  #$/   S$P  ,QD  #,A   S*@  ,S4  #-#   S4@  ,V4  #)[
M   REP  ,;,  ##>   O^P  +O\ 3"4  #\F   U)P  +28  "<E   B)
M'B,  !DC   4)   $28   XH   +*@  !RP   ,O    ,0(  #,$   U!P
M-PH  #D-   Z$   .Q4  #L=   [)@  .S$  #L^   [3@  .V   #IW   Y
MD@  .+   #?;   V_   -?\ 1RD  #LJ   R*@  *RD  "4G   A)@  &R<
M !4H   1*@  #BP   HO   &,0   30    V    .    #L!   ]!   /P<
M $$*  !##@  11$  $48  !%(0  12P  $0Y  !$2   1%L  $-Q  !"C0
M0:L  $#2   _^@  /O\ 0BT  #@N   O+0  *2L  "0J   =*@  %RP  !$N
M   -,0  "30   0W    .@   #P    _    00   $0   !&    2 ,  $H'
M  !,"P  3@X  % 3  !0'   4"<  $\T  !/0P  3U4  $YJ  !-A@  3*0
M $K*  !)^   2/\ /C(  #4Q   N+P  *2X  " N   9,0  $C,   XW   )
M.@   CT   !     1    $<   !)    3    $\   !1    4P   %4!  !8
M!@  6@L  %T.  !?%0  7B   %XL  !=/   7$X  %MC  !:?@  6)T  %?
M  !5\@  5/\ .C8  #,T   M,@  )#,  !LV   3.0  #CT   A!    10
M $D   !,    4    %,   !6    60   %L   !=    8    &(   !E
M: 4  &L+  !O$   ;Q@  &XE  !M-   ;48  &M;  !J=0  :)0  &:V  !D
MZ0  8O\ .#D  #(W   H.0  'CL  !4_   .1   !TD   !-    4@   %8
M  !:    7@   &(   !E    :    &L   !M    <    ',   !V    >0
M 'T$  "!"P  A1$  (0=  ""+   @#X  'Y4  !^:P  >XH  'JJ  !WU@
M=?T .#T  "P^   B00  %T8   ]+   '40   %<   !<    8@   &8   !K
M    ;P   '0   !X    >P   'X   "     @P   (8   "*    C0   )$
M  "6 P  FPP  )T3  ";(0  FC,  )=)  "48@  DW\  )"@  ".Q0  C/,
M,40  "5(   :30  $%,   A:    80   &@   !N    =    'D   !_
MA    (D   "-    D0   ),   "6    F0   )T   "@    I    *@   "L
M    L@,  +<-  "W%P  M2@  +(^  "P5@  K',  *J4  "IM   I>4 *D\
M !Y4   26P  "F(   !J    <P   'L   ""    B0   (X   "4    F@
M )\   "D    I@   *D   "M    L    +,   "W    NP   ,    #%
MRP   -$$  #5#@  TQT  - R  #-2P  RF8  ,:'  #"J0  P<L (EL  !9B
M   ,:P   70   !]    AP   )    "7    G@   *0   "K    L0   +8
M  "Z    O    ,    #$    R    ,L   #/    U    -H   #@    Y@
M .L   #Q!@  \!,  .XG  #L/P  ZEL  .=Z  #DFP  X+L _P   /L   #V
M    \P   /0 !0#V  P ^@ 1 /\ &0#_ "( _P L /\ -0#_ #T _P!% /P
M3 #Z %( ]P!8 /4 7@#S &0 \0!J .X <@#L 'H Z0"% .4 D0#A *  W0"R
M -@ S@#2 /8 P0#_ *T _P"> /\ E@#_ )  _P", /\ ^@   /(   #L
MZ0   .D   #L  4 \@ , /@ $@#W !L ]0 E /  +@#K #< Y@ ^ .( 10#=
M $L V !0 -, 5@#0 %P S0!B ,H :@#( '( Q0!\ ,( B "^ )8 N@"H +<
MOP"T .@ K@#_ )T _P"0 /\ B #_ (, _P"  /\ \    .4   #>    V@
M -L   #<    V  ' -$ #@#1 !4 T@ > ,L )P#% "\ P  W +T /0"Z $0
MMP!) +4 3P"R %4 L !; *X 80"L &D J0!S *< ?P"D (T H0"> )X L@";
M -4 F0#\ (P _P"" /\ >P#_ '8 _P!T /\ X@   -,   #*    QP   +P
M  "V    L  ! *\ "P"L !$ K0 8 *T ( "H "@ I  O *  -@"= #P FP!"
M )D 1P"7 $T E0!3 ), 60"1 &$ CP!J (P =0"* (, B "4 (8 IP"# ,(
M@@#P 'P _P!S /\ ;0#_ &H _P!H /\ SP   ,$   "Y    K0   *    "8
M    E    )$ !@"0  T D  2 (\ &0". "$ BP H (@ +P"& #4 A  Z ((
M0 "  $4 ?@!+ 'P 4@!Z %D > !B '8 ; !T 'D <@") '$ G0!O +0 ;0#?
M &P _P!E /\ 8 #_ %X _P!< /\ O@   +$   "@    D@   (D   ""
M?    'H  0!X  D =P . '@ % !W !H =  A '( )P!P "T ;@ S &P . !K
M #X :0!$ &@ 2@!F %$ 9 !: &, 9 !A '  7P!_ %X DP!= *D 7 #( %L
M]P!7 /\ 5 #_ %( _P!1 /\ L    )\   "-    ?P   '0   !N    :@
M &8   !E  0 8P + &, $ !C !4 8P ; &$ (0!? "< 70 L %P ,@!: #<
M60 ] %< 0P!6 $L 50!3 %, 7 !2 &@ 4 !W $\ B0!. )\ 30"Z $P Z0!+
M /\ 20#_ $< _P!' /\ H@   (T   !\    ;@   &4   !>    60   %<
M  !5  $ 5  ' %, #0!3 !$ 5  6 %( &P!1 "$ 3P F $X *P!, #$ 2P W
M $H /0!) $0 1P!, $8 5@!$ &$ 0P!P $( @0!! )< 0 "O #\ UP _ /\
M/@#_ #T _P ^ /\ E    '\   !O    8P   %D   !1    30   $H   !(
M    1P $ $< "@!&  X 1@ 1 $< %@!% !P 1  A $( )@!! "L 0  Q #X
M-P ] #X / !' #H 4  Y %L . !I #< >@ V (\ -0"G #4 Q@ T /4 - #_
M #0 _P U /\ B    '0   !E    6    $\   !(    0P   #\    ]
M/  " #P !P [  P .P / #L $@ Z !< .0 < #< (0 V "8 -0 L #0 ,@ S
M #D ,0!! #  2P O %8 +@!C "T <P L (@ + "@ "L NP K .H *P#_ "L
M_P L /\ ?P   &P   != 0  40(  $@#  !  P  .P(  #<    T    ,P
M #( !0 R  D ,@ - #$ $  Q !, ,  8 "\ '0 M "( +  H "L +@ J #4
M*0 ] "@ 1@ G %$ )@!> "4 ;@ D (( (P"9 ", LP B -X (@#_ ", _P D
M /\ =P   &4$  !6!@  2P<  $((   Z"   -0<  # &   M!0  + ,  "L
M P J  < *0 + "D #@ I !$ *  5 "< &0 F !X )0 D "0 *@ C #$ (@ Y
M "$ 0P @ $X 'P!: !X :0 = 'P ' "3 !L K  ; ,T &P#V !L _P < /\
M< 4  %\(  !1"@  1@L  #T+   U"P  , L  "L*   H"0  )0@  "0' @ C
M! 8 (P() "(!#  B  \ (0 2 "  %@ ? !L '@ @ !T )@ < "X &P V !H
M/P 9 $H & !7 !< 9@ 6 '@ %0"/ !4 I@ 4 ,, % #N !0 _P 5 /\ :P@
M %L+  !-#   0@T  #D-   Q#0  + T  "<-   C#   (0P  !\+ 0 >"@4
M'0@( !T&"P <!0T ' 00 !L$%  9!!@ &00> !@$(P 7!"L %@0S !4$/  4
M!$< $P-4 !(#8P 1 W4 $ ** ! !H@ / +P #P#E  \ _@ 0 /\ 9PL  %<-
M  !)#@  /@\  #4/   N#P  * \  "0.   @#@  '0X  !L- 0 9#00 & P'
M !@+"0 7"0P %PD. !8)$@ 5"18 % D; !,)(0 2"2@ $@DP !$).@ 0"44
M#PE2  X)80 -"7, # B(  L(GP *![< "@;;  H%]@ *!/\ 8PT  %,.  !&
M$   .Q$  #(1   K$0  )1   "$0   =$   &@\  !@/ 0 6#@0 %0X' !0-
M"0 3#0L $PP- !(,$  1#!0 $ P9 ! ,'P /#"< #@TO  T-.0 ,#44 "PU1
M  D-8  (#7$ !@V&  4-G0 $#+0  PS2  (,\0 ""_\ 7PX  % 0  !#$0
M.!(  "\2   H$@  (Q(  !X1   ;$0  &!$  !40 @ 4$ 4 $A ' !$/"0 0
M#PH $ X,  X.#@ .#Q( #0\7  P0'0 ,$"0 "A L  D0-@ ($$$ !A!.  40
M70 #$&\  1"$   0G   #[0   [4   .\P  #O\ 7!   $T2  ! $P  -A0
M "T4   F%   (1,  !P3   9$@  %A(  !01 P 2$08 $1$( ! 0"@ .$ L
M#1$+  P1#0 +$A$ "A(5  D2&@ ($B$ !A,I  43,P #$SX  A-+   36@
M$VP  !."   2FP  $K0  !'7   1]0  $?\ 6!(  $D4   ]%0  ,Q8  "L6
M   D%0  'Q4  !H4   7%   %!,! !,2!  1$@< $!()  X2"0 -$@D "Q,*
M  D4#0 '%0\ !A83  06&  #%A\  A8G   7,   %SL  !=(   76   %VH
M !:    6F0  %;0  !79   4]P  $_\ 510  $86   Z%P  ,!@  "@8   B
M%P  '18  !D6   6%0  $Q0# !(3!@ 0$P< #Q,'  T4!P +%0@ "18)  88
M#  #&@X  1H1   :%@  &QP  !LD   ;+0  &S@  !M&   <50  &V<  !M]
M   ;EP  &K,  !G;   8^0  %_\ 418  $,8   W&0  +AH  "8:   @&0
M&Q@  !@7   5%@$ $Q4% !$5!  /%00 #18$  L7!0 )&08 !AH(  (<"@
M'@T  " 0   @$P  (!D  " A   A*@  (34  "%"   A4@  (&0  "!Z   ?
ME0  '[$  ![;   =^@  '/\ 31D  #\;   T'   *QP  "0<   >&P  &AH
M !<8   4%P( $A<" ! 8 0 -&0$ "QH"  @< P %'00  A\&   A"   (PL
M "4.   F$0  )A8  "8>   G)P  )S(  "<_   F3@  )F   "9W   ED@
M)*\  "/:   B^P  (?\ 2!T  #P>   Q'P  *!X  "(>   ='   &1L  !8:
M   2&@  $!L   T<   +'0  "!\   0A   !(P(  "4$   G!@  *0D  "P,
M   N#P  +A,  "X:   N(P  +BX  "X[   N2@  +5P  "UR   LC@  *ZP
M "K4   I^P  */\ 1"   #@A   N(0  )B$  " @   <'@  &!T  !0=   0
M'@  #A\   LA   '(P   R4    G    *0   "P!   N P  , 8  #,*   U
M#0  -A$  #87   V'P  -BD  #8V   V10  -5<  #5M   TB0  ,J@  #'/
M   P^@  +_\ /R0  #0D   K)   )",  !\A   ;(   %B   !$A   .(P
M"B4   8H   "*@   "T    O    ,@   #0    W    .0,  #L&   ^"@
M0 X  $$2  !!&@  0"4  $ Q  ! 0   /U(  #YG   ]@@  /*(  #K'   Y
M^   ./\ .B@  # H   I)P  (R4  !\C   8)   $B4   XH   **@  !2T
M   P    ,P   #8    X    .P   #X   !     0@   $4"  !'!@  2@H
M $T.  !-%0  3!\  $PK  !+.@  2DP  $EA  !(?   1YL  $6_  !#\P
M0O\ -BP  "TK   G*0  (R<  !LH   4*@  #BT   HP   $,P   #<    Z
M    /0   $    !#    1@   $@   !+    30   %    !3 0  5@8  %D+
M  !;$   6QD  %HE  !9-   6$8  %=:  !5=   5),  %*U  !0Z@  3_\
M,S   "PN   G+   'BT  !8O   0,@  "C8   ,Z    /P   $(   !&
M20   $P   !/    4@   %4   !8    6@   %T   !@    8P   &<&  !K
M#   ;!(  &L>  !K+   :3T  &=2  !F:@  9(D  &&K  !?W   7?\ ,3,
M "PQ   B,@  &34  !$Y   */0   D(   !'    3    %    !4    6
M %L   !?    8@   &4   !H    :P   &X   !Q    =0   'D   !]!@
M@@T  ((6  " )   ?C4  'Q)  ![80  >'\  ':?  !SQ@  </< ,38  "8X
M   <.P  $D    M%   "2P   %$   !6    6P   &    !E    :0   &X
M  !R    =@   'D   !\    ?@   ((   "%    B0   (X   "3    F 8
M )P.  ";&@  F"L  )9   "260  D7,  (V5  "+M0  B.@ *SX  "!!   5
M1P  #4T   )4    6P   &$   !H    ;@   ',   !Y    ?@   (,   "(
M    C    (\   "2    E0   )D   "=    H0   *4   "J    L    +<'
M  "X$0  M2$  +(U  "O30  JFD  *B(  "FJ   HM$ (T@  !A.   .5
M!%P   !D    ;0   '4   !\    @P   (D   "/    E0   )L   "@
MHP   *8   "I    K0   +$   "U    N0   +X   #$    R@   -(   #:
M"@  UA8  -(I  #.00  REP  ,5\  #"G0  P;T '%4  !%<   '90   &X
M  !W    ?P   (@   "0    F    )\   "E    K0   +,   "X    N@
M +X   #"    Q@   ,H   #.    TP   -H   #@    YP   .T   #S
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M^_S^______________________________________________________\
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M\/'R\_3U]O?X^?K[_/W^_VUF=#$      P0A   !
M 0                    $    ! @,$!08'" D*"PP-#@\0$1(3%!46%Q@9
M&AL<'1X?("$B(R0E)B<H*2HK+"TN+S Q,C,T-38W.#DZ.SP]/C] 04)#1$5&
M1TA)2DM,34Y/4%%24U155E=865I;7%U>7V!A8F-D969G:&EJ:VQM;F]P<7)S
M='5V=WAY>GM\?7Y_@(&"@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F:FYR=GI^@
MH:*CI*6FIZBIJJNLK:ZOL+&RL[2UMK>XN;J[O+V^O\#!PL/$Q<;'R,G*R\S-
MSL_0T=+3U-76U]C9VMO<W=[?X.'BX^3EYN?HZ>KK[.WN[_#Q\O/T]?;W^/GZ
M^_S]_O\  0$" @,#! 0%!@8'!P@("0D*"PL,# T-#@\/$! 1$1(3$Q04%186
M%Q<8&1D:&AL<'!T>'A\@("$B(B,D)"4F)B<H*2DJ*RPM+2XO,#$R,C,T-38W
M.#DZ.SP]/C] 0D-$149(24I,34]04E-55UA:7%Y@8F1F:&IM;W%T=GE\?H&#
MAHF+CI"2E9>9FYV?H:.EIZBJK*VOL+*SM;:WN;J[O+V_P,'"P\3%QL?(R<K+
MS,W-SL_0T=+2T]35UM;7V-G9VMO;W-W=WM_?X.'AXN/CY.7EYN;GZ.CIZ>KK
MZ^SL[>[N[^_P\/'R\O/S]/3U]O;W]_CX^?GZ^_O\_/W]_O[_  $! @(# P0$
M!08&!P<(" D)"@L+# P-#0X/#Q 0$1$2$Q,4%!46%A<7&!D9&AH;'!P='AX?
M(" A(B(C)"0E)B8G*"DI*BLL+2TN+S Q,C(S-#4V-S@Y.CL\/3X_0$)#1$5&
M2$E*3$U/4%)355=86EQ>8&)D9FAJ;6]Q='9Y?'Z!@X:)BXZ0DI67F9N=GZ&C
MI:>HJJRMK["RL[6VM[FZN[R]O\#!PL/$Q<;'R,G*R\S-S<[/T-'2TM/4U=;6
MU]C9V=K;V]S=W=[?W^#AX>+CX^3EY>;FY^CHZ>GJZ^OL[.WN[N_O\/#Q\O+S
M\_3T]?;V]_?X^/GY^OO[_/S]_?[^__^E)0;_I# ._Z8Z&/^Q0R/_NTLR_\%5
M1?[#7EKRQ&5PY,)LAM>Z<)G,LG2JPZMVM[VF><*WH7W+L9V"TZN:B=REEY7F
MI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:E
MEY7FI9>5YJ67E>:EEY7FI9>5YO^E)0;_I# ._Z8Z&/^Q0R/_NTLR_\%51?[#
M7EKRQ&5PY,)LAM>Z<)G,LG2JPZMVM[VF><*WH7W+L9V"TZN:B=REEY7FI9>5
MYJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7F
MI9>5YJ67E>:EEY7FI9>5YO^E)0;_I# ._Z8Z&/^Q0R/_NTLR_\%51?[#7EKR
MQ&5PY,)LAM>Z<)G,LG2JPZMVM[VF><*WH7W+L9V"TZN:B=REEY7FI9>5YJ67
ME>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5
MYJ67E>:EEY7FI9>5YO^E)0;_I# ._Z8Z&/^Q0R/_NTLR_\%51?[#7EKRQ&5P
MY,)LAM>Z<)G,LG2JPZMVM[VF><*WH7W+L9V"TZN:B=REEY7FI9>5YJ67E>:E
MEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67
ME>:EEY7FI9>5YO^E)0;_I# ._Z8Z&/^Q0R/_NTLR_\%51?[#7EKRQ&5PY,)L
MAM>Z<)G,LG2JPZMVM[VF><*WH7W+L9V"TZN:B=REEY7FI9>5YJ67E>:EEY7F
MI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:E
MEY7FI9>5YO^E)0;_I# ._Z8Z&/^Q0R/_NTLR_\%51?[#7EKRQ&5PY,)LAM>Z
M<)G,LG2JPZMVM[VF><*WH7W+L9V"TZN:B=REEY7FI9>5YJ67E>:EEY7FI9>5
MYJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7F
MI9>5YO^E)0;_I# ._Z8Z&/^Q0R/_NTLR_\%51?[#7EKRQ&5PY,)LAM>Z<)G,
MLG2JPZMVM[VF><*WH7W+L9V"TZN:B=REEY7FI9>5YJ67E>:EEY7FI9>5YJ67
ME>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5
MYO^E)0;_I# ._Z8Z&/^Q0R/_NTLR_\%51?[#7EKRQ&5PY,)LAM>Z<)G,LG2J
MPZMVM[VF><*WH7W+L9V"TZN:B=REEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:E
MEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YO^E
M)0;_I# ._Z8Z&/^Q0R/_NTLR_\%51?[#7EKRQ&5PY,)LAM>Z<)G,LG2JPZMV
MM[VF><*WH7W+L9V"TZN:B=REEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7F
MI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YO^E)0;_
MI# ._Z8Z&/^Q0R/_NTLR_\%51?[#7EKRQ&5PY,)LAM>Z<)G,LG2JPZMVM[VF
M><*WH7W+L9V"TZN:B=REEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5
MYJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YO^E)0;_I# .
M_Z8Z&/^Q0R/_NTLR_\%51?[#7EKRQ&5PY,)LAM>Z<)G,LG2JPZMVM[VF><*W
MH7W+L9V"TZN:B=REEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67
ME>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YO^E)0;_I# ._Z8Z
M&/^Q0R/_NTLR_\%51?[#7EKRQ&5PY,)LAM>Z<)G,LG2JPZMVM[VF><*WH7W+
ML9V"TZN:B=REEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:E
MEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YO^E)0;_I# ._Z8Z&/^Q
M0R/_NTLR_\%51?[#7EKRQ&5PY,)LAM>Z<)G,LG2JPZMVM[VF><*WH7W+L9V"
MTZN:B=REEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7F
MI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YO^E)0;_I# ._Z8Z&/^Q0R/_
MNTLR_\%51?[#7EKRQ&5PY,)LAM>Z<)G,LG2JPZMVM[VF><*WH7W+L9V"TZN:
MB=REEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5
MYJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YO^E)0;_I# ._Z8Z&/^Q0R/_NTLR
M_\%51?[#7EKRQ&5PY,)LAM>Z<)G,LG2JPZMVM[VF><*WH7W+L9V"TZN:B=RE
MEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67
ME>:EEY7FI9>5YJ67E>:EEY7FI9>5YO^E)0;_I# ._Z8Z&/^Q0R/_NTLR_\%5
M1?[#7EKRQ&5PY,)LAM>Z<)G,LG2JPZMVM[VF><*WH7W+L9V"TZN:B=REEY7F
MI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:E
MEY7FI9>5YJ67E>:EEY7FI9>5YO^E)0;_I# ._Z8Z&/^Q0R/_NTLR_\%51?[#
M7EKRQ&5PY,)LAM>Z<)G,LG2JPZMVM[VF><*WH7W+L9V"TZN:B=REEY7FI9>5
MYJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7F
MI9>5YJ67E>:EEY7FI9>5YO^F)0;_I# ._Z<Z&/^R0R+_O$LR_\-41?S&75KQ
MR&1QX\9JA]; ;YO+N'*LPK%TNKNM=\2TJ7O-JZ-_U**>A=N9FH[AF9J.X9F:
MCN&9FH[AF9J.X9F:CN&9FH[AF9J.X9F:CN&9FH[AF9J.X9F:CN&9FH[AF9J.
MX9F:CN&9FH[AF9J.X?^F)0;_I3 ._Z@Z%_^S0R+_ODLQ_\541?G)7%OOS6-Q
MX\QIB-7&;9S)OW"NO;9RNK2P=<.KJGC*HJ5\T9FA@=B0G8G=D)V)W9"=B=V0
MG8G=D)V)W9"=B=V0G8G=D)V)W9"=B=V0G8G=D)V)W9"=B=V0G8G=D)V)W9"=
MB=V0G8G=D)V)W?^F)0;_I3 ._ZHZ%_^U0R+_P$LQ_<A31?;-6UOMT6%RX=!G
MB='+:YW"P&ZMMK=QN*RQ<\&CK';(FJAYSI*D?M2)H(78B:"%V(F@A=B)H(78
MB:"%V(F@A=B)H(78B:"%V(F@A=B)H(78B:"%V(F@A=B)H(78B:"%V(F@A=B)
MH(78B:"%V/^G)0;_I3 ._ZLZ%_^V0R'_P4LQ^LM21//16EKJV6!RWM9EB<O,
M:IR[P6VKK[EPMJ6T<KZ<KW3$E*MWRHNG>\^$I('4A*2!U(2D@=2$I('4A*2!
MU(2D@=2$I('4A*2!U(2D@=2$I('4A*2!U(2D@=2$I('4A*2!U(2D@=2$I('4
MA*2!U/^G)0;_IC ._ZTZ%O^X0B'^Q$HP]\Y21/#66%KGX%YRUMIDB,3-:9JT
MPVRHJ+MOLIZV<+J6LG+ CJYVQH:J>LI_IW_.?Z=_SG^G?\Y_IW_.?Z=_SG^G
M?\Y_IW_.?Z=_SG^G?\Y_IW_.?Z=_SG^G?\Y_IW_.?Z=_SG^G?\Y_IW_.?Z=_
MSO^H)0;_IS ._ZXY%O^Z0B#[QDHO]--10^O=5UKCYEQQSMMDA[W/:9BNQ6NE
MHKYNKYBY;[:0M7&\B+%TP8&N>,5[K'W)>ZQ]R7NL?<E[K'W)>ZQ]R7NL?<E[
MK'W)>ZQ]R7NL?<E[K'W)>ZQ]R7NL?<E[K'W)>ZQ]R7NL?<E[K'W)>ZQ]R?^H
M) ;_IS -_[ Y%?^]0A_WR4HO[]A00N;C55G<Z%MPQMUCA;;1:)6GR&NAG,%M
MJI.\;[&*N7&VA+5TNWVR=[]WL'S"=[!\PG>P?,)WL'S"=[!\PG>P?,)WL'S"
M=[!\PG>P?,)WL'S"=[!\PG>P?,)WL'S"=[!\PG>P?,)WL'S"=[!\PO^I) 7_
MJ# -_[,Y%/[ 0A[SS4HMZ=U/0.'I4UG3ZEMOO]]C@J_39Y&ARVJ=EL5MI8W
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MST8BX=]+--CK3TS/\U1BO.A>=*O>9(2=U&F0D<YMF8?);Z" Q7*E>L)TJ73
M>*QPOGNO:[R LFB[A+-HNX2S:+N$LVB[A+-HNX2S:+N$LVB[A+-HNX2S:+N$
MLVB[A+-HNX2S:+N$LVB[A+-HNX2S:+N$L_^F(03_J"L*_[@T#?/'/13DV$4>
MUN9)-<OQ3DS$]U-?L>Q=<*'B9'V5VVF'BM5NCX+0<95[S72:=LMWG7')>:!M
MQWVB:<6!I6;$A:9FQ(6F9L2%IF;$A:9FQ(6F9L2%IF;$A:9FQ(6F9L2%IF;$
MA:9FQ(6F9L2%IF;$A:9FQ(6F9L2%IO^H( 3_KBH(_+\S"^G//!#7X4(>RNU)
M-;_X34JW^U);IO%=:9CI972,XFI]@]UOA'S:<XEWUW>,<]5ZCV_3?9%LT8"4
M:-"$EF7/AY=ESX>79<^'EV7/AY=ESX>79<^'EV7/AY=ESX>79<^'EV7/AY=E
MSX>79<^'EV7/AY=ESX>79<^'E_^J( /_M2D&\,@Q!]K=,PS+ZD(AOO9(-;+_
M3$:I_U%5F_==8([P96J%ZVQQ?>=Q=G?D=GISXGE];^%\?VS?@(%IWH.#9]V'
MA67<B89EW(F&9=R)AF7<B89EW(F&9=R)AF7<B89EW(F&9=R)AF7<B89EW(F&
M9=R)AF7<B89EW(F&9=R)AO^M'P/YOR4#W]8B LOH,@^^]$$BL/]%,Z3_2D&<
M_U%-C_Y=5H7Y9EY]]&YD=O)S:'+O>&MN[GQM;.U_;VKL@G!GZH5R9>J)<V/I
MC'1CZ8QT8^F,=&/IC'1CZ8QT8^F,=&/IC'1CZ8QT8^F,=&/IC'1CZ8QT8^F,
M=&/IC'1CZ8QT8^F,=/^V' +HS10!S.8=!+[S,1*Q_SXBH_]"+Y;_2#J-_U!$
MA/]<2WO_9U%T_FY6;_QS66S[>%MI^7Q=9_A_7F;X@U]D]X9@8O:)86'VC&)A
M]HQB8?:,8F'VC&)A]HQB8?:,8F'VC&)A]HQB8?:,8F'VC&)A]HQB8?:,8F'V
MC&)A]HQB8?:,8O/$#P#.V@L O?,=!['_,A2C_SH?E?\_*HG_1C. _T\Z>/];
M0''_9D5L_VU(:/]S2F;_=TQD_WM-8O]_3F'_@D]@_X507O^)45[_BU%>_XM1
M7O^+45[_BU%>_XM17O^+45[_BU%>_XM17O^+45[_BU%>_XM17O^+45[_BU%>
M_XM17O^+4<S+"0"^Y@P!K_\>":3_,!.5_S4<A_\\)'S_1"MS_TTQ;/]8-6?_
M8SEC_VL[8?]Q/5__=3Y=_WD_7/]\0%O_?T%:_X)!6?^&0EC_B$)8_XA"6/^(
M0EC_B$)8_XA"6/^(0EC_B$)8_XA"6/^(0EC_B$)8_XA"6/^(0EC_B$)8_XA"
M6/^(0O^9'P7_EBL+_Y4V$O^@/AK_J$<F_ZY1-/^O6T7_K657^*EO:.VC>'GC
MFW^'VY*%E-2+C)[/A9&FRX"5K,=\F;'%>9ZUPG:CN<!TJKR]<;*^N6^QO[EO
ML;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^Q
MO_^9'P7_EBL+_Y4V$O^@/AK_J$<F_ZY1-/^O6T7_K657^*EO:.VC>'GCFW^'
MVY*%E-2+C)[/A9&FRX"5K,=\F;'%>9ZUPG:CN<!TJKR]<;*^N6^QO[EOL;^Y
M;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO_^9
M'P7_EBL+_Y4V$O^@/AK_J$<F_ZY1-/^O6T7_K657^*EO:.VC>'GCFW^'VY*%
ME-2+C)[/A9&FRX"5K,=\F;'%>9ZUPG:CN<!TJKR]<;*^N6^QO[EOL;^Y;[&_
MN6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO_^9'P7_
MEBL+_Y4V$O^@/AK_J$<F_ZY1-/^O6T7_K657^*EO:.VC>'GCFW^'VY*%E-2+
MC)[/A9&FRX"5K,=\F;'%>9ZUPG:CN<!TJKR]<;*^N6^QO[EOL;^Y;[&_N6^Q
MO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO_^9'P7_EBL+
M_Y4V$O^@/AK_J$<F_ZY1-/^O6T7_K657^*EO:.VC>'GCFW^'VY*%E-2+C)[/
MA9&FRX"5K,=\F;'%>9ZUPG:CN<!TJKR]<;*^N6^QO[EOL;^Y;[&_N6^QO[EO
ML;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO_^9'P7_EBL+_Y4V
M$O^@/AK_J$<F_ZY1-/^O6T7_K657^*EO:.VC>'GCFW^'VY*%E-2+C)[/A9&F
MRX"5K,=\F;'%>9ZUPG:CN<!TJKR]<;*^N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y
M;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO_^9'P7_EBL+_Y4V$O^@
M/AK_J$<F_ZY1-/^O6T7_K657^*EO:.VC>'GCFW^'VY*%E-2+C)[/A9&FRX"5
MK,=\F;'%>9ZUPG:CN<!TJKR]<;*^N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_
MN6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO_^9'P7_EBL+_Y4V$O^@/AK_
MJ$<F_ZY1-/^O6T7_K657^*EO:.VC>'GCFW^'VY*%E-2+C)[/A9&FRX"5K,=\
MF;'%>9ZUPG:CN<!TJKR]<;*^N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^Q
MO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO_^9'P7_EBL+_Y4V$O^@/AK_J$<F
M_ZY1-/^O6T7_K657^*EO:.VC>'GCFW^'VY*%E-2+C)[/A9&FRX"5K,=\F;'%
M>9ZUPG:CN<!TJKR]<;*^N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EO
ML;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO_^9'P7_EBL+_Y4V$O^@/AK_J$<F_ZY1
M-/^O6T7_K657^*EO:.VC>'GCFW^'VY*%E-2+C)[/A9&FRX"5K,=\F;'%>9ZU
MPG:CN<!TJKR]<;*^N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y
M;[&_N6^QO[EOL;^Y;[&_N6^QO_^9'P7_ERL+_Y<V$O^A/AK_JD8E_[!0-/^Q
M6D7_L&17]ZQM:>RG=WOAGGV*V9:#E]&.B:++B(ZKQX*3L<1^E[?!>IR[OG>B
MO[QUJL*U<:[#LW*OP;-RK\&S<J_!LW*OP;-RK\&S<J_!LW*OP;-RK\&S<J_!
MLW*OP;-RK\&S<J_!LW*OP?^9'P7_ERH*_Y@U$O^C/1K_K$8E_[-/-/^T64;_
MM&-8]K%L:^JM=7W?HWN-U9N!G,V2AJC'BXJQPH6/N;^ E+Z[?)K#N7FAQ[5V
MJ<JM=:S&JW:MQ*MVK<2K=JW$JW:MQ*MVK<2K=JW$JW:MQ*MVK<2K=JW$JW:M
MQ*MVK<2K=JW$JW:MQ/^:'P3_F"H*_YHT$O^E/1G_KD8E_[5.-/^W6$;_MV%9
M];5J;.FR<W_=J'B0TY]^H,J6@JS$CH>WOHB,O[J#D<6W?YC+M'RASZMXI<^E
M>:K(I'FLQJ1YK,:D>:S&I'FLQJ1YK,:D>:S&I'FLQJ1YK,:D>:S&I'FLQJ1Y
MK,:D>:S&I'FLQO^:'P3_F"H*_YLT$?^F/1G_KT4E_[=.-/^Z5T;_NV!9]+EI
M;>>V<8'<K':3T*1[H\B:?[' DX2\NXR)Q;>(D,NTAIG.LH:DT:1\I-&??:G*
MGGVJR)Y]JLB>?:K(GGVJR)Y]JLB>?:K(GGVJR)Y]JLB>?:K(GGVJR)Y]JLB>
M?:K(GGVJR/^;'P3_F2H*_YPT$?^G/!G_L44D_[E--/^\5T;^OE]9]+UG;N>Z
M;X+:L725SZAYIL6??;2^EX' N92*QK61DLNOC9C/JHJATIZ"H].9@:C,F(*I
MRIB"J<J8@JG*F(*IRIB"J<J8@JG*F(*IRIB"J<J8@JG*F(*IRIB"J<J8@JG*
MF(*IRO^;'P3_F2H*_YTT$?^I/!C_LD4D_[M-,_^_5D;]P5Y:\\%F;^:_;8/9
MMG.7S:UWJ,2E>[>^H8/ MIN)QJZ5C\RHD97/HHZ>TIF'HM.4AJ?-DX:HRY.&
MJ,N3AJC+DX:HRY.&J,N3AJC+DX:HRY.&J,N3AJC+DX:HRY.&J,N3AJC+DX:H
MR_^;'P3_F2H*_YXS$?^J/!C_LT4D_[Q,,__!54;[Q%U:\\5E;^7#;(38NW&8
MS+)UJ\.M?+:YI8&_L)Z&QJB9C,NAE9+0FY*;TY2.HM2/BJ;.CXJHRX^*J,N/
MBJC+CXJHRX^*J,N/BJC+CXJHRX^*J,N/BJC+CXJHRX^*J,N/BJC+CXJHR_^;
M'P3_FBH*_Y\S$/^K/!C_M40C_[Y,,_[#547YQUQ:\<ED;^7(:H76P6^:RKET
MJKZP>K:SJ7^_JJ*$QJ*=BLN;FI#/E9>9TH^4HM2*D*;.BH^HS(J/J,R*CZC,
MBH^HS(J/J,R*CZC,BH^HS(J/J,R*CZC,BH^HS(J/J,R*CZC,BH^HS/^<'P3_
MFBH*_Z S$/^L/!C_MD0C_[],,OS&5$7VREQ:[\UB<.3-:(;3Q6V:Q;QSJKFT
M>+6NK7V^I:>"Q9VBB,N5GX[/CYR6THN<HM.&E:;.AI2GS(:4I\R&E*?,AI2G
MS(:4I\R&E*?,AI2GS(:4I\R&E*?,AI2GS(:4I\R&E*?,AI2GS/^<'P3_FBD*
M_Z(S$/^M.Q?_MT0C_\%,,OG)4T7SS5I:[-)@<.#09H;.R&R:P+]QJ;2X=[6I
ML7R^GZR!Q9>HALJ0I(S.BJ*5T86BH=*!G*;.@9JGS(&:I\R!FJ?,@9JGS(&:
MI\R!FJ?,@9JGS(&:I\R!FJ?,@9JGS(&:I\R!FJ?,@9JGS/^<'@3_FRD*_Z,S
M$/^O.Q?_N40B_<-+,?;,4D3PTEE9Z-I?<-O59(;)S&J9NL-OJ*V[=+2BM'F]
MF*]]PY"L@\B)J8G,@Z>1SWZFG-!]I*;-?**HRWRBJ,M\HJC+?**HRWRBJ,M\
MHJC+?**HRWRBJ,M\HJC+?**HRWRBJ,M\HJC+?**HR_^='@3_FRD*_Z4R#_^Q
M.Q;_O$0A^L9+,?/144/KVE=9X]]=;]/;8X7"SVF7L<1MIZ2\<+*8M72[CK%X
MPH:M?<: JX+*>JF*S7:HE,YVJ:/,=ZNHRG>KJ,IWJZC*=ZNHRG>KJ,IWJZC*
M=ZNHRG>KJ,IWJZC*=ZNHRG>KJ,IWJZC*=ZNHRO^='@3_G"D*_Z<R#_^S.Q;_
MOD,@]<I++^[64$+FX597W.1;;LO>8X.ZT6B4J<=LHYN^;JZ0N'&WAK1TO7ZP
M>,)WKGS&<JR#R6VKC,IMJYG);JR?QVZLG\=NK)_';JR?QVZLG\=NK)_';JR?
MQVZLG\=NK)_';JR?QVZLG\=NK)_';JR?Q_^>'@3_G2D)_ZDR#O^V.A3ZPD,?
M\,Y*+N?=3T#BZ5)7TNA:;<'@8H"QU&>1H<IKGI3#;JB)O7&P@+ETMGFV=[IT
MM'N];K*!P&JPB,)GL)+#9K"6PV:PEL-FL);#9K"6PV:PEL-FL);#9K"6PV:P
MEL-FL);#9K"6PV:PEL-FL);#9K"6P_^?'@3_GBD)_ZTQ#?^Z.A/TQT(=Z-5*
M*]_D3#_7[%%6R>Y9:[?C87RHV&>+FL]KEXW);J"#Q'&G>\!TK'6]>+!PNWNS
M;+F MFBXAKADMX^Y8[:1NF.VD;ICMI&Z8[:1NF.VD;ICMI&Z8[:1NF.VD;IC
MMI&Z8[:1NF.VD;ICMI&Z8[:1NO^@'@3_H2@(_[$P"_O .1'LSD(9W]]'*-/I
M3$#*\5%5OO)8:*WF87>>W6>$DM5LCX?/;Y9^RW.<>,AVH7+&>:1NQ'RG:<*!
MJ6; AJQBOXVM8;^/KF&_CZYAOX^N8;^/KF&_CZYAOX^N8;^/KF&_CZYAOX^N
M8;^/KF&_CZYAOX^N8;^/KO^B'0/_IB<'_[<O"?+'. WAV$$4TN9&*L?P3$"^
M^%!3LO578Z+K87"5XV=[BMUMA('8<8MZU'60=-)YDW#0?)9LSG^9:,R#FV3+
MB)UARHV?8,F/GV#)CY]@R8^?8,F/GV#)CY]@R8^?8,F/GV#)CY]@R8^?8,F/
MGV#)CY]@R8^?8,F/G_^D'0/_K28%^[XM!N;0- C3XCP6Q^Y&*[OY2CZP_D]/
MIOI77)CQ86B,ZVAQ@^9N>'OB<WUUWWB!<=U[A&W;?X=JVH.)9]F&BF37BXQA
MUI".8-61CF#5D8Y@U9&.8-61CF#5D8Y@U9&.8-61CF#5D8Y@U9&.8-61CF#5
MD8Y@U9&.8-61CO^G' /_M2,#[LDF ]7?*0?'[#P9NOA$*ZW_2#NC_TU)FO]7
M5(WY85V$]&IE?/!P:G;M=FYQZWIQ;>E^=&OH@G9HYH5W9N6(>6/DC'IAXY%\
M8..2?&#CDGQ@XY)\8..2?&#CDGQ@XY)\8..2?&#CDGQ@XY)\8..2?&#CDGQ@
MXY)\8..2?/^K&P+WP!T!V=P2 <?K* JZ]SL:K/]!*:#_1C:5_TQ!C?]62X/_
M85)[_6M7=/IQ7&_X=E]L]GMA:?5_8V?T@V1E\X9F8_**9V'QCFA?\))I7_"3
M:E_PDVI?\)-J7_"3:E_PDVI?\)-J7_"3:E_PDVI?\)-J7_"3:E_PDVI?\)-J
M7_"3:O^W%0'6SPL Q^H3 KGW*0VL_SD:GO\^)I+_1#"'_TLY@/]40'C_849R
M_VI*;/]P36G_=E!F_WM19/]_4V/_@U1A_X958/Z)5E[^C5==_9)87/V36%S]
MDUA<_9-87/V36%S]DUA<_9-87/V36%S]DUA<_9-87/V36%S]DUA<_9-87/V3
M6-;$" #&U D N/<4!*O_*0Z>_S08D/\Z(83_02EZ_TDP<O]2-FS_7CIH_V@]
M9/]O0&'_=$%?_WE#7O]]1%W_@$5<_X1%6_^'1EK_BD=8_X]'6/^02%C_D$A8
M_Y!(6/^02%C_D$A8_Y!(6/^02%C_D$A8_Y!(6/^02%C_D$A8_Y!(6/^02,3'
M!P"WVP<!J?\6!I__*@V0_S 5@_\V''?_/B)N_T<H9O]0+&'_6B]=_V0Q6_]L
M,UG_<358_W4V5O]Y-E;_?#=5_W\W5/^".%/_A3E2_XDY4O^*.5+_BCE2_XHY
M4O^*.5+_BCE2_XHY4O^*.5+_BCE2_XHY4O^*.5+_BCE2_XHY4O^*.?^2'03_
MD"D)_XTU$/^8.Q?_H$0A_Z9.+?^G63S_I61,_Z%N6_>;>&KNE8%WYXZ)@N&&
MCXO<@)63V'R;F=1XH)[1=:2BSW.II<UQKJC,;[6JRFV^K<-IO:[#:;VNPVF]
MKL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KO^2'03_D"D)
M_XTU$/^8.Q?_H$0A_Z9.+?^G63S_I61,_Z%N6_>;>&KNE8%WYXZ)@N&&CXO<
M@)63V'R;F=1XH)[1=:2BSW.II<UQKJC,;[6JRFV^K<-IO:[#:;VNPVF]KL-I
MO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KO^2'03_D"D)_XTU
M$/^8.Q?_H$0A_Z9.+?^G63S_I61,_Z%N6_>;>&KNE8%WYXZ)@N&&CXO<@)63
MV'R;F=1XH)[1=:2BSW.II<UQKJC,;[6JRFV^K<-IO:[#:;VNPVF]KL-IO:[#
M:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KO^2'03_D"D)_XTU$/^8
M.Q?_H$0A_Z9.+?^G63S_I61,_Z%N6_>;>&KNE8%WYXZ)@N&&CXO<@)63V'R;
MF=1XH)[1=:2BSW.II<UQKJC,;[6JRFV^K<-IO:[#:;VNPVF]KL-IO:[#:;VN
MPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KO^2'03_D"D)_XTU$/^8.Q?_
MH$0A_Z9.+?^G63S_I61,_Z%N6_>;>&KNE8%WYXZ)@N&&CXO<@)63V'R;F=1X
MH)[1=:2BSW.II<UQKJC,;[6JRFV^K<-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]
MKL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KO^2'03_D"D)_XTU$/^8.Q?_H$0A
M_Z9.+?^G63S_I61,_Z%N6_>;>&KNE8%WYXZ)@N&&CXO<@)63V'R;F=1XH)[1
M=:2BSW.II<UQKJC,;[6JRFV^K<-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-I
MO:[#:;VNPVF]KL-IO:[#:;VNPVF]KO^2'03_D"D)_XTU$/^8.Q?_H$0A_Z9.
M+?^G63S_I61,_Z%N6_>;>&KNE8%WYXZ)@N&&CXO<@)63V'R;F=1XH)[1=:2B
MSW.II<UQKJC,;[6JRFV^K<-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#
M:;VNPVF]KL-IO:[#:;VNPVF]KO^2'03_D"D)_XTU$/^8.Q?_H$0A_Z9.+?^G
M63S_I61,_Z%N6_>;>&KNE8%WYXZ)@N&&CXO<@)63V'R;F=1XH)[1=:2BSW.I
MI<UQKJC,;[6JRFV^K<-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VN
MPVF]KL-IO:[#:;VNPVF]KO^3'03_D"D)_X\T$/^:.Q?_HD0@_ZE-+?^J6#S_
MJ&),_Z1L7/6?=FSLF7]ZY)&'AMZ)C9#8@Y.8TWZ9G]!ZG:3-=J*IRW2GK,EQ
MK:_';[2RP6RYM+QLN[&\;+NQO&R[L;QLN[&\;+NQO&R[L;QLN[&\;+NQO&R[
ML;QLN[&\;+NQO&R[L?^4'03_D2@)_Y$S$/^<.A;_I$,@_ZQ,+?^M5CW_K6!-
M_JEJ7O2E=&[JGWU]X9:#B]F.BI;3AY"@SH&5I\I\FJW'>)^RQ'6EML)RJ[G
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M.!/_LT =_[Q(*OS%3SOVR5=.[<U>8^++9'C2Q&J,Q+MOG+BR=:FMJWNSHZ:
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M)_'.33CJVU-+X-]98-#:7W;!T&6)L\EKF:;"<*6;O76OD;A[MHBU@+R!LH;
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M35?_F4U7_YE-5_^935?_F4U7_YE-5_^935?_F4U7_YE-5_^93<W!!@"^T <
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M#O^/.A3_ET(<_YY+)_^>5S3_G6)"_YEM3_^3>%SXC8)G\HB+<>R"DWGH?)F
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M5O"V:&GHLW![WJIWC="??)W'EX.GOY"*K[B+D;:RAIBZK8.@O:F!J;^E?K#
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MOJUBO[ZM8K^^K6*_OJUBO[ZM8K^^K?^6& /_F2$%_ZHH!O^Y, CPR#@-X=A
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M.DO_ICI+_Z8Z2_^F.DO_ICI+_Z8Z2_^F.DO_ICI+_Z8Z2_^F.K^\ P"PR@,
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M+0K_I#4/_ZP]%_ZR12+VN$PP[;Q40.2X75'7LF1CRZEL<\"A<X"WFGJ+KY2
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MC\V8?(_-F'R/S9A\C\V8?(_-F/^#& +_A"$%_Y4D!O^B*PC_K3,+_K<[$O3
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M85#VRF)0]LIB4/;*8E#VRF)0]LIB4/;*8E#VRF)0]LIB4/;*8O^C"P#6N 8
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M6?%?Y5GQ7^59\5_E6?%?Y5GQ7_]P'@/_;"D&_VDS"?]R-PW_>3X2_WU'&?^
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M9T[/\&=.S_!G3L_P9T[/\&=.S_!G3L_P9_^/"P#II 0 T;0& ,6_!@"\S0@
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M)P>'_B\-??XW%'3_/QML_T<@9O].)6#_5RE<_V M6?]I,%;_<3)3_W@T4?^
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M:EVD[VI=I.]J7:3O:EVD[VI=I.]J7:3O:O]Y$0'_C X _YX- -RN" #2NPD
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M8&Z,]U]NC/=?;HSW7VZ,]U]NC/=?;HSW7_]L$P'_?0\!_XT0 /^;$ #TJ \
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M6E:M^UI6K?M:5JW[6O]^"0#RD0( UJ$" ,JM!0# MP4 N,(% ++/"0"KU!<
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M%2G_J18H_[,6)__"%B?_QQ8G_\<6)__'%B?_QQ8G_\<6)__'%J2T  "6P
MA\P  'K:  !MZP  9/\% %S_#@%4_Q0!3?\< DC_) 1"_RP%/O\S!CK_.0<V
M_T (,_]%"##_2PDN_U$**_]7"BG_70LG_V0+)/]L#"+_=@T@_X -'O^,#AW_
MEPX<_Z$.&_^L#QO_K@\;_ZX/&_^N#QO_K@\;_ZX/&_^N#Y>\  "(R0  >=8
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M5<E7VE;%5^Q5PUOY3\)>_TK 7_]&O6#_0KI@_T"Z8/] NF#_0+I@_T"Z8/]
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M57Y]_U%^??]1?GW_47Y]_U%^??]1?GW_4?]C% '_<@\!_X$0 /^-$0#\F!(
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M2!19Z5$95>A:'%'I8B!.Z6LC2^ET)4CI?2=&Z8@J0^F3*T'JH"U ZJ\N/NO
M+CWLVRX]ZN\N/>C\+CWG_RT]Y_\M/>?_+3WG_RT]Y_\M/>?_+<6?  "UJ0
MJ+$  )R\  "0QP  A-(! 'K?!@!T]!, ;?0@ F;T*@1?]#0(6O4]"U3U10]/
M]4P23/55%$GV71=&]F481/9N&D'V=QP_]X$=/?>-'SOWF2 Y^*8A./BU(C?Y
MR"(V^>,B-OCS(C;W_"(V]_PB-O?\(C;W_"(V]_PB-O?\(K>F  "IK@  G+D
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M"A3_LPH4_[,*%/^S"A3_LPH4_[,*%/^S"I.[  "$QP  ==,  &?A  !8Z
M3OL  $C_  !!_PH ._\0 3;_%0$Q_QP!+?\B BG_* (E_RT"(O\R Q__. ,<
M_ST#&O]" Q?_2 05_TX$$_]5!!'_704/_V<%#?]R!0S_?04*_XD&"O^3!@G_
MG 8)_YP&"?^<!@G_G 8)_YP&"?^<!O\_*@+_/S #_T0P _](,P3_23D&_TA"
M"/]&30O_15L._T-I$?]!=Q/_0(45_S^1%O\^FQC_/J08_SVK&?\]LQK_/;H:
M_SW#&O\\S!O_/-L;_SSG&_\\\!O_//@;_SW_&_\]_QO_/?\;_SW_&O\]_QG_
M/?\9_SW_&?\]_QG_/?\9_SW_&?] *@+_02X#_T<N _]*,03_3#<&_TM "/]*
M2PO_2%D/_T9G$?]$=13_0X(6_T*/&/]!F1G_0:(:_T"I&_] L1O_/[@<_S_
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M1X]Q_T./<?]!CW'_08]Q_T&/<?]!CW'_0?];% '_: \ _W4/ /^ $0#_B1,
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M3AUNO58D:+Q=*F.[9#!?NFPT6KET.5:X?#Q3MX<_3[>20DRVGT1*MJU&2+;
M1DBWW45)MO)#2K7_04NU_SY+M/\]2[3_/4NT_SU+M/\]2[3_/>*#  #-D@
MP9\  +2G  "JKP  H+@  );  P",R@< ALT4 ('-)@)ZS#4(<\M!#VS*2A=F
MR5,=8<A;(US'8BA8QFHL5,9R,%#%?#--Q88V2L22.4?$GSM%Q*X\1,7!/$/%
MWSQ$Q/,[1,/_.47"_S=%P?\W1<'_-T7!_S=%P?\W1<'_-]6+  #%F@  MZ0
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M&3'Q_ADQ\?\9,?'_&3'Q_QDQ\?\9,?'_&;*D  "EJP  F+8  (O   !^R@
M<=4  &7>  !>]0H 6?P3 %/\'@%._"<"2OTP T7].05!_4 &/OY(!SO^3PDX
M_U<*-O]>"S/_9PPQ_W -+O]\#BS_B0\K_Y80*?^D$"C_M!$G_\<1)__A$2;_
M\A$F__81)O_V$2;_]A$F__81)O_V$:>I  "9LP  B[X  '[)  !PTP  9-X
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M0NXB[T+Y(NU"_R#K0_\?ZD/_'>E$_QSH1/\;Z$3_&^A$_QOH1/\;Z$3_&_]
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M-Z-@_S.C8?\QHV'_,:-A_S&C8?\QHV'_,?]3%0'_71  _V@/ /]P$@#_=Q8
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M.(9Q_SB&<?\XAG'_./];#P#_9P@ _W,( /-]" #>A@< V8P) -61"P#*DAX
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M2U:1TTM7DN]'6I+]0ER3_SY=D_\[79/_.UV3_SM=D_\[79/_._]N  #@?@
MSHL  ,25  "ZG0  L:,  *FI  "AK@L FZ\= 92N+@2,K#L,A:I&%7ZH3AQX
MIE8C<J1=*FVB9"]IH6LT9)]S.&">>SQ<G84_69R/0E6;G$53FZI'49NZ1U";
MT4=1F^Y$4YO\0%6;_SQ6F_\Z5IO_.E:;_SI6F_\Z5IO_.O%T  #9@P  R)
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M+T&\_RY!O/\M0;S_+4&\_RU!O/\M0;S_+<Z*  "_F   L:   *:H  ";L
MD+@  (6_  !ZQP0 ;\\) &O1%0!GT28!8]$T!%[00 A9T$H,5<]3$%'/6Q1.
MSV,82\YK&TC.=1Y%SG\@0LZ,(D#.F20^SJ@F/,ZZ)CS/U"8\S>\E.\S[)3O+
M_R4[RO\E.\K_)3O*_R4[RO\E.\K_)<.3  "UG@  J*8  )VN  "1M@  A;\
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M"B#\_ H@_/P*(/S\"J*G  "5L0  A[L  'G&  !LSP  7]D  %+?  !(Z
M0_\( #__$  [_QD -_\A #3_*0$P_S !+?\W BK_/@(G_T0")?]+ R+_4P,@
M_UP#'?]F!!O_<@09_X %%_^/!1;_GP85_Z\&%/_ !A3_U@83_^D&$__I!A/_
MZ083_^D&$__I!I>O  "(N@  >L4  &S/  !>V@  4.   $3F   \]0  -_\$
M #/_#0 O_Q, *_\: "C_(0 E_R<!(?\M 1[_,@$;_S@!&?\_ 1;_1@(4_TT"
M$?]6 A#_8 (._VP"#/][ PO_BP,*_YH#"O^H PG_M0,(_\(#"/_" PC_P@,(
M_\(#"/_" XJX  ![PP  ;,X  %[;  !/X@  0N<  #;L   Q_P  +/\  "?_
M!P C_PX (/\2 !S_&  8_QT %?\A !+_)@ 0_RP!#O\Q 0W_-P$*_SX!"/]&
M 07_3P$!_UD! /]F 0#_= $ _X(" /^0 @#_G ( _Z8" /^F @#_I@( _Z8"
M /^F O\N+P+_,RP"_S<M O\X, +_-S8#_S0_!/\Q2P;_+U@'_RQF"/\J= G_
M*8$*_RB-"_\HEPO_*)\+_RBF#/\GK0S_)[0,_R>[#/\GQ S_)\X,_RC>"_\H
MZ0O_*/,+_RC["_\H_PK_*?\*_RG_"O\I_PK_*/\*_RC_"O\H_PK_*/\*_RC_
M"O\P+0+_-BH"_SDJ O\[+@+_.C0#_S@\!/\V20;_,U8'_S%C"?\O<0K_+7X+
M_RV*#/\LE S_+)P-_RRD#?\LJPW_++$-_RRY#?\KP0W_+,L-_RS:#?\LYPW_
M+/$-_RSZ#?\L_PS^+?\,_2W_#/TM_PS]+/\+_2S_"_TL_PO]+/\+_2S_"_\R
M*P'_.2@"_STH O\_*@+_/C #_STZ!/\\1@;_.5,(_S=@"?\U;0O_,WH,_S*&
M#?\QD [_,9D._S&A#_\QJ __,*X/_S"U#_\PO1#_,,<0_S#4$/\PY!#_,>\0
M_C'Y#_LQ_P_Y,?\/^#'_#O<Q_P[W,?\.]C'_#O8Q_P[V,?\.]C'_#O\U* '_
M/"4!_T D O]#)P+_0RP#_T0W!/]"0P;_0$\(_SU<"O\[:0S_.78-_SB"#_\W
MC!#_-Y41_S:=$?\VI!+_-JL2_S:R$_\UNA/_-<,3_S7/$_PUX1/Y-NT3]C;W
M$_,V_Q/Q-O\2\#;_$O W_Q'O-_\1[S?_$.\W_Q#O-_\0[S?_$/\Y)0'_0"$!
M_T4@ ?]'(@+_22D"_THT!/])/P7_1DL(_T18"O]"90W_0'$/_SY]$?\]AQ+_
M/9$4_CR9%?T\H!7\.Z<6^CNN%_D[MA?X.[\7]CO*&/0[W!CP.^H8[3OV&.H[
M_Q?H//\7YSS_%N8]_Q7E/?\4Y3W_%.4]_Q3E/?\4Y3W_%/\](@'_1!X!_TD<
M ?]-'@'_4"8"_U$P _]0.P7_3D8(_TM3"_](8 [_1FP1^T5X$_A$@A7V0XP7
M]$*4&/-!G!GQ0:,;[T"J&^Y LASM/[L=ZS_&'ND_U1[E/^@?XD#T'M] _AW=
M0?\;VT+_&ME"_QC80O\7V$+_%]A"_Q?80O\7V$+_%_] 'P'_2!H!_TX8 ?]2
M&P'_5B,"_U@L _]7-P3_54('_U)-"_E06@[U36<2\4QR%NY*?1CK2(8;Z4>/
M'>=&EQ_E19X@XT2F(N%$KB/@0[<DWD/")=Q#T";70^4FTT3S)-!%_B+-1O\@
MS$?_'LI'_QS)2/\;R4C_&\E(_QO)2/\;R4C_&_]$&P'_3!8!_U(4 ?]8& '_
M71\!_U\H O]>,@/]73T&]EI)"O!750_J56(3YE)M&.)0=QS?3H$?W$R*(ME+
MDB352IHFTTFA*-%)J2G/2+(JS4B\*\M(R2S(2-\LQ4CO*\)*_"C 2_\EOTS_
M(KY-_R"]3?\?O4W_'KU-_QZ]3?\>O4W_'O]'& '_3Q,!_U81 /]>%0#_8AP!
M_V4D ?YE+0+T9#@%[6%#">9?40[@7%T4VEAH&M16<A[05'LBS%*$)LI0C"C'
M3Y0JQ4Z;+,-.HR[!3:POOTRV,+U,PC&[3-,RN$SI,;9.^"VT4/\JLU'_)[-2
M_R2R4O\BLE+_(K)2_R*R4O\BLE+_(O]*%0'_4Q$ _UL/ /]B$@#_:!< _VH?
M ?9K* 'L:S(#Y&D^!]QF3 W38E@4S5]C&\A<;2#$6G8DP5A^*+Y6ABN[58XN
MN5.6,+92GC*T4J8SLE&P-;!1O#:N4,LWK%#C-ZI2]#.I5/\NJ%;_*ZA7_RBH
M5_\EJ%?_):A7_R6H5_\EJ%?_)?]-$P#_5@X _U\- /]G$ #_;!, ^W 9 .]Q
M(@'D<2P"VW Z!=%L2 S):%04PV5?&[YB:"&Z7W$FMEUY*K-;@2VP6HDPKEB1
M,ZM7F36I5J$WIU:K.*55MCJC5<4[H57=.Y]6\#>?6/XRGUK_+IY;_RN>7/\H
MGES_*)Y<_RB>7/\HGES_*/]0$0#_60P _V,, /]K#0#_<!  ]703 .AV&@#=
M=R4!T78V!,AR1 S!;E 4NVM;&[9G9"&Q96TGK6)U*ZI@?"^G7X0RI%V,-*)<
ME#>?6YTYG5JF.YI9L3V86;\^EUG3/I5:[#N57?LUEE[_,99?_RV68/\JEF#_
M*I9@_RJ68/\JEF#_*O]2#P#_7 H _V8) /]N"@#V= P [W@. .%[$@#4?"
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M161XT45F>>Y :'O].FI[_S9K?/\R:WS_,FM\_S)K?/\R:WS_,O]A  #J;P
MV7H  ,R$  ##BP  NY$! +25 0"LEPX I9<A 9Z6,067DSX,D)!(%(J.41N$
MBUDA?XE@)WN'9RMWA6XP<X1U-&^"?3=K@8<[:("1/F5_G$%B?JE#8'ZY1%]^
MST1@?^Q 8H#\.F2 _S9E@?\S9H'_,F:!_S)F@?\R9H'_,O]D  #E<@  TWX
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M-E&6_S-2EO\P4I;_,%*6_S!2EO\P4I;_,.9R  #0@   PHP  +B6  "MG
MHZ$  )FF  ".K0  B*X1 (.N(@%]K3$$=ZP]"G*J1Q!LJ4\69ZA7&V.G7A]?
MIF4D6Z1M)UBD=2M4HW\N4:*),4ZAEC1+H:0V2:&T-DBAR#=(H.<U2:#Y,DJ?
M_S!+G_\N2Y__+4N?_RU+G_\M2Y__+=UY  #)A@  O)(  +&:  "FH   G*8
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M'#;$_QPVQ/\<-L3_'+Z1  "PFP  I*,  )BJ  ",L@  @+D  '3   !HQP
M7<T% %/3"@!/UQ( 3=@B $O8, !)V#P"1MA& T393P1!V5@&/]EA"#S9:PHZ
MV78,-]F"#C7:D \TVJ 0,MJQ$3';QQ$QVN<1,-CV$C#6_Q,OU/\3+]3_$R_4
M_Q,OU/\3+]3_$[.:  "FH0  FJD  (VQ  " N@  =,$  &C)  !<SP  4M4#
M $C<" !%Y1( 0^4> $'F*@ ^YC4!.^<^ 3GG1P(WYU #-.A9!#+H8@4PZ&T&
M+NEY!RSIAP@KZI8)*>JG"BCJN@HGZ]8*)^GP"B?G_0DFYO\*)N;_"B;F_PHF
MYO\*)N;_"JB@  "<IP  C[   (*Y  !TP@  :,H  %O1  !/UP  1=T  #[N
M"0 \\A$ .?,; #;S)0 T]"X ,?0W 2[U/P$L]4<!*?9/ B?V5P(E]V$#(_=L
M R'X>@0?^(D$'OF:!1SYJP4;^L %&OK>!1KY\@4:]_T%&?;_!1GV_P49]O\%
M&?;_!9ZF  "1KP  @[D  '7"  !GRP  6M,  $W:  !"WP  ..4  #7[!P Q
M_P\ +O\6 "O_'P I_R8 )?\M "/_-  @_SL!'O]# 1O_2P$9_U,!%O]= A3_
M:@(2_W@"$?^( A#_F@(0_ZL##O^^ P[_U0,._^T##O_P P[_\ ,.__ ##O_P
M Y.N  "$N   =L(  &?,  !:U0  3-P  #_A   UY@  +?0  "K_ @ F_PL
M(_\1 "#_%P =_QT &?\C !;_*0 4_R\ $O\U !#_/0 ._T4!#/]. 0K_6 $'
M_V4!!?]T 0/_A0$"_Y8! ?^F 0#_M0$ _\8! /_* 0#_R@$ _\H! /_* 8:W
M  !WP0  :,P  %K7  !+W@  /N0  #+I   G[0  (_\  !__   ;_P4 %_\,
M !3_$  1_Q0 #_\8  W_'0 +_R( "/\H  7_+@ "_S4  /\]  #_1P  _U(
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M.7-FT3IS9^TV=&G],'5J_RQV:_\I=VO_)W=K_R=W:_\G=VO_)_]7  #V8P
MWVT  -%U  #(>P  P7\" +N  P"T@1  K((C :6!,@2>?C\)F'M*$))Y4Q:-
M=EL;B71B((5R:22!<7 G?F]W*WMN?RYX;8@Q=6R2-'-KGC=P:JHY;FJY.FUJ
MSCIM:^LW;VW\,7!N_RUQ;O\J<6__*'%O_RAQ;_\H<6__*/]9  #K90  VW
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M,E][_RY@?/\K87S_*6%\_REA?/\I87S_*?5B  #>;P  S'H  ,"#  "WB0
MKXX  *:1  "=D@8 EY,7 )&3* &+DC8%A9!!"W^.2A%ZC%(6=8I:&W&(81]M
MAV@C:H9O)V:$=RMC@X N8(**,5V!EC1:@:,V6("R-U: Q3=6@.,V6('W,5F!
M_RU;@O\J6X+_*5N"_RE;@O\I6X+_*>QF  #8<P  QWX  +R'  "SC@  J9(
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M)$>:_R1'FO\D1YK_)-1W  #"A   MH\  *N6  "AG   EJ   (NE  !_J@
M=*X% &^O% !LKR0 :*\R F2N/05?K48)6ZQ/#5BL5A%4JUX44:IF%TZJ;AI+
MJ7@=2*F#($6HCR)#J)TD0:BM)4"HP"4_J-\E/Z;T(T"E_R) I?\A0*3_($"D
M_R! I/\@0*3_(,I^  "[BP  KY4  *2;  "9H0  CJ8  (*L  !WL0  :K8
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M#:Z8  "BGP  EJ8  (FN  !\M@  ;[T  &/#  !7R   3,T  $+2 P YV0D
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M$P >_1L '/TB !G^*0 7_C$ %?\Y !/_00 1_TH $/]5  [_80 ,_V\!#/^
M 0K_DP$)_Z8!"/^Z 0?_U $'_^L!!O_V 0;_]@$&__8!!O_V 8^L  " M@
M<K\  &/)  !6T0  2-@  #O=   PX@  )N8  !_P   <_P  &?\) !;_#@ 4
M_Q, $?\9  __'@ -_R0 "_\K  G_,@ &_SL  _]$  #_3P  _UP  /]K  #_
M?0  _Y   /^C  #_M   _\8  /_6  #_U@  _]8  /_6 (*U  !SOP  9,D
M %;3  !'VP  .N   "[E   CZ0  &NT  !7]   2_P  $/\"  [_"0 +_PT
M"/\0  3_$P !_Q@  /\>  #_)   _RL  /\S  #_/0  _TD  /]6  #_9@
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M*X16U2R#5^\I@UC^)(-9_R"$6O\>A%K_'(1:_QR$6O\<A%K_'/]. 0#_5P
MY5\  -AF  #.:@  QVP# ,-K!0"\;!( M&TE *UL-0.G:D('H6=-#)QE5A&8
M8UX5E&)E&)%@;!N.7W0>C%Y[(8E=@R2&7(PFA%N5*(%:H"I_6JPL?5J[+7Q:
MSRY[6^PK?%S\)GQ=_R)]7O\??5[_'7U>_QU]7O\=?5[_'?]0  #U60  X6,
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M;V3Y*'!E_R1Q9O\A<6;_'W%F_Q]Q9O\?<6;_'_]4  #H7P  UVD  ,IP  #
M=0  N7@  +)X  "K> T I'D= )YX+0&7=SH%DG5%"HQR3@Z(<%83A&]>%X!M
M9!I];&L=>FMS('=J>R-T:8,F<FB-*6]GF2QL9J4N:F:S+VEFQC!H9N0O:FCW
M*6MI_R5L:?\B;&K_(&QJ_R!L:O\@;&K_(/]7  #D8@  TFP  ,9S  "]>
MM7L  *U\  "E? H GWT: )E\*@&3>S@$C7E#"8AW3 Z#=502?W-;%GMR8AEX
M<&D==6]P(')N>"-O;8$F;&R+*6ILERQG:Z,N96NR+V1KQ#!B:^$O9&SV*F9M
M_R9F;?\C9V[_(&=N_R!G;O\@9V[_(/99  #@90  SF\  ,)V  "Y?   L7\
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MB@  C8H1 (B+(0"#BC "?HD[!7F'10ITADX.<(15$FR#7!9I@F,:9H%J'6*
M<B!??WLC7'Z%)EE]D2E7?)XK57RL+%-\OBU2?-HM4WSR*55\_R56?/\B5WS_
M(%=\_R!7?/\@5WS_(.5D  #/<   P7H  +:#  "MB0  HXP  )F.  "-CP
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M&,1\  "VB0  JI(  )^7  "5G   B:$  'VF  !QJ@  9*X  %JQ" !7L10
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M!";-M 0ES<X$)<ON!"3)_ 8CR/\'(\?_!R/'_P<CQ_\'(\?_!ZF6  ">G0
MDJ,  (6K  !XL@  :[@  %^^  !2P@  1\8  #W*   TSP0 *]0) ";9#P E
MV1D )=HE "3:,  CVSL (]M% "+<4  AW5L (-UH ![>=@ =WH<!'-^9 1K?
MK $9W\0!&-[G 1C<^ $8V_\"%]K_ A?:_P(7VO\"%]K_ J"<  "4HP  AZL
M 'FS  !LN@  7\$  %+&  !&R@  .\X  #'3   IV0  (=X% ![H#@ =Z!4
M&^D> !GI)P 8ZC  %NHY !7K0P 4[$X $NQ: !'M9P 0[G< $.Z*  [OG@ .
M\+, #?#-  SO[  ,[?P #.O_  SK_P ,Z_\ #.O_ )>C  ")JP  >[0  &V\
M  !?Q   4LH  $7.   YTP  +]@  "7=   =X0  &.P" !;W"P 4]Q$ $?@7
M !#X'@ .^24 #?DM  OZ-0 )^S\ !_M*  3\5P #_68  OYW  #]BP  _9\
M /RU  #\T0  _.T  /S\  #\_0  _/T  /S] (NK  !]M   ;KT  &#&  !2
MS0  1-(  #?8   LW0  (N$  !GE   3Z@  $/H   [_!@ -_PP "O\0  ?_
M%  $_QH  ?\@  #_)P  _S   /\Z  #_10  _U,  /]B  #_=0  _XH  /^?
M  #_LP  _\<  /_E  #_Y0  _^4  /_E '^T  !PO0  8<<  %/0  !#U@
M-MT  "KB   ?Y@  %NH  !#M   ,^@  "?\   ;_   "_P0  /\)  #_#0
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M&9U#X!J;1/,7F47_%9A&_Q.81O\1F$;_$)=&_Q"71O\0ET;_$/]"!0#_1P
M]T\  .53  #=50$ UU4& -52"P#+4QD PU0K +Q4.P&V4D@$L5%2!ZU07 JI
M3F0-IDUL#Z1,=!&A2WL3GTJ"%9U*BA>;29,8F4F<&I=(IAN52+(<E$C!'9)(
MV!V02>\;CTK^&(]+_Q:.2_\4CDS_$HY,_Q*.3/\2CDS_$O]%  #_2P  Z5,
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M'W=8_QMW6?\9=UG_%W=9_Q9W6?\6=UG_%O],  #I5@  V5\  ,ME  #!:
MNFD  +1H  "M9PT IF@< *!H+0&:9SH#E65%!I!C3@J,8E<-B6%>$(9?91.#
M7FP6@%US&'Y<>QI[7(,=>5N-'W9:F"%T6J0C<EJR)'%:Q"5O6N$E<%OV('%<
M_QQQ7?\:<5W_&'%=_Q=Q7?\7<5W_%_U/  #E60  TV(  ,=H  "];   MFT
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M&F)H_QEB:/\98FC_&>Q7  #98@  QVL  +QR  "S=P  JGD  *%Y  "7=P$
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M&@![@BD!=H$V G*!0 5N?TD(:GY0"V=]5PYD?%X187MF%%YZ;1=;>G8967F
M'%9XBQ]3>)@A47>F(E!WMR-/=\XC3W?L(5!W_1Y1=_\;4G?_&5)W_QE2=_\9
M4G?_&=YB  #(;@  NW<  +!_  "GA   G8<  )*'  "$AP  ?8<) 'B(%@!T
MB"8 <(@R FR'/01HAD8&985."6&%50Q>A%P/6X-C$EF":Q56@7074X!^&E"
MB1Q.?Y8>3'^E($I_MB%)?\PA27[K'TI^_!Q+?O\:2W[_&4Q^_QA,?O\83'[_
M&-5G  ##<P  MGP  *R$  "BB0  F(L  (V-  !\C0  =8X$ &^/$@!MD"$
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M$CB=LA,WGL@3-YWH$C:;^A(VFO\2-IG_$3>9_Q$WF?\1-YG_$;Y[  "QAP
MI8\  )N4  "0F   A)P  '>@  !KI   7Z<  %*J  !-JPX 2ZL: $JK)P!(
MJS, 1JL] 42K1@%"JTX"0*M6 SZK7P4[JV@&.:IS"#>J@ DTJH\+,JJ?##&J
ML PPJL<,,*GG#"^G^@TOIO\-+Z7_#2^E_PTOI?\-+Z7_#;:$  "JC@  GI0
M )29  "'G@  >Z,  &^H  !CK   5Z\  $NR  !!M08 /K81 #VV'@ [MBD
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M !#5\P 0T_\ $-+_ 1#1_P$0T?\!$-'_ 9R:  "1H0  @Z@  '6P  !HMP
M6[T  $[!  !"Q0  -\@  "W,   DT   '-4  !7:!0 0X@L $.,1  [D&@ .
MY", #>4M  SE-P +YD( "N9/  GG70 (YVT !N:   7FE0 $YJL  N;$  'F
MY@  Y_D  .?_  #F_P  YO\  .;_ ).A  "%J0  =[$  &FY  !;P   3L8
M $'*   US@  *M(  "'6   9VP  $M\   WC   +\0@ "?,.  ?S$P $\AH
M O(B  #R*@  \C0  /(_  #R3   \EP  /)M  #R@@  \I@  /.M  #SQ@
M].4  /3V  #T^P  ]/L  /3[ (>I  !YL@  :KH  %S"  !.R0  0,X  #/3
M   HV   'MT  !7A   /Y   "N@   7S   #_0$  /P(  #[#0  ^Q$  /L6
M  #\'@  _"8  /PP  #]/   _DD  /Y:  #^;0  _X(  /^8  #_K   _\
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M +D _P#" /\ S0#_ -\ _P#L /\ ^ #_ /\ _0#_ /T _P#] /\ _0#_ /T
M_P#] /\ _0#_ /\?(P#_'R$ _QXA /\9(P#_$RD _PXR /\,0 #_"4T!_P=:
M ?\$9P'_ W,!_P-] ?\#AP'_ X\ _P*6 /\"G #_ J( _P*H /\"KP#_ ;8
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M!;XKZP6Z*_D&N"S_!K8L_P6U+/\%M"S_!;0L_P6T+/\%M"S_!?\T# #_-@4
M_SD# /\\" #_/ T _3L3 /$X'0#H-2D X#0W -DS1@#1-%(!S3-= <DS9P+&
M,W #Q#)X!,$R@ 2_,H<%OC*/!KPRE@:Z,9X'N#&F![<QL BU,KP(LS+,";$R
MY0FM,_4)JS/_":HS_PBH,_\'J#/_!Z<S_P>G,_\'IS/_!_\W!P#_.@  _SX
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M$HE&_Q")1O\.B$;_#8A&_PV(1O\-B$;_#?]   #R1P  XT\  -13  #+50
MQ%0  ,!0! "Y3Q$ LE B *Q1,@"G43\"HE!* YY/4P6;3EP(F$UC"I5,:@R3
M2W$-D4IY#XY*@!&,28D2BDF2%(A(G!6&2*@6A4BU%X-(QQB!2.08@4KW%8!*
M_Q* 2_\0@$O_#X!+_PZ 2_\.@$O_#O]#  #L2P  W5,  ,Y8  #$6@  O5H
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M$FQ8_Q%L6/\1;%C_$?%+  #?5@  S%X  ,!D  "W9P  KF@  *=F  "?8@8
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M$^%8  #+8P  O6L  +)R  "I=@  H'@  )9W  "(<P  @7,+ 'QT%P!X="8
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M:P  M70  *M[  "B?P  EX$  (R!  !Z?@  <W\" &Y_$0!K@!X :( L &6
M-P%B@$ #7W](!%Q^4 99?E<(5WU>"U1\9@U1?&X/3WMX$4Q[@Q1*>I$62'J?
M%T9ZKQA%>L081'KD&$5Y^!9&>?\41GC_$D=X_Q%'>/\11WC_$<UE  "]<
ML7D  *>   "<A   DH8  (:&  !WA@  :X8  &:'#0!CAQD 8(@G %Z(,P%;
MB#P"6(=% U:'3013AE0&4(9;"$Z%8PI+A&P,281V#T:#@1%$@X\30H.=%$""
MKA4_@\(5/H+B%3^!]Q,_@?\20(#_$4" _Q! @/\00(#_$,9K  "W=@  K'\
M **%  "7B0  C(L  (&-  !SC@  98\  %V/"0!:D!0 6) A %:1+0!3D#@!
M49!! DZ020-,D% $2H]8!4>/8 =%CFD)0HYS"T"-?PT^C8T//(V<$#J-K!$Y
MC<$1.(WA$#B+]A XBO\/.8G_#SF)_PXYB?\..8G_#K]R  "R?0  IX8  )R*
M  "1C@  AI$  'J3  !ME0  7Y<  %29 0!/F0\ 3IH: $R:)P!*FC( 2)H\
M 4::1 %$FDP"0II4 T"97 0^F68%.YEP!SF8? @WF(H*-9B:"S.8JPLRF+\,
M,IC?"S&6]0LQE?\+,93_"S&3_PLQD_\+,9/_"[AZ  "LA0  H8L  ):0  "+
ME   ?Y<  '*;  !FG0  6J   $ZB  !%I D 0J03 $"D'P _I"H /J4T #RE
M/@ [I4<!.:5/ 3>E6 (UI6$",Z5L S&E>00OI(<%+:27!BRDJ08KI+T&*J3>
M!BJB]0<IH?\'*:#_""F?_P@IG_\(*9__"+&"  "EBP  FI$  )"6  "#F@
M=I\  &JB  !>I@  4JD  $:K   \K0  -:\, #.P%0 RL"$ ,; K "^P-0 N
ML3X +;%( "RQ40 KL5L *;%G 2>Q= $FL8,!)+&4 B.QI@(BLKL"(;+; B&O
M\P,@KO\#(*W_!!^L_P0?K/\$'ZS_!*J+  "=D0  DY<  (><  !ZH@  ;:<
M &"K  !5KP  2;$  #ZT   SMP  *KH# "2\#0 BO14 (;T@ "&]*@ @O3,
M'[X] !Z^1P =OE( '+]> !J_;  9OWP &+^. !? H0 6P+8 %,#3 !6^\0 5
MO/\!%;O_ 12Z_P(4NO\"%+K_ J&2  "6F   BIX  'VD  !OJ@  8J\  %:T
M  !*MP  /KH  #.]   JP   (<0  !G'!0 3RPL $<P2 !',&P 0S"4 #\TO
M  [-.@ .S48 #<U2  W.8  ,SG  "\Z#  K.EP )SJP ",[&  C.Z  (S?L
M"<O_  G+_P )R_\ "<O_ )B8  "-G@  ?Z4  '&L  !DLP  5[D  $J]   ^
MP   ,L,  "C&   ?R@  %\T  !'1   ,U@4 "-D,  ;9$@ %VAL !-HD  /;
M+@ !VSD  -Q%  #=4@  WF(  -YS  #>B   WYT  -^S  #?S@  X.X  -_Z
M  #?_P  W_\  -__ (^?  "!I@  <ZX  &6U  !8O0  2L(  #W%   QR0
M)LP  !W0   4U   #MD   G=   #X0   .,'  #C#0  Y!(  .49  #F(@
MYRL  .DV  #K0P  [%(  .QB  #M=@  [HP  .ZA  #OMP  []$  ._K  #P
M]@  \/8  /#V (2G  !UKP  9[<  %F_  !+Q@  /,H  "_.   DT@  &M@
M !+<   ,X   !>,   #G    ZP   .L   #M!0  [@L  / 0  #Q%0  \QX
M /0G  #W,P  ^4   /I1  #[8P  _'<  /V-  #]HP  _K8  /[)  #_WP
M_]\  /_? '>P  !HN0  6L$  $S*   \SP  +M0  "+:   7W@  $.(   GF
M    Z0   .P   #P    ]@   /8   #W    ^    /H'  #[#0  _1$  /\9
M  #_(P  _R\  /\^  #_3P  _V(  /]W  #_C0  _Y\  /^N  #_N@  _[H
M /^Z /\6(P#_%2$ _Q(A /\.) #_!BH _P S /\ 00#_ $X _P!< /\ : #_
M '0 _P!^ /\ AP#_ (\ _P"6 /\ G #_ *( _P"H /\ K@#_ +4 _P"] /\
MQP#_ -8 _P#G /X \P#^ /X _0#_ /P _P#[ /\ ^P#_ /L _P#[ /\ ^P#_
M /\:( #_&1X _Q8> /\0( #_"B4 _P0P /\ /0#_ $L _P!8 /\ 9 #_ '
M_P!Z /\ @P#_ (L _P"2 /\ F #_ )X _P"D /\ J@#_ +$ _0"Y /L PP#Z
M -  ^ #C /< \0#V /P ] #_ /0 _P#S /\ \P#_ /, _P#S /\ \P#_ /\=
M' #_'!D _QD9 /\4&P#_#B$ _PPL /\).0#_!48 _P)3 /\ 7P#_ &L _P!U
M /\ ?@#_ (8 _P". /\ E #^ )L _ "A /H IP#X *X ]0"U /, OP#Q ,L
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M /P050#X#V  ] ]J /$/= #O#GP [0Z$ .L.BP#I#I( YPZ9 .8.H #D#J<
MX@ZO . .N #>#L4 W [: -80[ #2$?H SQ+_ ,T2_P',$O\!RQ/_ <H3_P'*
M$O\!RA+_ ?\G#P#_)PP _R4) /\F#0#_)1, _R,< /\@* #['#4 ]1I" .\8
M3P#J%UH YA9E .,6;@#@%G< WA9_ -P6AP#9%HX UA:5 -06G #2%Z, T!>K
M ,X8M0#,&,$ RQC2 ,<:Z '#&_@!P!O_ ;X<_P&]'/\"O!S_ KP;_P*\&_\"
MO!O_ O\K# #_*P4 _RL# /\M"0#_+ X _RD5 /<F( #N(RT YR$Z .$?2 #;
M'U0 U2!? -$@: #.('$ S"%Y ,HA@0'((8@!QB&/ <0AE@'#(9X!P2*F ;\B
MKP&](KL"O"/* KDCXP*U)/0"LR3_ [$D_P.O)/\#KR3_ ZXD_P.N)/\#KB3_
M _\O!@#_+P  _S(  /\S @#Y,@@ ]R\. .LK%@#A)R( V"<R - I00#+*DX
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M"I,YR@N1.>4+CSKW"HTZ_PF,._\(C#O_!XP[_P>,._\'C#O_!_\X  #Q/@
MXT4  -1)  #+2@  Q4<  ,%!! "Z/Q$ LT$A *U",0"H0SX I$-) :!"4P*=
M05L#FT%B!)A :@660'$&E#]X!Y(_?PB0/X@*CSZ1"XT^FPR+/J8-B3ZS#8@^
MQ Z&/^ .A#_T#8- _PN#0/\*@D#_"8)!_PB"0?\(@D'_"/\\  #K0P  W$H
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M$VQ._1!L3_\.;$__#&Q/_PML3_\+;$__"^Y%  #<4   R5<  +U<  "T7@
MK%X  *1;  "<5@0 E582 )!7(0"+6"\ AU<[ 8-61 )_5DT#?%54!7I46P9W
M5&((=5-H"7-3< MQ4G@-;U*"#VU1C1%K49D2:5&F%&=1MA5F4<L595+I%&52
M^Q%F4_\/9E/_#693_PQF4_\,9E/_#.I)  #54P  Q5H  +I?  "P8@  J&(
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M#E=>_PU77O\-5U[_#=Y3  #(70  NV0  +!J  "F;0  G6X  )-M  "%9P
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M#,9D  "W;@  JW8  *)\  "7?P  C($  (&!  !R@   97\  %U_" !9?Q,
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M!2Z2I 8MDK<&+)+1!BR1[P8KC_\&*X[_!BN-_P<KC?\'*XW_![-X  "G@@
MG(@  )&,  "'D   >I,  &V5  !AEP  59D  $F;   _G $ .9T. #>=%P V
MGB( -)XL #.>-0 RGCX ,9Y' #"?4  NGUH +9]D 2N?<0$IGG\")YZ0 B:>
MH0(DGK4"(Y[. B.=[@,CF_X#(IK_!"*9_P0BF?\$(IG_!*R!  "@B   E8X
M (N2  !_E@  <IH  &6=  !9H   3J,  $*D   WI@  +J@% "FI#P HJ1@
M)ZHB ":J+  EJC4 )*H_ ".J2  BJU, (:M> ""K:@ >JWD ':N+ !NKG0 :
MJ[$ &:O* !FJ[ $9J/T!&*?_ ABF_P(8IO\"&*;_ J6)  "9CP  CY0  (.9
M  !UG@  :*(  %RF  !0J0  1*P  #FN   OL   )K,  !ZU!@ 9MP\ &+<7
M !>W(0 6MRH %;<T !2X/@ 3N$D $KA4 !*Y8@ 1N7$ $+F#  ^YEP .N:P
M#;G$  VXYP .MOL #K7_  ZT_P .M/\ #K3_ )R0  "2E0  AIL  'F@  !K
MI@  7JL  %*O  !&L@  .K4  "^W   EN@  ';T  !7    0PP8 "\8.  K%
M%0 )Q1X ",4H  ?%,@ &QCT !<9)  7&5P #QF8  L9W  '&BP  QJ   ,6V
M  #&T@  Q>\  ,7\  #%_P  Q?\  ,7_ )66  ")G   >Z,  &VI  !@KP
M4[0  $:X   ZNP  +KX  "3!   ;Q   $\<   [*   (S@$  = *  #0$
MT!8  -$>  #2)P  TS$  -0\  #520  UE@  -9I  #6?   UI(  -:G  #6
MOP  UN   -;S  #6_@  UO\  -;_ (R=  !^I   ;ZL  &&R  !4N0  1KT
M #G!   MQ   (L<  !G+   1S@  #-(   75    VP   -P#  #="@  W@\
M -\4  #A'   XB0  .0N  #F.@  YTD  .A9  #H:P  Z8$  .F8  #IK0
MZ<4  .GB  #I\@  Z?4  .GU ("E  !QK0  8[4  %6\  !'P@  .<8  "S*
M   @S@  %M(   _6   (VP   -\   #C    Y0   .<   #H 0  Z@<  .L-
M  #M$0  [Q@  /$A  #S*P  ]C@  /=(  #X6@  ^6T  /J$  #ZFP  ^J\
M /K"  #ZV@  ^M\  /K? '2N  !EM@  5KX  $C&   YRP  *]   !_4   4
MV@  #=\   7C    Y@   .D   #M    [P   /$   #S    ]0   /8"  #X
M"0  ^@X  /T3  #_'   _R@  /\V  #_1P  _UH  /]N  #_A0  _YH  /^K
M  #_N0  _[P  /^\ /\1( #_$!X _PP> /\$(0#_ "< _P P /\ /@#_ $P
M_P!9 /\ 90#_ '  _P!Z /\ @P#_ (L _P"2 /\ F #_ )X _P"D /\ J@#_
M +  _P"X /\ P@#_ ,X _P#B /X \ #] /L ^P#_ /L _P#[ /\ ^@#_ /H
M_P#Z /\ ^@#_ /\4' #_$AH _PX: /\(' #_ "$ _P M /\ .@#_ $@ _P!5
M /\ 80#_ &P _P!V /\ ?P#_ (< _P". /\ E #_ )H _@"@ /T I@#\ *P
M^P"T /D O0#X ,D ]P#< /4 [ #S /@ \P#_ /( _P#Q /\ \ #_ /  _P#P
M /\ \ #_ /\7& #_%18 _Q$5 /\,%P#_!1T _P H /\ -@#_ $, _P!0 /\
M7 #_ &< _P!Q /\ >@#\ (( ^@") /@ D #W )8 ]0"< /0 H@#S *@ \0"P
M /  N #N ,, [ #3 .H YP#I /4 YP#_ .8 _P#E /\ Y0#_ .4 _P#E /\
MY0#_ /\:$P#_&!$ _Q00 /\/$0#_#1D _PHD /\%, #_ 3X _P!+ /\ 5P#^
M &( ^@!L /4 =0#R 'T \ "$ .X BP#L )$ ZP"7 .D G@#G *0 Y@"L .0
MM #B +\ X #- -X XP#< /( V@#] -@ _P#6 /\ U0'_ -4!_P#5 O\ U0+_
M /\>$ #_' T _Q<+ /\5#@#_%!4 _Q$? /\.*@#_"S@ _0A% /@&40#T!%P
M[@1F .H$;P#F W< Y 1_ .($A@#@!(P W@23 -T%F@#;!:  V 6H -4%L0#2
M!;L T ;) ,X'X #,"/$ R0K_ ,<+_P#&#/\ Q0S_ ,4,_P#%#/\ Q0S_ /\A
M# #_( 8 _QP# /\="@#_&Q  _Q@8 /\4(P#V$3  [PX^ .H.2@#E#58 X0U@
M -T-:0#9#7$ U0UY -,-@0#1#8@ SPV/ ,T.E@#+#IT R@ZE ,@.K@#&#[D
MQ!#( ,(0WP"^$?( NQ+_ +D3_P"W$_\!MA/_ ;83_P&V$_\!MA/_ ?\E!@#_
M(P  _R,  /\D P#_(0H _1T1 /$:&P#H%B< X10U -H30P#3%$\ SA59 ,L5
M8P#(%FL Q19S ,,7>P#!%X( P!B) +X8D "\&)@ NQF@ +D9J0"W&;0 M1K"
M +0:U@"P&^T!K1S\ :L=_P&I'?\!J1W_ :@=_P&H'?\!J!W_ ?\H  #_)P
M_BH  .\J  #G)P$ YR() .0=$ #9&QT SQTM ,D>/ #$($D OR!3 +PA70"Y
M(64 MR)M +4B= "S(GP L2*# ; BB@&N(I(!K".; :LCI &I(Z\!IR.\ :8D
MS@&C).@"H"7Y IXE_P*=)?\"G"7_ ILE_P*;)?\"FR7_ O\L  #_+0  [3(
M .(T  #:,P  TRX# -(E"@#))1< P2<G +LI-@"V*D, LBM. *\K5P"L*V
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M"'TZ_@=\._\&?#O_!7P[_P5\._\%?#O_!?0W  #E0   TD<  ,5*  "\2P
MM4D  *]#  "I/@L HC\7 )U )@"8030 E$$_ )%!20&.05$!BT!9 HE 8 .'
M0&<#A3]M!(,_=06!/WT&?SZ'!WT^D0A[/IP)>CZI"7@^N IW/\T*=3_J"G1
M_ AT0/\'=$#_!G- _P9S0/\&<T#_!O$[  #?10  S$P  +]/  "V4   KD\
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M"6!._PA@3O\(8$[_".-'  #-4   OE<  +-;  "J70  H5T  )A:  "-4P
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M",]4  "^7@  L64  *=J  "=;0  E&T  (EL  !X90  ;V0  &ED#@!E9!D
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M"#UOHPD[<+4*.W#-"CIO[ D[;OX(.V[_"#MM_P<[;?\'.VW_![]B  "Q:P
MIG,  )UY  "2>P  AWP  'M\  !M>@  8'@  %9W 0!0=PX 3G@8 $QX) !+
M>2X 27DW $AY0 !&>4@!1'E/ 4)Y5P)!>6 "/WAI SQX= 0Z>((%.'B1!C=X
MH0<U>+,'-'C+!S1WZP<T=OT'-'7_!S5U_P8U=/\&-73_!KEH  "M<0  HGD
M )A^  "-@   @H$  ':"  !I@0  6X$  %&!  !(@ H 18$3 $.!'@!"@BD
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M 1R7Y0$<E?H!&Y3_ 1N3_P(;D_\"&Y/_ J=_  "<A@  D8L  (>/  !ZD@
M;94  &&8  !5FP  29T  #V>   SGP  *J$  "&C"@ ?HQ$ 'J,: !VD)  <
MI"T &Z0V !JD/P 9I$H &*15 !:E80 5I7  %*6! !.EE  2I:@ $:6_ !"D
MX@ 1HO@ $:'_ !&@_P$1H/\!$:#_ :"&  "5C   C)$  '^5  !QF@  9)X
M %BA  !,I   0*8  #6G   JJ0  (JP  !FN   2L D $+$0 !"Q&  .L2(
M#K$K  VQ-0 -L4  #+%+  NQ6  *L6< "+%X  >QBP %L:  !+"U  2PT  $
ML.\ !:_^  :N_P &KO\ !J[_ )B.  "/DP  @I@  '6=  !GH@  6J<  $ZK
M  !!K0  -:\  "NQ   AM   &+8  !&Y   -O , ![X,  .]$@ !O1D  +XB
M  "^*P  OC8  +Y!  "_3@  OUP  +]M  "_@   OI4  +ZJ  "^P@  O>0
M +WV  "]_P  O?\  +W_ )*4  "%F@  >*   &JF  !<JP  3[   $*S   U
MM@  *K@  ""[   7O@  $,$   O$   $QP   ,D'  #)#0  R1(  ,H9  #+
M(@  RRL  ,TU  #.00  SE   ,]@  #/<@  SX<  ,^=  #/LP  S\X  ,_K
M  #.^   SOX  ,[^ (B;  !ZH@  ;*@  %ZO  !0M0  0KD  #6\   IOP
M'L(  !7&   .R0  ",P   #0    TP   -4   #6!@  V P  -D1  #;%@
MW!\  -XH  #@-   XD$  .)1  #C8P  XW<  .2.  #DI   Y+H  .74  #E
MZ@  Y?,  .7S 'RC  !NJ@  8+(  %&Y  !#O@  -<(  "C&   <R0  $\T
M  S1   $U0   -H   #>    X0   .(   #D    Y0,  .<)  #I#@  ZQ(
M .T:  #O)   \C$  /1!  #T4P  ]68  /5\  #VDP  ]JD  />\  #WS@
M]]\  /?? '"L  !AM   4[L  $7#   VQP  )\P  !O0   1U0  "ML   #?
M    X@   .4   #I    [    .T   #P    \0   /,   #U!   ]PH  /H0
M  #\%@  _R$  /\N  #_0   _U,  /]H  #_@   _Y8  /^H  #_M@  _[\
M /^_ /\-' #_"AL _P(; /\ '@#_ "0 _P N /\ / #_ $H _P!6 /\ 8P#_
M &T _P!W /\ ?P#_ (< _P". /\ E #_ )H _P"@ /\ I@#_ *P _P"T /\
MO0#_ ,D _@#= /T [0#\ /H ^P#_ /H _P#Y /\ ^@#_ /H _P#Z /\ ^@#_
M /\0&0#_#1< _P86 /\ & #_ !X _P J /\ -P#_ $4 _P!2 /\ 7@#_ &D
M_P!R /\ >P#_ (( _P") /\ D #^ )8 _0"< /P H0#[ *@ ^0"O /@ N #V
M ,, ] #2 /, YP#R /8 \ #_ .\ _P#P /\ [P#_ .\ _P#N /\ [@#_ /\2
M% #_#Q( _PL2 /\ $@#_ !H _P E /\ ,P#_ $  _P!- /\ 60#_ &0 _0!M
M /L =@#Y 'T ]P"$ /4 BP#T )$ \P"7 /$ G0#P *, [@"J .P LP#J +T
MZ #+ .< X0#E /$ XP#] ., _P#B /\ X0#_ .$ _P#@ /\ X #_ /\4$ #_
M$0X _PT- /\'#P#_ A4 _P @ /\ +0#_ #H _P!' /D 4P#U %X \@!H /
M< #M '@ ZP!_ .D A0#H (P Y@"2 .4 F #C )\ X0"F -\ K@#< +@ V@#%
M -8 V0#4 .P T@#Y -$ _P#/ /\ S@#_ ,X _P#. /\ S@#_ /\7# #_% @
M_P\% /\."P#_#!$ _P<: /\!)@#\ #0 ] !! .T 30#I %@ Y@!B ., :@#@
M '( W@!Y -L @ #9 (8 U@"- -, DP#1 )H SP"A ,T J@#+ +, R0"_ ,8
MT #% .@ PP#V ,$ _P#  O\ OP/_ +\#_P"_ _\ OP/_ /\;!@#_%P  _Q0
M /\3!0#_$0T _PX4 /D*'P#P!BP Y@,Y . #1@#< U$ U@1; -($9 #/!6P
MS 5S ,H%>@#(!8$ Q@6' ,4&C@##!I8 P0:= +\&I@"]!K  NP>\ +D(S0"X
M"N4 M0OW +,-_P"Q#?\ L W_ + ._P"O#O\ KP[_ /\>  #_&P  _QL  /H:
M  #U%@4 ]A$- .L.%0#B"R( V LQ - ,/@#+#4H QPU5 ,0.7@#!#F8 OPYM
M +T.= "[#WL N0^" +<0B@"V$)$ M!": +(0HP"P$:T KQ&Z *T1R@"J$N4
MIQ3W *45_P"C%?\ HA7_ *(5_P"B%?\ HA7_ /\B  #_(   \",  .8D  #@
M(0  W!D% -L0# #0$1D R!,I ,(5-P"]%D0 N1=. +475P"S&&  L!AG *X8
M;@"L&74 JQE\ *D9A "H&HP IAJ4 *0:G@"C&Z@ H1NT )\<Q0">'-\ FAWS
M 9@>_P&7'O\!EA__ 94?_P&5'_\!E1__ ?\F  #T)P  YBT  -HO  #/+0
MRB<  ,<?" #!'!, NAXB +0?,0"O(#T JR%( *@B4@"F(EH HR-B *$C:0"@
M(V\ GB-W )PC?@";(X8 F22/ 9<DF0&6)*,!E"2P 9(EOP&1)=8!CB;O 8PG
M_P*+)_\"BB?_ HDG_P*))_\!B2?_ ?HI  #L,   W38  ,TX  #$-P  OC(
M +HK @"U)0X KB<= *@I*P"D*C@ H"I# )TK3 ":*U4 F"M< )8K8P"4*VH!
MDBMQ 9 L> &/+($!C2R* 8LLE **+)\"B"RK H8LN@*%+<X#@R[J X$N_ .
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M!&T[_P-M.O\#;3K_ ^HY  #50@  Q$@  +E+  "O2P  ITD  )]$  "8/@$
MD3P0 (P]'0"(/BH A#\U ($_/P!^/T@ ?#]/ 7H_5@%X/UT!=CYD G0^:P)R
M/G,#<#Y\ V\^AP1M/I,%:SZ@!FH^K@9I/\ '9S_>!V<_]09F0/\%9D#_!&9
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M!=5(  #"40  M5<  *I;  "@7   EUP  (U9  "!4P  =T\$ '%/$ !N4!P
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M!TA8H@='6;,(1EG*"$59Z@A&6?T&1EC_!D98_P5'6/\%1UC_!<=2  "X6P
MJV$  *%F  "8:   CFD  (-G  !R8   :%X  &%="0!<71, 6ET> %==*0!6
M7C, 5%X[ %)>0P!17DH!3UY2 4Y>60),7F$"2EYJ TA>=01&7H(%1%V0!D->
MH =!7K$'0%[(!T!>Z = 7?P&05W_!4%=_P5!7/\%05S_!<-6  "T7P  J&8
M )YJ  "5;0  BFT  ']L  !O9P  9&0  %MB!0!68A  5&(; %)C)0!08R\
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M RYRXP,N<?@#+G#_ RYO_P,N;_\#+F__ [-F  "G;P  G78  )-Z  "(?
M?GT  ')]  !D?   5WL  $QZ  !">0, /'D. #IZ%P Y>B$ .'HJ #=[,P V
M>SL -'M$ #-[3  R>U4 ,'M? "][:@$M>W<!*WN' 2I[F (H>ZH")WN_ B9[
MX0(F>O<")GC_ B9X_P(G=_\")W?_ JYL  "C=@  F7P  (Y_  "$@@  >(,
M &R$  !?A   480  $>$   \A   ,X0) #"$$0 OA!H +80D "R%+0 KA34
M*H4^ "F%1P HAE  )X9: ":&9@ DAG, (X:# "&&E0 @AJ<!'H:\ 1Z&W@ >
MA/4!'H+_ 1Z"_P$>@?\!'H'_ :AT  ">?0  DX(  (F%  !^B   <8H  &6+
M  !8C   3(T  $".   VC@  +(\  "60#  CD!, (I < "&0)0 @D2X 'Y$V
M !Z10  =D4D ')%4 !J18  9D6X &)%^ !:2D  5DJ0 %)&Y !.1V  3C_0
M%([_ !2-_P 4C/\!%(S_ :-]  "8@P  CH@  (2,  !WCP  :9$  %V3  !0
ME0  19<  #F8   NF0  )9H  !V; @ 6G0P %9T3 !2=&P 3G20 $ITM !&>
M-P 1GD$ $)Y,  ^>6  .GF< #9YW  R>B@ +G9X "IVR  F=S  )G.P "IO^
M  N:_P +F?\ "YG_ )R$  "1B@  B(X  'N2  !ME@  8)D  %2<  !(GP
M/*   #"A   FHP  ':4  !6G   0J04 "ZL-  BJ$P 'JAL !JHD  6J+@ $
MJC@  JI$  &J4   JEX  *IN  "J@0  JI4  *FJ  "IP0  J.0  *CV  "G
M_P  I_\  *?_ )6+  ",D   ?Y4  '&:  !CG@  5J(  $JF   ]J   ,:H
M ":K   =K0  %+    ZR   )M0$  K8*  "V#P  MA4  +<=  "W)0  MR\
M +@Y  "X1@  N%0  +AD  "X=@  N(L  +>@  "WM@  M],  +;O  "V_
MMO\  +;_ (^2  ""EP  =)T  &:B  !8IP  2ZP  #ZO   QL0  )K,  !RV
M   3N   #;L   :^    P0   ,($  #""P  PQ   ,05  #$'   Q20  ,8N
M  #(.@  R4<  ,E7  #):0  R7T  ,F4  #(J@  R,,  ,CD  #(]   R/T
M ,C] (69  !WGP  :*8  %JK  !-L0  /[4  #&X   EN@  &KT  !'    +
MPP   \<   #*    S0   ,X   #/ P  T D  -$.  #3$@  U1D  -<B  #:
M+0  W3D  -Y)  #>6@  WVX  -^%  #?G   W[(  -[+  #>Y@  W_0  -_T
M 'FA  !KJ   7*\  $ZU  ! NP  ,;X  "3!   9Q0  $,@   G,    SP
M -,   #9    W    -T   #?    X0   .(%  #D"P  YA   .@6  #J(
M[2L  / Z  #Q2P  \5X  /)S  #SBP  \Z(  /.V  #SR0  \^$  //A &VJ
M  !>L0  4+D  $&_   RQ   ),@  !?,   .T   !M4   #:    W@   .(
M  #F    Z0   .H   #L    [@   /    #R    ] 8  /8,  #Y$@  _!P
M /\I  #_.@  _TT  /]B  #_>   _Y   /^C  #_LP  _\$  /_! /\'&0#_
M 1< _P 7 /\ &@#_ "$ _P K /\ .0#_ $< _P!4 /\ 7P#_ &H _P!S /\
M>P#_ (, _P"* /\ D #_ )8 _P"; /\ H0#_ *@ _P"O /\ N #_ ,0 _@#5
M /P Z@#[ /@ ^@#_ /D _P#X /\ ^ #_ /8 _P#S /\ \0#_ /\+%0#_!1,
M_P 3 /\ % #_ !H _P G /\ - #_ $( _P!/ /\ 6P#_ &4 _P!N /\ =@#_
M 'X _P"% /X BP#] )$ ^P"7 /H G0#X *, ]P"K /8 LP#T +X \P#, /$
MXP#O /, [@#_ .T _P#L /\ ZP#_ .P _P#L /\ ZP#_ /\-$0#_"1  _P /
M /\ $ #_ !8 _P B /\ +P#_ #T _P!* /\ 50#] &  ^@!I /@ <0#V 'D
M] !_ /, A@#Q (P [P"2 .X F #L )\ ZP"F .D K@#G +@ Y0#% ., V@#A
M .T WP#[ -X _P#= /\ W0#_ -T _P#= /\ W0#_ /\/#0#_# L _P,) /\
M# #_ !( _P = /\ *0#[ #< ^ !$ /4 4 #R %H [@!C .P :P#I ', YP!Z
M .4 @ #C (8 X0", -\ DP#= )D VP"A -D J0#5 +( T@"^ -  S@#. .8
MS #V ,H _P#* /\ R0#_ ,@ _P#( /\ R #_ /\1" #_#0( _P<  /\%" #_
M  X _P 6 /< (@#O #  ZP ] .@ 20#D %0 X != -T 90#9 &T U0!S -(
M>@#0 (  S@"' ,P C0#* )0 R "; ,8 I #$ *T P@"X ,  QP"] -\ O #Q
M +L _@"Y /\ N #_ +@ _P"X /\ N #_ /\4  #_#P  _PT  /\,  #_!PD
M^ $0 .@ &@#C "@ W0 V -@ 0@#2 $T S@!7 ,H 7P#' &8 Q0!M ,, = #!
M 'H OP"! +T B "[ (\ N0"7 +< GP"U *@ LP"S +$ P@"O -@ K@+M *P#
M^P"K!?\ J@;_ *D&_P"I!O\ J0;_ /\6  #_$@  ]Q(  .P1  #F#@  Y08(
M -T#$@#4 R  S00M ,@$.@##!48 OP50 +P&6 "Y!F  MP=G +4';@"S!W4
ML0A[ *\(@@"N"8H K F2 *H)FP"H"J4 I@JP *4+OP"C#-0 H0WM )\._@"=
M#O\ G __ )L/_P";#_\ FP__ /\:  #W&0  ZAX  -\>  #5&@  T!," ,X,
M"P#'"Q8 P TE +H.,@"V#C\ L@]) *\04@"L$%H JA!A *@1: "F$6\ I!%V
M *(1?0"A$84 GQ*. )T2EP"<$J( FA.M )@3O "7%-  E!7L )(6_0"0%_\
MCQ?_ (X7_P".%_\ CA?_ /H=  #N(P  WR@  - J  #')P  P2$  +T9!0"Y
M$A  LA4> *T6+ "H%S@ I!A# *$93 "?&50 G!I< )H:8@"9&FD EQMP )4;
M=P"4&W\ DAR( ) <D@"/')T C1VI (L=MP"*'LH B!_G (8@^@"$(/\!@R#_
M 8,@_P&"(/\!@B#_ ?4D  #E+   TS$  ,8S  "\,0  MBT  + E  "L'0P
MIAX8 *$@)@"<(3( F2(] )4B1P"3(T\ D2-6 (\C70"-)&0 BR1K (DD<@"(
M)'H AB2# (0EC0"#)9@!@26D 8 FL@%^)L4!?2?B 7LG]P%Y*/\!>"C_ 7@H
M_P%X*/\!>"C_ >\K  #=,P  RCD  +X[  "T.@  K38  *8O  "A* < FR<3
M )8H( "1*2T CBHX (LK0@"(*TH ABM2 (0K6 ""+%\ @"QF '\L;0!]+'4
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M MT[  #'0P  N4D  *Y+  "D3   FTH  ))%  ")/P  @3H) 'LZ% !W.R
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M U%&H0101[$$3T?'!$Y'YP1.1_L$3D?_ TY'_P-/1_\#3T?_ \Q&  "[3@
MKU0  *17  ":6   D5<  (94  ![3@  <$H  &E(#0!E2!8 8DDA %])*P!=
M230 6TD\ %E)0P!724H 5DE2 %5*60%42F$!4DIJ 5%*=0)/2H$#3DJ/ TQ+
MGP1+2[ $2DO%!$E+Y@1)2_H$24O_ TI+_P-*2_\#2DO_ \A)  "X40  K%<
M *%;  "87   CEP  (-9  !V4P  :TX  &1-"@!?3!, 7$T> %I-* !833$
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M SI9X ,Z6/<#.EC_ SM7_P,[5_\#.U?_ [Q4  "N7   HV,  )EG  "0:0
MA6D  'EG  !K8@  8&   %5=  !.6PP 2UL4 $E<'P!'7"@ 1ETQ $5=.0!#
M74$ 0EU( $%>4 ! 7E@ /EYA 3Q>; $[7G@".5Z' C=>EP(V7JD#-5Z] S1?
MW0,T7O4#-5W_ C5=_P(U7/\"-5S_ KA9  "J80  H&<  )9L  ",;@  @6X
M '9L  !G:0  7&8  %%D  !(8@D 1&(1 $)B&P!!8R0 /V,M #YC-0 ]9#T
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M 1]R_P$@<?\!(''_ :EK  "><P  E'D  (I\  " ?@  ='\  &=_  !:?P
M37X  $-^   X?0  +WT" "A]#0 F?10 )'T< "-^)0 B?BT (7XV "%^/P ?
M?T@ 'G]2 !U_7@ <?VL &G]Z !E_C  7?Y\ %G^S !5_S@ 5?N\ %GS_ !9[
M_P 6>_\ %WO_ *1R  ":>@  CW\  (6"  ![A   ;88  &"'  !4AP  2(@
M #R(   RB   *(@  ""(!0 :B0X &8D5 !B)'0 7BB8 %HHN !6*-P 4BD$
M$XI, !*+6  1BV4 $(MU  ^+AP .BIL #8JO  R*R  ,B>H #8?\  Z'_P .
MAO\ #H;_ )][  "4@0  BH4  ("(  !SBP  98T  %F/  !,D   09(  #22
M   JD@  (9,  !F4   2E@8 #I<.  V7%0 ,EQT #)<F  N7+P *ESD "9=$
M  B74  &EUX !9=N  .6@  !EI0  )6H  "5O@  E.   )3T  "3_P !DO\
M 9+_ )B"  ".B   A8P  '>/  !JD@  794  %"8  !$F@  .)L  "R<   B
MG0  &9X  !*@   -H@( !Z,+  &C$   HQ<  *,?  "C)P  HS$  *0\  "D
M2   I%8  *1E  "C=P  HXL  *.@  "BM@  H=(  *'P  "@^P  H/\  *#_
M )&*  ")C@  >Y(  &V7  !@FP  4YX  $:A   YHP  +:0  ".F   9J
M$:H   RL   %K@   *\'  "O#0  KQ$  + 8  "P(   L2@  +$R  "R/@
MLDP  +);  "R;   LH$  +&7  "QK   L,8  +#H  "O]P  K_\  *__ (R0
M  !_E0  <9H  &.?  !5I   1Z@  #JJ   MK   (JX  !BP   0LP  "K4
M  *X    NP   +L   "\!P  O T  +T1  "^%@  OQX  , G  #!,@  PD
M ,-/  ##8   PW0  ,.+  ##H0  P[@  ,+7  #"[P  POH  ,'^ (&7  !S
MG0  9:,  %>H  !)K0  .[$  "VS   AM@  %KD   Z[   'O@   ,$   #%
M    QP   ,@   #)    R@4  ,L+  #-#P  SA0  - <  #3)@  UC(  -A!
M  #84P  V68  -E\  #9E   V:L  -G#  #9X0  V?   -GT ':?  !GI@
M6:P  $NR   \MP  +KH  "&]   5P   #<0   7'    R@   ,X   #2
MU0   -8   #9    VP   -T   #?!P  X0P  .,1  #F&0  Z20  .PR  #M
M0P  [E8  .]K  #OA   [YP  .^R  #OQ@  []T  ._D &JH  !;KP  3+8
M #Z\   OP   (,0  !3(   ,S    M    #4    V0   -X   #B    Y0
M .8   #H    Z0   .P   #N    \ (  /()  #U#P  ^!<  /PC  #_,P
M_T8  /]:  #_<0  _XD  /^?  #_L0  _\   /_& /\ %0#_ !0 _P 4 /\
M%P#_ !T _P H /\ -P#_ $0 _P!1 /\ 7 #_ &8 _P!O /\ =P#_ 'X _P"%
M /\ BP#_ )$ _P"7 /\ G0#_ *0 _P"K /\ M #^ +\ _0#. /L Y@#Y /8
M^ #_ /< _P#W /\ ]P#_ /  _P#L /\ Z0#_ /\#$@#_ !  _P 0 /\ $0#_
M !< _P D /\ ,@#_ #\ _P!, /\ 5P#_ &$ _P!J /\ <@#_ 'D _0"  /P
MA@#Z (P ^0"2 /@ F #V )\ ]0"F /0 K@#R +D \ #& .X W@#M /  ZP#^
M .H _P#I /\ Z0#_ .< _P#C /\ X #_ /\'#@#_  T _P + /\ # #_ !,
M_P ? /\ + #_ #H _P!& /X 4@#[ %P ^ !E /4 ; #S '0 \0!Z .\ @0#N
M (< [ "- .H DP#I )H YP"A .8 J0#C +, X0"_ -\ T #= .D V@#Y -D
M_P#7 /\ U0#_ -4 _P#5 /\ U #_ /\)"@#_ 04 _P # /\ "0#_ !  _P 9
M /L )@#W #0 ] !  /( 3 #N %8 Z@!? .< 9P#D &X X@!T .  >P#> ($
MW "' -H C0#6 )0 U "; -$ HP#/ *T S "X ,H QP#( .  Q@#S ,4 _P##
M /\ PP#_ ,, _P## /\ PP#_ /\+ 0#_ P  _P   /\  P#_  L \P 2 .X
M'P#J "T Y@ Z .( 10#> $\ V0!8 -0 8 #1 &@ S@!N ,P = #* 'L R "!
M ,8 AP#$ (X P@"6 ,  G@"^ *< NP"R +D P "W -0 M0#L +, ^P"S /\
ML@#_ +( _P"Q /\ L0#_ /\-  #_!@  _P,  /<   #T  , YP - .  & #:
M "4 TP R ,X /@#* $D Q@!2 ,, 6@#  &$ O@!H +P ;@"Z '0 N ![ +8
M@0"T (@ L@"0 +  F0"N *( K "M *H N@"H ,L I@#F *4 ]P"D /\ HP#_
M *( _P"B /\ H@#_ /\0  #[#   [PX  .8-  #?"0  V@ & -  $0#) !T
MQ  J +\ -P"[ $( MP!+ +0 5 "R %L KP!B *T : "K &X J0!U *@ >P"F
M (, I "+ *( E "@ )X G@&H )P"M0"; \8 F07B )@&] "6"/\ E0G_ )0)
M_P"4"?\ E G_ /P1  #Q%0  XQD  -89  #,%0  QQ   ,0'"@"] Q0 MP0A
M +(&+@"N"#H J@E$ *<)30"D"E4 H@I< * *8@">"VD G MO )L+=@"9#'X
MEPR& )8,D "4#)H D@VF )$-LP"/#<4 C0[B (L0]@")$/\ B!'_ (<1_P"'
M$?\ AQ'_ /89  #G(   UB0  ,@E  "_(@  N1P  +04 0"Q#0X J@X9 *4/
M)P"A$#, G1$^ )H11P"8$D\ E1)6 ),27 "1$F, D!-I (X3< ",$W@ BQ.!
M (D4BP"'%)8 AA6B (05L "#%L$ @1?= '\8] !]&?\ ?!G_ 'P9_P![&?\
M>QG_ .\A  #=*0  RBT  +XO  "U+   KB<  *@@  "C%P@ GA83 )D7(0"4
M&2T D1HX (X:00"+&TD B1M0 (<;5P"%'%X A!QD ((<:P" '', ?QU\ 'T=
MA@!\'I$ >AZ> '@?JP!W'[P =B#4 '0A\ !R(?\ <2+_ '$A_P!Q(?\ <2'_
M .@H  #2,   PC4  +<W  "M-0  I3$  )XK  "8(P( DAX0 (T@&P")(2<
MAB(R (,C/ "!(T0 ?B-+ 'PD4@![)%D >21? '<D9@!V)6X ="5W ',E@0!Q
M)HT ;R:9 &XFIP!M)[@ ;"?. 6HH[0%I*?\!:"G_ 6@I_P%H*/\!:"C_ >$N
M  #+-@  O#L  +$]  "G/0  GSD  )<S  "/+0  B"<, (,G%@!_*"( ?"DM
M 'DJ-P!W*C\ =2I' ',K3@!Q*U0 <"M; &XK8@!L*VH :RQR &DL?0!H+(D
M9BV6 64MI %D+K0!8R[* 6$OZ0%@+_T!8"__ 6 O_P%@+_\!8"[_ =HT  #%
M/   MT$  *Q#  "B0P  F4   ) Z  "(-   @"X( 'HM$@!W+AX <R\I '$P
M,P!O,#L ;3!# &LQ2@!I,5$ 9S%7 &8Q7@!D,68 8S)O &$R>0!@,H4!7S*2
M 5TSH0%<,[$!6S3& 5HTY@%9-?L!637_ 5DT_P%9-/\!633_ =(X  # 0
MLT4  *A(  ">2   E48  (M   "".P  >34$ ',S$ !O-!H ;#0E &DU+P!G
M-3< 938_ &,V1@!B-DT 8#94 %\V6P!=-V, 7#=K %LW=@%9-X(!6#B/ 58X
MG@%5.*\"5#G# E,YY )3.OD!4SG_ 5(Y_P%3.?\!4SG_ <T\  "\1   KTD
M *1,  ":3   D4L  (=&  !]0   <SL  &PX#0!H.1< 93DB &,Z*P!@.C0
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M D-&W )#1O4"0T;_ D-&_P%#1?\!0T7_ <%'  "R3P  IE0  )Q7  "26
MB%@  'Y5  !Q3P  9DH  %Q&!0!71@\ 5$88 %%&(@!/1BL 3D8S $Q'.@!+
M1T$ 2D=) $E(4 !(2%@ 1TAA $5); !$27@!0DF& 4%)E@% 2J<"/TJ[ CY+
MV (^2O,"/DK_ CY)_P$_2?\!/TG_ ;U*  "O4@  HU@  )E;  "070  AEP
M 'M9  !M4P  8D\  %=, 0!12@T 3DH5 $Q+'P!*2R@ 24LP $=+. !&3#\
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M 2Y7_P$N5_\!+E;_ ;)7  "E7P  FV4  )%I  "':@  ?&H  '%H  !C90
M6&(  $U?  !#70( /%L- #I<%  X7!T -UPF #5=+@ T738 ,UT^ #)=1@ Q
M7DX ,%Y7 "]>8@ M7FX +%]] "I?C@ I7Z  *%^S 2=?S  G7^T!)U[_ 2==
M_P$H7?\!*%S_ :U<  "B9   F&H  (YN  "#;P  >6\  &YN  !@:P  5&D
M $EG   _90  -6,) #)C$0 P8QD +V0A "YD*0 M9#$ +&0Y "ME0@ J94H
M*&54 "=E7P F9FL )&9Z "-FBP B9IT (&:Q !]FR0 ?9NL (&7^ "!D_P @
M8_\!(6/_ :EB  ">:@  E7   (IS  " =0  =74  &ET  !<<@  3W$  $1O
M   Z;@  ,&T# "EL#0 G;!0 )FP< "5M)  D;2P (VTT ")M/0 A;D8 (&Y0
M !YN6P =;F< '&YV !INAP 9;YH &&^N !9OQ@ 6;ND %VW\ !AL_P 8:_\
M&&O_ *1I  ":<0  D'8  (9Y  !\>P  <7L  &1[  !7>@  2GD  #]X   U
M>   *W<  ")V!P ==@\ ''<6 !MW'@ :=R8 &7<N !AW-P 7>$  %7A* !1X
M5@ 3>&, $GAR !%X@P 0>)< #WBK  YXPP .=^8 #G;Z  ]U_P 0=?\ $'3_
M )]Q  "5>   BWP  ()_  !W@0  :H(  %V"  !0@@  1((  #B"   N@@
M)((  !R"   4@@D $8,0 !"#%@ 0@QX #H,G  Z#,  -@SD #8-$  R#4  +
M@UT "8-L  B#?@ &@Y$ !8*E  ."NP $@=L !('R  6 _P &?_\ !G__ )IY
M  "0?@  AH,  'V%  !OAP  8HD  %6*  !)BP  /8P  #&,   FC   '8T
M !6.   /CP, "I ,  :0$0 $CQ@  X\@  &/*0  CS(  ) ]  "020  CU8
M (]E  "/=@  CXH  (Z?  ".M   C<\  (SN  ",^P  B_\  (O_ )2   "+
MA0  @HD  '2,  !FCP  69$  $R3  ! E0  -)8  "B6   >EP  %9@   ^:
M   *FP   IP)  "<#@  G!,  )P:  "<(@  G2L  )TU  "=0   G4X  )U<
M  "=;@  G($  )R7  "<K   F\8  )KH  "9^0  F?\  )C_ (Z(  "&C
M>)   &J4  !<EP  3YH  $*=   VG@  *9\  !^A   5H@  #J0   BF
MJ    *D$  "I"@  J0X  *D3  "J&@  JB(  *LK  "L-@  K$0  *Q3  "L
M8P  K'<  *N.  "KI   J[P  *K>  "I]   J?T  *G_ (F.  ![DP  ;9<
M %^<  !1H   1*0  #:F   JJ   'JD  !2K   -K@  !K    "R    M0
M +4   "U P  M@D  +<.  "X$@  N!D  +HA  "[*P  O#@  +U'  "]6
MO6L  +V!  "]F0  O;   +W,  "\Z@  O/<  +O^ 'Z5  !PFP  8J   %.E
M  !&J@  .*T  "JO   >L0  $[0   RW   #N0   +P   "_    P@   ,(
M  ##    Q    ,8&  #'#   R!   ,H6  #,(   SRL  - Z  #12P  T5X
M -)S  #2BP  TJ0  -.[  #3V   T^T  -/V '.=  !DHP  5JD  $>O   Y
MLP  *K8  !VY   2O   "K\   ##    Q@   ,D   #-    SP   -    #2
M    U    -8   #9 @  VP@  -X.  #A$P  Y!T  .@J  #H/   Z4\  .ED
M  #J?   ZY4  .NL  #KP@  [-4  .SE &:F  !8K   2;,  #NY   KO
M'<   !'$   )R    ,P   #/    TP   -D   #=    X    .$   #C
MY0   .<   #J    [    .X$  #Q"P  ]1(  /@<  #[*P  _3X  /Y3  #^
M:@  _X,  /^;  #_K@  _[X  /_* /\ $@#_ !  _P 1 /\ $P#_ !D _P F
M /\ - #_ $$ _P!- /\ 6 #_ &( _P!K /\ <P#_ 'H _P"! /\ AP#_ (T
M_P"3 /\ F0#_ *  _P"G /X KP#\ +H ^@#) /D X0#X /, ]P#_ /8 _P#U
M /\ \0#_ .D _P#D /\ X0#_ /\ #P#_  T _P - /\ #@#_ !0 _P A /\
M+@#_ #P _P!( /\ 4P#_ %T _P!F /X ;0#\ '4 ^P![ /D @@#X (@ ]P".
M /8 E #T )L \P"B /$ J@#O +0 [0#! .L U0#J .P Z #\ .< _P#E /\
MY@#_ .  _P#9 /\ U #_ /\ "P#_  @ _P & /\ "0#_ !  _P < /\ *0#_
M #8 _P!" /L 3@#W %< ] !@ /( : #O &\ [0!V .P ? #J (( Z "( .<
MC@#E )4 XP"< .$ I #? *X W0"Y -H R@#7 .0 U #V -$ _P#0 /\ T #_
M ,\ _P#+ /\ QP#_ /\  P#_    _P   /\ ! #_  T ^@ 6 /8 (P#S #
M\  \ .T 1P#I %$ Y0!: .( 8@#? &D W0!O -H =@#8 'P U "" -( B #0
M (\ S0"6 ,L G@#) *@ QP"S ,4 P0#" -@ P #O +\ _@"^ /\ O0#_ +P
M_P"\ /\ O #_ /\"  #_    _P   /\   #T  < [0 1 .@ ' #C "D WP U
M -L 00#6 $L T0!4 ,T 7 #* &, R !I ,8 ;P## '4 P0![ +\ @@"^ (@
MO "0 +H F "X *( M0"L +, N0"Q ,L KP#G *X ^ "L /\ JP#_ *P _P"L
M /\ JP#_ /\$  #_    ]@   .X   #G    WP , -8 %0#/ "( R@ N ,<
M.@## $0 P !- +P 50"Y %P MP!C +4 :0"S &\ L0!U *\ >P"M (( JP"*
M *D D@"G )P I0"F *, LP"A ,, GP#> )X \@"= /\ G #_ )P _P"; /\
MFP#_ /\'  #V"0  Z0L  -\*  #5!   S@ % ,8 $ #  !H NP G +< ,@"S
M #T L !& *T 3P"J %8 J !< *8 8P"D &@ H@!O *$ =0"? 'P G0"$ )L
MC0"9 )< EP"B )4 K@"3 +T D0#3 )  [0"/ /P C@#_ (T!_P"- ?\ C0'_
M /D.  #J$@  W!4  ,T5  #$$0  O@P  +H""@"T !( K@ > *H *@"F #4
MH@ _ *  2 "= 5  FP)6 )D"7 "7 V, E0-I ),#;P"1!'8 D 1_ (X%B ",
M!9( B@:> (@&J@"&![H A0C/ (0*ZP"""_P @0S_ ( ,_P" #/\ @ S_ /$5
M  #@'0  S2   ,$A  "X'0  L1<  *P0  "H"0T H@<6 )T)(P"9"BX E0LX
M ),,00"0#$D C@U0 (P-5P"*#5T B UC (<-:@"%#G$ @PYZ ((.A " #H\
M?@^; 'P/J ![$+@ >A#. '@1[ !V$O\ =1+_ '03_P!T$_\ =!/_ .@>  #3
M)@  PRH  +@J  "N*   IR,  * <  ";$P, E@\0 ) 0&P",$2< B1(R (83
M.P"$$T, @A1+ ( 440!^%%< ?!1> 'L590!Y%6P =Q5T '86?@!T%HH <A>6
M '$7I !O&+0 ;AC) &T9Z !K&OP :AO_ &H;_P!J&_\ :AO_ . F  #*+0
MO#$  + S  "G,0  GRP  )<F  "0'P  BA<, (48%@"!&2( ?AHL 'L;-@!Y
M&SX =QQ% '4<3 !S'%, <1U9 ' =8 !N'6< ;1YP &L>>@!J'H4 :!^2 &<?
MH !E(+  9"'% &,AY !B(OH 82+_ &$B_P!A(O\ 82+_ -<L  ##-   MC@
M *HY  "A.   F#4  ) O  "(*   @"$( 'L@$@!W(1T ="(G '$B,0!O(SD
M;2-! &LC2 !I(TX :"15 &8D6P!E)&, 8R5K &(E=0!A)8$ 7R:. %XFG0!=
M)ZT 6RC! %LHX !:*?< 62G_ %DI_P!9*?\ 62C_ ,\R  "^.0  L3T  *8_
M  "</P  DSP  (HV  "!,   >2H# '(F#P!N)QD :R@C &DH+ !F*34 92D\
M &,I0P!A*DH 8"I1 %XJ5P!=*E\ 7"MH %HK<@!9+'T 6"R+ %8MF@!5+:H
M5"Z] %,NW !2+_4 4B__ %(N_P!2+O\ 4B[_ ,HV  "Z/0  K4(  *)$  "8
M1   CT$  (4\  ![-P  <C$  &LL# !G+14 9"T? &$N* !?+C$ 72XY %PO
M0 !:+T8 6"]- %<O5 !6,%P 53!D %,Q;@!2,7H 43&( % REP!.,J@ 33.[
M $TTV !,-/, 3#3_ $PT_P!,,_\ 3#/_ ,8Z  "V0@  J48  )Y)  "520
MBT<  (%"  !W/0  ;3<  &0R"0!@,A( 73(< %HR)0!8,RT 5C,U %4S/ !3
M-$, 4C1* %$T40!0-%D 3S5A $TU; !,-G< 2S:% $HWE0!(-Z8 1SBX 4<X
MTP%&./$!1CC_ 48X_P!&./\ 1C?_ ,$^  "R10  IDH  )Q-  "230  B$L
M 'Y'  !S0@  :3T  %\W!@!:-A  5S<8 %0W(@!2-RH 4#<R $\X.0!-.$
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M 3=$_P$X1/\!.$/_ +=)  "I4   GE4  )18  "+60  @%@  '96  !H4
M74P  %-(  !*10D 1D01 $1$&0!"1"( 044I #]%,0 ^13@ /44_ #Q&1P [
M1D\ .D=8 #E'8@ X2&X -DA\ #5(C0 T29X ,TFQ #))R0 Q2>L ,DG^ #)(
M_P R2/\ ,TC_ +1,  "G5   G%D  ))<  "(70  ?ET  '-:  !E50  6U(
M %!.  !&2@4 0$D. #Y)%@ ]21X .THF #I*+@ Y2C4 .$L] #=+1  V2TT
M-$Q6 #-,8  R3&P ,4UZ #!-BP N39P +4ZO "Q.QP L3ND +$W] "U-_P M
M3/\ +4S_ +!0  "D6   F5T  (]A  "&8@  >V$  '!?  !B6P  6%@  $Y5
M  !#40$ .T\, #A/$P V3QL -4\C #10*P S4#( ,E Z #%00@ P44H +E%3
M "U270 L4FD *U)X "E2B  H4YH )U.M "93Q0 F4^< )E/\ "=2_P G4?\
M)U'_ *Q5  "@7   EF(  (UF  "#9P  >&8  &UE  !@80  55X  $I;   _
M6   -58( #%5$  P5A< +E8? "U6)P L5B\ *U<V "I7/@ I5T< *%=0 "98
M6@ E6&< )%AU "-9A@ A69@ (%FK !]9P@ ?6>4 'UCZ "!8_P @5_\ (5?_
M *A:  "=8@  DV<  (IK  !_;   =6P  &IK  !=:   464  $9C   [8
M,5X# "I=#0 H71, )ET; "5>(P D7BH (UXR ")>.@ A7D, (%], !]?5P >
M7V, '&!Q !M@@@ 98)4 &&"I !=@P  68.( %U_Y !A>_P 97O\ &5W_ *1@
M  "9:   D&X  (9P  !\<@  <G(  &9Q  !8;@  3&P  $%K   V:0  +6<
M "-F"  ?9@\ '685 !QF'0 ;9B4 &F8M !EG-0 89SX %V=( !9G4P 5:%\
M$VAN !)H?P 1:)( $&BF  ]HO0 .:.  $&?W !!F_P 19?\ $67_ )]G  "6
M;P  C',  ()V  !X>   ;7@  &!W  !3=@  1G0  #MS   Q<@  )W$  !YQ
M   6< H $W 0 !-P%P 2<!\ $7$G !!Q+P 0<3@ #G%"  YQ3@ -<5L #'%I
M  MQ>@ *<8T "'&A  9QM@ &<-( !W#O  AO_P );O\ "6[_ )MO  "1=0
MAWD  'Y\  !T?@  9GX  %E^  !-?@  0'T  #5]   J?   (7P  !A\   1
M? 0 #'P,  I\$0 )?!D "'PA  =\*0 &?#( !'P]  -\2  !?%4  'QC  !\
M=   ?(<  'N<  ![L0  >LL  'GK  !Y^@  >?\  'C_ )9W  ",?   @X
M 'F#  !LA   7H4  %&&  !%AP  .8<  "V'   CAP  &H<  !*'   -B $
M!HD*  &)#P  B10  (@;  "((P  B2P  (DV  ")0@  B$X  (A=  "(;0
MB($  (>5  "'JP  AL0  (7F  "$^   A/\  (3_ )!^  "'@P  ?H<  '&)
M  !CBP  5HT  $F/   \D0  ,)$  "21   :D@  $I,   V4   &E0   )8&
M  "6#   E1   )85  "6'0  EB0  )8N  "6.0  ED8  )95  "690  EG@
M )6.  "5I   E+P  )/?  "3]0  DO\  )+_ (N&  "#B@  =8T  &>0  !9
ME   3)<  #^9   RF@  )IL  !N<   2G0  #)\   2@    H@   *,!  "C
M!P  HPP  *,0  "D%0  I!P  *4E  "F+P  ICP  *9+  "F6P  IFX  *6$
M  "EFP  I+,  */0  "C[P  HOP  *+_ (:-  !XD0  :I4  %R9  !.G0
M0:   #.B   FHP  &Z4  !&G   *J0   :L   "M    KP   +    "P
ML 4  +$+  "R#P  LQ0  +0;  "U)   MS   +<_  "W4   MV(  +=X  "W
MD   MJD  +;"  "VY   MO4  +7^ 'N3  !MF   7YT  %"B  !"I@  -*D
M ":K   :K0  $*\   FR    M    +<   "Z    O    +T   "^    O@
M , "  #!"   P@T  ,02  #&&0  R20  ,HR  #+0P  RU4  ,QJ  #,@P
MS)P  ,NU  #,S@  S.D  ,SV '";  !AH0  4J8  $2K   VL   )[(  !JU
M   0N   ![L   "^    P0   ,0   #(    RP   ,L   #-    S@   -
M  #2    U0,  -@*  #;$   WA@  .(D  #C-0  Y$@  .5<  #F<P  YHT
M .:E  #FO   YM,  .?G &.D  !5J@  1K   #BU   HN0  &KP   _    %
MQ    ,<   #+    SP   -0   #8    W    -T   #?    X0   .,   #E
M    Z    .H   #M!@  \0X  /46  #X)0  ^3@  /E-  #Z8P  ^WP  /R5
M  #\J@  _+L  /W+ /\ #P#_  X _P . /\ $ #_ !8 _P C /\ , #_ #T
M_P!) /\ 5 #_ %X _P!F /\ ;@#_ '8 _P!\ /\ @@#_ (D _P"/ /\ E0#^
M )L _0"C /L JP#Z +4 ^0## /< VP#V /  ] #_ /, _P#R /\ [ #_ .(
M_P#< /\ U@#_ /\ # #_  D _P ( /\ "@#_ !( _P > /\ *P#_ #@ _P!$
M /\ 3P#_ %D _@!A /P :0#Z '  ^ !W /< ?0#V (, ] ") /( CP#Q )8
M[P"= .T I0#L *\ Z@"\ .@ S0#F .@ Y #Z ., _P#B /\ X #_ -4 _P#.
M /\ RP#_ /\ !@#_  $ _P   /\ ! #_  X _P 9 /\ )0#] #( ^P ^ /<
M20#S %, \ !< .X 8P#L &H Z@!Q .@ =P#F 'T Y "# .( B0#@ )  W@"7
M -P GP#9 *D U@"T -, Q #0 -X S@#S ,P _P#+ /\ R@#_ ,@ _P#" /\
MO@#_ /\   #_    _P   /\   #[  L ]@ 3 /$ ( #M "P Z@ X .< 0P#C
M $T X !6 -P 70#9 &0 U0!K -( <0#0 '8 S@!\ ,P @P#* (D R "1 ,8
MF0#$ *, P0"M +\ NP"] ,\ NP#K +D _ "W /\ MP#_ +8 _P"T /\ L0#_
M /\   #_    _P   /8   #N  4 YP / .$ &0#; "4 U0 Q -( / #. $8
MR@!/ ,< 5P#$ %X P0!D +\ :@"] '  NP!V +D ? "X (, M@"* +, DP"Q
M )P KP"G *T LP"K ,4 J0#A *< ]0"F /\ I0#_ *0 _P"D /\ I #_ /\
M  #\    \0   .@   #@    U  + ,P $P#' !\ P@ J +\ -0"\ #\ N !(
M +4 4 "S %< L !> *X 9 "L &D JP!O *D =0"G 'P I0"$ *, C "A )8
MGP"A )T K0": +P F #2 )< [@"5 /X E #_ )4 _P"5 /\ E0#_ /P!  #P
M!0  XP<  -4%  #,    Q0 $ +X #@"X !< LP C *\ +@"K #@ J0!! *8
M2@"C %$ H0!7 )\ 70"= &, FP!I )H ;P"8 '8 E@!] )0 A@"2 )  D ";
M (X IP", +8 B@#) (@ YP"' /D AP#_ (8 _P"& /\ A@#_ /0,  #D$
MT1(  ,41  "]#@  M@@  +$ " "K !$ I@ ; *$ )@"> #$ F@ Z )@ 0P"5
M $H DP!1 )$ 5P"/ %T C@!C (P :0"* '  B !W (8 @ "$ (L @@"6 (
MHP!^ +$ ?0#$ 'L"X0!Z _4 >@7_ 'D%_P!X!O\ > ;_ .H3  #6&@  QAT
M +H<  "Q&0  JA,  *0-  "?!0P F0 4 )4 'P"1 BD C0,S (L$/ "(!40
MA@9+ (0&40""!U< @0== '\'8P!]"&H >PAR 'H(? !X"88 =@F2 '0*H !S
M"J\ <0O! ' ,WP!O#?8 ;@[_ &T._P!M#O\ ;0[_ .$<  #+(P  O"8  +$F
M  "H)   H!X  )D8  "3$ ( C@L. (@+%P"$#"( @0TL 'X--0!\#CT >@Y%
M '@.2P!W#E$ =0]8 ',/7@!Q$&4 <!!N &X0=P!L$(( :Q"/ &D1G0!H$:T
M9A+  &42WP!D$_8 8Q3_ &,4_P!B%/\ 8A3_ -8D  ##*@  M2X  *HO  "@
M+0  F"@  ) B  ")&P  @A,( 'T1$@!Y$AP =A,G ',4, !Q%#@ ;Q4_ &T5
M1@!L%4P :A93 &@660!G%F$ 919I &07<@!B%WX 81B+ %\8F0!>&:D 7!F\
M %P:V !:&_, 6AS_ %D<_P!9'/\ 61S_ ,TJ  "],0  KS4  *0V  ";-
MDC$  (DK  "!)0  >1T# ',8#@!O&1@ ;!HB &D;*P!G&S, 91P[ &0<00!B
M'4@ 8!U. %\=50!='5P 7!YD %L>;@!9'WD 6!^' %8@E@!5(*8 5"&X %,A
MT@!2(O$ 4B/_ %(C_P!2(O\ 4B+_ ,@O  "X-@  JSH  * \  "6.P  C3@
M (,R  !Z+0  <B8  &H@# !F(!, 8R$= &$A)@!?(B\ 72(V %LB/0!:(T0
M6"-* %<C40!5(U@ 5"1A %,D:@!1)78 4"6# $\FDP!.)Z, 3">U $PHS@!+
M*.X 2RG_ $LH_P!+*/\ 2RC_ ,,T  "S.P  IS\  )Q!  "20   B3X  '\Y
M  !U,P  ;"T  &,G" !>)A$ 7"89 %DG(@!7)RL 52@R %0H.0!2*$  42A&
M % I30!.*54 32E= $PJ9P!+*G, 22N  $@KD !'+*$ 1BVS $4MRP!%+NP
M1"[_ $0N_P!%+?\ 12W_ +XX  "P/P  I$,  )E%  "/10  A4,  'L^  !Q
M.0  9S0  %XN! !8*PX 52L6 %(L'P!0+"< 3RPO $TM-@!,+3P 2BU# $DM
M2@!(+E( 1RY: $8O9 !%+W  0S!^ $(PC0!!,9X 0#*Q #\RR  _,^H /S/^
M #\R_P _,O\ /S+_ +L\  "M0P  H4<  )9)  ",20  @T@  'A$  !M/@
M8SD  %HT  !2, P 3S 3 $PP' !*,"0 23$K $<Q,@!&,3D 1#%  $,R1P!"
M,D\ 03-8 $ S8@ _-&T /C1[ #TUBP \-IP .S:O #HWQ@ Y-^@ .3?\ #HW
M_P Z-O\ .C;_ +=   "J1@  GDL  )1-  "*3@  @$P  '5(  !J0P  8#X
M %8Y  !--0D 2301 $<U&0!%-2$ 0S4H $$U+P! -38 /S8] #XV10 ]-TT
M/#=5 #LX8  Z.&L .3EY #@YB0 W.IL -3JM #4[Q  T.^8 -#O[ #4[_P U
M.O\ -3K_ +1#  "G2@  G$X  ))1  "(4@  ?E   '--  !G2   7$0  %(_
M  !(.@8 1#D/ $$Y%@ _.1X /CDF #PY+0 [.C0 .CH[ #D[0@ X.TH -SQ3
M #8\70 U/6D -#UW #,^AP Q/ID ,#^K "\_P@ O/^0 +S_Z # __P P/O\
M,#[_ +%'  "D30  F5(  (]5  "&5@  ?%4  '%2  !D3   64D  $]%  !%
M0 , /SX- #P^$P Z/AL .3XC #<^*@ V/S$ -3\X #0_0  S0$@ ,D!1 #%!
M6P P06< +D)U "U"A0 L0Y< *T.J "I#P  I1.( *D/Y "I#_P K0O\ *T+_
M *Y*  "A40  EU8  (U9  "#6@  >5H  &Y7  !A4@  5TX  $U+  !#1P
M.D,* #9#$0 T0Q@ ,T,@ #)$)P Q1"\ ,$0V "]%/0 M148 +$5/ "M&60 J
M1F0 *4=R "A'@P F1Y4 )4BH "1(O@ C2.  )$CW "5'_P E1_\ )D?_ *I/
M  "?50  E%H  (M>  "!7P  =UX  &M<  !?6   554  $M1  ! 30  -4H'
M #!)#@ N214 +4D= "Q))  K2BL *DHS "A*.P G2T, )DM, "5+5@ D3&(
M(TQP "%,@  @39, 'TVF !Y-NP =3MT 'DWV !Y,_P ?3/\ ($O_ *=3  "<
M6@  DE\  (AC  !^9   =&,  &EA  !<7@  4EL  $=8   \50  ,E(" "I0
M#  G3Q( )E 9 "50(  D4"@ (U O ")1-P A44  (%%) !Y24P =4E\ '%)M
M !I3?0 94Y  &%.D !93N0 54]D %E/T !=2_P 84?\ &5'_ *-9  "88
MCV4  (5H  ![:0  <6D  &9G  !99   36$  $)?   X7   +EH  "58"  @
M5PX 'E<4 !U7'  <6", &U@K !I8,P 96#P &%A% !994  565L %%EI !-:
M>@ 26HT $5JA !!:MP .6M4 $%GS !!9_P 16/\ $5C_ )]?  "59@  C&L
M ()M  !X;@  ;F\  &)M  !5:@  2&@  #YF   S90  *6,  "!A 0 88 L
M%6 0 !1@%P 38!X $F F !)@+@ 183< $&%   ]A2P .85@ #6%F  QB=@ +
M8HD "F&=  EAL@ (8<L "&'K  E@_0 *7_\ "U__ )MF  "2;0  B'$  'YS
M  !U=0  :G0  %QS  !/<@  0W   #AO   M;@  )&P  !MK   3:P0 #FH,
M  UJ$@ ,:AD "VHA  IJ*0 ):C( "&H\  =K1P %:U, !&MA  )K<0  :H0
M &J8  !JK0  :<8  &GG  !I^   :/\  &C_ )=M  "-<P  A'<  'MZ  !P
M>P  8WL  %9Z  !)>@  /7D  #%X   G=P  '78  !5V   /=@( "78*  1V
M#P  =A4  '8<  !V)   =2P  '4V  !U00  =4X  '5<  !U;   =7X  '23
M  !TJ   <\   '/C  !R]P  <O\  ''_ ))U  ")>@  @'X  ':   !I@0
M6X(  $Z"  !!@@  -8,  "F"   ?@0  %H$  !""   *@@   H,'  ""#0
M@A$  ((7  ""'@  @B8  ((O  "".P  @D<  ()5  "!90  @7@  (&-  "
MH@  ?[H  '_=  !^]   ??\  'W_ (U\  "$@0  >X0  &Z&  !@B   4HH
M $6+   YC   +(P  "&,   7C   $(T   F.   "CP   ) #  "/"0  CPX
M (\2  "0&   D!\  ) H  "0,@  D#\  )!-  "070  CW   (^%  ".G
MCK,  (W0  ",\   B_X  (O_ (B$  " B   <HL  &2-  !6D   2),  #N5
M   NE@  (I8  !>7   /F   ")D   ";    G0   )T   "= P  G0D  )T-
M  ">$0  GA<  )\?  "?*0  H#4  *!#  "@5   H&8  )][  ">DP  GJL
M )W&  "=Z0  G/D  )S_ (.+  !UC@  9Y(  %F6  !+F0  /9P  #">   C
MGP  %Z    ZB   'I    *8   "H    J@   *H   "J    JP$  *L'  "L
M#   K1   *X6  "O'@  L2D  +$X  "Q2   L5H  +%O  "QB   L:   +"Z
M  "OW0  K_(  *_] 'B1  !JE@  7)H  $V?   _HP  ,:8  ".G   7J0
M#JL   6N    L    +(   "U    MP   +<   "X    N0   +H   "\ P
MO0D  +X.  # %   PQX  ,4K  #%/   QDX  ,9B  #&>@  QI0  ,:M  #&
MR   Q>4  ,7S &R9  !>G@  3Z0  $&H   RK   )*\  !:Q   -M    [<
M  "Z    O0   ,    #$    Q@   ,8   #(    R0   ,L   #,    S@
M - &  #3#0  V!,  -P>  #>+0  WT   .!4  #A:P  X84  .&?  #AMP
MX<\  .'F &"A  !2IP  0ZT  #2R   EM0  %[D   V\   !OP   ,,   #'
M    R@   ,\   #3    U@   -<   #:    W    -\   #A    XP   .8
M  #I 0  [ L  / 2  #S'P  ]#$  /9&  #W7   ^'0  /B/  #YI@  ^;@
M /C) /\ #0#_  L _P + /\ #@#_ !, _P ? /\ + #_ #D _P!% /\ 4 #_
M %D _P!B /\ :@#_ '$ _P!W /\ ?@#_ (0 _@"* /T D #\ )< ^@"> /D
MIP#W +$ ]@"^ /4 T@#S .P \0#^ /  _P#P /\ Y@#_ -P _P#2 /\ S0#_
M /\ !P#_  0 _P " /\ !@#_ !  _P ; /\ )P#_ #, _P _ /\ 2@#^ %0
M^P!= /D 9 #W &L ]0!R /, > #R 'X \ "$ .\ B@#M )$ [ "9 .H H0#H
M *L Y@"V .0 QP#B ., X #W -X _P#= /\ V0#_ ,P _P#% /\ P0#_ /\
M  #_    _P   /\  0#_  T _P 6 /P (@#Y "X ]@ Y /, 10#O $X [ !7
M .D 7@#F &4 Y !L .( <@#@ '< WP!^ -T A #; (L V "2 -4 FP#2 *0
MSP"O ,T O@#+ -4 R0#O ,< _P#% /\ Q #_ +X _P"X /\ M0#_ /\   #_
M    _P   /X   #W  D \0 1 .L ' #G "@ Y  S .$ /@#= $@ V !1 -,
M6 #0 %\ S@!E ,P :P#* '$ R !W ,8 ?0#$ (0 P@", ,  E "^ )X NP"H
M +D M@"W ,@ M0#F +, ^@"Q /\ L #_ +  _P"L /\ J0#_ /\   #_
M^@   /$   #H  , X  - -@ %@#1 "( S0 M ,H -P#& $$ P@!* +\ 4@"]
M %D N@!? +@ 90"W &H M0!P +, =@"Q 'T KP"% *T C0"K )< J0"A *<
MK@"E +X H@#8 *  \@"? /\ G@#_ )X _P"> /\ G #_ /\   #W    ZP
M .$   #6    RP ) ,4 $0"_ !L NP F +< ,0"T #H L0!# *X 2P"K %(
MJ0!8 *< 7@"F &0 I !I *( < "@ '8 G@!^ )P A@": )  F "; )8 IP"4
M +8 D@#* )  Z0"/ /P C@#_ (T _P", /\ C0#_ /@   #I @  VP,  ,P!
M  #$    O0 " +8 #0"P !4 JP @ *< *@"D #0 H0 \ )X 1 "< $L F@!2
M )@ 6 "6 %T E0!C ), :0"1 '  CP!W (T @ "+ (H B0"5 (< H0"% *\
M@P#! ($ X "  /4 ?P#_ '\ _P!_ /\ ?P#_ .X*  #<#@  RA   +X.  "U
M"P  KP,  *D !P"C !  G@ 8 )D (P"6 "P DP U )  /@". $4 C !+ (H
M40"( %< A@!= (4 8P"# &H @0!Q '\ >@!] (0 >P"/ 'D G !W *H =0"[
M '0 U !R /  <@#_ '( _P!Q /\ <0#_ .,1  #-%P  OQD  +,9  "J%0
MHQ   )T*  "7 0H D0 2 (T &P") "4 A0 O (, -P"  #X ?@!% 'T 2P![
M %$ >0!7 '@ 70!V &0 = %K '(!= !P G\ ;@*+ &P#F !K Z8 :02W &@%
MS@!G!^P 9@C] &8)_P!E"?\ 90G_ -8:  #$(   MB,  *LC  "A(   F1L
M )(4  ",#@$ A@<- ( $% !\!AX >0<H '8(, !T"#@ <@D_ ' )10!O"DP
M;0I2 &P*6 !J"U\ : MG &<+< !E#'H 8PR' &(,E0!@#:0 7PVV %X-S@!<
M#NT 7 __ %L0_P!;$/\ 6Q#_ ,TA  "\*   KRL  *0K  ":*0  DB0  (D?
M  ""&   >Q$% '4-#P!Q#1< ;@XA &L.*@!I#S( 9Q Y &400 !D$$8 8Q!-
M &$04P!?$5H 7A%B %P1:P!;$78 61*# %@2D@!6$Z( 51.T %03RP!3%.P
M4A7_ %(6_P!2%?\ 4A7_ ,8H  "V+@  J3(  )\R  "5,0  C"T  (,G  !Z
M(0  <AH  &L3"P!G$Q, 9!0< &$4)0!?%2T 714T %P5.P!;%D( 619( %@6
M3P!6%U8 51=> %,79P!2&'( 4!A_ $\9C@!.&I\ 3!JP $L;QP!+&^D 2AS]
M $H<_P!*'/\ 2AS_ ,$M  "Q-   I3<  )HX  "0-P  AS0  'TO  !T*0
M;",  &0<!P!>&1  6QH8 %D;(0!7&RD 51LP %0<-P!2'#T 41Q$ $\=2P!.
M'5( 31U: $L>8P!*'FX 21]\ $<?BP!&()P 12&N $0AQ !#(N8 0R+\ $,B
M_P!#(O\ 0R+_ +PR  "M.   H3P  )<^  "-/0  @SH  'DU  !O,   9BH
M %XD @!7( T 5" 4 %$@'0!/(24 3B$L $PA,P!+(CH 22)  $@B1P!'(DX
M1B-7 $0C8 !#)&L 0B1Y $$EB  _)ID /B:K #TGP0 ])^, /2CZ #TH_P ]
M)_\ /2?_ +@V  "J/0  GD   )1"  "*0@  @#\  '8[  !L-@  8C   %DJ
M  !1)0L 3241 $LE&0!))2$ 1R8H $4F+P!$)C8 0R8] $(G1 !!)TL /RA4
M #XH70 ]*6D /"EV #LJA@ Y*Y< ."NI #<LOP W+.  -RSX #<L_P W+/\
M."S_ +4Z  "G0   G$0  )%&  "'1@  ?40  '-   !H.P  7S8  %4Q  !,
M*P< 1RD/ $4J%@!#*AX 02HE #\J+  ^*S, /2LY #PK00 [+$@ .BQ1 #DM
M6P X+F8 -BYS #4O@P T+Y4 ,S"G #(PO0 Q,=X ,3'W #(Q_P R,/\ ,S#_
M +$^  "D1   F4@  (]*  "%2@  >TD  '!%  !E0   6SL  %(V  !(,00
M0BX- #\N$P ]+AL .RXB #DO*0 X+R\ -R\V #8P/@ U,$8 -#%/ #,Q60 R
M,F0 ,3)Q # S@0 O-), +C2F "PUNP L-=L +#7U "TU_P M-/\ +C3_ *Y!
M  "B2   ETP  (U.  "#3@  >4T  &Y*  !B10  6$   $X\  !%-P  /3,+
M #DS$0 W,Q@ -C,? #0S)@ S,RT ,C0T #$T/  P-40 +S5, "XV5@ M-F(
M+#=O "LW?P J.)$ *#BD "<YN0 F.=@ )SGT "@Y_P H./\ *3C_ *M%  "?
M2P  E$\  (M2  "!4P  =U(  &Q/  !?20  5D8  $Q"  !"/0  .#@( #0X
M#P R.!4 ,3@= "\X)  N."L +3DR "PY.0 K.D$ *CI* "D[5  H.U\ )SQM
M "4\?0 D/8\ (SVB "(]MP A/M0 (3[S "(]_P C/?\ (SS_ *A)  "=3P
MDE,  (E6  !_5P  =58  &I3  !=3P  4TP  $I(  ! 1   -D % "\]#0 M
M/1, *ST: "H^(0 I/B@ *#XO "<^-P F/S\ )#]( "- 4@ B0%T (4%J "!!
M>@ >08T '4*@ !Q"M0 ;0M$ &T+Q !Q"_P =0?\ 'D'_ *5-  ":4P  D%@
M (9;  !]7   <EL  &=8  !;5   45(  $A.   ]2@  ,T<  "I#"P F0Q
M)4,6 "1#'@ C1"4 (D0L "%$-  @13P 'D5% !U%3P <1EH &T9H !E&>  8
M1XH %T>> !9'LP 42,X %4?O !9'_P 71O\ %T;_ *)2  "76   C5T  (1@
M  !Z80  <&   &5>  !96@  3U@  $14   Y40  +TX  "9+!@ @2@X 'DH3
M !U*&@ <2B$ &TLH !I+,  92S@ %TM" !9,3  53%< %$QE !--=0 238@
M$4V< !!-L0 .3LP #TWN !!-_P 13/\ $4S_ )Y7  "470  BV(  (%E  !W
M9@  ;68  &-D  !680  2EX  #];   U6   *U8  ")4 0 :4@H %E(0 !52
M%@ 44AT $U(D !)2+  14C0 $5(^ !!32  /4U0 #E-B  U4<@ ,5(0 "U28
M  E4K0 (5,4 "53G  I3^P +4O\ "U+_ )M=  "19   B&@  'YK  !T;
M:VP  %]J  !29P  160  #IB   P8   )EX  !U=   56P4 $%H,  Y:$0 .
M6A@ #5L@  Q;)P +6S  "ELZ  E;10 '6U$ !EM>  1;;0 #6X   5N4  !;
MJ   6\   %KB  !:]@ !6O\  EG_ )=D  ".:P  A&X  'MP  !R<@  9W$
M %EP  !,;@  0&P  #5K   J:0  (6<  !AF   19@$ #&4*  =E#P $910
M V0;  )D(P  9"P  &0U  !D0   9$P  &1:  !D:0  9'L  &2/  !CI
M8[L  &+=  !B]   8O\  &'_ )-L  ")<0  @'4  'AW  !M>   8'<  %)V
M  !&=0  .70  "YT   C<@  &G$  !)Q   -<0  !G$(  !P#0  <!(  ' 7
M  !O'P  ;R8  &\P  !O.P  ;T<  &]4  !O9   ;W4  &Z*  !MH   ;;8
M &S6  !K\@  :_\  &O_ (YS  "%>   ?7L  '-]  !E?@  6'X  $M^   ^
M?@  ,GX  "9]   <?   $WP   U\   &?0   'T%  !\"P  ? \  'P3  !\
M&0  ?"$  'PI  !\-   >T   'M.  ![7@  >V\  'J$  !ZF@  >;$  'C.
M  !W[P  =OX  ';_ (EZ  "!?P  >((  &N#  !=A0  3X8  $*'   UB
M*8<  !V'   4AP  #8@   :)    B@   (H   ")!@  B0P  (D/  ")$P
MB1H  (HB  "*+   BC@  (I&  ")5@  B6@  (E\  "(E   AZL  (;&  "%
MZ@  A?L  (3_ (6"  !]A@  ;X@  &&+  !3C0  18\  #B1   KD0  'Y(
M !22   -DP  !)0   "6    EP   )@   "7    EP4  )<+  "8#@  F!,
M )D:  "9(@  FBX  )H]  "930  F5X  )ES  "8BP  F*,  )>\  "6X@
MEO<  )7_ (")  !RC   9(\  %:3  !(E@  .ID  "R:   ?FP  %)P   R>
M   #GP   *$   "C    I0   *4   "E    I0   *8"  "G"   IPT  *@1
M  "I&0  JR,  *LQ  "K00  K%,  *QG  "K@   JIH  *JS  "JT   J>\
M *G[ '6/  !GE   69@  $J<   \GP  +:(  ""C   3I0  "Z<   &I
MJP   *X   "Q    L@   +(   "S    M    +4   "V    N 0  +D+  "[
M$   O1@  +\D  "_-0  P$<  ,!;  # <@  P(T  ,&F  # P0  O^,  +[S
M &J7  !;G   3:$  #ZE   OJ0  (:L  !.M   +L    +,   "U    N
M +P   "_    P0   ,$   ##    Q    ,8   #'    R0   ,L   #."
MT0\  -48  #8)P  V3D  -I-  #;9   VWX  -R9  #<L   W,D  -SC %V?
M  !/I0  0*H  #*O   BL@  %+4   JX    NP   +\   ##    Q@   ,L
M  #.    T0   -$   #4    U@   -D   #;    W@   .    #D    YP8
M .L.  #O&0  \"H  /(_  #S50  ]&T  /2(  #TH0  ]+8  /3' /\ "0#_
M  8 _P ' /\ # #_ !$ _P < /\ * #_ #0 _P!! /\ 3 #_ %4 _P!= /\
M90#_ &P _P!R /X > #\ 'X ^P"$ /H BP#Y )( ]P"9 /8 H@#T *P \P"Y
M /$ RP#P .@ [@#[ .T _P#L /\ X0#_ -( _P#) /\ Q #_ /\  0#_
M_P   /\ ! #_  X _P 7 /\ (P#_ "\ _P [ /T 1@#Z %  ]P!8 /0 7P#R
M &8 \ !L .\ <@#M '@ [ !^ .H A0#I (P YP"3 .4 G #C *8 X0"Q -\
MP0#= -T VP#T -D _P#6 /\ SP#_ ,0 _P"] /\ N0#_ /\   #_    _P
M /\   #_  L _  3 /< '@#T "H \@ U .X 0 #I $H Y@!2 ., 60#@ &
MW@!F -P ; #: '( UP!X -0 ?@#2 (4 T "- ,X E0#, )\ R0"J ,< N #%
M ,T PP#K ,  _@"_ /\ O@#_ +8 _P"P /\ K0#_ /\   #_    _P   /D
M  #R  8 ZP / .8 &0#A "0 W@ O -H .0#3 $, SP!, ,P 4P#) %H QP!@
M ,4 9@## &L P0!Q +\ =P"] 'X NP"& +D C@"W )@ M0"C +, L "Q ,(
MK@#@ *P ]P"K /\ J@#_ *@ _P"C /\ H #_ /\   #_    ]0   .L   #A
M    U@ , ,\ $P#* !X Q@ I ,( ,P"_ #T NP!% +@ 30"V %0 LP!: +$
M7P"P &4 K@!J *P < "K '< J0!_ *< AP"E )$ HP"< *  J0"> +@ G #.
M )H [@"9 /\ EP#_ )8 _P"6 /\ DP#_ /T   #Q    Y0   -D   #-
MQ  & +T #P"W !@ LP B +  + "M #8 J0 ^ *< 1@"D $T H@!3 *  60"?
M %X G0!D )L :@": '  F !W )8 @ "4 (H D0"5 (\ H@"- +  BP## (D
MXP"( /D A@#_ (8 _P"& /\ A@#_ /,   #C    T0   ,4   "]    M@
M *X "P"H !( I  < *  )@"< "\ F@ W )< /P"5 $8 D@!, )$ 4@"/ %@
MC0!= (L 8P"* &H B !Q (8 >0"$ (, @@"/ '\ FP!^ *D ? "[ 'H U0!X
M /( > #_ '< _P!W /\ =P#_ .<'  #1#   PPT  +@,  "N"   J    *(
M!0";  X E@ 5 )( 'P". "@ BP Q (@ .0"& $  A !& (( 3 "  %( ?P!7
M 'T 70![ &, >@!K '@ <P!V 'T = "( '$ E0!P *0 ;@"T &P R@!K .H
M:@#\ &H _P!J /\ :@#_ -H0  #&%   N!8  *T5  "D$@  G X  )8'  "0
M  D B@ 0 (4 & "! "$ ?@ J 'L ,@!Y #D =P!  '4 1@!S $P <@!1 '
M5P!N %X ;0!E &L ;@!I '< 9P"# &4 D0!C )\ 8@"O &  Q !? .0 7P'X
M %X"_P!> O\ 7@+_ ,X8  "]'0  L"   *4?  ";'   DQ<  (L1  "$#
M?@0+ 'D $@!U !L <@ C &\ *P!M 3, :P$Z &D"0 !G T8 9@-, &0$4@!C
M!%D 801@ %\%:0!>!7, 7 9_ %H&C0!9!YP 5PBM %8(P0!5">$ 5 OV %0+
M_P!4"_\ 5 O_ ,8?  "V)0  J2@  )XH  "4)0  BR$  (,;  ![%   = X#
M &X)#0!I"!0 9@D= &0*)0!B"BT 8 LT %X+.@!="T  6PQ' %H,30!8#%0
M5PU< %4-9 !4#6\ 4@U[ % .B@!/#IH 3@ZL $P/P@!,$., 2Q#Y $L0_P!+
M$?\ 2Q#_ +\F  "P*P  I"\  )DO  "/+0  ABD  'TD  !T'@  ;!<  &41
M!P!?#A  7 \7 %H0'P!8$"< 5A N %00-0!3$#L 4A%" % 12 !/$5  3A%7
M $P28 !+$FL 21)X $@3AP!&$Y< 112I $04O@!#%=\ 0Q;X $,6_P!#%O\
M0Q;_ +HK  "K,0  H#0  )4U  "+-   @3$  '@K  !O)@  9B   %X9 0!7
M% T 5!03 %$4&P!/%2, 3A4J $P5,0!+%C< 218^ $@61 !'%TP 11=4 $07
M70!#&&< 01AT $ 9@P _&I0 /1JF #P;NP [&]L .QSV #P<_P \'/\ /!S_
M +4P  "H-@  G#D  )$[  "'.@  ?C<  ',R  !J+0  82<  %DA  !1&PD
M3!D0 $H:%P!(&A\ 1AHF $4;+0!#&S, 0ALZ $$<00! '$@ /AQ0 #T=60 \
M'F0 .QYQ #D?@  X'Y( -R"D #8@N  U(=8 -2'T #4B_P U(?\ -B'_ +(T
M  "D.@  F3X  (\_  "%/P  >SP  ' X  !G,@  72T  %0H  !,(@4 1A\.
M $,?% !!'QL /Q\B #X@*0 ](#  .R V #HA/0 Y(44 .")- #<B5P V(V(
M-"-N #,D?@ R)(\ ,26B "\EM@ O)M( +R;R "\F_P P)O\ ,";_ *\X  "B
M/@  ED(  (Q#  ""0P  >$$  &X]  !C.   6C,  %$N  !(* $ 0"0, #TC
M$0 [)!@ .20? #@D)@ V)"P -24S #0E.@ S)D( ,B9* #$G5  P)U\ +RAL
M "XH>P L*8T *RJ@ "HJM  I*L\ *2OP "HK_P J*O\ *RK_ *P\  "?0@
ME$8  (I'  " 1P  =D4  &Q"  !A/0  5S@  $XS  !$+@  /"D) #<H$  U
M*!4 ,R@< #(H(P P*"D +RDP "\J-P N*C\ +2M( "PK4@ K+%T *BQJ "@M
M>0 G+8L )BZ> "4NLP D+\T )"_N "4O_P E+_\ )B[_ *D_  "=10  DDD
M (A+  !^3   =$H  &I'  !>0@  5#T  $LY  !!-   ."\& #(M#0 P+1,
M+BT9 "TM(  K+2< *BXN "DN-0 I+ST *"]& "<P3P E,%L )#%H ",Q=P B
M,HD (3*= !\SL0 >,\L 'C/M !\S_P @,_\ (3+_ *9#  ":20  D$T  (9/
M  !\4   <T\  &A,  !<1@  4D,  $D_   _.P  -C8" "XR#  K,A$ *3(7
M "@R'@ F,B0 )3,K "0S,@ C-#H (C1# "$U30 @-5@ 'S9E !XV=0 <-X<
M&S>; !HWKP 9.,@ &3CK !HX_P ;-_\ &S?_ *-'  "830  CE$  (13  ![
M5   <5,  &90  !:3   4$D  $=%   ]00  ,ST  "HY"0 E-PX (S<4 "(X
M&P A."( (#@H !\X,  >.3@ '3E! !PZ2P :.E8 &3MC !@[<@ 6.X4 %3R9
M !0\K0 3/<8 $SWI !0\_0 5//\ %CO_ *!+  "540  BU4  ()8  !Y60
M;E@  &16  !840  3D\  $5+   Z1P  ,$,  "= !0 @/@T '3X1 !P^%P ;
M/AX &CXE !D^+0 8/S4 %C\^ !4_2  40%, $T!@ !)!<  108( $$&7  ]!
MK  .0L0 #D+G  ]!_  00?\ $$#_ )U0  "35@  B5H  (!=  !V7@  ;%T
M &);  !65P  3%4  $%1   V3@  +$L  "-(   ;10D %T0/ !5$%  411L
M$T4B !)%*0 113$ $44[ !!&10 /1E  #D=>  U';0 ,1W\ "T>3  E'IP (
M1[X "$?@  E']@ *1O\ "T;_ )I5  "06P  AV   'UB  !S8P  :F(  &!A
M  !37@  1UH  #Q7   R50  *%(  !]0   73@0 $4P,  ],$0 .3!< #DP>
M  U-)0 ,32X "TTW  I-0@ )34T !TY:  9.:0 $3GL  DZ/  %.I   3;H
M $W;  %-\@ !3?\  DS_ )9;  "-8@  A&8  'IH  !Q:0  :&D  %QG  !/
M9   0F$  #=?   M7   (UH  !I8   25P$ #58)  E5#@ '51, !E4:  15
M(@ #52H  E4T  !5/@  54H  %97  !690  57<  %6+  !5H   5;8  %34
M  !4\0  4_T  %/_ )-B  "*:   @&P  '=N  !O;P  8VX  %9L  !):@
M/6@  #)F   G90  '6,  !5B   .80  "6 (  -@#0  7Q$  %\7  !?'@
M7R8  %\O  !?.@  7T4  %]3  !?80  7G(  %Z'  !=G   7;(  %S/  !<
M[P  6_T  %O_ )!J  "&;P  ?7(  '5T  !J=0  770  $]S  !"<@  -G
M "MO   @;@  %VT  !!L   *;    FL&  !K"P  :@\  &H4  !J&@  :B$
M &DJ  !I-   :4   &E.  !I7   :6T  &B"  !HF   9ZX  &;*  !E[0
M9?P  &3_ (MQ  ""=@  >GD  '![  !B>P  57L  $AZ   [>@  +WH  "-Y
M   9>   $7<   IW   #=P   '<"  !W"   =@T  '80  !V%0  =AL  '8C
M  !V+@  =3H  '5'  !U5@  =6@  '1\  !TD@  <ZH  '+$  !QZ0  </L
M '#_ (9Y  !_?0  =G\  &B!  !:@@  3((  #^#   RA   )8,  !J#   1
M@P  "H,   *#    A    (4   "$ P  @P@  (,-  "#$   @Q4  (0<  "$
M)@  A#(  (0_  "#3P  @V   ()U  ""C   @:0  ("]  !_XP  ?OD  '[_
M (*   !ZA   ;(8  %Z(  !0B@  0HL  #6-   GC0  &XT  !&.   *C@
M (\   "1    D@   )(   "2    D@$  )('  "2#   DA   ),5  "3'0
ME"@  )0V  "410  DU<  )-K  "3@@  DIP  )&V  "0V   C_,  (__ 'Z'
M  !PB@  88T  %.0  !%DP  -Y4  "F6   <EP  $9@   F9    FP   )P
M  ">    H    *    "@    H    *$   "A!   H@D  *,.  "D%   I1T
M *8J  "F.@  IDP  *5@  "E>   I9(  *2L  "DR0  H^L  *+Z '..  !D
MD0  5I4  $>9   YG   *IX  !V@   1H0  "*,   "E    IP   *D   "L
M    K@   *X   "N    KP   +    "Q    L@   +,&  "U#0  MQ,  +D>
M  "Y+@  ND   +I4  "[:@  NH4  +FA  "YNP  NMX  +GR &>5  !8F0
M2IX  #NB   LI@  ':@  !&J   'K    *\   "Q    M    +@   "[
MO    +P   "^    OP   ,    #"    Q    ,8   #( P  RPL  ,\2  #1
M(   T3(  -)&  #370  U'8  -22  #5JP  U<0  -3B %N=  !,H@  /:<
M "^L   ?KP  $;$   >U    N    +L   "^    P@   ,<   #*    S
M ,P   #.    T    -(   #5    V    -L   #?    X@   .8+  #K$P
M["0  .TX  #N3@  [V<  /""  #PG   \+(  /'% /\  P#_  $ _P $ /\
M"0#_  \ _P 8 /\ ) #_ #  _P \ /\ 1P#_ %$ _P!9 /\ 8 #] &< _ !M
M /H <P#Y 'D ^ !_ /8 A0#U (P \P"4 /( G0#P *< [@"S .P Q #K .$
MZ@#X .D _P#G /\ V0#_ ,L _P#" /\ O0#_ /\   #_    _P   /\   #_
M  P _P 4 /\ ( #_ "L _@ W /H 0@#V $L \@!3 /  6P#N &$ [ !G .H
M;0#H ', YP!Y .4 ?P#C (8 X0". -\ E@#= *  VP"L -@ NP#4 -$ TP#P
M -  _P#. /\ R #_ +T _P"V /\ L@#_ /\   #_    _P   /\   #]  @
M]P 0 /, &@#O "8 [0 Q .@ .P#C $4 X !- -P 50#9 %L U@!A -, 9P#1
M &P SP!R ,T > #+ '\ R0"' ,< D #% )H PP"E ,  L@"^ ,4 O #E +H
M^P"X /\ MP#_ +  _P"I /\ I0#_ /\   #_    _@   /4   #L  , Y0 -
M -\ %0#: "  U  J -  -0#+ #X R !' ,4 3@#" %4 P !; +X 80"\ &8
MN@!L +@ <@"V '@ M0"  +, B "Q )( K@"> *P J@"I +L J #5 *8 \P"D
M /\ HP#_ *$ _P"; /\ F #_ /\   #[    \    .4   #8    S@ ) ,<
M$0#" !H O@ D +L +@"W #@ M !  +$ 2 "N $X K !4 *H 6@"I %\ IP!E
M *4 :P"D '$ H@!X *  @0"> (L G "6 )D HP"7 +( E@#' ), Z "2 /X
MD0#_ )  _P"- /\ BP#_ /D   #K    W0   ,\   #&    O  $ +4 #0"P
M !4 K  > *@ * "E #$ H@ Y )\ 00"= $@ FP!. )D 4P"7 %D E@!> )0
M9 "2 &H D !Q (X >@", (, B@"/ (@ G "& *H A "\ (( W "! /8 @ #_
M '\ _P!_ /\ ?@#_ .P   #:    R0   +X   "V    K@   *< "0"A !
MG  8 )@ (@"5 "H D@ R )  .@"- $$ BP!' (D 30"' %( A@!8 (0 70""
M &0 @0!K '\ <P!] 'T >P"( '@ E0!V *, =0"T ', S !Q .T < #_ '
M_P!P /\ < #_ -\%  #*"@  O L  +$)  "H!   H0   )L  P"4  P CP 3
M (H &P"' "0 A  L ($ ,P!_ #H ?0!! 'L 1P!Y $P =P!2 '8 5P!T %T
M<@!D '  ;0!O '8 ; "" &H CP!I )T 9P"N &4 PP!D .0 8P#Z &, _P!B
M /\ 8P#_ - .  "_$@  LA,  *<2  "=$   E0L  (\#  ")  < @@ . 'X
M%0!Z !X =@ E '0 +0!Q #0 ;P Z &X 0 !L $8 :@!, &D 4@!G %@ 9@!?
M &0 9P!B '$ 8 !\ %X B0!< )@ 6P"I %D O !8 -P 6 #T %@ _P!7 /\
M5P#_ ,86  "V&@  JAT  )\<  "5&0  C10  (4/  !^"0  =P$* '( $ !N
M !< :@ ? &@ )P!E "X 9  T &( .P!@ $  7P!& %T 3 !< %, 6@!: %@
M8@!7 &P 50!W %, A0!2 )0 4 &E $\!N !. M( 303P $T%_P!-!?\ 307_
M +\=  "P(@  HR4  )DE  "/(@  A1T  'T8  !U$@  ;@T" &<&# !C Q$
M7P(9 %T#(0!;!"@ 600O %<%-0!6!3L 5 9! %,&1P!1!DX 4 =5 $X'7@!-
M"&< 2PAS $D)@0!("9( 1PJC $4*M@!$"]  1 SO $,-_P!##?\ 1 W_ +DD
M  "J*0  GBP  )0L  "**@  @"8  '<A  !N&P  9A0  %\/!0!9"PT 50H3
M %,+&P!1"R( 3PPI $T,+P!,##8 2PT\ $D-0@!(#4D 1@U1 $4.6@!$#F0
M0@YP $ .?P _#Y  /A"B #P0M@ [$-$ .Q'Q #L1_P [$?\ /!'_ +0I  "F
M+P  FC(  ) R  "&,0  ?"T  '(H  !I(P  81T  %D6  !1$0@ 3 \0 $H0
M%@!($!T 1A D $40*P!#$3$ 0A$W $$1/@! $44 /A)- #T25@ \$F$ .A-M
M #D3?  W%(T -A2? #45LP T%<T ,Q;N #06_P T%O\ -!;_ *\N  "B-
MES<  (PX  ""-@  >#0  &XN  !E*@  7"0  %0>  !,& 0 1A0- $(4$@!
M%!D /Q0@ #T5)P \%2T .Q4T #D6.@ X%D( -Q9* #874P U%UX ,QAJ #(9
M>0 P&8H +QJ= "X:L0 M&\H +1OL "T<_P N&_\ +AO_ *PR  "?.   E#L
M (H\  " /   =CD  &LT  !B+P  62H  % E  !''P  0!H* #P9$  Z&18
M.!D= #8:(P U&BD -!HP #,:-P R&SX ,1M' "\<4  N'5L +1UG "P>=@ J
M'H@ *1^; "@?K@ G(,< )B#J "<@_@ H(/\ *"#_ *DV  "=/   DC\  (=!
M  !]0   =#X  &DZ  !?-0  5C   $TK  !$)0  .R ' #8>#@ S'A, ,AX9
M # >(  O'B8 +A\M "T?-  L(#L *R!$ "HA3@ I(5@ )R)E "8B=  E(X4
M(R.9 "(DK0 A),4 (27H "(E_0 B)/\ (R3_ *8Z  ":/P  CT,  (5%  ![
M1   <D,  &<_  !=.@  4S8  $HQ  !!+   ."8# #$C#  N(A$ +"(6 "HB
M'0 I(B, *",J "<C,0 F)#D )25! "0E2P C)E8 (B9C "$G<@ ?)X, 'BB7
M !THJP ;*<, &RGF !PI^P =*?\ 'BC_ *,^  "80P  C4<  (-)  !Z20
M<$<  &9$  !:/P  43L  $<W   ^,@  -2T  "PH"0 H)P\ )R<4 "4G&@ D
M)R$ (R@G "(H+@ A*38 ("D_ !\J20 >*E0 '2M@ !LK;P :+($ &2R5 !<M
MJ0 6+<$ %BWD !<M^@ 8+?\ &2W_ *%!  "51P  BTL  ()-  !X30  ;DP
M &1)  !81   3T   $8]   ].   ,S0  "HO!@ D+ T (2P2 " L&  ?+1X
M'BTE !TM+  <+C0 &RX\ !HO1@ 8+U$ %S!> !8P;0 5,7\ $S&3 !(QJ  1
M,K\ $3+B !(R^0 3,?\ $S'_ )Y%  "32P  B4\  (!1  !V4@  ;5   &).
M  !620  348  $1#   [/P  ,3H  "<V P ?,@L '#(0 !LR%0 9,AL &#(B
M !<S*0 6,S$ %30Z !0T1  3-$\ $C5< !$U:P 0-GT #S:1  XVI@ --[P
M#3?=  TV]@ .-O\ #S;_ )M)  "13P  AU,  'Y6  !U5@  :E4  &!3  !5
M3P  3$P  $))   X10  +D$  "0]   <.@@ %C@. !4X$@ 4.!@ $SD? !(Y
M)@ 1.2X $#DW  \Z00 ..DP #3M9  T[:  +.WH "CN-  D\H@ '/+@ !SS5
M  @\\  )._\ "CO_ )A.  ".5   A5@  'Q;  !R6P  :%H  %Y8  !350
M25(  #Y.   T2P  *D<  "%$   80@, $D + ! _$  ./Q4 #C\<  U (P ,
M0"L "T T  I /@ )04H !T%6  9!90 $078  T&*  %!GP  0;0  $'0  %!
M[@ !0?P  D#_ )54  ",60  @UX  'E@  !P8   9F   %U>  !16P  15<
M #I4   O40  )4\  !Q,   42@  #D@(  M'#@ (1Q( !T<9  9'(  %2"@
M T@Q  )(.P  2$<  $A3  !(8@  2',  $B&  !(FP  2+$  $?,  !'[0
M1_L  $?_ )):  ")8   @&,  '=E  !N9@  968  %ED  !,8   0%T  #5;
M   J60  (%<  !=5   04P  "U('  51#0 !4!$  % 6  !0'0  4"4  % N
M  !0.   4$,  %!0  !07@  4&\  %"#  !/F   3ZX  $[)  !.ZP  3?L
M $W_ (]A  "&9@  ?6D  '1L  !L;0  86L  %-I  !&9P  .F0  "]C   D
M80  &E\  !)>   ,7   !EP&  !;"P  6@\  %H3  !:&0  62$  %DI  !9
M,P  63\  %E,  !96@  66L  %A^  !8E   5ZL  %?%  !6Z0  5?L  %7_
M (QH  "";0  >G   ')R  !G<@  6G$  $QP   _;@  ,VT  "AK   =:@
M%&@   UG   '9P   &8#  !F"0  90T  &41  !D%0  9!P  &0D  !D+@
M9#H  &-'  !C50  8V8  &-Z  !BD   8:<  &#!  !?Y@  7_H  %[_ (=O
M  !_=   >'<  &YX  !@>   4G<  $5W   X=@  *W8  "!T   6<P  #G,
M  =R    <@   '(   !Q!0  <0H  '$.  !P$0  <!<  ' >  !P)P  <#,
M &]   !O4   ;V   &YT  !NBP  ;:(  &R\  !KX@  :O@  &G_ (-W  !\
M>P  <WT  &5^  !7?P  27\  #Q_   O@   (G\  !=^   /?@  !WX   !_
M    ?P   '\   !^    ?@4  'X*  !^#0  ?A$  'X7  !^(   ?BL  'TY
M  !]2   ?5D  'QM  !\A   >YP  'JV  !YV@  >/4  '?_ (!_  !W@@
M:8,  %N%  !-A@  /X@  #*)   DB0  &(D   ^)   'B@   (L   ",
MC0   (T   ",    C    (P#  ","   C0T  (T1  "-%P  CB(  (XO  ".
M/P  C5   (UD  ",>P  C)4  (NN  "*S0  B>\  (G_ 'N%  !MB   7HH
M %"-  !"CP  -)$  ":2   9DP  #I0   :5    E@   )@   ":    FP
M )L   ";    FP   )L   "<    G04  )T+  ">$   GQ<  * D  "@-
MH$8  *!9  "?<   GXH  )ZE  ">P@  G>@  )SY '",  !ACP  4Y(  $26
M   VF0  )YL  !F<   /G0  !9\   "A    HP   *4   "H    J0   *D
M  "I    J@   *L   "L    K0   *X!  "P"0  L@\  +,8  "T)P  M#D
M +5-  "T9   M'X  +.:  "SM   L]4  +/P &23  !5EP  1YL  #B?   I
MH@  &J0   ZF   $J    *L   "M    L    +0   "V    N    +@   "Y
M    N@   +P   "]    OP   ,    ##    Q0<  ,D/  #*&@  RRP  ,Q
M  #-5@  SF\  ,V+  #,J   S,(  ,SB %B;  !)H   .J4  "RI   <JP
M#ZX   2Q    M    +<   "Z    O@   ,,   #&    R    ,@   #*
MRP   ,T   #/    T@   -4   #9    W0   .$%  #F#P  YQX  .@R  #I
M2   ZF   .M[  #KEP  [*X  .S" /\   #_    _P   /\ !@#_  T _P 5
M /\ (0#_ "P _P X /\ 0P#_ $P _@!4 /L 6P#Z &( ^ !H /8 ;@#U '0
M] !Z /( @ #Q (< [P"/ .T EP#K *$ Z0"M .< O0#E -@ Y #S .( _P#@
M /\ T #_ ,0 _P"\ /\ M@#_ /\   #_    _P   /\   #_  D _P 1 /\
M' #] "< ^0 R /4 /0#Q $8 [0!/ .L 5@#H %P Y@!B .0 : #C &X X0!S
M -\ >0#= (  V@"( -@ D0#4 )L T@"F ,\ M #, ,D R0#I ,@ _P#' /\
MP0#_ +< _P"O /\ JP#_ /\   #_    _P   /\   #X  4 \@ . .X %P#J
M "( Y@ L .$ -P#= $  V !) -, 4 #0 %8 S@!< ,P 8@#* &< R !M ,8
M<P#$ 'D P@"! ,  B@"^ )0 O "? +D K "V +X M #= +, ]P"Q /\ L #_
M *@ _P"B /\ G@#_ /\   #_    ^0   .\   #F    WP + -8 $@#0 !P
MS  F ,@ , #$ #H P !" +T 2@"[ %  N !6 +8 6P"U &$ LP!F +$ ; "P
M '( K@!Z *P @@"I (P IP"8 *4 I0"C +0 H #+ )\ [@"= /\ G #_ )D
M_P"4 /\ D0#_ /\   #V    Z@   -T   #/    QP & ,  #P"[ !< MP @
M +, *@"P #, K0 [ *H 0P"G $D I0!/ *, 50"B %H H !? )X 90"= &L
MFP!R )D >P"7 (4 E "0 )( G0"0 *P C@"_ (P X@"+ /H B0#_ (D _P"&
M /\ @P#_ /0   #D    U    ,@   "_    M0 ! *X "P"I !( I0 ; *$
M(P"> "P FP T )@ / "6 $, E !) )( 3@"0 %, C@!9 (T 7@"+ &0 B0!K
M (< <P"% 'T @P"( ($ E0!_ *0 ?0"U 'L SP!Y /$ > #_ '< _P!W /\
M=0#_ .4   #1    PP   +@   "O    J    *  !@":  X E0 5 )$ '@".
M "8 BP M (@ -0"& #P A !" (( 1P"  $T ?P!2 'T 6 ![ %X >0!E '@
M;0!V '8 <P"! '$ C@!O )T ;0"N &P Q !J .< :0#] &@ _P!H /\ :0#_
M -4#  ##!P  M@@  *L&  "B    FP   )0   "-  H B  0 (, & !_ "
M?  G 'H +@!W #4 =0 [ '0 00!R $< < !, &\ 4@!M %@ :P!? &D 9@!G
M '  90![ &, B !B )< 8 "G %X NP!= -P 7 #V %P _P!; /\ 6P#_ ,D-
M  "Y$   K!$  *$0  "7#0  CP@  (@   ""  4 >P - '< $@!S !H ;P A
M &P * !J "\ :  U &< .P!E $$ 8P!& &( 3 !@ %( 7P!9 %T 80!; &H
M60!U %< @@!5 )$ 5 "B %, M0!1 ,\ 4 #O %  _P!0 /\ 4 #_ +\4  "P
M&   I!H  )D9  "/%@  AQ$  '\-  !W!@  <0 ( &L #@!G !0 9  ; &$
M(@!> "D 70 O %L -0!9 #L 6 !! %8 1@!5 $T 4P!4 %( 7 !0 &4 3@!P
M $P ?0!+ (T 20"> $@ L !' ,< 1@#I $8 ^P!& /\ 10#_ +@;  "J(
MGB(  ),B  ")'P  @!H  '<5  !O$   : L  &$$"@!= !  60 6 %8 '0!4
M ", 4@ J %  , !/ #4 3@ [ $P 00!+ $@ 20!/ $<!5P!& 6$ 1 )L $,"
M>0!! XD 0 .: #X$K0 ]!,0 / 7E #P'^  \!_\ / ?_ +(B  "E)P  F2D
M (XI  "$)P  >R,  '$>  !I&   81(  %H- P!3" P 3P41 $P%%P!*!AX
M2 8D $<&*@!%!S  1 <V $,(/0!!"$, 0 A+ #X)4P ]"5T .PIH #H*=@ X
M"X< -PN9 #4+K  T#,( ,PSD #,-^0 S#?\ - W_ *TG  "@+   E2\  (LO
M  " +@  =RH  &TE  !D(   7!H  %04  !,#P8 1@P- $,,$@!!#!@ /PP?
M #X,)0 \#2L .PTR #H-.  X#3\ -PY' #8.4  T#EH ,PYF #$/=  P#X4
M+A"8 "T0JP L$,, *Q'E "P1^@ L$?\ +1'_ *HL  "=,0  DC0  (<U  !]
M-   =#$  &HK  !@)P  6"$  $\;  !'%@  0!$) #L0#P Y$!0 -Q ; #80
M(0 T$"< ,Q$M #(1-  Q$3L ,!%# "X230 M$E< +!)C "H3<0 I$X( )Q25
M "84J0 E%<  )!7C "46^@ F%O\ )A7_ *8Q  ":-@  CSD  (4Z  ![.0
M<38  &<Q  !=+0  5"@  $PB  !#'0  .Q<% #44#0 R$Q$ ,107 "\4'0 N
M%"0 +!0J "L5,0 J%3@ *19  "@62@ G%U0 )A=@ "08;P C&(  (1F3 " 9
MIP ?&;X 'AK@ !\:^  @&O\ (!K_ *,T  "8.@  C3T  (,^  !Y/0  ;SL
M &4W  !;,@  4BT  $DH  ! (P  .!X! # 9"@ L& \ *A@4 "D8&@ G&"
M)ADG "49+0 D&C4 (QH^ "(;1P A&U( (!Q> !\=;  ='7X '!V1 !H>I0 9
M'KP &!_= !D?]@ :'_\ &Q[_ *$X  "5/0  BT$  (%"  !W0@  ;4   &,\
M  !9-P  3S,  $8N   ]*0  -20  "T@!P G'0T )1T2 ",=%P A'1T (1TD
M " >*P ?'C( 'A\[ !T?10 <($\ &B%< !DA:@ 8(GL %B*/ !4BHP 4([H
M$R/: !0C]0 5(_\ %B/_ )X\  "300  B40  ']&  !U1@  ;$0  &)!  !7
M/   33@  $0T   \,   ,RL  "HF P C(@L ("$0 !XA%0 <(AL &R(A !HB
M*  :(S  &2,X !@D0@ 6)4T %259 !0F:  3)GD $B:- !$GH@ 0)[@ #B?6
M ! H]  1)_\ $2?_ )Q   "110  AT@  'U*  !T2@  :DD  &!&  !500
M3#X  $,Z   Z-@  ,3(  "@M   @*0D &R<. !DG$@ 8)Q@ %B<? !4H)0 4
M*"T $R@V !(I0  2*4L $2I7 ! J9@ .*W< #BN+  TLGP ,++4 "RS/  PL
M[P -+/\ #2O_ )E$  "/20  A4P  'Q.  !S3P  :4X  %Y+  !31P  2D0
M $)    Y/0  +S@  "4T   =, 4 %BT, !0L$  3+14 $BT< !$M(P 0+2H
M#RXS  XN/0 -+T@ #2]5  PP8P *,'0 "3"(  @QG  &,;$ !C'+  8QZP '
M,/P "##_ )=(  "-30  @U$  'I3  !Q5   9U(  %U0  !23   24H  $!&
M   U0@  *SX  "(Z   :-P$ $C0)  \S#@ .,Q, #3,9  TS(  ,-"@ "S0Q
M  HU.P (-48 !S52  4V8  $-G$  C:$   VF0  -J\  #;(   VZ   -OD
M 37_ )1-  "*4@  @58  'A8  !O60  95@  %M5  !14@  1T\  #Q,   Q
M2   )T0  !Y!   6/P  $#P'  LZ#0 ).A$ "#L7  8['@ %.R8 !#LN  ([
M.  !/$,  #Q/   \7@  /&X  #R!   \EP  /*P  #O%   [YP  ._@  #O_
M )%2  "(6   ?UP  '9=  !M7@  8UT  %I<  !.6   0E0  #=1   M3@
M(TL  !I)   21@  #40&  =##  #0Q   $,5  !#&P  0R,  $,K  !#-0
M0T   $--  !#6P  0VL  $-^  !#E   0JH  $+#  !!Y@  0?D  $'_ (Y8
M  "&7@  ?6$  '-C  !K9   8F,  %=A  !)70  /5H  #)8   G50  'E,
M !51   .3P  "4T%  )-"P  3 X  $P3  !+&   2Q\  $LH  !+,@  2ST
M $M)  !+5P  2V<  $I[  !*D   2:<  $G   !(Y   2/@  $?_ (M?  "#
M9   >F<  '%I  !I:@  7FD  %!F  !#9   -V$  "Q?   A70  &%L  !!9
M   *6    U<#  !7"0  5@T  %40  !5%0  5!L  %0C  !4+0  5#D  %1%
M  !44P  5&0  %-W  !3C0  4J0  %&]  !0X@  4/@  $__ (AG  !_:P
M=VX  &]P  !E<   5VX  $IL   ]:P  ,&D  "5H   :9@  $60   MC   $
M8@   &(!  !A!@  8 L  & .  !?$@  7Q<  %\>  !>*   7C,  %Y   !>
M3P  7E\  %UR  !=B   7*   %NY  !:WP  6?<  %C_ (1N  !\<@  =74
M &MV  !==0  3W0  $)S   U<P  *'(  !UP   3;P  #&X   1N    ;@
M &X   !L @  ; <  &L+  !K#@  :Q(  &H9  !J(@  :BT  &HZ  !I20
M:5H  &EL  !H@P  9YL  &:U  !EV   9/4  &3_ (!U  !Z>0  <'L  &)[
M  !4?   1GP  #E\   L?   'WL  !1Z   ->@  !'H   !Z    >@   'H
M  !Y    >0$  '@&  !X"P  > X  '@3  !X&@  >"4  '@R  !W00  =U(
M '=E  !V?   =94  '2O  !SS@  <O$  ''_ 'Y]  !U@   9X$  %B"  !*
M@P  /(0  "Z%   AA0  %84   V%   #A0   (8   "'    B    (@   "'
M    AP   (<   "'!   APD  (<.  "($P  B!P  (@I  "(.   ATH  (==
M  "&<P  AHT  (6G  "$Q0  @^P  (+^ 'B$  !JA@  7(@  $V*   _C
M,8X  "./   6CP  #9    *1    D@   ),   "5    E@   )8   "6
ME@   )8   "7    EP   )<'  "8#0  F1,  )H?  ":+0  FC\  )I2  ":
M:   F8,  )F?  "8N@  E^(  );X &V*  !?C0  4)   $&3   SE@  ))<
M !:8   -F0   9L   "=    GP   *$   "D    I0   *0   "E    I0
M *8   "G    J    *D   "J!   K P  *X3  "N(0  KC,  *Y'  "N70
MKG8  *Z3  "NK@  K<T  *SO &&1  !3E0  1)@  #6<   FGP  %Z$   VC
M    I0   *<   "J    K    +    "R    M    +,   "T    M0   +<
M  "X    N0   +L   "]    OP$  ,,+  #%%0  Q24  ,8Y  #'3P  QV@
M ,:%  #&H@  QKP  ,;> %69  !'G0  .*(  "FF   9J   #:L   "M
ML0   +0   "W    N@   +\   #!    Q    ,,   #%    Q@   ,@   #*
M    S0   ,\   #2    U@   -L   #@#   X1@  .,K  #D00  Y5H  .9T
M  #FD0  Y:P  .7$ /\   #_    _P   /\  0#_  H _P 2 /\ '0#_ "@
M_P T /\ /@#] $@ ^@!0 /< 5P#U %T ] !C /( :0#P &\ [P!T .T >P#K
M ($ Z0") .@ D@#F )P Y "H .( MP#? ,T W #N -D _P#9 /\ R@#_ +X
M_P"U /\ L #_ /\   #_    _P   /\   #_  8 _P / /P & #X ", ]  N
M /  . #K $( Z !* .4 40#B %@ X != -X 8P#< &@ V0!N -8 = #4 'L
MT0"" ,\ BP#- )4 R@"A ,@ KP#% ,$ P@#C ,  ^P#  /\ NP#_ +  _P"H
M /\ I #_ /\   #_    _P   /L   #S  $ [0 , .@ $P#C !X X  H -H
M,@#3 #P SP!$ ,P 2P#) %$ Q@!7 ,0 70#" &( P0!G +\ ;0"] '0 NP![
M +D A "W (X M "9 +( IP"O +< K0#0 *L \@"J /\ J0#_ *$ _P"; /\
MEP#_ /\   #_    ]    .D   #@    U0 ( ,X $ #) !@ Q0 B ,$ *P"\
M #4 N0 ] +8 10"S $L L0!1 *\ 5@"N %L K !A *H 9@"I &T I@!T *0
M? "B (8 H "2 )X GP"< *X F0## )< YP"6 /\ E0#_ )( _P"- /\ B@#_
M /P   #P    XP   -0   #(    OP # +D #0"S !, KP < *P )0"I "X
MI0 V *, /@"@ $0 G@!* )T 4 "; %4 F0!: )< 7P"6 &8 E !L )( =0"0
M 'X C@"* (L EP") *8 AP"X (4 U@"$ /8 @@#_ ($ _P!^ /\ ? #_ .T
M  #=    S    ,$   "X    K@   *< "0"B !  G@ 7 )H 'P"7 "< E  O
M )$ -P"/ #T C0!# (L 20") $X B !3 (8 60"$ %\ @@!E (  ;0!^ '<
M? "" 'H CP!X )X =0"O ', QP!R .P <0#_ '  _P!P /\ ;@#_ -T   #)
M    O    +$   "I    H0   )D  P"3  P C@ 2 (H &0"' "$ A  I ($
M, !_ #< ?0 ] 'L 0@!Y $@ > !- '8 4@!T %@ <@!? '$ 9P!O '  ; ![
M &H B !H )< 9@"H &4 O !C .$ 8@#Z &$ _P!A /\ 80#_ ,T!  "\!0
MKP4  *4"  "<    E    (T   "&  @ @0 . 'P % !X !L =0 C '( *0!P
M #  ;@ V &T / !K $$ :0!' &@ 3 !F %( 9 !9 &, 8 !A &D 7P!T %T
M@0!; )  60"A %< M !6 -  50#R %4 _P!4 /\ 50#_ ,$,  "R#@  I@\
M )L.  "2"P  B04  ((   ![  ( =0 + '  $ !L !8 :  = &8 (P!C "H
M80 P &  -@!> #L 70!! %L 1@!: $P 6 !3 %8 6P!4 &0 4@!N %$ >P!/
M (H 30"; $P K@!+ ,8 2@#J $D _@!) /\ 20#_ +D2  "J%@  GA<  )06
M  "*$P  @1   'D+  !Q P  :P & &4 #0!A !$ 70 8 %H '@!8 "0 5@ J
M %0 , !3 #8 40 [ %  00!. $< 30!. $L 5@!) %\ 1P!I $8 =@!$ (4
M0P"7 $$ J0!  +\ /P#B #\ ^  ^ /\ /P#_ +(9  "D'@  F!\  (X?  "$
M'   >A@  '(2  !J#@  8@@  %P!" !7  X 4P 3 %  &0!. !\ 3  E $H
M*P!( #  1P V $8 / !$ $( 0P!) $$ 40 _ %H /@!E #P <@ Z ($ .0"3
M #@ I0 V +H -@#; #4 ]  U /\ -0#_ *P@  "?)   E"8  (DF  !_)
M=2   &P;  !D%0  7!   %0, 0!.!@H 2@(/ $< % !$ !H 0@ @ $  )0 _
M "L /@$Q #P!-P [ CX .0)% #@#30 V U8 -01A #,$;@ Q!7X , 60 "\%
MHP M!K@ + ;4 "P'\  L"/\ + C_ *@E  ";*@  D"P  (8M  ![*P  <B<
M &@B  !?'0  5Q<  $\2  !(#@0 00H+ #X'$  [!A4 .0<; #@'(0 V""8
M-0@L #,(,@ R"3D ,0E! "\)20 N"E, + I> "L+;  I"WP * R/ "8,H@ E
M#+< ) S3 ",-\  D#?\ )0W_ *0J  "8+P  C3(  (,R  !Y,0  ;RX  &4I
M  !<)   4Q\  $L9  !#$P  /! & #4-#  S#!$ ,0P6 "\,'  N#2( +0TH
M "L-+@ J#34 *0T] "<.1@ F#E  ) Y< ",/:@ B#WL (!". !\0H@ =$+<
M'!#4 !T1\@ =$?\ 'A'_ *$O  "5,P  BC8  ( W  !V-@  ;3,  &,O  !9
M*@  4"4  $@@   _&@  .!4  # 1"  L$ X *A 2 "@0&  G$!X )1 D "00
M*@ C$3( (A$Z "$10P @$DX 'A): !T3:  ;$W@ &A.+ !@4H  7%+4 %A31
M !85\0 7%?\ &!3_ )XS  "3-P  B#H  'X[  !T.P  :S@  &$T  !7+P
M3BL  $4F   ](0  -!P  "T7!0 F$PP (Q,0 "(3%0 @$QH 'Q,A !X4)P =
M%"\ '!4W !L500 :%DL &197 !<790 6%W8 %!B) !,8G@ 2&+, $1G. !$9
M[P 2&?\ $QG_ )PV  "1.P  ACX  'P_  !S/P  :3T  %\Y  !5-0  3#
M $,L   Z)P  ,B(  "H> 0 B&0D 'A<. !P7$@ :%Q< &1@> !D8)  8&2P
M%QDT !8:/@ 5&DD $QM5 !(;8P 1''0 $!R'  \=G  .';$ #1W+  T=[  .
M'?\ #QW_ )DZ  "//P  A$(  'M$  !Q0P  :$(  %X^  !3.@  2C8  $$R
M   Y+0  ,2D  "@E   @( 8 &AT, !<<$  5'!4 %!T; !0=(@ 3'2D $AXR
M !$?/  0'T8 $"!3  X@80 -(7$ #"&%  LBF0 *(JX "2+'  DBYP *(OL
M"R'_ )<^  ",0P  @T8  'E(  !P2   9T8  %Q$  !2/P  23L  $ X   X
M-   +S   "<L   >)P, %B,* !(A#@ 1(1, $"(9 ! B(  /(B< #B,O  TD
M.0 ,)$0 "R50  HE7@ ))F\ !R:"  8FE@ $)JP  R;$  0FY0 $)O< !B;_
M )5"  "*1P  @4H  'A,  !O3   94L  %M(  !01   1T$  #\^   W.P
M+38  "0Q   ;+0  $RH'  \H#0 -)Q$ #2@6  PH'0 +*"4 "BDM  DI-P '
M*D( !BI.  0K7  #*VP  2M_   KE   *ZD  "O!   KXP  *_8  "K_ ))&
M  "(2P  ?T\  '91  !M40  8U   %I-  !/2@  1T<  #Y$   S0   *3P
M " X   7-   $3$%  PO#  )+A  !RX5  8O&P %+R,  R\K  (P-0  ,#\
M #!,   Q60  ,6D  #%\   QD0  ,:<  #"_   PX0  ,/4  "__ )!+  "&
M4   ?50  '56  !K5@  8E4  %A3  !.4   14T  #I)   O10  )4(  !P^
M   4.P  #CD%  DW"P $-@\  383   V&0  -B   #8I   V,@  -ST  #=)
M   W5P  -V<  #=Y   WCP  -J4  #:]   VX   -?4  #7_ (U0  "$5@
M?%H  ');  !I6P  8%L  %=9  !,5@  0%(  #5.   J2P  ($@  !=&   0
M0P  "T$$  1 "@  /PX  #X1   ^%@  /AT  #XF   ^+P  /CH  #Y&   ^
M5   /F0  #YV   ]C   /:,  #R[   \W@  ._4  #O_ (I7  ""7   >5\
M '!A  !H80  7V$  %1>  !'6P  .E<  "]5   E4@  &U   !)-   ,2P
M!DH#  !)"0  2 T  $<0  !'%   1AH  $8B  !&+   1C<  $9#  !&40
M1F   $5S  !%B0  1*   $2X  !#W   0O4  $+_ (A=  !_8@  =V4  &YG
M  !G:   6V8  $YC  !!80  -%X  "E<   ?6@  %5<   Y6   '5    %,!
M  !2!@  40L  %$.  !0$0  3Q8  $\>  !/)P  3S(  $\_  !/30  3ET
M $YO  !.A0  39T  $RU  !+V   2O4  $K_ (5E  !\:0  =&P  &UN  !B
M;0  5&L  $=I   Z9P  +64  ")D   88@  $&    E?    7@   %X   !=
M P  7 @  %L,  !:#P  6A,  %D9  !9(@  62T  %DZ  !92   6%@  %AK
M  !7@0  5YD  %:R  !5T@  5/0  %/_ (%L  !Y<   <W,  &AS  !:<@
M3'$  #]P   R;P  )6X  !IL   1:P  "6H   !J    :0   &D   !H
M9P,  &8(  !F#   9@\  &44  !E'   92<  &0T  !D0P  9%,  &1E  !C
M>P  8I0  &&M  !@S0  7_$  %[_ 'UT  !W=P  ;GD  %]Y  !1>0  0WD
M #9X   I>   ''<  !%V   *=0   '4   !U    =@   '4   !T    =
M ',"  !S!P  <PP  '(0  !R%0  <B   '(L  !R.P  <4P  '%?  !Q=
M<(X  &^H  !NQ@  ;.T  &O_ 'M[  !R?@  9'X  %5_  !'@   .8$  "N"
M   >@0  $H$   J!    @0   ((   "#    @P   (,   ""    @@   ((
M  ""    @@4  ((*  ""#P  @A<  ((C  "",@  @D,  (%6  "!;   @(8
M '^A  !^O0  ?>8  'S\ ':"  !H@P  684  $N'   \B0  +HH  ""+   3
MBP  "HL   ",    C0   (\   "1    D@   )$   "1    D0   )$   "1
M    D@   )("  "3"0  E \  )09  "4)P  E#@  )1,  "38@  DWP  ).8
M  "2LP  D=@  )#V &J(  !<B@  38T  #^0   PD@  (90  !25   *E@
M )<   "9    FP   )T   "?    H    *    "@    H    *$   "B
MHP   *0   "E    I@<  *@0  "H'   J"T  *E   "I5@  J6\  *F+  "H
MJ   I\<  *;L %^/  !0D@  098  #.9   CG   %)T   J?    H0   *,
M  "F    J    *P   "N    KP   *\   "P    L    +(   "S    M
M +8   "W    N@   +T'  "_$   OQ\  , S  # 20  P&(  ,!^  # FP
MP+<  +_8 %.7  !$FP  -9\  ":C   6I0  "Z<   "J    K0   +    "S
M    M@   +L   "]    P    +\   #!    P@   ,0   #&    R    ,H
M  #,    SP   -,   #:!P  VQ,  -TE  #>.P  WU,  .!N  #?C   W:D
M -W" /\   #_    _P   /\   #_  < _P 0 /\ &0#_ "0 _P O /P .@#Y
M $, ]0!+ /, 4@#Q %D [P!> .T 9 #K &D Z0!O .< =0#F 'P Y "$ .(
MC0#@ )< W0"B -H L0#5 ,4 T@#H -  _P#/ /\ Q #_ +@ _P"O /\ J0#_
M /\   #_    _P   /\   #_  ( ^P - /< %0#S !\ [P I .H - #F #T
MX@!% -X 3 #; %, V !8 -0 7@#2 &, T !I ,X ;@#, '4 R@!] ,@ A0#&
M )  P@"; ,  J0"^ +H NP#9 +D ]P"X /\ M #_ *D _P"B /\ G0#_ /\
M  #_    _P   /8   #N    YP * .$ $0#< !H UP C -  +@#+ #< QP _
M ,0 1@#! $T OP!2 +T 6 "[ %T N0!B +@ : "V &X M !U +$ ?@"O (@
MK0"3 *H H0"H +$ I@#( *0 [0"B /\ H@#_ )L _P"5 /\ D0#_ /\   #\
M    [@   .,   #8    S0 % ,8 #@#! !4 O0 > +D )P"U #  L@ X *\
M0 "L $8 J@!, *@ 40"G %8 I0!; *, 80"A &< GP!N )X =@"; (  F0",
M )< F0"4 *@ D@"\ )  WP". /L C@#_ (L _P"& /\ @P#_ /@   #I
MW    ,P   #!    N    +( "@"L !$ J  8 *4 (0"B "D G@ R )P .0"9
M #\ EP!% )4 2@"4 %  D@!5 )  6@"/ &  C0!G (L ;P") '@ A@"$ (0
MD0"" *  @ "R 'T S !\ /$ >P#_ 'H _P!W /\ =0#_ .8   #3    Q@
M +L   "Q    IP   *$ !0";  T EP 3 ), &P"0 ", C  K (H ,@"( #@
MA@ ^ (0 1 "" $D @0!. '\ 4P!] %D >P!@ 'D : !W '$ =0!\ ', B0!P
M )@ ;P"I &T OP!K .8 :@#_ &D _P!I /\ 9P#_ -,   ##    M0   *L
M  "C    FP   )(   ",  H AP 0 (, %@!_ !T ?0 D 'H *P!X #( =@ X
M '0 /0!R $( <0!( &\ 30!M %, ; !9 &H 80!H &H 9@!T &0 @0!A )$
M7P"B %X M@!< -4 6P#W %L _P!: /\ 6@#_ ,4   "V @  J0(  )\   "6
M    C@   (<   "   4 >@ , '4 $0!Q !@ ;@ > &L )0!I "L 9P Q &8
M-P!D #P 8P!! &$ 1P!? $T 7@!3 %P 6P!: &0 6 !N %8 >P!4 (H 4@";
M %$ K@!0 ,@ 3P#N $X _P!. /\ 30#_ +L*  "L#0  H T  )4,  ","
M@P(  'P   !U    ;@ ( &D #@!E !, 8@ 9 %\ 'P!= "4 6P K %D ,0!8
M #8 5@ [ %4 00!3 $< 40!. %  50!. %X 3 !H $H =0!( (0 1P"5 $4
MJ !$ +\ 0P#D $( _ !" /\ 0@#_ +(1  "E%   F14  (X3  "$$0  >PT
M ',(  !L    90 # %\ "P!;  \ 5P 4 %0 &@!1 !\ 3P E $X *P!, #
M2P V $D / !( $( 1@!( $4 4 !# %D 00!C #\ ;P ^ 'X / "0 #L HP Z
M +@ .0#9 #@ ]0 X /\ . #_ *P7  "?&P  DQT  (D<  !_&0  =14  &P0
M  !D#   708  %8 !@!1  P 30 0 $H %0!' !H 10 @ $0 )@!" "L 00 Q
M #\ -@ ^ #T / !$ #L 2P Y %0 -P!? #8 :P T 'H ,@", #$ G@ P +,
M+P#. "\ [P N /\ +@#_ *<>  ":(@  CR0  (0D  !Z(0  <1T  &<8  !?
M$P  5PX  % *  !) P@ 10 - $$ $0 ^ !8 /  ; #H (0 Y "8 -P L #8
M,@ T #@ ,P _ #$ 1P P %  +@!; "T 9P K '8 *@"( "@ G  G +  )@#)
M "4 Z@ E ?L )0'_ *(C  "6*   BRH  ($J  !W*   ;24  &0@  !;&P
M4A4  $L0  !## ( /0<) #D##@ V 1( ,P$7 #$!'  P 2( +P(G "T"+0 L
M S0 *@,[ "D$0P H!$T )@58 "4%90 C!G0 (@:& " &F@ ?!ZX '@?& !T'
MYP ="/@ '0G_ )\H  "3+0  B"\  'XO  !T+@  :BL  &$F  !8(0  3QP
M $<7   _$@  . X$ #$+"@ N" X *P<2 "D'%P H"!T )P@C "4(*0 D"3
M(PDW "$*0  @"DH 'PM5 !T+8@ ;#'( &@R% !@,F0 7#*T %@S& !4-Y@ 5
M#?D %@W_ )PM  "0,0  AC0  'PT  !R,P  :#$  %\L  !5)P  3",  $0=
M   \&   -!,  "T0!@ F#0L ) P/ "(,$P A#!D 'PP? !X-)0 =#2P &PTT
M !H./0 9#D< %PY3 !8.80 4#W$ $Q"$ !(0F  1$*X $!#& ! 0Z  0$/L
M$1#_ )DQ  ".-0  A#@  'HY  !P.   9S8  %TR  !3+0  2B@  $(D   Y
M'P  ,1H  "H5 0 C$0< '1 - !L/$  9#Q4 &! ; !<0(0 6$"D %1 Q !01
M.@ 3$44 $A)1 !$27P 0$F\ #A."  X3E@ -$ZL "Q/"  L4XP ,%/H #1/_
M )<U  ",.0  @CP  '@]  !O/0  93H  %LW  !2,@  22X  $ J   W)0
M+R$  "@<   @& , &10* !42#@ 4$A( $Q,8 !(3'P 1%"8 $10N ! 4.  /
M%4( #A9/  T67  ,%VP "Q=_  D8DP (&*@ !AB_  <8X  '&/4 "1C_ )4X
M  "*/0  @$   '=!  !M00  9#\  %H\  !0.   1S,  #XP   V*P  +B<
M "<C   ?'P  %QH( !(7#0 0%Q$ #Q<6  X8'  .&", #1DL  P:-0 +&D
M"AM,  D;6@ ''&D !1Q\  0=D0 "':8  1V\  (<W0 "'/(  QS_ ),\  "(
M00  ?T0  '5%  !L10  8T0  %E!  !//0  1CD  #XV   U,@  +BX  "4J
M   =)0  %"$$  \="P -'1  #!T4  L=&@ *'B( "!XJ  <?,P &(#X !"!*
M  ,A5P !(6<  "%Y   AC@  (:0  "&Z   AVP  (?(  "#^ )!   "&10
M?4@  '1*  !K2@  8DD  %A&  !.0@  13\  #T\   U.0  *S0  "(O   9
M*P  $B@$  TD"@ )(PX !B,2  4C&0 $)"   B0H  $E,0  )3P  "5(   F
M50  )F4  "9W   FC   )J(  ":Y   FV0  )?(  "7^ (Y%  "$20  >TT
M '-/  !J3P  8$X  %=+  !-2   1$4  #Q"   Q/0  )SD  !XU   5,@
M#RX#  HL"@ %*PX  2H1   J%@  *AX  "HF   K+P  *SD  "M%   L4P
M+&(  "QU   LB@  *Z   "NW   KU@  *O(  "K_ (Q)  ""3@  >E(  '%4
M  !H5   7U,  %91  !,3@  0TL  #='   M0P  (S\  !H\   2.   ##8#
M  8S"0  ,@T  #(0   Q%   ,1L  #$C   Q+   ,C<  #)#   R4   ,F
M #)R   RAP  ,9X  #&U   PU   ,/(  "__ (E/  " 5   >%<  &]9  !F
M60  7ED  %57  !)4P  /D\  #),   H2   'D4  !5"   .0   "#T"  $\
M"   .PP  #H/   Y$@  .1@  #D@   Y*0  .30  #E    Y3@  .5T  #EO
M   XA0  .)P  #>S   WT@  -O(  #7_ (=5  !_6@  =ET  &U?  !E7P
M75\  %)<  !$6   .%4  "U2   B3P  &$P  !!*   *2    T8!  !%!@
M1 H  $,-  !"$   014  $$=  !!)@  03$  $$]  !!2@  05H  $%L  !
M@0  /YD  #^Q   ^T   /?(  #S_ (1<  !\8   <V,  &QE  !D9@  660
M $MA   ^7@  ,EL  "99   <5@  $E0   Q2   $40   $\   !. P  30@
M $P,  !+#@  2Q(  $H9  !*(@  2BP  $HY  !*1P  2E8  $EH  !)?@
M2)8  $>O  !&S0  1?$  $3_ (%C  !Y9P  <FH  &ML  !@:P  4FD  $1F
M   W9   *F(  !]@   57@  #5T   9;    6@   %D   !8    5P0  %8(
M  !6#   51   %04  !4'0  5"<  %0T  !40@  4U(  %-D  !2>0  4I(
M %&K  !0R@  3^\  $[_ 'YJ  !W;@  <'$  &9Q  !8<   2F\  #QM   O
M;   (FH  !=I   .9P  !F8   !E    90   &4   !C    8@   &($  !A
M"   80T  & 0  !@%P  8"$  %\N  !?/   7TT  %Y>  !>=   78T  %RG
M  !;Q0  6NT  %G_ 'MR  !U=@  :W<  %UV  !/=@  074  #-U   F=
M&7,  !!R   '<0   '$   !Q    <0   '$   !O    ;P   &X   !N @
M;@@  &T,  !M$0  ;1H  &TF  !L-0  ;$8  &M8  !K;0  :H8  &FA  !H
MO@  9^@  &;^ 'EZ  !P?   87P  %-]  !$?0  -GX  "A^   ;?0  $'T
M  =]    ?0   'T   !^    ?P   'X   !]    ?0   'P   !\    ?
M 'P&  !\#   ?!(  'P=  !\+   ?#P  'Q/  ![90  >WX  'J:  !YM@
M>-\  '?Z '.   !E@0  5H,  $B$   YA@  *X<  !V'   1AP  !X@   "(
M    B0   (H   ",    C0   (T   ",    C    (P   ",    C    (T
M  "-!   C@P  (X3  "/(0  CC(  (Y&  ".6P  C70  (V0  ",K0  B\X
M (KS &B&  !:B   2XL  #R-   MCP  'I   !&1   'D@   ),   "5
MEP   )D   ";    G    )L   ";    G    )P   "=    G@   )X   "?
M    H0,  *(,  "B%@  HR8  *,Z  "C3P  HV@  **&  "BH@  HL   *'H
M %R-  !-D   /Y,  #"6   AF0  $IH   >;    G0   *    "B    I
M *@   "J    JP   *H   "K    K    *T   "N    KP   +$   "R
MM    +<!  "Y#0  N1H  +HM  "Z0P  NEL  +IW  "[E   N[$  +G2 %"5
M  !!F   ,IP  ".@   3H@  "*0   "G    J@   *P   "O    L@   +<
M  "Y    NP   +H   "\    O0   +\   #     P@   ,0   #&    R0
M ,T   #2 0  U \  -4?  #7-0  V$T  -AI  #7A@  UZ,  -:] /\   #_
M    _P   /\   #_  , _P - /\ %0#_ "  _  K /@ -0#T #\ \ !' .X
M3@#K %0 Z0!: .< 7P#E &0 XP!J .$ < #? '8 W0!^ -L AP#8 )$ TP"=
M ,\ JP#- +T RP#@ ,D ^P#' /\ O0#_ +$ _P"I /\ HP#_ /\   #_
M_P   /\   #\    ]@ + /$ $0#M !L Z0 E .0 , #? #D V@!! -4 2 #1
M $X SP!4 ,T 60#+ %X R0!C ,< :0#% &\ PP!W ,  ?P"^ (H NP"5 +@
MHP"V +0 M #- +( \@"P /\ K #_ *, _P"< /\ EP#_ /\   #_    ^@
M /$   #H    X  & -D #@#2 !8 S@ ? ,@ *0#$ #( P  Z +T 00"Z $@
MN !- +8 4P"T %@ L@!= +  8@"N &D K !O *H > "H (( I@". *0 FP"A
M *L GP#  )T Y@"; /\ F@#_ )0 _P". /\ B@#_ /\   #V    Z    -P
M  #.    Q@ ! +\ "P"Z !$ M@ : +( (@"N "L J@ T *@ .P"E $$ HP!'
M *$ 3 "? %$ G@!6 )P 7 ": &( F0!H )< < "5 'H D@"& )  DP"- *(
MBP"U (D TP"' /< A@#_ (0 _P!_ /\ ? #_ /(   #C    T@   ,4   "Z
M    L0   *L !P"E  X H0 4 )X ' ": "4 EP M )0 - "2 #H D !  (X
M10"- $H BP!0 (D 50"( %L A@!A (0 :0"" '( ?P!] 'T BP![ )H > "K
M '8 Q !T .L <P#_ ', _P!P /\ ;@#_ -\   #,    OP   +0   "K
MH0   )H  @"4  L D  0 (P %P"( !X A0 F (, +0"! #, ?P Y 'T /P![
M $0 >0!) '@ 3@!V %0 = !: ', 8@!P &L ;@!U &P @P!J )( : "C &8
MN !D -X 8P#[ &( _P!B /\ 8 #_ ,P   "\    KP   *4   "=    E
M (P   "&  < @0 - 'P $@!X !D =0 ? ', )@!Q "T ;P R &T . !K #T
M:@!" &@ 2 !G $X 90!4 &, 6P!A &0 7P!N %T >P!; (H 60"; %< KP!6
M ,L 50#R %0 _P!4 /\ 5 #_ +X   "P    I    )D   "0    B    ($
M  !Y  ( <P * &\ #P!K !0 9P : &4 ( !C "8 80 L %\ ,@!> #< 7  \
M %L 0@!9 $< 5P!. %8 50!4 %X 4@!H %  = !. (, 3 "5 $H J !) ,
M2 #H $< _P!' /\ 1P#_ +0)  "F"P  FPP  ) *  "&!0  ?@   '8   !O
M    :  % &, # !? !  6P 5 %@ &@!6 "$ 5  F %, + !1 #$ 4  V $X
M/ !- $( 2P!( $D 4 !( %@ 1@!B $0 ;@!" 'T 0 ". #\ H@ ] +@ /0#=
M #P ^  \ /\ / #_ *P0  "?$@  E!(  (D1  !_#P  =@P  &X%  !F
M8  ! %D " !5  T 40 1 $X %@!+ !L 20 A $@ )@!& "L 10 Q $, -@!"
M #P 0 !# #X 2P ] %, .P!= #D :0 W '@ -@") #0 G  S +$ ,@#. #(
M\0 Q /\ ,0#_ *86  ":&0  CAH  (0:  !Z%@  <!(  &@.  !?"@  6 ,
M %$ ! !,  H 2  . $0 $@!! !8 /P ; #T (0 \ "8 .@ L #D ,0 W #<
M-@ ^ #0 1@ S $\ ,0!9 "\ 90 N ', + "% "L F  J *T *0#& "@ Z@ H
M /X * #_ *$<  "5(   BB$  '\A  !U'P  ;!H  &,6  !:$0  4@T  $L'
M  !$  8 0  + #P #P X !( -@ 7 #0 '  S "$ ,0 G #  +  N #, +0 Z
M "L 0@ J $L * !5 "8 80 E '  ) "! "( E0 A *D ( #! "  Y  ? /D
M'P#_ )TB  "1)@  AB@  'PG  !R)0  :2(  %\=  !7&   3A,  $8.   _
M"P  . 4' #0 #  Q !  +@ 3 "P &  J !T *0 B "< *  F "X )  V ",
M/@ B $< ( !2 !\ 7@ = &T ' !^ !H D@ 9 *< & "] !< WP 7 ?4 %P+_
M )HG  ".*P  A"T  'DM  !P*P  9B@  %TD  !4'P  2QH  $,4   [$
M- T" "T)"0 I!0T )@,0 "0!$P B AD (0(> " ")  > RH '0,R !L$.@ :
M!40 &05/ !<&7  6!FH % =\ !,'D  2!Z4 $0>[ ! 'VP 0"/( $ G_ )<K
M  ",+P  @3$  '<R  !N,0  9"X  %LJ  !1)0  22   $ ;   X%@  ,1(
M "D.!  C# D 'PD- !T'$  ;!Q4 &0@: !@((  7"2< %@DN !4*-P 3"D$
M$@M- !$+6@ 0"VD #@Q[  X,D  -#*4 # V[  L-V0 +#?$ # W_ )4O  "*
M,P  ?S8  '8V  !L-0  8S,  %DO  !0*P  1R8  #XA   V'0  +A@  "<3
M   @$ 4 &0X* !4,#@ 4#!$ $PP6 !(,'  1#2, $ TK  \--  .#C\ #0Y*
M  P/6  +#V< "A!Y  @0C0 '$*( !A"X  40U  %$.\ !A#_ )(S  "(-P
M?CH  '0[  !K.@  83@  %@U  !.,   12P  #TG   U(P  +1\  "8:   >
M%@$ %Q,& !$0"P .#@X #@\3  T0&0 -$"  #! H  L1,@ *$3P "!)(  <2
M50 &$V4 !!-V  ,3BP !%*   !.V   3T0  $^X  !/[ ) V  "&.P  ?#X
M ',_  !J/P  8#T  %<Y  !--@  1#$  #PN   T*@  +"8  "4B   >'@
M%AH" ! 5"0 ,$PX "A,2  D4%P (%!\ !Q4F  85+P $%CH  Q9&  $74P
M%V(  !AT   8B0  &)\  !BU   7T   %^T  !?[ (XZ  "$/P  >T(  ')#
M  !H0P  7T(  %8_  !,.P  0S<  #LT   S,   +"P  "0I   ;)   $Q\"
M  T;"0 )&0T !AD1  09%@ "&1T  1HD   :+0  &S@  !M$   <40  '&
M !UR   =AP  ')T  !RS   <S@  &^T  !O\ (P^  ""0P  >48  '!(  !H
M2   7D8  %5$  !+0   0ST  #LZ   S-P  *C(  " M   7*0  $"4"  LB
M"0 %( T  1\0   ?%   'QL  " B   @*P  (38  "%!   A3P  (5X  ")P
M   BA0  (9L  "&R   AS0  (.T  !_\ (I#  " 2   >$L  &],  !F30
M74L  %1)  !*1@  0D,  #I    O.P  )3<  !PS   3+P  #2P"  <I"  !
M)PP  "8.   E$@  )AD  "8A   F*0  )C,  "<_   G30  )UP  "=M   G
M@@  )YD  ":P   ES   )>X  "3] (A(  !_3   =E   &Y1  !E4@  7%$
M %-/  !*3   04D  #5$   K0   (3P  !<Y   0-@  "C(!  ,P!P  +PL
M "X.   M$0  +18  "T>   M)P  +3$  "T]   M2@  +5D  "UK   M@
M+)<  "RO   KRP  *NX  "K^ (5-  !]4@  =54  &Q7  !C5P  6U8  %-5
M  !'40  .TT  #!)   E1@  '$,  !,_   -/0  !CH    X!0  -PD  #8-
M   U#P  -!0  #0;   T)   -"X  #0Z   T1P  -%<  #1H   T?0  ,Y4
M #*M   QR@  ,>X  ##_ (-3  ![6   <UL  &I=  !B70  6UT  $]:  !"
M5@  -E(  "I/   @3   %DD   Y'   (1    $(   !! P  /P<  #X+   ]
M#@  /1$  #P8   \(0  /"L  #PW   \1   /%,  #QE   [>@  .I(  #JK
M   YR   ..T  #?_ (%:  !Y7@  <6$  &EC  !B9   5V(  $E>   \6P
M+U@  "15   94P  $%$   I/   !30   $P   !*    200  $@(  !'#
M1@\  $84  !%'   12<  $4S  !%0   15   $1A  !$=@  0X\  $*H  !!
MQ@  0.P  #__ 'YA  !V90  ;V@  &AJ  !=:0  3V8  $)D   T80  *%\
M !U=   26P  "UD   )8    5@   %8   !4    4P   %($  !1"0  4 T
M % 0  !/&   3R(  $\N  !//   3TL  $Y=  !.<@  38L  $RE  !+P@
M2>H  $C_ 'MI  !T;   ;F\  &1O  !5;0  1VP  #EJ   L:0  (&<  !1E
M   -9    V(   !B    80   &    !?    7@   %T   !<!   7 D  %L-
M  !;$@  6QP  %HH  !:-@  6D8  %E8  !9;0  6(4  %>@  !6O0  5>@
M %/^ 'EP  !S=   :74  %MT  !,<P  /G,  #!R   C<0  %F\   UN   $
M;0   &T   !M    ;0   &P   !K    :@   &D   !I    :0,  &@)  !H
M#@  :!4  &<A  !G+P  9S\  &92  !F9@  97\  &2:  !CMP  8N$  &'\
M '=X  !M>@  7WH  %!Z  !">@  ,WL  "5[   8>@  #GD   1Y    >0
M 'D   !Z    >@   'H   !X    >    '<   !W    =P   '<!  !W"
M=PX  '<8  !W)@  =C8  '9)  !U7P  =7<  '23  !SKP  <M,  ''W '%^
M  !C?P  5(   $6"   V@P  *(0  !J$   .@P  !(0   "$    A0   (8
M  "(    B0   (@   "'    AP   (<   "'    AP   (@   "(    B <
M (D0  ")'   B2P  (@_  "(50  B&T  (>)  "&IP  A<<  (3O &:$  !7
MA@  2(@  #F*   JC   &XT   ^-   $C@   )    "1    DP   )4   "7
M    F    )8   "7    EP   )<   "8    F    )D   ":    FP   )T'
M  "=$0  G2$  )TS  "=20  G&(  )Q_  "<G   G+D  )OB %J+  !+C@
M/)$  "V3   >E0  $)8   28    F@   )P   ">    H0   *0   "F
MIP   *8   "G    IP   *@   "I    J@   *P   "M    KP   +$   "S
M"0  LQ4  +0G  "T/0  M54  +5P  "TC@  M*P  +3, $V2   _E@  +YH
M ""=   1GP  !:$   "C    I@   *D   "L    KP   +,   "U    MP
M +8   "W    N    +H   "[    O0   +\   #!    Q    ,<   #+
MS0P  ,X:  #/+P  ST@  -!B  #0@   T)T  -"X
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M[.WN[_#Q\O/T]?;W^/GZ^_S]_O]M9G0Q      ,!(0   0
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M________SW0U"P    I2I_______________________________EC0
M  !/I______________________________V:1T   D,!@E2L?__________
M___________________+.PX3-4Q;34Q>P___________________________
M__^I8#9@AI^VK*FXV?_____________________________@EXV^Y?______
M________________________________[?G_________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________^O9RKS'________
M___________________________/FH%M6D:(ZO______________________
M_________\1\/B80  !4L/______________________________X(,\
M   NA^W_____________________________K%,0       7;=;_________
M___________________[@#$        )8<S_________________________
M___26@(         7<S___________________________^H-0
M7-/___________________________]]#0          5-;_____________
M_____________^Y]10          1-3___________________________RJ
M9"\"   $(C=)6,[____________________________II&M!*#]C?Y6GNMK_
M_____________________________]6RK++,Y/K_____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________^6[EW=BR/_________________________________;GF<V
M"@ "C/_______________________________\A_/P4     7L__________
M____________________V8$Y        /*K_________________________
M____GDP         (Y#____________________________<;QH
M$'WY__________________________^O2            &_N____________
M______________^$$P           &3F_________________________^Q1
M             %?>_________________________[@5             $C6
M_________________________W04             #C/________________
M________^:):$P           "/%_________________________]^;7"P
M          VZ___________________________OL7U5.2(1!P$"$2*R____
M___________________________?OZ69F)J@K+W:____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________COIV ?/O_________
M_______________________RMX17, X ':S_________________________
M_____]**3!4      '+S____________________________UG\V
M $O)___________________________ZD3X          "^K____________
M_______________ 6@           !J5__________________________^-
M)             B$_________________________^=>              !W
M_________________________[0E              !J________________
M_________WT               !;]/_______________________2L
M          !,Z_______________________I0                 \X?__
M____________________, P                MV?__________________
M__^9BF$G               GU_______________________[;Z)52<
M       EW/_________________________^RIUV74H\,BTL,#E'WO______
M_________________________>;=UM+0T]GD________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________^_4N];_________________________________Y[B/:DLO
M%6_______________________________^2A9S0'     #S)____________
M________________UH([         !*7___________________________M
MA3$           !O__________________________^F0@            !0
MX?_______________________^QI               WR?______________
M_________[,O               BMO_______________________WD
M           0I_______________________\C0                 F?__
M____________________J0                  C/__________________
M____1@                  ?______________________?
M        =/____________________^7                    :O______
M_______________.                    8_______________________
M*2(!                8?______________________N:. 5S<7
M    :/__________________________^M.NE(9\=7%P<G>!E/__________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________;NIV":6G3____________________________
M___(DV4]&0   !V>____________________________VXY,$P        !N
M___________________________;?"P           !%U_______________
M__________^+*@             BM/_______________________\)$
M           #E________________________WT!                ?___
M____________________YS8                 :O__________________
M____G0                  6/______________________1@
M        1_C____________________I                    ->G_____
M______________^6                    )=O___________________^\
M                    &,[____________________K
M    #\+_____________________                    "KG_________
M____________)P                  "K7_____________________<
M                #;G_____________________X)R,<%5",R8;% \-#A(:
M)K_____________________________YY-C2SLS+S,_6X/S_____________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________________KT[SC
M________________________________TJF%94@L$@&%________________
M____________\:MQ/ \       !/X/_________________________5?S4
M           ?LO_______________________^-U'0              B?__
M_____________________Y C                9___________________
M____U4,                 2/;_____________________B@
M        +MW_____________________.                   %\C_____
M______________^^                    !+;___________________^<
M                     *7___________________^Z
M     )/____________________<                     (+_________
M____________                     '3_____________________$P
M                 &C_____________________0@
M &#_____________________>@                   %W_____________
M________T0                   &'______________________R0
M             &;______________________\FLF8E]=G%L:6=F9VMP>HS_
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___BQ:J1>6%W_____________________________]VF=U L#      QQ/__
M_______________________@DDX3            C___________________
M_____])P'0              8/______________________[F\/
M        -^+_____________________EAP                 %,#_____
M________________0                    */___________________^N
M                     (G___________________^>
M     '+___________________^\                     %__________
M___________:                     $W____________________Z
M                 #O_____________________#@
M "KY____________________,P                   !OI____________
M________7@                    _;____________________CP
M              ;0____________________T                     #*
M_____________________RL                   #(________________
M_____X                    #+______________________<6 04% P$
M      $&#1C+_______________________\Z^'8S\S-S]#2U-?<XNK_____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________\=K&____________________
M___________QQJ.$:$TR&  5J___________________________N7Q&&
M        <?_______________________]=\+P              .^/_____
M________________WV0)                #+7_____________________
M= ,                  (W____________________%%0
M     &K___________________^9                     $O_________
M__________^V                     ##]___________________7
M                 !GG___________________V
M  73____________________#@                    #!____________
M________+P                    "O____________________4@
M              ">____________________>0                    ".
M____________________I0                    " ________________
M____V                     !T_____________________S8
M          !M_____________________WP                   !I____
M_________________]<-                  !H____________________
M__]P                  !A________________________4#Q&3E1976%D
M:&QP=GZ)____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________OU;NCBW-:E?______
M____________________^+^.9$$A!0      4OS_____________________
M__>=5A@             %\'_____________________Y6P6
M     (W_____________________8P                   %[_________
M__________^=                     #7\__________________^A
M                 !'9___________________*
M  "[___________________N                      "A____________
M________#                     "*____________________+0
M              !V____________________30                    !D
M____________________;P                    !2________________
M____E                     ! ____________________O
M           P____________________Z@X                    B____
M_________________T0                    5____________________
M_X$                    +]?___________________\@+
M       "[/____________________]>                    Y?______
M_______________)'                   VO______________________
MG0$             !PX7Q?_______________________]6YO,''SM7;X>;M
M]/O_________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________C?S______________________________LQJ6(;50[
M(0< ,M[________________________7DEDI             *#_________
M_____________XDV                 &?_____________________9@
M                 #+V__________________^5
M  /(__________________^G                      "@____________
M_______7                      !\____________________
M              !>____________________)0                    !#
M____________________2                      L________________
M____:@                     8____________________BP
M           %\___________________KP                      X?__
M________________U0                      S___________________
M_R0                     OO___________________U0
M        KO___________________XL                     G_______
M_____________\L.                    DO____________________]7
M                    AO____________________^J"@
M    >?______________________;0                  9O__________
M____________]U4                 1?________________________]J
M(RLU/TI58&IU?H>1G/__________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________Z,^VG8-I3KG_________________________
M[+*#7#H= @       'O______________________\5M*0
M $#_____________________@QL                   ?+____________
M______^2                      "8__________________^D
M              !J___________________=                      !!
M____________________#@                     =________________
M____.0                      Z/__________________8
M            SO__________________A0                      M___
M________________J                       H___________________
MRP                      D/__________________[Q8
M        ??___________________SX                     ;/______
M_____________VD                     6O___________________YD
M                    2?___________________](6
M    .?____________________]8                    *?__________
M__________^B                    &?_____________________U5@
M                !/______________________NR\
M /C______________________ZLI                 ,______________
M___________)1P     '$R N/E)HA.W_____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________________T
MU<G____________________________ZTK"2=UU"* P  $K_____________
M___________%?447             !'8____________________Q%
M              "?__________________^B#                     !H
M__________________^4                       V________________
M___:                       '[/__________________%0
M            Q/__________________2                       HO__
M________________=0                      @___________________
MG0                      :?__________________PP
M        4O__________________YP\                     /O______
M_____________S,                     *____________________U@
M                    &/___________________X$
M    !?___________________ZP                      /__________
M_________]XB                     /+___________________]<
M                 -____________________^?
M ,S____________________H2@                   +?_____________
M________H!8                  )S______________________WH"
M             '?_______________________]Z"P              !4S_
M________________________HE=H=("-G*N\T.?_____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________[>/__________________________]*C>E@Z*2,<%@X&  "?
M_____________________ZQ2#@                !I________________
M___D0P                     T__________________]Y
M            X__________________-                        LO__
M________________$P                      A?__________________
M3P                      7?__________________@P
M        .O__________________L@                      '/______
M____________VP,                      O___________________RH
M                     /O__________________T\
M     .?__________________W0                      -3_________
M_________YL                      ,#__________________\0'
M                 *W___________________ S
M )K___________________]G                     (;_____________
M______^C                     '+____________________C1
M             %S_____________________D08                  $'_
M____________________ZU\                  !W_________________
M_____\I+                  #________________________+5P  #!@D
M,3].8'2+I\?__________________________]?G\O__________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________________^O4S<?"
MOKJWL["MJ:BE____________________W7Y3/S C&1$) @          V___
M______________]V                        I_________________^Z
M                        =?__________________!P
M        1O__________________3@                      &O______
M____________C                        /W_________________P0
M                     -O_________________\1D
M     +[__________________T0                      *3_________
M_________VL                      (W__________________Y$
M                 'G__________________[<
M &;__________________]XA                     %/_____________
M______]*                     #____________________]W
M             "O___________________^L"@                   !;_
M___________________G10                    #_________________
M____B@                    #_____________________UDT
M          #]_____________________Z<N                  #5____
M__________________^8*@          !A@M16#@____________________
M____J&-T@8^<J[O-XOK_________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________^?+MZF=E8Z)A(!\
M>'1P;&AED/________________^\:D@M&0H                 ,?______
M____________                         ___________________0@
M                     -S_________________C@
M     ++_________________S@                       (W_________
M_________RD                      &O__________________UH
M                 $[__________________X8
M #3__________________ZX                      ![_____________
M_____]07                      K___________________H]
M              #___________________]E                      #_
M__________________^.                      #_________________
M__^\&0                    #O___________________Q3@
M          #8____________________BP                    "_____
M________________S$,                   "A____________________
M_Y$9                  !Z______________________)T"@
M     !%?_______________________H=!,?+#A%4V)RA9NTTO7_________
M_________________]?H]/______________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________^_?S\>[LZ^OL\?__________________V;*9AWEM9%U644M&03PX
M,BTH(\3_________________2R4+                     )+_________
M________B                        &;_________________UP
M                 #W__________________S,
M !C__________________VP                       #_____________
M_____YT                       #__________________\D,
M              #V__________________$U                      #?
M__________________];                      #+________________
M__^"                      "W__________________^I!@
M          "C___________________3+P                    "-____
M________________7@                    !W____________________
MDP<                   !>____________________S4,
M      ! _____________________X<0                   <________
M_____________]A>                    ______________________^_
M3@      #APL/E)JAJ7(________________________PGR,FJ>VQ=;H_?__
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________________[N'7
MS\G#OKJVL:VIIZ:FIZ[_________________OH9M6TQ -R\H(AP6$ L$
M !3_________________UP4                       #_____________
M_____S0                       #V_________________W8
M              #2_________________[                        "R
M_________________^$D                      "6________________
M__]1                      !\__________________]Y
M          !F__________________^@                      !1____
M_______________'(P                     \___________________N
M2P                     G____________________=
M       0____________________HQ8                     ________
M____________V$P                     _____________________X@/
M                    _____________________\M3
M    ______________________^E.           "1TT3FN,____________
M____________F3E#45]N?8Z@M<OE_____________________________^OY
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________________^O,N:RAF9&+
MAH%\>'1P:VAF9FCQ_________________V%%,B,8#@8               ">
M_________________WX                       !U________________
M_\,                       !2__________________LW
M           R__________________]J                       6____
M______________^6                        __________________^_
M&P                      ___________________F0@
M        ____________________:0                      ________
M____________D (                     ____________________N2P
M                    ]/__________________Z%P
M    V?___________________Y$8                    O/__________
M_________\I3                    G?____________________^8+@
M           0*49FQ/_____________________N?QT,&B@W1E=I?I6OS.[_
M________________________YZ"JN<C8Z?S_________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______]]?#KYN+?V]C4TM'0TM?@_________________\Z>BGQQ:6%;5E%,
M2$,^.C8R+RXQ_________________](E$0,                     ____
M______________]"                        __________________]]
M                        __________________^P"P
M        ]O_________________=.0                      W/______
M____________8@                      Q?__________________B0
M                    K___________________KR(
M    F?__________________UD@                     @O__________
M_________W(                     :?___________________Z$H
M                3O___________________]-<
M,_____________________^6+@              %3)2=_______________
M_______@<A,   $/'R]"6'"+J,CL________________________RF]N?HZ>
ML,/8[_______________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________________Y
MX-+(P+JUL*RHI:*?G9N;G*"G__________________^"9%9+0SPV,"LG(AT8
M$PX)!   U/________________^2                        K?______
M___________,'@                      B__________________[4@
M                    ;?__________________@
M    4?__________________J1L                     .O__________
M________T$(                     (___________________]6@
M                #/___________________X\4
M /___________________[@^                     /______________
M_____^5M P                   /____________________^?-P
M        $"]0=/_____________________=<A0     !A<J05IUE+;:____
M____________________O%A$5&1UAIJOR./_________________________
M_____]+-X?'_________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________S[^OO]_______________________NN:B=
MEH^*AH)_>WAV=')S=7A_D/_________________K3SHP*"$;%1 +!P(
M    (___________________:0                       /__________
M________FPH                      /__________________R#D
M                 /__________________\&,
M /___________________XH.                     /______________
M_____[ T                     /___________________]5;
M             /____________________^%&@                   ^S_
M__________________^Q20              &#E=@?__________________
M___E>QX       PA.%)OC[/9________________________NU@I.4E:;("7
ML,WM_____________________________[.>M,77Z___________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________KOY^'<V=;4TM#0T-'3V>#K]___________________N(I^=W%L
M:&1A7EM96%=765YE<?__________________OS$?%A *!0
M /__________________[58                      .C_____________
M_____X($                     ,S__________________ZLO
M             +/__________________])7                     )O_
M__________________=\$                    (7_________________
M__^B-P                 %*Y3____________________+80(
M   ,+%!VGM'____________________UC3        TC.U=VF;[E________
M________________PV,8*CM,7W2-I\;G____________________________
M_ZA_EJB[T.?____________________________________]____________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____]W.Q;^\N;:TL[&RLK6YP,G5X____________________Y=L9%Y955%/
M3$I(1T9(2U!99J'__________________Z<F#@<"                 %;_
M_________________\Y0                     #K_________________
M__1Y"P                   "'___________________^?,@
M          [____________________$6                 @Q6H3_____
M_______________I?Q\           8G2W&:PNG_____________________
MITD      A<O2FB*KM7\________________________TW4>)CA*7G6/J\OO
M_____________________________ZYRA9BLPMOV____________________
M_______________?[___________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__^_LJJFHZ&@GY^AHZ:LM,#-W>S___________________^*6E-/2TA&1$-"
M04)#1TY9:7W___________________^>+@8                   #_____
M_______________#5@                  %4'____________________G
M>QH             "31@B[3_____________________GS\         !"5*
M<9G"Z_______________________QF8/    $RI$8H.GS?7_____________
M____________ZXXU*SY1:(&=O-[______________________________[YV
M?Y2IP=SY___________________________________2V//_____________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________;R\._O[_'S^/W____________________________X
ML)^:EY:6EIB;GZ2LML+1X>[____________________^CE!*1T5$1$1%1D=+
M45IH@ZG_____________________ID$!           '-F./NN'_________
M____________QF4*       $)TQSG,3L________________________Y8@O
M   3*D1B@J;,]/___________________________ZM0-DIA>Y:TUOK_____
M_________________________]*'?)BQR^G_________________________
M___________4SNW_____________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________^WEX^/DYNCM\?G______________________________;&4
MDI*5F9VCJ;*\T.W__________________________YU31TE-459@<XJOUOS_
M_________________________[)6 !HU4&V+KM+W____________________
M_________\UO/E][F;?7^?_______________________________^Z?@Z;"
MX?_____________________________________CSNO_________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________\
M
M
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MIUU4P#)VFUVD.(G=([-D9"5D[ 1JZ^#UTZ]6@"F1Y;BK!9,CUC@D[@3R!G(
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M9:XZ9ZBJXQJL;IZC0Y"[2DG/V^V.RSYKYL@PJF91N 4G&0N1Q]B".<\^MQP
M, CWUM-MGJC^53U5LRHT%-1C-@J]FT6Z9*43HTVY*4[84-L%5PE-N6Y&P(K9
MMEKFGB]/R;%1UP-KVVO35GL(JB;ZK"09I"*ZJ=T@*@^U<D(<$'.XCOC''!R!
MD<DFI70.K/Y0.-W3T*:!V8C4]CO'5GJ>G;HV4N#UC*T23Z>(6D24G=M\UJW4
MF8V-8K&)[VIEAUYJ&AV.98#;3LT:RRQ4>TI]BLQRBN^8U8 LZ[CC]C@>MYXP
M,@#GDYQD"OW0XK-3BE.*4XI3BE.*4XI7X,;%U]U':"VS\H=MOI\!ZB+A;*A'
M=*F>EZ V=LSJHW5IHN:V]/&QO4 5"ZME]HD5FX@5X8]N6D (IA>-;L C_-]5
M8"1EE;]?=^O>L!#*9&7<3M78"S%=QW X!;'LR./NU6G47UA?*UZ=O>RJ-3]<
M(V?*4)N[PE>55>BS<$C4]BPE6Z(;%M*H;OC-J0VQ+#2AB=E=4D:3K=6BPO>5
MEK(D;%5]V>?D)1B5GU"THR.#C ^Q.3P/6^R(P6./=[L9-BC]6GRHU<VUK2CV
M;5,=<*LUU1W/4=NLE4Z6]OQS^P]>)EM,DUJ\1Y;MQEZ'K"H1=>ONP6I.ZVJ^
MLA._,3,S"#WB2B)NDRBF^0'E21GR4\_8GW@ 989)SQYGBN.J^ISY47:<?I.!
M>@ Z!=-B;SI-3W1+7/H@V[6:IT[Q)FE][7G:%*CWK!M\9O;L14+G1=:U"M;Q
MBSH.A2DQ=0&&Y"SNS+43$J!I2%' )(W'8?5X.1]ECOCG^,50>E^L[Y0*N[7H
M/3K7]?GLFQQ>K++8-:670^]]B660KF[.N'JJH5]L-TW;;-G'.Z3KU2T1K^.V
MU39'8K$O#V1Z)9K=1R-"F1==4J T@PH4#![8)."S#N6./5&[D<]AP>,7GJT^
M5NT]T[0L9\V;_L/:]?8ZQ5S5@LG1'N78$W;MM43:<0QIK3.1*E;(H* HMEU9
M/36QJQOA"IVA2[<;%ZWC2Y&;JLLS8E0&F"]]Q]<YV8)(;U5QG RO(.3W\\$U
M<=^ZUOE5H,'J.CZ]HP8\FE;UIU;K=W9Z7=\G5JDZ>G+1MP&1GHR&#?,O>]K(
M%"5K5"9C&JZ+=*S7\W>1MS=FG(MY-:J*K;Y.1@\L!G:<*"?_ &O+L..>3Y;!
ME]06_=?]1/1+M?J&I.\H^K7'H1VD)NRI:$T_U%[6UE!]2$_>NG.8@69FB4FG
M6B;KLH+" [';K9E[AAIJNQ;LY!$2>'R3$F*N"WJ[@?L3G (&<KC(/;L<#OSC
M%:&O;;^4;U;U.3%LUOK?<Y<=*E[9J59UC9=/=1NT=8;,+,^4HW*'%#%W*;O;
MM=T(?/=/Q(E]'VM8'%4N(J8E>"KT/$U J!KI;Z<_K^0\?1]-8QX@8X!P>W!(
M/UP@G.3C*$'GO@8( .;@V?U;_*XT7158V*W0HXVT7J-ZO+)$5VJ=%FXMB3U9
ML^IY1FN=..BK=5:YLOW[#8W9' VK896\)F-B:K%^Q05:9@G&3A3; _7]?]!J
M2TH /'._C:3VR$7N#ZXY)]V!W&<]M+K<^4?TOJJQ[JLU7UI+FV3JOMO3/IGI
MXDM4V"@W^; GX:^TO1]_8G;!L')E\&L&]YW3"+"Q6JI'A!:K&M4T.0440[(1
M#_/^OZ]Z%Y%]8C(+!0H&#R< YSR"2N> 1CSS7[ZUYB;%@(,:RGARMC'AXQB?
ME(\-4<!)3;(3#<J>#'J>(4"&8>E\@8-1#ZA67$,9>=RC*U*S_&LQQ2G%*<4K
M\X^NW8%]U9M+H-V!!@;QE-75SJ+O3N^ -)4;:NRWR*-(=,V[HBN8NM%U)!V6
M>L-9;V;(4AT9HZ"D(T"Q(AI5:!WP&2QU58D%3S@$YQG]J<?1GV^>*_*?J+W/
MUPU_J=OFY="T_J"KE#'N6UYV@K+Z<NJG<5<OX<]T/](,MK2*MFDOG;7?FRY-
M;<5:M;LR(D/5(/7L\Q<3K#71[;'7&PM/U_7C]>?HPL9 Y(!"^M@X)!]1",C/
M'K9';R/&>1L=,]3ORJ 59L%^GZ%"4.!)ZJ:OIPFL5_I0VINVZ:DU6/IUV\S^
MTVH*H;*BYO=<+9MP25<TJ'*U.(CX6J1:9BY%2<KZ9*H%4[I>> !N"@;22!M#
M%CSSZV5'& .3S57U7KQ^4EIN@MI]5_4I7:-K&A:(J'2G9[#IZS:'M.O;QM1%
MVK&J;EU+#4JWW'8H0;%CI4,5L^#I%)!K,Q)OWIL&"EI1QZ+]A.4WR!69@ %4
M';M.6.%)VG<.WK#;COCGV?N3TVRNWY_0FI+#OX2$C=S6.C05DV+#5P!^-AJ[
M9+ (F9+JP0I11I&<59!K5=?*>)<</)C'CU):R3Z2%95R5!/<C)^G[GXJNWBK
M4XI3BE.*4XI3BE8&TUR.N%:GZG+NS#$598>2@I)^O6*P5&>9!E1'0BG(6U52
M3A;/6Y1##RU 3E>EXN:BR<-FQD@(8RR^VH1D$>WC@D'[HY'Q'-?SLL2_79TB
M=(D-;-!T_<UUVSL;J[ZEZ9LNP]11'5UU72=!TQKW:_4B-TYE5_4CUEO5YBX*
MYP4=K&K9NU.K^ 9BO2L+9+B28L^.N\%)[G';R^%:X+JG9LDODMN?;C)7@L3@
M^X'CCR%>CJDWS\I=L6@=6.L<4*\T&T"ZY'30:;IOIVW44^R.U6M,V"/V94.K
M"*NT9!S\Q-[ FMB4XC4D#4TWJ-@(3*I<.&3&RLZ?%3ND(;@@^0"G@8!!SGOG
M(QV.#SQFK.QU/?*L1FQAZX7KV!GZQK;8<17KC-B=+^R(MC=U9.Z^@.GDJ9J1
MN-BR(NO&Q.G&PXW<^<RN^AMQU5=LR_3JIAS[,^S]?U_STW2Y88X4KCCELN03
M\ N#QWP<'O5+O=17RI.XS=9B6S2E[C%5+J=Z7+;;8RFZBVMHMFE6%.T=H1^Q
MNGV3M<U9[ !OK3(5&AZ'8+)O*!'$UJI,ZMN6<*:D XZ%BI#.<^J?V)[8P=QW
M+[\+CGM@Y'!!KW+^4.^41J>JHBT[:KM=UK&36XM TRR;4NG2;LJCR=!E+OJ?
M=-QW3JRF:$N&X8>T;Q8UEL>AZPHX&VJE96X28JFPK7:P0I<.ARD^$J-\@ XX
M)4$[>1D$L  <'!P,^7).<9JFZ%UQ_*C3NC2.H36>E!2I_>4]TX6*9OANHNI'
M:5&9AIWHPA;4LFA:DI<]>3A:W8MQ# T26L>LX1%:K[KCRKH[[_EW+S&/U_7&
M.?U[<54-(1N QNVDG!/[ ]@3VR ./:><G-?K/TJ]076G>>K_ '1J;J"UF-7-
M5P&NHNTTZ=K.G]DP-1AK'Z>NVEUAW<=X+B8.]3$RY9+>8+'4N"M N :J21,S
M=%DX]56G%959BS C@ 8]4CR'&3W/?.,^7-?J+Q62G%*<4IQ2G%*<4IQ2G%*<
M4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*P4=5ZS#R]@L$178**GK:^ 5:IN.B(
M\&7LQ45'LQ,638)(8=HV9?C8H<>, >D7B7 X]AD,=38S2&TJ5G>*4XI3BE.*
M4XI3BE.*4XI3BE.*4XI3BE.*5@FZO66;(7<6:[!-6X^($KYUJ;B(]NR&0,>6
M4>!"%SB1\29$0$<::8)&O%+"&++*(990\0ZM:E9WBE.*4XI3BE.*4XI3BE.*
M4XI3BE.*5B&*_ C3DA9QH2('LLM'1L/*V%B-":G).)AGY$J'BY"6;92>;'1)
M,Q+$1H))#@P+\I(O"M-.&DJ=4K+\4IQ2G%*<4IQ2L%*5>LS<E S,U78*7F*J
M62?5Y64B(^0DJV>:(L PV!.+'>*ARRP77 B28]T=Y\1Q8SJULK4C*F![*SO%
M*<4IQ2G%*<4IQ2G%*P5@JU8M@X(EIKD#91(R6CY^-&L$1'S(\?.Q+WM$5- L
MR(Y+8DM&/YR]'R(Z6S GL^H,\TO[;BE9WBE.*4XI3BE.*4XI3BE.*4XI3BE.
M*4XI47N5'I6Q8 NJ;!J%7O56/<&=.K5RK\39X UT,ALL-PN&FQ#HXEP4IIHD
M9;PRU,$--O-90XA*L*8![C-2$448(8<((=@0,1AH4005IL<848=M+3 X[#24
M-,L,M(0VTTVA+;;:4H0E*4XQA2N_BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3
MBE.*4XI3BE.*4XI6GMOD^J 6]U:8=CV,:T@-X3!+T3KP8 FU6[30^EMMK6#?
MX69S/,ME-[."H!%/DZ3;X*3L#TE&AV6LUMH21#D55];D^0/ '<CSS^3!^/L&
MNUNN_6W"7'=QNDX>W60(2S61%>K^^=<)EX,INK4'>EP$*UN749S50X54O%TC
M]/:<JS15IMLF+$BKOMB":G;6>\XJOK88C)/) 8=\=@.0%SCCCWD#(%7188+J
M'N*NG&7L%BMM,DH+?VTJ]NAO6K[%1J-@T[6(G>K=$NDQ S$E<#XZ/M\Q4=,S
M/LHED-/#8MQD0X0D PW ZI()QRPYP<<< GG!SW^/P]E:\T7JJZU+I:M4A!:R
MH)T3=FI&2(8AJ;83HV5KE+V/JS5=NMC.P'MG"1-2J5LPO<^Y-53[]>MOO_7&
M-6Q3T<Y99-YJP*!F/EQC\H\\^8R0"/9S6:3=?E#+MJ+4LW9:&!KW9^=^A!7N
M$UH/X1SFHD4MM^2(E1;J;*G"X"O)$I +? *=;E!H2.FH4D^&E!I(U4 N0,C!
MSY<#&!WSSG)/&,<=B.]H5.P]6#/5MOJ'GX"X/Z,GZLI_5$BH:JNUZDR]5K<*
M ('%$+&"5-2NR9DR7M0#DK,>[H+,;,UJYNQ;WS*S(JGUMQ[[2..W!'''Q/."
M?+GOQIL+&_*F2M1NP-8LUTC28_4E]K8-DV$-1X^=LD_(A5^98V+KNLC5.6+J
M^SX>:CYVCTNCWJ<M=+8(FIRW_.NS4P:@13:J'Q,'&<A>.>^03QD<'/JX/([Y
MQBK(V(;\HS/V3:055J=K#KEQV/#RVJ6F[S3Z6/7*AKI5NI<] 25ICZO:+#48
MO;K(&N]F1KTK V.2%D92W1SJHN)PR$&J?7/MYY'EC (QQY-P>?,_0-Q]#T[;
M4;L.9LNP;WM&RPTCI+2[PP5NS$0M=5LN75<E[5*%I<8T]BLRH_N>F.+@VY0Z
M+KWO<T&+(*000]A5E#;B221M7&< $\[C@=CV&/+GOFMN>*O3BE.*4XI3BE:8
M;[*ZFB(S;8%6'-AZ@E=,:UA:-7BAG;69D<BADVA=BKDD?+BSFO\ ,DM(A$K5
MWJKL@=E,K'1M2) '#NT@JC;N>#CC!!Y_+QGX'Z*KG5]ZZ_?G+KT78](H_P S
MW_FP%=V%4UY-S#2L]JMV PBZ0FTUT\B08P_F\OFPVO!X9X( F"C8MI)S$H$H
MI?SQP<?8G)&<9SG'O/JX]E5;8=L_*41]SNLK4M-U6;#=F]?UF/KUG@9J)J<#
M'!V+J4<FLUN1B+].R%SDIV/'T0-+[2>#JE4#"GQG3Z?!^Z[ Y6U5S)DD '@<
M'(&<GM@DG(QSC@^X8J2_9;^4<DK58XR/U;KZ#B(T>',%-G-73T@(W)D;!L\%
M.T^-E NH #YY#1%(:J=K#V&/'UD&8R5(BIJ0)2U@PRIS(3@  8[X[=NWK<^?
MX/?6&@]H_*5C&7J05IJC2:PI8<B,KTK#S$>+=2<T305<:8JLV1MHH76]?5;Y
M3:UN-9D8ZV):&@28U1'MCA%CDE 7QDCGS]N>!QSC'<^8^'GTD;V^4G:?E$0F
MBJ=9@/8[@FNR,QK6?U^2>J/JX\E!3\U"O;QM;L("U,K<CG:V@X^U68IV.CX2
M.'8*LLS0%"S^2\\]P1SGOQGC'EG.:V&Z<-D=7]LOC\/U!:OJ=.J7V+X>=%F*
MM"S(K:[NZNNMEA/2<U<9%UL>3P;8B0JZJNHGH+W*2):78A#5=D;\JRECW&/U
M^/Y,\<XXSNWQ5J<4IQ2G%*_.C<)'6R5-4@Z(#'!CH;;-F,BH#74:0\WL*E#3
ME*;IE=V_).; %QJ]\N)S>WR[9$%;(IY4<(!)3]8@;$;&4%U6,[S[N>,=SVQG
MR'GYD'W'%>"N7CY0"<J>PT7>GTV'D)#2U]*I2*31I&NV6#VB[J>AV2GC>]I[
M:]XAY18=\L-SI'LSE=!8.D:H++.%!B9=!,5&Z0KR,$JV< \-C@ Y/GQGVBO!
M4*'U<LQ&NI.U7#:"[=5MH;7;G:F):HB8JDA2H:CV^>U6%.6-Z(IQ.PH>SW(2
MGK*F7F*;,"C6,K7DNX*FN%S;[]?U_44(?*G+<$Y&0<C!(R1CNP&?CM[<UN;T
M]67:EOT_4;#NNN!5/9I_O]%E@XV*-A(\? -HFH^%+"BY.8G)0066KPD3+L(E
M3!Y5;9R79*&KISC]?C%9!D@9X/GY?E/X\^W':KHXJ:<4IQ2G%*<4IQ2G%*<4
MIQ2G%*<4JLMBE;9'+HB-6QM0D6"+B"UL'YXO'!#"T++#_ODF"DXPMPT*U,*R
MP_ MN5FSQ<H4SF(ET5\,Y5GB50<\8'GSGMC\?PP#SWXK1;1LEUY1\]O6L7@(
MR8$33M@G:0N^PP*\ZW.;"C2EQU,CK,Y3BJY%52N."+BIA;4=3#&K>L^?RDVB
M9IX<=>E5&_G(\C@\9S[/9C_1QBHW;YCK.CJ166M'074/;)>(OD7L2YXWD_I6
MNSMAKU!J*#[;J2 /AX]@8>/V7?S8&(:?=CFT*#"V"N@3@5215BV51ZPX&2,Y
MY(SQR5R?:>!V]W'-9%NM=6MOFMP1<K9M\PL4C>^HI6DV&/-I='R/KF=WX9#[
M#J45 @ S^2XFLZ$.$E7;</;9 67'%@I%=7I>TXZ]1LE/\7Z^W\&/QFH(8@X+
M [E(\L+G!&#QPN2>>3@\'BMO= 6G>-@-V[&[FJ85>#JNRYF"UA)@Q1,;\Y==
MC..-P4E)D&VFPNS4\X(T.;+3,>'$0!+DBRS'-J.&F(Z(BL@).<C'L_7)]U;&
M<5-.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE4D?6-DNGF
M.-3;ZF'"7ELJ9F"!6\M+6I3>$C)RA+&$HRE.6DI\4YQE*5*QC"\ZI2XW$[\K
MDX]8CC/D/+CRSCX]Z\Y+9ZP979+EBI=B,7#H"N>,*,;>.,#MV!/<]"*OLE/;
M"I8K/W\^_P G./S?=._?X_3]_'?EMDO[8CN>^?;@<D\=N_QK-';:H -\I)__
M -AS_%^ \U9M4!FX^.6S.EY+)42M;65/K)6TQE#:<-K?7CR7G*TK7A/=6$)5
MC&%?'*4YD# 88[CGO[O9[^<UU;9)DCQ,^YLY&26(&!P6/?G)\\>WR$>F8:XD
M2A3X,DO 3BTJ';;/=%PTWXIQZ:F4X2GR3G&>ZL95ZG?"U*[J4E,\Y[<>W/Z_
MK^#%)'<F1BKG83P ^W ]F/:/CSWSY5TLPMR3C[H<YG..W_)-Y7?'UXSW5_']
M/QSC&<?#. R.^/PG[N?Q_P 6:E8[CS8X_P#.$_#_ $=OCYR^#$EADO>\R,N^
M6$8;1EY3^4JQY>2O)6/M<9QG&.V,Y[YQG/;'UV)! XP1W]_L^GVUGC5UW;SG
M/;G)^.?P>=:3[DU+U1V/84[,4F^G#54Q8RH4&/N\K6FH\9 K+2Q'8P10[&'T
M$(><<)0I_)6'$O+>2XM3#/TO0==Z-M-*MK?4-*BDO8PXN)9=/@NVE<N2'$K[
MFV%"H"';L(*@8&YOSUUOT;]5O4^IM0OM!ZCN(M&G,)L;>UUZ[TM;:%841H7M
M(C'&)1*KLTRF0RAA(SAF,<<ZZ<]=;^IM@G3=K7$F9@28C H,4=:#[0_F6R8,
MZV>RX;ZJ0&F!&RF'4MOI42LIKS95AA+B>7U5JO36H6UO'HNGI;7*3[Y)HK.*
MS7P/#=3$PC(,I:1D=2RG8$(#>L0?0_4QZ9^J-H>HW\_6&MRWVGRV8A@L[C5K
MG5I?3/&B=+F-Y]XMTCA6:-PL@,IF7=&1$K#;)Q!.7<J0K&6\]NV//*>WP[9[
MXQCXY[]\]_C\,X^]VYX@'!SC/N-?9F#$G!XQQSCZ/C^N:]*,*PG&%9[Y_I]?
MU\'!)QP*L 0.3G^*N7(J:<4K\W]@SORAU?/NY%&J(%YCI8V^LTH%A6HXY^JJ
M<L>_(C7))#L[;:Y[QK(]:B]!VBR9,>E;0HZQ38@@3^&I2&@58R7R..,G/([;
MCCOCRQGGZ,U#K0]\HZ["_.6O5R4<O437+I$25?>F=,15?-G9N_\ 3TZ2;JP1
M%PEH":K\;38K;J]/S6[(^/NT8E4J/? &B)R-CI%4C?C)[YY' R.,XP3]&3GO
MG'>L=9[+\J4Q@YV&H84A)BU9@PZ/@\:(CJC,6EN9UEF)A]=2]HV.?:888V#>
MV#]DB0V+$2H\2<.6+KM$VUFM2SJH)?R'8>[D^XY\_AYBIE6[!\I%B]"?.VC0
M:J;^Z-%C#AX*0U0D?.D29F3#-LHTT;8USB:=%U/,1+AP;E75N"5N39PQ!T=7
M2&@!56&[S'GSV[>T<CM\">1[Z_3#BK4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE
M.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4X
MI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE
M.*4XI3BE4)(;)NXTD<*BN#LM#E/M-(>C91]W#3;BDMY6\T4VR\I:<87ZC2$-
M+QGNC[7*<YTFN)@Q C& 2.0Q/'P//EY#Z:\U+JVH)+(@M54*S* T4S$ 'C+!
MPK9'<KA3G(\L\4;*NJO^08>?R1<MC]9F>WY_\/ GF.,Q@?\ J/V^&>]4&L:C
MQ_.T9]N()\X^B7'XL<>^K"D[)/"5B-EV(7*I$M3&"Q%M$NI$0XES.75,-*21
MA+BD-X0E:\99]9*7597CLK9+L$#;>2.1@G'!/;N!Q^'Z:[+W-PMK#,(#XK[=
MZ$,0F0>2 =PR<8!.1N /-=D]89N-AXHX2(\RC4-*-9=:??P"M;"7,LK;86VY
MYY<RI"5K5A*,MY2M/FK&,6)( ('?DY\OCC\=9)9Y4BB=8B6< NI!.PE<X(!!
MSDXY(Q@@C)J*MWJTJ_A0X^,?BCY+'^'&2L]OAW[9^C[_ -_$!B1VQP>?+C]>
MWZC +N?SC'."/4;CW=_U[9\ZFU9FI27]J]X@)%PSAK+;B&2&$K4OR\F_$A;F
M5*3C&%9RE7;&,XPI..^,YO6U!*\F[<N,8P0"._ES6ENYNI3>5%V)/U>LZWCR
M(&,6*B-D9&MVF8>E6'1&'U'MFQ4H  IAUYQUMMEEI:Q\M*9?=R0AU*/HNA]+
MZ!J&FVUW=ZI*MQ*',L45U:0K"P=E$92:&20,%"EF9@&R&50A4G\_];_50Z]Z
M?ZEU#2M*Z7MI=/M6A6UN;K3-6O'NT>&.1KA+BTN[>W:-W9U5$C9H]A21_%5P
M)YTX;QVQM2PST7?*()!1,=$).&FP(2?A64R&3!V$1CR9H\]!;I0[I!361EM+
M82$YEQ#B7DJ;YW4^@Z/I-O;RZ=J#W$TDWAO!)/;SMX>QV,J^!'&4",JHV\$,
M9!@@J0?0?4RZ]ZPZMU'4+3J'IZ'3[.VLQ/#?VUCJ%E&+CQHXUM)/3KFY65YH
MWDE3PF1HQ V]6#J5VSR2_@[V?T,^CE.,X=[*_P"4\LJ\N_CVPKNCQ[8SWQW[
M_5GQF!C.>?9]/Q^GM7V4,2Q7' [GZ,@Y[<U[N15Z<4IQ2M/K?KGJ'=O-9N3-
MX1;J_5=WS-[@=?A2CU+>$U^O2^VJNBEV.?B4PT'?P)B^SM%EH:+M=0.(HKXY
M$@[:+>1&@2(BJD'OG.#D#MCOD'VY!P.,@^9Y-:V732'RAF-F[GM5(W7!0T;?
MRH<ZK&0,D*0Y7(ZH4OJA:IM/CZ=LZKWBFUX!VT6'IZ:V%)0L;B1N!,=8YYLV
M/0M\ =4$/AL$9(./_:V@]P1R,G@]_=B^I_0NS+U1]4P>R+))7:S4+?LM-R=H
M*L355EK!IQ-WLS\0//-ZWCZ379*6(I'S0$DHT:O@"OE NY<:R4HLDE4D$@#.
M>><\9&>W''LQ_'6OT:S\H38+)2WHRX3XE>(LFUVXLB5KM'J(+M!HUWTM7]76
M3=<-9]7F6;,]L2NN;>M-DIM'>U]-G!&Q0]?,J;D0^4*JOKY&,XYYP!^UP3D9
MS]EV '?C@5+ZSK+Y0%O1%A+V#M"F7CJ7J.WF+QJ1X04.AZ_*KZX 2I6*H6=F
MLH?;G:66'/; EJDBQ@/3HY2JC*38H<O#AAQ*IP^#EANR,<<8\\^WN?N5)=G:
MKZQ:L;2([IVVD4]1Z'K[6M/77KE(4TXJYOURJ[N^>E@G;#9:78+:Y=I^>"T!
M' S"K*Q#K;-N)\G&..>TFY5."  #V&/+V'GGG.<>?\=0\'7/7Y9&Y)%ZN46T
M4Y:M:6:K@A62EXH=?B:UN+5]Q,B; #"ZUA=A62W!QD!?QY*1!O,12)ZC2%=K
MJJV39GY20"5&'/GCMYCVJ3V&>P(]G.,$5$*OKOY4T2OU$6W;L@YZQM%"YD)>
M( U)4 &6/G-ZEF1>XA_6=[78D$0OH)UR50)6HKC@6SG;O$R$B\-$X54"7S8?
M0 /QY_&//GM70%KKY59P%SWAO6LBH1IHR)''%IVK3)Y[8+=P-?&L99K@0<,U
M="JO[O0U7QT.Z]&$4_7W[HN>&^R1)JMB3VC&/8,YY]^/9QQ_UJ_4*AMVQFCT
MUF^N".WEJJUYJYNQY;)X+MK;B1$6%T,X>%K@Y@KDM@M8Y3%>@F7VE(=:AXUM
M20V57'89[^=2OBE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI
M3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.
M*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI50F;IJ@AA(?LDR1[,\ZQDA@8
M/T'<M+RC*VO6/:>\%*3GQRXTVK./CXX[\U#>1!BN'X)&<+CCS&6!Q[.,GV5P
MWZ@L4D>/9<.49DW*D>UBI()7=*K$<9&5!QW J5C7N#*K+]I;P7@ =S+#S"V4
M8,23ZC32&/!+JF5+7E]E25)?RUA#F,J<3E*\)S"9#&9.=HX(QR#D#&,XYR//
M'/-;J:E;/:/>KXGA(2K*5 D#;E4+C=M).Y2,-C!Y(P<=J[K#(KK%FS[5D$A?
MHM,X93[6HCU'&U,>&7,-86C++N5*R]Z64HSE*U=TXR\5/#$G.T\#CG.<8(\L
M8.><<4;4;=;1;P[_  F.U5VCQ"^XJ5QG:"-K$G=MP,@G(!CF-LU[/T!3'_<0
M_P#[=P)D(S@_@]WO[<]^WX*P)K-J_9)L^PK'^#ZY_G]U2EZW1+,$/8<^T*"*
M7AIEM+2<D*>RMU"FLHRYAM*D99=\E9=]/LWGQ6KNG"K[A@-S@^[FMWTJ(0K/
MZVQB !CUL\\8R!Q@\YQQQ7; VB.L62$A();6-AM3B"6VT9RAWRPE2<M.O)SC
M&4Y2K"LI5C/U9Q\>2&![9^GZ?XJO#.DV=H8;<9#  \]NQ/L^/NK7#8G6/J_6
M]OEZ9)Q5QE9.#=:'D"8:.B5@-E.,-/K&;=D9N-?=6PEY"'5I&]'U/)+;CF$^
M7/7:=T;JFI6<-[%+90Q3@M&L\LPD*!BH8B*"50&()4%MV,$@9Q7RCJ/ZM'2W
M36LWFB7-IK-W=6#)'<RV5M:-;K*T:R-$KW-];.S1JZAV$>S=D*S8)J5:=ZF*
M!NN:DZ_6@;+%RL9&9EU,6 $ =!0""1Q'W1GHZ4DV\J'?+%2XV^IA:L/I4SAU
M*'<MZFL],W^B0Q3W,EK+%+)X6ZWDD8HY5G4.LL43>LJL05##U3DC(SUNC/JG
M]/\ 6][<Z=ID&IVMW;6QO#'J$%O&);=98X9'B>VNKI<QR31!ED,9(D!3> ^V
M\BID45]8ZT/+6WA.5^"4Y2GR3Y8QW4M.<_#..^<8SC'?MWYYX#/F/P_Q>WCB
MOHC2!3@@_'C'W2?U\J]PI+1;6'FO+QSG*>RL=LXSCZ<9[9SCZ\9[XSG&<9X(
MP?UY^%2K!AD9'."#W!_#\?A7HY%6IQ2G%*<4K@ZZVPVX\\XAEEE"W7775I;;
M:;;3E;CCCB\X2A"$XRI:U9PE*<9SG.,8SGDJK.RHBEF8A55069F8X"J!DDDD
M   DDX%5=TC5G=E1$4L[NP5551EF9B0%4 $DD@ #)-85RS0+960LR8SA:),&
M'=''RLET>2D@O>( Q2!D.Y%R4#G!;3A/I,Y96A>7,8<1Y;2V%XT8E]'<1&":
MY5WQ&KP02^!-)&7*^)X<V8V6/<P8$;?5.--M3L%E,'I433+<P6;QQDRO'<W,
M/I,$4JQ!S"98,2HTNQ"A4[O67.#7L>H-!+DB) T0%J#E[&\4;!3X;3$/!2"8
MR3)?R5%M*9=9+6G#03F$GF#YR8$,0'C+^+#3[LN(UC1G:>*W54GMW+33QF2)
M5VRG<&0<N,QJWJ.ROZM;FY<9SQ@G)!' .#W'X.Y\JE DQ$GOGBA20!946:B-
MDAQRV'GP)%8 TJ@ QIM:G!C%1AHAZ1GDH>R&2P1A'I.(7G6:*5%C=XW194,L
M;,K*LD8D:(R(2 &3Q$>/<,C>K+G((JV1SSVX/N.,X/T$'X&LCS'2G%*<4IQ2
MG%*<4IQ2G%*<4KJ>?8'1ZA#S3#>7&FL./.(:1EU]U###?FO*4^H\\XVRTCOY
M..K0VC&5J3C,A68X4%C@G !)PH+,<#R506)[  D\"GZ_=[5 B-K:]86XTW9P
MI)UI-Y]1J":,L+J2-:.H'O,<I$&-(*Q,UPIQ(1L)G&)=9WF"*$^6VXRG>72[
M]@";9XP38X,Y2W!74@6L9 9VC'@W"@ND_P#20F'9U0@G&98Q^R!_IGV.6YB.
M)!ZH/K*>"OV6<@#((K(,7ZL$-L.I*D&FR?FKAA9<!8 L.+NN<)KK6,%Q;.</
M$K4ELUE6,.0KN<-S:8Y>?'E&L;E2P*1DKZ46"3V[X%ES<$[)6X0<H>TPYA,@
MYJP8$ \X.,9!'V6,=QGS'P\\5G(R>A)EM#L3+1TBVX]*#MJ#+8(PX_!R+D1,
M-HPVM65JBY1ER/.PG&?93$Y8>\',X3G!)#-$2)8I(R!$Q#HRX$\8FA)R!CQ8
MB)$S]DAW#(YJ00>Q![_@.#]P\5EN8JFG%*<4IQ2G%*<4IQ2G%*<4KBI248[K
M4E./CGNK.$X[8QE6<]\YQCX)QE6?O8QG.?AC/&">PS2HD[?J>VC+C<\&:CW9
M S2516'YC#T19Y1V&@I,;,4R9[4#(R+#[#10_JLH0RZ2\ML5"GL;8L;LG!@=
M#XD\)$NV'$MK$)IXV\4IM>*-E9E;!RP4 L0*KN7OD=@>.>#P#QY'VUW8NE<]
MHP*X<\.[F1FXO'M<9*B-9+K@JC9C/M!(30_L@PJ%O-R&7< &)2K 1)"\93R/
M0[C;N"!AX<$GJR1.=EPP2'U5<MN9B 8\>(F1O514[AG'O(Y!'89/<=L>?8^1
MK+1<W$33#!,1)@R+!,>!*L+#):?]2-E6EO1AV$H5E>!3VFW5B/J3ALA+3F6E
M*]-?CAEAEA9EEC>-EDDB8.I7$D1"RIR,;HV(#J.5)&<9% 0>WF,_0>U9/F.I
MIQ2G%*<4IQ2G%*<4IQ2G%*\Y98@ SYIQ(X08K2WB2RWFQQAV48\ENOOO*0TT
MTC&,Y6XXM*4X^.<XQRR(\C*B*SNQ"JB*69F/8*H!))\@ 2:=N]8'-RK'O#$4
MB7&?D/G!FK."BI?,<&L&*_FT^[#<BM/(!?S >$GA1BF&5,NCHPYE\AAIS/Z)
M<^'XIA98_1_2@SX0-;^D>B^+'N(,B^D9C]0,<ACC:K$1N&<9YSM]O.-V#[..
M>?QFL:G9%,R$B1>F%! J@@;)DF3C)>*::AY*05%A$$YD@!?97GCTY']A(]*0
M;SE#CHJ&G$.*R?)UYO,8A#OX[V^V*6&4F6.,2NJ^'(^Y5C.[Q%S&>0')! C<
MO?/EGD$<=L\BI<*<$;DE(9@I>0BG 3,"D,D9$-90VXZ&3AI:\L%-(=:6X.[X
M/(0XVI2,86G.=1D=-N]&3>H=-RE=Z$D!UR!N4D$!AD$@X/!JU>KE:4XI3BE.
M*4XI3BE.*4XI3BE=;KS+&$9>=:9PXZVRWEUQ+>''G5>+32,KSCR=<5G"6VT]
MU+5\$XSGX<LJL^=JLVU2S;03A5&68X!PJCDD\ <DU5G1,%W5 S*B[F"[G8X5
M!DC+,>%4<D\ $U%BKS5A0B)#,I[6(+$SDXX[%AR$QYQU;+0!-+'1%"&.%DA&
MN)%5'BI>D'G\+;&%>4VYA&[\F7P.UH#$WCVMMMF>. B:]B:>V5A,Z%5EA4R+
M*V(@NTLZ[ESIPZG87$D<=O<QSM+%=31F'=+&\=E<):W1$J*T6Z&X=8FC+B0O
MN"J0CE>U5SKB#E1SISK!F)T"MI;(CI0=#\U)0R; &&*^\$@<O#L5G)"B1G71
M&'4.AD/M&M.#IPBTN"@D5 R&"2YRLD;$0QS&!W95<LF)1M"L S AU4H0QW<C
M\..Q[D9X]O'F..X[@UEXR7BIH,>0AY("5!+;4\*9'%L&"DM(=6PMUA\=QQMU
MM#S;C*EH4I*74+;SG"DYQC%)%+"[1S1R1.AVNDB,C*2 0&5@""000".00>QJ
M00>0<CVBLCS'2G%*<4IQ2G%*<4J#YJM!ESC\XBX,V0;?6J10PIM3[1#BLY7D
MEIAW&6G%K\LK\T)RISSSGNORYA,4#$^HA;)W8QG/GD ]_C7.]"TR>64B&VDE
M5B90I4NKGOO56RK$@YR 20<\YKE@_7X@2Z]@^LL X4IAV+R8 EKU,N>2TN-9
M=_W[AW&%94K[IAQ.%>6%)QG#=  8]T0'8KN7OG/(SG.>?;GGO4^)I:1FU\6S
M6(>J8?$B SG."N[[+=SD^MN&>XK*GLUB/BFHZ2Q$A1"O%M@8I8XXJE)5ZN/1
M2XI&,N85]URI&<K\LY<RKOG.<W81JNUMH7R!P![>![?/VUFD6SBA6&401P'A
M$<HJ$YW>J&(RV?6R.<Y/OJ,X%U?GZ%UK\QK'\C_],]L\H/ \C']##S^FM-5T
M8'U6LP?=(G^54G%Q6I8',8$J*/ '2C&0QECO-,X[Y4A7IM*SEO/EW4ES'965
M95G"LJSGF0%", J0/(8('LX'OK>C-K,GAQ-#(B8]1&5POL. 3CSY[DYYSFN^
M(%@A,E-0J $*0YALQ(:VUN(=3W\6W\I4M:5)^V\4+SCQSY=L8SY<D8[#'!P<
M'//F#[ZM$L*[A#X??#;""01Y'!R,>^J*V)!=+I%G+(V7C5S%M?:&6?F>EHN-
MF'F\,(;$=.:4:,^XK(J&D,O$(RXH=#*4KRTAO&/1Z?<]3I:HNFMJ9M%+"/P(
MI9(0=Q+A"$91ZQ)8*<!B<C.:^=]26'U*Y-5FEZG'2B:Q(D1N/E"[M+:]= BK
M"\Z&>*1CX2HL;RJ6,2HH8HJ@235$3H4 F6?T\F@N&J89:F'ZD?'2)J!<N>;#
M1;HY)1+(JW4^:6\J0PX\C"NRG$8SC6U2?79%B75S?[ Q,*W:21INQ@E RJI8
M XR 6 ..QKI])6?0$$MW)T:O3S3E$2\DT>>VN9Q$6W(DSQ2RRI$SC(4E49US
M@LO%JEXA\/\ <Q0:2,I3G.'7$(<RGZ$Y4G*L9SCMC&$Y5C/P^&/ASCC.>.]>
MT;P\^L5S["0/P9KWCX8PTC WI^CVSX>EE.49^.>^<93G.,_'OWSW^GOW^/(J
MP  PN /=VKNXJ:<4IQ2HN5-E'.$ UA II32#FES#[C!4!'2D8>$*7"2B0SVY
M1N46T00XRPT*IIK(CV"WV%X:9?Z$=K'"$FOS)%&QA86R*\=Y/;W$,LD=W;F6
M$V[6X:-%9VDW-XB^&C#<R\N6^EG:2#2UBFE19U-Y(R2Z?;W5K/!%-970AN%N
MENBLDC+&D15?!?Q9$8*CX&QNUZO.PJ[8Y*3;=FL1M2"<.;&?C 4W)+BVX:3"
M%0" _".JCQX8-^3#E#4.DCCO$K262]G;L5O;U;H:<MO:-8646HRB(R)<2G3"
MH-U!+(9IDNE$SW4JP2V\16-W6,&-%K0U)M.T][(ZLUS?)J>HSZ1 UPL3VL U
MD,RV=S!$L$$EDYMH[*%[F&ZG#2QQO*PEED,CD+-6X+V)@J0$&]JG8RJCLC(4
M_P"E.23*%1L60V&V[["X\.IE37M>!V4,NCY4M"'F?/2AL+Z[\5XX9'\.SGU%
MVD(3=:0.1/<(TK+XRH^X-X9=BRO@$J^.C<:GIMAX*2W$4?C7]MI4:1*9-M]<
MHK6UK(L"OX#/&4*^,(T5&C)95=,TM4]WODE)C;''X(/FNH#8NGZ]B%92R@<"
MIXL,B%)2R3#5J<RW$P2T'OB8QEQ]]EQH-M&5XQTKK10JF2W<K'#H.GZM<>,2
MQ9[KT>-XXBD8 S+.#&K]E4@N3@UNK)GN/]M:,8]VX@GZ!@U.3[CJZ1,H#SA$
M1.EVFW3(-&.CP\2R\VB$A;!'SD@&:(TZJ/>BXF/FX<Z8]1G J%J <(0DA*%:
M26FI(E\ LL*6MI"]ZDC^$!;336\D$;HY'B"262&9(<$L1X@4E2:L60E>0=S$
M+@9Y4')!&<8 (S]'G4@%AYVO)CQ(,Y<S$#L5J%1'665+=+C8V/<,:F9W-B($
MF9VR3IH;P6,"S1:&B7X_#BY(5TLIYS7::"X,CS)X,K-<S&2WB0)))($,,'HZ
MO#!;P(X?UH4+*LF!$P15%L$=N1P,$^SN<\DG'M/.._)K(5>T1MLB094%F3CU
MF@!R+D+/QI<#98M@_#N143=>DVQY6')=]![Q'/&8<5Z3GCA6$*SBES;26LKQ
M.8Y DCQB:"1)[:5H\;C#<1%HIE&Y<M&S#D9[U",'4, 1D [6!5AGMN4X*GW$
M5(^:]6IQ2G%*<4IQ2G%*B:Y\R1-9$K0@\@.T[#%G3)KQ#,$3#'%28T@F E 1
MCV)2>C%1OD]&.>RCM8+$R2<SZR<<VO 2-"UPS1L1,B0HJM.LT:Q-&9XG>-HH
M)?%]64;V)1]J';49]F#VR?+!SV(!R1CM^$9JN3:UKZ(",5MJVBWR:A*+$3=K
M=NY@&0"8#7=B-MH%^(UB![/2XDR#L"\&9ML+4@Y#!$7#C.R+JHB,:'Z"7%_,
MZ?)5J]C#->RPVHLDDWK<7]NEJ]BNI2;KR5)X!L]%FNWCVRS,(P)9"V$K&,^*
MXD8(K/XA&"L;EQ)X0^MJ5;G>$#9"Y8[5Q%+/U6:HIK]Z;<;FY*-I73RUU1N3
M-= C3HFU:V--L31!-5=Q*#N24TVN#284R6R &XS/0SZ))W)1/LNU;=+ZI>"R
M*F".2\Z@/3/@W#R)+:ZDJ6Y5;H>$PCA(FV*R-(X,$RF,;%W5>ZB3Q/LF$=MZ
M5N4 AXO6SLYRS>KD@@##*=W)Q(K5U UJN1=_D1XF4ELT2A4Z]J0A8HC$TS>W
MY86NQ CRG'WQSWWXM"2%$!^DTDX937M"L+1C7M=!N;B6PC:6*+TZ^N[$$[G:
M$V*Q-<2NH 5HU64E=KY8QMG:,&LID #'!.U%?RYW9P/B<?AJPIIBAS3$PF==
M@FR HYZL3A6)0>-F($2V-QQ#\,[- E"2L$N;RN*(0VP:"^:[[N*8RMW KF-"
M!KZ%H3 LY5Y%N8$\)I(9WM#(%F$$B/%/X&)5)9'"#Q$; WBK':<YQP-I.<$!
ML<9[C/'F/+W5VEM62 6?)!$EV>,43*3!D(2V$J;%"%KK#$;6Z5D=F)%?67,
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M$^>.V?/O5+Z]0WMFT6C,O8K&VBLS,=9AJ7;HERO[9TY;CBG7%QD?.AX]VRU
MG !#6X_"4RHY(GJ"MR1#+6$C^@N;B;0K6$6]O:LM];2V<US;R"ZT;6[)$PLD
MUL_UR+4+:5T<MF%XY0'\-"QW\?4M'LM9-L;KQHY["ZBO+*Y@<P7UE<(P+>#.
MN[ZS/&&AGB(>*:)F5PQ"E=EJ]4(6KO6!R&:>&8L<N[.'1^7E+CF)$EAEDUV/
M$SCTPD'N,^V&M-?:/&.O/]DY<RG'F[W4KK4$LENF61[&V6TBFV@3O CN\2S2
MYW2F$/X43-RD2JF3C-;&GZ19:6^H-9H\2:E>-?3V^\FVCN9(T2=[>'&V$7#)
MXTZKP\SN_&[ DV,8QC&,8QC&,8QC&,=L8QCX8QC&/AC&,?#&,?1S0[]ZZ8
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MIFU,$0*^#IUM-'/,PCV[R]S;33 _7-Q;UN6L4RLQ^L61E)9C$K7-RQ9N<RN
MH&>0 CJO9<5^FI-<+K&O(2-S-6VYR]'$A2&+))1U=LU^L3\)Z+4@2MMV.BX9
MRPV6,]X19AX 44MI$J6Z![([X93\W6X6YU":3P;2SBO7F5K>.2XMK"W6?)C4
M$22S"WMI?#F2-WE!,*!]XSGH!=J*"S2% OK,%+L5X). !N89!( [G&*LW'QQ
M][\6?I_/SFUDIQ2G%*B\PDXB?JXC&9U@%IZ3EI$@$> >@RDA!X$$AY]<GAV8
M'4^9),R\4[7V&WO;()23CQQ<^RG;,6Q8+EF\!G*QQ1J[3B92[[FF@$>(6VI&
MT4HN&(V3@HC/AD@YR.^.23QCMC!SSR3D8'ER0.]7[Z!(>@X.0""W0\='2KF6
M)#2<J"//PZ'Q5Y<-DX*4DQHVS1:EL,L+CGXJ<>0MSR8%:PMU:^GH<@6>:-WT
M8))$ T>M1.T$I# !(IXHGDMI0&+"02P XPS'  I)V!Q)W[QD9''<@D CW88Y
M["O/JW57NZ4;V-;B(ZPWDL/#<;;V*B_KJV&5V2 $7[MV+"Q<GB'G)T-W"D9=
M+B1O8%--X9#%):SE$ZGJGB1MI]HLEO8J^9+1KM=0M4N(I''B:?-+%XT$#J<X
M25O$!)9V4\D3!WG!8]CM*,00.' ."P^ Q[ :V YPJR4XI3BE.*5&KC$G3M9E
MXB.9KY!<@,D9MJTQKDO +2MYKUO>,8T\.LUM+&'%M,>LVA9"6?45Z>%\W],N
M8K2_MKF=KQ(X)#(S:?.MM> A6V>!.RN(F+[0S[20A;;ZV#7,UFTGO],N[.W3
M3Y);B,1JFJ6S7E@P+KO])ME9#.NP,53>H,FPL=H(.O1VOS$V.*C[Q"S^SXL?
M,>Z9,V&>K50U97AUKRAS,)0H\G/O%Z.81E&!92/-4O[FWF12ESU\>TAUJ(V5
MQ-I-U9Z!<.)EBM;*SOM3ZAO75<KZ7K$Z#P$F=OZ9;S1 '<W@Y&VOGT_3\PU&
MUMM<LM0ZHM8S;//>ZC?Z;I'2VGQLQ4^@Z#;2$W#V\8(\*ZMYBQVKZ2 V\;!S
M@^ 84144R^PQ#%11 X$2='P8RP1"&6W!'GBDH!;B&0U+>($QEG#PX^!V%H6I
MO&?%VC^+=2"X9&>ZCN$>:YAFNW$TB,RR*L9,IN7E 5)<-L=][@@-7T"^C$%E
M";1)$CLY;22."TGM[&(P12(K1.\H$"V:0EGDA&S?''X<9#%:D_-"NI3BE.*5
M#)=D:3M]8CR6 B40XTI:&VI"IGR/H2#.!X:.D8>UJ6W#0,J&U*2;#@*D%3$E
M'GOK%2*&,8Z[N1%H[2YD4NIE:*V+1W4<9,;;II(Y;4 S3Q.8HF#Y2&.2-0Q=
MV51!Y([<9/(SSV!![ \GWD'XUK/U 2+PM@<K=BON@YF LHHLC&ZFW?'8@/3:
M&:2 \77;P"2ZXR24<.4\._(P9Q(93[J!2FAVFDM>CT&,-;BYM['789[9VCDU
M719#/DLQD"7%DZ ,J(R*RQSQJZJ"REB=V&0\X+1$'G9(,#XAL]^_=3W[BK'Z
M>H>8@X*; D*Y=*O'X-!?@8JQ;$B=FUIB,?#RIM% L8S[LYFO>.$.8$L"6G&,
MNLX!2EK+S;?/U^:&>>!X[FSNI-CK/+;Z?+IMRTH?DW]NP$'I&207M\AMIWY.
MTFT0(!X90<$ N' ']B02<>?/T5L)S@5EIQ2G%*<4J*7FIM7JI3M2?G;/6&IT
M%P!<_3)ERO6J*0[G&'"8*<9:=?BCLMX6RDQA'KMMNN>DI"\X6G:LKHV5U!=+
M!;7)@<.(+R$7%K*1V6>!B%E3.&*,=I(&01Q5'3>C)N=-PQN1MKC_ *K#D'WC
MD>6#7XKZZV/2]-W"0J=6W!HS4<?$W#*[+K_I1UIL+JPWSL1Z)E_WS$[1W!-5
M>>>S)R?LRQ)9;E5=D@%%/"CS0!#:7$?8M0T^\UBSCN[G2=<U:26TQ;W_ %1J
M5ATMH>GK+#ZLNF:3#<P#PX]P>,"Z$<@0.T,BG!XT4L<,A19K>$*_K16D4EW<
M28.-LLY1B6)&"?#W#)&X'!'ZVWF<BGJSK[9C^18(*'LU/GT.W^UVG5HT+'7#
M&*D?[_BV!LHE+"S$VPH*'H]SCTQC]N>C6B7HB5$"D0_E=C#(+F_TU=T[S6UW
M!BPM+74VFDM/Y[C\"5F!BMVEM%>:]LY/%%H)"JRQ.\;]9V&V.0X4*R-]<=X@
M _J'<!W;:Y"QN-IDVYVD!A<W./6:G%*<4J$D.C2%_ !4]$.O5RN/S.1D3$HS
M8 WI\QV)!)=A6$HBBX,X:+FF4F2#KQ#$B$E(8R/NQ"=Q0R6,CXE N+A8=W@Q
MF!U@02NHF8F5)D:6!MD8"M&Y+L?54UR-P'&0,]SGDX'';!P>_F.!Q6OF[83W
M';T6RO =0$!,RL>,[*WO4?L=MK>'H].00PK;K:4DI%,J@,(9IU1$;45..#NH
M;1)9(P\EKOZ-/X]H;2X?0;B&)W$5EJVZTN=LAWN]IJ,4<9B+NQ 62[P&!/A[
M<9QR#!R/%!.,LF&''&&0DYX'<+]/>K'TI29ZIL660GPM?>TVHJ*ET3]*JLI2
M).RIR&[G)]TJI[A L58&\/(2[@ C.7EN$>V#"D-Y0OG:S>P79MHX'O\ ;:K+
M$8+RZBO8K;UQB.SND"O+;G!V^(OJ@+L9E/%HU*YSMYP<JI4G_K+Y'X?2*O+G
M%K)3BE.*4XI4>ML(JRU>P0#:HI#\O$'@"O3D(/98<<P@9QL,N2KQ;XPTT&(5
MEDEZ,?)';-0UEA3[.%^HG;L;D6=[:W3"<K!/%*ZVUR]G</&C@R1PW2*[V\DB
M;D694<QEMP5L8.I?VIO;*[M 8 UQ;RQ(US;)>VZ2.A$<DUI(R1W,<;[7:%W5
M9 NTLN<C\_Z1KVU(O$!=K)4=P;;MM>ET8C=A=0%Y@-542J/J4J/-D-=Z=J>3
M!(]MT)UUN.6957I)6%(1[W1A:E*^C:EKML^GW6F6$NA:#I]U"1/IO3MA<:MJ
M-Z@(E2+5->O@)YR)%4R!+Q(<@GP#CCQVE]%PV]];:MK&HZOU)J]HV^UNM3N5
MMK"PD*-&S:9HUB(;"T!0E07@GF4?[=DDG>JV-B!RE/L+C<2V4!.H@_>!L!)S
M<FW'6I*8UZ.A'XIQ#D*_)3+=?4;+'MDQ(\>&1@]EO"FS!?G=J7:*[MP92LD!
MF\-+B.&,R6I\023+*")UCA-P$B0K*TCKX9/*/[H]P>,@XS@DX;R&.V2!R<CC
MZ1-^:56IQ2G%*B;?JEW8A>'"4C0M;9'\!["VL$@R=D%/O)DZLVGU&#XX:$$<
MBILE?9X68E Q6\802M6T<)9*,+NFN"V6MR)%2",*#%<GAHY&G<2PKV:&)V/*
MBH_9? >W@Y)\O=C@^\CRK3[<VRM>;)D!ZY'373_< XI10\I1MMFSVOK@F9%*
M<;653K@6RA<.7Z:4L,N,P^,^HE1");T',):];H^G7^G1M<R0Z]:/*$:*^TF.
M#4+3P74$+>6BDB5 ?6(,W8[3%N&3@=T<[08FQG*N2K9!QZK>1^ ]G.#6T>JJ
MN/5JH,.)9K%9@Y!:)$-=BL[%S=A!WAAT9KT59TB#F2\+&$-D8!)DWSS,Y>>_
M??HY:89\SJERUS=,S6UO;/&#&XM[9K,3,K,?2);8NR13R*5\18UC3@>INRS9
MD  X8L/(D[L>X'S'QR:LKG.JU.*4XI3BE5UMP6:/UG=XVO4_%_EI:O'PX].5
M<B->XGFI=OW8:'F[!MNG5GL"42_[U 1[P']'N I!F6%IZ&E-"FI64D]WZ!%%
M<),UYZ&M_P" 83XB/Z$Y"7/UQ%7PI#X;9^N93<*QR@F-PJ>(64KLWF/<&&"-
MXR4X)]8<CRYK\X]0ZUNT/98_2K>WM<]. 8$FV4?IKH^U=*2)[Y0@7OI?V1]\
M[%K4][2>4&CTY([-?KYTKE:!\2CKY*6W/H6K:C9S6\FLG2=0ZA>2,K'K'5NI
MQ1HJL_@CY.T+3[B#;&KG,:>/<1Q<GPPJDC0A@E4K'XL5LH.3#9QDDXY^N3RA
MLDC[+U%+9QN.:_36::<&GZM*#CGNK=,+@S\QD/%FJR ;'E&M.3,F4E$C%081
MT>RZI4:_W(DWX]D@=YI>5-?-X2&@N8F9  B3)XDLJ?7$D1"(8TS'+,Z2,/K@
M]6-9&5@1AND>X..>1G ['GD]P./I.*EG-6IIQ2G%*JPS;==$)(&2%+$^SO.,
MY>99$2VYEM64*6WAXQMSPSG&<I\T(7G';.4)S\.7V$#)]GES]W_-G[G-<&3J
M&T1W017+[&9=RK&%;:2,J&E#8..,J"17C^S-7O\ G7-Y^OX- 9^'_A#^GY>8
MR<>1/N'Z_K]VJ#J2S.<071Q_8P_RU9:!VC S\H-$L"2@I)>5I864R+Z*EMMK
M<RVI3!;ZT*4EM7CG+?CG..V5)[X[U$@+;<,"<XR!CCOY^ZMFVUJUNIT@1)D>
M3(4NJ;20"VWU9&() .#C'')%=$[MBO04H7%/!RQ3X3GI/NBLB>AAWQPI2$*(
M,8<5E&<^"L^GA.5XSA&5I[*S1ID4D$,<=R ,>7M([9Y^!JMSKMI:SR0-'.[1
MG:Q14VDX&0-\B$E2<'CD_8Y'-8;.\JRGZ8J?_P"XQOT_^$N8S=Q 9*O]Q?\
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MY-TT;6%G9 -XA(9O%MYS,-V#W; [@8//F-0Z:T#5;TWNIZ5I=_=[$BWWJM<
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M,N94.V8L-\@ED1;R,J2A64,./-X5G"G&\93@OI-38(+\W6W),8G#JI.,$KN
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M%2(;K+>7<K[M+2EU&S9S);W$4LL*7$0;$MO+)/%%-&P(9)'MI(IPASEA&X)
MQR"0:NI92 Q4^3 *2I\B X9<^S((JH=G556[]0!8F']T:\:4(+:+10=>VF K
M>R)9#$*4^?JB>GJ[)RXH[ACQ;84JS4;C'.$'"CL"VE$<Z^HCJZ;=#1M5?PET
M?4"':UMK[4+6>XT^(F= FJ007$<3L$5"\37=G)MC=F:U,@4+BD3QXE#&:+.'
M9$<)(>"3$S(S8R3AO#D&2,!]N<ZFU&N&:A.@:AKRE5_74[WS8JOTZ:R.8##
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MJ C[*G;O6=UHKLZ$K7.SQX N@;IB%QBG7):E[E9@E0HY4S $Y#!?C2(V.'E
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M_&; JJ)"=CH6N72-*7&WBCQ%I MQ%#G7&6)4:KS\I'LC,-V(> DH4Z6!PPE
M9)RF!WC14L'$_)=<TN/2KXQ6TUQ=Z?,@FTW4I[*6P34[8,T+WMK#*SL;1[J&
MXCMY2Q,B1AW6-RT2?8=!U635K$37,5M::C#(T&IZ9;WT6H/I5T56=+&[GA5%
M6\2TFMI;B+:!&\I5&D0+(]F\X]=JG%*<4K2SJ$ZEJU!19-)K4U46";7*SNKT
M;/N,:/<M%4S;$>3%M_8CW8U!SHLY5B[E&FF1@Q,B*Q&"K?0HE]XA8T:;[#0>
MG;F>5;RXANV6TB@U,Z;:2-9ZY>:5(LI^5M%,T#P72V<D:2LL;-(VWU5"AI$T
MY[E5&Q&0%F:(2MAX(YAC$4^U@R%P2 2 ![<D ^CIPH5F7$%$V>G6K3H(ILQ5
M[AH2<EX+8FJ98UH,(AFWZJF7G3I$*DRJSE/BAN>[$K);D(PZN!.A)*)CJ&^M
MO&5;:\MM7D9(;JSUV&*;3]4B0NZFTU2$!(WO8A&%9_KA"F.5+AQ)M6\ =E)>
M-H2"5>(LKQDX'K1L,DHV>/L3D%2@QSLW@=1=D""8$)#@ZO&M/LHS%P+M?D)
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MR)]B)&#N&9%QR<LQQP"<U.ZU!,UZ*:#PD!<@0I4A/R,=%C0S4[8C$H<FI]\
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M=VD>2^]$@TO3=5N99;A] L-SK<G3K8Y5)C"^R&1&1K=3-X*^)-O3'-;)(
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M%M]H?.'26K[D*L?&7$N(=PKGCIIE>>VDN4%TNJZ5I414$P&XOX9);@2$C?\
MSIM6-MHY<-P01BWB]B!P4=SGN%4@#'/[+RK$7+K @Z]9&*[&U"8*7#[CT!J^
M^'RY D:#!QW4+7TR=6M$.X$[*NRK4=+GPU?E!3V(5/MQ!F122&AV72<UGTE/
M<6[7$MW"@ET?7M3L4B5Y'GDT"?P[JUE#B(1&2))KB)T:8[%3<BEB%Q/=JK[
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M#25XPH@M[P]0A]6,*=>4MS.,95VY@D?Q'=]J)O=GV1KM1=Q)VHH^Q1<X5?(
M"I' Q[/;W^FO7RE*<4IQ2N*TI6E2%I2M"TY2M"\84E258SA25)SC.%)5C.<9
MQG&<9QG.,X[< D'(.".01W!]M*KX3 U07FM'ML TTMMD.OG)16ZU6ZZT2Y"U
MN!UU'C"'B2;YYQ#[[\.\S&^DO#N8U!;9*(\5W??==CTE"7NU)>X0FXN;FX*B
M:XGU"1FC>(1HJA9@9,C'B%"ID<5'J\'A3PIX4#L @P<Y]G'NSG J(S^CZDF
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MD+2TVG"GR'G7W58RMUQ;BE*SRI':61Y'(+R.SN0JJ"SDLQ"J J@DG"J H[
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M?B-)=&298[41PR.-T$>UC$N]-SM(N-4\/U5^P&U40  1HJ8 7 RW('!/&>.
M!6-LE>J&VP@8<B0>C\QT_0[K:JXEH0.9-0"I$[7*_=8TAM9H@Q1 8A#P1*6B
M5^Z_94K]%+R<Y;>XN]*=YEC$GB07UE:W!+O"A?,%Q<64BD([(KNJNI*CQ=Y!
M)%20KX'L*L1QG@[E##N.0#S[*QMJTG$S$B#)0I.(H@K<E1VY;W"_:I)<\548
MD:+#C1LN$IQ'M81%PZV$(PL490Q"T#^9&>V2UUF6&-XYE\55TB[TFT"[8Q M
MW*TKR-A3O.99MQ.';<H+86H:,$Y'!,BNV><E0!CGMP!\/+&<C!:RU@<.[+2-
MF&/AS83?>U;Y6$LOA*3(P]G)F01'2O#!:O8) &6>*2QYBF)6T/ES#:<9;5N7
MNLA(FM[4Q317O3VDZ;>;UDS%+:-;3DQ\H/%BDMU3<0Z;6? )PPYMWI,%]=:7
M=S-+'+I%_<7UMX;(!(T]I=63QS;D<F%XKIF*J4?>D9WA0RM/937]:C<T60BR
MAJ@-K^;*,!6G*/9'8ZP(+"EX!YPPE&&1I@J08<;SEQ?HFL"8'9SE+:,8+?6;
MZ<:M!<1R:D^LVL<<H.?$6>R,<MM>*L49+26L4+J0 H:)Y"[8W$\VZT#3;8Z%
M<6LT6D1=/WLLT)R/">WU%9H+NP=YI0$BO)KB-ERS;9XX1&F0JB2+-.,:<CJN
M(F/:0U,AHFCXQQN/B96*-&#;%S!$.PYTF*;E9SHIT<[B-6V%EQ!CC9(RG-$1
M0Q,L^H2&=F:UE-K#.IGN+>XBDE:3TM%N8K>2+$*R13J9P9<&-3&X'2:>>9&M
M]+B%NH6]A%[/:LMM:75I/% L1L9'LY[F*8M.T4]LPMF6 LLS+)&6SX(#$>V\
MVPHE>'RS#5Y+,+.7AXXEPI]#3AK[[C J7758&"94@0-G"!Q666&T-ITY9GF9
M6<1@K'%$!'%%""L,:QH66)$5Y"J@R2L#+*Y+R.SL6._!;I;JZH96\2::=C+-
M-.P>>1I75&F>1DB#L1%"A$4*;8XD2-54>WF*L].*4XI3BE.*5\SC"L9QGOVS
MC.,]LYQGMG';/;.,XSC/WLXSC./IQG&>/U]OXZ$9!'MXX)!^Z.1\1S4.8&FZ
MXZ&&"SF:KBGHR,&84^_[TK,4'$GJ-E9*5E9*1D+6X4>. ,T.TRS(M>U^HM9J
M6WG<;LLL=XTLTI6&Y;Q9G94C2&YFDF3;%%!!###9JJ-(Q(S$=F (\@5@M[=+
M6"&VB,AAAC2*/Q999Y0B+@&2>XDEGF;  +RN\C'EF8Y-8T>,U_=)/-EP&T38
M#Z*U#/\ MJ9*)L8-)MCSIK81T*8H&6@4RI(+^>Y8 $EDB/>8RXEP%;;5FEOK
M.+T;>5MTO3,NSPY;=[RU54+QS)OBG,2R+PDDD8616QB0$Y<*QSY[<>8.UN>W
M!&<>8SQ[JJ.V]/.9U5_ A9&+KD#-Z%B=(TH-D4LOYM!,&SY4F04PIUC) SC9
M4$R.EL[)#R0'O:5)4AI;O6M=?\ 6+S1RW$T.NS:U>.65/29&2W6,*V& 8%9V
M;,>U?$&W.6"T,>=P! !C$:C!.._)&1[1]RHCL_I "OX&_&@+N1 '[J@]%C D
MY@T',TNS:&E"I:MV45M$F&[)J-)3#>N&MX%8V(G'I&NX(Q@?:TWJQ[!]",ED
MMPFC3:VSKXYC-Y;ZY$L5Q;L3&XBV*9=KA7#>+R@VY;!+:"3TC#E3.L&/5!$;
MP,61AR,Y.W(XQMX/LL*S:4T+ A[7M=^%B1*YL"XTO:E_>M$ZJ+JT=<* -68^
MNVT)QPL%BN&LD5BO$F&L%M+D) 9O)CKR'ELKT+;6=<G?2K6P:5[C3[2]TRP%
MK!XMU):7[7,EQ:N KM<(5N;A41D(CC8[ -H(N\%NHF>0*$D=)9"[80/&$".,
MD!""BDD$989)JSW9J:LR9>,K0LG7DBD6.OE6B<B#(\F+F8YH#W;*0$#-Q;8E
MQ@C5F$+8F1SFXAU0"FV'3O-W _-$,-MX4MR\5P66WG2VAE21989#)XD=Q/!*
M6M)T"*&A9#,!("PCP-V<$MD#(P2N6!'(Q@J",,O/<'!QP3SB51<1'P[9;<>Q
MAC!\B;+&]G'G/7DI%W+YQ7W9QWT\OO9RYEEK*&&^_BTVA/PYJR2R2E#(VXQQ
MI$G"C$<8VHOJ@9P.,G+'S)-2 !G'F23\3WK)\QU-.*4XI3BE.*5UNLM/IPAY
MIMU"5MNI2XA*TI=9<2ZRXG"L9QAQIU"'6EX[*;<0E:,X4G&<2"1R"0<$9!QP
M001QY$$@CS!(/!I4,#8GZOD*.9:-M,#Y042$ZX7[39HQ.<2>9NP6B:GIIO$V
M$CM%I89C1,S#:LD9]GD4N)R+MNT%SOD)2VG^ORN FVVD.8_!@M88(#X#GZZ6
M,C^"?5]:+!WUY''<< >T=\DDGD=NW/?@U'8>I:HL0=8>AHL#(T39'=KP8+>)
M&();L4RN<85:9&$)4$<\Z43)3*F,S02V4&HPZ.TV^ ,H?8ENM4MWN1+*^Z6W
M&E3.3',IMX1 ?18YEWQ@(L4(;P7!*'#$K(VZ $8 @=CO'<>L<\D<'/)[CO\
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MDF)+5R##X09;5#'X)%NT($=P"&NBH$LTBB0R!RS,Q["1PP[YY8YSSGD?L?(
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M&!FAP1&F:275Q(K1M*WAOX&^) L<3FVB,,#O%&$C:2.)F42,ID.]V9BSN2
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M*$& FQ5"ECG&YRQ.>_&!Q@YXTMW/T).[4V19+^)LU41BR/C%/1DE7%S#@;S
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M4PPVQV;7@EGLVI+:5^&4YSAQ2\X5V5VYK$9KW-_H?IMS)<"Y,?B!,H8@X!1
MG!WKZI"AL$'#$D'FIK4ZZFK0S43@QPWP>>?4\M'IIPI]6%90RUYN>DTGMW\?
M-65.*<<SG&5YQ@ !P*Z=A:>A6ZP>(TN&9BQ&!ECV5<G:OGC)]8L<\U)>36Y6
MOFZ>JOI[Z=I& B=U;0@M?R-H#./@!9@>7><DPXUY@<Y]C,;&G(2@=XEAM>'E
MMJRIU/BE6.^<8)KF"W($TBQ[@2-V>0._8&N;?ZOIFEF,:A>0VIE#&,2E@7"E
M0Q&U3V+*#\153#?*/]$)F<8&ZAZ<[E7PQXA6?'?_ +:!Q_3\G-8ZKIZ\FZC
M'F0_^37*?K3I:/[/6K-?B9/Y.I()UX=(A_;V3>53?[_1XCSV._\ V\.G[_-=
M]?T>/[._A7XB3_(K2D^J+T3%GQ.HK!<=_P"G'\4)]_/N-9IOK.Z7W?BWN*M+
M[_\ *L36?_-7,!ZHZ?'?4[?[DOO_ .;]U8Q]4KH9OL>I+$_!;D_B@_TUP-ZK
M*!.#KCM-BSFZ+H4G+457ZC"3+46T0Y]HT79[?*1P5:J\(PZIO)QTA(>TH95^
M\@37U-LKQ2=3V,H,6D)/K%ZW$5O:0RB(,> ]U>21I:VL*MCQ'DDW@?TN.1L*
M;OUSI-W&T73J7/46HN"(+6PMKE8 _P!BKWE_/#%9V5LK%?%EFEWA3];CD;"F
MRM,Z_D==TO %AD!IBYV*;F[K?9D)M;(,E<;2<N1EE1[3F$N-Q4<E0T)#(6AM
MQ,1%@X=0EWU,<WM&T^33K+P[B1)KVXGGO;^= 0DM[=R&68QAN1%'E8( 0"((
MHP0#FNST]I<VDZ<(KN9+C4;NXN=1U2XB4K%-J%[*9IS"K $01 I;VX(!$$,6
MX!LBK7YUJ[E.*4XI3BE.*4XI3BE.*4XI3BE.*4XI6L'3CGU[%U.GM_;"D]2%
MF'8=QG&4N.15)H$6=A.<?3A@\0D5><?##S#K>?MD*QCRW37K7/5,@Y1^IKI5
M/D3%I^F0R8_ZLL;H<<;E8>5>.Z2.ZYZP<<HW5U\JMY$Q:?I<,@'MV2QNAQQN
M5AW! V?YZFO8TXI3BE.*4XI3BE.*4XI3BE.*4XI3BE:Q:O\ ^*7ZI_C_ *1T
M/\/O?Z#[%^O_ '.>6TK_ &3]5_\ F] _Q.Y_7G\5>.T;_9?UI_YKIG_$;NMG
M>>IKV-.*4XI3BE.*4XI3BE.*4XI3BE.*4XI6L?2M_P"U'97_ %P6\O\ 9_*\
M\MTG_4FJ_P#I'KW_ ,0EKR'1G]0ZO_Z4]2__ !:XK9SGJ:]?3BE.*4XI3BE.
M*4XI3BE.*4XI3BE5+OS^H7N?_4IV%_L2E^<CJ#_6'6_[4:E_B4U</J?_ &-]
M0_VCU;_$+BLGIS^I%JO_ %.*/_L8B^9=&_UGTK^UMC_BL59M _UBT7^U.G?X
MG#5C\Z5=:G%*<4IQ2G%*<4IQ2H? (M:926S.+:5'Y4OV'"5,93E7K9]/+"6L
M>LVSACNE:2.SF5>&>V5^HK/2O&TXV]N+16$X \4G?G&WG?N]4N7Y!0D8R.!M
M%<FQ75!<W1O64VY+>#@H>2_J[ GKA G!$F#G;W.XB($#[+R\[XK?SW<7XY9(
MC4LYQWSV]-*EI4EO..V4X4E*\8^"L>7?G55] **/47U1]FEP7!QR&(4@GVX)
M'L)X-<)X^J=[89R-S8*/:A",\%0Q!"X[!@#[1G->;V?:'?'BLO&<*Q_"(BLI
M^&<?PL*<SC.,?3GOC.,X[X[9^CF%FT;G!C(]R3@_^[G\OXZJ(^J21S,#D<F2
MTV\>T;L$?'@]N:F=D;N"VHG$$XREY/;WEE&1THR_XM>*\^U8[J$PKUO)#>/5
MSC*>Z%?#QYMJ;$&?T@-M_P!ISNSLRV0-G^V8VX+'&<\CG/;U%=7*VGH+('&/
M22"@!?"\GQ1S%G?E5&XY&0>!7EN#5S<="S6UJP/AE>"DCK$;=]I\O@I>2U)R
MIKP[8;2VKX*]3+F.^49PM#9A7%R!N)&TL'(VX[#9V.>Y.,C !'.::NNL%X#I
MQ^MA3XH1HE;Q,\$^*02F,;0IX.=P[5SI;5Q;R?\ .A:U-9PS[&EYP-Q[#G=S
MULX4)E6,-^/IXSAQ7Q7CNA./M\YI=FU]06^">=Q <#'&!AAR>_;Z?=?25U53
M-\HDE<)X6YHF;=EMW]*R ,;<Y/?L!6BV]HKKF(V?8WM9DRRZ$MP3YLIK\I20
M16@<!#X<;)9FB19/,A@S!*BW"4N)6M6/97<B88;;PKX>P9 W>>?;GW\8^'TX
M-?'.LK7ZL<G4-^W3TEP=%+1?)XL;G1X(UA\&/<LB7DD=R9Q+XAE:0,I8_6F\
M((JV+TLQ_5D)9;$O?)!N:HJ#2F,9FCJL?(*G_;A<LN1ZZZ^2\R(@#!Z3DF.(
M:<<<"RPA;B'E-U?;^QQW\O9[_+\M=[ZG$'U3(=0OSUI)*=--F!;)=SZ;/.;W
MQH]K0FP>1DB6 3"82L%9FBV*2'(VG4U<_GJEQ#K?S3]%/DA2A?'&/9.RD>GC
M'MGM7MO=:5XQZ?H^.,N>/=O%?5V_V7^?^*OI174_E3(8?)^T<$QXQX6",8\7
MQ/&]8$>KLX)\C.>5KJTXI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4X
MI3BE.*5KOMK>H=8+SKK6[(U^WE.LN,5VD1KR2VX%3J?3^=-^)'7EJLU2(4M!
M1CT@Z.7(8P@*-9==?4ZQYW5]=2U?Y-TU4O\ 7;A2MM8QG<MOD8]+U%TR+6SA
MR'=I"KR\1Q*S-E?*:[U+'92'2=(5-4ZDN5*VNFPL'%KN]7TW5'4[;.RM\AY&
ME9'E]6.)26++.=-ZW:U1KN!IF9!R:DQO;I2RV!Y'@18K9/R!,U9IQ_&<>?>0
MF3BW6$.96M@3V8;*U883GF]HVFKI.G6]EXAGE3Q);FX88:YN[B1Y[J=O/Z[/
M([*"253:F3MKI=/Z0-#TJUT\RFYF3Q9KRZ8>O=WUU*]Q>7+9Y^NW$LA0,2RQ
M[$).W-6?SJ5V:<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2M8-1*P?U"=5LL/]T!:
MEM05?VE/=33DI Z^S(R@Z5]L)RX'BQA,OMXSE3;O?"L8[X[^6T?ZYU%U;,O,
M8FT:UW Y!EM]-$LJ_%!=1JP\CQWS7CM"/B]4];3H,Q+/H-D''*M-:Z7XLR@]
MLQ^EQJPY(;.>^*V?YZFO8TXI3BE.*4XI3BE.*4XI3BE.*4XI3BE:Q]*W_M1V
M5_UP6\O]G\KGGEND_P"I-5_](]>_^(2UX_HS^H=7_P#2KJ;_ .+7'Y/N=JV<
MYZFO84XI3BE.*4XI3BE.*4XI3BE.*4XI52[\_J%[G_U*=A?[$I?G(Z@_UAUO
M^U&I?XE-7#ZG_P!C?4/]H]6_Q"XK)Z<_J1:K_P!3BC_[&(OF71O]9]*_M;8_
MXK%6;0/]8M%_M3IW^)PU8_.E76IQ2G%*<4IQ2G%*<4JGS]F&BFE"IAV4X'(=
M9Q@AYU#V,-+4CNZG",80M7CY93COA/?Q\E=O+G=BTB-T1VN&]95;**I4[@#Z
MI+9(&< XR>^!VKS4^NS122H+5<1LRX=V5_5)'K#;P>,X\NW/GYD[3-SVQF)$
MQW^\0]^?MW;QWS]?TX^&>;:Z!"V/YYD!/EL3&?9G=G\'G6JW4LR_[DB]Q\1\
M?^[]VI!7[T5,R@\>Y&-H0_ZF,NCNN.9:\&UN>HO"T8QZ?='BKXIRG*DYQWSC
MQSJWNCQVML\ZW#,4VX5U"ALL!@$'[+!R,9[8.,Y&QIW4$M[=QVSV@42;LNCL
M2F%+;F!7&W@ G(QD=^QZ9^_F1$H5'M13:TC*2A+A#KB%O8RC"O42E*.V$*\O
MN?Q5Y)[*SG'EVQCM]*2:WCG,Q^N G"!2%P2-I.<EACGM@\8XR:W_ %#+9W<M
MLMHI$1 #2.RE\@'< %QM.?5Y.1SQG P?V5#_ *HD3_OA['_^&>9?D>/_ (Y_
M[U?X_P!?+-:@ZIG/:TB^'BOG_P!WZ/;4TI]L(LV3DOQZ1?9,,J2ZRXMUES#O
MGCPSE:$^+B?#R[84KR3GZ,>/=7/O;-;41E9"^\L"K !AMQSP3QS]W\'9TC5G
MU(SA[<1>%M(=6+(V[(V\@888SP3D'L,<Z);TZZK-J?9UEH(&MHXH6ONAL-R,
M[+G DR?M 0Y>3AQF \M( <R1X"+2Z_EYMOUE+0IQ3#.EZH R3DCC&/?])QYX
M'W<BOD/6'U8=0Z;ZAO\ 18- @DCL6B03WES-#)<>)#'*9HXTBVB%O$VQ'>Y=
M5WDJ28TL7I;ZLYSJ!L]BKDK118%N&@TS+<S$2)<@!A>#A0O=Q_M(K.&"BL%9
M)!RAY676PC<9:[-^>* YSP1\17>^IY]4J[ZUU"]L+G1X[-;6S%V+NVGDFAR)
MHX? E$D2[))/$,D.')98I?5]7-;#6O8YE>FB(IF(:>0.VPK!!#SK?K^LRA[*
MVDH;[9;3YY:[^2ONC:\9SCMXISI%N4-N[YXXXP2.>_?CR''MKW6H:U)9W3VZ
MVZ,$"$,[LI?>@;*@*> 3M\\LK=L5.*O-N6&%&E'0U!+?4ZG+.596A7I.*1ZK
M*U)2I;3G;NG.4XSC.%)[J\?+.-EVL1G/Z^8]M=6PNC>6L=PT9B+EAM))'JL5
MW*2 2IQ[.#D9(&3(>5K<K6G?/2/I+J4D:[*[8B[K(&54(^/AE53;&T]<,MC2
M3XY):3!=>7&KC2CJG16<M/R;1;XR,+;'<:;=<2O!-;13E3)O.T$#;+)'W[Y\
M-ES].<>5<K4=%L-5:)KU;AC"'6/P+V]M  Y4MN%I/"')*C!<,5Y"XR<T,GY+
M3H[1_!KFX/S]3_4LK_QMLYY@.G6I[B;]\W'\K7+/1N@GO%?_ 'YU@?BOZ[D_
M)>='Z?HKNW?H[?'J;ZDL_#\^UN5^3+3]K-^^;G^5JOS+T#_BM1^_FM_I"O0C
MY,7I%;_@U[;>/R]2_4>K_P ;:F>/DRT_:S>W^J;G^5J#T3T^>#%J7W]UP?BU
M$5ZF_DTNDQK^!7]KX_+U(]16?U[1SRITFR;NLY_[W=?DF^'W!6,]"].-WAU+
M[_Z\/Q:D*]J/DX>E9OMXP6U,=OH[]1G4+G\?U[.SCE/D73_VD_[\O/Y>L3?4
M_P"F6[PZI_"'J#\?RGG\->Q'R=_2\WC&$P>T/A\/MNH;?ZO_ !MEY_\ 3]?(
M.B:<>Z7''LOKT?BN!6(_4XZ5;.8-6Y__ !)U$/?Y:H*]:/D_NF9O^#"[,^'T
M=]_[X5_XVQ\]_A]_OS&= TP]X[G[X7X_%<BL9^IITD>\&L'R_P!D_4WZ6KVH
MZ#NG!OMX0VR,=OO[WWBK_P ;8>?O<QGIK2"<F*[^C4]3'XKL50_4OZ/;O;:Q
M]'5'4X_%JXKU)Z&>G9&,8Q#[$[8^K.\=UJ_7?\_T^GF/YK:,>\5X??\ *NJ9
M_!>"L?\ ,KZ,R3Z-K))]O5?51_ =9P/HKMQT/]/./HAM@?ILW/G]=]SQ\U=%
M_P")O/OMJWY[5Q]2[HX?[EU;Z>I^IC^/5^?IKNQT3]/R?HB+_C^_3N3/Y_C>
M_I_'R/FIHO\ Q5X#VS\JZK^6]JZ_4RZ07M:ZJ/\ \R]2'\>JFNS'19H%/T1-
M^_/N;<.?UWG/(^:>B_\ %7N/9\JZIC[GIGX/IJX^IMTF.UOJO\).HOTK7:GH
MQT(GX8B;Y^?<NX,_KO/(/26B'O%>^W_7;51^*]JX^ISTJ.UOJG\(NH3^/4ZY
M?N,]"X_Y$7O\^X]O9_7>.5/2&AGO%???C5_SVK#ZGG2X[0:G_"#7_P!)5]QT
M;:'Q]$3>OTP[=_GO_'R/F=H7_$WWWXU?\^JW\S_IG_B-3^_^N_I&N7[C;0>?
MM7H*Y%-9_ACE;;VR0.[C_E7F7+ME#B,_6E6,XY'S-T _907K#S5M7U<J?<R^
MG88>T'(-3_,_Z7/#6NH.OFKZ[KC*?BIU'!'N.1[JN>@:NUWJR,=A]>4V J(!
M#F'C$0P#0Y$@^G&<)(DS\X6?*$I3G*4D2!)+R4?:8<PG&,<[6GZ7IVE1&#3K
M.WLXV.YQ!&%:1OVTK\O*_)]:1F;WUZ'2]%TG183!I6GVMA$QW2"WB5'E8=FF
MEYEF89P&E=V X!QQ4\YOUTZ<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2J?W'N"(U
M/!#*2*[8[U97U0^NZ!&*PY/7.R/)PD8,0=.<K'BQ5K03.S3V$ Q$<EQ]]WU5
M#L/\?6=8ATF!3M-S?W3&'3M/B.;B]N2/5C1>ZQ)D/<3MB.&,%F;)56X.OZ]!
MH=LAV&[U*\8P:5I<)S<ZA=M@)'&HR5A0D/<W# 1P1 LQW%$?KT5KB1UI0FH^
MQG,R]YLTS,7C8DT/C.&)6[V@GVV7<&[X1^\8YM(<%%_<V\^ZHD+R;2ORQR-"
MTV33+ 1W+K-?W4\U_J4Z#"S7UV_B3%,@?6XALMX>!]9AC! (Q4=-:3+H^F+%
M=R+/J5Y<7&I:K<+]C/J-Z_B7#+V^MQ#P[:'@?6((\@'-7)SLUWZ<4IQ2G%*<
M4IQ2G%*<4IQ2G%*<4KS&F"QP9<@<^V*$",^882\K"&AQ16EOD/NKSVPAMII"
MW%JSGLE*<YS\,<J[K&CR.P1$5G=F.%55!9F)\@ "2?("J22)%&\LC!(XT:1W
M8X5412S,Q/ "J"23V K7#I&')<TC#68QE8Y6Q++?MF*:<1EM:1+W=IZPP^<I
M5C&<>I!F1CF._P!2_AG..W/-='JYT*"ZD4J^I76HZH01@[-0O[BY@)'EFWDB
M/G\<5Y/H57;IVWO)%*/JMYJFKE2,'9J6I75U <'MNMI(3Y]\Y/>MF.>GKU].
M*4XI3BE.*4XI3BE.*4XI3BE.*54N_?ZA>Y_]2G87^Q*7YR.H/]8=;_M1J7^)
M35P^I_\ 8UU#_:/5O\0N*R>G?ZD6K/\ 4XH_^QF+YET;_6?2O[6V/^*Q5FT#
M_6+1?[4Z=_B<-6/SI5UJ<4IQ2G%*<4IQ2G%*A1-^K(SSK*R'G%M.*:6IH1U:
M,K1GQ5XKRE.%IQG&<86GNE7;NG.4]LYWDTZZ=0P50" ?6< @'MD>7OSVR >>
M*YDFJV2.REF8J2"5C+#([X/GV[]CY9KHQL6KY_KI6/Q^QN?R=_R<O\EW9_8I
M_?BL1UK3QW9^/^:.?N?0?N&L\39(8.-&EW2L8",RA(SB&G%+=4O"E>.&DH]1
M.48;7ES"TI\,H5A797;&<,5C<S3O;I'F6,$NI90% QSN)P0<C&"<@Y'&2-J7
M4+."WCNGD AE($;*C%F)R<;0-PQM.[(&",'G /(^PQ$<&*>21W'-2E8BFVUN
MJ>0I"7,+2E*>^$X0M.597X^.583G[;.,<F&QN9Y9(4CQ)"2)0S!0A!*X))P2
M2#C&<X)' S47.HV5K#%<32?6YP#"51G+@J&R !D  @G=C&0#R<5@L[!K./I=
M*^'_ ,3<_P /]/C]['-AM(O5^R6,?^N/R"M#YPZ5^WD_P#?Q5FX6QQ,]ZZ8Y
MU:EC^&76W65LKPESOA"\85CLI.<ISCNG.<XSCXXQWQWU+BTFMMOBJ 'SM*L&
M&1W'M!Q@\C!!XY! W[+4K2_\06SDF/!=61D(#9PPR,$$@C@Y!'(&1G778O5Y
MH;75LDJ=9Y:0)L$+EIB3:C:Z9)L!$.LH)P&LSTT,./MM/-K>0.MYMEQ>6'%I
M(;>:;U"ZJ<$@'_1_&*\3KGU3NC="U*XTK4+J=[VT*I<+!8S3I%(R*_A&7:$9
MU1E+A"P0ML8AU95E&H.I'4.YY23@:!*%KEXP'WJ3&R$*5$/.QZ7V!7#1\NM^
M@0VP02,R\E+OK-J?:SEOTUX7P&5NQ!KH],=>=,=5W%Q9Z+<R-=6\/I,EO-:R
MVSM '2)I4++L=4DDC1P&WJ74[=IS5PJLD+[\Q7EDX]Z^&%884R[X=\L^T8;]
M;*/2]3+'9W"?+XISC&,^><)YF\*3P_%V^I[<CVXSC.<9X[5Z<W]IZ7Z"9/YY
M('JE&VY*^(%WXV[MGK8SV]_%9_F.MVG%*UJWQ7NK2;D:ZYTW;.TA0(H<(]%I
M&VSJRV[#-DI!;XZHU^&)K6Q*.U&"CCI);+8*8D'"'7&7&G6$M*0YKS+<DKX$
MD*#!W>)&SDGRQM=,#Z*Y>HQZS(T7R5=:?;* _C"^LY[IF8E=AC,-W;!  &#!
M@^<@@C'-"XH?RI'_ !W4=T:_3]733M/Z/O?U??Z?KP[-1_KBU_>\G\M7,-OU
MAY:IH ^.D7Q_^ZC[GX:YXHGRHGU]1G1QG\G37M+'Q_3Y]'^'\_(V:CS]?M/=
M]8D_#]>JIMNLO+5>GO=G1[_]+5S^8GRH'U]1?1U_K;-HX^/Z>L_X/X^-FI?U
MQ:8X_P!SR_3_ +?]S]<QZ-UI^ZO3OWGO_P!+UV8HORGGU]1/1[_K;MH?>_U>
M?O\ QX\/4OZXM/WM+_+U!MNM?+5NG!_<;4#_ />*[<4;Y37Z^H?I!S^3IQV=
MC_;VSR/#U/\ KBS_ 'M*?_KC/X*CT;K;]UNF_O-J'Z8'Z\^6#W8H_P I?]?4
M'TB_FZ=-F8^O\>],_5_'_@Q'AZI_7-GY?[FEX]N/YX_'5?1>N>?Z+]-?3HFH
M\?\ \R/PY_C[DTGY2C_CNH#I(S]_QZ=]EX_7O'/(,>K>5U9?3:2_DN!Y_"J&
MUZ\YQK/3'NSH>HGV]_Z-#RQ^&NU-*^4AQG[??O2=G'_0]/>R<=\_GW;GMR/#
MUC^NK#]Z3_G7\=0;3KWRUKIC[PZCQ_\ S9S\/PUWII?RC&/X6^NE+/Y.G[8^
M,_\ ELY7PM9_KRP'_<YOI_W55#:?5!\M;Z6']P=2/_WO]?97>BF_*(8_A[VZ
M5\_'_C= [%Q\/A\/CNKX?7\?C^?D&+6O*\T_Z;*;\[K&UG]47]CKO20_ZW3^
MJ'\6NC/X*]":?\H/CMY[RZ7,_?[:%V)C[WW]T9_'_%RIBUWRO=-^FQG/_C!]
MS\-4-E]4GRU_I#/E_J<U7'P/^J#R]H[^ZNY-0Z__ (^>[^F#/WO'1&PL?5C[
M^Y<_7W_P_BY!AU_ROM,'QL+@_P#CA539?5,YQU!T?[O]3>J__P"0_EKT(J77
MOC^'NKIE5\/^-T;L!/Q^_P!OLQ9_']?*-#U$?L;_ $H?'3KD_P#CZJ;'ZI_E
MU#T;]/36K?\ ^0UWIJG7=\/+<_35G[_CI&_8_+V[[>SRA@ZFYQJ.D>[.F77X
M?Z(54V/U4?+J+HL?'IG5S_\ V(5VIJO71C^%N3IO5C\6D[XG^/[+F?U<KZ/U
M1^Z6C#^Y=T>/OB*HUA]57]CU)T2/CTOK!_\ [)_%79BK=<?U[AZ<L_DTQ>\?
MKVOGCT?JC]T]&^]5W^DZ@6'U51WZDZ)/PZ7U<?\ ]C-<\5?K?[?';W3KG/Q^
MC3=YQC\7PSM//Y_C^/\ %ROH_56?]=-$Q_:B[S]WY5_)[O?5_0?JI?;%T5_!
MK5__ /(:YXJ_6W]>WNGC/Y-.7C'Z]I9X]'ZJ_=/1/O5=_I*I%C]5#SZAZ+^C
MIK5_R]0USQ6>MCZ]M]//YM/WCZ/TH<>C]5?NGHF/[57?X_E+\E7%E]4WSZ@Z
M./\ ^7-5_3]<\5GK5[_';/3WG'XM07?_ "G_ )/KX]'ZK_=/1/O5>?I.I%E]
M4OSU_H\_#I[5!_\ ?37/%:ZT/KVOT^_FU%=OH_2=R/1^K/W3T/']J;P\?'Y3
M'XJN++ZI'GKW27T=/ZG^F_P?AKE\VNL[^ZMT_P#Z([K_ )3>/1^K/W4T/[TW
MGZ4J19_5&\]=Z2/]P-3'W/Z-_CS7WYM]9O\ =6T!^B2Z_P"4SE3;]7>6J:%C
MWZ3>_DU3^/XU<6?U1//7.E/?_0#4_P ']&_QU]Q6^LSZ]JZ _1+=?\I?T_>X
M]'ZO_=30?O3>_I2I]$^J%^[?2OWAU+]-5S^;?61]>U-!_FU-<\?KV5G^GU\C
MT;K#]U=!^]%[^'^BOXL5/HGU0?W;Z6^\6I?IFF*WUD?7M30>?[TUSQ]__IE?
MD^K'^[!MNL?+5M!']Q[T_P#W7O\ KBGHGU0/W:Z6^\>I?IFN7S<ZQO[JFA/T
M37/_ "E_T_6-MUCY:MH _N/>GZ?]=:GT3ZH'[M=+_>/4?TQ3YN=8O]U/0GZ)
MKG_E+Y'HW6/GJV@?>:]'_P!U-/1.O_W9Z7^\FH_I>ON:-U7S"<B2^]]<UD5?
M?#AM&T^^[-^&<9QG [UON<[%CKSW^#KD45E&<85A&<XSC+T#JR8%)M?TVV4]
MY+'16,^/,*;R_N85)]IA?'LJWR;UO/ZD_4NDV:'N^FZ S7&,<A'O]1N84/\
M9&!\<'&>\WUMH>G:ZEC;:LN?O.QI8?V27V3?9+W];B@LJPO$8$1Z(P$!"MJP
MG#<1  1H7@AK#[9"VD.8WM,T"RTV5[LO<7^I2ILFU34)?2+UX\Y\)'VI';P
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M6U%8Q<G]B <$DX)P2,YR <9]]>TGDT>VOC/.\27H498F1F&4V@E5W(',? )
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MWD?Y):YAZCN!_P &>I#V_P!RV7Z0-?<=>=WS_P"][]>N/I^G76JOY-S9^_\
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M5/XE:_U=C_;@SQZ?)^Y]_P#X.+^6JIZIN!VZ2ZK/PLK ?CU,?K^'LQUOW/\
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M<5A*$Y5G"4IQA*$)PE*<83CMS!+*TSEWQD\8 P !Y <GW\DG)K>M+2&RA$$
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M,_AJE)OHXUY9*_+4J=LUX/H#[6Z,UFF^O5A@J');XA+I6KO+5F5'JJ+ Z4#
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MDO&<]E*QWSC*L=WKJ.Y /'!X^'!J!X+G("%N3G;R?;W')^[BO.;8*LM2QCC
M7\LN*2IIYA1"$.([ISE/W%Q&<I^*?)&<X^G&,\LJ2]U##/L./H[CGW=ZH\UN
M>)&0XYPRDC@_ C]?96.S,T/'PRJ(_/'?_P#)_3/X^9A'=CMXO';#G';R(;';
MV?"L)DL.Y$)S_P WG_Y3^O%9ULV CP,2C*X\2/?PC."1VFVD/9[Y2A.,,MX6
MXO&<*3Z?CE:<I7C*<>*NV/;-(_AGQ'<9]5B21CD]SP/?V/'M%9@UO#'XJ^&D
M;8]91C/L' R3P>,9!R,9S7*)DH21R2J(>%=5A>%E>@UZ+F5K\O%QY*FVUKRK
MLK&'%85C.<9QY=^_$L<T>T2A@,83<=P 'D,$@8XXX^%();>3>8"A.0S[5VDD
MYPS9 )S@\\_&M<=F[4Z2(2W'Q&T9#6C]RCVA69)N;JK5AE1$+80^**68W!R2
MFEI&=;=0(Z1AUIIUM66D)<1Y<V:>Q1RL[0[QC(= Q&1D G:<<<XSG%>'UWJ#
MZG-KJ4UMK\VA/J<*QK.MUIZWMQ&"@>..65;2<JPC96$3.&5&4[0&&95IO873
MK;#9B-TF=1LR# S)LR#5X%JO&.!I=PPT4^-F+BWC!F'GDM9>0A]H9TAI#BFU
M/MX7:WFM)"RVS1$@ L$4*<9P"1M&1GCSQD>T5T.F=9Z*U&6Y@Z6FTDSI&LMU
M%86BV<IB#;%D=#;V[RQH[!=P#JC.H)4N,VO*2U5'+4Q*O1N3&T(\D$#I(=;0
MK'FVE:O1=RCNG.%I0K.,]E)5V[+3G/9MK?49(PULMQX1)P8W**2."0-RY[$$
M@=P1G(..Y=W&DI*4O#;&95&1)%XCJI&0"0C$9!R%)S@YQ@UF8XD H1IV,6PL
M//DEKV=.$-)\59\DX;PE/IYPKOE2,I3G&<]\X^/?.M.DT<K+<!Q+P6WDLQR.
M#N).X8[$$CWUNVTEO+"KVK1M#R%\, (,'!& !@@]P0"*]O,-9ZH;<EKW*-(5
MBAZ)KU2>N=H%FYJ0O>S@[07K*A5JNO0PA9$B!55Q\G;+?-R$_'BU>D,V6H(D
M(X2T3Y5G"9K2(V954DYPN,^9.< >7;OD^^JGZ4]\;?V'=^I'2>^:Y0@MG]-M
MXI< =<]3YL+&MMAUG9.OXC854FHJ$M9DK8*A8X\&1?BK743YZR(CR!X^4 GS
MX^;%PPJ%9B65@,J1R.Q!&1[2"/,'\51+7VZNIWJ+U_8-W:%7H* U^NR["@]6
M4G9D!?IRT;'!UM=+%0RI>V; K5UK\3J/YWSU6E'8F.&UUM4NM09$7(3WM,T[
M)U:)4!9AN7;CG (.3@D<G(QV]A]F?.MB>G??=:ZANG/474C& %U"K;8U95MI
MM1MF($9*K$98X :>(#F#VW,1RL0Z'GF29-EW$>0T/DYAWV1Q"^*LIRH;MD9Y
MQQ](XJAND+K"E.JC9?5%"-4CYIZ^T]:-7Q^JY>02</9]A4O8>N0[U';!FHPM
M24PD9:AC19FF1*QAI9NH'1!UA9!FSS(6'556+%N, $ >T@C.:W2L]FKU+K=@
MN-NFXRM56J0LI8[+8ILUB.AX& A GY*7F)60*6V,#'1L>,08:60XAD<9EQUQ
M:4(SG"K]JH#5NQMR;H*@M@Q%7A-5Z,DFTR4$%L2$GC]U;&@"4.YC9UVM#R]<
MBM+1DLSD.9A@;1\^KH7"EMCVNGZ[L'M,4$JH).".![^Y^CR_S>^MF^*M3BE.
M*4XI3BE.*4XI6I;&[=@;FM-LJ_3=&U5FIT"T2M(NN^]BA2\U257:NDO 6JF:
MOI$!+5N5V?)TZ8'>K=XL3]QI5.K%G9/KD;+7*S5VW5VOJKNSG;V!QD]L^8'F
M<?0/?6V+>',-MX=6AQW"$X=6VWEI"W,)QA:T-*<=4VA2N^4MJ=<RC&<)RXO.
M/+*K5HE6=U=1O4.G8ESZ:T:0KNIZ7=+MKBB36W(:[VJ0WG:M8V&2IE]EHPRE
M6VL"ZPUZ'?8.PTFOV@B+V=,3[E?DK6S4QX)^#:FE4RS<KMP,CG/)!P<$'@>_
MGGRJ&E]6V]MP]/\ JZY]+FKZD)O"T]0,EH':6OMRN6.6K&C[1KHN_P 7NMBZ
M3% >#D,AU24H!C58L33" K4',U0P>,;S:(]AM4%F(4J 26VD'(Q@D-SC/&.#
MCGOC!S6#E]H_*0Z[O>CH+9 O0Y)0^VMQU?7"HF@HWZ[<R(AP.8N%]E(+$^\-
M"-$U;6=2N=I0]+/)!<(AQ@%)=)/%'>5)9@5!"\G'#$G')/&T=AYYK]/N*O3B
ME.*4XI3BE.*4XI5,;AN^V:L$#&Z<TR[M:X3C$A["7.7>OZ[UE5GQ,#X8(V!:
M24S]R%!,61G C-#UO?Y9[(Q&"0 &,)+XJI)'89/Q 'TG_-S]TB!=$N];+U.=
M)F@NH"XPL'7;1MK7,)<YR"K*SW("*/E$NJ=!BG)1\B1=#8\,(;=+=4\[VRXI
M+?EAI"B,656(P2,X]GW:IV:V#UZ;'NNSBNG..Z2HS4%2O<OKNHS&Y\;A,M]I
ME:4#&0U_F71Z,4-#"Q4/M!JZ4@(3"TFO_-!\YYU"3FDMJ98YP!W(&2?(>8 /
MG[QQ5[;1OVV]7]/T=-.#:[L_4#)M:TH,>,*-98354GN/8UEK-"'-0"Y(S-P
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MM2><:5/J"PJH@^2Y=2C@ PD=Q;LT<NQ1@(D^^%G50!XBNX&Z1R>1>WPZ4O\
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MEV[9XJ#G!QWP<?'RK\8.A+IOVELSY.7I*M%%ZU]VZ@LQG37KN:K+.M(/435
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M?TG4$!RI](?3;:4>O!<SIC."]C<T%K.0Q$-738LAF1RN+BAHR5F\"G2JFF&
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ME18S,;'R 7L++K+CHRV5#J7A]2GV,D9=(?\ +7VDW5S</-'<JJMC:KM(-F
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MQLE/*HEWA=A5_P!E+<$PS9( >1&CGB<-_P#!0J&I0O#HCGW-W*D95_ QQ4D
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MG"Y5HRMR]*\,R1NP"Y2R1Q#8%REF-D!;U"FX>4M3 V)<^!CL=1^VRJS#$D.
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M*O3J2S;D"A5:(=B90:GT*L5MD6&) @_=T<E3L0Z:KVO"H"@%B,Y8Y/)QG '
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MNREM^FOS3C.5)\%^6,>.>VSN7CD<Y Y')'<#VXP<_"NGO3 .]<$D [A@D9R
M<\D8.0.1@Y[&N>7F<.9:RZWAW&$*RWEQ.',)<5E#:LH[^6,.+2I",YQV4K&4
MI[YQG'&1G&1GV>?L_'Q4[ER5W#< "5R,@$X!([X)! /F>!7B-EXJ-941(20(
M3"%BMK>)*99;0LTML -*UN+2E.23G6Q&.^<>H0M+*.Z\^/(9T09=U4 J"68
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MO47>FT,NN.K?8'.+C$@K']5Q([#V7DK==1C"MR6S6659BP#JMNO"#M!=)=
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:UPHX-[=27%QD9C:$$J=GN=>O;4XI3BE?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>51
<FILENAME>g425213g62c06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g425213g62c06.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1BL4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &)"^8H@X0DE-! 0      %\< 5H  QLE1QP!6@ #&R5'' (   (  !P"
M4  (<G(U,# W,S0< @4 -DUI8W)O<V]F="!0;W=E<E!O:6YT("T@1W)A<&AI
M8W,@9F]R($)U<VEN97-S(%-E8W1I;VX@-@ X0DE-!"4      !"C?HV=MPG.
M+"G"LY9:>0Z=.$))300Z      #E    $     $       MP<FEN=$]U='!U
M=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR
M;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0
M   !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "
M4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,
M8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0
M 0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP
M $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B
M;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L
M  !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P    ,
M4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX            $)L("!D
M;W5B0&_@            0G)D5%5N=$8C4FQT                0FQD(%5N
M=$8C4FQT                4G-L=%5N=$8C4'AL0'DJ=M         *=F5C
M=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P    !,
M969T56YT1B-2;'0               !4;W @56YT1B-2;'0
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M300-       $     #A"24T$&0      !    !XX0DE- _,       D
M      $ .$))32<0       *  $          3A"24T#]0      2  O9F8
M 0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:    !@
M     0 U     0 M    !@       3A"24T#^       <   ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@     ____________________
M_________P/H   X0DE-! @      !     !   "0    D      .$))300>
M       $     #A"24T$&@     #-0    8              =@   1#
M      $                          0             $0P   =@
M                 0                         0     0       &YU
M;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P
M(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   =@
M4F=H=&QO;F<   1#    !G-L:6-E<U9L3',    !3V)J8P    $       5S
M;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M      9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A
M=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N
M9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,
M969T;&]N9P          0G1O;6QO;F<   '8     %)G:'1L;VYG   $0P
M  -U<FQ415A4     0       &YU;&Q415A4     0       $US9V5415A4
M     0      !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB
M;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0
M  ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M
M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E
M96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E
M=&QO;F<         "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S
M971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*
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MRV_TB[7Z8;^<HWVW#I&+;3G4[MY!N=?MKMWLNI#69.VS<^M]C;V>SZ>.G&$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( '$!! ,!$0 "$0$#$0'_Q  >  $
M @,!  ,!            !PD&" H% 0(#!/_$ & 0  $$ @(  04'!Q0,#P$
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M!I%T_2S8':U3W8U4!3 Q8IM]=]MD=M'KMHZRIIMMJVV1\U78FV_"E+M]&M;
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MA8M20?2[=HH2EU-E-7I(4;A5<=D*^!P"*.!>^K%ML4@>L,?0\F525Y'HY\&
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M&KI:I2-Y+!APL3B;UP21AF^Z@WJSU&Y."<QS7WW@[)I^,9R<(_14)95ZW>2
M$18]W_(L@[>F:S'D ^%#"$<.H7(F[L8GKT<D(<7CQE1H"NP,!L6MG$P'$48E
ML!*R>4)H<K]N0Z3<PPWB6.XF:-]]^5-]][U8E9I*1!U>&A2(!TC817 C<M)#
M0/$KMFK\JG6S-7>*A$G3M5)!IH^?>@1<NMME-VS799=%NZ633;*D55M ]D^S
MY38540%D3Y6B0.)U8;>UK(U$/!#>UQAF7]F80[M-=5:+DI84U!FU?5IO'LXD
MR8P<1A]#11?J02ENA4CH4<_7R:*#4;_W#=ZK2&>(NS=W.)\"(0%PA1'6E%!B
M0R8?*.'R.; [6[Y=H*AQ*2LTD=-]LHY3=N6[G.^N=M4,I9U4V)IKL_?YO5IH
MX\N/]GZH?H?_ ):$O.E>!,5L"U\>[ IL^!2PZ.37L*J.47;,#P'UCU27S<NW
M13"FD4VTH32\UVA5Y=6OD6OBBS'TPF'W#$><M\,??;#^AY'RLVKK8':)U\<_
MH(915&^6!SC\6P4_H U?>KY\>\F/VOD\?GYMC@DNR,EK_P .M"E!6E8[N0#Q
MU&Q8.W>Z#MD*$.HJKSFS,"17D((](%_+L6&78QY*OXCM0?IQK]^\_P Y!X3>
M_BW</XR2P^CI/HZU?+&[FR_Y3RKU8ARAK*)PB<(G")PB<(G")PB<(G")PB<(
MG")PB<(G")PB<(G")PB<(G"*F7M Z(XKM4SFBH"%7<5MI7>CEU.')OAJ0U9B
MUAD6@&D=7S+L/7XN5$K MGYJ8D8I&O3AP[;OH"-?#+J7<CL8:D4D>49=OVQE
MUW:(Q-:OV)&M8XZXW,;#":\E',B_B89(>BW;\FN"J")]6+T@6C&UI10 B9ST
M^+NG8D^@7T,2/!8SBN U[\O1ST16I<E$X10 .?&FN3/_ ' =:OX1>V'\_"C3
MCH-W+2_J5!7EQ_L_5%]#_P#+0EYTKP*&E@6Q73:]!_@I;'K51RB[9@> ^L>J
M2^;DJ,*4VUZR*';AKHJ\NK7R+7Q19CZ83#[AB/.7.&/OMA_0\CY6;5TR?[1/
MAG^)JJ-\L#G^_8*?T :OO'_T3'X>SFU^"3O-E:W_  ZT?V@T6$MWN@_P4*OY
MOH57G-F@BN@=-W0:WK#+L8\E7\1VH?TXU^_:>SC]K..<@\)O?Q;FGW\E>/HZ
M3W\5ROEC=S9;\KY:)YU8ARAK*)PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"
M)PB<(G")PB<(G"*N2T:R[BEUJKN!YG2DK7\,7S3\,+2"Q9! \"FDY/49()2$
M,/Z45/8AID8'0^VQQ)A'6 VU(FMCMU7\I'Z-=4FSU^K?:BE3L%71I.6Y5ECB
MDZ.L(T'![&8&,=)W:4TE(Y@90CK.;4(]9$5K\XV)H& 3%G:4Q"D6T-!I*RK!
M7,FTW775R1;C\(G"* 1SXTMQ_0#UJ_A%[7_A[/ZBC3S7^;SJ@GRX_JOZH?H?
M^7&,_P".A+^ASI7@4'W@M?1]^ :ZO@<L*W:54<HNV8'@/K'JDOFY,0!IKYAL
MQ/FVJO+JU\BU\468^F$P^X8CSESAC[[H?T/(^5FU=; KV"=7'Q*?FL]2J-\L
M%\=<I_4-7_W$QS;'!)WERWS^T+[_ (\DBF%QZ="P=N]T';(4+Q$JKSFR])-=
M.-XK73=@L-=??R#6NQCR5?Q':A_3S7[?Y-I__P#/M<Y"X3;\N+=\))_^ND]^
MI7RQNYLMR1?+1%Z-I^4RZH4Y8)36)R3E+(M#I'6+G&K$)G9)HB[V:MWF-47S
M9#9NXT] Z2V\]+;.N,YSKG/CKG&)LS@VRKMBSY:TY&5E7RDW#,6 Z).P8;W,
M#G,OAN.<TYS3<0.M?J-:TC BO@Q(C@^&:. AO(!H#B!0W'0L ^N_=),>TR,_
MV/"7V_[M^'AZO'GN]R3+6E>PY+_N,OZ?6OE[.6=\8\_DHG3_ +*L+KH^'+2!
MA6Q1!PX=#!E"LY^"<NVBS%RM&OT_2MU%V;C75=LIMIGQV25UQOK[,XQS7T])
MQ[.G9N0FFM;,R4Q&E8[6N#VMC0(CH40->VYS0]I <+B!47%92'$;%ALBLKF1
M&->TD$$M< 6D@WBH(-#>LSYY5^TX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3
MA$X1.$3A%HC-UJ)5=<<3)$-WV)%2_8F_'\L/AL7:S(#&6JC"NDG_ +B3#I"0
MRN9HO'X+%0$LA!)*/7K\VC,+L$6NJ[C<BB/O'#U6VO[KU/V  B<\I/B=ACFQ
M I'=<9$R2:"\R%ER<>^:]BS0=B-ZUC(M0NFR.2&(:8GX60RP21?QFDYLPG8.
M_2->^-+T5@%RE+4(J6RB]Z1S @U&P8GF%BH>&-S4@'<,8=VOK-00?I'2^2B9
MCM]=747 9BI-.6?)(,E8]XFMNW4E%6/1E^=C2&PJ<8$%BDQ2V)%XUS#!6PC7
MKYB=5P13'8EX13MCV*%@$<.LK,I6#&:J%S)2N9D;KYB<--(K+(J;VH'2[TH!
MKH]>!\]WB& W2JJ<+)SLU=ZY8#K SI&BNM*35DL10Y%L];_5 [6[Y=8<0VVR
M+?&%-MDO0J^"N<Z^?^9VQPFGF_?YE1WY<?[/U0_0_P#RT)>=*\"?<"U@;A[,
M#G'84L>:_DY54<HNV8'@/K'JDOFYC@,*XW"EQ'( 3754A5Y=6OD6OBC3'TPF
M'W#$N<M<,??;#^AY+RLW=S8*Z9/]HN\,_P 3=^E5&^6"^.N4_J&K[[B<VOP1
M]YLK?0]G6C^T'3MPO%-:PEN]T'>"A>(JKSFS<2:8'0*\NK6-7)=589=C'DJ_
MB.U#^G&OW[S_ .'X>/.0>$V@RXMP##/DNNS9,^?2KY8W<V6_*^6B;Z?,N;KR
MBGQV>Q'ZN$L^/R_X/0G.CN#X$Y%Y/'^A&@I7\(C'"_3=6[4<54[5[H37A/\
M*U:6^/CX^/M]OC^'J_:Y<14G:!0784PNH:7Z=2QZ[?.C7C^) ZZ>/M^I4+?O
M+'X?S\XFRNORJRC/]>6I^VQEL:1[2E/FT"G)Q3:=2YO+T\H9W*%;NN07@+S(
M(V!&[5L2 A(Y*'$E$F$1#E\Q'1C)-1<?57WT:LFR"&FZRJBN^J>-E%-]\[;9
MZ.L3@^R.FK%L>9F+$@Q8\S9=GS$:)V1.AT2-%E(46*\ALPUH+WO<:-H!7"@
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MUCXA!B17LAMHQCC5S@"105) 7XC18<"&^+%=FPV"KG4+J"H%:-!)O.@%:/\
MUV+HUX>/U5Y3]CX^\?UO@[X\N8X+<MS_ #2SGM&SO_J6.]FK-_&#_<QO]-29
M4'E ^J]['L16=9G[^=,9Q*17C8Q</+HE-=.*CW$F]VV?2L,T9)>B9M5U<857
MTRIG7">F-M]M=<XVULA,I[#D8MI6G9[9>3@NA,B11.2<8M=&B-APQF08\2(<
MY[@+FFF)H 2OM+VG)3,00H,8OB$$AIAQ6U#14WN8!<+\5NCRH+WIPB<(G")P
MB<(G")PBT6.8_L6[)3>OXL%,978GN<,L&M+]9G((T ZN"XU( 1G(B3@Y G96
M7$S#"/@32#6"Q$ *!2RV9.HD1EL0P/#I,9=6^X10SY1"/FGA[UZ?Q$H,MVXV
MTM2:(MY\1*R9 !@7$4/P&;KE/@U4MFQ[B K"9F(>:=P!I(@PG).=&TC(SB+>
M$=SHK!Z-NK?HUJ=][^;G*M/Y*A.$4 #GQIKD^@#K5Z_]8O;#\/M\**7UV$=8
MWW"H*\N1]GZH?H?_ ):$O.E>!2GL!:^RV!T]A2V^Y51RB[9@> ^L>J2^;DWI
MXCUW<ZKRZM?(M?%%F/IA,/N&(\Y<X8^^V']#R/E9M72P.T3X9_B;ZU4;Y8+P
M_%KE/ZAJ_P#U_>3'M^U_%S:_!*3[3)6_\.M"[DCD5HL);O=!W@H7B*J\YLSG
M%W7?R7\ZPR[&/)5_$=J']/-?M?DVG^<A<)IKEQ;OA)(=%G2:OMC=S9;DB^6B
M+F\\HIX?BV.P_CC_ !X2^]Z#_1YT;P?BN1F3VR1//\(CW#654K5[H37A!^HU
M:5<N Q -,0;_ !<^K6L>NWSHUX?B0.NGA_FK%_WGC\,<XHRNNRJRC']>6ICC
MV[&6Q9#M*3^;0/)M\ZX[^RGAGL9V ^?ZMMK>&?D_P\GO;]KV>'.O\GA_!ZP,
M+[%LK]AE\=]"H<Y?-S1US,<_I7J%<?FL>W.?.Q[?]/K\?E_#/,SHYMEU[=&B
MM3RB_2O,N]:LOL+5[]%XG]ZC#G"4UW1F/GL;R[ELQE\)G@V_JA<$_.[+^37R
MBO7C1:S4HTAG\NJGO'Q]5IU]G[7PMA_9C/JYCK:I[#6L:7FR[0(U5[%CUKOR
MK[RO;,#PT/\ 6&&W4NXB[OL,VS\OY6QQZOG_ "-2?.%UL@X&FI<U/FX]7AGP
M]OCYWMQ^'Z/"BITCH!IIZ>8&^[56<>M&/"_JE]>,_DWA_9GQS_PV?;PI!K2H
M-:5P*M2\I-\1_L'^I>&^_(;Y=N#GOVL#YU&_8YE8^UNYTU_8;Y1BXNOD_P!'
MM]O_ .?H?)\GM^3L0@7TOQ-<<,[3M !VJ@*QWR3V/[^.J_F]ZS[U_P#D:>SX
M?S\UQPK79$VD/Z39W/\ #80J-867L/NA#_L1?)N]2["<YQKCQVSC&/GSG&,?
MKYYR8KROKZ1/_+T_VM?Y^$7SC?3;/AKMKMGV^&-L9SX?/ZL\(OMPB<(G")PB
M<(G"+3CL%U9F+Y(V\C(FXVW@6D3*0<?&2HU:*<W$1)'J-[D\,S(*LORGFDQ!
M3<B)04YO$G(\9)-IEIJMJLK&IMHIO%*[^A%M,)#J(B,0 NWD9B72@(EC%:RI
M#*OYR<D\LF^B&[^6EY1R[?R#]YOILX=.'+A7?=53;PSC3&NNLHM++"LFYHOM
M\(A4',ER0HZTK[6(KUH#L'(";B\Q W2ZM,Q([&5#I.3@)8%DQ\"39MF1E LH
M]VJ,Q,E#2R]G1&BY16^G1R::\_C&VF6Q>G9EA;YU9"E*5PI'E=;52$-8[2]7
MWNUL]K\HN6>?O'&^U0X0RU?(69'(--4]]E=58Y]E;773=#.Y-.FE-E/3U*M[
MR@W2/N5W%L@)-A(&I(29"X/\%G3(BNPB<.G+KW^EI;W2AM&TTLEA#T4@FEX*
M;84](GOGS?-SKG.UL@.$"S\D;.G9&<D9V:?-SW937RW$9C6<1!@YKN-B,.?6
M&77"E"T UK3"6I946?C0XL.)#8&0^+(?G5)#W.J,T&ZCM?,M!/K,_?7\Y=<O
MV9#/^A3E]]VRPK_O/:V%,92\"F)X^G0 =1Q6,]KLS\? _2?85Q_0RDNV'4FE
M'M7E56U,52;HXG"K62@+PEV['1K*1\(S2:[:2-/(N,KI[Q:NZFV-,IYU43QK
MG.<;>&GLN<II7*NVFVI*2\>6A-D9>5,*8S.,SX+XSBX<6Y[<TB*T"^M0:A9^
MS91\C+F#$<U[N,<_.96A#@T4]\&FHI4\NNJTJ[O^3R[J]IK\F+=&!*BAF*DA
MX:ADXJ=NHF6D$UH./PS76W4CZ96;Y26W_'I8UW\[&OJWQC/+GD5PE67DO8,&
MR9NS[0F8T.8FHQB2_8XA%L>*8C0#$BM=5H-#5M"<%CK1L>/.S+H[(L)C2QC<
MU^>7>]&QI KL*U%^LS]]?7_:/7']F0S_ '?J*>KEM]VRP_DBU@=8,F-F''BG
M+6_&B\/M=F?CX'Z3["O(Z=UYVGZV=?0FG2*I*M(I<74G]W4M"WE)HQSG$N02
M,NCA!-]3Z3G&4D7NB2GI--?%33?.OCKG7.=(96VU RARAM&V):#%@09QT!S(
M4?,XUG%2L" <_BW.9>Z$7"CC<16^JL<C+OE)2%+N(>Z&'@N;7-.<][Q2M#_O
M 7C'9>JL>T'DPN\%\7[9UO0@[04)$G4_I,,8J4N@K5D&26L:P8^A=J-*84;;
M*9W:;[^*.^VOF;:X]N,\VGDSPKV18=@V99,>S;2C1I&7,*)%@F6XI[C%>\&'
MGQFN  =2I;6M:BBPLY8<>9FHT=D:"UL1V<&NSZBX"AHTC0H%^LS]]OSEUR\/
MIE,_W/J*?Q\SONV6%\CVM3^U*5+=1''Z<;M.A>;VNS/Q\#])]A= 77R([.4Y
M2-7U9+4S6LM)@8=#C3Z3CKT?I,'SF.0PBJX:)N:AT<:(;Y\<Z86TU4\/;KC/
M- 6W/P[4MFU;2A,?#A3]H3DY#AQ*<8QDQ,1(K6/S26YS6O .:2VHN)%"K1+P
MS EX$$T<84&'#<6W EC TD WWD7=)HJ.[5\DKWKL"T;*/&$/UZ8,3<_,B]DQ
M=W,7;NV30E(Y*:;-'6Z-+;H[.6R+W1%?9'?9+973?*>V=,XSS>%E\,5BR%EV
M;(Q;*M1\62D).4?$AF5S'/EI:%!<YM8[79I=#):7 &A%0#<JY'L"8BQXT5L:
M"!$BQ(@!#Z@/>7 &C2*BM#2ZY8%CR,_?7&<9]Q=<O5G'_/*9_P!"G/?[MEA?
M(]K5(H;Y0BZF%(^H:\;KU\O:[,_'P/TGV%T:B4CV4'0,9$G%(5XX=08C"CB[
MM&]G>J"[B,AFT8JX2UWJ/"F$5%$-E$]=\8WQIMC&V,;>..<YQHPB3468#2&Q
M([XP::9P#HA>&G16AIC2JMK6T8&XT:&UPK04VKG)^LS]]?SEUR_9E,_Z%.=%
M^[;8?R1:]]:@F4I4Z1]VISZ-JJ7M<F?QB!T1/L++Z^\D5WM#CX'+G<5UX=M!
M4P&21TU;7,8:N'+>#FF4FNW0V4I75/59=)KNDEE3;">-]]<[YQKC.>>6T.&2
MQ9N1G92'9-J,=-2DU+M<XRN8UT>"^$US@(Y]ZUSPXTO(!H"0OI!L"9A1840Q
MH!$.(QY'W2I#7 D#WN-UVU=!!_(]E# $-!-K2%>-'1.*$ ^V=.+V=[(-EYB)
M=QR*Z^J=1;*9214<:J*8TQG?.FN<:8SMX8YSNK6JIL=#>Y__ %+H_'S?EV$G
M\5,Y\?VN%!K=3GWJ//R*0:HZ?=PZ]LD+-GX!3#]D,3[&7<LV=VS^KERDTW\_
M9)#9:F]$M5-_9KE3;&N,^W/AP@KI')KY\1SUYEN)VI$>T5_]?K+IZ"I^L8*6
M.8=C',I:6O.15CF*K2=BI;91TFSJ!1SMINE'J):^ATVV])OIG./-QG/+!DM:
M\&P;?LVUYB%%C09&,^(^%!S.->'0(L(!F>YC*AT0$U<+@=-%YIV Z:E8T!A#
M71&@!SJYHHX.OI4X#5I5#GUF?OK^<NN7[,AG_0IS>?NV6%0@61:P%=<I?L_C
MQ=MH>I5KVNS/Q\#])]A;2],_)Q]V>L_8,.N(D%:'(XD;:$C9Q$0ETE",BXWF
MQZ2AD=D5'U,(MM=45GNBROI-\9RGIMC3QV\W&:KEGPG65E-D_,V1*V=:$M'C
MQ96(V+',N8+1 F(<8AP9&>^I:TAM&TJ;Z!>VS['CR<TR.^+">UK7@M9GU.<T
MM!&< +JUO/(K5K\ANT=MU^L(0E/UQ"/E)>,D=7SR]Y+*&$F.RNRB6?<E196\
MY3TFOF^&,Z^.N?.\/5S6%@VE LJT&S<Q"?&AB#%AEC PNK$#:$9[FMH*7WUU
M+.QF.B,S6D U!O) NK=<">I:08ZA=U?#./@E4&/'U9_+T)_#.,9\?9BG\^./
ME]?AZ_D]7+S[>;)^3YO\R6PT_P KU:5Y>Q8FMG2?LJ:Z!I#M[49]J6S==57.
M,,0TE&98LKUG=5<JO<MMDE?[;J'".=$_0[>/K\[QSCS<?+ROY19225L24*6E
MI6- B,F61B^(V" 6-AQ6%H,-[G5)B--XI=KHOK!@OAN+G$&K:4!-;R#I %U-
M:L2"9ZTI9^[1/*Y&PR.29^E9OH6QE3-=T]],GI[D58J!(QAJCZ#95;W7ATXS
MYZ>J/N?^R>DTIB](KI%-]]:DKA2G")PB<(G")PB<(G")PB<(G")PB<(G"+23
MMX.V)I(U0=5?&VV4S<!,6 M-@H%9=D!@T6QXS0-WF@3 %3,3GH^"9-R*X8BN
MH#)#(LL.7CE]%#3MV[C'_O2Z(H G>WG9Z*DX,>BP9F02<C%720";K?J[V*'9
M*[=:W;=<M1D;CJ^DRI8HZ\-"<LN$XKY[:5LN2,-BG5?LS?>/^#D^FS2BOJZ.
MKG4TNKT\]>G!2;<8]V>?]DC0TK*1)D BK:6J0R&QC)"6L1VSC-G-]B'AM5,,
M/>D;UI*RY\PC*U'24N)<2,Y7#!\.34 R2>/6[CD[[[\JA0V_MCO7<],D\8U%
M(RNI&3$#[W011U']@!<ME,)N:MBX6&&A^>.@HIKHIWU,+"TS+M9PM=/&8.W(
M!M>$?.I!L,QOX_1UHI3AKP[;OCI"OHBLHUE%YL*4#WY*04U<:435XH/'1 .0
M$O)$TR;LHF\-[- H5N=,"<'F86$KMPNTA#1::>$<(Z7F_<:.GKZD6*:7-WGD
M063DRVJX9Q[]@C)VW%0:L+@##.%(">B%;138X)\V/-/<KAIPT5J*6RP@X>2E
MB239N$%A>38[#\E%]=]GK1>O/=D>V@QKA4I AP<A)PLUU9%K:BKE-5 84T<]
MD=,1LO7HP<;%ED3SQM4-8O79 +N!B.%8FWDR6:&U1R%;OY5H%<;J\J+R#:S3
M2R![J-9).T[)#,79W4DWL"68=8QRYIA*#OHJ:];IX C9I$%B9^#;ZL&TS9;<
M6:W=Y]>K)-Y?)1EPV:OE$YU;^FB+'V'9[OA#I&L$<4?'1Q$(A80QU?P-*7)8
MC#:P'\O3\'+$S>2$YN+%[) 9?4NL$A?QU?RT<65Q%C&GIXDW6ARAJP;[[\B+
M+H"_N]I''PI8I3@J)1:U<Q)M+ <S4%KR!AM-Q]:]<"\E!&\_N>C[>-GB$LMF
MT@D=U=!K]R-.*?E5I".*Y!.;B8>+]F/5Z4WWQKORK]D+U[>C(3DA5J%\K$,V
MC84:C6U56F=V0QGG5#Q=H?5(EW+FP8IZ5!D18+E_5LH)M8Y@1.Y%';5@8[D#
M#0:E&_/UT'2BC9/N+WA]Z9!13KBX7F4P6/?HHL* OW2.BY5K=PK71&932L_)
MCS^1:.Z^F9:U ^E0UB3&[Z"B)#,Z<P;B(792#DUZ:CS7^+:BV:ZV7IV%L2R9
M83N"MDQ:"3JL/+XJ9@ZIMX5A4")]#!J\]%3Q?:?P>;XGY61(I5W"UZ-#!&N)
M1,%)19H>:ET1(PFTHMY.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X
M1.$3A$X119*_9M!/HLMC[[:7X12GPB<(G")PBJ8\LW\46)^FNN/_ *SO"*UB
J*_XKC?\ P#/][I\(O[^$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>52
<FILENAME>g425213g62f04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g425213g62f04.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1>$4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %VB^69(X0DE-! 0      #@< 5H  QLE1QP"   "   < E  "%1I;2!2
M>6%N' (% !=0;W=E<E!O:6YT(%!R97-E;G1A=&EO;CA"24T$)0      $(E,
M*T ^4D:PQ&_V$<%;PI<X0DE-!#H      /$    0     0      "W!R:6YT
M3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90
M  !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE
M5$585     < 00!0 $0 +0 M #(       ]P<FEN=%!R;V]F4V5T=7!/8FIC
M    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M 0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"
M24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M%P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#
M<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O
M;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $
M      !21T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B
M0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M              !";&0@56YT1B-2;'0               !2<VQT56YT1B-0
M>&Q <L            IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O<"!5
M;G1&(U)L=                %-C;"!5;G1&(U!R8T!9            $&-R
M;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M    #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ "4S,P
M 0 " )3,S  !  (X0DE-!"8       X             /X   #A"24T$#0
M    !    %HX0DE-!!D       0    >.$))30/S       )           !
M #A"24TG$       "@ !          (X0DE- _4      $@ +V9F  $ ;&9F
M  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $
M-0    $ +0    8       $X0DE- _@      '   /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H     /__________________________
M__\#Z   .$))300(       0     0   D    )      #A"24T$1
M$     (   )    "0      X0DE-!!X       0     .$))300:      -!
M    !@             "_@  !SX    & &< -@ R &8 ,  T     0
M                   !              <^   "_@
M   !                         !     !        ;G5L;     (    &
M8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M    3&5F=&QO;F<          $)T;VUL;VYG   "_@    !29VAT;&]N9P
M!SX    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@
M  =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I
M;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP
M965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   OX     4F=H=&QO;F<   <^     W5R;%1%6%0
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M;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M   *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M    "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M    .$))3004       $    !#A"24T$#      ,Z@    $   "@    0@
M >   'O    ,S@ 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.
M#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M_\  $0@ 0@"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
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MU.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\
M["[ZR=0Q#;5DNZ6<BEQ:^K[8ZEW9[?;D8_YM;O?[_P#TFK.'US+S,FNBEW3;
M2XAU@IS3:\5@CU7UTMQF;]C'?G.8M)U5+W/+ZJW$GDM:23I_*]WT&)J*ZV93
M@VNM@#&D%K6!WN^E[FV.?_X%_GI!%[>.C;22222I))))2DDDSG-:TN<0UK1)
M)T  [E)3AYN+UW+QVUY=&(]M;_4W59.309;NV/\ T%+G_0=_,[WLWKGZ^H8I
MHJI-U$T$NKR7Y><^S<]MILWN;53<RS[0S$?=5O9790
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                _^+__TE#0U]04D]&24Q%  $)OLS^_AX "(!P041"10(0
M  !P<G1R0TU92TQA8B 'T  ' !H !0 I #5A8W-P05!03     !!1$)%
M                 0  ]M8  0    #3+4%$0D4
M                                          ID97-C    _    '1C
M<')T   !<    "MW='!T   !G    !1!,D(P   !L   H@9!,D(R   !L
MH@9!,D(Q  "CN   H@9",D$P  %%P  ".+1",D$Q  -^=  ".+1",D$R  6W
M*  ".+1G86UT  ?OW   D)%D97-C         !I5+E,N(%=E8B!#;V%T960@
M*%-73U I('8R
M                                                         '1E
M>'0     0V]P>7)I9VAT(#(P,# @061O8F4@4WES=&5M<RP@26YC+@  6%E:
M(        +5:  "\9P  DC!M9G0R      0#"0   0
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M6H)1@TB$/H4UABN'(8@7B0R* HKWB^V,XHW8CLV/PY"YD:^2I9.<E)*5B9:
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MZ*S6D"8\PZB2CVDHUZ5CD!L0!*7ABM0  (Q>@ "/Q\%0H&* 0KNUG3=P3;9
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M1<14J79F2KXHI@%6PK@]HXY&A++"HJ$U/:WXH.DB"JJ"EP0*YZE/AU\  (J
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M+X:]IFJBJH6>HHB-:(2PGMIW@H/OFV]@TX-8F%Y(^X+JE>,N!X+0E0T)48,
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MA-\;K:T=A80%$JJ;@VX  (,?@ ![6\;LD&5M9<%PCH!>_KP$C.A0 K;"BZ5
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MO*4SK2IKE:&"J<!;HYWVIKU*_YK%I/HY3I@?HL0ER)91F8P-0Y:@B/<  (
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MI+%RBN%B6ZT^B;!35:DWB*U#=*6&A_ R,:*3AYX>D*$TB"L&\9_ZA+$  (
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MI<"L;;18';PY;I])T[?L;Y4Z=;0!<($I4[$T<2T4EK'I<+@  *LI='L  (
M@ !RHL1W='!EP[^Q=(M8.KL$=-5)\;:&=4 ZEK)V=;\IC:]_=B$5%:_$=;L
M#ZGI>.<  (  @ !RH\,Z>[AEJKYR>T58)KFU>OU)UK4D>O<ZB+$#>Q(IGJWR
M>S@5;JW>>P0 HZ?3?2X  (  @ !RE<'M@MIE@+TF@?A7Y[AJ@4))J+/2@,PZ
M9J^M@)8IG*R*@) 5KZPP@,P!(:7X@,0  (  @ !R=L#2B@ME7[P'B,A7P+=%
MA[9)=;*HAMHZ4:YSAE$IGJM'ADD5[:JOAI !D:15@0\  (  @ !R4;_YD6AE
M2KL?C\M7LK9.CE1)9[&HC2(Z0:ULC%XIJ*HAC(46)ZE8BX,!\:+J@5   (
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M/XT&E)A[-XM^DL1J-8H4D/!87HC5CT9%;8?4C?$PRX<IC4T728>LC 4  (
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M2)L0<E%S/)C#<SIC)I:C=")1\)2V=0P_99,J=>DJTY)U=GH0.)3U=?(  (
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MFI7/F?AO@I.)E]1?>I%@E;E.GH]UD_$\I8WBDLTHSXS8DL4/:8V=BFL  (
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M/Z.(>*)G(J"3>.57[YW2>3U'L)M4>: V )EG>?XAZYC,>A4(G9EG>J<  (
M@ "" *5"@%!TD*(Z@ !F7Y].?[973IR,?X)'')H8?VDUBY@I?U\AH9=U?U@(
MKI>+?Y,  (  @ "!9*0EB$=S\*$DAWAEM9X\AJU6GYMYA?%&EICZA5PU&Y</
MA0(A6I9"A10(O)7?@]$  (  @ " V*-+D%]S:*!.CQEE+IUAC<M6%9J8C(]&
M$Y@2BX@TR)8'BO$A*Y4DBV((S)1@A?,  (  @ " ;:*0F(=R]Y^9ELYDN)RH
ME0)5G9G:DTU%II=1D?(T=Y4\D5LA%90>D.@(XI,.A@(  (  @ " %*(4H--R
MPY\;GKED?IP7G&U549DLFCA%4):5F*8T%Y2.F&$@QI-OE7\(Z)( A@8  (
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MZ:Q]?A9;=ZCS?=U--*64?<,]QZ*9?<8LT*!J?=$8YZ!:?;P"K)OZ?J\  (
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MM*B^HQE:+J3\H-!+N*%=GLD\>YXIG?,KZYN^FY,8T9KRD,@#K)6,@GP  (
M@ !J,K\#9K1=SKM : Y0X[>6:7!#([0%:L8T*K#H:_0C'Z\^;*(.(;%(:^,
M )\$<[   (  @ !I[;X];C)=S[HY;MA0];9";YQ#1;)W<&XT6Z\N<3$C<ZU*
M<9P.M:[H<.8  )W >"D  (  @ !IS;SG=61=G;C:=8!0U;3/=;A#)K#M=ADT
M4:V0=GPCD:N(=JX/'*S(=B8  )R)?"(  (  @ !IJ+MR?&M=8;=F?!Y0A[-=
M>^E"\J]W>]XT+:P4>_ CDZGR>_@/9ZKB>]@  )MH?Z$  (  @ !I>KHQ@W]=
M-;8C@MI05K(5@DM"M*XK@=<T%*JW@9HCE*B%@9X/J:DP@:X  )IL@    (
M@ !I3KD\BKM='K4<B<E01+$ B-Q"GJT-B! S_*F1AY(CG:<ZA\ /YJ>KAK@
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M,W_=@"* %W^G@ -O$W]Y?]Y<VW]D?\))@']F?ZTT>']^?Y0:RG_A?U<  (
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M.7MBK&Y[_'LAJ-EJWGKDI3Q8_GK2HAU&&7K@H!HQKWK&G9\8N'GRD+<  (
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M#X=3AE=S_(9KA<-C]862A1U2]839A(% G(1<A PL6X0@@[\2=X3H@X8  (
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M:9:895EL1)3C9WA<X9-D:7),29(/:TTZ-I$@;/4EV9$X;@$+/).5;70  (
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M<H^HB^]H/XX/BO19&(R)B>M)!HLNB/TWG(HEB%LCZXG B&L*V8EGAA0  (
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MH)[,:^)@-)Q_;4%1N9I=;I5" 9B ;](PHY=*<-0<9I?/<0<$()80<=(  (
M@ !Y:Y^B<EAL[IU"<R%?G9KT<^91(9C1=*Q!@I;R=6@P1)6Q=?X<-I8%=?L$
M4I/%=TT  (  @ !XQ)X0>AUL,IN[>F%>S9EX>IQ0?)=8>MQ [)6!>QTOTY0\
M>T\;]Y1G>S$$=)' ?$P  (  @ !X&YR_@>]KB)IR@;E>'I@U@79/R)83@2U
M:)0T@/@O9)+O@-P;M9+U@-@$CH_]@)T  (  @ !WAINZB=]J^IESB3A=DY<P
MB'5/.I4)AZT_XI,BAP<O&9&YAK$;CY&=AQ8$J(YV@R8  (  @ !W$9K=D==J
M@)B>D,1=%998CX9.NI0KCD@_;9) C4XNQ)#*C/0;AI!EC*0$QXTI@SL  (
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M.:>3<7-4F*2T<C=&WJ(#<P$W[9^Y<[HG&YYR="X2DJ 3<Y@  )6@>#   (
M@ !LH:CJ> A@KZ8#>%-3_:,L>)Q&:J!Z>.\WB9XS>4$FW9S<>6P2EYXR>/4
M )0P?&,  (  @ !L**>0?VQ@.*2O?U!3@:'9?RM%XY\F?P0W,9S0?O0FG9MP
M?O(2DIR&?N,  )+H@    (  @ !KO::'AO)?V:.EAG=3):#'A>1%A9X+A5 V
MV)NKA.4F;YHHA-42DIL#A+@  )'&@    (  @ !K9*6WCGU?D:+2C:]2WY_G
MC+)%.IT>B[LVAIJ\BQLF.YDEBTH2I9FHB:$  )#;@    (  @ !K)*4/EA!?
M5*(FE/52G)\SDY]$\YQ?DEDV0)GTD;,EZ9AAD;P2@IBMC(,  ) G@    (
M@ !J\*2AG>-?5J&DG*A2F9Z8FO=$V)NBF58V,YD7F,\E_)=JEN<2JI>IC)X
M"X^*@ @  (  @ !AL[A\8(E5]+5\8E))H;*09!@\8:_#9<,MNZV,9R4<DJU$
M9[@(7*ZD9VL  )-8<M@  (  @ !A,+>19]M5Q[1/:0))DK$5:C@\;ZX+:V8M
MY:N?;&0<\*L*;+H(\:P);&D  )(7=VX  (  @ !@ZK8+;NQ5=[*_;Y))7:]R
M<$4\0ZQ1<0<MUJG.<:<=%*D%<<D)7*FE<9T  )#A>X   (  @ !@JK1D==A5
M);$:=AE(_:W0=F$\!*JK=KHMJJ@@=PL=%Z<R=P8)J*=Z=S@  (^_?Q8  (
M@ !@:++U?-)4Z:^L?+](OJQ=?*T[N:DT?)PMCJ:5?*(=&:6.?)D)ZJ6(?1D
M ([!@    (  @ !@+K':@_%4QZZ!@Y=(HZLD@RH[FZ?Q@L$M;Z5(@H,=):00
M@J *)Z/,@CD  (WC@    (  @ !?_;#\BQ14M:V-BGU(F*H?B;P[BZ;AB0@M
M7:0QB+8=*Z+>B2 *9:)*AH@  (TS@    (  @ !?V;!7DD94LJS+D7Y(F*E(
MD'8[A:7YCXDM2Z-!CV4=&*'LCKP*?*$?AQ<  (R<@    (  @ !?P:_=F:!4
MNZPLF+U(HZB1EX$[AZ4TEH0M4J)MEBT=,Z$!DTX*DJ BAR8  (P @    (
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M6G54:HZ% 78E;&ESBW;V;B=@[G?+;]5-(GBC<6PWPWEF<L<>*'G8<U$  (
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M/&S(ET=_%&WNE3]M\&\+DR=;[G ND31(W'$WCX@T67'%CG$;D'!=C5@  (
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M 7L@<@%XY7MB<R=H>'NP=#=6^GP(=3I$+WQP=BDOEWS;=M@5Q7U(=H4  (
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M-W0PG,IT"W2>FGACYW4(F!-2UW6&E?- H78 E&8LVG8'D_X3]75WC7X  (
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M^H'%>)=LN(%X>2I=A($R>:A- ($->AX[(X$'>H$G+($R>JL-9H'1>ET  (
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M='Q@H:QI+WP3GSA9]GN\G+%)UGN'FJPX=GMKF> E)GL,ER,,BGM?B'H  (
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M>(E8?D1A&8AK?F12L(>.?FI#48;+?FTR-H9G?G<>G8:,?F,&C(7&?J\  (
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M\9GW7T)9.YA@8;1+3I;\8_L\"I7:9@<JXI5]9YX6+I>%9\<  ),-:;\  (
M?TIP]YH.9(QE9YA'9F]8M):B:$!*X94C:?@[MI/J:X,JKY-N;*L6,)47;)0
M+Y"^;K8  (  @ !P3Y@3;$)DHI9J;8Y8#I3+;LQ*/Y--;_L[-)(1<0DJ5I&"
M<<H6%9+<<84 <XYP=#,  (  @ !ODY8Q<^-CT926=*U7*Y,'=65)C9&/=A(Z
MF9!;=J@IY8_!=PD5WI#9=JT HHQK>40  (  @ !NUY2;>Y!C%Y,,>^)6<9&"
M?!U(T) )?$,Z$H[/?&<I=8XQ?'P5G(\.?#H PXJJ?:8  (  @ !N,I-;@UIB
M?)'6@SY5W)!(@OM(.X[*@J$YA(V&@E8I,(R^@C<5=HUD@F@ X(DG@)<  (
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MIJ*.9/%-DZ!M9K! ;)Y[:%8QTIS_:;\@\YS5:HH,3Y[Z:?T  (O[<LP  (
M@ !D*Z+H:G59#*"X:[A-&9Z4;/$_^)R:;AXQ?YL1;QH@T)K!;Y4,?9QL;P8
M (I[=Z(  (  @ !CG:$'<:M8:Y[B<GI,:)S)<SP_=9K1<_4Q$9E(=(T@D)C>
M=,,,CIH9=%4  (D4>^4  (  @ !C#I]N>/!7X9U3>5A+WIL[>:T^XYD_>>PP
MM)>I>B<@39<M>C$,CI@!>BH  (?1?YP  (  @ !BD)XL@%97<9P6@&%+=9GX
M@$@^?)?S@!HP599.?_H@)96B?_@,E98>@!$  (:T@    (  @ !B)ITMA[]7
M&9L8AWE+))CPAO@^*);<AF8O^I4RA@X?YI1MAD0,K)1TA0T  (7.@    (
M@ !AU9Q>CRM6S)I*CIM*TY@<C;X]V)7]C-LOKI1$C'8?BY-^C*\,B9,EB'H
M (4A@    (  @ !AE9O+ELU6OYFNEB1*Q9=LE.\]O94HDZPOJY-*DV<?L9);
MD>\,OY'LB)\  (2<@    (  @ !9([&M6F1.&J]27(U"9*T97JHUG*L88)XG
M+*GC8B,5DZMA8F@#1:FV8UH  (CG<?T  (  @ !8<+!G87U-NJWB8QM"(ZMJ
M9+DU?ZDN9CHG.J>]9V 5ZJC/9W #TJ:_:%$  (>@=K(  (  @ !8"*Z2:&A-
M2JP+:9!!T*F):K0U.*<X:\XG&*6L;)H6"J9S;'P$.:/S;7@  (9G>MT  (
M@ !7KJRG;SI,WZHF;_U!5Z>H<+DTYZ55<6TFWZ.\<>P6"J1.<:L$A*%<<OP
M (5!?HH  (  @ !74JK]=AQ,BJB"=HI!!*7_=NHTBJ.F=S,FNJ'U=VT6":)=
M=RD$PI\&>.$  (0^@    (  @ !6_ZFM?2-,4*<J?4I U:2=?4XT7J(W?3\F
MDJ!T?3,6&Z"7?18$_YSO?A8  (->@    (  @ !6NJB@A"U,*:82A!9 N:-U
M@\<T0:$"@VPF=)\T@T<6'9\M@X<%/ILA@GH  (*M@    (  @ !6A:?2BT-,
M$Z4RBOU JJ*#BF<T,I_^B<\F79XAB<H5_YX1B38%39FK@Y8  ((6@    (
M@ !68J<TDGY,#*1ZDB) IZ&ZD54T+I\CD*0F9YTOD)D6)ISVC>0%:IAP@ZD
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MU7',7&!]9W+Q7Y!LO'0;8HQ:X75$961'P79G:!,R\G=H:F 97G?-:UH  (
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M3&7?B IW)F>FAU9F]VE3AHQ5UFKMA<Q#?VQ.A2LOB&SGA+\6Z6QRA,   (
M@ "3CV)BDA*%961FD-AV1F8VCV9F(6?MC>)5#6F2C'U"UFKTBU8O%6MJBJP6
MG6LCB<<  (  @ "2WF$NFXF$LF,[F:%UCF4.EW5E;F;#E3I47FAMDSU"+VG2
MD;(NDVHND2465FH5C>4  (  @ "29F!-I/.$+F)=HF=T^V0IGX1DV676G)Q3
MV&=ZFA=!P6C9F%,N(FD8EV 5Y6E,CLX  (  @ ".?'CG6+&!)WE27 ERMWGA
M7RAB_GJ$8A-2 7LQ9-0_G7OO9UXK/'S%:5L0WGY0:6   (  =@F-4G7A8;J
M$':99$!QG'=29IMA_7@/:--1'WC/:NL^W7F5;-,JGWI';D 0B'N%;?8  (
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M=6QYC=YL06V<C,-= FZKBY%,QF^PBGL[2'!^B:8G^G!PB6D/+G)9AW   (
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M.7Q6:REES7R7;-A7&7S<;F9',GTM;]@UOGV6<1,AYGX8<;8(Q7^&<9L  (
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MSG/[DN!A<W1SD7]3$W35D 1#HW4YCLPRRW5ZCBL?W'3@C@T(8W?.A:L  (
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MH8,(<1E9]H+'<CA,2H*,<SX]-()P=",L;8*.=,H8G(,V=+("78,*=LT  (
M@ !Q?8%"=^!EN8$=>)%9#H#J>2)+78"W>9@\F8"3>?PKZ("I>D(82(#_>A,"
M;H%$>\   (  @ !PIG^0?_)D[W]_@"-84G]5@"=*M7\A@ P\!W[X?_ KLW[I
M?^48,W[S?^@"C7^]?_@  (  @ !O]GXYB MD87XZA\97SWX-ASU**WW*AI0[
M<GV;A@LK*7U]A=07]WTJAAT"EGYV@<   (  @ !O:7TFD"1CUWTOCW)717T
MCF=)JGRUC3PZ]7Q\C& JI'Q1C#P7D'NTBUL"GWUJ@<8  (  @ !N_7Q3F$MC
M:GQ@ET)6TWPLE;]).WO6E"(ZEWN-DQ(J6WM)DO\747IUCX\"D'R@@;P  (
M@ !I Y1_5PI=T)-(6?=1KI)57,5$49&57V(U>9$E8; D<I&B8U4/3Y2,8R<
M (@):9H  (  ?M1H'9(C7JA='Y$48/U1"9 A8SA#S(]194XU%X[,9Q\D/H\<
M:%L/:9%M9_H  (8B;F0  (  @ !G48^V9C=<0([,9_U04(WG::U#'(T;:STT
MC8R1;)4CXHS";6X/7HZ";.D  (1><Z<  (  @ !F?HUQ;;Q;7HR>;O]/8HO)
M<"I"98L%<3PS[(J <B C;XJ8<IT/-XO/<@X  (*\>)H  (  @ !EKXM]=4Q:
MEHJ\=A5.FXGQ=L)!GHDN=U S9HB?=\@C XBB=_T/#(E3=Y0  (%.?.4  (
M@ !D]XGB?/!9[HDP?4M. (AG?7M!"8>??8TRWH<$?9DBV8;,?:,/"X<2?;4
M ( ;@    (  @ !D6HB(A(M94H?FA'=-:(<@A"] =H94@] R6H6P@XHB@(58
M@XD/,X4A@T<  (  @    (  @ !CWH> C$59#8;OB^5-+X8?BR1 /X4LBCLR
M+X1GB; B-H0&B@$.Y8.@A_(  (  @    (  @ !C?(:QE!E8K88ADWQ,RX5-
MDE,_X81/D08QXX-SD&XB H+MD"H.VX)=B@L  (  @    (  @ !<X)[Q5=]2
M0IU96)]&P)P(6T4Y^9K[7;@KB9I]7[X:29O-8+@&A)Q*800  (.C;4D  (
M@ !<!IS=71U1K)M97U5&-YGT87DYE9C 8W(K49@490P:4)D19;0&WYC=9>,
M ((0<C$  (  @ !;7YJ%9$-0]9D;9?Q%GY>]9Z(Y!9:$:28JZI7%:E8:)I:'
M:K4'%Y6<:N0  ("7=Q0  (  @ !:MIA :UI0.);G;)Y$T967;<XX:I1A;N,J
M:I.?;[$9W90S;\X'+I*Q<",  (  >V4  (  @ !:#)9,<H%/DI4$<UM$,).W
M=!PWQI)\=+<J I&K=2T9E)(<=2$',9 J==X  (  ?RX  (  @ !9<Y2W><A/
M!I-]>D-#L9(N>I4W49#I>L,IF) $>M\9<9 M>LP'.XWX>]$  (  @    (
M@ !8\)-K@1-.EI(^@3M#3)#J@2,V[8^7@.PI+HZE@,X9((ZI@.L'4(P<@.
M (  @    (  @ !8B))<B&!.+Y$ZB#M"YX_FA\0VD(Z&AS8HW(U^AP88MXUS
MAT<'*XJCA-D  (  @    (  @ !8-Y&.C^5."9!RCZ-"PX\5CLXV;XV0C=LH
MXHQ7C<(8^8P(C*$'<HE4A0D  (  @    (  @ !0IJIA5$U&8JB85M([3:<-
M63TN[*7D6VD@AJ797/<.EZBC70@  * (8'P  (  <2X  (  @ !/QJB46RI%
MQ*;,73<ZOZ4>7S(NA:/!8/<@6Z-M8BL.QZ6R8@<  )UL914  (  =?@  (
M@ !//:938>]%+:268XXZ0:+K91@N$:%^9GD@$Z$'9U8.T:+A9PH  )K>:>X
M (  >CP  (  @ !.QZ0+:*=$HZ)9:=XYI*"V:P$MH9]);  ?P)Z_;)$.QJ _
M;"@  )AW;RL  (  ??\  (  @ !.2Z(+;W%$*Z!K<$XY,Y[%<1$M*YU,<:0?
MC)RE<?8.P)W9<8X -98 =0D  (  @    (  @ !-UZ!J=F!#RI[3=O XY)TH
M=U4LZYN>=Y$?6)K7=YP.V)NI=UX <9/:>E0  (  @    (  @ !-<Y\3?55#
M?YV#?:(XJYO/?; LMYHW?9X?)IE=?8P.T9GE?;4 L)()?LX  (  @    (
M@ !-))X#A%E#2IQSA'$X@9JVA#(LF9D(@]\?"I@2@^0.JIAW@WL M9"9@'L
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M[EHB<E]ZKET#<X=J>%^V=)U9"&)%=:=&=61Q=J0R866%=W8:*V4[=[8  (
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M[5 WGP1U]U.3G$1F!U:KF9E5)5F(ETE#+%O&E8TOR5P3E/L865YFD'8  (
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M\EZU>6EOK6$@>?Q@8&-9>G50$&5L>N8^1V<7>U$JT&=H>YT2-&IZ>V\  (
M@ "*$5F@@@A\TEQJ@@=NHE[R@=]?96%&@:!/)V-G@60]G64+@3LJ364D@2P1
MYFCW@3L  (  @ ")&5>9BT][YUI]BIYMQ5T8B;Q>EE]_B,A.9&&NA^T\^F-+
MAT(IZ6,GAO\1LV>PAD,  (  @ "(7%7VE()[,5CMDR=M$5N5D8Y=[%X"C^I-
MOV VCGL\6V'.C7$I;V%NC4D1@F:JBF(  (  @ "'V52ZG9EZJE>]FY]L@EIG
MF59=7ES2EPA-15\#E18[^F"/D],I"5_ODV@1)&7OBY<  (  @ "%,'&24T!X
M:G*65O-JI7.S6GA;I7387<E+7G7W8.<YEW<.8[LEF7?Y9=<+NGK$9@(  (
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M-V0Y?YIDW&8;?ZU6<&?0?Z-&]&E4?Y@V!FI??Y@B]VG*?Z,*WW 8?\<  (
M@ !]O& HB"9Q7F):A\ID#V1,AS15KF8-AH9&/6>8A>LU<&B3A8(BI&>DA8H*
MRV[/A$,  (  @ !]"EZ1D.5PLV#4C_9C9&+0CKM5#&24C6M%GV8>C% TU&<*
MBZ4B+F78B^D*LVWJASP  (  @ !\BUU7F9)P,E^HF"!BVV&EEDI4A&-DE&%%
M*63EDM8T>&6^DALAR61BD5$*:VYDAPL  (  @ !X_7GN4OYM!'IB5H]@#7L
M6?91UWNP72E"1WQH8!\P_WU!8JX<XGYL9",$A(#I9.T  (  >2!WLW9@6TAK
M]7<H7B]?#G?R8.]0_WBX8X5!E'E]9>8P='I'9^H<B'L%:/$$FWXI:;(  (
M?,!V?7,-8Y=JL'079=1=_'4)9_-/_'7J:>M N7:_:[@OQ7=];34<$'?+;=8$
MG'O%;KD  (  ?^]U1' %:]]I<W$Z;7U<NG)/;OY/$'-%<& _XG0N<9HO(73?
M<I8;IG2Z<N($GWFQ="@  (  @ !T$VU7=#=H2VZP=3I;HF_>=AU.!7#G=MX_
M/''6=XPNF7)[>!(;6''N>"($K7@9>;,  (  @ !S#FL8?)YG;VR/?1-:VFW/
M?5I-,F[B?7X^:F_.?9PN '!2?;T:X6^(?<($F'@\?H(  (  @ !R.FDSA/EF
MH6J^A.1:%FP*A)%,>&TEA"(]NFX0@\0M;FYU@Y<:F&V(@]X$FG@X@H,  (
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M;WS+9%Y3=GTR9GQ&+GV0:&XWBWWX:B<FZGZ*:V<2E'^):S\  (  ;WH  (
M@ !I;7EF:?A>3GH$:Z%247J%;2U%2WKW;I@VOWMH;\XF3'O;<*$2.7R/<$@
M (  =/X  (  @ !H8W;5<=-=5'>0<O5177@E<_5$47BB=-$V(WD+=8TER'E@
M=@,1]7GX=9X  (  >>(  (  @ !G<W2@><5<<'5X>F)0B'8>>M5#FG:=>R4U
M?W;_>V0E?7<?>Y(1UW>Y>V   (  ?@D  (  @ !FKG+(@;-;RW.]@=M/]G1K
M@<5#"W3C@8PTZ74Y@6,D]W4O@601J77:@8D  (  @    (  @ !F$G%)B9I;
M-')-B55/8G,!B+U"@G-TB 4T9W.[AXLD<G.)AYL12W1JAL$  (  @    (
M@ !EF' 6D89:OG$HD.I.ZW'@C]M"$W)+CK,T"W)^C@(D+W(ACC81$7,_BO
M (  @    (  @ !@IHQO49A6!XOM5-Q*=XNI5_T]G(N56N0O&HO7764>"(TI
M7OH)@(YJ7RD  (  :6D  (  ?G!?CXE26/Y5*XD16[M)JHC>7E4\]8C$8+PN
MH8CN8L8=R8GY8_@)I(JH8_T  (  ;BD  (  @ !>GX9!8&-4+88Q8IA(UX87
M9*\\+X8$9I8N!88D:"D=8H;U:/T)HX=1:.L  (  <V0  (  @ !=L(-H9\E3
M,H-W:7I'U8-Q:PT[9X-J;'HM58.);9P<XX0D;A@)AH1G;@P  (  >%L  (
M@ !<QH#H;SU23H$2<'%&]($<<84ZBX$5<F\LP($G<RT<9X&.<V,)88'C<XH
M (  ?*P  (  @ !;]'['=L11B'\*=X5&/7\?>!PYW7\7>(XL(W\4>.(<)7\H
M>/$)6G^T>9D  (  @    (  @ !;/'SP?CU0UWU/?I)%F7UO?K0Y1WUD?K<K
MFWU/?KH;T7TD?L0)C7W2?S,  (  @    (  @ !:K'MYA<M0='OYA<Y%1GP;
MA7@Y!GOQA/TK;WNVA,,;C7M:A1L)4GQ<@]\  (  @    (  @ !:.WI*C6Q0
M!7K7C2M$V7K_C&TXIWK-BY(K)WIUBT@;8GG9BS()3'LJADD  (  @    (
M@ !4I9;<4#U*C)7Q4U4_B95/5DHS)I4"6/HDSY5W6Q82[YA26Z@!@I2E78T
M (  ;10  (  @ !3GI/]5S])O)-$6> ^Q9*G7%TRB))$7ILD9Y*(8$\2V)3G
M8)D!U)$*8FD  (  <?@  (  @ !2RY$,7C](W)!Y8&<^"H_L8FTQV(^'9#DC
MY(^O98<2FY&D98X"!HW+9V<  (  =N0  (  @ !2 (Y"94!(!HW(9O$]*(U+
M:($Q+XSI:>$C5(T!:M 22HZ3:IT"'XKP;*0  (  >SP  (  @ !1.8O(;%5'
M1(MI;98\:XKW;K4P=(J/;YXBXXJ*<#T1_HN^;^8"+8AX<EH  (  ?P8  (
M@ !0@HFK<X!&F8EG=%P[THC]=0TOZHB,=8\B:8AH==<1XHD?=8@"1895>$H
M (  @    (  @ !/XH?B>JE&#(>X>RT[6(=4>W4O@(;5>Y<B!(:3>Z81J(;E
M>XL"<(2"?5<  (  @    (  @ !/8(9C@<1%B(92@? ZV(7V@=<O#(5P@:<A
MFX41@:81+X48@<,"88,1@74  (  @    (  @ !.^(4TB3-%6H5&B4 ZN83S
MB+TO$(0XB!0A[8.#B!H1Y(,=AR0"UX&T@>P  (  @    (  @ !(6*)Q3E\^
MWZ$\44(T::!G4_8H6: H5DX9PZ%S5[\(HZ,;6&4  )&47^0  (  <'H  (
M@ !'1Y_F5/X]^)[L5W<S>)X:6<4GCYVO6[P919ZA7-@(IY]S75D  ([<9'X
M (  =5$  (  @ !&FYT-6YT]-)PM7:PRPIMO7XXFVYKY8208PYN]8>H(EYO.
M8E   (Q#:5$  (  >:D  (  @ !&!YH\8CH\A)EO8]PQ]IB\958F0)A'9HL8
M1YCM9P8(@)A,9U\  (G>;GP  (  ?8   (  @ !%9)>X:.@[W9<,:BDQ7I98
M:T EJ)72; H7^Y9,;$L(=94/;*\  (?&="\  (  @    (  @ !$Q963;[X[
M2I4*<*<PY)1;<5\E3).^<=,7N)0 <= (DI(I<F0  (80>6<  (  @    (
M@ !$.Y/"=IPZSY-:=SDP@I*N=Y8D^)(!=[P7:)(>=YD(@H_2>)L  (2R?<H
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M E1M8]=SF5>Y9E!D EK/:*]35EVE:O)!8U_Q;1 MT6"=;MH5L6/@;XH  (
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MLD3*CZUMXDDPCDI? 4TFC/-/ U"5B] ]RU+<BODK+5)'BL84*EWKB9L  (
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M%U=Y:T)HE5IT;0M:%%TP;KI*/U^@<$HY%&%5<;0E^6#(<KT-N&EX<L\  (
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M2$I3E/)D'TX1DS95\U%;D7I&NE0+D!<V,55/CU$CWU50CV0,X6H\B+4  (
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M7EMO<;U=M5X)<NU0 F!4= %!+6)!=0 PFF,[==8=N&+[=CT&YW15=X0  (
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M!G*34:18>'/-555*T74&6-X[S78M7" JYW=#7MD6G7@P8!8 IW[F8EH  (
M>-IO#VSK5=QCNVYJ61-77V_<7"Y)Z7$V7R$[#7)J8= J4G-:9 ,60W0)9-<
MSGZD9R$  (  ?(1MEFBG7?=B4FIX8)%6-FPC8Q%(V&V=96DZ)F[=9X@IFF^?
M:3<5QW!]::T X'Z&;"H  (  ?[QL-62T9A=@^&;$:!)4XFB<:?='WFHV:[TY
M1FN$;4TH\&P1;H(576UN;JD \WYE<98  (  @ !JXV$C;D9?N&-F;Z13NV5D
M<.U&RF<7<A8XHVAN<R(H;6C#<^<5&VK)<]H!$WXN=QX  (  @ !IQ5X#=H!>
MR&!V=U!2YV*6=_]%]&1<>) WS66C>1$GV66J>7@4KFB:>6<!$GXP>_0  (
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MJ';!6 ),_7>Z6P5 *GBD7=@QR'F"8%,A''IG8A$,M'RL8CT  (  :D@  (
M?O1A\7&G7(-777+N7Q=+[G0289 _+W4/8]<P^G7F9= @@79X9QX,?'E!9QH
M (  ;U8  (  @ !@L&W59#)6&V]19C1*L'"7:!T^-W&L:=\P'G)^:UD?U7*S
M;#\,,'98;"   (  =-$  (  @ !?A&I<:^A5 VP$;5])I&UI;KP]+&Z+;_,O
M>&]/</D?2V\=<8@+_G/0<6X  (  >;(  (  @ !>=F=&<[)4!FD9=*1(OFJ<
M=70\:FO'=B(NSVQT=K ? VO;=OT+]'&9=Q\  (  ?=,  (  @ !=F&23>WA3
M2V:5>_-(&V@S?#H[TFE??&(N,VGH?(L>>FD=?*P+UV_"?3T  (  @    (
M@ !<YV)*@S)2I&1M@T%'?68A@P<[0V=,@K,MJV>S@HH=[&;J@K<+BFY<@GL
M (  @    (  @ !<8F!MBNQ2)F*JBJ5&_V1NB?4ZS&65B2TM2V78B,P=J&4F
MB2H+66T^AJH  (  @    (  @ !8\X-<3&!.JX.63]U#A(0$4SXW"H2:5F$H
MO(6 60(75H>)6EP$<8?56Z(  (  :34  (  ?AI7>'].4WQ-A'_55HI">8!@
M67$V+(#Q7!LH$X&Q7DD6\8,S7T,$C80(8&X  (  ;?$  (  @ !62'M:6K-,
M5'P?74!!>WS)7ZHU/GU?8=<G4WX"8Y$6:W[[9"\$BH"V958  (  <R0  (
M@ !5*W>B8?5+,7B28_U 5GE59>0T6'GW9YHFB'I_:.85TWKX:2\$<WW<:F\
M (  >"   (  @ !4&G0Y:4=**752:LX_578O;#8S8G;0;6PEXG<W;E@51W>$
M;EX$6GMI;^,  (  ?'(  (  @ !3)G$L<*M)0W)O<;L^A'-D<J8RH70&<V<E
M-W0]<^L5!72'<],$8GE#==\  (  @    (  @ !246YW> I(<V_G>*D]Q'#V
M>1HQ]7&6>6LDH7&;>9\4HG(F>8 $D'A*>W,  (  @    (  @ !1IFPG?W1'
M[VW,?[@]6&[W?[$QJ&^)?XTD96]2?XD40G Z?[ $7'BB@"<  (  @    (
M@ !1)6H_AO)';VP!AND\W&U!AG@Q.6W.A?,D$6UDA=L4$&ZDA;@$47BU@NL
M (  @    (  @ !,[XV@2M=#8(UJ3C8XU8V#46DLO8W_5$0>58]?5E<,@)'=
M5O8  (F*7#0  (  ;*T  (  @ !+DXG+491".(GF5(LWM8H75U KQ8I_6;X=
MF8N86VP,.8T56]8  (9.8-\  (  <8X  (  @ !*A87Z6&=!'(9+6NDVO(:4
M73PJUX;S7SL<W(?48(0+Y(B>8+\  (-49;H  (  =H@  (  @ !)C8)47T=
M%X+(84\UJX,C8RLJ 8.!9+\<((0Q9:L+B(2W9<(  ("J:MX  (  >NL  (
M@ !(FW[Q9CP_)W^/9\XTPG_^:3<I'H!/:E<;E8#!:O@+.X%@:OT  (  <'D
M (  ?KX  (  @ !'NGOB;4P^37RP;G S_GTV;V@H<7U]<"(:^WVF<&P+$WZ&
M<(<  (  =E4  (  @    (  @ !&^'DQ=%T]E7HM=1TS7'K+=:<GYGL%=@,:
M<GKG=A,*U'PV=FP  (  >T<  (  @    (  @ !&3W;0>VP\ZW@#>] RO7B\
M>_@G77CM?  9^GB$>_L*;7IO?*T  (  ?W@  (  @    (  @ !%TW3;@KP\
MAW9$@N R;W<@@I\G.G<Y@DL:)'9R@EL*SGBU@@8  (  @    (  @    (
M@ ! F9E%2*LWLIBM2^4MHYB43M0AJIE143L2>9PR4E,#4IF^5&   (2R7XH
M (  < T  (  @  _-Y6\3P0V5)6.4=DL+)695&(@2Y9 5F81;IBA5R\#"945
M63\  (&N9$   (  =0$  (  @  ^09(657@U.I(95^$K'I(^6@(?.I+76Z 0
MH)3#7!\"TI#/7BX  (  :2,  (  >70  (  @  ];XY]6_TT4(Z?7?8J&([5
M7ZD>9X]D8.@/_Y#782H"JHT&8SH  (  ;E8  (  ?5@  (  @  \FHL48IHS
M=(MI9"8I1(NM970=F8PB9DL/IXT09F<"F8G%:(<  (  = 0  (  @    (
M@  [RX?R:5TRIHB':H$HD(CE:VL=!HE":_$//XFD:]8"IH<#;C   (  >3L
M (  @    (  @  [%84I<"DQ](7^<.\G^(9W<7D<C8:_<;0.YX:N<88"EH3%
M=%,  (  ?9@  (  @    (  @  Z?(*[=PHQ78//=WPG=H1E=ZX<+H27=Z@.
MHX1)=Y(";H,">BL  (  @    (  @    (  @  Z#8"J?B<PYX'V?D\G"X*L
M?C$;XX+,?@$.D8)<?BX"B8&(?O\  (  @    (  @    (  @    /__  #_
M_P  __\  &UF=#(     ! ,)   !                     0
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MIDVJ3J]/M%"Z4<!2QU/.5-55UU;95]M8WEG@6N-;YUSJ7>U>\5_U8/AA_&,
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M?\Y_6,V9?ZA^S;3:?YE^>9P4?Z-^98-,?\9^A6J%?_Y^P%&_@&-_/3D @1*
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M06#6@<>+9$H8@9>(:#.B@8N%!.=<A(NHH-%L@YVD%;L0@M2?NJ1;@C>;E(V
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MC.Y^("QJB3M_T[VBHYR#<*OBG_*"?)G.G'.!M8=NF1^!)73%E>^ TF(*DL>
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M=W&I^':;>(.BKE_R>:J:_$E>>O:2NS+\?'2)C.<G=%720=#V=-G)F[I,=6K
M_Z-N=B2X@(RB=Q.P%77T>"NGB%]J>5N>CDCY>K&4^C*\?#:*@>*9A!%X&\V-
M@X5X>+@<@PYXX:(X@JMY9(P)@EQZ#'6\@A]ZV5^ @?![PTE5@>)\[#-\@@1^
M=>#A@HZ"J<Q<@A>!YK<2@;.!/Z$H@66 P8KI@2N :W2@@0F .5YS@/Z &4AU
M@16 'S+@@5J 2=]1@4&-0<K!@-F+;K66@(*)N)_%@$V(/HFR@"Z&\'.4@"F%
MOEV/@#6$BD>Z@&2#6#)6@+^"!]V_@"B7Q<DE?\>4]+0!?WR20IY<?U"/N8AT
M?TN-;G*'?UR+,5RW?W^(XT<3?\6&=#'=@#2#K-Q$?T*B0<>S?N*>>[*:?J":
MTIT'?H"72H=!?H*3W7&)?JJ0DUOO?N"-($9[?SF);3%T?[J%,-KZ?I"LOL9T
M?C&H!+%C?>ZC6)OC?=.>Q88]?=^:2'">?@R5T%LY?E:1-D7T?L*,.S$;?U&&
MCMGH?@*W,L5L?:2Q?K!<?5ZKQYKD?4.F(85>?5J@D6_F?9*:\EJ>?>&5%T6!
M?ER.T3#0?OF'P]D-?9?!F,26?3JZXJ]_?.VT%IH&?,VM3821?.>FFV\Y?2V?
MUUH:?8>8PT4A?@B1*S"3?J^(SMAF?4K+[L/N?.[$)Z[%?)B\-9E$?&^T.X/@
M?(BL6&ZF?-6D8%FL?3N<%$33?<B3/3!C?G2)K=+OC.MVV;^2BWQW5ZN]BBUW
MW9=?B/YX?(*IA^9Y0VW1AMYZ-%D8A=Y[1D1[A/%\H3!:A!I^:]%UBY2 P;YD
MBC6 /*JCB/1_T99:A]5_AH&OAM)_96SHA>-_9UA A/U_>T/,A"Q_NB_N@VZ
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MOCN P6?PM^R #5M*L6U_L4[#JK9_D$*)H[Y_I3;^G'1_UBQ@E,V .R-5C.J
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ME-B OHJRDH* 7GHZD$^ &FERCBE_\UB9C M_Y4@2B>-_XC?^A[I_^2D(A7^
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MDKE^BR(,BZ-_CGD#O0."D&U<MX&!N6&AL<F!#U7GJ]> HDH\I;& ;3[EGU*
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M>N)Y9&H&>ZEZ0E8.?(E[,D).?9=\22\Y?N=]D\CH=H* W;;E=TF @:0Y> >
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MGVR  &X@G!)_OV$@F+)_EE/BE4U_B$;&D=A_CSHWCD=_HRYEBJ!_RR0(ANF
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M*EC"G\1^+$RYFU5^4T#IEL9^DS6]D@U^Y2MFC3)_5"*/B%!_TGMPJU6%27
MISR$BF1'HPB#TUA=GK:#)TQZFDJ"F$# E<^"'S6WD2F!K"N'C&>!22+;AZ6
M\WL9JGZ,!F^SIF6*OF/^HBR)9%@6G=B("4P[F6^&NT"AE/*%?36SD%Z$12NC
MB[:#$2,:AQ:![7K0J=>2EF]YI;N0PV/&H7J.P5?<G1^,K4P$F+N*HT"#E$6(
MHC6WCZR&I2N]BQV$IB-.AJ&"P7J?J4^8[V]+I2^6BF.3H.B3W5>IG(B1#$O5
MF"2.0D!7D[R+?#6HCR6(P"O7BIR&!2-XAD&#<7ITJ/F?)F]-I,F<.6./H&R8
MQU>.F_*5%TO#EX*1@D!6DQ^. #6SCJB*D2OIBD"'*2.:A?6$ '&!N:-HW&:K
MM01JDEO%L#%L;5#*JO]N<$70I6EPHCL-GX%S"S#RF5AUG">CDNEX>A_"C')[
MAW%$N.1OUV:KM!)PR%O4KP)Q\5#DJ:IS3D7QI ATXSL]GB5VK#$UF 9XF2@*
MD:YZQ"!7BU=]#7$HMZ)V<V: LLIVR5NZK;!W3%#,J$]X$T7KHK-Y"CM.G-YZ
M,3%CEM)[=BA?D)5\Z"#7BF)^;7$'MD-\SV9,L6]\HEMYK%M\F5"CIP-\PT72
MH71]'SM/F[)]FS&%E;Q^+RBFCYU^Y"%%B9!_IW#>M12#%&8FL$*"<%M1JR^!
MX%!TI=N!9T7!H%.!&#M0FJ: Z#&CE,: PRCCCL2 MR&CB-Z NG"XM"R)4F83
MKT^(-EM"JC6'$5!CI.&%]46PGV"$\#M5F;>$!3&^D^N#*BD7C@B"7B'PB$B!
MIW"7LWF/8&8+KHN-R%L^J6:,"5!;I!"*046IGI>(C#M:F/B&Z3'9DS"%52E&
MC6J#TB(PA\Z";W!^LO65-V8-K?"3(5M"J+R0P%!9HU^.146?G>F+W#M4F%R)
MA3'FDJ"'0REKC.>%$B)DAVJ#%7!MLI::V687K7*8/5M-J"R5,5!<HL>1_$6C
MG5..W#M@E]"+U#'PDB>(Y2E]C(2&%R*-AQR#F\ZA;1AF^KOH;NQI/:BU<*UK
M<93J<EYMG("U=!)OSFQ6==IR%U@@=[]T?T0=>=]W)S#)?%EZ/LR^:K1QQ;IJ
M;,%RY*=@;JUT!I.^<(MU,'^D<FYV9VMB=&=WLU=)=GYY$D-T>,]ZFS!B>WA\
M8LKY:*=\?KBT:M)\@:7H;.1\C9)>;N9\MGYP</)\\VI<<Q=]059T=5M]ED+7
M=]I]^S '>JQ^;,D[9M>'#;;X:1N&"J0Y:T2%%I#K;6B$-7TI;YR#=FE.<>J"
MOU6E=%B" T)%=O^!/2^W>?> 5L>G95"1>[5Q9Z:/BZ*V:>6-GH]\;!Z+NWOU
M;F^)Z&A,<..(*%3B<W6&4T'!=D"$6B]R>5B"&\9?9!R;UK0R9GV9 Z%]:,:6
M&HY-:Q"3+WKA;7203&=D;_Z-:E0S<K**>$%+=9R'22\X>,^#M,5;8R:F$K,U
M98^B6Z!]9]R><HU1:BZ:>'G];*66AF:E;T22B%.?<@R.9$#J=1*)_B\(>%R%
M'<298G"P(+)V9-RK@9^R9R6FE(R :7>AA'DS:_B<>67X;JR78E,?<8F2$T"7
M=*",;R[@=_V&5<0:8?>YZ['T9&"T4I\99I^N5XO8:.BH+7B1:VNB!V5M;BF;
MT%*G<1657$ _=$".C"[ =["'6L""=/]F-*^/=?YHIIWE=O]J]8MX> %M,'B*
M>0YO<V5K>BYQT%)\>VET4#_$?-9W%"W3?I!Z2[\G<LAP>ZZ!<_]QU)SC=2-S
M'HJ$=D9T9W>C=W1UO62=>+YW*E'/>B5XKC]%>\1Z8BV.?:]\6+VO<-%ZGZSJ
M<B=Z\IMS<VI[0(DH=*][F79X=@5\ V.C=WE\?U$'>0I]!#ZZ>M-]G"U2?.1^
M2+PH;Q>$F:M9<(*#_IGI<=V#7H?;<SV"P750=+J".V*P=E.!O%!0> N!/#Y!
M>?N MBT=?#" &+J[;9^.>ZGX;QN-!)B-<(N+>H:-<@")Z'0_<Y.(7F',=5&&
MXD^F=RN%5#W4>3Z#J"SO>Y.!PKF2;'684ZC4;?R6 )=O;W63AH5[</J0^7-'
M<J".;&$!='&+W4\0=FN)/SUT>)V&:BS)>PV#0+BF:XBB"Z?H;1:>W):";I*;
M;(26<!^7W7)X<=B436!7<[R0KTZ3=<B,[STF>!6(\2RI>IV$C[?W:M>KF*<T
M;&>GB)7!;>&C'(/4;VV>@G&_<3"9Y5^Y<RJ5.4X@=4F07SSB=Z6+-BR/>D"%
MK[>&:F&TZ*:S:^VO[94I;5RJ?(,R;N"DSW$I<*6?(%\\<JJ98$VV=-J3;#R5
M=TJ-*2QZ>?6&GK+5?2%EI*-U?41H+),Y?8%JB8(<?=!LSW!P?BYO'UZ2?IUQ
MCDSP?R%T(CN-?\]W 2L(@+IZ5;'$>PQO2Z)J>VEPSY(;>\=R/H$3?#)SIV^$
M?*UU'5W*?4!VK$Q/?>IX5#LB?L)Z+2KF?]5\3+"<>2AXX:$J>:MY<I$->B1Y
M^8 ">JMZ?FZ5>T1[%%T%>_I[O$NZ?,M\<CK#?<U]/RK(?PE^):]&=WJ"2Y_0
M>!&"!X^A>*6!KG[/>42!46V%>@.! EPG>MV O$L5>]* =SI>?/B ,"JN?E1_
MVZX$=A6+H9Z/=KJ*CHYF=V")7'VD>!*(%VR5>.2&U5M>>>&%G$J#>O6$5CH'
M?#R"]BJ7?;>!:ZSZ=/B4\)V(=:B3#HUF=E:0^'RP=Q:.QFNX=_B,CEJP>06*
M4DH$>C>(!SF\>YN%C"J$?3&"T*PF=!2>'YRQ=,R;:XR/=7V8;'OA=D2516K^
M=S>2%EH:>%6.V$F=>92+?#F >Q.'YRIU?,&$!ZN'<VBG))P)="2CF8O==-.?
MJWLR=9F;A6I9=I:75EF+=\F3%4DW>1F.KCE+>J2* 2IH?&6%$*L?<O*O\9N.
M<ZZKB8M-=%2FHGJ<=1&A=6G2=@^</ED>=TN6]DC;>*V1@CD+>DR+S"I>?!R%
M[*6+A7QE.Y=_A,AGR(B-A$1J+'BV@]YL>VA1@X-NV%>]@S-Q5T=R@O!S_C=R
M@LQV]"AJ@M1Z7*2O@XAN4Y:5@Q)O[X>,@J]Q='?&@EQR]F=^@AATB%<-@>5V
M-$;J@<%W_#<C@<!Y^2AK@>A\/J.P@<!W195H@7!X"89_@2-XNW; @.EY;V:?
M@+]Z+U9:@*U[ T9H@*I[YC;;@,U\Y"AK@19^ :*;@!B (Y1(?]^ ((53?ZZ
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MB'A^,"+5A:1^_WX$FG:!P7*QE^"!B&;OE3V!0EK<DHV ]DZSC]F NT*6C2J
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M\RZ%E0]V<"8HCXUY*!\VBC![]6E;L(1PPE^3K&#_XO__24-#7U!23T9)3$4
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M:0R'&H_2:QF&/'[_;2J%4FW>;U^$;ER/<<>#F$N@=%6"NCL7=R:!SRNE>D"
MR:YO97Z1?Y[J9[*/X(Z\:=&.&'WX:_F,.FSP;DB*6UO5<,J(?DL9<X"&F3K&
M=G>$CRN.>;*"4:V!9%B:^9X!9IJ8?XW7:,*5QWT?:OF2\&PL;6&0%ELW;_Z-
M-$JL<LJ*.CJ&=>.'$RM[>3N#J*S08WBD0)U/9<"@YXT=9^R=.7QH:BB98&N
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M@-1]@R4G@0Y^<HOZ@%" @7^[@!F E'+E?^* A665?[. 7E@<?Y2 .TIM?Z"
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MV%72CE9WTTIAC%%XX#\2BDMZ!S19B$1[0RI5ADQ\HR&[A&U^$W6FDJ=\ &M
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MF$R 4E=8E9* .DU DK* %$,VC\1__#EHC--__# \B>N ""?>AQ: &R#MA'"
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MH!6#04[PG'6"T47@F)2"3SS[E):!X31UD(N!B2RTC'Z!126YB**!!B 0A1B
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MQT1[>,!SF36S>P5VM"@A?9-Z,9P::_5M%8ZY;;QNUX"W;W)PBG',<3-R-&*
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M;Y.$^G0-</R$>6:D<G6#V%C_=!>#-$M3=>Z"F#X@=_6!_S%_>CJ!7B8Y?*.
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MA,A^OQ_]@SA_<F*"D,& Z5GBCS6! %#IC6> WT>^BVV ICZAB7: ?C78AXV
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M/JB]56=I@)G]63YK@(K$7/]M?GK18,-O@VIX9*]QEEG\:-5SP4G>;3=V##I
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M=?5]^"<^>@A^WHZ/7,:!Y()27_*!VW5W8PF!K&@)9C&!9UI9:8R!(DR9;2N
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M=:"!E5L"=J*!<E"W=YV!+T94>+J ]3P<>@. S#*&>VB KRF0?0* C2($?I^
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M?+2$KU)Q?/N$*DD^?1R#>T (?56"X3<&?;^"6RZT?CV!ZB<7?N^!:R#'?[6
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M2*^ 97YX3D" 5' \4]> 0F&H6:> -%+\7\F -$2W9C> /#<5;/J 4RKH<\V
M>9?B0$R)O8L-1F&(PGVD3#Z'R6^14AN&T6$/6#&%W%*#7I6$ZD1T94&#]S;S
M;$."_"KL<TJ!_I;?/A^2LXHY1'J0QGS]2I:.X&\/4*N- V"B5OJ+*U(?79F)
M3$0L9'V'8C;8:ZV%7BKO<MZ#2Y8H/'6;(8F>0P"8.WR!24>5:FZR3X:2LF!A
M5?Z0 U'T7,>-0T0$8]>*:S:[:S2':BKR<HB$89=D765/_HH98&%4:7QM8W-8
MT6X[9JE=-U^<:A!AJU#=;;9F14*)<9EK&#2T==QP5B@O>F=V,)5Z6,=9:HC'
M7$E<_WM;7\U@CVU;8VMD'E[B9SMGM5!,:TYK;D(F;Z%O6#2+=%ASJ"A,>4]X
M?9.Z5)IBS(<86))E@WGN7'QH-FP-8'UJZEW,9+-MJD]R:3%PBD&/;?!SDC1&
M<PUV["AE>%=ZII((4-)L$(5_53)M['AS67=OR&KI7=%QI%S28FMSBDZU9TMU
MBT$4;&UWJS00<>9Z""A[=WU\II!V375U-X0<4C!V/W<S5LYW0VG!6WMX0UP(
M8&AY34X39:1Z;$"L:QY[GS/F<.A\^2B.=L%^>8\C2HY^/(+U3Y=^<78X5(-^
MFFCH67Y^O5M*7K5^Y4V:9#A_'4!=:?]_8C/$<!!_MRB>=B& &8X/2!2'"X(&
M36.&:'5M4I"%LF@[5\V$]5JQ74>$/4TF8PJ#C4 D:0R"XS.N;UF"-2BK=9V!
MA(TY1@R/BX%+2Y..$'3+4/:,>6>S5F>*V%H[7!:)0$R\8A2'JS_?:$J&%C.<
M;L.$;BBU=3""NXRB1'J7EH#!2BN52'1.3[22SV=)54N03EGK6R&-VTR&84>+
M9C^O9ZJ(Z3-\;DZ&42B^=-F#O(R^9%U08X!P9LE4MW.Z:519#F9^; %=:%C>
M;MAAU4LE<>AF;3W@=3%K/S$E>-=P@"7 ?+UV6(KL7_A9,G\78N5<R'*19=M@
M6F6':.AC[E@0;"1GD4J&;YYK6SUV<U)O6#$!=U]SMB7Q>YMXBXE46_%B#7VG
M7U-DV'%]8JEGH&219A%J:%=/::AM/TGZ;81P-CTD<9US5S#K=@MVRB8<>IQZ
MF8?"6%%JSGPO7!1LSW 37\!NSV-Z8WUPS59@9W=RU4E(:[)T^CRS<"AW/S#"
M=.MYP29!>;Q\?H9851IS='KD62UTL&[G72MUXV)J83IW$56J98-X2DBX:A=Y
MF#Q=;N!Z_#"H<^U\B29A>/Q^-H4J4E-[_'G75JU\=&W\6O)\V&&:7TI],E3X
M8]I]DDA*:+%^!3P;;<-^B#"3<Q1_'29[>%E_O80V3_>$37C]5(R$ FT\60V#
MDV#R7:2#%%1D8G2"G4?=9XB",COM;-"!TC")<EN!<B:1=]&!$(-Y3@:,5'A4
M4LV+1FR@5W^* F!K7$6(IU/K84F'5T=T9I:&$#NM;!"$T#!_<<2#@R:C=V*"
M,(+T3(*3]'?747*2,&PG5D:0%E_\6R^-W5.58%>+LD<Z9<N)D#MZ:W*'<#!?
M<5&%0B:Q=PJ#'X(;:XY0PW:V;6U4_FKN;W!90UZK<8]=E%(.<\YA_D5E=CYF
MESD\>-]K:BVM>])PKR-[?OAV>X!B9V%9 '5Q:;A<DFG?;!M@)5W.;I-COU%=
M<2]G;D3D= )K1SCO=P=O4RVC>EESP"/ ?<QXEG[O8XMA2'059DYD(VC/:0IF
M_ES>:]=IW%"C;LQLSD1@<?UOXSBF=6!S(RV:>0EVL2/\?,-ZBWV(8 UIB7+"
M8RUKJ&>:9CMMQUP.:59OZD_[;*1R%D/R<"MT8#AS<^1VS"V;=]]Y=B0Q>]U\
M5GPZ7/QQL7&I8&=S&6:58\!T>EL,9R9UUD]):L!W/T-D;IUXP#@?<J1Z6"V(
M=N1\&21=>Q9]]7LG6E-YNW"M7?UZ<&6U89A[#EI&941[H$ZD:2%\/$,";3Q\
M[3?J<8E]KRU_=@A^A22">F]_8WI(6 Z!CF_E6_"!D&4#7\*!:%FI8ZB!+4X<
M9\" ^T*B;!: V#?'<)6 Q"V =4R M"2A>>2 H'F;5BZ)&6])6D"(;F1Q7C^'
M?EDI8E&&<$VI9IN%;D(^:R>$>3>/;]2#D"U]=+*"H"2Z>7.!K7D>5+202F[6
M6.V._6/^70Z-15B^84"+8$U59:N)B4(':EV'P3=@;S>& BUC=$"$/B3.>1B"
MBG=L<P91!6SQ=%=5*V(<=<Q99%;5=U5=L4M">/!B'3^R>K%FO32O?)AKF"I7
M?L1PX"%D@1-VF778;QA8O6O/<-5<3&$N<IY?XE8;='-CA4JV=F)G0S]6>'YK
M,#2&>L%O3RIL?41SRR&]?]IXG72':W%@@FJ4;9)C:F T;ZUF5E5!<=%I2TH.
M=!-L6#[C=H9OC#1/>2%R["IU>_)VEB(*?LAZ>W-,:!YH.6EG:I)J=5\7;/EL
MM51\;V1N^TEL<?QQ4SY[=,)SRS0A=ZYV92I_>LEY.")-?=E\+W(?92EOXVA2
M9^5Q<UX@:I!S %.B;4)TBTCV<!YV*3XJ<S)WX30$=F9YL"J0><1[J2*%?0Q]
MMW$A8IQW=F>"99=X85UP:']Y-U+Z:W!Z!$A>;HEZWCW1<=A[TC/5=4M\V"J0
M>.9]\B*U?&!_#W!38&M^TF;%8YQ_&5S'9KE_-5)E:>!_0$??;3%_5SUY<+5_
M@C.Z=%=_O2J9>"A__2+<>]& .&^P7IF%Y68T8?>%C5Q!94&$[U'P:).$,T=X
M;!&#A#TA;\F"YS.-<Y6"62J@=XJ!QR+\>UV!,F\Y722,JF7'8*J+OUO69!:*
M95&.9XB(VT<N:R6'8#SS;P"%^3-G<OB$GRJ.=Q>#1B,5>P"!_VS2>LU1%6-*
M>X=5+EEM?&)98$\I?45=KT2D?BUB)3HP?RUFU3!5@$IKOB<X@9IQ#A^ @P1V
MLFMH=Q]856)$>#Q;Y5B5>5Y?@TZ$>H)C-40O>[-G"3GN?01K#S!*?G)O1R=H
M@!)SUA_L@;]XHFI <Z=?H&$M=1]BEU>[=HMEF$W&=_1HJ$.E>7!KUCF:>Q)O
M+S P?-!RLB>*?KEV>R!)@*%Z:VDH<'IFWV =<CUI.%:[<^UKETT-=9YN!$,1
M=VAPB3D]>5=S,3 ->V%U^B>A?8UX^""9?ZI\"F@D;:1N"U\S;ZEOQE7D<9EQ
M@DQ&<XQS0T*D=95U&#CS=\YW#B_V>AMY&2>Z?(9[2"#>?M=]?&<[:RIU)EY?
M;6UV1%4M;YEW5$NW<<1X84(U= =Y?3C-=G)ZN2_R>/I\!B?4>Z!]9B$7?B5^
MP69\:0=\$5W#:X=\F%2K;>=\^$M&<$%]2T'.<K5]L#B$=51^+B_D> 5^OB?G
M>MY_3R%&?9)_UV7D9SV"N5TY:>Z"K%0O;'R"7$K>;OZ!\D%V<9R!G#@Z=&J!
M7"_ =T*!+B?U>C^ ^R%L?1J P65R9<N)'%S0:*2(@U/+:UB'@$J';?N&4T$X
M<+>%.S@7<Z6$.R^I=J6#3"?Q><B"7R&+?+J!@&*$@MQ0X5GT@O%4]U$4@R!9
M*D?3@TM=@SY;@VYB#34#@YMFUBQ-@]MKV"1BA$-Q-1W5A,1VQV%#?VI7MUD#
M?]U;3U!'@$I>^T<V@*IBQ#WT@0AFMC35@7MJWRQ;@@)O."2J@K%SWAY2@W%X
MI6!#?!U>D%@,?.%AGD^$?9!DN4:/?BYG[#V ?M!K0S28?XQNR2Q:@%QR=B3B
M@4]V81Z^@DEZ6U]4>0YE7E<B>A=GV4ZE>P-J7T7P>^1L^CT'?,YOLC14?=)R
MD2Q.?NEUCR4-@!QXNQ\<@4E[YUYP=D]L'U9.=YAN!DWC>,%O\T5&>=QQZCRE
M>P9T #07?$YV-BQ"?:-X@24P?Q%ZZA]K@&Y]1UVE<^1RRU67=6QT(4U'=LYU
M;D3">"%VP3Q!>7YX*#/Z>O1YKBQ%?(%[1B53?BA\Z1^M?[=^>EST<<EY1%3R
M<X]Z"$RW=2AZLD1.=JM[63OJ>#5\%#/0>=A\YBQ=>X5]RB5Y?5]^KQ_C?Q]_
M@%QF< )_C%2(<@=_QTQG<]%_QD09=7-_LCO'=QQ_NS.F>.Q_W2Q">L& %"6/
M?+R 0" /?J2 7%O\;I"%FE0D<+^%3$P+<K2$GD//='B#T3N7=CR#(S.1>"F"
MCRP]>B*"#R6;?$*!C" R?D*!#UB*BSI085#XBI14@4D:B@!8OD#=B5Y=*SAQ
MB*=ATS RA^YFP2B=AT)KY"'8AK9Q51Q@AE%VV5=QA_U6UU 5A[A:@4A,AUI>
M14 ^AN)B+C@0AEAF2# 2A==JGBB_A69O("(UA1MSXASMA/%XIU:8A-5=24\[
MA-A@=4><A+ACLS^HA'9G$S>OA"AJG"_J@^AN6"C5@[ER-B*!@Z]V1AUG@[YZ
M3%72@=UCKTYV@AUF4T;<@C=I!S\C@C1KV#=0@BANSR^_@BQQ["C@@C]U)2*^
M@G)X@1W0@K9[QU41?REJ#4W!?ZML)D8Y?_YN3#Z7@#%P@C<*@&%RX2^;@*1U
M7RCH@/1W[B+Q@6!ZD1XI@=1]%U1??,1P6TT=?8IQZD6Q?A=S>CXM?GQU%3:^
M?MQVS2^(?TUXIRCS?])ZBR,<@'1\=!YS@1=^.U/%>K-V>4R4>[AW@$5"?'MX
M=#W9?0QY;C9[?9=Z@R]K?C)[LBD(?M9\[B-$?ZI^(1ZP@'M_,U-!>.=\64P6
M>B]\UD35>R9]+3V&>^!]@C9 ?(Q]\B\Z?5)^>"D#?@]_#B-O?O]_EA[A?_V
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M@5)^VSU5@9U^YC<Q@6Q^^3$D@0]_,"M4@,I_?"8H@)9_T2&:@)Z &QX%@,2
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M1$'_I$92_:I$8/2Q0F[KN$%[Y,%"AM_,1HW3SU*7P<1AI[.[;;.KM7B[I;&
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M<\*&J7/"AJESPH:I_[0D)>S*%B/-Y1,LN?8;1J?Z)EN8[C5LC.5$>H3>4X.
MV6**?-5LCWC2<9-UT'65<\]XEW'.>IAPS7R9;\U^FF[,@)MMS(*<;,N$G&S+
MA)QLRX2<;,N$G&S+A)QLRX2<;,N$G&S+A)QLRX2<;,N$G&S+A)QLRX2<;,N$
MG&S+A)QLRX2<]<$5&='?#!B\\Q,QJO\>1YK\+%F.\CQGA.I+<GWE6'IYX&.
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MHS0:_ZTS'OZX,B#PQ34@X],_'-C>12;*VTTZO=-43+#.6UVCR6%KF,1G=XW
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M4];6BU/6UHM3UM:+4];6BU/6UHM3UM:+_Y<D"?^I)@K^N!P)YLX1!<[C%PC
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MT"@'U-\R"\G?/AF]VT<LL=9//:315DR9S5Q9CLEB983&:&Y[Q&]V=,%U?&W
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M0_^154+^F%9!_9Y70/VF6$#\J5A _*E80/RI6$#\J5A _*E80/RI6$#\J5A
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MASTX_XP]-_^3/C;_E3XV_Y4^-O^5/C;_E3XV_Y4^-O^5/C;_E3XV_Y4^JL0
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M_Z5*.?^M2SC_N4LX_[E+./^Y2SC_N4LX_[E+./^Y2SC_N4LX_[E+OK4" +#
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M,2W_GC(M_YXR+?^>,BW_GC(M_YXR+?^>,BW_GC(M_YXRI,(  );/  "(WP
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M6SC_=V-!_W!L2/]L=T__9X)4_V.-6?U@EES\79]?^ENG8OA9KF3W6+9F]5?
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M23K\STDY_.-).?SC23G\XTDY_.-).?SC23G\XTDY_.-)QZT  +>W @"JPP(
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MI#H[]K [.O>_/#GXSSPX]^@\./?L/#CW[#PX]^P\./?L/#CW[#PX]^P\OZH
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M&B/_H!HB_ZH;(?^M&R'_K1LA_ZT;(?^M&R'_K1LA_ZT;FKX  (O*  !^UP
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M9'5\\V1U?/-D=7SS9'5\\V1U?/-D_VD6 ?]X$P'_AQ0 _Y,5 /&>%0#CJ!8
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MKDM(Q;]+1\;82T?%[4M&P_E-1<+_3D7"_TY%PO].1<+_3D7"_TY%PO].WY
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M+S?ST"\W\^<O-O'S+S;Q\R\V\?,O-O'S+S;Q\R\V\?,ON:<  *NP  "?NP
MDL8  (;0 0![W04 =/<1 &WW' %F^"8#7_@O!EKY. I4^4 .4/I'$4SZ3A1(
M^U461?M;&$+[8AI _&@</?QP'3K]>!\X_8(@-OV-(C3^F",R_J0D,?^Q)3#_
MOR8O_\\F+O_C)B[_XR8N_^,F+O_C)B[_XR8N_^,FK:T  )^W  "2P@  ALT
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M5X)O_5>";_U7@F_]5X)O_5>";_U7_V 5 ?]N$0'_>Q, _X84 /:/%@#GEA@
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M0$7 Z#]$OO9!0[W_0D.\_T-#O/]#0[S_0T.\_T-#O/]#UHT  ,:;  "XI0
MK:X  **V  "8OP( C<@& (/1"P!_TAH >=(J W+2-PALT4(/9M%+%6'04QI<
MSUL?6,]B(U3.:2=1SG$J3<YZ+4K.@S!(SHXR1<Z:-$/.J#5"SK@V0<_--4'.
MZ#5 S?4W/\O^.3[+_SD^R_\Y/LO_.3[+_SD^R_\YRI8  +RB  "OJ@  H[,
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M&RO[ZQLK^^L;*_OK&RO[ZQLK^^L;J*H  )JT  "-OP  @,D  '33  !GW@
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M2))@_T>28/]'DF#_1Y)@_T>28/]'_U@5 ?]C$0'_;A( _W<5 /M^& #M@QT
MXH<C =:'+@/,@ST+Q7])%+U[4QVW=ETELG-E+*UO;3*I;74WIFI\.Z)HA#Z?
M9HQ!G&641)ECG$>78J9)E&*P2Y)AODR08=!,CV+H3(YC^$N-8_]*C&3_28MD
M_TF+9/])BV3_28MD_TF+9/])_UH3 ?]F$ #_<1$ _WH2 />"% #HAQ< W8L<
M -"++ /'B#L*OX1'$[A_41RQ>UHDK'=B*Z=T:C&C<7(VGV]Y.YMM@#^8:XA"
ME6F019)HF4B/9J)*C&:M3(IENDV(9<Q.AV;F3H9G]DR&9_]+A6C_2X1H_TJ$
M:/]*A&C_2H1H_TJ$:/]*_UP2 ?]H#P#_=!  _WT0 /.%$ #DBQ$ UH\7 ,N.
M*@+"C#@)NHA$$K.$3QNL?U@CIWQ@*Z%X:#&==6\VF7-V.Y5Q?3^2;X5"CFV-
M18MLEDB(:Z!+A6JJ38-IMTZ!:<A/@&KC3X!K]$Y_:_],?VO_2W]K_TM_:_]+
M?VO_2W]K_TM_:_]+_UX0 ?]K#@#_=@X ^X - .J(#0#;CPP T)(5 ,>2)P*^
MCS8(MHQ"$:Z(31JHA%8BHH!>*IQ]93"7>FPUDW=S.H]U>SZ,<X)"B'*+1H5P
MDTF";YU,?VZH3GUNM4][;<90>F[@4'EO\DYY;_Y->6__3'EO_TMY;_]+>6__
M2WEO_TMY;_]+_V / /]M#0#_>0P [H,+ -N+"0#4D0H S)43 ,*5)0*YDS0'
ML8]!$*J,2QFCB%0AG81<*9>!8R^2?FHUCGQQ.8IZ>#V&>(!"@W:(17]UD4E\
M<YM,>7*F3G9RLU!U<L-0<W+=4'1S\$]T<_U-='/_3'1S_TQT<_],='/_3'1S
M_TQT<_],_V(. /]O# #\>PH WH8& -6." #/E D QY@1 +Z8(P&UEC(&K9,_
M#Z:021B?C%(@F(E:*).&82Z.@V@TB8%O.85_=CV!?7Y!?7N&17IYCTEV>)E,
M<W>D3G%WL5!O=L%0;G?94&YW[T]N=_Q.;G?_36]W_TQO=_],;W?_3&]W_TQO
M=_],_V0- /]R"@#P?@8 VH@% -"0!P#*EP@ PIL0 +F;(0&QFC &J9<]#J&4
M1Q>:D5 ?E(U8)XZ+7RV)B&8SA(9M.("$=#U[@GM!>("$171_C4AQ?9=+;7RB
M3FM\KT]I>[Y0:'S54&A\[4]I?/M.:7S_36I[_TQJ>_],:GO_3&I[_TQJ>_],
M_V8* /]U" #A@0( U(L% ,N3!@#$F@8 O9X. +6?'P&LGBX%I)L[#)V81166
ME4X>CY-6)8F072R$CF0R?XMK-WJ*<CQVB'E <H:!1&^%BD=K@Y5*:(*@366!
MK$YC@;Q/8H'13V*!ZTYC@?E-8X'_3&2 _TMD@/]+9(#_2V2 _TMD@/]+_VD(
M /MX! #<A $ SX\$ ,:7!0"_G04 MZ$, *^C' "GHBP$GZ Y"YB>0Q21FTP<
MBIA4(X267"I_E&(P>I)I-760<#IQCG<^;8U_0FF+B$9EBI))8HF>2U^(JDU>
MB+I.7(C.3EV(Z4U=A_A,78?_2UZ&_TM>AO]+7H;_2UZ&_TM>AO]+_VT% .I\
M  #5B   RI(# ,&: P"YH , L:8) *FG&0"BIRD#FJ4V"9*C01*+H4H:A)]2
M(7Z=6BAYFV N=)EG,V^7;CAKEG4\9Y1]0&.3AD-@D9!&7)&<25J0J4M8D+A,
M5Y#,3%>0YTM7C_=*5X[_2EB._TE8CO])6([_25B._TE8CO])_W$! ."   #/
MC   Q)8" +N> @"RI   J:H% **L%0";K"8"E*LT!XRJ/P^%J$@7?J90'GBD
M6"5SHEXK;J%E,&J?;#1EGG,Y89U[/%Z;A$!:FHY#5YF:1529IT=2F;9(49G*
M2%&8YDA1E_5(49?_1U&6_T=1EO]'49;_1U&6_T=1EO]']G<  -B%  #)D0
MOYL! +2B  "KJ   H;   )JR$0"4LR(!C;(P!86Q/ Q^KT84>*Y.&W*L5B%M
MJUPG:*EC+&2H:C!@IW$T7*9Y.%BE@CM5I(P^4:.80$^CI4)-H[1#3*/(0TRC
MY$-+H?1#2Z#_1$N@_T1+H/]$2Z#_1$N@_T1+H/]$XWT  ,^+  #"E@  MY\
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M+3S%_RX\Q?\N/,7_+CS%_RX\Q?\NQ),  +:?  "II@  G:X  )*W  "&OP
M>\<# '#/!P!GU@T 9-<: &#8*@%<V#8#6-A!!E382@I0V%(-3=A:$$K78A-'
MUVD61==R&$+7?!I V(<</=B3'CS8H1\ZV; @.=G#(#G9WR YU^\@.-7Y(C?4
M_R,WU/\C-]3_(S?4_R,WU/\CN9P  *ND  "?K   D[4  (>^  ![Q@  <,X#
M &76!P!=XPX 6N,; %;C)P%2Y#("3N0\!$KD1 9'Y4T(1>55"D+E7 Q Y60.
M/N9L$#OF=A(YYH 4-^>,%37GF18TYZ@7,NBX&#+HS!@QZ.48,>;T&#'E_!@Q
MY?P8,>7\&#'E_!@QY?P8KJ(  *&J  "4LP  B+T  'O&  !OS@  8]8! %C>
M!0!4[A  4>\; $WO)@%)\"\"1? X T'Q/P0^\4<%//).!CKR50<W\EP(-?-D
M"3/S;0HQ]'<,+_2"#2WTCPXK]9T/*O:K$"GVO! H]LX1)_?F$2?U\1$G]?$1
M)_7Q$2?U\1$G]?$1HZ@  ):R  "(NP  >\4  &_.  !BUP  5MX  $[P!P!*
M^A  1OL9 $+[(@$__"H!._TR CC].0(U_C\#,OY& S#_3 0N_U,%*_]:!2G_
M8@8G_VL&)/]V!R/_@@@A_Y ((/^="1__JPD>_[H)'?_)"1S_W0D<_]T)'/_=
M"1S_W0D<_]T)F+   (JZ  !\Q   ;\T  &+8  !5W@  2>0  $3[!0 __PX
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M_S^"9/\__UD. /]D"P#_;@H ZG<( -M]" #4@@H S(02 ,.%) &[@S0%LX!
M#*U\2Q2F>50;H79<(9QS9":8<6LKE&]R+Y%M>3..:X$VBVJ).8AHDCR%9YL_
M@F:F08!FLD-^9L%$?6;91'QG[T-\9_Q!?&C_0'QH_T!\:/\_?&C_/WQH_S]\
M:/\__UL, /]G"0#W<0< WGH% -2 !P#.A0D QX<1 +Z((@&VAS$$KX0^"ZB!
M21.B?5(:G'I:()=W82:3=6@KCW-O+XMQ=S.(;WXVA6Z&.H)MCSU_:YD_?&NC
M0GEJL$-X:K]$=FK4179K[4-V:_M"=FO_079L_T!V;/] =FS_0'9L_T!V;/]
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M1%]]Y4-@??9"8'W_06%]_T!A??] 87W_0&%]_T!A??] _V<  .-T  #2?P
MQX@! +Z/ @"VE0$ KI@& *::%0"?FB8"F)DS!I&7/PR+E4@4A9-0&G^16"!Z
MCU\E=HUE*G*+;"YNBG,R:HA[-F:'A#ECAHX\8(69/UV$ID%;A+1"6H3'0UJ$
MXT):@_1!6X/_0%N#_T!;@_\_6X/_/UN#_S];@_\__VH  -YX  #-@P  PHP
M +F3  "PF   IYT" *"?$@"9GR,!DYXQ!8R=/ N%FT82?YE.&'J75AYUEETC
M<)1C*&R2:BQHD7$P99!Y-&&.@C=>C8PZ6HR7/5B,I#]6B[) 5(O%0%2+X4!4
MBO,_58K^/U6)_SY5B?\^58G_/E6)_SY5B?\^[V\  -9\  #(AP  O9$  +28
M  "JG   H*(  )FD$ "3I2 !C*0N X6C.0E_HD,/>:!,%G2?4QMOG5H@:IQA
M)6:::"ECF6\M7YAW,%N7@#18EHHW5965.5*5HCM0E+ ]3Y3#/4^4WSQ/D_(\
M3Y+]/$^2_SQ/D?\\3Y'_/$^1_SQ/D?\\Y'0  ,^!  #"C   N)8  *V<  "C
MH0  F*@  )"J#0"+JQL A:LJ GZJ-@9XJ4$,<JA)$FVG41AIIE@<9*1?(6"C
M9B5=HFTI6:%U+%:A?B]3H(@R3Y^3-4V?H#=+GJ\X2I[!.$F>W3A)G? X29S\
M.$F;_SE)F_\Y29O_.4F;_SE)F_\YVWH  ,B'  "\D@  L9H  *:@  "<I@
MD:P  (>Q" "!LA8 ?+,F 7:R,P1QLCT):[%'#F:P3Q-BKU887JY='%JM9"!7
MK&LC5*QS)E"K?"E-JH8L2JJ2+TBIGS!&J:TR1:F_,D2JVC)$J.\R0Z?[,T.F
M_S-#I?\T0Z7_-$.E_S1#I?\TT($  ,&.  "UF   J9\  )ZE  "3K   B+(
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M&C/._QHSSO\:LYD  *:A  ":J0  CK$  (&Y  !UP   :L<  %[- P!4U @
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M:@(0_W@"#O^' @[_E@(-_Z0"#/^P @S_O@(,_\("#/_" @S_P@(,_\("A[8
M 'F_  !KR0  7M,  %#;  !#X   ..4  "_P   K_P  )_\( "3_#@ A_Q,
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M.FQJY#IM:_4X;6O_-VUK_S9M:_\V;6O_-FUK_S9M:_\V_UL  .MG  #9<0
MS'D  ,-^ @"[@@, M(0) *V%& "FA2@!GX0U!9F"0 J3?TD0C7U2%HE[61N$
M>6 ?@'=G(WQU;B=Y='4J=G-]+G-RAC%P<9 T;7";-FMOISAI;[4Z:&_'.F=O
MXCIG;_0X:&__-VAO_S9H;_\V:&__-FAO_S9H;_\V_UX  .1J  #3=   R'P
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M-EA^_S58?O\U6'[_-5A^_S58?O\UZ6@  -1T  #&?@  NX<  +*-  "HD0
MGI0  ):6#@"1EQP BY<K H66-P5_E$$*>9-)$'22415PD%@9;(]?'6B.9B%E
MC&TE88MT*%Z*?2Q;B8<O6(B2,56'GS-3AZTU4H>^-5&'UC51ANXU4H7[-%*%
M_S12A?\S4H7_,U*%_S-2A?\SXVP  ,YY  #!@P  MHL  *R1  "BE0  EYD
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M*4"@_RE H/\IR7X  +J+  "OE   HYH  )B@  "-I0  @JH  '6P  !LLPP
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MC04JW)T&*=RM!BC=P08HW=X&)]OO!R;9^0@FV/X))MC^"2;8_@DFV/X)I)T
M )BE  "+K0  ?K0  '&\  !EPP  6<D  $W-  !#TP$ .MD& #7D#0 SY!8
M,>0@ ##E*@ NYC, +>8\ "OG1  JYTP!*.A4 2?H70$EZ6<"(^ES B+J@0(@
MZI$#'^NA QWKL@,<[,<#'.SA QOJ\0,;Z?D#&^GY QOI^0,;Z?D#FJ0  (VL
M  !_M0  <KT  &7%  !9RP  3-   $'5   XW   +^$" "WQ#0 K\1, */(<
M ";R)  D\RL (O0R "'T.0 ?]4$ '?5) !OV40 9]UH!%_=E 17X<@$4^8$!
M$_F2 1+ZH@(1^K,"$/O& A#[W0(0^^D"$/OI A#[Z0(0^^D"CZL  (&T  !S
MO0  9L8  %G-  !+TP  0-D  #7>   LXP  )O$  "3^"@ A_Q  '_\6 !S_
M'  9_R( %_\H !7_+@ 3_S4 $O\\ !#_0P ._TP #?]6  O_8@ )_V\ "/]_
M 0?_D $%_Z !!/^N 03_O $#_\<! __' 0/_QP$#_\<!@[0  '6]  !GQ@
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M+GI:XRYZ6_4M>ES_+'E<_RMZ7/\J>ES_*GI<_RIZ7/\J_U$  /);  #>9
MSVH  ,=N @# < 0 NG , +)Q&@"K<2D!I7 W Y]N0@>:;$L,EFI4$9)H7!6.
M9F,8BV5I&XAC<!Z%8G@A@F%_)(!@B"9]7Y$I>U^<*WA>IRUV7K4N=5[&+W1>
MX2]T7_,N=%__+'1@_RMT8/\K=&#_*W1@_RMT8/\K_U,  .A>  #99P  RVT
M ,-Q 0"[<P( M7,) *UU%P"G=2<!H70T YMR/P>5<$D+D6Y2$(QL612):F 8
MA6EG&X)H;AY_9G4A?65])'IDA29W9(\I=6.:*W)BI2UP8K,O;V+$+VYBWB]N
M8_(N;F/^+6YC_RQN8_\K;F/_*VYC_RMN8_\K_U4  .5@  #3:0  R'   +]T
M  "W=P$ L'<' *AX%0"B>20 G'@R I9V/0:1=$<+C')/#XAP5Q.$;UX7@&UD
M&GUL:QUZ:W,@=VIZ(W1I@R9R:(TI;V>7+&UGHRYK9K$O:6;!,&EFVS!I9_ O
M:6?]+6EG_RQJ9_\K:F?_*VIG_RMJ9_\K_E@  .%C  #/;   Q',  +MX  "S
M>@  JWH$ *1[$@">?"( F'PO I)Z.P6,>$4*AW=-#H-U51)_<UP6>W)B&GAP
M:1UU;W @<FYX(V]M@29M;(LI:FR6*VAKH2YF:Z\O9&J_,&-KV#!C:^\O9&O\
M+61K_RUE:_\L96O_+&5K_RQE:_\L]%L  -UF  #+;P  P'8  +=[  "O?@
MIGX! )]_$ "9@!\ DX M HU_.06(?4,)@WM+#7YZ4Q)Z>%H6=G=A&7-U9QQP
M=&X?;7-V(FIR?R9H<8DH97"4*V)PH"U@;ZTO7V^]+UYOU"]>;^TO7V_[+5]O
M_RQ@;_\L8&__+&!O_RQ@;_\LZUX  -AI  #'<@  O'D  +-_  "K@@  H8(
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M*4^ _RE/@/\IVVH  ,=U  "Z?P  L(<  *:,  "<CP  CY$  (:3!0" E!(
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MD14ZJZ 6.:NP%SBKPQ<XJN$7-ZGS&#>G_ADVIO\:-J;_&C:F_QHVIO\:NH0
M *Z/  "BE@  EYL  (NA  !_I@  <ZL  &>O  !:M   4[8, %&W%P!/MR0
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M B'5N0(AU=("(-/K B#2]@,?T?\$']'_!!_1_P0?T?\$GYL  )2B  "'J0
M>;$  &VX  !@O@  5,,  $G'   ^RP  -= ! "W5!@ EVPL )-X2 "/>'  B
MWR4 (> N "#@-P ?X4  'N%* !WB4P <XUX &^-J !KD>  8Y(@!%^6: 1;F
MK $5YL !%.?= 1/E[P$3X_H!$^/Z 1/C^@$3X_H!EJ(  (FI  ![L0  ;KD
M &'   !4Q@  2,H  #W/   STP  *MD  "+> @ >ZPH '.P0 !OM%P 9[1\
M%^XF !7N+0 4[S4 $_ ] !'P1@ 0\5  #_);  [R:0 -\W@ #/2*  OUG  *
M]:X "?;"  GVV0 (]>T "/7M  CU[0 (]>T BZD  'VR  !ON@  8L(  %7)
M  !'S@  .](  #'8   GW0  '^$  !GH   6^ 8 %/H- !+[$@ 0_!< #OP=
M  W](P ,_2D "OXP  C_.  &_T$  _],  #_6   _V8  /]W  #_B0  _YL
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M'HY*Y1Z-2O8>BTO_'HM+_QV*2_\=BDO_'8I+_QV*2_\=_T4  /]-  #E5
MV5D  ,]; P#*6P8 Q%H/ +M;'@"U7"X!KUL[ JI:1@6F6% (HE99"Y]58 Z<
M4V@1F5)O$Y=1=A654'T7DU"$&9!/C1J.3I8<C$Z?'HI.JA^(3K<@AT[((85.
MXB&$3_,@@T__((-/_Q^"4/\?@E#_'H)0_QZ"4/\>_T<  /-1  #?6   T5T
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M(V];_R)O6_\B;UO_(6];_R%O6_\A^D\  .%:  #/8@  Q&<  +MK  "S;
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M(EQJ_R)<:O\BXUL  ,YF  # ;@  MG0  *QY  "C>P  F'D  )!Z"P"*>Q8
MA7PD (%\,0%\>SL$=WI$!G-Y3 IP>%,-;'=:$&EV81-G=6@69'1O&&%S>!M>
M<H$=7'&,(%IQF")8<*8D5G"U)55PR"55<.4E57#V)%9O_R-6;_\B5V__(E=O
M_R)7;_\BWU\  ,II  "\<@  LG@  *E]  "??P  DGX  (I_!P"$@!, @($A
M 'N!+@%W@#D#<H!"!6Y_2@AK?E$+:'U8#F1\7Q%B>V847WIM%UQY=1E9>'\<
M5WB*'E1WEB%2=J0B47:S(U!VQB10=N,C4'7U(U%U_R)1=/\A473_(5%T_R%1
M=/\AV&,  ,5M  "X=@  KGT  *6"  ":@P  C8,  (2$ P!]A1  >88> '6'
M*P%QAS8";88_!&F%1P=EA$\*8H-6#5^#7 ]<@F,26H%K%5> <QA4?WT:47^(
M'$]^E!]-?J(@2WVQ(4I]Q")*?>$A2WST(4M[_R!+>_\@2WO_($M[_R!+>_\@
MT&<  ,!R  "T>P  JH(  *"&  "5B   AX@  'R*  !VC X <HT: &Z.)P!J
MCC(!9HT\ V.-1 5@C$P(7(M3"EJ+6@U7BF$05(EH$E&(<15/B'H73(>%&DJ&
MDAQ(AJ =1H:O'D6%PAY%A=\>183R'D6#_AY%@O\>18+_'D6"_QY%@O\>RFT
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M#S.ENP\SI=0/,Z3N#S*B^Q RH?\1,J'_$3*A_Q$RH?\1M((  *B,  "=D@
MDI<  (:<  !YH0  ;:4  &&I  !5K   2Z\% $>P$ !%L!P 1+$G $*Q,@!!
MLCL /[)# 3VR2P$[LE,".;); S>R9 0ULFX%,[)Y!C&RAP<OL98(+K*F""VR
MN DLLM (++#L"2NO^0HKKO\+*JW_"RJM_PLJK?\+K8L  *"2  "5F   B9T
M 'VC  !QJ   9*T  %FQ  !-M   0K@  #NZ"@ XNQ, -[P> #6\*0 TO3(
M,[T[ #*]1  QODP +[Y5 2Z^7@$LOF@!*KYT BF^@@(GOY$#)K^B R2_M ,C
MO\L#([[H R.\]P0BN_\%(KO_!2*[_P4BN_\%I)(  )B8  ",G@  @*4  '.K
M  !GL   6[4  $^Y  !$O   .L   ##$!  JQPL *,@3 "?)'0 FR2< )<DP
M "3*.0 CRD( (LM+ "'+50 @S%\ '\QL !W->@ <S8H &\V< !G.K@$8SL4
M&,WD !C,] $8ROP!&,K_ AC*_P(8RO\"FYD  (^?  ""I@  =:T  &BS  !<
MN0  4+T  $3!   YQ   ,,@  "C, 0 @T 8 &=4+ !;7$  5V!D %=DB !39
M*P 3VC0 $]H] !+;2  1W%, $=U? !#=;0 0WGX #M^1  [@I  -X+@ #.#2
M  O?[0 ,WO< #-W[  S=^P ,W?L DI\  (6G  !WK@  :K4  %V\  !0P0
M1,4  #C)   NS0  )=$  ![5   6V@$ $=X& !#G#0 .YQ( #>@9  SH(0 +
MZ2D "NHQ  GJ.P 'ZT4 !>M1  3K7@ #ZVX  >N   #JE   ZJ<  .N\  #K
MT@  Z^D  .SO  #L[P  [.\ AZ<  'FO  !KMP  7KX  %'%  !#R0  -\T
M "W1   CU@  &]L  !/?   .XP  #.X"  KV"@ ']@X !?82  /V&   ]1X
M /4E  #U+@  ]3<  /9"  #V3@  ]ET  /9N  #V@0  ]I4  />G  #WMP
M^,<  /C0  #XT   ^-  >Z\  &VX  !@P   4L@  $3-   WT0  *]<  "'<
M   8X   $>0   SG   '[P  !/H   '_ P  _P@  /\-  #^$   _A0  /\:
M  #_(0  _RD  /\S  #_/@  _TL  /];  #_;   _X   /^2  #_H0  _ZT
M /^S  #_LP  _[, _QPF /\<) #_&B4 _Q4G /\1+@#_$#H _PY' ?\-4P'_
M"U\!_PIK ?\*=0'_"G\!_PJ' ?\*C@'_"I4!_PJ; ?\)H '_":4 _PFK /\)
ML0#_";@ _PG! /X)S #\"=X ^0GK /4)]@#S"?\ \@K_ /$*_P'Q"_\!\0O_
M ?$+_P'Q"_\!_Q\C /\?(0#_'B$ _QDD /\7+ #_%3< _Q-$ /\14 '_$%P!
M_PYG ?\.<@'_#GL!_PZ$ ?\.BP'_#I(!_PZ8 ?\.G0'_#J,!_@ZH ?P.K@'[
M#K4 ^@Z^ /@.R0#U#ML \@[J .X.]0#L#O\!ZP__ >H/_P'J$/\!Z1#_ >D0
M_P'I$/\!_R(? /\B' #_(1P _Q\@ /\?*0#_'#0 _QI  /\73 '_%5@!_Q1C
M ?\3;@'_$W<!_A.  ?P3B 'Z$HX!^1*5 ?@2F@'V$J !]1*F ?02K 'S$K,!
M\1*\ ? 2QP'M$M@!Z1/H >83]0'D%/\!XA3_ N$5_P+A%?\"X!7_ N 5_P+@
M%?\"_R4; /\F%P#_)!8 _R4< /\F)0#_)#  _R$[ /\?2 #_'50!_1M? ?D:
M:0'W&G,!]!E\ ?(9A 'Q&8L![QF1 >X9EP'L&9T!ZQFC >D9J@'H&;$!YQFZ
M >49Q0'C&=4!WQKH =P;]0+8&_\"U1S_ ]0<_P/3'/\$TAS_!-(<_P32'/\$
M_RD7 /\J$P#_*1( _RP8 /\L(0#_+"L _RDW /TG0P#W)4\!\R-: >\B9 'L
M(6X!Z2%W ><A?P'E(88!Y"&- >(@E 'A()H!WR"@ =X@IP'<(:\!VB&X M@A
MPP+5(=,"T2+G LTB] /*(_\$R"/_!<<C_P;&(_\&QB/_!L8C_P;&(_\&_RP2
M /\N#P#_,!  _S,4 /\S&P#_,B4 ^C P /(N/ #L+$D YRI5 >,J7P'@*6D!
MW2ER =HH>@'7*(("U2B) M,HD +1*)8#SRB< \XHHP/,**L#RBBS \DHO@3'
M*,P$Q2GB!,$J\0:^*OX'O"K_"+HJ_PBZ*O\(N2K_";DJ_PFY*O\)_S / /\R
M"P#_-@T _S@0 /\Y%0#Y-QX [S4H .<S-0#@,D( VS)/ -4Q6@'0,60"S3!M
M LLP=0/),'P#QR^#!,4OB@3$+Y$%PB^7!<$OG@:_+Z8&O2^O!KPON0>Z+\<'
MN##=![4P[@FR,/L*L##_"ZXP_PNN,/\+K3#_"ZTP_PNM,/\+_S,, /\V!@#_
M/ D _SX, /T]$ #O/!4 Y#D? -LY+0#2.CP S3I) <@Y5 '$.5X"P3AG [\W
M;P2]-W8%NS9]!KDVA >W-HL'MC62"+0UF@FS-:$)L36J"J\UM NN-<$+K#74
M"ZDVZ@RF-O@-I3;_#J,W_PZB-_\.HC?_#J(W_PZB-_\._S<' /\[ @#_0 ,
M\D(% .E""0#E/PX V#X6 ,Y )P#'038 PD%$ ;U!3P*Y0%D#MC]A!+0^:0:Q
M/7$'KSUX"*X\?PFL/(8*JCN-"ZD[E0RG.YT-I3NF#:,ZL ZB.[P/H#O-#YX[
MYA";//41FCS_$9D\_Q&8//\1F#S_$9@\_Q&8//\1_SH! /]   #O10  X4@
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MAD;]%H9&_Q:%1_\5A4?_%85'_Q6%1_\5_S\  .Q(  #=3P  SU,  ,95  #
M4P, NU$, +-2&0"M4RD J%,V :-20@*?44L$G%!4!IE/7 B63F,*E$UJ#)%,
M<0Z/2W@/C4M_$8M*AQ*)2I 4ATF:%85)I1>#2;$8@DG &(%*UAE_2NT8?DO\
M&'Y+_Q=]2_\7?4O_%GU+_Q9]2_\6_T,  .9,  #64P  R5@  ,!9  "Z6 $
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M&65:_QEE6O\9Z$\  --9  #$80  N68  +!H  "G:0  GF4  )=F#0"19QD
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MDQE4;* ;4FNO'%%KP1Q1:]P<46OQ&U)K_AI2:O\:4FK_&5)J_QE2:O\9U%P
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M%D& NA9 @-(607_M%D%^^Q9!??\607W_%D%]_Q9!??\6PFH  +5U  "J?0
MGX(  )*#  "%A   >84  &J)  !DB@, 8(P0 %V-&P!;CB< 6(XR %6..P%3
MCD,"4(Y* TZ-4@5,C5D&28Q@"$>,: I%BW(,0HM]#D"*B0\^BI@1/(JG$CN*
MN!(ZBL\2.XCK$CN'^A,[AO\3.X;_$SN&_Q,[AO\3O'$  *][  "E@P  F8<
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M R6I]00EJ/\%):?_!26G_P4EI_\%IXD  )N/  "1E   A)D  'B>  !KH@
M7Z8  %.J  !(K0  /;   #2S P OM0X +;46 "RU(  KMBD *K8R "FW.@ H
MMT, )[=, ":X50 DN%\ ([AK "*X> $@N(@!'[B9 1VYJP$<N< !'+C? 1RV
M\@$;M?P"&[3_ ANT_P(;M/\"GX\  )25  "(FP  >Z$  &ZF  !BJP  5K
M $JS   _M@  -;D  "R\   DOP8 '\(- !W"%  <PAX &\,F !K#+P 9Q#@
M&,1! !?$2@ 6Q54 %<5A !3&;P 3QG\ $L:1 !''I  0Q[D #\?4 !#&[@ 0
MQ/H $,/_ !##_P 0P_\ EY8  (N<  !^H@  <:D  &2O  !8M   2[@  $"[
M   UO@  *\$  "/%   ;R0$ %,P& !#0"P .T1$ #=$9  W1(0 ,T2H #-$T
M  O2/@ *TDD "=-5  G38@ (TW( !M2$  74F  $U*L  ]7   '5W  !U>T
M =7V  '5]@ !U?8 CIT  ("D  !SJP  9K$  %FX  !,O0  /\   #3#   J
MQP  (<H  !G.   2T@  #=8!  G;!0 &W T !-P1  /=&  !WB   -XH  #?
M,0  X#P  .%'  #B5   XV,  .-T  #DB   Y)L  .6N  #EP0  Y=4  .;G
M  #FYP  YN< @Z0  '6L  !HLP  6KL  $W!  ! Q   ,\@  "C,   ?T
M%]0  !#9   +W0  !>$   #D    Y0<  .8-  #G$0  Z!8  .D=  #J)0
MZRX  .TY  #O10  \%,  /%D  #Q=@  \HH  /.<  #SK0  ]+L  /3(  #T
MR   ],@ =ZT  &JU  !<O0  3\0  $#)   SS0  )]$  !W6   4W   #N
M  CC   !Y@   .H   #N    [@   .\$  #P"@  \0X  /,2  #T&   ]B
M /@J  #Z-0  _4,  /Y2  #_8P  _W8  /^)  #_F@  _Z8  /^P  #_L
M_[  _Q8C /\5(0#_$2$ _PTD /\)*P#_!C< _P-$ /\ 40#_ %T _P!H /\
M<@#_ 'L _P"# /\ B@#_ )$ _P"6 /\ G #_ *$ _0"F /L K #Y +, ]P"[
M /4 Q0#S -$ \@#D /$ \0#O /H [@#_ .X _P#M /\ [0#_ .T _P#M /\
M_QD@ /\8'0#_%1T _Q ? /\.*0#_##0 _PI! /\'30#_!5D _P1D /\$;@#_
M W< _P.  /\#AP#_ XT _0*3 /L"F0#Y IX ]P*D /4"J@#S ;  \0&X .\!
MP@#M <\ ZP'C .H![P#H OL YP3_ .8%_P#F!O\ Y@;_ .8&_P#F!O\ _QP;
M /\;&0#_%Q@ _Q4= /\3)0#_$3  _Q ] /\.20#_#%4 _PM@ /\+:@#]"W,
M^PM\ /D*@P#W"HH ]0J0 /0*E@#S"IL \0JA .\)IP#M":X ZPFV .@)P #F
M"<T Y GB .(*\ #?"_L W@S_ -P-_P#<#?\ VPW_ =L-_P';#?\!_Q\7 /\>
M$P#_&Q( _QP9 /\;(@#_&"P _Q4X /\31 #^$E  ^1%; /409@#S$&\ \!!W
M .X0?P#L$(8 ZA", .D0D@#H$)@ Y@^> .4/I0#C#ZP X0^T . /O@#>#\P
MVA#A -41\ #2$OL SQ+_ <X3_P'-$_\!S1/_ <P3_P',$_\!_R(2 /\B#P#_
M(0\ _R(4 /\B' #_("< _QTR /@;/@#R&4L [AA6 .H78 #G%FH Y!9R .(6
M>@#@%H( WA:( -P6CP#;%I4 V1:; -86H@#4%JD TA:Q - 7NP#.%\D S!C>
M ,@9[@'%&OL!PQK_ L$;_P+ &_\"P!O_ L ;_P+ &_\"_R8. /\E"P#_* P
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M"I,W_PJ2-_\*DC?_"I(W_PJ2-_\*_S,  /8Z  #D/P  V$(  ,Y" 0#)/@8
MQ#L/ +L^'0"U/RP L3\Z *T_10&I/T\!ICY8 J,]7P.A/6<$GSQM!9T\= :<
M.WL&FCN"!Y@[B@B6.Y,)E3J<"I,ZI@N1.K(+D#O #(X[U0R,/.P-BCS[#8D\
M_PV)//\,B#S_#(@\_PR(//\,_S<  .H_  #<10  SDD  ,5)  "_1@( ND,,
M +-$&0"M12< J$8U *1%00&@14L"G413 II#6P.80V(%ED)I!I1!< >2078(
MD$!^"8Y A@J-0(X+BT"8#(E H@V'0*X.A4"\#X1 SP^"0>D/@4'Y#X!!_P^
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M$'%+_Q!Q2_\0[$,  -E,  #(4P  O5<  +18  "L5P  I5(! )Y3#P"85!P
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MDQ)>6: 475FN%5M9OQ9;6=@66UGO%5M9_11<6?\37%G_$EQ9_Q)<6?\2W%
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M%$UGN11,9\\43&;K%$UF^Q--9O\23F7_$DYE_Q).9?\2S%H  +QC  "P:@
MI6\  )AN  ",;0  @&P  '=M  !Q;@L ;6\4 &EP(0!F<2P 9'$V 6%Q/@%>
M<48"7'!- UEP5 57<%L&56]B"%-O:@I0;G,,3FY^#DQMBA!*;9@126RG$DAL
MN!-';,T31VSJ$TAK^A)(:_\22&K_$4AJ_Q%(:O\1QUX  +AG  "L;@  H7(
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M"S:"]@LV@?\,-H#_##: _PPV@/\,MF\  *IX  "??P  D'X  (-_  !W@
M:X(  %Z'  !5B@  3HP& $J.$ !(CQH 1X\E $60+P!$D#@ 0I!  $"01P$_
MD$\!/9!6 CN07P(YD&@#-X]S!#6/@ 4SCXX&,8^>!S".KP<OCL,'+X[A!R^,
M] @OB_\(+XK_""^*_PDOBO\)L'8  *5_  "8A   BH0  'V%  !PAP  98H
M %J.  !/D@  1I4  $&8#  ^F!0 /9D? #N9*  ZFC$ .9HZ #>:0@ VFDH
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M 1.N_P$3KO\!FHT  )"2  "$EP  =9H  &B?  !;HP  4*@  $6L   [L
M,;(  ">U   @N   &+H' !2\#@ 3O!4 $KP> !&])@ 1O2X $+TW !"^00 .
MODP #KY7  V^90 ,OW0 "[^&  J^F0 (OJP ![["  >^WP (OO  "+WZ  B]
M_  (O?P DY0  (>9  !ZGP  ;*4  &"J  !3KP  1[,  #RV   QN   )[L
M !^^   7P0  $<0!  S("  (R0X !\D4  ;)'  %R20 !,HL  /*-@ "RD
M ,M,  #+60  RV@  ,MY  #,C   RY\  ,NS  #+R   S.(  ,SO  #,\0
MS/$ BIH  'RA  !OIP  8JT  %6S  !(N   .[L  #"^   FP0  '<0  !7(
M   /RP  "LX   32 @  TPH  -,/  #4%   U1H  -8B  #7*@  V30  -H_
M  #<2P  W%H  -UJ  #=?0  W9$  -VD  #>M@  WL@  -[>  #>X@  WN(
M?Z(  '&I  !DL   5K<  $F\   \P   +\0  "3'   ;RP  $\\   W2   '
MU@   -L   #>    WP,  . )  #A#@  XA(  .,7  #E'@  YB<  .@Q  #J
M/0  [$L  .Q:  #M;   [H   .Z4  #NI0  [K0  .["  #NQ@  [L8 =*H
M &:R  !8N0  2\   #W%   OR0  ),T  !G1   1U@  "]L   />    X0
M .4   #H    Z0   .H   #K!@  [0L  .\/  #P$P  \AH  /0C  #W+@
M^3L  /M*  #\6P  _6T  /V   #^DP  _J(  /ZM  #^KP  _J\ _Q ? /\.
M'0#_"AT _P$@ /\ * #_ #4 _P!! /\ 3@#_ %H _P!E /\ ;@#_ '< _P!_
M /X A@#\ (P ^P"2 /D EP#X )P ]P"B /8 IP#U *T \P"U /( O0#Q ,D
M[P#< .X ZP#M /< [ #_ .L _P#J /\ Z@#_ .H _P#J /\ _Q,< /\1&0#_
M#1D _P8< /\#)0#_ #$ _P ^ /\ 2@#_ %8 _P!A /\ :P#] ', ^@![ /<
M@P#U (D ] "/ /( E #Q )D \ "? .X I #M *L [ "R .H N@#H ,8 YP#6
M .4 Z #D /4 XP#^ .( _P#A /\ X0#_ .$ _P#A /\ _Q48 /\3% #_#Q0
M_PT9 /\+(@#_""T _P0Y /\!1@#_ %$ _@!< /H 9@#V &\ \@!W .\ ?@#M
M (4 ZP"+ .H D0#H )8 YP"< .8 H0#D *@ XP"O .$ N #? ,, W0#1 -L
MY@#9 /, UP#] -4"_P#4 O\ U /_ -0#_P#4 _\ _Q@3 /\5$ #_$@\ _Q(5
M /\1'0#_#B@ _PPT /\*00#Y"$P ]097 /$&80#M!FH Z05R .8%>@#D!8$
MX@6' . &C0#?!I( W0:8 -L&G@#9!J4 UP:M -0&M0#2!L  T ?/ ,X(Y0#,
M"?0 R@O_ ,@,_P#'#/\ QPS_ ,8,_P#&#/\ _QL. /\9# #_& T _Q@1 /\7
M& #_%"( ^Q$N /,0.@#M#D8 Z U2 .4-7 #A#64 W@UM -L-=0#8#7P U0V"
M -,-B0#1#8\ T V5 ,X-G #-#J, RPZK ,D.M #(#L  Q@[/ ,,0Y@# $?4
MO1+_ +P2_P"[$O\ NA+_ ;H2_P&Z$O\!_Q\* /\<! #_'P@ _Q\- /\=$@#X
M&AL [A8F .84,P#@$S\ VA-+ -035@#0$U\ SA1H ,L4;P#)%'< QQ5] ,85
MA #$%8H PQ61 ,$6F # %I\ OA:G +P7L "[%[P N1?+ +<8X@"S&?(!L1K_
M :\;_P&N&_\!KAO_ :T;_P&M&_\!_R($ /\B  #_)0( _"0' /<A# #L'1(
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M!X(W_P>"-_\']#(  .,[  #200  QD0  +U#  "W/P  L3L) *H[% "E/"(
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MDPMJ2)\,:$BM#6=)O0UF2=0.94GM#65*_ QE2O\+94K_"V5*_PME2O\+X$0
M ,M-  "]4@  LE8  *95  "<4@  E4X  (Y."0")3Q0 A5 @ (%0+ !^4#<
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M#E95N ]65<P/5E7I#E95^0U65?\-5U3_#%=4_PQ75/\,T4T  ,!6  "S7
MIUX  )I=  "/7   AE@  ']9  !Y6@T =%L7 '%;(P!N6RX :ULW &A;0 %E
M6T<!8UI. F%:50-?6EP$75IC!5Q::P9:670(6%E_"E99BPM469@-4UBF#E)9
MM@Y16<H/45GG#E%8^ U26/\-4EC_#%)8_PQ26/\,S5$  +Q9  "P7P  HV$
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M#$)F]0Q#9O\+0V7_"T-E_PM#9?\+OUP  +%D  "F:@  EFD  (EI  !]:0
M<6D  &=J  !B; $ 76T- %EN%@!7;R$ 57 K %-P-0!1<#T 4'!% 4YP3 %,
M<%,"2G!: TAP8@1&;VL%1&]U!D)O@@= ;H\)/VZ>"CUNKPH];L(*/&[@"CUM
M] H];/\*/6O_"CYK_PH^:_\*NF   *UI  "@;@  D6T  (1M  !X;0  ;&X
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M!"F$_P0IA/\$JG0  )Y[  ".>@  @'H  '1[  !H?@  78$  %*%  !)B0
M08P  #F0!0 UD0\ ,Y(7 #*2(0 QDBD ,),R "Z3.@ MDT$ +)-* "N44@ J
ME%P *)1G ">4<P$EE((!))23 2*3I $AD[<!()// 2&2[ $@D/H"((__ B"/
M_P(@C_\"I'P  )>   "'?P  >X   &Z"  !BA0  5XD  $V.  !"D@  .I8
M #*9   JG D *)T1 ":=&0 EG2( ))XJ ".>,@ BGCH (9Y" "">2P ?GU4
M'I]@ !R?;0 ;GWP &I^- !B?GP 7G[( %I_) !:>Z  6G/< %IO_ 1>;_P$7
MF_\!G8,  (^&  ""A@  =(<  &>+  !;CP  4),  $:8   \G   ,Z   "NC
M   CI@  '*@+ !JI$0 8J1@ %ZDA !:J*0 5JC$ %*HY !.J0P 3JTT $JM8
M !&K90 0JW0 #JN&  ZKF0 -JZP #*O!  RJWP ,J?( #:C\  VH_P -J/\
MEHH  (F,  !ZC0  ;)$  &"5  !4F@  29\  #^C   UIP  *ZH  ".N   ;
ML   %+,!  ^U"@ -MA  #+86  NV'P *MB< ";8O  BV.0 'MT, !K=/  2W
M6P #MVH  K=[  "WC@  MZ$  +:T  "VRP  MN4  +7Q  "U]P  M?< CY$
M (&4  !REP  99P  %BA  !,I@  0:L  #>O   LL@  ([4  !JX   3NP
M#KT   G !0 #P0T  ,$1  #!%P  PAX  ,(F  #"+P  PSD  ,1$  #$4
MQ%X  ,5O  #%@0  Q94  ,6H  #%O   Q-$  ,3F  #$[@  Q.X AI@  'F>
M  !KHP  7:D  %"N  !$LP  -[8  "RY   BO   &;\  !'"   ,Q0  !L@
M  #+    S <  ,P-  #-$0  S18  ,X=  #/)   T"T  -(X  #41   U%(
M -5A  #5<P  UH<  -:;  #6K0  U[\  -C.  #8W0  V-T >Z   &ZF  !@
MK0  4[,  $6X   XO   *[\  "'"   7Q@  $,D   K,   "T    -0   #7
M    V    -H%  #;"P  W X  -X3  #?&0  X2$  .,J  #E-@  YT,  .=3
M  #H9   Z7<  .F,  #JGP  ZJX  .JZ  #JPP  ZL, <*@  &*O  !5M@
M1[P  #G    LQ   (,@  !;,   .T   !]0   #9    W0   .$   #C
MY    .8   #G 0  Z0<  .L,  #L$   [A4  / =  #S)P  ]C,  /=#  #X
M5   ^68  /EZ  #ZC@  ^IX  /NI  #[L   ^[  _PL; /\'&0#_ !D _P <
M /\ )0#_ #( _P _ /\ 2P#_ %< _P!B /\ :P#_ ', _0![ /L @@#Z (@
M^ "- /< D@#V )@ ]0"= /0 H@#S *D \0"P .\ N #N ,, [ #1 .L Y@#I
M /, Z #^ .@ _P#H /\ Z #_ .@ _P#H /\ _PX8 /\*%0#_ 10 _P 8 /\
M(@#_ "X _P [ /\ 1P#_ %, _0!> /H 9P#W &\ ]0!W /, ?@#R (0 \ ")
M .\ CP#N )0 [ ": .L GP#I *4 Z "L .8 M #D +\ XP#, .$ X@#? /
MW@#[ -X _P#= /\ W0#_ -P _P#< /\ _Q 3 /\-$0#_!A  _P(5 /\ '@#_
M "D _P V /\ 0@#Z $X ] !9 /$ 8@#N &L [ !R .H >0#H '\ YP"% .4
MBP#D )  X@"6 .$ G #? *( W0"I -H L0#8 +L U0#( -( W0#1 .T T #Y
M ,\ _P#. /\ S0#_ ,T _P#- /\ _Q$/ /\.#0#_# T _PL2 /\'&0#_ B0
M_P P /8 / #O $D Z@!3 .< 70#D &8 X0!M -\ = #= 'L VP"! -D A@#6
M (P U "2 -( F #0 )X S@"F ,P K@#* +@ R #$ ,8 UP#% .H PP#W ,(
M_P#! ?\ P +_ , "_P#  O\ _Q0+ /\0!@#_$ D _Q . /\.% #_"AX ]08I
M .L$-@#C T( WP-. -L$5P#6!&  TP1H - $;P#.!78 S 5\ ,H%@@#)!8@
MQP6. ,8%E #$!9L P@6C , &JP"^!K4 O0;" +L(U "Z">D MPOX +4,_P"T
M#/\ M S_ +0,_P"T#/\ _Q<$ /\4  #_%@, _Q0) /\1#@#R#A4 Z PA -X*
M+@#6"SL T Q' ,P,40#)#%H Q@UB ,0-:@#"#7$ P UW +\-?0"]#H, O Z*
M +H.D0"Y#I@ MPZ@ +8.J0"T#[0 L@_! +$0U "N$>L JQ+Z *D2_P"H$_\
MIQ/_ *<3_P"G$_\ _QH  /\;  #Y&P  ZQD  .44!@#E$ X V0X7 ,\1)@#(
M$C0 Q!-  +\42P"\%%0 N15= +<59 "U%6L M!5Q +(5> "Q%GX KQ:% *X6
MC "L%I0 JQ>< *D7I@"G&+  IAB] *08SP"B&N< GQKW )T;_P&<&_\!G!O_
M 9L;_P&;&_\!_QT  /<A  #H)   W24  -0A 0#/&P@ RA<1 ,(:( "\'"T
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ME@-[-:$$>36N!'@UO@5W-M0%=C;M!70W_ 5T-_\$=#?_!'0W_P1T-_\$YS4
M -(]  ##0@  N$0  *Q"  "D/@  GSD  )HX#@"4.AD D#HF (T[,0"*.SL
MASM$ (0[3 "".U,!@#I: 7XZ8 %].F<">SIN GDZ=0)W.GX#=CJ(!'0ZDP1R
M.IX%<3JK!6\[NP9N.\\&;3OJ!FT\^@9L//\%;#S_!6P\_P5L//\%XCD  ,Q"
M  "^1P  L4@  *5&  "=0P  ES\  )(^"P"-/Q4 B3\A (5 +0""0#< ?T!
M 'U 2 ![0$\!>4!6 7<_70%U/V,"<S]J G$_<@-P/WH#;C^$!&P_D 5K/YP&
M:3^I!F@_N =G0,P'9D#H!V9 ^09E0/\&94#_!F5 _P5E0/\%W#X  ,=&  "Y
M2P  K$P  *!*  "71P  D4,  (M#" "&0Q( @D0> 'Y$*0![130 >44] '9%
M10!T1$P!<D13 7!$60%N1& ";$-G FM#;P-I0W<$9T.!!69#C09D0YD&8D.G
M!V%$M@A@1,H(8$3F"%]%^ =?1?\'8$7_!F!$_P9@1/\&UD$  ,-)  "V3@
MIT\  )M-  "22P  C$<  (5'! " 1Q  ?$@: 'A()@!U23  <TDZ '!)0@!N
M24D!;$A0 6I(5@%H2%T"9DAD F5(; -C2'4$84=_!6!'B@9>2)<'74BE"%M(
MM A;2,<)6DCD"%I)]@A:2?\'6DC_!EI(_P9:2/\&T44  +],  "R4@  HU$
M )=0  "-3@  ADH  (!* 0!Z2PX =DP7 '),(P!O3"T ;4TV &I,/P!H3$8
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M"4Q4\PA,4_\'3%/_!TU3_P9-4_\&Q4X  +96  "G6@  F%D  (M8  "!5P
M=U0  '!5  !J5@8 9E<0 &)7&@!@6"0 75@N %M9-P!963\ 5UE& %9930%4
M650!4UE; E%98P)/6&P#3EAV!$Q8@@5*6(\&25B>!TA8K@A'6, (1UC="$=8
M\@A'5_\'2%?_!TA7_P9(5_\&P5$  +)9  "C7   E%L  (=;  !]6@  <E@
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M!3AF_P4X9O\%M%X  *=E  "590  AF0  'IE  !O90  9&8  %EH  !2:@
M36P$ $EN#@!';A8 16\@ $1P*0!"<#( 07 Z $!Q0@ _<4D /7%1 #QQ60$Z
M<6(!.'%L C9P> (U<(8#,W"5 S)PI@0Q<+@$,'#0!#%O[ 0Q;OL$,6W_!#%L
M_P0Q;/\$KV0  *%I  "/:   @6@  '5I  !K:0  8&L  %5N  !-<0  1G,
M $)U"P _=A( /7<< #QW)0 Z>"T .7@U #AY/0 W>44 -GE- #5Y50 S>5X
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M:P =C7D '(V* !N-G  9C:X &(S$ !B,XP 9BO4 &8G_ 1F(_P$9B/\!G7<
M (QV  !]=@  <G<  &5Y  !:?   4(   $:$   \B0  -(P  "V0   EDP(
M'Y4, !V6$@ <EAH &Y<B !J7*@ 9ES( &)@Z !>80P 6F$T %9A8 !289  3
MF', $9B$ !"8E@ 0F*D #IB_  Z7W0 /EO( $)7\ !"4_P 0E/\ E7T  (5\
M  !X?   :WX  %^!  !4A@  2HH  $"/   VDP  +9<  "::   >G0  %Z #
M !*B#  0HQ( $*,9  ^C(0 .I"D #J0Q  VD.@ ,I$4 "Z10  JD7  )I&H
M!Z1[  :CC@ $HZ$  J.T  .BRP #HN8  Z'S  .A^P #H?L C8,  '^"  !Q
MA   9(<  %B,  !-D0  0I8  #B:   OG@  )J(  !ZE   7J   $:L   RN
M!P 'KPT  Z\2  *O&0 !KR$  *\I  "P,@  L#P  +!'  "P4P  L&$  +!Q
M  "P@P  KY<  *^J  "OOP  KMD  *[K  "N]   KO0 AXD  'B*  !JC@
M79,  %&8  !%G0  .Z(  #"F   GJ@  'JX  !:Q   0M   "[8   6Y P
MN@H  +H.  "Z$P  NQD  +LA  "\*   O#$  +T\  "^2   OE8  +YE  "^
M=P  OHP  +Z?  "]LP  OL<  +[>  "]ZP  O>L ?Y(  '"5  !BF@  59\
M $FE   ]JP  ,J\  "BT   >M@  %;D   Z\   )OP   L(   #$    Q00
M ,8*  #&#@  QQ(  ,@8  #)'P  RB<  ,PP  #./   SDD  ,]9  #/:@
MSWX  ,^3  #/I@  S[@  ,_(  #/VP  S]L =YP  &BA  !;IP  3JX  $&T
M   TMP  *+H  !V]   3P   #<0   ;'    R@   ,X   #0    T0   -("
M  #3"   U0P  -80  #9%0  VQP  -TD  #@+P  XCP  .-+  #D7   Y&\
M .6#  #EF   Y:D  .6V  #EPP  Y<, ;*4  %^L  !1L@  1+D  #6\   H
MP   ',0  !+(   ,RP   \\   #3    V    -P   #?    WP   .$   #C
M    Y ,  .8(  #H#0  Z1$  .P8  #N(@  \2X  /,\  #T30  ]5\  /9S
M  #WAP  ]YD  /BE  #XL   ^+  _P,7 /\ %0#_ !4 _P 8 /\ (P#_ "\
M_P \ /\ 2 #_ %0 _P!> /\ 9P#] &\ ^P!V /D ?0#X (, ]@"( /4 C@#T
M ), \@"8 /$ G@#P *0 [@"K .T LP#K +T Z@#+ .@ X0#G /$ Y@#] .4
M_P#D /\ Y #_ .0 _P#D /\ _P<3 /\ $0#_ !$ _P 5 /\ 'P#_ "L _P W
M /\ 1 #^ $\ ^@!: /< 8P#T &L \@!R /  >0#O '\ [0"$ .L B@#J (\
MZ "4 .< F@#E *  Y "G .( KP#@ +D W@#& -P V@#: .P V #Y -8 _P#6
M /\ UP#_ -@ _P#8 /\ _PH0 /\##@#_  T _P 2 /\ &@#_ "8 _  R /<
M/P#T $H \0!5 .T 7@#J &8 Z !N .4 = #C 'H X@"  .  A0#> (L W "0
M -L E@#8 )P U0"C -, JP#1 +4 S@#! ,P T0#+ .< R0#U ,@ _P#( /\
MR #_ ,@ _P#( /\ _PP, /\&" #_ @H _P / /\ %0#\ "  \0 L .P .0#I
M $4 Y0!/ .$ 60#> &$ VP!H -< ;P#4 '4 T@![ -  @ #. (8 S ", ,L
MD@#) )@ QP"@ ,4 J ## +$ P0"\ +\ RP"] ., O #R +L _0"[ /\ N@#_
M +H _P"Z /\ _PX% /\)  #_"04 _P8+ /\!$ #P !D Y@ E .$ ,@#< #\
MU@!) -$ 4P#. %L RP!C ,@ :@#& '  Q0!V ,, >P#! ($ P "' +X C@"\
M )0 NP"< +D I "W *X M0"Y +, R "Q -\ L 'O *\!^P"N O\ K0/_ *T#
M_P"M _\ _Q   /\.  #_#0  ]@L# /('"@#B 1$ VP(= -(#*P#, S< R 1#
M ,0$30#!!%8 O@5= +P%9 "Z!6L N 5Q +<%=@"U!7P LP:# +(&B0"P!I$
MKP>9 *T'H0"K!ZL J0BW *@)Q@"F"MT I0OP *,,_0"B#?\ H0W_ *$-_P"@
M#?\ _Q$  /P2  #L$P  XA,  -L/ P#6"0L S@@4 ,8*(@# ##  O T\ +@-
M1@"U#4\ L@Y7 + .7P"N#F4 K0YK *L.<0"J#G@ J Y^ *</A0"E#XT I ^6
M *(0GP"@$*D GQ"U )T1Q0";$=X F1+Q )<3_P"6%/\ E13_ )44_P"4%/\
M_Q4  .T;  #@'P  TA\  ,D;  #$% 4 P1 . +H2&P"T$RD L!0U *P50 "I
M%4D IA52 *0660"B%F  H19F )\6; ">%G( G!9Y )L7@ "9%X@ F!>1 )88
MFP"4&*8 DQFR )$9P0"0&M@ C1ON (L<_0"*'/\ BAS_ (D<_P")'/\ ]!T
M .0E  #3*0  QRH  +PF  "V(   M!D+ *X:%0"H'", I!TO *$>.@">'D0
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M G$OM@)P,,D";S#E FXQ]P)M,?\";3'_ FTQ_P)M,?\"WS(  ,DY  "[/@
MK#T  *$Z  ":-P  E3,  ) Q"@",,10 AS(@ (0S*P"!,S4 ?S,^ 'TS1@![
M,TT >3-4 '<S6@!V,V$ =#-G 7(T;P%Q-'<!;S2! 6XTC )L-)@":C6E FDU
MLP-H-<8#9S;B V8V]0-F-O\"9C;_ F8V_P)F-O\"V#<  ,0^  "U0@  ID$
M )L_  "3/   C3@  (@V!P"$-Q$ @#<< 'PX)P!Z.#$ =SDZ '4Y0@!S.4D
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M!%1#\0140_X#5$/_ U1#_P-40_\#R$(  +A)  "G2P  F$H  (U)  "#1P
M?4,  '9#  !Q1 H ;402 &I%'0!G12< 9$4P &)%. !@13\ 7T5' %U%30!;
M150 6D9; 5E&8P%71FP!5D9V E1&@0-31HX#4D><!%!'JP101[T$3T?6!4]'
M[P1/1_T$3T?_ T]'_P-01_\#Q$4  +5-  "C30  E4P  (E+  !_2@  >$8
M '%'  !L1P< :$@0 &1(&@!A220 7TDM %U)-0!;23T 64E$ %=)2@!625$
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M T)2_P-"4?\#ND\  *I4  "85   B50  'U3  !S4P  :5$  &)2  !<4P
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M< $N:GX!+6J. 2QJGP$K:K !*FK& 2IIY0$J:/8"*V?_ BMG_P(K9_\"J6$
M )5@  "$8   =V   &QA  !B80  6&,  $YF  !':   0&L  #IN!0 V;PX
M-' 5 #-P'@ R<28 ,'$N "]Q-0 N<CT +7)% "QR30 K<E< *G)A "ER;0 G
M<GL )G*+ "1RG $C<JX!(W+# 2-QX@$C</0!(V__ 2-N_P$C;O\!H64  (YD
M  !_9   <F0  &AE  !>9@  5&D  $EL  !";P  .W(  #1U   N> H *WD1
M "IY&  I>B$ )WHH "9Z,  E>S@ )'M  "-[2  B>U( (7M< "![:  ??'8
M'7R& !Q[F  ;>ZH &GN_ !I[W@ :>?( &WC^ !MW_P$;=_\!F6D  (AI  !Y
M:0  ;6D  &-J  !9;   3V\  $5S   ]=P  -7H  "Y]   G@0, (H,- ""$
M$@ ?A!H '80B !R%*@ ;A3$ &H4Y !F%0@ 8ADP %X96 !:&8P 5AG$ %(:!
M !*&DP 1AJ8 $86[ !"%U@ 1@^\ $8+[ !*"_P 2@?\ D6X  (%M  !T;@
M:6X  %UP  !3<P  27<  $!\   W@   +X,  ">'   AB@  &HT& !6/#0 3
MD!, $I : !*0(@ 1D"H $)$R !"1.P /D40 #I%/  V17  ,D6H "Y%Z  J1
MC0 (D)\ !Y"S  >/R0 'C^8 !X[T  B-_  (C?\ B7,  'MS  !O<P  8W4
M %=X  !-?0  0X$  #F&   PB@  *(X  "&1   :E0  $Y<   Z:"  +G X
M"9P3  B<&@ 'G"( !IPJ  2<,P #G#T  IU(  "=5   G6(  )QR  "<A
MG)<  )NJ  ";OP  FML  )KL  ":]0  F?@ @GD  '9Y  !H>@  7'X  %&"
M  !&AP  /(P  #*1   IE0  (9D  !F=   2H   #J,   FF!0 #IPP  *<0
M  "G%0  J!P  *@C  "H*P  J30  *D_  "I2P  J5D  *EH  "I>@  J8X
M *FA  "HM0  J,L  *?D  "G[P  I_, ?8   &^!  !AA   58D  $F.   ^
ME   -)D  "J>   AH@  &:8  !*I   -K   !Z\   "R    LP<  +,,  "S
M$   M!4  +0;  "U(@  MBL  +<U  "W0   N$X  +A=  "X;@  N((  +B7
M  "XJ@  M[X  +?2  "WY@  M^H =H@  &>+  !:D   3I8  $*<   WH@
M+*<  "*K   9KP  $;,   NV   $N0   +P   "^    O@   +\&  # "P
MP0\  ,(3  ##&0  Q"   ,4I  #'-   R$(  ,E1  #)8@  R74  ,F*  #)
MGP  RK$  ,K!  #)T0  R=D ;I,  &"8  !3G@  1J0  #JK   OL   )+4
M !FX   0O   "K\   '!    Q    ,@   #*    R@   ,P   #- P  S@@
M - -  #1$   TQ8  -8>  #:*   W30  -Y#  #?5   WV<  .!\  #@D0
MX*0  ."R  #@O@  X,, 9I\  %FF  !,K0  /[0  #*X   DO   &+\  !##
M   (QP   ,H   #-    T0   -4   #8    V0   -L   #=    WP   .$$
M  #C"@  Y0X  .<3  #J'   [2<  / U  #Q1@  \E@  /-K  #S@   ])0
M /2C  #TK@  ]+( _P 3 /\ $0#_ !$ _P 5 /\ 'P#_ "P _P Y /\ 10#_
M %  _P!: /X 8P#[ &L ^0!R /< > #U 'X ] "$ /( B0#Q (X \ "3 .X
MF0#M )\ [ "F .H K@#H +@ Y@#% .4 VP#C .T X@#[ .( _P#A /\ X0#_
M .$ _P#A /\ _P 0 /\ #@#_  T _P 2 /\ &P#_ "@ _P T /X 00#[ $P
M]P!6 /0 7P#Q &8 [P!M .P = #J 'H Z0!_ .< A0#F (H Y0"/ ., E0#A
M )L X "B -X J@#; +0 V0#  -8 T #3 .@ T@#W -$ _P#1 /\ T #_ -
M_P#0 /\ _P - /\ "0#_  H _P / /\ %@#[ "( ]P O /0 .P#P $< [0!1
M .D 6@#E &( X@!I .  ;P#> '4 W !Z -H @ #8 (4 U0"+ -, D0#1 )<
MSP"> ,T I@#+ *\ R0"Z ,< R0#% .( Q #R ,, _@#" /\ P0#_ ,( _P#"
M /\ _P,& /\  0#_  8 _P , /D $0#Q !T ZP I .< -@#C $$ WP!+ -L
M5 #5 %P T@!C ,\ :@#- '  RP!U ,D >P#( (  Q@"& ,4 C ## ), P0":
M +\ H@"] *L NP"V +D Q "W -H M@#M +0 ^@"T /\ M #_ +0 _P"T /\
M_P0  /\   #_    _P & .P #0#E !8 W@ B -< +P#1 #L S0!% ,H 3@#&
M %< Q !> ,$ 9 "_ &H O0!P +P =0"Z 'L N0"! +< AP"U (X LP"5 +(
MG@"P *< K@"R *P OP"J -$ J #H *@ ]P"G /\ IP#_ *8 _P"F /\ _P8
M /\%  #Q P  Z    .$ !P#5 !  S0 ; ,< )P## #, OP ^ +P 2 "Y %$
MM@!8 +0 7P"R &4 L !J *\ < "M '8 K !\ *H @@"I (D IP"1 *4 F@"C
M *0 H0"N *  NP"> <T G0+F )P$] ";!/\ F@7_ )H%_P"9!?\ _PH  /$.
M  #D$   V0\  ,X+  #( PL P@ 3 +P"'P"W RP LP0W + %0@"M!DH J@92
M *@'60"F!U\ I0=E *,':P"B"'$ H AW )\(?@"="(4 FPF. )H)EP"8"J$
ME@JL )4+N@"3"\P D@SE ) -]@"/#O\ C@[_ (X._P"-#O\ ]A$  .87  #6
M&P  QQD  +X5  "Y$   MPH- +$+%P"L#20 J XP *4..P"B#D0 GP], )T/
M4P";#UH F@]@ )@09@"7$&P E1!R ),0>0"2$($ D!"* (\1E "-$9\ BQ&J
M (H2N "($LL AA/F (44]P"#%?\ @Q7_ ((5_P""%?\ [1H  -PA  #*)0
MNR(  +$?  "K&@  J10& *42$0"@%!X G!4J )D5-0"6%CX E!9' )(63@"0
M%E4 CA=; (P780"+%V< B1=M (@7= "&&'P A1B& (,9D "!&9L @!JG 'X:
MM0!]&\< ?!SB 'H=]0!Y'?\ >!W_ '@=_P!X'?\ Y2(  - I  "_+   L"H
M *<G  "@(P  G1\  )H:#@"5'!@ D1TD (X>+P",'CD B1Y! (<?20"%'U
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M 6 P[P%?,/T!7S#_ 5\P_P%?,/\!S30  +P[  "I.@  FSH  ) X  ")-0
M@S(  '\P 0![+PX =S 6 '0P(0!Q,2L ;S$T &TQ/ !K,4, :C%* &@R4 !G
M,E< 93)= &0R90!B,FT 83-W %\S@@%>,XX!732< 5LTJ@%:-;L!6C72 5DU
M[0%9-?P!6#7_ 5@U_P%9-?\!R#@  +<^  "D/@  ECT  (L\  "#.@  ?3<
M '@T  !T- L <#43 &TU'0!J-2< :#8P &8V. !D-C\ 8S9& &$V30!@-E,
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M/04 9#T. &$^%P!>/B$ 7#XI %H^,0!8/CD 5SY  %4_1@!4/TT 4S]5 %)
M7 !00&4 3T!O 4Y!>@%-08<!2T&6 4I!I0))0K4"24++ DE"Z ))0OD"24'_
M DE!_P%)0?\!O4,  *I%  "810  BD4  ']%  !V0P  ;T   &A   !C00$
M7T$- %Q!% !90AT 5T(F %5"+@!30C8 44(] $]"0P!/0TL 3D-2 $U$6@!,
M1&, 2D1M 4E%> %(184!1T64 45%HP)%1K0"1$;) D1&YP)$1?@"1$7_ D5%
M_P)%1?\!ND8  *9(  "42   AD@  'M'  !R1@  :D(  &-#  !>1   6D4+
M %9%$@!41AL 448C $]&*P!.1C, 3$<Z $M'00!*1TD 24A0 $A(6 !'2&$
M1DEK $1)=@%#28,!0DF2 4%)H@) 2;,"/TK' C]*Y0(_2?<"0$G_ D!(_P)
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M<@ Y4G\!.%*. 3=2G@$V4J\!-5+$ 352X@$V4O4!-E'_ 390_P$W4/\!KD\
M )E/  ")3P  >T\  '!/  !F3P  7$X  %1/  !/40  2E(! $93# !#5!(
M050; $!5(P ^52L /58R #Q6.@ [5D$ .E9) #E740 X5UH -E=C #57;P T
M5WP!,U>, 3%7G $P5ZT!,%?" 3!7X $P5O0!,5;_ 3%5_P$Q5?\!J%(  )52
M  "$4@  =U(  &Q2  !B4@  6%,  $]4  !)5@  1%<  $!9"  ]6A  .UH7
M #E;(  X6R< -UPO #9<-@ U7#X -%Q& #-=3@ Q75< ,%UA "]=;  N77H
M+%V) "M=F@$J7:L!*EV_ 2E=W@$J7/(!*EO^ 2M;_P$K6O\!HU4  (]5  !_
M50  <E4  &=6  !>5@  5%<  $Q9  !%6P  /UT  #I?!  V8 T -&$3 #)B
M'  Q8B, ,&(K "]C,@ N8SH +6-" "QC2@ J9%, *61= "AD:0 G9'8 )F2&
M "5DEP D9*D (V2] ")DV@ C8_$ (V+] 21A_P$D8?\!G%@  (E8  !Z60
M;ED  &-9  !:6@  4%P  $A>  !!8   .F,  #1F   O: H +&D0 "II%P I
M:A\ *&HF "=J+@ F:S4 )6L] "1K1@ C:T\ (FQ9 "!L90 ?;'( 'FR" !UL
ME  <;*8 &VNZ !IKU  ;:NX '&G\ !QH_P <:/\ E5P  (-<  !U7   :5T
M %]=  !67@  3&$  $-D   \9P  -6H  "]M   H< 0 (W(- "%R$@ @<QH
M'W,A !YS*  ==#  ''0X !MT0  :=$H &714 !=U8  6=6X %75^ !1UD  3
M=*( $G2V !%TSP 2<^P $G+Z !-Q_P 3<?\ CF   'U@  !O80  96$  %MB
M  !19   2&<  #YK   W;@  ,'$  "EU   B>   ''L' !=]#@ 6?1, %7T;
M !1^(@ 3?BH $GXQ !%^.@ 1?D0 $'].  ]_6@ .?V@ #7]X  Q_B@ +?IT
M"GZP  E]Q@ *?>0 "GST  M[_0 +>O\ AF4  '=E  !J90  868  %9H  !,
M:P  0F\  #ES   Q=P  *GH  "-^   <@0  %80  !"'"  -B0X #(D4  R)
M&P +B2, "HDK  F),P (B3T !HE(  6)5  $B6$  HEQ  &)@P  B98  (BI
M  "'O@  A]H  (;L  "&]0  AOH ?FH  '%J  !G:P  6VP  %!P  !&=
M/'@  #-]   J@0  (X4  !R(   5C   $(\   R2!@ &DPP  I,1  "4%@
ME!T  )0D  "5+   E34  )5   "53   EED  )9I  "5>@  E8X  )2A  "4
MM0  D\P  )+F  "2\@  DO< >'   &UP  !@<@  5'4  $EY   _?@  -8,
M "R(   CC0  &Y$  !24   /EP  "IH   2= P  G@D  )\.  "?$@  H!<
M * =  "A)0  HBT  *(W  "C0P  HU   *-?  "C<0  HX0  **9  "BK0
MH<(  *'<  "AZP  H/( <W8  &9W  !9>P  38   $*%   XBP  +I   "25
M   ;F@  %)X   ZA   )I    J<   "J    JP0  *L*  "L#0  K1$  *T6
M  "N'   KR0  + M  "Q.0  L48  +)5  "R9@  LGD  +*.  "QHP  LK<
M +'*  "QX   L>D ;'X  %^"  !2AP  1HT  #N3   PF0  )IX  !RC   3
MIP  #:L   >N    L@   +4   "W    N    +D"  "Y"   N@P  +L0  "\
M%   O1L  +\C  #!+0  PCH  ,))  ##6@  PVP  ,2"  #$EP  Q*L  ,2\
M  #$RP  Q-H 98D  %B.  !+E0  /YL  #.B   HJ   ':T  !2Q   -M@
M!KD   "\    OP   ,,   #$    Q0   ,8   #'    R00  ,H)  #+#0
MS1$  ,\8  #2(0  U2T  -8\  #830  V5\  -IS  #:B@  VYX  -NN  #;
MN@  W,, 7I8  %&<  !$HP  .*H  "RQ   @MP  %;L   V^   $P@   ,4
M  #)    S0   -    #2    T@   -4   #6    V0   -L   #>!0  X H
M .(/  #E%@  Z"   .PM  #M/@  [5$  .YE  #O>@  [X\  /"?  #PJP
M\+, _P 0 /\ #@#_  X _P 2 /\ '0#_ "D _P U /\ 00#_ $T _@!6 /L
M7P#X &8 ]@!M /0 = #R 'D \0!_ /  A #N (D [0"/ .L E0#J )L Z "B
M .8 J@#E +, XP#  .$ T@#@ .H WP#Y -T _P#= /\ W0#_ -X _P#> /\
M_P - /\ "@#_  D _P / /\ & #_ "0 _@ Q /L /0#X $@ ] !2 /  6@#M
M &( ZP!I .D ;P#G '4 Y0!Z ., ?P#B (4 X "* -X D #< )8 V@"= -@
MI0#5 *\ T@"Z -  R@#. ., S0#T ,L _P#+ /\ RP#_ ,L _P#+ /\ _P (
M /\  P#_  4 _P , /P % #W !\ \@ K .\ -P#K $( YP!, .0 50#@ %T
MW0!D -H :@#8 '  U0!U -( >@#0 (  SP"% ,T BP#+ )( R0"9 ,< H0#%
M *H PP"U ,$ PP"_ -H O@#N +T _ "\ /\ O #_ +P _P"\ /\ _P   /\
M  #_    ^0 ' /$ $ #J !H Y  E -\ ,0#; #P UP!' -( 4 #. %< RP!>
M ,D 90#& &H Q0!P ,, =0#! 'H P "  +X A@"\ (T N@"4 +D G "W *4
MM0"P +, O0"Q ,\ KP#H *X ^ "N /\ K0#_ *T _P"M /\ _P   /\   #]
M    [@ ! ., # #: !0 T0 ? ,P *P#( #8 Q0!  ,( 2@"_ %( O !9 +H
M7P"X &4 M@!J +0 ;P"S '4 L0!Z +  @0"N (@ K0"/ *L F "I *$ IP"K
M *4 N "C ,@ H@#B *$ \P"@ /X H #_ *  _P"@ /\ _P   /8   #J
MX    -, !@#)  \ P@ 8 +T ) "Y "\ M@ Z +0 0P"Q $P K@!3 *P 60"J
M %\ J0!D *< :@"F &\ I !U *, >P"A (( H "* )X DP"< )T F@"G )@
MM "6 ,, E0#< )0 [P"3 /L DP#_ ), _P"2 /\ ^04  .H+  #<#0  RPH
M ,(%  "\  H M@ 1 +$ ' "N "@ J@ S *< /0"D $4 H@!- *  4P"> %D
MG !? )L 9 ": &H F !P )< =@"5 'X DP"& )(!CP"0 9D C@*D (P"L0"+
M \  B076 (@&[0"(!_H APC_ (8(_P"&"/\ [P\  -X4  #*%0  O!(  +,0
M  "N#   JP8- *<#%0"B!2  GP<L )P(-@"9"#\ EPE' )4)3@"3"50 D0I:
M ) *7P"."F4 C0IK (L*<@"*"WD B N" (<+C "%#)< @PRB ($-L " #<
M?PW8 'T.[P!\#_T >P__ 'L0_P![$/\ YA<  -$>  "]'0  KQP  *89  "A
M%0  GA $ )T-#P"8#AD E XE )$/+P"/$#D C!!! (H02 "($$\ AQ!5 (40
M6P"$$6$ @A%G ( 1;@!_$74 ?1%^ 'P2B !Z$I0 >!*@ '<3K@!U$[X =!35
M ',5[@!Q%OT <1;_ '$6_P!P%O\ W!\  ,8E  "S)0  I2,  )PA  "6'@
MDAD  )$4"P"-%!0 B14? (86*0"#%C, @1<\ ( 70P!^%TH ?!=0 'H75@!Y
M&%P =QAB '88:0!T&'$ <QEZ '$9A !O&I  ;AJ= &P;JP!K'+L :AS0 &D=
M[ !H'OL :![_ &<>_P!G'O\ T28  +TJ  "K*@  G2H  ),H  "-)0  B"(
M (8=!@"#&Q  ?QP: 'P=) !Z'2X =QXV '8>/@!T'D4 <A]+ '$?40!O'U@
M;A]> &P?90!K(&T :2!V &@A@0!F(8T 92*: &,BJ !B([@ 82/- & DZ0!@
M)/H 7R3_ %\D_P!?)/\ RBP  +8O  "D+P  EB\  (PM  "%*@  @"@  'TD
M  !Z(@T =B,5 ',C( !Q)"D ;R0R &TD.@!K)4$ :B5' &@E30!F)50 925:
M &0F80!B)FD 829R %\G?0!>)XH 72B7 %LII0!:*;4 6BK* %DJYP!8*O@
M6"K_ %@J_P!8*O\ Q3$  *\S  ">,P  D#,  (8R  !_+P  >2T  '4J  !R
M* H ;R@2 &LI&P!I*24 9RHM &4J-0!C*CT 8BI# & J2@!?*U  7BM7 %PK
M7@!;+&8 62QO %@M>@!7+8< 5BZ5 %0NHP!3+[, 4R_' %(OY0!2+_< 4B__
M %(O_P!2+_\ P38  *HV  "9-@  BS8  ($U  !Y,P  <S$  &\O  !K+@8
M:"T0 &0N& !B+B$ 8"\J %XO,0!<+SD 6R]  %DO1@!8+TT 5S!3 %8P6P!4
M,6, 4S%L %(R=P!1,H0 3S.2 $XSH0!-,[$ 333% 4PTXP%,-/8 3#3_ $PT
M_P!,,_\ NSD  *8Y  "5.0  ASD  'PY  !T-P  ;C0  &DS  !E,@( 83(-
M %XR% !<,QX 6C,F %@S+@!6,S4 530\ %,T0P!2-$H 4310 % U6 !.-6
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M<0!!/WX 0#^- #] G  ^0*T!/4#  3U W0$]0/(!/4#_ 3X__P$^/_\!KD
M )I   ")00  ?$$  '%!  !H0   83P  %L]  !6/@  4CX% $X_#@!,/Q4
M23\= $= )0!&0"P 1$ S $- .@!"04( 04%) $!!40 _0EH /D)C #U#;P \
M0WP .T.+ #I$FP Y1*L!.42^ 3A$VP$Y1/$!.4/^ 3E#_P$Y0_\!JD(  )9#
M  "&0P  >$,  &Y#  !E0P  74   %9   !10@  34(" $E## !&0Q( 1$0:
M $)$(@!!1"H /T4Q #Y%.  ]13\ /$9' #M&3P Z1E< .4=A #A';  W1WH
M-DB) #5(F0 T2*H -$B] #-(V0 T2/  -$?] #1'_P U1O\ ID0  ))%  ""
M1@  =48  &I&  !A10  640  %%$  !,1@  2$<  $1'"@!!2!  /TD8 #U)
M(  \22< .DHN #E*-@ X2CT -TM$ #9+3  U2U4 -$Q? #-,:@ R3'< ,4R&
M #!,EP O3:@ +DV[ "Y-U0 N3.\ +TS] "]+_P P2_\ H4<  (Y(  !^2
M<4@  &9)  !=2   54@  $Q)  !'2@  0DL  #],!@ [30X .4X5 #=.'0 V
M3R0 -4\K #-/,P R4#H ,5!" #!02@ O45( +E%< "U19P L474 *U&$ "I2
ME0 I4J8 *5*Y "A2T@ I4>X *5#\ "I0_P J3_\ G$H  (E*  !Z2P  ;4L
M &-,  !:3   44P  $A-  !#3P  /5   #E2 @ U4PP ,U02 #%4&0 P52$
M+E4H "U5+P L5C< *U8^ "I61@ I5D\ *%=9 "=79  F5W( )5>! "17D@ C
M5Z0 (E>W ")7SP B5^P (U;Z "-5_P D5?\ EDT  (1.  !U3@  :4X  %]/
M  !63P  35   $52   _4P  .58  #-8   O6@@ *UL/ "I;%0 H7!T )UPD
M "9<*P E7#, )%TZ "-=0P B74P (5U6 "!>80 ?7FX 'EY^ !U>CP <7J$
M&UZT !I=S  ;7>D &USY !Q;_P <6_\ D%$  'Y1  !P40  9%(  %M2  !2
M4P  2E0  $%7   [60  -5L  "Y>   H8 , )&(, ")C$0 A8Q@ 'V0@ !YD
M)P =9"X '&0V !ME/@ :94< &651 !AE70 796H %F5Z !5EBP 499X $V6Q
M !)ER  29.< $V/W !1B_P 48O\ B50  'A5  !K50  8%8  %=6  !/5P
M1ED  #U<   V7P  ,&(  "ED   C9P  '6H' !EL#@ 8;!, %FT: !5M(0 4
M;2D %&TP !-M.0 2;D( $6Y, !!N6  /;F4 #FYU  UNAP -;IH #&VM  MM
MP@ +;.  #&OS  UK_0 -:O\ @ED  ')9  !F60  7%H  %1:  !*7   05\
M #EC   Q9@  *FD  "1L   =;P  %W(  !)U"0 /=P\ #G<4  YW&P -=R,
M#'<J  MW,P *=SP "7='  AW4@ '=U\ !7=O  1W@  #=Y0  7:G  !VNP !
M==4  73K  )T]@ "=/P >UT  &U=  !B7@  65X  $Y@  !%8P  /&<  #-K
M   K;@  )'(  !YU   7>0  $GP   U_!@ )@0P !8$1  .!%@ "@1T  8$D
M  "!+0  @C8  ()   ""3   @ED  ()H  "">0  @HT  (&@  " M   @,L
M '_G  !^\@  ?OD =&(  &AB  !>8@  4V0  $EG   _:P  -G   "UT   E
M>   'GP  !>    1@P  #88   B)!  "BPH  (L.  "+$P  C!@  (P?  "-
M)@  C2\  (XY  ".1   CE$  (Y@  ".<0  CH4  (Z9  "-K0  C,,  (S?
M  "+[@  B_8 ;F@  &1G  !8:0  36P  $)Q   X=@  +WL  "9_   >A
M%H@  !",   ,CP  !I(   "5    E@<  )<,  "7#P  F!,  )D8  ":'P
MFR8  )LP  "<.P  G$@  )Q7  "<:   G'L  )R0  ";I0  F[H  )K0  ":
MYP  FO$ :FT  %YO  !1<@  1G<  #M\   Q@@  )X<  !Z,   6D0  $)4
M  J9   $G    *    "B    HP$  *,&  "D"P  I0X  *82  "G%P  J!X
M *HF  "K,0  JSX  *Q-  "L70  K'   *R%  "LFP  JZ\  *O#  "KV0
MJN@ 9'4  %=Y  !+?@  /X0  #2*   ID   'Y8  !:;   0GP  ":,   &G
M    J@   *X   "P    L    +$   "R P  M @  +4-  "V$   MQ4  +D=
M  "[)@  O#,  +U!  "]4@  O60  +YY  "^D   O:0  +VW  "]Q@  O=<
M7'\  %"%  !$BP  .)(  "R9   AGP  %Z0  !"I   )K@   +(   "V
MN0   +T   "_    OP   ,    #!    PP   ,0%  #&"@  QPX  ,D3  #+
M'   SB8  - U  #110  TE<  -)K  #3@@  TY<  -.I  #2N   TL0 58P
M $F3   ]F@  ,*(  "6H   :K@  $;0   FY    O0   ,$   #$    R
M ,L   #-    S0   ,\   #0    T@   -0   #8    V@8  -T,  #@$0
MXQH  .8G  #G.   Z$H  .E=  #J<@  ZX@  .N;  #LJ   [+( _P - /\
M"P#_  L _P 0 /\ &@#_ "8 _P R /\ /0#_ $@ ^P!2 /@ 6@#V &( \P!I
M /$ ;P#P '4 [@!Z .P ?P#K (0 Z0"* .@ D #F )8 Y "= .( I0#A *\
MWP"[ -T RP#; .8 V0#W -@ _P#8 /\ UP#_ -< _P#4 /\ _P ( /\ ! #_
M  0 _P - /\ %0#^ "$ ^@ L /< . #T $, \ !- .T 50#J %T YP!D .0
M:@#B '  X !U -X >@#= '\ VP"% -D BP#5 )$ TP"9 -$ H #/ *H S0"U
M ,L Q #) -T R #Q ,< _P#& /\ Q@#_ ,8 _P#' /\ _P   /\   #_
M_P * /@ $0#Q !P [  G .D ,@#F #T X@!' -T 4 #9 %@ U0!? -( 90#0
M &H S@!P ,P =0#* 'H R0!_ ,< A0#% (P PP"4 ,$ G "_ *4 O0"P +L
MO0"Z -  N #K +< ^P"V /\ M@#_ +8 _P"V /\ _P   /\   #]    \P %
M .D #@#A !8 VP A -4 +0#1 #< S@!! ,H 2@#' %( Q !9 ,( 7P#  &4
MO@!J +P ;P"[ '0 N0!Z +< @ "V (< M ". +( EP"P *  K@"J *T MP"K
M ,@ J0#C *@ ]0"G /\ IP#_ *< _P"F /\ _P   /X   #Q    Y0   -<
M"@#- !$ QP < ,( )@"_ #$ O  [ +H 1 "W $P M !3 +( 60"Q %\ KP!D
M *T :0"L &\ J@!T *D >@"G ($ I@") *0 D0"B )L H "E )X L@"= ,$
MFP#: )H [P"9 /T F #_ )@ _P"8 /\ _0   /    #A    T0   ,8 ! "]
M  T MP 5 +, ( "P "L K0 U *L /@"H $8 I@!- *0 5 "C %D H0!? *
M9 "> &D G0!N )L =0": 'L F "# )8 C "5 )8 DP"A )$ K0"/ +L C0#/
M (P Z0"+ /@ C #_ (P _P", /\ \P(  .('  #,!P  OP0  +<   "Q  @
MJP 0 *< &0"D "0 H  N )X -P"< $  F@!' )@ 3@"6 %0 E0!9 ), 7@"2
M &0 D !I (\ ;P"- '8 BP!^ (H B "( )( A@"= (4 J0"# +@ @0#* (
MY0"  /4 ?P#_ '\ _P!_ /\ Z T  - 0  "^$   L0X  *@-  "C"   H (,
M )P $P"8 !T E0 G )( ,0"0 #D C@%! (P!2 "* DX B0)4 (<"60"& E\
MA -D (,#:P"! W( @ 1Z 'X$A !]!8X >P6: 'D&IP!X!K4 =@?( '4(XP!U
M"?0 = K_ ',*_P!S"O\ W14  ,07  "Q%P  I18  )P3  "6$0  E T$ ),(
M#0".!Q4 BPD@ (@)*@"%"C, @PL[ ($+0@" "TD ?@M/ 'T,5 ![#%H >@Q@
M '@,9P!W#&X =0UV '0-@ !R#8P < V9 &\.I@!M#K4 ; [) &L/Y@!J$/<
M:1#_ &D0_P!I$/\ T!T  +D>  "H'@  FQT  )(;  "+&0  B!4  (<1!P"%
M#A  @0\: 'X0) ![$"T >1 V '<1/0!V$40 =!%* ',14 !Q$58 <!%< &X2
M8@!M$FH :Q)S &D3?0!H$XD 9A.6 &44HP!C%;, 8A7& &(6XP!A%O8 8!?_
M & 7_P!@%_\ QR(  + C  "?)   DB,  (DB  ""(   ?AT  'P9  !Z%0T
M=Q45 '06'P!Q%B@ ;Q<P &X7. !L%S\ :Q=% &D82P!H&%$ 9AA8 &487@!C
M&68 8AEO & 9>0!?&H4 71N2 %P;H0!;'+  6AS# %D=X !8'O0 6![_ %@>
M_P!8'O\ OR<  *DH  "9*   BR@  ((G  ![)0  =B,  ',@  !Q' D ;AP1
M &L<&@!I'2, 9QTL &4=,P!C'CH 8AY! & >1P!?'DT 7AY4 %P?6P!;'V(
M62!K %@@=@!6(8( 52&0 %0BG@!3(JX 4B/  %$CW0!1)/( 423_ %$D_P!1
M(_\ N2L  *,L  "3+   ABT  'PL  !T*@  ;R@  &LE  !I(@4 9B$. &,B
M%@!A(A\ 7R,G %TC+P!<(S8 6B,] %DD0P!7)$H 5B10 %4D5P!3)5\ 4B5H
M %$F<P!/)G\ 3B>- $THG !,**P 2RF^ $LIV@!**?$ 2BG_ $LI_P!+*?\
MLRX  )XO  ".,   @3   '<O  !O+@  :BL  &4J  !C)P$ 7R<, %PG$P!:
M)QL 6"@D %8H*P!5*#( 4R@Y %(I0 !0*48 3RE- $XI5 !-*EP 3"IE $HK
M< !)*WP 2"R+ $<MF@!&+:H 12Z\ $4NU@!%+N\ 12[^ $4N_P!%+?\ KC$
M )HR  "),P  ?#,  '(S  !K,0  92\  & M  !=+   62P) %8L$ !4+!@
M4BP@ % L* !.+2\ 32TV $PM/ !*+4, 22U* $@N40!'+ED 1B]C $4P;0!#
M,'H 0C&) $$QF !!,J@ 0#*[ #\RTP _,NX 0#+] $ R_P! ,O\ JC,  )8U
M  "&-0  >38  &XU  !F-0  83(  %PP  !7,   5# & %$P#@!.,!4 3#$=
M $HQ)0!(,2P 1S$R $8Q.0!$,4  0S)' $(R3P!!,U< 0#-@ #\T:P ^-7@
M/36' #PVE@ [-J< .S:Y #HVT0 Z-NT .S;\ #LV_P [-O\ IC8  )(W  ""
M.   =3@  &LX  !C-P  738  %<S  !3-   3S0# $LT# !)-!( 1C4: $4U
M(@!#-2D 034O $ U-@ _-CT /C9$ #TW3  \-U4 .SA> #HX:0 Y.78 .#F%
M #<ZE0 W.J4 -CJX #4ZSP V.NP -CK[ #8Y_P W.?\ HC@  (XY  !^.@
M<CL  &@[  !?.@  63D  %,V  !.-P  2C@  $8X"@!$.1  03D7 #\Y'P ^
M.28 /#DM #LZ-  Z.CL .3M" #@[2@ W.U, -CQ< #4\9P T/70 ,SV# #,^
MDP R/J0 ,3ZV #$^S0 Q/NH ,3[Z #(]_P R/?\ GCL  (L\  ![/   ;CT
M &0]  !</0  53P  $XZ  !).P  13P  $$]!P ^/0X /#T5 #H^'  Y/B,
M-SXJ #8_,0 U/S@ -#]  #- 2  R0%  ,4!: #!!90 O07( +D*! "U"D0 M
M0J( +$*U "M"RP L0ND +$+Y "U!_P M0?\ F3T  (<^  !W/P  :S\  &%
M  !9/P  4C\  $D^  !$/P  0$   #Q!!  Y0@T -T(2 #5#&0 S0R$ ,D,H
M #%$+P P1#8 +T0] "Y%10 M14X +$58 "M&8P J1F\ *49^ "A&CP G1Z$
M)D>S "9'R0 F1N< )T;X "A%_P H1?\ E4   ()!  !S0@  9T(  %Y"  !5
M0@  3D(  $5"   _1   .T4  #=&   T1PH ,4@0 "](%@ N21X +$DE "M)
M+  J23, *4HZ "A*0@ G2DL )DM5 "5+8  D2VT (TM\ ")+C0 A3)\ (4RQ
M "!,QP @2^8 (4OW ")*_P B2O\ D$,  'Y$  !O1   9$4  %I%  !210
M2D8  $%'   \2   -TD  #)+   N30< *TX. "E.$P G3QH )D\A "5/*  D
M3S  (U W ")0/P A4$@ (%!2 !]170 >46H '5%Y !Q1B@ ;49P &E&O !E1
MQ0 94>0 &E#V !M/_P <3_\ BD8  'E'  !K1P  8$@  %9(  !.2   1TD
M #Y+   Y3   ,TX  "Y0   H4P( )%0+ ")5$  @518 'U8> !Y6)  =5BP
M'%8S !M7.P :5T0 &5=. !A760 76&8 %5AU !18AP 46)H $U>L !)7P@ 2
M5^$ $U;T !15_P 45?\ A$D  '1*  !F2P  7$L  %-+  !+3   1$T  #Q/
M   U40  +U0  "E6   D60  'EL' !I=#0 871( %UT9 !9>(  57B< %%XN
M !->-P 27D  $5]* !%?50 07V( #U]Q  Y?@P -7Y8 #5^I  Q>O@ ,7MH
M#5WP  U<_  .7/\ ?DT  &Y.  !B3@  6$\  $]/  !(4   0%(  #A4   P
M5P  *EH  "1=   ?7P  &6(! !-E"0 19@\ $&84  ]F&P .9R( #6<I  UG
M,@ ,9SL "V=%  IG4  )9UT !V=L  9G?0 %9Y  !&:C  )FMP #9<\ !&7I
M  1D]0 $9/P =U$  &E2  !=4@  5%(  $Q3  !#50  .U@  #-;   K7@
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M  !ZK   ><(  'C?  !X[P  =_< :EL  %];  !66P  3%P  $)@   Y8P
M,&@  "AL   @<   &70  !-W   .>P  "7X   2! @  @@@  (,-  "#$
MA!0  (49  "&(   AB@  (<Q  "'/   ATD  (=7  "':   AWL  (>0  "&
MI0  A;H  (73  "$Z@  A/0 96   %Q@  !180  1F0  #QI   R;0  *7(
M "%W   9>P  $H    V#   (AP   HH   "-    C@0  (X)  "/#0  D!
M )$4  "2&0  DR   )0I  "5,P  E4   )9.  "67P  E7(  )6(  "5G0
ME+(  )3(  "3X@  D^X 864  %9F  !*:@  /VX  #5T   K>0  (7\  !F$
M   1B0  #(T   :1    E    )@   ":    FP   )P"  "=!P  G@L  )\.
M  "A$@  HA@  *,@  "E*0  IC8  *9$  "F50  IF@  *9]  "FE   I:D
M *2]  "DT0  I.0 6VP  $]P  !#=0  .'L  "V!   CAP  &8T  !&2   +
MEP  !)P   "@    HP   *8   "H    J0   *H   "L    K00  *X)  "P
M#0  L1$  +,7  "U(   MBL  +<Z  "W2P  N%P  +AQ  "XB   N)T  +BQ
M  "WP@  M]  5'8  $A\   \@@  ,8D  ":0   ;EP  $IT   RB   #IP
M *L   "N    L@   +8   "X    N    +H   "[    O0   +X   # !0
MP0L  ,,0  #&%@  R2   ,HN  #+/@  S%   ,QD  #->@  S9$  ,VD  #-
MM   S<  38,  $&*   UD0  *9D  !Z@   3I@  #*P   .Q    M@   +H
M  "^    P@   ,8   #(    R    ,H   #+    S0   ,X   #0    T@$
M -4(  #9#@  W14  .$A  #B,0  Y$,  .56  #F:P  YH(  .>6  #GI0
MYK  _P ) /\ !0#_  8 _P . /\ %@#_ "$ _P M /\ . #] $, ^0!- /4
M50#R %T \ !C .X :0#L &\ Z@!T .D >@#G '\ Y@"% .0 BP#C )$ X0"9
M -\ H0#< *H V@"V -< Q@#5 .$ TP#T -( _P#1 /\ T0#_ ,\ _P#* /\
M_P ! /\   #_  $ _P , /\ $@#Z !T ]@ H /, ,P#P #X [ !( .@ 4 #E
M %@ X@!> -\ 9 #= &H VP!O -D = #6 'H U !_ -( A0#0 (P S@"3 ,P
MG #) *4 QP"P ,8 O@#$ -0 P@#N ,$ _@#  /\ P #_ +\ _P"^ /\ _P
M /\   #_    ^@ ' /$ #P#K !@ Y@ C .( +@#@ #@ VP!" -4 2P#1 %(
MS@!9 ,L 7P#) &4 QP!J ,8 ;P#$ '0 P@!Z ,$ @ "_ (8 O0". +L E@"Y
M *  MP"J +8 MP"T ,H L@#F +$ ^ "P /\ KP#_ *\ _P"P /\ _P   /\
M  #W    Z@ " .$ # #7 !, T  = ,P * #) #( Q@ \ ,( 10"_ $T O !3
M +H 60"X %\ MP!D +4 :0"T &X L@!T +$ >@"O (  K0"( *P D0"J )H
MJ "E *8 L0"D ,$ HP#< *$ \@"A /\ H #_ *  _P"A /\ _P   /<   #H
M    V0   ,L " ## !  O0 8 +D (@"V "P M  V +( /P"O $< K !- *L
M5 "I %D IP!> *8 8P"E &@ HP!N *( = "@ 'H G@"" )P BP"; )4 F0"?
M )@ K "6 +H E #/ ), ZP"2 /L D@#_ )( _P"1 /\ ]P   .<   #3
MQ@   +L  @"S  P K0 2 *H ' "G "8 I  P *, . "@ $  G@!' )P 3@":
M %, F0!8 )< 70"6 &, E0!H ), ;@"2 '0 D !\ (\ A0"- (\ BP": (H
MIP"( +4 A@#' (4 Y "$ /4 A #_ (, _P"# /\ [    -,   #! 0  M
M *P   "F  < H  . )T %@": "  EP I )4 ,@"3 #H D0!! (\ 2 "- $T
MC !3 (L 6 ") %T B !C (< :0"% &\ @P!W (( @ "  (H ?@"6 'T HP![
M +  >@#" 'D W0!X /$ =P#] '@ _P!X /\ W@H  ,0+  "R#   I@L  )T(
M  "9!   E0 * )$ $0". !D BP C (D + "' #0 A0 [ (, 0@"" $@ @ !.
M '\ 4P!] %@ ? !> 'L 9 !Y &H > !R '8 >P!T (8 <P"2 '$ GP!P *T
M;@"^ &T!U@!M NT ; /Z &P#_P!L _\ SA   +<1  "F$@  FA$  )$0  "+
M#@  B0L# (<%# "$ 1, @0$< 'X")0!\ RX >@,V '@$/ !W!$, =05( '0%
M3@!S!50 <059 ' &7P!N!F8 ;09N &L'> !J!X, : B0 &<)G0!E":P 9 F\
M &,*U !C"^P 8@SZ &(,_P!B#/\ PQ8  *T7  "=&   D!@  (<6  "!%
M?1$  'P.!@!\"@X > H6 '4+'P!R"R@ < PP &\,-P!M##X ; Q$ &L-2@!I
M#4\ : U5 &<-7 !E#6, 8PYK &(.=0!@#H$ 7PZ. %T/G !<$*L 6Q"] %H0
MU@!9$?  61'] %D1_P!9$?\ N1L  *4=  "4'@  B!X  'X=  !X&P  =!@
M '$5  !Q$0D ;Q 1 &P0&0!I$"( 9Q$J &81,@!D$3D 8Q$_ &(110!@$DL
M7Q)1 %T26 !<$E\ 6A-H %D3<@!7%'T 5A2+ %05F0!3%:D 4A:Z %$6T@!1
M%^T 41?] %$7_P!1%_\ LB   )XB  ".(@  @2,  '<B  !P(0  ;!X  &D;
M  !G& 0 9A4. &,6%0!A%AX 7Q8F %T6+0!<%S0 6A<[ %D700!8&$< 5AA-
M %485 !3&%P 4AED %$9;@!/&GH 3AN( $T;EP!+'*8 2ARX $H=SP!)'>L
M21W[ $D=_P!*'?\ K"0  )@E  "()@  >R<  '$F  !J)0  9B,  &(A  !@
M'@  7AP+ %L;$@!9'!H 5QPB %4<*0!4'#  4QTW %$=/0!0'4, 3QU* $T>
M40!,'E@ 2Q]A $D?:P!(('< 1R"% $8AE !$(J0 1"*V $,BS !#(^D 0R/Z
M $,C_P!#(O\ IB<  ),I  "#*@  =BH  &TJ  !E*0  8"<  %PE  !9(P
M5R$' %4A#P!2(18 4"$> $XA)0!-(BP 3"(S $HB.0!)(D  2")& $<C30!%
M(U4 1"1> $,D:0!")74 0":# #\FD@ ^)Z, /B>T #TGR@ ]*.@ /2CY #TG
M_P ^)_\ HBH  (XK  !_+0  <BT  &@M  !A+   7"L  %@H  !4)@  428$
M $XE#0!,)1, 2B8: $@F(@!')BD 128O $0F-@!#)SP 02=# $ G2P _*%,
M/BE< #TI9@ \*G( .RJ! #HKD  Y*Z$ ."RR #<LR  W+.8 ."SX #@L_P X
M+/\ G2P  (HN  ![+P  ;S   &4P  !=+P  6"X  %,K  !0*@  3"H  $DJ
M"P!&*A$ 1"H7 $(J'P!!*B4 /RHL #XK,P ]*SD /"M  #LL2  Z+%  .2U9
M #@N9  W+G  -B]_ #4OCP T,)\ ,S"Q #(PQP R,.4 ,S#W #,P_P T+_\
MF2\  (<Q  !W,@  :S(  &(R  !:,@  5#$  $\O  !++0  1RX  $0N" !!
M+@X /RX4 #TN'  [+B( .2\I #@O+P W+S8 -C ^ #4P1@ U,4X -#%7 #,R
M8@ R,FX ,3-] # SC0 O-)X +C2P "TTQ0 M-., +C3V "\S_P O,_\ E3$
M (,S  !T-   :#4  %XU  !7-   430  $LR  !&,0  0C(  #\R!0 \,@T
M.3,2 #@S&0 V,R  -#,F #,S+0 R-#0 ,30[ # U0P P-4P +S95 "XV8  M
M-VP +#=[ "LWBP J.)P *3BN "@XPP H..( *3CU "HW_P J-_\ DC0  '\U
M  !Q-@  93<  %LW  !4-P  338  $<V  !"-0  /38  #HV @ W-PL -#<0
M #(W%@ Q.!T +S@D "XX*P M.3( +#DY "LY00 J.DD *CI3 "D[7@ H.VH
M)SMY "8\B0 E/)L )#RM ",\P@ C/.  )#ST "4[_P E._\ C38  'PX  !M
M.0  8CD  %@Z  !1.0  2CD  $0Y   ].0  .3H  #4[   R.P@ +SP. "T]
M%  L/1H *CTA "D]*  H/B\ )SXV "8^/@ E/T< )#]0 "- 6P B0&@ (4!V
M "! AP ?09D 'T&K !Y!P  >0=X 'T#S !] _@ @/_\ B3D  '@Z  !I.P
M7CP  %4\  !-/   1SP  $ \   X/0  -#X  #!    M004 *D(, "="$0 F
M0Q@ )$,> "-#)0 B0RP (40S "!$.P ?1$0 'D5. !U%60 <164 &T5T !I%
MA0 91I< &4:I !A&O@ 71=P &$7Q !E$_0 :1/\ A#P  ',]  !F/@  6S\
M %(_  !*/P  1#\  #U    V00  ,4,  "Q$   G1@$ )$<* "%(#P @210
M'DD; !U)(@ <22D &THP !I*.  92D$ &$I+ !=+50 62V( %4MQ !1+@@ 3
M2Y0 $DNG !)+O  12]D $DKP !-*_  42?\ ?S\  &]   !A00  5T(  $Y"
M  !'0@  04(  #I#   R10  +4<  "A)   C2P  'DT& !M/#0 84!$ %U 7
M !90'@ 54"4 %% L !-1-  243T $5%' !%14@ 045\ #U)M  Y2?@ -49$
M#5&D  Q1N  ,4=$ #5#L  U0^@ .3_\ >4,  &I$  !=1   4T4  $M%  !$
M10  /D8  #9(   O2@  *4P  "1/   ?40  &E,  !16"0 15PX $%@3 !!8
M&0 /6"  #E@H  U8,  -6#D #%A#  M83@ *6%H "%AH  =8>0 &6(P !5B?
M  18LP $5\H !5?F  57\P &5OP <T8  &1'  !92   4$@  $A(  !!20
M.DH  #)-   K4   )5(  "!5   :6   %5H  !!=!@ ,8 P "F 0  E@%0 (
M8!P !V C  5@*P $8#0  V ]  %@20  8%4  &!C  !@<P  8(8  %^:  !?
MK@  7\0  %[B  !>\   7O@ ;$H  %]+  !52P  3$P  $5,   ]3@  -5
M "Y3   G5@  (%D  !I<   57P  $&(   UE!  (9PL  V<.  !H$P  :!@
M &@?  !I)@  :2X  &DX  !I0P  :4\  &E=  !I;0  :8   &F4  !HJ0
M:+\  &?<  !F[@  9O< 9D\  %I/  !13P  2D\  $%1   X5   ,%<  "A;
M   A7@  &F(  !1E   0:   #&L   =N P !< D  ' -  !Q$   <10  '(:
M  !S(0  <R@  ',Q  !S/   =$@  '-6  !S9@  <WD  '..  !SHP  <KD
M ''2  !QZP  </0 85,  %93  !/4P  154  #M8   R7   *F   ")D   ;
M:   %&P   ]O   +<@  !G8   !Y    >@8  'H*  ![#@  ?!$  'T5  !^
M&P  ?R(  ( J  " -0  @$$  (!/  " 7P  @'$  ("&  " G0  ?[(  '[*
M  !^Y0  ??$ 7%@  %18  !)6@  /UT  #5A   L90  (VH  !MO   4<P
M#G<   E[   #?P   ((   "$    A@$  (8&  "("@  B0T  (H0  "+%0
MC!L  (XB  "/+   CS@  (]&  "/5@  CV@  (]^  "/E0  CJL  (W!  "-
MW   C.L 65T  $Y?  !#8@  .&8  "YL   D<0  ''<  !1\   .@0  "(4
M  ")    C0   )    "2    DP   )0   "6 P  EP@  )@,  ":#P  FQ,
M )T:  "?(P  H"X  * \  "@3   H%X  *!T  "?C   GZ(  )^W  ">RP
MGN  4V0  $=H   \;0  ,7,  "=Y   =?P  %(4   V+   &D    )0   "8
M    G    )\   "A    H@   *0   "E    IP   *@$  "J"0  K T  *T2
M  "P&0  LB,  +(Q  "R0@  LE0  +)I  "R@   LI@  +&L  "ROP  L<X
M3&X  $!S   U>@  *H$  !^(   5C@  #I4   ::    GP   *0   "H
MK    *\   "Q    L0   +,   "U    M@   +@   "Z    O 8  +X,  #
M$0  PQD  ,4F  #%-P  QDD  ,9=  #'<@  QXH  ,B?  #(KP  R+P 1GH
M #F!   NB0  (I   !>8   /GP  !Z4   "J    KP   +,   "W    O
M +\   #!    P@   ,0   #%    QP   ,D   #+    S0   ,\#  #2"@
MUA   -P:  #=*@  WCP  -]0  #@90  X7L  .&1  #BH@  XJT _P " /\
M  #_  , _P , /\ $P#_ !T _P H /X ,P#[ #X ]P!( /, 4 #P %< [0!>
M .L 9 #H &D YP!O .4 = #C 'D X@!_ .  A0#> (P W "3 -D G #6 *8
MTP"Q -$ P #/ -H S@#Q ,P _P#+ /\ RP#_ ,8 _P#! /\ _P   /\   #_
M    _P ( /L $ #V !D \@ D .\ +@#M #D Z !" ., 2P#@ %( W0!9 -D
M7P#6 &0 TP!I -$ ;@#/ '0 S@!Y ,P ?P#* (8 R ". ,8 E@#$ *  P@"K
M ,  N0"^ ,T O #J +L _ "Z /\ N@#_ +H _P"V /\ _P   /\   #^
M]  $ .L #0#D !0 WP ? -L *0#8 #, TP ] ,X 10#* $T QP!3 ,4 60##
M %\ P0!D +\ :0"] &X NP!S +H >0"X (  M@"( +0 D "R )H L0"E *\
ML@"M ,0 K #A *L ]@"J /\ J@#_ *H _P"J /\ _P   /T   #N    X@
M -4 "@#- !$ QP 9 ,0 (P#! "T OP W +L /P"W $< M0!. +( 4P"P %D
MKP!> *T 8P"L &@ JP!M *D <P"H 'H I@"! *0 B@"C )0 H0"? )\ K ">
M +L G #2 )L [@": /\ F@#_ )D _P"9 /\ _@   .X   #>    RP   ,$
M!0"Y  T M  4 +$ '@"N "< JP P *H .0"G $$ I !( *( 30"A %, GP!8
M )X 70"= &( FP!G )H ;0"8 ', EP![ )4 A "4 (X D@"9 )  I@". +0
MC0#( (P Y@"+ /D B@#_ (H _P"+ /\ \    -L   #'    N@   +    "H
M  H I  0 *  & "= "$ FP J )H ,P"8 #L E@!! )0 2 "2 $T D0!2 (\
M5P". %P C !A (L 9P"* &X B !U (< ?@"% (@ @P"4 (( H "  *\ ?P#
M 'X W0!] /( ?0#_ 'T _P!] /\ X    ,8   "U    J@   *(   ";  4
ME0 - )( $P"0 !P C0 D (L +0"* #0 B  [ (8 0@"% $< @P!- (( 4@"!
M %< ?P!< 'X 8@!] &@ >P!P 'H >0!X (, =@"/ '4 G !T *H <@"Z '$
MT0!P .P < #[ '  _P!P /\ S00  +<&  "G!P  FP8  ),$  ".    B@ (
M (8 #P"$ !8 @0 > '\ )P!] "X ?  V 'H / !Y $( =P!' '8 3 !U %(
M<P!7 '( 70!Q &, ;P!K &X = !L 'X :P"* &D F !H *8 9P"V &8 RP!E
M .< 90#W &4 _P!E /\ P P  *L-  ";#@  CPX  (8-  "!"P  ?@<! 'P!
M"P!Y !$ =P 8 '4 (0!S "D <0 P &\ -@!N #P ; !" &L 1P!J $T :0!2
M &@ 6 !F %\ 90!G &, < !B 7H 8 &' %\"E0!> J, 7 .S %P#QP!;!.0
M6P7T %L&_@!;!O\ M1   *$2  "1$P  A1,  'P2  !V$0  <PX  '(,! !Q
M!PT ;@02 &P$&P!I!2, 9P4J &8&,0!D!C< 8P8] &('0P!A!TD 7P=. %X(
M50!="%P 6PEC %H);0!8"G@ 5PJ% %8+DP!4"Z( 4PNS %(,QP!2#.0 40WU
M %$-_P!1#?\ K14  )D7  ")&   ?1D  '08  !M%P  :A0  &<1  !G#@<
M9@P. &,,%0!A#!T 7PPE %T-+ !<#3, 6PTY %H-/P!8#44 5PU+ %8.40!5
M#ED 4PYA %(.:P!0#W8 3A"# $T0D@!,$*( 2Q"R $H1R !)$>4 21'W $D2
M_P!)$?\ I1D  )(<  "#'0  =AX  &T=  !F'   8AH  %\7  !>% $ 7A$*
M %L0$0!9$1@ 5Q$@ %41)P!4$2X 4Q$T %$1.P!0$D$ 3Q)' $X23@!,$E4
M2Q-> $D39P!(%', 1A2  $45CP!$%9\ 0Q:P $(6Q0!"%^, 0A?V $(7_P!"
M%_\ GQT  (P@  !](0  <2(  &@B  !A(0  7!\  %D<  !7&0  518& %05
M#@!1%10 3Q8< $X6(P!,%BH 2Q8P $H6-P!)%ST 1Q=# $872@!%&%( 0QA:
M $(99 !!&7  /QI] #X;C0 ]&YT /!RN #L<PP ['.$ .QWU #L<_P \'/\
MFB$  (<C  !X)   ;"4  &,E  !<)   5R,  %,@  !1'@  3QP" $T;# !+
M&A$ 2!L8 $<;( !%&R8 1!LM $,<,P!"'#D 0!Q  #\=1P ^'4\ /1Y8 #P>
M8@ Z'VT .1][ #@@BP W(9L -B&M #4AP0 U(=\ -2'S #8A_P V(?\ EB,
M (,F  !T)P  :"@  %\H  !8)P  4R8  $\D  !,(@  22   $<@"0!$'P\
M0A\5 $ @'  _(", /B I #P@+P [(38 .B$] #DA1  X(DP -R)5 #8C7P T
M(VL ,R1Y #(EB0 Q)9H ,"6K # FOP O)MP ,";R # F_P Q)?\ D28  '\H
M  !Q*@  92H  %PJ  !5*@  3RD  $LH  !()0  1"0  $$D!0 _) T /202
M #LD&0 Y)!\ -R0F #8D+  U)3, -"4Z #,F00 R)DH ,2=3 # G70 O*&D
M+BEW "TIAP L*9@ *RJJ "HJO0 J*MH *RKQ "LJ_@ L*?\ C2@  'PJ  !M
M+   8BT  %DM  !1+0  3"P  $<K  !#*   /R@  #PH @ Y* L -R@0 #4H
M%@ S*!P ,B@C # H*0 O*3  +RHW "XJ/P M*T< +"M1 "LL6P J+&< *2UU
M "@MA0 G+9< )BZH "4NO  E+M@ )B[P "8N_0 G+?\ BBL  '@M  !J+@
M7R\  %8O  !.+P  2"X  $,M   _+   .RP  #<L   T+ D ,BP. # M$P N
M+1H +2T@ "LM)P J+BT *BXU "DO/0 H+T4 )S!. "8P60 E,64 )#%S ",Q
M@P B,I4 (3*G "$RNP @,M0 (3+O "(Q_  B,?\ ABT  '4O  !G,   7#$
M %,Q  !+,0  13$  $ P   [,   -C   #,P   P,08 +3$- "LQ$0 I,A<
M*#(> "<R)  E,RL )3,R "0S.@ C-$, (C1, "$U5P @-6, 'S5Q !XV@0 =
M-I, '#:E !LVN0 ;-M( '#;M !TV^P =-?\ @C   '$R  !C,P  630  % T
M  !)-   0C,  #TS   W,P  ,30  "XU   K-0( *#8+ "4W$  D-Q4 (C<;
M "$X(@ @."@ 'S@P !XX-P =.4  '#E) !LZ5  :.F  &3IN !@Z?P 7.Y$
M%SND !8[MP 5.]  %CKL !<Z^@ 8.?\ ?3(  &TT  !@-0  538  $TV  !&
M-@  0#8  #HV   T-@  +C@  "HY   F.@  (SL( " \#@ >/1( '3T8 !P]
M'P ;/B4 &CXM !D^-  7/CT %C]' !4_40 4/UX %#]L !- ?  20(\ $4"B
M !% M@ 00,X $3_K !(_^0 2/O\ >34  &DW  !<.   4CD  $HY  !#.0
M/3D  #<Y   Q.@  *SP  "<]   B/P  'D$$ !I""P 80Q  %T,5 !5$&P 4
M1"( $T0I !-$,0 21#H $45# !!%3@ 015L #D5I  Y%>0 -18P #46?  Q%
ML@ +1<D #$7E  U$]@ -1/\ =#D  &4Z  !8.P  3SL  $<\  ! /   .CP
M #0\   N/@  *$   "-"   ?1   &D8  !5("  22@T $4H2 !!*&  /2QX
M#DLE  U++0 -2S8 #$M   M+2@ *2U8 "4MD  A+=  '2X< !4N:  1+K@ $
M2L0 !4K@  5*\  &2?H ;CP  & ]  !4/@  2SX  $0^   ]/@  -S\  #%
M   J0@  )$4  !]'   :20  %4P  !%.!0 .40L "U$0  I1%  )41L "%$B
M  =1*0 %43( !%([  -21@ !4E(  %)?  !2;P  4H$  %&6  !1J0  4;\
M %#<  !0[@  4/< :$   %M!  !000  2$$  $%!   [0@  -$,  "U%   F
M2   ($L  !M-   64   $5,   Y5!  *6 H !E@.  )8$@  61<  %D=  !9
M)0  62T  %DV  !900  64T  %I:  !::0  67P  %F0  !9I0  6+H  %C5
M  !7[   5_8 8T0  %9%  !-10  144  #]%   W1P  +TD  "A,   B3P
M&U(  !95   16   #5H   E= P $7PD  & -  !@$   810  &$9  !B(
M8B<  &(Q  !B.P  8D<  &)5  !C9   8G8  &*+  !BH   8;8  &'/  !@
MZ@  8/4 74@  %))  !*2   0T@  #I*   R30  *E   "-3   <5P  %EH
M !%=   -8   "&,   -F 0  9P8  &@+  !I#@  :A$  &L5  !L&P  ;2(
M &TJ  !M-   ;4   &U.  !M70  ;6\  &V$  !LF@  ;+   &O(  !KY@
M:O, 6$T  $Y-  !(3   /DX  #51   L5   )%@  !U<   68   $&0   QG
M   ':P   6X   !P    <@,  '('  !S"P  =0X  '81  !W%@  >!P  'DC
M  !Z+0  >CD  'I'  !Z5@  >6@  'I\  !YE   >*H  'C!  !WWP  =^\
M5%$  $Q1  !"4@  .%4  "]9   F7@  'F(  !9G   0:P  "V\   5S
M=P   'H   !\    ?@   '\"  " !@  @0H  (,-  "$$0  AA4  (@<  ")
M)0  BC   (H^  ")30  B5\  (ES  "(BP  B*(  (>Y  "'T0  AN@ 4E8
M $=7   \6@  ,E\  "AD   ?:0  %F\  !!T   *>0   GT   "!    A0
M (@   "*    C    (T   "/    D 0  )((  "3#   E1   )<5  "9'0
MFR<  )LT  ";1   FE8  )IJ  "9@@  FIH  )BP  "8QP  E]X 2UP  $!@
M   U90  *VH  "%Q   7=P  $'T   F#   !B    (P   "1    E0   )@
M  ":    FP   )T   "?    H    *(   "D!0  I@H  *@.  "J%   K1T
M *TJ  "M.0  K4L  *U?  "M=P  K)   *NG  "KN@  J\L 168  #EK   N
M<0  (W@  !E_   0A@  "8T   "3    F    )T   "A    I0   *@   "K
M    JP   *X   "O    L0   +,   "U    MP$  +D'  "\#0  OQ,  ,(?
M  #"+@  PD   ,)4  #!:P  P8,  ,";  #!K0  P;P /G(  #)X   G@
M'(@  !*0   *EP   )T   "C    J    *T   "R    M@   +D   "[
MO    +X   #     P@   ,0   #&    R    ,L   #.!0  T0T  -84  #7
M(P  V#4  -E)  #:7@  VW4  -N,  #<GP  W*L _P   /\   #_    _P )
M /\ $ #_ !D _@ D /P +P#Y #D ] !# /  2P#M %( Z@!9 .< 7P#D &0
MX@!I .  ;@#> ', W !Y -H ?P#7 (8 U ". -$ E@#/ *$ S "L ,H NP#(
M -( Q@#N ,8 _P#% /\ Q0#_ +\ _P"Z /\ _P   /\   #_    _@ % /<
M#@#R !4 [@ ? .L *@#I #0 XP ] -X 10#9 $T U !3 -$ 60#. %X S !C
M ,H : #) &T QP!S ,4 >0## (  P0"( +\ D "] )L NP"F +D M "W ,@
MM@#F +4 ^P"T /\ M #_ +, _P"N /\ _P   /\   #X    [0   .4 "P#=
M !$ UP : -( ) #/ "X RP W ,< 0 ## $< P !. +X 4P"\ %D N@!> +@
M8P"V &@ M0!M +, <P"Q 'D KP"! *T B@"K )0 J0"@ *@ K0"F +X I0#;
M *0 ] "D /\ HP#_ *, _P"B /\ _P   /8   #F    UP   ,L !@#$  X
MO@ 5 +L 'P"Y "@ MP Q +0 .@"P $$ K0!( *L 3@"I %, IP!8 *8 7 "D
M &$ HP!G *$ ; "@ ', G@!Z )T @P"; (X F0"9 )< I@"6 +8 E0#, )0
MZP"3 /T DP#_ ), _P"3 /\ ]P   .0   #0    P0   +<  @"O  L JP 1
M *< &0"E "( HP K *( ,P"? #L G !" )L 2 "9 $T EP!2 )8 5P"5 %L
MDP!A )( 9@"0 &T CP!T (T ?0", (< B@"3 (@ H "' *\ A0#" (4 X@"$
M /< A #_ (0 _P"$ /\ Y0   ,T   "\    KP   *8   ">  < F@ . )8
M% "4 !T D@ E )$ +0"0 #4 C0 \ (P 0@"* $< B !, (< 40"& %8 A !;
M (, 8 "! &< @ !N 'X =P!] ($ >P"- 'H F@!X *D =P"Z '8 TP!V .\
M=@#^ '4 _P!U /\ T    +L   "K    GP   )<   "0  ( BP + (@ $ "&
M !< A  @ (( )P"! "\ ?P U 'T / !\ $$ >P!& 'D 2P!X %  =P!5 '8
M6P!T &$ <P!I '$ <0!P 'L ;@"' &T E0!K *, :@"T &H R0!I .@ :0#Y
M &D _P!I /\ P    *P   "< @  D (  (@   "#    ?P & 'L #0!Y !(
M=P : '8 (@!T "D <P P '$ -@!P #P ;P!! &T 1@!L $L :P!0 &H 5@!H
M %P 9P!D &4 ; !D '8 8P"" &$ D !@ )\ 7P"O %X PP!> .$ 7@#T %T
M_P!= /\ M <  * )  "0"P  A L  'P*  !W!P  = 0  '$ "0!O  \ ;0 5
M &L ' !I ", :  J &< ,0!E #8 9  \ &, 00!B $8 8 !, %\ 4@!> %@
M70!? %L : !: '( 6 !^ %< C !6 )L 50"K %0 O@!4 -H 4P#O %0 ^P!4
M /\ J0T  )8.  "'$   >A   '(0  !L#@  :0P  &<) P!F! L 9  0 &(
M%P!@ !X 7@ E %T *P!< #$ 6@ W %D / !8 $( 5P%' %8!3@!5 E0 4P)<
M %(#90!1 V\ 3P1[ $X$B@!-!9D 3 6I $L%O !*!M0 2@?M $H'^0!*!_\
MH1   (X2  !^%   <Q0  &H4  !D$P  8!$  %X/  !=#04 70D- %H&$@!8
M!QD 5@<@ %4')P!3!RT 4@@S %$(. !0"#X 3PE$ $X)2@!,"5$ 2PI9 $H*
M8@!("VT 1PMZ $8,B !$#)@ 0PRI $(-O !"#=4 0@WN $(-^P!"#?\ FA0
M (<6  !X&   ;!D  &,9  !=&   618  %83  !4$0  5 X( %,-#@!1#10
M3PT; $T-(@!,#2@ 2PTN $H-- !)#3H 1PY! $8.1P!%#D\ 1 Y7 $(/80!!
M$&P /Q!Y #X0B  ]$9@ .Q&I #L1O  Z$=8 .A'P #H2_0 [$?\ DQ@  ($:
M  !S'   9QT  %X=  !8'   4QL  % 8  !.%@  3!,# $P1"P!*$!  2!$7
M $81'@!%$20 1!$J $(1, !!$3< 0!(] #\21  ]$DP /!-4 #L37@ Y%&D
M.!1V #<5A0 V%98 -!:G #06N@ S%M, ,Q;N #06_  T%O\ CAL  'P=  !N
M'P  8R   %H@  !3(   3AX  $H=  !(&@  1A@  $46!P!#%0X 0143 #\5
M&@ ^%2  /14G #L5+0 Z%C, .18Z #@600 W%TD -1=1 #086P S&68 ,AES
M # :@P O&I0 +ANE "T;N  M&]  +1OL "X;^P N&_\ BAX  '@@  !J(@
M7R,  %8C  !/(@  2B$  $8@  !#'@  01L  #\: P ]&@P .QD1 #D9%@ W
M&AT -AHC #4:*0 T&C  ,QLV #$;/@ P'$8 +QQ/ "X=60 M'60 +!YQ "L?
M@0 J'Y( *1^D "@@MP G(,X )R#K "@@^@ I'_\ AB   '0C  !G)   7"4
M %,E  !,)0  1R0  $(C   _(0  /1\  #H>   W'@D -1X. #,>$P Q'AH
M,!X@ "\>)@ N'RT +1\S "P@.P K($, *B%, "DA5@ H(F( )B)O "4C?P D
M(Y  (R.B "(DM0 B),P (B3I ",D^0 D(_\ @B,  '$E  !C)@  62<  % H
M  !))P  0R<  #\F   [)   ."(  #4B   R(@8 ,"(- "XB$0 L(A< *B(=
M "DB(P H(RH )R,Q "8D.  E)4$ )"5* ",F5  B)F  (2=M " G?0 ?)X\
M'BBA !XHM  =*,H '2CH !XH^  ?)_\ ?B4  &XG  !@*0  5BD  $TJ  !&
M*@  02D  #PH   W)P  -"8  # F   M)@, *R<+ "@G$  G)Q0 )2<: "0G
M(0 C*"< (B@N "$I-@ @*3X 'RI( !XJ4@ =*UX '"MK !LK>P :+(T &2R?
M !@LL@ 8+,D &"SG !DK]P :*_\ >B<  &HJ  !=*P  4RP  $HL  !#+
M/BL  #DK   T*@  ,"H  "LJ   I*P  )BL( ",L#@ B+!( ("P8 !\L'@ >
M+24 '2TL !PM,P ;+CP &BY% !DO4  8+UP %R]I !8P>0 5,(L %#"> !0P
ML0 3,,< $S#E !0P]@ 5+_\ =BH  &<L  !:+0  4"X  $@N  !!+@  .RX
M #8M   Q+0  +"T  "<O   D+P  (3 % !\Q#  <,1  &S(5 !HR'  9,B(
M&#(I !<S,0 6,SD %3-# !0T30 3-%D $C1G !$U=P 1-8D $#6< ! UL  .
M-<8 #S3D ! T]0 0-/\ <BP  &,N  !7,   33   $4P   ^,   .#   #,P
M   O,   *3$  "0R   A,P  '34" !HV"0 7-PX %3<3 !0X&0 3.!\ $C@F
M !(X+@ 1.38 $#E  ! Y2P ..5< #CID  TZ=  ,.H8 ##J9  LYK  *.<$
M"CG>  LY\0 ,./P ;B\  %\Q  !3,@  2C,  $(S   [,P  -C,  #$R   L
M,P  )S0  "$V   =.   &3D  !4[!@ 2/0P $#X0 ! ^%0 ./AP #CXC  T^
M*@ ,/C, ##X\  L_1P */U( "#]@  <_;P &/X$ !3^4  0_J  #/KP !#[7
M  4^[  %/O< :3,  %LT  !0-0  1S4  #\U   Y-0  -#4  "XU   I-P
M(S@  !X[   :/   %C\  !)!!  .0PH #$0.  I$$P )1!D "$0@  =$)P &
M1"\ !40X  -%0@ "14X  $5;  !%:@  17P  $60  !$I   1+D  $31  !$
MZ@  0_4 9#8  %<W  !,.   0S@  #PX   W.   ,3@  "LY   E.P  (#T
M !I    60@  $D0   Y'!  +20D !TH-  1+$0 !2Q8  $L<  !+(P  2RL
M $LT  !+/@  3$D  $Q7  !,9@  3'<  $N,  !+H0  2[4  $K.  !*Z0
M2O4 7SH  %([  !(.P  0#L  #H[   T.P  +CP  "<^   B00  '$,  !9&
M   220  #DL   M. P '4 @  E$,  !1$   4A,  %,8  !3'P  4R8  %,O
M  !3.0  4T4  %-2  !380  4W(  %.'  !2G   4K$  %'*  !1YP  4?0
M63X  $X^  !%/@  /CX  #@^   P0   *4(  "-$   =1P  %TH  !)-   .
M4   "U,   95 @  5P<  %@+  !9#@  6A$  %H5  !;&@  7"$  %PJ  !<
M-   7#\  %Q-  !<6P  7&P  %R!  !;EP  6ZT  %K%  !:Y   6?, 5$(
M $I"  !"0@  /$(  #1#   L1@  )4D  !Y,   73P  $E,   Y6   *60
M!5L   !>    8 0  &$(  !B#   8PX  &01  !E%@  9AP  &<C  !G+0
M9SD  &=&  !G50  9V8  &=Z  !FD0  9:@  &7   !DW@  9/  3T8  $=&
M  ! 10  -T<  "]*   F30  'U$  !A5   260  #5P   A@   "8P   &8
M  !H    :@   &L$  !L"   ;0P  &\.  !P$@  <A<  ',=  !T)@  =#(
M '0_  !T3@  <U\  '1R  !SB@  <J$  '&X  !QU   <.P 3$H  $5*   [
M2P  ,DX  "E2   @5@  &%L  !)?   -9   !V@   !K    ;P   '(   !U
M    =@   '<   !Y @  >@8  'P*  !^#@  @!$  ((6  "$'@  A"D  (0V
M  "$10  A%8  (-J  "#@0  @ID  (&Q  " R0  @.4 2DX  #]0   U4P
M*U<  ")<   98@  $F<   QL   %<0   '4   !Y    ?0   ($   "#
MA0   (8   "(    B0   (L$  "-"   CPT  )(0  "4%@  EB   )8L  "6
M.P  EDP  )5@  "5=@  E)   ).G  "2O0  DM4 1%4  #E9   O70  )&,
M !II   2;P  #'4   1[    @    (4   ")    C0   )$   "3    E
M )8   "8    F@   )P   ">    H 8  *(+  "E$   J!<  *DC  "I,0
MJ4,  *E6  "H;0  IH<  *>>  "FLP  I<< /EX  #)C   G:@  '7   !-X
M   ,?P   X4   "+    D0   )8   ";    GP   *(   "D    I0   *<
M  "I    JP   *T   "P    L@   +4"  "W"0  NQ   +X8  "^)@  OC@
M +Y+  "]80  O'H  +N4  "ZJ0  NKD -VH  "MP   @>   %H    V(   %
MCP   )8   "<    H@   *<   "L    L    +,   "V    MP   +D   "[
M    O0   +\   #"    Q0   ,@   #*    S@@  -(0  #5&P  U2P  -1
M  #45P  TVX  -2&  #4FP  TZL _P   /\   #_    _P % /\ #@#_ !4
M_  @ /D *@#V #0 \0 ] .T 1@#I $T Y@!3 .0 60#A %X W@!C -P : #9
M &X U0!S -, >0#0 (  S@"( ,L D0#) )P Q@"G ,0 MP#" ,P P #L +\
M_P"^ /\ O0#_ +< _P"R /\ _P   /\   #_    ^@ ! /, "P#M !( Z  ;
M .4 )0#D "X WP X -@ 0 #2 $< S@!. ,L 5 #( %D Q@!> ,0 8P#" &<
MP !M +\ <P"] 'H NP"! +D BP"V )4 M "A +( KP"P ,( K@#C *X ^@"L
M /\ K0#_ *D _P"F /\ _P   /\   #R    Y@   -T !P#2  X S0 6 ,H
M( #( "D Q0 R ,  .@"\ $( N0!( +< 3@"U %, LP!8 +$ 70"P &( K@!G
M *P ; "J ', J0![ *< A "E (X HP": *$ J "? +D G@#2 )T \@"< /\
MG0#_ )P _P"9 /\ _    .X   #=    S    ,$  @"Z  P M@ 2 +( &@"P
M ", KP L *T - "I #P I@!" *0 2 "B $T H !2 )X 5P"= %L G !@ )H
M9@"9 &P EP!T )4 ?0"3 (< D0"3 )  H0". +$ C0#& (P Z "+ /T C #_
M (P _P", /\ [0   -@   #%    MP   *P   "F  @ H0 . )\ %0"= !X
MFP F )H +@"7 #4 E0 \ ), 0@"1 $< D !, (X 40"- %4 BP!: (H 8 ")
M &8 AP!M (4 =@"$ (  @@", (  F@!_ *D ?0"\ 'P W !\ /4 ? #_ 'P
M_P!\ /\ V0   ,$   "Q    I    )P   "4  , D  , (T $0"+ !@ B0 @
M (D * "' "\ A0 V (, / "" $$ @ !& '\ 2P!] $\ ? !4 'L 6@!Y &
M> !G '8 < !U 'H <P"& '$ DP!P *( ;P"T &X S !N .T ;@#^ &X _P!N
M /\ Q    *\   "@    E    (P   "&    @0 ( 'X #@!\ !0 >P ; 'D
M(@!X "D =P P '4 -@!T #L <@!  '$ 10!P $H ;P!/ &T 5 !L %L :P!B
M &D :@!H '0 9@"  &4 C@!C )T 8@"M &$ P@!A .0 80#X &$ _P!A /\
MM    *    "1    A@   'X   !Y    =0 # '$ "P!O !  ;0 6 &P '0!K
M "0 :P J &D , !H #8 9@ [ &4 0 !D $4 8P!* &$ 3P!@ %8 7P!= %T
M90!< &\ 6@!Z %D B !8 )@ 5P"H %8 NP!6 -@ 5@#Q %8 _P!6 /\ J $
M )0%  "%!P  >@<  '(&  !L!   :0$  &< !P!D  T 8P 1 &$ & !@ !\
M7P E %X *P!= #  6P V %H .P!9 $  6 !% %< 2P!6 %$ 50!8 %, 80!2
M &H 4 !V $\ A !. ), 30"D $P M@!, ,T 3 #K $P ^@!, /\ G0D  (L+
M  !\#0  < T  &@-  !B#   7PH  %T& 0!< 0D 6@ . %@ $P!7 !D 5@ @
M %4 )@!3 "L 4@ Q %$ -@!0 #L 3P!! $X 1P!- $T 2P!5 $H 70!) &<
M1P!S $8 @ !% )  1 "A $, L@!# ,@ 0P#F $, ]0!# /\ E0T  (,/  !T
M$   :1$  & 1  !:$   5@X  %0-  !3"@0 4P8+ %$#$ !/ 14 3@$; $P!
M(0!+ 2< 2@(L $D",@!( C< 1P,] $4#0P!$ TH 0P11 $($6@! !60 /P5P
M #X&?@ ]!HX / >? #L'L0 Z!\8 .@?C #H'\P Z"/P CA   'P2  !N%
M8A4  %H5  !4%   4!,  $T1  !+#@  2PT& $H*# !)"!$ 1P@6 $4('0!$
M"", 0@@H $$)+@! "3, /PDY #X*0  ]"D< / I/ #H+6  Y"V, . QO #8,
M?@ U#(X - V? #,-L0 R#<< ,@WC #(-]  R#?X B!,  '<5  !I%P  7A@
M %48  !/&   2A8  $<5  !%$P  0Q " $,." !"#0X 0 T2 #\-&  ]#1\
M/ TD #L-*@ Y#3  . XW #<./0 V#D4 -0Y- #,/5P R#V( ,1!N "\0?0 N
M$(X +1&@ "P1L@ K$<@ *Q'F "L1]@ L$?\ @Q8  '(9  !D&@  61L  %$;
M  !+&P  1AH  $(8   _%P  /A0  #P2!  [$0H .A 0 #@0%0 W$!L -1$A
M #01)P S$2T ,A$S # 1.@ O$D( +A)+ "T35  K$U\ *A1L "D4>P H%(P
M)Q6> "85L  E%<8 )17D "45]@ F%?\ ?AD  &X;  !@'0  5AX  $T>  !'
M'@  0AT  #X<   Z&@  .!@  #<6   U%0< -!0- #(4$@ P%!< +Q0= "T4
M(P L%2H *Q4P "H5-P I%C\ *!9( "<74@ F&%T )!AJ ",9>0 B&8H (1F<
M " 9KP ?&<0 'QGB " 9]  @&?\ >AL  &H>  !='P  4R   $H@  !$(
M/A\  #H>   W'0  -!P  #(9   P&00 +A@+ "P8$  J&!0 *1@: "<8(  F
M&28 )1DM "0:-0 C&CT (AM& "$;4  @'%L 'QUH !X==P ='8@ '!Z; !L>
MK0 :'L, &A[@ !H=\P ;'?\ =QT  &<@  !:(0  4"(  $@B  !!(@  .R(
M #<A   S(   ,!\  "T=   K'0  *!T( "8=#@ E'1( (QT7 "$='0 A'20
M(!XJ !\>,@ >'SH '1]# !P@30 ;(5D &B%F !DA=0 8(H< %R*9 !8BK  5
M(L$ %2+? !4A\@ 6(?X <R   &0B  !7(P  320  $4E   ^)   .20  #0C
M   P(@  +"(  "DA   F(0  )"$& "(A#  @(1  'B$5 !TB&P ;(B$ &R(H
M !HC+P 9(S@ &"1! !<D2P 6)5< %25D !0F<P 3)H4 $B:8 !$FJP 1)L
M$";= !$E\0 2)?T <"(  &$D  !4)@  2B8  $(G   \)@  -B8  #$E   M
M)0  *20  "8D   B)0  'R4# !TF"@ ;)@X &2<2 !@G&  7)Q\ %B<E !4H
M+0 4*#4 $RD^ !(I20 1*54 $2IB ! J<0 /*H, #BJ6  XJJ0 -*KT #2K7
M  TJ[@ .*?L ;"0  %TF  !1*   2"@  $ I   Y*   -"@  "\H   K)P
M)R<  "(H   >*0  &RH  !@K!P 6*PT %"P1 !,L%@ 2+!P $2TC ! M*@ 0
M+3( #RX\  XN1@ -+E( #2Y?  PO;@ ++W\ "B^2  DOI0 )+KD ""[0  DN
MZ0 *+O< :"<  %HI  !.*@  12L  #TK   W*P  ,2H  "TJ   I*@  )"H
M " K   ;+0  &"X  !4O!  2,0H $#(.  \R$P .,AD #3(@  TR)P ,,B\
M"S,X  HS0@ ),TX "#-;  8T:@ %-'L !#..  ,SH@ ",[8  C/-  ,SYP $
M,O, 9"H  %8L  !++0  0BT  #HM   T+0  +RP  "LL   F+   (BT  !TO
M   9,0  %3(  !(T P /-@D ##@-  HX$0 ).!8 "#@=  <X)  &."P !#@T
M  ,X/@ ".4H  #E7   Y90  .7<  #F+   XGP  .+,  #C*   XY@  -_(
M7RT  %(N  !(+P  /S   #@O   R+P  +2\  "DO   D,   'S$  !HS   5
M-0  $C<   \Y P ,.P@ "#T-  4^$  #/A0  #X:   ^(0  /B@  #XQ   _
M.P  /T8  #]3   _80  /W,  #^'   ^G   /K   #W'   ]Y   /?( 6C
M $XR  !$,@  /#(  #4R   P,0  *S$  "8R   @-   &S8  !8X   2.P
M#ST   P_ P (00@ !$,,  !##@  1!(  $46  !%'0  120  $4M  !&-@
M1D(  $9.  !&70  1FX  $6"  !%F   1*T  $3$  !#XP  0_( 530  $HU
M  !!-0  .34  #,T   N-   *#4  "(W   =.@  %SP  !(_   /00  #$0
M  A& 0 #2 8  $D*  !*#0  2Q   $P4  !-&0  3B   $XH  !.,@  33T
M $Y*  !.6   36D  $U]  !,E   3*H  $O!  !+X0  2O( 4#@  $8X   ]
M.   -S@  #$W   J.0  )#L  !X]   80   $T,   ]&   +20  !TL   ).
M    4 0  %$(  !2"P  4PX  %01  !5%0  5AL  %<C  !7+   5S@  %=$
M  !74@  5F,  %9W  !6C@  5:4  %2]  !3W0  4_  2SP  $(\   [.P
M-3L  "T\   F/P  'T(  !E%   32   #DL   M/   %40   %0   !7
M6 $  %H%  !;"   7 P  %T.  !?$0  8!8  &(=  !B)@  8C$  &(^  !A
M3   85T  &%P  !@B   8*   %^W  !>U   7>X 1T   #\_   Z/P  ,4
M "E#   A1@  &DH  !-.   .40  "E4   18    6P   %X   !A    8P
M &0!  !E!   9P@  &@+  !J#@  ;!(  &X7  !O(   ;RH  &\V  !N10
M;E4  &YH  !M?P  ;9@  &RP  !KR@  :N@ 1$0  #Y#   U1   *T<  "-+
M   ;3P  $U0   Y8   (7    F    !D    9P   &L   !M    ;P   '
M  !R    = (  '4&  !W"@  >0X  'P2  !^&   ?R(  '\N  !_/0  ?DT
M 'UA  !]=P  ?)   'NH  !ZP   >=\ 0T<  #E)   O3   )5   !Q5   4
M6P  #F    =E    :@   &X   !R    =@   'D   !\    ?@   '\   "!
M    @P   (4   "' P  B@@  (P-  "/$0  DAD  )(E  "2,P  DD0  )%7
M  "0;0  CX8  (Z?  "-M0  C,T /4X  #)1   H5@  'EP  !5B   .:
M!VX   !T    >0   'X   ""    A@   (D   ",    C@   )    "2
ME    )8   "8    FP   )X&  "A#   I!$  *8;  "F*0  ICH  *5-  "E
M8@  I'L  *.4  "AJP  H;\ -E<  "Q<   A8@  %VD   ]P   '=P   'X
M  "$    B@   (\   "4    F    )L   ">    GP   *(   "D    I@
M *@   "K    K0   +    "S!   MPP  +L2  "['P  NS   +M#  "Z6
MN7   +>+  "WH0  M[, ,&(  "5I   :<   $'@   F     B    (\   "6
M    FP   *$   "F    J@   *X   "P    L0   +0   "V    N    +L
M  "]    P    ,,   #'    RP,  ,\,  #3%0  TB4  -(X  #13@  T&4
M ,]^  #-E@  S*D _P   /\   #_    _P # /\ "P#\ !$ ^0 ; /< )0#S
M "\ [@ X .D 0 #F $@ X@!. -\ 5 #< %D V0!> -4 8P#3 &@ T !M ,X
M<P#+ 'H R "" ,8 C ## )< P "C +X L@"\ ,@ N@#J +D _P"X /\ L0#_
M *H _P"G /\ _P   /\   #[    ]@   .T !P#G  \ X@ 6 -\ ( #> "D
MV0 S -$ .P#, $( R !( ,4 3@#" %, P !8 +X 70"\ &( N@!G +D ;0"W
M '0 M0![ +( A0"P )  K@"< *P J@"I +T IP#> *8 ^0"E /\ HP#_ )T
M_P"; /\ _0   /8   #K    WP   -$  P#*  P Q0 2 ,, &P#  "0 O@ L
M +D -0"V #P LP!# +  2 "N $X K !2 *L 5P"I %P IP!A *8 9P"D &T
MH@!T *  ?0"> (@ G "5 )H HP"8 +0 E@#- )4 \0"4 /\ E0#_ )  _P".
M /\ \P   .8   #1    P@   +@   "Q  @ K0 / *H %@"H !X J  G *8
M+P"B #8 GP \ )T 0@"; $< F0!, )< 40"6 %4 E !: ), 8 "1 &8 D !N
M (X =@", ($ B@"- (@ FP"& *P A0#! (0 Y@"# /T A #_ (, _P"! /\
MY    ,L   "Z    K    *(   "<  0 F  , )8 $0"4 !D DP A )( * "/
M #  C0 V (L / ") $$ B !& (8 2P"% $\ A !4 (( 6@"! &  ?P!G 'X
M;P!\ 'H >@"& '@ E !W *0 =0"W '0 U !S /0 = #_ '0 _P!T /\ RP
M +8   "F    F@   )(   "*    A@ ( (, #@"! !0 @0 ; (  (P!_ "H
M?0 P 'L -@!Z #L > !  '< 10!U $D = !. ', 5 !Q %H < !A &X :0!M
M ', :P!_ &D C0!H )T 9P"N &8 QP!E .H 9@#_ &8 _P!G /\ N    *0
M  "5    B@   ($   !\    =@ $ '0 # !R !  <0 6 '  '0!P "0 ;@ J
M &T , !K #4 :@ Z &D /P!H $0 9P!) &4 3@!D %0 8P!; &$ 8P!@ &T
M7@!Y %T AP!; )8 6@"H %D O0!9 -\ 60#X %H _P!: /\ J    )4   "'
M    >P   ',   !N    :@ ! &< " !E  X 9  2 &, & !C !\ 8@ E &$
M*@!? #  7@ U %T .@!< #X 6P!$ %D 20!8 $\ 5P!6 %8 7@!4 &@ 4P!S
M %$ @0!0 )$ 3P"B $X M0!. -  3@#P $X _P!/ /\ G    (D   ![ P
M< ,  &@#  !B 0  7P   %T ! !;  L 60 / %@ % !7 !D 5P @ %8 )0!5
M "H 4P P %( - !1 #D 4  _ $\ 1 !. $L 30!2 $L 6@!* &, 20!O $<
M? !& (P 10"= $4 L !$ ,< 1 #H $0 ^@!% /\ D@0  ( '  !Q"@  9@H
M %X*  !9"0  50<  %0$  !2  < 4  , $\ $ !. !4 30 ; $P ( !+ "8
M2@ K $D , !( #4 1P Z $8 0 !% $8 0P!. $( 5@!! %\ 0 !K #X >  ]
M (@ / "9 #P JP \ ,$ .P#@ #L ]  [ /\ B0H  '@,  !J#@  7PX  %<.
M  !1#@  30P  $L+  !*" ( 200) $@ #0!& !$ 10 6 $0 ' !# "$ 0@ F
M $$ *P _ #$ /@ V #T /  \ $, .P!* #H 4@ Y %P . !H #8 =0 U (4
M- "6 #0 J  S +P ,P#8 #, [P S /L @@T  '$/  !D$   61$  %$1  !+
M$0  1Q   $0.  !"#0  00L% $$'"P _!0X /@,2 #P"&  [ AT .@,B #D#
M*  X RT -P,R #8$.0 U!#\ - 5' #,%4  Q!EH , 9F "\'<P N!X, +0>5
M "P'IP K![H *P?2 "L'ZP K!_< ?1   &P1  !?$P  5!0  $P4  !&%
M0A,  #X2   \$   .@X! #H-!@ Z"@P . D0 #8(%  U"!D - D? #())  Q
M"2D , DO "\*-@ N"CT +0I% "P+3@ K"UD *0QE "@,<P G#(, )@V5 "4-
MIP D#;L (PW2 ",-ZP C#?< >!(  &@4  !;%@  41<  $@7  !"%@  /18
M #D5   W$P  -1$  #,0 P S#@@ ,@T- # -$0 O#18 +0T; "P-(0 K#2<
M*@TM "D.-  H#CL )PY$ "4.3@ D#UD (Q!E "$0<P @$(0 'Q"6 !X0J0 =
M$+T '!#8 !T0[@ =$/D <Q0  &06  !7&   31D  $49   _&0  .A@  #47
M   R%@  ,!4  "X3   M$00 +! * "L0#@ I$!( *! 8 "80'@ E$"0 )! J
M ",1,0 B$3D (1%" " 22P >$E8 '1-C !P3<0 :$X( &125 !@4IP 7%+L
M%Q/4 !<3[@ 8$_H <!8  & 9  !4&@  2AL  $(<   \&P  -AL  #(:   O
M&0  +!@  "H6   H% $ )A,' "43#  C$Q  (A,5 " 3&@ ?$R$ 'A0G !T4
M+@ <%38 &Q4_ !H620 9%E0 &!=A !87<  5&($ %!B3 !,8I@ 2&+H $A?2
M !(7[  3%_H ;!D  %T;  !1'0  1QT  #\>   Y'0  -!T  "\<   K&P
M*!H  "89   D&   (A<$ " 7"@ >%PX '!<2 !H7%P 9&!X &1@D !@9+  7
M&30 %AH] !4:1P 4&U( $QM? !(<;@ 1''\ $!R2 ! <I0 /'+D #AS0  X;
MZ@ /&_@ :1L  %H=  !.'P  11\  #T@   V'P  ,1\  "T>   I'0  )1T
M ",<   @&P  '1L! !L;!P 9' T %QP0 !8<%0 5'!L %!TB !,=*0 2'C$
M$1XZ !$?10 0'U  #R!=  X@;  -('P #2"/  P@H@ +(+4 "R#*  L@Y0 ,
M'_0 91T  %<?  !,(0  0B$  #HA   T(0  +R$  "H@   F'P  (Q\  " >
M   ='@  &2   !8@!  4( L $B$. !$A$P 1(AD $"(?  \B)@ .(R\ #B,W
M  TC00 ,)$T "R19  HD9P ))'@ ""2+  <DG@ ')+$ !B3'  8CXP '(_$
M8A\  %0A  !)(P  0",  #@C   R(P  +",  "@B   D(0  (2$  !XA   :
M(0  %B,  !,D P 1)0@ #R8-  XG$0 -)Q8 #"<=  LG(P *)RL "2@T  @H
M/@ '*$D !BA5  4I9  $*70  RF'  (IFP !**\  "C%  $HX0 !)_  7B(
M %$D  !&)0  /24  #4E   O)0  *B0  "8D   B(P  'R,  !LD   8)0
M%"8  !$H P /*0@ #"P,  HL$  (+!0 !RP:  8L(0 %+"@  RTP  (M.@ !
M+44  "U2   N8   +G$  "V$   MF0  +:T  "S"   LX   +/  6B0  $TF
M  !#)P  .B<  #,G   M)P  *"8  "0F   A)@  '28  !DG   5*0  $2L
M  \L P -+@< "3 ,  8Q#@ #,1(  3(7   R'@  ,B4  #(M   R-@  ,T(
M #-.   S70  ,VT  #.!   RE@  ,JL  #'!   QWP  ,?  5B<  $HI   _
M*@  -RH  # J   K*0  )R@  ",H   >*0  &BH  !8L   2+@  #S    TQ
M @ *- < !34+  (V#@  -Q   #@4   X&@  ."(  #@J   Y,P  .3X  #E*
M   Y60  .6D  #E]   XDP  .*@  #>_   WW@  -O  42L  $8L   \+
M-"P  "XL   J*P  )2L  " L   ;+0  %R\  !,Q   0,P  #34   DW @ %
M.@8  3L*   \#0  /0\  #X2   _%P  0!X  $ E  ! +P  0#H  $!&  !
M5   0&4  #]X   _CP  /J8  #Z]   ]W   /?  32X  $(O   Y+P  ,B\
M "TN   H+@  (B\  !TP   8,@  $S4  ! W   ,.@  "3P   4^    000
M $((  !#"P  1 T  $80  !'%   2!D  $@A  !(*@  2#4  $A!  !(3P
M2&   $=S  !'B@  1J(  $6Y  !%V0  1/  2#(  #XR   V,@  ,#$  "LQ
M   E,@  'S0  !DV   3.0  $#P   P_   (0@   T0   !&    2 (  $H%
M  !+"   3 L  $X.  !/$0  414  %(<  !2)0  4C   %(\  !12@  45H
M %%M  !0A   3YT  $ZU  !-T@  3>X 0S8  #LV   T-0  +S0  "<U   A
M.   &CL  !0^   000  #$0   ='   "2@   $T   !/    40   %,"  !4
M!0  50@  %<+  !9#@  6Q$  %T7  !='P  72H  %TV  !<1   7%0  %MG
M  !;?@  6I<  %FO  !8RP  5^H /SD  #@Y   S.   *SD  ",\   </P
M%4,  !!'   +2@  !4X   !1    5    %<   !:    7    %T   !?
M8 0  &('  !D"P  9@X  &@2  !K&0  :R,  &HN  !J/   :DT  &E?  !H
M=0  9X\  &:H  !EP@  9., /3T  #<\   N/0  )4   !U$   620  $$T
M  I1   $50   %H   !=    8    &,   !F    :    &H   !K    ;0
M &\"  !Q!@  = H  '8.  !Y$P  >QL  'LG  !Z-0  >44  'A9  !X;0
M=X8  ':?  !UMP  =-( /$$  #)"   H10  ($H  !=.   05   "ED   )>
M    8P   &<   !K    ;P   '(   !U    =P   'D   ![    ?0   '\
M  ""    A ,  (<)  "*#@  CA,  (\>  ".*P  CCL  (U.  "+8P  BGP
M (J5  "(K0  A\4 -D<  "Q+   B3P  &54  !!;   *80   6<   !M
M<@   '<   ![    ?P   (,   "&    B    (H   "-    CP   )$   "4
M    EP   )H!  "=!P  H0T  *44  "D(0  I#$  *-$  "B60  H'   )^+
M  "=H@  G;< ,%   "55   ;6P  $F(   MI   !<    '<   !]    @P
M (@   "-    D0   )4   "8    F@   )P   "?    H0   *,   "F
MJ0   *P   "P    M <  +@.  "Z&   NB<  +DY  "X3@  MV4  +9^  "U
ME@  LZL *5L  !YB   4:0  #'$   )Y    @0   (D   "/    E@   )L
M  "@    I    *@   "K    K    *\   "R    M    +8   "Y    O
M ,    #$    R    ,T'  #2$   TAT  -$O  #01   SUL  ,US  #+C0
MRJ$ _P   /\   #[    ^@   /P " #X  \ ]0 7 /0 ( #Q "H ZP S .8
M.P#B $, W@!) -H 3P#6 %0 TP!9 -  7@#. &, RP!H ,D ;@#& '4 PP!]
M ,$ A@"^ )( NP"> +D K@"V ,, M #H +, _P"O /\ I0#_ )X _P"; /\
M_0   /<   #R    \    .<  P#A  P W  2 -@ &P#6 "0 T@ M ,P -@#&
M #T P@!# +\ 20"\ $X N@!3 +@ 6 "V %T M0!B +, 9P"Q &X KP!V *P
M?P"J (H J "7 *4 I@"C +D H0#9 *  ^0"> /\ F #_ )( _P"/ /\ \P
M .P   #C    TP   ,@   #!  D O0 / +L %@"Y !\ MP G +, +P"O #<
MK  ] *H 0P"H $@ I@!- *0 4@"C %8 H0!; )\ 80"> &< G !O )H > "7
M (, E0"0 ), G@"1 +  D #( (X \ "- /\ B@#_ (4 _P"" /\ YP   -T
M  #&    N    *X   "H  0 I0 , *$ $@"A !D H  B )\ *0"; #  F  W
M )8 /0"3 $( D@!' )  2P"/ %  C0!5 (P 6@"* &$ B !H (< < "% 'L
M@P"( ($ E@!_ *< ?0"\ 'P XP!\ /T ? #_ '@ _P!V /\ U@   ,    "O
M    HP   )D   "3    CP ) (T #@"+ !0 B@ < (H (P"( "H A0 P (,
M-@"" #L @ !  '\ 10!^ $H ? !/ 'L 5 !Z %H > !A '8 :0!U ', <P"
M '$ C@!O )\ ;@"R &T SP!L /0 ; #_ &L _P!I /\ P    *L   ";
MCP   (<   "     ?  $ 'H # !X !$ >  7 '@ '@!W "0 =0 J ', , !Q
M #4 <  Z &X /P!M $0 ; !) &L 3@!J %0 : !; &< 8P!E &T 9 !X &(
MAP!@ )< 7P"J %X P@!> .D 7@#_ %X _P!= /\ K    )D   "*    ?P
M '<   !Q    ;0   &H " !I  X :  2 &< & !G !\ 9P E &4 *@!C "\
M8@ T &$ .0!@ #X 7P!# %X 2 != $X 6P!5 %H 70!8 &< 5P!R %4 @0!4
M )$ 4P"C %( N !1 -P 40#Y %( _P!2 /\ G0   (L   !\    <0   &D
M  !D    8    %X !0!<  L 6P / %L % !: !D 6@ ? %D )0!7 "H 5@ O
M %4 - !4 #@ 4P ] %( 0P!0 $D 3P!0 $X 6 !- &( 2P!M $H >@!) (L
M2 "= $< L0!' ,P 1@#P $< _P!' /\ D    'X   !P    9@   %X   !9
M    5@   %,  0!2  @ 4  - $\ $ !/ !4 3@ : $X ( !- "4 3  J $H
M+@!) #, 2  X $< /@!& $0 10!+ $0 4P!# %T 00!H $  =0 _ (4 /@"7
M #T JP ] ,, /0#F #T ^P ^ /\ AP   '4#  !H!@  70<  %4&  !0!@
M3 0  $H!  !)  0 1P * $8 #@!% !$ 10 6 $0 &P!# "  0@ E $$ *@!
M "\ /P T #X .@ ] $  .P!' #H 3P Y %D . !D #< <0 V ($ -0"3 #0
MI@ T +L - #= #0 ]0 U /\ ?@8  &T)  !@"P  5@P  $X,  !("P  1 H
M $((  ! !0$ /P$' #X "P ]  X /  2 #L %P [ !P .@ A #D )0 W "H
M-@ P #4 -0 T #P ,P!# #( 3  Q %4 , !@ "\ ;0 N 'T +0"/ "P H@ L
M +8 + #0 "P [@ L /P =PH  &<,  !:#@  4 X  $D.  !##@  /@T  #L,
M   Y"P  . D# #<%"  V @T -0$0 #0 $P S !@ ,@ = #$ (@ P "< +P L
M "X ,@ M #@ + !  "L 20 J %( *0!= "@ :P G 7H )@&, "4 GP E +(
M)0#* "4 Z  E /< <@T  &(.  !6$   3!$  $01   ^$0  .1   #8/   S
M#@  ,0T! # +!0 P" H +P8- "X%$0 L!!0 *P,9 "H#'@ I R, * 0I "<$
M+P F!34 )04] "0%1@ C!E  (@9< "$':0 @!WD 'P>+ !X'G0 >![  '0;&
M !T&XP =!?, ;0X  %X1  !2$@  2!,  $ 3   Z$P  -1(  #$1   N$
M+ \  "H. P J#0< *0L+ "@)#@ G"1$ )0@6 "0(&P C"2  (@DF "$)+  @
M"C, 'PH[ !X+1  ="T\ ' Q; !L,:0 :#'D & R+ !@,G@ 7#+  %@S% !8,
MX0 6"_  :1   %H2  !.%   114  #T5   W%0  ,10  "T3   J$@  *!$
M "80 0 D$ 0 (PX( ",-#  B# \ ( P3 !\,&  >#1T '0TC !P-*@ ;#3(
M&@XZ !@.1  7#E  %@]< !4/:@ 3$'L $A"- !$0H  1$+, $ _) ! /Y  1
M#_( 91(  %<4  !+%@  0A<  #H7   T%P  +Q8  "H5   G%   )!,  "(3
M   @$@, 'A$& !T0"0 <$ T &P\0 !D0%0 8$!L %Q A !80*  5$3  %!$Y
M !,10P 2$DX $1): ! 2:0 0$WD #A.,  X3G@ -$[$ #1+%  P2X0 -$O$
M8A0  %06  !)&   /QD  #<9   Q&0  +!@  "@7   D%@  (18  !\5   <
M% ( &A,$ !D2!@ 7$@L %1(. !02$@ 3$Q@ $A,? !$3)@ 1%"T $!0V  \5
M00 .%4P #A97  T690 ,%W4 "Q>'  H7F@ )%JT "!;!  @6W0 )%>X 7Q8
M %$8  !&&@  /1H  #4;   O&@  *AH  "49   B&   'Q@  !P7   9%@$
M%Q8# !46!  3%@D $18- ! 7$0 /%Q8 #A<<  X8(P -&"H #!DS  P9/  +
M&D< "AI3  D:80 '&W$ !AN#  4;EP $&JH  QJ_  ,9V@ $&>P 7!@  $X:
M  !#'   .AP  #,<   L'   )QP  ",;   @&@  '1D  !H9   7& $ %1@"
M !(9!  0&P< #AL,  T<$  ,'!, "QP9  H<'P )'2< "!TO  <>.0 &'D,
M!!Y0  ,?7@ "'VX  1^    ?E0  'JD  !Z]   =V   '>P 6!H  $L<  !!
M'@  .!X  # >   J'@  )1T  "$<   >'   &QL  !@;   6&P$ $QL" !$<
M!  .'@< #!\+  H@#@ ((!( !B$7  4A'0 $(20  B(L  $B-0  (D   "--
M   C6@  (VL  "-^   CDP  (J<  "*\   AUP  (>T 51T  $@?   ^(
M-2   "X@   H(   (Q\  " >   ='0  &AT  !8=   3'@  $1\"  X@!  -
M(@< "B0+  8E#0 $)1   B84   F&@  )B$  "<I   G,@  )ST  "=)   H
M5P  *&<  "=[   GD   )Z4  ":[   FU@  )>T 42   $4A   [(@  ,B(
M "PB   F(0  (B$  !X@   ;'P  &"   !0@   1(@  #R,   TE P *)@8
M!B@*  ,I#0  *P\  "P2   L%P  +!X  "PF   M+P  +3D  "U&   M5
M+60  "UW   LC0  +*0  "NZ   KU@  *NX 32(  $$D   X)   ,"0  "DD
M   D(P  (2(  !TB   9(@  %2,  !(D   /)@  #2@   HJ @ &+ 4  BX)
M   O"P  , X  #(0   S%0  ,QL  #,B   S*P  ,S8  #-"   S4   ,V
M #-S   RB@  ,J$  #&X   PU@  ,.\ 224  #XF   T)P  +2<  "@F   C
M)0  'R0  !LE   6)@  $B@  ! J   -+   "BX   8P 0 ",@0  #0'   U
M"@  -PP  #@.   Z$@  .A<  #H?   Z)P  .C(  #H^   Z3   .EP  #IO
M   YA@  .)X  #BV   WU   -N\ 1"D  #HI   Q*0  *RD  "8H   B)P
M'2@  !@I   3*P  $"X   TP   ),@  !34   $W    .0(  #L%   \"
M/@L  #\-  !!$   0Q0  $,;  !#(P  0RX  $,Y  !#1P  0E<  $)J  !!
M@0  0)H  #^R   ^SP  /N\ /RP  #8L   O+   *BL  "4J   ?*P  &2T
M !0O   0,@  #34   @X   $.@   #P    _    00   $,"  !%!0  1@@
M $@+  !*#@  3!$  $T6  !-'@  32@  $TT  !,0@  3%$  $MD  !+>P
M2I0  $FM  !(R@  1^P .S   #,O   M+P  *"T  "(O   ;,0  %30  ! W
M   -.@  "#T   )     0P   $8   !(    2@   $P   !. 0  3P0  %$'
M  !3"P  50X  %@2  !9&0  6"(  %@N  !7/   5TL  %9>  !6<P  58T
M %2G  !2P@  4N8 .#,  #$R   L,0  )3(  !TU   6.   $3P   Q    '
M1    $<   !*    30   %    !3    50   %<   !9    6@   %P#  !>
M!P  80L  &0.  !F$P  9QP  &8G  !F-   940  &17  !D:P  8H4  &&?
M  !@N0  7MP -3<  # U   H-P  (#H  !@]   10@  #$8   9*    3P
M %,   !6    60   %P   !?    80   &0   !E    9P   &D   !L 0
M;@8  '$+  !T#P  =Q4  '<@  !V+0  =CT  '5/  !T8P  <WL  '*5  !P
MKP  ;\D -3H  "L[   B/P  &D,  !)(   ,30  !5(   !7    7    &
M  !D    :    &L   !N    <0   ',   !U    =P   'H   !\    ?P
M (($  "&"@  B@\  (P7  "+)   BC,  (E%  "'6P  AG(  (6+  "#I0
M@KP +T   "5$   <20  $TX   U4   $6@   &$   !F    :P   &\   !T
M    >0   'T   "     @P   (4   "'    B@   (P   "/    D@   )8
M  "9 @  G@D  *(0  "B&@  H2D  * [  "?4   G6<  )J!  ":F0  F:\
M*4D  !].   55   #EL   5B    :0   '    !W    ?0   ((   "&
MBP   (\   "3    E0   )<   ":    G0   *    "C    I@   *H   "N
M    L@   +<*  "[$0  NA\  +DP  "W10  M5P  +1T  "QC@  KZ0 (E0
M !A;   08@  !VH   !S    >P   ((   ")    D    )4   ":    GP
M *,   "F    J    *L   "N    L    +,   "V    N@   +T   #"
MQP   ,P!  #3"P  U!4  -,F  #1.@  T%$  ,UH  #+@0  RI8 _    /8
M  #R    \0   /, !0#T  P \@ 3 /  ' #M "4 Z  N .( -@#> #X V0!$
M -0 2@#1 $\ S@!4 ,L 60#) %X Q@!C ,0 :0#! '  O@!X +P @0"Y (T
MM@": +, JP"Q ,  KP#F *X _P"E /\ F@#_ )0 _P"/ /\ ]    .P   #H
M    YP   -\   #9  D T@ 0 ,\ %P#/ "  S  H ,8 , #  #< O  ^ +D
M1 "W $D M0!. +, 4P"Q %< KP!= *T 8@"K &D J0!Q *< >@"E (4 H@"3
M *  H@"= +8 FP#4 )D ^0"6 /\ C0#_ (@ _P"$ /\ Z    -\   #9
MR0   +\   "X  0 M0 - +, $@"Q !H L  B *T *@"I #$ I@ X *0 /0"B
M $, H !( )X 3 "< %$ FP!6 )D 7 "7 &( E0!I ), <@"1 'T CP"+ (T
MF@"+ *P B0#% (@ [@"& /\ ?P#_ 'H _P!X /\ V0   ,T   "[    K@
M *4   "?    G  ) )D #P"9 !4 F0 = )@ ) "4 "L D0 Q (X -P", #P
MBP!! (D 1@"( $L A@!0 (4 50"# %L @@!B (  :P!^ '4 ? "" 'H D@!X
M *, =P"Y '8 X !U /\ <@#_ &X _P!L /\ QP   +4   "E    F0   (\
M  ")    A0 $ (0 # "" !$ @@ 7 (( '@"  "4 ?@ K 'P ,0!Z #8 >0 [
M '< 0 !V $0 =0!) ', 3P!R %4 < !< &\ 9 !M &X ; !Z &H B@!H )L
M9P"O &8 S !E /4 9 #_ &$ _P!@ /\ M    *    "0    A0   'T   !W
M    <P   '  " !O  X ;P 2 &\ & !O !\ ;0 E &L *@!I #  :  T &<
M.0!F #X 90!# &, 2 !B $X 80!5 %\ 7@!> &< 7 !S %L @@!9 ), 6 "F
M %< OP!7 .H 5P#_ %8 _P!4 /\ H0   (X   !_    =0   &P   !H
M9    &$ ! !@  L 7P / %\ $P!? !D 7P ? %T )0!< "H 6P O %D ,P!8
M #@ 5P ] %8 0P!5 $D 4P!0 %( 6 !1 &$ 4 !M $X >P!- (P 3 "? $L
MM0!* -P 2@#Z $H _P!* /\ D@   (    !R    9P   %\   !:    5P
M %4  0!3  < 4@ , %( $ !2 !0 4@ : %$ 'P!/ "0 3@ I $T +@!, #,
M2P X $H /0!) $, 2 !* $8 4@!% %P 1 !G $, =0!" (8 00"8 $  K@!
M ,L /P#R $  _P!  /\ A0   '0   !G    70   %4   !/    3    $H
M  !(  0 1P * $< #0!& !$ 1@ 5 $8 &@!% !\ 1  D $, *0!" "T 00 S
M #\ .  ^ #X /0!% #P 3@ [ %< .@!B #D ;P X (  -P"3 #8 IP V ,
M-@#H #8 _@ V /\ ?    &L   !> @  5 ,  $T#  !' P  0P$  $$    _
M  $ /@ ' #T "P ]  X /  1 #P %@ \ !H .@ ? #D )  X "D -P N #8
M,P U #H - !! #, 20 R %, ,0!> #  :P O 'L +@". "T H@ M +@ +0#=
M "T ^  N /\ <P$  &0%  !7!P  30@  $8(  ! "   .P<  #@%   W P
M-@ $ #4 "  T  P -  / #0 $@ S !8 ,@ ; #$ (  P "0 +P I "X +P M
M #8 +  ] "L 10 J $\ *0!: "@ 9P G '< )@") "8 G0 E +, )0#/ "4
M\  F /\ ;08  %X)  !2"P  2 P  $ ,   Z"P  -@L  #(*   P"   +@8"
M "X#!@ M  H +  - "P $  K !, *@ 7 "D '  H "  )P E "8 *P E #(
M)  Y ", 0@ B $L (@!7 "$ 9  @ ', 'P"% !\ F0 > *X '@#' !X Z0 ?
M /H : D  %D,  !-#0  0PX  #P.   V#@  ,0T  "T-   J#   * L  "<)
M!  F!@@ )@0+ "4##@ D 1  ) $4 "(!&  A 1T (0 B "  *  ? "X '@$V
M !T!/P < 4D &P%4 !H!80 : 7  &0&" !@ E@ 8 *H & #! !@ X0 8 /0
M8PP  %4.  !)#P  0!   #@0   R$   +0\  "D.   F#@  (PT  "(, P @
M"P8 ( D) !\'#  >!@X '@41 !P%%0 ;!1H &@4? !H%)0 9!2L & 4S !<&
M/  6!D8 %@92 !4'7P 4!VX $P>  !('E  2!J< $@6\ !($V0 2 ^\ 7PX
M %$/  !&$   /!$  #41   O$0  *A$  "80   B$   ( \  !T. @ <#04
M&@T' !H+"@ 9"@T & D0 !<)$@ 6"1< %0D< !0)(@ 4"BD $PHQ !(*.@ 2
M"T4 $0M1 ! ,7P /#&X #@R   X,E  -"Z< #0NZ  T*T@ -"NH 7 \  $X1
M  !#$@  .A,  #(3   L$P  )Q(  ",1   ?$0  '!   !H0 @ 8#P0 %@X'
M !4."0 4#0L $PP- !(,$  2#!0 $0P: !$-(  0#2@ #PTP  X..P -#D8
M#0Y1  P/7@ +#VT "@]_  D/DP )#Z8 " ZY  @.T  '#N@ 6!$  $L2  !
M$P  -Q0  # 4   I%   )10  "$3   =$@  &A(  !<1 @ 5$04 $Q ' !(0
M"0 1#PH $ X,  X.#@ .#Q( #1 8  T0'@ ,$"4 #! M  L1-@ *$4$ "1%-
M  @26@ '$FH !A)\  42D  $$J0  Q&X  ,1SP "$>@ 51(  $D4   ^%0
M-18  "T6   G%@  (A4  !X4   ;%   &!,  !42 P 3$@4 $A$' ! 1"0 /
M$0H #1$+  P2#@ +$A$ "A(5  D3&P )$R( "!,J  <4,P %%#X !!5*  ,5
M6  "%6<  15Z   5C@  %:,  !2W   4SP  $^D 4A0  $86   [%P  ,A<
M "L7   E%P  (18  !P6   9%0  %A0! !03!  2$P8 $1((  \2"  .$PD
M#!0*  H5#0 (%A  !A83  46&0 $%Q\  Q<G  (8,  !&#L  !E'   950
M&60  !EW   9C   &*(  !BW   7SP  %^H 3Q8  $,8   Y&0  ,!D  "D9
M   C&0  'Q@  !L7   8%@  %14" !,5!0 1% 8 $!0&  X5!P ,%@@ "A<*
M  <9#  $&@X  AL2  $;%@  &QT  !PD   <+0  '#@  !U$   =4@  '6(
M !UU   =B@  '*   !RV   ;T   &NL 3!@  $ :   V&P  +1L  "8;   A
M&@  '1D  !D9   7&   %!<# !(6!  0%P0 #A<$  P9!0 *&@< !QP)  ,=
M"P  'PT  " 0   @%   (1H  "$B   A*@  (34  ")!   B3P  (E\  ")R
M   AB   (9\  ""V   ?T0  '^T 2!H  #T<   S'0  *QT  "0=   @'
M'!L  !@:   6&0$ $QD! !$9 0 .&@$ #!P"  H= P ''P4  R$(   B"@
M) P  "8.   F$@  )A@  "<?   G)P  )S(  "<^   G2P  )UP  "=N   F
MA0  )IT  "6T   DT0  (^X 1!T  #D?   P'P  *!\  ",>   >'0  &QP
M !@;   4'   $1P   X=   -'P  "B$   8B 0 #) 0  "8&   H"   *@L
M "L-   M$   +14  "T<   M)   +BX  "XZ   N2   +5@  "UJ   M@0
M+)H  "NR   JT   *>\ 0"   #8A   M(0  )B$  "$@   ='P  &AX  !8>
M   2'P  #R$   TB   *)   !B8   (H    *P(  "T$   O!@  , D  #(,
M   T#@  -1(  #48   U(   -2H  #4V   U0P  -5,  #1F   T?   ,Y8
M #*O   QS0  ,.\ /",  #(D   J)   )",  " B   <(0  %R$  !,C   0
M)0  #2<   DI   %*P   2X    P    ,@   #0!   V!   . 8  #H)   \
M#0  /A   #X4   ^'   /B8  #XQ   ^/P  /4X  #UA   \=P  .Y$  #JK
M   YR0  ..T -R<  "\G   H)@  (R4  !\D   9)0  %"8  ! H   -*P
M"2X   4P    ,P   #4    X    .@   #P    ^ 0  0 ,  $('  !$"@
M1@T  $D1  !)%P  2"$  $@L  !'.@  1TD  $9;  !%<0  1(L  $.E  !"
MPP  0>@ -"H  "PJ   G*   (B<  !PH   6*@  $2T   TP   ),P   S8
M   Y    /    #X   !!    0P   $8   !(    2@   $P#  !.!@  4 H
M %,.  !4$P  5!P  %,G  !3-   4T,  %)5  !1:@  4(,  $^>  !-N0
M3.  ,"T  "LL   F*P  'RP  !@N   2,@  #34   @Y   "/0   $    !#
M    1@   $D   !,    3@   %$   !3    50   %<   !9 0  7 8  %\*
M  !B#@  8Q4  &,?  !B+   83P  &!.  !?8@  7GL  %R6  !;L   6<\
M+S   "HO   B,   &C,  !,W   ..P  "#\   %$    2    $P   !/
M4@   %4   !8    6P   %T   !@    8@   &0   !F    :0   &T%  !P
M"P  =!   '08  !S)0  <C0  ')%  !P60  ;W$  &V+  !KI@  :L  +C,
M "4U   =.   %#P   Y!   '1P   $P   !1    50   %D   !=    80
M &4   !H    :P   &T   !O    <@   '0   !W    >@   'X   ""!
MA@L  (H1  ")'   B"L  (8]  "$4@  @V<  (&!  !_FP  ?K( *3H  " ]
M   60@  #T@   A.    5    %H   !@    9    &D   !N    <@   '8
M  !Z    ?0   (    ""    A0   (@   "+    C@   )(   "6    FP,
M * ,  "B$P  H"$  )\S  "=1P  FEX  )AW  "7CP  E:< (T,  !E(   1
M3@  "54   !<    8P   &H   !Q    =@   'L   "     A@   (H   ".
M    D0   ),   "6    F0   )P   "@    HP   *<   "K    L    +8$
M  "\#0  NA<  +DH  "W/   M%(  +)J  "OA0  K9P '$X  !-4   +7
M 60   !L    =    'P   "#    B0   (\   "4    F@   )\   "B
MI    *<   "J    K@   +$   "T    N    +P   #!    QP   ,T   #4
M!0  V!   -4>  #3,0  T$@  ,U?  #+=@  R(X
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M[>[O\/'R\_3U]O?X^?K[_/W^_VUF=#$      P0A   !
M     0                    $    ! @,$!08'" @)"@L,#0X/$!$2$Q05
M%A<8&1H:&QP='A\@(2(C)"4F)R@I*BLL+2XO,#$Q,C,T-38W.#DZ.SP]/C]
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MA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VO?
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MAJB'SH.HB<Z!IXS/@*>-SX"GC<^ IXW/@*>-SX"GC<^ IXW/@*>-SX"GC<^
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M@+&,PH"QC,* L8S"@+&,PH"QC,* L8S"@+&,PH"QC,* L8S"@+&,PH"QC,*
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MAJ.(U(.CC-2!HY'4@*29TX"FH=& IJ'1@*:AT8"FH=& IJ'1@*:AT8"FH=&
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MI+5EO*"R=+^>L7_"FZ^$PY:NA,61K83&C:V%QXJLALB'K(?)A:N(R8*KBLJ
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MV8Y^E]&-AZ+,C(VJQXJ1L<2(E+;#A9:XPH.9N<*!F[G!?YZZP7VAN\%[I+O
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MM\*1CKG C)"\OXB3OKV$E\"\@)O"NWV@P[M[IL2Z>JW%M'JNQ*]ZK\*L>[#
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MK9&[=K.0N'^WC;:$NXFTAKV%LHB_@K&+P7^QCL%\L9+">K&6P7FQF\%XLJ'
M=+&GP72QI\%TL:?!=+&GP72QI\%TL:?!=+&GP72QI\%TL:?!=+&GP?^N$@'_
MKQT-_ZXH)/^X)#'JRQHUT.(70[_P'5ZOZ"5UH-LQAY;12)20RER>C<5JI8O!
M=JJ)OGVOA;R LH*Z@[1^N8:V?+B)MWFWC+AWMX^Y=K:3NG6VE[ITMIVZ<[>D
MN7.WI+ESMZ2Y<[>DN7.WI+ESMZ2Y<[>DN7.WI+ESMZ2Y<[>DN?^P$ '_L1H-
M_[$E(_/$%R?4WQ KP>\72+#W(&"AZBMSE=\Y@HW73(V(T5V5ALQJFX3)=*"
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MJ:G,<:VJS'"RJ\MPMJO+;[RKR'# J\1QP*K$<<"JQ'' JL1QP*K$<<"JQ''
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MD*'+7YV8PVVHD;UYL8NX@[B#M(B]?;&0P7FQFL%UL:7!<J^OPG6HK\%WH[#
M>9^QOWN<LKU[G+*]>YRRO7N<LKU[G+*]>YRRO7N<LKU[G+*]>YRRO?^@$ '_
MI"0)_Z,R'/^H-"O_LR\T^;\M/.G-+T#9WB]*RN<T7[WJ.G.OWD&#H=-1D9?+
M8)V0Q&ZFC+]ZK8:[@;-_N(>X>K:-NW>UE;QUM9^\<K2HO6ZSLKYQK+*^=*>R
MOG:CLKUVH[*]=J.RO7:CLKUVH[*]=J.RO7:CLKUVH[*]=J.RO?^A$ '_I2,)
M_Z0Q'/^M+B?_N2DO[L@F,]K<)C?*YRQ/O?(R8Z_H.76AW4*$EM13D(_-8IJ*
MQW"BAL-ZJ("_@*U[O86Q=KN+M'.YDK5QN9JV<+FCM6VYJ[9JN+2X:[*VN&ZL
MMKANK+:X;JRVN&ZLMKANK+:X;JRVN&ZLMKANK+:X;JRVN/^C$ '_IR()_Z4O
M&_^S)R+TPB$FW=@=),OG(SR]\BI3K_,R9J'G.W:5WD:#C=96C8?09):$RW&<
M?\AXH7K%?J5VPH.I<L&)JV^_CZULOY:N:[Z=KFJ_IJYHOZZN9;VXL&6YN[!E
MN;NP9;F[L&6YN[!EN;NP9;F[L&6YN[!EN;NP9;F[L/^E$ '_J" (_ZPF%_R[
M'1KCT1,9S.49*;WR(D&O_2I5H?,T9I;I/W2,X4M_A=M9B(#59H]\T6^4=\YV
MF7/+?)QPR8&?;<B'H6K'C*-HQI*D9L69I63%H*5DQ:BE8\:RI&#$NZ9@Q+NF
M8,2[IF#$NZ9@Q+NF8,2[IF#$NZ9@Q+NF8,2[IO^H$ #_JAX(_[,=$>S)#@_.
MXPX5OO(8+:_^(D.A_RU5EO0Y9(SL16^$Y5%Y?N!<@'G<9X9TV6Z*<-9TCFS3
M>9%ITG^39]"$E63/BI=BSH^88,V5F5_-G)I>S:*;7<VKFUS-M)I<S;2:7,VT
MFES-M)I<S;2:7,VTFES-M)I<S;2:7,VTFO^K#P#_K1H'\L -",[3"@:^\ X:
MK_X9,*'_)$.5_S)2B_@_7H/Q2VA][%9P=^A?=G'D97ILX6Q^:=]R@6;=>(1C
MW'V&8=N"B%_:AXE=V8R+6]B2C%G7F(U8UIZ-5]:ECE;5K(Y6U:R.5M6LCE;5
MK(Y6U:R.5M6LCE;5K(Y6U:R.5M6LCO^O#0#_MPX#S<D( ;[8"0FN_1 <H?\<
M+Y7_*3^+_S=,@OY%5GSY4%YU]%ED;O%?:6CN9&UDZVIP8>IP<U_H=75=YWIW
M6^9_>%GEA'E8Y(E[5N..?%7BDWU4XIA^4N&>?E'AI7]1X:5_4>&E?U'AI7]1
MX:5_4>&E?U'AI7]1X:5_4>&E?_&T" #.P 8 O<X' :[@!PN@_Q(<E/\@*XK_
M+SB!_SU#>O])2W/_4E%L_E=79?M=6V'Y8UY>]VA@6_5M8ECT<F16\W=F5?)[
M9U/Q@&A1\(1I4/"):D_OCFM.[I-L3.Z9;4OMGVY+[9]N2^V?;DOMGVY+[9]N
M2^V?;DOMGVY+[9]N2^V?;M&Y P"\Q04 K=8# 9_X"PN3_Q88B?\D)(#_-"]Y
M_T$W</](/FC_3T-B_U5'7?]:2UG_8$U6_V504_]J45'_;E-/_W)43O]V54S^
M>U9+_7]72?V$6$C\B%E'^XU:1ON36T7ZF%Q%^IA<1?J87$7ZF%Q%^IA<1?J8
M7$7ZF%Q%^IA<1?J87+V] P"MS0$ GM\  9+_#0B'_QD2?O\I&W7_-2-L_SPJ
M9/]#+U[_2C18_U W5/]6.E'_6SQ._V ^2_]D0$K_:$%(_VQ"1O]P0T7_=$1$
M_WA%0O]]1D'_@4= _X9(/_^,23W_D4H]_Y%*/?^12CW_D4H]_Y%*/?^12CW_
MD4H]_Y%*/?^12J[%  ">UP  C_4  8;_#P1\_QL+<?\D$6?_+!=?_S4<6?\]
M(53_129/_TLI3/]2+$C_5R]&_UTP1/]A,D+_9C- _VHU/_]N-CW_<S<\_W<X
M._]\.3K_@3HX_X8Z-_^,.S;_DCPV_Y(\-O^2/#;_DCPV_Y(\-O^2/#;_DCPV
M_Y(\-O^2//^#$P'_A"(&_X4U%/^#1B3_?U4T_X%>0O^!9E#_?VY<^7QW9O-Z
M@&_N=XAWZG6/?>=RE8+D<)J%XVZ>B.%LHHO@:Z>-WVFKCMYHKY#=9[21W6:Z
MD=QEP9+<9<F2VV70DM)GTI'.:-*1SFC2D<YHTI'.:-*1SFC2D<YHTI'.:-*1
MSFC2D?^#$P'_A"(&_X4U%/^#1B3_?U4T_X%>0O^!9E#_?VY<^7QW9O-Z@&_N
M=XAWZG6/?>=RE8+D<)J%XVZ>B.%LHHO@:Z>-WVFKCMYHKY#=9[21W6:ZD=QE
MP9+<9<F2VV70DM)GTI'.:-*1SFC2D<YHTI'.:-*1SFC2D<YHTI'.:-*1SFC2
MD?^#$P'_A"(&_X4U%/^#1B3_?U4T_X%>0O^!9E#_?VY<^7QW9O-Z@&_N=XAW
MZG6/?>=RE8+D<)J%XVZ>B.%LHHO@:Z>-WVFKCMYHKY#=9[21W6:ZD=QEP9+<
M9<F2VV70DM)GTI'.:-*1SFC2D<YHTI'.:-*1SFC2D<YHTI'.:-*1SFC2D?^$
M$P'_A2(&_X8U%/^$1B3_@%4T_X1=0_^%95#_@VU=^(!U:/)]?G'L>H9YZ'>-
M?^5UDX7B<IB)X'"=C-]NHH[=;*:0W&NKDMMIKY3::+65VF>[E=IFPY;:9LR6
MTVC/ELQISY7(:L^6R&K/ELAJSY;(:L^6R&K/ELAJSY;(:L^6R&K/EO^%$@'_
MAR(&_X<U%/^%1B3_A%0U_XA<0_^(9%'^AVM>]X-R:?& ?'/K?85[YWJ,@N-W
MDH?@=)>,WG*<C]QPH9+;;J:4V6RJEMEJL)C8:;:9UVB]F==HQIK3:,R:S&K,
MF<9KS)K";,R:PFS,FL)LS)K";,R:PFS,FL)LS)K";,R:PFS,FO^&$@'_B"$&
M_X@U%/^&1B7_AU,U_XM;0_^,8E'^BFI>]H=Q:O"$>G3J@(-]Y7V*A.)ZD(K>
M=I:/W'2;DMIQH)78;Z68UFVKFM5KL)O5:K><U&F_G=1IR9W,:\J=QFS)G<!M
MR9V];LF=O6[)G;UNR9V];LF=O6[)G;UNR9V];LF=O6[)G?^'$@'_B2$&_XHU
M%/^(1B7_BE(U_XY:0_^/85'^CFA>]HMO:N^'>'7IA(%^Y("(AN!\CXS=>921
MVG::E=ASGYG5<*6;U&ZJGM-ML9_2:[B@TFO"H<ULQZ'&;L>AP&['H;MOQZ&X
M<,>AN'#'H;APQZ&X<,>AN'#'H;APQZ&X<,>AN'#'H?^($0'_BB$&_XLU%/^)
M1B7_C5$U_Y)80_^27E'^D&5>]HYL:^^+=7;HAWZ XX2&B-Y_C8_;>Y.4V'B9
MF=5UGIS3<J2?T7"JHM!NLJ/0;;JDSFS$I<9OQ*2_<,2ENG'$I;5QQ*6R<L2D
MLG+$I+)RQ*2R<L2DLG+$I+)RQ*2R<L2DLG+$I/^)$0'_BR$&_XPT%/^*1B7_
MD$\T_Y160_^46U'^DV%>]I%H:^Z.<';HBWN XH>#B=V#BI'9?I&7U7J7G--W
MG:#0=*2CSW&JILYOLZ?-;KVHQW#"J+YQP:FX<L&IM'/!J:]TPJBM=,*GK73"
MIZUTPJ>M=,*GK73"IZUTPJ>M=,*GK73"I_^*$0'_C"$&_XTT%/^+1B;_DTXT
M_Y930O^76%#^EEY>]I1D:NZ2;';GCW:!X8R BMR'B)+8@H^9TWV5G]!YG*/.
M=:.GS'*KJLMPM*O(<+^LOW.^K+=TOJVR=;ZLKG:_K*IVOZNH=\"JJ'? JJAW
MP*JH=\"JJ'? JJAWP*JH=\"JJ'? JO^+$0'_C2 &_XXT%/^-12;_EDTS_YE0
M0?^:54__FEI=]YA@:>^5:'7HDG" X8][BMR+A)/6AHR:TH"3H<Y[FJ;,=Z*J
MRG2KKLARN*_ =+ROMW6\L+!VO+"K=[ROJ'B]KZ5YOJVC>;ZMHWF^K:-YOJVC
M>;ZMHWF^K:-YOJVC>;ZMHWF^K?^+$ '_CB &_X\T%/^/1"7_F$HS_YM-0/^=
M44[_G5=;^)Q<:/":8W3HEVI_XI-UBMR/@)/6BHF;T820H\U^F*G)>:*NQW6M
ML<1TNK.W=KFSKWBYLZIYNK.F>KJRHWN[L:![O+"??+VNGWR]KI]\O:Z??+VN
MGWR]KI]\O:Z??+VNGWR]KO^,$ '_CR &_Y T%/^20R7_FD@R_YU*/_^?3DW_
MH%-:^:!89O&?7W+JG&5]XYAOB-R3>I+6CX2;T(B-H\N!EJO'>Z&QQ7:PM;IW
MM[:O>;>VJ'JXMJ-\N+2@?+FSGGVZLIQ^N[&;?KRPFWZ\L)M^O+";?KRPFWZ\
ML)M^O+";?KRPFWZ\L/^-$ '_CR &_Y$T%/^40R3_FT8Q_Z!(/O^B2TO_I%!8
M^J159/.D6G#KHF%[Y)]IA=Z:<Y#7E7Z9T(Z(H\J%DZS$?:#_XO__24-#7U!2
M3T9)3$4 !0FTO7BPN:]YM;FF>[:XH7VWMIU^N+6;?[FTF7^ZLYB NK*7@+NQ
MEX"[L9> N[&7@+NQEX"[L9> N[&7@+NQEX"[L?^-$ '_D" &_Y$T%/^70B3_
MG4,P_Z)%/?^E2$G_J$Q5_*E18?6J5VSNJ5UWYZAC@>&D;8O6GGF6RY6#HL"+
MCJVV@YJVKGZJNZ1\L[R>?K6ZFH"WMYB!N+66@;FTE8*ZLY2"NK*3@KNQDX*[
ML9."N[&3@KNQDX*[L9."N[&3@KNQDX*[L?^.$ '_D2 &_Y(T%/^902/_GT$O
M_Z1"._^H14?_K$E3_JY.7O6P4VCLLEIRY+-A>]NO;H3,IG:4P)Q^HK22B*ZI
MBI2WH(6DO9F"L;Z5@[2[DX2VN)*$N+:1A+FTD(2YLY"$NK*0A+JRD(2ZLI"$
MNK*0A+JRD(2ZLI"$NK*0A+JRD(2ZLO^/#P'_DB &_Y,T%/^:/R+_H3\N_Z=
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MOZMFL+^L::J_K&REOZMMHL"J;:+ JFVBP*IMHL"J;:+ JFVBP*IMHL"J;:+
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MK$<[]J]-1.VQ5$WELUM5W+!E8<ZH;''#GW2 N)9\C:Z/AIBEB)&AG8.=IY>
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M_Y\A!?^N( ;XO1@&X]$3!-#A'@G%ZBX9NNDZ*;#G0SFDY$I(F.)05HS@5V*
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M4\3>@5/$WH%3Q-Z!4\3>@5/$WH%3Q-Z!4\3>@?^2# #_H T V[<& ,K#!P#
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M@5RFWX%<IM^!7*;?@5RFWX%<IM^!7*;?@?^ #P'_C@X!_Z(- -NU" #.P0@
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M%P6;]2<0DO4T'(CV/B=_]D<R=O9..VSV5$)D]EI(7?9B35?V:U%2]G553?>
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M, ]1_S<32_\^%T;_11E!_TP;/?]2'3G_6!\V_U\A-/]F(C'_;B0O_W<E+?^
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M>6V,Y7AMC.5X;8SE>&V,Y7AMC.5X;8SE>/]N$P'_>Q$!_XT0 /^=$ #ZK!$
MVKL+ -7)"P#-SAL!PLPO"K?)/1FLQ4DIH<!2.)>\6D:-N&%1@[5H6WJR<&1R
MKWEK:ZR#<62KCW9?J9YZ6ZFO?%FJR7Q:I^)[7J#C>V&;XWICE^1Y9I3E=V:2
MYG=FDN9W9I+F=V:2YG=FDN9W9I+F=_]P$@'_@ X!_Y(. /*C"P#9LPD S[X)
M ,O,"0#$TQ< NM(L![#/.Q:ES$8FFLA0-8_$6$&%P5]-?+YG5G.\;UYKN7=E
M9+B":UZVCG!9M9US5;6N=52VR'53L^=V5ZOF=EJDYG9<H.=U7YSG=&":Z'1@
MFNAT8)KH=&":Z'1@FNAT8)KH=/]R$@'_A@P ^Y@) -FI!@#.M0< QL$' ,#/
M"0"ZVQ, L=HI!:?8-Q*<U$0ADM%-,(?.53Q]RUU'=,EE4&S';5=EQ79>7L2!
M8UG#CFA4PYUK4<.N;$_$R&U.PNUM4+CK;U.PZW!5J^IP6*;K<%FCZW!9H^MP
M6:/K<%FCZW!9H^MP6:/K</]W#P'_C0@ WJ " ,^N!0#$N04 N\4& +73"@"N
MX18!IN$I!IW@-Q&3WD(=B=Q,*7_:5#5UUUP_;=5D2&73;$]?TG946=*!6531
MCEU0T9U@3=*P8DO3R6)*TNUB2\CR9DV_\6A/N/!I4;+P:5*O[VE2K^]I4J_O
M:5*O[VE2K^]I4J_O:?]_"@#ME@  TJ8! ,2R P"YO , L,D& *G8"@"AYQD"
MF><J"9#G-Q2'YD(??>5**73D43-KXUDZ9.)A05[B:T=8XG5+4^& 3T_BC5-+
MXIM52>.L5T?DQ%=&X^E71MWV64?0]UQ)R/=>2L'V8$N]]F!+O?9@2[WV8$N]
M]F!+O?9@2[WV8/^)  #9G@  QZP! +FV @"NP0, I<X& )SD# "5[QT#C>\L
M"X7O.15\[T$><^]))VKN4"]B[E<U7.Y?.E;N:#]2[G%"3>]\1DGOB4E&\)9+
M0_"F34#QN4X_\MM//O#W3D+F^T]#W?M11-3\4T7/_%1%S_Q41<_\5$7/_%1%
MS_Q41<_\5.&5  #+I@  N[   *Z[ 0"BR ( F-4% )#X#P&)^" $@O@N"WGY
M-Q-P^3\;:/E&(F#Z32A:^E0M5/I<,4_[935+^VTX1_QW.T/\@ST__9 _//V?
M03K^KT,X_\9$-__J13;\_44[\O]$/NK_1#[F_T8^YO]&/N;_1C[F_T8^YO]&
M/N;_1M"?  "]K   KK4  *+"  "5SP  BMT# (3_$@%[_QX#=/\J"6S_,P]D
M_SL67?]#&U?_2B!1_U$D3/]8)TC_8"I$_V@L0/]Q+CS_>S$Y_X@R-?^6-#/_
MI#8Q_[8W+__0."[_[SDM__\Y,?__.3/\_SDS_/\Y,_S_.3/\_SDS_/\Y,_S_
M.<&H  "OL0  HKT  )3*  "'V   ??,' ';_$@%M_QH#9?\D!5[_+0I8_S8/
M4O\]$TS_119(_TP90_]3&S__6AX\_V$@./]I(37_<B,Q_WTE+O^*)BO_F2@I
M_Z<I)_^Y*R;_TBPE_^\L)/__+23__RTD__\M)/__+23__RTD__\M)/__+;&N
M  "CN0  E,8  (;3  !YX0  <?\( &?_#P%?_Q4"5_\> U'_)@5+_RX'1O\V
M"D'_/0P]_T0..?]+$#;_41(R_U@3+_]?%2S_9Q8I_W$7)O]\&"/_B1H@_Y@;
M'_^F'!W_MQT<_\H>'/_F'QO_\!\;__ ?&__P'QO_\!\;__ ?&__P'Z2U  "5
MP@  AL\  '?>  !K]   8O\# %G_"P%1_Q$!2O\7 D3_'P,__R8$.O\M!3;_
M- 8R_SH'+O] ""O_1@@H_TP))?]2"2+_60H@_V(+'?]K#!K_=@T7_X0.%?^2
M#Q3_H! 3_ZT1$_^Z$1/_PQ(3_\,2$__#$A/_PQ(3_\,2$__#$I>^  "&S
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M.O]"L#S_0K@]_T'!/O] RS__0-Q _S_I0/\_]$#_/OU!_T#_0/U"_T#V1?]
M\$;_0>E(_T'I2/]!Z4C_0>E(_T'I2/]!Z4C_0?]1'P+_3"D#_T<T!?]--@;_
M43L(_U5&$/]64!C_55P?_U)H)O]0="S_38 Q_TJ,-?](ESC_1J [_T6H//]$
ML#[_0[@__T/!0?]"S$'_0=Y"_T'K0_] ]4/_0/U#_T/_0_A&_T+P2/]#ZDG_
M1.-*_T7C2O]%XTK_1>-*_T7C2O]%XTK_1?]2'P+_32D#_THR!/]0,P;_53D(
M_UE#$/]:31C_65@@_U9D)_]3<2W_4'TS_TV)-_]+E#K_29X]_T>F/_]&KD'_
M1;="_T3!1/]$S$7_0]]%_T+M1O]"]T;_0_U&^4;_1O!)_T;I2_]'XDS_2-M-
M_TC;3?](VTW_2-M-_TC;3?](VTW_2/]3'@+_3B@#_TXO!/]4, ;_6C8(_UY
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M:WA\\&EX?/!I>'SP:7A\\&EX?/!I>'SP:?]@%P'_;A(!_WX0 /^,$0#_F1$
M\:03 ..N%@#6MAP!R[0P",&P/Q>WJTLEK:94,Z2A74"<G65*E)AL4XR5=%N&
MD7UB?XZ':'F,DFUTBIYQ<(BM=&V(P71MB>1S;X?J<7"$[&]R@^UM<X'N:W2
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M9F./\69CC_%F8X_Q9O]K$ '_?@D \9 $ -:> P#,J@8 Q+0& +Z^!0"XR!
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M*2W_ZBHL__\J+/__*B_Y_RHO^?\J+_G_*B_Y_RHO^?\J+_G_*KFF  "JK@
MG+D  ([%  "!T0  ==X  &WZ"0!E_Q$!7O\: E?_(P-2_RP%3/\T!TC_/ I#
M_T0,/_],#CS_4Q X_UL2-?]C%#+_;!8O_W<7+/^$&2G_DQHG_Z(<)?^T'23_
MS!XC_^T>(O_]'R+__Q\B__\?(O__'R+__Q\B__\?(O__'ZRK  "=M@  C\(
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M ?]T%0'_?1H!_X0A ?>)*@/MC30'Y(T]#=R+2!;1A50CR7]>+L)Z:#B\=7%
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M6X-O^UF#;_Q8@V_\6(-O_%B#;_Q8@V_\6/]6& '_9!$!_W(. /]^$ #_B!$
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M6G!\^UIP?/M:<'S[6O]?$0'_;PH _WX( .., P#6EP4 SZ ' ,JH" #$KA,
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M  #=B0  RI<  +ZB  "SJ@  J;,  *"\ @"8Q@8 D<P2 (O,)0*$RS0)?,E
M$G7(2AMMQU,C9\5<*F'$9#!<PVTV5\)V.E/"@3]/P8Y"2\&=14C!KD9'P<5&
M1\'J1D2^_TE%N?]*1[/_2TFM_TQ*J_],2JO_3$JK_TQ*J_],2JO_3.E_  #1
MD   PIX  +6G  "JKP  H+@  );! @",RP< A-4- (#5'@%YU2X%<M0\#&S3
M1Q1ETE ;7]%9(5K18B=5T&LL4=!U,$W/@31)SXXW1L^=.430KCM"T,8[0]#J
M.D#-_3X^R_] 0,/_0D&]_T-"N?]$0KG_1$*Y_T1"N?]$0KG_1-V(  #'F
MN*,  *NK  "@M   E;X  (O( P" T0< >.$- '3A'0%NX2L#:. W"&'@0@Y<
MX$T45^!6&5/@7QU/X&DB2^!S)4?@?BA$X(LK0N":+3_AJR\^XL$O/N+E+SS?
M^C$YWO\T.=G_-CK0_S@[S/\Y.\S_.3O,_SD[S/\Y.\S_.<V2  "\H   K:@
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M$Q[__Q,>__\3'O__$Q[__Q,>__\3'O__$Z:I  "8LP  BK\  'O*  !NU0
M8-\  %3G  !._P0 2?\. $/_%  __QT!.O\E C;_+ (R_S,#+_\Z RO_000H
M_T@$)?]/!2+_5P4@_V &'?]L!QK_>0<8_XH(%O^;"!7_K0D4_\,)$__C"1/_
M^ D3__\*$___"A/__PH3__\*$___"IJQ  "+O0  ?,@  &W4  !?X   4>8
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M0/<M[4#_+^L__S'D0?\RVT/_,]%$_S/+1O\SRT;_,\M&_S/+1O\SRT;_,_]
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M29-@_TB18/]'D6#_1Y%@_T>18/]'D6#_1_].& '_6A$!_V0. /]O$ #_=A,
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M2WMN_TM[;O]+>V[_2_]7$0#_8PH _W ' /!\!0#<A04 U(P( -"3"0#*EA0
MP9<I [F4.0NQD$86J8U0(**)6BJ<A6(REH)J.9%_<C^,?'I%AWJ#2H-XC4Y_
M=IA1>W6D5'ATLU9V=,A6=73H575U_5-U=/]1=7/_3W9R_TUV<?],=G'_3'9Q
M_TQV<?],=G'_3/]9$ #_9@< _W,$ .%_ 0#6B 0 SY & ,J6" #$FA( O)LF
M K28-PFLE404I)%.'YV.5RB6BF QD(=H.(N$<#^&@GA$@7^!27U]BTUX>Y91
M='JB5'%YL59O><56;GKF56YZ_%-O>?]1<'?_3W%V_TUQ=?],<77_3'%U_TQQ
M=?],<77_3/];#@#_:00 ]G<  -V"  #0BP, R9,% ,29!@"^GA  MI\D JZ=
M- BFFD$3GY9,'9B352>1D%XOBXUE-X6*;3V B'5#>X5^2':#B$QR@I-0;H"@
M4VM_KE5H?\)69W_C56B ^E-I?O]1:GS_3VM[_TUL>?],;'G_3&QY_TQL>?],
M;'G_3/]># #_; $ YGH  -:&  #+CP( Q)<$ +Z=! "XH@X L:,A :FB,@>A
MGS\1F9Q*&Y*94R6+EEPMA9-C-7^1:SMZCG-!=8Q\1G"*A4MKB)%/9X>=4F2&
MK%1BAK]588;A5&&&^5)CA/]098'_3V9__TUG?O],9W[_3&=^_TQG?O],9W[_
M3/]A"@#_;P  X'X  -")  #&DP$ OYL# +BA @"QI@L JJ@> :.G+P6;I3T/
ME*)(&8R?42*%G%DK?YIA,GF8:3ETE7$_;Y-Y1&J2@TAED(Y,88^;3UZ.JE);
MCKU26H[>4EN-^%!<B_]/7HC_3F"%_TQA@_]+88/_2V&#_TMA@_]+88/_2_]D
M!0#U=   VH(  ,N.  #!EP  N)X! +&E  "IJP< HZT: )RL+ 25JSH,C:A%
M%H:F3Q]_I%<H>:)?+W.@9C5MGFX[:)QW0&.:@45?F8Q)6YB93%>7J$Y5E[M/
M5)?<3E26]DY5E/]-6)#_3%F-_TM;BO]*6XK_2EN*_TI;BO]*6XK_2O]H  #E
M>0  T8<  ,62  "[G   L:(  *FI  "AL0( F[,5 )6S* *.LC8)AK!"$G^N
M3!MXK%0C<JI<*FRH9#%GIVPV8J5U.UVD?T!9HXI#5:*71U&AITE/H;I*3J+9
M24Z@]4E.G_])4)G_25*6_TA4DO]'5)+_1U22_T=4DO]'5)+_1_]N  #>?P
MRHT  +Z8  "SH   JJ<  *&N  "7M@  D;H0 (RZ(P&%N3(&?K@^#G>V21=Q
MM5(>:[-:)66R8BM@L6HP6[!S-5>O?3E3KHD]3ZV60$RMI4)*K;E#2:[80DBK
M]4-'JO]$2:7_1$N@_T1-G/]$39S_1$V<_T1-G/]$39S_1.IU  #2A@  PY,
M +>=  "LI   HJL  )BS  ".NP$ A<$, ('"'0![PBT#=<$Z"6_ 11%IOT\8
M8[Y7'EZ]7R-9O&@H5;MQ+5&[>S!-NH<T2KJ5-T>ZI3E%NK@Z1+K7.4.X]3M"
MMO\]0K/_/D2N_SY%J?\^1:G_/D6I_SY%J?\^1:G_/N!]  #)C0  NYH  *ZB
M  "CJ0  F+$  (ZY  "$P0( ><D' '3+% !PS"8!:\LU!67+0 I@RDL06\I4
M%E?)71I2R64?3LAO(TO(>B9'R(8I1,B4+$+(I"Y R+@O/\G7+S_']3 ]Q/\S
M.\/_-3R^_S8]N/\W/;C_-SVX_S<]N/\W/;C_-]&&  # E0  LI\  *6G  ":
MKP  CK<  (._  !XQP, ;L\' &77#0!CV!T 8-@M EO8.@17V$8)4]A0#4_8
M61%+UV(51]=L&$37=QM!UX0>/MB3(#S8HR$[V;<B.MK5(CK6\B,WU/\G-M+_
M*331_RLVRO\M-LK_+3;*_RTVRO\M-LK_+<60  "VG0  J*4  )RM  "/M@
M@[X  '?'  !LSP( 8M8' %KD#@!8Y!P 5.0I 5#D-0-,Y3\%2.5)!T7E4PI"
MYEP-/^9F#SSF<1(ZYWX4-^>,%C7GG!<SZ*X9,NG&&3+HZADQY?X9+^3_'"[D
M_QXMXO\@+>+_("WB_R MXO\@+>+_(+J:  "JHP  G:L  )"T  "#O0  =\8
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M!0[__P4.__\%#O__!96O  "&N@  =\4  &C0  !:VP  3.$  $#G   W\P
M,O\  "[_!P J_PX )O\3 "/_&@ ?_R  &_\F !C_*P$5_S(!$O\X 1#_0 $.
M_T@!#/]2 0G_70(&_VL"!/]] @+_D (!_Z," /^V @#_S0, _^P# /_L P#_
M[ , _^P# /_L XBY  !XQ   :=   %O=  !+XP  /ND  #+N   K_P  )O\
M "'_   =_P@ &O\- !;_$0 3_Q8 $/\:  [_'P +_R0 "?\J  ;_,  "_S<!
M /]  0#_2@$ _U8! /]D 0#_=0$ _X@! /^: 0#_J@$ _[L! /^[ 0#_NP$
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M,ZY-_S.J3O\RJ4[_,JE._S*I3O\RJ4[_,O]#&@'_3!, _U00 /]<$@#_81<
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M.XA?_SN(7_\[B%__._].$0#_6 H _V,' /IL!@#G<P8 W7@( -I["P#1?A<
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M1UZ![T9?@?]$8'__0F%]_T%B>_\_8WK_/V-Z_S]C>O\_8WK_/_]>  #I;0
MUGD  ,B$  "^C   MI,  *Z7  "FFP0 H)T7 )J=*0*3G#<(C)I#$(:831B
MEE4?>I1=)G6292QPD&PQ;(YU-F>-?CICBXD^7XJ505R)HT1:B;1%6(G+15B(
M[418B/]#68;_05N#_T!=@?\^78#_/EV _SY=@/\^78#_/O]B  #D<0  SWX
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M-T:@_S=(G/\W29K_-TF:_S=)FO\W29K_-^)T  #*@P  O(\  +"8  "EG@
MFZ0  )"K  "%L0  >K@$ ':Y% !RN24!;;DS!&BX/PACN$D.7K=2$UJV6AA6
MMF(<4K5K($ZT=21+M( G2+..*D6SG2Q"LZXM0;/%+D&SZ2U L/XO/Z__,3ZM
M_S) J/\R0:;_,D&F_S)!IO\R0:;_,M5\  #"B@  M98  *B=  "=HP  DJH
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M%BC:_Q8HVO\6*-K_%K.8  "EH   F:<  (NP  !^N   <<   &7(  !9S@
M3M,  $3;!  _Z0T />D7 #OJ(P YZBX -NLX 33K0@$Q[$L"+^U5 RWM7P,J
M[FL$*.YX!2;OB 8E[YH'(_"N!R+QR <B\.T'(>S_!R'K_P@@Z_\*'^K_"Q_J
M_PL?ZO\+'^K_"ZB?  ";I@  C:\  '^X  !QP0  9,H  %C0  !,U@  0=T
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M 82W  !TP0  9<P  %;8  !'WP  .>4  "WJ   C[@  '/T  !C_   5_P
M$?\$  __"P -_PX "?\1  ;_%0 #_QH  /\@  #_)@  _RX  /\W  #_00
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M*9U-_RF=3?\IG4W_*?]#$0#_2PP _U,( /]:"P#_7@T ^6 0 .MA%@#A8B$
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M/&UKZ3MM;/XY;6S_-VYL_S5N:_\T;FK_,FYJ_S)N:O\R;FK_,O]3  #T7P
MWFH  ,US  ##>@  NWX  +6!  "N@PD J(4: **%*P*;A#H'E8)%#I!_3Q6*
M?5@;AGM?((%Y9R5]=V\J>G9W+G9T@#)S<XLU;W*6.&QQHSII<+(\:'#&/&=P
MYSMG<?PY:''_-VAP_S5I;_\T:6[_,VEN_S-I;O\S:6[_,_]6  #K8@  V&X
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M-5:!_S18?_\S67W_,EE]_S)9??\R67W_,N]@  #;;@  QWH  +N#  "RBP
MJ)   )^3  "4E@  C9D. (F:'@"$FBX"?IDZ!WF710UTEDX3;Y56&&J37AUF
MDF4A8I%M)EZ/=BI;CH$M5XV-,%2,FC-1C*HU3XR]-4^,WC5/B_<T3XK_,U")
M_S)1AO\Q4H3_,5*$_S%2A/\Q4H3_,>IE  #2<P  PG\  +:(  "LD   HI0
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M)CND_R8[I/\F.Z3_)LQZ  "[B   KI(  **9  "7G@  C*0  ("J  !UKP
M:;0  %ZY!@!;NA0 6;LD %:[,0%3NST#4+M'!4V[4 =*NED*1[IB#42Z;!!!
MNG<3/KF$%3RYDQ<YN:,8.+FW&3>ZUADWN/0:-;;_'#2T_QXSL_\?,[+_(#.R
M_R SLO\@,[+_(,&#  "TD0  II@  )N>  "/I0  @JL  ':Q  !KM@  7[P
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M!:.=  "6I   B*P  'JU  !LO0  7\0  %/*  !'S@  /-,  #+:   JWP
M)>X) "/P$0 A\1D '_$B !WR*P ;\S0 &?0^ !?T2  5]5( $_9? !+V;@$1
M]X !$/B4 0_YJ@$.^<8!#OGM 0WV_P$-]/\!#?/_ 0WS_P$-\_\!#?/_ 9FC
M  "+K   ?+4  &V^  !?Q@  4LT  $72   YV   +]X  ";B   ?Z@  '/L&
M !G_#@ 7_Q, %/\: !+_(0 0_R@ #O\P  W_.0 +_T, "?].  ;_7  $_VP
M O^   '_E@  _ZT  /_*  #_\   __\  /__  #__P  __\  /__ (VK  !]
MM0  ;K\  &#(  !2T   0]<  #?=   KX@  (N8  !GJ   5^0  $O\  !#_
M"  ._PX #/\1  G_%@ &_QP  _\B  #_*@  _S,  /\]  #_20  _U<  /]I
M  #_?@  _Y4  /^L  #_QP  _^@  /_Z  #_^@  __H  /_Z ("U  !POP
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M+GU9YBU\6OHL>UK_*GM;_RA[6_\G>UK_)GI:_R5Z6O\E>EK_)?])  #[4@
MXUP  -)C  #':   P&L  +IK @"U:PT KFT= *AN+@&C;3P%G6M("IEJ40^4
M:%H4D&9B&(UE:AR*8W(@AV)Z(X1A@R:!8(PI?E^7*WM>HRUY7K$O=UW$+W5>
MXB]U7ODM=5__*W5?_REU7_\H=5[_)G5>_R9U7O\F=5[_)O]+  #P50  WE\
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M+61L_RMD:_\I96K_*&5J_RAE:O\H96K_*/U3  #C7P  SFD  ,%Q  "W=P
MKWL  *=]  ">?0  F'X1 ). (@".@#$"B7\^!H1]2 Q_?%$1>WI9%G=Y8!IS
M=V@>;W9P(6QU>"5I=((H9G..*V-RFBY@<:@O7G&Z,%UQU#!=<?(N7G'_+%YP
M_RM?</\I8&__*&!N_RA@;O\H8&[_*/%5  #>8@  RFT  +UU  "S>P  JX
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M)DZ!_R9.@?\F3H'_)N%C  #)<   NWL  +"$  "FB@  FXX  )&1  "$DP
M>I4" '67$@!RF"( ;Y@P FJ7.P1FET4(8I9.#%^55@];E%T36)-E%U63;AI1
MDG@=3I&$($N0D2-)D*$D1Y"R)D60RB9%C^TE18W_)46,_R5&B_\D1HK_)$:*
M_R1&BO\D1HK_)-AI  ##=@  M8$  *N*  "?CP  E9,  (J6  !^F@  <)T
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M%KN!  "NC@  H94  )::  ")H   ?:8  '&K  !EKP  6;0  $ZW  !#O 4
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M !/BL0 2X\\ $N#T !+>_P$1W?\!$=O_ A';_P(1V_\"$=O_ IZ:  "2H0
MA*D  ':Q  !HN   6[\  $[$  !"R   -\P  "W0   DU0  '-L  !7?!0 4
MZ0X $NH4 !'K'0 0ZR8 #NPP  [M.@ -[D8 "^Y3  KO8@ )\'0 "/&)  ?R
MH  %\KH !/'D  +Q_0 "[_\  ^W_  /M_P #[?\  ^W_ )6A  "&J0  >+(
M &FZ  !;P@  3<@  $#,   TT0  *M8  "';   9X   $N0   _P 0 -^0H
M"_H/  G[%0 '^QP !/PD  '\+   _#<  /Q"  #\4   _&$  /UU  #\C
M_*0  /S!  #\ZP  _/\  /W_  #]_P  _?\  /W_ (FI  !YL@  :KL  %S$
M  !.S   /]$  #+7   GW0  '>$  !7E   .Z   "O$   C]   %_P,  ?\)
M  #_#@  _Q(  /\7  #_'P  _R<  /\Q  #_/@  _TT  /]?  #_=0  _XT
M /^F  #_P@  _^<  /_\  #__P  __\  /__ 'RS  !LO   7<8  $[/   _
MU@  ,=T  "7B   :Y@  $>H   SN   %\@   /\   #_    _P   /\   #_
M!0  _PH  /\.  #_$@  _Q@  /\A  #_*P  _SD  /]*  #_70  _W,  /^,
M  #_I   _[D  /_4  #_W@  _]X  /_> /\8+ #_&2D _QDH /\5*P#_$#
M_PLX ?\#1 '_ %$!_P!> ?\ ; '_ '@!_P"" ?\ C '_ )0!_P"< /\ H@#_
M *@ _P"O /\ M@#_ +X _P#( /\ UP#_ .< _P#S /\ _0#_ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\;*0#_'28 _QPE /\9)P#_$RP _PXT
M /\+0 '_"$X!_P5; ?\#: '_ G0!_P)_ ?\"B '_ I$!_P*8 ?\"GP'_ :4
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M ^D3_P/I$_\#Z1/_ _\F'0#_*!@ _R@6 /\F%@#_)AT _R8H /\C- #_($
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M&Y-&YAN11_D;CT?_&HY'_QF.1_\8C4?_&(U'_Q>-1_\7C4?_%_\^ @#_0P
MZTL  -U1  #15   RE0! ,92!0#!41$ N5,B +-5,P&N5$$"JE1,!:935@BB
M45\,GU!G#YU/;Q&:3G<4F$Y_%I9-B!B33)$9D4R;&X]+IAV-2[,>BTO%'HE+
MXAZ'3/<>ADS_'85,_QR%3?\:A4S_&85,_QF%3/\9A4S_&?]   #\1P  Y5
M -56  #*60  PEH  +U8 P"X5PX L5D> *Q:+P&G6CT"HEE)!9Y84PF;5UL,
MEU9D$)55:Q*25',5CU-[%XU2A!J+48T<B%&7'H90HQ^$4+ @@E#!(8!0W2%^
M4?0@?5'_'WU1_QU]4?\<?5'_&WU1_QI]4?\:?5'_&O]"  #P2@  WU0  ,Y:
M  #$7@  O%\  +9>  "Q7 L JUX: *5@*P"@8#H"G%]%!9=>4 F47%@,D%M@
M$(U::!.+67 6B%AW&(57@!N#5HD=@%:4'WY5GR%[5:TB>52](WA5UR-W5?(B
M=E;_('96_Q]V5O\==E;_''96_QMV5O\;=E;_&_]%  #L3@  VE@  ,E>  "_
M8@  MV0  +%C  "K80@ I&,7 )]D* ":93<"EF1#!9%C30B.854,BF!=$(=?
M91.$7FP6@5UT&7Y<?1Q\6X8>>5J1('=:G2)T6:HD<EFZ)7%9TB5P6O C;UK_
M(F]:_R!P6O\><%K_'7!:_QQP6O\<<%K_'/](  #G4@  TUL  ,5B  "[9@
MLV@  *QH  "E9@4 GV<4 )II)0"5:30"D&A !(QG2@B(9E,,A&5;$(%D8A-^
M8VH6>V)R&7AA>AQV8(0><U^.(7!>FB-N7J@E;%VX)6I>SB9I7NXD:5[_(FI>
M_R!J7O\?:E[_'FI>_QUJ7O\=:E[_'?E*  #C50  SU\  ,%E  "W:@  KVP
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M'EMJ_QY;:O\>6VK_'NM3  #38   PFD  +9Q  "L=@  HWD  )EY  "-=P
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M$0!QB"  ;H@N 6J(.0)GAT,%8X=,"&"&4PM=A5L.6H1C$5>$:Q14@W4748*
M&DZ!C1Q+@9L>28&L'TB P2!'@.,?1W_Z'DA^_QY(??\=27S_'$E\_QQ)?/\<
M27S_'-9A  #";@  M'@  *J   "?A0  E(<  (B'  ![B0  <(P  &N.#0!H
MCQH 9H\I &*0-0%?CS\#7(](!5F.4 A6CE@+4XU@#E",:!!-C'(32HM]%DB*
MBAA%BID:0XJJ&T**OQM!BN$;08CY&T&&_QM!A?\;0H7_&D*$_QI"A/\:0H3_
M&LUG  "\=   KWX  *6&  ":B@  CHP  (*-  !UD   9Y0  &&5" !>EQ0
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M""VLN DLK-D(+*KU"BNH_PLJIO\,*J7_#2JE_PTJI?\-*J7_#;6   "HBP
MG)$  )&6  "%G   >*   &NE  !?J   4ZP  $BO   ]L@  -K4+ #2U%0 S
MMB$ ,K8L #&W-P PMT$ +[A+ "ZX50 LN& !*KAM 2FY>P(GN8T");F? R2Y
MM ,CN=(#([?T!"*U_P4AM/\&(;/_!R&R_P<ALO\'(;+_!ZV*  "@D0  E9<
M (B=  ![HP  ;J@  &&M  !5L0  2K0  #^W   TNP  *[X# "3"#  BPA0
M(L,? "'#*@ @Q#0 '\0_ ![%2@ =QE8 ',9C !O'<P :QX4 &<>9 !C(K@ 7
MR,L %\;Q 1?$_P$6P_\"%L'_ Q;!_P,6P?\#%L'_ Z.1  "8F   BYX  'VE
M  !PJP  8K$  %:V  !*N0  /KT  #3    JQ   (L@  !G,!  3T H $=(1
M !#2&@ 0TR4 #],P  [4/  .U$@ #=56  W590 ,UG@ #-:-  O8I  *V+X
M"=GF  K6_@ +U/\ "]+_  O2_P$+TO\!"]+_ 9J8  ".GP  @*8  '*M  !D
MM   5[H  $F_   ]P@  ,L8  "C)   ?S0  %]$  !'6   ,VP4 "-X+  ;?
M$0 %WQH !. D  +A+@ !XCH  .-'  #D5@  Y&<  .5[  #FD@  YJH  .?(
M  #G\   Z/\  .C_  #H_P  Z/\  .C_ )&?  ""IP  =*\  &6W  !7O@
M2<,  #S'   PRP  )<\  !S4   4V0  #MT   GA   "Y0   .D&  #I#0
MZ1$  .H8  #K(0  [2L  .\W  #Q10  \E8  /-H  #S?@  ])<  /6P  #V
MT   ]_,  /?_  #W_P  ]_\  /?_ (6G  !VL   9K@  %C!  !*R   .\P
M "[1   CU@  &=P  !'@   ,XP  !.<   #J    ]0   /0   #U!0  ]0L
M /8/  #V%   ^!T  /HG  #\-   _T,  /]5  #_:0  _X$  /^:  #_L@
M_\\  /_M  #_^0  __D  /_Y 'BP  !HN@  6<,  $O+   [T0  +=@  "'=
M   6X@  #N8   CJ    [0   /    #X    _P   /\   #_    _P   /\&
M  #_#   _Q   /\8  #_(@  _S   /]   #_4P  _VD  /^!  #_F0  _Z\
M /_#  #_U0  _]4  /_5 /\3* #_$R4 _Q$E /\-)P#_!BT _P U /\ 00#_
M $\ _P!< /\ :0#_ '0 _P!^ /\ B #_ )  _P"7 /\ G0#_ *0 _P"J /\
ML #_ +< _P#  /\ S #_ -\ _P#L /\ ^ #_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_ /\ _P#_ /\6)0#_%B( _Q0A /\0(P#_"B@ _P P /\ /0#_ $L
M_P!8 /\ 9 #_ '  _P!Z /\ A #_ (P _P"3 /\ F@#_ *  _P"F /\ K0#_
M +0 _P"\ /X R #] -D ^P#I /H ]@#Y /\ ^ #_ /@ _P#X /\ ^ #_ /D
M_P#Y /\ ^0#_ /\:(@#_&AX _Q@= /\3'@#_#B( _PHL /\'.0#_ T8 _P!3
M /\ 8 #_ &L _P!V /\ ?P#_ (@ _P"/ /\ E@#_ )T _P"C /X J0#\ +
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M O\E$P#_)1  _R0- /\C#@#_(Q0 _R(> /\?*0#_'#4 ^1E# /083P#O%UL
M[!=F .D7< #F%WD Y!>! .(7B0#@%Y$ WQ>8 -T7GP#;%Z< V1BQ -88NP#4
M&<H T!KA <P;\P')'/\"QAS_ L0<_P/#'/\#PQS_ \,<_P/#'/\#PQS_ _\H
M$ #_*0L _R@& /\K"P#_*Q  _RD7 /TF(@#T(RX ["$[ .8@20#B(%4 WB!@
M -HA:@#6(70 TR%\ = AA '/(HP!S2*3 <LBFP')(J,!R".L L8CM@+$(\0"
MPB3; KXE[@.[)?X$N"7_!;8E_P6U)?\&M27_!K4E_P6U)?\%M27_!?\L#0#_
M+04 _RX! /\Q!0#_,0L _2\0 /$K& #G*24 WR@S -@H0@#1*D\ S2M: ,DK
M90''*VX!Q"QV L(L?@+ +(8#OBR. [TLE@.[+)X$N2RG!+@LL06V++\%M2W1
M!;$MZ@:N+OL'JR[_"*DN_PBH+O\(J"W_"*@M_PBH+?\(J"W_"/\O" #_,0
M_S4  /8W  #J-@( YS,( .0O#P#9+AL SS$L ,DS/ #$-$D P#55 ;PU7P*Z
M-6@"MS5P [4T> 2S-( %L32(!K TD :N-)D'K#2B"*LTK FI-+D)IS3*"J4U
MY0JA-?@+GS7_#)TU_PR=-?\+G#7_"YPU_PN<-?\+G#7_"_\S @#_-0  ]CH
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M%7]'_Q1_1_\2?T?_$7]'_Q%_1_\1?T?_$?\[  #N0P  W$P  ,Q1  #!5
MN50  +11  "N30L J$\9 *-1*0">4C<!FE)# I=13@24458&D5!>"8Y/9@N,
M3FT-B4YU#X=-?A&%38<3@DR1%8!,G!9^2ZD7?$NX&'M+S1AY3.L8>$S^%W=,
M_Q5W3/\4=TS_$W=,_Q)W3/\2=TS_$O\^  #H1P  U5   ,96  "\6   M%D
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M%659_Q1E6?\495G_%.]&  #:4@  QEL  +IA  "P90  IF8  )UC  "580
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M%=U5  #%80  MVH  *QQ  "B=0  E'0  (ET  !\<P  =G4  '%W$ !O>!T
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M$CV$M1,\A,\3/(+P$CR!_Q(]@/\2/7__$CU^_Q$]?O\1/7[_$<5F  "U<0
MJGL  )^"  "2@@  A8(  'F#  !MA@  7XH  %B- 0!4C@\ 4H\; %"/)P!/
MD#, 39 ] 4N010))D$X#1I!6!$2/7P5"CV@'/X]S"3V.@ LZCH\,.(Z@#3>.
MLPXVCLP.-HWO#C6+_PXUB?\/-8C_#S:'_P\VA_\/-H?_#[YM  "P>0  I8(
M )F'  ",B   ?X@  '**  !FC0  6I$  %"5  !)EPD 1Y@3 $68( !$F2L
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M 1NO_@(:K?\"&JS_ QJK_P,:J_\#&JO_ ZB(  ";CP  D90  (2:  !VGP
M:*(  %NE  !/J0  1*T  #FP   OLP  )K8  !ZY!0 8NPX %[L6 !>\(  6
MO"H %;TU !2]0  3ODL $KY8 !*^9P 1OW@ $+^, !# H@ .P+H #L#A  ^]
M^P /O/\ $+K_ 1"Z_P$0NO\!$+K_ 9^/  "4E0  AYL  'FA  !KIP  7JP
M %*Q  !%M   .K8  "^Y   EO   ';\  !7#   /Q@4 "\H-  G*%  (RAT
M!\HG  ?*,@ &RSX !<M+  3,6@ #S&H  LQ^  ',E   S*L  ,W(  #,[0
MS/\  ,O_  '*_P !RO\  <K_ )>6  "*G   ?*,  &ZJ  !@L   4K8  $6Y
M   YO   +K\  "/#   ;Q@  $\H   W-   (T0   =0)  #4#@  U14  -8>
M  #8)P  V3$  -L^  #<2P  W5L  -YN  #>A   WYL  -^T  #>V0  W_<
M -__  #?_P  W_\  -__ (V=  !_I0  <*P  &&S  !3N@  1;\  #C"   L
MQ@  (<D  !C-   0T0  "]4   3:    W@   . !  #A"0  X@X  .03  #E
M&P  YR0  .DO  #K/   [4L  .Y=  #N<0  [XD  /"B  #PO   \.,  ._Y
M  #P_P  \/\  /#_ (&E  !RK0  8[4  %2]  !&Q   -\@  "K,   ?T
M%=4   [:   'W@   .(   #F    Z0   .H   #L    [@4  .\,  #Q$
M\Q<  /4@  #X*P  ^SD  /U*  #^7@  _W0  /^-  #_I@  _\   /_A  #_
M]0  __4  /_U '2N  !EMP  5L   $?(   XS0  *M(  !W8   3W0  #.(
M  /F    Z0   .P   #P    \P   /0   #V    ^    /H   #]!P  _PT
M /\2  #_&P  _R@  /\W  #_2@  _UX  /]V  #_CP  _Z8  /^Z  #_T0
M_]$  /_1 /\/) #_#B( _PLA /\#) #_ "D _P R /\ /@#_ $P _P!9 /\
M90#_ '  _P!Z /\ A #_ (P _P"2 /\ F0#_ )\ _P"E /\ JP#_ +( _P"Z
M /\ Q0#_ -, _P#G /\ ] #_ /\ _@#_ /\ _P#^ /\ _@#_ /X _P#^ /\
M_@#_ /\1(0#_$!X _PT= /\''P#_ ", _P M /\ .@#_ $@ _P!5 /\ 80#_
M &P _P!V /\ ?P#_ (< _P". /\ E0#_ )L _P"A /\ IP#^ *X _0"V /P
MP #[ ,T ^0#B /@ \ #W /P ]@#_ /4 _P#U /\ ]0#_ /4 _P#U /\ ]0#_
M /\5'0#_$QH _Q 9 /\+&0#_ !T _P I /\ -@#_ $, _P!0 /\ 7 #_ &<
M_P!Q /\ >@#^ (, _ "* /H D0#Y )< ^ "= /< HP#U *H ] "R /( NP#Q
M ,@ [P#< .X [ #M /H ZP#_ .H _P#J /\ Z@#_ .H _P#J /\ Z@#_ /\8
M&0#_%A4 _Q,3 /\.$P#_"QH _P<D /\", #_ #X _P!+ /\ 5P#_ &( _ !L
M /@ =0#U 'X \@"% /$ C #O ), [@"9 .P H #K *8 Z0"N .< MP#F ,,
MY #4 .( Z0#A /< WP#_ -T _P#= /\ W0#_ -T _P#= /\ W0#_ /\;$P#_
M&A  _Q8. /\2#@#_$A4 _P\? /\,*P#_"3@ _P9% /L#40#W EP \@)F .X"
M< #J G@ YP*  .8#AP#D XX X@.5 .$#G #?!*, W02K -L$M #8!<  U@70
M -,&YP#0"/@ S@K_ ,P+_P#+#/\ RPS_ ,L+_P#+"_\ RPO_ /\?$ #_'@L
M_QH' /\9"P#_&!$ _Q89 /\2) #Z$#  \PX^ .X-2@#I#%8 Y0QA .(,:@#>
M#7, VPU[ -D-@P#6#8H U V1 -(-F0#0#J  SPZI ,T.LP#+#K\ R@_0 ,81
MZ0#"$OD OQ/_ +T3_P&\$_\!O!/_ ;P3_P&[$_\!NQ/_ ?\B# #_(00 _R
M /\A!0#_'PP _QP1 /88' #L%2@ Y1,V -\20P#9$T\ TQ1: - 59 #-%FT
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M!I<O_P:6+_\&E2[_!94N_P65+O\%E2[_!?\L  #_+@  ZC4  -TY  #1.0
MRC8  ,<O!@#!+1$ NC A +0R,0"P-#X K#5* *DU5 &G-5T!I#5E J(U;0*@
M-70#GS5\!)TUA 2;-8T%FC27!I@TH0:6-*T'E#6["),UT B0->P(CC;^"(PV
M_PB+-O\(BS;_!XHU_P>*-?\'BC7_!_\O  #R-   XCP  -)!  #'0@  P$
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M#'%'_PMQ1O\+<4;_"_,Y  #@1   S$P  +Y1  "T4P  JE(  *).  "=2@$
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M#>-(  #+4P  NUL  +!A  "D8@  EV$  (Y?  "%7   ?UX' 'M?$P!X82$
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M$DMGLA))9\D226?K$DEF_Q!*9O\/2F7_#DME_PU+9/\-2V3_#=%4  "^7@
ML6<  *9M  "7;   BFL  ']K  !S:P  ;6T  &AN# !E<!< 8G$D &!Q, !>
M<3H!7'%# EEQ2P-7<5,$57!:!E)P8@=0<&L)3F]U"TMO@@U);H\/1VZ?$$5N
ML!%$;L<10VWJ$$1L_P]$:_\.16O_#45J_PU%:O\-16K_#<M8  "Z8P  K6P
M *%Q  "2<   A6\  'IO  !N<   97,  &!U!P!==A( 6W<? %EX*P!7>#8
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M!S"%^P@P@_\(,(+_"#"!_P@P@?\(,('_"+=K  "J=@  H'\  )!^  ""?@
M=G\  &J   !>@P  4X<  $J+  !!C@( /9 . #N0&  ZD2, .9$M #B2-P W
MDD  -I)) #234@ SDUP!,9-G 2^3= (MDH,#*Y*4 RJ2IP,HDKT$*)+A R>0
M^@0GCO\%)XW_!2>,_P4GC/\%)XS_!;%T  "E?@  F84  (J$  !]A   ;X4
M &.(  !8BP  38\  $.3   ZEP  ,IH' "Z;$  MFQH +)PD "N<+@ JG3@
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M  BS_P )LO\ ";+_ )J-  "0DP  A)@  '2<  !EH   5Z0  $NH  ! K
M-;   "JS   AM0  &+@  !&[   ,O@( !L +  + $0 !P1D  ,$B  #"*P
MPC8  ,-"  ##4   Q%\  ,1Q  #$AP  Q)T  ,2U  #$V@  Q/8  ,/_  ##
M_P  P_\  ,/_ ).4  "'F@  >*   &JF  !<K   3[$  $&U   UMP  *;H
M !^]   6P   $,,   K&   #R@   ,P%  #,#   S1$  ,X8  #.(0  T"H
M -$U  #30P  U%(  -1C  #5>   U8\  -6G  #6P@  UND  -;]  #6_P
MUO\  -;_ (J;  ![H@  ;*D  %ZP  !0M@  0KH  #2]   HP0  '<0  !3'
M   -RP  !LX   #2    UP   -D   #:!0  W L  -T0  #?%0  X1T  .,G
M  #E,P  YT(  .A4  #H9P  Z7X  .F7  #JKP  ZLX  .OO  #K_@  Z_\
M .O_ 'VC  !NJP  7[(  %&Z  !"P   -,,  "?'   ;RP  $L\   O3   "
MV    -T   #A    Y    .4   #G    Z0   .L'  #M#0  [Q$  /$9  #T
M)   ]S$  /E!  #Z50  ^FH  /N$  #[G0  _+8  /S2  #][0  _?0  /WT
M '&L  !AM0  4KT  $3$   TR0  )LT  !K2   0V   "-T   #A    Y0
M .@   #L    [P   /$   #S    ]0   /<   #Y 0  ^P@  /X.  #_%0
M_R$  /\O  #_00  _U8  /]M  #_AP  _Z   /^V  #_R@  _]0  /_4 /\+
M( #_!QX _P = /\ ( #_ "4 _P N /\ .P#_ $D _P!6 /\ 8@#_ &T _P!V
M /\ ?P#_ (< _P". /\ E #_ )H _P"@ /\ I@#_ *T _P"U /\ O@#_ ,L
M_P#A /\ \ #^ /T _0#_ /T _P#] /\ _0#_ /P _P#Y /\ ^0#_ /\-'0#_
M"QH _P09 /\ &@#_ !\ _P J /\ -P#_ $4 _P!1 /\ 7@#_ &@ _P!R /\
M>@#_ (( _P") /\ D #_ )8 _P"< /X H@#\ *D ^P"P /D N0#X ,8 ]@#9
M /4 ZP#T /D \P#_ /( _P#S /\ \P#_ /, _P#S /\ \P#_ /\0&0#_#A4
M_P@4 /\ % #_ !D _P E /\ ,@#_ $  _P!, /\ 60#_ &, _@!M /P =0#Z
M 'T ^0"$ /< BP#V )$ ] "7 /, G@#R *0 \ "L .X M #M ,  ZP#/ .D
MY@#H /4 Y@#_ .< _P#F /\ Y0#_ .4 _P#E /\ Y0#_ /\2% #_$!  _PP/
M /\#$ #_ !4 _P @ /\ + #_ #H _P!' /H 4P#W %X ] !G /$ < #O '@
M[0!_ .L A@#J (P Z "3 .< F0#E *  XP"G .$ L #? +H W0#) -L X #8
M /  UP#^ -4 _P#4 /\ TP#_ -, _P#3 /\ TP#_ /\5$ #_$@P _PX) /\+
M# #_"1( _P,: /\ )@#] #, ] !  .\ 30#K %@ Z !A .4 :@#B '( X !Z
M -X @ #< (< V@". -@ E0#4 )P T@"C -  K #. +8 S #$ ,H V0#( .T
MQP#[ ,4 _P#$ ?\ PP'_ ,0!_P#$ ?\ Q '_ /\8"P#_%04 _Q   /\0!@#_
M#PT _PP4 /P''P#Q RL YP Y .( 1@#> 5$ V@); -4"9 #2 VP SP-T ,T$
M>P#+!(( R@2) ,@%D #&!9@ Q 6@ ,(&J0#!!K0 OP;! +T(U0"[">P N O]
M +8,_P"U#?\ M W_ +0-_P"T#?\ M W_ /\;!0#_&   _Q<  /\6  #[$P8
M^A . .X,%@#C"2( V@DP -,*/@#."TH R@Q5 ,<-7@#%#6< P@YO ,$.=@"_
M#GX O0^% +P/C0"Z$)4 N!"= +<0IP"U$;( LQ'  +(1U0"N$^X JQ3^ *D5
M_P"G%?\ IQ7_ *84_P&F%/\!IA3_ ?\?  #_'   ^AX  .L>  #C'   WQ4%
M -X.#0#3#A@ RQ$H ,43-P# %$0 O!9/ +D760"W%V$ M!AI +,9<0"Q&7@
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M X,O_P.#+_\#@R__ _LI  #K,0  V3@  ,D\  "_/   MCD  + R  "L+0L
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M!N@[  #01@  OTT  +-1  "E40  FDX  ))+  "-1P  AT@+ (-*%@!_2R0
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M#%53L U44\4-4U/F#%-3_ M34_\)5%+_"%12_PA44O\'5%+_!]I&  ##4
MM5@  *A;  "96@  C5@  (17  ![5   =E8! '%7#P!N61L ;%HH &E:,P!G
M6ST!95M% 6-;30)A6E4#7UI<!%U:9 5;66P&6%EV"%99@@E46(\+4EB>#%!8
MK@U/6,,-3ECD#$Y8^PM/5_\)3U?_"$]6_PA05O\'4%;_!]-*  # 5   LEP
M *->  "570  B5P  '];  !V60  <%H  &M<#0!H71@ 9EXD &1?, !B7SH
M8%]# 5Y?2P)<7U("6E]: UA?80557FH&4UYT!U%=?PE/78T*35V<"TM=K Q*
M7<$,25WC#$E<^@I)6_\)2EO_"$I:_PA*6O\'2EK_!\Y.  "\6   KF   )]A
M  "18   A5\  'M?  !P70  :E\  &5A"@!B8A0 8&,A %YD+0!<9#< 6F1
M 5AD2 %69% "5&17 U)D7P109&<%3F-Q!DQC?0A)8HL)1V*:"D9BJ@M$8K\+
M1&+A"T1A^0I$8/\)1&#_"$5?_P=%7_\'15__!\A2  "X7   JV0  )MD  ",
M8P  @&,  '9C  !J8@  8V0  %]F!@!;9Q$ 66@= %=I*0!6:C, 5&H\ %)J
M10%0:DP!3FI4 DQJ7 -*:F4$2&EO!49I>@=$:8@(0FB8"4!HJ0H_:+T*/FC>
M"3YG]PD^9O\(/V7_!S]E_P<_9/\'/V3_!\-7  "S80  IVD  )9H  "'9P
M>V<  '%G  !E:   7&H  %AL 0!4;@X 4F\8 %!O) !.<"X 37 X $MQ00!*
M<4D!2'%1 49Q60)$<&(#0G!L!$!P> 4^<(8&/&^5!SIOI@@X;[L(.&_;!SAN
M]@<X;?\'.&S_!CEK_P8Y:O\&.6K_!KU<  "O9@  HFT  )%L  "":P  =VL
M &QL  !A;@  5W   %!S  !,=0H 2783 $=W'P!&=RD 17@S $-X/ !">$0
M07A- 3]X50$]>%X".WAH CEX= ,W>(($-7B3!3-WI 4R=[D%,7C7!3%V]04Q
M=/\%,7/_!3%R_P4R<O\%,G+_!;=C  "J;0  G'$  (MP  !]<   <G   &=Q
M  !<<P  47<  $IZ  !"?0, /WX. #U_&  \?R, .X M #J -@ Y@3\ .(%(
M #:!4  U@5H!,X%D 3&!< $O@7\"+8&/ RR!H0,J@;8#*8'2 RE_\P,I??\#
M*7S_ RE[_P,I>_\#*7O_ [%J  "E=   E78  (5U  !X=0  ;74  &%W  !7
M>@  3'X  $.!   [A0  -8@) #*)$0 QB1L ,(DE "^*+P NBC@ +8M! "R+
M2@ JBU0 *8M? "B+:P FBWH!)(N+ 2.+G@$BB[,!(8S. 2&*\0$@B/\"((;_
M B"%_P(AA?\"(87_ JMR  "A?   CWL  (!Z  !S>@  9GP  %M_  !0@@
M1H8  #R*   TC0  +)$  ":3#  DE!, (Y0< "*5)@ AE2\ ()4X !^60@ >
MEDP '998 !R69  :EW0 &9>& !B7F0 7EZX %9?) !:5[@ 6D_\!%I+_ 1:1
M_P$6D/\!%I#_ :5[  "9@P  B8$  'N   !L@@  7X0  %2(  !)BP  /Y
M #64   MEP  )9H  !V> 0 6H P %*$2 !2A&P 3H24 $J$N !&B.  1HD,
M$*)/  ^B7  .HVL #:-]  VCD@ ,HZ< "J+   NBY@ ,H/X #9__  V>_P -
MG?\ #9W_ )Z$  "2B0  @X@  '.(  !EBP  6(X  $R2  !!EP  -YL  "Z>
M   DH@  '*4  !6H   /JP0 "JX,  >M$@ &K1L !:TD  2N+@ "KCD  :Y%
M  "N4@  KF$  *YS  "NAP  KIT  *ZT  "NU0  K?0  *W_  "L_P  J_\
M *O_ ):+  ",D   >Y   &N2  !=E@  4)H  $2?   YHP  +Z<  "6K   <
MK@  %+$   ZT   )MP   ;@)  "X#@  N10  +D<  "Z)0  NB\  +LZ  "\
M1P  O%8  +QG  "\>P  O)$  +RI  "\Q   O.L  +O^  "[_P  N_\  +O_
M )"2  "#F   <YL  &.?  !5HP  1Z@  #NM   PL0  );0  !NW   2N@
M#+T   6_    PP   ,0"  #%"@  Q0X  ,84  #'&P  R"0  ,HN  #,.@
MS4D  ,U9  #-;   SH,  ,Z;  #-M0  SMH  ,[V  #-_P  S?\  ,W_ (:9
M  !WH   ::8  %JL  !,L@  /K8  #"Y   DO   &;\  !'"   *Q0   LD
M  #,    T    -$   #2 0  TP@  -4-  #7$0  VA@  -PA  #?+   X3H
M .)*  #C70  Y'(  .2+  #EI0  Y<   .7F  #E^   Y?\  .7_ 'JA  !K
MJ0  7*\  $VV   _O   ,+\  "/#   7QP  #\H   ?.    T0   -8   #<
M    WP   .    #B    Y    .8#  #H"0  Z0X  .P5  #N'@  \2L  /0Z
M  #U30  ]F$  /=Y  #XDP  ^*T  /G&  #YY   ^?,  /GS &VJ  !>L@
M3[H  $#!   QQ0  (LD  !;.   -T@  !-@   #=    X0   .0   #H
MZP   .T   #O    \0   /,   #V    ^ ,  /H+  #]$0  _QL  /\I  #_
M.P  _T\  /]F  #_?P  _YD  /^O  #_PP  _]8  /_6 /\$' #_ !D _P 9
M /\ ' #_ "( _P K /\ . #_ $8 _P!3 /\ 7@#_ &D _P!R /\ >@#_ ((
M_P") /\ CP#_ )4 _P"; /\ H0#_ *@ _P"O /\ N0#_ ,4 _P#9 /X [ #]
M /L ^P#_ /L _P#[ /\ ^@#_ /0 _P#P /\ \ #_ /\'& #_ 14 _P 4 /\
M%@#_ !L _P F /\ - #_ $( _P!. /\ 6@#_ &0 _P!M /\ =0#_ 'T _P"$
M /\ B@#] )  _ "6 /H G0#Y *, ^ "K /< M #U +\ ] #. /, Y@#Q /8
M\ #_ .\ _P#O /\ [@#_ .X _P#J /\ Z@#_ /\+% #_!A$ _P 0 /\ $ #_
M !8 _P B /\ +@#_ #P _P!) /\ 5 #^ %\ ^P!H /D < #W '@ ]0!_ /,
MA0#R (L \ "2 .\ F #M )\ [ "F .H K@#H +D YP#' .4 W@#C /  X@#^
M .  _P#@ /\ X0#_ .$ _P#A /\ X0#_ /\-$ #_"0T _P$, /\ # #_ !(
M_P < /\ * #\ #8 ^0!# /8 3@#R %D [P!B .P :P#J '( Z !Y .8 @ #D
M (8 X@", .$ DP#? )H W0"A -L J@#8 +0 U0#  -( TP#0 .H S@#Z ,T
M_P#- /\ S0#_ ,P _P#, /\ S #_ /\0# #_# < _P," /\ " #_  X _P 6
M /8 (@#P "\ [  \ .D 2 #E %, X0!< -X 90#; &P UP!S -0 >@#2 (
MT "' ,X C@#, )4 R@"= ,@ I0#& *\ Q "[ ,( RP#  .4 O@#U +T _P"\
M /\ O #_ +P _P"\ /\ O #_ /\1!0#_#@  _PH  /\( 0#_! H ^  0 .D
M&@#C "@ W@ U -D 00#3 $P SP!6 ,L 7P#) &8 Q@!N ,0 = #" 'L P0""
M +\ B0"] )  O "8 +H H0"X *L M@"W +0 QP"R .  L0'R *\"_P"N _\
MK03_ *T$_P"M!/\ K03_ /\4  #_$   _P\  /(-  #J"@  Z0,) -T $@#4
M !\ S0$M ,@".@#$ T4 P -0 +T$60"[!6$ N05H +<&;P"U!G8 M =] +('
MA "Q"(P KPB5 *T)G@"K":@ J@JU *@*Q0"F"]\ I WT *(._P"@#O\ GP[_
M )\._P"?#O\ GP[_ /\7  #_$P  [Q@  .09  #;%@  TA " ,\)"P#("!8
MP0HD +P,,@"W#3X M Y) +$.4P"O$%L K1!C *L0:@"I$7$ J!%X *81@ "E
M$8@ HQ*1 *$2FP"@$Z8 GA.S )P3PP";%-X EQ;T )46_P"4%_\ DQ?_ )(7
M_P"2%O\ DA;_ /\:  #T'0  Y2,  -4E  #*)   PAT  +X6! "[$!  M!,=
M *\5*P"K%C@ IQA# *4930"B&58 H!I= )X;90"=&VP FQQS )H<>P"8'(,
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M O J  #<-0  QSL  +H_  "L/   HC@  )PS  "8+P  E2X0 ) P' ",,BD
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M/P  O48  *Y'  "?10  E4,  (Y   ")/   A#P* ( ]% !]/B( >C\N 'A
M. !U04( <T%* ')!40%P05D!;D%@ FQ!9P)J07 #:$%Y V=!A 1E09$%8T&?
M!6%!K@9@0<(&7D'B!EY!^05=0?\$74#_ UU _P-=0/\#74#_ ]\Y  #(0P
MN4H  *E+  ";20  D$<  (A$  "#00  ?D$& 'I"$0!V0QX =$4J '%%-0!O
M1C\ ;49' &M&3P%J1E8!:$9= F9&90)D1FT#8D9V!&!&@@1>1HX%7$6<!EM%
MK 991K\'6$;?!EA&]P571?\$5T7_!%=$_P-81/\#6$3_ ]H]  #$1P  M4X
M *1.  "63   BTL  (-)  !]10  >$8" '1'$ !P2!L ;DDG &M*,@!J2SP
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M!TA2\P9(4O\%2%'_!$E1_P1)4/\#25#_ \I(  "Y4@  JE<  )A6  "*50
M?U0  '93  !L40  9U,  &)4" !?5A( 75<> %M7*0!96#, 6%@\ %991 !5
M64P!4UE3 5%96P)/6&0"35AM TM8> 1)6(8%1U>5!D57I09$5[@&0UC2!D-7
M\@9#5O\%0U7_!$15_P1$5/\#1%3_ \9,  "U5@  I5H  )19  "&6   >U@
M '%7  !F5@  85@  %U9! !96A  5UL; %5<)@!373  4ETY %%>00!/7DD
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M S)E_P,R9/\#,F3_ [=;  "I9   EF0  (9C  !X8P  ;6,  &1D  !990
M4&@  $EK  !#;00 0&X. #YO&  ];R( /' K #IP-  Y<3T .'%% #=Q3@ V
M<5< -'%A 3)Q;0$Q<7H!+W&* BUQG (K<:\"*G'( BIPZP(J;_\"*FW_ BIL
M_P(K;/\"*VS_ K%A  "D:0  D&@  (!G  !T9P  :6<  %]H  !5:P  2VX
M $-Q   \=   -W8* #1W$@ S>!P ,G@E #%Y+@ P>3< +WD_ "YY2  L>E(
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M *%Z  ".>0  ?G<  ')W  !D>   6'L  $U^  !"@@  .88  "^*   GC@
M()$  !B5   2F 4 #IH.  V:%  ,FAT "YHF  N:,  *FCL "9I&  B:4P &
MFV$ !9IR  2:A@ "FIL  )JQ  &9SP "F?   IC_  27_P %EO\ !9;_ )F!
M  "'?P  >GX  &M^  !=@0  4(4  $6)   [C0  ,9(  "B6   ?F0  &)T
M !&@   ,HP( !J4*  &E$   I18  *8?  "F*   IC(  *<]  "G2@  IU@
M *=H  "G?   IY$  *:H  "FPP  I>D  *7\  "E_P  I/\  *3_ )&'  ""
MA@  <H8  &.(  !5C   29$  #V6   RF@  *)X  !^B   7I@  $*D   NL
M   $KP   +$&  "Q#   LA$  +(7  "S'P  LR@  +0R  "U/P  M4T  +5=
M  "U<   M88  +6=  "UM@  M=P  +3W  "T_P  M/\  +3_ (N/  !ZC@
M:I$  %N5  !-F@  0)\  #6D   JJ   (*P  !:P   /M   ";<   &Y
MO0   +X   "^!@  OPP  , 0  #!%@  PAT  ,,G  #%,@  QD   ,91  #'
M8P  QW@  ,>1  #'J0  Q\<  ,?L  #'_@  Q_\  ,?_ (.7  !QF@  89X
M %*C  !%J0  .*X  "RS   @MP  %KH   Z]   &P    ,,   #'    R0
M ,H   #,    S0,  ,X)  #0#@  TA,  -0;  #8)0  VS(  -U"  #=5
MWFD  -Z!  #>G   W[4  -_9  #?\P  W_\  -__ '>?  !HI@  6:T  $JS
M   [N   +;L  !^_   4P@  #,8   /)    S    -    #5    V0   -H
M  #<    W@   .    #B!0  Y L  .<0  #J&   [20  / R  #Q1   \E@
M /-O  #TB@  ]*0  /2_  #TWP  ]/,  /3T &JH  !;KP  3+<  #V]   M
MP0  '\8  !/*   +S@   -(   #7    W    .    #E    YP   .D   #K
M    [0   .\   #Q    \P   /8'  #Y#@  _!8  /\B  #_,P  _T<  /]=
M  #_=@  _Y$  /^I  #_O@  _]@  /_; /\ & #_ !8 _P 5 /\ & #_ !X
M_P G /\ -@#_ $, _P!/ /\ 6@#_ &0 _P!M /\ =0#_ 'T _P"$ /\ B@#_
M )  _P"6 /\ G #_ *, _P"K /\ M #^ +\ _0#/ /L YP#Z /@ ^0#_ /D
M_P#Y /\ ]0#_ .X _P#I /\ YP#_ /\ % #_ !$ _P 1 /\ $@#_ !< _P C
M /\ ,0#_ #X _P!* /\ 5@#_ &  _P!H /\ < #_ '@ _0!^ /P A0#Z (L
M^0"1 /@ F #W )X ]0"F /0 K@#R +D \0#' .\ X #N /( [ #_ .P _P#L
M /\ ZP#_ .4 _P#@ /\ W@#_ /\#$ #_  X _P - /\ #0#_ !, _P > /\
M*P#_ #@ _P!% /X 4 #[ %H ^ !C /4 :P#S '( \0!Y .\ ?P#N (8 [ ",
M .H D@#I )D YP"@ .8 J0#D +, X0#  .  TP#> .L W #[ -L _P#: /\
MV@#_ -D _P#4 /\ T@#_ /\'#0#_  D _P & /\ "0#_  \ _P 8 /L )0#X
M #( ]0 _ /( 2@#M %0 Z@!= .< 90#D &P X@!S .  >@#> (  W "& -H
MC0#7 )0 U "; -( I #/ *T S0"Y ,L R0#) .0 R #V ,8 _P#% /\ Q@#_
M ,< _P#' /\ QP#_ /\*!@#_ 0  _P   /\ ! #_  L ]  2 .\ 'P#J "P
MY0 X .( 0P#= $X V0!7 -0 7P#1 &< S@!M ,P = #* 'H R "  ,8 AP#%
M (X PP"6 ,$ G@"_ *@ O0"S +H P@"Y -L MP#P +4 _P"V /\ M0#_ +4
M_P"U /\ M0#_ /\,  #_!   _P   /X   #V  , Z  - .  %P#9 "0 T0 Q
M ,T / #* $< Q@!1 ,, 60#  &  O@!G +P ;@"Z '0 N0![ +< @@"U (D
MLP"1 +( F@"P *0 K@"O *P O0"J -  J #K *< ^P"F /\ I@#_ *4 _P"E
M /\ I0#_ /\-  #_!P  ] D  .H)  #B!   V@ ' ,\ $0#( !P P@ I +X
M-0"[ $  MP!* +0 4P"R %L L !B *X : "L &\ JP!U *D ?0"H (0 I@"-
M *0 E@"C *  H0"K )\!N0"= \P G 3H )H&^0"9!_\ F C_ )<(_P"7"/\
MEPC_ /\0  #W$   Z!0  -P5  #.$0  Q@T  ,($"P"\ !0 MP$A +(#+@"N
M!3H JP9$ *@(30"F"%4 I E< *(*8P"@"FH GPMQ )T+> "<"X  F@R) )D,
MDP"7#)X E0VJ )0-N "2#<P D [J (X0_ ",$/\ BQ#_ (L0_P"+$/\ BA#_
M /L3  #M&@  W2   ,PA  "_'0  MQ<  +,1  "R"PT JPT9 *<.)@"C#S,
MGQ ^ )T11P":$5  F!)7 )827@"5$V4 DQ-L )(3<P"0%'P CQ2% (T5CP"+
M%9H BA6G (@6M0"&%LD A!?G ((8^P" &?\ ?QG_ '\9_P!_&/\ ?QC_ /4:
M  #D(P  SRD  , J  "S)@  JB(  *4<  "D%0@ H!03 )L6(0"7&"T E!DX
M )$:0@"/&TL C1Q2 (L<60")'6  B!UG (8>;P"%'G< @Q^  ((?BP" 'Y<
M?B"C 'T@L@![(,4 >2'D '<B^0!V(O\ =2+_ '0A_P!T(?\ ="'_ .\A  #;
M*P  QS$  +8Q  "I+@  H"H  )LF  "8(0$ E1X0 ) @&P"-(2@ B2,S (<D
M/0"%)$8 @R5. ($F50!_)EP ?B9C 'PG:P![)W, >2=\ '@HAP!V*), ="B@
M 7(HKP%Q*<$!;RG@ 6TI]P%L*?\!:RG_ 6LI_P%K*/\!:RC_ >@H  #0,@
MP#@  *XW  "A-0  F#(  )(M  ".*0  BR<, (<H%P"#*B, @"LO 'XL.0!\
M+$( >BU* '@N40!W+E@ =2Y@ ',O9P!R+V\ <"]Y 6\O@P%M+Y !:R^= 6DO
MK %H,+X!9S#; 64P]0%D,/\!8S#_ 6,O_P%C+_\!8R__ >(N  #*.   NCT
M *@\  ":.@  D3<  (HS  "&,   @RX) '\O$P![,!\ >#(K '8S-0!T,SX
M<C1& ' T3@!O-54 ;35< &PU9 !J-6P!:#5U 6<U@ %E-8P!8S6: F$VJ0)@
M-KL"7S;6 ETV\P)=-O\"7#;_ 5PU_P%<-?\!7#3_ =PS  #%/   M$$  *)
M  "5/@  BSP  (0Y  !_-@  >S0$ '<U$ !T-QP <3@G &\Y,@!M.3L :SI#
M &HZ2P!H.U( 9SM9 &4[80%C.VD!8CMR 6 [?0%>.XH"7#N7 EL[IP)9.[@#
M6#O2 U<[\0)6._\"5CO_ E8Z_P%6.O\!5CG_ =0W  # 00  KT0  )U#  "0
M0@  A4   'X^  !Y.P  =#H  '$Z#@!M/!@ :STD &D^+P!G/S@ 93]  &1
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M TI)H0-(2;,#1TG* T9)[ -&2/\"1DC_ D='_P)'1O\"1T;_ L9#  "V3
MHDP  )%,  "$2P  >4H  '!)  !I1@  9$<  %])!@!<2A  6DL; %A,)0!6
M3"\ 54TX %--0 !234@ 44Y/ $].5P!.3E\!3$YI 4I.<P)(38 "1DV/ T5-
MGP-#3;$#0DW( T%-Z@-!3/\"04S_ D)+_P)"2O\"0DK_ L)'  "S3P  GD\
M (U.  " 3@  =4T  &Q,  !C2@  7DP  %I- @!63@X 5$\8 %)0(@!142P
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M C%<Y0(Q6_P",5K_ C%9_P(R6?\!,EC_ ;94  "D60  D%@  (!8  !S5P
M:5<  &!8  !460  3EL  $A=  !#7P0 0& . #YA%P ]82  .V(I #IB,@ Y
M8CH .&-" #=C2P V8U0 -&-= #-C:  Q8W8!+V.% 2YCE@$L8ZD!*V._ 2IC
MXP$J8OL!*F#_ 2M?_P$K7_\!*U[_ ;%9  ">7   BUP  'M;  !O6P  95L
M %Q<  !17@  26   $-B   \90  .&<* #5H$@ T:!L ,VDD #)I+0 Q:34
M+VH] "YJ1@ M:D\ +&I9 "MK90 I:W( *&N" "9KDP D:Z< (VN] ")JX  C
M:?D!(V?_ 2-F_P$C9O\!)&7_ :Q@  "88   A6   '9?  !J7P  86   %=@
M  !-8P  1&8  #UH   V:P  ,&X$ "QP#@ J<14 *7$> "AQ)@ G<B\ )G(W
M "5R0  D<DH (G)4 "%S8  @<VT 'G-] !USD  ;<Z, &G.Y !ESW  :<?<
M&G#_ !MO_P ;;O\!&VW_ :9F  "190  ?V0  '%D  !F9   760  %)F  !(
M:0  /VP  #=O   P<P  *78  ")Y"  ?>Q  'GL7 !Q['P ;>R@ &GLP !E\
M.0 8?$, %WQ. !9\6@ 5?&< %'UX !)]BP 1?9\ $'VU  ]]U0 0>_4 $7G_
M !%X_P 2=_\ $G?_ )YK  "*:@  >FD  &UI  !B:0  5VH  $QM  !#<
M.70  #%X   I>P  (G\  !N"   4A0D $880 !&&%P 0AQ\ $(<H  Z',0 .
MASL #8=&  R'4P +AV$ "H=Q  F'A  'AY@ !H:N  6&R0 &A>P !X3_  B#
M_P )@O\ "8+_ )5Q  "#;P  =&X  &EN  !<;P  4'(  $9U   \>0  ,GT
M "J!   BA0  &XD  !2,   /CP, "I(+  :2$0 $DA@  I(@  &2*0  DC,
M ),^  "32P  DUD  )-I  "3>P  DI   )*F  "1OP  D>4  )#Z  "/_P
MC_\  (__ (UW  !]=0  <'0  &)U  !5>   27P  #^    TA   *XD  "*-
M   :D0  $Y0   Z7   )FP   9T(  "=#@  G1,  )X:  ">(@  GRL  )\U
M  "@0@  H%   *!?  "@<0  H(<  )^=  "?M0  GMH  )WV  "=_P  G/\
M )S_ (9]  !X?   :7P  %M_  !.@P  08@  #:,   LD0  (Y8  !J:   2
MG@  #:$   :D    IP   *D#  "I"@  J@X  *L3  "L&0  K2(  *XK  "O
M-P  KT4  *]4  "O9@  KWL  *Z4  "NJP  KLD  *[O  "M_P  K?\  *W_
M (&$  !QA   88<  %.+  !&D   .98  "Z;   CH   &J0  !*H   ,K
M!*\   "R    M@   +<   "W @  N @  +D-  "Z$@  NQ@  +TA  "^*P
MP#@  ,!(  # 6@  P6X  ,&&  #!H   P;H  ,'C  # ^0  P/\  ,#_ 'F-
M  !HD   690  $N:   ]H   ,:4  "6K   :KP  $;,   NX   "NP   +X
M  #!    Q    ,4   #&    QP   ,@%  #*"P  S \  ,X5  #0'P  TRL
M -4Z  #53   UF   -AW  #8D@  V*P  -G)  #9[   V?L  -C_ '"9  !@
MG@  4:0  $.J   UL   *+8  !RZ   1O@  "<$   #%    R    ,L   #/
M    T@   -,   #6    V    -L   #=    WP<  .(-  #E$P  Z!T  .PJ
M  #M/   [5$  .YG  #O@0  [YP  /"W  #PTP  \.P  /#T &>F  !8K0
M2;0  #JZ   JO@  ',(  !#&   'R@   ,X   #2    U@   -P   #@
MXP   .0   #F    Z    .L   #M    [P   /("  #U"@  ^!$  /P<  #_
M+   _S\  /]5  #_;@  _XH  /^D  #_N@  _]$  /_A /\ % #_ !( _P 2
M /\ % #_ !D _P E /\ ,@#_ #\ _P!+ /\ 5@#_ &  _P!H /\ < #_ '@
M_P!_ /\ A0#_ (L _P"1 /\ F #_ )X _@"F /T K@#\ +D ^@#( /D X@#X
M /0 ]P#_ /8 _P#V /\ [P#_ .< _P#B /\ W@#_ /\ $0#_  X _P . /\
M#P#_ !0 _P @ /\ +0#_ #H _P!& /\ 40#_ %L _P!C /X :P#\ ', ^@!Y
M /D @ #W (8 ]@", /4 D@#S )D \@"@ /  J0#N +, [0#! .L U@#J .X
MZ0#^ .< _P#G /\ Y0#_ -T _P#5 /\ T0#_ /\ #0#_  H _P ( /\ "0#_
M !  _P ; /\ * #_ #4 _P!  /H 2P#V %4 \P!> /$ 9@#N &T [ !T .L
M>@#I (  YP"& .8 C0#D ), X@"; .  HP#> *T W "Y -H R@#7 .8 U #X
M -( _P#2 /\ T@#_ ,X _P#) /\ Q@#_ /\ " #_  , _P   /\  P#_  T
M_  6 /< (@#S "X [P Z .P 10#H $\ Y !8 .$ 8 #> &< VP!M -D = #5
M 'H TP"  -$ AP#/ (X S0"5 ,L G@#) *< QP"S ,4 P@## -P P0#Q +\
M_P"_ /\ O@#_ +X _P"] /\ NP#_ /\   #_    _P   /\   #V  @ [@ 1
M .< &P#A "< W0 S -D /@#3 $D SP!2 ,L 60#( &$ Q@!G ,0 ;0#" ',
MP !Z +\ @ "] (@ NP"0 +D F "X *( M0"M +, NP"Q ,X L #J *\ _ "M
M /\ K0#_ *X _P"N /\ K@#_ /\"  #_    _0   /(   #H    W@ , -,
M%0#, "$ R  L ,0 . #! $( O0!+ +H 4P"X %H M@!A +0 9P"R &T L !T
M *\ >@"M (( K "* *H DP"H )T I@"H *0 M0"B ,8 H0#C )\ ]@"> /\
MG@#_ )X _P"> /\ G@#_ /\&  #[    [@4  .($  #5    RP & ,, #P"]
M !D N  E +0 ,0"Q #L K@!% *P 30"I %4 IP!; *4 8@"D &@ H@!N *$
M=0"? 'P G@"% )P C@": )@ F "D )8 L "5 ,$ DP#< )( \@"1 /\ D #_
M )  _P"/ /\ CP#_ /T*  #P#@  X1$  ,X0  #"#0  NP<  +< "@"Q !(
MK  > *@ *0"E #0 H@ ^ )\ 1P"= $\ FP!6 )D!7 "7 6, E@)I )0"< "3
M W@ D0.  ) $B@".!)4 C 6A (H%K@")!KX APC8 (8)\ "$"O\ @PO_ (,+
M_P"#"_\ @PO_ /80  #F%P  TAP  , :  "S%@  K!(  *@-  "F!PT H@46
M )T'(@"9"2X E@HX )0+00"2#$H D Q1 (X-6 ",#5X BPUE (D-; "(#G0
MA@Y] (4.AP"##I, @0^? ( 0K0!^$+X ?1#; 'H1] !X$O\ =Q+_ '<2_P!W
M$O\ =Q+_ .\7  #;(0  QB0  +0C  "H(   H!P  )L7  "9$00 F X0 ),0
M&P"/$2< C!(R (D3/ "'$T0 A11, (,44P"!%5H @!5@ 'X6: !]%F\ >Q9X
M 'D7@P!X%X\ =AB< '08J@!S&;L <AG4 &\:\0!N&_\ ;1O_ &T:_P!M&O\
M;1K_ .<@  #0*0  O"L  *LJ  ">*   EB0  ) @  "-'   C!<, (@8%@"$
M&B( @1LM 'X<-P!\'4  >AU( 'D>3P!W'E4 =A]< '0?8P!S'VL <2!T ' @
M?P!N(8L ;"&8 &LAIP!I(K@ :"+/ &8B[@!E(_\ 9"/_ &0B_P!D(O\ 9"'_
M . F  #(+P  M#$  *,P  "6+@  C2L  (<H  "$)   @B ( 'X@$@![(AX
M>",I '4D,P!S)3P <25# ' F2P!N)E( ;2=9 &LG8 !J)V@ :2AQ &<H>P!E
M*(@ 9"F5 &(II !@*;4 7RG+ %XJ[ !<*O\ 7"G_ %PI_P!<*?\ 7"C_ -@L
M  ##-0  K34  )TT  "0,P  AC$  ( M  !\*P  >2@# '8G$ !R*1H <"HE
M &TK+P!K+#@ :BQ  &@M1P!G+4X 92Y5 &0N70!C+F4 82]N %\O> !>+X0
M7"^2 %HOH0%9+[(!6##( 58PZ0%5,/X!52__ %4O_P!5+O\ 52[_ - Q  "]
M.@  J#D  )<X  "*-P  @#8  'HR  !U,   <BX  &XN#0!K+Q8 :3 A &8Q
M*P!D,C0 8S(] &$S1 !@,TL 7S12 %TT6@!<-&( 6C1K %DU=0!7-8( 5360
M 50UGP%2-; !437& 5 UYP%/-?T!3S7_ 4\T_P%/-/\!3S/_ <LV  "X/0
MHSP  )(\  "%.P  >SH  '0W  !O-0  ;#,  &@T"@!E-1, 8C8> & W* !>
M-S$ 73@Z %LX00!:.4@ 63E0 %<Y5P!6.E\ 5#IH %,Z<P!1.G\!3SJ- 4XZ
MG0%,.JX!2SK# 4HZY0%).OP!23G_ 4DY_P%)./\!2CC_ <<Z  "S0   GC\
M (X_  "!/@  =ST  ' [  !J.   9C@  &(Y!P!?.A$ 7#L; %H[)0!9/"X
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M 3I(WP$Z1_@!.D;_ 3I%_P$[1?\!.T3_ ;M%  "F2   DD<  ()'  !V1P
M:T<  &-&  !;0P  5D4  %)'  !.2 H 3$D2 $I)' !(2B4 1THN $9+-@!%
M2SX 0TM& $),30!!3%8 0$Q? #Y,:@ \3'8 .TR% 3E,E0$W3*<!-DR\ 35,
MW0$U2_<!-4O_ 35*_P$V2?\!-DG_ ;A)  "B2P  CDH  'Y*  !R2@  :$H
M %])  !52   4$H  $Q+  !)3 < 1DT0 $1.&0!"3R( 04\K $!0,P _4#L
M/E!# #Q12@ [45, .E%< #A19P W47, -5&" #-1DP$R4:4!,%&Z 2]1V@$O
M4/8!+T__ 3!._P$P3O\!,$W_ ;1-  "=30  BDT  'I-  !N30  9$T  %M-
M  !130  2T\  $90  !"4@, /U,- #U4%0 \5!X .E4G #E5+P X53< -U8_
M #961P U5E  ,U99 #)79  P5W$ +U>  "U7D0 K5Z, *E>X "E7U@ I5O4
M*57_ "I4_P$J4_\!*E+_ :]1  "840  A5$  '90  !J4   8%   %A1  !.
M4@  1U,  $%5   [6   .%D* #5:$0 T6AH ,ULB #);*P Q6S, +UP[ "Y<
M0P M7$P +%Q6 "M=8  I76T *%U\ "9=C@ D7:$ (UVU ")=T@ B7/, (EO_
M "-:_P C6?\ )%C_ *A5  "25   @%0  '%4  !F5   7%0  %15  !*5@
M0U@  #Q;   V70  ,& % "UA#@ K814 *F(= "EB)0 H8BX )V,V "9C/@ E
M8T< (V-1 ")D7  A9&D 'V1Y !YDB@ <9)X &V2S !EDS@ :8_$ &V'_ !M@
M_P <8/\ '%__ *%9  ",6   >U@  &U8  !B6   65@  %!9  !'6P  /EX
M #=@   Q8P  *F8  "1I"0 A:A  (&H7 !]J(  >:R@ '6LP !QK.0 ;:T(
M&FQ, !EL6  7;&4 %FQT !1LA@ 3;)H $FRO !%LR@ 1:^\ $FG_ !-H_P 3
M:/\ $V?_ )E=  "%70  =5P  &A<  !>7   55P  $M>  !"80  .60  #)G
M   K:@  )&T  !YP 0 7<PL %701 !1T&  3="$ $G4I !%U,@ 1=3L $'5&
M  ]U4@ .=5\ #75N  QU@0 +=94 "G6J  ATPP )=.< "G/]  MQ_P ,<?\
M#'#_ )%B  !_80  <&$  &1A  !:80  3V(  $5E   \:   ,VP  "MO   D
M<@  '78  !=Y   1? 0 #7\,  M_$@ *?QD "7\B  A_*@ &?S0 !7\_  1_
M2P "?U@  7]G  !_>0  ?XX  '^C  !^NP  ?>   'WW  !\_P  >_\  'O_
M (EG  !X9P  :V8  &%F  !49P  26D  #]M   U<0  +'4  "1Y   =?
M%H   !"#   ,A@( !HD*  &)#P  B10  (H;  "*(P  BRP  (LW  "+0P
MBU   (M?  "+<0  BX8  (N<  "*LP  B=,  (CS  "(_P  A_\  (?_ ()M
M  !S;   :&P  %IM  !.;P  0G,  #AW   N>P  )8   !V$   5B   $(P
M  N/   $D@   )0&  "5#   E1   )85  "7'   F"0  )@N  "9.0  F4<
M )E6  "9:   F7T  )F4  "8JP  E\@  );N  "6_P  E?\  )7_ 'MT  !O
M<P  87,  %-V  !&>@  .W\  #"$   FB   '8T  !22   .E@  "9D   &<
M    H    *$   "B!@  H@P  *00  "E%   I1P  *<D  "H+P  J#T  *E,
M  "I7@  J7(  *B)  "HH@  J+P  *?E  "F^P  IO\  *7_ '=[  !H>P
M67X  $N"   ^AP  ,HT  ">2   =EP  %)P   Z@   'I    *@   "K
MK@   *\   "P    L00  +,*  "T#@  M1,  +8;  "X)   NC$  +I   "Z
M4@  NV4  +M]  "ZEP  NK$  +K2  "Z\P  N?\  +G_ &^#  !?A@  48L
M $.0   VEP  *IT  !^B   5IP  #:P   6P    M    +<   "[    O@
M +\   #     P0   ,,!  #$!P  Q0T  ,<1  #*&0  S20  ,XS  #/1
MT%@  -!N  #1B   T*0  -#!  #1Y@  T?@  -'_ &>/  !7E   29H  #NA
M   NIP  (:T  !:S   .N   !KP   #     PP   ,8   #+    S0   ,X
M  #0    T0   -0   #6    V@(  -P)  #?#P  XQ<  .8D  #G-@  Z$D
M .E?  #J>   ZY0  .NO  #KS   [.@  .SV %^>  !0I   0JL  #2R   F
MN0  &;X   ["   $Q0   ,H   #-    T0   -@   #;    WP   .    #B
M    Y    .8   #I    ZP   .X   #Q!0  ]0T  /D6  #\)0  _3D  /Y/
M  #_9P  _X(  /^=  #_M0  _\L  /_D /\ $0#_  \ _P / /\ $0#_ !8
M_P B /\ +P#_ #L _P!' /\ 4@#_ %L _P!D /\ ; #_ ', _P!Z /\ @ #_
M (8 _P", /X DP#] )D ^P"A /H J0#X +0 ]P#" /8 V@#U /$ ] #_ /,
M_P#S /\ Z0#_ .  _P#8 /\ TP#_ /\ #@#_  L _P * /\ "P#_ !$ _P =
M /\ *@#_ #8 _P!! /\ 3 #_ %8 _@!? /L 9@#Y &T ]P!T /4 >@#T (
M\@"& /  C0#O )0 [0"; .P I #J *X Z0"Z .< S0#E .D Y #[ ., _P#B
M /\ W@#_ -$ _P#, /\ R #_ /\ "0#_  0 _P ! /\ ! #_  X _P 8 /\
M) #] #  ^P [ /< 1@#S %  [P!9 .P 8 #J &< YP!N .8 = #D 'H X@"
M .  AP#> (X W "5 -H G@#6 *@ U "S -$ PP#/ -\ S@#T ,P _P#+ /\
MRP#_ ,4 _P"_ /\ O #_ /\  @#_    _P   /\   #]  L ]P 3 /$ '@#M
M "H Z@ U .< 0 #B $H W0!2 -D 6@#5 &$ T@!G -  ;0#. ', S !Z ,H
M@ #( (< Q@"/ ,0 F #" *$ P "M +X NP"\ -  N@#M +D _@"X /\ N #_
M +< _P"S /\ L #_ /\   #_    _P   /D   #N  4 Y0 . -X & #8 ",
MT@ N ,\ .0#+ $, QP!, ,0 5 #! %L OP!A +P 9P"[ &T N0!S +< >@"U
M ($ M ") +( D@"P )L KP"G *P M "K ,8 J0#D *< ^ "F /\ I@#_ *4
M_P"E /\ I #_ /\   #_    ]0   .H   #>    T  * ,@ $@#" !T O@ H
M +L ,P"Y #T M0!& +( 30"P %4 K0!; *P 80"J &< J !M *< <P"E 'H
MI "" *( C "@ )8 GP"A )T K@"; +X F0#8 )< \0"6 /\ E@#_ )< _P"7
M /\ EP#_ /\   #U    YP$  -0   #)    P  $ +@ #@"S !8 KP A *L
M+ "H #8 I@ _ *, 1P"A $\ GP!5 )T 6P"; &$ F@!G )@ ;@"7 '4 E0!]
M )0 A@"2 )$ D "< (X J0", +@ BP#- (D ZP"( /T B #_ (@ _P"( /\
MB #_ /D&  #I#   U X  ,,,  "W"0  L (  *L "0"F !  H@ : )X )0";
M #  F  Y )8 00"4 $D D@!0 )  5@". %P C0!B (L :0"* '  B !X (<
M@0"% (P A "8 (( I0"  +0 ?@#( 'T!YP!\ OD >P/_ 'L$_P![!/\ >P3_
M /$.  #>%0  Q14  +04  "I$0  H0X  )X*  "; PP EP 3 ), '@"0 2D
MC0(S (H#/ "(!$, A@5+ (4&40"#!E< @@=> ( '9 !_"&P ?0AT 'P(?@!Z
M"8D > F6 '<*HP!U"K, <PO' '(,Y@!P#?L < W_ &\-_P!O#?\ ;PW_ .@6
M  #0'@  N1T  *D<  "=&@  E18  ) 3  "/#@, C@H. (D+%P"&#", @PTM
M ( --@!^#CX ? Y& 'L.30!Y#U, >!!: '8080!U$&@ <Q!Q '$1>P!P$8<
M;A&4 &P1H@!K$K( :1+' &@3YP!F$_T 913_ &44_P!E$_\ 91/_ -\>  #&
M)   L"0  * C  "4(0  BQ\  (8;  "#%P  @A(( '\1$@!\$AT >10H '84
M,0!T%3H <A9! '$62 !O%T\ ;A=6 &P770!K&&0 :1AM &@9=P!F&8, 9!F0
M &,:GP!A&J\ 8!K$ %X;Y !='/L 7!S_ %P;_P!<&_\ 7!O_ -4E  "]*@
MJ"D  )@I  ",*   @R4  'TB  !Y'P  >!L# '89#P!R&A@ ;QPC &T=+0!K
M'34 :1X] &@>1 !F'TL 91]2 &,@60!B(&$ 82!I %\A<P!=(7\ 7"&- %HB
MG !9(JP 5R+  %8CX0!5(_D 5"/_ %0B_P!4(O\ 5"+_ ,TK  "V+@  HBX
M )(N  "%+0  ?"L  '8H  !R)@  ;R,  &TA# !J(A4 9R,? &4D*0!C)#$
M8B4Y & F00!?)D@ 729/ %PG5@!;)UT 62=F %@H< !6*'P 5"B* %,IF0!1
M*:H 4"F^ $\IW@!.*?< 32G_ $TI_P!-*/\ 3BC_ ,@P  "P,@  G#(  (PR
M  " ,0  =C   ' M  !K*P  :"D  &8H"0!C*!$ 8"D< %XJ)0!<*RX 6RLV
M %DL/0!8+$0 5RU, %4M4P!4+5L 4RUC %$N;@!0+GH 3BZ( $POEP!++Z@
M22^[ $@OVP!(+_8 1R__ $<N_P!'+?\ 2"W_ ,0T  "K-0  ES4  (<U  ![
M-0  <C0  &LR  !F+P  8BX  %\M!0!<+A  6B\8 %@P(@!6,"L 53$S %,Q
M.@!2,D( 43)) % R4 !.,U@ 33-A $LS:P!*,W< 2#2% $<TE0!%-*8 0S2Y
M $(TU@!"-/0 0C3_ $(S_P!",O\ 0C+_ , X  "G.   DS@  (,X  !W.
M;3<  &8V  !A,P  73(  %DR @!7,PT 5#05 %(U'P!1-2@ 3S8P $XV. !,
M-S\ 2S=& $HW3@!).%8 1SA? $8X:0!$.'4 0SB# $$YDP! .:0 /CFX #TY
MTP \.?, /#C_ #TW_P ]-_\ /3;_ +L[  "B.P  CSL  '\[  !S.P  :CH
M &(Y  !=-P  6#8  %0W  !1. L 3SD3 $TY' !+.B4 2CHM $@[-0!'.SP
M1CQ$ $4\2P!$/%, 0CQ< $$]9P _/7, /CV! #P]D0 Z/:, .3VV #@]T0 W
M/?( -SS_ #@[_P X._\ .#K_ +8]  ">/@  BSX  'P^  !O/@  9CT  %X]
M  !8.P  4SH  $\[  !,/ @ 23T1 $<^&0!&/R( 1#\J $,_,@!"0#H 04!!
M $! 20 ^05$ /4%: #Q!9  Z07  .$%_ #=!CP U0J$ -$*T #)"S@ R0?
M,D#_ #- _P S/_\ -#[_ +%   ":0   AT   'A!  !L00  8D   %M   !4
M/P  3C\  $I   !&004 1$(. $)#%@! 0Q\ /T0G #Y$+P \1#< .T4^ #I%
M1@ Y14X .$98 #9&8@ U1FX ,T9\ #%&C0 P1I\ +D:S "U&S  M1N\ +47_
M "Y$_P N0_\ +D/_ *Q#  "60P  @T,  '1#  !H0P  7T,  %=#  !00P
M2$,  $1%  !!1@$ /D<, #Q($P Z2!P .4DD #A)+  V230 -4H[ #1*0P S
M2DP ,DI5 #!+7P O2VL +4MZ "Q+BP J2YT *$NQ "=+R@ G2^T )TK_ "A)
M_P H2/\ *4?_ *=&  "11@  ?T8  '!&  !E1@  6T8  %1&  !,1P  1$@
M #]*   [2P  -TP) #5-$  S3A@ ,DX@ #%/*  P3S  +T\X "Y/0  L4$@
M*U!2 "I07  H4&@ )U!W "50B  D4)L (E"O "%0R  @4.L (4__ ")._P B
M3?\ (TW_ *%)  ",20  >DD  &Q*  !A2@  6$H  %!*  !)2P  0$P  #M.
M   U4   ,5($ "U3#0 L5!0 *E0< "E5)  H52P )U4S "95/  E5D4 )%9.
M ")660 A5F4 'U9T !Y6A0 <5I@ &U:L !E6Q0 95ND &E7_ !M4_P ;4_\
M'%+_ )M-  "&30  =4T  &A-  !=30  5$T  $U.  !%3P  /%$  #93   Q
M50  *U@  "9:"0 C6Q  (EL7 "%<'P @7"< 'UPN !U<-P <74  &UU* !I=
M50 876$ %UUP !5=@0 4794 $UVJ !%=P@ 17>< $EO^ !-:_P 36O\ %%G_
M )11  " 40  <%$  &11  !940  45$  $E2  !!4P  .%8  #)9   K6P
M)5X  !]A P :8PP &&01 !=D&0 69"$ %60I !1E,0 393H $F5$ !%E4  0
M95T #V5K  YE?0 -99$ #&6E  IDO  *9.  "V/Y  QB_P -8?\ #6'_ (U5
M  !Z50  :U4  %]5  !650  3E4  $17   \60  -%P  "Q?   F8@  'V4
M !EH   3:P4 $&T-  YN$@ -;AH #&XB  QN*P +;C0 "FX^  AN2@ ';E<
M!FYE  1N=@ ";HH  &V?  !MM@  ;-8  &SS  %K_P ":O\  VK_ (5:  !T
M6@  9EH  %Q9  !360  2%H  #]=   V8   +F,  "9G   ?:@  &6T  !-Q
M   .= , "G<*  5W$  !=Q4  '<<  !W)   >"T  '@W  !X0P  >%   'A>
M  !X;P  >(0  'B9  !WL   =LT  '7P  !U_P  =/\  '3_ 'Y?  !N7P
M8EX  %E>  !-7P  0F(  #EE   P:   )VP  !]P   8=   $G<   U[   (
M?@   H (  "!#0  @1$  ((7  "#'@  @R8  (0P  "$.P  A$@  (17  "$
M:   A'P  (23  "#J@  @L4  ('K  "!_@  @/\  (#_ '=E  !I9   7V,
M %)D  !'9P  /&L  #%O   H<P  ('<  !A\   1?P  #(,   :'    B@
M (P#  ","0  C0X  (X1  "/%P  D!X  )$G  "2,@  DC\  )).  "27P
MDG,  )*+  "1H@  D;P  )#E  "/_   CO\  ([_ '%K  !F:@  6&L  $MM
M   _<0  -'8  "I[   @@   %X4  !")   +C0  !)$   "5    F    )D
M  ": P  FP@  )P-  ">$0  GQ8  * >  "B*   HC4  *-$  "C50  HVD
M **   "BF@  H;,  *#8  "@]@  G_\  )__ &YQ  !?<@  474  $1Y   W
M?@  +(0  "&*   7CP  $)0   J9   !G0   *    "D    IP   *@   "I
M    J@   *P&  "M"P  KQ   + 5  "R'@  M"D  +0Y  "T2@  M5T  +5S
M  "UC@  M:@  +3&  "S[0  LO\  ++_ &9Z  !7?0  28(  #R'   OC@
M(Y0  !B:   0GP  ":0   "I    K0   +    "T    MP   +@   "Y
MNP   +P   "^ @  P @  ,(.  #$%   QQX  ,@L  #)/0  RE   ,IF  #*
M?P  RIL  ,JX  #*W0  RO4  ,K_ %Z&  !/BP  09$  #.8   GGP  &Z4
M !&K   )L    +4   "Y    O0   ,$   #&    R    ,D   #+    S
M ,X   #0    T@   -0%  #9#   W1(  .$>  #B+@  XT(  .17  #E;P
MYHP  .:H  #EQ0  Y><  .;V %:4  !(FP  .J(  "RI   ?L   $[8   N\
M    P0   ,4   #)    S0   -(   #6    V@   -L   #>    X    .(
M  #D    YP   .D   #M    \ H  /01  #X'P  ^3(  /I(  #[7P  _'H
M /V7  #]KP  _<<  /WD /\ #@#_  T _P , /\ #@#_ !, _P > /\ *@#_
M #8 _P!" /\ 30#_ %< _P!? /\ 9P#_ &X _P!T /\ >@#_ ($ _0"' /P
MC0#Z )0 ^0"< /< I0#U *\ ] "\ /, SP#Q .P \ #^ .\ _P#O /\ XP#_
M -< _P#. /\ R@#_ /\ "@#_  8 _P $ /\ " #_ !  _P 9 /\ )0#_ #$
M_P ] /\ 1P#^ %$ ^P!9 /D 80#V &@ ] !N /, = #Q 'H [P"! .X AP#L
M (X Z@"6 .@ GP#F *D XP"U .( Q@#@ ., WP#X -T _P#= /\ U #_ ,D
M_P#" /\ O@#_ /\  P#_    _P   /\  0#_  T _P 4 /T ( #Z "L ]P V
M /, 00#O $L [ !4 .@ 6P#F &( XP!H .$ ;@#? '0 W !Z -H @0#8 (@
MU "0 -( F #/ *( S0"N ,L O #) -, QP#P ,8 _P#$ /\ Q #_ +L _P"V
M /\ LP#_ /\   #_    _P   /\   #W  @ \  0 .L &@#G "4 Y  P .$
M.P#< $4 U0!- -$ 50#. %L RP!B ,D 9P#' &T Q0!S ,, >@#! ($ OP")
M +T D@"[ )P N0"G +< M0"U ,@ LP#F +( ^P"Q /\ L #_ *X _P"J /\
MIP#_ /\   #_    _@   /$   #E  ( W  - -, % #- !\ R@ J ,< - #$
M #X P !' +P 3@"Z %4 MP!; +4 80"S &< L@!M +  <P"N 'H K "" *H
MBP"H )4 IP"@ *4 K0"C +X H0#; *  ] "? /\ G@#_ )\ _P"= /\ FP#_
M /\   #\    [@   .    #0    Q0 ( +X $ "Y !D M0 C +, +@"P #<
MK0!  *H 2 "H $\ I0!5 *, 6P"B &  H !F )\ ; "= ', FP![ )H A "8
M (X E@": )4 IP"3 +< D0#, )  [ "/ /\ C@#_ (X _P". /\ CP#_ /P
M  #O    VP   ,D   "]    M0 " *X # "I !, I0 = *( )P"@ #$ G0 Z
M )H 0@"8 $D E@!/ )0 50"3 %L D0!@ )  9P". &T C0!U (L ?@") (D
MB "5 (8 H@"% +$ @P#$ ($ Y "  /D ?P#_ (  _P"  /\ @ #_ /0"  #@
M"0  QP@  +<'  "L P  I@   *  !P";  \ F  7 )4 (0"2 "H CP S (T
M/ "+ $, B0!) (< 4 "& %4 A !; (, 80"! &@ @ !P 'X >0!\ (0 >P"0
M 'D G0!X *P =@"^ '4 W0!S /0 <P#_ ', _P!S /\ <P#_ .D-  #/$
MN1   *D0  ">#@  EPL  ),&  "0  L C  1 (D &@"& "0 @P N ($ -@!_
M #X ?0!$ 'P 2P!Z %$ >0!7 '< 70!V &0 = !L ',!=0!Q 8  ;P*- &X"
MF@!L ZH :P.[ &D$U@!H!O$ : ?_ &<'_P!G!_\ 9P?_ -\4  ##%P  KA<
M )X6  "3%0  BQ(  (80  "$# ( @P8- ( #% !\!1X >0<H '<(, !U"#@
M<PE  '()1@!P"DP ;PI3 &T+60!L"V$ :@MI &D,<@!G#'X 9@R+ &0-F0!B
M#:D 80V[ & -V !>#O, 70[_ %T._P!=#O\ 70[_ -0<  "Y'0  I!X  )4=
M  ")'   @1H  'L7  !X$P  >! & '<-#P!S#A@ < XB &X/*P!L$#, :A [
M &D00@!G$4D 9A%/ &015@!C$ET 81)F & 2;P!>$GL 7!.( %L3EP!9$Z<
M5Q2Z %84U0!5%?, 5!7_ %05_P!4%?\ 5!3_ ,HB  "P(@  G2,  (TC  "!
M(@  >2$  ',>  !O&P  ;A<  &T3# !J%!0 9Q4> &46)P!C%B\ 81<W & 7
M/@!>&$4 71A+ %P94@!:&5H 61EB %<:; !6&G< 5!J% %(;E !1&Z0 3QNW
M $X;T !-'/$ 3!S_ $P<_P!-'/\ 31O_ ,,F  "J)P  EB<  (<H  ![)P
M<B8  &PD  !H(0  9AX  &0;" !B&Q$ 7QP: %T=(P!;'BL 6AXS %@?.@!7
M'T$ 5B!( %0@3P!3(%< 42%? % A:0!.(70 32&" $LBD0!)(J( 2"*T $<B
MS0!&(^\ 12/_ $4B_P!&(O\ 1B'_ +PJ  "D*P  D2L  ((L  !V*P  ;2H
M &8I  !B)@  7R0  %TB! !;(0X 6"(6 %8C'P!4)"@ 4R0P %(E-P!0)3X
M3R9% $XF3 !,)E0 2R=< $DG9@!()W$ 1B=_ $4HCP!#**  02BR $ HRP _
M*.T /RC_ #\H_P! )_\ 0"?_ +<M  "?+@  C"\  'TO  !Q+P  :"X  &$M
M  !=*P  6B@  %<G  !4)PP 4B@3 % I' !.*24 32HL $LJ- !**SL 22M"
M $@L20!&+%$ 12Q: $0L9 !"+6\ 0"U] #\MC0 ]+9X /"VP #HMR  Z+>L
M.BW_ #HM_P Z+/\ .BS_ +(P  ";,0  B#(  'DR  !M,@  9#(  %TQ  !8
M+P  52P  %$L  !/+0D 3"T1 $HN&0!)+R( 1R\J $8P,0!%,#@ 0S _ $(Q
M1P!!,4\ 0#%7 #XQ80 ],FT .S)[ #DRBP X,IP -C*O #4RQP T,ND -#+_
M #4Q_P U,?\ -3#_ *TS  "6-   A#4  '4U  !I-0  8#4  %DT  !4,P
M4#   $PQ  !),08 1S(/ $4S%@!#,Q\ 0C0G $ T+@ _-38 /C4] #TU1  \
M-DP .C95 #DV7P W-FL -C9X #0WB0 R-YH ,3>M "\WQ0 O-^@ +S;^ # U
M_P P-?\ ,#3_ *DV  "2-@  @#<  '(X  !F.   73<  %8W  !0-@  2S0
M $<U  !$-@, 03<- #\X%  ^.!P /#DD #LY+  Z.3, .3HZ #@Z0@ V.DH
M-3I3 #0[70 R.V@ ,#MV "\[AP M.YD +#NL "H[PP I.^8 *CK] "HZ_P K
M.?\ +#C_ *0X  "..0  ?#H  &XZ  !C.@  6CH  %,Z  !-.@  1C@  $(Z
M   _.P  /#P+ #H\$0 X/1D -STA #8^*0 T/C  ,SXW #(_/P Q/T< ,#]0
M "X_6@ M0&8 *T!T "E A  H0)< )D"J "5 P0 D0.4 )#_\ "4^_P F/?\
M)CW_ )\[  "*/   >#T  &H]  !?/0  5CT  $\]  !)/0  0CT  #P^   Y
M/P  -D$( #1!#P R0A8 ,4(> "]#)0 N0RT +4,T "Q$/  K1$0 *D1- "A$
M6  G16, )45Q "-%@@ B194 ($6H !]%OP >1., 'T3[ !]#_P @0O\ (4'_
M )H^  "%/P  =$   &=   !<0   4T   $Q   !&0   /D$  #A#   T10
M,$8# "U'#0 K2!( *D@: "E((@ H22D )TDQ "5).0 D24$ (TI* ")*50 @
M2F$ 'TIO !U*?P ;2I( &DJF !A*O0 72N  &$GZ !E(_P :1_\ &D?_ )5"
M  " 0@  <$,  &-#  !80P  4$,  $E#  !"1   .T4  #5'   P20  *TL
M "9-"0 D3A  (DX6 "%/'0 @3R4 'T\L !Y/-0 =3ST '%!' !I040 94%T
M%U!K !90?  44(\ $U"D !%0N@ 14-X $4_X !)._P 33?\ %$W_ (]%  ![
M1@  :T8  %]'  !51P  34<  $9'   _1P  -TH  #%,   K3@  )E   "!3
M P <50P &E81 !E6&  75B  %E8G !56,  45CD $U=" !)730 15UD $%=H
M  ]7>0 .5XP #5>@  M7M@ +5M0 "U;T  Q5_P -5/\ #E/_ (A)  !V2@
M9TH  %M*  !12@  2DH  $-*   [3   ,TX  "Q1   F5   (58  !M9   5
M7 < $5X- !!>$P 07AH #EXB  Y>*@ -7C, #%X]  M>2  *7E0 "%YB  =>
M<P %7H8  UZ;  )>L0 "7<P  EWN  -<_P $6_\ !5O_ (%.  !P3@  8DX
M %=.  !.3@  1TX  #Y/   V40  +E0  "=7   A6@  &UT  !5@   08P,
M#&8+  AG$  &9Q4 !6<<  1G)  "9RT  6<W  !G0@  9TX  &=<  !G;0
M9X   &:5  !FK   9<<  &7K  !D_   9/\  &/_ 'I2  !J4P  75(  %12
M  !+4@  0E,  #E5   P6   *%L  "%?   :8@  %&4  !!H   ,:P$ !FX)
M  !O#@  ;Q(  &\8  !P'P  <"<  '$P  !Q.P  <4@  '%6  !Q9@  <7D
M '&/  !PIP  ;\$  &_G  !N_   ;?\  &W_ '-8  !E5P  6E<  %%6  !&
M5P  /%H  #)=   J80  (F0  !IH   4;   #F\   IR   $=@   '@%  !X
M"P  >0X  'H3  ![&0  ?"   'TI  !],P  ?4   'U.  !]7@  ?7(  'V(
M  !\H0  ?+H  'OB  !Z^@  >?\  'C_ &U=  !@7   5UP  $M=  ! 7P
M-6,  "MG   C:P  &F\  !-S   .=P  "'L   )^    @@   (,!  "$!@
MA0L  (8/  "($P  B1D  (HA  "+*P  BS<  (Q&  "+5@  BVD  (N   "+
MF0  BK,  (G8  "(]P  B/\  (?_ &AC  !>8@  46(  $1E   X:0  +FX
M "1S   :>   $WT   V!   &A0   (D   "-    D    )(   "2    E 4
M )4*  "7#@  F!(  )H8  ";(0  G"T  )T\  "=3   G%\  )QV  ";D0
MFZL  )K)  ":\   F?\  )C_ &5I  !7:0  26P  #UQ   P=@  )7P  !N!
M   2AP  #(P   21    E0   )D   "=    H    *$   "B    I    *4!
M  "G!P  J0P  *H1  "M&   KR(  *\P  "O00  KU0  *]K  "NA0  KJ$
M *Z^  "MY@  K/P  *S_ %YQ  !/=   0GD  #5_   HA0  '8P  !.2   ,
MF    YT   "B    I@   *H   "N    L    +$   "S    M    +8   "X
M    N@0  +P*  "^$   P1<  ,,D  ##-0  Q$D  ,1>  #%=P  Q9,  ,6O
M  #%T0  P_(  ,/_ %9\  !'@@  .H@  "R/   @E@  %)T   VC   #J0
M *X   "R    MP   +L   "_    P@   ,(   #%    Q@   ,@   #*
MS0   ,\   #2"   U0X  -L8  #=)P  WCH  -]0  #@:   X(0  .&A  #A
MO0  X>(  .#T $Z+  ! D@  ,ID  "6A   8J   #J\   6U    N@   +\
M  #$    R    ,X   #1    U    -4   #8    V@   -T   #?    X@
M .0   #G    ZP4  .\.  #T&0  ]2L  /9!  #W6   ^'(  /F0  #YJP
M^,0  /CA /\ "P#_  @ _P ) /\ # #_ !( _P : /\ )@#_ #( _P ^ /\
M2 #_ %( _P!: /\ 8@#_ &D _P!O /\ =0#^ 'L _ "! /L B #Y (\ ]P"7
M /4 H #S *H \@"W .\ R0#M .8 [ #[ .L _P#K /\ W0#_ ,X _P#& /\
MP@#_ /\ ! #_    _P   /\ !0#_  T _P 5 /\ (0#_ "P _P X /\ 0P#]
M $P ^0!4 /< 7 #T &, \@!I /  ;P#N '4 [ ![ .H @@#H (D YP"1 .0
MF@#B *0 X "P -T P #: -P V #T -4 _P#3 /\ RP#_ ,$ _P"[ /\ MP#_
M /\   #_    _P   /\   #_  H _0 1 /D &P#V "< ]  R /  / #L $8
MZ !. .0 5@#A %P W@!C -P : #9 &X U0!T -( >P#0 (( S0"* ,L DP#(
M )T Q@"H ,0 MP#! ,P P #K +X _P"] /\ O0#_ +0 _P"N /\ JP#_ /\
M  #_    _P   /H   #R  4 Z@ . .4 %@#@ "$ W0 K -L -@#3 #\ S@!(
M ,H 3P#' %8 Q !< ,( 80#  &< O@!M +P <P"Z 'H N "" +8 BP"T )8
ML@"A +  KP"N ,$ K0#@ *L ]P"J /\ J0#_ *8 _P"A /\ GP#_ /\   #_
M    ]P   .@   #<    T  * ,H $0#% !L P@ E +\ +P"\ #@ N !! +4
M2 "R $\ L !5 *X 6P"L &$ J@!F *@ ; "G ', I0![ *, A "A (X GP":
M )T IP"; +@ F@#0 )D [P"8 /\ EP#_ )8 _P"4 /\ D@#_ /\   #V
MY    -(   #%    NP % +4 #@"P !4 K  ? *H *0"H #( I0 Z *( 0@"@
M $D G@!/ )P 50": %H F !@ )8 9@"5 &P DP!T )( ?0"0 (< C@"3 (P
MH0"+ +  B@#% (@ Y@"' /L A@#_ (< _P"' /\ A@#_ /@   #E    S0
M +T   "S    J@   *, "@"? !$ FP 9 )D (P"7 "P E0 T )( / "0 $,
MC@!) (P 3P"* %0 B0!: (< 8 "& &8 A !N (, =P"! ($ ?P"- 'X FP!\
M *H >P"\ 'H VP!X /4 > #_ '@ _P!X /\ > #_ .T   #1 @  NP(  *P!
M  "B    FP   )8 !0"1  T C0 4 (L '0"( "8 A@ N (0 -@"" #T @ !#
M 'X 20!] $\ ? !5 'H 6P!Y &$ =P!I '4 <0!T 'P <@"( '$ E@!O *4
M;@"V &T S@!L .X :P#_ &L _P!K /\ :P#_ -\+  #"#   K@P  )X,  "3
M"P  C <  (@"  "%  D @0 0 '\ %P!\ "  >@ H '@ , !V #@ =  ^ ',
M1 !Q $H < !0 &X 5@!M %T ; !D &H ;0!H '< 9P"$ &4 D@!D *$ 8P"R
M &$ R0!@ .D 8 #\ &  _P!@ /\ 8 #_ - 0  "V$0  HA(  ),2  "($0
M@ \  'P-  !Y"0$ > ,+ '4 $0!S !H <  C &X!*P!L 3, :@(Y &D#0 !G
M T8 9@1, &4$4@!C!5D 8@5A & %:@!?!G0 70:! %P'CP!:!Y\ 60>P %<'
MQ@!6">< 5@K[ %4*_P!5"O\ 5@K_ ,85  "M%P  F1@  (H8  !_%P  =A8
M '$3  !N$   ;0T% &T)#0!J"10 9PH= &4*)@!C"RX 8@PU & ,/ !?#$(
M7@U( %P-3P!;#58 60U> %@.: !6#G, 50Z  %,.CP!1#I\ 4 ZQ $X.R !-
M$.H 31#] $T0_P!-$/\ 31#_ +P;  "E'   DAT  (,>  !W'0  ;QP  &D:
M  !F%P  9!0  &00" !B#Q  7Q 8 %T0(0!;$2D 6A$Q %@2. !7$CX 5A)%
M %023 !3$U, 41-; % 390!.%'  3!1] $L4C !)%)P 1Q6N $85Q0!%%>@
M11;^ $46_P!%%?\ 117_ +4?  ">(0  BR(  'PB  !Q(@  :"$  &(?  !?
M'0  7!H  %L7 @!:%0T 5Q84 %46'0!4%R4 4A@M %$8- !/&#L 3AE" $T9
M2 !+&E  2AI8 $@:8@!'&FT 11MZ $,;B0!"&YH 0!NL #\;P@ ^'.4 /1S\
M #X<_P ^&_\ /AO_ *\C  "8)   AB4  '<F  !L)@  8R4  %TD  !9(@
M5A\  %0=  !3' L 41P2 $X=&@!-'2( 2QXI $H>,0!)'S< 1Q\^ $8@10!%
M($T 0R!5 $(@7P! (6H /R%W #TAAP [(9@ .2&J #@BP  W(N, -R+[ #<B
M_P X(?\ ."'_ *HF  "4)P  @2D  ',I  !G*0  7RD  %@H  !4)@  42,
M $\B  !,(@< 2B(0 $@B%P!'(Q\ 120F $0D+@!")#0 024[ $ E0P _)4H
M/293 #PF7  Z)F< .29U #<GA  U)Y8 -">H #(GO@ Q)^$ ,2?Y #(F_P R
M)O\ ,R7_ *4I  "/*@  ?2P  &\L  !D+0  6RP  %4K  !0*@  3"@  $HF
M  !')P0 1"<- $(H% !!*!P /RDC #XI*P ]*3( /"HY #LJ0  Y*D@ ."M0
M #8K6@ U*V4 ,RMR #$K@@ P+)0 +BRG "PLO  K+-X +"SX "PK_P M*O\
M+2K_ *$L  "++0  >2X  &LO  !@+P  6"\  %$N  !,+@  2"P  $4K  !!
M*P  /RP+ #TL$0 [+1D .BXA #DN*  W+B\ -B\V #4O/@ T+T4 ,R]. #$P
M6  P,&, +C!P "PP@  J,)( *3"E "<PN@ F,-P )C#W "<O_P H+_\ *"[_
M )PN  "',   =C$  &@R  !=,@  53(  $XQ  !(,0  1#   $ O   \,
M.C$) #<Q$  V,A8 -3(> #,S)0 R,RP ,3,S # T.P O-$, +31, "PT5@ J
M-6$ *35N "<U?@ E-9  (S6C "(UN0 A-=D (33V "(T_P C,_\ (S+_ )@Q
M  "#,P  <C0  &4T  !:-0  434  $LT  !%-   0#0  #HS   W-   -#4&
M #(V#@ P-Q, +S<; "XW(@ M."D *S@Q "HX.  I.4  *#E) "8Y4P E.5\
M(SEL "$Z?  @.HX 'CJB !PZMP ;.=4 '#GU !TX_P =./\ 'C?_ ),T  !_
M-@  ;C<  &$W  !7-P  3C<  $@W  !"-P  /#<  #4X   R.0  +SH" "P[
M"P J/!$ *3P8 "@]'P F/28 )3TN "0]-0 C/CT (CY& " ^4  ?/EP '3]I
M !L_>0 :/XP &#^@ !8_M0 5/M( %C[S !<]_P 8//\ &#S_ (XW  !Z.
M:CD  %XZ  !3.@  2SH  $4Z   _.@  .3H  #(\   N/@  *4   "9!"  D
M0@X (D(4 "%"&P @0R, 'T,J !Y#,@ <0SH &T1# !I$30 81%D %T1G !5$
M=P 31(H $D2> !%$LP 01-  $$/R !%"_P 20O\ $T'_ (D[  !V/   9CT
M %H]  !0/0  2#T  $(]   \/0  -CX  "]    J0@  )40  "%& P =2 P
M&TD1 !E)%P 821X %TDF !9)+@ 52C8 %$I  !-*2@ 12E8 $$ID  ]*=  .
M2H< #4J;  Q*L  *2LH "TGL  Q(_P -1_\ #4?_ (,^  !Q/P  8D   %9
M  !-0   14   #]    Y00  ,D(  "M%   F1P  (4D  !Q+   63@< $U .
M !)0$P 14!D $% A  ]0*0 .4#$ #5 [  U11@ +45$ "E%?  E1;P '4($
M!5"6  -0JP "4,4  T_H  -/^P %3O\ !DW_ 'U"  !K0P  740  %)$  !*
M1   0T,  #Q$   U10  +D<  "=*   A3   '$\  !=1   25 , #E<*  M8
M$  *6!4 "%@<  =8)  &6"P !5@V  -80  !6$P  %A:  !8:0  6'P  %B1
M  !7IP  5\   %;E  !6^0  5?\  %7_ '9'  !F1P  64@  $]'  !'1P
M0$<  #A(   P2@  *4T  ")0   <4P  %E4  !%8   -6P( "5X)  1?#@
M7Q(  %\8  !@'P  8"<  & P  !@.P  8$<  &!4  !@8P  8'8  &"+  !?
MH@  7[L  %_B  !>^0  7?\  %W_ &]+  !A3   54P  $Q+  !$2P  .TP
M #).   K40  (U0  !Q7   66P  $5X   U@   (8P   F8'  !G#   9P\
M &@3  !I&0  :B$  &HI  !J-   :D   &I-  !J70  :F\  &J%  !JG0
M:;8  &C=  !H]P  9_\  &;_ &E1  !<4   4E   $I/   _4   -5,  "U6
M   D60  '5T  !9@   09   #&<   9J    ;@   &\#  !P"   <0T  '(0
M  !T%   =1L  '8C  !W+   =S@  '9&  !V5@  =F@  '9^  !VEP  =;$
M '33  !S]0  <_\  '+_ &-6  !850  4%0  $15   Y6   +UL  "9?   =
M8P  %6<  !!L   *<   !',   !V    >@   'P   !\ P  ?@@  '\,  "!
M$   @A0  (0;  "%)   AB\  (8]  "&30  A5\  (5U  "%CP  A*D  (/)
M  ""\0  @?\  (#_ %];  !66@  25L  #U>   R80  )V8  !YK   5<
M#G4   EY   !?@   ($   "%    B    (H   "+    C0$  (X&  "0"P
MD0\  ),4  "5&P  ER8  )<T  "71   EU8  )9L  "5A@  E:(  )3!  "3
MZ@  DO\  )+_ %UA  !/80  0F0  #9I   J;@  'W0  !5Y   .?P  !X0
M  ")    C@   )(   "6    F    )H   ";    G0   )\   "A P  HP@
M *4-  "G$P  J1P  *HH  "J.0  JDL  *IA  "I>@  J)D  *BU  "GW0
MI_@  *;_ %9H  !(;   .G   "YV   B?0  %X0   Z*   'D    )8   ":
M    GP   *,   "G    J@   *L   "M    KP   +$   "S    M0   +@%
M  "Z#   O1(  , <  # +0  P$   +]5  "_;@  OHL  +ZH  "^R0  O>\
M +S^ $YT  ! >0  ,G\  "6'   9C@  $)4   ><    H@   *<   "L
ML    +4   "Y    O    +T   "_    P0   ,,   #&    R    ,H   #-
M @  T L  -42  #6(0  US0  -A)  #98   VGP  -J:  #;M0  V]D  -OR
M $:"   XB0  *Y   !V8   2H   "J<   "N    M    +D   "^    P@
M ,@   #+    S@   ,\   #2    U    -8   #:    W0   -\   #B
MY@   .H*  #O$P  \"4  /(Z  #S40  ]&L  /2)  #UI0  ];\  /7= /\
M!@#_  , _P % /\ "P#_ !  _P 7 /\ (@#_ "T _P Y /\ 1 #_ $T _P!5
M /\ 70#_ &0 _P!J /\ < #] '8 ^P!\ /D @P#W (H ]0"2 /, FP#P *8
M[@"S .L Q #I .0 YP#Y .8 _P#E /\ TP#_ ,< _P"_ /\ NP#_ /\   #_
M    _P   /\  @#_  L _P 2 /\ '0#_ "@ _P S /\ /@#\ $< ^ !/ /0
M5P#Q %T [@!C .P :0#J &\ Z !U .8 ? #D (, X@"+ -\ E0#< )\ V0"K
M -4 NP#2 -0 SP#R ,T _P#, /\ Q0#_ +H _P"T /\ L #_ /\   #_
M_P   /\   #_  8 ^0 / /4 %P#S "( \0 M .T -P#G $  X@!) -\ 4 #;
M %< UP!= -0 8P#1 &@ SP!N ,P =0#* 'P R "$ ,4 C0#" )@ P "D +T
ML@"[ ,8 N0#H +@ _0"W /\ M@#_ *T _P"G /\ HP#_ /\   #_    _P
M /4   #K  $ Y  , -X $P#9 !P TP F -$ , #, #H R !" ,0 2@#  %
MO0!6 +L 7 "Y &$ MP!G +4 ;0"S '0 L0!\ *\ A0"M )  J@"< *@ J@"F
M +L I0#: *, ]0"C /\ H@#_ )X _P": /\ EP#_ /\   #^    [P   -\
M  #0    QP ' ,$ #P"\ !< N0 @ +< *@"U #, L  [ *T 0P"K $D J !/
M *8 50"D %H HP!@ *$ 9@"? &T G0!T )P ?0": (@ F "4 )8 H@"4 +(
MD@#) )$ ZP"1 /\ D #_ )  _P", /\ B@#_ /P   #L    V0   ,<   "Z
M    L0 " *L # "G !( I  ; *$ ) "@ "P G@ U )L / "8 $, E@!) )0
M3P"2 %0 D !: (\ 7P"- &8 BP!M (D =@"( (  A@", (0 F@"" *H @0"^
M (  X "  /D ?P#_ '\ _P!_ /\ ?@#_ /$   #8    P@   +,   "H
MH    )D !P"5  X D@ 5 )  '@". "8 C0 N (H -@"' #T A0!# (0 20""
M $X @0!4 '\ 60!^ &  ? !G 'H ;P!Y 'H =P"& '4 E !T *, <@"U '(
MSP!Q /$ < #_ '  _P!P /\ <0#_ .$   #$    L    *(   "7    D0
M (L  @"&  L @P 1 ($ & !_ "$ ?0 I 'P , !Y #< >  ] '8 0P!T $D
M<P!. '( 5 !P %H ;P!B &T :@!K '0 :@"  &@ C@!G )T 90"O &4 Q@!D
M .@ 9 #] &, _P!C /\ 9 #_ ,\%  "V!P  HP@  )0(  ")!P  @@,  'X
M  ![  8 =P . '4 $P!R !L <0 C &\ *P!M #( ;  X &H /@!I $0 9P!)
M &8 3P!E %8 8P!= &( 90!@ &\ 7P![ %T B0!< )D 6P"J %D OP!9 .$
M6 #X %@ _P!8 /\ 60#_ ,(,  "J#0  EPX  (D.  !]#@  =@T  '$*  !O
M!@  ;0 * &L $ !I !8 9P > &4 )@!C "T 80 S &  .0!? #\ 70!% %P
M2P!; %( 6@!9 %@ 8@!7 &P 50!X %, A@!2 )8 40"G %  NP!/ =L 3@+T
M $X#_P!.!/\ 3@/_ +@0  "A$@  CA,  '\3  !T$P  ;!(  &<0  !E#@
M8PL# &,&# !A!!$ 7@,9 %P$(0!;!2@ 608O %@&-0!6!SL 50=" %0'2 !3
M"$\ 40A6 % )7P!."6D 30EV $L*A !)"I0 2 JF $<*N@!&"M@ 10OS $4,
M_P!%#/\ 10S_ + 4  "9%@  AQ@  '@9  !M&   91<  %\6  !<$P  6A$
M %H.!@!:# T 5PP4 %4,' !3#20 4@TK % -,0!/#C@ 3@X^ $T.10!+#DT
M2@Y5 $@/7@!'#V@ 10]U $,0A !!$)4 0!"F #X0NP ]$-P /1'V #T1_P ]
M$/\ /A#_ *D9  "2&P  @1P  '(=  !G'0  7QP  %D;  !5&0  4Q8  %(3
M  !2$0H 4! 0 $X1& !,$2  2A(G $D2+@!($S0 1Q,[ $430@!$$TD 0Q12
M $$46P _%&4 /A5R #P5@0 Z%9( .!6D #<5N0 U%=@ -1;U #86_P V%O\
M-Q7_ *,<  "-'@  >R   &TA  !B(0  6B$  %0?  !0'@  31L  $P9  !+
M%@8 218. $<7%0!%%QP 1!@D $(8*@!!&#$ 0!DX #\9/P ]&48 /!I/ #H:
M6  Y&F, -QMO #4;?@ S&Y  ,ANB # ;MP O&], +QSS "\;_P P&_\ ,!O_
M )T?  "((@  =R,  &DD  !>)   5B0  % C  !+(@  2"   $8=  !%' (
M0QP, $$<$@ _'1D /ATA #P>)P ['BX .A\U #D?/  W'T0 -A], #0@5@ S
M(&  ,2!M "\@?  M(8X +"&@ "HAM0 I(=  *2'R "DA_P J(/\ *R#_ )DB
M  "$)0  <R8  &4G  !;)P  4R<  $PF  !')0  1"0  $(A   _(0  /2$)
M #LA$  Y(A8 ."(> #8C)0 U(RL -"0R #,D.0 R)$$ ,"1* "\E4P M)5X
M*R5K "HE>@ H)8P )B6? "0ELP C)<X (R7P "0E_P E)/\ )23_ )0E  "
M)P  ;RD  &(J  !7*@  3RH  $DI  !$*   0"<  #TF   Z)0  -R8& #4F
M#@ T)Q0 ,B<; #$H(@ P*"D +R@P "TI-P L*3\ *RE' "DI40 H*EP )BII
M "0J>  C*HH (2J= !\JL@ >*LP 'BKO !\I_P @*?\ (2C_ ) H  !\*@
M;"L  %\L  !4+   3"P  $8L  !!*P  /"L  #@J   U*@  ,BL# # K#  N
M+!$ +2P8 "PL'P J+28 *2TM "@M-  G+CP )BY% "0N3P C+EH (2]G !\O
M=@ =+X@ '"^; !HOL  8+\H &"[M !DN_P ;+?\ &RW_ (PK  !X+0  :"X
M %LO  !1+P  22\  $,O   ^+@  .2X  #0N   P+@  +2\  "LP"@ I,1
M)S$5 "8Q'  E,B, )#(J ",R,0 A,SD (#-" !\S3  =,U< &S-D !HT=  8
M-(8 %C2: !0SK@ 3,\@ $S/L !0S_P 5,O\ %C'_ (<N  !T+P  93$  %@Q
M  !.,@  1C(  $ Q   [,0  -C$  #$Q   K,P  *#0  "4U!@ C-@T (382
M " W&0 ?-R  'C<G !TX+@ ;.#8 &C@_ !DX20 7.54 %3EB !0Y<0 2.80
M$3F8 ! YK0 ..,< #CCK ! X_P 0-_\ $3;_ (,Q  !P,@  830  %4T  !+
M-   1#0  #TT   X-   ,S0  "TU   H-P  )#D  " Z @ =.PL &SP0 !D]
M%0 8/1P %STC !8]*P 5/C, %#X\ !(^1@ 1/E( $#Y?  \^;P ./H$ ##Z5
M  L^J0 */L$ "CWD  L]^P ,//\ #3O_ 'TT  !K-@  73<  %$W  !(-P
M03<  #LW   U-P  ,#<  "HY   E.P  (#T  !P_   7008 %$,- !)#$@ 1
M0Q@ $4,? !!$)P /1"\ #D0Y  U$0P ,1$X "T1;  E$:@ '1'P !D20  1#
MI0 "0[T  T/@  -#]@ $0O\ !D'_ '@X  !G.0  63H  $XZ  !%.@  /CH
M #@Z   S.@  +3L  "<]   A0   '$(  !=$   31@, #TD*  U*#P ,2A0
M"TH;  E*(P (2BL !THT  5*/@ $2DD  DI6  !*90  2G<  $J+  !*H0
M2;D  $G=  !)]0  2/\  $C_ '(\  !B/0  53X  $H^  !"/0  /#T  #8]
M   O/@  *4   "-"   =10  %T<  !-*   /3 ( "T\)  =0#0 #41$  %$7
M  !1'@  428  %$O  !1.0  440  %)1  !28   47(  %&'  !1G0  4;4
M %#8  !0]0  3_\  $__ &Q   !=00  44$  $=!  ! 0   .4   #)!   J
M0P  )$8  !Y(   72P  $DX   Y1   +4P$ !E8'  !7#   6!   %@3  !9
M&0  6B$  %HI  !:,P  6C\  %I,  !:6@  6FP  %J!  !9F0  6;$  %C1
M  !8]   5_\  %?_ &5%  !810  344  $5$   ^1   -44  "U'   E2@
M'DT  !A0   24P  #E8   I9   $7    %X$  !?"0  8 T  &$0  !B%0
M8QL  &0C  !D+0  9#@  &1%  !D5   9&8  &1[  !CDP  8ZT  &+,  !A
M\@  8?\  &#_ %]*  !32@  2DD  $-(   Y20  +TP  "=/   ?4@  &%4
M !)9   -70  "&    )C    9@   &@!  !I!0  :@H  &L-  !M$0  ;A8
M ' =  !Q)@  <3$  ' ^  !P3@  <%\  '!S  !OC0  ;Z<  &[&  !M[P
M;/\  &S_ %I/  !03@  2$T  #U.   S40  *50  "!8   87   $6    QD
M   &:    &L   !O    <@   '0   !U    =P0  '@)  !Z#0  ?!   'T6
M  !_'@  @"@  ( U  " 10  ?U8  ']K  !_A   ?J   'V^  !\Z0  >_\
M 'K_ %94  !.4P  0E0  #=6   L6@  (E\  !AC   1:   "VT   -R
M=@   'H   !]    @    (,   "$    A@   (<"  ")!P  BPP  (T0  "0
M%@  DA\  )(L  "2.P  DDT  )%B  "1>@  CY<  (^T  ".X0  C/L  (S_
M %59  !(6@  .UT  "]A   D9@  &6P  !%R   *=P   GT   ""    A@
M (L   ".    D0   ),   "5    EP   )D   ";    G00  )\*  "B#P
MI!8  *8A  "F,0  ID,  *57  "D<   HXX  *.K  "AT   H/4  )__ $YA
M  ! 9   ,VD  "=N   ;=0  $7P   N#    B0   (X   "3    F    )T
M  "A    I    *4   "G    J0   *L   "M    L    +(   "U"   N X
M +P6  "\)0  O#<  +M,  "Z9   N8$  +>B  "WP   M^H  +?\ $9K   Y
M<   *W<  !]_   3A@  "XX   &5    FP   *$   "F    JP   +    "S
M    MP   +<   "Z    O    +\   #!    Q    ,<   #*    S04  -$.
M  #4&0  U"L  -1   #36   TW0  -.2  #2L   TM,  -+R #YY   Q@
M(X@  !>1   -F0   Z    "G    K@   +,   "X    O0   ,(   #&
MR@   ,H   #-    SP   -(   #5    V0   -T   #?    XP   .<%  #K
M#P  [!\  .TS  #N2P  [V0  .^"  #PGP  \;D  /'8 /\   #_    _P $
M /\ "0#_  X _P 5 /\ '@#_ "D _P T /\ /P#_ $@ _P!0 /\ 6 #_ %X
M_P!E /T :P#[ '$ ^0!W /@ ?@#V (4 \P"- /$ EP#N *( ZP"O .@ P #F
M .  XP#X .( _P#; /\ RP#_ ,$ _P"Y /\ M #_ /\   #_    _P   /\
M  #_  D _P 0 /\ &0#_ ", _P N /T .0#Y $( ]0!* /( 4@#N %@ ZP!>
M .D 9 #F &H Y !P .( =@#? 'T W0"& -D CP#5 )H T0"G ,X M@#+ ,X
MR0#P ,< _P#% /\ NP#_ +0 _P"M /\ J0#_ /\   #_    _P   /\   #[
M  ( ]@ - /$ $P#M !X [  H .D ,@#C #L W0!$ -@ 2P#3 %$ T !8 ,T
M70#+ &, R0!H ,8 ;P#$ '8 P@!^ +\ AP"\ )( N@"? +< K0"U ,$ L@#D
M +$ _0"O /\ K #_ *4 _P"@ /\ G #_ /\   #_    ^P   .X   #D
MW  ( -, $ #/ !@ RP B ,D *P#& #0 P0 ] +T 1 "Z $L MP!1 +4 5@"R
M %P L !A *X 9P"L &X J@!V *@ ?P"F (H HP"6 *$ I0"? +8 G0#1 )P
M\P"; /\ G #_ )8 _P"3 /\ D #_ /\   #V    YP   -,   #&    O0 #
M +@ #0"S !, L0 < *\ )0"N "X J0 V *8 /0"C $0 H0!* )\ 3P"= %4
MFP!: )H 8 "8 &8 E@!N )0 =P"2 ($ D ". (X G ", *T B@## (D Z "(
M /\ B0#_ (< _P"% /\ @@#_ /,   #C    S    +P   "P    IP   *$
M" ">  \ FP 6 )D 'P"8 "< E@ O ), -P"1 #T C@!# (P 20"+ $X B0!4
M (< 60"% &  A !G (( ;P"  'H ?@"& 'P E !Z *0 >0"X '@ V !W /<
M> #_ '@ _P!W /\ =0#_ .8   #+    MP   *@   ">    E@   (\ ! "+
M  P B  2 (< &0"% "$ A  I (( , !_ #< ?0 ] 'P 0P!Z $@ >0!- '<
M4P!V %D = !A '( :0!Q ', ;P!_ &T C0!L )T :@"O &D R !H .T :0#_
M &D _P!I /\ :0#_ -(   "X    I0   )<   "-    A@   ($   !\  @
M>0 . '< % !V !P =  C ', *P!Q #$ ;P W &X /0!L $, :P!( &H 3@!H
M %0 9P!; &4 8P!C &T 8@!X &  AP!? )8 70"H %T O@!< .0 7 #[ %P
M_P!< /\ 7 #_ ,(   "J 0  F ,  (D$  !_ @  >    '0   !P  0 ;0 ,
M &L $0!I !< :  > &8 )0!E "P 8P R &( . !@ #T 7P!# %X 20!< $\
M6P!6 %H 7@!8 &@ 5P!S %4 @0!4 )$ 4@"C %$ MP!1 -8 40#U %$ _P!1
M /\ 4@#_ +8'  "?"0  C0L  'X,  !S"P  ; H  &@'  !E P  8P ' &$
M#0!? !, 70 : %P (0!; "< 60 M %@ ,P!6 #D 50 _ %0 10!3 $L 40!2
M %  6@!/ &0 30!O $P ?0!* (T 20"? $@ L@!' ,P 1P#O $8 _P!' /\
M1P#_ *P,  "5#@  @Q   '40  !K$   8P\  %X.  !;#   6@D" %D$"@!7
M  \ 50 5 %, ' !2 ", 40 I $\ +P!. #4 30$[ $P!00!* D@ 20)/ $@"
M5P!& V$ 10-M $,#>@!" XL 0 .< #\#KP ^ \@ /03J #T%_  ]!O\ /@;_
M *00  ".$@  ?!,  &X4  !D%   7!,  %82  !3$0  40X  % ,!0!0"0P
M3P<1 $T'%P!+"!\ 20@E $@)*P!'"3$ 1@DX $0*/@!#"D4 0@I- $ +50 _
M"U\ /0MK #P+>0 Z#(H . R< #<,KP U#,< -0SI #4-_0 U#?\ -@S_ )T3
M  "'%0  =A<  &D8  !>&   5A@  % 7  !-%0  2A,  $D1  !)#@< 2 T.
M $8-$P!$#1H 0PXA $(.* ! #BX /PXU #X//  ]#T, .Q!+ #H05  X$%X
M-A!K #00>0 R$(H ,1"< "\0L  M$,D +1'L "T1_P N$?\ +Q#_ )<6  ""
M&0  <1L  &0<  !9'   41P  $P;  !'&@  1!@  $,5  !"$P( 01(+ $ 1
M$  ^$A< /!(> #L3)0 Z$RL .!,R #<3.0 V%$  -!1( #,440 Q%%P ,!5H
M "X5=P L%8@ *A6: "@5K@ G%<< )A7J "<5_P H%?\ *17_ )$:  !]'
M;1X  & ?  !6'P  3A\  $@>  !#'0  0!P  #X:   ]&   .Q<' #D6#@ X
M%Q0 -A<; #48(@ S&"@ ,A@O #$9-@ P&3T +AE& "T:3P K&ED *AIF "@:
M=  F&H8 )!J9 "(:K0 A&L4 (!KH "$:_@ B&O\ (QK_ (T=  !Y'P  :2$
M %PB  !2(@  2B(  $0A   _(0  /"   #D>   X&P  -1P$ #0<#0 R'!(
M,!T8 "\='P N'24 +1XL "L>,P J'CL *1]# "<?30 F'U< )!]D "(?<@ @
M'X0 'Q^7 !T?JP ;'\, &Q_G !L?_0 ='_\ 'A[_ (D@  !U(@  92,  %DD
M  !/)0  1R4  $$D   \(P  .",  #4B   S(   ," ! "XA"@ L(1  *R$5
M "HB'  H(B, )R(I "8C,  E(S@ (R-! "(D2@ A)%4 'R1A !TD<  ;)((
M&225 !<DJ@ 6),$ %23E !8D_  7(_\ &2/_ (4B  !Q)   8B8  %8G  !,
M)P  1"<  #XG   Y)@  -28  #$E   N)   *R4  "DE!P G)@X )283 "0G
M&0 C)R  (B<G "$H+@ @*#8 'B@^ !TH2  ;*5, &2E? !@I;@ 6*8  %"F4
M !(IJ  1*<  $2CD !$H^P 3*/\ %"?_ ( E  !N)P  7R@  %,I  !)*@
M0BD  #LI   V*0  ,B@  "XH   J*   )BD  "0J!  B*PP ("L1 !\L%@ =
M+!T '"PD !LM*P :+3, &"T\ !<M10 6+E  %"Y= !(N;  1+GX $"Z2  XN
MIP -+;T #2W?  TM^0 .+/\ $"S_ 'PH  !J*@  6RL  % L  !&+   /RP
M #DL   T*P  +RL  "LK   F+   (BX  !\O   <, D &C$. !DQ$P 7,1H
M%C(A !4R*  4,C  $S(Y !(S0P 1,TX $#-;  XS:0 -,WH ##..  HSH@ (
M,KD "#+9  @R]  *,?\ "S'_ '<K  !F+0  6"X  $TO  !#+P  /"X  #8N
M   Q+@  +2X  "DN   C,   'S(  !LS   7-04 %#8, !(W$0 1-Q8 $3<=
M ! X)  /."P #C@U  TX/P ,.$H "SA7  DX90 '.'8 !3B*  ,XGP !-[4
M 3?3  (W\0 #-O\ !3;_ ',N  !B,   5#$  $DQ  !!,0  .3$  #0Q   O
M,   *S   "4R   @,P  &S8  !<X   3.@( $#P)  T]#@ ,/1, "ST9  H]
M(0 )/2D "#TQ  8^.P %/D8  SY2  $^80  /G(  #Z&   ]G   /;(  #W0
M   \\   //\  #S_ &TR  !=,P  4#0  $8T   ^-   -S0  #(S   M,P
M)S0  "(V   =.   &#H  !0]   0/P( #4$(  E##0 &1!$  T06  )$'0
M1"0  $0M  !$-@  1$$  $1.  !$7   1&T  $2!  !$F   0Z\  $/-  !"
M\   0O\  $+_ &@V  !8-P  3#@  $,X   [-P  -38  # V   I-P  (SD
M !X[   8/0  $T   !!"   -10$ "$<'  -)#   20\  $H3  !+&0  2R
M $LH  !+,@  2ST  $Q)  !,5P  2V@  $M]  !+E   2JP  $K*  !)[P
M2?\  $G_ &(Z  !4.P  23L  $ [   Y.@  ,SD  "PZ   E/   'S\  !E!
M   31   $$<   Q)   (3    D\%  !0"@  4 T  %$0  !2%0  5!L  %0C
M  !4+   5#<  %1$  !44@  5&,  %1W  !4CP  4Z@  %+&  !2[0  4?\
M %'_ %P_  !//P  13\  #X^   W/0  +SX  "=    @0P  &48  !-)   /
M3   "T\   92    5    %<"  !8!P  60L  %H.  !;$0  718  %X=  !?
M)@  7S$  %X]  !>3   7ET  %YQ  !=B0  7:,  %S!  !;ZP  6O\  %K_
M %9$  !+0P  0T(  #Q!   R0@  *44  "%(   :2P  $TX   Y2   *50
M UD   !;    7@   &    !B @  8P8  &4*  !F#@  :!$  &H7  !K'P
M:RD  &LV  !K10  :U8  &IJ  !J@@  :9T  &B[  !GYP  9O\  &7_ %%(
M  !(2   048  #='   L2@  (TT  !M1   350  #ED   A=   !80   &0
M  !G    :@   &P   !N    <    '(%  !S"0  =0T  '<1  !Z&   >R$
M 'LN  !Z/0  >DX  'EB  !Y>0  >)8  '>S  !UX   =/P  '/_ $Y-  !'
M3   .TT  #!/   F4P  '%@  !-<   -80  !F8   !J    ;P   '(   !V
M    >0   'P   !]    ?P   ($   "# @  A@<  (@,  "+$0  CA@  (XD
M  ".,P  C40  (Q8  "+;P  BHP  (FJ  "(SP  AO<  (7_ $U1  !!4P
M-%4  "E:   >7P  %&4   UJ   %<    '8   ![    ?P   (,   "'
MB@   (T   ".    D0   ),   "5    F    )H%  "=#   H!$  *,:  "C
M*   HCH  *%.  "@90  H($  )Z@  "=P0  F^X  )K_ $99   Y7   +6$
M "%G   6;@  #G4   5[    @0   (<   "-    D@   )8   ":    G0
M )\   "A    I    *8   "H    JP   *X   "Q P  M L  +@1  "Y'@
MN2\  +A#  "W6@  M78  +27  "TM0  L>(  +#\ #]D   Q:0  )6\  !AW
M   /?P  !H<   ".    E    )H   "@    I0   *H   "N    L0   +(
M  "U    MP   +H   "\    OP   ,,   #&    R0   ,X*  #2$P  TB,
M -$W  #03P  SFH  ,V*  #*JP  R\L  ,OO #=Q   I>   '8   !&)   (
MD0   )H   "A    IP   *T   "S    N0   +X   #"    Q0   ,8   #)
M    S    ,X   #2    U0   -H   #>    X0   .4   #J"P  ZQ<  .HK
M  #J0P  ZEX  .IZ  #KF0  Z[4  .O5 /\   #_    _P ! /\ !P#_  T
M_P 2 /\ &P#_ "4 _P O /\ .@#_ $, _P!+ /\ 4P#_ %H _0!@ /L 9@#Z
M &L ^ !R /8 > #T (  \0") .\ D@#L )T Z0"J .8 O #C -P WP#W -T
M_P#, /\ O@#_ +4 _P"P /\ K0#_ /\   #_    _P   /\   #_  8 _P -
M /\ % #_ !\ _P I /L ,P#W #T \P!% .\ 30#L %, Z !9 .4 7P#C &4
MX !J -T <0#: '@ U@"  -( B@#/ )4 S "B ,@ L@#% ,D P@#M ,  _P"[
M /\ L #_ *@ _P"D /\ H0#_ /\   #_    _0   /H   #X    \  ) .P
M$0#H !D YP C .4 +0#> #8 U@ ^ -$ 1@#- $P R@!2 ,@ 6 #% %T PP!C
M ,  :0"^ '  O !X +D @0"W (T M ": +$ J0"N +P K #A *H _ "H /\
MH #_ )D _P"6 /\ E #_ /\   #Y    \@   .<   #;    T0 $ ,H #0#'
M !0 Q  = ,( )@"_ "\ NP W +< /P"T $4 L0!+ *X 40"L %8 J@!< *@
M80"F &@ HP!P *$ >0"? (0 G0"1 )H H "8 +$ E@#, )4 \0"4 /\ D0#_
M (L _P"( /\ A@#_ /<   #L    W@   ,D   "\    M    *\ "@"K !
MJ0 7 *@ ( "G "@ H@ P )\ . "< #X F@!$ )@ 2@"6 $\ E !5 ), 6@"1
M &$ CP!H (T <0"+ 'L B0"( (< EP"% *@ @P"^ ($ Y "  /\ @ #_ 'P
M_P![ /\ >0#_ .D   #7    P0   +$   "F    G0   )< !0"4  T D@ 2
M )  &@"/ "( C@ J (L ,0") #@ AP ^ (4 0P"# $@ @0!. '\ 5 !^ %H
M? !A 'H :0!X ', =@!_ '4 C@!S )\ <0"S '  T !O /8 ;P#_ &\ _P!M
M /\ ; #_ -H   "_    K    )X   "3    C    (4   ""  D ?P / 'X
M%0!] !P ?  D 'H *P!W #$ =0 W '0 /0!R $( <0!( &\ 30!N %, ; !:
M &L 8@!I &P 9P!X &8 A@!D )< 8@"J &$ P@!@ .L 80#_ &$ _P!A /\
M8 #_ ,4   "M    FP   (T   "#    ?    '<   !R  4 <  , &X $0!L
M !< ;  > &L )0!I "P 9P Q &8 -P!D #T 8P!" &( 2 !@ $X 7P!5 %T
M70!< &8 6@!R %D @ !7 )  5@"C %4 N0!4 -X 5 #[ %0 _P!5 /\ 50#_
M +8   "?    C0   '\   !U    ;@   &D   !F  $ 8P ) &$ #@!@ !,
M7P 9 %X ( != "8 6P L %H ,@!8 #< 5P ] %8 0P!5 $D 4P!0 %( 6 !1
M &$ 3P!L $X >@!, (H 2P"< $H L0!) ,X 20#S $D _P!) /\ 2@#_ *H!
M  "4!0  @@<  '0(  !J"   8P8  %X$  !;    60 % %< # !6 !  5  5
M %, &P!2 "( 40 H %  +0!. #, 30 X $P /@!+ $4 2@!, $@ 5 !' %T
M1@!H $0 =0!# (4 00"8 $  JP!  ,4 /P#J #\ _P!  /\ 0 #_ * (  "*
M"P  >0T  &P-  !A#0  6@T  %4+  !2"0  4 8  $\"" !.  T 3  2 $L
M%P!* !X 20 C $< *0!& "\ 10 T $0 .@!" $$ 00!( $  4  ^ %H /0!D
M #P <@ Z (( .0"4 #@ IP W +X -@#C #8 ^0 V /\ -P#_ )@-  "##@
M<A   &41  !;$0  4Q   $X0  !*#@  2 T  $<* P!'!PH 100. $0"$P!"
M AH 00(@ $ #)0 ^ RL /00Q #P$-P [!#X .@5% #D%3@ W!5< -@5B #0&
M<  R!H  ,0:2 # &I0 O!;L +@7= "X&]0 M!_\ +@?_ )$0  !]$0  ;!,
M %\4  !5%   3A0  $@3  !$$@  01   $ .  ! #08 0 H, #X)$  \"18
M.PH< #D*(@ X"B@ -PLN #8+-0 U"SL ,PM# #(,3  P#%8 +PQA "T,;P K
M#'\ *@R2 "@,I0 G#+L )0S= "4-]0 F#?\ )PW_ (L2  !W%   9Q8  %L7
M  !1&   21<  $,7   _%0  /!0  #H2   Y$0$ .0\( #@.#0 W#A( -0X8
M #0.'P R#B4 ,0\L # /,@ O$#H +1!" "P02P J$%4 *!!A "80;P D$(
M(Q"3 "$0IP ?$+T 'A#@ !X1]P ?$/\ (!#_ (84  !S%P  8QD  %<:  !-
M&P  11H  $ :   [&0  .!@  #46   T%   ,Q($ #(2"P Q$A  +Q(5 "T2
M'  L$R( *Q,I "H3,  H$S< )Q0_ "842  D%%, (A1? " 5;0 ?%7X '161
M !L5I0 9%;L &!7> !@5^  9%/\ &A3_ ((7  !O&@  7QP  %,=  !*'0
M0AT  #P=   W'   -!L  #$:   O&0  +A8  "P7"  K%@X *1<3 "@7&0 G
M&"  )1@F "08+0 C&#0 (AD] " 91@ >&5$ '1E= !L::P 9&GP %QJ/ !4:
MHP 4&;H $AG; !,9]@ 4&?\ %1C_ 'T:  !K'0  7!\  % @  !'(   /R
M #D?   T'P  ,1X  "T=   K'   *1L  "<;!0 E&PP )!P1 "(<%@ A'!T
M(!TC !\=*@ >'3( '!XZ !L>1  9'DX %QY; !8>:0 4'WH $AZ- !$>H@ 0
M'K@ #A[8  \>]0 0'?\ $1W_ 'H=  !G'P  62$  $TB  !$(@  /"(  #8B
M   R(0  +B$  "H@   G(   )!\  "(@ @ @( H 'B$/ !TA%  <(1H &R(A
M !DB)P 8(B\ %R(X !4C00 4(TP $B-8 !$C9P 0(W@ #B.+  TCGP ,([0
M"R/0  LB\  ,(O\ #2'_ '8?  !D(@  5B,  $LD  !!)   .B0  #0D   O
M(P  *R,  "@C   D(P  (",  !TD   ;)0< &28- !<F$0 6)A< %2<> !0G
M)0 3)RP $B<U !$H/P 0*$H #BA6  TH9  ,*'0 "BB'  DHFP ')[$ !2?,
M  8G[  ')OX "";_ '$B  !@)   4R8  $@G   _)P  -R8  #$F   M)@
M*24  "4E   B)0  '2<  !DH   6*@0 %"L+ !(L$  1+!0 $"P; ! L(@ .
M+"D #BTR  TM.P ++48 "BU2  @M8  &+7  !"V#  (MF   +*X  "S)   L
MZP !*_P  BO_ &TE  !=)P  3R@  $4I   \*0  -2D  "\H   K*   )R<
M ",G   ?*   &RH  !<L   3+@( $# (  XQ#0 -,1( ##$7  LQ'@ *,28
M"#(N  <R-P %,D(  S).  $R7   ,FP  #)_   RE0  ,:P  #''   PZ@
M,/P  ##_ &@I  !8*@  3"L  $$L   Y+   ,BL  "TK   I*@  )2H  " K
M   <+   %RX  !,P   0,@( #C0'  HW#  '-Q  !3<4  ,W&P "-R(  #<J
M   X,P  .#X  #A*   X6   .&@  #A\   WD@  -ZD  #;%   VZ@  -OT
M #7_ &,L  !4+@  2"\  #XO   V+@  ,"X  "LM   G+0  (BT  !TO   8
M,0  %#,  ! U   .-P$ "CH'  8["P "/ X  #T2   ^%P  /AX  #XF   ^
M+P  /CH  #Y&   ^5   /F0  #YW   ^CP  /:<  #W#   \Z0  //T  #O_
M %XP  !0,0  1#(  #LR   T,0  +C   "DO   D,   'C(  !DT   4-@
M$#D   T[   */0  !4 %  !!"@  0@T  $,0  !$%   11H  $8B  !&*P
M1C4  $9!  !&3P  1E\  $9S  !%B@  1:0  $3   !#Z   0_X  $+_ %@T
M  !+-0  034  #DU   R-   +3,  "8T   @-0  &C@  !0Z   0/0  #4
M  E"   $10   $<#  !(!P  2@L  $L.  !,$0  3A4  $\<  !/)0  3R\
M $\\  !/2@  3UH  $YM  !.A0  3:   $R\  !+YP  2_X  $K_ %,Y  !'
M.0  /CD  #<X   Q-P  *3<  "$Y   ;/   %3\  !!"   ,10  !T@   )*
M    30   $\   !1!   4@<  %0+  !5#@  5Q$  %D7  !:'P  62D  %DV
M  !91   650  %AG  !8?P  5YH  %:W  !5XP  5/T  %3_ $X]  !#/0
M/#P  #4[   L/   )#X  !Q!   51   $$@   M+   %3@   %$   !4
M5P   %D   !;    70(  %X&  !@"P  8@X  &02  !G&   9R(  &8N  !F
M/   9DT  &5@  !E=P  9),  &.Q  !AW0  8/P  %__ $E"  !!00  .C\
M #!    F0P  'D8  !5*   03@  "E(   -6    6@   %T   !@    8P
M &4   !G    :0   &L!  !M!0  ;PH  '(.  !U$@  =QL  '8F  !V-0
M=48  '19  !T;P  <XL  '*I  !PS0  ;_<  &[_ $9&  ! 10  -48  "I(
M   @3   %U$  !!6   )6@   5\   !C    :    &L   !O    <@   '4
M  !W    >0   'L   !]    @ ,  (,(  "&#0  B1,  (H=  "**P  B3P
M (A/  "&9@  A8$  (2@  ""P@  @?   '__ $9+   Z3   +D\  "-3   8
M6   $%X   ED    :0   &\   !T    >    'P   "!    A    (<   "(
M    BP   (X   "0    DP   )8   "9!P  G0T  *$4  "@(0  H#$  )Y$
M  "=6P  G'8  )F6  "9M0  EN4  )7^ #]2   R50  )EH  !M@   19P
M"6T   !T    >P   ($   "&    BP   )    "4    EP   )D   "<
MGP   *$   "D    IP   *H   "M    L08  +4-  "X%@  MR8  +8Y  "U
M4   M&H  +*)  "PJ@  KL\  *WU #=<   K80  'F@  !-P   +>    (
M  "'    C@   )4   ":    GP   *0   "H    K    *T   "P    LP
M +4   "X    NP   +\   ##    QP   ,L%  #1#@  T1L  - N  #/10
MS5\  ,M^  #)G@  R+X  ,7I "]I   C<   %GD   V!   !BP   ),   ";
M    H@   *@   "N    M    +@   "]    P    ,(   #%    R    ,L
M  #.    T0   -8   #;    WP   .0   #H!@  ZQ$  .HC  #J.@  Z50
M .=R  #EDP  X[,  ./4 /\   #_    _P   /\ ! #_  L _P 0 /\ %P#_
M "$ _P K /\ -0#_ #X _P!' /\ 3@#_ %4 _ !; /H 80#X &8 ]@!M /0
M<P#R 'L [P"$ .T C@#J )D Y@"G ., N0#? -4 VP#W -8 _P#  /\ L@#_
M *H _P"E /\ H@#_ /\   #_    _@   /P   #\  , _@ + /\ $0#_ !H
M_0 D /D +@#T #@ \ !  .P 2 #I $X Y@!4 .( 6@#? %\ W !E -@ :P#4
M '( T ![ ,T A0#* )$ QP"> ,, K@#  ,4 O0#K +L _P"P /\ I #_ )P
M_P"8 /\ E0#_ /\   #Z    ]    /$   #R    Z@ % .< #@#B !4 X0 >
M .$ * #8 #$ T  Y ,L 0 #( $< Q0!- ,( 4P"_ %@ O0!> +L 9 "Y &L
MM@!S +0 ? "Q (@ K@"5 *L I "H +@ I@#< *, ^P"? /\ E0#_ (\ _P"+
M /\ B0#_ /D   #O    YP   -\   #/    R    ,$ "@"_ !$ O  8 +L
M(0"Y "H M  R +$ .@"N $  JP!& *@ 3 "F %$ HP!6 *$ 7 "? &, G0!J
M )L <P"9 'X E@", )0 FP"2 *T D #' (X \ "- /\ A@#_ (  _P!] /\
M? #_ .T   #@    T0   +\   "S    J@   *8 !0"B  T H0 3 *  &P"?
M ", FP K )@ ,@"5 #D DP _ )$ 1 "/ $H C@!/ (P 50"* %L B !C (8
M:P"$ '8 @@"" (  D@!^ *, ? "Z 'H X0!Y /\ =P#_ '( _P!P /\ ;P#_
M -T   #+    M@   *<   "=    E    (X  0"+  H B0 0 (@ %0"' !T
MAP E (0 + "" #( ?P X 'T /0![ $, >0!( '@ 3@!V %0 =0!; ', 8P!Q
M &X ;P!Z &T B0!L )H :@"N &D S !H /8 9P#_ &4 _P!D /\ 8P#_ ,H
M  "T    H0   ),   ")    @@   'L   !X  4 =@ , '4 $0!T !@ <P ?
M '( )0!P "P ;@ R &P -P!J #P :0!" &@ 2 !F $X 90!5 &, 70!B &8
M8 !R %X @ != )( 6P"E %H O@!9 .D 60#_ %D _P!8 /\ 6 #_ +D   "B
M    D    (,   !Y    <0   &T   !I  $ 9@ ) &4 #@!D !, 8P 9 &,
M( !A "8 8  L %X ,0!< #< 6P \ %H 0@!8 $@ 5P!/ %8 5P!4 &  4P!L
M %$ >0!0 (H 3P"> $X M !- -H 30#[ $T _P!- /\ 30#_ *H   "4
M@@   '4   !K    9    &    !=    6@ % %@ # !7 !  5@ 5 %8 &P!5
M "$ 4P G %( + !1 #$ 3P W $X /0!- $, 3 !* $H 4@!) %L 2 !F $8
M<P!% (0 1 "7 $, K !" ,D 0@#Q $( _P!# /\ 0P#_ )X   ")    > ,
M &H$  !A!   6@,  %4!  !2    4  " $X "0!-  T 3  1 $L %P!* !P
M20 B $@ )P!' "T 10 R $0 . !# #X 0@!% $$ 30 _ %8 /@!A #T ;@ [
M 'X .@"1 #D I@ X +\ . #H #@ _P Y /\ .0#_ )4#  " !P  ;PD  &(*
M  !8"P  40H  $P(  !)!@  1P,  $8 !@!$  L 0P / $( $P!! !@ 00 >
M #\ (P ^ "D /0 N #L -  Z #H .0!! #@ 20 W %( -@!= #0 :@ S 'H
M,@", #$ H0 P +@ +P#> "\ ^0 O /\ , #_ (P)  !X#   : T  %P.  !2
M#@  2PX  $4-  !!#   /PH  #X( @ ]! @ / $- #L $  Z !4 .0 : #@
M(  V "4 -0 K #0 ,  S #< ,@ ^ #$ 1@ O %  +@!: "T 9P K '< *@")
M "D G0 H +, )P#1 "< \@ G /\ )P#_ (8,  !R#@  8Q   %81  !-$0
M11$  $ 0   \#P  .0X  #<-   V"P0 -@@* #4&#@ T!1( ,@07 #$%'  P
M!2( +P4H "X&+@ M!C0 *P8\ "H&1  I!TX )P=9 "8'90 D!W4 (P>' "('
MFP @!K  ( ;+ !\%[0 ?!OX 'P?_ ( .  !M$0  7A(  %(3  !($P  01,
M #L3   W$@  -!$  #(0   P#P$ , T& # +"P O"A  +0H4 "P+&0 J"Q\
M*0LE "@,*P G##( )@PZ "0,0P C#$T (0U8 " -90 >#74 ' V( !H-G  9
M#;$ & S* !<,ZP 7#?P & S_ 'L1  !I$P  6A4  $X6  !%%@  /18  #@5
M   S%0  ,!0  "T3   K$@  *A # "H/"  I#@T * X1 "8.%@ E#QT ) \C
M ",/*0 A$#$ (! Y !X00@ =$$P &Q!8 !D09@ 7$'8 %1") !00G@ 2$+,
M$1#. !$0[@ 2$/X $A#_ '<3  !E%0  5Q<  $L8  !"&0  .AD  #08   P
M%P  +!<  "D6   G%0  )A0! "42!  C$@L (A(/ "$2%  @$AH 'A,@ !T3
M)P <$RX &A,V !D40  7%$H %A16 !049  2%'0 $12' ! 4G  .%+$ #13*
M  T4ZP .$_X #A/_ ',5  !A&   4QH  $@;   _&P  -QL  #(:   M&@
M*1D  "88   D&   (A<  " 6 0 >%@@ '18- !L7$@ :%Q< &1<= !@8)  6
M&"L %1@T !08/0 2&4@ $1E4 ! 98@ .&7( #1F$  P9F  *&:T "1C&  D8
MYP )&/H "A?_ &\8  !>&@  4!P  $4=   \'0  -1T  "\=   J'   )AL
M ",;   A&@  'AH  !P:   :&P4 &!L, !8<$  5'!4 %!P; !,<(@ 2'2D
M$1TQ ! =.P .'44 #1Y1  P>7@ *'FT "1Z   <>E  %':H  QW"  ,=Y@ $
M'/@ !1S_ &L:  !;'0  31X  $(?   Z'P  ,A\  "T?   H'@  )!X  "$=
M   >'0  '!T  !@>   5'P( $R ) !(A#@ 0(1( $"$8  XA'P .(B8 #2(N
M  PB-P *(D$ "2)-  <B6@ %(FD  R)\  $BD0  (J@  "'    AY0  (/@
M "#_ &<=  !7'P  2B$  $ A   W(@  ,"$  "HA   F(   (B   !\?   <
M'P  &2   !8A   2(P( $"0'  XF#  ,)A  "R85  HF'  ))B( ""8J  8G
M,P $)ST  R=)  $G5@  )V8  "=Y   GCP  )J8  ":_   EY   )?D  "3_
M &,@  !4(@  1R,  #TD   T)   +B,  "@C   D(@  (2(  !XA   :(@
M%R,  !,D   0)@( #B@'  LJ"P (*PX !BL3  0K&  "*Q\  2PG   L,
M+#H  "Q%   L4P  +&,  "QV   LC   *Z0  "N^   JY   *OH  "G_ %\C
M  !0)0  1"8  #HF   R)@  *R8  "8E   C)   'R0  !LD   7)0  %"<
M !$I   .*P( "RT&  <O"P $, X  # 1   Q%0  ,1P  #$C   R+   ,C8
M #)"   R3P  ,E\  #)R   QB0  ,:(  #"\   PY   +_L  "__ %HG  !,
M*   0"D  #<I   O*0  *2@  "4G   A)@  '"<  !@H   4*@  $2P   XN
M   +, $ !S(%  ,T"0  -0P  #8/   W$@  .!@  #@@   X*   .#(  #D]
M   Y2P  .5L  #AN   XA0  -Y\  #>Z   VY   -?P  #7_ %4J  !(+
M/2P  #0L   M*P  *"H  "0I   >*@  &2L  !0M   1+P  #3$   HT   '
M-@   C@$   Z!P  .PH  #T-   ^$   0!0  $ ;  ! )   0"X  $ Y  !
M1P  0%8  $!I  ! @   /YL  #ZW   ]XP  //P  #S_ % O  !#+P  .2\
M #(O   L+0  )RP  " M   :+P  %3$  !$S   --@  "3@   4[    /0
M $ !  !!!   0P<  $4+  !&#@  2!$  $H6  !*'@  2B@  $HT  !)0@
M25$  $ED  !(>P  2)<  $>T  !&X   1?P  $3_ $HS   _,P  -C,  # Q
M   J,   (S$  !PS   6-0  $3@   T[   (/@   T$   !#    1@   $@
M  !*    3 0  $X'  !/"P  40X  %02  !5&0  52(  %0N  !4/   5$L
M %->  !3=   4I   %&N  !0UP  3_L  $[_ $4W   \-P  -38  "\T   F
M-0  'C<  !<Z   1/0  #$$   =$    2    $H   !-    4    %,   !5
M    5P   %@"  !;!@  70L  %\.  !B$P  8AL  &(G  !B-   844  &!7
M  !@;0  7XD  %VG  !<S   6O@  %G_ $$\   Z.P  -#D  "HZ   A/
M&$   !%#   ,1P  !DL   !/    4P   %8   !9    7    %\   !A
M8P   &4   !G 0  :@4  &T*  !P#@  <Q4  '(@  !R+0  <3T  '!/  !O
M90  ;H   &V?  !KP0  :?$  &C_ #]    Y/@  +C\  "1"   :1@  $DH
M  Q/   $5    %@   !=    80   &4   !H    :P   &X   !Q    <P
M '4   !X    >P   'X#  "!"@  A0\  (<7  "&)   A30  (1&  ""70
M@78  '^6  !^M@  ?.<  'K_ #]$   S10  *$@  !U,   34@  #%<   -=
M    8P   &@   !M    <0   '8   !Z    ?@   ($   "#    A@   (D
M  "+    C@   )(   "5 0  F0D  )X0  ">&@  G2D  )P\  ":4@  F&P
M ):+  "4J@  DM0  )#Z #A+   L3@  (%,  !59   -8    V<   !N
M=    'H   "     A    (H   ".    D@   )4   "7    F@   )T   "@
M    HP   *<   "K    KP   +0)  "X$   MQX  +4P  "S1@  L6   *]^
M  "LH   J\$  *GN #%5   D6P  &&$   YI   %<0   'D   "!    B
M (\   "4    F@   )\   "D    J    *D   "L    KP   +,   "U
MN0   +T   #!    Q@   ,L   #1"@  TQ0  -$E  #0.P  S50  ,IQ  #(
MD@  Q;,  ,/> "EB   <:0  $7$   =[    A    (T   "5    G0   *,
M  "I    KP   +0   "Y    O    +X   #"    Q0   ,@   #,    T
M -0   #:    WP   .0   #J    [@P  .T:  #L+P  ZDD  .AE  #FA@
MY*4  .+& /\   #_    _P   /P  0#\  @ _@ . /\ % #_ !T _P F /\
M, #_ #H _P!" /\ 20#^ %  ^P!6 /D 7 #V &( ] !H /( ;P#P '8 [0!_
M .H B0#G )4 Y "C .  M0#; -  U0#V ,H _P"V /\ J #_ )\ _P": /\
ME@#_ /\   #[    ]@   /,   #S    ]@ ) /H #@#] !8 ^P @ /< *@#R
M #, [0 [ .D 0P#F $D X@!/ -X 50#; %L U@!@ -( 9P#/ &X S !V ,D
M@ #& (P P@": +\ J@"[ ,$ N #I +8 _P"G /\ F@#_ )( _P"- /\ B@#_
M /H   #Q    Z@   .<   #G    Y  ! .  "P#; !$ V@ : -L (P#1 "P
MR@ T ,8 .P#" $( OP!( +P 3@"Z %, N !9 +8 7P"S &8 L0!N *X =P"L
M (, J0"1 *8 H0"C +4 H #8 )X ^P"5 /\ BP#_ (4 _P"  /\ ?@#_ .\
M  #C    V@   -,   #&    OP   +D !@"W  X M  4 +0 '0"S "4 K@ M
M *L - "G #L I !! *$ 1@"? $P G0!1 )L 5P"9 %X EP!E )4 ;@"3 'D
MD "' (X EP", *D B0#$ (@ [P"% /\ ? #_ '8 _P!S /\ <@#_ .    #0
M    Q@   +8   "I    H0   )T  0"9  H F  0 )@ %@"7 !X E  F )$
M+0"/ #0 C  Z (H /P"( $4 AP!* (4 4 "# %8 @0!> (  9@!^ '$ ? !]
M 'D C0!W *  =0"V ', WP!R /\ ;@#_ &D _P!G /\ 90#_ ,P   "^
MJP   )T   "3    B@   (4   ""  4 @  - '\ $0!_ !@ @  @ 'T )@!Z
M "T =P S '4 . !T #X <@!# '  20!O $\ ;0!6 &P 7@!J &@ : !U &<
MA !E )8 9 "K &( R0!A /8 8 #_ %P _P!; /\ 6@#_ +T   "I    EP
M (D   !^    >    ',   !O  $ ;0 ) &P #@!K !, :P 9 &H ( !H "8
M9@ L &4 ,@!C #< 8@ \ &  0@!? $@ 70!/ %P 5P!: &$ 60!M %< >P!6
M (X 50"B %, NP!2 .D 4@#_ %  _P!/ /\ 3P#_ *T   "8    A@   '@
M  !N    9P   &,   !@    70 % %P "P!; !  6P 5 %L &P!: "$ 6  F
M %8 + !4 #$ 4P V %( / !1 $( 3P!) $X 40!- %L 2P!F $H = !) (4
M2 "9 $< L0!& -@ 1@#\ $4 _P!% /\ 10#_ )\   ")    >    &P   !B
M    6P   %8   !3    40 " $\ " !/  T 3@ 1 $X %@!- !P 3  A $H
M)@!) "P 2  Q $< -P!% #T 1 !$ $, 3 !" %4 0 !@ #\ ;@ ^ 'X /0"2
M #P J0 [ ,< .P#S #L _P [ /\ / #_ ),   !^    ;@   &$   !8
M40   $P   !)    1P   $4 !0!$  L 0P . $, $@!# !< 0@ = $  (@ _
M "< /@ L #T ,@ [ #@ .@ _ #D 1P X %  -P!; #4 :  T '@ ,P", #(
MH@ Q +P ,0#G #$ _P R /\ ,P#_ (D   !V P  9@4  %D'  !0!P  208
M $,%  !  P  /@$  #P  P [  @ .@ - #H $  Y !0 .0 9 #< '@ V ",
M-0 H #0 +@ S #0 ,@ [ #  0P O $P +@!7 "T 9  L ', *P"' "H G  I
M +4 *0#< "D ^P I /\ *@#_ ($$  !N"   7PH  %,+  !*"P  0@L  #T*
M   Y"0  -@@  #4%   T @8 ,P * #( #@ Q !$ ,0 5 #  &@ O !\ +@ D
M "P *@ K #  *@ W "D /P H $D )P!4 "8 8  D &\ (P"" "( EP A *X
M(0#, "$ \P A /\ (@#_ 'L)  !H#   6@T  $X.  !%#@  /0X  #@-   S
M#0  , P  "X+   M"0, +08( "P$#  K @\ *@$2 "D!%P H 1P )P A "8
M)P E "T )  T ",!/0 B 48 (0%1 !\!70 > 6P ' %_ !L E  : *H &@#%
M !H ZP 9 /\ &@#_ '4,  !D#@  50\  $H0  ! $   .1   #,0   O#P
M+ X  "D.   G#0$ )PP% "<*"@ F" T )0<0 "0&%  B!AD (08? " ')  ?
M!RL '@<R !T'.@ <"$0 &@A/ !D(7  7"&L %@A] !4'D0 4!Z< $P:_ !(%
MY  2!?H $@7_ '$.  !?$   41$  $82   ]$@  -A(  # 2   K$0  *!$
M "40   C$   (@X$ "$-!P A# L ( L. !\+$@ ="Q< ' P< !L,(@ :#"D
M&0PQ !@,.0 6#4, %0U/ !,-7  2#6L $ U^  \-D@ .#:< #0R^  T,X  -
M#/4 #0S_ &T0  !<$0  3A,  $,4   Z%   ,A0  "T4   H$P  )1,  "(2
M   @$0  'A$# !P0!0 <#P@ &P\, !H.$  9#Q0 %P\: !8/(0 5$"@ %! P
M !(0.0 1$$0 $!!0  X070 -$&L #!!\  L0D  )$*4 "!"\  <0WP '$/0
M!P__ &D1  !8%   2Q4  $ 6   W%@  ,!8  "H6   F%0  (A4  !\4   =
M$P  &A," !D2!  7$@8 %A(* !42#@ 4$A( $A(8 !$3'@ 1$R4 $!,N  X3
M-P -%$  #!1+  L46  )%&< !Q1X  84C0 $%*,  Q.[  (3W0 !$O0  A+_
M &43  !5%@  2!<  #T8   T&   +1@  "@8   C%P  (!<  !T6   :%0
M&!4" !85!  4%04 $A8( !$6#0 0%Q  #A<5  X7&P -%R( #!<I  L8,@ )
M&#P !QA'  485  $&&,  AAU  $8BP  %Z$  !>Y   7W0  %O4  !;_ &$6
M  !2&   11H  #L:   R&@  *QH  "4:   A&0  'A@  !L8   8%P  %A<"
M !07 P 2& 4 $!D'  X;"P ,&P\ "QL3  H;&  ('!\ !QPF  4<+P $'#@
M AQ$   =40  '6   !UR   <B   '*   !NY   ;W@  &O8  !K_ %X8  !/
M&@  0AP  #@<   O'0  *1P  ",<   ?&P  '!H  !D9   7&0$ %!D" !(:
M P 0&P0 #AT'  P>"P )'PX !B 1  4@%@ #(!P  2$C   A*P  (34  "%
M   A3@  (5T  "%O   AA@  ()X  ""X   ?W@  'O@  ![_ %H;  !+'0
M/QX  #4?   M'P  )QX  "(=   >'0  &QP  !@;   5&P  $AP  ! = @ .
M'P0 #"$&  DB"@ %(PT  B00   E$P  )1D  "8@   F*   )C(  "8]   F
M2@  )EH  "9L   F@P  )9P  "6W   DWP  (_D  "/_ %4>  !'(   /"$
M #(A   K(0  )2   " ?   ='@  &AT  !8>   3'@  $"    XA   ,(P(
M""4%  4G"0  * L  "H.   K$0  +!8  "P=   L)0  +"X  "PZ   L1P
M+%8  "QI   L@   *YH  "JU   IWP  *?L  "C_ %$B  !$(P  ."0  "\D
M   H(P  (R(  !\A   <(   %R   !,A   0(P  #B0   LF   (*   !"H$
M   L!P  +@D  # ,   Q#P  ,Q,  #,9   S(0  ,RH  #,U   S0P  ,U(
M #-E   R>P  ,I<  #&S   PW@  +_L  "[_ $PE   _)@  -2<  "TF   G
M)0  (B0  !XC   9(P  %"0  !$F   .*   "RH   <L   #+P   #$"   S
M!   -0<  #<*   Y#0  .A   #L5   ['0  .R8  #LQ   [/@  .TX  #M@
M   Z=P  .9(  #BP   WVP  -OP  #7_ $<I   [*@  ,BH  "LI   E)P
M(28  !LG   5*   $2H   XL   *+P  !C$   $T    -@   #@    [ 0
M/00  #\'  !!"@  0PX  $41  !%&   12$  $4L  !$.0  1$@  $1;  !#
M<0  0HT  $&K  ! T@  /_H  #[_ $(M   X+@  +RT  "DK   D*@  '2H
M !<L   1+@  #3$   DT   $-P   #H    \    /P   $$   !$    1@
M $@#  !*!P  3 L  $X.  !0$P  4!P  % G  !/-   3T,  $]5  !.:@
M388  $RD  !*R@  2?@  $C_ #XR   U,0  +B\  "DN   @+@  &3$  !(S
M   .-P  "3H   (]    0    $0   !'    20   $P   !/    40   %,
M  !5 0  6 8  %H+  !=#@  7Q4  %X@  !>+   73P  %Q.  !;8P  6GX
M %B=  !7P   5?(  %3_ #HV   S-   +3(  "0S   ;-@  $SD   X]   (
M00   $4   !)    3    %    !3    5@   %D   !;    70   &    !B
M    90   &@%  !K"P  ;Q   &\8  !N)0  ;30  &U&  !K6P  :G4  &B4
M  !FM@  9.D  &+_ #@Y   R-P  *#D  !X[   5/P  #D0   =)    30
M %(   !6    6@   %X   !B    90   &@   !K    ;0   '    !S
M=@   'D   !]!   @0L  (41  "$'0  @BP  ( ^  !^5   ?FL  'N*  !Z
MJ@  =]8  '7] #@]   L/@  (D$  !=&   /2P  !U$   !7    7    &(
M  !F    :P   &\   !T    >    'L   !^    @    (,   "&    B@
M (T   "1    E@,  )L,  "=$P  FR$  )HS  "720  E&(  )-_  "0H
MCL4  (SS #%$   E2   &DT  !!3   (6@   &$   !H    ;@   '0   !Y
M    ?P   (0   ")    C0   )$   "3    E@   )D   "=    H    *0
M  "H    K    +(#  "W#0  MQ<  +4H  "R/@  L%8  *QS  "JE   J;0
M *7E "I/   >5   $EL   IB    :@   ',   ![    @@   (D   ".
ME    )H   "?    I    *8   "I    K0   +    "S    MP   +L   #
M    Q0   ,L   #1!   U0X  -,=  #0,@  S4L  ,IF  #&AP  PJD  ,'+
M ");   68@  #&L   %T    ?0   (<   "0    EP   )X   "D    JP
M +$   "V    N@   +P   #     Q    ,@   #+    SP   -0   #:
MX    .8   #K    \08  / 3  #N)P  [#\  .I;  #G>@  Y)L  ."[ /\
M  #[    ]@   /,   #T  4 ]@ , /H $0#_ !D _P B /\ + #_ #4 _P ]
M /\ 10#\ $P ^@!2 /< 6 #U %X \P!D /$ :@#N '( [ !Z .D A0#E )$
MX0"@ -T L@#8 ,X T@#V ,$ _P"M /\ G@#_ )8 _P"0 /\ C #_ /H   #R
M    [    .D   #I    [  % /( # #X !( ]P ; /4 )0#P "X ZP W .8
M/@#B $4 W0!+ -@ 4 #3 %8 T !< ,T 8@#* &H R !R ,4 ? #" (@ O@"6
M +H J "W +\ M #H *X _P"= /\ D #_ (@ _P"# /\ @ #_ /    #E
MW@   -H   #;    W    -@ !P#1  X T0 5 -( '@#+ "< Q0 O ,  -P"]
M #T N@!$ +< 20"U $\ L@!5 +  6P"N &$ K !I *D <P"G '\ I "- *$
MG@"> +( FP#5 )D _ ", /\ @@#_ 'L _P!V /\ = #_ .(   #3    R@
M ,<   "\    M@   +   0"O  L K  1 *T & "M "  J  H *0 +P"@ #8
MG0 \ )L 0@"9 $< EP!- )4 4P"3 %D D0!A (\ :@", '4 B@"# (@ E "&
M *< @P#" (( \ !\ /\ <P#_ &T _P!J /\ : #_ ,\   #!    N0   *T
M  "@    F    )0   "1  8 D  - )  $@"/ !D C@ A (L * "( "\ A@ U
M (0 .@"" $  @ !% 'X 2P!\ %( >@!9 '@ 8@!V &P = !Y '( B0!Q )T
M;P"T &T WP!L /\ 90#_ &  _P!> /\ 7 #_ +X   "Q    H    )(   ")
M    @@   'P   !Z  $ >  ) '< #@!X !0 =P : '0 (0!R "< <  M &X
M,P!L #@ :P ^ &D 1 !H $H 9@!1 &0 6@!C &0 80!P %\ ?P!> ), 70"I
M %P R !; /< 5P#_ %0 _P!2 /\ 40#_ +    "?    C0   '\   !T
M;@   &H   !F    90 $ &, "P!C !  8P 5 &, &P!A "$ 7P G %T + !<
M #( 6@ W %D /0!7 $, 5@!+ %4 4P!3 %P 4@!H %  =P!/ (D 3@"? $T
MN@!, .D 2P#_ $D _P!' /\ 1P#_ *(   "-    ?    &X   !E    7@
M %D   !7    50 ! %0 !P!3  T 4P 1 %0 %@!2 !L 40 A $\ )@!. "L
M3  Q $L -P!* #T 20!$ $< 3 !& %8 1 !A $, < !" ($ 00"7 $  KP _
M -< /P#_ #X _P ] /\ /@#_ )0   !_    ;P   &,   !9    40   $T
M  !*    2    $< ! !'  H 1@ . $8 $0!' !8 10 < $0 (0!" "8 00 K
M $  ,0 ^ #< /0 ^ #P 1P Z %  .0!; #@ :0 W 'H -@"/ #4 IP U ,8
M- #U #0 _P T /\ -0#_ (@   !T    90   %@   !/    2    $,    _
M    /0   #P  @ \  < .P , #L #P [ !( .@ 7 #D '  W "$ -@ F #4
M+  T #( ,P Y #$ 00 P $L +P!6 "X 8P M ', + "( "P H  K +L *P#J
M "L _P K /\ + #_ '\   !L    70$  %$"  !( P  0 ,  #L"   W
M-    #,    R  4 ,@ ) #( #0 Q !  ,0 3 #  &  O !T +0 B "P *  K
M "X *@ U "D /0 H $8 )P!1 "8 7@ E &X ) "" ", F0 C +, (@#> "(
M_P C /\ ) #_ '<   !E!   5@8  $L'  !""   .@@  #4'   P!@  +04
M "P#   K  , *@ ' "D "P I  X *0 1 "@ %0 G !D )@ > "4 )  D "H
M(P Q "( .0 A $, ( !. !\ 6@ > &D '0!\ !P DP ; *P &P#- !L ]@ ;
M /\ ' #_ ' %  !?"   40H  $8+   ]"P  -0L  # +   K"@  * D  "4(
M   D!P( (P0& ",""0 B 0P (@ / "$ $@ @ !8 'P ; !X (  = "8 '  N
M !L -@ : #\ &0!* !@ 5P 7 &8 %@!X !4 CP 5 *8 % ## !0 [@ 4 /\
M%0#_ &L(  !;"P  30P  $(-   Y#0  ,0T  "P-   G#0  (PP  "$,   ?
M"P$ '@H% !T("  =!@L ' 4- !P$$  ;!!0 &008 !D$'@ 8!", %P0K !8$
M,P 5!#P % 1' !,#5  2 V, $0-U ! "B@ 0 :( #P"\  \ Y0 / /X $ #_
M &<+  !7#0  20X  #X/   U#P  +@\  "@/   D#@  ( X  !T.   ;#0$
M&0T$ !@,!P 8"PD %PD, !<)#@ 6"1( %0D6 !0)&P 3"2$ $@DH !(),  1
M"3H $ E%  \)4@ ."6$ #0ES  P(B  +")\ "@>W  H&VP *!?8 "@3_ &,-
M  !3#@  1A   #L1   R$0  *Q$  "40   A$   '1   !H/   8#P$ %@X$
M !4.!P 4#0D $PT+ !,,#0 2#!  $0P4 ! ,&0 0#!\ #PPG  X-+P -#3D
M# U%  L-40 )#6  " UQ  8-A@ %#9T ! RT  ,,T@ "#/$  @O_ %\.  !0
M$   0Q$  #@2   O$@  *!(  ",2   >$0  &Q$  !@1   5$ ( %! % !(0
M!P 1#PD $ \* ! .#  .#@X #@\2  T/%P ,$!T #! D  H0+  )$#8 "!!!
M  803@ %$%T  Q!O  $0A   $)P   ^T   .U   #O,   [_ %P0  !-$@
M0!,  #84   M%   )A0  "$3   <$P  &1(  !82   4$0, $A$& !$1"  0
M$ H #A +  T1"P ,$0T "Q(1  H2%0 )$AH "!(A  83*0 %$S,  Q,^  (3
M2P  $UH  !-L   3@@  $IL  !*T   1UP  $?4  !'_ %@2  !)%   /14
M #,6   K%@  )!4  !\5   :%   %Q0  !03 0 3$@0 $1(' ! 2"0 .$@D
M#1()  L3"@ )% T !Q4/  86$P $%A@  Q8?  (6)P  %S   !<[   72
M%U@  !=J   6@   %ID  !6T   5V0  %/<  !/_ %44  !&%@  .A<  # 8
M   H&   (A<  !T6   9%@  %A4  !,4 P 2$P8 $!,'  \3!P -% < "Q4(
M  D6"0 && P  QH.  $:$0  &A8  !L<   ;)   &RT  !LX   ;1@  '%4
M !MG   ;?0  &Y<  !JS   9VP  &/D  !?_ %$6  !#&   -QD  "X:   F
M&@  (!D  !L8   8%P  %18! !,5!0 1%00 #Q4$  T6!  +%P4 "1D&  8:
M"  "' H  !X-   @$   (!,  " 9   @(0  (2H  "$U   A0@  (5(  "!D
M   @>@  'Y4  !^Q   >VP  '?H  !S_ $T9   _&P  -!P  "L<   D'
M'AL  !H:   7&   %!<" !(7 @ 0& $ #1D!  L: @ (' , !1T$  (?!@
M(0@  ",+   E#@  )A$  "86   F'@  )R<  "<R   G/P  )DX  "9@   F
M=P  )9(  "2O   CV@  (OL  "'_ $@=   \'@  ,1\  "@>   B'@  '1P
M !D;   6&@  $AH  ! ;   -'   "QT   @?   $(0   2,"   E!   )P8
M "D)   L#   +@\  "X3   N&@  +B,  "XN   N.P  +DH  "U<   M<@
M+(X  "NL   JU   *?L  "C_ $0@   X(0  +B$  "8A   @(   '!X  !@=
M   4'0  $!X   X?   +(0  !R,   ,E    )P   "D    L 0  +@,  # &
M   S"@  -0T  #81   V%P  -A\  #8I   V-@  -D4  #57   U;0  -(D
M #*H   QSP  ,/H  "__ #\D   T)   *R0  "0C   ?(0  &R   !8@   1
M(0  #B,   HE   &*    BH    M    +P   #(    T    -P   #D#   [
M!@  /@H  $ .  !!$@  01H  $ E  ! ,0  0$   #]2   ^9P  /8(  #RB
M   ZQP  .?@  #C_ #HH   P*   *2<  ",E   ?(P  &"0  !(E   .*
M"BH   4M    ,    #,    V    .    #L    ^    0    $(   !% @
M1P8  $H*  !-#@  314  $P?  !,*P  2SH  $I,  !)80  2'P  $>;  !%
MOP  0_,  $+_ #8L   M*P  )RD  ",G   ;*   %"H   XM   *,   !#,
M   W    .@   #T   !     0P   $8   !(    2P   $T   !0    4P$
M %8&  !9"P  6Q   %L9  !:)0  630  %A&  !76@  570  %23  !2M0
M4.H  $__ #,P   L+@  )RP  !XM   6+P  $#(   HV   #.@   #\   !"
M    1@   $D   !,    3P   %(   !5    6    %H   !=    8    &,
M  !G!@  :PP  &P2  !K'@  :RP  &D]  !G4@  9FH  &2)  !AJP  7]P
M %W_ #$S   L,0  (C(  !DU   1.0  "CT   )"    1P   $P   !0
M5    %@   !;    7P   &(   !E    :    &L   !N    <0   '4   !Y
M    ?08  ((-  ""%@  @"0  'XU  !\20  >V$  'A_  !VGP  <\8  '#W
M #$V   F.   '#L  !)    +10   DL   !1    5@   %L   !@    90
M &D   !N    <@   '8   !Y    ?    'X   ""    A0   (D   ".
MDP   )@&  "<#@  FQH  )@K  "60   DED  )%S  "-E0  B[4  (CH "L^
M   @00  %4<   U-   "5    %L   !A    :    &X   !S    >0   'X
M  "#    B    (P   "/    D@   )4   "9    G0   *$   "E    J@
M +    "W!P  N!$  +4A  "R-0  KTT  *II  "HB   IJ@  *+1 "-(   8
M3@  #E0   1<    9    &T   !U    ?    (,   ")    CP   )4   ";
M    H    *,   "F    J0   *T   "Q    M0   +D   "^    Q    ,H
M  #2    V@H  -86  #2*0  SD$  ,I<  #%?   PIT  ,&] !Q5   17
M!V4   !N    =P   '\   "(    D    )@   "?    I0   *T   "S
MN    +H   "^    P@   ,8   #*    S@   -,   #:    X    .<   #M
M    \P   /0.  #R'@  [S8  .Q1  #H;@  Y)   -^Q
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MZ>KK[.WN[_#Q\O/T]?;W^/GZ^_S]_O]M9G0Q      ,$(0   0
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MH#X:_ZA')O^N433_KUM%_ZUE5_BI;VCMHWAYXYM_A]N2A934BXR>SX61ILN
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MXTDSS^M.2<;M5%VWZEQNJ.)C?9K9:8J.TFV4A,QQFWO(=:%SQ'BF;L)\J6G
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M/E+_DSY2_Y,^4O^3/E+_DSY2_Y,^4O^3/E+_DSY2_Y,^4O^3/E+_DSZ]Q04
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M1/6[7U;MNV=IX[5N?=:L<X_*HWJ=P9N I[B4A["QCXZVJXJ5NZ:'G;ZBA:7
MGX2OP99^L,&4?[:XDX"[LI. N[*3@+NRDX"[LI. N[*3@+NRDX"[LI. N[*3
M@+NRDX"[LI. N[+_D!H#_XXF!_^5+0S_H341_ZL]&/^S1B3_NDTS^KY51/._
M75;JOV5JW[AK?M"O<8_%IGB<NY]^I[*8A:^KDXNVI8Z3NY^+FKZ;B:+!F(BL
MPI""K\*/@[6YCX2ZLX^$NK./A+JSCX2ZLX^$NK./A+JSCX2ZLX^$NK./A+JS
MCX2ZLX^$NK/_D!H#_XXE!_^6+ O_HC40_ZP]&/^U12/_O$PR^,%40_##7%;G
MPV-JVKMI?LRR<(_ JG:<MJ)\IZV<@J^EEXFVGI.0NYF/F+Z4C:#!D8RIPHN(
MKL**B+2ZBHBYM(J(N;2*B+FTBHBYM(J(N;2*B+FTBHBYM(J(N;2*B+FTBHBY
MM(J(N;3_D1H#_X\E!_^8+ O_I#00_ZX]&/^W12/_OTPR]L530^[(6U;CQF%J
MU+]H?L>V;HZ[K72<L:9ZIJ>@@*^?FX:UF)>.NY.5E;Z.DIW!BI*GPH:.KL*$
MC;2[A8RYM(6,N;2%C+FTA8RYM(6,N;2%C+FTA8RYM(6,N;2%C+FTA8RYM(6,
MN;3_D1H#_X\E!_^9+ O_IC0/_[ \%_^Y1"+\P4LQ],E20NO-657?R6!JS\)F
M?<*Y;(VVL7*;JZMXIJ*E?JZ9H(2UDIV+NHR:D[Z'F)O A)>EPH"6K\)_DK.\
M@)&XM8"1N+6 D;BU@)&XM8"1N+6 D;BU@)&XM8"1N+6 D;BU@)&XM8"1N+7_
MDAH#_Y E!_^;+ K_IS0/_[(\%O^[1"'YQ4LP\<Y10>?26%3:SEYIRL9E?+V]
M:XRPMG":I;!VI9RJ?*V3IH*TC*.)N8:@D+V!GIF_?9ZBP7N>K\%YF;.\>I>X
MM7J7N+5ZE[BU>I>XM7J7N+5ZE[BU>I>XM7J7N+5ZE[BU>I>XM7J7N+7_DAD#
M_Y E!_^=*PK_JC,._[4\%?R_1"#TR$HN[=-0/^/85E/3TEUHQ<IC>[?":8NJ
MNV^8G[9THY6Q>JR-K8"RA:J'MW^GCKMZII>^=Z:@OW2FK;]SH;2[=)ZXM72>
MN+5TGKBU=)ZXM72>N+5TGKBU=)ZXM72>N+5TGKBU=)ZXM72>N+7_DQD#_Y$D
M!_^?*PG_K#,-_[@[%/C#0Q[OS4HLY]I//=W>55'-V%MGOL]B>K#(9XFDPFV7
MF;QRH8^X>*F&M7ZP?[*%M7FPC+ATKY6[<*^?O&ZOK+QMJ[6Y;J>YM&ZGN;1N
MI[FT;J>YM&ZGN;1NI[FT;J>YM&ZGN;1NI[FT;J>YM&ZGN;3_E!D#_Y(D!_^B
M*@C_L#(,_KPZ$O+'0ASHTTDIX>%,.]3C4U'&W5IEM]5@>*G/9H>=R6N4D<5P
MGH?!=J9_OGRL>+R$L7*ZB[1MN9.V:KB<N&>WI[AGM[>V:+*[L6BRN[%HLKNQ
M:+*[L6BRN[%HLKNQ:+*[L6BRN[%HLKNQ:+*[L6BRN['_E1@#_Y4C!O^E*0?_
MM#$*^,$Z$.O.0AC@W4<EU>5+.\OG45"]XUECK]Y?=*+898.6TVJ/BLYOF7_(
M<Z%UQ'BG;L%]JVF^A*YEO8NQ8;R3LE^\G;)?O*RQ8K^^K6*_OJUBO[ZM8K^^
MK6*_OJUBO[ZM8K^^K6*_OJUBO[ZM8K^^K6*_OJW_EA@#_YDA!?^J* ;_N3 (
M\,@X#>'80!/4XT4FRNM+.\'L3T^SZ%=@IN5?;YKB9GR.W&R&A-5QCWK0=95S
MS7J;;,I_GV?'A*)CQHJD7\21IES$F:=:PZ2G6L2PIUK$L*=:Q+"G6L2PIUK$
ML*=:Q+"G6L2PIUK$L*=:Q+"G6L2PIUK$L*?_F!<"_YX@!/^O)@7XP"X&YM S
M"-7A/!3)ZD4HO_)*.[7Q3DRI[U9;G>U?:)+J9W.'XVU\?MYR@G;:>(APUWV,
M:]2"D&;2AY)CT8R57\^2EES.F9A9SJ*96,VKFEC-JYI8S:N:6,VKFEC-JYI8
MS:N:6,VKFEC-JYI8S:N:6,VKFEC-JYK_FA<"_Z4> _^W(P/MR28#UMXI!LGI
M.Q>^\T0IL_A).JCW34B?]E55E/5?8(GQ:&B [&]P>.AU=7+E>GEMXG]]:>"$
M@&7?B8)BW8Z$7]R3AEW;F8=:VJ&)6-FHB5C9J(E8V:B)6-FHB5C9J(E8V:B)
M6-FHB5C9J(E8V:B)6-FHB5C9J(G_G!8"_ZT; O;!'0';VA,!R>@I";WS.QFR
M_4,HIOY'-IS]3$.3_55-BOU?5H'Y:5UY]7!B<_)V9V[P?&IJ[H%M9^R&;V3K
MBW%AZH]R7^F4=%WHF75:YZ!W6.:F>%CFIGA8YJ9X6.:F>%CFIGA8YJ9X6.:F
M>%CFIGA8YJ9X6.:F>%CFIGC_HA4!_[<5 -C/"P#*YQ,"O/,I"['].QFD_T F
MF?]%,H__2SR'_U1$?_]?2WC_:5!Q_W!4;/UV6&G[?%IF^H%<8_B&7F'WBU]?
M]I!A7O:58ESUFF-:]*!D6/.E95CSI658\Z5E6/.E95CSI658\Z5E6/.E95CS
MI658\Z5E6/.E95CSI67_K1  UL,( ,C3"@"[]!4#K_\J#:/_-QB7_STBB_]#
M+('_2C1Z_U(Z<_]>/V[_:$-I_V]'9O]U26/_>TMA_X%,7_^%3EW_BD]<_X]0
M6O^345G_F%)7_YY35O^C5%;_HU16_Z-45O^C5%;_HU16_Z-45O^C5%;_HU16
M_Z-45O^C5%;_HU39N@4 Q<<' +G9" "L_Q<%HO\K#97_,Q:)_SD>?O] )77_
M2"MM_U P9_]:-&/_93=@_VTY7O]S.US_>#U:_WT^6/^"/U?_AD!6_XM 5?^/
M053_E$)3_YI#4?^?0U'_GT-1_Y]#4?^?0U'_GT-1_Y]#4?^?0U'_GT-1_Y]#
M4?^?0U'_GT/&O@4 M\T% *KD" &?_QD&E/\H#(?_+A-[_S49<?\]'FG_12-B
M_TTF6_]6*5C_7RQ6_V@M5/]N+U/_<S!2_W@Q4?]\,5#_@#)/_X0S3O^(,TW_
MC#1,_Y(T2_^6-4O_EC5+_Y8U2_^6-4O_EC5+_Y8U2_^6-4O_EC5+_Y8U2_^6
M-4O_EC6WQ , J=0" )SY"P*3_QL%A?\C"GG_*0]N_S$49?\Y&%W_01M7_TH>
M4_]2(%#_62)-_V C2_]F)$K_:R5)_V\E2/]S)D?_=R9&_WLG1?]^)T7_@BA$
M_X<H0_^+*4/_BRE#_XLI0_^+*4/_BRE#_XLI0_^+*4/_BRE#_XLI0_^+*4/_
MBRG_@QP#_X G!_][,PW_AC@1_XY &?^322+_E54M_Y-A.?^0;47_BWA/_X:$
M6?R"CF'W?99H]'B=;O%THW/N<:EW[&ZN>NILLWWI:KE_YVC @>9GQX/C9<^%
MW6/8AM-@VH?38-J'TV#:A]-@VH?38-J'TV#:A]-@VH?38-J'TV#:A]-@VH?_
M@QP#_X G!_][,PW_AC@1_XY &?^322+_E54M_Y-A.?^0;47_BWA/_X:$6?R"
MCF'W?99H]'B=;O%THW/N<:EW[&ZN>NILLWWI:KE_YVC @>9GQX/C9<^%W6/8
MAM-@VH?38-J'TV#:A]-@VH?38-J'TV#:A]-@VH?38-J'TV#:A]-@VH?_@QP#
M_X G!_][,PW_AC@1_XY &?^322+_E54M_Y-A.?^0;47_BWA/_X:$6?R"CF'W
M?99H]'B=;O%THW/N<:EW[&ZN>NILLWWI:KE_YVC @>9GQX/C9<^%W6/8AM-@
MVH?38-J'TV#:A]-@VH?38-J'TV#:A]-@VH?38-J'TV#:A]-@VH?_@QP#_X G
M!_][,PW_AC@1_XY &?^322+_E54M_Y-A.?^0;47_BWA/_X:$6?R"CF'W?99H
M]'B=;O%THW/N<:EW[&ZN>NILLWWI:KE_YVC @>9GQX/C9<^%W6/8AM-@VH?3
M8-J'TV#:A]-@VH?38-J'TV#:A]-@VH?38-J'TV#:A]-@VH?_@QP#_X G!_][
M,PW_AC@1_XY &?^322+_E54M_Y-A.?^0;47_BWA/_X:$6?R"CF'W?99H]'B=
M;O%THW/N<:EW[&ZN>NILLWWI:KE_YVC @>9GQX/C9<^%W6/8AM-@VH?38-J'
MTV#:A]-@VH?38-J'TV#:A]-@VH?38-J'TV#:A]-@VH?_@QP#_X G!_]],@S_
MB#<1_Y _&/^522+_EU0M_Y9?.?^3:T7_CG=1_XB"6_J$C&3U?Y1K\7J;<NYV
MHG?K<J=[Z6^M?^=LLH+E:KB$Y&F_A^)HQXG@9L^*UF/6C,]BV(K/8MB*SV+8
MBL]BV(K/8MB*SV+8BL]BV(K/8MB*SV+8BL]BV(K_A!L#_X$G!_^ ,0S_BS81
M_Y,^&/^91R+_G%(M_YI=.O^8:4?_DW13_HY^7_>(B6GQ@I%R[7V8>>EXGW_E
M=*2$XW"JB.!ML(S>:[>/W6J_D=MIR)/59L^5RV31D\9EU([&9=2.QF74CL9E
MU([&9=2.QF74CL9EU([&9=2.QF74CL9EU([_A1L#_X(F!_^", S_CC40_Y8]
M&/^<1B'_H% M_Y];._^<9DC_F'%6^Y-\8O2-AFWNAXYWZ("5@.1ZG(?@=:*,
MW7*HD=IOKY78;;>9U6O G-)IR9[)9<F>PF?-F+YIT9.^:=&3OFG1D[YIT9.^
M:=&3OFG1D[YIT9.^:=&3OFG1D[YIT9/_AAL#_X,F!_^%+PO_D#00_YD]%_^?
M1B'_HT\M_Z-:._^@9$G_G6]8^IAY9?&2@W'JBXQ\Y(.2AM]]F8[:>*"5UG2G
MFM-PKI_1;;:CSVO I<=FPJ? :,:BNVK+F[=LSI:W;,Z6MVS.EK=LSI:W;,Z6
MMVS.EK=LSI:W;,Z6MVS.EK=LSI;_AAL#_X,F!_^'+@O_DS00_YL\%_^A12#_
MITTM_Z98._^D8DK\H6Q9]YQV:.^6@'7GCXF!X(>0C-J EI75>IZ=T76EH\UP
MK*C+;;6LQVN^K;UHOZRX:\.FLVW(G[!OS)FP;\R9L&_,F;!OS)FP;\R9L&_,
MF;!OS)FP;\R9L&_,F;!OS)G_AQH#_X0E!_^)+0O_E3,/_YT\%O^D1"#_JDPM
M_ZI7._ZH8$OXI6I:\Z%T:NV<?GGDDX:&W(N-DM6#E)S/?)NERW>CJL=TJZW$
M<[6OOW"\L+5KO+"P;L&IK'#&HJERRIRI<LJ<J7+*G*ERRIRI<LJ<J7+*G*ER
MRIRI<LJ<J7+*G*ERRIS_AQH#_X0E!_^++ K_ES,/_Y\[%O^F1!__K$LL_ZY5
M._NL7TOUJFA<[J9Q;.>@>GS?EX**U8Z(F,V%CZ''@)>GPGN>K+UXIZ^Z=K"Q
MMW6ZLJUPNK*I<;^LI73$I*-UR9ZC=<F>HW7)GJ-UR9ZC=<F>HW7)GJ-UR9ZC
M=<F>HW7)GJ-UR9[_B!H#_X4E!_^,*PK_F#(._Z$[%?^I0Q__KTLL_[%4._BQ
M74OQKV9<ZJMO;N&C=G_5F7V/S)&$F<6*C**^A).HN7^:K;1\H["P>JNSK7FV
MM*9TN;2B=;VOGW?#IIUYQZ"=><>@G7G'H)UYQZ"=><>@G7G'H)UYQZ"=><>@
MG7G'H)UYQZ#_B!H#_X4E!_^.*@K_FC(._Z,Z%?^K0A[_L4HK_;53._:U7$ON
MLV1=Y:YL;]NE<X'.G7J/Q96!F;Z.B**WB)"IL827KJR G[&H?JBTI7VRM9]Z
MN+:;>;NQF7O!J)A\QJ*8?,:BF'S&HIA\QJ*8?,:BF'S&HIA\QJ*8?,:BF'S&
MHIA\QJ+_B1H#_X8E!O^0*@K_G#$-_Z4Z%/^M0A[_M$HK^[A2.O.Y6DOJN&)>
MX;%J<-.I<('(H'>/OYE^F;>2A:*PC(RIJHB4KJ6$G+*@@J2UG8&NMIE_M[>4
M?;JSDW_ JI)_Q:.2?\6CDG_%HY)_Q:.2?\6CDG_%HY)_Q:.2?\6CDG_%HY)_
MQ:/_B1D#_X8D!O^1*0G_G3$-_Z<Y%/^O0AW_MDDJ^+Q0.O"]64OGO&%>W+5G
M<<ZL;X'#I'6.N9Q\F;&6@J*JD8JIHXR1KIZ)F;*9AJ&UEH6KMY.%MK>.@;FT
MCH._JXV#Q*6-@\2EC8/$I8V#Q*6-@\2EC8/$I8V#Q*6-@\2EC8/$I8V#Q*7_
MB1D#_X<D!O^3*0G_GS$-_ZDY$_^Q01S_N4DI]L!/.>W"5TKDOU]=UKEF<,FP
M;8"^J'..M*!ZF:N:@**DE8>IG9&.KI>.EK*2BY^UCXJIMXR*M+B(AKBUB(>^
MK(B'PZ:(A\.FB(?#IHB'PZ:(A\.FB(?#IHB'PZ:(A\.FB(?#IHB'PZ;_BAD#
M_X<D!O^4*0G_H3 ,_ZLY$O^T01S\NT@H],-...O'5DK@PUY=T;QE;\2S:X"Y
MJW&-KZ1WF*:>?J&>FH2HEY:,KI&3E+*,D9RUB(^FMX6/L;B"C+>V@HR^K8.,
MPZ:#C,.F@XS#IH.,PZ:#C,.F@XS#IH.,PZ:#C,.F@XS#IH.,PZ;_BAD#_X@D
M!O^6* C_HS ,_ZTX$O^V0!OZOD@G\<=.-^?,54C<QUQ<S+]C;[^W:7^TL'",
MJ:EUEZ"C>Z"8GX*HD9N)K8J9DK*%EIJU@96DMWZ5K[=[DK>V?9&]KGV0PJ=]
MD,*G?9#"IWV0PJ=]D,*G?9#"IWV0PJ=]D,*G?9#"IWV0PJ?_BQD#_XDD!O^8
M* C_I2\+_[ X$?^Y0!GXPD<F[LM-->305$;5RUM;Q\-B;KJ[:'ZNM&Z+HZYS
MEIJI>I^2I8"FBJ&'K(2?C[%^G9BT>IRAMGB;K+9UFK>V=YB]KGB6PJ=XEL*G
M>);"IWB6PJ=XEL*G>);"IWB6PJ=XEL*G>);"IWB6PJ?_C!@#_XHC!O^:)P?_
MIR\*_[,W#_R]/QCSQD8CZM!,,N#54D7/SUE:P<A@;+3 9GRHNFR*G;1RE92P
M>)Z+K'ZE@ZB%JGVFC*]XI)6R=*.?M'&CJK5OI+FT<*"^K7*=PJ=RG<*G<IW"
MIW*=PJ=RG<*G<IW"IW*=PJ=RG<*G<IW"IW*=PJ?_C!@#_XPB!O^=)P?_JBX)
M_[8V#O?!/A;MS$8@Y-A++MG<4$3)U%A8N\U>:Z[&97JBP&J(E[MPDHVW=9N$
MLWRB?;&#J':OBJQQK9.O;:V=L6JMJ;)IK;>Q:JF_K&NFPZ9KIL.F:Z;#IFNF
MPZ9KIL.F:Z;#IFNFPZ9KIL.F:Z;#IFNFPZ;_C1@"_X\@!?^@)@;_KBT(_;LU
M#/''/1/ETT0<W>!(+=#A3T+"VU96M--=:*?-8WB:R&B%C\-NCX7 =)A]O7J>
M=KJ!I'"YB:AKN)*J9[><K&6XJ*UCN+:M9+7!J66PQ:1EL,6D9;#%I&6PQ:1E
ML,6D9;#%I&6PQ:1EL,6D9;#%I&6PQ:3_CA<"_Y,?!/^D)07_LRP&]\$S">C.
M/ _<WD 9T.5(+L?E34*YX%54K-M;99_58722T&:!A\ULBW[*<I-VR'F9;\:!
MGFK%B:)EQ9*D8L2=IE_$IZ==Q+2G7L/$I%^]R*!?O<B@7[W(H%^]R*!?O<B@
M7[W(H%^]R*!?O<B@7[W(H%^]R*#_D!<"_Y@=!/^I(P3_N2D$[L@Q!MW:- K0
MY$$;QNM'+KSJ3$&PYE-2H^-:89?@86Z,W6AY@MMN@GK9=8ERU7R/:]*"DV7/
MB)=@S8^:7,R7G%K+H)U8RZN=5\NZG5G,S)E9S,R96<S,F5G,S)E9S,R96<S,
MF5G,S)E9S,R96<S,F5G,S)G_DA8"_YT< _^O( +VP"4"XM,D ]#C,@S%[$ =
MNO%'+[#O2S^E[5%.FNM:6H_J8F6%Z&IN?>=R=77C>'MOX'Z :=V$A&3;BH=@
MV9&)7=B8BUK6H(U8UJB.5M6TCE35P8Y4U<&.5-7!CE35P8Y4U<&.5-7!CE35
MP8Y4U<&.5-7!CE35P8[_E!4"_Z09 O^W' 'IRQ8!T>$= L7L,0ZZ]4 >KO=%
M+J/U2CR:]%!(D/-:4X;S8UM^\FQB=_%S:''N>FULZX!P9^F&<V/GC'9@YI)X
M7>28>EKCGGM8XZ5]5N*O?E3AN'Y4X;A^5.&X?E3AN'Y4X;A^5.&X?E3AN'Y4
MX;A^5.&X?E3AN'[_F!,!_ZT4 ?/##P#2V L Q.P>!+CV,1&M_3X>HOU#*Y?\
M2#>._$]!A?Q927W\8U!W_&U6</MT6FOY>EYH]X%A9/6'8V'SC65?\I-G7?&9
M:%KPGFE8[Z5K5N^M;%3NM&U4[K1M5.ZT;53NM&U4[K1M5.ZT;53NM&U4[K1M
M5.ZT;53NM&W_HQ  \;D, ,[)"0#$WPL MO<?!JS_,A*@_SL=E/]!)XK_1S&!
M_TXY>O]8/W/_8D5N_VQ):?]S3&;_>D]C_X!18/^&4U[_C%1<_Y)56OZ85UG]
MG5A7_*195?NK6E3[L5M4^[%;5/NQ6U3[L5M4^[%;5/NQ6U3[L5M4^[%;5/NQ
M6U3[L5OPKP@ S;\' ,#-" "T[@X"J?\A")__,1&2_S<:A_\^(GW_12EU_TTP
M;O]5-6G_8#EE_VH\8?]Q/E__=T!<_WY"6O^$0UG_B417_X]%5O^41E7_FD=3
M_Z!(4O^G25'_K4I1_ZU*4?^M2E'_K4I1_ZU*4?^M2E'_K4I1_ZU*4?^M2E'_
MK4K/N 0 OL,% ++4!@"F_A #G/\C")#_+0^$_S,6>?\[''#_0R)I_THG8O]2
M*EW_7"U:_V4P6/]M,5;_<S-4_WDT4_]^-5+_A#90_XDW3_^..$[_DSA-_YDY
M3/^@.DO_ICI+_Z8Z2_^F.DO_ICI+_Z8Z2_^F.DO_ICI+_Z8Z2_^F.DO_ICJ_
MO , L,H# */< P&9_Q(#C_\B"(+_* UV_R\2;?\W%V7_/QM>_T<>6/].(53_
M5R-1_U\E3O]E)DW_;"=+_W$H2O]V*4G_>RI(_X J1_^%*T;_B2M%_XXL1/^4
M+$/_FBU#_YHM0_^:+4/_FBU#_YHM0_^:+4/_FBU#_YHM0_^:+4/_FBVQP@$
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M!O^-)@?_FBT*_Z0U#_^L/1?^LD4B]KA,,.V\5$#DN%U1U[)D8\NI;'/ H7.
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M3U#_NU!/_\-13__#44__PU%/_\-13__#44__PU%/_\-13__#44__PU':KP(
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MC(:,H(B-D9J%E9:6@IZ:DH"GG8]_LYZ-@,*>BX#,FHN!TI**@-B)B8#;AHF
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M.$3_Q3A$_\4X1/_%.$3_Q3A$_\4X1/_%.$3_Q3C!LP  LKX" *7, 0"9W0,
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MY'B"@N1X@H+D>(*"Y'C_<1H"_WH< _^*'0/_ER,$_Z(I!?RL,0GQLSD/Z+I
M%]V\2"7/ME(XPZ];2+FH8E:OHFIBIYQP;)^7=W68DWY\DI"&@HR-CH>'BI>+
M@XB@CG^'JY%\A[F1>X?+D7R(V(E]A]Z"?8;D>GV&Y'E]AN1Y?8;D>7V&Y'E]
MAN1Y?8;D>7V&Y'G_<1H"_WP: _^-' /_FB(#_Z4H!/FO+P?NN#<,Y+\_%-C
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M7$KC\UQ*X_-<2N/S7$KC\UQ*X_-<2N/S7$KC\USYF0, U*P" ,6W! "YPP4
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M:E>O\6=7K_%G5Z_Q9U>O\6=7K_%G5Z_Q9U>O\6?_?PX!_Y,+ .&E!0#2LP<
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M_U*F:?]2IFG_4J9I_U+_6R "_V<< O]T&@+_?R #_X@G!/^.+P?]DC<,])1
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M9FB3]F!HDO=?:)+W7VB2]U]HDO=?:)+W7VB2]U__;Q$!_X$. /^1#@#RH P
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M55"Z_E50NOY54+K^55"Z_E7_A0( W9@  ,VF @#!L0, M[H# *[&!@"GTPH
MH-T5 )G=* 20VS<.AME"&7W62R1UU%0M;=)<-6?18SQAT&M!7,]R1EC/>TE4
MSH1-4,Z/4$W.FU)+SJE32<ZY5$C/SU1(SNM32<[X4$K+_TY*RO]-2LK_34K*
M_TU*RO]-2LK_34K*_TWGCP  T9\  ,.K 0"WM ( K;\# */+!@";V0H E.4:
M 8WE*P:$Y#4->^,_%G/B2!YLX5(F9N%:+&#@8C);X&HV5^!R.E/?>SU0WX5
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M,P8Z_SD'-O] "#/_10@P_TL)+O]1"BO_5PHI_UT+)_]D"R3_; PB_W8-(/^
M#1[_C X=_Y<.'/^A#AO_K \;_ZX/&_^N#QO_K@\;_ZX/&_^N#QO_K@^7O
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M8/] NF#_0+I@_T#_4B$"_UX= O]I&@+_<Q\#_WHF!/]^+P;_@3@+^X%!$O.
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M6WB"_E9Y@?]1>8'_47F!_U%Y@?]1>8'_47F!_U'_91,!_W4. /^##@#_D X
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M4F&8_U)AF/]289C_4F&8_U+_<@L _X,% -^3 0#1GP0 R:H& ,&R!0"[O00
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M(3CXM2(W^<@B-OGC(C;X\R(V]_PB-O?\(C;W_"(V]_PB-O?\(C;W_"*WI@
MJ:X  )RY  "0Q   @\\  '?;  !O]@H 9_\3 6#_'0):_R<#5/\P!4__. A*
M_T *1O](#$/_3PY _U8//?]>$#O_91(X_VX3-O]W%#3_@A4R_X\6,/^;%R__
MJ1<N_[<8+?_(&"S_X1@L_^\8+/_O&"S_[Q@L_^\8+/_O&"S_[QBKJP  GK4
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M_V$4 ?]L$@'_=A<!_WT< ?^#(P+TABP$ZH@U!^&'0 [6@DP9S7U8),9W8BW
M<VLUNV]T/+=L?$&S:81&KV>,2:QEE$RI8YQ/IF*E4:1AKU.B8+Q5H&#-59Y@
MYE2>9/=-GV?_1Y]I_T.>:?\_G6G_/9UI_SV=:?\]G6G_/9UI_SW_5Q<!_V,2
M ?]O$0'_>10!_X$9 ?N'( 'OC"<"Y(XP!=J-/0S/ATH8QX)5([]]7RVY>&@U
MLW1P/*]Q>$*K;H!&IVR(2J1ID$Z@:)A1G6:A4YMEJU689+A7EF3(6)1DX5B5
M:/10EFO_2I=L_T66;?]!EFW_0)9M_T"6;?] EFW_0)9M_T#_614!_V80 ?]R
M$ #_?1( _X46 /:,&P'JD2(!WY0K ].1.@O)C$<7P(=3(KF"7"RR?64UK7EM
M/*AU=4*C<WU'H'"$2YQNC$Z9;)52E6N>5))IJ%>0:;19CFC#68QHW%J-;/)3
MCV[_3)!P_T>/<?]#CW'_08]Q_T&/<?]!CW'_08]Q_T'_6Q0!_V@/ /]U#P#_
M@!$ _XD3 /*0%P#EEAP V9DF LV5. K$D$46NXM1(;.&6BRM@F,TIWYK.Z%Z
M<D&==WI&F76!2Y5SB4^2<9%2CF^;58MNI5B(;;!:AFR_6X1MU5N&;^]5B'+]
M3HET_TF)=/]$B'3_0XAT_T.(=/]#B'3_0XAT_T/_71(!_VL. /]X#@#_@P\
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M1W*$_T=RA/]'<H3_1W*$_T?_9@T _W4' /:#!0#<CP, TI@& ,RA!P#(J @
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M/$3%P3Q#Q=\\1,3S.T3#_SE%PO\W1<'_-T7!_S=%P?\W1<'_-T7!_S?5BP
MQ9H  +>D  "KK   H+0  ):^  "+QP0 @= ( 'C9#@!UV2 !;]@O!&G8/ EC
MUD807M90%5G56!I5U& ?4=1H(D[4<29+TWLI2-.%*T73DBY"U)\O0=2O,#_5
MPC$_U>$P/]/R,#_2_2\_T?\N/]#_+C_0_RX_T/\N/]#_+C_0_R[*E   NZ$
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M$2?_X1$F__(1)O_V$2;_]A$F__81)O_V$2;_]A&GJ0  F;,  (N^  !^R0
M<-,  &3>  !8YP  4O\) $W_$0!'_QD!0_\B 3[_*@(Z_S(#-_\Y S/_/P0P
M_T8%+?]-!2O_5 8H_UL')O]C!R/_;0@A_WD)'_^'"1[_E0H=_Z,*'/^Q"AO_
MP L:_]8+&O_?"QK_WPL:_]\+&O_?"QK_WPN;L0  C;P  '['  !PT@  8]X
M %7D  !+]0  1O\% $#_#@ [_Q0 -_\; 3/_(P$O_RD"*_\P BC_-0(E_SL#
M(O]! Q__1P,=_TX#&O]5!!C_7@05_V@%$_]T!1'_@@40_Y &$/^=!@__J08.
M_[4&#O^Z!@[_N@8._[H&#O^Z!@[_N@:.N@  ?\4  '#1  !BW@  5.4  $;K
M   __@  .?\  #3_"0 O_PX *_\4 "?_&@$C_R$!'_\E 1S_*@$9_R\!%O\T
M A3_.@(1_T "$/]& @[_3@(,_U8""?]@ P?_; ,$_W@# _^& P+_D0,!_YT#
M ?^A P'_H0,!_Z$# ?^A P'_H0/_-BT"_SDN O\^+@/_0#(#_T X!/\^00;_
M/$P(_SI:"O\X: S_-G8._S6##_\TCQ#_,YD1_S.A$?\SJ1+_,K 2_S*W$O\R
MOQ+_,L@3_S+3$_\RXQ/_,NT3_S+V$O\S_A+_,_\2_S/_$O\S_Q'_,_\1_S/_
M$/\S_Q#_,_\0_S/_$/\S_Q#_-BT"_SLL O] + /_0R\#_T,U!/]"/@;_0$H(
M_SY7"_\\90W_.G,/_SB $/\WC!'_-Y82_S:?$_\VIQ/_-JX4_S:U%/\VO!3_
M-<45_S70%?\UX!7_-NL5_S;T%?\V_13_-O\4_S;_%/XW_Q/^-O\3_3;_$OTV
M_Q+]-O\2_3;_$OTV_Q+_-RP"_SXJ O]#*@+_1BT#_T<R!/]&/ ;_14@(_T-5
M"_]!8@W_/W 0_SU]$?\\B1/_.Y,4_SN<%?\ZI!;_.JL6_SJR%_\ZN1?_.<(7
M_SG,%_\YW1C_.>D8_SGS&/\Z^QC\.O\7^CK_%_DZ_Q;X.O\6^#K_%?@Z_Q7X
M.O\5^#K_%?@Z_Q7_.2L"_T$G O]&)P+_2BD#_TLO!/],.0;_2T4(_TA1"_]&
M7@[_1&P1_T)Y$_]!A17_0(\7_T"8&/\_H!C_/Z<9_SZN&O\^MAK_/KX;_S[(
M&_\]UAS^/>8<^S[Q'/@^^ASU/O\<\S[_&O(__QGQ/_\9\3__&/$__QCQ/_\8
M\3__&/$__QC_/2@"_T4D O]*(P+_3B4#_U$L!/]2-@;_44$(_T]-#/],6@__
M2F<2_TAT%?]'@!?_1HL9_T64&_]$G!S_0Z0=_D.K'OU"LA_\0KH@^D+$(/E"
MT"'V0>(A\D+N(N]"^2+M0O\@ZT/_'^I#_QWI1/\<Z$3_&^A$_QOH1/\;Z$3_
M&^A$_QO_0"4"_T@A O]/( +_4R$"_U<I _]9,P7_6#X(_U9)#/]251#_46,4
M_T]O%_Y->QK[2X8=^4J/'_=)F"'V2)\B]$>F)/-'KB7Q1K8F\$:_)^]%RRCL
M1=XIZ$7L*>5&^"CB1_\FX4C_)-])_R+>2?\@W4G_']U)_Q_=2?\?W4G_']U)
M_Q__0R("_TP> ?]3' +_61X"_UTF _]?, 3_7SH'_UU%"_]:4!#]6%X5^%5J
M&?53=AWR48 A[T^*).U-DR;K3)HIZ4NB*^=*J2SE2;$NY$B[+^)(QS'@2-DQ
MW$CJ,=A)]B[42_\KTDS_*=!-_R;/3O\ESD[_(\Y._R/.3O\CSD[_(\Y._R/_
M1Q\!_U : ?]7& '_7AP!_V,C O]F+ 3_9C8&_V1!"OIB3 _T7UD5[UQE&^M9
M<"#G5GLEY%2$*>%1C2W>4)4PW$^=,ME.I3/63:TUTTVW-M%,PC?/3-$XS$SF
M.,E-]#7'3_\QQ5'_+L12_RO#4_\IPE/_)\)3_R?"4_\GPE/_)\)3_R?_2AP!
M_U07 ?]<%0'_8QD!_VD@ O]L*0/_;3(%^6P]"?)I1P[K9E05Y6-@'.!?:R+;
M7'4HUEE_+=)7B##/59 SS%28-LI3H#C'4J<ZQ5&P.\-0NSS!4,D]OU#?/;Q1
M\#NZ4_PWN57_,[A7_R^W6/\MMUC_*[=8_RNW6/\KMUC_*[=8_RO_31H!_U<4
M ?]@$@'_:!<!_VX= ?]R)0+[<RX#\G,X!^EQ0PWB;E 4VVE<'--E9B3.8G J
MR5]Z+\9<@C/#6XHVP%F2.;U8FCN[5J(^N%6K/[95M4&T5,)"LE340K!5ZD&N
M5_D\KEG_-ZU;_S.M7/\PK5W_+JU=_RZM7?\NK5W_+JU=_R[_4!<!_UH2 ?]D
M$ #_;10 _W,: ?]W(0'T>2D"ZGHS!>)X/PK9=$P3SW!8',EK8B3$:&PKOV5U
M,+MB?36X8(4XM5Z-/+)<E3ZO6YU!K5JF0ZM9KT2I6;Q%IUC,1J18Y4:D6_9
MHU[_.Z-?_S>C8/\SHV'_,:-A_S&C8?\QHV'_,:-A_S'_4Q4!_UT0 /]H#P#_
M<!( _W<6 /M\' 'N?R0!Y( M ]I_.PC/>DD2QW54&\%Q7R2[;6@KMFIP,;)G
M>3:O98 ZJV.(/:AAD$"F8)A#HUZA1:!>JT>>7;=(G%W&29I<WTF:7_)$FF+_
M/IIC_SF;9?\VFV7_,YME_S.;9?\SFV7_,YME_S/_51,!_V . /]K#@#_=!
M_WL2 /6!%P#HA!X WH<G =&$-P?(?T81P'M1&[EV6R.T<F4KKV]M,:IL=3:G
M:GPZHVB$/J!FC$&=9)1$FF.=1Y=BITF58;)+DV'!3)%AV$R18^]'DF7]09)G
M_SR3:?\XDVK_-9-J_S63:O\UDVK_-9-J_S7_5Q$!_V,- /]N# #_=PX _W\/
M /"%$0#CB18 UHLC <N(-0;"A$,0NH!/&K-[62.M=V(JJ'1J,:-Q<3:?;GD[
MG&R!/YAJB$*5:9%%DF>:2(]FHTJ-9:],BF6]38EET4Z)9^Q*BFG[0XMK_SZ,
M;?\ZC&[_-XQN_S>,;O\WC&[_-XQN_S?_61  _V4+ /]Q"P#_>@L \8(, .B)
M#0#=C@X SX\@ <:-,@:]B4$/M81-&:Z 5B*G?%\JHGAG,)UU;S:9<W8ZE7%]
M/Y)OA4*.;8Y&BVR628AJH$N%:JQ-@VFZ3X%IS$^!:NA,@VWY181O_S^%</\[
MAG'_.(9Q_SB&<?\XAG'_.(9Q_SC_6P\ _V<( /]S" #S?0@ WH8' -F,"0#5
MD0L RI(> ,&0, 6XC3\.L(A*&*F$5"&B@%TIG7UE,)AZ;#63=W,ZCW5[/HQS
M@D*(<HM&A7"428)OGDQ_;JE.?&VW3WMMR5!Z;N9-?''X1GYS_T%_=/\]@'7_
M.H!U_SJ =?\Z@'7_.H!U_SK_70X _VH& /]V!@#D@ , V8D& -*/" #/E H
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M1U&;ND=0F]%'49ON1%.;_$!5F_\\5IO_.E:;_SI6F_\Z5IO_.E:;_SKQ=
MV8,  ,B0  "^F@  LZ$  *JG  "AK@  E[4& )*V& ",M2H#A;0W"7ZR0A%W
ML$P8<:Y4'VRM6R5GJV(J8JII+UZI<3-:J'HW5J>#.E.FCCU0IIM 3:6I04NE
MND)+IM%"2Z7M/TVE_#Q.I/\Y3Z3_-T^D_S=/I/\W3Z3_-T^D_S?D>@  SXD
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M)3O,^R4[R_\E.\K_)3O*_R4[RO\E.\K_)3O*_R7#DP  M9X  *BF  "=K@
MD;8  (6_  !YQP  ;\X$ &36"0!>WA$ 6]X@ %?>+0)3WSH$4-]$!DS?3@E)
MWU<,1M]?#T/?:!%!WW$3/M]\%3S?B1<ZX)89.."E&C?@MQHVX<T:-M_L&C7>
M^1HTW?\;--S_&S3<_QLTW/\;--S_&S3<_QNYG   JJ0  )ZK  "2M0  A;X
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M!A/_Z083_^D&$__I!A/_Z0:7KP  B+H  'K%  !LSP  7MH  %#@  !$Y@
M//4  #?_!  S_PT +_\3 "O_&@ H_R$ )?\G 2'_+0$>_S(!&_\X 1G_/P$6
M_T8"%/]- A'_5@(0_V "#O]L @S_>P,+_XL#"O^: PK_J ,)_[4#"/_" PC_
MP@,(_\(#"/_" PC_P@.*N   >\,  &S.  !>VP  3^(  $+G   V[   ,?\
M "S_   G_P< (_\. "#_$@ <_Q@ &/\= !7_(0 2_R8 $/\L 0[_,0$-_S<!
M"O\^ 0C_1@$%_T\! ?]9 0#_9@$ _W0! /^" @#_D ( _YP" /^F @#_I@(
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M1((5]D.,%_1"E!CS09P9\4&C&^] JAON0+(<[3^['>L_QA[I/]4>Y3_H'^)
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M*K-1_R>S4O\DLE+_(K)2_R*R4O\BLE+_(K)2_R+_2A4!_U,1 /];#P#_8A(
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M+(YE_RR.9?\LCF7_+(YE_RS_50X _U\& /]I!@#T<@8 XG@& -M\"0#9?PP
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M_S'_7P( ]VP  -YW  #0@0  QX@! ,"- P"YD0, LI,1 *N3(P&CD3,&G(Y
M#96+2A6/B%,<B89;(H2#8BB @6DM?']P,7A^=S5T?( X<7N)/&YZDS]K>9Y"
M:'BK1&9XNT5D>-%%9GGN0&A[_3IJ>_\V:WS_,FM\_S)K?/\R:WS_,FM\_S+_
M80  ZF\  -EZ  #,A   PXL  +N1 0"TE0$ K)<. *67(0&>EC$%EY,^#)"0
M2!2*CE$;A(M9(7^)8"=[AV<K=X5N,'.$=31O@GTW:X&'.VB D3YE?YQ!8GZI
M0V!^N41??L]$8'_L0&* _#ID@/\V98'_,V:!_S)F@?\R9H'_,F:!_S+_9
MY7(  --^  #'AP  OH\  +:5  "NF0  IIL, *"<'@"9FRX$DID["HN61A*%
ME$\9?Y%7'WJ/7B5UCF4J<8QL+FV*<S)IB7LV9HB$.6*&CSU?A9H_7(6H05J%
MMT)9A<Q"6H7J/UR&^SI>AO\V7X?_,E^'_S)?A_\R7X?_,E^'_S+]:   X'8
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M-4F@^3)*G_\P2Y__+DN?_RU+G_\M2Y__+4N?_RW=>0  R88  +R2  "QF@
MIJ   )RF  "1K   AK(  'VV#0!YMAT =;8L F^U.09JM$,+9;-,$6"R5!9<
ML5L:6+!C'E6O:R%1KW,E3JY]*$NMB"I(K94M1:VC+D2MLR]#K<@O0JSG+T.K
M^2U$J_\K1*K_*42J_RE$JO\I1*K_*42J_RG1@   P8T  +68  "IGP  GJ4
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M$R_4_Q,OU/\3+]3_$R_4_Q.SF@  IJ$  )JI  "-L0  @+H  '3!  !HR0
M7,\  %+5 P!(W @ 1>42 $/E'@!!YBH /N8U 3OG/@$YYT<"-^=0 S3H600R
MZ&(%,.AM!B[I>0<LZ8<(*^J6"2GJIPHHZKH*)^O6"B?I\ HGY_T))N;_"B;F
M_PHFYO\*)N;_"B;F_PJHH   G*<  (^P  ""N0  =,(  &C*  !;T0  3]<
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M 0#_R@&&MP  =\$  &C,  !:UP  2]X  #[D   RZ0  )^T  "/_   ?_P
M&_\% !?_#  4_Q  $?\4  __&  -_QT "_\B  C_*  %_RX  O\U  #_/0
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M0),6X#^;%]\_HAC=/JH9VSZS&M@^O1K6/LH;TC[?&\X^[QO+/_L:R4#_&,=
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M'J)2_QVB4O\=HE+_':)2_QW_2@\ _U(* /]:"0#_8 L _V4. /5G$0#H:!@
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M.6YJN3IM:LXZ;6OK-V]M_#%P;O\M<6[_*G%O_RAQ;_\H<6__*'%O_RC_60
MZV4  -MP  #->   Q'X  +R" 0"VA $ KH4. *>&( "@A3 #FH(]"). 2 ^.
M?5$5B7M9&H1Y8!^ =V<C?'5N)WET=2IV<WTN<W*&,7!QD#1M<)PW:F^H.6AO
MMSIG;\LZ9W#I-VEQ^C)K<O\M;'/_*FQS_RAL<_\H;'/_*&QS_RC_7   YV@
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M7'KE-UY[^#)?>_\N8'S_*V%\_REA?/\I87S_*6%\_RGU8@  WF\  ,QZ  #
M@P  MXD  *^.  "FD0  G9(& )>3%P"1DR@!BY(V!86000M_CDH1>HQ2%G6*
M6AMQB&$?;8=H(VJ&;R=FA'<K8X. +F""BC%=@98T6H&C-EB LC=6@,4W5H#C
M-EB!]S%9@?\M6X+_*EN"_RE;@O\I6X+_*5N"_RGL9@  V',  ,=^  "\AP
MLXX  *F2  "@E0  EI@! )"9$P"*F20!A9@R!'^6/@EYE$@.=)-0%&^15QEK
MD%X=:(YE(62-;25@C'4H78M^*UJ*B"Y7B90Q5(FA,U*(L#11B,,U4(CB-%*(
M]C!3B/\L5(C_*56(_RA5B/\H58C_*%6(_RCF:P  T'@  ,*#  "WC   K9(
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M(4"D_R! I/\@0*3_($"D_R#*?@  NXL  *^5  "DFP  F:$  (ZF  ""K
M=[$  &JV  !CN X 8;@= %ZX+ %:N#@"5[A"!5.X2PA0MU,+3;=;#DJV8Q!'
MMFL31+5U%D*U@1@_M8X:/;6<'#NUK!PZM< =.;7?'#FS]!PYLO\<.;'_&SFP
M_QLYL/\;.;#_&SFP_QO!A@  M),  *>:  "<H   D:<  (6M  !YLP  ;;@
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M!1_@_P6DG@  F*4  (NN  !]M@  <+X  &/&  !6RP  2]   $#5   VW
M+^4' "WM$  K[A@ *>XB "?O*P E[S0 (_ \ "'P10 ?\4X '?)8 1OR9 $9
M\W$!&/.! 1?TD@(5]*4"%/6Z A/UU@(3].\"$O+\ A+P_P(2\/\"$O#_ A+P
M_P*:I   C:T  '^V  !QOP  8\<  %;.  !)TP  /=H  #/?   JXP  )O0%
M "3[#0 A_!, 'OT; !S](@ 9_BD %_XQ !7_.0 3_T$ $?]* !#_50 ._V$
M#/]O 0S_@ $*_Y,!"?^F 0C_N@$'_]0!!__K 0;_]@$&__8!!O_V 0;_]@&/
MK   @+8  '*_  !CR0  5M$  $C8   [W0  ,.(  ";F   ?\   '/\  !G_
M"0 6_PX %/\3 !'_&0 /_QX #?\D  O_*P )_S( !O\[  /_1   _T\  /]<
M  #_:P  _WT  /^0  #_HP  _[0  /_&  #_U@  _]8  /_6  #_U@""M0
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M+'U:NRU\6L\N>UOL*WQ<_"9\7?\B?5[_'WU>_QU]7O\=?5[_'7U>_QW_4
M]5D  .%C  #2:@  R6X  ,)P 0"]< , MG 0 *YQ(@"H<#("H6X_!IQL2@N7
M:E,0DFA;%(YF8AB+96D;B&-P'H5B>"&"88 D@&"))GU?DBE[7ITK>%ZI+79>
MN"YU7LPO=%[I+75@^B=V8?\C=V+_('=B_QYW8O\>=V+_'G=B_Q[_4@  [%P
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M+V1L]BIF;?\F9FW_(V=N_R!G;O\@9V[_(&=N_R#V60  X&4  ,YO  #"=@
MN7P  +%_  "I@   H( ' )F!%P"4@2@!CH U XA^00B#?$H-?GI2$7IX615V
M=V 9<W9G''!T;A]M<W8C:G)_)F=QB2ED<94K8G"A+6!PL"]><,(O77#?+U]Q
M]2I@<?\F87+_(V)R_R!B<O\@8G+_(&)R_R#O7   W&D  ,IR  "^>@  M8
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M(E"#_Q]0@_\?4(/_'U"#_Q_>:0  R74  +R   "RB   J(T  )V1  "3DP
MA98  'Z7"P!YEQD =9<H 7&7-0-LEC\&:)5("F244 UADU<179)>%5J19AA7
MD&X;5(]W'E&.@2!.CHTC2XV:)4F-J29(C;LG1XW4)T>,\"1(C/\B28O_($J+
M_QY*B_\>2HO_'DJ+_Q[5;@  PWL  +>%  "LC0  HI(  )>6  ",F0  ?YP
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M%#2K_Q2[A0  KY   *.7  "8G0  C*,  ("H  !TK0  :+(  %RV  !0N@$
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M 1S?F0$:WZP!&=_$ 1C>YP$8W/@!&-O_ A?:_P(7VO\"%]K_ A?:_P*@G
ME*,  (>K  !YLP  ;+H  %_!  !2Q@  1LH  #O.   QTP  *=D  "'>!0 >
MZ X '>@5 !OI'@ 9Z2< &.HP !;J.0 5ZT, %.Q. !+L6@ 1[6< $.YW !#N
MB@ .[YX #O"S  WPS0 ,[^P #.W\  SK_P ,Z_\ #.O_  SK_P"7HP  B:L
M 'NT  !MO   7\0  %+*  !%S@  .=,  "_8   EW0  '>$  !CL @ 6]PL
M%/<1 !'X%P 0^!X #ODE  WY+0 +^C4 "?L_  ?[2@ $_%<  _UF  +^=P
M_8L  /V?  #\M0  _-$  /SM  #\_   _/T  /S]  #\_0"+JP  ?;0  &Z]
M  !@Q@  4LT  $32   WV   +-T  "+A   9Y0  $^H  !#Z   ._P8 #?\,
M  K_$  '_Q0 !/\:  '_(   _R<  /\P  #_.@  _T4  /]3  #_8@  _W4
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M')1(P1V22-@=D$GO&X]*_AB/2_\6CDO_%(Y,_Q*.3/\2CDS_$HY,_Q+_10
M_TL  .E3  #>6   TUL  ,U;! #*6 < PE@5 +I:)P"S6C<!KEA$!*E73P>D
M55@*H51@#9Y3:!";46\3F%!V%990?A>43X89DDZ.&H].F!R-3:(=BTVN'XI-
MO""(3= @ATWK'X9/_!N&4/\8AE#_%H90_Q2&4?\4AE'_%(91_Q3_1P  ^$\
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M)7!;]B!Q7/\<<5W_&G%=_QAQ7?\7<5W_%W%=_Q?]3P  Y5D  --B  #':
MO6P  +9M  "O;   IVL+ *!L&0";;"H!E6LW I!I0P6+:$P)AV94#(-E6Q"
M8V(3?6)I%7IA<!AX87@:=6"!'7-?BQ]P7I8B;EZB)&Q>L"5K7L$F:5[>)FI?
M]"%K8/\=:V'_&VQA_QEL8?\8;&'_&&QA_QCU40  XEP  ,]E  ##:P  N6\
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M'%UM_QI=;?\976W_&5UM_QGH6@  TF8  ,-O  "X=@  KWL  *9^  "=?@
MD7P  (I\#P"%?1X @7TM 7Q\.0-W>D,&<WE+"7!X4PQL=UH0:79A$V9U:!9C
M=&\887-X&UYR@AY;<HT@67&:(E=QJ"15<;DE5''0)51Q[B)6<?X>5W'_'%=Q
M_QI8<?\96''_&5AQ_QGC7@  S6D  +]S  "T>@  JW\  **"  "8@P  BX$
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M%T6%_Q?-;0  O7@  +&"  "GB@  G(X  )*0  "&DP  >94  &R7  !FEPX
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M"S*JGPPQJK ,,*K'##"IYPPOI_H-+Z;_#2^E_PTOI?\-+Z7_#2^E_PVVA
MJHX  )Z4  "4F0  AYX  'NC  !OJ   8ZP  %>O  !+L@  0;4& #ZV$0 ]
MMAX .[8I #JW-  YMSX -[=' #:W4 $TMUH!,K=D C"W;P,NMWP$++>+!2JW
MG 4IMZX&*+C%!2BWY@4GM?D')K/_!R:R_P@FLO\()K+_"":R_PBOC0  HI0
M )>:  "+H   ?J8  '&K  !EL   6;0  $VW  !"NP  .+X! "_""0 MPQ(
M+,,> "O#*0 JQ#, *<0] "C%1P GQ5$ )L5< "7&:  CQG8!(L:& 2#&F $?
MQJL!'L?! 1[&Y $=Q/@"',+_ QS!_P,<P?\$','_!!S!_P2EE   FIH  (ZA
M  "!IP  <ZX  &>T  !:N0  3KT  $+    XPP  +\<  ";+!  >T H &]$1
M !K2&@ 9TB4 &-,O !C3.@ 7U$0 %M10 !7570 4U6L $]9\ !+7CP 1V*0
M$-F[ !#9W@ 0U?, $-/_ !#2_P$0T?\!$-'_ 1#1_P&<F@  D:$  (.H  !U
ML   :+<  %N]  !.P0  0L4  #?(   MS   )-   !S5   5V@4 $.(+ !#C
M$0 .Y!H #N0C  WE+0 ,Y3< "^9"  KF3P )YUT ".=M  ;F@  %YI4 !.:K
M  +FQ  !YN8  .?Y  #G_P  YO\  .;_  #F_P"3H0  A:D  '>Q  !IN0
M6\   $[&  !!R@  -<X  "K2   AU@  &=L  !+?   -XP  "_$(  GS#@ '
M\Q, !/(:  +R(@  \BH  /(T  #R/P  \DP  /)<  #R;0  \H(  /*8  #S
MK0  \\8  /3E  #T]@  ]/L  /3[  #T^P"'J0  >;(  &JZ  !<P@  3LD
M $#.   STP  *-@  ![=   5X0  #^0   KH   %\P   _T!  #\"   ^PT
M /L1  #[%@  _!X  /PF  #\,   _3P  /Y)  #^6@  _FT  /^"  #_F
M_ZP  /_   #_V   _^0  /_D  #_Y ![L@  ;+L  %W$  !/S0  0-(  #+9
M   FW@  &^(  !+F   ,Z@  !>T   #T    _P   /\   #_    _P0  /\)
M  #_#@  _Q(  /\8  #_(0  _RL  /\W  #_1@  _U@  /]K  #_@   _Y4
M /^F  #_LP  _[L  /^[  #_NP#_&R8 _QPD /\:) #_%2< _Q M /\*-@#_
M!4, _P%0 ?\ 7@'_ &L!_P!V ?\ @0#_ (H _P"2 /\ F@#_ *  _P"F /\
MK #_ +( _P"Y /\ P@#_ ,T _P#? /\ [ #_ /@ _P#_ /T _P#] /\ _0#_
M /T _P#] /\ _0#_ /T _P#_'R, _Q\A /\>(0#_&2, _Q,I /\.,@#_#$
M_PE- ?\'6@'_!&<!_P-S ?\#?0'_ X<!_P./ /\"E@#_ IP _P*B /\"J #_
M J\ _P&V /\!O@#_ <D _P'; /\ Z@#\ /8 ^ #_ /<"_P#W _\ ]@3_ /8$
M_P#V!?\ ]@7_ /8%_P#_(A\ _R(< /\A' #_'A\ _Q@D /\5+P#_$CP _Q!)
M /\.5@'_#&(!_PMN ?\+>0'_"X(!_PN+ ?\+D@'_"ID!_PJ? /\*I0#_"JL
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M"+,RS FQ,N4)K3/U":LS_PFJ,_\(J#/_!Z@S_P>G,_\'IS/_!Z<S_P?_-P<
M_SH  /\^  #Z00$ \4$& /$_#0#F/!( VSH? - [,0#*/$  Q#Q- < \6 *\
M.V$#N3MJ!;8Z<@:T.GH'LCF!"+ YB FO.9 *K3B8"JLXH0NI.*H,J#BV#:8X
MQ0VD.-X.H3GQ#9\Z_PR>.O\+G3K_"IPZ_PF<.O\)G#K_"9PZ_PG_.P( _SX
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M&(%*]Q6 2O\2@$O_$(!+_P^ 2_\.@$O_#H!+_P[_0P  [$L  -U3  #.6
MQ%H  +U:  "X5P$ L50. *I6'@"E5BX GU8[ 9M51@.75% %DU-8")!27PJ-
M468,BU!M#HA/=!"&3WP2A$Z%$X).CA6 39D7?DVD&'Q-LAEZ3<,:>4W?&GA.
M]!=X3_\4>$__$GA0_Q!X4/\/>%#_#WA0_P_]1@  YT\  -97  #(7   OU\
M +=?  "Q7   JED, *1:&@">6RH F5LX 91:0P.064P%C%A5"(E77 J&5F,,
M@U5J#H%4<1!_4WD2?5.!%'I2BQ9X4I48=E&A&711KQMS4< ;<5';''%2\AEQ
M4_\5<53_$W)4_Q%R5/\0<E3_$')4_Q#S2   XU,  -!;  #$8   NF,  +-C
M  "L80  I%X) )U?%P"87R< DU\U 8Y>0 .*74H%AEQ2!X-;60J 6F ,?5EG
M#GM8;A!X6'42=E=^%'16B!=R5I,8;U:?&FY5K!ML5;T<:U;5'6M6\!IK5_\7
M:UC_%&Q8_Q)L6/\1;%C_$6Q8_Q'Q2P  WU8  ,Q>  # 9   MV<  *YH  "G
M9@  GV(& )AC% "29"0 C6,R 8EB/0*$84<$@6!/!WU?5@EZ7ET+=UUD#75<
M:Q!S7',2<%M[%&Y;A1=L6I 9:EJ<&VA9JAQF6KH=95K1'65:[AME6_X79EO_
M%69<_Q-G7/\29US_$F=<_Q+M3@  VED  ,AA  "\9P  LVH  *ML  "B:@
MF6<" ))G$0"-9R$ B&<O 81F.P)_940$>V1-!GAC5 EU8EL+<F%A#7!A:0]M
M8' 2:U]Y%&E?@Q=F7HX99%Z:&V)>J!QA7K@=7U[.'5]>[!M@7_T885__%6%?
M_Q-B7_\28E__$F)?_Q+J40  U%P  ,1D  "Y:@  L&X  *=P  ">;@  E&L
M (UJ$ "':QX @VLL 'YK. )Z:D(#=FE*!G-H4@AP9UD*;69@#6ME9P]H9&X1
M9F1W%&1C@19A8XP87V*8&EUBIAQ;8K8=6F+,'5IBZAQ;8_P87&/_%EQC_Q1=
M8_\376/_$UUC_Q/F50  SU\  ,%H  "V;@  K'(  *1T  ":<P  CF\  (=O
M#0"";QL ?7 I 'EO-0%U;C\#<FU(!6YL4 =K;%<*:6M>#&9J90YD:6P186EU
M$U]H?Q9<:(H86F>6&EAGI!Q69[0=56?*'55GZ!M69_L85V?_%E=H_Q189_\3
M6&?_$UAG_Q/A6   RV,  +UK  "R<@  J78  *!X  "6=P  B',  (%S"P!\
M=!< >'0F '1T,@%P<ST";7-&!&IR3@=G<54)9'!<"V%P8PY?;VH07&YS$EIN
M?!57;8@756R4&5-LHQM1;+,<4&S('$]LYQM1;/H846S_%5)L_Q12;/\34FS_
M$U)L_Q/<7   QV<  +EO  "O=@  I7L  )Q\  "1?   @G@  'IY!P!U>10
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M$T*#G11 @JX5/X/"%3Z"XA4_@?<3/X'_$D" _Q% @/\00(#_$$" _Q#&:P
MMW8  *Q_  "BA0  EXD  (R+  "!C0  <XX  &6/  !=CPD 6I 4 %B0(0!6
MD2T 4Y X 5&000).D$D#3)!0!$J/6 5'CV '18YI"4*.<PM C7\-/HV-#SR-
MG! ZC:P1.8W!$3B-X1 XB_80.(K_#SF)_P\YB?\..8G_#CF)_PZ_<@  LGT
M *>&  "<B@  D8X  (:1  !ZDP  ;94  %^7  !4F0$ 3YD/ $Z:&@!,FB<
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M B&RVP(AK_,#(*[_ R"M_P0?K/\$'ZS_!!^L_P2JBP  G9$  ).7  "'G
M>J(  &VG  !@JP  5:\  $FQ   ^M   ,[<  "JZ P DO T (KT5 "&](  A
MO2H (+TS !^^/0 >OD< ';Y2 !R_7@ :OVP &;]\ !B_C@ 7P*$ %L"V !3
MTP 5OO$ %;S_ 16[_P$4NO\"%+K_ A2Z_P*AD@  EI@  (J>  !]I   ;ZH
M &*O  !6M   2K<  #ZZ   SO0  *L   "'$   9QP4 $\L+ !',$@ 1S!L
M$,PE  _-+P .S3H #LU&  W-4@ -SF  #,YP  O.@P *SI< "<ZL  C.Q@ (
MSN@ ",W[  G+_P )R_\ "<O_  G+_P"8F   C9X  '^E  !QK   9+,  %>Y
M  !*O0  /L   #+#   HQ@  '\H  !?-   1T0  #-8%  C9#  &V1( !=H;
M  3:)  #VRX  =LY  #<10  W5(  -YB  #><P  WH@  -^=  #?LP  W\X
M .#N  #?^@  W_\  -__  #?_P"/GP  @:8  '.N  !EM0  6+T  $K"   ]
MQ0  ,<D  ";,   =T   %-0   [9   )W0   ^$   #C!P  XPT  .02  #E
M&0  YB(  .<K  #I-@  ZT,  .Q2  #L8@  [78  .Z,  #NH0  [[<  ._1
M  #OZP  \/8  /#V  #P]@"$IP  =:\  &>W  !9OP  2\8  #S*   OS@
M)-(  !K8   2W   #.    7C    YP   .L   #K    [04  .X+  #P$
M\14  /,>  #T)P  ]S,  /E   #Z40  ^V,  /QW  #]C0  _:,  /ZV  #^
MR0  _]\  /_?  #_WP!WL   :+D  %K!  !,R@  /,\  "[4   BV@  %]X
M !#B   )Y@   .D   #L    \    /8   #V    ]P   /@   #Z!P  ^PT
M /T1  #_&0  _R,  /\O  #_/@  _T\  /]B  #_=P  _XT  /^?  #_K@
M_[H  /^Z  #_N@#_%B, _Q4A /\2(0#_#B0 _P8J /\ ,P#_ $$ _P!. /\
M7 #_ &@ _P!T /\ ?@#_ (< _P"/ /\ E@#_ )P _P"B /\ J #_ *X _P"U
M /\ O0#_ ,< _P#6 /\ YP#^ /, _@#^ /T _P#\ /\ ^P#_ /L _P#[ /\
M^P#_ /L _P#_&B  _QD> /\6'@#_$"  _PHE /\$, #_ #T _P!+ /\ 6 #_
M &0 _P!P /\ >@#_ (, _P"+ /\ D@#_ )@ _P"> /\ I #_ *H _P"Q /T
MN0#[ ,, ^@#0 /@ XP#W /$ ]@#\ /0 _P#T /\ \P#_ /, _P#S /\ \P#_
M /, _P#_'1P _QP9 /\9&0#_%!L _PXA /\,+ #_"3D _P5& /\"4P#_ %\
M_P!K /\ =0#_ 'X _P"& /\ C@#_ )0 _@"; /P H0#Z *< ^ "N /4 M0#S
M +\ \0#+ /  WP#N .X [ #Y .L _P#J /\ Z@'_ .D!_P#I ?\ Z0'_ .D!
M_P#_(!< _Q\4 /\<$P#_%Q4 _Q8= /\3* #_$#0 _PU! /\,3@#_"5H _PAF
M /\(< #^!WD _ >! /H'B0#X!Y  ]@:6 /,&G0#Q!J, [P:J .T&L@#_XO__
M24-#7U!23T9)3$4 " GJ!KL Z ;( .8&W #D!NP X@CZ . *_P#>"_\ W0O_
M -T,_P#<#/\ W S_ -P,_P#_(Q( _R,0 /\A#@#_'A  _QX8 /\<(P#_&"\
M_Q0[ /\220#\$%4 ^ ]@ /0/:@#Q#W0 [PY\ .T.A #K#HL Z0Z2 .<.F0#F
M#J  Y ZG .(.KP#@#K@ W@[% -P.V@#6$.P TA'Z ,\2_P#-$O\!S!+_ <L3
M_P'*$_\!RA+_ <H2_P'_)P\ _R<, /\E"0#_)@T _R43 /\C' #_("@ ^QPU
M /4:0@#O&$\ ZA=: .8690#C%FX X!9W -X6?P#<%H< V1:. -86E0#4%IP
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M!*(L_P3_,@  _S,  /DX  #I.0  XCD  -XU!P#>+@T T2\; ,DQ+ ##,SL
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M#8D^LPV(/L0.AC_@#H0_] V#0/\+@T#_"H) _PF"0?\(@D'_"()!_PC_/
MZT,  -Q*  #,3P  PU   +Q.  "W20$ L48. *I(' "D22P H$DZ )M)10&8
M2$X"E$=7 Y)'7@6/1F4&C49L!XM%<PF)17L*AT2#"X5$C0R#1)<.@4.B#W]#
MKQ!^0\ 0?$3:$7M$\0]Z1?\->D;_"WI&_PIZ1O\)>D;_"7I&_PGU/@  YD@
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M%652Z11E4OL19E/_#V93_PUF4_\,9E/_#&93_PSJ20  U5,  ,5:  "Z7P
ML&(  *AB  "?7P  EEH  (]:$ "*6QX A5LL (%;. %]6T$">EI* W=9401T
M6%@&<5A?!V]79@EM5VT+:U9V#6E6?P]G58H19567$V-5I!1A5;058%7(%E]5
MYQ5@5OH28%;_#V%7_PYA5_\-85?_#&%7_PSG3   T58  ,%>  "V8P  K68
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M$%)B_PY28O\-4F+_#5)B_PW95@  Q&   +=H  "L;@  HW$  )IS  "/<0
M?VL  'AK!0!R:Q( ;FP? &ML+ !H;#<!9FQ  F-K2 -@:T\$7FI6!EQJ70=9
M:64)5VEM"U5I=PU3:((/4&B/$4YGG1--9ZP42VC %$MHWA1+9_423&?_#TQG
M_PY-9_\-36?_#4UG_PW26@  P&0  +-L  "I<@  H'8  )9W  "*=@  >7$
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M"SIZ_PO :0  LG0  *=\  "=@0  DH0  (>&  ![AP  ;H<  &"'  !5AP$
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M B>>D (FGJ$"))ZU B.>S@(CG>X#(YO^ R*:_P0BF?\$(IG_!"*9_P2L@0
MH(@  )6.  "+D@  ?Y8  '*:  !EG0  6:   $ZC  !"I   -Z8  "ZH!0 I
MJ0\ **D8 ">J(@ FJBP ):HU "2J/P CJD@ (JM3 "&K7@ @JVH 'JMY !VK
MBP ;JYT &JNQ !FKR@ 9JNP!&:C] 1BG_P(8IO\"&*;_ ABF_P*EB0  F8\
M (^4  "#F0  =9X  &BB  !<I@  4*D  $2L   YK@  +[   ":S   >M08
M&;</ !BW%P 7MR$ %K<J !6W-  4N#X $[A) !*X5  2N6( $;EQ !"Y@P /
MN9< #KFL  VYQ  -N.< #K;[  ZU_P .M/\ #K3_  ZT_P"<D   DI4  (:;
M  !YH   :Z8  %ZK  !2KP  1K(  #JU   OMP  );H  !V]   5P   $,,&
M  O&#@ *Q14 "<4>  C%*  'Q3( !L8]  7&20 %QE<  \9F  +&=P !QHL
M ,:@  #%M@  QM(  ,7O  #%_   Q?\  ,7_  #%_P"5E@  B9P  'NC  !M
MJ0  8*\  %.T  !&N   .KL  "Z^   DP0  &\0  !/'   .R@  ",X!  '0
M"@  T!   - 6  #1'@  TB<  -,Q  #4/   U4D  -98  #6:0  UGP  -:2
M  #6IP  UK\  -;@  #6\P  UOX  -;_  #6_P",G0  ?J0  &^K  !AL@
M5+D  $:]   YP0  +<0  "+'   9RP  $<X   S2   %U0   -L   #< P
MW0H  -X/  #?%   X1P  .(D  #D+@  YCH  .=)  #H60  Z&L  .F!  #I
MF   Z:T  .G%  #IX@  Z?(  .GU  #I]0" I0  <:T  &.U  !5O   1\(
M #G&   LR@  (,X  !;2   /U@  "-L   #?    XP   .4   #G    Z $
M .H'  #K#0  [1$  .\8  #Q(0  \RL  /8X  #W2   ^%H  /EM  #ZA
M^IL  /JO  #ZP@  ^MH  /K?  #ZWP!TK@  9;8  %:^  !(Q@  .<L  "O0
M   ?U   %-H   W?   %XP   .8   #I    [0   .\   #Q    \P   /4
M  #V @  ^ D  /H.  #]$P  _QP  /\H  #_-@  _T<  /]:  #_;@  _X4
M /^:  #_JP  _[D  /^\  #_O #_$2  _Q > /\,'@#_!"$ _P G /\ , #_
M #X _P!, /\ 60#_ &4 _P!P /\ >@#_ (, _P"+ /\ D@#_ )@ _P"> /\
MI #_ *H _P"P /\ N #_ ,( _P#. /\ X@#^ /  _0#[ /L _P#[ /\ ^P#_
M /H _P#Z /\ ^@#_ /H _P#_%!P _Q(: /\.&@#_"!P _P A /\ +0#_ #H
M_P!( /\ 50#_ &$ _P!L /\ =@#_ '\ _P"' /\ C@#_ )0 _P": /X H #]
M *8 _ "L /L M #Y +T ^ #) /< W #U .P \P#X /, _P#R /\ \0#_ /
M_P#P /\ \ #_ /  _P#_%Q@ _Q46 /\1%0#_#!< _P4= /\ * #_ #8 _P!#
M /\ 4 #_ %P _P!G /\ <0#_ 'H _ "" /H B0#X )  ]P"6 /4 G #T *(
M\P"H /$ L #P +@ [@## .P TP#J .< Z0#U .< _P#F /\ Y0#_ .4 _P#E
M /\ Y0#_ .4 _P#_&A, _Q@1 /\4$ #_#Q$ _PT9 /\*) #_!3  _P$^ /\
M2P#_ %< _@!B /H ; #U '4 \@!] /  A #N (L [ "1 .L EP#I )X YP"D
M .8 K #D +0 X@"_ .  S0#> ., W #R -H _0#8 /\ U@#_ -4!_P#5 ?\
MU0+_ -4"_P#_'A  _QP- /\7"P#_%0X _Q05 /\1'P#_#BH _PLX /T(10#X
M!E$ ] 1< .X$9@#J!&\ Y@-W .0$?P#B!(8 X 2, -X$DP#=!9H VP6@ -@%
MJ #5!;$ T@6[ - &R0#.!^  S CQ ,D*_P#'"_\ Q@S_ ,4,_P#%#/\ Q0S_
M ,4,_P#_(0P _R & /\< P#_'0H _QL0 /\8& #_%", ]A$P .\./@#J#DH
MY0U6 .$-8 #=#6D V0UQ -4->0#3#8$ T0V( ,\-CP#-#I8 RPZ= ,H.I0#(
M#JX Q@^Y ,00R #"$-\ OA'R +L2_P"Y$_\ MQ/_ ;83_P&V$_\!MA/_ ;83
M_P'_)08 _R,  /\C  #_) , _R$* /T=$0#Q&AL Z!8G .$4-0#:$T, TQ1/
M ,X560#+%6, R!9K ,46<P##%WL P1>" , 8B0"^&)  O!B8 +L9H "Y&:D
MMQFT +4:P@"T&M8 L!OM :T<_ &K'?\!J1W_ :D=_P&H'?\!J!W_ :@=_P'_
M*   _R<  /XJ  #O*@  YR<! .<B"0#D'1  V1L= ,\=+0#)'CP Q"!) +\@
M4P"\(5T N2%E +<B;0"U(G0 LR)\ +$B@P&P(HH!KB*2 :PCFP&K(Z0!J2.O
M :<CO &F),X!HR3H J E^0*>)?\"G27_ IPE_P*;)?\"FR7_ ILE_P+_+
M_RT  .TR  #B-   VC,  -,N P#2)0H R247 ,$G)P"[*38 MBI# +(K3@"O
M*U< K"M@ *HK9P&H*V\!IBMV :0K?0&C*X0"H2N- I\KE0*>*Y\"G"NJ YHK
MM@.9+,<#ERSB Y0M]022+?\#D2W_ Y N_P.0+?\#D"W_ Y M_P/_,   \C,
M .0Z  #6/0  S#P  ,<Y  ##,04 O2X1 +4P(0"P,C  JS,] *<S20"D,U(
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M2@  O$L  +5)  "O0P  J3X+ *(_%P"=0"8 F$$T )1!/P"104D!CD%1 8M
M60*)0& #AT!G X4_;02#/W4%@3]]!G\^AP=]/I$(>SZ<"7H^J0EX/K@*=S_-
M"G4_Z@IT0/P(=$#_!W1 _P9S0/\&<T#_!G- _P;Q.P  WT4  ,Q,  "_3P
MME   *Y/  "G2@  H$0' )I%% "51B( D$8P (Q'/ ")1D4!AD9. 8-&50*!
M15P#?D5C!'Q$:@1Z1'$%>41Y!G=$@@AU0XT)<T.9"G%#I@MP0[4,;D3)#&U$
MYPQM1?H*;$7_"&Q%_P=L1?\';$7_!VQ%_P?L/P  V$D  ,=0  "[5   L54
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M"EM2_PE;4?\(6U'_"%M1_PC?2@  R5,  +M:  "P7P  IF$  )UA  "47@
MB%<  (!6"@!Z5Q4 =E<B '-8+@!P5SD ;5=! 6I720)H5E "9E97 V167@1B
M564%8%5M!UY5=PA<58(*6E6.#%E5G U75:L.5E6^#U55VP]55?,-557_"U95
M_PE65?\)5E7_"%95_PC;30  Q5<  +A>  "M8@  HV4  )IE  "08P  @UP
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M"$=B_PC*6   NF(  *YI  "C;@  FG$  )!R  "$<0  =&L  &EI  !C:0L
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M!3AXD08W>*$'-7BS!S1XRP<T=^L'-';]!S1U_P<U=?\&-73_!C5T_P:Y:
MK7$  *)Y  "8?@  C8   (*!  !V@@  :8$  %N!  !1@0  2( * $6!$P!#
M@1X 0H(I $&",@! @CL /H)# #V"2P [@E,!.8)< 3>"9@(U@G$#,X)_ S&!
MC@0P@9\$+H&Q!2V!R 4M@>D$+7_\!2U^_P4M??\%+7W_!2U]_P6S;@  J'@
M )U_  "2@P  B(8  'V'  !PB   8XD  %6*  !+B@  08H" #N+#@ YBQ<
M.(PB #>,+  VC#4 -(P] #.,1@ RC4\ ,8U8 "^-8@$MC&X!*XQ[ 2J,BP(H
MC)P")HRO B6,Q@(EB^@")8K[ R6(_P,EB/\#)8?_ R6'_P.M=@  HX   )>%
M  "-B0  @HP  ':.  !ID   7)(  %"3  !$E   .I4  #&6"  MEQ$ +)<:
M "N7)  JERT *9<V "B8/P GF$@ )IA2 "687  CF&@ (IAW ""8AP ?F)D!
M'9BL 1R8PP$<E^4!')7Z 1N4_P$;D_\"&Y/_ AN3_P*G?P  G(8  )&+  "'
MCP  >I(  &V5  !AF   59L  $F=   ]G@  ,Y\  "JA   AHPH 'Z,1 !ZC
M&@ =I"0 '*0M !ND-@ :I#\ &:1* !BD50 6I6$ %:5P !2E@0 3I90 $J6H
M !&EOP 0I.( $:+X !&A_P 1H/\!$:#_ 1&@_P&@A@  E8P  (R1  !_E0
M<9H  &2>  !8H0  3*0  $"F   UIP  *JD  "*L   9K@  $K ) !"Q$  0
ML1@ #K$B  ZQ*P -L34 #;%   RQ2P +L5@ "K%G  BQ>  'L8L !;&@  2P
MM0 $L-  !+#O  6O_@ &KO\ !J[_  :N_P"8C@  CY,  (*8  !UG0  9Z(
M %JG  !.JP  0:T  #6O   KL0  (;0  !BV   1N0  #;P#  >^#  #O1(
M ;T9  "^(@  OBL  +XV  "^00  OTX  +]<  "_;0  OX   +Z5  "^J@
MOL(  +WD  "]]@  O?\  +W_  "]_P"2E   A9H  'B@  !JI@  7*L  $^P
M  !"LP  -;8  "JX   @NP  %[X  !#!   +Q   !,<   #)!P  R0T  ,D2
M  #*&0  RR(  ,LK  #--0  SD$  ,Y0  #/8   SW(  ,^'  #/G0  S[,
M ,_.  #/ZP  SO@  ,[^  #._@"(FP  >J(  &RH  !>KP  4+4  $*Y   U
MO   *;\  !["   5Q@  #LD   C,    T    -,   #5    U@8  -@,  #9
M$0  VQ8  -P?  #>*   X#0  .)!  #B40  XV,  .-W  #DC@  Y*0  .2Z
M  #EU   Y>H  .7S  #E\P!\HP  ;JH  &"R  !1N0  0[X  #7"   HQ@
M',D  !/-   ,T0  !-4   #:    W@   .$   #B    Y    .4#  #G"0
MZ0X  .L2  #M&@  [R0  /(Q  #T00  ]%,  /5F  #U?   ]I,  /:I  #W
MO   ]\X  /??  #WWP!PK   8;0  %.[  !%PP  -L<  "?,   ;T   $=4
M  K;    WP   .(   #E    Z0   .P   #M    \    /$   #S    ]00
M /<*  #Z$   _!8  /\A  #_+@  _T   /]3  #_:   _X   /^6  #_J
M_[8  /^_  #_OP#_#1P _PH; /\"&P#_ !X _P D /\ +@#_ #P _P!* /\
M5@#_ &, _P!M /\ =P#_ '\ _P"' /\ C@#_ )0 _P": /\ H #_ *8 _P"L
M /\ M #_ +T _P#) /X W0#] .T _ #Z /L _P#Z /\ ^0#_ /H _P#Z /\
M^@#_ /H _P#_$!D _PT7 /\&%@#_ !@ _P > /\ *@#_ #< _P!% /\ 4@#_
M %X _P!I /\ <@#_ 'L _P"" /\ B0#_ )  _@"6 /T G #\ *$ ^P"H /D
MKP#X +@ ]@## /0 T@#S .< \@#V /  _P#O /\ \ #_ .\ _P#O /\ [@#_
M .X _P#_$A0 _P\2 /\+$@#_ !( _P : /\ )0#_ #, _P!  /\ 30#_ %D
M_P!D /T ;0#[ '8 ^0!] /< A #U (L ] "1 /, EP#Q )T \ "C .X J@#L
M +, Z@"] .@ RP#G .$ Y0#Q ., _0#C /\ X@#_ .$ _P#A /\ X #_ .
M_P#_%!  _Q$. /\-#0#_!P\ _P(5 /\ ( #_ "T _P Z /\ 1P#Y %, ]0!>
M /( : #P '  [0!X .L ?P#I (4 Z ", .8 D@#E )@ XP"? .$ I@#? *X
MW "X -H Q0#6 -D U #L -( ^0#1 /\ SP#_ ,X _P#. /\ S@#_ ,X _P#_
M%PP _Q0( /\/!0#_#@L _PP1 /\'&@#_ 28 _  T /0 00#M $T Z0!8 .8
M8@#C &H X !R -X >0#; (  V0"& -8 C0#3 ), T0": ,\ H0#- *H RP"S
M ,D OP#& -  Q0#H ,, ]@#! /\ P +_ +\#_P"_ _\ OP/_ +\#_P#_&P8
M_Q<  /\4  #_$P4 _Q$- /\.% #Y"A\ \ 8L .8#.0#@ T8 W -1 -8$6P#2
M!&0 SP5L ,P%<P#*!7H R 6! ,8%AP#%!HX PP:6 ,$&G0"_!J8 O0:P +L'
MO "Y",T N KE +4+]P"S#?\ L0W_ + -_P"P#O\ KP[_ *\._P#_'@  _QL
M /\;  #Z&@  ]18% /81#0#K#A4 X@LB -@+,0#0##X RPU* ,<-50#$#EX
MP0YF +\.;0"]#G0 NP][ +D/@@"W$(H MA"1 +00F@"R$*, L!&M *\1N@"M
M$<H JA+E *<4]P"E%?\ HQ7_ *(5_P"B%?\ HA7_ *(5_P#_(@  _R   / C
M  #F)   X"$  -P9!0#;$ P T!$9 ,@3*0#"%3< O19$ +D73@"U%U< LQA@
M + 89P"N&&X K!EU *L9? "I&80 J!J, *8:E "D&IX HQNH *$;M "?',4
MGAS? )H=\P&8'O\!EQ[_ 98?_P&5'_\!E1__ 94?_P'_)@  ]"<  .8M  #:
M+P  SRT  ,HG  #''P@ P1P3 +H>(@"T'S$ KR ] *LA2 "H(E( IB): *,C
M8@"A(VD H"-O )XC=P"<(WX FR.& )DDCP&7))D!EB2C 90DL &2);\!D276
M 8XF[P&,)_\"BR?_ HHG_P*))_\"B2?_ 8DG_P'Z*0  [#   -TV  #-.
MQ#<  +XR  "Z*P( M24. *XG'0"H*2L I"HX * J0P"=*TP FBM5 )@K7 "6
M*V, E"MJ 9(K<0&0+'@!CRR! 8TLB@&++)0"BBR? H@LJP*&++H"A2W. X,N
MZ@.!+OP#@"[_ G\N_P)_+O\"?B[_ GXN_P+T+@  Y#<  -(]  #%/P  NS\
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M!69 _P1F0/\$9C__!&8__P3E/0  ST8  +],  "T3P  JE   *)/  "92@
MD40  (I!#0"$0AD @$,F 'U$,@!Z1#P =T1$ '5$3 %R1%,!<$-9 6]#8 )M
M0V<":T-O VE#>01H0X,%9D./!F1#G0=C0ZL'84.]"&!$V0A@1/,'8$3_!E]$
M_P5?1/\$8$3_!&!$_P3@00  RDH  +M0  "P4P  IU4  )Y3  "53P  BTD
M (-'"P!]1Q4 >4<B '9(+@!S2#@ <4A! &Y(20%L2% !:DA6 6A(70)F1V0"
M94=L V-'=@1A1X %8$>-!EY'F@=<1ZD(6TB["%I(U A:2/$'6DG_!EI)_P5:
M2/\%6DC_!%I(_P3;1   QDT  +A3  "M5P  HUD  )I8  "15   ADX  'U+
M" !W2Q( <TP? '!,*P!M3#4 :TP^ &A,1@!F3$T!9$Q3 6),6@)A3&("7TQJ
M UY,<P1<2WX%6DN*!EA+F =73*<(5DRY"55,T0E43.\(5$W_!E5,_P953/\%
M54S_!55,_P752   PE$  +57  "J6P  H%P  )=<  "-60  @5,  '=/! !Q
M3Q  ;E < &I0* !H4#( 95 [ &-00P!A4$H!7U!1 5U06 )<4%\"6E!G UA0
M<0174'L%55"(!E-0E@=24*4(4%"W"5!0S@E/4.T(4%#_!U!0_P904/\%4%#_
M!5!0_P702P  OU0  +):  "G7@  G6   )1@  ")70  ?%<  ')4  !L4PX
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M!41=D 9#7J '05ZQ!T!>R = 7N@'0%W\!D%=_P5!7?\%05S_!4%<_P7#5@
MM%\  *AF  ">:@  E6T  (IM  !_;   ;V<  &1D  !;8@4 5F(0 %1B&P!2
M8R4 4&,O $YD. !-9$  2V1( $ID3P%(9%<!1F1? D5D: )#9',#06-_!#]C
MC@4]8YX&/&.P!CMDQ@8[9.8&.V/Z!3MB_P4[8O\%/&'_!#QA_P2^6P  L&,
M *5J  ";;P  D7(  (9R  ![<0  ;&T  &!K  !5:0  3V@- $UI%P!+:2$
M26HK $AJ- !':CT 16M$ $1K3 !":U0!06M< 3]J90(]:G ".VI] SEJC 0W
M:IP$-FJN!35JQ 4U:N4%-6GY!#5I_P0U:/\$-6C_!#5H_P2Y8   K&D  *%P
M  "8=0  C7<  ()W  !W=P  :70  %QS  !1<0  2' * $5P$@!#<1T 0G$G
M $!R,  _<C@ /G)  #UR2  [<E  .G)9 3AR8P$V<FT"-')Z C-RB0,Q<IH#
M+W*L RYRP0,N<N,#+G'X RYP_P,N;_\#+F__ RYO_P.S9@  IV\  )UV  "3
M>@  B'P  'Y]  !R?0  9'P  %=[  !,>@  0GD# #QY#@ Z>A< .7HA #AZ
M*@ W>S, -GL[ #1[1  S>TP ,GM5 #![7P O>VH!+7MW 2M[AP$J>Y@"*'NJ
M B=[OP(F>^$")GKW B9X_P(F>/\")W?_ B=W_P*N;   HW8  )E\  ".?P
MA((  'B#  !LA   7X0  %&$  !'A   /(0  #.$"0 PA!$ +X0: "V$)  L
MA2T *X4U "J%/@ IA4< *(90 ">&6@ FAF8 )(9S ".&@P AAI4 ((:G 1Z&
MO $>AMX 'H3U 1Z"_P$>@O\!'H'_ 1Z!_P&H=   GGT  )."  ")A0  ?H@
M '&*  !EBP  6(P  $R-  ! C@  -HX  "R/   ED P (Y 3 "*0'  AD"4
M()$N !^1-@ >D4  '9%) !R15  :D6  &9%N !B1?@ 6DI  %9*D !21N0 3
MD=@ $X_T !2._P 4C?\ %(S_ 12,_P&C?0  F(,  (Z(  "$C   =X\  &F1
M  !=DP  4)4  $67   YF   +ID  "6:   =FP( %IT, !6=$P 4G1L $YTD
M !*=+0 1GC< $9Y! !">3  /GE@ #IYG  V>=P ,GHH "YV>  J=L@ )G<P
M"9SL  J;_@ +FO\ "YG_  N9_P"<A   D8H  (B.  ![D@  ;98  &"9  !4
MG   2)\  #R@   PH0  )J,  !VE   5IP  $*D%  NK#0 (JA, !ZH;  :J
M)  %JBX !*HX  *J1  !JE   *I>  "J;@  JH$  *J5  "IJ@  J<$  *CD
M  "H]@  I_\  *?_  "G_P"5BP  C)   '^5  !QF@  8YX  %:B  !*I@
M/:@  #&J   FJP  ':T  !2P   .L@  ";4!  *V"@  M@\  +85  "W'0
MMR4  +<O  "X.0  N$8  +A4  "X9   N'8  +B+  "WH   M[8  +?3  "V
M[P  MOP  +;_  "V_P"/D@  @I<  '2=  !FH@  6*<  $NL   ^KP  ,;$
M ":S   <M@  $[@   V[   &O@   ,$   #"!   P@L  ,,0  #$%0  Q!P
M ,4D  #&+@  R#H  ,E'  #)5P  R6D  ,E]  #)E   R*H  ,C#  #(Y
MR/0  ,C]  #(_0"%F0  =Y\  &BF  !:JP  3;$  #^U   QN   );H  !J]
M   1P   "\,   /'    R@   ,T   #.    SP,  - )  #1#@  TQ(  -49
M  #7(@  VBT  -TY  #>20  WEH  -]N  #?A0  WYP  -^R  #>RP  WN8
M -_T  #?] !YH0  :Z@  %RO  !.M0  0+L  #&^   DP0  &<4  !#(   )
MS    ,\   #3    V0   -P   #=    WP   .$   #B!0  Y L  .80  #H
M%@  ZB   .TK  #P.@  \4L  /%>  #R<P  \XL  /.B  #SM@  \\D  //A
M  #SX0!MJ@  7K$  %"Y  !!OP  ,L0  "3(   7S   #M    ;5    V@
M -X   #B    Y@   .D   #J    [    .X   #P    \@   /0&  #V#
M^1(  /P<  #_*0  _SH  /]-  #_8@  _W@  /^0  #_HP  _[,  /_!  #_
MP0#_!QD _P$7 /\ %P#_ !H _P A /\ *P#_ #D _P!' /\ 5 #_ %\ _P!J
M /\ <P#_ 'L _P"# /\ B@#_ )  _P"6 /\ FP#_ *$ _P"H /\ KP#_ +@
M_P#$ /X U0#\ .H ^P#X /H _P#Y /\ ^ #_ /@ _P#V /\ \P#_ /$ _P#_
M"Q4 _P43 /\ $P#_ !0 _P : /\ )P#_ #0 _P!" /\ 3P#_ %L _P!E /\
M;@#_ '8 _P!^ /\ A0#^ (L _0"1 /L EP#Z )T ^ "C /< JP#V +, ] "^
M /, S #Q ., [P#S .X _P#M /\ [ #_ .L _P#L /\ [ #_ .L _P#_#1$
M_PD0 /\ #P#_ !  _P 6 /\ (@#_ "\ _P ] /\ 2@#_ %4 _0!@ /H :0#X
M '$ ]@!Y /0 ?P#S (8 \0", .\ D@#N )@ [ "? .L I@#I *X YP"X .4
MQ0#C -H X0#M -\ ^P#> /\ W0#_ -T _P#= /\ W0#_ -T _P#_#PT _PP+
M /\#"0#_  P _P 2 /\ '0#_ "D ^P W /@ 1 #U %  \@!: .X 8P#L &L
MZ0!S .< >@#E (  XP"& .$ C #? ), W0"9 -L H0#9 *D U0"R -( O@#0
M ,X S@#F ,P ]@#* /\ R@#_ ,D _P#( /\ R #_ ,@ _P#_$0@ _PT" /\'
M  #_!0@ _P . /\ %@#W "( [P P .L /0#H $D Y !4 .  70#= &4 V0!M
M -4 <P#2 'H T "  ,X AP#, (T R@"4 ,@ FP#& *0 Q "M ,( N #  ,<
MO0#? +P \0"[ /X N0#_ +@ _P"X /\ N #_ +@ _P#_%   _P\  /\-  #_
M#   _P<) /@!$ #H !H XP H -T -@#8 $( T@!- ,X 5P#* %\ QP!F ,4
M;0## '0 P0!Z +\ @0"] (@ NP"/ +D EP"W )\ M0"H +, LP"Q ,( KP#8
M *X"[0"L _L JP7_ *H&_P"I!O\ J0;_ *D&_P#_%@  _Q(  /<2  #L$0
MY@X  .4&" #= Q( U ,@ ,T$+0#(!#H PP5& +\%4 "\!E@ N09@ +<'9P"U
M!VX LP=U +$(>P"O"(( K@F* *P)D@"J"9L J JE *8*L "E"[\ HPS4 *$-
M[0"?#OX G0[_ )P/_P";#_\ FP__ )L/_P#_&@  ]QD  .H>  #?'@  U1H
M - 3 @#.# L QPL6 , -)0"Z#C( M@X_ +(/20"O$%( K!!: *H080"H$6@
MIA%O *01=@"B$7T H1&% )\2C@"=$I< G!*B )H3K0"8$[P EQ30 )05[ "2
M%OT D!?_ (\7_P".%_\ CA?_ (X7_P#Z'0  [B,  -\H  #0*@  QR<  ,$A
M  "]&04 N1(0 +(5'@"M%BP J!<X *080P"A&4P GQE4 )P:7 ":&F( F1II
M )<;< "5&W< E!M_ )(<B "0')( CQR= (T=J0"+';< BA[* (@?YP"&(/H
MA"#_ 8,@_P&#(/\!@B#_ 8(@_P'U)   Y2P  -,Q  #&,P  O#$  +8M  "P
M)0  K!T, *8>& "A("8 G"$R )DB/0"5(D< DR-/ )$C5@"/(UT C21D (LD
M:P"))'( B"1Z (8D@P"$)8T @R68 8$EI & )K(!?B;% 7TGX@%[)_<!>2C_
M 7@H_P%X*/\!>"C_ 7@H_P'O*P  W3,  ,HY  "^.P  M#H  *TV  "F+P
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M ED^_P+6/P  PT<  +5,  "J4   H%   )=/  ".2P  A$4  'I !@!U/Q$
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M TY*CP-,2Y\$2TNP!$I+Q01)2^8$24OZ!$E+_P-*2_\#2DO_ TI+_P/(20
MN%$  *Q7  "A6P  F%P  (Y<  "#60  =E,  &M.  !D30H 7TP3 %Q-'@!:
M32@ 6$TQ %9-.@!434$ 4TY( %).3P!03E<!3TY? 4U.: %,3G,"2D]_ DE/
MC0-'3YT$1D^N!$5/PP1$4.0$1$_Y!$5/_P-%3_\#14[_ T5._P/$3   M54
M *E;  "?7@  E6   (M@  " 7@  <E<  &=3  !>40< 65$1 %=1&P!4424
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M S5>O0,T7]T#-%[U S5=_P(U7?\"-5S_ C5<_P*X60  JF$  *!G  "6;
MC&X  (%N  !V;   9VD  %QF  !19   2&() $1B$0!"8AL 06,D #]C+0 ^
M8S4 /60] #QD10 [9$T .615 #AD7P V9&D!-61V 3-DA0$Q994",&6G B]E
MNP(N9=H"+F3T BYC_P(O8_\"+V+_ B]B_P*S7@  IV8  )QM  "3<0  B',
M 'US  !R<@  9'   %AN  !-;   0FH# #QI#@ Z:A8 .6H@ #AJ*  V:S$
M-6LY #1K00 S;$D ,FQ2 #%L7  O;&8 +FQS "QL@@$J;),!*6RE 2ALN0$G
M;=8!)VOR 2=J_P$G:O\!*&G_ BAI_P*N9   HVP  )ES  ".=@  A'@  'EY
M  !M>   8'<  %-V  !(=0  /G,  #1R"@ Q<Q$ ,',: "]S(P N<RL +70T
M "QT/  K=$0 *71- "AU5P G=6, )75O "1U?P B=9  (76B "!UMP ?==(
M'W3Q !]S_P$?<O\!(''_ 2!Q_P&I:P  GG,  )1Y  "*?   @'X  '1_  !G
M?P  6G\  $U^  !#?@  .'T  "]] @ H?0T )GT4 "1]'  C?B4 (GXM "%^
M-@ A?C\ 'W]( !Y_4@ =?UX '']K !I_>@ 9?XP %W^? !9_LP 5?\X %7[O
M !9\_P 6>_\ %GO_ !=[_P"D<@  FGH  (]_  "%@@  >X0  &V&  !@AP
M5(<  $B(   \B   ,H@  "B(   @B 4 &HD. !F)%0 8B1T %XHF !:*+@ 5
MBC< %(I! !.*3  2BU@ $8ME !"+=0 /BX< #HJ;  V*KP ,BL@ #(GJ  V'
M_  .A_\ #H;_  Z&_P"?>P  E($  (J%  " B   <XL  &6-  !9CP  3)
M $&2   TD@  *I(  "&3   9E   $I8&  Z7#@ -EQ4 #)<=  R7)@ +ER\
M"I<Y  F71  (EU  !I=>  67;@ #EH   9:4  "5J   E;X  )3@  "4]
MD_\  9+_  &2_P"8@@  CH@  (6,  !WCP  :I(  %V5  !0F   1)H  #B;
M   LG   (IT  !F>   2H   #:("  >C"P !HQ   *,7  "C'P  HR<  *,Q
M  "D/   I$@  *16  "D90  HW<  *.+  "CH   HK8  *'2  "A\   H/L
M *#_  "@_P"1B@  B8X  'N2  !MEP  8)L  %.>  !&H0  .:,  "VD   C
MI@  &:@  !&J   ,K   !:X   "O!P  KPT  *\1  "P&   L"   +$H  "Q
M,@  LCX  +),  "R6P  LFP  +*!  "QEP  L:P  +#&  "PZ   K_<  *__
M  "O_P",D   ?Y4  '&:  !CGP  5:0  $>H   ZJ@  +:P  "*N   8L
M$+,   JU   "N    +L   "[    O <  +P-  "]$0  OA8  +\>  # )P
MP3(  ,)   ##3P  PV   ,-T  ##BP  PZ$  ,.X  #"UP  PN\  ,+Z  #!
M_@"!EP  <YT  &6C  !7J   2:T  #NQ   MLP  (;8  !:Y   .NP  ![X
M  #!    Q0   ,<   #(    R0   ,H%  #+"P  S0\  ,X4  #0'   TR8
M -8R  #800  V%,  -EF  #9?   V90  -FK  #9PP  V>$  -GP  #9] !V
MGP  9Z8  %FL  !+L@  /+<  "ZZ   AO0  %<    W$   %QP   ,H   #.
M    T@   -4   #6    V0   -L   #=    WP<  .$,  #C$0  YAD  .DD
M  #L,@  [4,  .Y6  #O:P  [X0  .^<  #OL@  [\8  ._=  #OY !JJ
M6Z\  $RV   ^O   +\   "#$   4R   #,P   +0    U    -D   #>
MX@   .4   #F    Z    .D   #L    [@   / "  #R"0  ]0\  /@7  #\
M(P  _S,  /]&  #_6@  _W$  /^)  #_GP  _[$  /_   #_Q@#_ !4 _P 4
M /\ % #_ !< _P = /\ * #_ #< _P!$ /\ 40#_ %P _P!F /\ ;P#_ '<
M_P!^ /\ A0#_ (L _P"1 /\ EP#_ )T _P"D /\ JP#_ +0 _@"_ /T S@#[
M .8 ^0#V /@ _P#W /\ ]P#_ /< _P#P /\ [ #_ .D _P#_ Q( _P 0 /\
M$ #_ !$ _P 7 /\ ) #_ #( _P _ /\ 3 #_ %< _P!A /\ :@#_ '( _P!Y
M /T @ #\ (8 ^@", /D D@#X )@ ]@"? /4 I@#T *X \@"Y /  Q@#N -X
M[0#P .L _@#J /\ Z0#_ .D _P#G /\ XP#_ .  _P#_!PX _P - /\ "P#_
M  P _P 3 /\ 'P#_ "P _P Z /\ 1@#^ %( ^P!< /@ 90#U &P \P!T /$
M>@#O ($ [@"' .P C0#J ), Z0": .< H0#F *D XP"S .$ OP#? -  W0#I
M -H ^0#9 /\ UP#_ -4 _P#5 /\ U0#_ -0 _P#_"0H _P$% /\  P#_  D
M_P 0 /\ &0#[ "8 ]P T /0 0 #R $P [@!6 .H 7P#G &< Y !N .( = #@
M 'L W@"! -P AP#: (T U@"4 -0 FP#1 *, SP"M ,P N #* ,< R #@ ,8
M\P#% /\ PP#_ ,, _P## /\ PP#_ ,, _P#_"P$ _P,  /\   #_  , _P +
M /, $@#N !\ Z@ M .8 .@#B $4 W@!/ -D 6 #4 &  T0!H ,X ;@#, '0
MR@![ ,@ @0#& (< Q ". ,( E@#  )X O@"G +L L@"Y ,  MP#4 +4 [ "S
M /L LP#_ +( _P"R /\ L0#_ +$ _P#_#0  _P8  /\#  #W    ]  # .<
M#0#@ !@ V@ E -, ,@#. #X R@!) ,8 4@## %H P !A +X : "\ &X N@!T
M +@ >P"V ($ M "( +( D "P )D K@"B *P K0"J +H J #+ *8 Y@"E /<
MI #_ *, _P"B /\ H@#_ *( _P#_$   ^PP  .\.  #F#0  WPD  -H !@#0
M !$ R0 = ,0 *@"_ #< NP!" +< 2P"T %0 L@!; *\ 8@"M &@ JP!N *D
M=0"H 'L I@"# *0 BP"B )0 H "> )X!J "< K4 FP/& )D%X@"8!O0 E@C_
M )4)_P"4"?\ E G_ )0)_P#\$0  \14  .,9  #6&0  S!4  ,<0  #$!PH
MO0,4 +<$(0"R!BX K@@Z *H)1 "G"4T I I5 *(*7 "@"F( G@MI )P+;P";
M"W8 F0Q^ )<,A@"6#)  E R: )(-I@"1#;, CPW% (T.X@"+$/8 B1#_ (@1
M_P"'$?\ AQ'_ (<1_P#V&0  YR   -8D  #()0  OR(  +D<  "T% $ L0T.
M *H.&0"E#R< H1 S )T1/@":$4< F!)/ )425@"3$EP D1)C ) 3:0".$W
MC!-X (L3@0")%(L AQ26 (85H@"$%;  @Q;! ($7W0!_&/0 ?1G_ 'P9_P!\
M&?\ >QG_ 'L9_P#O(0  W2D  ,HM  "^+P  M2P  *XG  "H(   HQ<( )X6
M$P"9%R$ E!DM )$:. ".&D$ BQM) (D;4 "'&U< A1Q> (0<9 ""'&L @!QS
M '\=? !]'88 ?!Z1 'H>G@!X'ZL =Q^\ '8@U !T(?  <B'_ '$B_P!Q(?\
M<2'_ '$A_P#H*   TC   ,(U  "W-P  K34  *4Q  ">*P  F"," )(>$ "-
M(!L B2$G (8B,@"#(SP @2-$ 'XC2P!\)%( >R19 'DD7P!W)&8 =B5N '0E
M=P!S)8$ <2:- &\FF0!N)J< ;2>X &PGS@%J*.T!:2G_ 6@I_P%H*?\!:"C_
M 6@H_P'A+@  RS8  +P[  "Q/0  IST  )\Y  "7,P  CRT  (@G# "#)Q8
M?R@B 'PI+0!Y*C< =RH_ '4J1P!S*TX <2M4 ' K6P!N*V( ;"MJ &LL<@!I
M+'T :"R) &8ME@%E+:0!9"ZT 6,NR@%A+^D!8"_] 6 O_P%@+_\!8"__ 6 N
M_P':-   Q3P  +=!  "L0P  HD,  )E   "0.@  B#0  ( N" !Z+1( =RX>
M ',O*0!Q,#, ;S [ &TP0P!K,4H :3%1 &<Q5P!F,5X 9#%F &,R;P!A,GD
M8#*% 5\RD@%=,Z$!7#.Q 5LTQ@%:-.8!637[ 5DU_P%9-/\!633_ 5DT_P'2
M.   P$   +-%  "H2   GD@  )5&  "+0   @CL  'DU! !S,Q  ;S0: &PT
M)0!I-2\ 9S4W &4V/P!C-D8 8C9- & V5 !?-EL 73=C %PW:P!;-W8!63>"
M 5@XCP%6.)X!53BO E0YPP)3.>0"4SKY 5,Y_P%2.?\!4SG_ 5,Y_P'-/
MO$0  *])  "D3   FDP  )%+  "'1@  ?4   ',[  !L. T :#D7 &4Y(@!C
M.BL 8#HT %XZ/ !=.D, 6SI* %H[4 !8.U@ 5SM@ %8[: !5/',!4SQ_ 5(\
MC0%0/9P!3SVL DX^P0)-/N$"33[X DT^_P%-/O\!33W_ 4T]_P')0   N$@
M *Q-  "A4   EU$  (Y/  "$2P  >44  &Y   !F/0L 8CT4 %\]'@!</B@
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M C]*NP(^2]@"/DKS CY*_P(^2?\!/TG_ 3])_P&]2@  KU(  *-8  "96P
MD%T  (9<  ![60  ;5,  &)/  !73 $ 44H- $Y*%0!,2Q\ 2DLH $E+, !'
M2S@ 1DP_ $5,1@!$3$X 0TU6 $)-7P! 36H /TUV 3U.A $\3I0!.TZE 3E/
MN0(Y3]0".4_R 3E._P$Y3O\!.4W_ 3I-_P&Z3@  K%8  *%;  "77P  C6$
M (-A  !X7@  :5@  %]6  !44@  3$\+ $E/$@!'4!P 15 E $-0+0!"4#4
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M 2=>_P$G7?\!*%W_ 2A<_P&M7   HF0  )AJ  ".;@  @V\  'EO  !N;@
M8&L  %1I  !)9P  /V4  #5C"0 R8Q$ ,&,9 "]D(0 N9"D +60Q "QD.0 K
M94( *F5* "AE5  G95\ )F9K "1F>@ C9HL (F:= "!FL0 ?9LD 'V;K "!E
M_@ @9/\ (&/_ 2%C_P&I8@  GFH  )5P  "*<P  @'4  '5U  !I=   7'(
M $]Q  !$;P  .FX  #!M P I; T )VP4 "9L'  E;20 )&TL "-M-  B;3T
M(6Y& "!N4  >;EL '6YG !QN=@ :;H< &6^: !AOK@ 6;\8 %F[I !=M_  8
M;/\ &&O_ !AK_P"D:0  FG$  )!V  "&>0  ?'L  '%[  !D>P  5WH  $IY
M   _>   -7@  "MW   B=@< '78/ !QW%@ ;=QX &G<F !EW+@ 8=S< %WA
M !5X2@ 4>%8 $WAC !)X<@ 1>(, $'B7  ]XJP .>,, #G?F  YV^@ /=?\
M$'7_ !!T_P"?<0  E7@  (M\  ""?P  =X$  &J"  !=@@  4((  $2"   X
M@@  +H(  "2"   <@@  %(() !&#$  0@Q8 $(,>  Z#)P .@S  #8,Y  V#
M1  ,@U  "X-=  F#;  (@WX !H.1  6"I0 #@KL !(';  2!\@ %@/\ !G__
M  9__P":>0  D'X  (:#  !]A0  ;X<  &*)  !5B@  28L  #V,   QC
M)HP  !V-   5C@  #X\#  J0#  &D!$ !(\8  ./(  !CRD  (\R  "0/0
MD$D  (]6  "/90  CW8  (^*  ".GP  CK0  (W/  ",[@  C/L  (O_  "+
M_P"4@   BX4  (*)  !TC   9H\  %F1  !,DP  0)4  #26   HE@  'I<
M !68   /F@  "IL   *<"0  G X  )P3  "<&@  G"(  )TK  "=-0  G4
M )U.  "=7   G6X  )R!  "<EP  G*P  )O&  ":Z   F?D  )G_  "8_P".
MB   AHP  'B0  !JE   7)<  $^:  !"G0  -IX  "F?   ?H0  %:(   ZD
M   (I@   *@   "I!   J0H  *D.  "I$P  JAH  *HB  "K*P  K#8  *Q$
M  "L4P  K&,  *QW  "KC@  JZ0  *N\  "JW@  J?0  *G]  "I_P")C@
M>Y,  &V7  !?G   4:   $2D   VI@  *J@  !ZI   4JP  #:X   :P
ML@   +4   "U    M0,  +8)  "W#@  N!(  +@9  "Z(0  NRL  +PX  "]
M1P  O5@  +UK  "]@0  O9D  +VP  "]S   O.H  +SW  "[_@!^E0  <)L
M &*@  !3I0  1JH  #BM   JKP  'K$  !.T   ,MP   [D   "\    OP
M ,(   #"    PP   ,0   #&!@  QPP  ,@0  #*%@  S"   ,\K  #0.@
MT4L  -%>  #2<P  THL  -*D  #3NP  T]@  -/M  #3]@!SG0  9*,  %:I
M  !'KP  .;,  "JV   =N0  $KP   J_    PP   ,8   #)    S0   ,\
M  #0    T@   -0   #6    V0(  -L(  #>#@  X1,  .0=  #H*@  Z#P
M .E/  #I9   ZGP  .N5  #KK   Z\(  .S5  #LY0!FI@  6*P  $FS   [
MN0  *[P  !W    1Q   "<@   #,    SP   -,   #9    W0   .    #A
M    XP   .4   #G    Z@   .P   #N!   \0L  /42  #X'   ^RL  /T^
M  #^4P  _FH  /^#  #_FP  _ZX  /^^  #_R@#_ !( _P 0 /\ $0#_ !,
M_P 9 /\ )@#_ #0 _P!! /\ 30#_ %@ _P!B /\ :P#_ ', _P!Z /\ @0#_
M (< _P"- /\ DP#_ )D _P"@ /\ IP#^ *\ _ "Z /H R0#Y .$ ^ #S /<
M_P#V /\ ]0#_ /$ _P#I /\ Y #_ .$ _P#_  \ _P - /\ #0#_  X _P 4
M /\ (0#_ "X _P \ /\ 2 #_ %, _P!= /\ 9@#^ &T _ !U /L >P#Y ((
M^ "( /< C@#V )0 ] "; /, H@#Q *H [P"T .T P0#K -4 Z@#L .@ _ #G
M /\ Y0#_ .8 _P#@ /\ V0#_ -0 _P#_  L _P ( /\ !@#_  D _P 0 /\
M' #_ "D _P V /\ 0@#[ $X ]P!7 /0 8 #R &@ [P!O .T =@#L 'P Z@""
M .@ B #G (X Y0"5 ., G #A *0 WP"N -T N0#: ,H UP#D -0 ]@#1 /\
MT #_ -  _P#/ /\ RP#_ ,< _P#_  , _P   /\   #_  0 _P - /H %@#V
M ", \P P /  / #M $< Z0!1 .4 6@#B &( WP!I -T ;P#: '8 V !\ -0
M@@#2 (@ T "/ ,T E@#+ )X R0"H ,< LP#% ,$ P@#8 ,  [P"_ /X O@#_
M +T _P"\ /\ O #_ +P _P#_ @  _P   /\   #_    ]  ' .T $0#H !P
MXP I -\ -0#; $$ U@!+ -$ 5 #- %P R@!C ,@ :0#& &\ PP!U ,$ >P"_
M (( O@"( +P D "Z )@ N "B +4 K "S +D L0#+ *\ YP"N /@ K #_ *L
M_P"L /\ K #_ *L _P#_!   _P   /8   #N    YP   -\ # #6 !4 SP B
M ,H +@#' #H PP!$ ,  30"\ %4 N0!< +< 8P"U &D LP!O +$ =0"O 'L
MK0"" *L B@"I )( IP"< *4 I@"C +, H0## )\ W@"> /( G0#_ )P _P"<
M /\ FP#_ )L _P#_!P  ]@D  .D+  #?"@  U00  ,X !0#& !  P  : +L
M)P"W #( LP ] +  1@"M $\ J@!6 *@ 7 "F &, I !H *( ;P"A '4 GP!\
M )T A "; (T F0"7 )< H@"5 *X DP"] )$ TP"0 .T CP#\ (X _P"- ?\
MC0'_ (T!_P#Y#@  ZA(  -P5  #-%0  Q!$  +X,  "Z @H M  2 *X '@"J
M "H I@ U *( /P"@ $@ G0%0 )L"5@"9 EP EP-C )4#:0"3 V\ D01V ) $
M?P".!8@ C 62 (H&G@"(!JH A@>Z (4(SP"$"NL @@O\ ($,_P" #/\ @ S_
M ( ,_P#Q%0  X!T  ,T@  #!(0  N!T  +$7  "L$   J D- *('%@"="2,
MF0HN )4+. "3#$$ D Q) (X-4 ",#5< B@U= (@-8P"'#6H A0YQ (,.>@""
M#H0 @ Z/ 'X/FP!\#Z@ >Q"X 'H0S@!X$>P =A+_ '42_P!T$_\ =!/_ '03
M_P#H'@  TR8  ,,J  "X*@  KB@  *<C  "@'   FQ,# )8/$ "0$!L C!$G
M (D2,@"&$SL A!-# ((42P" %%$ ?A17 'P47@![%64 >15L '<5= !V%GX
M=!:* '(7E@!Q%Z0 ;QBT &X8R0!M&>@ :QK\ &H;_P!J&_\ :AO_ &H;_P#@
M)@  RBT  +PQ  "P,P  IS$  )\L  "7)@  D!\  (H7# "%&!8 @1DB 'X:
M+ ![&S8 >1L^ '<<10!U'$P <QQ3 '$=60!P'6  ;AUG &T>< !K'GH :AZ%
M &@?D@!G'Z  92"P &0AQ0!C(>0 8B+Z &$B_P!A(O\ 82+_ &$B_P#7+
MPS0  +8X  "J.0  H3@  )@U  "0+P  B"@  ( A" ![(!( =R$= '0B)P!Q
M(C$ ;R,Y &TC00!K(T@ :2-. &@D50!F)%L 921C &,E:P!B)74 826! %\F
MC@!>)IT 72>M %LHP0!;*.  6BGW %DI_P!9*?\ 62G_ %DH_P#/,@  OCD
M +$]  "F/P  G#\  ),\  "*-@  @3   'DJ P!R)@\ ;B<9 &LH(P!I*"P
M9BDU &4I/ !C*4, 82I* & J40!>*E< 72I? %PK: !:*W( 62Q] %@LBP!6
M+9H 52VJ %0NO0!3+MP 4B_U %(O_P!2+O\ 4B[_ %(N_P#*-@  NCT  *U"
M  "B1   F$0  (]!  "%/   >S<  '(Q  !K+ P 9RT5 &0M'P!A+B@ 7RXQ
M %TN.0!<+T  6B]& %@O30!7+U0 5C!< %4P9 !3,6X 4C%Z %$QB !0,I<
M3C*H $TSNP!---@ 3#3S $PT_P!,-/\ 3#/_ $PS_P#&.@  MD(  *E&  ">
M20  E4D  (M'  "!0@  =ST  &TW  !D,@D 8#(2 %TR' !:,B4 6#,M %8S
M-0!5,SP 4S1# %(T2@!1-%$ 4#19 $\U80!--6P 3#9W $LVA0!*-Y4 2#>F
M $<XN %'.-,!1CCQ 48X_P%&./\ 1CC_ $8W_P#!/@  LD4  *9*  "<30
MDDT  (A+  !^1P  <T(  &D]  !?-P8 6C80 %<W& !4-R( 4C<J % W,@!/
M.#D 33A  $PX1P!+.$X 2CE6 $DY7P!(.FD 1SIU $4[@P!$.Y, 0SRD 4(\
MM@%!/= !03WP 4$]_P%!//\!03S_ 4$\_P"^0@  KTD  *-.  "94   CU$
M (50  ![3   ;T8  &5"  !:/0( 5#L. %$[%0!/.Q\ 33LG $L[+P!)/#8
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M #))_@ R2/\ ,DC_ #-(_P"T3   IU0  )Q9  "27   B%T  'Y=  !S6@
M954  %M2  !03@  1DH% $!)#@ ^218 /4D> #M*)@ Z2BX .4HU #A+/0 W
M2T0 -DM- #1,5@ S3&  ,DQL #%->@ P38L +DV< "U.KP L3L< +$[I "Q-
M_0 M3?\ +4S_ "U,_P"P4   I%@  )E=  "/80  AF(  'MA  !P7P  8EL
M %A8  !.50  0U$! #M/#  X3Q, -D\; #5/(P T4"L ,U R #)0.@ Q4$(
M,%%* "Y14P M4ET +%)I "M2>  I4H@ *%.: "=3K0 F4\4 )E/G "93_  G
M4O\ )U'_ "=1_P"L50  H%P  )9B  "-9@  @V<  'AF  !M90  8&$  %5>
M  !*6P  /U@  #56"  Q51  ,%87 "Y6'P M5B< +%8O "M7-@ J5SX *5='
M "A74  F6%H )5AG "18=0 C688 (5F8 "!9JP ?6<( 'UGE !]8^@ @6/\
M(%?_ "%7_P"H6@  G6(  )-G  "*:P  ?VP  '5L  !J:P  76@  %%E  !&
M8P  .V   #%> P J70T *%T3 "9=&P E7B, )%XJ "->,@ B7CH (5Y# "!?
M3  ?7U< 'E]C !Q@<0 ;8(( &6"5 !A@J0 78,  %F#B !=?^0 87O\ &5[_
M !E=_P"D8   F6@  )!N  "&<   ?'(  ')R  !F<0  6&X  $QL  !!:P
M-FD  "UG   C9@@ 'V8/ !UF%0 <9AT &V8E !IF+0 99S4 &&<^ !=G2  6
M9U, %6A? !-H;@ 2:'\ $6B2 !!HI@ /:+T #FC@ !!G]P 09O\ $67_ !%E
M_P"?9P  EF\  (QS  ""=@  >'@  &UX  !@=P  4W8  $9T   [<P  ,7(
M "=Q   ><0  %G * !-P$  3<!< $G ? !%Q)P 0<2\ $'$X  YQ0@ .<4X
M#7%;  QQ:0 +<7H "G&-  AQH0 &<;8 !G#2  =P[P (;_\ "6[_  EN_P";
M;P  D74  (=Y  !^?   ='X  &9^  !9?@  37X  $!]   U?0  *GP  "%\
M   8?   $7P$  Q\#  *?!$ "7P9  A\(0 '?"D !GPR  1\/0 #?$@  7Q5
M  !\8P  ?'0  'R'  ![G   >[$  'K+  !YZP  >?H  'G_  !X_P"6=P
MC'P  (.   !Y@P  ;(0  %Z%  !1A@  18<  #F'   MAP  (X<  !J'   2
MAP  #8@!  :)"@ !B0\  (D4  "(&P  B",  (DL  ")-@  B4(  (A.  "(
M70  B&T  (B!  "'E0  AZL  (;$  "%Y@  A/@  (3_  "$_P"0?@  AX,
M 'Z'  !QB0  8XL  %:-  !)CP  /)$  #"1   DD0  &I(  !*3   -E
M!I4   "6!@  E@P  )40  "6%0  EAT  )8D  "6+@  ECD  )9&  "650
MEF4  )9X  "5C@  E:0  )2\  "3WP  D_4  )+_  "2_P"+A@  @XH  '6-
M  !GD   690  $R7   _F0  ,IH  ":;   ;G   $IT   R?   $H    *(
M  "C 0  HP<  *,,  "C$   I!4  *0<  "E)0  IB\  *8\  "F2P  IEL
M *9N  "EA   I9L  *2S  "CT   H^\  *+\  "B_P"&C0  >)$  &J5  !<
MF0  3IT  $&@   SH@  )J,  !NE   1IP  "JD   &K    K0   *\   "P
M    L    + %  "Q"P  L@\  +,4  "T&P  M20  +<P  "W/P  MU   +=B
M  "W>   MY   +:I  "VP@  MN0  +;U  "U_@![DP  ;9@  %^=  !0H@
M0J8  #2I   FJP  &JT  !"O   )L@   +0   "W    N@   +P   "]
MO@   +X   #  @  P0@  ,(-  #$$@  QAD  ,DD  #*,@  RT,  ,M5  #,
M:@  S(,  ,R<  #+M0  S,X  ,SI  #,]@!PFP  8:$  %*F  !$JP  -K
M ">R   :M0  $+@   >[    O@   ,$   #$    R    ,L   #+    S0
M ,X   #0    T@   -4#  #8"@  VQ   -X8  #B)   XS4  .1(  #E7
MYG,  .:-  #FI0  YKP  .;3  #GYP!CI   5:H  $:P   XM0  *+D  !J\
M   /P   !<0   #'    RP   ,\   #4    V    -P   #=    WP   .$
M  #C    Y0   .@   #J    [08  /$.  #U%@  ^"4  /DX  #Y30  ^F,
M /M\  #\E0  _*H  /R[  #]RP#_  \ _P . /\ #@#_ !  _P 6 /\ (P#_
M #  _P ] /\ 20#_ %0 _P!> /\ 9@#_ &X _P!V /\ ? #_ (( _P") /\
MCP#_ )4 _@"; /T HP#[ *L ^@"U /D PP#W -L ]@#P /0 _P#S /\ \@#_
M .P _P#B /\ W #_ -8 _P#_  P _P ) /\ " #_  H _P 2 /\ '@#_ "L
M_P X /\ 1 #_ $\ _P!9 /X 80#\ &D ^@!P /@ =P#W 'T ]@"# /0 B0#R
M (\ \0"6 .\ G0#M *4 [ "O .H O #H ,T Y@#H .0 ^@#C /\ X@#_ .
M_P#5 /\ S@#_ ,L _P#_  8 _P ! /\   #_  0 _P . /\ &0#_ "4 _0 R
M /L /@#W $D \P!3 /  7 #N &, [ !J .H <0#H '< Y@!] .0 @P#B (D
MX "0 -X EP#< )\ V0"I -8 M #3 ,0 T #> ,X \P#, /\ RP#_ ,H _P#(
M /\ P@#_ +X _P#_    _P   /\   #_    ^P + /8 $P#Q "  [0 L .H
M. #G $, XP!- .  5@#< %T V0!D -4 :P#2 '$ T !V ,X ? #, (, R@")
M ,@ D0#& )D Q "C ,$ K0"_ +L O0#/ +L ZP"Y /P MP#_ +< _P"V /\
MM #_ +$ _P#_    _P   /\   #V    [@ % .< #P#A !D VP E -4 ,0#2
M #P S@!& ,H 3P#' %< Q !> ,$ 9 "_ &H O0!P +L =@"Y 'P N "# +8
MB@"S ), L0"< *\ IP"M +, JP#% *D X0"G /4 I@#_ *4 _P"D /\ I #_
M *0 _P#_    _    /$   #H    X    -0 "P#, !, QP ? ,( *@"_ #4
MO  _ +@ 2 "U %  LP!7 +  7@"N &0 K !I *L ;P"I '4 IP!\ *4 A "C
M (P H0"6 )\ H0"= *T F@"\ )@ T@"7 .X E0#^ )0 _P"5 /\ E0#_ )4
M_P#\ 0  \ 4  .,'  #5!0  S    ,4 ! "^  X N  7 +, (P"O "X JP X
M *D 00"F $H HP!1 *$ 5P"? %T G0!C )L :0": &\ F !V )8 ?0"4 (8
MD@"0 )  FP". *< C "V (H R0"( .< AP#Y (< _P"& /\ A@#_ (8 _P#T
M#   Y!   -$2  #%$0  O0X  +8(  "Q  @ JP 1 *8 &P"A "8 G@ Q )H
M.@"8 $, E0!* ), 40"1 %< CP!= (X 8P", &D B@!P (@ =P"& (  A "+
M (( E@"  *, ?@"Q 'T Q ![ N$ >@/U 'H%_P!Y!?\ > ;_ '@&_P#J$P
MUAH  ,8=  "Z'   L1D  *H3  "D#0  GP4, )D % "5 !\ D0(I (T#,P"+
M!#P B 5$ (8&2P"$!E$ @@=7 ($'70!_!V, ?0AJ 'L(<@!Z"'P > F& '8)
MD@!T"J  <PJO '$+P0!P#-\ ;PWV &X._P!M#O\ ;0[_ &T._P#A'   RR,
M +PF  "Q)@  J"0  * >  "9&   DQ " (X+#@"("Q< A PB ($-+ !^#34
M? X] 'H.10!X#DL =PY1 '4/6 !S#UX <1!E ' 0;@!N$'< ;!"" &L0CP!I
M$9T :!&M &82P !E$M\ 9!/V &,4_P!C%/\ 8A3_ &(4_P#6)   PRH  +4N
M  "J+P  H"T  )@H  "0(@  B1L  ((3" !]$1( >1(< '83)P!S%#  <10X
M &\5/P!M%48 ;!5, &H64P!H%ED 9Q9A &46:0!D%W( 8A=^ &$8BP!?&)D
M7AFI %P9O !<&M@ 6AOS %H<_P!9'/\ 61S_ %D<_P#-*@  O3$  *\U  "D
M-@  FS0  )(Q  ")*P  @24  'D= P!S& X ;QD8 &P:(@!I&RL 9QLS &4<
M.P!D'$$ 8AU( & =3@!?'54 71U< %P>9 !;'FX 61]Y %@?AP!6()8 52"F
M %0AN !3(=( 4B+Q %(C_P!2(_\ 4B+_ %(B_P#(+P  N#8  *LZ  "@/
MECL  (TX  "#,@  >BT  '(F  !J( P 9B 3 &,A'0!A(28 7R(O %TB-@!;
M(CT 6B-$ %@C2@!7(U$ 52-8 %0D80!3)&H 425V % E@P!/)I, 3B>C $PG
MM0!,*,X 2RCN $LI_P!+*/\ 2RC_ $LH_P##-   LSL  *<_  "<00  DD
M (D^  !_.0  =3,  &PM  !C)P@ 7B81 %PF&0!9)R( 5R<K %4H,@!4*#D
M4BA  %$H1@!0*4T 3BE5 $TI70!,*F< 2RIS $DK@ !(*Y  1RRA $8MLP!%
M+<L 12[L $0N_P!$+O\ 12W_ $4M_P"^.   L#\  *1#  "910  CT4  (5#
M  ![/@  <3D  &<T  !>+@0 6"L. %4K%@!2+!\ 4"PG $\L+P!-+38 3"T\
M $HM0P!)+4H 2"Y2 $<N6@!&+V0 12]P $,P?@!",(T 03&> $ RL0 _,L@
M/S/J #\S_@ _,O\ /S+_ #\R_P"[/   K4,  *%'  "620  C$D  (-(  !X
M1   ;3X  &,Y  !:-   4C , $\P$P!,,!P 2C D $DQ*P!',3( 1C$Y $0Q
M0 !#,D< 0C)/ $$S6 ! ,V( /S1M #XT>P ]-8L /#:< #LVKP Z-\8 .3?H
M #DW_  Z-_\ .C;_ #HV_P"W0   JD8  )Y+  "430  BDX  (!,  !U2
M:D,  & ^  !6.0  334) $DT$0!'-1D 134A $,U* !!-2\ 0#4V #\V/0 ^
M-D4 /3=- #PW50 [.&  .CAK #DY>0 X.8D -SJ; #4ZK0 U.\0 -#OF #0[
M^P U._\ -3K_ #4Z_P"T0P  ITH  )Q.  "240  B%(  'Y0  !S30  9T@
M %Q$  !2/P  2#H& $0Y#P!!.18 /SD> #XY)@ \.2T .SHT #HZ.P Y.T(
M.#M* #<\4P V/%T -3UI #0]=P S/H< ,3Z9 # _JP O/\( +S_D "\_^@ P
M/_\ ,#[_ # ^_P"Q1P  I$T  )E2  "/50  AE8  'Q5  !Q4@  9$P  %E)
M  !/10  14 # #\^#0 \/A, .CX; #D^(P W/BH -C\Q #4_.  T/T  ,T!(
M #) 40 Q05L ,$%G "Y"=0 M0H4 +$.7 "M#J@ J0\  *43B "I#^0 J0_\
M*T+_ "M"_P"N2@  H5$  )=6  "-60  @UH  'E:  !N5P  85(  %=.  !-
M2P  0T<  #I#"@ V0Q$ -$,8 #-#(  R1"< ,40O #!$-@ O13T +45& "Q%
M3P K1ED *D9D "E'<@ H1X, )D>5 "5(J  D2+X (TC@ "1(]P E1_\ )4?_
M "9'_P"J3P  GU4  )1:  "+7@  @5\  '=>  !K7   7U@  %55  !+40
M0$T  #5*!P P20X +DD5 "U)'0 L220 *THK "I*,P H2CL )TM# "9+3  E
M2U8 )$QB "-,<  A3(  ($V3 !]-I@ >3;L '4[= !Y-]@ >3/\ 'TS_ "!+
M_P"G4P  G%H  ))?  "(8P  ?F0  '1C  !I80  7%X  %);  !'6   /%4
M #)2 @ J4 P )T\2 "90&0 E4"  )% H "-0+P B43< (5%  "!120 >4E,
M'5)? !Q2;0 :4WT &5.0 !A3I  64[D %5/9 !93]  74O\ &%'_ !E1_P"C
M60  F&   (]E  "%:   >VD  '%I  !F9P  660  $UA  !"7P  .%P  "Y:
M   E6 @ (%<. !Y7%  =5QP '%@C !M8*P :6#, &5@\ !A810 665  %5E;
M !19:0 36GH $EJ- !%:H0 06K< #EK5 !!9\P 06?\ $5C_ !%8_P"?7P
ME68  (QK  "";0  >&X  &YO  !B;0  56H  $AH   ^9@  ,V4  "EC   @
M80$ && + !5@$  48!< $V > !)@)@ 28"X $6$W !!A0  /84L #F%8  UA
M9@ ,8G8 "V*)  IAG0 )8;( "&'+  AAZP )8/T "E__  M?_P";9@  DFT
M (AQ  !^<P  =74  &IT  !<<P  3W(  $-P   X;P  +6X  "1L   ;:P
M$VL$  YJ#  -:A( #&H9  MJ(0 *:BD "6HR  AJ/  ':T< !6M3  1K80 "
M:W$  &J$  !JF   :JT  &G&  !IYP  :?@  &C_  !H_P"7;0  C7,  (1W
M  ![>@  <'L  &-[  !6>@  27H  #UY   Q>   )W<  !UV   5=@  #W8"
M  EV"@ $=@\  '85  !V'   =B0  '4L  !U-@  =4$  '5.  !U7   =6P
M '5^  !TDP  =*@  '/   !SXP  <O<  '+_  !Q_P"2=0  B7H  (!^  !V
M@   :8$  %N"  !.@@  08(  #6#   I@@  'X$  !:!   0@@  "H(   *#
M!P  @@T  ((1  ""%P  @AX  ((F  ""+P  @CL  ()'  ""50  @64  (%X
M  "!C0  @*(  '^Z  !_W0  ?O0  'W_  !]_P"-?   A($  'N$  !NA@
M8(@  %**  !%BP  .8P  "R,   AC   %XP  !"-   )C@   H\   "0 P
MCPD  (\.  "/$@  D!@  ) ?  "0*   D#(  ) _  "030  D%T  (]P  "/
MA0  CIP  (ZS  "-T   C/   (O^  "+_P"(A   @(@  '*+  !DC0  5I
M $B3   [E0  +I8  "*6   7EP  #Y@   B9    FP   )T   "=    G0,
M )T)  "=#0  GA$  )X7  "?'P  GRD  * U  "@0P  H%0  *!F  "?>P
MGI,  )ZK  "=Q@  G>D  )SY  "<_P"#BP  =8X  &>2  !9E@  2YD  #V<
M   PG@  (Y\  !>@   .H@  !Z0   "F    J    *H   "J    J@   *L!
M  "K!P  K P  *T0  "N%@  KQX  +$I  "Q.   L4@  +%:  "Q;P  L8@
M +&@  "PN@  K]T  *_R  "O_0!XD0  :I8  %R:  !-GP  /Z,  #&F   C
MIP  %ZD   ZK   %K@   +    "R    M0   +<   "W    N    +D   "Z
M    O ,  +T)  "^#@  P!0  ,,>  #%*P  Q3P  ,9.  #&8@  QGH  ,:4
M  #&K0  QL@  ,7E  #%\P!LF0  7IX  $^D  !!J   ,JP  "2O   6L0
M#;0   .W    N@   +T   #     Q    ,8   #&    R    ,D   #+
MS    ,X   #0!@  TPT  -@3  #<'@  WBT  -]   #@5   X6L  .&%  #A
MGP  X;<  .'/  #AY@!@H0  4J<  $.M   TL@  );4  !>Y   -O    ;\
M  ##    QP   ,H   #/    TP   -8   #7    V@   -P   #?    X0
M .,   #F    Z0$  .P+  #P$@  \Q\  /0Q  #V1@  ]UP  /AT  #XCP
M^:8  /FX  #XR0#_  T _P + /\ "P#_  X _P 3 /\ 'P#_ "P _P Y /\
M10#_ %  _P!9 /\ 8@#_ &H _P!Q /\ =P#_ 'X _P"$ /X B@#] )  _ "7
M /H G@#Y *< ]P"Q /8 O@#U -( \P#L /$ _@#P /\ \ #_ .8 _P#< /\
MT@#_ ,T _P#_  < _P $ /\  @#_  8 _P 0 /\ &P#_ "< _P S /\ /P#_
M $H _@!4 /L 70#Y &0 ]P!K /4 <@#S '@ \@!^ /  A #O (H [0"1 .P
MF0#J *$ Z "K .8 M@#D ,< X@#C .  ]P#> /\ W0#_ -D _P#, /\ Q0#_
M ,$ _P#_    _P   /\   #_  $ _P - /\ %@#\ "( ^0 N /8 .0#S $4
M[P!. .P 5P#I %X Y@!E .0 ; #B '( X !W -\ ?@#= (0 VP"+ -@ D@#5
M )L T@"D ,\ KP#- +X RP#5 ,D [P#' /\ Q0#_ ,0 _P"^ /\ N #_ +4
M_P#_    _P   /\   #^    ]P ) /$ $0#K !P YP H .0 ,P#A #X W0!(
M -@ 40#3 %@ T !? ,X 90#, &L R@!Q ,@ =P#& 'T Q "$ ,( C #  )0
MO@"> +L J "Y +8 MP#( +4 Y@"S /H L0#_ +  _P"P /\ K #_ *D _P#_
M    _P   /H   #Q    Z  # .  #0#8 !8 T0 B ,T +0#* #< Q@!! ,(
M2@"_ %( O0!9 +H 7P"X &4 MP!J +4 < "S '8 L0!] *\ A0"M (T JP"7
M *D H0"G *X I0"^ *( V "@ /( GP#_ )X _P"> /\ G@#_ )P _P#_
M]P   .L   #A    U@   ,L "0#% !$ OP ; +L )@"W #$ M  Z +$ 0P"N
M $L JP!2 *D 6 "G %X I@!D *0 :0"B '  H !V )X ?@"< (8 F@"0 )@
MFP"6 *< E "V )( R@"0 .D CP#\ (X _P"- /\ C #_ (T _P#X    Z0(
M -L#  #, 0  Q    +T  @"V  T L  5 *L ( "G "H I  T *$ / "> $0
MG !+ )H 4@"8 %@ E@!= )4 8P"3 &D D0!P (\ =P"- (  BP"* (D E0"'
M *$ A0"O (, P0"! .  @ #U '\ _P!_ /\ ?P#_ '\ _P#N"@  W X  ,H0
M  "^#@  M0L  *\#  "I  < HP 0 )X & "9 ", E@ L ), -0"0 #X C@!%
M (P 2P"* %$ B !7 (8 70"% &, @P!J ($ <0!_ 'H ?0"$ 'L CP!Y )P
M=P"J '4 NP!T -0 <@#P '( _P!R /\ <0#_ '$ _P#C$0  S1<  +\9  "S
M&0  JA4  *,0  "="@  EP$* )$ $@"- !L B0 E (4 +P"# #< @  ^ 'X
M10!] $L >P!1 'D 5P!X %T =@!D '0!:P!R 70 < )_ &X"BP!L Y@ :P.F
M &D$MP!H!<X 9P?L &8(_0!F"?\ 90G_ &4)_P#6&@  Q"   +8C  "K(P
MH2   )D;  "2%   C X! (8'#0" !!0 ? 8> 'D'* !V"#  = @X '()/P!P
M"44 ;PI, &T*4@!L"E@ :@M? &@+9P!G"W  90QZ &,,AP!B#)4 8 VD %\-
MM@!>#<X 7 [M %P/_P!;$/\ 6Q#_ %L0_P#-(0  O"@  *\K  "D*P  FBD
M )(D  ")'P  @A@  'L1!0!U#0\ <0T7 &X.(0!K#BH :0\R &<0.0!E$$
M9!!& &,030!A$%, 7Q%: %X18@!<$6L 6Q%V %D2@P!8$I( 5A.B %43M !4
M$\L 4Q3L %(5_P!2%O\ 4A7_ %(5_P#&*   MBX  *DR  "?,@  E3$  (PM
M  "#)P  >B$  '(:  !K$PL 9Q,3 &04' !A%"4 7Q4M %T5- !<%3L 6Q9"
M %D62 !8%D\ 5A=6 %477@!3%V< 4AAR % 8?P!/&8X 3AJ? $P:L !+&\<
M2QOI $H<_0!*'/\ 2AS_ $H<_P#!+0  L30  *4W  ":.   D#<  (<T  !]
M+P  ="D  &PC  !D' < 7AD0 %L:& !9&R$ 5QLI %4;, !4'#< 4AP] %$<
M1 !/'4L 3AU2 $T=6@!+'F, 2AYN $D?? !''XL 1B"< $4AK@!$(<0 0R+F
M $,B_ !#(O\ 0R+_ $,B_P"\,@  K3@  *$\  "7/@  C3T  (,Z  !Y-0
M;S   &8J  !>) ( 5R - %0@% !1(!T 3R$E $XA+ !,(3, 2R(Z $DB0 !(
M(D< 1R). $8C5P!$(V  0R1K $(D>0!!)8@ /R:9 #XFJP ])\$ /2?C #TH
M^@ ]*/\ /2?_ #TG_P"X-@  JCT  )Y   "40@  BD(  ( _  !V.P  ;#8
M &(P  !9*@  424+ $TE$0!+)1D 224A $<F* !%)B\ 1"8V $,F/0!")T0
M02=+ #\H5  ^*%T /2EI #PI=@ [*H8 .2N7 #@KJ0 W++\ -RS@ #<L^  W
M+/\ -RS_ #@L_P"U.@  IT   )Q$  "11@  AT8  'U$  !S0   :#L  %\V
M  !5,0  3"L' $<I#P!%*A8 0RH> $$J)0 _*BP /BLS #TK.0 \*T$ .RQ(
M #HL40 Y+5L ."YF #8N<P U+X, -"^5 #,PIP R,+T ,3'> #$Q]P R,?\
M,C#_ #,P_P"Q/@  I$0  )E(  "/2@  A4H  'M)  !P10  94   %L[  !2
M-@  2#$$ $(N#0 _+A, /2X; #LN(@ Y+RD ."\O #<O-@ V,#X -3!& #0Q
M3P S,5D ,C)D #$R<0 P,X$ +S23 "XTI@ L-;L +#7; "PU]0 M-?\ +33_
M "XT_P"N00  HD@  )=,  "-3@  @TX  'E-  !N2@  8D4  %A   !./
M13<  #TS"P Y,Q$ -S,8 #8S'P T,R8 ,S,M #(T-  Q-#P ,#5$ "\U3  N
M-E8 +39B "PW;P K-W\ *CB1 "@XI  G.;D )CG8 "<Y]  H.?\ *#C_ "DX
M_P"K10  GTL  )1/  "+4@  @5,  '=2  !L3P  7TD  %9&  !,0@  0CT
M #@X"  T. \ ,C@5 #$X'0 O."0 +C@K "TY,@ L.3D *SI! "HZ2@ I.U0
M*#M? "<\;0 E/'T )#V/ ",]H@ B/;< (3[4 "$^\P B/?\ (SW_ ",\_P"H
M20  G4\  ))3  ")5@  ?U<  '56  !J4P  74\  %-,  !*2   0$0  #9
M!0 O/0T +3T3 "L]&@ J/B$ *3XH "@^+P G/C< )C\_ "0_2  C0%( (D!=
M "%!:@ @07H 'D&- !U"H  <0K4 &T+1 !M"\0 <0O\ '4'_ !Y!_P"E30
MFE,  )!8  "&6P  ?5P  ');  !G6   6U0  %%2  !(3@  /4H  #-'   J
M0PL )D,0 "5#%@ D0QX (T0E ")$+  A1#0 ($4\ !Y%10 =14\ '$9: !M&
M:  91G@ &$>* !='G@ 61[, %$C. !5'[P 61_\ %T;_ !=&_P"B4@  EU@
M (U=  "$8   >F$  '!@  !E7@  65H  $]8  !$5   .5$  "].   F2P8
M($H. !Y*$P =2AH '$HA !M+*  :2S  &4LX !=+0@ 63$P %4Q7 !1,90 3
M374 $DV( !%-G  03;$ #D[,  ]-[@ 03?\ $4S_ !%,_P">5P  E%T  (MB
M  "!90  =V8  &UF  !C9   5F$  $I>   _6P  -5@  "M6   B5 $ &E(*
M !92$  54A8 %%(= !-2)  24BP $5(T !%2/@ 04T@ #U-4  Y38@ -5'(
M#%2$  M4F  )5*T "%3%  E4YP *4_L "U+_  M2_P";70  D60  (AH  !^
M:P  =&P  &ML  !?:@  4F<  $5D   Z8@  ,&   "9>   =70  %5L% !!:
M#  .6A$ #EH8  U;(  ,6R< "ULP  I;.@ )6T4 !UM1  9;7@ $6VT  UN
M  %;E   6Z@  %O   !:X@  6O8  5K_  )9_P"79   CFL  (1N  ![<
M<G(  &=Q  !9<   3&X  $!L   U:P  *FD  "%G   89@  $68!  QE"@ '
M90\ !&44  -D&P "9",  &0L  !D-0  9$   &1,  !D6@  9&D  &1[  !D
MCP  8Z0  &.[  !BW0  8O0  &+_  !A_P"3;   B7$  (!U  !X=P  ;7@
M &!W  !2=@  1G4  #ET   N=   (W(  !IQ   2<0  #7$   9Q"   < T
M ' 2  !P%P  ;Q\  &\F  !O,   ;SL  &]'  !O5   ;V0  &]U  !NB@
M;:   &VV  !LU@  :_(  &O_  !K_P".<P  A7@  'U[  !S?0  97X  %A^
M  !+?@  /GX  #)^   F?0  ''P  !-\   -?   !GT   !]!0  ? L  'P/
M  !\$P  ?!D  'PA  !\*0  ?#0  'M   ![3@  >UX  'MO  !ZA   >IH
M 'FQ  !XS@  =^\  ';^  !V_P")>@  @7\  'B"  !K@P  784  $^&  !"
MAP  -8@  "F'   =AP  %(<   V(   &B0   (H   "*    B08  (D,  ")
M#P  B1,  (D:  "*(@  BBP  (HX  "*1@  B58  (EH  ")?   B)0  (>K
M  "&Q@  A>H  (7[  "$_P"%@@  ?88  &^(  !ABP  4XT  $6/   XD0
M*Y$  !^2   4D@  #9,   24    E@   )<   "8    EP   )<%  "7"P
MF X  )@3  "9&@  F2(  )HN  ":/0  F4T  )E>  "9<P  F(L  )BC  "7
MO   EN(  );W  "5_P" B0  <HP  &2/  !6DP  2)8  #J9   LF@  'YL
M !2<   ,G@   Y\   "A    HP   *4   "E    I0   *4   "F @  IP@
M *<-  "H$0  J1D  *LC  "K,0  JT$  *Q3  "L9P  JX   *J:  "JLP
MJM   *GO  "I^P!UCP  9Y0  %F8  !*G   /)\  "VB   @HP  $Z4   NG
M   !J0   *L   "N    L0   +(   "R    LP   +0   "U    M@   +@$
M  "Y"P  NQ   +T8  "_)   OS4  ,!'  # 6P  P'(  ,"-  #!I@  P,$
M +_C  "^\P!JEP  6YP  $VA   ^I0  +ZD  "&K   3K0  "[    "S
MM0   +@   "\    OP   ,$   #!    PP   ,0   #&    QP   ,D   #+
M    S@@  -$/  #5&   V"<  -DY  #:30  VV0  -M^  #<F0  W+   -S)
M  #<XP!=GP  3Z4  $"J   RKP  (K(  !2U   *N    +L   "_    PP
M ,8   #+    S@   -$   #1    U    -8   #9    VP   -X   #@
MY    .<&  #K#@  [QD  / J  #R/P  \U4  /1M  #TB   ]*$  /2V  #T
MQP#_  D _P & /\ !P#_  P _P 1 /\ ' #_ "@ _P T /\ 00#_ $P _P!5
M /\ 70#_ &4 _P!L /\ <@#^ '@ _ !^ /L A #Z (L ^0"2 /< F0#V *(
M] "L /, N0#Q ,L \ #H .X ^P#M /\ [ #_ .$ _P#2 /\ R0#_ ,0 _P#_
M  $ _P   /\   #_  0 _P . /\ %P#_ ", _P O /\ .P#] $8 ^@!0 /<
M6 #T %\ \@!F /  ; #O '( [0!X .P ?@#J (4 Z0", .< DP#E )P XP"F
M .$ L0#? ,$ W0#= -L ] #9 /\ U@#_ ,\ _P#$ /\ O0#_ +D _P#_
M_P   /\   #_    _P + /P $P#W !X ]  J /( -0#N $  Z0!* .8 4@#C
M %D X !@ -X 9@#< &P V@!R -< > #4 'X T@"% -  C0#. )4 S "? ,D
MJ@#' +@ Q0#- ,, ZP#  /X OP#_ +X _P"V /\ L #_ *T _P#_    _P
M /\   #Y    \@ & .L #P#F !D X0 D -X +P#: #D TP!# ,\ 3 #, %,
MR0!: ,< 8 #% &8 PP!K ,$ <0"_ '< O0!^ +L A@"Y (X MP"8 +4 HP"S
M +  L0#" *X X "L /< JP#_ *H _P"H /\ HP#_ *  _P#_    _P   /4
M  #K    X0   -8 # #/ !, R@ > ,8 *0#" #, OP ] +L 10"X $T M@!4
M +, 6@"Q %\ L !E *X :@"L '  JP!W *D ?P"G (< I0"1 *, G "@ *D
MG@"X )P S@": .X F0#_ )< _P"6 /\ E@#_ ), _P#]    \0   .4   #9
M    S0   ,0 !@"]  \ MP 8 +, (@"P "P K0 V *D /@"G $8 I !- *(
M4P"@ %D GP!> )T 9 "; &H F@!P )@ =P"6 (  E "* )$ E0"/ *( C0"P
M (L PP") ., B #Y (8 _P"& /\ A@#_ (8 _P#S    XP   -$   #%
MO0   +8   "N  L J  2 *0 ' "@ "8 G  O )H -P"7 #\ E0!& )( 3 "1
M %( CP!8 (T 70"+ &, B@!J (@ <0"& 'D A "# (( CP!_ )L ?@"I 'P
MNP!Z -4 > #R '@ _P!W /\ =P#_ '< _P#G!P  T0P  ,,-  "X#   K@@
M *@   "B  4 FP . )8 %0"2 !\ C@ H (L ,0"( #D A@!  (0 1@"" $P
M@ !2 '\ 5P!] %T >P!C 'H :P!X ', =@!] '0 B !Q )4 < "D &X M !L
M ,H :P#J &H _ !J /\ :@#_ &H _P#:$   QA0  +@6  "M%0  I!(  )P.
M  "6!P  D  ) (H $ "% !@ @0 A 'X *@![ #( >0 Y '< 0 !U $8 <P!,
M '( 40!P %< ;@!> &T 90!K &X :0!W &< @P!E )$ 8P"? &( KP!@ ,0
M7P#D %\!^ !> O\ 7@+_ %X"_P#.&   O1T  + @  "E'P  FQP  ),7  "+
M$0  A P  'X$"P!Y !( =0 ; '( (P!O "L ;0$S &L!.@!I D  9P-& &8#
M3 !D!%( 8P19 &$$8 !?!6D 7@5S %P&?P!:!HT 60>< %<(K0!6",$ 50GA
M %0+]@!4"_\ 5 O_ %0+_P#&'P  MB4  *DH  ">*   E"4  (LA  "#&P
M>Q0  '0. P!N"0T :0@4 &8)'0!D"B4 8@HM & +- !>"SH 70M  %L,1P!:
M#$T 6 Q4 %<-7 !5#60 5 UO %(->P!0#HH 3PZ: $X.K !,#\( 3!#C $L0
M^0!+$/\ 2Q'_ $L0_P"_)@  L"L  *0O  "9+P  CRT  (8I  !])   =!X
M &P7  !E$0< 7PX0 %P/%P!:$!\ 6! G %80+@!4$#4 4Q [ %(10@!0$4@
M3Q%0 $X15P!,$F  2Q)K $D2> !($X< 1A.7 $44J0!$%+X 0Q7? $,6^ !#
M%O\ 0Q;_ $,6_P"Z*P  JS$  * T  "5-0  BS0  ($Q  !X*P  ;R8  &8@
M  !>&0$ 5Q0- %04$P!1%!L 3Q4C $X5*@!,%3$ 2Q8W $D6/@!(%D0 1Q=,
M $475 !$%UT 0QAG $$8= ! &8, /QJ4 #T:I@ \&[L .QO; #L<]@ \'/\
M/!S_ #P<_P"U,   J#8  )PY  "1.P  ASH  'XW  !S,@  :BT  &$G  !9
M(0  41L) $P9$ !*&A< 2!H? $8:)@!%&RT 0QLS $(;.@!!'$$ 0!Q( #X<
M4  ]'5D /!YD #L><0 Y'X  .!^2 #<@I  V(+@ -2'6 #4A]  U(O\ -2'_
M #8A_P"R-   I#H  )D^  "//P  A3\  'L\  !P.   9S(  %TM  !4*
M3"(% $8?#@!#'Q0 01\; #\?(@ ^("D /2 P #L@-@ Z(3T .2%% #@B30 W
M(E< -B-B #0C;@ S)'X ,B2/ #$EH@ O);8 +R;2 "\F\@ O)O\ ,";_ # F
M_P"O.   HCX  )9"  ",0P  @D,  'A!  !N/0  8S@  %HS  !1+@  2"@!
M $ D#  ](Q$ .R08 #DD'P X)"8 -B0L #4E,P T)3H ,R9" #(F2@ Q)U0
M,"=? "\H;  N*'L +"F- "LJH  J*K0 *2K/ "DK\  J*_\ *BK_ "LJ_P"L
M/   GT(  )1&  "*1P  @$<  '9%  !L0@  83T  %<X  !.,P  1"X  #PI
M"0 W*!  -2@5 #,H'  R*", ,"@I "\I,  O*C< +BH_ "TK2  L*U( *RQ=
M "HL:@ H+7D )RV+ "8NG@ E+K, )"_- "0O[@ E+_\ )2__ "8N_P"I/P
MG44  )))  "(2P  ?DP  '1*  !J1P  7D(  %0]  !+.0  030  #@O!@ R
M+0T ,"T3 "XM&0 M+2  *RTG "HN+@ I+C4 *2\] "@O1@ G,$\ )3!; "0Q
M:  C,7< (C*) "$RG0 ?,[$ 'C/+ !XS[0 ?,_\ (#/_ "$R_P"F0P  FDD
M )!-  "&3P  ?%   '-/  !H3   7$8  %)#  !)/P  /SL  #8V @ N,@P
M*S(1 "DR%P H,AX )C(D "4S*P D,S( (S0Z "(T0P A-4T (#58 !\V90 >
M-G4 '#>' !LWFP :-Z\ &3C( !DXZP :./\ &S?_ !LW_P"C1P  F$T  (Y1
M  "$4P  >U0  '%3  !F4   6DP  %!)  !'10  /4$  #,]   J.0D )3<.
M ",W%  B.!L (3@B " X*  ?.#  'CDX !TY00 <.DL &CI6 !D[8P 8.W(
M%CN% !4\F0 4/*T $SW& !,]Z0 4//T %3S_ !8[_P"@2P  E5$  (M5  ""
M6   >5D  &Y8  !D5@  6%$  $Y/  !%2P  .D<  #!#   G0 4 (#X- !T^
M$0 </A< &SX> !H^)0 9/BT &#\U !8_/@ 5/T@ %$!3 !- 8  207  $4&"
M !!!EP /0:P #D+$  Y"YP /0?P $$'_ !! _P"=4   DU8  (E:  " 70
M=EX  &Q=  !B6P  5E<  $Q5  !!40  -DX  "Q+   C2   &T4) !=$#P 5
M1!0 %$4; !-%(@ 212D $44Q !%%.P 01D4 #T90  Y'7@ -1VT #$=_  M'
MDP )1Z< "$>^  A'X  )1_8 "D;_  M&_P":50  D%L  (=@  !]8@  <V,
M &IB  !@80  4UX  $=:   \5P  ,E4  "A2   ?4   %TX$ !%,#  /3!$
M#DP7  Y,'@ -324 #$TN  M--P *34( "4U-  =.6@ &3FD !$Y[  ).CP !
M3J0  $VZ  !-VP !3?(  4W_  ),_P"66P  C6(  (1F  !Z:   <6D  &AI
M  !<9P  3V0  $)A   W7P  +5P  "-:   :6   $E<!  U6"0 )50X !U43
M  95&@ $52(  U4J  )5-   53X  %5*  !65P  5F4  %5W  !5BP  5:
M %6V  !4U   5/$  %/]  !3_P"38@  BF@  (!L  !W;@  ;V\  &-N  !6
M;   26H  #UH   R9@  )V4  !UC   58@  #F$   E@"  #8 T  %\1  !?
M%P  7QX  %\F  !?+P  7SH  %]%  !?4P  7V$  %YR  !>AP  79P  %VR
M  !<SP  7.\  %O]  !;_P"0:@  AF\  'UR  !U=   :G4  %UT  !/<P
M0G(  #9P   K;P  (&X  !=M   0;   "FP   )K!@  :PL  &H/  !J%
M:AH  &HA  !I*@  :30  &E   !I3@  :5P  &EM  !H@@  :)@  &>N  !F
MR@  9>T  &7\  !D_P"+<0  @G8  'IY  !P>P  8GL  %5[  !(>@  .WH
M "]Z   C>0  &7@  !%W   *=P   W<   !W @  =P@  '8-  !V$   =A4
M '8;  !V(P  =BX  '4Z  !U1P  =58  '5H  !T?   =)(  '.J  !RQ
M<>D  '#[  !P_P"&>0  ?WT  '9_  !H@0  6H(  $R"   _@P  ,H0  "6#
M   :@P  $8,   J#   "@P   (0   "%    A ,  (,(  "##0  @Q   (,5
M  "$'   A"8  (0R  "$/P  @T\  (-@  ""=0  @HP  (&D  " O0  ?^,
M '[Y  !^_P""@   >H0  &R&  !>B   4(H  $*+   UC0  )XT  !N-   1
MC@  "HX   "/    D0   )(   "2    D@   )(!  "2!P  D@P  )(0  "3
M%0  DQT  )0H  "4-@  E$4  )-7  "3:P  DX(  )*<  "1M@  D-@  (_S
M  "/_P!^AP  <(H  &&-  !3D   19,  #>5   IE@  ')<  !&8   )F0
M )L   "<    G@   *    "@    H    *    "A    H00  *()  "C#@
MI!0  *4=  "F*@  ICH  *9,  "E8   I7@  *62  "DK   I,D  */K  "B
M^@!SC@  9)$  %:5  !'F0  .9P  "J>   =H   $:$   BC    I0   *<
M  "I    K    *X   "N    K@   *\   "P    L0   +(   "S!@  M0T
M +<3  "Y'@  N2X  +I   "Z5   NVH  +J%  "YH0  N;L  +K>  "Y\@!G
ME0  6)D  $J>   [H@  +*8  !VH   1J@  !ZP   "O    L0   +0   "X
M    NP   +P   "\    O@   +\   #     P@   ,0   #&    R ,  ,L+
M  #/$@  T2   -$R  #21@  TUT  -1V  #4D@  U:L  -7$  #4X@!;G0
M3*(  #VG   OK   'Z\  !&Q   'M0   +@   "[    O@   ,(   #'
MR@   ,P   #,    S@   -    #2    U0   -@   #;    WP   .(   #F
M"P  ZQ,  .PD  #M.   [DX  .]G  #P@@  \)P  /"R  #QQ0#_  , _P !
M /\ ! #_  D _P / /\ & #_ "0 _P P /\ / #_ $< _P!1 /\ 60#_ &
M_0!G /P ;0#Z ', ^0!Y /@ ?P#V (4 ]0", /, E #R )T \ "G .X LP#L
M ,0 ZP#A .H ^ #I /\ YP#_ -D _P#+ /\ P@#_ +T _P#_    _P   /\
M  #_    _P , /\ % #_ "  _P K /X -P#Z $( ]@!+ /( 4P#P %L [@!A
M .P 9P#J &T Z !S .< >0#E '\ XP"& .$ C@#? )8 W0"@ -L K #8 +L
MU #1 -, \ #0 /\ S@#_ ,@ _P"] /\ M@#_ +( _P#_    _P   /\   #_
M    _0 ( /< $ #S !H [P F .T ,0#H #L XP!% .  30#< %4 V0!; -8
M80#3 &< T0!L ,\ <@#- '@ RP!_ ,D AP#' )  Q0": ,, I0#  +( O@#%
M +P Y0"Z /L N #_ +< _P"P /\ J0#_ *4 _P#_    _P   /X   #U
M[  # .4 #0#? !4 V@ @ -0 *@#0 #4 RP ^ ,@ 1P#% $X P@!5 ,  6P"^
M &$ O !F +H ; "X '( M@!X +4 @ "S (@ L0"2 *X G@"L *H J0"[ *@
MU0"F /, I #_ *, _P"A /\ FP#_ )@ _P#_    ^P   /    #E    V
M ,X "0#' !$ P@ : +X ) "[ "X MP X +0 0 "Q $@ K@!. *P 5 "J %H
MJ0!? *< 90"E &L I !Q *( > "@ ($ G@"+ )P E@"9 *, EP"R )8 QP"3
M .@ D@#^ )$ _P"0 /\ C0#_ (L _P#Y    ZP   -T   #/    Q@   +P
M! "U  T L  5 *P '@"H "@ I0 Q *( .0"? $$ G0!( )L 3@"9 %, EP!9
M )8 7@"4 &0 D@!J )  <0". 'H C "# (H CP"( )P A@"J (0 O "" -P
M@0#V (  _P!_ /\ ?P#_ 'X _P#L    V@   ,D   "^    M@   *X   "G
M  D H0 0 )P & "8 "( E0 J )( ,@"0 #H C0!! (L 1P") $T AP!2 (8
M6 "$ %T @@!D ($ :P!_ ', ?0!] 'L B !X )4 =@"C '4 M !S ,P <0#M
M '  _P!P /\ < #_ '  _P#?!0  R@H  +P+  "Q"0  J 0  *$   ";  ,
ME  , (\ $P"* !L AP D (0 + "! #, ?P Z 'T 00![ $< >0!, '< 4@!V
M %< = != '( 9 !P &T ;P!V &P @@!J (\ :0"= &< K@!E ,, 9 #D &,
M^@!C /\ 8@#_ &, _P#0#@  OQ(  +(3  "G$@  G1   )4+  "/ P  B0 '
M (( #@!^ !4 >@ > '8 )0!T "T <0 T &\ .@!N $  ; !& &H 3 !I %(
M9P!8 &8 7P!D &< 8@!Q &  ? !> (D 7 "8 %L J0!9 +P 6 #< %@ ] !8
M /\ 5P#_ %< _P#&%@  MAH  *H=  "?'   E1D  (T4  "%#P  ?@D  '<!
M"@!R !  ;@ 7 &H 'P!H "< 90 N &0 - !B #L 8 !  %\ 1@!= $P 7 !3
M %H 6@!8 &( 5P!L %4 =P!3 (4 4@"4 % !I0!/ ;@ 3@+2 $T$\ !-!?\
M307_ $T%_P"_'0  L"(  *,E  "9)0  CR(  (4=  !]&   =1(  &X- @!G
M!@P 8P,1 %\"&0!= R$ 6P0H %D$+P!7!34 5@4[ %0&00!3!D< 409. % '
M50!.!UX 30AG $L(<P!)"8$ 2 F2 $<*HP!%"K8 1 O0 $0,[P!##?\ 0PW_
M $0-_P"Y)   JBD  )XL  "4+   BBH  ( F  !W(0  ;AL  &84  !?#P4
M60L- %4*$P!3"QL 40LB $\,*0!-#"\ 3 PV $L-/ !)#4( 2 U) $8-40!%
M#EH 1 YD $(.< ! #G\ /P^0 #X0H@ \$+8 .Q#1 #L1\0 [$?\ .Q'_ #P1
M_P"T*0  IB\  )HR  "0,@  AC$  'PM  !R*   :2,  &$=  !9%@  41$(
M $P/$ !*$!8 2! = $80) !%$"L 0Q$Q $(1-P!!$3X 0!%% #X230 ]$E8
M/!)A #H3;0 Y$WP -Q2- #84GP U%;, -!7- #,6[@ T%O\ -!;_ #06_P"O
M+@  HC0  )<W  ",.   @C8  '@T  !N+@  92H  %PD  !4'@  3!@$ $84
M#0!"%!( 0!09 #\4(  ]%2< /!4M #L5-  Y%CH .!9" #<62@ V%U, -1=>
M #,8:@ R&7D ,!F* "\:G0 N&K$ +1O* "T;[  M'/\ +AO_ "X;_P"L,@
MGS@  )0[  "*/   @#P  '8Y  !K-   8B\  %DJ  !0)0  1Q\  $ :"@ \
M&1  .AD6 #@9'0 V&B, -1HI #0:,  S&C< ,AL^ #$;1P O'%  +AU; "T=
M9P L'G8 *AZ( "D?FP H'ZX )R#' "8@Z@ G(/X *"#_ "@@_P"I-@  G3P
M )(_  "'00  ?4   '0^  !I.@  7S4  %8P  !-*P  1"4  #L@!P V'@X
M,QX3 #(>&0 P'B  +QXF "X?+0 M'S0 +" [ "L@1  J(4X *2%8 "<B90 F
M(G0 )2.% ",CF0 B)*T (23% "$EZ  B)?T (B3_ ",D_P"F.@  FC\  (]#
M  "%10  >T0  ')#  !G/P  73H  %,V  !*,0  02P  #@F P Q(PP +B(1
M "PB%@ J(AT *2(C "@C*@ G(S$ )B0Y "4E00 D)4L (R96 "(F8P A)W(
M'R># !XHEP =**L &RG# !LIY@ <*?L '2G_ !XH_P"C/@  F$,  (U'  "#
M20  >DD  '!'  !F1   6C\  %$[  !'-P  /C(  #4M   L* D *"</ "<G
M%  E)QH )"<A ",H)P B*"X (2DV " I/P ?*DD 'BI4 !TK8  ;*V\ &BR!
M !DLE0 7+:D %BW! !8MY  7+?H &"W_ !DM_P"A00  E4<  (M+  ""30
M>$T  &Y,  !D20  6$0  $]   !&/0  /3@  #,T   J+P8 )"P- "$L$@ @
M+!@ 'RT> !XM)0 =+2P '"XT !LN/  :+T8 &"]1 !<P7@ 6,&T %3%_ !,Q
MDP 2,:@ $3*_ !$RX@ 2,OD $S'_ !,Q_P">10  DTL  (E/  " 40  =E(
M &U0  !B3@  5DD  $U&  !$0P  .S\  #$Z   G-@, 'S(+ !PR$  ;,A4
M&3(; !@R(@ 7,RD %C,Q !4T.@ 4-$0 $S1/ !(U7  1-6L $#9]  \VD0 .
M-J8 #3>\  TWW0 --O8 #C;_  \V_P";20  D4\  (=3  !^5@  =58  &I5
M  !@4P  54\  $Q,  !"20  .$4  "Y!   D/0  '#H( !8X#@ 5.!( %#@8
M !,Y'P 2.28 $3DN ! Y-P /.D$ #CI,  T[60 -.V@ "SMZ  H[C0 )/*(
M!SRX  <\U0 (//  "3O_  H[_P"83@  CE0  (58  !\6P  <EL  &A:  !>
M6   4U4  $E2   ^3@  -$L  "I'   A1   &$(# !) "P 0/Q  #C\5  X_
M'  -0", #$ K  M -  *0#X "4%*  =!5@ &064 !$%V  -!B@ !09\  $&T
M  !!T  !0>X  4'\  ) _P"55   C%D  (->  !Y8   <&   &9@  !=7@
M45L  $57   Z5   +U$  "5/   <3   %$H   Y("  +1PX "$<2  ='&0 &
M1R  !4@H  -(,0 "2#L  $A'  !(4P  2&(  $AS  !(A@  2)L  $BQ  !'
MS   1^T  $?[  !'_P"26@  B6   (!C  !W90  ;F8  &5F  !99   3&
M $!=   U6P  *ED  "!7   750  $%,   M2!P %40T  5 1  !0%@  4!T
M % E  !0+@  4#@  %!#  !04   4%X  %!O  !0@P  3Y@  $^N  !.R0
M3NL  $W[  !-_P"/80  AF8  'UI  !T;   ;&T  &%K  !3:0  1F<  #ID
M   O8P  )&$  !I?   27@  #%P   9<!@  6PL  %H/  !:$P  6AD  %DA
M  !9*0  63,  %D_  !93   65H  %EK  !8?@  6)0  %>K  !7Q0  5ND
M %7[  !5_P",:   @FT  'IP  !R<@  9W(  %IQ  !,<   /VX  #-M   H
M:P  '6H  !1H   -9P  !V<   !F P  9@D  &4-  !E$0  9!4  &0<  !D
M)   9"X  &0Z  !C1P  8U4  &-F  !C>@  8I   &&G  !@P0  7^8  %_Z
M  !>_P"';P  ?W0  'AW  !N>   8'@  %)W  !%=P  .'8  "MV   @=
M%G,   YS   '<@   '(   !R    <04  '$*  !Q#@  <!$  ' 7  !P'@
M<"<  ' S  !O0   ;U   &]@  !N=   ;HL  &VB  !LO   :^(  &KX  !I
M_P"#=P  ?'L  '-]  !E?@  5W\  $E_   \?P  +X   ")_   7?@  #WX
M  =^    ?P   '\   !_    ?@   'X%  !^"@  ?@T  'X1  !^%P  ?B
M 'XK  !].0  ?4@  'U9  !\;0  ?(0  'N<  !ZM@  >=H  'CU  !W_P"
M?P  =X(  &F#  !;A0  388  #^(   RB0  )(D  !B)   /B0  !XH   "+
M    C    (T   "-    C    (P   ", P  C @  (T-  "-$0  C1<  (XB
M  ".+P  CC\  (U0  "-9   C'L  (R5  "+K@  BLT  (GO  ")_P![A0
M;8@  %Z*  !0C0  0H\  #21   FD@  &9,   Z4   &E0   )8   "8
MF@   )L   ";    FP   )L   ";    G    )T%  "="P  GA   )\7  "@
M)   H#0  *!&  "@60  GW   )^*  ">I0  GL(  )WH  "<^0!PC   88\
M %.2  !$E@  -ID  ">;   9G   #YT   6?    H0   *,   "E    J
M *D   "I    J0   *H   "K    K    *T   "N 0  L D  +(/  "S&
MM"<  +0Y  "U30  M&0  +1^  "SF@  L[0  +/5  "S\ !DDP  59<  $>;
M   XGP  *:(  !JD   .I@  !*@   "K    K0   +    "T    M@   +@
M  "X    N0   +H   "\    O0   +\   #     PP   ,4'  #)#P  RAH
M ,LL  #,0   S58  ,YO  #-BP  S*@  ,S"  #,X@!8FP  2:   #JE   L
MJ0  '*L   ^N   $L0   +0   "W    N@   +X   ##    Q@   ,@   #(
M    R@   ,L   #-    SP   -(   #5    V0   -T   #A!0  Y@\  .<>
M  #H,@  Z4@  .I@  #K>P  ZY<  .RN  #LP@#_    _P   /\   #_  8
M_P - /\ %0#_ "$ _P L /\ . #_ $, _P!, /X 5 #[ %L ^@!B /@ : #V
M &X ]0!T /0 >@#R (  \0"' .\ CP#M )< ZP"A .D K0#G +T Y0#8 .0
M\P#B /\ X #_ -  _P#$ /\ O #_ +8 _P#_    _P   /\   #_    _P )
M /\ $0#_ !P _0 G /D ,@#U #T \0!& .T 3P#K %8 Z !< .8 8@#D &@
MXP!N .$ <P#? 'D W0"  -H B #8 )$ U "; -( I@#/ +0 S #) ,D Z0#(
M /\ QP#_ ,$ _P"W /\ KP#_ *L _P#_    _P   /\   #_    ^  % /(
M#@#N !< Z@ B .8 + #A #< W0!  -@ 20#3 %  T !6 ,X 7 #, &( R@!G
M ,@ ;0#& ', Q !Y ,( @0#  (H O@"4 +P GP"Y *P M@"^ +0 W0"S /<
ML0#_ +  _P"H /\ H@#_ )X _P#_    _P   /D   #O    Y@   -\ "P#6
M !( T  < ,P )@#( #  Q  Z ,  0@"] $H NP!0 +@ 5@"V %L M0!A +,
M9@"Q &P L !R *X >@"L (( J0", *< F "E *4 HP"T *  RP"? .X G0#_
M )P _P"9 /\ E #_ )$ _P#_    ]@   .H   #=    SP   ,< !@#   \
MNP 7 +< ( "S "H L  S *T .P"J $, IP!) *4 3P"C %4 H@!: *  7P">
M &4 G0!K )L <@"9 'L EP"% )0 D "2 )T D "L (X OP", .( BP#Z (D
M_P") /\ A@#_ (, _P#T    Y    -0   #(    OP   +4  0"N  L J0 2
M *4 &P"A ", G@ L )L - "8 #P E@!# )0 20"2 $X D !3 (X 60"- %X
MBP!D (D :P"' ', A0!] (, B "! )4 ?P"D 'T M0![ ,\ >0#Q '@ _P!W
M /\ =P#_ '4 _P#E    T0   ,,   "X    KP   *@   "@  8 F@ . )4
M%0"1 !X C@ F (L +0"( #4 A@ \ (0 0@"" $< @ !- '\ 4@!] %@ >P!>
M 'D 90!X &T =@!V ', @0!Q (X ;P"= &T K@!L ,0 :@#G &D _0!H /\
M: #_ &D _P#5 P  PP<  +8(  "K!@  H@   )L   "4    C0 * (@ $ "#
M !@ ?P @ 'P )P!Z "X =P U '4 .P!T $$ <@!' '  3 !O %( ;0!8 &L
M7P!I &8 9P!P &4 >P!C (@ 8@"7 &  IP!> +L 70#< %P ]@!< /\ 6P#_
M %L _P#)#0  N1   *P1  "A$   EPT  (\(  "(    @@ % 'L #0!W !(
M<P : &\ (0!L "@ :@ O &@ -0!G #L 90!! &, 1@!B $P 8 !2 %\ 60!=
M &$ 6P!J %D =0!7 (( 50"1 %0 H@!3 +4 40#/ %  [P!0 /\ 4 #_ %
M_P"_%   L!@  *0:  "9&0  CQ8  (<1  !_#0  =P8  '$ " !K  X 9P 4
M &0 &P!A "( 7@ I %T +P!; #4 60 [ %@ 00!6 $8 50!- %, 5 !2 %P
M4 !E $X < !, 'T 2P"- $D G@!( +  1P#' $8 Z0!& /L 1@#_ $4 _P"X
M&P  JB   )XB  "3(@  B1\  ( :  !W%0  ;Q   &@+  !A! H 70 0 %D
M%@!6 !T 5  C %( *@!0 #  3P U $X .P!, $$ 2P!( $D 3P!' 5< 1@%A
M $0"; !# GD 00.) $ #F@ ^!*T /03$ #P%Y0 \!_@ / ?_ #P'_P"R(@
MI2<  )DI  ".*0  A"<  'LC  !Q'@  :1@  &$2  !:#0, 4P@, $\%$0!,
M!1< 2@8> $@&) !'!BH 10<P $0'-@!#"#T 00A# $ (2P ^"5, /0E= #L*
M:  Z"G8 . N' #<+F0 U"ZP - S" #,,Y  S#?D ,PW_ #0-_P"M)P  H"P
M )4O  "++P  @"X  '<J  !M)0  9"   %P:  !4%   3 \& $8,#0!##!(
M00P8 #\,'P ^#"4 / TK #L-,@ Z#3@ . T_ #<.1P V#E  - Y: #,.9@ Q
M#W0 , ^% "X0F  M$*L +!## "L1Y0 L$?H +!'_ "T1_P"J+   G3$  )(T
M  "'-0  ?30  '0Q  !J*P  8"<  %@A  !/&P  1Q8  $ 1"0 [$ \ .1 4
M #<0&P V$"$ -! G #,1+0 R$30 ,1$[ # 10P N$DT +1)7 "P28P J$W$
M*1." "<4E0 F%*D )17  "05XP E%OH )A;_ "85_P"F,0  FC8  (\Y  "%
M.@  >SD  '$V  !G,0  72T  %0H  !,(@  0QT  #L7!0 U% T ,A,1 #$4
M%P O%!T +A0D "P4*@ K%3$ *A4X "D60  H%DH )Q=4 "878  D&&\ (QB
M "$9DP @&:< 'QF^ !X:X  ?&O@ (!K_ " :_P"C-   F#H  (T]  "#/@
M>3T  &\[  !E-P  6S(  %(M  !)*   0",  #@> 0 P&0H +!@/ "H8%  I
M&!H )Q@@ "89)P E&2T )!HU ",:/@ B&T< (1M2 " <7@ ?'6P '1U^ !P=
MD0 :'J4 &1Z\ !@?W0 9'_8 &A__ !L>_P"A.   E3T  (M!  "!0@  =T(
M &U   !C/   63<  $\S  !&+@  /2D  #4D   M( < )QT- "4=$@ C'1<
M(1T= "$=)  @'BL 'QXR !X?.P ='T4 '"!/ !HA7  9(6H &")[ !8BCP 5
M(J, %".Z !,CV@ 4(_4 %2/_ !8C_P">/   DT$  (E$  !_1@  =48  &Q$
M  !B00  5SP  $TX  !$-   /#   #,K   J)@, (R(+ " A$  >(14 '"(;
M !LB(0 :(B@ &B,P !DC.  8)$( %B5- !4E60 4)F@ $R9Y !(FC0 1)Z(
M$">X  XGU@ 0*/0 $2?_ !$G_P"<0   D44  (=(  !]2@  =$H  &I)  !@
M1@  54$  $P^  !#.@  .C8  #$R   H+0  ("D) !LG#@ 9)Q( &"<8 !8G
M'P 5*"4 %"@M !,H-@ 2*4  $BE+ !$J5P 0*F8 #BMW  XKBP -+)\ #"RU
M  LLSP ,+.\ #2S_  TK_P"91   CTD  (5,  !\3@  <T\  &E.  !>2P
M4T<  $I$  !"0   .3T  "\X   E-   '3 % !8M#  4+!  $RT5 !(M'  1
M+2, $"TJ  \N,P .+CT #2](  TO50 ,,&, "C!T  DPB  (,9P !C&Q  8Q
MRP &,>L !S#\  @P_P"72   C4T  (-1  !Z4P  <50  &=2  !=4   4DP
M $E*  ! 1@  -4(  "L^   B.@  &C<! !(T"0 /,PX #C,3  TS&0 -,R
M##0H  LT,0 *-3L "#5&  <U4@ %-F  !#9Q  (VA   -ID  #:O   VR
M-N@  #;Y  $U_P"430  BE(  (%6  !X6   ;UD  &58  !;50  45(  $=/
M   \3   ,4@  "=$   >00  %C\  ! \!P +.@T "3H1  @[%P &.QX !3LF
M  0[+@ ".S@  3Q#   \3P  /%X  #QN   \@0  /)<  #RL   [Q0  .^<
M #OX   [_P"14@  B%@  ']<  !V70  ;5X  &-=  !:7   3E@  $)4   W
M40  +4X  "-+   :20  $D8   U$!@ '0PP  T,0  !#%0  0QL  $,C  !#
M*P  0S4  $-   !#30  0UL  $-K  !#?@  0Y0  $*J  !"PP  0>8  $'Y
M  !!_P".6   AEX  'UA  !S8P  :V0  &)C  !780  25T  #U:   R6
M)U4  !Y3   540  #D\   E-!0 "30L  $P.  !,$P  2Q@  $L?  !+*
M2S(  $L]  !+20  2U<  $MG  !*>P  2I   $FG  !)P   2.0  $CX  !'
M_P"+7P  @V0  'IG  !Q:0  :6H  %YI  !09@  0V0  #=A   L7P  (5T
M !A;   060  "E@   -7 P  5PD  %8-  !5$   514  %0;  !4(P  5"T
M %0Y  !410  5%,  %1D  !3=P  4XT  %*D  !1O0  4.(  %#X  !/_P"(
M9P  ?VL  '=N  !O<   97   %=N  !*;   /6L  #!I   E:   &F8  !%D
M   +8P  !&(   !B 0  808  & +  !@#@  7Q(  %\7  !?'@  7B@  %XS
M  !>0   7D\  %Y?  !=<@  78@  %R@  !;N0  6M\  %GW  !8_P"$;@
M?'(  '5U  !K=@  774  $]T  !"<P  -7,  "AR   =<   $V\   QN   $
M;@   &X   !N    ; (  &P'  !K"P  :PX  &L2  !J&0  :B(  &HM  !J
M.@  :4D  &E:  !I;   :(,  &>;  !FM0  9=@  &3U  !D_P" =0  >GD
M '![  !B>P  5'P  $9\   Y?   +'P  !][   4>@  #7H   1Z    >@
M 'H   !Z    >0   'D!  !X!@  > L  '@.  !X$P  >!H  '@E  !X,@
M=T$  '=2  !W90  =GP  '65  !TKP  <\X  '+Q  !Q_P!^?0  =8   &>!
M  !8@@  2H,  #R$   NA0  (84  !6%   -A0   X4   "&    AP   (@
M  "(    AP   (<   "'    AP0  (<)  "'#@  B!,  (@<  "(*0  B#@
M (=*  "'70  AG,  (:-  "%IP  A,4  (/L  ""_@!XA   :H8  %R(  !-
MB@  /XP  #&.   CCP  %H\   V0   "D0   )(   "3    E0   )8   "6
M    E@   )8   "6    EP   )<   "7!P  F T  )D3  ":'P  FBT  )H_
M  ":4@  FF@  )F#  "9GP  F+H  )?B  "6^ !MB@  7XT  %"0  !!DP
M,Y8  "27   6F   #9D   &;    G0   )\   "A    I    *4   "D
MI0   *4   "F    IP   *@   "I    J@0  *P,  "N$P  KB$  *XS  "N
M1P  KET  *YV  "NDP  KJX  *W-  "L[P!AD0  4Y4  $28   UG   )I\
M !>A   -HP   *4   "G    J@   *P   "P    L@   +0   "S    M
M +4   "W    N    +D   "[    O0   +\!  ##"P  Q14  ,4E  #&.0
MQT\  ,=H  #&A0  QJ(  ,:\  #&W@!5F0  1YT  #BB   II@  &:@   VK
M    K0   +$   "T    MP   +H   "_    P0   ,0   ##    Q0   ,8
M  #(    R@   ,T   #/    T@   -8   #;    X P  .$8  #C*P  Y$$
M .5:  #F=   YI$  .6L  #EQ #_    _P   /\   #_  $ _P * /\ $@#_
M !T _P H /\ - #_ #X _0!( /H 4 #W %< ]0!= /0 8P#R &D \ !O .\
M= #M 'L ZP"! .D B0#H )( Y@"< .0 J #B +< WP#- -P [@#9 /\ V0#_
M ,H _P"^ /\ M0#_ +  _P#_    _P   /\   #_    _P & /\ #P#\ !@
M^  C /0 +@#P #@ ZP!" .@ 2@#E %$ X@!8 .  70#> &, W !H -D ;@#6
M '0 U ![ -$ @@#/ (L S0"5 ,H H0#( *\ Q0#! ,( XP#  /L P #_ +L
M_P"P /\ J #_ *0 _P#_    _P   /\   #[    \P ! .T # #H !, XP >
M .  * #: #( TP \ ,\ 1 #, $L R0!1 ,8 5P#$ %T P@!B ,$ 9P"_ &T
MO0!T +L >P"Y (0 MP". +0 F0"R *< KP"W *T T "K /( J@#_ *D _P"A
M /\ FP#_ )< _P#_    _P   /0   #I    X    -4 " #. !  R0 8 ,4
M(@#! "L O  U +D /0"V $4 LP!+ +$ 40"O %8 K@!; *P 80"J &8 J0!M
M *8 = "D 'P H@"& *  D@"> )\ G "N )D PP"7 .< E@#_ )4 _P"2 /\
MC0#_ (H _P#\    \    .,   #4    R    +\  P"Y  T LP 3 *\ ' "L
M "4 J0 N *4 -@"C #X H !$ )X 2@"= %  FP!5 )D 6@"7 %\ E@!F )0
M; "2 '4 D !^ (X B@"+ )< B0"F (< N "% -8 A #V (( _P"! /\ ?@#_
M 'P _P#M    W0   ,P   #!    N    *X   "G  D H@ 0 )X %P": !\
MEP G )0 +P"1 #< CP ] (T 0P"+ $D B0!. (@ 4P"& %D A !? (( 90"
M &T ?@!W 'P @@!Z (\ > "> '4 KP!S ,< <@#L '$ _P!P /\ < #_ &X
M_P#=    R0   +P   "Q    J0   *$   "9  , DP , (X $@"* !D AP A
M (0 *0"! #  ?P W 'T /0![ $( >0!( '@ 30!V %( = !8 '( 7P!Q &<
M;P!P &P >P!J (@ : "7 &8 J !E +P 8P#A &( ^@!A /\ 80#_ &$ _P#-
M 0  O 4  *\%  "E @  G    )0   "-    A@ ( ($ #@!\ !0 >  ; '4
M(P!R "D <  P &X -@!M #P :P!! &D 1P!H $P 9@!2 &0 60!C &  80!I
M %\ = != ($ 6P"0 %D H0!7 +0 5@#0 %4 \@!5 /\ 5 #_ %4 _P#!#
ML@X  *8/  ";#@  D@L  (D%  ""    >P " '4 "P!P !  ;  6 &@ '0!F
M ", 8P J &$ , !@ #8 7@ [ %T 00!; $8 6@!, %@ 4P!6 %L 5 !D %(
M;@!1 'L 3P"* $T FP!, *X 2P#& $H Z@!) /X 20#_ $D _P"Y$@  JA8
M )X7  "4%@  BA,  ($0  !Y"P  <0,  &L !@!E  T 80 1 %T & !: !X
M6  D %8 *@!4 #  4P V %$ .P!0 $$ 3@!' $T 3@!+ %8 20!? $< :0!&
M '8 1 "% $, EP!! *D 0 "_ #\ X@ _ /@ /@#_ #\ _P"R&0  I!X  )@?
M  ".'P  A!P  'H8  !R$@  :@X  &((  !< 0@ 5P . %, $P!0 !D 3@ ?
M $P )0!* "L 2  P $< -@!& #P 1 !" $, 20!! %$ /P!: #X 90 \ '(
M.@"! #D DP X *4 -@"Z #8 VP U /0 -0#_ #4 _P"L(   GR0  )0F  ")
M)@  ?R0  '4@  !L&P  9!4  %P0  !4# $ 3@8* $H"#P!' !0 1  : $(
M( !  "4 /P K #X!,0 \ 3< .P(^ #D"10 X TT -@-6 #4$80 S!&X ,05^
M # %D  O!:, +0:X "P&U  L!_  + C_ "P(_P"H)0  FRH  ) L  "&+0
M>RL  '(G  !H(@  7QT  %<7  !/$@  2 X$ $$*"P ^!Q  .P85 #D'&P X
M!R$ -@@F #4(+  S"#( ,@DY #$)00 O"4D +@I3 "P*7@ K"VP *0M\ "@,
MCP F#*( )0RW "0,TP C#?  ) W_ "4-_P"D*@  F"\  (TR  "#,@  >3$
M &\N  !E*0  7"0  %,?  !+&0  0Q,  #P0!@ U#0P ,PP1 #$,%@ O#!P
M+@TB "T-*  K#2X *@TU "D-/0 G#D8 )@Y0 "0.7  C#VH (@][ " 0C@ ?
M$*( '1"W !P0U  =$?( '1'_ !X1_P"A+P  E3,  (HV  " -P  =C8  &TS
M  !C+P  62H  % E  !((   /QH  #@5   P$0@ +! . "H0$@ H$!@ )Q >
M "40)  D$"H (Q$R "(1.@ A$4, (!). !X26@ =$V@ &Q-X !H3BP 8%*
M%Q2U !84T0 6%?$ %Q7_ !@4_P">,P  DS<  (@Z  !^.P  =#L  &LX  !A
M-   5R\  $XK  !%)@  /2$  #0<   M%P4 )A,, ",3$  B$Q4 (!,: !\3
M(0 >%"< '10O !P5-P ;%4$ &A9+ !D65P 7%V4 %A=V !08B0 3&)X $ABS
M !$9S@ 1&>\ $AG_ !,9_P"<-@  D3L  (8^  !\/P  <S\  &D]  !?.0
M534  $PP  !#+   .B<  #(B   J'@$ (AD) !X7#@ <%Q( &A<7 !D8'@ 9
M&"0 &!DL !<9-  6&CX %1I) !,;50 2&V, $1QT ! <AP /'9P #AVQ  T=
MRP -'>P #AW_  \=_P"9.@  CS\  (1"  ![1   <4,  &A"  !>/@  4SH
M $HV  !!,@  .2T  #$I   H)0  (" & !H=#  7'!  %1P5 !0=&P 4'2(
M$QTI !(>,@ 1'SP $!]& ! @4P .(&$ #2%Q  PAA0 +(ID "B*N  DBQP )
M(N< "B+[  LA_P"7/@  C$,  (-&  !Y2   <$@  &=&  !<1   4C\  $D[
M  ! .   .#0  "\P   G+   'B<# !8C"@ 2(0X $2$3 ! B&0 0(B  #R(G
M  XC+P -)#D #"1$  LE4  *)5X "29O  <F@@ &)I8 !":L  ,FQ  $)N4
M!";W  8F_P"50@  BD<  (%*  !X3   ;TP  &5+  !;2   4$0  $=!   _
M/@  -SL  "TV   D,0  &RT  !,J!P /* T #2<1  TH%@ ,*!T "R@E  HI
M+0 )*3< !RI"  8J3@ $*UP  RML  $K?P  *Y0  "NI   KP0  *^,  "OV
M   J_P"21@  B$L  ']/  !V40  ;5$  &-0  !:30  3TH  $='   ^1
M,T   "D\   @.   %S0  !$Q!0 ,+PP "2X0  <N%0 &+QL !2\C  ,O*P "
M,#4  # _   P3   ,5D  #%I   Q?   ,9$  #&G   POP  ,.$  ##U   O
M_P"02P  AE   'U4  !U5@  :U8  &)5  !84P  3E   $5-   Z20  +T4
M "5"   </@  %#L   XY!0 )-PL !#8/  $V$P  -AD  #8@   V*0  -C(
M #<]   W20  -U<  #=G   W>0  -X\  #:E   VO0  -N   #7U   U_P"-
M4   A%8  'Q:  !R6P  :5L  &!;  !760  3%8  $!2   U3@  *DL  "!(
M   71@  $$,   M!!  $0 H  #\.   ^$0  /A8  #X=   ^)@  /B\  #XZ
M   ^1@  /E0  #YD   ^=@  /8P  #VC   \NP  /-X  #OU   [_P"*5P
M@EP  'E?  !P80  :&$  %]A  !47@  1UL  #I7   O50  )5(  !M0   2
M30  #$L   9* P  20D  $@-  !'$   1Q0  $8:  !&(@  1BP  $8W  !&
M0P  1E$  $9@  !%<P  18D  $2@  !$N   0]P  $+U  !"_P"(70  ?V(
M '=E  !N9P  9V@  %MF  !.8P  06$  #1>   I7   'UH  !57   .5@
M!U0   !3 0  4@8  %$+  !1#@  4!$  $\6  !/'@  3R<  $\R  !//P
M3TT  $Y=  !.;P  3H4  $V=  !,M0  2]@  $KU  !*_P"%90  ?&D  '1L
M  !M;@  8FT  %1K  !':0  .F<  "UE   B9   &&(  !!@   )7P   %X
M  !>    70,  %P(  !;#   6@\  %H3  !9&0  62(  %DM  !9.@  64@
M %A8  !8:P  5X$  %>9  !6L@  5=(  %3T  !3_P"!;   >7   '-S  !H
M<P  6G(  $QQ   _<   ,F\  "5N   :;   $6L   EJ    :@   &D   !I
M    :    &<#  !F"   9@P  &8/  !E%   91P  &4G  !D-   9$,  &13
M  !D90  8WL  &*4  !AK0  8,T  %_Q  !>_P!]=   =W<  &YY  !?>0
M47D  $-Y   V>   *7@  !QW   1=@  "G4   !U    =0   '8   !U
M=    '0   !S @  <P<  ',,  !R$   <A4  '(@  !R+   <CL  '%,  !Q
M7P  <70  '".  !OJ   ;L8  &SM  !K_P![>P  <GX  &1^  !5?P  1X
M #F!   K@@  'H$  !*!   *@0   ($   ""    @P   (,   "#    @@
M ((   ""    @@   ((%  """@  @@\  ((7  ""(P  @C(  ()#  "!5@
M@6P  ("&  !_H0  ?KT  'WF  !\_ !V@@  :(,  %F%  !+AP  /(D  "Z*
M   @BP  $XL   J+    C    (T   "/    D0   )(   "1    D0   )$
M  "1    D0   )(   "2 @  DPD  )0/  "4&0  E"<  )0X  "43   DV(
M )-\  "3F   DK,  )'8  "0]@!JB   7(H  $V-   _D   ,)(  "&4   4
ME0  "I8   "7    F0   )L   "=    GP   *    "@    H    *    "A
M    H@   *,   "D    I0   *8'  "H$   J!P  *@M  "I0   J58  *EO
M  "IBP  J*@  *?'  "F[ !?CP  4)(  $&6   SF0  (YP  !2=   *GP
M *$   "C    I@   *@   "L    K@   *\   "O    L    +    "R
MLP   +0   "V    MP   +H   "]!P  OQ   +\?  # ,P  P$D  ,!B  #
M?@  P)L  ,"W  "_V !3EP  1)L  #6?   FHP  %J4   NG    J@   *T
M  "P    LP   +8   "[    O0   ,    "_    P0   ,(   #$    Q@
M ,@   #*    S    ,\   #3    V@<  -L3  #=)0  WCL  -]3  #@;@
MWXP  -VI  #=P@#_    _P   /\   #_    _P ' /\ $ #_ !D _P D /\
M+P#\ #H ^0!# /4 2P#S %( \0!9 .\ 7@#M &0 ZP!I .D ;P#G '4 Y@!\
M .0 A #B (T X "7 -T H@#: +$ U0#% -( Z #0 /\ SP#_ ,0 _P"X /\
MKP#_ *D _P#_    _P   /\   #_    _P " /L #0#W !4 \P ? .\ *0#J
M #0 Y@ ] .( 10#> $P VP!3 -@ 6 #4 %X T@!C -  :0#. &X S !U ,H
M?0#( (4 Q@"0 ,( FP#  *D O@"Z +L V0"Y /< N #_ +0 _P"I /\ H@#_
M )T _P#_    _P   /\   #V    [@   .< "@#A !$ W  : -< (P#0 "X
MRP W ,< /P#$ $8 P0!- +\ 4@"] %@ NP!= +D 8@"X &@ M@!N +0 =0"Q
M 'X KP"( *T DP"J *$ J "Q *8 R "D .T H@#_ *( _P"; /\ E0#_ )$
M_P#_    _    .X   #C    V    ,T !0#&  X P0 5 +T '@"Y "< M0 P
M +( . "O $  K !& *H 3 "H %$ IP!6 *4 6P"C &$ H0!G )\ ;@"> '8
MFP"  )D C "7 )D E "H )( O "0 -\ C@#[ (X _P"+ /\ A@#_ (, _P#X
M    Z0   -P   #,    P0   +@   "R  H K  1 *@ & "E "$ H@ I )X
M,@"< #D F0 _ )< 10"5 $H E !0 )( 50"0 %H CP!@ (T 9P"+ &\ B0!X
M (8 A "$ )$ @@"@ (  L@!] ,P ? #Q 'L _P!Z /\ =P#_ '4 _P#F
MTP   ,8   "[    L0   *<   "A  4 FP - )< $P"3 !L D  C (P *P"*
M #( B  X (8 /@"$ $0 @@!) ($ 3@!_ %, ?0!9 'L 8 !Y &@ =P!Q '4
M? !S (D < "8 &\ J0!M +\ :P#F &H _P!I /\ :0#_ &< _P#3    PP
M +4   "K    HP   )L   "2    C  * (< $ "# !8 ?P = 'T ) !Z "L
M>  R '8 . !T #T <@!" '$ 2 !O $T ;0!3 &P 60!J &$ : !J &8 = !D
M ($ 80"1 %\ H@!> +8 7 #5 %L ]P!; /\ 6@#_ %H _P#%    M@(  *D"
M  "?    E@   (X   "'    @  % 'H # !U !$ <0 8 &X '@!K "4 :0 K
M &< ,0!F #< 9  \ &, 00!A $< 7P!- %X 4P!< %L 6@!D %@ ;@!6 'L
M5 "* %( FP!1 *X 4 #( $\ [@!. /\ 3@#_ $T _P"["@  K T  * -  "5
M#   C @  (,"  !\    =0   &X " !I  X 90 3 &( &0!? !\ 70 E %L
M*P!9 #$ 6  V %8 .P!5 $$ 4P!' %$ 3@!0 %4 3@!> $P : !* '4 2 "$
M $< E0!% *@ 1 "_ $, Y !" /P 0@#_ $( _P"R$0  I10  )D5  ".$P
MA!$  'L-  !S"   ;    &4  P!?  L 6P / %< % !4 !H 40 ? $\ )0!.
M "L 3  P $L -@!) #P 2 !" $8 2 !% %  0P!9 $$ 8P _ &\ /@!^ #P
MD  [ *, .@"X #D V0 X /4 . #_ #@ _P"L%P  GQL  ),=  ")'   ?QD
M '45  !L$   9 P  %T&  !6  8 40 , $T $ !* !4 1P : $4 ( !$ "8
M0@ K $$ ,0 _ #8 /@ ] #P 1  [ $L .0!4 #< 7P V &L - !Z #( C  Q
M )X , "S "\ S@ O .\ +@#_ "X _P"G'@  FB(  (\D  "$)   >B$  '$=
M  !G&   7Q,  %<.  !0"@  20,( $4 #0!! !$ /@ 6 #P &P Z "$ .0 F
M #< +  V #( -  X #, /P Q $< , !0 "X 6P M &< *P!V "H B  H )P
M)P"P "8 R0 E .H )0'[ "4!_P"B(P  EB@  (LJ  "!*@  =R@  &TE  !D
M(   6QL  %(5  !+$   0PP" #T'"0 Y PX -@$2 #,!%P Q 1P , $B "\"
M)P M BT + ,T "H#.P I!$, * 1- "8%6  E!64 (P9T "(&A@ @!IH 'P>N
M !X'Q@ =!^< '0CX !T)_P"?*   DRT  (@O  !^+P  ="X  &HK  !A)@
M6"$  $\<  !'%P  /Q(  #@.!  Q"PH +@@. "L'$@ I!Q< * @= "<((P E
M""D ) DP ",)-P A"D  ( I* !\+50 ="V( &PQR !H,A0 8#)D %PRM !8,
MQ@ 5#>8 %0WY !8-_P"<+0  D#$  (8T  !\-   <C,  &@Q  !?+   52<
M $PC  !$'0  /!@  #03   M$ 8 )@T+ "0,#P B#!, (0P9 !\,'P >#24
M'0TL !L--  :#CT &0Y' !<.4P 6#F$ % ]Q !,0A  2$)@ $1"N ! 0Q@ 0
M$.@ $!#[ !$0_P"9,0  CC4  (0X  !Z.0  <#@  &<V  !=,@  4RT  $HH
M  !")   .1\  #$:   J%0$ (Q$' !T0#0 ;#Q  &0\5 !@0&P 7$"$ %A I
M !40,0 4$3H $Q%% !(240 1$E\ $!)O  X3@@ .$Y8 #1.K  L3P@ +%.,
M#!3Z  T3_P"7-0  C#D  ((\  !X/0  ;ST  &4Z  !;-P  4C(  $DN  !
M*@  -R4  "\A   H'   (!@# !D4"@ 5$@X %!(2 !,3&  2$Q\ $10F !$4
M+@ 0%#@ #Q5"  X63P -%EP #!=L  L7?P )&), "!BH  88OP '&.  !QCU
M  D8_P"5.   BCT  (!   !W00  ;4$  &0_  !:/   4#@  $<S   ^,
M-BL  "XG   G(P  'Q\  !<:"  2%PT $!<1  \7%@ .&!P #A@C  T9+  ,
M&C4 "QI   H;3  )&UH !QQI  4<?  $'9$  AVF  $=O  "'-T  ASR  ,<
M_P"3/   B$$  ']$  !U10  ;$4  &-$  !900  3ST  $8Y   ^-@  -3(
M "XN   E*@  '24  !0A!  /'0L #1T0  P=%  +'1H "AXB  @>*@ ''S,
M!B ^  0@2@ #(5<  2%G   A>0  (8X  "&D   AN@  (=L  "'R   @_@"0
M0   AD4  'U(  !T2@  :TH  &))  !81@  3D(  $4_   ]/   -3D  "LT
M   B+P  &2L  !(H!  -) H "2,.  8C$@ %(QD !"0@  (D*  !)3$  "4\
M   E2   )E4  "9E   F=P  )HP  ":B   FN0  )MD  "7R   E_@".10
MA$D  'M-  !S3P  :D\  &!.  !72P  34@  $1%   \0@  ,3T  "<Y   >
M-0  %3(   \N P *+ H !2L.  $J$0  *A8  "H>   J)@  *R\  "LY   K
M10  +%,  "QB   L=0  +(H  "N@   KMP  *]8  "KR   J_P",20  @DX
M 'I2  !Q5   :%0  %]3  !640  3$X  $-+   W1P  +4,  ",_   :/
M$C@   PV P &,PD  #(-   R$   ,10  #$;   Q(P  ,2P  #(W   R0P
M,E   #)@   R<@  ,H<  #&>   QM0  ,-0  ##R   O_P")3P  @%0  'A7
M  !O60  9ED  %Y9  !55P  25,  #Y/   R3   *$@  !Y%   50@  #D
M  @] @ !/ @  #L,   Z#P  .1(  #D8   Y(   .2D  #DT   Y0   .4X
M #E=   Y;P  .(4  #B<   WLP  -](  #;R   U_P"'50  ?UH  '9=  !M
M7P  95\  %U?  !27   1%@  #A5   M4@  (D\  !A,   02@  "D@   -&
M 0  108  $0*  !##0  0A   $$5  !!'0  028  $$Q  !!/0  04H  $%:
M  !!;   0($  #^9   _L0  /M   #WR   \_P"$7   ?&   '-C  !L90
M9&8  %ED  !+80  /EX  #);   F60  '%8  !)4   ,4@  !%$   !/
M3@,  $T(  !,#   2PX  $L2  !*&0  2B(  $HL  !*.0  2D<  $I6  !)
M:   27X  $B6  !'KP  1LT  $7Q  !$_P"!8P  >6<  ')J  !K;   8&L
M %)I  !$9@  -V0  "IB   ?8   %5X   U=   &6P   %H   !9    6
M %<$  !6"   5@P  %40  !4%   5!T  %0G  !4-   5$(  %-2  !39
M4GD  %*2  !1JP  4,H  $_O  !._P!^:@  =VX  '!Q  !F<0  6'   $IO
M   \;0  +VP  ")J   7:0  #F<   9F    90   &4   !E    8P   &(
M  !B!   80@  &$-  !@$   8!<  & A  !?+@  7SP  %]-  !>7@  7G0
M %V-  !<IP  6\4  %KM  !9_P![<@  =78  &MW  !==@  3W8  $%U   S
M=0  )G0  !ES   0<@  !W$   !Q    <0   '$   !Q    ;P   &\   !N
M    ;@(  &X(  !M#   ;1$  &T:  !M)@  ;#4  &Q&  !K6   :VT  &J&
M  !IH0  :+X  &?H  !F_@!Y>@  <'P  &%\  !3?0  1'T  #9^   H?@
M&WT  !!]   '?0   'T   !]    ?@   '\   !^    ?0   'T   !\
M?    'P   !\!@  ? P  'P2  !\'0  ?"P  'P\  !\3P  >V4  'M^  !Z
MF@  >;8  'C?  !W^@!S@   98$  %:#  !(A   .88  "N'   =AP  $8<
M  >(    B    (D   "*    C    (T   "-    C    (P   ",    C
M (P   "-    C00  (X,  ".$P  CR$  (XR  ".1@  CEL  (UT  "-D
MC*T  (O.  "*\P!HA@  6H@  $N+   \C0  +8\  !Z0   1D0  !Y(   "3
M    E0   )<   "9    FP   )P   ";    FP   )P   "<    G0   )X
M  ">    GP   *$#  "B#   HA8  *,F  "C.@  HT\  *-H  "BA@  HJ(
M *+   "AZ !<C0  39   #^3   PE@  (9D  !*:   'FP   )T   "@
MH@   *0   "H    J@   *L   "J    JP   *P   "M    K@   *\   "Q
M    L@   +0   "W 0  N0T  +D:  "Z+0  ND,  +I;  "Z=P  NY0  +NQ
M  "YT@!0E0  09@  #*<   CH   $Z(   BD    IP   *H   "L    KP
M +(   "W    N0   +L   "Z    O    +T   "_    P    ,(   #$
MQ@   ,D   #-    T@$  -0/  #5'P  US4  -A-  #8:0  UX8  ->C  #6
MO0#_    _P   /\   #_    _P # /\ #0#_ !4 _P @ /P *P#X #4 ]  _
M /  1P#N $X ZP!4 .D 6@#G %\ Y0!D ., :@#A '  WP!V -T ?@#; (<
MV "1 -, G0#/ *L S0"] ,L X #) /L QP#_ +T _P"Q /\ J0#_ *, _P#_
M    _P   /\   #_    _    /8 "P#Q !$ [0 ; .D )0#D #  WP Y -H
M00#5 $@ T0!. ,\ 5 #- %D RP!> ,D 8P#' &D Q0!O ,, =P#  '\ O@"*
M +L E0"X *, M@"T +0 S0"R /( L #_ *P _P"C /\ G #_ )< _P#_
M_P   /H   #Q    Z    .  !@#9  X T@ 6 ,X 'P#( "D Q  R ,  .@"]
M $$ N@!( +@ 30"V %, M !8 +( 70"P &( K@!I *P ;P"J '@ J "" *8
MC@"D )L H0"K )\ P "= .8 FP#_ )H _P"4 /\ C@#_ (H _P#_    ]@
M .@   #<    S@   ,8  0"_  L N@ 1 +8 &@"R "( K@ K *H - "H #L
MI0!! *, 1P"A $P GP!1 )X 5@"< %P F@!B )D : "7 '  E0!Z )( A@"0
M ), C0"B (L M0") -, AP#W (8 _P"$ /\ ?P#_ 'P _P#R    XP   -(
M  #%    N@   +$   "K  < I0 . *$ % "> !P F@ E )< +0"4 #0 D@ Z
M )  0 ". $4 C0!* (L 4 ") %4 B !; (8 80"$ &D @@!R '\ ?0!] (L
M>P": '@ JP!V ,0 = #K ', _P!S /\ < #_ &X _P#?    S    +\   "T
M    JP   *$   ":  ( E  + )  $ ", !< B  > (4 )@"# "T @0 S '\
M.0!] #\ >P!$ 'D 20!X $X =@!4 '0 6@!S &( < !K &X =0!L (, :@"2
M &@ HP!F +@ 9 #> &, ^P!B /\ 8@#_ &  _P#,    O    *\   "E
MG0   )0   ",    A@ ' ($ #0!\ !( >  9 '4 'P!S "8 <0 M &\ ,@!M
M #@ :P ] &H 0@!H $@ 9P!. &4 5 !C %L 80!D %\ ;@!= 'L 6P"* %D
MFP!7 *\ 5@#+ %4 \@!4 /\ 5 #_ %0 _P"^    L    *0   "9    D
M (@   "!    >0 " ', "@!O  \ :P 4 &< &@!E "  8P F &$ + !? #(
M7@ W %P / !; $( 60!' %< 3@!6 %4 5 !> %( : !0 '0 3@"# $P E0!*
M *@ 20#  $@ Z !' /\ 1P#_ $< _P"T"0  I@L  )L,  "0"@  A@4  'X
M  !V    ;P   &@ !0!C  P 7P 0 %L %0!8 !H 5@ A %0 )@!3 "P 40 Q
M %  -@!. #P 30!" $L 2 !) %  2 !8 $8 8@!$ &X 0@!] $  C@ _ *(
M/0"X #T W0 \ /@ / #_ #P _P"L$   GQ(  )02  ")$0  ?P\  '8,  !N
M!0  9@   &   0!9  @ 50 - %$ $0!. !8 2P ; $D (0!( "8 1@ K $4
M,0!# #8 0@ \ $  0P ^ $L /0!3 #L 70 Y &D -P!X #8 B0 T )P ,P"Q
M #( S@ R /$ ,0#_ #$ _P"F%@  FAD  (X:  "$&@  >A8  ' 2  !H#@
M7PH  %@#  !1  0 3  * $@ #@!$ !( 00 6 #\ &P ] "$ /  F #H +  Y
M #$ -P W #8 /@ T $8 ,P!/ #$ 60 O &4 +@!S "P A0 K )@ *@"M "D
MQ@ H .H * #^ "@ _P"A'   E2   (HA  !_(0  =1\  &P:  !C%@  6A$
M %(-  !+!P  1  & $  "P \  \ .  2 #8 %P T !P ,P A #$ )P P "P
M+@ S "T .@ K $( *@!+ "@ 50 F &$ )0!P "0 @0 B )4 (0"I "  P0 @
M .0 'P#Y !\ _P"=(@  D28  (8H  !\)P  <B4  &DB  !?'0  5Q@  $X3
M  !&#@  /PL  #@%!P T  P ,0 0 "X $P L !@ *@ = "D (@ G "@ )@ N
M "0 -@ C #X (@!' "  4@ ? %X '0!M !P ?@ : )( &0"G !@ O0 7 -\
M%P'U !<"_P":)P  CBL  (0M  !Y+0  <"L  &8H  !=)   5!\  $L:  !#
M%   .Q   #0- @ M"0D *04- "8#$  D 1, (@(9 "$"'@ @ B0 '@,J !T#
M,@ ;!#H &@5$ !D%3P 7!EP %@9J !0'?  3!Y  $@>E !$'NP 0!]L $ CR
M ! )_P"7*P  C"\  ($Q  !W,@  ;C$  &0N  !;*@  424  $D@  ! &P
M.!8  #$2   I#@0 (PP) !\)#0 =!Q  &P<5 !D(&@ 8""  %PDG !8)+@ 5
M"C< $PI! !(+30 1"UH $ MI  X,>P .#)  #0RE  P-NP +#=D "PWQ  P-
M_P"5+P  BC,  '\V  !V-@  ;#4  &,S  !9+P  4"L  $<F   ^(0  -AT
M "X8   G$P  (! % !D."@ 5# X % P1 !,,%@ 2#!P $0TC ! -*P /#30
M#@X_  T.2@ ,#U@ "P]G  H0>0 ($(T !Q"B  80N  %$-0 !1#O  80_P"2
M,P  B#<  'XZ  !T.P  :SH  &$X  !8-0  3C   $4L   ])P  -2,  "T?
M   F&@  'A8! !<3!@ 1$ L #@X.  X/$P -$!D #1 @  P0*  +$3( "A$\
M  @22  '$E4 !A-E  03=@ #$XL  12@   3M@  $]$  !/N   3^P"0-@
MACL  'P^  !S/P  :C\  & ]  !7.0  338  $0Q   \+@  -"H  "PF   E
M(@  'AX  !8: @ 0%0D #!,.  H3$@ )%!< "!0?  <5)@ &%2\ !!8Z  ,6
M1@ !%U,  !=B   8=   &(D  !B?   8M0  %]   !?M   7^P"..@  A#\
M 'M"  !R0P  :$,  %]"  !6/P  3#L  $,W   [-   ,S   "PL   D*0
M&R0  !,? @ -&PD "1D-  89$0 $&18  AD=  $:)   &BT  !LX   ;1
M'%$  !Q@   =<@  '8<  !R=   <LP  ',X  !OM   ;_ ",/@  @D,  'E&
M  !P2   :$@  %Y&  !51   2T   $,]   [.@  ,S<  "HR   @+0  %RD
M ! E @ +(@D !2 -  $?$   'Q0  !\;   @(@  ("L  "$V   A00  (4\
M "%>   B<   (H4  "&;   AL@  (<T  "#M   ?_ "*0P  @$@  'A+  !O
M3   9DT  %U+  !420  2D8  $)#   Z0   +SL  "4W   <,P  $R\   TL
M @ '*0@  2<,   F#@  )1(  "89   F(0  )BD  "8S   G/P  )TT  "=<
M   G;0  )X(  ">9   FL   )<P  "7N   D_0"(2   ?TP  '90  !N40
M95(  %Q1  !33P  2DP  $%)   U1   *T   "$\   7.0  $#8   HR 0 #
M, <  "\+   N#@  +1$  "T6   M'@  +2<  "TQ   M/0  +4H  "U9   M
M:P  +8   "R7   LKP  *\L  "KN   J_@"%30  ?5(  '55  !L5P  8U<
M %M6  !350  1U$  #M-   P20  )48  !Q#   3/P  #3T   8Z    . 4
M #<)   V#0  -0\  #04   T&P  -"0  #0N   T.@  -$<  #17   T:
M-'T  #.5   RK0  ,<H  #'N   P_P"#4P  >U@  '-;  !J70  8ET  %M=
M  !/6@  0E8  #92   J3P  ($P  !9)   .1P  "$0   !"    00,  #\'
M   ^"P  /0X  #T1   \&   /"$  #PK   \-P  /$0  #Q3   \90  .WH
M #J2   ZJP  .<@  #CM   W_P"!6@  >5X  '%A  !I8P  8F0  %=B  !)
M7@  /%L  "]8   D50  &5,  !!1   *3P   4T   !,    2@   $D$  !(
M"   1PP  $8/  !&%   11P  $4G  !%,P  14   $50  !$80  1'8  $./
M  !"J   0<8  $#L   __P!^80  =F4  &]H  !H:@  76D  $]F  !"9
M-&$  "A?   =70  $EL   M9   "6    %8   !6    5    %,   !2!
M40D  % -  !0$   3Q@  $\B  !/+@  3SP  $]+  !.70  3G(  $V+  !,
MI0  2\(  $GJ  !(_P![:0  =&P  &YO  !D;P  56T  $=L   Y:@  +&D
M "!G   490  #60   -B    8@   &$   !@    7P   %X   !=    7 0
M %P)  !;#0  6Q(  %L<  !:*   6C8  %I&  !96   66T  %B%  !7H
M5KT  %7H  !3_@!Y<   <W0  &EU  !;=   3',  #YS   P<@  (W$  !9O
M   -;@  !&T   !M    ;0   &T   !L    :P   &H   !I    :0   &D#
M  !H"0  : X  &@5  !G(0  9R\  &<_  !F4@  9F8  &5_  !DF@  8[<
M &+A  !A_ !W>   ;7H  %]Z  !0>@  0GH  #-[   E>P  &'H   YY   $
M>0   'D   !Y    >@   'H   !Z    >    '@   !W    =P   '<   !W
M 0  =P@  '<.  !W&   =R8  '8V  !V20  =5\  '5W  !TDP  <Z\  '+3
M  !Q]P!Q?@  8W\  %2   !%@@  -H,  "B$   :A   #H,   2$    A
M (4   "&    B    (D   "(    AP   (<   "'    AP   (<   "(
MB    (@'  ")$   B1P  (DL  "(/P  B%4  (AM  "'B0  AJ<  (7'  "$
M[P!FA   5X8  $B(   YB@  *HP  !N-   /C0  !(X   "0    D0   ),
M  "5    EP   )@   "6    EP   )<   "7    F    )@   "9    F@
M )L   "=!P  G1$  )TA  "=,P  G4D  )QB  "<?P  G)P  )RY  ";X@!:
MBP  2XX  #R1   MDP  'I4  !"6   $F    )H   "<    G@   *$   "D
M    I@   *<   "F    IP   *<   "H    J0   *H   "L    K0   *\
M  "Q    LPD  +,5  "T)P  M#T  +55  "U<   M(X  +2L  "TS !-D@
M/Y8  "^:   @G0  $9\   6A    HP   *8   "I    K    *\   "S
MM0   +<   "V    MP   +@   "Z    NP   +T   "_    P0   ,0   #'
M    RP   ,T,  #.&@  SR\  ,](  #08@  T(   -"=  #0N
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M" D*"PT.#Q$2$Q06%Q@:&QP='R A(B0E)B@I*BLM+B\P,C,T-C<X.3L\/3Y
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MY>;GZ.GJZ^SM[N_P\?+S]/7V]_CY^OO\_?[_;69T,0     # 2$   $
M               !                     0    $" P0%!@<(" D*"PP-
M#@\0$1(3%!46%Q@9&AH;'!T>'R A(B,D)28G*"DJ*RPM+B\P,3$R,S0U-C<X
M.3H[/#T^/T!!0D-$149'2$E*2TQ-3D]045)35%565UA96EM<75Y?8&%B8V1E
M9F=H:6IK;&UN;W!Q<G-T=79W>'EZ>WQ]?G^ @8*#A(6&AXB)BHN,C8Z/D)&2
MDY25EI>8F9J;G)V>GZ"AHJ.DI::GJ*FJJZRMKK"QLK.TM;:WN+FZN[R]OK_
MP<+#Q,7&Q\C)RLO,S<[/T-'3U-76U]C9VMO<W=[?X.'BX^3EYN?HZ>KK[.WN
M[_'R\_3U]O?X^?K[_/W^_P ! 0(" P,$! 4&!@<'" @)"0H+"PP,#0T.#P\0
M$!$1$A,3%!05%A87%Q@9&1H:&QP<'1X>'R @(2(B(R0D)28F)R@I*2HK+"TM
M+B\P,3(R,S0U-C<X.3H[/#T^/T!"0T1%1DA)2DQ-3U!24U576%I<7F!B9&9H
M:FUO<71V>7Q^@8.&B8N.D)*5EYF;G9^AHZ6GJ*JLK:^PLK.UMK>YNKN\O;_
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M____________TEH"         %W,____________________________J#4
M         %S3____________________________?0T          %36____
M_______________________N?44          $34____________________
M_______\JF0O @  !"(W25C.____________________________Z:1K02@_
M8W^5I[K:_______________________________5LJRRS.3Z____________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________ENY=W8LC_____________________________
M____VYYG-@H  HS________________________________(?S\%     %[/
M_____________________________]F!.0       #RJ________________
M_____________YY,         ".0____________________________W&\:
M         !!]^?__________________________KT@           !O[O__
M________________________A!,           !DYO__________________
M_______L40            !7WO________________________^X%0
M      !(UO________________________]T%              XS_______
M__________________FB6A,            CQ?______________________
M___?FUPL           -NO__________________________[[%]53DB$0<!
M A$BLO______________________________W[^EF9B:H*R]VO__________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________X[Z=@'S[
M________________________________\K>$5S . !VL________________
M_______________2BDP5      !R\____________________________]9_
M-@        !+R?__________________________^I$^           OJ___
M________________________P%H            :E?__________________
M________C20            (A/_________________________G7@
M        =_________________________^T)0              :O______
M__________________]]                6_3_____________________
M__TK                3.O______________________Z4
M    /.'______________________S ,                +=G_________
M____________F8IA)P              )]?______________________^V^
MB54G            )=S__________________________LJ==EU*/#(M+# Y
M1][_______________________________WFW=;2T-/9Y/______________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________OU+O6________________________________
M_^>XCVI++Q5O_______________________________DH6<T!P     \R?__
M_________________________]:".P         2E___________________
M________[84Q            ;___________________________ID(
M        4.'________________________L:0              -\G_____
M__________________^S+P              (K;_____________________
M__]Y                $*?_______________________(T
M     )G______________________ZD                  (S_________
M_____________T8                  '______________________WP
M                 '3_____________________EP
M &K_____________________S@                   &/_____________
M_________RDB 0               &'______________________[FC@%<W
M%P           &C___________________________K3KI2&?'5Q<')W@93_
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________V[J=@FEIT___________________
M____________R)-E/1D    =GO___________________________]N.3!,
M        ;O__________________________VWPL            1=?_____
M____________________BRH             (K3_____________________
M___"1                Y?_______________________]] 0
M     '_______________________^<V                 &K_________
M_____________YT                  %C______________________T8
M                 $?X____________________Z0
M #7I____________________E@                   "7;____________
M________O                    !C.____________________ZP
M              _"_____________________P                    JY
M_____________________R<                   JU________________
M_____W                    VY_____________________^"<C'!50C,F
M&Q0/#0X2&B:_____________________________^>38TL[,R\S/UN#\____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____Z].\X________________________________]*IA65(+!(!A?______
M______________________&K<3P/        3^#_____________________
M____U7\U            '[+________________________C=1T
M     (G_______________________^0(P               &?_________
M_____________]5#                 $CV_____________________XH
M                 "[=_____________________S@
M !?(____________________O@                    2V____________
M________G                     "E____________________N@
M              "3____________________W                     ""
M_____________________P                    !T________________
M_____Q,                   !H_____________________T(
M          !@_____________________WH                   !=____
M_________________]$                   !A____________________
M__\D                  !F_______________________)K)F)?79Q;&EG
M9F=K<'J,____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________XL6JD7EA=______________________________=IG=0+ P
M    ,<3_________________________X)).$P           (__________
M_______________2<!T              &#______________________^YO
M#P               #?B_____________________Y8<
M !3 _____________________T                    "C____________
M________K@                    ")____________________G@
M              !R____________________O                     !?
M____________________V@                    !-________________
M____^@                     [_____________________PX
M           J^?___________________S,                    ;Z?__
M_________________UX                    /V___________________
M_X\                    &T/___________________]
M        RO____________________\K                    R/______
M______________^                     R______________________W
M%@$%!0,!       !!@T8R________________________.OAV,_,S<_0TM37
MW.+J________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________________________________________':QO__________
M____________________\<:CA&A-,A@ %:O_________________________
M_[E\1A@          ''________________________7?"\
M #OC_____________________]]D"0                RU____________
M_________W0#                  "-____________________Q14
M              !J____________________F0                    !+
M____________________M@                     P_?______________
M____UP                     9Y___________________]@
M           %T____________________PX                     P?__
M_________________R\                     K___________________
M_U(                     GO___________________WD
M        CO___________________Z4                     @/______
M_____________]@                     =/____________________\V
M                    ;?____________________]\
M    :?_____________________7#0                  :/__________
M____________<                   8?_______________________U \
M1DY465UA9&AL<'9^B?__________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________[]6[HXMS
M6I7___________________________B_CF1!(04      %+\____________
M___________WG588             !?!_____________________^5L%@
M              "-_____________________V,                   !>
M____________________G0                     U_/______________
M____H0                     1V?__________________R@
M            N___________________[@                      H?__
M_________________PP                     BO__________________
M_RT                     =O___________________TT
M        9/___________________V\                     4O______
M_____________Y0                     0/___________________[P
M                    ,/___________________^H.
M    (O____________________]$                    %?__________
M__________^!                    "_7____________________("P
M                 NS_____________________7@
M .7_____________________R1P                  -K_____________
M_________YT!              <.%\7________________________5N;S!
MQ\[5V^'F[?3[________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________XW\______________________________
M[,:EB&U4.R$' #+>________________________UY)9*0            "@
M______________________^)-@                !G________________
M_____V8                    R]O__________________E0
M           #R/__________________IP                      H/__
M________________UP                      ?/__________________
M_P                      7O___________________R4
M        0____________________T@                     +/______
M_____________VH                     &/___________________XL
M                    !?/__________________Z\
M     .'__________________]4                      ,__________
M__________\D                     +[___________________]4
M                 *[___________________^+
M )_____________________+#@                   )+_____________
M________5P                   (;_____________________J@H
M             'G______________________VT                  &;_
M______________________=5                 $7_________________
M________:B,K-3]*56!J=7Z'D9S_________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________^C/MIV#:4ZY________________
M_________^RR@UPZ'0(       ![_______________________%;2D
M          ! _____________________X,;                   'R___
M________________D@                      F/__________________
MI                       :O__________________W0
M        0?___________________PX                     '?______
M_____________SD                      .C__________________V
M                     ,[__________________X4
M     +?__________________Z@                      */_________
M_________\L                      )#__________________^\6
M                 'W___________________\^
M &S___________________]I                     %K_____________
M______^9                     $G____________________2%@
M             #G_____________________6                    "G_
M____________________H@                   !G_________________
M____]58                   3______________________[LO
M          #X______________________^K*0                #/____
M____________________R4<     !Q,@+CY2:(3M____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________]-7)____________________________^M*PDG==0B@,  !*____
M____________________Q7U%%P             1V/__________________
M_\10                    G___________________H@P
M        :/__________________E                       -O______
M____________V@                      !^S__________________Q4
M                     ,3__________________T@
M     *+__________________W4                      (/_________
M_________YT                      &G__________________\,
M                 %+__________________^</
M #[___________________\S                     "O_____________
M______]8                     !C___________________^!
M              7___________________^L                      #_
M___________________>(@                    #R________________
M____7                     #?____________________GP
M          #,____________________Z$H                   "W____
M_________________Z 6                  "<____________________
M__]Z @                !W________________________>@L
M      5,_________________________Z)7:'2 C9RKO-#G____________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________^WC___________________________2HWI8.BDC
M'!8.!@  G_____________________^L4@X                 :?______
M____________Y$,                     -/__________________>0
M                     ./_________________S0
M     ++__________________Q,                      (7_________
M_________T\                      %W__________________X,
M                 #K__________________[(
M !S__________________]L#                      +_____________
M______\J                      #[__________________]/
M              #G__________________]T                      #4
M__________________^;                      # ________________
M___$!P                    "M___________________P,P
M          ":____________________9P                    "&____
M________________HP                    !R____________________
MXT0                   !<_____________________Y$&
M      !!_____________________^M?                   =________
M_______________*2P                  ________________________
MRU<   P8)#$_3F!TBZ?'___________________________7Y_+_________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___KU,W'PKZZM[.PK:FHI?___________________]U^4S\P(QD1"0(
M     -O_________________=@                       *?_________
M________N@                       '7__________________P<
M                 $;__________________TX
M !K__________________XP                       #]____________
M_____\$                       #;__________________$9
M              "^__________________]$                      "D
M__________________]K                      "-________________
M__^1                      !Y__________________^W
M          !F___________________>(0                    !3____
M________________2@                     _____________________
M=P                     K____________________K H
M       6____________________YT4                     ________
M_____________XH                     _____________________]9-
M                    _?____________________^G+@
M    U?______________________F"H           88+45@X/__________
M_____________ZAC=(&/G*N[S>+Z________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________________GR[>I
MG96.B82 ?'AT<&QH99#_________________O&I(+1D*
M #'__________________P                        /_____________
M_____T(                       #<_________________XX
M              "R_________________\X                       "-
M__________________\I                      !K________________
M__]:                      !.__________________^&
M           T__________________^N                       >____
M_______________4%P                     *___________________Z
M/0                      ____________________90
M        ____________________C@                      ________
M____________O!D                     [___________________\4X
M                    V/___________________XL
M    O____________________\Q#                    H?__________
M__________^1&0                  >O_____________________R= H
M               17_______________________Z'03'RPX15-B<H6;M-+U
M___________________________7Z/3_____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________OW\_'N[.OK[/'__________________]FRF8=Y;61=
M5E%+1D$\.#(M*"/$_________________TLE"P                    "2
M_________________X@                       !F________________
M_]<                        ]__________________\S
M           8__________________]L                        ____
M______________^=                        ___________________)
M#                       ]O_________________Q-0
M        W___________________6P                      R_______
M____________@@                      M___________________J08
M                    H___________________TR\
M    C?___________________UX                     =___________
M_________Y,'                    7O___________________\U#
M                0/____________________^'$
M'/_____________________87@                   /______________
M________OTX       X<+#Y2:H:ER/_______________________\)\C)JG
MML76Z/W_____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____^[AU\_)P[ZZMK&MJ:>FIJ>N_________________[Z&;5M,0#<O*"(<
M%A +!      4_________________]<%                        ____
M______________\T                        ]O________________]V
M                        TO________________^P
M        LO_________________A)                       EO______
M____________40                      ?/__________________>0
M                    9O__________________H
M    4?__________________QR,                     //__________
M________[DL                     )____________________W0
M                $/___________________Z,6
M /___________________]A,                     /______________
M______^(#P                   /_____________________+4P
M             /______________________I3@           D=-$YKC/__
M_____________________YDY0U%?;GV.H+7+Y?______________________
M_______K^?__________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________________K
MS+FLH9F1BX:!?'AT<&MH9F9H\?________________]A13(C& X&
M        GO________________]^                        =?______
M___________#                        4O_________________[-P
M                    ,O__________________:@
M    %O__________________E@                       /__________
M________OQL                      /__________________YD(
M                 /___________________VD
M /___________________Y "                     /______________
M_____[DL                     /3__________________^A<
M             -G___________________^1&                    +S_
M___________________*4P                   )W_________________
M____F"X             $"E&9L3_____________________[G\=#!HH-T97
M:7Z5K\SN_________________________^>@JKG(V.G\________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________?7PZ^;BW]O8U-+1T-+7X/_________________.GHI\
M<6EA6U913$A#/CHV,B\N,?_________________2)1$#
M     /__________________0@                       /__________
M________?0                       /__________________L L
M                 /;_________________W3D
M -S__________________V(                      ,7_____________
M_____XD                      *___________________Z\B
M             )G__________________]9(                     (+_
M__________________]R                     &G_________________
M__^A*                    $[____________________37
M         #/_____________________EBX              !4R4G?_____
M________________X'(3   !#Q\O0EAPBZC([/______________________
M_\IO;GZ.GK##V.______________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________^>#2R,"ZM;"LJ*6BGYV;FYR@I___________________@F162T,\
M-C K)R(=&!,."00  -3_________________D@
M *W_________________S!X                      (O_____________
M____^U(                      &W__________________X
M             %'__________________ZD;                     #K_
M_________________]!"                     "/_________________
M__5H                      S___________________^/%
M          #___________________^X/@                    #_____
M_______________E;0,                   #_____________________
MGS<              ! O4'3_____________________W7(4      87*D%:
M=92VVO_______________________[Q81%1D=8::K\CC________________
M_______________2S>'Q________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________\^_K[_?__________________
M____[KFHG9:/BH:"?WMX=G1R<W5X?Y#_________________ZT\Z,"@A&Q40
M"P<"         "/__________________VD                       #_
M_________________YL*                      #_________________
M_\@Y                      #___________________!C
M          #___________________^*#@                    #_____
M______________^P-                     #____________________5
M6P                    #_____________________A1H
M      /L____________________L4D              !@Y78'_________
M____________Y7L>       ,(3A2;X^SV?_______________________[M8
M*3E)6FR E[#-[?____________________________^SGK3%U^O_________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________Z[^?AW-G6U-+0T-#1T]G@Z_?_________________
M_[B*?G=Q;&AD85Y;65A75UE>97'__________________[\Q'Q80"@4
M          #__________________^U6                      #H____
M______________^"!                     #,__________________^K
M+P                    "S___________________25P
M      ";___________________W?!                    "%________
M____________HC<                 !2N4____________________RV$"
M            #"Q0=I[1____________________]8TP       -(SM7=IF^
MY?_______________________\-C&"H[3%]TC:?&Y___________________
M__________^H?Y:HN]#G_____________________________________?__
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________=SL6_O+FVM+.QLK*UN<#)U>/___________________^7
M;&1>65513TQ*2$=&2$M066:A__________________^G)@X' @
M      !6___________________.4                      Z________
M___________T>0L                    A____________________GS(
M                   .____________________Q%@                (
M,5J$____________________Z7\?           &)TMQFL+I____________
M_________Z=)      (7+TIHBJ[5_/_______________________]-U'B8X
M2EYUCZO+[_____________________________^N<H68K,+;]O__________
M________________________W^__________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________O[*JIJ.AH)^?H:.FK+3 S=WL____________________BEI3
M3TM(1D1#0D%"0T=.66E]____________________GBX&
M    ____________________PU8                  !5!____________
M________YWL:              DT8(NT_____________________Y\_
M      0E2G&9PNO______________________\9F#P   !,J1&*#I\WU____
M_____________________^N.-2L^46B!G;S>________________________
M______^^=G^4J<'<^?__________________________________TMCS____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________V\O#O[^_Q\_C]____________________
M________^+"?FI>6EI:8FY^DK+;"T>'N_____________________HY02D=%
M1$1$149'2U%::(.I_____________________Z9! 0          !S9CC[KA
M_____________________\9E"@      !"=,<YS$[/__________________
M_____^6(+P  $RI$8H*FS/3___________________________^K4#9*87N6
MM-;Z_______________________________2AWR8L<OI________________
M____________________U,[M____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________MY>/CY.;H[?'Y________________________
M______VQE)*2E9F=HZFRO-#M__________________________^=4T=)35%6
M8'.*K];\__________________________^R5@ :-5!MBZ[2]___________
M___________________-;SY?>YFWU_G_____________________________
M___NGX.FPN'_____________________________________X\[K________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________
M
M
M                                  #_________________________
M____________________________________________________________
M____________________________________________________________
M_________________________P    #_X4%R:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E
M:&E(>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E
M.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 Y+C M8S P,2 W
M.2XQ-&5C8C0R+" R,#(R+S$R+S R+3$Y.C$R.C0T(" @(" @(" B/@H@(" \
M<F1F.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O
M,C(M<F1F+7-Y;G1A>"UN<R,B/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D
M9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"\B"B @(" @(" @(" @('AM;&YS.G!D9CTB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(*(" @(" @(" @(" @>&UL;G,Z
M9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(@H@(" @(" @
M(" @("!X;6QN<SIP:&]T;W-H;W ](FAT=' Z+R]N<RYA9&]B92YC;VTO<&AO
M=&]S:&]P+S$N,"\B"B @(" @(" @(" @('AM;&YS.GAM<$U-/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @("!X;6QN<SIS
M=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U
M<F-E179E;G0C(@H@(" @(" @(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(*(" @(" @
M(" @(" @>&UL;G,Z=&EF9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]T:69F+S$N
M,"\B"B @(" @(" @(" @('AM;&YS.F5X:68](FAT=' Z+R]N<RYA9&]B92YC
M;VTO97AI9B\Q+C O(CX*(" @(" @(" @/'AM<#I#<F5A=&5$871E/C(P,C,M
M,#<M,#-4,C,Z,3(Z-#DK,#4Z,S \+WAM<#I#<F5A=&5$871E/@H@(" @(" @
M(" \>&UP.D-R96%T;W)4;V]L/DUI8W)O<V]F=,*N(%!O=V5R4&]I;G3"KB R
M,#$V/"]X;7 Z0W)E871O<E1O;VP^"B @(" @(" @(#QX;7 Z36]D:69Y1&%T
M93XR,#(S+3 W+3 T5# P.C4Q.C0Q*S U.C,P/"]X;7 Z36]D:69Y1&%T93X*
M(" @(" @(" @/'AM<#I-971A9&%T841A=&4^,C R,RTP-RTP-%0P,#HU,3HT
M,2LP-3HS,#PO>&UP.DUE=&%D871A1&%T93X*(" @(" @(" @/'!D9CI0<F]D
M=6-E<CY-:6-R;W-O9G3"KB!0;W=E<E!O:6YTPJX@,C Q-CPO<&1F.E!R;V1U
M8V5R/@H@(" @(" @(" \9&,Z8W)E871O<CX*(" @(" @(" @(" @/')D9CI3
M97$^"B @(" @(" @(" @(" @(#QR9&8Z;&D^5&EM(%)Y86X\+W)D9CIL:3X*
M(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+V1C.F-R96%T;W(^
M"B @(" @(" @(#QD8SIT:71L93X*(" @(" @(" @(" @/')D9CI!;'0^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M9&5F875L="(^4&]W
M97)0;VEN="!0<F5S96YT871I;VX\+W)D9CIL:3X*(" @(" @(" @(" @/"]R
M9&8Z06QT/@H@(" @(" @(" \+V1C.G1I=&QE/@H@(" @(" @(" \9&,Z9F]R
M;6%T/FEM86=E+V5P<V8\+V1C.F9O<FUA=#X*(" @(" @(" @/'!H;W1O<VAO
M<#I#;VQO<DUO9&4^-#PO<&AO=&]S:&]P.D-O;&]R36]D93X*(" @(" @(" @
M/'!H;W1O<VAO<#I)0T-0<F]F:6QE/E4N4RX@5V5B($-O871E9" H4U=/4"D@
M=C(\+W!H;W1O<VAO<#I)0T-0<F]F:6QE/@H@(" @(" @(" \>&UP34TZ26YS
M=&%N8V5)1#YX;7 N:6ED.F-B,V$W,&$Q+3<P.60M9&$T82TY931F+30Q-F5D
M-S,P8C@Q9CPO>&UP34TZ26YS=&%N8V5)1#X*(" @(" @(" @/'AM<$U-.D1O
M8W5M96YT240^861O8F4Z9&]C:60Z<&AO=&]S:&]P.C1C,#(S9&0W+3DX,#0M
M-&$T,RUA,6,Q+3DY-3@Y93 R,C@U,CPO>&UP34TZ1&]C=6UE;G1)1#X*(" @
M(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YX;7 N9&ED.CDW83(Q
M86$S+39F,S M9#(T,BTY,C8T+3@X93AC.39A,3AE83PO>&UP34TZ3W)I9VEN
M86Q$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*(" @(" @
M(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z.3=A,C%A83,M-F8S,"UD,C0R
M+3DR-C0M.#AE.&,Y-F$Q.&5A/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(S+3 W+3 T5# P.C4Q.C,Q*S U
M.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F
M='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @,C0N,B H5VEN9&]W<RD\+W-T
M179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC
M:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E
M9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS
M=&%N8V5)1#YX;7 N:6ED.CDP.3(U.#8W+3@S93 M,#8T,2TY-CDT+68U8F9A
M9&0W9&(Q93PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @
M/'-T179T.G=H96X^,C R,RTP-RTP-%0P,#HU,3HT,2LP-3HS,#PO<W1%=G0Z
M=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^
M061O8F4@4&AO=&]S:&]P(#(T+C(@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R
M94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S
M=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V
M=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S
M/F9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G
M92]E<'-F/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^9&5R
M:79E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M<&%R86UE=&5R<SYC;VYV97)T960@9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O
M8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^
M"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F
M.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.F-B,V$W,&$Q
M+3<P.60M9&$T82TY931F+30Q-F5D-S,P8C@Q9CPO<W1%=G0Z:6YS=&%N8V5)
M1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,RTP-RTP-%0P
M,#HU,3HT,2LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P(#(T+C(@*%=I
M;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @
M(" \+WAM<$U-.DAI<W1O<GD^"B @(" @(" @(#QX;7!-33I$97)I=F5D1G)O
M;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(#QS=%)E
M9CII;G-T86YC94E$/GAM<"YI:60Z.3 Y,C4X-C<M.#-E,"TP-C0Q+3DV.30M
M9C5B9F%D9#=D8C%E/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @(" \
M<W12968Z9&]C=6UE;G1)1#YX;7 N9&ED.CDW83(Q86$S+39F,S M9#(T,BTY
M,C8T+3@X93AC.39A,3AE83PO<W12968Z9&]C=6UE;G1)1#X*(" @(" @(" @
M(" @/'-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#YX;7 N9&ED.CDW83(Q86$S
M+39F,S M9#(T,BTY,C8T+3@X93AC.39A,3AE83PO<W12968Z;W)I9VEN86Q$
M;V-U;65N=$E$/@H@(" @(" @(" \+WAM<$U-.D1E<FEV961&<F]M/@H@(" @
M(" @(" \=&EF9CI/<FEE;G1A=&EO;CXQ/"]T:69F.D]R:65N=&%T:6]N/@H@
M(" @(" @(" \=&EF9CI84F5S;VQU=&EO;CXS,# P,# P+S$P,# P/"]T:69F
M.EA297-O;'5T:6]N/@H@(" @(" @(" \=&EF9CI94F5S;VQU=&EO;CXS,# P
M,# P+S$P,# P/"]T:69F.EE297-O;'5T:6]N/@H@(" @(" @(" \=&EF9CI2
M97-O;'5T:6]N56YI=#XR/"]T:69F.E)E<V]L=71I;VY5;FET/@H@(" @(" @
M(" \97AI9CI#;VQO<E-P86-E/C8U-3,U/"]E>&EF.D-O;&]R4W!A8V4^"B @
M(" @(" @(#QE>&EF.E!I>&5L6$1I;65N<VEO;CXQ.#4T/"]E>&EF.E!I>&5L
M6$1I;65N<VEO;CX*(" @(" @(" @/&5X:68Z4&EX96Q91&EM96YS:6]N/C<V
M-CPO97AI9CI0:7AE;%E$:6UE;G-I;VX^"B @(" @(#PO<F1F.D1E<V-R:7!T
M:6]N/@H@(" \+W)D9CI21$8^"CPO>#IX;7!M971A/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L 0P !
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
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M:W)K,54*HH^3!\9R0>!G'?'-8IK\*#9PS&82)6+\O&O#0C>L04AE2\RE?Q=
M0N>:GN7/4,4PLE+NF%%JDUF2CU:T3L1%(@1ZWAF$ DJVK[5M&)*>$F<X/; Y
M/'.[C/QY_+L!B;7/X<6UZ^SM\L5BKMI7E,D6O.ESM*C:Y3+5)S.[B\$UK;ED
M]9JBDH!&2$AB^IPT=%MD0!.'E$EYAF!7CA0PJJ8U.<Y\Q)//N-I^7 Q_/-5[
M8_A+;/+/-2DL_BLHMV$N_MTZZIL?F"]M<?IVV_X*F=N5YNS2D_-5*\TN%KQ9
M-+Q4M.H,B.OF""<PR](^=2RDDJTPH?0X]LG&2NTG';)'%2>Q?#'VNS\P_M+5
M#*=.O#RR0MG;9 Q[ER\46[PKN(P14]MCF/@[%6Y1@]80MBQ'2J] 62+Y5;R3
MYDE8" VG4&D@V4\).^"#QR"0>%V]Q[CO[U*J'\/#:_C/< 3<G2JU;8;(A4T5
ME6X9'O#ZJ/["CCZ-Q4-RF:Y(SCMM/6QS08F/@WTG-J2"+]VW"TO&BUR45L1U
M7"-0Q8#D\]SC. ,X]3@#O_05N_I5]-*4TI32E-*4TI32E-*4TI32E-*4TI32
ME-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E:L[YF-WD]D^
M\*-QFTM3_(\AM:W L<?L:*C+N;N\NSO$UM0JK2G-Z^4\\XM3B=48(UY&$(>7
M5ECM$XTIGAD0%5DF?#?&<[&QCOG!QCXY[5T1T*R[NL,0UNM6SS'.\ZEX!>8^
MVFU'+"NX;$^XG+60J3F":R2K';ALT[=MOF=7$GFB[LZCBM9L%KA(2+_ \K/'
M8S]:KE@4K\XB\K\_GG//]WS]:P@LO**^W"@@JQP2QW,JG#$ <^V2<8YJ6UO.
M_P 5UQ=L?9@D(O-,TJZVZ?$EBJGA23VLW&@X]R-FW%&7+"IM18Y5ANV[DL+N
M,J8QC:_/U&>ND_&H2*5<<TV#N4G(Y(=.UW'\O\?3T[?G0/*2#SRL@"[< D$;
M2?C@9 R >>15.V;-OQ%,BW7"=KM*FZE&FX<S[3IB#S9&_#?R_!V^.KUZV1;@
M664)J<VX,XL92ZQ]5RW+P](CG+MBK"1TT:N2:43.BJR&Q.V>WY'L?O\ Z9^-
M6EI&9/M85@20C#@HQ.5YR-V!SZX]:V"C-X/Q9']JV[-[QAZ_8ZDK6VV'DM=#
MJ>T.[9!J%IK^5,GQ<7NON]XRVT>2T5MZLV,ZR)2+X[LCIQ(52&D7\H\:/S$_
M$U3?XU<7FX\I!Q'G"DCS'S'.>,#T].^#VJ&R6]'XOK;%EW(?#MR3M4;N$@8&
M<R3&[6,O/(VF8QF*QEU\HACF@EP[)Y(O#=C<J=CF G9B/Q!F&$JT->D'2.5+
MHE._B;'M*KOEQPI.&() /8 G@8R3V' /)/) K]!.W^P9.MF"\.6C-4!%U7+]
MBQC1YO)];A&\PRAX.^2=;CGEJBXUA8$D)Z.9LYI9XBA&S282L<F0&4@91T@J
MH96=<[1N[XYQ[U;VE5II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II
M2FE*:4II2FE*:4II2FE*:4II2NK/<;M+W./-P.9LW[8YS;[(EW,;;JCMPRC!
M;AVEV.%";424R2Y@+QC]:G14T%GCW\=E2>1M6+YT*Q%34G#0<F6V-^^];$?K
M]?A6)D;<S*5\RA3NSP!GD <'OVX^)XKK@P1\)C,];W./H=0(AE@O!.4]M<!"
MYGO5AR(VRSE/".+=B6*L,7O'M'I\*X6QP[Q[F>S-Y6 R8K+R$.\BEH&2!)E:
MEF]:6@%6")M_^BI')SG&W&!R1SZY QQCDDUE*7\%_/\ 6\04G#I+AA&N5^GX
MKJ.*)0E/MN4VC:^I5W?=@K<I,WJ6;?A%BX@+#<,48TM%0D8Z-?/B,+))Q<>V
MF5H1U(3#&N3_ +>:M6!E55ROE&#C(W>93D\<$@'./4^O>I?0_@Z9NQK.4]]3
M<ET&%C8ZRTV2MK!&ZY3<DG(3&GQ'6.YO&\2D@_AG:';INV"/0PM"-S>F;Q\H
M!H%'JJRR\V>E7"$CL??C)_M9P,_#(].^.PJ$U?X/NY:/9SLE,0&T=&1FMS+/
M-%EQG 96W"Q^%\CTIOC_ "W0:9192*B<?UV:I"> G5UK61J =BM<GF0\B)VJ
M?O,[%.S5A:'501/G)"#+9(#-@C! !\HQM!!]<L.2!7)J?P6\[4NOG)%6W![G
M(5NV9;3L!WS)RUDR:UL[3)NW+/D7?K).PKG\)OEIZIY,QG%U^KO'TLM#SK"3
MH5<:*13MA)R4FUKG\NWY<?K\.]4\ @<%02%!;S9&ULY!.<Y''/SJ1WWX0NZ"
MX6#/CAKF+&T47)3S+"CG(C:[9E1R+GV.R9N<QKFFH1>=HP6+FL4M+;[0*?-8
MVQHOC4\JL[1?LR-1I<(O+1CAG^GMZ?=^O7-7&)CGS8SNR<G+9;(W#TVC@8.?
MD!7;=LHVW3NU?'.1L8OY6(=U)]N&SCD#$D%!R4])1M"Q%D&[O;/2*"C^(&Z#
MB/4K;1\X1<Q; [N(9.5E21SUTB/<&E9438"/3<Q'). 3D#GV'%;B:5?32E-*
M4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*5HMNNWMO=J]X
MQ-2E=KFX3-)<U6.,H=#LV)G>"4X!_DR6C;I/ML=.2Y-S5CF<93P5BB3=C4DE
MX8E2*P%HU"R&F%C1B:L;.5(&QFSZC&/YY_*K8C]W^V5U?;!B1]G7$T%F&EU-
MS<\@8HF,D4E&\X_A8R#9V.Q+6Z+;3SI&,&JPK]K*690'2S:'BG#:8=N"1#MH
M^75<'4G;D!L9(SR.,G\/7V]:UPR;\4G:S4*+2LD8TN$/N+IERGLS5D)["=LJ
M5ICX">PGMVR1N2L,3.N0F$DV4A)TW'*S.)9G$'"CJQUZ25(2$>!( JUI5 !'
MF!SV/L"?S X]^#V.:L.E_$<V3W'"7\OH[EL*P./XYQ4X6WR$ODRGE+1KM<(-
MM/1>/[(LWEED$+>=HNL",4W.X5?!'R+B/]4U8NEDE5\1,;MPQQ\>_;MFK=:;
MK=M$C+U:!C<\XHDIF\M<=/Z1&1MXK\@\ND=EUO8W>,9.HHLWRYK-%WII3[8[
MK4E">N8R;2LS[E!P9"(?J(*KO7(&X9.,#WSSQ^N/6OA:-V^UZE90=X2MVX'$
M-<R^PK3^X/<:3%^K;"[-:U&0+^U/Y5>NKR!)-))M5HN2LZB)VX.AKD>]G2H&
MBFJSLBFY<XR,^WZ]?AW^%:0M_C';56VUS;_O!M#>WU?"FXG/B&!JW.K'I\RK
M27KU.Z.FETRB2#M3UO4JRRC:2^D+4W2<RM@J"+I(TS$)IM9!9H SP*Q^.@17
M.=K' /S['[^/E6P]8^(AM1E0?)7/*U1PY(!N#S)MMK,1ENVT^HR=]O6$<@!C
M:U2%,;*6!U\UK3RR+Q:$1)*F:KF&>@6DDSC9.79,%57B1?4@>8KR1S@D9X].
M.Y^1YK[9G^(ILTP12+_>KSGFB*,L9)3A[E UR<CI^XQ"U:R''XHGV+FK,G0R
MK:0B<B2;6I/&;Q%JLG,"JT*4RJ"I2J-(B@DL !W]Q]W?X?.MNZS9Z]<ZY7[?
M4YF.L-8M<'%66M3L2Z2>1DY 3K!O*0\Q&NT3&2=1\E'.FSUFY2,9-=LLFJ0P
ME, Z5<"#V(YY'\_Y5G=*K32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4T
MI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E
M>ICD(')SE('ZF,!0_O$0TJA(')( ]R<5QQ?,@'@7C4!_07"(#_=UZID>X_$5
M;XD?_.)_UE_OKZD614_HUDE/\Q0AO_NB.JY!['-7!E/9@?D0?Y5]=*K32E-*
M4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*50>;
M=O\ 7LXSVW^?G9R:AG&WK.D1GBNH1!6)D9V?AZ)D"A(PLV+ULX4+#JQ^0I%Z
MJ9@9L]]8Q9 1P5$5TU%4(SCG&#G\ 1C\ZT3R#\('!V4[QE&5O63\NRN+<E6;
M<-D5/"S1Q2(FOU'*VZ/%[W$>7[]"7-A3D\CO3R-4E)=>OUBP6B7J\!-2CAXG
M&NV36)C(T#CM6-H5;.2<$E@., D8)[9/RSCD_#&/D/A$4.U-)61R1N R_D+(
M]ELURL-MR1)PV,*\_G&]BVBWC9I P:58I=*KE0BF%-QI>7TRQ=,H8):8MK<C
MN<?O(LR42UKGM\/[\U3P00<L3DDGL,^0H.WL"?O]JX4#\(.K5U:*NC'=!G%3
M.]*GL+/<5YN=5W"AY3']8P'BO)&&<?TH*"CC-#&MIC4Z'E_(S*:F+'5W=DDI
M";8R2<LS5A&) 9XQZ?SJOA#@[B6&,-@<  @# &,<GT[_ "J8X[^$WA[%N3]J
M.5:EDS)J4]LUQ_"XQP^A)$IT@T4JCQ'(">7"V\/PT@>;ELR*W]1Y+OV8Q"-)
M<UZ%)CIC66+FQ,IQGO\ 'O\ K]#\!01 %&!.4&U?D<Y'W\<]QCOC-6%*_#FH
M,KNA-N*-E+);:ON\YUC=%,8-11HYJ++;B:;A\,&UW(BEG7J:N3F;!G0D&!5Z
M.PN;:K/)Z/0E%F7IG$A&O:57PQNW9/VMV.,;L;<GC/8GC..<^@QXC?AM8?;[
M>=GFVJ<L%CMV/=G]GC;##-[&PKKX,FLV>,\FXL>5K(+ T8$:O!3%?RE-'DF\
M6V9'55:-$@.#8[E)53PUVHO<)^?S^?K6G;/X!>V6&A:-7:]E7,<?#T^=R>D_
M:S)<?7W\7XRR=DZ*RFXQG8 R%2[0@HE79F(1CH:Y(MRVIQ%/)'YV\E9$T8_B
MU6"!!CDG!;O@\,VXJ<@\9X![@<#WJ^+%\);%-FE]Z\_(9;RBE,;]:Z\ALX.F
M36CHD0?0UF+,8CFZ8@>KK$@E\40('IK1BN,BQNT8<)B[)R]G+\Z,JX1 %SDY
M<8.,=\\$#L,#C'KW.2<UN_5]L^((>]UG-MBH="N>Y2%IL34)?<?(X^IL3E:S
M%8UU&N23]W-P,.P&+3G&I7(N86%!E",F[Q6-CF+:.(DW(J_:,[L>;&,UL!I5
MU-*4TI4)MU5>V0[(S2:5C"M2K%42*14Z:PJB02J<)+H"!R 02CU=8&*;@!)P
M/5BDC+E2'*[3V]#^8Y_V5'7]C+>&/P[EH0F[*@$AB<<^5E.1C'.>/;UBA,9R
MQ./]E"AN X_H'(?_ ,T?/ZC_ ,GC5!&W)\0\_P"C\LYY]<?G6M'ID\> ;O=_
MT&''_:?[?QJPI&&<O89&+3DET5TDVI#/A*8RC@6Y2E.9<I5"&'O"'</PIR!^
M!$3  @.;T_KZU*/$S1+&)"" H+D9+;1CD9'<\GGO4;1IDDG^].F,'@?Z);W#
MW\"Y$.!]^/;G]=/U^O:L0MG'_&9^X_B/,,'[Z^MGITA8*'8J@UL;R'?S<:\8
MMI]H13U$<=R0"E.FF1RDJ9/P8BQ$W2"ATE50352.)3EW]-O$L=0L[V6W2[CM
MIDE>WD("S!#G:25< ^JDHP# $JPR#':]I,^L:%JFD6^H3:;/J%G-;17\ 8R6
MK2K@.JK)$Q7^%U26)V1G"R(Q##5_&6U*YT2\UZV/\OO95E"NU'+F*;L9- 9)
M,S=9$62RKF==(%;+&5+Z@#ME^I(IBD*102+)]KK/6UAJFFW5C'H,5O)<(J),
MTL+B(AU?Q%5+6-BZ[?)AUP>3D95O(.D_H>USIW7]-UBXZWN;Z"QF:66S2VNX
MOK2M%)'X#O+J4\8B<O\ O T,FY00H5]KINJ=$YE14!40 0  ()1'IX^X"!@X
MY\B/CW\??7G?YU[P5)/?CV_P_#\ZY.E7TTI32E-*4TI32E-*4TI32E-*4TI3
M2E-*4TI32E-*4TI32E-*4TI32E-*4TI32E8*Q6>MU"+7F[5/0];AVW'?DYR1
M:1;%,1YZ2"Y>*HI"H<0X32 PJ*&X*F4QA -8Y98H$,DTB11K]IY'5%'S9B!S
MZ#//I6K>7UGI\#7-_=V]G;I]J>ZFC@B7/8%Y65<GL%SECP 36E]OW^8N921J
MYB^MW/,MG4ZB,V53B'2$<Z6+X,1-VX;JRS@I3" "M&P$@B8/J(J8O CSUQU/
M9(_A64-QJ,YX5+>,A6."<;F!D(X[I%(/NKS;4/I8T*.<V6AV6I=27Q!\.+3[
M:1878<;1(Z-.PS_%#:3*1R":L[$]YW 9(AI&5NN-4L1C\Q!*&CWKXCE^[C#-
MTE!</4': OV:R2YCH?FQ[,ZW B5JD"?6INZ==:E>1227=E]0._$2,X9F0J#N
M<,NY2"<<HN<'R#',]T_JG5>LVTUQJ>BKT^?&VVT,LHDED@**=\B2+XL;*Q*>
M>&,MR0B@ FRCT6RR(B:5N#HA1\B@T]2HGY^W)G#4GC_L ^_CQXUO^!(WVIFQ
M[#)_JH_+M4V=.O)>9M0?XJF\KC_KQC_S/C\*]0Q-%& WJI23=&4_?.<S<ABA
MP8/R^MNN8!ZC ?GN ;J(0.H4Q4(>T6B>K.<C!R1[')['D_=SZXR#5=%M\-XD
MLSD]V\BGU[$JQ')!SDGR@9VE@WQ/AFHG\&>3?/\ !\S ?[O0?K_7JOU.,CO)
MCYCCC_5QQZ>W>L9T"P/>2XSV_P [&#_ZOC[L<UP%L%UH_)F\S8FYA$1 2N6)
MP#^OB/3,/ _H</ZPU:;*/T>0'XE3_P"R/YUC?INS/V+B[0_"2,C_ -4#_P"=
M6.4P[9& ">NY*FV)R^4T72:ZB7CV QT7Y" 'Z_LIP\^2#JTVD@YCN9%/H#DC
M\F&/PK"=!O(AFTUBYB(SA7#,ISV!*R@#&2,[#W[5CU&VX:M *C=U 7-N3SV#
M&03<F('O]2Z40J)^/8"N%Q'[ (CQJTC4(NQCG'?!(!^7(0_+!-863JNS!*/:
M:B@YV$JLA'S9;<Y]<!W]<>E<='<(I!.$V61J1/598XB4':3=99HIT_O*)I.D
MVJJB7@3=351X  '@3>^K1J!0A;F"2(DXS@E?SP2/]7=WJQ>JFMG6+5M,NK%R
M2/$52\9QZ@.$8CXH9 !ZFKHK-[J-Q1[M;GX^3$"@91LDN4CU#G[+LE>ATB/^
M>D #X$!$! 1W8IXIA^[D5L=P#R/F#R/PKHK/4K#4%W6=U%-@ LBL!(N1G#QM
MAU/S45+=9:WJ:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2OS3
M[]9;=6PW(Y_<0M<W>6?*K"[X"#8= X<N6X_'^%GF*UJ7#'R*];3>),:Y,P)+
MY;2S26R-LHQ>[:#2J++$"D8_82#.*10!W7]?+/Z_1K6??N; ).1X8!9<@#GD
M9'!/.01Z' /,MGM]WQ1PN^Z* B<(1466C7@U9H,*^VUYXE3T^++N_P 48?I=
MD);T31U&SA!Y%P#:;KER85J=JAGD"6&0EX]%G7XV?3CWY\^^/]GP)X^!HTDN
M&PH!!7C&< L!GO@Y7)(&<8X]*XUDWV_%0K-JQA1T\(Q,OZ')^:,?SE_5VT9W
M6K^=7V.=U4CB.N,VS&DJ70^#8ZT80;,\JQUNG'$S5I=63&?BIM6I5F=8O*?K
M]?K_ !KXDF0"H[D9P?,0<8X[<<Y&:G$_NU^)=6\5XQR)98N%@V.5\^;DJL^<
M5[9;G#*5@PQ1L-RN6H7#%?MF.:9>5+E9'NY&<J550:9(3C:S6*U"RT>#1F\<
MV.,G@54M(%R2!EG_ (2< %MHP.26P,UKG%YL^(9DBNVZ4SG$9#G'F0<8?"*S
M%3\)QNW_ #E0H&LV.YYOQ.GN67@;K3;/'2$5(XL?N)=Y?*!-31)-9BXCY*SP
M/X.IMF;3E3C''N>??MCXC[ZL4R'E\G*Q-MVD!22=WKGC@']&K62WY_% D&N2
M$6&%P2M"*U32D("2VEYNC(S;C;I;>ECK"C?'I[3)6EK#;HHV<V]6.VYC?7G&
M[N#B8-M5C695^PK,W'-&-!^OU^ON[U=OEP>!G_5.%.[;CW;C!R/7TQD5L[D%
MKGO<S\,C<@[S2URG [C<,+[S6>.I;!+W-FW6SW^WX$ELS4?"&0(*J4*Z-K9*
MQ>1(F,K=K8T56=MM+M<C(QSUBREFGR<$%)-S02<G>JOMVY!+ ';P#W)QQVSZ
M>E4;;\L[T-H5JV@X(VZ8PN]NQ?=,;XMO%UMF9H?='N1LEZRK?,A0\%E?&DQE
M9>2R#-X:&DT=9>\QJ]R,E7F#F0,KT,JO5+!'JU[_ .SM^%,NFP*"05#<Y)9B
M?,"3D\+R.WMFJVS#N$W\YWQ1F&GOH2ZTZ^QF<,&+M,>57:?N!J+G!WX6^(-B
MVJ0\>KG!2T-ZKN/JMNPDS>9'NCC'Y(9@\J19J4"5@ZDZ.@W=OCV_V8_*A+NI
M'(.>P4^7#$=^QXY[@^GO4H+O4^*@TDS(+8TB'[+$SZ&C;J(;7,HHGSL5M\1:
MX[5Y23J*Z5W,GCXDKMY9P&=S)LD[XBP8IA96Y_P5) X3I_C_ (?G5OB39[ @
M 9XQN)?!QYN %Y.?N]C7&7MT/Q$,W8_SQCJ=Q;?H<Z2U=G9:!H>WC..-;+M^
MM-'W[X6IU+QQ!Y@?2;^ W),<JX'5M>2Y^UXW8-(J-@8&1E5Q;52=28-:_K]?
MR^ZJ[Y"""O&1G QMPX '/VLKYB?G\JLFX?$)^(U4F^YF:2PPQ?+X_I.?9M6G
M6#;CENEPVWJ4H&?:ECK# (98G[7'T_=NOE[#4U9LPM8'%J\$]DY"KM8F$<,&
MLR@Q-3]?KVX^?/Y/$E&X[1QNP-I&,, N<D9W#D<@9[$U2#+?3OCR%/VS*.-L
M8N]QURVXS.^G&F/9F*P-G_#Z$R6KX/V96^FJW_!QKXJNA;YR8O=\E4:'<V@W
M*</6RUR@LZ?-K/TAK_A^NV?UZU3?(3E1O(\0# 89\JD9'8$YQR,Y'H#5X1&_
M;XD+:O;<IZ7Q82S0%KS=?Z;;I.G;2]Q9;Q?J!$VO#L13IMI1+FRHD+0U'<;;
MLGDF'TY<J^VDDJ='WZFEGZ]"W*L!2KA)(=IV\$X&!R1Q@GT]\X(/MGM7Z)=*
MV*@5TKUFG%(\T!/#$IM@7!RAZAXT!<R@IBFJ*K,ISJ"0I3%[:A0(7JZBCR)@
M'#*DCE=C[ ,YY(SG&#QW[=C]WQC-1M;RX,1M;GP0@?>F]X]Q.W:=T8).,$8;
M@ \<DU%V=(OB*Z!U;>82)K)G/Q)2R_TE. F_)63*DJ/ >$U! AQ^DP@41U8L
M4P(S+D>HRQ_GC/RXS\*T8].U164F_P#*&!(\:=^ 0?LLH#=NQ(!['OQ801<N
M$W)/_FQ@CW4>#9FQX.8&;KI3+Z@$Q_*^@Y%%0.4044%<R9^")D$<^&R3G@C
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MM)=#/;D2)G'84%O_ /O"]0'Q)+WI;HV!\'P(8X[RY121P6:'5LOC.XBXCQZ
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M=>=#&F98LU&R(U.FU16>$*UB)\YP J"B"QCF00<.S /IA267CW_TG8.SF4!
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MV''^9SOXVX\)0??.3C&<<XQ\9U/)AL=V9."7C29#,QD0KBS@&@M".Q*7T@J
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M)P 521[%$&,>D)U2-V#!-0Z?C_5G6FI:W.VH]0:B752PM[9<I;P \^%:6J9
M./M-AI7 W32-@M7I$-KT+]$^AF4FVTJVQM>XF/CZIJDZ+G8N ;B\G;[0AA00
MP@EPD,09AJ"MG#=[O'76CMMU;/@G#BJRK=;,%Q3!.PS34ANRO\D,1%ZFDJ81
M5*"%60D%6KIOVW%QC3'.D7STWNKZP2NG1FPLSD?7)@!)(.0=O#8SV A#%6',
MZY('G#=5_21])K-#T/9'I'IEF9'ZEU-<7MU$,HYM,+(JMG< M@LS1R( ^I0$
ME18M(V#;9<,(.LC9QFRY5M"1OF<Y>\Q2R98 CHH$[SL85^]4C5R=12G[ME=V
M%V0W E=E#I*60TSI&"2=0(+C5[Z1LC>CS%W/<K I?<3ZF4RMD9#"NDZ>^A+I
M#1Y?VEKIN.K=:9_&GU'7I&GA:;NSK9,\D3@GG-X]Y(" ?$&.,/>_B<;<J$X;
M4;#]=LN7ITG#"&K^,:Z5&#%4G45-JP7%-L5T@ %#H^01TD0"F+T%$ , >P:9
M]&&MSP">_>RT*S102U[($:./XQ("L6.V)GB_E7J:W5G:HEO:P@1Q@)%#;1+'
M$BC@+&B!5"C& $4CT J+JY\^([EV%26Q1MF8XC=OEDRJO,NF9-&D6R*>1 ZZ
M(2U@@[*\>.41B5"(J4%)!FI\Q(9P\*#45-Q=!^CW2;AAJO4KZLB*<)I0=FE?
M$>%/@V\]NBJ1,"POV+@Q^53N N\>^E4>';"(D\F4C@ GL"RMD\=X\#GD]JC!
MMO/Q9[</=LN[O&%)15'J%A4X8'QVY3@').O^3B+.<Q \=(2:I>H.06$!Y';_
M &_]%=IQ;=*:E>D#'B7<NP,1GG'[0EQGO_FU/N,\"SP=3?[5U&G;A%!].?\
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MEXJ%;J1P3_D)P#_SYSCGDCP./:I%)915CL7V;(X5>1>*5UA)/2P#54QW$CZ
MA#<H.O2=1&OUB9TZ!FL+1)!TH"*XH=!]RRC^N310EEA\641[WY5<G[7\.?8
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MII2FE*:4II2FE*:4II2FE*:4II2N.[:-7S=5H\02<MER]"J"Q"J)J%]^#%,
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M5BY]*.$-VN&\WM0])7,D)CCV]G3#H24=$!".0>/S@ !];!W"N4?)A$*HH8W
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M/N(B(B/N(B(CYTI7G2E-*4TI32E-*4TI7@1 H"8P@4I0$3&$0    Y$1$?
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M.$E6NVU<CN>!GW/Z_P *UH4^)Q2(^IUJ]RN*;T%/E,>Q=HG)1F\@"2U>N#[
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MQC!]CD=P:]6V1(]Q7I&P!'/BHQSI%JHW_*,=0ZYD2IF(J!NV4@"L'<ZN!)P
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MFL*6E-W6E42!7QPH^I=KKT3+NZQ)*U=*MHR$'<J_7H..LU;2E5(N<CHF-A[
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M+]/2DV2-X$>=>A_3CI"6W6VJ@ "'6M.M+Y1@;2)[8V,S#WWS6DLA))R[-SC
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MH,6ZKDCJ07(F<Z#%%PJ4HF( :T=2O#86-S>",RF",N(P2-S$A5W$ D("P9R
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MU8=8LQZR'Y)_C7#/EVH)CP8\EX_1D'_EM6_7(>>6X_T?\:QG7+%>_C?]G_\
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M:6P:0AY6PSL)9.6(&2.%'"B+;,&25>VVU]\<@$[YK%.+G'W.4[QRN!S"(<\
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MDO\ >D__  "_Z-*I@>P_ 5X["/\ O*7_ ,&3_1I3:O\ 9'X"O'IFX^[=$?\
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M6^?C^^4?F*NZ" '1VB8'>Q!QZ_:?[\G%</8TD1/;["&(' K6&U**?J)RRRJ
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MM>I1\ZFN/_\ .9^_?_\ E)^^,<_'-19/[L_"S7_]0M?I6J'^U*K_ /:["?\
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M(UCQ[WIM@4@@ACA,^F2RSM-)<0'"-+$[2RM/!)*23AH2I!5_U,I*IKI)+I&
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M!CE$IA 0 HAK3-J4LJ0S"4RKB9$V*I&,@2#:JC ((#$X!&,YK9MX]%MX)KB
MVZP2 P32F1G4AL9B8NS8W9&5&"P(/(Q6/<.,>.&+:,7<1QV3,QSMD.\Y+VC*
M"85!!4ARJB)Q.83]:ANHW!C<B!1!X>IH[2[)0[@!FPAR!C;QR    , 8' [U
MB>3I^2".V:6V,,)+1H)'&PL26(8$-YB3G).3WY Q\9UCC-;'MC:6#Y+_ "=K
M1T@-E,_=G3C"L>V O5'KLZQ%T#IE(F8BH+)N$3E0.W,10J(AJ3&?Q?WVX28
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MI(E*7J,=,!,;CJ.81,81,(CKF[J::Y,LL\LDTK@LTDC%W8CD9+'T[ 9P. ,
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M@I\6!RH? *'<"C,.:MC6A4A32E-*4TI32E-*4TI5/6\?Q#=ZY6R#UH,!!Z_
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MIU>[?Q2P!"+P@)..PQG!"@\8.>2U0T73$\^LPWG4UT-0:8 QV<>5LXF8X"L
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M3[\WY_VUQ3_#%NI__7Q[CR_H)9R; 0_^V/'G[^/ZN/.I:/Z5+.-0/]P?2[X
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MWTT\74Z_2(@(K>E!3DW<.!S"=P<G)G#HP$**A4T!&W4KY9WVIA+: 8C& H.
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M"@<B4VN:NYWD:25SF29R21[N><#G &=J@=O*.PXF+MTL;..V@&&*"&)1R0H
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M&O1"E*1F]0=I"$<25D2AW4%6)S0\Z4Q7,0L154\<WE.HNE8!!^WNFI!?:)<
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M2/OJ%8UVN[IL:V'$M(E;]/3TI>[+1I'<=>:Q:K\K6CT&A8 VL0EGLSVV33.
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M?$88</@#G@YQG/;T/';V]>',4$DM(NG_ ,W70]2H"@I"W!;MCT%*)2G]0G]
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M^1O$7;G&[L<.2W.<5.2ATE O(CP !R8>3#P''(C]Q'W$?N.H<\DGW]NU3P&
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MC@QE$52E!,!CYI;]]0R4=.R1$2D#K)[+0^IPUSI3IIFJ,"TNGRD".1^[&/:
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MDP%PLX(HRX]6V [A%(AH.UL=3BN(Y)KT/$K$N@EE?<-I&W:Z!3R>Y(*_:&2
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MN*I/X4=NA:K35%1?=9B"U6D8V,>@H5)NN8AFRBS5P50B#MHN)13 Q4G3940
MBZ1C;"ZH0=@ON02-C3 D' )&UVSV*DC'9@<889R?M?2-XC;4;%)"<".2XBCD
MR%1L>'(RN"%=&P1D*ZGLP)U:L>P78-<) 9F7QM4U5SO)21$L=D.VQ# SV;D5
MY64=^@B+@R8 L\>N3G.<J ="!&S-$$V;-H@CU]K](_5EI$(H-=.T)%&&>#3Y
MG$<,:Q1());=WVHB@ ;CEBSG+N[&QET=_,9;0Y);*W0 )8Y)PDH!)/Y  <
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M[J\ITRV@V>//,"\,9=UC0$Q!I2S2.J*HAW$GMWQQ:SF#;9EDI!JV1L4V]PL
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MO>MC#"]IT_I]OH]F.TNU'NF _B)QX49/J7^L..XFS4A9]!1O+^T>JM4GUFZ
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M!U"S3]990I[*[A'B+-8S9Z,:@W6*C^VHN72S5X*KA!R!D0(W:BD7MJ =;K
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M8+Y+MP9OLA2B<RU9?F HTKR")DX%)P51-,WJ%$5G#DIQ315,Q<,0=MFSXCI
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M[=T@DX0.'!TEDRJ)F_3DIP$.0]P'CD!\@(#JA 88(!!]#S5KHDBE'574\%6
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<@5D-8Z4TI32E-*4TI32E-*4TI32E-*4TI7__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>53
<FILENAME>g425213g63f05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g425213g63f05.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1%H4&AO=&]S:&]P(#,N,  X0DE-! 0
M    $4R^1"@X0DE-! 0      #@< 5H  QLE1QP"   "   < E  "%1I;2!2
M>6%N' (% !=0;W=E<E!O:6YT(%!R97-E;G1A=&EO;CA"24T$)0      $(E,
M*T ^4D:PQ&_V$<%;PI<X0DE-!#H      /$    0     0      "W!R:6YT
M3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90
M  !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE
M5$585     < 00!0 $0 +0 M #(       ]P<FEN=%!R;V]F4V5T=7!/8FIC
M    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M 0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"
M24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M%P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#
M<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O
M;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $
M      !21T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B
M0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M              !";&0@56YT1B-2;'0               !2<VQT56YT1B-0
M>&Q <L            IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O<"!5
M;G1&(U)L=                %-C;"!5;G1&(U!R8T!9            $&-R
M;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M    #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ "4S,P
M 0 ! )3,S  !  $X0DE-!"8       X             /X   #A"24T#\@
M    "@  ________   X0DE-! T       0   !:.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         "
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!$0      !     "   "0    D      .$))300>
M       $     #A"24T$&@     #00    8              3    =D
M!@!G #8 ,P!F #  -0    $                          0
M   '9    3                       0                         0
M     0       &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T
M,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M
M;&]N9P   3      4F=H=&QO;F<   =D    !G-L:6-E<U9L3',    !3V)J
M8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R
M;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@
M  UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   $P     %)G
M:'1L;VYG   '9     -U<FQ415A4     0       &YU;&Q415A4     0
M     $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .8V5L
M;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R
M>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV
M97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M"V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE
M    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M  QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
M #A"24T$*       #
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                              #_XO__24-#7U!23T9)3$4  0F^S/[^
M'@ (@'!!1$)% A   '!R=')#35E+3&%B( ?0  < &@ % "D -6%C<W!!4%!,
M     $%$0D4                    !  #VU@ !     -,M041"10
M                                                        "F1E
M<V,   #\    =&-P<G0   %P    *W=T<'0   &<    %$$R0C    &P  "B
M!D$R0C(   &P  "B!D$R0C$  *.X  "B!D(R03   47   (XM$(R03$  WYT
M  (XM$(R03( !;<H  (XM&=A;70 !^_<  "0D61E<V,         &E4N4RX@
M5V5B($-O871E9" H4U=/4"D@=C(
M
M            =&5X=     !#;W!Y<FEG:'0@,C P,"!!9&]B92!3>7-T96US
M+"!);F,N  !865H@        M5H  +QG  "2,&UF=#(     ! ,)   !
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MJ&ZI>*J"JXZLG*VKKKNOS+#?L?.S";0@M3BV4;=LN(>YI+K"N^&] ;XAOT/
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MG7-ZYCH?FO9[C2 IFIA\<0  E=-_RJS.KRB"@YMHJN2!F8E^IMJ X';[HQ.
M8V.HGYN )D]3G'^ (SETF@6 3!^AF9:!%P  E(Z  *O?KCV++IJ*J?Z)C8B]
MI>V(&G8QHC"&^V+DGKR&($Z?FZ:%CCC5F2R%2Q\NF*N&1@  DW"  *L2K6J3
MYYFJJ3>1FH?,I3"/A'50H6B-O6(2G?R,44WHFNB+.#A!F&J*HA[*E]>+LP
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M:8QBLF&7IGM[K::5-&H&J223&%?MI/"1743AH3^0-3 ^GE*0*A<^GC:.N
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M&((?O])XRW(6NGQXN6&CM6EXZE!QL*=Y4SX+K'-YY"FFJ99Z:@]FJUE["P
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M8H!"N[6=-W!-MD":<U_/L0F8+$ZNK":6<3R5I]"5LBC"I):5O! KI..*[@
MC#B  (]FP-6HE'_\NRJDT' 6M:JAAU^BL&^>WTZ)JY.=!SQ]ISJ<K"BXH^":
M;A!.I :+!@  C!F  (\FP%&P]7_,NJ&LDV_VM1^HRU^-K^.EV$YWJPFD&CQO
MIKRB_RBSHU.;A1!LHT2+&P  B_^  ([4O_"YR7^NNBVTFV_MM)NP+5^'KU&L
M^DY[JG"K7#R IB"G]2C<HLB;H!"PHKB+2   B^N  (2TT)]X\W77REEX@V:N
MQ&]X6U<1OM9X?4:SN9-XVC4'M0AY6"#VLG=YK@?KLME[10  B?F  (1BSY^
M;G6;R7Y_9V9PPXQ^K5;.O=9^1$9QN'1^*339L\Q^4"#VL/Y^GPAGL.I_YP
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MSW5*Q.^B.68WOLR?.U:AN.F<_49<LVZ;N34.KIJ;K2'-JS*6VPJ1JA^')0
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M@EUZ2U5@@D][ CDF@IE[TQ/?A)U\CN ?@J""O<KW@BF!][3=@<6!39W?@7F
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MB)(_I.2$A8%LH6:#I&^RGC&"_ET?FSR"B$EYF*."1#0LEK*"*QIMEQF"Q@
MBV"  *&PIY6.+Y%CH_:,@X!]H("*_F[;G42)LEQ5FEF(JTC+E\6'X3.AE=&'
M>!H3EAJ(.   BG>  *#CIM26YI"7HS64FG^IG\*2?VX"G(B0GUN<F8F.]D@L
MEOV-OS,FE0*-+QG(E2V,[0  B:^  * ZIB*?WH_MHHF<\W[\GQ::-6U6F]J7
MMEKXF-J5AD>@ECF3Y3*[E#N3B1F$E%:0Z@  B0>  )^=I:&H\H]GH@6E9WYW
MGHJB!FS(FT:>\UINF$Z<6T<JE;*:DS)BDYV:$!E0DZ*1'0  B'R  )\6I4.R
M-([FH:2N$'WTGB.J%6Q(FMJF>EGUE^"CE$:^E4RB#C(1DRZ?=!DFDQ"1 0
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M4X3LK<^*PG3[J:2)8&19I;&(/U+6HAB':$ ]GO*&V"O2G+J&P1(KG@:&R@
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M;(+*JQ>S$7+5IM"N\6(JHK^K?%#<GPFI<SZ>F]2FS2J\F62<Y1(&F>:,,
MA>*  (AVO^5S47GANO5SK6K9MD-T*ULGL<ITS$J*K9YUASB3JA1V1B12J"MV
MMPI8J@=W%P  A@R  (@>OP5[+GFYN@AZU&JNM3QZK%KTL*MZMDI/K&YZ[CA?
MJ-5[0R0TIL=[@0J?J"Y\8@  A;:  (?>O?*"Z7EBN/V!]&I>M":!+EJ6KX^
MM4GVJTR =#@:IZR ;"03I8& E K?IH.!)@  A6N  (>7O.>*F'D!M_6)&VGG
MLR*'U%HLKH&&UTF4JD&&+3?/IIV%U2/RI%N&& L7I0>%40  A2F  (<^O J2
M8'BEMQ:08FF$LD&.IEG K9Z-,TD_J4Z,'#>/I:R+EB/7HU:,/@M*H[F'H@
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M_6V9Q;9S-U]8P']SFE!SNX)T)T">MM]TRR]%LR%U9!L&L?AU:P-OL$UWB0
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MY&U4P)J5D%[WNQ^3CE #M=61]D!/L.Z0["]AK-*1 1P5JJ:0"P7DI^&#^P
M@QV  'L7Q82?=6U'O^J<LU[WNF":1U *M0R89D!;L"6772]YK "7>1Q+J:.3
M(08[ILZ$-P  @QV  'KVQ0:G,&T_OUNC_5[\N<&A+% 6M&&?%$!GKW6>62^-
MJU:<TQQXJ."30 :'I>N$:@  @QR  'K<Q)VO/FT^ON&KDU\)N3BH6U JL\RF
M,T"%KM>DSB^YJK"@11RSJ#&39P;(I4:$E@  @QR  .8?=G!S&- ;=TMS\;F
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M")B.F'-P08>EECQQ:76PE#QRC&*UDFASMTZ2D-5TYSC4C\)U]!ZCD(9VA
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MQI0-DR^:48,*D0Z7WG$DCQJ5AEYWC5J3:$K*B]^1KC68BL60QQPCBO*/D0
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M+HJTH*1WA7K#G<%WZ6GDFQ%X7E?\F)MXYT3=EH)Y>B_JE2IY[16FEM1YW
MA0"  )D+HH9_P8GJGWU_7GH*G)9_#6D?F>U^X%=&EWI^T$0[E69^V2]BE =^
MZ!54E7A_"   A 2  )A*H66(2HD-GF.'1'D8FX:&4VA.F-F%A%: EG.$XT.3
ME&2$:B[>DO^$*Q4'E#Z$@   @RB  )=^H'R0W8A#G7R/0GA'FJ&-O6=TE_>,
M6%71E8&+&D+\DWN*-2YLD@R)T13*DQN)0   @FR  );7G["9JX>7G+F7>G>7
MF=^55V;)ER^34U4OE+>1C4)[DIN00"X,D2>0#A22DA2-1@  @<Z  )9&GQRB
MCX<8G"B?SW<5F42=#68YEHJ:=%2=E!6804'_D?R6R2VTD&V6A11AD3B-R
M@4N  )7.GK&KEX:=F[VH3G:2F-*D^66VE@ZAUU0>DY6?44&'D8*>$"U8C^F;
MX!0YD(2-K   @."  )5UGF*T\(8[FVNQ*78BF'BM1F5!E:JIKE.TDRJG#D$O
MD1*E.BT.CWV>=A0"D R-AP  @(N  (R<KS1N 'Y7JWMO%V]=J -P+U]YI,!Q
M2TZ,H;MR:#Q!GS=S=R?-G?=T) TOH+ASQ0  @G^  (PLKCEV07X&JGIVCF\
MINUV\E\:HY5W;$XKH(-W^SOHG?1XC">$G)EXY TZGN)XT0  @<6  (NZK0U^
M77USJ5A]_VY\I<)]NUZ+HFE]HDVGGU9]J#MYG,=]QB<SFU=]W@T_G39^.P
M@2&  (LPJ^J&9WS/J#J%=VW#I*N$HEWKH4V#^4T1GD.#@3L F[2#-B;@FC6#
M+0T_F[6#$0  @).  (J;JOF.@WPTITV-#6T>H\&+M%U!H&**@4R)G4R)B3J-
MFL&([":4F3&(_PT_FER'/0  @!J  (H0JD&6Q'NNII:4S6R8HP62[%RZGZ&1
M.4P)G(6/T3HRF=V.]"9;F#^/6PU"F2>(]P  @ "  (FHJ9Z?('M I?B<JVPF
MHF2:1EQ(GOV8&$NAF]Z67#GCF2Z5AB8VEUZ4W U*F!&(_   @ "  (E+J32G
MIWL%I8JDO6OGH>2ASEOXGF*?(TM*FSF=.3F*F)F<K"7SELN9<@U*ESF(_
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MDG$%LG&#L&+&KCV"\5/*JCB"9D/)II:"%#)RHZ2!\!ZDHF*"%@:VH7^!Y
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M1V_0KRNI5F&$JL&F75)DIH*CZT*0HJVBPS&4GX^?\QYVG<F4F0>@F\6%*
M@ "  '*OQ4ALWF6EP*QMM%@=O#ENGTG3M^QOE3IUM %P@2E3L31Q+126L>EP
MN   JRET>P  @ "  '*BQ'=T<&7#O[%TBU@ZNP1TU4GQMH9U0#J6LG9UORF-
MKW]V(145K\1UNP /J>EXYP  @ "  '*CPSI[N&6JOG)[15@FN;5Z_4G6M21Z
M]SJ(L0-[$BF>K?)[.!5NK=Y[! "CI]-]+@  @ "  '*5P>V"VF6 O2:!^%?G
MN&J!0DFHL]* S#IFKZV EBF<K(J D!6OK#" S $AI?B Q   @ "  ')VP-**
M"V5?O >(R%? MT6'MDEULJB&VCI1KG.&42F>JT>&217MJJ^&D &1I%6!#P
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M6IFDA@^%MXB0A3Z% ':+A(:$4V-Y@^V#PT]<@WF#23FF@SB"XQ_&@YB"N
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M&I6D@F"S,X1>@7RNZW(\@*FJH%]\@!"F[TO7?Z^D>C;-?UBA>1V>?PV4!P
M@ "  )ZFE1YI3H_4DR9K(W_ND7ELU&[,D -N:ER-CK!O]DD/C9UQ=#/6C1!R
MLAF'CJ)R]@  @Q9ZO)WLDY1R6H\6D<AS37\4D"=T,VWZCJQU%%O$C5AU^4A5
MC$5VV3,HBZUWBAC]C0!W@P  @:%^'YT8DA-[3HX0D&)[?7XACL9[IVT C5A[
MV%K@C U\&$>.BP%\7S)^BF-\D1A^BWQ\;   @%J  )P9D+>$*XS]CPN#LWSV
MC7Z#-6P)C!""N%GZBM:"6$;.B=.""3'EB3"!S1@1BA*!V0  @ "  )LFCX2-
M+(P C>*,$'OXC%Z*Z6L(BO:)OUDMB;6(LD8<B+Z'W#%9B!>'4!>PB,:'6
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MS(+7G$QJC7/?F@)L-&/$E^]MQ5*'E@MO23_LE(9PL2M*D^AQLQ!LEMYQ+P
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M1W\7EGB1RW !E#R00& *DA^.ND\SD#.-8#TECI^,:BDBC;:,70^+CL")D0
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M9W7>I-9Q1V>MH>=R+%B!GR=S%D@PG*MS_C9GFL-TRR(KFD=U'@B FW1U,0
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MAW+WGYF6SF2XG*B5 E6=F=J3346FEU&1\C1WE3R16R$5E!Z0Z CBDPZ& @
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MZ&E@K=AW&UP"JD=W8$V@INMWPSXHH^QX+2T0H<=XA!CNH>EX5 )>G?EZ6
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M F>QJ2V;.UHRI8:95DO8H@:7HSR4GNR6M2OKG).6=AB[F\:0N0.)EE."9
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M:UUAMV9\'E"'LUU[Z4+RKW=[WC0MK!1[\".3J?)[^ ]GJN)[V   FVA_H0
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MZUTCLQ.?25!1KK6=?$*6JIN<)3/IIPN;;B.QI)28(A!6I(.+#   E[*
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M8*T$=8)GOIIL=G%I[X:^=UIK_7(/>$)M^UQ:>2QO[D53>@]QNRL#>M]S&0>
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MT5^XA MLRDOQ@_)NK#:!A"!P2!QEA6%PY@  @$QVNJ&8@[AM@Y*G@T5O"8*
M@NAP;7$U@I]QOE[#@FMS!$L7@EIT.S7 @GUU.!O(@V]U9@  @ !ZN:"+@=EV
MU9%F@8AWBX%=@3MX*W 2@0-XP%W @-YY54HX@-=YY#4%@/-Z3QLW@9IZ+
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M\XRV>]RC57R.>Z>@:VMW>WF=<EF)>W&:R4:/>X.8PS(?>VV7^1D@>L20_0
M@ "  )M]>W^OGXPY>V*L;GO\>R&HV6K>>N2E/%C^>M*B'489>N"@&C&O>L:=
MGQBX>?*0MP  @ "  )31CPQCDH;RC9UE\7?PC'EH(&>?BXEJ)U8;BKML%4,]
MBBIMX2YVBBEO1Q/(C)MO%   @ !Z0)00C2UL>H8KB_=M_G<.BN5O:&;+B?1P
MP%59B25R"T*1B)-S/RW?B'UT'A-BBGUSK   @ !]MI,QBU]U1X4<BDUV#G88
MB4AVQ&74B&1W<%1]AY]X&D'7AQ-XN2U)ANYY'Q,#B']XF@  @ "  )(LB;A]
M^X0+B+)^)'3RA\%^-63JAN)^.U.IABY^1T$NA:E^52S+A79^5!*YAJ!^!@
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M]X"7A&6H5W%C@V*E16$_@F*B(5!8@9>?F#Y6@0J>92J;@(Z;-1%Q@$6+RP
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M67<JD+&$!VCXCQB#H5G&C9J#,4FHC$&"R3@%BU&"AR0XBOZ"9PKMBO&![@
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M<&X3H"9DE6"KG>YFH%(@F^=HBD)8FAYJ3C#BF/YKPQR!F<%L/P/?F*%LO@
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MWVKZF7.).%V3ES"(=4\ZE0F'K3_BDR*'!R\9D;F&L1N/D9V'%@2HCG:#)@
M@ "  '<1FMV1UVJ F)Z0Q%T5EEB/ADZZE"N.2#]MDD"-3B[$D,J,]!N&D&6,
MI 3'C2F#.P  @ "  ':SFD69ZVI+F :8@US=E:Z6RTYSDV&5##\>D663UBYC
MC_N3TALPCXR1/035C!R#10  @ "  '9KF=:B*VH"EXV@>UR+E2>>7$X<DLR<
M1#[2D,2;&2XGCTN9\!L'CLV21@38BU*#1@  @ "  &X&K3EADV(#JEUCDE4Z
MI[=E@T=II3MG5SA-HQUH]R<VHA=J&Q(JI']IIP  F--N8@  @ "  &V#K!!I
M/V&ZJ1MJCU3]ID9KX4= HZ!M*C@WH6!N4R<_H#%O&Q)QHBUNB@  ERUS:0
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M?5^1HM*-KU+?G^>,LD4ZG1Z+NS:&FKR+&R8[F26+2A*EF:B)H0  D-N
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M[%5WLK]ODDE=KW)P13Q#K%%Q!RW6J<YQIQT4J05QR0E<J:5QG0  D.%[@
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M1E2RK,N1?DB8J4B0=CN%I?F/B2U+HT&/91T8H>R.O I\H1^'%P  C)R
M@ "  %_!K]V9H%2[K"R8O4BCJ)&7@3N'I326A"U2HFV6+1TSH0&33@J2H"*'
M)@  C "     @ "  ,$39Q5?[:[3:3EBM)OM:SYE8(@B;21G[G-I;OAJ:5VW
M<+ELT4;'<D5O$"S/<R9PW0H$=BIQ%+\@9"5JT:U+9HILA9J.:+]N+(;H:M)O
MRW)&;,]Q8%RH;K%RZT7)<$ET4ROH</%U70EM=&AU:[U)895UIZN&9"!V3ID'
M9GUV\X5S:+-WI7#X:M)X7%N!;-!Y$43*;G!YKRL/;MEZ"@CI<MQZ+;MW7TN
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MPY9Z=Z]ANH8T>%QD='2G>11F^V'P>=-I9TX&>IMKMSB+>V9MOQ[+?#MNTP
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M5I @;>^./G_X;Q.,]V[-<"R+G5R]<46*54F-<DR)-C3;<O*(8QOO<<N(2P
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MF(E&?3EII'H!?61KAVF1?9QM35?M?>-N_D3[?D%PCS Y?KUQR18V?[-QNP
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MB8/;=0R4(W2W=7V2?&21=>Z0P5-]=FR/*4%!=N*-X2U:=OR-4Q0Y=GZ+%@
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M4WP=@Z1PHVWM@T)QVUYW@O-R^DW?@KMT"SO8@K%T^B>S@O=UAPV>@^=T[P
M@ "  (A/@A1WZ'KZ@<5XEVRX@7AY*EV$@3)YJ$T @0UZ'CLC@0=Z@2<L@3)Z
MJPUF@=%Z70  @ "  (=*@%: BWG]@!N HVO"?]^ EER+?Z: ;DQG?WN 23JH
M?WV +2;<?XZ $ U2?_Y_Z   @ "  (9H?P>)3WDV?MB(TVL"?IN((UO"?EZ'
M5DN-?C>&ESG]?BR&"291?B2%V0T-?GJ$HP  @ "  (6Q??.2$7AY?<R1!FI'
M?8V/MUL-?4Z.4$K<?2F-#SEF?1:,+"7U?..,.@SJ?3*(E@  @ "  (4B?1V:
MU7?G?/N91&FP?+>77UIY?&^58DI)?$:3LCC3?#22L26">^:22@S+?">(I@
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MZ6]$BNYVJF'>B?EW5%.%B1-W\4/7B%UX>S*CA_9XYQ[=B$9X[09\AY)YOP
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M36Q2A;Z=RU[JA+B;QE""@Z69HD$V@L*8)3"&@B:7MAV!@:^3\P9]@12$8P
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MD&,7DPQ[XE9QD8)\'4C0D E\0SH2CL]\9REUCC%\?!6<CPY\.@##BJI]I@
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ML%H2I!]>%4WPHB-@94"KH%MBC3'RGP5D:"#GGQ-EB@O[H;ME&@  C91MT@
M@ "  &2SI,QC)UFFHHYD\4V3H&UFL$!LGGMH5C'2G/]IOR#SG-5JB@Q/GOII
M_0  B_MRS   @ "  &0KHNAJ=5D,H+AKN$T9GI1L\3_XG)IN'C%_FQ%O&B#0
MFL%OE0Q]G&QO!@  BGMWH@  @ "  &.=H0=QJUAKGN)R>DQHG,ES/#]UFM%S
M]3$1F4ATC2"0F-YTPPR.FAET50  B11[Y0  @ "  &,.GVYX\%?AG5-Y6$O>
MFSMYK3[CF3]Y[#"TEZEZ)R!-ERUZ,0R.F %Z*@  A]%_G   @ "  &*0GBR
M5E=QG!: 84MUF?B 2#Y\E_. &C!5EDY_^B EE:)_^ R5EAZ $0  AK2
M@ "  &(FG2V'OU<9FQB'>4LDF/"&^#XHEMR&9B_ZE3*&#A_FE&V&1 RLE'2%
M#0  A<Z     @ "  &'5G%Z/*U;,FDJ.FTK3F!R-OCW8E?V,VR^NE$2,=A^+
MDWZ,KPR)DR6(>@  A2&     @ "  &&5F\N6S5:_F:Z6)$K%EVR4[SV]E2B3
MK"^KDTJ39Q^QDEN1[PR_D>R(GP  A)R     @ "  %DCL:U:9$X:KU)<C4)D
MK1E>JC6<JQA@GB<LJ>-B(Q63JV%B: -%J;9C6@  B.=Q_0  @ "  %APL&=A
M?4VZK>)C&T(CJVIDN35_J2YF.B<ZI[UG8!7JJ,]G< /2IK]H40  AZ!VL@
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M+4PIIA*$%D"YHW6#QS1!H0*#;"9TGS2#1Q8=GRV#AP4^FR&">@  @JV
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M?E1\9J&H77^!?9)@8!F!78(M8GR!)G#^9+B XE[H9N& I$N7:-2 =S;H:@.
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M#H=G9Z9_/'@S:5Y_1F?X:OE_.5;&;(A_+$0Y;>U_*# :;IY_'A=2;@9^\
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ML8$G>5)<"7*W>>%?*&+^>H1B$U(!>S%DU#^=>^]G7BL\?,5I6Q#>?E!I8
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MMGM';>.%>FT.;O^%#%W'< F$@DU_<0>#_SOC<=N#F2A;<?^#90]:<Z&"^@
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MXG1H?LIC7V;4?NUEM5@7?QYGYT@+?V!I\C9P?\IKN2)G@(1LR0C?@>ELF@
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M:F]F=1"*WF(,=8F*$%.E=?&)*$0T=EB(73-<=J"'V2!*=CN(#PAR>-B%50
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MYV>LA3YILUL+A.EK9DTCA*%L^3WXA'AN9"T'A*%O?1D A9EOH ).A1-Q-@
M@ "  ')P@S]OWV:A@PAQ&5GV@L=R.$Q*@HQS/CTT@G!T(RQM@HYTRAB<@S9T
ML@)=@PIVS0  @ "  '%]@4)WX&6Y@1UXD5D.@.IY(DM=@+=YF#R9@)-Y_"OH
M@*EZ0AA(@/]Z$P)N@41[P   @ "  '"F?Y!_\F3O?W^ (UA2?U6 )TJU?R&
M##P'?OA_\"NS?NE_Y1@S?O-_Z *-?[U_^   @ "  &_V?CF("V1A?CJ'QE?/
M?@V'/4HK?<J&E#MR?9N&"RLI?7V%U!?W?2J&'0*6?G:!P   @ "  &]I?2:0
M)&/7?2^/<E=%?0".9TFJ?+6-/#KU?'R,8"JD?%&,/!>0>[2+6P*??6J!Q@
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MO%M>C)YN_T]BB\EP*D)EBP5Q/#/LBH!R("-OBIARG0\WB\]R#@  @KQXF@
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M&5BMAB&3?$S+A4V24S_AA$^1!C'C@W.0;B("@NV0*@[;@EV*"P  @ "
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M@4^2E01S6T0PD[=T'#?&DGQTMRH"D:MU+1F4DAQU(0<QD"IUW@  @ !_+@
M@ "  %ESE+=YR$\&DWUZ0T.QDBYZE3=1D.EZPRF8D 1ZWQEQD"UZS <[C?A[
MT0  @ "     @ "  %CPDVN!$TZ6DCZ!.T-,D.J!(S;MCY> ["DNCJ6 SAD@
MCJF ZP=0C!R X   @ "     @ "  %B(DER(8$XOD3J(.T+GC^:'Q#:0CH:'
M-BC<C7Z'!ABWC7.'1P<KBJ.$V0  @ "     @ "  %@WD8Z/Y4X)D'*/HT+#
MCQ6.SC9OC9"-VRCBC%>-PACYC B,H0=RB52%"0  @ "     @ "  %"FJF%4
M349BJ)A6TCM-IPU9/2[LI>1;:2"&I=E<]PZ7J*-="   H A@?   @ !Q+@
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M8$/*GM-V\#CDG2AW52SKFYYWD1]8FM=WG [8FZEW7@!QD]IZ5   @ "
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M68N>74-I9GQ/7_5K7&O,8GYM/%H\9.)O"4=W9OMPO#,K:"UR+AJZ9Y%RSP
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M&H5[46V61':(5,6426:15]N24E6=6K>0DT.,7/J/+3 L77B.?!BY7SF,[0
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M;G]386APUW#^8ZMR)6&A9<9S6%#^9\-T>#\;:6-U@"MQ:>MV11*2;$=V#
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MF7JJ5[V;GVR"6F>95EU>7-*7"$U%7P.5%COZ8(^3TRD)7^^3:!$D9>^+EP
M@ "  (4P<9)30'AJ<I96\VJE<[-:>%NE=-A=R4M>=?=@YSF7=PYCNR69=_EE
MUPNZ>L1F @  @ !UPH/';=)<#G<W;S!? VF!<(1ASEJE<<UD<TJ"<P9F[3CA
M=")I)"4+=,AJM@N-=_=JJ@  @ !YX8)P:EUDW772; %G%VA8;8-I,EF-;NYK
M*4F8<$!L_S@C<5YNGB2"<;QOL@ME=8)OB@  @ !]@($.9S-ML'1P:0QO-V<
M:K9PH5B5;$!Q\DB];:YS(C=];LQT*R07;N%TRPM.<UYTLP  @ "  '^Z9')V
M@'-(9G-W8V7<:#YX(E=@:=UXP4?/:UIY5#:D;'AYTR-M;#EZ%0L*<9MZ90
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M_FT$>F)6CV ->P!9]E'7>[!=*4)'?&A@'S#_?4%BKASB?FQD(P2$@.ED[0
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MGF=O;(]]$UK:;<]]6DTR;N)]?CYJ;\Y]G"X <%)]O1KA;XA]P@28>#Q^@@
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M3F"0?\%=(51F@ =?T$<0@%5B4SA#@+EDD"=T@6MF1!+7@OMF7P  @0EJ8@
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MLUO+<[V!VT_V=&N!Q4,+=..!C#3I=3F!8R3W=2^!9!&I==J!B0  @ "
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M8U0MAC%BF$C7AA=DKSPOA@1FEBX%AB1H*1UBAO5H_0FCAU%HZP  @ !S9
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MRU!T>_F%SD5&?!N%>#D&>_&$_2MO>[:$PQN->UJ%&PE2?%R#WP  @ "
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M0$@&C<AF\3THC4MH@3$OC.EIX2-4C0%JT!)*CI-JG0(?BO!LI   @ ![/
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M,T5:A4:)0#JYA/.(O2\0A#B(%"'M@X.(&A'D@QV') +7@;2![   @ "
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MZ#O=EPQJ*3%>EEAK0"6HE=)L"A?[EDQL2PAUE0]LKP  A\9T+P  @ "
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M2GEW]6F]3H]XJEC84EQY7D:<56AZ$#,75F9ZLQP*6--[*@&Q?21]B)5G/:F
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MF8/56+M:_G4M6[9>2F5_7HUA=E2C83%D>$* 8VIG2BZY9%UIMQ9.9F!JV@
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MGGQ^1P:'#6Z72T2&;5^>3QZ%S4^44GZ%0SY85-2$WRN;5$R$Q!157:*$^@
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M1G>T6UMBWVHM7AQE8UM<8*-GQ4MI8NAJ SH+9*%L#2:Y9))MF0X3:X=MQ0
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MI7'23 J,PV2J3[:+LE9W4OB*G$<G5:J)N#:$5PJ)*R0W5L*)8@TE:<B'-@
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MTVN:7MIIOE[D841KEU$[8W)M6$(794MNZS%M9F5P11Y89=YQ 0<.=!-QS@
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MFF<M4>V1HEJP5/602TTO5X*.XCZ866&-TBZ*692->1Q 6YZ-&0:==-.$>0
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M1E^X8V9OI%.[961P[4;*9Q=R%CBC:&YS(BAM:,-SYQ4;:LESV@$3?BYW'@
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M6EG<>KA0^$X'>XA4@D$#?&17W3)T?4Q:VR&4?H!=#0S,@*!=>   @ !EG0
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MLE0&:1ETI$B^:IQU=#QJ:\=V(B[/;'1VL!\#:]MV_0OT<9EW'P  @ !]TP
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M?$V$?]56BD)Y@&!9<38L@/%<&R@3@;%>21;Q@S-?0P2-A A@;@  @ !M\0
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M"DAS;^=XJ3W$</9Y&C'U<99Y:R2A<9MYGQ2B<B9Y@ 20>$I[<P  @ "
M@ "  %&F;"=_=$?O;<Q_N#U8;O=_L3&H;XE_C21E;U)_B11"<#I_L 1<>**
M)P  @ "     @ "  %$E:C^&\D=O; &&Z3S<;4&&>#$Y;<Z%\R01;62%VQ00
M;J2%N 11>+6"ZP  @ "     @ "  $SOC:!*UT-@C6I.-CC5C8-1:2R]C?]4
M1!Y5CU]65PR D=U6]@  B8I<-   @ !LK0  @ "  $N3B<M1E$(XB>94BS>U
MBA=74"O%BG]9OAV9BYA;; PYC15;U@  ADY@WP  @ !QC@  @ "  $J%A?I8
M9T$<ADM:Z3:\AI1=/"K7AO-?.QS<A]1@A ODB)Y@OP  @U1EN@  @ !VB
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M;#SK> -[T#*]>+Q[^"==>.U\ !GZ>(1[^PIM>F]\K0  @ !_>   @ "
M@ "  $73=-N"O#R'=D2"X#)O=R""GR<Z=SF"2QHD=G*"6PK.>+6"!@  @ "
M    @ "     @ "  $"9F45(JS>RF*U+Y2VCF)1.U"&JF5%1.Q)YG#)24P-2
MF;Y48   A+)?B@  @ !P#0  @ "  #\WE;Q/!#94E8Y1V2PLE9E48B!+ED!6
M9A%NF*%7+P,)E159/P  @:YD0   @ !U 0  @ "  #Y!DA95>#4ZDAE7X2L>
MDCY: A\ZDM=;H!"@E,-<'P+2D,]>+@  @ !I(P  @ !Y=   @ "  #UOCGU;
M_310CI]=]BH8CM5?J1YGCV1@Z __D-=A*@*JC09C.@  @ !N5@  @ !]6
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M)S#G@?9^3R<+@JQ^,1OC@LQ^ 0Z1@EQ^+@*)@8A^_P  @ "     @ "
M@ "     __\  /__  #__P  ;69T,@     $ PD   $
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MN____P"  (  YD]_SG]8S9E_J'[-M-I_F7YYG!1_HWYE@TQ_QGZ%:H5__G[
M4;^ 8W\].0"!$H /_,5^?(LTY+5^8XELS$!^78?,LYI^;H9FFMA^F(5#@AA^
MV81/:5I_+X-G4*Y_KX*A.!2 =H'F^KQ]-I9QXOM],).2RLM]/I#/LCI]:8Y>
MF9-]K(PL@.]^!XHB:$Y^=8@33\%_#(8 -T%_Z(.L^.-\+J&WX4%\,YV_R3-\
M39GPL,)\A997F$5\WY,:?\M]3X_S9U9]T8RU3N]^?(E--H=_9X5<]S=[8ZT#
MWZ5[9J?KQZI[AZ,*KV![R9YIEOA\*YGX?K)\KY6W9FY]0Y%!3BY]_8Q[->5^
M](;O];QZRKA5WB]ZQ[(4QD-ZY*P4KAE[+*9AE=Q[F:#:?:1\))M9995\R)6H
M38)]D8^!-5M^D8A?]'=Z4L.JW.QZ1KPRQ0EZ7;4*K/EZIZX[E.E['Z>;?-E[
MMJ#H9-A\8)G=3.U]-9)0-.A^/8FG\V-Y]\\!V]AYX\9 P_IY\KWDJ_=Z.K7L
ME )ZN*XD?"![6Z9 9$A\$)WE3&]\ZI3C-(E]]XK%\G5YM-I:VNMYE] RPP]Y
MG\:4JQAYX[UJDSMZ9+1J>W=[#:M 8\)[S*&63 E\KY<S-#U]OHNV[E.(VWXV
MUX:'Q'W"P)^&PWUPJ8R%YGU5DE*%*GUU>P>$AGW&8\2#\7XU3(^#>'[I-9*#
M*(  [#V'?8C+UA2&<(= OVN%@X7CJ&.$NX3!D1Z$&X/?>=2#E(,M8IR#'8*-
M2Y*"PX(6--B"D('!ZGJ&1Y-EU'2%39#:O?R$;XYSIPN#Q(Q8C^V#.8IW>,J"
MRHB]8;:":8<#2LV")H5,-#."!X-OZ-N%3YW^TN"$7YITO'J#CI<4I:N"YY/H
MCK2"<I$+=[N"%8Y!8-:!QXMD2AB!EXAH,Z*!BX4$YUR$BZB@T6R#G:05NQ""
MU)^ZI%N"-YN4C8"!PI>5=KJ!>).[8 B!.8^R276!&HME,R2!'X9[Y@"#\;-+
MT!N#!*VZN<V".JA8HS*!HZ,MC'N!-IX@=<B [ID47TJ OI/;2.2 KXXZ,KF
MP8?/Y-6#<[WXSOJ"A[=6N+6!O+#BHB^!)JJHBY^ Q*2*=1& @YY57J> 5)?1
M2&F 4Y#9,F" <HC[X]:##LBES@6"),#BM\:!5[E3H4J O['ZBM" 8:J[=&N
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M68L\C0R!W(FG>9^!?X@V9B>!.(;.4N*! X5>/]Z [H/8+9V ]H(>PPZ"I)A
ML4Z!]I6^GN"!99,VB]N \I"P>)6 GHXV94N <8O34CN 48E2/VV 4X:@+6:
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M.*2 MH9O*:Z F(-?J;:#ZJ#'FG:#%9W-BGN"2)J*>>Z!EY<9:3F!#I.C6)B
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ME$A_WX @A5-_KH #==Q_AW_B9=I_>G_+5<=_AG^^1@5_IG^U-J9_\7^L*&N
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MBH7#J(=WB& &FBYX,&,;BOAX[V8#>N)YPFC1:C]ZIFNG66U[HVZ>2.5\O7'
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M,+:!Q'KE)0&!VGS<C.V![WAP@**!GGDN<\&!4'G89FJ!"'IY6)B VGLE2L:
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M<\&%JY*0: *$I9"%6]2#EXXT3YR"LXOF0XN" 8F>.""!7H=>+5F [H4!(^^
MHX*C?G^& 9L4<V6%(ICD9Y^$%Y826W6# Y+F3T^"'(_!0U>!<8RE. . X(F/
M+5. B(9F) 6 48-5>#.99E\I;;^7,F((8L&5(63I5SJ3!6?62V^0Q&K>/Z^.
M;&X7-'V,"'%]*>F)JG4](*J':'E0=XZ7N&:?;4:5I6C%8DZ3D&KW5N*1;6T\
M2S*/,V^?/Y",\7(L-'Z*IW3?*A>(:7?:(1*&1GL-=O>5X6WA;)F3[V]E8<*1
MZW#P5F"/UG*12M.-LW1*/UB+CG8H-'*)97@C*CR'2GI3(6V%2'RD=DZ4('3Y
M:^*2077I80*05';85=*.5G?32F&,47C@/Q**2WH'-%F(1'M#*E6&3'RC(;N$
M;7X3=::2IWP :T"0V7QA8&6.^7RS53N-!WS]2?^+%'U7/LV)+WW$-#R'1GX]
M*F:%;G[((?Z#L7]:=1.1?H+\:KF/OH+/7^F-XX)[5,6+]H(029F*#H&J/J*(
M+X%5-"N&9($+*G6$KH# (C6#%(!W=)N0AHG*:D..U(D+7W>,_8@,5%F+%(;G
M23V)-H7#/F>'9X2J-"N%GX.;*HB$"8*!(F."DH%J=#R/T9!L:@B.*8\H7S^,
M2HUT5!Z*3XM]20F(;XF2/BV&MX>V- .%!H7I*I2#@80+(HB"*((U<_*/29;6
M:<&-GI4(7O6+N9*:4]F)N8_72-.'V(TB/@N&)8I_,_:$AH?L*IN#&852(J:!
MTX+;;4*B;UZP8WB?I&& 65J<UF1C3N:9VF=B1$R6HFJ'.=&306WB+_6/R7%I
M)L^,2W5"'P>(\GE4;*F@_&6]8QR>-&?B60^;4&HC3K:81&R#1#:5#&\*.=B1
MO''!,!R.6W2>)Q^*^W>^'XB'PGL";#&?.FR-8IF<A6X=6*R9K&_"3EZ6J7&)
M0_Z3A7-P.<603W6!,#&-#'>Q)V&)SWH4'_>&N7R*:[6=?',P8A&:V'0Y6!V8
M$75,3?R5(G9W0[22&7>^.:*/ 7DC,#F+WGJ@)Y6(Q7Q!(%>%U7WJ:SB< 'G#
M89R9;'I*5ZV6KWK,38V3RWM00W:0TWON.7Z-VGRE,#F*U7UJ)[V'WGY%(*F%
M$W\B:LJ:UH!+83V83(!25UB5DH Z34"2LH 40S:/Q'_\.6B,TW_\,#R)ZX (
M)]Z'%H ;(.V$<( P:FV9Z8:D8/.79H8L5Q>4JH5T30&1R82>0OF.Y8/3.4:,
M X,9,$>)(8)N)_Z&:X&_(26#Z8$5:B>9*HR_8+*6K(O#5M:3\(II3,:1#8C?
M0L>.+8=>.16+787K,#>(A(2.*!Z%W8,K(5*#?('4:>^8HI*R8*>6(I%)5LN3
M68\[3+*08(S<0L6-=8J9.2J*K8AS,%"'](9G*#:%;X1:(7:#)8)P8JRKREX:
M67VH<V#74#>DXV.]1M&@\6;0/6F<I6H9-#B8'6V=*[63=W%-(_J.QW5%'96*
M5'E58A6JD&3!62^G(F;A4 2C9VDP1KV?7&NO/7&;"FYB-%^6CG%+*_R1^W1:
M)&B-:'>C'BV)%GKX8;VHWFLD6-2E=&R\3\6AP&YX1HN=N'!J/5V9=W*'-&V5
M$W35+#&0G'= ),6,+'G9'K"( GQS87"G&G%66'VCO')S3VF@%7.I1E.<(W4)
M/3N7^G:2-&V3M7@]+%>/7WH!)1&+%7OF'R"'%7W%82.EDG=X6#BB07@A3RF>
MHGC31A.:N7F4/266I7I^-&R2?7N&+':.1WR=)5&*(WW*'W^&2W[O8-VD77V2
M6 JA#GW*3P:=<7WM1?29C7X0/0V5A'Y*-'61:7ZD+)6-47\.)8B)4G^"'\^%
MHW_P8*.C9H-Z5^J@%8-!3O"<=8+11>"8E()///N4EH'A-'60BX&)++2,?H%%
M);F(HH$&(!"%&(#*8':BJ(DJ5]B?3XB 3N6;J(=X1=:7Q(9*/.Z3S(4O-&B/
MUX0J++R+VX,^)>"($8)7($2$J(%_8%FB&(ZD5].>KXV'3N*:_XOA1=.7%XH
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M]GPC31YNQGS%/'ERZ7V"+0!W8WY;L$%7JX/$H)=;18-$D&!>O(+!?Y]B+X)
M;I1ES(')759II(%D3'UMK8#^/!ER"("=+.1VM( WKN55TXVIGUM9CXQ(CSU=
M)HK6?I-@OHE=;:%D@8?H7)QH?X9[2_1LO84+.\5Q28.'+,QV'X'CK<Y43Y=F
MGEU8)Y4?CE-;U)*W?;M?AY!#;-UC;8W36_MGD(M?2X9K\8C:.X1PJ(8T++EU
MHH-;K/M3(:#GG9Q7"YVRC9I:QII/?0U>B);;;#QBAY-M6VUFS8_V2QYK4(QC
M.TQP(XB;+*EU.X2>K'-22:H,G1A6/*78C1-9^*%S?(A=OYT!:\5ARYB86PUF
M)I0B2LIJPX^&.P]OM8JM+)QTZ(6LJMQJ#%JLF_IK_5XUC'9M\6&>?#QO[F3S
M:X1R!&A06J%T/VO+2@MVI&]T.=)Y4W-U*JY\6G@ J5IF\&23FMUI-&<<BW=K
M9&F3>UMMF6P":KQOZ&YZ6?IR9'$.28QU#W/&.85X"G;'*I][6GHPI\QD)6Y6
MF4%FIF_KB@UI#7%U>@IK>G+_:9]N!G2761)PPG9$2-YSKG@,.1]VZ7H%*I%Z
M=GP_IC=AJ'?ME[%D67BAB(UF[GE)>-)IBGGM:(YL47J?6#IO2'MA2$5R<7PR
M.,AUZ7T?*H5YK'XII+]?@8%IEE-B6H%'AS]E&8$/=Y5GW8#+9YYJSX".5W1M
M_H!@1[MQ7H U.'UU"X /*GIX_7_IHXI=O(K1E3%@LXG8AC)CD(B[=IQF=X>+
M9K]IC89;5L]LX84R1T9P<80(.#QT38+.*G)X:(%ZHI1<290/E$A?6)([A59B
M29 T==!E2HX39@AH@HOR5CUK^8G-1NIOJ(>=. ISK85/*FMWZX+8H=Q;*)T1
MDY5>19I?A*1A0I=H=2AD4I1096MGHY$Y5;1K.XX<1HMO"XKJ-]YS*H>,*F5W
MA80$H6-:6:6]DQ5=?*(HA!I@>IX[=*!CCIHI9/5F[)8<55AJF9('1CIN@XW6
M-Z9RP(EU*F!W,X3^GJ5QF%J.D2)RS5X?@MMT&&&*<\1U=V3?9"AV[F@]5&1X
MAVN_1/EZ1F]R-?5\27.!*!9^F7@:G6)NI6/:D 9P+&9^@;]QKVD*<LES06N,
M8U)T[FX:4[AVPW#'1'MXP'.9-;-[!7:T*"%]DWHQG!IK]6T5CKEMO&[7@+=O
M<G"*<<QQ,W(T8H!S$G/L4Q9U(76]1 ]W6W>I-7]YX'G(*"M\JGPGFK!ICW8F
MC59KA'<:?TQM9W?Y<*9O4WC.87]Q;7FL4DQSM'J<0X)V*'N=-3AXY'R[*#-[
MW7WWF6%G@'\<C!5IF7]*?AIKHG]7;XEMM7]08*UO]7]-4:!R<7]80P]U&']I
M-0%X!G^!*#I[+'^=F$QESX@"BPYH X=F?29J)H:;;J9L6H6T7^-NO(3*41%Q
M68/F0JYT+8,$--%W2((5*$!ZE8$5EV]D;)"]BCEFM(]5?%IHZXVL;>IK-HO?
M7SMMN(H.4(YP=8@[0F)S989A-*]VIX1M*$5Z&();ELEC59D\B9-EK)<'>[-G
M[I1\;4UJ1I'!7JALWX\%4 YOO8Q$0@URRHEU-(]V)(:!*$EYL8-QEEEBBJ%N
MB1EDZ9YK>RYG+)KW;,EIB9=,7CEL+9.@3[IO'H_P0<-R1HPL-%UUO8A%*$UY
M7X18DJYY85J(ADUYW%X0>2)Z?V%W:RI[.V3,7+)\"V@O3AI\]6NZ/^A]_6]V
M,BQ_0'.2):F PG@OD9=VE&-$A4UW867S>"-X.6B+:DEY(6L>6_=Z'VV_38E[
M/G"!/X9\?W-K,@9]_':?)<]_LWHPD'AT!FOCA!5U$&W'=QYV%&^;:59W*'%H
M6S-X5G-#3/=YJW4W/RE[(W=),>5\V7F/)?!^PWP/CT5QM'1R@MYR[765=>]T
M&W:A:'MU57>H6GEVM7BS3')X/'G1/MQYZ7L#,<M[UGQ5)@Q]\7W&CAIOO7SG
M@=MQ&'U3=/!R:'V=9W1SQ'W06;-U2'X(2\YW WY-/F]XX'Z:,9]Z^7[S)B5]
M/7]4C2)N(85(@.EODX3Z= UP_(1Y9J1R=8/86/]T%X,T2U-U[H*8/B!W]8'_
M,7]Z.H%>)CE\HX"SC%ILSHU\@"EN5(QR<U9OS8LA9?MQ6HFG6&ES&8@H2N%U
M#H:G/>5W+84D,6MYEX.-)DI\)('DB\%KPI5V?Y!M5Y.O<KUNVI&*96UP<H\O
M5^5R1HS/2FYT68IL/9MVDH@",5=Y$85[)EA[O(+FBU1J^ITF?QULF9JF<D%N
M'Y>H9/1ONY1G5X%QEY$B2B1SO(W:/5MV$(J&,2]XK(<;)F-[:8.[AO"!;5J$
M>X*!.%W\;UR!,F%<8GZ!1&2U52^!7F@@1\Z!B&NV.N&!QV]^+H"",G.F(VR"
MSWA!A?E^T&*X>JE^Z&5I;H=_#F@+8<E_06JN5)]_@FUC1V9_VG ].J: 2G-
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MB6;&44R,)&F21G2*KFQ].[&).6^7,8:'R'+9*!2&<'9E( F%/GHC;O:-_FB
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M8IJ%[(G$6+Z% 8BJ3I2#](=51'6#!H83.HJ"283G,4N!GH/2*,.!*H*K(9F
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M?8+&C']8?)J5@%E;^9@W<Y!?695V9DIBTI*&6-!FDH^;2V1JHHRR/HIN[(G
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M6[M]RW[24K)^ 7[[26U^(7\10"1^4'\P-RA^F']?+M!^]'^?)P1_B7_<()V
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MV'O2,]5U2WS8*I!XYGWR(K5\8'\/<%-@:W[29L5CG'\97,=FN7\U4F5IX']
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M3)1[N'> 14)\>WAT/=E]#'EN-GM]EWJ#+VM^,GNR*0A^UGSN(T1_JGXA'K"
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M"7H^3'B+$6'01>J*?&2D/S&)KV>/.'N(K&J?,<F'B6W@*V6&;W%&):^%:G3
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M(9J GH ;'@6 Q(!4  #__P  __\  /__  !M9G0Q      ,$(0   0
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ML[MMLZNU>+NEL8#!GZZ$QIBKA,J0J(3.B*:&T8*DC-. I)+3@*22TX"DDM.
MI)+3@*22TX"DDM. I)+3@*22TX"DDM. I)+3@*22TX"DDM. I)+3@*22TX"D
MDM/_I3<J_Z%$0?^E15'^K$)?];0_;.V\/GCGQT"!X-9&A\G-49JXPF"JK+IM
MM:6U>+R@L8#!FZZ$Q96LA,B.JH3+AZB&SH*GB\]_IH_0?Z:/T'^FC]!_IH_0
M?Z:/T'^FC]!_IH_0?Z:/T'^FC]!_IH_0?Z:/T'^FC]!_IH_0?Z:/T'^FC]#_
MI38J_Z)#0?^G0U#_KC]=][<\:?#".W/FT#]YT]D_BK[+49VOP&&LI;ENMJ"U
M>;R<LH' F*^$PY*NA,:,K(7(AZJ'RH*IBLQ_J8[-?ZF.S7^ICLU_J8[-?ZF.
MS7^ICLU_J8[-?ZF.S7^ICLU_J8[-?ZF.S7^ICLU_J8[-?ZF.S7^ICLW_IC8J
M_Z)"0?^I0$__LCM;^;TX9>S+.&W<W#5XQ]8^CK/)4J"GP&.MG[EPMIJU>KR8
MLH&_E+&%PH^OA<2+KH;%AJV'QX*LBLA_JXW)?ZN-R7^KC<E_JXW)?ZN-R7^K
MC<E_JXW)?ZN-R7^KC<E_JXW)?ZN-R7^KC<E_JXW)?ZN-R7^KC<G_IS4J_Z-"
M0?^L/$W_MS97\L4S7^'6-F/-XS%\NM,_D:G(5*&?P&6MF;IRM9:V>[J4LX*^
MDK*%P(VQAL&)L(?#AJ^(Q(*NBL6 KHS%@*Z,Q8"NC,6 KHS%@*Z,Q8"NC,6
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M-6R,Y41ZA-Y3@X#98HI\U6R/>-)QDW70=95SSWB7<<YZF'#-?)EOS7Z:;LR
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M047_KSU0_K@[6?/$/&'FT4-DV=]#<\C<2H6WT%>5JL=EHJ# <*R9NGFTE+:
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MOKY]HK^]>JC O'FOP;1YL,&P>K# L'JPP+!ZL,"P>K# L'JPP+!ZL,"P>K#
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M9UU:^&M?6/=N8%?W<6%6]G1A5?9V8E3U=V-3]7EC4_1\9%+T?F11](!E4?2
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MM'R5N;1\E;FT?)6YM'R5N;3_E2P._Y4]'O^@/2?_J#LP_[ \-_VX/SSQP41
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M8_\Z)%S_0BA6_TDL4?]/+T[_53%+_UHS2/]>-4;_8C9$_V8W0_]I.$'_;#A
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M/#;_ISTU_[$^-/^^/C/_RC\S_\H_,__*/S/_RC\S_\H_,__*/S/_RC^XL@
MJKT  )W*  "1V ( B/L- 7__&0)V_R0&;O\M#&;_-1)?_SP76/]#&U/_21Y.
M_T\A2O]5)$;_6R9#_V G0/]F*3[_:RH[_W(K.?]Y+3;_@2XT_XHO,?^4,##_
MG#$N_Z4R+?^O,RS_MS,L_[<S+/^W,RS_MS,L_[<S+/^W,RS_MS.KN   GL4
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M6S/Y=F0Z]7!N0?%L>4CM:(--ZF2,4>=AE57E7YU8XUVE6N%;K5S>6K9>W%G
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M<.ERCG'J<8UQZW",<>MPC''K<(QQZW",<>MPC''K<(QQZW#_8R #_W(; _^
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M6DC%^UI(Q?M:2,7[6DC%^UKWD00 U*(" ,>O! "ZN0, L,0% *?0"0"?X1
MF.$A X_@, F&X#L2?=]$&W7>321NW54K9]Q<,F+;9#==VVL[6=IR/U7:>D-2
MVH-%3MJ-2$S:F$I)VJ5+2-NS3$?<Q$Q&W-Y,1MKM3$38^4]#V/M/0]C[3T/8
M^T]#V/M/0]C[3T/8^T_;F@  RJD" +NS @"PO0, I<D% )O6"0"4Z!0!C.DE
M!(3H,PM[Z#P4<^A$&VOH2R)DYU(H7N=9+5GG8#)5YV@U4N=O.$_G=SM,YX ]
M2>>)/T?HE$%$Z)]"0NFL0T'IND1 ZLU$0.KD1$#H]41 Y_A#0.?X0T#G^$-
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M9F^"\F5P@?-D<('S9'"!\V1P@?-D<('S9'"!\V3_:Q0!_WL2 ?^*$@#_EA(
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M7U><]U]7G/=?5YSW7U><]U__>@P _8L) -J;! #.IP8 Q+ & +RY! "UP0X
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M1<+_3D7"_T[?D   S)\  +^J 0"SLP$ J;T" )_'!0"6T@D CMH2 (C;) *
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M(S+^I"0Q_[$E,/^_)B__SR8N_^,F+O_C)B[_XR8N_^,F+O_C)B[_XR:MK0
MG[<  )+"  "&S0  >=H  '#R" !H_Q$ 8?\: 5K_(P-4_RL$3_\S!DK_.PA&
M_T(+0_])#4#_3PX]_U40.O];$3C_81,U_V@4,_]O%3#_>!8N_X(7+/^-&2K_
MF1HI_Z0:*/^O&R?_NAPF_\<<)O_''";_QQPF_\<<)O_''";_QQRAM   D[\
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MX4^[0.!/QT#>3]A!V4_H0=1/]$/03OY%SD[_1LA0_T;"4?]'P%'_1\!1_T?
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M6GQR_%E\<OQ7?'+]5WQR_5=\<OU7?'+]5WQR_5?_8A0!_W$1 ?]]$0#_B!(
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M5V>#_%=G@_Q79X/\5V>#_%?_; X _WL, /*)"0#9E08 SYX( ,FF" #!JQ
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M-4+.N#9!S\TU0<[H-4#-]3<_R_XY/LO_.3[+_SD^R_\Y/LO_.3[+_SG*E@
MO*(  *^J  "CLP  F+P  (W& P""SP< >-D+ '/>& !NWB8":-XS!6+>/@I=
MWD@/6=Y0%%7>6!=1WF ;3MYG'DO=;R!(WG@C1MZ!)4/>C"=!WI@I/]ZF*C[?
MM2H]X,@J/=_C*CS=\2L[W/LM.MS]+CK<_2XZW/TN.MS]+CK<_2[ GP  L:<
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M+?N^&BS[SQLK^^<;*_OK&RO[ZQLK^^L;*_OK&RO[ZQNHJ@  FK0  (V_  "
MR0  =-,  &?>  !>\@@ 6?X1 %/_&@%._R,"2?\K T7_,P1!_SH%/O]!!CO_
M1P<X_TX(-?]4"3/_6@DQ_V$*+_]I"RS_<@PJ_WT-*/^(#B;_E0\E_Z$0)/^N
M$2/_NA(B_\H2(O_0$B+_T!(B_] 2(O_0$B+_T!*<L@  CKP  (''  !ST0
M9]T  %GC  !3_08 3?\. $C_%@!#_QX!/_\F CK_+0(W_S,#,_\Y S#_/P0N
M_T0$*_]*!2G_4 4G_U8&)/]=!B+_90<@_VX''?]Y"!O_A0@:_Y()&?^>"1C_
MJ D7_[,)%_^W"1?_MPD7_[<)%_^W"1?_MPF0N@  @L4  '30  !GW   6.,
M $WP  !'_P( 0O\, #S_$0 X_Q@!-/\? 3#_)0$L_RL"*?\P B7_-0(C_SH"
M(/\_ Q[_1 ,<_TD#&?]/ Q?_5@05_UX$$O]H!!'_<@4/_WX%#O^*!0[_E 4-
M_YX%#?^B!0W_H@4-_Z(%#?^B!0W_H@7_.2\"_SPP _]!,0/_1#0$_T0Z!O]$
M10C_15$,_T-=$?]!:1;_/G89_SR!'/\ZC![_.98@_SB>(?\WI2/_-ZLC_S:R
M)/\VN27_-L E_S7*)O\UUR;_->4F_S7O)O\U^";_-O\F_C;_)OPV_R;\-O\G
M^C;_*/HV_RCZ-O\H^C;_*/HV_RC_.2\"_SXO _]$+P/_1C($_T@X!O](0PC_
M2$\-_T=;$O]$9Q;_0G,:_S]_'?\]BA__/),A_SN;(_\ZHB3_.:DE_SFP)O\X
MMB;_.+XG_SC')_\XTRC_..,H_SCM*/XX]RC[./XG^3G_)_@X_RGX./\J]CC_
M*O8X_RKV./\J]CC_*O8X_RK_.B\"_T$L _]&+ /_2B\$_TPW!?]-00C_3$P-
M_TM8$O](9!?_1G ;_T-\'O]!AR#_/Y C_SZ8)/\]H"7_/:8F_SRM)_\\M"C_
M.[LI_SO$*?\[SRG^.^ J^SOK*O@[]2GV//XI]#S_*O,[_ROR._\L[SO_+>\[
M_RWO._\M[SO_+>\[_RW_/"T"_T0I O]**0/_3BP$_U$T!?]2/@C_4DH-_U!5
M$O]-81?_2FT;_TAX'_]%@R+_0XTD_T*5)O]!G2?_0*,H_T"J*?X_L2K]/[@K
M_#_!*_H_RROW/]PL]3_I+/$_]"OO/_TL[3__+>P^_R_K/O\PYS__,.<__S#G
M/_\PYS__,.<__S#_0"H"_T@F O].)@/_4BD#_U8R!?]7/ ?_5T<,_U51$O]2
M71?_4&D<_TUT(/]*?R/]2(DF^T>1*/I&F2GX1: J]T2G*_5$K2ST0[4M\T.]
M+?)#R"[P0]<N[$/G+NE$\RWF0_PPY$+_,>-"_S+A0O\SW$/_--Q#_S3<0_\T
MW$/_--Q#_S3_0R<"_TLC O]2(@+_6"<#_UPO!/]=.0?_7D,,_UM.$?]86!?^
M560<^E)O(/=0>B3T380G\DR-*?!*E2OO29PM[4FC+NQ(JB_J1[$OZ4>Z,.='
MQ3#F1](PXDCE,-]'\C+;1_LTV$;_-=5&_S;21O\WS4C_-\U(_S?-2/\WS4C_
M-\U(_S?_1B0"_T\@ O]6'P+_720#_V$L!/]C-0;_9$ +_V)*$/I>5!;U6U\<
M\5AK(.Y5=27K4W\HZ%&(*^9/D2WD3I@OXDV@,.%,IS'?3*XRW4NW,]M+PC39
M2L\UU4OD-=!+\#;-2OLXRDK_.LA*_SK&2_\[P4S_.\%,_SO!3/\[P4S_.\%,
M_SO_2B$"_U,= O];' +_8B("_V<I _]I,@7_:CP)^6A&#_)E4!7M85L:Z%YF
M(.1;<27A6'LIWE:$+-M4C"_84I0RU%&;--)0HS703ZHWSDZR.,Q.O#G*3LDZ
MR$[=.L1/[3O!3OD]OD[_/;Q._SZZ3_\^ME#_/K90_SZV4/\^ME#_/K90_S[_
M31X"_U8: ?]?&@'_9R "_VPF O]O+@3Y<#@'\F]"#.ML2Q+E:5<9WV5B']IA
M;"74778JT%M^+\U9AS+*5X\UR%:6-\94G3G$4Z4[P5.M/+]2MSZ]4L,_O%+3
M/[E2Z#^U4O9!LU+_0;%3_T&O4_]!K%3_0:Q4_T&L5/]!K%3_0:Q4_T'_4!P!
M_UH7 ?]D& '_;!T!_W$C OUU*@/S=C,%ZW8]"N-S1P_<;U,7U&M>'\YF9R;*
M8W$KQF!Y,,)>@32_7(DWO5J1.KI9F#RX6* ^ME>H0+16LD*R5KU#L%7,0ZU6
MXT2K5O-$J%?^1*=7_T2E6/]$HEC_1*)8_T2B6/]$HEC_1*)8_T3_4QD!_UT4
M ?]H%@'_<!H!_W8@ ?=Z)@+M?"X#Y'PX!]QZ1 W2=4\6RW!:'L9L8R;!:&PL
MO69U,;EC?36V880YLU^,/+!=E#^N7)M!JUND0ZE:K46G6KA&I5G'1Z-:WD>A
M6N]'GUO\1YU;_T>;7/]&FES_1II<_T::7/]&FES_1II<_T;_51<!_V 2 ?]K
M% '_=!< _WH< ?)_(@'G@2D"WH(S!--_0 S+>DP5Q'96'KYQ8"6Y;F@LM&MQ
M,K%H>3:M9H ZJF2(/:=BCT"E8)=#HE^@19]>J4>=7K1)FUW"2IE=UDJ77NQ*
MEE_Z295?_TF38/](DF#_1Y)@_T>28/]'DF#_1Y)@_T?_6!4!_V,1 ?]N$@#_
M=Q4 ^WX8 .V#'0#BAR,!UH<N \R#/0O%?TD4O7M3';=V726R<V4LK6]M,JEM
M=3>F:GP[HFB$/I]FC$&<991$F6.<1Y=BIDF48K!+DF&^3)!AT$R/8NA,CF/X
M2XUC_TJ,9/])BV3_28MD_TF+9/])BV3_28MD_TG_6A,!_V80 /]Q$0#_>A(
M]X(4 .B'%P#=BQP T(LL \>(.PJ_A$<3N']1'+%[6B2L=V(KIW1J,:-Q<C:?
M;WD[FVV /YAKB$*5:9!%DFB92(]FHDJ,9JU,BF6Z38AES$Z'9N9.AF?V3(9G
M_TN%:/]+A&C_2H1H_TJ$:/]*A&C_2H1H_TK_7!(!_V@/ /]T$ #_?1  \X40
M .2+$0#6CQ< RXXJ L*,. FZB$02LX1/&ZQ_6".G?& KH7AH,9UU;S:9<W8[
ME7%]/Y)OA4*.;8U%BVR62(AKH$N%:JI-@VFW3H%IR$^ :N-/@&OT3G]K_TQ_
M:_]+?VO_2W]K_TM_:_]+?VO_2W]K_TO_7A !_VL. /]V#@#[@ T ZH@- -N/
M# #0DA4 QY(G KZ/-@BVC$(1KHA-&JB$5B*B@%XJG'UE,)=Z;#63=W,ZCW5[
M/HQS@D*(<HM&A7"328)OG4Q_;JA.?6ZU3WMMQE!Z;N!0>6_R3GEO_DUY;_],
M>6__2WEO_TMY;_]+>6__2WEO_TO_8 \ _VT- /]Y# #N@PL VXL) -21"@#,
ME1, PI4E KF3- >QCT$0JHQ+&:.(5"&=A%PIEX%C+Y)^:C6.?'$YBGIX/89X
M@$*#=HA%?W6127QSFTQY<J9.=G*S4'5RPU!S<MU0='/P3W1S_4UT<_],='/_
M3'1S_TQT<_],='/_3'1S_TS_8@X _V\, /Q["@#>A@8 U8X( ,^4"0#'F!$
MOI@C ;66,@:MDS\/II!)&)^,4B"8B5HHDX9A+HZ#:#2)@6\YA7]V/8%]?D%]
M>X9%>GF/279XF4QS=Z1.<7>Q4&]VP5!N=]E0;G?O3VYW_$YN=_]-;W?_3&]W
M_TQO=_],;W?_3&]W_TS_9 T _W(* /!^!@#:B 4 T) ' ,J7" #"FQ  N9LA
M ;&:, :IEST.H91'%YJ14!^4C5@GCHM?+8F(9C.$AFTX@(1T/7N">T%X@(1%
M='^-2'%]ETMM?*).:WRO3VE[OE!H?-50:'SM3VE\^TYI?/]-:GO_3&I[_TQJ
M>_],:GO_3&I[_TS_9@H _W4( .&! @#4BP4 RY,& ,2:!@"]G@X M9\? :R>
M+@6DFSL,G9A%%9:53AZ/DU8EB9!=+(2.9#)_BVLW>HIR/':(>4!RAH%$;X6*
M1VN#E4IH@J!-98&L3F.!O$]B@=%/8H'K3F.!^4UC@?],9(#_2V2 _TMD@/]+
M9(#_2V2 _TO_:0@ ^W@$ -R$ 0#/CP0 QI<% +^=!0"WH0P KZ,< *>B+ 2?
MH#D+F)Y#%)&;3!R*F%0CA)9<*G^48C!ZDFDU=9!P.G&.=SYMC7]":8N(1F6*
MDDEBB9Y+7XBJ35Z(NDY<B,Y.78CI35V'^$Q=A_]+7H;_2UZ&_TM>AO]+7H;_
M2UZ&_TO_;04 ZGP  -6(  #*D@, P9H# +F@ P"QI@D J:<9 **G*0.:I38)
MDJ-!$HNA2AJ$GU(A?IU:*'F;8"YTF6<S;Y=N.&N6=3QGE'U 8Y.&0V"1D$9<
MD9Q)6I"I2UB0N$Q7D,Q,5Y#G2U>/]TI7CO]*6([_25B._TE8CO])6([_25B.
M_TG_<0$ X(   ,^,  #$E@( NYX" +*D  "IJ@4 HJP5 )NL)@*4JS0'C*H_
M#X6H2!=^IE >>*18)7.B7BMNH64P:I]L-&6><SEAG7L\7IN$0%J:CD-7F9I%
M5)FG1U*9MDA1F<I(49CF2%&7]4A1E_]'49;_1U&6_T=1EO]'49;_1U&6_T?V
M=P  V(4  ,F1  "_FP$ M*(  *NH  "AL   FK(1 )2S(@&-LC %A;$\#'ZO
M1A1XKDX;<JQ6(6VK7"=HJ6,L9*AJ,&"G<31<IGDX6*6".U6DC#Y1HYA 3Z.E
M0DVCM$-,H\A#3*/D0TNA]$-+H/]$2Z#_1$N@_T1+H/]$2Z#_1$N@_T3C?0
MSXL  ,*6  "WGP  K:8  *.M  "9M0  D+D. (NZ'@&$NBT#?;DY"7>X0Q!Q
MMDP7:[53'6:T6B)BLV$F7K)H*UJQ;RY6L'<R4["!-4^OBSA,KY<Z2JZD/$BN
MLSU'KL<]1Z[C/$:M\SU&J_X^1:O_/T6K_S]%J_\_1:O_/T6K_S_:@P  QY$
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M(#G7[R XU?DB-]3_(S?4_R,WU/\C-]3_(S?4_R.YG   JZ0  )^L  "3M0
MA[X  'O&  !PS@, 9=8' %WC#@!:XQL 5N,G 5+D,@).Y#P$2N1$!D?E30A%
MY54*0N5<#$#E9 X^YFP0.^9V$CGF@!0WYXP5->>9%C3GJ!<RZ+@8,NC,&#'H
MY1@QYO08,>7\&#'E_!@QY?P8,>7\&#'E_!BNH@  H:H  )2S  "(O0  >\8
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M!1'_O 41_[P%$?^\!1'_O 6,N   ?<(  &_,  !BV   5-\  $?E   ^\0
M.?\! #3_"P P_Q  +/\6 "G_'  F_R( (O\G 1__+ $<_S$!&O\V 1C_/ $5
M_T$!$_]( A'_3P(0_U<"#?]A @S_; (*_WD""?^& PC_D@,'_YT#!O^E P;_
MI0,&_Z4#!O^E P;_I0/_,3$"_S8N O\Z+P+_.S(#_SLY!/\[0P7_.4\'_SA<
M"O\V: W_-'00_S* $O\QBQ3_,)06_S";%_\OHA?_+Z@8_RZO&?\NM1G_+KP9
M_R[%&O\NSQK_+N :_R[K&O\N]!K_+OP:_"__&?LO_QKZ+O\;^B[_'/HN_QSZ
M+O\<^B[_'/HN_QS_,R\"_SDL O\]+0+_/C #_S\V!/\_007_/4T'_SQ9"O\Z
M90[_.'(1_S9]$_\UB!7_-)$7_S.9&/\SH!G_,J89_S*L&O\QLQK_,;H;_S'"
M&_\QS!O_,=T;_S'I&_TQ\QOZ,OL;^#+_&_<R_QSV,?\=]3'_'O4Q_Q[U,?\>
M]3'_'O4Q_Q[_-2P"_SPJ O] *@+_0BT#_T,T!/]$/P7_0DH'_T%6"O\_8@[_
M/6X1_SMZ%/\YA!;_.(X8_S>6&?\VG1K_-J0;_S6J'/\UL!S_-;<=_S6_'?\U
MR1W\-=@=^C7G'?<U\1WT-?H=\C7_'O$U_Q_P-?\@[S3_(>\T_R'O-/\A[S3_
M(>\T_R'_."H"_S\G O]#)@+_1BD"_TDR _])/ 7_2$<'_T93"_]$7P__0FH2
M_T!V%?\^@!C_/(H9_SR2&_\[FAS].J =_#JG'?LYK1[Z.;0?^3F\'_@YQA_V
M.=,?\CGD'^\Y\!_L.OH?ZCG_(>DY_R/H.?\DYSG_).<Y_R7G.?\EYSG_)><Y
M_R7_/"<"_T,C O]((@+_3"8"_T\O _]0.07_3D,'_TQ/"_]*6P__2&83_T5Q
M%OQ#?!GZ0H8;^$&.'/9 EA[U/YT?\S^C(/(^JB#Q/K$A\#ZY(>X^PR'M/L\A
MZC[B(>8_[R'C/ODCX3W_)=\]_R?>/?\HW#W_*-P]_RC</?\HW#W_*-P]_RC_
M/R,!_T<@ ?],'@'_420"_U4L _]6-03_53\&_U-*"OY05@_Z3F(3]DMM%_-)
M=QKP1X$<[D:*'NQ%DB#K1)DAZ4.@(NA#IR/F0ZXCY4*V).1"P"3B0\PDWT/@
M)-M#[2760O@HTT+_*M%"_RO/0?\KSD'_+,Y!_RS.0?\LSD'_+,Y!_RS_0R !
M_TH< ?]0&P'_5R$!_ULH O]<,@/_6SL&_%E&"?9640[Q5%T3[5%H%^E/<AKF
M37P=Y$N%(.)*CB'@294CWDB<)-Q'HR;:1ZLGV$:S*-5&O"C31L@IT4;<*LU'
M["K)1O<LQT;_+L1&_R_#1O\OPD;_+\%&_R_!1O\OP4;_+\%&_R__1AT!_TX8
M ?]6& '_7!X!_V E O]B+0/\8C<%]&!!".Y=3 WH6E@2XUAC%]]5;AO;4G<?
MV%" (M1/B23139 GSTR7*,U,GBK+2Z8KR4JM+,=*MRW&2L(NQ$K1+\%+YR^]
M2O0QNTK_,KA*_S*W2_\SMDO_,[9+_S.V2_\SMDO_,[9+_S/_2AH!_U(5 ?]:
M%@'_81L!_V8A ?YH*0+T:#(#[&<\!N5D2 O?8500V5Y>%]);:1S.6'(@RU9[
M),A4@R?%4HLJPU&2+,%0F2Z_3Z$OO4^H,;M.L3*Y3KPSMT[*-+5.X32R3O$U
MKT_]-JU/_S:L3_\VJT__-JM/_S:K3_\VJT__-JM/_S;_31<!_U42 ?]?% #_
M9A@ _VL= ?AM) 'M;BP"Y6TV!-UK0PC49T\0S61:%\A@9!W$76TBP5MV)KU9
M?BF[5X4LN%:-+[95E#&T5)PSLE.D-+!2K3:M4K<WK%+%.*I2VCBG4NTYI5/Z
M.:-3_SFB4_\YH53_.*%4_SBA5/\XH53_.*%4_SC_3Q0!_UD0 /]C$@#_:A0
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M$0#9?1@ SGTJ L5[.0:^=T4.MW10%;%P61RM;6(BJ&II)Z5H<2RA9G@OGF2
M,YMBAS:888\XEF"8.Y-?H3V17JL_CUZX0(U>R$&+7N%!BE_S0(E?_S^)8/\^
MB&#_/HA@_SV(8/\]B&#_/8A@_SW_5P\ _V(, /]L# #X= P Z7H, -Y^# #2
M@14 R($G <!_-@:X?$(-LGA-%:QU5ANG<E\BHF]F)YYL;BR;:G4PEVA\,Y1G
MA#:198PYCF25/(QCGCZ)8JA AV*U0H5BQ4*$8MY#@V/Q0H)C_4&"9/] @F3_
M/X)D_S^"9/\_@F3_/X)D_S__60X _V0+ /]N"@#J=P@ VWT( -2""@#,A!(
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M/7EPED!V;Z%"=&ZN1')NO45P;M%%<&_K1'!O^D-Q;_]!<6__0'%P_T!Q</]
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M05N$M$):A,=#6H3C0EJ#]$%;@_] 6X/_0%N#_S];@_\_6X/_/UN#_S__:@
MWG@  ,V#  #"C   N9,  +"8  "GG0( H)\2 )F?(P&3GC$%C)T\"X6;1A)_
MF4X8>I=6'G6672-PE&,H;))J+&B1<3!ED'DT88Z"-UZ-C#I:C)<]6(RD/U:+
MLD!4B\5 5(OA0%2*\S]5BOX_58G_/E6)_SY5B?\^58G_/E6)_S[O;P  UGP
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M,D2H[S)#I_LS0Z;_,T.E_S1#I?\T0Z7_-$.E_S30@0  P8X  +68  "IGP
MGJ4  ).L  "(L@  ?+D" ':Z$0!RNR$ ;KLN FB[.@9DND,*7[I,#ENY4Q)7
MN%H65+AA&5&W:1Q.MW$?2[9Z(DBVA"5%MI G0[6=*4&UK"I MKXJ/[;8*C^T
M[BH^L_HL/;+_+3VQ_RT]L?\M/;'_+3VQ_RW'B0  N94  *R=  "AI   EJL
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M#RS?_1 LW_T0+-_]$"S?_1"HH   G*<  (^P  "#N   =L$  &K)  !>SP
M4]4! $G<!@!%Z0\ 0ND9 $#J)  ]ZBX .NLV 3CL/@$V[$8",^U- S'M50,O
M[ET$+>YE!2ON< 4I[WL&*.^)!R;PEP<E\*<()/&X""/QS @B\N4((O#S""+O
M]0@B[_4((N_U""+O]0B>I@  D:\  (2X  !WP0  :LD  %W0  !1UP  1MT
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M(\!!_R2^0?\DO4'_);U!_R6]0?\EO4'_);U!_R7_0A@!_TD3 /]0% #_5AD
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M,)14_S"45/\PE%3_,)14_S#_3PX _U@+ /]@"P#[9@P \&L- .1M#@#6;A8
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M.&EOM3IH;\<Z9V_B.F=O]#AH;_\W:&__-FAO_S9H;_\V:&__-FAO_S;_7@
MY&H  --T  #(?   OX$! +>% 0"OAP< J(D5 *&))0&;B#,$E(8^"8Z$1P^)
M@5 5A']7&G]^7AY[?&4B>'IL)G1Y<RIQ>'LM;G>$,&MVCC-H=9DV9G2E.&1S
MLSEB<\0Z8G/@.F)S\SAC<_\W8W/_-F-S_S9C<_\V8W/_-F-S_S;_80  X&T
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M-5&&[C52A?LT4H7_-%*%_S-2A?\S4H7_,U*%_S/C;   SGD  ,&#  "VBP
MK)$  **5  "7F0  CYL+ (J=& "$G2<!?IPT!'F;/@ASFD<-;YE/$FJ85A=F
MEUT;8Y5C'E^4:B)<DW(E69)[*%61A2M2D9 N4)"=,$Z0JS%,D+PR3)#3,DR/
M[3),COHR3(W_,4R,_S%,C/\Q3(S_,4R,_S'<<0  R'X  +N(  "QD0  II8
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M(CJL_R,ZK/\C.JS_(SJL_R/ A@  LY(  *>9  "<GP  D*8  (2L  !YL0
M;;<  &&\!0!=O1( 6KX@ %B^+0%4OC@"4;Y"!$Z^2@9,OE((2;Y9"D:^8 Q$
MOF@.0;UQ$3^]?!,\O8@5.KV5%CB]I!<WO;48-KW*&#>\YQ<UN_89-;K_&C2Y
M_QLTN?\;-+G_&S2Y_QNXCP  JI@  )^?  "3I@  AZP  'NS  !ON0  8[X
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M QOI^0.:I   C:P  '^U  !RO0  9<4  %G+  !,T   0=4  #C<   OX0(
M+?$- "OQ$P H\AP )O(D "3S*P B]#( (?0Y !_U00 =]4D &_91 !GW6@$7
M]V4!%?AR 13Y@0$3^9(!$OJB A'ZLP(0^\8"$/O= A#[Z0(0^^D"$/OI A#[
MZ0*/JP  @;0  '.]  !FQ@  6<T  $O3  ! V0  -=X  "SC   F\0  )/X*
M "'_$  ?_Q8 '/\< !G_(@ 7_R@ %?\N !/_-0 2_SP $/]#  [_3  -_U8
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M'JQ!_QZL0?\>K$'_'JQ!_Q[_0A$ _T<- /]/#@#_4Q$ _U85 /-7' #H5B4
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M+79>M2YU7L8O=%[A+W1?\RYT7_\L=&#_*W1@_RMT8/\K=&#_*W1@_RO_4P
MZ%X  -EG  #+;0  PW$! +MS @"U<PD K747 *=U)P&A=#0#FW(_!Y5P20N1
M;E(0C&Q9%(EJ8!B%:6<;@FAN'G]F=2%]97TD>F2%)G=DCREU8YHK<F*E+7!B
MLR]O8L0O;F+>+VYC\BYN8_XM;F/_+&YC_RMN8_\K;F/_*VYC_RO_50  Y6
M --I  #(<   OW0  +=W 0"P=P< J'@5 *)Y) "<>#("EG8]!I%T1PN,<D\/
MB'!7$X1O7A> ;60:?6QK'7IK<R!W:GHC=&F#)G)HC2EO9Y<L;6>C+FMFL2]I
M9L$P:6;;,&EG\"]I9_TM:6?_+&IG_RMJ9_\K:F?_*VIG_RO^6   X6,  ,]L
M  #$<P  NW@  +-Z  "K>@0 I'L2 )Y\(@"8?"\"DGH[!8QX10J'=TT.@W55
M$G]S7!9[<F(:>'!I'75O<"!R;G@C;VV!)FULBREJ;)8K:&NA+F9KKR]D:K\P
M8VO8,&-K[R]D:_PM9&O_+65K_RQE:_\L96O_+&5K_RST6P  W68  ,MO  #
M=@  MWL  *]^  "F?@$ GW\0 )F 'P"3@"T"C7\Y!8A]0PF#>TL-?GI3$GIX
M6A9V=V$9<W5G''!T;A]M<W8B:G)_)FAQB2AE<)0K8G"@+6!OK2]?;[TO7F_4
M+UYO[2]?;_LM7V__+&!O_RQ@;_\L8&__+&!O_RSK7@  V&D  ,=R  "\>0
MLW\  *N"  "A@@  F8,. )2$'0".A"L!B(,V!(."0 A^@$D,>7]1$'5]6!1R
M?%\8;GME&VMZ;!YH>70B97A])6)WAR=@=I(J776>+%MUJRY:=+LO6771+UET
M["Y9=/HM6G3_+%IT_RM:=/\K6G3_*UIT_ROF80  T6T  ,-V  "Y?0  KX,
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M)TF'_R=)A_\G28?_)TF'_R?1;P  P7L  +6$  "KC   H)   )64  ")EP
M?IH  '>;#@!SG!P ;YTI 6N<-0)FG#\%8IM'"%^:3PM<FE8/6)E<$E688Q53
MF&L74)=S&DV6?1U*E8D?1Y65(465I"-$E+,C0Y3((T.4Y2-#DO4D0Y'_)$.0
M_R1#D/\D0Y#_)$.0_R3*=0  NX$  +"+  "DD0  FI4  (^9  "#G0  =*(
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M$S"S_Q.RC@  I94  )J;  ".H@  @J@  '6M  !ILP  7K<  %.[  !'P 4
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M !CDB $7Y9H!%N:L 17FP $4Y]T!$^7O 1/C^@$3X_H!$^/Z 1/C^@&6H@
MB:D  'NQ  !NN0  8<   %3&  !(R@  /<\  #/3   JV0  (MX" ![K"@ <
M[!  &^T7 !GM'P 7[B8 %>XM !3O-0 3\#T $?!& !#Q4  /\EL #O)I  WS
M>  ,](H "_6<  KUK@ )]L( "?;9  CU[0 (]>T "/7M  CU[0"+J0  ?;(
M &^Z  !BP@  5<D  $?.   [T@  ,=@  "?=   ?X0  &>@  !;X!@ 4^@T
M$OL2 !#\%P ._!T #?TC  S]*0 *_C  "/\X  ;_00 #_TP  /]8  #_9@
M_W<  /^)  #_FP  _ZL  /^[  #_S@  _\\  /_/  #_SP!_L@  <;H  &/#
M  !6RP  2-$  #K6   OW0  )>$  !SE   4Z0  $?<   __ 0 -_PD "_\-
M  C_$  &_Q0  _\8  #_'@  _R,  /\J  #_,@  _SP  /]'  #_5   _V,
M /]S  #_A0  _Y<  /^D  #_L@  _[(  /^R  #_L@#_(BD!_R,G ?\C* '_
M("L!_QPQ ?\:/0'_&$D!_Q96 O\48@+_$VX"_Q)X O\2@@+_$HL"_Q*2 O\2
MF0+_$IX"_Q*D O\2J0+_$J\"_Q*V O\2O0+_$L<"_Q+4 OT2Y0+Z$O$"]Q+Z
M O43_P+T$_\#]!/_ _03_P/T$_\#]!/_ _03_P/_)"<!_R8D ?\F) '_)"<!
M_R(O ?\@.@'_'D8!_QQ3 O\:7P+_&&H"_Q=U O\7?P+_%X@"_Q>/ O\7E@+_
M%YP"_Q>A O\7IP+_%ZT"_Q>S _X7NP/]%\4#^A?1 _<7Y +T%^\"\1CZ N\8
M_P/N&/\$[AC_!.T8_P7M&/\%[1C_!>T8_P7_)R,!_RD@ /\I( #_*", _RDM
M ?\G-P'_)4,!_R-/ O\A6P+_'V8"_QUQ O\=>P/_'80#_QV, _X=DP/\')D#
M^QR? _H<I /Y'*H#]QRQ _8<N0/U'<(#\QW. _ =X0/L'>X#Z1[Y!.@>_P7F
M'O\&Y1[_!N4>_P?E'O\'Y1[_!^4>_P?_*Q\ _RT< /\M&P#_+B  _R\I /\O
M- '_+#\!_RI+ O\H5P+_)F("_25M _HD=P/X(X #]B.( _4CCP/S(Y4$\B.;
M!/$CH03O(Z@$[B.N!.TCM@3K([\$ZB/,!.<CX 3C).T$X"3Y!MXD_P?<)/\(
MVR3_"=HD_PG:)/\)VB3_"=HD_PG_+AL _S$7 /\R%@#_-1P _S8E /\V+P'_
M-#H!_S%& ?LO4@+W+5T"\RQH _ K<@/N*GL$["J$!.HJBP3H*I(%YRF8!>8I
MG@7D*:4%XRFL!>$IM 7@*KT%WBK*!=LJW@76*NT'TBKX"<\K_PK-*O\+S"K_
M#,LJ_PS+*O\,RRK_#,LJ_PS_,A< _S42 /\X$@#_.Q@ _ST@ /\\*@#^.S4!
M]SE! ?$V30+L-%@"Z#-C ^4R;03C,G8$X#%_!=XQAP7<,(X&VC"5!M@PFP?6
M+Z('U"^I"-(OL0C0+[H)SS#&"<TPV G),>H*QC'W#,,Q_P[!,?\/P#'_#[\Q
M_P^_,?\0OS'_$+\Q_Q#_-A, _SD/ /\^$ #_010 _T,: /]"(P#U02X [3XZ
M ><]1@'A/%,"W3I> ]DY: 34.'$&T3AZ!\\W@0C--X@)RS:/"LHVE@K(-IT+
MQC6D#,4UK S#-;4-P37 #< VSPZ]-N8.N3;T$+<V_Q&U-O\2M#;_$[,V_Q.S
M-O\3LS;_$[,V_Q/_.1  _ST+ /]##0#_1Q  _T@4 /5'' #K1B8 XT0R -Q$
M00'40TT"ST%8!,M 8@;(/VL(Q3YT"<,]>PO!/8,,OSR*#;T\D Z[/)</NCN?
M$+@[IQ"V.[ 1M3N[$K,[R1*Q.^ 3KCSQ%*L\_16I//\6J#S_%J@\_Q:G//\6
MISS_%J<\_Q;_/0T _T(( /]("@#_2PP ^DP/ .Q,% #A2AT UDHL ,Y+.P')
M2D@"Q$A3!,!'70>\1F8)ND1N"[=#=@VU0WT.LT*$$+%!BQ&P09(2KD":$ZQ
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M'XA.MR"'3L@AA4[B(81/\R"#3_\@@T__'X)0_Q^"4/\>@E#_'H)0_Q[_1P
M\U$  -]8  #170  R6 " ,-@! "]7@T M6 : *YA*@"I8#<"I%Y#!)]=30B;
M6U4+F%E=#I589!&25VL3CU9R%HU5>1B+5($:B%.)'(93DAZ$4IP?@E*G(8!2
MM")_4L0C?5+>(WQ3\2)\4_XA>U3_(7M4_R![5/\@>U3_('M4_R#_2@  Z50
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M)FE>["5J7_LD:E__(VI?_R)J7_\B:E__(FI?_R+P4@  W5T  ,ME  # :P
MMVX  *]O  "G;@$ H&\0 )IP'P"4<"P!CV\X XIM0@:&;$L)@FI2#'YI60][
M:& 2=V9F%'5F;A=R974:<&1^'6UCB!]K8Y(B:6*>)&=BJR5E8KHF9&+/)F1B
MZB9E8OHD96/_(V5C_R)E8_\B96/_(F5C_R+K50  V&   ,AH  "\;@  LW$
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M(U9O_R)7;_\B5V__(E=O_R+?7P  RFD  +QR  "R>   J7T  )]_  "2?@
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M&S^+_QO"<P  M7X  *J'  "?C   E)   (B3  ![E0  ;)D  &6;! !@G!
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M!R^QE@@NLJ8(+;*X"2RRT @LL.P)*Z_Y"BNN_PLJK?\+*JW_"RJM_PNMBP
MH)(  )68  ")G0  ?:,  '&H  !DK0  6;$  $VT  !"N   .[H* #B[$P W
MO!X -;PI #2],@ SO3L ,KU$ #&^3  OOE4!+KY> 2R^: $JOG0"*;Z" B>_
MD0,FOZ(#)+^T R._RP,CON@#([SW!"*[_P4BN_\%(KO_!2*[_P6DD@  F)@
M (R>  " I0  <ZL  &>P  !;M0  3[D  $2\   ZP   ,,0$ "K'"P HR!,
M)\D= ";))P ER3  ),HY "/*0@ BRTL (<M5 "#,7P ?S&P '<UZ !S-B@ ;
MS9P &<ZN 1C.Q0 8S>0 &,ST 1C*_ $8RO\"&,K_ AC*_P*;F0  CY\  (*F
M  !UK0  :+,  %RY  !0O0  1,$  #G$   PR   *,P! "#0!@ 9U0L %M<0
M !78&0 5V2( %-DK !/:-  3VCT $MM( !'<4P 1W5\ $-UM !#>?@ .WY$
M#N"D  W@N  ,X-( "]_M  S>]P ,W?L #-W[  S=^P"2GP  A:<  '>N  !J
MM0  7;P  %#!  !$Q0  .,D  "[-   ET0  'M4  !;: 0 1W@8 $.<-  [G
M$@ -Z!D #.@A  OI*0 *ZC$ ">H[  ?K10 %ZU$ !.M>  /K;@ !ZX   .J4
M  #JIP  Z[P  .O2  #KZ0  [.\  .SO  #L[P"'IP  >:\  &NW  !>O@
M4<4  $/)   WS0  +=$  "/6   ;VP  $]\   [C   ,[@( "O8*  ?V#@ %
M]A(  _88  #U'@  ]24  /4N  #U-P  ]D(  /9.  #V70  ]FX  /:!  #V
ME0  ]Z<  />W  #XQP  ^-   /C0  #XT ![KP  ;;@  &#   !2R   1,T
M #?1   KUP  (=P  !C@   1Y   #.<   ?O   $^@   ?\#  #_"   _PT
M /X0  #^%   _QH  /\A  #_*0  _S,  /\^  #_2P  _UL  /]L  #_@
M_Y(  /^A  #_K0  _[,  /^S  #_LP#_'"8 _QPD /\:)0#_%2< _Q$N /\0
M.@#_#D<!_PU3 ?\+7P'_"FL!_PIU ?\*?P'_"H<!_PJ. ?\*E0'_"IL!_PF@
M ?\)I0#_":L _PFQ /\)N #_"<$ _@G, /P)W@#Y">L ]0GV /,)_P#R"O\
M\0K_ ?$+_P'Q"_\!\0O_ ?$+_P'_'R, _Q\A /\>(0#_&20 _Q<L /\5-P#_
M$T0 _Q%0 ?\07 '_#F<!_PYR ?\.>P'_#H0!_PZ+ ?\.D@'_#I@!_PZ= ?\.
MHP'^#J@!_ ZN ?L.M0#Z#KX ^ [) /4.VP#R#NH [@[U .P._P'K#_\!Z@__
M >H0_P'I$/\!Z1#_ >D0_P'_(A\ _R(< /\A' #_'R  _Q\I /\<- #_&D
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M";DJ_PG_, \ _S(+ /\V#0#_.!  _SD5 /DW'@#O-2@ YS,U . R0@#;,D\
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M-P< _SL" /]  P#R0@4 Z4() .4_#@#8/A8 SD G ,=!-@#"040!O4%/ KE
M60.V/V$$M#YI!K$]<0>O/7@(KCQ_":P\A@JJ.XT+J3N5#*<[G0VE.Z8-HSJP
M#J([O ^@.\T/GCOF$)L\]1&://\1F3S_$9@\_Q&8//\1F#S_$9@\_Q'_.@$
M_T   .]%  #A2   V4@% --&"0#,11( Q$<B +U(,0"X2#\!LT=* K!&5 2L
M15T%JD1D!Z=#; BE0G,*HT)Z"Z%!@0R@08@-GD"0#YQ F!":0*$1F$"L$I=
MN!*50,@3DT#A$Y%!\Q200?\4CT'_%(Y"_Q..0O\3CD+_$XY"_Q/_/   ^40
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M&G=.ZQIW3_H9=D__&79/_QAV3_\7=D__%W9/_Q?X1@  XE   -!7  #$7
MNUX  +1=  "N6@8 IEL3 *!<(@";7"\ EUL[ I):10./64T&BUA5"(A77 J&
M5F,,@U5J#H%4<1!^5'@2?%. %'I2B19X4I08=E*?&712JQIR4KH;<5+-''!2
MZ!MP4_D:<%/_&G!3_QEP4_\8<%/_&'!3_QCO20  W5,  ,M:  # 7P  MV(
M *]A  "H7@( H5\0 )M@'@"68"P D6 X 8U>0@.)74L%A5Q2!X);60J 6F ,
M?5EG#GM8;A!X6'42=E=]%'17AQ9R5I$8;U:<&FY6J1ML5K@<:U;+'6I6YAQJ
M5_<;:E?_&FI7_QEK5_\9:U?_&6M7_QGK3   V%8  ,A>  "\8@  LV4  *ME
M  "C8@  G&(. )9C' "19"D C&,U 8AB/P.$84@%@&!0!WU?5PEZ7ET+=UUD
M#75<:Q!S7'(2<%M[%&Y;A!=L6H\8:EJ:&FA:IQQF6K8=95K('65:Y!UE6O8<
M95K_&V5:_QIE6O\995K_&65:_QGH3P  TUD  ,1A  "Y9@  L&@  *=I  ">
M90  EV8- )%G&0",:"< AV<R 8-F/0)_948$>V1-!GAC5 EU8EL+<F%A#7!A
M:0]M8' 2:U]Y%&E?@A9G7HT995Z8&F->I1QA7K0=8%[''6!>XQU@7O4<8%[_
M&V!>_QIA7O\:85[_&F%>_QKD4@  SUP  ,!D  "V:0  K&P  *-L  "9:0
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M&4UO_QG.8   OFH  +)R  "H>   G7L  )!Z  "$>@  >GL  '1\# !O?A<
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M#SZ*F!$\BJ<2.XJX$CJ*SQ([B.L2.X?Z$SN&_Q,[AO\3.X;_$SN&_Q.\<0
MKWL  *6#  "9AP  C(@  '^)  !SC   99   %R3  !7E0P 5)86 %*6(@!0
MERT 39<V $N7/P%)ET<"1Y=. T66501#EET%099E!CZ5;P@\E7H).I6'"SB5
ME0PVE*4--92V#C24S TTD^D--)+X#C20_P\TD/\/-)#_#S20_P^U>   JH(
M )Z(  "3C0  AHX  'F0  !MDP  89<  %6;  !-G@8 29\0 $>?&P!&H"8
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M 1RYP $<N-\!'+;R 1NU_ (;M/\"&[3_ ANT_P*?CP  E)4  (B;  ![H0
M;J8  &*K  !6L   2K,  #^V   UN0  ++P  "2_!@ ?P@T '<(4 !S"'@ ;
MPR8 &L,O !G$.  8Q$$ %\1* !;%50 5Q6$ %,9O !/&?P 2QI$ $<>D !#'
MN0 /Q]0 $,;N !#$^@ 0P_\ $,/_ !##_P"7E@  BYP  'ZB  !QJ0  9*\
M %BT  !+N   0+L  #6^   KP0  (\4  !O) 0 4S 8 $- +  [1$0 -T1D
M#=$A  S1*@ ,T30 "](^  K220 )TU4 "=-B  C3<@ &U(0 !=28  34JP #
MU<   =7<  '5[0 !U?8  =7V  '5]@".G0  @*0  '.K  !FL0  6;@  $R]
M   _P   -,,  "K'   AR@  &<X  !+2   -U@$ "=L%  ;<#0 $W!$  ]T8
M  '>(   WB@  -\Q  #@/   X4<  .)4  #C8P  XW0  .2(  #DFP  Y:X
M .7!  #EU0  YN<  .;G  #FYP"#I   =:P  &BS  !:NP  3<$  $#$   S
MR   *,P  !_0   7U   $-D   O=   %X0   .0   #E!P  Y@T  .<1  #H
M%@  Z1T  .HE  #K+@  [3D  .]%  #P4P  \60  /%V  #RB@  \YP  /.M
M  #TNP  ],@  /3(  #TR !WK0  :K4  %R]  !/Q   0,D  #/-   GT0
M'=8  !3<   .X   ".,   'F    Z@   .X   #N    [P0  / *  #Q#@
M\Q(  /08  #V(   ^"H  /HU  #]0P  _E(  /]C  #_=@  _XD  /^:  #_
MI@  _[   /^P  #_L #_%B, _Q4A /\1(0#_#20 _PDK /\&-P#_ T0 _P!1
M /\ 70#_ &@ _P!R /\ >P#_ (, _P"* /\ D0#_ )8 _P"< /\ H0#] *8
M^P"L /D LP#W +L ]0#% /, T0#R .0 \0#Q .\ ^@#N /\ [@#_ .T _P#M
M /\ [0#_ .T _P#_&2  _Q@= /\5'0#_$!\ _PXI /\,- #_"D$ _P=- /\%
M60#_!&0 _P1N /\#=P#_ X  _P.' /\#C0#] I, ^P*9 /D"G@#W J0 ]0*J
M /,!L #Q ;@ [P'" .T!SP#K >, Z@'O .@"^P#G!/\ Y@7_ .8&_P#F!O\
MY@;_ .8&_P#_'!L _QL9 /\7& #_%1T _Q,E /\1, #_$#T _PY) /\,50#_
M"V  _PMJ /T+<P#["WP ^0J# /<*B@#U"I  ] J6 /,*FP#Q"J$ [PFG .T)
MK@#K";8 Z G  .8)S0#D">( X@KP -\+^P#>#/\ W W_ -P-_P#;#?\!VPW_
M =L-_P'_'Q< _QX3 /\;$@#_'!D _QLB /\8+ #_%3@ _Q-$ /X24 #Y$5L
M]1!F /,0;P#P$'< [A!_ .P0A@#J$(P Z1"2 .@0F #F#YX Y0^E .,/K #A
M#[0 X ^^ -X/S #:$.$ U1'P -(2^P#/$O\!SA/_ <T3_P'-$_\!S!/_ <P3
M_P'_(A( _R(/ /\A#P#_(A0 _R(< /\@)P#_'3( ^!L^ /(92P#N&%8 ZA=@
M .<6:@#D%G( XA9Z . 6@@#>%H@ W!:/ -L6E0#9%IL UA:B -06J0#2%K$
MT!>[ ,X7R0#,&-X R!GN <4:^P'#&O\"P1O_ L ;_P+ &_\"P!O_ L ;_P+_
M)@X _R4+ /\H# #_*1  _R@6 /XF( #T)"L ["$X .8@1 #A'U  W1]; -D>
M90#5'FT TA]U - ??0#.'X, S!^* <L?D ')'Y<!R!^> <8?I0'%(*T!PR"W
M <$@Q ' (=8!O"+J KDB^ .V(O\#M2/_ [0C_P2S(_\$LR/_!+,C_P3_*0L
M_RH% /\N" #_+PP _RT0 /,K%P#H*"( X"8O -DF/0#2)TH S2=5 ,HH7P#'
M*&@!Q2AO <,G=P'!)WX!OR>$ ;XGBP*\)Y("NR>9 KDGH *W)ZD#MBBS [0H
MOP.S*,\#L"GF!*TI]@2K*O\%J2K_!J@J_P:H*O\&J"K_!J@J_P;_+04 _S
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M#(P\[ V*//L-B3S_#8D\_PR(//\,B#S_#(@\_PS_-P  ZC\  -Q%  #.20
MQ4D  +]& @"Z0PP LT09 *U%)P"H1C4 I$5! :!%2P*=1%,"FD-; YA#8@66
M0FD&E$%P!Y)!=@B00'X)CD"&"HU C@N+0)@,B4"B#8= K@Z%0+P/A$#/#X)!
MZ0^!0?D/@$'_#X!"_PZ 0O\.@$+_#H!"_P[Z.P  Y40  --+  #'3@  OD\
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M$FM._Q)K3O\1:T[_$6M._Q'H1@  TU   ,16  "Y6@  L%P  *9:  "?5@
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M$E==_Q+64P  Q%P  +=C  "L:   H&@  )5G  "*8P  @V4" 'UF#P!X9AH
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M$$IMF!%);*<22&RX$T=LS1-';.H32&OZ$DAK_Q)(:O\12&K_$4AJ_Q''7@
MN&<  *QN  "A<@  DW(  (=Q  !Z<0  <7(  &MT!P!F=1$ 8W8= &!W* !>
M=S, 6W@\ 5EW0P)6=TL#5'=2!%)V6050=F '3G5H"$MU<0I)='P,1W2(#D5S
ME@]#<Z400G.V$4%SRQ%"<N@10G+X$4)Q_Q!#</\00W#_$$-P_Q#!8P  LVP
M *AS  ";=@  CG4  (%V  !U=@  :7@  &-Z @!>? X 7'T9 %E^) !7?R\
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M!R^.PP<OCN$'+XST""^+_P@OBO\(+XK_"2^*_PFP=@  I7\  )B$  "*A
M?84  '"'  !EB@  6HX  $^2  !&E0  09@, #Z8%  ]F1\ .YDH #J:,0 Y
MFCH -YI" #::2@ UFE(!,YI: 3&:9 $OFF\"+9I[ BR:B@,JFIH#*9JL!"B:
MP 0GF=X#)Y?R!">6_04GE?\%)Y7_!2>5_P6I?@  GH4  )*)  "$B@  =HP
M &J/  !>DP  5)<  $F;  ! GP  -Z($ #*C#@ QHQ< ,*0A "ZD*@ MI#(
M+*4Z "NE0P JI4L *:54 "BE7@ FI6D ):5V 2.EA0$BI98!(*:H 1^ENP$>
MI=<!'J3O 1ZB^P(>H?\"'J'_ AZA_P*BA@  EXP  (N/  !]D0  ;Y0  &.8
M  !7G0  3:$  $.E   XJ   ,*L  "BN!P DKQ  (Z\7 "&O(0 @L"D '[ Q
M !ZP.@ =L4( '+%, !NQ5@ :L6$ &;)O !BR?@ 6LI  %;*B !2RM@ 3LLX
M$['K !.O^0 3KO\!$Z[_ 1.N_P&:C0  D)(  (27  !UF@  :)\  %NC  !0
MJ   1:P  #NP   QL@  )[4  ""X   8N@< %+P. !.\%0 2O!X $;TF !&]
M+@ 0O3< $+Y!  Z^3  .OE< #;YE  R_=  +OX8 "KZ9  B^K  'OL( ![[?
M  B^\  (O?H "+W\  B]_ "3E   AYD  'J?  !LI0  8*H  %.O  !'LP
M/+8  #&X   GNP  '[X  !?!   1Q $ #,@(  C)#@ 'R10 !LD<  7))  $
MRBP  \HV  +*0   RTP  ,M9  #+:   RWD  ,R,  #+GP  R[,  ,O(  #,
MX@  S.\  ,SQ  #,\0"*F@  ?*$  &^G  !BK0  5;,  $BX   [NP  ,+X
M ";!   =Q   %<@   _+   *S@  !-("  #3"@  TP\  -04  #5&@  UB(
M -<J  #9-   VC\  -Q+  #<6@  W6H  -U]  #=D0  W:0  -ZV  #>R
MWMX  -[B  #>X@!_H@  <:D  &2P  !6MP  2;P  #S    OQ   ),<  !O+
M   3SP  #=(   ?6    VP   -X   #? P  X D  .$.  #B$@  XQ<  .4>
M  #F)P  Z#$  .H]  #L2P  [%H  .UL  #N@   [I0  .ZE  #NM   [L(
M .[&  #NQ@!TJ@  9K(  %BY  !+P   /<4  "_)   DS0  &=$  !'6   +
MVP   ]X   #A    Y0   .@   #I    Z@   .L&  #M"P  [P\  / 3  #R
M&@  ]",  /<N  #Y.P  ^TH  /Q;  #];0  _8   /Z3  #^H@  _JT  /ZO
M  #^KP#_$!\ _PX= /\*'0#_ 2  _P H /\ -0#_ $$ _P!. /\ 6@#_ &4
M_P!N /\ =P#_ '\ _@"& /P C #[ )( ^0"7 /@ G #W *( ]@"G /4 K0#S
M +4 \@"] /$ R0#O -P [@#K .T ]P#L /\ ZP#_ .H _P#J /\ Z@#_ .H
M_P#_$QP _Q$9 /\-&0#_!AP _P,E /\ ,0#_ #X _P!* /\ 5@#_ &$ _P!K
M /T <P#Z 'L ]P"# /4 B0#T (\ \@"4 /$ F0#P )\ [@"D .T JP#L +(
MZ@"Z .@ Q@#G -8 Y0#H .0 ]0#C /X X@#_ .$ _P#A /\ X0#_ .$ _P#_
M%1@ _Q,4 /\/% #_#1D _PLB /\(+0#_!#D _P%& /\ 40#^ %P ^@!F /8
M;P#R '< [P!^ .T A0#K (L Z@"1 .@ E@#G )P Y@"A .0 J #C *\ X0"X
M -\ PP#= -$ VP#F -D \P#7 /T U0+_ -0"_P#4 _\ U /_ -0#_P#_&!,
M_Q40 /\2#P#_$A4 _Q$= /\.* #_##0 _PI! /D(3 #U!E< \09A .T&:@#I
M!7( Y@5Z .0%@0#B!8< X :- -\&D@#=!I@ VP:> -D&I0#7!JT U :U -(&
MP #0!\\ S@CE ,P)] #*"_\ R S_ ,<,_P#'#/\ Q@S_ ,8,_P#_&PX _QD,
M /\8#0#_&!$ _Q<8 /\4(@#[$2X \Q Z .T.1@#H#5( Y0U< .$-90#>#6T
MVPUU -@-? #5#8( TPV) -$-CP#0#94 S@V< ,T.HP#+#JL R0ZT ,@.P #&
M#L\ PQ#F , 1]0"]$O\ O!+_ +L2_P"Z$O\!NA+_ ;H2_P'_'PH _QP$ /\?
M" #_'PT _QT2 /@:&P#N%B8 YA0S . 3/P#:$TL U!-6 - 37P#.%&@ RQ1O
M ,D4=P#'%7T QA6$ ,05B@##%9$ P1:8 , 6GP"^%J< O!>P +L7O "Y%\L
MMQCB +,9\@&Q&O\!KQO_ :X;_P&N&_\!K1O_ :T;_P'_(@0 _R(  /\E @#\
M) < ]R$, .P=$@#A&AP V!HJ - ;. #+'44 QQU0 ,,>6@# 'F( OAYJ +P?
M<0"Z'W@ N1]^ +<?A0"V'XP M!^3 +,?F@&Q(*,!L""L :X@MP&L(<8!JR'=
M :<B[P*E(OT"HR/_ J(C_P*B(_\"H2/_ J$C_P+_)0  _R@  /(J  #E*P
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M"7H\_PAZ//\(>CS_"'H\_PCN-P  W4$  ,M&  "_20  MDD  *Y&  "I000
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M"V!-_PO<1P  QU   +E6  "N60  HE@  )A6  "040  B5(& (-3$0!_4QT
M>U0I 'A4- !U5#T!<E-% 7!33 )M4E,":U)9 VE28 1G46<&95%O!V-1> AB
M48,*8%&/"UY0FPU=4*D.6U&Y#EM1S@]:4>H.6U'Z#5M1_PQ;4?\,6U'_"UM1
M_PO62@  PU,  +99  "K7   GEH  )-9  "+5   A%8# 'Y6$ !Z5QH =E<F
M '-8,0!P5SH ;5=" 6I720)H5E "9E97 V167@1B564%8%5M!UY5=@A=58$*
M6U6-"UE4F@U85*<.5E6X#U95S ]65>D.5E7Y#595_PU75/\,5U3_#%=4_PS1
M30  P%8  +-<  "G7@  FET  (]<  "&6   ?UD  'E:#0!T6Q< <5LC &Y;
M+@!K6S< :%M  65;1P%C6DX"85I5 U]:7 1=6F,%7%IK!EI9= A867\*5EF+
M"U19F U36*8.4EFV#E%9R@]16><.45CX#5)8_PU26/\,4EC_#%)8_PS-40
MO%D  +!?  "C80  EF   (M?  "!6P  >5T  '-># !O7A4 :U\@ &A?*P!F
M8#4 8V ] 6%?10%?7TP"75]3 UM?6@197F$%5UYI!E5><@A37GT)45V)"U!=
ME@Q.7:0-35VT#DQ=R Y,7>8.35WW#4U<_PQ-7/\,3ES_#$Y<_PS)5   N5P
M *UC  "?8P  DF,  (=B  !\8   =&$  &YB"0!I8Q( 9F,= &-D* !A9#(
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M"CUNP@H\;N */6WT"CUL_PH]:_\*/FO_"CYK_PJZ8   K6D  *!N  "1;0
MA&T  'AM  !L;@  87   %MR  !6= H 4G42 %!V'0!.=R< 3'<Q $MX.0!)
M>$$ 2'A) 49X4 %$=U<"0G=? T!W: ,^=W,$/'9_!CIVC0<Y=IP(-W6M"#=U
MP @V==X(-W3R"#=S_@@W<O\(-W+_"#=R_PBU9@  J6\  )IQ  "+<0  ?G$
M '-R  !H<P  7'8  %1Y  !.>P4 2GT/ $A^& !&?R, 17\L $. -0!"@#T
M08!% #^ 3 $]@%0!/(!< CI_90(X?V\#-G]\!#1_B@0R?YH%,7ZJ!C!^O08P
M?MH&,'WP!C![_08P>_\&,'K_!C!Z_P:P;   I'4  )1U  "&=0  >78  &YW
M  !C>0  5WT  $^!  !'A   0H8, #^'$P ]B!T /(@G #N),  ZB3@ .(E
M #>)2  VB4\ -(E8 3.)80$QB6P!+XEX BV)AP(LB9<#*HBG RF(N@,IB-0#
M*8;N RF%_ 0IA/\$*83_!"F$_P2J=   GGL  (YZ  " >@  ='L  &A^  !=
M@0  4H4  $F)  !!C   .9 % #61#P SDA< ,I(A #&2*0 PDS( +I,Z "V3
M00 LDTH *Y12 "J47  HE&< )Y1S 264@@$DE),!(I.D 2&3MP$@D\\!(9+L
M 2"0^@(@C_\"((__ B"/_P*D?   EX   (=_  ![@   ;H(  &*%  !7B0
M38X  $*2   ZE@  ,ID  "J<"0 HG1$ )IT9 "6=(@ DGBH (YXR "*>.@ A
MGD( ()Y+ !^?50 >GV  ')]M !N??  :GXT &)^? !>?L@ 6G\D %I[H !:<
M]P 6F_\!%YO_ 1>;_P&=@P  CX8  (*&  !TAP  9XL  %N/  !0DP  1I@
M #R<   SH   *Z,  ".F   <J L &JD1 !BI&  7J2$ %JHI !6J,0 4JCD
M$ZI# !.K30 2JU@ $:ME !"K=  .JX8 #JN9  VKK  ,J\$ #*K?  RI\@ -
MJ/P #:C_  VH_P"6B@  B8P  'J-  !LD0  8)4  %2:  !)GP  /Z,  #6G
M   KJ@  (ZX  !NP   4LP$ #[4*  VV$  ,MA8 "[8?  JV)P )MB\ "+8Y
M  >W0P &MT\ !+=;  .W:@ "MWL  +>.  "WH0  MK0  +;+  "VY0  M?$
M +7W  "U]P"/D0  @90  '*7  !EG   6*$  $RF  !!JP  -Z\  "RR   C
MM0  &K@  !.[   .O0  "< %  /!#0  P1$  ,$7  #"'@  PB8  ,(O  ##
M.0  Q$0  ,10  #$7@  Q6\  ,6!  #%E0  Q:@  ,6\  #$T0  Q.8  ,3N
M  #$[@"&F   >9X  &NC  !=J0  4*X  $2S   WM@  ++D  "*\   9OP
M$<(   S%   &R    ,L   #,!P  S T  ,T1  #-%@  SAT  ,\D  #0+0
MTC@  -1$  #44@  U6$  -5S  #6AP  UIL  -:M  #7OP  V,X  -C=  #8
MW0![H   ;J8  &"M  !3LP  1;@  #B\   KOP  (<(  !?&   0R0  "LP
M  +0    U    -<   #8    V@4  -L+  #<#@  WA,  -\9  #A(0  XRH
M .4V  #G0P  YU,  .AD  #I=P  Z8P  .J?  #JK@  ZKH  .K#  #JPP!P
MJ   8J\  %6V  !'O   .<   "S$   @R   %LP   [0   'U    -D   #=
M    X0   .,   #D    Y@   .<!  #I!P  ZPP  .P0  #N%0  \!T  /,G
M  #V,P  ]T,  /A4  #Y9@  ^7H  /J.  #ZG@  ^ZD  /NP  #[L #_"QL
M_P<9 /\ &0#_ !P _P E /\ ,@#_ #\ _P!+ /\ 5P#_ &( _P!K /\ <P#]
M 'L ^P"" /H B #X (T ]P"2 /8 F #U )T ] "B /, J0#Q +  [P"X .X
MPP#L -$ ZP#F .D \P#H /X Z #_ .@ _P#H /\ Z #_ .@ _P#_#A@ _PH5
M /\!% #_ !@ _P B /\ +@#_ #L _P!' /\ 4P#] %X ^@!G /< ;P#U '<
M\P!^ /( A #P (D [P"/ .X E #L )H ZP"? .D I0#H *P Y@"T .0 OP#C
M ,P X0#B -\ \ #> /L W@#_ -T _P#= /\ W #_ -P _P#_$!, _PT1 /\&
M$ #_ A4 _P > /\ *0#_ #8 _P!" /H 3@#T %D \0!B .X :P#L '( Z@!Y
M .@ ?P#G (4 Y0"+ .0 D #B )8 X0"< -\ H@#= *D V@"Q -@ NP#5 ,@
MT@#= -$ [0#0 /D SP#_ ,X _P#- /\ S0#_ ,T _P#_$0\ _PX- /\,#0#_
M"Q( _P<9 /\") #_ #  ]@ \ .\ 20#J %, YP!= .0 9@#A &T WP!T -T
M>P#; ($ V0"& -8 C #4 )( T@"8 -  G@#. *8 S "N ,H N #( ,0 Q@#7
M ,4 Z@## /< P@#_ ,$!_P#  O\ P +_ , "_P#_% L _Q & /\0"0#_$ X
M_PX4 /\*'@#U!BD ZP0V .,#0@#? TX VP17 -8$8 #3!&@ T 1O ,X%=@#,
M!7P R@6" ,D%B #'!8X Q@64 ,0%FP#"!:, P :K +X&M0"]!L( NPC4 +H)
MZ0"W"_@ M0S_ +0,_P"T#/\ M S_ +0,_P#_%P0 _Q0  /\6 P#_% D _Q$.
M /(.%0#H#"$ W@HN -8+.P#0#$< S Q1 ,D,6@#&#6( Q UJ ,(-<0# #7<
MOPU] +T.@P"\#HH N@Z1 +D.F "W#J  M@ZI +0/M "R#\$ L1#4 *X1ZP"K
M$OH J1+_ *@3_P"G$_\ IQ/_ *<3_P#_&@  _QL  /D;  #K&0  Y10& .40
M#@#9#A< SQ$F ,@2- #$$T  OQ1+ +P45 "Y%5T MQ5D +45:P"T%7$ LA5X
M +$6?@"O%H4 KA:, *P6E "K%YP J1>F *<8L "F&+T I!C/ *(:YP"?&O<
MG1O_ 9P;_P&<&_\!FQO_ 9L;_P'_'0  ]R$  .@D  #=)0  U"$! ,\;" #*
M%Q$ PAH@ +P<+0"W'3H LQY% + >3P"M'E< JQY? *D?9@"H'VP IA]S *4?
M>0"C'X  HA^' * @CP"?()@ G2"B )L@K &:(;D!F"'* 98BY &4(_4!DB/_
M 9$C_P&0(_\!D"/_ 9 C_P'_(@  ZRD  -TN  #/+P  QRT  ,$G P"](@T
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M!6P\_P7B.0  S$(  +Y'  "Q2   I48  )U#  "7/P  DCX+ (T_%0")/R$
MA4 M () -P!_0$  ?4!( 'M 3P%Y0%8!=S]= 74_8P)S/VH"<3]R W _>@-N
M/X0$;#^0!6L_G 9I/ZD&:#^X!V= S =F0.@'9D#Y!F5 _P9E0/\&94#_!65
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M!EY(EP==2*4(6TBT"%M(QPE:2.0(6DGV"%I)_P=:2/\&6DC_!EI(_P;110
MOTP  +)2  "C40  EU   (U.  "&2@  @$H! 'I+#@!V3!< <DPC &],+0!M
M338 :DP_ &A,1@!F3$T!9$Q3 6),6@)A3&$"7TQI UY,<@1<3'P%6DR(!EE,
ME0=73*,(5DRR"%5,Q@E53.()54SU"%5,_P=53/\'5DS_!E9,_P;,2   O%
M *]5  "@5   DU,  (E1  "!30  >DX  '5/# !P3Q4 ;5 @ &I0*@!G4#,
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M"$=8P A'6-T(1UCR"$=7_P=(5_\'2%?_!DA7_P;!40  LED  *-<  "46P
MAUL  'U:  !R6   :UD  &5: P!@6PX 75P7 %I<(0!872L 5ETT %1>/ !3
M7D0 45Y+ 5!>4@%.7ED"3%YA DM=:@-)770$1UV !45=C09$79P'0UVL!T)=
MO@A"7=H(0ESQ!T)<_@=#6_\&0UO_!D-;_P:]50  KUT  )]?  "07@  @UX
M 'A=  !M7   95T  %]?  !:8 P 5V$4 %5B'@!28B@ 46,Q $]C.0!.8T$
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M!#%N^P0Q;?\$,6S_!#%L_P2O9   H6D  (]H  "!:   =6D  &MI  !@:P
M56X  $UQ  !&<P  0G4+ #]V$@ ]=QP /'<E #IX+0 Y>#4 .'D] #=Y10 V
M>4T -7E5 #-Y7@ Q>6@!,'ET 2YY@P(M>9("*WBC BIXM0(J>,P"*G?J BIV
M^0,J=?\#*G3_ RIT_P.J:@  FFT  (EL  !\;0  <&T  &9N  !;<0  4'4
M $AX  !!>P  .GX% #9_#@ T@!8 ,X$@ #*!*  P@3  +X(X "Z"0  M@D@
M+()0 "N"6@ J@F0 *()P ":"?P$E@H\!)(*@ 2."L@$B@LD!(H'G 2)_]P$B
M?O\"(GW_ B)]_P*E<0  DW$  (-Q  !V<0  ;'(  &!U  !6>   3'P  $.
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M !"4_P"5?0  A7P  'A\  !K?@  7X$  %2&  !*B@  0(\  #:3   MEP
M)IH  !Z=   7H , $J(, !"C$@ 0HQD #Z,A  ZD*0 .I#$ #:0Z  RD10 +
MI%  "J1<  FD:@ 'I'L !J..  2CH0 "H[0  Z++  .BY@ #H?,  Z'[  .A
M^P"-@P  ?X(  '&$  !DAP  6(P  $V1  !"E@  .)H  "^>   FH@  'J4
M !>H   1JP  #*X'  >O#0 #KQ(  J\9  &O(0  KRD  + R  "P/   L$<
M +!3  "P80  L'$  +"#  "OEP  KZH  *^_  "NV0  KNL  *[T  "N] "'
MB0  >(H  &J.  !=DP  49@  $6=   [H@  ,*8  ">J   >K@  %K$  !"T
M   +M@  !;D#  "Z"@  N@X  +H3  "[&0  NR$  +PH  "\,0  O3P  +Y(
M  "^5@  OF4  +YW  "^C   OI\  +VS  "^QP  OMX  +WK  "]ZP!_D@
M<)4  &*:  !5GP  2:4  #VK   RKP  *+0  !ZV   5N0  #KP   F_   "
MP@   ,0   #%!   Q@H  ,8.  #'$@  R!@  ,D?  #*)P  S#   ,X\  #.
M20  SUD  ,]J  #/?@  SY,  ,^F  #/N   S\@  ,_;  #/VP!WG   :*$
M %NG  !.K@  0;0  #2W   HN@  ';T  !/    -Q   !L<   #*    S@
M -    #1    T@(  -,(  #5#   UA   -D5  #;'   W20  . O  #B/
MXTL  .1<  #D;P  Y8,  .68  #EJ0  Y;8  .7#  #EPP!LI0  7ZP  %&R
M  !$N0  -;P  "C    <Q   $L@   S+   #SP   -,   #8    W    -\
M  #?    X0   .,   #D P  Y@@  .@-  #I$0  [!@  .XB  #Q+@  \SP
M /1-  #U7P  ]G,  />'  #WF0  ^*4  /BP  #XL #_ Q< _P 5 /\ %0#_
M !@ _P C /\ +P#_ #P _P!( /\ 5 #_ %X _P!G /T ;P#[ '8 ^0!] /@
M@P#V (@ ]0". /0 DP#R )@ \0"> /  I #N *L [0"S .L O0#J ,L Z #A
M .< \0#F /T Y0#_ .0 _P#D /\ Y #_ .0 _P#_!Q, _P 1 /\ $0#_ !4
M_P ? /\ *P#_ #< _P!$ /X 3P#Z %H ]P!C /0 :P#R '( \ !Y .\ ?P#M
M (0 ZP"* .H CP#H )0 YP": .4 H #D *< X@"O .  N0#> ,8 W #: -H
M[ #8 /D U@#_ -8 _P#7 /\ V #_ -@ _P#_"A  _P,. /\ #0#_ !( _P :
M /\ )@#\ #( ]P _ /0 2@#Q %4 [0!> .H 9@#H &X Y0!T ., >@#B (
MX "% -X BP#< )  VP"6 -@ G #5 *, TP"K -$ M0#. ,$ S #1 ,L YP#)
M /4 R #_ ,@ _P#( /\ R #_ ,@ _P#_# P _P8( /\""@#_  \ _P 5 /P
M( #Q "P [  Y .D 10#E $\ X0!9 -X 80#; &@ UP!O -0 =0#2 'L T "
M ,X A@#, (P RP"2 ,D F #' *  Q0"H ,, L0#! +P OP#+ +T XP"\ /(
MNP#] +L _P"Z /\ N@#_ +H _P#_#@4 _PD  /\)!0#_!@L _P$0 /  &0#F
M "4 X0 R -P /P#6 $D T0!3 ,X 6P#+ &, R !J ,8 < #% '8 PP![ ,$
M@0#  (< O@". +P E "[ )P N0"D +< K@"U +D LP#( +$ WP"P >\ KP'[
M *X"_P"M _\ K0/_ *T#_P#_$   _PX  /\-  #V"P, \@<* .(!$0#; AT
MT@,K ,P#-P#(!$, Q 1- ,$$5@"^!5T O 5D +H%:P"X!7$ MP5V +4%? "S
M!H, L@:) + &D0"O!YD K0>A *L'JP"I"+< J G& *8*W0"E"_  HPS] *(-
M_P"A#?\ H0W_ * -_P#_$0  _!(  .P3  #B$P  VP\# -8)"P#."!0 Q@HB
M , ,, "\#3P N U& +4-3P"R#E< L Y? *X.90"M#FL JPYQ *H.> "H#GX
MIP^% *4/C0"D#Y8 HA"? * 0J0"?$+4 G1'% )L1W@"9$O$ EQ/_ )84_P"5
M%/\ E13_ )04_P#_%0  [1L  . ?  #2'P  R1L  ,04!0#!$ X NA(; +03
M*0"P%#4 K!5  *D520"F%5( I!99 *(68 "A%F8 GQ9L )X6<@"<%GD FQ>
M )D7B "8%Y$ EAB; )08I@"3&;( D1G! ) :V "-&^X BQS] (H<_P"*'/\
MB1S_ (D<_P#T'0  Y"4  -,I  #'*@  O"8  +8@  "T&0L KAH5 *@<(P"D
M'2\ H1XZ )X>1 ";'DP F1Y4 )<?6P"5'V$ E!]G )(?;0"1'W0 CR!\ (X@
MA ",((T BB"7 (DAH@"'(:X AB*] (4BT0&"(^L!@23[ 8 D_P%_)/\!?R3_
M 7\D_P'L)0  VRT  ,DQ  "\,0  L2X  *LI  "G) 4 HR,1 )XD'0":)2H
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M FPTF )J-:4":36S V@UQ@-G-N(#9C;U V8V_P)F-O\"9C;_ F8V_P+8-P
MQ#X  +5"  "F00  FS\  ),\  "-.   B#8' (0W$0" -QP ?#@G 'HX,0!W
M.3H =3E" ',Y20!Q.5  <#E7 &XY70!L.60!:SEK 6DY= %H.7X"9CF) F0Y
ME0-C.J(#8CJQ V$ZPP-@.^ $7SOS U\[_P-?._\#7SO_ E\[_P+1.P  P$(
M +!%  "A1   E4,  (U   "'/0  @CL" 'T[#@!Y/!@ =3TC ',]+0!P/38
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M!%!'O01/1]8%3T?O!$]'_01/1_\#3T?_ U!'_P/$10  M4T  *--  "53
MB4L  ']*  !X1@  <4<  &Q'!P!H2!  9$@: &%)) !?22T 74DU %M)/0!9
M240 5TE* %9)40!52ED!5$IA 5)*:0%12G0"3TI_ TY*C --2IL$3$NJ!$M+
MO 1*2],%2DON!$M+_01+2O\#2TK_ TM*_P/!2   LE   *!/  "13P  A4X
M 'M-  !S20  ;$H  &=+! !B3 X 7TP7 %Q-(0!:32H 6$TR %9-.@!434$
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M SQ7^@,]5O\#/5;_ SU6_P.V4P  I5<  )17  "%5@  >58  &]6  !E50
M7%8  %=8  !260< 3EH0 $Q:& !*6R$ 2%PJ $=<,@!%7#H 1%U! $-=2 !"
M75  0%U8 #]=80$]76L!/%UV CI=A (Y79,".%VC S==M0,V7<L#-ESH S=<
M^0,W6_\#.%O_ SA:_P.R5P  H%H  (]9  "!60  =5D  &M9  !@6@  5EL
M %%=  !,7@( 2& - $5@% !$81X 0F(F $!B+@ _8C8 /F,^ #UC10 \8TT
M.V-5 #EC7@ X8V@!-F-T 35C@0$S8Y$",F.A C%CLP(Q8\@",6+G C%A^ (Q
M8?\",F#_ C)@_P*N7   FUT  (I=  !\70  <%T  &9=  !<7@  4F   $QB
M  !%90  068* #YG$0 \:!H .V@B #EI*P X:3( -VHZ #9J00 U:DD -&I2
M #-J6P Q:F4 ,&IP 2YJ?@$M:HX!+&J? 2MJL $J:L8!*FGE 2IH]@(K9_\"
M*V?_ BMG_P*I80  E6   (1@  !W8   ;&$  &)A  !88P  3F8  $=H  !
M:P  .FX% #9O#@ T<!4 ,W > #)Q)@ P<2X +W$U "YR/0 M<D4 +')- "MR
M5P J<F$ *7)M "=R>P F<HL )'*< 2-RK@$C<L,!(W'B 2-P] $C;_\!(V[_
M 2-N_P&A90  CF0  ']D  !R9   :&4  %YF  !4:0  26P  $)O   [<@
M-'4  "YX"@ K>1$ *GD8 "EZ(0 G>B@ )GHP "5[.  D>T  (WM( ")[4@ A
M>UP ('MH !]\=@ =?(8 ''N8 !M[J@ :>[\ &GO> !IY\@ ;>/X &W?_ 1MW
M_P&9:0  B&D  'EI  !M:0  8VH  %EL  !/;P  17,  #UW   U>@  +GT
M ">! P B@PT ((02 !^$&@ =A"( '(4J !N%,0 :A3D &85" !B&3  7AE8
M%H9C !6&<0 4AH$ $H:3 !&&I@ 1A;L $(76 !&#[P 1@OL $H+_ !*!_P"1
M;@  @6T  '1N  !I;@  77   %-S  !)=P  0'P  #>    O@P  )X<  "&*
M   :C08 %8\- !.0$P 2D!H $I B !&0*@ 0D3( $)$[  ^11  .D4\ #9%<
M  R1:@ +D7H "I&-  B0GP 'D+, !X_)  >/Y@ 'CO0 "(W\  B-_P")<P
M>W,  &]S  !C=0  5W@  $U]  !#@0  .88  #"*   HC@  (9$  !J5   3
MEP  #IH(  N<#@ )G!, ")P:  ><(@ &G"H !)PS  .</0 "G4@  )U4  "=
M8@  G'(  )R$  "<EP  FZH  )N_  ":VP  FNP  )KU  "9^ "">0  =GD
M &AZ  !<?@  48(  $:'   \C   ,I$  "F5   AF0  &9T  !*@   .HP
M":8%  .G#   IQ   *<5  "H'   J",  *@K  "I-   J3\  *E+  "I60
MJ6@  *EZ  "IC@  J:$  *BU  "HRP  I^0  *?O  "G\P!]@   ;X$  &&$
M  !5B0  28X  #Z4   TF0  *IX  "&B   9I@  $JD   VL   'KP   +(
M  "S!P  LPP  +,0  "T%0  M!L  +4B  "V*P  MS4  +=   "X3@  N%T
M +AN  "X@@  N)<  +BJ  "WO@  M](  +?F  "WZ@!VB   9XL  %J0  !.
ME@  0IP  #>B   LIP  (JL  !FO   1LP  "[8   2Y    O    +X   "^
M    OP8  , +  #!#P  PA,  ,,9  #$(   Q2D  ,<T  #(0@  R5$  ,EB
M  #)=0  R8H  ,F?  #*L0  RL$  ,G1  #)V0!NDP  8)@  %.>  !&I
M.JL  "^P   DM0  &;@  !"\   *OP   <$   #$    R    ,H   #*
MS    ,T#  #."   T T  -$0  #3%@  UAX  -HH  #=-   WD,  -]4  #?
M9P  X'P  ."1  #@I   X+(  ."^  #@PP!FGP  6:8  $RM   _M   ,K@
M "2\   8OP  $,,   C'    R@   ,T   #1    U0   -@   #9    VP
M -T   #?    X00  .,*  #E#@  YQ,  .H<  #M)P  \#4  /%&  #R6
M\VL  /.   #TE   ]*,  /2N  #TL@#_ !, _P 1 /\ $0#_ !4 _P ? /\
M+ #_ #D _P!% /\ 4 #_ %H _@!C /L :P#Y '( ]P!X /4 ?@#T (0 \@")
M /$ C@#P ), [@"9 .T GP#L *8 Z@"N .@ N #F ,4 Y0#; ., [0#B /L
MX@#_ .$ _P#A /\ X0#_ .$ _P#_ !  _P . /\ #0#_ !( _P ; /\ * #_
M #0 _@!! /L 3 #W %8 ] !? /$ 9@#O &T [ !T .H >@#I '\ YP"% .8
MB@#E (\ XP"5 .$ FP#@ *( W@"J -L M #9 ,  U@#0 -, Z #2 /< T0#_
M -$ _P#0 /\ T #_ -  _P#_  T _P ) /\ "@#_  \ _P 6 /L (@#W "\
M]  [ /  1P#M %$ Z0!: .4 8@#B &D X !O -X =0#< 'H V@"  -@ A0#5
M (L TP"1 -$ EP#/ )X S0"F ,L KP#) +H QP#) ,4 X@#$ /( PP#^ ,(
M_P#! /\ P@#_ ,( _P#_ P8 _P ! /\ !@#_  P ^0 1 /$ '0#K "D YP V
M ., 00#? $L VP!4 -4 7 #2 &, SP!J ,T < #+ '4 R0![ ,@ @ #& (8
MQ0", ,, DP#! )H OP"B +T JP"[ +8 N0#$ +< V@"V .T M #Z +0 _P"T
M /\ M #_ +0 _P#_!   _P   /\   #_  8 [  - .4 %@#> "( UP O -$
M.P#- $4 R@!. ,8 5P#$ %X P0!D +\ :@"] '  O !U +H >P"Y ($ MP"'
M +4 C@"S )4 L@"> +  IP"N +( K "_ *H T0"H .@ J #W *< _P"G /\
MI@#_ *8 _P#_!@  _P4  /$#  #H    X0 ' -4 $ #- !L QP G ,, ,P"_
M #X O !( +D 40"V %@ M !? +( 90"P &H KP!P *T =@"L 'P J@"" *D
MB0"G )$ I0": *, I "A *X H "[ )X!S0"= N8 G 3T )L$_P":!?\ F@7_
M )D%_P#_"@  \0X  .00  #9#P  S@L  ,@#"P#" !, O (? +<#+ "S!#<
ML 5" *T&2@"J!E( J =9 *8'7P"E!V4 HP=K *((<0"@"'< GPA^ )T(A0";
M"8X F@F7 )@*H0"6"JP E0NZ ),+S "2#.4 D WV (\._P".#O\ C@[_ (T.
M_P#V$0  YA<  -8;  #'&0  OA4  +D0  "W"@T L0L7 *P-) "H#C  I0X[
M *(.1 "?#TP G0]3 )L/6@":#V  F!!F )<0; "5$'( DQ!Y )(0@0"0$(H
MCQ&4 (T1GP"+$:H BA*X (@2RP"&$^8 A13W (,5_P"#%?\ @A7_ ((5_P#M
M&@  W"$  ,HE  "[(@  L1\  *L:  "I% 8 I1(1 * 4'@"<%2H F14U )86
M/@"4%D< DA9. ) 650".%UL C!=A (L79P")%VT B!=T (88? "%&(8 @QF0
M ($9FP" &J< ?AJU 'T;QP!\'.( >AWU 'D=_P!X'?\ >!W_ '@=_P#E(@
MT"D  +\L  "P*@  IR<  * C  "='P  FAH. )4<& "1'20 CAXO (P>.0")
M'D$ AQ]) (4?4 "#'U8 @A]< ( ?8@!_'VD ?2!P 'P@> !Z(($ >2&, '<A
MEP!U(J0 ="*R ',CPP!R(]\ <"3S &\D_P!O)/\ ;B3_ &XD_P#=*0  R#
M +<R  "H,   GBX  )<J  "3)P  D",* (PC$P"()!\ A"4J ((E- " )CT
M?29$ 'PF2P!Z)E( >"98 '<F7@!U)F4 ="=L '(G= !Q)WT ;RB( &XHE !L
M**$ :RFO 6HIP %I*ML!9RKQ 6<K_P%F*_\!9BK_ 68J_P'4+P  PC8  *\V
M  "A-0  EC0  ) P  "*+0  ARH& (,I$ !_*AH ?"LE 'DK+P!W+#@ =2Q
M ',L1P!Q+$T <"Q4 &XL6@!M+&$ :RUH &HM< !H+7H 9RZ% &4ND0%D+IX!
M8B^L 6$OO0%A,-4!8##O 5\P_0%?,/\!7S#_ 5\P_P'--   O#L  *DZ  ";
M.@  D#@  (DU  "#,@  ?S ! 'LO#@!W,!8 =# A '$Q*P!O,30 ;3$\ &LQ
M0P!J,4H :#)0 &<R5P!E,ET 9#)E &(R;0!A,W< 7S." 5XSC@%=-)P!6S2J
M 5HUNP%:-=(!637M 5DU_ %8-?\!6#7_ 5DU_P'(.   MSX  *0^  "6/0
MBSP  (,Z  !]-P  >#0  '0T"P!P-1, ;34= &HU)P!H-C  9C8X &0V/P!C
M-D8 839- & V4P!>-UH 73=B %PW:@!:.'0!63A_ 5<XC %6.9D!53FH E0Y
MN0)3.L\"4SKK E,Z^P%3.O\!4SG_ 5,Y_P'$/   LD$  *!   "20   AC\
M 'X]  !X.@  <S@  &XY" !J.1$ 9SD: &0Z) !B.BP 8#HT %XZ/ !=.T,
M6SM* %H[4 !8.U< 5SM? %8\9P!4/'$!4SQ\ 5(]B0%1/9<!3SVF DX^MP).
M/LT"3C[I DT^^@)./O\!3CW_ 4X]_P' /P  KD,  )Q#  ".0P  @D(  'I
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M D1%^ )$1?\"147_ D5%_P&Z1@  ID@  )1(  "&2   >T<  ')&  !J0@
M8T,  %Y$  !:10L 5D42 %1&&P!11B, 3T8K $Y&,P!,1SH 2T=! $I'20!)
M2%  2$A8 $=(80!&26L 1$EV 4-)@P%"29(!04FB D!)LP(_2L<"/TKE C])
M]P) 2?\"0$C_ D!(_P&V20  HDH  )%*  "#2@  =TH  &Y)  !E10  7D<
M %E(  !520@ 44H0 $]*& !,2B$ 2DLI $E+,0!'2S@ 1DP_ $5,1@!$3$X
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M 3%5_P&H4@  E5(  (12  !W4@  ;%(  &)2  !84P  3U0  $E6  !$5P
M0%D( #U:$  [6A< .5L@ #A;)P W7"\ -EPV #5</@ T7$8 ,UU. #%=5P P
M76$ +UUL "Y=>@ L78D *UV: 2I=JP$J7;\!*5W> 2I<\@$J6_X!*UO_ 2M:
M_P&C50  CU4  ']5  !R50  9U8  %Y6  !45P  3%D  $5;   _70  .E\$
M #9@#0 T81, ,F(< #%B(P P8BL +V,R "YC.@ M8T( +&-* "ID4P I9%T
M*&1I "=D=@ F9(8 )627 "1DJ0 C9+T (F3: "-C\0 C8OT!)&'_ 21A_P&<
M6   B5@  'I9  !N60  8UD  %I:  !07   2%X  $%@   Z8P  -&8  "]H
M"@ L:1  *FD7 "EJ'P H:B8 )VHN "9K-0 E:ST )&M& "-K3P B;%D (&QE
M !]L<@ >;(( '6R4 !QLI@ ;:[H &FO4 !MJ[@ <:?P '&C_ !QH_P"57
M@UP  '5<  !I70  7UT  %9>  !,80  0V0  #QG   U:@  +VT  "AP!  C
M<@T (7(2 "!S&@ ?<R$ 'G,H !UT,  <=#@ &W1  !IT2@ 9=%0 %W5@ !9U
M;@ 5=7X %'60 !-TH@ 2=+8 $73/ !)S[  2<OH $W'_ !-Q_P".8   ?6
M &]A  !E80  6V(  %%D  !(9P  /FL  #=N   P<0  *74  ")X   <>P<
M%WT. !9]$P 5?1L %'XB !-^*@ 2?C$ $7XZ !%^1  0?TX #W]:  Y_:  -
M?W@ #'^*  M^G0 *?K  "7W&  I]Y  *?/0 "WO]  MZ_P"&90  =V4  &IE
M  !A9@  5F@  $QK  !";P  .7,  #%W   J>@  (WX  !R!   5A   $(<(
M  V)#@ ,B10 #(D;  N)(P *B2L "8DS  B)/0 &B4@ !8E4  2)80 "B7$
M 8F#  ")E@  B*D  (>^  "'V@  ANP  (;U  "&^@!^:@  <6H  &=K  !;
M;   4'   $9T   \>   ,WT  "J!   CA0  '(@  !6,   0CP  #)(&  :3
M#  "DQ$  )06  "4'0  E"0  )4L  "5-0  E4   )5,  "660  EFD  )5Z
M  "5C@  E*$  )2U  "3S   DN8  )+R  "2]P!X<   ;7   &!R  !4=0
M27D  #]^   U@P  +(@  ".-   ;D0  %)0   ^7   *F@  !)T#  ">"0
MGPX  )\2  "@%P  H!T  *$E  "B+0  HC<  *-#  "C4   HU\  *-Q  "C
MA   HID  **M  "AP@  H=P  *'K  "@\@!S=@  9G<  %E[  !-@   0H4
M #B+   ND   ))4  !N:   4G@  #J$   FD   "IP   *H   "K!   JPH
M *P-  "M$0  K18  *X<  "O)   L"T  +$Y  "Q1@  LE4  +)F  "R>0
MLHX  +&C  "RMP  L<H  +'@  "QZ0!L?@  7X(  %*'  !&C0  .Y,  #"9
M   FG@  '*,  !.G   -JP  !ZX   "R    M0   +<   "X    N0(  +D(
M  "Z#   NQ   +P4  "]&P  OR,  ,$M  #".@  PDD  ,-:  ##;   Q((
M ,27  #$JP  Q+P  ,3+  #$V@!EB0  6(X  $N5   _FP  ,Z(  "BH   =
MK0  %+$   VV   &N0   +P   "_    PP   ,0   #%    Q@   ,<   #)
M!   R@D  ,L-  #-$0  SQ@  -(A  #5+0  UCP  -A-  #97P  VG,  -J*
M  #;G@  VZX  -NZ  #<PP!>E@  49P  $2C   XJ@  ++$  ""W   5NP
M#;X   3"    Q0   ,D   #-    T    -(   #2    U0   -8   #9
MVP   -X%  #@"@  X@\  .46  #H(   ["T  .T^  #M40  [F4  .]Z  #O
MCP  \)\  /"K  #PLP#_ !  _P . /\ #@#_ !( _P = /\ *0#_ #4 _P!!
M /\ 30#^ %8 ^P!? /@ 9@#V &T ] !T /( >0#Q '\ \ "$ .X B0#M (\
MZP"5 .H FP#H *( Y@"J .4 LP#C ,  X0#2 .  Z@#? /D W0#_ -T _P#=
M /\ W@#_ -X _P#_  T _P * /\ "0#_  \ _P 8 /\ ) #^ #$ ^P ] /@
M2 #T %( \ !: .T 8@#K &D Z0!O .< =0#E 'H XP!_ .( A0#@ (H W@"0
M -P E@#: )T V "E -4 KP#2 +H T #* ,X XP#- /0 RP#_ ,L _P#+ /\
MRP#_ ,L _P#_  @ _P # /\ !0#_  P _  4 /< 'P#R "L [P W .L 0@#G
M $P Y !5 .  70#= &0 V@!J -@ < #5 '4 T@!Z -  @ #/ (4 S0"+ ,L
MD@#) )D QP"A ,4 J@## +4 P0## +\ V@"^ .X O0#\ +P _P"\ /\ O #_
M +P _P#_    _P   /\   #Y  < \0 0 .H &@#D "4 WP Q -L / #7 $<
MT@!0 ,X 5P#+ %X R0!E ,8 :@#% '  PP!U ,$ >@#  (  O@"& +P C0"Z
M )0 N0"< +< I0"U +  LP"] +$ SP"O .@ K@#X *X _P"M /\ K0#_ *T
M_P#_    _P   /T   #N  $ XP , -H % #1 !\ S  K ,@ -@#% $  P@!*
M +\ 4@"\ %D N@!? +@ 90"V &H M !O +, =0"Q 'H L "! *X B "M (\
MJP"8 *D H0"G *L I0"X *, R "B .( H0#S *  _@"@ /\ H #_ *  _P#_
M    ]@   .H   #@    TP & ,D #P#" !@ O0 D +D +P"V #H M !# +$
M3 "N %, K !9 *H 7P"I &0 IP!J *8 ;P"D '4 HP![ *$ @@"@ (H G@"3
M )P G0": *< F "T )8 PP"5 -P E #O ), ^P"3 /\ DP#_ )( _P#Y!0
MZ@L  -P-  #+"@  P@4  +P "@"V !$ L0 < *X * "J #, IP ] *0 10"B
M $T H !3 )X 60"< %\ FP!D )H :@"8 '  EP!V )4 ?@"3 (8 D@&/ ) !
MF0". J0 C *Q (L#P ")!=8 B ;M (@'^@"'"/\ A@C_ (8(_P#O#P  WA0
M ,H5  "\$@  LQ   *X,  "K!@T IP,5 *(%( "?!RP G @V )D(/P"7"4<
ME0E. ),)5 "1"EH D I? (X*90"-"FL BPIR (H+>0"("X( APN, (4,EP"#
M#*( @0VP ( -P !_#=@ ?0[O 'P/_0![#_\ >Q#_ 'L0_P#F%P  T1X  +T=
M  "O'   IAD  *$5  ">$ 0 G0T/ )@.&0"4#B4 D0\O (\0.0",$$$ BA!(
M (@03P"'$%4 A1!; (0180""$6< @!%N '\1=0!]$7X ?!*( 'H2E !X$J
M=Q.N '43O@!T%-4 <Q7N '$6_0!Q%O\ <1;_ ' 6_P#<'P  QB4  +,E  "E
M(P  G"$  )8>  "2&0  D10+ (T4% ")%1\ AA8I (,6,P"!%SP @!=# 'X7
M2@!\%U  >A=6 'D87 !W&&( =AAI '08<0!S&7H <1F$ &\:D !N&IT ;!NK
M &L<NP!J'-  :1WL &@>^P!H'O\ 9Q[_ &<>_P#1)@  O2H  *LJ  "=*@
MDR@  (TE  "((@  AAT& (,;$ !_'!H ?!TD 'H=+@!W'C8 =AX^ '0>10!R
M'TL <1]1 &\?6 !N'UX ;!]E &L@;0!I('8 :"&! &8AC0!E(IH 8R*H &(C
MN !A(\T 8"3I & D^@!?)/\ 7R3_ %\D_P#*+   MB\  *0O  "6+P  C"T
M (4J  " *   ?20  'HB#0!V(Q4 <R,@ '$D*0!O)#( ;20Z &LE00!J)4<
M:"5- &8E5 !E)5H 9"9A &(F:0!A)G( 7R=] %XGB@!=*)< 6RFE %HIM0!:
M*LH 62KG %@J^ !8*O\ 6"K_ %@J_P#%,0  KS,  )XS  "0,P  AC(  '\O
M  !Y+0  =2H  '(H"@!O*!( :RD; &DI)0!G*BT 92HU &,J/0!B*D, 8"I*
M %\K4 !>*U< 7"M> %LL9@!9+&\ 6"UZ %<MAP!6+I4 5"ZC %,OLP!3+\<
M4B_E %(O]P!2+_\ 4B__ %(O_P#!-@  JC8  )DV  "+-@  @34  'DS  !S
M,0  ;R\  &LN!@!H+1  9"X8 &(N(0!@+RH 7B\Q %PO.0!;+T  62]& %@O
M30!7,%, 5C!; %0Q8P!3,6P 4C)W %$RA !/,Y( 3C.A $TSL0!--,4!3#3C
M 4PT]@!,-/\ 3#3_ $PS_P"[.0  ICD  )4Y  "'.0  ?#D  '0W  !N-
M:3,  &4R @!A,@T 7C(4 %PS'@!:,R8 6#,N %8S-0!5-#P 4S1# %(T2@!1
M-%  4#58 $XU8 !--FH 3#9U $LW@@!*-Y  23B? $@XL %'.,,!1SCA 4<X
M]0%'./\!1SC_ 4<X_P&W.P  HCP  )$\  "#/   >#P  ' Z  !J-P  9#8
M & V  !<-@L 63<2 %8W&@!4-R, 4C<K % W,@!/.#D 33A  $PX1P!+.$X
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M 3E#_P&J0@  ED,  (9#  !X0P  ;D,  &5#  !=0   5D   %%"  !-0@(
M24,, $9#$@!$1!H 0D0B $%$*@ _13$ /D4X #U%/P \1D< .T9/ #I&5P Y
M1V$ .$=L #='>@ V2(D -4B9 #1(J@ T2+T ,TC9 #1(\  T1_T -$?_ #5&
M_P"F1   DD4  ()&  !U1@  :D8  &%%  !91   440  $Q&  !(1P  1$<*
M $%($  _21@ /4D@ #Q))P Z2BX .4HV #A*/0 W2T0 -DM, #5+50 T3%\
M,TQJ #),=P Q3(8 ,$R7 "]-J  N3;L +DW5 "Y,[P O3/T +TO_ #!+_P"A
M1P  CD@  'Y(  !Q2   9DD  %U(  !52   3$D  $=*  !"2P  /TP& #M-
M#@ Y3A4 -TX= #9/)  U3RL ,T\S #)0.@ Q4$( ,%!* "]14@ N45P +5%G
M "Q1=0 K480 *E*5 "E2I@ I4KD *%+2 "E1[@ I4/P *E#_ "I/_P"<2@
MB4H  'I+  !M2P  8TP  %I,  !13   2$T  $-/   ]4   .5(" #53#  S
M5!( ,509 #!5(0 N52@ +54O "Q6-P K5CX *E9& "E63P H5UD )U=D "97
M<@ E5X$ )%>2 "-7I  B5[< (E?/ ")7[  C5OH (U7_ "15_P"630  A$X
M '5.  !I3@  7T\  %9/  !-4   15(  #]3   Y5@  ,U@  "]:"  K6P\
M*EL5 "A<'0 G7"0 )EPK "5<,P D73H (UU# ")=3  A758 (%YA !]>;@ >
M7GX '5Z/ !Q>H0 ;7K0 &EW, !M=Z0 ;7/D '%O_ !Q;_P"040  ?E$  '!1
M  !D4@  6U(  %)3  !*5   05<  #M9   U6P  +EX  "A@ P D8@P (F,1
M "%C&  ?9"  'F0G !UD+@ <9#8 &V4^ !IE1P 995$ &&5= !=E:@ 697H
M%66+ !1EG@ 39;$ $F7( !)DYP 38_< %&+_ !1B_P")5   >%4  &M5  !@
M5@  5U8  $]7  !&60  /5P  #9?   P8@  *60  "-G   =:@< &6P. !AL
M$P 6;1H %6TA !1M*0 4;3  $VTY !)N0@ 1;DP $&Y8  ]N90 .;G4 #6Z'
M  UNF@ ,;:T "VW"  MLX  ,:_, #6O]  UJ_P""60  <ED  &99  !<6@
M5%H  $I<  !!7P  .6,  #%F   J:0  )&P  !UO   7<@  $G4)  ]W#P .
M=Q0 #G<;  UW(P ,=RH "W<S  IW/  )=T< "'=2  =W7P %=V\ !'>   -W
ME  !=J<  ':[  %UU0 !=.L  G3V  )T_ ![70  ;5T  &)>  !97@  3F
M $5C   \9P  ,VL  "MN   D<@  'G4  !=Y   2?   #7\&  F!#  %@1$
M X$6  *!'0 !@20  ($M  ""-@  @D   (),  ""60  @F@  ()Y  ""C0
M@:   ("T  " RP  ?^<  '[R  !^^0!T8@  :&(  %YB  !39   26<  #]K
M   V<   +70  "5X   >?   %X   !&#   -A@  "(D$  *+"@  BPX  (L3
M  ",&   C!\  (TF  "-+P  CCD  (Y$  ".40  CF   (YQ  ".A0  CID
M (VM  ",PP  C-\  (ON  "+]@!N:   9&<  %AI  !-;   0G$  #AV   O
M>P  )G\  !Z$   6B   $(P   R/   &D@   )4   "6!P  EPP  )</  "8
M$P  F1@  )H?  ";)@  FS   )P[  "<2   G%<  )QH  "<>P  G)   )NE
M  ";N@  FM   )KG  ":\0!J;0  7F\  %%R  !&=P  .WP  #&"   GAP
M'HP  !:1   0E0  "ID   2<    H    *(   "C 0  HP8  *0+  "E#@
MIA(  *<7  "H'@  JB8  *LQ  "K/@  K$T  *Q=  "L<   K(4  *R;  "K
MKP  J\,  *O9  "JZ !D=0  5WD  $M^   _A   -(H  "F0   ?E@  %IL
M !"?   )HP   :<   "J    K@   +    "P    L0   +(#  "T"   M0T
M +80  "W%0  N1T  +LF  "\,P  O4$  +U2  "]9   OGD  +Z0  "]I
MO;<  +W&  "]UP!<?P  4(4  $2+   XD@  +)D  "&?   7I   $*D   FN
M    L@   +8   "Y    O0   +\   "_    P    ,$   ##    Q 4  ,8*
M  #'#@  R1,  ,L<  #.)@  T#4  -%%  #25P  TFL  -."  #3EP  TZD
M -*X  #2Q !5C   29,  #V:   PH@  ):@  !JN   1M   ";D   "]
MP0   ,0   #(    RP   ,T   #-    SP   -    #2    U    -@   #:
M!@  W0P  . 1  #C&@  YB<  .<X  #H2@  Z5T  .IR  #KB   ZYL  .RH
M  #LL@#_  T _P + /\ "P#_ !  _P : /\ )@#_ #( _P ] /\ 2 #[ %(
M^ !: /8 8@#S &D \0!O /  =0#N 'H [ !_ .L A #I (H Z "0 .8 E@#D
M )T X@"E .$ KP#? +L W0#+ -L Y@#9 /< V #_ -@ _P#7 /\ UP#_ -0
M_P#_  @ _P $ /\ ! #_  T _P 5 /X (0#Z "P ]P X /0 0P#P $T [0!5
M .H 70#G &0 Y !J .( < #@ '4 W@!Z -T ?P#; (4 V0"+ -4 D0#3 )D
MT0"@ ,\ J@#- +4 RP#$ ,D W0#( /$ QP#_ ,8 _P#& /\ Q@#_ ,< _P#_
M    _P   /\   #_  H ^  1 /$ ' #L "< Z0 R .8 /0#B $< W0!0 -D
M6 #5 %\ T@!E -  :@#. '  S !U ,H >@#) '\ QP"% ,4 C ## )0 P0"<
M +\ I0"] +  NP"] +H T "X .L MP#[ +8 _P"V /\ M@#_ +8 _P#_
M_P   /T   #S  4 Z0 . .$ %@#; "$ U0 M -$ -P#. $$ R@!* ,< 4@#$
M %D P@!? ,  90"^ &H O !O +L = "Y 'H MP"  +8 AP"T (X L@"7 +
MH "N *H K0"W *L R "I ., J #U *< _P"G /\ IP#_ *8 _P#_    _@
M /$   #E    UP * ,T $0#' !P P@ F +\ ,0"\ #L N@!$ +< 3 "T %,
ML@!9 +$ 7P"O &0 K0!I *P ;P"J '0 J0!Z *< @0"F (D I "1 *( FP"@
M *4 G@"R )T P0"; -H F@#O )D _0"8 /\ F #_ )@ _P#]    \    .$
M  #1    Q@ $ +T #0"W !4 LP @ +  *P"M #4 JP ^ *@ 1@"F $T I !4
M *, 60"A %\ H !D )X :0"= &X FP!U )H >P"8 (, E@", )4 E@"3 *$
MD0"M (\ NP"- ,\ C #I (L ^ ", /\ C #_ (P _P#S @  X@<  ,P'  "_
M!   MP   +$ " "K !  IP 9 *0 ) "@ "X G@ W )P 0 ": $< F !. )8
M5 "5 %D DP!> )( 9 "0 &D CP!O (T =@"+ 'X B@"( (@ D@"& )T A0"I
M (, N "! ,H @ #E (  ]0!_ /\ ?P#_ '\ _P#H#0  T!   +X0  "Q#@
MJ T  *,(  "@ @P G  3 )@ '0"5 "< D@ Q )  .0". 4$ C %( (H"3@")
M E0 AP)9 (8"7P"$ V0 @P-K ($#<@" !'H ?@2$ 'T%C@![!9H >0:G '@&
MM0!V!\@ =0CC '4)] !T"O\ <PK_ ',*_P#=%0  Q!<  +$7  "E%@  G!,
M )81  "4#00 DP@- (X'%0"+"2  B DJ (4*,P"#"SL @0M" ( +20!^"T\
M?0Q4 'L,6@!Z#&  > QG '<,;@!U#78 = V  '(-C !P#9D ;PZF &T.M0!L
M#LD :P_F &H0]P!I$/\ :1#_ &D0_P#0'0  N1X  *@>  ";'0  DAL  (L9
M  "(%0  AQ$' (4.$ "!#QH ?A D 'L0+0!Y$#8 =Q$] '811 !T$4H <Q%0
M '$15@!P$5P ;A)B &T2:@!K$G, :1-] &@3B0!F$Y8 912C &,5LP!B%<8
M8A;C &$6]@!@%_\ 8!?_ & 7_P#'(@  L",  )\D  "2(P  B2(  ((@  !^
M'0  ?!D  'H5#0!W%14 =!8? '$6* !O%S  ;A<X &P7/P!K%T4 :1A+ &@8
M40!F&%@ 91A> &,99@!B&6\ 8!EY %\:A0!=&Y( 7!NA %L<L !:',, 61W@
M %@>] !8'O\ 6![_ %@>_P"_)P  J2@  )DH  "+*   @B<  'LE  !V(P
M<R   '$<"0!N'!$ :QP: &D=(P!G'2P 91TS &,>.@!B'D$ 8!Y' %\>30!>
M'E0 7!]; %L?8@!9(&L 6"!V %8A@@!5(9  5"*> %,BK@!2(\  42/= %$D
M\@!1)/\ 423_ %$C_P"Y*P  HRP  ),L  "&+0  ?"P  '0J  !O*   :R4
M &DB!0!F(0X 8R(6 &$B'P!?(R< 72,O %PC-@!:(ST 621# %<D2@!6)%
M5217 %,E7P!2)6@ 429S $\F?P!.)XT 32B< $PHK !+*;X 2RG: $HI\0!*
M*?\ 2RG_ $LI_P"S+@  GB\  (XP  "!,   =R\  &\N  !J*P  92H  &,G
M 0!?)PP 7"<3 %HG&P!8*"0 5B@K %4H,@!3*#D 4BE  % I1@!/*4T 3BE4
M $TJ7 !,*F4 2BMP $DK? !(+(L 1RV: $8MJ@!%+KP 12[6 $4N[P!%+OX
M12[_ $4M_P"N,0  FC(  (DS  !\,P  <C,  &LQ  !E+P  8"T  %TL  !9
M+ D 5BP0 %0L& !2+"  4"PH $XM+P!-+38 3"T\ $HM0P!)+4H 2"Y1 $<N
M60!&+V, 13!M $,P>@!",8D 03&8 $$RJ ! ,KL /S+3 #\R[@! ,OT 0#+_
M $ R_P"J,P  EC4  (8U  !Y-@  ;C4  &8U  !A,@  7#   %<P  !4, 8
M43 . $XP%0!,,1T 2C$E $@Q+ !',3( 1C$Y $0Q0 !#,D< 0C)/ $$S5P!
M,V  /S1K #XU>  ]-8< /#:6 #LVIP [-KD .C;1 #HV[0 [-OP .S;_ #LV
M_P"F-@  DC<  ((X  !U.   :S@  &,W  !=-@  5S,  %,T  !/- , 2S0,
M $DT$@!&-1H 134B $,U*0!!-2\ 0#4V #\V/0 ^-D0 /3=, #PW50 [.%X
M.CAI #DY=@ X.84 -SJ5 #<ZI0 V.K@ -3K/ #8Z[  V.OL -CG_ #<Y_P"B
M.   CCD  'XZ  !R.P  :#L  %\Z  !9.0  4S8  $XW  !*.   1C@* $0Y
M$ !!.1< /SD? #XY)@ \.2T .SHT #HZ.P Y.T( .#M* #<[4P V/%P -3QG
M #0]=  S/8, ,SZ3 #(^I  Q/K8 ,3[- #$^Z@ Q/OH ,CW_ #(]_P">.P
MBSP  'L\  !N/0  9#T  %P]  !5/   3CH  $D[  !%/   03T' #X]#@ \
M/14 .CX< #D^(P W/BH -C\Q #4_.  T/T  ,T!( #) 4  Q0%H ,$%E "]!
M<@ N0H$ +4*1 "U"H@ L0K4 *T++ "Q"Z0 L0OD +4'_ "U!_P"9/0  ASX
M '<_  !K/P  84   %D_  !2/P  23X  $0_  ! 0   /$$$ #E"#0 W0A(
M-4,9 #-#(0 R0R@ ,40O #!$-@ O1#T +D5% "U%3@ L15@ *T9C "I&;P I
M1GX *$:/ "='H0 F1[, )D?) "9&YP G1O@ *$7_ "A%_P"50   @D$  '-"
M  !G0@  7D(  %5"  !.0@  14(  #]$   [10  -T8  #1'"@ Q2!  +T@6
M "Y)'@ L224 *TDL "I),P I2CH *$I" "=*2P F2U4 )4M@ "1+;0 C2WP
M(DN- "%,GP A3+$ ($S' "!+Y@ A2_< (DK_ ")*_P"00P  ?D0  &]$  !D
M10  6D4  %)%  !*1@  04<  #Q(   W20  ,DL  "Y-!P K3@X *4X3 "=/
M&@ F3R$ )4\H "1/,  C4#< (E _ "%02  @4%( 'U%= !Y1:@ =47D '%&*
M !M1G  :4:\ &5'% !E1Y  :4/8 &T__ !Q/_P"*1@  >4<  &M'  !@2
M5D@  $Y(  !'20  /DL  #E,   S3@  +E   "A3 @ D5 L (E40 "!5%@ ?
M5AX 'E8D !U6+  <5C, &U<[ !I71  95TX &%=9 !=89@ 56'4 %%B' !18
MF@ 35ZP $E?" !)7X0 35O0 %%7_ !15_P"$20  =$H  &9+  !<2P  4TL
M $M,  !$30  /$\  #51   O5   *58  "19   >6P< &ET- !A=$@ 771D
M%EX@ !5>)P 47BX $UXW !)>0  17TH $5]5 !!?8@ /7W$ #E^#  U?E@ -
M7ZD #%Z^  Q>V@ -7?  #5S\  Y<_P!^30  ;DX  &).  !83P  3T\  $A0
M  ! 4@  .%0  #!7   J6@  )%T  !]?   98@$ $V4) !%F#P 09A0 #V8;
M  YG(@ -9RD #6<R  QG.P +9T4 "F=0  EG70 '9VP !F=]  5GD  $9J,
M F:W  -ESP $9>D !&3U  1D_ !W40  :5(  %U2  !44@  3%,  $-5   [
M6   ,UL  "M>   E80  'V0  !EG   3:@  #VT&  MP#  (<!$ !W 6  5P
M'0 $<"0  W L  )P-0  <#\  '!*  !P5P  <&4  '!V  !PB@  ;YX  &^R
M  !NR   ;>4  &WR  !M^0!P5@  8U8  %E6  #_XO__24-#7U!23T9)3$4
M! E15P  1U@  #Y;   V7P  +F(  "9F   ?:@  &6T  !-P   .<P  "W8$
M  5X"P !> \  'D3  !Y&0  >1\  'HF  !Z+P  >CD  'I$  !Z4   >E\
M 'IP  !Z@P  >I@  'JL  !YP@  >-\  'CO  !W]P!J6P  7UL  %9;  !,
M7   0F   #EC   P:   *&P  "!P   9=   $W<   Y[   )?@  !($"  ""
M"   @PT  (,0  "$%   A1D  (8@  "&*   AS$  (<\  "'20  AU<  (=H
M  "'>P  AY   (:E  "%N@  A=,  (3J  "$] !E8   7&   %%A  !&9
M/&D  #)M   I<@  (7<  !E[   2@   #8,   B'   "B@   (T   ".!
MC@D  (\-  "0$   D10  )(9  "3(   E"D  )4S  "50   EDX  )9?  "5
M<@  E8@  )6=  "4L@  E,@  )/B  "3[@!A90  5F8  $IJ   _;@  -70
M "MY   A?P  &80  !&)   ,C0  !I$   "4    F    )H   ";    G (
M )T'  ">"P  GPX  *$2  "B&   HR   *4I  "F-@  ID0  *95  "F:
MIGT  *:4  "EJ0  I+T  *31  "DY !;;   3W   $-U   X>P  +8$  ".'
M   9C0  $9(   N7   $G    *    "C    I@   *@   "I    J@   *P
M  "M!   K@D  + -  "Q$0  LQ<  +4@  "V*P  MSH  +=+  "X7   N'$
M +B(  "XG0  N+$  +?"  "WT !4=@  2'P  #R"   QB0  )I   !N7   2
MG0  #*(   .G    JP   *X   "R    M@   +@   "X    N@   +L   "]
M    O@   , %  #!"P  PQ   ,86  #)(   RBX  ,L^  #,4   S&0  ,UZ
M  #-D0  S:0  ,VT  #-P !-@P  08H  #61   IF0  'J   !.F   ,K
M [$   "V    N@   +X   #"    Q@   ,@   #(    R@   ,L   #-
MS@   -    #2 0  U0@  -D.  #=%0  X2$  .(Q  #D0P  Y58  .9K  #F
M@@  YY8  .>E  #FL #_  D _P % /\ !@#_  X _P 6 /\ (0#_ "T _P X
M /T 0P#Y $T ]0!5 /( 70#P &, [@!I .P ;P#J '0 Z0!Z .< ?P#F (4
MY "+ ., D0#A )D WP"A -P J@#: +8 UP#& -4 X0#3 /0 T@#_ -$ _P#1
M /\ SP#_ ,H _P#_  $ _P   /\  0#_  P _P 2 /H '0#V "@ \P S /
M/@#L $@ Z !0 .4 6 #B %X WP!D -T :@#; &\ V0!T -8 >@#4 '\ T@"%
M -  C #. ), S "< ,D I0#' +  Q@"^ ,0 U #" .X P0#^ ,  _P#  /\
MOP#_ +X _P#_    _P   /\   #Z  < \0 / .L & #F ", X@ N .  . #;
M $( U0!+ -$ 4@#. %D RP!? ,D 90#' &H Q@!O ,0 = #" 'H P0"  +\
MA@"] (X NP"6 +D H "W *H M@"W +0 R@"R .8 L0#X +  _P"O /\ KP#_
M +  _P#_    _P   /<   #J  ( X0 , -< $P#0 !T S  H ,D ,@#& #P
MP@!% +\ 30"\ %, N@!9 +@ 7P"W &0 M0!I +0 ;@"R '0 L0!Z *\ @ "M
M (@ K "1 *H F@"H *4 I@"Q *0 P0"C -P H0#R *$ _P"@ /\ H #_ *$
M_P#_    ]P   .@   #9    RP ( ,, $ "] !@ N0 B +8 + "T #8 L@ _
M *\ 1P"L $T JP!4 *D 60"G %X I@!C *4 : "C &X H@!T *  >@"> ((
MG "+ )L E0"9 )\ F "L )8 N@"4 ,\ DP#K )( ^P"2 /\ D@#_ )$ _P#W
M    YP   -,   #&    NP " +, # "M !( J@ < *< )@"D #  HP X *
M0 "> $< G !. )H 4P"9 %@ EP!= )8 8P"5 &@ DP!N )( = "0 'P CP"%
M (T CP"+ )H B@"G (@ M0"& ,< A0#D (0 ]0"$ /\ @P#_ (, _P#L
MTP   ,$!  "T    K    *8 !P"@  X G0 6 )H ( "7 "D E0 R ), .@"1
M $$ CP!( (T 30", %, BP!8 (D 70"( &, AP!I (4 ;P"# '< @@"  (
MB@!^ )8 ?0"C 'L L !Z ,( >0#= '@ \0!W /T > #_ '@ _P#>"@  Q L
M +(,  "F"P  G0@  )D$  "5  H D0 1 (X &0"+ ", B0 L (< - "% #L
M@P!" (( 2 "  $X ?P!3 'T 6 !\ %X >P!D 'D :@!X '( =@![ '0 A@!S
M )( <0"? '  K0!N +X ;0'6 &T"[0!L _H ; /_ &P#_P#.$   MQ$  *82
M  ":$0  D1   (L.  ")"P, AP4, (0!$P"! 1P ?@(E 'P#+@!Z S8 > 0\
M '<$0P!U!4@ = 5. ',%5 !Q!5D < 9? &X&9@!M!FX :P=X &H'@P!H")
M9PF= &4)K !D";P 8PK4 &,+[ !B#/H 8@S_ &(,_P##%@  K1<  )T8  "0
M&   AQ8  ($4  !]$0  ? X& 'P*#@!X"A8 =0L? '(+* !P##  ;PPW &T,
M/@!L#$0 :PU* &D-3P!H#54 9PU< &4-8P!C#FL 8@YU & .@0!?#HX 70^<
M %P0JP!;$+T 6A#6 %D1\ !9$?T 61'_ %D1_P"Y&P  I1T  )0>  "('@
M?AT  '@;  !T&   <14  '$1"0!O$!$ ;! 9 &D0(@!G$2H 9A$R &01.0!C
M$3\ 8A%% & 22P!?$E$ 71)8 %P27P!:$V@ 61-R %<4?0!6%(L 5!69 %,5
MJ0!2%KH 41;2 %$7[0!1%_T 41?_ %$7_P"R(   GB(  (XB  "!(P  =R(
M ' A  !L'@  :1L  &<8! !F%0X 8Q85 &$6'@!?%B8 718M %P7- !:%SL
M61=! %@81P!6&$T 51A4 %,87 !2&60 41EN $\:>@!.&X@ 31N7 $L<I@!*
M'+@ 2AW/ $D=ZP!)'?L 21W_ $H=_P"L)   F"4  (@F  ![)P  <28  &HE
M  !F(P  8B$  & >  !>' L 6QL2 %D<&@!7'"( 51PI %0<, !3'3< 41T]
M % =0P!/'4H 31Y1 $P>6 !+'V$ 21]K $@@=P!'((4 1B&4 $0BI !$(K8
M0R+, $,CZ0!#(_H 0R/_ $,B_P"F)P  DRD  (,J  !V*@  ;2H  &4I  !@
M)P  7"4  %DC  !7(0< 52$/ %(A%@!0(1X 3B$E $TB+ !,(C, 2B(Y $DB
M0 !((D8 1R-- $4C50!$)%X 0R1I $(E=0! )H, /R:2 #XGHP ^)[0 /2?*
M #THZ  ]*/D /2?_ #XG_P"B*@  CBL  '\M  !R+0  :"T  &$L  !<*P
M6"@  %0F  !1)@0 3B4- $PE$P!*)AH 2"8B $<F*0!%)B\ 1"8V $,G/ !!
M)T, 0"=+ #\H4P ^*5P /2EF #PJ<@ [*H$ .BN0 #DKH0 X++( -RS( #<L
MY@ X+/@ ."S_ #@L_P"=+   BBX  'LO  !O,   93   %TO  !8+@  4RL
M % J  !,*@  22H+ $8J$0!$*A< 0BH? $$J)0 _*BP /BLS #TK.0 \*T
M.RQ( #HL4  Y+5D ."YD #<N<  V+W\ -2^/ #0PGP S,+$ ,C#' #(PY0 S
M,/< ,S#_ #0O_P"9+P  AS$  '<R  !K,@  8C(  %HR  !4,0  3R\  $LM
M  !'+@  1"X( $$N#@ _+A0 /2X< #LN(@ Y+RD ."\O #<O-@ V,#X -3!&
M #4Q3@ T,5< ,S)B #(R;@ Q,WT ,#.- "\TG@ N-+  +33% "TTXP N-/8
M+S/_ "\S_P"5,0  @S,  '0T  !H-0  7C4  %<T  !1-   2S(  $8Q  !"
M,@  /S(% #PR#0 Y,Q( .#,9 #8S(  T,R8 ,S,M #(T-  Q-#L ,#5# # U
M3  O-E4 +C9@ "TW;  L-WL *S>+ "HXG  I.*X *#C# "@XX@ I./4 *C?_
M "HW_P"2-   ?S4  '$V  !E-P  6S<  %0W  !--@  1S8  $(U   ]-@
M.C8" #<W"P T-Q  ,C<6 #$X'0 O."0 +C@K "TY,@ L.3D *SE! "HZ20 J
M.E, *3M> "@[:@ G.WD )CR) "4\FP D/*T (SS" ",\X  D//0 )3O_ "4[
M_P"--@  ?#@  &TY  !B.0  6#H  %$Y  !*.0  1#D  #TY   Y.@  -3L
M #(["  O/ X +3T4 "P]&@ J/2$ *3TH "@^+P G/C8 )CX^ "4_1P D/U
M(T!; ") :  A0'8 ($"' !]!F0 ?0:L 'D'  !Y!W@ ?0/, 'T#^ " __P")
M.0  >#H  &D[  !>/   53P  $T\  !'/   0#P  #@]   T/@  ,$   "U!
M!0 J0@P )T(1 "9#&  D0QX (T,E ")#+  A1#, ($0[ !]$1  >14X '459
M !Q%90 ;170 &D6% !E&EP 91JD &$:^ !=%W  81?$ &43] !I$_P"$/
M<ST  &8^  !;/P  4C\  $H_  !$/P  /4   #9!   Q0P  +$0  "=& 0 D
M1PH (4@/ "!)%  >21L '4DB !Q)*0 ;2C  &DHX !E*00 82DL %TM5 !9+
M8@ 52W$ %$N" !-+E  22Z< $DN\ !%+V0 22O  $TK\ !1)_P!_/P  ;T
M &%!  !70@  3D(  $="  !!0@  .D,  #)%   M1P  *$D  "-+   >308
M&T\- !A0$0 74!< %E > !50)0 44"P $U$T !)1/0 144< $5%2 !!17P /
M4FT #E)^  U1D0 -4:0 #%&X  Q1T0 -4.P #5#Z  Y/_P!Y0P  :D0  %U$
M  !310  2T4  $1%   ^1@  -D@  "]*   I3   )$\  !]1   :4P  %%8)
M !%7#@ 06!, $%@9  ]8(  .6"@ #5@P  U8.0 ,6$, "UA.  I86@ (6&@
M!UAY  98C  %6)\ !%BS  17R@ %5^8 !5?S  96_ !S1@  9$<  %E(  !0
M2   2$@  $%)   Z2@  ,DT  "M0   E4@  (%4  !I8   56@  $%T&  Q@
M#  *8!  "6 5  A@'  '8", !6 K  1@-  #8#T  6!)  !@50  8&,  &!S
M  !@A@  7YH  %^N  !?Q   7N(  %[P  !>^ !L2@  7TL  %5+  !,3
M14P  #U.   U4   +E,  "=6   @60  &EP  !5?   08@  #64$  AG"P #
M9PX  &@3  !H&   :!\  &DF  !I+@  :3@  &E#  !I3P  :5T  &EM  !I
M@   :90  &BI  !HOP  9]P  &;N  !F]P!F3P  6D\  %%/  !*3P  05$
M #A4   P5P  *%L  "%>   :8@  %&4  !!H   ,:P  !VX#  %P"0  < T
M '$0  !Q%   <AH  ',A  !S*   <S$  ',\  !T2   <U8  '-F  !S>0
M<XX  '.C  !RN0  <=(  ''K  !P] !A4P  5E,  $]3  !%50  .U@  #)<
M   J8   (F0  !MH   4;   #V\   MR   &=@   'D   !Z!@  >@H  'L.
M  !\$0  ?14  'X;  !_(@  @"H  ( U  " 00  @$\  (!?  " <0  @(8
M ("=  !_L@  ?LH  '[E  !]\0!<6   5%@  $E:   _70  -6$  "QE   C
M:@  &V\  !1S   .=P  "7L   -_    @@   (0   "& 0  A@8  (@*  ")
M#0  BA   (L5  ",&P  CB(  (\L  "/.   CT8  (]6  "/:   CWX  (^5
M  ".JP  C<$  (W<  ",ZP!970  3E\  $-B   X9@  +FP  "1Q   <=P
M%'P   Z!   (A0   (D   "-    D    )(   "3    E    )8#  "7"
MF P  )H/  ";$P  G1H  )\C  "@+@  H#P  *!,  "@7@  H'0  )^,  "?
MH@  G[<  )[+  ">X !39   1V@  #QM   Q<P  )WD  !U_   4A0  #8L
M  :0    E    )@   "<    GP   *$   "B    I    *4   "G    J 0
M *H)  "L#0  K1(  + 9  "R(P  LC$  +)"  "R5   LFD  +*   "RF
ML:P  +*_  "QS@!,;@  0',  #5Z   J@0  'X@  !6.   .E0  !IH   "?
M    I    *@   "L    KP   +$   "Q    LP   +4   "V    N    +H
M  "\!@  O@P  , 1  ##&0  Q28  ,4W  #&20  QET  ,=R  #'B@  R)\
M ,BO  #(O !&>@  .8$  "Z)   BD   %Y@   ^?   'I0   *H   "O
MLP   +<   "\    OP   ,$   #"    Q    ,4   #'    R0   ,L   #-
M    SP,  -(*  #6$   W!H  -TJ  #>/   WU   .!E  #A>P  X9$  .*B
M  #BK0#_  ( _P   /\  P#_  P _P 3 /\ '0#_ "@ _@ S /L /@#W $@
M\P!0 /  5P#M %X ZP!D .@ :0#G &\ Y0!T ., >0#B '\ X "% -X C #<
M ), V0"< -8 I@#3 +$ T0#  ,\ V@#. /$ S #_ ,L _P#+ /\ Q@#_ ,$
M_P#_    _P   /\   #_  @ ^P 0 /8 &0#R "0 [P N .T .0#H $( XP!+
M .  4@#= %D V0!? -8 9 #3 &D T0!N ,\ = #. 'D S !_ ,H A@#( (X
MQ@"6 ,0 H #" *L P "Y +X S0"\ .H NP#\ +H _P"Z /\ N@#_ +8 _P#_
M    _P   /X   #T  0 ZP - .0 % #? !\ VP I -@ ,P#3 #T S@!% ,H
M30#' %, Q0!9 ,, 7P#! &0 OP!I +T ;@"[ ', N@!Y +@ @ "V (@ M "0
M +( F@"Q *4 KP"R *T Q "L .$ JP#V *H _P"J /\ J@#_ *H _P#_
M_0   .X   #B    U0 * ,T $0#' !D Q  C ,$ +0"_ #< NP _ +< 1P"U
M $X L@!3 +  60"O %X K0!C *P : "K &T J0!S *@ >@"F ($ I "* *,
ME "A )\ GP"L )X NP"< -( FP#N )H _P": /\ F0#_ )D _P#^    [@
M -X   #+    P0 % +D #0"T !0 L0 > *X )P"K #  J@ Y *< 00"D $@
MH@!- *$ 4P"? %@ G@!= )T 8@"; &< F@!M )@ <P"7 'L E0"$ )0 C@"2
M )D D "F (X M "- ,@ C #F (L ^0"* /\ B@#_ (L _P#P    VP   ,<
M  "Z    L    *@ "@"D !  H  8 )T (0"; "H F@ S )@ .P"6 $$ E !(
M )( 30"1 %( CP!7 (X 7 ", &$ BP!G (H ;@"( '4 AP!^ (4 B "# )0
M@@"@ (  KP!_ ,  ?@#= 'T \@!] /\ ?0#_ 'T _P#@    Q@   +4   "J
M    H@   )L !0"5  T D@ 3 )  ' "- "0 BP M (H - "( #L A@!" (4
M1P"# $T @@!2 ($ 5P!_ %P ?@!B 'T : ![ '  >@!Y '@ @P!V (\ =0"<
M '0 J@!R +H <0#1 '  [ !P /L < #_ '  _P#-!   MP8  *<'  ";!@
MDP0  (X   "*  @ A@ / (0 %@"! !X ?P G 'T +@!\ #8 >@ \ 'D 0@!W
M $< =@!, '4 4@!S %< <@!= '$ 8P!O &L ;@!T &P ?@!K (H :0"8 &@
MI@!G +8 9@#+ &4 YP!E /< 90#_ &4 _P# #   JPT  )L.  "/#@  A@T
M ($+  !^!P$ ? $+ 'D $0!W !@ =0 A ', *0!Q #  ;P V &X / !L $(
M:P!' &H 30!I %( : !8 &8 7P!E &< 8P!P &(!>@!@ 8< 7P*5 %X"HP!<
M [, 7 /' %L$Y !;!?0 6P;^ %L&_P"U$   H1(  )$3  "%$P  ?!(  '81
M  !S#@  <@P$ '$'#0!N!!( ; 0; &D%(P!G!2H 9@8Q &0&-P!C!CT 8@=#
M &$'20!?!TX 7@A5 %T(7 !;"6, 6@EM %@*> !7"H4 5@N3 %0+H@!3"[,
M4@S' %(,Y !1#?4 40W_ %$-_P"M%0  F1<  (D8  !]&0  =!@  &T7  !J
M%   9Q$  &<.!P!F# X 8PP5 &$,'0!?#"4 70TL %P-,P!;#3D 6@T_ %@-
M10!7#4L 5@Y1 %4.60!3#F$ 4@YK % /=@!.$(, 31"2 $P0H@!+$+( 2A'(
M $D1Y0!)$?< 21+_ $D1_P"E&0  DAP  (,=  !V'@  ;1T  &8<  !B&@
M7Q<  %X4 0!>$0H 6Q 1 %D1& !7$2  51$G %01+@!3$30 41$[ % 200!/
M$D< 3A). $P250!+$UX 21-G $@4<P!&%(  116/ $05GP!#%K  0A;% $(7
MXP!"%_8 0A?_ $(7_P"?'0  C"   'TA  !Q(@  :"(  &$A  !<'P  61P
M %<9  !5%@8 5!4. %$5% !/%AP 3A8C $P6*@!+%C  2A8W $D7/0!'%T,
M1A=* $484@!#&%H 0AED $$9<  _&GT /AN- #T;G0 \'*X .QS# #L<X0 [
M'?4 .QS_ #P<_P":(0  AR,  '@D  !L)0  8R4  %PD  !7(P  4R   %$>
M  !/' ( 31L, $L:$0!(&Q@ 1QL@ $4;)@!$&RT 0QPS $(<.0! '$  /QU'
M #X=3P ]'E@ /!YB #H?;0 Y'WL .""+ #<AFP V(:T -2'! #4AWP U(?,
M-B'_ #8A_P"6(P  @R8  '0G  !H*   7R@  %@G  !3)@  3R0  $PB  !)
M(   1R ) $0?#P!"'Q4 0" < #\@(P ^("D /" O #LA-@ Z(3T .2%$ #@B
M3  W(E4 -B-? #0C:P S)'D ,B6) #$EF@ P):L ,":_ "\FW  P)O( ,";_
M #$E_P"1)@  ?R@  '$J  !E*@  7"H  %4J  !/*0  2R@  $@E  !$)
M020% #\D#0 ])!( .R09 #DD'P W)"8 -B0L #4E,P T)3H ,R9! #(F2@ Q
M)U, ,"== "\H:0 N*7< +2F' "PIF  K*JH *BJ] "HJV@ K*O$ *RK^ "PI
M_P"-*   ?"H  &TL  !B+0  62T  %$M  !,+   1RL  $,H   _*   /"@"
M #DH"P W*!  -2@6 #,H'  R*", ,"@I "\I,  O*C< +BH_ "TK1P L*U$
M*RQ; "HL9P I+74 *"V% "<MEP F+J@ )2Z\ "4NV  F+O  )B[] "<M_P"*
M*P  >"T  &HN  !?+P  5B\  $XO  !(+@  0RT  #\L   [+   -RP  #0L
M"0 R+ X ,"T3 "XM&@ M+2  *RTG "HN+0 J+C4 *2\] "@O10 G,$X )C!9
M "4Q90 D,7, (S&# "(RE0 A,J< (3*[ " RU  A,N\ (C'\ "(Q_P"&+0
M=2\  &<P  !<,0  4S$  $LQ  !%,0  0#   #LP   V,   ,S   # Q!@ M
M,0T *S$1 "DR%P H,AX )S(D "4S*P E,S( )#,Z ",T0P B-$P (357 " U
M8P ?-7$ 'C:! !TVDP <-J4 &S:Y !LVT@ <-NT '3;[ !TU_P"",   <3(
M &,S  !9-   4#0  $DT  !",P  /3,  #<S   Q-   +C4  "LU @ H-@L
M)3<0 "0W%0 B-QL (3@B " X*  ?.#  'C@W !TY0  <.4D &SI4 !HZ8  9
M.FX &#I_ !<[D0 7.Z0 %CNW !4[T  6.NP %SKZ !@Y_P!],@  ;30  & U
M  !5-@  338  $8V  ! -@  .C8  #0V   N.   *CD  "8Z   C.P@ (#P.
M !X]$@ =/1@ '#T? !L^)0 :/BT &3XT !<^/0 6/T< %3]1 !0_7@ 4/VP
M$T!\ !) CP 10*( $4"V !! S@ 1/^L $C_Y !(^_P!Y-0  :3<  %PX  !2
M.0  2CD  $,Y   ].0  -SD  #$Z   K/   )ST  "(_   >000 &D(+ !A#
M$  70Q4 %40; !1$(@ 31"D $T0Q !)$.@ 114, $$5. !!%6P .16D #D5Y
M  U%C  -19\ #$6R  M%R0 ,1>4 #43V  U$_P!T.0  93H  %@[  !/.P
M1SP  $ \   Z/   -#P  "X^   H0   (T(  !]$   :1@  %4@( !)*#0 1
M2A( $$H8  ]+'@ .2R4 #4LM  U+-@ ,2T  "TM*  I+5@ )2V0 "$MT  =+
MAP %2YH !$NN  1*Q  %2N  !4KP  9)^@!N/   8#T  %0^  !+/@  1#X
M #T^   W/P  ,4   "I"   D10  'T<  !I)   53   $4X%  Y1"P +41
M"E$4  E1&P (42( !U$I  51,@ $4CL  U)&  %24@  4E\  %)O  !2@0
M498  %&I  !1OP  4-P  %#N  !0]P!H0   6T$  %!!  !(00  04$  #M"
M   T0P  +44  "9(   @2P  &TT  !90   14P  #E4$  I8"@ &6 X  E@2
M  !9%P  61T  %DE  !9+0  638  %E!  !930  6EH  %II  !9?   69
M %FE  !8N@  6-4  %?L  !7]@!C1   5D4  $U%  !%10  /T4  #='   O
M20  *$P  ")/   ;4@  %E4  !%8   -6@  "5T#  1?"0  8 T  & 0  !A
M%   81D  &(@  !B)P  8C$  &([  !B1P  8E4  &-D  !B=@  8HL  &*@
M  !AM@  8<\  &#J  !@]0!=2   4DD  $I(  !#2   .DH  #)-   J4
M(U,  !Q7   66@  $5T   U@   (8P   V8!  !G!@  : L  &D.  !J$0
M:Q4  &P;  !M(@  ;2H  &TT  !M0   ;4X  &U=  !M;P  ;80  &R:  !L
ML   :\@  &OF  !J\P!830  3DT  $A,   ^3@  -5$  "Q4   D6   '5P
M !9@   09   #&<   =K   !;@   '    !R P  <@<  ',+  !U#@  =A$
M '<6  !X'   >2,  'HM  !Z.0  >D<  'I6  !Y:   >GP  'F4  !XJ@
M>,$  '??  !W[P!440  3%$  $)2   X50  +UD  "9>   >8@  %F<  !!K
M   +;P  !7,   !W    >@   'P   !^    ?P(  ( &  "!"@  @PT  (01
M  "&%0  B!P  (DE  "*,   BCX  (E-  ")7P  B7,  (B+  "(H@  A[D
M (?1  "&Z !25@  1U<  #Q:   R7P  *&0  !]I   6;P  $'0   IY   "
M?0   ($   "%    B    (H   ",    C0   (\   "0!   D@@  ),,  "5
M$   EQ4  )D=  ";)P  FS0  )M$  ":5@  FFH  )F"  ":F@  F+   )C'
M  "7W@!+7   0&   #5E   K:@  (7$  !=W   0?0  "8,   &(    C
M )$   "5    F    )H   ";    G0   )\   "@    H@   *0%  "F"@
MJ X  *H4  "M'0  K2H  *TY  "M2P  K5\  *UW  "LD   JZ<  *NZ  "K
MRP!%9@  .6L  "YQ   C>   &7\  !"&   )C0   ),   "8    G0   *$
M  "E    J    *L   "K    K@   *\   "Q    LP   +4   "W 0  N0<
M +P-  "_$P  PA\  ,(N  #"0   PE0  ,%K  #!@P  P)L  ,&M  #!O  ^
M<@  ,G@  ">    <B   $I    J7    G0   *,   "H    K0   +(   "V
M    N0   +L   "\    O@   ,    #"    Q    ,8   #(    RP   ,X%
M  #1#0  UA0  -<C  #8-0  V4D  -I>  #;=0  VXP  -R?  #<JP#_
M_P   /\   #_  D _P 0 /\ &0#^ "0 _  O /D .0#T $, \ !+ .T 4@#J
M %D YP!? .0 9 #B &D X !N -X <P#< 'D V@!_ -< A@#4 (X T0"6 ,\
MH0#, *P R@"[ ,@ T@#& .X Q@#_ ,4 _P#% /\ OP#_ +H _P#_    _P
M /\   #^  4 ]P . /( %0#N !\ ZP J .D - #C #T W@!% -D 30#4 %,
MT0!9 ,X 7@#, &, R@!H ,D ;0#' ', Q0!Y ,, @ #! (@ OP"0 +T FP"[
M *8 N0"T +< R "V .8 M0#[ +0 _P"T /\ LP#_ *X _P#_    _P   /@
M  #M    Y0 + -T $0#7 !H T@ D ,\ +@#+ #< QP!  ,, 1P#  $X O@!3
M +P 60"Z %X N !C +8 : "U &T LP!S +$ >0"O ($ K0"* *L E "I *
MJ "M *8 O@"E -L I #T *0 _P"C /\ HP#_ *( _P#_    ]@   .8   #7
M    RP & ,0 #@"^ !4 NP ? +D * "W #$ M  Z +  00"M $@ JP!. *D
M4P"G %@ I@!< *0 80"C &< H0!L *  <P"> 'H G0"# )L C@"9 )D EP"F
M )8 M@"5 ,P E #K ), _0"3 /\ DP#_ ), _P#W    Y    -    #!
MMP " *\ "P"K !$ IP 9 *4 (@"C "L H@ S )\ .P"< $( FP!( )D 30"7
M %( E@!7 )4 6P"3 &$ D@!F )  ;0"/ '0 C0!] (P AP"* ), B "@ (<
MKP"% ,( A0#B (0 ]P"$ /\ A #_ (0 _P#E    S0   +P   "O    I@
M )X !P":  X E@ 4 )0 '0"2 "4 D0 M )  -0"- #P C !" (H 1P"( $P
MAP!1 (8 5@"$ %L @P!@ ($ 9P"  &X ?@!W 'T @0![ (T >@": '@ J0!W
M +H =@#3 '8 [P!V /X =0#_ '4 _P#0    NP   *L   "?    EP   )
M @"+  L B  0 (8 %P"$ "  @@ G ($ +P!_ #4 ?0 \ 'P 00![ $8 >0!+
M '@ 4 !W %4 =@!; '0 80!S &D <0!Q '  >P!N (< ;0"5 &L HP!J +0
M:@#) &D Z !I /D :0#_ &D _P#     K    )P"  "0 @  B    (,   !_
M  8 >P - 'D $@!W !H =@ B '0 *0!S #  <0 V '  / !O $$ ;0!& &P
M2P!K %  :@!6 &@ 7 !G &0 90!L &0 =@!C (( 80"0 &  GP!? *\ 7@##
M %X X0!> /0 70#_ %T _P"T!P  H D  ) +  "$"P  ? H  '<'  !T!
M<0 ) &\ #P!M !4 :P < &D (P!H "H 9P Q &4 -@!D #P 8P!! &( 1@!@
M $P 7P!2 %X 6 != %\ 6P!H %H <@!8 'X 5P", %8 FP!5 *L 5 "^ %0
MV@!3 .\ 5 #[ %0 _P"I#0  E@X  (<0  !Z$   <A   &P.  !I#   9PD#
M &8$"P!D !  8@ 7 &  '@!> "4 70 K %P ,0!: #< 60 \ %@ 0@!7 4<
M5@%. %4"5 !3 EP 4@-E %$#;P!/!'L 3@2* $T%F0!,!:D 2P6\ $H&U !*
M!^T 2@?Y $H'_P"A$   CA(  'X4  !S%   :A0  &03  !@$0  7@\  %T-
M!0!="0T 6@82 %@'&0!6!R  50<G %,'+0!2"#, 40@X % (/@!/"40 3@E*
M $P)40!+"ED 2@IB $@+;0!'"WH 1@R( $0,F !##*D 0@V\ $(-U0!"#>X
M0@W[ $(-_P":%   AQ8  '@8  !L&0  8QD  %T8  !9%@  5A,  %01  !4
M#@@ 4PT. %$-% !/#1L 30TB $P-* !+#2X 2@TT $D-.@!'#D$ 1@Y' $4.
M3P!$#E< 0@]A $$0;  _$'D /A"( #T1F  [$:D .Q&\ #H1U@ Z$?  .A+]
M #L1_P"3&   @1H  ',<  !G'0  7AT  %@<  !3&P  4!@  $X6  !,$P,
M3!$+ $H0$ !($1< 1A$> $41) !$$2H 0A$P $$1-P! $CT /Q)$ #T23  \
M$U0 .Q-> #D4:0 X%'8 -Q6% #85E@ T%J< -!:Z #,6TP S%NX -!;\ #06
M_P".&P  ?!T  &X?  !C(   6B   %,@  !.'@  2AT  $@:  !&&   118'
M $,5#@!!%1, /Q4: #X5(  ]%2< .Q4M #H6,P Y%CH .!9! #<720 U%U$
M-!A; #,99@ R&7, ,!J# "\:E  N&Z4 +1NX "T;T  M&^P +AO[ "X;_P"*
M'@  >"   &HB  !?(P  5B,  $\B  !*(0  1B   $,>  !!&P  /QH# #T:
M#  [&1$ .1D6 #<:'0 V&B, -1HI #0:,  S&S8 ,1L^ # <1@ O'$\ +AU9
M "T=9  L'G$ *Q^! "H?D@ I'Z0 *""W "<@S@ G(.L *"#Z "D?_P"&(
M=",  &<D  !<)0  4R4  $PE  !')   0B,  #\A   ]'P  .AX  #<>"0 U
M'@X ,QX3 #$>&@ P'B  +QXF "X?+0 M'S, +" [ "L@0P J(4P *2%6 "@B
M8@ F(F\ )2-_ "0CD  C(Z( (B2U "(DS  B).D (R3Y "0C_P""(P  <24
M &,F  !9)P  4"@  $DG  !#)P  /R8  #LD   X(@  -2(  #(B!@ P(@T
M+B(1 "PB%P J(AT *2(C "@C*@ G(S$ )B0X "4E00 D)4H (R94 "(F8  A
M)VT ("=] !\GCP >**$ 'BBT !THR@ =*.@ 'BCX !\G_P!^)0  ;B<  & I
M  !6*0  32H  $8J  !!*0  /"@  #<G   T)@  ,"8  "TF P K)PL *"<0
M "<G%  E)QH )"<A ",H)P B*"X (2DV " I/@ ?*D@ 'BI2 !TK7@ <*VL
M&RM[ !HLC0 9+)\ &"RR !@LR0 8+.< &2OW !HK_P!Z)P  :BH  %TK  !3
M+   2BP  $,L   ^*P  .2L  #0J   P*@  *RH  "DK   F*P@ (RP. "(L
M$@ @+!@ 'RP> !XM)0 =+2P '"TS !LN/  :+D4 &2]0 !@O7  7+VD %C!Y
M !4PBP 4,)X %#"Q !,PQP 3,.4 %##V !4O_P!V*@  9RP  %HM  !0+@
M2"X  $$N   [+@  -BT  #$M   L+0  )R\  "0O   A, 4 'S$, !PQ$  ;
M,A4 &C(< !DR(@ 8,BD %S,Q !8S.0 5,T, %#1- !,T60 2-&< $35W !$U
MB0 0-9P $#6P  XUQ@ /-.0 $#3U ! T_P!R+   8RX  %<P  !-,   13
M #XP   X,   ,S   "\P   I,0  )#(  "$S   =-0( &C8) !<W#@ 5-Q,
M%#@9 !,X'P 2."8 $C@N !$Y-@ 0.4  $#E+  XY5P ..F0 #3IT  PZA@ ,
M.ID "SFL  HYP0 *.=X "SGQ  PX_ !N+P  7S$  %,R  !*,P  0C,  #LS
M   V,P  ,3(  "PS   G-   (38  !TX   9.0  %3L& !(]#  0/A  $#X5
M  X^'  ./B, #3XJ  P^,P ,/CP "S]'  H_4@ (/V  !S]O  8_@0 %/Y0
M!#^H  ,^O  $/M< !3[L  4^]P!I,P  6S0  % U  !'-0  /S4  #DU   T
M-0  +C4  "DW   C.   'CL  !H\   6/P  $D$$  Y#"@ ,1 X "D03  E$
M&0 (1"  !T0G  9$+P %1#@  T5"  )%3@  15L  $5J  !%?   19   $2D
M  !$N0  1-$  $3J  !#]0!D-@  5S<  $PX  !#.   /#@  #<X   Q.
M*SD  "4[   @/0  &D   !9"   21   #D<$  M)"0 '2@T !$L1  %+%@
M2QP  $LC  !+*P  2S0  $L^  !,20  3%<  $QF  !,=P  2XP  $NA  !+
MM0  2LX  $KI  !*]0!?.@  4CL  $@[  ! .P  .CL  #0[   N/   )SX
M ")!   <0P  %D8  !))   .2P  "TX#  =0"  "40P  %$0  !2$P  4Q@
M %,?  !3)@  4R\  %,Y  !310  4U(  %-A  !3<@  4X<  %*<  !2L0
M4<H  %'G  !1] !9/@  3CX  $4^   ^/@  .#X  #!    I0@  (T0  !U'
M   72@  $DT   Y0   +4P  !E4"  !7!P  6 L  %D.  !:$0  6A4  %L:
M  !<(0  7"H  %PT  !</P  7$T  %Q;  !<;   7($  %N7  !;K0  6L4
M %KD  !9\P!40@  2D(  $)"   \0@  -$,  "Q&   E20  'DP  !=/   2
M4P  #E8   I9   %6P   %X   !@!   80@  &(,  !C#@  9!$  &46  !F
M'   9R,  &<M  !G.0  9T8  &=5  !G9@  9WH  &:1  !EJ   9<   &3>
M  !D\ !/1@  1T8  $!%   W1P  +TH  "9-   ?40  &%4  !)9   -7
M"&    )C    9@   &@   !J    :P0  &P(  !M#   ;PX  ' 2  !R%P
M<QT  '0F  !T,@  =#\  '1.  !S7P  ='(  '.*  !RH0  <;@  ''4  !P
M[ !,2@  14H  #M+   R3@  *5(  "!6   86P  $E\   UD   ':    &L
M  !O    <@   '4   !V    =P   'D"  !Z!@  ? H  'X.  " $0  @A8
M (0>  "$*0  A#8  (1%  "$5@  @VH  (.!  ""F0  @;$  (#)  " Y0!*
M3@  /U   #53   K5P  (EP  !EB   29P  #&P   5Q    =0   'D   !]
M    @0   (,   "%    A@   (@   ")    BP0  (T(  "/#0  DA   )06
M  "6(   EBP  )8[  "63   E6   )5V  "4D   DZ<  )*]  "2U0!$50
M.5D  "]=   D8P  &FD  !)O   ,=0  !'L   "     A0   (D   "-
MD0   ),   "4    E@   )@   ":    G    )X   "@!@  H@L  *40  "H
M%P  J2,  *DQ  "I0P  J58  *AM  "FAP  IYX  *:S  "EQP ^7@  ,F,
M "=J   =<   $W@   Q_   #A0   (L   "1    E@   )L   "?    H@
M *0   "E    IP   *D   "K    K0   +    "R    M0(  +<)  "[$
MOA@  +XF  "^.   ODL  +UA  "\>@  NY0  +JI  "ZN0 W:@  *W   "!X
M   6@   #8@   6/    E@   )P   "B    IP   *P   "P    LP   +8
M  "W    N0   +L   "]    OP   ,(   #%    R    ,H   #."   TA
M -4;  #5+   U$   -17  #3;@  U(8  -2;  #3JP#_    _P   /\   #_
M  4 _P . /\ %0#\ "  ^0 J /8 - #Q #T [0!& .D 30#F %, Y !9 .$
M7@#> &, W !H -D ;@#5 ', TP!Y -  @ #. (@ RP"1 ,D G #& *< Q "W
M ,( S #  .P OP#_ +X _P"] /\ MP#_ +( _P#_    _P   /\   #Z  $
M\P + .T $@#H !L Y0 E .0 +@#? #@ V !  -( 1P#. $X RP!4 ,@ 60#&
M %X Q !C ,( 9P#  &T OP!S +T >@"[ ($ N0"+ +8 E0"T *$ L@"O +
MP@"N ., K@#Z *P _P"M /\ J0#_ *8 _P#_    _P   /(   #F    W0 '
M -( #@#- !8 R@ @ ,@ *0#% #( P  Z +P 0@"Y $@ MP!. +4 4P"S %@
ML0!= +  8@"N &< K !L *H <P"I 'L IP"$ *4 C@"C )H H0"H )\ N0">
M -( G0#R )P _P"= /\ G #_ )D _P#\    [@   -T   #,    P0 " +H
M# "V !( L@ : +  (P"O "P K0 T *D / "F $( I !( *( 30"@ %( G@!7
M )T 6P"< &  F@!F )D ; "7 '0 E0!] ), AP"1 ), D "A (X L0"- ,8
MC #H (L _0", /\ C #_ (P _P#M    V    ,4   "W    K    *8 " "A
M  X GP 5 )T '@"; "8 F@ N )< -0"5 #P DP!" )$ 1P"0 $P C@!1 (T
M50"+ %H B@!@ (D 9@"' &T A0!V (0 @ "" (P @ ": '\ J0!] +P ? #<
M 'P ]0!\ /\ ? #_ 'P _P#9    P0   +$   "D    G    )0  P"0  P
MC0 1 (L & ") "  B0 H (< +P"% #8 @P \ (( 00"  $8 ?P!+ 'T 3P!\
M %0 >P!: 'D 8 !X &< =@!P '4 >@!S (8 <0"3 '  H@!O +0 ;@#, &X
M[0!N /X ;@#_ &X _P#$    KP   *    "4    C    (8   "!  @ ?@ .
M 'P % ![ !L >0 B '@ *0!W #  =0 V '0 .P!R $  <0!% '  2@!O $\
M;0!4 &P 6P!K &( :0!J &@ = !F (  90". &, G0!B *T 80#" &$ Y !A
M /@ 80#_ &$ _P"T    H    )$   "&    ?@   'D   !U  , <0 + &\
M$ !M !8 ;  = &L ) !K "H :0 P &@ -@!F #L 90!  &0 10!C $H 80!/
M &  5@!? %T 70!E %P ;P!: 'H 60"( %@ F !7 *@ 5@"[ %8 V !6 /$
M5@#_ %8 _P"H 0  E 4  (4'  !Z!P  <@8  &P$  !I 0  9P ' &0 #0!C
M !$ 80 8 &  'P!? "4 7@ K %T , !; #8 6@ [ %D 0 !8 $4 5P!+ %8
M40!5 %@ 4P!A %( :@!0 '8 3P"$ $X DP!- *0 3 "V $P S0!, .L 3 #Z
M $P _P"="0  BPL  'P-  !P#0  : T  &(,  !?"@  708! %P!"0!:  X
M6  3 %< &0!6 "  50 F %, *P!2 #$ 40 V %  .P!/ $$ 3@!' $T 30!+
M %4 2@!= $D 9P!' ', 1@"  $4 D !$ *$ 0P"R $, R !# .8 0P#U $,
M_P"5#0  @P\  '00  !I$0  8!$  %H0  !6#@  5 T  %,*! !3!@L 40,0
M $\!%0!. 1L 3 $A $L!)P!* BP 20(R $@"-P!' ST 10-# $0#2@!#!%$
M0@1: $ %9  _!7  /@9^ #T&C@ \!Y\ .P>Q #H'Q@ Z!^, .@?S #H(_ ".
M$   ?!(  &X4  !B%0  6A4  %04  !0$P  31$  $L.  !+#08 2@H, $D(
M$0!'"!8 10@= $0((P!"""@ 00DN $ ),P _"3D /@I  #T*1P \"D\ .@M8
M #D+8P X#&\ -@Q^ #4,C@ T#9\ ,PVQ #(-QP R#>, ,@WT #(-_@"($P
M=Q4  &D7  !>&   51@  $\8  !*%@  1Q4  $43  !#$ ( 0PX( $(-#@!
M#1( /PT8 #T-'P \#20 .PTJ #D-,  X#C< -PX] #8.10 U#DT ,P]7 #(/
M8@ Q$&X +Q!] "X0C@ M$:  +!&R "L1R  K$>8 *Q'V "P1_P"#%@  <AD
M &0:  !9&P  41L  $L;  !&&@  0A@  #\7   ^%   /!($ #L1"@ Z$!
M.! 5 #<0&P U$2$ -!$G #,1+0 R$3, ,!$Z "\20@ N$DL +1-4 "L37P J
M%&P *11[ "@4C  G%9X )A6P "45Q@ E%>0 )17V "85_P!^&0  ;AL  & =
M  !6'@  31X  $<>  !"'0  /AP  #H:   X&   -Q8  #45!P T% T ,A02
M # 4%P O%!T +10C "P5*@ K%3  *A4W "D6/P H%D@ )Q=2 "8870 D&&H
M(QEY "(9B@ A&9P (!FO !\9Q  ?&>( (!GT " 9_P!Z&P  :AX  %T?  !3
M(   2B   $0@   ^'P  .AX  #<=   T'   ,AD  # 9!  N& L +!@0 "H8
M%  I&!H )Q@@ "89)@ E&2T )!HU ",:/0 B&T8 (1M0 " <6P ?'6@ 'AUW
M !T=B  <'IL &QZM !H>PP :'N  &AWS !L=_P!W'0  9R   %HA  !0(@
M2"(  $$B   [(@  -R$  #,@   P'P  +1T  "L=   H'0@ )AT. "4=$@ C
M'1< (1T= "$=)  @'BH 'QXR !X?.@ ='T, '"!- !LA60 :(68 &2%U !@B
MAP 7(ID %B*L !4BP0 5(M\ %2'R !8A_@!S(   9"(  %<C  !-)   124
M #XD   Y)   -",  # B   L(@  *2$  "8A   D(08 (B$, " A$  >(14
M'2(; !LB(0 ;(B@ &B,O !DC.  8)$$ %R1+ !8E5P 5)60 %"9S !,FA0 2
M)I@ $2:K !$FP  0)MT $27Q !(E_0!P(@  820  %0F  !*)@  0B<  #PF
M   V)@  ,24  "TE   I)   )B0  "(E   ?)0, '28* !LF#@ 9)Q( &"<8
M !<G'P 6)R4 %2@M !0H-0 3*3X $BE) !$I50 1*F( $"IQ  \J@P .*I8
M#BJI  TJO0 -*M< #2KN  XI^P!L)   728  %$H  !(*   0"D  #DH   T
M*   +R@  "LG   G)P  (B@  !XI   ;*@  &"L' !8K#0 4+!$ $RP6 !(L
M'  1+2, $"TJ ! M,@ /+CP #BY&  TN4@ -+E\ #"]N  LO?P *+Y( "2^E
M  DNN0 (+M  "2[I  HN]P!H)P  6BD  $XJ  !%*P  /2L  #<K   Q*@
M+2H  "DJ   D*@  ("L  !LM   8+@  %2\$ !(Q"@ 0,@X #S(3  XR&0 -
M,B  #3(G  PR+P +,S@ "C-"  DS3@ (,UL !C1J  4T>P $,XX  S.B  (S
MM@ ",\T  S/G  0R\P!D*@  5BP  $LM  !"+0  .BT  #0M   O+   *RP
M "8L   B+0  '2\  !DQ   5,@  $C0#  \V"0 ,. T "C@1  DX%@ (.!T
M!S@D  8X+  $.#0  S@^  (Y2@  .5<  #EE   Y=P  .8L  #B?   XLP
M.,H  #CF   W\@!?+0  4BX  $@O   _,   ."\  #(O   M+P  *2\  "0P
M   ?,0  &C,  !4U   2-P  #SD#  P["  (/0T !3X0  ,^%   /AH  #XA
M   ^*   /C$  #\[   _1@  /U,  #]A   _<P  /X<  #Z<   ^L   /<<
M #WD   ]\@!:,   3C(  $0R   \,@  -3(  # Q   K,0  )C(  " T   ;
M-@  %C@  !([   //0  ##\#  A!"  $0PP  $,.  !$$@  118  $4=  !%
M)   12T  $8V  !&0@  1DX  $9=  !&;@  18(  $68  !$K0  1,0  $/C
M  !#\@!5-   2C4  $$U   Y-0  ,S0  "XT   H-0  (C<  !TZ   7/
M$C\   ]!   ,1   "$8!  -(!@  20H  $H-  !+$   3!0  $T9  !.(
M3B@  $XR  !-/0  3DH  $Y8  !-:0  37T  $R4  !,J@  2\$  $OA  !*
M\@!0.   1C@  #TX   W.   ,3<  "HY   D.P  'CT  !A    30P  #T8
M  M)   '2P   DX   !0!   40@  %(+  !3#@  5!$  %45  !6&P  5R,
M %<L  !7.   5T0  %=2  !68P  5G<  %:.  !5I0  5+T  %/=  !3\ !+
M/   0CP  #L[   U.P  +3P  "8_   ?0@  &44  !-(   .2P  "T\   51
M    5    %<   !8 0  6@4  %L(  !<#   70X  %\1  !@%@  8AT  &(F
M  !B,0  8CX  &%,  !A70  87   &"(  !@H   7[<  %[4  !=[@!'0
M/S\  #H_   Q0   *4,  "%&   :2@  $TX   Y1   *50  !%@   !;
M7@   &$   !C    9 $  &4$  !G"   : L  &H.  !L$@  ;A<  &\@  !O
M*@  ;S8  &Y%  !N50  ;F@  &U_  !MF   ;+   &O*  !JZ !$1   /D,
M #5$   K1P  (TL  !M/   35   #E@   A<   "8    &0   !G    :P
M &T   !O    <    '(   !T @  =08  '<*  !Y#@  ?!(  'X8  !_(@
M?RX  '\]  !^30  ?6$  'UW  !\D   >Z@  'K   !YWP!#1P  .4D  "],
M   E4   '%4  !1;   .8   !V4   !J    ;@   '(   !V    >0   'P
M  !^    ?P   ($   "#    A0   (<#  "*"   C T  (\1  "2&0  DB4
M )(S  "21   D5<  )!M  "/A@  CI\  (VU  ",S0 ]3@  ,E$  "A6   >
M7   %6(   YH   ';@   '0   !Y    ?@   ((   "&    B0   (P   ".
M    D    )(   "4    E@   )@   ";    G@8  *$,  "D$0  IAL  *8I
M  "F.@  I4T  *5B  "D>P  HY0  *&K  "AOP V5P  +%P  "%B   7:0
M#W    =W    ?@   (0   "*    CP   )0   "8    FP   )X   "?
MH@   *0   "F    J    *L   "M    L    +,$  "W#   NQ(  +L?  "[
M,   NT,  +I8  "Y<   MXL  +>A  "WLP P8@  )6D  !IP   0>   "8
M  "(    CP   )8   ";    H0   *8   "J    K@   +    "Q    M
M +8   "X    NP   +T   #     PP   ,<   #+ P  SPP  -,5  #2)0
MTC@  -%.  #090  SWX  ,V6  #,J0#_    _P   /\   #_  , _P + /P
M$0#Y !L ]P E /, +P#N #@ Z0!  .8 2 #B $X WP!4 -P 60#9 %X U0!C
M -, : #0 &T S@!S ,L >@#( (( Q@", ,, EP#  *, O@"R +P R "Z .H
MN0#_ +@ _P"Q /\ J@#_ *< _P#_    _P   /L   #V    [0 ' .< #P#B
M !8 WP @ -X *0#9 #, T0 [ ,P 0@#( $@ Q0!. ,( 4P#  %@ O@!= +P
M8@"Z &< N0!M +< = "U 'L L@"% +  D "N )P K "J *D O0"G -X I@#Y
M *4 _P"C /\ G0#_ )L _P#]    ]@   .L   #?    T0 # ,H # #% !(
MPP ; ,  ) "^ "P N0 U +8 / "S $, L !( *X 3@"L %( JP!7 *D 7 "G
M &$ I@!G *0 ;0"B '0 H !] )X B "< )4 F@"C )@ M "6 ,T E0#Q )0
M_P"5 /\ D #_ (X _P#S    Y@   -$   #"    N    +$ " "M  \ J@ 6
M *@ '@"H "< I@ O *( -@"? #P G0!" )L 1P"9 $P EP!1 )8 50"4 %H
MDP!@ )$ 9@"0 &X C@!V (P @0"* (T B "; (8 K "% ,$ A #F (, _0"$
M /\ @P#_ ($ _P#D    RP   +H   "L    H@   )P ! "8  P E@ 1 )0
M&0"3 "$ D@ H (\ , "- #8 BP \ (D 00"( $8 A@!+ (4 3P"$ %0 @@!:
M ($ 8 !_ &< ?@!O 'P >@!Z (8 > "4 '< I !U +< = #4 ', ] !T /\
M= #_ '0 _P#+    M@   *8   ":    D@   (H   "&  @ @P . ($ % "!
M !L @  C '\ *@!] #  >P V 'H .P!X $  =P!% '4 20!T $X <P!4 '$
M6@!P &$ ;@!I &T <P!K '\ :0"- &@ G0!G *X 9@#' &4 Z@!F /\ 9@#_
M &< _P"X    I    )4   "*    @0   'P   !V  0 =  , '( $ !Q !8
M<  = '  ) !N "H ;0 P &L -0!J #H :0 _ &@ 1 !G $D 90!. &0 5 !C
M %L 80!C &  ;0!> 'D 70"' %L E@!: *@ 60"] %D WP!9 /@ 6@#_ %H
M_P"H    E0   (<   ![    <P   &X   !J  $ 9P ( &4 #@!D !( 8P 8
M &, 'P!B "4 80 J %\ , !> #4 70 Z %P /@!; $0 60!) %@ 3P!7 %8
M5@!> %0 : !3 ', 40"! %  D0!/ *( 3@"U $X T !. /  3@#_ $\ _P"<
M    B0   'L#  !P P  : ,  &(!  !?    70 $ %L "P!9  \ 6  4 %<
M&0!7 "  5@ E %4 *@!3 #  4@ T %$ .0!0 #\ 3P!$ $X 2P!- %( 2P!:
M $H 8P!) &\ 1P!\ $8 C !% )T 10"P $0 QP!$ .@ 1 #Z $4 _P"2!
M@ <  '$*  !F"@  7@H  %D)  !5!P  5 0  %( !P!0  P 3P 0 $X %0!-
M !L 3  @ $L )@!* "L 20 P $@ -0!' #H 1@!  $4 1@!# $X 0@!6 $$
M7P!  &L /@!X #T B  \ )D / "K #P P0 [ .  .P#T #L _P")"@  > P
M &H.  !?#@  5PX  %$.  !-#   2PL  $H( @!)! D 2  - $8 $0!% !8
M1  < $, (0!" "8 00 K #\ ,0 ^ #8 /0 \ #P 0P [ $H .@!2 #D 7  X
M &@ -@!U #4 A0 T )8 - "H #, O  S -@ ,P#O #, ^P""#0  <0\  &00
M  !9$0  41$  $L1  !'$   1 X  $(-  !!"P4 00<+ #\%#@ ^ Q( / (8
M #L"'0 Z R( .0,H #@#+0 W S( -@0Y #4$/P T!4< ,P50 #$&6@ P!F8
M+P=S "X'@P M!Y4 + >G "L'N@ K!]( *P?K "L']P!]$   ;!$  %\3  !4
M%   3!0  $84  !"$P  /A(  #P0   Z#@$ .@T& #H*#  X"1  -@@4 #4(
M&0 T"1\ ,@DD #$)*0 P"2\ +PHV "X*/0 M"D4 + M. "L+60 I#&4 * QS
M "<,@P F#94 )0VG "0-NP C#=( (PWK ",-]P!X$@  :!0  %L6  !1%P
M2!<  $(6   ]%@  .14  #<3   U$0  ,Q # #,."  R#0T , T1 "\-%@ M
M#1L + TA "L-)P J#2T *0XT "@..P G#D0 )0Y. "0/60 C$&4 (1!S " 0
MA  ?$)8 'A"I !T0O0 <$-@ '1#N !T0^0!S%   9!8  %<8  !-&0  11D
M #\9   Z&   -1<  #(6   P%0  +A,  "T1!  L$ H *Q . "D0$@ H$!@
M)A > "40)  D$"H (Q$Q "(1.0 A$4( (!)+ !X25@ =$V, '!-Q !H3@@ 9
M%)4 &!2G !<4NP 7$]0 %Q/N !@3^@!P%@  8!D  %0:  !*&P  0AP  #P;
M   V&P  ,AH  "\9   L&   *A8  "@4 0 F$P< )1,, ",3$  B$Q4 (!,:
M !\3(0 >%"< '10N !P5-@ ;%3\ &A9) !D65  8%V$ %A=P !48@0 4&),
M$QBF !(8N@ 2%]( $A?L !,7^@!L&0  71L  %$=  !''0  /QX  #D=   T
M'0  +QP  "L;   H&@  )AD  "08   B%P0 (!<* !X7#@ <%Q( &A<7 !D8
M'@ 9&"0 &!DL !<9-  6&CT %1I' !0;4@ 3&U\ $AQN !$<?P 0')( $!RE
M  \<N0 .'-  #AOJ  \;^ !I&P  6AT  $X?  !%'P  /2   #8?   Q'P
M+1X  "D=   E'0  (QP  " ;   =&P$ &QL' !D<#0 7'!  %AP5 !4<&P 4
M'2( $QTI !(>,0 1'CH $1]% ! ?4  /(%T #B!L  T@?  -((\ #""B  L@
MM0 +(,H "R#E  P?] !E'0  5Q\  $PA  !"(0  .B$  #0A   O(0  *B
M "8?   C'P  (!X  !T>   9(   %B $ !0@"P 2(0X $2$3 !$B&0 0(A\
M#R(F  XC+P .(S< #2-!  PD30 +)%D "B1G  DD>  ()(L !R2>  <DL0 &
M),< !B/C  <C\0!B'P  5"$  $DC  ! (P  .",  #(C   L(P  *"(  "0A
M   A(0  'B$  !HA   6(P  $R0# !$E"  /)@T #B<1  TG%@ ,)QT "R<C
M  HG*P )*#0 ""@^  <H20 &*%4 !2ED  0I=  #*8<  BF;  $HKP  *,4
M 2CA  $G\ !>(@  420  $8E   ])0  -24  "\E   J)   )B0  "(C   ?
M(P  &R0  !@E   4)@  $2@#  \I"  ,+ P "BP0  @L%  '+!H !BPA  4L
M*  #+3   BTZ  $M10  +5(  "Y@   N<0  +80  "V9   MK0  +,(  "S@
M   L\ !:)   328  $,G   Z)P  ,R<  "TG   H)@  )"8  "$F   =)@
M&2<  !4I   1*P  #RP#  TN!P ), P !C$.  ,Q$@ !,A<  #(>   R)0
M,BT  #(V   S0@  ,TX  #-=   S;0  ,X$  #*6   RJP  ,<$  #'?   Q
M\ !6)P  2BD  #\J   W*@  ,"H  "LI   G*   (R@  !XI   :*@  %BP
M !(N   /,   #3$"  HT!P %-0L  C8.   W$   .!0  #@:   X(@  ."H
M #DS   Y/@  .4H  #E9   Y:0  .7T  #B3   XJ   -[\  #?>   V\ !1
M*P  1BP  #PL   T+   +BP  "HK   E*P  ("P  !LM   7+P  $S$  ! S
M   --0  "3<"  4Z!@ !.PH  #P-   ]#P  /A(  #\7  ! '@  0"4  $ O
M  ! .@  0$8  $!4  ! 90  /W@  #^/   ^I@  /KT  #W<   ]\ !-+@
M0B\  #DO   R+P  +2X  "@N   B+P  '3   !@R   3-0  $#<   PZ   )
M/   !3X   !!!   0@@  $,+  !$#0  1A   $<4  !(&0  2"$  $@J  !(
M-0  2$$  $A/  !(8   1W,  $>*  !&H@  1;D  $79  !$\ !(,@  /C(
M #8R   P,0  *S$  "4R   ?-   &38  !,Y   0/   ##\   A"   #1
M $8   !( @  2@4  $L(  !,"P  3@X  $\1  !1%0  4AP  %(E  !2,
M4CP  %%*  !16@  46T  %"$  !/G0  3K4  $W2  !-[@!#-@  .S8  #0U
M   O-   )S4  "$X   :.P  %#X  !!!   ,1   !T<   )*    30   $\
M  !1    4P(  %0%  !5"   5PL  %D.  !;$0  71<  %T?  !=*@  738
M %Q$  !<5   6V<  %M^  !:EP  6:\  %C+  !7Z@ _.0  .#D  #,X   K
M.0  (SP  !P_   50P  $$<   M*   %3@   %$   !4    5P   %H   !<
M    70   %\   !@!   8@<  &0+  !F#@  :!(  &L9  !K(P  :BX  &H\
M  !J30  :5\  &AU  !GCP  9J@  &7"  !DXP ]/0  -SP  "X]   E0
M'40  !9)   030  "E$   15    6@   %T   !@    8P   &8   !H
M:@   &L   !M    ;P(  '$&  !T"@  =@X  'D3  ![&P  >R<  'HU  !Y
M10  >%D  'AM  !WA@  =I\  '6W  !TT@ \00  ,D(  "A%   @2@  %TX
M !!4   *60   EX   !C    9P   &L   !O    <@   '4   !W    >0
M 'L   !]    ?P   ((   "$ P  APD  (H.  ".$P  CQX  (XK  "..P
MC4X  (MC  "*?   BI4  (BM  "'Q0 V1P  +$L  ")/   950  $%L   IA
M   !9P   &T   !R    =P   'L   !_    @P   (8   "(    B@   (T
M  "/    D0   )0   "7    F@$  )T'  "A#0  I10  *0A  "D,0  HT0
M *)9  "@<   GXL  )VB  "=MP P4   )54  !M;   28@  "VD   %P
M=P   'T   "#    B    (T   "1    E0   )@   ":    G    )\   "A
M    HP   *8   "I    K    +    "T!P  N X  +H8  "Z)P  N3D  +A.
M  "W90  MGX  +66  "SJP I6P  'F(  !1I   ,<0   GD   "!    B0
M (\   "6    FP   *    "D    J    *L   "L    KP   +(   "T
MM@   +D   "\    P    ,0   #(    S0<  -(0  #2'0  T2\  -!$  #/
M6P  S7,  ,N-  #*H0#_    _P   /L   #Z    _  ( /@ #P#U !< ]  @
M /$ *@#K #, Y@ [ .( 0P#> $D V@!/ -8 5 #3 %D T !> ,X 8P#+ &@
MR0!N ,8 =0## 'T P0"& +X D@"[ )X N0"N +8 PP"T .@ LP#_ *\ _P"E
M /\ G@#_ )L _P#]    ]P   /(   #P    YP # .$ # #< !( V  ; -8
M) #2 "T S  V ,8 /0#" $, OP!) +P 3@"Z %, N !8 +8 70"U &( LP!G
M +$ ;@"O '8 K !_ *H B@"H )< I0"F *, N0"A -D H #Y )X _P"8 /\
MD@#_ (\ _P#S    [    .,   #3    R    ,$ "0"]  \ NP 6 +D 'P"W
M "< LP O *\ -P"L #T J@!# *@ 2 "F $T I !2 *, 5@"A %L GP!A )X
M9P"< &\ F@!X )< @P"5 )  DP"> )$ L "0 ,@ C@#P (T _P"* /\ A0#_
M (( _P#G    W0   ,8   "X    K@   *@ ! "E  P H0 2 *$ &0"@ "(
MGP I )L , "8 #< E@ ] ), 0@"2 $< D !+ (\ 4 "- %4 C !: (H 80"(
M &@ AP!P (4 >P"# (@ @0"6 '\ IP!] +P ? #C 'P _0!\ /\ > #_ '8
M_P#6    P    *\   "C    F0   ),   "/  D C0 . (L % "* !P B@ C
M (@ *@"% #  @P V (( .P"  $  ?P!% 'X 2@!\ $\ >P!4 'H 6@!X &$
M=@!I '4 <P!S (  <0". &\ GP!N +( ;0#/ &P ] !L /\ :P#_ &D _P#
M    JP   )L   "/    AP   (    !\  0 >@ , '@ $0!X !< >  > '<
M) !U "H <P P '$ -0!P #H ;@ _ &T 1 !L $D :P!. &H 5 !H %L 9P!C
M &4 ;0!D '@ 8@"' &  EP!? *H 7@#" %X Z0!> /\ 7@#_ %T _P"L
MF0   (H   !_    =P   '$   !M    :@ ( &D #@!H !( 9P 8 &< 'P!G
M "4 90 J &, +P!B #0 80 Y &  /@!? $, 7@!( %T 3@!; %4 6@!= %@
M9P!7 '( 50"! %0 D0!3 *, 4@"X %$ W !1 /D 4@#_ %( _P"=    BP
M 'P   !Q    :0   &0   !@    7@ % %P "P!;  \ 6P 4 %H &0!: !\
M60 E %< *@!6 "\ 50 T %0 . !3 #T 4@!# %  20!/ %  3@!8 $T 8@!+
M &T 2@!Z $D BP!( )T 1P"Q $< S !& /  1P#_ $< _P"0    ?@   '
M  !F    7@   %D   !6    4P ! %( " !0  T 3P 0 $\ %0!. !H 3@ @
M $T )0!, "H 2@ N $D ,P!( #@ 1P ^ $8 1 !% $L 1 !3 $, 70!! &@
M0 !U #\ A0 ^ )< /0"K #T PP ] .8 /0#[ #X _P"'    =0,  &@&  !=
M!P  508  % &  !,!   2@$  $D ! !'  H 1@ . $4 $0!% !8 1  ; $,
M( !" "4 00 J $  +P _ #0 /@ Z #T 0  [ $< .@!/ #D 60 X &0 -P!Q
M #8 @0 U ), - "F #0 NP T -T - #U #4 _P!^!@  ;0D  & +  !6#
M3@P  $@+  !$"@  0@@  $ % 0 _ 0< /@ + #T #@ \ !( .P 7 #L '  Z
M "$ .0 E #< *@ V #  -0 U #0 /  S $, ,@!, #$ 50 P &  +P!M "X
M?0 M (\ + "B "P M@ L -  + #N "P _ !W"@  9PP  %H.  !0#@  20X
M $,.   ^#0  .PP  #D+   X"0, -P4( #8"#0 U 1  -  3 #, &  R !T
M,0 B #  )P O "P +@ R "T .  L $  *P!) "H 4@ I %T * !K "<!>@ F
M 8P )0"? "4 L@ E ,H )0#H "4 ]P!R#0  8@X  %80  !,$0  1!$  #X1
M   Y$   -@\  #,.   Q#0$ , L% # ("@ O!@T +@41 "P$%  K QD *@,>
M "D#(P H!"D )P0O "8%-0 E!3T ) 5& ",&4  B!EP (0=I " '>0 ?!XL
M'@>= !X'L  =!L8 '0;C !T%\P!M#@  7A$  %(2  !($P  0!,  #H3   U
M$@  ,1$  "X0   L#P  *@X# "H-!P I"PL * D. "<)$0 E"!8 ) @; ",)
M(  B"28 (0DL " *,P ?"CL '@M$ !T+3P <#%L &PQI !H,>0 8#(L & R>
M !<,L  6#,4 %@SA !8+\ !I$   6A(  $X4  !%%0  /14  #<5   Q%
M+1,  "H2   H$0  )A ! "00!  C#@@ (PT, "(,#P @#!, 'PP8 !X-'0 =
M#2, ' TJ !L-,@ :#CH & Y$ !<.4  6#UP %0]J !,0>P 2$(T $1"@ !$0
MLP 0#\D $ _D !$/\@!E$@  5Q0  $L6  !"%P  .A<  #07   O%@  *A4
M "<4   D$P  (A,  " 2 P >$08 '1 ) !P0#0 ;#Q  &1 5 !@0&P 7$"$
M%A H !41,  4$3D $Q%# !(23@ 1$EH $!)I ! 3>0 .$XP #A.>  T3L0 -
M$L4 #!+A  T2\0!B%   5!8  $D8   _&0  -QD  #$9   L&   *!<  "06
M   A%@  'Q4  !P4 @ :$P0 &1(& !<2"P 5$@X %!(2 !,3&  2$Q\ $1,F
M !$4+0 0%#8 #Q5!  X53  .%E< #19E  P7=0 +%X< "A>:  D6K0 (%L$
M"!;=  D5[@!?%@  41@  $8:   ]&@  -1L  "\:   J&@  )1D  "(8   ?
M&   '!<  !D6 0 7%@, %18$ !,6"0 1%@T $!<1  \7%@ .%QP #A@C  T8
M*@ ,&3, #!D\  L:1P *&E, "1IA  <;<0 &&X, !1N7  0:J@ #&K\  QG:
M  09[ !<&   3AH  $,<   Z'   ,QP  "P<   G'   (QL  " :   =&0
M&AD  !<8 0 5& ( $AD$ ! ;!P .&PP #1P0  P<$P +'!D "AP?  D=)P (
M'2\ !QXY  8>0P $'E   Q]>  (?;@ !'X   !^5   >J0  'KT  !W8   =
M[ !8&@  2QP  $$>   X'@  ,!X  "H>   E'0  (1P  !X<   ;&P  &!L
M !8; 0 3&P( $1P$  X>!P ,'PL "B .  @@$@ &(1< !2$=  0A)  "(BP
M 2(U   B0   (TT  "-:   C:P  (WX  ".3   BIP  (KP  "'7   A[0!5
M'0  2!\  #X@   U(   +B   "@@   C'P  (!X  !T=   :'0  %AT  !,>
M   1'P( #B $  TB!P *) L !B4-  0E$  ")A0  "8:   F(0  )RD  "<R
M   G/0  )TD  "A7   H9P  )WL  ">0   GI0  )KL  ";6   E[0!1(
M12$  #LB   R(@  +"(  "8A   B(0  'B   !L?   8(   %"   !$B   /
M(P  #24#  HF!@ &* H  RD-   K#P  +!(  "P7   L'@  +"8  "TO   M
M.0  +48  "U4   M9   +7<  "R-   LI   *[H  "O6   J[@!-(@  020
M #@D   P)   *20  "0C   A(@  '2(  !DB   5(P  $B0   \F   -*
M"BH"  8L!0 "+@D  "\+   P#@  ,A   #,5   S&P  ,R(  #,K   S-@
M,T(  #-0   S8   ,W,  #**   RH0  ,;@  ##6   P[P!))0  /B8  #0G
M   M)P  *"8  ",E   ?)   &R4  !8F   2*   $"H   TL   *+@  !C !
M  (R!   - <  #4*   W#   . X  #H2   Z%P  .A\  #HG   Z,@  .CX
M #I,   Z7   .F\  #F&   XG@  .+8  #?4   V[P!$*0  .BD  #$I   K
M*0  )B@  "(G   =*   &"D  !,K   0+@  #3    DR   %-0   3<    Y
M @  .P4  #P(   ^"P  /PT  $$0  !#%   0QL  $,C  !#+@  0SD  $-'
M  !"5P  0FH  $&!  ! F@  /[(  #[/   ^[P _+   -BP  "\L   J*P
M)2H  !\K   9+0  %"\  ! R   --0  "#@   0Z    /    #\   !!
M0P(  $4%  !&"   2 L  $H.  !,$0  318  $T>  !-*   330  $Q"  !,
M40  2V0  $M[  !*E   2:T  $C*  !'[  [,   ,R\  "TO   H+0  (B\
M !LQ   5-   $#<   TZ   (/0   D    !#    1@   $@   !*    3
M $X!  !/!   40<  %,+  !5#@  6!(  %D9  !8(@  6"X  %<\  !72P
M5EX  %9S  !5C0  5*<  %+"  !2Y@ X,P  ,3(  "PQ   E,@  '34  !8X
M   1/   #$    =$    1P   $H   !-    4    %,   !5    5P   %D
M  !:    7 ,  %X'  !A"P  9 X  &83  !G'   9B<  &8T  !E1   9%<
M &1K  !BA0  89\  &"Y  !>W  U-P  ,#4  "@W   @.@  &#T  !%"   ,
M1@  !DH   !/    4P   %8   !9    7    %\   !A    9    &4   !G
M    :0   &P!  !N!@  <0L  '0/  !W%0  =R   '8M  !V/0  =4\  '1C
M  !S>P  <I4  '"O  !OR0 U.@  *SL  "(_   :0P  $D@   Q-   %4@
M %<   !<    8    &0   !H    :P   &X   !Q    <P   '4   !W
M>@   'P   !_    @@0  (8*  "*#P  C!<  (LD  "*,P  B44  (=;  "&
M<@  A8L  (.E  ""O  O0   )40  !Q)   33@  #50   1:    80   &8
M  !K    ;P   '0   !Y    ?0   (    "#    A0   (<   "*    C
M (\   "2    E@   )D"  ">"0  HA   *(:  "A*0  H#L  )]0  "=9P
MFH$  )J9  "9KP I20  'TX  !54   .6P  !6(   !I    <    '<   !]
M    @@   (8   "+    CP   ),   "5    EP   )H   "=    H    *,
M  "F    J@   *X   "R    MPH  +L1  "Z'P  N3   +=%  "U7   M'0
M +&.  "OI  B5   &%L  !!B   ':@   ',   ![    @@   (D   "0
ME0   )H   "?    HP   *8   "H    JP   *X   "P    LP   +8   "Z
M    O0   ,(   #'    S $  -,+  #4%0  TR8  -$Z  #040  S6@  ,N!
M  #*E@#\    ]@   /(   #Q    \P % /0 # #R !, \  < .T )0#H "X
MX@ V -X /@#9 $0 U !* -$ 3P#. %0 RP!9 ,D 7@#& &, Q !I ,$ < "^
M '@ O "! +D C0"V )H LP"K +$ P "O .8 K@#_ *4 _P": /\ E #_ (\
M_P#T    [    .@   #G    WP   -D "0#2 !  SP 7 ,\ ( #, "@ Q@ P
M ,  -P"\ #X N0!$ +< 20"U $X LP!3 +$ 5P"O %T K0!B *L :0"I '$
MIP!Z *4 A0"B ), H "B )T M@"; -0 F0#Y )8 _P"- /\ B #_ (0 _P#H
M    WP   -D   #)    OP   +@ ! "U  T LP 2 +$ &@"P "( K0 J *D
M,0"F #@ I  ] *( 0P"@ $@ G@!, )P 40"; %8 F0!< )< 8@"5 &D DP!R
M )$ ?0"/ (L C0": (L K ") ,4 B #N (8 _P!_ /\ >@#_ '@ _P#9
MS0   +L   "N    I0   )\   "<  D F0 / )D %0"9 !T F  D )0 *P"1
M #$ C@ W (P / "+ $$ B0!& (@ 2P"& %  A0!5 (, 6P"" &( @ !K 'X
M=0!\ (( >@"2 '@ HP!W +D =@#@ '4 _P!R /\ ;@#_ &P _P#'    M0
M *4   "9    CP   (D   "%  0 A  , (( $0"" !< @@ > (  )0!^ "L
M?  Q 'H -@!Y #L =P!  '8 1 !U $D <P!/ '( 50!P %P ;P!D &T ;@!L
M 'H :@"* &@ FP!G *\ 9@#, &4 ]0!D /\ 80#_ &  _P"T    H    )
M  "%    ?0   '<   !S    <  ( &\ #@!O !( ;P 8 &\ 'P!M "4 :P J
M &D , !H #0 9P Y &8 /@!E $, 8P!( &( 3@!A %4 7P!> %X 9P!< ',
M6P"" %D DP!8 *8 5P"_ %< Z@!7 /\ 5@#_ %0 _P"A    C@   '\   !U
M    ;    &@   !D    80 $ &  "P!?  \ 7P 3 %\ &0!? !\ 70 E %P
M*@!; "\ 60 S %@ . !7 #T 5@!# %4 20!3 %  4@!8 %$ 80!0 &T 3@![
M $T C !, )\ 2P"U $H W !* /H 2@#_ $H _P"2    @    '(   !G
M7P   %H   !7    50 ! %, !P!2  P 4@ 0 %( % !2 !H 40 ? $\ ) !.
M "D 30 N $P ,P!+ #@ 2@ ] $D 0P!( $H 1@!2 $4 7 !$ &< 0P!U $(
MA@!! )@ 0 "N $  RP _ /( 0 #_ $  _P"%    =    &<   !=    50
M $\   !,    2@   $@ ! !'  H 1P - $8 $0!& !4 1@ : $4 'P!$ "0
M0P I $( +0!! #, /P X #X /@ ] $4 / !. #L 5P Z &( .0!O #@ @  W
M ), -@"G #8 P  V .@ -@#^ #8 _P!\    :P   %X"  !4 P  30,  $<#
M  !# 0  00   #\  0 ^  < /0 + #T #@ \ !$ /  6 #P &@ Z !\ .0 D
M #@ *0 W "X -@ S #4 .@ T $$ ,P!) #( 4P Q %X , !K "\ >P N (X
M+0"B "T N  M -T +0#X "X _P!S 0  9 4  %<'  !-"   1@@  $ (   [
M!P  . 4  #<#   V  0 -0 ( #0 #  T  \ -  2 #, %@ R !L ,0 @ #
M)  O "D +@ O "T -@ L #T *P!% "H 3P I %H * !G "< =P F (D )@"=
M "4 LP E ,\ )0#P "8 _P!M!@  7@D  %(+  !(#   0 P  #H+   V"P
M,@H  # (   N!@( +@,& "T "@ L  T +  0 "L $P J !< *0 < "@ (  G
M "4 )@ K "4 ,@ D #D (P!" "( 2P B %< (0!D "  <P ? (4 'P"9 !X
MK@ > ,< '@#I !\ ^@!H"0  60P  $T-  !##@  / X  #8.   Q#0  +0T
M "H,   H"P  )PD$ "8&"  F! L )0,. "0!$  D 10 (@$8 "$!'0 A "(
M(  H !\ +@ > 38 '0$_ !P!20 ; 50 &@%A !H!<  9 8( & "6 !@ J@ 8
M ,$ & #A !@ ] !C#   50X  $D/  ! $   .!   #(0   M#P  *0X  "8.
M   C#0  (@P# " +!@ @"0D 'P<, !X&#@ >!1$ ' 45 !L%&@ :!1\ &@4E
M !D%*P 8!3, %P8\ !8&1@ 6!E( %0=? !0';@ 3!X  $@>4 !(&IP 2!;P
M$@39 !(#[P!?#@  40\  $80   \$0  -1$  "\1   J$0  )A   "(0   @
M#P  '0X" !P-!0 :#0< &@L* !D*#0 8"1  %PD2 !8)%P 5"1P % DB !0*
M*0 3"C$ $@HZ !(+10 1"U$ $ Q?  \,;@ .#(  #@R4  T+IP -"[H #0K2
M  T*Z@!<#P  3A$  $,2   Z$P  ,A,  "P3   G$@  (Q$  !\1   <$
M&A " !@/!  6#@< %0X) !0-"P 3# T $@P0 !(,%  1#!H $0T@ ! -*  /
M#3  #@X[  T.1@ -#E$ # ]>  L/;0 *#W\ "0^3  D/I@ (#KD " [0  <.
MZ !8$0  2Q(  $ 3   W%   ,!0  "D4   E%   (1,  !T2   :$@  %Q$"
M !41!0 3$ < $A ) !$/"@ 0#@P #@X.  X/$@ -$!@ #1 >  P0)0 ,$"T
M"Q$V  H100 )$4T "!):  <2:@ &$GP !1*0  02I  #$;@  Q'/  (1Z !5
M$@  210  #X5   U%@  +18  "<6   B%0  'A0  !L4   8$P  %1(# !,2
M!0 2$0< $!$)  \1"@ -$0L #!(.  L2$0 *$A4 "1,;  D3(@ ($RH !Q0S
M  44/@ $%4H  Q58  (59P !%7H  !6.   5HP  %+<  !3/   3Z0!2%
M1A8  #L7   R%P  *Q<  "47   A%@  '!8  !D5   6% $ %!,$ !(3!@ 1
M$@@ #Q((  X3"0 ,% H "A4-  @6$  &%A, !189  07'P #%R<  A@P  $8
M.P  &4<  !E5   99   &7<  !F,   8H@  &+<  !?/   7Z@!/%@  0Q@
M #D9   P&0  *1D  ",9   ?&   &Q<  !@6   5%0( $Q4% !$4!@ 0% 8
M#A4'  P6"  *%PH !QD,  0:#@ "&Q(  1L6   ;'0  '"0  !PM   <.
M'40  !U2   =8@  '74  !V*   <H   '+8  !O0   :ZP!,&   0!H  #8;
M   M&P  )AL  "$:   =&0  &1D  !<8   4%P, $A8$ ! 7!  .%P0 #!D%
M  H:!P '' D  QT+   ?#0  (!   " 4   A&@  (2(  "$J   A-0  (D$
M ")/   B7P  (G(  "&(   AGP  (+8  !_1   ?[0!(&@  /1P  #,=   K
M'0  )!T  " <   <&P  &!H  !89 0 3&0$ $1D!  X: 0 ,' ( "AT#  <?
M!0 #(0@  "(*   D#   )@X  "82   F&   )Q\  "<G   G,@  )SX  "=+
M   G7   )VX  ":%   FG0  );0  "31   C[@!$'0  .1\  # ?   H'P
M(QX  !X=   ;'   &!L  !0<   1'   #AT   T?   *(0  !B(!  ,D!
M)@8  "@(   J"P  *PT  "T0   M%0  +1P  "TD   N+@  +CH  "Y(   M
M6   +6H  "V!   LF@  *[(  "K0   I[P! (   -B$  "TA   F(0  (2
M !T?   :'@  %AX  !(?   /(0  #2(   HD   &)@   B@    K @  +00
M "\&   P"0  ,@P  #0.   U$@  -1@  #4@   U*@  -38  #5#   U4P
M-&8  #1\   SE@  ,J\  #'-   P[P \(P  ,B0  "HD   D(P  ("(  !PA
M   7(0  $R,  ! E   -)P  "2D   4K   !+@   #     R    - $  #8$
M   X!@  .@D  #P-   ^$   /A0  #X<   ^)@  /C$  #X_   ]3@  /6$
M #QW   [D0  .JL  #G)   X[0 W)P  +R<  "@F   C)0  'R0  !DE   4
M)@  $"@   TK   )+@  !3     S    -0   #@    Z    /    #X!  !
M P  0@<  $0*  !&#0  21$  $D7  !((0  2"P  $<Z  !'20  1EL  $5Q
M  !$BP  0Z4  $+#  !!Z  T*@  +"H  "<H   B)P  '"@  !8J   1+0
M#3    DS   #-@   #D    \    /@   $$   !#    1@   $@   !*
M3 ,  $X&  !0"@  4PX  %03  !4'   4R<  %,T  !30P  4E4  %%J  !0
M@P  3YX  $VY  !,X  P+0  *RP  "8K   ?+   &"X  !(R   --0  "#D
M  (]    0    $,   !&    20   $P   !.    40   %,   !5    5P
M %D!  !<!@  7PH  &(.  !C%0  8Q\  &(L  !A/   8$X  %]B  !>>P
M7)8  %NP  !9SP O,   *B\  "(P   :,P  $S<   X[   (/P   40   !(
M    3    $\   !2    50   %@   !;    70   &    !B    9    &8
M  !I    ;04  ' +  !T$   =!@  ',E  !R-   <D4  '!9  !O<0  ;8L
M &NF  !JP  N,P  )34  !TX   4/   #D$   ='    3    %$   !5
M60   %T   !A    90   &@   !K    ;0   &\   !R    =    '<   !Z
M    ?@   (($  "&"P  BA$  (D<  "(*P  ACT  (12  "#9P  @8$  '^;
M  !^L@ I.@  (#T  !9"   /2   "$X   !4    6@   &    !D    :0
M &X   !R    =@   'H   !]    @    ((   "%    B    (L   ".
MD@   )8   "; P  H P  *(3  "@(0  GS,  )U'  ":7@  F'<  )>/  "5
MIP C0P  &4@  !%.   )50   %P   !C    :@   '$   !V    >P   (
M  "&    B@   (X   "1    DP   )8   "9    G    *    "C    IP
M *L   "P    M@0  +P-  "Z%P  N2@  +<\  "T4@  LFH  *^%  "MG  <
M3@  $U0   M<   !9    &P   !T    ?    (,   ")    CP   )0   ":
M    GP   *(   "D    IP   *H   "N    L0   +0   "X    O    ,$
M  #'    S0   -0%  #8$   U1X  -,Q  #02   S5\  ,MV  #(C@
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M^_S^______________________________________________________\
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MXN/DY>;GZ.GJZ^SM[N_P\?+S]/7V]_CY^OO\_?[_;69T,0     #!"$   $
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M@K&+PH"PC,* L(S"@+",PH"PC,* L(S"@+",PH"PC,* L(S"@+",PH"PC,*
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MA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:]\ 0%?C
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MP(JL<<"+K'' BZQQP(NL<<"+K'' BZQQP(NL<<"+K'' BZQQP(NL<<"+K''
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ML'ZDT;!^I-&P?J31_[@4#O^X'B?_M"I&]Z\V:=ZG0H_'FV*QQ)MRML*;?[G
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MB9#.LX>2T+*$E=*Q@IG3L8&>U*Z HM2L@*/2K("CTJR H]*L@*/2K("CTJR
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MUI.2H-:3DJ#6_;L1#?V\&2;^N21&]K0N:MRK.I+'H%RQQ*%HML&E<;J^IWK
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MB:N&RH>KALJ%JHC*@ZJ)RX&JB\N JHS+@*J,RX"JC,N JHS+@*J,RX"JC,N
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M"?^Q(Q[_KC$Z_ZD^6>VB2WG9FER7R)5RL,65?;7#EX6XP9>+N[^3C+V^CX[
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MQ+%ZK<2Q>JW$L7JMQ+%ZK<2Q>JW$_ZL:!?^K)1?_J30O_Z1"2OF?3V;HF5R
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M[))I>N&1<XK8CWR8T(Z$I,J.C*W&C9"TQ(J3M\.&E;C"A)BYP8&;NL%_G;O
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MO+R;B,*YE8K'M8V-SK"&EM2I@J#6H8*DT)V"J,N:@ZK(F8.MQ9>$K\*6A+#
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M\[8Y<.J_-WWCRC6'U-$WE;["2ZFPN6"UJ+1PO:.P?L*=K83'DJJ$RXBGALZ
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MHJ;-=*:HS7*IJ<QQK:K,<+*KRW"VJ\MOO*O(<,"KQ'' JL1QP*K$<<"JQ''
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MM+J*B[2ZBHNTNHJ+M+J*B[2Z_YP0 ?^A)@K_H#8<_YY",?^E0#[_JT!,_[%
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M;,R:_X82 ?^((0;_B#44_X9&)?^'4S7_BUM#_XQB4?Z*:E[VAW%J\(1Z=.J
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M2CO_HTL[_Z-+._^C2SO_HTL[_Z-+._^C2SO_HTL[_Z-+MKH" *;*  "8W
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M9T7NYV=&Z^AG1NOH9T;KZ&=&Z^AG1NOH9T;KZ&=&Z^AG[J(  ,VT @"\O@0
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M2X#48%=VT6AA;<]P:67->G!>S(9U6,R5>53,IGM1S;Q\4,SB?%/!X']5M]^
M6+'>@5JKWH%<IM^!7*;?@5RFWX%<IM^!7*;?@5RFWX%<IM^!_X / ?^.#@'_
MH@T V[4( ,[!" #&T D OND2 K3I)0JJZ#,7H.8^)9;E1S*+XTX_@.%527;@
M75-MWF9;9=UO85[=>F=8W(9K4]R5;U#=IG%-WKMR3=_A<4[1YW10QN9W4K[D
M>%.XY'E5LN-Z5;+C>E6RXWI5LN-Z5;+C>E6RXWI5LN-Z_X,. ?^6"P#=JP0
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MYW68;N=UF&[G=9ANYW68;N=U_V<6 ?]D( /_<!X#_WXB!?^++ G_DS<0_YA
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M@(#;A8" W8. ?]Z!@'[@?X!]X7V ?>-[@'SD>H!\Y'J ?.1Z@'SD>H!\Y'J
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M>F.7Y'EFE.5W9I+F=V:2YG=FDN9W9I+F=V:2YG=FDN9W_W 2 ?^ #@'_D@X
M\J,+ -FS"0#/O@D R\P) ,33%P"ZTBP'L,\[%J7,1B::R% UC\18087!7TU\
MOF=6<[QO7FNY=V5DN()K7K:.<%FUG7-5M:YU5+;(=5.SYW97J^9V6J3F=ER@
MYW5?G.=T8)KH=&":Z'1@FNAT8)KH=&":Z'1@FNAT_W(2 ?^&# #[F D V:D&
M ,ZU!P#&P0< P,\) +K;$P"QVBD%I]@W$IS41"&2T4TPA\Y5/'W+74=TR650
M;,=M5V7%=EY>Q(%C6<..:%3#G6M1PZYL3\3(;4["[6U0N.MO4[#K<%6KZG!8
MINMP6:/K<%FCZW!9H^MP6:/K<%FCZW!9H^MP_W</ ?^-" #>H ( SZX% ,2Y
M!0"[Q08 M=,* *[A%@&FX2D&G> W$9/>0AV)W$PI?]I4-7777#]MU61(9=-L
M3U_2=E19TH%95-&.75#1G6!-TK!B2]/)8DK2[6)+R/)F3;_Q:$^X\&E1LO!I
M4J_O:5*O[VE2K^]I4J_O:5*O[VE2K^]I_W\* .V6  #2I@$ Q+(# +F\ P"P
MR08 J=@* *'G&0*9YRH)D.<W%(?F0A]]Y4HI=.11,VOC63IDXF%!7N)K1UCB
M=4M3X8!/3^*-4TOBFU5)XZQ71^3$5T;CZ5=&W?991]#W7$G(]UY*P?9@2[WV
M8$N]]F!+O?9@2[WV8$N]]F!+O?9@_XD  -F>  #'K $ N;8" *[! P"ES@8
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M;W*#[6US@>YK=(#P:72 \&ET@/!I=(#P:72 \&ET@/!I_V$7 ?]Q$ '_@@X
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M9%R7\V1<E_-D7)?S9%R7\V1<E_-D_W - /^$! #=E@  SJ,# ,2N! "[MP0
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MD@\;_Z(0&O^R$1G_R!(8_^43%__Z%!?_^A07__H4%__Z%!?_^A07__H4G[,
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M8']S^%Y^<_E<?G+Z6GYR^UE^<OM9?G+[67YR^UE^<OM9_U@7 ?]G$ '_=0X
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M6FN!^UIK@?M::X'[6FN!^UIK@?M:_V(0 /]R!P#X@@, VX\" ,^:!0#)HP8
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M45&>_U%1GO]1_W8  -V)  #*EP  OJ(  +.J  "ILP  H+P" )C&!@"1S!(
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MMB8U\=(F-._S)C3L_R8RZ_\H,N?_*S/D_RPSY/\L,^3_+#/D_RPSY/\LP9P
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M"13_PPD3_^,)$__X"1/__PH3__\*$___"A/__PH3__\*FK$  (N]  !\R
M;=0  %_@  !1Y@  1_4  $'_   \_PD -_\0 #+_%0$N_QT!*O\C 2;_*0$B
M_R\"'_\U AS_.P(9_T(#%O]) Q/_40,1_UH##_]F! W_= 0+_X4$"O^6!0G_
MJ 4(_[D%!__0!0?_XP4'_^,%!__C!0?_XP4'_^,%C;H  'W'  !MTP  7^
M %#G  !"[0  .O\  #7_   O_P( *O\* ";_#P B_Q0 'O\: 1K_'P$6_R,!
M$_\H 1#_+0$._S,!#/\Y @K_00('_TD" _]3 @#_7@( _VP" /]\ P#_C0,
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M3I!C_TR.9/]+C&3_2HMD_TB+9/](BV3_2(MD_TB+9/](_U 6 ?]<$ #_: T
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M379Q_TQV<?],=G'_3'9Q_TQV<?],_UD0 /]F!P#_<P0 X7\! -:(! #/D 8
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M2V&#_TMA@_]+_V0% /5T  #:@@  RXX  ,&7  "XG@$ L:4  *FK!P"CK1H
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MN#I$NM<Y0[CU.T*V_SU"L_\^1*[_/D6I_SY%J?\^1:G_/D6I_SY%J?\^X'T
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M&3'E_ADOY/\<+N3_'BWB_R MXO\@+>+_("WB_R MXO\@NIH  *JC  "=JP
MD+0  (.]  !WQ@  :\\  %_6  !4W@0 4? 0 $WP&P!*\"8!1O$P D+R.@,^
M\D,$._-+!3CS5 <V]%T(,_1H"3#U= LN]8$,+/:1#BKVH@\H][<0)_C6$2?V
M]!$F\_\1)O'_$27Q_Q,E\?\3)?'_$R7Q_Q,E\?\3K:$  *"I  "2LP  A+P
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M P#_[ , _^P# /_L P#_[ , _^P#B+D  'C$  !IT   6]T  $OC   ^Z0
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M.*Q0_SBG4?\WHU+_-J!3_S6?4_\UGU/_-9]3_S6?4_\U_T87 ?]0$0#_6 T
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M/H)C_SV"8_\\@F/_/()C_SR"8_\\_U / /];!P#_9@, [&\" -QV P#4? <
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M/VUR_S]M<O\__UD' /]E  #B<@  T7P  ,>$  # B@( N8\" +.2# "LE!T
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MLD%2DLE"4I'K05*0_T!2C_\_58O_/E:(_SU7A_\]5X?_/5>'_SU7A_\]^6<
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M+4"P_B\_K_\Q/JW_,D"H_S)!IO\R0:;_,D&F_S)!IO\RU7P  ,**  "UE@
MJ)T  )VC  "2J@  A[$  'RW  !PO@, :,(. &;#'0!CPRT!7L,Y!%K#1 A6
MPDX,4L)7$$_!7Q1+P6D72,%S&D7 ?AU"P(P@/\";(CW K2,\P<0C/,#I(SJ^
M_B8XO/\H-[O_*3BX_RHXMO\K.+;_*SBV_RLXMO\KR84  +F3  "LG   H*(
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M""#K_PH?ZO\+'^K_"Q_J_PL?ZO\+J)\  )NF  "-KP  ?[@  ''!  !DR@
M6-   $S6  !!W0  ..0  #7V#  S]Q0 ,/<> "[X)P K^3  */DX 2;Z0 $C
M^TD!(?M2 1[\70(<_6D"&OUY QC^BP,7_YX#%?^S!!3_TP04_O0$$_S_ Q/Z
M_P,3^?\#$_G_ Q/Y_P,3^?\#G:4  (^N  " N   <L(  &3+  !6TP  2=H
M #[?   TY   +O0  "O_"@ H_Q  )?\7 "+_'P ?_R8 '/\M !G_-  7_SP
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M',TZ_Q[+.O\>RCK_'\0[_Q_ //\>P#S_'L \_Q[ //\>_SD; ?] %0#_11$
M_TH3 /].&0#_4"(!_U L ?U.-P+V2T,$\$E0!^M(70KG1FD-XT5T$.!$?A/=
M0X<5VT*0%]A!F!C50* 9TT"I&]% LAS/0+T=S4#,'<I!Y![&0/0@PD#_(K]
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M+992_RR44O\KE%+_*Y12_RN44O\K_T80 /]."0#_5@4 _EX& .]B!P#G90H
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M,7EB_S%Y8O\Q_T\' /]9  #F9   UVP  ,QS  #$=P( OWD$ +EZ#@"R?"
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ML#MA=L0\87;E.V%V^SEB=O\W8W7_-6-S_S1D<O\S9'+_,V1R_S-D<O\S_U@
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M-4^+]S1/BO\S4(G_,E&&_S%2A/\Q4H3_,5*$_S%2A/\QZF4  -)S  #"?P
MMH@  *R0  "BE   F)@  (R<  "$GPH @* 9 'RA*0%WH#8%<I]!"FV>2P]H
MG5,49)Q;&6";8QU<FFLA6)ET)568?BE1EXHL3I:8+DN6J#!*EKPQ29;<,$F4
M]C!)D_\P29+_,$J0_R]+C?\O2XW_+TN-_R]+C?\OXFL  ,IY  "\A0  L8\
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M'C.S_Q\SLO\@,[+_(#.R_R SLO\@P8,  +21  "FF   FYX  (^E  ""JP
M=K$  &NV  !?O   5,$# $S%#0!+Q1D 2<8H $C&-0!%QT !0\=* T#'4P0^
MQUT&.\=G"#G'<PHWQX ,-,>0#3+'H0XQR+4/,,C3#S#&]! NQ/\3+<+_%2S!
M_Q8KP/\7*\#_%RO _Q<KP/\7N(T  *J7  ">G@  D:4  (2L  !XL@  :[D
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M 0WS_P$-\_\!F:,  (NL  !\M0  ;;X  %_&  !2S0  1=(  #G8   OW@
M)N(  !_J   <^P8 &?\. !?_$P 4_QH $O\A !#_*  ._S  #?\Y  O_0P )
M_TX !O]<  3_;  "_X   ?^6  #_K0  _\H  /_P  #__P  __\  /__  #_
M_P  __\ C:L  'VU  !NOP  8,@  %+0  !#UP  -]T  "OB   BY@  &>H
M !7Y   2_P  $/\(  [_#@ ,_Q$ "?\6  ;_'  #_R(  /\J  #_,P  _ST
M /])  #_5P  _VD  /]^  #_E0  _ZP  /_'  #_Z   __H  /_Z  #_^@
M__H @+4  '"_  !AR0  4M,  $/;   UX0  *>8  ![J   5[@  $/@   [_
M   +_P  "/\   3_!@  _PH  /\.  #_$0  _Q4  /\;  #_(P  _RL  /\V
M  #_0P  _U,  /]E  #_>@  _Y$  /^F  #_N   _\\  /_/  #_SP  _\\
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M!?$<_P;P'/\'[QW_".\=_PGO'/\)[AS_">X<_PGN'/\)_RHB ?\N'0#_,!L
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M&;4Z_QBR._\8L3O_&+$[_QBQ._\8_SD2 /\_#0#_0PD _T@, /]+$ #_3!4
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M(XA2_R.(4O\C_T4' /]+  #P50  WUL  --@  #,80, R&$& ,-A$0"[9"0
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MKR]P8L$P;V+?,&YC]RYO8_\L;V/_*F]C_RAO8O\G;V+_)V]B_R=O8O\G_TT
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M,%UQ\BY><?\L7G#_*U]P_RE@;_\H8&[_*&!N_RA@;O\H\54  -YB  #*;0
MO74  +-[  "K@   HH(  )B!  "1@P\ C84? (B%+@*#A#L%?H-%"GJ!3@]U
M@%84<7]>&&Y]9AQJ?&T@9WMV(V-Z@"=@>8LJ77B8+%IWIBY8=[@O5W?1+U=W
M\2Y8=O\L6';_*EEU_RE:=/\H6G3_)UIT_R=:=/\G[5D  -=F  #%<0  N7H
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M)4:+_R1&BO\D1HK_)$:*_R1&BO\DV&D  ,-V  "U@0  JXH  )^/  "5DP
MBI8  'Z:  !PG0  :Y\. &B?' !FH"H!8J W E^?005;GTH(6)Y2"U2>6@Y1
MG6(23IQK%4N<=1A(FX$:19N/'4*:GQ] FK @/YK((#^9ZQ\_F/\@/I;_(3Z5
M_R$_E/\A/Y3_(3^4_R$_E/\AS7   +Q]  "PB   I(\  )F4  ".F   @YT
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MM   3K<  $.\!0! O1$ /[T> #Z^*P \OC8 .[]! #F_2P$WOU0"-<!? C/
M:@0QP'<%+\"&!BW EP<KP*H(*L'"""K YP<IO?T**+S_#">Z_PTGN?\.)[G_
M#B>Y_PXGN?\.LHP  *64  "9F@  C:$  '^G  !RK0  9K,  %JX  !/NP
M1+\  #K$ @ PR0@ +LH1 "W*'0 LRRD *\LU "O,0  JS4H *,U6 "?.80 F
MSF\!),Y_ 2//D0(ASZ4"(-"] B#/Y (?S?H#'LO_!![*_P4=R?\&'<G_!AW)
M_P8=R?\&J)0  )R:  "0H0  @J@  '2O  !GM@  6[P  $[   !#PP  .<<
M "_,   GT 0 ']8* !O:$  ;VQH &MLF !K<,0 9W3P &-U( !C>50 7WV(
M%N!R !7@A0 4X9H $^*Q !+CSP 2X/0 $M[_ 1'=_P$1V_\"$=O_ A';_P(1
MV_\"GIH  )*A  "$J0  =K$  &BX  !;OP  3L0  $+(   WS   +=   "35
M   <VP  %=\% !3I#@ 2ZA0 $>L= !#K)@ .[#  #NTZ  WN1@ +[E, "N]B
M  GP=  (\8D !_*@  7RN@ $\>0  O']  +O_P #[?\  ^W_  /M_P #[?\
ME:$  (:I  !XL@  :;H  %O"  !-R   0,P  #31   JU@  (=L  !G@   2
MY   #_ !  WY"@ +^@\ "?L5  ?['  $_"0  ?PL  #\-P  _$(  /Q0  #\
M80  _74  /R,  #\I   _,$  /SK  #\_P  _?\  /W_  #]_P  _?\ B:D
M 'FR  !JNP  7,0  $[,   _T0  ,M<  "?=   =X0  %>4   [H   *\0
M"/T   7_ P !_PD  /\.  #_$@  _Q<  /\?  #_)P  _S$  /\^  #_30
M_U\  /]U  #_C0  _Z8  /_"  #_YP  __P  /__  #__P  __\ ?+,  &R\
M  !=Q@  3L\  #_6   QW0  )>(  !KF   1Z@  #.X   7R    _P   /\
M  #_    _P   /\%  #_"@  _PX  /\2  #_&   _R$  /\K  #_.0  _TH
M /]=  #_<P  _XP  /^D  #_N0  _]0  /_>  #_W@  _]X _Q@L /\9*0#_
M&2@ _Q4K /\0, #_"S@!_P-$ ?\ 40'_ %X!_P!L ?\ > '_ ((!_P", ?\
ME '_ )P _P"B /\ J #_ *\ _P"V /\ O@#_ ,@ _P#7 /\ YP#_ /, _P#]
M /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _QLI /\=)@#_'"4
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M!=P<_P7<'/\%VQS_!=L<_P7;'/\%_RH9 /\M$P#_+1$ _RT1 /\N&0#_+2(
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M$J([_Q*B._\2_S@* /\\  #_00  ]44  .9& @#A10< XT(- -5#&0#,12P
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ML"""4,$A@%#=(7Y1]"!]4?\??5'_'7U1_QQ]4?\;?5'_&GU1_QI]4?\:_T(
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M)FE>[B1I7O\B:E[_(&I>_Q]J7O\>:E[_'6I>_QUJ7O\=^4H  .-5  #/7P
MP64  +=J  "O;   IVP  )]J 0"9:Q$ E&TB )!N,0&+;3T$AVQ'!X-K4 M_
M:E@/?&A@$WAG9Q9V9V\9<V9X''!E@1YM9(PA:F.8(VABIB5F8K8F9&+,)F1B
M["5D8O\C9&+_(65B_Q]E8O\>96+_'65B_QUE8O\=\DP  -]8  #*8@  O6D
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M(%1P_Q]5</\>56__'55O_QU5;_\=Y5<  ,UD  "^;0  LG4  *A[  "??@
MDWT  (=]  " ?P< ?( 5 'B!) !U@C(!<8$]!&V 1@=I@$\*9G]6#6-^7A%@
M?68477QN%UI[=QI7>H(=5'J/'U%YG2%/>:XB3GG#(DUXY2)-=_LA3G?_'TYV
M_QY/=?\=3W7_'4]U_QU/=?\=WUP  ,AH  "Y<@  KGH  *6   ":@@  CH(
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M%SJ._Q<ZCO\7Q6X  +9[  "JA0  GHL  )2/  "(D@  >Y0  &Z7  !BFP
M5YX  %*@#@!1H!L 3Z$H $VA- !+H3X!2:%' D>A4 -$H5@%0J%A!S^@:PD]
MH'<+.J"%#3B@E XVH*8/-:"[$#2@W0\TG?<0,YS_$C.:_Q(SF?\3,YG_$S.9
M_Q,SF?\3O7<  *^#  "CBP  F)$  (V5  "!F0  <YP  &>?  !;H@  3Z8
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MA0 9QYD &,BN !?(RP 7QO$!%\3_ 1;#_P(6P?\#%L'_ Q;!_P,6P?\#HY$
M )B8  "+G@  ?:4  '"K  !BL0  5K8  $JY   ^O0  -,   "K$   BR
M&<P$ !/0"@ 1TA$ $-(: !#3)0 /TS  #M0\  [42  -U58 #=5E  S6>  ,
MUHT "]BD  K8O@ )V>8 "M;^  O4_P +TO\ "]+_ 0O2_P$+TO\!FI@  (Z?
M  " I@  <JT  &2T  !7N@  2;\  #W"   RQ@  *,D  !_-   7T0  $=8
M  S;!0 (W@L !M\1  7?&@ $X"0  N$N  'B.@  XT<  .16  #D9P  Y7L
M .:2  #FJ@  Y\@  .?P  #H_P  Z/\  .C_  #H_P  Z/\ D9\  (*G  !T
MKP  9;<  %>^  !)PP  /,<  ##+   ESP  '-0  !39   .W0  ">$   +E
M    Z08  .D-  #I$0  ZA@  .LA  #M*P  [S<  /%%  #R5@  \V@  /-^
M  #TEP  ];   /;0  #W\P  ]_\  /?_  #W_P  ]_\ A:<  ':P  !FN
M6,$  $K(   [S   +M$  "/6   9W   $>    SC   $YP   .H   #U
M]    /4%  #U"P  ]@\  /84  #X'0  ^B<  /PT  #_0P  _U4  /]I  #_
M@0  _YH  /^R  #_SP  _^T  /_Y  #_^0  __D >+   &BZ  !9PP  2\L
M #O1   MV   (=T  !;B   .Y@  ".H   #M    \    /@   #_    _P
M /\   #_    _P8  /\,  #_$   _Q@  /\B  #_,   _T   /]3  #_:0
M_X$  /^9  #_KP  _\,  /_5  #_U0  _]4 _Q,H /\3)0#_$24 _PTG /\&
M+0#_ #4 _P!! /\ 3P#_ %P _P!I /\ = #_ 'X _P"( /\ D #_ )< _P"=
M /\ I #_ *H _P"P /\ MP#_ ,  _P#, /\ WP#_ .P _P#X /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _Q8E /\6(@#_%"$ _Q C /\** #_
M #  _P ] /\ 2P#_ %@ _P!D /\ < #_ 'H _P"$ /\ C #_ ), _P": /\
MH #_ *8 _P"M /\ M #_ +P _@#( /T V0#[ .D ^@#V /D _P#X /\ ^ #_
M /@ _P#X /\ ^0#_ /D _P#Y /\ _QHB /\:'@#_&!T _Q,> /\.(@#_"BP
M_P<Y /\#1@#_ %, _P!@ /\ :P#_ '8 _P!_ /\ B #_ (\ _P"6 /\ G0#_
M *, _@"I /P L #Z +D ]P#$ /4 T@#S .8 \@#T /$ _P#P /\ [P#_ .\
M_P#O /\ \ #_ /  _P#P /\ _QX= /\>&0#_'!< _Q<8 /\3'@#_$2@ _PXT
M /\,00#_"DX _PA; /\'9@#_!G$ _P9Z /\&@P#^!HL _ :2 /H&F0#X!I\
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M \,<_P/#'/\#_R@0 /\I"P#_* 8 _RL+ /\K$ #_*1< _28B /0C+@#L(3L
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MM Z;.\4.F3O@#I8[] ^4//\/DCS_#Y(\_PZ1//\-D3S_#9$\_PV1//\-_S4
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M&'E,ZQAX3/X7=TS_%7=,_Q1W3/\3=TS_$G=,_Q)W3/\2_SX  .A'  #54
MQE8  +Q8  "T60  K58  *=3!P"A5!4 G%8E )A7- &45T "D%=*!(U64P:*
M55L)AU1C"X14:@Z"4W(0@%)Z$GU2@Q1[48X6>%"9&'90IAET4+4:<U#)&G%0
MZ!IP4?P8<%'_%W!1_Q5P4?\4<5#_$W%0_Q-Q4/\3]4   .1+  #/5   P5H
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M&%]=_Q=@7?\68%W_%6!=_Q5@7?\5ZTH  -16  ##7@  MF4  *QI  "B:0
MF&<  (]E  ")9@P A6@9 (%I* !^:C4!>FD_ W9I205S:%$(<&=9"FUG8 UK
M9F<0:&5P$F5D>15C9(,78&./&5YBG1M<8JP<6F*_'%EBWQQ98O<:6F+_&5IA
M_Q=;8?\66V'_%5MA_Q5;8?\5YTT  ,]9  "_8@  LV@  *EM  ">;0  DVL
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M%$MP_Q1+</\4U%H  ,!F  "S;P  J'8  )UY  "/>   A'@  '=Y  !O?
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M#P!2CQL 4(\G $^0,P!-D#T!2Y!% DF03@-&D%8$1(]?!4*/: <_CW,)/8Z
M"SJ.CPPXCJ --XZS#C:.S XVC>\.-8O_#C6)_P\UB/\/-H?_#S:'_P\VA_\/
MOFT  +!Y  "E@@  F8<  (R(  !_B   <HH  &:-  !:D0  4)4  $F7"0!'
MF!, 19@@ $29*P!#F38 09I  $":2 $^FE$"/)I: CJ:9 ,WFF\%-9E]!C.9
MC <QF9T(+YFP""Z9R@@NF.T(+I;_"BV4_PHMD_\++9+_"RV2_PLMDO\+MG4
M *J!  ">B   DXT  (:.  !XCP  :Y(  %^5  !4F0  29T  $"@   ZH@T
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M  [ N@ .P.$ #[W[  ^\_P 0NO\!$+K_ 1"Z_P$0NO\!GX\  )25  "'FP
M>:$  &NG  !>K   4K$  $6T   ZM@  +[D  "6\   =OP  %<,   _&!0 +
MR@T "<H4  C*'0 'RB< !\HR  ;+/@ %RTL !,Q:  /,:@ "S'X  <R4  #,
MJP  S<@  ,SM  #,_P  R_\  <K_  '*_P !RO\ EY8  (J<  !\HP  ;JH
M &"P  !2M@  1;D  #F\   NOP  (\,  !O&   3R@  #<T   C1   !U D
M -0.  #5%0  UAX  -@G  #9,0  VSX  -Q+  #=6P  WFX  -Z$  #?FP
MW[0  -[9  #?]P  W_\  -__  #?_P  W_\ C9T  '^E  !PK   8;,  %.Z
M  !%OP  .,(  "S&   AR0  &,T  !#1   +U0  !-H   #>    X $  .$)
M  #B#@  Y!,  .4;  #G)   Z2\  .L\  #M2P  [ET  .YQ  #OB0  \*(
M /"\  #PXP  [_D  /#_  #P_P  \/\ @:4  '*M  !CM0  5+T  $;$   W
MR   *LP  !_0   5U0  #MH   ?>    X@   .8   #I    Z@   .P   #N
M!0  [PP  /$0  #S%P  ]2   /@K  #[.0  _4H  /Y>  #_=   _XT  /^F
M  #_P   _^$  /_U  #_]0  __4 =*X  &6W  !6P   1\@  #C-   JT@
M'=@  !/=   ,X@   ^8   #I    [    /    #S    ]    /8   #X
M^@   /T'  #_#0  _Q(  /\;  #_*   _S<  /]*  #_7@  _W8  /^/  #_
MI@  _[H  /_1  #_T0  _]$ _P\D /\.(@#_"R$ _P,D /\ *0#_ #( _P ^
M /\ 3 #_ %D _P!E /\ < #_ 'H _P"$ /\ C #_ )( _P"9 /\ GP#_ *4
M_P"K /\ L@#_ +H _P#% /\ TP#_ .< _P#T /\ _P#^ /\ _P#_ /X _P#^
M /\ _@#_ /X _P#^ /\ _Q$A /\0'@#_#1T _P<? /\ (P#_ "T _P Z /\
M2 #_ %4 _P!A /\ ; #_ '8 _P!_ /\ AP#_ (X _P"5 /\ FP#_ *$ _P"G
M /X K@#] +8 _ #  /L S0#Y .( ^ #P /< _ #V /\ ]0#_ /4 _P#U /\
M]0#_ /4 _P#U /\ _Q4= /\3&@#_$!D _PL9 /\ '0#_ "D _P V /\ 0P#_
M %  _P!< /\ 9P#_ '$ _P!Z /X @P#\ (H ^@"1 /D EP#X )T ]P"C /4
MJ@#T +( \@"[ /$ R #O -P [@#L .T ^@#K /\ Z@#_ .H _P#J /\ Z@#_
M .H _P#J /\ _Q@9 /\6%0#_$Q, _PX3 /\+&@#_!R0 _P(P /\ /@#_ $L
M_P!7 /\ 8@#\ &P ^ !U /4 ?@#R (4 \0", .\ DP#N )D [ "@ .L I@#I
M *X YP"W .8 PP#D -0 X@#I .$ ]P#? /\ W0#_ -T _P#= /\ W0#_ -T
M_P#= /\ _QL3 /\:$ #_%@X _Q(. /\2%0#_#Q\ _PPK /\). #_!D4 ^P-1
M /<"7 #R F8 [@)P .H"> #G H  Y@.' .0#C@#B Y4 X0.< -\$HP#=!*L
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M /\E  #_)@  ^R<  /$E P#P(0L Z!P2 -X9'0#4&RT S1T\ ,@?20#%(%4
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M") U[ B.-OX(C#;_"(LV_PB+-O\'BC7_!XHU_P>*-?\'_R\  /(T  #B/
MTD$  ,="  # 0   NSH! +8V#@"P.1P JCLL *8\.@"C/48 GSU0 9T]60*:
M/6$#F#UH!)8\< 64/'<&DCR !Y$\B >/.Y((C3N="8L[J0J).[<+B#O*"X4\
MZ N#//L+@CS_"H$\_PJ!//\)@3S_"($\_PB!//\(_S,  .PZ  #:0P  RD<
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M#VI,_PYJ2_\-:DO_#&I+_PQJ2_\,\#T  -M(  #'4   NE4  +!8  "E5@
MG%,  )=/  "14 X C%(< (E4*P"%5#< @E1" 7]42P-\5%,$>E-:!GA38@AU
M4FD)<U)Q"W%1>@UN480/;%"0$&I0G!)H4*L39E"\$V50V!-D4/,29%#_$&10
M_P]D4/\.94__#65/_PQE3_\,[$$  -1,  ##5   MED  *Q<  "@6@  EU<
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M#E9;_PU66_\-WDP  ,=6  "X7P  K60  *!E  "39   B6,  ']A  !Y8@,
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MC0Q!=9T./W6N#CYUQ0X]=>@./G/]#3YR_PT^<?\,/W'_##]P_PP_</\,Q5X
M +5I  "I<0  G'4  (UT  " =   =70  &EV  !>>0  6'P! %1]#@!2?AH
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M RB2O00HDN$#)Y#Z!">._P4GC?\%)XS_!2>,_P4GC/\%L70  *5^  "9A0
MBH0  'V$  !OA0  8X@  %B+  !-CP  0Y,  #J7   RF@< +IL0 "V;&@ L
MG"0 *YPN "J=.  IG4$ *)U+ ">>50 FGF$ )9YN ".>?@$BGI !()ZC 1^>
MN0$>GMT!'ISX AZ:_P(>F?\#'I?_ QZ7_P,>E_\#JGT  )Z%  "3BP  A8H
M '6+  !HC@  6Y$  %"5  !&F0  .YT  #*@   JHP  (J8) !^G$0 >IQH
M':@D !RH+0 ;J#< &JE! !FI3  8J5@ %ZIF !:J=@ 5JHD %*J> !.KM  2
MJ], $JCU !.G_P$3I?\!$Z7_ 1.D_P$3I/\!HX8  )>,  "-D0  ?9(  &V5
M  !@F   5)P  $B@   ^I   -*<  "JK   AK@  &;$  !*S!P /M1  #K47
M  ZU(0 -M2L #;4V  RV00 +MDX "K9<  FV;  (MG\ ![:4  :VJ@ %ML4
M!K;J  >U_P (M/\ "+/_  FR_P )LO\ FHT  )"3  "$F   =)P  &6@  !7
MI   2Z@  $"L   UL   *K,  "&U   8N   $;L   R^ @ &P L  L 1  '!
M&0  P2(  ,(K  #"-@  PT(  ,-0  #$7P  Q'$  ,2'  #$G0  Q+4  ,3:
M  #$]@  P_\  ,/_  ##_P  P_\ DY0  (>:  !XH   :J8  %RL  !/L0
M0;4  #6W   IN@  '[T  !;    0PP  "L8   /*    S 4  ,P,  #-$0
MSA@  ,XA  #0*@  T34  --#  #44@  U&,  -5X  #5CP  U:<  -;"  #6
MZ0  UOT  -;_  #6_P  UO\ BIL  'NB  !LJ0  7K   %"V  !"N@  -+T
M "C!   =Q   %,<   W+   &S@   -(   #7    V0   -H%  #<"P  W1
M -\5  #A'0  XR<  .4S  #G0@  Z%0  .AG  #I?@  Z9<  .JO  #JS@
MZ^\  .O^  #K_P  Z_\ ?:,  &ZK  !?L@  4;H  $+    TPP  )\<  !O+
M   2SP  "],   +8    W0   .$   #D    Y0   .<   #I    ZP<  .T-
M  #O$0  \1D  /0D  #W,0  ^4$  /I5  #Z:@  ^X0  /N=  #\M@  _-(
M /WM  #]]   _?0 <:P  &&U  !2O0  1,0  #3)   FS0  &M(  !#8   (
MW0   .$   #E    Z    .P   #O    \0   /,   #U    ]P   /D!  #[
M"   _@X  /\5  #_(0  _R\  /]!  #_5@  _VT  /^'  #_H   _[8  /_*
M  #_U   _]0 _PL@ /\''@#_ !T _P @ /\ )0#_ "X _P [ /\ 20#_ %8
M_P!B /\ ;0#_ '8 _P!_ /\ AP#_ (X _P"4 /\ F@#_ *  _P"F /\ K0#_
M +4 _P"^ /\ RP#_ .$ _P#P /X _0#] /\ _0#_ /T _P#] /\ _ #_ /D
M_P#Y /\ _PT= /\+&@#_!!D _P : /\ 'P#_ "H _P W /\ 10#_ %$ _P!>
M /\ : #_ '( _P!Z /\ @@#_ (D _P"0 /\ E@#_ )P _@"B /P J0#[ +
M^0"Y /@ Q@#V -D ]0#K /0 ^0#S /\ \@#_ /, _P#S /\ \P#_ /, _P#S
M /\ _Q 9 /\.%0#_"!0 _P 4 /\ &0#_ "4 _P R /\ 0 #_ $P _P!9 /\
M8P#^ &T _ !U /H ?0#Y (0 ]P"+ /8 D0#T )< \P"> /( I #P *P [@"T
M .T P #K ,\ Z0#F .@ ]0#F /\ YP#_ .8 _P#E /\ Y0#_ .4 _P#E /\
M_Q(4 /\0$ #_# \ _P,0 /\ %0#_ "  _P L /\ .@#_ $< ^@!3 /< 7@#T
M &< \0!P .\ > #M '\ ZP"& .H C #H ), YP"9 .4 H #C *< X0"P -\
MN@#= ,D VP#@ -@ \ #7 /X U0#_ -0 _P#3 /\ TP#_ -, _P#3 /\ _Q40
M /\2# #_#@D _PL, /\)$@#_ QH _P F /T ,P#T $  [P!- .L 6 #H &$
MY0!J .( <@#@ 'H W@"  -P AP#: (X V "5 -0 G #2 *, T "L ,X M@#,
M ,0 R@#9 ,@ [0#' /L Q0#_ ,0!_P## ?\ Q '_ ,0!_P#$ ?\ _Q@+ /\5
M!0#_$   _Q & /\/#0#_#!0 _ <? /$#*P#G #D X@!& -X!40#: EL U0)D
M -(#; #/ W0 S01[ ,L$@@#*!(D R 60 ,8%F #$!:  P@:I ,$&M "_!L$
MO0C5 +L)[ "X"_T M@S_ +4-_P"T#?\ M W_ +0-_P"T#?\ _QL% /\8  #_
M%P  _Q8  /L3!@#Z$ X [@P6 .,)(@#:"3  TPH^ ,X+2@#*#%4 QPU> ,4-
M9P#"#F\ P0YV +\.?@"]#X4 O ^- +H0E0"X$)T MQ"G +41L@"S$<  LA'5
M *X3[@"K%/X J17_ *<5_P"G%?\ IA3_ :84_P&F%/\!_Q\  /\<  #Z'@
MZQX  .,<  #?%04 W@X- -,.& #+$2@ Q1,W , 41 "\%D\ N1=9 +<780"T
M&&D LQEQ +$9> "O&H  KAJ( *P;D "K&YD J1NC *<<K@"F'+P I!W/ *$>
MZ@&>'OP!G!__ 9L?_P&:'_\!FA[_ 9D>_P&9'O\!_R(  /\A  #L)P  X"H
M -0I  #-)   RAP( ,09$@"]'"( MQXQ +,@/@"O(4D K2)3 *HC7 "H)&0
MIB1L *0D<P"C)'H H26" : EBP&>)90!G26> 9LFJ@&9)K<!F";) I4GY@*2
M)_D"D"C_ H\H_P*.)_\"CB?_ HXG_P*.)_\"_R8  /(I  #C,0  TC0  ,@T
M  # ,   NRD" +@C#@"Q)AP K"@K *@J. "D*T0 H2Q. )\M5P"=+5\ FRUG
M 9DM;@&8+G4!EBY] I0NA@*3+I "D2Z: X\NI@.-+K,#C"[% XHOX02'+_8$
MA2__!(0O_P.$+_\#@R__ X,O_P.#+_\#^RD  .LQ  #9.   R3P  +\\  "V
M.0  L#(  *PM"P"G+Q< HC$F )XS- ":-$  F#5* )4U4P"3-5L!D35B 8\U
M:0*--7$"C#5Y XHU@@.(-8L$AC66!(0UH@6"-:\%@37 !G\VW 9]-O0&>S;_
M!7LV_P5Z-O\$>C;_!'HU_P1Z-?\$]2T  .0W  #0/P  PD,  +=$  "M0
MISH  *,V!@"=-Q, F3DB )4Z+P"2/#L CSQ& (P\3P&*/%<!B#Q> H8\90*$
M/&T#@CQU!( \?01_/(<%?3R2!GL[G@=Y.ZP'=SN\"'8\U0AT//$(<SS_!W(\
M_P9R//\%<CS_!7([_P5R._\%\3(  -X]  #)1   O$@  +!)  "F1@  GT$
M )L] 0"5/1  D3\= (U!*P"*0C@ AT-" (1#2P&"0U,!@$-; GY"8@-\0FD$
M>D)Q!7A">@9V080'=$&/"')!FPAP0:D);T&Y"FU!T IL0>X):T+_"&I"_P=J
M0?\&:D'_!FI!_P5J0?\%[3<  -9"  #$20  MTT  *M-  "@2@  F$<  )-"
M  ".0PT B44: (9&* "#1S0 @$@_ 'Y(2 %[2% ">4A7 G=(7P-U2&8$<T=N
M!7%'=@9O1X ';4:,"6M&F II1J8+9T:V"V9&S ME1NP+9$?_"61&_PAD1O\'
M9$;_!F1%_P9D1?\&Z#L  -!&  "_30  LU$  *51  ":3@  DDL  (U'  "'
M2 L @TH6 ']+) !]3#$ >DT\ '=-10%U34T"<TU5 G%-7 -O36,$;4QK!6M,
M<P=I2WT(9DN)"61+E@IB2Z0+84NT#%]+R@Q>2^H+7DO^"EY+_PE>2O\(7DK_
M!UY*_P=>2O\'XS\  ,M)  "\40  L%4  *%4  "64@  C5   (=,  "!30@
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MC0I-79P+2UVL#$I=P0Q)7>,,25SZ"DE;_PE*6_\(2EK_"$I:_P=*6O\'SDX
M +Q8  "N8   GV$  )%@  "%7P  >U\  '!=  !J7P  96$* &)B% !@8R$
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M"#AONP@X;]L'.&[V!SAM_P<X;/\&.6O_!CEJ_P8Y:O\&O5P  *]F  "B;0
MD6P  ()K  !W:P  ;&P  &%N  !7<   4',  $QU"@!)=A, 1W<? $9W*0!%
M>#, 0W@\ $)X1 !!>$T!/WA5 3UX7@([>&@".7AT S=X@@0U>),%,W>D!3)W
MN04Q>-<%,7;U!3%T_P4Q<_\%,7+_!3)R_P4R<O\%MV,  *IM  "<<0  BW
M 'UP  !R<   9W$  %QS  !1=P  2GH  $)] P _?@X /7\8 #Q_(P [@"T
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M !:3_P$6DO\!%I'_ 1:0_P$6D/\!I7L  )F#  ")@0  >X   &R"  !?A
M5(@  $F+   _D   -90  "V7   EF@  '9X! !:@#  4H1( %*$; !.A)0 2
MH2X $:(X !&B0P 0HD\ #Z)<  ZC:P -HWT #:.2  RCIP *HL  "Z+F  R@
M_@ -G_\ #9[_  V=_P -G?\ GH0  )*)  "#B   <X@  &6+  !8C@  3)(
M $&7   WFP  +IX  "2B   <I0  %:@   ^K!  *K@P !ZT2  :M&P %K20
M!*XN  *N.0 !KD4  *Y2  "N80  KG,  *Z'  "NG0  KK0  *[5  "M]
MK?\  *S_  "K_P  J_\ EHL  (R0  ![D   :Y(  %V6  !0F@  1)\  #FC
M   OIP  ):L  !RN   4L0  #K0   FW   !N D  +@.  "Y%   N1P  +HE
M  "Z+P  NSH  +Q'  "\5@  O&<  +Q[  "\D0  O*D  +S$  "\ZP  N_X
M +O_  "[_P  N_\ D)(  (.8  !SFP  8Y\  %6C  !'J   .ZT  #"Q   E
MM   &[<  !*Z   ,O0  !;\   ##    Q (  ,4*  #%#@  QA0  ,<;  #(
M)   RBX  ,PZ  #-20  S5D  ,UL  #.@P  SIL  ,VU  #.V@  SO8  ,W_
M  #-_P  S?\ AID  '>@  !II@  6JP  $RR   ^M@  ,+D  "2\   9OP
M$<(   K%   "R0   ,P   #0    T0   -(!  #3"   U0T  -<1  #:&
MW"$  -\L  #A.@  XDH  .-=  #D<@  Y(L  .6E  #EP   Y>8  .7X  #E
M_P  Y?\ >J$  &NI  !<KP  3;8  #^\   POP  (\,  !?'   /R@  !\X
M  #1    U@   -P   #?    X    .(   #D    Y@,  .@)  #I#@  [!4
M .X>  #Q*P  ]#H  /5-  #V80  ]WD  /B3  #XK0  ^<8  /GD  #Y\P
M^?, ;:H  %ZR  !/N@  0,$  #'%   BR0  %LX   W2   $V    -T   #A
M    Y    .@   #K    [0   .\   #Q    \P   /8   #X P  ^@L  /T1
M  #_&P  _RD  /\[  #_3P  _V8  /]_  #_F0  _Z\  /_#  #_U@  _]8
M_P0< /\ &0#_ !D _P < /\ (@#_ "L _P X /\ 1@#_ %, _P!> /\ :0#_
M '( _P!Z /\ @@#_ (D _P"/ /\ E0#_ )L _P"A /\ J #_ *\ _P"Y /\
MQ0#_ -D _@#L /T ^P#[ /\ ^P#_ /L _P#Z /\ ] #_ /  _P#P /\ _P<8
M /\!%0#_ !0 _P 6 /\ &P#_ "8 _P T /\ 0@#_ $X _P!: /\ 9 #_ &T
M_P!U /\ ?0#_ (0 _P"* /T D #\ )8 ^@"= /D HP#X *L ]P"T /4 OP#T
M ,X \P#F /$ ]@#P /\ [P#_ .\ _P#N /\ [@#_ .H _P#J /\ _PL4 /\&
M$0#_ !  _P 0 /\ %@#_ "( _P N /\ / #_ $D _P!4 /X 7P#[ &@ ^0!P
M /< > #U '\ \P"% /( BP#P )( [P"8 .T GP#L *8 Z@"N .@ N0#G ,<
MY0#> ., \ #B /X X #_ .  _P#A /\ X0#_ .$ _P#A /\ _PT0 /\)#0#_
M 0P _P , /\ $@#_ !P _P H /P -@#Y $, ]@!. /( 60#O &( [ !K .H
M<@#H 'D Y@"  .0 A@#B (P X0"3 -\ F@#= *$ VP"J -@ M #5 ,  T@#3
M -  Z@#. /H S0#_ ,T _P#- /\ S #_ ,P _P#, /\ _Q , /\,!P#_ P(
M_P ( /\ #@#_ !8 ]@ B /  +P#L #P Z0!( .4 4P#A %P W@!E -L ; #7
M ', U !Z -( @ #0 (< S@". ,P E0#* )T R "E ,8 KP#$ +L P@#+ ,
MY0"^ /4 O0#_ +P _P"\ /\ O #_ +P _P"\ /\ _Q$% /\.  #_"@  _P@!
M /\$"@#X !  Z0 : ., * #> #4 V0!! -, 3 #/ %8 RP!? ,D 9@#& &X
MQ !T ,( >P#! (( OP") +T D "\ )@ N@"A +@ JP"V +< M #' +( X "Q
M ?( KP+_ *X#_P"M!/\ K03_ *T$_P"M!/\ _Q0  /\0  #_#P  \@T  .H*
M  #I PD W0 2 -0 'P#- 2T R (Z ,0#10#  U  O019 +L%80"Y!6@ MP9O
M +4&=@"T!WT L@>$ +$(C "O")4 K0F> *L)J "J"K4 J K% *8+WP"D#?0
MH@[_ * ._P"?#O\ GP[_ )\._P"?#O\ _Q<  /\3  #O&   Y!D  -L6  #2
M$ ( SPD+ ,@(%@#!"B0 O PR +<-/@"T#DD L0Y3 *\06P"M$&, JQ!J *D1
M<0"H$7@ IA&  *41B "C$I$ H1*; * 3I@">$[, G!/# )L4W@"7%O0 E1;_
M )07_P"3%_\ DA?_ )(6_P"2%O\ _QH  /0=  #E(P  U24  ,HD  #"'0
MOA8$ +L0$ "T$QT KQ4K *L6. "G&$, I1E- *(95@"@&ET GAME )T;; ";
M'', FAQ[ )@<@P"7'8T E1V7 ),>H@"2'J\ D!Z_ (\?V ",(/$!B2#_ 8@@
M_P&'(/\!AR#_ 88@_P&&(/\!^AX  .LF  #:+0  RC   +XN  "U*   L"(
M *X;# "H'1< HQ\F )\A,P"<(CX F2-( )<D40"5)%D DR5@ )(E9P"0)FX
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M FHU_P)J-?\"ZC   -,Z  #"00  LT,  *5!  ";/@  E3H  ) V  ",-0T
MB#<8 (0X)0"!.C$ ?SL\ 'P[10!Z/$T >#Q5 7<\7 %U/&,!<SQJ G$\<P)P
M/'P#;CN' VP[E 1J.Z$$:#NQ!6<\Q05E/.4%9#SZ!&0\_P-C._\#8SO_ V,[
M_P)C._\"Y34  ,T_  "]1@  KD<  )]%  "50P  CD   (D\  "$/ H @#T4
M 'T^(@!Z/RX >$ X '5!0@!S04H <D%1 7!!60%N06 ";$%G FI!< -H07D#
M9T&$!&5!D05C09\%84&N!F!!P@9>0>(&7D'Y!5U!_P1=0/\#74#_ UU _P-=
M0/\#WSD  ,A#  "Y2@  J4L  )M)  "01P  B$0  (-!  !^008 >D(1 '9#
M'@!T12H <44U &]&/P!M1D< :T9/ 6I&5@%H1ET"9D9E F1&;0-B1G8$8$:"
M!%Y&C@5<19P&6T6L!EE&OP=81M\&6$;W!5=%_P171?\$5T3_ UA$_P-81/\#
MVCT  ,1'  "U3@  I$X  )9,  "+2P  @TD  'U%  !X1@( =$<0 '!(&P!N
M22< :THR &I+/ !H2T0 9DM, 61+4P%B2UH"8$MB E]+:@-=2W0$6TI_!5E*
MC 572IH&54JJ!U1*O0=32MP'4DKV!E)*_P522?\$4DG_ U)(_P-32/\#U$$
M ,!+  "R40  H%   ))/  "'3@  ?DP  'A(  !R2@  ;DL- &M-& !H3B0
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M!D17N 9#6-(&0U?R!D-6_P5#5?\$1%7_!$14_P-$5/\#QDP  +56  "E6@
ME%D  (98  ![6   <5<  &96  !A6   75D$ %E:$ !76QL 55PF %-=, !2
M73D 45Y! $]>20!-7E$!3%Y8 4I>80)(76L#1EUV T1=@P1"79(%0%VC!C]=
MM@8^7= &/5SQ!3Y;_P0^6O\$/EK_ SY9_P,_6?\#P5   +%:  "A70  D%P
M ();  !V6P  ;5L  &%;  !;70  5EX  %)@#0!081< 3F(B $UB+ !,8S4
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M BIO_P(J;?\"*FS_ BML_P(K;/\"L6$  *1I  "0:   @&<  '1G  !I9P
M7V@  %5K  !+;@  0W$  #QT   W=@H -'<2 #-X'  R>"4 ,7DN #!Y-P O
M>3\ +GE( "QZ4@ K>EP *GIH "AZ=@ F>H<!)7J9 2-ZK $B>L4!(GGI 2)W
M_P$B=O\!(G7_ B)T_P(C=/\"K&@  )UN  "*;0  >VP  &]L  !E;   6FX
M %!Q  !%=0  /7@  #9\   N?P( *8$- ">"%  F@AX )8(G "2"+P C@S@
M(H-" "&#2P @A%8 'X1B !Z$<0 <A(( &X25 !J$J0 8A,$ &(/F !B!_0 9
M@/\!&7__ 1E^_P$9?O\!IG   )5S  "$<@  =G$  &MQ  !><P  5'8  $EY
M   _?0  -X$  "^$   GB   ((L% !N-#@ :C14 &8T> !B.)P 7CC  %HXY
M !6.0P 4CT\ $X]; !*/:@ 1CWL $(^/  ^/I  .C[L #8_@  Z-^@ /B_\
M$(K_ !")_P 0B?\ H7H  (YY  !^=P  <G<  &1X  !8>P  37X  $*"   Y
MA@  +XH  ">.   @D0  &)4  !*8!0 .F@X #9H4  R:'0 +FB8 "YHP  J:
M.P )FD8 ")I3  :;80 %FG( !)J&  *:FP  FK$  9G/  *9\  "F/\ !)?_
M  66_P %EO\ F8$  (=_  !Z?@  :WX  %V!  !0A0  18D  #N-   QD@
M*)8  !^9   8G0  $:    RC @ &I0H  :40  "E%@  IA\  *8H  "F,@
MIST  *=*  "G6   IV@  *=\  "GD0  IJ@  *;#  "EZ0  I?P  *7_  "D
M_P  I/\ D8<  (*&  !RA@  8X@  %6,  !)D0  /98  #*:   HG@  'Z(
M !>F   0J0  "ZP   2O    L08  +$,  "R$0  LA<  +,?  "S*   M#(
M +4_  "U30  M5T  +5P  "UA@  M9T  +6V  "UW   M/<  +3_  "T_P
MM/\ BX\  'J.  !JD0  6Y4  $V:  ! GP  -:0  "JH   @K   %K    ^T
M   )MP   ;D   "]    O@   +X&  "_#   P!   ,$6  #"'0  PR<  ,4R
M  #&0   QE$  ,=C  #'>   QY$  ,>I  #'QP  Q^P  ,?^  #'_P  Q_\
M@Y<  '&:  !AG@  4J,  $6I   XK@  ++,  ""W   6N@  #KT   ;
MPP   ,<   #)    R@   ,P   #- P  S@D  - .  #2$P  U!L  -@E  #;
M,@  W4(  -U4  #>:0  WH$  -Z<  #?M0  W]D  -_S  #?_P  W_\ =Y\
M &BF  !9K0  2K,  #NX   MNP  '[\  !3"   ,Q@   \D   #,    T
M -4   #9    V@   -P   #>    X    .(%  #D"P  YQ   .H8  #M)
M\#(  /%$  #R6   \V\  /2*  #TI   ]+\  /3?  #T\P  ]/0 :J@  %NO
M  !,MP  /;T  "W!   ?Q@  $\H   O.    T@   -<   #<    X    .4
M  #G    Z0   .L   #M    [P   /$   #S    ]@<  /D.  #\%@  _R(
M /\S  #_1P  _UT  /]V  #_D0  _ZD  /^^  #_V   _]L _P 8 /\ %@#_
M !4 _P 8 /\ '@#_ "< _P V /\ 0P#_ $\ _P!: /\ 9 #_ &T _P!U /\
M?0#_ (0 _P"* /\ D #_ )8 _P"< /\ HP#_ *L _P"T /X OP#] ,\ ^P#G
M /H ^ #Y /\ ^0#_ /D _P#U /\ [@#_ .D _P#G /\ _P 4 /\ $0#_ !$
M_P 2 /\ %P#_ ", _P Q /\ /@#_ $H _P!6 /\ 8 #_ &@ _P!P /\ > #]
M 'X _ "% /H BP#Y )$ ^ "8 /< G@#U *8 ] "N /( N0#Q ,< [P#@ .X
M\@#L /\ [ #_ .P _P#K /\ Y0#_ .  _P#> /\ _P,0 /\ #@#_  T _P -
M /\ $P#_ !X _P K /\ . #_ $4 _@!0 /L 6@#X &, ]0!K /, <@#Q 'D
M[P!_ .X A@#L (P Z@"2 .D F0#G *  Y@"I .0 LP#A ,  X #3 -X ZP#<
M /L VP#_ -H _P#: /\ V0#_ -0 _P#2 /\ _P<- /\ "0#_  8 _P ) /\
M#P#_ !@ ^P E /@ ,@#U #\ \@!* .T 5 #J %T YP!E .0 ; #B ', X !Z
M -X @ #< (8 V@"- -< E #4 )L T@"D ,\ K0#- +D RP#) ,D Y #( /8
MQ@#_ ,4 _P#& /\ QP#_ ,< _P#' /\ _PH& /\!  #_    _P $ /\ "P#T
M !( [P ? .H + #E #@ X@!# -T 3@#9 %< U !? -$ 9P#. &T S !T ,H
M>@#( (  Q@"' ,4 C@## )8 P0"> +\ J "] +, N@#" +D VP"W /  M0#_
M +8 _P"U /\ M0#_ +4 _P"U /\ _PP  /\$  #_    _@   /8  P#H  T
MX  7 -D ) #1 #$ S0 \ ,H 1P#& %$ PP!9 ,  8 "^ &< O !N +H = "Y
M 'L MP"" +4 B0"S )$ L@": +  I "N *\ K "] *H T "H .L IP#[ *8
M_P"F /\ I0#_ *4 _P"E /\ _PT  /\'  #T"0  Z@D  .($  #:  < SP 1
M ,@ ' #" "D O@ U +L 0 "W $H M !3 +( 6P"P &( K@!H *P ;P"K '4
MJ0!] *@ A "F (T I "6 *, H "A *L GP&Y )T#S "<!.@ F@;Y )D'_P"8
M"/\ EPC_ )<(_P"7"/\ _Q   /<0  #H%   W!4  ,X1  #&#0  P@0+ +P
M% "W 2$ L@,N *X%.@"K!D0 J A- *8(50"D"5P H@IC * *:@"?"W$ G0MX
M )P+@ ":#(D F0R3 )<,G@"5#:H E VX )(-S "0#NH CA#\ (P0_P"+$/\
MBQ#_ (L0_P"*$/\ ^Q,  .T:  #=(   S"$  +\=  "W%P  LQ$  +(+#0"K
M#1D IPXF *,/,P"?$#X G1%' )H14 "8$E< EA)> )4390"3$VP DA-S ) 4
M? "/%(4 C16/ (L5F@"*%:< B!:U (86R0"$%^< @AC[ ( 9_P!_&?\ ?QG_
M '\8_P!_&/\ ]1H  .0C  #/*0  P"H  +,F  "J(@  I1P  *05" "@%!,
MFQ8A )<8+0"4&3@ D1I" (\;2P"-'%( BQQ9 (D=8 "('6< AAYO (4>=P"#
M'X  @A^+ ( ?EP!^(*, ?2"R 'L@Q0!Y(>0 =R+Y '8B_P!U(O\ ="'_ '0A
M_P!T(?\ [R$  -LK  #',0  MC$  *DN  "@*@  FR8  )@A 0"5'A  D" ;
M (TA* ")(S, AR0] (4D1@"#)4X @295 '\F7 !^)F, ?"=K 'LG<P!Y)WP
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MC %C-9H"83:I F VNP)?-M8"73;S ETV_P)<-O\!7#7_ 5PU_P%<-/\!W#,
M ,4\  "T00  HD   )4^  "+/   A#D  '\V  ![- 0 =S40 '0W' !Q."<
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M E$^_P%1/O\!SSL  +U%  "J1P  F48  (M%  "!1   >4(  '0^  !O/P
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M?@)!4HT"/U*= SY2KP,]4L8#/%+I CQ1_@(\4/\"/4__ CU/_P(]3O\"ODL
M *Y3  ":4@  B5$  'Q1  !Q4   :%   %Y.  !840  5%(  %%3# !.5!0
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M 2QCJ0$K8[\!*F/C 2IB^P$J8/\!*U__ 2M?_P$K7O\!L5D  )Y<  "+7
M>UL  &];  !E6P  7%P  %%>  !)8   0V(  #QE   X9PH -6@2 #1H&P S
M:20 ,FDM #%I-0 O:CT +FI& "UJ3P L:ED *VME "EK<@ H:X( )FN3 "1K
MIP C:[T (FK@ "-I^0$C9_\!(V;_ 2-F_P$D9?\!K&   )A@  "%8   =E\
M &I?  !A8   5V   $UC  !$9@  /6@  #9K   P;@0 +' . "IQ%0 I<1X
M*'$F "=R+P F<C< )7)  "1R2@ B<E0 (7-@ "!S;0 ><WT '7.0 !MSHP :
M<[D &7/< !IQ]P :</\ &V__ !MN_P$;;?\!IF8  )%E  !_9   <60  &9D
M  !=9   4F8  $AI   _;   -V\  #!S   I=@  (GD( !][$  >>Q< ''L?
M !M[*  :>S  &7PY !A\0P 7?$X %GQ: !5\9P 4?7@ $GV+ !%]GP 0?;4
M#WW5 !![]0 1>?\ $7C_ !)W_P 2=_\ GFL  (IJ  !Z:0  ;6D  &)I  !7
M:@  3&T  $-P   Y=   ,7@  "E[   B?P  &X(  !2%"0 1AA  $887 !"'
M'P 0AR@ #H<Q  Z'.P -AT8 #(=3  N'80 *AW$ "8>$  >'F  &AJX !8;)
M  :%[  'A/\ "(/_  F"_P )@O\ E7$  (-O  !T;@  :6X  %QO  !0<@
M1G4  #QY   R?0  *H$  "*%   ;B0  %(P   ^/ P *D@L !I(1  22&  "
MDB   9(I  "2,P  DSX  )-+  "360  DVD  )-[  "2D   DJ8  )&_  "1
MY0  D/H  (__  "/_P  C_\ C7<  'UU  !P=   8G4  %5X  !)?   /X
M #2$   KB0  (HT  !J1   3E   #I<   F;   !G0@  )T.  "=$P  GAH
M )XB  "?*P  GS4  *!"  "@4   H%\  *!Q  "@AP  GYT  )^U  ">V@
MG?8  )W_  "<_P  G/\ AGT  'A\  !I?   6W\  $Z#  !!B   -HP  "R1
M   CE@  &IH  !*>   -H0  !J0   "G    J0,  *D*  "J#@  JQ,  *P9
M  "M(@  KBL  *\W  "O10  KU0  *]F  "O>P  KI0  *ZK  "NR0  KN\
M *W_  "M_P  K?\ @80  '&$  !AAP  4XL  $:0   YE@  +IL  ".@   :
MI   $J@   RL   $KP   +(   "V    MP   +<"  "X"   N0T  +H2  "[
M&   O2$  +XK  # .   P$@  ,!:  #!;@  P88  ,&@  #!N@  P>,  ,#Y
M  # _P  P/\ >8T  &B0  !9E   2YH  #V@   QI0  ):L  !JO   1LP
M"[@   *[    O@   ,$   #$    Q0   ,8   #'    R 4  ,H+  #,#P
MSA4  - ?  #3*P  U3H  -5,  #68   V'<  -B2  #8K   V<D  -GL  #9
M^P  V/\ <)D  &">  !1I   0ZH  #6P   HM@  '+H  !&^   )P0   ,4
M  #(    RP   ,\   #2    TP   -8   #8    VP   -T   #?!P  X@T
M .43  #H'0  ["H  .T\  #M40  [F<  .^!  #OG   \+<  /#3  #P[
M\/0 9Z8  %BM  !)M   .KH  "J^   <P@  $,8   ?*    S@   -(   #6
M    W    .    #C    Y    .8   #H    ZP   .T   #O    \@(  /4*
M  #X$0  _!P  /\L  #_/P  _U4  /]N  #_B@  _Z0  /^Z  #_T0  _^$
M_P 4 /\ $@#_ !( _P 4 /\ &0#_ "4 _P R /\ /P#_ $L _P!6 /\ 8 #_
M &@ _P!P /\ > #_ '\ _P"% /\ BP#_ )$ _P"8 /\ G@#^ *8 _0"N /P
MN0#Z ,@ ^0#B /@ ] #W /\ ]@#_ /8 _P#O /\ YP#_ .( _P#> /\ _P 1
M /\ #@#_  X _P / /\ % #_ "  _P M /\ .@#_ $8 _P!1 /\ 6P#_ &,
M_@!K /P <P#Z 'D ^0"  /< A@#V (P ]0"2 /, F0#R *  \ "I .X LP#M
M ,$ ZP#6 .H [@#I /X YP#_ .< _P#E /\ W0#_ -4 _P#1 /\ _P - /\
M"@#_  @ _P ) /\ $ #_ !L _P H /\ -0#_ $  ^@!+ /8 50#S %X \0!F
M .X ;0#L '0 ZP!Z .D @ #G (8 Y@"- .0 DP#B )L X "C -X K0#< +D
MV@#* -< Y@#4 /@ T@#_ -( _P#2 /\ S@#_ ,D _P#& /\ _P ( /\  P#_
M    _P # /\ #0#\ !8 ]P B /, +@#O #H [ !% .@ 3P#D %@ X0!@ -X
M9P#; &T V0!T -4 >@#3 (  T0"' ,\ C@#- )4 RP"> ,D IP#' +, Q0#"
M ,, W #! /$ OP#_ +\ _P"^ /\ O@#_ +T _P"[ /\ _P   /\   #_
M_P   /8 " #N !$ YP ; .$ )P#= #, V0 ^ -, 20#/ %( RP!9 ,@ 80#&
M &< Q !M ,( <P#  'H OP"  +T B "[ )  N0"8 +@ H@"U *T LP"[ +$
MS@"P .H KP#\ *T _P"M /\ K@#_ *X _P"N /\ _P(  /\   #]    \@
M .@   #>  P TP 5 ,P (0#( "P Q  X ,$ 0@"] $L N@!3 +@ 6@"V &$
MM !G +( ;0"P '0 KP!Z *T @@"L (H J@"3 *@ G0"F *@ I "U *( Q@"A
M ., GP#V )X _P"> /\ G@#_ )X _P"> /\ _P8  /L   #N!0  X@0  -4
M  #+  8 PP / +T &0"X "4 M  Q +$ .P"N $4 K !- *D 50"G %L I0!B
M *0 : "B &X H0!U )\ ? "> (4 G ". )H F "8 *0 E@"P )4 P0"3 -P
MD@#R )$ _P"0 /\ D #_ (\ _P"/ /\ _0H  / .  #A$0  SA   ,(-  "[
M!P  MP * +$ $@"L !X J  I *4 - "B #X GP!' )T 3P"; %8 F0%< )<!
M8P"6 FD E )P ),#> "1 X  D 2* (X$E0",!:$ B@6N (D&O@"'"-@ A@GP
M (0*_P"#"_\ @PO_ (,+_P"#"_\ ]A   .87  #2'   P!H  +,6  "L$@
MJ T  *8'#0"B!18 G0<B )D)+@"6"C@ E M! )(,2@"0#%$ C@U8 (P-7@"+
M#64 B0UL (@.= "&#GT A0Z' (,.DP"!#Y\ @!"M 'X0O@!]$-L >A'T '@2
M_P!W$O\ =Q+_ '<2_P!W$O\ [Q<  -LA  #&)   M",  *@@  "@'   FQ<
M )D1! "8#A  DQ ; (\1)P",$C( B1,\ (<31 "%%$P @Q13 ($56@" %6
M?A9H 'T6;P![%G@ >1># '@7CP!V&)P =!BJ ',9NP!R&=0 ;QKQ &X;_P!M
M&_\ ;1K_ &T:_P!M&O\ YR   - I  "\*P  JRH  )XH  "6)   D"   (T<
M  ",%PP B!@6 (0:(@"!&RT ?APW 'P=0 !Z'4@ >1Y/ '<>50!V'UP =!]C
M ',?:P!Q('0 <"!_ &XABP!L(9@ :R&G &DBN !H(L\ 9B+N &4C_P!D(_\
M9"+_ &0B_P!D(?\ X"8  ,@O  "T,0  HS   )8N  "-*P  AR@  (0D  ""
M( @ ?B 2 'LB'@!X(RD =20S ',E/ !Q)4, <"9+ &XF4@!M)UD :R=@ &HG
M: !I*'$ 9RA[ &4HB !D*94 8BFD & IM0!?*<L 7BKL %PJ_P!<*?\ 7"G_
M %PI_P!<*/\ V"P  ,,U  "M-0  G30  ) S  "&,0  @"T  'PK  !Y* ,
M=B<0 '(I&@!P*B4 ;2LO &LL. !J+$  :"U' &<M3@!E+E4 9"Y= &,N90!A
M+VX 7R]X %XOA !<+Y( 6B^A 5DOL@%8,,@!5C#I 54P_@%5+_\ 52__ %4N
M_P!5+O\ T#$  +TZ  "H.0  ES@  (HW  " -@  >C(  '4P  !R+@  ;BX-
M &LO%@!I,"$ 9C$K &0R- !C,CT 83-$ & S2P!?-%( 731: %PT8@!:-&L
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M?0%*/XL!2#^; 4<_K %%/\$!1#_C 40^^P%$/O\!1#W_ 40]_P%%//\!PSX
M *]#  ":0@  BD(  'U!  !S0   :S\  &4\  !@/   7#X$ %D^#P!7/Q@
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M 3=,IP$V3+P!-4S= 35+]P$U2_\!-4K_ 39)_P$V2?\!N$D  *)+  ".2@
M?DH  ')*  !H2@  7TD  %5(  !02@  3$L  $E,!P!&31  1$X9 $)/(@!!
M3RL 0% S #]0.P ^4$, /%%* #M14P Z45P .%%G #=1<P U48( ,U&3 3)1
MI0$P4;H!+U': 2]0]@$O3_\!,$[_ 3!._P$P3?\!M$T  )U-  "*30  >DT
M &Y-  !D30  6TT  %%-  !+3P  1E   $)2 P _4PT /505 #Q4'@ Z52<
M.54O #A5-P W5C\ -E9' #564  S5ED ,E=D #!7<0 O5X  +5>1 "M7HP J
M5[@ *5?6 "E6]0 I5?\ *E3_ 2I3_P$J4O\!KU$  )A1  "%40  =E   &I0
M  !@4   6%$  $Y2  !'4P  054  #M8   X60H -5H1 #1:&@ S6R( ,ELK
M #%;,P O7#L +EQ# "U<3  L7%8 *UU@ "E=;0 H77P )EV. "1=H0 C7;4
M(EW2 ")<\P B6_\ (UK_ "-9_P D6/\ J%4  ))4  " 5   <50  &94  !<
M5   5%4  $I6  !#6   /%L  #9=   P8 4 +6$. "MA%0 J8AT *6(E "AB
M+@ G8S8 )F,^ "5C1P C8U$ (F1< "%D:0 ?9'D 'F2* !QDG@ ;9+, &63.
M !IC\0 ;8?\ &V#_ !Q@_P <7_\ H5D  (Q8  ![6   ;5@  &)8  !96
M4%D  $=;   ^7@  -V   #%C   J9@  )&D) "%J$  @:A< 'VH@ !YK*  =
M:S  '&LY !MK0@ :;$P &6Q8 !=L90 6;'0 %&R& !-LF@ 2;*\ $6S* !%K
M[P 2:?\ $VC_ !-H_P 39_\ F5T  (5=  !U7   :%P  %Y<  !57   2UX
M $)A   Y9   ,F<  "MJ   D;0  'G ! !=S"P 5=!$ %'08 !-T(0 2=2D
M$74R !%U.P 0=48 #W52  YU7P -=6X #'6!  MUE0 *=:H "'3#  ETYP *
M<_T "W'_  QQ_P ,</\ D6(  ']A  !P80  9&$  %IA  !/8@  164  #QH
M   S;   *V\  "1R   ==@  %WD  !%\!  -?PP "W\2  I_&0 )?R( "'\J
M  9_-  %?S\ !']+  )_6  !?V<  ']Y  !_C@  ?Z,  'Z[  !]X   ??<
M 'S_  ![_P  >_\ B6<  'AG  !K9@  868  %1G  !):0  /VT  #5Q   L
M=0  )'D  !U\   6@   $(,   R& @ &B0H  8D/  ")%   BAL  (HC  "+
M+   BS<  (M#  "+4   BU\  (MQ  "+A@  BYP  (JS  ")TP  B/,  (C_
M  "'_P  A_\ @FT  '-L  !H;   6FT  $YO  !"<P  .'<  "Y[   E@
M'80  !6(   0C   "X\   22    E 8  )4,  "5$   EA4  )<<  "8)
MF"X  )DY  "91P  F58  )EH  "9?0  F90  )BK  "7R   ENX  );_  "5
M_P  E?\ >W0  &]S  !A<P  4W8  $9Z   [?P  ,(0  ":(   =C0  %)(
M  Z6   )F0   9P   "@    H0   *(&  "B#   I!   *44  "E'   IR0
M *@O  "H/0  J4P  *E>  "I<@  J(D  *BB  "HO   I^4  *;[  "F_P
MI?\ =WL  &A[  !9?@  2X(  #Z'   RC0  )Y(  !V7   4G   #J    >D
M    J    *L   "N    KP   +    "Q!   LPH  +0.  "U$P  MAL  +@D
M  "Z,0  ND   +I2  "[90  NWT  +J7  "ZL0  NM(  +KS  "Y_P  N?\
M;X,  %^&  !1BP  0Y   #:7   JG0  'Z(  !6G   -K   !;    "T
MMP   +L   "^    OP   ,    #!    PP$  ,0'  #%#0  QQ$  ,H9  #-
M)   SC,  ,]$  #06   T&X  -&(  #0I   T,$  -'F  #1^   T?\ 9X\
M %>4  !)F@  .Z$  "ZG   AK0  %K,   ZX   &O    ,    ##    Q@
M ,L   #-    S@   -    #1    U    -8   #: @  W D  -\/  #C%P
MYB0  .<V  #H20  Z5\  .IX  #KE   ZZ\  .O,  #LZ   [/8 7YX  %"D
M  !"JP  -+(  ":Y   9O@  #L(   3%    R@   ,T   #1    V    -L
M  #?    X    .(   #D    Y@   .D   #K    [@   /$%  #U#0  ^18
M /PE  #].0  _D\  /]G  #_@@  _YT  /^U  #_RP  _^0 _P 1 /\ #P#_
M  \ _P 1 /\ %@#_ "( _P O /\ .P#_ $< _P!2 /\ 6P#_ &0 _P!L /\
M<P#_ 'H _P"  /\ A@#_ (P _@"3 /T F0#[ *$ ^@"I /@ M #W ,( ]@#:
M /4 \0#T /\ \P#_ /, _P#I /\ X #_ -@ _P#3 /\ _P . /\ "P#_  H
M_P + /\ $0#_ !T _P J /\ -@#_ $$ _P!, /\ 5@#^ %\ ^P!F /D ;0#W
M '0 ]0!Z /0 @ #R (8 \ "- .\ E #M )L [ "D .H K@#I +H YP#- .4
MZ0#D /L XP#_ .( _P#> /\ T0#_ ,P _P#( /\ _P ) /\ ! #_  $ _P $
M /\ #@#_ !@ _P D /T , #[ #L ]P!& /, 4 #O %D [ !@ .H 9P#G &X
MY@!T .0 >@#B (  X "' -X C@#< )4 V@"> -8 J #4 +, T0## ,\ WP#.
M /0 S #_ ,L _P#+ /\ Q0#_ +\ _P"\ /\ _P " /\   #_    _P   /T
M"P#W !, \0 > .T *@#J #4 YP!  .( 2@#= %( V0!: -4 80#2 &< T !M
M ,X <P#, 'H R@"  ,@ AP#& (\ Q "8 ,( H0#  *T O@"[ +P T "Z .T
MN0#^ +@ _P"X /\ MP#_ +, _P"P /\ _P   /\   #_    ^0   .X !0#E
M  X W@ 8 -@ (P#2 "X SP Y ,L 0P#' $P Q !4 ,$ 6P"_ &$ O !G +L
M;0"Y ', MP!Z +4 @0"T (D L@"2 +  FP"O *< K "T *L Q@"I .0 IP#X
M *8 _P"F /\ I0#_ *4 _P"D /\ _P   /\   #U    Z@   -X   #0  H
MR  2 ,( '0"^ "@ NP S +D /0"U $8 L@!- +  50"M %L K !A *H 9P"H
M &T IP!S *4 >@"D (( H@", *  E@"? *$ G0"N )L O@"9 -@ EP#Q )8
M_P"6 /\ EP#_ )< _P"7 /\ _P   /4   #G 0  U    ,D   #   0 N  .
M +, %@"O "$ JP L *@ -@"F #\ HP!' *$ 3P"? %4 G0!; )L 80": &<
MF !N )< =0"5 'T E "& )( D0"0 )P C@"I (P N "+ ,T B0#K (@ _0"(
M /\ B #_ (@ _P"( /\ ^08  .D,  #4#@  PPP  +<)  "P @  JP ) *8
M$ "B !H G@ E )L , "8 #D E@!! )0 20"2 %  D !6 (X 7 "- &( BP!I
M (H < "( '@ AP"! (4 C "$ )@ @@"E (  M !^ ,@ ?0'G 'P"^0![ _\
M>P3_ 'L$_P![!/\ \0X  -X5  #%%0  M!0  *D1  "A#@  G@H  )L## "7
M !, DP > ) !*0"- C, B@,\ (@$0P"&!4L A091 (,&5P""!UX @ =D '\(
M; !]"'0 ? A^ 'H)B0!X"98 =PJC '4*LP!S"\< <@SF ' -^P!P#?\ ;PW_
M &\-_P!O#?\ Z!8  - >  "Y'0  J1P  )T:  "5%@  D!,  (\. P"."@X
MB0L7 (8,(P"##2T @ TV 'X./@!\#D8 >PY- 'D/4P!X$%H =A!A '40: !S
M$'$ <1%[ ' 1AP!N$90 ;!&B &L2L@!I$L< :!/G &83_0!E%/\ 913_ &43
M_P!E$_\ WQX  ,8D  "P)   H",  )0A  "+'P  AAL  (,7  ""$@@ ?Q$2
M 'P2'0!Y%"@ =A0Q '05.@!R%D$ <19( &\73P!N%U8 ;!== &L89 !I&&T
M:!EW &89@P!D&9  8QJ? &$:KP!@&L0 7AOD %T<^P!<'/\ 7!O_ %P;_P!<
M&_\ U24  +TJ  "H*0  F"D  (PH  "#)0  ?2(  'D?  !X&P, =AD/ '(:
M& !O'", ;1TM &L=-0!I'CT :!Y$ &8?2P!E'U( 8R!9 &(@80!A(&D 7R%S
M %TA?P!<(8T 6B*< %DBK !7(L  5B/A %4C^0!4(_\ 5"+_ %0B_P!4(O\
MS2L  +8N  "B+@  DBX  (4M  !\*P  =B@  '(F  !O(P  ;2$, &HB%0!G
M(Q\ 920I &,D,0!B)3D 8"9! %\F2 !=)D\ 7"=6 %LG70!9)V8 6"AP %8H
M? !4*(H 4RF9 %$IJ@!0*;X 3RG> $XI]P!-*?\ 32G_ $TH_P!.*/\ R#
M + R  "<,@  C#(  ( Q  !V,   <"T  &LK  !H*0  9B@) &,H$0!@*1P
M7BHE %PK+@!;*S8 62P] %@L1 !7+4P 52U3 %0M6P!3+6, 42YN % N>@!.
M+H@ 3"^7 $LOJ !)+[L 2"_; $@O]@!'+_\ 1R[_ $<M_P!(+?\ Q#0  *LU
M  "7-0  AS4  'LU  !R-   :S(  &8O  !B+@  7RT% %PN$ !:+Q@ 6# B
M %8P*P!5,3, 4S$Z %(R0@!1,DD 4#)0 $XS6 !-,V$ 2S-K $HS=P!(-(4
M1S25 $4TI@!#-+D 0C36 $(T] !"-/\ 0C/_ $(R_P!",O\ P#@  *<X  "3
M.   @S@  '<X  !M-P  9C8  &$S  !=,@  63(" %<S#0!4-!4 4C4? %$U
M* !/-C  3C8X $PW/P!+-T8 2C=. $DX5@!'.%\ 1CAI $0X=0!#.(, 03F3
M $ YI  ^.;@ /3G3 #PY\P \./\ /3?_ #TW_P ]-O\ NSL  *([  "/.P
M?SL  ',[  !J.@  8CD  %TW  !8-@  5#<  %$X"P!/.1, 33D< $LZ)0!*
M.BT 2#LU $<[/ !&/$0 13Q+ $0\4P!"/%P 03UG #\]<P ^/8$ /#V1 #H]
MHP Y/;8 .#W1 #<]\@ W//\ .#O_ #@[_P X.O\ MCT  )X^  "+/@  ?#X
M &\^  !F/0  7CT  %@[  !3.@  3SL  $P\" !)/1$ 1SX9 $8_(@!$/RH
M0S\R $) .@!!0$$ 0$!) #Y!40 ]05H /$%D #I!<  X07\ -T&/ #5"H0 T
M0K0 ,D+. #)!\  R0/\ ,T#_ #,__P T/O\ L4   )I   "'0   >$$  &Q!
M  !B0   6T   %0_  !./P  2D   $9!!0!$0@X 0D,6 $!#'P _1"< /D0O
M #Q$-P [13X .D5& #E%3@ X1E@ -D9B #5&;@ S1GP ,4:- #!&GP N1K,
M+4;, "U&[P M1?\ +D3_ "Y#_P N0_\ K$,  )9#  "#0P  =$,  &A#  !?
M0P  5T,  %!#  !(0P  1$4  $%& 0 ^1PP /$@3 #I('  Y220 .$DL #9)
M-  U2CL -$I# #-*3  R2E4 ,$M? "]+:P M2WH +$N+ "I+G0 H2[$ )TO*
M "=+[0 G2O\ *$G_ "A(_P I1_\ IT8  )%&  !_1@  <$8  &5&  !;1@
M5$8  $Q'  !$2   /TH  #M+   W3 D -4T0 #-.&  R3B  ,4\H #!/,  O
M3S@ +D]  "Q02  K4%( *E!< "A0:  G4'< )5"( "10FP B4*\ (5#( "!0
MZP A3_\ (D[_ ")-_P C3?\ H4D  (Q)  !Z20  ;$H  &%*  !82@  4$H
M $E+  ! 3   .TX  #50   Q4@0 +5,- "Q4%  J5!P *54D "A5+  G53,
M)E4\ "5610 D5DX (E99 "%690 ?5G0 'E:% !Q6F  ;5JP &5;% !E6Z0 :
M5?\ &U3_ !M3_P <4O\ FTT  (9-  !U30  :$T  %U-  !430  34X  $5/
M   \40  -E,  #%5   K6   )EH) "-;$  B6Q< (5P? "!<)P ?7"X '5PW
M !Q=0  ;74H &EU5 !A=80 777  %5V! !1=E0 37:H $5W" !%=YP 26_X
M$UK_ !-:_P 46?\ E%$  (!1  !P40  9%$  %E1  !140  25(  $%3   X
M5@  ,ED  "M;   E7@  'V$# !IC#  89!$ %V09 !9D(0 59"D %&4Q !-E
M.@ 2940 $650 !!E70 /96L #F5]  UED0 ,9:4 "F2\  IDX  +8_D #&+_
M  UA_P -8?\ C54  'I5  !K50  7U4  %95  !.50  1%<  #Q9   T7
M+%\  "9B   ?90  &6@  !-K!0 0;0T #FX2  UN&@ ,;B( #&XK  MN-  *
M;CX "&Y*  =N5P &;F4 !&YV  )NB@  ;9\  &VV  !LU@  ;/,  6O_  )J
M_P #:O\ A5H  '1:  !F6@  7%D  %-9  !(6@  /UT  #9@   N8P  )F<
M !]J   9;0  $W$   YT P *=PH !7<0  %W%0  =QP  '<D  !X+0  >#<
M 'A#  !X4   >%X  'AO  !XA   >)D  '>P  !VS0  =?   '7_  !T_P
M=/\ ?E\  &Y?  !B7@  65X  $U?  !"8@  .64  #!H   G;   'W   !AT
M   2=P  #7L   A^   "@ @  ($-  "!$0  @A<  (,>  "#)@  A#   (0[
M  "$2   A%<  (1H  "$?   A),  (.J  ""Q0  @>L  ('^  " _P  @/\
M=V4  &ED  !?8P  4F0  $=G   \:P  ,6\  "AS   @=P  &'P  !%_   ,
M@P  !H<   "*    C ,  (P)  "-#@  CA$  (\7  "0'@  D2<  )(R  "2
M/P  DDX  ))?  "2<P  DHL  )&B  "1O   D.4  (_\  "._P  CO\ <6L
M &9J  !8:P  2VT  #]Q   T=@  *GL  ""    7A0  $(D   N-   $D0
M )4   "8    F0   )H#  ";"   G T  )X1  "?%@  H!X  *(H  "B-0
MHT0  *-5  "C:0  HH   **:  "ALP  H-@  *#V  "?_P  G_\ ;G$  %]R
M  !1=0  1'D  #=^   LA   (8H  !>/   0E   "ID   &=    H    *0
M  "G    J    *D   "J    K 8  *T+  "O$   L!4  +(>  "T*0  M#D
M +1*  "U70  M7,  +6.  "UJ   M,8  +/M  "R_P  LO\ 9GH  %=]  !)
M@@  /(<  "^.   CE   &)H  !"?   )I    *D   "M    L    +0   "W
M    N    +D   "[    O    +X"  # "   P@X  ,04  #''@  R"P  ,D]
M  #*4   RF8  ,I_  #*FP  RK@  ,K=  #*]0  RO\ 7H8  $^+  !!D0
M,Y@  ">?   ;I0  $:L   FP    M0   +D   "]    P0   ,8   #(
MR0   ,L   #,    S@   -    #2    U 4  -D,  #=$@  X1X  .(N  #C
M0@  Y%<  .5O  #FC   YJ@  .7%  #EYP  YO8 5I0  $B;   ZH@  +*D
M !^P   3M@  "[P   #!    Q0   ,D   #-    T@   -8   #:    VP
M -X   #@    X@   .0   #G    Z0   .T   #P"@  ]!$  /@?  #Y,@
M^D@  /M?  #\>@  _9<  /VO  #]QP  _>0 _P . /\ #0#_  P _P . /\
M$P#_ !X _P J /\ -@#_ $( _P!- /\ 5P#_ %\ _P!G /\ ;@#_ '0 _P!Z
M /\ @0#] (< _ "- /H E #Y )P ]P"E /4 KP#T +P \P#/ /$ [ #P /X
M[P#_ .\ _P#C /\ UP#_ ,X _P#* /\ _P * /\ !@#_  0 _P ( /\ $ #_
M !D _P E /\ ,0#_ #T _P!' /X 40#[ %D ^0!A /8 : #T &X \P!T /$
M>@#O ($ [@"' .P C@#J )8 Z "? .8 J0#C +4 X@#& .  XP#? /@ W0#_
M -T _P#4 /\ R0#_ ,( _P"^ /\ _P # /\   #_    _P ! /\ #0#_ !0
M_0 @ /H *P#W #8 \P!! .\ 2P#L %0 Z !; .8 8@#C &@ X0!N -\ = #<
M 'H V@"! -@ B #4 )  T@"8 ,\ H@#- *X RP"\ ,D TP#' /  Q@#_ ,0
M_P#$ /\ NP#_ +8 _P"S /\ _P   /\   #_    _P   /< " #P !  ZP :
M .< )0#D #  X0 [ -P 10#5 $T T0!5 ,X 6P#+ &( R0!G ,< ;0#% ',
MPP!Z ,$ @0"_ (D O0"2 +L G "Y *< MP"U +4 R "S .8 L@#[ +$ _P"P
M /\ K@#_ *H _P"G /\ _P   /\   #^    \0   .4  @#<  T TP 4 ,T
M'P#* "H QP T ,0 /@#  $< O !. +H 50"W %L M0!A +, 9P"R &T L !S
M *X >@"L (( J@"+ *@ E0"G *  I0"M *, O@"A -L H #T )\ _P"> /\
MGP#_ )T _P"; /\ _P   /P   #N    X    -    #%  @ O@ 0 +D &0"U
M ", LP N +  -P"M $  J@!( *@ 3P"E %4 HP!; *( 8 "@ &8 GP!L )T
M<P"; 'L F@"$ )@ C@"6 )H E0"G ), MP"1 ,P D #L (\ _P". /\ C@#_
M (X _P"/ /\ _    .\   #;    R0   +T   "U  ( K@ , *D $P"E !T
MH@ G *  ,0"= #H F@!" )@ 20"6 $\ E !5 ), 6P"1 &  D !G (X ;0"-
M '4 BP!^ (D B0"( )4 A@"B (4 L0"# ,0 @0#D (  ^0!_ /\ @ #_ (
M_P"  /\ ] (  . )  #'"   MP<  *P#  "F    H  ' )L #P"8 !< E0 A
M )( *@"/ #, C0 \ (L 0P") $D AP!0 (8 50"$ %L @P!A ($ : "  '
M?@!Y 'P A ![ )  >0"= '@ K !V +X =0#= ', ] !S /\ <P#_ ', _P!S
M /\ Z0T  ,\0  "Y$   J1   )X.  "7"P  DP8  )  "P", !$ B0 : (8
M) "# "X @0 V '\ /@!] $0 ? !+ 'H 40!Y %< =P!= '8 9 !T &P <P%U
M '$!@ !O HT ;@*: &P#J@!K [L :036 &@&\0!H!_\ 9P?_ &<'_P!G!_\
MWQ0  ,,7  "N%P  GA8  ),5  "+$@  AA   (0, @"#!@T @ ,4 'P%'@!Y
M!R@ =P@P '4(. !S"4  <@E& ' *3 !O"E, ;0M9 &P+80!J"VD :0QR &<,
M?@!F#(L 9 V9 &(-J0!A#;L 8 W8 %X.\P!=#O\ 70[_ %T._P!=#O\ U!P
M +D=  "D'@  E1T  (D<  "!&@  >Q<  '@3  !X$ 8 =PT/ ',.& !P#B(
M;@\K &P0,P!J$#L :1!" &<120!F$4\ 9!%6 &,270!A$F8 8!)O %X2>P!<
M$X@ 6Q.7 %D3IP!7%+H 5A35 %45\P!4%?\ 5!7_ %05_P!4%/\ RB(  + B
M  "=(P  C2,  ($B  !Y(0  <QX  &\;  !N%P  ;1,, &H4% !G%1X 918G
M &,6+P!A%S< 8!<^ %X810!=&$L 7!E2 %H96@!9&6( 5QIL %8:=P!4&H4
M4AN4 %$;I !/&[< 3AO0 $T<\0!,'/\ 3!S_ $T<_P!-&_\ PR8  *HG  "6
M)P  AR@  'LG  !R)@  ;"0  &@A  !F'@  9!L( &(;$0!?'!H 71TC %L>
M*P!:'C, 6!\Z %<?00!6($@ 5"!/ %,@5P!1(5\ 4"%I $XA= !-(8( 2R*1
M $DBH@!((K0 1R+- $8C[P!%(_\ 12+_ $8B_P!&(?\ O"H  *0K  "1*P
M@BP  '8K  !M*@  9BD  &(F  !?)   72($ %LA#@!8(A8 5B,? %0D* !3
M)#  4B4W % E/@!/)D4 3B9, $PF5 !+)UP 22=F $@G<0!&)W\ 12B/ $,H
MH !!*+( 0"C+ #\H[0 _*/\ /RC_ $ G_P! )_\ MRT  )\N  ",+P  ?2\
M '$O  !H+@  82T  %TK  !:*   5R<  %0G# !2*!, 4"D< $XI)0!-*BP
M2RHT $HK.P!)*T( 2"Q) $8L40!%+%H 1"QD $(M;P! +7T /RV- #TMG@ \
M+;  .BW( #HMZP Z+?\ .BW_ #HL_P Z+/\ LC   )LQ  "(,@  >3(  &TR
M  !D,@  73$  %@O  !5+   42P  $\M"0!,+1$ 2BX9 $DO(@!'+RH 1C Q
M $4P. !#,#\ 0C%' $$Q3P! ,5< /C%A #TR;0 [,GL .3*+ #@RG  V,J\
M-3+' #0RZ0 T,O\ -3'_ #4Q_P U,/\ K3,  )8T  "$-0  =34  &DU  !@
M-0  630  %0S  !0,   3#$  $DQ!@!',@\ 13,6 $,S'P!"-"< 0#0N #\U
M-@ ^-3T /35$ #PV3  Z-E4 .39? #<V:P V-G@ -#>) #(WF@ Q-ZT +S?%
M "\WZ  O-OX ,#7_ # U_P P-/\ J38  )(V  " -P  <C@  &8X  !=-P
M5C<  % V  !+-   1S4  $0V P!!-PT /S@4 #XX'  \.20 .SDL #HY,P Y
M.CH .#I" #8Z2@ U.E, -#M= #([:  P.W8 +SN' "T[F0 L.ZP *CO# "D[
MY@ J.OT *CK_ "LY_P L./\ I#@  (XY  !\.@  ;CH  &,Z  !:.@  4SH
M $TZ  !&.   0CH  #\[   \/ L .CP1 #@]&0 W/2$ -CXI #0^,  S/C<
M,C\_ #$_1P P/U  +C]: "U 9@ K0'0 *4"$ "A EP F0*H )4#! "1 Y0 D
M/_P )3[_ "8]_P F/?\ GSL  (H\  !X/0  :CT  %\]  !6/0  3ST  $D]
M  !"/0  /#X  #D_   V00@ -$$/ #)"%@ Q0AX +T,E "Y#+0 M0S0 +$0\
M "M$1  J1$T *$18 "=%8P E17$ (T6" ")%E0 @1:@ 'T6_ !Y$XP ?1/L
M'T/_ "!"_P A0?\ FCX  (4_  !T0   9T   %Q   !30   3$   $9    ^
M00  .$,  #1%   P1@, +4<- "M($@ J2!H *4@B "A)*0 G23$ )4DY "1)
M00 C2DH (DI5 "!*80 ?2F\ '4I_ !M*D@ :2J8 &$J] !=*X  82?H &4C_
M !I'_P :1_\ E4(  (!"  !P0P  8T,  %A#  !00P  24,  $)$   [10
M-4<  #!)   K2P  )DT) "1.$  B3A8 (4\= "!/)0 ?3RP 'D\U !U//0 <
M4$< &E!1 !E070 74&L %E!\ !10CP 34*0 $5"Z !%0W@ 13_@ $D[_ !--
M_P 43?\ CT4  'M&  !K1@  7T<  %5'  !-1P  1D<  #]'   W2@  ,4P
M "M.   F4   (%,# !Q5#  :5A$ &588 !=6(  65B< %58P !16.0 35T(
M$E=- !%760 05V@ #U=Y  Y7C  -5Z  "U>V  M6U  +5O0 #%7_  U4_P .
M4_\ B$D  '9*  !G2@  6TH  %%*  !*2@  0TH  #M,   S3@  +%$  "94
M   A5@  &UD  !5<!P 17@T $%X3 !!>&@ .7B( #EXJ  U>,P ,7CT "UY(
M  I>5  (7F( !UYS  5>A@ #7IL  EZQ  )=S  "7>X  US_  1;_P %6_\
M@4X  '!.  !B3@  5TX  $Y.  !'3@  /D\  #91   N5   )U<  "%:   ;
M70  %6   !!C P ,9@L "&<0  9G%0 %9QP !&<D  )G+0 !9S<  &="  !G
M3@  9UP  &=M  !G@   9I4  &:L  !EQP  9>L  &3\  !D_P  8_\ >E(
M &I3  !=4@  5%(  $M2  !"4P  .54  #!8   H6P  (5\  !IB   490
M$&@   QK 0 &;@D  &\.  !O$@  ;Q@  ' ?  !P)P  <3   '$[  !Q2
M<58  '%F  !Q>0  <8\  '"G  !OP0  ;^<  &[\  !M_P  ;?\ <U@  &57
M  !:5P  458  $97   \6@  ,ET  "IA   B9   &F@  !1L   .;P  "G(
M  1V    > 4  '@+  !Y#@  >A,  'L9  !\(   ?2D  'TS  !]0   ?4X
M 'U>  !]<@  ?8@  'RA  !\N@  >^(  'KZ  !Y_P  >/\ ;5T  &!<  !7
M7   2UT  $!?   U8P  *V<  "-K   :;P  $W,   YW   (>P   GX   ""
M    @P$  (0&  "%"P  A@\  (@3  ")&0  BB$  (LK  "+-P  C$8  (M6
M  "+:0  BX   (N9  "*LP  B=@  (CW  "(_P  A_\ :&,  %YB  !18@
M1&4  #AI   N;@  )',  !IX   3?0  #8$   :%    B0   (T   "0
MD@   )(   "4!0  E0H  )<.  "8$@  FA@  )LA  "<+0  G3P  )U,  "<
M7P  G'8  )N1  ";JP  FLD  )KP  "9_P  F/\ 96D  %=I  !);   /7$
M #!V   E?   &X$  !*'   ,C   !)$   "5    F0   )T   "@    H0
M *(   "D    I0$  *<'  "I#   JA$  *T8  "O(@  KS   *]!  "O5
MKVL  *Z%  "NH0  KKX  *WF  "L_   K/\ 7G$  $]T  !">0  -7\  "B%
M   =C   $Y(   R8   #G0   *(   "F    J@   *X   "P    L0   +,
M  "T    M@   +@   "Z!   O H  +X0  #!%P  PR0  ,,U  #$20  Q%X
M ,5W  #%DP  Q:\  ,71  ##\@  P_\ 5GP  $>"   ZB   +(\  ""6   4
MG0  #:,   .I    K@   +(   "W    NP   +\   #"    P@   ,4   #&
M    R    ,H   #-    SP   -((  #5#@  VQ@  -TG  #>.@  WU   .!H
M  #@A   X:$  .&]  #AX@  X/0 3HL  $"2   RF0  ):$  !BH   .KP
M!;4   "Z    OP   ,0   #(    S@   -$   #4    U0   -@   #:
MW0   -\   #B    Y    .<   #K!0  [PX  /09  #U*P  ]D$  /=8  #X
M<@  ^9   /FK  #XQ   ^.$ _P + /\ " #_  D _P , /\ $@#_ !H _P F
M /\ ,@#_ #X _P!( /\ 4@#_ %H _P!B /\ :0#_ &\ _P!U /X >P#\ ($
M^P"( /D CP#W )< ]0"@ /, J@#R +< [P#) .T Y@#L /L ZP#_ .L _P#=
M /\ S@#_ ,8 _P#" /\ _P $ /\   #_    _P % /\ #0#_ !4 _P A /\
M+ #_ #@ _P!# /T 3 #Y %0 ]P!< /0 8P#R &D \ !O .X =0#L 'L Z@""
M .@ B0#G )$ Y ": .( I #@ +  W0#  -H W #8 /0 U0#_ -, _P#+ /\
MP0#_ +L _P"W /\ _P   /\   #_    _P   /\ "@#] !$ ^0 ; /8 )P#T
M #( \  \ .P 1@#H $X Y !6 .$ 7 #> &, W !H -D ;@#5 '0 T@![ -
M@@#- (H RP"3 ,@ G0#& *@ Q "W ,$ S #  .L O@#_ +T _P"] /\ M #_
M *X _P"K /\ _P   /\   #_    ^@   /( !0#J  X Y0 6 .  (0#= "L
MVP V -, /P#. $@ R@!/ ,< 5@#$ %P P@!A ,  9P"^ &T O !S +H >@"X
M (( M@"+ +0 E@"R *$ L "O *X P0"M .  JP#W *H _P"I /\ I@#_ *$
M_P"? /\ _P   /\   #W    Z    -P   #0  H R@ 1 ,4 &P#" "4 OP O
M +P . "X $$ M0!( +( 3P"P %4 K@!; *P 80"J &8 J !L *< <P"E 'L
MHP"$ *$ C@"? )H G0"G )L N ": -  F0#O )@ _P"7 /\ E@#_ )0 _P"2
M /\ _P   /8   #D    T@   ,4   "[  4 M0 . +  %0"L !\ J@ I *@
M,@"E #H H@!" *  20"> $\ G !5 )H 6@"8 &  E@!F )4 ; "3 '0 D@!]
M )  AP". ), C "A (L L "* ,4 B #F (< ^P"& /\ AP#_ (< _P"& /\
M^    .4   #-    O0   +,   "J    HP * )\ $0"; !D F0 C )< + "5
M #0 D@ \ )  0P". $D C !/ (H 5 ") %H AP!@ (8 9@"$ &X @P!W ($
M@0!_ (T ?@"; 'P J@![ +P >@#; '@ ]0!X /\ > #_ '@ _P!X /\ [0
M -$"  "[ @  K $  *(   ";    E@ % )$ #0"- !0 BP = (@ )@"& "X
MA  V (( /0"  $, ?@!) 'T 3P!\ %4 >@!; 'D 80!W &D =0!Q '0 ? !R
M (@ <0"6 &\ I0!N +8 ;0#. &P [@!K /\ :P#_ &L _P!K /\ WPL  ,(,
M  "N#   G@P  ),+  ",!P  B (  (4 "0"! !  ?P 7 'P ( !Z "@ >  P
M '8 . !T #X <P!$ '$ 2@!P %  ;@!6 &T 70!L &0 :@!M &@ =P!G (0
M90"2 &0 H0!C +( 80#) &  Z0!@ /P 8 #_ &  _P!@ /\ T!   +81  "B
M$@  DQ(  (@1  " #P  ? T  'D) 0!X PL =0 1 ', &@!P ", ;@$K &P!
M,P!J CD :0-  &<#1@!F!$P 9012 &,%60!B!6$ 8 5J %\&= !=!H$ 7 >/
M %H'GP!9![  5P?& %8)YP!6"OL 50K_ %4*_P!6"O\ QA4  *T7  "9&
MBA@  '\7  !V%@  <1,  &X0  !M#04 ;0D- &H)% !G"AT 90HF &,++@!B
M##4 8 P\ %\,0@!>#4@ 7 U/ %L-5@!9#5X 6 YH %8.<P!5#H  4PZ/ %$.
MGP!0#K$ 3@[( $T0Z@!-$/T 31#_ $T0_P!-$/\ O!L  *4<  "2'0  @QX
M '<=  !O'   :1H  &87  !D%   9! ( &(/$ !?$!@ 71 A %L1*0!:$3$
M6!(X %<2/@!6$D4 5!), %,34P!1$UL 4!-E $X4< !,%'T 2Q2, $D4G !'
M%:X 1A7% $45Z !%%OX 11;_ $45_P!%%?\ M1\  )XA  "+(@  ?"(  '$B
M  !H(0  8A\  %\=  !<&@  6Q<" %H5#0!7%A0 518= %07)0!2&"T 41@T
M $\8.P!.&4( 31E( $L:4 !*&E@ 2!IB $<:;0!%&WH 0QN) $(;F@! &ZP
M/QO" #X<Y0 ]'/P /AS_ #X;_P ^&_\ KR,  )@D  "&)0  =R8  &PF  !C
M)0  720  %DB  !6'P  5!T  %,<"P!1'!( 3AT: $T=(@!+'BD 2AXQ $D?
M-P!''SX 1B!% $4@30!#(%4 0B!? $ A:@ _(7< /2&' #LAF  Y(:H ."+
M #<BXP W(OL -R+_ #@A_P X(?\ JB8  )0G  "!*0  <RD  &<I  !?*0
M6"@  %0F  !1(P  3R(  $PB!P!*(A  2"(7 $<C'P!%)"8 1"0N $(D- !!
M)3L 0"5# #\E2@ ])E, /"9< #HF9P Y)G4 -R>$ #4GE@ T)Z@ ,B>^ #$G
MX0 Q)_D ,B;_ #(F_P S)?\ I2D  (\J  !]+   ;RP  &0M  !;+   52L
M % J  !,*   2B8  $<G! !$)PT 0B@4 $$H'  _*2, /BDK #TI,@ \*CD
M.RI  #DJ2  X*U  -BM: #4K90 S*W( ,2N" # LE  N+*< +"R\ "LLW@ L
M+/@ +"O_ "TJ_P M*O\ H2P  (LM  !Y+@  :R\  & O  !8+P  42X  $PN
M  !(+   12L  $$K   _+ L /2P1 #LM&0 Z+B$ .2XH #<N+P V+S8 -2\^
M #0O10 S+TX ,3!8 # P8P N,'  +#"  "HPD@ I,*4 )S"Z "8PW  F,/<
M)R__ "@O_P H+O\ G"X  (<P  !V,0  :#(  %TR  !5,@  3C$  $@Q  !$
M,   0"\  #PP   Z,0D -S$0 #8R%@ U,AX ,S,E #(S+  Q,S, ,#0[ "\T
M0P M-$P +#16 "HU80 I-6X )S5^ "4UD  C-:, (C6Y "$UV0 A-/8 (C3_
M ",S_P C,O\ F#$  (,S  !R-   930  %HU  !1-0  2S0  $4T  ! -
M.C,  #<T   T-08 ,C8. # W$P O-QL +C<B "TX*0 K.#$ *C@X "DY0  H
M.4D )CE3 "4Y7P C.6P (3I\ " ZC@ >.J( '#JW !LYU0 <.?4 '3C_ !TX
M_P >-_\ DS0  '\V  !N-P  83<  %<W  !.-P  2#<  $(W   \-P  -3@
M #(Y   O.@( +#L+ "H\$0 I/!@ *#T? "8])@ E/2X )#TU ",^/0 B/D8
M(#Y0 !\^7  =/VD &S]Y !H_C  8/Z  %C^U !4^T@ 6/O, %SW_ !@\_P 8
M//\ CC<  'HX  !J.0  7CH  %,Z  !+.@  13H  #\Z   Y.@  ,CP  "X^
M   I0   )D$( "1"#@ B0A0 (4(; "!#(P ?0RH 'D,R !Q#.@ ;1$, &D1-
M !A$60 71&< %41W !-$B@ 21)X $42S !!$T  00_( $4+_ !)"_P 30?\
MB3L  '8\  !F/0  6CT  % ]  !(/0  0CT  #P]   V/@  +T   "I"   E
M1   (48# !U(#  ;21$ &4D7 !A)'@ 7228 %DDN !5*-@ 42D  $TI* !%*
M5@ 02F0 #TIT  Y*AP -2IL #$JP  I*R@ +2>P #$C_  U'_P -1_\ @SX
M '$_  !B0   5D   $U   !%0   /T   #E!   R0@  *T4  "9'   A20
M'$L  !9.!P 34 X $E 3 !%0&0 04"$ #U I  Y0,0 -4#L #5%&  M140 *
M45\ "5%O  =0@0 %4)8  U"K  )0Q0 #3^@  T_[  5._P &3?\ ?4(  &M#
M  !=1   4D0  $I$  !#0P  /$0  #5%   N1P  )TH  "%,   <3P  %U$
M !)4 P .5PH "U@0  I8%0 (6!P !U@D  98+  %6#8  UA   %83   6%H
M %AI  !8?   6)$  %>G  !7P   5N4  %;Y  !5_P  5?\ =D<  &9'  !9
M2   3T<  $='  ! 1P  .$@  #!*   I30  (E   !Q3   650  $5@   U;
M @ )7@D !%\.  !?$@  7Q@  & ?  !@)P  8#   & [  !@1P  8%0  &!C
M  !@=@  8(L  %^B  !?NP  7^(  %[Y  !=_P  7?\ ;TL  &%,  !53
M3$L  $1+   [3   ,DX  "M1   C5   '%<  !9;   17@  #6    AC   "
M9@<  &<,  !G#P  :!,  &D9  !J(0  :BD  &HT  !J0   :DT  &I=  !J
M;P  :H4  &J=  !IM@  :-T  &CW  !G_P  9O\ :5$  %Q0  !24   2D\
M #]0   U4P  +58  "19   =70  %F   !!D   ,9P  !FH   !N    ;P,
M ' (  !Q#0  <A   '04  !U&P  =B,  '<L  !W.   =D8  '96  !V:
M=GX  ':7  !UL0  =-,  '/U  !S_P  <O\ 8U8  %A5  !05   1%4  #E8
M   O6P  )E\  !UC   59P  $&P   IP   $<P   '8   !Z    ?    'P#
M  !^"   ?PP  ($0  ""%   A!L  (4D  "&+P  ACT  (9-  "%7P  A74
M (6/  "$J0  @\D  (+Q  "!_P  @/\ 7UL  %9:  !)6P  /5X  #)A   G
M9@  'FL  !5P   .=0  "7D   %^    @0   (4   "(    B@   (L   "-
M 0  C@8  ) +  "1#P  DQ0  )4;  "7)@  ES0  )=$  "75@  EFP  )6&
M  "5H@  E,$  )/J  "2_P  DO\ 76$  $]A  !"9   -FD  "IN   ?=
M%7D   Y_   'A    (D   ".    D@   )8   "8    F@   )L   "=
MGP   *$#  "C"   I0T  *<3  "I'   JB@  *HY  "J2P  JF$  *EZ  "H
MF0  J+4  *?=  "G^   IO\ 5F@  $AL   Z<   +G8  ")]   7A   #HH
M  >0    E@   )H   "?    HP   *<   "J    JP   *T   "O    L0
M +,   "U    N 4  +H,  "]$@  P!P  , M  # 0   OU4  +]N  "^BP
MOJ@  +[)  "][P  O/X 3G0  $!Y   R?P  )8<  !F.   0E0  !YP   "B
M    IP   *P   "P    M0   +D   "\    O0   +\   #!    PP   ,8
M  #(    R@   ,T"  #0"P  U1(  -8A  #7-   V$D  -E@  #:?   VIH
M -NU  #;V0  V_( 1H(  #B)   KD   '9@  !*@   *IP   *X   "T
MN0   +X   #"    R    ,L   #.    SP   -(   #4    U@   -H   #=
M    WP   .(   #F    Z@H  .\3  #P)0  \CH  /-1  #T:P  ](D  /6E
M  #UOP  ]=T _P & /\  P#_  4 _P + /\ $ #_ !< _P B /\ +0#_ #D
M_P!$ /\ 30#_ %4 _P!= /\ 9 #_ &H _P!P /T =@#[ 'P ^0"# /< B@#U
M )( \P"; /  I@#N +, ZP#$ .D Y #G /D Y@#_ .4 _P#3 /\ QP#_ +\
M_P"[ /\ _P   /\   #_    _P " /\ "P#_ !( _P = /\ * #_ #, _P ^
M /P 1P#X $\ ] !7 /$ 70#N &, [ !I .H ;P#H '4 Y@!\ .0 @P#B (L
MWP"5 -P GP#9 *L U0"[ -( U #/ /( S0#_ ,P _P#% /\ N@#_ +0 _P"P
M /\ _P   /\   #_    _P   /\ !@#Y  \ ]0 7 /, (@#Q "T [0 W .<
M0 #B $D WP!0 -L 5P#7 %T U !C -$ : #/ &X S !U ,H ? #( (0 Q0"-
M ,( F #  *0 O0"R +L Q@"Y .@ N #] +< _P"V /\ K0#_ *< _P"C /\
M_P   /\   #_    ]0   .L  0#D  P W@ 3 -D ' #3 "8 T0 P ,P .@#(
M $( Q !* ,  4 "] %8 NP!< +D 80"W &< M0!M +, = "Q 'P KP"% *T
MD "J )P J "J *8 NP"E -H HP#U *, _P"B /\ G@#_ )H _P"7 /\ _P
M /X   #O    WP   -    #'  < P0 / +P %P"Y "  MP J +4 ,P"P #L
MK0!# *L 20"H $\ I@!5 *0 6@"C &  H0!F )\ ;0"= '0 G !] )H B "8
M )0 E@"B )0 L@"2 ,D D0#K )$ _P"0 /\ D #_ (P _P"* /\ _    .P
M  #9    QP   +H   "Q  ( JP , *< $@"D !L H0 D *  + "> #4 FP \
M )@ 0P"6 $D E !/ )( 5 "0 %H CP!? (T 9@"+ &T B0!V (@ @ "& (P
MA ": (( J@"! +X @ #@ (  ^0!_ /\ ?P#_ '\ _P!^ /\ \0   -@   #"
M    LP   *@   "@    F0 ' )4 #@"2 !4 D  > (X )@"- "X B@ V (<
M/0"% $, A !) (( 3@"! %0 ?P!9 'X 8 !\ &< >@!O 'D >@!W (8 =0"4
M '0 HP!R +4 <@#/ '$ \0!P /\ < #_ '  _P!Q /\ X0   ,0   "P
MH@   )<   "1    BP " (8 "P"# !$ @0 8 '\ (0!] "D ?  P 'D -P!X
M #T =@!# '0 20!S $X <@!4 '  6@!O &( ;0!J &L = !J (  : ". &<
MG0!E *\ 90#& &0 Z !D /T 8P#_ &, _P!D /\ SP4  +8'  "C"   E @
M (D'  "" P  ?@   'L !@!W  X =0 3 '( &P!Q ", ;P K &T ,@!L #@
M:@ ^ &D 1 !G $D 9@!/ &4 5@!C %T 8@!E &  ;P!? 'L 70") %P F0!;
M *H 60"_ %D X0!8 /@ 6 #_ %@ _P!9 /\ P@P  *H-  "7#@  B0X  'T.
M  !V#0  <0H  &\&  !M  H :P 0 &D %@!G !X 90 F &, +0!A #, 8  Y
M %\ /P!= $4 7 !+ %L 4@!: %D 6 !B %< ; !5 '@ 4P"& %( E@!1 *<
M4 "[ $\!VP!. O0 3@/_ $X$_P!. _\ N!   *$2  ".$P  ?Q,  '03  !L
M$@  9Q   &4.  !C"P, 8P8, &$$$0!> QD 7 0A %L%* !9!B\ 6 8U %8'
M.P!5!T( 5 =( %,(3P!1"%8 4 E? $X):0!-"78 2PJ$ $D*E !("J8 1PJZ
M $8*V !%"_, 10S_ $4,_P!%#/\ L!0  )D6  "'&   >!D  &T8  !E%P
M7Q8  %P3  !:$0  6@X& %H,#0!7#!0 50P< %,-) !2#2L 4 TQ $\.. !.
M#CX 30Y% $L.30!*#E4 2 ]> $</: !%#W4 0Q"$ $$0E0! $*8 /A"[ #T0
MW  ]$?8 /1'_ #T0_P ^$/\ J1D  )(;  "!'   <AT  &<=  !?'   61L
M %49  !3%@  4A,  %(1"@!0$!  3A$8 $P1( !*$B< 21(N $@3- !'$SL
M11-" $0320!#%%( 011; #\490 ^%7( /!6! #H5D@ X%:0 -Q6Y #45V  U
M%O4 -A;_ #86_P W%?\ HQP  (T>  ![(   ;2$  &(A  !:(0  5!\  % >
M  !-&P  3!D  $L6!@!)%@X 1Q<5 $47' !$&"0 0A@J $$8,0! &3@ /QD_
M #T91@ \&D\ .AI8 #D:8P W&V\ -1M^ #,;D  R&Z( ,!NW "\;TP O'/,
M+QO_ # ;_P P&_\ G1\  (@B  !W(P  :20  %XD  !6)   4",  $LB  !(
M(   1AT  $4< @!#' P 01P2 #\=&0 ^'2$ /!XG #L>+@ Z'S4 .1\\ #<?
M1  V'TP -"!6 #,@8  Q(&T +R!\ "TAC@ L(:  *B&U "DAT  I(?( *2'_
M "H@_P K(/\ F2(  (0E  !S)@  92<  %LG  !3)P  3"8  $<E  !$)
M0B$  #\A   ](0D .R$0 #DB%@ X(AX -B,E #4C*P T)#( ,R0Y #(D00 P
M)$H +R53 "TE7@ K)6L *B5Z "@EC  F)9\ )"6S ",ES@ C)?  )"7_ "4D
M_P E)/\ E"4  ( G  !O*0  8BH  %<J  !/*@  22D  $0H  ! )P  /28
M #HE   W)@8 -28. #0G%  R)QL ,2@B # H*0 O*#  +2DW "PI/P K*4<
M*2E1 "@J7  F*FD )"IX ",JB@ A*IT 'RJR !XJS  >*N\ 'RG_ " I_P A
M*/\ D"@  'PJ  !L*P  7RP  %0L  !,+   1BP  $$K   \*P  ."H  #4J
M   R*P, ,"L, "XL$0 M+!@ +"P? "HM)@ I+2T *"TT "<N/  F+D4 )"Y/
M ",N6@ A+V< 'R]V !TOB  <+YL &B^P !@OR@ 8+NT &2[_ !LM_P ;+?\
MC"L  '@M  !H+@  6R\  %$O  !)+P  0R\  #XN   Y+@  -"X  # N   M
M+P  *S * "DQ$  G,14 )C$< "4R(P D,BH (S(Q "$S.0 @,T( 'S-, !TS
M5P ;,V0 &C1T !@TA@ 6-)H %#.N !,SR  3,^P %#/_ !4R_P 6,?\ ARX
M '0O  !E,0  6#$  $XR  !&,@  0#$  #LQ   V,0  ,3$  "LS   H-
M)34& ",V#0 A-A( (#<9 !\W(  >-R< '3@N !LX-@ :.#\ &3A) !<Y50 5
M.6( %#EQ !(YA  1.9@ $#FM  XXQP ...L $#C_ ! W_P 1-O\ @S$  ' R
M  !A-   530  $LT  !$-   /30  #@T   S-   +34  "@W   D.0  (#H"
M !T["P ;/!  &3T5 !@]'  7/2, %CTK !4^,P 4/CP $CY& !$^4@ 0/E\
M#SYO  X^@0 ,/I4 "SZI  H^P0 */>0 "SW[  P\_P -._\ ?30  &LV  !=
M-P  43<  $@W  !!-P  .S<  #4W   P-P  *CD  "4[   @/0  '#\  !=!
M!@ 40PT $D,2 !%#&  10Q\ $$0G  ]$+P .1#D #41#  Q$3@ +1%L "41J
M  =$?  &1)  !$.E  )#O0 #0^   T/V  1"_P &0?\ >#@  &<Y  !9.@
M3CH  $4Z   ^.@  .#H  #,Z   M.P  )ST  "%    <0@  %T0  !-& P /
M20H #4H/  Q*%  +2AL "4HC  A**P '2C0 !4H^  1*20 "2E8  $IE  !*
M=P  2HL  $JA  !)N0  2=T  $GU  !(_P  2/\ <CP  &(]  !5/@  2CX
M $(]   \/0  -CT  "\^   I0   (T(  !U%   71P  $TH   ], @ +3PD
M!U -  -1$0  41<  %$>  !1)@  42\  %$Y  !11   4E$  %)@  !1<@
M48<  %&=  !1M0  4-@  %#U  !/_P  3_\ ;$   %U!  !100  1T$  $!
M   Y0   ,D$  "I#   D1@  'D@  !=+   23@  #E$   M3 0 &5@<  %<,
M  !8$   6!,  %D9  !:(0  6BD  %HS  !:/P  6DP  %I:  !:;   6H$
M %F9  !9L0  6-$  %CT  !7_P  5_\ 944  %A%  !-10  140  #Y$   U
M10  +4<  "5*   >30  &%   !)3   .5@  "ED   1<    7@0  %\)  !@
M#0  81   &(5  !C&P  9",  &0M  !D.   9$4  &14  !D9@  9'L  &.3
M  !CK0  8LP  &'R  !A_P  8/\ 7TH  %-*  !*20  0T@  #E)   O3
M)T\  !]2   850  $ED   U=   (8    F,   !F    : $  &D%  !J"@
M:PT  &T1  !N%@  <!T  '$F  !Q,0  <#X  '!.  !P7P  <',  &^-  !O
MIP  ;L8  &WO  !L_P  ;/\ 6D\  %!.  !(30  /4X  #-1   I5   (%@
M !A<   18   #&0   9H    :P   &\   !R    =    '4   !W!   > D
M 'H-  !\$   ?18  '\>  " *   @#4  (!%  !_5@  ?VL  '^$  !^H
M?;X  'SI  ![_P  >O\ 5E0  $Y3  !"5   -U8  "Q:   B7P  &&,  !%H
M   +;0   W(   !V    >@   'T   "     @P   (0   "&    AP(  (D'
M  "+#   C1   ) 6  "2'P  DBP  )([  "230  D6(  )%Z  "/EP  C[0
M ([A  ",^P  C/\ 55D  $A:   [70  +V$  "1F   9;   $7(   IW   "
M?0   ((   "&    BP   (X   "1    DP   )4   "7    F0   )L   "=
M!   GPH  *(/  "D%@  IB$  *8Q  "F0P  I5<  *1P  "CC@  HZL  *'0
M  "@]0  G_\ 3F$  $!D   S:0  )VX  !MU   1?   "X,   ")    C@
M ),   "8    G0   *$   "D    I0   *<   "I    JP   *T   "P
ML@   +4(  "X#@  O!8  +PE  "\-P  NTP  +ID  "Y@0  MZ(  +?   "W
MZ@  M_P 1FL  #EP   K=P  'W\  !.&   +C@   94   ";    H0   *8
M  "K    L    +,   "W    MP   +H   "\    OP   ,$   #$    QP
M ,H   #-!0  T0X  -09  #4*P  U$   --8  #3=   TY(  -*P  #2TP
MTO( /GD  #&    CB   %Y$   V9   #H    *<   "N    LP   +@   "]
M    P@   ,8   #*    R@   ,T   #/    T@   -4   #9    W0   -\
M  #C    YP4  .L/  #L'P  [3,  .Y+  #O9   [X(  /"?  #QN0  \=@
M_P   /\   #_  0 _P ) /\ #@#_ !4 _P > /\ *0#_ #0 _P _ /\ 2 #_
M %  _P!8 /\ 7@#_ &4 _0!K /L <0#Y '< ^ !^ /8 A0#S (T \0"7 .X
MH@#K *\ Z #  .8 X #C /@ X@#_ -L _P#+ /\ P0#_ +D _P"T /\ _P
M /\   #_    _P   /\ "0#_ !  _P 9 /\ (P#_ "X _0 Y /D 0@#U $H
M\@!2 .X 6 #K %X Z0!D .8 :@#D '  X@!V -\ ?0#= (8 V0"/ -4 F@#1
M *< S@"V ,L S@#) /  QP#_ ,4 _P"[ /\ M #_ *T _P"I /\ _P   /\
M  #_    _P   /L  @#V  T \0 3 .T '@#L "@ Z0 R ., .P#= $0 V !+
M -, 40#0 %@ S0!= ,L 8P#) &@ Q@!O ,0 =@#" 'X OP"' +P D@"Z )\
MMP"M +4 P0"R .0 L0#] *\ _P"L /\ I0#_ *  _P"< /\ _P   /\   #[
M    [@   .0   #<  @ TP 0 ,\ & #+ "( R0 K ,8 - #! #T O0!$ +H
M2P"W %$ M0!6 +( 7 "P &$ K@!G *P ;@"J '8 J !_ *8 B@"C )8 H0"E
M )\ M@"= -$ G #S )L _P"< /\ E@#_ ), _P"0 /\ _P   /8   #G
MTP   ,8   "]  , N  - +, $P"Q !P KP E *X +@"I #8 I@ ] *, 1 "A
M $H GP!/ )T 50"; %H F@!@ )@ 9@"6 &X E !W )( @0"0 (X C@"< (P
MK0"* ,, B0#H (@ _P") /\ AP#_ (4 _P"" /\ \P   .,   #,    O
M +    "G    H0 ( )X #P"; !8 F0 ? )@ )P"6 "\ DP W )$ /0". $,
MC !) (L 3@") %0 AP!9 (4 8 "$ &< @@!O (  >@!^ (8 ? "4 'H I !Y
M +@ > #8 '< ]P!X /\ > #_ '< _P!U /\ Y@   ,L   "W    J    )X
M  "6    CP $ (L # "( !( AP 9 (4 (0"$ "D @@ P '\ -P!] #T ? !#
M 'H 2 !Y $T =P!3 '8 60!T &$ <@!I '$ <P!O '\ ;0"- &P G0!J *\
M:0#( &@ [0!I /\ :0#_ &D _P!I /\ T@   +@   "E    EP   (T   "&
M    @0   'P " !Y  X =P 4 '8 ' !T ", <P K '$ ,0!O #< ;@ ] &P
M0P!K $@ :@!. &@ 5 !G %L 90!C &, ;0!B '@ 8 "' %\ E@!= *@ 70"^
M %P Y !< /L 7 #_ %P _P!< /\ P@   *H!  "8 P  B00  '\"  !X
M=    '  ! !M  P :P 1 &D %P!H !X 9@ E &4 + !C #( 8@ X &  /0!?
M $, 7@!) %P 3P!; %8 6@!> %@ : !7 ', 50"! %0 D0!2 *, 40"W %$
MU@!1 /4 40#_ %$ _P!2 /\ M@<  )\)  "-"P  ?@P  ',+  !L"@  : <
M &4#  !C  < 80 - %\ $P!= !H 7  A %L )P!9 "T 6  S %8 .0!5 #\
M5 !% %, 2P!1 %( 4 !: $\ 9 !- &\ 3 !] $H C0!) )\ 2 "R $< S !'
M .\ 1@#_ $< _P!' /\ K P  )4.  "#$   =1   &L0  !C#P  7@X  %L,
M  !:"0( 600* %< #P!5 !4 4P < %( (P!1 "D 3P O $X -0!- 3L 3 %!
M $H"2 !) D\ 2 )7 $8#80!% VT 0P-Z $(#BP!  YP /P.O #X#R  ]!.H
M/07\ #T&_P ^!O\ I!   (X2  !\$P  ;A0  &04  !<$P  5A(  %,1  !1
M#@  4 P% % )# !/!Q$ 30<7 $L('P!)""4 2 DK $<),0!&"3@ 1 H^ $,*
M10!""DT 0 M5 #\+7P ]"VL / MY #H,B@ X#)P -PRO #4,QP U#.D -0W]
M #4-_P V#/\ G1,  (<5  !V%P  :1@  %X8  !6&   4!<  $T5  !*$P
M21$  $D.!P!(#0X 1@T3 $0-&@!##B$ 0@XH $ .+@ _#C4 /@\\ #T/0P [
M$$L .A!4 #@07@ V$&L -!!Y #(0B@ Q$)P +Q"P "T0R0 M$>P +1'_ "X1
M_P O$/\ EQ8  ((9  !Q&P  9!P  %D<  !1'   3!L  $<:  !$&   0Q4
M $(3 @!!$@L 0!$0 #X2%P \$AX .Q,E #H3*P X$S( -Q,Y #840  T%$@
M,Q11 #$47  P%6@ +A5W "P5B  J%9H *!6N "<5QP F%>H )Q7_ "@5_P I
M%?\ D1H  'T<  !M'@  8!\  %8?  !.'P  2!X  $,=  ! '   /AH  #T8
M   [%P< .18. #@7%  V%QL -1@B #,8*  R&"\ ,1DV # 9/0 N&48 +1I/
M "L:60 J&F8 *!IT "8:A@ D&ID (AJM "$:Q0 @&N@ (1K^ "(:_P C&O\
MC1T  'D?  !I(0  7"(  %(B  !*(@  1"$  #\A   \(   .1X  #@;   U
M' 0 -!P- #(<$@ P'1@ +QT? "X=)0 M'BP *QXS "H>.P I'T, )Q]- "8?
M5P D'V0 (A]R " ?A  ?'Y< '1^K !L?PP ;'^< &Q_] !T?_P >'O\ B2
M '4B  !E(P  620  $\E  !')0  020  #PC   X(P  -2(  #,@   P( $
M+B$* "PA$  K(14 *B(< "@B(P G(BD )B,P "4C.  C(T$ (B1* "$D50 ?
M)&$ '21P !LD@@ 9))4 %R2J !8DP0 5).4 %B3\ !<C_P 9(_\ A2(  '$D
M  !B)@  5B<  $PG  !$)P  /B<  #DF   U)@  ,24  "XD   K)0  *24'
M "<F#@ E)A, )"<9 ",G(  B)R< (2@N " H-@ >*#X '2A( !LI4P 9*5\
M&"EN !8I@  4*90 $BFH !$IP  1*.0 $2C[ !,H_P 4)_\ @"4  &XG  !?
M*   4RD  $DJ  !"*0  .RD  #8I   R*   +B@  "HH   F*0  )"H$ "(K
M#  @*Q$ 'RP6 !TL'0 <+"0 &RTK !HM,P 8+3P %RU% !8N4  4+ET $BYL
M !$N?@ 0+I( #BZG  TMO0 -+=\ #2WY  XL_P 0+/\ ?"@  &HJ  !;*P
M4"P  $8L   _+   .2P  #0K   O*P  *RL  "8L   B+@  'R\  !PP"0 :
M,0X &3$3 !<Q&@ 6,B$ %3(H !0R,  3,CD $C-# !$S3@ 0,UL #C-I  TS
M>@ ,,XX "C.B  @RN0 (,MD "#+T  HQ_P +,?\ =RL  &8M  !8+@  32\
M $,O   \+@  -BX  #$N   M+@  *2X  ",P   ?,@  &S,  !<U!0 4-@P
M$C<1 !$W%@ 1-QT $#@D  \X+  ..#4 #3@_  PX2@ +.%< "3AE  <X=@ %
M.(H  SB?  $WM0 !-],  C?Q  ,V_P %-O\ <RX  &(P  !4,0  23$  $$Q
M   Y,0  -#$  "\P   K,   )3(  " S   ;-@  %S@  !,Z @ 0/ D #3T.
M  P]$P +/1D "CTA  D]*0 (/3$ !CX[  4^1@ #/E(  3YA   ^<@  /H8
M #V<   ]L@  /=   #SP   \_P  //\ ;3(  %TS  !0-   1C0  #XT   W
M-   ,C,  "TS   G-   (C8  !TX   8.@  %#T  ! _ @ -00@ "4,-  9$
M$0 #1!8  D0=  !$)   1"T  $0V  !$00  1$X  $1<  !$;0  1($  $28
M  !#KP  0\T  $+P  !"_P  0O\ :#8  %@W  !,.   0S@  #LW   U-@
M,#8  "DW   C.0  'CL  !@]   30   $$(   U% 0 (1P<  TD,  !)#P
M2A,  $L9  !+(   2R@  $LR  !+/0  3$D  $Q7  !+:   2WT  $N4  !*
MK   2LH  $GO  !)_P  2?\ 8CH  %0[  !).P  0#L  #DZ   S.0  +#H
M "4\   ?/P  &4$  !-$   01P  #$D   A,   "3P4  % *  !0#0  41
M %(5  !4&P  5",  %0L  !4-P  5$0  %12  !48P  5'<  %2/  !3J
M4L8  %+M  !1_P  4?\ 7#\  $\_  !%/P  /CX  #<]   O/@  )T   "!#
M   91@  $TD   ],   +3P  !E(   !4    5P(  %@'  !9"P  6@X  %L1
M  !=%@  7AT  %\F  !?,0  7CT  %Y,  !>70  7G$  %V)  !=HP  7,$
M %OK  !:_P  6O\ 5D0  $M#  !#0@  /$$  #)"   I10  (4@  !I+   3
M3@  #E(   I5   #60   %L   !>    8    &("  !C!@  90H  &8.  !H
M$0  :A<  &L?  !K*0  :S8  &M%  !K5@  :FH  &J"  !IG0  :+L  &?G
M  !F_P  9?\ 44@  $A(  !!1@  -T<  "Q*   C30  &U$  !-5   .60
M"%T   %A    9    &<   !J    ;    &X   !P    <@4  ',)  !U#0
M=Q$  'H8  ![(0  >RX  'H]  !Z3@  >6(  'EY  !XE@  =[,  '7@  !T
M_   <_\ 3DT  $=,   [30  ,$\  "93   <6   $UP   UA   &9@   &H
M  !O    <@   '8   !Y    ?    'T   !_    @0   (,"  "&!P  B P
M (L1  ".&   CB0  (XS  "-1   C%@  (MO  "*C   B:H  (C/  "&]P
MA?\ 35$  $%3   T50  *5H  !Y?   490  #6H   5P    =@   'L   !_
M    @P   (<   "*    C0   (X   "1    DP   )4   "8    F@4  )T,
M  "@$0  HQH  *,H  "B.@  H4X  *!E  "@@0  GJ   )W!  ";[@  FO\
M1ED  #E<   M80  (6<  !9N   .=0  !7L   "!    AP   (T   "2
ME@   )H   "=    GP   *$   "D    I@   *@   "K    K@   +$#  "T
M"P  N!$  +D>  "Y+P  N$,  +=:  "U=@  M)<  +2U  "QX@  L/P /V0
M #%I   E;P  &'<   ]_   &AP   (X   "4    F@   *    "E    J@
M *X   "Q    L@   +4   "W    N@   +P   "_    PP   ,8   #)
MS@H  -(3  #2(P  T3<  -!/  #.:@  S8H  ,JK  #+RP  R^\ -W$  "EX
M   =@   $8D   B1    F@   *$   "G    K0   +,   "Y    O@   ,(
M  #%    Q@   ,D   #,    S@   -(   #5    V@   -X   #A    Y0
M .H+  #K%P  ZBL  .I#  #J7@  ZGH  .N9  #KM0  Z]4 _P   /\   #_
M  $ _P ' /\ #0#_ !( _P ; /\ )0#_ "\ _P Z /\ 0P#_ $L _P!3 /\
M6@#] &  ^P!F /H :P#X '( ]@!X /0 @ #Q (D [P"2 .P G0#I *H Y@"\
M ., W #? /< W0#_ ,P _P"^ /\ M0#_ +  _P"M /\ _P   /\   #_
M_P   /\ !@#_  T _P 4 /\ 'P#_ "D ^P S /< /0#S $4 [P!- .P 4P#H
M %D Y0!? ., 90#@ &H W0!Q -H > #6 (  T@"* ,\ E0#, *( R "R ,4
MR0#" .T P #_ +L _P"P /\ J #_ *0 _P"A /\ _P   /\   #]    ^@
M /@   #P  D [  1 .@ &0#G ", Y0 M -X -@#6 #X T0!& ,T 3 #* %(
MR !8 ,4 70## &, P !I +X < "\ '@ N0"! +< C0"T )H L0"I *X O "L
M .$ J@#\ *@ _P"@ /\ F0#_ )8 _P"4 /\ _P   /D   #R    YP   -L
M  #1  0 R@ - ,< % #$ !T P@ F +\ +P"[ #< MP _ +0 10"Q $L K@!1
M *P 5@"J %P J !A *8 : "C '  H0!Y )\ A "= )$ F@"@ )@ L0"6 ,P
ME0#Q )0 _P"1 /\ BP#_ (@ _P"& /\ ]P   .P   #>    R0   +P   "T
M    KP * *L $ "I !< J  @ *< * "B #  GP X )P /@": $0 F !* )8
M3P"4 %4 DP!: )$ 80"/ &@ C0!Q (L >P") (@ AP"7 (4 J "# +X @0#D
M (  _P"  /\ ? #_ 'L _P!Y /\ Z0   -<   #!    L0   *8   "=
MEP % )0 #0"2 !( D  : (\ (@". "H BP Q (D . "' #X A0!# (, 2 "!
M $X ?P!4 'X 6@!\ &$ >@!I '@ <P!V '\ =0". ', GP!Q +, < #0 &\
M]@!O /\ ;P#_ &T _P!L /\ V@   +\   "L    G@   ),   ",    A0
M (( "0!_  \ ?@ 5 'T ' !\ "0 >@ K '< ,0!U #< =  ] '( 0@!Q $@
M;P!- &X 4P!L %H :P!B &D ; !G '@ 9@"& &0 EP!B *H 80#" &  ZP!A
M /\ 80#_ &$ _P!@ /\ Q0   *T   ";    C0   (,   !\    =P   '(
M!0!P  P ;@ 1 &P %P!L !X :P E &D + !G #$ 9@ W &0 /0!C $( 8@!(
M &  3@!? %4 70!= %P 9@!: '( 60"  %< D !6 *, 50"Y %0 W@!4 /L
M5 #_ %4 _P!5 /\ M@   )\   "-    ?P   '4   !N    :0   &8  0!C
M  D 80 . &  $P!? !D 7@ @ %T )@!; "P 6@ R %@ -P!7 #T 5@!# %4
M20!3 %  4@!8 %$ 80!/ &P 3@!Z $P B@!+ )P 2@"Q $D S@!) /, 20#_
M $D _P!* /\ J@$  )0%  ""!P  = @  &H(  !C!@  7@0  %L   !9  4
M5P , %8 $ !4 !4 4P ; %( (@!1 "@ 4  M $X ,P!- #@ 3  ^ $L 10!*
M $P 2 !4 $< 70!& &@ 1 !U $, A0!! )@ 0 "K $  Q0 _ .H /P#_ $
M_P!  /\ H @  (H+  !Y#0  ; T  &$-  !:#0  50L  %()  !0!@  3P((
M $X #0!, !( 2P 7 $H '@!) ", 1P I $8 +P!% #0 1  Z $( 00!! $@
M0 !0 #X 6@ ] &0 / !R #H @@ Y )0 . "G #< O@ V ., -@#Y #8 _P W
M /\ F T  (,.  !R$   91$  %L1  !3$   3A   $H.  !(#0  1PH# $<'
M"@!%! X 1 (3 $("&@!! B  0 ,E #X#*P ]!#$ / 0W #L$/@ Z!44 .05.
M #<%5P V!6( - 9P #(&@  Q!I( , :E "\%NP N!=T +@;U "T'_P N!_\
MD1   'T1  !L$P  7Q0  %44  !.%   2!,  $02  !!$   0 X  $ -!@!
M"@P /@D0 #P)%@ ["AP .0HB #@**  W"RX -@LU #4+.P S"T, ,@Q, # ,
M5@ O#&$ +0QO "L,?P J#)( * RE "<,NP E#-T )0WU "8-_P G#?\ BQ(
M '<4  !G%@  6Q<  %$8  !)%P  0Q<  #\5   \%   .A(  #D1 0 Y#P@
M. X- #<.$@ U#A@ - X? #(.)0 Q#RP , \R "\0.@ M$$( +!!+ "H050 H
M$&$ )A!O "00@  C$), (1"G !\0O0 >$.  'A'W !\0_P @$/\ AA0  ',7
M  !C&0  5QH  $T;  !%&@  0!H  #L9   X&   -18  #04   S$@0 ,A(+
M #$2$  O$A4 +1(< "P3(@ K$RD *A,P "@3-P G%#\ )A1( "044P B%%\
M(!5M !\5?@ =%9$ &Q6E !D5NP 8%=X &!7X !D4_P :%/\ @A<  &\:  !?
M'   4QT  $H=  !"'0  /!T  #<<   T&P  ,1H  "\9   N%@  +!<( "L6
M#@ I%Q, *!<9 "<8(  E&"8 )!@M ",8-  B&3T (!E& !X940 =&5T &QIK
M !D:?  7&H\ %1JC !09N@ 2&=L $QGV !09_P 5&/\ ?1H  &L=  !<'P
M4"   $<@   _(   .1\  #0?   Q'@  +1T  "L<   I&P  )QL% "4;#  D
M'!$ (AP6 "$<'0 @'2, 'QTJ !X=,@ <'CH &QY$ !D>3@ 7'EL %AYI !0?
M>@ 2'HT $1ZB ! >N  .'M@ #Q[U ! =_P 1'?\ >AT  &<?  !9(0  32(
M $0B   \(@  -B(  #(A   N(0  *B   "<@   D'P  (B " " @"@ >(0\
M'2$4 !PA&@ ;(B$ &2(G !@B+P 7(C@ %2-! !0C3  2(U@ $2-G ! C>  .
M(XL #2.?  PCM  +(]  "R+P  PB_P -(?\ =A\  &0B  !6(P  2R0  $$D
M   Z)   -"0  "\C   K(P  *",  "0C   @(P  '20  !LE!P 9)@T %R81
M !8F%P 5)QX %"<E !,G+  2)S4 $2@_ ! H2@ .*%8 #2AD  PH=  **(<
M"2B;  <GL0 %)\P !B?L  <F_@ ()O\ <2(  & D  !3)@  2"<  #\G   W
M)@  ,28  "TF   I)0  )24  "(E   =)P  &2@  !8J!  4*PL $BP0 !$L
M%  0+!L $"PB  XL*0 .+3( #2T[  LM1@ *+5( ""U@  8M<  $+8,  BV8
M   LK@  +,D  "SK  $K_  "*_\ ;24  %TG  !/*   12D  #PI   U*0
M+R@  "LH   G)P  (R<  !\H   ;*@  %RP  !,N @ 0, @ #C$-  TQ$@ ,
M,1< "S$>  HQ)@ (,BX !S(W  4R0@ #,DX  3)<   R;   ,G\  #*5   Q
MK   ,<<  ##J   P_   ,/\ :"D  %@J  !,*P  02P  #DL   R*P  +2L
M "DJ   E*@  ("L  !PL   7+@  $S   ! R @ .- < "C<,  <W$  %-Q0
M S<;  (W(@  -RH  #@S   X/@  .$H  #A8   X:   .'P  #>2   WJ0
M-L4  #;J   V_0  -?\ 8RP  %0N  !(+P  /B\  #8N   P+@  *RT  "<M
M   B+0  '2\  !@Q   4,P  $#4   XW 0 *.@< !CL+  (\#@  /1(  #X7
M   ^'@  /B8  #XO   ^.@  /D8  #Y4   ^9   /G<  #Z/   ]IP  /<,
M #SI   \_0  ._\ 7C   % Q  !$,@  .S(  #0Q   N,   *2\  "0P   >
M,@  &30  !0V   0.0  #3L   H]   %0 4  $$*  !"#0  0Q   $04  !%
M&@  1B(  $8K  !&-0  1D$  $9/  !&7P  1G,  $6*  !%I   1,   $/H
M  !#_@  0O\ 6#0  $LU  !!-0  .34  #(T   M,P  )C0  " U   :.
M%#H  ! ]   -0   "4(   1%    1P,  $@'  !*"P  2PX  $P1  !.%0
M3QP  $\E  !/+P  3SP  $]*  !/6@  3FT  $Z%  !-H   3+P  $OG  !+
M_@  2O\ 4SD  $<Y   ^.0  -S@  #$W   I-P  (3D  !L\   5/P  $$(
M  Q%   '2    DH   !-    3P   %$$  !2!P  5 L  %4.  !7$0  61<
M %H?  !9*0  638  %E$  !95   6&<  %A_  !7F@  5K<  %7C  !4_0
M5/\ 3CT  $,]   \/   -3L  "P\   D/@  '$$  !5$   02   "TL   5.
M    40   %0   !7    60   %L   != @  7@8  & +  !B#@  9!(  &<8
M  !G(@  9BX  &8\  !F30  96   &5W  !DDP  8[$  &'=  !@_   7_\
M24(  $%!   Z/P  ,$   "9#   >1@  %4H  !!.   *4@   U8   !:
M70   &    !C    90   &<   !I    :P$  &T%  !O"@  <@X  '42  !W
M&P  =B8  '8U  !U1@  =%D  '1O  !SBP  <JD  '#-  !O]P  ;O\ 1D8
M $!%   U1@  *D@  "!,   740  $%8   E:   !7P   &,   !H    :P
M &\   !R    =0   '<   !Y    >P   'T   "  P  @P@  (8-  ")$P
MBAT  (HK  ")/   B$\  (9F  "%@0  A*   (+"  "!\   ?_\ 1DL  #I,
M   N3P  (U,  !A8   07@  "60   !I    ;P   '0   !X    ?    ($
M  "$    AP   (@   "+    C@   )    "3    E@   )D'  "=#0  H10
M * A  "@,0  GD0  )U;  "<=@  F98  )FU  "6Y0  E?X /U(  #)5   F
M6@  &V   !%G   );0   '0   ![    @0   (8   "+    D    )0   "7
M    F0   )P   "?    H0   *0   "G    J@   *T   "Q!@  M0T  +@6
M  "W)@  MCD  +50  "T:@  LHD  +"J  "NSP  K?4 -UP  "MA   >:
M$W    MX    @    (<   ".    E0   )H   "?    I    *@   "L
MK0   +    "S    M0   +@   "[    OP   ,,   #'    RP4  -$.  #1
M&P  T"X  ,]%  #-7P  RWX  ,F>  #(O@  Q>D +VD  "-P   6>0  #8$
M  &+    DP   )L   "B    J    *X   "T    N    +T   #     P@
M ,4   #(    RP   ,X   #1    U@   -L   #?    Y    .@&  #K$0
MZB,  .HZ  #I5   YW(  .63  #CLP  X]0 _P   /\   #_    _P $ /\
M"P#_ !  _P 7 /\ (0#_ "L _P U /\ /@#_ $< _P!. /\ 50#\ %L ^@!A
M /@ 9@#V &T ] !S /( >P#O (0 [0". .H F0#F *< XP"Y -\ U0#; /<
MU@#_ ,  _P"R /\ J@#_ *4 _P"B /\ _P   /\   #^    _    /P  P#^
M  L _P 1 /\ &@#] "0 ^0 N /0 . #P $  [ !( .D 3@#F %0 X@!: -\
M7P#< &4 V !K -0 <@#0 'L S0"% ,H D0#' )X PP"N ,  Q0"] .L NP#_
M +  _P"D /\ G #_ )@ _P"5 /\ _P   /H   #T    \0   /(   #J  4
MYP . .( %0#A !X X0 H -@ ,0#0 #D RP!  ,@ 1P#% $T P@!3 +\ 6 "]
M %X NP!D +D :P"V ', M !\ +$ B "N )4 JP"D *@ N "F -P HP#[ )\
M_P"5 /\ CP#_ (L _P") /\ ^0   .\   #G    WP   ,\   #(    P0 *
M +\ $0"\ !@ NP A +D *@"T #( L0 Z *X 0 "K $8 J !, *8 40"C %8
MH0!< )\ 8P"= &H FP!S )D ?@"6 (P E "; )( K0"0 ,< C@#P (T _P"&
M /\ @ #_ 'T _P!\ /\ [0   .    #1    OP   +,   "J    I@ % *(
M#0"A !, H  ; )\ (P"; "L F  R )4 .0"3 #\ D0!$ (\ 2@". $\ C !5
M (H 6P"( &, A@!K (0 =@"" (( @ "2 'X HP!\ +H >@#A 'D _P!W /\
M<@#_ '  _P!O /\ W0   ,L   "V    IP   )T   "4    C@ ! (L "@")
M !  B  5 (< '0"' "4 A  L (( ,@!_ #@ ?0 ] 'L 0P!Y $@ > !. '8
M5 !U %L <P!C '$ ;@!O 'H ;0") &P F@!J *X :0#, &@ ]@!G /\ 90#_
M &0 _P!C /\ R@   +0   "A    DP   (D   ""    >P   '@ !0!V  P
M=0 1 '0 & !S !\ <@ E '  + !N #( ;  W &H / !I $( : !( &8 3@!E
M %4 8P!= &( 9@!@ '( 7@"  %T D@!; *4 6@"^ %D Z0!9 /\ 60#_ %@
M_P!8 /\ N0   *(   "0    @P   'D   !Q    ;0   &D  0!F  D 90 .
M &0 $P!C !D 8P @ &$ )@!@ "P 7@ Q %P -P!; #P 6@!" %@ 2 !7 $\
M5@!7 %0 8 !3 &P 40!Y %  B@!/ )X 3@"T $T V@!- /L 30#_ $T _P!-
M /\ J@   )0   ""    =0   &L   !D    8    %T   !:  4 6  , %<
M$ !6 !4 5@ ; %4 (0!3 "< 4@ L %$ ,0!/ #< 3@ ] $T 0P!, $H 2@!2
M $D 6P!( &8 1@!S $4 A !$ )< 0P"L $( R0!" /$ 0@#_ $, _P!# /\
MG@   (D   !X P  :@0  &$$  !: P  50$  %(   !0  ( 3@ ) $T #0!,
M !$ 2P 7 $H ' !) "( 2  G $< +0!% #( 1  X $, /@!" $4 00!- #\
M5@ ^ &$ /0!N #L ?@ Z )$ .0"F #@ OP X .@ . #_ #D _P Y /\ E0,
M ( '  !O"0  8@H  %@+  !1"@  3 @  $D&  !' P  1@ & $0 "P!#  \
M0@ 3 $$ & !! !X /P C #X *0 ] "X .P T #H .@ Y $$ . !) #< 4@ V
M %T - !J #, >@ R (P ,0"A #  N  O -X +P#Y "\ _P P /\ C D  '@,
M  !H#0  7 X  %(.  !+#@  10T  $$,   _"@  /@@" #T$"  \ 0T .P 0
M #H %0 Y !H .  @ #8 )0 U "L -  P #, -P R #X ,0!& "\ 4  N %H
M+0!G "L =P J (D *0"= "@ LP G -$ )P#R "< _P G /\ A@P  '(.  !C
M$   5A$  $T1  !%$0  0!   #P/   Y#@  -PT  #8+!  V" H -08. #0%
M$@ R!!< ,04< # %(@ O!2@ +@8N "T&-  K!CP *@9$ "D'3@ G!UD )@=E
M "0'=0 C!X< (@>; " &L  @!LL 'P7M !\&_@ ?!_\ @ X  &T1  !>$@
M4A,  $@3  !!$P  .Q,  #<2   T$0  ,A   # / 0 P#08 , L+ "\*$  M
M"A0 + L9 "H+'P I"R4 * PK "<,,@ F##H ) Q# ",,30 A#5@ ( UE !X-
M=0 <#8@ &@V< !D-L0 8#,H %PSK !<-_  8#/\ >Q$  &D3  !:%0  3A8
M $46   ]%@  .!4  #,5   P%   +1,  "L2   J$ , *@\( "D.#0 H#A$
M)@X6 "4/'0 D#R, (P\I "$0,0 @$#D 'A!" !T03  ;$%@ &1!F !<0=@ 5
M$(D %!"> !(0LP 1$,X $1#N !(0_@ 2$/\ =Q,  &45  !7%P  2Q@  $(9
M   Z&0  -!@  # 7   L%P  *18  "<5   F% $ )1($ ",2"P B$@\ (1(4
M " 2&@ >$R  '1,G !P3+@ :$S8 &11  !<42@ 6%%8 %!1D !(4=  1%(<
M$!2<  X4L0 -%,H #13K  X3_@ .$_\ <Q4  &$8  !3&@  2!L  #\;   W
M&P  ,AH  "T:   I&0  )A@  "08   B%P  (!8! !X6"  =%@T &Q<2 !H7
M%P 9%QT &!@D !88*P 5&#0 %!@] !(92  1&50 $!EB  X9<@ -&80 #!F8
M  H9K0 )&,8 "1CG  D8^@ *%_\ ;Q@  %X:  !0'   11T  #P=   U'0
M+QT  "H<   F&P  (QL  "$:   >&@  '!H  !H;!0 8&PP %AP0 !4<%0 4
M'!L $QPB !(=*0 1'3$ $!T[  X=10 -'E$ #!Y>  H>;0 )'H  !QZ4  4=
MJ@ #'<(  QWF  0<^  %'/\ :QH  %L=  !-'@  0A\  #H?   R'P  +1\
M "@>   D'@  (1T  !X=   <'0  &!X  !4? @ 3( D $B$. ! A$@ 0(1@
M#B$?  XB)@ -(BX #"(W  HB00 )(DT !R):  4B:0 #(GP  2*1   BJ
M(<   "'E   @^   (/\ 9QT  %<?  !*(0  0"$  #<B   P(0  *B$  "8@
M   B(   'Q\  !P?   9(   %B$  !(C @ 0) < #B8,  PF$  +)A4 "B8<
M  DF(@ ()BH !B<S  0G/0 #)TD  2=6   G9@  )WD  ">/   FI@  )K\
M "7D   E^0  )/\ 8R   %0B  !'(P  /20  #0D   N(P  *",  "0B   A
M(@  'B$  !HB   7(P  $R0  ! F @ .* < "RH+  @K#@ &*Q, !"L8  (K
M'P !+"<  "PP   L.@  +$4  "Q3   L8P  +'8  "R,   KI   *[X  "KD
M   J^@  *?\ 7R,  % E  !$)@  .B8  #(F   K)@  )B4  ",D   ?)
M&R0  !<E   4)P  $2D   XK @ ++08 !R\+  0P#@  ,!$  #$5   Q'
M,2,  #(L   R-@  ,D(  #)/   R7P  ,G(  #&)   QH@  ,+P  ##D   O
M^P  +_\ 6B<  $PH  ! *0  -RD  "\I   I*   )2<  "$F   <)P  &"@
M !0J   1+   #BX   LP 0 ',@4  S0)   U#   -@\  #<2   X&   ."
M #@H   X,@  .3T  #E+   Y6P  .&X  #B%   WGP  -[H  #;D   U_
M-?\ 52H  $@L   ]+   -"P  "TK   H*@  )"D  !XJ   9*P  %"T  !$O
M   -,0  "C0   <V   ". 0  #H'   ["@  /0T  #X0  ! %   0!L  $ D
M  ! +@  0#D  $!'  ! 5@  0&D  $"    _FP  /K<  #WC   \_   //\
M4"\  $,O   Y+P  ,B\  "PM   G+   ("T  !HO   5,0  $3,   TV   )
M.   !3L    ]    0 $  $$$  !#!P  10L  $8.  !($0  2A8  $H>  !*
M*   2C0  $E"  !)40  260  $A[  !(EP  1[0  $;@  !%_   1/\ 2C,
M #\S   V,P  ,#$  "HP   C,0  '#,  !8U   1.   #3L   @^   #00
M $,   !&    2    $H   !,!   3@<  $\+  !1#@  5!(  %49  !5(@
M5"X  %0\  !42P  4UX  %-T  !2D   4:X  %#7  !/^P  3O\ 13<  #PW
M   U-@  +S0  "8U   >-P  %SH  !$]   ,00  !T0   !(    2@   $T
M  !0    4P   %4   !7    6 (  %L&  !="P  7PX  &(3  !B&P  8B<
M &(T  !A10  8%<  &!M  !?B0  7:<  %S,  !:^   6?\ 03P  #H[   T
M.0  *CH  "$\   80   $4,   Q'   &2P   $\   !3    5@   %D   !<
M    7P   &$   !C    90   &<!  !J!0  ;0H  ' .  !S%0  <B   '(M
M  !Q/0  <$\  &]E  !N@   ;9\  &O!  !I\0  :/\ /T   #D^   N/P
M)$(  !I&   22@  #$\   14    6    %T   !A    90   &@   !K
M;@   '$   !S    =0   '@   ![    ?@,  ($*  "%#P  AQ<  (8D  "%
M-   A$8  ()=  "!=@  ?Y8  'ZV  !\YP  >O\ /T0  #-%   H2   '4P
M !-2   ,5P   UT   !C    :    &T   !Q    =@   'H   !^    @0
M (,   "&    B0   (L   ".    D@   )4!  "9"0  GA   )X:  "=*0
MG#P  )I2  "8;   EHL  )2J  "2U   D/H .$L  "Q.   @4P  %5D   U@
M   #9P   &X   !T    >@   (    "$    B@   (X   "2    E0   )<
M  ":    G0   *    "C    IP   *L   "O    M D  +@0  "W'@  M3
M +-&  "Q8   KWX  *R@  "KP0  J>X ,54  "1;   880  #FD   5Q
M>0   ($   "(    CP   )0   ":    GP   *0   "H    J0   *P   "O
M    LP   +4   "Y    O0   ,$   #&    RP   -$*  #3%   T24  - [
M  #-5   RG$  ,B2  #%LP  P]X *6(  !QI   1<0  !WL   "$    C0
M )4   "=    HP   *D   "O    M    +D   "\    O@   ,(   #%
MR    ,P   #0    U    -H   #?    Y    .H   #N#   [1H  .PO  #J
M20  Z&4  .:&  #DI0  XL8 _P   /\   #_    _  ! /P " #^  X _P 4
M /\ '0#_ "8 _P P /\ .@#_ $( _P!) /X 4 #[ %8 ^0!< /8 8@#T &@
M\@!O /  =@#M '\ Z@") .< E0#D *, X "U -L T #5 /8 R@#_ +8 _P"H
M /\ GP#_ )H _P"6 /\ _P   /L   #V    \P   /,   #V  D ^@ . /T
M%@#[ "  ]P J /( ,P#M #L Z0!# .8 20#B $\ W@!5 -L 6P#6 &  T@!G
M ,\ ;@#, '8 R0"  ,8 C #" )H OP"J +L P0"X .D M@#_ *< _P": /\
MD@#_ (T _P"* /\ ^@   /$   #J    YP   .<   #D  $ X  + -L $0#:
M !H VP C -$ + #* #0 Q@ [ ,( 0@"_ $@ O !. +H 4P"X %D M@!? +,
M9@"Q &X K@!W *P @P"I )$ I@"A *, M0"@ -@ G@#[ )4 _P"+ /\ A0#_
M (  _P!^ /\ [P   .,   #:    TP   ,8   "_    N0 & +< #@"T !0
MM  = +, )0"N "T JP T *< .P"D $$ H0!& )\ 3 "= %$ FP!7 )D 7@"7
M &4 E0!N ), >0"0 (< C@"7 (P J0") ,0 B #O (4 _P!\ /\ =@#_ ',
M_P!R /\ X    -    #&    M@   *D   "A    G0 ! )D "@"8 !  F  6
M )< '@"4 "8 D0 M (\ - ", #H B@ _ (@ 10"' $H A0!0 (, 5@"! %X
M@ !F 'X <0!\ 'T >0"- '< H !U +8 <P#? '( _P!N /\ :0#_ &< _P!E
M /\ S    +X   "K    G0   ),   "*    A0   (( !0"   T ?P 1 '\
M& "  "  ?0 F 'H +0!W #, =0 X '0 /@!R $, < !) &\ 3P!M %8 ; !>
M &H : !H '4 9P"$ &4 E@!D *L 8@#) &$ ]@!@ /\ 7 #_ %L _P!: /\
MO0   *D   "7    B0   'X   !X    <P   &\  0!M  D ;  . &L $P!K
M !D :@ @ &@ )@!F "P 90 R &, -P!B #P 8 !" %\ 2 != $\ 7 !7 %H
M80!9 &T 5P![ %8 C@!5 *( 4P"[ %( Z0!2 /\ 4 #_ $\ _P!/ /\ K0
M )@   "&    >    &X   !G    8P   &    !=  4 7  + %L $ !; !4
M6P ; %H (0!8 "8 5@ L %0 ,0!3 #8 4@ \ %$ 0@!/ $D 3@!1 $T 6P!+
M &8 2@!T $D A0!( )D 1P"Q $8 V !& /P 10#_ $4 _P!% /\ GP   (D
M  !X    ;    &(   !;    5@   %,   !1  ( 3P ( $\ #0!. !$ 3@ 6
M $T ' !, "$ 2@ F $D + !( #$ 1P W $4 /0!$ $0 0P!, $( 50!  &
M/P!N #X ?@ ] )( / "I #L QP [ /, .P#_ #L _P \ /\ DP   'X   !N
M    80   %@   !1    3    $D   !'    10 % $0 "P!#  X 0P 2 $,
M%P!" !T 0  B #\ )P ^ "P /0 R #L .  Z #\ .0!' #@ 4  W %L -0!H
M #0 >  S (P ,@"B #$ O  Q .< ,0#_ #( _P S /\ B0   '8#  !F!0
M60<  % '  !)!@  0P4  $ #   ^ 0  /  # #L "  Z  T .@ 0 #D %  Y
M !D -P > #8 (P U "@ -  N #, -  R #L , !# "\ 3  N %< +0!D "P
M<P K (< *@"< "D M0 I -P *0#[ "D _P J /\ @00  &X(  !?"@  4PL
M $H+  !""P  /0H  #D)   V"   -04  #0"!@ S  H ,@ . #$ $0 Q !4
M,  : "\ 'P N "0 +  J "L ,  J #< *0 _ "@ 20 G %0 )@!@ "0 ;P C
M (( (@"7 "$ K@ A ,P (0#S "$ _P B /\ >PD  &@,  !:#0  3@X  $4.
M   ]#@  . T  #,-   P#   +@L  "T) P M!@@ + 0, "L"#P J 1( *0$7
M "@!'  G "$ )@ G "4 +0 D #0 (P$] "(!1@ A 5$ 'P%= !X!;  < 7\
M&P"4 !H J@ : ,4 &@#K !D _P : /\ =0P  &0.  !5#P  2A   $ 0   Y
M$   ,Q   "\/   L#@  *0X  "<- 0 G# 4 )PH* "8(#0 E!Q  ) 84 "(&
M&0 A!A\ ( <D !\'*P >!S( '0<Z !P(1  :"$\ &0A< !<(:P 6"'T %0>1
M !0'IP 3!K\ $@7D !(%^@ 2!?\ <0X  %\0  !1$0  1A(  #T2   V$@
M,!(  "L1   H$0  )1   ",0   B#@0 (0T' "$,"P @"PX 'PL2 !T+%P <
M#!P &PPB !H,*0 9##$ & PY !8-0P 5#4\ $PU< !(-:P 0#7X #PV2  X-
MIP -#+X #0S@  T,]0 -#/\ ;1   %P1  !.$P  0Q0  #H4   R%   +10
M "@3   E$P  (A(  " 1   >$0, '! % !P/"  ;#PP &@X0 !D/%  7#QH
M%@\A !40*  4$#  $A Y !$01  0$%  #A!=  T0:P ,$'P "Q"0  D0I0 (
M$+P !Q#?  <0]  '#_\ :1$  %@4  !+%0  0!8  #<6   P%@  *A8  "85
M   B%0  'Q0  !T3   :$P( &1($ !<2!@ 6$@H %1(. !02$@ 2$A@ $1,>
M !$3)0 0$RX #A,W  T40  ,%$L "Q18  D49P '%'@ !A2-  04HP #$[L
M A/=  $2]  "$O\ 91,  %46  !(%P  /1@  #08   M&   *!@  ",7   @
M%P  '18  !H5   8%0( %A4$ !05!0 2%@@ $18- ! 7$  .%Q4 #A<;  T7
M(@ ,%RD "Q@R  D8/  '&$< !1A4  088P "&'4  1B+   7H0  %[D  !?=
M   6]0  %O\ 818  %(8  !%&@  .QH  #(:   K&@  )1H  "$9   >&
M&Q@  !@7   6%P( %!<# !(8!0 0&0< #AL+  P;#P +&Q, "AL8  @<'P '
M'"8 !1PO  0<.  "'$0  !U1   =8   '7(  !R(   <H   &[D  !O>   :
M]@  &O\ 7A@  $\:  !"'   .!P  "\=   I'   (QP  !\;   <&@  &1D
M !<9 0 4&0( $AH# ! ;!  .'0< #!X+  D?#@ &(!$ !2 6  ,@'  !(2,
M "$K   A-0  (4   "%.   A70  (6\  "&&   @G@  (+@  !_>   >^
M'O\ 6AL  $L=   _'@  -1\  "T?   G'@  (AT  !X=   ;'   &!L  !4;
M   2'   $!T"  X?!  ,(08 "2(*  4C#0 ")!   "43   E&0  )B   "8H
M   F,@  )CT  "9*   F6@  )FP  ":#   EG   );<  "3?   C^0  (_\
M51X  $<@   \(0  ,B$  "LA   E(   (!\  !T>   :'0  %AX  !,>   0
M(   #B$   PC @ ()04 !2<)   H"P  *@X  "L1   L%@  +!T  "PE   L
M+@  +#H  "Q'   L5@  +&D  "R    KF@  *K4  "G?   I^P  */\ 42(
M $0C   X)   +R0  "@C   C(@  'R$  !P@   7(   $R$  ! C   .)
M"R8   @H   $*@0  "P'   N"0  , P  #$/   S$P  ,QD  #,A   S*@
M,S4  #-#   S4@  ,V4  #)[   REP  ,;,  ##>   O^P  +O\ 3"4  #\F
M   U)P  +28  "<E   B)   'B,  !DC   4)   $28   XH   +*@  !RP
M  ,O    ,0(  #,$   U!P  -PH  #D-   Z$   .Q4  #L=   [)@  .S$
M #L^   [3@  .V   #IW   YD@  .+   #?;   V_   -?\ 1RD  #LJ   R
M*@  *RD  "4G   A)@  &R<  !4H   1*@  #BP   HO   &,0   30    V
M    .    #L!   ]!   /P<  $$*  !##@  11$  $48  !%(0  12P  $0Y
M  !$2   1%L  $-Q  !"C0  0:L  $#2   _^@  /O\ 0BT  #@N   O+0
M*2L  "0J   =*@  %RP  !$N   -,0  "30   0W    .@   #P    _
M00   $0   !&    2 ,  $H'  !,"P  3@X  % 3  !0'   4"<  $\T  !/
M0P  3U4  $YJ  !-A@  3*0  $K*  !)^   2/\ /C(  #4Q   N+P  *2X
M " N   9,0  $C,   XW   ).@   CT   !     1    $<   !)    3
M $\   !1    4P   %4!  !8!@  6@L  %T.  !?%0  7B   %XL  !=/
M7$X  %MC  !:?@  6)T  %?   !5\@  5/\ .C8  #,T   M,@  )#,  !LV
M   3.0  #CT   A!    10   $D   !,    4    %,   !6    60   %L
M  !=    8    &(   !E    : 4  &L+  !O$   ;Q@  &XE  !M-   ;48
M &M;  !J=0  :)0  &:V  !DZ0  8O\ .#D  #(W   H.0  'CL  !4_   .
M1   !TD   !-    4@   %8   !:    7@   &(   !E    :    &L   !M
M    <    ',   !V    >0   'T$  "!"P  A1$  (0=  ""+   @#X  'Y4
M  !^:P  >XH  'JJ  !WU@  =?T .#T  "P^   B00  %T8   ]+   '40
M %<   !<    8@   &8   !K    ;P   '0   !X    >P   'X   "
M@P   (8   "*    C0   )$   "6 P  FPP  )T3  ";(0  FC,  )=)  "4
M8@  DW\  )"@  ".Q0  C/, ,40  "5(   :30  $%,   A:    80   &@
M  !N    =    'D   !_    A    (D   "-    D0   ),   "6    F0
M )T   "@    I    *@   "L    L@,  +<-  "W%P  M2@  +(^  "P5@
MK',  *J4  "IM   I>4 *D\  !Y4   26P  "F(   !J    <P   'L   ""
M    B0   (X   "4    F@   )\   "D    I@   *D   "M    L    +,
M  "W    NP   ,    #%    RP   -$$  #5#@  TQT  - R  #-2P  RF8
M ,:'  #"J0  P<L (EL  !9B   ,:P   70   !]    AP   )    "7
MG@   *0   "K    L0   +8   "Z    O    ,    #$    R    ,L   #/
M    U    -H   #@    Y@   .L   #Q!@  \!,  .XG  #L/P  ZEL  .=Z
M  #DFP  X+L _P   /L   #V    \P   /0 !0#V  P ^@ 1 /\ &0#_ "(
M_P L /\ -0#_ #T _P!% /P 3 #Z %( ]P!8 /4 7@#S &0 \0!J .X <@#L
M 'H Z0"% .4 D0#A *  W0"R -@ S@#2 /8 P0#_ *T _P"> /\ E@#_ )
M_P", /\ ^@   /(   #L    Z0   .D   #L  4 \@ , /@ $@#W !L ]0 E
M /  +@#K #< Y@ ^ .( 10#= $L V !0 -, 5@#0 %P S0!B ,H :@#( '(
MQ0!\ ,( B "^ )8 N@"H +< OP"T .@ K@#_ )T _P"0 /\ B #_ (, _P"
M /\ \    .4   #>    V@   -L   #<    V  ' -$ #@#1 !4 T@ > ,L
M)P#% "\ P  W +T /0"Z $0 MP!) +4 3P"R %4 L !; *X 80"L &D J0!S
M *< ?P"D (T H0"> )X L@"; -4 F0#\ (P _P"" /\ >P#_ '8 _P!T /\
MX@   -,   #*    QP   +P   "V    L  ! *\ "P"L !$ K0 8 *T ( "H
M "@ I  O *  -@"= #P FP!" )D 1P"7 $T E0!3 ), 60"1 &$ CP!J (P
M=0"* (, B "4 (8 IP"# ,( @@#P 'P _P!S /\ ;0#_ &H _P!H /\ SP
M ,$   "Y    K0   *    "8    E    )$ !@"0  T D  2 (\ &0". "$
MBP H (@ +P"& #4 A  Z (( 0 "  $4 ?@!+ 'P 4@!Z %D > !B '8 ; !T
M 'D <@") '$ G0!O +0 ;0#? &P _P!E /\ 8 #_ %X _P!< /\ O@   +$
M  "@    D@   (D   ""    ?    'H  0!X  D =P . '@ % !W !H =  A
M '( )P!P "T ;@ S &P . !K #X :0!$ &@ 2@!F %$ 9 !: &, 9 !A '
M7P!_ %X DP!= *D 7 #( %L ]P!7 /\ 5 #_ %( _P!1 /\ L    )\   "-
M    ?P   '0   !N    :@   &8   !E  0 8P + &, $ !C !4 8P ; &$
M(0!? "< 70 L %P ,@!: #< 60 ] %< 0P!6 $L 50!3 %, 7 !2 &@ 4 !W
M $\ B0!. )\ 30"Z $P Z0!+ /\ 20#_ $< _P!' /\ H@   (T   !\
M;@   &4   !>    60   %<   !5  $ 5  ' %, #0!3 !$ 5  6 %( &P!1
M "$ 3P F $X *P!, #$ 2P W $H /0!) $0 1P!, $8 5@!$ &$ 0P!P $(
M@0!! )< 0 "O #\ UP _ /\ /@#_ #T _P ^ /\ E    '\   !O    8P
M %D   !1    30   $H   !(    1P $ $< "@!&  X 1@ 1 $< %@!% !P
M1  A $( )@!! "L 0  Q #X -P ] #X / !' #H 4  Y %L . !I #< >@ V
M (\ -0"G #4 Q@ T /4 - #_ #0 _P U /\ B    '0   !E    6    $\
M  !(    0P   #\    ]    /  " #P !P [  P .P / #L $@ Z !< .0 <
M #< (0 V "8 -0 L #0 ,@ S #D ,0!! #  2P O %8 +@!C "T <P L (@
M+ "@ "L NP K .H *P#_ "L _P L /\ ?P   &P   != 0  40(  $@#  !
M P  .P(  #<    T    ,P   #( !0 R  D ,@ - #$ $  Q !, ,  8 "\
M'0 M "( +  H "L +@ J #4 *0 ] "@ 1@ G %$ )@!> "4 ;@ D (( (P"9
M ", LP B -X (@#_ ", _P D /\ =P   &4$  !6!@  2P<  $((   Z"
M-0<  # &   M!0  + ,  "L  P J  < *0 + "D #@ I !$ *  5 "< &0 F
M !X )0 D "0 *@ C #$ (@ Y "$ 0P @ $X 'P!: !X :0 = 'P ' "3 !L
MK  ; ,T &P#V !L _P < /\ < 4  %\(  !1"@  1@L  #T+   U"P  , L
M "L*   H"0  )0@  "0' @ C! 8 (P() "(!#  B  \ (0 2 "  %@ ? !L
M'@ @ !T )@ < "X &P V !H /P 9 $H & !7 !< 9@ 6 '@ %0"/ !4 I@ 4
M ,, % #N !0 _P 5 /\ :P@  %L+  !-#   0@T  #D-   Q#0  + T  "<-
M   C#   (0P  !\+ 0 >"@4 '0@( !T&"P <!0T ' 00 !L$%  9!!@ &00>
M !@$(P 7!"L %@0S !4$/  4!$< $P-4 !(#8P 1 W4 $ ** ! !H@ / +P
M#P#E  \ _@ 0 /\ 9PL  %<-  !)#@  /@\  #4/   N#P  * \  "0.   @
M#@  '0X  !L- 0 9#00 & P' !@+"0 7"0P %PD. !8)$@ 5"18 % D; !,)
M(0 2"2@ $@DP !$).@ 0"44 #PE2  X)80 -"7, # B(  L(GP *![< "@;;
M  H%]@ *!/\ 8PT  %,.  !&$   .Q$  #(1   K$0  )1   "$0   =$
M&@\  !@/ 0 6#@0 %0X' !0-"0 3#0L $PP- !(,$  1#!0 $ P9 ! ,'P /
M#"< #@TO  T-.0 ,#44 "PU1  D-8  (#7$ !@V&  4-G0 $#+0  PS2  (,
M\0 ""_\ 7PX  % 0  !#$0  .!(  "\2   H$@  (Q(  !X1   ;$0  &!$
M !40 @ 4$ 4 $A ' !$/"0 0#PH $ X,  X.#@ .#Q( #0\7  P0'0 ,$"0
M"A L  D0-@ ($$$ !A!.  4070 #$&\  1"$   0G   #[0   [4   .\P
M#O\ 7!   $T2  ! $P  -A0  "T4   F%   (1,  !P3   9$@  %A(  !01
M P 2$08 $1$( ! 0"@ .$ L #1$+  P1#0 +$A$ "A(5  D2&@ ($B$ !A,I
M  43,P #$SX  A-+   36@  $VP  !."   2FP  $K0  !'7   1]0  $?\
M6!(  $D4   ]%0  ,Q8  "L6   D%0  'Q4  !H4   7%   %!,! !,2!  1
M$@< $!()  X2"0 -$@D "Q,*  D4#0 '%0\ !A83  06&  #%A\  A8G   7
M,   %SL  !=(   76   %VH  !:    6F0  %;0  !79   4]P  $_\ 510
M $86   Z%P  ,!@  "@8   B%P  '18  !D6   6%0  $Q0# !(3!@ 0$P<
M#Q,'  T4!P +%0@ "18)  88#  #&@X  1H1   :%@  &QP  !LD   ;+0
M&S@  !M&   <50  &V<  !M]   ;EP  &K,  !G;   8^0  %_\ 418  $,8
M   W&0  +AH  "8:   @&0  &Q@  !@7   5%@$ $Q4% !$5!  /%00 #18$
M  L7!0 )&08 !AH(  (<"@  '@T  " 0   @$P  (!D  " A   A*@  (34
M "%"   A4@  (&0  "!Z   ?E0  '[$  ![;   =^@  '/\ 31D  #\;   T
M'   *QP  "0<   >&P  &AH  !<8   4%P( $A<" ! 8 0 -&0$ "QH"  @<
M P %'00  A\&   A"   (PL  "4.   F$0  )A8  "8>   G)P  )S(  "<_
M   F3@  )F   "9W   ED@  )*\  "/:   B^P  (?\ 2!T  #P>   Q'P
M*!X  "(>   ='   &1L  !8:   2&@  $!L   T<   +'0  "!\   0A   !
M(P(  "4$   G!@  *0D  "P,   N#P  +A,  "X:   N(P  +BX  "X[   N
M2@  +5P  "UR   LC@  *ZP  "K4   I^P  */\ 1"   #@A   N(0  )B$
M " @   <'@  &!T  !0=   0'@  #A\   LA   '(P   R4    G    *0
M "P!   N P  , 8  #,*   U#0  -A$  #87   V'P  -BD  #8V   V10
M-5<  #5M   TB0  ,J@  #'/   P^@  +_\ /R0  #0D   K)   )",  !\A
M   ;(   %B   !$A   .(P  "B4   8H   "*@   "T    O    ,@   #0
M   W    .0,  #L&   ^"@  0 X  $$2  !!&@  0"4  $ Q  ! 0   /U(
M #YG   ]@@  /*(  #K'   Y^   ./\ .B@  # H   I)P  (R4  !\C   8
M)   $B4   XH   **@  !2T    P    ,P   #8    X    .P   #X   !
M    0@   $4"  !'!@  2@H  $T.  !-%0  3!\  $PK  !+.@  2DP  $EA
M  !(?   1YL  $6_  !#\P  0O\ -BP  "TK   G*0  (R<  !LH   4*@
M#BT   HP   $,P   #<    Z    /0   $    !#    1@   $@   !+
M30   %    !3 0  5@8  %D+  !;$   6QD  %HE  !9-   6$8  %=:  !5
M=   5),  %*U  !0Z@  3_\ ,S   "PN   G+   'BT  !8O   0,@  "C8
M  ,Z    /P   $(   !&    20   $P   !/    4@   %4   !8    6@
M %T   !@    8P   &<&  !K#   ;!(  &L>  !K+   :3T  &=2  !F:@
M9(D  &&K  !?W   7?\ ,3,  "PQ   B,@  &34  !$Y   */0   D(   !'
M    3    %    !4    6    %L   !?    8@   &4   !H    :P   &X
M  !Q    =0   'D   !]!@  @@T  ((6  " )   ?C4  'Q)  ![80  >'\
M ':?  !SQ@  </< ,38  "8X   <.P  $D    M%   "2P   %$   !6
M6P   &    !E    :0   &X   !R    =@   'D   !\    ?@   ((   "%
M    B0   (X   "3    F 8  )P.  ";&@  F"L  )9   "260  D7,  (V5
M  "+M0  B.@ *SX  "!!   51P  #4T   )4    6P   &$   !H    ;@
M ',   !Y    ?@   (,   "(    C    (\   "2    E0   )D   "=
MH0   *4   "J    L    +<'  "X$0  M2$  +(U  "O30  JFD  *B(  "F
MJ   HM$ (T@  !A.   .5   !%P   !D    ;0   '4   !\    @P   (D
M  "/    E0   )L   "@    HP   *8   "I    K0   +$   "U    N0
M +X   #$    R@   -(   #:"@  UA8  -(I  #.00  REP  ,5\  #"G0
MP;T '%4  !%<   '90   &X   !W    ?P   (@   "0    F    )\   "E
M    K0   +,   "X    N@   +X   #"    Q@   ,H   #.    TP   -H
M  #@    YP   .T   #S    ] X  /(>  #O-@  [%$  .AN  #DD   W[$
M                      $#! 4&" D*"PT.#Q$2$Q06%Q@:&QP='R A(B0E
M)B@I*BLM+B\P,C,T-C<X.3L\/3Y 04)$149'24I+34Y/4%)35%576%E;7%U>
M8&%B8V5F9VEJ:VQN;W!Q<W1U=WAY>GQ]?H"!@H.%AH>(BHN,CH^0D9.4E9:8
MF9J<G9Z?H:*CI*:GJ*JKK*VOL+&SM+6VN+FZN[V^O\'"P\3&Q\C)R\S-S]#1
MTM35UM?9VMO=WM_@XN/DYN?HZ>OL[>[P\?+T]?;W^?K[_/[_____________
M_________________________________________P
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M[8Z(>.>'CX'B@)6*W7N:D-IWH);6=*::U'&LGM)OLJ'0;;FCSVS#IL5GPZ;
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MBI6[IH>=OJ*%I<"?A*_!EGZPP91_MKB3@+NRDX"[LI. N[*3@+NRDX"[LI.
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M-1EQ_ST>:?]%(V+_329;_U8I6/]?+%;_:"U4_VXO4_]S,%+_>#%1_WPQ4/^
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MC"(&_YTG!_^J+@G_MC8.]\$^%NW,1B#DV$LNV=Q01,G46%B[S5YKKL9E>J+
M:HB7NW"2C;=UFX2S?*)]L8.H=J^*K'&MDZ]MK9VQ:JVILFFMM[%JJ;^L:Z;#
MIFNFPZ9KIL.F:Z;#IFNFPZ9KIL.F:Z;#IFNFPZ9KIL.F:Z;#IO^-& +_CR %
M_Z F!O^N+0C]NS4,\<<]$^731!S=X$@MT.%/0L+;5E:TTUUHI\UC>)K(:(6/
MPVZ/A<!TF'V]>IYVNH&D<+F)J&NXDJIGMYRL9;BHK6.XMJUDM<&I9;#%I&6P
MQ:1EL,6D9;#%I&6PQ:1EL,6D9;#%I&6PQ:1EL,6D9;#%I/^.%P+_DQ\$_Z0E
M!?^S+ ;WP3,)Z,X\#]S>0!G0Y4@NQ^5-0KG@552LVUMEG]5A=)+09H&'S6R+
M?LIRDW;(>9EOQH&>:L6)HF7%DJ1BQ)VF7\2GIUW$M*=>P\2D7[W(H%^]R*!?
MO<B@7[W(H%^]R*!?O<B@7[W(H%^]R*!?O<B@7[W(H/^0%P+_F!T$_ZDC!/^Y
M*03NR#$&W=HT"M#D01O&ZT<NO.I,0;#F4U*CXUIAE^!A;HS=:'F"VVZ">MEU
MB7+5?(]KTH*39<^(EV#-CYI<S)><6LN@G5C+JYU7R[J=6<S,F5G,S)E9S,R9
M6<S,F5G,S)E9S,R96<S,F5G,S)E9S,R96<S,F?^2%@+_G1P#_Z\@ O; )0+B
MTR0#T.,R#,7L0!VZ\4<OL.]+/Z7M44Z:ZUI:C^IB987H:FY]YW)U=>-X>V_@
M?H!IW82$9-N*AV#9D8E=V)B+6M:@C5C6J(Y6U;2.5-7!CE35P8Y4U<&.5-7!
MCE35P8Y4U<&.5-7!CE35P8Y4U<&.5-7!CO^4%0+_I!D"_[<< >G+%@'1X1T"
MQ>PQ#KKU0!ZN]T4NH_5*/)KT4$B0\UI3AO-C6W[R;&)W\7-H<>YZ;6SK@'!G
MZ89S8^>,=F#FDGA=Y)AZ6N.>>UCCI7U6XJ]^5.&X?E3AN'Y4X;A^5.&X?E3A
MN'Y4X;A^5.&X?E3AN'Y4X;A^5.&X?O^8$P'_K10!\\,/ -+8"P#$[!X$N/8Q
M$:W]/AZB_4,KE_Q(-X[\3T&%_%E)??QC4'?\;59P^W1::_EZ7FCW@6%D]8=C
M8?.-95_RDV==\9EH6O">:5COI6M6[ZUL5.ZT;53NM&U4[K1M5.ZT;53NM&U4
M[K1M5.ZT;53NM&U4[K1M5.ZT;?^C$ #QN0P SLD) ,3?"P"V]Q\&K/\R$J#_
M.QV4_T$GBO]',8'_3CEZ_U@_<_]B16[_;$EI_W-,9O]Z3V/_@%%@_X937O^,
M5%S_DE5:_IA76?V=6%?\I%E5^ZM:5/NQ6U3[L5M4^[%;5/NQ6U3[L5M4^[%;
M5/NQ6U3[L5M4^[%;5/NQ6_"O" #-OP< P,T( +3N#@*I_R$(G_\Q$9+_-QJ'
M_SXB??]%*77_33!N_U4U:?]@.67_:CQA_W$^7_]W0%S_?D):_X1#6?^)1%?_
MCT56_Y1&5?^:1U/_H$A2_Z=)4?^M2E'_K4I1_ZU*4?^M2E'_K4I1_ZU*4?^M
M2E'_K4I1_ZU*4?^M2L^X! "^PP4 LM0& *;^$ .<_R,(D/\M#X3_,Q9Y_SL<
M</]#(FG_2B=B_U(J7?]<+5K_93!8_VTQ5O]S,U3_>313_WXU4O^$-E#_B3=/
M_XXX3O^3.$W_F3E,_Z Z2_^F.DO_ICI+_Z8Z2_^F.DO_ICI+_Z8Z2_^F.DO_
MICI+_Z8Z2_^F.K^\ P"PR@, H]P# 9G_$@./_R((@O\H#7;_+Q)M_S<79?\_
M&U[_1QY8_TXA5/]7(U'_7R5._V4F3?]L)TO_<2A*_W8I2?][*DC_@"I'_X4K
M1O^)*T7_CBQ$_Y0L0_^:+4/_FBU#_YHM0_^:+4/_FBU#_YHM0_^:+4/_FBU#
M_YHM0_^:+;'" 0"CT@  E>L# 8S_$P. _QP&=/\C"FG_*@Y@_S(26?\Z%5/_
M0A=._TD92_]1&DC_6!Q&_UT=1/]C'4/_9QY!_VP?0/]P'S__=" ^_W@@/?]\
M(#S_@2$[_X<A._^,(CO_C"([_XPB._^,(CO_C"([_XPB._^,(CO_C"([_XPB
M._^,(O]Z'0/_=B@&_W(S"_]\-P__A#\5_XA('?^+4R?_B6 Q_X9M._^">43_
M?H9,_WN14_]WFEC_=*)=_'&H8?INKF3X:[1G]VFZ:?5HP6OS9LAM[V/-;^QA
MTW#G7]UQXEWE<]U;YG/=6^9SW5OF<]U;YG/=6^9SW5OF<]U;YG/=6^9SW5OF
M<_]Z'0/_=B@&_W(S"_]\-P__A#\5_XA('?^+4R?_B6 Q_X9M._^">43_?H9,
M_WN14_]WFEC_=*)=_'&H8?INKF3X:[1G]VFZ:?5HP6OS9LAM[V/-;^QATW#G
M7]UQXEWE<]U;YG/=6^9SW5OF<]U;YG/=6^9SW5OF<]U;YG/=6^9SW5OF<_]Z
M'0/_=B@&_W(S"_]\-P__A#\5_XA('?^+4R?_B6 Q_X9M._^">43_?H9,_WN1
M4_]WFEC_=*)=_'&H8?INKF3X:[1G]VFZ:?5HP6OS9LAM[V/-;^QATW#G7]UQ
MXEWE<]U;YG/=6^9SW5OF<]U;YG/=6^9SW5OF<]U;YG/=6^9SW5OF<_]Z'0/_
M=B@&_W(S"_]\-P__A#\5_XA('?^+4R?_B6 Q_X9M._^">43_?H9,_WN14_]W
MFEC_=*)=_'&H8?INKF3X:[1G]VFZ:?5HP6OS9LAM[V/-;^QATW#G7]UQXEWE
M<]U;YG/=6^9SW5OF<]U;YG/=6^9SW5OF<]U;YG/=6^9SW5OF<_]Z' /_=R<&
M_W0R"_]_-@__ACT5_XM''?^.42?_C%XQ_XEK//^%=T;_@8-._WV/5O]YF%S\
M=:!A^7*F9?=OK6GU;+-L\VJY;_)HP''P9LAS[&3-=>AAU';C7]YWVUWC>=5=
MY7;57>5VU5WE=M5=Y7;57>5VU5WE=M5=Y7;57>5VU5WE=O][' /_=R<&_W<P
M"O^"-0[_BCP5_X]&'?^23R?_D5PR_XYH/?^*=$C_AH!2_X&+6OQ]E6'X>)UG
M]72D;?)QJG'P;K!T[FNV=^QIOGKJ9\=]YV7.?^)BUH#97]V!T%_@?LQ@XWO,
M8.-[S&#C>\Q@XWO,8.-[S&#C>\Q@XWO,8.-[S&#C>_]\' /_>"8&_WHO"O^%
M,P[_C3L4_Y)$'/^63B?_E5HR_Y)E/O^.<4K_BGU5_H6(7OF DF?T>YIN\':A
M<^URIWCJ;ZY]Z&RT@.9IO(/D9\:&X67/B-EBUXK/8=F(R&+=@L1CX'_$8^!_
MQ&/@?\1CX'_$8^!_Q&/@?\1CX'_$8^!_Q&/@?_]]&P/_>28&_WPN"O^(,@[_
MD#H4_Y5#'/^:3"?_F5@S_Y9C/_^2;DS_CGI7_(F%8O6$CVOP?I=S['F>>NAT
MI8#E<*N%XFRSB>!JNXS>:,:/VF;1DLYBT9+'9-6,P67;AKUFW8*]9MV"O6;=
M@KUFW8*]9MV"O6;=@KUFW8*]9MV"O6;=@O]]&P/_>B8&_W\L"O^+,0W_DSH3
M_YA"'/^=2R;_G58S_YMA0/^7;$W[DG9:]XV!9O*(C'#L@I1YYWN;@>-UHHC?
M<:F.W&VQDMEKNY;7:<B9S&3+F\5ESI? 9]*1NFC8BK9IVX:V:=N&MFG;AK9I
MVX:V:=N&MFG;AK9IVX:V:=N&MFG;AO]^&P/_>R8&_X$K"?^-,0W_E3D3_YM"
M&_^@2B;_H50S_Y]?0?N<:4_VEW-=\9)^:NR,B'7GA9& XGZ8B=UXH)'8<J>7
MTFVOG<]LN9_,:\6@PV?'H+QHRYNW:M"4LFS5C:]LV8FO;-F)KVS9B:]LV8FO
M;-F)KVS9B:]LV8FO;-F)KVS9B?]^&@/_>R4&_X,J"?^/, S_F#@2_YY!&_^C
M22;_IE(S_:1=0?>A9U#QG'%?ZY=[;>6/@WK>AXN&U7Z2D<]XF9?*=*&<QW&J
MG\-OLZ'!;K^CNFO%H[-KR)^O;<V8JV_2D:EPUHRI<-:,J7#6C*EPUHRI<-:,
MJ7#6C*EPUHRI<-:,J7#6C/]_&@/_?"4&_X8I"/^2+PS_FS@2_Z% &O^G2"7_
MJE$R^:E;0?.F9%'LHFYAY9IV<-R1?G_2B8:+RX*-D\5]E9G >)V>O'6EH;ES
MKJ2V<KFELG##IJMOQJ*H<<N;I'/0DZ)TU(ZB=-2.HG34CJ)TU(ZB=-2.HG34
MCJ)TU(ZB=-2.HG34CO^ &@/_?"4&_X@H"/^4+PO_G3<1_Z0_&?^J1R3]KD\R
M]JU90>^K8E+GIFMBWIYR<]*5>H'*C8*+PX>*D[V!D9JW?9F?LWFAHZ]WJJ:L
M=K2GJG;!J*-SPZ6@=<F>GG?/EIQWTI&<=]*1G'?2D9QWTI&<=]*1G'?2D9QW
MTI&<=]*1G'?2D?^ &@/_?24&_XHG"/^6+@O_GS80_Z<_&/^M1R/[LDXQ\[)7
M0>NQ8%+BJFADUJ)P=,R9=X'#DG^+O(N&E+6&CIJO@96@JGZ=I*9[IJ>C>K"I
MH7F\J9MWP:B9><>@F'K-F)=[T9.7>]&3EWO1DY=[T9.7>]&3EWO1DY=[T9.7
M>]&3EWO1D_^!&@/_?B0&_XPF!_^8+@K_HC80_ZD^&/^O1B/XM4TP\+=60.>U
M7E+=KF9DT*5N<\:==8"]EGR+M9"#E*Z*BYNHAI*@HX*:I9]_HZB;?JVJF'VY
MJY1[P*J3?<:BDG[,F9%_T)21?]"4D7_0E)%_T)21?]"4D7_0E)%_T)21?]"4
MD7_0E/^!&0/_?B0&_XTF!_^:+0K_I#4/_ZP]%_ZR12+VN$PP[;Q40.2X75'7
MLF1CRZEL<\"A<X"WFGJ+KY2 DZB/B)NBBH^@G(>7I9>$H*B4@JFJD8*UJXV!
MOZN-@<6DC(++FXR"SY6,@L^5C(+/E8R"SY6,@L^5C(+/E8R"SY6,@L^5C(+/
ME?^"&0/_?R0&_X\E!_^<+0G_IC4._ZX]%ORU12'SO$LNZL%2/^"\6U'1M6-C
MQJUJ<KNE<7^RGG>*J9A^DZ*3A9J;CXV@EHR5I9&)G:B-AZ>KBH>RK(>'OZR&
MAL2EAX;*G(>&SI>'ALZ7AX;.EX>&SI>'ALZ7AX;.EX>&SI>'ALZ7AX;.E_^"
M&0/_@",%_Y$E!O^>+ G_J#0-_[$\%?JX1!_POTLMY\51/=S 6E#-N&%BP;!H
M<;:I;WZLHG6)I)U\DIR8@IJ5E(J@CY&2I8J.FZB&C:6K@XRPK(&-OJR B\.F
M@8O)G8&+S9B!B\V8@8O-F(&+S9B!B\V8@8O-F(&+S9B!B\V8@8O-F/^#&0/_
M@B(%_Y,D!O^@+ C_JS,-_[0\%/>\0Q[NQ$HKY,E1.]7$6$_(O&!AO+1G<+&M
M;7VGIW.)GJ)YDI:=@)F/FHB?B9>0I(.4F*A_DZ*J?)*MJWJ2NZQZD<.F>Y#)
MGGR/S9A\C\V8?(_-F'R/S9A\C\V8?(_-F'R/S9A\C\V8?(_-F/^#& +_A"$%
M_Y4D!O^B*PC_K3,+_K<[$O3 0ASJR4DHX,U/.=#'5T[#P%Y@M[AE;ZNR:WRA
MK'&'F*=XD)"C?IB)H(6>@IV-HWV;EJ=XF:"I=9FKJG.9N*MSF,.F=9;)GG:5
MS9EVE<V9=I7-F7:5S9EVE<V9=I7-F7:5S9EVE<V9=I7-F?^$& +_AR %_Y<C
M!?^E*@?_L3(*^[LZ$/'%01GGST@EV])-.,O+54R]Q%U>L;YC;J6X:GN;LF^&
MDJYVCXFJ?):"IX.<>Z2+H7:BE*5QH9VG;J"IJ6RAMJEMH<.F;YW)GG"<S9AP
MG,V8<)S-F'"<S9APG,V8<)S-F'"<S9APG,V8<)S-F/^%& +_BAX$_YHB!/^H
M*0;_M3 (]L X#NO+0!7AV$8@T]A+-L705$NWR5M<J\-B;)^^:'B4N6Z#B[5S
MC(.R>I-[KX&9=:V)GF^KDJ)KJIRD:*JGI6:JM*9FJ\6D:*;*G&FDS9=II,V7
M::3-EVFDS9=II,V7::3-EVFDS9=II,V7::3-E_^&%P+_C1P$_YXA!/^L)P7]
MNB\&[\<V"N/4/A#8WT,?R]Y*-+[64DBPT%I:I,I@:9C&9G:-P6R A+YRB7N[
M>)!TN7^5;K>'FFFVD)UEM9N@8K2FH6"ULZ%?ML6@8;',FF*NSY5BKL^58J[/
ME6*NSY5BKL^58J[/E6*NSY5BKL^58J[/E?^'%P+_D1H#_Z(@ _^R)0/UP"L$
MYL\Q!MC>. _,Y4,@P^)),[;>44:IV%A7G-)>99#.9'*&RVI\?,APA'3&=XIN
MQ'Z/:,.'E&/"D)=?P9N97,&FFEO"LYM:P\6:6[[/E5RZTI%<NM*17+K2D5RZ
MTI%<NM*17+K2D5RZTI%<NM*17+K2D?^)%@+_EAD"_Z@= OZX(0+LR2("V=TE
M!,SE-Q'"ZD,BM^=(,ZSD3T2@X%93E-U=8(C:8VM^UFIU==1P?6[2=X-GT7^(
M8M"'BU[0D8Y:T)R06-"GD5;0M9)5TL>15LW4CE;(UHM6R-:+5LC6BU;(UHM6
MR-:+5LC6BU;(UHM6R-:+5LC6B_^+%0+_G1<!_Z\9 ?3!& '=V!$ S.4F!<'N
M-Q.V[T(CJ^U',J'K3$"6Z55-B^==6(+F96%YY&QI<N1T;VSC?'1GXH1X8N*-
M>U[BE7Y;X)Z 6-^G@E7>L8-3WKZ#4M[2@U'9W()1V=R"4=G<@E'9W()1V=R"
M4=G<@E'9W()1V=R"4=G<@O^/$P+_I!,!_K@2 -;,"P#,Y!$!P.\F![7U.!6J
M]$ BG_-&,)7R2SR,\51&@O!=3WKP9E9T\&Y<;N]V86GO?F1E[X9H8>^.:E[N
MEFU;[9YO6.NE<%;KKG%4ZKAR4NK'<U'IU7-1Z=5S4>G5<U'IU7-1Z=5S4>G5
M<U'IU7-1Z=5S4>G5<_^8$ '_K@X U,$) ,G/"0"^\!("L_DG"JG[.!6>^SXA
MD_M$+(GZ2C6!^E,^>?I=17+Z9DIM^F].:/IV4F3Z?E5A^H977_N.6ESZEEM:
M^9U=5_BE7E7WK&!3][5A4O;!85#VRF)0]LIB4/;*8E#VRF)0]LIB4/;*8E#V
MRF)0]LIB4/;*8O^C"P#6N 8 QL0' +O4"0"P_!0#IO\I"YS_-160_SL>AO]"
M)GW_22YU_U$T;_];.FG_93YE_VY!8O]U1%__?$9<_X-(6O^+25C_DTM6_YM,
M5?^B35/_J4Y1_[%/4/^[4$__PU%/_\-13__#44__PU%/_\-13__#44__PU%/
M_\-13__#4=JO @#&O 4 N<D% *W;" "C_Q<$FO\K"X[_,1*#_S@:>?] ('#_
M1R9I_T\K8_]8+U__8C)<_VLT6O]R-EC_>#A6_W\Y5/^&.U+_C3Q1_Y4]3_^<
M/D[_HSY-_ZH_2_^S0$K_N4%*_[E!2O^Y04K_N4%*_[E!2O^Y04K_N4%*_[E!
M2O^Y0<BU @"XP00 J] # )_K"0&6_QH%B_\F"G__+0]U_S45;/\]&F7_1!Y>
M_TPB6/]4)57_72=2_V4I4/]L*D[_<RM-_WDL3/]_+4K_A2Y)_XPO2/^2,$?_
MF3!%_Z Q1/^I,D/_KC)#_ZXR0_^N,D/_KC)#_ZXR0_^N,D/_KC)#_ZXR0_^N
M,KBZ @"JR   G=D  )+_# *)_QH$??\A"'+_* QH_S 08/\X%%K_0!=4_T@:
M3_]/'$S_5QU)_UT>1_]C($7_:2!$_V\A0O]T(D'_>B) _X C/_^&)#[_C"0]
M_Y(E//^9)3O_GB8[_YXF._^>)CO_GB8[_YXF._^>)CO_GB8[_YXF._^>)JO!
M  "=T   C^$  (;_#@)Z_Q4#;O\<!F3_(PE<_RL,5?\S#T__.Q%)_T(31O])
M%$+_3Q9 _U46/O]:%SS_7Q@[_V08.?]H&3C_;1DW_W(:-O]W&C7_?!HT_X$;
M,_^(&S+_C1LR_XT;,O^-&S+_C1LR_XT;,O^-&S+_C1LR_XT;,O^-&_]P'@/_
M;"D&_VDS"?]R-PW_>3X2_WU'&?^ 42'_?E\I_WQM,O]Y>SG_=HA _W.31?]P
MG4K_;J9._VNM4?]IM%/_:+M5_V;#5_]CQUG[8<Q;]U_37/->W5WP7.->ZUOI
M7^=9[V#E6?%?Y5GQ7^59\5_E6?%?Y5GQ7^59\5_E6?%?Y5GQ7_]P'@/_;"D&
M_VDS"?]R-PW_>3X2_WU'&?^ 42'_?E\I_WQM,O]Y>SG_=HA _W.31?]PG4K_
M;J9._VNM4?]IM%/_:+M5_V;#5_]CQUG[8<Q;]U_37/->W5WP7.->ZUOI7^=9
M[V#E6?%?Y5GQ7^59\5_E6?%?Y5GQ7^59\5_E6?%?Y5GQ7_]P'@/_;"D&_VDS
M"?]R-PW_>3X2_WU'&?^ 42'_?E\I_WQM,O]Y>SG_=HA _W.31?]PG4K_;J9.
M_VNM4?]IM%/_:+M5_V;#5_]CQUG[8<Q;]U_37/->W5WP7.->ZUOI7^=9[V#E
M6?%?Y5GQ7^59\5_E6?%?Y5GQ7^59\5_E6?%?Y5GQ7_]P'@/_;"@&_VLQ"?]U
M-@W_>SP2_W]&&?^#4"'_@5XJ_WYK,_][>#O_>(9"_W622/]RFTW_<*11_VVL
M5/]KLE?_:;E:_V?!7/QEQU[X8LQ?]6#38?!>W6+L7.1CZ%OI9.):[V3@6O!B
MX%KP8N!:\&+@6O!BX%KP8N!:\&+@6O!BX%KP8O]Q'0/_;2@&_VXP"?]X- S_
M?SL2_X-$&?^'3B'_AELK_X-H-/]_=3W_?()%_WF.3/]VF5+_<J%6_V^I6OYM
ML%[\:K=A^VB^8_EFQF7T8\QG\&'3:>M?WFOF7>5LX%OI;=E<[FC67.]GUESO
M9]9<[V?67.]GUESO9]9<[V?67.]GUESO9_]R'0/_;B@&_W$N"?][,@S_@SH1
M_X=#&/^*3"'_BEDK_X=E-?^#<C__?WY(_WR+4/]YEE;_=9]<_7*F8/INK63X
M;+1H]FF\:_1GQ6WP9,QPZV'3<N5?WW/>7.5TUESH<<]>[6S-7NYKS5[N:\U>
M[FO-7NYKS5[N:\U>[FO-7NYKS5[N:_]S' /_;R<&_W0M"/]^,0S_ACD1_XM"
M&/^.2R'_CE8K_XMC-O^';T'_@WM+_W^'4_Y\DEO\>)QA^72D9_9PJVOS;;)O
M\6JZ<^]HPW;K9<QXYF+5>MY?WWS37>-[S5_F=L=@ZG#&8.QNQF#L;L9@[&[&
M8.QNQF#L;L9@[&[&8.QNQF#L;O]T' /_<"<&_W8K"/^!+PO_B3@0_XY &/^2
M22'_DU0L_Y!@-_^,;$/_AW=-^X.#5_A_CF#V>I=G\W:@;O!RJ'/M;J]XZVNX
M?.AHPG_F9LV"WV+8A-%?W(7*8.!_Q6'C>K]CZ'2^8^EROF/I<KYCZ7*^8^ER
MOF/I<KYCZ7*^8^EROF/I<O]T' /_<"8&_WDJ"/^%+@O_C3<0_Y(_%_^62"#_
MEU(L_Y5>./Z1:43ZC'10]8=_6_*"B67N?9-NZG>;=>=RHWSD;JN!X6JSAMYG
MO8K:9<J-TF+4CLABV(K"8]R$O&7@?K=FY7BV9N9VMF;F=K9FYG:V9N9VMF;F
M=K9FYG:V9N9VMF;F=O]U&P/_<28&_WPH!_^(+0K_D#8/_Y8^%O^:1R#_G% K
M_YI;./F79D7TDG!2[XQ[7^J%A6KE?HUTX'B5?=MRG874;:2+T&JMCLUHMY#+
M:,.1R&?1DK]EU(^Y9]F)M&C=@K!IXGRN:N1YKFKD>:YJY'FN:N1YKFKD>:YJ
MY'FN:N1YKFKD>?]V&P/_<B8%_W\G!_^*+ K_DS4._YD]%O^>1A__H4XK^Z!9
M./6<8T;OF&U4Z)!W8N*(?V_:@(=[TGJ/@\UUEXG)<9^-Q6ZHD<)LL9._:[R5
MO6O+E;9IT)2Q:]6-K&S;AJAMX'^G;>)\IVWB?*=MXGRG;>)\IVWB?*=MXGRG
M;>)\IVWB?/]V&P/_<R4%_X$F!_^-+ G_EC0._YT\%?^A1![^I4PJ]Z57./"B
M84?IG&I6X91R9=B,>W//A8-\R7^+A,-ZDXJ_=IN/NG.CD[=PK):T;[>7L6_$
MF*QMS9BI;].0I7#8B:%QWH*@<>!_H''@?Z!QX'^@<>!_H''@?Z!QX'^@<>!_
MH''@?_]W&P/_="4%_X,E!O^0*PG_F3,-_Z [%/^E0QW[J4LI\ZI4..RH7D?C
MH6=7VIEO9\^1>'/'BH!]P82(A;M_CXNU>I>0L7>?E*UTJ)>J<[*9IW*_FJ1R
MRYJA<]"3GG36C)MUW(2:==Z!FG7>@9IUWH&:==Z!FG7>@9IUWH&:==Z!FG7>
M@?]X&@/_=B0%_X8C!O^2*@C_FS(,_Z,Z$_^H0ASXK4HH\*]2-^>L7$?>I618
MT9UM9LB5=7/ CGQ]N8F$A;.#C(RM?Y.1J7N;E:5YI)FA=ZZ;GG:ZG)UWRIR9
M=\^6EWC4CI5XVX:4>-V#E'C=@Y1XW8.4>-V#E'C=@Y1XW8.4>-V#E'C=@_]X
M&@/_>",%_X@C!O^4*@C_GC$+_Z8Z$OZK0AOUL$DG[+50-N.P6D;8J6-7S*%K
M9L*:<G*ZDWI\LXV!A:R(B8RFA)"1H8"8EIU]H9J9>ZJ<EGNVG91[QIZ2>\V8
MD7S3D(]\V8B/?-R%CWS<A8]\W(6/?-R%CWS<A8]\W(6/?-R%CWS<A?]Y&@/_
M>B(%_XHB!?^6*0?_H#$+_Z@Y$?NO01KRM$@FZ;E/--^T6472K6%6QZ5I9;V>
M<'*TEW=\K9%^A::,AHR@B(V1FH65EI:"GIJ2@*>=CW^SGHV PIZ+@,R:BX'2
MDHJ V(F)@-N&B8#;AHF VX:)@-N&B8#;AHF VX:)@-N&B8#;AO]Y&@+_>R$$
M_XLB!?^8* ?_HS *_ZLX$/FR0!CON$<DYKU.,]NX5T3-L&!6PJEG9+BB;G&O
MFW5[IY9\A*"1@XN:C8N1E(J3EH^'FYJ+A:6=B(2PGX6$OY^%A<N;A871DX6%
MV(J$A-J'A(3:AX2$VH>$A-J'A(3:AX2$VH>$A-J'A(3:A_]Z&0+_?2 $_XTA
M!?^;* ;_I2\)_ZXW#O:V/Q?LO$8BX\%.,-6\5D/(M%Y5O:QF8[.F;'"JGW-[
MH9IZA)J6@8N4DHB1CH^0EHF,F9J$BJ.=@8JNGWZ*O)]^BLJ<?XK0E'^)UHM_
MB-F(?XC9B'^(V8A_B-F(?XC9B'^(V8A_B-F(?XC9B/]Z&0+_?QX$_Y A!/^=
M)P7_J"X(_K(V#?.Z/A7IP44?W\5,+]"_5$+$MUU3N+!D8JZJ:F^DI'%ZG)]W
M@Y2;?HJ.F(:0AY6.E8*2EYE]D*"<>H^KGGB/N9]WD<J=>9#/E7F.UHQYC=B)
M>8W8B7F-V(EYC=B)>8W8B7F-V(EYC=B)>8W8B?][&0+_@1T$_Y(@!/^@)@7_
MJRT'^[4U"_"^/1+FQT0<VLE)+LO#4T&^O%M2L[5B8:BO:6Z?JF]XEJ5U@8ZA
M?(F'GH./@9N+E'N9E)AWEYZ;<Y:IG7&6MIYPE\B=<I;/E7.4U8QTD]B)=)/8
MB723V(ETD]B)=)/8B723V(ETD]B)=)/8B?]\& +_A!P#_Y4? _^C)03_KRP&
M][HS">S$.P_BSD(8T\Y(+,;'4D"YP%I1K;IA7Z.T9VR9L&UWD*MT@(BH>H>!
MI8&->J*)DG6@DI9PGIN9;)ZGFVJ>M)QIG\6;;)[0E&V:UHQMF=B);9G8B6V9
MV(EMF=B);9G8B6V9V(EMF=B);9G8B?]]& +_AQH#_Y@> _^F(P/_LRD$\\ Q
M!^?+. O=V#H6S=)&*L#,4#ZSQEA/I\!?79R[96J2MVMTB;-Q?8&O>(1ZK7^*
M=*J'CVZICY-IIYJ69J>EF&.GLIEBJ,.89:?1DV:CUHMGH=F)9Z'9B6>AV8EG
MH=F)9Z'9B6>AV8EGH=F)9Z'9B?]^%P+_BQ@"_YP< O^K(0+[N28#[<<L!-_5
M,0;3WCD4QMA$*+G13CNLS%9,H,==6I7"8V>+OVEQ@KMO>7JX=H!SMGV&;;2%
MBVBSCH]CLIB28+&DDUZRL91<LL*47K+3D%^LV8E@JMJ&8*K:AF"JVH9@JMJ&
M8*K:AF"JVH9@JMJ&8*K:AO]_%P+_D!8"_Z$: ?^Q'0'TP" !X]$@ =/?+ ;)
MXCL4OM]$);+93#BETU1)F<];5X[+86.$R&AL>\5N=7/#=7MLP7R!9\"$A6*_
MCHE>OIB+6KZDC5B^L8Y7O\*-6+_7BUFXW(59MMV#6;;=@UFVW8-9MMV#6;;=
M@UFVW8-9MMV#6;;=@_^!%@+_E10!_Z<6 ?VX%P#IRQ$ T]\6 <CG+ >^YCL6
ML^1$):CA2S6<W5)$D=E94H;58%U\TV9F=-%M;FS/='1FSGQY8<V%?5S,CH!9
MS)F#5LREA%3,LX53S<2%4\W=@U/&X'Y4P^%]5,/A?53#X7U4P^%]5,/A?53#
MX7U4P^%]5,/A??^'$P'_G!(!_ZX1 -K""@#0T@H Q^@8 ;SL+ JRZSP7J.I#
M)9WH2#.2YE! B.192W[B8%1VX6A<;^!O8FC?=VACWG]L7MZ(<%K>D7-7WIMU
M5-ZG=U+?M'A0W\1X3^#>>$_6Y75/T^=T3]/G=$_3YW1/T^=T3]/G=$_3YW1/
MT^=T3]/G=/^/#P'_I X V[@( ,W%"0#%U0H NO$: [#R+0RF\3L8F_!!))'O
M1R^'[DXZ?NY80W?M84IP[6E0:NQQ567L>5EA[(%<7>R*7UKLDV%7[9UC5>VG
M95+MLV91[L!G3^_4:$[KYFA-Z.AH3>CH:$WHZ&A-Z.AH3>CH:$WHZ&A-Z.AH
M3>CH:/^9"P#=K@0 S+P& ,')!P"XVPH K?@<!*3X+PV9^#D7C_@_(87X1BI\
M^$TR=?=7.6[W8#]I]VE#9/AQ1V'X>4I=^(%,6OB)3UCXDE%6^9M24_FE5%'Z
MKU50^KM63OK*5TW[XU=,^^E73/OI5TS[Z5=,^^E73/OI5TS[Z5=,^^E73/OI
M5^6E  #.M 0 O[\% +3.!@"JZPT!H/\?!I?_+PV,_S85@O\]'7C_1"1P_TPJ
M:O]4+V7_7C-A_V<W7?]O.5K_=CQ8_WX^5O^&/U/_CD%1_Y="4/^@0T[_J45-
M_[-%2_^^1DK_T$=)_]Q'2?_<1TG_W$=)_]Q'2?_<1TG_W$=)_]Q'2?_<1]&N
M  "_N0, LL4# *?5!0"<_0\"E/\B!HG_*PQ^_S(2=?\Z&&S_0AUE_TDB7_]1
M)5K_6BA7_V,K5/]K+5+_<B]0_WDP3_^ ,4W_B#)+_Y T2O^8-4C_H35'_ZHV
M1O^S-T3_OSA$_\4X1/_%.$3_Q3A$_\4X1/_%.$3_Q3A$_\4X1/_%.,&S  "R
MO@( I<P! )G= P"0_Q("AO\?!7O_)PIQ_RX.:/\V$V'_/A=:_T8:5?]-'5'_
M51]._UT@2_]D(DG_:R-'_W$D1O]X)43_?R9#_X8G0?^.*$#_EB@__YXI/?^G
M*3S_L"H\_[0J//^T*CS_M"H\_[0J//^T*CS_M"H\_[0J//^T*K.X 0"EQ@
ME]4  (OO! &$_Q,"=_\:!&W_(@=D_RH+7/\R#E7_.1%0_T$32_](%4C_3Q=%
M_U880O]<&4#_81H^_V<://]M&SO_<QPY_WD<./^ '3;_B!TU_X\>-/^7'C+_
MH!\R_Z0?,O^D'S+_I!\R_Z0?,O^D'S+_I!\R_Z0?,O^D'Z;   "7S@  B=X
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M34GXX$U(]_--2/?T34CW]$U(]_1-2/?T34CW]$U(]_1-2/?T3=JC  #'L0(
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M:D_%[6A0P/-D4;WU85&]]6%1O?5A4;WU85&]]6%1O?5A4;WU8?^&"@#PF@0
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M-3__[S4__^\U/__O-3__[S4__^\U/__O-<2J  "SLP  I[\  )K+  "/V@(
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M<%^?ZVMAG?)E8IKV8&*9]UYBF?=>8IGW7F*9]UYBF?=>8IGW7O]S$ '_A0P
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M3DK*_TU*RO]-2LK_34K*_TU*RO]-2LK_3>>/  #1GP  PZL! +>T @"MOP,
MH\L& )O9"@"4Y1H!C>4K!H3D-0U[XS\6<^)('FSA4B9FX5HL8.!B,EO@:C97
MX'(Z4]][/5#?A4!-WX]#2N";14C@J$9&X+A'1>',1T7@Z$=%W_9&1=[_1$7>
M_T1%WO]$1=[_1$7>_T1%WO]$1=[_1-F7  #'I@  N+   *RY 0"BQ0( F-$&
M (_K#0")[A\"@.XK!GCM- QP[3T3:.U&&6+M3AY=[5<C6>U@)U7M:"I2[7$M
M3^UY+TSM@S)*[HTT1^Z8-47NI3=#[[,X0O#$.$'PWSE![^\X0.W].$#L_SA
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M:6^&ZV-RA_E<<X;]5G.%_U)SA?]2<X7_4G.%_U)SA?]2<X7_4O]H$0'_> T
M_X8- /:3# #>H D UJD* -*R#0#'LB("O:\S"K.K01>JITPDH:)5,)F>73J2
MFF1"BY=K2864<E" DGE5>X^!6G:-B5YRC))B;HJ=96N)J6=HB;AH9XG+:&F+
MZ6-LC?E<;8S]5VV*_U)MBO]2;8K_4FV*_U)MBO]2;8K_4O]K$ '_>PL _XH*
M .*8!@#6HP@ T*P) ,NU"P#!MA\!N+0Q":ZP/Q:DK$HBG*A3+I2D6SB,H&)
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M5%NA_U!;H?]06Z'_4%NA_U!;H?]06Z'_4/]W!P#PB0  UI@  ,ND P#!K00
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M.4/8_SE#V/\Y0]C_.="6  #!HP  LJP  *>U  "<P   D<H# (?6!P" Z1$
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M7']S[%:!=OM/@WC_2H-X_T6">/]$@GC_1()X_T2">/]$@GC_1/]?$0'_;0P
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M36R*_TALB?]';(G_1VR)_T=LB?]';(G_1_]I"P#_> 0 Y8<  -:2 P#-G 4
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M0E*I_T)2J?]"4JG_0O)\  #7C   R)D  +VC  "RJP  J;(  *"[ @"7Q D
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M"AW_HPH<_[$*&__ "QK_U@L:_]\+&O_?"QK_WPL:_]\+&O_?"YNQ  "-O
M?L<  '#2  !CW@  5>0  $OU  !&_P4 0/\. #O_%  W_QL!,_\C 2__*0(K
M_S "*/\U B7_.P,B_T$#'_]' QW_3@,:_U4$&/]>!!7_: 43_W0%$?^"!1#_
MD 80_YT&#_^I!@[_M08._[H&#O^Z!@[_N@8._[H&#O^Z!HZZ  !_Q0  <-$
M &+>  !4Y0  1NL  #_^   Y_P  -/\) "__#@ K_Q0 )_\: 2/_(0$?_R4!
M'/\J 1G_+P$6_S0"%/\Z A'_0 (0_T8"#O]. @S_5@()_V #!_]L P3_> ,#
M_X8# O^1 P'_G0,!_Z$# ?^A P'_H0,!_Z$# ?^A _\V+0+_.2X"_SXN _]
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M3)%C[T>29?U!DF?_/)-I_SB3:O\UDVK_-9-J_S63:O\UDVK_-?]7$0'_8PT
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M0GIX_SY[>?\Z>WG_.GMY_SI[>?\Z>WG_.O]?# #_; 0 ]7D" -Z# @#3BP4
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M/&.,_SQCC/\\8XS_//]J  #F>@  U88  ,F1  # F0$ N)\! +"E  "HJ0X
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M&C;AS1HVW^P:-=[Y&C3=_QLTW/\;--S_&S3<_QLTW/\;--S_&[F<  "JI
MGJL  )*U  "%O@  ><<  &W/  !BU@, 6.$( %7J$P!1ZR  3>LK 4GK-0)%
M[#X$0NQ'!3_L3P<][5@).NU@"CCM:@PV[G0-,^Z #C+NC@\P[YT0+N^M$2WP
MP!$M\-X1+.[Q$2SL_A$LZ_\0+.O_$"SK_Q LZ_\0+.O_$*VB  "@J0  D[,
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M PG_M0,(_\(#"/_" PC_P@,(_\(#"/_" XJX  ![PP  ;,X  %[;  !/X@
M0N<  #;L   Q_P  +/\  "?_!P C_PX (/\2 !S_&  8_QT %?\A !+_)@ 0
M_RP!#O\Q 0W_-P$*_SX!"/]& 07_3P$!_UD! /]F 0#_= $ _X(" /^0 @#_
MG ( _Z8" /^F @#_I@( _Z8" /^F O\N+P+_,RP"_S<M O\X, +_-S8#_S0_
M!/\Q2P;_+U@'_RQF"/\J= G_*8$*_RB-"_\HEPO_*)\+_RBF#/\GK0S_)[0,
M_R>[#/\GQ S_)\X,_RC>"_\HZ0O_*/,+_RC["_\H_PK_*?\*_RG_"O\I_PK_
M*/\*_RC_"O\H_PK_*/\*_RC_"O\P+0+_-BH"_SDJ O\[+@+_.C0#_S@\!/\V
M20;_,U8'_S%C"?\O<0K_+7X+_RV*#/\LE S_+)P-_RRD#?\LJPW_++$-_RRY
M#?\KP0W_+,L-_RS:#?\LYPW_+/$-_RSZ#?\L_PS^+?\,_2W_#/TM_PS]+/\+
M_2S_"_TL_PO]+/\+_2S_"_\R*P'_.2@"_STH O\_*@+_/C #_STZ!/\\1@;_
M.5,(_S=@"?\U;0O_,WH,_S*&#?\QD [_,9D._S&A#_\QJ __,*X/_S"U#_\P
MO1#_,,<0_S#4$/\PY!#_,>\0_C'Y#_LQ_P_Y,?\/^#'_#O<Q_P[W,?\.]C'_
M#O8Q_P[V,?\.]C'_#O\U* '_/"4!_T D O]#)P+_0RP#_T0W!/]"0P;_0$\(
M_SU<"O\[:0S_.78-_SB"#_\WC!#_-Y41_S:=$?\VI!+_-JL2_S:R$_\UNA/_
M-<,3_S7/$_PUX1/Y-NT3]C;W$_,V_Q/Q-O\2\#;_$O W_Q'O-_\1[S?_$.\W
M_Q#O-_\0[S?_$/\Y)0'_0"$!_T4@ ?]'(@+_22D"_THT!/])/P7_1DL(_T18
M"O]"90W_0'$/_SY]$?\]AQ+_/9$4_CR9%?T\H!7\.Z<6^CNN%_D[MA?X.[\7
M]CO*&/0[W!CP.^H8[3OV&.H[_Q?H//\7YSS_%N8]_Q7E/?\4Y3W_%.4]_Q3E
M/?\4Y3W_%/\](@'_1!X!_TD< ?]-'@'_4"8"_U$P _]0.P7_3D8(_TM3"_](
M8 [_1FP1^T5X$_A$@A7V0XP7]$*4&/-!G!GQ0:,;[T"J&^Y LASM/[L=ZS_&
M'ND_U1[E/^@?XD#T'M] _AW=0?\;VT+_&ME"_QC80O\7V$+_%]A"_Q?80O\7
MV$+_%_] 'P'_2!H!_TX8 ?]2&P'_5B,"_U@L _]7-P3_54('_U)-"_E06@[U
M36<2\4QR%NY*?1CK2(8;Z4>/'>=&EQ_E19X@XT2F(N%$KB/@0[<DWD/")=Q#
MT";70^4FTT3S)-!%_B+-1O\@S$?_'LI'_QS)2/\;R4C_&\E(_QO)2/\;R4C_
M&_]$&P'_3!8!_U(4 ?]8& '_71\!_U\H O]>,@/]73T&]EI)"O!750_J56(3
MYE)M&.)0=QS?3H$?W$R*(ME+DB352IHFTTFA*-%)J2G/2+(JS4B\*\M(R2S(
M2-\LQ4CO*\)*_"C 2_\EOTS_(KY-_R"]3?\?O4W_'KU-_QZ]3?\>O4W_'O]'
M& '_3Q,!_U81 /]>%0#_8AP!_V4D ?YE+0+T9#@%[6%#">9?40[@7%T4VEAH
M&M16<A[05'LBS%*$)LI0C"C'3Y0JQ4Z;+,-.HR[!3:POOTRV,+U,PC&[3-,R
MN$SI,;9.^"VT4/\JLU'_)[-2_R2R4O\BLE+_(K)2_R*R4O\BLE+_(O]*%0'_
M4Q$ _UL/ /]B$@#_:!< _VH? ?9K* 'L:S(#Y&D^!]QF3 W38E@4S5]C&\A<
M;2#$6G8DP5A^*+Y6ABN[58XNN5.6,+92GC*T4J8SLE&P-;!1O#:N4,LWK%#C
M-ZI2]#.I5/\NJ%;_*ZA7_RBH5_\EJ%?_):A7_R6H5_\EJ%?_)?]-$P#_5@X
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M-8=G_S&':/\NAVG_+8=I_RV':?\MAVG_+?]7# #_800 _FP# .1U 0#;>P4
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M,7%X_S%Q>/\Q<7C_,?]? @#W;   WG<  -"!  #'B $ P(T# +F1 P"RDQ$
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M+T.MR"]"K.<O0ZOY+42K_RM$JO\I1*K_*42J_RE$JO\I1*K_*=&   #!C0
MM9@  *F?  ">I0  DZP  (BR  !]N   <;X& &Z_%0!JOR8!9K\S V&^/P==
MOD@+6;U1#U6]61-1O& 73KQH&DN[<1U(NWL?1;J'(D*ZE"1 NJ(F/KJS)CVZ
MR"8]NN@F/;CY)3VW_R0]MO\C/;;_(SVV_R,]MO\C/;;_(\>(  "YE0  K)T
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M,-CV$C#6_Q,OU/\3+]3_$R_4_Q,OU/\3+]3_$[.:  "FH0  FJD  (VQ  "
MN@  =,$  &C)  !<SP  4M4# $C<" !%Y1( 0^4> $'F*@ ^YC4!.^<^ 3GG
M1P(WYU #-.A9!#+H8@4PZ&T&+NEY!RSIAP@KZI8)*>JG"BCJN@HGZ]8*)^GP
M"B?G_0DFYO\*)N;_"B;F_PHFYO\*)N;_"JB@  "<IP  C[   (*Y  !TP@
M:,H  %O1  !/UP  1=T  #[N"0 \\A$ .?,; #;S)0 T]"X ,?0W 2[U/P$L
M]4<!*?9/ B?V5P(E]V$#(_=L R'X>@0?^(D$'OF:!1SYJP4;^L %&OK>!1KY
M\@4:]_T%&?;_!1GV_P49]O\%&?;_!9ZF  "1KP  @[D  '7"  !GRP  6M,
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M&\L_^QK)0/\8QT#_%\9!_Q7%0?\4Q$'_%,1!_Q3$0?\4Q$'_%/]!%P#_1Q(
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M)IE6_R.95O\AF5?_'YE7_Q^95_\?F5?_'_]-#0#_508 _UT% /MD!P#O:0D
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M"0#$=A< O'8J ;1T.@6N<48,IVY1$J)K6AB>:6(=FF=I(99E<2639'@HD&*
M*XUAB"Z+8)$QB%^:,X9>I36#7K(W@E["-X!>W#B 7_(S@6'_+8)B_RF"8_\F
M@F3_)8)D_R6"9/\E@F3_)?]3!@#_70  YV<  -MO  #0= ( RG@% ,9Y!P"^
M>A4 MGHH :]X-P6H=D0+HG-.$IQP5QB8;5\=E&MG(9!J;B6-:'4HBF=]*X=E
MA2Z$9(XQ@6.7-']BHC9\8J\X>F*^.7EBU3EY8^\T>F7^+WMF_RM\9_\H?&?_
M)GQG_R9\9_\F?&?_)O]5 P#_8   XVH  -5R  #,> $ Q7L# ,!]!0"Y?A(
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M-%&(PS50B.(T4HCV,%.(_RQ4B/\I58C_*%6(_RA5B/\H58C_*.9K  #0>
MPH,  +>,  "MD@  HY8  )J:  ".G@  AY\0 (.?( !^GR\">)T[!W.<10QN
MFTT1:9E5%F687!IAEV,>7I9J(5N5<B57E'PH5).&*U&2DBY.DJ P3)*O,4N2
MPC%*D> Q3)'U+4V1_RI.D/\H3I#_)DZ0_R9.D/\F3I#_)MYP  #)?0  O(D
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M'#FR_QPYL?\;.;#_&SFP_QLYL/\;.;#_&\&&  "TDP  IYH  )R@  "1IP
MA:T  'FS  !MN   8KT! %;"!P!3PQ0 4L,C %#$, %-Q#L"2L1% T?$3@5%
MQ%<'0L-?"4##: L]PW(-.\-^#SC#C!$VPYL2-<.K$S/#P!,SP^ 3,\'U$S+
M_Q0RO_\4,;[_%#&^_Q0QOO\4,;[_%+B0  "KF0  GZ   ).G  "'K@  >[0
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M A+P_P(2\/\"$O#_ IJD  "-K0  ?[8  '&_  !CQP  5LX  $G3   ]V@
M,]\  "KC   F] 4 )/L- "'\$P >_1L '/TB !G^*0 7_C$ %?\Y !/_00 1
M_TH $/]5  [_80 ,_V\!#/^  0K_DP$)_Z8!"/^Z 0?_U $'_^L!!O_V 0;_
M]@$&__8!!O_V 8^L  " M@  <K\  &/)  !6T0  2-@  #O=   PX@  )N8
M !_P   <_P  &?\) !;_#@ 4_Q, $?\9  __'@ -_R0 "_\K  G_,@ &_SL
M _]$  #_3P  _UP  /]K  #_?0  _Y   /^C  #_M   _\8  /_6  #_U@
M_]8  /_6 (*U  !SOP  9,D  %;3  !'VP  .N   "[E   CZ0  &NT  !7]
M   2_P  $/\"  [_"0 +_PT "/\0  3_$P !_Q@  /\>  #_)   _RL  /\S
M  #_/0  _TD  /]6  #_9@  _W@  /^*  #_FP  _Z@  /^Q  #_L0  _[$
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M)@'_+B,!_R\B ?\O)0'_+"L!_RHU O\G00+_)$X#_R); _\@: 3_'G0$_QV
M!/\=B@3_'9(%_QV:!?\=H07_':<%_QVM!?\=M 3_';T$_QW'!/\=U 3^'>8$
M^QWR!/<>^P/U'O\$]![_!/,>_P3S'O\$\A[_!/(>_P3R'O\$\A[_!/\N(@'_
M,A\!_S0> ?\S( '_,B8!_S(R ?\O/@+_+$H#_RI7 _\G9 3_)G %_R5[!?\D
MA07_)(X&_R26!O\DG0;_)*,&_R2J!OTDL0;\)+D&^R3#!ODDSP;V).,&\B3P
M!>XE^@7M)?\&ZR7_!NHE_P;I)?\&Z27_!NDE_P;I)?\&Z27_!O\R'@'_-AL
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M3A8 _T\? /U.*0'T3#0![$A! N9'3@3@15L&VT1F"=9"< S207D.ST""$,U
MBA'*/Y$3R3^9%,<^H!7%/J@6PSZQ%\$^O!? /LL8O3[B&+H^\A>W/_\6M4#_
M%+1 _Q.S0?\1LT'_$+-!_Q"S0?\0LT'_$/] $ #_1@P _TL* /]1#0#_4Q$
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M&HM6_QJ+5O\:BU;_&O],! #_4P  [%P  -]B  #49@$ SF@% ,MG" #"9Q8
MNF@H ;-G. .M944'J&-0#*-A61&?7V$5FUUH&)A<<!N56G<>DUE_(9!8AR..
M5X\EC%>9)XE6HRF'5J\JA56_*X16U2R#5^\I@UC^)(-9_R"$6O\>A%K_'(1:
M_QR$6O\<A%K_'/]. 0#_5P  Y5\  -AF  #.:@  QVP# ,-K!0"\;!( M&TE
M *UL-0.G:D('H6=-#)QE5A&88UX5E&)E&)%@;!N.7W0>C%Y[(8E=@R2&7(PF
MA%N5*(%:H"I_6JPL?5J[+7Q:SRY[6^PK?%S\)GQ=_R)]7O\??5[_'7U>_QU]
M7O\=?5[_'?]0  #U60  X6,  -)J  #);@  PG ! +UP P"V<!  KG$B *AP
M,@*A;C\&G&Q*"Y=J4Q"2:%L4CF9B&(ME:1N(8W >A6)X(8)A@"2 8(DF?5^2
M*7M>G2MX7JDM=EZX+G5>S"]T7NDM=6#Z)W9A_R-W8O\@=V+_'G=B_QYW8O\>
M=V+_'O]2  #L7   W&8  ,YM  #$<@  O70  +=T 0"P= X J74? *)T+P*<
M<CT%EW!'"I%N40^-;%D4B6I@%X5I9QN":&X>?V9U(7UE?21Z9(8G=V.0*75C
MFRQR8J<N<&*V+V]BR2]N8N8N;V3Y*'!E_R1Q9O\A<6;_'W%F_Q]Q9O\?<6;_
M'_]4  #H7P  UVD  ,IP  # =0  N7@  +)X  "K> T I'D= )YX+0&7=SH%
MDG5%"HQR3@Z(<%83A&]>%X!M9!I];&L=>FMS('=J>R-T:8,F<FB-*6]GF2QL
M9J4N:F:S+VEFQC!H9N0O:FCW*6MI_R5L:?\B;&K_(&QJ_R!L:O\@;&K_(/]7
M  #D8@  TFP  ,9S  "]>   M7L  *U\  "E? H GWT: )E\*@&3>S@$C7E#
M"8AW3 Z#=502?W-;%GMR8AEX<&D==6]P(')N>"-O;8$F;&R+*6ILERQG:Z,N
M96NR+V1KQ#!B:^$O9&SV*F9M_R9F;?\C9V[_(&=N_R!G;O\@9V[_(/99  #@
M90  SF\  ,)V  "Y?   L7\  *F   "@@ < F8$7 )2!* &.@#4#B'Y!"(-\
M2@U^>E(1>GA9%79W8!ES=F<<<'1N'VUS=B-J<G\F9W&)*61QE2MB<*$M8'"P
M+UYPPB]=<-\O7W'U*F!Q_R9A<O\C8G+_(&)R_R!B<O\@8G+_(.]<  #<:0
MRG(  +YZ  "U@   K80  *2%  ":A0, E(44 (Z&)0&)A#,#@X,^!WZ!2 MY
M?U 0=7Y7%'%]7AAN>V4;:WIL'FAY=")E>'TE8G>'*%]VDRI<=I\L6G6N+EEU
MP"Y8==TN67;S*EMV_R9<=_\C7'?_(%QW_R!<=_\@7'?_(.I@  #5;   Q78
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M)$B,_R))B_\@2HO_'DJ+_QY*B_\>2HO_'M5N  ##>P  MX4  *R-  "BD@
MEY8  (R9  !_G   =9X% '"?$P!MGR, :9\P 66>.P1AGD4'79U-"EJ<5 U7
MFUP15)IC%%&::Q=.F7092YA_'$B8BQY%EYD@0Y>H(4*7NB)!E],B09;O($*5
M_AY"E?\=0Y3_'$.4_QQ#E/\<0Y3_',QU  "\@0  L8P  *:2  ";EP  D9L
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M#BRX_PXLN/\.++C_#K./  "FEP  FYT  (^C  "#J@  =K   &JU  !>N@
M4KX  $?" 0 ]QP8 .,D0 #?)&P VRB< -<HS #3+/0 SRT< ,<M1 3#+6P$N
MS&4"+,QQ BK,?P,IS) $)\RA!";-M 0ES<X$)<ON!"3)_ 8CR/\'(\?_!R/'
M_P<CQ_\'(\?_!ZF6  ">G0  DJ,  (6K  !XL@  :[@  %^^  !2P@  1\8
M #W*   TSP0 *]0) ";9#P EV1D )=HE "3:,  CVSL (]M% "+<4  AW5L
M(-UH ![>=@ =WH<!'-^9 1K?K $9W\0!&-[G 1C<^ $8V_\"%]K_ A?:_P(7
MVO\"%]K_ J"<  "4HP  AZL  'FS  !LN@  7\$  %+&  !&R@  .\X  #'3
M   IV0  (=X% ![H#@ =Z!4 &^D> !GI)P 8ZC  %NHY !7K0P 4[$X $NQ:
M !'M9P 0[G< $.Z*  [OG@ .\+, #?#-  SO[  ,[?P #.O_  SK_P ,Z_\
M#.O_ )>C  ")JP  >[0  &V\  !?Q   4LH  $7.   YTP  +]@  "7=   =
MX0  &.P" !;W"P 4]Q$ $?@7 !#X'@ .^24 #?DM  OZ-0 )^S\ !_M*  3\
M5P #_68  OYW  #]BP  _9\  /RU  #\T0  _.T  /S\  #\_0  _/T  /S]
M (NK  !]M   ;KT  &#&  !2S0  1-(  #?8   LW0  (N$  !GE   3Z@
M$/H   [_!@ -_PP "O\0  ?_%  $_QH  ?\@  #_)P  _S   /\Z  #_10
M_U,  /]B  #_=0  _XH  /^?  #_LP  _\<  /_E  #_Y0  _^4  /_E '^T
M  !PO0  8<<  %/0  !#U@  -MT  "KB   ?Y@  %NH  !#M   ,^@  "?\
M  ;_   "_P0  /\)  #_#0  _Q   /\4  #_&@  _R$  /\I  #_-   _T
M /].  #_7@  _W(  /^'  #_F@  _ZH  /^Y  #_N0  _[D  /^Y /\@*0'_
M(B<!_R(G ?\?*@'_&3 !_Q(Y ?\010'_#5,!_PQ@ ?\*;0+_"7D"_PF$ O\)
MC@'_"98!_PF= ?\)HP'_":D!_PFP ?\(MP'_"+X!_PC( ?\(U@'_".8!_PCQ
M ?\(^P#_"/\ _PC_ /\)_P'_"?\!_PG_ ?\)_P'_"?\!_PG_ ?\C)@'_)20
M_R4D /\C)P'_'2P!_Q@U ?\50@'_$E !_Q!= O\.:@+_#G8"_PZ  O\.B@+_
M#I("_PZ: O\.H +_#J8!_PVM ?\-LP'_#;L!_PW% ?\-T0'_#>,!_PWO ?X-
M^@'Z#?\!^0[_ ?D._P'Y#O\!^ [_ ?@._P'X#O\!^ [_ ?\F(P#_*"  _R@@
M /\F(@#_(B@!_R R ?\</P'_&4P!_Q=9 O\590+_$W$"_Q-\ O\3A@+_$XX"
M_Q*6 O\2G0+_$J,"_Q*I O\2L +_$K<"_Q+! O\2S ']$M\!^1/M ?43^ 'S
M$_\!\A/_ ?$3_P+P%/\"\!3_ O 4_P+P%/\"\!3_ O\J'P#_+!P _RP; /\K
M'0#_*20 _R@O ?\E.P'_(D@!_Q]4 O\=80+_&VT"_QIW O\:@0+_&HH"_QJ2
M O\:F0+]&I\"_!JF OL:K +Y&K0"^!J] O8:R +S&ML"[QKJ NP;]P+I&_\"
MZ!O_ ^<<_P/F'/\#Y1S_ ^4;_P/E&_\#Y1O_ _\M&P#_,!< _S$5 /\P%@#_
M,2  _S J /\N-@'_*T,!_RA/ O\F7 +_)&<"_"-R _DC? /W(H4#]2*- _,B
ME0/R(IL#\"*B ^\BJ0/M(K$#["*Y ^HBQ0/H(M4#Y"/I ^ C]@3>(_\$VR3_
M!-DD_P38)/\$UR3_!-8D_P36)/\$UB3_!/\Q%@#_-!( _S81 /\W$P#_.1L
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M#J)!_PZB0?\.HD'_#O\_"0#_1   _TH  /=. @#L4 8 ZD\+ .-,$ #63!X
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M)6M>P29I7MXF:E_T(6M@_QUK8?\;;&'_&6QA_QAL8?\8;&'_&/51  #B7
MSV4  ,-K  "Y;P  L7$  *IQ  "B;P@ FV\7 )9P)P"0;S4"BVY !89L20B"
M:E(,?FE9#WMH8!)W9F84=69N%W)E=AIP9'X=;6.('VMCDR)I8J D9F*N)65B
MOR9D8MHF9&/R(F5D_QYF9/\;9V3_&6=E_QAG9?\89V7_&/!3  #=7P  RV@
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M(E9Q_AY7<?\<5W'_&EAQ_QE8<?\96''_&>->  #-:0  OW,  +1Z  "K?P
MHH(  )B#  "+@0  A($- '^"&@![@BD!=H$V G*!0 5N?TD(:GY0"V=]5PYD
M?%X187MF%%YZ;1=;>G8967F '%9XBQ]3>)@A47>F(E!WMR-/=\XC3W?L(5!W
M_1Y1=_\;4G?_&5)W_QE2=_\94G?_&=YB  #(;@  NW<  +!_  "GA   G8<
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M%3Z/_Q4^C_\5/H__%<5S  "W?P  K(D  *&/  "6DP  BY8  '^9  !SG
M9)\  %R@"0!9H!0 5Z$B %6A+P!2H3D!4*%# DV@2P1*H%,%2*!:!T6?8PE#
MGVP+0)YV#CZ>@Q [GI$1.9V@$CB=LA,WGL@3-YWH$C:;^A(VFO\2-IG_$3>9
M_Q$WF?\1-YG_$;Y[  "QAP  I8\  )N4  "0F   A)P  '>@  !KI   7Z<
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M!*64  ":F@  CJ$  (&G  !SK@  9[0  %JY  !.O0  0L   #C#   OQP
M)LL$ ![0"@ ;T1$ &M(: !G2)0 8TR\ &-,Z !?41  6U%  %=5= !35:P 3
MUGP $M>/ !'8I  0V;L $-G> !#5\P 0T_\ $-+_ 1#1_P$0T?\!$-'_ 9R:
M  "1H0  @Z@  '6P  !HMP  6[T  $[!  !"Q0  -\@  "W,   DT   '-4
M !7:!0 0X@L $.,1  [D&@ .Y", #>4M  SE-P +YD( "N9/  GG70 (YVT
M!N:   7FE0 $YJL  N;$  'FY@  Y_D  .?_  #F_P  YO\  .;_ ).A  "%
MJ0  =[$  &FY  !;P   3L8  $'*   US@  *M(  "'6   9VP  $M\   WC
M   +\0@ "?,.  ?S$P $\AH  O(B  #R*@  \C0  /(_  #R3   \EP  /)M
M  #R@@  \I@  /.M  #SQ@  ].4  /3V  #T^P  ]/L  /3[ (>I  !YL@
M:KH  %S"  !.R0  0,X  #/3   HV   'MT  !7A   /Y   "N@   7S   #
M_0$  /P(  #[#0  ^Q$  /L6  #\'@  _"8  /PP  #]/   _DD  /Y:  #^
M;0  _X(  /^8  #_K   _\   /_8  #_Y   _^0  /_D 'NR  !LNP  7<0
M $_-  ! T@  ,MD  ";>   ;X@  $N8   SJ   %[0   /0   #_    _P
M /\   #_!   _PD  /\.  #_$@  _Q@  /\A  #_*P  _S<  /]&  #_6
M_VL  /^   #_E0  _Z8  /^S  #_NP  _[L  /^[ /\;)@#_'"0 _QHD /\5
M)P#_$"T _PHV /\%0P#_ 5 !_P!> ?\ :P'_ '8!_P"! /\ B@#_ )( _P":
M /\ H #_ *8 _P"L /\ L@#_ +D _P#" /\ S0#_ -\ _P#L /\ ^ #_ /\
M_0#_ /T _P#] /\ _0#_ /T _P#] /\ _0#_ /\?(P#_'R$ _QXA /\9(P#_
M$RD _PXR /\,0 #_"4T!_P=: ?\$9P'_ W,!_P-] ?\#AP'_ X\ _P*6 /\"
MG #_ J( _P*H /\"KP#_ ;8 _P&^ /\!R0#_ =L _P#J /P ]@#X /\ ]P+_
M /<#_P#V!/\ ]@3_ /8%_P#V!?\ ]@7_ /\B'P#_(AP _R$< /\>'P#_&"0
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M \$D_P/!)/\#P23_ _\P#P#_,@L _S,( /\V#0#_-A( _S4: /TR)0#T,#(
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M0ZP4CT.Z%8U#S16+1.@5BD7Z$HE&_Q")1O\.B$;_#8A&_PV(1O\-B$;_#?]
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M&7I-PQIY3=\:>$[T%WA/_Q1X3_\2>%#_$'A0_P]X4/\/>%#_#_U&  #G3P
MUE<  ,A<  "_7P  MU\  +%<  "J60P I%H: )Y;*@"96S@!E%I# Y!93 6,
M6%4(B5=<"H968PR#56H.@51Q$']3>1)]4X$4>E*+%GA2E1AV4:$9=%&O&W-1
MP!MQ4=L<<5+R&7%3_Q5Q5/\3<E3_$7)4_Q!R5/\0<E3_$/-(  #C4P  T%L
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M&V!?_1AA7_\585__$V)?_Q)B7_\28E__$NI1  #47   Q&0  +EJ  "P;@
MIW   )YN  "4:P  C6H0 (=K'@"#:RP ?FLX GIJ0@-V:4H&<VA2"'!G60IM
M9F -:V5G#VAD;A%F9'<49&.!%F%CC!A?8I@:76*F'%MBMAU:8LP=6F+J'%MC
M_!A<8_\67&/_%%UC_Q-=8_\376/_$^95  #/7P  P6@  +9N  "L<@  I'0
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M$TUR_Q)-<O\237+_$M1@  #":P  M70  *M[  "B?P  EX$  (R!  !Z?@
M<W\" &Y_$0!K@!X :( L &6 -P%B@$ #7W](!%Q^4 99?E<(5WU>"U1\9@U1
M?&X/3WMX$4Q[@Q1*>I$62'J?%T9ZKQA%>L081'KD&$5Y^!9&>?\41GC_$D=X
M_Q%'>/\11WC_$<UE  "]<   L7D  *>   "<A   DH8  (:&  !WA@  :X8
M &:'#0!CAQD 8(@G %Z(,P%;B#P"6(=% U:'3013AE0&4(9;"$Z%8PI+A&P,
M281V#T:#@1%$@X\30H.=%$""KA4_@\(5/H+B%3^!]Q,_@?\20(#_$4" _Q!
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M"[AZ  "LA0  H8L  ):0  "+E   ?Y<  '*;  !FG0  6J   $ZB  !%I D
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M !? H0 6P+8 %,#3 !6^\0 5O/\!%;O_ 12Z_P(4NO\"%+K_ J&2  "6F
MBIX  'VD  !OJ@  8J\  %:T  !*MP  /KH  #.]   JP   (<0  !G'!0 3
MRPL $<P2 !',&P 0S"4 #\TO  [-.@ .S48 #<U2  W.8  ,SG  "\Z#  K.
MEP )SJP ",[&  C.Z  (S?L "<O_  G+_P )R_\ "<O_ )B8  "-G@  ?Z4
M '&L  !DLP  5[D  $J]   ^P   ,L,  "C&   ?R@  %\T  !'1   ,U@4
M"-D,  ;9$@ %VAL !-HD  /;+@ !VSD  -Q%  #=4@  WF(  -YS  #>B
MWYT  -^S  #?S@  X.X  -_Z  #?_P  W_\  -__ (^?  "!I@  <ZX  &6U
M  !8O0  2L(  #W%   QR0  )LP  !W0   4U   #MD   G=   #X0   .,'
M  #C#0  Y!(  .49  #F(@  YRL  .DV  #K0P  [%(  .QB  #M=@  [HP
M .ZA  #OMP  []$  ._K  #P]@  \/8  /#V (2G  !UKP  9[<  %F_  !+
MQ@  /,H  "_.   DT@  &M@  !+<   ,X   !>,   #G    ZP   .L   #M
M!0  [@L  / 0  #Q%0  \QX  /0G  #W,P  ^4   /I1  #[8P  _'<  /V-
M  #]HP  _K8  /[)  #_WP  _]\  /_? '>P  !HN0  6L$  $S*   \SP
M+M0  "+:   7W@  $.(   GF    Z0   .P   #P    ]@   /8   #W
M^    /H'  #[#0  _1$  /\9  #_(P  _R\  /\^  #_3P  _V(  /]W  #_
MC0  _Y\  /^N  #_N@  _[H  /^Z /\6(P#_%2$ _Q(A /\.) #_!BH _P S
M /\ 00#_ $X _P!< /\ : #_ '0 _P!^ /\ AP#_ (\ _P"6 /\ G #_ *(
M_P"H /\ K@#_ +4 _P"] /\ QP#_ -8 _P#G /X \P#^ /X _0#_ /P _P#[
M /\ ^P#_ /L _P#[ /\ ^P#_ /\:( #_&1X _Q8> /\0( #_"B4 _P0P /\
M/0#_ $L _P!8 /\ 9 #_ '  _P!Z /\ @P#_ (L _P"2 /\ F #_ )X _P"D
M /\ J@#_ +$ _0"Y /L PP#Z -  ^ #C /< \0#V /P ] #_ /0 _P#S /\
M\P#_ /, _P#S /\ \P#_ /\=' #_'!D _QD9 /\4&P#_#B$ _PPL /\).0#_
M!48 _P)3 /\ 7P#_ &L _P!U /\ ?@#_ (8 _P". /\ E #^ )L _ "A /H
MIP#X *X ]0"U /, OP#Q ,L \ #? .X [@#L /D ZP#_ .H _P#J ?\ Z0'_
M .D!_P#I ?\ Z0'_ /\@%P#_'Q0 _QP3 /\7%0#_%AT _Q,H /\0- #_#4$
M_PQ. /\)6@#_"&8 _PAP /X'>0#\!X$ ^@>) /@'D #V!I8 \P:= /$&HP#O
M!JH [0:R /_B__])0T-?4%)/1DE,10 (">H&NP#H!L@ Y@;< .0&[ #B"/H
MX K_ -X+_P#="_\ W0S_ -P,_P#<#/\ W S_ /\C$@#_(Q  _R$. /\>$ #_
M'A@ _QPC /\8+P#_%#L _Q)) /P050#X#V  ] ]J /$/= #O#GP [0Z$ .L.
MBP#I#I( YPZ9 .8.H #D#J< X@ZO . .N #>#L4 W [: -80[ #2$?H SQ+_
M ,T2_P',$O\!RQ/_ <H3_P'*$O\!RA+_ ?\G#P#_)PP _R4) /\F#0#_)1,
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M!I8T_P66-/\%EC3_!?\U  #_.   ZCX  -]"  #50@  SS\# ,TX" #%.!4
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M"O)"  #@3   SE,  ,%8  "X6@  L%D  *E6  "B4@< FU(5 )93) "14S(
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M%&%5M!5@5<@67U7G%6!6^A)@5O\/85?_#F%7_PUA5_\,85?_#.=,  #15@
MP5X  +9C  "M9@  I&8  )MD  "07@  B5X. (1?&P" 7RD ?%\U 7A?/P)T
M7D<#<5U/!&]<5@5L7%P':EMC"6A;:PMF6G,-9%I]#V):B!%?69037EFB%%Q9
MLA5;6<866EGE%5M:^1);6O\07%K_#EQ:_PU<6O\-7%K_#>-/  #-60  OF$
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M%$MG]1),9_\/3&?_#DUG_PU-9_\-36?_#=):  # 9   LVP  *ER  "@=@
MEG<  (IV  !Y<0  <7$  &MQ#P!H<1P 9G(H &-R- !@<CT!7G)% EMQ30-9
M<50%5W!;!E1P8PA2;VL*4&]T#$UN@ Y+;HT026Z;$4=MJQ)&;KX316[<$D9M
M]!%&;?\/1VW_#D=L_PU';/\-1VS_#<Q?  "\:0  L'$  *5W  "<>P  D7P
M (9[  !U>   :W<  &5W# !A>!< 7W@D %UY, !:>3H!6'E" E9X2@)3>%$$
M47=8!4]W8 =,=F@(2G9R"DAU?0Q%=8H.0W69#T)UJ1! =;P00'79$$!T\P]
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M"3.#_PDS@_\),X/_";EP  "M>@  HH(  )>'  "-B@  @8P  '6.  !HCP
M6I   $^1  !'D@H 1)(3 $.3'P!!DRH 0),T #^3/0 ]DT4 .Y-- 3J35@$X
MDU\"-I-I S23=0,RDH,$,)*3!2Z2I 8MDK<&+)+1!BR1[P8KC_\&*X[_!BN-
M_P<KC?\'*XW_![-X  "G@@  G(@  )&,  "'D   >I,  &V5  !AEP  59D
M $F;   _G $ .9T. #>=%P VGB( -)XL #.>-0 RGCX ,9Y' #"?4  NGUH
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M )R0  "2E0  AIL  'F@  !KI@  7JL  %*O  !&L@  .K4  "^W   EN@
M';T  !7    0PP8 "\8.  K%%0 )Q1X ",4H  ?%,@ &QCT !<9)  7&5P #
MQF8  L9W  '&BP  QJ   ,6V  #&T@  Q>\  ,7\  #%_P  Q?\  ,7_ )66
M  ")G   >Z,  &VI  !@KP  4[0  $:X   ZNP  +KX  "3!   ;Q   $\<
M  [*   (S@$  = *  #0$   T!8  -$>  #2)P  TS$  -0\  #520  UE@
M -9I  #6?   UI(  -:G  #6OP  UN   -;S  #6_@  UO\  -;_ (R=  !^
MI   ;ZL  &&R  !4N0  1KT  #G!   MQ   (L<  !G+   1S@  #-(   75
M    VP   -P#  #="@  W@\  -\4  #A'   XB0  .0N  #F.@  YTD  .A9
M  #H:P  Z8$  .F8  #IK0  Z<4  .GB  #I\@  Z?4  .GU ("E  !QK0
M8[4  %6\  !'P@  .<8  "S*   @S@  %M(   _6   (VP   -\   #C
MY0   .<   #H 0  Z@<  .L-  #M$0  [Q@  /$A  #S*P  ]C@  /=(  #X
M6@  ^6T  /J$  #ZFP  ^J\  /K"  #ZV@  ^M\  /K? '2N  !EM@  5KX
M $C&   YRP  *]   !_4   4V@  #=\   7C    Y@   .D   #M    [P
M /$   #S    ]0   /8"  #X"0  ^@X  /T3  #_'   _R@  /\V  #_1P
M_UH  /]N  #_A0  _YH  /^K  #_N0  _[P  /^\ /\1( #_$!X _PP> /\$
M(0#_ "< _P P /\ /@#_ $P _P!9 /\ 90#_ '  _P!Z /\ @P#_ (L _P"2
M /\ F #_ )X _P"D /\ J@#_ +  _P"X /\ P@#_ ,X _P#B /X \ #] /L
M^P#_ /L _P#[ /\ ^@#_ /H _P#Z /\ ^@#_ /\4' #_$AH _PX: /\(' #_
M "$ _P M /\ .@#_ $@ _P!5 /\ 80#_ &P _P!V /\ ?P#_ (< _P". /\
ME #_ )H _@"@ /T I@#\ *P ^P"T /D O0#X ,D ]P#< /4 [ #S /@ \P#_
M /( _P#Q /\ \ #_ /  _P#P /\ \ #_ /\7& #_%18 _Q$5 /\,%P#_!1T
M_P H /\ -@#_ $, _P!0 /\ 7 #_ &< _P!Q /\ >@#\ (( ^@") /@ D #W
M )8 ]0"< /0 H@#S *@ \0"P /  N #N ,, [ #3 .H YP#I /4 YP#_ .8
M_P#E /\ Y0#_ .4 _P#E /\ Y0#_ /\:$P#_&!$ _Q00 /\/$0#_#1D _PHD
M /\%, #_ 3X _P!+ /\ 5P#^ &( ^@!L /4 =0#R 'T \ "$ .X BP#L )$
MZP"7 .D G@#G *0 Y@"L .0 M #B +\ X #- -X XP#< /( V@#] -@ _P#6
M /\ U0'_ -4!_P#5 O\ U0+_ /\>$ #_' T _Q<+ /\5#@#_%!4 _Q$? /\.
M*@#_"S@ _0A% /@&40#T!%P [@1F .H$;P#F W< Y 1_ .($A@#@!(P W@23
M -T%F@#;!:  V 6H -4%L0#2!;L T ;) ,X'X #,"/$ R0K_ ,<+_P#&#/\
MQ0S_ ,4,_P#%#/\ Q0S_ /\A# #_( 8 _QP# /\="@#_&Q  _Q@8 /\4(P#V
M$3  [PX^ .H.2@#E#58 X0U@ -T-:0#9#7$ U0UY -,-@0#1#8@ SPV/ ,T.
ME@#+#IT R@ZE ,@.K@#&#[D Q!#( ,(0WP"^$?( NQ+_ +D3_P"W$_\!MA/_
M ;83_P&V$_\!MA/_ ?\E!@#_(P  _R,  /\D P#_(0H _1T1 /$:&P#H%B<
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M!/PS  #K.@  W$$  ,U$  ##1   O4$  +@[ 0"R-PX JS@< *4Y*P"A.C@
MG3M$ )H[30&7.E8!E#I= I(Z9 *0.FL#CCER XPY>@2*.8(%B3F+!8<YE0:%
M.: '@SFM!X(YO B!.=,(?SKN"'TZ_@=\._\&?#O_!7P[_P5\._\%?#O_!?0W
M  #E0   TD<  ,5*  "\2P  M4D  *]#  "I/@L HC\7 )U )@"8030 E$$_
M )%!20&.05$!BT!9 HE 8 .'0&<#A3]M!(,_=06!/WT&?SZ'!WT^D0A[/IP)
M>CZI"7@^N IW/\T*=3_J"G1 _ AT0/\'=$#_!G- _P9S0/\&<T#_!O$[  #?
M10  S$P  +]/  "V4   KD\  *=*  "@1 < FD44 )5&(@"01C  C$<\ (E&
M10&&1DX!@T95 H%%7 -^16,$?$1J!'I$<05Y1'D&=T2""'5#C0ES0YD*<4.F
M"W!#M0QN1,D,;43G#&U%^@IL1?\(;$7_!VQ%_P=L1?\';$7_!^P_  #820
MQU   +M4  "Q50  J50  *%0  "92@( DDD1 (U*'P")2RP A4PX ()+0@%_
M2TH!?$I2 GE*6 -W2E\$=4EF!7-);09Q278';TA_"&U(B@EL2)8+:DBC#&A(
ML@UG2,4-9DGD#69)^ MF2?\)9DK_"&9)_P=F2?\'9DG_!^A#  #230  PE,
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M#U55\PU55?\+5E7_"595_PE65?\(5E7_"-M-  #%5P  N%X  *UB  "C90
MFF4  )!C  "#7   >UL& '5;$@!Q6Q\ ;EPK &M<-@!H6S\!95M' 6-;3@)A
M6E4#7UI<!%U:8P5;6FL&65EU"%=9@ I568P+5%F:#5)9J@Y16;P.4%G8#E!9
M\@U16?\+45G_"E%9_PE16?\(45G_"-11  #"6@  M&$  *IF  "@:   EVD
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M"4%G_PA"9_\(0F?_",5=  "V9@  JFT  *!S  "6=@  BW<  (!V  !P<@
M97$  %QP!P!8<!$ 5G = %1Q* !2<3, 4'$\ $]R1 %-<4L!2W%3 DEQ6@-'
M<6($17!L!4-P=P9!<(0'/W"3"#UOHPD[<+4*.W#-"CIO[ D[;OX(.V[_"#MM
M_P<[;?\'.VW_![]B  "Q:P  IG,  )UY  "2>P  AWP  'M\  !M>@  8'@
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M ZUV  "C@   EX4  (V)  ""C   =HX  &F0  !<D@  4),  $24   ZE0
M,98( "V7$0 LEQH *Y<D "J7+0 IES8 *)@_ ">82  FF%( )9A< ".8:  B
MF'< ()B' !^8F0$=F*P!')C# 1R7Y0$<E?H!&Y3_ 1N3_P(;D_\"&Y/_ J=_
M  "<A@  D8L  (>/  !ZD@  ;94  &&8  !5FP  29T  #V>   SGP  *J$
M "&C"@ ?HQ$ 'J,: !VD)  <I"T &Z0V !JD/P 9I$H &*15 !:E80 5I7
M%*6! !.EE  2I:@ $:6_ !"DX@ 1HO@ $:'_ !&@_P$1H/\!$:#_ :"&  "5
MC   C)$  '^5  !QF@  9)X  %BA  !,I   0*8  #6G   JJ0  (JP  !FN
M   2L D $+$0 !"Q&  .L2( #K$K  VQ-0 -L4  #+%+  NQ6  *L6< "+%X
M  >QBP %L:  !+"U  2PT  $L.\ !:_^  :N_P &KO\ !J[_ )B.  "/DP
M@I@  '6=  !GH@  6J<  $ZK  !!K0  -:\  "NQ   AM   &+8  !&Y   -
MO , ![X,  .]$@ !O1D  +XB  "^*P  OC8  +Y!  "_3@  OUP  +]M  "_
M@   OI4  +ZJ  "^P@  O>0  +WV  "]_P  O?\  +W_ )*4  "%F@  >*
M &JF  !<JP  3[   $*S   UM@  *K@  ""[   7O@  $,$   O$   $QP
M ,D'  #)#0  R1(  ,H9  #+(@  RRL  ,TU  #.00  SE   ,]@  #/<@
MSX<  ,^=  #/LP  S\X  ,_K  #.^   SOX  ,[^ (B;  !ZH@  ;*@  %ZO
M  !0M0  0KD  #6\   IOP  'L(  !7&   .R0  ",P   #0    TP   -4
M  #6!@  V P  -D1  #;%@  W!\  -XH  #@-   XD$  .)1  #C8P  XW<
M .2.  #DI   Y+H  .74  #EZ@  Y?,  .7S 'RC  !NJ@  8+(  %&Y  !#
MO@  -<(  "C&   <R0  $\T   S1   $U0   -H   #>    X0   .(   #D
M    Y0,  .<)  #I#@  ZQ(  .T:  #O)   \C$  /1!  #T4P  ]68  /5\
M  #VDP  ]JD  />\  #WS@  ]]\  /?? '"L  !AM   4[L  $7#   VQP
M)\P  !O0   1U0  "ML   #?    X@   .4   #I    [    .T   #P
M\0   /,   #U!   ]PH  /H0  #\%@  _R$  /\N  #_0   _U,  /]H  #_
M@   _Y8  /^H  #_M@  _[\  /^_ /\-' #_"AL _P(; /\ '@#_ "0 _P N
M /\ / #_ $H _P!6 /\ 8P#_ &T _P!W /\ ?P#_ (< _P". /\ E #_ )H
M_P"@ /\ I@#_ *P _P"T /\ O0#_ ,D _@#= /T [0#\ /H ^P#_ /H _P#Y
M /\ ^@#_ /H _P#Z /\ ^@#_ /\0&0#_#1< _P86 /\ & #_ !X _P J /\
M-P#_ $4 _P!2 /\ 7@#_ &D _P!R /\ >P#_ (( _P") /\ D #^ )8 _0"<
M /P H0#[ *@ ^0"O /@ N #V ,, ] #2 /, YP#R /8 \ #_ .\ _P#P /\
M[P#_ .\ _P#N /\ [@#_ /\2% #_#Q( _PL2 /\ $@#_ !H _P E /\ ,P#_
M $  _P!- /\ 60#_ &0 _0!M /L =@#Y 'T ]P"$ /4 BP#T )$ \P"7 /$
MG0#P *, [@"J .P LP#J +T Z #+ .< X0#E /$ XP#] ., _P#B /\ X0#_
M .$ _P#@ /\ X #_ /\4$ #_$0X _PT- /\'#P#_ A4 _P @ /\ +0#_ #H
M_P!' /D 4P#U %X \@!H /  < #M '@ ZP!_ .D A0#H (P Y@"2 .4 F #C
M )\ X0"F -\ K@#< +@ V@#% -8 V0#4 .P T@#Y -$ _P#/ /\ S@#_ ,X
M_P#. /\ S@#_ /\7# #_% @ _P\% /\."P#_#!$ _P<: /\!)@#\ #0 ] !!
M .T 30#I %@ Y@!B ., :@#@ '( W@!Y -L @ #9 (8 U@"- -, DP#1 )H
MSP"A ,T J@#+ +, R0"_ ,8 T #% .@ PP#V ,$ _P#  O\ OP/_ +\#_P"_
M _\ OP/_ /\;!@#_%P  _Q0  /\3!0#_$0T _PX4 /D*'P#P!BP Y@,Y . #
M1@#< U$ U@1; -($9 #/!6P S 5S ,H%>@#(!8$ Q@6' ,4&C@##!I8 P0:=
M +\&I@"]!K  NP>\ +D(S0"X"N4 M0OW +,-_P"Q#?\ L W_ + ._P"O#O\
MKP[_ /\>  #_&P  _QL  /H:  #U%@4 ]A$- .L.%0#B"R( V LQ - ,/@#+
M#4H QPU5 ,0.7@#!#F8 OPYM +T.= "[#WL N0^" +<0B@"V$)$ M!": +(0
MHP"P$:T KQ&Z *T1R@"J$N4 IQ3W *45_P"C%?\ HA7_ *(5_P"B%?\ HA7_
M /\B  #_(   \",  .8D  #@(0  W!D% -L0# #0$1D R!,I ,(5-P"]%D0
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M H8LN@*%+<X#@R[J X$N_ . +O\"?R[_ G\N_P)^+O\"?B[_ O0N  #D-P
MTCT  ,4_  "[/P  M#P  *\U  "I+PL HR\7 )XQ)@"9,C, EC(^ )(S2 "0
M,U  C3-8 (LS7@&),V4!AS-L 88S<P&$,WP"@C.% H SCP-_,YH#?3.G WPS
MM01Z,\D$>33F!'<U^01V-?\#=37_ W4U_P-U-?\#=37_ _ S  #=/0  RD,
M +Y%  "U1@  K4,  *8]  "@-@8 F383 )0X(0"0.2X C#DY (DY0P"'.4P
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M"&!$\P=@1/\&7T3_!5]$_P1@1/\$8$3_!.!!  #*2@  NU   +!3  "G50
MGE,  )5/  "+20  @T<+ 'U'%0!Y1R( =D@N '-(. !Q2$$ ;DA) 6Q(4 %J
M2%8!:$A= F9'9 )E1VP#8T=V!&%'@ 5@1XT&7D>:!UQ'J0A;2+L(6DC4"%I(
M\0=:2?\&6DG_!5I(_P5:2/\$6DC_!-M$  #&30  N%,  *U7  "C60  FE@
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M!DM4_P5+5/\%2U3_!<Q.  "[5P  KEX  *1B  ":9   D60  (9B  !W6P
M;5@  &98# !B6!8 7U@B %U9+ !;638 65D^ %=91@!664T!5%E4 5)96P)1
M66,#3UEL TU9=P1+6(0%25B2!TA8H@='6;,(1EG*"$59Z@A&6?T&1EC_!D98
M_P5'6/\%1UC_!<=2  "X6P  JV$  *%F  "8:   CFD  (-G  !R8   :%X
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M!+E@  "L:0  H7   )AU  "-=P  @G<  '=W  !I=   7',  %%Q  !(< H
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M "&&E0 @AJ<!'H:\ 1Z&W@ >A/4!'H+_ 1Z"_P$>@?\!'H'_ :AT  ">?0
MDX(  (F%  !^B   <8H  &6+  !8C   3(T  $".   VC@  +(\  "60#  C
MD!, (I < "&0)0 @D2X 'Y$V !Z10  =D4D ')%4 !J18  9D6X &)%^ !:2
MD  5DJ0 %)&Y !.1V  3C_0 %([_ !2-_P 4C/\!%(S_ :-]  "8@P  CH@
M (2,  !WCP  :9$  %V3  !0E0  19<  #F8   NF0  )9H  !V; @ 6G0P
M%9T3 !2=&P 3G20 $ITM !&>-P 1GD$ $)Y,  ^>6  .GF< #9YW  R>B@ +
MG9X "IVR  F=S  )G.P "IO^  N:_P +F?\ "YG_ )R$  "1B@  B(X  'N2
M  !ME@  8)D  %2<  !(GP  /*   #"A   FHP  ':4  !6G   0J04 "ZL-
M  BJ$P 'JAL !JHD  6J+@ $JC@  JI$  &J4   JEX  *IN  "J@0  JI4
M *FJ  "IP0  J.0  *CV  "G_P  I_\  *?_ )6+  ",D   ?Y4  '&:  !C
MG@  5J(  $JF   ]J   ,:H  ":K   =K0  %+    ZR   )M0$  K8*  "V
M#P  MA4  +<=  "W)0  MR\  +@Y  "X1@  N%0  +AD  "X=@  N(L  +>@
M  "WM@  M],  +;O  "V_   MO\  +;_ (^2  ""EP  =)T  &:B  !8IP
M2ZP  #ZO   QL0  )K,  !RV   3N   #;L   :^    P0   ,($  #""P
MPQ   ,05  #$'   Q20  ,8N  #(.@  R4<  ,E7  #):0  R7T  ,F4  #(
MJ@  R,,  ,CD  #(]   R/T  ,C] (69  !WGP  :*8  %JK  !-L0  /[4
M #&X   EN@  &KT  !'    +PP   \<   #*    S0   ,X   #/ P  T D
M -$.  #3$@  U1D  -<B  #:+0  W3D  -Y)  #>6@  WVX  -^%  #?G
MW[(  -[+  #>Y@  W_0  -_T 'FA  !KJ   7*\  $ZU  ! NP  ,;X  "3!
M   9Q0  $,@   G,    SP   -,   #9    W    -T   #?    X0   .(%
M  #D"P  YA   .@6  #J(   [2L  / Z  #Q2P  \5X  /)S  #SBP  \Z(
M /.V  #SR0  \^$  //A &VJ  !>L0  4+D  $&_   RQ   ),@  !?,   .
MT   !M4   #:    W@   .(   #F    Z0   .H   #L    [@   /    #R
M    ] 8  /8,  #Y$@  _!P  /\I  #_.@  _TT  /]B  #_>   _Y   /^C
M  #_LP  _\$  /_! /\'&0#_ 1< _P 7 /\ &@#_ "$ _P K /\ .0#_ $<
M_P!4 /\ 7P#_ &H _P!S /\ >P#_ (, _P"* /\ D #_ )8 _P"; /\ H0#_
M *@ _P"O /\ N #_ ,0 _@#5 /P Z@#[ /@ ^@#_ /D _P#X /\ ^ #_ /8
M_P#S /\ \0#_ /\+%0#_!1, _P 3 /\ % #_ !H _P G /\ - #_ $( _P!/
M /\ 6P#_ &4 _P!N /\ =@#_ 'X _P"% /X BP#] )$ ^P"7 /H G0#X *,
M]P"K /8 LP#T +X \P#, /$ XP#O /, [@#_ .T _P#L /\ ZP#_ .P _P#L
M /\ ZP#_ /\-$0#_"1  _P / /\ $ #_ !8 _P B /\ +P#_ #T _P!* /\
M50#] &  ^@!I /@ <0#V 'D ] !_ /, A@#Q (P [P"2 .X F #L )\ ZP"F
M .D K@#G +@ Y0#% ., V@#A .T WP#[ -X _P#= /\ W0#_ -T _P#= /\
MW0#_ /\/#0#_# L _P,) /\ # #_ !( _P = /\ *0#[ #< ^ !$ /4 4 #R
M %H [@!C .P :P#I ', YP!Z .4 @ #C (8 X0", -\ DP#= )D VP"A -D
MJ0#5 +( T@"^ -  S@#. .8 S #V ,H _P#* /\ R0#_ ,@ _P#( /\ R #_
M /\1" #_#0( _P<  /\%" #_  X _P 6 /< (@#O #  ZP ] .@ 20#D %0
MX != -T 90#9 &T U0!S -( >@#0 (  S@"' ,P C0#* )0 R "; ,8 I #$
M *T P@"X ,  QP"] -\ O #Q +L _@"Y /\ N #_ +@ _P"X /\ N #_ /\4
M  #_#P  _PT  /\,  #_!PD ^ $0 .@ &@#C "@ W0 V -@ 0@#2 $T S@!7
M ,H 7P#' &8 Q0!M ,, = #! 'H OP"! +T B "[ (\ N0"7 +< GP"U *@
MLP"S +$ P@"O -@ K@+M *P#^P"K!?\ J@;_ *D&_P"I!O\ J0;_ /\6  #_
M$@  ]Q(  .P1  #F#@  Y08( -T#$@#4 R  S00M ,@$.@##!48 OP50 +P&
M6 "Y!F  MP=G +4';@"S!W4 L0A[ *\(@@"N"8H K F2 *H)FP"H"J4 I@JP
M *4+OP"C#-0 H0WM )\._@"=#O\ G __ )L/_P";#_\ FP__ /\:  #W&0
MZAX  -\>  #5&@  T!," ,X,"P#'"Q8 P TE +H.,@"V#C\ L@]) *\04@"L
M$%H JA!A *@1: "F$6\ I!%V *(1?0"A$84 GQ*. )T2EP"<$J( FA.M )@3
MO "7%-  E!7L )(6_0"0%_\ CQ?_ (X7_P".%_\ CA?_ /H=  #N(P  WR@
M - J  #')P  P2$  +T9!0"Y$A  LA4> *T6+ "H%S@ I!A# *$93 "?&50
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M G$N] )P+_\";R__ F\O_P%N+_\!;B__ >@Q  #3.@  PS\  +=!  "N00
MICX  )XX  "7,0$ D2X0 (PO' "(,"@ A#$S ($R/0!_,D8 ?3)- 'LR5 !Y
M,EL =S)A '4R:0%T,G !<C)Y 7 SA %O,Y ";3.= FPSJP)J-+P":335 V@U
M\0)G-?\"9S7_ F8U_P)F-?\"9C3_ N(V  #,/P  O40  +)'  "H1P  H$0
M )@_  "0.0  B#0- (,U%P!_-B0 ?#<O 'DW.0!W.$( =#A) '(X4 !Q.%<
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M U1#_P-40_\"5$/_ M!"  "_2@  LE   *=3  "=5   E%,  (I0  !_2@
M=44" &Y##@!K1!D 9T4D &5%+@!B13< 844_ %]%1@!=14T 6T54 %I&6P%9
M1F,!5T9L E9&=P)41H,#4T:1 U%&H0101[$$3T?'!$Y'YP1.1_L$3D?_ TY'
M_P-/1_\#3T?_ \Q&  "[3@  KU0  *17  ":6   D5<  (94  ![3@  <$H
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M \!0  "R6   IEX  )QB  "290  B&4  'UB  !N7   8UD  %E6 P!45@X
M4588 $]6(@!-5RP 3%<T $I7/ !)6$0 2%A+ $=84P!%6%L!1%AD 4)8;@%
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M 3%EE0(P9:<"+V6[ BYEV@(N9/0"+F/_ B]C_P(O8O\"+V+_ K->  "G9@
MG&T  )-Q  "(<P  ?7,  ')R  !D<   6&X  $UL  !":@, /&D. #IJ%@ Y
M:B  .&HH #9K,0 U:SD -&M! #-L20 R;%( ,6Q< "]L9@ N;', +&R" 2IL
MDP$I;*4!*&RY 2=MU@$G:_(!)VK_ 2=J_P$H:?\"*&G_ JYD  "C;   F7,
M (YV  "$>   >7D  &UX  !@=P  4W8  $AU   ^<P  -'(* #%S$0 P<QH
M+W,C "YS*P M=#0 +'0\ "MT1  I=$T *'57 "=U8P E=6\ )'5_ ")UD  A
M=:( ('6W !]UT@ ?=/$ 'W/_ 1]R_P$@<?\!(''_ :EK  "><P  E'D  (I\
M  " ?@  ='\  &=_  !:?P  37X  $-^   X?0  +WT" "A]#0 F?10 )'T<
M "-^)0 B?BT (7XV "%^/P ??T@ 'G]2 !U_7@ <?VL &G]Z !E_C  7?Y\
M%G^S !5_S@ 5?N\ %GS_ !9[_P 6>_\ %WO_ *1R  ":>@  CW\  (6"  ![
MA   ;88  &"'  !4AP  2(@  #R(   RB   *(@  ""(!0 :B0X &8D5 !B)
M'0 7BB8 %HHN !6*-P 4BD$ $XI, !*+6  1BV4 $(MU  ^+AP .BIL #8JO
M  R*R  ,B>H #8?\  Z'_P .AO\ #H;_ )][  "4@0  BH4  ("(  !SBP
M98T  %F/  !,D   09(  #22   JD@  (9,  !F4   2E@8 #I<.  V7%0 ,
MEQT #)<F  N7+P *ESD "9=$  B74  &EUX !9=N  .6@  !EI0  )6H  "5
MO@  E.   )3T  "3_P !DO\  9+_ )B"  ".B   A8P  '>/  !JD@  794
M %"8  !$F@  .)L  "R<   BG0  &9X  !*@   -H@( !Z,+  &C$   HQ<
M *,?  "C)P  HS$  *0\  "D2   I%8  *1E  "C=P  HXL  *.@  "BM@
MH=(  *'P  "@^P  H/\  *#_ )&*  ")C@  >Y(  &V7  !@FP  4YX  $:A
M   YHP  +:0  ".F   9J   $:H   RL   %K@   *\'  "O#0  KQ$  + 8
M  "P(   L2@  +$R  "R/@  LDP  +);  "R;   LH$  +&7  "QK   L,8
M +#H  "O]P  K_\  *__ (R0  !_E0  <9H  &.?  !5I   1Z@  #JJ   M
MK   (JX  !BP   0LP  "K4   *X    NP   +L   "\!P  O T  +T1  "^
M%@  OQX  , G  #!,@  PD   ,-/  ##8   PW0  ,.+  ##H0  P[@  ,+7
M  #"[P  POH  ,'^ (&7  !SG0  9:,  %>H  !)K0  .[$  "VS   AM@
M%KD   Z[   'O@   ,$   #%    QP   ,@   #)    R@4  ,L+  #-#P
MSA0  - <  #3)@  UC(  -A!  #84P  V68  -E\  #9E   V:L  -G#  #9
MX0  V?   -GT ':?  !GI@  6:P  $NR   \MP  +KH  "&]   5P   #<0
M  7'    R@   ,X   #2    U0   -8   #9    VP   -T   #?!P  X0P
M .,1  #F&0  Z20  .PR  #M0P  [E8  .]K  #OA   [YP  .^R  #OQ@
M[]T  ._D &JH  !;KP  3+8  #Z\   OP   (,0  !3(   ,S    M    #4
M    V0   -X   #B    Y0   .8   #H    Z0   .P   #N    \ (  /()
M  #U#P  ^!<  /PC  #_,P  _T8  /]:  #_<0  _XD  /^?  #_L0  _\
M /_& /\ %0#_ !0 _P 4 /\ %P#_ !T _P H /\ -P#_ $0 _P!1 /\ 7 #_
M &8 _P!O /\ =P#_ 'X _P"% /\ BP#_ )$ _P"7 /\ G0#_ *0 _P"K /\
MM #^ +\ _0#. /L Y@#Y /8 ^ #_ /< _P#W /\ ]P#_ /  _P#L /\ Z0#_
M /\#$@#_ !  _P 0 /\ $0#_ !< _P D /\ ,@#_ #\ _P!, /\ 5P#_ &$
M_P!J /\ <@#_ 'D _0"  /P A@#Z (P ^0"2 /@ F #V )\ ]0"F /0 K@#R
M +D \ #& .X W@#M /  ZP#^ .H _P#I /\ Z0#_ .< _P#C /\ X #_ /\'
M#@#_  T _P + /\ # #_ !, _P ? /\ + #_ #H _P!& /X 4@#[ %P ^ !E
M /4 ; #S '0 \0!Z .\ @0#N (< [ "- .H DP#I )H YP"A .8 J0#C +,
MX0"_ -\ T #= .D V@#Y -D _P#7 /\ U0#_ -4 _P#5 /\ U #_ /\)"@#_
M 04 _P # /\ "0#_ !  _P 9 /L )@#W #0 ] !  /( 3 #N %8 Z@!? .<
M9P#D &X X@!T .  >P#> ($ W "' -H C0#6 )0 U "; -$ HP#/ *T S "X
M ,H QP#( .  Q@#S ,4 _P## /\ PP#_ ,, _P## /\ PP#_ /\+ 0#_ P
M_P   /\  P#_  L \P 2 .X 'P#J "T Y@ Z .( 10#> $\ V0!8 -0 8 #1
M &@ S@!N ,P = #* 'L R "! ,8 AP#$ (X P@"6 ,  G@"^ *< NP"R +D
MP "W -0 M0#L +, ^P"S /\ L@#_ +( _P"Q /\ L0#_ /\-  #_!@  _P,
M /<   #T  , YP - .  & #: "4 TP R ,X /@#* $D Q@!2 ,, 6@#  &$
MO@!H +P ;@"Z '0 N ![ +8 @0"T (@ L@"0 +  F0"N *( K "M *H N@"H
M ,L I@#F *4 ]P"D /\ HP#_ *( _P"B /\ H@#_ /\0  #[#   [PX  .8-
M  #?"0  V@ & -  $0#) !T Q  J +\ -P"[ $( MP!+ +0 5 "R %L KP!B
M *T : "K &X J0!U *@ >P"F (, I "+ *( E "@ )X G@&H )P"M0"; \8
MF07B )@&] "6"/\ E0G_ )0)_P"4"?\ E G_ /P1  #Q%0  XQD  -89  #,
M%0  QQ   ,0'"@"] Q0 MP0A +(&+@"N"#H J@E$ *<)30"D"E4 H@I< * *
M8@">"VD G MO )L+=@"9#'X EPR& )8,D "4#)H D@VF )$-LP"/#<4 C0[B
M (L0]@")$/\ B!'_ (<1_P"'$?\ AQ'_ /89  #G(   UB0  ,@E  "_(@
MN1P  +04 0"Q#0X J@X9 *4/)P"A$#, G1$^ )H11P"8$D\ E1)6 ),27 "1
M$F, D!-I (X3< ",$W@ BQ.! (D4BP"'%)8 AA6B (05L "#%L$ @1?= '\8
M] !]&?\ ?!G_ 'P9_P![&?\ >QG_ .\A  #=*0  RBT  +XO  "U+   KB<
M *@@  "C%P@ GA83 )D7(0"4&2T D1HX (X:00"+&TD B1M0 (<;5P"%'%X
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M 6 O_P%@+_\!8"[_ =HT  #%/   MT$  *Q#  "B0P  F4   ) Z  "(-
M@"X( 'HM$@!W+AX <R\I '$P,P!O,#L ;3!# &LQ2@!I,5$ 9S%7 &8Q7@!D
M,68 8S)O &$R>0!@,H4!7S*2 5TSH0%<,[$!6S3& 5HTY@%9-?L!637_ 5DT
M_P%9-/\!633_ =(X  # 0   LT4  *A(  ">2   E48  (M   "".P  >34$
M ',S$ !O-!H ;#0E &DU+P!G-3< 938_ &,V1@!B-DT 8#94 %\V6P!=-V,
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M/10 7ST> %P^* !:/C$ 6#XX %<^0 !5/T8 5#]- %,_50!20%T 4$!F $]
M< %.0'P!3$&* 4M!F@)*0:L"24*^ DA"W@)(0O8"2$+_ DA"_P%(0?\!2$'_
M <5$  "U2P  J5   )Y4  "55   BU,  (!0  !U2@  :D8  &%"" !<01$
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M 3Q.E $[3J4!.4^Y CE/U (Y3_(!.4[_ 3E._P$Y3?\!.DW_ ;I.  "L5@
MH5L  )=?  "-80  @V$  'A>  !I6   7U8  %12  !,3PL 24\2 $=0' !%
M4"4 0U M $)0-0!!43P 0%%$ #]13  ^4E0 /%)= #M29P Z4G, .%." 3=3
MD@$U4Z0!-%.W 3-4T0$S4_$!-%/_ 312_P$T4O\!-%+_ ;92  "I6@  GF
M )1D  "+9@  @&4  '1C  !F7@  7%P  %%8  !'50< 0E40 $!5&  _5B$
M/58J #Q6,@ [5CD .E=! #E720 X5U$ -UA: #5890 T6'$ ,EB  3%8D $O
M6:(!+EFU 2U9SP$M6>\!+EC_ 2Y7_P$N5_\!+E;_ ;)7  "E7P  FV4  )%I
M  "':@  ?&H  '%H  !C90  6&(  $U?  !#70( /%L- #I<%  X7!T -UPF
M #5=+@ T738 ,UT^ #)=1@ Q7DX ,%Y7 "]>8@ M7FX +%]] "I?C@ I7Z
M*%^S 2=?S  G7^T!)U[_ 2==_P$H7?\!*%S_ :U<  "B9   F&H  (YN  "#
M;P  >6\  &YN  !@:P  5&D  $EG   _90  -6,) #)C$0 P8QD +V0A "YD
M*0 M9#$ +&0Y "ME0@ J94H *&54 "=E7P F9FL )&9Z "-FBP B9IT (&:Q
M !]FR0 ?9NL (&7^ "!D_P @8_\!(6/_ :EB  ">:@  E7   (IS  " =0
M=74  &ET  !<<@  3W$  $1O   Z;@  ,&T# "EL#0 G;!0 )FP< "5M)  D
M;2P (VTT ")M/0 A;D8 (&Y0 !YN6P =;F< '&YV !INAP 9;YH &&^N !9O
MQ@ 6;ND %VW\ !AL_P 8:_\ &&O_ *1I  ":<0  D'8  (9Y  !\>P  <7L
M &1[  !7>@  2GD  #]X   U>   *W<  ")V!P ==@\ ''<6 !MW'@ :=R8
M&7<N !AW-P 7>$  %7A* !1X5@ 3>&, $GAR !%X@P 0>)< #WBK  YXPP .
M=^8 #G;Z  ]U_P 0=?\ $'3_ )]Q  "5>   BWP  ()_  !W@0  :H(  %V"
M  !0@@  1((  #B"   N@@  )((  !R"   4@@D $8,0 !"#%@ 0@QX #H,G
M  Z#,  -@SD #8-$  R#4  +@UT "8-L  B#?@ &@Y$ !8*E  ."NP $@=L
M!('R  6 _P &?_\ !G__ )IY  "0?@  AH,  'V%  !OAP  8HD  %6*  !)
MBP  /8P  #&,   FC   '8T  !6.   /CP, "I ,  :0$0 $CQ@  X\@  &/
M*0  CS(  ) ]  "020  CU8  (]E  "/=@  CXH  (Z?  ".M   C<\  (SN
M  ",^P  B_\  (O_ )2   "+A0  @HD  '2,  !FCP  69$  $R3  ! E0
M-)8  "B6   >EP  %9@   ^:   *FP   IP)  "<#@  G!,  )P:  "<(@
MG2L  )TU  "=0   G4X  )U<  "=;@  G($  )R7  "<K   F\8  )KH  "9
M^0  F?\  )C_ (Z(  "&C   >)   &J4  !<EP  3YH  $*=   VG@  *9\
M !^A   5H@  #J0   BF    J    *D$  "I"@  J0X  *D3  "J&@  JB(
M *LK  "L-@  K$0  *Q3  "L8P  K'<  *N.  "KI   J[P  *K>  "I]
MJ?T  *G_ (F.  ![DP  ;9<  %^<  !1H   1*0  #:F   JJ   'JD  !2K
M   -K@  !K    "R    M0   +4   "U P  M@D  +<.  "X$@  N!D  +HA
M  "[*P  O#@  +U'  "]6   O6L  +V!  "]F0  O;   +W,  "\Z@  O/<
M +O^ 'Z5  !PFP  8J   %.E  !&J@  .*T  "JO   >L0  $[0   RW   #
MN0   +P   "_    P@   ,(   ##    Q    ,8&  #'#   R!   ,H6  #,
M(   SRL  - Z  #12P  T5X  -)S  #2BP  TJ0  -.[  #3V   T^T  -/V
M '.=  !DHP  5JD  $>O   YLP  *K8  !VY   2O   "K\   ##    Q@
M ,D   #-    SP   -    #2    U    -8   #9 @  VP@  -X.  #A$P
MY!T  .@J  #H/   Z4\  .ED  #J?   ZY4  .NL  #KP@  [-4  .SE &:F
M  !8K   2;,  #NY   KO   '<   !'$   )R    ,P   #/    TP   -D
M  #=    X    .$   #C    Y0   .<   #J    [    .X$  #Q"P  ]1(
M /@<  #[*P  _3X  /Y3  #^:@  _X,  /^;  #_K@  _[X  /_* /\ $@#_
M !  _P 1 /\ $P#_ !D _P F /\ - #_ $$ _P!- /\ 6 #_ &( _P!K /\
M<P#_ 'H _P"! /\ AP#_ (T _P"3 /\ F0#_ *  _P"G /X KP#\ +H ^@#)
M /D X0#X /, ]P#_ /8 _P#U /\ \0#_ .D _P#D /\ X0#_ /\ #P#_  T
M_P - /\ #@#_ !0 _P A /\ +@#_ #P _P!( /\ 4P#_ %T _P!F /X ;0#\
M '4 ^P![ /D @@#X (@ ]P". /8 E #T )L \P"B /$ J@#O +0 [0#! .L
MU0#J .P Z #\ .< _P#E /\ Y@#_ .  _P#9 /\ U #_ /\ "P#_  @ _P &
M /\ "0#_ !  _P < /\ *0#_ #8 _P!" /L 3@#W %< ] !@ /( : #O &\
M[0!V .P ? #J (( Z "( .< C@#E )4 XP"< .$ I #? *X W0"Y -H R@#7
M .0 U #V -$ _P#0 /\ T #_ ,\ _P#+ /\ QP#_ /\  P#_    _P   /\
M! #_  T ^@ 6 /8 (P#S #  \  \ .T 1P#I %$ Y0!: .( 8@#? &D W0!O
M -H =@#8 'P U "" -( B #0 (\ S0"6 ,L G@#) *@ QP"S ,4 P0#" -@
MP #O +\ _@"^ /\ O0#_ +P _P"\ /\ O #_ /\"  #_    _P   /\   #T
M  < [0 1 .@ ' #C "D WP U -L 00#6 $L T0!4 ,T 7 #* &, R !I ,8
M;P## '4 P0![ +\ @@"^ (@ O "0 +H F "X *( M0"L +, N0"Q ,L KP#G
M *X ^ "L /\ JP#_ *P _P"L /\ JP#_ /\$  #_    ]@   .X   #G
MWP , -8 %0#/ "( R@ N ,< .@## $0 P !- +P 50"Y %P MP!C +4 :0"S
M &\ L0!U *\ >P"M (( JP"* *D D@"G )P I0"F *, LP"A ,, GP#> )X
M\@"= /\ G #_ )P _P"; /\ FP#_ /\'  #V"0  Z0L  -\*  #5!   S@ %
M ,8 $ #  !H NP G +< ,@"S #T L !& *T 3P"J %8 J !< *8 8P"D &@
MH@!O *$ =0"? 'P G0"$ )L C0"9 )< EP"B )4 K@"3 +T D0#3 )  [0"/
M /P C@#_ (T!_P"- ?\ C0'_ /D.  #J$@  W!4  ,T5  #$$0  O@P  +H"
M"@"T !( K@ > *H *@"F #4 H@ _ *  2 "= 5  FP)6 )D"7 "7 V, E0-I
M ),#;P"1!'8 D 1_ (X%B ",!9( B@:> (@&J@"&![H A0C/ (0*ZP"""_P
M@0S_ ( ,_P" #/\ @ S_ /$5  #@'0  S2   ,$A  "X'0  L1<  *P0  "H
M"0T H@<6 )T)(P"9"BX E0LX ),,00"0#$D C@U0 (P-5P"*#5T B UC (<-
M:@"%#G$ @PYZ ((.A " #H\ ?@^; 'P/J ![$+@ >A#. '@1[ !V$O\ =1+_
M '03_P!T$_\ =!/_ .@>  #3)@  PRH  +@J  "N*   IR,  * <  ";$P,
ME@\0 ) 0&P",$2< B1(R (83.P"$$T, @A1+ ( 440!^%%< ?!1> 'L590!Y
M%6P =Q5T '86?@!T%HH <A>6 '$7I !O&+0 ;AC) &T9Z !K&OP :AO_ &H;
M_P!J&_\ :AO_ . F  #*+0  O#$  + S  "G,0  GRP  )<F  "0'P  BA<,
M (48%@"!&2( ?AHL 'L;-@!Y&SX =QQ% '4<3 !S'%, <1U9 ' =8 !N'6<
M;1YP &L>>@!J'H4 :!^2 &<?H !E(+  9"'% &,AY !B(OH 82+_ &$B_P!A
M(O\ 82+_ -<L  ##-   MC@  *HY  "A.   F#4  ) O  "(*   @"$( 'L@
M$@!W(1T ="(G '$B,0!O(SD ;2-! &LC2 !I(TX :"15 &8D6P!E)&, 8R5K
M &(E=0!A)8$ 7R:. %XFG0!=)ZT 6RC! %LHX !:*?< 62G_ %DI_P!9*?\
M62C_ ,\R  "^.0  L3T  *8_  "</P  DSP  (HV  "!,   >2H# '(F#P!N
M)QD :R@C &DH+ !F*34 92D\ &,I0P!A*DH 8"I1 %XJ5P!=*E\ 7"MH %HK
M<@!9+'T 6"R+ %8MF@!5+:H 5"Z] %,NW !2+_4 4B__ %(N_P!2+O\ 4B[_
M ,HV  "Z/0  K4(  *)$  "81   CT$  (4\  ![-P  <C$  &LL# !G+14
M9"T? &$N* !?+C$ 72XY %PO0 !:+T8 6"]- %<O5 !6,%P 53!D %,Q;@!2
M,7H 43&( % REP!.,J@ 33.[ $TTV !,-/, 3#3_ $PT_P!,,_\ 3#/_ ,8Z
M  "V0@  J48  )Y)  "520  BT<  (%"  !W/0  ;3<  &0R"0!@,A( 73(<
M %HR)0!8,RT 5C,U %4S/ !3-$, 4C1* %$T40!0-%D 3S5A $TU; !,-G<
M2S:% $HWE0!(-Z8 1SBX 4<XTP%&./$!1CC_ 48X_P!&./\ 1C?_ ,$^  "R
M10  IDH  )Q-  "230  B$L  'Y'  !S0@  :3T  %\W!@!:-A  5S<8 %0W
M(@!2-RH 4#<R $\X.0!-.$  3#A' $LX3@!*.58 23E? $@Z:0!'.G4 13N#
M $0[DP!#/*0!0CRV 4$]T %!/? !03W_ 4$\_P%!//\!03S_ +Y"  "O20
MHTX  )E0  "/40  A5   'M,  !O1@  94(  %H] @!4.PX 43L5 $\['P!-
M.R< 2SLO $D\-@!'/#T 1SQ$ $8]2P!%/50 1#Y< $,^9P!"/W, 0#^! #\_
MD0 ^0*( /4"U 3Q!S@$\0>X!/$'_ 3Q _P$\0/\!/3__ ;I%  "L3   H5$
M )=4  "-50  @U0  'A1  !L2P  84<  %9"  !/0 P 3#\3 $E ' !'0"0
M1D L $1 ,P!#0#H 0D%" $%!20! 0E$ /T): #Y#90 ]0W$ .T-_ #I$CP Y
M1*  .$6S 3=%RP$W1>P!-T7_ 3=$_P$X1/\!.$/_ +=)  "I4   GE4  )18
M  "+60  @%@  '96  !H4   74P  %-(  !*10D 1D01 $1$&0!"1"( 044I
M #]%,0 ^13@ /44_ #Q&1P [1D\ .D=8 #E'8@ X2&X -DA\ #5(C0 T29X
M,TFQ #))R0 Q2>L ,DG^ #)(_P R2/\ ,TC_ +1,  "G5   G%D  ))<  "(
M70  ?ET  '-:  !E50  6U(  %!.  !&2@4 0$D. #Y)%@ ]21X .THF #I*
M+@ Y2C4 .$L] #=+1  V2TT -$Q6 #-,8  R3&P ,4UZ #!-BP N39P +4ZO
M "Q.QP L3ND +$W] "U-_P M3/\ +4S_ +!0  "D6   F5T  (]A  "&8@
M>V$  '!?  !B6P  6%@  $Y5  !#40$ .T\, #A/$P V3QL -4\C #10*P S
M4#( ,E Z #%00@ P44H +E%3 "U270 L4FD *U)X "E2B  H4YH )U.M "93
MQ0 F4^< )E/\ "=2_P G4?\ )U'_ *Q5  "@7   EF(  (UF  "#9P  >&8
M &UE  !@80  55X  $I;   _6   -58( #%5$  P5A< +E8? "U6)P L5B\
M*U<V "I7/@ I5T< *%=0 "986@ E6&< )%AU "-9A@ A69@ (%FK !]9P@ ?
M6>4 'UCZ "!8_P @5_\ (5?_ *A:  "=8@  DV<  (IK  !_;   =6P  &IK
M  !=:   464  $9C   [8   ,5X# "I=#0 H71, )ET; "5>(P D7BH (UXR
M ")>.@ A7D, (%], !]?5P >7V, '&!Q !M@@@ 98)4 &&"I !=@P  68.(
M%U_Y !A>_P 97O\ &5W_ *1@  "9:   D&X  (9P  !\<@  <G(  &9Q  !8
M;@  3&P  $%K   V:0  +6<  "-F"  ?9@\ '685 !QF'0 ;9B4 &F8M !EG
M-0 89SX %V=( !9G4P 5:%\ $VAN !)H?P 1:)( $&BF  ]HO0 .:.  $&?W
M !!F_P 19?\ $67_ )]G  "6;P  C',  ()V  !X>   ;7@  &!W  !3=@
M1G0  #MS   Q<@  )W$  !YQ   6< H $W 0 !-P%P 2<!\ $7$G !!Q+P 0
M<3@ #G%"  YQ3@ -<5L #'%I  MQ>@ *<8T "'&A  9QM@ &<-( !W#O  AO
M_P );O\ "6[_ )MO  "1=0  AWD  'Y\  !T?@  9GX  %E^  !-?@  0'T
M #5]   J?   (7P  !A\   1? 0 #'P,  I\$0 )?!D "'PA  =\*0 &?#(
M!'P]  -\2  !?%4  'QC  !\=   ?(<  'N<  ![L0  >LL  'GK  !Y^@
M>?\  'C_ )9W  ",?   @X   'F#  !LA   7H4  %&&  !%AP  .8<  "V'
M   CAP  &H<  !*'   -B $ !HD*  &)#P  B10  (@;  "((P  B2P  (DV
M  ")0@  B$X  (A=  "(;0  B($  (>5  "'JP  AL0  (7F  "$^   A/\
M (3_ )!^  "'@P  ?H<  '&)  !CBP  5HT  $F/   \D0  ,)$  "21   :
MD@  $I,   V4   &E0   )8&  "6#   E1   )85  "6'0  EB0  )8N  "6
M.0  ED8  )95  "690  EG@  )6.  "5I   E+P  )/?  "3]0  DO\  )+_
M (N&  "#B@  =8T  &>0  !9E   3)<  #^9   RF@  )IL  !N<   2G0
M#)\   2@    H@   *,!  "C!P  HPP  *,0  "D%0  I!P  *4E  "F+P
MICP  *9+  "F6P  IFX  *6$  "EFP  I+,  */0  "C[P  HOP  *+_ (:-
M  !XD0  :I4  %R9  !.G0  0:   #.B   FHP  &Z4  !&G   *J0   :L
M  "M    KP   +    "P    L 4  +$+  "R#P  LQ0  +0;  "U)   MS
M +<_  "W4   MV(  +=X  "WD   MJD  +;"  "VY   MO4  +7^ 'N3  !M
MF   7YT  %"B  !"I@  -*D  ":K   :K0  $*\   FR    M    +<   "Z
M    O    +T   "^    O@   , "  #!"   P@T  ,02  #&&0  R20  ,HR
M  #+0P  RU4  ,QJ  #,@P  S)P  ,NU  #,S@  S.D  ,SV '";  !AH0
M4J8  $2K   VL   )[(  !JU   0N   ![L   "^    P0   ,0   #(
MRP   ,L   #-    S@   -    #2    U0,  -@*  #;$   WA@  .(D  #C
M-0  Y$@  .5<  #F<P  YHT  .:E  #FO   YM,  .?G &.D  !5J@  1K
M #BU   HN0  &KP   _    %Q    ,<   #+    SP   -0   #8    W
M -T   #?    X0   .,   #E    Z    .H   #M!@  \0X  /46  #X)0
M^3@  /E-  #Z8P  ^WP  /R5  #\J@  _+L  /W+ /\ #P#_  X _P . /\
M$ #_ !8 _P C /\ , #_ #T _P!) /\ 5 #_ %X _P!F /\ ;@#_ '8 _P!\
M /\ @@#_ (D _P"/ /\ E0#^ )L _0"C /L JP#Z +4 ^0## /< VP#V /
M] #_ /, _P#R /\ [ #_ .( _P#< /\ U@#_ /\ # #_  D _P ( /\ "@#_
M !( _P > /\ *P#_ #@ _P!$ /\ 3P#_ %D _@!A /P :0#Z '  ^ !W /<
M?0#V (, ] ") /( CP#Q )8 [P"= .T I0#L *\ Z@"\ .@ S0#F .@ Y #Z
M ., _P#B /\ X #_ -4 _P#. /\ RP#_ /\ !@#_  $ _P   /\ ! #_  X
M_P 9 /\ )0#] #( ^P ^ /< 20#S %, \ !< .X 8P#L &H Z@!Q .@ =P#F
M 'T Y "# .( B0#@ )  W@"7 -P GP#9 *D U@"T -, Q #0 -X S@#S ,P
M_P#+ /\ R@#_ ,@ _P#" /\ O@#_ /\   #_    _P   /\   #[  L ]@ 3
M /$ ( #M "P Z@ X .< 0P#C $T X !6 -P 70#9 &0 U0!K -( <0#0 '8
MS@!\ ,P @P#* (D R "1 ,8 F0#$ *, P0"M +\ NP"] ,\ NP#K +D _ "W
M /\ MP#_ +8 _P"T /\ L0#_ /\   #_    _P   /8   #N  4 YP / .$
M&0#; "4 U0 Q -( / #. $8 R@!/ ,< 5P#$ %X P0!D +\ :@"] '  NP!V
M +D ? "X (, M@"* +, DP"Q )P KP"G *T LP"K ,4 J0#A *< ]0"F /\
MI0#_ *0 _P"D /\ I #_ /\   #\    \0   .@   #@    U  + ,P $P#'
M !\ P@ J +\ -0"\ #\ N !( +4 4 "S %< L !> *X 9 "L &D JP!O *D
M=0"G 'P I0"$ *, C "A )8 GP"A )T K0": +P F #2 )< [@"5 /X E #_
M )4 _P"5 /\ E0#_ /P!  #P!0  XP<  -4%  #,    Q0 $ +X #@"X !<
MLP C *\ +@"K #@ J0!! *8 2@"C %$ H0!7 )\ 70"= &, FP!I )H ;P"8
M '8 E@!] )0 A@"2 )  D "; (X IP", +8 B@#) (@ YP"' /D AP#_ (8
M_P"& /\ A@#_ /0,  #D$   T1(  ,41  "]#@  M@@  +$ " "K !$ I@ ;
M *$ )@"> #$ F@ Z )@ 0P"5 $H DP!1 )$ 5P"/ %T C@!C (P :0"* '
MB !W (8 @ "$ (L @@"6 (  HP!^ +$ ?0#$ 'L"X0!Z _4 >@7_ 'D%_P!X
M!O\ > ;_ .H3  #6&@  QAT  +H<  "Q&0  JA,  *0-  "?!0P F0 4 )4
M'P"1 BD C0,S (L$/ "(!40 A@9+ (0&40""!U< @0== '\'8P!]"&H >PAR
M 'H(? !X"88 =@F2 '0*H !S"J\ <0O! ' ,WP!O#?8 ;@[_ &T._P!M#O\
M;0[_ .$<  #+(P  O"8  +$F  "H)   H!X  )D8  "3$ ( C@L. (@+%P"$
M#"( @0TL 'X--0!\#CT >@Y% '@.2P!W#E$ =0]8 ',/7@!Q$&4 <!!N &X0
M=P!L$(( :Q"/ &D1G0!H$:T 9A+  &42WP!D$_8 8Q3_ &,4_P!B%/\ 8A3_
M -8D  ##*@  M2X  *HO  "@+0  F"@  ) B  ")&P  @A,( 'T1$@!Y$AP
M=A,G ',4, !Q%#@ ;Q4_ &T51@!L%4P :A93 &@660!G%F$ 919I &07<@!B
M%WX 81B+ %\8F0!>&:D 7!F\ %P:V !:&_, 6AS_ %D<_P!9'/\ 61S_ ,TJ
M  "],0  KS4  *0V  ";-   DC$  (DK  "!)0  >1T# ',8#@!O&1@ ;!HB
M &D;*P!G&S, 91P[ &0<00!B'4@ 8!U. %\=50!='5P 7!YD %L>;@!9'WD
M6!^' %8@E@!5(*8 5"&X %,AT@!2(O$ 4B/_ %(C_P!2(O\ 4B+_ ,@O  "X
M-@  JSH  * \  "6.P  C3@  (,R  !Z+0  <B8  &H@# !F(!, 8R$= &$A
M)@!?(B\ 72(V %LB/0!:(T0 6"-* %<C40!5(U@ 5"1A %,D:@!1)78 4"6#
M $\FDP!.)Z, 3">U $PHS@!+*.X 2RG_ $LH_P!+*/\ 2RC_ ,,T  "S.P
MIS\  )Q!  "20   B3X  '\Y  !U,P  ;"T  &,G" !>)A$ 7"89 %DG(@!7
M)RL 52@R %0H.0!2*$  42A& % I30!.*54 32E= $PJ9P!+*G, 22N  $@K
MD !'+*$ 1BVS $4MRP!%+NP 1"[_ $0N_P!%+?\ 12W_ +XX  "P/P  I$,
M )E%  "/10  A4,  'L^  !Q.0  9S0  %XN! !8*PX 52L6 %(L'P!0+"<
M3RPO $TM-@!,+3P 2BU# $DM2@!(+E( 1RY: $8O9 !%+W  0S!^ $(PC0!!
M,9X 0#*Q #\RR  _,^H /S/^ #\R_P _,O\ /S+_ +L\  "M0P  H4<  )9)
M  ",20  @T@  'A$  !M/@  8SD  %HT  !2, P 3S 3 $PP' !*,"0 23$K
M $<Q,@!&,3D 1#%  $,R1P!",D\ 03-8 $ S8@ _-&T /C1[ #TUBP \-IP
M.S:O #HWQ@ Y-^@ .3?\ #HW_P Z-O\ .C;_ +=   "J1@  GDL  )1-  "*
M3@  @$P  '5(  !J0P  8#X  %8Y  !--0D 2301 $<U&0!%-2$ 0S4H $$U
M+P! -38 /S8] #XV10 ]-TT /#=5 #LX8  Z.&L .3EY #@YB0 W.IL -3JM
M #4[Q  T.^8 -#O[ #4[_P U.O\ -3K_ +1#  "G2@  G$X  ))1  "(4@
M?E   '--  !G2   7$0  %(_  !(.@8 1#D/ $$Y%@ _.1X /CDF #PY+0 [
M.C0 .CH[ #D[0@ X.TH -SQ3 #8\70 U/6D -#UW #,^AP Q/ID ,#^K "\_
MP@ O/^0 +S_Z # __P P/O\ ,#[_ +%'  "D30  F5(  (]5  "&5@  ?%4
M '%2  !D3   64D  $]%  !%0 , /SX- #P^$P Z/AL .3XC #<^*@ V/S$
M-3\X #0_0  S0$@ ,D!1 #%!6P P06< +D)U "U"A0 L0Y< *T.J "I#P  I
M1.( *D/Y "I#_P K0O\ *T+_ *Y*  "A40  EU8  (U9  "#6@  >5H  &Y7
M  !A4@  5TX  $U+  !#1P  .D,* #9#$0 T0Q@ ,T,@ #)$)P Q1"\ ,$0V
M "]%/0 M148 +$5/ "M&60 J1F0 *4=R "A'@P F1Y4 )4BH "1(O@ C2.
M)$CW "5'_P E1_\ )D?_ *I/  "?50  E%H  (M>  "!7P  =UX  &M<  !?
M6   554  $M1  ! 30  -4H' #!)#@ N214 +4D= "Q))  K2BL *DHS "A*
M.P G2T, )DM, "5+5@ D3&( (TQP "%,@  @39, 'TVF !Y-NP =3MT 'DWV
M !Y,_P ?3/\ ($O_ *=3  "<6@  DE\  (AC  !^9   =&,  &EA  !<7@
M4EL  $=8   \50  ,E(" "I0#  G3Q( )E 9 "50(  D4"@ (U O ")1-P A
M44  (%%) !Y24P =4E\ '%)M !I3?0 94Y  &%.D !93N0 54]D %E/T !=2
M_P 84?\ &5'_ *-9  "88   CV4  (5H  ![:0  <6D  &9G  !99   36$
M $)?   X7   +EH  "58"  @5PX 'E<4 !U7'  <6", &U@K !I8,P 96#P
M&%A% !994  565L %%EI !-:>@ 26HT $5JA !!:MP .6M4 $%GS !!9_P 1
M6/\ $5C_ )]?  "59@  C&L  ()M  !X;@  ;F\  &)M  !5:@  2&@  #YF
M   S90  *6,  "!A 0 88 L %6 0 !1@%P 38!X $F F !)@+@ 183< $&%
M  ]A2P .85@ #6%F  QB=@ +8HD "F&=  EAL@ (8<L "&'K  E@_0 *7_\
M"U__ )MF  "2;0  B'$  'YS  !U=0  :G0  %QS  !/<@  0W   #AO   M
M;@  )&P  !MK   3:P0 #FH,  UJ$@ ,:AD "VHA  IJ*0 ):C( "&H\  =K
M1P %:U, !&MA  )K<0  :H0  &J8  !JK0  :<8  &GG  !I^   :/\  &C_
M )=M  "-<P  A'<  'MZ  !P>P  8WL  %9Z  !)>@  /7D  #%X   G=P
M'78  !5V   /=@( "78*  1V#P  =A4  '8<  !V)   =2P  '4V  !U00
M=4X  '5<  !U;   =7X  '23  !TJ   <\   '/C  !R]P  <O\  ''_ ))U
M  ")>@  @'X  ':   !I@0  6X(  $Z"  !!@@  -8,  "F"   ?@0  %H$
M !""   *@@   H,'  ""#0  @A$  ((7  ""'@  @B8  ((O  "".P  @D<
M ()5  "!90  @7@  (&-  " H@  ?[H  '_=  !^]   ??\  'W_ (U\  "$
M@0  >X0  &Z&  !@B   4HH  $6+   YC   +(P  "&,   7C   $(T   F.
M   "CP   ) #  "/"0  CPX  (\2  "0&   D!\  ) H  "0,@  D#\  )!-
M  "070  CW   (^%  ".G   CK,  (W0  ",\   B_X  (O_ (B$  " B
M<HL  &2-  !6D   2),  #N5   NE@  (I8  !>7   /F   ")D   ";
MG0   )T   "= P  G0D  )T-  ">$0  GA<  )\?  "?*0  H#4  *!#  "@
M5   H&8  )][  ">DP  GJL  )W&  "=Z0  G/D  )S_ (.+  !UC@  9Y(
M %F6  !+F0  /9P  #">   CGP  %Z    ZB   'I    *8   "H    J@
M *H   "J    JP$  *L'  "L#   K1   *X6  "O'@  L2D  +$X  "Q2
ML5H  +%O  "QB   L:   +"Z  "OW0  K_(  *_] 'B1  !JE@  7)H  $V?
M   _HP  ,:8  ".G   7J0  #JL   6N    L    +(   "U    MP   +<
M  "X    N0   +H   "\ P  O0D  +X.  # %   PQX  ,4K  #%/   QDX
M ,9B  #&>@  QI0  ,:M  #&R   Q>4  ,7S &R9  !>G@  3Z0  $&H   R
MK   )*\  !:Q   -M    [<   "Z    O0   ,    #$    Q@   ,8   #(
M    R0   ,L   #,    S@   - &  #3#0  V!,  -P>  #>+0  WT   .!4
M  #A:P  X84  .&?  #AMP  X<\  .'F &"A  !2IP  0ZT  #2R   EM0
M%[D   V\   !OP   ,,   #'    R@   ,\   #3    U@   -<   #:
MW    -\   #A    XP   .8   #I 0  [ L  / 2  #S'P  ]#$  /9&  #W
M7   ^'0  /B/  #YI@  ^;@  /C) /\ #0#_  L _P + /\ #@#_ !, _P ?
M /\ + #_ #D _P!% /\ 4 #_ %D _P!B /\ :@#_ '$ _P!W /\ ?@#_ (0
M_@"* /T D #\ )< ^@"> /D IP#W +$ ]@"^ /4 T@#S .P \0#^ /  _P#P
M /\ Y@#_ -P _P#2 /\ S0#_ /\ !P#_  0 _P " /\ !@#_ !  _P ; /\
M)P#_ #, _P _ /\ 2@#^ %0 ^P!= /D 9 #W &L ]0!R /, > #R 'X \ "$
M .\ B@#M )$ [ "9 .H H0#H *L Y@"V .0 QP#B ., X #W -X _P#= /\
MV0#_ ,P _P#% /\ P0#_ /\   #_    _P   /\  0#_  T _P 6 /P (@#Y
M "X ]@ Y /, 10#O $X [ !7 .D 7@#F &4 Y !L .( <@#@ '< WP!^ -T
MA #; (L V "2 -4 FP#2 *0 SP"O ,T O@#+ -4 R0#O ,< _P#% /\ Q #_
M +X _P"X /\ M0#_ /\   #_    _P   /X   #W  D \0 1 .L ' #G "@
MY  S .$ /@#= $@ V !1 -, 6 #0 %\ S@!E ,P :P#* '$ R !W ,8 ?0#$
M (0 P@", ,  E "^ )X NP"H +D M@"W ,@ M0#F +, ^@"Q /\ L #_ +
M_P"L /\ J0#_ /\   #_    ^@   /$   #H  , X  - -@ %@#1 "( S0 M
M ,H -P#& $$ P@!* +\ 4@"] %D N@!? +@ 90"W &H M0!P +, =@"Q 'T
MKP"% *T C0"K )< J0"A *< K@"E +X H@#8 *  \@"? /\ G@#_ )X _P">
M /\ G #_ /\   #W    ZP   .$   #6    RP ) ,4 $0"_ !L NP F +<
M,0"T #H L0!# *X 2P"K %( J0!8 *< 7@"F &0 I !I *( < "@ '8 G@!^
M )P A@": )  F "; )8 IP"4 +8 D@#* )  Z0"/ /P C@#_ (T _P", /\
MC0#_ /@   #I @  VP,  ,P!  #$    O0 " +8 #0"P !4 JP @ *< *@"D
M #0 H0 \ )X 1 "< $L F@!2 )@ 6 "6 %T E0!C ), :0"1 '  CP!W (T
M@ "+ (H B0"5 (< H0"% *\ @P#! ($ X "  /4 ?P#_ '\ _P!_ /\ ?P#_
M .X*  #<#@  RA   +X.  "U"P  KP,  *D !P"C !  G@ 8 )D (P"6 "P
MDP U )  /@". $4 C !+ (H 40"( %< A@!= (4 8P"# &H @0!Q '\ >@!]
M (0 >P"/ 'D G !W *H =0"[ '0 U !R /  <@#_ '( _P!Q /\ <0#_ .,1
M  #-%P  OQD  +,9  "J%0  HQ   )T*  "7 0H D0 2 (T &P") "4 A0 O
M (, -P"  #X ?@!% 'T 2P![ %$ >0!7 '@ 70!V &0 = %K '(!= !P G\
M;@*+ &P#F !K Z8 :02W &@%S@!G!^P 9@C] &8)_P!E"?\ 90G_ -8:  #$
M(   MB,  *LC  "A(   F1L  )(4  ",#@$ A@<- ( $% !\!AX >0<H '8(
M, !T"#@ <@D_ ' )10!O"DP ;0I2 &P*6 !J"U\ : MG &<+< !E#'H 8PR'
M &(,E0!@#:0 7PVV %X-S@!<#NT 7 __ %L0_P!;$/\ 6Q#_ ,TA  "\*
MKRL  *0K  ":*0  DB0  (D?  ""&   >Q$% '4-#P!Q#1< ;@XA &L.*@!I
M#S( 9Q Y &400 !D$$8 8Q!- &$04P!?$5H 7A%B %P1:P!;$78 61*# %@2
MD@!6$Z( 51.T %03RP!3%.P 4A7_ %(6_P!2%?\ 4A7_ ,8H  "V+@  J3(
M )\R  "5,0  C"T  (,G  !Z(0  <AH  &L3"P!G$Q, 9!0< &$4)0!?%2T
M714T %P5.P!;%D( 619( %@63P!6%U8 51=> %,79P!2&'( 4!A_ $\9C@!.
M&I\ 3!JP $L;QP!+&^D 2AS] $H<_P!*'/\ 2AS_ ,$M  "Q-   I3<  )HX
M  "0-P  AS0  'TO  !T*0  ;",  &0<!P!>&1  6QH8 %D;(0!7&RD 51LP
M %0<-P!2'#T 41Q$ $\=2P!.'5( 31U: $L>8P!*'FX 21]\ $<?BP!&()P
M12&N $0AQ !#(N8 0R+\ $,B_P!#(O\ 0R+_ +PR  "M.   H3P  )<^  "-
M/0  @SH  'DU  !O,   9BH  %XD @!7( T 5" 4 %$@'0!/(24 3B$L $PA
M,P!+(CH 22)  $@B1P!'(DX 1B-7 $0C8 !#)&L 0B1Y $$EB  _)ID /B:K
M #TGP0 ])^, /2CZ #TH_P ])_\ /2?_ +@V  "J/0  GD   )1"  "*0@
M@#\  '8[  !L-@  8C   %DJ  !1)0L 3241 $LE&0!))2$ 1R8H $4F+P!$
M)C8 0R8] $(G1 !!)TL /RA4 #XH70 ]*6D /"EV #LJA@ Y*Y< ."NI #<L
MOP W+.  -RSX #<L_P W+/\ ."S_ +4Z  "G0   G$0  )%&  "'1@  ?40
M '-   !H.P  7S8  %4Q  !,*P< 1RD/ $4J%@!#*AX 02HE #\J+  ^*S,
M/2LY #PK00 [+$@ .BQ1 #DM6P X+F8 -BYS #4O@P T+Y4 ,S"G #(PO0 Q
M,=X ,3'W #(Q_P R,/\ ,S#_ +$^  "D1   F4@  (]*  "%2@  >TD  '!%
M  !E0   6SL  %(V  !(,00 0BX- #\N$P ]+AL .RXB #DO*0 X+R\ -R\V
M #8P/@ U,$8 -#%/ #,Q60 R,F0 ,3)Q # S@0 O-), +C2F "PUNP L-=L
M+#7U "TU_P M-/\ +C3_ *Y!  "B2   ETP  (U.  "#3@  >4T  &Y*  !B
M10  6$   $X\  !%-P  /3,+ #DS$0 W,Q@ -C,? #0S)@ S,RT ,C0T #$T
M/  P-40 +S5, "XV5@ M-F( +#=O "LW?P J.)$ *#BD "<YN0 F.=@ )SGT
M "@Y_P H./\ *3C_ *M%  "?2P  E$\  (M2  "!4P  =U(  &Q/  !?20
M5D8  $Q"  !"/0  .#@( #0X#P R.!4 ,3@= "\X)  N."L +3DR "PY.0 K
M.D$ *CI* "D[5  H.U\ )SQM "4\?0 D/8\ (SVB "(]MP A/M0 (3[S "(]
M_P C/?\ (SS_ *A)  "=3P  DE,  (E6  !_5P  =58  &I3  !=3P  4TP
M $I(  ! 1   -D % "\]#0 M/1, *ST: "H^(0 I/B@ *#XO "<^-P F/S\
M)#]( "- 4@ B0%T (4%J "!!>@ >08T '4*@ !Q"M0 ;0M$ &T+Q !Q"_P =
M0?\ 'D'_ *5-  ":4P  D%@  (9;  !]7   <EL  &=8  !;5   45(  $A.
M   ]2@  ,T<  "I#"P F0Q  )4,6 "1#'@ C1"4 (D0L "%$-  @13P 'D5%
M !U%3P <1EH &T9H !E&>  81XH %T>> !9'LP 42,X %4?O !9'_P 71O\
M%T;_ *)2  "76   C5T  (1@  !Z80  <&   &5>  !96@  3U@  $14   Y
M40  +TX  "9+!@ @2@X 'DH3 !U*&@ <2B$ &TLH !I+,  92S@ %TM" !9,
M3  53%< %$QE !--=0 238@ $4V< !!-L0 .3LP #TWN !!-_P 13/\ $4S_
M )Y7  "470  BV(  (%E  !W9@  ;68  &-D  !680  2EX  #];   U6
M*U8  ")4 0 :4@H %E(0 !52%@ 44AT $U(D !)2+  14C0 $5(^ !!32  /
M4U0 #E-B  U4<@ ,5(0 "U28  E4K0 (5,4 "53G  I3^P +4O\ "U+_ )M=
M  "19   B&@  'YK  !T;   :VP  %]J  !29P  160  #IB   P8   )EX
M !U=   56P4 $%H,  Y:$0 .6A@ #5L@  Q;)P +6S  "ELZ  E;10 '6U$
M!EM>  1;;0 #6X   5N4  !;J   6\   %KB  !:]@ !6O\  EG_ )=D  ".
M:P  A&X  'MP  !R<@  9W$  %EP  !,;@  0&P  #5K   J:0  (6<  !AF
M   19@$ #&4*  =E#P $910  V0;  )D(P  9"P  &0U  !D0   9$P  &1:
M  !D:0  9'L  &2/  !CI   8[L  &+=  !B]   8O\  &'_ )-L  ")<0
M@'4  'AW  !M>   8'<  %)V  !&=0  .70  "YT   C<@  &G$  !)Q   -
M<0  !G$(  !P#0  <!(  ' 7  !O'P  ;R8  &\P  !O.P  ;T<  &]4  !O
M9   ;W4  &Z*  !MH   ;;8  &S6  !K\@  :_\  &O_ (YS  "%>   ?7L
M '-]  !E?@  6'X  $M^   ^?@  ,GX  "9]   <?   $WP   U\   &?0
M 'T%  !\"P  ? \  'P3  !\&0  ?"$  'PI  !\-   >T   'M.  ![7@
M>V\  'J$  !ZF@  >;$  'C.  !W[P  =OX  ';_ (EZ  "!?P  >((  &N#
M  !=A0  3X8  $*'   UB   *8<  !V'   4AP  #8@   :)    B@   (H
M  ")!@  B0P  (D/  ")$P  B1H  (HB  "*+   BC@  (I&  ")5@  B6@
M (E\  "(E   AZL  (;&  "%Z@  A?L  (3_ (6"  !]A@  ;X@  &&+  !3
MC0  18\  #B1   KD0  'Y(  !22   -DP  !)0   "6    EP   )@   "7
M    EP4  )<+  "8#@  F!,  )D:  "9(@  FBX  )H]  "930  F5X  )ES
M  "8BP  F*,  )>\  "6X@  EO<  )7_ (")  !RC   9(\  %:3  !(E@
M.ID  "R:   ?FP  %)P   R>   #GP   *$   "C    I0   *4   "E
MI0   *8"  "G"   IPT  *@1  "I&0  JR,  *LQ  "K00  K%,  *QG  "K
M@   JIH  *JS  "JT   J>\  *G[ '6/  !GE   69@  $J<   \GP  +:(
M ""C   3I0  "Z<   &I    JP   *X   "Q    L@   +(   "S    M
M +4   "V    N 0  +D+  "[$   O1@  +\D  "_-0  P$<  ,!;  # <@
MP(T  ,&F  # P0  O^,  +[S &J7  !;G   3:$  #ZE   OJ0  (:L  !.M
M   +L    +,   "U    N    +P   "_    P0   ,$   ##    Q    ,8
M  #'    R0   ,L   #."   T0\  -48  #8)P  V3D  -I-  #;9   VWX
M -R9  #<L   W,D  -SC %V?  !/I0  0*H  #*O   BL@  %+4   JX
MNP   +\   ##    Q@   ,L   #.    T0   -$   #4    U@   -D   #;
M    W@   .    #D    YP8  .L.  #O&0  \"H  /(_  #S50  ]&T  /2(
M  #TH0  ]+8  /3' /\ "0#_  8 _P ' /\ # #_ !$ _P < /\ * #_ #0
M_P!! /\ 3 #_ %4 _P!= /\ 90#_ &P _P!R /X > #\ 'X ^P"$ /H BP#Y
M )( ]P"9 /8 H@#T *P \P"Y /$ RP#P .@ [@#[ .T _P#L /\ X0#_ -(
M_P#) /\ Q #_ /\  0#_    _P   /\ ! #_  X _P 7 /\ (P#_ "\ _P [
M /T 1@#Z %  ]P!8 /0 7P#R &8 \ !L .\ <@#M '@ [ !^ .H A0#I (P
MYP"3 .4 G #C *8 X0"Q -\ P0#= -T VP#T -D _P#6 /\ SP#_ ,0 _P"]
M /\ N0#_ /\   #_    _P   /\   #_  L _  3 /< '@#T "H \@ U .X
M0 #I $H Y@!2 ., 60#@ &  W@!F -P ; #: '( UP!X -0 ?@#2 (4 T "-
M ,X E0#, )\ R0"J ,< N #% ,T PP#K ,  _@"_ /\ O@#_ +8 _P"P /\
MK0#_ /\   #_    _P   /D   #R  8 ZP / .8 &0#A "0 W@ O -H .0#3
M $, SP!, ,P 4P#) %H QP!@ ,4 9@## &L P0!Q +\ =P"] 'X NP"& +D
MC@"W )@ M0"C +, L "Q ,( K@#@ *P ]P"K /\ J@#_ *@ _P"C /\ H #_
M /\   #_    ]0   .L   #A    U@ , ,\ $P#* !X Q@ I ,( ,P"_ #T
MNP!% +@ 30"V %0 LP!: +$ 7P"P &4 K@!J *P < "K '< J0!_ *< AP"E
M )$ HP"< *  J0"> +@ G #. )H [@"9 /\ EP#_ )8 _P"6 /\ DP#_ /T
M  #Q    Y0   -D   #-    Q  & +T #P"W !@ LP B +  + "M #8 J0 ^
M *< 1@"D $T H@!3 *  60"? %X G0!D )L :@": '  F !W )8 @ "4 (H
MD0"5 (\ H@"- +  BP## (D XP"( /D A@#_ (8 _P"& /\ A@#_ /,   #C
M    T0   ,4   "]    M@   *X "P"H !( I  < *  )@"< "\ F@ W )<
M/P"5 $8 D@!, )$ 4@"/ %@ C0!= (L 8P"* &H B !Q (8 >0"$ (, @@"/
M '\ FP!^ *D ? "[ 'H U0!X /( > #_ '< _P!W /\ =P#_ .<'  #1#
MPPT  +@,  "N"   J    *( !0";  X E@ 5 )( 'P". "@ BP Q (@ .0"&
M $  A !& (( 3 "  %( ?P!7 'T 70![ &, >@!K '@ <P!V 'T = "( '$
ME0!P *0 ;@"T &P R@!K .H :@#\ &H _P!J /\ :@#_ -H0  #&%   N!8
M *T5  "D$@  G X  )8'  "0  D B@ 0 (4 & "! "$ ?@ J 'L ,@!Y #D
M=P!  '4 1@!S $P <@!1 '  5P!N %X ;0!E &L ;@!I '< 9P"# &4 D0!C
M )\ 8@"O &  Q !? .0 7P'X %X"_P!> O\ 7@+_ ,X8  "]'0  L"   *4?
M  ";'   DQ<  (L1  "$#   ?@0+ 'D $@!U !L <@ C &\ *P!M 3, :P$Z
M &D"0 !G T8 9@-, &0$4@!C!%D 801@ %\%:0!>!7, 7 9_ %H&C0!9!YP
M5PBM %8(P0!5">$ 5 OV %0+_P!4"_\ 5 O_ ,8?  "V)0  J2@  )XH  "4
M)0  BR$  (,;  ![%   = X# &X)#0!I"!0 9@D= &0*)0!B"BT 8 LT %X+
M.@!="T  6PQ' %H,30!8#%0 5PU< %4-9 !4#6\ 4@U[ % .B@!/#IH 3@ZL
M $P/P@!,$., 2Q#Y $L0_P!+$?\ 2Q#_ +\F  "P*P  I"\  )DO  "/+0
MABD  'TD  !T'@  ;!<  &41!P!?#A  7 \7 %H0'P!8$"< 5A N %00-0!3
M$#L 4A%" % 12 !/$5  3A%7 $P28 !+$FL 21)X $@3AP!&$Y< 112I $04
MO@!#%=\ 0Q;X $,6_P!#%O\ 0Q;_ +HK  "K,0  H#0  )4U  "+-   @3$
M '@K  !O)@  9B   %X9 0!7% T 5!03 %$4&P!/%2, 3A4J $P5,0!+%C<
M218^ $@61 !'%TP 11=4 $0770!#&&< 01AT $ 9@P _&I0 /1JF #P;NP [
M&]L .QSV #P<_P \'/\ /!S_ +4P  "H-@  G#D  )$[  "'.@  ?C<  ',R
M  !J+0  82<  %DA  !1&PD 3!D0 $H:%P!(&A\ 1AHF $4;+0!#&S, 0ALZ
M $$<00! '$@ /AQ0 #T=60 \'F0 .QYQ #D?@  X'Y( -R"D #8@N  U(=8
M-2'T #4B_P U(?\ -B'_ +(T  "D.@  F3X  (\_  "%/P  >SP  ' X  !G
M,@  72T  %0H  !,(@4 1A\. $,?% !!'QL /Q\B #X@*0 ](#  .R V #HA
M/0 Y(44 .")- #<B5P V(V( -"-N #,D?@ R)(\ ,26B "\EM@ O)M( +R;R
M "\F_P P)O\ ,";_ *\X  "B/@  ED(  (Q#  ""0P  >$$  &X]  !C.
M6C,  %$N  !(* $ 0"0, #TC$0 [)!@ .20? #@D)@ V)"P -24S #0E.@ S
M)D( ,B9* #$G5  P)U\ +RAL "XH>P L*8T *RJ@ "HJM  I*L\ *2OP "HK
M_P J*O\ *RK_ *P\  "?0@  E$8  (I'  " 1P  =D4  &Q"  !A/0  5S@
M $XS  !$+@  /"D) #<H$  U*!4 ,R@< #(H(P P*"D +RDP "\J-P N*C\
M+2M( "PK4@ K+%T *BQJ "@M>0 G+8L )BZ> "4NLP D+\T )"_N "4O_P E
M+_\ )B[_ *D_  "=10  DDD  (A+  !^3   =$H  &I'  !>0@  5#T  $LY
M  !!-   ."\& #(M#0 P+1, +BT9 "TM(  K+2< *BXN "DN-0 I+ST *"]&
M "<P3P E,%L )#%H ",Q=P B,HD (3*= !\SL0 >,\L 'C/M !\S_P @,_\
M(3+_ *9#  ":20  D$T  (9/  !\4   <T\  &A,  !<1@  4D,  $D_   _
M.P  -C8" "XR#  K,A$ *3(7 "@R'@ F,B0 )3,K "0S,@ C-#H (C1# "$U
M30 @-5@ 'S9E !XV=0 <-X< &S>; !HWKP 9.,@ &3CK !HX_P ;-_\ &S?_
M *-'  "830  CE$  (13  ![5   <5,  &90  !:3   4$D  $=%   ]00
M,ST  "HY"0 E-PX (S<4 "(X&P A."( (#@H !\X,  >.3@ '3E! !PZ2P :
M.E8 &3MC !@[<@ 6.X4 %3R9 !0\K0 3/<8 $SWI !0\_0 5//\ %CO_ *!+
M  "540  BU4  ()8  !Y60  ;E@  &16  !840  3D\  $5+   Z1P  ,$,
M "= !0 @/@T '3X1 !P^%P ;/AX &CXE !D^+0 8/S4 %C\^ !4_2  40%,
M$T!@ !)!<  108( $$&7  ]!K  .0L0 #D+G  ]!_  00?\ $$#_ )U0  "3
M5@  B5H  (!=  !V7@  ;%T  &);  !65P  3%4  $%1   V3@  +$L  "-(
M   ;10D %T0/ !5$%  411L $T4B !)%*0 113$ $44[ !!&10 /1E  #D=>
M  U';0 ,1W\ "T>3  E'IP (1[X "$?@  E']@ *1O\ "T;_ )I5  "06P
MAV   'UB  !S8P  :F(  &!A  !37@  1UH  #Q7   R50  *%(  !]0   7
M3@0 $4P,  ],$0 .3!< #DP>  U-)0 ,32X "TTW  I-0@ )34T !TY:  9.
M:0 $3GL  DZ/  %.I   3;H  $W;  %-\@ !3?\  DS_ )9;  "-8@  A&8
M 'IH  !Q:0  :&D  %QG  !/9   0F$  #=?   M7   (UH  !I8   25P$
M#58)  E5#@ '51, !E4:  15(@ #52H  E4T  !5/@  54H  %97  !690
M57<  %6+  !5H   5;8  %34  !4\0  4_T  %/_ )-B  "*:   @&P  '=N
M  !O;P  8VX  %9L  !):@  /6@  #)F   G90  '6,  !5B   .80  "6 (
M  -@#0  7Q$  %\7  !?'@  7R8  %\O  !?.@  7T4  %]3  !?80  7G(
M %Z'  !=G   7;(  %S/  !<[P  6_T  %O_ )!J  "&;P  ?7(  '5T  !J
M=0  770  $]S  !"<@  -G   "MO   @;@  %VT  !!L   *;    FL&  !K
M"P  :@\  &H4  !J&@  :B$  &DJ  !I-   :4   &E.  !I7   :6T  &B"
M  !HF   9ZX  &;*  !E[0  9?P  &3_ (MQ  ""=@  >GD  '![  !B>P
M57L  $AZ   [>@  +WH  "-Y   9>   $7<   IW   #=P   '<"  !W"
M=@T  '80  !V%0  =AL  '8C  !V+@  =3H  '5'  !U5@  =6@  '1\  !T
MD@  <ZH  '+$  !QZ0  </L  '#_ (9Y  !_?0  =G\  &B!  !:@@  3((
M #^#   RA   )8,  !J#   1@P  "H,   *#    A    (4   "$ P  @P@
M (,-  "#$   @Q4  (0<  "$)@  A#(  (0_  "#3P  @V   ()U  ""C
M@:0  ("]  !_XP  ?OD  '[_ (*   !ZA   ;(8  %Z(  !0B@  0HL  #6-
M   GC0  &XT  !&.   *C@   (\   "1    D@   )(   "2    D@$  )('
M  "2#   DA   ),5  "3'0  E"@  )0V  "410  DU<  )-K  "3@@  DIP
M )&V  "0V   C_,  (__ 'Z'  !PB@  88T  %.0  !%DP  -Y4  "F6   <
MEP  $9@   F9    FP   )P   ">    H    *    "@    H    *$   "A
M!   H@D  *,.  "D%   I1T  *8J  "F.@  IDP  *5@  "E>   I9(  *2L
M  "DR0  H^L  *+Z '..  !DD0  5I4  $>9   YG   *IX  !V@   1H0
M"*,   "E    IP   *D   "L    K@   *X   "N    KP   +    "Q
ML@   +,&  "U#0  MQ,  +D>  "Y+@  ND   +I4  "[:@  NH4  +FA  "Y
MNP  NMX  +GR &>5  !8F0  2IX  #NB   LI@  ':@  !&J   'K    *\
M  "Q    M    +@   "[    O    +P   "^    OP   ,    #"    Q
M ,8   #( P  RPL  ,\2  #1(   T3(  -)&  #370  U'8  -22  #5JP
MU<0  -3B %N=  !,H@  /:<  "^L   ?KP  $;$   >U    N    +L   "^
M    P@   ,<   #*    S    ,P   #.    T    -(   #5    V    -L
M  #?    X@   .8+  #K$P  ["0  .TX  #N3@  [V<  /""  #PG   \+(
M /'% /\  P#_  $ _P $ /\ "0#_  \ _P 8 /\ ) #_ #  _P \ /\ 1P#_
M %$ _P!9 /\ 8 #] &< _ !M /H <P#Y 'D ^ !_ /8 A0#U (P \P"4 /(
MG0#P *< [@"S .P Q #K .$ Z@#X .D _P#G /\ V0#_ ,L _P#" /\ O0#_
M /\   #_    _P   /\   #_  P _P 4 /\ ( #_ "L _@ W /H 0@#V $L
M\@!3 /  6P#N &$ [ !G .H ;0#H ', YP!Y .4 ?P#C (8 X0". -\ E@#=
M *  VP"L -@ NP#4 -$ TP#P -  _P#. /\ R #_ +T _P"V /\ L@#_ /\
M  #_    _P   /\   #]  @ ]P 0 /, &@#O "8 [0 Q .@ .P#C $4 X !-
M -P 50#9 %L U@!A -, 9P#1 &P SP!R ,T > #+ '\ R0"' ,< D #% )H
MPP"E ,  L@"^ ,4 O #E +H ^P"X /\ MP#_ +  _P"I /\ I0#_ /\   #_
M    _@   /4   #L  , Y0 - -\ %0#: "  U  J -  -0#+ #X R !' ,4
M3@#" %4 P !; +X 80"\ &8 N@!L +@ <@"V '@ M0"  +, B "Q )( K@">
M *P J@"I +L J #5 *8 \P"D /\ HP#_ *$ _P"; /\ F #_ /\   #[
M\    .4   #8    S@ ) ,< $0#" !H O@ D +L +@"W #@ M !  +$ 2 "N
M $X K !4 *H 6@"I %\ IP!E *4 :P"D '$ H@!X *  @0"> (L G "6 )D
MHP"7 +( E@#' ), Z "2 /X D0#_ )  _P"- /\ BP#_ /D   #K    W0
M ,\   #&    O  $ +4 #0"P !4 K  > *@ * "E #$ H@ Y )\ 00"= $@
MFP!. )D 4P"7 %D E@!> )0 9 "2 &H D !Q (X >@", (, B@"/ (@ G "&
M *H A "\ (( W "! /8 @ #_ '\ _P!_ /\ ?@#_ .P   #:    R0   +X
M  "V    K@   *< "0"A !  G  8 )@ (@"5 "H D@ R )  .@"- $$ BP!'
M (D 30"' %( A@!8 (0 70"" &0 @0!K '\ <P!] 'T >P"( '@ E0!V *,
M=0"T ', S !Q .T < #_ '  _P!P /\ < #_ -\%  #*"@  O L  +$)  "H
M!   H0   )L  P"4  P CP 3 (H &P"' "0 A  L ($ ,P!_ #H ?0!! 'L
M1P!Y $P =P!2 '8 5P!T %T <@!D '  ;0!O '8 ; "" &H CP!I )T 9P"N
M &4 PP!D .0 8P#Z &, _P!B /\ 8P#_ - .  "_$@  LA,  *<2  "=$
ME0L  (\#  ")  < @@ . 'X %0!Z !X =@ E '0 +0!Q #0 ;P Z &X 0 !L
M $8 :@!, &D 4@!G %@ 9@!? &0 9P!B '$ 8 !\ %X B0!< )@ 6P"I %D
MO !8 -P 6 #T %@ _P!7 /\ 5P#_ ,86  "V&@  JAT  )\<  "5&0  C10
M (4/  !^"0  =P$* '( $ !N !< :@ ? &@ )P!E "X 9  T &( .P!@ $
M7P!& %T 3 !< %, 6@!: %@ 8@!7 &P 50!W %, A0!2 )0 4 &E $\!N !.
M M( 303P $T%_P!-!?\ 307_ +\=  "P(@  HR4  )DE  "/(@  A1T  'T8
M  !U$@  ;@T" &<&# !C Q$ 7P(9 %T#(0!;!"@ 600O %<%-0!6!3L 5 9!
M %,&1P!1!DX 4 =5 $X'7@!-"&< 2PAS $D)@0!("9( 1PJC $4*M@!$"]
M1 SO $,-_P!##?\ 1 W_ +DD  "J*0  GBP  )0L  "**@  @"8  '<A  !N
M&P  9A0  %\/!0!9"PT 50H3 %,+&P!1"R( 3PPI $T,+P!,##8 2PT\ $D-
M0@!(#4D 1@U1 $4.6@!$#F0 0@YP $ .?P _#Y  /A"B #P0M@ [$-$ .Q'Q
M #L1_P [$?\ /!'_ +0I  "F+P  FC(  ) R  "&,0  ?"T  '(H  !I(P
M81T  %D6  !1$0@ 3 \0 $H0%@!($!T 1A D $40*P!#$3$ 0A$W $$1/@!
M$44 /A)- #T25@ \$F$ .A-M #D3?  W%(T -A2? #45LP T%<T ,Q;N #06
M_P T%O\ -!;_ *\N  "B-   ES<  (PX  ""-@  >#0  &XN  !E*@  7"0
M %0>  !,& 0 1A0- $(4$@! %!D /Q0@ #T5)P \%2T .Q4T #D6.@ X%D(
M-Q9* #874P U%UX ,QAJ #(9>0 P&8H +QJ= "X:L0 M&\H +1OL "T<_P N
M&_\ +AO_ *PR  "?.   E#L  (H\  " /   =CD  &LT  !B+P  62H  % E
M  !''P  0!H* #P9$  Z&18 .!D= #8:(P U&BD -!HP #,:-P R&SX ,1M'
M "\<4  N'5L +1UG "P>=@ J'H@ *1^; "@?K@ G(,< )B#J "<@_@ H(/\
M*"#_ *DV  "=/   DC\  (=!  !]0   =#X  &DZ  !?-0  5C   $TK  !$
M)0  .R ' #8>#@ S'A, ,AX9 # >(  O'B8 +A\M "T?-  L(#L *R!$ "HA
M3@ I(5@ )R)E "8B=  E(X4 (R.9 "(DK0 A),4 (27H "(E_0 B)/\ (R3_
M *8Z  ":/P  CT,  (5%  ![1   <D,  &<_  !=.@  4S8  $HQ  !!+
M."8# #$C#  N(A$ +"(6 "HB'0 I(B, *",J "<C,0 F)#D )25! "0E2P C
M)E8 (B9C "$G<@ ?)X, 'BB7 !THJP ;*<, &RGF !PI^P =*?\ 'BC_ *,^
M  "80P  C4<  (-)  !Z20  <$<  &9$  !:/P  43L  $<W   ^,@  -2T
M "PH"0 H)P\ )R<4 "4G&@ D)R$ (R@G "(H+@ A*38 ("D_ !\J20 >*E0
M'2M@ !LK;P :+($ &2R5 !<MJ0 6+<$ %BWD !<M^@ 8+?\ &2W_ *%!  "5
M1P  BTL  ()-  !X30  ;DP  &1)  !81   3T   $8]   ].   ,S0  "HO
M!@ D+ T (2P2 " L&  ?+1X 'BTE !TM+  <+C0 &RX\ !HO1@ 8+U$ %S!>
M !8P;0 5,7\ $S&3 !(QJ  1,K\ $3+B !(R^0 3,?\ $S'_ )Y%  "32P
MB4\  (!1  !V4@  ;5   &).  !620  348  $1#   [/P  ,3H  "<V P ?
M,@L '#(0 !LR%0 9,AL &#(B !<S*0 6,S$ %30Z !0T1  3-$\ $C5< !$U
M:P 0-GT #S:1  XVI@ --[P #3?=  TV]@ .-O\ #S;_ )M)  "13P  AU,
M 'Y6  !U5@  :E4  &!3  !53P  3$P  $))   X10  +D$  "0]   <.@@
M%C@. !4X$@ 4.!@ $SD? !(Y)@ 1.2X $#DW  \Z00 ..DP #3M9  T[:  +
M.WH "CN-  D\H@ '/+@ !SS5  @\\  )._\ "CO_ )A.  ".5   A5@  'Q;
M  !R6P  :%H  %Y8  !350  25(  #Y.   T2P  *D<  "%$   80@, $D +
M ! _$  ./Q4 #C\<  U (P ,0"L "T T  I /@ )04H !T%6  9!90 $078
M T&*  %!GP  0;0  $'0  %![@ !0?P  D#_ )54  ",60  @UX  'E@  !P
M8   9F   %U>  !16P  15<  #I4   O40  )4\  !Q,   42@  #D@(  M'
M#@ (1Q( !T<9  9'(  %2"@  T@Q  )(.P  2$<  $A3  !(8@  2',  $B&
M  !(FP  2+$  $?,  !'[0  1_L  $?_ )):  ")8   @&,  '=E  !N9@
M968  %ED  !,8   0%T  #5;   J60  (%<  !=5   04P  "U('  51#0 !
M4!$  % 6  !0'0  4"4  % N  !0.   4$,  %!0  !07@  4&\  %"#  !/
MF   3ZX  $[)  !.ZP  3?L  $W_ (]A  "&9@  ?6D  '1L  !L;0  86L
M %-I  !&9P  .F0  "]C   D80  &E\  !)>   ,7   !EP&  !;"P  6@\
M %H3  !:&0  62$  %DI  !9,P  63\  %E,  !96@  66L  %A^  !8E
M5ZL  %?%  !6Z0  5?L  %7_ (QH  "";0  >G   ')R  !G<@  6G$  $QP
M   _;@  ,VT  "AK   =:@  %&@   UG   '9P   &8#  !F"0  90T  &41
M  !D%0  9!P  &0D  !D+@  9#H  &-'  !C50  8V8  &-Z  !BD   8:<
M &#!  !?Y@  7_H  %[_ (=O  !_=   >'<  &YX  !@>   4G<  $5W   X
M=@  *W8  "!T   6<P  #G,   =R    <@   '(   !Q!0  <0H  '$.  !P
M$0  <!<  ' >  !P)P  <#,  &]   !O4   ;V   &YT  !NBP  ;:(  &R\
M  !KX@  :O@  &G_ (-W  !\>P  <WT  &5^  !7?P  27\  #Q_   O@
M(G\  !=^   /?@  !WX   !_    ?P   '\   !^    ?@4  'X*  !^#0
M?A$  'X7  !^(   ?BL  'TY  !]2   ?5D  'QM  !\A   >YP  'JV  !Y
MV@  >/4  '?_ (!_  !W@@  :8,  %N%  !-A@  /X@  #*)   DB0  &(D
M  ^)   'B@   (L   ",    C0   (T   ",    C    (P#  ","   C0T
M (T1  "-%P  CB(  (XO  "./P  C5   (UD  ",>P  C)4  (NN  "*S0
MB>\  (G_ 'N%  !MB   7HH  %"-  !"CP  -)$  ":2   9DP  #I0   :5
M    E@   )@   ":    FP   )L   ";    FP   )L   "<    G04  )T+
M  ">$   GQ<  * D  "@-   H$8  *!9  "?<   GXH  )ZE  ">P@  G>@
M )SY '",  !ACP  4Y(  $26   VF0  )YL  !F<   /G0  !9\   "A
MHP   *4   "H    J0   *D   "I    J@   *L   "L    K0   *X!  "P
M"0  L@\  +,8  "T)P  M#D  +5-  "T9   M'X  +.:  "SM   L]4  +/P
M &23  !5EP  1YL  #B?   IH@  &J0   ZF   $J    *L   "M    L
M +0   "V    N    +@   "Y    N@   +P   "]    OP   ,    ##
MQ0<  ,D/  #*&@  RRP  ,Q   #-5@  SF\  ,V+  #,J   S,(  ,SB %B;
M  !)H   .J4  "RI   <JP  #ZX   2Q    M    +<   "Z    O@   ,,
M  #&    R    ,@   #*    RP   ,T   #/    T@   -4   #9    W0
M .$%  #F#P  YQX  .@R  #I2   ZF   .M[  #KEP  [*X  .S" /\   #_
M    _P   /\ !@#_  T _P 5 /\ (0#_ "P _P X /\ 0P#_ $P _@!4 /L
M6P#Z &( ^ !H /8 ;@#U '0 ] !Z /( @ #Q (< [P"/ .T EP#K *$ Z0"M
M .< O0#E -@ Y #S .( _P#@ /\ T #_ ,0 _P"\ /\ M@#_ /\   #_
M_P   /\   #_  D _P 1 /\ ' #] "< ^0 R /4 /0#Q $8 [0!/ .L 5@#H
M %P Y@!B .0 : #C &X X0!S -\ >0#= (  V@"( -@ D0#4 )L T@"F ,\
MM #, ,D R0#I ,@ _P#' /\ P0#_ +< _P"O /\ JP#_ /\   #_    _P
M /\   #X  4 \@ . .X %P#J "( Y@ L .$ -P#= $  V !) -, 4 #0 %8
MS@!< ,P 8@#* &< R !M ,8 <P#$ 'D P@"! ,  B@"^ )0 O "? +D K "V
M +X M #= +, ]P"Q /\ L #_ *@ _P"B /\ G@#_ /\   #_    ^0   .\
M  #F    WP + -8 $@#0 !P S  F ,@ , #$ #H P !" +T 2@"[ %  N !6
M +8 6P"U &$ LP!F +$ ; "P '( K@!Z *P @@"I (P IP"8 *4 I0"C +0
MH #+ )\ [@"= /\ G #_ )D _P"4 /\ D0#_ /\   #V    Z@   -T   #/
M    QP & ,  #P"[ !< MP @ +, *@"P #, K0 [ *H 0P"G $D I0!/ *,
M50"B %H H !? )X 90"= &L FP!R )D >P"7 (4 E "0 )( G0"0 *P C@"_
M (P X@"+ /H B0#_ (D _P"& /\ @P#_ /0   #D    U    ,@   "_
MM0 ! *X "P"I !( I0 ; *$ (P"> "P FP T )@ / "6 $, E !) )( 3@"0
M %, C@!9 (T 7@"+ &0 B0!K (< <P"% 'T @P"( ($ E0!_ *0 ?0"U 'L
MSP!Y /$ > #_ '< _P!W /\ =0#_ .4   #1    PP   +@   "O    J
M *  !@":  X E0 5 )$ '@". "8 BP M (@ -0"& #P A !" (( 1P"  $T
M?P!2 'T 6 ![ %X >0!E '@ ;0!V '8 <P"! '$ C@!O )T ;0"N &P Q !J
M .< :0#] &@ _P!H /\ :0#_ -4#  ##!P  M@@  *L&  "B    FP   )0
M  "-  H B  0 (, & !_ "  ?  G 'H +@!W #4 =0 [ '0 00!R $< < !,
M &\ 4@!M %@ :P!? &D 9@!G '  90![ &, B !B )< 8 "G %X NP!= -P
M7 #V %P _P!; /\ 6P#_ ,D-  "Y$   K!$  *$0  "7#0  CP@  (@   ""
M  4 >P - '< $@!S !H ;P A &P * !J "\ :  U &< .P!E $$ 8P!& &(
M3 !@ %( 7P!9 %T 80!; &H 60!U %< @@!5 )$ 5 "B %, M0!1 ,\ 4 #O
M %  _P!0 /\ 4 #_ +\4  "P&   I!H  )D9  "/%@  AQ$  '\-  !W!@
M<0 ( &L #@!G !0 9  ; &$ (@!> "D 70 O %L -0!9 #L 6 !! %8 1@!5
M $T 4P!4 %( 7 !0 &4 3@!P $P ?0!+ (T 20"> $@ L !' ,< 1@#I $8
M^P!& /\ 10#_ +@;  "J(   GB(  ),B  ")'P  @!H  '<5  !O$   : L
M &$$"@!= !  60 6 %8 '0!4 ", 4@ J %  , !/ #4 3@ [ $P 00!+ $@
M20!/ $<!5P!& 6$ 1 )L $,">0!! XD 0 .: #X$K0 ]!,0 / 7E #P'^  \
M!_\ / ?_ +(B  "E)P  F2D  (XI  "$)P  >R,  '$>  !I&   81(  %H-
M P!3" P 3P41 $P%%P!*!AX 2 8D $<&*@!%!S  1 <V $,(/0!!"$, 0 A+
M #X)4P ]"5T .PIH #H*=@ X"X< -PN9 #4+K  T#,( ,PSD #,-^0 S#?\
M- W_ *TG  "@+   E2\  (LO  " +@  =RH  &TE  !D(   7!H  %04  !,
M#P8 1@P- $,,$@!!#!@ /PP? #X,)0 \#2L .PTR #H-.  X#3\ -PY' #8.
M4  T#EH ,PYF #$/=  P#X4 +A"8 "T0JP L$,, *Q'E "P1^@ L$?\ +1'_
M *HL  "=,0  DC0  (<U  !]-   =#$  &HK  !@)P  6"$  $\;  !'%@
M0!$) #L0#P Y$!0 -Q ; #80(0 T$"< ,Q$M #(1-  Q$3L ,!%# "X230 M
M$E< +!)C "H3<0 I$X( )Q25 "84J0 E%<  )!7C "46^@ F%O\ )A7_ *8Q
M  ":-@  CSD  (4Z  ![.0  <38  &<Q  !=+0  5"@  $PB  !#'0  .Q<%
M #44#0 R$Q$ ,107 "\4'0 N%"0 +!0J "L5,0 J%3@ *19  "@62@ G%U0
M)A=@ "08;P C&(  (1F3 " 9IP ?&;X 'AK@ !\:^  @&O\ (!K_ *,T  "8
M.@  C3T  (,^  !Y/0  ;SL  &4W  !;,@  4BT  $DH  ! (P  .!X! # 9
M"@ L& \ *A@4 "D8&@ G&"  )ADG "49+0 D&C4 (QH^ "(;1P A&U( (!Q>
M !\=;  ='7X '!V1 !H>I0 9'KP &!_= !D?]@ :'_\ &Q[_ *$X  "5/0
MBT$  (%"  !W0@  ;4   &,\  !9-P  3S,  $8N   ]*0  -20  "T@!P G
M'0T )1T2 ",=%P A'1T (1TD " >*P ?'C( 'A\[ !T?10 <($\ &B%< !DA
M:@ 8(GL %B*/ !4BHP 4([H $R/: !0C]0 5(_\ %B/_ )X\  "300  B40
M ']&  !U1@  ;$0  &)!  !7/   33@  $0T   \,   ,RL  "HF P C(@L
M("$0 !XA%0 <(AL &R(A !HB*  :(S  &2,X !@D0@ 6)4T %259 !0F:  3
M)GD $B:- !$GH@ 0)[@ #B?6 ! H]  1)_\ $2?_ )Q   "110  AT@  'U*
M  !T2@  :DD  &!&  !500  3#X  $,Z   Z-@  ,3(  "@M   @*0D &R<.
M !DG$@ 8)Q@ %B<? !4H)0 4*"T $R@V !(I0  2*4L $2I7 ! J9@ .*W<
M#BN+  TLGP ,++4 "RS/  PL[P -+/\ #2O_ )E$  "/20  A4P  'Q.  !S
M3P  :4X  %Y+  !31P  2D0  $)    Y/0  +S@  "4T   =, 4 %BT, !0L
M$  3+14 $BT< !$M(P 0+2H #RXS  XN/0 -+T@ #2]5  PP8P *,'0 "3"(
M  @QG  &,;$ !C'+  8QZP ',/P "##_ )=(  "-30  @U$  'I3  !Q5
M9U(  %U0  !23   24H  $!&   U0@  *SX  "(Z   :-P$ $C0)  \S#@ .
M,Q, #3,9  TS(  ,-"@ "S0Q  HU.P (-48 !S52  4V8  $-G$  C:$   V
MF0  -J\  #;(   VZ   -OD  37_ )1-  "*4@  @58  'A8  !O60  95@
M %M5  !14@  1T\  #Q,   Q2   )T0  !Y!   6/P  $#P'  LZ#0 ).A$
M"#L7  8['@ %.R8 !#LN  ([.  !/$,  #Q/   \7@  /&X  #R!   \EP
M/*P  #O%   [YP  ._@  #O_ )%2  "(6   ?UP  '9=  !M7@  8UT  %I<
M  !.6   0E0  #=1   M3@  (TL  !I)   21@  #40&  =##  #0Q   $,5
M  !#&P  0R,  $,K  !#-0  0T   $--  !#6P  0VL  $-^  !#E   0JH
M $+#  !!Y@  0?D  $'_ (Y8  "&7@  ?6$  '-C  !K9   8F,  %=A  !)
M70  /5H  #)8   G50  'E,  !51   .3P  "4T%  )-"P  3 X  $P3  !+
M&   2Q\  $LH  !+,@  2ST  $M)  !+5P  2V<  $I[  !*D   2:<  $G
M  !(Y   2/@  $?_ (M?  "#9   >F<  '%I  !I:@  7FD  %!F  !#9
M-V$  "Q?   A70  &%L  !!9   *6    U<#  !7"0  5@T  %40  !5%0
M5!L  %0C  !4+0  5#D  %1%  !44P  5&0  %-W  !3C0  4J0  %&]  !0
MX@  4/@  $__ (AG  !_:P  =VX  &]P  !E<   5VX  $IL   ]:P  ,&D
M "5H   :9@  $60   MC   $8@   &(!  !A!@  8 L  & .  !?$@  7Q<
M %\>  !>*   7C,  %Y   !>3P  7E\  %UR  !=B   7*   %NY  !:WP
M6?<  %C_ (1N  !\<@  =74  &MV  !==0  3W0  $)S   U<P  *'(  !UP
M   3;P  #&X   1N    ;@   &X   !L @  ; <  &L+  !K#@  :Q(  &H9
M  !J(@  :BT  &HZ  !I20  :5H  &EL  !H@P  9YL  &:U  !EV   9/4
M &3_ (!U  !Z>0  <'L  &)[  !4?   1GP  #E\   L?   'WL  !1Z   -
M>@  !'H   !Z    >@   'H   !Y    >0$  '@&  !X"P  > X  '@3  !X
M&@  >"4  '@R  !W00  =U(  '=E  !V?   =94  '2O  !SS@  <O$  ''_
M 'Y]  !U@   9X$  %B"  !*@P  /(0  "Z%   AA0  %84   V%   #A0
M (8   "'    B    (@   "'    AP   (<   "'!   APD  (<.  "($P
MB!P  (@I  "(.   ATH  (==  "&<P  AHT  (6G  "$Q0  @^P  (+^ 'B$
M  !JA@  7(@  $V*   _C   ,8X  "./   6CP  #9    *1    D@   ),
M  "5    E@   )8   "6    E@   )8   "7    EP   )<'  "8#0  F1,
M )H?  ":+0  FC\  )I2  "::   F8,  )F?  "8N@  E^(  );X &V*  !?
MC0  4)   $&3   SE@  ))<  !:8   -F0   9L   "=    GP   *$   "D
M    I0   *0   "E    I0   *8   "G    J    *D   "J!   K P  *X3
M  "N(0  KC,  *Y'  "N70  KG8  *Z3  "NK@  K<T  *SO &&1  !3E0
M1)@  #6<   FGP  %Z$   VC    I0   *<   "J    K    +    "R
MM    +,   "T    M0   +<   "X    N0   +L   "]    OP$  ,,+  #%
M%0  Q24  ,8Y  #'3P  QV@  ,:%  #&H@  QKP  ,;> %69  !'G0  .*(
M "FF   9J   #:L   "M    L0   +0   "W    N@   +\   #!    Q
M ,,   #%    Q@   ,@   #*    S0   ,\   #2    U@   -L   #@#
MX1@  .,K  #D00  Y5H  .9T  #FD0  Y:P  .7$ /\   #_    _P   /\
M 0#_  H _P 2 /\ '0#_ "@ _P T /\ /@#] $@ ^@!0 /< 5P#U %T ] !C
M /( :0#P &\ [P!T .T >P#K ($ Z0") .@ D@#F )P Y "H .( MP#? ,T
MW #N -D _P#9 /\ R@#_ +X _P"U /\ L #_ /\   #_    _P   /\   #_
M  8 _P / /P & #X ", ]  N /  . #K $( Z !* .4 40#B %@ X != -X
M8P#< &@ V0!N -8 = #4 'L T0"" ,\ BP#- )4 R@"A ,@ KP#% ,$ P@#C
M ,  ^P#  /\ NP#_ +  _P"H /\ I #_ /\   #_    _P   /L   #S  $
M[0 , .@ $P#C !X X  H -H ,@#3 #P SP!$ ,P 2P#) %$ Q@!7 ,0 70#"
M &( P0!G +\ ;0"] '0 NP![ +D A "W (X M "9 +( IP"O +< K0#0 *L
M\@"J /\ J0#_ *$ _P"; /\ EP#_ /\   #_    ]    .D   #@    U0 (
M ,X $ #) !@ Q0 B ,$ *P"\ #4 N0 ] +8 10"S $L L0!1 *\ 5@"N %L
MK !A *H 9@"I &T I@!T *0 ? "B (8 H "2 )X GP"< *X F0## )< YP"6
M /\ E0#_ )( _P"- /\ B@#_ /P   #P    XP   -0   #(    OP # +D
M#0"S !, KP < *P )0"I "X I0 V *, /@"@ $0 G@!* )T 4 "; %4 F0!:
M )< 7P"6 &8 E !L )( =0"0 'X C@"* (L EP") *8 AP"X (4 U@"$ /8
M@@#_ ($ _P!^ /\ ? #_ .T   #=    S    ,$   "X    K@   *< "0"B
M !  G@ 7 )H 'P"7 "< E  O )$ -P"/ #T C0!# (L 20") $X B !3 (8
M60"$ %\ @@!E (  ;0!^ '< ? "" 'H CP!X )X =0"O ', QP!R .P <0#_
M '  _P!P /\ ;@#_ -T   #)    O    +$   "I    H0   )D  P"3  P
MC@ 2 (H &0"' "$ A  I ($ , !_ #< ?0 ] 'L 0@!Y $@ > !- '8 4@!T
M %@ <@!? '$ 9P!O '  ; ![ &H B !H )< 9@"H &4 O !C .$ 8@#Z &$
M_P!A /\ 80#_ ,T!  "\!0  KP4  *4"  "<    E    (T   "&  @ @0 .
M 'P % !X !L =0 C '( *0!P #  ;@ V &T / !K $$ :0!' &@ 3 !F %(
M9 !9 &, 8 !A &D 7P!T %T @0!; )  60"A %< M !6 -  50#R %4 _P!4
M /\ 50#_ ,$,  "R#@  I@\  )L.  "2"P  B04  ((   ![  ( =0 + '
M$ !L !8 :  = &8 (P!C "H 80 P &  -@!> #L 70!! %L 1@!: $P 6 !3
M %8 6P!4 &0 4@!N %$ >P!/ (H 30"; $P K@!+ ,8 2@#J $D _@!) /\
M20#_ +D2  "J%@  GA<  )06  "*$P  @1   'D+  !Q P  :P & &4 #0!A
M !$ 70 8 %H '@!8 "0 5@ J %0 , !3 #8 40 [ %  00!. $< 30!. $L
M5@!) %\ 1P!I $8 =@!$ (4 0P"7 $$ J0!  +\ /P#B #\ ^  ^ /\ /P#_
M +(9  "D'@  F!\  (X?  "$'   >A@  '(2  !J#@  8@@  %P!" !7  X
M4P 3 %  &0!. !\ 3  E $H *P!( #  1P V $8 / !$ $( 0P!) $$ 40 _
M %H /@!E #P <@ Z ($ .0"3 #@ I0 V +H -@#; #4 ]  U /\ -0#_ *P@
M  "?)   E"8  (DF  !_)   =2   &P;  !D%0  7!   %0, 0!.!@H 2@(/
M $< % !$ !H 0@ @ $  )0 _ "L /@$Q #P!-P [ CX .0)% #@#30 V U8
M-01A #,$;@ Q!7X , 60 "\%HP M!K@ + ;4 "P'\  L"/\ + C_ *@E  ";
M*@  D"P  (8M  ![*P  <B<  &@B  !?'0  5Q<  $\2  !(#@0 00H+ #X'
M$  [!A4 .0<; #@'(0 V""8 -0@L #,(,@ R"3D ,0E! "\)20 N"E, + I>
M "L+;  I"WP * R/ "8,H@ E#+< ) S3 ",-\  D#?\ )0W_ *0J  "8+P
MC3(  (,R  !Y,0  ;RX  &4I  !<)   4Q\  $L9  !#$P  /! & #4-#  S
M#!$ ,0P6 "\,'  N#2( +0TH "L-+@ J#34 *0T] "<.1@ F#E  ) Y< ",/
M:@ B#WL (!". !\0H@ =$+< '!#4 !T1\@ =$?\ 'A'_ *$O  "5,P  BC8
M ( W  !V-@  ;3,  &,O  !9*@  4"4  $@@   _&@  .!4  # 1"  L$ X
M*A 2 "@0&  G$!X )1 D "00*@ C$3( (A$Z "$10P @$DX 'A): !T3:  ;
M$W@ &A.+ !@4H  7%+4 %A31 !85\0 7%?\ &!3_ )XS  "3-P  B#H  'X[
M  !T.P  :S@  &$T  !7+P  3BL  $4F   ](0  -!P  "T7!0 F$PP (Q,0
M "(3%0 @$QH 'Q,A !X4)P =%"\ '!4W !L500 :%DL &197 !<790 6%W8
M%!B) !,8G@ 2&+, $1G. !$9[P 2&?\ $QG_ )PV  "1.P  ACX  'P_  !S
M/P  :3T  %\Y  !5-0  3#   $,L   Z)P  ,B(  "H> 0 B&0D 'A<. !P7
M$@ :%Q< &1@> !D8)  8&2P %QDT !8:/@ 5&DD $QM5 !(;8P 1''0 $!R'
M  \=G  .';$ #1W+  T=[  .'?\ #QW_ )DZ  "//P  A$(  'M$  !Q0P
M:$(  %X^  !3.@  2C8  $$R   Y+0  ,2D  "@E   @( 8 &AT, !<<$  5
M'!4 %!T; !0=(@ 3'2D $AXR !$?/  0'T8 $"!3  X@80 -(7$ #"&%  LB
MF0 *(JX "2+'  DBYP *(OL "R'_ )<^  ",0P  @T8  'E(  !P2   9T8
M %Q$  !2/P  23L  $ X   X-   +S   "<L   >)P, %B,* !(A#@ 1(1,
M$"(9 ! B(  /(B< #B,O  TD.0 ,)$0 "R50  HE7@ ))F\ !R:"  8FE@ $
M)JP  R;$  0FY0 $)O< !B;_ )5"  "*1P  @4H  'A,  !O3   94L  %M(
M  !01   1T$  #\^   W.P  +38  "0Q   ;+0  $RH'  \H#0 -)Q$ #2@6
M  PH'0 +*"4 "BDM  DI-P '*D( !BI.  0K7  #*VP  2M_   KE   *ZD
M "O!   KXP  *_8  "K_ ))&  "(2P  ?T\  '91  !M40  8U   %I-  !/
M2@  1T<  #Y$   S0   *3P  " X   7-   $3$%  PO#  )+A  !RX5  8O
M&P %+R,  R\K  (P-0  ,#\  #!,   Q60  ,6D  #%\   QD0  ,:<  #"_
M   PX0  ,/4  "__ )!+  "&4   ?50  '56  !K5@  8E4  %A3  !.4
M14T  #I)   O10  )4(  !P^   4.P  #CD%  DW"P $-@\  383   V&0
M-B   #8I   V,@  -ST  #=)   W5P  -V<  #=Y   WCP  -J4  #:]   V
MX   -?4  #7_ (U0  "$5@  ?%H  ');  !I6P  8%L  %=9  !,5@  0%(
M #5.   J2P  ($@  !=&   00P  "T$$  1 "@  /PX  #X1   ^%@  /AT
M #XF   ^+P  /CH  #Y&   ^5   /F0  #YV   ]C   /:,  #R[   \W@
M._4  #O_ (I7  ""7   >5\  '!A  !H80  7V$  %1>  !'6P  .E<  "]5
M   E4@  &U   !)-   ,2P  !DH#  !)"0  2 T  $<0  !'%   1AH  $8B
M  !&+   1C<  $9#  !&40  1F   $5S  !%B0  1*   $2X  !#W   0O4
M $+_ (A=  !_8@  =V4  &YG  !G:   6V8  $YC  !!80  -%X  "E<   ?
M6@  %5<   Y6   '5    %,!  !2!@  40L  %$.  !0$0  3Q8  $\>  !/
M)P  3S(  $\_  !/30  3ET  $YO  !.A0  39T  $RU  !+V   2O4  $K_
M (5E  !\:0  =&P  &UN  !B;0  5&L  $=I   Z9P  +64  ")D   88@
M$&    E?    7@   %X   != P  7 @  %L,  !:#P  6A,  %D9  !9(@
M62T  %DZ  !92   6%@  %AK  !7@0  5YD  %:R  !5T@  5/0  %/_ (%L
M  !Y<   <W,  &AS  !:<@  3'$  #]P   R;P  )6X  !IL   1:P  "6H
M  !J    :0   &D   !H    9P,  &8(  !F#   9@\  &44  !E'   92<
M &0T  !D0P  9%,  &1E  !C>P  8I0  &&M  !@S0  7_$  %[_ 'UT  !W
M=P  ;GD  %]Y  !1>0  0WD  #9X   I>   ''<  !%V   *=0   '4   !U
M    =@   '4   !T    =    ',"  !S!P  <PP  '(0  !R%0  <B   '(L
M  !R.P  <4P  '%?  !Q=   <(X  &^H  !NQ@  ;.T  &O_ 'M[  !R?@
M9'X  %5_  !'@   .8$  "N"   >@0  $H$   J!    @0   ((   "#
M@P   (,   ""    @@   ((   ""    @@4  ((*  ""#P  @A<  ((C  ""
M,@  @D,  (%6  "!;   @(8  '^A  !^O0  ?>8  'S\ ':"  !H@P  684
M $N'   \B0  +HH  ""+   3BP  "HL   ",    C0   (\   "1    D@
M )$   "1    D0   )$   "1    D@   )("  "3"0  E \  )09  "4)P
ME#@  )1,  "38@  DWP  ).8  "2LP  D=@  )#V &J(  !<B@  38T  #^0
M   PD@  (90  !25   *E@   )<   "9    FP   )T   "?    H    *
M  "@    H    *$   "B    HP   *0   "E    I@<  *@0  "H'   J"T
M *E   "I5@  J6\  *F+  "HJ   I\<  *;L %^/  !0D@  098  #.9   C
MG   %)T   J?    H0   *,   "F    J    *P   "N    KP   *\   "P
M    L    +(   "S    M    +8   "W    N@   +T'  "_$   OQ\  , S
M  # 20  P&(  ,!^  # FP  P+<  +_8 %.7  !$FP  -9\  ":C   6I0
M"Z<   "J    K0   +    "S    M@   +L   "]    P    +\   #!
MP@   ,0   #&    R    ,H   #,    SP   -,   #:!P  VQ,  -TE  #>
M.P  WU,  .!N  #?C   W:D  -W" /\   #_    _P   /\   #_  < _P 0
M /\ &0#_ "0 _P O /P .@#Y $, ]0!+ /, 4@#Q %D [P!> .T 9 #K &D
MZ0!O .< =0#F 'P Y "$ .( C0#@ )< W0"B -H L0#5 ,4 T@#H -  _P#/
M /\ Q #_ +@ _P"O /\ J0#_ /\   #_    _P   /\   #_  ( ^P - /<
M%0#S !\ [P I .H - #F #T X@!% -X 3 #; %, V !8 -0 7@#2 &, T !I
M ,X ;@#, '4 R@!] ,@ A0#& )  P@"; ,  J0"^ +H NP#9 +D ]P"X /\
MM #_ *D _P"B /\ G0#_ /\   #_    _P   /8   #N    YP * .$ $0#<
M !H UP C -  +@#+ #< QP _ ,0 1@#! $T OP!2 +T 6 "[ %T N0!B +@
M: "V &X M !U +$ ?@"O (@ K0"3 *H H0"H +$ I@#( *0 [0"B /\ H@#_
M )L _P"5 /\ D0#_ /\   #\    [@   .,   #8    S0 % ,8 #@#! !4
MO0 > +D )P"U #  L@ X *\ 0 "L $8 J@!, *@ 40"G %8 I0!; *, 80"A
M &< GP!N )X =@"; (  F0", )< F0"4 *@ D@"\ )  WP". /L C@#_ (L
M_P"& /\ @P#_ /@   #I    W    ,P   #!    N    +( "@"L !$ J  8
M *4 (0"B "D G@ R )P .0"9 #\ EP!% )4 2@"4 %  D@!5 )  6@"/ &
MC0!G (L ;P") '@ A@"$ (0 D0"" *  @ "R 'T S !\ /$ >P#_ 'H _P!W
M /\ =0#_ .8   #3    Q@   +L   "Q    IP   *$ !0";  T EP 3 ),
M&P"0 ", C  K (H ,@"( #@ A@ ^ (0 1 "" $D @0!. '\ 4P!] %D >P!@
M 'D : !W '$ =0!\ ', B0!P )@ ;P"I &T OP!K .8 :@#_ &D _P!I /\
M9P#_ -,   ##    M0   *L   "C    FP   )(   ",  H AP 0 (, %@!_
M !T ?0 D 'H *P!X #( =@ X '0 /0!R $( <0!( &\ 30!M %, ; !9 &H
M80!H &H 9@!T &0 @0!A )$ 7P"B %X M@!< -4 6P#W %L _P!: /\ 6@#_
M ,4   "V @  J0(  )\   "6    C@   (<   "   4 >@ , '4 $0!Q !@
M;@ > &L )0!I "L 9P Q &8 -P!D #P 8P!! &$ 1P!? $T 7@!3 %P 6P!:
M &0 6 !N %8 >P!4 (H 4@"; %$ K@!0 ,@ 3P#N $X _P!. /\ 30#_ +L*
M  "L#0  H T  )4,  ","   @P(  'P   !U    ;@ ( &D #@!E !, 8@ 9
M %\ 'P!= "4 6P K %D ,0!8 #8 5@ [ %4 00!3 $< 40!. %  50!. %X
M3 !H $H =0!( (0 1P"5 $4 J !$ +\ 0P#D $( _ !" /\ 0@#_ +(1  "E
M%   F14  (X3  "$$0  >PT  ',(  !L    90 # %\ "P!;  \ 5P 4 %0
M&@!1 !\ 3P E $X *P!, #  2P V $D / !( $( 1@!( $4 4 !# %D 00!C
M #\ ;P ^ 'X / "0 #L HP Z +@ .0#9 #@ ]0 X /\ . #_ *P7  "?&P
MDQT  (D<  !_&0  =14  &P0  !D#   708  %8 !@!1  P 30 0 $H %0!'
M !H 10 @ $0 )@!" "L 00 Q #\ -@ ^ #T / !$ #L 2P Y %0 -P!? #8
M:P T 'H ,@", #$ G@ P +, +P#. "\ [P N /\ +@#_ *<>  ":(@  CR0
M (0D  !Z(0  <1T  &<8  !?$P  5PX  % *  !) P@ 10 - $$ $0 ^ !8
M/  ; #H (0 Y "8 -P L #8 ,@ T #@ ,P _ #$ 1P P %  +@!; "T 9P K
M '8 *@"( "@ G  G +  )@#) "4 Z@ E ?L )0'_ *(C  "6*   BRH  ($J
M  !W*   ;24  &0@  !;&P  4A4  $L0  !## ( /0<) #D##@ V 1( ,P$7
M #$!'  P 2( +P(G "T"+0 L S0 *@,[ "D$0P H!$T )@58 "4%90 C!G0
M(@:& " &F@ ?!ZX '@?& !T'YP ="/@ '0G_ )\H  "3+0  B"\  'XO  !T
M+@  :BL  &$F  !8(0  3QP  $<7   _$@  . X$ #$+"@ N" X *P<2 "D'
M%P H"!T )P@C "4(*0 D"3  (PDW "$*0  @"DH 'PM5 !T+8@ ;#'( &@R%
M !@,F0 7#*T %@S& !4-Y@ 5#?D %@W_ )PM  "0,0  AC0  'PT  !R,P
M:#$  %\L  !5)P  3",  $0=   \&   -!,  "T0!@ F#0L ) P/ "(,$P A
M#!D 'PP? !X-)0 =#2P &PTT !H./0 9#D< %PY3 !8.80 4#W$ $Q"$ !(0
MF  1$*X $!#& ! 0Z  0$/L $1#_ )DQ  ".-0  A#@  'HY  !P.   9S8
M %TR  !3+0  2B@  $(D   Y'P  ,1H  "H5 0 C$0< '1 - !L/$  9#Q4
M&! ; !<0(0 6$"D %1 Q !01.@ 3$44 $A)1 !$27P 0$F\ #A."  X3E@ -
M$ZL "Q/"  L4XP ,%/H #1/_ )<U  ",.0  @CP  '@]  !O/0  93H  %LW
M  !2,@  22X  $ J   W)0  +R$  "@<   @& , &10* !42#@ 4$A( $Q,8
M !(3'P 1%"8 $10N ! 4.  /%4( #A9/  T67  ,%VP "Q=_  D8DP (&*@
M!AB_  <8X  '&/4 "1C_ )4X  "*/0  @$   '=!  !M00  9#\  %H\  !0
M.   1S,  #XP   V*P  +B<  "<C   ?'P  %QH( !(7#0 0%Q$ #Q<6  X8
M'  .&", #1DL  P:-0 +&D  "AM,  D;6@ ''&D !1Q\  0=D0 "':8  1V\
M  (<W0 "'/(  QS_ ),\  "(00  ?T0  '5%  !L10  8T0  %E!  !//0
M1CD  #XV   U,@  +BX  "4J   =)0  %"$$  \="P -'1  #!T4  L=&@ *
M'B( "!XJ  <?,P &(#X !"!*  ,A5P !(6<  "%Y   AC@  (:0  "&Z   A
MVP  (?(  "#^ )!   "&10  ?4@  '1*  !K2@  8DD  %A&  !.0@  13\
M #T\   U.0  *S0  "(O   9*P  $B@$  TD"@ )(PX !B,2  4C&0 $)"
M B0H  $E,0  )3P  "5(   F50  )F4  "9W   FC   )J(  ":Y   FV0
M)?(  "7^ (Y%  "$20  >TT  '-/  !J3P  8$X  %=+  !-2   1$4  #Q"
M   Q/0  )SD  !XU   5,@  #RX#  HL"@ %*PX  2H1   J%@  *AX  "HF
M   K+P  *SD  "M%   L4P  +&(  "QU   LB@  *Z   "NW   KU@  *O(
M "K_ (Q)  ""3@  >E(  '%4  !H5   7U,  %91  !,3@  0TL  #='   M
M0P  (S\  !H\   2.   ##8#  8S"0  ,@T  #(0   Q%   ,1L  #$C   Q
M+   ,C<  #)#   R4   ,F   #)R   RAP  ,9X  #&U   PU   ,/(  "__
M (E/  " 5   >%<  &]9  !F60  7ED  %57  !)4P  /D\  #),   H2
M'D4  !5"   .0   "#T"  $\"   .PP  #H/   Y$@  .1@  #D@   Y*0
M.30  #E    Y3@  .5T  #EO   XA0  .)P  #>S   WT@  -O(  #7_ (=5
M  !_6@  =ET  &U?  !E7P  75\  %)<  !$6   .%4  "U2   B3P  &$P
M !!*   *2    T8!  !%!@  1 H  $,-  !"$   014  $$=  !!)@  03$
M $$]  !!2@  05H  $%L  ! @0  /YD  #^Q   ^T   /?(  #S_ (1<  !\
M8   <V,  &QE  !D9@  660  $MA   ^7@  ,EL  "99   <5@  $E0   Q2
M   $40   $\   !. P  30@  $P,  !+#@  2Q(  $H9  !*(@  2BP  $HY
M  !*1P  2E8  $EH  !)?@  2)8  $>O  !&S0  1?$  $3_ (%C  !Y9P
M<FH  &ML  !@:P  4FD  $1F   W9   *F(  !]@   57@  #5T   9;
M6@   %D   !8    5P0  %8(  !6#   51   %04  !4'0  5"<  %0T  !4
M0@  4U(  %-D  !2>0  4I(  %&K  !0R@  3^\  $[_ 'YJ  !W;@  <'$
M &9Q  !8<   2F\  #QM   O;   (FH  !=I   .9P  !F8   !E    90
M &4   !C    8@   &($  !A"   80T  & 0  !@%P  8"$  %\N  !?/
M7TT  %Y>  !>=   78T  %RG  !;Q0  6NT  %G_ 'MR  !U=@  :W<  %UV
M  !/=@  074  #-U   F=   &7,  !!R   '<0   '$   !Q    <0   '$
M  !O    ;P   &X   !N @  ;@@  &T,  !M$0  ;1H  &TF  !L-0  ;$8
M &M8  !K;0  :H8  &FA  !HO@  9^@  &;^ 'EZ  !P?   87P  %-]  !$
M?0  -GX  "A^   ;?0  $'T   =]    ?0   'T   !^    ?P   'X   !]
M    ?0   'P   !\    ?    'P&  !\#   ?!(  'P=  !\+   ?#P  'Q/
M  ![90  >WX  'J:  !YM@  >-\  '?Z '.   !E@0  5H,  $B$   YA@
M*X<  !V'   1AP  !X@   "(    B0   (H   ",    C0   (T   ",
MC    (P   ",    C    (T   "-!   C@P  (X3  "/(0  CC(  (Y&  ".
M6P  C70  (V0  ",K0  B\X  (KS &B&  !:B   2XL  #R-   MCP  'I
M !&1   'D@   ),   "5    EP   )D   ";    G    )L   ";    G
M )P   "=    G@   )X   "?    H0,  *(,  "B%@  HR8  *,Z  "C3P
MHV@  **&  "BH@  HL   *'H %R-  !-D   /Y,  #"6   AF0  $IH   >;
M    G0   *    "B    I    *@   "J    JP   *H   "K    K    *T
M  "N    KP   +$   "R    M    +<!  "Y#0  N1H  +HM  "Z0P  NEL
M +IW  "[E   N[$  +G2 %"5  !!F   ,IP  ".@   3H@  "*0   "G
MJ@   *P   "O    L@   +<   "Y    NP   +H   "\    O0   +\   #
M    P@   ,0   #&    R0   ,T   #2 0  U \  -4?  #7-0  V$T  -AI
M  #7A@  UZ,  -:] /\   #_    _P   /\   #_  , _P - /\ %0#_ "
M_  K /@ -0#T #\ \ !' .X 3@#K %0 Z0!: .< 7P#E &0 XP!J .$ < #?
M '8 W0!^ -L AP#8 )$ TP"= ,\ JP#- +T RP#@ ,D ^P#' /\ O0#_ +$
M_P"I /\ HP#_ /\   #_    _P   /\   #\    ]@ + /$ $0#M !L Z0 E
M .0 , #? #D V@!! -4 2 #1 $X SP!4 ,T 60#+ %X R0!C ,< :0#% &\
MPP!W ,  ?P"^ (H NP"5 +@ HP"V +0 M #- +( \@"P /\ K #_ *, _P"<
M /\ EP#_ /\   #_    ^@   /$   #H    X  & -D #@#2 !8 S@ ? ,@
M*0#$ #( P  Z +T 00"Z $@ N !- +8 4P"T %@ L@!= +  8@"N &D K !O
M *H > "H (( I@". *0 FP"A *L GP#  )T Y@"; /\ F@#_ )0 _P". /\
MB@#_ /\   #V    Z    -P   #.    Q@ ! +\ "P"Z !$ M@ : +( (@"N
M "L J@ T *@ .P"E $$ HP!' *$ 3 "? %$ G@!6 )P 7 ": &( F0!H )<
M< "5 'H D@"& )  DP"- *( BP"U (D TP"' /< A@#_ (0 _P!_ /\ ? #_
M /(   #C    T@   ,4   "Z    L0   *L !P"E  X H0 4 )X ' ": "4
MEP M )0 - "2 #H D !  (X 10"- $H BP!0 (D 50"( %L A@!A (0 :0""
M '( ?P!] 'T BP![ )H > "K '8 Q !T .L <P#_ ', _P!P /\ ;@#_ -\
M  #,    OP   +0   "K    H0   )H  @"4  L D  0 (P %P"( !X A0 F
M (, +0"! #, ?P Y 'T /P![ $0 >0!) '@ 3@!V %0 = !: ', 8@!P &L
M;@!U &P @P!J )( : "C &8 N !D -X 8P#[ &( _P!B /\ 8 #_ ,P   "\
M    KP   *4   "=    E    (P   "&  < @0 - 'P $@!X !D =0 ? ',
M)@!Q "T ;P R &T . !K #T :@!" &@ 2 !G $X 90!4 &, 6P!A &0 7P!N
M %T >P!; (H 60"; %< KP!6 ,L 50#R %0 _P!4 /\ 5 #_ +X   "P
MI    )D   "0    B    ($   !Y  ( <P * &\ #P!K !0 9P : &4 ( !C
M "8 80 L %\ ,@!> #< 7  \ %L 0@!9 $< 5P!. %8 50!4 %X 4@!H %
M= !. (, 3 "5 $H J !) ,  2 #H $< _P!' /\ 1P#_ +0)  "F"P  FPP
M ) *  "&!0  ?@   '8   !O    :  % &, # !? !  6P 5 %@ &@!6 "$
M5  F %, + !1 #$ 4  V $X / !- $( 2P!( $D 4 !( %@ 1@!B $0 ;@!"
M 'T 0 ". #\ H@ ] +@ /0#= #P ^  \ /\ / #_ *P0  "?$@  E!(  (D1
M  !_#P  =@P  &X%  !F    8  ! %D " !5  T 40 1 $X %@!+ !L 20 A
M $@ )@!& "L 10 Q $, -@!" #P 0 !# #X 2P ] %, .P!= #D :0 W '@
M-@") #0 G  S +$ ,@#. #( \0 Q /\ ,0#_ *86  ":&0  CAH  (0:  !Z
M%@  <!(  &@.  !?"@  6 ,  %$ ! !,  H 2  . $0 $@!! !8 /P ; #T
M(0 \ "8 .@ L #D ,0 W #< -@ ^ #0 1@ S $\ ,0!9 "\ 90 N ', + "%
M "L F  J *T *0#& "@ Z@ H /X * #_ *$<  "5(   BB$  '\A  !U'P
M;!H  &,6  !:$0  4@T  $L'  !$  8 0  + #P #P X !( -@ 7 #0 '  S
M "$ ,0 G #  +  N #, +0 Z "L 0@ J $L * !5 "8 80 E '  ) "! "(
ME0 A *D ( #! "  Y  ? /D 'P#_ )TB  "1)@  AB@  'PG  !R)0  :2(
M %\=  !7&   3A,  $8.   _"P  . 4' #0 #  Q !  +@ 3 "P &  J !T
M*0 B "< *  F "X )  V ", /@ B $< ( !2 !\ 7@ = &T ' !^ !H D@ 9
M *< & "] !< WP 7 ?4 %P+_ )HG  ".*P  A"T  'DM  !P*P  9B@  %TD
M  !4'P  2QH  $,4   [$   - T" "T)"0 I!0T )@,0 "0!$P B AD (0(>
M " ")  > RH '0,R !L$.@ :!40 &05/ !<&7  6!FH % =\ !,'D  2!Z4
M$0>[ ! 'VP 0"/( $ G_ )<K  ",+P  @3$  '<R  !N,0  9"X  %LJ  !1
M)0  22   $ ;   X%@  ,1(  "D.!  C# D 'PD- !T'$  ;!Q4 &0@: !@(
M(  7"2< %@DN !4*-P 3"D$ $@M- !$+6@ 0"VD #@Q[  X,D  -#*4 # V[
M  L-V0 +#?$ # W_ )4O  "*,P  ?S8  '8V  !L-0  8S,  %DO  !0*P
M1R8  #XA   V'0  +A@  "<3   @$ 4 &0X* !4,#@ 4#!$ $PP6 !(,'  1
M#2, $ TK  \--  .#C\ #0Y*  P/6  +#V< "A!Y  @0C0 '$*( !A"X  40
MU  %$.\ !A#_ )(S  "(-P  ?CH  '0[  !K.@  83@  %@U  !.,   12P
M #TG   U(P  +1\  "8:   >%@$ %Q,& !$0"P .#@X #@\3  T0&0 -$"
M#! H  L1,@ *$3P "!)(  <250 &$V4 !!-V  ,3BP !%*   !.V   3T0
M$^X  !/[ ) V  "&.P  ?#X  ',_  !J/P  8#T  %<Y  !--@  1#$  #PN
M   T*@  +"8  "4B   >'@  %AH" ! 5"0 ,$PX "A,2  D4%P (%!\ !Q4F
M  85+P $%CH  Q9&  $74P  %V(  !AT   8B0  &)\  !BU   7T   %^T
M !?[ (XZ  "$/P  >T(  ')#  !H0P  7T(  %8_  !,.P  0S<  #LT   S
M,   +"P  "0I   ;)   $Q\"  T;"0 )&0T !AD1  09%@ "&1T  1HD   :
M+0  &S@  !M$   <40  '&   !UR   =AP  ')T  !RS   <S@  &^T  !O\
M (P^  ""0P  >48  '!(  !H2   7D8  %5$  !+0   0ST  #LZ   S-P
M*C(  " M   7*0  $"4"  LB"0 %( T  1\0   ?%   'QL  " B   @*P
M(38  "%!   A3P  (5X  ")P   BA0  (9L  "&R   AS0  (.T  !_\ (I#
M  " 2   >$L  &],  !F30  74L  %1)  !*1@  0D,  #I    O.P  )3<
M !PS   3+P  #2P"  <I"  !)PP  "8.   E$@  )AD  "8A   F*0  )C,
M "<_   G30  )UP  "=M   G@@  )YD  ":P   ES   )>X  "3] (A(  !_
M3   =E   &Y1  !E4@  7%$  %-/  !*3   04D  #5$   K0   (3P  !<Y
M   0-@  "C(!  ,P!P  +PL  "X.   M$0  +18  "T>   M)P  +3$  "T]
M   M2@  +5D  "UK   M@   +)<  "RO   KRP  *NX  "K^ (5-  !]4@
M=54  &Q7  !C5P  6U8  %-5  !'40  .TT  #!)   E1@  '$,  !,_   -
M/0  !CH    X!0  -PD  #8-   U#P  -!0  #0;   T)   -"X  #0Z   T
M1P  -%<  #1H   T?0  ,Y4  #*M   QR@  ,>X  ##_ (-3  ![6   <UL
M &I=  !B70  6UT  $]:  !"5@  -E(  "I/   @3   %DD   Y'   (1
M $(   !! P  /P<  #X+   ]#@  /1$  #P8   \(0  /"L  #PW   \1
M/%,  #QE   [>@  .I(  #JK   YR   ..T  #?_ (%:  !Y7@  <6$  &EC
M  !B9   5V(  $E>   \6P  +U@  "15   94P  $%$   I/   !30   $P
M  !*    200  $@(  !'#   1@\  $84  !%'   12<  $4S  !%0   15
M $1A  !$=@  0X\  $*H  !!Q@  0.P  #__ 'YA  !V90  ;V@  &AJ  !=
M:0  3V8  $)D   T80  *%\  !U=   26P  "UD   )8    5@   %8   !4
M    4P   %($  !1"0  4 T  % 0  !/&   3R(  $\N  !//   3TL  $Y=
M  !.<@  38L  $RE  !+P@  2>H  $C_ 'MI  !T;   ;F\  &1O  !5;0
M1VP  #EJ   L:0  (&<  !1E   -9    V(   !B    80   &    !?
M7@   %T   !<!   7 D  %L-  !;$@  6QP  %HH  !:-@  6D8  %E8  !9
M;0  6(4  %>@  !6O0  5>@  %/^ 'EP  !S=   :74  %MT  !,<P  /G,
M #!R   C<0  %F\   UN   $;0   &T   !M    ;0   &P   !K    :@
M &D   !I    :0,  &@)  !H#@  :!4  &<A  !G+P  9S\  &92  !F9@
M97\  &2:  !CMP  8N$  &'\ '=X  !M>@  7WH  %!Z  !">@  ,WL  "5[
M   8>@  #GD   1Y    >0   'D   !Z    >@   'H   !X    >    '<
M  !W    =P   '<!  !W"   =PX  '<8  !W)@  =C8  '9)  !U7P  =7<
M '23  !SKP  <M,  ''W '%^  !C?P  5(   $6"   V@P  *(0  !J$   .
M@P  !(0   "$    A0   (8   "(    B0   (@   "'    AP   (<   "'
M    AP   (@   "(    B <  (D0  ")'   B2P  (@_  "(50  B&T  (>)
M  "&IP  A<<  (3O &:$  !7A@  2(@  #F*   JC   &XT   ^-   $C@
M )    "1    DP   )4   "7    F    )8   "7    EP   )<   "8
MF    )D   ":    FP   )T'  "=$0  G2$  )TS  "=20  G&(  )Q_  "<
MG   G+D  )OB %J+  !+C@  /)$  "V3   >E0  $)8   28    F@   )P
M  ">    H0   *0   "F    IP   *8   "G    IP   *@   "I    J@
M *P   "M    KP   +$   "S"0  LQ4  +0G  "T/0  M54  +5P  "TC@
MM*P  +3, $V2   _E@  +YH  ""=   1GP  !:$   "C    I@   *D   "L
M    KP   +,   "U    MP   +8   "W    N    +H   "[    O0   +\
M  #!    Q    ,<   #+    S0P  ,X:  #/+P  ST@  -!B  #0@   T)T
M -"X                       ! P0%!@@)"@L-#@\1$A,4%A<8&AL<'1\@
M(2(D)28H*2HK+2XO,#(S-#8W.#D[/#T^0$%"1$5&1TE*2TU.3U!24U155UA9
M6UQ=7F!A8F-E9F=I:FML;F]P<7-T=7=X>7I\?7Z @8*#A8:'B(J+C(Z/D)&3
ME)66F)F:G)V>GZ&BHZ2FIZBJJZRMK["QL[2UMKBYNKN]OK_!PL/$QL?(R<O,
MS<_0T=+4U=;7V=K;W=[?X.+CY.;GZ.GK[.WN\/'R]/7V]_GZ^_S^________
M______________________________________________\
M         0,$!08("0H+#0X/$1(3%!87&!H;'!T?("$B)"4F*"DJ*RTN+S R
M,S0V-S@Y.SP]/D!!0D1%1D=)2DM-3D]04E-455=865M<75Y@86)C969G:6IK
M;&YO<'%S='5W>'EZ?'U^@(&"@X6&AXB*BXR.CY"1DY25EIB9FIR=GI^AHJ.D
MIJ>HJJNLK:^PL;.TM;:XN;J[O;Z_P<+#Q,;'R,G+S,W/T-'2U-76U]G:V]W>
MW^#BX^3FY^CIZ^SM[O#Q\O3U]O?Y^OO\_O__________________________
M____________________________                      $#! 4&" D*
M"PT.#Q$2$Q06%Q@:&QP='R A(B0E)B@I*BLM+B\P,C,T-C<X.3L\/3Y 04)$
M149'24I+34Y/4%)35%576%E;7%U>8&%B8V5F9VEJ:VQN;W!Q<W1U=WAY>GQ]
M?H"!@H.%AH>(BHN,CH^0D9.4E9:8F9J<G9Z?H:*CI*:GJ*JKK*VOL+&SM+6V
MN+FZN[V^O\'"P\3&Q\C)R\S-S]#1TM35UM?9VMO=WM_@XN/DYN?HZ>OL[>[P
M\?+T]?;W^?K[_/[_____________________________________________
M_________P ! @,$!08'" D*"PP-#@\0$1(3%!46%Q@9&AL<'1X?("$B(R0E
M)B<H*2HK+"TN+S Q,C,T-38W.#DZ.SP]/C] 04)#1$5&1TA)2DM,34Y/4%%2
M4U155E=865I;7%U>7V!A8F-D969G:&EJ:VQM;F]P<7)S='5V=WAY>GM\?7Y_
M@(&"@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F:FYR=GI^@H:*CI*6FIZBIJJNL
MK:ZOL+&RL[2UMK>XN;J[O+V^O\#!PL/$Q<;'R,G*R\S-SL_0T=+3U-76U]C9
MVMO<W=[?X.'BX^3EYN?HZ>KK[.WN[_#Q\O/T]?;W^/GZ^_S]_O]M9G0Q
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M__________^H-0          7-/___________________________]]#0
M        5-;__________________________^Y]10          1-3_____
M______________________RJ9"\"   $(C=)6,[_____________________
M_______II&M!*#]C?Y6GNMK______________________________]6RK++,
MY/K_________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________^6[EW=BR/______________
M___________________;GF<V"@ "C/______________________________
M_\A_/P4     7L______________________________V8$Y        /*K_
M____________________________GDP         (Y#_________________
M___________<;QH         $'WY__________________________^O2
M         &_N__________________________^$$P           &3F____
M_____________________^Q1             %?>____________________
M_____[@5             $C6_________________________W04
M     #C/________________________^:):$P           "/%________
M_________________]^;7"P           VZ________________________
M___OL7U5.2(1!P$"$2*R_______________________________?OZ69F)J@
MK+W:________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______COIV ?/O________________________________RMX17, X ':S_
M_____________________________]**3!4      '+S________________
M____________UG\V         $O)___________________________ZD3X
M         "^K___________________________ 6@           !J5____
M______________________^-)             B$____________________
M_____^=>              !W_________________________[0E
M      !J_________________________WT               !;]/______
M_________________2L               !,Z_______________________
MI0                 \X?______________________, P
M   MV?____________________^9BF$G               GU___________
M____________[;Z)52<            EW/_________________________^
MRIUV74H\,BTL,#E'WO_______________________________>;=UM+0T]GD
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________^_4N];_________________
M________________Y[B/:DLO%6_______________________________^2A
M9S0'     #S)____________________________UH([         !*7____
M_______________________MA3$           !O____________________
M______^F0@            !0X?_______________________^QI
M       WR?_______________________[,O               BMO______
M_________________WD                0I_______________________
M\C0                 F?______________________J0
M    C/______________________1@                  ?___________
M___________?                    =/____________________^7
M                :O_____________________.
M8_______________________*2(!                8?______________
M________N:. 5S<7            :/__________________________^M.N
ME(9\=7%P<G>!E/______________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________;NIV":6G3____
M___________________________(DV4]&0   !V>____________________
M________VXY,$P        !N___________________________;?"P
M      !%U_________________________^+*@             BM/______
M_________________\)$               #E_______________________
M_WT!                ?_______________________YS8
M    :O______________________G0                  6/__________
M____________1@                  1_C____________________I
M                ->G___________________^6
M)=O___________________^\                    &,[_____________
M_______K                    #\+_____________________
M            "KG_____________________)P                  "K7_
M____________________<                   #;G_________________
M____X)R,<%5",R8;% \-#A(:)K_____________________________YY-C2
MSLS+S,_6X/S_________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________KT[SC________________________________TJF%
M94@L$@&%____________________________\:MQ/ \       !/X/______
M___________________5?S4            ?LO______________________
M_^-U'0              B?_______________________Y C
M    9_______________________U4,                 2/;_________
M____________B@                  +MW_____________________.
M                %\C___________________^^
M!+;___________________^<                     *7_____________
M______^Z                     )/____________________<
M             (+_____________________                     '3_
M____________________$P                   &C_________________
M____0@                   &#_____________________>@
M         %W_____________________T0                   &'_____
M_________________R0                  &;_____________________
M_\FLF8E]=G%L:6=F9VMP>HS_____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________BQ:J1>6%W________________________
M_____]VF=U L#      QQ/_________________________@DDX3
M    C________________________])P'0              8/__________
M____________[F\/                -^+_____________________EAP
M                %,#_____________________0
M */___________________^N                     (G_____________
M______^>                     '+___________________^\
M             %_____________________:                     $W_
M___________________Z                     #O_________________
M____#@                   "KY____________________,P
M         !OI____________________7@                    _;____
M________________CP                    ;0____________________
MT                     #*_____________________RL
M      #(_____________________X                    #+________
M______________<6 04% P$       $&#1C+_______________________\
MZ^'8S\S-S]#2U-?<XNK_________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M\=K&_______________________________QQJ.$:$TR&  5J___________
M________________N7Q&&           <?_______________________]=\
M+P              .^/_____________________WV0)
M#+7_____________________= ,                  (W_____________
M_______%%0                   &K___________________^9
M             $O___________________^V                     ##]
M___________________7                     !GG________________
M___V                      73____________________#@
M          #!____________________+P                    "O____
M________________4@                    ">____________________
M>0                    ".____________________I0
M      " ____________________V                     !T________
M_____________S8                   !M_____________________WP
M                  !I_____________________]<-
M  !H______________________]P                  !A____________
M____________4#Q&3E1976%D:&QP=GZ)____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______OU;NCBW-:E?__________________________^+^.9$$A!0
M4OS_______________________>=5A@             %\'_____________
M________Y6P6                 (W_____________________8P
M             %[___________________^=                     #7\
M__________________^A                     !'9________________
M___*                      "[___________________N
M          "A____________________#                     "*____
M________________+0                    !V____________________
M30                    !D____________________;P
M      !2____________________E                     ! ________
M____________O                      P____________________Z@X
M                   B_____________________T0
M   5_____________________X$                    +]?__________
M_________\@+                   "[/____________________]>
M                Y?_____________________)'
MVO______________________G0$             !PX7Q?______________
M_________]6YO,''SM7;X>;M]/O_________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________C?S_______________
M_______________LQJ6(;50[(0< ,M[________________________7DEDI
M             *#______________________XDV                 &?_
M____________________9@                   #+V________________
M__^5                      /(__________________^G
M          "@___________________7                      !\____
M________________                      !>____________________
M)0                    !#____________________2
M       L____________________:@                     8________
M____________BP                     %\___________________KP
M                    X?__________________U0
M    S____________________R0                     OO__________
M_________U0                     KO___________________XL
M                G____________________\L.
MDO____________________]7                    AO______________
M______^J"@                  >?______________________;0
M            9O______________________]U4                 1?__
M______________________]J(RLU/TI58&IU?H>1G/__________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________Z,^VG8-I3KG_
M________________________[+*#7#H= @       'O_________________
M_____\5M*0               $#_____________________@QL
M          ?+__________________^2                      "8____
M______________^D                      !J___________________=
M                      !!____________________#@
M       =____________________.0                      Z/______
M____________8                       SO__________________A0
M                    M___________________J
M    H___________________RP                      D/__________
M________[Q8                     ??___________________SX
M                ;/___________________VD
M6O___________________YD                     2?______________
M_____](6                    .?____________________]8
M            *?____________________^B                    &?__
M___________________U5@                  !/__________________
M____NR\                  /C______________________ZLI
M         ,_________________________)1P     '$R N/E)HA.W_____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________TU<G____________________________ZTK"2
M=UU"* P  $K________________________%?447             !'8____
M________________Q%                    "?__________________^B
M#                     !H__________________^4
M       V___________________:                       '[/______
M____________%0                      Q/__________________2
M                    HO__________________=0
M    @___________________G0                      :?__________
M________PP                      4O__________________YP\
M                /O___________________S,
M*____________________U@                     &/______________
M_____X$                     !?___________________ZP
M             /___________________]XB                     /+_
M__________________]<                     -__________________
M__^?                     ,S____________________H2@
M         +?_____________________H!8                  )S_____
M_________________WH"                 '?_____________________
M__]Z"P              !4S_________________________HE=H=("-G*N\
MT.?_________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________[>/_____________________
M_____]*C>E@Z*2,<%@X&  "?_____________________ZQ2#@
M      !I___________________D0P                     T________
M__________]Y                        X__________________-
M                    LO__________________$P
M    A?__________________3P                      7?__________
M________@P                      .O__________________L@
M                '/__________________VP,
M O___________________RH                      /O_____________
M_____T\                      .?__________________W0
M             -3__________________YL                      ,#_
M_________________\0'                     *W_________________
M__ S                     )K___________________]G
M         (;___________________^C                     '+_____
M_______________C1                    %S_____________________
MD08                  $'_____________________ZU\
M     !W______________________\I+                  #_________
M_______________+5P  #!@D,3].8'2+I\?_________________________
M_]?G\O______________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________^O4S<?"OKJWL["MJ:BE____________________W7Y3
M/S C&1$) @          V_________________]V
M    I_________________^Z                        =?__________
M________!P                      1O__________________3@
M                &O__________________C
M /W_________________P0                       -O_____________
M____\1D                      +[__________________T0
M             *3__________________VL                      (W_
M_________________Y$                      'G_________________
M_[<                      &;__________________]XA
M         %/___________________]*                     #______
M______________]W                     "O___________________^L
M"@                   !;____________________G10
M      #_____________________B@                    #_________
M____________UDT                   #]_____________________Z<N
M                  #5______________________^8*@          !A@M
M16#@________________________J&-T@8^<J[O-XOK_________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________^?+MZF=E8Z)A(!\>'1P;&AED/________________^\:D@M&0H
M                ,?__________________
M ___________________0@                       -S_____________
M____C@                       ++_________________S@
M             (W__________________RD                      &O_
M_________________UH                      $[_________________
M_X8                      #3__________________ZX
M         ![__________________]07                      K_____
M______________H]                      #___________________]E
M                      #___________________^.
M      #___________________^\&0                    #O________
M___________Q3@                    #8____________________BP
M                  "_____________________S$,
M  "A_____________________Y$9                  !Z____________
M__________)T"@               !%?_______________________H=!,?
M+#A%4V)RA9NTTO7__________________________]?H]/______________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________^_?S\>[LZ^OL\?______________
M____V;*9AWEM9%U644M&03PX,BTH(\3_________________2R4+
M             )+_________________B                        &;_
M________________UP                       #W_________________
M_S,                      !C__________________VP
M          #__________________YT                       #_____
M_____________\D,                      #V__________________$U
M                      #?__________________];
M      #+__________________^"                      "W________
M__________^I!@                    "C___________________3+P
M                  "-____________________7@
M  !W____________________DP<                   !>____________
M________S4,                   ! _____________________X<0
M               <_____________________]A>
M______________________^_3@      #APL/E)JAJ7(________________
M________PGR,FJ>VQ=;H_?______________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________[N'7S\G#OKJVL:VIIZ:FIZ[_________________
MOH9M6TQ -R\H(AP6$ L$     !3_________________UP4
M          #__________________S0                       #V____
M_____________W8                       #2_________________[
M                      "R_________________^$D
M      "6__________________]1                      !\________
M__________]Y                      !F__________________^@
M                  !1___________________'(P
M   \___________________N2P                     G____________
M________=                      0____________________HQ8
M                ____________________V$P
M_____________________X@/                    ________________
M_____\M3                    ______________________^E.
M    "1TT3FN,________________________F3E#45]N?8Z@M<OE________
M_____________________^OY____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________^O,N:RAF9&+AH%\>'1P:VAF9FCQ_________________V%%
M,B,8#@8               ">_________________WX
M      !U_________________\,                       !2________
M__________LW                       R__________________]J
M                   6__________________^6
M    __________________^_&P                      ____________
M_______F0@                      ____________________:0
M                ____________________D (
M____________________N2P                     ]/______________
M____Z%P                     V?___________________Y$8
M            O/___________________\I3                    G?__
M__________________^8+@             0*49FQ/__________________
M___N?QT,&B@W1E=I?I6OS.[_________________________YZ"JN<C8Z?S_
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________]]?#KYN+?V]C4TM'0TM?@________
M_________\Z>BGQQ:6%;5E%,2$,^.C8R+RXQ_________________](E$0,
M                    __________________]"
M    __________________]]                        ____________
M______^P"P                      ]O_________________=.0
M                W/__________________8@
MQ?__________________B0                      K_______________
M____KR(                     F?__________________UD@
M            @O___________________W(                     :?__
M_________________Z$H                    3O__________________
M_]-<                    ,_____________________^6+@
M    %3)2=______________________@<A,   $/'R]"6'"+J,CL________
M________________RF]N?HZ>L,/8[_______________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________YX-+(P+JUL*RHI:*?G9N;G*"G____________
M______^"9%9+0SPV,"LG(AT8$PX)!   U/________________^2
M                K?_________________,'@
MB__________________[4@                      ;?______________
M____@                       4?__________________J1L
M            .O__________________T$(                     (___
M________________]6@                     #/__________________
M_X\4                     /___________________[@^
M         /___________________^5M P                   /______
M______________^?-P              $"]0=/_____________________=
M<A0     !A<J05IUE+;:________________________O%A$5&1UAIJOR./_
M_____________________________]+-X?'_________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________________S[^OO]____
M___________________NN:B=EH^*AH)_>WAV=')S=7A_D/______________
M___K3SHP*"$;%1 +!P(         (___________________:0
M             /__________________FPH                      /__
M________________R#D                      /__________________
M\&,                      /___________________XH.
M         /___________________[ T                     /______
M_____________]5;                     /____________________^%
M&@                   ^S___________________^Q20
M&#E=@?_____________________E>QX       PA.%)OC[/9____________
M____________NU@I.4E:;("7L,WM_____________________________[.>
MM,77Z_______________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________KOY^'<V=;4TM#0T-'3V>#K]___
M________________N(I^=W%L:&1A7EM96%=765YE<?__________________
MOS$?%A *!0               /__________________[58
M         .C__________________X($                     ,S_____
M_____________ZLO                     +/__________________])7
M                     )O___________________=\$
M     (7___________________^B-P                 %*Y3_________
M___________+80(            ,+%!VGM'____________________UC3
M      TC.U=VF;[E________________________PV,8*CM,7W2-I\;G____
M_________________________ZA_EJB[T.?_________________________
M___________]________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________]W.Q;^\N;:TL[&RLK6YP,G5X_______
M_____________Y=L9%Y955%/3$I(1T9(2U!99J'__________________Z<F
M#@<"                 %;__________________\Y0
M     #K___________________1Y"P                   "'_________
M__________^?,@                    [____________________$6
M              @Q6H3____________________I?Q\           8G2W&:
MPNG_____________________ITD      A<O2FB*KM7\________________
M________TW4>)CA*7G6/J\OO_____________________________ZYRA9BL
MPMOV___________________________________?[___________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________^_LJJFHZ&@GY^AHZ:LM,#-W>S_________
M__________^*6E-/2TA&1$-"04)#1TY9:7W___________________^>+@8
M                  #____________________#5@
M%4'____________________G>QH             "31@B[3_____________
M________GS\         !"5*<9G"Z_______________________QF8/
M$RI$8H.GS?7_________________________ZXXU*SY1:(&=O-[_________
M_____________________[YV?Y2IP=SY____________________________
M_______2V//_________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________;R\._O[_'S^/W_____
M_______________________XL)^:EY:6EIB;GZ2LML+1X>[_____________
M_______^CE!*1T5$1$1%1D=+45IH@ZG_____________________ID$!
M       '-F./NN'_____________________QF4*       $)TQSG,3L____
M____________________Y8@O   3*D1B@J;,]/______________________
M_____ZM0-DIA>Y:TUOK______________________________]*'?)BQR^G_
M___________________________________4SNW_____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________^WEX^/DYNCM\?G_________
M_____________________;&4DI*5F9VCJ;*\T.W_____________________
M_____YU31TE-459@<XJOUOS__________________________[)6 !HU4&V+
MKM+W_____________________________\UO/E][F;?7^?______________
M_________________^Z?@Z;"X?__________________________________
M___CSNO_____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________________________\
M
M
M                                                 /__________
M____________________________________________________________
M____________________________________________________________
M________________________________________     /_A07-H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME="!B96=I;CTB[[N_(B!I
M9#TB5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED(C\^"CQX.GAM<&UE=&$@>&UL
M;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E
M(#<N,BUC,# P(#$Q-BYD964S83<W+" R,#(R+S Y+S Q+3$S.C4W.C X(" @
M(" @(" B/@H@(" \<F1F.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N
M;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@(" @(" \<F1F.D1E
M<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7 ]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B"B @(" @(" @(" @('AM
M;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(*(" @(" @
M(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q
M+C$O(@H@(" @(" @(" @("!X;6QN<SIP:&]T;W-H;W ](FAT=' Z+R]N<RYA
M9&]B92YC;VTO<&AO=&]S:&]P+S$N,"\B"B @(" @(" @(" @('AM;&YS.GAM
M<$U-/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @
M(" @("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP
M+W-4>7!E+U)E<V]U<F-E179E;G0C(@H@(" @(" @(" @("!X;6QN<SIS=%)E
M9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E
M4F5F(R(*(" @(" @(" @(" @>&UL;G,Z=&EF9CTB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]T:69F+S$N,"\B"B @(" @(" @(" @('AM;&YS.F5X:68](FAT=' Z
M+R]N<RYA9&]B92YC;VTO97AI9B\Q+C O(CX*(" @(" @(" @/'AM<#I#<F5A
M=&5$871E/C(P,C,M,#<M,#-4,C,Z,3(Z-#DK,#4Z,S \+WAM<#I#<F5A=&5$
M871E/@H@(" @(" @(" \>&UP.D-R96%T;W)4;V]L/DUI8W)O<V]F=,*N(%!O
M=V5R4&]I;G3"KB R,#$V/"]X;7 Z0W)E871O<E1O;VP^"B @(" @(" @(#QX
M;7 Z36]D:69Y1&%T93XR,#(S+3 X+3 R5#$R.C0Y.C4X+3 W.C P/"]X;7 Z
M36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T841A=&4^,C R,RTP
M."TP,E0Q,CHT.3HU."TP-SHP,#PO>&UP.DUE=&%D871A1&%T93X*(" @(" @
M(" @/'!D9CI0<F]D=6-E<CY-:6-R;W-O9G3"KB!0;W=E<E!O:6YTPJX@,C Q
M-CPO<&1F.E!R;V1U8V5R/@H@(" @(" @(" \9&,Z8W)E871O<CX*(" @(" @
M(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D^5&EM(%)Y
M86X\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \
M+V1C.F-R96%T;W(^"B @(" @(" @(#QD8SIT:71L93X*(" @(" @(" @(" @
M/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M
M9&5F875L="(^4&]W97)0;VEN="!0<F5S96YT871I;VX\+W)D9CIL:3X*(" @
M(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+V1C.G1I=&QE/@H@(" @
M(" @(" \9&,Z9F]R;6%T/FEM86=E+V5P<V8\+V1C.F9O<FUA=#X*(" @(" @
M(" @/'!H;W1O<VAO<#I#;VQO<DUO9&4^-#PO<&AO=&]S:&]P.D-O;&]R36]D
M93X*(" @(" @(" @/'!H;W1O<VAO<#I)0T-0<F]F:6QE/E4N4RX@5V5B($-O
M871E9" H4U=/4"D@=C(\+W!H;W1O<VAO<#I)0T-0<F]F:6QE/@H@(" @(" @
M(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED.C8W-3!A8C4R+6(V-C@M8C,T
M,"TY,3)D+6,W,C$Y-C9A9&8Y9CPO>&UP34TZ26YS=&%N8V5)1#X*(" @(" @
M(" @/'AM<$U-.D1O8W5M96YT240^861O8F4Z9&]C:60Z<&AO=&]S:&]P.C9B
M-V(X8V0U+3)A.&8M8C@T92TX-&4S+65A-#,S-3$W-64W,3PO>&UP34TZ1&]C
M=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YX
M;7 N9&ED.F$U.#(U.6,U+61D9&$M964T.2UB86-C+3<V-S%E-C5C969B,SPO
M>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ2&ES
M=&]R>3X*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z834X,C4Y
M8S4M9&1D82UE930Y+6)A8V,M-S8W,64V-6-E9F(S/"]S=$5V=#II;G-T86YC
M94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(S+3 W+3 T
M5# P.C4W.C0W*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @,C0N,B H
M5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C,Y-F$W-S@Q+3<U-&0M9C<T
M-BUB8C1B+38W93,S-6(V.&-E-SPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @
M(" @(" @(" @(" @/'-T179T.G=H96X^,C R,RTP."TP,E0Q,CHT.3HU."TP
M-SHP,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O
M9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P(#(S+C4@*%=I;F1O=W,I/"]S
M=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^8V]N
M=F5R=&5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IP87)A;65T97)S/F9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O
M<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IA8W1I;VX^9&5R:79E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z<&%R86UE=&5R<SYC;VYV97)T960@9G)O;2!A<'!L:6-A
M=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T179T
M.G!A<F%M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @
M(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T
M:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N
M:6ED.C8W-3!A8C4R+6(V-C@M8C,T,"TY,3)D+6,W,C$Y-C9A9&8Y9CPO<W1%
M=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^
M,C R,RTP."TP,E0Q,CHT.3HU."TP-SHP,#PO<W1%=G0Z=VAE;CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S
M:&]P(#(S+C4@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D
M/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z
M4V5Q/@H@(" @(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @(" @(#QX;7!-
M33I$97)I=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(#QS=%)E9CII;G-T86YC94E$/GAM<"YI:60Z,SDV83<W.#$M-S4T
M9"UF-S0V+6)B-&(M-C=E,S,U8C8X8V4W/"]S=%)E9CII;G-T86YC94E$/@H@
M(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)1#YX;7 N9&ED.F$U.#(U.6,U
M+61D9&$M964T.2UB86-C+3<V-S%E-C5C969B,SPO<W12968Z9&]C=6UE;G1)
M1#X*(" @(" @(" @(" @/'-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#YX;7 N
M9&ED.F$U.#(U.6,U+61D9&$M964T.2UB86-C+3<V-S%E-C5C969B,SPO<W12
M968Z;W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \+WAM<$U-.D1E<FEV
M961&<F]M/@H@(" @(" @(" \=&EF9CI/<FEE;G1A=&EO;CXQ/"]T:69F.D]R
M:65N=&%T:6]N/@H@(" @(" @(" \=&EF9CI84F5S;VQU=&EO;CXS,# P,# P
M+S$P,# P/"]T:69F.EA297-O;'5T:6]N/@H@(" @(" @(" \=&EF9CI94F5S
M;VQU=&EO;CXS,# P,# P+S$P,# P/"]T:69F.EE297-O;'5T:6]N/@H@(" @
M(" @(" \=&EF9CI297-O;'5T:6]N56YI=#XR/"]T:69F.E)E<V]L=71I;VY5
M;FET/@H@(" @(" @(" \97AI9CI#;VQO<E-P86-E/C8U-3,U/"]E>&EF.D-O
M;&]R4W!A8V4^"B @(" @(" @(#QE>&EF.E!I>&5L6$1I;65N<VEO;CXQ.#DR
M/"]E>&EF.E!I>&5L6$1I;65N<VEO;CX*(" @(" @(" @/&5X:68Z4&EX96Q9
M1&EM96YS:6]N/C,P-#PO97AI9CI0:7AE;%E$:6UE;G-I;VX^"B @(" @(#PO
M<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO>#IX;7!M971A/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD
M/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$!_\  $0@ 80)= P$1  (1 0,1 ?_$ !X  0 " P$! 0$!
M       &!P0%" D# @$*_\0 ,Q   @(#  (!!0 " 0(%! , ! 4#!@$"!P (
M$@D1$Q05%B$7(C$8(R0R,T%188$E)L'_Q  ; 0$! 0$! 0$!
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M/DM]LJ[F"W>-M4&TI[%_SL>L]"FLHYF*]<*XW%UJWXGF7B^NDUNF-,R77\4
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M:<V'V!Z9?JY0N?DK:/'?5M4CT@9W.X6NSJ#CE"2%,'2*A8E8A+UTI!DLSBO
M0DRL#0Q""R\N \(DDP+3'4B1]Q<CR7 ;'ZE'M]8[_4V5*]2KXEH*'E!'4[C1
MK'0^I17:ZK-.&\PZN]%%;3\NQ44;M*ZLO2^94NFJ+L?=K)T[E+=4[00*W2_(
MC\_/[KF7OD> @7D022 T&+ B9D"#)(@ A9UK^IW[D5YA6ET?H>\T96.DUNW1
MH3A^SSG@Z6SE'_)JW9H^1\A;45<.M<GQ<CL:K>TD797?JA<B-:D0BG2D[%HO
M/]-HF3-Y%KQ ];] L@OZBONK6VET*L_J>-NJ%6<P"KJ]54O81H"J:;]"]B>>
M=3MK2S5?D]L<6.KG/.0T46F(4-%ULZ83LO/++88B:J4X<@E"]PDZ;0($&1F2
M;8M $3N3!D5O%]9;O9C.QU=9Z<%-NA5OCR/H;?EJ@[I9_1D!1L'J!(\:NTV_
M,PTDM:10^S-H<$ID5F;7!<LY64/<0Z<:YFRG+/>NM+"#$D7D?#<B!(&HS%Q
ML)7H)ZI^X7:.\=<?<[Z;ZPVSAZH'A_*NJKWCH6_3#9?W:ITAY9*.>VL?.Z<E
M_L5]W;&Z"$&"?5I\:8UF-#C=:6FM4,NC7EQ(+8$ @WC L9 O)/I!Z#T.\+:>
M$3PB>$3PB>$3PB>$3PB>$3PB>$3PB>$3PB>$3PB>$3PB>$3PB>$3PB>$3PB>
M$3PB>$3PB>$3PB>$3PB>$3PB>$3PB>$3PB>$3PB>$7XDCTETWBETTDBDTVCD
MCDUQOI)IOC.N^F^FV,Z[:;:YSKMKMC.-L9SC.,XSX1?,444$48((: ,(."$4
M006&,<444>/6$<88>'72*"""+32*&&+36.*/77337777&,$6$J1I449L2-.K
M31,6;!VPB5+Q%T9[EL1L6U;FZ"0PZE,V96^Y+ ^?$A9I&^TQ,LDFV=LD6T\(
MGA$\(GA$\(GA$\(GA%KC%"E@8I8'JUQQZ$N<]&<8$,28F.*7&*"C5),T6\RX
MLE2Q8+)R0]X9IEQQ@4F^PQ4\6Y%L?")X1/")X1/")X1/")X1/")X1/")X1/"
M)X1/")X1/")X1/")X1:(6KUD)^TM85=1"6AV("O=6050O'?MP%GY/YH31Q$/
MHQ/$7_EE_1&+)EA$_+)^#2/Y[?<BWOA$\(GA$\(GA$\(GA$\(GA$\(GA$\(G
MA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(G
MA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(G
MA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(G
MA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(G
MA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(G
MA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(G
MA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA%XG]*^ICV
M#E?LW[:\YL7,ZQ+RWUSV(,YU)D.Q*[1[%,M^->NER+YA3;7*8QJ2*W\_:]<?
M72X'-5DYCVC3UI?4*B9I6.DW!&7,O()!&,?[L6'(B;R(Q!W7VC^L6/ 6> R]
M5.FSM4-$[)87]8J=C!M-TFL/%57<#K')3JO_ (ZI+MG'B6_#&M$'[/),C&&Z
M)<J+4CJ= 4X(G!)WEXC8G,FPFP QM)B"I#RKZG%LZ#[15[CTG*$3*FWOAL%^
MJ;R@7@&W(&EVK-P]I$=IK7/.J$"(:GUAET1;Q:KM.0H)EG.(SD _2+0YL8T%
M;A5$D%27 1D<Q%IP<$FT87U]K?J<7#@W4>5\[3>OEPU*=)ZWT:[URQRI3^M/
M*:R3]Y.8TGD_.JFZ< VZX@$\:!&>V &YFIJJSZ#S9&6K8DW74E*4?4+2  <B
M9BX,V&03;;H-PJHMOUO%E%K%8M;SU3Z-8$5C.MX8]GY;:M>DT9D)S\J *Z6:
MGVU52@X+=3DK*U\JKFCL<!>0=;;C8T<"O$?/6S%@0U0 #I)GE>W/KM_P"5U%
M0_J0CM)O9C;J?%'7*UOK?S?I/2S6L=P$N<-L6\IZIUCD-J4A#C5U$0"[(M'*
MB]ZT##JWVL 3Q=M!M!/M! 85%0$.)$!H)S,Z20<>0B)F51WLG[N^V7JTGX;5
M[.@HSOHI/ :?T>_XFHN[PWOG9F%N25>Z>OOKZ#'UKD*55:JO$>38-(X2NG7Q
MJA9UXFJ\KN4BVS9P4<YS0,$Q)MDVL+M$WQ))Y+363ZSNZ1CTL8/U,OAX?,;_
M -(K3N8KH*):T@K/*P^@,[4P;5_2NL&->Z%_)YRP<JN:-<1QL5%KYZPTN48]
MC8;(""K,^%T@Q!@?GE&XF%: WU,G5YYQWZVU/C5AHQW"/93@7&I8K.2MLQMA
M4=']H$'$;,,[K2\E(TY]=PD?]9\97FLC36O5ZRTJV#GV+!A204G>2"0"(<T&
M<W< 9&T#/+T51*/K4ZFI^?EN/5JPUAS<G=("*6.NIJQP/Y_1*YZGVZLA4=QO
M2=-^@]$@K'MI7;%9>>"JTDR-%SCJ+>%\T"KL$IQ0UB!.@X!S:^FTQF'3!V'6
M%J+W]7KHAO'X^G<^XM4*DJ85+V2))*N/0)[/9*C<.8>L[#O- HS6I**XD7Q]
MDD*!-K_2.)N+,L:UINF/2 V9G)^9D&5[PG  %[DP;";;3S!(5D=7^KJ5R</I
M&S/UEL9$W*.@N>66QN\OXM+I^;NGIW<>J@I@;&RIQ\$K"]\BYCS:S\Y!A@)S
M9[?[!\]YKJ2(V$:M,$-6)\).DPZ\"8)$3S$1)$R!E1@GZK/2$-TN,5LY%3@$
M-2?]200UX*Z'#["*!+EZ15WFG1>P7QV@#&Y!3 D_M&ZN%\>ZU*W*(*;7&SY;
M++I6\Z.BR*IF[8'BQR'=Q)V/B,VBQ\UT1ZP?4AF]DNNUGG&?7JY<Y0VRH1.U
M=NLED&G/BL6./<?[*4A/JNM?!VA3;H>L:B)K6.]+C=3)-"=$PL#;[+2VVIJ<
M!IB>MP8G'+:=C;E/I]X71/"+ECVMZAU/F=>Y?%R!8&SM70>N+J%-H53LWN<9
M3-0^@VXDE=6]^C\G"*.R74 1,S,KTH"$"*-G^Q1.@P\A0DC'/\W'YF!)%"A^
M\G0:ZDYY_P I\+4URTVBPV*I.$ZCIO[\Q%CY_;J!SB\H*&%M39(+=>S+I=&1
M_/N?!OMLVJ@TNU6>2W $+X%1Q8#SN+R1G)! @6WS%[ ^L3K'U*2K8PMPZ7B$
M+0:E<3LO>[ ,FZAHWM*6KHA2-\4)_6A:#]D7;Q6&RY3;.<'-L"5,V5II):VF
M5.FK G>$_P IP3S-HM89N!$S/K&!%]2FS,9F4%:X+6[=$FF>A&V"M=S_ *M-
M:FH@/9=[*73K&/RC;%DK9U?]7[82N=RKU!!#6UTA9E1H,<X;)"=YBTR8$&=B
MZ<8AIOY#=;YM]19XC.<2L/7AO/61)K_A0S47S#!XR%J@_M;NC*/KLE'"&3ZN
MY_4._;O/A8&<%65VSGC& FR2,[(!52%\1X2020"+[.,D;"&Y/,;R!5+#ZG-O
M(+Z:.EHO-2/Y',;:PI,=?Z3->2VMXISGVQ0FVJGBC5NNR==Y%+/Z_P!>=NW*
M_P#P5C4:U9A&<\+G9GF!24-2SB!@&.1@N (Y@Z;\MI7<_KQ[/8[W=NXTW% 9
MT_\ X9MTU6_IG.P66[[(]IO53DV8*(A F%4;[S426Q0)RL-!2J?::>Y%=SDL
MF"Q26VNU%PB-)C\^_JNK?"TGA$\(GA%XA>X_O_[H\+]@>L<XY#Z_5/H?*:H-
MZ[Y&ZJ:KLTX'+R;@]@-Z9OU+0&Q 8;#VZIDZU[CV*Y"OW6WL4C>V;'J-XH\E
MR>]P,  CPWO:3><18C3$W!F+3/\ U']UO8_V>Z#TSFQZ_GM'?Q\D;WQ9O%RY
MPW']:>@!=%GI0_$.]#Y[]':+CT2);C9V0"PIWKQ&ZB0O7%+S9*F4"W$*M<YQ
M(L#$XP9@@^*2<;-G.(5?57ZG_8>=<,]<[CW?D:WI=^]D/7R]>Q=:*Y4J<<OI
MB-1RKGC;IW5Z/8A+.[ZFP5,*14ER@Q5:CG(\-[:V\&O@UI&0F+,.?GY"R*AA
MDB2YI=81@21<FX\]U+><?5U!Z#?N&4&#USLT>_8^FON=8N*CH=?=T#;12PYR
M!_7YE:9DJ<3KQ2+_ )'A+Z37U,:!A1!J3T?6"6SEU>,5F5%4$@:3<QS&UY'J
M?0K41_46[Q!6?>EV91Z)(5ZY\ZL3SE<.J"RB N;9K[O^]'K#6<7DTRV#A1U2
M&J>N_*+):7']*I*4F6]UMCNQUZH3"R5LIWCIJ"!X6R.IUU&P9(V8/F22,+NG
MT/\ 9O?V[]7>:]M.'6!V5R(P17@1*)*N2CWJJGSH;9A&L-=/FP-?G<!$%US#
MAC.6Q0$+'0TYZAFL:'ET8[4T'GG:_E)^Z[ \+2>$3PB\I_?CV_\ ;;U[[#RK
MGWK-P5#W4&[</[O<[2*5 XU<4VSUEQS&E\PN)IH3D //,$ESZ,OFZX'&%/8(
M*7N=849HG\ R(I^3^?M'-<WN>WX6AUC,R(.QM,@'XK2!B394?ZG?4D]B.X=L
MX%0[W1:4E$ZNL7C6?G==H[6&_4A7OZO5'N ?L ^?ONS1-@.0]!NCMG2:/&JX
MI::D%*,+6+%V@7I$@]68E&O+B)W L!? ),DBQFT!V,RI=#[X^R?%Q>BM.V4^
MG]T"B]P&'IMS,'B_/+1R4W6_[T@2P\];6\BR]%[)'-7^J6YTHYS&S"&5AT-M
MD)HPGL8;N0=$36YH.J'>/2-((\INZ9L-H/3%=O/K>JDRNX'C^L-DL>U9Z")2
M=":UU2N'5L/>6P>QR"13?[4=6EBWG'36TWKB;/2.;N-3<VW3J_&L;6=+I<MY
M5A0U0/Y7&\6O%W"_(F+#-PNOKI[8=I0^[M$]255&3D =2_X]ZK6+D777^XR+
M@*^G=2V[O#8C1GF%V]_J_2:)SNKIB-/TEXPO?Z7)*G>2(FLQ);U'4&P+B1,S
M ^*>H,?/HO2#PMIX1/")X1/"+DKW.]K,^GG)E75,<.[5W_\ J=%I?/LTOA-4
MQ;[<!BX&SB_Y*<N_/!^%&M_6_4VG^^W[3QBB3YV&PTR<*6*C]#9TN=<"&B3?
M?R&ZQO<WN=RX+S>FVBDR5T,ZR=/04UFQM0=6*7J4S.O6MN07KK>.P<(I@YNQ
MB( **>R=1K@.NI<L8W])K(N5F%7.TZ<07 $G80;_ # RN0S?</VC!O3&"5-R
M$[G:V^W9;"\0[V!DW<5"MX]4:O7C@EL8Y".0BS6#OKRSG8!NYP"Q8"&$HL%@
M'1$3VLLZC>"(O>TB.F\R+SRYPI4S^H\8'45/0X>8JI4Y]6=MB*S#>XBRJNQG
MN7K=6TBCL5HCKL<?&[=28>V,_P#F.D$5JYRTXY-^N,_:8ASN24[R]FDCI%K@
M7Y9G?'SR1OJ&7)]BL$J>&**DHL5FYH'LUZ5TZ17_ !ZY86_KHOOQ5CA0TARI
M2-:YM[)U)?6_U[&\3OSD5P*//2BJTL-H+>HV-ASDX%LBQ!O?ENIS=_>IO7^Y
MO.$U?D:BR601['6$V''4\UAK*SVL?!Z[H[MU<%Y_9F%1H+C;N8Y]2M@\ED(L
MHE(M?X4(>T0?[!0O ,=2,WM DB#:^;JMZ_\ 4DFMK%W9%'-QEU#JGJ?U_P!C
MF=3<6B'7L)I%%HG ^BUQ<YK<"W8"AH;&IZJ[5UIY,?:=;E.G,:C#I!$V1W!0
M/G8@:2Z"/$0 #C SN9/(96T)^HTRC4],= <73/T_*EU.E>6RO=>_J\_>'7[H
MPO/T1].N<'-OTW="KLDYAO3[P0(L_P &.KEM1P(;&0AW***Z\R,<C.X'+KT]
M+Q]Q_J%L+ CPW3\JT1E#B<><SU%M=$K+I$P5_P <99M(IZA!"M5K*L8#UO\
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M5]9<46C)XHY@.HV]!_C^\=S$3O56J%4\JSL'#V)Y&' 5+_A\).H3M:TW_/K
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MLJV8F2Z;,&L)X4NQ(N3AM8BH),D!:YTQL9!C63.91=<[Z8R1'\HL9WTQG?\
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MRM@(V3Q2EPNRY9IP=B,$LEZG#=5ED:'%,,#AFOR3)%@P?\A21S"R=7R/>/\
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M"!WQ1!/EBM38U<1GU_3^XZ74YLG0?F?AK8<6!LOZ!3B%B',G]<_^X/$*%+-
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M]'PM[R)=('BFMKT5+_GT^NJ)KVVD#0I!8QB@P52B>;181:QK43NA?Q&Y<3
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M6*D+" .6>W]GYO9>C88OC6AV[QY0^<,T%7YG@M+7#J'9;'?6.Y5L_8KPPNQ
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MXVU^6<$9UU^6,YSY]0]F>W2[3_"^. MXSPG$Z;V!@4B^^W@O%ES[ZE_U:?\
M\V_NJ,>]VY1:7,#<[JG-((_S:B"K=KY5-L#BZ?EVA^>V6VOY=Y9\_*63&F--
M]Y,1X^VNFNN/<H=B=J<+1-)G9G:+C!>ZI[CQ7B<8#H'=6TMP)D 3DRG?4?\
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M%C74\O\ I?@LI^Y.VHVH:60TC8C;6'$>9,XUR21:XOBXOY<U3C3W6]7$S*P
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M#J3PB_>O59GN::F7T](RRY5-4J:[U,VGBU<7GQU4LJ2N+98F_/-J76#JO8[
M-8;-LT4CLK"Y?&;2S2%=(C3MCEY8C$*2]/\ 3?DW4-*<(27;:<GIR"B5&)!2
M&"5:H=U'F-ZJ_2*!66T+:O/"1%E8M]04,0MZR576)0W[:EH>>H)R#J0M!@7
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M*9 & &ES'. ;L 8 @"T+LOC= ]SD?1U37KW2J=8N>0BF:,TRJU:M&,Q.Z8V
M:2,/7@U%Q+KAS($7]\6,+ P\,G_E&Y_]-+^=XOM+@^(X=U&CV)V?P51S@1Q-
M"KV@ZJP!X=I:*_&5:4%HT.U4R8)(AT$;;3<UTFK4>.3N[C>_A8UW+>)@QR[;
M\\==4\(N9?:_T_X![M<T7<B]CZ7+>J&IN]:Z& I@L%@K4P]IJFYF%9F&-;9*
MV&T&X;)FL.#W(V&+ 8E1;QXE_#-"67L:\0X2 0X=",'T5C]4XOSGM*VK(^F5
MM9;J[4[<%=!:R]6JW5<:M5R5ZC#A?I70#$!JN'@L!1D0LL.NT;,9>9I-KN+C
M7<J0#$SX3(\X(OTNN;K#]/SA]FMSNULFO0M8VN>A_H5<-T@$JM6TZG2>C4BZ
MQ5L&*K8/@C9C=4MSF'#-HUV7.)UT2_8:OJPD,19=3#C<G>TP+M<WER<<]"I?
MCTYYYJ7&5I;ND:Z+N@L^A5@+^K6-PJB788>P#VJOI8Y:A)(57[1#WCJ$3+-D
MF?V$&-^)I7; CTKU;U4E=(YG^U[8ZG*BZ?T$XFF)0[Z-NA'+JA!:X*6B8/4L
MJNI8Z"%^+HFZO:&LCM#9+NUC#LK7_(6;O14Z7C:5'2MI-S$Q90TP=SDFQ N0
M03B;S/G<0L[H7HMR'I+%26]>7X=:J4AA9K(3"J$5UHX6\AO?#%EL<"/:<Z,.
M<A<YZ&]4_P S)\=+83PK3G%39$#3;$DT-MFT6FUA ^BU#7T4ICQ[2-V_1>B'
MTRE<RIW/)*N06EF8W.:C=*AZJ@=7"T3J)2_QK[>MK[8-/3PJ>*-,EB5?EDIY
M155W)H',Q $>I))YS(\H6+T7T$YK<*Z4K1V:T5\X"OIL4F!CL"[J=8Z95.9K
M>1T_KI*4&"NV%S9$M$3*4,M?_P S7T1@.)DV2KQ/)Y6^Q',F8L?I,0"1Y6\E
MB\]]"JU7*!E-;>EW5]TQET:U=:?=6KHU;K3.2\75OV4JQ%)Z\<ELE;! 8H.[
M]"J909:P\>,)IALA'KCD542J*Z!$29DF=[S^AC'W7]B^G!Z[P\Z(YCI)?/\
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MYO15SL^E+]3(99.C_M+.ZL#;3B6:P_M80;6$233_ "+\F^)_Y'\_#G&N&O\
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M4_/K/YTRI6L2*T^F=%XD<&=L?;>7.=Y9Y,??[_;>>7;>7;7[_P"_A\OAC/\
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F/")X1/")X1/")X1/")X1/")X1/")X1/")X1/")X1/")X1/"+_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>54
<FILENAME>g425213g64f07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g425213g64f07.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1I44&AO=&]S:&]P(#,N,  X0DE-! 0
M    &CB^9Q(X0DE-! 0      $ < 5H  QLE1QP!6@ #&R5'' (   (  !P"
M4  (5&EM(%)Y86X< @4 %U!O=V5R4&]I;G0@4')E<V5N=&%T:6]N.$))300E
M       00V(G)3S=1\##NZ 9N5,EG#A"24T$.@      \0   !     !
M   +<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0
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M;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP
M $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/
M8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M1W)N(&1O=6) ;^            !";" @9&]U8D!OX            $)R9%15
M;G1&(U)L=                $)L9"!5;G1&(U)L=                %)S
M;'15;G1&(U!X;$!RP           "G9E8W1O<D1A=&%B;V]L 0    !09U!S
M96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M    5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M       08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M
M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12
M:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M
M   0 [_^-0 "  $#O_XU  (  3A"24T$)@      #@             _@
M.$))300-       $    6CA"24T$&0      !    !XX0DE- _,       D
M          $ .$))32<0       *  $          CA"24T#]0      2  O
M9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:
M!@       0 U     0 M    !@       3A"24T#^       <   ________
M_____________________P/H     /____________________________\#
MZ     #_____________________________ ^@     ________________
M_____________P/H   X0DE-! @      !     !   "0    D      .$))
M300>       $     #A"24T$&@     #-0    8              GH   .$
M          $                          0             #A    GH
M                     0                         0     0
M &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   GH
M    4F=H=&QO;F<   .$    !G-L:6-E<U9L3',    !3V)J8P    $
M  5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N
M97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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M=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*
M    #     (_\        #A"24T$$0       0$ .$))3004       $
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M<?\ R*4V_NM_SC_Y%)3-)0FW]UO^<?\ R*4V_NM_SC_Y%)3-)0FW]UO^<?\
MR*4V_NM_SC_Y%)3-)0FW]UO^<?\ R*4V_NM_SC_Y%)3-"NR<?'=4VZQM9O>*
MJ0XQN>0YXK9_+V5O4IM_=;_G'_R*J9Q?ZV#N 'ZR.#/^"O\ ()*;R2YW(>*\
M_.8WJHQ+7/#W!["=K?1:RNIGK_HG;;S3>WT?YS]/1_PE=_IV+U%EM5EN=]KQ
MC47.=[??8X_HG,V-]M-='\O]/9^E_P",2G322224_P#_T/2<?&MKZCEY#@/3
MN;4*R#K+ _?(_M*XLLY6:[JQJH<30US665V56%OT6V/=7DMJKKIVL/YUN7Z]
MGZ+]76HG2!TOJ I2222:I22222E))))*4DDDDI22222E))))*4J74/Y[!_\
M#(_\]7JP[*QF7LQGVL;D6 NKI+@'N ^DYE?TW;57ZA_/8/\ X9'_ )ZO24OD
M])Z=E/=9=0UUCXW/$M<=I:6^]FUWMV*TQC*V-KK:&,8 UK6B  -&M: I))*4
MDDLGJ5I/6,#&9>^E[R7EK'N#7-9-CFV5>D^JS?Z>S^DTV?\ &)*?_]'N*+,8
M=?V-L;8\.L;H*R0XA]SJ_:[UVL8T^ZST]GK?HEN'=
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                _^% !VAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\
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M$0'_Q  >  $  @(# 0$!            !P@!!@0%"0,""O_$ &00  $#! $
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MX5M@@DHICZ>E:3J6N7)M-)LYK^X6,RO';@,4C4@&21B0D:;F50SLH+,J@EB
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M8N-BG)PZ]MCECCW 8)9XY.G[K+K=.+=#&^>6-LKVMXKTJ&.T$X)P,X4%B?H
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M16RYL 2C^K%XX/Y+R'9^O+);!<R+9F.TVY,R?UC)1@23-!G@CBM&="1<OH1
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M,",N61"P)12%X<R!E@QP"<9SS)KT=[;*?(Z0^=Q+^?\ RG_?HKYWM'KKY/\
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M\T^""Q+;I@NW(8#:JX^3S\*QRJ]D_@_\Z2_\G^!#<7^ZNP[+_P!6]M/\V/\
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M'"RUVDJFR?2AB7>CF0X>X;#VV)J[$S/&CNNUF&XKC!4-Q56&3\I5(#<<;@<
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BK5*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>55
<FILENAME>g425213g69e65.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g425213g69e65.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !Z 1@# 1$  A$! Q$!_\0
M'@    <! 0$!              0%!@<("0,""@'_Q !%$   !@$" 0D%!@4"
M!0,%   " P0%!@<!  AW"1$2$S@Y=K6V%!4W=;06(35XL;,7(C9R<Q@C)C%6
MEM09)4$R0E%QA?_$ !P!  $% 0$!               ! @,%!P0&"/_$ $\1
M   $!  '"@H%"P0# 0$    ! @,$!081!Q(A-C=UM!,Q-4%S=':QLK,(%#,T
M46%Q<K7P%2(R@9$6.(*%H<'"P\33X1="T?$C4F(D5/_:  P# 0 "$0,1 #\
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M&]C$1F:=RQ\?&(B,S+%N1$9F07,"#G/-@0<Y_P#QC.,Y^[_G]V,\^N4=(]:
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M4UO_ &0UC[#_ "9]2ATJOL;[G?$-8>IFG237/*F.;S/97PB/(/>U':(> ]A
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M,?V1ZLZQ\YH_I3+.T8IZ"\UKOH7.>PD&ZG[/VX;_ !1#S [4%19Y47[TR[E
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MJ3I&:/1<<BN5K)MUM13][9(BTNT:@[O%4E:KF%OD:@#T9*0-J(O(#Y/\;_\
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M F(=1(QIG'", %6WE!:IKK!44$X!2FWJP4%A4IE"-0$LYY+, %0C6%$*TIV
MBQ@U,J()4$&8$4>46: 0, !EOMD[2-V^$[A\Y*UM%39N2+G4G[@QPL^5=]U?
M:(,S:_\ #+=AP<._5UUVU1PG2FM_[(:Q]A_DSZE#I5?8WW.^(:P]3-.DFN>5
M,<WF>ROA$>0>]J.T0\!["!GYA >D\Z4\_$]'OZLP%YLKE?X2&G6R?LS5M_;*
M?64AUF=:9RS+VPNQPXZX?R*/TNTH8#[7>^:F7'3=!]+9>MUJ?0_":EIOMRX4
M<-PLOEHK^8(YY//XU;T/RE[D?4$5U85_P-1O2JG>XB0R \O%\V?[: D[*>QS
MRE'#&K//)CJ:LL[\'.LIIW$&&PGFD?[C?:,%JC[K'=EQWJ3]^.:6;Z3Z4U)-
M.J(#6N#XKE6>L;8\C7V*6;B-/_K46L:POYYOZO@.[6+>5>:%RB_W!T![;6?%
M0_20M>E/19^KD_$"'S^G3.>ME_#%!/ICM42OYI9?[CGJ>J-'L!S60]4*.>D-
M*4QYY4O5&!GT#^&W]P;F/[(]6=8^<T?TIEG:,4]!>:UWT+G/82#=3]G[<-_B
MB'F!VH*BSRHOWIEW*!T4KF#A ]V3[0X+-;)?AG(_&ZSR-AUX7"KP[ :I:VR-
M&DX%<VYGKU[X=+1DQN5[V2&\4-NWEL%ULE'Z#H_4M6=],QE-8:>)9KFD^ZEP
M2H1WN*WC?/?()%J:8Z"F^C<KVJ$$,MT_.=(9K\.C F;*NV5N \#[@O-PZFPB
MZ/Z7UE2VSJ$6#G215^K:LVQL,;9%\&M]WY>%/Z/FK+"-G!@TZ5)ZH856#3-K
M"AT47V(P7FY&+^B;U\4PSRE\UFWA!\(TUS*8=_##2_!VX*J76$#LSP)[Z^UO
M7_R2O?53KKXPJCAV%Y&$VAT<N%#2#)>;R?X@^"L[[R5MXHU[Y)'=,B\[T<_@
MNPP&3;3/#ZYE&R0@-51WD#_Q#M3RB2Z? YX.\\C^ZB!)(=,T;K6>[-&!C;3/
MB%N1X(V[]<AUR2/SJ;ZLF'6D5E \,5KT=G_>I$W\EO\ BUS?+H/]3*-6=$^5
MF7)PG:B!Z/ ;Y>H^2EG;C14'EHOCO3O##/K%[UYO"1PK ZO+:7QY+PA,XJ>U
M2YMSH;N]#O+*=^9[;O-&74529Y2_E9)WC(@PBZ8:=Y>D]M:'1?WQY?&UM]'I
M=*K2&6M$=RD([^< 6OF?A2!ZVB=Z3;/B_<Q]9*=)3^?$;SN>=J*#J#TUS[6%
M7[1%AQ\C/V@+JX;F^M6;4^#KAB8\Q7M3 Z?!_P YJEU87Q!L3+N0=9S(Q6-'
MGZR-S#)NGAMI;@Y)M]K&"U[:6([+G9T2JV#9VLK^90]B25PLK1A8"(3([A,F
M[P_P]-,W*R"K;4Q]H:3B4.Q#ZQ*V3>M8O1Z2,_7??(N.V\-SRNMZHOK^KZ[J
MP==U72ZKK>CCK.KZ?,/J^GS]#I8Z71YNE]_/H#1TT %-)UM#_B!*+:DDCM%=
M("K02L#8E8)K6-1V"Q0B/1U6SKD43CS=,H>[I3(P8O0.3TJ0KB3EBJ2O9K^I
M<CUC8SA1  J3FFH!#DE%K$+.%=((;.J:B#9*W4T:J1'M;#[-'4IC@L#U1*A8
M>W$8"K/PF+P<:8:9@ ,BQC %N?S\[_KWQ03;)VD;M\)W#YR5K:*FS<D7.I/W
M!C@9\J[[J^T09FU_X9;L.#AWZNNNVJ.$Z4UO_9#6/L/\F?4H=*K[&^YWQ#6'
MJ9ITDUSRICF\SV5\(CR#WM1VB'@/80,_,(#TGG2GGXGH]_5F O-E<K_"0TZV
M3]F:MO[93ZRD.LSK3.69>V%V.''7#^11^EVE# ?:[WS4RXZ;H/I;+UNM3Z'X
M34M-]N7"CAN%E\M%?S!'/)Y_&K>A^4O<CZ@BNK"O^!J-Z54[W$2&0'EXOFS_
M &T!)V4]CGE*.&-6>>3'4U99WX.=933N(,-A/-(_W&^T8+5'W6.[+CO4G[\<
MTLWTGTIJ2:=40&M<'Q7*L]8VQY&OL4LW$:?_ %J+6-87\\W]7P'=K%O*O-"Y
M1?[@Z ]MK/BH?I(6O2GHL_5R?B!#Y_3IG/6R_AB@GTQVJ)7\TLO]QSU/5&CV
M YK(>J%'/2&E*8\\J7JC SZ!_#;^X-S']D>K.L?.:/Z4RSM&*>@O-:[Z%SGL
M)!NI^S]N&_Q1#S [4%19Y47[TR[E Z*5S!P@>[)]H<%FMDOPSD?C=9Y&PZ\+
MA5X=@-4M;9&C2<"N;<SUZ]\.EHR8W*][)#>*&W;RV"ZV2C]!T?J6K.^F8RFL
M-/$LUS2?=2X)4([W%;QOGOD$BU-,=!3?1N5[5""&6Z?G.D,U^'1@3-E7;*W
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MW[WKWO4*9.=V;ED,@LJ,L-$QB7K8W<=Q2^&N.*P;D#')*1A]BRJE892V7,"
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MXL>00PN6QQ0=*XS!P5)MFDMF0)M95SHCD$7*H^L9Y9D+CTIB\3C,A>'J./\
M*@):Q\7I]7L/*?7[3%/6B9;J*G@RMBH*M'"O*P76Y,E+G9%0[>+]IU@>5B6F
M(2=%4M?;4K,V_P"\&:4U$724D/Z&5%QNNU$"FT\80K62PHQ*IT^D.A\\?S^
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M)%039.TB2F9(GB$R@D^W#26'3"9OPE^T=,[)7Z.TAF/R>?GO5@[/P5[)""Y
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M/CU?1)@AC&<Z*$Z5(>Y&M,<;VU 8X'I4*),<L&G$H,3HTI(S!%IR@@ !]:
M:  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  : #__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>56
<FILENAME>g425213g72w54.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g425213g72w54.jpg
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M =W?<:>\G?38 [N^XT]Y.^FP!W=]QI[R=]-@#N[[C3WD[Z; '=WW&GO)WTV
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P#!VG/7!O\
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M6SL=1:/&V6.0K/*KJ7E5W$KN5(2[YJH]8P!@# & , 8 P!@# & , 8 P!@#
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MO,J;J&J>9.=!-ST+OKIWS[P4;Y1L6:9LP8-(NT1O=.20@/I?W?OD^^:-) 8
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M:=)U)-U;W M=;M'5HWGKB#9N-PJ@0XFTD5T]1)N5H7J'D]:'M$6FNV4>D<)
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M8  PID$>J%]:,8M4>U'*> AS#8G"'^F>[[1@/)PZ2S5Z'P4EB5[BC[F-(YT
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M8 R<.DL]>AX?6[Q3^_6IOB-_RN-GG"*-:&:;\"3TFYC_ #G>QHLC97TFA@#
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MX$NR1CG23.HF9$YTR&.B<Q#F2.8H"9,QDS'3,8@B)1,F<Q!$!$IC%$!$#^\
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MOMJ[GOU\12=-+;#P!485"WP_%NOS6JO;77Y06$,Y!I#TB\%?+7P@[2I]#4V
MV"YN:+3MB2.IH8]BVI$:.M.P*O!;YF-;P"+&4=3%TC=/OKHZ@V,?$S$LHZ3
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MQ=.CY[#Y+5WH?]H^<:$WF+255CREV^P Q$VK1P"@C38@0,)G*2ABB "!>11
M.]ZG/*Q6=NG))YI2\]-<8]J]52W*O/7U9#)[R]TON,F>.F':/V^G-6&=RJK\
M@[(<@5-1HS;@0WI:DOV0&;)$,;^#D;F'\&0UB/I>9ZO8XA@]4=>V,_W5*].;
M^(P[=0 $;W2@ PE$;97>1@ !$H]V&?(>0]X>7\ \P']\!#/+'8%&=EB.Z;/I
MA*VV<Y%]5LNQ!&3/(/\ I(Y#O!_U;%_P?T?*8D\<]S)GVR.?)D7^;X [F3/M
MD<^3(O\ -\ K->B$VSMO,\*X/)%60$\;MWL9E&[5OV+JNM=<P &R:8& XB B
M)N8AU0Y"',<L;8%O-)]+*-R8D%.;L/D>Y/H_"^@KAY8,A#:W@5*H?C,X7B)*
MB@H;>6MRD6*0BADS#9X\"G*10#)F$H\A #E$H_O@.8Q37%"DNI)CUU?]U>'I
M@\*A]*QM+^*D9,]C/SLCD0ZAN8=S8L.8=4?X&_/*+&7E(6< 0FY@!'F(2D@
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M (EM0L;, 8HFL;DY0, F(,;& !@ 0$2B(-^8=8.]S#OASYAW\JJ3)]W & ,
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M+5'M1RG@(<PV(PA_IGN^T8 R<.DL]>AX?6[Q3^_6IOB-_P KC9YPBC6AFF_
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M-?W>5=U2W9E529& , 8 P!@# & , 8!_ )IE,<Y2$*=02BH<"E QQ*'(HG,
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M2504%)0P$6243-R.0P!S=!7Y]$'OF+[8?#29D\:O"ITS88',U<(N ((SE:$
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MV'R/?^F5P,L&0AM=P**)H\9O"ZJJH1))/>>MCJ**'*FF0A;/'"8QSF$"E*4
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M&G\6;_U*?^G*^DT.U&G\6;_U*?\ IP!VHT_BS?\ J4_]. .U&G\6;_U*?^G
M':C3^+-_ZE/_ $X [4:?Q9O_ %*?^G (2>F?112K&A!2233$9Z^ (IIE((@$
M?6>0#U0#GR_XYN6P_A,]T$!WD4>&.YCO.780&YO,C3-?#6 #Q$:( 0 0'<.M
M@$!#F @-QAP$! >\("'>$!]7(6DF+T\U3,.%>G:YOSK/9]BUESWM1I_%F_\
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M75RKM/E9V'!9.Z'KP;[EXW)OS7J65XLLXPPFJG/$Q1*P5Y7/:V,DL6:N/6,
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MA-Q. #PP]%_"A]YMS>8C3S%*==G=\0Y.^&O[O*NZI;LRJI,C & , 8 P!@#
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MF7<K*KJ**& [=@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MU.Y:[N=0LP4B*D)NX]P+17I"!ES5>)BXBP2,A/E82#@T4V:0<PLH]!$"QKP
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M]SJJC8'I++5+%7SLQD30X.R3,0\CC-AERQ\L:+!<'(I=T2Q4F9CU^V0CWHI
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MM!3"G#EKJ>;.TI/NU!S1K*:(D6L;/N(U,%:5;M2^%MVJO*;SX.!@# & , 8
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JZ8+$M&A9.:D% !1]*/07?.S@!EUU#=_ .TX P!@# & , 8 P!@# /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>57
<FILENAME>g425213g85l79.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g425213g85l79.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( 0@!1 ,!$0 "$0$#$0'_Q  >  $
M  <! 0$              P0%!@<("0(* ?_$ & 0   % P," P4$!00*#@0/
M  $"! 4& P<1  @A$C%!46$)$R)Q@121H? 5%C*QP1<CT>$8&3="4G:4M-7Q
M)"4F,S578F-RD[+#TM,T5F2%)S9#1D=3<X*#DI6BL[7%_\0 &0$! 0$! 0$
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M;4ST')Y75G-:J HP]J&7- - - - - - - - - - - - - - - - - - - -
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MBS<2J.RJLDTX@^AFT]G+96+BU>#VDB#; X;6D4CE5**L1UM*.M;Q+790^O\
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M-UHX3C/*_=HNQ^ NDJF%SKM;-[;6GA)7:%2FRVW:X[3;N["O;G?=C=YO3O\
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MAE]L'3JC,'N-')&O62>JGE5>/_JS;1:T1=P!M1"M>'_J]$[ON5*.NFAD: :
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M%7,+.^WI>Z4=%]#(T T T!0I0R'DL9D4<IN[LP'D#$[LA'UA4E1/K(=U;U"
MKNRK#4ZI4CLVC7!8W*34JA:"RC1JC3.!.D0.$<LVJ;O;86TLGM;<[\,%P;?2
M-1$-N;;MGL/M:"WUFY[MH*N98WN,N=N/NTXODWG=M+AU;5OD@F#5+(!<ZV2<
MMUBL[=%8[<20R2LA.-RG+SO+<N59)6B=K5I$'9FRME(O8V+K(['WJ;RUP>G>
MK()7.[F2USG5PYF^'0H6F@YRB5.YA5.%5O8FEG8&I-1I)$#8RM*!"B1T24C#
M4&6Y>2X&8-"#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#
M0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#
M0#0#0#0#0#0#0#0&LE]=TD,L&],K))V5]<U#XV&=$M1H*C-3)2(KKI#$K IK
MT3%,!Z FR "42F ,Y <;PX'B3<PEWVN.AG%B\+B)I)@:K[2:T5']J(3SSR"=
MFQV[@/Z4Y].,CWP&M>5BB56O<YKT,^9MU_1;Q_:E63IU?=&A\^SY_9V;_2GW
M]M%^.?\ 96;].V^&[@>9MU_1"K>U0LA0'XXA/NGP-]G9L#Z?\)CSWP'IX:B_
M&W9KOHJT](F:/,VZ_HE/[:W8_P#]3+@_]0R_Z3U?*>__ (O['F;=?T>/[:[8
M_P 87<( \1^S- __ .B'[]3R]^D?(\Q:$U2]JG9&J43$AEPQ  SG[(S_ .D^
M XYSVT\MZK>O"VNVOL\Q:'@WM5K)$'F%W! /$13LO'T!S'QT\O==-)U[M>@\
MS;K^BC*/:X6*3U IF@UR#"(XZBI63I^H_I7./H/RU?+AP\2]YTCBAYFW7]$S
M3]K18DY ,$*N,&<<?9&3_2P=OI\M/*Q:^E>D]W'F;=?T>3^UJL43.83<; #C
ME.Q%_P"T[E+]Y@],Z>4YB>G['F;=?T0_[;=8C C^I-Q> $1_F8[V#_WWIY3>
M:TR^QYFW7]$TC]K)8Q:;%.%7%+WSU4(^;&.^0IO)Q^7&/4!T?X_^RB)F-XSY
M_P!#S-NOZ(]?VK=D* AU0NX0@(XS]G90QQGG_;0?EWT\ITAS.B[^-=)>9MU_
M12E7M<K$),>\A%QC=1ND.B@PASC/_P H[TPQP(<"(Y\-/*=)<3TM>N^8\S;K
M^B8H^UJL57I^\+"KB%#&?BH, _\ \;Q4Q]0#GCOG$\MY-<Z9].W:H\Q:%02>
MU9L:K XEAUP2 3&<I68V<Y_P7,>V!^>GE-7<<J>K@>9MU/=3VJ]C2& /U/N
M<,\B5,S9 ,^1G0,CCL&0Y# B&KY6+CR=]'IWE$O,VZGY1]JM9&M6+2+#+@@)
MNP_9V4>P^0.GU[Z>4ZUMJHUWV'F;=?T5(_M1+*EQ_N/N";(9X2LO'IRZ\C\L
MZGEO)KG3OB/,VZ_H\?VT>RP"(?J;<+]DPEPE9Q$1* "(#AT$ #D.<CZAYO+>
M;2Z\9S7R/,VZF_=MYTVW,@T;GC0E5HVV3(/T@C2KO=?:Z-'W]:@!:_N3U*76
M)J)C? <P=)@S@<@&&H;6AM.4GJ7OJ%&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@
M&@&@&@.,_M,ZXTKA6^ IS$.$(4F*("(8$7Y:01$.PY*(@&0'Q'C&==_Q?QQ6
MOKM%%G?^SECNN'RSE2Z+#@6J'23X0X$0#(<9\>/Z?7C6W>-XI5NRGB[Q-S!A
M5R=P!=GII@(CSP7P\^.,^/[_  "O_&W6'?75U5J0]);$NH=DU4@4SDI"4! 0
MX ! ?/J* &SD.![#X\Z.)Y.JJME#<168NGHH!1Z[O2((=(EQX\AV#R_/\!TE
M)N$K4UGC,JFC]'*!2JC\ "<0J!TX'I#CR''/CX>/';GOJ>)ZOUWX=NJT!7&E
M[,>F("8.D0YY[@(#D!_/'/CJIIW25+PJ1$4TUO.RL)M2[T.@W0)<@'/ #D>P
M!C&/GGZZ3%W5*D45Y;3R;M11R!C-V? %:0"' N3" AQ@>!#RQ_#CCOK-7WO]
ML%1HO A2 ?>%X#_D^7R_$?GX:@/(O88,83@(@/@(%^X2B XQV#[^-67_ '7W
M!* _&-U![T<8\3_,>!]> \_QU 5QD?LU I]0=(B.1$<@/;OG/KV#P[XSK6%Q
MW5<*J)LV"L*W4#U! IBB4I@$<]&!# @(9Q^[[_,\3K*3RMZ74WK7T0+.>G8"
MU"#[PI"B8 *!0 ,F ![X#/[_ *:CJWD":3/AZ:?XC@)3%P'[)NP9$0SD _#(
MCYZ3W[3JEE/L"X69[+[DQC5 $!$,X*7L \ (@ >?&1[^/;%3UWVNHI"A;WV5
MY'NJ]$&H;!P O&,](>//?/?\XSG5>*>_Z=*=<J FF]X#[200$HB AS\(B'(#
MCMV_A\]1/K315S<//IE-(%\?I(IA(( 4!$/BQT_$(^(@(" ?ACRQJQ,SG+F\
M);S6*3>F<M@]G< $H%*/2.*N!*  /QT:@&#ZX)W\N,:D:QE,RHSK39JE;94!
M]4NST0';-9P0[&B5,WS$R]<)A^IA$=>?'_)\O9';#_%=YFR>LFAH!H!H!H!H
M!H!H!H!H!H!H!H!H!H!H!H!H!H#B;[4=4*>X]N,#CJ@JL1[9^&0+,=\^/IKM
M^-M)QF_HY8[KA\LY&/KH">A7,:H/4(#SGD $0R/W ''?PUM*T\>-UK2OVZ(P
M:U/$DHTEP@)S%R(B.3!SR//@. _.-'7V7!<7V^(+;73*C1)TDK 8V0$1*8,X
M'GL&0 ...,AX>>G'[]/[!0%4TH@ #[T $1#^^P'/S'O^[ZCJ4[I7J._0I->;
M4_V?>%,(Y#/4'&>.V<Y <X$<AJTT]7^EWF"[8[+*=2D8HUB]0%P'Q /(A@,?
M7M^.IWWWQR!<XOI!IG,)RB/2/B'U[#@/'G@/30&'I%)B4UW04Y2?&/(&SSD>
M>_ 9\L>6?#5KWOETL#S3EH%H (U0-@N/V@]/'.>/D >G.=)V77[]N1<\OKW]
M*Z7)<9@4"GP<H#CQ/V[^>,!\_P"G2=EUKU]B9]_?SS)(DP YS%-5# Y[F[X#
M'./X8_I2[_',<^^_[+MC$H,:L8 J%-R.,F+P'&0Y#GP[Y_@"_??-@O6I(J50
MP@>K@W6'5SQR'(<?T^''CJ1W*[R[E Q_)Y'3IF*6E7P4#YQGJ\!'@<B/''C@
M/#TMHB^OQWJ"21RT]-*<??@;/27D,< //[6>_; !\M)U4]Y]IS=L=Z%V1B5A
M63J@/4 >DW'Q!P'/IS]/OSJ C&E9#"<#5,8,(%Y ,\]^V?O[^F@)YGDH5UA2
M%KB&!#_!P/S[?U!GYZ=]]\@992/H@ !5  * =/4 C\7&<YR.!^6 $=:\6;OK
M2^K45?'6D K%!S]X)C 8#%P&,C@ $P@7PQG@PY\.?/D*FI7116=ESUR622!]
M:NS(YJFUNRAS#DQX8G,(AXB*U:(C]>^O-CKB>5;';#_%=YFSFLFAH!H!H!H!
MH!H!H!H!H!H!H!H!H!H!H!H!H!H#AK[5JN6C<FVHF[?J$K'OQG]8EOAKM^)2
MJ3>L:47R<L=UP^6</+E2TC2TKU]>L6F2A345<F$."4P^ .P  %Y_B(]]=7"H
MGJG:U*.)<N+\H2,'(A[W@1D\O6L]=TH4AH*Q3^\/4$:><B& .' <CSSWX[B.
MN?BPS$_K7G'*\M7.B_'BB8WM[S3MDRY;AF6@ U"N:<2B'?WA/+U-VY]1T\6'
M5>LO*(2N[_1/#B<ZZ=*996TC8M2MN/835"E%S3F#I$>GWQ!R/<,?$ YYP&-5
M8L*NUZPZK]A8&]%Q_H]4[ZM]4O4192$QA P!UD^$._\ A9QYCHL5ZIS17I1J
MTUI/*P\&SWK+_P#S#X7+F;-QK0U 05*VB4F0 3>\ !P @'^%_#G1XDZRJMYA
M8'MUS3Y>DPS.T4NZ@DR RE&J&H4 R)R\\8SY\^7USQG5UATM?7*RTZ:F8AU7
M?+[,(3:\K>E?C(CKJ1#>\Z0ZC% 0-ZY,&1X$/'\0UEN,TN/]K/Z-+"VO:L4]
M'\:U)BA=%,:CD%)#T^DHB81QR(ACIYYYQ]!UI.LQR5K1G7ND$\+]9CE7*:NM
M-BFK+JIZ9#^[4%#L.  ![#VSD?#GL&/32?[=;WI3*CF9'A?O=I/9Q+;X)5RD
MIZ*[":L)A/6#!<YZ><CX=A[9#G^(:B=XAY</>MI]5!7AC/A+KEK&L[1!?\9N
MJF)7+FK3+3'.3B; ]PQP)@]<>OAJJ,^^/].2/"TIUID^$1/QS,L(KAH%O46D
MK]Z;@2@7XL#VR&! >,_7(<=L(TK27LMS.5N?P8HG]T$;>KI)15@6H)\F"H($
MX$H]AR'4.?7U /);1_/?)W3-)2\OC/31Y1'JII".YZ;[(8_VLAB]&>3X#.,Y
MYSGMR #VR'&D[3Z45;-O5Z/)UL/"U>B];<.-)CB73%+HIC)%!P4TPZC"(_$
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MO4*!#N2T2AV#[14#[Q*8!$/01$-+]]ZE\.'3W(1G1R,(&%>KR 8#"BH7\"F
M,^N,Z%\.'1$Q2?WJ@(#3=%H" =(=5<Y^/_Q!-]_?MSP&DO7OMLCP87=(]59
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M>_&G[OVU$K?GMPXM#I-5NJ3:V978GMF=%*JE6=.JHG+5)U$#G//("4 *'/\
MRNKP'&JL#FM+:<^?3Y8OS-T5&U:D\J_HVNHVG2L[ +<E2&+2J43A7$ Y,(E$
MHF,/<PB ^?;@/#72,+I1UK;EZ66U#S^*75M5S34KXCEE8Y]7.M\ZQIYKG!/5
MJHSG 2@0HX&F01Z1+@!R(%-TB')BB.0 0'7'$H;R[RI&>AZOQXTU#O6MX=I[
MLZ,Q'6"F!S>Z*8I!^'HJ?MD$,=0#X\" AD? 1#OG6?CKQ[T.RFSXRK-=OH0=
M4T- >B#S@0 0-\(_#U" "(<E#CX@QQ\Q#QT([<*WB8R>QE:W\36+ZE18*>J
M"4Q*8&*(? (E'J$!QR(AZ#CYZJ5WI'<_WLKG'\F.*7V6>K^K[9E$F,76-"^M
M5JT*QJ50X /241.02A^U^S@Q!('(CV-R(X$,9<S3GG6,H<1SKQ9<&.4DFE1N
MK[BO!5UO89L9'I$1#P$0P./756_?]G53%5#/S0HT!$I!3$X!5$Q:><F,0,GP
M #@ \ R. R(?70CG*]DJ1QKG3]7-B+!0)0_S%"Z5D=4K<@K4JQ1J (B(@('
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MJ[S6*[6SJ3Q/6>+?WW/"+Y8H(FHG ?<%  +X$ 0\@'G'XY$-*5C57Y\:6S7
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MZ3&'NB&(00$P@ B!<9 <\=NW;.>>.X9QJP]M8SC7NO(3W6CUO<A*6/CDAL>
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MRK4/8ZV+H% M.XER@#N/Q1[/T_VJX_'5\S_JO5CR]^G[/9_8]60.42C<>Y0
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M /*#?^#3P8M.J^QX\.O1_0_LEK&_\8T?_P H-_X-/!BTZK['CPZ]'] =R]C
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MDTIG?)>BOM--@3ADM$Q  >P=NGP'OW#MY<@''AJ=Z>P),R&B '#H$P"&1R.
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MEXK1[K1Q#!9IU%$3',6H/(C@,CSS\^>//MC(CK )FDM(!,%/@>X"8<@'8!#
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MP4]'"G'!AJ'$<8Z<F$>>>V1].<^8#JIQ9^ZXS$\H>]X0*A^J+F<A@ 0()0P
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M42VY4:M#67MVU27;H6.ZC<#O;X]Q:3349VZ.LB^*+V BA:L.[G;9(1NKMCN
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M@@.0X'_I:O\ DX_E?/ J;W*5"B'2'2(Y#N/D(\<_GQTQ*$G$.=;*M/2 >SF
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MB/2$4%@]G#:B'0.S<)@UU+_0A=MW"8LUC;@1R9Q2E/;;6UGC?'FR26;;%SC
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M>=UZ17U</)#Z2-O7]PZU7^)##_F5/7EQ7?%^YWPV7!>QF/4*- - - - - -
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M-5?&XVU,JNJGXHU:S>EIICU2<CQ5]WUB.1R8PCXZXMRV]6=4H26A?NH4: :
$: __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>58
<FILENAME>g425213g86y35.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g425213g86y35.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1^\4&AO=&]S:&]P(#,N,  X0DE-! 0
M    'Z"^@)8X0DE-! 0      %\< 5H  QLE1QP!6@ #&R5'' (   (  !P"
M4  (<G(U,# W,S0< @4 -DUI8W)O<V]F="!0;W=E<E!O:6YT("T@1W)A<&AI
M8W,@9F]R($)U<VEN97-S(%-E8W1I;VX@-@ X0DE-!"4      !"C?HV=MPG.
M+"G"LY9:>0Z=.$))300Z      #E    $     $       MP<FEN=$]U='!U
M=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR
M;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0
M   !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "
M4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,
M8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0
M 0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP
M $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B
M;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L
M  !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P    ,
M4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX            $)L("!D
M;W5B0&_@            0G)D5%5N=$8C4FQT                0FQD(%5N
M=$8C4FQT                4G-L=%5N=$8C4'AL0( [;I@        *=F5C
M=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P    !,
M969T56YT1B-2;'0               !4;W @56YT1B-2;'0
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M300-       $     #A"24T$&0      !    !XX0DE- _,       D
M      $ .$))32<0       *  $          3A"24T#]0      2  O9F8
M 0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:    !@
M     0 U     0 M    !@       3A"24T#^       <   ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@     ____________________
M_________P/H   X0DE-! @      !     !   "0    D      .$))300>
M       $     #A"24T$&@     #-0    8              ?0   94
M      $                          0             &5    ?0
M                 0                         0     0       &YU
M;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P
M(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   ?0
M4F=H=&QO;F<   94    !G-L:6-E<U9L3',    !3V)J8P    $       5S
M;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M      9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A
M=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N
M9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,
M969T;&]N9P          0G1O;6QO;F<   'T     %)G:'1L;VYG   &5
M  -U<FQ415A4     0       &YU;&Q415A4     0       $US9V5415A4
M     0      !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB
M;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0
M  ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M
M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E
M96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E
M=&QO;F<         "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S
M971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*
M#     (_\        #A"24T$$0       0$ .$))3004       $    "CA"
M24T$#      5"P    $   "@    ,0   >   %O@   4[P 8  '_V/_B#%A)
M0T-?4%)/1DE,10 ! 0  #$A,:6YO A   &UN=')21T(@6%E:( ?.  ( "0 &
M #$  &%C<W!-4T94     $E%0R!S4D="               !  #VU@ !
M -,M2% @(
M            $6-P<G0   %0    ,V1E<V,   &$    ;'=T<'0   'P
M%&)K<'0   ($    %')865H   (8    %&=865H   (L    %&)865H   )
M    %&1M;F0   )4    <&1M9&0   +$    B'9U960   -,    AG9I97<
M  /4    )&QU;6D   /X    %&UE87,   0,    )'1E8V@   0P    #')4
M4D,   0\   (#&=44D,   0\   (#&)44D,   0\   (#'1E>'0     0V]P
M>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY  !D97-C
M         !)S4D="($E%0S8Q.38V+3(N,0              $G-21T(@245#
M-C$Y-C8M,BXQ
M                  !865H@        \U$  0    $6S%A96B
M            6%E:(        &^B   X]0   Y!865H@        8ID  +>%
M   8VEA96B         DH   #X0  +;/9&5S8P         6245#(&AT=' Z
M+R]W=W<N:65C+F-H               6245#(&AT=' Z+R]W=W<N:65C+F-H
M
M &1E<V,         +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R
M('-P86-E("T@<U)'0@              +DE%0R V,3DV-BTR+C$@1&5F875L
M="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M  !D97-C         "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@
M245#-C$Y-C8M,BXQ               L4F5F97)E;F-E(%9I97=I;F<@0V]N
M9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X    !6%E:(
M    3 E6 %    !7'^=M96%S          $                        "
MCP    )S:6<@     $-25"!C=7)V        !      %  H #P 4 !D '@ C
M "@ +0 R #< .P!  $4 2@!/ %0 60!> &, : !M '( =P!\ ($ A@"+ )
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M%,X4
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M4W4B:O2%TF&DNUKU.6FX]NG$1<: /47:1.4HI'-&RJA#IB8AB&.)0 W** &
M!SPRHL"S+-@R)DH+X+YB;$&(XQ8L7Q"PG 1'N (.-0*X4T+4"*]Y?>(-&U&
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MT'-. <"=P$%723L&HX!HG,Q1W9E10!J21:&<"L!A(*((%6%450. E%,"\OE
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M-E>O8L2VLA[QZ!6IIW6SCNVYY]K76>LUL3B<AL^YM1HI' _YWXUQN$ZS-O\
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M-ZLNN%@86$;):V+]>RZH05??N7NG,I)P$W)$BDTD4D8]BG67$J<RK5JLA7O
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1F$3")A$PB81,(F$3")A%_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>59
<FILENAME>g425213g96b78.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g425213g96b78.jpg
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M5^28[- 41_U;$:JJ^YIO6^I\UA8WC!;9+FN:]I:V0XA#@YV/K;*Z,&VQM=D
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MTCJ"#8/T$6LA <"TBP000>A!%$'WA:,_^2V]/K_=6YC_ /Q3'^;9T?SQQ/\
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M5,>E);65@AI"&-JUK:MDRTX?K?QWO7O\]QOCK>_?]T_MG3Q,)D^!/.1;V.F
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M^;W8IA;>FA+9N^;K%CITL;#MOONL[IGCTDY0)#2YEBQ1O$+A]%D=#U[=51<
M]4.\7CUMNG>"$N@#X]'&7#L5?&6U!^4X8T1H%'-V9V5+%J@Z@K'SUB)$./%9
M?:DQ=N1Y#LF1K3C&IES-?#X\4PL&@,J4$ZB6NW!!V&UML#>@;-JN+,[](IXM
M1TE\X(O:FQ%W3W@?#XQGZ;7G=;^M>LEYA^,Y:L1H5:I=C\IFPIIHM(DS'G*%
MVB& UJ;"<BHCI;G,O./L_;O(5$^"&%ZE?/;S=LG.?-@PXSHVAL8@ >''4>7'
MH%B^A]W87NL?"G7Q_.W[YH(Z;C);705T%?=O<G^CYZH5V\R/,[RCX!9*"/K8
M/F59NUGJYN(>ED9DR%7NJ@*8J(8A/PF6$RY+9MB<U(A/(9CI:?B+9?WM$K=<
M[-&1!%$(&QACFN#PXESJCT[]@#=[>77M?@4SG\1S8RXD!LQ /:LAH%>5'IXV
M5Z>)?J?7?J/K+^0'@Z4H(^#3:C;>\B EL8/RWRKDSF\R:I;L\6Y ;A?9$FXD
MC4=F.^A^"O3&W'INEK^G$V8),"/&$+6&-L0Y@))<6E]ZK/5U@TW8>\;7PIY#
MQ_*B).F\H@;5[)8!TWV\_=X*&_2/\]K=W?U3?+;Q_-5>,.KU/$^012O%F2S\
MJ8ZBG]OJ=<0T1ANQT,)7,C%-R6UQ'=)B*:5&4F4ES4A%LO/=D86/CF, 1F/3
M("?:#(BRR+VU6":[]ANL'!;_ #SFWV;EW[SDQ$=NP\%(/H_^JC=O,/J?F'0+
M9S^#6QW'.>';O6)XX_*)2B(Z!8Y8AR"58E0F&6R*D_;2&Y<-Q$;V6ZPJ-_JT
M/N,W-$\4#>0V/EO#@0XDN ;T<3X[$UWOWK)P&=[I\]CG.<&1DBS=$/<-A7X[
M>"Q#TN?54O7F1XS^I"=N//H%7E^._"9=U!I$6*43T9@EJ+U\@B#*7-'Q]Q",
M1RF-H7.9TN-*^]TI,.+N-M+\YN?ZQ)C2B%L)A>7C22=0MC@2"2T$%HV'B=J6
M/@LKWX?%0YQ<68P()H[F*>^W38'P\18WPCTO_4>NO3/3D]2;N=@IL-@_XY4Z
M;810N$;DKB'=,\^MAV!&<ER(:GQ[FY0K<>5(0U*1]-Q+[+&MIW'RV9Q$SY.+
M.Z%H,!=[.MWMCF%[0XV:(!_H]B!M2IP<UPKBY!/LM=7D1"[H>O8;]=O'<R#X
MT^K-?^M^CSYD^7ISG0L==>!WV-4X=>@6&8Z(.*DN<G=&2]SI,%4T:TE5RVU.
MC:1+6M$);L=]"I:6X])<T29F-D"%K#$P Q62UQN0C?K3@X7?T]ZOB3/?P'B#
MW.-MD #NI K'[#IU^@[WV&-%/4WOG5O0=ZAYBSJ,-$WFL]IKU 77XAV8^'E2
M(_3><CVR34YV&F?'B+AV%+KL%27WM/1W64S-H>2\W8YY'$FY;86M<&%IC!(:
M7.C<T[[D6'#<'9!*Z7T;G>XG:=K;.Y(]8AW/O)/GX#HO _ZH%\YOZ%/CYYD#
MZ,.G7FW=T,<\W7I)N6V&CR8MY[) <(N3FHFI[T-46G_6;A)2T_IV2VPN8I#2
MGW);G_Z_+E.@:7/A#!%J.FP(Q=W9%,-^?:U1TA9Z-8[@=)]9< 6G>O6)SX>
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MO9O:JPYP9@NQ3"#J9..9JIP+]54*JAM8-D] 1:R9D[V>D,$8/L.DQ17_ ,P
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M81,(F$3")A$PB81,(F$3"*V%XCLV"ZPS\=N;VE2=*W\=;^._Y>_\M;WK^O\
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MO'=H-M^\8(!&@Q O.?K J0+(H::C_A^Y*Q,ACQ8!GRFSS.9$U[1"]NHEP+G
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M5-AR/O&TQFMQ=NJVA*/K?QO:<0W]-?LXG_5)VY[?O_K/Y>^7$Q70"5KGM=K
M:"VS5:MS8%'VNF]>*V^'X#\7GA[XW<RFC19H#5NZPVCN/9%^]9@!%NBX[C3K
MC3BEJ1[;:VK:?9&E:]][4E._?>U?R]OVUK^?[^VMF&,Q@AQ!)KITH778;[K>
MQX3"T@D$DCI=;>9KK?ALK]F99TPB81,(F$3")A$PB81,(F$3")A$PB81,(F$
M3")A$PB81,(F$3")A$PB81,(F$3")A$PB816\JE2H+Z4[5K>])]]IWO6_;2M
M;WKWU^_MO7_R_H_?^64DO0:Z[=Z[A8Y03&ZNM?Q%_8H]MWWJ:7$2V[)0Y][K
M3RT+=2O;.MS?IZ<4G?R^E[Z9^.E;^._BW_3I.:>27^JMISKU"R";(]H@'IW#
M?+I6RYN:9/4&TYX)> X@D'3[= ]Z)T@#I>GW*.NH/&4\WJ&VY))MU3C/WCJ'
M9*'7-IB.;C_<N)4E:O??LIOZF]^ZM:6GW4G6\T\\RC"QJ=("2W4076?9)&H]
M>VU]Z(\1RN,&<<*PJ=*#J;S"'/!/L'3J/4[T1JZ]5@'D')LK5#Y2J---1Y"Q
MWS(N1Y$UEYTFD8#5'5,6TI+BING%3%,[=W]?3FY"D?Q?4S3XP^<8F 6NE!+
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MN N,L!>0W8$FZ&H@=0#LJ;Q/]'CR\YCZ-_FOX9W='-Q'=O(>_?G2CA&;A^*
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M+&16'K8*)UN*0-)Z=^F_7K0]Y(6QG*.XTKL\SH;%&;L$J!S6]V?FQH^1"OC
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$,(O_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
